PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Banyard, J; Bao, L; Zetter, BR				Banyard, J; Bao, L; Zetter, BR			Type XXIII collagen, a new transmembrane collagen identified in metastatic tumor cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							XIII-COLLAGEN; XVII COLLAGEN; GROWTH-FACTOR; FURIN; ADHESION; EXPRESSION; INTEGRINS; COMPONENT; PRECURSOR; PROTEIN	We have identified a transmembrane collagen, collagen XXIII, in rat prostate carcinoma cells. Differential display of mRNA expression in prostate carcinoma sublines with varying metastatic potential revealed overexpression of this transcript in the metastatic AT6.1 subline. cDNA cloning identified a 2733-bp transcript from AT6.1 RNA, encoding a protein of 532 amino acids, together with a 3067-bp human homologue, resulting in a 540-amino acid protein. Collagen XXIII is predicted to be a type II membrane protein consisting of an aminoterminal cytoplasmic domain, a transmembrane region, and three collagenous domains flanked by short noncollagenous domains. Collagen XXIII is a new member of the transmembrane collagen family, showing structural homology with the transmembrane collagens XIII and XXV. We present evidence that collagen XXIII is expressed as a similar to75-kDa protein at the cell surface and that it can be cleaved by furin protease activity. Cleavage results in a similar to60-kDa soluble protein that forms a multimeric complex and exhibits a low affinity interaction with heparin.	Harvard Univ, Childrens Hosp, Sch Med, ProgramVasc Biol, Boston, MA 02115 USA; Harvard Univ, Childrens Hosp, Sch Med, Dept Surg, Boston, MA 02115 USA	Harvard University; Boston Children's Hospital; Harvard Medical School; Harvard University; Boston Children's Hospital; Harvard Medical School	Zetter, BR (corresponding author), Harvard Univ, Childrens Hosp, Sch Med, ProgramVasc Biol, Enders 1074,300 Longwood Ave, Boston, MA 02115 USA.				NATIONAL CANCER INSTITUTE [R01CA037393] Funding Source: NIH RePORTER; NCI NIH HHS [R01CA37393] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; Bao LR, 1996, NAT MED, V2, P1322, DOI 10.1038/nm1296-1322; Bassi DE, 2001, P NATL ACAD SCI USA, V98, P10326, DOI 10.1073/pnas.191199198; Bassi DE, 2001, MOL CARCINOGEN, V31, P224, DOI 10.1002/mc.1057; DAVIS GE, 1992, BIOCHEM BIOPH RES CO, V182, P1025, DOI 10.1016/0006-291X(92)91834-D; Eyal Y, 1999, BIOTECHNIQUES, V27, P656, DOI 10.2144/99274bm04; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; Gagnon ML, 2000, P NATL ACAD SCI USA, V97, P2573, DOI 10.1073/pnas.040337597; Hagg P, 1998, J BIOL CHEM, V273, P15590, DOI 10.1074/jbc.273.25.15590; Hagg P, 2001, MATRIX BIOL, V19, P727, DOI 10.1016/S0945-053X(00)00119-0; Hashimoto T, 2002, EMBO J, V21, P1524, DOI 10.1093/emboj/21.7.1524; Hopkinson SB, 1998, J INVEST DERMATOL, V111, P1015, DOI 10.1046/j.1523-1747.1998.00452.x; ISAACS JT, 1986, PROSTATE, V9, P261, DOI 10.1002/pros.2990090306; Knight CG, 2000, J BIOL CHEM, V275, P35, DOI 10.1074/jbc.275.1.35; Kvist AP, 1999, MATRIX BIOL, V18, P261, DOI 10.1016/S0945-053X(99)00018-9; Mbikay M, 1997, BRIT J CANCER, V75, P1509, DOI 10.1038/bjc.1997.258; Miyoshi E, 1997, J BIOL CHEM, V272, P14349, DOI 10.1074/jbc.272.22.14349; Myllyharju J, 2001, ANN MED, V33, P7, DOI 10.3109/07853890109002055; Nakayama K, 1997, BIOCHEM J, V327, P625, DOI 10.1042/bj3270625; Nykvist P, 2000, J BIOL CHEM, V275, P8255, DOI 10.1074/jbc.275.11.8255; Nykvist P, 2001, J BIOL CHEM, V276, P38673, DOI 10.1074/jbc.M102589200; Park PW, 2000, J BIOL CHEM, V275, P29923, DOI 10.1074/jbc.R000008200; Peltonen S, 1999, J INVEST DERMATOL, V113, P635, DOI 10.1046/j.1523-1747.1999.00736.x; PFAFF M, 1993, EXP CELL RES, V206, P167, DOI 10.1006/excr.1993.1134; RUGGIERO F, 1994, EXP CELL RES, V210, P215, DOI 10.1006/excr.1994.1032; Schacke H, 1998, J BIOL CHEM, V273, P25937, DOI 10.1074/jbc.273.40.25937; SIEBERT PD, 1995, NUCLEIC ACIDS RES, V23, P1087, DOI 10.1093/nar/23.6.1087; Snellman A, 2000, EMBO J, V19, P5051, DOI 10.1093/emboj/19.19.5051; Sonnhammer E L, 1998, Proc Int Conf Intell Syst Mol Biol, V6, P175; TAKAHASHI S, 1993, BIOCHEM BIOPH RES CO, V195, P1019, DOI 10.1006/bbrc.1993.2146; Tu HM, 2002, J BIOL CHEM, V277, P23092, DOI 10.1074/jbc.M107583200; [No title captured]	32	66	71	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 6	2003	278	23					20989	20994		10.1074/jbc.M210616200	http://dx.doi.org/10.1074/jbc.M210616200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	684WY	12644459	hybrid			2022-12-25	WOS:000183230500071
J	Chen, S; Yin, XL; Zhu, XY; Ji, SY; Chen, C; Cai, MM; Zhang, SW; Zong, HL; Hu, Y; Yuan, ZH; Shen, ZH; Gu, JX				Chen, S; Yin, XL; Zhu, XY; Ji, SY; Chen, C; Cai, MM; Zhang, SW; Zong, HL; Hu, Y; Yuan, ZH; Shen, ZH; Gu, JX			The C-terminal kinase domain of the p34cdc2-related PITSLRE protein kinase (p110C) associates with p21-activated kinase 1 and inhibits its activity during anoikis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-CYCLE; RETINOBLASTOMA PROTEIN; NEURITE OUTGROWTH; GENE-COMPLEX; APOPTOSIS; PAK; ACTIVATION; EXPRESSION; FAMILY; 1P36	The PITSLRE protein kinases are parts of the large family of p34cdc2-related kinases. During apoptosis induced by some stimuli, specific PITSLRE isoforms are cleaved by caspase to produce a protein that contains the C-terminal kinase domain of the PITSLRE proteins (p110C). The p110C induces apoptosis when it is ectopically expressed in Chinese hamster ovary cells. In our study, similar induction of this p110C was observed during anoikis in NIH3T3 cells. To investigate the molecular mechanism of apoptosis mediated by p110C, we used the yeast two-hybrid system to screen a human fetal liver cDNA library and identified p21-activated kinase 1 (PAK1) as an interacting partner of p110C. The association of p110C with PAK1 was further confirmed by in vitro binding assay, in vivo coimmunoprecipitation, and confocal microscope analysis. The interaction of p110C with PAK1 occurred within the residues 210-332 of PAK1. Neither association between p58(PITSLRE) or p110(PITSLRE) and PAK1 nor association between p110C and PAK2 or PAK3 was observed. Anoikis was increased and PAK1 activity was inhibited when NIH3T3 cells were transfected with p110C. Furthermore, the binding of p110C with PAK1 and inhibition of PAK1 activity were also observed during anoikis. Taken together, these data suggested that PAK1 might participate in the apoptotic pathway mediated by p110C.	Fudan Univ, Shanghai Med Ctr, Ctr Gene Res, Shanghai 200032, Peoples R China; Fudan Univ, Shanghai Med Ctr, Dept Biochem, Shanghai 200032, Peoples R China; Fudan Univ, Shanghai Med Ctr, Dept Mol Virus, Shanghai 200032, Peoples R China	Fudan University; Fudan University; Fudan University	Gu, JX (corresponding author), Fudan Univ, Shanghai Med Ctr, Ctr Gene Res, Shanghai 200032, Peoples R China.	jxgu@shmu.edu.cn	Zong, Hongliang/F-9366-2013	Zong, Hongliang/0000-0002-5855-5733				Ariza ME, 1999, J BIOL CHEM, V274, P28505, DOI 10.1074/jbc.274.40.28505; Bagheri-Yarmand R, 2001, J BIOL CHEM, V276, P29403, DOI 10.1074/jbc.M103129200; Bagrodia S, 1999, TRENDS CELL BIOL, V9, P350, DOI 10.1016/S0962-8924(99)01618-9; Berry DE, 1996, ONCOGENE, V12, P1809; Beyaert R, 1997, J BIOL CHEM, V272, P11694, DOI 10.1074/jbc.272.18.11694; Bokoch GM, 1998, CELL DEATH DIFFER, V5, P637, DOI 10.1038/sj.cdd.4400405; Brown JL, 1996, CURR BIOL, V6, P598, DOI 10.1016/S0960-9822(02)00546-8; BUNNELL BA, 1990, P NATL ACAD SCI USA, V87, P7467, DOI 10.1073/pnas.87.19.7467; Cai MM, 2002, MOL CELL BIOCHEM, V238, P49, DOI 10.1023/A:1019950819784; Cornelis S, 2000, MOL CELL, V5, P597, DOI 10.1016/S1097-2765(00)80239-7; Dan C, 2002, MOL CELL BIOL, V22, P567, DOI 10.1128/MCB.22.2.567-577.2002; Daniels RH, 1998, EMBO J, V17, P754, DOI 10.1093/emboj/17.3.754; Dave BJ, 1999, CANCER GENET CYTOGEN, V108, P120, DOI 10.1016/S0165-4608(98)00138-1; Dickinson LA, 2002, J BIOL CHEM, V277, P25465, DOI 10.1074/jbc.M202266200; EIPERS PG, 1991, GENOMICS, V11, P621, DOI 10.1016/0888-7543(91)90069-Q; Faure S, 1997, EMBO J, V16, P5550, DOI 10.1093/emboj/16.18.5550; Gururajan R, 1998, GENOME RES, V8, P929, DOI 10.1101/gr.8.9.929; Ibuki Y, 2000, BIOCHEM BIOPH RES CO, V279, P872, DOI 10.1006/bbrc.2000.4018; Jaffer ZM, 2002, INT J BIOCHEM CELL B, V34, P713, DOI 10.1016/S1357-2725(01)00158-3; Knaus UG, 1998, INT J BIOCHEM CELL B, V30, P857, DOI 10.1016/S1357-2725(98)00059-4; LAHTI JM, 1995, MOL CELL BIOL, V15, P1; LAHTI JM, 1994, NAT GENET, V7, P370, DOI 10.1038/ng0794-370; LI HM, 1995, GENE, V153, P237, DOI 10.1016/0378-1119(94)00801-X; Loyer P, 1998, J CELL SCI, V111, P1495; Maller JL, 1991, CURR OPIN CELL BIOL, V3, P269; MANSER E, 1994, NATURE, V367, P40, DOI 10.1038/367040a0; MEYERSON M, 1992, EMBO J, V11, P2909, DOI 10.1002/j.1460-2075.1992.tb05360.x; MOCK BA, 1994, MAMM GENOME, V5, P191, DOI 10.1007/BF00352357; Nelson MA, 1999, CANCER GENET CYTOGEN, V108, P91, DOI 10.1016/S0165-4608(98)00122-8; Pandey A, 2002, ONCOGENE, V21, P3939, DOI 10.1038/sj.onc.1205478; Sanders LC, 1999, SCIENCE, V283, P2083, DOI 10.1126/science.283.5410.2083; Sauer K, 1996, MOL BIOL CELL, V7, P1759, DOI 10.1091/mbc.7.11.1759; Schurmann A, 2000, MOL CELL BIOL, V20, P453, DOI 10.1128/MCB.20.2.453-461.2000; SCHWARTZMAN RA, 1993, ENDOCR REV, V14, P133, DOI 10.1210/er.14.2.133; Sells MA, 1999, TRENDS CELL BIOL, V9, P355, DOI 10.1016/S0962-8924(99)01642-6; Sells MA, 1997, TRENDS CELL BIOL, V7, P162, DOI 10.1016/S0962-8924(97)01003-9; Shalom-Barak T, 2002, J BIOL CHEM, V277, P40659, DOI 10.1074/jbc.M206650200; SHAN B, 1994, MOL CELL BIOL, V14, P8166, DOI 10.1128/MCB.14.12.8166; Shi JQ, 2003, J BIOL CHEM, V278, P5062, DOI 10.1074/jbc.M206427200; SHI L, 1994, SCIENCE, V263, P1143, DOI 10.1126/science.8108732; Souopgui J, 2002, EMBO J, V21, P6429, DOI 10.1093/emboj/cdf644; Tang D, 1998, J BIOL CHEM, V273, P28549, DOI 10.1074/jbc.273.44.28549; Tang Y, 2000, J BIOL CHEM, V275, P9106, DOI 10.1074/jbc.275.13.9106; Thomas A, 2000, ONCOGENE, V19, P5259, DOI 10.1038/sj.onc.1203895; Trembley JH, 2002, J BIOL CHEM, V277, P2589, DOI 10.1074/jbc.M109755200; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; Wolf D, 2001, NAT MED, V7, P1217, DOI 10.1038/nm1101-1217; XIANG JL, 1994, J BIOL CHEM, V269, P15786; YONISHROUACH E, 1993, MOL CELL BIOL, V13, P1415, DOI 10.1128/MCB.13.3.1415; Yoshii S, 2001, MOL CELL BIOL, V21, P6796, DOI 10.1128/MCB.21.20.6796-6807.2001; ZHANG SJ, 1995, J BIOL CHEM, V270, P23934, DOI 10.1074/jbc.270.41.23934; Zhang SW, 2002, J BIOL CHEM, V277, P35314, DOI 10.1074/jbc.M202179200; Zhang SW, 2001, MOL CELL BIOCHEM, V221, P161, DOI 10.1023/A:1010932211745	53	40	46	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 30	2003	278	22					20029	20036		10.1074/jbc.M300818200	http://dx.doi.org/10.1074/jbc.M300818200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	682EH	12624090	hybrid			2022-12-25	WOS:000183078000060
J	Auzanneau, C; Thoreau, V; Kitzis, A; Becq, F				Auzanneau, C; Thoreau, V; Kitzis, A; Becq, F			A novel voltage-dependent chloride current activated by extracellular acidic pH in cultured rat Sertoli cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FUNCTIONAL EXPRESSION; CL-CHANNEL; SECRETION; MEMBRANE; OOCYTES; GLUCOSE; PROTEIN; CLONING; MEMBERS; FAMILY	Sertoli cells from mammalian testis are key cells involved in development and maintenance of stem cell spermatogonia as well as secretion of a chloride- and potassium-rich fluid into the lumen of seminiferous tubules. Using whole-cell patch clamp experiments, a novel chloride current was identified. It is activated only in the presence of an extracellular acidic pH, with an estimated half-maximal activation at pH 5.5. The current is strongly outwardly rectifying, activated with a fast time-dependent onset of activation but a slow time-dependent kinetic at depolarization pulses. The pH-activated chloride current was not detected at physiological or basic pH and is not sensitive to intracellular or extracellular Ca2+ variation. Diphenylamine-2-carboxylic acid and 4,4'-diisothiocyanatostilbene-2,2'-disulfonic acid blocked the induced currents, and its anionic selectivity sequence was Cl- > Br- > I- > gluconate. We have performed a reverse transcription-PCR analysis to search for voltage-dependent chloride rClC channels in cultured rat Sertoli cells. Among the nine members of the family only rClC-2, rClC-3, rClC-6, and rClC-7 have been identified. The inwardly rectifying rClC-2 chloride current was activated by hyperpolarization but not by pH variation. A different depolarization-activated outwardly rectifying chloride current was activated only by hypotonic challenge and may correspond either to rClC-3 or rClC-6. Immunolocalization experiments demonstrate that rClC-7 resides in the intracellular compartment of Sertoli cells. This study provides the first functional identification of a native acid-activated chloride current. Based on our molecular analysis of rClC proteins, this new chloride current does not correspond to rClC-2, rClC-3, rClC-6, or rClC-7 channels. The potential physiological role of this native current in an epithelial cell from the reproductive system is discussed.	Univ Poitiers, CNRS, UMR 6558, Lab Biomembranes & Signalisat Cellulaire, F-86022 Poitiers, France; CHU Poitiers, UPRES EA 2622, Lab Genet Cellulaire & Mol, F-86022 Poitiers, France	Centre National de la Recherche Scientifique (CNRS); Universite de Poitiers; CHU Poitiers; Universite de Poitiers	Becq, F (corresponding author), Univ Poitiers, CNRS, UMR 6558, Lab Biomembranes & Signalisat Cellulaire, 40 Ave Recteur Pineau, F-86022 Poitiers, France.	frederic.becq@univ-poitiers.fr	Becq, Frederic/P-9233-2016	Becq, Frederic/0000-0003-3915-0973				Boockfor FR, 1998, AM J PHYSIOL-CELL PH, V274, pC922, DOI 10.1152/ajpcell.1998.274.4.C922; Bosl MR, 2001, EMBO J, V20, P1289, DOI 10.1093/emboj/20.6.1289; Brandt S, 1995, FEBS LETT, V377, P15, DOI 10.1016/0014-5793(95)01298-2; Breton S, 1998, AM J PHYSIOL-CELL PH, V275, pC1134, DOI 10.1152/ajpcell.1998.275.4.C1134; Buyse G, 1998, BIOCHEM J, V330, P1015, DOI 10.1042/bj3301015; Diewald L, 2002, BIOCHEM BIOPH RES CO, V291, P421, DOI 10.1006/bbrc.2002.6462; Estevez R, 2001, NATURE, V414, P558, DOI 10.1038/35107099; Friedrich T, 1999, J BIOL CHEM, V274, P896, DOI 10.1074/jbc.274.2.896; Fritsch J, 1996, J PHYSIOL-LONDON, V490, P115, DOI 10.1113/jphysiol.1996.sp021130; Furukawa T, 1998, AM J PHYSIOL-CELL PH, V274, pC500, DOI 10.1152/ajpcell.1998.274.2.C500; Halestrap AP, 1999, BIOCHEM J, V343, P281, DOI 10.1042/0264-6021:3430281; Hamamah S, 1998, HUM REPROD, V13, P20, DOI 10.1093/humrep/13.suppl_4.20; Jackson VN, 1997, BIOCHEM J, V324, P447, DOI 10.1042/bj3240447; JEGOU B, 1992, BAILLIERE CLIN ENDOC, V6, P273, DOI 10.1016/S0950-351X(05)80151-X; Jentsch TJ, 2002, PHYSIOL REV, V82, P503, DOI 10.1152/physrev.00029.2001; Jordt SE, 1997, EMBO J, V16, P1582, DOI 10.1093/emboj/16.7.1582; Kawasaki E, 1999, BRAIN RES, V838, P166, DOI 10.1016/S0006-8993(99)01730-8; Kawasaki Masanobu, 1999, American Journal of Physiology, V277, pC948; KIEFERLE S, 1994, P NATL ACAD SCI USA, V91, P6943, DOI 10.1073/pnas.91.15.6943; Kornak U, 2001, CELL, V104, P205, DOI 10.1016/S0092-8674(01)00206-9; Lalevee N, 1997, BIOL REPROD, V56, P680, DOI 10.1095/biolreprod56.3.680; Lalevee N, 1999, J MEMBRANE BIOL, V169, P167, DOI 10.1007/s002329900528; LIN H, 1994, EXP EYE RES, V59, P679, DOI 10.1006/exer.1994.1153; Mauduit C, 1999, HUM REPROD UPDATE, V5, P535, DOI 10.1093/humupd/5.5.535; Nilius B, 1996, GEN PHARMACOL-VASC S, V27, P1131, DOI 10.1016/S0306-3623(96)00061-4; RICCIOLI A, 1995, P NATL ACAD SCI USA, V92, P5808, DOI 10.1073/pnas.92.13.5808; Riera MF, 2002, J ENDOCRINOL, V173, P335, DOI 10.1677/joe.0.1730335; ROBINSON R, 1981, BIOL REPROD, V24, P1032, DOI 10.1095/biolreprod24.5.1032; RUSSEL LD, 1993, SERTOLI CELL, P270; Rychkov GY, 1996, J PHYSIOL-LONDON, V497, P423, DOI 10.1113/jphysiol.1996.sp021778; STEINMEYER K, 1991, NATURE, V354, P301, DOI 10.1038/354301a0; Steinmeyer K, 1995, J BIOL CHEM, V270, P31172, DOI 10.1074/jbc.270.52.31172; Taranta A, 1997, MOL CELL ENDOCRINOL, V126, P117, DOI 10.1016/S0303-7207(96)03973-1; THIEMANN A, 1992, NATURE, V356, P57, DOI 10.1038/356057a0; Uchida S, 2000, MOL CELL BIOL, V20, P7319, DOI 10.1128/MCB.20.19.7319-7331.2000; Vanoye CG, 2002, J PHYSIOL-LONDON, V539, P373, DOI 10.1113/jphysiol.2001.013115; VERHOEVEN G, 1979, MOL CELL ENDOCRINOL, V13, P241, DOI 10.1016/0303-7207(79)90084-4; Waldegger S, 2000, J BIOL CHEM, V275, P24527, DOI 10.1074/jbc.M001987200	38	49	49	1	4	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 23	2003	278	21					19230	19236		10.1074/jbc.M301096200	http://dx.doi.org/10.1074/jbc.M301096200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	679PY	12637509	hybrid			2022-12-25	WOS:000182932200067
J	Chen, SJ; Nguyen, N; Tamura, K; Karin, M; Tukey, RH				Chen, SJ; Nguyen, N; Tamura, K; Karin, M; Tukey, RH			The role of the Ah receptor and p38 in Benzo[a]pyrene-7,8-dihydrodiol and Benzo[a]pyrene-7,8-dihydrodiol-9,10-epoxide-induced apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYCYCLIC AROMATIC-HYDROCARBONS; TOBACCO-SMOKE CARCINOGENS; OXIDE-INDUCED APOPTOSIS; CYTOCHROME-C RELEASE; POLY(ADP-RIBOSE) POLYMERASE; NH2-TERMINAL KINASE-1; METABOLIC-ACTIVATION; DEATH RECEPTORS; PROTEIN-KINASES; P450 1A1	Polycyclic aromatic hydrocarbons (PAHs) are ubiquitous contaminants in the environment. Benzo[ a] pyrene ( B[ a] P), a prototypical member of this class of chemicals, affects cellular signal transduction pathways and induces apoptosis. In this study, the proximate carcinogen of B[ a] P metabolism, trans-7,8-dihydroxy-7,8-dihydrobenzo[ a] pyrene ( B[ a] P-7,8-dihydrodiol) and the ultimate carcinogen, B[ a]P-r-7,t-8-dihydrodiol-t-9,10-epoxide(+/-) ( BPDE-2) were found to induce apoptosis in human HepG2 cells. Apoptosis initiated by B[ a] P-7,8-dihydrodiol was linked to activation of the Ah receptor and induction of CYP1A1, an event that can lead to the formation of BPDE-2. With both B[ a] P-7,8-dihydrodiol and BPDE-2 treatment, changes in anti- and pro-apoptotic events in the Bcl-2 family of proteins correlated with the release of mitochondrial cytochrome c and caspase activation. The onset of apoptosis as monitored by caspase activation was linked to mitogen-activated protein ( MAP) kinases. Utilizing mouse hepa1c1c7 cells and the Arnt-deficient BPRc1 cells, activation of MAP kinase p38 by B[a]P-7,8-dihydrodiol was shown to be Ah receptor-dependent, indicating that metabolic activation by CYP1A1 was required. This was in contrast to p38 activation by BPDE-2, an event that was independent of Ah receptor function. Confirmation that MAP kinases play a critical role in BPDE-2-induced apoptosis was shown by inhibiting caspase activation of poly( ADP-ribose) polymerase 1 (PARP-1) by chemical inhibitors of p38 and ERK1/2. Furthermore, mouse embryo p38(-/-) fibroblasts were shown to be resistant to the actions of BPDE-2-induced apoptosis as determined by annexin V analysis, cytochrome c release, and cleavage of PARP-1. These results confirm that the Ah receptor plays a critical role in B[ a] P-7,8-dihydrodiol-induced apoptosis while p38 MAP kinase links the actions of an electrophilic metabolite like BPDE-2 to the regulation of programmed cell death.	Univ Calif San Diego, Dept Pharmacol, Lab Environm Toxicol, La Jolla, CA 92093 USA; Univ Calif San Diego, Dept Chem, Lab Environm Toxicol, La Jolla, CA 92093 USA; Univ Calif San Diego, Dept Biochem, Lab Environm Toxicol, La Jolla, CA 92093 USA; Univ Calif San Diego, Dept Pharmacol, Lab Gene Regulat, La Jolla, CA 92093 USA	University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego	Tukey, RH (corresponding author), Univ Calif San Diego, Dept Pharmacol, Lab Environm Toxicol, La Jolla, CA 92093 USA.			Chen, Shujuan/0000-0002-1068-195X	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P42ES010337] Funding Source: NIH RePORTER; NIEHS NIH HHS [ES10337] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; Bostrom CE, 2002, ENVIRON HEALTH PERSP, V110, P451, DOI 10.1289/ehp.02110s3451; Boulares AH, 2002, CANCER RES, V62, P4439; Boulares AH, 2002, J BIOL CHEM, V277, P372, DOI 10.1074/jbc.M107738200; Chang LF, 2001, NATURE, V410, P37, DOI 10.1038/35065000; Chen YH, 1996, J BIOL CHEM, V271, P26261, DOI 10.1074/jbc.271.42.26261; Cheng AW, 2001, J BIOL CHEM, V276, P43320, DOI 10.1074/jbc.M107698200; Chiarugi A, 2002, TRENDS PHARMACOL SCI, V23, P122, DOI 10.1016/S0165-6147(00)01902-7; Chiarugi A, 2002, SCIENCE, V297, P200, DOI 10.1126/science.1074592; Chin BY, 1998, AM J PHYSIOL-LUNG C, V275, pL942, DOI 10.1152/ajplung.1998.275.5.L942; CONNEY AH, 1994, DRUG METAB REV, V26, P125, DOI 10.3109/03602539409029788; CONNEY AH, 1982, CANCER RES, V42, P4875; Corchero J, 2001, PHARMACOGENETICS, V11, P1, DOI 10.1097/00008571-200102000-00001; Cross TG, 2000, EXP CELL RES, V256, P34, DOI 10.1006/excr.2000.4836; Cryns V, 1998, GENE DEV, V12, P1551, DOI 10.1101/gad.12.11.1551; D'Amours D, 1999, BIOCHEM J, V342, P249, DOI 10.1042/0264-6021:3420249; Germain M, 1999, J BIOL CHEM, V274, P28379, DOI 10.1074/jbc.274.40.28379; Ghatan S, 2000, J CELL BIOL, V150, P335, DOI 10.1083/jcb.150.2.335; Gradin K, 1996, MOL CELL BIOL, V16, P5221; GROVER PL, 1973, BIOCHEM PHARMACOL, V22, P661, DOI 10.1016/0006-2952(73)90398-5; Hecht SS, 2002, ENVIRON MOL MUTAGEN, V39, P119, DOI 10.1002/em.10071; ISRAEL DI, 1984, J BIOL CHEM, V259, P5400; Jyonouchi H, 1999, CARCINOGENESIS, V20, P139, DOI 10.1093/carcin/20.1.139; KAPITULNIK J, 1978, CANCER RES, V38, P354; KOURI RE, 1980, JNCI-J NATL CANCER I, V64, P617; Kwon YW, 2002, J BIOL CHEM, V277, P1837, DOI 10.1074/jbc.M105033200; Lei W, 1998, CANCER RES, V58, P2102; LEVIN W, 1977, CANCER RES, V37, P2721; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; Liu XS, 1999, J BIOL CHEM, V274, P13836, DOI 10.1074/jbc.274.20.13836; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; Mandlekar S, 2001, APOPTOSIS, V6, P469, DOI 10.1023/A:1012437607881; MCMANUS ME, 1990, PROG CLIN BIOL RES, V340, P139; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; Ortiz MA, 2001, CANCER RES, V61, P8504; Page TJ, 2002, MOL PHARMACOL, V62, P313, DOI 10.1124/mol.62.2.313; Pearson G, 2001, ENDOCR REV, V22, P153, DOI 10.1210/er.22.2.153; Pfeifer GP, 2002, ONCOGENE, V21, P7435, DOI 10.1038/sj.onc.1205803; Phillips DH, 1999, MUTAT RES-GEN TOX EN, V443, P139, DOI 10.1016/S1383-5742(99)00016-2; POSTLIND H, 1993, TOXICOL APPL PHARM, V118, P255, DOI 10.1006/taap.1993.1031; Roth W, 2002, NAT MED, V8, P216, DOI 10.1038/nm0302-216; Rubin H, 2001, CARCINOGENESIS, V22, P1903, DOI 10.1093/carcin/22.12.1903; Salas VM, 1998, TOXICOL APPL PHARM, V151, P367, DOI 10.1006/taap.1998.8455; Sanchez-Prieto R, 2000, CANCER RES, V60, P2464; Shimada T, 1999, CHEM RES TOXICOL, V12, P623, DOI 10.1021/tx990028s; Shimada T, 2002, CARCINOGENESIS, V23, P1199, DOI 10.1093/carcin/23.7.1199; SHIMADA T, 1989, CANCER RES, V49, P6304; Shimada T, 2001, DRUG METAB DISPOS, V29, P1176; Shimada T, 1996, CANCER RES, V56, P2979; SHIMADA T, 1994, CARCINOGENESIS, V15, P2523, DOI 10.1093/carcin/15.11.2523; SIMS P, 1974, NATURE, V252, P326, DOI 10.1038/252326a0; Soldani C, 2002, APOPTOSIS, V7, P321, DOI 10.1023/A:1016119328968; Soucek P, 1995, BIOCHEMISTRY-US, V34, P16013, DOI 10.1021/bi00049a015; Strassburg CP, 1998, J BIOL CHEM, V273, P8719, DOI 10.1074/jbc.273.15.8719; Tamura K, 2000, CELL, V102, P221, DOI 10.1016/S0092-8674(00)00027-1; THAKKER DR, 1976, P NATL ACAD SCI USA, V73, P3381, DOI 10.1073/pnas.73.10.3381; Wani MA, 1999, CARCINOGENESIS, V20, P765, DOI 10.1093/carcin/20.5.765; WISLOCKI PG, 1976, CANCER RES, V36, P3350; Yoshii S, 2001, MOL CELL BIOL, V21, P6796, DOI 10.1128/MCB.21.20.6796-6807.2001; YUEH MF, 2003, J BIOL CHEM; Zhuang SG, 2000, J BIOL CHEM, V275, P25939, DOI 10.1074/jbc.M001185200	62	65	68	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 23	2003	278	21					19526	19533		10.1074/jbc.M300780200	http://dx.doi.org/10.1074/jbc.M300780200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	679PY	12637498	hybrid			2022-12-25	WOS:000182932200103
J	Goerges, AL; Nugent, MA				Goerges, AL; Nugent, MA			Regulation of vascular endothelial growth factor binding and activity by extracellular pH	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPARAN-SULFATE PROTEOGLYCANS; FIBROBLAST-GROWTH; CELL-SURFACE; FACTOR EXPRESSION; FACTOR VEGF; TUMOR PH; ANGIOGENESIS; RECEPTOR; MATRIX; MOLECULES	Angiogenesis, the growth of new blood vessels, is regulated by a number of factors, including hypoxia and vascular endothelial growth factor ( VEGF). Although the effects of hypoxia have been studied intensely, less attention has been given to other extracellular parameters such as pH. Thus, the present study investigates the consequences of acidic pH on VEGF binding and activity in endothelial cell cultures. We found that the binding of VEGF(165) and VEGF(121) to endothelial cells increased as the extracellular pH was decreased from 7.5 to 5.5. Binding of VEGF(165) and VEGF(121) to endothelial extracellular matrix was also increased at acidic pH. These effects were, in part, a reflection of increased heparin binding, because VEGF(165) and VEGF(121) showed increased retention on heparin-Sepharose at pH 5.5 compared with pH 7.5. Consistent with these findings, soluble heparin competed for VEGF binding to endothelial cells under acidic conditions. However, at neutral pH ( 7.5) low concentrations of heparin (0.1-1.0 mug/ml) potentiated VEGF binding. Extracellular pH also regulated VEGF activation of the extracellular signal-regulated kinases 1 and 2 (Erk1/2). VEGF(165) and VEGF(121) activation of Erk1/ 2 at pH 7.5 peaked after 5 min, whereas at pH 6.5 the peak was shifted to 10 min. At pH 5.5, neither VEGF isoform was able to activate Erk1/ 2, suggesting that the increased VEGF bound to the cells at low pH was sequestered in a stored state. Therefore, extracellular pH might play an important role in regulating VEGF interactions with cells and the extracellular matrix, which can modulate VEGF activity.	Boston Univ, Sch Med, Dept Biochem, Boston, MA 02118 USA	Boston University	Nugent, MA (corresponding author), Boston Univ, Sch Med, Dept Biochem, Boston, MA 02118 USA.			Nugent, Matthew/0000-0002-8630-4712	NHLBI NIH HHS [HL56200] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL056200] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Akimoto T, 2002, AM J PHYSIOL-REG I, V283, pR487, DOI 10.1152/ajpregu.00699.2001; BASHKIN P, 1989, BIOCHEMISTRY-US, V28, P1737, DOI 10.1021/bi00430a047; Bernfield M, 1999, ANNU REV BIOCHEM, V68, P729, DOI 10.1146/annurev.biochem.68.1.729; Brogi E, 1996, J CLIN INVEST, V97, P469, DOI 10.1172/JCI118437; Burbridge M F, 1999, Angiogenesis, V3, P281, DOI 10.1023/A:1009092511894; D'Arcangelo D, 2000, CIRC RES, V86, P312, DOI 10.1161/01.RES.86.3.312; DANGELO G, 1995, P NATL ACAD SCI USA, V92, P6374, DOI 10.1073/pnas.92.14.6374; Esko JD, 2001, J CLIN INVEST, V108, P169, DOI 10.1172/JCI200113530; Fannon M, 2000, BIOCHEMISTRY-US, V39, P1434, DOI 10.1021/bi991895z; FOLKMAN J, 1995, NAT MED, V1, P27, DOI 10.1038/nm0195-27; Forsten KE, 2001, J CELL PHYSIOL, V189, P356, DOI 10.1002/jcp.10033; Gengrinovitch S, 1999, J BIOL CHEM, V274, P10816, DOI 10.1074/jbc.274.16.10816; Gerber HP, 1997, J BIOL CHEM, V272, P23659, DOI 10.1074/jbc.272.38.23659; GITAYGOREN H, 1992, J BIOL CHEM, V267, P6093; Iozzo RV, 2001, J CLIN INVEST, V108, P349, DOI 10.1172/JCI13738; Keyt BA, 1996, J BIOL CHEM, V271, P7788, DOI 10.1074/jbc.271.13.7788; Kleeff J, 1998, J CLIN INVEST, V102, P1662, DOI 10.1172/JCI4105; MOSCATELLI D, 1988, J CELL BIOL, V107, P753, DOI 10.1083/jcb.107.2.753; NUGENT MA, 1992, BIOCHEMISTRY-US, V31, P8876, DOI 10.1021/bi00152a026; Nugent MA, 2000, INT J BIOCHEM CELL B, V32, P115, DOI 10.1016/S1357-2725(99)00123-5; PARK JE, 1993, MOL BIOL CELL, V4, P1317, DOI 10.1091/mbc.4.12.1317; Park PW, 2000, J BIOL CHEM, V275, P29923, DOI 10.1074/jbc.R000008200; RAPRAEGER AC, 1991, SCIENCE, V252, P1705, DOI 10.1126/science.1646484; Risau W, 1997, NATURE, V386, P671, DOI 10.1038/386671a0; Robinson CJ, 2001, J CELL SCI, V114, P853; Sasisekharan R, 1997, Angiogenesis, V1, P45, DOI 10.1023/A:1018318914258; Sharma B, 1998, J CLIN INVEST, V102, P1599, DOI 10.1172/JCI3793; SHWEIKI D, 1995, P NATL ACAD SCI USA, V92, P768, DOI 10.1073/pnas.92.3.768; TANNOCK IF, 1972, BRIT J RADIOL, V45, P515, DOI 10.1259/0007-1285-45-535-515; TESSLER S, 1994, J BIOL CHEM, V269, P12456; Turnbull J, 2001, TRENDS CELL BIOL, V11, P75, DOI 10.1016/S0962-8924(00)01897-3; Veikkola T, 2000, CANCER RES, V60, P203; VLODAVSKY I, 1987, P NATL ACAD SCI USA, V84, P2292, DOI 10.1073/pnas.84.8.2292; Wahl ML, 2000, GEN PHARMACOL-VASC S, V35, P277, DOI 10.1016/S0306-3623(01)00115-X; Wight Thomas N., 1992, Current Opinion in Cell Biology, V4, P793, DOI 10.1016/0955-0674(92)90102-I; Wijelath ES, 2002, CIRC RES, V91, P25, DOI 10.1161/01.RES.0000026420.22406.79; WIKEHOOLEY JL, 1984, RADIOTHER ONCOL, V2, P343, DOI 10.1016/S0167-8140(84)80077-8; WIKEHOOLEY JL, 1984, EUR J CANCER CLIN ON, V20, P619, DOI 10.1016/0277-5379(84)90006-3; Woods A, 1998, MATRIX BIOL, V17, P477, DOI 10.1016/S0945-053X(98)90095-6; Yamagata M, 1998, BRIT J CANCER, V77, P1726, DOI 10.1038/bjc.1998.289; YAYON A, 1991, CELL, V64, P841, DOI 10.1016/0092-8674(91)90512-W	41	55	58	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 23	2003	278	21					19518	19525		10.1074/jbc.M211208200	http://dx.doi.org/10.1074/jbc.M211208200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	679PY	12637571	hybrid			2022-12-25	WOS:000182932200102
J	Kim, M; Ahn, JW; Jin, UH; Choi, D; Paek, KH; Pai, HS				Kim, M; Ahn, JW; Jin, UH; Choi, D; Paek, KH; Pai, HS			Activation of the programmed cell death pathway by inhibition of proteasome function in plants	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HYPERSENSITIVE RESPONSE; ARABIDOPSIS-THALIANA; DISEASE RESISTANCE; UBIQUITIN SYSTEM; 26S PROTEASOME; CYTOCHROME-C; APOPTOSIS; TOBACCO; MITOCHONDRIA; EXPRESSION	Proteasomes constitute the major machinery to degrade or process proteins by ATP/ubiquitin-mediated proteolysis. Recent findings suggest a pivotal role of the ubiquitin/ proteasome pathway in the regulation of apoptosis in animal cells. Here we show that virus-induced gene silencing of two different subunits of the 26 S proteasome, the alpha6 subunit of the 20 S proteasome and RPN9 subunit of 19 S regulatory complex, both activated the programmed cell death (PCD) program, accompanied by reduced proteasome activity and accumulation of polyubiquitinated proteins. These results demonstrate that disruption of proteasome function leads to PCD in plant cells. The affected cells showed morphological markers of PCD, including nuclear condensation and DNA fragmentation, accompanied by the 10-fold higher production of reactive oxygen species and increased ion leakage for 3-fold. Similar to apoptosis in animal system, mitochondrial membrane potential was decreased, cytochrome c released from mitochondria to cytosol, and caspase 9- and caspase 3-like proteolytic activities detected in the cells. Interestingly, this proteasome-mediated PCD stimulated the expression of only a subset of transcripts that are highly induced during pathogen-mediated hypersensitive response cell death, indicating that the two PCD pathways are differentially regulated. Taken together, these results provide the first direct evidence that proteasomes play a role in the regulatory program of PCD in plants. Controlled inhibition of proteasome activities may be involved in developmentally or environmentally activated plant cell death programs.	Korea Res Inst Biosci & Biotechnol, Lab Plant Genom, Taejon 305600, South Korea; Korea Univ, Grad Sch Biotechnol, Seoul 136701, South Korea	Korea Research Institute of Bioscience & Biotechnology (KRIBB); Korea University	Pai, HS (corresponding author), Korea Res Inst Biosci & Biotechnol, Lab Plant Genom, POB 115, Taejon 305600, South Korea.		Choi, Doil/F-5002-2011					Angell SM, 1999, PLANT J, V20, P357, DOI 10.1046/j.1365-313X.1999.t01-1-00597.x; Austin MJ, 2002, SCIENCE, V295, P2077, DOI 10.1126/science.1067747; Azevedo C, 2002, SCIENCE, V295, P2073, DOI 10.1126/science.1067554; Balk J, 1999, FEBS LETT, V463, P151, DOI 10.1016/S0014-5793(99)01611-7; Basset G, 2002, PLANT PHYSIOL, V128, P1149, DOI 10.1104/pp.010612; BECKER F, 1993, PLANT J, V3, P875, DOI 10.1111/j.1365-313X.1993.00875.x; Beers EP, 2000, PLANT MOL BIOL, V44, P399, DOI 10.1023/A:1026556928624; Bethke PC, 2001, PLANT J, V25, P19, DOI 10.1046/j.1365-313x.2001.00930.x; Callis J, 2000, CURR OPIN PLANT BIOL, V3, P381, DOI 10.1016/S1369-5266(00)00100-X; D'Silva I, 1998, EXP CELL RES, V245, P389, DOI 10.1006/excr.1998.4256; del Pozo O, 1998, CURR BIOL, V8, P1129, DOI 10.1016/S0960-9822(98)70469-5; Doelling JH, 2001, PLANT J, V27, P393, DOI 10.1046/j.1365-313X.2001.01106.x; EMORI Y, 1991, MOL CELL BIOL, V11, P344, DOI 10.1128/MCB.11.1.344; Ferri KF, 2001, BIOESSAYS, V23, P111, DOI 10.1002/1521-1878(200102)23:2<111::AID-BIES1016>3.3.CO;2-P; Fu HY, 2001, EMBO J, V20, P7096, DOI 10.1093/emboj/20.24.7096; Girod PA, 1999, PLANT CELL, V11, P1457; Gray WM, 2002, CURR BIOL, V12, pR352, DOI 10.1016/S0960-9822(02)00857-6; Green DR, 1998, CELL, V94, P695, DOI 10.1016/S0092-8674(00)81728-6; Grimm L M, 1999, Results Probl Cell Differ, V23, P209; Heath MC, 2000, PLANT MOL BIOL, V44, P321, DOI 10.1023/A:1026592509060; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; Hofmann K, 1998, TRENDS BIOCHEM SCI, V23, P204, DOI 10.1016/S0968-0004(98)01217-1; Jacobson MD, 1997, CELL, V88, P347, DOI 10.1016/S0092-8674(00)81873-5; Jesenberger V, 2002, NAT REV MOL CELL BIO, V3, P112, DOI 10.1038/nrm731; Korthout HAAJ, 2000, FEBS LETT, V475, P139, DOI 10.1016/S0014-5793(00)01643-4; Lacomme C, 1999, P NATL ACAD SCI USA, V96, P7956, DOI 10.1073/pnas.96.14.7956; Lam E, 2001, NATURE, V411, P848, DOI 10.1038/35081184; Lee SS, 2003, PLANT J, V33, P825, DOI 10.1046/j.1365-313X.2003.01672.x; Li ZY, 2002, J BIOL CHEM, V277, P42686, DOI 10.1074/jbc.M207183200; Liu Y, 2002, PLANT CELL, V14, P1483, DOI 10.1105/tpc.002493; Martin SJ, 2002, CELL, V109, P793, DOI 10.1016/S0092-8674(02)00802-4; Mlejnek P, 2002, PLANTA, V215, P158, DOI 10.1007/s00425-002-0733-5; Orlowski RZ, 1999, CELL DEATH DIFFER, V6, P303, DOI 10.1038/sj.cdd.4400505; OZAKI M, 1992, J BIOL CHEM, V267, P21678; Peart JR, 2002, P NATL ACAD SCI USA, V99, P10865, DOI 10.1073/pnas.152330599; Pontier D, 1999, PLANT MOL BIOL, V39, P1243, DOI 10.1023/A:1006133311402; Pontier D, 1998, MOL PLANT MICROBE IN, V11, P544, DOI 10.1094/MPMI.1998.11.6.544; Rubin DM, 1998, EMBO J, V17, P4909, DOI 10.1093/emboj/17.17.4909; SATO T, 1994, P NATL ACAD SCI USA, V91, P9238, DOI 10.1073/pnas.91.20.9238; STELLER H, 1995, SCIENCE, V267, P1445, DOI 10.1126/science.7878463; Sun YL, 1999, FEBS LETT, V462, P317, DOI 10.1016/S0014-5793(99)01539-2; Swidzinski JA, 2002, PLANT J, V30, P431, DOI 10.1046/j.1365-313X.2002.01301.x; Tsujimoto Y, 2002, BIOCHIMIE, V84, P187, DOI 10.1016/S0300-9084(02)01370-6; Uren AG, 2000, MOL CELL, V6, P961, DOI 10.1016/S1097-2765(05)00086-9; Vaux DL, 1999, CELL, V96, P245, DOI 10.1016/S0092-8674(00)80564-4; Voges D, 1999, ANNU REV BIOCHEM, V68, P1015, DOI 10.1146/annurev.biochem.68.1.1015; Waterhouse PM, 2001, NATURE, V411, P834, DOI 10.1038/35081168; Wertz IE, 1996, TRENDS BIOCHEM SCI, V21, P359, DOI 10.1016/0968-0004(96)40002-0; WILSON I, 1997, CURR BIOL, V7, P175; Woffenden BJ, 1998, PLANT PHYSIOL, V118, P419, DOI 10.1104/pp.118.2.419; Wojcik C, 2002, J BIOL CHEM, V277, P6188, DOI 10.1074/jbc.M109996200; Wojcik C, 1999, CELL MOL LIFE SCI, V56, P908, DOI 10.1007/s000180050483; Xu Y, 2000, PLANT PHYSIOL, V122, P1323, DOI 10.1104/pp.122.4.1323; Zhang H, 2001, ANAL BIOCHEM, V298, P170, DOI 10.1006/abio.2001.5348	54	169	180	1	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 23	2003	278	21					19406	19415		10.1074/jbc.M210539200	http://dx.doi.org/10.1074/jbc.M210539200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	679PY	12637532	hybrid			2022-12-25	WOS:000182932200089
J	Baker, KM; Wei, G; Schaffner, AE; Ostrowski, MC				Baker, KM; Wei, G; Schaffner, AE; Ostrowski, MC			Ets-2 and components of mammalian SWI/SNF form a repressor complex that negatively regulates the BRCA1 promoter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SPORADIC BREAST-CANCER; COLONY-STIMULATING FACTOR; TRANSCRIPTION FACTORS; OVARIAN-CANCER; CELL-CYCLE; MATRIX METALLOPROTEINASES; SACCHAROMYCES-CEREVISIAE; GLUCOCORTICOID RECEPTOR; REMODELING COMPLEXES; GENE-EXPRESSION	Ets-2 is a transcriptional activator that can be modulated by ras-dependent phosphorylation. Evidence is presented indicating that ets-2 can also act as a transcriptional repressor. In the breast cancer cell line MCF-7, exogenous ets-2 repressed the activity of a BRCA1 promoter-luciferase reporter dependent on a conserved ets-2-binding site in this promoter. Conditional overproduction of ets-2 in MCF-7 cells resulted in repression of endogenous BRCA1 mRNA expression. To address the mechanism by which ets-2 could act as a repressor, a biochemical approach was used to identify proteins that interacted with the ets-2 pointed domain. From this analysis, components of the mammalian SWI/SNF chromatin remodeling complex were found to interact with ets-2. Brg-1, the ATP-hydrolyzing component of the SWI/SNF complex, along with the BAF57/p50 and Ini1 subunits could be co-immunoprecipitated from cells with ets-2. The pointed domain of ets-2 directly interacted in vitro with the C-terminal region of Brg-1 in a phosphorylation-dependent manner. The combination of Brg-1 and ets-2 could repress the BRCA1 promoter reporter in transfection assays. These results support a role for ets-2 as a repressor and indicate that components of the mammalian SNF/SWI complex are required as co-repressors.	Ohio State Univ, Dept Mol Genet, Columbus, OH 43210 USA; Ohio State Univ, Ctr Comprehens Canc, Columbus, OH 43210 USA	University System of Ohio; Ohio State University; James Cancer Hospital & Solove Research Institute; University System of Ohio; Ohio State University	Ostrowski, MC (corresponding author), Ohio State Univ, Dept Mol Genet, 484 W 12th Ave, Columbus, OH 43210 USA.		Ostrowski, Michael/H-3108-2011	Ostrowski, Michael/0000-0003-2948-6297	NCI NIH HHS [CA-53271] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA053271] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Atlas E, 2000, ONCOGENE, V19, P1933, DOI 10.1038/sj.onc.1203516; Bianco T, 2000, CARCINOGENESIS, V21, P147, DOI 10.1093/carcin/21.2.147; BRUNNER D, 1994, NATURE, V370, P386, DOI 10.1038/370386a0; Catteau A, 1999, ONCOGENE, V18, P1957, DOI 10.1038/sj.onc.1202509; DUNAIEF JL, 1994, CELL, V79, P119, DOI 10.1016/0092-8674(94)90405-7; Foos G, 2001, METHOD ENZYMOL, V333, P61; Ford D, 1998, AM J HUM GENET, V62, P676, DOI 10.1086/301749; Fowles LF, 1998, MOL CELL BIOL, V18, P5148, DOI 10.1128/MCB.18.9.5148; Fryer CJ, 1998, NATURE, V393, P88, DOI 10.1038/30032; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; Graves BJ, 1998, ADV CANCER RES, V75, P1, DOI 10.1016/S0065-230X(08)60738-1; Ha HY, 2001, CANCER RES, V61, P984; Haas TL, 1999, J BIOL CHEM, V274, P22679, DOI 10.1074/jbc.274.32.22679; Hager GL, 2001, PROG NUCLEIC ACID RE, V66, P279; KWOK RPS, 1994, NATURE, V370, P223, DOI 10.1038/370223a0; LANGER SJ, 1988, MOL CELL BIOL, V8, P3872, DOI 10.1128/MCB.8.9.3872; Liu R, 2001, CELL, V106, P309, DOI 10.1016/S0092-8674(01)00446-9; Magdinier F, 1998, ONCOGENE, V17, P3169, DOI 10.1038/sj.onc.1202248; Martens JA, 2002, GENE DEV, V16, P2231, DOI 10.1101/gad.1009902; McCarthy SA, 1997, MOL CELL BIOL, V17, P2401, DOI 10.1128/MCB.17.5.2401; MUCHARDT C, 1993, EMBO J, V12, P4279, DOI 10.1002/j.1460-2075.1993.tb06112.x; Muchardt C, 2001, ONCOGENE, V20, P3067, DOI 10.1038/sj.onc.1204331; ONEILL EM, 1994, CELL, V78, P137, DOI 10.1016/0092-8674(94)90580-0; Patton SE, 1998, CANCER RES, V58, P2253; Rabault B, 1996, ONCOGENE, V13, P877; Rice JC, 1998, ONCOGENE, V17, P1807, DOI 10.1038/sj.onc.1202086; Schnitzler G, 1998, CELL, V94, P17, DOI 10.1016/S0092-8674(00)81217-9; Sementchenko VI, 1998, ONCOGENE, V17, P2883, DOI 10.1038/sj.onc.1202220; Sevilla L, 1999, MOL CELL BIOL, V19, P2624; Sif S, 2001, GENE DEV, V15, P603, DOI 10.1101/gad.872801; Smith JL, 2000, MOL CELL BIOL, V20, P8026, DOI 10.1128/MCB.20.21.8026-8034.2000; STACEY KJ, 1995, MOL CELL BIOL, V15, P3430; Sudarsanam P, 2000, TRENDS GENET, V16, P345, DOI 10.1016/S0168-9525(00)02060-6; Suen TC, 1999, J BIOL CHEM, V274, P31297, DOI 10.1074/jbc.274.44.31297; Thakur S, 1999, J BIOL CHEM, V274, P8837, DOI 10.1074/jbc.274.13.8837; Thant AA, 1997, FEBS LETT, V406, P28, DOI 10.1016/S0014-5793(97)00230-5; THOMPSON ME, 1995, NAT GENET, V9, P444, DOI 10.1038/ng0495-444; Treisman R, 1996, CURR OPIN CELL BIOL, V8, P205, DOI 10.1016/S0955-0674(96)80067-6; Trouche D, 1997, P NATL ACAD SCI USA, V94, P11268, DOI 10.1073/pnas.94.21.11268; Ueno H, 1997, CANCER RES, V57, P2055; Wasylyk C, 1997, ONCOGENE, V14, P899, DOI 10.1038/sj.onc.1200914; WASYLYK C, 1992, CELL GROWTH DIFFER, V3, P617; Weng LP, 1999, CANCER RES, V59, P5808; XU CF, 1995, HUM MOL GENET, V4, P2259, DOI 10.1093/hmg/4.12.2259; Xu CF, 1997, J BIOL CHEM, V272, P20994, DOI 10.1074/jbc.272.34.20994; Yang BS, 1996, MOL CELL BIOL, V16, P538; Zhang HS, 2000, CELL, V101, P79, DOI 10.1016/S0092-8674(00)80625-X	47	67	70	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 16	2003	278	20					17876	17884		10.1074/jbc.M209480200	http://dx.doi.org/10.1074/jbc.M209480200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677YX	12637547	hybrid, Green Published			2022-12-25	WOS:000182838300037
J	Mathieu, N; Spicuglia, S; Gorbatch, S; Cabaud, O; Fernex, C; Verthuy, C; Hempel, WM; Hueber, AO; Ferrier, P				Mathieu, N; Spicuglia, S; Gorbatch, S; Cabaud, O; Fernex, C; Verthuy, C; Hempel, WM; Hueber, AO; Ferrier, P			Assessing the role of the T cell receptor beta gene enhancer in regulating coding joint formation during V(D)J recombination	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALLELIC EXCLUSION; THYMOCYTE DIFFERENTIATION; CD4(+)CD8(+) THYMOCYTE; BCL-2 EXPRESSION; DEFICIENT MICE; RAG PROTEINS; B-CELLS; LOCUS; DNA; ACCESSIBILITY	To assess the role of the T cell receptor (TCR) beta gene enhancer (Ebeta) in regulating the processing of VDJ recombinase-generated coding ends, we assayed TCRbeta rearrangement of Ebeta-deleted (DeltaEbeta) thymocytes in which cell death is inhibited via expression of a Bcl-2 transgene. Compared with DeltaEbeta, DeltaEbeta Bcl-2 thymocytes show a small accumulation of TCRbeta standard recombination products, including coding ends, that involves the proximal Dbeta-Jbeta and Vbeta14 loci but not the distal 5' Vbeta genes. These effects are detectable in double negative pro-T cells, predominate in double positive pre-T cells, and correlate with regional changes in chromosomal structure during double negative-to-double positive differentiation. We propose that Ebeta, by driving long range nucleoprotein interactions and the control of locus expression and chromatin structure, indirectly contributes to the stabilization of coding ends within the recombination processing complexes. The results also illustrate Ebeta-dependent and -independent changes in chromosomal structure, suggesting distinct modes of regulation of TCRbeta allelic exclusion depending on the position within the locus.	Univ Mediterranee, CNRS, INSERM, Ctr Immunol Marseille Luminy, F-13288 Marseille, France	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Aix-Marseille Universite	Ferrier, P (corresponding author), CIML, Case 906, F-13288 Marseille 9, France.		Anne-Odile, Hueber/G-4352-2013; Anne-Odile, Hueber/P-9860-2019; Spicuglia, Salvatore/L-2268-2016	Anne-Odile, Hueber/0000-0003-3816-2446; Anne-Odile, Hueber/0000-0003-3816-2446; Spicuglia, Salvatore/0000-0002-8101-7108				Akashi K, 1997, CELL, V89, P1033, DOI 10.1016/S0092-8674(00)80291-3; Bassing CH, 2002, CELL, V109, pS45, DOI 10.1016/S0092-8674(02)00675-X; Bories JC, 1996, P NATL ACAD SCI USA, V93, P7871, DOI 10.1073/pnas.93.15.7871; Bouvier G, 1996, P NATL ACAD SCI USA, V93, P7877, DOI 10.1073/pnas.93.15.7877; Chattopadhyay S, 1998, J BIOL CHEM, V273, P29838, DOI 10.1074/jbc.273.45.29838; Chattopadhyay S, 1998, J IMMUNOL, V160, P1256; Chen F, 2001, J IMMUNOL, V166, P1771, DOI 10.4049/jimmunol.166.3.1771; Fugmann SD, 2000, ANNU REV IMMUNOL, V18, P495, DOI 10.1146/annurev.immunol.18.1.495; Gellert M, 2002, ANNU REV BIOCHEM, V71, P101, DOI 10.1146/annurev.biochem.71.090501.150203; Glusman G, 2001, IMMUNITY, V15, P337, DOI 10.1016/S1074-7613(01)00200-X; Guo J, 2002, NAT IMMUNOL, V3, P469, DOI 10.1038/ni791; Hempel WM, 1998, GENE DEV, V12, P2305, DOI 10.1101/gad.12.15.2305; Hesslein DGT, 2001, ADV IMMUNOL, V78, P169, DOI 10.1016/S0065-2776(01)78004-2; Jenuwein T, 1997, NATURE, V385, P269, DOI 10.1038/385269a0; Khor B, 2002, CURR OPIN IMMUNOL, V14, P230, DOI 10.1016/S0952-7915(02)00326-6; Krangel MS, 2001, J EXP MED, V193, pF27, DOI 10.1084/jem.193.7.F27; KRIMPENFORT P, 1988, EMBO J, V7, P745, DOI 10.1002/j.1460-2075.1988.tb02871.x; Laird DJ, 2000, P NATL ACAD SCI USA, V97, P6924, DOI 10.1073/pnas.97.13.6924; Lang J, 1997, J EXP MED, V186, P1513, DOI 10.1084/jem.186.9.1513; Leduc I, 2000, J IMMUNOL, V165, P1364, DOI 10.4049/jimmunol.165.3.1364; LEWIS SM, 1994, ADV IMMUNOL, V56, P29; LINETTE GP, 1994, IMMUNITY, V1, P197, DOI 10.1016/1074-7613(94)90098-1; Ma YM, 2002, CELL, V108, P781, DOI 10.1016/S0092-8674(02)00671-2; Maraskovsky E, 1997, CELL, V89, P1011, DOI 10.1016/S0092-8674(00)80289-5; Mathieu N, 2000, J EXP MED, V192, P625, DOI 10.1084/jem.192.5.625; Melek M, 2000, CELL, V101, P625, DOI 10.1016/S0092-8674(00)80874-0; Melek M, 1998, SCIENCE, V280, P301, DOI 10.1126/science.280.5361.301; MIZUUCHI K, 1992, ANNU REV BIOCHEM, V61, P1011; Mizuuchi M, 2001, EMBO J, V20, P6927, DOI 10.1093/emboj/20.23.6927; Mostoslavsky R, 2001, NATURE, V414, P221, DOI 10.1038/35102606; Mundy CL, 2002, MOL CELL BIOL, V22, P69, DOI 10.1128/MCB.22.1.69-77.2002; Neiditch MB, 2002, MOL CELL, V9, P871, DOI 10.1016/S1097-2765(02)00494-X; PIRCHER H, 1990, EUR J IMMUNOL, V20, P417, DOI 10.1002/eji.1830200227; RATHBUN G, 1989, NATURE, V342, P863, DOI 10.1038/342863a0; Rich T, 2000, NATURE, V407, P777, DOI 10.1038/35037717; Roth DB, 2000, CELL, V103, P699, DOI 10.1016/S0092-8674(00)00173-2; Saintigny Y, 2001, EMBO J, V20, P2596, DOI 10.1093/emboj/20.10.2596; Sekiguchi J, 2001, MOL CELL, V8, P1383, DOI 10.1016/S1097-2765(01)00423-3; Sekiguchi J, 2001, P NATL ACAD SCI USA, V98, P3243, DOI 10.1073/pnas.051632098; Senoo M, 2001, INT IMMUNOL, V13, P1405, DOI 10.1093/intimm/13.11.1405; SHINKAI Y, 1994, INT IMMUNOL, V6, P995, DOI 10.1093/intimm/6.7.995; Sieh P, 2001, J IMMUNOL, V167, P2121, DOI 10.4049/jimmunol.167.4.2121; STRASSER A, 1991, CELL, V67, P889, DOI 10.1016/0092-8674(91)90362-3; Struhl K, 1998, GENE DEV, V12, P599, DOI 10.1101/gad.12.5.599; Tevelev A, 2000, J BIOL CHEM, V275, P8341, DOI 10.1074/jbc.275.12.8341; Tillman RE, 2002, J EXP MED, V195, P309, DOI 10.1084/jem.20011803; Tripathi R, 2002, J IMMUNOL, V168, P2316, DOI 10.4049/jimmunol.168.5.2316; Whitehurst CE, 1999, IMMUNITY, V10, P313, DOI 10.1016/S1074-7613(00)80031-X; Whitehurst CE, 2001, MOL IMMUNOL, V38, P55, DOI 10.1016/S0161-5890(01)00031-1; Young F, 1997, IMMUNITY, V6, P23, DOI 10.1016/S1074-7613(00)80239-3; ZHU CM, 1995, IMMUNITY, V2, P101, DOI 10.1016/1074-7613(95)90082-9	51	24	24	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 16	2003	278	20					18101	18109		10.1074/jbc.M212647200	http://dx.doi.org/10.1074/jbc.M212647200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677YX	12639959	hybrid			2022-12-25	WOS:000182838300067
J	Cho, DSC; Yang, WD; Lee, JT; Shiekhattar, R; Murray, JM; Nishikura, K				Cho, DSC; Yang, WD; Lee, JT; Shiekhattar, R; Murray, JM; Nishikura, K			Requirement of dimerization for RNA editing activity of adenosine deaminases acting on RNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PRE-MESSENGER-RNAS; DNA BINDING DOMAIN; PROTEIN-KINASE PKR; B R/G SITE; GLUR-B; CAENORHABDITIS-ELEGANS; IN-VITRO; SUBSTRATE RECOGNITION; CYTIDINE DEAMINASE; CANDIDATE ENZYME	Adenosine deaminases acting on RNA (ADAR) convert adenosine residues into inosines in double-stranded RNA. Three vertebrate ADAR gene family members, ADAR1, ADAR2, and ADAR3, have been identified. The catalytic domain of all three ADAR gene family members is very similar to that of Escherichia coli cytidine deaminase and APOBEC-1. Homodimerization is essential for the enzyme activity of those cytidine deaminases. In this study, we investigated the formation of complexes between differentially epitope-tagged ADAR monomers by sequential affinity chromatography and size exclusion column chromatography. Both ADAR1 and ADAR2 form a stable enzymatically active homodimer complex, whereas ADAR3 remains as a monomeric, enzymatically inactive form. No heterodimer complex formation among different ADAR gene family members was detected. Analysis of HeLa and mouse brain nuclear extracts suggested that endogenous ADAR1 and ADAR2 both form a homodimer complex. Interestingly, endogenous ADAR3 also appears to form a homodimer complex, indicating the presence of a brain-specific mechanism for ADAR3 dimerization. Homodimer formation may be necessary for ADAR to act as active deaminases. Analysis of dimer complexes consisting of one wild-type and one mutant monomer suggests functional interactions between the two subunits during site-selective RNA editing.	Wistar Inst Anat & Biol, Philadelphia, PA 19104 USA; Univ Penn, Dept Cell & Dev Biol, Philadelphia, PA 19104 USA	The Wistar Institute; University of Pennsylvania	Nishikura, K (corresponding author), Wistar Inst Anat & Biol, 3601 Spruce St, Philadelphia, PA 19104 USA.							Bass BL, 2002, ANNU REV BIOCHEM, V71, P817, DOI 10.1146/annurev.biochem.71.110601.135501; BETTS L, 1994, J MOL BIOL, V235, P635, DOI 10.1006/jmbi.1994.1018; Burns CM, 1997, NATURE, V387, P303, DOI 10.1038/387303a0; Carpick BW, 1997, J BIOL CHEM, V272, P9510, DOI 10.1074/jbc.272.14.9510; Chen CX, 2000, RNA, V6, P755, DOI 10.1017/S1355838200000170; Dabiri GA, 1996, EMBO J, V15, P34, DOI 10.1002/j.1460-2075.1996.tb00331.x; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Eckmann CR, 2001, MOL BIOL CELL, V12, P1911, DOI 10.1091/mbc.12.7.1911; Fitzgerald LW, 1999, NEUROPSYCHOPHARMACOL, V21, pS82, DOI 10.1038/sj.npp.1395328; Gerber A, 1997, RNA, V3, P453; Gerber A, 1998, EMBO J, V17, P4780, DOI 10.1093/emboj/17.16.4780; Gerber AP, 2001, TRENDS BIOCHEM SCI, V26, P376, DOI 10.1016/S0968-0004(01)01827-8; Gerber AP, 1999, SCIENCE, V286, P1146, DOI 10.1126/science.286.5442.1146; Herb A, 1996, P NATL ACAD SCI USA, V93, P1875, DOI 10.1073/pnas.93.5.1875; Herbert A, 1997, P NATL ACAD SCI USA, V94, P8421, DOI 10.1073/pnas.94.16.8421; Higuchi M, 2000, NATURE, V406, P78, DOI 10.1038/35017558; HIGUCHI M, 1993, CELL, V75, P1361, DOI 10.1016/0092-8674(93)90622-W; Hough RF, 1999, NUCLEIC ACIDS RES, V27, P3424, DOI 10.1093/nar/27.17.3424; HOUGH RF, 1994, J BIOL CHEM, V269, P9933; Jaikaran DCJ, 2002, J BIOL CHEM, V277, P37624, DOI 10.1074/jbc.M204126200; KIM U, 1994, J BIOL CHEM, V269, P13480; KIM U, 1994, P NATL ACAD SCI USA, V91, P11457, DOI 10.1073/pnas.91.24.11457; Knight SW, 2002, MOL CELL, V10, P809, DOI 10.1016/S1097-2765(02)00649-4; KOHLER M, 1993, NEURON, V10, P491, DOI 10.1016/0896-6273(93)90336-P; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; Lai F, 1997, MOL CELL BIOL, V17, P2413, DOI 10.1128/MCB.17.5.2413; LAI F, 1995, J BIOL CHEM, V270, P17098, DOI 10.1074/jbc.270.29.17098; LAU PP, 1994, P NATL ACAD SCI USA, V91, P8522, DOI 10.1073/pnas.91.18.8522; Liu Y, 1999, J BIOL CHEM, V274, P18351, DOI 10.1074/jbc.274.26.18351; LOMELI H, 1994, SCIENCE, V266, P1709, DOI 10.1126/science.7992055; Maas S, 2003, J BIOL CHEM, V278, P1391, DOI 10.1074/jbc.R200025200; Maas S, 1996, J BIOL CHEM, V271, P12221, DOI 10.1074/jbc.271.21.12221; MACGINNITIE AJ, 1995, J BIOL CHEM, V270, P14768, DOI 10.1074/jbc.270.24.14768; Melcher T, 1996, J BIOL CHEM, V271, P31795, DOI 10.1074/jbc.271.50.31795; Melcher T, 1996, NATURE, V379, P460, DOI 10.1038/379460a0; Morse DP, 2002, P NATL ACAD SCI USA, V99, P7906, DOI 10.1073/pnas.112704299; Navaratnam N, 1998, J MOL BIOL, V275, P695, DOI 10.1006/jmbi.1997.1506; NISHIKURA K, 1991, EMBO J, V10, P3523, DOI 10.1002/j.1460-2075.1991.tb04916.x; Niswender CM, 1999, J BIOL CHEM, V274, P9472, DOI 10.1074/jbc.274.14.9472; OCONNELL MA, 1994, P NATL ACAD SCI USA, V91, P10596, DOI 10.1073/pnas.91.22.10596; OCONNELL MA, 1995, MOL CELL BIOL, V15, P1389; Ohman M, 2000, RNA, V6, P687, DOI 10.1017/S1355838200000200; Ortega LG, 1996, VIROLOGY, V215, P31, DOI 10.1006/viro.1996.0004; Palladino MJ, 2000, CELL, V102, P437, DOI 10.1016/S0092-8674(00)00049-0; PATTERSON JB, 1995, MOL CELL BIOL, V15, P5376, DOI DOI 10.1128/MCB.15.10.5376; Poulsen H, 2001, MOL CELL BIOL, V21, P7862, DOI 10.1128/MCB.21.22.7862-7871.2001; RAIZKIN O, 2001, P NATL ACAD SCI USA, V98, P6571; Rueter SM, 1999, NATURE, V399, P75, DOI 10.1038/19992; Slavov D, 2000, GENE, V250, P53, DOI 10.1016/S0378-1119(00)00175-X; SLAVOV D, 2000, GENE, V250, P45; Tan SL, 1998, MOL CELL BIOL, V18, P2431, DOI 10.1128/MCB.18.5.2431; Tonkin LA, 2002, EMBO J, V21, P6025, DOI 10.1093/emboj/cdf607; WAGNER RW, 1988, MOL CELL BIOL, V8, P770, DOI 10.1128/MCB.8.2.770; Wang Q, 2000, SCIENCE, V290, P1765, DOI 10.1126/science.290.5497.1765; Wang QD, 2000, J NEUROCHEM, V74, P1290; Wong SK, 2001, RNA, V7, P846, DOI 10.1017/S135583820101007X	56	143	161	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 9	2003	278	19					17093	17102		10.1074/jbc.M213127200	http://dx.doi.org/10.1074/jbc.M213127200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677QG	12618436	hybrid			2022-12-25	WOS:000182818600087
J	Kornilova, AY; Das, C; Wolfe, MS				Kornilova, AY; Das, C; Wolfe, MS			Differential effects of inhibitors on the gamma-secretase complex - Mechanistic implications	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-APP; PRESENILIN; IDENTIFICATION; NICASTRIN; TARGETS; PATHWAY; APH-1; PEN-2	gamma-Secretase is a protease complex of four integral membrane proteins, with presenilin (PS) as the apparent catalytic component, and this enzyme processes the transmembrane domains of a variety of substrates, including the amyloid beta-protein precursor and the Notch receptor. Here we explore the mechanisms of structurally diverse gamma-secretase inhibitors by examining their ability to displace an active site-directed photoprobe from PS heterodimers. Most gamma-secretase inhibitors, including a potent inhibitor of the PS-like signal peptide peptidase, blocked the photoprobe from binding to PS1, indicating that these compounds either bind directly to the active site or alter it through an allosteric interaction. Conversely, some reported inhibitors failed to displace this interaction, demonstrating that these compounds do not interfere with the protease by affecting its active site. Differential effects of the inhibitors with respect to photoprobe displacement and in cell-based and cell-free assays suggest that these compounds are important mechanistic tools for deciphering the workings of this intramembrane-cleaving protease complex and its similarity to other polytopic aspartyl proteases.	Brigham & Womens Hosp, Ctr Neurol Dis, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School	Wolfe, MS (corresponding author), Brigham & Womens Hosp, Ctr Neurol Dis, Boston, MA 02115 USA.	mwolfe@rics.bwh.harvard.edu	Das, Chittaranjan/AAM-1686-2020		NIA NIH HHS [AG17574] Funding Source: Medline; NINDS NIH HHS [NS41355] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS041355] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG017574] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Dovey HF, 2001, J NEUROCHEM, V76, P173, DOI 10.1046/j.1471-4159.2001.00012.x; Esler WP, 2002, NAT CELL BIOL, V4, pE110, DOI 10.1038/ncb0502-e110b; Esler WP, 2002, P NATL ACAD SCI USA, V99, P2720, DOI 10.1073/pnas.052436599; Esler WP, 2001, SCIENCE, V293, P1449, DOI 10.1126/science.1064638; Esler WP, 2000, NAT CELL BIOL, V2, P428, DOI 10.1038/35017062; Francis R, 2002, DEV CELL, V3, P85, DOI 10.1016/S1534-5807(02)00189-2; Goutte C, 2002, P NATL ACAD SCI USA, V99, P775, DOI 10.1073/pnas.022523499; Gu YJ, 2003, J BIOL CHEM, V278, P7374, DOI 10.1074/jbc.M209499200; Li YM, 2000, P NATL ACAD SCI USA, V97, P6138, DOI 10.1073/pnas.110126897; Li YM, 2000, NATURE, V405, P689, DOI 10.1038/35015085; McLendon C, 2000, FASEB J, V14, P2383; Micchelli CA, 2002, FASEB J, V16, P79, DOI 10.1096/fj.02-0394fje; Petit A, 2001, NAT CELL BIOL, V3, P507, DOI 10.1038/35074581; Ponting CP, 2002, HUM MOL GENET, V11, P1037, DOI 10.1093/hmg/11.9.1037; Seiffert D, 2000, J BIOL CHEM, V275, P34086, DOI 10.1074/jbc.M005430200; Steiner H, 2002, J BIOL CHEM, V277, P39062, DOI 10.1074/jbc.C200469200; Tian GC, 2002, J BIOL CHEM, V277, P31499, DOI 10.1074/jbc.M112328200; Weihofen A, 2002, SCIENCE, V296, P2215, DOI 10.1126/science.1070925; Wolfe MS, 2002, SCIENCE, V296, P2156, DOI 10.1126/science.1073844; Wolfe MS, 2001, J MED CHEM, V44, P2039, DOI 10.1021/jm0004897; Wolfe MS, 2001, J BIOL CHEM, V276, P5413, DOI 10.1074/jbc.R000026200; Wolfe MS, 1999, BIOCHEMISTRY-US, V38, P4720, DOI 10.1021/bi982562p; Wolfe MS, 1999, NATURE, V398, P513, DOI 10.1038/19077; Yu G, 2000, NATURE, V407, P48, DOI 10.1038/35024009; Yu ZH, 1996, J AM CHEM SOC, V118, P5846, DOI 10.1021/ja954069w	25	100	107	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 9	2003	278	19					16470	16473		10.1074/jbc.C300019200	http://dx.doi.org/10.1074/jbc.C300019200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677QG	12644463	hybrid			2022-12-25	WOS:000182818600004
J	Narayanan, K; Ramachandran, A; Hao, JJ; He, G; Park, KW; Cho, M; George, A				Narayanan, K; Ramachandran, A; Hao, JJ; He, G; Park, KW; Cho, M; George, A			Dual functional roles of dentin matrix protein 1 - Implications in biomineralization and gene transcription by activation of intracellular Ca2+ store	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RING-FINGER DOMAIN; OSTEOBLAST DIFFERENTIATION; NUCLEAR EXPORT; BONE-FORMATION; EXPRESSION; TRANSPORT; LOCALIZATION; PHOSPHATE; INDUCTION; PATHWAY	Dentin matrix protein 1 (DMP1) is a bone- and teeth-specific protein initially identified from mineralized dentin. Here we report that DMP1 is primarily localized in the nuclear compartment of undifferentiated osteoblasts. In the nucleus, DMP1 acts as a transcriptional component for activation of osteoblast-specific genes like osteocalcin. During the early phase of osteoblast maturation, Ca2+ surges into the nucleus from the cytoplasm, triggering the phosphorylation of DMP1 by a nuclear isoform of casein kinase II. This phosphorylated DMP1 is then exported out into the extracellular matrix, where it regulates nucleation of hydroxyapatite. Thus, DMP1 is a unique molecule that initiates osteoblast differentiation by transcription in the nucleus and orchestrates mineralized matrix formation extracellularly, at later stages of osteoblast maturation. The data presented here represent a paradigm shift in the understanding of DMP1 function. This information is crucial in understanding normal bone formation, remodeling, fracture healing, and skeletal tissue repair.	Univ Illinois, Dept Oral Biol, Chicago, IL 60612 USA; Univ Illinois, Dept Bioengn, Chicago, IL 60607 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	George, A (corresponding author), Univ Illinois, Dept Oral Biol, 801 S Paulina St, Chicago, IL 60612 USA.		Narayanan, Karthikeyan/D-1957-2010	Narayanan, Karthikeyan/0000-0001-5136-2296; Cho, Myoung Rae/0000-0002-8191-8045; GEORGE, ANNE/0000-0002-9008-7642	NIDCR NIH HHS [DE-11657, DE-13836] Funding Source: Medline; NIGMS NIH HHS [GM60741] Funding Source: Medline; NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [R01DE011657] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R56DE011657, R01DE013836] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM060741] Funding Source: NIH RePORTER	NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Adebanjo OA, 2000, AM J PHYSIOL-RENAL, V278, pF784, DOI 10.1152/ajprenal.2000.278.5.F784; Beck GR, 2000, P NATL ACAD SCI USA, V97, P8352, DOI 10.1073/pnas.140021997; Boyd SD, 2000, NAT CELL BIOL, V2, P563, DOI 10.1038/35023500; DEMAUREX N, 1992, J BIOL CHEM, V267, P2318; DSouza RN, 1997, J BONE MINER RES, V12, P2040, DOI 10.1359/jbmr.1997.12.12.2040; Ducy P, 1997, CELL, V89, P747, DOI 10.1016/S0092-8674(00)80257-3; Ducy P, 1999, GENE DEV, V13, P1025, DOI 10.1101/gad.13.8.1025; Faust M, 2000, CELL TISSUE RES, V301, P329, DOI 10.1007/s004410000256; GEORGE A, 1994, J HISTOCHEM CYTOCHEM, V42, P1527, DOI 10.1177/42.12.7983353; GEORGE A, 1993, J BIOL CHEM, V268, P12624; GERASIMENKO OV, 1995, CELL, V80, P439, DOI 10.1016/0092-8674(95)90494-8; Geyer RK, 2000, NAT CELL BIOL, V2, P569, DOI 10.1038/35023507; HARLOW E, 1998, ANTIBODIES LAB MANUA, P421; He G, 2003, CONNECT TISSUE RES, V44, P240, DOI 10.1080/03008200390181726; Humbert JP, 1996, J BIOL CHEM, V271, P478, DOI 10.1074/jbc.271.1.478; Jans DA, 1996, PHYSIOL REV, V76, P651, DOI 10.1152/physrev.1996.76.3.651; Kao HY, 2001, J BIOL CHEM, V276, P47496, DOI 10.1074/jbc.M107631200; Karsenty G, 2001, ENDOCRINOLOGY, V142, P2731, DOI 10.1210/en.142.7.2731; Lundgren T, 2001, CALCIFIED TISSUE INT, V68, P192, DOI 10.1007/s002230010015; MacDougall M, 1998, J BONE MINER RES, V13, P422, DOI 10.1359/jbmr.1998.13.3.422; McKinsey TA, 2000, NATURE, V408, P106, DOI 10.1038/35040593; Misteli T, 2001, SCIENCE, V291, P843, DOI 10.1126/science.291.5505.843; Nakashima K, 2002, CELL, V108, P17, DOI 10.1016/S0092-8674(01)00622-5; Narayanan K, 2001, P NATL ACAD SCI USA, V98, P4516, DOI 10.1073/pnas.081075198; Otto F, 1997, CELL, V89, P765, DOI 10.1016/S0092-8674(00)80259-7; Srinivasan R, 1999, CONNECT TISSUE RES, V40, P251, DOI 10.3109/03008209909000703; Timmerman LA, 1996, NATURE, V383, P837, DOI 10.1038/383837a0; Yoneda Y, 2000, GENES CELLS, V5, P777, DOI 10.1046/j.1365-2443.2000.00366.x	28	191	200	0	21	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 9	2003	278	19					17500	17508		10.1074/jbc.M212700200	http://dx.doi.org/10.1074/jbc.M212700200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677QG	12615915	hybrid			2022-12-25	WOS:000182818600138
J	Schweppe, RE; Melton, AA; Brodsky, KS; Aveline, LD; Resing, KA; Ahn, NG; Gutierrez-Hartmann, A				Schweppe, RE; Melton, AA; Brodsky, KS; Aveline, LD; Resing, KA; Ahn, NG; Gutierrez-Hartmann, A			Purification and mass spectrometric identification of GA-binding protein (GABP) as the functional pituitary Ets factor binding to the basal transcription element of the prolactin promoter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENE-EXPRESSION; RESPONSE ELEMENT; SIGNALING PATHWAY; INSULIN; CELLS; RAS; FAMILY; KINASE; ALPHA; COMPONENTS	The Ets-binding site within the basal transcription element (BTE) of the rat prolactin (rPRL) promoter is critical for both basal and growth factor-regulated rPRL gene expression. Here we report the purification and identification of the factor that binds to the BTE. This factor was purified from GH3 pituitary nuclear extracts using ammonium sulfate fractionation, heparin-Sepharose and Mono Q chromatography, and BTE-affinity magnetic beads. We purified two proteins of 57 and 47 kDa and identified the 57-kDa protein by mass spectrometry as the Ets factor GABPalpha. Western blot analysis identified the 47-kDa protein as GABPbeta1. Co-transfection of dominant-negative GABPbeta1 blocks prolactin promoter basal activity by 85-88% in GH3 cells in the presence or absence of FGF-4. Additionally, expression of wild-type GABPalpha/beta1 selectively activates a minimal BTE promoter 24-28-fold in GH3 cells, and this activation is dependent on the Ets-binding site. Finally, small interfering RNA depletion of GABP in GH3 cells results in the loss of prolactin protein. Thus, we have identified GABPalpha/GABPbeta1 as a critical and functionally relevant Ets factor that regulates rPRL promoter activity via the BTE site.	Univ Colorado, Hlth Sci Ctr, Dept Biochem & Mol Genet, Program Mol Biol, Denver, CO 80262 USA; Univ Colorado, Hlth Sci Ctr, Dept Med, Denver, CO 80262 USA; Univ Colorado, Hlth Sci Ctr, Colorado Canc Ctr, Denver, CO 80262 USA; Univ Colorado, Dept Chem & Biochem, Boulder, CO 80309 USA; Univ Colorado, Howard Hughes Med Inst, Boulder, CO 80309 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Boulder; Howard Hughes Medical Institute; University of Colorado System; University of Colorado Boulder	Gutierrez-Hartmann, A (corresponding author), Univ Colorado, Hlth Sci Ctr, Dept Biochem & Mol Genet, Program Mol Biol, 4200 E 9th Ave,Box B-151, Denver, CO 80262 USA.		Gutierrez-Hartmann, Arthur/F-1295-2011	Schweppe, Rebecca/0000-0001-7502-0151	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R29AR039730] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK046868, R56DK046868] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR39730] Funding Source: Medline; NIDDK NIH HHS [DK46868] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Boccia LM, 1996, MOL CELL BIOL, V16, P1929; Bochert MA, 1998, BIOCHEM BIOPH RES CO, V246, P176, DOI 10.1006/bbrc.1998.8560; Bradford AP, 1996, J BIOL CHEM, V271, P24639, DOI 10.1074/jbc.271.40.24639; Bradford AP, 1997, MOL CELL BIOL, V17, P1065, DOI 10.1128/MCB.17.3.1065; Briguet A, 2000, J NEUROSCI, V20, P5989, DOI 10.1523/JNEUROSCI.20-16-05989.2000; BROWN TA, 1992, GENE DEV, V6, P2502, DOI 10.1101/gad.6.12b.2502; Castillo AI, 1998, ONCOGENE, V16, P1981, DOI 10.1038/sj.onc.1200204; CONRAD KE, 1994, MOL CELL BIOL, V14, P1553, DOI 10.1128/MCB.14.3.1553; DELABROUSSE FC, 1994, GENE DEV, V8, P1853, DOI 10.1101/gad.8.15.1853; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; ENG JK, 1994, J AM SOC MASS SPECTR, V5, P976, DOI 10.1016/1044-0305(94)80016-2; Graves BJ, 1998, SCIENCE, V279, P1000, DOI 10.1126/science.279.5353.1000; Graves BJ, 1998, ADV CANCER RES, V75, P1, DOI 10.1016/S0065-230X(08)60738-1; GUTIERREZHARTMANN A, 1987, P NATL ACAD SCI USA, V84, P5211, DOI 10.1073/pnas.84.15.5211; IVERSON RA, 1990, MOL ENDOCRINOL, V4, P1564, DOI 10.1210/mend-4-10-1564; JACKSON SM, 1992, MOL CELL BIOL, V12, P2708, DOI 10.1128/MCB.12.6.2708; JACOB KK, 1995, J BIOL CHEM, V270, P27773, DOI 10.1074/jbc.270.46.27773; Jacob KK, 2001, J BIOL CHEM, V276, P24931, DOI 10.1074/jbc.M102826200; Jacob KK, 1999, ENDOCRINOLOGY, V140, P4542, DOI 10.1210/en.140.10.4542; Jacob KK, 1999, MOL CELL ENDOCRINOL, V152, P137, DOI 10.1016/S0303-7207(99)00043-X; Janknecht R, 1996, MOL CELL BIOL, V16, P1550; KEECH CA, 1989, MOL ENDOCRINOL, V3, P832, DOI 10.1210/mend-3-5-832; LAMARCO KL, 1989, GENE DEV, V3, P1372, DOI 10.1101/gad.3.9.1372; Lewis TS, 2000, MOL CELL, V6, P1343, DOI 10.1016/S1097-2765(00)00132-5; LIANG J, 1992, MOL ENDOCRINOL, V6, P885, DOI 10.1210/me.6.6.885; Nuchprayoon I, 1997, BLOOD, V89, P4546, DOI 10.1182/blood.V89.12.4546; Ouyang LH, 1996, J BIOL CHEM, V271, P10425, DOI 10.1074/jbc.271.18.10425; PEERS B, 1992, EUR J BIOCHEM, V210, P53, DOI 10.1111/j.1432-1033.1992.tb17389.x; Ryan AK, 1997, GENE DEV, V11, P1207, DOI 10.1101/gad.11.10.1207; Schaeffer L, 1998, EMBO J, V17, P3078, DOI 10.1093/emboj/17.11.3078; Schweppe RE, 1997, J BIOL CHEM, V272, P30852, DOI 10.1074/jbc.272.49.30852; Schweppe RE, 2001, NUCLEIC ACIDS RES, V29, P1251, DOI 10.1093/nar/29.5.1251; STANLEY FM, 1992, J BIOL CHEM, V267, P16719; THEILL LE, 1993, ENDOCR REV, V14, P670, DOI 10.1210/er.14.6.670; THOMPSON CC, 1991, SCIENCE, V253, P762, DOI 10.1126/science.1876833; Treier M, 1996, CURR OPIN CELL BIOL, V8, P833, DOI 10.1016/S0955-0674(96)80085-8; Wang YH, 1999, MOL ENDOCRINOL, V13, P1094, DOI 10.1210/me.13.7.1094; Wasylyk B, 1998, TRENDS BIOCHEM SCI, V23, P213, DOI 10.1016/S0968-0004(98)01211-0; WASYLYK B, 1997, TRANSCRIPTION FACTOR, P251	40	24	24	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 9	2003	278	19					16863	16872		10.1074/jbc.M213063200	http://dx.doi.org/10.1074/jbc.M213063200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677QG	12618435	hybrid			2022-12-25	WOS:000182818600057
J	Stockklausner, C; Klocker, N				Stockklausner, C; Klocker, N			Surface expression of inward rectifier potassium channels is controlled by selective Golgi export	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOPLASMIC-RETICULUM; ER EXPORT; MEMBRANE-TRANSPORT; CELL-SURFACE; LIPID RAFTS; TRAFFICKING; CLATHRIN; PROTEINS; SUBUNIT; MOTIFS	Traffic of integral membrane proteins along the secretory pathway is not simply a default process but can be selective. Such selectivity is achieved by sequence information within the cargo protein that recruits coat protein complexes to drive the formation of transport vesicles. A number of sequence motifs have been identified in the cytoplasmic domains of ion channels that regulate early trafficking events between the endoplasmic reticulum and the Golgi complex. Here, we demonstrate that the following trafficking step from the Golgi compartment to the plasma membrane can also be selective. The N-terminal domain of the inward rectifier potassium channel Kir2.1 contains specific sequence information that is necessary for its efficient export from the Golgi complex. Lack of this information results in accumulation of the protein within the Golgi and a significant decrease in cell surface expression. As similar results were obtained for the N terminus of another Kir channel subfamily member, Kir4.1, which could functionally substitute for the Kir2.1 N terminus, we propose a more general role of the identified N-terminal domains for post-Golgi trafficking of Kir channels.	Univ Freiburg, Dept Physiol 2, D-79104 Freiburg, Germany	University of Freiburg	Klocker, N (corresponding author), Univ Freiburg, Dept Physiol 2, Hermann Herder Str 7, D-79104 Freiburg, Germany.							Antonny B, 2001, CURR OPIN CELL BIOL, V13, P438, DOI 10.1016/S0955-0674(00)00234-9; Aridor M, 1996, NATURE, V383, P220, DOI 10.1038/383220a0; BABILA T, 1994, NEURON, V12, P615, DOI 10.1016/0896-6273(94)90217-8; BALCH WE, 1994, CELL, V76, P841, DOI 10.1016/0092-8674(94)90359-X; Boehm M, 2001, MOL BIOL CELL, V12, P2907, DOI 10.1091/mbc.12.10.2907; Cosson P, 1998, EMBO J, V17, P6863, DOI 10.1093/emboj/17.23.6863; COSSON P, 1994, SCIENCE, V263, P1629, DOI 10.1126/science.8128252; Cullen PJ, 2001, CURR BIOL, V11, pR882, DOI 10.1016/S0960-9822(01)00523-1; Delling M, 2002, J NEUROSCI, V22, P7154; Ford MGJ, 2001, SCIENCE, V291, P1051, DOI 10.1126/science.291.5506.1051; Ford MGJ, 2002, NATURE, V419, P361, DOI 10.1038/nature01020; Griffith LC, 2001, CURR BIOL, V11, pR226, DOI 10.1016/S0960-9822(01)00111-7; Hagemeier C, 1996, Methods Mol Biol, V57, P45; Kirchhausen T, 2000, ANNU REV BIOCHEM, V69, P699, DOI 10.1146/annurev.biochem.69.1.699; Klumperman J, 2000, CURR OPIN CELL BIOL, V12, P445, DOI 10.1016/S0955-0674(00)00115-0; LI M, 1992, SCIENCE, V257, P1225, DOI 10.1126/science.1519059; Llopis J, 1998, P NATL ACAD SCI USA, V95, P6803, DOI 10.1073/pnas.95.12.6803; Ma D, 2002, NEURON, V33, P715, DOI 10.1016/S0896-6273(02)00614-1; Ma D, 2002, CURR OPIN NEUROBIOL, V12, P287, DOI 10.1016/S0959-4388(02)00319-7; Ma DK, 2001, SCIENCE, V291, P316, DOI 10.1126/science.291.5502.316; Martin TFJ, 2001, CURR OPIN CELL BIOL, V13, P493, DOI 10.1016/S0955-0674(00)00241-6; Nelson WJ, 2001, TRENDS CELL BIOL, V11, P483, DOI 10.1016/S0962-8924(01)02145-6; Nickel W, 1998, HISTOCHEM CELL BIOL, V109, P477, DOI 10.1007/s004180050249; Niethammer P, 2002, J CELL BIOL, V157, P521, DOI 10.1083/jcb.200109059; Nishimura N, 2002, P NATL ACAD SCI USA, V99, P6755, DOI 10.1073/pnas.092150699; Orci L, 1997, CELL, V90, P335, DOI 10.1016/S0092-8674(00)80341-4; Pfeffer SR, 2001, CURR BIOL, V11, pR109, DOI 10.1016/S0960-9822(01)00042-2; ROBINSON MS, 1994, CURR OPIN CELL BIOL, V6, P538, DOI 10.1016/0955-0674(94)90074-4; Rothman JE, 1996, SCIENCE, V272, P227, DOI 10.1126/science.272.5259.227; Schekman R, 1996, SCIENCE, V271, P1526, DOI 10.1126/science.271.5255.1526; SCHUTZE MP, 1994, EMBO J, V13, P1696, DOI 10.1002/j.1460-2075.1994.tb06434.x; SHEN NV, 1993, NEURON, V11, P67; Simonsen A, 2001, CURR OPIN CELL BIOL, V13, P485, DOI 10.1016/S0955-0674(00)00240-4; Stockklausner C, 2001, FEBS LETT, V493, P129, DOI 10.1016/S0014-5793(01)02286-4; Tinker A, 1996, CELL, V87, P857, DOI 10.1016/S0092-8674(00)81993-5; Votsmeier C, 2001, EMBO J, V20, P6742, DOI 10.1093/emboj/20.23.6742; Zerangue N, 1999, NEURON, V22, P537, DOI 10.1016/S0896-6273(00)80708-4	37	63	65	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 9	2003	278	19					17000	17005		10.1074/jbc.M212243200	http://dx.doi.org/10.1074/jbc.M212243200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677QG	12609985	hybrid			2022-12-25	WOS:000182818600075
J	Oertle, T; Merkler, D; Schwab, ME				Oertle, T; Merkler, D; Schwab, ME			Do cancer cells die because of Nogo-B?	ONCOGENE			English	Article						ASY; Nogo-B; apoptosis; cancer; endoplasmatic reticulum; SaOS-2	NSP-ENCODED RETICULONS; ENDOPLASMIC-RETICULUM; LUNG-CANCER; SUBCELLULAR-LOCALIZATION; NEUROENDOCRINE MARKERS; GENE FAMILY; PROTEIN; APOPTOSIS; BCL-2; SURVIVAL	Nogo-A is a potent neurite outgrowth inhibitory protein in vitro and is suggested to play a role in the lack of regeneration in the central nervous system of adult higher vertebrates. A shorter splice isoform, ASY/Nogo-B, has recently been reported to act as a proapoptotic protein, the loss of which would be typical for cancer cells. Here, we show that the osteosarcoma cell line SaOS-2 and the cell line CHO do express high levels of endogenous Nogo-B and that stable transfectants overexpressing high levels of Nogo-B do not differ significantly from the respective parental wild-type or control cell lines both in respect to cell proliferation and to spontaneous apoptosis or cell death induced by staurosporine and tunicamycin. The deletion of the second transmembrane domain of Nogo-B, which has been claimed to abolish its proapoptotic activity, leads to a shift of the protein from the ER to a cytoplasmic localization, suggesting that ER stress of highly overexpressed Nogo-B may lead to aversive cellular reactions under particular conditions. Our data do not support a function of Nogo-B as a physiological proapoptotic protein in certain types of cancer.	Univ Zurich, Brain Res Inst, CH-8057 Zurich, Switzerland; Swiss Fed Inst Technol, Dept Biol, CH-8057 Zurich, Switzerland	University of Zurich; Swiss Federal Institutes of Technology Domain; ETH Zurich	Oertle, T (corresponding author), Univ Zurich, Brain Res Inst, Winterthurerstr 190, CH-8057 Zurich, Switzerland.		Schwab, Martin E/B-6818-2016; Merkler, Doron/N-9157-2016	Merkler, Doron/0000-0002-0247-2007				Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Annis MG, 2001, ONCOGENE, V20, P1939, DOI 10.1038/sj.onc.1204288; Bongarzone ER, 2001, J NEUROSCI RES, V65, P485, DOI 10.1002/jnr.1178; Chen MS, 2000, NATURE, V403, P434, DOI 10.1038/35000219; CORY S, 1995, ANNU REV IMMUNOL, V13, P513, DOI 10.1146/annurev.iy.13.040195.002501; Gross A, 1999, GENE DEV, V13, P1899, DOI 10.1101/gad.13.15.1899; Hacki J, 2000, ONCOGENE, V19, P2286, DOI 10.1038/sj.onc.1203592; Herr I, 2001, BLOOD, V98, P2603, DOI 10.1182/blood.V98.9.2603; Huber AB, 2002, J NEUROSCI, V22, P3553; Li Q, 2001, ONCOGENE, V20, P3929, DOI 10.1038/sj.onc.1204536; MICHEL A, 1999, ELECT J PATHOL HISTO, V5, P993; Morris NJ, 1999, BBA-MOL CELL RES, V1450, P68, DOI 10.1016/S0167-4889(99)00033-6; Nagase T, 1998, DNA Res, V5, P355, DOI 10.1093/dnares/5.6.355; Nakagawa T, 2000, NATURE, V403, P98, DOI 10.1038/47513; Nilsson I, 1998, J MOL BIOL, V284, P1165, DOI 10.1006/jmbi.1998.2217; Oertle T, 2003, J MOL BIOL, V325, P299, DOI 10.1016/S0022-2836(02)01179-8; Pahl HL, 1999, PHYSIOL REV, V79, P683, DOI 10.1152/physrev.1999.79.3.683; Senden N, 1997, HISTOCHEM CELL BIOL, V108, P155, DOI 10.1007/s004180050157; Senden NHM, 1996, EUR J CELL BIOL, V69, P197; SENDEN NHM, 1994, EUR J CELL BIOL, V65, P341; Senden NHM, 1997, J PATHOL, V182, P13; Shi YG, 2002, MOL CELL, V9, P459, DOI 10.1016/S1097-2765(02)00482-3; STELLER H, 1995, SCIENCE, V267, P1445, DOI 10.1126/science.7878463; Tagami S, 2000, ONCOGENE, V19, P5736, DOI 10.1038/sj.onc.1203948; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; VANDEVELDE HJK, 1994, J CELL SCI, V107, P2403; VANDEVELDE HJK, 1994, CANCER RES, V54, P4769; Woynarowska BA, 2002, BBA-MOL BASIS DIS, V1587, P309, DOI 10.1016/S0925-4439(02)00094-7	29	61	69	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 6	2003	22	9					1390	1399		10.1038/sj.onc.1206278	http://dx.doi.org/10.1038/sj.onc.1206278			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	652CA	12618765				2022-12-25	WOS:000181360900014
J	Lozach, PY; Lortat-Jacob, H; de Lavalette, AD; Staropoli, I; Foung, S; Amara, A; Houles, C; Fieschi, F; Schwartz, O; Virelizier, JL; Arenzana-Seisdedos, F; Altmeyer, R				Lozach, PY; Lortat-Jacob, H; de Lavalette, AD; Staropoli, I; Foung, S; Amara, A; Houles, C; Fieschi, F; Schwartz, O; Virelizier, JL; Arenzana-Seisdedos, F; Altmeyer, R			DC-SIGN and L-SIGN are high affinity binding receptors for hepatitis C virus glycoprotein E2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DENSITY-LIPOPROTEIN RECEPTOR; DENDRITIC CELL; ENDOPLASMIC-RETICULUM; ENVELOPE GLYCOPROTEINS; TRANSMEMBRANE DOMAIN; CANDIDATE RECEPTOR; ENDOTHELIAL-CELLS; TRANS-INFECTION; IN-VITRO; T-CELLS	The hepatitis C virus (HCV) genome codes for highly mannosylated envelope proteins, which are naturally retained in the endoplasmic reticulum. We found that the HCV envelope glycoprotein E2 binds the dendritic cell-specific intercellular adhesion molecule 3-grabbing nonintegrin (DC-SIGN) and the related liver endothelial cell lectin L-SIGN through high-mannose N-glycans. Competing ligands such as mannan and an antibody directed against the carbohydrate recognition domains (CRD) abrogated binding. While no E2 interaction with distant monomeric CRDs on biosensor chips could be detected, binding is observed if CRDs are closely seeded (K-d = 48 nM) and if the CRD is part of the oligomeric-soluble extracellular domain of DC-SIGN (K-d = 30 nM). The highest affinity is seen for plasma membrane- expressed DC-SIGN and L-SIGN (K-d = 3 and 6 nM, respectively). These results indicate that several high- mannose N-glycans in a structurally defined cluster on E2 bind to several subunits of the oligomeric lectin CRD. High affinity interaction of viral glycoproteins with oligomeric lectins might represent a strategy by which HCV targets to and concentrates in the liver and infects dendritic cells.	Inst Pasteur, Unite Immunol Virale, F-75015 Paris, France; Inst Pasteur, Grp Virus & Immun, F-75015 Paris, France; UJF, CNRS, CEA, Inst Biol Struct,Unite Mixte Rech 5075, F-38027 Grenoble 01, France; Stanford Univ, Med Ctr, Dept Pathol, Stanford, CA 94305 USA	Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); CEA; Centre National de la Recherche Scientifique (CNRS); Stanford University	Altmeyer, R (corresponding author), Inst Pasteur, Unite Immunol Virale, 28 Rue Dr Roux, F-75015 Paris, France.	altmeyer@pasteur.fr	AMARA, Ali/ABX-9903-2022; Schwartz, Olivier/AAZ-3765-2021; Fieschi, Franck/W-2748-2019; Amara, Ali/E-8803-2017; Lozach, Pierre-Yves/H-7072-2015; Arenzana-Seisdedos, Fernando/E-5835-2016	Schwartz, Olivier/0000-0002-0729-1475; Lozach, Pierre-Yves/0000-0002-9966-1452; SANCHEZ, Corinne/0000-0003-3895-0194; FIESCHI, Franck/0000-0003-1194-8107; AMARA, Ali/0000-0002-0283-1815; Foung, Steven/0000-0001-7149-6160	NATIONAL CANCER INSTITUTE [P01CA034233] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI047355] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [R01DA006596] Funding Source: NIH RePORTER; NCI NIH HHS [CA34233] Funding Source: Medline; NIAID NIH HHS [AI47355] Funding Source: Medline; NIDA NIH HHS [DA06596] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA))		Agnello V, 1999, P NATL ACAD SCI USA, V96, P12766, DOI 10.1073/pnas.96.22.12766; Agnello V, 1998, HEPATOLOGY, V28, P573, DOI 10.1002/hep.510280240; Aizaki H, 1998, HEPATOLOGY, V27, P621, DOI 10.1002/hep.510270242; Alter HJ, 2000, SEMIN LIVER DIS, V20, P17, DOI 10.1055/s-2000-9505; Alter MJ, 2002, HEPATOLOGY, V36, pS93, DOI 10.1053/jhep.2002.36389; Alvarez CP, 2002, J VIROL, V76, P6841, DOI 10.1128/JVI.76.13.6841-6844.2002; Bain C, 2001, GASTROENTEROLOGY, V120, P512, DOI 10.1053/gast.2001.21212; Bashirova AA, 2001, J EXP MED, V193, P671, DOI 10.1084/jem.193.6.671; Baumert TF, 1998, J VIROL, V72, P3827, DOI 10.1128/JVI.72.5.3827-3836.1998; BERGLUND P, 1993, BIO-TECHNOL, V11, P916, DOI 10.1038/nbt0893-916; Blanchard E, 2002, J VIROL, V76, P4073, DOI 10.1128/JVI.76.8.4073-4079.2002; CAMERON PU, 1992, SCIENCE, V257, P383, DOI 10.1126/science.1352913; Chanel C, 2002, AIDS, V16, P2337, DOI 10.1097/00002030-200211220-00016; Choukhi A, 1998, J VIROL, V72, P3851, DOI 10.1128/JVI.72.5.3851-3858.1998; Cocquerel L, 1998, J VIROL, V72, P2183, DOI 10.1128/JVI.72.3.2183-2191.1998; Cocquerel L, 2003, J VIROL, V77, P1604, DOI 10.1128/JVI.77.2.1604-1609.2003; Cocquerel L, 2002, EMBO J, V21, P2893, DOI 10.1093/emboj/cdf295; Cocquerel L, 1999, J VIROL, V73, P2641, DOI 10.1128/JVI.73.4.2641-2649.1999; CURTIS BM, 1992, P NATL ACAD SCI USA, V89, P8356, DOI 10.1073/pnas.89.17.8356; De Beeck AO, 2000, J BIOL CHEM, V275, P31428, DOI 10.1074/jbc.M003003200; De Beeck AO, 2001, J GEN VIROL, V82, P2589, DOI 10.1099/0022-1317-82-11-2589; Dubuisson J, 2000, CURR TOP MICROBIOL, V242, P135; Dubuisson J, 1996, J VIROL, V70, P778, DOI 10.1128/JVI.70.2.778-786.1996; Ellgaard L, 1999, SCIENCE, V286, P1882, DOI 10.1126/science.286.5446.1882; Feinberg H, 2001, SCIENCE, V294, P2163, DOI 10.1126/science.1066371; Flint M, 2000, REV MED VIROL, V10, P101, DOI 10.1002/(SICI)1099-1654(200003/04)10:2&lt;101::AID-RMV268&gt;3.0.CO;2-W; Geijtenbeek TBH, 2003, J EXP MED, V197, P7, DOI 10.1084/jem.20021229; Geijtenbeek TBH, 2000, CELL, V100, P587, DOI 10.1016/S0092-8674(00)80694-7; Geijtenbeek TBH, 2000, CELL, V100, P575, DOI 10.1016/S0092-8674(00)80693-5; Hadlock KG, 2000, J VIROL, V74, P10407, DOI 10.1128/JVI.74.22.10407-10416.2000; Halary F, 2002, IMMUNITY, V17, P653, DOI 10.1016/S1074-7613(02)00447-8; Kwon DS, 2002, IMMUNITY, V16, P135, DOI 10.1016/S1074-7613(02)00259-5; LANFORD RE, 1994, VIROLOGY, V202, P606, DOI 10.1006/viro.1994.1381; Lerat H, 1998, BLOOD, V91, P3841, DOI 10.1182/blood.V91.10.3841.3841_3841_3849; LILJESTROM P, 1991, BIO-TECHNOL, V9, P1356, DOI 10.1038/nbt1291-1356; Lin G, 2003, J VIROL, V77, P1337, DOI 10.1128/JVI.77.2.1337-1346.2003; MAEDA N, 2002, J BIOL CHEM, V20, P20; MAJOR ME, 2001, FIELDS VIROLOGY, V1, P1127; Matsuura Y, 2001, VIROLOGY, V286, P263, DOI 10.1006/viro.2001.0971; Meanger J, 1997, BIOTECHNIQUES, V23, P432, DOI 10.2144/97233bm18; Merola M, 2001, J VIROL, V75, P11205, DOI 10.1128/JVI.75.22.11205-11217.2001; Mitchell DA, 2001, J BIOL CHEM, V276, P28939, DOI 10.1074/jbc.M104565200; Monazahian M, 1999, J MED VIROL, V57, P223, DOI 10.1002/(SICI)1096-9071(199903)57:3<223::AID-JMV2>3.0.CO;2-4; Navas MC, 2002, J MED VIROL, V67, P152, DOI 10.1002/jmv.2204; Percherancier Y, 2001, J BIOL CHEM, V276, P31936, DOI 10.1074/jbc.M104013200; Petracca R, 2000, J VIROL, V74, P4824, DOI 10.1128/JVI.74.10.4824-4830.2000; Pileri P, 1998, SCIENCE, V282, P938, DOI 10.1126/science.282.5390.938; Pohlmann S, 2001, P NATL ACAD SCI USA, V98, P2670, DOI 10.1073/pnas.051631398; Saunier B, 2003, J VIROL, V77, P546, DOI 10.1128/JVI.77.1.546-559.2003; Scarselli E, 2002, EMBO J, V21, P5017, DOI 10.1093/emboj/cdf529; Soilleux EJ, 2002, J LEUKOCYTE BIOL, V71, P445; Soilleux EJ, 2001, J PATHOL, V195, P586, DOI 10.1002/path.1026; Sol-Foulon N, 2002, IMMUNITY, V16, P145, DOI 10.1016/S1074-7613(02)00260-1; Staropoli I, 2000, J BIOL CHEM, V275, P35137, DOI 10.1074/jbc.M003868200; Tailleux L, 2003, J EXP MED, V197, P121, DOI 10.1084/jem.20021468; Takikawa S, 2000, J VIROL, V74, P5066, DOI 10.1128/JVI.74.11.5066-5074.2000; Wellnitz S, 2002, J VIROL, V76, P1181, DOI 10.1128/JVI.76.3.1181-1193.2002; Zhu XG, 2000, BIOCHEMISTRY-US, V39, P11194, DOI 10.1021/bi000432m	58	293	313	0	18	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 30	2003	278	22					20358	20366		10.1074/jbc.M301284200	http://dx.doi.org/10.1074/jbc.M301284200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	682EH	12609975	Green Published, hybrid			2022-12-25	WOS:000183078000100
J	Wang, B; Alam, SL; Meyer, HH; Payne, M; Stemmler, TL; Davis, DR; Sundquist, WI				Wang, B; Alam, SL; Meyer, HH; Payne, M; Stemmler, TL; Davis, DR; Sundquist, WI			Structure and ubiquitin interactions of the conserved zinc finger domain of Npl4	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR-MAGNETIC-RESONANCE; ELONGATION-FACTOR TFIIS; TORSION ANGLE DYNAMICS; CRYSTAL-STRUCTURE; ENDOPLASMIC-RETICULUM; COUPLING-CONSTANTS; HYDROGEN-BONDS; BINDING DOMAIN; UBA DOMAINS; SH3 DOMAIN	Ubiquitylated proteins are directed into a large number of different cellular pathways through interactions with effector proteins that contain conserved ubiquitin binding motifs. Here, we report the solution structure and ubiquitin binding properties of one such motif, the Npl4 zinc finger or RanBP2/Nup358 zinc finger (NZF) domain. Npl4 NZF forms a compact module composed of four antiparallel beta-strands linked by three ordered loops. A single zinc ion is coordinated by four conserved cysteines from the first and third loops, which form two rubredoxin knuckles. Npl4 NZF binds specifically, but weakly, to free ubiquitin using a conserved (TF14)-T-13 dipeptide to interact with the "Ile-44" surface of ubiquitin. Our studies reveal the structure of this versatile class of protein binding domains and provide a means for identifying the subset of NZF domains likely to bind ubiquitin.	Univ Utah, Dept Biochem, Salt Lake City, UT 84132 USA; Univ Utah, Dept Med Chem, Salt Lake City, UT 84132 USA; Wayne State Univ, Sch Med, Dept Biochem & Mol Biol, Detroit, MI 48201 USA; Yale Univ, Sch Med, Dept Cell Biol, New Haven, CT 06520 USA	Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; Wayne State University; Yale University	Sundquist, WI (corresponding author), Univ Utah, Dept Biochem, Salt Lake City, UT 84132 USA.	wes@biochem.utah.edu	Meyer, Hemmo/GNH-5784-2022	Meyer, Hemmo/0000-0003-1883-1796; Stemmler, Timothy/0000-0002-6298-088X	NCRR NIH HHS [RR13030] Funding Source: Medline; NIDDK NIH HHS [R01 DK068139] Funding Source: Medline; NIGMS NIH HHS [1R01 GM60919, R01 GM055508, R01 GM55508, R01 GM060919] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [S10RR013030] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK068139] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM060919, R01GM055508] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADMAN E, 1975, P NATL ACAD SCI USA, V72, P4854, DOI 10.1073/pnas.72.12.4854; Babst M, 1998, EMBO J, V17, P2982, DOI 10.1093/emboj/17.11.2982; Babst M, 2002, DEV CELL, V3, P283, DOI 10.1016/S1534-5807(02)00219-8; BALLARDIN A, 1978, BIOCHEMISTRY-US, V17, P4443, DOI 10.1021/bi00614a014; BAX A, 1994, METHOD ENZYMOL, V239, P79; Bays NW, 2002, CURR BIOL, V12, pR366, DOI 10.1016/S0960-9822(02)00862-X; Beal R, 1996, P NATL ACAD SCI USA, V93, P861, DOI 10.1073/pnas.93.2.861; Bertolaet BL, 2001, NAT STRUCT BIOL, V8, P417, DOI 10.1038/87575; Bishop N, 2001, J BIOL CHEM, V276, P11735, DOI 10.1074/jbc.M009863200; BLAKE PR, 1994, ADV BIOPH C, V4, P1; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Buchberger A, 2002, TRENDS CELL BIOL, V12, P216, DOI 10.1016/S0962-8924(02)02269-9; Cheever ML, 2001, NAT CELL BIOL, V3, P613, DOI 10.1038/35083000; Chen HT, 2000, PROTEIN SCI, V9, P1743, DOI 10.1110/ps.9.9.1743; CLORE GM, 1994, METHOD ENZYMOL, V239, P349; DELANEY SJ, 1991, P NATL ACAD SCI USA, V88, P7214, DOI 10.1073/pnas.88.16.7214; Dieckmann T, 1998, NAT STRUCT BIOL, V5, P1042, DOI 10.1038/4220; Falquet L, 2002, NUCLEIC ACIDS RES, V30, P235, DOI 10.1093/nar/30.1.235; Fauser S, 2001, MAMM GENOME, V12, P406, DOI 10.1007/s003350010291; Garcia E, 1999, EMBO J, V18, P3404, DOI 10.1093/emboj/18.12.3404; GARRETT DS, 1994, J MAGN RESON SER B, V104, P99, DOI 10.1006/jmrb.1994.1061; Garrus JE, 2001, CELL, V107, P55, DOI 10.1016/S0092-8674(01)00506-2; GRAHAM WH, 1992, BIOPOLYMERS, V32, P1755, DOI 10.1002/bip.360321216; Grzesiek S, 1996, NAT STRUCT BIOL, V3, P340, DOI 10.1038/nsb0496-340; Guntert P, 1997, J MOL BIOL, V273, P283, DOI 10.1006/jmbi.1997.1284; Haj FG, 2002, SCIENCE, V295, P1708, DOI 10.1126/science.1067566; Hammarstrom A, 1996, BIOCHEMISTRY-US, V35, P12723, DOI 10.1021/bi961149j; Herrmann T, 2002, J MOL BIOL, V319, P209, DOI 10.1016/S0022-2836(02)00241-3; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; Hetzer M, 2001, NAT CELL BIOL, V3, P1086, DOI 10.1038/ncb1201-1086; Hicke L, 2001, NAT REV MOL CELL BIO, V2, P195, DOI 10.1038/35056583; Hofmann K, 1996, TRENDS BIOCHEM SCI, V21, P172, DOI 10.1016/0968-0004(96)30015-7; Hofmann K, 2001, TRENDS BIOCHEM SCI, V26, P347, DOI 10.1016/S0968-0004(01)01835-7; Hsu ST, 2002, BIOCHEMISTRY-US, V41, P7670, DOI 10.1021/bi025679t; KLUG A, 1995, FASEB J, V9, P597, DOI 10.1096/fasebj.9.8.7768350; Kondo H, 1997, NATURE, V388, P75, DOI 10.1038/40411; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; KUBONIWA H, 1994, J BIOMOL NMR, V4, P871, DOI 10.1007/BF00398416; Laskowski RA, 1996, J BIOMOL NMR, V8, P477, DOI 10.1007/BF00228148; Madura K, 2002, CELL CYCLE, V1, P233, DOI 10.4161/cc.1.4.130; Martinez-Noel G, 1999, FEBS LETT, V454, P257, DOI 10.1016/S0014-5793(99)00823-6; Martinez-Yamout M, 2000, J MOL BIOL, V300, P805, DOI 10.1006/jmbi.2000.3923; Meissner A, 2000, J MAGN RESON, V143, P387, DOI 10.1006/jmre.1999.1998; Meyer HH, 2002, EMBO J, V21, P5645, DOI 10.1093/emboj/cdf579; Moraes TF, 2001, NAT STRUCT BIOL, V8, P669, DOI 10.1038/90373; MORI S, 1995, J MAGN RESON SER B, V108, P94, DOI 10.1006/jmrb.1995.1109; Mueller TD, 2002, J MOL BIOL, V319, P1243, DOI 10.1016/S0022-2836(02)00302-9; MUHANDIRAM DR, 1993, J BIOMOL NMR, V3, P463; Nakielny S, 1999, EMBO J, V18, P1982, DOI 10.1093/emboj/18.7.1982; PASCAL SM, 1994, J MAGN RESON SER B, V103, P197, DOI 10.1006/jmrb.1994.1031; Pellecchia M, 2001, J AM CHEM SOC, V123, P4633, DOI 10.1021/ja005850t; Pickart CM, 2001, ANNU REV BIOCHEM, V70, P503, DOI 10.1146/annurev.biochem.70.1.503; Pornillos O, 2002, EMBO J, V21, P2397, DOI 10.1093/emboj/21.10.2397; QIAN XQ, 1993, NATURE, V365, P277, DOI 10.1038/365277a0; QIAN XQ, 1993, BIOCHEMISTRY-US, V32, P9944, DOI 10.1021/bi00089a010; Raiborg C, 2002, NAT CELL BIOL, V4, P394, DOI 10.1038/ncb791; Sarisky CA, 2001, J MOL BIOL, V307, P1411, DOI 10.1006/jmbi.2000.4345; Scheuring S, 2001, J MOL BIOL, V312, P469, DOI 10.1006/jmbi.2001.4917; Shekhtman A, 2002, BIOCHEM BIOPH RES CO, V296, P1222, DOI 10.1016/S0006-291X(02)02006-5; Sieker LC, 2000, J BIOL INORG CHEM, V5, P505, DOI 10.1007/PL00021450; Singh BB, 1999, J BIOL CHEM, V274, P37370, DOI 10.1074/jbc.274.52.37370; Sloper-Mould KE, 2001, J BIOL CHEM, V276, P30483, DOI 10.1074/jbc.M103248200; Strack B, 2002, J VIROL, V76, P5472, DOI 10.1128/JVI.76.11.5472-5479.2002; SUKEGAWA J, 1993, CELL, V72, P29, DOI 10.1016/0092-8674(93)90047-T; Tsai B, 2002, NAT REV MOL CELL BIO, V3, P246, DOI 10.1038/nrm780; VanDemark AP, 2001, CELL, V105, P711, DOI 10.1016/S0092-8674(01)00387-7; VanDemark AP, 2002, CURR OPIN STRUC BIOL, V12, P822, DOI 10.1016/S0959-440X(02)00389-5; Walters KJ, 2002, BIOCHEMISTRY-US, V41, P1767, DOI 10.1021/bi011892y; Wang B, 1998, STRUCTURE, V6, P555, DOI 10.1016/S0969-2126(98)00058-6; WU J, 1995, J BIOL CHEM, V270, P14209, DOI 10.1074/jbc.270.23.14209; Yaseen NR, 1999, P NATL ACAD SCI USA, V96, P5516, DOI 10.1073/pnas.96.10.5516; YOKOYAMA N, 1995, NATURE, V376, P184, DOI 10.1038/376184a0; ZHANG OW, 1994, J BIOMOL NMR, V4, P845, DOI 10.1007/BF00398413	73	121	123	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 30	2003	278	22					20225	20234		10.1074/jbc.M300459200	http://dx.doi.org/10.1074/jbc.M300459200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	682EH	12644454	Green Accepted, hybrid			2022-12-25	WOS:000183078000084
J	Liu, JJ; Hou, SC; Shen, CKJ				Liu, JJ; Hou, SC; Shen, CKJ			Erythroid gene suppression by NF-kappa B	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ERYTHROLEUKEMIA CELL-DIFFERENTIATION; TRANSCRIPTION FACTOR NF-E2; DNA-BINDING PROTEIN; GLOBIN GENE; ALPHA-GLOBIN; MAMMALIAN-CELLS; IN-VITRO; EXPRESSION; ENHANCER; FAMILY	NF-kappaB/Rel transcription factors play essential roles to mediate the immune response and apoptosis, and they have also been implicated in cellular differentiation such as erythropoiesis. To elucidate the possible role(s) of NF-kappaB in erythroid gene regulation and erythropoiesis, we have carried out transient transfection studies of the human embryonic/ fetal erythroid cell line K562 and mouse adult erythroid MEL cells. It is shown that tumor necrosis factor-alpha represses the transcription activity directed by either alpha or zeta globin promoter in a dose-dependent manner. Furthermore, different NF-kappaB family members could effectively repress the transfected alpha-like globin promoters in K562 as well as in MEL cells. The involvement of NF-kappaB pathway is supported by the ability of a NF-kappaB-specific, dominant negative mutant to block the tumor necrosis factor-alpha or p65-mediated suppression of the alpha-like globin promoter activities. The suppression appears to be mediated through cis-linked HS-40 enhancer. Finally, stably transfected K562 cells overexpressing p65 contain reduced amounts of the p45/ NF-E2 RNA and functional NF-E2 proteins. Our studies have identified a new set of targets of NF-kappaB. We suggest that the relatively high activity of the NF-kappaB pathway in early erythroid progenitors is involved in the suppression of erythroid-specific genes. Later in differentiation, together with other changes, the decline of the amounts of the NF-kappaB family of factors leads to derepression and consequent increase of NF-E2, which in turn would activate a subset of erythroid-specific genes.	Acad Sinica, Inst Mol Biol, Nankang, Taiwan; Natl Taiwan Univ, Inst Mol Med, Taipei 115, Taiwan; Natl Def Univ, Coll Life Sci, Taipei 115, Taiwan	Academia Sinica - Taiwan; National Taiwan University; National Defense University - Taiwan	Shen, CKJ (corresponding author), Acad Sinica, Inst Mol Biol, Nankang, Taiwan.		shen, Che-Kun James/L-1343-2015					Amrolia PJ, 1997, P NATL ACAD SCI USA, V94, P10051, DOI 10.1073/pnas.94.19.10051; ANDREWS NC, 1993, NATURE, V362, P722, DOI 10.1038/362722a0; Armstrong JA, 1996, MOL CELL BIOL, V16, P5634; BALLARD DW, 1992, P NATL ACAD SCI USA, V89, P1875, DOI 10.1073/pnas.89.5.1875; Blau C A, 1994, Curr Opin Hematol, V1, P136; BROWN K, 1993, P NATL ACAD SCI USA, V90, P2532, DOI 10.1073/pnas.90.6.2532; Bulger M, 1999, GENE DEV, V13, P2465, DOI 10.1101/gad.13.19.2465; Daftari P, 1999, ONCOGENE, V18, P5482, DOI 10.1038/sj.onc.1202916; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Engel JD, 2000, CELL, V100, P499, DOI 10.1016/S0092-8674(00)80686-8; Ferry AE, 1997, J BIOL CHEM, V272, P20030, DOI 10.1074/jbc.272.32.20030; Foo SY, 1999, TRENDS GENET, V15, P229; FRIEND C, 1971, P NATL ACAD SCI USA, V68, P378; GARINGO AD, 1995, J BIOL CHEM, V270, P9169, DOI 10.1074/jbc.270.16.9169; Gerritsen ME, 1997, P NATL ACAD SCI USA, V94, P2927, DOI 10.1073/pnas.94.7.2927; Greenwel P, 2000, MOL CELL BIOL, V20, P912, DOI 10.1128/MCB.20.3.912-918.2000; Grossmann M, 1999, P NATL ACAD SCI USA, V96, P11848, DOI 10.1073/pnas.96.21.11848; Grosveld F, 1999, CURR OPIN GENET DEV, V9, P152, DOI 10.1016/S0959-437X(99)80023-9; Guttridge DC, 1999, MOL CELL BIOL, V19, P5785; Hatada EN, 2000, CURR OPIN IMMUNOL, V12, P52, DOI 10.1016/S0952-7915(99)00050-3; HIGGS DR, 1989, BLOOD, V73, P1081; Igarashi K, 1998, J BIOL CHEM, V273, P11783, DOI 10.1074/jbc.273.19.11783; IP YT, 1991, CELL, V64, P439; Karin M, 2000, ANNU REV IMMUNOL, V18, P621, DOI 10.1146/annurev.immunol.18.1.621; KOTKOW KJ, 1995, MOL CELL BIOL, V15, P4640; Lee FS, 1998, P NATL ACAD SCI USA, V95, P9319, DOI 10.1073/pnas.95.16.9319; LEE HY, 1995, J EXP MED, V181, P1169, DOI 10.1084/jem.181.3.1169; LOZZIO CB, 1975, BLOOD, V45, P321, DOI 10.1182/blood.V45.3.321.321; MILLER IJ, 1993, MOL CELL BIOL, V13, P2776, DOI 10.1128/MCB.13.5.2776; Motohashi H, 1997, NUCLEIC ACIDS RES, V25, P2953, DOI 10.1093/nar/25.15.2953; Nagai T, 1998, J BIOL CHEM, V273, P5358, DOI 10.1074/jbc.273.9.5358; ORKIN SH, 1995, EUR J BIOCHEM, V231, P271, DOI 10.1111/j.1432-1033.1995.tb20697.x; PEREZ P, 1995, MOL CELL BIOL, V15, P3523; Perkins ND, 2000, TRENDS BIOCHEM SCI, V25, P434, DOI 10.1016/S0968-0004(00)01617-0; ROMBEL I, 1995, P NATL ACAD SCI USA, V92, P6454, DOI 10.1073/pnas.92.14.6454; Sambrook J., 2002, MOL CLONING LAB MANU; SATMATOYANNOPOU.G, 1987, MOL BASIS BLOOD DIS, P66; Sayer MS, 2000, J BIOL CHEM, V275, P25292, DOI 10.1074/jbc.M908695199; SCOTT ML, 1993, GENE DEV, V7, P1266, DOI 10.1101/gad.7.7a.1266; SELLS MA, 1995, GENE, V152, P187, DOI 10.1016/0378-1119(94)00685-L; SHIVDASANI RA, 1995, P NATL ACAD SCI USA, V92, P8690, DOI 10.1073/pnas.92.19.8690; STRAUSS EC, 1992, MOL CELL BIOL, V12, P2135, DOI 10.1128/MCB.12.5.2135; Suhasini M, 1997, ONCOGENE, V15, P1859, DOI 10.1038/sj.onc.1201530; TALBOT D, 1991, EMBO J, V10, P1391, DOI 10.1002/j.1460-2075.1991.tb07659.x; THANOS D, 1995, CELL, V80, P529, DOI 10.1016/0092-8674(95)90506-5; TOTH CR, 1995, J BIOL CHEM, V270, P7661, DOI 10.1074/jbc.270.13.7661; TSAI SF, 1989, NATURE, V339, P446, DOI 10.1038/339446a0; Tsang AP, 1997, CELL, V90, P109, DOI 10.1016/S0092-8674(00)80318-9; Wang ZB, 1999, EMBO J, V18, P2218, DOI 10.1093/emboj/18.8.2218; WEIH F, 1995, CELL, V80, P331, DOI 10.1016/0092-8674(95)90416-6; Wen SC, 2000, MOL CELL BIOL, V20, P1993, DOI 10.1128/MCB.20.6.1993-2003.2000; Zhang MY, 1998, BLOOD, V91, P4136, DOI 10.1182/blood.V91.11.4136.411k26_4136_4144; ZHANG QY, 1995, J BIOL CHEM, V270, P8501, DOI 10.1074/jbc.270.15.8501	53	44	45	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 23	2003	278	21					19534	19540		10.1074/jbc.M212278200	http://dx.doi.org/10.1074/jbc.M212278200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	679PY	12642582	hybrid			2022-12-25	WOS:000182932200104
J	Pinakoulaki, E; Pfitzner, U; Ludwig, B; Varotsis, C				Pinakoulaki, E; Pfitzner, U; Ludwig, B; Varotsis, C			Direct detection of Fe(IV)=O intermediates in the cytochrome alpha alpha 3 oxidase from Paracoccus denitrificans/H2O2 reaction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RESONANCE RAMAN EVIDENCE; C-OXIDASE; HYDROGEN-PEROXIDE; ELECTRON-TRANSFER; THERMUS-THERMOPHILUS; AMBIENT-TEMPERATURE; DIOXYGEN ACTIVATION; OXYGEN ACTIVATION; BACILLUS-SUBTILIS; CARBON-MONOXIDE	We report the first evidence for the formation of the "607- and 580-nm forms" in the cytochrome oxidase aa(3)/ H2O2 reaction without the involvement of tyrosine 280. The pK(a) of the 607-580-nm transition is 7.5. The 607-nm form is also formed in the mixed valence cytochrome oxidase/O-2 reaction in the absence of tyrosine 280. Steady-state resonance Raman characterization of the reaction products of both the wild-type and Y280H cytochrome aa(3) from Paracoccus denitrificans indicate the formation of six-coordinate low spin species, and do not support, in contrast to previous reports, the formation of a porphyrin pi-cation radical. We observe three oxygen isotope-sensitive Raman bands in the oxidized wildtype aa(3)/H2O2 reaction at 804, 790, and 358 cm(-1). The former two are assigned to the Fe(IV) = O stretching mode of the 607- and 580- nm forms, respectively. The 14 cm(-1) frequency difference between the oxoferryl species is attributed to variations in the basicity of the proximal to heme a(3) His-411, induced by the oxoferryl conformations of the heme a(3)-Cu-B pocket during the 607 - 580- nm transition. We suggest that the 804 - 790 cm(-1) oxoferryl transition triggers distal conformational changes that are subsequently communicated to the proximal His-411 heme a(3) site. The 358 cm(-1) mode has been found for the first time to accumulate with the 804 cm(-1) mode in the peroxide reaction. These results indicate that the mechanism of oxygen reduction must be reexamined.	Univ Crete, Dept Chem, Iraklion 71409, Crete, Greece; Goethe Univ Frankfurt, Biozentrum, Inst Biochem, D-60439 Frankfurt, Germany	University of Crete; Goethe University Frankfurt	Varotsis, C (corresponding author), Univ Crete, Dept Chem, Iraklion 71409, Crete, Greece.	varotsis@edu.uoc.gr		Varotsis, Constantinos/0000-0003-2771-8891; Pinakoulaki, Eftychia/0000-0003-3320-6112				BABCOCK GT, 1992, NATURE, V356, P301, DOI 10.1038/356301a0; Bassan A, 2002, J AM CHEM SOC, V124, P11056, DOI 10.1021/ja026488g; DAWSON JH, 1988, SCIENCE, V240, P433, DOI 10.1126/science.3358128; Einarsdottir O, 2002, J INORG BIOCHEM, V91, P87, DOI 10.1016/S0162-0134(02)00377-X; FABIAN M, 1995, BIOCHEMISTRY-US, V34, P13802, DOI 10.1021/bi00042a011; Fabian M, 1999, P NATL ACAD SCI USA, V96, P13114, DOI 10.1073/pnas.96.23.13114; Fabian M, 2001, BIOCHEMISTRY-US, V40, P1867, DOI 10.1021/bi002373i; Fabian M, 1999, BIOCHEMISTRY-US, V38, P6270, DOI 10.1021/bi982541v; FergusonMiller S, 1996, CHEM REV, V96, P2889, DOI 10.1021/cr950051s; Gennis RB, 1998, BBA-BIOENERGETICS, V1365, P241, DOI 10.1016/S0005-2728(98)00075-9; Han S, 2000, J BIOL CHEM, V275, P1910, DOI 10.1074/jbc.275.3.1910; HAN SH, 1990, J AM CHEM SOC, V112, P9445, DOI 10.1021/ja00182a001; HAN SW, 1990, NATURE, V348, P89, DOI 10.1038/348089a0; HASHIMOTO S, 1986, P NATL ACAD SCI USA, V83, P2417, DOI 10.1073/pnas.83.8.2417; HAYASHI Y, 1978, ARCH BIOCHEM BIOPHYS, V190, P446, DOI 10.1016/0003-9861(78)90297-7; HENDLER RW, 1991, BIOPHYS J, V60, P415, DOI 10.1016/S0006-3495(91)82067-7; IWATA S, 1995, NATURE, V376, P660, DOI 10.1038/376660a0; Kannt A, 1998, BIOPHYS J, V74, P708, DOI 10.1016/S0006-3495(98)73996-7; Kim Y, 2001, J AM CHEM SOC, V123, P757, DOI 10.1021/ja0027867; Kitagawa T, 2000, J INORG BIOCHEM, V82, P9, DOI 10.1016/S0162-0134(00)00155-0; KONSTANTINOV AA, 1992, FEBS LETT, V312, P71, DOI 10.1016/0014-5793(92)81412-F; Koutsoupakis K, 2002, J BIOL CHEM, V277, P32860, DOI 10.1074/jbc.M204943200; MacMillan F, 1999, BIOCHEMISTRY-US, V38, P9179, DOI 10.1021/bi9911987; MCDONALD MR, 1995, INORG CHEM, V34, P229, DOI 10.1021/ic00105a038; McDonald MR, 1997, INORG CHEM, V36, P3119, DOI 10.1021/ic9608713; Michel H, 1998, P NATL ACAD SCI USA, V95, P12819, DOI 10.1073/pnas.95.22.12819; Michel H, 1999, BIOCHEMISTRY-US, V38, P15129, DOI 10.1021/bi9910934; Michel H, 1998, ANNU REV BIOPH BIOM, V27, P329, DOI 10.1146/annurev.biophys.27.1.329; Morgan JE, 2001, BIOCHEMISTRY-US, V40, P6882, DOI 10.1021/bi010246w; OERTLING WA, 1988, BIOCHEMISTRY-US, V27, P5395, DOI 10.1021/bi00415a002; OERTLING WA, 1990, INORG CHEM, V29, P2633, DOI 10.1021/ic00339a021; OGURA T, 1990, J AM CHEM SOC, V112, P5630, DOI 10.1021/ja00170a032; Ogura T, 1996, J AM CHEM SOC, V118, P5443, DOI 10.1021/ja951922i; OGURA T, 1993, J AM CHEM SOC, V115, P8527, DOI 10.1021/ja00072a002; OGURA T, 1990, J BIOL CHEM, V265, P14721; Ostermeier C, 1997, P NATL ACAD SCI USA, V94, P10547, DOI 10.1073/pnas.94.20.10547; PALMER G, 1998, EBEC SHORT REP, V10, P85; Pecoraro C, 2001, BIOCHEMISTRY-US, V40, P9695, DOI 10.1021/bi010115v; Pfitzner U, 1998, J BIOENERG BIOMEMBR, V30, P89, DOI 10.1023/A:1020515713103; Pinakoulaki E, 2002, J BIOL CHEM, V277, P13563, DOI 10.1074/jbc.M112200200; POULOS TL, 1988, ADV INORG BIOCHEM, V7, P1; Proshlyakov DA, 2000, SCIENCE, V290, P1588, DOI 10.1126/science.290.5496.1588; Proshlyakov DA, 1996, BIOCHEMISTRY-US, V35, P8580, DOI 10.1021/bi952096t; Proshlyakov DA, 1996, BIOCHEMISTRY-US, V35, P76, DOI 10.1021/bi9511705; PROSHLYAKOV DA, 1994, J BIOL CHEM, V269, P29385; Proshlyakov DA, 1998, P NATL ACAD SCI USA, V95, P8020, DOI 10.1073/pnas.95.14.8020; Rigby SEJ, 2000, BIOCHEMISTRY-US, V39, P5921, DOI 10.1021/bi992614q; Soulimane T, 2000, EMBO J, V19, P1766, DOI 10.1093/emboj/19.8.1766; Sundaramoorthy M, 1995, STRUCTURE, V3, P1367, DOI 10.1016/S0969-2126(01)00274-X; TSUKIHARA T, 1995, SCIENCE, V269, P1069, DOI 10.1126/science.7652554; Uchida T, 2000, BIOCHEMISTRY-US, V39, P6669, DOI 10.1021/bi992538r; VAROTSIS C, 1993, P NATL ACAD SCI USA, V90, P237, DOI 10.1073/pnas.90.1.237; VAROTSIS C, 1990, APPL SPECTROSC, V44, P742, DOI 10.1366/0003702904087550; Varotsis C, 1998, J PHYS CHEM B, V102, P7670, DOI 10.1021/jp9824095; VAROTSIS C, 1995, BBA-BIOENERGETICS, V1231, P111, DOI 10.1016/0005-2728(95)00076-U; VAROTSIS C, 1990, BIOCHEMISTRY-US, V29, P7357, DOI 10.1021/bi00484a001; VAROTSIS C, 1989, J AM CHEM SOC, V111, P6439, DOI 10.1021/ja00198a075; VAROTSIS C, 1990, J AM CHEM SOC, V112, P1297, DOI 10.1021/ja00159a091; VAROTSIS C, 1990, J BIOL CHEM, V265, P11131; VAROTSIS CA, 1995, J AM CHEM SOC, V117, P11260, DOI 10.1021/ja00150a025; Varotsis Constantinos, 1993, V226, P409; Verkhovsky MI, 1996, P NATL ACAD SCI USA, V93, P12235, DOI 10.1073/pnas.93.22.12235; VYGODINA TV, 1988, ANN NY ACAD SCI, V550, P124, DOI 10.1111/j.1749-6632.1988.tb35329.x; Vygodina TV, 1998, BIOCHEMISTRY-US, V37, P3053, DOI 10.1021/bi971876u; WENG LC, 1991, BIOCHEMISTRY-US, V30, P5727, DOI 10.1021/bi00237a014; WIKSTROM M, 1989, NATURE, V338, P776, DOI 10.1038/338776a0; WRIGGLESWORTH JM, 1984, BIOCHEM J, V217, P715, DOI 10.1042/bj2170715; WU W, 1992, J AM CHEM SOC, V114, P1182, DOI 10.1021/ja00030a009; Yoshikawa S, 1998, SCIENCE, V280, P1723, DOI 10.1126/science.280.5370.1723	69	32	32	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 23	2003	278	21					18761	18766		10.1074/jbc.M211925200	http://dx.doi.org/10.1074/jbc.M211925200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	679PY	12637529	hybrid			2022-12-25	WOS:000182932200009
J	Grant, GA; Hu, ZQ; Xu, XL				Grant, GA; Hu, ZQ; Xu, XL			Hybrid tetramers reveal elements of cooperativity in Escherichia coli D-3-phosphoglycerate dehydrogenase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							L-LACTATE DEHYDROGENASE; MODULATED ALLOSTERIC REGULATION; EFFECTOR-BINDING; PHOSPHOGLYCERATE DEHYDROGENASE; DOMAIN INTERFACE; INHIBITION; MECHANISM; ACTIVATION; ENZYMES; SITE	D-3-Phosphoglycerate dehydrogenase from Escherichia coli is a tetramer of identical subunits that is inhibited when L-serine binds at allosteric sites between subunits. Co-expression of two genes, the native gene containing a charge difference mutation and a gene containing a mutation that eliminates serine binding, produces hybrid tetramers that can be separated by ion exchange chromatography. Activity in the hybrid tetramer with only a single intact serine binding site is inhibited by similar to58% with a Hill coefficient of 1. Thus, interaction at a single regulatory domain interface does not, in itself, lead to the positive cooperativity of inhibition manifest in the native enzyme. Tetramers with only two intact serine binding sites purify as a mixture that displays a maximum inhibition level that is less than that of native enzyme, suggesting the presence of a population of tetramers that are unable to be fully inhibited. Differential analysis of this mixture supports the conclusion that it contains two forms of the tetramer. One form contains two intact serine binding sites at the same interface and is not fully inhibitable. The second form is a fully inhibitable population that has one serine binding site at each interface. Overall, the hybrid tetramers show that the positive cooperativity observed for serine binding is mediated across the nucleotide binding domain interface, and the negative cooperativity is mediated across the regulatory domain interface. That is, they reveal a pattern in which the binding of serine at one interface leads to negative cooperativity of binding of a subsequent serine at the same interface and positive cooperativity of binding of a subsequent serine to the opposite interface. This trend is propagated to subsequent binding sites in the tetramer such that the negative cooperativity that is originally manifest at one interface is decreased by subsequent binding of ligand at the opposite interface.	Washington Univ, Sch Med, Dept Mol Biol & Pharmacol, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Med, St Louis, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL)	Grant, GA (corresponding author), Washington Univ, Sch Med, Dept Mol Biol & Pharmacol, Box 8103,660 S Euclid Ave, St Louis, MO 63110 USA.							AlRabiee R, 1996, J BIOL CHEM, V271, P23235, DOI 10.1074/jbc.271.38.23235; AlRabiee R, 1996, J BIOL CHEM, V271, P13013, DOI 10.1074/jbc.271.22.13013; BELL JE, 1988, PROTEINS ENZYMES, P465; Choe JY, 2000, BIOCHEMISTRY-US, V39, P8565, DOI 10.1021/bi000574g; Fushinobu S, 1998, J BIOL CHEM, V273, P2971, DOI 10.1074/jbc.273.5.2971; Fushinobu S, 1996, J BIOL CHEM, V271, P25611, DOI 10.1074/jbc.271.41.25611; Grant GA, 2000, BIOCHEMISTRY-US, V39, P7316, DOI 10.1021/bi000218y; Grant GA, 1999, PROTEIN SCI, V8, P2501; Grant GA, 1996, PROTEIN SCI, V5, P34; Grant GA, 2002, J BIOL CHEM, V277, P39548, DOI 10.1074/jbc.M208019200; Grant GA, 2001, J BIOL CHEM, V276, P17844, DOI 10.1074/jbc.M009957200; Grant GA, 2001, J BIOL CHEM, V276, P1078, DOI 10.1074/jbc.M007512200; GRANT GA, BIOCHEMISTRY, V38, P16548; IWATA S, 1994, NAT STRUCT BIOL, V1, P176, DOI 10.1038/nsb0394-176; Neet K E, 1980, Methods Enzymol, V64, P139; Nelson SW, 2002, J BIOL CHEM, V277, P15539, DOI 10.1074/jbc.M112304200; SCHULLER DJ, 1995, NAT STRUCT BIOL, V2, P69, DOI 10.1038/nsb0195-69; SCHULLER DJ, 1989, J BIOL CHEM, V264, P2645; SUGIMOTO E, 1968, J BIOL CHEM, V243, P2090; SUGIMOTO E, 1968, J BIOL CHEM, V243, P2081; TOBEY KL, 1986, J BIOL CHEM, V261, P2179; Zhao GS, 1996, J BACTERIOL, V178, P232, DOI 10.1128/jb.178.1.232-239.1996	22	12	13	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 16	2003	278	20					18170	18176		10.1074/jbc.M213050200	http://dx.doi.org/10.1074/jbc.M213050200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677YX	12644455	hybrid			2022-12-25	WOS:000182838300076
J	Ollagnier-de Choudens, S; Nachin, L; Sanakis, Y; Loiseau, L; Barras, F; Fontecave, M				Ollagnier-de Choudens, S; Nachin, L; Sanakis, Y; Loiseau, L; Barras, F; Fontecave, M			SufA from Erwinia chrysanthemi - Characterization of a scaffold protein required for iron-sulfur cluster assembly	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FE-S CLUSTER; ESCHERICHIA-COLI; BIOTIN SYNTHASE; SACCHAROMYCES-CEREVISIAE; GENE-CLUSTER; MITOCHONDRIAL PROTEINS; 2FE-2S CLUSTER; NIFS GENE; ISCU; BIOGENESIS	SufA is a component of the recently discovered suf operon, which has been shown to play an important function in bacteria during iron-sulfur cluster biosynthesis and resistance to oxidative stress. The SufA protein from Erwinia chrysanthemi, a Gram-negative plant pathogen, has been purified to homogeneity and characterized. It is a homodimer with the ability to assemble rather labile [2Fe-2S] and [4Fe-4S] clusters as shown by Mossbauer spectroscopy. These clusters can be transferred to apoproteins such as ferredoxin or biotin synthase during a reaction that is not inhibited by bathophenanthroline, an iron chelator. Cluster assembly in these proteins is much more efficient when iron and sulfur are provided by holoSufA than by free iron sulfate and sodium sulfide. We propose the function of SufA is that of a scaffold protein for [Fe-S] cluster assembly and compare it to IscA, a member of the isc operon also involved in cluster biosynthesis in both prokaryotes and eukaryotes. Mechanistic and physiological implications of these results are also discussed.	Univ Grenoble 1, CNRS,UMR 5047, CEA,Dept Response & Dynam Cellulaire Chim Biochim, Lab Chim & Biochim,Ctr Redox Biol, F-38054 Grenoble 09, France; Univ Gothenburg, S-40530 Gothenburg, Sweden; Natl Ctr Sci Res Demokritos, Inst Sci Mat, Athens 15310, Greece; Univ Ioannina, Dept Biol Applicat & Technol, GR-45110 Ioannina, Greece; CNRS, IBSM, Lab Chim Bacterienne, F-13402 Marseille 20, France	CEA; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); University of Gothenburg; National Centre of Scientific Research "Demokritos"; University of Ioannina; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Aix-Marseille Universite	Fontecave, M (corresponding author), Univ Grenoble 1, CNRS,UMR 5047, CEA,Dept Response & Dynam Cellulaire Chim Biochim, Lab Chim & Biochim,Ctr Redox Biol, 17 Ave Martyrs, F-38054 Grenoble 09, France.	mfontecave@cea.fr		Ollagnier de Choudens, Sandrine/0000-0002-0080-6659; Barras, Frederic/0000-0003-3458-2574				Agar JN, 2000, J BIOL INORG CHEM, V5, P167, DOI 10.1007/s007750050361; Agar JN, 2000, BIOCHEMISTRY-US, V39, P7856, DOI 10.1021/bi000931n; Agar JN, 2000, J AM CHEM SOC, V122, P2136, DOI 10.1021/ja9944195; ASHTON WT, 1978, J HETEROCYCLIC CHEM, V15, P489, DOI 10.1002/jhet.5570150324; Beinert H, 2000, J BIOL INORG CHEM, V5, P2, DOI 10.1007/s007750050002; Beinert H, 1997, SCIENCE, V277, P653, DOI 10.1126/science.277.5326.653; BEINERT H, 1983, ANAL BIOCHEM, V131, P373, DOI 10.1016/0003-2697(83)90186-0; BORTOLIGERMAN I, 1994, MOL MICROBIOL, V11, P545, DOI 10.1111/j.1365-2958.1994.tb00335.x; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Ellis KES, 2001, MOL MICROBIOL, V41, P973, DOI 10.1046/j.1365-2958.2001.02588.x; FISH WW, 1988, METHOD ENZYMOL, V158, P357, DOI 10.1016/0076-6879(88)58067-9; Flint DH, 1996, J BIOL CHEM, V271, P16068; Frazzon J, 2001, P NATL ACAD SCI USA, V98, P14751, DOI 10.1073/pnas.011579098; Garland SA, 1999, J MOL BIOL, V294, P897, DOI 10.1006/jmbi.1999.3294; Hantke K, 2002, J MOL MICROB BIOTECH, V4, P217; Hoff KG, 2002, J BIOL CHEM, V277, P27353, DOI 10.1074/jbc.M202814200; Hoff KG, 2000, P NATL ACAD SCI USA, V97, P7790, DOI 10.1073/pnas.130201997; Jensen LT, 2000, MOL CELL BIOL, V20, P3918, DOI 10.1128/MCB.20.11.3918-3927.2000; Kato S, 2002, P NATL ACAD SCI USA, V99, P5948, DOI 10.1073/pnas.082123599; Kaut A, 2000, J BIOL CHEM, V275, P15955, DOI 10.1074/jbc.M909502199; Kispal G, 1999, EMBO J, V18, P3981, DOI 10.1093/emboj/18.14.3981; Krebs C, 2001, BIOCHEMISTRY-US, V40, P14069, DOI 10.1021/bi015656z; Lange H, 2000, P NATL ACAD SCI USA, V97, P1050, DOI 10.1073/pnas.97.3.1050; Li J, 1999, J BIOL CHEM, V274, P33025, DOI 10.1074/jbc.274.46.33025; Li J, 2001, J BIOL CHEM, V276, P1503, DOI 10.1074/jbc.M007198200; Lill R, 1999, BIOL CHEM, V380, P1157, DOI 10.1515/BC.1999.147; Lima CD, 2002, J MOL BIOL, V315, P1199, DOI 10.1006/jmbi.2001.5308; Lutz T, 2001, J MOL BIOL, V307, P815, DOI 10.1006/jmbi.2001.4527; Mansy SS, 2002, J BIOL CHEM, V277, P21397, DOI 10.1074/jbc.M201439200; Manzella L, 1998, YEAST, V14, P839, DOI 10.1002/(SICI)1097-0061(19980630)14:9<839::AID-YEA283>3.0.CO;2-A; Mihara H, 2002, J BIOCHEM, V131, P679, DOI 10.1093/oxfordjournals.jbchem.a003151; Mihara H, 1999, J BIOL CHEM, V274, P14768, DOI 10.1074/jbc.274.21.14768; Morimoto K, 2002, FEBS LETT, V519, P123, DOI 10.1016/S0014-5793(02)02736-9; Muhlenhoff U, 2002, J BIOL CHEM, V277, P29810, DOI 10.1074/jbc.M204675200; Nachin L, 2003, EMBO J, V22, P427, DOI 10.1093/emboj/cdg061; Nachin L, 2001, MOL MICROBIOL, V39, P960, DOI 10.1046/j.1365-2958.2001.02288.x; Nakamura M, 1999, J BIOCHEM, V126, P10, DOI 10.1093/oxfordjournals.jbchem.a022409; Nishio K, 2000, J BIOL CHEM, V275, P22615, DOI 10.1074/jbc.C000279200; Ollagnier-de Choudens S, 2000, BIOCHEMISTRY-US, V39, P4165, DOI 10.1021/bi992090u; Ollagnier-de Choudens S, 2002, J BIOL CHEM, V277, P13449, DOI 10.1074/jbc.M111324200; Ollagnier-de-Choudens S, 2002, FEBS LETT, V532, P465, DOI 10.1016/S0014-5793(02)03733-X; Ollagnier-de-Choudens S, 2001, J BIOL CHEM, V276, P22604, DOI 10.1074/jbc.M102902200; Ollagnier-de-Choudens S, 2002, BIOCHEMISTRY-US, V41, P9145, DOI 10.1021/bi0122011; Patzer SI, 1999, J BACTERIOL, V181, P3307, DOI 10.1128/JB.181.10.3307-3309.1999; Pelzer W, 2000, FEBS LETT, V476, P134, DOI 10.1016/S0014-5793(00)01711-7; ROMAO MJ, 1995, SCIENCE, V270, P1170, DOI 10.1126/science.270.5239.1170; Schilke B, 1999, P NATL ACAD SCI USA, V96, P10206, DOI 10.1073/pnas.96.18.10206; SEATON BL, 1994, P NATL ACAD SCI USA, V91, P2066, DOI 10.1073/pnas.91.6.2066; Silberg JJ, 2001, J BIOL CHEM, V276, P1696, DOI 10.1074/jbc.M009542200; Skovran E, 2000, J BACTERIOL, V182, P3896, DOI 10.1128/JB.182.14.3896-3903.2000; Smith AD, 2001, J AM CHEM SOC, V123, P11103, DOI 10.1021/ja016757n; Strain J, 1998, J BIOL CHEM, V273, P31138, DOI 10.1074/jbc.273.47.31138; TA DT, 1992, J BIOL CHEM, V267, P11120; Takahashi Y, 1999, J BIOCHEM, V126, P917, DOI 10.1093/oxfordjournals.jbchem.a022535; Tamarit J, 1999, J BIOL CHEM, V274, P31291, DOI 10.1074/jbc.274.44.31291; Tokumoto U, 2002, J BIOCHEM, V131, P713, DOI 10.1093/oxfordjournals.jbchem.a003156; Tokumoto U, 2001, J BIOCHEM, V130, P63, DOI 10.1093/oxfordjournals.jbchem.a002963; Ugulava NB, 2001, BIOCHEMISTRY-US, V40, P8352, DOI 10.1021/bi010463x; Ugulava NB, 2001, BIOCHEMISTRY-US, V40, P8343, DOI 10.1021/bi0104625; Urbina HD, 2001, J BIOL CHEM, V276, P44521, DOI 10.1074/jbc.M106907200; Voisine C, 2000, MOL CELL BIOL, V20, P3677, DOI 10.1128/MCB.20.10.3677-3684.2000; Voisine C, 2001, P NATL ACAD SCI USA, V98, P1483, DOI 10.1073/pnas.98.4.1483; Wu G, 2002, BIOCHEMISTRY-US, V41, P5024, DOI 10.1021/bi016073s; Wu G, 2002, J BIOL INORG CHEM, V7, P526, DOI 10.1007/s00775-001-0330-2; Wu SP, 2002, BIOCHEMISTRY-US, V41, P8876, DOI 10.1021/bi0256781; Yuvaniyama P, 2000, P NATL ACAD SCI USA, V97, P599, DOI 10.1073/pnas.97.2.599; ZHENG LM, 1994, BIOCHEMISTRY-US, V33, P4714, DOI 10.1021/bi00181a031; Zheng LM, 1998, J BIOL CHEM, V273, P13264, DOI 10.1074/jbc.273.21.13264; Zheng M, 2001, J BACTERIOL, V183, P4562, DOI 10.1128/JB.183.15.4562-4570.2001	69	66	68	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 16	2003	278	20					17993	18001		10.1074/jbc.M300285200	http://dx.doi.org/10.1074/jbc.M300285200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677YX	12637501	hybrid			2022-12-25	WOS:000182838300052
J	Shand, JH; Beattie, J; Song, H; Phillips, K; Kelly, SM; Flint, DJ; Allan, GJ				Shand, JH; Beattie, J; Song, H; Phillips, K; Kelly, SM; Flint, DJ; Allan, GJ			Specific amino acid substitutions determine the differential contribution of the N- and C-terminal domains of insulin-like growth factor (IGF)-binding protein-5 in binding IGF-I	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CIRCULAR-DICHROISM; EXTRACELLULAR-MATRIX; HEPARIN-BINDING; SECONDARY STRUCTURE; SITE; IGFBP-3; LOCALIZATION; FRAGMENTS; RECEPTOR; REGION	We have previously reported that two highly conserved amino acids in the C-terminal domain of rat insulin-like growth factor-binding protein (IGFBP)-5, Gly(203) and Gln(209), are involved in binding to insulin-like growth factor (IGF)-1. Here we report that mutagenesis of both amino acids simultaneously (C-Term mutant) results in a cumulative effect and an even greater reduction in IGF-I binding: 30-fold measured by solution phase IGF binding assay and 10-fold by biosensor analysis. We compared these reductions in ligand binding to the effects of specific mutations of five amino acids in the N-terminal domain (N-Term mutant), which had previously been shown by others to cause a very large reduction in IGF-I binding (1). Our results confirm this as the major IGF-binding site. To prove that the mutations in either N- or C-Term were specific for IGF-I binding, we carried out CD spectroscopy and showed that these alterations did not lead to gross conformational changes in protein structure for either mutant. Combining these mutations in both domains (N+C-Term mutant) has a cumulative effect and leads to a 126-fold reduction in IGF-I binding as measured by biosensor. Furthermore, the equivalent mutations in the C terminus of rat IG-FBP2 (C-Term 2) also results in a significant reduction in IGF-I binding, suggesting that the highly conserved Gly and Gln residues have a conserved IGF-I binding function in all six IGFBPs. Finally, although these residues lie within a major heparin-binding site in IGFBP-5 and -3, we also show that the mutations in C-Term have no effect on heparin binding.	Hannah Res Inst, Ayr KA6 5HL, Scotland; Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA; Univ Glasgow, Inst Biomed & Life Sci, Glasgow G12 8QQ, Lanark, Scotland	Harvard University; Harvard Medical School; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; University of Glasgow	Allan, GJ (corresponding author), Hannah Res Inst, Ayr KA6 5HL, Scotland.		Kelly, Sharon/K-4611-2013	Kelly, Sharon/0000-0002-3516-1387				Allan GJ, 2002, ENDOCRINOLOGY, V143, P4310, DOI 10.1210/en.2001-211191; ANDRESS DL, 1993, BIOCHEM BIOPH RES CO, V195, P25, DOI 10.1006/bbrc.1993.2004; ARAI T, 1994, J BIOL CHEM, V269, P20388; Arai T, 1996, J BIOL CHEM, V271, P6099, DOI 10.1074/jbc.271.11.6099; BINOUX M, 1991, ACTA ENDOCRINOL-COP, V124, P41; Bramani S, 1999, J MOL ENDOCRINOL, V23, P117, DOI 10.1677/jme.0.0230117; Carrick FE, 2001, J BIOL CHEM, V276, P27120, DOI 10.1074/jbc.M101317200; CHERNAUSEK SD, 1995, J BIOL CHEM, V270, P11377, DOI 10.1074/jbc.270.19.11377; CLEMMONS DR, 1993, MOL REPROD DEV, V35, P368, DOI 10.1002/mrd.1080350409; CONOVER CA, 1989, J CLIN INVEST, V83, P852, DOI 10.1172/JCI113968; EFTINK MR, 1976, BIOCHEMISTRY-US, V15, P672, DOI 10.1021/bi00648a035; Firth SM, 1999, J ENDOCRINOL, V160, P379, DOI 10.1677/joe.0.1600379; Forbes BE, 1998, J BIOL CHEM, V273, P4647, DOI 10.1074/jbc.273.8.4647; Galanis M, 2001, J ENDOCRINOL, V169, P123, DOI 10.1677/joe.0.1690123; Ho PJ, 1997, ENDOCRINOLOGY, V138, P3811, DOI 10.1210/en.138.9.3811; Hobba GD, 1996, J BIOL CHEM, V271, P30529, DOI 10.1074/jbc.271.48.30529; Hobba GD, 1998, J BIOL CHEM, V273, P19691, DOI 10.1074/jbc.273.31.19691; HOSSENLOPP P, 1986, ANAL BIOCHEM, V154, P138, DOI 10.1016/0003-2697(86)90507-5; HUHTALA ML, 1986, BIOCHEM BIOPH RES CO, V141, P263, DOI 10.1016/S0006-291X(86)80363-1; Hwa V, 1999, ENDOCR REV, V20, P761, DOI 10.1210/er.20.6.761; Imai Y, 2000, J BIOL CHEM, V275, P18188, DOI 10.1074/jbc.M000070200; Kalus W, 1998, EMBO J, V17, P6558, DOI 10.1093/emboj/17.22.6558; MANAVALAN P, 1983, NATURE, V305, P831, DOI 10.1038/305831a0; Parker A, 1996, J BIOL CHEM, V271, P13523, DOI 10.1074/jbc.271.23.13523; Parker A, 1998, MOL BIOL CELL, V9, P2383, DOI 10.1091/mbc.9.9.2383; PROVENCHER SW, 1981, BIOCHEMISTRY-US, V20, P33, DOI 10.1021/bi00504a006; Schneider MR, 2002, J ENDOCRINOL, V172, P423, DOI 10.1677/joe.0.1720423; SOMMER A, 1993, GROWTH REGULAT, V3, P46; SOMMER A, 1991, MODERN CONCEPTS INSU, P329; Song H, 2000, J MOL ENDOCRINOL, V24, P43, DOI 10.1677/jme.0.0240043; Song H, 2001, J MOL ENDOCRINOL, V26, P229, DOI 10.1677/jme.0.0260229; Sreerama N, 2000, ANAL BIOCHEM, V287, P252, DOI 10.1006/abio.2000.4880; Vorwerk P, 2002, ENDOCRINOLOGY, V143, P1677, DOI 10.1210/en.143.5.1677; WANG JF, 1988, BIOCHEM BIOPH RES CO, V157, P718, DOI 10.1016/S0006-291X(88)80309-7; WU J, 1992, ANAL BIOCHEM, V200, P359, DOI 10.1016/0003-2697(92)90479-Q	35	47	48	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 16	2003	278	20					17859	17866		10.1074/jbc.M300526200	http://dx.doi.org/10.1074/jbc.M300526200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677YX	12626499	hybrid			2022-12-25	WOS:000182838300035
J	Boutaud, O; Li, JY; Zagol, I; Shipp, EA; Davies, SS; Roberts, LJ; Oates, JA				Boutaud, O; Li, JY; Zagol, I; Shipp, EA; Davies, SS; Roberts, LJ; Oates, JA			Levuglandinyl adducts of proteins are formed via a prostaglandin H-2 synthase-dependent pathway after platelet activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ARACHIDONIC-ACID; COVALENT BINDING; LYSYL ADDUCTS; IDENTIFICATION; ENDOPEROXIDES; PRODUCTS	The product of oxygenation of arachidonic acid by the prostaglandin H synthases (PGHS), prostaglandin H-2 (PGH(2)), undergoes rearrangement to the highly reactive gamma-ketoaldehydes, levuglandin (LG) E-2, and LGD(2). We have demonstrated previously that LGE(2) reacts with the epsilon-amine of lysine to form both the levuglandinyl-lysine Schiff base and the pyrrole-derived levuglandinyl-lysine lactam adducts. We also have reported that these levuglandinyl-lysine adducts are formed on purified PGHSs following the oxygenation of arachidonic acid. We now present evidence that the levuglandinyl-lysine lactam adduct is formed in human platelets upon activation with exogenous arachidonic acid or thrombin. After proteolytic digestion of the platelet proteins, and isolation of the adducted amino acid residues, this adduct was identified by liquid chromatography-tandem mass spectrometry. We also demonstrate that formation of these adducts is inhibited by indomethacin, a PGHS inhibitor, and is enhanced by an inhibitor of thromboxane synthase. These data establish that levuglandinyl-lysine adducts are formed via a PGHS-dependent pathway in whole cells, even in the presence of an enzyme that metabolizes PGH(2). They also demonstrate that a physiological stimulus is sufficient to lead to the lipid modification of proteins through the levuglandin pathway in human platelets.	Vanderbilt Univ, Dept Pharmacol, Nashville, TN 37232 USA; Vanderbilt Univ, Dept Med, Nashville, TN 37232 USA	Vanderbilt University; Vanderbilt University	Boutaud, O (corresponding author), Vanderbilt Univ, Dept Pharmacol, Nashville, TN 37232 USA.	olivier.boutaud@vanderbilt.edu		Davies, Sean/0000-0001-9879-8062	NCI NIH HHS [CA 68485] Funding Source: Medline; NIGMS NIH HHS [GM 15431, GM 42056] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA068485] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P01GM015431, P50GM015431, R37GM042056, R01GM042056] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bernoud-Hubac N, 2001, J BIOL CHEM, V276, P30964, DOI 10.1074/jbc.M103768200; Boutaud O, 2002, J NEUROCHEM, V82, P1003, DOI 10.1046/j.1471-4159.2002.01064.x; Boutaud O, 2002, P NATL ACAD SCI USA, V99, P7130, DOI 10.1073/pnas.102588199; Boutaud O, 2001, BIOCHEMISTRY-US, V40, P6948, DOI 10.1021/bi002629k; Boutaud O, 1999, BIOCHEMISTRY-US, V38, P9389, DOI 10.1021/bi990470+; Brame CJ, 1999, J BIOL CHEM, V274, P13139, DOI 10.1074/jbc.274.19.13139; BUSER CA, 1994, BIOCHEMISTRY-US, V33, P13093, DOI 10.1021/bi00248a019; Davies SS, 2002, FASEB J, V16, P715, DOI 10.1096/fj.01-0696fje; IYER RS, 1989, PROSTAGLANDINS, V37, P471, DOI 10.1016/0090-6980(89)90096-8; LAGARDE M, 1980, THROMB RES, V17, P581, DOI 10.1016/0049-3848(80)90098-5; LECOMTE M, 1990, J BIOL CHEM, V265, P5178; MILLER DB, 1990, J ORG CHEM, V55, P3164, DOI 10.1021/jo00297a036; MURTHI KK, 1993, BIOCHEMISTRY-US, V32, P4090, DOI 10.1021/bi00066a034; SALOMON RG, 1984, J AM CHEM SOC, V106, P8296, DOI 10.1021/ja00338a050; WILSON AGE, 1979, PROSTAGLANDINS, V18, P409, DOI 10.1016/S0090-6980(79)80060-X	15	29	32	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 9	2003	278	19					16926	16928		10.1074/jbc.M300940200	http://dx.doi.org/10.1074/jbc.M300940200			3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677QG	12637576	hybrid			2022-12-25	WOS:000182818600065
J	Hu, YZ; Mivechi, NF				Hu, YZ; Mivechi, NF			HSF-1 interacts with Ral-binding protein 1 in a stress-responsive, multiprotein complex with HSP90 in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK FACTOR-1; SIGNAL-REGULATED KINASE; FACTOR-I; TRANSCRIPTIONAL ACTIVITY; MOLECULAR CHAPERONES; SYNAPTIC VESICLES; PUTATIVE EFFECTOR; ACTIVATION; GTPASE; PHOSPHORYLATION	Heat shock factor 1 (HSF1) regulates the rapid and transient expression of heat shock genes in response to stress. The transcriptional activity of HSF1 is tightly controlled, and under physiological growth conditions, the HSF1 monomer is in a heterocomplex with the molecular chaperone HSP90. Through unknown mechanisms, transcriptionally repressed HSF1.HSP90 heterocomplexes dissociate following stress, which triggers HSF1 activation and heat shock gene transcription. Using a yeast two-hybrid screening system, we have identified Ral-binding protein 1 (RalBP1) as an additional HSF1-interacting protein. We show that RalBP1 and HSF1 interact in vivo, and transient cotransfection of HSF1 and RalBP1 into hsf1(-/-) mouse embryo fibroblasts represses HSP70 expression. Furthermore, transient cotransfection of HSF1 and the constitutively active form of RalA (RalA23V), an upstream activator of the RalBP1 signaling pathway, increases the heat-inducible expression of HSP70, whereas the dominant negative form (RalA28N) suppresses HSP70 expression. We further find that alpha-tubulin and HSP90 are also present in the RalBP1.HSF1 heterocomplexes in unstressed cells. Upon heat shock, the Ral signaling pathway is activated, and the resulting RalGTP binds RalBP1. Concurrently, HSF1 is activated, leaves the RalBP1.HSF1.HSP90.alpha-tubulin heterocomplexes, and translocates into the nucleus, where it then activates transcription. In conclusion, these observations reveal that the RalGTP signal transduction pathway is critical for activation of the stress-responsive HSF1 and perhaps HSP90 molecular chaperone system.	Med Coll Georgia, Inst Mol Med & Genet, Augusta, GA 30912 USA; Med Coll Georgia, Dept Radiol, Augusta, GA 30912 USA	University System of Georgia; Augusta University; University System of Georgia; Augusta University	Mivechi, NF (corresponding author), Med Coll Georgia, Inst Mol Med & Genet, 1120 15th St CB2803, Augusta, GA 30912 USA.	mivechi@immag.mcg.edu			NCI NIH HHS [CA85947, CA62130] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA062130, R01CA085947] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aronheim A, 1997, MOL CELL BIOL, V17, P3094, DOI 10.1128/MCB.17.6.3094; Bharadwaj S, 1999, MOL CELL BIOL, V19, P8033; Bhattacharya M, 2002, NAT CELL BIOL, V4, P547, DOI 10.1038/ncb821; BIELINSKI DF, 1993, BIOCHIM BIOPHYS ACTA, V1151, P246, DOI 10.1016/0005-2736(93)90109-D; CANTOR SB, 1995, MOL CELL BIOL, V15, P4578; Chen H, 1998, NATURE, V394, P793, DOI 10.1038/29555; Chu BY, 1996, J BIOL CHEM, V271, P30847, DOI 10.1074/jbc.271.48.30847; Dai RJ, 2000, J BIOL CHEM, V275, P18210, DOI 10.1074/jbc.M000958200; De Ruiter ND, 2000, MOL CELL BIOL, V20, P8480, DOI 10.1128/MCB.20.22.8480-8488.2000; De Ruiter ND, 2001, MOL CELL BIOL, V21, P8225, DOI 10.1128/MCB.21.23.8225-8235.2001; Feig LA, 1996, TRENDS BIOCHEM SCI, V21, P438, DOI 10.1016/S0968-0004(96)10058-X; Franke B, 1997, EMBO J, V16, P252, DOI 10.1093/emboj/16.2.252; Goi T, 2000, EMBO J, V19, P623, DOI 10.1093/emboj/19.4.623; Guo YL, 2001, J BIOL CHEM, V276, P45791, DOI 10.1074/jbc.M105931200; He B, 1998, MOL CELL BIOL, V18, P6624, DOI 10.1128/MCB.18.11.6624; Henry DO, 2000, MOL CELL BIOL, V20, P8084, DOI 10.1128/MCB.20.21.8084-8092.2000; Hofer F, 1998, CURR BIOL, V8, P839, DOI 10.1016/S0960-9822(98)70327-6; Holmberg CI, 2001, EMBO J, V20, P3800, DOI 10.1093/emboj/20.14.3800; Ikeda M, 1998, J BIOL CHEM, V273, P814, DOI 10.1074/jbc.273.2.814; JIANG H, 1995, NATURE, V378, P409, DOI 10.1038/378409a0; Jullien-Flores V, 2000, J CELL SCI, V113, P2837; JULLIENFLORES V, 1995, J BIOL CHEM, V270, P22473, DOI 10.1074/jbc.270.38.22473; Kline MP, 1997, MOL CELL BIOL, V17, P2107, DOI 10.1128/MCB.17.4.2107; Knauf U, 1996, GENE DEV, V10, P2782, DOI 10.1101/gad.10.21.2782; Kops GJPL, 1999, NATURE, V398, P630, DOI 10.1038/19328; Liang P, 1997, J CELL SCI, V110, P1431; Luo JQ, 1998, P NATL ACAD SCI USA, V95, P3632, DOI 10.1073/pnas.95.7.3632; MCCORMICK F, 1995, MOL REPROD DEV, V42, P500, DOI 10.1002/mrd.1080420419; Miller MJ, 1997, J BIOL CHEM, V272, P5600, DOI 10.1074/jbc.272.9.5600; Morimoto RI, 1998, GENE DEV, V12, P3788, DOI 10.1101/gad.12.24.3788; Moskalenko S, 2002, NAT CELL BIOL, V4, P66, DOI 10.1038/ncb728; Nakashima S, 1999, EMBO J, V18, P3629, DOI 10.1093/emboj/18.13.3629; Ohta Y, 1999, P NATL ACAD SCI USA, V96, P2122, DOI 10.1073/pnas.96.5.2122; Ouwens DM, 2002, EMBO J, V21, P3782, DOI 10.1093/emboj/cdf361; Park SH, 1995, ONCOGENE, V11, P2349; Pishvaee B, 1998, CELL, V95, P443, DOI 10.1016/S0092-8674(00)81611-6; Quaroni A, 1999, J CELL SCI, V112, P707; Reuther GW, 2000, CURR OPIN CELL BIOL, V12, P157, DOI 10.1016/S0955-0674(99)00071-X; RodriguezViciana P, 1997, CELL, V89, P457, DOI 10.1016/S0092-8674(00)80226-3; SARGE KD, 1993, MOL CELL BIOL, V13, P1392, DOI 10.1128/MCB.13.3.1392; Satyal SH, 1998, GENE DEV, V12, P1962, DOI 10.1101/gad.12.13.1962; Scita G, 2000, EMBO J, V19, P2393, DOI 10.1093/emboj/19.11.2393; Soncin F, 2000, INT J MOL MED, V6, P705; Sugihara K, 2002, NAT CELL BIOL, V4, P73, DOI 10.1038/ncb720; Suzuki J, 2000, MOL CELL BIOL, V20, P4658, DOI 10.1128/MCB.20.13.4658-4665.2000; Urano T, 1996, EMBO J, V15, P810, DOI 10.1002/j.1460-2075.1996.tb00416.x; VOLKNANDT W, 1993, FEBS LETT, V317, P53, DOI 10.1016/0014-5793(93)81490-Q; Ward Y, 2001, MOL CELL BIOL, V21, P5958, DOI 10.1128/MCB.21.17.5958-5969.2001; White MA, 1996, J BIOL CHEM, V271, P16439, DOI 10.1074/jbc.271.28.16439; Wolthuis RMF, 1998, CURR BIOL, V8, P471, DOI 10.1016/S0960-9822(98)70183-6; Wolthuis RMF, 1999, CURR OPIN GENET DEV, V9, P112, DOI 10.1016/S0959-437X(99)80016-1; Wolthuis RMF, 1998, MOL CELL BIOL, V18, P2486, DOI 10.1128/MCB.18.5.2486; Wolthuis RMF, 1997, EMBO J, V16, P6748, DOI 10.1093/emboj/16.22.6748; Xia WL, 1997, J BIOL CHEM, V272, P4094, DOI 10.1074/jbc.272.7.4094; Yamaguchi A, 1997, J BIOL CHEM, V272, P31230, DOI 10.1074/jbc.272.50.31230; Zou JY, 1998, CELL, V94, P471, DOI 10.1016/S0092-8674(00)81588-3	56	89	95	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 9	2003	278	19					17299	17306		10.1074/jbc.M300788200	http://dx.doi.org/10.1074/jbc.M300788200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677QG	12621024	hybrid			2022-12-25	WOS:000182818600114
J	Mott, HR; Nietlispach, D; Hopkins, LJ; Mirey, G; Camonis, JH; Owen, D				Mott, HR; Nietlispach, D; Hopkins, LJ; Mirey, G; Camonis, JH; Owen, D			Structure of the GTPase-binding domain of Sec5 and elucidation of its Ral binding site	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KAPPA-B COMPLEX; CRYSTAL-STRUCTURE; EXOCYST COMPLEX; TRANSCRIPTION FACTOR; ANGSTROM RESOLUTION; NMR-SPECTROSCOPY; EFFECTOR DOMAIN; SEC6/8 COMPLEX; PROTEIN CDC42; DNA COMPLEX	The exocyst complex is involved in the final stages of exocytosis, when vesicles are targeted to the plasma membrane and dock. The regulation of exocytosis is vital for a number of processes, for example, cell polarity, embryogenesis, and neuronal growth formation. Regulation of the exocyst complex in mammals was recently shown to be dependent upon binding of the small G protein, Ral, to Sec5, a central component of the exocyst. This interaction is thought to be necessary for anchoring the exocyst to secretory vesicles. We have determined the structure of the Ral-binding domain of Sec5 and shown that it adopts a fold that has not been observed in a G protein effector before. This fold belongs to the immunoglobulin superfamily in a subclass known as IPT domains. We have mapped the Ral binding site on this domain and found that it overlaps with protein-protein interaction sites on other IPT domains but that it is completely different from the G protein-geranyl-geranyl interaction face of the Ig-like domain of the Rho guanine nucleotide dissociation inhibitor. This mapping, along with available site-directed mutagenesis data, allows us to predict how Ral and Sec5 may interact.	Univ Cambridge, Dept Biochem, Cambridge CB2 1GA, England; Inst Curie, F-75248 Paris 05, France	University of Cambridge; UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie	Owen, D (corresponding author), Univ Cambridge, Dept Biochem, 80 Tennis Court Rd, Cambridge CB2 1GA, England.		Mirey, Gladys/H-5676-2019; Mott, Helen/AAV-3873-2020	Mirey, Gladys/0000-0002-0095-1864; Mott, Helen/0000-0002-7890-7097; Nietlispach, Daniel/0000-0003-4364-9291				Abdul-Manan N, 1999, NATURE, V399, P379, DOI 10.1038/20726; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BARTON GJ, 1993, PROTEIN ENG, V6, P37, DOI 10.1093/protein/6.1.37; Bork P, 1999, TRENDS BIOCHEM SCI, V24, P261, DOI 10.1016/S0968-0004(99)01416-4; Brymora A, 2001, J BIOL CHEM, V276, P29792, DOI 10.1074/jbc.C100320200; Chen FE, 1998, NATURE, V391, P410, DOI 10.1038/34956; Chen L, 1998, NATURE, V392, P42, DOI 10.1038/32100; Chen YQ, 1998, NAT STRUCT BIOL, V5, P67, DOI 10.1038/nsb0198-67; Cornilescu G, 1999, J BIOMOL NMR, V13, P289, DOI 10.1023/A:1008392405740; Cramer P, 1997, EMBO J, V16, P7078, DOI 10.1093/emboj/16.23.7078; Dauter Z, 1999, BIOCHEMISTRY-US, V38, P8385, DOI 10.1021/bi990256l; Ferentz AE, 2000, Q REV BIOPHYS, V33, P29, DOI 10.1017/S0033583500003589; GHOSH G, 1995, NATURE, V373, P303, DOI 10.1038/373303a0; Gosser YQ, 1997, NATURE, V387, P814, DOI 10.1038/42961; Guo W, 1999, J BIOL CHEM, V274, P23558, DOI 10.1074/jbc.274.33.23558; Guo W, 1999, EMBO J, V18, P1071, DOI 10.1093/emboj/18.4.1071; Guo W, 2001, NAT CELL BIOL, V3, P353, DOI 10.1038/35070029; Hoffman GR, 2000, CELL, V100, P345, DOI 10.1016/S0092-8674(00)80670-4; Hsu SC, 1999, TRENDS CELL BIOL, V9, P150, DOI 10.1016/S0962-8924(99)01516-0; Huang L, 1997, NAT STRUCT BIOL, V4, P609, DOI 10.1038/nsb0897-609; Huxford T, 1998, CELL, V95, P759, DOI 10.1016/S0092-8674(00)81699-2; Jacobs MD, 1998, CELL, V95, P749, DOI 10.1016/S0092-8674(00)81698-0; Jullien-Flores V, 2000, J CELL SCI, V113, P2837; JULLIENFLORES V, 1995, J BIOL CHEM, V270, P22473, DOI 10.1074/jbc.270.38.22473; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KRAULIS PJ, 1994, BIOCHEMISTRY-US, V33, P3515, DOI 10.1021/bi00178a008; Linge JP, 2001, METHOD ENZYMOL, V339, P71, DOI 10.1016/S0076-6879(01)39310-2; Lu GG, 2000, J APPL CRYSTALLOGR, V33, P176, DOI 10.1107/S0021889899012339; Luo JQ, 1998, P NATL ACAD SCI USA, V95, P3632, DOI 10.1073/pnas.95.7.3632; Maesaki R, 1999, MOL CELL, V4, P793, DOI 10.1016/S1097-2765(00)80389-5; Matern HT, 2001, P NATL ACAD SCI USA, V98, P9648, DOI 10.1073/pnas.171317898; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; Morreale A, 2000, NAT STRUCT BIOL, V7, P384; Moskalenko S, 2002, NAT CELL BIOL, V4, P66, DOI 10.1038/ncb728; Mott HR, 1999, NATURE, V399, P384, DOI 10.1038/20732; MULLER CW, 1995, NATURE, V373, P311, DOI 10.1038/373311a0; Nakashima S, 1999, EMBO J, V18, P3629, DOI 10.1093/emboj/18.13.3629; NASSAR M, 1995, NATURE, V375, P554, DOI 10.1038/375554a0; Nietlispach D, 2002, J AM CHEM SOC, V124, P11199, DOI 10.1021/ja025865m; Novick P, 2002, TRENDS CELL BIOL, V12, P247, DOI 10.1016/S0962-8924(02)02293-6; Ostermeier C, 1999, CELL, V96, P363, DOI 10.1016/S0092-8674(00)80549-8; Owen D, 2000, BIOCHEMISTRY-US, V39, P1243, DOI 10.1021/bi991567z; Polzin A, 2002, MOL CELL BIOL, V22, P1714, DOI 10.1128/MCB.22.6.1714-1722.2002; Robinson NCG, 1999, MOL CELL BIOL, V19, P3580; Scheffzek K, 2000, NAT STRUCT BIOL, V7, P122, DOI 10.1038/72392; Stroud JC, 2002, NAT STRUCT BIOL, V9, P90, DOI 10.1038/nsb749; Sugihara K, 2002, NAT CELL BIOL, V4, P73, DOI 10.1038/ncb720; Tarricone C, 2001, NATURE, V411, P215, DOI 10.1038/35075620; Vetter IR, 1999, FEBS LETT, V451, P175, DOI 10.1016/S0014-5793(99)00555-4; Wang J, 1999, CELL, V97, P791, DOI 10.1016/S0092-8674(00)80790-4; Zhang XY, 2001, J BIOL CHEM, V276, P46745, DOI 10.1074/jbc.M107464200	51	24	26	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 9	2003	278	19					17053	17059		10.1074/jbc.M300155200	http://dx.doi.org/10.1074/jbc.M300155200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677QG	12624092	Green Published, hybrid			2022-12-25	WOS:000182818600082
J	Wahl, JK; Kim, YJ; Cullen, JM; Johnson, KR; Wheelock, MJ				Wahl, JK; Kim, YJ; Cullen, JM; Johnson, KR; Wheelock, MJ			N-cadherin-catenin complexes form prior to cleavage of the proregion and transport to the plasma membrane	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-CELL ADHESION; TYROSINE KINASE SUBSTRATE; ALPHA-CATENIN; CARCINOMA-CELLS; BETA-CATENIN; REGION; IDENTIFICATION; EXPRESSION; P120(CTN); PROTEINS	Cadherins are calcium-dependent glycoproteins that function as cell-cell adhesion molecules and are linked to the actin cytoskeleton via catenins. Newly synthesized cadherins contain a prosequence that must be proteolytically removed to generate a functional adhesion molecule. The goal of this study was to examine the proteolytic processing of N-cadherin and the assembly of the cadherin-catenin complex in cells that express endogenous N-cadherin. A monoclonal antibody specific for the proregion of human N-cadherin was generated and used to examine N-cadherin processing. Our data show that newly synthesized proN-cadherin is phosphorylated and proteolytically processed prior to transport to the plasma membrane. In addition, we show that beta-catenin and plakoglobin associate only with phosphorylated proN-cadherin, whereas p120(ctn) can associate with both phosphorylated and non-phosphorylated proN-cadherin. Immunoprecipitations using anti-proN-cadherin showed that cadherin-catenin complexes are assembled prior to localization at the plasma membrane. These data suggest that a core N-cadherin-catenin complex assembles in the endoplasmic reticulum or Golgi compartment and is transported to the plasma membrane where linkage to the actin cytoskeleton can be established.	Univ Nebraska, Med Ctr, Coll Dent, Omaha, NE 68198 USA; Eppley Canc Ctr, Omaha, NE 68198 USA	University of Nebraska System; University of Nebraska Medical Center	Wahl, JK (corresponding author), Univ Nebraska, Med Ctr, Coll Dent, 987696 Nebraska Med Ctr, Omaha, NE 68198 USA.		Cullen, John M/I-2051-2019		NIDCR NIH HHS [DE12308] Funding Source: Medline; NIGMS NIH HHS [GM51188] Funding Source: Medline; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE012308] Funding Source: NIH RePORTER	NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Aono S, 1999, J CELL BIOL, V145, P551, DOI 10.1083/jcb.145.3.551; Chen HY, 1997, J CELL SCI, V110, P345; DANIEL JM, 1995, MOL CELL BIOL, V15, P4819; Finnemann S, 1997, J BIOL CHEM, V272, P11856, DOI 10.1074/jbc.272.18.11856; Gumbiner BM, 2000, J CELL BIOL, V148, P399, DOI 10.1083/jcb.148.3.399; HINCK L, 1994, J CELL BIOL, V125, P1327, DOI 10.1083/jcb.125.6.1327; Huber AH, 2001, CELL, V105, P391, DOI 10.1016/S0092-8674(01)00330-0; Islam S, 1996, J CELL BIOL, V135, P1643, DOI 10.1083/jcb.135.6.1643; JOHNSON KR, 1993, EXP CELL RES, V207, P252, DOI 10.1006/excr.1993.1191; Kim JB, 2000, J CELL BIOL, V151, P1193, DOI 10.1083/jcb.151.6.1193; KNUDSEN KA, 1995, J CELL BIOL, V130, P67, DOI 10.1083/jcb.130.1.67; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lewis JE, 1997, J CELL BIOL, V136, P919, DOI 10.1083/jcb.136.4.919; Lickert H, 2000, J BIOL CHEM, V275, P5090, DOI 10.1074/jbc.275.7.5090; Mary S, 2002, MOL BIOL CELL, V13, P285, DOI 10.1091/mbc.01-07-0337; Nakayama K, 1997, BIOCHEM J, V327, P625, DOI 10.1042/bj3270625; Navarro P, 1998, J CELL BIOL, V140, P1475, DOI 10.1083/jcb.140.6.1475; Nieman MT, 1999, J CELL BIOL, V147, P631, DOI 10.1083/jcb.147.3.631; Nieset JE, 1997, J CELL SCI, V110, P1013; Nollet F, 2000, J MOL BIOL, V299, P551, DOI 10.1006/jmbi.2000.3777; Ohkubo T, 1999, J BIOL CHEM, V274, P21409, DOI 10.1074/jbc.274.30.21409; Ozawa M, 2002, J BIOL CHEM, V277, P19600, DOI 10.1074/jbc.M202029200; OZAWA M, 1992, J CELL BIOL, V116, P989, DOI 10.1083/jcb.116.4.989; OZAWA M, 1990, J CELL BIOL, V111, P1645, DOI 10.1083/jcb.111.4.1645; Pokutta S, 2000, MOL CELL, V5, P533, DOI 10.1016/S1097-2765(00)80447-5; Posthaus H, 1998, FEBS LETT, V438, P306, DOI 10.1016/S0014-5793(98)01330-1; REYNOLDS AB, 1994, MOL CELL BIOL, V14, P8333, DOI 10.1128/MCB.14.12.8333; RIMM DL, 1995, P NATL ACAD SCI USA, V92, P8813, DOI 10.1073/pnas.92.19.8813; SACCO PA, 1995, J BIOL CHEM, V270, P20201, DOI 10.1074/jbc.270.34.20201; SHIBAMOTO S, 1995, J CELL BIOL, V128, P949, DOI 10.1083/jcb.128.5.949; STAPPERT J, 1994, CELL ADHES COMMUN, V2, P319, DOI 10.3109/15419069409014207; Thoreson MA, 2000, J CELL BIOL, V148, P189, DOI 10.1083/jcb.148.1.189; Wahl JK, 2002, HYBRIDOMA HYBRIDOM, V21, P37, DOI 10.1089/15368590252917629; Wheelock MJ, 1996, CURR TOP MEMBR, V43, P169; Wheelock MJ, 2001, J MAMMARY GLAND BIOL, V6, P275, DOI 10.1023/A:1011319507155; Yagi T, 2000, GENE DEV, V14, P1169; Yap AS, 1998, J CELL BIOL, V141, P779, DOI 10.1083/jcb.141.3.779	37	95	97	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 9	2003	278	19					17269	17276		10.1074/jbc.M211452200	http://dx.doi.org/10.1074/jbc.M211452200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677QG	12604612	hybrid			2022-12-25	WOS:000182818600110
J	Hannah, BLA; Misenheimer, TM; Annis, DS; Mosher, DF				Hannah, BLA; Misenheimer, TM; Annis, DS; Mosher, DF			A polymorphism in thrombospondin-1 associated with familial premature coronary heart disease causes a local change in conformation of the Ca2+-binding repeats	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OLIGOMERIC MATRIX PROTEIN; MULTIPLE EPIPHYSEAL DYSPLASIA; PLATELET THROMBOSPONDIN; GROWTH-FACTOR; MONOCLONAL-ANTIBODIES; ENDOPLASMIC-RETICULUM; COMP GENE; PSEUDOACHONDROPLASIA; MUTATIONS; CALCIUM	A single nucleotide polymorphism that substitutes a serine for an asparagine at residue 700 in the Ca2+ binding repeats of thrombospondin-1 is associated with familial premature coronary heart disease. We expressed the Ca2+-binding repeats alone (Ca) or with the third epidermal growth factor-like module (E3Ca), without (Asn-700) or with (Ser-700) the disease-associated polymorphism. The intrinsic fluorescence of a single tryptophan (Trp-698) adjacent to the polymorphic residue was quenched cooperatively by adding Ca2+. The third epidermal growth factor-like repeat dramatically altered the Ca2+ -dependent fluorescence transition for the Asn-700 constructs; the half-effective concentration (EC50) of Ca Asn-700 was 390 muM, and the EC50 of E3Ca Asn-700 was 70 muM. The Ser-700 polymorphism shifted the EC50 to higher Ca2+ concentrations (Ca Ser-700 EC50 of 950 pm and E3Ca Ser-700 EC50 of 110 pm). This destabilizing effect is due to local conformational changes, as the Ser-700 polymorphism did not influence the secondary structure of E3Ca or Ca as assessed by far UV circular dichroism. At 200 pm Ca2+, in which both E3Ca Asn-700 and Ser-700 are in the Ca2+-replete conformation at 37 degreesC, the fluorescence of E3Ca Ser-700 reverted to the Ca2+-depleted spectrum at 50degreesC compared with 65degreesC for E3Ca Asn-700. These findings indicate that the Ser-700 polymorphism subtly but significantly sensitizes the calcium-binding repeats to removal of Ca2+ and thermal denaturation.	Univ Wisconsin, Med Sci Ctr, Dept Med, Madison, WI 53706 USA; Univ Wisconsin, Mol & Cellular Pharmacol Program, Madison, WI 53706 USA; Univ Wisconsin, Med Scientist Training Program, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison	Hannah, BLA (corresponding author), Univ Wisconsin, Med Sci Ctr, Dept Med, Madison, WI 53706 USA.	bahannah@students.wisc.edu			NHLBI NIH HHS [HL54462] Funding Source: Medline; NIGMS NIH HHS [T32 GM08688] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL054462] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008688] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Adams JC, 2001, ANNU REV CELL DEV BI, V17, P25, DOI 10.1146/annurev.cellbio.17.1.25; ADAMS JC, 1995, THROMBOSPONDIN GENE, P16; Adolph KW, 2001, GENE, V269, P177, DOI 10.1016/S0378-1119(01)00441-3; Alonso MT, 1998, CELL CALCIUM, V24, P87, DOI 10.1016/S0143-4160(98)90076-8; *AM HEART ASS, 2000, 2001 HEART STROK STA, P18; Ballo R, 1997, AM J MED GENET, V68, P396, DOI 10.1002/(SICI)1096-8628(19970211)68:4<396::AID-AJMG4>3.3.CO;2-R; Barrero MJ, 1997, J BIOL CHEM, V272, P27694, DOI 10.1074/jbc.272.44.27694; Briggs MD, 2002, HUM MUTAT, V19, P465, DOI 10.1002/humu.10066; BRIGGS MD, 1995, NAT GENET, V10, P330, DOI 10.1038/ng0795-330; Chen H, 2000, J BIOL CHEM, V275, P26538, DOI 10.1074/jbc.M909780199; Cohn DH, 1996, ANN NY ACAD SCI, V785, P188, DOI 10.1111/j.1749-6632.1996.tb56258.x; CREIGHTON TE, 1997, PROTEIN STRUCTURE PR, P279; Deere M, 1999, AM J MED GENET, V85, P486, DOI 10.1002/(SICI)1096-8628(19990827)85:5<486::AID-AJMG10>3.0.CO;2-O; Delot E, 1999, HUM MOL GENET, V8, P123, DOI 10.1093/hmg/8.1.123; DIXIT VM, 1986, J BIOL CHEM, V261, P1962; GALVIN NJ, 1985, J CELL BIOL, V101, P1434, DOI 10.1083/jcb.101.4.1434; HECHT JT, 1995, NAT GENET, V10, P325, DOI 10.1038/ng0795-325; Hecht JT, 2001, MATRIX BIOL, V20, P251, DOI 10.1016/S0945-053X(01)00136-6; Ikegawa S, 1998, HUM GENET, V103, P633, DOI 10.1007/s004390050883; Kiryushko DV, 2002, PFLUG ARCH EUR J PHY, V443, P643, DOI 10.1007/s00424-001-0739-z; Kleerekoper Q, 2002, J BIOL CHEM, V277, P10581, DOI 10.1074/jbc.M109944200; LAKOWICZ JR, 1983, PRINCIPLES FLUORESCE, P219; LAWLER J, 1985, J BIOL CHEM, V260, P3762; LAWLER J, 1982, J BIOL CHEM, V257, P2257; LAWLER J, 1983, J BIOL CHEM, V258, P2098; Loughlin J, 1998, HUM MUTAT, pS10; Maddox BK, 1997, J BIOL CHEM, V272, P30993, DOI 10.1074/jbc.272.49.30993; Maddox BK, 2000, J BIOL CHEM, V275, P11412, DOI 10.1074/jbc.275.15.11412; MAJACK RA, 1985, J CELL BIOL, V101, P1059, DOI 10.1083/jcb.101.3.1059; MAJACK RA, 1987, J BIOL CHEM, V262, P8821; MIANO JM, 1993, ARTERIOSCLER THROMB, V13, P211, DOI 10.1161/01.ATV.13.2.211; Misenheimer TM, 2001, J BIOL CHEM, V276, P45882, DOI 10.1074/jbc.M104218200; Mosher DF, 2002, METHOD CELL BIOL, V69, P69, DOI 10.1016/S0091-679X(02)69008-9; OROURKE KM, 1992, J BIOL CHEM, V267, P24921; Pimanda JE, 2002, BLOOD, V100, P2832, DOI 10.1182/blood-2002-03-0770; RAUGI GJ, 1990, AM J PATHOL, V137, P179; SPEZIALE MV, 1990, J BIOL CHEM, V265, P17859; Susic S, 1997, CLIN GENET, V51, P219; Thur J, 2001, J BIOL CHEM, V276, P6083, DOI 10.1074/jbc.M009512200; Topol EJ, 2001, CIRCULATION, V104, P2641, DOI 10.1161/hc4701.100910; TURK JL, 1986, ARCH BIOCHEM BIOPHYS, V245, P446, DOI 10.1016/0003-9861(86)90236-5; Vranka J, 2001, MATRIX BIOL, V20, P439, DOI 10.1016/S0945-053X(01)00148-2; Xie LJ, 2001, J EXP MED, V193, P1341, DOI 10.1084/jem.193.12.1341; YABKOWITZ R, 1993, J CELL PHYSIOL, V157, P24, DOI 10.1002/jcp.1041570104	44	23	23	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 14	2003	278	11					8929	8934		10.1074/jbc.M211185200	http://dx.doi.org/10.1074/jbc.M211185200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	654YF	12643280	hybrid			2022-12-25	WOS:000181524000010
J	Mehta, PB; Jenkins, BL; McCarthy, L; Thilak, L; Robson, CN; Neal, DE; Leung, HY				Mehta, PB; Jenkins, BL; McCarthy, L; Thilak, L; Robson, CN; Neal, DE; Leung, HY			MEK5 overexpression is associated with metastatic prostate cancer, and stimulates proliferation, MMP-9 expression and invasion	ONCOGENE			English	Article						MAPK; MEK5; ERK5; prostate cancer; metastasis	NF-KAPPA-B; BONE MORPHOGENETIC PROTEIN-6; SIGNAL-REGULATED KINASE; BREAST-CANCER; TRANSFORMING GROWTH-FACTOR-BETA-1; MATRIX METALLOPROTEINASES; TIMP-2 EXPRESSION; GENE-EXPRESSION; CARCINOMA-CELLS; GROWTH-FACTOR	The novel mitogen/extracellular-signal-regulated kinase kinase 5/extracellular signal-regulated kinase-5 (MEK5/ERK5) pathway has been implicated in the regulation of cellular proliferation. MEK5 expression has been detected in prostate cancer cells, although the significance of the MEK5/ERK5 pathway in human prostate cancer has not been tested. We examined MEK5 expression in 127 cases of prostate cancer and 20 cases of benign prostatic hypertrophy (BPH) by immunohistochemistry and compared the results to clinical parameters. We demonstrated that MEK5 expression is increased in prostate cancer as compared to benign prostatic tissue. Strong MEK5 expression correlates with the presence of bony metastases and less favourable disease-specific survival. Furthermore, among the patients with high Gleason score of 8-10, MEK5 overexpression has an additional prognostic value in survival. MEK5 transfection experiments confirm its ability to induce proliferation (P<0.0001), motility (P=0.0001) and invasion in prostate cancer cells (P=0.0001). MEK5 expression drastically increased MMP-9, but not MMP-2 mRNA expression. Luciferase report assays suggest that the -670/MMP-9 promoter is upregulated by MEK5 and electromobility shift assay further suggests the involvement of activator protein-I (AP-1), but not the NF-kappaB, binding site in the MMP-9 promoter. Using an AP-1 luciferase construct, activation of MEK5 was confirmed to enhance AP-1 activities up to twofold. Taken together, our results establish MEK5 as a key signalling molecule associated with prostate carcinogenesis. As the MEK5/ERK5 interaction is highly specific, it represents a potential target of therapy.	Univ Newcastle Upon Tyne, Sch Med, Dept Surg, Prostate Res Grp, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England	Newcastle University - UK	Leung, HY (corresponding author), Univ Newcastle Upon Tyne, Sch Med, Dept Surg, Prostate Res Grp, Framlington Pl, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.			Leung, Hing Y./0000-0002-3933-3975; Neal, David/0000-0002-6033-5086				Abe J, 1996, J BIOL CHEM, V271, P16586, DOI 10.1074/jbc.271.28.16586; Adler HL, 1999, J UROLOGY, V161, P182, DOI 10.1016/S0022-5347(01)62092-5; Autzen P, 1998, BRIT J CANCER, V78, P1219, DOI 10.1038/bjc.1998.658; Dong Z, 2001, INT J CANCER, V93, P507, DOI 10.1002/ijc.1358; EASTHAM JA, 1995, LAB INVEST, V73, P628; ENGLISH JM, 1995, J BIOL CHEM, V270, P28897, DOI 10.1074/jbc.270.48.28897; Esparis-Ogando A, 2002, MOL CELL BIOL, V22, P270, DOI 10.1128/MCB.22.1.270-285.2002; Foda HD, 2001, DRUG DISCOV TODAY, V6, P478, DOI 10.1016/S1359-6446(01)01752-4; Greenlee RT, 2001, CA-CANCER J CLIN, V51, P15, DOI 10.3322/canjclin.51.1.15; HAMDY FC, 1994, BRIT J CANCER, V69, P177, DOI 10.1038/bjc.1994.30; Hamdy FC, 1997, CANCER RES, V57, P4427; Hayakawa J, 1999, J BIOL CHEM, V274, P31648, DOI 10.1074/jbc.274.44.31648; Hetman M, 1999, J BIOL CHEM, V274, P22569, DOI 10.1074/jbc.274.32.22569; Jenkins BL, 2001, BRIT J CANCER, V85, P22; Kamakura S, 1999, J BIOL CHEM, V274, P26563, DOI 10.1074/jbc.274.37.26563; Kato Y, 1997, EMBO J, V16, P7054, DOI 10.1093/emboj/16.23.7054; Kato Y, 1998, NATURE, V395, P713, DOI 10.1038/27234; KOSTENUIK PJ, 1992, CLIN EXP METASTAS, V10, P411, DOI 10.1007/BF00133470; McCawley LJ, 2000, MOL MED TODAY, V6, P149, DOI 10.1016/S1357-4310(00)01686-5; McCawley LJ, 1999, J BIOL CHEM, V274, P4347, DOI 10.1074/jbc.274.7.4347; Okamoto M, 1997, CANCER RES, V57, P141; Pearson G, 2001, J BIOL CHEM, V276, P7927, DOI 10.1074/jbc.M009764200; Price DT, 1999, J UROLOGY, V162, P1537, DOI 10.1016/S0022-5347(05)68354-1; Ricca A, 2000, INT J CANCER, V86, P188, DOI 10.1002/(SICI)1097-0215(20000415)86:2<188::AID-IJC7>3.3.CO;2-N; Robinson D, 1996, P NATL ACAD SCI USA, V93, P5958, DOI 10.1073/pnas.93.12.5958; SATO H, 1993, ONCOGENE, V8, P395; Scorilas A, 2001, BRIT J CANCER, V84, P1488, DOI 10.1054/bjoc.2001.1810; Sebolt-Leopold JS, 1999, NAT MED, V5, P810, DOI 10.1038/10533; Sehgal G, 1998, AM J PATHOL, V152, P591; Stack MS, 1998, INT J ONCOL, V12, P569; Stadheim TA, 2000, BIOCHEM PHARMACOL, V59, P407, DOI 10.1016/S0006-2952(99)00330-5; STEARNS ME, 1993, CANCER RES, V53, P878; Stone AA, 2000, EXP CELL RES, V254, P110, DOI 10.1006/excr.1999.4731; Thomas RJ, 1999, ENDOCRINOLOGY, V140, P4451, DOI 10.1210/en.140.10.4451; Troussard AA, 2000, ONCOGENE, V19, P5444, DOI 10.1038/sj.onc.1203928; Wood M, 1997, CLIN EXP METASTAS, V15, P246, DOI 10.1023/A:1018421431388; Yan CH, 2001, J BIOL CHEM, V276, P1164, DOI 10.1074/jbc.M008681200; ZHOU GC, 1995, J BIOL CHEM, V270, P12665, DOI 10.1074/jbc.270.21.12665	38	146	154	0	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 6	2003	22	9					1381	1389		10.1038/sj.onc.1206154	http://dx.doi.org/10.1038/sj.onc.1206154			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	652CA	12618764	Bronze			2022-12-25	WOS:000181360900013
J	Lee, SY; Andoh, T; Murphy, DL; Chiueh, CC				Lee, SY; Andoh, T; Murphy, DL; Chiueh, CC			17 beta-estradiol activates ICI 182,780-sensitive estrogen receptors and cyclic GMP-dependent thioredoxin expression for neuroprotection	FASEB JOURNAL			English	Article						cognition; human SH-SY5Y neuroblastoma cell; MnSOD; NOS1/nNOS	NITRIC-OXIDE SYNTHASE; STRESS-INDUCED APOPTOSIS; SIGNAL-REGULATED KINASE; OXIDATIVE STRESS; PROTEIN-KINASE; DOPAMINERGIC-NEURONS; CELL-DEATH; MAMMALIAN THIOREDOXIN; S-NITROSOGLUTATHIONE; NEUROTROPHIC FACTOR	Clinical studies suggest that estrogen may improve cognition in Alzheimer's patients. Basic experiments demonstrate that 17beta-estradiol protects against neurodegeneration in both cell and animal models. In the present study, a human SH-SY5Y cell model was used to investigate molecular mechanisms underlying the receptor-mediated neuroprotection of physiological concentrations of 17beta-estradiol. 17beta-Estradiol (<10 nM) concomitantly increased neuronal nitric oxide synthase (NOS1) expression and cell viability. 17 beta-Estradiol-induced neuroprotection was blocked by the receptor antagonist ICI 182,780, also prevented by inhibitors of NOS1 (7-nitroindazole), guanylyl cyclase (LY 83,583), and cGMP-dependent protein kinase (PKG) (Rp-8-pCPT-cGMPs). In addition to the expression of NOS1 and MnSOD, 17 beta-estradiol increased the expression of the redox protein thioredoxin (Trx), which was blocked by the inhibition of either cGMP formation or PKG activity. The expression of heme oxygenase 2 and brain-derived neurotrophic factor was not altered. Estrogen receptor-enhanced cell viability against oxidative stress may be linked to Trx expression because the Trx reductase inhibitor, 5,5'-dithio-bis(2-nitrobenzoic acid) significantly reduced the cytoprotective effect of 17 beta-estradiol. Furthermore, Trx (1 mu M) inhibited lipid peroxidation, proapoptotic caspase-3, and cell death during oxidative stress caused by serum deprivation. We conclude that cGMP-dependent expression of Trx--the redox protein with potent antioxidative and antiapoptotic properties--may play a pivotal role in estrogen-induced neuroprotection.	NIMH, Clin Sci Lab, NIH, Bethesda, MD 20892 USA; Penn State Univ, Milton S Hershey Med Ctr, Dept Anat & Neurosci, Coll Med, Hershey, PA 17033 USA; Toyama Med & Pharmaceut Univ, Dept Appl Pharmacol, Fac Pharmaceut Sci, Toyama 9300194, Japan	National Institutes of Health (NIH) - USA; NIH National Institute of Mental Health (NIMH); Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health; University of Toyama	Chiueh, CC (corresponding author), NIMH, Clin Sci Lab, NIH, 10-3D-41, Bethesda, MD 20892 USA.	chiueh@helix.nih.gov		Lee, Sang/0000-0003-3911-8316				Andoh T, 2000, FASEB J, V14, P2144; Andoh T, 2003, J BIOL CHEM, V278, P885, DOI 10.1074/jbc.M209914200; Andoh T, 2002, ANN NY ACAD SCI, V962, P1, DOI 10.1111/j.1749-6632.2002.tb04051.x; Andoh T, 2002, J BIOL CHEM, V277, P9655, DOI 10.1074/jbc.M110701200; Asthana S, 2001, NEUROLOGY, V57, P605, DOI 10.1212/WNL.57.4.605; Bai J, 2002, NEUROSCI LETT, V321, P81, DOI 10.1016/S0304-3940(02)00058-7; Behl C, 1997, MOL PHARMACOL, V51, P535, DOI 10.1124/mol.51.4.535; Belcher SM, 1999, DEV BRAIN RES, V115, P57, DOI 10.1016/S0165-3806(99)00050-4; Belcher SM, 2001, J PHARMACOL EXP THER, V299, P408; Berco M, 2001, J SOC GYNECOL INVEST, V8, P245, DOI 10.1016/S1071-5576(01)00111-3; Beyer C, 2000, J NEUROSCI RES, V59, P107, DOI 10.1002/(SICI)1097-4547(20000101)59:1<107::AID-JNR13>3.0.CO;2-W; Bidmon HJ, 2001, J CHEM NEUROANAT, V22, P167, DOI 10.1016/S0891-0618(01)00126-0; Bolli R, 2001, J MOL CELL CARDIOL, V33, P1897, DOI 10.1006/jmcc.2001.1462; Bruce-Keller AJ, 2000, ENDOCRINOLOGY, V141, P3646, DOI 10.1210/en.141.10.3646; Chiueh CC, 1999, ANN NY ACAD SCI, V890, P301, DOI 10.1111/j.1749-6632.1999.tb08007.x; CHIUEH CC, 2001, MAPPING PROGR ALZHEI, P447; Culmsee C, 1999, J CEREBR BLOOD F MET, V19, P1263, DOI 10.1097/00004647-199911000-00011; Das KC, 1997, AM J RESP CELL MOL, V17, P713, DOI 10.1165/ajrcmb.17.6.2809; Dawson VL, 1996, J CHEM NEUROANAT, V10, P179, DOI 10.1016/0891-0618(96)00148-2; Dubal DB, 1999, J NEUROSCI, V19, P6385; Dubal DB, 2001, P NATL ACAD SCI USA, V98, P1952, DOI 10.1073/pnas.98.4.1952; Duran MG, 2000, OBSTET GYNECOL, V95, P284, DOI 10.1016/S0029-7844(99)00567-0; Estevez AG, 1998, J NEUROSCI, V18, P3708; FILLIT H, 1986, PSYCHONEUROENDOCRINO, V11, P337, DOI 10.1016/0306-4530(86)90019-3; Garcia-Duran M, 1999, CIRC RES, V85, P1020; Garcia-Segura LM, 2001, PROG NEUROBIOL, V63, P29, DOI 10.1016/S0301-0082(00)00025-3; Goetz RM, 1999, P NATL ACAD SCI USA, V96, P2788, DOI 10.1073/pnas.96.6.2788; Green P S, 2000, Novartis Found Symp, V230, P202, DOI 10.1002/0470870818.ch15; Green PS, 2000, INT J DEV NEUROSCI, V18, P347, DOI 10.1016/S0736-5748(00)00017-4; Greene K, 1997, WOMEN POLIT, V17, P17, DOI 10.1300/J014v17n03_02; HALL ED, 1991, J CEREBR BLOOD F MET, V11, P292, DOI 10.1038/jcbfm.1991.61; Harms C, 2001, J NEUROSCI, V21, P2600, DOI 10.1523/JNEUROSCI.21-08-02600.2001; Hawkins V, 1999, J BIOMED SCI, V6, P433, DOI 10.1159/000025419; HAYASHI T, 1993, J BIOL CHEM, V268, P11380; Hirota K, 1999, J BIOL CHEM, V274, P27891, DOI 10.1074/jbc.274.39.27891; Hirota K, 1997, P NATL ACAD SCI USA, V94, P3633, DOI 10.1073/pnas.94.8.3633; Hisamoto K, 2001, J BIOL CHEM, V276, P3459, DOI 10.1074/jbc.M005036200; Holmgren A, 2000, ANTIOXID REDOX SIGN, V2, P811, DOI 10.1089/ars.2000.2.4-811; Horimoto H, 2000, J SURG RES, V92, P56, DOI 10.1006/jsre.2000.5845; Howard SA, 2001, EXP NEUROL, V168, P385, DOI 10.1006/exnr.2000.7619; Howell A, 2000, CANCER-AM CANCER SOC, V89, P817, DOI 10.1002/1097-0142(20000815)89:4<817::AID-CNCR14>3.0.CO;2-6; Ivanova T, 2001, J NEUROSCI RES, V66, P221, DOI 10.1002/jnr.1214; Jover T, 2002, J NEUROSCI, V22, P2115, DOI 10.1523/JNEUROSCI.22-06-02115.2002; Khaldi A, 2002, ANN NY ACAD SCI, V962, P53, DOI 10.1111/j.1749-6632.2002.tb04055.x; Kim H, 2001, NEUROSCI LETT, V302, P58, DOI 10.1016/S0304-3940(01)01659-7; Kim YM, 1999, J NEUROSCI, V19, P6740, DOI 10.1523/JNEUROSCI.19-16-06740.1999; Kuntz MA, 1997, J BIOL CHEM, V272, P27949, DOI 10.1074/jbc.272.44.27949; Kuroki Y, 2001, EUR J NEUROSCI, V13, P472, DOI 10.1046/j.0953-816x.2000.01409.x; Lee SR, 2000, P NATL ACAD SCI USA, V97, P2521, DOI 10.1073/pnas.050579797; Liu H, 2000, MOL CELL BIOL, V20, P2198, DOI 10.1128/MCB.20.6.2198-2208.2000; McEwen B, 2001, P NATL ACAD SCI USA, V98, P7093, DOI 10.1073/pnas.121146898; Murad F, 1994, Adv Pharmacol, V26, P19, DOI 10.1016/S1054-3589(08)60049-6; Nethrapalli IS, 2001, ENDOCRINOLOGY, V142, P5145, DOI 10.1210/en.142.12.5145; Nuedling S, 2001, FEBS LETT, V502, P103, DOI 10.1016/S0014-5793(01)02675-8; Paech K, 1997, SCIENCE, V277, P1508, DOI 10.1126/science.277.5331.1508; Pantazis NJ, 1998, J NEUROCHEM, V70, P1826; Patrone C, 2000, ENDOCRINOLOGY, V141, P1839, DOI 10.1210/en.141.5.1839; Pelligrino DA, 1998, NEUROREPORT, V9, P3285, DOI 10.1097/00001756-199810050-00026; Rauhala P, 2000, ANN NY ACAD SCI, V899, P238; Rauhala P, 1998, FASEB J, V12, P165, DOI 10.1096/fasebj.12.2.165; Rauhala P, 1996, SYNAPSE, V23, P58, DOI 10.1002/(SICI)1098-2396(199605)23:1<58::AID-SYN7>3.0.CO;2-G; Roof RL, 2000, J NEUROTRAUM, V17, P367, DOI 10.1089/neu.2000.17.367; Sahlin L, 1997, BIOL REPROD, V57, P1056, DOI 10.1095/biolreprod57.5.1056; Saitoh M, 1998, EMBO J, V17, P2596, DOI 10.1093/emboj/17.9.2596; Samuels A, 2001, BONE, V29, P24, DOI 10.1016/S8756-3282(01)00471-9; Sawada H, 2000, FASEB J, V14, P1202, DOI 10.1096/fasebj.14.9.1202; Sawada H, 2002, NEUROPHARMACOLOGY, V42, P1056, DOI 10.1016/S0028-3908(02)00049-7; Sawada H, 2000, NEUROSCI BIOBEHAV R, V24, P143, DOI 10.1016/S0149-7634(99)00059-7; Shao LE, 2002, ANN NY ACAD SCI, V962, P140, DOI 10.1111/j.1749-6632.2002.tb04064.x; Shumaker SA, 1998, CONTROL CLIN TRIALS, V19, P604, DOI 10.1016/S0197-2456(98)00038-5; Simpkins JW., 1997, AM J MED, V103, p19S, DOI 10.1016/s0002-9343(97)00260-x; Singh M, 2000, J NEUROSCI, V20, P1694; Singh M, 2001, ENDOCRINE, V14, P407, DOI 10.1385/ENDO:14:3:407; Singleton JR, 1996, CANCER RES, V56, P4522; Smith MA, 2000, BBA-MOL BASIS DIS, V1502, P139, DOI 10.1016/S0925-4439(00)00040-5; Stoltzner SE, 2001, NEUROREPORT, V12, P2797, DOI 10.1097/00001756-200109170-00009; Takagi Y, 1999, P NATL ACAD SCI USA, V96, P4131, DOI 10.1073/pnas.96.7.4131; Takuma K, 2001, J BIOL CHEM, V276, P48093, DOI 10.1074/jbc.M108622200; Tanaka T, 2000, FREE RADICAL RES, V33, P851, DOI 10.1080/10715760000301361; Ueno M, 1999, J BIOL CHEM, V274, P35809, DOI 10.1074/jbc.274.50.35809; Urushitani M, 2000, J NEUROSCI RES, V61, P443, DOI 10.1002/1097-4547(20000815)61:4<443::AID-JNR11>3.0.CO;2-W; Wade CB, 2001, ENDOCRINOLOGY, V142, P2336, DOI 10.1210/en.142.6.2336; Wang L, 2001, P NATL ACAD SCI USA, V98, P2792, DOI 10.1073/pnas.041617498; WANG L, 2002, SCI STKE, V138, P1; Watters JJ, 1997, ENDOCRINOLOGY, V138, P4030, DOI 10.1210/en.138.9.4030; WEINER CP, 1994, P NATL ACAD SCI USA, V91, P5212, DOI 10.1073/pnas.91.11.5212; Wirtz-Brugger F, 2000, NEUROSCIENCE, V99, P737, DOI 10.1016/S0306-4522(00)00243-8; Wise PM, 2002, TRENDS ENDOCRIN MET, V13, P229, DOI 10.1016/S1043-2760(02)00611-2; Wise PM, 2001, ENDOCRINOLOGY, V142, P969, DOI 10.1210/en.142.3.969; Xia S, 2002, NEUROBIOL DIS, V9, P282, DOI 10.1006/nbdi.2002.0478	90	73	76	0	8	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2003	17	3					947	+		10.1096/fj.02-0807fje	http://dx.doi.org/10.1096/fj.02-0807fje			20	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	661LT	12626428				2022-12-25	WOS:000181892600021
J	Tabernero, L; Rodwell, VW; Stauffacher, CV				Tabernero, L; Rodwell, VW; Stauffacher, CV			Crystal structure of a statin bound to a class II hydroxymethylglutaryl-CoA reductase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COENZYME-A REDUCTASE; ISOPENTENYL DIPHOSPHATE BIOSYNTHESIS; PSEUDOMONAS-MEVALONII; 3-HYDROXY-3-METHYLGLUTARYL-COA REDUCTASE; CATALYSIS; CLONING; PROTEIN; PURIFICATION; ESSENTIALITY; EXPRESSION	Hydroxymethylglutaryl-CoA (HMG-CoA) reductase is the primary target in the current clinical treatment of hypercholesterolemias with specific inhibitors of the "statin" family. Statins are excellent inhibitors of the class I (human) enzyme but relatively poor inhibitors of the class II enzymes of important bacterial pathogens. To investigate the molecular basis for this difference we determined the x-ray structure of the class II Pseudomonas mevalonii HMG-CoA reductase in complex with the statin drug lovastatin. The structure shows lovastatin bound in the active site and its interactions with residues critically involved in catalysis and substrate binding. Binding of lovastatin also displaces the flap domain of the enzyme, which contains the catalytic residue His-381. Comparison with the structures of statins bound to the human enzyme revealed a similar mode of binding but marked differences in specific interactions that account for the observed differences in affinity. We suggest that these differences might be exploited to develop selective class II inhibitors for use as antibacterial agents against pathogenic microorganisms.	Univ Manchester, Sch Biol Sci, Manchester M13 9PT, Lancs, England; Purdue Univ, Dept Biol Sci, W Lafayette, IN 47907 USA; Purdue Univ, Dept Biochem, W Lafayette, IN 47907 USA	University of Manchester; Purdue University System; Purdue University; Purdue University West Lafayette Campus; Purdue University System; Purdue University; Purdue University West Lafayette Campus	Tabernero, L (corresponding author), Univ Manchester, Sch Biol Sci, Oxford Rd, Manchester M13 9PT, Lancs, England.		Tabernero, Lydia/F-3795-2018	Tabernero, Lydia/0000-0001-8867-455X	NHLBI NIH HHS [HL 52115] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL052115] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALBERTS AW, 1980, P NATL ACAD SCI-BIOL, V77, P3957, DOI 10.1073/pnas.77.7.3957; Bischoff KM, 1996, J BACTERIOL, V178, P19, DOI 10.1128/jb.178.1.19-23.1996; Bochar DA, 1999, BIOCHEMISTRY-US, V38, P8879, DOI 10.1021/bi9902687; Bochar DA, 1999, MOL GENET METAB, V66, P122, DOI 10.1006/mgme.1998.2786; BRUNGER AT, 1992, XPLOR MANUAL VERSION; CORSINI A, 1995, PHARMACOL RES, V31, P9, DOI 10.1016/1043-6618(95)80042-5; Dairi T, 2000, MOL GEN GENET, V262, P957, DOI 10.1007/PL00008664; ENGH RA, 1991, ACTA CRYSTALLOGR A, V47, P392, DOI 10.1107/S0108767391001071; EVANS SV, 1993, J MOL GRAPHICS, V11, P134, DOI 10.1016/0263-7855(93)87009-T; FRIMPONG K, 1994, J BIOL CHEM, V269, P11478; Hedl M, 2002, J BACTERIOL, V184, P2116, DOI 10.1128/JB.184.8.2116-2122.2002; Istvan ES, 2000, EMBO J, V19, P819, DOI 10.1093/emboj/19.5.819; Istvan ES, 2001, CURR OPIN STRUC BIOL, V11, P746, DOI 10.1016/S0959-440X(01)00276-7; Istvan ES, 2001, SCIENCE, V292, P1160, DOI 10.1126/science.1059344; JORDANSTARCK TC, 1989, J BIOL CHEM, V264, P17913; Kim DY, 2000, PROTEIN SCI, V9, P1226, DOI 10.1110/ps.9.6.1226; Kuzuyama T, 2000, J BACTERIOL, V182, P891, DOI 10.1128/JB.182.4.891-897.2000; LAWRENCE CM, 1995, SCIENCE, V268, P1758, DOI 10.1126/science.7792601; LAWRENCE CM, 1995, ACTA CRYSTALLOGR D, V51, P386, DOI 10.1107/S0907444994009819; OTWINOWSKI Z, 1993, P CCP4 STUD WEEK DAT; POPJAK G, 1979, J LIPID RES, V20, P716; Rodwell VW, 2000, METHOD ENZYMOL, V324, P259; Rohmer M., 1999, COMPR NAT PROD CHEM, V2, P45, DOI 10.1016/B978-0-08-091283-7.00036-9; SUDI J, 1976, BIOCHEM J, V153, P491, DOI 10.1042/bj1530491; Tabernero L, 1999, P NATL ACAD SCI USA, V96, P7167, DOI 10.1073/pnas.96.13.7167; Takahashi S, 1999, J BACTERIOL, V181, P1256, DOI 10.1128/JB.181.4.1256-1263.1999; WALLACE AC, 1995, PROTEIN ENG, V8, P127, DOI 10.1093/protein/8.2.127; Wilding EI, 2000, J BACTERIOL, V182, P4319, DOI 10.1128/JB.182.15.4319-4327.2000; Wilding EI, 2000, J BACTERIOL, V182, P5147, DOI 10.1128/JB.182.18.5147-5152.2000	29	39	43	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 30	2003	278	22					19933	19938		10.1074/jbc.M213006200	http://dx.doi.org/10.1074/jbc.M213006200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	682EH	12621048	hybrid			2022-12-25	WOS:000183078000048
J	Grimshaw, JPA; Jelesarov, I; Siegenthaler, RK; Christen, P				Grimshaw, JPA; Jelesarov, I; Siegenthaler, RK; Christen, P			Thermosensor action of GrpE - The DnaK chaperone system at heat shock temperatures	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE EXCHANGE FACTOR; ESCHERICHIA-COLI; MOLECULAR CHAPERONES; PROTEIN; HSP70; RECEPTOR; BINDING; CYCLE; CHANNEL; GENE	Temperature directly controls functional properties of the DnaK/DnaJ/GrpE chaperone system. The rate of the high to low affinity conversion of DnaK shows a non-Arrhenius temperature dependence and above similar to40 degreesC even decreases. In the same temperature range, the ADP/ATP exchange factor GrpE undergoes an extensive, fully reversible thermal transition (Grimshaw, J. P. A., Jelesarov, I., Schonfeld, H. J., and Christen, P. (2001) J. Biol. Chem. 276, 6098-6104). To show that this transition underlies the thermal regulation of the chaperone system, we introduced an intersubunit disulfide bond into the paired long helices of the GrpE dimer. The transition was absent in disulfide-linked GrpE R40C but was restored by reduction. With disulfide-stabilized GrpE, the rate of ADP/ATP exchange and conversion of DnaK from its ADP-liganded high affinity R state to the ATP-liganded low affinity T state continuously increased with increasing temperature. With reduced GrpE R40C, the conversion became slower at temperatures >40 degreesC, as observed with wild-type GrpE. Thus, the long helix pair in the GrpE dimer acts as a thermosensor that, by decreasing its ADP/ATP exchange activity, induces a shift of the DnaK.substrate complexes toward the high affinity R state and in this way adapts the DnaK/DnaJ/GrpE system to heat shock conditions.	Univ Zurich, Inst Biochem, CH-8057 Zurich, Switzerland	University of Zurich	Christen, P (corresponding author), Univ Zurich, Inst Biochem, Winterhurerstr 190, CH-8057 Zurich, Switzerland.	christen@bioc.unizh.ch						ANG D, 1989, J BACTERIOL, V171, P2748, DOI 10.1128/jb.171.5.2748-2755.1989; Arsene F, 2000, INT J FOOD MICROBIOL, V55, P3, DOI 10.1016/S0168-1605(00)00206-3; Brehmer D, 2001, NAT STRUCT BIOL, V8, P427, DOI 10.1038/87588; CASPERS P, 1994, CELL MOL BIOL, V40, P635; Caterina MJ, 1997, NATURE, V389, P816, DOI 10.1038/39807; DAUBEROSGUTHORPE P, 1988, PROTEINS, V4, P31, DOI 10.1002/prot.340040106; Feifel B, 1996, EUR J BIOCHEM, V237, P318, DOI 10.1111/j.1432-1033.1996.0318n.x; Gelinas AD, 2002, J MOL BIOL, V323, P131, DOI 10.1016/S0022-2836(02)00915-4; Grimshaw JPA, 2001, J BIOL CHEM, V276, P6098, DOI 10.1074/jbc.M009290200; Groemping Y, 2001, J MOL BIOL, V314, P167, DOI 10.1006/jmbi.2001.5116; Han WJ, 2003, BIOCHEM J, V369, P627, DOI 10.1042/BJ20020943; Harrison CJ, 1997, SCIENCE, V276, P431, DOI 10.1126/science.276.5311.431; Hartl FU, 2002, SCIENCE, V295, P1852, DOI 10.1126/science.1068408; HARTL FU, 1992, ANNU REV BIOPH BIOM, V21, P293, DOI 10.1146/annurev.bb.21.060192.001453; HELLEBUST H, 1990, J BACTERIOL, V172, P5030, DOI 10.1128/jb.172.9.5030-5034.1990; Hurme R, 1997, CELL, V90, P55, DOI 10.1016/S0092-8674(00)80313-X; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LALORAYA S, 1994, P NATL ACAD SCI USA, V91, P6481, DOI 10.1073/pnas.91.14.6481; LANDRY SJ, 1992, NATURE, V355, P455, DOI 10.1038/355455a0; LANGER T, 1992, NATURE, V356, P683, DOI 10.1038/356683a0; Laufen T, 1999, P NATL ACAD SCI USA, V96, P5452, DOI 10.1073/pnas.96.10.5452; LIBEREK K, 1991, P NATL ACAD SCI USA, V88, P2874, DOI 10.1073/pnas.88.7.2874; Mayer MP, 2002, ADV PROTEIN CHEM, V59, P1; MCCARTY JS, 1995, J MOL BIOL, V249, P126, DOI 10.1006/jmbi.1995.0284; McKemy DD, 2002, NATURE, V416, P52, DOI 10.1038/nature719; NEIDHARDT FC, 1987, ESCHERICHIA COLI SAL, P1334; Neupert W, 2002, NAT REV MOL CELL BIO, V3, P555, DOI 10.1038/nrm878; Packschies L, 1997, BIOCHEMISTRY-US, V36, P3417, DOI 10.1021/bi962835l; PALLEROS DR, 1993, NATURE, V365, P664, DOI 10.1038/365664a0; PALLEROS DR, 1992, J BIOL CHEM, V267, P5279; Peier AM, 2002, CELL, V108, P705, DOI 10.1016/S0092-8674(02)00652-9; Pierpaoli EV, 1997, J MOL BIOL, V269, P757, DOI 10.1006/jmbi.1997.1072; Pierpaoli EV, 1998, J BIOL CHEM, V273, P6643, DOI 10.1074/jbc.273.12.6643; Plotnikov VV, 1997, ANAL BIOCHEM, V250, P237, DOI 10.1006/abio.1997.2236; SCHMID D, 1994, SCIENCE, V263, P971, DOI 10.1126/science.8310296; SCHONFELD HJ, 1995, J BIOL CHEM, V270, P2183, DOI 10.1074/jbc.270.5.2183; Servant P, 2000, P NATL ACAD SCI USA, V97, P3538, DOI 10.1073/pnas.070426197; SZABO A, 1994, P NATL ACAD SCI USA, V91, P10345, DOI 10.1073/pnas.91.22.10345; Takayama S, 2001, NAT CELL BIOL, V3, pE237, DOI 10.1038/ncb1001-e237; Theyssen H, 1996, J MOL BIOL, V263, P657, DOI 10.1006/jmbi.1996.0606; Zhu XT, 1996, SCIENCE, V272, P1606, DOI 10.1126/science.272.5268.1606	41	49	51	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 23	2003	278	21					19048	19053		10.1074/jbc.M300924200	http://dx.doi.org/10.1074/jbc.M300924200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	679PY	12639955	hybrid			2022-12-25	WOS:000182932200044
J	Moreau, C; Cartron, PF; Hunt, A; Meflah, K; Green, DR; Evan, G; Vallette, FM; Juin, P				Moreau, C; Cartron, PF; Hunt, A; Meflah, K; Green, DR; Evan, G; Vallette, FM; Juin, P			Minimal BH3 peptides promote cell death by antagonizing anti-apoptotic proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME-C RELEASE; OUTER MITOCHONDRIAL-MEMBRANE; SMALL-MOLECULE INHIBITORS; BCL-2 FAMILY MEMBERS; INTRACELLULAR-LOCALIZATION; CONFORMATIONAL CHANGE; BAX OLIGOMERIZATION; INDUCE APOPTOSIS; X-L; SURVIVAL	The pro-apoptotic "BH3 domain-only" proteins of the Bcl-2 family ( e. g. Bid and Bad) transduce multiple death signals to the mitochondrion. They interact with the anti-apoptotic Bcl-2 family members and induce apoptosis by a mechanism that requires the presence of at least one of the multidomain pro-apoptotic proteins Bax or Bak. Although the BH3 domain of Bid can promote the pro-apoptotic assembly and function of Bax/Bak by itself, other BH3 domains do not function as such. The latter point raises the question of whether, and how, these BH3 domains induce apoptosis. We show here that a peptide comprising the minimal BH3 domain from Bax induces apoptosis but is unable to stimulate the apoptotic activity of microinjected recombinant Bax. This relies on the inability of the peptide to directly induce Bax translocation to mitochondria or a change in its conformation. This peptide nevertheless interferes with Bax/Bcl-xL interactions in vitro and stimulates the apoptotic activity of Bax when combined with Bcl-xL. Similarly, a peptide derived from the BH3 domain of Bad stimulates Bax activity only in the presence of Bcl-xL. Thus, BH3 domains do not necessarily activate multidomain pro-apoptotic proteins directly but promote apoptosis by releasing active multidomain pro-apoptotic proteins from their anti-apoptotic counterparts.	INSERM, U419, F-44035 Nantes, France; Univ Calif San Francisco, San Francisco Canc Ctr, San Francisco, CA 94123 USA; La Jolla Inst Allergy & Immunol, San Diego, CA 92121 USA	Institut National de la Sante et de la Recherche Medicale (Inserm); University of California System; University of California San Francisco; La Jolla Institute for Immunology	Juin, P (corresponding author), INSERM, U419, 9 Quai Moncousu, F-44035 Nantes, France.		Green, Douglas R/N-8083-2018; JUIN, Philippe/Q-1338-2019; Vallette, Francois M/K-9047-2015; JUIN, Philippe P/H-3636-2014; Cartron, Pierre Francois/K-9802-2015; Vallette, Francois/N-2361-2018	Green, Douglas R/0000-0002-7332-1417; JUIN, Philippe/0000-0002-4997-3888; Vallette, Francois M/0000-0002-3296-8572; JUIN, Philippe P/0000-0002-4997-3888; Cartron, Pierre-Francois/0000-0002-3393-784X; Vallette, Francois/0000-0003-0802-0519				Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; Antonsson B, 2000, BIOCHEM J, V345, P271, DOI 10.1042/0264-6021:3450271; Cartron PF, 2002, FEBS LETT, V512, P95, DOI 10.1016/S0014-5793(02)02227-5; Cartron PF, 2002, HUM MOL GENET, V11, P675, DOI 10.1093/hmg/11.6.675; Cheng EHYA, 2001, MOL CELL, V8, P705, DOI 10.1016/S1097-2765(01)00320-3; Cosulich SC, 1997, CURR BIOL, V7, P913, DOI 10.1016/S0960-9822(06)00410-6; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; Degterev A, 2001, J CELL BIOL, V155, P695, DOI 10.1083/jcb.200110147; Degterev A, 2001, NAT CELL BIOL, V3, P173, DOI 10.1038/35055085; Desagher S, 1999, J CELL BIOL, V144, P891, DOI 10.1083/jcb.144.5.891; Enyedy IJ, 2001, J MED CHEM, V44, P4313, DOI 10.1021/jm010016f; Eskes R, 2000, MOL CELL BIOL, V20, P929, DOI 10.1128/MCB.20.3.929-935.2000; Finnegan NM, 2001, BRIT J CANCER, V85, P115, DOI 10.1054/bjoc.2001.1850; Goping IS, 1998, J CELL BIOL, V143, P207, DOI 10.1083/jcb.143.1.207; Green DR, 2000, CELL, V102, P1, DOI 10.1016/S0092-8674(00)00003-9; Gross A, 1998, EMBO J, V17, P3878, DOI 10.1093/emboj/17.14.3878; Hsu YT, 1997, P NATL ACAD SCI USA, V94, P3668, DOI 10.1073/pnas.94.8.3668; Hsu YT, 1997, J BIOL CHEM, V272, P13829, DOI 10.1074/jbc.272.21.13829; Hunt A, 2001, SCIENCE, V293, P1784, DOI 10.1126/science.1065206; Juin P, 1999, GENE DEV, V13, P1367, DOI 10.1101/gad.13.11.1367; Juin P, 2002, MOL CELL BIOL, V22, P6158, DOI 10.1128/MCB.22.17.6158-6169.2002; Kelekar A, 1998, TRENDS CELL BIOL, V8, P324, DOI 10.1016/S0962-8924(98)01321-X; Korsmeyer SJ, 2000, CELL DEATH DIFFER, V7, P1166, DOI 10.1038/sj.cdd.4400783; Kuwana T, 2002, CELL, V111, P331, DOI 10.1016/S0092-8674(02)01036-X; Letai A, 2002, CANCER CELL, V2, P183, DOI 10.1016/S1535-6108(02)00127-7; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; Madesh M, 2002, J BIOL CHEM, V277, P5651, DOI 10.1074/jbc.M108171200; Mahajan NP, 1998, NAT BIOTECHNOL, V16, P547, DOI 10.1038/nbt0698-547; Nakano K, 2001, MOL CELL, V7, P683, DOI 10.1016/S1097-2765(01)00214-3; Nomura M, 1999, CANCER RES, V59, P5542; Oda E, 2000, SCIENCE, V288, P1053, DOI 10.1126/science.288.5468.1053; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; Perez D, 2000, MOL CELL, V6, P53, DOI 10.1016/S1097-2765(00)00007-1; Ruffolo SC, 2000, CELL DEATH DIFFER, V7, P1101, DOI 10.1038/sj.cdd.4400739; Sattler M, 1997, SCIENCE, V275, P983, DOI 10.1126/science.275.5302.983; Shangary S, 2002, BIOCHEMISTRY-US, V41, P9485, DOI 10.1021/bi025605h; Suzuki M, 2000, CELL, V103, P645, DOI 10.1016/S0092-8674(00)00167-7; Terradillos O, 2002, FEBS LETT, V522, P29, DOI 10.1016/S0014-5793(02)02871-5; Tremblais K, 1999, BIOCHEM BIOPH RES CO, V260, P582, DOI 10.1006/bbrc.1999.0904; Tzung SP, 2001, NAT CELL BIOL, V3, P183, DOI 10.1038/35055095; von Ahsen O, 2000, J CELL BIOL, V150, P1027, DOI 10.1083/jcb.150.5.1027; Wang K, 1996, GENE DEV, V10, P2859, DOI 10.1101/gad.10.22.2859; Wei MC, 2001, SCIENCE, V292, P727, DOI 10.1126/science.1059108; Wolter KG, 1997, J CELL BIOL, V139, P1281, DOI 10.1083/jcb.139.5.1281; Yu J, 2001, MOL CELL, V7, P673, DOI 10.1016/S1097-2765(01)00213-1; Zong WX, 2001, GENE DEV, V15, P1481, DOI 10.1101/gad.897601	47	74	78	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 23	2003	278	21					19426	19435		10.1074/jbc.M209472200	http://dx.doi.org/10.1074/jbc.M209472200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	679PY	12642586	hybrid			2022-12-25	WOS:000182932200091
J	Park, E; Na, M; Choi, JH; Kim, S; Lee, JR; Yoon, JY; Park, D; Sheng, M; Kim, E				Park, E; Na, M; Choi, JH; Kim, S; Lee, JR; Yoon, JY; Park, D; Sheng, M; Kim, E			The Shank family of postsynaptic density proteins interacts with and promotes synaptic accumulation of the beta PIX guanine nucleotide exchange factor for Rac1 and Cdc42	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DENDRITIC SPINE MORPHOLOGY; PDZ-DOMAIN; SCAFFOLDING PROTEINS; BINDING-PROTEIN; SMALL GTPASES; RAT-BRAIN; RECEPTOR; RHO; ACTIN; LOCALIZATION	The Shank/ProSAP family of multidomain proteins is known to play an important role in organizing synaptic multiprotein complexes. Here we report a novel interaction between Shank and betaPIX, a guanine nucleotide exchange factor for the Rac1 and Cdc42 small GTPases. This interaction is mediated by the PDZ domain of Shank and the C-terminal leucine zipper domain and the PDZ domain-binding motif at the extreme C terminus of betaPIX. Shank colocalizes with betaPIX at excitatory synaptic sites in cultured neurons. In brain, Shank forms a complex with betaPIX and betaPIX-associated signaling molecules including p21-associated kinase (PAK), an effector kinase of Rac1/Cdc42. Importantly, overexpression of Shank in cultured neurons promotes synaptic accumulation of betaPIX and PAK. Considering the involvement of Rac1 and PAK in spine dynamics, these results suggest that Shank recruits betaPIX and PAK to spines for the regulation of postsynaptic structure.	Korea Adv Inst Sci & Technol, Dept Biol Sci, Taejon 305701, South Korea; Seoul Natl Univ, Sch Biol Sci, Seoul 151742, South Korea; MIT, Howard Hughes Med Inst, Cambridge, MA 02139 USA; MIT, RIKEN MIT Neurosci Res Ctr, Picower Ctr Learning & Memory, Cambridge, MA 02139 USA	Korea Advanced Institute of Science & Technology (KAIST); Seoul National University (SNU); Howard Hughes Medical Institute; Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT); RIKEN	Kim, E (corresponding author), Korea Adv Inst Sci & Technol, Dept Biol Sci, Taejon 305701, South Korea.	kime@mail.kaist.ac.kr	Kim, Eunjoon/C-1566-2011	Sheng, Morgan/0000-0002-8703-5366				Allison DW, 1998, J NEUROSCI, V18, P2423; Bagrodia S, 1999, TRENDS CELL BIOL, V9, P350, DOI 10.1016/S0962-8924(99)01618-9; Bagrodia S, 1998, J BIOL CHEM, V273, P23633, DOI 10.1074/jbc.273.37.23633; Banker G., 1991, CULTURING NERVE CELL; Bockers TM, 2001, J BIOL CHEM, V276, P40104, DOI 10.1074/jbc.M102454200; Bockmann J, 2002, J NEUROCHEM, V83, P1013, DOI 10.1046/j.1471-4159.2002.01204.x; Boeckers TM, 1999, J NEUROSCI, V19, P6506; Boeckers TM, 2002, J NEUROCHEM, V81, P903, DOI 10.1046/j.1471-4159.2002.00931.x; CHO KO, 1992, NEURON, V9, P929, DOI 10.1016/0896-6273(92)90245-9; Choi J, 2002, J BIOL CHEM, V277, P12359, DOI 10.1074/jbc.M200528200; Du YR, 1998, MOL CELL BIOL, V18, P5838, DOI 10.1128/MCB.18.10.5838; Ehlers MD, 2002, TRENDS NEUROSCI, V25, P64, DOI 10.1016/S0166-2236(02)02061-1; Feng W, 2002, J BIOL CHEM, V277, P41140, DOI 10.1074/jbc.M207206200; HARRIS KM, 1994, ANNU REV NEUROSCI, V17, P341, DOI 10.1146/annurev.ne.17.030194.002013; Hering H, 2001, NAT REV NEUROSCI, V2, P880, DOI 10.1038/35104061; HUTTNER WB, 1983, J CELL BIOL, V96, P1374, DOI 10.1083/jcb.96.5.1374; Im YJ, 2003, J BIOL CHEM, V278, P8501, DOI 10.1074/jbc.M212263200; Kennedy MB, 2000, SCIENCE, V290, P750, DOI 10.1126/science.290.5492.750; Kim CH, 1999, J NEUROSCI, V19, P4314; Kim E, 1997, J CELL BIOL, V136, P669, DOI 10.1083/jcb.136.3.669; KIM E, 1995, NATURE, V378, P85, DOI 10.1038/378085a0; Kim S, 2000, BIOCHEM BIOPH RES CO, V272, P721, DOI 10.1006/bbrc.2000.2845; Kim S, 2001, J BIOL CHEM, V276, P10581, DOI 10.1074/jbc.C000806200; Ko J, 2003, J NEUROSCI, V23, P1667; Koh CG, 2001, J CELL SCI, V114, P4239; Kreienkamp HJ, 2000, J BIOL CHEM, V275, P32387, DOI 10.1074/jbc.C000490200; Krucker T, 2000, P NATL ACAD SCI USA, V97, P6856, DOI 10.1073/pnas.100139797; Lim S, 2001, MOL CELL NEUROSCI, V17, P385, DOI 10.1006/mcne.2000.0940; Lim S, 1999, J BIOL CHEM, V274, P29510, DOI 10.1074/jbc.274.41.29510; Luo LQ, 2000, NAT REV NEUROSCI, V1, P173, DOI 10.1038/35044547; Luo LQ, 1996, NATURE, V379, P837, DOI 10.1038/379837a0; Manser E, 1998, MOL CELL, V1, P183, DOI 10.1016/S1097-2765(00)80019-2; Matus A, 2000, SCIENCE, V290, P754, DOI 10.1126/science.290.5492.754; Mok H, 2002, J NEUROSCI, V22, P5253; Naisbitt S, 1999, NEURON, V23, P569, DOI 10.1016/S0896-6273(00)80809-0; Nakayama AY, 2000, J NEUROSCI, V20, P5329, DOI 10.1523/JNEUROSCI.20-14-05329.2000; Oh WK, 1997, BIOCHEM BIOPH RES CO, V235, P794, DOI 10.1006/bbrc.1997.6875; Okamoto PM, 2001, J BIOL CHEM, V276, P48458, DOI 10.1074/jbc.M104927200; Park SH, 2002, ACTA CRYSTALLOGR D, V58, P1353, DOI 10.1107/S0907444902009162; Parnas D, 2001, NEURON, V32, P415, DOI 10.1016/S0896-6273(01)00485-8; Penzes P, 2001, NEURON, V29, P229, DOI 10.1016/S0896-6273(01)00193-3; Penzes P, 2001, J NEUROSCI, V21, P8426, DOI 10.1523/JNEUROSCI.21-21-08426.2001; Penzes P, 2000, J BIOL CHEM, V275, P6395, DOI 10.1074/jbc.275.9.6395; Penzes P, 2003, NEURON, V37, P263, DOI 10.1016/S0896-6273(02)01168-6; Premont RT, 1998, P NATL ACAD SCI USA, V95, P14082, DOI 10.1073/pnas.95.24.14082; Sala C, 2001, NEURON, V31, P115, DOI 10.1016/S0896-6273(01)00339-7; Satoh K, 1997, GENES CELLS, V2, P415, DOI 10.1046/j.1365-2443.1997.1310329.x; Sheng M, 2000, J CELL SCI, V113, P1851; Sheng M, 2001, ANNU REV NEUROSCI, V24, P1, DOI 10.1146/annurev.neuro.24.1.1; Sheng M, 2002, SCIENCE, V298, P776, DOI 10.1126/science.1075333; Soltau M, 2002, MOL CELL NEUROSCI, V21, P575, DOI 10.1006/mcne.2002.1201; Takeuchi M, 1997, J BIOL CHEM, V272, P11943, DOI 10.1074/jbc.272.18.11943; Tashiro A, 2000, CEREB CORTEX, V10, P927, DOI 10.1093/cercor/10.10.927; Tobaben S, 2000, J BIOL CHEM, V275, P36204, DOI 10.1074/jbc.M006448200; Tu JC, 1999, NEURON, V23, P583, DOI 10.1016/S0896-6273(00)80810-7; Turner CE, 2001, CURR OPIN CELL BIOL, V13, P593, DOI 10.1016/S0955-0674(00)00256-8; Werner LA, 1997, GENE, V187, P107, DOI 10.1016/S0378-1119(96)00732-9; Wyszynski M, 2002, NEURON, V34, P39, DOI 10.1016/S0896-6273(02)00640-2; Yao I, 1999, J BIOL CHEM, V274, P27463, DOI 10.1074/jbc.274.39.27463; Ye B, 2000, NEURON, V26, P603, DOI 10.1016/S0896-6273(00)81198-8; Zitzer H, 1999, J BIOL CHEM, V274, P18153, DOI 10.1074/jbc.274.26.18153; Zitzer H, 1999, J BIOL CHEM, V274, P32997, DOI 10.1074/jbc.274.46.32997	62	125	132	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 23	2003	278	21					19220	19229		10.1074/jbc.M301052200	http://dx.doi.org/10.1074/jbc.M301052200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	679PY	12626503	hybrid			2022-12-25	WOS:000182932200066
J	Yahiro, K; Wada, A; Nakayama, M; Kimura, T; Ogushi, K; Niidome, T; Aoyagi, H; Yoshino, K; Yonezawa, K; Moss, J; Hirayama, T				Yahiro, K; Wada, A; Nakayama, M; Kimura, T; Ogushi, K; Niidome, T; Aoyagi, H; Yoshino, K; Yonezawa, K; Moss, J; Hirayama, T			Protein-tyrosine phosphatase alpha, RPTP alpha, is a Helicobacter pylori VacA receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VACUOLATING CYTOTOXIN; GASTRIC CELLS; TOXIN; BINDING; BETA; SENSITIVITY; INDUCTION; INFECTION; CLONING; DISEASE	Helicobacter pylori vacuolating cytotoxin, VacA, induces vacuolation, mitochondrial damage, cytochrome c release, and apoptosis of gastric epithelial cells. To detect gastric proteins that serve as VacA receptors, we used VacA co-immunoprecipitation techniques following biotinylation of the cell surface and identified p250, a receptor-like protein-tyrosine phosphatase beta (RPTPbeta) as a VacA-binding protein (Yahiro, K., Niidome, T., Kimura, M., Hatakeyama, T., Aoyagi, H., Kurazono, H., Imagawa, K., Wada, A., Moss, J., and Hirayama, T. (1999) J. Biol. Chem. 274, 36693-36699). VacA causes vacuolation of G401 cells, a human kidney tumor cell line, although they do not express RPTPbeta. By co-immunoprecipitation with VacA, we identified p140 as a potential receptor in those cells. p140 purified by chromatography on a peanut agglutinin affinity matrix contained internal amino acid sequences of RGEENTDYVNASFIDGYRQK and AEGILDVFQTVK, which are identical to those in RPTPalpha. The peptide mass fingerprinting of p140 by time of flight-MS analysis also supported this identification. Treatment of G401 cells with RPTPalpha-morpholino antisense oligonucleotide before exposure to toxin inhibited vacuolation. These data suggest that RPTPbeta acts as a receptor for VacA in G401 cells. Thus, two receptor tyrosine phosphatases, RPTPalpha and RPTPbeta, serve as VacA receptors.	Nagasaki Univ, Inst Trop Med, Dept Bacteriol, Nagasaki 8528523, Japan; Japan Sci & Technol Corp, PRESTO, Saitama, Japan; Nagasaki Univ, Fac Engn, Dept Appl Chem, Nagasaki 8528521, Japan; Kobe Univ, Biosignal Res Ctr, Kobe, Hyogo 6578501, Japan; NHLBI, Pulm Crit Care Med Branch, NIH, Bethesda, MD 20892 USA	Nagasaki University; Japan Science & Technology Agency (JST); Nagasaki University; Kobe University; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)	Hirayama, T (corresponding author), Nagasaki Univ, Inst Trop Med, Dept Bacteriol, Nagasaki 8528523, Japan.	hirayama@net.nagasaki-u.ac.jp	Niidome, Takuro/F-1508-2010	Niidome, Takuro/0000-0002-8070-8708; Yahiro, Kinnosuke/0000-0002-9813-0780	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [ZIAHL000659, Z01HL000659] Funding Source: NIH RePORTER	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Czajkowsky DM, 1999, P NATL ACAD SCI USA, V96, P2001, DOI 10.1073/pnas.96.5.2001; Del Giudice G, 2001, ANNU REV IMMUNOL, V19, P523, DOI 10.1146/annurev.immunol.19.1.523; Eaton KA, 1997, INFECT IMMUN, V65, P3462, DOI 10.1128/IAI.65.8.3462-3464.1997; Galmiche A, 2000, EMBO J, V19, P6361, DOI 10.1093/emboj/19.23.6361; Garner JA, 1996, INFECT IMMUN, V64, P4197, DOI 10.1128/IAI.64.10.4197-4203.1996; GHIRA P, 1995, INFECT IMMUN, V63, P4154, DOI 10.1128/IAI.63.10.4154-4160.1995; Hara K, 2002, CELL, V110, P177, DOI 10.1016/S0092-8674(02)00833-4; KAPLAN R, 1990, P NATL ACAD SCI USA, V87, P7000, DOI 10.1073/pnas.87.18.7000; Kimura M, 1999, MICROB PATHOGENESIS, V26, P45, DOI 10.1006/mpat.1998.0241; Kuck D, 2001, INFECT IMMUN, V69, P5080, DOI 10.1128/IAI.69.8.5080-5087.2001; LEUNK RD, 1988, J MED MICROBIOL, V26, P93, DOI 10.1099/00222615-26-2-93; MANETTI R, 1995, INFECT IMMUN, V63, P4476, DOI 10.1128/IAI.63.11.4476-4480.1995; MARCHETTI M, 1995, SCIENCE, V267, P1655, DOI 10.1126/science.7886456; Massari P, 1998, INFECT IMMUN, V66, P3981, DOI 10.1128/IAI.66.8.3981-3984.1998; Molinari M, 1997, J BIOL CHEM, V272, P25339, DOI 10.1074/jbc.272.40.25339; Nakajima S, 1997, GASTROENTEROLOGY, V113, P746, DOI 10.1016/S0016-5085(97)70167-7; Padilla PI, 2000, J BIOL CHEM, V275, P15200, DOI 10.1074/jbc.275.20.15200; Peek RM, 2002, NAT REV CANCER, V2, P28, DOI 10.1038/nrc703; Peles E, 1998, TRENDS BIOCHEM SCI, V23, P121, DOI 10.1016/S0968-0004(98)01195-5; PHADNIS SH, 1994, INFECT IMMUN, V62, P1557, DOI 10.1128/IAI.62.5.1557-1565.1994; Qi MS, 2001, J BIOL CHEM, V276, P15868, DOI 10.1074/jbc.M005911200; Ricci V, 2000, MOL BIOL CELL, V11, P3897, DOI 10.1091/mbc.11.11.3897; Ricci V, 1997, J PATHOL, V183, P453; SAP J, 1990, P NATL ACAD SCI USA, V87, P6112, DOI 10.1073/pnas.87.16.6112; SOUTHERN JA, 1991, J GEN VIROL, V72, P1551, DOI 10.1099/0022-1317-72-7-1551; Supajatura V, 2002, J IMMUNOL, V168, P2603, DOI 10.4049/jimmunol.168.6.2603; Suzuki J, 2001, J CLIN INVEST, V107, P363, DOI 10.1172/JCI10254; Szabo I, 1999, EMBO J, V18, P5517, DOI 10.1093/emboj/18.20.5517; TELFORD JL, 1994, J EXP MED, V179, P1653, DOI 10.1084/jem.179.5.1653; Yahiro K, 1997, BIOCHEM BIOPH RES CO, V238, P629, DOI 10.1006/bbrc.1997.7345; Yahiro K, 1999, J BIOL CHEM, V274, P36693, DOI 10.1074/jbc.274.51.36693	32	99	106	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 23	2003	278	21					19183	19189		10.1074/jbc.M300117200	http://dx.doi.org/10.1074/jbc.M300117200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	679PY	12626515	hybrid			2022-12-25	WOS:000182932200062
J	Rosenfeld, SS; Fordyce, PM; Jefferson, GM; King, PH; Block, SM				Rosenfeld, SS; Fordyce, PM; Jefferson, GM; King, PH; Block, SM			Stepping and stretching - How kinesin uses internal strain to walk processively	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ATP HYDROLYSIS; KINETIC MECHANISM; LOADING DIRECTION; DIMERIC KINESIN; MOLECULAR MOTOR; FORCE CLAMP; MYOSIN-V; RELEASE; PATHWAY; MOTILITY	The ability of kinesin to travel long distances on its microtubule track without dissociating has led to a variety of models to explain how this remarkable degree of processivity is maintained. All of these require that the two motor domains remain enzymatically "out of phase," a behavior that would ensure that, at any given time, one motor is strongly attached to the microtubule. The maintenance of this coordination over many mechanochemical cycles has never been explained, because key steps in the cycle could not be directly observed. We have addressed this issue by applying several novel spectroscopic approaches to monitor motor dissociation, phosphate release, and nucleotide binding during processive movement by a dimeric kinesin construct. Our data argue that the major effect of the internal strain generated when both motor domains of kinesin bind the microtubule is to block ATP from binding to the leading motor. This effect guarantees the two motor domains remain out of phase for many mechanochemical cycles and provides an efficient and adaptable mechanism for the maintenance of processive movement.	Univ Alabama, Dept Neurol, MEB 510, Birmingham, AL 35294 USA; Dept Vet Affairs Med Ctr, Neurol Serv, Birmingham, AL 35294 USA; Stanford Univ, Dept Phys, Stanford, CA 94305 USA; Stanford Univ, Dept Appl Phys, Stanford, CA 94305 USA; Stanford Univ, Dept Biol Sci, Stanford, CA 94305 USA	University of Alabama System; University of Alabama Birmingham; Stanford University; Stanford University; Stanford University	Rosenfeld, SS (corresponding author), Univ Alabama, Dept Neurol, MEB 510, 1813 6th Ave S, Birmingham, AL 35294 USA.	stevensr@uab.edu	Fordyce, Polly/AAY-6365-2020	Fordyce, Polly/0000-0002-9505-0638; King, Peter/0000-0001-9391-7464	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM051453] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM051453] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Block SM, 2003, P NATL ACAD SCI USA, V100, P2351, DOI 10.1073/pnas.0436709100; Brendza KM, 2000, J BIOL CHEM, V275, P22187, DOI 10.1074/jbc.M001124200; BRUNE M, 1994, BIOCHEMISTRY-US, V33, P8262, DOI 10.1021/bi00193a013; Crevel I, 1999, EMBO J, V18, P5863, DOI 10.1093/emboj/18.21.5863; Cross RA, 2000, PHILOS T ROY SOC B, V355, P459, DOI 10.1098/rstb.2000.0587; De la Cruz EM, 2001, J BIOL CHEM, V276, P32373, DOI 10.1074/jbc.M104136200; Derenyi I, 1996, P NATL ACAD SCI USA, V93, P6775, DOI 10.1073/pnas.93.13.6775; Farrell CM, 2002, J BIOL CHEM, V277, P17079, DOI 10.1074/jbc.M108793200; GELLES J, 1988, NATURE, V331, P450, DOI 10.1038/331450a0; GILBERT SP, 1995, NATURE, V373, P671, DOI 10.1038/373671a0; Gilbert SP, 1998, BIOCHEMISTRY-US, V37, P792, DOI 10.1021/bi971117b; HACKNEY DD, 1994, P NATL ACAD SCI USA, V91, P6865, DOI 10.1073/pnas.91.15.6865; Hackney DD, 2002, BIOCHEMISTRY-US, V41, P4437, DOI 10.1021/bi0159229; Hancock WO, 1999, P NATL ACAD SCI USA, V96, P13147, DOI 10.1073/pnas.96.23.13147; Hua W, 2002, SCIENCE, V295, P844, DOI 10.1126/science.1063089; Jiang W, 1997, J BIOL CHEM, V272, P7626, DOI 10.1074/jbc.272.12.7626; Kawaguchi K, 2001, SCIENCE, V291, P667, DOI 10.1126/science.291.5504.667; Kozielski F, 1997, CELL, V91, P985, DOI 10.1016/S0092-8674(00)80489-4; Ma YZ, 1997, J BIOL CHEM, V272, P724, DOI 10.1074/jbc.272.2.724; MA YZ, 1995, BIOCHEMISTRY-US, V34, P13242, DOI 10.1021/bi00040a040; Ma YZ, 1997, J BIOL CHEM, V272, P717, DOI 10.1074/jbc.272.2.717; Moyer ML, 1998, BIOCHEMISTRY-US, V37, P800, DOI 10.1021/bi9711184; Rice S, 1999, NATURE, V402, P778, DOI 10.1038/45483; Rief M, 2000, P NATL ACAD SCI USA, V97, P9482, DOI 10.1073/pnas.97.17.9482; Rosenfeld SS, 2002, J BIOL CHEM, V277, P36731, DOI 10.1074/jbc.M205261200; Rosenfeld SS, 2001, J BIOL CHEM, V276, P40167, DOI 10.1074/jbc.M103899200; Schief WR, 2001, CURR OPIN CELL BIOL, V13, P19, DOI 10.1016/S0955-0674(00)00169-1; SCHNAPP BJ, 1990, P NATL ACAD SCI USA, V87, P10053, DOI 10.1073/pnas.87.24.10053; Schnitzer MJ, 2000, NAT CELL BIOL, V2, P718, DOI 10.1038/35036345; Schnitzer MJ, 1997, NATURE, V388, P386, DOI 10.1038/41111; SVOBODA K, 1994, CELL, V77, P773, DOI 10.1016/0092-8674(94)90060-4; Uemura S, 2003, NAT STRUCT BIOL, V10, P308, DOI 10.1038/nsb911; Uemura S, 2002, P NATL ACAD SCI USA, V99, P5977, DOI 10.1073/pnas.092546199; Vale RD, 2000, SCIENCE, V288, P88, DOI 10.1126/science.288.5463.88; Veigel C, 2002, NAT CELL BIOL, V4, P59, DOI 10.1038/ncb732; Visscher K, 1999, NATURE, V400, P184, DOI 10.1038/22146; Xing J, 2000, J BIOL CHEM, V275, P35413, DOI 10.1074/jbc.M004232200; Young EC, 1998, BIOCHEMISTRY-US, V37, P3467, DOI 10.1021/bi972172n	38	149	153	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 16	2003	278	20					18550	18556		10.1074/jbc.M300849200	http://dx.doi.org/10.1074/jbc.M300849200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677YX	12626516	Green Accepted, hybrid			2022-12-25	WOS:000182838300126
J	Chang, DW; Ditsworth, D; Liu, HT; Srinivasula, SM; Alnemri, ES; Yang, XL				Chang, DW; Ditsworth, D; Liu, HT; Srinivasula, SM; Alnemri, ES; Yang, XL			Oligomerization is a general mechanism for the activation of apoptosis initiator and inflammatory procaspases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYSTEINE PROTEASE; CYTOCHROME-C; CASPASE-2; APAF-1	Proteolytic activation of initiator procaspases is a crucial step in the cellular commitment to apoptosis. Alternative models have been postulated for the activation mechanism, namely the oligomerization or induced proximity model and the allosteric regulation model. While the former holds that procaspases become activated upon proper oligomerization by an adaptor protein, the latter states that the adaptor is an allosteric regulator for procaspases. The allosteric regulation model has been applied for the activation of procaspase-9 by apoptotic protease-activating factor (Apaf-1) in an oligomeric complex known as the apoptosome. Using approaches that allow for controlled oligomerization, we show here that aggregation of multiple procaspase-9 molecules can induce their activation independent of the apoptosome. Oligomerization-induced procaspase-9 activation, both within the apoptosome and in artificial systems, requires stable homophilic association of the protease domains, raising the possibility that the function of Apaf-1 is not only to oligomerize procaspase-9 but also to maintain the interaction of the caspase-9 protease domain after processing. In addition, we provide biochemical evidence that other apoptosis initiator caspases (caspase-2 and -10) as well as a procaspase involved in inflammation (murine caspase-11) are also activated by oligomerization. Thus, oligomerization of precursor molecules appears to be a general mechanism for the activation of both apoptosis initiator and inflammatory procaspases.	Univ Penn, Sch Med, Abramson Family Canc Res Inst, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Canc Biol, Philadelphia, PA 19104 USA; Thomas Jefferson Univ, Kimmel Canc Inst, Ctr Apoptosis Res, Philadelphia, PA 19107 USA; Thomas Jefferson Univ, Kimmel Canc Inst, Dept Microbiol & Immunol, Philadelphia, PA 19107 USA	University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania; Jefferson University; Jefferson University	Yang, XL (corresponding author), Univ Penn, Sch Med, Abramson Family Canc Res Inst, Philadelphia, PA 19104 USA.	xyang@mail.med.upenn.edu	Alnemri, Emad S/B-4526-2010		NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM060911] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG014357] Funding Source: NIH RePORTER; NIA NIH HHS [AG14357] Funding Source: Medline; NIGMS NIH HHS [GM60911] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; Chang DW, 2002, EMBO J, V21, P3704, DOI 10.1093/emboj/cdf356; Chang HY, 2000, MICROBIOL MOL BIOL R, V64, P821, DOI 10.1128/MMBR.64.4.821-846.2000; Clackson T, 1998, P NATL ACAD SCI USA, V95, P10437, DOI 10.1073/pnas.95.18.10437; FernandesAlnemri T, 1996, P NATL ACAD SCI USA, V93, P7464, DOI 10.1073/pnas.93.15.7464; Guo Y, 2002, J BIOL CHEM, V277, P13430, DOI 10.1074/jbc.M108029200; Hengartner MO, 2000, NATURE, V407, P770, DOI 10.1038/35037710; Lassus P, 2002, SCIENCE, V297, P1352, DOI 10.1126/science.1074721; Martin DA, 1998, J BIOL CHEM, V273, P4345, DOI 10.1074/jbc.273.8.4345; Muzio M, 1998, J BIOL CHEM, V273, P2926, DOI 10.1074/jbc.273.5.2926; Nicholson DW, 1999, CELL DEATH DIFFER, V6, P1028, DOI 10.1038/sj.cdd.4400598; Paroni G, 2002, J BIOL CHEM, V277, P15147, DOI 10.1074/jbc.M112338200; Poyet JL, 2001, J BIOL CHEM, V276, P28309, DOI 10.1074/jbc.C100250200; Renatus M, 2001, P NATL ACAD SCI USA, V98, P14250, DOI 10.1073/pnas.231465798; Rodriguez J, 1999, GENE DEV, V13, P3179, DOI 10.1101/gad.13.24.3179; Saleh A, 1999, J BIOL CHEM, V274, P17941, DOI 10.1074/jbc.274.25.17941; Shi YG, 2002, MOL CELL, V9, P459, DOI 10.1016/S1097-2765(02)00482-3; Srinivasula SM, 1998, MOL CELL, V1, P949, DOI 10.1016/S1097-2765(00)80095-7; Srinivasula SM, 2002, J BIOL CHEM, V277, P21119, DOI 10.1074/jbc.C200179200; Stennicke HR, 1999, J BIOL CHEM, V274, P8359, DOI 10.1074/jbc.274.13.8359; THORNBERRY NA, 1992, NATURE, V356, P768, DOI 10.1038/356768a0; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; WANG L, 1994, CELL, V78, P739, DOI 10.1016/S0092-8674(94)90422-7; Wang SY, 1998, CELL, V92, P501, DOI 10.1016/S0092-8674(00)80943-5; Wang XD, 2001, GENE DEV, V15, P2922; Yang XL, 1998, MOL CELL, V1, P319, DOI 10.1016/S1097-2765(00)80032-5; Yang XL, 1998, SCIENCE, V281, P1355, DOI 10.1126/science.281.5381.1355; Zou H, 1999, J BIOL CHEM, V274, P11549, DOI 10.1074/jbc.274.17.11549	28	54	57	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 9	2003	278	19					16466	16469		10.1074/jbc.C300089200	http://dx.doi.org/10.1074/jbc.C300089200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677QG	12637514	hybrid			2022-12-25	WOS:000182818600003
J	Nogami, K; Wakabayashi, H; Fay, PJ				Nogami, K; Wakabayashi, H; Fay, PJ			Mechanisms of factor Xa-catalyzed cleavage of the factor VIIIa A1 subunit resulting in cofactor inactivation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-C; A2 SUBUNIT; PROCOAGULANT ACTIVITY; A1/A3-C1-C2 DIMER; INTERACTIVE SITE; HEAVY-CHAIN; FACTOR-IXA; FACTOR VA; BINDING; IDENTIFICATION	Activation of factor VIII by factor Xa is followed by proteolytic inactivation resulting from cleavage within the A1 subunit (residues 1-372) of factor VIIIa. Factor Xa attacks two sites in A1, Arg(336), which precedes the highly acidic C-terminal region, and a recently identified site at Lys(36). By using isolated A1 subunit as substrate for proteolysis, production of the terminal fragment, A1(37-336), was shown to proceed via two pathways identified by the intermediates A1(1-336) and A1(37-372) and generated by initial cleavage at Arg(336) and Lys(36), respectively. Appearance of the terminal product by the former pathway was 7-8-fold slower than the product obtained by the latter pathway. The isolated A1 subunit was cleaved slowly, independent of the presence of phospholipid. The A1/A3-C1-C2 dimer demonstrated an similar to3-fold increased cleavage rate constant, and inclusion of phospholipid further enhanced this value by similar to2-fold. Although association of A1 or A1(37-372) with A3-C1-C2 enhanced the rate of cleavage at Arg(336), inclusion of A3-C1-C2 did not affect the cleavage at Lys(36) in A1(1-336). A synthetic peptide 337-372 blocked the cleavage at Lys(36) (IC50=230 muM) while showing little if any effect on cleavage at Arg(336). Proteolysis at Lys(36), and to a lesser extent Arg(336), was inhibited in a dose-dependent manner by heparin. These results suggest that inactivating cleavages catalyzed by factor Xa at Lys(36) and Arg(336) are regulated in part by the A3-C1-C2 subunit. Furthermore, cleavage at Lys36 appears to be selectively modulated by the C-terminal acidic region of A1, a region that may interact with factor Xa via its heparin-binding exosite.	Univ Rochester, Med Ctr, Sch Med & Dent, Dept Biochem & Biophys, Rochester, NY 14642 USA; Univ Rochester, Sch Med & Dent, Dept Med, Rochester, NY 14642 USA	University of Rochester; University of Rochester	Fay, PJ (corresponding author), Univ Rochester, Med Ctr, Sch Med & Dent, Dept Biochem & Biophys, POB 610,601 Elmwood Ave, Rochester, NY 14642 USA.	Philip_Fay@urmc.rochester.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL030616, R01HL038199] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 38199, HL 30616] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANDERSSON LO, 1986, P NATL ACAD SCI USA, V83, P2979, DOI 10.1073/pnas.83.9.2979; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHURCH WR, 1984, P NATL ACAD SCI-BIOL, V81, P6934, DOI 10.1073/pnas.81.22.6934; EATON D, 1986, BIOCHEMISTRY-US, V25, P505, DOI 10.1021/bi00350a035; FAY PJ, 1993, J BIOL CHEM, V268, P17861; Fay PJ, 1998, J BIOL CHEM, V273, P19049, DOI 10.1074/jbc.273.30.19049; Fay PJ, 1996, J BIOL CHEM, V271, P6027, DOI 10.1074/jbc.271.11.6027; FAY PJ, 1991, J BIOL CHEM, V266, P20139; FAY PJ, 1992, J BIOL CHEM, V267, P13246; FAY PJ, 1991, J BIOL CHEM, V266, P8957; FAY PJ, 1986, BIOCHIM BIOPHYS ACTA, V871, P268, DOI 10.1016/0167-4838(86)90208-6; Fay PJ, 2001, J BIOL CHEM, V276, P12434, DOI 10.1074/jbc.M009539200; Fay PJ, 1999, J BIOL CHEM, V274, P15401, DOI 10.1074/jbc.274.22.15401; FOSTER PA, 1988, J CLIN INVEST, V82, P123, DOI 10.1172/JCI113559; Kalafatis M, 2002, BIOCHEMISTRY-US, V41, P12715, DOI 10.1021/bi026208+; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMPHEAR BJ, 1992, BLOOD, V80, P3120; Lapan KA, 1997, J BIOL CHEM, V272, P2082; Lapan KA, 1998, THROMB HAEMOSTASIS, V80, P418, DOI 10.1055/s-0037-1615223; LOLLAR P, 1993, METHOD ENZYMOL, V222, P128; LOLLAR P, 1989, BIOCHEMISTRY-US, V28, P666, DOI 10.1021/bi00428a038; LOLLAR P, 1991, J BIOL CHEM, V266, P12481; MANN KG, 1990, BLOOD, V76, P1; MIMMS LT, 1981, BIOCHEMISTRY-US, V20, P833, DOI 10.1021/bi00507a028; Nogami K, 2003, J BIOL CHEM, V278, P1634, DOI 10.1074/jbc.M209811200; Nogami K, 1999, J BIOL CHEM, V274, P31000, DOI 10.1074/jbc.274.43.31000; OBRIEN DP, 1992, BIOCHEMISTRY-US, V31, P2805, DOI 10.1021/bi00125a022; OBrien LM, 1997, BLOOD, V90, P3943, DOI 10.1182/blood.V90.10.3943; Parker ET, 1997, BIOCHEMISTRY-US, V36, P9365, DOI 10.1021/bi970599o; Pratt KP, 1999, NATURE, V402, P439, DOI 10.1038/46601; REGAN LM, 1995, J BIOL CHEM, V270, P8546, DOI 10.1074/jbc.270.15.8546; Regan LM, 1996, J BIOL CHEM, V271, P3982; Rezaie AR, 2000, J BIOL CHEM, V275, P3320, DOI 10.1074/jbc.275.5.3320; Rosenblum MEK, 2002, J BIOL CHEM, V277, P11664, DOI 10.1074/jbc.M200037200; VANDIEIJEN G, 1981, J BIOL CHEM, V256, P3433; VEHAR GA, 1984, NATURE, V312, P337, DOI 10.1038/312337a0	36	23	23	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 9	2003	278	19					16502	16509		10.1074/jbc.M213044200	http://dx.doi.org/10.1074/jbc.M213044200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677QG	12606556	hybrid			2022-12-25	WOS:000182818600010
J	Rick, PD; Barr, K; Sankaran, K; Kajimura, J; Rush, JS; Waechter, CJ				Rick, PD; Barr, K; Sankaran, K; Kajimura, J; Rush, JS; Waechter, CJ			Evidence that the wzxE gene of Escherichia coli K-12 encodes a protein involved in the transbilayer movement of a trisaccharide-lipid intermediate in the assembly of enterobacterial common antigen	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAPID TRANSMEMBRANE MOVEMENT; WATER-SOLUBLE ANALOG; IN-VITRO SYNTHESIS; GLC-P-DOLICHOL; O-ANTIGEN; ENDOPLASMIC-RETICULUM; RFE-GENE; MEMBRANE-VESICLES; CHAIN GROWTH; PIG BRAIN	The assembly of many bacterial cell surface polysaccharides requires the transbilayer movement of polyisoprenoid-linked saccharide intermediates across the cytoplasmic membrane. It is generally believed that transverse diffusion of glycolipid intermediates is mediated by integral membrane proteins called translocases or "flippases." The bacterial genes proposed to encode these translocases have been collectively designated wzx genes. The wzxE gene of Escherichia coli K-12 has been implicated in the transbilayer movement of Fuc4NAc-ManNAcA-GlcNAc-P-P-undecaprenol (lipid III), the donor of the trisaccharide repeat unit in the biosynthesis of enterobacterial common antigen (ECA). Previous studies (Feldman, M.F., Marolda, C.L., Monteiro, M. A., Perry, M.B., Parodi, A.J., and Valvano, M. (1999) J. Biol. Chem. 274, 35129-35138) provided indirect evidence that the wzx(016) gene product of E. coli K-12 encoded a translocase capable of mediating the transbilayer movement of N-acetylglucosaminylpyrophosphorylundecaprenol (GlcNAc-P-P-Und), an early intermediate in the synthesis of ECA and many lipopolysaccharide O antigens. Therefore, genetic and biochemical studies were conducted to determine if the putative Wzx(O16) translocase was capable of mediating the transport of N-acetylglucosaminylpyrophosphorylnerol (GlcNAc-P-P-Ner), a water-soluble analogue of GlcNAc-P-P-Und. [H-3] GlcNAc-P-P-Ner was transported into sealed, everted cytoplasmic membrane vesicles of E. coli K-12 as well as a deletion mutant lacking both the wzx016 and wzxC genes. In contrast, [H-3] GlcNAc-P-P-Ner was not transported into membrane vesicles prepared from a wzxE-null mutant, and metabolic radiolabeling experiments revealed the accumulation of lipid III in this mutant. The WzxE transport system exhibited substrate specificity by recognizing both a pyrophosphoryl-linked saccharide and an unsaturated alpha-isoprene unit in the carrier lipid. These results support the conclusion that the wzxE gene encodes a membrane protein involved in the transbilayer movement of lipid III in E. coli.	Uniformed Serv Univ Hlth Sci, Dept Biochem & Mol Biol, Bethesda, MD 20814 USA; Univ Kentucky, Coll Med, Dept Mol & Cellular Biochem, Lexington, KY 40536 USA	Uniformed Services University of the Health Sciences - USA; University of Kentucky	Rick, PD (corresponding author), Uniformed Serv Univ Hlth Sci, Dept Biochem & Mol Biol, 4301 Jones Bridge Rd, Bethesda, MD 20814 USA.	rickp@usuhs.mil			NIGMS NIH HHS [GM52882, GM36365] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM036365] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABEIJON C, 1990, J BIOL CHEM, V265, P14691; ABEIJON C, 1992, TRENDS BIOCHEM SCI, V17, P32, DOI 10.1016/0968-0004(92)90424-8; ALEXANDER DC, 1994, J BACTERIOL, V176, P7079, DOI 10.1128/JB.176.22.7079-7084.1994; AMBUDKAR SV, 1984, J BIOL CHEM, V259, P6142; Anand M, 2001, MOL BIOL CELL, V12, P487, DOI 10.1091/mbc.12.2.487; BARR K, 1989, J BACTERIOL, V171, P1326, DOI 10.1128/jb.171.3.1326-1332.1989; BARR K, 1987, J BIOL CHEM, V262, P7142; BISHOP WR, 1985, CELL, V42, P51, DOI 10.1016/S0092-8674(85)80100-8; Blattner FR, 1997, SCIENCE, V277, P1453, DOI 10.1126/science.277.5331.1453; BRAY D, 1967, BIOCHEM BIOPH RES CO, V28, P334, DOI 10.1016/0006-291X(67)90314-2; DANILOV LL, 1989, CHEM PHYS LIPIDS, V51, P191, DOI 10.1016/0009-3084(89)90006-6; DANILOV LL, 1981, FEBS LETT, V131, P310, DOI 10.1016/0014-5793(81)80392-4; DITTMER JC, 1964, J LIPID RES, V5, P126; DUNPHY PJ, 1967, BIOCHIM BIOPHYS ACTA, V136, P136, DOI 10.1016/0304-4165(67)90329-7; Feldman MF, 1999, J BIOL CHEM, V274, P35129, DOI 10.1074/jbc.274.49.35129; FUTAI M, 1974, J MEMBRANE BIOL, V15, P15, DOI 10.1007/BF01870079; GUZMAN LM, 1995, J BACTERIOL, V177, P4121, DOI 10.1128/jb.177.14.4121-4130.1995; HANOVER JA, 1979, J BIOL CHEM, V254, P9237; Helenius J, 2002, NATURE, V415, P447, DOI 10.1038/415447a; HIRSCHBERG CB, 1987, ANNU REV BIOCHEM, V56, P63, DOI 10.1146/annurev.bi.56.070187.000431; Hrafnsdottir S, 1997, BIOCHEMISTRY-US, V36, P4969, DOI 10.1021/bi962513h; Huijbregts RPH, 1996, BBA-BIOMEMBRANES, V1280, P41, DOI 10.1016/0005-2736(95)00272-3; Keenleyside WJ, 1999, ENDOTOXIN IN HEALTH AND DISEASE, P331; Kol MA, 2002, SEMIN CELL DEV BIOL, V13, P163, DOI 10.1016/S1084-9521(02)00044-7; Kubelt J, 2002, BIOCHEMISTRY-US, V41, P5605, DOI 10.1021/bi0118714; KUHN HM, 1983, INFECT IMMUN, V40, P696, DOI 10.1128/IAI.40.2.696-700.1983; Lannert H, 1998, J BIOL CHEM, V273, P2939, DOI 10.1074/jbc.273.5.2939; LENNARZ WJ, 1987, BIOCHEMISTRY-US, V26, P7205, DOI 10.1021/bi00397a001; Liu D, 1996, J BACTERIOL, V178, P2102, DOI 10.1128/jb.178.7.2102-2107.1996; LUGOWSKI C, 1983, CARBOHYD RES, V118, P173, DOI 10.1016/0008-6215(83)88045-8; MACPHERSON DF, 1995, GENE, V155, P9, DOI 10.1016/0378-1119(94)00918-I; MCCLOSKEY MA, 1980, BIOCHEMISTRY-US, V19, P2061, DOI 10.1021/bi00551a009; MCGRATH BC, 1991, J BACTERIOL, V173, P649, DOI 10.1128/jb.173.2.649-654.1991; MCMURRY L, 1980, P NATL ACAD SCI-BIOL, V77, P3974, DOI 10.1073/pnas.77.7.3974; MEIERDIETER U, 1992, J BIOL CHEM, V267, P746; MENON A, 1995, TRENDS CELL BIOL, V5, P355, DOI 10.1016/S0962-8924(00)89069-8; Menon AK, 2000, CURR BIOL, V10, P241, DOI 10.1016/S0960-9822(00)00356-0; Menon AK, 2002, SEMIN CELL DEV BIOL, V13, P159, DOI 10.1016/S1084-9521(02)00043-5; Miller J.H., 1992, SHORT COURSE BACTERI, P150; NEUHARD J, 1976, J BACTERIOL, V126, P999, DOI 10.1128/JB.126.2.999-1001.1976; PERLIN DS, 1986, ARCH BIOCHEM BIOPHYS, V248, P53, DOI 10.1016/0003-9861(86)90400-5; REENSTRA WW, 1980, BIOCHEMISTRY-US, V19, P1, DOI 10.1021/bi00542a001; REEVES PR, 1994, NEW COMPR BIOCH, V27, P281; Rick P, 1996, ESCHERICHIA COLI SAL, P104; Rick PD, 1998, GLYCOBIOLOGY, V8, P557, DOI 10.1093/glycob/8.6.557; RICK PD, 1994, J BACTERIOL, V176, P2877, DOI 10.1128/JB.176.10.2877-2884.1994; RICK PD, 1985, J BACTERIOL, V162, P494, DOI 10.1128/JB.162.2.494-503.1985; ROBBINS PW, 1967, SCIENCE, V158, P1536, DOI 10.1126/science.158.3808.1536; ROTHFIELD L, 1964, J BIOL CHEM, V239, P2788; ROTHMAN JE, 1977, P NATL ACAD SCI USA, V74, P1821, DOI 10.1073/pnas.74.5.1821; RUSH JS, 1993, J BIOL CHEM, V268, P13110; RUSH JS, 1995, J CELL BIOL, V130, P529, DOI 10.1083/jcb.130.3.529; Rush JS, 1997, GLYCOBIOLOGY, V7, P315, DOI 10.1093/glycob/7.2.315; Rush JS, 1998, GLYCOBIOLOGY, V8, P1207, DOI 10.1093/glycob/8.12.1207; Rush JS, 1998, GLYCOBIOLOGY, V8, P1195, DOI 10.1093/glycob/8.12.1195; Schenk B, 2001, GLYCOBIOLOGY, V11, p61R, DOI 10.1093/glycob/11.5.61R; SILHAVY TJ, 1984, EXPT GENE FUSIONS, P104; STEVENSON G, 1994, J BACTERIOL, V176, P4144, DOI 10.1128/JB.176.13.4144-4156.1994; TROTTER PJ, 1994, BBA-LIPID LIPID MET, V1213, P241, DOI 10.1016/0005-2760(94)00073-5; VIDUGIRIENE J, 1994, J CELL BIOL, V127, P333, DOI 10.1083/jcb.127.2.333; Vidugiriene J, 1999, J BIOL CHEM, V274, P15203, DOI 10.1074/jbc.274.21.15203; WANG RF, 1991, GENE, V100, P195, DOI 10.1016/0378-1119(91)90366-J; YAMAGUCHI A, 1991, FEBS LETT, V282, P415, DOI 10.1016/0014-5793(91)80527-A; YAO ZJ, 1994, J BACTERIOL, V176, P4133, DOI 10.1128/JB.176.13.4133-4143.1994; ZACHOWSKI A, 1993, BIOCHEM J, V294, P1; ZACHOWSKI A, 1990, EXPERIENTIA, V46, P644, DOI 10.1007/BF01939703; ZHU XY, 1992, J BIOL CHEM, V267, P8895	67	87	92	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 9	2003	278	19					16534	16542		10.1074/jbc.M301750200	http://dx.doi.org/10.1074/jbc.M301750200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677QG	12621029	hybrid			2022-12-25	WOS:000182818600014
J	Rudrabhatla, P; Rajasekharan, R				Rudrabhatla, P; Rajasekharan, R			Mutational analysis of stress-responsive peanut dual specificity protein kinase - Identification of tyrosine residues involved in regulation of protein kinase activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHORYLATION SITES; MAP KINASE; SCHIZOSACCHAROMYCES-POMBE; SUBSTRATE-SPECIFICITY; CRYSTAL-STRUCTURE; C-THETA; ACTIVATION; DOMAIN; AUTOPHOSPHORYLATION; PP60C-SRC	We recently reported that Arachis hypogaea serine/threonine/tyrosine (STY) protein kinase is developmentally regulated and is induced by abiotic stresses (Rudrabhatla, P., and Rajasekharan, R. (2002) Plant Physiol. 130, 380-390). Other than MAPKs, the site of tyrosine phosphorylation has not been documented for any plant kinases. To study the role of tyrosines in the phosphorylation of STY protein kinase, four conserved tyrosine residues were sequentially substituted with phenylalanine and expressed as histidine fusion proteins. Mass spectrometry experiments showed that STY protein kinase autophosphorylated within the predicted kinase ATP-binding motif, activation loop, and an additional site in the C terminus. The protein kinase activity was abolished by substitution of Tyr(297) with Phe in the activation loop between subdomains VII and VIII. In addition, replacing Tyr(148) in the ATP-binding motif and Tyr(317) in the C-terminal domain with Phe not only obliterated the ability of the STY protein kinase protein to be phosphorylated, but also inhibited histone phosphorylation, suggesting that STY protein kinase is phosphorylated at multiple sites. Replacing Tyr(213) in the Thr-Glu-Tyr sequence motif with Phe resulted in a 4-fold increase in autophosphorylation and 2.8-fold increase in substrate phosphorylation activities. Mutants Y148F, Y297F, and Y317F displayed dramatically lower phosphorylation efficiency (k(cat)/K-m) with ATP and histone, whereas mutant Y213F showed increased phosphorylation. Our results suggest that autophosphorylation of Tyr(148), Tyr(213), Tyr(297), and Tyr(317) is important for the regulation of STY protein kinase activity. Our study reveals the first example of Thr-Glu-Tyr domain-mediated autoinhibition of kinases.	Indian Inst Sci, Dept Biochem, Bangalore 560012, Karnataka, India	Indian Institute of Science (IISC) - Bangalore	Rajasekharan, R (corresponding author), Indian Inst Sci, Dept Biochem, Bangalore 560012, Karnataka, India.	lipid@biochem.iisc.ernet.in	Rajasekharan, Ram/R-2257-2019; R, Rajasekharan/D-3420-2009	Rajasekharan, Ram/0000-0002-2124-6013; Rudrabhatla, Parvathi/0000-0002-7537-3130; Ram, Rajasekharan/0000-0002-4114-0654				ALESSI DR, 1994, EMBO J, V13, P1610, DOI 10.1002/j.1460-2075.1994.tb06424.x; ALI N, 1994, J BIOL CHEM, V269, P31626; Barizza E, 1999, FEBS LETT, V447, P191, DOI 10.1016/S0014-5793(99)00272-0; Becker W, 1998, J BIOL CHEM, V273, P25893, DOI 10.1074/jbc.273.40.25893; BENLEVY R, 1995, EMBO J, V14, P5920, DOI 10.1002/j.1460-2075.1995.tb00280.x; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CARMEL G, 1994, J BIOL CHEM, V269, P7304; CARTWRIGHT CA, 1987, CELL, V49, P83, DOI 10.1016/0092-8674(87)90758-6; COOPER JA, 1993, CELL, V73, P1051, DOI 10.1016/0092-8674(93)90634-3; COOPER JA, 1988, P NATL ACAD SCI USA, V85, P4232, DOI 10.1073/pnas.85.12.4232; Crosby D, 2002, J BIOL CHEM, V277, P9958, DOI 10.1074/jbc.M108965200; Dajani R, 2001, CELL, V105, P721, DOI 10.1016/S0092-8674(01)00374-9; DELEAGE G, 1993, COMPUT APPL BIOSCI, V9, P197; Elion EA, 1998, SCIENCE, V281, P1625, DOI 10.1126/science.281.5383.1625; FENG SB, 1994, SCIENCE, V266, P1241, DOI 10.1126/science.7526465; FENG XH, 1993, BIOCHIM BIOPHYS ACTA, V1172, P200, DOI 10.1016/0167-4781(93)90295-O; GOULD KL, 1991, EMBO J, V10, P3297, DOI 10.1002/j.1460-2075.1991.tb04894.x; Grietzen KF, 1999, J BIOL CHEM, V274, P32063, DOI 10.1074/jbc.274.45.32063; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; HEIERHORST J, 1994, J BIOL CHEM, V269, P21086; HILL CS, 1995, CELL, V80, P199, DOI 10.1016/0092-8674(95)90403-4; Hubbard SR, 1998, J BIOL CHEM, V273, P11987, DOI 10.1074/jbc.273.20.11987; HUNTER T, 1995, CELL, V80, P225, DOI 10.1016/0092-8674(95)90405-0; Johnson LN, 1996, CELL, V85, P149, DOI 10.1016/S0092-8674(00)81092-2; Kawakami Y, 2000, P NATL ACAD SCI USA, V97, P7423, DOI 10.1073/pnas.120175097; KAZUHISA K, 2000, NATURE, V407, P37; KMIECIK TE, 1987, CELL, V49, P65, DOI 10.1016/0092-8674(87)90756-2; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEI JY, 1994, J BIOL CHEM, V269, P21078; Liu YH, 2000, J BIOL CHEM, V275, P3603, DOI 10.1074/jbc.275.5.3603; MORGAN DO, 1994, CURR OPIN CELL BIOL, V6, P239, DOI 10.1016/0955-0674(94)90142-2; MUNOZ G, 1990, ANAL BIOCHEM, V190, P233, DOI 10.1016/0003-2697(90)90185-C; PAYNE DM, 1991, EMBO J, V10, P885, DOI 10.1002/j.1460-2075.1991.tb08021.x; PIWNICAWORMS H, 1987, CELL, V49, P75, DOI 10.1016/0092-8674(87)90757-4; RIEDEL H, 1987, SCIENCE, V236, P197, DOI 10.1126/science.3494307; Rudrabhatla P, 2002, PLANT PHYSIOL, V130, P380, DOI 10.1104/pp.005173; Sambrook J, 1989, MOL CLONING LABORATO, p1 25; SAYLE RA, 1995, TRENDS BIOCHEM SCI, V20, P374, DOI 10.1016/S0968-0004(00)89080-5; Sessa G, 2000, EMBO J, V19, P2257, DOI 10.1093/emboj/19.10.2257; Shah K, 2001, J BIOL CHEM, V276, P41263, DOI 10.1074/jbc.M102381200; SODERLING TR, 1990, J BIOL CHEM, V265, P1823; STEINBERG RA, 1993, MOL CELL BIOL, V13, P2332, DOI 10.1128/MCB.13.4.2332; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; SUZUKI K, 1995, PLANT CELL, V7, P639, DOI 10.1105/tpc.7.5.639; Tregear JW, 1996, PLANT SCI, V117, P107, DOI 10.1016/0168-9452(96)04400-7; Vertommen D, 2000, J BIOL CHEM, V275, P19567, DOI 10.1074/jbc.M001357200; Weijland A, 1997, P NATL ACAD SCI USA, V94, P3590, DOI 10.1073/pnas.94.8.3590; Wilkins MR, 1997, ELECTROPHORESIS, V18, P403, DOI 10.1002/elps.1150180314; Xu WQ, 1999, MOL CELL, V3, P629, DOI 10.1016/S1097-2765(00)80356-1; Zhang H, 2001, J BIOL CHEM, V276, P45598, DOI 10.1074/jbc.M107176200; Zhang SQ, 2001, TRENDS PLANT SCI, V6, P520, DOI 10.1016/S1360-1385(01)02103-3; ZHENG CF, 1994, EMBO J, V13, P1123, DOI 10.1002/j.1460-2075.1994.tb06361.x	52	18	23	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 9	2003	278	19					17328	17335		10.1074/jbc.M300024200	http://dx.doi.org/10.1074/jbc.M300024200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677QG	12624102	hybrid			2022-12-25	WOS:000182818600118
J	Ohtsuka, T; Ryu, H; Minamishima, YA; Ryo, A; Lee, SW				Ohtsuka, T; Ryu, H; Minamishima, YA; Ryo, A; Lee, SW			Modulation of p53 and p73 levels by cyclin G: implication of a negative feedback regulation	ONCOGENE			English	Article						p53; p73; cyclin G; siRNA; negative feedback regulation	DNA-DAMAGE; P53-INDUCED APOPTOSIS; G2/M ARREST; MDM2; GENE; GROWTH; CELLS; DEGRADATION; PROMOTES; PROTEIN	Cyclin G is a transcriptional target gene of tumor suppressor p53. Recent studies present evidence that cyclin G may play a central role in the p53-Mdm2 autoregulated module, but the precise function of cyclin G remains elusive. Here, we show a negative effect of cyclin G on the stability of p53 and p73. Cyclin G expression resulted in a dramatic decrease of p53 protein levels in response to DNA damage and abrogated irradiation-mediated G1 arrest along with an increase of S phase in MCF7 cells containing wild-type p53. In p53-null Saos2 cells, cyclin G inhibited p73 induction in response to genotoxic stress and delayed the camptothecin-mediated cell cycle arrest. Cyclin G interacts with p53 as well as p73, and its binding to p53 or p73 presumably mediates downregulation of p53 and p73. We also found that cyclin G-mediated reduction of p53 but not of p73 is Mdm2-dependent. Moreover, inhibition of cyclin G by small interfering RNA (siRNA) caused the accumulation of p53 and p73 protein levels in response to DNA damage. Therefore, our results imply that cyclin G is transcriptionally activated by p53 or p73, and, in turn, cyclin G negatively regulates the stabilization of p53 family proteins through an unknown mechanism different from ubiquitination or transcriptional control.	Harvard Univ, Sch Med, Inst Med, Boston, MA 02115 USA; Beth Israel Deaconess Med Ctr, Div Hematol & Oncol, Canc Biol Program, Boston, MA 02215 USA; Univ Massachusetts, Sch Med, Dept Neurol, Worcester, MA 01605 USA; Mem Hlth Care Ctr, Worcester, MA 01605 USA	Harvard University; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center; University of Massachusetts System; University of Massachusetts Worcester	Lee, SW (corresponding author), Harvard Univ, Sch Med, Inst Med, 77 Ave Louis Pasteur,Room 921, Boston, MA 02115 USA.		Minamishima, Yoji Andrew/E-5380-2010	Minamishima, Yoji Andrew/0000-0001-7995-9318; Ryu, Hoon/0000-0001-6544-3732	NCI NIH HHS [CA85681, CA78356, CA80058] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA085681, R01CA078356] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Attardi LD, 2000, GENE DEV, V14, P704; Bean LJH, 2002, J BIOL CHEM, V277, P1864, DOI 10.1074/jbc.M108881200; BUCKBINDER L, 1995, NATURE, V377, P646, DOI 10.1038/377646a0; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; BURNS TF, 1999, J CELL PHYSL, V181, P371; Chen XB, 2002, DEV CELL, V2, P518, DOI 10.1016/S1534-5807(02)00182-X; Chen XB, 2001, ONCOGENE, V20, P769, DOI 10.1038/sj.onc.1204149; Di Como CJ, 1999, MOL CELL BIOL, V19, P1438; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Gong JG, 1999, NATURE, V399, P806; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; HE TC, 1996, P NATL ACAD SCI USA, V93, P8390; Inoue T, 2001, FEBS LETT, V490, P196, DOI 10.1016/S0014-5793(01)02123-8; Kimura SH, 2002, GENES CELLS, V7, P869, DOI 10.1046/j.1365-2443.2002.00564.x; Kimura SH, 2001, ONCOGENE, V20, P3290, DOI 10.1038/sj.onc.1204270; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Lin YP, 2000, NAT GENET, V26, P122, DOI 10.1038/79102; Maki CG, 1997, MOL CELL BIOL, V17, P355, DOI 10.1128/MCB.17.1.355; MIYASHITA T, 1995, CELL, V80, P293; Nakano K, 2001, MOL CELL, V7, P683, DOI 10.1016/S1097-2765(01)00214-3; Oda E, 2000, SCIENCE, V288, P1053, DOI 10.1126/science.288.5468.1053; OKAMOTO K, 1994, EMBO J, V13, P4816, DOI 10.1002/j.1460-2075.1994.tb06807.x; Okamoto K, 1999, ONCOGENE, V18, P4606, DOI 10.1038/sj.onc.1202821; Okamoto K, 2002, MOL CELL, V9, P761, DOI 10.1016/S1097-2765(02)00504-X; Polyak K, 1996, GENE DEV, V10, P1945, DOI 10.1101/gad.10.15.1945; Reimers L, 1999, J BIOL CHEM, V274, P11022, DOI 10.1074/jbc.274.16.11022; Shimizu A, 1998, BIOCHEM BIOPH RES CO, V242, P529, DOI 10.1006/bbrc.1997.8004; SKOTZKO M, 1995, CANCER RES, V55, P5493; Smith ML, 1997, EXP CELL RES, V230, P61, DOI 10.1006/excr.1996.3402; TAMURA K, 1993, ONCOGENE, V8, P2113; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Vousden KH, 2000, CELL, V103, P691, DOI 10.1016/S0092-8674(00)00171-9; Wu GS, 1997, NAT GENET, V17, P141, DOI 10.1038/ng1097-141; Yu J, 1999, P NATL ACAD SCI USA, V96, P14517, DOI 10.1073/pnas.96.25.14517; ZAUBERMAN A, 1995, ONCOGENE, V10, P2361; Zeng XY, 1999, MOL CELL BIOL, V19, P3257	37	68	69	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 20	2003	22	11					1678	1687		10.1038/sj.onc.1206306	http://dx.doi.org/10.1038/sj.onc.1206306			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	655YH	12642871				2022-12-25	WOS:000181580500010
J	Koc, A; Wheeler, LJ; Mathews, CK; Merrill, GF				Koc, A; Wheeler, LJ; Mathews, CK; Merrill, GF			Replication-independent MCB gene induction and deoxyribonucleotide accumulation at G(1)/S in Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-CYCLE REGULATION; DNA-BINDING ACTIVITY; S-PHASE; RIBONUCLEOTIDE REDUCTASE; DEPENDENT TRANSCRIPTION; BUDDING YEAST; THIOREDOXIN; PROTEIN; AP-1; IDENTIFICATION	In Saccharomyces cerevisiae, many genes encoding enzymes involved in deoxyribonucleotide synthesis are expressed preferentially near the G(1)/S boundary of the! cell cycle. The relationship between the induction of deoxyribonucleotide-synthesizing genes, deoxyribonucleoside triphosphate levels, and replication initiation was investigated using a factor-synchronized wildtype yeast or dbf4 yeast that are temperature-sensitive for replication initiation. Neither the timing nor extent of gene induction was inhibited when a factor-arrested dbf4 cells were released into medium containing the ribonucleotide reductase inhibitor hydroxyurea, which blocks replication fork progression, or were released at 37 degreesC, which blocks replication origin firing. Thus, the induction of deoxyribonucleotide-synthesizing genes at G(1)/S was fully independent of DNA chain elongation or initiation. Deoxyribonucleoside triphosphate levels increased severalfold at G(1)/S in wild-type cells and in,dbf4 mutants incubated at the non-permissive temperature. Thus, deoxyribonucleoside triphosphate accumulation, like the induction of deoxyribonucleotide-synthesizing genes, was not dependent on replication initiation. Deoxyribonucleoside triphosphate accumulation at G(1)/S was suppressed in cells lacking Swi6, a transcription factor required for normal cell cycle regulation of deoxyribonucleotide-synthesizing genes. The results suggest that cells use gene induction at G(1)/S as a mechanism to pre-emptively, rather than reflexively, increase the synthesis of DNA precursors to meet the demand of the replication forks for deoxyribonucleotides.	Oregon State Univ, Genet Program, Corvallis, OR 97331 USA; Oregon State Univ, Dept Biochem & Biophys, Corvallis, OR 97331 USA	Oregon State University; Oregon State University	Merrill, GF (corresponding author), Oregon State Univ, Genet Program, Corvallis, OR 97331 USA.		KOÇ, AHMET/ABI-3322-2020	KOÇ, AHMET/0000-0003-3484-2137	NATIONAL CANCER INSTITUTE [R01CA082633] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES000210] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM055134] Funding Source: NIH RePORTER; NCI NIH HHS [CA82633] Funding Source: Medline; NIEHS NIH HHS [ES00210] Funding Source: Medline; NIGMS NIH HHS [GM55134] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLEN JB, 1994, GENE DEV, V8, P2401, DOI 10.1101/gad.8.20.2401; AVES SJ, 1985, EMBO J, V4, P457, DOI 10.1002/j.1460-2075.1985.tb03651.x; BENEZRA R, 1994, CELL, V79, P1057, DOI 10.1016/0092-8674(94)90036-1; BJURSELL KG, 1972, EUR J BIOCHEM, V29, P348, DOI 10.1111/j.1432-1033.1972.tb01995.x; CHAPMAN JW, 1989, EXP CELL RES, V180, P419, DOI 10.1016/0014-4827(89)90068-2; DIRICK L, 1992, NATURE, V357, P508, DOI 10.1038/357508a0; ELLEDGE SJ, 1993, BIOESSAYS, V15, P333, DOI 10.1002/bies.950150507; ELLEDGE SJ, 1990, GENE DEV, V4, P740, DOI 10.1101/gad.4.5.740; FOSTER R, 1993, MOL CELL BIOL, V13, P3792, DOI 10.1128/MCB.13.6.3792; HARTWELL LH, 1974, SCIENCE, V183, P46, DOI 10.1126/science.183.4120.46; HEREFORD LM, 1981, CELL, V24, P367, DOI 10.1016/0092-8674(81)90326-3; Hirota K, 1997, P NATL ACAD SCI USA, V94, P3633, DOI 10.1073/pnas.94.8.3633; JOHNSTON LH, 1982, MOL GEN GENET, V186, P445, DOI 10.1007/BF00729467; Jordan A, 1998, ANNU REV BIOCHEM, V67, P71, DOI 10.1146/annurev.biochem.67.1.71; Jorgensen P, 2002, SCIENCE, V297, P395, DOI 10.1126/science.1070850; KOCH C, 1993, SCIENCE, V261, P1551, DOI 10.1126/science.8372350; KOHALMI SE, 1991, J MOL BIOL, V220, P933, DOI 10.1016/0022-2836(91)90364-C; LOWNDES NF, 1992, NATURE, V357, P505, DOI 10.1038/357505a0; Machado AK, 1997, J BIOL CHEM, V272, P17045, DOI 10.1074/jbc.272.27.17045; MATTHEWS JR, 1992, NUCLEIC ACIDS RES, V20, P3821, DOI 10.1093/nar/20.15.3821; MCINTOSH EM, 1991, MOL CELL BIOL, V11, P329, DOI 10.1128/MCB.11.1.329; MERRILL GF, 1992, BIOESSAYS, V14, P823, DOI 10.1002/bies.950141206; MULLER EGD, 1994, J BIOL CHEM, V269, P24466; NORDENSKJOLD BA, 1970, J BIOL CHEM, V245, P5360; NORTH TW, 1980, J BIOL CHEM, V255, P6640; Partridge JF, 1997, J BIOL CHEM, V272, P9071; PRICE C, 1991, J MOL BIOL, V218, P543, DOI 10.1016/0022-2836(91)90700-G; SCHENK H, 1994, P NATL ACAD SCI USA, V91, P1672, DOI 10.1073/pnas.91.5.1672; SCHMIDT EE, 1989, J BIOL CHEM, V264, P21247; Sclafani RA, 2000, J CELL SCI, V113, P2111; Ueno M, 1999, J BIOL CHEM, V274, P35809, DOI 10.1074/jbc.274.50.35809; WALLIS JW, 1989, CELL, V58, P409, DOI 10.1016/0092-8674(89)90855-6; WHITE JHM, 1987, EXP CELL RES, V171, P223, DOI 10.1016/0014-4827(87)90265-5; XANTHOUDAKIS S, 1992, EMBO J, V11, P653, DOI 10.1002/j.1460-2075.1992.tb05097.x	34	23	23	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 14	2003	278	11					9345	9352		10.1074/jbc.M213013200	http://dx.doi.org/10.1074/jbc.M213013200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	654YF	12643263	hybrid			2022-12-25	WOS:000181524000062
J	Fannon, M; Forsten-Williams, K; Dowd, CJ; Freedman, DA; Folkman, J; Nugent, MA				Fannon, M; Forsten-Williams, K; Dowd, CJ; Freedman, DA; Folkman, J; Nugent, MA			Binding inhibition of angiogenic factors by heparan sulfate proteoglycans in aqueous humor: potential mechanism for maintenance of an avascular environment	FASEB JOURNAL			English	Article						VEGF; endothelial cell; bFGF; heparin binding; computational model	FIBROBLAST GROWTH-FACTOR; SMOOTH-MUSCLE CELLS; HIGH-AFFINITY; BASEMENT-MEMBRANE; BFGF BINDING; TGF-BETA; NEOVASCULARIZATION; PURIFICATION; MITOGENESIS; RECEPTORS	Aqueous humor is a clear fluid, primarily a blood filtrate, which circulates through the anterior chamber of the eye and bathes the cornea. We explored the possibility that components in the aqueous humor play a direct part in maintaining the avascular environment of the cornea. We report here that heparan sulfate proteoglycan (HSPG) was found in bovine aqueous humor and that it directly inhibits binding of basic fibroblast growth factor and vascular endothelial growth factor to cell-surface heparan sulfate. We demonstrate that this holds true for all heparin binding proteins tested but not for epidermal growth factor, which does not bind heparin. Furthermore, we show, with mathematical modeling, that the concentration of HSPG in aqueous humor ( 4 mug/ml), when combined with the clearance of aqueous humor from the eye due to circulation, is sufficient to block the binding of heparin binding growth factors to corneal endothelium. This mechanism suggests a physiological process to control bioavailability of angiogenic growth factors in the cornea.	Childrens Hosp, Dept Surg, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA; Virginia Polytech Inst & State Univ, Dept Chem Engn, Blacksburg, VA 24061 USA; Boston Univ, Sch Med, Dept Biochem, Boston, MA 02118 USA; Boston Univ, Sch Med, Dept Ophthalmol, Boston, MA 02118 USA	Harvard University; Boston Children's Hospital; Harvard University; Harvard Medical School; Virginia Polytechnic Institute & State University; Boston University; Boston University	Fannon, M (corresponding author), Childrens Hosp, Dept Surg, 300 Longwood Ave, Boston, MA 02115 USA.	michael.fannon@tch.harvard.edu		Nugent, Matthew/0000-0002-8630-4712				AUSPRUNK DH, 1978, LAB INVEST, V38, P284; Brown CT, 1999, J BIOL CHEM, V274, P7111, DOI 10.1074/jbc.274.11.7111; BROWN RA, 1988, ANN RHEUM DIS, V47, P881, DOI 10.1136/ard.47.11.881; BRUBAKER RF, 1991, INVEST OPHTH VIS SCI, V32, P3145; CASTELLOT JJ, 1985, J CELL PHYSIOL, V124, P13, DOI 10.1002/jcp.1041240104; Collen A, 2000, CANCER RES, V60, P6196; DANIELSON KG, 1992, MATRIX, V12, P22, DOI 10.1016/S0934-8832(11)80101-0; Dowd CJ, 1999, J BIOL CHEM, V274, P5236, DOI 10.1074/jbc.274.8.5236; Fannon M, 2000, BIOCHEMISTRY-US, V39, P1434, DOI 10.1021/bi991895z; Fannon M, 1996, J BIOL CHEM, V271, P17949, DOI 10.1074/jbc.271.30.17949; FARNDALE RW, 1986, BIOCHIM BIOPHYS ACTA, V881, P46, DOI 10.1016/0304-4165(86)90095-4; Forsten K E, 1994, J Comput Biol, V1, P15; FORSTEN KE, 1994, MOL IMMUNOL, V31, P739, DOI 10.1016/0161-5890(94)90148-1; Forsten KE, 1997, J CELL PHYSIOL, V172, P209, DOI 10.1002/(SICI)1097-4652(199708)172:2<209::AID-JCP8>3.0.CO;2-S; Forsten KE, 2000, J THEOR BIOL, V205, P215, DOI 10.1006/jtbi.2000.2064; Funaki H, 2001, INVEST OPHTH VIS SCI, V42, P1193; GALLAGHER JT, 1990, BIOCHEM SOC T, V18, P207, DOI 10.1042/bst0180207; GIMBRONE MA, 1973, J NATL CANCER I, V50, P219, DOI 10.1093/jnci/50.1.219; GOSPODAROWICZ D, 1986, J CELL PHYSIOL, V128, P475, DOI 10.1002/jcp.1041280317; Hayasaka K, 1998, LIFE SCI, V63, P1089, DOI 10.1016/S0024-3205(98)00205-7; HONDERMARCK H, 1992, DEV BRAIN RES, V68, P247, DOI 10.1016/0165-3806(92)90067-7; Huang SH, 1996, EXP EYE RES, V62, P481, DOI 10.1006/exer.1996.0058; Krufka A, 1996, BIOCHEMISTRY-US, V35, P11131, DOI 10.1021/bi960125+; LIOTE F, 1991, REV RHUM, V58, pS51; Liu DF, 2002, P NATL ACAD SCI USA, V99, P568, DOI 10.1073/pnas.012578299; Loughnan MS, 1996, AUST NZ J OPHTHALMOL, V24, P289, DOI 10.1111/j.1442-9071.1996.tb01596.x; MALI M, 1993, J BIOL CHEM, V268, P24215; Moulton KS, 1999, CIRCULATION, V99, P1726, DOI 10.1161/01.CIR.99.13.1726; Namiki Mari, 1994, Nippon Ganka Gakkai Zasshi, V98, P334; NGUYEN M, 1993, J NATL CANCER I, V85, P241, DOI 10.1093/jnci/85.3.241; NUGENT MA, 1993, CIRC RES, V73, P1051, DOI 10.1161/01.RES.73.6.1051; NUGENT MA, 1992, BIOCHEMISTRY-US, V31, P8876, DOI 10.1021/bi00152a026; NUGENT MA, 1994, INV OPHTHAL VIS SCI, V34, P3049; Ornstein DL, 2001, INT J HEMATOL, V73, P157, DOI 10.1007/BF02981932; RAPRAEGER AC, 1991, SCIENCE, V252, P1705, DOI 10.1126/science.1646484; SAKSELA O, 1988, J CELL BIOL, V107, P743, DOI 10.1083/jcb.107.2.743; Schechter J, 2000, EXP EYE RES, V70, P777, DOI 10.1006/exer.2000.0837; Sheibani N, 2000, BIOCHEM BIOPH RES CO, V267, P257, DOI 10.1006/bbrc.1999.1903; Sperinde GV, 2000, BIOCHEMISTRY-US, V39, P3788, DOI 10.1021/bi992243d; Sperinde GV, 1998, BIOCHEMISTRY-US, V37, P13153, DOI 10.1021/bi980600z; Thompson RW, 1990, GROWTH FACTORS, V3, P221, DOI 10.3109/08977199009043906; Tripathi RC, 1997, EXP EYE RES, V64, P335, DOI 10.1006/exer.1996.0215; TRIPATHI RC, 1992, EXP EYE RES, V54, P447, DOI 10.1016/0014-4835(92)90056-X; Wallentin N, 1998, INVEST OPHTH VIS SCI, V39, P1410; Whalen GF, 1989, GROWTH FACTORS, V1, P157, DOI 10.3109/08977198909029125; Whitelock J, 2001, Methods Mol Biol, V171, P27; YANG VC, 1985, J BIOL CHEM, V260, P1849; YAYON A, 1991, CELL, V64, P841, DOI 10.1016/0092-8674(91)90512-W	49	34	35	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAR	2003	17	3					902	+		10.1096/fj.02-0935fje	http://dx.doi.org/10.1096/fj.02-0935fje			20	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	661LT	12626427				2022-12-25	WOS:000181892600020
J	Tralhao, JG; Schaefer, L; Micegova, M; Evaristo, C; Schonherr, E; Kayal, S; Veiga-Fernandes, H; Danel, C; Iozzo, RV; Kresse, H; Lemarchand, P				Tralhao, JG; Schaefer, L; Micegova, M; Evaristo, C; Schonherr, E; Kayal, S; Veiga-Fernandes, H; Danel, C; Iozzo, RV; Kresse, H; Lemarchand, P			In vivo selective and distant killing of cancer cells, using adenovirus-mediated decorin gene transfer	FASEB JOURNAL			English	Article						decorin; apoptosis; tumor; proteoglycan	TUMOR-SUPPRESSOR GENE; DOWN-REGULATION; TRANSGENE EXPRESSION; GROWTH SUPPRESSION; APOPTOSIS; THERAPY; INHIBITION; P53; PROTEOGLYCANS; TUMORIGENICITY	Decorin is a well-known, ubiquitous proteoglycan that is a normal component of the ECM. Upon transgenic expression of decorin, tumor cells with diverse histogenetic background overexpress p21(WAF1), a potent inhibitor of cyclin-dependent kinase activity, become arrested in G1, and fail to generate tumors in immunocompromised animals. Because decorin is a secreted protein, it has been recently suggested that decorin could act as an autocrine and paracrine regulator of tumor growth. Here, we demonstrate that adenovirus (Ad)-mediated transfer and expression of human decorin cDNA induced in vivo apoptosis of xenograft tumor cells in nude mice. This oncolytic activity was observed when the Ad vector encoding the decorin cDNA was injected intratumorally (i.t.) or i.v. Importantly, i.t. injection of the decorin Ad vector led to growth inhibition of the injected tumor associated with similar growth inhibition of a distant contralateral tumor, demonstrating a distant decorin antitumoral effect. Immunochemistry against human decorin and decorin quantitation in tumors confirmed that decorin migrated to the tumor distant site. Furthermore, decorin effect was specific to tumor cells, because neither apoptosis nor growth inhibition were observed in nontumoral human cells such as hepatocytes, endothelial cells, and fibroblasts, despite p21 overexpression.	Univ Paris 05, Fac Necker Enfants Malad, INSERM, E0016, Paris, France; Univ Munster, Dept Internal Med, D-4400 Munster, Germany; Univ Munster, Inst Physiol Chem & Pathobiochem, D-4400 Munster, Germany; Fac Necker Enfants Malad, INSERM, U411, Paris, France; Thomas Jefferson Univ, Dept Pathol Anat & Cell Biol, Philadelphia, PA 19107 USA	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; University of Munster; University of Munster; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Jefferson University	Lemarchand, P (corresponding author), Fac Med, INSERM, U533, 1 Rue Gaston Veil, F-44035 Nantes 1, France.	patricia.lemarchand@nantes.inserm.fr	lemarchand, patricia/C-3247-2011; Iozzo, Renato/AAS-1980-2020; Evaristo, Cesar/O-8430-2016	lemarchand, patricia/0000-0002-5330-2008; Tralhao, Jose/0000-0002-5641-6975; Schaefer, Liliana/0000-0002-3318-3005; Iozzo, Renato/0000-0002-5908-5112; Evaristo, Cesar/0000-0002-2281-1045; Veiga-Fernandes, Henrique/0000-0001-6216-1836				Addison CL, 1998, GENE THER, V5, P1400, DOI 10.1038/sj.gt.3300731; Benchoua A, 2002, J BIOL CHEM, V277, P34217, DOI 10.1074/jbc.M203941200; Bui LA, 1997, HUM GENE THER, V8, P2173, DOI 10.1089/hum.1997.8.18-2173; Claudio PP, 2000, CANCER RES, V60, P372; Csordas G, 2000, J BIOL CHEM, V275, P32879, DOI 10.1074/jbc.M005609200; Danel C, 1998, HUM GENE THER, V9, P1487, DOI 10.1089/hum.1998.9.10-1487; EASTHAM JA, 1995, CANCER RES, V55, P5151; Evan GI, 2001, NATURE, V411, P342, DOI 10.1038/35077213; Evdokiou A, 2002, INT J CANCER, V99, P491, DOI 10.1002/ijc.10376; Ghaneh P, 2001, GENE THER, V8, P199, DOI 10.1038/sj.gt.3301394; Griscelli F, 1998, P NATL ACAD SCI USA, V95, P6367, DOI 10.1073/pnas.95.11.6367; HOSONO S, 1991, ONCOGENE, V6, P237; Iozzo RV, 1999, J BIOL CHEM, V274, P4489, DOI 10.1074/jbc.274.8.4489; Iozzo RV, 1997, CRIT REV BIOCHEM MOL, V32, P141, DOI 10.3109/10409239709108551; Isaka Y, 1996, NAT MED, V2, P418, DOI 10.1038/nm0496-418; Jacotot E, 2000, PATHOL BIOL, V48, P271; Ji L, 1999, CANCER RES, V59, P3333; Kataoka M, 2000, ONCOGENE, V19, P1589, DOI 10.1038/sj.onc.1203466; Kim KH, 2000, CLIN CANCER RES, V6, P335; Kischkel FC, 2000, IMMUNITY, V12, P611, DOI 10.1016/S1074-7613(00)80212-5; Kolb M, 2001, AM J PHYSIOL-LUNG C, V280, pL1327, DOI 10.1152/ajplung.2001.280.6.L1327; Kolb M, 2001, AM J RESP CRIT CARE, V163, P770, DOI 10.1164/ajrccm.163.3.2006084; Kuo CJ, 2001, P NATL ACAD SCI USA, V98, P4605, DOI 10.1073/pnas.081615298; LABARCA C, 1980, ANAL BIOCHEM, V102, P344, DOI 10.1016/0003-2697(80)90165-7; LEMARCHAND P, 1992, P NATL ACAD SCI USA, V89, P6482, DOI 10.1073/pnas.89.14.6482; Li H, 2001, HUM GENE THER, V12, P515, DOI 10.1089/104303401300042429; Marshall E, 1999, SCIENCE, V286, P2244, DOI 10.1126/science.286.5448.2244; Mercer DF, 2001, NAT MED, V7, P927, DOI 10.1038/90968; Nash MA, 1999, CANCER RES, V59, P6192; Nielsen LL, 1998, HUM GENE THER, V9, P681, DOI 10.1089/hum.1998.9.5-681; Pan GH, 1997, SCIENCE, V277, P815, DOI 10.1126/science.277.5327.815; Park KH, 2001, LUNG CANCER-J IASLC, V31, P149, DOI 10.1016/S0169-5002(00)00195-1; Reed CC, 2002, ONCOGENE, V21, P3688, DOI 10.1038/sj.onc.1205470; Santra M, 1997, J CLIN INVEST, V100, P149, DOI 10.1172/JCI119507; SANTRA M, 1995, P NATL ACAD SCI USA, V92, P7016, DOI 10.1073/pnas.92.15.7016; Santra M, 2000, J BIOL CHEM, V275, P35153, DOI 10.1074/jbc.M006821200; Sauter BV, 2000, P NATL ACAD SCI USA, V97, P4802, DOI 10.1073/pnas.090065597; Schaefer L, 2001, FASEB J, V15, P559; Schonherr E, 1999, EUR J CELL BIOL, V78, P44, DOI 10.1016/S0171-9335(99)80006-5; Steiner MS, 2000, CANCER RES, V60, P4419; STROM SC, 1982, J NATL CANCER I, V68, P771; Terradillos O, 1997, ONCOGENE, V14, P395, DOI 10.1038/sj.onc.1200850; Thurston G, 2000, NAT MED, V6, P460, DOI 10.1038/74725; Tsao YP, 1999, J VIROL, V73, P4983, DOI 10.1128/JVI.73.6.4983-4990.1999; Worgall S, 1997, HUM GENE THER, V8, P37, DOI 10.1089/hum.1997.8.1-37; Zaretzky FR, 1999, INFECT IMMUN, V67, P5352, DOI 10.1128/IAI.67.10.5352-5360.1999; Zhao JS, 1999, AM J PHYSIOL-LUNG C, V277, pL412, DOI 10.1152/ajplung.1999.277.2.L412	47	99	118	0	3	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2003	17	1					464	+		10.1096/fj.02-0534fje	http://dx.doi.org/10.1096/fj.02-0534fje			21	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	653TT	12631584	Green Submitted, Green Accepted, Green Published			2022-12-25	WOS:000181453700013
J	Guo, XC; Gerl, RE; Schrader, JW				Guo, XC; Gerl, RE; Schrader, JW			Defining the involvement of p38 alpha MAPK in the production of anti- and proinflammatory cytokines using an SB 203580-resistant form of the kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; TNF-ALPHA PRODUCTION; T-CELLS; CELLULAR STRESSES; SUBSTRATE-SPECIFICITY; SIGNALING PATHWAY; GAMMA EXPRESSION; NITRIC-OXIDE; MAST-CELLS; P38 GROUP	Despite its lack of specificity, the inhibitor SB 203580 has been widely used to implicate p38 mitogen-activated protein kinase ( MAPK) in the synthesis of many cytokines. Here we show unequivocally that the production of interleukin (IL)-1beta, IL-6, IL-10, and tumor necrosis factor alpha (TNFalpha) requires p38 MAPK activity by demonstrating that the inhibitory effects of SB 203580 were reversed by expression of an SB 203580-resistant form of p38alpha (SBR-p38alpha) that fails to bind to SB 203580. This strategy established the requirement for p38 activity for the lipopolysaccharide-stimulated production of IL-10, IL-1beta, and IL-6 by the monocytic cell WEHI 274 and the production of IL-6 and TNFalpha stimulated by ligation of the Fc-gamma receptor of the mast cell MC/9. Expression of SBR-p38alpha) in primary macrophages abrogated the ability of SB 203580 to inhibit the lipopolysaccharide-stimulated production of TNFalpha but not of IL-10. Expression of SBR-p38alpha in primary T lymphocytes abrogated the ability of SB 203580 to inhibit the production of interferon-gamma induced by co-ligation of CD3 and CD28 but not the production of interferon-gamma or IL-10 induced by IL-12. These results suggest that the levels of p38 MAPK activity required for maximal cytokine production vary with different cytokines and stimuli.	Univ British Columbia, Biomed Res Ctr, Vancouver, BC V6T 1Z3, Canada	University of British Columbia	Schrader, JW (corresponding author), Univ British Columbia, Biomed Res Ctr, 2222 Hlth Sci Mall, Vancouver, BC V6T 1Z3, Canada.							Baldassare JJ, 1999, J IMMUNOL, V162, P5367; Beyaert R, 1996, EMBO J, V15, P1914, DOI 10.1002/j.1460-2075.1996.tb00542.x; Borsch-Haubold AG, 1998, J BIOL CHEM, V273, P28766, DOI 10.1074/jbc.273.44.28766; Clerk A, 1998, FEBS LETT, V426, P93, DOI 10.1016/S0014-5793(98)00324-X; CUENDA A, 1995, FEBS LETT, V364, P229, DOI 10.1016/0014-5793(95)00357-F; Cuenda A, 1997, EMBO J, V16, P295, DOI 10.1093/emboj/16.2.295; Enslen H, 1998, J BIOL CHEM, V273, P1741, DOI 10.1074/jbc.273.3.1741; Eyers PA, 1999, FEBS LETT, V451, P191, DOI 10.1016/S0014-5793(99)00552-9; Eyers PA, 1998, CHEM BIOL, V5, P321, DOI 10.1016/S1074-5521(98)90170-3; Feng GJ, 1999, J IMMUNOL, V163, P6403; Fernandez E, 2000, BLOOD, V95, P1356, DOI 10.1182/blood.V95.4.1356.004k23_1356_1361; Foey AD, 1998, J IMMUNOL, V160, P920; Foltz IN, 1997, J BIOL CHEM, V272, P3296, DOI 10.1074/jbc.272.6.3296; Goedert M, 1997, EMBO J, V16, P3563, DOI 10.1093/emboj/16.12.3563; Graves JD, 1996, P NATL ACAD SCI USA, V93, P13814, DOI 10.1073/pnas.93.24.13814; Guan ZH, 1997, J BIOL CHEM, V272, P8083, DOI 10.1074/jbc.272.12.8083; Gum RJ, 1998, J BIOL CHEM, V273, P15605, DOI 10.1074/jbc.273.25.15605; Hale KK, 1999, J IMMUNOL, V162, P4246; Hall-Jackson CA, 1999, ONCOGENE, V18, P2047, DOI 10.1038/sj.onc.1202603; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; Ishizuka T, 1998, J IMMUNOL, V161, P3624; Jiang Y, 1997, J BIOL CHEM, V272, P30122, DOI 10.1074/jbc.272.48.30122; KARASUYAMA H, 1988, EUR J IMMUNOL, V18, P97, DOI 10.1002/eji.1830180115; Koprak S, 1999, CELL IMMUNOL, V192, P87, DOI 10.1006/cimm.1998.1448; Kotlyarov A, 1999, NAT CELL BIOL, V1, P94, DOI 10.1038/10061; KUMAR S, 1995, J BIOL CHEM, V270, P29043, DOI 10.1074/jbc.270.49.29043; Kumar S, 1997, BIOCHEM BIOPH RES CO, V235, P533, DOI 10.1006/bbrc.1997.6849; Lali FV, 2000, J BIOL CHEM, V275, P7395, DOI 10.1074/jbc.275.10.7395; Lechner C, 1996, P NATL ACAD SCI USA, V93, P4355, DOI 10.1073/pnas.93.9.4355; LEE JC, 1994, NATURE, V372, P739, DOI 10.1038/372739a0; Li ZJ, 1996, BIOCHEM BIOPH RES CO, V228, P334, DOI 10.1006/bbrc.1996.1662; Lian JP, 1999, J IMMUNOL, V163, P4527; Mertens S, 1996, FEBS LETT, V383, P273, DOI 10.1016/0014-5793(96)00255-4; Oppmann B, 2000, IMMUNITY, V13, P715, DOI 10.1016/S1074-7613(00)00070-4; RAINGEAUD J, 1995, J BIOL CHEM, V270, P7420, DOI 10.1074/jbc.270.13.7420; Rincon M, 1998, EMBO J, V17, P2817, DOI 10.1093/emboj/17.10.2817; Salmon RA, 2001, EUR J IMMUNOL, V31, P3218, DOI 10.1002/1521-4141(200111)31:11<3218::AID-IMMU3218>3.0.CO;2-9; Salmon RA, 1997, J IMMUNOL, V159, P5309; Salojin KV, 1999, J IMMUNOL, V163, P844; Schafer PH, 1999, J IMMUNOL, V162, P659; Stein B, 1997, J BIOL CHEM, V272, P19509, DOI 10.1074/jbc.272.31.19509; Sugawara T, 1998, IMMUNITY, V9, P565, DOI 10.1016/S1074-7613(00)80639-1; Tamura K, 2000, CELL, V102, P221, DOI 10.1016/S0092-8674(00)00027-1; Wang XS, 1997, J BIOL CHEM, V272, P23668, DOI 10.1074/jbc.272.38.23668; WELHAM MJ, 1992, J IMMUNOL, V149, P2772; Whitmarsh AJ, 1997, MOL CELL BIOL, V17, P2360, DOI 10.1128/MCB.17.5.2360; Winston BW, 1997, J IMMUNOL, V159, P4491; Young PR, 1997, J BIOL CHEM, V272, P12116, DOI 10.1074/jbc.272.18.12116; Zhang J, 1999, J IMMUNOL, V162, P3819; Zhang SM, 2000, J IMMUNOL, V165, P1374, DOI 10.4049/jimmunol.165.3.1374	50	71	74	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 20	2003	278	25					22237	22242		10.1074/jbc.M300847200	http://dx.doi.org/10.1074/jbc.M300847200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	689QF	12637577	hybrid			2022-12-25	WOS:000183503900009
J	Bergqvist, A; Sundstrom, S; Dimberg, LY; Gylfe, E; Masucci, MG				Bergqvist, A; Sundstrom, S; Dimberg, LY; Gylfe, E; Masucci, MG			The hepatitis C virus core protein modulates T cell responses by inducing spontaneous and altering T-cell receptor-triggered Ca2+ oscillations	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LYMPHOTOXIN-BETA RECEPTOR; NONSTRUCTURAL 5A PROTEIN; BLOOD MONONUCLEAR-CELLS; GENE-EXPRESSION; ENDOPLASMIC-RETICULUM; INOCULATED CHIMPANZEES; MEMBRANE-PERMEABILITY; OXIDATIVE STRESS; ANTIGEN RECEPTOR; IMMUNE-RESPONSE	Alterations of cytokine responses are thought to favor the establishment of persistent hepatitis C virus (HCV) infection, enhancing the risk of liver cirrhosis and hepatocellular carcinoma. Expression of the HCV core (C) protein modulates transcription of the IL-2 promoter in T lymphocytes by activating the nuclear factor of activated T lymphocyte (NFAT) pathway. Here we report on the effect of HCV C on Ca2+ signaling, which is essential for activation of NFAT. Expression of HCV C correlated with increased levels of cytosolic Ca2+ and spontaneous Ca2+ oscillations in transfected Jurkat cells. Triggering of the T-cell receptor induced a prolonged Ca2+ response characterized by vigorous high frequent oscillations in a high proportion of the responding cells. This was associated with decreased sizes and accelerated emptying of the intracellular calcium stores. The effect of HCV C on calcium mobilization was not dependent on phospholipase C-gamma(1) (PLC-gamma) activity or increased inositol 1,4,5-trisphosphate (IP3) production and did not require functional IP3 receptors, suggesting that insertion of the viral protein in the endoplasmic reticulum membrane may be sufficient to promote Ca2+ leakage with dramatic downstream consequences on the magnitude and duration of the response. Our data suggest that expression of HCV C in infected T lymphocytes may contribute to the establishment of persistent infections by inducing Ca2+ oscillations that regulate both the efficacy and information content of Ca2+ signals and are ultimately responsible for induction of gene expression and functional differentiation.	Karolinska Inst, Ctr Microbiol & Tumor Biol, MTC, SE-17177 Stockholm, Sweden; Uppsala Univ, Biomed Ctr, Dept Med Biochem & Microbiol, SE-75237 Uppsala, Sweden; Uppsala Univ, Biomed Ctr, Dept Med Cell Biol, SE-75237 Uppsala, Sweden	Karolinska Institutet; Uppsala University; Uppsala University	Bergqvist, A (corresponding author), Karolinska Inst, Ctr Microbiol & Tumor Biol, MTC, Box 280, SE-17177 Stockholm, Sweden.		Berqgvist, Anders/ABA-5530-2021; Masucci, Maria/AAC-6666-2019; Masucci, Maria G/B-8588-2009	Masucci, Maria/0000-0002-5541-2809; Bergqvist, Anders/0000-0002-5789-8777; Gylfe, Erik/0000-0002-8414-2107				Aldabe R, 1997, J VIROL, V71, P6214, DOI 10.1128/JVI.71.8.6214-6217.1997; ALTER MJ, 1997, HEPATOLOGY S1, V26, P62; Bassett SE, 1999, J VIROL, V73, P1118, DOI 10.1128/JVI.73.2.1118-1126.1999; Bassett SE, 1998, J VIROL, V72, P2589, DOI 10.1128/JVI.72.4.2589-2599.1998; Bergqvist A, 2001, J VIROL, V75, P772, DOI 10.1128/JVI.75.2.772-781.2001; BLIGHT K, 1994, HEPATOLOGY, V20, P553, DOI 10.1016/0270-9139(94)90087-6; BOUFFARD P, 1992, J INFECT DIS, V166, P1276, DOI 10.1093/infdis/166.6.1276; Bronowicki JP, 1998, HEPATOLOGY, V28, P211, DOI 10.1002/hep.510280127; CARRASCO L, 1995, ADV VIRUS RES, V45, P61, DOI 10.1016/S0065-3527(08)60058-5; Chen CM, 1997, J VIROL, V71, P9417, DOI 10.1128/JVI.71.12.9417-9426.1997; Cooper S, 1999, IMMUNITY, V10, P439, DOI 10.1016/S1074-7613(00)80044-8; CRIBIER B, 1995, J GEN VIROL, V76, P2485, DOI 10.1099/0022-1317-76-10-2485; DIEPOLDER HM, 1995, LANCET, V346, P1006, DOI 10.1016/S0140-6736(95)91691-1; Dolmetsch RE, 1998, NATURE, V392, P933, DOI 10.1038/31960; Dolmetsch RE, 1997, NATURE, V386, P855, DOI 10.1038/386855a0; FLANAGAN WM, 1991, NATURE, V352, P803, DOI 10.1038/352803a0; Gale M, 1998, MOL CELL BIOL, V18, P5208, DOI 10.1128/MCB.18.9.5208; Gale MJ, 1997, VIROLOGY, V230, P217, DOI 10.1006/viro.1997.8493; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; Guse AH, 1999, NATURE, V398, P70, DOI 10.1038/18024; GYLFE E, 1988, J BIOL CHEM, V263, P5044; Healy JI, 1997, IMMUNITY, V6, P419, DOI 10.1016/S1074-7613(00)80285-X; JAIN J, 1992, NATURE, V356, P801, DOI 10.1038/356801a0; JAYARAMAN T, 1995, P NATL ACAD SCI USA, V92, P6007, DOI 10.1073/pnas.92.13.6007; Kiselyov K, 1998, NATURE, V396, P478, DOI 10.1038/24890; Kolykhalov AA, 1997, SCIENCE, V277, P570, DOI 10.1126/science.277.5325.570; Large MK, 1999, J IMMUNOL, V162, P931; Lewis RS, 2001, ANNU REV IMMUNOL, V19, P497, DOI 10.1146/annurev.immunol.19.1.497; Li WH, 1998, NATURE, V392, P936, DOI 10.1038/31965; Ma HT, 2000, SCIENCE, V287, P1647, DOI 10.1126/science.287.5458.1647; Martire G, 2001, VIROLOGY, V280, P176, DOI 10.1006/viro.2000.0733; Maruyama T, 1997, J BIOCHEM-TOKYO, V122, P498; Matsumoto M, 1997, J VIROL, V71, P1301, DOI 10.1128/JVI.71.2.1301-1309.1997; Mizutani T, 1996, J VIROL, V70, P7219, DOI 10.1128/JVI.70.10.7219-7223.1996; Moradpour D, 1996, J MED VIROL, V48, P234, DOI 10.1002/(SICI)1096-9071(199603)48:3<234::AID-JMV4>3.0.CO;2-9; Moriya K, 2001, CANCER RES, V61, P4365; NEGULESCU PA, 1994, P NATL ACAD SCI USA, V91, P2873, DOI 10.1073/pnas.91.7.2873; Nel AE, 2002, J ALLERGY CLIN IMMUN, V109, P758, DOI 10.1067/mai.2002.124259; NORTHROP JP, 1993, J BIOL CHEM, V268, P2917; Okuda M, 2002, GASTROENTEROLOGY, V122, P366, DOI 10.1053/gast.2002.30983; Putney JW, 2001, J CELL SCI, V114, P2223; RAVAGGI A, 1994, J HEPATOL, V20, P833, DOI 10.1016/S0168-8278(05)80157-6; Ray RB, 1998, J BIOL CHEM, V273, P2256, DOI 10.1074/jbc.273.4.2256; Ray RB, 2001, FEMS MICROBIOL LETT, V202, P149, DOI 10.1111/j.1574-6968.2001.tb10796.x; Ronnstrand L, 1999, J BIOL CHEM, V274, P22089, DOI 10.1074/jbc.274.31.22089; Seow HF, 1998, VET IMMUNOL IMMUNOP, V63, P139, DOI 10.1016/S0165-2427(98)00090-7; SHIMIZU YK, 1992, P NATL ACAD SCI USA, V89, P5477, DOI 10.1073/pnas.89.12.5477; Soguero C, 2002, J VIROL, V76, P9345, DOI 10.1128/JVI.76.18.9345-9354.2002; STRAUS DB, 1992, CELL, V70, P585, DOI 10.1016/0092-8674(92)90428-F; Taylor DR, 1999, SCIENCE, V285, P107, DOI 10.1126/science.285.5424.107; TIAN P, 1995, J VIROL, V69, P5763, DOI 10.1128/JVI.69.9.5763-5772.1995; vanKuppeveld FJM, 1997, EMBO J, V16, P3519, DOI 10.1093/emboj/16.12.3519; VARA JA, 1986, NUCLEIC ACIDS RES, V14, P4617, DOI 10.1093/nar/14.11.4617; WEINER AJ, 1992, P NATL ACAD SCI USA, V89, P3468, DOI 10.1073/pnas.89.8.3468; WEISS A, 1984, J IMMUNOL, V133, P123; Yanagi M, 1997, P NATL ACAD SCI USA, V94, P8738, DOI 10.1073/pnas.94.16.8738; Yasui K, 1998, J VIROL, V72, P6048, DOI 10.1128/JVI.72.7.6048-6055.1998; Zhu NL, 1998, J VIROL, V72, P3691, DOI 10.1128/JVI.72.5.3691-3697.1998; [No title captured]	59	53	54	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 23	2003	278	21					18877	18883		10.1074/jbc.M300185200	http://dx.doi.org/10.1074/jbc.M300185200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	679PY	12639962	hybrid			2022-12-25	WOS:000182932200023
J	Johnson, KA; van Etten, D; Nanda, N; Graham, RM; Terkeltaub, RA				Johnson, KA; van Etten, D; Nanda, N; Graham, RM; Terkeltaub, RA			Distinct transglutaminase 2-independent and transglutaminase 2-dependent pathways mediate articular chondrocyte hypertrophy	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL MEMBRANE GLYCOPROTEIN-1; X COLLAGEN-SYNTHESIS; TISSUE TRANSGLUTAMINASE; RETINOIC ACID; BONE-FORMATION; DIFFERENTIAL REGULATION; NATRIURETIC PEPTIDE; THYROID-HORMONES; GENE-EXPRESSION; FACTOR XIIIA	Altered chondrocyte differentiation, including development of chondrocyte hypertrophy, mediates osteoarthritis and pathologic articular cartilage matrix calcification. Similar changes in endochondral chondrocyte differentiation are essential for physiologic growth plate mineralization. In both articular and growth plate cartilages, chondrocyte hypertrophy is associated with up-regulated expression of certain protein-crosslinking enzymes ( transglutaminases (TGs)) including the unique dual-functioning TG and GTPase TG2. Here, we tested if TG2 directly mediates the development of chondrocyte hypertrophic differentiation. To do so, we employed normal bovine chondrocytes and mouse knee chondrocytes from recently described TG2 knockout mice, which are phenotypically normal. We treated chondrocytes with the osteoarthritis mediator IL-1beta, with the all-trans form of retinoic acid ( ATRA), which promotes endochondral chondrocyte hypertrophy and pathologic calcification, and with C-type natriuretic peptide, an essential factor in endochondral development. IL-1beta and ATRA induced TG transamidation activity and calcification in wild-type but not in TG2 (-/-) mouse knee chondrocytes. In addition, ATRA induced multiple features of hypertrophic differentiation ( including type X collagen, alkaline phosphatase, and MMP-13), and these effects required TG2. Significantly, TG2 (-/-) chondrocytes lost the capacity for ATRA-induced expression of Cbfa1, a transcription factor necessary for ATRA-induced chondrocyte hypertrophy. Finally, C-type natriuretic peptide, which did not modulate TG activity, comparably promoted Cbfa1 expression and hypertrophy ( without associated calcification) in TG2 (+/+) and TG2 (-/-) chondrocytes. Thus, distinct TG2-independent and TG2-dependent mechanisms promote Cbfa1 expression, articular chondrocyte hypertrophy, and calcification. TG2 is a potential site for intervention in pathologic calcification promoted by IL-1beta and ATRA.	Univ Calif San Diego, Vet Affairs Med Ctr, La Jolla, CA 92161 USA; Univ New S Wales, Sch Biochem & Mol Genet, Victor Chang Cardiac Res Inst, Mol Cardiol Unit, Kensington, NSW 2010, Australia	University of California System; University of California San Diego; US Department of Veterans Affairs; Veterans Health Administration (VHA); University of New South Wales Sydney; Victor Chang Cardiac Research Institute	Terkeltaub, RA (corresponding author), Univ Calif San Diego, Vet Affairs Med Ctr, 3350 La Jolla Village Dr, La Jolla, CA 92161 USA.				NATIONAL INSTITUTE ON AGING [P01AG007996] Funding Source: NIH RePORTER; NIA NIH HHS [P01AGO7996] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		AESCHLIMANN D, 1993, J CELL BIOL, V120, P1461, DOI 10.1083/jcb.120.6.1461; ALINI M, 1994, J BONE MINER RES, V9, P1077; Alini M, 1996, J BONE MINER RES, V11, P105; Anwar R, 1998, BLOOD, V91, P149, DOI 10.1182/blood.V91.1.149.149_149_153; Attur MG, 1998, P ASSOC AM PHYSICIAN, V110, P65; Boskey Adele L, 2002, Curr Rheumatol Rep, V4, P245, DOI 10.1007/s11926-002-0072-3; Candi E, 2001, J BIOL CHEM, V276, P35014, DOI 10.1074/jbc.M010157200; Chen JSK, 1999, INT J BIOCHEM CELL B, V31, P817, DOI 10.1016/S1357-2725(99)00045-X; Chusho H, 2001, P NATL ACAD SCI USA, V98, P4016, DOI 10.1073/pnas.071389098; CUNY JF, 1989, ANN DERMATOL VENER, V116, P95; De Laurenzi V, 2001, MOL CELL BIOL, V21, P148, DOI 10.1128/MCB.21.1.148-155.2001; Dogan S, 2002, BIOL REPROD, V66, P596, DOI 10.1095/biolreprod66.3.596; Ducy P, 1997, CELL, V89, P747, DOI 10.1016/S0092-8674(00)80257-3; Egea PF, 2001, J MOL BIOL, V307, P557, DOI 10.1006/jmbi.2000.4409; Enomoto H, 2000, J BIOL CHEM, V275, P8695, DOI 10.1074/jbc.275.12.8695; ERLEBACHER A, 1995, CELL, V80, P371, DOI 10.1016/0092-8674(95)90487-5; Fesus L, 2002, TRENDS BIOCHEM SCI, V27, P534, DOI 10.1016/S0968-0004(02)02182-5; Gerstenfeld LC, 1996, J CELL BIOCHEM, V62, P1; Gionti E, 1999, CELL BIOL INT, V23, P41, DOI 10.1006/cbir.1998.0316; Goldring MB, 2000, ARTHRITIS RHEUM-US, V43, P1916, DOI 10.1002/1529-0131(200009)43:9<1916::AID-ANR2>3.0.CO;2-I; Griffin M, 2002, BIOCHEM J, V368, P377, DOI 10.1042/BJ20021234; Haroon ZA, 1999, FASEB J, V13, P1787, DOI 10.1096/fasebj.13.13.1787; Hashimoto S, 1998, P NATL ACAD SCI USA, V95, P3094, DOI 10.1073/pnas.95.6.3094; Hessle L, 2002, P NATL ACAD SCI USA, V99, P9445, DOI 10.1073/pnas.142063399; ISHIKAWA K, 1989, J BONE JOINT SURG AM, V71A, P875, DOI 10.2106/00004623-198971060-00012; IWAMOTO M, 1994, MICROSC RES TECHNIQ, V28, P483, DOI 10.1002/jemt.1070280604; Iwamoto M, 2003, OSTEOARTHR CARTILAGE, V11, P6, DOI 10.1053/joca.2002.0860; Jimenez MJG, 2001, J CELL BIOL, V155, P1333, DOI 10.1083/jcb.200106147; Johnson K, 1999, ARTHRITIS RHEUM-US, V42, P1986, DOI 10.1002/1529-0131(199909)42:9<1986::AID-ANR26>3.0.CO;2-O; Johnson K, 2001, AM J PATHOL, V159, P149, DOI 10.1016/S0002-9440(10)61682-3; JOHNSON K, 2003, IN PRESS ARTHRITIS R; Kaartinen MT, 2002, J BONE MINER RES, V17, P2161, DOI 10.1359/jbmr.2002.17.12.2161; KLIEWER SA, 1992, NATURE, V355, P446, DOI 10.1038/355446a0; Komori T, 1997, CELL, V89, P755, DOI 10.1016/S0092-8674(00)80258-5; Koyama E, 1999, DEV BIOL, V208, P375, DOI 10.1006/dbio.1999.9207; Krane SM, 2001, J CLIN INVEST, V107, P31, DOI 10.1172/JCI11892; Linsenmayer TF, 1998, PROG NUCLEIC ACID RE, V60, P79, DOI 10.1016/S0079-6603(08)60890-9; McCarthy G M, 1999, Curr Rheumatol Rep, V1, P101, DOI 10.1007/s11926-999-0005-5; Merz D, 2002, ARTHRITIS RHEUM-US, V46, pS221; Miyazawa T, 2002, ENDOCRINOLOGY, V143, P3604, DOI 10.1210/en.2002-220307; MORK NJ, 1992, ACTA DERM-VENEREOL, V72, P445; Nanda N, 2001, J BIOL CHEM, V276, P20673, DOI 10.1074/jbc.M010846200; Nurminskaya M, 1998, J CELL BIOL, V142, P1135, DOI 10.1083/jcb.142.4.1135; Nurminskaya M, 1996, DEV DYNAM, V206, P260, DOI 10.1002/(SICI)1097-0177(199607)206:3<260::AID-AJA4>3.0.CO;2-G; PACIFICI M, 1991, EXP CELL RES, V195, P38, DOI 10.1016/0014-4827(91)90497-I; POOLE AR, 1989, ANAT REC, V224, P167; Rosenthal AK, 1997, ARTHRITIS RHEUM, V40, P966, DOI 10.1002/art.1780400526; Rosenthal AK, 1999, J RHEUMATOL, V26, P395; Rosenthal AK, 1996, CALCIFIED TISSUE INT, V59, P128, DOI 10.1007/s002239900099; Shimizu T, 2000, CANCER RES, V60, P4544; SLAUGHTER TF, 1992, ANAL BIOCHEM, V205, P166, DOI 10.1016/0003-2697(92)90594-W; Sohn J, 2003, J CLIN INVEST, V111, P121, DOI 10.1172/JCI200315937; Takeda S, 2001, GENE DEV, V15, P467, DOI 10.1101/gad.845101; Terkeltaub RA, 2002, J RHEUMATOL, V29, P411; VIGNON E, 1983, ANN RHEUM DIS, V42, P82, DOI 10.1136/ard.42.1.82; Vincan E, 1996, MOL CELL BIOCHEM, V157, P107; VONDERMARK K, 1992, ARTHRITIS RHEUM-US, V35, P806, DOI 10.1002/art.1780350715; Wang DS, 2001, J BIOL CHEM, V276, P33995, DOI 10.1074/jbc.M007757200	58	68	68	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 23	2003	278	21					18824	18832		10.1074/jbc.M301055200	http://dx.doi.org/10.1074/jbc.M301055200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	679PY	12606540	hybrid			2022-12-25	WOS:000182932200017
J	Arinze, IJ; Kawai, Y				Arinze, IJ; Kawai, Y			Sp family of transcription factors is involved in valproic acid-induced expression of G alpha(i2)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN PHOSPHATASE 1; HISTONE DEACETYLASE; SODIUM-BUTYRATE; GENE PROMOTER; IN-VITRO; MOOD STABILIZER; ALPHA-SUBUNIT; RECEPTOR GENE; OKADAIC ACID; CALYCULIN-A	Valproic acid-induced gene expression has been attributed to the DNA-binding activity of the transcription factor activator protein 1 (AP-1). Using K562 cells, we have studied valproic acid-induced transcription from the human Galpha(i2) gene promoter, which lacks AP-1-binding motifs. We find that valproic acid-induced expression of Galpha(i2) is inhibited by mithramycin A, a compound that interferes with Sp1 binding to GC boxes in DNA. Three Sp1-binding sequences, located at +68/+75, +50/+36, and +92/+85 in the promoter, accounted for about 60% of this transcriptional effect, as judged by transient transfection assays. Electrophoretic mobility shift assays indicated that these sites bind members of the Sp family of transcription factors. Binding to DNA was inhibited by mithramycin A and was greater in nuclear extracts from cells treated with valproic acid than in control cells. Okadaic acid, calyculin A, and fostriecin, which are potent inhibitors of protein phosphatase, suppressed the transcriptional response to valproic acid. This inhibitory effect was not observed when promoter constructs containing mutations in the referenced Sp1-binding sites were used for transfections. In nuclear extracts from cells cultured in the presence of these inhibitors, the binding of Sp1/Sp3 to DNA probes was much less than in control cells. Alkaline phosphatase treatment of nuclear extracts resulted in enhanced binding of Sp proteins to the DNA probes. These results are consistent with the idea that dephosphorylating conditions enhanced Sp binding to the DNA probes as well as Sp-mediated transcription induced by valproic acid. This study demonstrates that the gene expression-inducing effect of valproic acid occurs, in part, through the Sp family of transcription factors.	Meharry Med Coll, Dept Biochem, Nashville, TN 37208 USA	Meharry Medical College	Arinze, IJ (corresponding author), Meharry Med Coll, Dept Biochem, 1005 Dr David B Todd Jr Blvd, Nashville, TN 37208 USA.	iarinze@mail.mmc.edu						Archer SY, 1998, P NATL ACAD SCI USA, V95, P6791, DOI 10.1073/pnas.95.12.6791; ARDINGER HH, 1988, AM J MED GENET, V29, P171, DOI 10.1002/ajmg.1320290123; Armstrong SA, 1997, J BIOL CHEM, V272, P13489, DOI 10.1074/jbc.272.21.13489; BLUME SW, 1991, J CLIN INVEST, V88, P1613, DOI 10.1172/JCI115474; Chen G, 1998, J NEUROCHEM, V70, P1768; Chen G, 1999, MOL BRAIN RES, V64, P52, DOI 10.1016/S0169-328X(98)00303-9; Cuisset L, 1997, J BIOL CHEM, V272, P24148, DOI 10.1074/jbc.272.39.24148; Daniel S, 1996, J BIOL CHEM, V271, P14692, DOI 10.1074/jbc.271.25.14692; Davis MG, 2000, BIOCHEM J, V346, P455, DOI 10.1042/0264-6021:3460455; DILIBERTI JH, 1984, AM J MED GENET, V19, P473, DOI 10.1002/ajmg.1320190308; Doetzlhofer A, 1999, MOL CELL BIOL, V19, P5504; Favre B, 1997, J BIOL CHEM, V272, P13856, DOI 10.1074/jbc.272.21.13856; Garcia A, 2000, J BIOL CHEM, V275, P9385, DOI 10.1074/jbc.275.13.9385; Gottlicher M, 2001, EMBO J, V20, P6969, DOI 10.1093/emboj/20.24.6969; Greenwel P, 1997, J BIOL CHEM, V272, P19738, DOI 10.1074/jbc.272.32.19738; Hinnebusch BF, 2002, J NUTR, V132, P1012, DOI 10.1093/jn/132.5.1012; HOUT C, 1987, CAN J NEUROL SCI, V14, P290; ISHIHARA H, 1989, BIOCHEM BIOPH RES CO, V159, P871, DOI 10.1016/0006-291X(89)92189-X; JOFFE RT, 1993, CAN J PSYCHIAT, V38, pS46; Johannessen CU, 2000, NEUROCHEM INT, V37, P103, DOI 10.1016/S0197-0186(00)00013-9; KINGSLEY C, 1992, MOL CELL BIOL, V12, P4251, DOI 10.1128/MCB.12.10.4251; Lacroix I, 2002, J BIOL CHEM, V277, P9598, DOI 10.1074/jbc.M111444200; Lai CF, 2000, J BIOL CHEM, V275, P36400, DOI 10.1074/jbc.M002131200; Leung-Pineda V, 2002, J BIOL CHEM, V277, P16585, DOI 10.1074/jbc.M110972200; Li JH, 2002, J BIOL CHEM, V277, P39967, DOI 10.1074/jbc.M200840200; Manji HK, 2001, BRIT J PSYCHIAT, V178, pS107, DOI 10.1192/bjp.178.41.s107; Marks PA, 2000, JNCI-J NATL CANCER I, V92, P1210, DOI 10.1093/jnci/92.15.1210; MARTINEZFRIAS ML, 1990, AM J MED GENET, V37, P277, DOI 10.1002/ajmg.1320370224; Mitchell PB, 1999, AUST NZ J PSYCHIAT, V33, pS99, DOI 10.1111/j.1440-1614.1999.00672.x; NAU H, 1991, PHARMACOL TOXICOL, V69, P310, DOI 10.1111/j.1600-0773.1991.tb01303.x; Phiel CJ, 2001, J BIOL CHEM, V276, P36734, DOI 10.1074/jbc.M101287200; Phiel CJ, 2001, ANNU REV PHARMACOL, V41, P789, DOI 10.1146/annurev.pharmtox.41.1.789; Poncelet AC, 2001, J BIOL CHEM, V276, P6983, DOI 10.1074/jbc.M006442200; Quandt K, 1995, NUCLEIC ACIDS RES, V23, P4878, DOI 10.1093/nar/23.23.4878; ROBERT E, 1982, LANCET, V2, P937, DOI 10.1016/s0140-6736(82)90908-4; Rohlff C, 1997, J BIOL CHEM, V272, P21137, DOI 10.1074/jbc.272.34.21137; Ross S, 2002, MOL CELL, V10, P831, DOI 10.1016/S1097-2765(02)00682-2; SADOCK BJ, 2000, COMPREHENSIVE TXB PS, P1284; Sands SA, 2000, NEUROPSYCHOPHARMACOL, V22, P27, DOI 10.1016/S0893-133X(99)00072-X; Sapetschnig A, 2002, EMBO J, V21, P5206, DOI 10.1093/emboj/cdf510; Sowa Y, 1999, ANN NY ACAD SCI, V886, P195, DOI 10.1111/j.1749-6632.1999.tb09415.x; Sowa Y, 1997, BIOCHEM BIOPH RES CO, V241, P142, DOI 10.1006/bbrc.1997.7786; Suske G, 1999, GENE, V238, P291, DOI 10.1016/S0378-1119(99)00357-1; Taniura S, 2002, J BIOL CHEM, V277, P16823, DOI 10.1074/jbc.M200527200; Tunnicliff G, 1999, J PHYSIOL PHARMACOL, V50, P347; Walsh AH, 1997, FEBS LETT, V416, P230, DOI 10.1016/S0014-5793(97)01210-6; Warrell RP, 1998, JNCI-J NATL CANCER I, V90, P1621, DOI 10.1093/jnci/90.21.1621; WEINSTEIN LS, 1988, FEBS LETT, V232, P333, DOI 10.1016/0014-5793(88)80764-6; WEINSTEIN LS, 1990, MOL ENDOCRINOL, V4, P958, DOI 10.1210/mend-4-7-958; Werling U, 2001, MOL PHARMACOL, V59, P1269, DOI 10.1124/mol.59.5.1269; Wlodarczyk BC, 1996, TERATOLOGY, V54, P284, DOI 10.1002/(SICI)1096-9926(199612)54:6<284::AID-TERA3>3.3.CO;2-J; Yang JQ, 2001, J BIOL CHEM, V276, P25742, DOI 10.1074/jbc.M102821200; Yoo J, 2002, J BIOL CHEM, V277, P11904, DOI 10.1074/jbc.M111788200; YOSHIDA M, 1990, J BIOL CHEM, V265, P17174; Yuan PX, 1999, J NEUROCHEM, V73, P2299, DOI 10.1046/j.1471-4159.1999.0732299.x; Yuan PX, 2001, J BIOL CHEM, V276, P31674, DOI 10.1074/jbc.M104309200	56	36	38	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 16	2003	278	20					17785	17791		10.1074/jbc.M209430200	http://dx.doi.org/10.1074/jbc.M209430200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677YX	12624107	hybrid			2022-12-25	WOS:000182838300026
J	Chicka, MC; Strehler, EE				Chicka, MC; Strehler, EE			Alternative splicing of the first intracellular loop of plasma membrane Ca2+-ATPase isoform 2 alters its membrane targeting	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSMEMBRANE CONDUCTANCE REGULATOR; CALCIUM-PUMP; CA2+ PUMP; PROTEIN; ATPASE; EXPRESSION; CALMODULIN; EXCHANGER; DOMAINS; NEURONS	Plasma membrane Ca2+-ATPases (PMCAs) are involved in local Ca2+ signaling and in the spatial control of Ca2+ extrusion, but how different PMCA isoforms are targeted to specific membrane domains is unknown. In polarized MDCK epithelial cells, a green fluorescent protein-tagged PMCA4b construct was targeted to the basolateral membrane, whereas a green fluorescent protein-tagged PMCA2b construct was localized to both the apical and basolateral domain. The PDZ protein-binding COOH-terminal tail of PMCA2b was not responsible for its apical membrane localization, as a chimeric pump made of an NH2-terminal portion from PMCA4 and a COOH-terminal tail from PMCA2b was targeted to the basolateral domain. Deletion of the last six residues of the COOH terminus of either PMCA2b or PMCA4b did not alter their membrane targeting, suggesting that PDZ protein interactions are not essential for proper membrane localization of the pumps. Instead, we found that alternative splicing affecting the first cytosolic loop determined apical membrane targeting of PMCA2. Only the "w" form, which contains a 45-amino acid residue insertion, showed prominent apical membrane localization. By contrast, the x and z splice variants containing insertions of 14 and 0 residues, respectively, localized to the basolateral membrane. The w splice insert was the crucial determinant of apical PMCA2 localization, and this was independent of the splice configuration at the COOH-terminal end of the pump; both PMCA2w/b and PMCA2w/a showed prominent apical targeting, whereas PMCA2x/b, PMCA2z/b, and PMCA2z/a were confined to the basolateral membrane. These data report the first differential effect of alternative splicing within the first cytosolic loop of PMCA2 and help explain the selective enrichment of specific PMCA2 isoforms in specialized membrane compartments such as stereocilia of auditory hair cells.	Mayo Clin & Mayo Fdn, Dept Biochem & Mol Biol, Rochester, MN 55905 USA	Mayo Clinic	Strehler, EE (corresponding author), Mayo Clin & Mayo Fdn, Dept Biochem & Mol Biol, 200 1st St SW, Rochester, MN 55905 USA.	strehler.emanuel@mayo.edu			NIGMS NIH HHS [GM-58710] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM058710] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADAMO HP, 1992, BIOCHEM J, V283, P355, DOI 10.1042/bj2830355; Ausubel FM, 1998, CURRENT PROTOCOLS MO; Berridge MJ, 2000, NAT REV MOL CELL BIO, V1, P11, DOI 10.1038/35036035; Blaustein MP, 1999, PHYSIOL REV, V79, P763, DOI 10.1152/physrev.1999.79.3.763; Bootman MD, 2001, J CELL SCI, V114, P2213; BRODIN P, 1992, EUR J BIOCHEM, V204, P939, DOI 10.1111/j.1432-1033.1992.tb16715.x; Bruce JIE, 2002, J BIOL CHEM, V277, P48172, DOI 10.1074/jbc.M208393200; CARAFOLI E, 1991, PHYSIOL REV, V71, P129, DOI 10.1152/physrev.1991.71.1.129; CARAFOLI E, 1994, FASEB J, V8, P993, DOI 10.1096/fasebj.8.13.7926378; Caride AJ, 2001, J BIOL CHEM, V276, P39797, DOI 10.1074/jbc.M104380200; DeMarco SJ, 2002, J BIOL CHEM, V277, P10506, DOI 10.1074/jbc.M111616200; DeMarco SJ, 2001, J BIOL CHEM, V276, P21594, DOI 10.1074/jbc.M101448200; Dumont RA, 2001, J NEUROSCI, V21, P5066, DOI 10.1523/JNEUROSCI.21-14-05066.2001; Elwess NL, 1997, J BIOL CHEM, V272, P17981, DOI 10.1074/jbc.272.29.17981; Fanning AS, 1999, CURR OPIN CELL BIOL, V11, P432, DOI 10.1016/S0955-0674(99)80062-3; Hall RA, 1998, NATURE, V392, P626, DOI 10.1038/33458; HEIM R, 1992, EUR J BIOCHEM, V205, P333, DOI 10.1111/j.1432-1033.1992.tb16784.x; Hung AY, 2002, J BIOL CHEM, V277, P5699, DOI 10.1074/jbc.R100065200; Kaech SM, 1998, CELL, V94, P761, DOI 10.1016/S0092-8674(00)81735-3; Kim E, 1998, J BIOL CHEM, V273, P1591, DOI 10.1074/jbc.273.3.1591; Kip SN, 2003, AM J PHYSIOL-RENAL, V284, pF122, DOI 10.1152/ajprenal.00161.2002; Krizaj D, 2002, J COMP NEUROL, V451, P1, DOI 10.1002/cne.10281; Moyer BD, 1999, J CLIN INVEST, V104, P1353, DOI 10.1172/JCI7453; Penniston JT, 1998, J MEMBRANE BIOL, V165, P101, DOI 10.1007/s002329900424; Reinhardt TA, 2000, AM J PHYSIOL-CELL PH, V279, pC1595, DOI 10.1152/ajpcell.2000.279.5.C1595; Reinhardt TA, 1999, AM J PHYSIOL-CELL PH, V276, pC796, DOI 10.1152/ajpcell.1999.276.4.C796; Rogers MS, 2001, J BIOL CHEM, V276, P12182, DOI 10.1074/jbc.M010056200; Rongo C, 1998, CELL, V94, P751, DOI 10.1016/S0092-8674(00)81734-1; Schuh K, 2001, J CELL BIOL, V155, P201, DOI 10.1083/jcb.200104131; Short DB, 1998, J BIOL CHEM, V273, P19797, DOI 10.1074/jbc.273.31.19797; Strehler EE, 2001, PHYSIOL REV, V81, P21, DOI 10.1152/physrev.2001.81.1.21; Toyoshima C, 2000, NATURE, V405, P647, DOI 10.1038/35015017; Usachev YM, 2002, NEURON, V33, P113, DOI 10.1016/S0896-6273(01)00557-8; Usachev YM, 2001, J NEUROCHEM, V76, P1756, DOI 10.1046/j.1471-4159.2001.00169.x; Wang SS, 1998, FEBS LETT, V427, P103, DOI 10.1016/S0014-5793(98)00402-5; WEINMAN EJ, 1995, J CLIN INVEST, V95, P2143, DOI 10.1172/JCI117903; Zacharias DA, 1996, CURR BIOL, V6, P1642, DOI 10.1016/S0960-9822(02)70788-4; Zhong N, 2001, J NEUROSCI, V21, P9598, DOI 10.1523/JNEUROSCI.21-24-09598.2001	38	85	87	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 16	2003	278	20					18464	18470		10.1074/jbc.M301482200	http://dx.doi.org/10.1074/jbc.M301482200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677YX	12624087	hybrid			2022-12-25	WOS:000182838300114
J	Chou, KM; Cheng, YC				Chou, KM; Cheng, YC			The exonuclease activity of human apurinic/apyrimidinic endonuclease (APE1)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-REPAIR ENZYME; BASE EXCISION-REPAIR; HUMAN APURINIC ENDONUCLEASE; POLYMERASE-BETA; 3'-TO-5' EXONUCLEASE; NUCLEOSIDE ANALOG; BINDING ACTIVITY; L-CONFIGURATION; HAP1; REF-1	Human DNA apurinic/apyrimidinic endonuclease (APE1) plays a key role in the DNA base excision repair process. In this study, we further characterized the exonuclease activity of APE1. The magnesium requirement and pH dependence of the exonuclease and endonuclease activities of APE1 are significantly different. APE1 showed a similar K-m value for matched, 3' mispaired, or nucleoside analog beta-L-dioxolane-cytidine terminated nicked DNA as well as for DNA containing a tetrahydrofuran, an abasic site analog. The k(cat) for exonuclease activity on matched, 3' mispaired, and beta-L-dioxolanecytidine nicked DNA are 2.3, 61.2, and 98.8 min(-1), respectively, and 787.5 min(-1) for APE1 endonuclease. Site- directed APE1 mutant proteins ( E96A, E96Q, D210E, D210N, and H309N), which target amino acid residues in the endonuclease active site, also showed significant decrease in exonuclease activity. Gp(4)G was the only potent inhibitor to compete against the substrates of endonuclease and exonuclease activities among all tested naturally occurring ribo-, deoxyribonucleoside/nucleotides, NAD(+), NADP(+), and Ap(4)A. The K-i values of Gp(4)G for the endonuclease and exonuclease activities of APE1 are 10 +/- 0.6 and 1 +/- 0.2 muM, respectively. Given the relative concentrations of Gp(4)G, 3' mispaired, and abasic DNA, Gp(4)G may play an important role in regulating APE1 activity in cells. The data presented here suggest that the APE1 exonuclease and AP endonuclease are two distinct activities. APE1 may exist in two different conformations, and each conformation has a preference for a substrate. The different conformations can be affected by MgCl2 or salt concentrations.	Yale Univ, Sch Med, Dept Pharmacol, New Haven, CT 06520 USA	Yale University	Cheng, YC (corresponding author), Yale Univ, Sch Med, Dept Pharmacol, 333 Cedar St,SHM B315, New Haven, CT 06520 USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI038204] Funding Source: NIH RePORTER; NCI NIH HHS [CA 73477] Funding Source: Medline; NIAID NIH HHS [AI 38204] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BAMBARA RA, 1991, BIOCHIM BIOPHYS ACTA, V1088, P11, DOI 10.1016/0167-4781(91)90147-E; BARZILAY G, 1995, NUCLEIC ACIDS RES, V23, P1544, DOI 10.1093/nar/23.9.1544; BARZILAY G, 1995, NAT STRUCT BIOL, V2, P561, DOI 10.1038/nsb0795-561; Beernink PT, 2001, J MOL BIOL, V307, P1023, DOI 10.1006/jmbi.2001.4529; Bennett RAO, 1997, P NATL ACAD SCI USA, V94, P7166, DOI 10.1073/pnas.94.14.7166; Chou KM, 2000, J BIOL CHEM, V275, P31009, DOI 10.1074/jbc.M004082200; Chou KM, 2002, NATURE, V415, P655, DOI 10.1038/415655a; COSTE H, 1987, J BIOL CHEM, V262, P12096; DERSE D, 1981, J BIOL CHEM, V256, P8525; Evans AR, 2000, MUTAT RES-DNA REPAIR, V461, P83, DOI 10.1016/S0921-8777(00)00046-X; Giles FJ, 2002, J CLIN ONCOL, V20, P656, DOI 10.1200/JCO.20.3.656; Gorman MA, 1997, EMBO J, V16, P6548, DOI 10.1093/emboj/16.21.6548; GRAU PP, 1988, FEBS LETT, V236, P291, DOI 10.1016/0014-5793(88)80040-1; GRAU VP, 1982, J BIOL CHEM, V257, P1848; Grove KL, 1996, CANCER RES, V56, P4187; GROVE KL, 1995, CANCER RES, V55, P3008; Huang P, 1998, ONCOGENE, V17, P261, DOI 10.1038/sj.onc.1201946; KUNKEL TA, 1985, J BIOL CHEM, V260, P5787; Lindahl T, 2000, MUTAT RES-REV MUTAT, V462, P129, DOI 10.1016/S1383-5742(00)00024-7; Lindahl T, 1999, SCIENCE, V286, P1897, DOI 10.1126/science.286.5446.1897; LIU JJ, 1994, J BIOL CHEM, V269, P11787; MATSUMOTO Y, 1995, SCIENCE, V269, P699, DOI 10.1126/science.7624801; McLennan AG, 2000, PHARMACOL THERAPEUT, V87, P73, DOI 10.1016/S0163-7258(00)00041-3; Mol CD, 2000, NATURE, V403, P451, DOI 10.1038/35000249; Pelicano H, 2000, MOL PHARMACOL, V57, P1051; RENART MF, 1976, BIOCHEMISTRY-US, V15, P4962, DOI 10.1021/bi00668a003; Rothwell DG, 2000, NUCLEIC ACIDS RES, V28, P2207, DOI 10.1093/nar/28.11.2207; RUTH JL, 1981, MOL PHARMACOL, V20, P415; Schluter H, 1998, J CLIN INVEST, V101, P682, DOI 10.1172/JCI119882; SKALSKI V, 1995, BIOCHEM PHARMACOL, V50, P815, DOI 10.1016/0006-2952(95)00205-E; SMITH RE, 1982, J BIOL CHEM, V257, P485; Sokhansanj BA, 2002, NUCLEIC ACIDS RES, V30, P1817, DOI 10.1093/nar/30.8.1817; SPECTOR T, 1979, J BIOL CHEM, V254, P2308; TSURUMI T, 1992, VIROLOGY, V189, P803, DOI 10.1016/0042-6822(92)90611-R; WALKER LJ, 1993, MOL CELL BIOL, V13, P5370, DOI 10.1128/MCB.13.9.5370; WALKER LJ, 1994, NUCLEIC ACIDS RES, V22, P4884, DOI 10.1093/nar/22.23.4884; WARNER AH, 1968, DEV BIOL, V18, P278, DOI 10.1016/0012-1606(68)90036-5; Wilson DM, 2001, MUTAT RES-DNA REPAIR, V485, P283, DOI 10.1016/S0921-8777(01)00063-5; WILSON DM, 1995, J BIOL CHEM, V270, P16002, DOI 10.1074/jbc.270.27.16002; XANTHOUDAKIS S, 1992, EMBO J, V11, P3323, DOI 10.1002/j.1460-2075.1992.tb05411.x; Xanthoudakis S, 1996, P NATL ACAD SCI USA, V93, P8919, DOI 10.1073/pnas.93.17.8919; XANTHOUDAKIS S, 1994, P NATL ACAD SCI USA, V91, P23, DOI 10.1073/pnas.91.1.23; XANTHOUDAKIS S, 1992, EMBO J, V11, P653, DOI 10.1002/j.1460-2075.1992.tb05097.x; YAMAKAWA M, 1982, P NATL ACAD SCI-BIOL, V79, P6142, DOI 10.1073/pnas.79.20.6142	44	93	98	1	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 16	2003	278	20					18289	18296		10.1074/jbc.M212143200	http://dx.doi.org/10.1074/jbc.M212143200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677YX	12624104	hybrid			2022-12-25	WOS:000182838300092
J	Lauer-Fields, JL; Sritharan, T; Stack, MS; Nagase, H; Fields, GB				Lauer-Fields, JL; Sritharan, T; Stack, MS; Nagase, H; Fields, GB			Selective hydrolysis of triple-helical substrates by matrix metalloproteinase-2 and-9	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEMBRANE COLLAGEN ALPHA-1(IV)531-543; DEGRADATION SEQUENCE-ANALYSIS; IV COLLAGEN; TISSUE INHIBITOR; PEPTIDE MODELS; CELL-MIGRATION; MELANOMA-CELLS; CLEAVAGE SITE; MATRIX-METALLOPROTEINASE-9; ACTIVATION	The role of proteases in the tumor cell invasion process is multifaceted. Members of the matrix metalloproteinase (MMP) family have been implicated in primary and metastatic tumor growth, angiogenesis, and degradation of extracellular matrix (ECM) components. Differentiating between the up-regulation of MMP production and the presence of activated MMPs can be difficult but may well dictate which MMPs are critical to invasion. Because the hydrolysis of collagens is one of the committed steps in ECM turnover, we have investigated selective MMP action on collagenous substrates as a means to evaluate active MMPs. Two triple-helical peptide (THP) models of the MMP-9 cleavage site in type V collagen, alpha1(V)436-450 THP and alpha1(V)436-447 fTHP, were hydrolyzed by MMP-2 and MMP-9 at the Gly-Val bond, analogous to the bond cleaved by MMP-9 in the corresponding native collagen. Kinetic analyses showed k(cat)/K-m values of 14,002 and 5,449 s(-1)M(-1) for MMP-2 and -9 hydrolysis of alpha1(V)436-447 fTHP, respectively. These values, along with individual k(cat) and K-m values, are comparable with collagen hydrolysis by MMP-2 and -9. Neither THP was hydrolyzed by MMP-1, -3, -13, or -14. alpha1(V)436-447 fTHP and a general fluorogenic THP were used to screen for triple-helical peptidase activity in alpha(2)beta(1) integrin-stimulated melanoma cells. Binding of the alpha(2)beta(1) integrin resulted in the production of substantial triple-helical peptidase activity, the majority (>95%) of which was non-MMP-2/-9. THPs were found to provide highly selective substrates for members of the MMP family and can be used to evaluate active MMP production in cellular systems.	Florida Atlantic Univ, Dept Chem & Biochem, Boca Raton, FL 33431 USA; Northwestern Univ, Sch Med, Dept Cell & Mol Biol, Chicago, IL 60611 USA; Univ London Imperial Coll Sci Technol & Med, Div Rheumatol, Kennedy Inst, London W6 8LH, England	State University System of Florida; Florida Atlantic University; Northwestern University; Imperial College London; University of Oxford	Fields, GB (corresponding author), Florida Atlantic Univ, Dept Chem & Biochem, 777 Glades Rd, Boca Raton, FL 33431 USA.	fieldsg@fau.edu			NCI NIH HHS [CA 98799, CA 77402] Funding Source: Medline; NIAMS NIH HHS [AR 39189] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA098799, R01CA077402] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR039189] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		AIMES RT, 1995, J BIOL CHEM, V270, P5872, DOI 10.1074/jbc.270.11.5872; Bergers G, 2000, NAT CELL BIOL, V2, P737, DOI 10.1038/35036374; Bremer C, 2001, NAT MED, V7, P743, DOI 10.1038/89126; Chang C, 2001, TRENDS CELL BIOL, V11, pS37, DOI 10.1016/S0962-8924(01)82222-4; Chen EI, 2002, J BIOL CHEM, V277, P4485, DOI 10.1074/jbc.M109469200; Chung L, 2000, J BIOL CHEM, V275, P29610, DOI 10.1074/jbc.M004039200; Corcoran ML, 1996, ENZYME PROTEIN, V49, P7, DOI 10.1159/000468613; Deryugina EI, 1998, CANCER RES, V58, P3743; Emsley J, 2000, CELL, V101, P47, DOI 10.1016/S0092-8674(00)80622-4; FIELDS CG, 1993, PEPTIDE RES, V6, P39; FIELDS GB, 1991, J THEOR BIOL, V153, P585, DOI 10.1016/S0022-5193(05)80157-2; FIELDS GB, 2001, PEPTIDES WAVE FUTURE, P975; Fiore E, 2002, ONCOGENE, V21, P5213, DOI 10.1038/sj.onc.1205684; FREIJE JMP, 1994, J BIOL CHEM, V269, P16766; Giannelli G, 1997, SCIENCE, V277, P225, DOI 10.1126/science.277.5323.225; Henkel W, 1999, BIOCHEMISTRY-US, V38, P13610, DOI 10.1021/bi9905157; Hofmann UB, 2000, J INVEST DERMATOL, V115, P337, DOI 10.1046/j.1523-1747.2000.00068.x; Huang W, 1996, FEBS LETT, V384, P155, DOI 10.1016/0014-5793(96)00304-3; ITOH Y, 1995, BIOCHEM J, V308, P645, DOI 10.1042/bj3080645; Kleiner DE, 1999, CANCER CHEMOTH PHARM, V43, pS42, DOI 10.1007/s002800051097; Knauper V, 1996, J BIOL CHEM, V271, P1544, DOI 10.1074/jbc.271.3.1544; Knight CG, 2000, J BIOL CHEM, V275, P35, DOI 10.1074/jbc.275.1.35; Knight CG, 1998, J BIOL CHEM, V273, P33287, DOI 10.1074/jbc.273.50.33287; Knutson JR, 1996, MOL BIOL CELL, V7, P383, DOI 10.1091/mbc.7.3.383; LABROSSE KR, 1976, ANAL BIOCHEM, V70, P218, DOI 10.1016/S0378-5173(83)90103-5; Lauer JL, 1998, BIOCHEMISTRY-US, V37, P5279, DOI 10.1021/bi972958l; Lauer-Fields JL, 2000, J CHROMATOGR A, V890, P117, DOI 10.1016/S0021-9673(00)00396-4; Lauer-Fields JL, 2000, J BIOL CHEM, V275, P13282, DOI 10.1074/jbc.275.18.13282; Lauer-Fields JL, 2002, BIOL CHEM, V383, P1095, DOI 10.1515/BC.2002.118; Lauer-Fields JL, 2002, BIOPOLYMERS, V66, P19, DOI 10.1002/bip.10201; Lauer-Fields JL, 2001, BIOCHEMISTRY-US, V40, P5795, DOI 10.1021/bi0101190; MACDOUGALL JR, 1995, CANCER RES, V55, P4174; McCawley LJ, 2000, MOL MED TODAY, V6, P149, DOI 10.1016/S1357-4310(00)01686-5; MILES AJ, 1994, J BIOL CHEM, V269, P30939; MILES AJ, 1995, J BIOL CHEM, V270, P29047, DOI 10.1074/jbc.270.49.29047; Mitchell PG, 1996, J CLIN INVEST, V97, P761, DOI 10.1172/JCI118475; MORODOMI T, 1992, BIOCHEM J, V285, P603, DOI 10.1042/bj2850603; Mott JD, 1997, KIDNEY INT, V52, P1302, DOI 10.1038/ki.1997.455; NAGASE H, 1994, J BIOL CHEM, V269, P20952; Nagase H, 1996, BIOPOLYMERS, V40, P399, DOI 10.1002/(SICI)1097-0282(1996)40:4<399::AID-BIP5>3.0.CO;2-R; Nelson AR, 2000, J CLIN ONCOL, V18, P1135, DOI 10.1200/JCO.2000.18.5.1135; NIYIBIZI C, 1994, BIOCHEM BIOPH RES CO, V202, P328, DOI 10.1006/bbrc.1994.1931; Ntayi C, 2001, EXP CELL RES, V270, P110, DOI 10.1006/excr.2001.5306; Ohuchi E, 1997, J BIOL CHEM, V272, P2446, DOI 10.1074/jbc.272.4.2446; Ottl J, 2000, CHEM BIOL, V7, P119, DOI 10.1016/S1074-5521(00)00077-6; Ramos-DeSimone N, 1999, J BIOL CHEM, V274, P13066, DOI 10.1074/jbc.274.19.13066; RIIKONEN T, 1995, J BIOL CHEM, V270, P13548, DOI 10.1074/jbc.270.22.13548; Stolow MA, 1996, MOL BIOL CELL, V7, P1471, DOI 10.1091/mbc.7.10.1471; Vo HP, 1998, INT J ONCOL, V13, P1127; Woessner J.F., 2000, PROTEIN PROFILE SER; Xia T, 1996, BBA-PROTEIN STRUCT M, V1293, P259, DOI 10.1016/0167-4838(95)00259-6; Xu JS, 2001, J CELL BIOL, V154, P1069, DOI 10.1083/jcb.200103111; Yang MZ, 1998, J BIOL CHEM, V273, P17893, DOI 10.1074/jbc.273.28.17893; YOUNG TN, 1995, J BIOL CHEM, V270, P999, DOI 10.1074/jbc.270.3.999; Yu YC, 1998, J AM CHEM SOC, V120, P9979, DOI 10.1021/ja981654z; Yu YC, 1996, J AM CHEM SOC, V118, P12515, DOI 10.1021/ja9627656; ZUCKER S, 1994, CLIN EXP METASTAS, V12, P13, DOI 10.1007/BF01784329	57	83	89	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 16	2003	278	20					18140	18145		10.1074/jbc.M211330200	http://dx.doi.org/10.1074/jbc.M211330200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677YX	12642591	hybrid			2022-12-25	WOS:000182838300072
J	Cheung-Flynn, J; Roberts, PJ; Riggs, DL; Smith, DF				Cheung-Flynn, J; Roberts, PJ; Riggs, DL; Smith, DF			C-terminal sequences outside the tetratricopeptide repeat domain of FKBP51 and FKBP52 cause differential binding to hsp90	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK PROTEINS; GLUCOCORTICOID RECEPTOR; FK506-BINDING IMMUNOPHILIN; PROGESTERONE-RECEPTOR; STEROID-RECEPTORS; MOLECULAR-CLONING; SQUIRREL-MONKEY; TPR DOMAINS; COMPLEXES; PHOSPHATASE-5	Hsp90 assembles with steroid receptors and other client proteins in association with one or more Hsp90-binding cochaperones, some of which contain a common tetratricopeptide repeat (TPR) domain. Included in the TPR cochaperones are the Hsp70-Hsp90-organizing protein Hop, the FK506-binding immunophilins FKBP52 and FKBP51, the cyclosporin A-binding immunophilin CyP40, and protein phosphatase PP5. The TPR domains from these proteins have similar x-ray crystallographic structures and target cochaperone binding to the MEEVD sequence that terminates Hsp90. However, despite these similarities, the TPR cochaperones have distinctive properties for binding Hsp90 and assembling with Hsp90.steroid receptor complexes. To identify structural features that differentiate binding of FKBP51 and FKBP52 to Hsp90, we generated an assortment of truncation mutants and chimeras that were compared for coimmunoprecipitation with Hsp90. Although the core TPR domain (approximately amino acids 260-400) of FKBP51 and FKBP52 is required for Hsp90 binding, the C-terminal 60 amino acids (similar to400-end) also influence Hsp90 binding. More specifically, we find that amino acids 400-420 play a critical role for Hsp90 binding by either FKBP. Within this 20-amino acid region, we have identified a consensus sequence motif that is also present in some other TPR cochaperones. Additionally, the final 30 amino acids of FKBP51 enhance binding to Hsp90, whereas the corresponding region of FKBP52 moderates binding to Hsp90. Taking into account the x-ray crystal structure for FKBP51, we conclude that the C-terminal regions of FKBP51 and FKBP52 outside the core TPR domains are likely to assume alternative conformations that significantly impact Hsp90 binding.	Mayo Clin Scottsdale, Dept Biochem & Mol Biol, SC Johnson Res Ctr, Scottsdale, AZ 85259 USA	Mayo Clinic; Mayo Clinic Phoenix; SC Johnson & Son	Smith, DF (corresponding author), Mayo Clin Scottsdale, Dept Biochem & Mol Biol, SC Johnson Res Ctr, 13400 E Shea Blvd, Scottsdale, AZ 85259 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK048218] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK48218] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ballinger CA, 1999, MOL CELL BIOL, V19, P4535; Barent RL, 1998, MOL ENDOCRINOL, V12, P342, DOI 10.1210/me.12.3.342; BAUGHMAN G, 1995, MOL CELL BIOL, V15, P4395; Blatch GL, 1999, BIOESSAYS, V21, P932, DOI 10.1002/(SICI)1521-1878(199911)21:11<932::AID-BIES5>3.0.CO;2-N; CALLEBAUT I, 1992, P NATL ACAD SCI USA, V89, P6270, DOI 10.1073/pnas.89.14.6270; Carrello A, 1999, J BIOL CHEM, V274, P2682, DOI 10.1074/jbc.274.5.2682; Chen MS, 1996, J BIOL CHEM, V271, P32315, DOI 10.1074/jbc.271.50.32315; Chen SY, 1996, MOL ENDOCRINOL, V10, P682, DOI 10.1210/me.10.6.682; Chen SY, 1998, CELL STRESS CHAPERON, V3, P118, DOI 10.1379/1466-1268(1998)003<0118:DIOPAT>2.3.CO;2; Cheung J, 2000, MOL ENDOCRINOL, V14, P939, DOI 10.1210/me.14.7.939; Das AK, 1998, EMBO J, V17, P1192, DOI 10.1093/emboj/17.5.1192; Davies TH, 2002, J BIOL CHEM, V277, P4597, DOI 10.1074/jbc.C100531200; Denny WB, 2000, ENDOCRINOLOGY, V141, P4107, DOI 10.1210/en.141.11.4107; Gatto GJ, 2000, NAT STRUCT BIOL, V7, P1091; HONORE B, 1992, J BIOL CHEM, V267, P8485; Kumar A, 2001, J MOL BIOL, V307, P271, DOI 10.1006/jmbi.2000.4465; Lassle M, 1997, J BIOL CHEM, V272, P1876, DOI 10.1074/jbc.272.3.1876; Ma Q, 1997, J BIOL CHEM, V272, P8878; Meng X, 1998, GENOMICS, V52, P130, DOI 10.1006/geno.1998.5412; Meyer BK, 1998, MOL CELL BIOL, V18, P978, DOI 10.1128/MCB.18.2.978; Nair SC, 1997, MOL CELL BIOL, V17, P594, DOI 10.1128/MCB.17.2.594; OWENSGRILLO JK, 1995, J BIOL CHEM, V270, P20479, DOI 10.1074/jbc.270.35.20479; PEATTIE DA, 1992, P NATL ACAD SCI USA, V89, P10974, DOI 10.1073/pnas.89.22.10974; RADANYI C, 1994, P NATL ACAD SCI USA, V91, P11197, DOI 10.1073/pnas.91.23.11197; Ramsey AJ, 2000, J BIOL CHEM, V275, P17857, DOI 10.1074/jbc.M001625200; Ratajczak T, 1996, J BIOL CHEM, V271, P2961, DOI 10.1074/jbc.271.6.2961; RATAJCZAK T, 1993, J BIOL CHEM, V268, P13187; Reynolds PD, 1999, J CLIN ENDOCR METAB, V84, P663, DOI 10.1210/jc.84.2.663; Richter K, 2001, J CELL PHYSIOL, V188, P281, DOI 10.1002/jcp.1131; Riggs DL, 2003, EMBO J, V22, P1158, DOI 10.1093/emboj/cdg108; Russell LC, 1999, J BIOL CHEM, V274, P20060, DOI 10.1074/jbc.274.29.20060; Scammell JG, 2001, GEN COMP ENDOCR, V124, P152, DOI 10.1006/gcen.2001.7696; Scheufler C, 2000, CELL, V101, P199, DOI 10.1016/S0092-8674(00)80830-2; Silverstein AM, 1997, J BIOL CHEM, V272, P16224, DOI 10.1074/jbc.272.26.16224; Sinars CR, 2003, P NATL ACAD SCI USA, V100, P868, DOI 10.1073/pnas.0231020100; TAI PKK, 1992, SCIENCE, V256, P1315, DOI 10.1126/science.1376003; Taylor P, 2001, STRUCTURE, V9, P431, DOI 10.1016/S0969-2126(01)00603-7	37	70	73	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 9	2003	278	19					17388	17394		10.1074/jbc.M300955200	http://dx.doi.org/10.1074/jbc.M300955200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677QG	12611898	hybrid			2022-12-25	WOS:000182818600125
J	Grewal, T; de Diego, I; Kirchhoff, MF; Tebar, F; Heeren, J; Rinninger, F; Enrich, C				Grewal, T; de Diego, I; Kirchhoff, MF; Tebar, F; Heeren, J; Rinninger, F; Enrich, C			High density lipoprotein-induced signaling of the MAPK pathway involves scavenger receptor type BI-mediated activation of Ras	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; SELECTIVE LIPID UPTAKE; HUMAN SKIN FIBROBLASTS; PLASMA-MEMBRANE; CHOLESTEROL EFFLUX; SR-BI; BINDING; CELLS; RAF-1; COMPLEXES	High density lipoprotein (HDL) stimulates multiple signaling pathways. HDL-induced activation of the mitogen-activated protein kinase (MAPK) pathway can be mediated by protein kinase C (PKC) and/or pertussis toxin-sensitive G-proteins. Although HDL-induced activation of MAPK involves Raf-1, Mek, and Erk1/2, the upstream contribution of p21(ras) (Ras) on the activation of Raf-1 and MAPK remains elusive. Here we examine the effect of HDL on Ras activity and demonstrate that HDL induces PKC-independent activation of Ras that is completely blocked by pertussis toxin, thus implicating heterotrimeric G-proteins. In addition, the HDL-induced activation of Ras is inhibited by a neutralizing antibody against scavenger receptor type BI. We conclude that the binding of HDL to scavenger receptor type BI activates Ras in a PKC-independent manner with subsequent induction of the MAPK signaling cascade.	Univ Barcelona, Fac Med, IDIBAPS, Dept Cellular Biol, Barcelona 08036, Spain; Univ Hamburg, Hosp Eppendorf, Inst Med Biochem & Mol Biol, Dept Mol Cell Biol, D-20246 Hamburg, Germany; Univ Hamburg, Hosp Eppendorf, Dept Internal Med, D-20246 Hamburg, Germany	University of Barcelona; Hospital Clinic de Barcelona; IDIBAPS; University of Hamburg; University of Hamburg	Enrich, C (corresponding author), Univ Barcelona, Fac Med, IDIBAPS, Dept Cellular Biol, Casanova 143, Barcelona 08036, Spain.		de Diego Martinez, Iñaki/AAB-4712-2019; Tebar, Francesc/H-1498-2015; Eckhardt, Erik/G-1567-2010	de Diego Martinez, Iñaki/0000-0002-6156-4032; Tebar, Francesc/0000-0002-9522-9726; Grewal, Thomas/0000-0002-7937-8887; Enrich, Carlos/0000-0003-0382-2993				Babitt J, 1997, J BIOL CHEM, V272, P13242, DOI 10.1074/jbc.272.20.13242; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Calvo M, 2000, ELECTROPHORESIS, V21, P3386, DOI 10.1002/1522-2683(20001001)21:16<3386::AID-ELPS3386>3.3.CO;2-C; Cockerill GW, 1999, INT REV CYTOL, V188, P257; Deeg MA, 1997, ARTERIOSCL THROM VAS, V17, P1667, DOI 10.1161/01.ATV.17.9.1667; deRooij J, 1997, ONCOGENE, V14, P623, DOI 10.1038/sj.onc.1201005; Fidge NH, 1999, J LIPID RES, V40, P187; Frank PG, 2001, AM J PHYSIOL-CELL PH, V280, pC1204, DOI 10.1152/ajpcell.2001.280.5.C1204; Garver WS, 1997, ARTERIOSCL THROM VAS, V17, P2698, DOI 10.1161/01.ATV.17.11.2698; Gu XJ, 2000, J BIOL CHEM, V275, P29993, DOI 10.1074/jbc.275.39.29993; HARTWIG JH, 1992, NATURE, V356, P618, DOI 10.1038/356618a0; HAVEL RJ, 1955, J CLIN INVEST, V34, P1345, DOI 10.1172/JCI103182; Ikemoto M, 2000, P NATL ACAD SCI USA, V97, P6538, DOI 10.1073/pnas.100114397; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Li XA, 2002, J BIOL CHEM, V277, P11058, DOI 10.1074/jbc.M110985200; Marais R, 1998, SCIENCE, V280, P109, DOI 10.1126/science.280.5360.109; MARAIS R, 1995, EMBO J, V14, P3136, DOI 10.1002/j.1460-2075.1995.tb07316.x; Nofer JR, 2002, ATHEROSCLEROSIS, V161, P1, DOI 10.1016/S0021-9150(01)00651-7; Nofer JR, 2001, THROMB HAEMOSTASIS, V85, P730; Okamoto T, 1998, J BIOL CHEM, V273, P5419, DOI 10.1074/jbc.273.10.5419; Pons M, 2001, FEBS LETT, V501, P69, DOI 10.1016/S0014-5793(01)02635-7; RINNINGER F, 1994, HEPATOLOGY, V19, P1100, DOI 10.1002/hep.1840190507; Simons K, 2000, NAT REV MOL CELL BIO, V1, P31, DOI 10.1038/35036052; von Eckardstein A, 2001, ARTERIOSCL THROM VAS, V21, P13, DOI 10.1161/01.ATV.21.1.13; Wang N, 2000, J BIOL CHEM, V275, P33053, DOI 10.1074/jbc.M005438200; Webb BLJ, 2000, BRIT J PHARMACOL, V130, P1433, DOI 10.1038/sj.bjp.0703452; Xu SZ, 1997, J LIPID RES, V38, P1289; Yuhanna IS, 2001, NAT MED, V7, P853, DOI 10.1038/89986	28	64	68	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 9	2003	278	19					16478	16481		10.1074/jbc.C300085200	http://dx.doi.org/10.1074/jbc.C300085200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677QG	12637559	hybrid			2022-12-25	WOS:000182818600006
J	Hall, MC; Torres, MP; Schroeder, GK; Borchers, CH				Hall, MC; Torres, MP; Schroeder, GK; Borchers, CH			Mnd2 and Swm1 are core subunits of the Saccharomyces cerevisiae anaphase-promoting complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							YEAST; IDENTIFICATION; PROTEIN; APC11; PROTEOLYSIS; MEIOSIS; SPORULATION; CHECKPOINT; MITOSIS; SCREEN	The anaphase-promoting complex (APC) is a multi-subunit E3 ubiquitin ligase that regulates the metaphase-anaphase transition and exit from mitosis in eukaryotic cells. Eleven subunits have been previously identified in APC from budding yeast. We have identified two additional subunits, Mnd2 and Swm1, by mass spectrometry. Both Mnd2 and Swm1 were found specifically associated with a highly purified preparation of APC from haploid yeast whole cell extract. Moreover, the APC co-purified with epitope-tagged Mnd2 and Swm1. Both proteins were present in APC preparations from haploid cells arrested in G(1), S, and M phases and from meiotic diploid cells, indicating that they are constitutive components of the complex throughout the yeast cell cycle. Mnd2 interacted strongly with Cdc23, Apc5, and Apc1 when coexpressed in an in vitro transcription/translation reaction. Swm1 also interacted with Cdc23 and Apc5 in this system. Previous studies described meiotic defects for mutations in MND2 and SWM1. Here, we show that mnd2Delta and swm1Delta haploid strains exhibit slow growth and accumulation of G(2)/M cells comparable with that seen in apc9Delta or apc10Delta strains and consistent with an APC defect. Taken together, these results demonstrate that Swm1 and Mnd2 are functional components of the yeast APC.	Univ N Carolina, Dept Biochem & Biophys, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill	Borchers, CH (corresponding author), Univ N Carolina, Dept Biochem & Biophys, CB 7260 Mary Ellen Jones Bldg, Chapel Hill, NC 27599 USA.		, UNC Flow Cytometry Core/AGU-9839-2022; BORCHERS, Christoph/U-5964-2019; Hall, Mark C./D-1698-2011	Torres, Matthew/0000-0001-7296-4536; Hall, Mark/0000-0001-6429-2506				Blanco MA, 2001, J CELL SCI, V114, P2135; Bolte M, 2002, P NATL ACAD SCI USA, V99, P4385, DOI 10.1073/pnas.072385099; CAO L, 1990, CELL, V61, P1089, DOI 10.1016/0092-8674(90)90072-M; Chu S, 1998, SCIENCE, V282, P699, DOI 10.1126/science.282.5389.699; Cooper KF, 2000, P NATL ACAD SCI USA, V97, P14548, DOI 10.1073/pnas.250351297; Foiani M, 2000, MUTAT RES-FUND MOL M, V451, P187, DOI 10.1016/S0027-5107(00)00049-X; Gelbart ME, 2001, MOL CELL BIOL, V21, P2098, DOI 10.1128/MCB.21.6.2098-2106.2001; Gmachl M, 2000, P NATL ACAD SCI USA, V97, P8973, DOI 10.1073/pnas.97.16.8973; Grossberger R, 1999, J BIOL CHEM, V274, P14500, DOI 10.1074/jbc.274.20.14500; Harper JW, 2002, GENE DEV, V16, P2179, DOI 10.1101/gad.1013102; Hwang LH, 1997, MOL BIOL CELL, V8, P1877, DOI 10.1091/mbc.8.10.1877; Leverson JD, 2000, MOL BIOL CELL, V11, P2315, DOI 10.1091/mbc.11.7.2315; Musacchio A, 2002, NAT REV MOL CELL BIO, V3, P731, DOI 10.1038/nrm929; Ohta T, 1999, MOL CELL, V3, P535, DOI 10.1016/S1097-2765(00)80482-7; Peters JM, 2002, MOL CELL, V9, P931, DOI 10.1016/S1097-2765(02)00540-3; Peters JM, 1996, SCIENCE, V274, P1199, DOI 10.1126/science.274.5290.1199; Primig M, 2000, NAT GENET, V26, P415, DOI 10.1038/82539; Rabitsch KP, 2001, CURR BIOL, V11, P1001, DOI 10.1016/S0960-9822(01)00274-3; Tang ZY, 2001, MOL BIOL CELL, V12, P3839, DOI 10.1091/mbc.12.12.3839; Ufano S, 1999, MOL CELL BIOL, V19, P2118; Yoon HJ, 2002, CURR BIOL, V12, P2048, DOI 10.1016/S0960-9822(02)01331-3; Yu HT, 1998, SCIENCE, V279, P1219, DOI 10.1126/science.279.5354.1219; Zachariae W, 1996, SCIENCE, V274, P1201, DOI 10.1126/science.274.5290.1201; Zachariae W, 1998, SCIENCE, V279, P1216, DOI 10.1126/science.279.5354.1216; Zhao XL, 1998, MOL CELL, V2, P329, DOI 10.1016/S1097-2765(00)80277-4	25	50	56	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 9	2003	278	19					16698	16705		10.1074/jbc.M213109200	http://dx.doi.org/10.1074/jbc.M213109200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677QG	12609981	Green Published, hybrid			2022-12-25	WOS:000182818600034
J	Maggi, LB; Moran, JM; Buller, RML; Corbett, JA				Maggi, LB; Moran, JM; Buller, RML; Corbett, JA			ERK activation is required for double-stranded RNA- and virus-induced interleukin-1 expression by macrophages	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NITRIC-OXIDE SYNTHASE; NF-KAPPA-B; DEPENDENT PROTEIN-KINASE; TRANSCRIPTIONAL ACTIVATION; TARGETED DELETION; ENDOTHELIAL-CELLS; INTERFERON-GAMMA; VIRAL-INFECTION; POTENTIAL ROLE; TNF-ALPHA	Double-stranded (ds) RNA, which accumulates during viral replication, activates the antiviral response of infected cells. In this study, we have identified a requirement for extracellular signal-regulated kinase (ERK) in the regulation of interleukin 1 (IL-1) expression by macrophages in response to dsRNA and viral infection. Treatment of RAW 264.7 cells or mouse macrophages with dsRNA stimulates ERK phosphorylation that is first apparent following a 15-min incubation and persists for up to 60 min, the accumulation of iNOS and IL-1 mRNA following a 6-h incubation, and the expression of iNOS and IL-1 at the protein level following a 24-h incubation. Inhibitors of ERK activation prevent dsRNA-induced ERK phosphorylation and IL-1 expression by macrophages. The regulation of macrophage activation by ERK appears to be selective for IL-1, as ERK inhibition does not attenuate dsRNA-induced iNOS expression by macrophages. dsRNA stimulates both ERK activation and IL-1 expression by macrophages isolated from dsRNA-dependent protein kinase (PKR)-deficient mice, indicating that PKR does not participate in this antiviral response. These findings support a novel PKR-independent role for ERK in the regulation of the antiviral response of IL-1 expression and release by macrophages.	St Louis Univ, Sch Med, Edward A Doisy Dept Biochem & Mol Biol, St Louis, MO 63104 USA; St Louis Univ, Sch Med, Dept Mol Microbiol & Immunol, St Louis, MO 63104 USA	Saint Louis University; Saint Louis University	Corbett, JA (corresponding author), St Louis Univ, Sch Med, Edward A Doisy Dept Biochem & Mol Biol, 1402 S Grand Blvd, St Louis, MO 63104 USA.	corbettj@slu.edu	Maggi, Leonard/L-5217-2019	Maggi, Leonard/0000-0003-0138-0984	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI044458] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK052194] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-44458] Funding Source: Medline; NIDDK NIH HHS [DK-52194] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Alexopoulou L, 2001, NATURE, V413, P732, DOI 10.1038/35099560; Arnush M, 1998, J IMMUNOL, V160, P2684; BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; Baldassare JJ, 1999, J IMMUNOL, V162, P5367; Baltzis D, 2002, J BIOL CHEM, V277, P38364, DOI 10.1074/jbc.M203564200; Bandyopadhyay SK, 2000, J IMMUNOL, V164, P2077, DOI 10.4049/jimmunol.164.4.2077; Barber GN, 2001, CELL DEATH DIFFER, V8, P113, DOI 10.1038/sj.cdd.4400823; BECKERMAN KP, 1993, J IMMUNOL, V150, P888; Blair LA, 2001, DIABETES, V50, P283, DOI 10.2337/diabetes.50.2.283; BUKRINSKY MI, 1995, J EXP MED, V181, P735, DOI 10.1084/jem.181.2.735; Chan ED, 1999, J IMMUNOL, V162, P415; Chan ED, 2001, INFECT IMMUN, V69, P2001, DOI 10.1128/IAI.69.4.2001-2010.2001; Chu WM, 1999, IMMUNITY, V11, P721, DOI 10.1016/S1074-7613(00)80146-6; DaSilva J, 1997, J BIOL CHEM, V272, P28373, DOI 10.1074/jbc.272.45.28373; Der SD, 1997, P NATL ACAD SCI USA, V94, P3279, DOI 10.1073/pnas.94.7.3279; Eliopoulos AG, 1999, J BIOL CHEM, V274, P16085, DOI 10.1074/jbc.274.23.16085; Flodstrom M, 2001, VIROLOGY, V281, P205, DOI 10.1006/viro.2000.0801; Gale M, 1998, PHARMACOL THERAPEUT, V78, P29, DOI 10.1016/S0163-7258(97)00165-4; GODAMBE SA, 1993, CYTOKINE, V5, P327, DOI 10.1016/1043-4666(93)90064-C; GREEN LC, 1982, ANAL BIOCHEM, V126, P131, DOI 10.1016/0003-2697(82)90118-X; Harcourt JL, 2001, EUR J BIOCHEM, V268, P1373, DOI 10.1046/j.1432-1327.2001.02003.x; Heitmeier MR, 1998, J BIOL CHEM, V273, P15301, DOI 10.1074/jbc.273.24.15301; HIBBS JB, 1990, INT CONGR SER, V897, P189; Hill JR, 1996, ANAL BIOCHEM, V236, P14, DOI 10.1006/abio.1996.0125; Hirasawa K, 1999, J VIROL, V73, P8541, DOI 10.1128/JVI.73.10.8541-8548.1999; HOVANESSIAN AG, 1993, TRANSLATIONAL REGULA, P163; Iordanov MS, 2001, MOL CELL BIOL, V21, P61, DOI 10.1128/MCB.21.1.61-72.2001; Ishii T, 2001, ONCOGENE, V20, P1900, DOI 10.1038/sj.onc.1204267; Jacobs BL, 1996, VIROLOGY, V219, P339, DOI 10.1006/viro.1996.0259; KARUPIAH G, 1993, SCIENCE, V261, P1445, DOI 10.1126/science.7690156; KOROMILAS AE, 1995, J BIOL CHEM, V270, P25426, DOI 10.1074/jbc.270.43.25426; Kreil TR, 1996, VIROLOGY, V219, P304, DOI 10.1006/viro.1996.0252; KUMAR A, 1994, P NATL ACAD SCI USA, V91, P6288, DOI 10.1073/pnas.91.14.6288; Kumar A, 1997, EMBO J, V16, P406, DOI 10.1093/emboj/16.2.406; Maggi LB, 2002, J BIOL CHEM, V277, P38449, DOI 10.1074/jbc.M206247200; Maggi LB, 2000, EMBO J, V19, P3630, DOI 10.1093/emboj/19.14.3630; Marecki S, 2001, J IMMUNOL, V166, P6829, DOI 10.4049/jimmunol.166.11.6829; Marecki S, 2000, CELL BIOCHEM BIOPHYS, V33, P127, DOI 10.1385/CBB:33:2:127; MILHAUD PG, 1991, J INTERFERON RES, V11, P261, DOI 10.1089/jir.1991.11.261; Nath A, 1999, J BIOL CHEM, V274, P17098, DOI 10.1074/jbc.274.24.17098; OFFERMANN MK, 1995, EUR J BIOCHEM, V232, P28, DOI 10.1111/j.1432-1033.1995.tb20777.x; Pahan K, 1998, J BIOL CHEM, V273, P2591, DOI 10.1074/jbc.273.5.2591; Reiss CS, 1998, J VIROL, V72, P4547, DOI 10.1128/JVI.72.6.4547-4551.1998; Samuel CE, 1997, INT J HEMATOL, V65, P227; Scarim AL, 2001, AM J PATHOL, V159, P273, DOI 10.1016/S0002-9440(10)61693-8; Weber JD, 1997, J BIOL CHEM, V272, P32966, DOI 10.1074/jbc.272.52.32966; Williams BRG, 1999, ONCOGENE, V18, P6112, DOI 10.1038/sj.onc.1203127; Yang YL, 1995, EMBO J, V14, P6095, DOI 10.1002/j.1460-2075.1995.tb00300.x; Zandi E, 1999, MOL CELL BIOL, V19, P4547; Zaragoza C, 1999, J IMMUNOL, V163, P5497	50	37	37	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 9	2003	278	19					16683	16689		10.1074/jbc.M211744200	http://dx.doi.org/10.1074/jbc.M211744200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677QG	12609986	hybrid			2022-12-25	WOS:000182818600032
J	Maglich, JM; Parks, DJ; Moore, LB; Collins, JL; Goodwin, B; Billin, AN; Stoltz, CA; Kliewer, SA; Lambert, MH; Willson, TM; Moore, JT				Maglich, JM; Parks, DJ; Moore, LB; Collins, JL; Goodwin, B; Billin, AN; Stoltz, CA; Kliewer, SA; Lambert, MH; Willson, TM; Moore, JT			Identification of a novel human constitutive androstane receptor (CAR) agonist and its use in the identification of CAR target genes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PREGNANE-X-RECEPTOR; RESPONSIVE NUCLEAR TRANSLOCATION; HEPATIC DRUG-METABOLISM; HUMAN CYP2B6 GENE; XENOBIOTIC RECEPTOR; ENHANCER MODULE; TRANSCRIPTIONAL ACTIVATION; CYP3A4 GENE; BILE-ACIDS; PXR	The orphan nuclear constitutive androstane receptor (CAR) is proposed to play a central role in the response to xenochemical stress. Identification of CAR target genes in humans has been limited by the lack of a selective CAR agonist. We report the identification of 6-(4-chlorophenyl) imidazo[2,1-b][1,3] thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl) oxime (CITCO) as a novel human CAR agonist with the following characteristics: (a) potent activity in an in vitro fluorescence-based CAR activation assay; (b) selectivity for CAR over other nuclear receptors, including the xenobiotic pregnane X receptor (PXR); (c) the ability to induce human CAR nuclear translocation; and (d) the ability to induce the prototypical CAR target gene CYP2B6 in primary human hepatocytes. Using primary cultures of human hepatocytes, the effects of CITCO on gene expression were compared with those of the PXR ligand rifampicin. The relative expression of a number of genes encoding proteins involved in various aspects of steroid and xenobiotic metabolism was analyzed. Notably, CAR and PXR activators differentially regulated the expression of several genes, demonstrating that these two nuclear receptors subserve overlapping but distinct biological functions in human hepatocytes.	GlaxoSmithKline, Nucl Receptor Discovery Res, Res Triangle Pk, NC 27709 USA	GlaxoSmithKline	Moore, JT (corresponding author), GlaxoSmithKline, Nucl Receptor Discovery Res, 5 Moore Dr,V-116B, Res Triangle Pk, NC 27709 USA.		feinstein, doug/M-9414-2019	Billin, Andrew/0000-0001-7752-0934				Bertilsson G, 1998, P NATL ACAD SCI USA, V95, P12208, DOI 10.1073/pnas.95.21.12208; Blumberg B, 1998, GENE DEV, V12, P3195, DOI 10.1101/gad.12.20.3195; Code EL, 1997, DRUG METAB DISPOS, V25, P985; David G B, 1975, Prog Histochem Cytochem, V7, P1; Forman BM, 1998, NATURE, V395, P612, DOI 10.1038/26996; Gibson GG, 2002, XENOBIOTICA, V32, P165, DOI 10.1080/00498250110102674; Goodwin B, 2001, MOL PHARMACOL, V60, P427; Goodwin B, 2002, MOL PHARMACOL, V62, P359, DOI 10.1124/mol.62.2.359; Goodwin B, 1999, MOL PHARMACOL, V56, P1329, DOI 10.1124/mol.56.6.1329; Honkakoski P, 1998, MOL CELL BIOL, V18, P5652, DOI 10.1128/MCB.18.10.5652; Iwata H, 2002, COMP BIOCHEM PHYS C, V131, P501, DOI 10.1016/S1532-0456(02)00038-8; Jones SA, 2000, MOL ENDOCRINOL, V14, P27, DOI 10.1210/me.14.1.27; Kalow W, 2001, Pharmacogenomics J, V1, P234; Kawamoto T, 1999, MOL CELL BIOL, V19, P6318; Kliewer SA, 2002, ENDOCR REV, V23, P687, DOI 10.1210/er.2001-0038; Lamba JK, 2002, PHARMACOGENETICS, V12, P121, DOI 10.1097/00008571-200203000-00006; LAMBERT MH, 1997, PRACTICAL APPL COMPU, P243; Lehmann JM, 1998, J CLIN INVEST, V102, P1016, DOI 10.1172/JCI3703; Liddle C, 2002, SEMIN LIVER DIS, V22, P115, DOI 10.1055/s-2002-30098; Maglich JM, 2002, MOL PHARMACOL, V62, P638, DOI 10.1124/mol.62.3.638; Moore JT, 2000, TOXICOLOGY, V153, P1, DOI 10.1016/S0300-483X(00)00300-0; Moore LB, 2000, P NATL ACAD SCI USA, V97, P7500, DOI 10.1073/pnas.130155097; Moore LB, 2000, J BIOL CHEM, V275, P15122, DOI 10.1074/jbc.M001215200; Moore LB, 2002, MOL ENDOCRINOL, V16, P977, DOI 10.1210/me.16.5.977; Parks DJ, 1999, SCIENCE, V284, P1365, DOI 10.1126/science.284.5418.1365; Rochel N, 2000, MOL CELL, V5, P173, DOI 10.1016/S1097-2765(00)80413-X; Smirlis D, 2001, J BIOL CHEM, V276, P12822, DOI 10.1074/jbc.M005930200; Staudinger JL, 2001, P NATL ACAD SCI USA, V98, P3369, DOI 10.1073/pnas.051551698; Sueyoshi T, 1999, J BIOL CHEM, V274, P6043, DOI 10.1074/jbc.274.10.6043; Sugatani J, 2001, HEPATOLOGY, V33, P1232, DOI 10.1053/jhep.2001.24172; Tyndale R, 1999, NICOTINE TOB RES, V1, P63; Tzameli I, 2000, MOL CELL BIOL, V20, P2951, DOI 10.1128/MCB.20.9.2951-2958.2000; Tzameli I, 2001, TRENDS ENDOCRIN MET, V12, P7, DOI 10.1016/S1043-2760(00)00332-5; Ueda A, 2002, MOL PHARMACOL, V61, P1, DOI 10.1124/mol.61.1.1; WATKINS PB, 1995, HEPATOLOGY, V22, P994, DOI 10.1002/hep.1840220342; Watkins RE, 2001, SCIENCE, V292, P2329, DOI 10.1126/science.1060762; Wei P., 2002, Pharmacogenomics Journal, V2, P117, DOI 10.1038/sj.tpj.6500087; Westlind A, 1999, BIOCHEM BIOPH RES CO, V259, P201, DOI 10.1006/bbrc.1999.0752; Xie HG, 2001, ANNU REV PHARMACOL, V41, P815, DOI 10.1146/annurev.pharmtox.41.1.815; Xie W, 2000, GENE DEV, V14, P3014, DOI 10.1101/gad.846800; Xie W, 2001, P NATL ACAD SCI USA, V98, P3375, DOI 10.1073/pnas.051014398	41	341	358	0	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 9	2003	278	19					17277	17283		10.1074/jbc.M300138200	http://dx.doi.org/10.1074/jbc.M300138200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677QG	12611900	hybrid			2022-12-25	WOS:000182818600111
J	Pauwels, F; Vergauwen, B; Vanrobaeys, F; Devreese, B; Van Beeumen, JJ				Pauwels, F; Vergauwen, B; Vanrobaeys, F; Devreese, B; Van Beeumen, JJ			Purification and characterization of a chimeric enzyme from Haemophilus influenzae Rd that exhibits glutathione-dependent peroxidase activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; HYDROGEN-PEROXIDE; OXIDATIVE STRESS; THIOREDOXIN; IDENTIFICATION; REDUCTASE; PROTEINS; PEROXIREDOXINS; GLUTAREDOXIN; ANTIOXIDANT	While belonging to the same family of antioxidant enzymes, members of the peroxiredoxins do not necessarily employ one and the same method for their reduction. Most representatives become reduced with the aid of thioredoxin, whereas some members use AhpF, tryparedoxin, or cyclophilin A. Recent research on a new peroxiredoxin isoform (type C) from Populus trichocarpa has shown that these particular types may also use glutaredoxin instead of thioredoxin. This finding is supported by the occurrence of chimeric proteins composed of a peroxiredoxin and glutaredoxin region. A gene encoding such a fusion protein is enclosed in the Haemophilus influenzae Rd genome. We expressed the H. influenzae protein, denoted here as PGdx, in Escherichia coli and purified the recombinant enzyme. In vitro assays demonstrate that PGdx, in the presence of dithiothreitol or glutathione, is able to protect super-coiled DNA against the metal ion-catalyzed oxidation-system. Enzymatic assays did, indeed, characterize PGdx as a peroxidase, requiring the glutathione redox cycle for the reduction of hydrogen peroxide (k(cat)/K-m 5.01 x 10(6) s(-1) M-1) as well as the small organic hydroperoxide tert-butylhydroperoxide (k(cat)/K-m 5.67 x 10(4) s(-1) M-1). Enzymatic activity as function of the glutathione concentration deviated from normal Michaelis-Menten kinetics, giving a sigmoidal pattern with an apparent Hill coefficient of 2.9. Besides the formation of a disulfide-linked PGdx dimer, it was also shown by mass spectrometric analysis that cysteine 49, which is equivalent to the active site cysteine of the peroxiredoxins, undergoes glutathionylation during purification under nonreducing conditions. Based on these results, we propose a model for the catalytic mechanism.	Univ Ghent, Lab Prot Biochem & Prot Engn, B-9000 Ghent, Belgium	Ghent University	Van Beeumen, JJ (corresponding author), Univ Ghent, Lab Prot Biochem & Prot Engn, KL Ledeganckstr 35, B-9000 Ghent, Belgium.	Jozef.vanbeeumen@rug.ac.be	Devreese, Bart/B-2011-2009; Devreese, Bart/K-2841-2019	Devreese, Bart/0000-0002-9764-2581; Devreese, Bart/0000-0002-9764-2581				ASLUND F, 1994, P NATL ACAD SCI USA, V91, P9813, DOI 10.1073/pnas.91.21.9813; BARCAK GJ, 1991, METHOD ENZYMOL, V204, P321; Barrett WC, 1999, BIOCHEMISTRY-US, V38, P6699, DOI 10.1021/bi990240v; BIRNBOIM HC, 1979, NUCLEIC ACIDS RES, V7, P1513; BISHAI WR, 1994, INFECT IMMUN, V62, P4855, DOI 10.1128/IAI.62.11.4855-4860.1994; BISHAI WR, 1994, J BACTERIOL, V176, P2914, DOI 10.1128/JB.176.10.2914-2921.1994; Calzi ML, 1997, BIOCHEMISTRY-US, V36, P13357, DOI 10.1021/bi9713660; CHAE HZ, 1994, J BIOL CHEM, V269, P27670; Copeland R. A., 2000, ENZYMES PRACTICAL IN, P367; Craig JE, 2001, FEMS MICROBIOL LETT, V203, P55, DOI 10.1016/S0378-1097(01)00328-7; FARR SB, 1991, MICROBIOL REV, V55, P561, DOI 10.1128/MMBR.55.4.561-585.1991; FLEISCHMANN RD, 1995, SCIENCE, V269, P496, DOI 10.1126/science.7542800; Fratelli M, 2002, P NATL ACAD SCI USA, V99, P3505, DOI 10.1073/pnas.052592699; Goyer A, 1999, FEBS LETT, V444, P165, DOI 10.1016/S0014-5793(99)00051-4; GRAVINA SA, 1993, BIOCHEMISTRY-US, V32, P3368, DOI 10.1021/bi00064a021; Halliwell B, 1989, FREE RADICALS BIOL M, VUK; Harris JR, 2001, BBA-PROTEIN STRUCT M, V1547, P221, DOI 10.1016/S0167-4838(01)00184-4; HOLLANDER R, 1976, A VAN LEEUW J MICROB, V42, P429, DOI 10.1007/BF00410174; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lee J, 1999, J BIOL CHEM, V274, P4537, DOI 10.1074/jbc.274.8.4537; Lee SP, 2001, J BIOL CHEM, V276, P29826, DOI 10.1074/jbc.M101822200; Lind C, 2002, ARCH BIOCHEM BIOPHYS, V406, P229, DOI 10.1016/S0003-9861(02)00468-X; Nogoceke E, 1997, BIOL CHEM, V378, P827, DOI 10.1515/bchm.1997.378.8.827; Pericone CD, 2000, INFECT IMMUN, V68, P3990, DOI 10.1128/IAI.68.7.3990-3997.2000; Prinz WA, 1997, J BIOL CHEM, V272, P15661, DOI 10.1074/jbc.272.25.15661; Rhee SG, 1999, BIOFACTORS, V10, P207, DOI 10.1002/biof.5520100218; Ritz D, 2001, ANNU REV MICROBIOL, V55, P21, DOI 10.1146/annurev.micro.55.1.21; Rouhier N, 2002, J BIOL CHEM, V277, P13609, DOI 10.1074/jbc.M111489200; Rouhier N, 2001, PLANT PHYSIOL, V127, P1299, DOI 10.1104/pp.010586; Seaver LC, 2001, J BACTERIOL, V183, P7173, DOI 10.1128/JB.183.24.7173-7181.2001; SEGEL IH, 1975, ENZYME KINETICS, P347; Shenton D, 2002, J BIOL CHEM, V277, P16853, DOI 10.1074/jbc.M200559200; Sullivan DM, 2000, BIOCHEMISTRY-US, V39, P11121, DOI 10.1021/bi0007674; THOMAS JA, 1995, ARCH BIOCHEM BIOPHYS, V319, P1, DOI 10.1006/abbi.1995.1261; Vergauwen B, 2003, J BACTERIOL, V185, P1572, DOI 10.1128/JB.185.5.1572-1581.2003; Vergauwen B, 2001, J BIOL CHEM, V276, P20890, DOI 10.1074/jbc.M102026200; Wood ZA, 2002, BIOCHEMISTRY-US, V41, P5493, DOI 10.1021/bi012173m	37	47	51	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 9	2003	278	19					16658	16666		10.1074/jbc.M300157200	http://dx.doi.org/10.1074/jbc.M300157200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677QG	12606554	hybrid			2022-12-25	WOS:000182818600029
J	Seeger, M; Hartmann-Petersen, R; Wilkinson, CRM; Wallace, M; Samejima, I; Taylor, MS; Gordon, C				Seeger, M; Hartmann-Petersen, R; Wilkinson, CRM; Wallace, M; Samejima, I; Taylor, MS; Gordon, C			Interaction of the anaphase-promoting complex/cyclosome and proteasome protein complexes with multiubiquitin chain-binding proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NON-ATPASE SUBUNIT; FISSION YEAST; 26S PROTEASOME; SCHIZOSACCHAROMYCES-POMBE; SACCHAROMYCES-CEREVISIAE; REGULATORY COMPLEX; DNA-REPAIR; UBIQUITIN; DEGRADATION; DOMAIN	Fission yeast Rhp23 and Pus1 represent two families of multiubiquitin chain-binding proteins that associate with the proteasome. We show that both proteins bind to different regions of the proteasome subunit Mts4. The binding site for Pus1 was mapped to a cluster of repetitive sequences also found in the proteasome subunit SpRpn2 and the anaphase-promoting complex/cyclosome (APC/C) subunit Cut4. The putative role of Pus1 as a factor involved in allocation of ubiquitinylated substrates for the proteasome is discussed.	Western Gen Hosp, MRC, Human Genet Unit, Edinburgh EH4 2XU, Midlothian, Scotland	University of Edinburgh	Gordon, C (corresponding author), Western Gen Hosp, MRC, Human Genet Unit, Crewe Rd, Edinburgh EH4 2XU, Midlothian, Scotland.	Colin.Gordon@hgu.mrc.ac.uk	Hartmann-Petersen, Rasmus/K-4434-2014; Taylor, Martin S/C-3825-2009	Hartmann-Petersen, Rasmus/0000-0002-4155-7791; Taylor, Martin S/0000-0001-7656-330X				Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Dai RM, 2001, NAT CELL BIOL, V3, P740, DOI 10.1038/35087056; DEVERAUX Q, 1994, J BIOL CHEM, V269, P7059; Elsasser S, 2002, NAT CELL BIOL, V4, P725, DOI 10.1038/ncb845; Ferrell K, 2000, TRENDS BIOCHEM SCI, V25, P83, DOI 10.1016/S0968-0004(99)01529-7; Fu HY, 1998, J BIOL CHEM, V273, P1970, DOI 10.1074/jbc.273.4.1970; Funakoshi M, 2002, P NATL ACAD SCI USA, V99, P745, DOI 10.1073/pnas.012585199; Glickman MH, 1998, CELL, V94, P615, DOI 10.1016/S0092-8674(00)81603-7; GORDON C, 1993, NATURE, V366, P355, DOI 10.1038/366355a0; Groll M, 1997, NATURE, V386, P463, DOI 10.1038/386463a0; HARACSKA L, 1995, EUR J BIOCHEM, V231, P720, DOI 10.1111/j.1432-1033.1995.0720d.x; Haracska L, 1997, FEBS LETT, V412, P331, DOI 10.1016/S0014-5793(97)00808-9; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; HIRANO T, 1986, EMBO J, V5, P2973, DOI 10.1002/j.1460-2075.1986.tb04594.x; Hiyama H, 1999, J BIOL CHEM, V274, P28019, DOI 10.1074/jbc.274.39.28019; Hofmann K, 2001, TRENDS BIOCHEM SCI, V26, P347, DOI 10.1016/S0968-0004(01)01835-7; Kleijnen MF, 2000, MOL CELL, V6, P409, DOI 10.1016/S1097-2765(00)00040-X; Lam YA, 2002, NATURE, V416, P763, DOI 10.1038/416763a; Lambertson D, 1999, GENETICS, V153, P69; Leggett DS, 2002, MOL CELL, V10, P495, DOI 10.1016/S1097-2765(02)00638-X; Luders J, 2000, J BIOL CHEM, V275, P4613, DOI 10.1074/jbc.275.7.4613; Lupas A, 1997, TRENDS BIOCHEM SCI, V22, P195, DOI 10.1016/S0968-0004(97)01058-X; MAUNDRELL K, 1990, J BIOL CHEM, V265, P10857; MORENO S, 1991, METHOD ENZYMOL, V194, P795; Ortolan TG, 2000, NAT CELL BIOL, V2, P601, DOI 10.1038/35023547; Page AM, 1999, ANNU REV BIOCHEM, V68, P583, DOI 10.1146/annurev.biochem.68.1.583; Rao H, 2002, J BIOL CHEM, V277, P11691, DOI 10.1074/jbc.M200245200; Saeki Y, 2002, BIOCHEM BIOPH RES CO, V296, P813, DOI 10.1016/S0006-291X(02)02002-8; Saeki Y, 2002, BIOCHEM BIOPH RES CO, V293, P986, DOI 10.1016/S0006-291X(02)00340-6; Schauber C, 1998, NATURE, V391, P715, DOI 10.1038/35661; Tongaonkar P, 2000, MOL CELL BIOL, V20, P4691, DOI 10.1128/MCB.20.13.4691-4698.2000; vanNocker S, 1996, MOL CELL BIOL, V16, P6020; Voges D, 1999, ANNU REV BIOCHEM, V68, P1015, DOI 10.1146/annurev.biochem.68.1.1015; Walters KJ, 2002, BIOCHEMISTRY-US, V41, P1767, DOI 10.1021/bi011892y; Weissman AM, 2001, NAT REV MOL CELL BIO, V2, P169, DOI 10.1038/35056563; Wilkinson CRM, 2001, NAT CELL BIOL, V3, P939, DOI 10.1038/ncb1001-939; Wilkinson CRM, 1997, J BIOL CHEM, V272, P25768, DOI 10.1074/jbc.272.41.25768; Wilkinson CRM, 2000, J BIOL CHEM, V275, P15182, DOI 10.1074/jbc.275.20.15182; Xie YM, 2000, P NATL ACAD SCI USA, V97, P2497, DOI 10.1073/pnas.060025497; You JX, 2001, J BIOL CHEM, V276, P19871, DOI 10.1074/jbc.M100034200; Young P, 1998, J BIOL CHEM, V273, P5461, DOI 10.1074/jbc.273.10.5461	41	54	54	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 9	2003	278	19					16791	16796		10.1074/jbc.M208281200	http://dx.doi.org/10.1074/jbc.M208281200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677QG	12615927	hybrid			2022-12-25	WOS:000182818600047
J	Yang, JH; Hu, GH; Wang, SW; Li, YC; Martin, R; Li, K; Yao, ZB				Yang, JH; Hu, GH; Wang, SW; Li, YC; Martin, R; Li, K; Yao, ZB			Calcineurin/nuclear factors of activated T cells (NFAT)-activating and immunoreceptor tyrosine-based activation motif (ITAM)-containing protein (CNAIP), a novel ITAM-containing protein that activates the calcineurin/NFAT-signaling pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NATURAL-KILLER-CELLS; DEPENDENT PATHWAY; GENE-EXPRESSION; NUCLEAR FACTORS; DEFICIENT MICE; NFAT; ANTIGEN; TRANSCRIPTION; PREDICTION; KINASE	We report in this study the identification and characterization of a novel protein that we designated as calcineurin/NFAT- activating and immunoreceptor tyrosine-based activation motif (ITAM)-containing protein (CNAIP). The predicted 270-amino acid sequence contains an N-terminal signal peptide, an immunoglobin domain in the extracellular region, a transmembrane domain and an ITAM in the cytoplasmic tail. Quantitative reverse transcription-PCR showed that CNAIP was preferentially expressed in neutrophils, monocytes, mast cells, and other immune-related cells. Co-transfection of CNAIP expression constructs with luciferase reporter plasmids in HMC-1 cells resulted in activation of interleukin-13 and tumor necrosis factor-alpha promoters, which was mediated through the calcineurin/NFAT-signaling pathway. Mutation of either or both tyrosines in the ITAM abolished transcriptional activation induced by CNAIP, indicating that the ITAM is indispensable for CNAIP function in activating cytokine gene promoters. Thus, it is concluded that CNAIP is a novel ITAM-containing protein that activates the calcineurin/NFAT-signaling pathway and the downstream cytokine gene promoters.	Tanox Biosyst Inc, Dept Exploratory Biol, Houston, TX 77025 USA		Li, K (corresponding author), Tanox Biosyst Inc, Dept Exploratory Biol, Houston, TX 77025 USA.	kli@tanox.com; byao@tanox.com						Ali H, 2000, J IMMUNOL, V165, P7215, DOI 10.4049/jimmunol.165.12.7215; ARAMBURU J, 1995, J EXP MED, V182, P801, DOI 10.1084/jem.182.3.801; Berland R, 2000, CURR TOP MICROBIOL, V252, P131; Bouchon A, 2000, J IMMUNOL, V164, P4991, DOI 10.4049/jimmunol.164.10.4991; Bouchon A, 2001, NATURE, V410, P1103, DOI 10.1038/35074114; Bueno OF, 2002, P NATL ACAD SCI USA, V99, P9398, DOI 10.1073/pnas.152665399; CAMBIER JC, 1995, J IMMUNOL, V155, P3281; Chan AC, 1996, CURR OPIN IMMUNOL, V8, P394, DOI 10.1016/S0952-7915(96)80130-0; Crabtree GR, 1999, CELL, V96, P611, DOI 10.1016/S0092-8674(00)80571-1; Crabtree GR, 2002, CELL, V109, pS67, DOI 10.1016/S0092-8674(02)00699-2; Daeron M, 1997, ANNU REV IMMUNOL, V15, P203, DOI 10.1146/annurev.immunol.15.1.203; Eddy SR, 1998, BIOINFORMATICS, V14, P755, DOI 10.1093/bioinformatics/14.9.755; Falquet L, 2002, NUCLEIC ACIDS RES, V30, P235, DOI 10.1093/nar/30.1.235; Feske S, 2001, NAT IMMUNOL, V2, P316, DOI 10.1038/86318; Fischer D, 1999, PROTEINS, P209; Furuke K, 1999, J IMMUNOL, V162, P1988; Hirokawa T, 1998, BIOINFORMATICS, V14, P378, DOI 10.1093/bioinformatics/14.4.378; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Hodge MR, 1996, IMMUNITY, V4, P397, DOI 10.1016/S1074-7613(00)80253-8; HUTCHINSON LE, 1995, J BIOL CHEM, V270, P16333, DOI 10.1074/jbc.270.27.16333; Isakov N, 1997, J LEUKOCYTE BIOL, V61, P6, DOI 10.1002/jlb.61.1.6; Isakov N, 1997, IMMUNOL RES, V16, P85, DOI 10.1007/BF02786325; JOHNSON SA, 1995, J IMMUNOL, V155, P4596; Kelley LA, 2000, J MOL BIOL, V299, P499, DOI 10.1006/jmbi.2000.3741; Khan WN, 2001, IMMUNOL RES, V23, P147, DOI 10.1385/IR:23:2-3:147; Kiani A, 2000, IMMUNITY, V12, P359, DOI 10.1016/S1074-7613(00)80188-0; Kiani A, 2001, BLOOD, V98, P1480, DOI 10.1182/blood.V98.5.1480; Lanier LL, 2001, NAT IMMUNOL, V2, P23, DOI 10.1038/83130; Love PE, 2000, IMMUNITY, V12, P591, DOI 10.1016/S1074-7613(00)80210-1; Luo C, 1996, MOL CELL BIOL, V16, P3955; Macian F, 2000, EMBO J, V19, P4783, DOI 10.1093/emboj/19.17.4783; Marone G, 1997, INT ARCH ALLERGY IMM, V114, P207, DOI 10.1159/000237670; Masuda ES, 1998, CELL SIGNAL, V10, P599, DOI 10.1016/S0898-6568(98)00019-9; Moller S, 2001, BIOINFORMATICS, V17, P646, DOI 10.1093/bioinformatics/17.7.646; Nielsen H, 1999, PROTEIN ENG, V12, P3, DOI 10.1093/protein/12.1.3; Palanki MSS, 2002, CURR MED CHEM, V9, P219, DOI 10.2174/0929867023371265; Peng SL, 2001, IMMUNITY, V14, P13, DOI 10.1016/S1074-7613(01)00085-1; Perkins D, 1996, J IMMUNOL, V156, P4154; Qian DP, 1996, J EXP MED, V183, P611, DOI 10.1084/jem.183.2.611; Rao A, 1997, ANNU REV IMMUNOL, V15, P707, DOI 10.1146/annurev.immunol.15.1.707; Stranick KS, 1997, J BIOL CHEM, V272, P16453, DOI 10.1074/jbc.272.26.16453; TING AT, 1991, J IMMUNOL, V147, P3122	42	13	18	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 9	2003	278	19					16797	16801		10.1074/jbc.M211060200	http://dx.doi.org/10.1074/jbc.M211060200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677QG	12615919	hybrid			2022-12-25	WOS:000182818600048
J	Raasi, S; Pickart, CM				Raasi, S; Pickart, CM			Rad23 ubiquitin-associated domains (UBA) inhibit 26 S proteasome-catalyzed proteolysis by sequestering lysine 48-linked polyubiquitin chains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE EXCISION-REPAIR; PROTEIN-PROTEIN INTERACTIONS; DAMAGE-INDUCIBLE PROTEINS; DNA-REPAIR; SACCHAROMYCES-CEREVISIAE; MULTIUBIQUITIN-CHAIN; DEGRADATION SIGNAL; BINDING PROTEIN; YEAST; ENZYME	Most substrates of the 26 S proteasome are recognized only following conjugation to a Lys(48)-linked polyubiquitin chain. Rad(23) is one member of a family of proteins that possesses an N-terminal ubiquitin-like domain (UbL) and a C-terminal ubiquitin-associated domain(s) (UBA). Recent studies have shown that LTbLs interact with 26 S proteasomes, whereas UBAs bind polyubiquitin chains. These biochemical properties suggest that UbL-UBA proteins may shuttle polyubiquitinated substrates to proteasomes. Here we show that contrary to prediction from this model, the effect of human Rad23A on the degradation of polyubiquitinated substrates catalyzed by purified proteasomes is exclusively inhibitory. Strong inhibition is dependent on the presence of both UBAs, independent of the UbL, and can be explained by competition between the UBA domains and the proteasome for binding to substrate-linked polyubiquitin chains. The UBA domains bind Lys(48)-linked polyubiquitin chains in strong preference to Lys(63) or Lys(29)-linked chains, leading to selective inhibition of the assembly and disassembly of Lys(48)-linked chains. These results place constraints on the mechanism(s) by which UbL-UBA proteins promote proteasome-catalyzed proteolysis and reveal new properties of UBA domains.	Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Dept Biochem & Mol Biol, Baltimore, MD 21205 USA	Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health	Pickart, CM (corresponding author), Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Dept Biochem & Mol Biol, 615 N Wolfe St, Baltimore, MD 21205 USA.				NIDDK NIH HHS [DK46984] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK046984] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Amerik AY, 1997, EMBO J, V16, P4826; Baumeister W, 1998, CELL, V92, P367, DOI 10.1016/S0092-8674(00)80929-0; Beal R, 1996, P NATL ACAD SCI USA, V93, P861, DOI 10.1073/pnas.93.2.861; Beal RE, 1998, BIOCHEMISTRY-US, V37, P2925, DOI 10.1021/bi972514p; Bertolaet BL, 2001, NAT STRUCT BIOL, V8, P417, DOI 10.1038/87575; Bertolaet BL, 2001, J MOL BIOL, V313, P955, DOI 10.1006/jmbi.2001.5105; Biggins S, 1996, J CELL BIOL, V133, P1331, DOI 10.1083/jcb.133.6.1331; CHAU V, 1989, SCIENCE, V243, P1576, DOI 10.1126/science.2538923; Chen L, 2001, EMBO REP, V2, P933, DOI 10.1093/embo-reports/kve203; Chen L, 2002, MOL CELL BIOL, V22, P4902, DOI 10.1128/MCB.22.13.4902-4913.2002; Clarke DJ, 2001, MOL CELL BIOL, V21, P1997, DOI 10.1128/MCB.21.6.1997-2007.2001; Deng L, 2000, CELL, V103, P351, DOI 10.1016/S0092-8674(00)00126-4; Dieckmann T, 1998, NAT STRUCT BIOL, V5, P1042, DOI 10.1038/4220; Elder RT, 2002, NUCLEIC ACIDS RES, V30, P581, DOI 10.1093/nar/30.2.581; Elsasser S, 2002, NAT CELL BIOL, V4, P725, DOI 10.1038/ncb845; FINLEY D, 1994, MOL CELL BIOL, V14, P5501, DOI 10.1128/MCB.14.8.5501; Funakoshi M, 2002, P NATL ACAD SCI USA, V99, P745, DOI 10.1073/pnas.012585199; Gillette TG, 2001, GENE DEV, V15, P1528, DOI 10.1101/gad.869601; HAAS AL, 1985, J BIOL CHEM, V260, P2464; Haldeman MT, 1997, BIOCHEMISTRY-US, V36, P10526, DOI 10.1021/bi970750u; HERSHKO A, 1983, J BIOL CHEM, V258, P8206; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; Hicke L, 2001, NAT REV MOL CELL BIO, V2, P195, DOI 10.1038/35056583; Hiyama H, 1999, J BIOL CHEM, V274, P28019, DOI 10.1074/jbc.274.39.28019; Hoege C, 2002, NATURE, V419, P135, DOI 10.1038/nature00991; Hofmann K, 1996, TRENDS BIOCHEM SCI, V21, P172, DOI 10.1016/0968-0004(96)30015-7; Hofmann RM, 2001, J BIOL CHEM, V276, P27936, DOI 10.1074/jbc.M103378200; JOHNSON ES, 1995, J BIOL CHEM, V270, P17442, DOI 10.1074/jbc.270.29.17442; Koegl M, 1999, CELL, V96, P635, DOI 10.1016/S0092-8674(00)80574-7; Lam YA, 2002, NATURE, V416, P763, DOI 10.1038/416763a; Lambertson D, 1999, GENETICS, V153, P69; Lommel L, 2002, CURR GENET, V42, P9, DOI 10.1007/s00294-002-0332-9; Lommel L, 2000, NUCLEIC ACIDS RES, V28, P4839, DOI 10.1093/nar/28.24.4839; MASUTANI C, 1994, EMBO J, V13, P1831, DOI 10.1002/j.1460-2075.1994.tb06452.x; Miao F, 2000, J BIOL CHEM, V275, P28433, DOI 10.1074/jbc.M001064200; Mueller TD, 2002, J MOL BIOL, V319, P1243, DOI 10.1016/S0022-2836(02)00302-9; Ng JMY, 2002, MOL CELL BIOL, V22, P1233, DOI 10.1128/MCB.22.4.1233-1245.2002; Ortolan TG, 2000, NAT CELL BIOL, V2, P601, DOI 10.1038/35023547; Pickart CM, 2000, TRENDS BIOCHEM SCI, V25, P544, DOI 10.1016/S0968-0004(00)01681-9; Piotrowski J, 1997, J BIOL CHEM, V272, P23712, DOI 10.1074/jbc.272.38.23712; Rao H, 2002, J BIOL CHEM, V277, P11691, DOI 10.1074/jbc.M200245200; Russell SJ, 1999, MOL CELL, V3, P687, DOI 10.1016/S1097-2765(01)80001-0; Saeki Y, 2002, BIOCHEM BIOPH RES CO, V293, P986, DOI 10.1016/S0006-291X(02)00340-6; Schauber C, 1998, NATURE, V391, P715, DOI 10.1038/35661; Sloper-Mould KE, 2001, J BIOL CHEM, V276, P30483, DOI 10.1074/jbc.M103248200; SPENCE J, 1995, MOL CELL BIOL, V15, P1265; Spence J, 2000, CELL, V102, P67, DOI 10.1016/S0092-8674(00)00011-8; Suzuki T, 2001, J BIOL CHEM, V276, P21601, DOI 10.1074/jbc.M100826200; Thrower JS, 2000, EMBO J, V19, P94, DOI 10.1093/emboj/19.1.94; vanNocker S, 1996, MOL CELL BIOL, V16, P6020; Varadan R, 2002, J MOL BIOL, V324, P637, DOI 10.1016/S0022-2836(02)01198-1; Varshavsky A, 2000, BIOL CHEM, V381, P779, DOI 10.1515/BC.2000.101; Verma R, 2002, SCIENCE, V298, P611, DOI 10.1126/science.1075898; Verma R, 2000, MOL BIOL CELL, V11, P3425, DOI 10.1091/mbc.11.10.3425; Walters KJ, 2002, BIOCHEMISTRY-US, V41, P1767, DOI 10.1021/bi011892y; WATKINS JF, 1993, MOL CELL BIOL, V13, P7757, DOI 10.1128/MCB.13.12.7757; Wilkinson CRM, 2001, NAT CELL BIOL, V3, P939, DOI 10.1038/ncb1001-939; WILKINSON KD, 1995, BIOCHEMISTRY-US, V34, P14535, DOI 10.1021/bi00044a032; Yao TT, 2002, NATURE, V419, P403, DOI 10.1038/nature01071; You JX, 2001, J BIOL CHEM, V276, P19871, DOI 10.1074/jbc.M100034200; You JX, 1999, BIOTECHNIQUES, V27, P950, DOI 10.2144/99275st01	61	193	200	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 14	2003	278	11					8951	8959		10.1074/jbc.M212841200	http://dx.doi.org/10.1074/jbc.M212841200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	654YF	12643283	hybrid			2022-12-25	WOS:000181524000013
J	Benn, DE; Croxson, MS; Tucker, K; Bambach, CP; Richardson, AL; Delbridge, L; Pullan, PT; Hammond, J; Marsh, DJ; Robinson, BG				Benn, DE; Croxson, MS; Tucker, K; Bambach, CP; Richardson, AL; Delbridge, L; Pullan, PT; Hammond, J; Marsh, DJ; Robinson, BG			Novel succinate dehydrogenase subunit B (SDHB) mutations in familial phaeochromocytomas and paragangliomas, but an absence of somatic SDHB mutations in sporadic phaeochromocytomas	ONCOGENE			English	Article						phaeochromocytoma; paraganglioma; SDHB; SDHD; leaky splicing	GERM-LINE MUTATIONS; COMPLEX-II GENE; RET; VHL	Phaeochromocytomas arising in adrenal or extra-adrenal sites and paragangliomas of the head and neck, in particular of the carotid bodies, occur sporadically and also in a familial setting. In addition to mutations in RET and VHL in familial disease, germline mutations in SDHD and SDHB genes that encode subunits of mitochondrial complex 11 have also been associated with the development of familial phaeochromocytomas. To further investigate the role of SDHD and SDHB in the development of these tumours we determined the occurrence of germline SDHD and SDHB mutations in four patients with a family history of phaeochromocytoma with associated head and neck paraganglioma, one patient with a family history of phaeochromocytoma only and two patients with apparently sporadic extra-adrenal phaeochromocytoma, one of whom had early onset disease. Secondly, we investigated whether somatic SDHB mutations correlated with loss of heterozygosity at 1p36 in a subgroup of 11 sporadic and three MEN 2-associated RET-mutation-positive phaeochromocytomas. Novel SDHB mutations were identified in the probands from four families and two apparently sporadic cases (six of seven probands studied), including two missense mutations, a single nonsense and frameshift mutation, as well as two splice site mutations, one of which was shown to have partial penetrance resulting in 'leaky' splicing Further, five intronic polymorphisms in SDHB were found. No SDHD mutations were identified. In addition, no somatic SDHB mutations were found in the remaining allele of the 11 sporadic adrenal phaeochromocytomas with allelic loss at 1p36 or the three MEN 2-associated RET-mutation-positive phaeochromocytomas. Therefore, we conclude that SDHB has a major role in the pathogenesis of familial phaeochromocytomas, but the possible role of SDHB in sporadic tumours showing allelic loss at 1p36 has yet to be ascertained.	Royal N Shore Hosp, Kolling Inst Med Res, St Leonards, NSW 2065, Australia; Univ Sydney, Dept Mol Med, Sydney, NSW 2006, Australia; Auckland Hosp, Dept Endocrinol, Auckland, New Zealand; Prince Wales Hosp, Hereditary Canc Clin, Sydney, NSW 2031, Australia; Univ New S Wales, Sch Med, Sydney, NSW 2031, Australia; Royal N Shore Hosp, Dept Surg, St Leonards, NSW 2065, Australia; Univ Sydney, Dept Surg, Sydney, NSW 2006, Australia; Sir Charles Gairdner Hosp, Dept Endocrinol & Diabet, Nedlands, WA 6009, Australia; Univ WA, Dept Med, Nedlands, WA 6009, Australia; Melbourne Hypertens Clin, Melbourne, Vic 3002, Australia; Univ Sydney, Dept Med, Sydney, NSW 2006, Australia	Royal North Shore Hospital; University of Sydney; Kolling Institute of Medical Research; University of Sydney; Auckland City Hospital; University of New South Wales Sydney; Royal North Shore Hospital; University of Sydney; University of Western Australia; University of Western Australia; University of Sydney	Marsh, DJ (corresponding author), Royal N Shore Hosp, Kolling Inst Med Res, St Leonards, NSW 2065, Australia.	Debbie_Marsh@med.usyd.edu.au; bgr@med.usyd.edu.au	Marsh, Deborah J/I-1491-2014	Marsh, Deborah J/0000-0001-5899-4931; Delbridge, leigh/0000-0001-8281-8831				Astuti, 2002, AM J HUM GENET, V70, P565; Astuti D, 2001, LANCET, V357, P1181, DOI 10.1016/S0140-6736(00)04378-6; Astuti D, 2001, AM J HUM GENET, V69, P49, DOI 10.1086/321282; Baysal BE, 2000, SCIENCE, V287, P848, DOI 10.1126/science.287.5454.848; Baysal BE, 2002, J MED GENET, V39, P178, DOI 10.1136/jmg.39.3.178; Baysal BE, 2001, OTOLARYNG CLIN N AM, V34, P863, DOI 10.1016/S0030-6665(05)70352-2; Baysal BE, 2001, J MOL MED, V79, P495, DOI 10.1007/s001090100267; Benn DE, 2000, CANCER RES, V60, P7048; BENN DE, 2002, CURR OPIN ENDOCRINOL, V9, P79; Caron H, 2001, GENE CHROMOSOME CANC, V30, P168, DOI 10.1002/1098-2264(200102)30:2<168::AID-GCC1072>3.0.CO;2-E; Elder EE, 2002, WORLD J SURG, V26, P965, DOI 10.1007/s00268-002-6626-8; ENG C, 1995, J MED GENET, V32, P934, DOI 10.1136/jmg.32.12.934; Gimenez-Roqueplo AP, 2002, J CLIN ENDOCR METAB, V87, P4771, DOI 10.1210/jc.2002-020525; Gimm O, 2000, CANCER RES, V60, P6822; Hofstra RMW, 1996, J CLIN ENDOCR METAB, V81, P2881, DOI 10.1210/jc.81.8.2881; KNUDSON AG, 1993, NAT GENET, V5, P103, DOI 10.1038/ng1093-103; Koch CA, 2002, ONCOGENE, V21, P479, DOI 10.1038/sj.onc.1205133; Lack EE, 1997, ATLAS TUMOR PATHOL, V3, P223; LECKSCHAT S, 1993, SOMAT CELL MOLEC GEN, V19, P505, DOI 10.1007/BF01233256; LEE SP, 1977, PATHOLOGY, V9, P173, DOI 10.3109/00313027709085255; Neumann HPH, 2002, NEW ENGL J MED, V346, P1459, DOI 10.1056/NEJMoa020152; Niemann S, 2000, NAT GENET, V26, P268, DOI 10.1038/81551; Scheffler IE, 1998, PROG NUCLEIC ACID RE, V60, P267, DOI 10.1016/S0079-6603(08)60895-8; SOLCIA E, 2000, WORLD HLTH ORG INT H; Svenson IK, 2001, AM J HUM GENET, V69, P1407, DOI 10.1086/324593; Taschner PEM, 2001, GENE CHROMOSOME CANC, V31, P274, DOI 10.1002/gcc.1144; Williamson C, 1997, J MED GENET, V34, P617, DOI 10.1136/jmg.34.8.617	27	90	94	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 6	2003	22	9					1358	1364		10.1038/sj.onc.1206300	http://dx.doi.org/10.1038/sj.onc.1206300			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	652CA	12618761				2022-12-25	WOS:000181360900010
J	Weinreb, O; Mandel, S; Youdim, MBH				Weinreb, O; Mandel, S; Youdim, MBH			CDNA gene expression profile homology of antioxidants and their antiapoptotic and proapoptotic activities in human neuroblastoma cells	FASEB JOURNAL			English	Article						dopamine; R-apomorphine; melatonin; apoptosis; neurodegenerative diseases	DOPAMINE-INDUCED APOPTOSIS; ACTIVATED PROTEIN-KINASE; ANTI-PARKINSON DRUG; OXIDATIVE STRESS; PC12 CELLS; INDUCED NEUROTOXICITY; NEURONAL CELLS; ASCORBIC-ACID; BCL-2 FAMILY; DNA-DAMAGE	Antioxidants have concentration-dependent neuroprotective and proapoptotic activities in models of Parkinson's disease. The aim of our study was to determine gene-protein pathways of the antioxidants, dopamine (DA), R-apomorphine (R-APO), melatonin, and green tea polyphenol (-)-epigallocatechin-3-gallate (EGCG), in neuroblastoma cells, using a customized cDNA microarray and quantitative reverse transcriptase-polymerase chain reaction gene expression techniques. We demonstrate a concentration-dependent correlation between these compounds and modulation of cell survival/cell death-related gene pathways. High toxic concentration of DA (500 muM), R-APO (50 muM), melatonin (50 muM), and EGCG (50 muM) exhibited a similar profile of proapoptotic gene expression, increasing the level of bax, caspase-6, fas ligand, and the cell-cycle inhibitor gadd45 genes, while decreasing antiapoptotic bcl-2 and bcl-xL. Conversely, the low neuroprotective concentrations (1-10 muM) of these compounds induced an antiapoptotic response. Melatonin displayed an extremely low index of mortality, which may be partially explained by the observation that a high concentration did not significantly affect the expression of mitochondrial Bcl-2 family members, bcl-2 and bax. Protein analysis of Bcl-2, Bax, and activated caspase-3 correlated with the gene expression pattern. Our results provide for the first time new insights into the molecular events involved in the dose-dependent neuroprotective and neurotoxic activities of catechols and indole amine compounds.	Technion Israel Inst Technol, Fac Med, Dept Pharmacol, IL-31096 Haifa, Israel; Technion Israel Inst Technol, Eve Topf & USA Natl Parkinson Fdn, Ctr Excellence Neurodegenerat Dis Res, Fac Med, IL-31096 Haifa, Israel; Technion Israel Inst Technol, Dept Pharmacol, Fac Med, IL-31096 Haifa, Israel; Technion Israel Inst Technol, Rappaport Family Res Inst, Fac Med, IL-31096 Haifa, Israel	Technion Israel Institute of Technology; Rappaport Faculty of Medicine; Technion Israel Institute of Technology; Rappaport Faculty of Medicine; Technion Israel Institute of Technology; Rappaport Faculty of Medicine; Technion Israel Institute of Technology; Rappaport Faculty of Medicine	Youdim, MBH (corresponding author), Technion Israel Inst Technol, Fac Med, Dept Pharmacol, POB 9697, IL-31096 Haifa, Israel.	Youdim@tx.technion.ac.il						Antolin I, 2002, BRAIN RES, V943, P163, DOI 10.1016/S0006-8993(02)02551-9; Baas H, 1998, CLIN NEUROPHARMACOL, V21, P86; Barzilai A, 2001, CELL MOL NEUROBIOL, V21, P215, DOI 10.1023/A:1010991020245; Bernardi P, 2001, TRENDS BIOCHEM SCI, V26, P112, DOI 10.1016/S0968-0004(00)01745-X; Blum D, 2001, PROG NEUROBIOL, V65, P135, DOI 10.1016/S0301-0082(01)00003-X; BURNS RS, 1983, P NATL ACAD SCI-BIOL, V80, P4546, DOI 10.1073/pnas.80.14.4546; Cheng EHYA, 2001, MOL CELL, V8, P705, DOI 10.1016/S1097-2765(01)00320-3; Choi YT, 2001, LIFE SCI, V70, P603, DOI 10.1016/S0024-3205(01)01438-2; Cory S, 2002, NAT REV CANCER, V2, P647, DOI 10.1038/nrc883; DAVIES AM, 1995, TRENDS NEUROSCI, V18, P355, DOI 10.1016/0166-2236(95)93928-Q; El-Bacha RD, 2001, BIOCHEM PHARMACOL, V61, P73, DOI 10.1016/S0006-2952(00)00524-4; Fallon J, 1997, EXP NEUROL, V144, P193, DOI 10.1006/exnr.1997.6416; Gassen M, 1996, EUR J PHARMACOL, V308, P219, DOI 10.1016/0014-2999(96)00291-9; Gassen M, 1998, MOVEMENT DISORD, V13, P242, DOI 10.1002/mds.870130208; GASSEN M, 1998, ANTIOXIDANT CYTOPROT; Gerlach M, 1997, MOVEMENT DISORD, V12, P258; Gitto E, 2001, J PHARM PHARMACOL, V53, P1393, DOI 10.1211/0022357011777747; Gotz M E, 1990, J Neural Transm Suppl, V29, P241; GOTZ ME, 1994, PHARMACOL THERAPEUT, V63, P37, DOI 10.1016/0163-7258(94)90055-8; Grunblatt E, 2001, J NEUROCHEM, V77, P146, DOI 10.1046/j.1471-4159.2001.t01-1-00227.x; Grunblatt E, 2001, J NEUROCHEM, V78, P1, DOI 10.1046/j.1471-4159.2001.00397.x; Grunblatt E, 1999, MOVEMENT DISORD, V14, P612, DOI 10.1002/1531-8257(199907)14:4<612::AID-MDS1010>3.0.CO;2-6; HALLIWELL B, 1992, J NEUROCHEM, V59, P1609, DOI 10.1111/j.1471-4159.1992.tb10990.x; Hattori A, 1998, NEUROREPORT, V9, P2569, DOI 10.1097/00001756-199808030-00026; Jin BK, 1998, NEUROSCI LETT, V245, P61, DOI 10.1016/S0304-3940(98)00170-0; Junn E, 2001, J NEUROCHEM, V78, P374, DOI 10.1046/j.1471-4159.2001.00425.x; Kang CD, 1998, NEUROSCI LETT, V256, P37, DOI 10.1016/S0304-3940(98)00751-4; Kroemer G, 2000, NAT MED, V6, P513, DOI 10.1038/74994; Levites Y, 2002, BIOCHEM PHARMACOL, V63, P21, DOI 10.1016/S0006-2952(01)00813-9; Levites Y, 2002, J BIOL CHEM, V277, P30574, DOI 10.1074/jbc.M202832200; Levites Y, 2001, J NEUROCHEM, V78, P1073, DOI 10.1046/j.1471-4159.2001.00490.x; Lin JK, 2000, J AGR FOOD CHEM, V48, P2736, DOI 10.1021/jf000066d; Linert W, 1996, BBA-MOL BASIS DIS, V1316, P160, DOI 10.1016/0925-4439(96)00020-8; LOU Y, 1998, J BIOL CHEM, V273, P3756; Maruyama W, 2002, J NEURAL TRANSM, V109, P467, DOI 10.1007/s007020200038; Maruyama W, 2001, J NEUROCHEM, V78, P727, DOI 10.1046/j.1471-4159.2001.00448.x; Mayo JC, 1998, J PINEAL RES, V24, P179, DOI 10.1111/j.1600-079X.1998.tb00531.x; Nicholson DW, 1997, TRENDS BIOCHEM SCI, V22, P299, DOI 10.1016/S0968-0004(97)01085-2; Olivier G, 2001, J PINEAL RES, V31, P320, DOI 10.1034/j.1600-079X.2001.310406.x; Reiter RJ, 1999, ANN NY ACAD SCI, V890, P471, DOI 10.1111/j.1749-6632.1999.tb08028.x; Reiter RJ, 2000, J BIOMED SCI, V7, P444, DOI 10.1007/BF02253360; RIEDERER P, 1989, J NEUROCHEM, V52, P515, DOI 10.1111/j.1471-4159.1989.tb09150.x; Sakagami H, 1997, ANTICANCER RES, V17, P221; SANER A, 1971, MOL PHARMACOL, V7, P147; Schmittgen TD, 2000, J BIOCHEM BIOPH METH, V46, P69, DOI 10.1016/S0165-022X(00)00129-9; Schroeter H, 2000, FREE RADICAL BIO MED, V29, P1222, DOI 10.1016/S0891-5849(00)00415-9; Seo JH, 2002, FASEB J, V16, P1826, DOI 10.1096/fj.02-0041fje; Shen YX, 2002, J PINEAL RES, V32, P163, DOI 10.1034/j.1600-079x.2002.1o839.x; Simantov R, 1996, NEUROSCIENCE, V74, P39, DOI 10.1016/0306-4522(96)00102-9; TODD RD, 1992, BIOL PSYCHIAT, V31, P794, DOI 10.1016/0006-3223(92)90311-M; WALKINSHAW G, 1995, J CLIN INVEST, V95, P2458, DOI 10.1172/JCI117946; WALKINSHAW G, 1994, NEUROSCIENCE, V63, P975, DOI 10.1016/0306-4522(94)90566-5; Wolfler A, 2001, FEBS LETT, V502, P127, DOI 10.1016/S0014-5793(01)02680-1; Youdim M B, 1987, Adv Neurol, V45, P127; Youdim MBH, 2000, J NEURAL TRANSM-SUPP, P83; YOUDIM MBH, 2001, DRUGS PREVENT CELL D, V86	56	107	113	0	11	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2003	17	3					935	+		10.1096/fj.02-0712fje	http://dx.doi.org/10.1096/fj.02-0712fje			26	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	661LT	12626434				2022-12-25	WOS:000181892600028
J	Yunta, M; Lazo, PA				Yunta, M; Lazo, PA			Apoptosis protection and survival signal by the CD53 tetraspanin antigen	ONCOGENE			English	Article						CD53; tetraspanin antigen; apoptosis; AKT	B-CELL LYMPHOMA; GENE-EXPRESSION; KAI1/CD82 EXPRESSION; HOMOTYPIC ADHESION; PROTEIN MRP-1/CD9; BREAST-CANCER; GROWTH-FACTOR; MOTILITY; METASTASIS; IDENTIFICATION	The CD53 antigen is a tetraspanin protein of the lymphoid-myeloid lineage, but its implication in biological effects is hardly known. Radioresistant tumor cells express very high levels of this antigen. We have studied the effect of CD53 antigen ligation on the survival response of tumor cells to serum deprivation, a well-known stimulator of cell death that may mimic the tumor environment; for this aim IR938F and Jurkat cells, a Band T-cell lymphoma, were used. Ligation of CD53 triggers a survival response and reduces the number of cells that enter apoptosis. In CD53- stimulated cells there is a significant reduction in caspase activation, measured by caspase processing of poly ADP-ribose polymerase, as well as a reduction in the fragmentation of DNA. CD53-stimulated cells also have an increase in the level of bcl-X-L and a reduction of bax protein, two components of the mitochondrial apoptotic pathway, changing their ratio by 24-fold in the direction of survival. This survival signal appears to be mediated by activation of the AKT, as detected by its phosphorylation in Ser473 upon CD53 ligation. The CD53 antigen interactions might contribute to cell survival in poorly vascularized regions of the tumor mass.	Univ Salamanca, CSIC, Inst Biol Mol & Celular Canc, Ctr Invest Canc, E-37007 Salamanca, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Investigacion del Cancer (CIC); CSIC-USAL - Instituto de Biologia Molecular y Celular del Cancer de Salamanca (IBMCC); University of Salamanca	Lazo, PA (corresponding author), Univ Salamanca, CSIC, Inst Biol Mol & Celular Canc, Ctr Invest Canc, Campus Miguel de Unamuno, E-37007 Salamanca, Spain.		Lazo, Pedro A./M-6435-2014	Lazo, Pedro A./0000-0001-8997-3025; Yunta, Monica/0000-0002-8060-9582				Alizadeh AA, 2000, NATURE, V403, P503, DOI 10.1038/35000501; ANGELISOVA P, 1990, IMMUNOGENETICS, V32, P281, DOI 10.1007/BF00187099; Barcia R, 1996, CELL IMMUNOL, V169, P107, DOI 10.1006/cimm.1996.0097; Berditchevski F, 2001, J CELL SCI, V114, P4143; BOISE LH, 1993, CELL, V74, P597, DOI 10.1016/0092-8674(93)90508-N; BOSCA L, 1994, J EXP MED, V179, P1119, DOI 10.1084/jem.179.4.1119; Boucheix C, 2001, CELL MOL LIFE SCI, V58, P1189, DOI 10.1007/PL00000933; DONG JT, 1995, SCIENCE, V268, P884, DOI 10.1126/science.7754374; Ferrer M, 1998, CLIN EXP IMMUNOL, V113, P346; Frisch SM, 1997, CURR OPIN CELL BIOL, V9, P701, DOI 10.1016/S0955-0674(97)80124-X; Frisch SM, 2001, CURR OPIN CELL BIOL, V13, P555, DOI 10.1016/S0955-0674(00)00251-9; Gottlieb TM, 2002, ONCOGENE, V21, P1299, DOI 10.1038/sj.onc.1205181; Guo XZ, 1996, CANCER RES, V56, P4876; Hemler ME, 2001, J CELL BIOL, V155, P1103, DOI 10.1083/jcb.200108061; Henkel GW, 2002, INT IMMUNOL, V14, P723, DOI 10.1093/intimm/dxf040; Hernandez-Torres J, 2001, J BIOL CHEM, V276, P35405, DOI 10.1074/jbc.M104723200; Herr I, 2001, BLOOD, V98, P2603, DOI 10.1182/blood.V98.9.2603; HIGASHIYAMA M, 1995, CANCER RES, V55, P6040; Higashiyama M, 1997, INT J CANCER, V74, P205, DOI 10.1002/(SICI)1097-0215(19970422)74:2<205::AID-IJC12>3.0.CO;2-C; Huang CI, 1998, AM J PATHOL, V153, P973, DOI 10.1016/S0002-9440(10)65639-8; Igney FH, 2002, NAT REV CANCER, V2, P277, DOI 10.1038/nrc776; IKEYAMA S, 1993, J EXP MED, V177, P1231, DOI 10.1084/jem.177.5.1231; Kennedy SG, 1997, GENE DEV, V11, P701, DOI 10.1101/gad.11.6.701; Lagaudriere-Gesbert C, 1997, CELL IMMUNOL, V182, P105, DOI 10.1006/cimm.1997.1223; Lazo PA, 1997, CELL IMMUNOL, V178, P132, DOI 10.1006/cimm.1997.1139; Levy S, 1998, ANNU REV IMMUNOL, V16, P89, DOI 10.1146/annurev.immunol.16.1.89; Longhurst CM, 2002, J BIOL CHEM, V277, P32445, DOI 10.1074/jbc.M204420200; Maecker HT, 1997, FASEB J, V11, P428, DOI 10.1096/fasebj.11.6.9194523; MASELLISSMITH A, 1990, J IMMUNOL, V144, P1607; MIYAKE M, 1995, CANCER RES, V55, P4127; MIYASHITA T, 1994, ONCOGENE, V9, P1799; Mollinedo F, 1997, CLIN DIAGN LAB IMMUN, V4, P229, DOI 10.1128/CDLI.4.2.229-231.1997; Musashi M, 2000, INT J HEMATOL, V72, P12; Puls KL, 2002, INT IMMUNOL, V14, P249, DOI 10.1093/intimm/14.3.249; RADFORD KJ, 1995, INT J CANCER, V62, P631, DOI 10.1002/ijc.2910620523; Scheid MP, 2001, NAT REV MOL CELL BIO, V2, P760, DOI 10.1038/35096067; Shi YG, 2002, MOL CELL, V9, P459, DOI 10.1016/S1097-2765(02)00482-3; Shibagaki N, 1999, EUR J IMMUNOL, V29, P4081, DOI 10.1002/(SICI)1521-4141(199912)29:12<4081::AID-IMMU4081>3.3.CO;2-9; Stipp CS, 2001, J BIOL CHEM, V276, P40545, DOI 10.1074/jbc.M107338200; Sugiura T, 1999, J CELL BIOL, V146, P1375, DOI 10.1083/jcb.146.6.1375; Testa JE, 1999, CANCER RES, V59, P3812; TRAVIS GH, 1991, NEURON, V6, P61, DOI 10.1016/0896-6273(91)90122-G; Uchida S, 1999, BRIT J CANCER, V79, P1168, DOI 10.1038/sj.bjc.6690186; Van Soest S, 1999, SURV OPHTHALMOL, V43, P321, DOI 10.1016/S0039-6257(98)00046-0; Voehringer DW, 2000, P NATL ACAD SCI USA, V97, P2680, DOI 10.1073/pnas.97.6.2680; Wang YD, 2002, ONCOGENE, V21, P2584, DOI 10.1038/sj.onc.1205355; Yanez-Mo M, 1998, J CELL BIOL, V141, P791, DOI 10.1083/jcb.141.3.791; Yunta M, 2002, EUR J BIOCHEM, V269, P1012, DOI 10.1046/j.0014-2956.2001.02741.x; Zhang XA, 2001, J BIOL CHEM, V276, P25005, DOI 10.1074/jbc.M102156200	49	43	46	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 27	2003	22	8					1219	1224		10.1038/sj.onc.1206183	http://dx.doi.org/10.1038/sj.onc.1206183			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	650EK	12606948				2022-12-25	WOS:000181249700010
J	Collet, JP; Lesty, C; Montalescot, G; Weisel, JW				Collet, JP; Lesty, C; Montalescot, G; Weisel, JW			Dynamic changes of fibrin architecture during fibrin formation and intrinsic fibrinolysis of fibrin-rich clots	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMINOGEN-ACTIVATOR INHIBITOR-1; ACUTE MYOCARDIAL-INFARCTION; CONFOCAL MICROSCOPY; LYSIS; THROMBOLYSIS; RESISTANCE; ELECTRON; DISSOLUTION; TURBIDITY; ABCIXIMAB	Clotting and fibrinolysis are initiated simultaneously in vivo, and fibrinolysis usually occurs without any individualized lysis front ( intrinsic fibrinolysis). We have developed a novel model to assess whether morphological changes resulting from intrinsic fibrinolysis are similar to those previously reported at the lysis front using externally applied lytic agents. Fibrin assembly and fibrinolysis were followed in real- time by confocal microscopy using gold- labeled fibrinogen molecules. An increase in fiber absorbance ( 30%, p < 0.01) and a decrease in fiber diameter ( 60%, p < 0.01) due to the ongoing accumulation and packing of fibrin molecules were the most significant detectable features occurring during fibrin assembly. Similar features with a similar magnitude were observed during fibrin dissolution, but in the reverse order and with a 3- fold increase in duration. Then, lysing fibers were progressively transected laterally, and thinner fibers were cleaved at a 2.5- fold faster rate than thicker fibers ( p < 0.001). Frayed lysing fibers were seen to interact progressively with adjoining fibers ( agglomeration), leading to a 76 and 88% increase in the network pore diameter ( p < 0.05) and fiber diameter ( p < 0.01), respectively. At the maximum decrease in fiber absorbance ( 46%, p < 0.05), the network suddenly collapsed with the release of large fragments that gradually vanished. Morphological changes of fibrin that occur during intrinsic fibrinolysis are similar as those observed next to the lysis front, although they are not restricted spatially to the clot/ surrounding milieu interface but are observed through the entire clot.	CHU Pitie Salpetriere, Inst Cardiol, AP HP, F-75013 Paris, France; CHU Pitie Salpetriere, Hematol Lab, F-75013 Paris, France; Univ Penn, Sch Med, Dept Cell & Dev Biol, Philadelphia, PA 19104 USA	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; UDICE-French Research Universities; Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; UDICE-French Research Universities; Sorbonne Universite; University of Pennsylvania	Collet, JP (corresponding author), CHU Pitie Salpetriere, Inst Cardiol, AP HP, 47 Blvd Hosp, F-75013 Paris, France.							Anand S, 1996, CIRCULATION, V94, P763, DOI 10.1161/01.CIR.94.4.763; BLINC A, 1994, THROMB HAEMOSTASIS, V71, P230; BRAATEN JV, 1993, BLOOD, V81, P1290; BRAATEN JV, 1994, BLOOD, V83, P982; CARR ME, 1995, BLOOD COAGUL FIBRIN, V6, P567, DOI 10.1097/00001721-199509000-00011; CARR ME, 1978, MACROMOLECULES, V11, P46, DOI 10.1021/ma60061a009; Collet JP, 2002, CIRC RES, V90, P428, DOI 10.1161/hh0402.105095; Collet JP, 2001, CIRCULATION, V103, P2328; Collet JP, 2000, ARTERIOSCL THROM VAS, V20, P1354, DOI 10.1161/01.ATV.20.5.1354; Collett JP, 2001, ARTERIOSCL THROM VAS, V21, P142, DOI 10.1161/01.ATV.21.1.142; Crespo J, 1995, SIGNAL PROCESS, V47, P201, DOI 10.1016/0165-1684(95)00108-5; DIAMOND SL, 1993, BIOPHYS J, V65, P2622, DOI 10.1016/S0006-3495(93)81314-6; Diamond SL, 1999, ANNU REV BIOMED ENG, V1, P427, DOI 10.1146/annurev.bioeng.1.1.427; GABRIEL DA, 1992, J BIOL CHEM, V267, P24259; Handt S, 1996, BLOOD, V87, P4204, DOI 10.1182/blood.V87.10.4204.bloodjournal87104204; *ISIS 2 COLL GROUP, 1988, LANCET, V330, P1287; JANG IK, 1989, CIRCULATION, V79, P920, DOI 10.1161/01.CIR.79.4.920; Kolev K, 1997, J BIOL CHEM, V272, P13666, DOI 10.1074/jbc.272.21.13666; KUNITADA S, 1992, BLOOD, V79, P1420; LESTY C, 1986, CYTOMETRY, V7, P117, DOI 10.1002/cyto.990070202; Russ J. C., 2016, IMAGE PROCESSING HDB, V7th; SABOVIC M, 1989, THROMB HAEMOSTASIS, V62, P1083; Sakharov DV, 1996, J BIOL CHEM, V271, P2133, DOI 10.1074/jbc.271.4.2133; SERRA J, 1988, IMAGE ANAL MATH MORP, V2, P110; Sinkovic A, 1998, AM HEART J, V136, P406, DOI 10.1016/S0002-8703(98)70213-3; SUENSON E, 1984, EUR J BIOCHEM, V149, P193; Veklich Y, 1998, BLOOD, V92, P4721, DOI 10.1182/blood.V92.12.4721.424k13_4721_4729; Weisel JW, 1999, THROMB HAEMOSTASIS, V82, P277; WEISEL JW, 1992, BIOPHYS J, V63, P111, DOI 10.1016/S0006-3495(92)81594-1; Zhu YH, 1999, CIRCULATION, V99, P3050, DOI 10.1161/01.CIR.99.23.3050	30	105	107	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 13	2003	278	24					21331	21335		10.1074/jbc.M212734200	http://dx.doi.org/10.1074/jbc.M212734200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	687AT	12642590	hybrid			2022-12-25	WOS:000183354200005
J	Burnay, M; Crambert, G; Kharoubi-Hess, S; Geering, K; Horisberger, JD				Burnay, M; Crambert, G; Kharoubi-Hess, S; Geering, K; Horisberger, JD			Electrogenicity of Na,K- and H,K-ATPase activity and presence of a positively charged amino acid in the fifth transmembrane segment	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GASTRIC H+,K+-ATPASE ACTIVITY; NA,K-ATPASE ALPHA-SUBUNIT; NA+-K+ PUMP; FUNCTIONAL EXPRESSION; BETA-SUBUNIT; SARCOPLASMIC-RETICULUM; SCANNING MUTAGENESIS; PRIMARY SEQUENCE; XENOPUS OOCYTES; CALCIUM-PUMP	The transport activity of the Na, K-ATPase (a 3 Na+ for 2 K+ ion exchange) is electrogenic, whereas the closely related gastric and non-gastric H,K-ATPases perform electroneutral cation exchange. We have studied the role of a highly conserved serine residue in the fifth transmembrane segment of the Na,K-ATPase, which is replaced with a lysine in all known H,K-ATPases. Ouabain-sensitive Rb-86 uptake and K+-activated currents were measured in Xenopus oocytes expressing the Bufo bladder H,K-ATPase or the Bufo Na,K-ATPase in which these residues, Lys(800) and Ser(782), respectively, were mutated. Mutants K800A and K800E of the H,K-ATPase showed K+-stimulated and ouabain-sensitive electrogenic transport. In contrast, when the positive charge was conserved (K800R), no K+-induced outward current could be measured, even though rubidium transport activity was present. Conversely, the S782R mutant of the Na,K-ATPase had non-electrogenic transport activity, whereas the S782A mutant was electrogenic. The K800S mutant of the H,K-ATPase had a more complex behavior, with electrogenic transport only in the absence of extracellular Na+. Thus, a single positively charged residue in the fifth transmembrane segment of the alpha-subunit can determine the electrogenicity and therefore the stoichiometry of cation transport by these ATPases.	Univ Lausanne, Inst Pharmacol & Toxicol, CH-1005 Lausanne, Switzerland	University of Lausanne	Horisberger, JD (corresponding author), Univ Lausanne, Inst Pharmacol & Toxicol, Bugnon 27, CH-1005 Lausanne, Switzerland.	Jean-Daniel.Horisberger@ipharm.unil.ch	Horisberger, Jean-Daniel/A-2538-2009	Crambert, Gilles/0000-0001-7065-9124				APELL HJ, 1989, J MEMBRANE BIOL, V110, P103, DOI 10.1007/BF01869466; Arguello JM, 1999, ARCH BIOCHEM BIOPHYS, V367, P341, DOI 10.1006/abbi.1999.1278; Axelsen KB, 1998, J MOL EVOL, V46, P84, DOI 10.1007/PL00006286; Blostein R, 1997, J BIOL CHEM, V272, P24987, DOI 10.1074/jbc.272.40.24987; Burnay M, 2001, AM J PHYSIOL-RENAL, V281, pF869, DOI 10.1152/ajprenal.2001.281.5.F869; Cougnon M, 1998, P NATL ACAD SCI USA, V95, P6516, DOI 10.1073/pnas.95.11.6516; DEWEER P, 1985, KIDNEY PHYSL PATHOPH, P31; EFTHYMIADIS A, 1993, CELL BIOL INT, V17, P1107, DOI 10.1006/cbir.1993.1043; Favre I, 1996, BIOPHYS J, V71, P3110, DOI 10.1016/S0006-3495(96)79505-X; GEERING K, 1989, AM J PHYSIOL, V257, pC851, DOI 10.1152/ajpcell.1989.257.5.C851; Geering K, 1996, J CELL BIOL, V133, P1193, DOI 10.1083/jcb.133.6.1193; GIRARDET M, 1981, BIOCHEMISTRY-US, V20, P6684, DOI 10.1021/bi00526a025; Grishin AV, 1998, J BIOL CHEM, V273, P27772, DOI 10.1074/jbc.273.43.27772; Guennoun S, 2000, FEBS LETT, V482, P144, DOI 10.1016/S0014-5793(00)02050-0; Hermsen HPH, 2000, BIOCHEMISTRY-US, V39, P1330, DOI 10.1021/bi991396y; Horisberger JD, 2002, J PHYSIOL-LONDON, V539, P669, DOI 10.1113/jphysiol.2001.013201; Humphrey W, 1996, J MOL GRAPH MODEL, V14, P33, DOI 10.1016/0263-7855(96)00018-5; JAISSER F, 1992, J BIOL CHEM, V267, P16895; JAISSER F, 1994, J GEN PHYSIOL, V103, P605, DOI 10.1085/jgp.103.4.605; JAISSER F, 1993, PFLUG ARCH EUR J PHY, V425, P446, DOI 10.1007/BF00374871; JAISSER F, 1993, J CELL BIOL, V123, P1421, DOI 10.1083/jcb.123.6.1421; JAUNIN P, 1992, J BIOL CHEM, V267, P577; Jorgensen PL, 2001, BBA-BIOENERGETICS, V1505, P57, DOI 10.1016/S0005-2728(00)00277-2; NELSON RM, 1989, ANAL BIOCHEM, V180, P147, DOI 10.1016/0003-2697(89)90103-6; Ogawa H, 2002, P NATL ACAD SCI USA, V99, P15977, DOI 10.1073/pnas.202622299; Pedersen PA, 1998, BIOCHEMISTRY-US, V37, P17818, DOI 10.1021/bi981898w; Peluffo RD, 2000, J GEN PHYSIOL, V116, P47, DOI 10.1085/jgp.116.1.47; RABON EC, 1990, ANNU REV PHYSIOL, V52, P321; Rice WJ, 1996, J BIOL CHEM, V271, P31412, DOI 10.1074/jbc.271.49.31412; Swarts HGP, 2001, J BIOL CHEM, V276, P36909, DOI 10.1074/jbc.M103945200; Sweadner KJ, 2001, BIOCHEM J, V356, P685, DOI 10.1042/0264-6021:3560685; Toyoshima C, 2000, NATURE, V405, P647, DOI 10.1038/35015017; Toyoshima C, 2002, NATURE, V418, P605, DOI 10.1038/nature00944; Vagin O, 2001, BIOCHEMISTRY-US, V40, P7480, DOI 10.1021/bi0105328; Vilsen B, 1999, BIOCHEMISTRY-US, V38, P11389, DOI 10.1021/bi990951t; WANG X, 1995, AM J PHYSIOL, V37, pC590; Wang XY, 1996, J PHYSIOL-LONDON, V491, P579, DOI 10.1113/jphysiol.1996.sp021241; Zillikens S, 2000, BBA-BIOMEMBRANES, V1509, P155, DOI 10.1016/S0005-2736(00)00289-3	38	44	45	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 23	2003	278	21					19237	19244		10.1074/jbc.M300946200	http://dx.doi.org/10.1074/jbc.M300946200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	679PY	12637496	hybrid			2022-12-25	WOS:000182932200068
J	Kelly, A; Vereker, E; Nolan, Y; Brady, M; Barry, C; Loscher, CE; Mills, KHG; Lynch, MA				Kelly, A; Vereker, E; Nolan, Y; Brady, M; Barry, C; Loscher, CE; Mills, KHG; Lynch, MA			Activation of p38 plays a pivotal role in the inhibitory effect of lipopolysaccharide and interleukin-1 beta on long term potentiation in rat dentate gyrus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR-KAPPA-B; PROTECTS HIPPOCAMPAL-NEURONS; AGE-RELATED-CHANGES; TRANSCRIPTION FACTOR; INDUCED APOPTOSIS; DIETARY SUPPLEMENTATION; NUCLEAR TRANSLOCATION; ENTORHINAL CORTEX; GLUTAMATE RELEASE; ARACHIDONIC-ACID	Lipopolysaccharide (LPS), a component of the cell wall of Gram-negative bacteria, has been shown to induce profound changes both peripherally and centrally. It has recently been reported that intraperitoneal injection of LPS inhibited long term potentiation (LTP) in perforant path-granule cell synapses and that this effect was coupled with an increase in the concentration of the proinflammatory cytokine, interleukin-1beta (IL-1beta). The LPS-induced effects were abrogated by inhibition of caspase-1, suggesting that IL-1beta may mediate the effects of LPS. Here we report that the inhibition of LTP induced by LPS and IL-1beta was coupled with stimulation of the stress-activated protein kinase p38 in hippocampus and entorhinal cortex and that this effect was abrogated by the p38 inhibitor SB203580, while the effect of LPS was markedly attenuated in C57BL/6 IL-1RI(-/-) mice. The data also indicate that activation of the transcription factor, nuclear factor kappaB (NFkappaB), may play a role, since the inhibitory effect of LPS and IL-1beta on LTP was attenuated by the NFkappaB inhibitor, SN50; consistently, LPS and IL-1beta led to activation of NFkappaB in entorhinal cortex. We suggest that one consequence of these LPS- and IL-1beta-induced changes is a compromise in glutamate release in dentate gyrus, which was coupled with the inhibition of LTP. The evidence is consistent with the idea that the LPS- induced impairment in LTP is mediated by IL-1beta and is a consequence of activation of p38.	Univ Dublin Trinity Coll, Inst Neurosci, Dept Physiol, Dublin 2, Ireland; Univ Dublin Trinity Coll, Dept Biochem, Dublin 2, Ireland	Trinity College Dublin; Trinity College Dublin	Kelly, A (corresponding author), Univ Dublin Trinity Coll, Inst Neurosci, Dept Physiol, Dublin 2, Ireland.	aikelly@tcd.ie	Mills, Kingston H/F-5684-2013	Mills, Kingston H/0000-0003-3646-8222; Nolan, Yvonne/0000-0003-2426-234X; Lynch, Marina/0000-0002-4631-0499; Kelly, Aine/0000-0002-9255-0848				BAEUERLE PA, 1994, ANNU REV IMMUNOL, V14, P649; BARGER SW, 1995, P NATL ACAD SCI USA, V92, P9328, DOI 10.1073/pnas.92.20.9328; Behrens MM, 1999, NEUROSCIENCE, V94, P917, DOI 10.1016/S0306-4522(99)00212-2; BELLINGER FP, 1993, BRAIN RES, V628, P227, DOI 10.1016/0006-8993(93)90959-Q; BENVENISTE EN, 1997, IMMUNOLOGY NERVOUS S, P419; BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CANEVARI L, 1994, BRAIN RES, V667, P115, DOI 10.1016/0006-8993(94)91720-5; Carter AB, 1999, J BIOL CHEM, V274, P30858, DOI 10.1074/jbc.274.43.30858; Clemens JA, 1997, MOL BRAIN RES, V48, P187, DOI 10.1016/S0169-328X(97)00092-2; Coogan A, 1997, NEUROREPORT, V8, P2107, DOI 10.1097/00001756-199707070-00004; Coogan AN, 1999, NEUROSCIENCE, V93, P57, DOI 10.1016/S0306-4522(99)00100-1; Cunningham AJ, 1996, NEUROSCI LETT, V203, P17, DOI 10.1016/0304-3940(95)12252-4; Goodman Y, 1996, J NEUROCHEM, V66, P869, DOI 10.1046/j.1471-4159.1996.66020869.x; Grilli M, 1996, SCIENCE, V274, P1383, DOI 10.1126/science.274.5291.1383; Guay J, 1997, J CELL SCI, V110, P357; HAAN EA, 1981, J NEUROCHEM, V37, P243, DOI 10.1111/j.1471-4159.1981.tb05315.x; Hunot S, 1997, P NATL ACAD SCI USA, V94, P7531, DOI 10.1073/pnas.94.14.7531; Junger WG, 1997, J TRAUMA, V42, P437, DOI 10.1097/00005373-199703000-00011; Kaltschmidt B, 1997, P NATL ACAD SCI USA, V94, P2642, DOI 10.1073/pnas.94.6.2642; KALTSCHMIDT C, 1993, MECH DEVELOP, V43, P135, DOI 10.1016/0925-4773(93)90031-R; KATSUKI H, 1990, EUR J PHARMACOL, V181, P323, DOI 10.1016/0014-2999(90)90099-R; Kelly A, 2000, HIPPOCAMPUS, V10, P431, DOI 10.1002/1098-1063(2000)10:4<431::AID-HIPO9>3.0.CO;2-Z; Lee M, 2000, INT J IMMUNOPHARMACO, V22, P615, DOI 10.1016/S0192-0561(00)00024-2; Luo YQ, 1998, J BIOL CHEM, V273, P3756, DOI 10.1074/jbc.273.6.3756; Lynch MA, 1999, MOL PSYCHIATR, V4, P15, DOI 10.1038/sj.mp.4000438; Lynch MA, 1998, PROG NEUROBIOL, V56, P571, DOI 10.1016/S0301-0082(98)00054-9; Maroney AC, 1998, J NEUROSCI, V18, P104; Matsuoka Y, 1999, EXP BRAIN RES, V124, P215, DOI 10.1007/s002210050616; Mattson MP, 1997, J NEUROSCI RES, V49, P681, DOI 10.1002/(SICI)1097-4547(19970915)49:6<681::AID-JNR3>3.0.CO;2-3; Mattson MP, 2000, J NEUROCHEM, V74, P443, DOI 10.1046/j.1471-4159.2000.740443.x; Maulik N, 1998, FEBS LETT, V429, P365, DOI 10.1016/S0014-5793(98)00632-2; McGahon B, 1996, NEUROSCIENCE, V72, P847, DOI 10.1016/0306-4522(95)00579-X; McGahon B, 1997, NEUROSCIENCE, V81, P9, DOI 10.1016/S0306-4522(97)00116-4; McGahon BM, 1999, NEUROBIOL AGING, V20, P643, DOI 10.1016/S0197-4580(99)00027-5; McGahon BM, 1999, NEUROSCIENCE, V94, P305, DOI 10.1016/S0306-4522(99)00219-5; Meberg PJ, 1996, MOL BRAIN RES, V38, P179, DOI 10.1016/0169-328X(95)00229-L; Mielke K, 2000, PROG NEUROBIOL, V61, P45, DOI 10.1016/S0301-0082(99)00042-8; Mielke K, 1999, NEUROSCIENCE, V91, P471, DOI 10.1016/S0306-4522(98)00667-8; Mullany P, 1997, NEUROPHARMACOLOGY, V36, P973, DOI 10.1016/S0028-3908(97)00073-7; Murray CA, 1998, J BIOL CHEM, V273, P12161, DOI 10.1074/jbc.273.20.12161; Murray CA, 1997, NEUROBIOL AGING, V18, P343, DOI 10.1016/S0197-4580(97)80317-X; Murray CA, 1998, J NEUROSCI, V18, P2974; Namgung U, 2000, J NEUROSCI, V20, P6442, DOI 10.1523/JNEUROSCI.20-17-06442.2000; Nick JA, 1996, J IMMUNOL, V156, P4867; O'Donnell E, 2000, EUR J NEUROSCI, V12, P345, DOI 10.1046/j.1460-9568.2000.00900.x; ONeill LAJ, 1997, TRENDS NEUROSCI, V20, P252, DOI 10.1016/S0166-2236(96)01035-1; ORDRONNEAU P, 1991, J IMMUNOL METHODS, V142, P169, DOI 10.1016/0022-1759(91)90103-M; Ozawa H, 1999, NEUROSCI LETT, V262, P57, DOI 10.1016/S0304-3940(99)00034-8; Pahl HL, 1999, ONCOGENE, V18, P6853, DOI 10.1038/sj.onc.1203239; Park DS, 1996, J BIOL CHEM, V271, P21898, DOI 10.1074/jbc.271.36.21898; Qin ZH, 1999, J NEUROSCI, V19, P4023; Qin ZH, 1998, MOL PHARMACOL, V53, P33, DOI 10.1124/mol.53.1.33; RADA P, 1991, BRAIN RES, V550, P287, DOI 10.1016/0006-8993(91)91330-4; RAINGEAUD J, 1995, J BIOL CHEM, V270, P7420, DOI 10.1074/jbc.270.13.7420; Rong YQ, 1996, J NEUROCHEM, V67, P662; SALMINEN A, 1995, BIOCHEM BIOPH RES CO, V212, P939, DOI 10.1006/bbrc.1995.2060; Taglialatela G, 1997, J NEUROSCI RES, V47, P155; Takagi Y, 2000, NEUROSCI LETT, V294, P117, DOI 10.1016/S0304-3940(00)01552-4; Tamatani M, 2000, J NEUROCHEM, V75, P683, DOI 10.1046/j.1471-4159.2000.0750683.x; Terai K, 1997, BRAIN RES, V769, P385, DOI 10.1016/S0006-8993(97)00849-4; ToliverKinsky T, 1997, J NEUROSCI RES, V48, P580, DOI 10.1002/(SICI)1097-4547(19970615)48:6<580::AID-JNR11>3.0.CO;2-Z; Uciechowski P, 1996, FEBS LETT, V394, P273, DOI 10.1016/0014-5793(96)00967-2; Vereker E, 2000, J NEUROSCI, V20, P6811, DOI 10.1523/JNEUROSCI.20-18-06811.2000; Vereker E, 2000, J BIOL CHEM, V275, P26252, DOI 10.1074/jbc.M002226200; Yu ZF, 1999, J NEUROSCI, V19, P8856, DOI 10.1523/JNEUROSCI.19-20-08856.1999; Zhang SJ, 1998, MOL BRAIN RES, V63, P121, DOI 10.1016/S0169-328X(98)00267-8	67	135	140	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 23	2003	278	21					19453	19462		10.1074/jbc.M301938200	http://dx.doi.org/10.1074/jbc.M301938200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	679PY	12609991	hybrid, Green Published			2022-12-25	WOS:000182932200095
J	Sogabe, S; Yoshizumi, A; Fukami, TA; Shiratori, Y; Shimizu, S; Takagi, H; Nakamori, S; Wada, M				Sogabe, S; Yoshizumi, A; Fukami, TA; Shiratori, Y; Shimizu, S; Takagi, H; Nakamori, S; Wada, M			The crystal structure and stereospecificity of levodione reductase from Corynebacterium aquaticum M-13	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							3-ALPHA,20-BETA-HYDROXYSTEROID DEHYDROGENASE; TROPINONE REDUCTASE; ANGSTROM RESOLUTION; SUBSTRATE-BINDING; ACTIVE-SITE; PURIFICATION; MECHANISM; RESIDUES; COMPLEX; PSEUDOTROPINE	The (6R)-2,2,6-trimethyl-1,4-cyclohexanedione ( levodione) reductase (LVR) of the soil isolate bacterium Corynebacterium aquaticum M-13 is a NAD(H)-linked enzyme that catalyzes reversible oxidoreduction between (4R)-hydroxy-(6R)-2,2,6-trimethylcyclohexanone (actinol) and levodione. Here the crystal structure of a ternary complex of LVR with NADH and its inhibitor 2-methyl-2,4-pentanediol has been determined by molecular replacement and refined at 1.6-Angstrom resolution with a crystallographic R factor of 0.199. The overall structure is similar to those of other short-chain alcohol dehydrogenase/ reductase enzymes. The positions of NADH and 2-methyl-2,4-pentanediol indicate the binding site of the substrate and identify residues that are likely to be important in the catalytic reaction. Modeling of the substrate binding in the active site suggests that the specificity of LVR is determined by electrostatic interactions between the negatively charged surface of Glu-103 of LVR and the positively charged surface on the re side of levodione. Mutant LVR enzymes in which Glu-103 is substituted with alanine (E103A), glutamine (E103Q), asparagines (E103N), or aspartic acid (E103D) show a 2-6-fold increase in K-m values as compared with wild-type LVR and a much lower enantiomeric excess of the reaction products (60%) than the wild-type enzyme (95%). Together, these data indicate that Glu-103 has an important role in determining the stereospecificity of LVR.	Fukui Prefectural Univ, Dept Biosci, Matsuoka, Fukui 9101195, Japan; Nippon Roche Res Ctr, Kanagawa 2478530, Japan; Kyoto Univ, Grad Sch Agr, Div Appl Life Sci, Sakyo Ku, Kyoto 6068502, Japan	Fukui Prefectural University; Roche Holding; Kyoto University	Wada, M (corresponding author), Fukui Prefectural Univ, Dept Biosci, 4-1-1 Kenjyojima, Matsuoka, Fukui 9101195, Japan.	masaru@fpu.ac.jp	Wada, Masaru/B-7775-2012; Wada, Masaru/AAX-1401-2021	Takagi, Hiroshi/0000-0002-1786-3174				Andersson A, 1997, FEBS LETT, V400, P173, DOI 10.1016/S0014-5793(96)01382-8; Andersson A, 1996, STRUCTURE, V4, P1161, DOI 10.1016/S0969-2126(96)00124-4; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Breton R, 1996, STRUCTURE, V4, P905, DOI 10.1016/S0969-2126(96)00098-6; BURDEN RS, 1970, TETRAHEDRON LETT, P4071; Dinger MB, 1999, CHEM COMMUN, P2525, DOI 10.1039/a907476g; DRAGER B, 1988, AGR BIOL CHEM TOKYO, V52, P2663; GERBER PR, 1992, BIOPOLYMERS, V32, P1003, DOI 10.1002/bip.360320811; GHOSH D, 1994, STRUCTURE, V2, P973, DOI 10.1016/S0969-2126(94)00099-9; GHOSH D, 1994, STRUCTURE, V2, P629, DOI 10.1016/S0969-2126(00)00064-2; HASHIMOTO T, 1992, PLANT PHYSIOL, V100, P836, DOI 10.1104/pp.100.2.836; JORNVALL H, 1995, BIOCHEMISTRY-US, V34, P6003, DOI 10.1021/bi00018a001; KOELEN KJ, 1982, PLANTA MED, V44, P227, DOI 10.1055/s-2007-971454; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LAWRENCE MC, 2000, J APPL CRYSTALLOGR, V33, P990; LESLIE AGW, 1991, CRYSTALLOGRAPHIC COM, P50; LEUENBERGER HGW, 1976, HELV CHIM ACTA, V59, P1832, DOI 10.1002/hlca.19760590541; Liao DI, 2001, STRUCTURE, V9, P19, DOI 10.1016/S0969-2126(00)00548-7; MATTHEWS BW, 1968, J MOL BIOL, V33, P491, DOI 10.1016/0022-2836(68)90205-2; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; Nakajima K, 1999, J BIOL CHEM, V274, P16563, DOI 10.1074/jbc.274.23.16563; Nakajima K, 1998, P NATL ACAD SCI USA, V95, P4876, DOI 10.1073/pnas.95.9.4876; ORR GA, 1984, ANAL BIOCHEM, V142, P232, DOI 10.1016/0003-2697(84)90544-X; Otagiri M, 2001, J BIOCHEM, V129, P205, DOI 10.1093/oxfordjournals.jbchem.a002845; Parikh S, 1999, BIOCHEMISTRY-US, V38, P13623, DOI 10.1021/bi990529c; RAMACHANDRAN GN, 1963, J MOL BIOL, V7, P95, DOI 10.1016/S0022-2836(63)80023-6; READ RJ, 1986, ACTA CRYSTALLOGR A, V42, P140, DOI 10.1107/S0108767386099622; Rossmann MG, 1999, ACTA CRYSTALLOGR D, V55, P1631, DOI 10.1107/S0907444999008379; Tanaka N, 1996, BIOCHEMISTRY-US, V35, P7715, DOI 10.1021/bi951904d; VIOLA RE, 1979, ANAL BIOCHEM, V96, P334, DOI 10.1016/0003-2697(79)90590-6; Wada M, 1999, APPL ENVIRON MICROB, V65, P4399; WALLACE AC, 1995, PROTEIN ENG, V8, P127, DOI 10.1093/protein/8.2.127; Yamamoto K, 2001, J BIOCHEM, V129, P303, DOI 10.1093/oxfordjournals.jbchem.a002858; Yamashita A, 1999, BIOCHEMISTRY-US, V38, P7630, DOI 10.1021/bi9825044; Yoshisumi A, 2001, BIOSCI BIOTECH BIOCH, V65, P830, DOI 10.1271/bbb.65.830	35	22	23	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 23	2003	278	21					19387	19395		10.1074/jbc.M208146200	http://dx.doi.org/10.1074/jbc.M208146200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	679PY	12621044	hybrid			2022-12-25	WOS:000182932200087
J	Deregibus, MC; Buttiglieri, S; Russo, S; Bussolati, B; Camussi, G				Deregibus, MC; Buttiglieri, S; Russo, S; Bussolati, B; Camussi, G			CD40-dependent activation of phosphatidylinositol 3-kinase/Akt pathway mediates endothelial cell survival and in vitro angiogenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE; CD40 LIGAND; GROWTH-FACTOR; SMOOTH-MUSCLE; EXPRESSION; CD154; INHIBITION; LIGATION; FAMILY; ATHEROSCLEROSIS	CD40 has been involved in tumor and inflammatory neoangiogenesis. In this study we determined that stimulation of endothelial CD40 with sCD154 induced resistance to apoptosis and in vitro vessel-like formation by human microvascular endothelial cells (HMEC). These effects were determined to be mediated by CD40-dependent signaling because they were inhibited by a soluble CD40-muIg fusion protein. Moreover, apoptosis of HMEC was associated with an impairment of Akt phosphorylation, which was restored by stimulation with sCD154. The anti-apoptotic effect as well as in vitro vessel-like formation and Akt phosphorylation were inhibited by treatment of HMEC with two unrelated pharmacological inhibitors of phosphatidylinositol 3-kinase (PI3K), wortmannin and LY294002. CD40 stimulation induced a rapid increase in Akt enzymatic activity that was not prevented by cycloheximide, an inhibitor of protein synthesis. The enhanced Akt activity induced by stimulation of endothelial CD40 was temporarily correlated with the association of CD40 with TRAF6, c-Cbl, and the p85 subunit of PI3K. Expression of negative-dominant Akt inhibited the activation of endogenous Akt through CD40 stimulation, despite the observation that association of CD40 with TRAF6, c-Cbl, and PI3K was intact. The defective activation of Akt abrogated not only the anti-apoptotic effect of CD40 stimulation but also the proliferative response, the enhanced motility, and the in vitro formation of vessel-like tubular structures by CD40-stimulated HMEC. In conclusion, these results suggest that endothelial CD40, through activation of the PI3K/Akt signaling pathway, regulates cell survival, proliferation, migration, and vessel-like structure formation, all steps considered critical for angiogenesis.	Univ Turin, Dipartimento Med Interna, Cattedra Nefrol, I-10126 Turin, Italy; CeRMS, I-10126 Turin, Italy	University of Turin	Camussi, G (corresponding author), Osped Maggiore S Giovanni Battista, Dipartimento Med Interna, Cattedra Nefrol, Corso Dogliotti 14, I-10126 Turin, Italy.	giovanni.camussi@unito.it	Bussolati, Benedetta/AAA-9058-2022; buttiglieri, stefano/L-3005-2013; Camussi, Giovanni/J-7624-2016	Bussolati, Benedetta/0000-0002-3663-5134; Camussi, Giovanni/0000-0003-2795-232X				Alessi DR, 1997, CURR BIOL, V7, P261, DOI 10.1016/S0960-9822(06)00122-9; Arch RH, 1998, GENE DEV, V12, P2821, DOI 10.1101/gad.12.18.2821; Arron JR, 2001, J BIOL CHEM, V276, P30011, DOI 10.1074/jbc.M100414200; Biancone L, 1999, INT J MOL MED, V3, P343; Biancone L, 1999, J IMMUNOL, V163, P6201; Bussolati B, 2002, INT J CANCER, V100, P654, DOI 10.1002/ijc.10545; CHENG GH, 1995, SCIENCE, V267, P1494, DOI 10.1126/science.7533327; CLARK EA, 1986, P NATL ACAD SCI USA, V83, P4494, DOI 10.1073/pnas.83.12.4494; Conaldi PG, 1997, J INFECT DIS, V175, P693, DOI 10.1093/infdis/175.3.693; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; Dechanet J, 1997, J IMMUNOL, V159, P5640; DEL PL, 1997, SCIENCE, V278, P687; Deregibus MC, 2002, J BIOL CHEM, V277, P25195, DOI 10.1074/jbc.M200921200; Foy TM, 1996, ANNU REV IMMUNOL, V14, P591, DOI 10.1146/annurev.immunol.14.1.591; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; Franke TF, 1997, CELL, V88, P435, DOI 10.1016/S0092-8674(00)81883-8; Gerber HP, 1998, J BIOL CHEM, V273, P30336, DOI 10.1074/jbc.273.46.30336; Grewal IS, 1998, ANNU REV IMMUNOL, V16, P111, DOI 10.1146/annurev.immunol.16.1.111; Henn V, 1998, NATURE, V391, P591, DOI 10.1038/35393; HU HM, 1994, J BIOL CHEM, V269, P30069; Ishida T, 1996, J BIOL CHEM, V271, P28745, DOI 10.1074/jbc.271.46.28745; KARMANN K, 1995, P NATL ACAD SCI USA, V92, P4342, DOI 10.1073/pnas.92.10.4342; Kluth B, 1997, CANCER RES, V57, P891; Kotamraju S, 2000, J BIOL CHEM, V275, P33585, DOI 10.1074/jbc.M003890200; Lutgens E, 2002, TRENDS CARDIOVAS MED, V12, P27, DOI 10.1016/S1050-1738(01)00142-6; Mach F, 1998, NATURE, V394, P200, DOI 10.1038/28204; Mach F, 1997, P NATL ACAD SCI USA, V94, P1931, DOI 10.1073/pnas.94.5.1931; Mach F, 1999, AM J PATHOL, V154, P229, DOI 10.1016/S0002-9440(10)65269-8; Malinin NL, 1997, NATURE, V385, P540, DOI 10.1038/385540a0; McCarthy JV, 1998, J BIOL CHEM, V273, P16968, DOI 10.1074/jbc.273.27.16968; Melter M, 2000, BLOOD, V96, P3801, DOI 10.1182/blood.V96.12.3801.h8003801_3801_3808; Montesano R, 1997, J CELL PHYSIOL, V173, P152, DOI 10.1002/(SICI)1097-4652(199711)173:2<152::AID-JCP14>3.0.CO;2-I; Nishitoh H, 1998, MOL CELL, V2, P389, DOI 10.1016/S1097-2765(00)80283-X; Pullen SS, 1998, BIOCHEMISTRY-US, V37, P11836, DOI 10.1021/bi981067q; Reul RM, 1997, TRANSPLANTATION, V64, P1765, DOI 10.1097/00007890-199712270-00025; Schonbeck U, 2000, P NATL ACAD SCI USA, V97, P7458, DOI 10.1073/pnas.97.13.7458; Schonbeck U, 2001, CIRC RES, V89, P1092, DOI 10.1161/hh2401.101272; Schonbeck U, 1997, J BIOL CHEM, V272, P19569, DOI 10.1074/jbc.272.31.19569; Shiojima I, 2002, CIRC RES, V90, P1243, DOI 10.1161/01.RES.0000022200.71892.9F; Shu HB, 1997, IMMUNITY, V6, P751, DOI 10.1016/S1074-7613(00)80450-1; Slupsky JR, 1998, THROMB HAEMOSTASIS, V80, P1008; Takeuchi M, 1996, J BIOL CHEM, V271, P19935, DOI 10.1074/jbc.271.33.19935; Talapatra S, 2001, J PHARMACOL EXP THER, V298, P873; Thienel U, 1999, CELL IMMUNOL, V198, P87, DOI 10.1006/cimm.1999.1583; Urbich C, 2001, J CLIN INVEST, V108, P1451, DOI 10.1172/JCI200113620; WEIHUA W, 2000, J BIOL CHEM, V275, P40113; Werneburg BG, 2001, J BIOL CHEM, V276, P43334, DOI 10.1074/jbc.M104994200; Wong BR, 1999, MOL CELL, V4, P1041, DOI 10.1016/S1097-2765(00)80232-4; Young LS, 1998, IMMUNOL TODAY, V19, P502, DOI 10.1016/S0167-5699(98)01340-1; Yuasa T, 1998, J BIOL CHEM, V273, P22681, DOI 10.1074/jbc.273.35.22681; Zhang L, 1997, SCIENCE, V276, P1268, DOI 10.1126/science.276.5316.1268; Zhou HL, 2000, J CELL BIOL, V151, P483, DOI 10.1083/jcb.151.3.483	52	86	87	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 16	2003	278	20					18008	18014		10.1074/jbc.M300711200	http://dx.doi.org/10.1074/jbc.M300711200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677YX	12637493	hybrid			2022-12-25	WOS:000182838300054
J	Di Venere, A; Salucci, ML; van Zadelhoff, G; Veldink, G; Mei, G; Rosato, N; Finazzi-Agro, A; Maccarrone, M				Di Venere, A; Salucci, ML; van Zadelhoff, G; Veldink, G; Mei, G; Rosato, N; Finazzi-Agro, A; Maccarrone, M			Structure-to-function relationship of mini-lipoxygenase, a 60-kDa fragment of soybean lipoxygenase-1 with lower stability but higher enzymatic activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROGRAMMED CELL-DEATH; ACID-BINDING PROTEIN; MOLTEN GLOBULE STATE; N-TERMINAL DOMAIN; INTERNAL CAVITIES; ORGANELLE DEGRADATION; MEMBRANE-BINDING; VOLUME CHANGES; BURIED WATERS; 5-LIPOXYGENASE	Lipoxygenase-1 (Lox-1) is a member of the lipoxygenase family, a class of dioxygenases that take part in the metabolism of polyunsatured fatty acids in eukaryotes. Tryptic digestion of soybean Lox-1 is known to produce a 60 kDa fragment, termed "mini-Lox," which shows enhanced catalytic efficiency and higher membrane-binding ability than the native enzyme (Maccarrone, M., Salucci, M. L., van Zadelhoff, G., Malatesta, F., Veldink, G. Vliegenthart, J. F. G., and Finazzi-Agro, A. (2001) Biochemistry 40, 6819-6827). In this study, we have investigated the stability of mini-Lox in guanidinium hydrochloride and under high pressure by fluorescence and circular dichroism spectroscopy. Only a partial unfolding could be obtained at high pressure in the range 1-3000 bar at variance with guanidinium hydrochloride. However, in both cases a reversible denaturation was observed. The denaturation experiments demonstrate that mini-Lox is a rather unstable molecule, which undergoes a two-step unfolding transition at moderately low guanidinium hydrochloride concentration (0-4.5 M). Both chemical- and physical-induced denaturation suggest that mini-Lox is more hydrated than Lox-1, an observation also confirmed by 1-anilino-8-naphthalenesulfonate (ANS) binding studies. We have also investigated the occurrence of substrate-induced changes in the protein tertiary structure by dynamic fluorescence techniques. In particular, eicosatetraynoic acid, an irreversible inhibitor of lipoxygenase, has been used to mimic the effect of substrate binding. We demonstrated that mini-Lox is indeed characterized by much larger conformational changes than those occurring in the native Lox-1 upon binding of eicosatetraynoic acid. Finally, by both activity and fluorescence measurements we have found that 1-anilino-8-naphthalenesulfonate has access to the active site of mini-Lox but not to that of intact Lox-1. These findings strongly support the hypothesis that the larger hydration of mini-Lox renders this molecule more flexible, and therefore less stable.	Univ Teramo, Dept Biomed Sci, I-64100 Teramo, Italy; INFM, I-16152 Genoa, Italy; Univ Roma Tor Vergata, Dept Expt Med & Biochem Sci, I-00133 Rome, Italy; Univ Aquila, Dept Pure & Appl Biol, I-67100 Laquila, Italy; Univ Utrecht, Dept Bioorgan Chem, Bijvoet Ctr Biomol Res, NL-3584 CH Utrecht, Netherlands; Osped San Giovanni Calibita, Div Neurol, CRCCS, AFaR, I-00100 Rome, Italy	University of Teramo; Consiglio Nazionale delle Ricerche (CNR); Istituto Nazionale per la Fisica della Materia (INFM-CNR); University of Rome Tor Vergata; University of L'Aquila; Utrecht University	Maccarrone, M (corresponding author), Univ Teramo, Dept Biomed Sci, I-64100 Teramo, Italy.	Maccarrone@vet.unite.it	van Zadelhoff, Guus/F-2260-2010	Di Venere, Almerinda/0000-0002-9493-0270				AGRO AF, 1975, FEBS LETT, V52, P73; Arighi CN, 1998, BIOCHEMISTRY-US, V37, P16802, DOI 10.1021/bi981827x; BOYINGTON JC, 1993, SCIENCE, V260, P1482, DOI 10.1126/science.8502991; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRAND L, 1972, ANNU REV BIOCHEM, V41, P843, DOI 10.1146/annurev.bi.41.070172.004211; Brash AR, 1999, J BIOL CHEM, V274, P23679, DOI 10.1074/jbc.274.34.23679; CANTOR CR, 1980, BIOPHYSICAL CHEM 3, P849; CARDAMONE M, 1992, BIOCHEM J, V282, P589, DOI 10.1042/bj2820589; Carlile AJ, 2000, MOL PLANT MICROBE IN, V13, P538, DOI 10.1094/MPMI.2000.13.5.538; Chen XS, 2001, J BIOL CHEM, V276, P811, DOI 10.1074/jbc.M008203200; Di Venere A, 1998, EUR J BIOCHEM, V257, P337, DOI 10.1046/j.1432-1327.1998.2570337.x; Di Venere A, 2000, J BIOL CHEM, V275, P3915, DOI 10.1074/jbc.275.6.3915; FINAZZIAGRO A, 1973, BIOCHIM BIOPHYS ACTA, V326, P462, DOI 10.1016/0005-2760(73)90146-X; FORDHUTCHINSON AW, 1994, ANNU REV BIOCHEM, V63, P383, DOI 10.1146/annurev.bi.63.070194.002123; Frye KJ, 1998, PROTEIN SCI, V7, P2217, DOI 10.1002/pro.5560071020; Funk CD, 2001, SCIENCE, V294, P1871, DOI 10.1126/science.294.5548.1871; Gillmor SA, 1997, NAT STRUCT BIOL, V4, P1003, DOI 10.1038/nsb1297-1003; GRATTON E, 1983, BIOPHYS J, V44, P315, DOI 10.1016/S0006-3495(83)84305-7; Grechkin A, 1998, PROG LIPID RES, V37, P317, DOI 10.1016/S0163-7827(98)00014-9; Grullich C, 2001, FEBS LETT, V489, P51, DOI 10.1016/S0014-5793(01)02080-4; Hammarberg T, 2000, J BIOL CHEM, V275, P38787, DOI 10.1074/jbc.M006136200; Hemak J, 2002, J MOL MODEL, V8, P102, DOI 10.1007/s00894-002-0076-y; HUBBARD SJ, 1994, PROTEIN ENG, V7, P613, DOI 10.1093/protein/7.5.613; Inoue K, 2000, NAT STRUCT BIOL, V7, P547; Jenkins AE, 2002, BIOCHEMISTRY-US, V41, P2022, DOI 10.1021/bi015769i; Jones SM, 2002, J BIOL CHEM, V277, P38550, DOI 10.1074/jbc.M206070200; KLEIN BP, 1985, PHYTOCHEMISTRY, V24, P1903, DOI 10.1016/S0031-9422(00)83089-7; Kobashigawa Y, 1999, PROTEIN SCI, V8, P2765; Kuhn H, 1999, ADV EXP MED BIOL, V447, P5; KUWAJIMA K, 1989, PROTEINS, V6, P87, DOI 10.1002/prot.340060202; Maccarrone M, 2000, EUR J BIOCHEM, V267, P5078, DOI 10.1046/j.1432-1327.2000.01564.x; Maccarrone M, 2001, CELL DEATH DIFFER, V8, P776, DOI 10.1038/sj.cdd.4400908; Maccarrone M, 2001, BIOCHEMISTRY-US, V40, P6819, DOI 10.1021/bi010187m; Maccarrone M, 1999, J AM SOC NEPHROL, V10, P1991; Malvezzi-Campeggi F, 2001, BIOCHEM BIOPH RES CO, V289, P1295, DOI 10.1006/bbrc.2001.6109; MEI G, 1994, J MOL BIOL, V242, P559, DOI 10.1006/jmbi.1994.1600; Millar DP, 1996, CURR OPIN STRUC BIOL, V6, P637, DOI 10.1016/S0959-440X(96)80030-3; MYERS JK, 1995, PROTEIN SCI, V4, P2138, DOI 10.1002/pro.5560041020; PRYSE KM, 1992, BIOCHEMISTRY-US, V31, P5127, DOI 10.1021/bi00137a006; PTITSYN OB, 1990, FEBS LETT, V262, P20, DOI 10.1016/0014-5793(90)80143-7; RAMACHANDRAN S, 1992, BIOCHEMISTRY-US, V31, P7700, DOI 10.1021/bi00148a034; RASHIN AA, 1986, BIOCHEMISTRY-US, V25, P3619, DOI 10.1021/bi00360a021; Royer CA, 2002, BBA-PROTEIN STRUCT M, V1595, P201, DOI 10.1016/S0167-4838(01)00344-2; Rusterucci C, 1999, J BIOL CHEM, V274, P36446, DOI 10.1074/jbc.274.51.36446; SCHILSTRA MJ, 1994, BIOCHEMISTRY-US, V33, P3974, DOI 10.1021/bi00179a025; Silva JL, 2001, TRENDS BIOCHEM SCI, V26, P612, DOI 10.1016/S0968-0004(01)01949-1; Srinivasulu S, 1996, BBA-PROTEIN STRUCT M, V1294, P115, DOI 10.1016/0167-4838(95)00263-4; Sudharshan E, 1997, FEBS LETT, V406, P184, DOI 10.1016/S0014-5793(97)00268-8; Sudharshan E, 1999, J BIOL CHEM, V274, P35351, DOI 10.1074/jbc.274.50.35351; Sudharshan E, 2000, BBA-PROTEIN STRUCT M, V1480, P13, DOI 10.1016/S0167-4838(00)00099-6; van Leyen K, 1998, NATURE, V395, P392, DOI 10.1038/26500; Vidugiris GJA, 1998, BIOPHYS J, V75, P463, DOI 10.1016/S0006-3495(98)77534-4; Walther M, 2002, J BIOL CHEM, V277, P27360, DOI 10.1074/jbc.M203234200; WASYLEWSKI Z, 1992, EUR J BIOCHEM, V206, P235, DOI 10.1111/j.1432-1033.1992.tb16921.x; WILLIAMS MA, 1994, PROTEIN SCI, V3, P1224, DOI 10.1002/pro.5560030808	55	23	25	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 16	2003	278	20					18281	18288		10.1074/jbc.M212122200	http://dx.doi.org/10.1074/jbc.M212122200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677YX	12626522	Green Published, hybrid			2022-12-25	WOS:000182838300091
J	Ha, H; Kwak, HB; Lee, SK; Na, DS; Rudd, CE; Lee, ZH; Kim, HH				Ha, H; Kwak, HB; Lee, SK; Na, DS; Rudd, CE; Lee, ZH; Kim, HH			Membrane rafts play a crucial role in receptor activator of nuclear factor kappa B signaling and osteoclast function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NECROSIS-FACTOR RECEPTOR; LIPID RAFTS; PHOSPHATIDYLINOSITOL 3-KINASE; DEFECTIVE INTERLEUKIN-1; BINDING PROTEIN; BONE-RESORPTION; FAMILY-MEMBER; TRAF FAMILY; ASSOCIATION; DIFFERENTIATION	Membrane lipid rafts play a key role in immune cell activation by recruiting and excluding specific signaling components of immune cell surface receptors upon the receptor engagement. Despite this, the role of these microdomains in the regulation of osteoclasts as controlled by receptor activator of nuclear factor kappaB ( RANK) has yet to be established. In this study, we demonstrate that the raft microdomain expression plays an essential role in osteoclast function and differentiation. Expression of raft component flotillin greatly increased during osteoclast differentiation, whereas engagement of RANK induced the translocation of tumor necrosis factor receptor-associated factor 6 to rafts where Src was constitutively resident. Disruption of rafts blocked TRAF6 translocation and Akt activation by RANK ligand in osteoclasts and further reduced the survival of osteoclasts. Actin ring formation and bone resorption by osteoclasts were also found to require the integrity of rafts. Our observations demonstrate for the first time that RANK-mediated signaling and osteoclast function are critically dependent on the expression and integrity of raft membrane microdomains.	Chosun Univ, Sch Dent, Gwangju 501759, South Korea; Chosun Univ, Natl Res Lab Bone Metab, Gwangju 501759, South Korea; Chosun Univ, Res Ctr Proteineous Mat, Gwangju 501759, South Korea; Univ Ulsan, Coll Med, Dept Biochem, Seoul 138736, South Korea; Univ London Imperial Coll Sci Technol & Med, Hammersmith Hosp, Fac Med, Dept Haematol, London W12 ONN, England	Chosun University; Chosun University; Chosun University; University of Ulsan; Imperial College London	Kim, HH (corresponding author), Chosun Univ, Sch Dent, 375 Seosuk Dong, Gwangju 501759, South Korea.	hhbkim@snu.ac.kr	Lee, SeungKu/GSN-5012-2022; Rudd, Christopher E/GOH-2021-2022; Rudd, Christopher E/ABF-7259-2021	Lee, SeungKu/0000-0001-5120-5557; Rudd, Christopher E/0000-0001-5295-9019; 				Armstrong AP, 2002, J BIOL CHEM, V277, P44347, DOI 10.1074/jbc.M202009200; Arron JR, 2002, J EXP MED, V196, P923, DOI 10.1084/jem.20020774; Bilderback TR, 1997, J BIOL CHEM, V272, P10922; BOYCE BF, 1992, J CLIN INVEST, V90, P1622, DOI 10.1172/JCI116032; Brown DA, 1998, ANNU REV CELL DEV BI, V14, P111, DOI 10.1146/annurev.cellbio.14.1.111; BROWN DA, 1992, CELL, V68, P533, DOI 10.1016/0092-8674(92)90189-J; Cantley LC, 2002, SCIENCE, V296, P1655, DOI 10.1126/science.296.5573.1655; Cherukuri A, 2001, IMMUNITY, V14, P657, DOI 10.1016/S1074-7613(01)00156-X; Cottin V, 2002, J IMMUNOL, V168, P4095, DOI 10.4049/jimmunol.168.8.4095; Darnay BG, 1998, J BIOL CHEM, V273, P20551, DOI 10.1074/jbc.273.32.20551; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; Dougall WC, 1999, GENE DEV, V13, P2412, DOI 10.1101/gad.13.18.2412; Duong LT, 1998, J CLIN INVEST, V102, P881, DOI 10.1172/JCI3212; Feng X, 2001, J BIOL CHEM, V276, P8341, DOI 10.1074/jbc.M007116200; Galibert L, 1998, J BIOL CHEM, V273, P34120, DOI 10.1074/jbc.273.51.34120; HORNE WC, 1992, J CELL BIOL, V119, P1003, DOI 10.1083/jcb.119.4.1003; Hostager BS, 2000, J BIOL CHEM, V275, P15392, DOI 10.1074/jbc.M909520199; Hsu HL, 1999, P NATL ACAD SCI USA, V96, P3540, DOI 10.1073/pnas.96.7.3540; Iwamoto T, 2001, J BIOL CHEM, V276, P46031, DOI 10.1074/jbc.M104464200; Jimi E, 1999, J IMMUNOL, V163, P434; KILSDONK EPC, 1995, J BIOL CHEM, V270, P17250, DOI 10.1074/jbc.270.29.17250; Kim HH, 1999, FEBS LETT, V443, P297, DOI 10.1016/S0014-5793(98)01731-1; Ko YG, 1999, J IMMUNOL, V162, P7217; Kobayashi N, 2001, EMBO J, V20, P1271, DOI 10.1093/emboj/20.6.1271; Kong YY, 1999, NATURE, V397, P315, DOI 10.1038/16852; Lacey DL, 2000, AM J PATHOL, V157, P435, DOI 10.1016/S0002-9440(10)64556-7; Lakkakorpi PT, 1997, EXP CELL RES, V237, P296, DOI 10.1006/excr.1997.3797; Lakkakorpi PT, 1999, J BIOL CHEM, V274, P4900, DOI 10.1074/jbc.274.8.4900; Lee SE, 2002, BONE, V30, P71, DOI 10.1016/S8756-3282(01)00657-3; Lee SP, 2001, J BIOL CHEM, V276, P29826, DOI 10.1074/jbc.M101822200; Lomaga MA, 1999, GENE DEV, V13, P1015, DOI 10.1101/gad.13.8.1015; LOWE C, 1993, P NATL ACAD SCI USA, V90, P4485, DOI 10.1073/pnas.90.10.4485; Martin M, 2001, J EXP MED, V194, P1675, DOI 10.1084/jem.194.11.1675; Naito A, 1999, GENES CELLS, V4, P353, DOI 10.1046/j.1365-2443.1999.00265.x; PLEIMAN CM, 1994, SCIENCE, V263, P1609, DOI 10.1126/science.8128248; Shin JN, 2002, J BIOL CHEM, V277, P8346, DOI 10.1074/jbc.M110964200; Simons K, 2000, NAT REV MOL CELL BIO, V1, P31, DOI 10.1038/35036052; SORIANO P, 1991, CELL, V64, P693, DOI 10.1016/0092-8674(91)90499-O; Suda T, 1999, ENDOCR REV, V20, P345, DOI 10.1210/er.20.3.345; Tansey MG, 2000, NEURON, V25, P611, DOI 10.1016/S0896-6273(00)81064-8; Teitelbaum SL, 2000, SCIENCE, V289, P1504, DOI 10.1126/science.289.5484.1504; Udagawa N., 2002, PRINCIPLES BONE BIOL, V2nd ed.; Vereb G, 2000, P NATL ACAD SCI USA, V97, P6013, DOI 10.1073/pnas.97.11.6013; Vidalain PO, 2000, EMBO J, V19, P3304, DOI 10.1093/emboj/19.13.3304; Waheed AA, 2001, P NATL ACAD SCI USA, V98, P4926, DOI 10.1073/pnas.091090798; Wong BR, 1999, MOL CELL, V4, P1041, DOI 10.1016/S1097-2765(00)80232-4; Wong BR, 1998, J BIOL CHEM, V273, P28355, DOI 10.1074/jbc.273.43.28355; WU H, 1993, J CELL BIOL, V120, P1417, DOI 10.1083/jcb.120.6.1417; Xing LP, 2001, GENE DEV, V15, P241, DOI 10.1101/gad.840301; ZHANG D, 1995, J CELL SCI, V108, P2285	50	99	107	0	3	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 16	2003	278	20					18573	18580		10.1074/jbc.M212626200	http://dx.doi.org/10.1074/jbc.M212626200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677YX	12637570	hybrid			2022-12-25	WOS:000182838300129
J	Kitada, H; Miyata, M; Nakamura, T; Tozawa, A; Honma, W; Shimada, M; Nagata, K; Sinal, CJ; Guo, GL; Gonzalez, FJ; Yamazoe, Y				Kitada, H; Miyata, M; Nakamura, T; Tozawa, A; Honma, W; Shimada, M; Nagata, K; Sinal, CJ; Guo, GL; Gonzalez, FJ; Yamazoe, Y			Protective role of hydroxysteroid sulfotransferase in lithocholic acid-induced liver toxicity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SALT EXPORT PUMP; FARNESOID-X-RECEPTOR; BILE-ACID; NUCLEAR RECEPTOR; LIQUID-CHROMATOGRAPHY; MOLECULAR-CLONING; GENE-EXPRESSION; PROTEIN-3 MRP3; MOUSE-LIVER; RAT	Supplement of 1% lithocholic acid (LCA) in the diet for 5-9 days resulted in elevated levels of the marker for liver damage aspartate aminotransferase and alkaline phosphatase activities in both farnesoid X receptor (FXR)-null and wild-type female mice. The levels were clearly higher in wild-type mice than in FXR-null mice, despite the diminished expression of a bile salt export pump in the latter. Consistent with liver toxicity marker activities, serum and liver levels of bile acids, particularly LCA and taurolithocholic acid, were clearly higher in wild-type mice than in FXR-null mice after 1% LCA supplement. Marked increases in hepatic sulfating activity for LCA (5.5-fold) and hydroxysteroid sulfotransferase (St) 2a (5.8-fold) were detected in liver of FXR-null mice. A 7.4-fold higher 3alpha-sulfated bile acid concentration was observed in bile of FXR-null mice fed an LCA diet compared with that of wild-type mice. Liver St2a content was inversely correlated with levels of alkaline phosphatase. In contrast, microsomal LCA 6beta-hydroxylation was not increased and was in fact lower in FXR-null mice compared in wild-type mice. Clear decreases in mRNA encoding sodium taurocholate cotransporting polypeptide, organic anion transporting polypeptide 1, and liver-specific organic anion transporter-1 function in bile acid import were detected in LCA-fed mice. These transporter levels are higher in FXR-null mice than wild-type mice after 1% LCA supplement. No obvious changes were detected in the Mrp2, Mrp3, and Mrp4 mRNAs. These results indicate hydroxysteroid sulfotransferase-mediated LCA sulfation as a major pathway for protection against LCA-induced liver damage. Furthermore, Northern blot analysis using FXR-null, pregnane X receptor-null, and FXR-pregnane X receptor double-null mice suggests a repressive role of these nuclear receptors on basal St2a expression.	Tohoku Univ, Grad Sch Pharmaceut Sci, Div Drug Metab & Mol Toxicol, Aoba Ku, Sendai, Miyagi 9808578, Japan; NCI, Metab Lab, NIH, Bethesda, MD 20892 USA	Tohoku University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Miyata, M (corresponding author), Tohoku Univ, Grad Sch Pharmaceut Sci, Div Drug Metab & Mol Toxicol, Aoba Ku, Sendai, Miyagi 9808578, Japan.			Sinal, Christopher/0000-0001-8301-3349				Akita H, 2001, BBA-BIOMEMBRANES, V1511, P7, DOI 10.1016/S0005-2736(00)00355-2; Ananthanarayanan M, 2001, J BIOL CHEM, V276, P28857, DOI 10.1074/jbc.M011610200; Araya Z, 1999, BBA-MOL CELL BIOL L, V1438, P47, DOI 10.1016/S1388-1981(99)00031-1; CAREY MC, 1979, BIOCHIM BIOPHYS ACTA, V575, P16, DOI 10.1016/0005-2760(79)90126-7; Chiang JYL, 2000, J BIOL CHEM, V275, P10918, DOI 10.1074/jbc.275.15.10918; COWEN AE, 1975, GASTROENTEROLOGY, V69, P59; DIONNE S, 1994, BIOCHEM PHARMACOL, V48, P1187, DOI 10.1016/0006-2952(94)90156-2; Gerloff T, 1998, J BIOL CHEM, V273, P10046, DOI 10.1074/jbc.273.16.10046; Goodwin B, 2000, MOL CELL, V6, P517, DOI 10.1016/S1097-2765(00)00051-4; Hirohashi T, 2000, J BIOL CHEM, V275, P2905, DOI 10.1074/jbc.275.4.2905; Hirohashi T, 1999, J BIOL CHEM, V274, P15181, DOI 10.1074/jbc.274.21.15181; Hofmann Alan F., 1994, P677; Kast HR, 2001, MOL ENDOCRINOL, V15, P1720, DOI 10.1210/me.15.10.1720; Kato T, 1996, DIGEST DIS SCI, V41, P1564, DOI 10.1007/BF02087901; KONG ANT, 1993, PHARMACEUT RES, V10, P627, DOI 10.1023/A:1018926825475; KONG ANT, 1994, CHEM-BIOL INTERACT, V92, P161, DOI 10.1016/0009-2797(94)90061-2; Konig J, 1999, BBA-BIOMEMBRANES, V1461, P377, DOI 10.1016/S0005-2736(99)00169-8; KUIPERS F, 1986, AM J PHYSIOL, V251, pG189, DOI 10.1152/ajpgi.1986.251.2.G189; Kullak-Ublick GA, 2000, SEMIN LIVER DIS, V20, P273, DOI 10.1055/s-2000-9426; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Lu TT, 2000, MOL CELL, V6, P507, DOI 10.1016/S1097-2765(00)00050-2; MAKINO I, 1974, J LIPID RES, V15, P132; Makishima M, 2002, SCIENCE, V296, P1313, DOI 10.1126/science.1070477; Makishima M, 1999, SCIENCE, V284, P1362, DOI 10.1126/science.284.5418.1362; Nagata K, 2000, ANNU REV PHARMACOL, V40, P159, DOI 10.1146/annurev.pharmtox.40.1.159; OELBERG DG, 1984, J CLIN INVEST, V73, P1507, DOI 10.1172/JCI111356; Parks DJ, 1999, SCIENCE, V284, P1365, DOI 10.1126/science.284.5418.1365; Repa JJ, 2000, SCIENCE, V289, P1524, DOI 10.1126/science.289.5484.1524; Runge-Morris M, 1999, MOL PHARMACOL, V56, P1198, DOI 10.1124/mol.56.6.1198; Schuetz EG, 2001, J BIOL CHEM, V276, P39411, DOI 10.1074/jbc.M106340200; Shimada M, 2001, BRAIN RES, V920, P222, DOI 10.1016/S0006-8993(01)03061-X; Sinal CJ, 2000, CELL, V102, P731, DOI 10.1016/S0092-8674(00)00062-3; Song CS, 2001, J BIOL CHEM, V276, P42549, DOI 10.1074/jbc.M107557200; Sonoda J, 2002, P NATL ACAD SCI USA, V99, P13801, DOI 10.1073/pnas.212494599; Staudinger JL, 2001, P NATL ACAD SCI USA, V98, P3369, DOI 10.1073/pnas.051551698; STIEHL A, 1974, EUR J CLIN INVEST, V4, P59, DOI 10.1111/j.1365-2362.1974.tb00373.x; STIEHL A, 1975, GASTROENTEROLOGY, V68, P534; Suzuki H, 1998, SEMIN LIVER DIS, V18, P359, DOI 10.1055/s-2007-1007170; TAKIKAWA H, 1991, BIOCHIM BIOPHYS ACTA, V1091, P173, DOI 10.1016/0167-4889(91)90058-6; Takikawa H, 1984, Gastroenterol Jpn, V19, P104; TAZUKE Y, 1994, BIOSCI BIOTECH BIOCH, V58, P889, DOI 10.1271/bbb.58.889; Urizar NL, 2000, J BIOL CHEM, V275, P39313, DOI 10.1074/jbc.M007998200; Wang HB, 1999, MOL CELL, V3, P543, DOI 10.1016/S1097-2765(00)80348-2; XEI W, 2001, P NATL ACAD SCI USA, V98, P3375; YAMADA J, 1991, ANAL BIOCHEM, V199, P132, DOI 10.1016/0003-2697(91)90280-7; Yousef IM, 1997, DRUG METAB REV, V29, P167, DOI 10.3109/03602539709037579; Yu JH, 2002, J BIOL CHEM, V277, P31441, DOI 10.1074/jbc.M200474200	47	125	128	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 16	2003	278	20					17838	17844		10.1074/jbc.M210634200	http://dx.doi.org/10.1074/jbc.M210634200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677YX	12637555	hybrid			2022-12-25	WOS:000182838300032
J	Kozel, BA; Wachi, H; Davis, EC; Mecham, RP				Kozel, BA; Wachi, H; Davis, EC; Mecham, RP			Domains in tropoelastin that mediate elastin deposition in vitro and in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SUPRAVALVULAR AORTIC-STENOSIS; CARBOXY-TERMINUS; TRANSGENIC MICE; POINT MUTATIONS; BANDED FIBERS; CUTIS LAXA; GENE; PROTEINS; FIBRILLIN-1; EXPRESSION	Elastic fiber assembly is a complicated process involving multiple different proteins and enzyme activities. However, the specific protein-protein interactions that facilitate elastin polymerization have not been defined. To identify domains in the tropoelastin molecule important for the assembly process, we utilized an in vitro assembly model to map sequences within tropoelastin that facilitate its association with fibrillin-containing microfibrils in the extracellular matrix. Our results show that an essential assembly domain is located in the C-terminal region of the molecule, encoded by exons 29-36. Fine mapping studies using an exon deletion strategy and synthetic peptides identified the hydrophobic sequence in exon 30 as a major functional element in this region and suggested that the assembly process is driven by the propensity of this sequence to form beta-sheet structure. Tropoelastin molecules lacking the C-terminal assembly domain expressed as transgenes in mice did not assemble nor did they interfere with assembly of full-length normal mouse elastin. In addition to providing important information about elastin assembly in general, the results of this study suggest how removal or alteration of the C terminus through stop or frameshift mutations might contribute to the elastin-related diseases supravalvular aortic stenosis and cutis laxa.	Washington Univ, Sch Med, Dept Cell Biol & Physiol, St Louis, MO 63110 USA; Hoshi Univ, Sch Pharm, Dept Clin Chem, Tokyo 142850, Japan; McGill Univ, Dept Anat & Cell Biol, Montreal, PQ H3A 2B2, Canada	Washington University (WUSTL); Hoshi University; McGill University	Mecham, RP (corresponding author), Washington Univ, Sch Med, Dept Cell Biol & Physiol, Campus Box 8228,660 S Euclid Ave, St Louis, MO 63110 USA.		Kozel, Beth/AAP-9177-2020; Davis, Elaine/F-3449-2012	Kozel, Beth/0000-0002-9757-7118; 	NHLBI NIH HHS [HL53325, HL61006, HL62295] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL053325, R01HL062295, P50HL061006, R01HL053325] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Baskar JF, 1996, J VIROL, V70, P3215, DOI 10.1128/JVI.70.5.3215-3226.1996; Baskar JF, 1996, J VIROL, V70, P3207, DOI 10.1128/JVI.70.5.3207-3214.1996; Bochicchio B, 2001, MATRIX BIOL, V20, P243, DOI 10.1016/S0945-053X(01)00139-1; BRESSAN GM, 1986, J ULTRA MOL STRUCT R, V94, P209, DOI 10.1016/0889-1605(86)90068-6; BRESSAN GM, 1983, J ULTRA MOL STRUCT R, V82, P335, DOI 10.1016/S0022-5320(83)80021-5; BrownAugsburger P, 1996, BIOCHEM J, V318, P149, DOI 10.1042/bj3180149; CAPUTO CB, 1992, ARCH BIOCHEM BIOPHYS, V292, P199, DOI 10.1016/0003-9861(92)90068-8; CLEARY EG, 1983, INT REV CONNECT TISS, V10, P97; COCAPRADOS M, 1986, P NATL ACAD SCI USA, V83, P8754, DOI 10.1073/pnas.83.22.8754; COX BA, 1974, J BIOL CHEM, V249, P997; CURRAN ME, 1993, CELL, V73, P159, DOI 10.1016/0092-8674(93)90168-P; EWART AK, 1994, J CLIN INVEST, V93, P1071, DOI 10.1172/JCI117057; Gosline J, 2002, PHILOS T R SOC B, V357, P121, DOI 10.1098/rstb.2001.1022; GROSSO LE, 1993, BIOCHEMISTRY-US, V32, P13369, DOI 10.1021/bi00211a052; HAMODRAKAS SJ, 1985, J MOL BIOL, V186, P583, DOI 10.1016/0022-2836(85)90132-9; HAMODRAKAS SJ, 1988, PROTEIN ENG, V2, P201, DOI 10.1093/protein/2.3.201; Hanson PI, 1997, CELL, V90, P523, DOI 10.1016/S0092-8674(00)80512-7; HEUSER JE, 1983, J MOL BIOL, V169, P155, DOI 10.1016/S0022-2836(83)80179-X; HINEK A, 1993, J BIOL CHEM, V268, P1405; Hsiao H, 1999, CONNECT TISSUE RES, V40, P83, DOI 10.3109/03008209909029104; INDIK Z, 1989, AM J MED GENET, V34, P81, DOI 10.1002/ajmg.1320340115; Jensen SA, 2000, J BIOL CHEM, V275, P28449, DOI 10.1074/jbc.M004265200; Keene DR, 1997, J HISTOCHEM CYTOCHEM, V45, P1069, DOI 10.1177/002215549704500805; KOEDOOD M, 1995, J VIROL, V69, P2194, DOI 10.1128/JVI.69.4.2194-2207.1995; Li DY, 1997, HUM MOL GENET, V6, P1021, DOI 10.1093/hmg/6.7.1021; Mecham R, 1977, Adv Exp Med Biol, V79, P209; MECHAM RP, 1977, BIOCHEMISTRY-US, V16, P3825, DOI 10.1021/bi00636a017; Metcalfe K, 2000, EUR J HUM GENET, V8, P955, DOI 10.1038/sj.ejhg.5200564; Milewicz DM, 2000, MATRIX BIOL, V19, P471, DOI 10.1016/S0945-053X(00)00099-8; Ritty TM, 1999, J BIOL CHEM, V274, P8933, DOI 10.1074/jbc.274.13.8933; Robb BW, 1999, MOL BIOL CELL, V10, P3595, DOI 10.1091/mbc.10.11.3595; Robson P, 2000, MOL BIOL EVOL, V17, P1739, DOI 10.1093/oxfordjournals.molbev.a026272; ROBSON P, 1993, J BIOL CHEM, V268, P1440; ROSS R, 1969, J CELL BIOL, V40, P366, DOI 10.1083/jcb.40.2.366; Sechler JL, 1995, CIBA F SYMP, V192, P148; Tassabehji M, 1997, HUM MOL GENET, V6, P1029, DOI 10.1093/hmg/6.7.1029; Tassabehji M, 1998, HUM MOL GENET, V7, P1021, DOI 10.1093/hmg/7.6.1021; Trask TM, 2000, J BIOL CHEM, V275, P24400, DOI 10.1074/jbc.M003665200; Urban Z, 1999, HUM GENET, V104, P135, DOI 10.1007/s004390050926; Urban Z, 2000, HUM GENET, V106, P577, DOI 10.1007/s004390050028; Urban Z, 2001, HUM GENET, V109, P512, DOI 10.1007/s00439-001-0608-z; van Beek JD, 2002, P NATL ACAD SCI USA, V99, P10266, DOI 10.1073/pnas.152162299; WIRTSCHAFTER ZT, 1967, J CELL BIOL, V33, P481, DOI 10.1083/jcb.33.3.481; Zhang MC, 1999, J BIOL CHEM, V274, P981, DOI 10.1074/jbc.274.2.981	44	105	105	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 16	2003	278	20					18491	18498		10.1074/jbc.M212715200	http://dx.doi.org/10.1074/jbc.M212715200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677YX	12626514	hybrid			2022-12-25	WOS:000182838300118
J	Pankov, R; Cukierman, E; Clark, K; Matsumoto, K; Hahn, C; Poulin, B; Yamada, KM				Pankov, R; Cukierman, E; Clark, K; Matsumoto, K; Hahn, C; Poulin, B; Yamada, KM			Specific beta(1) integrin site selectively regulates Akt/protein kinase B signaling via local activation of protein phosphatase 2A	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FOCAL ADHESION KINASE; INTESTINAL EPITHELIAL-CELLS; BETA-1 CYTOPLASMIC DOMAIN; PHOSPHATIDYLINOSITOL 3-KINASE; TYROSINE PHOSPHORYLATION; MONOCLONAL-ANTIBODY; FIBRONECTIN RECEPTOR; EXTRACELLULAR-MATRIX; PLASMA-MEMBRANE; STIMULATED AKT	Integrin transmembrane receptors generate multiple signals, but how they mediate specific signaling is not clear. Here we test the hypothesis that particular sequences along the beta(1) integrin cytoplasmic domain may exist that are intimately related to specific integrin-mediated signaling pathways. Using systematic alanine mutagenesis of amino acids conserved between different beta integrin cytoplasmic domains, we identified the tryptophan residue at position 775 of human beta(1) integrin as specific and necessary for integrin-mediated protein kinase B/Akt survival signaling. Stable expression of a beta(1) integrin mutated at this amino acid in GD25 beta(1)-null cells resulted in reduction of Akt phosphorylation at both Ser(473) and Thr(308) activation sites. As a consequence, the cells were substantially more sensitive to serum starvation-induced apoptosis when compared with cells expressing wild type beta(1) integrin. This inactivation of Akt resulted from increased dephosphorylation by a localized active population of protein phosphatase 2A. Both Akt and protein phosphatase 2A were present in beta(1) integrin-organized cytoplasmic complexes, but the activity of this phosphatase was 2.5 times higher in the complexes organized by the mutant integrin. The mutation of Trp(775) specifically affected Akt signaling, without effects on other integrin-activated pathways including phosphoinositide 3-kinase, MAPK, JNK, and p38 nor did it influence activation of the integrin-responsive kinases focal adhesion kinase and Src. The identification of Trp(775) as a specific site for integrin-mediated Akt signaling supports the concept of specificity of signaling along the integrin cytoplasmic domain.	NIDCR, CDBRB, NIH, Bethesda, MD 20892 USA; NHLBI, Lab Cell Signaling, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR); National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)	Pankov, R (corresponding author), NIDCR, CDBRB, NIH, Bldg 30,Rm 421,30 Convent Dr MSC 4370, Bethesda, MD 20892 USA.	roumen.pankov@nih.gov	Pankov, Roumen G/B-3284-2014; Cukierman, Edna/A-3951-2013; Pankov, Roumen/AAK-3205-2021; cukierman, edna/AAU-8932-2020	Pankov, Roumen G/0000-0002-3157-3659; Pankov, Roumen/0000-0002-3157-3659; cukierman, edna/0000-0002-1452-9576; Yamada, Kenneth/0000-0003-1512-6805	NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [ZIADE000524] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [Z01DE000524] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Alahari SK, 2002, INT REV CYTOL, V220, P145; Alessi DR, 1997, CURR BIOL, V7, P776, DOI 10.1016/S0960-9822(06)00336-8; Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x; Almeida EAC, 2000, J CELL BIOL, V149, P741, DOI 10.1083/jcb.149.3.741; Anderson KE, 1998, CURR BIOL, V8, P684, DOI 10.1016/S0960-9822(98)70274-X; Andjelkovic M, 1996, P NATL ACAD SCI USA, V93, P5699, DOI 10.1073/pnas.93.12.5699; ARGRAVES WS, 1987, J CELL BIOL, V105, P1183, DOI 10.1083/jcb.105.3.1183; Bachelder RE, 1999, J CELL BIOL, V147, P1063, DOI 10.1083/jcb.147.5.1063; BAZZONI G, 1995, J BIOL CHEM, V270, P25570, DOI 10.1074/jbc.270.43.25570; Bodeau AL, 2001, J CELL SCI, V114, P2795; Bokel C, 2002, DEV CELL, V3, P311, DOI 10.1016/S1534-5807(02)00265-4; BRIESEWITZ R, 1995, MOL BIOL CELL, V6, P997, DOI 10.1091/mbc.6.8.997; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; CALALB MB, 1995, MOL CELL BIOL, V15, P954; Calderwood DA, 1999, J BIOL CHEM, V274, P28071, DOI 10.1074/jbc.274.40.28071; Calderwood DA, 2002, J BIOL CHEM, V277, P21749, DOI 10.1074/jbc.M111996200; Casamayor A, 1999, BIOCHEM J, V342, P287, DOI 10.1042/0264-6021:3420287; COOPER JA, 1986, MOL CELL BIOL, V6, P4467, DOI 10.1128/MCB.6.12.4467; Damsky CH, 2002, CURR OPIN CELL BIOL, V14, P594, DOI 10.1016/S0955-0674(02)00368-X; Danilkovitch A, 2000, MOL CELL BIOL, V20, P2218, DOI 10.1128/MCB.20.6.2218-2227.2000; Dedhar S, 2000, CURR OPIN CELL BIOL, V12, P250, DOI 10.1016/S0955-0674(99)00083-6; Dudek H, 1997, SCIENCE, V275, P661, DOI 10.1126/science.275.5300.661; Erdreich-Epstein A, 2000, CANCER RES, V60, P712; FASSLER R, 1995, J CELL BIOL, V128, P979, DOI 10.1083/jcb.128.5.979; Franke TF, 1997, SCIENCE, V275, P665, DOI 10.1126/science.275.5300.665; Frisch SM, 2001, CURR OPIN CELL BIOL, V13, P555, DOI 10.1016/S0955-0674(00)00251-9; Giancotti FG, 1999, SCIENCE, V285, P1028, DOI 10.1126/science.285.5430.1028; GILMORE AP, 1993, J CELL BIOL, V122, P337, DOI 10.1083/jcb.122.2.337; Ginsberg Mark H., 1992, Current Opinion in Cell Biology, V4, P766, DOI 10.1016/0955-0674(92)90099-X; Guilherme A, 1998, J BIOL CHEM, V273, P33119, DOI 10.1074/jbc.273.50.33119; GUTKIND JS, 1990, MOL CELL BIOL, V10, P3806, DOI 10.1128/MCB.10.7.3806; HEMLER ME, 1984, J IMMUNOL, V132, P3011; HONEYMAN TW, 1983, BIOCHEM J, V212, P489, DOI 10.1042/bj2120489; HORWITZ A, 1986, NATURE, V320, P531, DOI 10.1038/320531a0; Howe A, 1998, CURR OPIN CELL BIOL, V10, P220, DOI 10.1016/S0955-0674(98)80144-0; Howe AK, 2002, CURR OPIN GENET DEV, V12, P30, DOI 10.1016/S0959-437X(01)00260-X; Hughes PE, 1996, J BIOL CHEM, V271, P6571, DOI 10.1074/jbc.271.12.6571; Hynes RO, 2002, CELL, V110, P673, DOI 10.1016/S0092-8674(02)00971-6; Ilic D, 1998, J CELL BIOL, V143, P547; Ivaska J, 2002, MOL CELL BIOL, V22, P1352, DOI 10.1128/MCB.22.5.1352-1359.2002; Janssens V, 2001, BIOCHEM J, V353, P417, DOI 10.1042/0264-6021:3530417; JOHNSON RP, 1994, J BIOL CHEM, V269, P12611; Juliano RL, 2002, ANNU REV PHARMACOL, V42, P283, DOI 10.1146/annurev.pharmtox.42.090401.151133; Kaapa A, 1999, EXP CELL RES, V250, P524, DOI 10.1006/excr.1999.4533; KauffmanZeh A, 1997, NATURE, V385, P544, DOI 10.1038/385544a0; Kennedy SG, 1997, GENE DEV, V11, P701, DOI 10.1101/gad.11.6.701; King WG, 1997, MOL CELL BIOL, V17, P4406, DOI 10.1128/MCB.17.8.4406; KMIECIK TE, 1987, CELL, V49, P65, DOI 10.1016/0092-8674(87)90756-2; KOHN AD, 1995, EMBO J, V14, P4288, DOI 10.1002/j.1460-2075.1995.tb00103.x; Kozlova NI, 2001, ONCOGENE, V20, P4710, DOI 10.1038/sj.onc.1204619; LACALLE RA, 1989, GENE, V79, P375, DOI 10.1016/0378-1119(89)90220-5; Le Gall M, 2000, MOL BIOL CELL, V11, P1103, DOI 10.1091/mbc.11.3.1103; Lee JW, 2002, BBA-MOL CELL RES, V1542, P23, DOI 10.1016/S0167-4889(01)00161-6; Lee JW, 2000, MOL BIOL CELL, V11, P1973, DOI 10.1091/mbc.11.6.1973; LENTER M, 1993, P NATL ACAD SCI USA, V90, P9051, DOI 10.1073/pnas.90.19.9051; Levy L, 2000, MOL BIOL CELL, V11, P453, DOI 10.1091/mbc.11.2.453; Liu SC, 2000, J CELL SCI, V113, P3563; Maehama T, 1998, J BIOL CHEM, V273, P13375, DOI 10.1074/jbc.273.22.13375; Matter ML, 2001, J BIOL CHEM, V276, P27757, DOI 10.1074/jbc.M102014200; Meier R, 1998, EMBO J, V17, P7294, DOI 10.1093/emboj/17.24.7294; MIEKKA SI, 1982, THROMB RES, V27, P1, DOI 10.1016/0049-3848(82)90272-9; Millward TA, 1999, TRENDS BIOCHEM SCI, V24, P186, DOI 10.1016/S0968-0004(99)01375-4; Miranti CK, 2002, NAT CELL BIOL, V4, pE83, DOI 10.1038/ncb0402-e83; MOULD AP, 1995, FEBS LETT, V363, P118, DOI 10.1016/0014-5793(95)00301-O; Mulrooney J, 2000, EXP CELL RES, V258, P332, DOI 10.1006/excr.2000.4964; Mulrooney JP, 2001, J CELL SCI, V114, P2525; OTEY CA, 1993, J BIOL CHEM, V268, P21193; OTEY CA, 1990, J CELL BIOL, V111, P721, DOI 10.1083/jcb.111.2.721; OTOOLE TE, 1994, J CELL BIOL, V124, P1047, DOI 10.1083/jcb.124.6.1047; RESZKA AA, 1992, J CELL BIOL, V117, P1321, DOI 10.1083/jcb.117.6.1321; Sakai T, 1998, J CELL BIOL, V141, P527, DOI 10.1083/jcb.141.2.527; Sakai T, 2001, P NATL ACAD SCI USA, V98, P3808, DOI 10.1073/pnas.240456398; Sato S, 2000, P NATL ACAD SCI USA, V97, P10832, DOI 10.1073/pnas.170276797; SCHALLER MD, 1994, MOL CELL BIOL, V14, P1680, DOI 10.1128/MCB.14.3.1680; Schwartz MA, 2002, NAT CELL BIOL, V4, pE65, DOI 10.1038/ncb0402-e65; Schwartz MA, 2001, TRENDS CELL BIOL, V11, P466, DOI 10.1016/S0962-8924(01)02152-3; Sontag E, 2001, CELL SIGNAL, V13, P7, DOI 10.1016/S0898-6568(00)00123-6; Stokoe D, 1997, SCIENCE, V277, P567, DOI 10.1126/science.277.5325.567; Stupack DG, 2001, J CELL BIOL, V155, P459, DOI 10.1083/jcb.200106070; Stupack DG, 2002, J CELL SCI, V115, P3729, DOI 10.1242/jcs.00071; TAPLEY P, 1989, ONCOGENE, V4, P325; Tian B, 2002, J BIOL CHEM, V277, P24667, DOI 10.1074/jbc.M203565200; Tran H, 2002, J CELL SCI, V115, P2031; Vinogradova O, 2002, CELL, V110, P587, DOI 10.1016/S0092-8674(02)00906-6; Wennerberg K, 1996, J CELL BIOL, V132, P227, DOI 10.1083/jcb.132.1.227; Wennerberg K, 1998, J CELL SCI, V111, P1117; Wennerberg K, 2000, MOL CELL BIOL, V20, P5758, DOI 10.1128/MCB.20.15.5758-5765.2000; YAMADA KM, 1995, CURR OPIN CELL BIOL, V7, P681, DOI 10.1016/0955-0674(95)80110-3; Yellaturu CR, 2002, J BIOL CHEM, V277, P40148, DOI 10.1074/jbc.M206376200; Zhou SY, 1997, P NATL ACAD SCI USA, V94, P11345, DOI 10.1073/pnas.94.21.11345	91	83	84	1	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 16	2003	278	20					18671	18681		10.1074/jbc.M300879200	http://dx.doi.org/10.1074/jbc.M300879200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677YX	12637511	hybrid			2022-12-25	WOS:000182838300140
J	Qiao, ZS; Min, CY; Hua, QX; Weiss, MA; Feng, YM				Qiao, ZS; Min, CY; Hua, QX; Weiss, MA; Feng, YM			In vitro refolding of human proinsulin - Kinetic intermediates, putative disulfide-forming pathway, folding initiation site, and potential role of C-peptide in folding process	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR-I; PANCREATIC TRYPSIN-INHIBITOR; ENGINEERED INSULIN MONOMER; STRUCTURAL INFORMATION; MASS-SPECTROMETRY; NATIVE MOLECULE; RIBONUCLEASE-A; SMALL PROTEINS; IGF-I; BPTI	Human insulin is a double-chain peptide that is synthesized in vivo as a single-chain human proinsulin (HPI). We have investigated the disulfide-forming pathway of a single-chain porcine insulin precursor (PIP). Here we further studied the folding pathway of HPI in vitro. While the oxidized refolding process of HPI was quenched, four obvious intermediates (namely P1, P2, P3, and P4, respectively) with three disulfide bridges were isolated and characterized. Contrary to the folding pathway of PIP, no intermediates with one- or two-disulfide bonds could be captured under different refolding conditions. CD analysis showed that P1, P2, and P3 retained partially structural conformations, whereas P4 contained little secondary structure. Based on the time-dependent distribution, disulfide pair analysis, and disulfide-reshuffling process of the intermediates, we have proposed that the folding pathway of HPI is significantly different from that of PIP. These differences reveal that the C-peptide not only facilitates the folding of HPI but also governs its kinetic folding pathway of HPI. Detailed analysis of the molecular folding process reveals that there are some similar folding mechanisms between PIP and HPI. These similarities imply that the initiation site for the folding of PIP/HPI may reside in the central alpha-helix of the B-chain. The formation of disulfide A20-B19 may guide the transfer of the folding information from the B-chain template to the unstructured A-chain. Furthermore, the implications of this in vitro refolding study on the in vivo folding process of HPI have been discussed.	Chinese Acad Sci, Shanghai Inst Biol Sci, Inst Biochem & Cell Biol, Shanghai 200031, Peoples R China; Case Western Reserve Univ, Sch Med, Dept Biochem, Cleveland, OH 44016 USA	Chinese Academy of Sciences; Shanghai Institutes for Biological Sciences, CAS; Case Western Reserve University	Feng, YM (corresponding author), Chinese Acad Sci, Shanghai Inst Biol Sci, Inst Biochem & Cell Biol, 320 Yue Yang Rd, Shanghai 200031, Peoples R China.	fengym@sunm.shcnc.ac.cn						Alm E, 1999, CURR OPIN STRUC BIOL, V9, P189, DOI 10.1016/S0959-440X(99)80027-X; ANFINSEN CB, 1973, SCIENCE, V181, P223, DOI 10.1126/science.181.4096.223; Baker D, 2000, NATURE, V405, P39, DOI 10.1038/35011000; BAKER EN, 1988, PHILOS T ROY SOC B, V319, P369, DOI 10.1098/rstb.1988.0058; BALDWIN RL, 1989, TRENDS BIOCHEM SCI, V14, P291, DOI 10.1016/0968-0004(89)90067-4; BEDARKAR S, 1977, NATURE, V270, P449, DOI 10.1038/270449a0; Bulaj G, 1999, PROTEIN SCI, V8, P1825, DOI 10.1110/ps.8.9.1825; Bullesbach EE, 1997, BIOCHEMISTRY-US, V36, P10735, DOI 10.1021/bi970393n; CHAN SJ, 1990, P NATL ACAD SCI USA, V87, P9319, DOI 10.1073/pnas.87.23.9319; CHANG JY, 1995, J BIOL CHEM, V270, P9207, DOI 10.1074/jbc.270.16.9207; CHANG JY, 1994, J BIOL CHEM, V269, P22087; Chang JY, 1996, BIOCHEMISTRY-US, V35, P11702, DOI 10.1021/bi9606915; CHATRENET B, 1993, J BIOL CHEM, V268, P20988; Chen LM, 2002, J BIOCHEM, V131, P855, DOI 10.1093/oxfordjournals.jbchem.a003175; Creighton T E, 1986, Methods Enzymol, V131, P83; Creighton TE, 1997, BIOL CHEM, V378, P731; Creighton TE, 1996, FASEB J, V10, P110, DOI 10.1096/fasebj.10.1.8566531; CREIGHTON TE, 1984, J MOL BIOL, V179, P497, DOI 10.1016/0022-2836(84)90077-9; DARBY NJ, 1995, J MOL BIOL, V249, P463, DOI 10.1006/jmbi.1995.0309; DAVIDSON HW, 1987, BIOCHEM J, V245, P575, DOI 10.1042/bj2450575; DAVIDSON HW, 1988, NATURE, V333, P93, DOI 10.1038/333093a0; FRANK BH, 1972, BIOCHEMISTRY-US, V11, P4926, DOI 10.1021/bi00776a008; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; Guo ZY, 2002, BIOCHEMISTRY-US, V41, P1556, DOI 10.1021/bi011166v; Guo ZY, 2001, BIOL CHEM, V382, P443, DOI 10.1515/BC.2001.054; HIROMICHI NS, 1980, SCI SINICA, V23, P1053; HOBER S, 1992, BIOCHEMISTRY-US, V31, P1749, DOI 10.1021/bi00121a024; Hua QX, 1996, J MOL BIOL, V259, P297, DOI 10.1006/jmbi.1996.0320; HUA QX, 1995, NAT STRUCT BIOL, V2, P129, DOI 10.1038/nsb0295-129; Hua QX, 2002, BIOCHEMISTRY-US, V41, P14700, DOI 10.1021/bi0202981; Hua QX, 2002, J BIOL CHEM, V277, P43443, DOI 10.1074/jbc.M206107200; Hua QX, 1996, J MOL BIOL, V264, P390, DOI 10.1006/jmbi.1996.0648; Hua QX, 2001, BIOCHEMISTRY-US, V40, P12299, DOI 10.1021/bi011021o; HWANG C, 1992, SCIENCE, V257, P1496, DOI 10.1126/science.1523409; KIM PS, 1990, ANNU REV BIOCHEM, V59, P631, DOI 10.1146/annurev.biochem.59.1.631; KIM PS, 1982, ANNU REV BIOCHEM, V51, P459, DOI 10.1146/annurev.bi.51.070182.002331; LOW BW, 1974, NATURE, V248, P339, DOI 10.1038/248339a0; MATTHEWS CR, 1993, ANNU REV BIOCHEM, V62, P653, DOI 10.1146/annurev.bi.62.070193.003253; MILLER JA, 1993, BIOCHEMISTRY-US, V32, P5203, DOI 10.1021/bi00070a032; Milner SJ, 1999, BIOTECHNOL BIOENG, V62, P693; Olsen HB, 1996, BIOCHEMISTRY-US, V35, P8836, DOI 10.1021/bi960292+; Qiao ZS, 2001, BIOCHEMISTRY-US, V40, P2662, DOI 10.1021/bi001613r; RINDERKNECHT E, 1978, FEBS LETT, V89, P283, DOI 10.1016/0014-5793(78)80237-3; RINDERKNECHT E, 1978, J BIOL CHEM, V253, P2769; Rosenfeld RD, 1997, ARCH BIOCHEM BIOPHYS, V342, P298, DOI 10.1006/abbi.1997.9996; ROTHWARF DM, 1993, BIOCHEMISTRY-US, V32, P2671, DOI 10.1021/bi00061a027; ROY M, 1990, J BIOL CHEM, V265, P5448; SMIT AB, 1988, NATURE, V331, P535, DOI 10.1038/331535a0; SNELL CR, 1975, J BIOL CHEM, V250, P6291; STEINER DF, 1978, DIABETES, V27, P145, DOI 10.2337/diab.27.1.S145; STEINER DF, 1967, SCIENCE, V157, P697, DOI 10.1126/science.157.3789.697; STEINER DF, 1971, J BIOL CHEM, V246, P1365; STEINER DF, 1973, NATURE, V243, P528, DOI 10.1038/243528a0; STEINER DF, 1988, HORM METAB RES, V20, P443, DOI 10.1055/s-2007-1010855; STEINER DF, 1967, T NEW YORK ACAD SCI, V30, P60, DOI 10.1111/j.2164-0947.1967.tb02452.x; STEINER DF, 1968, P NATL ACAD SCI USA, V60, P622, DOI 10.1073/pnas.60.2.622; TANG JG, 1990, BIOCHEM J, V268, P429, DOI 10.1042/bj2680429; WANG CC, 1991, TRENDS BIOCHEM SCI, V16, P279, DOI 10.1016/0968-0004(91)90114-B; Wedemeyer WJ, 2000, BIOCHEMISTRY-US, V39, P4207, DOI 10.1021/bi992922o; WEISS MA, 1990, BIOCHEMISTRY-US, V29, P8389, DOI 10.1021/bi00488a028; Weiss MA, 2000, BIOCHEMISTRY-US, V39, P15429, DOI 10.1021/bi001905s; WEISS MA, 1991, BIOCHEMISTRY-US, V30, P7373, DOI 10.1021/bi00244a004; WEISSMAN JS, 1992, P NATL ACAD SCI USA, V89, P9900, DOI 10.1073/pnas.89.20.9900; WEISSMAN JS, 1992, CELL, V71, P841, DOI 10.1016/0092-8674(92)90559-U; WEISSMAN JS, 1991, SCIENCE, V253, P1386, DOI 10.1126/science.1716783; Winter J, 2002, J BIOL CHEM, V277, P310, DOI 10.1074/jbc.M107832200; Wu J, 1998, PROTEIN SCI, V7, P1017; Xu XB, 1996, BIOCHEMISTRY-US, V35, P6406, DOI 10.1021/bi960090d; Yan H, 2003, PROTEIN SCI, V12, P768, DOI 10.1110/ps.0237203; Yang Y, 1999, J BIOL CHEM, V274, P37598, DOI 10.1074/jbc.274.53.37598	70	70	75	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 16	2003	278	20					17800	17809		10.1074/jbc.M300906200	http://dx.doi.org/10.1074/jbc.M300906200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677YX	12624089	hybrid			2022-12-25	WOS:000182838300028
J	Stephens, AN; Khan, MA; Roucou, X; Nagley, P; Devenish, RJ				Stephens, AN; Khan, MA; Roucou, X; Nagley, P; Devenish, RJ			The molecular neighborhood of subunit 8 of yeast mitochondrial F1F0-ATP synthase probed by cysteine scanning mutagenesis and chemical modification	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CENTRAL HYDROPHOBIC DOMAIN; ATP SYNTHASE; SACCHAROMYCES-CEREVISIAE; ENZYME COMPLEX; ROTARY MOTOR; F0 SECTOR; H+-ATPASE; 2ND STALK; MEMBRANE; ROTATION	The detailed membrane topography and neighboring polypeptides of subunit 8 in yeast mitochondrial ATP synthase have been determined using a combination of cysteine scanning mutagenesis and chemical modification. 46 single cysteine substitution mutants encompassing the length of the subunit 8 protein were constructed by site-directed mutagenesis. Expression of each cysteine variant in yeast lacking endogenous subunit 8 restored respiratory phenotype to cells and had little measurable effect on ATP hydrolase function. The exposure of each introduced cysteine residue to the aqueous environment was assessed in isolated mitochondria using the fluorescent thiol-modifying probe fluorescein 5-maleimide. The first 14 and last 13 amino acids of subunit 8 were accessible to fluorescein 5-maleimide in osmotically lysed mitochondria and are thus extrinsic to the lipid bilayer, indicating a 21-amino acid transmembrane span. The C-terminal region of subunit 8 was partially occluded by other ATP synthase subunits, especially in a small region surrounding Val-40 that was demonstrated to play an important role in maintaining the stability of the F-1-F-0 interaction. Cross-linking using heterobifunctional reagents revealed the proximity of subunit 8 to subunits b, d, and f in the matrix and to subunits b, f, and 6 in the intermembrane space. A disulfide bridge was also formed between subunit 8(F7C) or (M10C) and residue Cys-23 of subunit 6, demonstrating a close interaction between these two hydrophobic membrane subunits and confirming the location of the N termini of each in the intermembrane space. We conclude that subunit 8 is an integral component of the stator stalk of yeast mitochondrial F1F0-ATP synthase.	Monash Univ, Dept Biochem & Mol Biol, Clayton, Vic 3800, Australia	Monash University	Devenish, RJ (corresponding author), Monash Univ, Dept Biochem & Mol Biol, Clayton Campus, Clayton, Vic 3800, Australia.		Stephens, Andrew/G-5161-2013					ABRAHAMS JP, 1994, NATURE, V370, P621, DOI 10.1038/370621a0; ALTENBACH C, 1990, SCIENCE, V248, P1088, DOI 10.1126/science.2160734; Arnold I, 1998, EMBO J, V17, P7170, DOI 10.1093/emboj/17.24.7170; Arnold I, 1999, J BIOL CHEM, V274, P36, DOI 10.1074/jbc.274.1.36; Bateson M, 1999, J BIOL CHEM, V274, P7462, DOI 10.1074/jbc.274.11.7462; Bottcher B, 2000, BBA-BIOENERGETICS, V1458, P404, DOI 10.1016/S0005-2728(00)00090-6; Boyer PD, 1997, ANNU REV BIOCHEM, V66, P717, DOI 10.1146/annurev.biochem.66.1.717; DEVENISH RJ, 1992, ANN NY ACAD SCI, V671, P403, DOI 10.1111/j.1749-6632.1992.tb43814.x; Devenish RJ, 2000, BBA-BIOENERGETICS, V1458, P428, DOI 10.1016/S0005-2728(00)00092-X; Frillingos S, 1998, FASEB J, V12, P1281, DOI 10.1096/fasebj.12.13.1281; GALANIS M, 1990, BIOCHEM INT, V22, P1059; Gibbons C, 2000, NAT STRUCT BIOL, V7, P1055; GRASSO DG, 1991, EUR J BIOCHEM, V199, P203, DOI 10.1111/j.1432-1033.1991.tb16110.x; HADIKUSUMO RG, 1984, BIOCHIM BIOPHYS ACTA, V765, P258, DOI 10.1016/0005-2728(84)90164-6; Hasler K, 1998, FEBS LETT, V426, P301, DOI 10.1016/S0014-5793(98)00358-5; Joseph-Liauzun E, 1998, J BIOL CHEM, V273, P2146, DOI 10.1074/jbc.273.4.2146; Kaim G, 2002, FEBS LETT, V525, P156, DOI 10.1016/S0014-5793(02)03097-1; Karlin A, 1998, METHOD ENZYMOL, V293, P123; Karrasch S, 1999, J MOL BIOL, V290, P379, DOI 10.1006/jmbi.1999.2897; KLEBE RJ, 1983, GENE, V25, P333, DOI 10.1016/0378-1119(83)90238-X; Law RHP, 1995, METHOD ENZYMOL, V260, P133, DOI 10.1016/0076-6879(95)60135-X; LAW RHP, 1988, FEBS LETT, V236, P501, DOI 10.1016/0014-5793(88)80086-3; MACREADIE IG, 1983, NUCLEIC ACIDS RES, V11, P4435, DOI 10.1093/nar/11.13.4435; MARZUKI S, 1989, BIOCHIM BIOPHYS ACTA, V975, P222, DOI 10.1016/S0005-2728(89)80252-X; MCENERY MW, 1989, J BIOL CHEM, V264, P12029; MICHON T, 1988, EUR J BIOCHEM, V172, P621, DOI 10.1111/j.1432-1033.1988.tb13934.x; NAGLEY P, 1988, TRENDS GENET, V4, P46, DOI 10.1016/0168-9525(88)90066-2; NAGLEY P, 1990, BIOENERGETICS, P305; NAGLEY P, 1989, TRENDS BIOCHEM SCI, V14, P31, DOI 10.1016/0968-0004(89)90087-X; Nishio K, 2002, P NATL ACAD SCI USA, V99, P13448, DOI 10.1073/pnas.202149599; NORAIS N, 1991, J BIOL CHEM, V266, P16541; Panke O, 2000, FEBS LETT, V472, P34, DOI 10.1016/S0014-5793(00)01436-8; Papakonstantinou T, 1996, CURR GENET, V30, P12, DOI 10.1007/s002940050094; PAPAKONSTANTINOU T, 1995, EUR J BIOCHEM, V227, P745, DOI 10.1111/j.1432-1033.1995.tb20197.x; PAPAKONSTANTINOU T, 1993, BIOCHIM BIOPHYS ACTA, V1144, P22, DOI 10.1016/0005-2728(93)90026-C; Papakonstantinou T, 1996, BIOCHEM MOL BIOL INT, V39, P253; PAUL MF, 1989, EUR J BIOCHEM, V185, P163, DOI 10.1111/j.1432-1033.1989.tb15098.x; Paumard P, 2002, BIOCHEMISTRY-US, V41, P10390, DOI 10.1021/bi025923g; Paumard P, 2000, BIOCHEMISTRY-US, V39, P4199, DOI 10.1021/bi992438l; Revington M, 1999, J BIOL CHEM, V274, P31094, DOI 10.1074/jbc.274.43.31094; Roucou X, 1999, EUR J BIOCHEM, V261, P444, DOI 10.1046/j.1432-1327.1999.00289.x; Roudeau S, 1999, J BIOENERG BIOMEMBR, V31, P85, DOI 10.1023/A:1005407525915; Sambongi Y, 1999, SCIENCE, V286, P1722, DOI 10.1126/science.286.5445.1722; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; Soubannier V, 1999, BIOCHEMISTRY-US, V38, P15017, DOI 10.1021/bi9916067; Soubannier V, 2002, J BIOL CHEM, V277, P10739, DOI 10.1074/jbc.M111882200; Spannagel C, 1998, BIOCHEMISTRY-US, V37, P615, DOI 10.1021/bi9714971; Spannagel C, 1997, EUR J BIOCHEM, V247, P1111, DOI 10.1111/j.1432-1033.1997.01111.x; Spannagel C, 1998, BBA-BIOMEMBRANES, V1414, P260, DOI 10.1016/S0005-2736(98)00174-6; Steiner-Mordoch S., 1999, J BIOL CHEM, V274, P19480; Stephens AN, 2000, EUR J BIOCHEM, V267, P6443, DOI 10.1046/j.1432-1327.2000.01733.x; Stock D, 1999, SCIENCE, V286, P1700, DOI 10.1126/science.286.5445.1700; STRAFFON AFL, 1994, BIOCHEM BIOPH RES CO, V203, P1567, DOI 10.1006/bbrc.1994.2365; Tamura N, 2001, J BIOL CHEM, V276, P20330, DOI 10.1074/jbc.M007993200; Tsunoda SP, 2001, P NATL ACAD SCI USA, V98, P6560, DOI 10.1073/pnas.111128098; Tsunoda SP, 2001, P NATL ACAD SCI USA, V98, P898, DOI 10.1073/pnas.031564198; Valiyaveetil FI, 1998, J BIOL CHEM, V273, P16241, DOI 10.1074/jbc.273.26.16241; VELOURS J, 1986, BIOCHEM BIOPH RES CO, V138, P78, DOI 10.1016/0006-291X(86)90249-4; VELOURS J, 1984, EMBO J, V3, P207, DOI 10.1002/j.1460-2075.1984.tb01785.x; Wilkens S, 1998, NATURE, V393, P29, DOI 10.1038/29908; Yasuda R, 2001, NATURE, V410, P898, DOI 10.1038/35073513; Yasuda R, 1998, CELL, V93, P1117, DOI 10.1016/S0092-8674(00)81456-7; YOSHIDA M, 1975, J BIOL CHEM, V250, P7910	63	33	35	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 16	2003	278	20					17867	17875		10.1074/jbc.M300967200	http://dx.doi.org/10.1074/jbc.M300967200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677YX	12626501	hybrid			2022-12-25	WOS:000182838300036
J	Takemoto-Kimura, S; Terai, H; Takamoto, M; Ohmae, S; Kikumura, S; Segi, E; Arakawa, Y; Furuyashiki, T; Narumiya, S; Bito, H				Takemoto-Kimura, S; Terai, H; Takamoto, M; Ohmae, S; Kikumura, S; Segi, E; Arakawa, Y; Furuyashiki, T; Narumiya, S; Bito, H			Molecular cloning and characterization of CLICK-III/CaMKI gamma, a novel membrane-anchored neuronal Ca2+/calmodulin-dependent protein kinase (CaMK)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LONG-TERM POTENTIATION; CENTRAL-NERVOUS-SYSTEM; RAT-BRAIN; SYNAPTIC PLASTICITY; CREB PHOSPHORYLATION; GENE-EXPRESSION; IV KINASE; CALMODULIN; ACTIVATION; CALCIUM	During a screen for novel putative Ca2+/calmodulin-dependent protein kinase (CaMK)-like CREB kinases (CLICKs), we have cloned a full-length cDNA for CLICK-III/CaMKIgamma, an isoform of the CaMKI family with an extended C-terminal domain ending with CAAX motif (where AA is aliphatic acid). As expected from the similarity of its kinase domain with the other CaMKI isoforms, full activation of CLICK-III/CaMKIgamma required both Ca2+/CaM and phosphorylation by CaMKK. We also found that Ca2+/cAMP-response element-binding protein (CREB) was a good substrate for CLICK-III/CaMKIgamma, at least in vitro. Interestingly enough, CLICKIII/CaMKIgamma transcripts were most abundant in neurons, with the highest levels in limited nuclei such as the central nucleus of the amygdala (CeA) and the ventromedial hypothalamus. Consistent with the presence of the CAAX motif, CLICK-III/CaMKIgamma was found to be anchored to various membrane compartments, especially to Golgi and plasma membranes. Both point mutation in the CAAX motif and treatment with compactin, a 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitor, disrupted such membrane localization, suggesting that membrane localization of CLICK-III/CaMKIgamma occurred in a prenylation-dependent way. These findings provide a novel mechanism by which neuronal CaMK activity could be targeted to specific membrane compartments.	Kyoto Univ, Fac Med, Dept Pharmacol, Sakyo Ku, Kyoto 6068315, Japan; Japan Sci & Technol Corp, PRESTO, Sakyo Ku, Kyoto 6068315, Japan; Univ Tokyo, Grad Sch Med, Dept Neurochem, Bunkyo Ku, Tokyo 1130033, Japan	Kyoto University; Japan Science & Technology Agency (JST); University of Tokyo	Bito, H (corresponding author), Kyoto Univ, Fac Med, Dept Pharmacol, Sakyo Ku, Kyoto 6068315, Japan.		Bito, Haruhiko/A-8635-2008; Furuyashiki, Tomoyuki/B-8760-2014; Furuyashiki, Tomoyuki/AAG-5283-2019; Arakawa, Yoshiki/H-6067-2017	Furuyashiki, Tomoyuki/0000-0001-8089-8399; Furuyashiki, Tomoyuki/0000-0001-8089-8399; Arakawa, Yoshiki/0000-0003-4626-4645; Segi-Nishida, Eri/0000-0002-0803-6513; Bito, Haruhiko/0000-0001-6315-9594; Ohmae, Shogo/0000-0003-1726-4961				Anderson KA, 1998, J BIOL CHEM, V273, P31880, DOI 10.1074/jbc.273.48.31880; Berridge MJ, 1998, NATURE, V395, P645, DOI 10.1038/27094; Bito H, 1996, CELL, V87, P1203, DOI 10.1016/S0092-8674(00)81816-4; Bito H, 1997, CURR OPIN NEUROBIOL, V7, P419, DOI 10.1016/S0959-4388(97)80072-4; Bito H, 1998, CELL CALCIUM, V23, P143, DOI 10.1016/S0143-4160(98)90113-0; BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; Choy E, 1999, CELL, V98, P69, DOI 10.1016/S0092-8674(00)80607-8; Davis M, 2001, MOL PSYCHIATR, V6, P13, DOI 10.1038/sj.mp.4000812; Deisseroth K, 1996, NEURON, V16, P89, DOI 10.1016/S0896-6273(00)80026-4; Edelman AM, 1996, J BIOL CHEM, V271, P10806, DOI 10.1074/jbc.271.18.10806; El-Husseini AED, 2002, NAT REV NEUROSCI, V3, P791, DOI 10.1038/nrn940; ERONDU NE, 1985, J NEUROSCI, V5, P3270; Flanagan-Cato LM, 2001, HORM BEHAV, V40, P178, DOI 10.1006/hbeh.2001.1679; Fujisawa H, 2001, J BIOCHEM-TOKYO, V129, P193, DOI 10.1093/oxfordjournals.jbchem.a002843; FUKUNAGA K, 1995, J BIOL CHEM, V270, P6119, DOI 10.1074/jbc.270.11.6119; HARIBABU B, 1995, EMBO J, V14, P3679, DOI 10.1002/j.1460-2075.1995.tb00037.x; Harris KM, 1999, CURR OPIN NEUROBIOL, V9, P343, DOI 10.1016/S0959-4388(99)80050-6; Ho N, 2000, J NEUROSCI, V20, P6459, DOI 10.1523/JNEUROSCI.20-17-06459.2000; Hook SS, 2001, ANNU REV PHARMACOL, V41, P471, DOI 10.1146/annurev.pharmtox.41.1.471; Hudmon A, 2002, ANNU REV BIOCHEM, V71, P473, DOI 10.1146/annurev.biochem.71.110601.135410; Kang HJ, 2001, CELL, V106, P771, DOI 10.1016/S0092-8674(01)00497-4; Kasahara J, 2001, J BIOL CHEM, V276, P24044, DOI 10.1074/jbc.M100247200; KENNEDY MB, 1994, ANNU REV BIOCHEM, V63, P571, DOI 10.1146/annurev.biochem.63.1.571; Kitani T, 1997, J BIOCHEM-TOKYO, V122, P243; Kutzleb C, 1998, J CELL BIOL, V143, P795, DOI 10.1083/jcb.143.3.795; Liao JK, 2002, J CLIN INVEST, V110, P285, DOI 10.1172/JCI200216421; Lisman J, 2002, NAT REV NEUROSCI, V3, P175, DOI 10.1038/nrn753; Malinow R, 2002, ANNU REV NEUROSCI, V25, P103, DOI 10.1146/annurev.neuro.25.112701.142758; Matsushita M, 1998, J BIOL CHEM, V273, P21473, DOI 10.1074/jbc.273.34.21473; Matthies H, 1997, NEUROSCIENCE, V79, P341, DOI 10.1016/S0306-4522(96)00703-8; Mauch DH, 2001, SCIENCE, V294, P1354, DOI 10.1126/science.294.5545.1354; Naito Y, 1997, J BIOL CHEM, V272, P32704, DOI 10.1074/jbc.272.51.32704; NAKAMURA Y, 1995, NEUROSCIENCE, V68, P181, DOI 10.1016/0306-4522(95)00092-W; OIDA H, 1995, BRIT J PHARMACOL, V116, P2828, DOI 10.1111/j.1476-5381.1995.tb15933.x; OKUNO S, 1994, J BIOCHEM, V116, P923, DOI 10.1093/oxfordjournals.jbchem.a124617; Picciotto M R, 1996, Adv Pharmacol, V36, P251, DOI 10.1016/S1054-3589(08)60585-2; PICCIOTTO MR, 1995, SYNAPSE, V20, P75, DOI 10.1002/syn.890200111; RIBAR TJ, 2002, J NEUROSCI, V20, P1; Sakagami H, 2000, EUR J NEUROSCI, V12, P89, DOI 10.1046/j.1460-9568.2000.00883.x; Schneggenburger R, 2002, TRENDS NEUROSCI, V25, P206, DOI 10.1016/S0166-2236(02)02139-2; SHENG M, 1991, SCIENCE, V252, P1427, DOI 10.1126/science.1646483; Silva AJ, 1998, ANNU REV NEUROSCI, V21, P127, DOI 10.1146/annurev.neuro.21.1.127; Soderling TR, 2001, CHEM REV, V101, P2341, DOI 10.1021/cr0002386; Thiagarajan TC, 2002, NEURON, V36, P1103, DOI 10.1016/S0896-6273(02)01049-8; TOKUMITSU H, 1994, J BIOL CHEM, V269, P28640; TOKUMITSU H, 1995, J BIOL CHEM, V270, P19320, DOI 10.1074/jbc.270.33.19320; Ueda T, 1999, J NEUROCHEM, V73, P2119; Verploegen S, 2000, BLOOD, V96, P3215; Wei F, 2002, NAT NEUROSCI, V5, P573, DOI 10.1038/nn0602-855; WOODS SC, 1999, FUNDAMENTAL NEUROSCI, P1090; Yokokura H, 1997, ADV SEC MESS PHOSPH, V31, P151; Yokokura H, 1997, BBA-PROTEIN STRUCT M, V1338, P8, DOI 10.1016/S0167-4838(97)00004-6; Zhang FL, 1996, ANNU REV BIOCHEM, V65, P241, DOI 10.1146/annurev.bi.65.070196.001325	53	47	52	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 16	2003	278	20					18597	18605		10.1074/jbc.M300578200	http://dx.doi.org/10.1074/jbc.M300578200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677YX	12637513	hybrid			2022-12-25	WOS:000182838300132
J	Van Impe, K; De Corte, V; Eichinger, L; Bruyneel, E; Mareel, M; Vandekerckhove, JL; Gettemans, J				Van Impe, K; De Corte, V; Eichinger, L; Bruyneel, E; Mareel, M; Vandekerckhove, JL; Gettemans, J			The nucleo-cytoplasmic actin-binding protein CapG lacks a nuclear export sequence present in structurally related proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IN-VIVO; SIGNAL; PHOSPHORYLATION; LOCALIZATION; EXPRESSION; TRANSPORT; RNAS; GELSOLIN; RECEPTOR; COFILIN	Despite thorough structure-function analyses, it remains unclear how CapG, a ubiquitous F-actin barbed end capping protein that controls actin microfilament turnover in cells, is able to reside in the nucleus and cytoplasm, whereas structurally related actin-binding proteins are predominantly cytoplasmic. Here we report the molecular basis for the different subcellular localization of CapG, severin, and fragminP. Green fluorescent protein-tagged fragminP and severin accumulate in the nucleus upon treatment of transfected cells with the CRM1 inhibitor leptomycin B. We identified a nuclear export sequence in severin and fragminP, which is absent in CapG. Deletion of amino acids Met(1)-Leu(27) resulted in nuclear accumulation of severin and fragminP. Tagging this sequence to CapG triggered nuclear export, whereas mutation of single leucine residues (Leu(17), Leu(21), and Leu(27)) in the export sequence inhibited nuclear export. Based on these findings, a nuclear export signal was identified in myopodin, a muscle-specific actin-binding protein, and the Bloom syndrome protein, a RecQ-like helicase. Deletion of the myopodin nuclear export sequence blocked invasion into collagen type I of C2C12 cells transiently overexpressing myopodin. Our findings explain regulated subcellular targeting of distinct classes of actin-binding proteins.	Univ Ghent VIB, Fac Med & Hlth Sci, Dept Biochem,Rommelaere Inst, B-9000 Ghent, Belgium; Univ Cologne, Fak Med, Inst Biochem 1, D-50931 Cologne, Germany; Ghent Univ Hosp, Dept Radiotherapy & Nucl Med, Expt Cancerol Lab, B-9000 Ghent, Belgium	Flanders Institute for Biotechnology (VIB); Ghent University; University of Cologne; Ghent University; Ghent University Hospital	Gettemans, J (corresponding author), Univ Ghent VIB, Fac Med & Hlth Sci, Dept Biochem,Rommelaere Inst, Albert Baertsoenkaai 3, B-9000 Ghent, Belgium.	jan.gettemans@rug.ac.be	Eichinger, Ludwig/AAJ-8895-2021	Eichinger, Ludwig/0000-0003-1594-6117				ANDRE E, 1988, J BIOL CHEM, V263, P722; Bogerd HP, 1996, MOL CELL BIOL, V16, P4207; BRACKE ME, 2001, METASTASIS RES PROTO, P81; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROCK AM, 1988, DEV BIOL, V128, P30, DOI 10.1016/0012-1606(88)90263-1; Constantin B, 1998, J CELL SCI, V111, P1695; Dobbelstein M, 1997, EMBO J, V16, P4276, DOI 10.1093/emboj/16.14.4276; FISCHER U, 1995, CELL, V82, P475, DOI 10.1016/0092-8674(95)90436-0; Fornerod M, 1997, CELL, V90, P1051, DOI 10.1016/S0092-8674(00)80371-2; GETTEMANS J, 1995, J BIOL CHEM, V270, P2644, DOI 10.1074/jbc.270.6.2644; Gorlich D, 1999, ANNU REV CELL DEV BI, V15, P607, DOI 10.1146/annurev.cellbio.15.1.607; Heger P, 2001, TRAFFIC, V2, P544, DOI 10.1034/j.1600-0854.2001.20804.x; Henderson BR, 2000, EXP CELL RES, V256, P213, DOI 10.1006/excr.2000.4825; Hirota T, 2000, J CELL BIOL, V149, P1073, DOI 10.1083/jcb.149.5.1073; Hofmann W, 2001, J CELL BIOL, V152, P895, DOI 10.1083/jcb.152.5.895; JOHNSTON PA, 1990, J BIOL CHEM, V265, P17946; Kudo N, 1998, EXP CELL RES, V242, P540, DOI 10.1006/excr.1998.4136; Mattaj IW, 1998, ANNU REV BIOCHEM, V67, P265, DOI 10.1146/annurev.biochem.67.1.265; MERTENS N, 1995, GENE, V164, P9, DOI 10.1016/0378-1119(95)00505-Z; Nagaoka R, 1996, CELL MOTIL CYTOSKEL, V35, P200, DOI 10.1002/(SICI)1097-0169(1996)35:3<200::AID-CM3>3.0.CO;2-C; Nakielny S, 1999, CELL, V99, P677, DOI 10.1016/S0092-8674(00)81666-9; Nebl G, 1996, J BIOL CHEM, V271, P26276, DOI 10.1074/jbc.271.42.26276; OHTA Y, 1989, J BIOL CHEM, V264, P16143; ONODA K, 1993, CELL MOTIL CYTOSKEL, V26, P227, DOI 10.1002/cm.970260306; ONODA K, 1993, J BIOL CHEM, V268, P4106; Rando OJ, 2000, TRENDS CELL BIOL, V10, P92, DOI 10.1016/S0962-8924(99)01713-4; Samstag Y, 1996, J IMMUNOL, V156, P4167; Sandri-Goldin RM, 1998, GENE DEV, V12, P868, DOI 10.1101/gad.12.6.868; Sklyarova T, 2002, J BIOL CHEM, V277, P39840, DOI 10.1074/jbc.M207052200; Sotiropoulos A, 1999, CELL, V98, P159, DOI 10.1016/S0092-8674(00)81011-9; Ting HJ, 2002, P NATL ACAD SCI USA, V99, P661, DOI 10.1073/pnas.022469899; TJampens D, 1997, J CELL SCI, V110, P1215; VLEMINCKX K, 1991, CELL, V66, P107, DOI 10.1016/0092-8674(91)90143-M; Wada A, 1998, EMBO J, V17, P1635, DOI 10.1093/emboj/17.6.1635; Weins A, 2001, J CELL BIOL, V155, P393, DOI 10.1083/jcb.200012039; WEN W, 1994, J BIOL CHEM, V269, P32214; Witke W, 2001, J CELL BIOL, V154, P775, DOI 10.1083/jcb.200101113; Wulfkuhle JD, 1999, J CELL SCI, V112, P2125	38	41	42	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 16	2003	278	20					17945	17952		10.1074/jbc.M209946200	http://dx.doi.org/10.1074/jbc.M209946200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677YX	12637565	hybrid			2022-12-25	WOS:000182838300045
J	Wang, BE; Shou, JY; Ross, S; Koeppen, H; de Sauvage, FJ; Gao, WQ				Wang, BE; Shou, JY; Ross, S; Koeppen, H; de Sauvage, FJ; Gao, WQ			Inhibition of epithelial ductal branching in the prostate by sonic hedgehog is indirectly mediated by stromal cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN HOMOLOG; GROWTH; MORPHOGENESIS; EXPRESSION; GENE; PROLIFERATION; INDUCTION; RECEPTOR; PROTEIN; DIFFERENTIATION	Sonic hedgehog (Shh), a vertebrate homologue of the Drosophila segment-polarity gene hedgehog, has been reported to play an important role during normal development of various tissues. Abnormal activities of Shh signaling pathway have been implicated in tumorigenesis such as basal cell carcinomas and medulloblastomas. Here we show that Shh signaling negatively regulates prostatic epithelial ductal morphogenesis. In organo-typic cultures of developing rat prostates, Shh inhibited cell proliferation and promoted differentiation of luminal epithelial cells. The expression pattern of Shh and its receptors suggests a paracrine mechanism of action. The Shh receptors Ptc1 ((P) under bara (t) under bar ched (1) under bar) and Ptc2 were found to be expressed in prostatic stromal cells adjacent to the epithelium, where Shh itself was produced. This paracrine model was confirmed by co-culturing the developing prostate in the presence of stromal cells transfected with a vector expressing a constitutively active form of Smoothened, the real effector of the Shh signaling pathway. Furthermore, expression of activin A and TGF-beta1 that were shown previously to inhibit prostatic epithelial branching was up-regulated following Shh treatment in the organotypic cultures. Taken together, these results suggest that Shh negatively regulates prostatic ductal branching indirectly by acting on the surrounding stromal cells, at least partly via up-regulating expression of activin A and TGF-beta1.	Genentech Inc, Dept Mol Oncol, San Francisco, CA 94080 USA; Genentech Inc, Dept Pathol, San Francisco, CA 94080 USA; Genentech Inc, Dept Mol Biol, San Francisco, CA 94080 USA	Roche Holding; Genentech; Roche Holding; Genentech; Roche Holding; Genentech	Gao, WQ (corresponding author), Genentech Inc, Dept Mol Oncol, MS 72,1 DNA Way, San Francisco, CA 94080 USA.	gao@gene.com	de Sauvage, Frederic/ABE-8400-2020; Gao, Wei/GXH-0380-2022	de Sauvage, Frederic/0000-0002-5275-2584; Shou, Jianyong/0000-0002-3752-7215				Abate-Shen C, 2000, GENE DEV, V14, P2410, DOI 10.1101/gad.819500; Alcedo J, 2000, MOL CELL, V6, P457, DOI 10.1016/S1097-2765(00)00044-7; Alcedo J, 1996, CELL, V86, P221, DOI 10.1016/S0092-8674(00)80094-X; Altaba ARI, 1999, DEVELOPMENT, V126, P3205; Alvarez J, 2002, DEVELOPMENT, V129, P1913; Ball EMA, 2001, DEV BIOL, V238, P1, DOI 10.1006/dbio.2001.0399; Bellusci S, 1997, DEVELOPMENT, V124, P53; Berman DM, 2002, SCIENCE, V297, P1559, DOI 10.1126/science.1073733; Cancilla B, 2001, DEV BIOL, V237, P145, DOI 10.1006/dbio.2001.0364; Carpenter D, 1998, P NATL ACAD SCI USA, V95, P13630, DOI 10.1073/pnas.95.23.13630; Chen Y, 1996, CELL, V87, P553, DOI 10.1016/S0092-8674(00)81374-4; Chen Y, 1998, DEVELOPMENT, V125, P4943; CHUNG LWK, 1995, CANCER SURV, V23, P33; CHUNG LWK, 1983, PROSTATE, V4, P503, DOI 10.1002/pros.2990040509; Cooper MK, 1998, SCIENCE, V280, P1603, DOI 10.1126/science.280.5369.1603; Cunha G R, 1989, Cancer Treat Res, V46, P159; CUNHA GR, 1980, BIOL REPROD, V22, P19, DOI 10.1095/biolreprod22.1.19; CUNHA GR, 1987, ENDOCR REV, V8, P338, DOI 10.1210/edrv-8-3-338; Denef N, 2000, CELL, V102, P521, DOI 10.1016/S0092-8674(00)00056-8; GOODRICH L, 1991, SCIENCE, V277, P1109; Grapin-Botton A, 2001, GENE DEV, V15, P444, DOI 10.1101/gad.846001; Hahn H, 1996, CELL, V85, P841, DOI 10.1016/S0092-8674(00)81268-4; Hammerschmidt M, 1997, TRENDS GENET, V13, P14, DOI 10.1016/S0168-9525(96)10051-2; Hayward SW, 1996, ACTA ANAT, V155, P81; Hayward SW, 1996, ANN NY ACAD SCI, V784, P50, DOI 10.1111/j.1749-6632.1996.tb16227.x; Hayward SW, 1997, BRIT J UROL, V79, P18, DOI 10.1111/j.1464-410X.1997.tb16917.x; Hayward SW, 2001, CANCER RES, V61, P8135; Hebrok M, 2000, DEVELOPMENT, V127, P4905; Hebrok M, 1998, GENE DEV, V12, P1705, DOI 10.1101/gad.12.11.1705; HYNES M, 1995, NEURON, V15, P35, DOI 10.1016/0896-6273(95)90062-4; Ingham PW, 2000, CURR BIOL, V10, P1315, DOI 10.1016/S0960-9822(00)00755-7; Ingham PW, 2001, GENE DEV, V15, P3059, DOI 10.1101/gad.938601; INGHAM PW, 1991, NATURE, V353, P184, DOI 10.1038/353184a0; Johnson RL, 2000, MOL CELL, V6, P467, DOI 10.1016/S1097-2765(00)00045-9; Johnson RL, 1996, SCIENCE, V272, P1668, DOI 10.1126/science.272.5268.1668; Kalderon D, 2000, CELL, V103, P371, DOI 10.1016/S0092-8674(00)00129-X; Khandwala HM, 2000, ENDOCR REV, V21, P215, DOI 10.1210/er.21.3.215; Kim IY, 1996, CLIN CANCER RES, V2, P1255; KOOISTRA A, 1995, PROSTATE, V26, P123, DOI 10.1002/pros.2990260304; Lamm MLG, 2002, DEV BIOL, V249, P349, DOI 10.1006/dbio.2002.0774; Lamm MLG, 2001, DEV BIOL, V232, P301, DOI 10.1006/dbio.2001.0187; Lipschutz JH, 1997, PROSTATE, V32, P35; LU LH, 1994, CELL VISION, V1, P169; Machold R, 2002, TRENDS NEUROSCI, V25, P10, DOI 10.1016/S0166-2236(00)01982-2; Marigo V, 1996, NATURE, V384, P176, DOI 10.1038/384176a0; Marti E, 2002, TRENDS NEUROSCI, V25, P89, DOI 10.1016/S0166-2236(02)02062-3; MARTI E, 1995, NATURE, V375, P322, DOI 10.1038/375322a0; McMahon AP, 2003, CURR TOP DEV BIOL, V53, P1, DOI 10.1016/S0070-2153(03)53002-2; Morgan BA, 1998, DEV BIOL, V201, P1, DOI 10.1006/dbio.1998.8969; Olumi AF, 1999, CANCER RES, V59, P5002; Pepicelli CV, 1998, CURR BIOL, V8, P1083, DOI 10.1016/S0960-9822(98)70446-4; Podlasek CA, 1999, DEV BIOL, V209, P28, DOI 10.1006/dbio.1999.9229; Ramalho-Santos M, 2000, DEVELOPMENT, V127, P2763; ROBERTS DJ, 1995, DEVELOPMENT, V121, P3163; Robinson EJ, 1998, PROSTATE, V37, P149, DOI 10.1002/(SICI)1097-0045(19981101)37:3<149::AID-PROS4>3.0.CO;2-E; ROELINK H, 1994, CELL, V76, P761, DOI 10.1016/0092-8674(94)90514-2; SHANNON JM, 1984, BIOL REPROD, V31, P175, DOI 10.1095/biolreprod31.1.175; Shou JY, 2002, P NATL ACAD SCI USA, V99, P2830, DOI 10.1073/pnas.052705299; Shou JY, 2001, CANCER RES, V61, P7291; Signoretti S, 2000, AM J PATHOL, V157, P1769, DOI 10.1016/S0002-9440(10)64814-6; Stone DM, 1996, NATURE, V384, P129, DOI 10.1038/384129a0; SUGIMURA Y, 1986, BIOL REPROD, V34, P961, DOI 10.1095/biolreprod34.5.961; Sung SY, 2002, DIFFERENTIATION, V70, P506, DOI 10.1046/j.1432-0436.2002.700905.x; Taipale J, 2000, NATURE, V406, P1005, DOI 10.1038/35023008; TIMMS BG, 1994, J UROLOGY, V151, P1427, DOI 10.1016/S0022-5347(17)35273-4; van den Brink GR, 2001, GASTROENTEROLOGY, V121, P317, DOI 10.1053/gast.2001.26261; vandenHeuvel M, 1996, NATURE, V382, P547, DOI 10.1038/382547a0; Villavicencio EH, 2000, AM J HUM GENET, V67, P1047, DOI 10.1016/S0002-9297(07)62934-6; Wallace VA, 1999, CURR BIOL, V9, P445, DOI 10.1016/S0960-9822(99)80195-X; Wechsler-Reya RJ, 1999, NEURON, V22, P103, DOI 10.1016/S0896-6273(00)80682-0; Williams RH, 1996, CLIN CANCER RES, V2, P635; Wolk A, 1998, J NATL CANCER I, V90, P911, DOI 10.1093/jnci/90.12.911; Wong YC, 2002, DIFFERENTIATION, V70, P633, DOI 10.1046/j.1432-0436.2002.700916.x; Xie JW, 1998, NATURE, V391, P90, DOI 10.1038/34201; Yu J, 2002, DEVELOPMENT, V129, P5301; Zhang J, 2001, DEV BIOL, V229, P188, DOI 10.1006/dbio.2000.9953; Zhao H, 2002, BIOCHEM BIOPH RES CO, V294, P464, DOI 10.1016/S0006-291X(02)00484-9; Zheng JL, 2000, NAT NEUROSCI, V3, P580, DOI 10.1038/75753; Zheng JL, 2000, DEVELOPMENT, V127, P4551; Zhou L, 1996, DEV BIOL, V175, P227, DOI 10.1006/dbio.1996.0110	80	71	82	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 16	2003	278	20					18506	18513		10.1074/jbc.M300968200	http://dx.doi.org/10.1074/jbc.M300968200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677YX	12626524	hybrid			2022-12-25	WOS:000182838300120
J	Wiebe, MS; Nowling, TK; Rizzino, A				Wiebe, MS; Nowling, TK; Rizzino, A			Identification of novel domains within Sox-2 and Sox-11 involved in autoinhibition of DNA binding and partnership specificity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EMBRYONAL CARCINOMA-CELLS; TRANSCRIPTIONAL ACTIVATION DOMAINS; PROTEIN-PROTEIN INTERACTIONS; SYNERGISTIC ACTION; GLIAL-CELLS; GENE; ETS-1; EXPRESSION; ENHANCER; COMPLEX	Sox transcription factors play key regulatory roles throughout development, binding DNA through a consensus (A/T)(A/T)CAA(A/T)G sequence. Although many different Sox proteins bind to this sequence, it has been observed that gene regulatory elements are commonly responsive to only a small subset of the entire family, implying that regulatory mechanisms exist to permit selective DNA binding and/or transactivation by Sox family members. To identify and explore the mechanisms modulating gene activation by Sox proteins further, we compared the function of Sox-2 and Sox-11. This led to the discovery that Sox proteins are regulated differentially at multiple levels, including transactivation, protein partnerships with Pit-Oct-Unc (POU) transcription factors, and DNA binding autoregulation. Specifically, we determined that Sox-11 activates transcription more strongly than Sox-2 and that the transactivation domain of Sox-11 is primarily responsible for this capability. Additionally, we demonstrate that the Sox-11 DNA binding domain is responsible for selective cooperation with the POU factor Brn-2. This requirement cannot be replaced by the DNA binding domain of Sox-2, indicating that the DNA binding domain of Sox proteins is critical for Sox-POU partnerships. Interestingly, we have also determined that a conserved domain of Sox-11 has the novel capability of autoinhibiting its ability to bind DNA in vitro and to activate gene expression in vivo. Our findings suggest that the autoinhibitory domain can repress promiscuous binding of Sox-11 to DNA and plays an important role in regulating the recruitment of Sox-11 to specific genes.	Univ Nebraska, Med Ctr, Eppley Inst Res Canc & Allied Dis, Omaha, NE 68198 USA; Univ Nebraska, Med Ctr, Dept Pathol & Microbiol, Omaha, NE 68198 USA	University of Nebraska System; University of Nebraska Medical Center; University of Nebraska System; University of Nebraska Medical Center	Rizzino, A (corresponding author), Univ Nebraska, Med Ctr, Eppley Inst Res Canc & Allied Dis, 986805 Nebraska Med Ctr, Omaha, NE 68198 USA.		Wiebe, Matt/AAC-4642-2021; Wiebe, Matthew/X-5007-2019	Wiebe, Matthew/0000-0001-6337-6556	NCI NIH HHS [CA 74771, CA 36727, CA 09476] Funding Source: Medline; NATIONAL CANCER INSTITUTE [T32CA009476, R01CA074771, P30CA036727] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ambrosetti DC, 2000, J BIOL CHEM, V275, P23387, DOI 10.1074/jbc.M000932200; Ambrosetti DC, 1997, MOL CELL BIOL, V17, P6321, DOI 10.1128/MCB.17.11.6321; Blau J, 1996, MOL CELL BIOL, V16, P2044; Bojovic BB, 2001, J BIOL CHEM, V276, P4509, DOI 10.1074/jbc.M005509200; Cheung M, 2000, MOL BRAIN RES, V79, P180, DOI 10.1016/S0169-328X(00)00109-1; Collignon J, 1996, DEVELOPMENT, V122, P509; Cowley DO, 2000, GENE DEV, V14, P366; CURATOLA AM, 1990, MOL CELL BIOL, V10, P2475, DOI 10.1128/MCB.10.6.2475; Das D, 2001, J BIOL CHEM, V276, P32597, DOI 10.1074/jbc.M011792200; Goetz TL, 2000, MOL CELL BIOL, V20, P81, DOI 10.1128/MCB.20.1.81-90.2000; Greenall A, 2001, J BIOL CHEM, V276, P16207, DOI 10.1074/jbc.M011582200; HAGMAN J, 1992, P NATL ACAD SCI USA, V89, P8889, DOI 10.1073/pnas.89.19.8889; Hansen S, 1998, J MOL BIOL, V275, P575, DOI 10.1006/jmbi.1997.1507; HARLEY VR, 1994, NUCLEIC ACIDS RES, V22, P1500, DOI 10.1093/nar/22.8.1500; ISACKSON PJ, 1983, BIOCHIM BIOPHYS ACTA, V748, P436, DOI 10.1016/0167-4838(83)90190-5; Jay P, 1997, HUM MOL GENET, V6, P1069, DOI 10.1093/hmg/6.7.1069; Johnson LR, 1998, MOL REPROD DEV, V50, P377; Kamachi Y, 1998, DEVELOPMENT, V125, P2521; Kamachi Y, 2001, GENE DEV, V15, P1272, DOI 10.1101/gad.887101; Kamachi Y, 1999, MOL CELL BIOL, V19, P107; Kanda H, 1998, GENE, V211, P251, DOI 10.1016/S0378-1119(98)00100-0; Katan-Khaykovich Y, 2001, EUR J BIOCHEM, V268, P3108, DOI 10.1046/j.1432-1327.2001.02211.x; KELLY D, 1995, MOL REPROD DEV, V40, P135, DOI 10.1002/mrd.1080400202; Kuhlbrodt K, 1998, J BIOL CHEM, V273, P16050, DOI 10.1074/jbc.273.26.16050; Kuhlbrodt K, 1998, J NEUROSCI, V18, P237, DOI 10.1523/jneurosci.18-01-00237.1998; Lee KB, 2000, J MOL BIOL, V304, P135, DOI 10.1006/jmbi.2000.4206; Lefebvre V, 1998, EMBO J, V17, P5718, DOI 10.1093/emboj/17.19.5718; MA YG, 1992, DEV BIOL, V154, P45, DOI 10.1016/0012-1606(92)90046-J; Mirmira RG, 2000, J BIOL CHEM, V275, P14743, DOI 10.1074/jbc.275.19.14743; Nishimoto M, 1999, MOL CELL BIOL, V19, P5453; NOWLING T, 2002, J BIOL CHEM; Nowling TK, 2000, J BIOL CHEM, V275, P3810, DOI 10.1074/jbc.275.6.3810; Peirano RI, 2000, NUCLEIC ACIDS RES, V28, P3047, DOI 10.1093/nar/28.16.3047; PETERSEN JM, 1995, SCIENCE, V269, P1866, DOI 10.1126/science.7569926; Ramstein J, 1999, EUR J BIOCHEM, V260, P692, DOI 10.1046/j.1432-1327.1999.00185.x; Scholtz B, 1996, DEV BIOL, V173, P420, DOI 10.1006/dbio.1996.0037; Stemmer C, 2002, J BIOL CHEM, V277, P1092, DOI 10.1074/jbc.M109503200; SUN XH, 1991, CELL, V64, P459, DOI 10.1016/0092-8674(91)90653-G; Tutter AV, 2001, GENE DEV, V15, P3342, DOI 10.1101/gad.946501; UWANOGHO D, 1995, MECH DEVELOP, V49, P23, DOI 10.1016/0925-4773(94)00299-3; VANDEWETERING M, 1993, EMBO J, V12, P3847, DOI 10.1002/j.1460-2075.1993.tb06063.x; Wegner M, 1999, NUCLEIC ACIDS RES, V27, P1409, DOI 10.1093/nar/27.6.1409; YUAN HB, 1995, GENE DEV, V9, P2635, DOI 10.1101/gad.9.21.2635; Zhao Q, 2000, J MOL BIOL, V296, P509, DOI 10.1006/jmbi.1999.3457	44	52	55	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 16	2003	278	20					17901	17911		10.1074/jbc.M212211200	http://dx.doi.org/10.1074/jbc.M212211200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677YX	12637543	Green Published, hybrid			2022-12-25	WOS:000182838300040
J	Yun, CY; Velazquez-Dones, AL; Lyman, SK; Fu, XD				Yun, CY; Velazquez-Dones, AL; Lyman, SK; Fu, XD			Phosphorylation-dependent and -independent nuclear import of RS domain-containing splicing factors and regulators	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SUBNUCLEAR LOCALIZATION; RICH DOMAINS; PROTEIN; SR; BETA; TRANSPORTIN-SR2; RECEPTOR; ABSENCE; EXPORT; RAN	SR proteins and related RS domain-containing polypeptides are an important class of splicing regulators in higher eukaryotic cells. The RS domain facilitates nuclear import of SR proteins and mediates protein-protein interactions during spliceosome assembly; both functions appear to subject to regulation by phosphorylation. Previous studies have identified two nuclear import receptors for SR proteins, transportin-SR1 and transportin-SR2. Here we show that transportin-SR1 and transportin-SR2 are the alternatively spliced products of the same gene and that transportin-SR2 is the predominant transcript in most cells and tissues examined. While both receptors import typical SR proteins in a phosphorylation-dependent manner, they differentially import the RS domain-containing splicing regulators hTra2alpha and hTra2beta in different phosphorylation states. We suggest that differential regulation of nuclear import may serve as a mechanism for homeostasis of RS domain-containing splicing factors and regulators in the nucleus and for selective cellular responses to signaling.	Univ Calif San Diego, Dept Cellular & Mol Med, La Jolla, CA 92093 USA; Scripps Res Inst, Dept Cell Biol, La Jolla, CA 92037 USA	University of California System; University of California San Diego; Scripps Research Institute	Fu, XD (corresponding author), Univ Calif San Diego, Dept Cellular & Mol Med, 9500 Gilman Dr, La Jolla, CA 92093 USA.	xdfu@ucsd.edu			NIGMS NIH HHS [GM52872] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM052872] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADAM SA, 1990, J CELL BIOL, V111, P807, DOI 10.1083/jcb.111.3.807; Allemand E, 2002, MOL BIOL CELL, V13, P2436, DOI 10.1091/mbc.E02-02-0102; BERGET SM, 1995, J BIOL CHEM, V270, P2411, DOI 10.1074/jbc.270.6.2411; Burge CB, 1999, RNA WORLD, P525; Caceres JF, 1997, J CELL BIOL, V138, P225, DOI 10.1083/jcb.138.2.225; Cazalla D, 2002, MOL CELL BIOL, V22, P6871, DOI 10.1128/MCB.22.19.6871-6882.2002; CINGOLANI G, 1990, NATURE, V99, P221; Forwood JK, 2001, BIOCHEMISTRY-US, V40, P5208, DOI 10.1021/bi002732+; FU XD, 1995, RNA, V1, P663; Gilbert W, 2001, RNA, V7, P302, DOI 10.1017/S1355838201002369; Graveley BR, 2000, RNA, V6, P1197, DOI 10.1017/S1355838200000960; GUI JF, 1994, NATURE, V369, P678, DOI 10.1038/369678a0; HEDLEY ML, 1995, P NATL ACAD SCI USA, V92, P11524, DOI 10.1073/pnas.92.25.11524; Hofmann Y, 2000, P NATL ACAD SCI USA, V97, P9618, DOI 10.1073/pnas.160181697; Huang YQ, 2001, MOL CELL, V7, P899, DOI 10.1016/S1097-2765(01)00233-7; Kataoka N, 1999, J CELL BIOL, V145, P1145, DOI 10.1083/jcb.145.6.1145; Lai MC, 2001, P NATL ACAD SCI USA, V98, P10154, DOI 10.1073/pnas.181354098; Lai MC, 2000, J BIOL CHEM, V275, P7950, DOI 10.1074/jbc.275.11.7950; Lam MHC, 1999, J BIOL CHEM, V274, P7391, DOI 10.1074/jbc.274.11.7391; LI H, 1991, CELL, V67, P335, DOI 10.1016/0092-8674(91)90185-2; MELCHIOR F, 1993, J CELL BIOL, V123, P1649, DOI 10.1083/jcb.123.6.1649; Palacios I, 1997, EMBO J, V16, P6783, DOI 10.1093/emboj/16.22.6783; Palmeri D, 1999, MOL CELL BIOL, V19, P1218; Paschal BM, 1996, P NATL ACAD SCI USA, V93, P7679, DOI 10.1073/pnas.93.15.7679; Pemberton LF, 1997, J CELL BIOL, V139, P1645, DOI 10.1083/jcb.139.7.1645; Prasad J, 1999, MOL CELL BIOL, V19, P6991; Sanford JR, 2001, P NATL ACAD SCI USA, V98, P10184, DOI 10.1073/pnas.181340498; Senger B, 1998, EMBO J, V17, P2196, DOI 10.1093/emboj/17.8.2196; Shin CS, 2002, CELL, V111, P407, DOI 10.1016/S0092-8674(02)01038-3; Tacke R, 1998, CELL, V93, P139, DOI 10.1016/S0092-8674(00)81153-8; Takizawa CG, 1999, P NATL ACAD SCI USA, V96, P7938, DOI 10.1073/pnas.96.14.7938; Truant R, 1999, MOL CELL BIOL, V19, P1210; van Oordt WV, 2000, J CELL BIOL, V149, P307, DOI 10.1083/jcb.149.2.307; Wang HY, 1998, J CELL BIOL, V140, P737, DOI 10.1083/jcb.140.4.737; Xiao SH, 1997, GENE DEV, V11, P334, DOI 10.1101/gad.11.3.334; Yeakley JM, 1999, J CELL BIOL, V145, P447, DOI 10.1083/jcb.145.3.447; Yun CY, 2000, J CELL BIOL, V150, P707, DOI 10.1083/jcb.150.4.707; Zhou ZL, 2002, NATURE, V419, P182, DOI 10.1038/nature01031	38	37	38	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 16	2003	278	20					18050	18055		10.1074/jbc.M211714200	http://dx.doi.org/10.1074/jbc.M211714200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677YX	12637531	hybrid			2022-12-25	WOS:000182838300060
J	Barnham, KJ; McKinstry, WJ; Multhaup, G; Galatis, D; Morton, CJ; Curtain, CC; Williamson, NA; White, AR; Hinds, MG; Norton, RS; Beyreuther, K; Masters, CL; Parker, MW; Cappai, R				Barnham, KJ; McKinstry, WJ; Multhaup, G; Galatis, D; Morton, CJ; Curtain, CC; Williamson, NA; White, AR; Hinds, MG; Norton, RS; Beyreuther, K; Masters, CL; Parker, MW; Cappai, R			Structure of the Alzheimer's disease amyloid precursor protein copper binding domain - A regulator of neuronal copper homeostasis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OXIDATIVE STRESS; A-BETA; NEURODEGENERATIVE DISEASE; SUPEROXIDE-DISMUTASE; HYDROGEN-PEROXIDE; CRYSTAL-STRUCTURE; PICHIA-PASTORIS; REDUCTION; METALS; ZINC	A major source of free radical production in the brain derives from copper. To prevent metal-mediated oxidative stress, cells have evolved complex metal transport systems. The Alzheimer's disease amyloid precursor protein (APP) is a major regulator of neuronal copper homeostasis. APP knockout mice have elevated copper levels in the cerebral cortex, whereas APP-overexpressing transgenic mice have reduced brain copper levels. Importantly, copper binding to APP can greatly reduce amyloid beta production in vitro. To understand this interaction at the molecular level we solved the structure of the APP copper binding domain (CuBD) and found that it contains a novel copper binding site that favors Cu(I) coordination. The surface location of this site, structural homology of CuBD to copper chaperones, and the role of APP in neuronal copper homeostasis are consistent with the CuBD acting as a neuronal metallotransporter.	Univ Melbourne, Dept Pathol, Parkville, Vic 3010, Australia; Mental Hlth Res Inst, Parkville, Vic 3052, Australia; St Vincents Inst Med Res, Biota Struct Biol Lab, Fitzroy, Vic 3065, Australia; Free Univ Berlin, Inst Biochem Chem, D-14195 Berlin, Germany; Monash Univ, Sch Phys & Mat Engn, Clayton, Vic 3168, Australia; Royal Melbourne Hosp, Walter & Eliza Hall Inst Med Res, Melbourne, Vic 3050, Australia; Univ Heidelberg, Ctr Mol Biol, D-69120 Heidelberg, Germany	University of Melbourne; Florey Institute of Neuroscience & Mental Health; St. Vincent's Institute of Medical Research; Free University of Berlin; Monash University; Royal Melbourne Hospital; Walter & Eliza Hall Institute; Ruprecht Karls University Heidelberg	Parker, MW (corresponding author), St Vincents Inst Med Res, Biota Struct Biol Lab, 9 Princes St, Fitzroy, Vic 3065, Australia.		Williamson, Nicholas A/O-9812-2016; Parker, Michael W/F-9069-2013; Morton, Craig/GON-8638-2022; McKinstry, William J/D-2612-2013; Hinds, Mark Gavin/AAD-3653-2020; Cappai, Roberto/B-3347-2010; White, Anthony/P-5596-2016	Williamson, Nicholas A/0000-0002-2173-3452; Parker, Michael W/0000-0002-3101-1138; Morton, Craig/0000-0001-5452-5193; McKinstry, William J/0000-0001-9668-9364; Hinds, Mark Gavin/0000-0002-2856-5375; Cappai, Roberto/0000-0002-9505-8496; White, Anthony/0000-0003-1802-9891; Curtain, Cyril/0000-0001-6955-320X; Norton, Raymond/0000-0001-8893-0584				ADMAN ET, 1991, ADV PROTEIN CHEM, V42, P145; Andrews NC, 2001, P NATL ACAD SCI USA, V98, P6543, DOI 10.1073/pnas.131192498; Atwood CS, 1998, J BIOL CHEM, V273, P12817, DOI 10.1074/jbc.273.21.12817; Borchardt T, 2000, CELL MOL BIOL, V46, P785; Borchardt T, 1999, BIOCHEM J, V344, P461, DOI 10.1042/0264-6021:3440461; Brown DR, 2002, MOL BIOTECHNOL, V22, P165, DOI 10.1385/MB:22:2:165; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Bush AI, 2000, CURR OPIN CHEM BIOL, V4, P184, DOI 10.1016/S1367-5931(99)00073-3; Carri MT, 2001, FUNCT NEUROL, V16, P181; Casella L., 1993, BIOINORGANIC CHEM CO, P292; Cherny RA, 2001, NEURON, V30, P665, DOI 10.1016/S0896-6273(01)00317-8; Cherny RA, 1999, J BIOL CHEM, V274, P23223, DOI 10.1074/jbc.274.33.23223; Cobine PA, 2002, BIOCHEMISTRY-US, V41, P5822, DOI 10.1021/bi025515c; Curtain CC, 2001, J BIOL CHEM, V276, P20466, DOI 10.1074/jbc.M100175200; Day CL, 1999, CELL DEATH DIFFER, V6, P1125, DOI 10.1038/sj.cdd.4400584; Hardy J, 2002, SCIENCE, V297, P353, DOI 10.1126/science.1072994; Hart PJ, 1996, PROTEIN SCI, V5, P2175, DOI 10.1002/pro.5560051104; Henry A, 1997, PROTEIN EXPRES PURIF, V10, P283, DOI 10.1006/prep.1997.0748; HESSE L, 1994, FEBS LETT, V349, P109, DOI 10.1016/0014-5793(94)00658-X; HOLM L, 1993, J MOL BIOL, V233, P123, DOI 10.1006/jmbi.1993.1489; Huang XD, 1999, BIOCHEMISTRY-US, V38, P7609, DOI 10.1021/bi990438f; Huang XD, 1999, J BIOL CHEM, V274, P37111, DOI 10.1074/jbc.274.52.37111; Kim YJ, 2001, INORG CHEM, V40, P4481, DOI 10.1021/ic001396i; KLAUS W, 1993, J MOL BIOL, V232, P897, DOI 10.1006/jmbi.1993.1438; LAROCHE Y, 1994, BIO-TECHNOL, V12, P1119, DOI 10.1038/nbt1194-1119; Laskowski RA, 1996, J BIOMOL NMR, V8, P477, DOI 10.1007/BF00228148; MARTINS RN, 1986, J NEUROCHEM, V46, P1042, DOI 10.1111/j.1471-4159.1986.tb00615.x; MASTERS CL, 2002, 7 INT GEN SPRINGF AL; Maynard CJ, 2002, J BIOL CHEM, V277, P44670, DOI 10.1074/jbc.M204379200; Multhaup G, 1996, SCIENCE, V271, P1406, DOI 10.1126/science.271.5254.1406; Multhaup G, 1998, BIOCHEMISTRY-US, V37, P7224, DOI 10.1021/bi980022m; Opazo C, 2002, J BIOL CHEM, V277, P40302, DOI 10.1074/jbc.M206428200; PEISACH J, 1974, ARCH BIOCHEM BIOPHYS, V165, P691, DOI 10.1016/0003-9861(74)90298-7; Portnoy ME, 1999, J BIOL CHEM, V274, P15041, DOI 10.1074/jbc.274.21.15041; Poulos TL, 1999, NAT STRUCT BIOL, V6, P709, DOI 10.1038/11464; Prigge ST, 1997, SCIENCE, V278, P1300, DOI 10.1126/science.278.5341.1300; Puig S, 2002, CURR OPIN CHEM BIOL, V6, P171, DOI 10.1016/S1367-5931(02)00298-3; Rae TD, 1999, SCIENCE, V284, P805, DOI 10.1126/science.284.5415.805; Rossjohn J, 1999, NAT STRUCT BIOL, V6, P327; Sattler M, 1999, PROG NUCL MAG RES SP, V34, P93, DOI 10.1016/S0079-6565(98)00025-9; Sayre LM, 1999, CURR OPIN CHEM BIOL, V3, P220, DOI 10.1016/S1367-5931(99)80035-0; Sayre LM, 2000, J NEUROCHEM, V74, P270, DOI 10.1046/j.1471-4159.2000.0740270.x; Scheuermann S, 2001, J BIOL CHEM, V276, P33923, DOI 10.1074/jbc.M105410200; Smith MA, 1997, J NEUROSCI, V17, P2653; Uversky VN, 2001, J BIOL CHEM, V276, P44284, DOI 10.1074/jbc.M105343200; Waggoner DJ, 1999, NEUROBIOL DIS, V6, P221, DOI 10.1006/nbdi.1999.0250; White AR, 1999, J NEUROSCI, V19, P9170; White AR, 1999, BRAIN RES, V842, P439, DOI 10.1016/S0006-8993(99)01861-2; White AR, 2002, J NEUROSCI, V22, P365, DOI 10.1523/JNEUROSCI.22-02-00365.2002	49	231	242	1	22	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 9	2003	278	19					17401	17407		10.1074/jbc.M300629200	http://dx.doi.org/10.1074/jbc.M300629200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677QG	12611883	hybrid			2022-12-25	WOS:000182818600127
J	Brannstrom, K; Segerman, B; Gullberg, M				Brannstrom, K; Segerman, B; Gullberg, M			Molecular dissection of GTP exchange and hydrolysis within the ternary complex of tubulin heterodimers and Op18/stathmin family members	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STATHMIN; PROTEIN; BINDING; DISSOCIATION; ENCODES; MODEL	The ubiquitous Op18 and the neural RB3 and SCG10 proteins are members of the oncoprotein18/stathmin family of microtubule regulators. These proteins bind two tubulin heterodimers via two imperfect helical repeats to form a complex of heterodimers aligned head-to-tail. Here we have analyzed GTP exchange and GTP hydrolysis at the exchangeable GTP-binding site (E-site) of tubulin heterodimers in complex with Op18, RB3, or SCG10. These proteins stimulate a low and indistinguishable rate of GTP hydrolysis, and our results show that GTP exchange is blocked at both E-sites of the ternary complex, whereas GTP hydrolysis only occurs at one of the two E-sites. Results from mutational analysis of clusters of hydrophobic residues within the first helical repeat of Op18 suggest that GTP is hydrolyzed at the E-site that is interfaced between the head-to-tail arranged heterodimers, which is consistent with predicted GTPase productive interactions between the two tubulin heterodimers. Our mutational analysis has also indicated that Op18/stathmin family members actively restrain the otherwise potent GTPase productive interactions that are generated by longitudinal interactions within protofilaments. We conclude that tubulin heterodimers in complex with Op18/stathmin family members are subject to allosteric effects that prevent futile cycles of GTP hydrolysis.	Umea Univ, Dept Biol Mol, SE-90187 Umea, Sweden	Umea University	Gullberg, M (corresponding author), Umea Univ, Dept Biol Mol, SE-90187 Umea, Sweden.	Martin.Gullberg@molbiol.umu.se	Brännström, Kristoffer/D-3648-2009; Brännström, Kristoffer/AAC-1204-2020	Gullberg, Martin/0000-0002-3984-4572				Amayed P, 2000, BIOCHEMISTRY-US, V39, P12295, DOI 10.1021/bi000279w; Belmont LD, 1996, CELL, V84, P623, DOI 10.1016/S0092-8674(00)81037-5; Cassimeris L, 2002, CURR OPIN CELL BIOL, V14, P18, DOI 10.1016/S0955-0674(01)00289-7; Charbaut E, 2001, J BIOL CHEM, V276, P16146, DOI 10.1074/jbc.M010637200; Curmi PA, 1997, J BIOL CHEM, V272, P25029, DOI 10.1074/jbc.272.40.25029; Desai A, 1997, ANNU REV CELL DEV BI, V13, P83, DOI 10.1146/annurev.cellbio.13.1.83; DOYE V, 1989, J BIOL CHEM, V264, P12134; Gigant B, 2000, CELL, V102, P809, DOI 10.1016/S0092-8674(00)00069-6; Holmfeldt P, 2002, CURR BIOL, V12, P1034, DOI 10.1016/S0960-9822(02)00897-7; Holmfeldt P, 2001, MOL BIOL CELL, V12, P73, DOI 10.1091/mbc.12.1.73; Howell B, 1999, MOL BIOL CELL, V10, P105, DOI 10.1091/mbc.10.1.105; Jourdain L, 1997, BIOCHEMISTRY-US, V36, P10817, DOI 10.1021/bi971491b; Larsson N, 1999, J CELL BIOL, V146, P1289, DOI 10.1083/jcb.146.6.1289; Larsson NL, 1999, MOL CELL BIOL, V19, P2242; Mejillano MR, 1996, ARCH BIOCHEM BIOPHYS, V336, P130, DOI 10.1006/abbi.1996.0540; Mori N, 2002, J NEUROSCI RES, V70, P264, DOI 10.1002/jnr.10353; Muller DR, 2001, ANAL CHEM, V73, P1927, DOI 10.1021/ac001379a; Nogales E, 1999, CELL, V96, P79, DOI 10.1016/S0092-8674(00)80961-7; SECKLER R, 1990, J BIOL CHEM, V265, P7655; Segerman B, 2000, J BIOL CHEM, V275, P35759, DOI 10.1074/jbc.M005875200; Segerman B, 2003, J CELL SCI, V116, P197, DOI 10.1242/jcs.00205; STEIN R, 1988, NEURON, V1, P463, DOI 10.1016/0896-6273(88)90177-8; Steinmetz MO, 2000, EMBO J, V19, P572, DOI 10.1093/emboj/19.4.572; Wallon G, 2000, EMBO J, V19, P213, DOI 10.1093/emboj/19.2.213	24	12	14	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 9	2003	278	19					16651	16657		10.1074/jbc.M300131200	http://dx.doi.org/10.1074/jbc.M300131200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677QG	12606544	hybrid			2022-12-25	WOS:000182818600028
J	Cunha, CA; Macieira, S; Dias, JM; Almeida, G; Goncalves, LL; Costa, C; Lampreia, J; Huber, R; Moura, JJG; Moura, I; Romao, MJ				Cunha, CA; Macieira, S; Dias, JM; Almeida, G; Goncalves, LL; Costa, C; Lampreia, J; Huber, R; Moura, JJG; Moura, I; Romao, MJ			Cytochrome c nitrite reductase from Desulfovibrio desulfuricans ATCC 27774 - The relevance of the two calcium sites in the structure of the catalytic subunit (NrfA)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HORSERADISH-PEROXIDASE C; CRYSTAL-STRUCTURE; WOLINELLA-SUCCINOGENES; ANGSTROM RESOLUTION; LIGNIN PEROXIDASE; IDENTIFICATION; ENVIRONMENT; REFINEMENT; MEMBRANE; CLEAVAGE	The gene encoding cytochrome c nitrite reductase (NrfA) from Desulfovibrio desulfuricans ATCC 27774 was sequenced and the crystal structure of the enzyme was determined to 2.3-Angstrom resolution. In comparison with homologous structures, it presents structural differences mainly located at the regions surrounding the putative substrate inlet and product outlet, and includes a well defined second calcium site with octahedral geometry, coordinated to propionates of hemes 3 and 4, and caged by a loop non-existent in the previous structures. The highly negative electrostatic potential in the environment around hemes 3 and 4 suggests that the main role of this calcium ion may not be electrostatic but structural, namely in the stabilization of the conformation of the additional loop that cages it and influences the solvent accessibility of heme 4. The NrfA active site is similar to that of peroxidases with a nearby calcium site at the heme distal side nearly in the same location as occurs in the class II and class III peroxidases. This fact suggests that the calcium ion at the distal side of the active site in the NrfA enzymes may have a similar physiological role to that reported for the peroxidases.	Univ Nova Lisboa, Fac Ciencias & Tecnol, Dept Quim, REQUIMTE CQFB, P-2829516 Caparica, Portugal; Inst Super Ciencias Saude Sul, P-2825511 Caparica, Portugal; Max Planck Inst Biochem, Abt Strukturforsch, D-82152 Martinsried, Germany	Universidade Nova de Lisboa; Max Planck Society	Romao, MJ (corresponding author), Univ Nova Lisboa, Fac Ciencias & Tecnol, Dept Quim, REQUIMTE CQFB, P-2829516 Caparica, Portugal.	mromao@dq.fct.unl.pt	Gonçalves, Luisa/A-4120-2016; Almeida, Gabriela/GXV-3687-2022; Almeida, Maria Gabriela/D-8265-2013; Romao, Maria J/A-4115-2013; Costa, Cristina/A-9966-2012; Lampreia, Jorge/A-9927-2012; Moura, Isabel/D-6339-2013; Moura, José J G/D-6426-2013; UCIBIO, U Cienc Biom Apl/F-7948-2017	Gonçalves, Luisa/0000-0002-3654-8612; Almeida, Maria Gabriela/0000-0002-4508-7379; Romao, Maria J/0000-0002-3004-0543; Costa, Cristina/0000-0002-8611-9023; Lampreia, Jorge/0000-0001-8846-0041; Moura, Isabel/0000-0003-0971-4977; Moura, José J G/0000-0002-4726-2388; UCIBIO, U Cienc Biom Apl/0000-0002-3004-0543; Goncalves, Luisa/0000-0002-2385-7395				Abrahams JP, 1996, ACTA CRYSTALLOGR D, V52, P30, DOI 10.1107/S0907444995008754; Angove HC, 2002, J BIOL CHEM, V277, P23374, DOI 10.1074/jbc.M200495200; Aubert C, 1997, J BIOL CHEM, V272, P15128, DOI 10.1074/jbc.272.24.15128; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Bamford VA, 2002, BIOCHEMISTRY-US, V41, P2921, DOI 10.1021/bi015765d; BARTON GJ, 1993, PROTEIN ENG, V6, P37, DOI 10.1093/protein/6.1.37; COSTA C, 1990, FEBS LETT, V276, P67, DOI 10.1016/0014-5793(90)80508-G; Costa C, 1996, J BIOL CHEM, V271, P23191, DOI 10.1074/jbc.271.38.23191; Cowtan K., 1994, JOINT CCP4 ESF EACBM, V31, P34; delaFortelle E, 1997, METHOD ENZYMOL, V276, P472, DOI 10.1016/S0076-6879(97)76073-7; Dias JM, 1999, STRUCTURE, V7, P65, DOI 10.1016/S0969-2126(99)80010-0; Dias JM, 2000, ACTA CRYSTALLOGR D, V56, P215, DOI 10.1107/S0907444999016066; Einsle O, 2000, J BIOL CHEM, V275, P39608, DOI 10.1074/jbc.M006188200; Einsle O, 1999, NATURE, V400, P476, DOI 10.1038/22802; Einsle O, 2002, J AM CHEM SOC, V124, P11737, DOI 10.1021/ja0206487; Ferguson SJ, 1998, CURR OPIN CHEM BIOL, V2, P182, DOI 10.1016/S1367-5931(98)80059-8; Gajhede M, 1997, NAT STRUCT BIOL, V4, P1032, DOI 10.1038/nsb1297-1032; George SJ, 1999, BIOCHEM J, V344, P237, DOI 10.1042/0264-6021:3440237; GOODIN DB, 1993, BIOCHEMISTRY-US, V32, P3313, DOI 10.1021/bi00064a014; Henriksen A, 1999, J BIOL CHEM, V274, P35005, DOI 10.1074/jbc.274.49.35005; Hooft RWW, 1996, NATURE, V381, P272, DOI 10.1038/381272a0; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KASSNER RJ, 1973, J AM CHEM SOC, V95, P2674, DOI 10.1021/ja00789a044; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KUNISHIMA N, 1994, J MOL BIOL, V235, P331, DOI 10.1016/S0022-2836(05)80037-3; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIU MC, 1994, METHOD ENZYMOL, V243, P303; LIU MC, 1981, J BIOL CHEM, V256, P3159; MATTHEWS BW, 1968, J MOL BIOL, V33, P491, DOI 10.1016/0022-2836(68)90205-2; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; Moura I, 1997, ANAEROBE, V3, P279, DOI 10.1006/anae.1997.0093; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Nielsen H, 1997, PROTEIN ENG, V10, P1, DOI 10.1093/protein/10.1.1; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Page CC, 1999, NATURE, V402, P47, DOI 10.1038/46972; Perrakis A, 1999, NAT STRUCT BIOL, V6, P458, DOI 10.1038/8263; POULOS TL, 1980, J BIOL CHEM, V255, P575; POULOS TL, 1993, J BIOL CHEM, V268, P4429; RAFFERTY SP, 1990, BIOCHEMISTRY-US, V29, P9365, DOI 10.1021/bi00492a009; RodriguezLopez JN, 1996, J BIOL CHEM, V271, P4023; SCHRODER I, 1985, ARCH MICROBIOL, V140, P380, DOI 10.1007/BF00446982; Schuller DJ, 1996, STRUCTURE, V4, P311, DOI 10.1016/S0969-2126(96)00035-4; Simon J, 2000, MOL MICROBIOL, V35, P686, DOI 10.1046/j.1365-2958.2000.01742.x; Simon J, 2002, FEMS MICROBIOL REV, V26, P285, DOI 10.1111/j.1574-6976.2002.tb00616.x; Simon J, 2001, EUR J BIOCHEM, V268, P5776, DOI 10.1046/j.0014-2956.2001.02520.x; Stach P, 2000, J INORG BIOCHEM, V79, P381, DOI 10.1016/S0162-0134(99)00248-2; STEENKAMP DJ, 1981, J BIOL CHEM, V256, P5450; SUNDARAMOORTHY M, 1994, J BIOL CHEM, V269, P32759; Sutherland GRJ, 1997, BIOCHEMISTRY-US, V36, P3654, DOI 10.1021/bi962195m; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; VITELLO LB, 1993, BIOCHEMISTRY-US, V32, P9807, DOI 10.1021/bi00088a036	53	81	83	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 9	2003	278	19					17455	17465		10.1074/jbc.M211777200	http://dx.doi.org/10.1074/jbc.M211777200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677QG	12618432	Green Published, hybrid			2022-12-25	WOS:000182818600133
J	Filee, P; Vreuls, C; Herman, R; Thamm, I; Aerts, T; De Deyn, PP; Frere, JM; Joris, B				Filee, P; Vreuls, C; Herman, R; Thamm, I; Aerts, T; De Deyn, PP; Frere, JM; Joris, B			Dimerization and DNA binding properties of the Bacillus licheniformis 749/I BlaI repressor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-LACTAMASE SYNTHESIS; STAPHYLOCOCCUS-AUREUS; PROTEIN; INDUCTION; TRANSDUCER; SYSTEM; DIMER; GENES; FATE	In the absence of penicillin, the beta-lactamase encoding gene blaP of Bacillus licheniformis 749/I is negatively regulated by the transcriptional repressor BlaI. Three palindromic operator regions are recognized by BlaI: two in the blaP promoter (OP1 and OP2) and one (OP3) in the promoter of the blaI-blaR1 operon. In this study, the dissociation constant of the purified BlaI dimer was estimated at 25 muM by equilibrium ultracentrifugation. Quantitative Western blot analysis indicates that the intracellular concentrations of BlaI in B. licheniformis 749/I and Bacillus subtilis transformed by a multicopy plasmid harboring the beta-lactamase locus (blaP-blaI-blaR1) were lower than (1.9 muM) or in the same range as (75 muM) the dissociation constant, respectively. This suggests that BlaI is partially dimeric in the cytoplasm of these strains and interacts in vivo with its operators as a preformed dimer. This hypothesis is supported by band shift assays on an operator containing a randomized half-operator sequence. The global dissociation constants of the operator-BlaI dimer complexes were measured by band shift assays and estimated as K-dOP1=1.7+/-0.5 10(-15) M-2, K-dOP2=3.3+/-0.9 10(-15) M-2, and K-dOP3=10.5+/-2.5 10(-15) M-2. The role of the DNA binding properties of BlaI on the beta-lactamase regulation is discussed.	Univ Liege, Inst Chim B6A, Ctr Ingn Prot, B-4000 Liege, Belgium; Univ Liege, Inst Phys B5, Lab Phys Biomed, B-4000 Liege, Belgium; Univ Antwerp, Dept Biomed Sci, B-2610 Antwerp, Belgium	University of Liege; University of Liege; University of Antwerp	Joris, B (corresponding author), Univ Liege, Inst Chim B6A, Ctr Ingn Prot, B-4000 Liege, Belgium.	bjoris@ulg.ac.be						Abril AM, 1997, BIOCHEMISTRY-US, V36, P11901, DOI 10.1021/bi970994e; Clarke SR, 2001, MICROBIOL-UK, V147, P803, DOI 10.1099/00221287-147-4-803; Dyke JW, 1979, BETA LACTAMASES, V291-310; Filee P, 2002, MOL MICROBIOL, V44, P685, DOI 10.1046/j.1365-2958.2002.02888.x; Filee P, 2001, BIOTECHNIQUES, V30, P1044, DOI 10.2144/01305rr03; Gabelica V, 2002, RAPID COMMUN MASS SP, V16, P1723, DOI 10.1002/rcm.776; Gregory PD, 1997, MOL MICROBIOL, V24, P1025, DOI 10.1046/j.1365-2958.1997.4051770.x; Hardt K, 1997, MOL MICROBIOL, V23, P935, DOI 10.1046/j.1365-2958.1997.2761642.x; HOLLADAY LA, 1974, ANAL BIOCHEM, V57, P506, DOI 10.1016/0003-2697(74)90106-7; JORIS B, 1990, FEMS MICROBIOL LETT, V70, P107, DOI 10.1016/0378-1097(90)90111-3; JORIS B, 1994, N COMP BIOC, V27, P505; KELLY L, 1990, BIOCHEMISTRY-US, V29, P5062, DOI 10.1021/bi00473a010; KIM B, 1992, SCIENCE, V255, P203, DOI 10.1126/science.1553548; KOBAYASHI T, 1987, J BACTERIOL, V169, P3873, DOI 10.1128/jb.169.9.3873-3878.1987; Kohler JJ, 1999, P NATL ACAD SCI USA, V96, P11735, DOI 10.1073/pnas.96.21.11735; Lewis RA, 1999, FEMS MICROBIOL LETT, V178, P271, DOI 10.1016/S0378-1097(99)00366-3; Mohana-Borges R, 2000, J BIOL CHEM, V275, P4708, DOI 10.1074/jbc.275.7.4708; NICHOLLS NJ, 1987, FEBS LETT, V221, P179, DOI 10.1016/0014-5793(87)80375-7; Orth P, 2000, NAT STRUCT BIOL, V7, P215; RYFFEL C, 1990, GENE, V94, P137, DOI 10.1016/0378-1119(90)90481-6; SHERRATT DJ, 1973, J GEN MICROBIOL, V76, P217, DOI 10.1099/00221287-76-1-217; Steinmetzer K, 1998, J MOL BIOL, V283, P595, DOI 10.1006/jmbi.1998.2122; Strausak D, 1997, J BIOL CHEM, V272, P8932; SULLIVAN MA, 1984, GENE, V29, P21, DOI 10.1016/0378-1119(84)90161-6; WITTMAN V, 1988, J BACTERIOL, V170, P3206, DOI 10.1128/jb.170.7.3206-3212.1988; WITTMAN V, 1993, J BACTERIOL, V175, P7383, DOI 10.1128/JB.175.22.7383-7390.1993; Zhang HZ, 2001, SCIENCE, V291, P1962, DOI 10.1126/science.1055144; ZHU YF, 1992, J BACTERIOL, V174, P6171, DOI 10.1128/JB.174.19.6171-6178.1992	28	15	15	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 9	2003	278	19					16482	16487		10.1074/jbc.M210887200	http://dx.doi.org/10.1074/jbc.M210887200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677QG	12615920	hybrid			2022-12-25	WOS:000182818600007
J	Gentle, A; Liu, YY; Martin, JE; Conti, GL; McBrien, NA				Gentle, A; Liu, YY; Martin, JE; Conti, GL; McBrien, NA			Collagen gene expression and the altered accumulation of scleral collagen during the development of high myopia	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FORM-DEPRIVATION MYOPIA; TREE SHREW SCLERA; FIBRIL DIAMETER; EYE ENLARGEMENT; VIII COLLAGEN; HUMAN CORNEAL; AXIAL MYOPIA; RECOVERY; TURNOVER; PROLINE	The development of high myopia is associated with reduced scleral collagen accumulation, scleral thinning, and loss of scleral tissue, in both humans and animal models. Reduced collagen fibril diameter is also observed in the sclera of eyes with high myopia. The present study investigated aspects of scleral collagen synthesis and degradation, in a mammalian model of high myopia, to elucidate the factors underlying scleral changes. General synthesis and degradation of scleral collagen was investigated in monocularly deprived tree shrews, through the in vivo administration of [H-3] proline and subsequent assay of scleral tissue for [H-3] collagen. In addition, PCR enriched cDNA, produced from tree shrew scleral mRNA, was used to synthesize probes for hybridization to custom gene arrays consisting of partial sequences for 11 collagen subtypes. Finally, real-time reverse transcriptase-PCR was employed to investigate collagen type I, III, and V mRNA expression in the sclera of myopic, contralateral control, and normal tree shrew eyes. Scleral [H-3] proline incorporation was reduced at the posterior pole of myopic eyes following 5 days of monocular deprivation (-36+/-4%), whereas [H-3] proline content was similar in treated and control eyes before myopia induction (-1+/-8%) but was reduced in myopic eyes following 5 (-8+/-2%), 12 (-15+/-4%), and 24 (-10+/-4%) days of myopia induction. The majority of the collagens investigated were found to be expressed in the sclera, with 11 subtypes being identified. Collagen type I mRNA expression was reduced in the sclera of myopic eyes (-20+/-7%), however, collagen type III (+2+/-9%) and type V (-1+/-6%) expression was unchanged relative to control, resulting in a net increase in the ratio of expression of collagen type III/type I and collagen type V/type I (22 and 25%, respectively). These results show that reduced scleral collagen accumulation in myopic eyes is a result of both decreased collagen synthesis and accelerated collagen degradation. Furthermore, changes in collagen synthesis are driven by reduced type I collagen production. Short term increases in the ratio of newly synthesized collagen type III/type I and type V/type I are likely to be important in the increasing frequency of small diameter scleral collagen fibrils observed in high myopia and may be important in the subsequent development of posterior staphyloma in humans with pathological myopia.	Univ Melbourne, Dept Optometry & Vis Sci, Parkville, Vic 3010, Australia	University of Melbourne	McBrien, NA (corresponding author), Univ Melbourne, Dept Optometry & Vis Sci, Parkville, Vic 3010, Australia.							Arokoski JPA, 1999, J BIOMED MATER RES, V48, P99; AVETISOV ES, 1984, METAB PEDIATR SYST O, V7, P183; Birk DE, 1997, EUR J CELL BIOL, V72, P352; BIRK DE, 1990, J CELL SCI, V95, P649; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CURCIO CA, 1987, SCIENCE, V236, P579, DOI 10.1126/science.3576186; Curtin B J, 1977, Trans Am Ophthalmol Soc, V75, P67; CURTIN BJ, 1979, ARCH OPHTHALMOL-CHIC, V97, P912, DOI 10.1001/archopht.1979.01020010470017; CURTIN BJ, 1957, T AM ACAD OPHTHALMOL, V62, P777; CURTIN BJ, 1985, MYOPIAS BASIC SCI CL; Fitzgerald J, 2001, FEBS LETT, V505, P275, DOI 10.1016/S0014-5793(01)02754-5; FUNATA M, 1990, GRAEF ARCH CLIN EXP, V228, P174, DOI 10.1007/BF02764314; Gentle A, 1999, EXP EYE RES, V68, P155, DOI 10.1006/exer.1998.0587; Gentle A, 2002, CYTOKINE, V18, P344, DOI 10.1006/cyto.2002.1046; Gentle A, 2001, BIOTECHNIQUES, V31, P502, DOI 10.2144/01313st03; GROSSNIKLAUS HE, 1992, RETINA-J RET VIT DIS, V12, P127, DOI 10.1097/00006982-199212020-00009; Guggenheim JA, 1996, INVEST OPHTH VIS SCI, V37, P1380; Ihanamaki T, 2001, EXP EYE RES, V72, P423, DOI 10.1006/exer.2000.0972; JACKSON SH, 1975, BIOCHIM BIOPHYS ACTA, V381, P359, DOI 10.1016/0304-4165(75)90241-X; KITTELBERGER R, 1990, CONNECT TISSUE RES, V24, P303, DOI 10.3109/03008209009152157; Koyano Y, 1997, BIOTECHNIQUES, V22, P706; LAURENT GJ, 1982, BIOCHEM J, V206, P535, DOI 10.1042/bj2060535; LAURENT GJ, 1978, BIOCHEM J, V176, P393, DOI 10.1042/bj1760393; LEE RE, 1981, EXP EYE RES, V32, P737, DOI 10.1016/0014-4835(81)90023-3; MARSHALL GE, 1993, CURR EYE RES, V12, P143, DOI 10.3109/02713689308999482; McBrien NA, 2000, INVEST OPHTH VIS SCI, V41, P3713; MCBRIEN NA, 1993, INVEST OPHTH VIS SCI, V34, P205; MCBRIEN NA, 1992, VISION RES, V32, P843, DOI 10.1016/0042-6989(92)90027-G; McBrien NA, 2001, INVEST OPHTH VIS SCI, V42, P2179; MULLER B, 1989, J COMP NEUROL, V282, P581, DOI 10.1002/cne.902820409; NEWSOME DA, 1982, INVEST OPHTH VIS SCI, V22, P376; NORTON TT, 1995, INVEST OPHTH VIS SCI, V36, pS760; NORTON TT, 1995, VISION RES, V35, P1271, DOI 10.1016/0042-6989(94)00243-F; PHILLIPS JR, 1995, OPHTHAL PHYSL OPT, V15, P357, DOI 10.1016/0275-5408(95)00062-I; Rada JA, 2000, INVEST OPHTH VIS SCI, V41, P2050; Reddy GK, 1996, CLIN BIOCHEM, V29, P225, DOI 10.1016/0009-9120(96)00003-6; Sandberg-Lall M, 2000, EXP EYE RES, V70, P401, DOI 10.1006/exer.1998.0826; Siegwart JT, 1999, VISION RES, V39, P387, DOI 10.1016/S0042-6989(98)00150-3; Siegwart JT, 1998, VISION RES, V38, P3505, DOI 10.1016/S0042-6989(98)00053-4; Siegwart JT, 2001, INVEST OPHTH VIS SCI, V42, P1153; SIEGWART JT, 1994, LAB ANIM SCI, V44, P213; Sorsby A, 1969, MED RES COUNC SPEC R, V309, P1; TAMURA Y, 1991, INVEST OPHTH VIS SCI, V32, P2636; Verzijl N, 2000, J BIOL CHEM, V275, P39027, DOI 10.1074/jbc.M006700200; Wessel H, 1997, INVEST OPHTH VIS SCI, V38, P2408; WIESEL TN, 1977, NATURE, V266, P66, DOI 10.1038/266066a0; ZORN N, 1992, INVEST OPHTH VIS SCI, V33, pS1053	47	141	162	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 9	2003	278	19					16587	16594		10.1074/jbc.M300970200	http://dx.doi.org/10.1074/jbc.M300970200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677QG	12606541	hybrid			2022-12-25	WOS:000182818600020
J	Johansson, CC; Dahle, MK; Blomqvist, SR; Gronning, LM; Aandahl, EM; Enerback, S; Tasken, K				Johansson, CC; Dahle, MK; Blomqvist, SR; Gronning, LM; Aandahl, EM; Enerback, S; Tasken, K			A winged helix forkhead (FOXD2) tunes sensitivity to cAMP in T lymphocytes through regulation of cAMP-dependent protein kinase RI alpha	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA; SIGNALING PATHWAYS; BINDING-SITES; B ACTIVATION; SUBUNIT; GENE; EXPRESSION; CELLS; SPECIFICITY; MECHANISMS	Forkhead/winged helix ( FOX) transcription factors are essential for control of the cell cycle and metabolism. Here, we show that spleens from Mf2-/- (FOXD2-/-) mice have reduced mRNA (50%) and protein (35%) levels of the RIalpha subunit of the cAMP-dependent protein kinase. In T cells from Mf2-/- mice, reduced levels of RIalpha translates functionally into similar to2-fold less sensitivity to cAMP-mediated inhibition of proliferation triggered through the T cell receptor-CD3 complex. In Jurkat T cells, FOXD2 overexpression increased the endogenous levels of RIalpha through induction of the RIalpha1b promoter. FOXD2 overexpression also increased the sensitivity of the promoter to cAMP. Finally, co-expression experiments demonstrated that protein kinase Balpha/Akt1 work together with FOXD2 to induce the RIalpha1b promoter (10-fold) and increase endogenous RIalpha protein levels further. Taken together, our data indicate that FOXD2 is a physiological regulator of the RIalpha1b promoter in vivo working synergistically with protein kinase B to induce cAMP-dependent protein kinase RIalpha expression, which increases cAMP sensitivity and sets the threshold for cAMP-mediated negative modulation of T cell activation.	Univ Oslo, Inst Basic Med Sci, Dept Biochem Med, N-0317 Oslo, Norway; Univ Gothenburg, Dept Biochem Med, SE-40530 Gothenburg, Sweden	University of Oslo; University of Gothenburg	Tasken, K (corresponding author), Univ Oslo, Inst Basic Med Sci, Dept Biochem Med, N-0317 Oslo, Norway.		Dahle, Maria K/AAK-5130-2021	Dahle, Maria K/0000-0003-0380-084X; Aandahl, Einar Martin/0000-0002-0115-8382; Tasken, Kjetil/0000-0003-2841-4697				Aandahl EM, 1998, FASEB J, V12, P855, DOI 10.1096/fasebj.12.10.855; Ahmed NN, 1997, P NATL ACAD SCI USA, V94, P3627, DOI 10.1073/pnas.94.8.3627; Aukrust P, 1999, J IMMUNOL, V162, P1178; Barradeau S, 2000, FEBS LETT, V476, P272, DOI 10.1016/S0014-5793(00)01653-7; Cass LA, 1999, MOL CELL BIOL, V19, P5882; Cederberg A, 2001, CELL, V106, P563, DOI 10.1016/S0092-8674(01)00474-3; Dahle MK, 2002, J BIOL CHEM, V277, P22902, DOI 10.1074/jbc.M200131200; Dahle MK, 2001, EUR J BIOCHEM, V268, P5920, DOI 10.1046/j.0014-2956.2001.02542.x; Dahle MK, 2001, MOL REPROD DEV, V59, P11, DOI 10.1002/mrd.1001; DOSTMANN WRG, 1990, J BIOL CHEM, V265, P10484; Ernstsson S, 1997, GENOMICS, V46, P78, DOI 10.1006/geno.1997.4986; Ernstsson S, 1996, J BIOL CHEM, V271, P21094, DOI 10.1074/jbc.271.35.21094; Filippa N, 1999, MOL CELL BIOL, V19, P4989; Herberg FW, 2000, J MOL BIOL, V298, P329, DOI 10.1006/jmbi.2000.3662; Hoover F, 2002, MOL CELL NEUROSCI, V19, P125, DOI 10.1006/mcne.2001.1053; Jones RG, 2000, J EXP MED, V191, P1721, DOI 10.1084/jem.191.10.1721; KAMMER GM, 1988, IMMUNOL TODAY, V9, P222, DOI 10.1016/0167-5699(88)91220-0; Kops GJPL, 2000, J ANAT, V197, P571, DOI 10.1046/j.1469-7580.2000.19740571.x; Kume T, 2000, MOL CELL BIOL, V20, P1419, DOI 10.1128/MCB.20.4.1419-1425.2000; Laxminarayana D, 1999, J IMMUNOL, V162, P5639; OGREID D, 1989, EUR J BIOCHEM, V181, P19; ORELLANA SA, 1990, J BIOL CHEM, V265, P3048; OYEN O, 1987, BIOL REPROD, V37, P947, DOI 10.1095/biolreprod37.4.947; PIERROU S, 1994, EMBO J, V13, P5002, DOI 10.1002/j.1460-2075.1994.tb06827.x; POTHIER F, 1992, DNA CELL BIOL, V11, P83, DOI 10.1089/dna.1992.11.83; Reif K, 1997, J BIOL CHEM, V272, P14426, DOI 10.1074/jbc.272.22.14426; Richards JS, 2001, MOL ENDOCRINOL, V15, P209, DOI 10.1210/me.15.2.209; SKALHEGG BS, 1994, SCIENCE, V263, P84, DOI 10.1126/science.8272870; Solberg R, 1997, ENDOCRINOLOGY, V138, P169, DOI 10.1210/en.138.1.169; Stambolic V, 1998, CELL, V95, P29, DOI 10.1016/S0092-8674(00)81780-8; Tasken K, 1997, ADV SEC MESS PHOSPH, V31, P191; Vang T, 2001, J EXP MED, V193, P497, DOI 10.1084/jem.193.4.497	32	16	17	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 9	2003	278	19					17573	17579		10.1074/jbc.M300311200	http://dx.doi.org/10.1074/jbc.M300311200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677QG	12621056	hybrid			2022-12-25	WOS:000182818600147
J	Leitinger, B				Leitinger, B			Molecular analysis of collagen binding by the human discoidin domain receptors, DDR1 and DDR2 - Identification of collagen binding sites in DDR2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VON-WILLEBRAND-FACTOR; TYROSINE KINASE; CRYSTAL-STRUCTURE; MEMBRANE-BINDING; C2 DOMAIN; FACTOR V; CANCER; PROLIFERATION; EXPRESSION; PROTEIN	The widely expressed mammalian discoidin domain receptors (DDRs), DDR1 and DDR2, are unique among receptor tyrosine kinases in that they are activated by the extracellular matrix protein collagen. Various collagen types bind to and activate the DDRs, but the molecular details of collagen recognition have not been well defined. In this study, recombinant extracellular domains of DDR1 and DDR2 were produced to explore DDR-collagen binding in detail. In solid phase assays, both DDRs bound collagen I with high affinity. DDR1 recognized collagen I only as a dimeric and not as a monomeric construct, indicating a requirement for receptor dimerization in the DDR1-collagen interaction. The DDRs contain a discoidin homology domain in their extracellular domains, and the isolated discoidin domain of DDR2 bound collagen I with high affinity. Furthermore, the discoidin domain of DDR2, but not of DDR1, was sufficient for transmembrane receptor signaling. To map the collagen binding site within the discoidin domain of DDR2, mutant constructs were created, in which potential surface-exposed loops in DDR2 were exchanged for the corresponding loops of functionally unrelated discoidin domains. Three spatially adjacent surface loops within the DDR2 discoidin domain were found to be critically involved in collagen binding of the isolated DDR2 extracellular domain. In addition, the same loops were required for collagen-dependent receptor activation. It is concluded that the loop region opposite to the polypeptide chain termini of the DDR2 discoidin domain constitutes the collagen recognition site.	UCL, Sackler Inst Muscular Skeletal Res, Dept Med, London WC1E 6JJ, England	University of London; University College London	Leitinger, B (corresponding author), UCL, Sackler Inst Muscular Skeletal Res, Dept Med, 5 Univ St, London WC1E 6JJ, England.	b.leitinger@ucl.ac.uk						Agarwal G, 2002, BIOCHEMISTRY-US, V41, P11091, DOI 10.1021/bi020087w; ALVES F, 1995, ONCOGENE, V10, P609; BARKER KT, 1995, ONCOGENE, V10, P569; Baumgartner S, 1998, PROTEIN SCI, V7, P1626, DOI 10.1002/pro.5560070717; Bhatt RS, 2000, GENE DEV, V14, P2216, DOI 10.1101/gad.821600; Curat CA, 2001, J BIOL CHEM, V276, P45952, DOI 10.1074/jbc.M104360200; Emsley J, 2000, CELL, V101, P47, DOI 10.1016/S0092-8674(00)80622-4; FAWCETT J, 1992, NATURE, V360, P481, DOI 10.1038/360481a0; Gilbert GE, 2002, J BIOL CHEM, V277, P6374, DOI 10.1074/jbc.M104732200; HORTON RM, 1993, METHOD ENZYMOL, V217, P270; Hou GP, 2001, J CLIN INVEST, V107, P727, DOI 10.1172/JCI10720; Jansson M, 2001, J CELL SCI, V114, P2043; Kim SW, 2000, BIOCHEMISTRY-US, V39, P1951, DOI 10.1021/bi992256r; Kohfeldt E, 1998, J MOL BIOL, V282, P99, DOI 10.1006/jmbi.1998.2004; L'hote CGML, 2001, FASEB J, V15, P234, DOI 10.1096/fj.01-0414fje; Labrador JP, 2001, EMBO REP, V2, P446, DOI 10.1093/embo-reports/kve094; LAVAL S, 1994, CELL GROWTH DIFFER, V5, P1173; Lee CC, 2003, STRUCTURE, V11, P99, DOI 10.1016/S0969-2126(02)00941-3; Macedo-Ribeiro S, 1999, NATURE, V402, P434, DOI 10.1038/46594; Nemoto T, 1997, PATHOBIOLOGY, V65, P195, DOI 10.1159/000164123; Olaso E, 2002, J BIOL CHEM, V277, P3606, DOI 10.1074/jbc.M107571200; Olaso E, 2001, J CLIN INVEST, V108, P1369, DOI 10.1172/JCI12373; Perez JL, 1996, ONCOGENE, V12, P1469; Pratt KP, 1999, NATURE, V402, P439, DOI 10.1038/46601; Romijn RAP, 2001, J BIOL CHEM, V276, P9985, DOI 10.1074/jbc.M006548200; Sasaki T, 1998, EMBO J, V17, P1625, DOI 10.1093/emboj/17.6.1625; Sasaki T, 2000, FASEB J, V14, P761, DOI 10.1096/fasebj.14.5.761; Schlessinger J, 2000, CELL, V103, P211, DOI 10.1016/j.cell.2010.06.011; Shawver LK, 2002, CANCER CELL, V1, P117, DOI 10.1016/S1535-6108(02)00039-9; Shrivastava A, 1997, MOL CELL, V1, P25, DOI 10.1016/S1097-2765(00)80004-0; Symersky J, 1997, NAT STRUCT BIOL, V4, P833, DOI 10.1038/nsb1097-833; Vogel W, 2000, J BIOL CHEM, V275, P5779, DOI 10.1074/jbc.275.8.5779; Vogel W, 1997, MOL CELL, V1, P13, DOI 10.1016/S1097-2765(00)80003-9; Vogel WF, 2001, MOL CELL BIOL, V21, P2906, DOI 10.1128/MCB.21.8.2906-2917.2001; Weiner HL, 2000, NEUROSURGERY, V47, P1400, DOI 10.1097/00006123-200012000-00028	35	153	160	1	22	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 9	2003	278	19					16761	16769		10.1074/jbc.M301370200	http://dx.doi.org/10.1074/jbc.M301370200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677QG	12611880	hybrid			2022-12-25	WOS:000182818600043
J	Montalvetti, A; Fernandez, A; Sanders, JM; Ghosh, S; Van Brussel, E; Oldfield, E; Docampo, R				Montalvetti, A; Fernandez, A; Sanders, JM; Ghosh, S; Van Brussel, E; Oldfield, E; Docampo, R			Farnesyl pyrophosphate synthase is an essential enzyme in Trypanosoma brucei - In vitro RNA interference and in vivo inhibition studies	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NITROGEN-CONTAINING BISPHOSPHONATES; LEISHMANIA-DONOVANI; GENE-EXPRESSION; GROWTH; ALENDRONATE; SEQUENCE; PROTEIN; TARGET; LENGTH; DRUGS	We report the cloning and sequencing of a gene encoding the farnesyl pyrophosphate synthase (FPPS) of Trypanosoma brucei. The protein (TbFPPS) is an attractive target for drug development because the growth of T. brucei has been shown to be inhibited by analogs of its substrates, the nitrogen containing bisphosphonates currently in use in bone resorption therapy. The protein predicted from the nucleotide sequence of the gene has 367 amino acids and a molecular mass of 42 kDa. Several sequence motifs found in other FPPSs are present in TbFPPS, including an 11-mer peptide insertion present also in the Trypanosoma cruzi FPPS. Heterologous expression of TbFPPS in Escherichia coli produced a functional enzyme that was inhibited by several nitrogen-containing bisphosphonates, such as pamidronate and risedronate. Risedronate was active in vivo against T. brucei infection in mice (giving a 60% survival rate), but pamidronate was not effective. The essential nature of TbFPPS was studied using RNA interference (RNAi) to inhibit the expression of the gene. Expression of TbFPPS double-stranded RNA in procyclic trypomastigotes caused specific degradation of mRNA. After 4 days of RNAi, the parasite growth rate declined and the cells subsequently died. Similar results were obtained with bloodstream form trypomastigotes, except that the RNAi system in this case was leaky and mRNA levels and parasites recovered with time. Molecular modeling and structure-activity investigations of enzyme and in vitro growth inhibition data resulted in similar pharmacophores, further validating TbFPPS as the target for bisphosphonates. These results establish that FPPS is essential for parasite viability and validate this enzyme as a target for drug development.	Univ Illinois, Dept Pathobiol, Mol Parasitol Lab, Urbana, IL 61802 USA; Univ Illinois, Coll Vet Med, Ctr Zoonoses Res, Urbana, IL 61802 USA; Univ Illinois, Dept Chem, Urbana, IL 61801 USA	University of Illinois System; University of Illinois Urbana-Champaign; University of Illinois System; University of Illinois Urbana-Champaign; University of Illinois System; University of Illinois Urbana-Champaign	Docampo, R (corresponding author), Univ Illinois, Dept Pathobiol, Mol Parasitol Lab, 2001 S Lincoln Av, Urbana, IL 61802 USA.	rodoc@uiuc.edu	ghosh, subhash/C-3907-2012		NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM065307] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-65307] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		*ACC INC, 2002, INS 2 PROGR 2000 1; Barrett MP, 1999, LANCET, V353, P1113, DOI 10.1016/S0140-6736(98)00416-4; BELMANT C, 2000, Patent No. 2782721; Bergstrom JD, 2000, ARCH BIOCHEM BIOPHYS, V373, P231, DOI 10.1006/abbi.1999.1502; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brown DL, 1999, J CLIN PHARMACOL, V39, P651, DOI 10.1177/00912709922008272; Cromartie TH, 1999, PESTIC BIOCHEM PHYS, V63, P114, DOI 10.1006/pest.1999.2397; Das H, 2001, BLOOD, V98, P1616, DOI 10.1182/blood.V98.5.1616; DING VDH, 1991, BIOCHEM J, V275, P61, DOI 10.1042/bj2750061; DIXON M, 1972, BIOCHEM J, V129, P197, DOI 10.1042/bj1290197; Docampo Roberto, 2001, Current Drug Targets - Infectious Disorders, V1, P51, DOI 10.2174/1568005013343191; DUMAS M, 2000, B WORLD HEALTH ORGAN, V78, P9; Dunford JE, 2001, J PHARMACOL EXP THER, V296, P235; EUBANK WB, 1982, J PARASITOL, V68, P599, DOI 10.2307/3280916; Felsenstein J., 1989, CLADISTICS, V5, P164, DOI DOI 10.1111/J.1096-0031.1989.TB00562.X; Frisch G.W., 2016, GAUSSIAN 16 REVISION; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; Gardner MJ, 2002, NATURE, V419, P498, DOI 10.1038/nature01097; Grove JE, 2000, J BONE MINER RES, V15, P971, DOI 10.1359/jbmr.2000.15.5.971; Hill JE, 2000, BIOCHEM J, V351, P281, DOI 10.1042/0264-6021:3510281; HIRUMI H, 1989, J PARASITOL, V75, P985, DOI 10.2307/3282883; Inc Accelrys, 2000, CAT 4 6 PROGR; Keller RK, 1999, BIOCHEM BIOPH RES CO, V266, P560, DOI 10.1006/bbrc.1999.1849; Koyama T, 1999, BIOSCI BIOTECH BIOCH, V63, P1671, DOI 10.1271/bbb.63.1671; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Martin MB, 1999, BIOCHEM BIOPH RES CO, V263, P754, DOI 10.1006/bbrc.1999.1404; Martin MB, 2002, J MED CHEM, V45, P2904, DOI 10.1021/jm0102809; Martin MB, 2001, J MED CHEM, V44, P909, DOI 10.1021/jm0002578; Montalvetti A, 2001, J BIOL CHEM, V276, P33930, DOI 10.1074/jbc.M103950200; Morris JC, 2001, MOL BIOCHEM PARASIT, V117, P111, DOI 10.1016/S0166-6851(01)00334-6; Reilly JF, 2002, BIOCHEM J, V366, P501, DOI 10.1042/BJ20020560; Rodan GA, 1998, ANNU REV PHARMACOL, V38, P375, DOI 10.1146/annurev.pharmtox.38.1.375; Rodan GA, 2000, SCIENCE, V289, P1508, DOI 10.1126/science.289.5484.1508; Rodriguez N, 2002, J INFECT DIS, V186, P138, DOI 10.1086/341074; Rogers MJ, 1997, CANCER, V80, P1652, DOI 10.1002/(SICI)1097-0142(19971015)80:8+<1652::AID-CNCR15>3.0.CO;2-Z; SAITOU N, 1987, MOL BIOL EVOL, V4, P406, DOI 10.1093/oxfordjournals.molbev.a040454; SAYLE RA, 1995, TRENDS BIOCHEM SCI, V20, P374, DOI 10.1016/S0968-0004(00)89080-5; SHINODA H, 1983, CALCIFIED TISSUE INT, V35, P87, DOI 10.1007/BF02405012; Sicard H, 2001, MOL MED, V7, P711, DOI 10.1007/BF03401961; SUNBERG RJ, 1991, CHEMTECH, V21, P304; Szajnman SH, 2001, BIOORG MED CHEM LETT, V11, P789, DOI 10.1016/S0960-894X(01)00057-9; Takeuchi M, 1998, CHEM PHARM BULL, V46, P1703; Tarshis LC, 1996, P NATL ACAD SCI USA, V93, P15018, DOI 10.1073/pnas.93.26.15018; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; van Beek E, 1999, BIOCHEM BIOPH RES CO, V264, P108, DOI 10.1006/bbrc.1999.1499; van Beek E, 1999, BIOCHEM BIOPH RES CO, V255, P491, DOI 10.1006/bbrc.1999.0224; Wang CC, 1997, PARASITOLOGY, V114, pS31; Wang LS, 2001, J CLIN INVEST, V108, P1349, DOI 10.1172/JCI13584; Wang ZF, 2000, J BIOL CHEM, V275, P40174, DOI 10.1074/jbc.M008405200; Widler L, 2002, J MED CHEM, V45, P3721, DOI 10.1021/jm020819i; Wirtz E, 1999, MOL BIOCHEM PARASIT, V99, P89, DOI 10.1016/S0166-6851(99)00002-X; Yardley V, 2002, ANTIMICROB AGENTS CH, V46, P929, DOI 10.1128/AAC.46.3.929-931.2002	52	80	87	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 9	2003	278	19					17075	17083		10.1074/jbc.M210467200	http://dx.doi.org/10.1074/jbc.M210467200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677QG	12618430	hybrid			2022-12-25	WOS:000182818600085
J	Pezza, JA; Choi, KH; Berardini, TZ; Beernink, PT; Allen, KN; Tolan, DR				Pezza, JA; Choi, KH; Berardini, TZ; Beernink, PT; Allen, KN; Tolan, DR			Spatial clustering of isozyme-specific residues reveals unlikely determinants of isozyme specificity in fructose-1,6-bisphosphate aldolase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; NUCLEOTIDE-SEQUENCE; MUSCLE ALDOLASE; MESSENGER-RNA; ESCHERICHIA-COLI; TERMINAL REGION; F-ACTIN; BINDING; IDENTIFICATION; EXPRESSION	Vertebrate fructose-1,6-bisphosphate aldolase exists as three isozymes (A, B, and C) that demonstrate kinetic properties that are consistent with their physiological role and tissue-specific expression. The isozymes demonstrate specific substrate cleavage efficiencies along with differences in the ability to interact with other proteins; however, it is unknown how these differences are conferred. An alignment of 21 known vertebrate aldolase sequences was used to identify all of the amino acids that are specific to each isozyme, or isozyme-specific residues (ISRs). The location of ISRs on the tertiary and quaternary structures of aldolase reveals that ISRs are found largely on the surface (24 out of 27) and are all outside of hydrogen bonding distance to any active site residue. Moreover, ISRs cluster into two patches on the surface of aldolase with one of these patches, the terminal surface patch, overlapping with the actin-binding site of aldolase A and overlapping an area of higher than average temperature factors derived from the x-ray crystal structures of the isozymes. The other patch, the distal surface patch, comprises an area with a different electrostatic surface potential when comparing isozymes. Despite their location distal to the active site, swapping ISRs between aldolase A and B by multiple site mutagenesis on recombinant expression plasmids is sufficient to convert the kinetic properties of aldolase A to those of aldolase B. This implies that ISRs influence catalysis via changes that alter the structure of the active site from a distance or via changes that alter the interaction of the mobile C-terminal portion with the active site. The methods used in the identification and analysis of ISRs discussed here can be applied to other protein families to reveal functionally relevant residue clusters not accessible by conventional primary sequence alignment methods.	Boston Univ, Sch Med, Dept Physiol & Biophys, Boston, MA 02118 USA; Boston Univ, Dept Biol, Boston, MA 02215 USA	Boston University; Boston University	Allen, KN (corresponding author), Boston Univ, Sch Med, Dept Physiol & Biophys, 715 Albany st, Boston, MA 02118 USA.		Allen, Karen N./J-7045-2019	Allen, Karen N./0000-0001-7296-0551; Berardini, Tanya/0000-0002-3837-8864; Tolan, Dean/0000-0002-0598-7241	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM060616] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM60616] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Agius L, 1996, BIOCHEM J, V315, P651, DOI 10.1042/bj3150651; AHN AH, 1994, DEVELOPMENT, V120, P2081; Baron CB, 1999, BIOCHEM J, V341, P805, DOI 10.1042/0264-6021:3410805; BEERNINK PT, 1994, PROTEIN SCI, V3, P1383, DOI 10.1002/pro.5560030904; BEERNINK PT, 1992, PROTEIN EXPRES PURIF, V3, P332, DOI 10.1016/1046-5928(92)90009-L; Berardini TZ, 1999, COMP BIOCHEM PHYS B, V122, P53, DOI 10.1016/S0305-0491(98)10140-2; Berardini TZ, 1997, COMP BIOCHEM PHYS A, V117, P471, DOI 10.1016/S0300-9629(96)00396-9; BERTHIAUME L, 1993, J BIOL CHEM, V268, P10826; BERTHIAUME L, 1991, J BIOL CHEM, V266, P17099; Blom N, 1997, NAT STRUCT BIOL, V4, P36, DOI 10.1038/nsb0197-36; CASARI G, 1995, NAT STRUCT BIOL, V2, P171, DOI 10.1038/nsb0295-171; Choi KH, 2001, BIOCHEMISTRY-US, V40, P13868, DOI 10.1021/bi0114877; Dalby AR, 2001, ACTA CRYSTALLOGR D, V57, P1526, DOI 10.1107/S0907444901012719; FUNARI VA, 2001, THESIS BOSTON U; HEDSTROM L, 1992, SCIENCE, V255, P1249, DOI 10.1126/science.1546324; HERS HG, 1953, BIOCHIM BIOPHYS ACTA, V11, P427, DOI 10.1016/0006-3002(53)90062-6; HIGGINS DG, 1988, GENE, V73, P237, DOI 10.1016/0378-1119(88)90330-7; Hikasa H, 1997, BBA-GENE STRUCT EXPR, V1354, P189, DOI 10.1016/S0167-4781(97)00086-9; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Holland LZ, 1997, BIOCHEMISTRY-US, V36, P3207, DOI 10.1021/bi962664k; Horecker B. L, 1972, ENZYMES, P213, DOI DOI 10.1016/S1874-6047(08)60450-3; HUBBARD SJ, 1991, J MOL BIOL, V220, P507, DOI 10.1016/0022-2836(91)90027-4; JOH K, 1985, GENE, V39, P17; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kao AW, 1999, J BIOL CHEM, V274, P17742, DOI 10.1074/jbc.274.25.17742; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KUSAKABE T, 1994, J BIOCHEM-TOKYO, V115, P1172, DOI 10.1093/oxfordjournals.jbchem.a124475; Kusakabe T, 1997, ARCH BIOCHEM BIOPHYS, V344, P184, DOI 10.1006/abbi.1997.0204; Landgraf R, 2001, J MOL BIOL, V307, P1487, DOI 10.1006/jmbi.2001.4540; LEBHERZ HG, 1969, BIOCHEMISTRY-US, V8, P109, DOI 10.1021/bi00829a016; LEBIODA L, 1991, INT J BIOL MACROMOL, V13, P97, DOI 10.1016/0141-8130(91)90055-Y; Lichtarge O, 1997, J MOL BIOL, V274, P325, DOI 10.1006/jmbi.1997.1395; Lichtarge O, 1996, J MOL BIOL, V257, P342, DOI 10.1006/jmbi.1996.0167; Llewellyn L, 1998, BBA-GENE STRUCT EXPR, V1443, P375, DOI 10.1016/S0167-4781(98)00229-2; Lu M, 2001, J BIOL CHEM, V276, P30407, DOI 10.1074/jbc.M008768200; MARTIN RG, 1961, J BIOL CHEM, V236, P1372; MORRIS AJ, 1993, J BIOL CHEM, V268, P1095; MOTOKI K, 1993, J BIOL CHEM, V268, P1677; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; OREILLY G, 1993, FEBS LETT, V321, P69, DOI 10.1016/0014-5793(93)80623-3; Peitsch MC, 1996, BIOCHEM SOC T, V24, P274, DOI 10.1042/bst0240274; PENHOET EE, 1969, BIOCHEMISTRY-US, V8, P4391, DOI 10.1021/bi00839a025; PENHOET EE, 1971, J BIOL CHEM, V246, P318; PENHOET EE, 1968, THESIS U WASHINGTON; RACKER E, 1952, J BIOL CHEM, V196, P347; Rellos P, 2000, J BIOL CHEM, V275, P1145, DOI 10.1074/jbc.275.2.1145; ROTTMANN WH, 1987, BIOCHIMIE, V69, P137, DOI 10.1016/0300-9084(87)90246-X; ROTTMANN WH, 1984, P NATL ACAD SCI USA, V81, P2734; SAKAKIBARA M, 1985, BIOCHEM BIOPH RES CO, V131, P413, DOI 10.1016/0006-291X(85)91818-2; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHULZ GE, 1979, PRINCIPLES PROTEIN S, P10; STAUFFER JK, 1992, NUCLEIC ACIDS RES, V20, P327, DOI 10.1093/nar/20.2.327; SYGUSCH J, 1987, P NATL ACAD SCI USA, V84, P7846, DOI 10.1073/pnas.84.22.7846; TAYLOR JW, 1985, NUCLEIC ACIDS RES, V13, P8749, DOI 10.1093/nar/13.24.8749; TOLAN DR, 1987, AM J HUM GENET, V41, P907; TOLAN DR, 1984, J BIOL CHEM, V259, P1127; Wang JA, 1996, J BIOL CHEM, V271, P6861, DOI 10.1074/jbc.271.12.6861; ZIMMER DB, 1986, J BIOL CHEM, V261, P1424	58	24	25	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 9	2003	278	19					17307	17313		10.1074/jbc.M209185200	http://dx.doi.org/10.1074/jbc.M209185200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677QG	12611890	hybrid			2022-12-25	WOS:000182818600115
J	Tomari, Y; Hino, N; Nagaike, T; Suzuki, T; Ueda, T				Tomari, Y; Hino, N; Nagaike, T; Suzuki, T; Ueda, T			Decreased CCA-addition in human mitochondrial tRNAs bearing a pathogenic A4317G or A10044G mutation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANTICODON WOBBLE NUCLEOTIDE; MODIFICATION DEFECT; ESCHERICHIA-COLI; NUCLEOTIDYLTRANSFERASES; SUBSTITUTIONS; SEQUENCE; LOOP	Pathogenic point mutations in mitochondrial tRNA genes are known to cause a variety of human mitochondrial diseases. Reports have associated an A4317G mutation in the mitochondrial tRNAIle gene with fatal infantile cardiomyopathy and an A10044G mutation in the mitochondrial tRNAGly gene with sudden infant death syndrome. Here we demonstrate that both mutations inhibit in vitro CCA-addition to the respective tRNA by the human mitochondrial CCA-adding enzyme. Structures of these two mutant tRNAs were examined by nuclease probing. In the case of the A4317G tRNAIle mutant, structural rearrangement of the T-arm region, conferring an aberrantly stable T-arm structure and an increased T-m value, was clearly observed. In the case of the A10044G tRNAGly mutant, high nuclease sensitivity in both the T- and D-loops suggested a weakened interaction between the loops. These are the first reported instances of inefficient CCA-addition being one of the apparent molecular pathogeneses caused by pathogenic point mutations in human mitochondrial tRNA genes.	Univ Tokyo, Dept Integrated Biosci, Grad Sch Frontier Sci, Kashiwa, Chiba 2778562, Japan	University of Tokyo	Suzuki, T (corresponding author), Univ Tokyo, Dept Integrated Biosci, Grad Sch Frontier Sci, Bldg FSB-301,5-1-5 Kashiwanoha, Kashiwa, Chiba 2778562, Japan.	t-suzuki@k.u-tokyo.ac.jp	Tomari, Yukihide/A-8009-2009; Ueda, Takuya/K-5217-2014; Suzuki, Tsutomu/J-1776-2015	Tomari, Yukihide/0000-0001-8442-0851; Ueda, Takuya/0000-0002-7760-8271; Suzuki, Tsutomu/0000-0002-9731-1731				Degoul F, 1998, HUM MOL GENET, V7, P347, DOI 10.1093/hmg/7.3.347; DONISKELLER H, 1980, NUCLEIC ACIDS RES, V8, P3133, DOI 10.1093/nar/8.14.3133; Florentz C, 2001, EMBO REP, V2, P481, DOI 10.1093/embo-reports/kve111; HEGG LA, 1990, NUCLEIC ACIDS RES, V18, P5975, DOI 10.1093/nar/18.20.5975; Helm M, 2000, RNA, V6, P1356, DOI 10.1017/S1355838200001047; Kelley SO, 2001, J BIOL CHEM, V276, P10607, DOI 10.1074/jbc.M008320200; Kogelnik AM, 1998, NUCLEIC ACIDS RES, V26, P112, DOI 10.1093/nar/26.1.112; Levinger L, 1998, J BIOL CHEM, V273, P1015, DOI 10.1074/jbc.273.2.1015; Li ZL, 1996, BIOCHEM J, V314, P49, DOI 10.1042/bj3140049; LOCKARD RE, 1981, NUCLEIC ACIDS RES, V9, P5125, DOI 10.1093/nar/9.19.5125; MILLIGAN JF, 1989, METHOD ENZYMOL, V180, P51; Nagaike T, 2001, J BIOL CHEM, V276, P40041, DOI 10.1074/jbc.M106202200; Reichert AS, 2000, NUCLEIC ACIDS RES, V28, P2043, DOI 10.1093/nar/28.10.2043; ROSSMANITH W, 1995, J BIOL CHEM, V270, P12885, DOI 10.1074/jbc.270.21.12885; Santorelli FM, 1996, PEDIATR NEUROL, V15, P145, DOI 10.1016/0887-8994(96)00163-4; Schon EA, 1997, J BIOENERG BIOMEMBR, V29, P131, DOI 10.1023/A:1022685929755; Shi PY, 1998, EMBO J, V17, P3197, DOI 10.1093/emboj/17.11.3197; SPACCIAPOLI P, 1989, J BIOL CHEM, V264, P3799; Spacciapoli P, 1990, J Mol Recognit, V3, P149, DOI 10.1002/jmr.300030403; Sprinzl M, 1998, NUCLEIC ACIDS RES, V26, P148, DOI 10.1093/nar/26.1.148; Suzuki T, 2002, EMBO J, V21, P6581, DOI 10.1093/emboj/cdf656; TANAKA M, 1990, LANCET, V336, P1452, DOI 10.1016/0140-6736(90)93162-I; Yasukawa T, 2000, NUCLEIC ACIDS RES, V28, P3779, DOI 10.1093/nar/28.19.3779; Yasukawa T, 2000, J BIOL CHEM, V275, P4251, DOI 10.1074/jbc.275.6.4251; Yasukawa T, 2000, FEBS LETT, V467, P175, DOI 10.1016/S0014-5793(00)01145-5; Yasukawa T, 2001, EMBO J, V20, P4794, DOI 10.1093/emboj/20.17.4794	26	29	34	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 9	2003	278	19					16828	16833		10.1074/jbc.M213216200	http://dx.doi.org/10.1074/jbc.M213216200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677QG	12621050	hybrid			2022-12-25	WOS:000182818600052
J	Yi, XL; Yin, XM; Dong, Z				Yi, XL; Yin, XM; Dong, Z			Inhibition of Bid-induced apoptosis by Bcl-2 - tBid insertion, Bax translocation, and Bax/Bak oligomerization suppressed	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME-C RELEASE; OUTER MITOCHONDRIAL-MEMBRANE; BH3 DOMAIN; CONFORMATIONAL CHANGE; FAMILY PROTEINS; CELL-SURVIVAL; DEATH; HYPOXIA; HETERODIMERIZATION; REOXYGENATION	Bcl-2 family proteins are important regulators of apoptosis. They can be pro-apoptotic (e.g. Bid, Bax, and Bak) or anti-apoptotic (e.g. Bcl-2 and Bcl-x(L)). The current study examined Bid-induced apoptosis and its inhibition by Bcl-2. Transfection of Bid led to apoptosis in HeLa cells. In these cells, Bid was processed into active forms of truncated Bid or tBid. Following processing, tBid translocated to the membrane-bound organellar fraction. Bcl-2 co-transfection inhibited Bid-induced apoptosis but did not prevent Bid processing or tBid translocation. On the other hand, Bcl-2 blocked the release of mitochondrial cytochrome c in Bid-transfected cells, suggesting actions at the mitochondrial level. Alkaline treatment stripped off tBid from the membrane-bound organellar fraction of Bid plus Bcl-2-co-transfected cells, but not from cells transfected with only Bid, suggesting inhibition of tBid insertion into mitochondrial membranes by Bcl-2. Bcl-2 also prevented Bid-induced Bax translocation from cytosol to the membrane-bound organellar fraction. Finally, Bcl-2 diminished Bid-induced oligomerization of Bax and Bak within the membrane-bound organellar fraction, shown by cross-linking experiments. In conclusion, Bcl-2 inhibited Bid-induced apoptosis at the mitochondrial level by blocking cytochrome c release, without suppressing Bid processing or activation. Critical steps blocked by Bcl-2 included tBid insertion, Bax translocation, and Bax/Bak oligomerization in the mitochondrial membranes.	Med Coll Georgia, Dept Anat & Cell Biol, Augusta, GA 30912 USA; Univ Pittsburgh, Sch Med, Dept Pathol, Pittsburgh, PA 15261 USA	University System of Georgia; Augusta University; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Dong, Z (corresponding author), Med Coll Georgia, Dept Cellular Biol & Anat, 1459 Laney Walker Blvd, Augusta, GA 30912 USA.				NATIONAL CANCER INSTITUTE [K01CA074885, R01CA083817] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK058831] Funding Source: NIH RePORTER; NCI NIH HHS [CA83817, CA74885] Funding Source: Medline; NIDDK NIH HHS [DK58831] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; Alimonti JB, 2001, J BIOL CHEM, V276, P6974, DOI 10.1074/jbc.M008444200; Antonsson B, 2000, EXP CELL RES, V256, P50, DOI 10.1006/excr.2000.4839; Antonsson B, 2001, J BIOL CHEM, V276, P11615, DOI 10.1074/jbc.M010810200; Cheng EHYA, 2001, MOL CELL, V8, P705, DOI 10.1016/S1097-2765(01)00320-3; Cory S, 2002, NAT REV CANCER, V2, P647, DOI 10.1038/nrc883; Desagher S, 1999, J CELL BIOL, V144, P891, DOI 10.1083/jcb.144.5.891; Dong Z, 2000, BIOCHEM J, V347, P669, DOI 10.1042/0264-6021:3470669; Dong Z, 2001, J BIOL CHEM, V276, P18702, DOI 10.1074/jbc.M011774200; Eskes R, 2000, MOL CELL BIOL, V20, P929, DOI 10.1128/MCB.20.3.929-935.2000; Esposti MD, 2001, MOL CELL BIOL, V21, P7268, DOI 10.1128/MCB.21.21.7268-7276.2001; Esposti MD, 2002, APOPTOSIS, V7, P433, DOI 10.1023/A:1020035124855; FUJIKI Y, 1982, J CELL BIOL, V93, P97, DOI 10.1083/jcb.93.1.97; Goping IS, 1998, J CELL BIOL, V143, P207, DOI 10.1083/jcb.143.1.207; Gottlieb RA, 2002, METHODS, V26, P341, DOI 10.1016/S1046-2023(02)00040-3; Green DR, 2002, CANCER CELL, V1, P19, DOI 10.1016/S1535-6108(02)00024-7; Grinberg M, 2002, J BIOL CHEM, V277, P12237, DOI 10.1074/jbc.M104893200; Gross A, 1999, GENE DEV, V13, P1899, DOI 10.1101/gad.13.15.1899; Gross A, 1999, J BIOL CHEM, V274, P1156, DOI 10.1074/jbc.274.2.1156; HANADA M, 1995, J BIOL CHEM, V270, P11962, DOI 10.1074/jbc.270.20.11962; Hsu YT, 1998, J BIOL CHEM, V273, P10777, DOI 10.1074/jbc.273.17.10777; Kaufmann T, 2003, J CELL BIOL, V160, P53, DOI 10.1083/jcb.200210084; Kelekar A, 1998, TRENDS CELL BIOL, V8, P324, DOI 10.1016/S0962-8924(98)01321-X; Khaled AR, 1999, P NATL ACAD SCI USA, V96, P14476, DOI 10.1073/pnas.96.25.14476; Kuwana T, 2002, CELL, V111, P331, DOI 10.1016/S0092-8674(02)01036-X; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Li SC, 2002, J BIOL CHEM, V277, P26912, DOI 10.1074/jbc.M200726200; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; Mahajan NP, 1998, NAT BIOTECHNOL, V16, P547, DOI 10.1038/nbt0698-547; Martinou JC, 2001, NAT REV MOL CELL BIO, V2, P63, DOI 10.1038/35048069; Mikhailov V, 2003, J BIOL CHEM, V278, P5367, DOI 10.1074/jbc.M203392200; Mikhailov V, 2001, J BIOL CHEM, V276, P18361, DOI 10.1074/jbc.M100655200; Nomura M, 2003, J BIOL CHEM, V278, P2058, DOI 10.1074/jbc.M207880200; Perez D, 2000, MOL CELL, V6, P53, DOI 10.1016/S1097-2765(00)00007-1; RAFF MC, 1993, SCIENCE, V262, P695, DOI 10.1126/science.8235590; Reed JC, 2002, NAT REV DRUG DISCOV, V1, P111, DOI 10.1038/nrd726; Reed JC, 1998, ONCOGENE, V17, P3225, DOI 10.1038/sj.onc.1202591; Saikumar P, 1998, ONCOGENE, V17, P3401, DOI 10.1038/sj.onc.1202590; SEDLAK TW, 1995, P NATL ACAD SCI USA, V92, P7834, DOI 10.1073/pnas.92.17.7834; Stoka V, 2001, J BIOL CHEM, V276, P3149, DOI 10.1074/jbc.M008944200; Tafani M, 2002, J BIOL CHEM, V277, P49569, DOI 10.1074/jbc.M208915200; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; Vaux DL, 1999, CELL, V96, P245, DOI 10.1016/S0092-8674(00)80564-4; Wang K, 1996, GENE DEV, V10, P2859, DOI 10.1101/gad.10.22.2859; Waterhouse NJ, 2001, J CELL BIOL, V153, P319, DOI 10.1083/jcb.153.2.319; Wei MC, 2001, SCIENCE, V292, P727, DOI 10.1126/science.1059108; Yin XM, 2000, CELL RES, V10, P161, DOI 10.1038/sj.cr.7290045; YIN XM, 1994, NATURE, V369, P321, DOI 10.1038/369321a0; Zong WX, 2001, GENE DEV, V15, P1481, DOI 10.1101/gad.897601	49	104	121	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 9	2003	278	19					16992	16999		10.1074/jbc.M300039200	http://dx.doi.org/10.1074/jbc.M300039200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677QG	12624108	hybrid			2022-12-25	WOS:000182818600074
J	Yamazaki, K; Aso, T; Ohnishi, Y; Ohno, M; Tamura, K; Shuin, T; Kitajima, S; Nakabeppu, Y				Yamazaki, K; Aso, T; Ohnishi, Y; Ohno, M; Tamura, K; Shuin, T; Kitajima, S; Nakabeppu, Y			Mammalian elongin A is not essential for cell viability but is required for proper cell cycle progression with limited alteration of gene expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-POLYMERASE-II; TRANSCRIPTION ELONGATION-FACTOR; TUMOR-SUPPRESSOR PROTEIN; FACTOR-SIII; STEM-CELLS; IDENTIFICATION; BINDING; ACTIVATION; DISRUPTION; MUTATIONS	Elongin A is a transcription elongation factor that increases the overall rate of mRNA chain elongation by RNA polymerase II To investigate the function of Elongin A in vivo, the two alleles of the Elongin A gene have been disrupted by homologous recombination in murine embryonic stem (ES) cells. The Elongin A-deficient ES cells are viable, but show a slow growth phenotype because they undergo a delayed mitosis. The cDNA microarray and RNase protection assay using the wildtype and Elongin A-deficient ES cells indicate that the expression of only a small subset of genes is affected in the mutant cells. Taken together, our results suggest that Elongin A regulates transcription of a subset but not all of genes and reveal a linkage between Elongin A function and cell cycle progression.	Kochi Med Sch, Fac Med, Dept Chem, Nanko Ku, Kochi 7838505, Japan; Kochi Med Sch, Fac Med, Dept Urol, Nanko Ku, Kochi 7838505, Japan; Japan Sci & Technol Corp, CREST, Higashi Ku, Fukuoka 8128582, Japan; Kyushu Univ, Med Inst Bioregulat, Higashi Ku, Fukuoka 8128582, Japan; Japan Sci & Technol, CREST, Higashi Ku, Fukuoka 8128582, Japan; Tokyo Med & Dent Univ, Dept Biochem Genet, Inst Med Res, Bunkyo Ku, Tokyo 1138510, Japan	Kochi University; Kochi University; Japan Science & Technology Agency (JST); Kyushu University; Japan Science & Technology Agency (JST); Tokyo Medical & Dental University (TMDU)	Aso, T (corresponding author), Kochi Med Sch, Fac Med, Dept Chem, Nanko Ku, Oko Cho, Kochi 7838505, Japan.		Nakabeppu, Yusaku/A-8902-2011	Nakabeppu, Yusaku/0000-0002-6739-242X				Apone LM, 1996, GENE DEV, V10, P2368, DOI 10.1101/gad.10.18.2368; Aso T, 1996, EMBO J, V15, P5557, DOI 10.1002/j.1460-2075.1996.tb00940.x; ASO T, 1995, SCIENCE, V269, P1439, DOI 10.1126/science.7660129; ASO T, 1995, FASEB J, V9, P1419, DOI 10.1096/fasebj.9.14.7589983; Aso T, 2000, J BIOL CHEM, V275, P6546, DOI 10.1074/jbc.275.9.6546; Aso T, 1999, CYTOGENET CELL GENET, V86, P259, DOI 10.1159/000015355; BRADSHER JN, 1993, J BIOL CHEM, V268, P25587; Chavez S, 2000, EMBO J, V19, P5824, DOI 10.1093/emboj/19.21.5824; Chavez S, 1997, GENE DEV, V11, P3459, DOI 10.1101/gad.11.24.3459; Conaway JW, 2000, TRENDS BIOCHEM SCI, V25, P375, DOI 10.1016/S0968-0004(00)01615-7; DENG CX, 1993, MOL CELL BIOL, V13, P2134, DOI 10.1128/MCB.13.4.2134; DUAN DR, 1995, SCIENCE, V269, P1402, DOI 10.1126/science.7660122; GARRETT KP, 1994, P NATL ACAD SCI USA, V91, P5237, DOI 10.1073/pnas.91.12.5237; GARRETT KP, 1995, P NATL ACAD SCI USA, V92, P7172, DOI 10.1073/pnas.92.16.7172; Joyner AL, 1993, GENE TARGETING PRACT; Kamura T, 2001, J BIOL CHEM, V276, P29748, DOI 10.1074/jbc.M103093200; KIBEL A, 1995, SCIENCE, V269, P1444, DOI 10.1126/science.7660130; KISHIDA T, 1995, CANCER RES, V55, P4544; Lee TI, 2000, NATURE, V405, P701, DOI 10.1038/35015104; MANSOUR SL, 1988, NATURE, V336, P348, DOI 10.1038/336348a0; Martin J, 1999, MOL CELL BIOL, V19, P5548; ODA S, 1995, ONCOGENE, V10, P1343; Piruat JI, 1998, EMBO J, V17, P4859, DOI 10.1093/emboj/17.16.4859; PRICE DH, 1989, MOL CELL BIOL, V9, P1465, DOI 10.1128/MCB.9.4.1465; RANCOURT DE, 1995, GENE DEV, V9, P108, DOI 10.1101/gad.9.1.108; Reines D, 1996, TRENDS BIOCHEM SCI, V21, P351, DOI 10.1016/0968-0004(96)10045-1; Robertson E. J., 1987, TERATOCARCINOMAS EMB; Roeder RG, 1996, TRENDS BIOCHEM SCI, V21, P327, DOI 10.1016/0968-0004(96)10050-5; Selby CP, 1997, P NATL ACAD SCI USA, V94, P11205, DOI 10.1073/pnas.94.21.11205; Tominaga Y, 1997, CARCINOGENESIS, V18, P889, DOI 10.1093/carcin/18.5.889; Um M, 2001, MOL CELL BIOL, V21, P2435, DOI 10.1128/MCB.21.7.2435-2448.2001; Uptain SM, 1997, ANNU REV BIOCHEM, V66, P117, DOI 10.1146/annurev.biochem.66.1.117; Wind M, 2000, BIOESSAYS, V22, P327, DOI 10.1002/(SICI)1521-1878(200004)22:4<327::AID-BIES3>3.0.CO;2-4; Yamazaki K, 2002, J BIOL CHEM, V277, P26444, DOI 10.1074/jbc.M202859200	34	15	15	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 11	2003	278	15					13585	13589		10.1074/jbc.C300047200	http://dx.doi.org/10.1074/jbc.C300047200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	666RD	12604609	hybrid			2022-12-25	WOS:000182189500124
J	Geisen, C; Karsunky, H; Yucel, R; Moroy, T				Geisen, C; Karsunky, H; Yucel, R; Moroy, T			Loss of P27(Kip1) cooperates with cyclin E in T-cell lymphomagenesis	ONCOGENE			English	Article						cyclin E; p27(Kip11); oncogene cooperation; lymphomagenesis	MALIGNANT TRANSFORMATION; TRANSGENIC MICE; CDK INHIBITORS; PROGNOSTIC IMPLICATIONS; ONCOGENIC ACTIVITY; RESTRICTION POINT; TUMOR SUPPRESSION; DEPENDENT KINASES; HA-RAS; MYC	Cyclin E and p27(Kip1) are key regulators for cyclin-dependent kinases (Cdks) acting at the G1-/S-phase transition of the cell cycle. Whereas cyclin E is required for the activation of Cdk2, p27(Kip1) is a specific Cdk inhibitor and can block cell division. High levels of cyclin E and low levels of p27(Kip1) expression have been associated with malignant lymphomas in humans; the level of p27(Kip1) is even considered of prognostic significance. However, mice that lack p27(Kip1) do not develop any malignant lymphomas despite a pronounced lymphoid hyperplasia in thymus and spleen. We have previously described transgenic mice that carry a construct in which the cyclin E cDNA is under the control of the CD2 promoter/enhancer region and thus express high levels of cyclin E in the T-cell compartment (CD2-cyclin E). These animals are not predisposed for T-cell lymphomas in the absence of other cooperating events. Here we show that T-cells from CD2-cyclin E mice that at the same time are deficient for p27(Kip1) show a significantly higher Cdk2 activity than cells from wilde-type or single mutant animals. Accordingly, a higher percentage of T cells in S/G2/M phase is found in CD2-cyclin E/p27(Kip2-/-) mice. After a long latency period of over 200 days, these animals develop spontaneous monoclonal T cell lymphoma whereas none of the single CD2-cyclin E transgenics or the p27(Kip1)-deficient mice showed any sign of lymphoid malignancies. Our findings demonstrate that a deregulation of control mechanisms at the G1/S transition by the combination of high cyclin E levels in the absence of p27(Kip1) is sufficient to predispose mice to develop lymphoid malignancies and further support a role of p27(Kip1) as a tumor suppressor and of cyclin E as a dominant oncogene.	Univ Essen Gesamthsch Klinikum, IFZ, Inst Zellbiol Tumorforsch, D-45122 Essen, Germany	University of Duisburg Essen	Moroy, T (corresponding author), Univ Essen Gesamthsch Klinikum, IFZ, Inst Zellbiol Tumorforsch, Virchowstr 173, D-45122 Essen, Germany.		Moroy, Tarik/D-9923-2011					Bartek J, 1996, CURR OPIN CELL BIOL, V8, P805, DOI 10.1016/S0955-0674(96)80081-0; BODRUG SE, 1994, EMBO J, V13, P2124, DOI 10.1002/j.1460-2075.1994.tb06488.x; Bortner DM, 1997, MOL CELL BIOL, V17, P453, DOI 10.1128/MCB.17.1.453; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; Di Cristofano A, 2001, NAT GENET, V27, P222, DOI 10.1038/84879; Donnellan R, 1999, FASEB J, V13, P773, DOI 10.1096/fasebj.13.8.773; Erlanson M, 1998, BLOOD, V92, P770; Erlanson M, 2001, LEUKEMIA LYMPHOMA, V40, P461, DOI 10.3109/10428190109097645; Fero ML, 1996, CELL, V85, P733, DOI 10.1016/S0092-8674(00)81239-8; Fero ML, 1998, NATURE, V396, P177, DOI 10.1038/24179; GALAKTIONOV K, 1995, SCIENCE, V269, P1575, DOI 10.1126/science.7667636; Geisen C, 2002, J BIOL CHEM, V277, P39909, DOI 10.1074/jbc.M205919200; Haas K, 1997, ONCOGENE, V15, P179, DOI 10.1038/sj.onc.1201171; Haas K, 1997, ONCOGENE, V15, P2615, DOI 10.1038/sj.onc.1201434; HALL M, 1995, ONCOGENE, V11, P1581; Hall M, 1996, ADV CANCER RES, V68, P67, DOI 10.1016/S0065-230X(08)60352-8; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Harper JW, 1996, CURR OPIN GENET DEV, V6, P56; Hogan B, 1994, MANIPULATING MOUSE E; Hwang HC, 2002, P NATL ACAD SCI USA, V99, P11293, DOI 10.1073/pnas.162356099; Karsunky H, 1999, ONCOGENE, V18, P7816, DOI 10.1038/sj.onc.1203205; Kiyokawa H, 1996, CELL, V85, P721, DOI 10.1016/S0092-8674(00)81238-6; LOVEC H, 1994, ONCOGENE, V9, P323; LOVEC H, 1994, EMBO J, V13, P3487, DOI 10.1002/j.1460-2075.1994.tb06655.x; Luscher B, 2001, GENE, V277, P1, DOI 10.1016/S0378-1119(01)00697-7; Martins CP, 2002, EMBO J, V21, P3739, DOI 10.1093/emboj/cdf364; Minella AC, 2002, CURR BIOL, V12, P1817, DOI 10.1016/S0960-9822(02)01225-3; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; MOROY T, 1993, P NATL ACAD SCI USA, V90, P10734, DOI 10.1073/pnas.90.22.10734; MOROY T, 1990, EMBO J, V9, P3659, DOI 10.1002/j.1460-2075.1990.tb07577.x; Nakayama K, 1996, CELL, V85, P707, DOI 10.1016/S0092-8674(00)81237-4; PlanasSilva MD, 1997, CURR OPIN CELL BIOL, V9, P768, DOI 10.1016/S0955-0674(97)80076-2; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; REYNISDOTTIR I, 1995, GENE DEV, V9, P1831, DOI 10.1101/gad.9.15.1831; Ruas M, 1998, BBA-REV CANCER, V1378, pF115, DOI 10.1016/S0304-419X(98)00017-1; Sambrook J., 2002, MOL CLONING LAB MANU; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; Slingerland J, 2000, J CELL PHYSIOL, V183, P10, DOI 10.1002/(SICI)1097-4652(200004)183:1<10::AID-JCP2>3.0.CO;2-I; Weinberg RA, 1996, CELL, V85, P457, DOI 10.1016/S0092-8674(00)81244-1	40	26	26	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 20	2003	22	11					1724	1729		10.1038/sj.onc.1206340	http://dx.doi.org/10.1038/sj.onc.1206340			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	655YH	12642875				2022-12-25	WOS:000181580500014
J	Seker, H; Rubbi, C; Linke, SP; Bowman, ED; Garfield, S; Hansen, L; Borden, KLB; Milner, J; Harris, CC				Seker, H; Rubbi, C; Linke, SP; Bowman, ED; Garfield, S; Hansen, L; Borden, KLB; Milner, J; Harris, CC			UV-C-induced DNA damage leads to p53-dependent nuclear trafficking of PML	ONCOGENE			English	Article						P53; PML; DNA repair; BLM	NUCLEOTIDE EXCISION-REPAIR; ACUTE PROMYELOCYTIC LEUKEMIA; BLOOM-SYNDROME; PREMATURE SENESCENCE; TUMOR SUPPRESSION; SYNDROME PROTEIN; MESSENGER-RNA; ONCOGENIC RAS; CELL-CYCLE; P53	The promyelocytic leukemia protein (PML) is a nuclear phosphoprotein that localizes to distinct domains in the nucleus, described as PML nuclear bodies (PML-NBs). Recent findings indicate that PML regulates the p53 response to oncogenic signals. Here, we define a p53-dependent role for PML in response to DNA damage. We exposed cells to ultraviolet light (UV-C) and imaged the nuclear distribution of PML, p53, and the BLM helicase by confocal microscopy. After DNA damage, PML partially relocated out of the PML-NBs, and colocalized with BLM and p53 at sites of DNA repair. In addition, using the isogenic HCT116 cell tines (p53+/+ and -/-), we show that the redistribution of PML was dependent on functional p53. Western analysis revealed that the level of PML protein remained unaltered after UV-C treatment. These results are consistent with the hypothesis that PML, in conjunction with p53 and BLM, contributes to the cellular response to UV-C-induced DNA damage and its repair.	NCI, Human Carcinogenesis Lab, CCR, NIH, Bethesda, MD 20892 USA; Univ York, Dept Biol, YCR Lab P53, York YO1 5DD, N Yorkshire, England; NCI, Expt Carcinogenesis Lab, CCR, NIH, Bethesda, MD 20892 USA; Creighton Univ, Sch Med, Dept Biomed Sci, Omaha, NE 68178 USA; Mt Sinai Sch Med, Dept Physiol & Biophys, Struct Biol Program, New York, NY 10029 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University of York - UK; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Creighton University; Icahn School of Medicine at Mount Sinai	Harris, CC (corresponding author), NCI, Human Carcinogenesis Lab, CCR, NIH, 37 Convent Dr,Bldg 37,Room 2C05, Bethesda, MD 20892 USA.	Curtis_Harris@nih.gov		Linke, Steven/0000-0001-8584-4947	NATIONAL CANCER INSTITUTE [Z01BC005795, ZIABC005795] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adamson AL, 2001, J VIROL, V75, P2388, DOI 10.1128/JVI.75.5.2388-2399.2001; Ahn JH, 2000, VIROLOGY, V274, P39, DOI 10.1006/viro.2000.0448; Auerbach Arleen D., 1997, Current Opinion in Pediatrics, V9, P600, DOI 10.1097/00008480-199712000-00010; Bischof O, 2001, J CELL BIOL, V153, P367, DOI 10.1083/jcb.153.2.367; BOOTSMA D, 1993, NATURE, V363, P114, DOI 10.1038/363114a0; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; Chan JYH, 1997, BIOCHEM BIOPH RES CO, V240, P640, DOI 10.1006/bbrc.1997.7692; Cohen N, 2001, EMBO J, V20, P4547, DOI 10.1093/emboj/20.16.4547; CONCHELLO JA, 1994, APPL OPTICS, V33, P3740, DOI 10.1364/AO.33.003740; de Boer J, 2000, CARCINOGENESIS, V21, P453, DOI 10.1093/carcin/21.3.453; DETHE H, 1991, CELL, V66, P675, DOI 10.1016/0092-8674(91)90113-D; Ellis NA, 2001, HUM GENET, V108, P167, DOI 10.1007/s004390000447; Ellis NA, 1999, AM J HUM GENET, V65, P1368, DOI 10.1086/302616; ELLIS NA, 1995, CELL, V83, P655, DOI 10.1016/0092-8674(95)90105-1; Ferbeyre G, 2000, GENE DEV, V14, P2015; Fogal V, 2000, EMBO J, V19, P6185, DOI 10.1093/emboj/19.22.6185; Ford JM, 1997, J BIOL CHEM, V272, P28073, DOI 10.1074/jbc.272.44.28073; GERMAN J, 1993, MEDICINE, V72, P393, DOI 10.1097/00005792-199311000-00003; Gottifredi V, 2001, TRENDS CELL BIOL, V11, P184, DOI 10.1016/S0962-8924(01)01983-3; Guo A, 2000, NAT CELL BIOL, V2, P730, DOI 10.1038/35036365; Hu P, 2001, HUM MOL GENET, V10, P1287, DOI 10.1093/hmg/10.12.1287; Ishov AM, 1999, J CELL BIOL, V147, P221, DOI 10.1083/jcb.147.2.221; Lallemand-Breitenbach V, 2001, J EXP MED, V193, P1361, DOI 10.1084/jem.193.12.1361; Leveillard T, 1996, EMBO J, V15, P1615, DOI 10.1002/j.1460-2075.1996.tb00506.x; Maul GG, 2000, J STRUCT BIOL, V129, P278, DOI 10.1006/jsbi.2000.4239; Maul GG, 1995, J CELL BIOCHEM, V59, P498, DOI 10.1002/jcb.240590410; Melnick A, 1999, BLOOD, V93, P3167, DOI 10.1182/blood.V93.10.3167.410k44_3167_3215; Negorev D, 2001, ONCOGENE, V20, P7234, DOI 10.1038/sj.onc.1204764; Pearson M, 2000, NATURE, V406, P207, DOI 10.1038/35018127; Quignon F, 1998, NAT GENET, V20, P259, DOI 10.1038/3068; Robles AI, 1999, ONCOGENE, V18, P4681, DOI 10.1038/sj.onc.1202862; Rubbi CP, 2000, ONCOGENE, V19, P85, DOI 10.1038/sj.onc.1203378; Rubbi CP, 2001, CARCINOGENESIS, V22, P1789, DOI 10.1093/carcin/22.11.1789; Ruggero D, 2000, BIOESSAYS, V22, P827, DOI 10.1002/1521-1878(200009)22:9<827::AID-BIES8>3.3.CO;2-T; Salomoni P, 2002, CELL, V108, P165, DOI 10.1016/S0092-8674(02)00626-8; Sanz MM, 2000, CYTOGENET CELL GENET, V91, P217, DOI 10.1159/000056848; Stadler M, 1995, ONCOGENE, V11, P2565; STUURMAN N, 1992, J CELL SCI, V101, P773; Tchang F, 1999, EXP CELL RES, V251, P46, DOI 10.1006/excr.1999.4570; Vallian S, 1998, MOL CELL BIOL, V18, P7147, DOI 10.1128/MCB.18.12.7147; van Brabant AJ, 2000, ANNU REV GENOM HUM G, V1, P409, DOI 10.1146/annurev.genom.1.1.409; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Wang WS, 2000, EMBO J, V19, P3428, DOI 10.1093/emboj/19.13.3428; Wang XW, 2001, J BIOL CHEM, V276, P32948, DOI 10.1074/jbc.M103298200; WANG XW, 1995, NAT GENET, V10, P188, DOI 10.1038/ng0695-188; Wang XW, 1996, GENE DEV, V10, P1219, DOI 10.1101/gad.10.10.1219; Wang ZG, 1998, NAT GENET, V20, P266, DOI 10.1038/3073; Wood RD, 1997, J BIOL CHEM, V272, P23465, DOI 10.1074/jbc.272.38.23465; Wu WS, 2001, MOL CELL BIOL, V21, P2259, DOI 10.1128/MCB.21.7.2259-2268.2001; Yankiwski V, 2001, BMC CELL BIOL, V2, DOI 10.1186/1471-2121-2-11; Zhan QM, 1999, ONCOGENE, V18, P2892, DOI 10.1038/sj.onc.1202667; Zhong S, 2000, NAT CELL BIOL, V2, pE85, DOI 10.1038/35010583; Zong S, 1999, ONCOGENE, V18, P7941, DOI 10.1038/sj.onc.1203367	53	41	43	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 20	2003	22	11					1620	1628		10.1038/sj.onc.1206140	http://dx.doi.org/10.1038/sj.onc.1206140			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	655YH	12642865				2022-12-25	WOS:000181580500004
J	Tagliafico, E; Siena, M; Zanocco-Marani, T; Manfredini, R; Tenedini, E; Montanari, M; Grande, A; Ferrari, S				Tagliafico, E; Siena, M; Zanocco-Marani, T; Manfredini, R; Tenedini, E; Montanari, M; Grande, A; Ferrari, S			Requirement of the coiled-coil domains of p92(c-Fes) for nuclear localization in myeloid cells upon induction of differentiation	ONCOGENE			English	Article						c-Fes; oligomerization; myeloid differentiation; phosphorylation; nuclear localization; tyrosine kinase	FES TYROSINE KINASE; HUMAN C-FES; GREEN FLUORESCENT PROTEIN; HEMATOPOIETIC STEM-CELLS; VITAMIN-D-RECEPTOR; RETROVIRAL VECTORS; FPS FES; EXPRESSION; FPS/FES; GENE	The nonreceptor tyrosine kinase Fes is implicated in myeloid cells differentiation. It has been observed that its localization can be cytoplasmic, perinuclear, or nuclear. To further characterize this point, we studied Fes subcellular localization in myeloid cell lines (HL60 and K562) and in COS1 cells. Fes was observed in both the nucleus and the cytoplasm of HL60, K562 cells over-expressing Fes and only in the cytoplasm of COS1 cells, suggesting that nuclear localization is cell context dependent. Moreover, in myeloid cells, the treatment with differentiation-inducing agents such as retinoic acid, phorbol esters and vitamin D, is followed by an increase of the oligomeric form of Fes in the nucleus. In fact, oligomerization seems to be necessary for translocation to occur, since Fes mutants missing the coiled-coil domains are not able to form oligomers and fail to localize in the nucleus. The active form of Fes is tyrosine phosphorylated; however, phosphorylation is not required for Fes to localize in the nucleus, since tyrosine kinase inhibitors do not block the translocation process.	Univ Modena, Dipartimento Sci Biomed, Sez Chim Biol, I-41100 Modena, Italy	Universita di Modena e Reggio Emilia	Ferrari, S (corresponding author), Univ Modena, Dipartimento Sci Biomed, Sez Chim Biol, Via Campi 287, I-41100 Modena, Italy.		Manfredini, Rossella/C-5625-2015; Tagliafico, Enrico/C-9079-2009; Ferrari, Sergio/A-1110-2010; Zanocco Marani, Tommaso/D-5801-2015; tenedini, elena/ABB-3411-2020; Grande, Alexis/D-5816-2015	Manfredini, Rossella/0000-0003-0660-6110; Tagliafico, Enrico/0000-0003-0981-2542; Ferrari, Sergio/0000-0002-4822-2521; Zanocco Marani, Tommaso/0000-0002-9911-7078; Grande, Alexis/0000-0003-3319-1707; TENEDINI, Elena/0000-0003-0285-765X				ARECES LB, 1994, MOL CELL BIOL, V14, P4606, DOI 10.1128/MCB.14.7.4606; BENNETT JM, 1976, BRIT J HAEMATOL, V33, P451, DOI 10.1111/j.1365-2141.1976.tb03563.x; BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; CANCE WG, 1994, CELL GROWTH DIFFER, V5, P1347; CARE A, 1994, ONCOGENE, V9, P739; CHALFIE M, 1994, SCIENCE, V263, P802, DOI 10.1126/science.8303295; Cheng HY, 1999, MOL CELL BIOL, V19, P8335; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DREXLER HG, 1987, LEUKEMIA, V1, P697; EMILIA G, 1986, BRIT J HAEMATOL, V62, P287, DOI 10.1111/j.1365-2141.1986.tb02931.x; FELDMAN RA, 1985, P NATL ACAD SCI USA, V82, P2379, DOI 10.1073/pnas.82.8.2379; FERRARI S, 1994, LEUKEMIA, V8, pS91; FERRARI S, 1995, CELL DEATH DIFFER, V2, P155; FERRARI S, 1985, BRIT J HAEMATOL, V59, P21, DOI 10.1111/j.1365-2141.1985.tb02959.x; Grande A, 1999, BLOOD, V93, P3276, DOI 10.1182/blood.V93.10.3276.410k08_3276_3285; Grande A, 1997, CELL DEATH DIFFER, V4, P497, DOI 10.1038/sj.cdd.4400270; GREER P, 1994, MOL CELL BIOL, V14, P6755, DOI 10.1128/MCB.14.10.6755; Greer P, 2002, NAT REV MOL CELL BIO, V3, P278, DOI 10.1038/nrm783; Haas J, 1996, CURR BIOL, V6, P315, DOI 10.1016/S0960-9822(02)00482-7; Hackenmiller R, 2000, IMMUNITY, V13, P397, DOI 10.1016/S1074-7613(00)00039-X; Hackenmiller R, 2002, DEV BIOL, V245, P255, DOI 10.1006/dbio.2002.0643; Haigh J, 1996, CELL GROWTH DIFFER, V7, P931; HAZAN B, 1993, CELL GROWTH DIFFER, V4, P443; HJERMSTAD SJ, 1993, ONCOGENE, V8, P2283; Hovland AR, 2001, J NEUROSCI RES, V64, P302; Hunter T, 2000, CELL, V100, P113, DOI 10.1016/S0092-8674(00)81688-8; INOUYE S, 1994, FEBS LETT, V341, P277, DOI 10.1016/0014-5793(94)80472-9; IZUHARA K, 1994, J BIOL CHEM, V269, P18623; JUCKER M, 1992, ONCOGENE, V7, P943; Khokhlatchev AV, 1998, CELL, V93, P605, DOI 10.1016/S0092-8674(00)81189-7; Li JZ, 1996, J BIOL CHEM, V271, P32930, DOI 10.1074/jbc.271.51.32930; MACDONALD I, 1985, MOL CELL BIOL, V5, P2543, DOI 10.1128/MCB.5.10.2543; Manfredini R, 1999, CANCER RES, V59, P3803; MANFREDINI R, 1993, J EXP MED, V178, P381, DOI 10.1084/jem.178.2.381; Manfredini R, 1997, BLOOD, V89, P135, DOI 10.1182/blood.V89.1.135.135_135_145; MANTOVANI R, 1992, EMBO J, V11, P3315, DOI 10.1002/j.1460-2075.1992.tb05410.x; MATSUDA T, 1995, J BIOL CHEM, V270, P11037, DOI 10.1074/jbc.270.19.11037; MILLER AD, 1989, BIOTECHNIQUES, V7, P980; Nair SC, 1996, CELL STRESS CHAPERON, V1, P237, DOI 10.1379/1466-1268(1996)001<0237:APOMCI>2.3.CO;2; NELSON KL, 1998, J BIOL CHEM; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; Pendergast AM, 1996, CURR OPIN CELL BIOL, V8, P174, DOI 10.1016/S0955-0674(96)80063-9; Phillips RL, 2000, SCIENCE, V288, P1635, DOI 10.1126/science.288.5471.1635; Pinna LA, 1996, BBA-MOL CELL RES, V1314, P191, DOI 10.1016/S0167-4889(96)00083-3; Read RD, 1997, J BIOL CHEM, V272, P18498, DOI 10.1074/jbc.272.29.18498; Rogers JA, 1996, J BIOL CHEM, V271, P17519, DOI 10.1074/jbc.271.29.17519; SAWYERS CL, 1994, CELL, V77, P121, DOI 10.1016/0092-8674(94)90240-2; Smithgall TE, 1998, CRIT REV ONCOGENESIS, V9, P43, DOI 10.1615/CritRevOncog.v9.i1.40; SONGYANG Z, 1994, MOL CELL BIOL, V14, P2777, DOI 10.1128/MCB.14.4.2777; YATES KE, 1995, ONCOGENE, V10, P1239; YU G, 1989, J BIOL CHEM, V264, P10276; Zirngibl R, 2001, EXP CELL RES, V266, P87, DOI 10.1006/excr.2001.5217; Zirngibl RA, 2002, MOL CELL BIOL, V22, P2472, DOI 10.1128/MCB.22.8.2472-2486.2002	53	9	9	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 20	2003	22	11					1712	1723		10.1038/sj.onc.1206279	http://dx.doi.org/10.1038/sj.onc.1206279			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	655YH	12642874				2022-12-25	WOS:000181580500013
J	Albert, CJ; Thukkani, AK; Heuertz, RM; Slungaard, A; Hazen, SL; Ford, DA				Albert, CJ; Thukkani, AK; Heuertz, RM; Slungaard, A; Hazen, SL; Ford, DA			Eosinophil peroxidase-derived reactive brominating species target the vinyl ether bond of plasmalogens generating a novel chemoattractant, alpha-bromo fatty aldehyde	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MYELOPEROXIDASE TARGET; HYPOCHLOROUS ACID; PROTEIN ADDUCTS; CHLORIDE SYSTEM; ANIMAL-CELLS; OXIDATION; IDENTIFICATION; CHOLESTEROL; NEUTROPHIL; PHAGOCYTES	Plasmalogens are a subclass of glycerophospholipids that are enriched in the plasma membrane of many mammalian cells. The vinyl ether bond of plasmalogens renders them susceptible to oxidation. Accordingly, it was hypothesized that reactive brominating species, a unique oxidant formed at the sites of eosinophil activation, such as in asthma, might selectively target plasmalogens for oxidation. Here we show that reactive brominating species produced by the eosinophil peroxidase system of activated eosinophils attack the vinyl ether bond of plasmalogens. Reactive brominating species produced by eosinophil peroxidase target the vinyl ether bond of plasmalogens resulting in the production of a neutral lipid and lysophosphatidylcholine. Chromatographic and mass spectrometric analyses of this neutral lipid demonstrated that it was 2-bromohexadecanal (2-BrHDA). Reactive brominating species produced by eosinophil peroxidase attacked the plasmalogen vinyl ether bond at acidic pH. Bromide was the preferred substrate for eosinophil peroxidase, and chloride was not appreciably used even at a 1000-fold molar excess. Furthermore, 2-BrHDA production elicited by eosinophil peroxidase-derived reactive brominating species in the presence of 100 pm NaBr doubled with the addition of 100 mm NaCl. The potential physiological significance of this pathway was suggested by the demonstration that 2-BrHDA was produced by phorbol myristate acetate-stimulated eosinophils and by the demonstration that 2-BrHDA is a phagocyte chemoattractant. Taken together, the present studies demonstrate the targeting of the vinyl ether bond of plasmalogens by the reactive brominating species produced by eosinophil peroxidase and by activated eosinophils, resulting in the production of brominated fatty aldehydes.	St Louis Univ, Sch Med, Hlth Sci Ctr, Dept Biochem & Mol Biol, St Louis, MO 63104 USA; St Louis Univ, Hlth Sci Ctr, Dept Internal Med, St Louis, MO 63104 USA; St Louis Univ, Hlth Sci Ctr, Dept Mol Microbiol & Immunol, St Louis, MO 63104 USA; Cleveland Clin Fdn, Ctr Cardiovasc Diagnost & Prevent, Dept Cell Biol, Cleveland, OH 44195 USA; Cleveland Clin Fdn, Ctr Cardiovasc Diagnost & Prevent, Dept Cardiovasc Med, Cleveland, OH 44195 USA; Univ Minnesota, Dept Med, Sect Hematol Oncol & Transplantat, Minneapolis, MN 55455 USA	Saint Louis University; Saint Louis University; Saint Louis University; Cleveland Clinic Foundation; Cleveland Clinic Foundation; University of Minnesota System; University of Minnesota Twin Cities	Ford, DA (corresponding author), St Louis Univ, Sch Med, Hlth Sci Ctr, Dept Biochem & Mol Biol, 1402 S Grand Blvd, St Louis, MO 63104 USA.		Hazen, Stanley L/ABD-5845-2021; Ford, David/D-1819-2018	Ford, David/0000-0002-0029-1560	NHLBI NIH HHS [HL61878, R01 HL 42665, HL70937, HL51199] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL061878, R01HL070937, R01HL042665, R01HL051199] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Albert CJ, 2002, J BIOL CHEM, V277, P4694, DOI 10.1074/jbc.M110875200; Albert CJ, 2001, J BIOL CHEM, V276, P23733, DOI 10.1074/jbc.M101447200; Aldridge RE, 2002, FREE RADICAL BIO MED, V33, P847, DOI 10.1016/S0891-5849(02)00976-0; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Caldwell RA, 1998, CIRC RES, V83, P533, DOI 10.1161/01.RES.83.5.533; Carr AC, 1996, ARCH BIOCHEM BIOPHYS, V327, P227, DOI 10.1006/abbi.1996.0114; Carr AC, 1997, REDOX REP, V3, P263, DOI 10.1080/13510002.1997.11747122; Carr AC, 1996, ARCH BIOCHEM BIOPHYS, V332, P63, DOI 10.1006/abbi.1996.0317; CHILTON FH, 1988, J BIOL CHEM, V263, P5260; CURZIO M, 1982, RES COMMUN CHEM PATH, V36, P463; FORD DA, 1989, P NATL ACAD SCI USA, V86, P3479, DOI 10.1073/pnas.86.10.3479; Ford DA, 1996, FEBS LETT, V394, P99, DOI 10.1016/0014-5793(96)00930-1; GROSS RW, 1985, BIOCHEMISTRY-US, V24, P1662, DOI 10.1021/bi00328a014; GUTHMANN F, 1995, INT J BIOCHEM CELL B, V27, P1021, DOI 10.1016/1357-2725(95)00078-4; HAN XL, 1992, ANAL BIOCHEM, V200, P119, DOI 10.1016/0003-2697(92)90286-G; HAN XL, 1994, P NATL ACAD SCI USA, V91, P10635, DOI 10.1073/pnas.91.22.10635; Hartley DP, 1997, CHEM RES TOXICOL, V10, P895, DOI 10.1021/tx960181b; Hazen SL, 1996, J BIOL CHEM, V271, P23080, DOI 10.1074/jbc.271.38.23080; HAZEN SL, 1993, J CLIN INVEST, V91, P2513, DOI 10.1172/JCI116487; HEINECKE JW, 1994, BIOCHEMISTRY-US, V33, P10127, DOI 10.1021/bi00199a041; Hunt JF, 2002, AM J RESP CRIT CARE, V165, P101, DOI 10.1164/ajrccm.165.1.2104131; IDE M, 1994, J IMMUNOL METHODS, V168, P187, DOI 10.1016/0022-1759(94)90054-X; JORG A, 1982, BIOCHIM BIOPHYS ACTA, V701, P185, DOI 10.1016/0167-4838(82)90112-1; KLEBANOFF SJ, 1984, METHOD ENZYMOL, V105, P399; KLEBANOFF SJ, 1980, ANN INTERN MED, V93, P480, DOI 10.7326/0003-4819-93-3-480; MacPherson JC, 2001, J IMMUNOL, V166, P5763, DOI 10.4049/jimmunol.166.9.5763; Mitra SN, 2000, REDOX REP, V5, P215, DOI 10.1179/135100000101535771; MORAND OH, 1988, J BIOL CHEM, V263, P11597; MURPHY EJ, 1992, LIPIDS, V27, P150, DOI 10.1007/BF02535816; PAK JH, 1987, BIOCHEMISTRY-US, V26, P4824, DOI 10.1021/bi00389a033; POST JA, 1988, FEBS LETT, V240, P78, DOI 10.1016/0014-5793(88)80343-0; ROSENFELD ME, 1990, ARTERIOSCLEROSIS, V10, P336, DOI 10.1161/01.ATV.10.3.336; RUSTOW B, 1994, BIOCHEM J, V302, P665; TEITZ NW, 1999, TEITZ TXB CLIN CHEM, P2216; THOMAS EL, 1995, J BIOL CHEM, V270, P2906, DOI 10.1074/jbc.270.7.2906; Thukkani AK, 2002, J BIOL CHEM, V277, P3842, DOI 10.1074/jbc.M109489200; van Dalen CJ, 2001, BIOCHEM J, V358, P233, DOI 10.1042/0264-6021:3580233; vanDalen CJ, 1997, BIOCHEM J, V327, P487; WEISS SJ, 1989, NEW ENGL J MED, V320, P365; WEISS SJ, 1986, SCIENCE, V234, P200, DOI 10.1126/science.3018933; Williams SD, 1997, FEBS LETT, V420, P33, DOI 10.1016/S0014-5793(97)01482-8; Wu WJ, 2000, J CLIN INVEST, V105, P1455, DOI 10.1172/JCI9702; Zeng YC, 1998, BIOCHEMISTRY-US, V37, P2346, DOI 10.1021/bi9725172; ZIGMOND SH, 1973, J EXP MED, V137, P387, DOI 10.1084/jem.137.2.387; ZOELLER RA, 1988, J BIOL CHEM, V263, P11590	45	35	38	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 14	2003	278	11					8942	8950		10.1074/jbc.M211634200	http://dx.doi.org/10.1074/jbc.M211634200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	654YF	12643282	hybrid			2022-12-25	WOS:000181524000012
J	Kalinina, EV; Fricker, LD				Kalinina, EV; Fricker, LD			Palmitoylation of carboxypeptidase D - Implications for intracellular trafficking	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANS-GOLGI-NETWORK; METALLOCARBOXYPEPTIDASE-D; ATT-20 CELLS; CYTOPLASMIC DOMAIN; LOCALIZATION; PROTEINS; ENZYME; EXPRESSION; PITUITARY; RECEPTOR	Covalent lipid modifications mediate protein-membrane and protein-protein interactions and are often essential for function. The purposes of this study were to examine the Cys residues of the transmembrane domain of metallocarboxypeptidase D (CPD) that could be a target for palmitoylation and to clarify the function of this modification. CPD is an integral membrane protein that cycles between the trans Golgi network and the plasma membrane. We constructed AtT-20 cells stably expressing various constructs carrying a reporter protein (albumin) fused to a transmembrane domain and the CPD cytoplasmic tail. Some of the constructs contained the three Cys residues present in the CPD transmembrane region, while other constructs contained Ala in place of the Cys. Constructs carrying Cys residues were palmitoylated, while those constructs lacking the Cys residues were not. Because palmitoylation of several proteins affects their association with cholesterol and sphingolipid-rich membrane domains or caveolae, we tested endogenous CPD and several of the reporter constructs for resistance to extraction with Triton X-100. A construct containing the Cys residues of the CPD transmembrane domain was soluble in Triton X-100 as was endogenous palmitoylated CPD, indicating that palmitoylation does not target CPD to detergent-resistant membrane rafts. Interestingly, constructs of CPD that lack palmitoylation sites have an increased half-life, a slightly more diffuse steady-state localization, and a slower rate of exit from the Golgi as compared with constructs containing palmitoylation sites. Thus, the covalent attachment of palmitic acid to the Cys residues of CPD has a functional significance in the trafficking of the protein.	Yeshiva Univ Albert Einstein Coll Med, Dept Mol Pharmacol, Bronx, NY 10461 USA	Yeshiva University; Albert Einstein College of Medicine	Fricker, LD (corresponding author), Yeshiva Univ Albert Einstein Coll Med, Dept Mol Pharmacol, 1300 Morris Pk Ave, Bronx, NY 10461 USA.		Kalinina, Elena/D-9252-2012	Kalinina, Elena/0000-0003-0180-090X	NCI NIH HHS [CA13330] Funding Source: Medline; NIDA NIH HHS [K02 DA00194] Funding Source: Medline; NIDDK NIH HHS [R01 DK55711] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA013330] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK055711] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [K02DA000194] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		Barrett A.J., 1998, HDB PROTEOLYTIC ENZY, P1318; Eng FJ, 1999, MOL BIOL CELL, V10, P35, DOI 10.1091/mbc.10.1.35; Fan XM, 1999, DNA CELL BIOL, V18, P121, DOI 10.1089/104454999315501; Fricker L. D., 2002, ENZYMES, V23, P421; Fricker LD, 1996, J BIOL CHEM, V271, P30619, DOI 10.1074/jbc.271.48.30619; FRICKER LD, 1998, HDB PROTEOLYTIC ENZY, P1349; Hawtin SR, 2001, J BIOL CHEM, V276, P38139; Ishikawa T, 1998, GENE, V215, P361, DOI 10.1016/S0378-1119(98)00270-4; Kalinina E, 2002, J CELL BIOCHEM, V85, P101, DOI 10.1002/jcb.10112; KUROKI K, 1995, J BIOL CHEM, V270, P15022, DOI 10.1074/jbc.270.25.15022; KURZCHALIA TV, 1992, J CELL BIOL, V118, P1003, DOI 10.1083/jcb.118.5.1003; Melkonian KA, 1999, J BIOL CHEM, V274, P3910, DOI 10.1074/jbc.274.6.3910; MILLIGAN G, 1995, TRENDS BIOCHEM SCI, V20, P181, DOI 10.1016/S0968-0004(00)89004-0; MITRA A, 1994, J BIOL CHEM, V269, P19876; Mumby SM, 1997, CURR OPIN CELL BIOL, V9, P148, DOI 10.1016/S0955-0674(97)80056-7; Nakayama K, 1997, BIOCHEM J, V327, P625, DOI 10.1042/bj3270625; Resh MD, 1999, BBA-MOL CELL RES, V1451, P1, DOI 10.1016/S0167-4889(99)00075-0; Reznik SE, 2001, CELL MOL LIFE SCI, V58, P1790, DOI 10.1007/PL00000819; Schweizer A, 1999, BIOCHEM J, V340, P649, DOI 10.1042/0264-6021:3400649; Sidyelyeva G, 2002, J BIOL CHEM, V277, P49613, DOI 10.1074/jbc.M209652200; SONG LX, 1995, J BIOL CHEM, V270, P7963, DOI 10.1074/jbc.270.14.7963; SONG LX, 1995, J BIOL CHEM, V270, P25007, DOI 10.1074/jbc.270.42.25007; Song LX, 1996, J BIOL CHEM, V271, P28884, DOI 10.1074/jbc.271.46.28884; Tan FL, 1997, BIOCHEM J, V327, P81, DOI 10.1042/bj3270081; Urban S, 1999, J BIOL CHEM, V274, P5707, DOI 10.1074/jbc.274.9.5707; van de Loo JWHP, 2000, BIOCHEM J, V352, P827, DOI 10.1042/0264-6021:3520827; Varlamov O, 1999, J BIOL CHEM, V274, P14759, DOI 10.1074/jbc.274.21.14759; Varlamov O, 1997, ENDOCRINOLOGY, V138, P4883, DOI 10.1210/en.138.11.4883; Varlamov O, 1998, J CELL SCI, V111, P877; Varlamov O, 2001, J CELL SCI, V114, P311; Varlamov O, 1999, J BIOL CHEM, V274, P14040, DOI 10.1074/jbc.274.20.14040; Xin XN, 1997, DNA CELL BIOL, V16, P897, DOI 10.1089/dna.1997.16.897	32	19	20	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 14	2003	278	11					9244	9249		10.1074/jbc.M209379200	http://dx.doi.org/10.1074/jbc.M209379200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	654YF	12643288	hybrid			2022-12-25	WOS:000181524000048
J	Chinwalla, V; Chien, A; Odero, M; Neilly, MB; Zeleznik-Le, NJ; Rowley, JD				Chinwalla, V; Chien, A; Odero, M; Neilly, MB; Zeleznik-Le, NJ; Rowley, JD			A t(11;15) fuses MLL to two different genes, AF15q14 and a novel gene MPFYVE on chromosome 15	ONCOGENE			English	Article						t(11;15)(q23;ql5); MLL; AF15q14; MPFYVE; FYVE domain; leukemia	ACUTE LYMPHOBLASTIC-LEUKEMIA; ACUTE MYELOID LEUKEMIAS; DROSOPHILA-TRITHORAX; 11Q23 TRANSLOCATIONS; FYVE-FINGER; REARRANGEMENTS; TRANSCRIPTS; BINDING; LEUKEMOGENESIS; DUPLICATION	The mixed lineage leukemia gene (MLL, also known as HRX, ALL-1 and Htrx) located at 11q23 is involved in translocations with over 40 different chromosomal bands in a variety of leukemia subtypes. Here we report our analysis of a rare but recurring translocation, t(11;15)(q23;q14). This translocation has been described in a small subset of cases with both acute myeloblastic leukemia and ALL. Recent studies have shown that MLL is fused to AF15q14 in the t(11;15). Here we analyse a sample from another patient with this translocation and confirm the presence of an MLL-AF15q14 fusion. However, we have also identified and cloned another fusion transcript from the same patient sample. In this fusion transcript, MLL is fused to a novel gene, MLL partner containing FYVE domain (MPFYVE). Both MLL-AF15q14 and MLL-MPFYVE are in-frame fusion transcripts with the potential to code for novel fusion proteins. MPFYVE is also located on chromosome 15, approximately 170kb telomeric to AF15q14. MPFYVE contains a highly conserved motif, the FYVE domain which, in other proteins, has been shown to bind to phosphotidyl-inositol-3 phosphate (PtdIns(3)P). The MLL-MPFYVE fusion may be functionally important in the leukemia process in at least some patients containing this translocation.	Univ Chicago, Dept Med, Hematol Oncol Sect, Chicago, IL 60637 USA	University of Chicago	Rowley, JD (corresponding author), Univ Chicago, Dept Med, Hematol Oncol Sect, Chicago, IL 60637 USA.		Odero/ABG-9860-2020	Odero/0000-0002-8858-2054	NCI NIH HHS [CA 84405, CA42557, CA78438, CA40046, T32 CA09595] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA084405, R29CA078438, R35CA042557, T32CA009595] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADAMS MD, 1991, SCIENCE, V252, P1651, DOI 10.1126/science.2047873; Ayton PM, 2001, ONCOGENE, V20, P5695, DOI 10.1038/sj.onc.1204639; BERNARD OA, 1995, GENE CHROMOSOME CANC, V13, P75, DOI 10.1002/gcc.2870130202; BREEN TR, 1993, DEVELOPMENT, V117, P119; Burd CG, 1998, MOL CELL, V2, P157, DOI 10.1016/S1097-2765(00)80125-2; Caldas C, 1998, GENE, V208, P167, DOI 10.1016/S0378-1119(97)00640-9; DiMartino JF, 1999, BRIT J HAEMATOL, V106, P614, DOI 10.1046/j.1365-2141.1999.01439.x; Divoky V, 2000, GENE, V247, P111, DOI 10.1016/S0378-1119(00)00111-6; Gaullier JM, 1998, NATURE, V394, P432, DOI 10.1038/28767; GIBBONS B, 1990, BRIT J HAEMATOL, V74, P264, DOI 10.1111/j.1365-2141.1990.tb02581.x; GU Y, 1992, CELL, V71, P701, DOI 10.1016/0092-8674(92)90603-A; Hanson RD, 1999, P NATL ACAD SCI USA, V96, P14372, DOI 10.1073/pnas.96.25.14372; Hayette S, 2000, ONCOGENE, V19, P4446, DOI 10.1038/sj.onc.1203789; HERNANDEZ JM, 1995, LEUKEMIA, V9, P1162; Hillion J, 1997, BLOOD, V90, P3714, DOI 10.1182/blood.V90.9.3714; HUNGER SP, 1993, BLOOD, V81, P3197; KANEKO Y, 1988, LEUKEMIA, V2, P672; KUEFER MU, 1997, BLOOD S, V90, P1235; Lavau C, 2000, P NATL ACAD SCI USA, V97, P10984, DOI 10.1073/pnas.190167297; Lavau C, 2000, EMBO J, V19, P4655, DOI 10.1093/emboj/19.17.4655; Lavau C, 1997, EMBO J, V16, P4226, DOI 10.1093/emboj/16.14.4226; MARTINEZCLIMENT JA, 1995, LEUKEMIA, V9, P1299; Nilson I, 1996, BRIT J HAEMATOL, V93, P966, DOI 10.1046/j.1365-2141.1996.d01-1748.x; NUCIFORA G, 1994, P NATL ACAD SCI USA, V91, P4004, DOI 10.1073/pnas.91.9.4004; Patki V, 1998, NATURE, V394, P433, DOI 10.1038/28771; RAIMONDI SC, 1989, BLOOD, V73, P1627; Rowley JD, 1999, SEMIN HEMATOL, V36, P59; ROWLEY JD, 1993, SEMIN CANCER BIOL, V4, P377; RUBNITZ JE, 1994, BLOOD, V84, P570; SCHWABE JWR, 1994, NAT STRUCT BIOL, V1, P345, DOI 10.1038/nsb0694-345; Stenmark H, 1999, J CELL SCI, V112, P4175; Stenmark H, 1996, J BIOL CHEM, V271, P24048, DOI 10.1074/jbc.271.39.24048; THIRMAN MJ, 1993, NEW ENGL J MED, V329, P909, DOI 10.1056/NEJM199309233291302; TKACHUK DC, 1992, CELL, V71, P691, DOI 10.1016/0092-8674(92)90602-9; Waring PM, 1997, CURR TOP MICROBIOL, V220, P1; Whitman SP, 2001, CANCER RES, V61, P59; YU BD, 1995, NATURE, V378, P505, DOI 10.1038/378505a0; ZELEZNIKLE NJ, 1994, P NATL ACAD SCI USA, V91, P10610, DOI 10.1073/pnas.91.22.10610	38	17	21	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 6	2003	22	9					1400	1410		10.1038/sj.onc.1206273	http://dx.doi.org/10.1038/sj.onc.1206273			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	652CA	12618766	Green Published			2022-12-25	WOS:000181360900015
J	Schroeder, JA; Adriance, MC; Thompson, MC; Camenisch, TD; Gendler, SJ				Schroeder, JA; Adriance, MC; Thompson, MC; Camenisch, TD; Gendler, SJ			MUC1 alters beta-catenin-dependent tumor formation and promotes cellular invasion	ONCOGENE			English	Article						MUC 1; beta-catenin; C-src; erbB; breast cancer; invasion	GROWTH-FACTOR RECEPTOR; CARCINOMA-ASSOCIATED ANTIGEN; ACTIN-BUNDLING PROTEIN; BREAST-CANCER; EPISIALIN MUC1; MAMMARY-GLAND; E-CADHERIN; TYROSINE PHOSPHORYLATION; TRANSGENIC MICE; C-SRC	MUC1 is aberrantly expressed in greater than 90% of all breast carcinomas, yet its function as a tumor antigen is not fully understood. Recently, studies have shown that MUC1 interacts with beta-catenin, erbB receptors, src, GSK-3beta and protein kinase Cdelta, possibly in a complex that promotes the disassembly of adherens junctions and the invasion of cells. Here we show that the deletion of Muc1 expression from MMTV-Wnt-1 transgenic mice results in a significant increase in the time to mammary gland tumor onset. Analysis of MMTV-Wnt-1 tumors on a wild-type Muc1 background shows a tumor-specific complex formation between Muc1 and beta-catenin that can be observed in both the membrane and the cytoplasm of transformed epithelium. Analysis of primary human adenocarcinomas revealed that this MUC1/beta-catenin interaction occurs in both primary and metastatic tumors, but is dramatically increased in metastatic lesions. Addition of MUC1-cytoplasmic domain peptides to the invasive MDA-MB-468 and MDA-MB-231 cell lines increases their invasive capability, and these peptides colocalize with both beta-catenin and the focal adhesion protein vinculin, primarily at sites of membrane invasion into a collagen matrix. These data indicate a potential mechanism for MUC1 promotion of invasive tumorigenesis in the breast through the modulation of beta-catenin localization and subsequent cytoskeletal dynamics.	Mayo Clin & Mayo Grad Sch Med, Tumor Biol Program, Scottsdale, AZ 85259 USA; Mayo Clin & Mayo Grad Sch Med, Dept Biochem & Mol Biol, Scottsdale, AZ 85259 USA	Mayo Clinic; Mayo Clinic Phoenix; Mayo Clinic; Mayo Clinic Phoenix	Gendler, SJ (corresponding author), Mayo Clin & Mayo Grad Sch Med, Tumor Biol Program, Scottsdale, AZ 85259 USA.	gendler.sandra@mayo.edu		Camenisch, Todd/0000-0002-7797-9822; schroeder, joyce/0000-0003-1277-5172	NCI NIH HHS [CA90204, F32 CA081703-03, F32 CA081703, CA64389, CA81703] Funding Source: Medline; NATIONAL CANCER INSTITUTE [F32CA081703, F31CA090204, R01CA064389] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adams JC, 1997, MOL BIOL CELL, V8, P2345, DOI 10.1091/mbc.8.11.2345; Biscardi JS, 1998, MOL CARCINOGEN, V21, P261, DOI 10.1002/(SICI)1098-2744(199804)21:4<261::AID-MC5>3.0.CO;2-N; BURCHELL J, 1984, INT J CANCER, V34, P763, DOI 10.1002/ijc.2910340605; GENDLER SJ, 1995, ANNU REV PHYSIOL, V57, P607, DOI 10.1146/annurev.ph.57.030195.003135; Hazan RB, 1998, J BIOL CHEM, V273, P9078, DOI 10.1074/jbc.273.15.9078; Hazan RB, 1996, CELL ADHES COMMUN, V4, P399, DOI 10.3109/15419069709004457; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; HILKENS J, 1995, CANCER LETT, V90, P27, DOI 10.1016/0304-3835(94)03674-8; Kondo K, 1998, CANCER RES, V58, P2014; Li Y, 2000, ONCOGENE, V19, P1002, DOI 10.1038/sj.onc.1203273; Li YQ, 1998, MOL CELL BIOL, V18, P7216, DOI 10.1128/MCB.18.12.7216; Li YQ, 2001, J BIOL CHEM, V276, P35239, DOI 10.1074/jbc.C100359200; Li YQ, 2001, J BIOL CHEM, V276, P6061, DOI 10.1074/jbc.C000754200; Lin SY, 2000, P NATL ACAD SCI USA, V97, P4262, DOI 10.1073/pnas.060025397; MCGUCKIN MA, 1995, HUM PATHOL, V26, P432, DOI 10.1016/0046-8177(95)90146-9; Michaelson JS, 2001, ONCOGENE, V20, P5093, DOI 10.1038/sj.onc.1204586; Piedra J, 2001, J BIOL CHEM, V276, P20436, DOI 10.1074/jbc.M100194200; Rahn JJ, 2001, CANCER, V91, P1973, DOI 10.1002/1097-0142(20010601)91:11<1973::AID-CNCR1222>3.0.CO;2-A; Ren J, 2002, J BIOL CHEM, V277, P17616, DOI 10.1074/jbc.M200436200; Schroeder JA, 2002, J BIOL CHEM, V277, P22692, DOI 10.1074/jbc.M201975200; Schroeder JA, 2001, J BIOL CHEM, V276, P13057, DOI 10.1074/jbc.M011248200; Shtutman M, 1999, P NATL ACAD SCI USA, V96, P5522, DOI 10.1073/pnas.96.10.5522; SPICER AP, 1995, J BIOL CHEM, V270, P30093; Tao YS, 1996, J CELL BIOL, V134, P1271, DOI 10.1083/jcb.134.5.1271; TSUKAMOTO AS, 1988, CELL, V55, P619, DOI 10.1016/0092-8674(88)90220-6; Walsh MD, 1999, BREAST CANCER RES TR, V58, P255; WESSELING J, 1995, J CELL BIOL, V129, P255, DOI 10.1083/jcb.129.1.255; Wesseling J, 1996, MOL BIOL CELL, V7, P565, DOI 10.1091/mbc.7.4.565; Yamamoto M, 1997, J BIOL CHEM, V272, P12492, DOI 10.1074/jbc.272.19.12492; Yamashiro S, 1998, MOL BIOL CELL, V9, P993, DOI 10.1091/mbc.9.5.993; ZOTTER S, 1988, CANCER RES, V111, P55; ZRIHANLICHT S, 1994, FEBS LETT, V356, P130, DOI 10.1016/0014-5793(94)01251-2	32	146	151	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 6	2003	22	9					1324	1332		10.1038/sj.onc.1206291	http://dx.doi.org/10.1038/sj.onc.1206291			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	652CA	12618757				2022-12-25	WOS:000181360900006
J	Thorland, EC; Myers, SL; Gostout, BS; Smith, DI				Thorland, EC; Myers, SL; Gostout, BS; Smith, DI			Common fragile sites are preferential targets for HPV16 integrations in cervical tumors	ONCOGENE			English	Article						common fragile sites; cervical cancer; human papillomavirus; viral integration; RS-PCR	HUMAN-PAPILLOMAVIRUS TYPE-16; VIRAL INTEGRATION; MOLECULAR CHARACTERIZATION; CELL-LINE; E2 GENE; CANCER; CARCINOMA; REGION; DNA; ONCOGENES	The development of cervical cancer is highly associated with human papillomavirus (HPV) infection. HPV integration into the genome of infected cervical cells is temporally associated with the acquisition of the malignant phenotype. A relationship between the sites of HPV integration in cervical cancer and the position of the common fragile sites (CFSs) has been observed at both the cytogenetic and molecular levels. To further explore this relationship at the molecular level, we used RS-PCR to rapidly isolate cellular sequences flanking the sites of HPV16 integration in 26 primary cervical tumors. Human bacterial artificial chromosome clones were isolated based on these flanking sequences and used as probes for fluorescence in situ hybridization on aphidicolin-stimulated metaphases. Our data demonstrate that 11/23 HPV16 integrations in cervical tumors occurred within CFSs (P < 0.001). In addition, we show that deletions and complex rearrangements frequently occur in the cellular sequences targeted by the integrations and that integrations cluster in FRA13C (13q22), FRA3B (3p14.2), and FRA17B (17q23). Finally, our data suggest that cellular genes, such as Notch 1, are disrupted by the HPV16 integrations, which may contribute to the malignant phenotype.	Mayo Clin & Mayo Fdn, Dept Expt Pathol, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Dept Biochem & Mol Biol, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Dept Tumor Biol, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Dept Obstet & Gynecol, Rochester, MN 55905 USA	Mayo Clinic; Mayo Clinic; Mayo Clinic; Mayo Clinic	Smith, DI (corresponding author), Mayo Clin & Mayo Fdn, Dept Expt Pathol, Hilton 8,200 1st St SW, Rochester, MN 55905 USA.	smith.david@mayo.edu			NCI NIH HHS [CA48031] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA048031] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		An WF, 2000, NATURE, V403, P553, DOI 10.1038/35000592; Arlt MF, 2002, GENE CHROMOSOME CANC, V33, P82, DOI 10.1002/gcc.10000; BAKER CC, 1987, J VIROL, V61, P962, DOI 10.1128/JVI.61.4.962-971.1987; BauerHofmann R, 1996, VIROLOGY, V217, P33, DOI 10.1006/viro.1996.0090; BECKER NA, 2002, IN PRESS ONCOGENE; Burge C, 1997, J MOL BIOL, V268, P78, DOI 10.1006/jmbi.1997.0951; CANNIZZARO LA, 1988, CANCER GENET CYTOGEN, V33, P93, DOI 10.1016/0165-4608(88)90054-4; Capobianco AJ, 1997, MOL CELL BIOL, V17, P6265, DOI 10.1128/MCB.17.11.6265; Chen CS, 2001, GENE CHROMOSOME CANC, V31, P333, DOI 10.1002/gcc.1152; Choo KB, 1996, J MED VIROL, V49, P15, DOI 10.1002/(SICI)1096-9071(199605)49:1<15::AID-JMV3>3.3.CO;2-4; CHOO KB, 1995, CANCER LETT, V93, P249, DOI 10.1016/0304-3835(95)03817-G; CHOO KB, 1987, VIROLOGY, V161, P259, DOI 10.1016/0042-6822(87)90195-4; CHOO KB, 1990, VIROLOGY, V178, P621, DOI 10.1016/0042-6822(90)90366-Y; CROOK T, 1988, P NATL ACAD SCI USA, V85, P8820, DOI 10.1073/pnas.85.23.8820; CULLEN AP, 1991, J VIROL, V65, P606, DOI 10.1128/JVI.65.2.606-612.1991; Desseyn JL, 1997, J BIOL CHEM, V272, P3168, DOI 10.1074/jbc.272.6.3168; Dong JT, 2000, CANCER RES, V60, P3880; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; ELLISEN LW, 1991, CELL, V66, P649, DOI 10.1016/0092-8674(91)90111-B; Gallego MI, 1997, MOL CARCINOGEN, V19, P114, DOI 10.1002/(SICI)1098-2744(199707)19:2<114::AID-MC6>3.0.CO;2-F; Girard L, 1996, GENE DEV, V10, P1930, DOI 10.1101/gad.10.15.1930; GLOVER TW, 1986, CANCER GENET CYTOGEN, V19, P141, DOI 10.1016/0165-4608(86)90381-X; Gostout BS, 1998, AM J OBSTET GYNECOL, V179, P56, DOI 10.1016/S0002-9378(98)70251-0; HECHT F, 1988, CANCER GENET CYTOGEN, V31, P17, DOI 10.1016/0165-4608(88)90005-2; Huang HJ, 1998, GENE CHROMOSOME CANC, V21, P152, DOI 10.1002/(SICI)1098-2264(199802)21:2<152::AID-GCC11>3.0.CO;2-T; Inohara N, 1998, J BIOL CHEM, V273, P12296, DOI 10.1074/jbc.273.20.12296; JEON S, 1995, J VIROL, V69, P2989, DOI 10.1128/JVI.69.5.2989-2997.1995; Ji YG, 2000, GENOME RES, V10, P597, DOI 10.1101/gr.10.5.597; KAHN T, 1994, CANCER RES, V54, P1305; Kainu T, 2000, P NATL ACAD SCI USA, V97, P9603, DOI 10.1073/pnas.97.17.9603; Kalantari M, 1998, INT J GYNECOL PATHOL, V17, P146, DOI 10.1097/00004347-199804000-00009; Krummel KA, 2000, GENOMICS, V69, P37, DOI 10.1006/geno.2000.6321; Lazo PA, 1999, BRIT J CANCER, V80, P2008, DOI 10.1038/sj.bjc.6690635; Luft F, 2001, INT J CANCER, V92, P9, DOI 10.1002/1097-0215(200102)9999:9999<::AID-IJC1144>3.0.CO;2-L; Mangelsdorf M, 2000, CANCER RES, V60, P1683; McCarthy JV, 1998, J BIOL CHEM, V273, P16968, DOI 10.1074/jbc.273.27.16968; Mishmar D, 1998, P NATL ACAD SCI USA, V95, P8141, DOI 10.1073/pnas.95.14.8141; Morelli C, 2002, ONCOGENE, V21, P7266, DOI 10.1038/sj.onc.1205573; Paige AJW, 2000, CANCER RES, V60, P1690; PECORARO G, 1989, P NATL ACAD SCI USA, V86, P563, DOI 10.1073/pnas.86.2.563; POPESCU NC, 1989, CANCER GENET CYTOGEN, V42, P157, DOI 10.1016/0165-4608(89)90084-8; POPESCU NC, 1990, HUM GENET, V84, P383; Rangarajan A, 2001, VIROLOGY, V286, P23, DOI 10.1006/viro.2001.0867; Reuter S, 1998, EMBO J, V17, P215, DOI 10.1093/emboj/17.1.215; Richards RI, 2001, TRENDS GENET, V17, P339, DOI 10.1016/S0168-9525(01)02303-4; Sarkar G, 1993, PCR Methods Appl, V2, P318; Sastre-Garau X, 2000, J GEN VIROL, V81, P1983, DOI 10.1099/0022-1317-81-8-1983; Shaulian E, 2001, ONCOGENE, V20, P2390, DOI 10.1038/sj.onc.1204383; Smith DI, 1998, INT J ONCOL, V12, P187; Thome M, 1998, CURR BIOL, V8, P885, DOI 10.1016/S0960-9822(07)00352-1; Thorland EC, 2000, CANCER RES, V60, P5916; VERMA RS, 1989, HUMAN CHROMOSOME MAN; Vernon SD, 1997, INT J CANCER, V74, P50, DOI 10.1002/(SICI)1097-0215(19970220)74:1<50::AID-IJC9>3.3.CO;2-P; WAGATSUMA M, 1990, J VIROL, V64, P813, DOI 10.1128/JVI.64.2.813-821.1990; Walboomers JMM, 1999, J PATHOL, V189, P12, DOI 10.1002/(SICI)1096-9896(199909)189:1&lt;12::AID-PATH431&gt;3.0.CO;2-F; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286; Wilke CM, 1996, HUM MOL GENET, V5, P187, DOI 10.1093/hmg/5.2.187; Yordy JS, 2000, ONCOGENE, V19, P6503, DOI 10.1038/sj.onc.1204036; YUNIS JJ, 1987, ONCOGENE, V1, P59; YUNIS JJ, 1984, SCIENCE, V226, P1199, DOI 10.1126/science.6239375; ZAGOURAS P, 1995, P NATL ACAD SCI USA, V92, P6414, DOI 10.1073/pnas.92.14.6414	61	198	210	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 27	2003	22	8					1225	1237		10.1038/sj.onc.1206170	http://dx.doi.org/10.1038/sj.onc.1206170			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	650EK	12606949				2022-12-25	WOS:000181249700011
J	Wilms, H; Rosenstiel, P; Sievers, J; Deuschl, G; Zecca, L; Lucius, R				Wilms, H; Rosenstiel, P; Sievers, J; Deuschl, G; Zecca, L; Lucius, R			Activation of microglia by human neuromelanin is NF-kappa B-dependent and involves p38 mitogen-activated protein kinase: implications for Parkinson's disease	FASEB JOURNAL			English	Article						nitric oxide; interleukin-6; tumor necrosis factor alpha; neurodegeneration	TUMOR-NECROSIS-FACTOR; NITRIC-OXIDE SYNTHASE; BETA-AMYLOID STIMULATION; SUBSTANTIA-NIGRA; TNF-ALPHA; DOPAMINERGIC NEURODEGENERATION; MPTP MODEL; IN-VITRO; BRAIN; MACROPHAGES	It has been suggested that microglial inflammation augments the progression of Parkinson's disease (PD). However, endogenous factors initiating microglial activation are largely unknown. We therefore investigated the effects of human neuromelanin (NM) on the release of neurotoxic mediators and the underlying signaling pathways from rat microglia in vitro. The addition of NM to microglial cultures induced positive chemotactic effects, activated the proinflammatory transcription factor nuclear factor kappaB (NF-kappaB) via phosphorylation and degradation of the inhibitor protein kappaB (IkappaB), and led to an up-regulation of tumor necrosis factor alpha, interleukin-6, and nitric oxide. The impairment of NF-kappaB function by the IkappaB kinase inhibitor sulfasalazine was paralleled by a decline in neurotoxic mediators. NM also activated p38 mitogen-activated protein kinase (MAPK), the inhibition of this pathway by SB203580 diminished phosphorylation of the transactivation domain of the p65 subunit of NF-kappaB. These findings demonstrate a crucial role of NM in the pathogenesis of PD by augmentation of microglial activation, leading to a vicious cycle of neuronal death, exposure of additional neuromelanin, and chronification of inflammation. The antagonization of microglial activation by a pharmacological intervention targeting microglial NF-kappaB or p38 MAPK could point to additional venues in the treatment of PD.	Univ Kiel, Neurol Klin, D-24105 Kiel, Germany; Univ Kiel, Inst Anat, D-24098 Kiel, Germany; CNR, Inst Biomed Technol, I-20090 Milan, Italy	University of Kiel; University of Kiel; Consiglio Nazionale delle Ricerche (CNR); Istituto di Tecnologie Biomediche (ITB-CNR)	Wilms, H (corresponding author), Univ Kiel, Neurol Klin, Niemannsweg 147, D-24105 Kiel, Germany.	h.wilms@neurologie.uni-kiel.de	Sievers, Jobst/A-8672-2010; Rosenstiel, Philip/A-5137-2009; Wilms, Henrik/J-3082-2013; Lucius, Ralph/B-1614-2010; Deuschl, Gunther/A-7986-2010	Rosenstiel, Philip/0000-0002-9692-8828; Deuschl, Gunther/0000-0002-4176-9196	Telethon [E.0828] Funding Source: Medline	Telethon(Fondazione Telethon)		Aisen P, 1999, CURR OPIN CHEM BIOL, V3, P200, DOI 10.1016/S1367-5931(99)80033-7; Akama KT, 2000, J BIOL CHEM, V275, P7918, DOI 10.1074/jbc.275.11.7918; Akama KT, 1998, P NATL ACAD SCI USA, V95, P5795, DOI 10.1073/pnas.95.10.5795; Bal-Price A, 2001, J NEUROSCI, V21, P6480; BANATI RB, 1993, GLIA, V7, P111, DOI 10.1002/glia.440070117; BARGER SW, 1995, P NATL ACAD SCI USA, V92, P9328, DOI 10.1073/pnas.92.20.9328; BOKA G, 1994, NEUROSCI LETT, V172, P151, DOI 10.1016/0304-3940(94)90684-X; CHAO CC, 1993, J IMMUNOL, V151, P1473; Combs CK, 2000, J NEUROSCI, V20, P558, DOI 10.1523/JNEUROSCI.20-02-00558.2000; Combs CK, 2001, J NEUROSCI, V21, P1179; Davies SP, 2000, BIOCHEM J, V351, P95, DOI 10.1042/0264-6021:3510095; Du YS, 2001, P NATL ACAD SCI USA, V98, P14669, DOI 10.1073/pnas.251341998; GEBICKEHAERTER PJ, 1989, J NEUROSCI, V9, P183; GIBB WRG, 1992, BRAIN RES, V581, P283, DOI 10.1016/0006-8993(92)90719-P; GIULIAN D, 1993, ADV NEUROL, V59, P315; GIULIAN D, 1986, J NEUROSCI, V6, P2163; Hunot S, 1997, P NATL ACAD SCI USA, V94, P7531, DOI 10.1073/pnas.94.14.7531; Ishikawa A, 1998, J NEUROL, V245, pP4, DOI 10.1007/PL00007745; KARIN M, 2000, ANNU REV IMMUNOL, P18621; KASTNER A, 1992, J NEUROCHEM, V59, P1080, DOI 10.1111/j.1471-4159.1992.tb08350.x; Kim WG, 2000, J NEUROSCI, V20, P6309, DOI 10.1523/JNEUROSCI.20-16-06309.2000; Langston JW, 1999, ANN NEUROL, V46, P598, DOI 10.1002/1531-8249(199910)46:4<598::AID-ANA7>3.0.CO;2-F; Liberatore GT, 1999, NAT MED, V5, P1403; LINDQUIST NG, 1988, NEUROSCI LETT, V93, P1, DOI 10.1016/0304-3940(88)90002-X; Locksley RM, 2001, CELL, V104, P487, DOI 10.1016/S0092-8674(01)00237-9; Ma TC, 2000, ARZNEIMITTELFORSCH, V50, P512; McGeer PL, 1995, BRAIN RES REV, V21, P195, DOI 10.1016/0165-0173(95)00011-9; McGeer PL, 2001, ADV NEUROL, V86, P83; Mihm MJ, 2001, J NEUROSCI, V21, part. no., DOI 10.1523/JNEUROSCI.21-11-j0003.2001; MOGI M, 1994, NEUROSCI LETT, V165, P208, DOI 10.1016/0304-3940(94)90746-3; Pal PK, 1999, NEUROTOXICOLOGY, V20, P227; Rosenstiel P, 2001, MICROSC RES TECHNIQ, V54, P18, DOI 10.1002/jemt.1116; Saccani S, 2002, NAT IMMUNOL, V3, P69, DOI 10.1038/ni748; Shoham S, 2000, CELL MOL BIOL, V46, P743; SIEVERS J, 1994, GLIA, V12, P245, DOI 10.1002/glia.440120402; SOKOLOWSKI AL, 1990, PHARMACOL TOXICOL, V66, P252, DOI 10.1111/j.1600-0773.1990.tb00743.x; Van Deventer SJH, 2001, GASTROENTEROLOGY, V121, P1242; Waetzig GH, 2002, J IMMUNOL, V168, P5342, DOI 10.4049/jimmunol.168.10.5342; Wilms H, 1999, J NEUROIMMUNOL, V98, P89, DOI 10.1016/S0165-5728(99)00066-1; Wilms H, 1997, CELL TISSUE RES, V287, P447, DOI 10.1007/s004410050769; Wu DC, 2002, J NEUROSCI, V22, P1763, DOI 10.1523/JNEUROSCI.22-05-01763.2002; Zandi E, 1997, CELL, V91, P243, DOI 10.1016/S0092-8674(00)80406-7; Zecca L, 1996, NEUROSCIENCE, V73, P407, DOI 10.1016/0306-4522(96)00047-4; Zecca L, 2000, J NEUROCHEM, V74, P1758, DOI 10.1046/j.1471-4159.2000.0741758.x; Zecca L, 2001, J NEUROCHEM, V76, P1766, DOI 10.1046/j.1471-4159.2001.00186.x; ZIELASEK J, 1992, CELL IMMUNOL, V141, P111, DOI 10.1016/0008-8749(92)90131-8	46	241	255	0	14	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2003	17	1					500	+		10.1096/fj.02-0314fje	http://dx.doi.org/10.1096/fj.02-0314fje			20	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	653TT	12631585				2022-12-25	WOS:000181453700015
J	Clifton, IJ; Doan, LX; Sleeman, MC; Topf, M; Suzuki, H; Wilmouth, RC; Schofield, CJ				Clifton, IJ; Doan, LX; Sleeman, MC; Topf, M; Suzuki, H; Wilmouth, RC; Schofield, CJ			Crystal structure of carbapenem synthase (CarC)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-LACTAM SYNTHETASE; KETOGLUTARATE DIOXYGENASE; ANTIBIOTIC PRODUCTION; CLAVAMINATE SYNTHASE; ERWINIA-CAROTOVORA; GENE-CLUSTER; SERRATIA; ACID; BIOSYNTHESIS; DYNAMICS	The proposed biosynthetic pathway to the carbapenem antibiotics proceeds via epimerization/desaturation of a carbapenam in an unusual process catalyzed by an iron- and 2-oxoglutarate-dependent oxygenase, CarC. Crystal structures of CarC complexed with Fe(II) and 2-oxoglutarate reveal it to be hexameric (space group C2221), consistent with solution studies. CarC monomers contain a double-stranded beta-helix core that supports ligands binding a single Fe(II) to which 2-oxoglutarate complexes in a bi-dentate manner. A structure was obtained with L-N-acetylproline acting as a substrate analogue. Quantum mechanical/molecular mechanical modeling studies with stereoisomers of carbapenams and carbapenems were used to investigate substrate binding. The combined work will stimulate further mechanistic studies and aid in the engineering of carbapenem biosynthesis.	Oxford Ctr Mol Sci, Oxford OX1 3QZ, England; Dyson Perrins Lab, Oxford OX1 3QZ, England; Phys & Theoret Chem Lab, Oxford OX1 3QZ, England; Nanyang Technol Univ, Sch Biol Sci, Singapore 637616, Singapore	University of Oxford; University of Oxford; University of Oxford; Nanyang Technological University & National Institute of Education (NIE) Singapore; Nanyang Technological University	Wilmouth, RC (corresponding author), Oxford Ctr Mol Sci, S Parks Rd, Oxford OX1 3QZ, England.	RCWilmouth@ntu.edu.sg; christopher.schofield@chem.ox.ac.uk		Schofield, Christopher/0000-0002-0290-6565; Topf, Maya/0000-0002-8185-1215				*ACC INC, 1997, QUANTA; Bachmann BO, 1998, P NATL ACAD SCI USA, V95, P9082, DOI 10.1073/pnas.95.16.9082; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BESLER BH, 1990, J COMPUT CHEM, V11, P431, DOI 10.1002/jcc.540110404; BROOKS BR, 1983, J COMPUT CHEM, V4, P187, DOI 10.1002/jcc.540040211; Burzlaff NI, 1999, NATURE, V401, P721, DOI 10.1038/44400; Bycroft BW, 2003, TETRAHEDRON LETT, V44, P973, DOI 10.1016/S0040-4039(02)02731-4; BYCROFT BW, 1987, J CHEM SOC CHEM COMM, P1623, DOI 10.1039/c39870001623; BYCROFT BW, 1989, J CHEM SOC CHEM COMM, P423, DOI 10.1039/c39890000423; Clifton IJ, 2001, EUR J BIOCHEM, V268, P6625, DOI 10.1046/j.0014-2956.2001.02617.x; Cox ARJ, 1998, MICROBIOL-UK, V144, P201, DOI 10.1099/00221287-144-1-201; delaFortelle E, 1997, METHOD ENZYMOL, V276, P472, DOI 10.1016/S0076-6879(97)76073-7; DEWAR MJS, 1985, J AM CHEM SOC, V107, P3902, DOI 10.1021/ja00299a024; Elkins JM, 2002, BIOCHEMISTRY-US, V41, P5185, DOI 10.1021/bi016014e; FIELD MJ, 1990, J COMPUT CHEM, V11, P700, DOI 10.1002/jcc.540110605; Frisch M. J., 1998, GAUSSIAN98; Fusetti F, 2002, STRUCTURE, V10, P259, DOI 10.1016/S0969-2126(02)00704-9; Hogan DA, 1999, J BACTERIOL, V181, P5876, DOI 10.1128/JB.181.18.5876-5879.1999; Ishibashi H, 2002, SYNTHESIS-STUTTGART, P695, DOI 10.1055/s-2002-25759; Iwata-Reuyl D, 1999, J AM CHEM SOC, V121, P11356, DOI 10.1021/ja992649d; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KAHAN JS, 1979, J ANTIBIOT, V32, P1; Kanno O, 2000, J ANTIBIOT, V53, P404, DOI 10.7164/antibiotics.53.404; Kershaw NJ, 2002, EUR J BIOCHEM, V269, P2052, DOI 10.1046/j.1432-1033.2002.02853.x; Li RF, 2000, J AM CHEM SOC, V122, P9296, DOI 10.1021/ja001723l; Livermore DM, 2000, CURR OPIN MICROBIOL, V3, P489, DOI 10.1016/S1369-5274(00)00128-4; Lloyd MD, 1999, TETRAHEDRON, V55, P10201, DOI 10.1016/S0040-4020(99)00547-5; Lloyd MD, 1999, J MOL BIOL, V287, P943, DOI 10.1006/jmbi.1999.2594; MacKerell AD, 1998, J PHYS CHEM B, V102, P3586, DOI 10.1021/jp973084f; MCGOWAN S, 1995, MICROBIOL-SGM, V141, P541, DOI 10.1099/13500872-141-3-541; McGowan SJ, 1999, ANTON LEEUW INT J G, V75, P135, DOI 10.1023/A:1001768428383; McGowan SJ, 1996, MOL MICROBIOL, V22, P415, DOI 10.1046/j.1365-2958.1996.00125.x; McGowan SJ, 1997, MOL MICROBIOL, V26, P545, DOI 10.1046/j.1365-2958.1997.6001974.x; McGowan SJ, 1998, TRENDS MICROBIOL, V6, P203, DOI 10.1016/S0966-842X(98)01251-7; McNaughton HJ, 1998, CHEM COMMUN, P2325, DOI 10.1039/a806713i; Miller MT, 2001, NAT STRUCT BIOL, V8, P684, DOI 10.1038/90394; Murshudov GN, 1999, ACTA CRYSTALLOGR D, V55, P247, DOI 10.1107/S090744499801405X; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; NICOLAOU KC, 1996, CLASSICS TOTAL SYNTH, P249; PARKER WL, 1982, J ANTIBIOT, V35, P653, DOI 10.7164/antibiotics.35.653; Que L, 2000, NAT STRUCT BIOL, V7, P182, DOI 10.1038/73270; STEINBACH PJ, 1994, J COMPUT CHEM, V15, P667, DOI 10.1002/jcc.540150702; Stubbe J, 2000, CURR OPIN STRUC BIOL, V10, P731, DOI 10.1016/S0959-440X(00)00153-6; Tanaka H, 2002, TETRAHEDRON LETT, V43, P93, DOI 10.1016/S0040-4039(01)02073-1; TANNER DD, 1979, J ORG CHEM, V44, P1674, DOI 10.1021/jo01324a020; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; Thomson NR, 2000, MOL MICROBIOL, V36, P539, DOI 10.1046/j.1365-2958.2000.01872.x; WARSHEL A, 1976, J MOL BIOL, V103, P227, DOI 10.1016/0022-2836(76)90311-9; WILLIAMSON JM, 1986, CRIT REV BIOTECHNOL, V4, P111, DOI 10.3109/07388558609150792; Zhang ZH, 2002, FEBS LETT, V517, P7, DOI 10.1016/S0014-5793(02)02520-6; Zhang ZH, 2000, NAT STRUCT BIOL, V7, P127	51	81	83	0	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 6	2003	278	23					20843	20850		10.1074/jbc.M213054200	http://dx.doi.org/10.1074/jbc.M213054200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	684WY	12611886	hybrid			2022-12-25	WOS:000183230500053
J	Chiang, YC; Teng, SC; Su, YN; Hsieh, FJ; Wu, KJ				Chiang, YC; Teng, SC; Su, YN; Hsieh, FJ; Wu, KJ			c-Myc directly regulates the transcription of the NBS1 gene involved in DNA double-strand break repair	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-PROLIFERATION; S-PHASE; NUCLEAR-LOCALIZATION; MYC/MAX/MAD NETWORK; TARGETED DISRUPTION; ESTROGEN-RECEPTOR; CATALYTIC SUBUNIT; MAMMALIAN-CELLS; MRE11 COMPLEX; BINDING	The c-myc proto-oncogene encodes a ubiquitous transcription factor involved in the control of cell growth and implicated in inducing tumorigenesis. Understanding the function of c-Myc and its role in cancer depends upon the identification of c-Myc target genes. Nijmegen breakage syndrome (NBS) is a chromosomal-instability syndrome associated with cancer predisposition, radiosensitivity, and chromosomal instability. The NBS gene product, NBS1 (p95 or nibrin), is a part of the hMre11 complex, a central player associated with double-strand break (DSB) repair. NBS1 contains domains characteristic for proteins involved in DNA repair, recombination, and replication. Here we show that c-Myc directly activates NBS1. c-Myc-mediated induction of NBS1 gene transcription occurs in different tissues, is independent of cell proliferation, and is mediated by a c-Myc binding site in the intron 1 region of NBS1 gene. Overexpression of NBS1 in Rat1a cells increased cell proliferation. These results indicate that NBS1 is a direct transcriptional target of c-Myc and links the function of c-Myc to the regulation of DNA DSB repair pathway operating during DNA replication.	Natl Taiwan Univ, Coll Med, Dept Med Genet, Taipei 100, Taiwan; Natl Taiwan Univ, Coll Med, Dept Obstet & Gynecol, Taipei 100, Taiwan; Natl Taiwan Univ, Coll Med, Grad Inst Microbiol, Taipei 100, Taiwan	National Taiwan University; National Taiwan University; National Taiwan University	Wu, KJ (corresponding author), Natl Taiwan Univ, Coll Med, Dept Med Genet, Taipei 100, Taiwan.	kjwu@ha.mc.ntu.edu.tw	Chiang, Yun/GRJ-5251-2022; Wu, Kou-Juey/P-4654-2015	TENG, SHU-CHUN/0000-0002-6492-2560				BLACKWELL TK, 1993, MOL CELL BIOL, V13, P5216, DOI 10.1128/MCB.13.9.5216; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; Bouchard C, 2001, GENE DEV, V15, P2042, DOI 10.1101/gad.907901; Bouchard C, 1998, TRENDS CELL BIOL, V8, P202, DOI 10.1016/S0962-8924(98)01251-3; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Costanzo V, 2001, MOL CELL, V8, P137, DOI 10.1016/S1097-2765(01)00294-5; Dang CV, 1999, MOL CELL BIOL, V19, P1; DELLAFAVERA R, 1982, P NATL ACAD SCI-BIOL, V79, P6497, DOI 10.1073/pnas.79.21.6497; Desai-Mehta A, 2001, MOL CELL BIOL, V21, P2184, DOI 10.1128/MCB.21.6.2184-2191.2001; Eisenman RN, 2001, GENE DEV, V15, P2023, DOI 10.1101/gad928101; Frank SR, 2001, GENE DEV, V15, P2069, DOI 10.1101/gad.906601; Grandori C, 2000, ANNU REV CELL DEV BI, V16, P653, DOI 10.1146/annurev.cellbio.16.1.653; GU W, 1993, P NATL ACAD SCI USA, V90, P2935, DOI 10.1073/pnas.90.7.2935; Iritani BM, 1999, P NATL ACAD SCI USA, V96, P13180, DOI 10.1073/pnas.96.23.13180; Johnston LA, 1999, CELL, V98, P779, DOI 10.1016/S0092-8674(00)81512-3; Kang J, 2002, EMBO J, V21, P1447, DOI 10.1093/emboj/21.6.1447; Karran P, 2000, CURR OPIN GENET DEV, V10, P144, DOI 10.1016/S0959-437X(00)00069-1; KATO GJ, 1990, MOL CELL BIOL, V10, P5914, DOI 10.1128/MCB.10.11.5914; KEMPKES B, 1995, EMBO J, V14, P88, DOI 10.1002/j.1460-2075.1995.tb06978.x; Lim DS, 2000, NATURE, V404, P613, DOI 10.1038/35007091; LITTLEWOOD TD, 1995, NUCLEIC ACIDS RES, V23, P1686, DOI 10.1093/nar/23.10.1686; Lutz W, 2002, BBA-REV CANCER, V1602, P61, DOI 10.1016/S0304-419X(02)00036-7; Maser RS, 2001, MOL CELL BIOL, V21, P6006, DOI 10.1128/MCB.21.17.6006-6016.2001; Maser RS, 2001, NAT GENET, V27, P417, DOI 10.1038/86920; Menssen A, 2002, P NATL ACAD SCI USA, V99, P6274, DOI 10.1073/pnas.082005599; Myung KJ, 2001, CELL, V104, P397, DOI 10.1016/S0092-8674(01)00227-6; Nesbit CE, 1999, ONCOGENE, V18, P3004, DOI 10.1038/sj.onc.1202746; Petrini JHJ, 2000, CURR OPIN CELL BIOL, V12, P293, DOI 10.1016/S0955-0674(00)00091-0; Ranganathan V, 2001, CURR BIOL, V11, P962, DOI 10.1016/S0960-9822(01)00267-6; SASSON S, 1991, PATHOL BIOL, V39, P59; STONE J, 1987, MOL CELL BIOL, V7, P1697, DOI 10.1128/MCB.7.5.1697; Trumpp A, 2001, NATURE, V414, P768, DOI 10.1038/414768a; VANDERZWET MK, 1999, MUTAT RES, V434, P17; Varon R, 2001, CANCER RES, V61, P3570; Watson JD, 2002, J BIOL CHEM, V277, P36921, DOI 10.1074/jbc.M201493200; Wilda M, 2000, HUM MOL GENET, V9, P1739, DOI 10.1093/hmg/9.12.1739; Wu KJ, 1999, SCIENCE, V283, P676, DOI 10.1126/science.283.5402.676; Wu KJ, 2002, ONCOGENE, V21, P7872, DOI 10.1038/sj.onc.1205986; Wu KJ, 1999, NAT GENET, V21, P220, DOI 10.1038/6010; Wu XH, 2000, NATURE, V405, P477, DOI 10.1038/35013089; Zhao S, 2000, NATURE, V405, P473, DOI 10.1038/35013083; Zhu J, 2001, CURR BIOL, V11, P105, DOI 10.1016/S0960-9822(01)00019-7	42	71	72	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 23	2003	278	21					19286	19291		10.1074/jbc.M212043200	http://dx.doi.org/10.1074/jbc.M212043200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	679PY	12637527	hybrid			2022-12-25	WOS:000182932200074
J	Mishra, SK; Mazumdar, A; Vadlamudi, RK; Li, F; Wang, RA; Yu, W; Jordan, VC; Santen, RJ; Kumar, R				Mishra, SK; Mazumdar, A; Vadlamudi, RK; Li, F; Wang, RA; Yu, W; Jordan, VC; Santen, RJ; Kumar, R			MICoA, a novel metastasis-associated protein 1 (MTA1) interacting protein coactivator, regulates estrogen receptor-alpha transactivation functions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HISTONE ACETYLTRANSFERASE ACTIVITY; NUCLEAR RECEPTOR; TRANSCRIPTIONAL REPRESSION; CO-REPRESSOR; COMPLEX; COREPRESSOR; ACETYLATION; ACTIVATION; BINDING; PHOSPHORYLATION	The transcriptional activity of estrogen receptor-alpha (ER-alpha) is modified by coactivators, corepressors, and chromatin remodeling complexes. We have previously shown that the metastasis-associated protein-1 (MTA1), a component of histone deacetylase and nucleosome remodeling complexes, represses ER-driven transcription by recruiting histone deacetylases to the estrogen receptor element (ERE)-containing target gene chromatin in breast cancer cells. Using a yeast two-hybrid screening to clone MTA1-interacting proteins, we identified a previously uncharacterized molecule, which we named as MTA1-interacting coactivator (MICoA). Our findings suggest that estrogen signaling promotes nuclear translocation of MICoA and that MICoA interacts with MTA1 both in vitro and in vivo. MICoA binds to the C-terminal region of MTA1, whereas MTA1 binds to the N-terminal MICoA containing one nuclear receptor interaction LSRLL motif. We showed that MICoA is an ER coactivator, cooperates with other ER coactivators, stimulates ER-transactivation functions, and associates with the endogenous ER and its target gene promoter chromatin. MTA1 also repressed MICoA-mediated stimulation of ERE-mediated transcription in the presence of ER and ER variants with naturally occurring mutations, such as D351Y and K303R, and that it interfered with the association of MICoA with the ER-target gene chromatin. Because chromatin is a highly dynamic structure and because MTA1 and MICoA could be detected within the same complex, these findings suggest that MTA1 and MICoA might transmodulate functions of each other and any potential deregulation of MTA1 is likely to contribute to the functional inactivation of the ER pathway, presumably by derecruitment of MICoA from ER target promoter chromatin.	Univ Texas, MD Anderson Canc Ctr, Dept Mol & Cellular Oncol, Houston, TX 77030 USA; Univ Virginia, Sch Med, Dept Internal Med, Charlottesville, VA 22908 USA; Northwestern Univ, Robert H Lurie Comprehens Canc Ctr, Chicago, IL 60611 USA	University of Texas System; UTMD Anderson Cancer Center; University of Virginia; Ann & Robert H. Lurie Children's Hospital of Chicago; Northwestern University; Robert H. Lurie Comprehensive Cancer Center	Kumar, R (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Mol & Cellular Oncol, 1515 Holcombe Blvd, Houston, TX 77030 USA.	rkumar@mdanderson.org	Wang, Brian/HGA-9535-2022; JORDAN, V.Craig/AAX-3562-2020	Mishra, Sandip/0000-0002-0776-6581	NATIONAL CANCER INSTITUTE [R01CA084456] Funding Source: NIH RePORTER; NCI NIH HHS [CA84456, CA80066] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Barlev NA, 1998, MOL CELL BIOL, V18, P1349, DOI 10.1128/MCB.18.3.1349; BEATO M, 1995, CELL, V83, P851, DOI 10.1016/0092-8674(95)90201-5; Berger SL, 2002, CURR OPIN GENET DEV, V12, P142, DOI 10.1016/S0959-437X(02)00279-4; Blanco JCG, 1998, GENE DEV, V12, P1638, DOI 10.1101/gad.12.11.1638; BOYD J, 1996, CELLULAR MOL MECH HO, P151; CATHERINO WH, 1995, MOL ENDOCRINOL, V9, P1053, DOI 10.1210/me.9.8.1053; Chambon P, 1996, FASEB J, V10, P940, DOI 10.1096/fasebj.10.9.8801176; Chen HW, 1997, CELL, V90, P569, DOI 10.1016/S0092-8674(00)80516-4; CHEN JD, 1995, NATURE, V377, P454, DOI 10.1038/377454a0; Espinos E, 1999, MOL CELL BIOL, V19, P3474; Fan S, 1999, SCIENCE, V284, P1354, DOI 10.1126/science.284.5418.1354; Fischle W, 2002, MOL CELL, V9, P45, DOI 10.1016/S1097-2765(01)00429-4; Freedman LP, 1999, CELL, V97, P5, DOI 10.1016/S0092-8674(00)80708-4; GEORGE FW, 1988, PHYSL REPRODUCTION, V1, P3; Glass CK, 2000, GENE DEV, V14, P121; Graham JD, 2000, STEROIDS, V65, P579, DOI 10.1016/S0039-128X(00)00116-1; Grant PA, 1998, CELL, V94, P45, DOI 10.1016/S0092-8674(00)81220-9; Heery DM, 1997, NATURE, V387, P733, DOI 10.1038/42750; Heinzel T, 1997, NATURE, V387, P43, DOI 10.1038/387043a0; Henttu PMA, 1997, MOL CELL BIOL, V17, P1832, DOI 10.1128/MCB.17.4.1832; Huang NW, 1998, EMBO J, V17, P3398, DOI 10.1093/emboj/17.12.3398; Inoue M, 1996, CYTOGENET CELL GENET, V73, P134; Jenster G, 1997, P NATL ACAD SCI USA, V94, P7879, DOI 10.1073/pnas.94.15.7879; Jepsen K, 2002, J CELL SCI, V115, P689; Kadosh D, 1998, GENE DEV, V12, P797, DOI 10.1101/gad.12.6.797; Kumar R, 2002, NATURE, V418, P654, DOI 10.1038/nature00889; Kuo MH, 1998, GENE DEV, V12, P627, DOI 10.1101/gad.12.5.627; Levenson AS, 2001, J STEROID BIOCHEM, V76, P61, DOI 10.1016/S0960-0760(00)00143-6; Lin RJ, 1998, NATURE, V391, P811, DOI 10.1038/35895; Lomvardas S, 2002, MOL CELL, V9, P209, DOI 10.1016/S1097-2765(02)00463-X; Mahoney MG, 2002, ONCOGENE, V21, P2161, DOI 10.1038/sj.onc.1205277; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; Martinez-Balbas MA, 1998, EMBO J, V17, P2886, DOI 10.1093/emboj/17.10.2886; Mazumdar A, 2001, NAT CELL BIOL, V3, P30, DOI 10.1038/35050532; McInerney EM, 1998, GENE DEV, V12, P3357, DOI 10.1101/gad.12.21.3357; McKenna NJ, 1999, ENDOCR REV, V20, P321, DOI 10.1210/er.20.3.321; McMahon C, 1999, P NATL ACAD SCI USA, V96, P5382, DOI 10.1073/pnas.96.10.5382; Nagy L, 1997, CELL, V89, P373, DOI 10.1016/S0092-8674(00)80218-4; Nan XS, 1998, NATURE, V393, P386, DOI 10.1038/30764; Nye AC, 2002, MOL CELL BIOL, V22, P3437, DOI 10.1128/MCB.22.10.3437-3449.2002; Pikaart MI, 1998, GENE DEV, V12, P2852, DOI 10.1101/gad.12.18.2852; Sassone-Corsi P, 2002, SCIENCE, V296, P2176, DOI 10.1126/science.1070963; Schafer JM, 2000, CANCER RES, V60, P5097; Smith CL, 1997, MOL ENDOCRINOL, V11, P657, DOI 10.1210/me.11.6.657; Song RX, 2002, MOL CELL ENDOCRINOL, V193, P29, DOI 10.1016/S0303-7207(02)00093-X; Spencer TE, 1997, NATURE, V389, P194, DOI 10.1038/38304; TORA L, 1989, CELL, V59, P477, DOI 10.1016/0092-8674(89)90031-7; TSAI MJ, 1994, ANNU REV BIOCHEM, V63, P451, DOI 10.1146/annurev.biochem.63.1.451; Vadlamudi RK, 2001, J BIOL CHEM, V276, P38272; Voegel JJ, 1998, EMBO J, V17, P507, DOI 10.1093/emboj/17.2.507; Wang CG, 2001, J BIOL CHEM, V276, P18375, DOI 10.1074/jbc.M100800200; Xue YT, 1998, MOL CELL, V2, P851, DOI 10.1016/S1097-2765(00)80299-3; Yamamoto Y, 2001, J BIOL CHEM, V276, P42684, DOI 10.1074/jbc.M107844200; You A, 2001, P NATL ACAD SCI USA, V98, P1454, DOI 10.1073/pnas.98.4.1454; Zamir I, 1997, P NATL ACAD SCI USA, V94, P14400, DOI 10.1073/pnas.94.26.14400; Zhang X, 1998, MOL ENDOCRINOL, V12, P513, DOI 10.1210/me.12.4.513; Zhang Y, 1999, GENE DEV, V13, P1924, DOI 10.1101/gad.13.15.1924	57	53	55	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 23	2003	278	21					19209	19219		10.1074/jbc.M301968200	http://dx.doi.org/10.1074/jbc.M301968200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	679PY	12639951	hybrid			2022-12-25	WOS:000182932200065
J	Stromer, T; Ehrnsperger, M; Gaestel, M; Buchner, J				Stromer, T; Ehrnsperger, M; Gaestel, M; Buchner, J			Analysis of the interaction of small heat shock proteins with unfolding proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-B-CRYSTALLIN; EHRLICH ASCITES TUMOR; MOLECULAR CHAPERONES; QUATERNARY STRUCTURE; THERMAL PROTECTION; ESCHERICHIA-COLI; OVER-EXPRESSION; A-CRYSTALLIN; HSP25; STRESS	The ubiquitous small heat shock proteins (sHsps) are efficient molecular chaperones that interact with nonnative proteins, prevent their aggregation, and support subsequent refolding. No obvious substrate specificity has been detected so far. A striking feature of sHsps is that they form large complexes with nonnative proteins. Here, we used several well established model chaperone substrates, including citrate synthase, alpha-glucosidase, rhodanese, and insulin, and analyzed their interaction with murine Hsp25 and yeast Hsp26 upon thermal unfolding. The two sHsps differ in their modes of activation. In contrast to Hsp25, Hsp26 undergoes a temperature-dependent dissociation that is required for efficient substrate binding. Our analysis shows that Hsp25 and Hsp26 reacted in a similar manner with the nonnative proteins. For all substrates investigated, complexes of defined size and shape were formed. Interestingly, several different nonnative proteins could be incorporated into defined sHsp-substrate complexes. The first substrate protein bound seems to determine the complex morphology. Thus, despite the differences in quaternary structure and mode of activation, the formation of large uniform sHsp-substrate complexes seems to be a general feature of sHsps, and this unique chaperone mechanism is conserved from yeast to mammals.	Tech Univ Munich, Inst Organ Chem & Biochem, D-85747 Garching, Germany; Hannover Med Sch, Inst Biochem, D-30625 Hannover, Germany	Technical University of Munich; Hannover Medical School	Buchner, J (corresponding author), Tech Univ Munich, Inst Organ Chem & Biochem, Lichtenbergstr 4, D-85747 Garching, Germany.		Gaestel, Matthias/A-6560-2013; Buchner, Johannes/A-2651-2010	Gaestel, Matthias/0000-0002-4944-4652; Buchner, Johannes/0000-0003-1282-7737				Andreasi B F, 1995, BIOPHYS J, V69, P2720; AOYAMA A, 1993, MOL CELL BIOL, V13, P1824, DOI 10.1128/MCB.13.3.1824; ARRIGO AP, 1988, MOL CELL BIOL, V8, P5059, DOI 10.1128/MCB.8.12.5059; Bova MP, 2002, J BIOL CHEM, V277, P38468, DOI 10.1074/jbc.M205594200; Buchner J, 1998, METHOD ENZYMOL, V290, P339, DOI 10.1016/S0076-6879(98)90030-1; BUCHNER J, 1991, BIOCHEMISTRY-US, V30, P1586, DOI 10.1021/bi00220a020; Buchner J, 1996, FASEB J, V10, P10, DOI 10.1096/fasebj.10.1.8566529; de Jong WW, 1998, INT J BIOL MACROMOL, V22, P151, DOI 10.1016/S0141-8130(98)00013-0; Derham BK, 1999, PROG RETIN EYE RES, V18, P463, DOI 10.1016/S1350-9462(98)00030-5; Ehrnsperger M, 1999, J BIOL CHEM, V274, P14867, DOI 10.1074/jbc.274.21.14867; Ehrnsperger M, 1998, ANAL BIOCHEM, V259, P218, DOI 10.1006/abio.1998.2630; Ehrnsperger M, 2000, METH MOL B, V99, P421; Ehrnsperger M, 1997, EMBO J, V16, P221, DOI 10.1093/emboj/16.2.221; Ehrnsperger M., 1998, STRUCTURE FUNCTION S, P533; FARAHBAKHSH ZT, 1995, BIOCHEMISTRY-US, V34, P8812, DOI 10.1021/bi00027a033; FARAHBAKHSH ZT, 1995, BIOCHEMISTRY-US, V34, P509, DOI 10.1021/bi00002a015; GAESTEL M, 1989, EUR J BIOCHEM, V179, P209, DOI 10.1111/j.1432-1033.1989.tb14542.x; Giese KC, 2002, J BIOL CHEM, V277, P46310, DOI 10.1074/jbc.M208926200; Haley DA, 1998, J MOL BIOL, V277, P27, DOI 10.1006/jmbi.1997.1611; Haley DA, 2000, J MOL BIOL, V298, P261, DOI 10.1006/jmbi.2000.3657; Haslbeck M, 1999, EMBO J, V18, P6744, DOI 10.1093/emboj/18.23.6744; Haslbeck M, 2002, CELL MOL LIFE SCI, V59, P1649, DOI 10.1007/PL00012492; Haslbeck Martin, 2002, Prog Mol Subcell Biol, V28, P37; HOLLNEUGEBAUER B, 1991, BIOCHEMISTRY-US, V30, P11609; HORWITZ J, 1992, P NATL ACAD SCI USA, V89, P10449, DOI 10.1073/pnas.89.21.10449; Horwitz J, 2003, EXP EYE RES, V76, P145, DOI 10.1016/S0014-4835(02)00278-6; INGOLIA TD, 1982, P NATL ACAD SCI-BIOL, V79, P2360, DOI 10.1073/pnas.79.7.2360; JAENICKE R, 1993, CURR BIOL, V3, P234, DOI 10.1016/0960-9822(93)90342-L; JAKOB U, 1993, J BIOL CHEM, V268, P1517; Kim KK, 1998, NATURE, V394, P595, DOI 10.1038/29106; KNAUF U, 1992, FEBS LETT, V309, P297, DOI 10.1016/0014-5793(92)80793-G; KOPETZKI E, 1989, YEAST, V5, P11, DOI 10.1002/yea.320050104; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANDRY J, 1989, J CELL BIOL, V109, P7, DOI 10.1083/jcb.109.1.7; Lee GJ, 2000, PLANT PHYSIOL, V122, P189, DOI 10.1104/pp.122.1.189; Lee GJ, 1997, EMBO J, V16, P659, DOI 10.1093/emboj/16.3.659; LINDQUIST S, 1988, ANNU REV GENET, V22, P631, DOI 10.1146/annurev.ge.22.120188.003215; MEHLEN P, 1993, EUR J BIOCHEM, V215, P277, DOI 10.1111/j.1432-1033.1993.tb18032.x; MENDOZA JA, 1992, J BIOL CHEM, V267, P17631; Nakamoto H, 2000, FEBS LETT, V483, P169, DOI 10.1016/S0014-5793(00)02097-4; Narberhaus F, 2002, MICROBIOL MOL BIOL R, V66, P64, DOI 10.1128/MMBR.66.1.64-93.2002; SANGER F, 1949, BIOCHEM J, V45, P563, DOI 10.1042/bj0450563; SPECTOR A, 1971, BIOCHEM J, V124, P337, DOI 10.1042/bj1240337; Studer S, 2000, J BIOL CHEM, V275, P37212, DOI 10.1074/jbc.M004701200; Sun WN, 2002, BBA-GENE STRUCT EXPR, V1577, P1, DOI 10.1016/S0167-4781(02)00417-7; van Boekel MAM, 1999, BBA-PROTEIN STRUCT M, V1434, P114, DOI 10.1016/S0167-4838(99)00178-8; Van Montfort R, 2002, ADV PROTEIN CHEM, V59, P105; van Montfort RLM, 2001, NAT STRUCT BIOL, V8, P1025, DOI 10.1038/nsb722; VANDENIJSSEL PRLA, 1994, FEBS LETT, V355, P54, DOI 10.1016/0014-5793(94)01175-3; WANG KY, 1995, INVEST OPHTH VIS SCI, V36, P311	50	135	145	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 16	2003	278	20					18015	18021		10.1074/jbc.M301640200	http://dx.doi.org/10.1074/jbc.M301640200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677YX	12637495	hybrid			2022-12-25	WOS:000182838300055
J	Bedogni, B; Pani, G; Colavitti, R; Riccio, A; Borrello, S; Murphy, M; Smith, R; Eboli, ML; Galeotti, T				Bedogni, B; Pani, G; Colavitti, R; Riccio, A; Borrello, S; Murphy, M; Smith, R; Eboli, ML; Galeotti, T			Redox regulation of cAMP-responsive element-binding protein and induction of manganous superoxide dismutase in nerve growth factor-dependent cell survival	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FORKHEAD TRANSCRIPTION FACTOR; TUMOR-NECROSIS-FACTOR; SIGNAL-TRANSDUCTION; CORTICAL-NEURONS; OXIDATIVE STRESS; OXYGEN RADICALS; APOPTOSIS; KINASE; SYSTEM; PHOSPHORYLATION	Reactive oxygen species (ROS) act as both signaling molecules and mediators of cell damage in the nervous system and are implicated in the pathogenesis of neurodegenerative diseases. Neurotrophic factors such as the nerve-derived growth factor (NGF) support neuronal survival during development and promote regeneration after neuronal injury through the activation of intracellular signals whose molecular effectors and downstream targets are still largely unknown. Here we present evidence that early oxidative signals initiated by NGF in PC12 cells, an NGF-responsive cell line, play a critical role in preventing apoptosis induced by serum deprivation. This redox-signaling cascade involves phosphatidylinositol 3-kinase, the small GTPase Rac-1, and the transcription factor cAMP-responsive element-binding protein ( CREB), a molecule essential to promote NGF-dependent survival. We found that ROS are necessary for NGF-dependent phosphorylation of CREB, an event directly correlated with CREB activity, whereas hydrogen peroxide induces a robust CREB phosphorylation. Cells exposed to NGF show a late decrease in the intracellular content of ROS when compared with untreated cells and increased expression of the mitochondrial antioxidant enzyme manganese superoxide dismutase, a general inhibitor of cell death. Accordingly, serum deprivatio-induced apoptosis was selectively inhibited by low concentrations of the mitochondrially targeted antioxidant Mito Q (mitoquinol/mitoquinone). Taken together, these data demonstrate that the oxidant-dependent activation of CREB is a component of NGF survival signaling in PC12 cells and outline an intriguing circuitry by which a cytosolic redox cascade promotes cell survival at least in part by increasing mitochondrial resistance to oxidative stress.	Univ Sacred Heart, Sch Med, Inst Gen Pathol, I-00168 Rome, Italy; Johns Hopkins Univ, Sch Med, Dept Neurosci, Baltimore, MD 21205 USA; MRC, Dunn Human Nutr Unit, Cambridge CB2 2XY, England; Univ Otago, Dept Chem, Dunedin, New Zealand	Catholic University of the Sacred Heart; IRCCS Policlinico Gemelli; Johns Hopkins University; UK Research & Innovation (UKRI); Medical Research Council UK (MRC); MRC Human Nutrition Research; University of Otago	Galeotti, T (corresponding author), Univ Sacred Heart, Sch Med, Inst Gen Pathol, Largo F Vito 1, I-00168 Rome, Italy.		Pani, Giovambattista/AAB-1446-2019; Murphy, Michael P/C-2120-2009	Murphy, Michael P/0000-0003-1115-9618; Pani, Giovambattista/0000-0001-7133-8728				Abid MR, 2001, FASEB J, V15, P2548, DOI 10.1096/fj.01-0338fje; Ahn S, 1998, MOL CELL BIOL, V18, P967, DOI 10.1128/MCB.18.2.967; BEAUCHAM.C, 1971, ANAL BIOCHEM, V44, P276, DOI 10.1016/0003-2697(71)90370-8; Brunet A, 2001, CURR OPIN NEUROBIOL, V11, P297, DOI 10.1016/S0959-4388(00)00211-7; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Colavitti R, 2002, J BIOL CHEM, V277, P3101, DOI 10.1074/jbc.M107711200; Coniglio SJ, 2001, J BIOL CHEM, V276, P28113, DOI 10.1074/jbc.M102299200; Crossthwaite AJ, 2002, J NEUROCHEM, V80, P24, DOI 10.1046/j.0022-3042.2001.00637.x; DEMPLE B, 1991, CELL, V67, P837, DOI 10.1016/0092-8674(91)90355-3; Deshpande SS, 2000, FASEB J, V14, P1705, DOI 10.1096/fj.99-0910com; Du KY, 2000, MOL CELL BIOL, V20, P4320, DOI 10.1128/MCB.20.12.4320-4327.2000; DUGAN LL, 1995, J NEUROSCI, V15, P6377; Dugan LL, 1997, P NATL ACAD SCI USA, V94, P4086, DOI 10.1073/pnas.94.8.4086; Finkbeiner S, 2000, NEURON, V25, P11, DOI 10.1016/S0896-6273(00)80866-1; Finkel T, 1998, CURR OPIN CELL BIOL, V10, P248, DOI 10.1016/S0955-0674(98)80147-6; HECHT D, 1992, BIOCHEM BIOPH RES CO, V188, P773, DOI 10.1016/0006-291X(92)91123-8; Hensley K, 2000, FREE RADICAL BIO MED, V28, P1456, DOI 10.1016/S0891-5849(00)00252-5; HIROSE K, 1993, FASEB J, V7, P361, DOI 10.1096/fasebj.7.2.8440412; Huang P, 2000, NATURE, V407, P390, DOI 10.1038/35030140; JACKSON GR, 1994, DEV NEUROSCI-BASEL, V16, P285, DOI 10.1159/000112121; Jacobson MD, 1996, TRENDS BIOCHEM SCI, V21, P83, DOI 10.1016/0968-0004(96)20008-8; Kaplan DR, 2000, CURR OPIN NEUROBIOL, V10, P381, DOI 10.1016/S0959-4388(00)00092-1; KEHRER JP, 1993, CRIT REV TOXICOL, V23, P21, DOI 10.3109/10408449309104073; Kelso GF, 2001, J BIOL CHEM, V276, P4588, DOI 10.1074/jbc.M009093200; Kim HP, 1999, J BIOL CHEM, V274, P37455, DOI 10.1074/jbc.274.52.37455; Kops GJPL, 2002, NATURE, V419, P316, DOI 10.1038/nature01036; Lee SR, 1998, J BIOL CHEM, V273, P15366, DOI 10.1074/jbc.273.25.15366; LINDVALL O, 1994, TRENDS NEUROSCI, V17, P490, DOI 10.1016/0166-2236(94)90139-2; LOWE SW, 1994, P NATL ACAD SCI USA, V91, P2026, DOI 10.1073/pnas.91.6.2026; LOWENSTEIN CJ, 1992, CELL, V70, P705, DOI 10.1016/0092-8674(92)90301-R; Maehara K, 2001, FASEB J, V15, P2025, DOI 10.1096/fj.00-0909fje; Maher P, 2000, CELL MOL LIFE SCI, V57, P1287, DOI 10.1007/PL00000766; Mai L, 2002, J NEUROCHEM, V82, P75, DOI 10.1046/j.1471-4159.2002.00939.x; MATTSON MP, 1995, J NEUROCHEM, V65, P1740; Melov S, 1998, NAT GENET, V18, P159, DOI 10.1038/ng0298-159; Merad-Boudia M, 1998, BIOCHEM PHARMACOL, V56, P645, DOI 10.1016/S0006-2952(97)00647-3; Mills EM, 1998, J BIOL CHEM, V273, P22165, DOI 10.1074/jbc.273.35.22165; Moldovan L, 1999, ANTIOXID REDOX SIGN, V1, P29, DOI 10.1089/ars.1999.1.1-29; Ozdinler PH, 2001, J COMP NEUROL, V438, P377; Palazzotti B, 1999, INT J CANCER, V82, P145, DOI 10.1002/(SICI)1097-0215(19990702)82:1<145::AID-IJC24>3.3.CO;2-2; Pani G, 2000, J BIOL CHEM, V275, P38891, DOI 10.1074/jbc.M007319200; Pani G, 2000, BIOCHEM J, V347, P173, DOI 10.1042/0264-6021:3470173; Patapoutian A, 2001, CURR OPIN NEUROBIOL, V11, P272, DOI 10.1016/S0959-4388(00)00208-7; Pugazhenthi S, 2000, J BIOL CHEM, V275, P10761, DOI 10.1074/jbc.275.15.10761; Rhee S.G., 2000, SCI STKE; Riccio A, 1999, SCIENCE, V286, P2358, DOI 10.1126/science.286.5448.2358; SCHULZEOSTHOFF K, 1993, EMBO J, V12, P3095, DOI 10.1002/j.1460-2075.1993.tb05978.x; Sundaresan M, 1996, BIOCHEM J, V318, P379, DOI 10.1042/bj3180379; Suzukawa K, 2000, J BIOL CHEM, V275, P13175, DOI 10.1074/jbc.275.18.13175; Teixeira HD, 1998, P NATL ACAD SCI USA, V95, P7872, DOI 10.1073/pnas.95.14.7872; Warner BB, 1996, AM J PHYSIOL-LUNG C, V271, pL150, DOI 10.1152/ajplung.1996.271.1.L150; WONG GHW, 1989, CELL, V58, P923, DOI 10.1016/0092-8674(89)90944-6; Woo CH, 2000, J BIOL CHEM, V275, P32357, DOI 10.1074/jbc.M005638200; Xing J, 1998, MOL CELL BIOL, V18, P1946, DOI 10.1128/MCB.18.4.1946; YAO RJ, 1995, SCIENCE, V267, P2003, DOI 10.1126/science.7701324; Yuan JY, 2000, NATURE, V407, P802, DOI 10.1038/35037739	56	120	120	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 9	2003	278	19					16510	16519		10.1074/jbc.M301089200	http://dx.doi.org/10.1074/jbc.M301089200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677QG	12609977	hybrid			2022-12-25	WOS:000182818600011
J	Collins, BM; Cubeddu, L; Naidoo, N; Harrop, SJ; Kornfeld, GD; Dawes, IW; Curmi, PMG; Mabbutt, BC				Collins, BM; Cubeddu, L; Naidoo, N; Harrop, SJ; Kornfeld, GD; Dawes, IW; Curmi, PMG; Mabbutt, BC			Homomeric ring assemblies of eukaryotic Sm proteins have affinity for both RNA and DNA - Crystal structure of an oligomeric complex of yeast SmF	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SNRNP CORE; ELECTRON-MICROSCOPY; FUNCTIONAL-ANALYSIS; U6 SNRNA; BINDING; DOMAIN; MODEL; HFQ; IDENTIFICATION; HETEROMER	Sm and Sm-like proteins are key components of small ribonucleoproteins involved in many RNA and DNA processing pathways. In eukaryotes, these complexes contain seven unique Sm or Sm-like (Lsm) proteins assembled as hetero-heptameric rings, whereas in Archaea and bacteria six or seven-membered rings are made from only a single polypeptide chain. Here we show that single Sm and Lsm proteins from yeast also have the capacity to assemble into homo-oligomeric rings. Formation of homo-oligomers by the spliceosomal small nuclear ribonucleoprotein components SmE and SmF preclude hetero-interactions vital to formation of functional small nuclear RNP complexes in vivo. To better understand these unusual complexes, we have determined the crystal structure of the homomeric assembly of the spliceosomal protein SmF. Like its archaeal/bacterial homologs, the SmF complex forms a homomeric ring but in an entirely novel arrangement whereby two heptameric rings form a co-axially stacked dimer via interactions mediated by the variable loops of the individual SmF protein chains. Furthermore, we demonstrate that the homomeric assemblies of yeast Sm and Lsm proteins are capable of binding not only to oligo(U) RNA but, in the case of SmF, also to oligo(dT) single-stranded DNA.	Macquarie Univ, Dept Chem, Sydney, NSW 2109, Australia; Univ Cambridge, Dept Clin Biochem, Cambridge Inst Med Res, Cambridge CB2 2XY, England; Univ New S Wales, Sch Biochem & Mol Genet, Sydney, NSW 2052, Australia; St Vincents Hosp, Ctr Immunol, Darlinghurst, NSW 2010, Australia; Univ New S Wales, Sch Phys, Sydney, NSW 2052, Australia	Macquarie University; University of Cambridge; University of New South Wales Sydney; St Vincents Hospital Sydney; University of New South Wales Sydney	Mabbutt, BC (corresponding author), Macquarie Univ, Dept Chem, Sydney, NSW 2109, Australia.	bridget.mabbutt@mq.edu.au	Curmi, Paul/G-7185-2011; Collins, Brett/J-1563-2014	Curmi, Paul/0000-0001-5762-7638; Collins, Brett/0000-0002-6070-3774				Achsel T, 1999, EMBO J, V18, P5789, DOI 10.1093/emboj/18.20.5789; Achsel T, 2001, P NATL ACAD SCI USA, V98, P3685, DOI 10.1073/pnas.071033998; Anantharaman V, 2002, NUCLEIC ACIDS RES, V30, P1427, DOI 10.1093/nar/30.7.1427; BLUMENTHAL T, 1995, TRENDS GENET, V11, P132, DOI 10.1016/S0168-9525(00)89026-5; Bouveret E, 2000, EMBO J, V19, P1661, DOI 10.1093/emboj/19.7.1661; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Burge CB, 1999, RNA WORLD, P525; Camasses A, 1998, MOL CELL BIOL, V18, P1956, DOI 10.1128/MCB.18.4.1956; CATHALA G, 1990, NUCLEIC ACIDS RES, V18, P201, DOI 10.1093/nar/18.1.201; Collins BM, 2001, J MOL BIOL, V309, P915, DOI 10.1006/jmbi.2001.4693; COOPER M, 1995, EMBO J, V14, P2066, DOI 10.1002/j.1460-2075.1995.tb07198.x; Diederichs K, 1997, NAT STRUCT BIOL, V4, P269, DOI 10.1038/nsb0497-269; Dodson EJ, 1997, METHOD ENZYMOL, V277, P620, DOI 10.1016/S0076-6879(97)77034-4; Fury MG, 1997, EXP CELL RES, V237, P63, DOI 10.1006/excr.1997.3750; HERMANN H, 1995, EMBO J, V14, P2076, DOI 10.1002/j.1460-2075.1995.tb07199.x; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kambach C, 1999, CELL, V96, P375, DOI 10.1016/S0092-8674(00)80550-4; KASTNER B, 1990, P NATL ACAD SCI USA, V87, P1710, DOI 10.1073/pnas.87.5.1710; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LAURENT TC, 1964, J CHROMATOGR, V14, P317, DOI 10.1016/S0021-9673(00)86637-6; LESLIE AGW, 1992, JOINT CCP PLUS ESF E, V26; Liu Q, 1997, CELL, V90, P1013, DOI 10.1016/S0092-8674(00)80367-0; MacKenzie AE, 2001, NAT STRUCT BIOL, V8, P13, DOI 10.1038/82983; MATTHEWS BW, 1968, J MOL BIOL, V33, P491, DOI 10.1016/0022-2836(68)90205-2; Mayes AE, 1999, EMBO J, V18, P4321, DOI 10.1093/emboj/18.15.4321; Meister G, 2001, CURR BIOL, V11, P1990, DOI 10.1016/S0960-9822(01)00592-9; Moller T, 2002, MOL CELL, V9, P23, DOI 10.1016/S1097-2765(01)00436-1; Mura C, 2001, P NATL ACAD SCI USA, V98, P5532, DOI 10.1073/pnas.091102298; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; Neylon C, 2000, BIOCHEMISTRY-US, V39, P11989, DOI 10.1021/bi001174w; Palfi Z, 2000, P NATL ACAD SCI USA, V97, P8967, DOI 10.1073/pnas.150236097; Plessel G, 1997, J MOL BIOL, V265, P87, DOI 10.1006/jmbi.1996.0713; Raker VA, 1999, MOL CELL BIOL, V19, P6554; Raker VA, 1996, EMBO J, V15, P2256, DOI 10.1002/j.1460-2075.1996.tb00579.x; Salgado-Garrido J, 1999, EMBO J, V18, P3451, DOI 10.1093/emboj/18.12.3451; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; Schumacher MA, 2002, EMBO J, V21, P3546, DOI 10.1093/emboj/cdf322; Selenko P, 2001, NAT STRUCT BIOL, V8, P27; SERAPHIN B, 1995, EMBO J, V14, P2089, DOI 10.1002/j.1460-2075.1995.tb07200.x; Seto AG, 1999, NATURE, V401, P177, DOI 10.1038/43694; Stark H, 2001, NATURE, V409, P539, DOI 10.1038/35054102; Tharun S, 2000, NATURE, V404, P515, DOI 10.1038/35006676; Thore S, 2003, J BIOL CHEM, V278, P1239, DOI 10.1074/jbc.M207685200; Toro I, 2002, J MOL BIOL, V320, P129, DOI 10.1016/S0022-2836(02)00406-0; Toro I, 2001, EMBO J, V20, P2293, DOI 10.1093/emboj/20.9.2293; Urlaub H, 2001, EMBO J, V20, P187, DOI 10.1093/emboj/20.1.187; Walke S, 2001, J MOL BIOL, V308, P49, DOI 10.1006/jmbi.2001.4549; Winn MD, 2001, ACTA CRYSTALLOGR D, V57, P122, DOI 10.1107/S0907444900014736; Zhang AX, 2002, MOL CELL, V9, P11, DOI 10.1016/S1097-2765(01)00437-3	49	27	28	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 9	2003	278	19					17291	17298		10.1074/jbc.M211826200	http://dx.doi.org/10.1074/jbc.M211826200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677QG	12618433	hybrid			2022-12-25	WOS:000182818600113
J	Ikeyama, S; Wang, XT; Li, J; Podlutsky, A; Martindale, JL; Kokkonen, G; van Huizen, R; Gorospe, M; Holbrook, NJ				Ikeyama, S; Wang, XT; Li, J; Podlutsky, A; Martindale, JL; Kokkonen, G; van Huizen, R; Gorospe, M; Holbrook, NJ			Expression of the pro-apoptotic gene gadd153/chop is elevated in liver with aging and sensitizes cells to oxidant injury	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; EXTENDED LIFE-SPAN; OXIDATIVE STRESS; CAENORHABDITIS-ELEGANS; ENDOPLASMIC-RETICULUM; CALORIC RESTRICTION; SIGNAL-TRANSDUCTION; HYDROGEN-PEROXIDE; CELLULAR-RESPONSE; GROWTH	Aging is generally accompanied by reduced tolerance to oxidative stress and altered responsiveness to proliferative signals. We have shown that hepatocytes derived from aged rats (24-26 months) exhibit greater sensitivity to H2O2 treatment and reduced proliferation following epidermal growth factor (EGF) treatment than cells of young adult rats (5-6 months). Here we examined the effects of aging and calorie restriction (CR) on expression of the oxidative stress-inducible and pro-apoptotic gene gadd153 (chop) in these hepatocytes, and we investigated its influence on sensitivity to oxidants. We show that aging was associated with elevated expression of gadd153, both basally and in response to H2O2 treatment. CR, which attenuates age-associated declines in stress tolerance, prevented the age-related increase in gadd153 expression. EGF treatment also resulted in gadd153 induction in old cells. This effect was absent in young cells and in old cells of CR rats. gadd153 induction by EGF was reactive oxygen species-dependent and correlated with heightened sensitivity to subsequent H2O2 treatment, suggesting that elevated Gadd153 contributes to the greater sensitivity of EGF-pretreated old cells to oxidative stress. Additional support for this hypothesis was provided by experiments with Rat1 fibroblasts in which conditional expression of Gadd153 conferred increased sensitivity to H2O2. We propose a model whereby the diminished ability of old hepatocytes to overcome an EGF-triggered reactive oxygen species load leads to induction of the proapoptotic gene gadd153, which, in turn, sensitizes the cells to oxidant injury. Our findings point to gadd153 expression levels as an important factor in liver aging.	Yale Univ, Sch Med, Sect Geriatr, New Haven, CT 06520 USA; NIA, Biol Cellulaire & Mol Lab, IRP, Baltimore, MD 21224 USA	Yale University; National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA)	Holbrook, NJ (corresponding author), Yale Univ, Sch Med, Sect Geriatr, Dept Internal Med, POB 208025, New Haven, CT 06511 USA.	nikki-holbrook@yale.edu	Podlutsky, Andrej/F-5421-2015; Martindale, Jennifer Luethy/AAD-1963-2022	Martindale, Jennifer Luethy/0000-0002-3234-6861	NATIONAL INSTITUTE ON AGING [ZIAAG000511, P30AG021342, Z01AG000511] Funding Source: NIH RePORTER; NIA NIH HHS [T30AG21342] Funding Source: Medline; PHS HHS [T30-3489] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		AMES BN, 1993, P NATL ACAD SCI USA, V90, P7915, DOI 10.1073/pnas.90.17.7915; Anantharaju A, 2002, GERONTOLOGY, V48, P343, DOI 10.1159/000065506; Bae YS, 1997, J BIOL CHEM, V272, P217, DOI 10.1074/jbc.272.1.217; Beckman KB, 1998, PHYSIOL REV, V78, P547, DOI 10.1152/physrev.1998.78.2.547; BURDON RH, 1995, FREE RADICAL BIO MED, V18, P775, DOI 10.1016/0891-5849(94)00198-S; CARLSON SG, 1993, MOL CELL BIOL, V13, P4736, DOI 10.1128/MCB.13.8.4736; Chen CH, 1996, ONCOGENE, V13, P1659; Droge W, 2002, PHYSIOL REV, V82, P47, DOI 10.1152/physrev.00018.2001; Fabrizio P, 2001, SCIENCE, V292, P288, DOI 10.1126/science.1059497; Finkel T, 1998, CURR OPIN CELL BIOL, V10, P248, DOI 10.1016/S0955-0674(98)80147-6; Finkel T, 2000, NATURE, V408, P239, DOI 10.1038/35041687; FORNACE AJ, 1989, MOL CELL BIOL, V9, P4196, DOI 10.1128/MCB.9.10.4196; Gately DP, 1996, BRIT J CANCER, V73, P18, DOI 10.1038/bjc.1996.4; GOOD RA, 1992, INT J IMMUNOPHARMACO, V14, P361, DOI 10.1016/0192-0561(92)90165-H; Guarente L, 2000, NATURE, V408, P255, DOI 10.1038/35041700; Guyton KZ, 1996, J BIOL CHEM, V271, P4138, DOI 10.1074/jbc.271.7.3604; Hall DM, 2000, FASEB J, V14, P78, DOI 10.1096/fasebj.14.1.78; HARMAN D, 1956, J GERONTOL, V11, P298, DOI 10.1093/geronj/11.3.298; Holbrook NJ, 2002, BIOCHEM PHARMACOL, V64, P999, DOI 10.1016/S0006-2952(02)01169-3; HORNSBY PJ, 2001, HDB BIOL AGING, P207; Ikeyama S, 2002, FASEB J, V16, pA1163, DOI 10.1096/fj.01-0409fje; IKEYAMA S, 2003, IN PRESS EXP GERONTO; Knebel A, 1996, EMBO J, V15, P5314, DOI 10.1002/j.1460-2075.1996.tb00916.x; KRIEGERBRAUER HI, 1995, BIOCHEM J, V307, P549, DOI 10.1042/bj3070549; LARSEN PL, 1993, P NATL ACAD SCI USA, V90, P8905, DOI 10.1073/pnas.90.19.8905; Lee CK, 2002, P NATL ACAD SCI USA, V99, P14988, DOI 10.1073/pnas.232308999; Lee CK, 2000, NAT GENET, V25, P294, DOI 10.1038/77046; Lin YJ, 1998, SCIENCE, V282, P943, DOI 10.1126/science.282.5390.943; LITHGOW GJ, 1995, P NATL ACAD SCI USA, V92, P7540, DOI 10.1073/pnas.92.16.7540; LIU Y, 2002, HDB BIOL AGING, P179; LO YYC, 1995, J BIOL CHEM, V270, P11727, DOI 10.1074/jbc.270.20.11727; LUETHY JD, 1990, J BIOL CHEM, V265, P16521; Martindale JL, 2002, J CELL PHYSIOL, V192, P1, DOI 10.1002/jcp.10119; MASORO EJ, 2001, HDB BIOL AGING, P396; McCullough KD, 2001, MOL CELL BIOL, V21, P1249, DOI 10.1128/MCB.21.4.1249-1259.2001; Migliaccio E, 1999, NATURE, V402, P309, DOI 10.1038/46311; Murakami S, 1996, GENETICS, V143, P1207; Ogg S, 1997, NATURE, V389, P994, DOI 10.1038/40194; PARNHAM MJ, 1984, BIOCHEM PHARMACOL, V33, P3247, DOI 10.1016/0006-2952(84)90085-6; RON D, 1992, GENE DEV, V6, P439, DOI 10.1101/gad.6.3.439; SACHSENMAIER C, 1994, CELL, V78, P963, DOI 10.1016/0092-8674(94)90272-0; SCHIEVEN GL, 1994, J BIOL CHEM, V269, P20718; Seglen P O, 1976, Methods Cell Biol, V13, P29, DOI 10.1016/S0091-679X(08)61797-5; SOBAL RS, 2002, FREE RADIC BIOL MED, V33, P37; STADTMAN ER, 1992, SCIENCE, V257, P1220, DOI 10.1126/science.1355616; SUNDARESAN M, 1995, SCIENCE, V270, P296, DOI 10.1126/science.270.5234.296; WANG JF, 1992, HEPATOLOGY, V15, P1112, DOI 10.1002/hep.1840150623; Wang XZ, 1996, MOL CELL BIOL, V16, P4273; Zanella CL, 1996, CANCER RES, V56, P5334; Zinszner H, 1998, GENE DEV, V12, P982, DOI 10.1101/gad.12.7.982	50	65	70	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 9	2003	278	19					16726	16731		10.1074/jbc.M300677200	http://dx.doi.org/10.1074/jbc.M300677200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677QG	12609979	hybrid			2022-12-25	WOS:000182818600038
J	Moore, ML; Park, EA; McMillin, JB				Moore, ML; Park, EA; McMillin, JB			Upstream stimulatory factor represses the induction of carnitine palmitoyltransferase-I beta expression by PGC-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROLIFERATOR-ACTIVATED RECEPTOR; TRANSCRIPTIONAL COACTIVATOR PGC-1; MITOCHONDRIAL CREATINE-KINASE; NEONATAL CARDIAC MYOCYTES; PPAR-GAMMA COACTIVATOR-1; HEAVY-CHAIN GENE; E-BOX; SKELETAL-MUSCLE; TRANSGENIC MICE; FACTOR USF	Transcriptional regulation of carnitine palmitoyltransferase-1beta (CPT-1beta) is coordinated with contractile gene expression through cardiac-enriched transcription factors, GATA4 and SRF. Metabolic modulation of CPT-1beta promoter activity has been described with the stimulation of gene expression by oleate that is mediated through the peroxisome proliferator-activated receptor (PPAR) pathway. The coactivator, peroxisomal proliferator-activated receptor gamma coactivator (PGC-1), enhances gene expression through interactions with nuclear hormone receptors and the myocyte enhancer factor 2 (MEF2) family. PGC-1 and MEF2A synergistically activate CPT-1beta promoter activity. This stimulation is enhanced by mutation of the E-box sequences that flank the MEF2A binding site. These elements bind the upstream stimulatory factors (USF1 and USF2), which activate transcription in CV-1 fibroblasts. However, overexpression of the USF proteins in myocytes depresses CPT-1beta activity and significantly reduces MEF2A and PGC-1 synergy. Co-immunoprecipitation studies demonstrate that PGC-1 and USF2 proteins can physically interact. Our studies demonstrate that PGC-1 stimulates CPT-1beta gene expression through MEF2A. USF proteins have a novel role in repressing the expression of the CPT-1beta gene and modulating the induction by the coactivator, PGC-1.	Univ Texas, Sch Med, Dept Pathol & Lab Med, Hlth Sci Ctr, Houston, TX 77030 USA; Texas Med Ctr, Grad Sch Biomed Sci, Houston, TX 77030 USA; Univ Tennessee, Dept Pharmacol, Memphis, TN 38163 USA	University of Texas System; University of Texas Health Science Center Houston; Baylor College of Medicine; University of Texas System; University of Texas Health Science Center Houston; University of Tennessee System; University of Tennessee Health Science Center	McMillin, JB (corresponding author), Univ Texas, Sch Med, Dept Pathol & Lab Med, Hlth Sci Ctr, 6431 Fannin, Houston, TX 77030 USA.				NHLBI NIH HHS [R01 HL38863] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL038863] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Barger PM, 2000, J CLIN INVEST, V105, P1723, DOI 10.1172/JCI9056; Barger PM, 2001, J BIOL CHEM, V276, P44495, DOI 10.1074/jbc.M105945200; Brandt JM, 1998, J BIOL CHEM, V273, P23786, DOI 10.1074/jbc.273.37.23786; Cheng GM, 1999, J BIOL CHEM, V274, P12819, DOI 10.1074/jbc.274.18.12819; Christensen TH, 1999, GENE EXPRESSION, V8, P247; Cook GA, 2001, J MOL CELL CARDIOL, V33, P317, DOI 10.1006/jmcc.2000.1304; GOPALSRIVASTAVA R, 1995, MOL CELL BIOL, V15, P7081; Han SY, 2001, FEBS LETT, V505, P57, DOI 10.1016/S0014-5793(01)02777-6; Knutti D, 2001, TRENDS ENDOCRIN MET, V12, P360, DOI 10.1016/S1043-2760(01)00457-X; Knutti D, 2001, P NATL ACAD SCI USA, V98, P9713, DOI 10.1073/pnas.171184698; Lehman JJ, 2002, CLIN EXP PHARMACOL P, V29, P339, DOI 10.1046/j.1440-1681.2002.03655.x; Lehman JJ, 2000, J CLIN INVEST, V106, P847, DOI 10.1172/JCI10268; Lenka N, 1998, PROG NUCLEIC ACID RE, V61, P309, DOI 10.1016/S0079-6603(08)60830-2; Luo X, 1996, MOL CELL BIOL, V16, P1367; Mably JD, 1996, CIRC RES, V79, P4, DOI 10.1161/01.RES.79.1.4; Mascaro C, 1998, J BIOL CHEM, V273, P8560, DOI 10.1074/jbc.273.15.8560; McGarry JD, 1997, EUR J BIOCHEM, V244, P1, DOI 10.1111/j.1432-1033.1997.00001.x; MCMILLIN JB, 1993, METHODS TOXICOL, V2, P301; Michael LF, 2001, P NATL ACAD SCI USA, V98, P3820, DOI 10.1073/pnas.061035098; Molkentin JD, 1996, J MOL CELL CARDIOL, V28, P1211, DOI 10.1006/jmcc.1996.0112; Moore ML, 2001, J BIOL CHEM, V276, P1026, DOI 10.1074/jbc.M009352200; MOSS JB, 1994, J BIOL CHEM, V269, P12731; MULLER MM, 1989, NUCLEIC ACIDS RES, V17, P6420, DOI 10.1093/nar/17.15.6420; NAVANKASATTUSAS S, 1994, MOL CELL BIOL, V14, P7331, DOI 10.1128/MCB.14.11.7331; Nicholas SB, 1999, AM J PHYSIOL-HEART C, V277, pH324, DOI 10.1152/ajpheart.1999.277.1.H324; Oberkofler H, 2002, J BIOL CHEM, V277, P16750, DOI 10.1074/jbc.M200475200; Ojamaa K, 1995, J BIOL CHEM, V270, P31276, DOI 10.1074/jbc.270.52.31276; Puigserver P, 1998, CELL, V92, P829, DOI 10.1016/S0092-8674(00)81410-5; Puigserver P, 2001, MOL CELL, V8, P971, DOI 10.1016/S1097-2765(01)00390-2; Qin WN, 1999, HISTOCHEM J, V31, P357, DOI 10.1023/A:1003748108062; Qin WN, 1997, J BIOL CHEM, V272, P25210, DOI 10.1074/jbc.272.40.25210; Qyang YB, 1999, MOL CELL BIOL, V19, P1508; SAWADOGO M, 1985, CELL, V43, P165, DOI 10.1016/0092-8674(85)90021-2; Shield MA, 1996, MOL CELL BIOL, V16, P5058; SIRITO M, 1994, NUCLEIC ACIDS RES, V22, P427, DOI 10.1093/nar/22.3.427; Tcherepanova I, 2000, J BIOL CHEM, V275, P16302, DOI 10.1074/jbc.M001364200; van der Lee KAJM, 2000, J LIPID RES, V41, P41; Vaulont S, 2000, J BIOL CHEM, V275, P31555, DOI 10.1074/jbc.R000016200; Vega RB, 2000, MOL CELL BIOL, V20, P1868, DOI 10.1128/MCB.20.5.1868-1876.2000; Wang DC, 1998, GENOMICS, V48, P314, DOI 10.1006/geno.1997.5184; Wang GL, 2002, BIOCHEM J, V362, P609, DOI 10.1042/0264-6021:3620609; Wu PF, 1999, DIABETES, V48, P1593, DOI 10.2337/diabetes.48.8.1593; Wu YF, 2002, J BIOL CHEM, V277, P8898, DOI 10.1074/jbc.M110761200; Wu ZD, 1999, CELL, V98, P115, DOI 10.1016/S0092-8674(00)80611-X; Xia Y, 1996, J BIOL CHEM, V271, P12082, DOI 10.1074/jbc.271.20.12082; Xiao QX, 2002, AM J PHYSIOL-HEART C, V283, pH213, DOI 10.1152/ajpheart.01085.2001; Yoon JC, 2001, NATURE, V413, P131, DOI 10.1038/35093050; YUTZEY KE, 1992, NUCLEIC ACIDS RES, V20, P5105, DOI 10.1093/nar/20.19.5105	48	38	39	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 9	2003	278	19					17263	17268		10.1074/jbc.M210486200	http://dx.doi.org/10.1074/jbc.M210486200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677QG	12611894	hybrid			2022-12-25	WOS:000182818600109
J	Uchida, K; Miyauchi, H; Furuichi, T; Michikawa, T; Mikoshiba, K				Uchida, K; Miyauchi, H; Furuichi, T; Michikawa, T; Mikoshiba, K			Critical regions for activation gating of the inositol 1,4,5-trisphosphate receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIGAND-BINDING SITE; CALCIUM-RELEASE; TRISPHOSPHATE RECEPTORS; CONFORMATIONAL-CHANGES; SIGNAL-TRANSDUCTION; COMPLEX-FORMATION; MOUSE CEREBELLUM; INSP3 RECEPTOR; PURKINJE-CELL; CHANNEL	To understand the molecular mechanism of ligand-induced gating of the inositol 1,4,5-trisphosphate (IP3) receptor (IP3R)/Ca2+ release channel, we analyzed the channel properties of deletion mutants retaining both the IP3-binding and channel-forming domains of IP(3)R1. Using intrinsically IP3R-deficient cells as the host cells for receptor expression, we determined that six of the mutants, those lacking residues 1-223, 651-1130, 1267-2110, 1845-2042, 1845-2216, and 2610-2748, did not exhibit any measurable Ca2+ release activity, whereas the mutants lacking residues 1131-1379 and 2736-2749 retained the activity. Limited trypsin digestion showed that not only the IP3-gated Ca2+-permeable mutants lacking residues 1131-1379 and 2736-2749, but also two nonfunctional mutants lacking residues 1-223 and 651-1130, retained the normal folding structure of at least the C-terminal channel-forming domain. These results indicate that two regions of IP(3)R1, viz. residues 1-223 and 651-1130, are critical for IP3-induced gating. We also identified a highly conserved cysteine residue at position 2613, which is located within the C-terminal tail, as being essential for channel opening. Based on these results, we propose a novel five-domain structure model in which both N-terminal and internal coupling domains transduce ligand-binding signals to the C-terminal tail, which acts as a gatekeeper that triggers opening of the activation gate of IP(3)R1 following IP3 binding.	Univ Tokyo, Inst Med Sci, Dept Basic Med Sci, Div Mol Neurobiol,Minato Ku, Tokyo 1088639, Japan; Keio Univ, Sch Med, Dept Pediat, Shinjuku Ku, Tokyo 1608582, Japan; Japanese Red Cross Med Ctr, Dept Neurosurg, Shibuya Ku, Tokyo 1508935, Japan; Univ Tokyo, Dept Neurosurg, Bunkyo Ku, Tokyo 1138655, Japan; RIKEN, Brain Sci Inst, Lab Mol Neurogenesis, Wako, Saitama 3510198, Japan; RIKEN, Brain Sci Inst, Dev Neurobiol Lab, Wako, Saitama 3510198, Japan; Japan Sci & Technol Corp, Int Cooperat Res Project, Calcium Oscillat Project, Minato Ku, Tokyo 1080071, Japan	University of Tokyo; Keio University; Japanese Red Cross Medical Center; University of Tokyo; RIKEN; RIKEN; Japan Science & Technology Agency (JST)	Mikoshiba, K (corresponding author), Univ Tokyo, Inst Med Sci, Dept Basic Med Sci, Div Mol Neurobiol,Minato Ku, 4-6-1 Shirokanedai, Tokyo 1088639, Japan.		Furuichi, Teiichi/B-5086-2014; Mikoshiba, Katsuhiko/N-7943-2015	Furuichi, Teiichi/0000-0002-9676-1888; 				BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; Boehning D, 2001, BIOPHYS J, V81, P117, DOI 10.1016/S0006-3495(01)75685-8; BOOTMAN MD, 1992, J BIOL CHEM, V267, P25113; Bosanac I, 2002, NATURE, V420, P696, DOI 10.1038/nature01268; Broillet MC, 2000, J BIOL CHEM, V275, P15135, DOI 10.1074/jbc.275.20.15135; Cingolani G, 1999, NATURE, V399, P221, DOI 10.1038/20367; DANOFF SK, 1991, P NATL ACAD SCI USA, V88, P2951, DOI 10.1073/pnas.88.7.2951; DeSmedt H, 1997, BIOCHEM J, V322, P575; FADOOL DA, 1992, NEURON, V9, P907, DOI 10.1016/0896-6273(92)90243-7; Feng W, 2002, J BIOL CHEM, V277, P44722, DOI 10.1074/jbc.M207675200; FERRIS CD, 1992, NATURE, V356, P350, DOI 10.1038/356350a0; FINCH EA, 1991, SCIENCE, V252, P443, DOI 10.1126/science.2017683; FURUICHI T, 1989, NATURE, V342, P32, DOI 10.1038/342032a0; FURUICHI T, 1995, J NEUROCHEM, V64, P953, DOI 10.1046/j.1471-4159.1995.64030953.x; Galvan DL, 1999, J BIOL CHEM, V274, P29483, DOI 10.1074/jbc.274.41.29483; Gordon SE, 1997, NEURON, V19, P431, DOI 10.1016/S0896-6273(00)80951-4; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; GYORKE S, 1993, SCIENCE, V260, P807, DOI 10.1126/science.8387229; Hamada K, 2002, J BIOL CHEM, V277, P21115, DOI 10.1074/jbc.C200244200; HIROTA J, 1995, J BIOL CHEM, V270, P19046, DOI 10.1074/jbc.270.32.19046; Huber AH, 1997, CELL, V90, P871, DOI 10.1016/S0092-8674(00)80352-9; Jiang YX, 2002, NATURE, V417, P515, DOI 10.1038/417515a; Jiang YX, 2002, NATURE, V417, P523, DOI 10.1038/417523a; Joseph SK, 1997, J BIOL CHEM, V272, P1579, DOI 10.1074/jbc.272.3.1579; KAPLIN AI, 1994, J BIOL CHEM, V269, P28972; MAEDA N, 1990, EMBO J, V9, P61, DOI 10.1002/j.1460-2075.1990.tb08080.x; MAEDA N, 1991, J BIOL CHEM, V266, P1109; MAEDA N, 1988, J NEUROCHEM, V51, P1724, DOI 10.1111/j.1471-4159.1988.tb01151.x; MEYER T, 1990, BIOCHEMISTRY-US, V29, P32, DOI 10.1021/bi00453a004; MEYER T, 1990, P NATL ACAD SCI USA, V87, P3841, DOI 10.1073/pnas.87.10.3841; Michikawa T, 1999, NEURON, V23, P799, DOI 10.1016/S0896-6273(01)80037-4; MICHIKAWA T, 1994, J BIOL CHEM, V269, P9184; MIGNERY GA, 1990, EMBO J, V9, P3893, DOI 10.1002/j.1460-2075.1990.tb07609.x; MISSIAEN L, 1991, NATURE, V352, P241, DOI 10.1038/352241a0; Miyakawa T, 2001, EMBO J, V20, P1674, DOI 10.1093/emboj/20.7.1674; MIYAWAKI A, 1991, P NATL ACAD SCI USA, V88, P4911, DOI 10.1073/pnas.88.11.4911; MIYAWAKI A, 1990, NEURON, V5, P11, DOI 10.1016/0896-6273(90)90029-F; MONKAWA T, 1995, J BIOL CHEM, V270, P14700, DOI 10.1074/jbc.270.24.14700; MUALLEM S, 1989, J BIOL CHEM, V264, P205; NAKADE S, 1991, BIOCHEM J, V277, P125, DOI 10.1042/bj2770125; NAKAGAWA T, 1991, P NATL ACAD SCI USA, V88, P6244, DOI 10.1073/pnas.88.14.6244; NUCIFORA FC, 1995, MOL BRAIN RES, V32, P291, DOI 10.1016/0169-328X(95)00089-B; PRICE NC, 1989, PROTEOLYTIC ENZYMES, P163; Rosenbaum T, 2002, NEURON, V33, P703, DOI 10.1016/S0896-6273(02)00599-8; Sayers LG, 1997, BIOCHEM J, V323, P273, DOI 10.1042/bj3230273; Schulte U, 1998, J BIOL CHEM, V273, P34575, DOI 10.1074/jbc.273.51.34575; Schulteis CT, 1996, BIOCHEMISTRY-US, V35, P12133, DOI 10.1021/bi961083s; Sienaert I, 2002, BIOCHEM J, V365, P269, DOI 10.1042/BJ20020144; Sienaert I, 1997, J BIOL CHEM, V272, P25899, DOI 10.1074/jbc.272.41.25899; SUDHOF TC, 1991, EMBO J, V10, P3199, DOI 10.1002/j.1460-2075.1991.tb04882.x; Sugawara H, 1997, EMBO J, V16, P3078, DOI 10.1093/emboj/16.11.3078; SUPATTAPONE S, 1988, J BIOL CHEM, V263, P1530; Tu JC, 1998, NEURON, V21, P717, DOI 10.1016/S0896-6273(00)80589-9; Yoneshima H, 1997, BIOCHEM J, V322, P591, DOI 10.1042/bj3220591; Yoshikawa F, 1999, J BIOL CHEM, V274, P328, DOI 10.1074/jbc.274.1.328; Yoshikawa F, 1996, J BIOL CHEM, V271, P18277, DOI 10.1074/jbc.271.30.18277; Yoshikawa F, 1999, J BIOL CHEM, V274, P316, DOI 10.1074/jbc.274.1.316; Yoshikawa F, 1999, BIOCHEM BIOPH RES CO, V257, P792, DOI 10.1006/bbrc.1999.0498; Zhang SB, 2003, J BIOL CHEM, V278, P4048, DOI 10.1074/jbc.M209960200	59	114	119	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 9	2003	278	19					16551	16560		10.1074/jbc.M300646200	http://dx.doi.org/10.1074/jbc.M300646200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677QG	12621039	Green Submitted, hybrid			2022-12-25	WOS:000182818600016
J	Litvin, TN; Kamenetsky, M; Zarifyan, A; Buck, J; Levin, LR				Litvin, TN; Kamenetsky, M; Zarifyan, A; Buck, J; Levin, LR			Kinetic properties of "soluble" adenylyl cyclase - Synergism between calcium and bicarbonate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IN-VIVO; ACROSOME REACTION; DIVALENT-CATIONS; SPERM; CALMODULIN; SPERMATOZOA; MOTILITY; PHOSPHORYLATION; PURIFICATION; CAPACITATION	"Soluble" adenylyl cyclase (sAC) is a widely expressed source of cAMP in mammalian cells that is evolutionarily, structurally, and biochemically distinct from the G protein-responsive transmembrane adenylyl cyclases. In contrast to transmembrane adenylyl cyclases, sAC is insensitive to heterotrimeric G protein regulation and forskolin stimulation and is uniquely modulated by bicarbonate ions. Here we present the first report detailing kinetic analysis and biochemical properties of purified recombinant sAC. We confirm that bicarbonate regulation is conserved among mammalian sAC orthologs and demonstrate that bicarbonate stimulation is consistent with an increase in the V-max of the enzyme with little effect on the apparent K-m for substrate, ATP-Mg2+. Bicarbonate can further increase sAC activity by relieving substrate inhibition. We also identify calcium as a direct modulator of sAC activity. In contrast to bicarbonate, calcium stimulates sAC activity by decreasing its apparent K-m for ATP-Mg2+. Because of their different mechanisms, calcium and bicarbonate synergistically activate sAC therefore, small changes of either calcium or bicarbonate will lead to significant changes in cellular cAMP levels.	Cornell Univ, Weill Med Coll, Dept Pharmacol, New York, NY 10021 USA	Cornell University	Buck, J (corresponding author), Cornell Univ, Weill Med Coll, Dept Pharmacol, New York, NY 10021 USA.	jobuck@med.cornell.edu		Levin, Lonny/0000-0002-5204-6356	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD038722] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM062328] Funding Source: NIH RePORTER; NICHD NIH HHS [HD 42060, HD 38722] Funding Source: Medline; NIDA NIH HHS [DA 07274] Funding Source: Medline; NIGMS NIH HHS [GM 62328] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BRAUN T, 1975, J CYCLIC NUCL PROT, V1, P271; BRAUN T, 1991, METHOD ENZYMOL, V195, P130; BRAUN T, 1975, P NATL ACAD SCI USA, V72, P1097, DOI 10.1073/pnas.72.3.1097; Breitbart H, 2002, MOL CELL ENDOCRINOL, V187, P139, DOI 10.1016/S0303-7207(01)00704-3; Buck J, 1999, P NATL ACAD SCI USA, V96, P79, DOI 10.1073/pnas.96.1.79; Buck J, 2002, METHOD ENZYMOL, V345, P95; CALI JJ, 1994, J BIOL CHEM, V269, P12190; Chen YQ, 2000, SCIENCE, V289, P625, DOI 10.1126/science.289.5479.625; CHOI EJ, 1992, BIOCHEMISTRY-US, V31, P6492, DOI 10.1021/bi00143a019; Cooper Dermot M.F., 1998, Advances in Second Messenger and Phosphoprotein Research, V32, P23; COOPER DMF, 1995, NATURE, V374, P421, DOI 10.1038/374421a0; Darszon A, 1999, PHYSIOL REV, V79, P481, DOI 10.1152/physrev.1999.79.2.481; GARBERS DL, 1982, J BIOL CHEM, V257, P8980; GORDELADZE JO, 1981, J CLIN ENDOCR METAB, V53, P465, DOI 10.1210/jcem-53-3-465; Hurley JH, 1999, J BIOL CHEM, V274, P7599, DOI 10.1074/jbc.274.12.7599; HYNE RV, 1979, BIOL REPROD, V21, P1135, DOI 10.1095/biolreprod21.5.1135; Kulanand J, 2001, ANDROLOGIA, V33, P95, DOI 10.1046/j.1439-0272.2001.00410.x; LEE MA, 1986, BIOL REPROD, V34, P349, DOI 10.1095/biolreprod34.2.349; LEVIN LR, 1992, CELL, V68, P479, DOI 10.1016/0092-8674(92)90185-F; LEVIN LR, 1995, J BIOL CHEM, V270, P7573, DOI 10.1074/jbc.270.13.7573; LEVINE N, 1971, J PHYSIOL-LONDON, V213, P557, DOI 10.1113/jphysiol.1971.sp009400; MAGNUS O, 1990, ARCH ANDROLOGY, V24, P159, DOI 10.3109/01485019008986875; OKAMURA N, 1985, J BIOL CHEM, V260, P9699; Ren DJ, 2001, NATURE, V413, P603, DOI 10.1038/35098027; RODRIGUEZMARTINEZ H, 1990, INT J ANDROL, V13, P238, DOI 10.1111/j.1365-2605.1990.tb00982.x; ROJAS FJ, 1993, ENDOCRINOLOGY, V133, P3030, DOI 10.1210/en.133.6.3030; Sinclair ML, 2000, MOL REPROD DEV, V56, P6, DOI 10.1002/(SICI)1098-2795(200005)56:1&lt;6::AID-MRD2&gt;3.0.CO;2-M; STENGEL D, 1984, ANN NY ACAD SCI, V438, P18, DOI 10.1111/j.1749-6632.1984.tb38272.x; TANG WJ, 1991, J BIOL CHEM, V266, P8595; TAUSSIG R, 1995, J BIOL CHEM, V270, P1, DOI 10.1074/jbc.270.1.1; Tesmer JJG, 1997, SCIENCE, V278, P1907, DOI 10.1126/science.278.5345.1907; Tesmer JJG, 1999, SCIENCE, V285, P756, DOI 10.1126/science.285.5428.756; Visconti PE, 2002, J REPROD IMMUNOL, V53, P133, DOI 10.1016/S0165-0378(01)00103-6; Wayman GA, 1996, MOL CELL BIOL, V16, P6075; Wei J, 1996, J BIOL CHEM, V271, P24231, DOI 10.1074/jbc.271.39.24231; Wuttke M S, 2001, JOP, V2, P154; Zimmermann G, 1998, J BIOL CHEM, V273, P19650, DOI 10.1074/jbc.273.31.19650; Zippin JH, 2002, FASEB J, V16, P82, DOI 10.1096/fj.02-0598fje; Zippin JH, 2001, TRENDS ENDOCRIN MET, V12, P366, DOI 10.1016/S1043-2760(01)00454-4	39	261	272	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 2	2003	278	18					15922	15926		10.1074/jbc.M212475200	http://dx.doi.org/10.1074/jbc.M212475200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	675EL	12609998	hybrid			2022-12-25	WOS:000182680000060
J	Ariumi, Y; Ego, T; Kaida, A; Matsumoto, M; Pandolfi, PP; Shimotohno, K				Ariumi, Y; Ego, T; Kaida, A; Matsumoto, M; Pandolfi, PP; Shimotohno, K			Distinct nuclear body components, PML and SMRT, regulate the trans-acting function of HTLV-1 tax oncoprotein	ONCOGENE			English	Article						HTLV-1; tax; PML; SMRT; CBP; nuclear body	CELL LEUKEMIA-VIRUS; ACUTE PROMYELOCYTIC LEUKEMIA; CREB BINDING-PROTEIN; REPLICATION COMPARTMENTS; VIRAL TRANSACTIVATOR; TUMOR SUPPRESSION; COACTIVATOR CBP; TYPE-1 TAX; RAR-ALPHA; BODIES	Several viruses target cellular promyelocytic leukemia (PML)-nuclear bodies (PML-NBs) to induce their disruption, marked morphological changes in these structures or the relocation to PML-NB components to the cytoplasm of infected cells. PML conversely interferes with viral replication. We demonstrate that PML acts as a coactivator for the human T-cell leukemia virus type I (HTLV-1) Tax oncoprotein without direct binding. Tax was identified within interchromatin granule clusters (IGCs)/RNA splicing bodies (SBs), not PML-NBs; Tax expression did not affect PML-NB formation. Moreover, PML and CBP/p300 cooperatively activated Tax-mediated HTLV-1-LTR-dependent gene expression. Interestingly, two PML mutants, PML-RAR and PMLDelta216-331, which fail to form PML-NBs, could also coactivate Tax-mediated trans-acting function but had no effect on retinoic acid receptor (RAR)- or p53-dependent gene expression. In contrast, SMRT (silencing mediator for retinoic acid and thyroid hormone receptors), a nuclear corepressor found within the matrix-associated deacetylase (MAD) nuclear body, relocatized into Tax-associated nuclear bodies upon coexpression with Tax. SMRT coactivated the trans-acting function of Tax through direct binding. Coexpression of SMRT and PML resulted in an additive activation of Tax trans-acting function. Thus, crosstalk between distinct nuclear bodies may control Tax function.	Kyoto Univ, Inst Virus Res, Lab Human Tumor Viruses, Sakyo Ku, Kyoto 6068507, Japan; Cornell Univ, Grad Sch Med Sci, Mem Sloan Kettering Canc Ctr, Dept Human Genet,Mol Biol Program, New York, NY 10021 USA	Kyoto University; Cornell University; Memorial Sloan Kettering Cancer Center	Shimotohno, K (corresponding author), Kyoto Univ, Inst Virus Res, Lab Human Tumor Viruses, Sakyo Ku, Kyoto 6068507, Japan.	kshimoto@virus.kyoto-u.ac.jp	Ariumi, Yasuo/F-5804-2013					Ahn JH, 1997, J VIROL, V71, P4599, DOI 10.1128/JVI.71.6.4599-4613.1997; Akagi T, 1997, ONCOGENE, V14, P2071, DOI 10.1038/sj.onc.1201045; Ariumi Y, 2000, ONCOGENE, V19, P1491, DOI 10.1038/sj.onc.1203450; Ariumi Y, 2001, BIOCHEM BIOPH RES CO, V287, P556, DOI 10.1006/bbrc.2001.5626; Borden KLB, 1998, J VIROL, V72, P758, DOI 10.1128/JVI.72.1.758-766.1998; Burkham J, 1998, J VIROL, V72, P10100, DOI 10.1128/JVI.72.12.10100-10107.1998; Burton M, 2000, J VIROL, V74, P2351, DOI 10.1128/JVI.74.5.2351-2364.2000; Chelbi-Alix MK, 1998, J VIROL, V72, P1043, DOI 10.1128/JVI.72.2.1043-1051.1998; Day PM, 1998, J VIROL, V72, P142, DOI 10.1128/JVI.72.1.142-150.1998; Desbois C, 1996, SCIENCE, V273, P951, DOI 10.1126/science.273.5277.951; DETHE H, 1991, CELL, V66, P675, DOI 10.1016/0092-8674(91)90113-D; Doucas V, 1999, P NATL ACAD SCI USA, V96, P2633, DOI 10.1073/pnas.96.6.2633; Doucas V, 1996, GENE DEV, V10, P196, DOI 10.1101/gad.10.2.196; Doucas V, 1999, P NATL ACAD SCI USA, V96, P2627, DOI 10.1073/pnas.96.6.2627; DOUCAS V, 1996, BIOCHIM BIOPHYS ACTA, V1288, P25; Downes M, 2000, P NATL ACAD SCI USA, V97, P10330, DOI 10.1073/pnas.97.19.10330; DYCK JA, 1994, CELL, V76, P333, DOI 10.1016/0092-8674(94)90340-9; EVERETT RD, 1994, EMBO J, V13, P5062, DOI 10.1002/j.1460-2075.1994.tb06835.x; Everett RD, 1999, J VIROL, V73, P417, DOI 10.1128/JVI.73.1.417-426.1999; GODDARD AD, 1991, SCIENCE, V254, P1371, DOI 10.1126/science.1720570; Gottifredi V, 2001, TRENDS CELL BIOL, V11, P184, DOI 10.1016/S0962-8924(01)01983-3; Ishov AM, 1996, J CELL BIOL, V134, P815, DOI 10.1083/jcb.134.4.815; KAKIZUKA A, 1991, CELL, V66, P663, DOI 10.1016/0092-8674(91)90112-C; Kamitani T, 1998, J BIOL CHEM, V273, P26675, DOI 10.1074/jbc.273.41.26675; Kwok RPS, 1996, NATURE, V380, P642, DOI 10.1038/380642a0; MAUL GG, 1993, J GEN VIROL, V74, P2679, DOI 10.1099/0022-1317-74-12-2679; Maul GG, 1998, BIOESSAYS, V20, P660, DOI 10.1002/(SICI)1521-1878(199808)20:8<660::AID-BIES9>3.0.CO;2-M; MORI K, 1987, J GEN VIROL, V68, P499, DOI 10.1099/0022-1317-68-2-499; Muller S, 1998, EMBO J, V17, P61, DOI 10.1093/emboj/17.1.61; Muller S, 1999, J VIROL, V73, P5137; NOSAKA T, 1993, EXP CELL RES, V208, P89; Ordentlich P, 1999, P NATL ACAD SCI USA, V96, P2639, DOI 10.1073/pnas.96.6.2639; PANDOLFI PP, 1991, ONCOGENE, V6, P1285; PUVIONDUTILLEUL F, 1995, EXP CELL RES, V218, P9, DOI 10.1006/excr.1995.1125; Regad T, 2001, EMBO J, V20, P3495, DOI 10.1093/emboj/20.13.3495; Salomoni P, 2002, CELL, V108, P165, DOI 10.1016/S0092-8674(02)00626-8; Semmes OJ, 1996, J VIROL, V70, P6347, DOI 10.1128/JVI.70.9.6347-6357.1996; Suzuki T, 1999, ONCOGENE, V18, P4137, DOI 10.1038/sj.onc.1202766; Swindle CS, 1999, J VIROL, V73, P1001, DOI 10.1128/JVI.73.2.1001-1009.1999; Szekely L, 1996, J VIROL, V70, P2562, DOI 10.1128/JVI.70.4.2562-2568.1996; Turelli P, 2001, MOL CELL, V7, P1245, DOI 10.1016/S1097-2765(01)00255-6; Van Orden K, 1999, J BIOL CHEM, V274, P26321, DOI 10.1074/jbc.274.37.26321; Wang ZG, 1998, SCIENCE, V279, P1547; Yamaoka S, 1996, EMBO J, V15, P873, DOI 10.1002/j.1460-2075.1996.tb00422.x; Yoshida M, 2001, ANNU REV IMMUNOL, V19, P475, DOI 10.1146/annurev.immunol.19.1.475; Zhong S, 2000, NAT CELL BIOL, V2, pE85, DOI 10.1038/35010583; Zhong S, 2000, BLOOD, V95, P2748, DOI 10.1182/blood.V95.9.2748.009k31a_2748_2752	47	22	22	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 20	2003	22	11					1611	1619		10.1038/sj.onc.1206244	http://dx.doi.org/10.1038/sj.onc.1206244			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	655YH	12642864				2022-12-25	WOS:000181580500003
J	Jenniskens, GJ; Koopman, WJH; Willems, PHGM; Pecker I; Veerkamp, JH; van Kuppevelt, TH				Jenniskens, GJ; Koopman, WJH; Willems, PHGM; Pecker, I; Veerkamp, JH; van Kuppevelt, TH			Phenotypic knockout of heparan sulfates in myotubes impairs excitation-induced calcium spiking	FASEB JOURNAL			English	Article						basal lamina; blocking antibodies; heparan sulfate proteoglycan; heparanase, skeletal muscle	SKELETAL-MUSCLE; INTRACELLULAR IMMUNIZATION; MAMMALIAN HEPARANASE; BASEMENT-MEMBRANES; PROTEOGLYCANS; AGRIN; CA2+; METASTASIS; ANTIBODIES; CHANNELS	Little is known about the physiological functions of heparan sulfates (HSs), which are present in the basal lamina surrounding skeletal muscle fibers. Here, we present a new system in which HS is phenotypically knocked out by endogenous expression of epitope-specific anti-HS antibodies. Single-chain antibodies, containing an immunoglobulin leader peptide, were produced by using various expression systems. Antibodies were detected in the Golgi apparatus, the site of HS biosynthesis. Likewise, the HS-degrading enzyme heparanase was expressed. Endogenous expression of antibodies or heparanase in myoblasts resulted in HS-defective myotubes. Excitability and calcium kinetics of HS-defective myotubes were severely compromised, as determined by analysis of electrically induced calcium spikes via video-speed UV confocal laser scanning microscopy. Phenotypically knocking out of individual HS epitopes resulted in specific effects on excitability and calcium kinetics. These data indicate important roles for HSs in skeletal muscle calcium kinetics.	Univ Nijmegen, Dept Biochem 194, Med Ctr, NCMLS, NL-6500 HB Nijmegen, Netherlands; Univ Nijmegen, Microscop Imaging Ctr, Med Ctr, NL-6500 HB Nijmegen, Netherlands; InSight Ltd, IL-76121 Rehovot, Israel	Radboud University Nijmegen; Radboud University Nijmegen	van Kuppevelt, TH (corresponding author), Univ Nijmegen, Dept Biochem 194, Med Ctr, NCMLS, POB 9101, NL-6500 HB Nijmegen, Netherlands.	A.vankuppevelt@ncmls.kun.nl	Koopman, Werner J.H./D-3592-2009; van Kuppevelt, A.H.M.S.M./L-4463-2015; Koopman, Werner J.H./AAC-9668-2020; Willems, P.H.G.M./L-4759-2015	Koopman, Werner J.H./0000-0002-5340-6747; Koopman, Werner J.H./0000-0002-5340-6747; Willems, P.H.G.M./0000-0002-0915-1599				Bernfield M, 1999, ANNU REV BIOCHEM, V68, P729, DOI 10.1146/annurev.biochem.68.1.729; BEZPROZVANNY IB, 1993, MOL BIOL CELL, V4, P347, DOI 10.1091/mbc.4.3.347; BIOCCA S, 1995, TRENDS CELL BIOL, V5, P248, DOI 10.1016/S0962-8924(00)89019-4; BOWDEN DC, 1996, J NEUROCHEM, V66, P2580; BRANDAN E, 1985, J CELL BIOL, V101, P985, DOI 10.1083/jcb.101.3.985; CAMPANELLI JT, 1994, CELL, V77, P663, DOI 10.1016/0092-8674(94)90051-5; Costell M, 1999, J CELL BIOL, V147, P1109, DOI 10.1083/jcb.147.5.1109; Dennissen MABA, 2002, J BIOL CHEM, V277, P10982, DOI 10.1074/jbc.M104852200; FERNS MJ, 1993, NEURON, V11, P491, DOI 10.1016/0896-6273(93)90153-I; Gallagher JT, 2001, J CLIN INVEST, V108, P357, DOI 10.1172/JCI13713; GORDONSMITH EC, 1989, CLIN HAEMATOL, V2, P1; GOSH TK, 1988, J BIOL CHEM, V263, P11075; HOCH W, 1994, J CELL BIOL, V126, P1, DOI 10.1083/jcb.126.1.1; Hulett MD, 1999, NAT MED, V5, P803, DOI 10.1038/10525; INCE C, 1985, PFLUG ARCH EUR J PHY, V403, P240, DOI 10.1007/BF00583594; Iozzo RV, 2001, J CLIN INVEST, V108, P165, DOI 10.1172/JCI13560; Jenniskens GJ, 2000, J NEUROSCI, V20, P4099; KNAUS HG, 1990, J BIOL CHEM, V265, P11156; KNAUS HG, 1992, P NATL ACAD SCI USA, V89, P3586, DOI 10.1073/pnas.89.8.3586; KOBAYASHI S, 1988, BIOCHEM BIOPH RES CO, V153, P625, DOI 10.1016/S0006-291X(88)81141-0; Koopman WJH, 2001, BIOPHYS J, V81, P57, DOI 10.1016/S0006-3495(01)75679-2; LACINOVA L, 1993, J PHYSIOL-LONDON, V465, P181, DOI 10.1113/jphysiol.1993.sp019672; LAMB GD, 1994, J PHYSIOL-LONDON, V474, P319, DOI 10.1113/jphysiol.1994.sp020024; Lander AD, 2000, J CELL BIOL, V148, P227, DOI 10.1083/jcb.148.2.227; Marasco WA, 1997, GENE THER, V4, P11, DOI 10.1038/sj.gt.3300346; Martinez M, 1996, J MUSCLE RES CELL M, V17, P575, DOI 10.1007/BF00124356; Nicole S, 2000, NAT GENET, V26, P480, DOI 10.1038/82638; NISSIM A, 1994, EMBO J, V13, P692, DOI 10.1002/j.1460-2075.1994.tb06308.x; No D, 1996, P NATL ACAD SCI USA, V93, P3346, DOI 10.1073/pnas.93.8.3346; Patel S, 1998, J BIOL CHEM, V273, P3121, DOI 10.1074/jbc.273.6.3121; Patton BL, 1997, J CELL BIOL, V139, P1507, DOI 10.1083/jcb.139.6.1507; Portier GL, 1999, IN VITRO CELL DEV-AN, V35, P219, DOI 10.1007/s11626-999-0030-8; RAPRAEGER A, 1989, J CELL BIOL, V109, P2509, DOI 10.1083/jcb.109.5.2509; RITOV VB, 1985, FEBS LETT, V188, P77, DOI 10.1016/0014-5793(85)80878-4; ROGALSKI TM, 1993, GENE DEV, V7, P1471, DOI 10.1101/gad.7.8.1471; SPILLMANN D, 1994, CURR OPIN STRUC BIOL, V4, P677, DOI 10.1016/S0959-440X(94)90165-1; Turnbull J, 2001, TRENDS CELL BIOL, V11, P75, DOI 10.1016/S0962-8924(00)01897-3; van Kuppevelt TH, 1998, J BIOL CHEM, V273, P12960, DOI 10.1074/jbc.273.21.12960; Vlodavsky I, 2001, J CLIN INVEST, V108, P341, DOI 10.1172/JCI200113662; Vlodavsky I, 1999, NAT MED, V5, P793, DOI 10.1038/10518; WALLACE BG, 1990, J NEUROSCI, V10, P3576	41	9	9	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAR	2003	17	3					878	+		10.1096/fj.02-0572fje	http://dx.doi.org/10.1096/fj.02-0572fje			24	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	661LT	12626439				2022-12-25	WOS:000181892600031
J	Bhavesh, NS; Sinha, R; Mohan, PMK; Hosur, RV				Bhavesh, NS; Sinha, R; Mohan, PMK; Hosur, RV			NMR elucidation of early folding hierarchy in HIV-1 protease	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLTEN GLOBULE STATE; HYDROGEN-EXCHANGE; DYNAMIC CHARACTERIZATION; ALPHA-LACTALBUMIN; DENATURED STATE; X-RAY; INTERMEDIATE; APOMYOGLOBIN; SPECTROSCOPY; PREFERENCES	Folding studies on proteases by the conventional hydrogen exchange experiments are severely hampered because of interference from the autolytic reaction in the interpretation of the exchange data. We report here NMR identification of the hierarchy of early conformational transitions (folding propensities) in HIV-1 protease by systematic monitoring of the changes in the state of the protein as it is subjected to different degrees of denaturation by guanidine hydrochloride. Secondary chemical shifts, H-N-H-alpha coupling constants, H-1-N-15 nuclear Overhauser effects, and N-15 transverse relaxation parameters have been used to report on the residual structural propensities, motional restrictions, conformational transitions, etc., and the data suggest that even under the strongest denaturing conditions (6 M guanidine) hydrophobic clusters as well as different native and non-native secondary structural elements are transiently formed. These constitute the folding nuclei, which include residues spanning the active site, the hinge region, and the dimerization domain. Interestingly, the proline residues influence the structural propensities, and the small amino acids, Gly and Ala, enhance the flexibility of the protein. On reducing the denaturing conditions, partially folded forms appear. The residues showing high folding propensities are contiguous along the sequence at many locations or are in close proximity on the native protein structure, suggesting a certain degree of local cooperativity in the conformational transitions. The dimerization domain, the flaps, and their hinges seem to exhibit the highest folding propensities. The data suggest that even the early folding events may involve many states near the surface of the folding funnel.	Tata Inst Fundamental Res, Dept Chem Sci, Bombay 400005, Maharashtra, India	Tata Institute of Fundamental Research (TIFR)	Hosur, RV (corresponding author), Tata Inst Fundamental Res, Dept Chem Sci, Homi Bhabha Rd, Bombay 400005, Maharashtra, India.	hosur@tifr.res.in	Bhavesh, Neel Sarovar/F-3127-2015; Poluri, Krishna Mohan/H-6083-2013; Mohan, PM/C-9594-2018	Bhavesh, Neel Sarovar/0000-0002-7248-4978; Poluri, Krishna Mohan/0000-0003-3801-7134; Mohan, PM/0000-0001-6194-3772				Arai M, 2000, ADV PROTEIN CHEM, V53, P209; Balbach J, 1999, J MOL BIOL, V285, P829, DOI 10.1006/jmbi.1998.2364; Baldwin RL, 1999, TRENDS BIOCHEM SCI, V24, P77, DOI 10.1016/S0968-0004(98)01345-0; Baldwin RL, 2002, SCIENCE, V295, P1657, DOI 10.1126/science.1069893; Barbar E, 1999, BIOPOLYMERS, V51, P191, DOI 10.1002/(SICI)1097-0282(1999)51:3<191::AID-BIP3>3.0.CO;2-B; Bhavesh NS, 2001, FEBS LETT, V509, P218, DOI 10.1016/S0014-5793(01)03066-6; Chamberlain AK, 2000, ADV PROTEIN CHEM, V53, P283; CHYAN CL, 1993, BIOCHEMISTRY-US, V32, P5681, DOI 10.1021/bi00072a025; Dabora JM, 1996, BIOCHEMISTRY-US, V35, P11951, DOI 10.1021/bi9611671; Dill KA, 1997, NAT STRUCT BIOL, V4, P10, DOI 10.1038/nsb0197-10; Dinner AR, 2000, TRENDS BIOCHEM SCI, V25, P331, DOI 10.1016/S0968-0004(00)01610-8; Dobson Christopher M., 1999, Current Opinion in Structural Biology, V9, P92, DOI 10.1016/S0959-440X(99)80012-8; Dobson CM, 1998, NAT STRUCT BIOL, V5, P504, DOI 10.1038/744; Dyson HJ, 1996, ANNU REV PHYS CHEM, V47, P369, DOI 10.1146/annurev.physchem.47.1.369; Dyson HJ, 2001, METHOD ENZYMOL, V339, P258; Eliezer D, 2000, BIOCHEMISTRY-US, V39, P2894, DOI 10.1021/bi992545f; Eliezer D, 1998, NAT STRUCT BIOL, V5, P148; Englander SW, 2000, ANNU REV BIOPH BIOM, V29, P213, DOI 10.1146/annurev.biophys.29.1.213; FARROW NA, 1994, BIOCHEMISTRY-US, V33, P5984, DOI 10.1021/bi00185a040; FERSHT AR, 1999, STRUCTURE MECH PROTE, P517; GABORIAUD C, 1987, FEBS LETT, V224, P149, DOI 10.1016/0014-5793(87)80439-8; HUGHSON FM, 1990, SCIENCE, V249, P1544, DOI 10.1126/science.2218495; JENNINGS PA, 1993, SCIENCE, V262, P892, DOI 10.1126/science.8235610; Kazmirski SL, 2001, P NATL ACAD SCI USA, V98, P4349, DOI 10.1073/pnas.071054398; Killick TR, 1999, PROTEIN SCI, V8, P1286, DOI 10.1110/ps.8.6.1286; Klein-Seetharaman J, 2002, SCIENCE, V295, P1719, DOI 10.1126/science.1067680; Kumar M, 2002, BIOCHEM BIOPH RES CO, V294, P395, DOI 10.1016/S0006-291X(02)00482-5; Penkett CJ, 1997, J MOL BIOL, V274, P152, DOI 10.1006/jmbi.1997.1369; Pillai B, 2001, PROTEINS, V43, P57, DOI 10.1002/1097-0134(20010401)43:1<57::AID-PROT1017>3.0.CO;2-D; Plotkin SS, 2002, Q REV BIOPHYS, V35, P111, DOI 10.1017/S0033583502003761; Ramachandran G N, 1968, Adv Protein Chem, V23, P283, DOI 10.1016/S0065-3233(08)60402-7; Raschke TM, 1999, NAT STRUCT BIOL, V6, P825; Raschke TM, 1997, NAT STRUCT BIOL, V4, P298, DOI 10.1038/nsb0497-298; RICHARDS FM, 2002, ADV PROT CHEM UNFOLD, V42; SCHULMAN BA, 1995, J MOL BIOL, V253, P651, DOI 10.1006/jmbi.1995.0579; Schwarzinger S, 2002, BIOCHEMISTRY-US, V41, P12681, DOI 10.1021/bi020381o; Schwarzinger S, 2001, J AM CHEM SOC, V123, P2970, DOI 10.1021/ja003760i; Shortle D, 2001, SCIENCE, V293, P487, DOI 10.1126/science.1060438; Yao J, 2001, BIOCHEMISTRY-US, V40, P3561, DOI 10.1021/bi002776i	39	33	33	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 30	2003	278	22					19980	19985		10.1074/jbc.M301615200	http://dx.doi.org/10.1074/jbc.M301615200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	682EH	12644464	hybrid			2022-12-25	WOS:000183078000054
J	Zhou, RB; Wolk, CP				Zhou, RB; Wolk, CP			A two-component system mediates developmental regulation of biosynthesis of a heterocyst polysaccharide	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SP-STRAIN PCC-7120; SIGNAL-TRANSDUCTION PROTEIN; ANABAENA SP; CYANOBACTERIUM-ANABAENA; ESCHERICHIA-COLI; PCC 7120; NOSTOC-PUNCTIFORME; MOLECULAR ANALYSIS; NITROGEN-FIXATION; HEPARAN-SULFATE	Some cyanobacteria couple oxygenic photosynthesis in vegetative cells with O-2-sensitive N-2 fixation in differentiated cells called heterocysts. Heterocyst differentiation involves extensive biochemical and structural changes that collectively permit heterocysts to assimilate N-2 aerobically and supply the products of N-2 fixation to vegetative cells. HepK and DevR are required for the development of functional heterocysts in Anabaena and Nostoc, respectively. We show that HepK is an autokinase and that Anabaena DevR(A) is its cognate response regulator, together comprising part or all of a two-component system that mediates developmental regulation of biosynthesis of a heterocyst envelope polysaccharide. Recombinant N-hexahistidine-tagged HepK (H(6)HepK), the cytoplasmic portion H-6'HepK of H(6)HepK, H(6)DevR, and H(6)DevR(A) were overexpressed in Escherichia coli and purified to homogeneity. H-6'HepK, but not H(6)HepK, autophosphorylates with [gamma-P-32]ATP. ADP, specifically, elicits dephosphorylation of phosphorylated H-6'HepK. The phosphoryl group of H-6'HepK is transferred rapidly and efficiently to both H(6)DevR and H(6)DevRA but not to His-tagged OmpR, whose cognate sensor kinase is EnvZ. Sequence comparisons, the results of site-specific mutagenesis, and tests of chemical stability support identification of HepK-His(348) and DevR-Asp(53) as the phosphorylated residues. The mutation HepK-H348A abolishes both in vitro autokinase activity and in vivo functionality of HepK. Heterocysts of both hepK Anabaena and devR(A) Anabaena lack an envelope polysaccharide layer and are nonfunctional. Consistent with the normal site of deposition of that polysaccharide, a hepK::gfp transcriptional fusion is expressed principally in proheterocysts. HepK/DevR(A) is the first two-component system identified that regulates the biosynthesis of a polysaccharide as part of a patterned differentiation process.	Michigan State Univ, MSU DOE Plant Res Lab, E Lansing, MI 48824 USA; Michigan State Univ, Dept Plant Biol, E Lansing, MI 48824 USA; Anhui Normal Univ, Coll Life Sci, Wuhu 241000, Anhui, Peoples R China	Michigan State University; United States Department of Energy (DOE); Michigan State University; Anhui Normal University	Wolk, CP (corresponding author), Michigan State Univ, MSU DOE Plant Res Lab, E Lansing, MI 48824 USA.	wolk@msu.edu						AUSTIN S, 1994, J BACTERIOL, V176, P3460, DOI 10.1128/JB.176.12.3460-3465.1994; Bainbridge BW, 2001, ACTA ODONTOL SCAND, V59, P131, DOI 10.1080/000163501750266710; BLACK K, 1995, J BACTERIOL, V177, P6440, DOI 10.1128/jb.177.22.6440-6448.1995; BLACK TA, 1993, MOL MICROBIOL, V9, P77, DOI 10.1111/j.1365-2958.1993.tb01670.x; BLANCO G, 1993, MOL MICROBIOL, V9, P869, DOI 10.1111/j.1365-2958.1993.tb01745.x; BOURRET RB, 1990, P NATL ACAD SCI USA, V87, P41, DOI 10.1073/pnas.87.1.41; CAI YP, 1990, J BACTERIOL, V172, P3138, DOI 10.1128/jb.172.6.3138-3145.1990; Callahan SM, 2001, MOL MICROBIOL, V40, P941, DOI 10.1046/j.1365-2958.2001.02437.x; Campbell EL, 1996, J BACTERIOL, V178, P2037, DOI 10.1128/jb.178.7.2037-2043.1996; CARDEMIL L, 1979, J BIOL CHEM, V254, P736; CARDEMIL L, 1981, J PHYCOL, V17, P234; CARDEMIL L, 1981, BIOCHIM BIOPHYS ACTA, V674, P265, DOI 10.1016/0304-4165(81)90384-6; CHALFIE M, 1994, SCIENCE, V263, P802, DOI 10.1126/science.8303295; Cheng HP, 1998, J BACTERIOL, V180, P5183, DOI 10.1128/JB.180.19.5183-5191.1998; DHARMAWARDENE MW, 1973, ARCH MIKROBIOL, V90, P281, DOI 10.1007/BF00408924; DUCLOS B, 1991, METHOD ENZYMOL, V201, P10; ElhaI J, 1997, J BACTERIOL, V179, P1998, DOI 10.1128/jb.179.6.1998-2005.1997; ELHAI J, 1990, EMBO J, V9, P3379, DOI 10.1002/j.1460-2075.1990.tb07539.x; Ellehauge E, 1998, MOL MICROBIOL, V30, P807, DOI 10.1046/j.1365-2958.1998.01113.x; Esko JD, 2002, ANNU REV BIOCHEM, V71, P435, DOI 10.1146/annurev.biochem.71.110601.135458; Fabret C, 1999, J BACTERIOL, V181, P1975, DOI 10.1128/JB.181.7.1975-1983.1999; FAN Q, 2002, MICROBIAL PLANT META, P13; Federle MJ, 1999, J BACTERIOL, V181, P3649, DOI 10.1128/JB.181.12.3649-3657.1999; Fisher M, 2002, ANTICANCER RES, V22, P1737; FORST S, 1989, P NATL ACAD SCI USA, V86, P6052, DOI 10.1073/pnas.86.16.6052; Grebe TW, 1999, ADV MICROB PHYSIOL, V41, P139, DOI 10.1016/S0065-2911(08)60167-8; Hagen KD, 1999, J BACTERIOL, V181, P4430, DOI 10.1128/JB.181.14.4430-4434.1999; Heath A, 1999, INFECT IMMUN, V67, P5298, DOI 10.1128/IAI.67.10.5298-5305.1999; Hebbar PB, 2000, J BACTERIOL, V182, P3572, DOI 10.1128/JB.182.12.3572-3581.2000; Hidaka Y, 1997, FEBS LETT, V400, P238, DOI 10.1016/S0014-5793(96)01396-8; Hirsch AM, 1999, CURR OPIN PLANT BIOL, V2, P320, DOI 10.1016/S1369-5266(99)80056-9; HU NT, 1981, VIROLOGY, V114, P236, DOI 10.1016/0042-6822(81)90269-5; Hwang I, 2001, NATURE, V413, P383, DOI 10.1038/35096500; IUCHI S, 1992, J BACTERIOL, V174, P5617, DOI 10.1128/JB.174.17.5617-5623.1992; JIN SG, 1990, J BACTERIOL, V172, P525, DOI 10.1128/jb.172.2.525-530.1990; Kaneko T, 2001, DNA RES, V8, P205, DOI 10.1093/dnares/8.5.205; Koksharova OA, 2002, J BACTERIOL, V184, P3931, DOI 10.1128/JB.184.14.3931-3940.2002; Lander ES, 2001, NATURE, V409, P860, DOI 10.1038/35057062; LEE HS, 1993, J BACTERIOL, V175, P7683, DOI 10.1128/JB.175.23.7683-7688.1993; Liu DA, 2002, J BACTERIOL, V184, P6873, DOI 10.1128/JB.184.24.6873-6881.2002; Loomis WF, 1998, CURR OPIN MICROBIOL, V1, P643, DOI 10.1016/S1369-5274(98)80109-4; Lord E, 2000, TRENDS PLANT SCI, V5, P368, DOI 10.1016/S1360-1385(00)01744-1; Matsushita M, 2002, BIOORGAN MED CHEM, V10, P855, DOI 10.1016/S0968-0896(01)00355-8; MURRY MA, 1989, ARCH MICROBIOL, V151, P469, DOI 10.1007/BF00454860; Nigou J, 2002, MICROBES INFECT, V4, P945, DOI 10.1016/S1286-4579(02)01621-0; Ohmori M, 2001, DNA RES, V8, P271, DOI 10.1093/dnares/8.6.271; Pelley RP, 2000, CRIT REV ONCOGENESIS, V11, P189; Raetz CRH, 2002, ANNU REV BIOCHEM, V71, P635, DOI 10.1146/annurev.biochem.71.110601.135414; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Sasisekharan R, 2002, NAT REV CANCER, V2, P521, DOI 10.1038/nrc842; Shaulsky G, 1998, DEVELOPMENT, V125, P691; Showalter AM, 2001, CELL MOL LIFE SCI, V58, P1399, DOI 10.1007/PL00000784; Stephenson K., 2002, Current Drug Targets - Infectious Disorders, V2, P235, DOI 10.2174/1568005023342443; Stock AM, 2000, ANNU REV BIOCHEM, V69, P183, DOI 10.1146/annurev.biochem.69.1.183; STOCK JB, 1978, P NATL ACAD SCI USA, V75, P3659, DOI 10.1073/pnas.75.8.3659; Thelen JJ, 1998, J BIOL CHEM, V273, P26618, DOI 10.1074/jbc.273.41.26618; THOMAS J, 1977, J BACTERIOL, V129, P1545, DOI 10.1128/JB.129.3.1545-1555.1977; Thomason P, 2000, J CELL SCI, V113, P3141; Venter JC, 2001, SCIENCE, V291, P1304, DOI 10.1126/science.1058040; WALSBY A E, 1985, Proceedings of the Royal Society of London Series B Biological Sciences, V226, P345, DOI 10.1098/rspb.1985.0099; Willats WGT, 2001, PLANT MOL BIOL, V47, P9, DOI 10.1023/A:1010662911148; Wolk C.P., 1994, MOL BIOL CYANOBACTER, P769, DOI DOI 10.1007/978-94-011-0227-8_27; Wolk CP, 2000, PROKARYOTIC DEVELOPMENT, P83; Wong FCY, 2001, J BACTERIOL, V183, P2654, DOI 10.1128/JB.183.8.2654-2661.2001; Wu JG, 1999, P NATL ACAD SCI USA, V96, P13068, DOI 10.1073/pnas.96.23.13068; Xu XD, 2001, J BACTERIOL, V183, P393, DOI 10.1128/JB.183.1.393-396.2001; Yeh KC, 1998, P NATL ACAD SCI USA, V95, P13976, DOI 10.1073/pnas.95.23.13976; Zacharski LR, 2002, CURR OPIN PULM MED, V8, P379, DOI 10.1097/00063198-200209000-00006; Zhou RB, 2002, J BACTERIOL, V184, P2529, DOI 10.1128/JB.184.9.2529-2532.2002; Zhu JS, 1998, J BACTERIOL, V180, P4233, DOI 10.1128/JB.180.16.4233-4242.1998	70	30	33	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 30	2003	278	22					19939	19946		10.1074/jbc.M300577200	http://dx.doi.org/10.1074/jbc.M300577200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	682EH	12637541	hybrid			2022-12-25	WOS:000183078000049
J	Gong, XM; Agalarov, R; Brettel, K; Carmeli, C				Gong, XM; Agalarov, R; Brettel, K; Carmeli, C			Control of electron transport in photosystem I by the iron-sulfur cluster F-X in response to intra- and intersubunit interactions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SYNECHOCOCCUS-SP; ACCEPTOR COMPLEX; 4FE-4S CLUSTERS; CORE; CENTERS; PROTEIN; PSAC; A(1); IDENTIFICATION; RECONSTITUTION	Photosystem I (PS I) is a transmembraneal multisubunit complex that mediates light-induced electron transfer from plactocyanine to ferredoxin. The electron transfer proceeds from an excited chlorophyll a dimer (P700) through a chlorophyll a (A(0)), a phylloquinone (A(1)), and a [4Fe-4S] iron-sulfur cluster F-X, all located on the core subunits PsaA and PsaB, to iron-sulfur clusters F-A and F-B, located on subunit PsaC. Earlier, it was attempted to determine the function of F-X in the absence of F-A/B mainly by chemical dissociation of subunit PsaC. However, not all PsaC subunits could be removed from the PS I preparations by this procedure without partially damaging F-X. We therefore removed subunit PsaC by interruption of the psaC2 gene of PS I in the cyanobacterium Synechocystis sp. PCC 6803. Cells could not grow under photosynthetic conditions when subunit PsaC was deleted, yet the PsaC-deficient mutant cells grew under heterotrophic conditions and assembled the core subunits of PS I in which light-induced electron transfer from P700 to A(1) occurred. The photoreduction of F-X was largely inhibited, as seen from direct measurement of the extent of electron transfer from A(1) to F-X. From the crystal structure it can be seen that the removal of subunits PsaC, PsaD, and PsaE in the PsaC-deficient mutant resulted in the braking of salt bridges between these subunits and PsaB and PsaA and the formation of a net of two negative surface charges on PsaA/B. The potential induced on F-X by these surface charges is proposed to inhibit electron transport from the quinone. In the complete PS I complex, replacement of a cysteine ligand of F-X by serine in site-directed mutation C565S/D566E in subunit PsaB caused an similar to10-fold slow down of electron transfer from the quinone to F-X without much affecting the extent of this electron transfer compared with wild type. Based on these and other results, we propose that F-X might have a major role in controlling electron transfer through PS I.	Tel Aviv Univ, Dept Biochem, IL-69978 Tel Aviv, Israel; CEA Saclay, CNRS, URA 2096, F-91191 Gif Sur Yvette, France; CEA, Serv Bioenerget, F-91191 Gif Sur Yvette, France	Tel Aviv University; CEA; Centre National de la Recherche Scientifique (CNRS); CEA; UDICE-French Research Universities; Universite Paris Saclay	Carmeli, C (corresponding author), Tel Aviv Univ, Dept Biochem, IL-69978 Tel Aviv, Israel.	ccarmeli@post.tau.ac.il						ANDERSON SL, 1991, J BACTERIOL, V173, P2761, DOI 10.1128/JB.173.9.2761-2767.1991; ARNON DI, 1949, PLANT PHYSIOL, V24, P1, DOI 10.1104/pp.24.1.1; BERTINI I, 1995, EUR J BIOCHEM, V232, P192, DOI 10.1111/j.1432-1033.1995.tb20799.x; BRETTEL K, 1988, FEBS LETT, V239, P93, DOI 10.1016/0014-5793(88)80552-0; Brettel K, 1997, BBA-BIOENERGETICS, V1318, P322, DOI 10.1016/S0005-2728(96)00112-0; Brettel K, 1998, PHOTOSYNTHESIS: MECHANISMS AND EFFECTS, VOLS I-V, P611; BRETTEL K, 1989, BIOCHIM BIOPHYS ACTA, V976, P246, DOI 10.1016/S0005-2728(89)80237-3; Brettel K, 1995, PHOTOSYNTH RES, V45, P183, DOI 10.1007/BF00015559; Brettel K, 1998, BBA-BIOENERGETICS, V1363, P175, DOI 10.1016/S0005-2728(98)00010-3; CHITNIS PR, 1991, PHOTOSYNTHETIC APPAR, P177; CROWDER MS, 1983, BIOCHIM BIOPHYS ACTA, V722, P23, DOI 10.1016/0005-2728(83)90153-6; EVANS MCW, 1974, FEBS LETT, V49, P111, DOI 10.1016/0014-5793(74)80644-7; EVANS MCW, 1980, BIOCHIM BIOPHYS ACTA, V590, P89, DOI 10.1016/0005-2728(80)90148-6; Faller P, 2001, P NATL ACAD SCI USA, V98, P14368, DOI 10.1073/pnas.251382598; FISH LE, 1986, J BIOL CHEM, V261, P8134; GOLBECK JH, 1988, FEBS LETT, V228, P268, DOI 10.1016/0014-5793(88)80013-9; GOLBECK JH, 1976, ANAL BIOCHEM, V73, P539, DOI 10.1016/0003-2697(76)90205-0; GOLBECK JH, 1977, ARCH BIOCHEM BIOPHYS, V178, P140, DOI 10.1016/0003-9861(77)90178-3; Golbeck JH, 1991, CURRENT TOPICS BIOEN; GONG XM, 2002, THESIS TEL AVIV U TE; Guergova-Kuras M, 2001, P NATL ACAD SCI USA, V98, P4437, DOI 10.1073/pnas.081078898; HERBERT SK, 1992, P NATL ACAD SCI USA, V89, P8716, DOI 10.1073/pnas.89.18.8716; HIYAMA T, 1971, ARCH BIOCHEM BIOPHYS, V147, P99, DOI 10.1016/0003-9861(71)90314-6; HIYAMA T, 1978, BIOCHIM BIOPHYS ACTA, V257, P160; Joliot P, 1999, BIOCHEMISTRY-US, V38, P11130, DOI 10.1021/bi990857c; Jordan P, 2001, NATURE, V411, P909, DOI 10.1038/35082000; KING TE, 1967, METHOD ENZYMOL, V10, P634; Kurnikov IV, 2001, J PHYS CHEM B, V105, P5359, DOI 10.1021/jp002540o; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lanzilotta WN, 1997, BIOCHEMISTRY-US, V36, P12976, DOI 10.1021/bi9715371; LI N, 1991, BIOCHEMISTRY-US, V30, P7863, DOI 10.1021/bi00245a028; LOVENBERG W, 1963, J BIOL CHEM, V238, P3899; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LUNEBERG J, 1994, FEBS LETT, V338, P197, DOI 10.1016/0014-5793(94)80364-1; MARCUS RA, 1985, BIOCHIM BIOPHYS ACTA, V811, P265, DOI 10.1016/0304-4173(85)90014-X; MATHIAS RT, 1992, NATO ADV SCI I C-MAT, V335, P473; MEHARI T, 1991, BIOCHIM BIOPHYS ACTA, V1056, P139, DOI 10.1016/S0005-2728(05)80280-4; MOENNELOCCOZ P, 1994, BIOCHEMISTRY-US, V33, P10037, DOI 10.1021/bi00199a030; NECHUSHTAI R, 1983, P NATL ACAD SCI-BIOL, V80, P1179, DOI 10.1073/pnas.80.5.1179; PARRETT KG, 1989, BIOCHIM BIOPHYS ACTA, V973, P324, DOI 10.1016/S0005-2728(89)80439-6; PARRETT KG, 1990, BIOCHIM BIOPHYS ACTA, V1015, P341, DOI 10.1016/0005-2728(90)90039-7; PRENTKI P, 1984, GENE, V29, P303, DOI 10.1016/0378-1119(84)90059-3; Rabinowitz J, 1972, Methods Enzymol, V24, P431; RIPPKA R, 1979, J GEN MICROBIOL, V111, P1, DOI 10.1099/00221287-111-1-1; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SAUER K, 1978, BIOCHIM BIOPHYS ACTA, V503, P120, DOI 10.1016/0005-2728(78)90166-4; Schlodder E, 1998, BIOCHEMISTRY-US, V37, P9466, DOI 10.1021/bi973182r; SETIF P, 1989, BIOCHEMISTRY-US, V28, P2689, DOI 10.1021/bi00432a049; SETIF P, 1993, BIOCHEMISTRY-US, V32, P7846, DOI 10.1021/bi00082a002; Shen GZ, 2002, J BIOL CHEM, V277, P20355, DOI 10.1074/jbc.M201104200; SMART LB, 1993, P NATL ACAD SCI USA, V90, P1132, DOI 10.1073/pnas.90.3.1132; STEINMULLER K, 1992, PLANT MOL BIOL, V20, P997, DOI 10.1007/BF00027170; SUN ASK, 1971, BIOCHIM BIOPHYS ACTA, V234, P399, DOI 10.1016/0005-2728(71)90207-6; TINDALL KR, 1988, BIOCHEMISTRY-US, V27, P6008, DOI 10.1021/bi00416a027; Tjus SE, 2001, PLANT PHYSIOL, V125, P2007, DOI 10.1104/pp.125.4.2007; VANDEREST A, 1994, BIOCHEMISTRY-US, V33, P11789, DOI 10.1021/bi00205a015; Vassiliev IR, 1997, BIOPHYS J, V72, P301, DOI 10.1016/S0006-3495(97)78669-7; WARREN PV, 1993, BIOCHEMISTRY-US, V32, P4411, DOI 10.1021/bi00067a034; WILLIAMS JGK, 1988, METHOD ENZYMOL, V167, P766; Yu JP, 1997, J BIOL CHEM, V272, P8032, DOI 10.1074/jbc.272.12.8032; YU JP, 1995, PLANT MOL BIOL, V29, P331, DOI 10.1007/BF00043656; Zeng MT, 2002, BBA-BIOENERGETICS, V1556, P254, DOI 10.1016/S0005-2728(02)00370-5; Zeng MT, 1998, PHOTOSYNTHESIS: MECHANISMS AND EFFECTS, VOLS I-V, P643	64	20	22	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 23	2003	278	21					19141	19150		10.1074/jbc.M301808200	http://dx.doi.org/10.1074/jbc.M301808200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	679PY	12626505	hybrid			2022-12-25	WOS:000182932200056
J	Rossman, KL; Cheng, L; Mahon, GM; Rojas, RJ; Snyder, JT; Whitehead, IP; Sondek, J				Rossman, KL; Cheng, L; Mahon, GM; Rojas, RJ; Snyder, JT; Whitehead, IP; Sondek, J			Multifunctional roles for the PH domain of Dbs in regulating rho GTPase activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GUANINE-NUCLEOTIDE EXCHANGE; PLECKSTRIN HOMOLOGY DOMAIN; HIGH-AFFINITY BINDING; GUANOSINE TRIPHOSPHATASES; CRYSTAL-STRUCTURE; ONCOGENIC DBL; TRANSFORMATION; RAC; IDENTIFICATION; MUTAGENESIS	Dbl family members are guanine nucleotide exchange factors specific for Rho guanosine triphosphatases (GTPases) and invariably possess tandem Dbl (DH) and pleckstrin homology (PH) domains. Dbs, a Dbl family member specific for Cdc42 and RhoA, exhibits transforming activity when overexpressed in NIH 3T3 mouse fibroblasts. In this study, the PH domain of Dbs was mutated to impair selectively either guanine nucleotide exchange or phosphoinositide binding in vitro and resulting physiological alterations were assessed. As anticipated, substitution of residues within the PH domain of Dbs integral to the interface with GTPases reduced nucleotide exchange and eliminated the ability of Dbs to transform NIH 3T3 cells. More interestingly, substitutions within the PH domain that prevent interaction with phosphoinositides yet do not alter in vitro activation of GTPases also do not transform NIH 3T3 cell and fail to activate RhoA in vivo despite proper subcellular localization. Therefore, the PH domain of Dbs serves multiple roles in the activation of GTPases and cannot be viewed as a simple membrane-anchoring device. In particular, the data suggest that binding of phosphoinositides to the PH domain within the context of membrane surfaces may direct orientations or conformations of the linked DH and PH domains to regulate GTPases activation.	Univ N Carolina, Dept Pharmacol, Chapel Hill, NC 27599 USA; Univ N Carolina, Dept Biochem & Biophys, Chapel Hill, NC 27599 USA; Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA; Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Microbiol & Mol Genet, Newark, NJ 07103 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; Rutgers State University New Brunswick; Rutgers State University Medical Center	Sondek, J (corresponding author), Univ N Carolina, Dept Pharmacol, CB 7365,1106 MEJ Bldg, Chapel Hill, NC 27599 USA.			Sondek, John/0000-0002-1127-8310	NATIONAL CANCER INSTITUTE [R29CA077493] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM062299] Funding Source: NIH RePORTER; NCI NIH HHS [CA-77493] Funding Source: Medline; NIGMS NIH HHS [R01-GM62299] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aghazadeh B, 1998, NAT STRUCT BIOL, V5, P1098, DOI 10.1038/4209; Bishop AL, 2000, BIOCHEM J, V348, P241, DOI 10.1042/0264-6021:3480241; Chen RH, 1997, EMBO J, V16, P1351, DOI 10.1093/emboj/16.6.1351; Cheng L, 2002, MOL CELL BIOL, V22, P6895, DOI 10.1128/MCB.22.19.6895-6905.2002; CLARK GJ, 1995, METHOD ENZYMOL, V255, P395; CONNOLLY ML, 1993, J MOL GRAPH MODEL, V11, P139, DOI 10.1016/0263-7855(93)87010-3; Crompton AM, 2000, J BIOL CHEM, V275, P25751, DOI 10.1074/jbc.M002050200; Ewing TJA, 2001, J COMPUT AID MOL DES, V15, P411, DOI 10.1023/A:1011115820450; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Han JW, 1998, SCIENCE, V279, P558, DOI 10.1126/science.279.5350.558; HART MJ, 1994, J BIOL CHEM, V269, P62; Hoffman GR, 2002, FEBS LETT, V513, P85, DOI 10.1016/S0014-5793(01)03310-5; Isakoff SJ, 1998, EMBO J, V17, P5374, DOI 10.1093/emboj/17.18.5374; Kubiseski TJ, 1997, J BIOL CHEM, V272, P1799, DOI 10.1074/jbc.272.3.1799; LEMMON MA, 1995, P NATL ACAD SCI USA, V92, P10472, DOI 10.1073/pnas.92.23.10472; Lemmon MA, 2000, BIOCHEM J, V350, P1, DOI 10.1042/0264-6021:3500001; Lemmon MA, 2001, BIOCHEM SOC T, V29, P377, DOI 10.1042/BST0290377; Liu XH, 1998, CELL, V95, P269, DOI 10.1016/S0092-8674(00)81757-2; Myszka DG, 1997, CURR OPIN BIOTECH, V8, P50, DOI 10.1016/S0958-1669(97)80157-7; Nimnual AS, 1998, SCIENCE, V279, P560, DOI 10.1126/science.279.5350.560; Reid T, 1996, J BIOL CHEM, V271, P13556, DOI 10.1074/jbc.271.23.13556; Robbe K, 2003, J BIOL CHEM, V278, P4756, DOI 10.1074/jbc.M210412200; Rossman KL, 2002, EMBO J, V21, P1315, DOI 10.1093/emboj/21.6.1315; Russo C, 2001, J BIOL CHEM, V276, P19524, DOI 10.1074/jbc.M009742200; Schmidt A, 2002, GENE DEV, V16, P1587, DOI 10.1101/gad.1003302; Snyder JT, 2001, J BIOL CHEM, V276, P45868, DOI 10.1074/jbc.M106731200; Snyder JT, 2002, NAT STRUCT BIOL, V9, P468, DOI 10.1038/nsb796; Soisson SM, 1998, CELL, V95, P259, DOI 10.1016/S0092-8674(00)81756-0; VAN AL, 1997, GENE DEV, V11, P2295; Vanni C, 2002, J BIOL CHEM, V277, P19745, DOI 10.1074/jbc.M111025200; Welch HCE, 2002, CELL, V108, P809, DOI 10.1016/S0092-8674(02)00663-3; Wells CD, 2001, J BIOL CHEM, V276, P28897, DOI 10.1074/jbc.M102913200; WHITEHEAD I, 1995, ONCOGENE, V10, P713; WHITEHEAD I, 1995, J BIOL CHEM, V270, P18388, DOI 10.1074/jbc.270.31.18388; Whitehead IP, 1996, J BIOL CHEM, V271, P18643, DOI 10.1074/jbc.271.31.18643; Whitehead IP, 1997, BIOCHIM BIOPHYS ACTA, V1332, P1; Whitehead LP, 1999, MOL CELL BIOL, V19, P7759; Worthylake DK, 2000, NATURE, V408, P682, DOI 10.1038/35047014; Zheng J, 1997, J BIOL CHEM, V272, P30340, DOI 10.1074/jbc.272.48.30340; Zheng Y, 1996, J BIOL CHEM, V271, P19017, DOI 10.1074/jbc.271.32.19017	40	66	68	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 16	2003	278	20					18393	18400		10.1074/jbc.M300127200	http://dx.doi.org/10.1074/jbc.M300127200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677YX	12637522	Green Published			2022-12-25	WOS:000182838300105
J	Souto, RP; Vallega, G; Wharton, J; Vinten, J; Tranum-Jensen, J; Pilch, PF				Souto, RP; Vallega, G; Wharton, J; Vinten, J; Tranum-Jensen, J; Pilch, PF			Immunopurification and characterization of rat adipocyte caveolae suggest their dissociation from insulin signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STIMULATED GLUT4 TRANSLOCATION; PLASMA-MEMBRANE; CELL-SURFACE; LIPID RAFTS; GLUCOSE-TRANSPORT; ADIPOSE-CELLS; TYROSINE PHOSPHORYLATION; HETEROOLIGOMERIC COMPLEX; GLUT4-ENRICHED VESICLES; AMINE OXIDASE	Adipocytes play an important role in the insulin-dependent regulation of organismal fuel metabolism and express caveolae at levels as high or higher than any other cell type. Recently, a link between insulin signaling and caveolae has been suggested; nevertheless, adipocyte caveolae have been the subject of relatively few studies, and their contents have been minimally characterized. With the aid of a new monoclonal antibody, we developed a rapid procedure for the immunoisolation of caveolae derived from the plasma membrane of adipocytes, and we characterized their protein content. We find that immunopurified adipocyte caveolae have a relatively limited protein composition, and they lack the raft protein, flotillin, and insulin receptors. Immunogold labeling and electron microscopy of the adipocyte plasma membrane confirmed the lack of insulin receptors in caveolae. In addition to caveolins, the structural components of caveolae, their major protein constituents, are the semicarbazide-sensitive amine oxidase and the scavenger lipoprotein receptor CD36. The results are consistent with a role for caveolae in lipid flux in and of adipocytes.	Boston Univ, Sch Med, Dept Biochem, Boston, MA 02118 USA; Univ Copenhagen, Panum Inst, Dept Med Physiol, DK-2200 Copenhagen N, Denmark; Univ Copenhagen, Panum Inst, Dept Anat, DK-2200 Copenhagen N, Denmark	Boston University; University of Copenhagen; University of Copenhagen	Pilch, PF (corresponding author), Boston Univ, Sch Med, Dept Biochem, 715 Albany St,K412, Boston, MA 02118 USA.	ppilch@bu.edu	Souto, Ricardo/F-7828-2012	Souto, Ricardo/0000-0002-6281-5956; Pilch, Paul/0000-0003-1997-0499	NIDDK NIH HHS [DK56935, DK30425] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK030425, R01DK056935] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ABUMRAD NA, 1993, J BIOL CHEM, V268, P17665; Anderson RGW, 1998, ANNU REV BIOCHEM, V67, P199, DOI 10.1146/annurev.biochem.67.1.199; Baumann CA, 2000, NATURE, V407, P202, DOI 10.1038/35025089; Bergman RN, 1997, RECENT PROG HORM RES, V52, P359; Bickel PE, 1997, J BIOL CHEM, V272, P13793, DOI 10.1074/jbc.272.21.13793; Bickel PE, 2002, AM J PHYSIOL-ENDOC M, V282, pE1, DOI 10.1152/ajpendo.2002.282.1.E1; Brown DA, 2000, J BIOL CHEM, V275, P17221, DOI 10.1074/jbc.R000005200; CARPENTIER JL, 1976, J LIPID RES, V17, P335; CHAKRABARTI R, 1994, J BIOL CHEM, V269, P7926; Chiang SH, 2001, NATURE, V410, P944, DOI 10.1038/35073608; CONRAD PA, 1995, J CELL BIOL, V131, P1421, DOI 10.1083/jcb.131.6.1421; Drab M, 2001, SCIENCE, V293, P2449, DOI 10.1126/science.1062688; Enrique-Tarancon G, 1998, J BIOL CHEM, V273, P8025, DOI 10.1074/jbc.273.14.8025; Febbraio M, 1999, J BIOL CHEM, V274, P19055, DOI 10.1074/jbc.274.27.19055; Febbraio M, 2001, J CLIN INVEST, V108, P785, DOI 10.1172/JCI200114006; FIEDLER K, 1994, EMBO J, V13, P1729, DOI 10.1002/j.1460-2075.1994.tb06437.x; Fielding CJ, 2000, BBA-MOL CELL BIOL L, V1529, P210, DOI 10.1016/S1388-1981(00)00150-5; Fruhbeck G, 2001, AM J PHYSIOL-ENDOC M, V280, pE827, DOI 10.1152/ajpendo.2001.280.6.E827; Fujimoto T, 2001, J CELL BIOL, V152, P1079, DOI 10.1083/jcb.152.5.1079; Gagescu R, 2000, MOL BIOL CELL, V11, P2775, DOI 10.1091/mbc.11.8.2775; Galbiati F, 2001, CELL, V106, P403, DOI 10.1016/S0092-8674(01)00472-X; Gustavsson J, 1999, FASEB J, V13, P1961, DOI 10.1096/fasebj.13.14.1961; Henley JR, 1998, J CELL BIOL, V141, P85, DOI 10.1083/jcb.141.1.85; Jalkanen S, 2001, EMBO J, V20, P3893, DOI 10.1093/emboj/20.15.3893; JAMES DE, 1988, NATURE, V333, P183, DOI 10.1038/333183a0; Jiang ZY, 2002, J BIOL CHEM, V277, P509, DOI 10.1074/jbc.M108280200; KANDROR K, 1994, J BIOL CHEM, V269, P138; KANDROR KV, 1995, J CELL BIOL, V129, P999, DOI 10.1083/jcb.129.4.999; Kandror KV, 1996, AM J PHYSIOL-ENDOC M, V271, pE1, DOI 10.1152/ajpendo.1996.271.1.E1; KANDROR KV, 1995, BIOCHEM J, V307, P383, DOI 10.1042/bj3070383; Kanzaki M, 2001, J BIOL CHEM, V276, P42436, DOI 10.1074/jbc.M108297200; Karlsson M, 2001, FASEB J, V15, P249, DOI 10.1096/fj.01-0646fje; Kimura A, 2002, J BIOL CHEM, V277, P30153, DOI 10.1074/jbc.M203375200; Krieger M, 1999, ANNU REV BIOCHEM, V68, P523, DOI 10.1146/annurev.biochem.68.1.523; KUBLAOUI B, 1995, J BIOL CHEM, V270, P59, DOI 10.1074/jbc.270.1.59; Kurzchalia TV, 1999, CURR OPIN CELL BIOL, V11, P424, DOI 10.1016/S0955-0674(99)80061-1; Lee J, 1997, BIOCHEMISTRY-US, V36, P2701, DOI 10.1021/bi961815g; LISANTI MP, 1994, J CELL BIOL, V126, P111, DOI 10.1083/jcb.126.1.111; Liu PS, 1999, NAT CELL BIOL, V1, P369, DOI 10.1038/14067; Malide D, 2000, J CELL SCI, V113, P4203; MASTICK CC, 1995, J CELL BIOL, V129, P1523, DOI 10.1083/jcb.129.6.1523; Maxfield FR, 1997, ADV EXP MED BIOL, V419, P355; Moldes M, 1999, J BIOL CHEM, V274, P9515, DOI 10.1074/jbc.274.14.9515; Morris NJ, 1997, J BIOL CHEM, V272, P9388; Morrison RF, 2000, J NUTR, V130, p3116S, DOI 10.1093/jn/130.12.3116S; Neudauer CL, 1998, CURR BIOL, V8, P1151, DOI 10.1016/S0960-9822(07)00486-1; Nystrom FH, 1999, MOL ENDOCRINOL, V13, P2013, DOI 10.1210/me.13.12.2013; Oh P, 1999, J BIOL CHEM, V274, P23144, DOI 10.1074/jbc.274.33.23144; Oh P, 1998, J CELL BIOL, V141, P101, DOI 10.1083/jcb.141.1.101; Ostermeyer AG, 2001, J CELL BIOL, V152, P1071, DOI 10.1083/jcb.152.5.1071; Parton RG, 2002, J BIOL CHEM, V277, P46769, DOI 10.1074/jbc.M205683200; Parton RG, 2003, NAT REV MOL CELL BIO, V4, P162, DOI 10.1038/nrm1017; PILCH PF, 1983, J CELL BIOL, V96, P133, DOI 10.1083/jcb.96.1.133; Pol A, 2001, J CELL BIOL, V152, P1057, DOI 10.1083/jcb.152.5.1057; Pol A, 1999, HEPATOLOGY, V29, P1848, DOI 10.1002/hep.510290602; Razani B, 2002, J BIOL CHEM, V277, P8635, DOI 10.1074/jbc.M110970200; Razani B, 2001, J BIOL CHEM, V276, P38121; ROBINSON LJ, 1992, J CELL BIOL, V117, P1181, DOI 10.1083/jcb.117.6.1181; RODBELL M, 1964, J BIOL CHEM, V239, P375; Ros-Baro A, 2001, P NATL ACAD SCI USA, V98, P12050, DOI 10.1073/pnas.211341698; SATOH S, 1993, J BIOL CHEM, V268, P17820; Scherer PE, 1997, J BIOL CHEM, V272, P29337, DOI 10.1074/jbc.272.46.29337; SCHERER PE, 1994, J CELL BIOL, V127, P1233, DOI 10.1083/jcb.127.5.1233; SCHERER PE, 1995, J BIOL CHEM, V270, P16395, DOI 10.1074/jbc.270.27.16395; SCHNITZER JE, 1995, P NATL ACAD SCI USA, V92, P1759, DOI 10.1073/pnas.92.5.1759; SIMPSON IA, 1983, BIOCHIM BIOPHYS ACTA, V763, P393, DOI 10.1016/0167-4889(83)90101-5; SLOT JW, 1985, EUR J CELL BIOL, V38, P87; Smart EJ, 1999, MOL CELL BIOL, V19, P7289; Souza SC, 1998, J BIOL CHEM, V273, P24665, DOI 10.1074/jbc.273.38.24665; Stan RV, 1997, MOL BIOL CELL, V8, P595, DOI 10.1091/mbc.8.4.595; THOIDIS G, 1993, J BIOL CHEM, V268, P11691; Thomsen P, 2002, MOL BIOL CELL, V13, P238, DOI 10.1091/mbc.01-06-0317; Vainio S, 2002, EMBO REP, V3, P95, DOI 10.1093/embo-reports/kvf010; Vinten J, 2001, CELL TISSUE RES, V305, P99, DOI 10.1007/s004410100389; VOLDSTEDLUND M, 1993, J MEMBRANE BIOL, V136, P63; Volonte D, 1999, J BIOL CHEM, V274, P12702, DOI 10.1074/jbc.274.18.12702; Watson RT, 2001, J CELL BIOL, V154, P829, DOI 10.1083/jcb.200102078; Westermann M, 1999, HISTOCHEM CELL BIOL, V111, P71, DOI 10.1007/s004180050335; Wiley HS, 2001, TRAFFIC, V2, P12, DOI 10.1034/j.1600-0854.2001.020103.x; Yamamoto M, 1998, J BIOL CHEM, V273, P26962, DOI 10.1074/jbc.273.41.26962	80	82	82	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 16	2003	278	20					18321	18329		10.1074/jbc.M211541200	http://dx.doi.org/10.1074/jbc.M211541200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677YX	12637562	hybrid			2022-12-25	WOS:000182838300096
J	Bagheri-Yarmand, R; Vadlamudi, RK; Kumar, R				Bagheri-Yarmand, R; Vadlamudi, RK; Kumar, R			Activating transcription factor 4 overexpression inhibits proliferation and differentiation of mammary epithelium resulting in impaired lactation and accelerated involution	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLAND DEVELOPMENT; LEUCINE-ZIPPER; DNA-BINDING; CELL-DEATH; TRANSGENIC MICE; LOBULOALVEOLAR DEVELOPMENT; TARGETED EXPRESSION; RESPONSE ELEMENT; C/EBP-BETA; CYCLIN D1	The basic leucine zipper containing activating transcription factors (ATFs) modulates the expression of growth-regulating genes. In this study, we sought to determine specifically the consequences of ATF4 expression on mammary gland development in transgenic mice. Overexpression of ATF4 severely impaired normal development of the mammary gland, which was associated with reduced proliferation and differentiation of mammary alveolar epithelium and up-regulation of p21(WAF1) and p27(Kip1). In addition, there was also impaired lactation accompanied by decreased expression of alpha-lactoalbumin, whey acidic protein, and beta-casein, possibly because of the down-regulation of STAT5a tyrosine phosphorylation. Mammary gland involution in ATF4-transgenic mice was accelerated, compared with wild type littermates by whole mount analysis. In addition, day 18 of lactation in transgenic mice was phenotypically equivalent to day 3 of involution in wild type mice, as determined by the TUNEL assay and expression of Bax. The concentration of the proapoptotic molecule caspase-3 was increased during lactation in ATF4-transgenic animal. Mammary glands from ATF4-transgenic mice also showed significant nuclear translocation of activated STAT3 and up-regulation of one of its target genes, insulin-like growth factor-binding protein-5, which is thought to facilitate apoptosis by sequestering insulin-like growth factor. Together, these findings suggest that ATF4 may play a role during mammary gland development and that down-regulation of ATF4 may be important for the onset of involution in the mammary gland.	Univ Texas, MD Anderson Canc Ctr, Dept Mol & Cellular Oncol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center	Bagheri-Yarmand, R (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Mol & Cellular Oncol, 1515 Holcombe Blvd,108, Houston, TX 77030 USA.			Bagheri-Yarmand, Rozita/0000-0001-5139-6381	NCI NIH HHS [CA16672, CA 90970] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA016672, R01CA090970] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; Butscher WG, 1998, J BIOL CHEM, V273, P552, DOI 10.1074/jbc.273.1.552; Chapman RS, 1999, GENE DEV, V13, P2604, DOI 10.1101/gad.13.19.2604; Chapman RS, 2000, ONCOGENE, V19, P6386, DOI 10.1038/sj.onc.1204016; CHEVRAY PM, 1992, P NATL ACAD SCI USA, V89, P5789, DOI 10.1073/pnas.89.13.5789; FANTL V, 1995, GENE DEV, V9, P2364, DOI 10.1101/gad.9.19.2364; Fata JE, 2000, CELL, V103, P41, DOI 10.1016/S0092-8674(00)00103-3; Fawcett TW, 1999, BIOCHEM J, V339, P135, DOI 10.1042/0264-6021:3390135; Gachon F, 1998, J VIROL, V72, P8332, DOI 10.1128/JVI.72.10.8332-8337.1998; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; Gombart A. F., 1997, Proceedings of the American Association for Cancer Research Annual Meeting, V38, P185; Hadsell DL, 1996, ENDOCRINOLOGY, V137, P321, DOI 10.1210/en.137.1.321; HAI T, 1991, P NATL ACAD SCI USA, V88, P3720, DOI 10.1073/pnas.88.9.3720; Hai T, 2001, GENE, V273, P1, DOI 10.1016/S0378-1119(01)00551-0; Heermeier K, 1996, MECH DEVELOP, V56, P197, DOI 10.1016/0925-4773(96)88032-4; Hengst L, 1996, SCIENCE, V271, P1861, DOI 10.1126/science.271.5257.1861; Hettmann T, 2000, DEV BIOL, V222, P110, DOI 10.1006/dbio.2000.9699; Jones FE, 1999, ONCOGENE, V18, P3481, DOI 10.1038/sj.onc.1202698; Jones FE, 1999, J CELL BIOL, V147, P77, DOI 10.1083/jcb.147.1.77; Jove R, 2000, ONCOGENE, V19, P2466, DOI 10.1038/sj.onc.1203549; JUNGLING S, 1994, EUR J BIOCHEM, V226, P925, DOI 10.1111/j.1432-1033.1994.00925.x; KARPINSKI BA, 1992, P NATL ACAD SCI USA, V89, P4820, DOI 10.1073/pnas.89.11.4820; Kato Y, 1999, MOL CELL ENDOCRINOL, V154, P151, DOI 10.1016/S0303-7207(99)00078-7; Krane IM, 1996, ONCOGENE, V12, P1781; Lassot I, 2001, MOL CELL BIOL, V21, P2192, DOI 10.1128/MCB.21.6.2192-2202.2001; Liang GS, 1997, J BIOL CHEM, V272, P24088, DOI 10.1074/jbc.272.38.24088; Liu XW, 1997, GENE DEV, V11, P179, DOI 10.1101/gad.11.2.179; Lundgren K, 1997, GENE DEV, V11, P714, DOI 10.1101/gad.11.6.714; MARTE BM, 1995, MOL ENDOCRINOL, V9, P14, DOI 10.1210/me.9.1.14; Mielnicki LM, 1996, BIOCHEM BIOPH RES CO, V228, P586, DOI 10.1006/bbrc.1996.1702; Millard SS, 1997, J BIOL CHEM, V272, P7093, DOI 10.1074/jbc.272.11.7093; Miyoshi K, 2001, J CELL BIOL, V155, P531, DOI 10.1083/jcb.200107065; Neuenschwander S, 1996, J CLIN INVEST, V97, P2225, DOI 10.1172/JCI118663; NISHIZAWA M, 1992, FEBS LETT, V299, P36, DOI 10.1016/0014-5793(92)80094-W; Pati D, 1999, MOL CELL BIOL, V19, P5001; Philp JAC, 1996, FEBS LETT, V396, P77, DOI 10.1016/0014-5793(96)01069-1; PRODUST LM, 2001, J BIOL CHEM, V276, P505; Reddy TR, 1997, ONCOGENE, V14, P2785, DOI 10.1038/sj.onc.1201119; Robinson GW, 1998, GENE DEV, V12, P1907, DOI 10.1101/gad.12.12.1907; ROBINSON GW, 1995, DEVELOPMENT, V121, P2079; Seagroves TN, 1998, GENE DEV, V12, P1917, DOI 10.1101/gad.12.12.1917; Sheaff RJ, 1997, GENE DEV, V11, P1464, DOI 10.1101/gad.11.11.1464; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Shimizu M, 1998, EXP CELL RES, V239, P93, DOI 10.1006/excr.1997.3884; SICINSKI P, 1995, CELL, V82, P621, DOI 10.1016/0092-8674(95)90034-9; STRANGE R, 1992, DEVELOPMENT, V115, P49; TALAMANTES F, 1984, AM J PHYSIOL, V247, P126; Talukder AH, 2000, CANCER RES, V60, P276; Tanaka T, 1998, GENES CELLS, V3, P801, DOI 10.1046/j.1365-2443.1998.00230.x; Teglund S, 1998, CELL, V93, P841, DOI 10.1016/S0092-8674(00)81444-0; Tonner E, 2002, DEVELOPMENT, V129, P4547; Tonner E, 1997, ENDOCRINOLOGY, V138, P5101, DOI 10.1210/en.138.12.5101; Travers MT, 1996, ENDOCRINOLOGY, V137, P1530, DOI 10.1210/en.137.5.1530; VALLEJO M, 1993, P NATL ACAD SCI USA, V90, P4679, DOI 10.1073/pnas.90.10.4679; VINSON CR, 1993, GENE DEV, V7, P1047, DOI 10.1101/gad.7.6.1047; WALKER NI, 1989, AM J ANAT, V185, P19, DOI 10.1002/aja.1001850104; Wang RA, 2002, EMBO J, V21, P5437, DOI 10.1093/emboj/cdf543	57	33	37	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 9	2003	278	19					17421	17429		10.1074/jbc.M300761200	http://dx.doi.org/10.1074/jbc.M300761200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677QG	12611881	hybrid, Green Published			2022-12-25	WOS:000182818600129
J	Yu, ASL; Enck, AH; Lencer, WI; Schneeberger, EE				Yu, ASL; Enck, AH; Lencer, WI; Schneeberger, EE			Claudin-8 expression in Madin-Darby canine kidney cells augments the paracellular barrier to cation permeation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TIGHT JUNCTION STRANDS; EPITHELIAL-CELLS; MDCK CELLS; RABBIT GALLBLADDER; SELECTIVE CHANNELS; ADHESION MOLECULE; PROTEIN; OCCLUDIN; PERMEABILITY; MECHANISM	Claudins are a family of integral membrane proteins of the tight junction that are thought to participate in the permeation of solutes across epithelia via the paracellular pathway. Claudin-8 is expressed in the distal renal tubule, which has a characteristically low passive permeability to monovalent cations. To test the hypothesis that claudin-8 plays a role in forming a tight paracellular barrier to cations, stably transfected Madin-Darby canine kidney II cell lines with inducible expression of claudin-8 were generated. Induction of claudin-8 expression was associated with down-regulation of endogenous claudin-2 protein. Other tight junction proteins were expressed and targeted normally, and the number of junctional strands was minimally altered. By Ussing chamber and radiotracer flux studies, claudin-8 expression was found to reduce paracellular permeability to monovalent inorganic and organic cations and to divalent cations but not to anions or neutral solutes. The size selectivity, charge dependence, and activation energy of paracellular cation permeation were all unchanged. These observations are consistent with a model in which claudin-2 encodes a highly cation-permeable channel, whereas claudin-8 acts primarily as a cation barrier. When exogenous claudin-8 is expressed, it replaces endogenous claudin-2, inserting in its place into existing tight junction strands, thereby reducing the apparent number of functional cation pores. Our findings suggest that claudin-8 plays an important role in the paracellular cation barrier of the distal renal tubule.	Univ So Calif, Keck Sch Med, Div Nephrol, Dept Med, Los Angeles, CA 90033 USA; Univ So Calif, Keck Sch Med, Dept Physiol & Biophys, Los Angeles, CA 90033 USA; Brigham & Womens Hosp, Div Renal, Boston, MA 02115 USA; Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA; Childrens Hosp, Dept Pediat, Boston, MA 02115 USA; Harvard Digest Dis Ctr, Boston, MA 02115 USA	University of Southern California; University of Southern California; Harvard University; Brigham & Women's Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Boston Children's Hospital; Harvard University; Harvard Medical School	Yu, ASL (corresponding author), Univ So Calif, Keck Sch Med, Div Nephrol, Dept Med, 2025 Zonal Ave,RMR 406, Los Angeles, CA 90033 USA.	alanyu@usc.edu	Yu, Alan/AID-7467-2022	Yu, Alan/0000-0002-1776-2533; Lencer, Wayne/0000-0001-7346-2730	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL025822] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK034854] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL25822] Funding Source: Medline; NIDDK NIH HHS [DK34854] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Amasheh S, 2002, J CELL SCI, V115, P4969, DOI 10.1242/jcs.00165; BARRY PH, 1971, J MEMBRANE BIOL, V4, P358, DOI 10.1007/BF02431979; BARRY PH, 1970, J MEMBRANE BIOL, V3, P93, DOI [10.1007/BF01868022, 10.1007/BF01868023]; CEREIJIDO M, 1978, J CELL BIOL, V77, P853, DOI 10.1083/jcb.77.3.853; Cohen CJ, 2001, P NATL ACAD SCI USA, V98, P15191, DOI 10.1073/pnas.261452898; Colegio OR, 2002, AM J PHYSIOL-CELL PH, V283, pC142, DOI 10.1152/ajpcell.00038.2002; Cunningham SA, 2000, J BIOL CHEM, V275, P34750, DOI 10.1074/jbc.M002718200; DeCoursey TE, 1998, J GEN PHYSIOL, V112, P503, DOI 10.1085/jgp.112.4.503; Denker BM, 1998, AM J PHYSIOL-RENAL, V274, pF1, DOI 10.1152/ajprenal.1998.274.1.F1; DIAMOND JM, 1969, ANNU REV PHYSIOL, V31, P581, DOI 10.1146/annurev.ph.31.030169.003053; Dowland LK, 2000, J BIOL CHEM, V275, P37765, DOI 10.1074/jbc.M004840200; DWYER TM, 1980, J GEN PHYSIOL, V75, P469, DOI 10.1085/jgp.75.5.469; Fanning AS, 1999, J AM SOC NEPHROL, V10, P1337; FINKELST.A, 1970, BIOCHIM BIOPHYS ACTA, V205, P1, DOI 10.1016/0005-2728(70)90055-1; Furuse M, 1998, J CELL BIOL, V143, P391, DOI 10.1083/jcb.143.2.391; FURUSE M, 1993, J CELL BIOL, V123, P1777, DOI 10.1083/jcb.123.6.1777; Furuse M, 1999, J CELL BIOL, V147, P891, DOI 10.1083/jcb.147.4.891; Furuse M, 2001, J CELL BIOL, V153, P263, DOI 10.1083/jcb.153.2.263; Furuse M, 2002, J CELL BIOL, V156, P1099, DOI 10.1083/jcb.200110122; Inai T, 1999, EUR J CELL BIOL, V78, P849, DOI 10.1016/S0171-9335(99)80086-7; Itoh M, 1999, J CELL BIOL, V147, P1351, DOI 10.1083/jcb.147.6.1351; KIMIZUKA H, 1964, J THEOR BIOL, V6, P290, DOI 10.1016/0022-5193(64)90035-9; Kiuchi-Saishin Y, 2002, J AM SOC NEPHROL, V13, DOI 10.1681/ASN.V134875; Kobayashi J, 2002, HISTOCHEM CELL BIOL, V117, P29, DOI 10.1007/s00418-001-0359-x; LU Y, 2001, J AM SOC NEPHROL, V12, P756; Martin-Padura I, 1998, J CELL BIOL, V142, P117, DOI 10.1083/jcb.142.1.117; McCarthy KM, 2000, J CELL SCI, V113, P3387; McCarthy KM, 1996, J CELL SCI, V109, P2287; McCleskey EW, 1999, J GEN PHYSIOL, V113, P765, DOI 10.1085/jgp.113.6.765; MISFELDT DS, 1976, P NATL ACAD SCI USA, V73, P1212, DOI 10.1073/pnas.73.4.1212; MORENO JH, 1975, J MEMBRANE BIOL, V21, P197, DOI 10.1007/BF01941070; Morita K, 1999, P NATL ACAD SCI USA, V96, P511, DOI 10.1073/pnas.96.2.511; Nasdala I, 2002, J BIOL CHEM, V277, P16294, DOI 10.1074/jbc.M111999200; Rahner C, 2001, GASTROENTEROLOGY, V120, P411, DOI 10.1053/gast.2001.21736; Reyes JL, 2002, KIDNEY INT, V62, P476, DOI 10.1046/j.1523-1755.2002.00479.x; Simon DB, 1999, SCIENCE, V285, P103, DOI 10.1126/science.285.5424.103; Tsukita S, 2000, J CELL BIOL, V149, P13, DOI 10.1083/jcb.149.1.13; Turksen K, 2002, DEVELOPMENT, V129, P1775; Van Itallie C, 2001, J CLIN INVEST, V107, P1319, DOI 10.1172/JCI12464; WEDNER HJ, 1969, J MEMBRANE BIOL, V1, P92, DOI 10.1007/BF01869776; WRIGHT EM, 1971, J MEMBRANE BIOL, V4, P331, DOI 10.1007/BF02431978; YU A, 2001, J AM SOC NEPHROL, V12, P45	42	226	236	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 9	2003	278	19					17350	17359		10.1074/jbc.M213286200	http://dx.doi.org/10.1074/jbc.M213286200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677QG	12615928	hybrid, Green Published			2022-12-25	WOS:000182818600121
J	Bohula, EA; Salisbury, AJ; Sohail, M; Playford, MP; Riedemann, J; Southern, EM; Macaulay, VM				Bohula, EA; Salisbury, AJ; Sohail, M; Playford, MP; Riedemann, J; Southern, EM; Macaulay, VM			The efficacy of small interfering RNAs targeted to the type 1 insulin-like growth factor receptor (IGF1R) is influenced by secondary structure in the IGF1R transcript	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR-I RECEPTOR; CULTURED-MAMMALIAN-CELLS; DOUBLE-STRANDED-RNA; ANTISENSE OLIGONUCLEOTIDES; MELANOMA-CELLS; EXPRESSION; HYBRIDIZATION; CLEAVAGE; SIRNAS; CANCER	The type 1 insulin-like growth factor receptor (IGF1R) is often overexpressed by tumors and mediates growth and apoptosis protection. We previously showed that antisense reagents complementary to the IGF1R translation start site enhance radio- and chemosensitivity and impair Atm function. However these agents induce relatively modest IGF1R down-regulation and affect insulin receptor levels. To identify alternative sites for molecular targeting, we utilized scanning oligonucleotide arrays to probe the secondary structure of IGF1R mRNA. This strategy enabled selection of antisense oligonucleotides that generated high heteroduplex yield with IGF1R but not insulin receptor transcripts. Antisense oligonucleotides that hybridized strongly to IGF1R mRNA caused IGF1R down-regulation within intact tumor cells, whereas weakly hybridizing oligonucleotides were inactive. Furthermore, the ability of small interfering RNAs (siRNAs) to block IGF1R expression correlated with the accessibility of the target sequence within the transcript. Thus, siRNAs corresponding to weakly hybridizing oligonucleotides caused minor IGF1R down-regulation, whereas siRNAs homologous to accessible targets induced profound sequence-specific IGF1R gene silencing, blocked IGF signaling, and enhanced tumor cell radiosensitivity. This indicates that secondary structure in the target transcript has a major effect on siRNA efficacy. These findings have implications for siRNA design and suggest that IGF1R-targeting agents incorporating this mode of action have potential as anticancer therapy.	Weatherall Inst Mol Med, Canc Res UK Mol Oncol Labs, Oxford OX3 9DS, England; Univ Oxford, Dept Biochem, Oxford OX1 3QU, England	University of Oxford; University of Oxford	Macaulay, VM (corresponding author), Weatherall Inst Mol Med, Canc Res UK Mol Oncol Labs, Headley Way,Headington, Oxford OX3 9DS, England.		Bohula, Erin/AAW-7276-2020					DONISKELLER H, 1979, NUCLEIC ACIDS RES, V7, P179, DOI 10.1093/nar/7.1.179; Dunbar PR, 2000, J IMMUNOL, V165, P6644, DOI 10.4049/jimmunol.165.11.6644; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Elbashir SM, 2001, EMBO J, V20, P6877, DOI 10.1093/emboj/20.23.6877; Fire A, 1998, NATURE, V391, P806, DOI 10.1038/35888; Hakam A, 1999, HUM PATHOL, V30, P1128, DOI 10.1016/S0046-8177(99)90027-8; Hammond SM, 2001, NAT REV GENET, V2, P110, DOI 10.1038/35052556; Harborth J, 2001, J CELL SCI, V114, P4557; Hellawell GO, 2003, BJU INT, V91, P271, DOI 10.1046/j.1464-410X.2003.04061.x; Hellawell GO, 2002, CANCER RES, V62, P2942; Holen T, 2002, NUCLEIC ACIDS RES, V30, P1757, DOI 10.1093/nar/30.8.1757; Kanter-Lewensohn L, 2000, GROWTH FACTORS, V17, P193, DOI 10.3109/08977190009001068; Lee NS, 2002, NAT BIOTECHNOL, V20, P500, DOI 10.1038/nbt0502-500; Ligensa T, 2001, J BIOL CHEM, V276, P33419, DOI 10.1074/jbc.M104509200; LIMA WF, 1992, BIOCHEMISTRY-US, V31, P12055, DOI 10.1021/bi00163a013; Macaulay VM, 2001, ONCOGENE, V20, P4029, DOI 10.1038/sj.onc.1204565; Martinez J, 2002, CELL, V110, P563, DOI 10.1016/S0092-8674(02)00908-X; MICHEL F, 1990, J MOL BIOL, V216, P585, DOI 10.1016/0022-2836(90)90386-Z; RESNICOFF M, 1994, CANCER RES, V54, P4848; Sohail M, 2002, Adv Biochem Eng Biotechnol, V77, P43; Sohail M, 2001, NUCLEIC ACIDS RES, V29, P2041, DOI 10.1093/nar/29.10.2041; Sohail M, 1999, RNA, V5, P646, DOI 10.1017/S1355838299982195; Stein CA, 2001, J CLIN INVEST, V108, P641, DOI 10.1172/JCI13885; ULLRICH A, 1986, EMBO J, V5, P2503, DOI 10.1002/j.1460-2075.1986.tb04528.x; Valentinis, 1997, BIOCHIM BIOPHYS ACTA, V1332, P105; Vickers TA, 2003, J BIOL CHEM, V278, P7108, DOI 10.1074/jbc.M210326200; Wraight CJ, 2000, NAT BIOTECHNOL, V18, P521, DOI 10.1038/75382	27	199	235	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 2	2003	278	18					15991	15997		10.1074/jbc.M300714200	http://dx.doi.org/10.1074/jbc.M300714200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	675EL	12604614	hybrid			2022-12-25	WOS:000182680000069
J	Nojima, H; Tokunaga, C; Eguchi, S; Oshiro, N; Hidayat, S; Yoshino, K; Hara, K; Tanaka, N; Avruch, J; Yonezawa, K				Nojima, H; Tokunaga, C; Eguchi, S; Oshiro, N; Hidayat, S; Yoshino, K; Hara, K; Tanaka, N; Avruch, J; Yonezawa, K			The mammalian target of rapamycin (mTOR) partner, raptor, binds the mTOR substrates p70 S6 kinase and 4E-BP1 through their TOR signaling (TOS) motif	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; CELL-GROWTH; AMINO-ACID; PHAS-I; EIF-4E BP1; PHOSPHORYLATION; PATHWAY; IDENTIFICATION; TRANSLATION; INSULIN	The mammalian target of rapamycin (mTOR) controls multiple cellular functions in response to amino acids and growth factors, in part by regulating the phosphorylation of p70 S6 kinase (p70S6k) and eukaryotic initiation factor 4E-binding protein 1 (4E-BP1). Raptor (regulatory associated protein of mTOR) is a recently identified mTOR binding partner that also binds p70S6k and 4E-BP1 and is essential for TOR signaling in vivo. Herein we demonstrate that raptor binds to p70S6k and 4E-BP1 through their respective TOS (conserved TOR signaling) motifs to be required for amino acid- and mTOR-dependent regulation of these mTOR substrates in vivo. A point mutation of the TOS motif also eliminates all in vitro mTOR-catalyzed 4E-BP1 phosphorylation and abolishes the raptor-dependent component of mTOR-catalyzed p70S6k phosphorylation in vitro. Raptor appears to serve as an mTOR scaffold protein, the binding of which to the TOS motif of mTOR substrates is necessary for effective mTOR-catalyzed phosphorylation in vivo and perhaps for conferring their sensitivity to rapamycin and amino acid sufficiency.	Kobe Univ, Biosignal Res Ctr, Nada Ku, Kobe, Hyogo 6578501, Japan; Japan Sci & Technol Corp, CREST, Okayama 7000914, Japan; Okayama Univ, Grad Sch Med & Dent, Dept Gastroenterol Surg Transplant & Surg Oncol, Okayama 7000914, Japan; Massachusetts Gen Hosp, Dept Mol Biol, Boston, MA 02114 USA; Massachusetts Gen Hosp, Diabet Unit, Med Serv, Boston, MA 02114 USA; Harvard Univ, Sch Med, Dept Med, Boston, MA 02114 USA	Kobe University; Japan Science & Technology Agency (JST); Okayama University; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School	Yonezawa, K (corresponding author), Kobe Univ, Biosignal Res Ctr, Nada Ku, 1-1 Rokkodai Cho, Kobe, Hyogo 6578501, Japan.				NATIONAL CANCER INSTITUTE [R01CA073818] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK017776, R37DK017776] Funding Source: NIH RePORTER; NCI NIH HHS [CA 73818] Funding Source: Medline; NIDDK NIH HHS [DK 17776] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Alessi DR, 1998, CURR BIOL, V8, P69, DOI 10.1016/S0960-9822(98)70037-5; Avruch J, 2001, Prog Mol Subcell Biol, V26, P115; BROWN EJ, 1995, NATURE, V377, P441, DOI 10.1038/377441a0; Brunn GJ, 1997, SCIENCE, V277, P99, DOI 10.1126/science.277.5322.99; Burnett PE, 1998, P NATL ACAD SCI USA, V95, P1432, DOI 10.1073/pnas.95.4.1432; CHUNG J, 1992, CELL, V69, P1227, DOI 10.1016/0092-8674(92)90643-Q; Fox HL, 1998, AM J PHYSIOL-CELL PH, V274, pC206, DOI 10.1152/ajpcell.1998.274.1.C206; Hara K, 1997, J BIOL CHEM, V272, P26457, DOI 10.1074/jbc.272.42.26457; Hara K, 2002, CELL, V110, P177, DOI 10.1016/S0092-8674(02)00833-4; Hara K, 1998, J BIOL CHEM, V273, P14484, DOI 10.1074/jbc.273.23.14484; Isotani S, 1999, J BIOL CHEM, V274, P34493, DOI 10.1074/jbc.274.48.34493; Kim DH, 2002, CELL, V110, P163, DOI 10.1016/S0092-8674(02)00808-5; Kwiatkowski DJ, 2002, HUM MOL GENET, V11, P525, DOI 10.1093/hmg/11.5.525; LIN TA, 1995, J BIOL CHEM, V270, P18531, DOI 10.1074/jbc.270.31.18531; Loewith R, 2002, MOL CELL, V10, P457, DOI 10.1016/S1097-2765(02)00636-6; Manning BD, 2002, MOL CELL, V10, P151, DOI 10.1016/S1097-2765(02)00568-3; Nishiuma T, 1998, BIOCHEM BIOPH RES CO, V252, P440, DOI 10.1006/bbrc.1998.9671; Patti ME, 1998, J CLIN INVEST, V101, P1519, DOI 10.1172/JCI1326; PEARSON RB, 1995, EMBO J, V14, P5279, DOI 10.1002/j.1460-2075.1995.tb00212.x; PRICE DJ, 1992, SCIENCE, V257, P973, DOI 10.1126/science.1380182; Schalm SS, 2002, CURR BIOL, V12, P632, DOI 10.1016/S0960-9822(02)00762-5; Schmelzle T, 2000, CELL, V103, P253, DOI 10.1016/S0092-8674(00)00117-3; Shigemitsu K, 1999, J BIOL CHEM, V274, P1058, DOI 10.1074/jbc.274.2.1058; vonManteuffel SR, 1996, P NATL ACAD SCI USA, V93, P4076, DOI 10.1073/pnas.93.9.4076; Wang XM, 1998, BIOCHEM J, V334, P261, DOI 10.1042/bj3340261; Weng QP, 1998, J BIOL CHEM, V273, P16621, DOI 10.1074/jbc.273.26.16621; WENG QP, 1995, MOL CELL BIOL, V15, P2333; Xu G, 1998, J BIOL CHEM, V273, P28178, DOI 10.1074/jbc.273.43.28178	28	484	501	1	28	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 2	2003	278	18					15461	15464		10.1074/jbc.C200665200	http://dx.doi.org/10.1074/jbc.C200665200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	675EL	12604610	hybrid, Green Published, Green Submitted			2022-12-25	WOS:000182680000002
J	Bell, M; Engelberg, D				Bell, M; Engelberg, D			Phosphorylation of Tyr-176 of the yeast MAPK Hog1/p38 is not vital for Hog1 biological activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; SIGNAL-TRANSDUCTION; PATHWAY; TRANSCRIPTION; STRESS; ERK2; KSS1	Mitogen-activated protein kinases are crucial components in the life of eukaryotic cells. The current dogma for MAPK activation is that dual phosphorylation of neighboring Thr and Tyr residues at the phosphorylation lip is an absolute requirement for their catalytic and biological activity. In this study we addressed the role of Tyr and Thr phosphorylation in the yeast MAPK Hog1/p38. Taking advantage of the recently isolated hyperactive mutants, whose intrinsic basal activity is independent of upstream regulation, we demonstrate that Tyr-176 is not required for basal catalytic and biological activity but is essential for the salt-induced amplification of Hog1 catalysis. We show that intact Thr-174 is absolutely essential for biology and catalysis of the mutants but is mainly required for structural reasons and not as a phosphoacceptor. The roles of Thr-174 and Tyr-176 in wild type Hog1 molecules were also tested. Unexpectedly we found that Hog1(Y176F) is biologically active, capable of induction of Hog1 target genes and of rescuing hog1Delta cells from osmotic stress. Hog1(Y176F) was not able, however, to mediate growth arrest induced by constitutively active MAPK kinase/Pbs2. We propose that Thr-174 is essential for stabilizing the basal active conformation, whereas Tyr-176 is not. Tyr-176 serves as a regulatory element required for stimuli-induced amplification of kinase activity.	Hebrew Univ Jerusalem, Inst Life Sci, Dept Biol Chem, IL-91904 Jerusalem, Israel	Hebrew University of Jerusalem	Engelberg, D (corresponding author), Hebrew Univ Jerusalem, Inst Life Sci, Dept Biol Chem, IL-91904 Jerusalem, Israel.							Bardwell L, 1998, GENE DEV, V12, P2887, DOI 10.1101/gad.12.18.2887; Bell M, 2001, J BIOL CHEM, V276, P25351, DOI 10.1074/jbc.M101818200; Bellon S, 1999, STRUCTURE, V7, P1057, DOI 10.1016/S0969-2126(99)80173-7; Bilsland-Marchesan E, 2000, MOL CELL BIOL, V20, P3887, DOI 10.1128/MCB.20.11.3887-3895.2000; Blume-Jensen P, 2001, NATURE, V411, P355, DOI 10.1038/35077225; Canagarajah BJ, 1997, CELL, V90, P859, DOI 10.1016/S0092-8674(00)80351-7; CHEN W, 1987, CELL, V50, P1047, DOI 10.1016/0092-8674(87)90171-1; COBB MH, 1995, J BIOL CHEM, V270, P14843, DOI 10.1074/jbc.270.25.14843; Cobb MH, 2000, TRENDS BIOCHEM SCI, V25, P7, DOI 10.1016/S0968-0004(99)01508-X; Cohen P, 2001, EUR J BIOCHEM, V268, P5001, DOI 10.1046/j.0014-2956.2001.02473.x; Cohen P, 2002, NAT CELL BIOL, V4, pE127, DOI 10.1038/ncb0502-e127; Davis RJ, 2000, CELL, V103, P239, DOI 10.1016/S0092-8674(00)00116-1; GARTNER A, 1992, GENE DEV, V6, P1280, DOI 10.1101/gad.6.7.1280; HUNTER T, 1992, CELL, V70, P375, DOI 10.1016/0092-8674(92)90162-6; Khokhlatchev AV, 1998, CELL, V93, P605, DOI 10.1016/S0092-8674(00)81189-7; Kyriakis JM, 2001, PHYSIOL REV, V81, P807, DOI 10.1152/physrev.2001.81.2.807; Madhani HD, 1997, CELL, V91, P673, DOI 10.1016/S0092-8674(00)80454-7; Ono K, 2000, CELL SIGNAL, V12, P1, DOI 10.1016/S0898-6568(99)00071-6; Pearson G, 2001, ENDOCR REV, V22, P153, DOI 10.1210/er.22.2.153; Prowse CN, 2001, J BIOL CHEM, V276, P40817, DOI 10.1074/jbc.M105860200; ROBBINS DJ, 1993, J BIOL CHEM, V268, P5097; SCHULLER C, 1994, EMBO J, V13, P4382, DOI 10.1002/j.1460-2075.1994.tb06758.x; Warmka J, 2001, MOL CELL BIOL, V21, P51, DOI 10.1128/MCB.21.1.51-60.2001	23	33	38	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 25	2003	278	17					14603	14606		10.1074/jbc.C300006200	http://dx.doi.org/10.1074/jbc.C300006200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	672HX	12637550	hybrid			2022-12-25	WOS:000182516100005
J	Slutsky, SG; Kamaraju, AK; Levy, AM; Chebath, J; Revel, M				Slutsky, SG; Kamaraju, AK; Levy, AM; Chebath, J; Revel, M			Activation of myelin genes during transdifferentiation from melanoma to glial cell phenotype	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR SOX10; CULTURED SCHWANN-CELLS; INTERLEUKIN-6 RECEPTOR-INTERLEUKIN-6 CHIMERA; PROTEIN ZERO GENES; HUMAN MBP PROMOTER; WAARDENBURG-SYNDROME; GROWTH-INHIBITION; TRANSGENIC MICE; NERVOUS-SYSTEM; MESSENGER-RNA	Induction of myelin genes occurs around birth in the last stage of Schwann cells differentiation and is reactivated in case of nerve injury. Previous studies showed that activation of the gp130 receptor system, using as ligand interleukin-6 fused to its soluble receptor (IL6RIL6), causes induction of myelin genes such as myelin basic protein (MBP) and myelin protein zero (Po) in embryonic dorsal root ganglia Schwann cells. We also reported that in murine melanoma B16/F10.9 cells, IL6RIL6 causes a shut-off of melanogenesis mediated by a down-regulation of the paired-homeodomain factor Pax3. The present work demonstrates that these IL6RIL6-treated F10.9 cells undergo transdifferentiation to a myelinating glial phenotype characterized by induction of the transcriptional activities of both Po and MBP promoters and accumulation of myelin gene products. For both Po and MBP promoters, a repression by Pax3 and stimulation by Sox10 can be demonstrated. Because after IL6RIL6-treatment, Pax3 disappears from the F10.9 cells (as it does in mature myelinating Schwann cells) whereas the level of Sox10 rather increases, we modulated the relative level of these factors and show their involvement in the induction of myelin gene expression by IL6RIL6. In addition, however, we show that a C/G-rich CACC box in the Po promoter is required for activation by IL6RIL6, as well as by ectopic Sox10, and identify a Kruppel-type zinc finger factor acting through this CACC box, which stimulates Po promoter activity.	Weizmann Inst Sci, Dept Mol Genet, IL-76100 Rehovot, Israel	Weizmann Institute of Science	Revel, M (corresponding author), Weizmann Inst Sci, Dept Mol Genet, IL-76100 Rehovot, Israel.			Slutsky, Guy/0000-0001-5135-5694; Chebath, Judith/0000-0002-8151-7428				Bai LC, 2000, J BIOL CHEM, V275, P30725, DOI 10.1074/jbc.M004249200; Betz UAK, 1998, J EXP MED, V188, P1955, DOI 10.1084/jem.188.10.1955; Bondurand N, 2000, HUM MOL GENET, V9, P1907, DOI 10.1093/hmg/9.13.1907; Bondurand N, 2001, HUM MOL GENET, V10, P2783, DOI 10.1093/hmg/10.24.2783; BOSMAN C, 1995, TUMORI, V81, P208, DOI 10.1177/030089169508100312; Brown AM, 1997, J BIOL CHEM, V272, P28939, DOI 10.1074/jbc.272.46.28939; CHAVRIER P, 1990, EMBO J, V9, P1209, DOI 10.1002/j.1460-2075.1990.tb08228.x; Chebath J, 1997, EUR CYTOKINE NETW, V8, P359; Cheng LL, 1996, NEURON, V16, P309, DOI 10.1016/S0896-6273(00)80049-5; Desarnaud F, 2000, BRAIN RES, V865, P12, DOI 10.1016/S0006-8993(00)02130-2; Desarnaud F, 1998, J NEUROCHEM, V71, P1765; DONG Z, 1995, NEURON, V15, P585, DOI 10.1016/0896-6273(95)90147-7; Dupin E, 2000, P NATL ACAD SCI USA, V97, P7882, DOI 10.1073/pnas.97.14.7882; FORAN DR, 1992, J NEUROSCI, V12, P4890; Forghani R, 2001, J NEUROSCI, V21, P3780, DOI 10.1523/JNEUROSCI.21-11-03780.2001; GOUJETZALC C, 1993, EUR J NEUROSCI, V5, P624, DOI 10.1111/j.1460-9568.1993.tb00528.x; GOW A, 1992, J CELL BIOL, V119, P605, DOI 10.1083/jcb.119.3.605; Haggiag S, 2001, J NEUROSCI RES, V64, P564, DOI 10.1002/jnr.1108; Haggiag S, 1999, FEBS LETT, V457, P200, DOI 10.1016/S0014-5793(99)01040-6; Jessen KR, 1998, MICROSC RES TECHNIQ, V41, P393, DOI 10.1002/(SICI)1097-0029(19980601)41:5<393::AID-JEMT6>3.0.CO;2-R; JESSEN KR, 1991, GLIA, V4, P185, DOI 10.1002/glia.440040210; Kamachi Y, 2000, TRENDS GENET, V16, P182, DOI 10.1016/S0168-9525(99)01955-1; Kamaraju AK, 2002, J BIOL CHEM, V277, P15132, DOI 10.1074/jbc.M200004200; KATZ A, 1993, J IMMUNOTHER, V13, P98, DOI 10.1097/00002371-199302000-00004; KIOUSSI C, 1995, NEURON, V15, P553, DOI 10.1016/0896-6273(95)90144-2; Kioussi C, 1996, TRENDS GENET, V12, P84, DOI 10.1016/0168-9525(96)81411-9; Kollet O, 1999, BLOOD, V94, P923, DOI 10.1182/blood.V94.3.923.415k08_923_931; Kuhlbrodt K, 1998, J NEUROSCI, V18, P237, DOI 10.1523/jneurosci.18-01-00237.1998; Law DJ, 1999, BIOCHEM BIOPH RES CO, V262, P113, DOI 10.1006/bbrc.1999.1180; Law GL, 1998, J BIOL CHEM, V273, P19955, DOI 10.1074/jbc.273.32.19955; LEDOUARIN NM, 1994, CURR OPIN GENET DEV, V4, P685, DOI 10.1016/0959-437X(94)90135-P; Lee M, 2000, J BIOL CHEM, V275, P37978, DOI 10.1074/jbc.M003816200; LEMKE G, 1988, NEURON, V1, P73, DOI 10.1016/0896-6273(88)90211-5; LEMKE G, 1988, DEVELOPMENT, V102, P499; LI XB, 1994, J NEUROCHEM, V63, P28; Melnikova IN, 2000, NEUROPHARMACOLOGY, V39, P2615, DOI 10.1016/S0028-3908(00)00125-8; MESSING A, 1992, NEURON, V8, P507, DOI 10.1016/0896-6273(92)90279-M; MIURA M, 1989, GENE, V75, P31; MONUKI ES, 1993, MECH DEVELOP, V42, P15, DOI 10.1016/0925-4773(93)90095-F; MORGAN L, 1994, DEVELOPMENT, V120, P1399; MORGAN L, 1991, J CELL BIOL, V112, P457, DOI 10.1083/jcb.112.3.457; Nagarajan R, 2001, NEURON, V30, P355, DOI 10.1016/S0896-6273(01)00282-3; Oh JW, 1997, ONCOGENE, V15, P569, DOI 10.1038/sj.onc.1201213; Peirano RI, 2000, MOL CELL BIOL, V20, P3198, DOI 10.1128/MCB.20.9.3198-3209.2000; PORGADOR A, 1989, J IMMUNOGENET, V16, P291; Potterf SB, 2000, HUM GENET, V107, P1, DOI 10.1007/s004390050001; Reed JA, 1999, AM J PATHOL, V155, P549, DOI 10.1016/S0002-9440(10)65150-4; Saberan-Djoneidi D, 2000, GENE, V248, P223, DOI 10.1016/S0378-1119(00)00116-5; SPRINKLE TJ, 1985, NEUROCHEM RES, V10, P919, DOI 10.1007/BF00964629; Stoll G, 1999, BRAIN PATHOL, V9, P313; Stolt CC, 2002, GENE DEV, V16, P165, DOI 10.1101/gad.215802; Taga T, 1997, ANNU REV IMMUNOL, V15, P797, DOI 10.1146/annurev.immunol.15.1.797; TOPILKO P, 1994, NATURE, V371, P796, DOI 10.1038/371796a0; TRAPP BD, 1988, J NEUROSCI, V8, P3515; Verastegui C, 2000, J BIOL CHEM, V275, P30757, DOI 10.1074/jbc.C000445200; Watanabe A, 1998, NAT GENET, V18, P283, DOI 10.1038/ng0398-283; Wegner M, 2000, GLIA, V29, P118, DOI 10.1002/(SICI)1098-1136(20000115)29:2<118::AID-GLIA4>3.0.CO;2-Q; WRABETZ L, 1993, J NEUROSCI RES, V36, P455, DOI 10.1002/jnr.490360412; Wrabetz L, 1998, J NEUROBIOL, V34, P10, DOI 10.1002/(SICI)1097-4695(199801)34:1<10::AID-NEU2>3.0.CO;2-F; ZHANG XP, 1993, J NEUROCHEM, V60, P2010, DOI 10.1111/j.1471-4159.1993.tb03485.x; Zorick TS, 1996, CURR OPIN CELL BIOL, V8, P870, DOI 10.1016/S0955-0674(96)80090-1; Zorick TS, 1999, DEVELOPMENT, V126, P1397	62	41	44	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 14	2003	278	11					8960	8968		10.1074/jbc.M210569200	http://dx.doi.org/10.1074/jbc.M210569200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	654YF	12643284	hybrid			2022-12-25	WOS:000181524000014
J	Chuang, JI; Chang, TY; Liu, HS				Chuang, JI; Chang, TY; Liu, HS			Glutathione depletion-induced apoptosis of Ha-ras-transformed NIH3T3 cells can be prevented by melatonin	ONCOGENE			English	Article						reactive oxygen species; glutathione; melatonine; apoptosis; Ha-ras	CANCER CELLS; BUTHIONINE SULFOXIMINE; SELECTIVE ACTIVATION; NIH/3T3 CELLS; NEWBORN RATS; IN-VITRO; GROWTH; EXPRESSION; ONCOGENE; DEATH	It is well known that intracellular antioxidant glutathione (GSH) plays major roles in the maintenance of redox status and defense of oxidative stress. Ras, a small GTP-binding protein, may send growth-stimulating message to the nucleus through downstream Rac oncoprotein and superoxide (O-2(radical anion)). These findings led us to investigate the effects of GSH and melatonin, a free-radical scavenger, on Ras-Rac-O-2(radical anion)-related growth signal transduction. Our results demonstrate that overexpression of the inducible Ha-ras oncogene by isopropyl-beta-D-thiogalactoside (IPTG) increases the levels of reactive oxygen species (ROS, including O-2(radical anion) and hydrogen peroxide (H2O2)) and GSH in an Ha-ras-transformed NIH/3T3 fibroblast cell line. On the contrary, melatonin significantly suppresses ras-triggered cell growth by inhibiting the increase of ROS and GSH. Moreover, severe apoptosis of this transformed cell line occurred when the cell redox balance between ROS and GSH was dramatically changed in the presence of IPTG and L-buthionine-[S,R]-sulfoximine (BSO, a specific inhibitor of GSH synthetase). That BSO-induced cell apoptosis needs Ras to increase the ROS level was demonstrated by the free-radical scavenger melatonin. It effectively blocked cell apoptosis, but cell growth was also slowed without affecting Ras expression. Based on our studies, two approaches can be applied to treating ras-related cancers. One is utilizing melatonin to suppress cancer cell proliferation, and the other is utilizing BSO to induce cancer-cell apoptosis. Cotreatment of ras-related cancer cells with melatonin and BSO stops cell growth as well as apoptosis. Whether these cancer cells will undergo further regression or become recurrent merits investigation.	Natl Cheng Kung Univ, Coll Med, Dept Microbiol & Immunol, Tainan 701, Taiwan; Natl Cheng Kung Univ, Coll Med, Dept Physiol, Tainan 701, Taiwan; Natl Cheng Kung Univ, Coll Med, Dept Parasitol, Tainan 701, Taiwan	National Cheng Kung University; National Cheng Kung University; National Cheng Kung University	Liu, HS (corresponding author), Natl Cheng Kung Univ, Coll Med, Dept Microbiol & Immunol, Tainan 701, Taiwan.			Liu, Hsiao-Sheng/0000-0003-0576-7203				ABE M, 1994, J PINEAL RES, V17, P94, DOI 10.1111/j.1600-079X.1994.tb00119.x; Agapito MT, 2001, J PINEAL RES, V31, P23, DOI 10.1034/j.1600-079X.2001.310104.x; Barranco SC, 2000, DIS COLON RECTUM, V43, P1133, DOI 10.1007/BF02236562; Beal MF, 1998, BBA-BIOENERGETICS, V1366, P211, DOI 10.1124/jpet.112.192138; Blask DE, 1997, CANCER RES, V57, P1909; Chang MY, 1999, EXP CELL RES, V248, P589, DOI 10.1006/excr.1999.4436; Chen ST, 1999, EXP BRAIN RES, V124, P241, DOI 10.1007/s002210050619; Chen ST, 2002, J PINEAL RES, V32, P262, DOI 10.1034/j.1600-079X.2002.01871.x; Chuang JI, 2001, J CHEM NEUROANAT, V21, P215, DOI 10.1016/S0891-0618(01)00109-0; Cos S, 2000, FRONT NEUROENDOCRIN, V21, P133, DOI 10.1006/frne.1999.0194; Granzotto M, 2001, J PINEAL RES, V31, P206, DOI 10.1034/j.1600-079X.2001.310303.x; Griffith OW, 1999, FREE RADICAL BIO MED, V27, P922, DOI 10.1016/S0891-5849(99)00176-8; Guha A, 1998, CAN J NEUROL SCI, V25, P267, DOI 10.1017/S0317167100034272; GUO N, 1992, NEUROSCIENCE, V51, P835, DOI 10.1016/0306-4522(92)90524-6; Irani K, 1998, BIOCHEM PHARMACOL, V55, P1339; Irani K, 1997, SCIENCE, V275, P1649, DOI 10.1126/science.275.5306.1649; ITO M, 1984, J INTERFERON RES, V22, P603; Joneson T, 1998, J BIOL CHEM, V273, P17991, DOI 10.1074/jbc.273.29.17991; Karbownik M, 2001, INT J BIOCHEM CELL B, V33, P735, DOI 10.1016/S1357-2725(01)00059-0; Kilic E, 1999, J CEREBR BLOOD F MET, V19, P511, DOI 10.1097/00004647-199905000-00005; Kuo ML, 1996, BIOCHEM PHARMACOL, V52, P481, DOI 10.1016/0006-2952(96)00251-1; Li ZR, 1997, J PINEAL RES, V22, P117, DOI 10.1111/j.1600-079X.1997.tb00312.x; Lissoni P, 1996, ONCOLOGY, V53, P43; LISSONI P, 1999, METATONIN PROMOTION, P175; Liu HS, 1998, BRIT J CANCER, V77, P1777, DOI 10.1038/bjc.1998.296; Marelli MM, 2000, PROSTATE, V45, P238, DOI 10.1002/1097-0045(20001101)45:3<238::AID-PROS6>3.0.CO;2-W; Mayo JC, 1998, J PINEAL RES, V25, P12, DOI 10.1111/j.1600-079X.1998.tb00380.x; Mediavilla MD, 1999, LIFE SCI, V65, P415, DOI 10.1016/S0024-3205(99)00262-3; MEISTER A, 1994, CANCER RES, V54, pS1969; MILLER AC, 1993, MOL CELL BIOL, V13, P4416, DOI 10.1128/MCB.13.7.4416; Neri B, 1998, ANTICANCER RES, V18, P1329; OLANOW CW, 1993, TRENDS NEUROSCI, V16, P439, DOI 10.1016/0166-2236(93)90070-3; Panzer A, 1998, CANCER LETT, V122, P17, DOI 10.1016/S0304-3835(97)00360-1; Petranka J, 1999, J PINEAL RES, V26, P129, DOI 10.1111/j.1600-079X.1999.tb00574.x; Reiter RJ, 2000, J BIOMED SCI, V7, P444, DOI 10.1007/BF02253360; Reiter RJ, 2002, CARDIOVASC DRUG THER, V16, P5, DOI 10.1023/A:1015376328431; Roth JA, 1997, BRAIN RES, V768, P63, DOI 10.1016/S0006-8993(97)00549-0; ROTHE G, 1990, J LEUKOCYTE BIOL, V47, P440, DOI 10.1002/jlb.47.5.440; Schnelldorfer T, 2000, CANCER-AM CANCER SOC, V89, P1440, DOI 10.1002/1097-0142(20001001)89:7<1440::AID-CNCR5>3.3.CO;2-S; Seyfried J, 1999, NEUROSCI LETT, V264, P1, DOI 10.1016/S0304-3940(99)00107-X; THRALL BD, 1991, CARCINOGENESIS, V12, P1319, DOI 10.1093/carcin/12.7.1319; Toffa S, 1997, J NEURAL TRANSM, V104, P67, DOI 10.1007/BF01271295; Vahrmeijer AL, 2000, BIOCHEM PHARMACOL, V59, P1557, DOI 10.1016/S0006-2952(00)00286-0; WALSH AC, 1995, CANCER LETT, V95, P105, DOI 10.1016/0304-3835(95)03871-S; Weijzen S, 1999, LEUKEMIA, V13, P502, DOI 10.1038/sj.leu.2401367; Xu MF, 2001, J PINEAL RES, V31, P301, DOI 10.1034/j.1600-079X.2001.310403.x	46	48	52	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 6	2003	22	9					1349	1357		10.1038/sj.onc.1206289	http://dx.doi.org/10.1038/sj.onc.1206289			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	652CA	12618760				2022-12-25	WOS:000181360900009
J	Akbar, MT; Lundberg, AMC; Liu, K; Vidyadaran, S; Wells, KE; Dolatshad, H; Wynn, S; Wells, DJ; Latchman, DS; de Belleroche, J				Akbar, MT; Lundberg, AMC; Liu, K; Vidyadaran, S; Wells, KE; Dolatshad, H; Wynn, S; Wells, DJ; Latchman, DS; de Belleroche, J			The neuroprotective effects of heat shock protein 27 overexpression in transgenic animals against kainate-induced seizures and hippocampal cell death	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMALL STRESS PROTEINS; KAINIC ACID; NEURONAL CELLS; CYTOCHROME-C; IN-VIVO; MOLECULAR CHAPERONES; NEGATIVE REGULATOR; CARDIAC MYOCYTES; CULTURED NEURONS; GANGLION NEURONS	The 27-kDa heat shock protein (HSP27) has a potent ability to increase cell survival in response to a wide range of cellular challenges. In order to investigate the mode of action of HSP27 in vivo, we have developed transgenic lines, which express human HSP27 at high levels throughout the brain, spinal cord, and other tissues. In view of the particular property of HSP27 compared with other HSPs to protect neurons against apoptosis, we have tested these transgenic lines in a well established in vivo model of neurotoxicity produced by kainic acid, where apoptotic cell death occurs. Our results demonstrate for the first time the marked protective effects of HSP27 overexpression in vivo, which significantly reduces kainate-induced seizure severity and mortality rate (> 50%) in two independent lines and markedly reduces neuronal cell death in the CA3 region of hippocampus. This reduced seizure severity in HSP27 transgenic animals was associated with a marked attenuation of caspase 3 induction and apoptotic features. These studies clearly demonstrate that HSP27 has a major neuroprotective effect in the central nervous system in keeping with its properties demonstrated in culture and highlight an early stage in the cell death pathway that is affected by HSP27.	Charing Cross Hosp, Imperial Coll, Fac Med, Dept Neuromuscular Dis,Div Neurosci & Psychol Med, London W6 8RF, England; UCL, Inst Child Hlth, London WC1N 1EH, England	Imperial College London; University of London; University College London	de Belleroche, J (corresponding author), Charing Cross Hosp, Imperial Coll, Fac Med, Dept Neuromuscular Dis,Div Neurosci & Psychol Med, Fulham Palace Rd, London W6 8RF, England.	j.belleroche@imperial.ac.uk	Vidyadaran, Sharmili/S-9616-2019	Dolatshad, Hamid/0000-0002-4724-1720; Wells, Dominic/0000-0002-1425-6344				Akbar MT, 2001, MOL BRAIN RES, V93, P148, DOI 10.1016/S0169-328X(01)00199-1; Amin V, 1996, NEUROSCI LETT, V206, P45, DOI 10.1016/0304-3940(96)12421-6; AMIN V, 1995, NEUROSCI LETT, V200, P85, DOI 10.1016/0304-3940(95)12074-E; Becker AJ, 1999, MOL BRAIN RES, V67, P172, DOI 10.1016/S0169-328X(99)00060-1; BENARI Y, 1985, NEUROSCIENCE, V14, P375, DOI 10.1016/0306-4522(85)90299-4; Bengzon J, 1997, P NATL ACAD SCI USA, V94, P10432, DOI 10.1073/pnas.94.19.10432; Benjamin IJ, 1998, CIRC RES, V83, P117, DOI 10.1161/01.RES.83.2.117; Benn SC, 2002, NEURON, V36, P45, DOI 10.1016/S0896-6273(02)00941-8; Brar BK, 1999, J MOL CELL CARDIOL, V31, P135, DOI 10.1006/jmcc.1998.0857; Bruey JM, 2000, NAT CELL BIOL, V2, P645, DOI 10.1038/35023595; CARPER SW, 1990, NUCLEIC ACIDS RES, V18, P6457, DOI 10.1093/nar/18.21.6457; Charette SJ, 2000, MOL CELL BIOL, V20, P7602, DOI 10.1128/MCB.20.20.7602-7612.2000; Chen ZG, 2002, BRAIN RES, V931, P135, DOI 10.1016/S0006-8993(02)02268-0; Christians ES, 2002, CRIT CARE MED, V30, pS43, DOI 10.1097/00003246-200201001-00006; Cumming DVE, 1996, BASIC RES CARDIOL, V91, P79; Cumming DVE, 1996, J MOL CELL CARDIOL, V28, P2343, DOI 10.1006/jmcc.1996.0227; Djebaili M, 2001, MOL BRAIN RES, V93, P190, DOI 10.1016/S0169-328X(01)00197-8; Ehrnsperger M, 1997, EMBO J, V16, P221, DOI 10.1093/emboj/16.2.221; Feder ME, 1999, ANNU REV PHYSIOL, V61, P243, DOI 10.1146/annurev.physiol.61.1.243; FROHLI E, 1993, GENE, V128, P273, DOI 10.1016/0378-1119(93)90574-M; Gillardon F, 1997, MOL BRAIN RES, V50, P16, DOI 10.1016/S0169-328X(97)00162-9; HEADS RJ, 1995, J MOL CELL CARDIOL, V27, P1669, DOI 10.1016/S0022-2828(95)90722-X; Hu RQ, 1998, BRAIN RES, V810, P229, DOI 10.1016/S0006-8993(98)00863-4; Hutter JJ, 1996, CIRCULATION, V94, P1408, DOI 10.1161/01.CIR.94.6.1408; Juan TSC, 1996, ONCOGENE, V13, P749; Kaasinen K, 2000, EUR J NEUROSCI, V12, P540, DOI 10.1046/j.1460-9568.2000.00940.x; Kalwy SA, 2003, MOL BRAIN RES, V111, P91, DOI 10.1016/S0169-328X(02)00692-7; Kitamura Y, 1998, NEUROSCI LETT, V255, P57, DOI 10.1016/S0304-3940(98)00714-9; Lee JE, 2001, EXP NEUROL, V170, P129, DOI 10.1006/exnr.2000.7614; LEWIS SA, 1984, P NATL ACAD SCI-BIOL, V81, P2743, DOI 10.1073/pnas.81.9.2743; LINDQUIST S, 1988, ANNU REV GENET, V22, P631, DOI 10.1146/annurev.ge.22.120188.003215; Liu HT, 1999, P NATL ACAD SCI USA, V96, P12096, DOI 10.1073/pnas.96.21.12096; LOWENSTEIN DH, 1991, NEURON, V7, P1053, DOI 10.1016/0896-6273(91)90349-5; MAILHOS C, 1993, NEUROSCIENCE, V55, P621, DOI 10.1016/0306-4522(93)90428-I; MAILHOS C, 1994, J NEUROCHEM, V63, P1787; MARBER MS, 1995, J CLIN INVEST, V95, P1446, DOI 10.1172/JCI117815; Martin JL, 1997, CIRCULATION, V96, P4343; Mehlen P, 1996, J BIOL CHEM, V271, P16510, DOI 10.1074/jbc.271.28.16510; MESTRIL R, 1994, J CLIN INVEST, V93, P759, DOI 10.1172/JCI117030; NIWA H, 1991, GENE, V108, P193, DOI 10.1016/0378-1119(91)90434-D; Pandey P, 2000, ONCOGENE, V19, P1975, DOI 10.1038/sj.onc.1203531; Paul C, 2002, MOL CELL BIOL, V22, P816, DOI 10.1128/MCB.22.3.816-834.2002; Paxinos G., 2001, MOUSE BRAIN STEREOTA; POLLARD H, 1994, NEUROSCIENCE, V63, P7, DOI 10.1016/0306-4522(94)90003-5; Preville X, 1999, EXP CELL RES, V247, P61, DOI 10.1006/excr.1998.4347; Puig B, 2002, NEUROSCI LETT, V321, P182, DOI 10.1016/S0304-3940(01)02518-6; RACINE RJ, 1972, ELECTROEN CLIN NEURO, V32, P281, DOI 10.1016/0013-4694(72)90177-0; Rajdev S, 2000, ANN NEUROL, V47, P782, DOI 10.1002/1531-8249(200006)47:6<782::AID-ANA11>3.0.CO;2-3; RORDORF G, 1991, NEURON, V7, P1043, DOI 10.1016/0896-6273(91)90348-4; Royle SJ, 1999, BRAIN RES, V816, P337, DOI 10.1016/S0006-8993(98)01122-6; Samali A, 1996, EXP CELL RES, V223, P163, DOI 10.1006/excr.1996.0070; Schauwecker PE, 1997, P NATL ACAD SCI USA, V94, P4103, DOI 10.1073/pnas.94.8.4103; SCHWOB JE, 1980, NEUROSCIENCE, V5, P991, DOI 10.1016/0306-4522(80)90181-5; Sharp FR, 1999, TRENDS NEUROSCI, V22, P97, DOI 10.1016/S0166-2236(98)01392-7; STEWARD O, 1991, P NATL ACAD SCI USA, V88, P6819, DOI 10.1073/pnas.88.15.6819; TORRE ER, 1993, BRAIN RES, V631, P256, DOI 10.1016/0006-8993(93)91543-2; UNEY JB, 1993, FEBS LETT, V334, P313, DOI 10.1016/0014-5793(93)80701-U; Wagstaff MJD, 1996, MOL BRAIN RES, V42, P236, DOI 10.1016/S0169-328X(96)00127-1; Wagstaff MJD, 1999, J BIOL CHEM, V274, P5061, DOI 10.1074/jbc.274.8.5061; Wyatt S, 1996, MOL BRAIN RES, V39, P52, DOI 10.1016/0169-328X(95)00352-S; Yang DD, 1997, NATURE, V389, P865, DOI 10.1038/39899; Yenari MA, 1999, MOL MED TODAY, V5, P525, DOI 10.1016/S1357-4310(99)01599-3; Zhang JH, 2001, BIOCHEM BIOPH RES CO, V285, P1143, DOI 10.1006/bbrc.2001.5313	63	127	140	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 30	2003	278	22					19956	19965		10.1074/jbc.M207073200	http://dx.doi.org/10.1074/jbc.M207073200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	682EH	12639970	hybrid			2022-12-25	WOS:000183078000051
J	Cicchillitti, L; Fasanaro, P; Biglioli, P; Capogrossi, MC; Martelli, F				Cicchillitti, L; Fasanaro, P; Biglioli, P; Capogrossi, MC; Martelli, F			Oxidative stress induces protein phosphatase 2A-dependent dephosphorylation of the pocket proteins pRb, p107, and p130	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-CYCLE ARREST; 2A SUBUNIT INTERACTION; RETINOBLASTOMA PROTEIN; IN-VITRO; SERINE/THREONINE PHOSPHATASE; CATALYTIC SUBUNIT; DNA-REPLICATION; OKADAIC ACID; PPP2R1B GENE; G(1) ARREST	Oxidative stress induces cell death and growth arrest. In this study, the regulation and the functional role of the retinoblastoma family proteins pRb, p107, and p130 in the cellular response to oxidative stress were investigated. Treatment of endothelial cells with H2O2 induced rapid hypophosphorylation of the retinoblastoma family proteins. This event did not require p53 or p21(Waf1/Cip1/Sdi1) and was not associated with cyclin/cyclin-dependent kinase down-modulation. Four lines of evidence indicate that H2O2-induced hypophosphorylation of pRb, p107, and p130 was because of the activity of protein phosphatase 2A (PP2A). First, cell treatment with two phosphatase inhibitors, okadaic acid and calyculin A, prevented the hypophosphorylation of the retinoblastoma family proteins, at concentrations that specifically inhibit PP2A. Second, SV40 small t, which binds and inhibits PP2A, when overexpressed prevented H2O2-induced dephosphorylation of the retinoblastoma family proteins, whereas a SV40 small t mutant unable to bind PP2A was totally inert. Third, PP2A core enzyme physically interacted with pRb and p107, both in H2O2-treated and untreated cells. Fourth, a PP2A phosphatase activity was co-immunoprecipitated with pRb, and the activity of pRb-associated PP2A was positively modulated by cell treatment with H2O2. Because DNA damaging agents inhibit DNA synthesis in a pRb-dependent manner, it was determined whether the PP2A-mediated dephosphorylation of the retinoblastoma family proteins played a role in this S-phase response. Indeed, it was found that inhibition of PP2A by SV40 small t overexpression prevented DNA synthesis inhibition induced by H2O2.	IRCCS, Ist Dermopat Immacolata, Lab Patol Vasc, I-00167 Rome, Italy; IRCCS, Ist Cardiol Fdn I Monzino, Lab Biol Vasc & Terapia Genica, Milan, Italy; IRCCS, Ist Cardiol Fdn I Monzino, Dipartimento Chirurg Cardiovasc, Milan, Italy	IRCCS Istituto Dermopatico dell'Immacolata (IDI); IRCCS Centro Cardiologico Monzino; IRCCS Centro Cardiologico Monzino	Martelli, F (corresponding author), IRCCS, Ist Dermopat Immacolata, Lab Patol Vasc, Via Monti di Creta 104, I-00167 Rome, Italy.	f.martelli@idi.it	Martelli, Fabio/AAL-3788-2020	Martelli, Fabio/0000-0002-8624-7738				Agami R, 2000, CELL, V102, P55, DOI 10.1016/S0092-8674(00)00010-6; ALBERTS AS, 1993, P NATL ACAD SCI USA, V90, P388, DOI 10.1073/pnas.90.2.388; Barnouin K, 2002, J BIOL CHEM, V277, P13761, DOI 10.1074/jbc.M111123200; Bartek J, 2001, CURR OPIN CELL BIOL, V13, P738, DOI 10.1016/S0955-0674(00)00280-5; Ben-Israel H, 2002, FRONT BIOSCI-LANDMRK, V7, pD1369, DOI 10.2741/ben; Bennin DA, 2002, J BIOL CHEM, V277, P27449, DOI 10.1074/jbc.M111693200; Bochkov VN, 2002, BLOOD, V99, P199, DOI 10.1182/blood.V99.1.199; Bosco G, 2001, NAT CELL BIOL, V3, P289, DOI 10.1038/35060086; BREWIS ND, 1993, EMBO J, V12, P987, DOI 10.1002/j.1460-2075.1993.tb05739.x; Calin GA, 2000, ONCOGENE, V19, P1191, DOI 10.1038/sj.onc.1203389; Cenciarelli C, 1999, MOL CELL BIOL, V19, P5203; CHEN MX, 1994, EMBO J, V13, P4278, DOI 10.1002/j.1460-2075.1994.tb06748.x; Chen QM, 1998, BIOCHEM J, V332, P43, DOI 10.1042/bj3320043; Davies KJA, 2000, IUBMB LIFE, V50, P279, DOI 10.1080/15216540051081010; DOU QP, 1995, P NATL ACAD SCI USA, V92, P9019, DOI 10.1073/pnas.92.20.9019; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; Esposito F, 2000, FEBS LETT, V470, P211, DOI 10.1016/S0014-5793(00)01318-1; Favre B, 1997, J BIOL CHEM, V272, P13856, DOI 10.1074/jbc.272.21.13856; Feschenko MS, 2002, J PHARMACOL EXP THER, V302, P111, DOI 10.1124/jpet.302.1.111; Finkel T, 1998, CURR OPIN CELL BIOL, V10, P248, DOI 10.1016/S0955-0674(98)80147-6; Finkel T, 2000, NATURE, V408, P239, DOI 10.1038/35041687; FRISCHER H, 1977, J LAB CLIN MED, V89, P1080; Gaetano C, 2000, GENE THER, V7, P1624, DOI 10.1038/sj.gt.3301296; Gorospe M, 1999, GENE EXPRESSION, V7, P377; Harbour JW, 2000, GENE DEV, V14, P2393, DOI 10.1101/gad.813200; Harbour JW, 1999, CELL, V98, P859, DOI 10.1016/S0092-8674(00)81519-6; Harrington EA, 1998, P NATL ACAD SCI USA, V95, P11945, DOI 10.1073/pnas.95.20.11945; Irani K, 1997, SCIENCE, V275, P1649, DOI 10.1126/science.275.5306.1649; Janssens V, 2001, BIOCHEM J, V353, P417, DOI 10.1042/0264-6021:3530417; Kawabe T, 1997, NATURE, V385, P454, DOI 10.1038/385454a0; Kennedy BK, 2000, GENE DEV, V14, P2855, DOI 10.1101/gad.842600; Knudsen KE, 2000, MOL CELL BIOL, V20, P7751, DOI 10.1128/MCB.20.20.7751-7763.2000; LECHNER MS, 1994, J VIROL, V68, P4262, DOI 10.1128/JVI.68.7.4262-4273.1994; Li M, 1996, J BIOL CHEM, V271, P11059, DOI 10.1074/jbc.271.19.11059; Liu CWY, 1999, J BIOL CHEM, V274, P29470, DOI 10.1074/jbc.274.41.29470; Mates J M, 1999, Front Biosci, V4, pD339; Millward TA, 1999, TRENDS BIOCHEM SCI, V24, P186, DOI 10.1016/S0968-0004(99)01375-4; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; Munger K, 2002, FRONT BIOSCI-LANDMRK, V7, pD641, DOI 10.2741/munger; MUNGRE S, 1994, J VIROL, V68, P1675, DOI 10.1128/JVI.68.3.1675-1681.1994; Myles T, 2001, BIOCHEM J, V357, P225, DOI 10.1042/0264-6021:3570225; Noda T, 2001, FASEB J, V15, P2131, DOI 10.1096/fj.01-0131com; PALLAS DC, 1990, CELL, V60, P167, DOI 10.1016/0092-8674(90)90726-U; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; Pennaneach V, 2001, MOL CELL, V7, P715, DOI 10.1016/S1097-2765(01)00217-9; Pipas JM, 2001, SEMIN CANCER BIOL, V11, P23, DOI 10.1006/scbi.2000.0343; Resjo S, 1999, BIOCHEM J, V341, P839, DOI 10.1042/0264-6021:3410839; Royzman I, 1999, GENE DEV, V13, P827, DOI 10.1101/gad.13.7.827; Rubin E, 2001, ONCOGENE, V20, P3776, DOI 10.1038/sj.onc.1204518; Ruediger R, 2001, ONCOGENE, V20, P1892, DOI 10.1038/sj.onc.1204279; Ruediger R, 2001, ONCOGENE, V20, P10, DOI 10.1038/sj.onc.1204059; Rundell K, 2001, SEMIN CANCER BIOL, V11, P5, DOI 10.1006/scbi.2000.0341; Sellers WR, 1997, J CLIN ONCOL, V15, P3301, DOI 10.1200/JCO.1997.15.11.3301; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; SUGANUMA M, 1988, P NATL ACAD SCI USA, V85, P1768, DOI 10.1073/pnas.85.6.1768; SUNDARESAN M, 1995, SCIENCE, V270, P296, DOI 10.1126/science.270.5234.296; Swanton C, 2001, INT J EXP PATHOL, V82, P3, DOI 10.1046/j.1365-2613.2001.00165.x; Takagi Y, 2000, GUT, V47, P268, DOI 10.1136/gut.47.2.268; Tamrakar S, 2000, FRONT BIOSCI-LANDMRK, V5, pD121, DOI 10.2741/Tamrakar; Tan XQ, 1998, TRENDS CELL BIOL, V8, P116, DOI 10.1016/S0962-8924(97)01208-7; Tang H, 1998, J BIOL CHEM, V273, P29156, DOI 10.1074/jbc.273.44.29156; Ugi S, 2002, MOL CELL BIOL, V22, P2375, DOI 10.1128/MCB.22.7.2375-2387.2002; Voorhoeve PM, 1999, ONCOGENE, V18, P515, DOI 10.1038/sj.onc.1202316; Voorhoeve PM, 1999, ONCOGENE, V18, P679, DOI 10.1038/sj.onc.1202289; Wang SS, 1998, SCIENCE, V282, P284, DOI 10.1126/science.282.5387.284; Watanabe G, 1996, P NATL ACAD SCI USA, V93, P12861, DOI 10.1073/pnas.93.23.12861; WOLF D, 1985, P NATL ACAD SCI USA, V82, P790, DOI 10.1073/pnas.82.3.790; XIONG Y, 1993, GENE DEV, V7, P1572, DOI 10.1101/gad.7.8.1572; Yan Y, 1999, J BIOL CHEM, V274, P31917, DOI 10.1074/jbc.274.45.31917; Zarkowska T, 1997, J BIOL CHEM, V272, P12738, DOI 10.1074/jbc.272.19.12738	70	94	96	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 23	2003	278	21					19509	19517		10.1074/jbc.M300511200	http://dx.doi.org/10.1074/jbc.M300511200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	679PY	12621062	hybrid			2022-12-25	WOS:000182932200101
J	Guidotti, JE; Bregerie, O; Robert, A; Debey, P; Brechot, C; Desdouets, C				Guidotti, JE; Bregerie, O; Robert, A; Debey, P; Brechot, C; Desdouets, C			Liver cell polyploidization: A pivotal role for binuclear hepatocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PARTIAL-HEPATECTOMY; MITOTIC SPINDLE; CITRON KINASE; DNA-CONTENT; PROTEIN; PLOIDY; CYCLE; RAT; CENTROSOME; P53	Polyploidy is a general physiological process indicative of terminal differentiation. During liver growth, this process generates the appearance of tetraploid (4n) and octoploid (8n) hepatocytes with one or two nuclei. The onset of polyploidy in the liver has been recognized for quite some time; however, the cellular mechanisms that govern it remain unknown. In this report, we observed the sequential appearance during liver growth of binuclear diploid (2 x 2n) and mononuclear 4n hepatocytes from a diploid hepatocyte population. To identify the cell cycle modifications involved in hepatocyte polyploidization, mitosis was then monitored in primary cultures of rat hepatocytes. Twenty percent of mononuclear 2n hepatocytes failed to undergo cytokinesis with no observable contractile movement of the ring. This process led to the formation of binuclear 2 x 2n hepatocytes. This tetraploid condition following cleavage failure did not activate the p53-dependent checkpoint in G(1). In fact, binuclear hepatocytes were able to proceed through S phase, and the formation of a bipolar spindle during mitosis constituted the key step leading to the genesis of two mononuclear 4n hepatocytes. Finally, we studied the duplication and clustering of centrosomes in the binuclear hepatocyte. These cells exhibited two centrosomes in G1 that were duplicated during S phase and then clustered by pairs at opposite poles of the cell during metaphase. This event led only to mononuclear 4n progeny and maintained the tetraploidy status of hepatocytes.	CHU Necker, INSERM, U370, F-75015 Paris, France; Museum Natl Hist Nat, UMR 8646, CNRS, INSERM,U565, F-75005 Paris, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); Museum National d'Histoire Naturelle (MNHN)	Desdouets, C (corresponding author), CHU Necker, INSERM, U370, 156 Rue Vaugirard, F-75015 Paris, France.	desdouet@necker.fr	robert, aude/F-9584-2015; Desdouets, Chantal/M-3430-2017; Guidotti, Jacques-Emmanuel/M-9014-2018	robert, aude/0000-0003-3095-4190; guidotti, jacques-emmanuel/0000-0001-9285-8167				Andreassen PR, 2001, MOL BIOL CELL, V12, P1315, DOI 10.1091/mbc.12.5.1315; Bellamy COC, 1997, FASEB J, V11, P591, DOI 10.1096/fasebj.11.7.9212083; Borel F, 2002, P NATL ACAD SCI USA, V99, P9819, DOI 10.1073/pnas.152205299; Chassoux D, 1999, ANAL QUANT CYTOL, V21, P489; Fujikawa K, 2002, P NATL ACAD SCI USA, V99, P4313, DOI 10.1073/pnas.052715699; Galitski T, 1999, SCIENCE, V285, P251, DOI 10.1126/science.285.5425.251; GOMEZLECHON MJ, 1981, CELL MOL BIOL, V27, P695; Hirose K, 2001, J BIOL CHEM, V276, P5821, DOI 10.1074/jbc.M007252200; KUDRYAVTSEV BN, 1993, VIRCHOWS ARCH B, V64, P387, DOI 10.1007/BF02915139; Lange BMH, 2002, CURR OPIN CELL BIOL, V14, P35, DOI 10.1016/S0955-0674(01)00291-5; LEE KS, 1995, MOL CELL BIOL, V15, P7143; Liu HF, 2003, J BIOL CHEM, V278, P2541, DOI 10.1074/jbc.M210391200; Mackay AM, 1998, J CELL BIOL, V140, P991, DOI 10.1083/jcb.140.5.991; Madaule P, 1998, NATURE, V394, P491, DOI 10.1038/28873; Martin NC, 2002, J CELL PHYSIOL, V191, P138, DOI 10.1002/jcp.10057; Martineau-Thuillier S, 1998, CHROMOSOMA, V107, P461, DOI 10.1007/s004120050330; Mayor T, 2000, J CELL BIOL, V151, P837, DOI 10.1083/jcb.151.4.837; McIntyre M, 1999, ONCOGENE, V18, P4577, DOI 10.1038/sj.onc.1202815; Meraldi P, 2002, EMBO J, V21, P483, DOI 10.1093/emboj/21.4.483; Minamishima YA, 2002, CANCER RES, V62, P995; Mollinari C, 2002, J CELL BIOL, V157, P1175, DOI 10.1083/jcb.200111052; MOSSIN L, 1994, EXP CELL RES, V214, P551, DOI 10.1006/excr.1994.1293; NADAL C, 1967, EXP CELL RES, V48, P518, DOI 10.1016/0014-4827(67)90318-7; NISLOW C, 1992, NATURE, V359, P543, DOI 10.1038/359543a0; Nunez F, 2000, FASEB J, V14, P1073, DOI 10.1096/fasebj.14.9.1073; Ravid K, 2002, J CELL PHYSIOL, V190, P7, DOI 10.1002/jcp.10035; SAETER G, 1988, CARCINOGENESIS, V9, P939, DOI 10.1093/carcin/9.6.939; SCHWARZE PE, 1984, CARCINOGENESIS, V5, P1267, DOI 10.1093/carcin/5.10.1267; Seglen PO, 1997, CELL BIOL TOXICOL, V13, P301, DOI 10.1023/A:1007487425047; SIGAL SH, 1995, DIFFERENTIATION, V59, P35, DOI 10.1046/j.1432-0436.1995.5910035.x; Sigal SH, 1999, AM J PHYSIOL-GASTR L, V276, pG1260, DOI 10.1152/ajpgi.1999.276.5.G1260; Skoufias DA, 2000, J CELL BIOL, V151, P1575, DOI 10.1083/jcb.151.7.1575; Terada Y, 1998, EMBO J, V17, P667, DOI 10.1093/emboj/17.3.667; WHEATLEY DN, 1972, EXP CELL RES, V74, P455, DOI 10.1016/0014-4827(72)90401-6; Wu H, 1996, GENE DEV, V10, P245, DOI 10.1101/gad.10.3.245; Yin L, 1998, HEPATOLOGY, V27, P73, DOI 10.1002/hep.510270113	36	226	232	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 23	2003	278	21					19095	19101		10.1074/jbc.M300982200	http://dx.doi.org/10.1074/jbc.M300982200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	679PY	12626502	Green Published, hybrid			2022-12-25	WOS:000182932200050
J	Gaillard, H; Fitzgerald, DJ; Smith, CL; Peterson, CL; Richmond, TJ; Thoma, F				Gaillard, H; Fitzgerald, DJ; Smith, CL; Peterson, CL; Richmond, TJ; Thoma, F			Chromatin remodeling activities act on UV-damaged nucleosomes and modulate DNA damage accessibility to photolyase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE EXCISION-REPAIR; YEAST SWI/SNF COMPLEX; RIBOSOMAL-RNA GENE; SACCHAROMYCES-CEREVISIAE; HISTONE OCTAMER; IN-VITRO; POSITIONED NUCLEOSOME; NONTRANSCRIBED STRAND; PYRIMIDINE DIMERS; CRYSTAL-STRUCTURE	Nucleosomes inhibit DNA repair in vitro, suggesting that chromatin remodeling activities might be required for efficient repair in vivo. To investigate how structural and dynamic properties of nucleosomes affect damage recognition and processing, we investigated repair of UV lesions by photolyase on a nucleosome positioned at one end of a 226-bp-long DNA fragment. Repair was slow in the nucleosome but efficient outside. No disruption or movement of the nucleosome was observed after UV irradiation and during repair. However, incubation with the nucleosome remodeling complex SWI/SNF and ATP altered the conformation of nucleosomal DNA as judged by UV photo-footprinting and promoted more homogeneous repair. Incubation with yISW2 and ATP moved the nucleosome to a more central position, thereby altering the repair pattern. This is the first demonstration that two different chromatin remodeling complexes can act on UV-damaged nucleosomes and modulate repair. Similar activities might relieve the inhibitory effect of nucleosomes on DNA repair processes in living cells.	ETH Honggerberg, Inst Zellbiol, CH-8093 Zurich, Switzerland; ETH Honggerberg, Inst Mol Biol, Dept Biol, CH-8093 Zurich, Switzerland; Univ Massachusetts, Sch Med, Program Mol Med, Worcester, MA 01605 USA	Swiss Federal Institutes of Technology Domain; ETH Zurich; Swiss Federal Institutes of Technology Domain; ETH Zurich; University of Massachusetts System; University of Massachusetts Worcester	Thoma, F (corresponding author), ETH Honggerberg, Inst Zellbiol, CH-8093 Zurich, Switzerland.		Gaillard, Helene/M-2914-2014	Gaillard, Helene/0000-0002-5740-0641; Smith, Corey/0000-0002-9716-2545	NIGMS NIH HHS [R01 GM049650, R37 GM049650] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM049650, R37GM049650] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Alexiadis V, 2002, GENE DEV, V16, P2767, DOI 10.1101/gad.1032102; Araki M, 2000, MUTAT RES-DNA REPAIR, V459, P147, DOI 10.1016/S0921-8777(99)00067-1; BANG DD, 1992, NUCLEIC ACIDS RES, V20, P3925, DOI 10.1093/nar/20.15.3925; Boyer LA, 2000, J BIOL CHEM, V275, P18864, DOI 10.1074/jbc.M002810200; Citterio E, 2000, MOL CELL BIOL, V20, P7643, DOI 10.1128/MCB.20.20.7643-7653.2000; COTE J, 1994, SCIENCE, V265, P53, DOI 10.1126/science.8016655; Cote J, 1998, P NATL ACAD SCI USA, V95, P4947, DOI 10.1073/pnas.95.9.4947; de Boer J, 2000, CARCINOGENESIS, V21, P453, DOI 10.1093/carcin/21.3.453; Eberharter A, 2001, EMBO J, V20, P3781, DOI 10.1093/emboj/20.14.3781; EISEN JA, 1995, NUCLEIC ACIDS RES, V23, P2715, DOI 10.1093/nar/23.14.2715; Frit P, 2002, MOL CELL, V10, P1391, DOI 10.1016/S1097-2765(02)00732-3; Fyodorov DV, 2001, CELL, V106, P523, DOI 10.1016/S0092-8674(01)00478-0; GALE JM, 1987, P NATL ACAD SCI USA, V84, P6644, DOI 10.1073/pnas.84.19.6644; GALE JM, 1988, J MOL BIOL, V204, P949, DOI 10.1016/0022-2836(88)90054-X; Green CM, 2002, EMBO REP, V3, P28, DOI 10.1093/embo-reports/kvf005; Guyon JR, 1999, MOL CELL BIOL, V19, P2088; Guzder SN, 1998, J BIOL CHEM, V273, P6292, DOI 10.1074/jbc.273.11.6292; Hamiche A, 1999, CELL, V97, P833, DOI 10.1016/S0092-8674(00)80796-5; Hara R, 2002, MOL CELL BIOL, V22, P6779, DOI 10.1128/MCB.22.19.6779-6787.2002; Hara R, 2000, MOL CELL BIOL, V20, P9173, DOI 10.1128/MCB.20.24.9173-9181.2000; HAYES JJ, 1991, BIOCHEMISTRY-US, V30, P8434, DOI 10.1021/bi00098a022; Hoeijmakers JHJ, 2001, NATURE, V411, P366, DOI 10.1038/35077232; Jaskelioff M, 2000, MOL CELL BIOL, V20, P3058, DOI 10.1128/MCB.20.9.3058-3068.2000; Kassabov SR, 2002, MOL CELL BIOL, V22, P7524, DOI 10.1128/MCB.22.21.7524-7534.2002; Kent NA, 2001, GENE DEV, V15, P619, DOI 10.1101/gad.190301; Kosmoski JV, 2001, P NATL ACAD SCI USA, V98, P10113, DOI 10.1073/pnas.181073398; Kosmoski JV, 1999, BIOCHEMISTRY-US, V38, P9485, DOI 10.1021/bi990297h; Langst G, 1999, CELL, V97, P843, DOI 10.1016/S0092-8674(00)80797-7; Langst G, 2001, J CELL SCI, V114, P2561; LINXWEILER W, 1984, NUCLEIC ACIDS RES, V12, P9395, DOI 10.1093/nar/12.24.9395; Liu XQ, 2000, BIOCHEMISTRY-US, V39, P557, DOI 10.1021/bi991771m; Liu XQ, 2000, J BIOL CHEM, V275, P23729, DOI 10.1074/jbc.M002206200; Logie C, 1997, EMBO J, V16, P6772, DOI 10.1093/emboj/16.22.6772; LOSA R, 1990, NUCLEIC ACIDS RES, V18, P3495, DOI 10.1093/nar/18.12.3495; Luger K, 1997, NATURE, V389, P251, DOI 10.1038/38444; LYAMICHEV V, 1991, NUCLEIC ACIDS RES, V19, P4491, DOI 10.1093/nar/19.16.4491; Mann DB, 1997, P NATL ACAD SCI USA, V94, P2215, DOI 10.1073/pnas.94.6.2215; MATSUMOTO H, 1994, PHOTOCHEM PHOTOBIOL, V60, P134, DOI 10.1111/j.1751-1097.1994.tb05079.x; Narlikar GJ, 2002, CELL, V108, P475, DOI 10.1016/S0092-8674(02)00654-2; Nilsen H, 2002, EMBO J, V21, P5943, DOI 10.1093/emboj/cdf581; OwenHughes T, 1996, SCIENCE, V273, P513, DOI 10.1126/science.273.5274.513; Park H, 2002, P NATL ACAD SCI USA, V99, P15965, DOI 10.1073/pnas.242422699; PARK HW, 1995, SCIENCE, V268, P1866, DOI 10.1126/science.7604260; Peterson CL, 2000, FEBS LETT, V476, P68, DOI 10.1016/S0014-5793(00)01673-2; Roberts RJ, 1998, ANNU REV BIOCHEM, V67, P181, DOI 10.1146/annurev.biochem.67.1.181; Sancar GB, 2000, MUTAT RES-FUND MOL M, V451, P25, DOI 10.1016/S0027-5107(00)00038-5; Schieferstein U, 1998, EMBO J, V17, P306, DOI 10.1093/emboj/17.1.306; Schieferstein U, 1996, BIOCHEMISTRY-US, V35, P7705, DOI 10.1021/bi953011r; Sengupta SM, 2001, J BIOL CHEM, V276, P12636, DOI 10.1074/jbc.M010470200; Shen XT, 2000, NATURE, V406, P541, DOI 10.1038/35020123; Smerdon MJ, 1999, PROG NUCLEIC ACID RE, V62, P227; Suter B, 1997, EMBO J, V16, P2150, DOI 10.1093/emboj/16.8.2150; Suter B, 2002, J MOL BIOL, V319, P395, DOI 10.1016/S0022-2836(02)00291-7; Thoma F, 1999, EMBO J, V18, P6585, DOI 10.1093/emboj/18.23.6585; Tijsterman M, 1999, MOL CELL BIOL, V19, P934; Tsukiyama T, 1999, GENE DEV, V13, P686, DOI 10.1101/gad.13.6.686; Ura K, 2001, EMBO J, V20, P2004, DOI 10.1093/emboj/20.8.2004; Utley RT, 1997, J BIOL CHEM, V272, P12642, DOI 10.1074/jbc.272.19.12642; Vande Berg BJ, 1998, J BIOL CHEM, V273, P20276, DOI 10.1074/jbc.273.32.20276; VERHAGE R, 1994, MOL CELL BIOL, V14, P6135, DOI 10.1128/MCB.14.9.6135; Vignali M, 2000, MOL CELL BIOL, V20, P1899, DOI 10.1128/MCB.20.6.1899-1910.2000; WANG ZG, 1991, J BIOL CHEM, V266, P22472; Wellinger RE, 1997, EMBO J, V16, P5046, DOI 10.1093/emboj/16.16.5046; Whitehouse I, 1999, NATURE, V400, P784, DOI 10.1038/23506; Widom J, 1998, ANNU REV BIOPH BIOM, V27, P285, DOI 10.1146/annurev.biophys.27.1.285	65	63	65	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 16	2003	278	20					17655	17663		10.1074/jbc.M300770200	http://dx.doi.org/10.1074/jbc.M300770200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677YX	12637512	hybrid			2022-12-25	WOS:000182838300011
J	Ha, N; Ceryak, S; Patierno, SR				Ha, N; Ceryak, S; Patierno, SR			Chromium (VI) activates ataxia telangiectasia mutated (ATM) protein - Requirement of ATM for both apoptosis and recovery from terminal growth arrest	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-CYCLE; DNA-DAMAGE; IONIZING-RADIATION; OXIDATIVE STRESS; CROSS-LINKS; HUMAN LUNG; DEREGULATED APOPTOSIS; MEDIATED REACTIONS; HUMAN FIBROBLASTS; STRAND BREAKS	The ataxia telangiectasia mutated (ATM) protein plays a central role in early stages of DNA double strand break (DSB) detection and controls cellular responses to this damage. Although hypersensitive to ionizing radiation-induced clonogenic lethality, ataxia telangiectasia cells are paradoxically deficient in their ability to undergo ionizing radiation-induced apoptosis. This contradiction illustrates the complexity of the central role of ATM in DNA damage response and the need for further understanding. Certain hexavalent chromium (Cr(VI)) compounds are implicated as occupational respiratory carcinogens at doses that are both genotoxic and cytotoxic. Cr(VI) induces a broad spectrum of DNA damage, but Cr(VI)-induced DSBs have not been reported. Here, we examined the role of ATM in the cellular response to Cr(VI) and found that Cr(VI) activates ATM. We also show that physiological targets of ATM, p53 Ser-15 and Chk2 Thr-68, were phosphorylated by Cr(VI) exposure in an ATM-dependent fashion. We found that ATM-/- cells were markedly resistant to Cr(VI)induced apoptosis but considerably more sensitive to Cr(VI)-induced clonogenic lethality than wild type cells, indicating that resistance to Cr(VI)-induced apoptosis did not confer a selective survival advantage. However, analysis of long term growth arrest revealed a striking difference: ATM-/- cells were markedly less able to recover from Cr(VI)-induced growth arrest. This indicates that terminal growth arrest is the fate of these apoptosis-resistant cells. In summary, ATM is involved in cellular response to a complex genotoxin that may not directly induce DSBs. Our data suggest that ATM is a major signal initiator for genotoxin-induced apoptosis but, paradoxically, also contributes to maintenance of cell survival by facilitating recovery/escape from terminal growth arrest. The results also strongly suggest that terminal growth arrest is not merely an extended or even irreversible form of checkpoint arrest, but instead an independent and unique cell fate pathway.	George Washington Univ, Med Ctr, Dept Pharmacol, Program Mol & Cellular Oncol, Washington, DC 20037 USA	George Washington University	Patierno, SR (corresponding author), George Washington Univ, Med Ctr, Dept Pharmacol, Program Mol & Cellular Oncol, 2300 I St NW, Washington, DC 20037 USA.				NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES009961] Funding Source: NIH RePORTER; NIEHS NIH HHS [ES05304, ES09961] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Adamson AW, 2002, J BIOL CHEM, V277, P38222, DOI 10.1074/jbc.M204409200; Bagchi D, 2001, MOL CELL BIOCHEM, V222, P149, DOI 10.1023/A:1017958028256; Bakkenist CJ, 2003, NATURE, V421, P499, DOI 10.1038/nature01368; Banin S, 1998, SCIENCE, V281, P1674, DOI 10.1126/science.281.5383.1674; Baskaran R, 1997, NATURE, V387, P516, DOI 10.1038/387516a0; BRIDGEWATER LC, 1994, CARCINOGENESIS, V15, P2421, DOI 10.1093/carcin/15.11.2421; Canman CE, 1998, SCIENCE, V281, P1677, DOI 10.1126/science.281.5383.1677; CANTONI O, 1984, CARCINOGENESIS, V5, P1207, DOI 10.1093/carcin/5.9.1207; Carlisle DL, 2000, MOL CARCINOGEN, V28, P111, DOI 10.1002/1098-2744(200006)28:2<111::AID-MC7>3.0.CO;2-Y; Carlisle DL, 2000, TOXICOL SCI, V55, P60, DOI 10.1093/toxsci/55.1.60; CERYAK S, 2003, IN PRESS MOL CELL BI; Duchaud E, 1996, CANCER RES, V56, P1400; Enns L, 1998, RADIAT RES, V150, P11, DOI 10.2307/3579639; Gadbois DM, 1997, CANCER RES, V57, P3174; Gately DP, 1998, MOL BIOL CELL, V9, P2361, DOI 10.1091/mbc.9.9.2361; Gilad S, 1996, HUM MOL GENET, V5, P433, DOI 10.1093/hmg/5.4.433; Helleday T, 2000, ENVIRON MOL MUTAGEN, V35, P114, DOI 10.1002/(SICI)1098-2280(2000)35:2<114::AID-EM6>3.0.CO;2-Q; Hirao A, 2000, SCIENCE, V287, P1824, DOI 10.1126/science.287.5459.1824; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; Kastan MB, 2000, NAT REV MOL CELL BIO, V1, P179, DOI 10.1038/35043058; Keegan KS, 1996, GENE DEV, V10, P2423, DOI 10.1101/gad.10.19.2423; Khanna KK, 2001, NAT GENET, V27, P247, DOI 10.1038/85798; Khosravi R, 1999, P NATL ACAD SCI USA, V96, P14973, DOI 10.1073/pnas.96.26.14973; Kim ST, 1999, J BIOL CHEM, V274, P37538, DOI 10.1074/jbc.274.53.37538; Krepkiy D, 2001, MOL CELL BIOCHEM, V222, P213, DOI 10.1023/A:1017982717778; Lavin LF, 1999, INT J RADIAT BIOL, V75, P1201; Lee SA, 2001, J BIOL CHEM, V276, P11783, DOI 10.1074/jbc.M004517200; Liu KJ, 2001, MOL CELL BIOCHEM, V222, P221, DOI 10.1023/A:1017938918686; MARTIN SJ, 1995, J EXP MED, V182, P1545, DOI 10.1084/jem.182.5.1545; Matsuoka S, 2000, P NATL ACAD SCI USA, V97, P10389, DOI 10.1073/pnas.190030497; Matsuoka S, 1998, SCIENCE, V282, P1893, DOI 10.1126/science.282.5395.1893; Miyakoda M, 2002, ONCOGENE, V21, P1090, DOI 10.1038/sj.onc.1205196; Morgan SE, 1997, ADV CANCER RES, V71, P1, DOI 10.1016/S0065-230X(08)60095-0; Morrison C, 2000, EMBO J, V19, P463, DOI 10.1093/emboj/19.3.463; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; O'Brien TJ, 2002, DNA REPAIR, V1, P617, DOI 10.1016/S1568-7864(02)00078-2; Pritchard DE, 2001, CELL GROWTH DIFFER, V12, P487; Qian Y, 2001, MOL CELL BIOCHEM, V222, P199, DOI 10.1023/A:1017926531890; Ryan KM, 1998, MOL CELL BIOL, V18, P3692, DOI 10.1128/MCB.18.7.3692; Saito S, 2002, J BIOL CHEM, V277, P12491, DOI 10.1074/jbc.C200093200; SAVITSKY K, 1995, HUM MOL GENET, V4, P2025, DOI 10.1093/hmg/4.11.2025; Shackelford RE, 2001, J BIOL CHEM, V276, P21951, DOI 10.1074/jbc.M011303200; Shiloh Y, 1997, ANNU REV GENET, V31, P635, DOI 10.1146/annurev.genet.31.1.635; Siliciano JD, 1997, GENE DEV, V11, P3471, DOI 10.1101/gad.11.24.3471; Singh J, 1998, TOXICOL SCI, V45, P72; Singh J, 1998, TOXICOL SCI, V46, P260, DOI 10.1093/toxsci/46.2.260; Tibbetts RS, 1999, GENE DEV, V13, P152, DOI 10.1101/gad.13.2.152; Vit JP, 2000, INT J RADIAT BIOL, V76, P841, DOI 10.1080/09553000050029002; Wang SW, 2001, CARCINOGENESIS, V22, P757, DOI 10.1093/carcin/22.5.757; Wei Y, 1998, P NATL ACAD SCI USA, V95, P7480, DOI 10.1073/pnas.95.13.7480; Westphal CH, 1997, NAT GENET, V16, P397, DOI 10.1038/ng0897-397; XU J, 1994, CARCINOGENESIS, V15, P1443, DOI 10.1093/carcin/15.7.1443; Xu J, 1996, CARCINOGENESIS, V17, P1511, DOI 10.1093/carcin/17.7.1511; Yang DQ, 2000, NAT CELL BIOL, V2, P893, DOI 10.1038/35046542; Ye JP, 1999, J BIOL CHEM, V274, P34974, DOI 10.1074/jbc.274.49.34974; Zhang YG, 2002, J BIOL CHEM, V277, P3124, DOI 10.1074/jbc.M110245200; Zhang Z, 2001, MOL CELL BIOCHEM, V222, P77, DOI 10.1023/A:1017963307358	57	56	59	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 16	2003	278	20					17885	17894		10.1074/jbc.M210560200	http://dx.doi.org/10.1074/jbc.M210560200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677YX	12637545	hybrid			2022-12-25	WOS:000182838300038
J	Hinkley, CS; Hirsch, HA; Gu, LP; LaMere, B; Henry, RW				Hinkley, CS; Hirsch, HA; Gu, LP; LaMere, B; Henry, RW			The small nuclear RNA-activating protein 190 Myb DNA binding domain stimulates TATA box-binding protein-TATA box recognition	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYMERASE-III TRANSCRIPTION; PROXIMAL SEQUENCE ELEMENT; SNRNA GENE-TRANSCRIPTION; OCT-1 POU DOMAIN; FACTOR-TFIIIB; COMPLEX SNAP(C); HUMAN U6; EUKARYOTIC TRANSCRIPTION; PROMOTER ELEMENTS; TBP	Human U6 small nuclear RNA (snRNA) gene transcription by RNA polymerase III requires cooperative promoter binding involving the snRNA-activating protein complex (SNAP(c)) and the TATA-box binding protein (TBP). To investigate the role of SNAP(c) for TBP function at U6 promoters, TBP recruitment assays were performed using full-length TBP and a mini-SNAP(c) containing SNAP43, SNAP50, and a truncated SNAP190. Mini-SNAP(c) efficiently recruits TBP to the U6 TATA box, and two SNAP(c) subunits, SNAP43 and SNAP190, directly interact with the TBP DNA binding domain. Truncated SNAP190 containing only the Myb DNA binding domain is sufficient for TBP recruitment to the TATA box. Therefore, the SNAP190 Myb domain functions both to specifically recognize the proximal sequence element present in the core promoters of human snRNA genes and to stimulate TBP recognition of the neighboring TATA box present in human U6 snRNA promoters. The SNAP190 Myb domain also stimulates complex assembly with TBP and Brf2, a subunit of a snRNA-specific TFIIIB complex. Thus, interactions between the DNA binding domains of SNAP190 and TBP at juxtaposed promoter elements define the assembly of a RNA polymerase III-specific preinitiation complex.	Michigan State Univ, Dept Biochem & Mol Biol, E Lansing, MI 48824 USA; Michigan State Univ, Biochem Res Training Program, E Lansing, MI 48824 USA; Michigan State Univ, Cell & Mol Biol Program, E Lansing, MI 48824 USA	Michigan State University; Michigan State University; Michigan State University	Henry, RW (corresponding author), Michigan State Univ, Dept Biochem & Mol Biol, 409 Biochem Bldg,Wilson Rd, E Lansing, MI 48824 USA.	henryrw@pilot.msu.edu			NIGMS NIH HHS [R01 GM59805] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM059805] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Albright SR, 2000, GENE, V242, P1, DOI 10.1016/S0378-1119(99)00495-3; Bai L, 1996, MOL CELL BIOL, V16, P5419; BERNUES J, 1993, EMBO J, V12, P3573, DOI 10.1002/j.1460-2075.1993.tb06031.x; BURATOWSKI S, 1992, CELL, V71, P221, DOI 10.1016/0092-8674(92)90351-C; Cabart P, 2001, J BIOL CHEM, V276, P43056, DOI 10.1074/jbc.M108515200; DAS G, 1995, NATURE, V374, P657, DOI 10.1038/374657a0; Ford E, 1998, GENE DEV, V12, P3528, DOI 10.1101/gad.12.22.3528; GOOMER RS, 1992, NUCLEIC ACIDS RES, V20, P4903, DOI 10.1093/nar/20.18.4903; Hampsey M, 1997, CURR BIOL, V7, pR44, DOI 10.1016/S0960-9822(06)00018-2; Henry RW, 1998, COLD SPRING HARB SYM, V63, P111, DOI 10.1101/sqb.1998.63.111; HENRY RW, 1995, NATURE, V374, P653, DOI 10.1038/374653a0; Henry RW, 1996, EMBO J, V15, P7129, DOI 10.1002/j.1460-2075.1996.tb01104.x; Henry RW, 1998, GENE DEV, V12, P2664, DOI 10.1101/gad.12.17.2664; Hernandez N, 2001, J BIOL CHEM, V276, P26733, DOI 10.1074/jbc.R100032200; HERNANDEZ N, 1993, GENE DEV, V7, P1291, DOI 10.1101/gad.7.7b.1291; Hernandez N, 1992, TRANSCRIPTIONAL REGU, P281; Hirsch HA, 2000, MOL CELL BIOL, V20, P9182, DOI 10.1128/MCB.20.24.9182-9191.2000; KASSAVETIS GA, 1991, P NATL ACAD SCI USA, V88, P7308, DOI 10.1073/pnas.88.16.7308; KASSAVETIS GA, 1992, CELL, V71, P1055, DOI 10.1016/0092-8674(92)90399-W; LOBO SM, 1992, CELL, V71, P1029, DOI 10.1016/0092-8674(92)90397-U; LOBO SM, 1989, CELL, V58, P55, DOI 10.1016/0092-8674(89)90402-9; LOBO SM, 1994, TRANSCRIPTION MECH R, P127; LOPEZDELEON A, 1992, CELL, V71, P211, DOI 10.1016/0092-8674(92)90350-L; Ma B, 2001, J BIOL CHEM, V276, P5027, DOI 10.1074/jbc.M009301200; Ma BC, 2002, MOL CELL BIOL, V22, P8067, DOI 10.1128/MCB.22.22.8067-8078.2002; McCulloch V, 2000, EMBO J, V19, P4134, DOI 10.1093/emboj/19.15.4134; MEYERS RE, 1993, MOL CELL BIOL, V13, P7953, DOI 10.1128/MCB.13.12.7953; Mital R, 1996, MOL CELL BIOL, V16, P7031; Mittal V, 1999, GENE DEV, V13, P1807, DOI 10.1101/gad.13.14.1807; Mittal V, 1997, SCIENCE, V275, P1136, DOI 10.1126/science.275.5303.1136; Mittal V, 1996, MOL CELL BIOL, V16, P1955; MURPHY S, 1992, MOL CELL BIOL, V12, P3247, DOI 10.1128/MCB.12.7.3247; Parkhurst KM, 1999, J MOL BIOL, V289, P1327, DOI 10.1006/jmbi.1999.2835; Paule MR, 2000, NUCLEIC ACIDS RES, V28, P1283, DOI 10.1093/nar/28.6.1283; Roeder RG, 1996, METHOD ENZYMOL, V273, P165; Sadowski CL, 1996, P NATL ACAD SCI USA, V93, P4289, DOI 10.1073/pnas.93.9.4289; SADOWSKI CL, 1993, GENE DEV, V7, P1535, DOI 10.1101/gad.7.8.1535; Schramm L, 2000, GENE DEV, V14, P2650, DOI 10.1101/gad.836400; SIMMEN KA, 1992, NUCLEIC ACIDS RES, V20, P5889, DOI 10.1093/nar/20.22.5889; Stunkel W, 1997, MOL CELL BIOL, V17, P4397; TAGGART AKP, 1992, CELL, V71, P1015, DOI 10.1016/0092-8674(92)90396-T; Tansey WP, 1997, CELL, V88, P729, DOI 10.1016/S0092-8674(00)81916-9; Teichmann M, 2000, P NATL ACAD SCI USA, V97, P14200, DOI 10.1073/pnas.97.26.14200; WALDSCHMIDT R, 1991, EMBO J, V10, P2595, DOI 10.1002/j.1460-2075.1991.tb07801.x; WANG ZX, 1995, P NATL ACAD SCI USA, V92, P7026, DOI 10.1073/pnas.92.15.7026; WHITE RJ, 1992, CELL, V71, P1041, DOI 10.1016/0092-8674(92)90398-V; Willis IM, 2002, GENE DEV, V16, P1337, DOI 10.1101/gad.998102; WILLIS IM, 1993, EUR J BIOCHEM, V212, P1, DOI 10.1111/j.1432-1033.1993.tb17626.x; Wong MW, 1998, MOL CELL BIOL, V18, P368, DOI 10.1128/MCB.18.1.368; Yoon JB, 1996, MOL CELL BIOL, V16, P1; Zhao XM, 2002, CELL, V108, P615, DOI 10.1016/S0092-8674(02)00648-7; Zhao XY, 2001, MOL CELL, V7, P539, DOI 10.1016/S1097-2765(01)00201-5	52	21	27	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 16	2003	278	20					18649	18657		10.1074/jbc.M204247200	http://dx.doi.org/10.1074/jbc.M204247200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677YX	12621023	hybrid			2022-12-25	WOS:000182838300137
J	Mao, HP; Li, FH; Ruchalski, K; Mosser, DD; Schwartz, JH; Wang, YH; Borkan, SC				Mao, HP; Li, FH; Ruchalski, K; Mosser, DD; Schwartz, JH; Wang, YH; Borkan, SC			hsp72 inhibits focal adhesion kinase degradation in ATP-depleted renal epithelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SHOCK-PROTEIN HSP70; SIGNAL-TRANSDUCTION; SUBLETHAL INJURY; TERMINAL DOMAIN; GROWTH-FACTOR; APOPTOSIS; FAK; INTEGRIN; CYTOSKELETAL; CASPASES	Prior heat stress (HS) or the selective overexpression of hsp72 prevents apoptosis caused by exposure to metabolic inhibitors by protecting the mitochondrial membrane and partially reducing caspase-3 activation. Focal adhesion kinase (FAK), a tyrosine kinase, exhibits antiapoptotic properties and is a potential target for degradation by caspase-3. This study tested the hypothesis that hsp72 interacts with FAK, preventing caspase-3-mediated degradation during ATP depletion. ATP depletion (5 mM NaCN and 5 mM 2-deoxy-D-glucose in the absence of medium glucose) caused FAK degradation within 15 min. FAK degradation was completely prevented by a caspase-3-specific inhibitor. HS induced the accumulation of hsp72, increased the interaction between hsp72 and FAK, and significantly inhibited FAK degradation during ATP depletion. Selective overexpression of wild-type hsp72 (but not hsp72DeltaEEVD) reproduced the protective effects of HS on FAK cleavage. Purified hsp72 prevented the degradation of FAK by caspase-3 in vitro in a dose-dependent manner without affecting caspase-3 activity. Interaction between hsp72 and FAK is critical because both exogenous ATP and deletion of the substrate-binding site decreased protection of FAK by hsp72. These data indicate that FAK is an early target of injury in cells exposed to metabolic inhibitors and demonstrate that hsp72 reduces caspase-3-mediated proteolysis of FAK, an anti-apoptotic protein.	Boston Univ, Boston Med Ctr, Dept Med, Renal Sect, Boston, MA 02118 USA; Zhongshan Univ, Affiliated Hosp 1, Dept Nephrol, Guangzhou 510080, Peoples R China; Tufts Univ, Dept Pathol, Boston, MA 02111 USA; Tufts Univ New England Med Ctr, Boston, MA 02111 USA; Univ Guelph, Dept Mol Biol & Genet, Guelph, ON N1G 2W1, Canada	Boston Medical Center; Boston University; Sun Yat Sen University; Tufts University; Tufts Medical Center; University of Guelph	Borkan, SC (corresponding author), Evans Biomed Res Ctr, Renal Sect, Rm 547,650 Albany St, Boston, MA 02118 USA.	sborkan@bu.edu	Mosser, Dick D/A-7391-2008; Schwartz, John/AAO-8158-2021	Schwartz, John/0000-0002-1660-8681; Mosser, Richard/0000-0002-9183-2288; Mao, Haiping/0000-0002-3608-3851; Borkan, Steven/0000-0003-3062-9486	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK053387, R01DK052898] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-52898, DK-53387] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Alahari SK, 2002, INT REV CYTOL, V220, P145; BALER R, 1992, J CELL BIOL, V117, P1151, DOI 10.1083/jcb.117.6.1151; Beere HM, 2000, NAT CELL BIOL, V2, P469, DOI 10.1038/35019501; Bellas RE, 2002, AM J PHYSIOL-LUNG C, V282, pL1135, DOI 10.1152/ajplung.00174.2001; Bergin E, 2000, AM J PHYSIOL-RENAL, V278, pF758, DOI 10.1152/ajprenal.2000.278.5.F758; Borkan SC, 1997, AM J PHYSIOL-RENAL, V272, pF347, DOI 10.1152/ajprenal.1997.272.3.F347; CALALB MB, 1995, MOL CELL BIOL, V15, P954; CHEN HC, 1995, J BIOL CHEM, V270, P16995, DOI 10.1074/jbc.270.28.16995; Feldenberg LR, 1999, AM J PHYSIOL-RENAL, V276, pF837, DOI 10.1152/ajprenal.1999.276.6.F837; Fink AL, 1999, PHYSIOL REV, V79, P425, DOI 10.1152/physrev.1999.79.2.425; FREEMAN BC, 1995, EMBO J, V14, P2281, DOI 10.1002/j.1460-2075.1995.tb07222.x; Gabai VL, 2002, MOL CELL BIOL, V22, P3415, DOI 10.1128/MCB.22.10.3415-3424.2002; Gervais FG, 1998, J BIOL CHEM, V273, P17102, DOI 10.1074/jbc.273.27.17102; Grossmann J, 2001, GASTROENTEROLOGY, V120, P79, DOI 10.1053/gast.2001.20879; Harrington EO, 2001, AM J PHYSIOL-LUNG C, V280, pL342, DOI 10.1152/ajplung.2001.280.2.L342; Hartl FU, 1996, NATURE, V381, P571, DOI 10.1038/381571a0; HILDEBRAND JD, 1995, MOL BIOL CELL, V6, P637, DOI 10.1091/mbc.6.6.637; ILLC D, 1995, NATURE, V377, P539; Jaattela M, 1998, EMBO J, V17, P6124, DOI 10.1093/emboj/17.21.6124; Jones G, 2001, CANCER RES, V61, P4978; Joza N, 2001, NATURE, V410, P549, DOI 10.1038/35069004; Kasahara T, 2002, ANTIOXID REDOX SIGN, V4, P491, DOI 10.1089/15230860260196290; KROSHIAN VM, 1994, AM J PHYSIOL, V266, pF21, DOI 10.1152/ajprenal.1994.266.1.F21; Kwon O, 1998, J CLIN INVEST, V101, P2054, DOI 10.1172/JCI772; Li CY, 2000, J BIOL CHEM, V275, P25665, DOI 10.1074/jbc.M906383199; Li F, 2002, AM J PHYSIOL-CELL PH, V283, pC917, DOI 10.1152/ajpcell.00517.2001; LI GC, 1992, P NATL ACAD SCI USA, V89, P2036, DOI 10.1073/pnas.89.6.2036; Lieberthal W, 1997, J AM SOC NEPHROL, V8, P175; Lieberthal W, 1998, AM J PHYSIOL-RENAL, V274, pF315, DOI 10.1152/ajprenal.1998.274.2.F315; MIYAMOTO S, 1995, J CELL BIOL, V131, P791, DOI 10.1083/jcb.131.3.791; Mosser DD, 2000, MOL CELL BIOL, V20, P7146, DOI 10.1128/MCB.20.19.7146-7159.2000; Mosser DD, 1997, MOL CELL BIOL, V17, P5317, DOI 10.1128/MCB.17.9.5317; NOIRI E, 1994, KIDNEY INT, V46, P1050, DOI 10.1038/ki.1994.366; Ravagnan L, 2001, NAT CELL BIOL, V3, P839, DOI 10.1038/ncb0901-839; Ridyard MS, 2001, CELL BIOL INT, V25, P215, DOI 10.1006/cbir.2000.0634; Ruest PJ, 2000, CELL GROWTH DIFFER, V11, P41; RYAN MJ, 1994, KIDNEY INT, V45, P48, DOI 10.1038/ki.1994.6; Sakurai S, 2002, BIOCHEM BIOPH RES CO, V293, P174, DOI 10.1016/S0006-291X(02)00192-4; Sasaki H, 2002, GYNECOL ONCOL, V85, P339, DOI 10.1006/gyno.2002.6632; Schaller MD, 2001, BBA-MOL CELL RES, V1540, P1, DOI 10.1016/S0167-4889(01)00123-9; SCHUMER M, 1992, AM J PATHOL, V140, P831; Sieg DJ, 2000, NAT CELL BIOL, V2, P249, DOI 10.1038/35010517; Sonoda Y, 2000, J BIOL CHEM, V275, P16309, DOI 10.1074/jbc.275.21.16309; Stewart A, 2002, BIOCHEM BIOPH RES CO, V299, P62, DOI 10.1016/S0006-291X(02)02547-0; van de Water B, 1999, J BIOL CHEM, V274, P13328, DOI 10.1074/jbc.274.19.13328; Wang YH, 1999, KIDNEY INT, V55, P2224, DOI 10.1046/j.1523-1755.1999.00476.x; Wang YH, 1996, AM J PHYSIOL-RENAL, V270, pF1057, DOI 10.1152/ajprenal.1996.270.6.F1057; Wang YH, 2002, CELL STRESS CHAPERON, V7, P137, DOI 10.1379/1466-1268(2002)007<0137:HEESIA>2.0.CO;2; Wen LP, 1997, J BIOL CHEM, V272, P26056, DOI 10.1074/jbc.272.41.26056; Zhao J, 2001, MOL BIOL CELL, V12, P4066, DOI 10.1091/mbc.12.12.4066; Zuk A, 1998, AM J PHYSIOL-CELL PH, V275, pC711, DOI 10.1152/ajpcell.1998.275.3.C711	51	39	40	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 16	2003	278	20					18214	18220		10.1074/jbc.M300126200	http://dx.doi.org/10.1074/jbc.M300126200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677YX	12611892	hybrid			2022-12-25	WOS:000182838300082
J	Wan, KF; Sambi, BS; Tate, R; Waters, C; Pyne, NJ				Wan, KF; Sambi, BS; Tate, R; Waters, C; Pyne, NJ			The inhibitory gamma subunit of the type 6 retinal cGMP phosphodiesterase functions to link c-Src and G-protein-coupled receptor kinase 2 in a signaling unit that regulates p42/p44 mitogen-activated protein kinase by epidermal growth factor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GUANOSINE-MONOPHOSPHATE PHOSPHODIESTERASE; MEDIATED TYROSINE PHOSPHORYLATION; AIRWAY SMOOTH-MUSCLE; G(BETA-GAMMA) SUBUNITS; FACTOR STIMULATION; BETA-ARRESTIN; INSULIN; CELLS; INTERNALIZATION; REQUIRES	The inhibitory gamma subunit of the retinal photoreceptor type 6 cGMP phosphodiesterase (PDEgamma) is phosphorylated by G-protein-coupled receptor kinase 2 on threonine 62 and regulates the epidermal growth factor-dependent stimulation of p42/p44 mitogen-activated protein kinase in human embryonic kidney 293 cells. We report here that PDEgamma is in a pre-formed complex with c-Src and that stimulation of cells with epidermal growth factor promotes the association of GRK2 with this complex. c-Src has a critical role in the stimulation of the p42/p44 mitogen-activated protein kinase cascade by epidermal growth factor, because c-Src inhibitors block the activation of this kinase by the growth factor. Mutation of Thr-62 (to Ala) in PDEgamma produced a GRK2 phosphorylation-resistant mutant that was less effective in associating with GRK2 in response to epidermal growth factor and did not potentiate the stimulation of p42/p44 mitogen-activated protein kinase by this growth factor. The transcript for a short splice variant version of PDEgamma lacking the Thr-62 phosphorylation site is also expressed in certain mammalian cells and, in common with the Thr-62 mutant, failed to potentiate the stimulatory effect of epidermal growth factor on p42/p44 mitogen-activated protein kinase. The mutation of Thr-22 (to Ala) in PDEgamma, which is a site for phosphorylation by p42/p44 mitogen-activated protein kinase, resulted in a prolonged activation of p42/p44 mitogen-activated protein kinase by epidermal growth factor, suggesting a role for this phosphorylation event in the negative feedback control of PDEgamma.	Univ Strathclyde, Strathclyde Inst Biomed Sci, Dept Physiol & Pharmacol, Glasgow G4 0NR, Lanark, Scotland	University of Strathclyde	Pyne, NJ (corresponding author), Univ Strathclyde, Strathclyde Inst Biomed Sci, Dept Physiol & Pharmacol, 27 Taylor St, Glasgow G4 0NR, Lanark, Scotland.			Tate, Rothwelle/0000-0001-5857-4267; Pyne, Nigel/0000-0002-5657-4578				Ahn S, 1999, J BIOL CHEM, V274, P1185, DOI 10.1074/jbc.274.3.1185; Alderton F, 2001, J BIOL CHEM, V276, P28578, DOI 10.1074/jbc.M102771200; Clague MJ, 1998, BIOCHEM J, V336, P271, DOI 10.1042/bj3360271; Conway AM, 1999, BIOCHEM J, V337, P171, DOI 10.1042/0264-6021:3370171; Daaka Y, 1998, J BIOL CHEM, V273, P685, DOI 10.1074/jbc.273.2.685; Dalle S, 2001, J BIOL CHEM, V276, P15688, DOI 10.1074/jbc.M010884200; Fedorov YV, 1998, MOL CELL BIOL, V18, P5780, DOI 10.1128/MCB.18.10.5780; Ferguson SSG, 1996, SCIENCE, V271, P363, DOI 10.1126/science.271.5247.363; Hallak H, 2000, J BIOL CHEM, V275, P2255, DOI 10.1074/jbc.275.4.2255; Lin FT, 1998, J BIOL CHEM, V273, P31640, DOI 10.1074/jbc.273.48.31640; Lochhead A, 1997, J BIOL CHEM, V272, P18397, DOI 10.1074/jbc.272.29.18397; Luttrell LM, 1999, CURR OPIN CELL BIOL, V11, P177, DOI 10.1016/S0955-0674(99)80023-4; LUTTRELL LM, 1995, J BIOL CHEM, V270, P16495, DOI 10.1074/jbc.270.28.16495; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; Paglia MJ, 2002, J BIOL CHEM, V277, P5017, DOI 10.1074/jbc.M106328200; Rakhit S, 2000, MOL PHARMACOL, V58, P413, DOI 10.1124/mol.58.2.413; Rakhit S, 2001, MOL PHARMACOL, V60, P63, DOI 10.1124/mol.60.1.63; Sarnago S, 1999, J BIOL CHEM, V274, P34411, DOI 10.1074/jbc.274.48.34411; STRYER L, 1991, J BIOL CHEM, V266, P10711; Tate RJ, 2002, GENOMICS, V79, P582, DOI 10.1006/geno.2002.6740; Tate Rothwelle J., 1998, Cell Biochemistry and Biophysics, V29, P133, DOI 10.1007/BF02737832; VAN BT, 1995, NATURE, V376, P781; Wan KF, 2001, J BIOL CHEM, V276, P37802; Wang HY, 2000, J BIOL CHEM, V275, P36086, DOI 10.1074/jbc.M004404200	24	25	25	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 16	2003	278	20					18658	18663		10.1074/jbc.M212103200	http://dx.doi.org/10.1074/jbc.M212103200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677YX	12624098	hybrid			2022-12-25	WOS:000182838300138
J	Yin, SM; Ho, CK; Shuman, S				Yin, SM; Ho, CK; Shuman, S			Structure-function analysis of T4 RNA ligase 2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VIRUS-DNA-LIGASE; RNA CAPPING ENZYME; CRYSTAL-STRUCTURE; MUTATIONAL ANALYSIS; ADENYLYLATION SITE; NICK RECOGNITION; CATALYSIS; COMPLEX; MOTIFS; IV	Bacteriophage T4 RNA ligase 2 (Rnl2) exemplifies a polynucleotide ligase family that includes the trypanosome RNA-editing ligases and putative RNA ligases encoded by eukaryotic viruses and archaea. Here we analyzed 12 individual amino acids of Rnl2 that were identified by alanine scanning as essential for strand joining. We determined structure-activity relationships via conservative substitutions and examined mutational effects on the isolated steps of ligase adenylylation and phosphodiester bond formation. The essential residues of Rnl2 are located within conserved motifs that define a superfamily of nucleotidyl transferases that act via enzyme-(lysyl-N)-NMP intermediates. Our mutagenesis results underscore a shared active site architecture in Rnl2-like ligases, DNA ligases, and mRNA capping enzymes. They also highlight two essential signature residues, Glu(34) and Asn(40), that flank the active site lysine nucleophile (Lys(35)) and are unique to the Rnl2-like ligase family.	Sloan Kettering Inst, Program Mol Biol, New York, NY 10021 USA	Memorial Sloan Kettering Cancer Center	Shuman, S (corresponding author), Sloan Kettering Inst, Program Mol Biol, New York, NY 10021 USA.	s-shuman@ski.mskcc.org	Ho, KIong/GPP-6051-2022		NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM063611] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM63611] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AMITSUR M, 1987, EMBO J, V6, P2499, DOI 10.1002/j.1460-2075.1987.tb02532.x; CRANSTON JW, 1974, J BIOL CHEM, V249, P7447; Doherty AJ, 2000, J MOL BIOL, V296, P43, DOI 10.1006/jmbi.1999.3423; Engler M.J., 1982, ENZYMES, V15, P3, DOI [10.1016/S1874-6047(08)60273-5, DOI 10.1016/S1874-6047(08)60273-5]; Hakansson K, 1997, CELL, V89, P545, DOI 10.1016/S0092-8674(00)80236-6; HEAPHY S, 1987, BIOCHEMISTRY-US, V26, P1688, DOI 10.1021/bi00380a030; Ho CK, 2002, P NATL ACAD SCI USA, V99, P12709, DOI 10.1073/pnas.192184699; Kaufmann G, 2000, TRENDS BIOCHEM SCI, V25, P70, DOI 10.1016/S0968-0004(99)01525-X; Lee JY, 2000, EMBO J, V19, P1119, DOI 10.1093/emboj/19.5.1119; McManus MT, 2001, RNA, V7, P167, DOI 10.1017/S1355838201002072; Odell M, 2000, MOL CELL, V6, P1183, DOI 10.1016/S1097-2765(00)00115-5; Rusche LN, 2001, MOL CELL BIOL, V21, P979, DOI 10.1128/MCB.21.4.979-989.2001; Schnaufer A, 2001, SCIENCE, V291, P2159, DOI 10.1126/science.1058655; Sekiguchi J, 1997, J VIROL, V71, P9679, DOI 10.1128/JVI.71.12.9679-9684.1997; Shuman S, 2001, PROG NUCLEIC ACID RE, V66, P1; SHUMAN S, 1995, VIROLOGY, V211, P73, DOI 10.1006/viro.1995.1380; SHUMAN S, 1994, P NATL ACAD SCI USA, V91, P12046, DOI 10.1073/pnas.91.25.12046; Shuman S, 2001, COLD SPRING HARB SYM, V66, P301, DOI 10.1101/sqb.2001.66.301; SHUMAN S, 1995, MOL MICROBIOL, V17, P405, DOI 10.1111/j.1365-2958.1995.mmi_17030405.x; SILBER R, 1972, P NATL ACAD SCI USA, V69, P3009, DOI 10.1073/pnas.69.10.3009; Sriskanda V, 1998, NUCLEIC ACIDS RES, V26, P525, DOI 10.1093/nar/26.2.525; Sriskanda V, 1998, NUCLEIC ACIDS RES, V26, P4618, DOI 10.1093/nar/26.20.4618; Sriskanda V, 2000, NUCLEIC ACIDS RES, V28, P2221, DOI 10.1093/nar/28.11.2221; Sriskanda V, 2002, J BIOL CHEM, V277, P9661, DOI 10.1074/jbc.M110613200; Sriskanda V, 2002, NUCLEIC ACIDS RES, V30, P903, DOI 10.1093/nar/30.4.903; Subramanya HS, 1996, CELL, V85, P607, DOI 10.1016/S0092-8674(00)81260-X; SUGINO A, 1977, J BIOL CHEM, V252, P1732; THOGERSEN HC, 1985, EUR J BIOCHEM, V147, P325, DOI 10.1111/j.1432-1033.1985.tb08753.x; Uhlenbeck O.C., 1982, ENZYMES, V15, P31, DOI [10.1016/s1874-6047(08)60274-7, DOI 10.1016/S1874-6047(08)60274-7]; Wang SP, 1997, P NATL ACAD SCI USA, V94, P9573, DOI 10.1073/pnas.94.18.9573	30	57	63	0	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 16	2003	278	20					17601	17608		10.1074/jbc.M300817200	http://dx.doi.org/10.1074/jbc.M300817200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677YX	12611899	hybrid			2022-12-25	WOS:000182838300005
J	Engblom, AC; Johansen, FF; Kristiansen, U				Engblom, AC; Johansen, FF; Kristiansen, U			Actions and interactions of extracellular potassium and kainate on expression of 13 gamma-aminobutyric acid type A receptor subunits in cultured mouse cerebellar granule neurons	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL RT-PCR; GABA(A) RECEPTOR; A RECEPTOR; MESSENGER-RNAS; DELTA-SUBUNIT; RAT-BRAIN; POSTNATAL-DEVELOPMENT; CORTICAL-NEURONS; ALPHA-SUBUNITS; PATCH-CLAMP	Cerebellar granule neurons in culture are a popular model for studying neuronal signaling and development. Depolarizing concentrations of K+ are routinely used to enhance cell survival, and kainate is sometimes added to eliminate GABAergic neurons. We have investigated the effect of these measures on expression of mRNA for gamma-aminobutyric acid type A (GABA(A)) receptor alpha1-6, beta1-3, gamma1-3, and delta subunits in cultures of mouse cerebellar granule neurons grown for 7 or 12 days in vitro (DIV) using semi-quantitative reverse transcription-PCR. We detected mRNA for the alpha1, alpha2, alpha5, alpha6, beta2, beta3, beta2, and delta subunits in all the cell cultures, but the expression levels of the alpha5-, alpha6-, and beta2-subunit mRNAs were significantly dependent on the composition of the culture medium. Both an increase of the extracellular K+ concentration from 5 to 25 mM and the addition of 50 muM kainate immediately depolarized the neurons but prolonged exposure (7-8 DIV)-induced compensatory hyperpolarization. 25 mM K+ caused a shift from alpha6 to alpha5 expression measured at 7 and 12 DIV, which was mimicked by kainate in 12 DIV cultures. The expression of beta2 was decreased by 25 mM K+ in 7 DIV cultures and by kainate in 12 DIV cultures. The effects on beta2 expression could not be ascribed to depolarization. Alterations of alpha6 mRNA expression were reflected in altered sensitivity to GABA and furosemide of the resulting receptors. Our study has shown that a depolarizing K+ concentration as well as kainate in the culture medium significantly disturbs maturation of GABA(A) receptor subunit expression.	Royal Danish Sch Pharm, Dept Pharmacol, DK-2100 Copenhagen, Denmark; Univ Copenhagen, Neuropathol Lab, DK-2100 Copenhagen, Denmark	Royal Danish School of Pharmacy; University of Copenhagen	Kristiansen, U (corresponding author), Royal Danish Sch Pharm, Dept Pharmacol, 2 Univ Pk, DK-2100 Copenhagen, Denmark.							Alsbo CW, 2001, EUR J NEUROSCI, V13, P1673, DOI 10.1046/j.0953-816x.2001.01539.x; Barnard EA, 1998, PHARMACOL REV, V50, P291; BESSHO Y, 1994, NEURON, V12, P87, DOI 10.1016/0896-6273(94)90154-6; Bhave SV, 1999, J NEUROSCI, V19, P3277, DOI 10.1523/jneurosci.19-09-03277.1999; Bonnert TP, 1999, P NATL ACAD SCI USA, V96, P9891, DOI 10.1073/pnas.96.17.9891; Brooks-Kayal AR, 2001, J NEUROCHEM, V77, P1266, DOI 10.1046/j.1471-4159.2001.00329.x; CARUNCHO HJ, 1995, NEUROSCIENCE, V67, P583, DOI 10.1016/0306-4522(95)00065-Q; CONDORELLI DF, 1993, J NEUROCHEM, V61, P2133, DOI 10.1111/j.1471-4159.1993.tb07451.x; Courtney MJ, 1997, J NEUROSCI, V17, P4201; DARLISON MG, 1995, SEMIN NEUROSCI, V7, P115, DOI 10.1006/smns.1995.0013; Dingledine R, 1999, PHARMACOL REV, V51, P7; GALLO V, 1987, J NEUROSCI, V7, P2203; Gault LM, 1997, J NEUROSCI, V17, P2391; Gault LM, 1998, J NEUROCHEM, V70, P1907; HACK NJ, 1995, DEV BRAIN RES, V87, P55, DOI 10.1016/0165-3806(95)00054-H; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; Hansen SL, 2001, BRIT J PHARMACOL, V133, P539, DOI 10.1038/sj.bjp.0704121; HARRIS BT, 1995, MOL BRAIN RES, V28, P338, DOI 10.1016/0169-328X(94)00240-F; Jechlinger M, 1998, J NEUROSCI, V18, P2449; Jensen JB, 1998, NEUROCHEM INT, V32, P505, DOI 10.1016/S0197-0186(97)00130-7; JOHANSEN FF, 1995, NEUROCHEM INT, V26, P239, DOI 10.1016/0197-0186(94)00129-I; Jones A, 1997, J NEUROSCI, V17, P1350; Koester J., 1991, PRINCIPLES NEURAL SC, V3, P81; KORPI ER, 1995, MOL PHARMACOL, V47, P283; Korpi ER, 2002, PROG NEUROBIOL, V67, P113, DOI 10.1016/S0301-0082(02)00013-8; LAURIE DJ, 1992, J NEUROSCI, V12, P4151; LAURIE DJ, 1992, J NEUROSCI, V12, P1063; Lee YH, 2000, J NEUROCHEM, V74, P2401, DOI 10.1046/j.1471-4159.2000.0742401.x; MATHEWS GC, 1994, NEURON, V13, P149, DOI 10.1016/0896-6273(94)90465-0; McKernan RM, 1996, TRENDS NEUROSCI, V19, P139, DOI 10.1016/S0166-2236(96)80023-3; Mellor JR, 1998, J NEUROSCI, V18, P2822; MOGENSEN HS, 1994, INT J DEV NEUROSCI, V12, P451, DOI 10.1016/0736-5748(94)90029-9; Montpied P, 1998, DEV NEUROSCI-BASEL, V20, P74, DOI 10.1159/000017301; Mossmann T., 1983, J IMMUNOL METHODS, V65, P55; Nusser Z, 1999, EUR J NEUROSCI, V11, P1685, DOI 10.1046/j.1460-9568.1999.00581.x; Pirker S, 2000, NEUROSCIENCE, V101, P815, DOI 10.1016/S0306-4522(00)00442-5; POLLARD S, 1995, J BIOL CHEM, V270, P21285, DOI 10.1074/jbc.270.36.21285; POULTER MO, 1992, J NEUROSCI, V12, P2888, DOI 10.1523/JNEUROSCI.12-08-02888.1992; QUIRK K, 1994, J BIOL CHEM, V269, P16020; Rudolph U, 2001, TRENDS PHARMACOL SCI, V22, P188, DOI 10.1016/S0165-6147(00)01646-1; Saxena NC, 1996, MOL PHARMACOL, V49, P567; Schousboe A., 1989, DISSECTION TISSUE CU, P203; Sieghart W, 1999, NEUROCHEM INT, V34, P379, DOI 10.1016/S0197-0186(99)00045-5; SIEGHART W, 1995, PHARMACOL REV, V47, P181; Sigel E, 2000, J NEUROCHEM, V74, P2590, DOI 10.1046/j.1471-4159.2000.0742590.x; Sinkkonen ST, 2000, J NEUROSCI, V20, P3588, DOI 10.1523/JNEUROSCI.20-10-03588.2000; THOMPSON CL, 1994, J NEUROCHEM, V62, P2037; Vallano ML, 1996, J NEUROSCI, V16, P631; VERDOORN TA, 1994, MOL PHARMACOL, V45, P475; Wisden W, 1996, NEUROPHARMACOLOGY, V35, P1139, DOI 10.1016/S0028-3908(96)00076-7; WOOD KA, 1993, NEURON, V11, P621, DOI 10.1016/0896-6273(93)90074-2; ZHENG TM, 1994, P NATL ACAD SCI USA, V91, P10952, DOI 10.1073/pnas.91.23.10952	52	14	14	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 9	2003	278	19					16543	16550		10.1074/jbc.M300548200	http://dx.doi.org/10.1074/jbc.M300548200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677QG	12621038	hybrid			2022-12-25	WOS:000182818600015
J	Jirawatnotai, S; Moons, DS; Stocco, CO; Franks, R; Hales, DB; Gibori, G; Kiyokawa, H				Jirawatnotai, S; Moons, DS; Stocco, CO; Franks, R; Hales, DB; Gibori, G; Kiyokawa, H			The cyclin-dependent kinase inhibitors p27(Kip1) and p21(Cip1) cooperate to restrict proliferative life span in differentiating ovarian cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MURINE FIBROBLASTS LACKING; CDK INHIBITORS; MICE LACKING; GRANULOSA-CELLS; ONCOGENIC RAS; SENESCENCE; G1; P16(INK4A); CULTURE; CANCER	The timing of cellular exit from the cell cycle during differentiation is specific for each cell type or lineage. Granulosa cells in the ovary establish quiescence within several hours after the ovulation-inducing luteinizing hormone surge, whereas they undergo differentiation into corpora lutea. The expression of Cdk inhibitors p21(Cip1/Waf1) and p27(Kip1) is up-regulated during this process, suggesting that these cell cycle inhibitors are involved in restricting proliferative capacity of differentiating granulosa cells. Here we demonstrate that the lack of p27(Kip1) and p21(Cip1) synergistically renders granulosa cells extended an proliferative life span. Immunohistochemical analyses demonstrated that corpora lutea of p27(Kip1), p21(Cip1) double-null mice showed large numbers of cells with bromodeoxyuridine incorporation and high proliferative cell nuclear antigen expression, which were more remarkable than those in p27(Kip1) single-deficient mice showing modest hyperproliferation. In contrast, differentiating granulosa cells in p21(Cip1-)deficient mice ceased proliferation similarly to those in wild-type mice. Interestingly, granulosa cells isolated from p27(Kip1), p21(Cip1) double-null mice exhibited markedly prolonged proliferative life span in culture, unlike cells with other genotypes. Cultured p27(Kip1), p21(Cip1) double-null granulosa cells maintained expression of steroidogenic enzymes and gonadotropin receptors through 8-10 passages and could undergo further differentiation in responses to cAMP accumulation. Thus, the cooperation of p27(Kip1) and p21(Cip1) is critical for withdrawal of granulosa cells from the cell cycle, in concert with luteal differentiation and possibly culture-induced senescence.	Univ Illinois, Coll Med, Dept Mol Genet, Chicago, IL 60607 USA; Univ Illinois, Coll Med, Dept Physiol & Biophys, Chicago, IL 60607 USA; Univ Illinois, Coll Med, Res Resources Ctr, Chicago, IL 60607 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Kiyokawa, H (corresponding author), Univ Illinois, Coll Med, Dept Mol Genet, 900 S Ashland Ave,M-C 669, Chicago, IL 60607 USA.	kiyokawa@uic.edu		Kiyokawa, Hiroaki/0000-0002-7942-6455	NICHD NIH HHS [HD38085] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD038085] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Bagui TK, 2000, MOL CELL BIOL, V20, P8748, DOI 10.1128/MCB.20.23.8748-8757.2000; BRUGAROLAS J, 1995, NATURE, V377, P552, DOI 10.1038/377552a0; Campisi J, 1996, EXP GERONTOL, V31, P7, DOI 10.1016/0531-5565(95)02024-1; Campisi J, 2001, EXP GERONTOL, V36, P607, DOI 10.1016/S0531-5565(00)00230-8; Cheng MG, 1998, P NATL ACAD SCI USA, V95, P1091, DOI 10.1073/pnas.95.3.1091; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; Fero ML, 1996, CELL, V85, P733, DOI 10.1016/S0092-8674(00)81239-8; HALES DB, 1989, ENDOCRINOLOGY, V124, P2099, DOI 10.1210/endo-124-5-2099; Harbour JW, 1999, CELL, V98, P859, DOI 10.1016/S0092-8674(00)81519-6; HIRSHFIELD AN, 1991, INT REV CYTOL, V124, P43; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; Kamijo T, 1997, CELL, V91, P649, DOI 10.1016/S0092-8674(00)80452-3; Kiyokawa H, 1998, CURR TOP MICROBIOL, V227, P105; Kiyokawa H, 1996, CELL, V85, P721, DOI 10.1016/S0092-8674(00)81238-6; Krimpenfort P, 2001, NATURE, V413, P83, DOI 10.1038/35092584; Kwon YH, 2002, J BIOL CHEM, V277, P41417, DOI 10.1074/jbc.M203388200; LaBaer J, 1997, GENE DEV, V11, P847, DOI 10.1101/gad.11.7.847; Moons DS, 2002, ENDOCRINOLOGY, V143, P3001, DOI 10.1210/en.143.8.3001; Moons DS, 2002, ENDOCRINOLOGY, V143, P647, DOI 10.1210/en.143.2.647; Nakayama K, 1996, CELL, V85, P707, DOI 10.1016/S0092-8674(00)81237-4; Nevins JR, 2001, HUM MOL GENET, V10, P699, DOI 10.1093/hmg/10.7.699; ORLY J, 1980, CELL, V20, P817, DOI 10.1016/0092-8674(80)90328-1; Pantoja C, 1999, ONCOGENE, V18, P4974, DOI 10.1038/sj.onc.1202880; PARDEE AB, 1989, SCIENCE, V246, P603, DOI 10.1126/science.2683075; RAO MC, 1978, CELL, V14, P71, DOI 10.1016/0092-8674(78)90302-1; Reed SI, 1997, CANCER SURV, V29, P7; Robker RL, 1998, BIOL REPROD, V59, P476, DOI 10.1095/biolreprod59.3.476; Robker RL, 1998, MOL ENDOCRINOL, V12, P924, DOI 10.1210/me.12.7.924; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Sharpless NE, 2001, NATURE, V413, P86, DOI 10.1038/35092592; Sherr CJ, 2000, CELL, V102, P407, DOI 10.1016/S0092-8674(00)00046-5; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Sicinski P, 1996, NATURE, V384, P470, DOI 10.1038/384470a0; Sugimoto M, 2002, ONCOGENE, V21, P8067, DOI 10.1038/sj.onc.1206019; Tong W, 1998, CELL GROWTH DIFFER, V9, P787; Tsutsui T, 1999, MOL CELL BIOL, V19, P7011; Vidal A, 2000, GENE, V247, P1, DOI 10.1016/S0378-1119(00)00092-5; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; Zhang PM, 1998, GENE DEV, V12, P3162, DOI 10.1101/gad.12.20.3162; Zhang PM, 1999, GENE DEV, V13, P213, DOI 10.1101/gad.13.2.213; Zindy F, 2001, MOL CELL BIOL, V21, P3244, DOI 10.1128/MCB.21.9.3244-3255.2001; Zou XH, 2002, GENE DEV, V16, P2923, DOI 10.1101/gad.1033002	43	52	53	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 9	2003	278	19					17021	17027		10.1074/jbc.M301206200	http://dx.doi.org/10.1074/jbc.M301206200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677QG	12609976	hybrid			2022-12-25	WOS:000182818600078
J	Kilkenny, DM; Rocheleau, JV; Price, J; Reich, MB; Miller, GG				Kilkenny, DM; Rocheleau, JV; Price, J; Reich, MB; Miller, GG			c-Src regulation of fibroblast growth factor-induced proliferation in murine embryonic fibroblasts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE KINASES; FAMILY KINASES; CELL-PROLIFERATION; FACTOR RECEPTOR-1; PROTEIN; ASSOCIATION; REQUIREMENT; ACTIVATION	Activated fibroblast growth factor receptor 1 (FGFR1) propagates FGF signals through multiple intracellular pathways via intermediates FRS2, PLCgamma, and Ras. Conflicting reports exist concerning the interaction between FGFR1 and Src family kinases. To address the role of c-Src in FGFR1 signaling, we compared proliferative responses of murine embryonic fibroblasts (MEF) deficient in c-Src, Yes, and Fyn to MEF expressing either endogenous levels or overexpressing c-Src. MEF with endogenous c-Src had significantly greater FGF-induced DNA synthesis and proliferation than cells lacking or overexpressing c-Src. This was related directly to c-Src expression by analysis of c-Src-deficient cells transfected with and sorted for varying levels of a c-Src expression vector. This suggests an "optimal" quantity of c-Src expression for FGF-induced proliferation. To determine if this was a general phenomenon for growth factor signaling pathways utilizing c-Src, responses to epidermal growth factor (EGF), platelet-derived growth factor (PDGF), and lysophosphatidic acid (LPA) were examined. As for FGF, responses to EGF were clearly inhibited when c-Src was absent or overexpressed. In contrast, varying levels of c-Src had little effect on responses to PDGF or LPA. The data show that mitogenic pathways activated by FGF-1 and EGF are regulated by c-Src protein levels and appear to differ significantly from those activated by PDGF and LPA.	Vanderbilt Univ, Sch Med, Dept Med, Nashville, TN 37232 USA; Vanderbilt Univ, Dept Physiol & Mol Biophys, Nashville, TN 37232 USA; Vanderbilt Vet Affairs Med Ctr, Flow Cytometry Pathol Lab, Nashville, TN 37232 USA	Vanderbilt University; Vanderbilt University; Vanderbilt University	Miller, GG (corresponding author), Vanderbilt Univ, Sch Med, Dept Med, A3310 Med Ctr N, Nashville, TN 37232 USA.	Geraldine.Miller@vanderbilt.edu		Rocheleau, Jonathan/0000-0002-1760-2564	NCI NIH HHS [P30CA68485] Funding Source: Medline; NHLBI NIH HHS [T32-HL69765-01, HL53771] Funding Source: Medline; NIDDK NIH HHS [DK20593] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA068485] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL053771, T32HL069765] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P60DK020593] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BASILICO C, 1992, ADV CANCER RES, V59, P115, DOI 10.1016/S0065-230X(08)60305-X; Bastaki M, 1997, ARTERIOSCL THROM VAS, V17, P454, DOI 10.1161/01.ATV.17.3.454; Bevan P, 2001, J CELL SCI, V114, P1429; Broome MA, 2000, ONCOGENE, V19, P2867, DOI 10.1038/sj.onc.1203608; CHACKALAPARAMPI.I, 1998, CELL, V52, P801; Dickson C, 2000, BREAST CANCER RES, V2, P191, DOI 10.1186/bcr53; Dikov MM, 1998, J BIOL CHEM, V273, P15811, DOI 10.1074/jbc.273.25.15811; Fincham VJ, 2000, MOL CELL BIOL, V20, P6518, DOI 10.1128/MCB.20.17.6518-6536.2000; JAYE M, 1992, BIOCHIM BIOPHYS ACTA, V1135, P185, DOI 10.1016/0167-4889(92)90136-Y; JOHNSON DE, 1993, ADV CANCER RES, V60, P1; Klinghoffer RA, 1999, EMBO J, V18, P2459, DOI 10.1093/emboj/18.9.2459; Klint P, 1999, ONCOGENE, V18, P3354, DOI 10.1038/sj.onc.1202680; Klint Peter, 1999, Frontiers in Bioscience, V4, pD165, DOI 10.2741/Klint; Kouhara H, 1997, CELL, V89, P693, DOI 10.1016/S0092-8674(00)80252-4; LANDGREN E, 1995, ONCOGENE, V10, P2027; Landgren E, 1998, ONCOGENE, V17, P283, DOI 10.1038/sj.onc.1201936; LaVallee TM, 1998, J CELL BIOL, V141, P1647, DOI 10.1083/jcb.141.7.1647; Liu JL, 1999, ONCOGENE, V18, P6700, DOI 10.1038/sj.onc.1203050; Lowell CA, 1996, GENE DEV, V10, P1845, DOI 10.1101/gad.10.15.1845; Miller GG, 1999, CIRCULATION, V100, P2396, DOI 10.1161/01.CIR.100.24.2396; Ong SH, 2001, P NATL ACAD SCI USA, V98, P6074, DOI 10.1073/pnas.111114298; Powers CJ, 2000, ENDOCR-RELAT CANCER, V7, P165, DOI 10.1677/erc.0.0070165; ROCHE S, 1995, SCIENCE, V269, P1567, DOI 10.1126/science.7545311; ROCHE S, 1995, MOL CELL BIOL, V15, P1102; RODIER JM, 1995, J CELL BIOL, V131, P761, DOI 10.1083/jcb.131.3.761; SORIANO P, 1991, CELL, V64, P693, DOI 10.1016/0092-8674(91)90499-O; STEIN PL, 1994, GENE DEV, V8, P1999, DOI 10.1101/gad.8.17.1999; Tartaglia M, 2001, DNA CELL BIOL, V20, P367, DOI 10.1089/10445490152122488; TWAMLEYSTEIN GM, 1993, P NATL ACAD SCI USA, V90, P7696, DOI 10.1073/pnas.90.16.7696; Yamashita T, 2000, BIOCHEM BIOPH RES CO, V277, P494, DOI 10.1006/bbrc.2000.3696; Yayon A, 1997, ONCOGENE, V14, P2999, DOI 10.1038/sj.onc.1201159; ZHAN X, 1994, J BIOL CHEM, V269, P20221; ZHAO XM, 1994, J CLIN INVEST, V94, P992, DOI 10.1172/JCI117466	33	33	40	0	1	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 9	2003	278	19					17448	17454		10.1074/jbc.M209698200	http://dx.doi.org/10.1074/jbc.M209698200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677QG	12621028	hybrid			2022-12-25	WOS:000182818600132
J	Lovato, P; Brender, C; Agnholt, J; Kelsen, J; Kaltoft, K; Svejgaard, A; Eriksen, KW; Woetmann, A; Odum, N				Lovato, P; Brender, C; Agnholt, J; Kelsen, J; Kaltoft, K; Svejgaard, A; Eriksen, KW; Woetmann, A; Odum, N			Constitutive STAT3 activation in intestinal T cells from patients with Crohn's disease	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INFLAMMATORY BOWEL-DISEASE; IFN-GAMMA; PATHWAY; GROWTH; INTERLEUKIN-12; EXPRESSION; RESPONSES; LYMPHOMA; PROTEINS; SIGNALS	Via cytoplasmic signal transduction pathways, cytokines induce a variety of biological responses and modulate the outcome of inflammatory diseases and malignancies. Crohn's disease is a chronic inflammatory bowel disease of unknown etiology. Perturbation of the intestinal cytokine homeostasis is believed to play a pivotal role, but the pathogenesis of Crohn's disease is not fully understood. Here, we study intestinal T cells from Crohn's disease and healthy volunteers. We show that STAT3 and STAT4 are constitutively activated in Crohn's patients but not in healthy volunteers. The activation is specific, because other STAT proteins are not constitutively activated. Furthermore, the STAT3 regulated protein, SOCS3, is also constitutively expressed in Crohn's patients but not in healthy volunteers. Taken together, these data provide evidence of abnormal STAT/SOCS signaling in Crohn's disease. This aberrant activation, so far noted only in malignant cells, establish a new critical approach for better understanding the immunopathogenesis of Crohn's disease.	Univ Copenhagen, Panum Inst, Inst Med Microbiol & Immunol, DK-2200 Copenhagen, Denmark; Univ Copenhagen, Inst Mol Biol, DK-2200 Copenhagen, Denmark; Aarhus Univ Hosp, Dept Med V, DK-8000 Aarhus, Denmark; Aarhus Univ, Inst Human Genet, DK-8000 Aarhus C, Denmark; Natl Univ Hosp, Tissue Typing Lab, Dept Clin Immunol, DK-2200 Copenhagen, Denmark	University of Copenhagen; University of Copenhagen; Aarhus University; Aarhus University	Odum, N (corresponding author), Univ Copenhagen, Panum Inst, Inst Med Microbiol & Immunol, Panum 22-5,Blegdamsvej 3C, DK-2200 Copenhagen, Denmark.		Woetmann, Anders/AAJ-3171-2020	Woetmann, Anders/0000-0002-3008-735X; Lovato, Paola/0000-0002-4097-9634; Agnholt, Jorgen/0000-0003-2822-6442				Brender C, 2001, BLOOD, V97, P1056, DOI 10.1182/blood.V97.4.1056; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; Fiocchi C, 1998, GASTROENTEROLOGY, V115, P182, DOI 10.1016/S0016-5085(98)70381-6; Fuss IJ, 1996, J IMMUNOL, V157, P1261; Garcia R, 2001, ONCOGENE, V20, P2499, DOI 10.1038/sj.onc.1204349; GouilleuxGruart V, 1996, BLOOD, V87, P1692; Hirano T, 2000, ONCOGENE, V19, P2548, DOI 10.1038/sj.onc.1203551; Horvath CM, 2000, TRENDS BIOCHEM SCI, V25, P496, DOI 10.1016/S0968-0004(00)01624-8; KALTOFT K, 1992, IN VITRO CELL DEV-AN, V28A, P161; Kim TK, 1996, SCIENCE, V273, P1717, DOI 10.1126/science.273.5282.1717; Leonard WJ, 1998, ANNU REV IMMUNOL, V16, P293, DOI 10.1146/annurev.immunol.16.1.293; MIGONE TS, 1995, SCIENCE, V269, P79, DOI 10.1126/science.7604283; Monteleone G, 1997, GASTROENTEROLOGY, V112, P1169, DOI 10.1016/S0016-5085(97)70128-8; Naka T, 1997, NATURE, V387, P924, DOI 10.1038/43219; Nielsen M, 1997, P NATL ACAD SCI USA, V94, P6764, DOI 10.1073/pnas.94.13.6764; NIELSEN M, 1994, EXP CLIN IMMUNOGENET, V11, P23; QUELLE FW, 1995, MOL CELL BIOL, V15, P3336; Schindler C, 1999, EXP CELL RES, V253, P7, DOI 10.1006/excr.1999.4670; Simpson SJ, 1998, J EXP MED, V187, P1225, DOI 10.1084/jem.187.8.1225; Song JI, 2000, ONCOGENE, V19, P2489, DOI 10.1038/sj.onc.1203483; Starr R, 1999, BIOESSAYS, V21, P47, DOI 10.1002/(SICI)1521-1878(199901)21:1<47::AID-BIES6>3.0.CO;2-N; Starr R, 1997, NATURE, V387, P917, DOI 10.1038/43206; Suzuki A, 2001, J EXP MED, V193, P471, DOI 10.1084/jem.193.4.471; Wirtz S, 1999, J IMMUNOL, V162, P1884; Zhang Q, 2002, J IMMUNOL, V168, P466, DOI 10.4049/jimmunol.168.1.466; Zushi SI, 1998, INT J CANCER, V78, P326, DOI 10.1002/(SICI)1097-0215(19981029)78:3<326::AID-IJC12>3.0.CO;2-4	26	150	173	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 9	2003	278	19					16777	16781		10.1074/jbc.M207999200	http://dx.doi.org/10.1074/jbc.M207999200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677QG	12615922	hybrid			2022-12-25	WOS:000182818600045
J	Sakai, N; Maruyama, T; Sakurai, R; Masuda, H; Yamamoto, Y; Shimizu, A; Kishi, I; Asada, H; Yamagoe, S; Yoshimura, Y				Sakai, N; Maruyama, T; Sakurai, R; Masuda, H; Yamamoto, Y; Shimizu, A; Kishi, I; Asada, H; Yamagoe, S; Yoshimura, Y			Involvement of histone acetylation in ovarian steroid-induced decidualization of human endometrial stromal cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IN-VITRO DECIDUALIZATION; FACTOR BINDING PROTEIN-1; PROGESTERONE-RECEPTOR; PROLACTIN EXPRESSION; SIGNAL TRANSDUCER; MENSTRUAL-CYCLE; TRICHOSTATIN-A; GENE PROMOTER; GROWTH; TRANSCRIPTION	Histone acetyltransferases and histone deacetylases (HDACs) determine the acetylation status of histones, regulating gene transcription. Decidualization is the progestin-induced differentiation of estrogen-primed endometrial stromal cells (ESCs), which is crucial for implantation and maintenance of pregnancy. We here show that trichostatin A (TSA), a specific HDAC inhibitor, enhances the up-regulation of decidualization markers such as insulin-like growth factor binding protein-1 (IGFBP-1) and prolactin in a dose-dependent manner that is directed by 17beta-estradiol (E-2) plus progesterone (P-4) in cultured ESCs, but not glandular cells, both isolated from human endometrium. Morphological changes resembling decidual transformation were also augmented by co-addition of TSA. Acid urea triton gel analysis and immunoblot using acetylated histone type-specific antibodies demonstrated that treatment with E-2 plus P-4 significantly increased the levels of acetylated H3 and H4 whose increment was augmented by co-treatment with TSA. Chromatin immunoprecipitation assay revealed that treatment with E-2 plus P-4 increased the amount of proximal progesterone-responsive region of IGFBP-1 promoter associated with acetylated H4, which was dramatically enhanced by co-addition of TSA. Taken together, our results suggest that histone acetylation is deeply involved in differentiation of human ESCs and that TSA has a potential as an enhancer of decidualization through promotion of progesterone action.	Keio Univ, Dept Obstet & Gynecol, Sch Med, Shinjuku Ku, Tokyo 1608582, Japan; Natl Inst Infect Dis, Dept Bioact Mol, Shinjuku Ku, Tokyo 1628640, Japan	Keio University; National Institute of Infectious Diseases (NIID)	Maruyama, T (corresponding author), Keio Univ, Dept Obstet & Gynecol, Sch Med, Shinjuku Ku, Shinanomach 35, Tokyo 1608582, Japan.							Brar AK, 2001, PHYSIOL GENOMICS, V7, P135, DOI 10.1152/physiolgenomics.00061.2001; Brar AK, 1997, ENDOCRINE, V6, P301, DOI 10.1007/BF02820507; Brosens JJ, 1999, ENDOCRINOLOGY, V140, P4809, DOI 10.1210/en.140.10.4809; CHRIVIA JC, 1993, NATURE, V365, P855, DOI 10.1038/365855a0; ECKNER R, 1994, GENE DEV, V8, P869, DOI 10.1101/gad.8.8.869; Gao JG, 1999, MOL CELL ENDOCRINOL, V153, P11, DOI 10.1016/S0303-7207(99)00096-9; GAO JG, 1994, DNA CELL BIOL, V13, P829, DOI 10.1089/dna.1994.13.829; Gao JG, 2000, MOL ENDOCRINOL, V14, P1954, DOI 10.1210/me.14.12.1954; Gao JG, 1996, MOL ENDOCRINOL, V10, P613, DOI 10.1210/me.10.6.613; GIUDICE LC, 1994, FERTIL STERIL, V61, P1; Gregory CW, 2002, J CLIN ENDOCR METAB, V87, P2960, DOI 10.1210/jc.87.6.2960; GURPIDE E, 1992, HORMONES IN GYNECOLOGICAL ENDOCRINOLOGY, P717; HUANG JR, 1987, ENDOCRINOLOGY, V121, P2011; IRWIN JC, 1989, FERTIL STERIL, V52, P761; Jabbour HN, 1998, J CLIN ENDOCR METAB, V83, P2545, DOI 10.1210/jc.83.7.2545; JIN CF, 1994, PCR METH APPL, V3, P252; Johnstone RW, 2002, NAT REV DRUG DISCOV, V1, P287, DOI 10.1038/nrd772; Kuo MH, 1998, BIOESSAYS, V20, P615, DOI 10.1002/(SICI)1521-1878(199808)20:8<615::AID-BIES4>3.0.CO;2-H; Lockwood CJ, 1998, ENDOCRINOLOGY, V139, P4607, DOI 10.1210/en.139.11.4607; Mak IYH, 2002, J CLIN ENDOCR METAB, V87, P2581, DOI 10.1210/jc.87.6.2581; Maruyama T, 1999, ENDOCRINOLOGY, V140, P2632, DOI 10.1210/en.140.6.2632; Maruyama T, 1997, MOL HUM REPROD, V3, P989, DOI 10.1093/molehr/3.11.989; Maruyama T, 1999, ENDOCRINOLOGY, V140, P365, DOI 10.1210/en.140.1.365; Maruyama T, 1999, ENDOCRINOLOGY, V140, P5982, DOI 10.1210/endo.140.12.7184; NOYES RW, 1950, FERTIL STERIL, V1, P3, DOI 10.1016/s0015-0282(16)30062-0; Popovici RM, 2000, ENDOCRINOLOGY, V141, P3510, DOI 10.1210/en.141.9.3510; Robyr D, 2000, MOL ENDOCRINOL, V14, P329, DOI 10.1210/me.14.3.329; Roth SY, 2001, ANNU REV BIOCHEM, V70, P81, DOI 10.1146/annurev.biochem.70.1.81; SERRA MJ, 1979, BIOL REPROD, V20, P214, DOI 10.1095/biolreprod20.2.214; Sterner DE, 2000, MICROBIOL MOL BIOL R, V64, P435, DOI 10.1128/MMBR.64.2.435-459.2000; TABIBZADEH S, 1991, ENDOCR REV, V12, P272, DOI 10.1210/edrv-12-3-272; Takakura M, 2001, NUCLEIC ACIDS RES, V29, P3006, DOI 10.1093/nar/29.14.3006; TANG BQ, 1993, ENDOCRINOLOGY, V133, P2197, DOI 10.1210/en.133.5.2197; Tazuke SI, 1998, P NATL ACAD SCI USA, V95, P10188, DOI 10.1073/pnas.95.17.10188; Telgmann R, 1997, ENDOCRINOLOGY, V138, P929, DOI 10.1210/en.138.3.929; VanLint C, 1996, GENE EXPRESSION, V5, P245; Vo N, 2001, J BIOL CHEM, V276, P13505, DOI 10.1074/jbc.R000025200; WEST MHP, 1980, BIOCHEMISTRY-US, V19, P3238, DOI 10.1021/bi00555a022; Wieser F, 2002, MOL HUM REPROD, V8, P644, DOI 10.1093/molehr/8.7.644; Xu JM, 1998, SCIENCE, V279, P1922, DOI 10.1126/science.279.5358.1922; Yamamoto Y, 2002, MOL HUM REPROD, V8, P1117, DOI 10.1093/molehr/8.12.1117; YOSHIDA M, 1990, J BIOL CHEM, V265, P17174; YOSHIDA M, 1995, BIOESSAYS, V17, P423, DOI 10.1002/bies.950170510	43	60	64	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 9	2003	278	19					16675	16682		10.1074/jbc.M211715200	http://dx.doi.org/10.1074/jbc.M211715200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677QG	12609987	hybrid			2022-12-25	WOS:000182818600031
J	Yin, HY; Havrilla, CM; Gao, L; Morrow, JD; Porter, NA				Yin, HY; Havrilla, CM; Gao, L; Morrow, JD; Porter, NA			Mechanisms for the formation of isoprostane endoperoxides from arachidonic acid - "Dioxetane" intermediate versus beta-fragmentation of peroxyl radicals	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NONCYCLOOXYGENASE; HYDROPEROXIDES; PROSTAGLANDINS; CHROMATOGRAPHY; SPECTROMETRY; OXYGENATION; DERIVATIVES; CYCLIZATION; PRODUCTS; SERIES	The isoprostanes are a class of autoxidation products generated from arachidonic acid (or its esters) by a free radical initiated process. The potent biological activity of these compounds has been attracting intense research interest since they were detected in humans as well as animal models in the early 1990s. The measurement of these compounds has been regarded as one of the most useful non-invasive biomarkers for oxidative stress status. Two mechanisms for the formation of these compounds have been proposed. In the first mechanism, a peroxyl radical undergoes successive 5-exo cyclizations analogous to the enzymatic mechanism proposed for prostaglandin biosynthesis. The second mechanism starts with a 4-exo cyclization of a peroxyl radical leading to an intermediate dioxetane, a mechanism that has also been proposed for prostaglandin biosynthesis as well as for the formation of 4-hydroxy nonenal (HNE). Autoxidation of cholesteryl-15-HpETE under free radical conditions provides Type IV isoprostanes. The "dioxetane" mechanism for isoprostane generation from 15-HpETE requires that optically pure products are formed from an optically pure reactant, whereas an alternate mechanism for the process involving beta-fragmentation of the 15-peroxyl would give racemic isoprostane products. We have carried out a test of the mechanism based upon these stereochemical requirements. The results of analysis of the product mixture derived from autoxidation of optically pure Ch-15-HpETE by atmospheric pressure chemical ionization-mass spectrometry coupled with chiral high performance liquid chromatography indicate that the major isoprostane diastereomers are formed as a racemic mixture. These experimental results are consistent with a mechanism for isoprostane formation involving beta-fragmentation of the 15-peroxyl radical followed by re-addition of oxygen to form the 11-HPETE peroxyl, and they exclude a mechanism proceeding through the formation of a dioxetane intermediate.	Vanderbilt Univ, Dept Chem, Nashville, TN 37235 USA; Vanderbilt Univ, Dept Pharmacol, Ctr Mol Toxicol, Nashville, TN 37235 USA	Vanderbilt University; Vanderbilt University	Porter, NA (corresponding author), Vanderbilt Univ, Dept Chem, Box 1822,Stn B, Nashville, TN 37235 USA.	n.porter@vanderbilt.edu		yin, hui yong/0000-0001-7049-1560	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL017921, R37HL017921] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES000267] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P01GM015431, P50GM015431] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL17921] Funding Source: Medline; NIEHS NIH HHS [P30 ES00267] Funding Source: Medline; NIGMS NIH HHS [GM15431] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AVERY MA, 1990, TETRAHEDRON LETT, V31, P1799, DOI 10.1016/S0040-4039(00)98789-6; Cheng Y, 2002, SCIENCE, V296, P539, DOI 10.1126/science.1068711; Colombani D, 1996, PROG POLYM SCI, V21, P439, DOI 10.1016/0079-6700(95)00024-0; COREY EJ, 1994, TETRAHEDRON LETT, V35, P539, DOI 10.1016/S0040-4039(00)75832-1; Cyrus T, 2001, CIRCULATION, V103, P2277; ESTERBAUER H, 1991, FREE RADICAL BIO MED, V11, P81, DOI 10.1016/0891-5849(91)90192-6; Esterbauer H., 1991, MEMBRANE LIPID OXIDA; Funk CD, 2001, SCIENCE, V294, P1871, DOI 10.1126/science.294.5548.1871; GARDNER HW, 1993, J BIOL CHEM, V268, P6971; Gardner HW, 1998, PLANT PHYSIOL, V116, P1359, DOI 10.1104/pp.116.4.1359; Havrilla CM, 2000, J AM CHEM SOC, V122, P8042, DOI 10.1021/ja001180f; HAYNES RK, 1990, J CHEM SOC CHEM COMM, P449, DOI 10.1039/c39900000449; HAYNES RK, 1990, J CHEM SOC CHEM COMM, P451, DOI 10.1039/c39900000451; Kaur K, 1997, CHEM RES TOXICOL, V10, P1387, DOI 10.1021/tx970112c; KIEFER H, 1966, TETRAHEDRON LETT, P6163; Lawson JA, 1999, J BIOL CHEM, V274, P24441, DOI 10.1074/jbc.274.35.24441; MENDENHALL GD, 1983, TETRAHEDRON LETT, V24, P451; Morrow JD, 1999, METHOD ENZYMOL, V300, P3; MORROW JD, 1990, P NATL ACAD SCI USA, V87, P9383, DOI 10.1073/pnas.87.23.9383; MORROW JD, 1990, ANAL BIOCHEM, V184, P1, DOI 10.1016/0003-2697(90)90002-Q; Mueller MJ, 1998, CHEM BIOL, V5, pR323, DOI 10.1016/S1074-5521(98)90660-3; Murphy RC, 2001, CHEM REV, V101, P479, DOI 10.1021/cr9900883; OCONNOR DE, 1984, J AM CHEM SOC, V106, P3577, DOI 10.1021/ja00324a028; PORTER NA, 1995, LIPIDS, V30, P277, DOI 10.1007/BF02536034; PORTER NA, 1980, FREE RADICALS BIOL, V4, P261; Pratico D, 2001, TRENDS ENDOCRIN MET, V12, P243, DOI 10.1016/S1043-2760(01)00411-8; PRYOR WA, 1990, FREE RADICAL BIO MED, V8, P541, DOI 10.1016/0891-5849(90)90153-A; Pudukulathan Z, 1998, J AM CHEM SOC, V120, P11953, DOI 10.1021/ja982596k; Roberts LJ, 2002, CELL MOL LIFE SCI, V59, P808, DOI 10.1007/s00018-002-8469-8; Roberts LJ, 2000, FREE RADICAL BIO MED, V28, P505, DOI 10.1016/S0891-5849(99)00264-6; Rocca B, 2002, INT IMMUNOPHARMACOL, V2, P603, DOI 10.1016/S1567-5769(01)00204-1; Rokach J, 1998, SYNTHESIS-STUTTGART, P569; Rokach J, 1997, PROSTAG OTH LIPID M, V54, P823, DOI 10.1016/S0090-6980(97)00183-4; Schneider C, 2000, ANAL BIOCHEM, V287, P186, DOI 10.1006/abio.2000.4847; Schneider C, 2001, J BIOL CHEM, V276, P20831, DOI 10.1074/jbc.M101821200; Singh G, 2000, ANAL CHEM, V72, P3007, DOI 10.1021/ac000374a; Thomas MJ, 2001, FREE RADICAL BIO MED, V30, P1337, DOI 10.1016/S0891-5849(01)00527-5; Timmins GS, 1997, CHEM RES TOXICOL, V10, P1090, DOI 10.1021/tx970075p; VONWILLER SC, 1995, J AM CHEM SOC, V117, P11098, DOI 10.1021/ja00150a009; YIN H, 2002, THESIS VANDERBILT U; Yin HY, 2002, J AM CHEM SOC, V124, P7745, DOI 10.1021/ja0201092	41	50	52	2	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 9	2003	278	19					16720	16725		10.1074/jbc.M300604200	http://dx.doi.org/10.1074/jbc.M300604200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677QG	12609993	hybrid			2022-12-25	WOS:000182818600037
J	Komarova, EA; Neznanov, N; Komarov, PG; Chernov, MV; Wang, KH; Gudkov, AV				Komarova, EA; Neznanov, N; Komarov, PG; Chernov, MV; Wang, KH; Gudkov, AV			p53 inhibitor pifithrin alpha can suppress heat shock and glucocorticoid signaling pathways	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RADIATION-INDUCED APOPTOSIS; TRANSCRIPTION FACTORS; RECEPTOR; HEAT-SHOCK-PROTEIN-70; ACTIVATION; THYMOCYTES; ELEMENTS; NEURONS; STRESS; CELLS	Pifithrin alpha (PFTalpha) is a chemical compound isolated for its ability to suppress p53-mediated transactivation. It can protect cells from p53-mediated apoptosis induced by various stimuli and reduce sensitivity of mice to gamma radiation. Identification of molecular targets of PFTalpha is likely to provide new insights into mechanisms of regulation of p53 pathway and is important for predicting potential risks associated with administration of PFTalpha-like p53 inhibitors in vivo. We found that PFTalpha, in addition to p53, can suppress heat shock and glucocorticoid receptor signaling but has no effect on nuclear factor-kappaB signaling. PFTalpha reduces activation of heat shock transcription factor (HSF1) and increases cell sensitivity to heat. Moreover, it reduces activation of glucocorticoid receptor and rescues mouse thymocytes in vitro and in vivo from apoptotic death after dexamethasone treatment. PFTalpha affected both signaling pathways in a p53-independent manner. These observations suggest that PFTalpha targets some unknowm factor that is common for three major signal transduction pathways.	Cleveland Clin Fdn, Lerner Res Inst, Dept Mol Biol, Cleveland, OH 44195 USA; Cleveland Clin Fdn, Lerner Res Inst, Dept Virol, Cleveland, OH 44195 USA; Quark Biotech Inc, Cleveland, OH 44195 USA	Cleveland Clinic Foundation; Cleveland Clinic Foundation	Gudkov, AV (corresponding author), Cleveland Clin Fdn, Lerner Res Inst, Dept Mol Biol, 9500 Euclid Ave, Cleveland, OH 44195 USA.	gudkov@ccf.org		Gudkov, Andrei/0000-0003-2548-0154	NCI NIH HHS [CA 17579] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BEERE HM, 2001, SCI STKE; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; Chen YC, 1999, PHOTOCHEM PHOTOBIOL, V70, P78, DOI 10.1111/j.1751-1097.1999.tb01952.x; Culmsee C, 2001, J NEUROCHEM, V77, P220, DOI 10.1046/j.1471-4159.2001.00220.x; Duan WZ, 2002, ANN NEUROL, V52, P597, DOI 10.1002/ana.10350; Galang CK, 1996, J BIOL CHEM, V271, P7992, DOI 10.1074/jbc.271.14.7992; Gerondakis S, 1998, CURR OPIN IMMUNOL, V10, P353, DOI 10.1016/S0952-7915(98)80175-1; Gordon SA, 1997, ARCH SURG-CHICAGO, V132, P1277; Hache RJG, 1999, J BIOL CHEM, V274, P1432, DOI 10.1074/jbc.274.3.1432; Jakubowicz-Gil J, 2002, BIOCHEM PHARMACOL, V64, P1591, DOI 10.1016/S0006-2952(02)01356-4; Jolly C, 2000, JNCI-J NATL CANCER I, V92, P1564, DOI 10.1093/jnci/92.19.1564; Kelly KJ, 2003, J AM SOC NEPHROL, V14, P128, DOI 10.1097/01.ASN.0000040596.23073.01; Komarov PG, 1999, SCIENCE, V285, P1733, DOI 10.1126/science.285.5434.1733; Komarova EA, 2001, BIOCHEM PHARMACOL, V62, P657, DOI 10.1016/S0006-2952(01)00733-X; Komarova EA, 1998, SEMIN CANCER BIOL, V8, P389, DOI 10.1006/scbi.1998.0101; Kondratov RV, 1996, MOL BIOL+, V30, P363; Li XX, 2002, EXP HEMATOL, V30, P285, DOI 10.1016/S0301-472X(02)00777-4; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; Morimoto R I, 1996, EXS, V77, P139; Nakanoma T, 2001, INT J UROL, V8, P623, DOI 10.1046/j.1442-2042.2001.00389.x; Natoli G, 1998, J BIOL CHEM, V273, P31262, DOI 10.1074/jbc.273.47.31262; Neznanov N, 2001, J VIROL, V75, P10409, DOI 10.1128/JVI.75.21.10409-10420.2001; Pirkkala L, 2001, FASEB J, V15, P1118, DOI 10.1096/fj00-0294rev; TRUSS M, 1991, MOL CELL BIOL, V11, P3247, DOI 10.1128/MCB.11.6.3247; WILLIAMS GT, 1990, MOL CELL BIOL, V10, P3125, DOI 10.1128/MCB.10.6.3125; Winoto A, 2002, CELL, V109, pS57, DOI 10.1016/S0092-8674(02)00710-9; Zhu XX, 2002, J MED CHEM, V45, P5090, DOI 10.1021/jm020044d	27	98	104	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 2	2003	278	18					15465	15468		10.1074/jbc.C300011200	http://dx.doi.org/10.1074/jbc.C300011200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	675EL	12637507	hybrid			2022-12-25	WOS:000182680000003
J	Meinhart, A; Silberzahn, T; Cramer, P				Meinhart, A; Silberzahn, T; Cramer, P			The mRNA transcription/processing factor Ssu72 is a potential tyrosine phosphatase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-POLYMERASE-II; PHOSPHOTYROSYL PROTEIN PHOSPHATASE; SACCHAROMYCES-CEREVISIAE; CRYSTAL-STRUCTURE; TERMINAL DOMAIN; FUNCTIONAL INTERACTION; GENE-EXPRESSION; PHOSPHORYLATION; COMPLEX; TFIIB	Ssu72 is an essential and highly conserved protein involved in mRNA transcription and X-end processing. The biochemical function of Ssu72 was so far unknown. We report here evidence that Ssu72 is a phosphatase that resembles protein tyrosine phosphatases (PTPases). First, recombinant Ssu72 cleaves the phosphotyrosine analogue p-nitrophenylphosphate, and this catalytic activity is impaired by PTPase-inhibiting agents. Second, the Ssu72 sequence contains the CX5R signature motif of PTPases; mutation of the catalytic cysteine in this motif abolishes Ssu72 activity in vitro and has been shown to confer lethality in vivo. Third, secondary structure prediction and site-directed mu-tagenesis predict that Ssu72 adopts the fold of PTPases of the low molecular weight family. Distinguishing features, such as a short "aspartate loop" at the active site, suggest however that Ssu72 is the founding member of a new phosphatase subfamily. The novel Ssu72 activity may regulate coupling events during mRNA biogenesis.	Univ Munich, Inst Biochem, Gene Ctr, D-81377 Munich, Germany	University of Munich	Cramer, P (corresponding author), Univ Munich, Inst Biochem, Gene Ctr, Feodor Lynen Str 25, D-81377 Munich, Germany.		Meinhart, Anton/M-9647-2014					BARFORD D, 1995, NAT STRUCT BIOL, V2, P1043, DOI 10.1038/nsb1295-1043; Barilla D, 2001, P NATL ACAD SCI USA, V98, P445, DOI 10.1073/pnas.021545298; Burke TR, 1998, BIOPOLYMERS, V47, P225, DOI 10.1002/(SICI)1097-0282(1998)47:3<225::AID-BIP3>3.0.CO;2-O; CHAMBERS RS, 1995, J BIOL CHEM, V270, P14962, DOI 10.1074/jbc.270.25.14962; Cho H, 2001, P NATL ACAD SCI USA, V98, P8525, DOI 10.1073/pnas.131213698; Cho H, 1999, GENE DEV, V13, P1540, DOI 10.1101/gad.13.12.1540; Cramer Patrick, 2001, Science (Washington D C), V292, P1863, DOI 10.1126/science.1059493; DAVIS JP, 1994, J BIOL CHEM, V269, P8734; Denu JM, 1998, BIOCHEMISTRY-US, V37, P5633, DOI 10.1021/bi973035t; DENU JM, 1995, BIOCHEMISTRY-US, V34, P3396, DOI 10.1021/bi00010a031; Denu JM, 1998, CURR OPIN CHEM BIOL, V2, P633, DOI 10.1016/S1367-5931(98)80095-1; Dichtl B, 2002, MOL CELL, V10, P1139, DOI 10.1016/S1097-2765(02)00707-4; DUYSTER J, 1995, P NATL ACAD SCI USA, V92, P1555, DOI 10.1073/pnas.92.5.1555; Fauman EB, 1996, TRENDS BIOCHEM SCI, V21, P413, DOI 10.1016/S0968-0004(96)10059-1; Gavin AC, 2002, NATURE, V415, P141, DOI 10.1038/415141a; Kim JH, 2000, ARCH BIOCHEM BIOPHYS, V382, P72, DOI 10.1006/abbi.2000.1996; Kobor MS, 1999, MOL CELL, V4, P55, DOI 10.1016/S1097-2765(00)80187-2; Kobor MS, 2002, BBA-GENE STRUCT EXPR, V1577, P261, DOI 10.1016/S0167-4781(02)00457-8; Maniatis T, 2002, NATURE, V416, P499, DOI 10.1038/416499a; Orphanides G, 2002, CELL, V108, P439, DOI 10.1016/S0092-8674(02)00655-4; OSTANIN K, 1995, J BIOL CHEM, V270, P18491, DOI 10.1074/jbc.270.31.18491; Pappas DL, 2000, MOL CELL BIOL, V20, P8343, DOI 10.1128/MCB.20.22.8343-8351.2000; Prelich G, 2002, EUKARYOT CELL, V1, P153, DOI 10.1128/EC.1.2.153-162.2002; Ramponi G, 1997, INT J BIOCHEM CELL B, V29, P279, DOI 10.1016/S1357-2725(96)00109-4; ROST B, 1994, PROTEINS, V20, P216, DOI 10.1002/prot.340200303; STUCKEY JA, 1994, NATURE, V370, P571, DOI 10.1038/370571a0; SU XD, 1994, NATURE, V370, P575, DOI 10.1038/370575a0; Sun ZW, 1996, MOL CELL BIOL, V16, P1557; Sun ZW, 1996, NUCLEIC ACIDS RES, V24, P2560, DOI 10.1093/nar/24.13.2560; Wang SS, 2000, BIOCHEMISTRY-US, V39, P1903, DOI 10.1021/bi991348d; WEST ML, 1995, GENETICS, V140, P1223; WO YYP, 1992, J BIOL CHEM, V267, P10856; Wu WH, 1999, GENETICS, V153, P643; Yan D, 1999, P NATL ACAD SCI USA, V96, P14789, DOI 10.1073/pnas.96.26.14789; Zhang M, 1998, J BIOL CHEM, V273, P21714, DOI 10.1074/jbc.273.34.21714; ZHANG ZT, 1994, J BIOL CHEM, V269, P25947	36	44	46	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 2	2003	278	18					15917	15921		10.1074/jbc.M301643200	http://dx.doi.org/10.1074/jbc.M301643200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	675EL	12606538	hybrid			2022-12-25	WOS:000182680000059
J	Fitzsimmons, S; Ireland, H; Barr, NI; Cuthbert, AP; Going, JJ; Newbold, R; Parkinson, EK				Fitzsimmons, S; Ireland, H; Barr, NI; Cuthbert, AP; Going, JJ; Newbold, R; Parkinson, EK			Human squamous cell carcinomas lose a mortality gene from chromosome 6q14.3 to q15	ONCOGENE			English	Article						chromosome 6; senescence; keratinocyte; squamous cancer	TUMOR-SUPPRESSOR GENE; FUNCTIONAL EVIDENCE; GROWTH-ARREST; NASOPHARYNGEAL CARCINOMA; INDEFINITE DIVISION; HIGH-FREQUENCY; HUMAN CANCERS; SENESCENCE; REGION; IDENTIFICATION	Normal human keratinocytes possess a finite replicative lifespan. Most advanced squamous cell carcinomas (SCCs), however, are immortal, a phenotype that is associated with p53 and INK4A dysfunction, high levels of telomerase and loss of heterozygosity (LOH) at several genetic loci, suggestive of the dysfunction of other mortality genes. We show here that human chromosome 6 specifically reduces the proliferation or viability of a human SCC line, BICR31, possessing LOH across the chromosome. This was determined by an 88% reduction in colony yield (P < 0.001), following the reintroduction of an intact normal chromosome 6 by monochromosome transfer. Deletion analysis of immortal segregants using polymorphic markers revealed the loss of a 2.9 Mbp interval, centred on marker D6S1045 at 6q14.3-q15, in 6/19 segregants. Crucially, allelic losses of this region were not identified in control hybrids constructed between chromosome 6 and the BICR6 SCC cell line that is heterozygous for chromosome 6 and which showed no reduction in colony formation relative to the control chromosome transfers. This indicates that the minimally deleted region at D6S1045 is not the result of fragile sites, a recombination hot spot, or a feature of the monochromosome transfer technique. LOH of D6S1045 was found in 2/9 immortal SCC lines and was part of a minimally deleted region of line BICR19. Furthermore, allelic imbalance, consistent with LOH, was detected in 31 17 advanced SCCs of the tongue. These results suggest the existence of a suppressor of SCC immortality and tumour development at chromosome 6q14.3-q15, which is important to a subset of human SCCs.	Beatson Inst Canc Res, Canc Res UK Beatson Labs, Glasgow G61 1BD, Lanark, Scotland; Brunel Univ, Dept Biol & Biochem, Uxbridge UBS 3PH, Middx, England; Univ Glasgow, Glasgow Royal Infirm, Dept Pathol, Glasgow G4 0SF, Lanark, Scotland	Beatson Institute; Brunel University; University of Glasgow	Parkinson, EK (corresponding author), Beatson Inst Canc Res, Canc Res UK Beatson Labs, Garscube Estate,Switchback Rd, Glasgow G61 1BD, Lanark, Scotland.			Going, James/0000-0001-9120-919X				Azzalin CM, 1997, CYTOGENET CELL GENET, V78, P112, DOI 10.1159/000134640; Banga SS, 1997, ONCOGENE, V14, P313, DOI 10.1038/sj.onc.1200842; Benitez J, 1997, CANCER RES, V57, P4217; CASEY G, 1993, HUM MOL GENET, V2, P1921, DOI 10.1093/hmg/2.11.1921; Cheng Y, 1998, P NATL ACAD SCI USA, V95, P3042, DOI 10.1073/pnas.95.6.3042; CLARK LJ, 1993, BRIT J CANCER, V68, P617, DOI 10.1038/bjc.1993.396; Cooney KA, 1996, CANCER RES, V56, P4150; CUTHBERT AP, 1995, CYTOGENET CELL GENET, V71, P68, DOI 10.1159/000134066; Cuthbert AP, 1999, JNCI-J NATL CANCER I, V91, P37, DOI 10.1093/jnci/91.1.37; EDINGTON KG, 1995, MOL CARCINOGEN, V13, P254, DOI 10.1002/mc.2940130408; EDWARDS NL, 1978, SCIENCE, V201, P628, DOI 10.1126/science.27864; Engelman JA, 1998, FEBS LETT, V436, P403, DOI 10.1016/S0014-5793(98)01134-X; England NL, 1996, CARCINOGENESIS, V17, P1567, DOI 10.1093/carcin/17.8.1567; FANTES JA, 1995, GENOMICS, V25, P447, DOI 10.1016/0888-7543(95)80045-N; Forsyth NR, 2002, ONCOGENE, V21, P5135, DOI 10.1038/sj.onc.1205688; FUJIKAWAYAMAMOTO K, 1994, CELL STRUCT FUNCT, V19, P391, DOI 10.1247/csf.19.391; Going JJ, 1996, J PATHOL, V179, P121; GREEN RJ, 1988, HUM GENET, V81, P9, DOI 10.1007/BF00283720; Guan XY, 1996, BLOOD, V88, P1418, DOI 10.1182/blood.V88.4.1418.bloodjournal8841418; Hassfeld W, 1998, NUCLEIC ACIDS RES, V26, P439, DOI 10.1093/nar/26.2.439; Hatcher CJ, 2001, DEV BIOL, V230, P177, DOI 10.1006/dbio.2000.0134; HENSLER PJ, 1994, MOL CELL BIOL, V14, P2291, DOI 10.1128/MCB.14.4.2291; Jacobs JJL, 2000, NAT GENET, V26, P291, DOI 10.1038/81583; Karlsson C, 1996, CANCER RES, V56, P241; KOI M, 1993, SCIENCE, V260, P361, DOI 10.1126/science.8469989; LEVY FO, 1994, GENOMICS, V22, P637, DOI 10.1006/geno.1994.1439; Lo KW, 2001, CANCER RES, V61, P3877; Loughran O, 1997, ONCOGENE, V14, P1955, DOI 10.1038/sj.onc.1201028; Morelli C, 1997, CANCER RES, V57, P4153; Nathrath MH, 2002, ONCOGENE, V21, P5975, DOI 10.1038/sj.onc.1205764; NING Y, 1991, P NATL ACAD SCI USA, V88, P5635, DOI 10.1073/pnas.88.13.5635; OGATA T, 1993, MOL CELL BIOL, V13, P6036, DOI 10.1128/MCB.13.10.6036; Parkinson EK, 1997, EUR J CANCER, V33, P727, DOI 10.1016/S0959-8049(97)00063-4; Resta R, 1998, IMMUNOL REV, V161, P95, DOI 10.1111/j.1600-065X.1998.tb01574.x; RIMESSI P, 1994, ONCOGENE, V9, P3467; Robertson GP, 1998, P NATL ACAD SCI USA, V95, P9418, DOI 10.1073/pnas.95.16.9418; SANDHU AK, 1994, P NATL ACAD SCI USA, V91, P5498, DOI 10.1073/pnas.91.12.5498; Sandhu AK, 1996, ONCOGENE, V12, P247; SASAKI M, 1994, CANCER RES, V54, P6090; Sheng ZM, 1996, BRIT J CANCER, V73, P144, DOI 10.1038/bjc.1996.27; STANTON P, 1994, BRIT J CANCER, V70, P427, DOI 10.1038/bjc.1994.322; Steenbergen RDM, 2001, JNCI-J NATL CANCER I, V93, P865, DOI 10.1093/jnci/93.11.865; Turker MS, 1999, CANCER RES, V59, P1837; UEJIMA H, 1995, GENE CHROMOSOME CANC, V14, P120, DOI 10.1002/gcc.2870140206; WANG XW, 1992, CARCINOGENESIS, V13, P555, DOI 10.1093/carcin/13.4.555; Wu CL, 1999, GENE CHROMOSOME CANC, V25, P16, DOI 10.1002/(SICI)1098-2264(199905)25:1<16::AID-GCC3>3.3.CO;2-U; Yi CH, 1999, GENOMICS, V55, P10, DOI 10.1006/geno.1998.5632; Zhu ZQ, 1998, NAT GENET, V20, P337, DOI 10.1038/3804; [No title captured]	49	4	4	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 20	2003	22	11					1737	1746		10.1038/sj.onc.1206295	http://dx.doi.org/10.1038/sj.onc.1206295			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	655YH	12642877				2022-12-25	WOS:000181580500016
J	Hyland, S; Beerli, RR; Barbas, CF; Hynes, NE; Wels, W				Hyland, S; Beerli, RR; Barbas, CF; Hynes, NE; Wels, W			Generation and functional characterization of intracellular antibodies interacting with the kinase domain of human EGF receptor	ONCOGENE			English	Article						epidermal growth factor receptor; receptor tyrosine kinase; single-chain Fv antibody; intrabody; yeast two-hybrid	GROWTH-FACTOR RECEPTOR; SINGLE-CHAIN ANTIBODY; ERBB SIGNALING NETWORK; MONOCLONAL-ANTIBODY; TARGETED THERAPY; HIV-1 INFECTION; FV FRAGMENTS; V-H; INHIBITION; PROTEIN	Intracellular expression of single-chain antibodies (scFvs) represents a promising approach for selective interference with cellular proto-oncogenes such as the epidermal growth factor receptor (EGFR). Previously, we have shown that intrabodies targeted to the lumen of the endoplasmic reticulum prevent the transit of EGFR or the related ErbB2 molecule to the cell surface, thereby inactivating their transforming potential. While intramolecular disulfide bridges important for antibody stability are correctly formed during expression in the secretory pathway, scFvs expressed in the reducing environment of the cytosol are often inactive. To overcome this problem and to generate antibody fragments that interact with the intracellular domain of human EGFR in the cytoplasm, here we have chosen a two-step approach combining classical selection of scFvs by phage display with subsequent expression in yeast. After enrichment of EGFR-specific antibody fragments from a combinatorial library by biopanning, a yeast two-hybrid screen was performed using the intracellular domain of EGFR as bait. Screening of 1.5 x 10(5) preselected scFv plasmids under highly stringent conditions yielded 223 colonies that represented at least five independent scFv clones functional in the intracellular milieu of eukaryotic cells. Interaction of selected antibody fragments with the intracellular domain of EGFR was confirmed in GST pull-down and coimmunoprecipitation experiments. Upon cytoplasmic expression in human tumor cells, scFvs colocalized with EGFR at the plasma membrane demonstrating their functionality in vivo.	Georg Speyer Haus, Chemotherapeut Forschungsinst, D-60596 Frankfurt, Germany; Scripps Res Inst, Skaggs Inst Chem Biol, La Jolla, CA 92037 USA; Scripps Res Inst, Dept Mol Biol, La Jolla, CA 92037 USA; Friedrich Miescher Inst, CH-4002 Basel, Switzerland	Octapharma; Scripps Research Institute; Scripps Research Institute; Friedrich Miescher Institute for Biomedical Research	Wels, W (corresponding author), Georg Speyer Haus, Chemotherapeut Forschungsinst, Paul Ehrlich Str 42-44, D-60596 Frankfurt, Germany.	wels@em.uni-frankfurt.de		Wels, Winfried/0000-0001-9858-3643				Altenschmidt U, 1997, INT J CANCER, V73, P117, DOI 10.1002/(SICI)1097-0215(19970926)73:1<117::AID-IJC18>3.0.CO;2-D; Andris-Widhopf J, 2001, PHAGE DISPLAY LAB MA, V1st; Bach H, 2001, J MOL BIOL, V312, P79, DOI 10.1006/jmbi.2001.4914; Barbas C. F., 2001, PHAGE DISPLAY LAB MA; BARBAS CF, 1991, P NATL ACAD SCI USA, V88, P7978, DOI 10.1073/pnas.88.18.7978; Baselga J, 2000, J CLIN ONCOL, V18, P904, DOI 10.1200/JCO.2000.18.4.904; Beerli RR, 1996, BREAST CANCER RES TR, V38, P11, DOI 10.1007/BF01803779; BEERLI RR, 1994, BIOCHEM BIOPH RES CO, V204, P666, DOI 10.1006/bbrc.1994.2511; BEERLI RR, 1994, J BIOL CHEM, V269, P23931; BEERLI RR, 1995, MOL CELL BIOL, V15, P6496; BIOCCA S, 1995, BIO-TECHNOL, V13, P1110, DOI 10.1038/nbt1095-1110; BIOCCA S, 1994, BIO-TECHNOL, V12, P396, DOI 10.1038/nbt0494-396; Cardinale A, 2001, EUR J BIOCHEM, V268, P268, DOI 10.1046/j.1432-1327.2001.01876.x; Cattaneo A, 1999, TRENDS BIOTECHNOL, V17, P115, DOI 10.1016/S0167-7799(98)01268-2; De Jaeger G, 2000, FEBS LETT, V467, P316, DOI 10.1016/S0014-5793(00)01182-0; DESHANE J, 1994, GENE THER, V1, P332; DOWNWARD J, 1984, NATURE, V307, P521, DOI 10.1038/307521a0; DUAN LX, 1994, P NATL ACAD SCI USA, V91, P5075, DOI 10.1073/pnas.91.11.5075; Gargano N, 1997, J GEN VIROL, V78, P2591, DOI 10.1099/0022-1317-78-10-2591; Goncalves J, 2002, J BIOL CHEM, V277, P32036, DOI 10.1074/jbc.M201906200; GrausPorta D, 1997, EMBO J, V16, P1647, DOI 10.1093/emboj/16.7.1647; Gschwind A, 2001, ONCOGENE, V20, P1594, DOI 10.1038/sj.onc.1204192; GULLICK WJ, 1985, EMBO J, V4, P2869, DOI 10.1002/j.1460-2075.1985.tb04016.x; GULLICK WJ, 1991, BRIT MED BULL, V47, P87, DOI 10.1093/oxfordjournals.bmb.a072464; HILLS D, 1995, INT J CANCER, V63, P537, DOI 10.1002/ijc.2910630414; HOLLIGER P, 1993, P NATL ACAD SCI USA, V90, P6444, DOI 10.1073/pnas.90.14.6444; Jannot CB, 1996, ONCOGENE, V13, P275; Jermutus L, 2001, P NATL ACAD SCI USA, V98, P75, DOI 10.1073/pnas.011311398; Kabat EA, 1991, SEQUENCES PROTEINS I; Karunagaran D, 1996, EMBO J, V15, P254, DOI 10.1002/j.1460-2075.1996.tb00356.x; Kile BT, 2002, TRENDS BIOCHEM SCI, V27, P235, DOI 10.1016/S0968-0004(02)02085-6; KING CR, 1985, SCIENCE, V229, P974, DOI 10.1126/science.2992089; Klapper LN, 2000, ADV CANCER RES, V77, P25; Lener M, 2000, EUR J BIOCHEM, V267, P1196, DOI 10.1046/j.1432-1327.2000.01125.x; Marasco WA, 1997, GENE THER, V4, P11, DOI 10.1038/sj.gt.3300346; MARASCO WA, 1995, IMMUNOTECHNOLOGY, V1, P1, DOI 10.1016/1380-2933(95)00001-1; Martineau P, 1998, J MOL BIOL, V280, P117, DOI 10.1006/jmbi.1998.1840; Mendelsohn J, 2000, ONCOGENE, V19, P6550, DOI 10.1038/sj.onc.1204082; Mendelsohn J, 1997, CLIN CANCER RES, V3, P2703; MHASHILKAR AM, 1995, EMBO J, V14, P1542, DOI 10.1002/j.1460-2075.1995.tb07140.x; Ohage EC, 1999, J MOL BIOL, V291, P1129, DOI 10.1006/jmbi.1999.3020; Olayioye MA, 2000, EMBO J, V19, P3159, DOI 10.1093/emboj/19.13.3159; Parisien JP, 2001, VIROLOGY, V283, P230, DOI 10.1006/viro.2001.0856; Persic L, 1997, GENE, V187, P1, DOI 10.1016/S0378-1119(96)00627-0; Proba K, 1997, J MOL BIOL, V265, P161, DOI 10.1006/jmbi.1996.0726; Rader C, 1997, CURR OPIN BIOTECH, V8, P503, DOI 10.1016/S0958-1669(97)80075-4; RUSSO MW, 1985, J BIOL CHEM, V260, P5205; Shin DM, 2001, CLIN CANCER RES, V7, P1204; Steinberger P, 2000, P NATL ACAD SCI USA, V97, P805, DOI 10.1073/pnas.97.2.805; Tse E, 2002, J MOL BIOL, V317, P85, DOI 10.1006/jmbi.2002.5403; Visintin M, 1999, P NATL ACAD SCI USA, V96, P11723, DOI 10.1073/pnas.96.21.11723; Worn A, 2000, J BIOL CHEM, V275, P2795, DOI 10.1074/jbc.275.4.2795; Worn A, 1998, FEBS LETT, V427, P357, DOI 10.1016/S0014-5793(98)00463-3; Worn A, 2001, J MOL BIOL, V305, P989, DOI 10.1006/jmbi.2000.4265; Xu JL, 2000, IMMUNITY, V13, P37, DOI 10.1016/S1074-7613(00)00006-6; Yarden Y, 2001, NAT REV MOL CELL BIO, V2, P127, DOI 10.1038/35052073; Yi KS, 2001, ONCOGENE, V20, P7954, DOI 10.1038/sj.onc.1204959; Zhu QA, 1999, J IMMUNOL METHODS, V231, P207, DOI 10.1016/S0022-1759(99)00158-1	58	34	46	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 13	2003	22	10					1557	1567		10.1038/sj.onc.1206299	http://dx.doi.org/10.1038/sj.onc.1206299			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	652ZZ	12629519				2022-12-25	WOS:000181411900013
J	Li, H; Fredriksson, L; Li, X; Eriksson, U				Li, H; Fredriksson, L; Li, X; Eriksson, U			PDGF-D is a potent transforming and angiogenic growth factor	ONCOGENE			English	Article						PDGF; VEGF; transformation; growth factor; tumour growth; angiogenesis	BETA-RECEPTOR; PHOSPHATIDYLINOSITOL 3-KINASE; ENDOTHELIAL-CELLS; IN-VIVO; EXPRESSION; CANCER; TUMORS; ALPHA; MICE; ACTIVATION	Platelet-derived growth factors (PDGFs) are important for normal tissue growth and maintenance. Overexpression of the classical PDGFs, PDGF-A and PDGF-B, has been linked to several diseases, including cancer, fibrotic disease and atherosclerosis. Recently, two novel PDGFs, PDGF-C and PDGF-D, were discovered. It has not yet been established whether PDGF-C and PDGF-D are linked to disease phenotypes like the classical PDGFs. PDGF-B, the cellular homologue of the viral simian sarcoma oncogene v-sis, is known to potently induce cellular transformation through activation of PDGF receptor (PDGFR)-beta. In this work, we have determined the transformation efficacy of PDGF-D in comparison with that of PDGF-C and PDGF-B. PDGF-D is a potent transforming growth factor for NIH/3T3 cells, and the transformed cells displayed stress fibre reorganization, increased proliferation rate, anchorage-independent growth in soft agar, ability to induce tumours in nude mice, and upregulation of vascular endothelial growth factor. Morphological analyses of the vasculatures from the PDGF-isoform-expressing tumours revealed marked differences suggesting differential signalling through the two PDGF receptors in tumour vessel development and remodelling. In summary, these results suggest that PDGF-D induce cellular transformation and promote tumour growth by accelerating the proliferation rate of the tumour cells, and by stimulation of tumour neovascularization.	Ludwig Inst Canc Res, Stockholm Branch, S-17177 Stockholm, Sweden	Ludwig Institute for Cancer Research	Eriksson, U (corresponding author), Ludwig Inst Canc Res, Stockholm Branch, Box 240, S-17177 Stockholm, Sweden.			Fredriksson, Linda/0000-0003-4952-2742				Abramsson A, 2002, CIRCULATION, V105, P112, DOI 10.1161/hc0102.101437; BATTEGAY EJ, 1994, J CELL BIOL, V125, P917, DOI 10.1083/jcb.125.4.917; Bergsten E, 2001, NAT CELL BIOL, V3, P512, DOI 10.1038/35074588; Boehm T, 1997, NATURE, V390, P404, DOI 10.1038/37126; BORK P, 1991, FEBS LETT, V282, P9, DOI 10.1016/0014-5793(91)80433-4; Bostrom H, 1996, CELL, V85, P863, DOI 10.1016/S0092-8674(00)81270-2; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRONZERT DA, 1987, P NATL ACAD SCI USA, V84, P5763, DOI 10.1073/pnas.84.16.5763; Cao RH, 2002, FASEB J, V16, P1575, DOI 10.1096/fj.02-0319com; Eberhard A, 2000, CANCER RES, V60, P1388; ERIKSSON A, 1992, EMBO J, V11, P543, DOI 10.1002/j.1460-2075.1992.tb05085.x; FLEMING TP, 1992, CANCER RES, V52, P4550; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; GAZIT A, 1984, CELL, V39, P89, DOI 10.1016/0092-8674(84)90194-6; Gilbertson DG, 2001, J BIOL CHEM, V276, P27406, DOI 10.1074/jbc.M101056200; Hashizume H, 2000, AM J PATHOL, V156, P1363, DOI 10.1016/S0002-9440(10)65006-7; Heldin CH, 1999, PHYSIOL REV, V79, P1283, DOI 10.1152/physrev.1999.79.4.1283; HSU S, 1995, J CELL PHYSIOL, V165, P239, DOI 10.1002/jcp.1041650204; JAIN RK, 1988, CANCER RES, V48, P2641; LaRochelle WJ, 2002, CANCER RES, V62, P2468; LaRochelle WJ, 2001, NAT CELL BIOL, V3, P517, DOI 10.1038/35074593; Li XR, 2000, NAT CELL BIOL, V2, P302, DOI 10.1038/35010579; Lindahl P, 1997, SCIENCE, V277, P242, DOI 10.1126/science.277.5323.242; Lokker NA, 2002, CANCER RES, V62, P3729; NISTER M, 1991, J BIOL CHEM, V266, P16755; Risau W, 1992, GROWTH FACTORS, V7, P261, DOI 10.3109/08977199209046408; Simon MP, 1997, NAT GENET, V15, P95, DOI 10.1038/ng0197-95; SORIANO P, 1994, GENE DEV, V8, P1888, DOI 10.1101/gad.8.16.1888; Uutela M, 2001, CIRCULATION, V103, P2242; Wang DG, 1999, CANCER RES, V59, P1464; Yu JH, 2000, J BIOL CHEM, V275, P19076, DOI 10.1074/jbc.M910329199; Zwerner JP, 2001, ONCOGENE, V20, P626, DOI 10.1038/sj.onc.1204133	32	116	130	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 13	2003	22	10					1501	1510		10.1038/sj.onc.1206223	http://dx.doi.org/10.1038/sj.onc.1206223			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	652ZZ	12629513				2022-12-25	WOS:000181411900007
J	Wang-Johanning, F; Frost, AR; Jian, BX; Epp, L; Lu, DW; Johanning, GL				Wang-Johanning, F; Frost, AR; Jian, BX; Epp, L; Lu, DW; Johanning, GL			Quantitation of HERV-K env gene expression and splicing in human breast cancer	ONCOGENE			English	Article						breast carcinoma; retrovirus; HERV envelope; and real-time RT-PCR	ENDOGENOUS RETROVIRUS-K; MAMMARY-TUMOR VIRUS; HTDV/HERV-K; IDENTIFICATION; GENOME; CORF; TRANSCRIPTS; PROTEIN; LOCALIZATION; CARCINOMAS	Human endogenous retroviruses (HERVs) comprise up to 8% of the human genome. In previous studies, we demonstrated that type I HERV-K envelope (env) transcripts are expressed in most human breast cancers, but not in normal breast tissues. In the current study, we report that type 2 HERV-K env transcripts are also present in human breast cancers. By real-time RT-PCR, the expression of HERV-K env transcripts was 5-10-fold higher in breast cancer cell lines treated with estradiol and progesterone than in cells without treatment, and expression was significantly higher in most breast cancer tissues than in normal breast tissues. Furthermore, both types of HERV-K env transcripts were capable of being spliced into subgenomic env transcripts and various splice donor and acceptor sites were detected in breast cancers. The selective expression and distribution of multiple HERV-K endogenous retroviral element splice variants in breast cancer, but not in normal controls, suggests that they are novel breast tumor markers.	Univ Alabama, Dept Med, Birmingham, AL 35294 USA; Univ Alabama, Dept Pathol, Birmingham, AL 35294 USA; Univ Alabama, Dept Nutr Sci, Birmingham, AL 35294 USA; Washington Univ, Med Ctr, Dept Pathol & Immunol, Lauren V Ackerman Lab Surg Pathol, St Louis, MO USA	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; Washington University (WUSTL)	Wang-Johanning, F (corresponding author), Univ Alabama, Dept Med, 1824 6th Ave S, Birmingham, AL 35294 USA.	fengj@uab.edu						Armbruester V, 2002, CLIN CANCER RES, V8, P1800; ASCH BB, 1993, INT J CANCER, V54, P813, DOI 10.1002/ijc.2910540516; Barbulescu M, 1999, CURR BIOL, V9, P861, DOI 10.1016/S0960-9822(99)80390-X; Boese A, 2000, ONCOGENE, V19, P4328, DOI 10.1038/sj.onc.1203794; Boese A, 2000, FEBS LETT, V468, P65, DOI 10.1016/S0014-5793(00)01197-2; Etkind PR, 1997, VIROLOGY, V234, P304, DOI 10.1006/viro.1997.8670; FRANKLIN GC, 1988, J VIROL, V62, P1203, DOI 10.1128/JVI.62.4.1203-1210.1988; Lander ES, 2001, NATURE, V409, P860, DOI 10.1038/35057062; LOWER R, 1995, J VIROL, V69, P141; LOWER R, 1993, P NATL ACAD SCI USA, V90, P4480, DOI 10.1073/pnas.90.10.4480; Magin C, 2000, VIROLOGY, V274, P11, DOI 10.1006/viro.2000.0438; Magin C, 1999, J VIROL, V73, P9496, DOI 10.1128/JVI.73.11.9496-9507.1999; Mayer J, 1999, NAT GENET, V21, P257, DOI 10.1038/6766; MEDSTRAND P, 1993, J VIROL, V67, P6778, DOI 10.1128/JVI.67.11.6778-6787.1993; Natoli F, 1996, CANCER LETT, V99, P121, DOI 10.1016/0304-3835(95)04060-9; ONO M, 1987, J VIROL, V61, P2059, DOI 10.1128/JVI.61.6.2059-2062.1987; ONO M, 1986, J VIROL, V60, P589, DOI 10.1128/JVI.60.2.589-598.1986; Schiavetti F, 2002, CANCER RES, V62, P5510; Sugimoto J, 2001, GENOMICS, V72, P137, DOI 10.1006/geno.2001.6473; Tristem M, 2000, J VIROL, V74, P3715, DOI 10.1128/JVI.74.8.3715-3730.2000; Wang-Johanning F, 2002, CANCER-AM CANCER SOC, V94, P2199, DOI 10.1002/cncr.10439; Wang-Johanning F, 2001, CLIN CANCER RES, V7, P1553; Yang J, 1999, P NATL ACAD SCI USA, V96, P13404, DOI 10.1073/pnas.96.23.13404; Yin H, 1997, AIDS RES HUM RETROV, V13, P507, DOI 10.1089/aid.1997.13.507	24	138	165	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 13	2003	22	10					1528	1535		10.1038/sj.onc.1206241	http://dx.doi.org/10.1038/sj.onc.1206241			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	652ZZ	12629516				2022-12-25	WOS:000181411900010
J	Casas, F; Daury, L; Grandemange, S; Busson, M; Seyer, P; Hatier, R; Carazo, A; Cabello, G; Wrutniak-Cabello, C				Casas, F; Daury, L; Grandemange, S; Busson, M; Seyer, P; Hatier, R; Carazo, A; Cabello, G; Wrutniak-Cabello, C			Endocrine regulation of mitochondrial activity: involvement of truncated RXR alpha and c-Erb A alpha 1 proteins	FASEB JOURNAL			English	Article						mitochondrial import; mitochondrial transcription; mt-DNA; triiodothyronine; 9-cis-retinoic acid	THYROID-HORMONE ACTION; RETINOID-X-RECEPTOR; RAT-LIVER; RNA-SYNTHESIS; PEROXISOME PROLIFERATORS; MYOBLAST DIFFERENTIATION; GENE-EXPRESSION; CELL-DEATH; VITAMIN-A; ACID	The importance of mitochondrial activity has recently been extended to the regulation of developmental processes. Numerous pathologies associated with organelle's dysfunctions emphasize their physiological importance. However, regulation of mitochondrial genome transcription, a key element for organelle's function, remains poorly understood. After characterization in the organelle of a truncated form of the triiodothyronine nuclear receptor (p43), a T3-dependent transcription factor of the mitochondrial genome, our purpose was to search for other mitochondrial receptors involved in the regulation of organelle transcription. We show that a 44 kDa protein related to RXRalpha (mt-RXR), another nuclear receptor, is located in the mitochondrial matrix. We found that mt-RXR is produced after cytosolic or intramitochondrial enzymatic cleavage of the RXRalpha nuclear receptor. After mitochondrial import and binding to specific sequences of the organelle genome, mt-RXR induces a ligand-dependent increase in mitochondrial RNA levels. mt-RXR physically interacts with p43 and acts alone or through a heterodimerical complex activated by 9-cis-retinoic acid and T3 to increase RNA levels. These data indicate that hormonal regulation of mitochondrial transcription occurs through pathways similar to those that take place in the nucleus and open a new way to better understand hormone and vitamin action at the cellular level.	INRA, UMR Differenciat Cellulaire & Croissance 866, Unite Endocrinol Cellulaire, INRA UMII ENSAM, F-34060 Montpellier 1, France; Fac Med Vandoeuvre Nancy, EMI 0014, INSERM, Electron Microscope Unit, F-54505 Vandoeuvre Les Nancy, France	INRAE; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Lorraine	Cabello, G (corresponding author), INRA, UMR Differenciat Cellulaire & Croissance 866, Unite Endocrinol Cellulaire, INRA UMII ENSAM, 2 Pl Viala, F-34060 Montpellier 1, France.	cabello@ensam.inra.fr	Grandemange, Stéphanie/G-7928-2015	Francois, Casas/0000-0002-5535-8195; Daury, Laetitia/0000-0002-1296-7150				BEER DG, 1982, BIOCHEM BIOPH RES CO, V109, P1276, DOI 10.1016/0006-291X(82)91915-5; Berdanier CD, 2001, DIABETES RES CLIN PR, V54, pS11, DOI 10.1016/S0168-8227(01)00331-X; Cai Y, 1996, ARCH BIOCHEM BIOPHYS, V325, P107, DOI 10.1006/abbi.1996.0013; Casas F, 1999, MOL CELL BIOL, V19, P7913; Casas F, 2000, FEBS LETT, V478, P4, DOI 10.1016/S0014-5793(00)01814-7; CHOU SY, 1995, ENDOCRINOLOGY, V136, P5520, DOI 10.1210/en.136.12.5520; Desvergne B, 1999, ENDOCR REV, V20, P649, DOI 10.1210/er.20.5.649; Enriquez JA, 1999, MOL CELL BIOL, V19, P657; Estornell E, 2000, BRIT J NUTR, V84, P927; Fleischer S, 1974, Methods Enzymol, V31, P6; Gaemers IC, 1998, MOL REPROD DEV, V50, P1, DOI 10.1002/(SICI)1098-2795(199805)50:1&lt;1::AID-MRD1&gt;3.0.CO;2-P; Gao G, 2000, J CELL BIOCHEM, V80, P53; Greenawalt J W, 1974, Methods Enzymol, V31, P310; Hamai N, 1997, CELL STRUCT FUNCT, V22, P421, DOI 10.1247/csf.22.421; HERTZ R, 1991, BIOCHEM J, V274, P745, DOI 10.1042/bj2740745; Imai T, 2001, P NATL ACAD SCI USA, V98, P224, DOI 10.1073/pnas.011528898; KANEKO T, 1988, MOL CELL BIOL, V8, P3311, DOI 10.1128/MCB.8.8.3311; Larsson NG, 1998, NAT GENET, V18, P231, DOI 10.1038/ng0398-231; LI G, 1994, INT J ONCOL, V5, P301; LIEBERHERR M, 1987, J BIOL CHEM, V262, P13168; Loeffler M, 2000, EXP CELL RES, V256, P19, DOI 10.1006/excr.2000.4833; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; MARTINO G, 1986, MOL BIOL REP, V11, P205, DOI 10.1007/BF00419598; MatsushimaNishiwaki R, 1996, BIOCHEM BIOPH RES CO, V225, P946, DOI 10.1006/bbrc.1996.1276; Nagaya T, 1998, J BIOL CHEM, V273, P33166, DOI 10.1074/jbc.273.50.33166; Neupert W, 1997, ANNU REV BIOCHEM, V66, P863, DOI 10.1146/annurev.biochem.66.1.863; Noguchi M, 1997, P NATL ACAD SCI USA, V94, P11534, DOI 10.1073/pnas.94.21.11534; Ostronoff LK, 1996, BIOCHEM J, V316, P183, DOI 10.1042/bj3160183; Prufer K, 2002, MOL ENDOCRINOL, V16, P961, DOI 10.1210/me.16.5.961; Ragan MT, 1987, MITOCHONDRIA PRACTIC, P79; Rochard P, 2000, J BIOL CHEM, V275, P2733, DOI 10.1074/jbc.275.4.2733; ROCHETTEEGLY C, 1994, BIOCHEM BIOPH RES CO, V204, P525, DOI 10.1006/bbrc.1994.2491; Ruiz-Lozano P, 1998, DEVELOPMENT, V125, P533; SANYAL A, 1995, J BIOL CHEM, V270, P11970, DOI 10.1074/jbc.270.20.11970; VANDENBOGERT C, 1992, J CELL PHYSIOL, V152, P632, DOI 10.1002/jcp.1041520323; VANITALLIE CM, 1988, MOL ENDOCRINOL, V2, P332, DOI 10.1210/mend-2-4-332; VANITALLIE CM, 1992, ENDOCRINOLOGY, V130, P567, DOI 10.1210/en.130.2.567; Wood DE, 1998, ONCOGENE, V17, P1069, DOI 10.1038/sj.onc.1202034; Wrutniak C, 1998, ANN NY ACAD SCI, V839, P93, DOI 10.1111/j.1749-6632.1998.tb10738.x; WRUTNIAK C, 1995, J BIOL CHEM, V270, P16347, DOI 10.1074/jbc.270.27.16347; Wrutniak-Cabello C, 2001, J MOL ENDOCRINOL, V26, P67, DOI 10.1677/jme.0.0260067	41	78	85	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAR	2003	17	3					426	436		10.1096/fj.02-0732com	http://dx.doi.org/10.1096/fj.02-0732com			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	661LT	12631582				2022-12-25	WOS:000181892600041
J	Sun, L; Iqbal, J; Dolgilevich, S; Yuen, T; Wu, XB; Moonga, BS; Adebanjo, OA; Bevis, PJR; Lund, F; Huang, CLH; Blair, HC; Abe, E; Zaidi, M				Sun, L; Iqbal, J; Dolgilevich, S; Yuen, T; Wu, XB; Moonga, BS; Adebanjo, OA; Bevis, PJR; Lund, F; Huang, CLH; Blair, HC; Abe, E; Zaidi, M			Disordered osteoclast formation and function in a CD38 (ADP-ribosyl cyclase)-deficient mouse establishes an essential role for CD38 in bone resorption	FASEB JOURNAL			English	Article						Ca2+ channel; osteoclast; ryanodine receptor; bone resorption; osteoporosis	CYCLIC ADP-RIBOSE; PANCREATIC BETA-CELLS; CD38/ADP-RIBOSYL CYCLASE; INTRACELLULAR CALCIUM; INSULIN-SECRETION; EXTRACELLULAR CALCIUM; HUMAN ERYTHROCYTES; SIGNALING PATHWAY; RAT OSTEOCLASTS; OUTER SURFACE	We have evaluated the role of the ADP-ribosyl cyclase, CD38, in bone remodeling, a process by which the skeleton is being renewed constantly through the coordinated activity of osteoclasts and osteoblasts. CD38 catalyzes the cyclization of its substrate, NAD(+),to the Ca2+-releasing second messenger, cyclic ADP-ribose (cADPr). We have shown previously that CD38 is expressed both in osteoblasts and osteoclasts. Its activation in the osteoclast triggers Ca2+ release through ryanodine receptors (RyRs), stimulation of interleukin-6 (IL-6), and an inhibition of bone resorption. Here, we have examined the consequences of deleting the CD38 gene in mice on skeletal remodeling. We report that CD38(-/-) mice displayed a markedly reduced bone mineral density (BMD) at the femur, tibia, and lumbar spine at 3 months and at the lumbar spine at 4 months, with full normalization of the BMD at all sites at 5 months. The osteoporosis at 3 months was accompanied by a reduction in primary spongiosa and increased osteoclast surfaces on histomorphometric analysis. Hematopoetic stem cells isolated ex vivo from CD38(-/-) mice showed a dramatic similar tofourfold increase in osteoclast formation in response to incubation for 6 days with RANK-L and M-CSF. The osteoclasts so formed in these cultures showed a similar to2.5-fold increase in resorptive activity compared with wild-type cells. However, when adherent bone marrow stromal cells were allowed to mature into alkaline phosphatase-positive colony-forming units (CFU-Fs), those derived from CD38(-/-) mice showed a significant reduction in differentiation compared with wild-type cells. Real-time RTPCR on mRNA isolated from osteoclasts at day 6 showed a significant reduction in IL-6 and IL-6 receptor mRNA, together with significant decreases in the expression of all calcineurin A isoforms, alpha, beta, and gamma. These findings establish a critical role for CD38 in osteoclast formation and bone resorption. We speculate that CD38 functions as a cellular NAD(+) "sensor," particularly during periods of active motility and secretion.	Mt Sinai Sch Med, Mt Sinai Bone Program, New York, NY USA; Mt Sinai Sch Med, Dept Med & Geriatr, New York, NY USA; Vet Affairs Med Ctr, Div Endocrinol, New York, NY USA; Vet Affairs Med Ctr, Ctr Geriatr Res Educ & Clin, New York, NY USA; Trudeau Inst Inc, Lake Placid, NY USA; Univ Cambridge, Physiol Lab, Cambridge CB2 3EG, England; Univ Pittsburgh, Dept Pathol, Pittsburgh, PA USA	Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; US Department of Veterans Affairs; Veterans Health Administration (VHA); Geriatric Research Education & Clinical Center; US Department of Veterans Affairs; Veterans Health Administration (VHA); Trudeau Institute; University of Cambridge; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Zaidi, M (corresponding author), Mt Sinai Sch Med, Div Endocrinol, Box 1055,1 Gustave Levy Pl, New York, NY 10029 USA.	mone.zaidi@mssm.edu	Huang, Christopher LH/A-6248-2008	Zaidi, Mone/0000-0001-5911-9522	NIA NIH HHS [R01 AG14197-07] Funding Source: Medline	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Abe E, 2000, J BONE MINER RES, V15, P663, DOI 10.1359/jbmr.2000.15.4.663; Adebanjo OA, 1998, J CELL BIOL, V142, P1347, DOI 10.1083/jcb.142.5.1347; Adebanjo OA, 2000, BIOCHEM BIOPH RES CO, V273, P884, DOI 10.1006/bbrc.2000.3041; Adebanjo OA, 1999, NAT CELL BIOL, V1, P409, DOI 10.1038/15640; Adebanjo OA, 2000, AM J PHYSIOL-RENAL, V278, pF784, DOI 10.1152/ajprenal.2000.278.5.F784; Adebanjo OA, 1996, AM J PHYSIOL-RENAL, V270, pF469, DOI 10.1152/ajprenal.1996.270.3.F469; Antonelli A, 2001, DIABETES, V50, P985, DOI 10.2337/diabetes.50.5.985; Cockayne DA, 1998, BLOOD, V92, P1324, DOI 10.1182/blood.V92.4.1324.416k26_1324_1333; De Flora Antonio, 1998, Cell Biochemistry and Biophysics, V28, P45; Deaglio S, 2001, FASEB J, V15, P580; DeFlora A, 1996, BIOCHEM J, V320, P665, DOI 10.1042/bj3200665; Fernandez JE, 1998, J BIOL REG HOMEOS AG, V12, P81; Ferrero E, 1999, IMMUNOGENETICS, V49, P597, DOI 10.1007/s002510050654; Franco L, 1998, FASEB J, V12, P1507; Fukushi Y, 2001, J BIOL CHEM, V276, P649, DOI 10.1074/jbc.M004469200; HOWARD M, 1993, SCIENCE, V262, P1056, DOI 10.1126/science.8235624; KATO I, 1995, J BIOL CHEM, V270, P30045, DOI 10.1074/jbc.270.50.30045; Kato I, 1999, J BIOL CHEM, V274, P1869, DOI 10.1074/jbc.274.4.1869; Khoo KM, 2000, J BIOL CHEM, V275, P24807, DOI 10.1074/jbc.M908231199; LEE CL, 2000, HUMAN CD38 RELATED M, P39; LEE HC, 1991, CELL REGUL, V2, P203, DOI 10.1091/mbc.2.3.203; LEE HC, 1993, BIOCHEM BIOPH RES CO, V191, P639, DOI 10.1006/bbrc.1993.1265; LEE HC, 1994, VITAM HORM, V48, P199, DOI 10.1016/S0083-6729(08)60499-9; MALGAROLI A, 1989, J BIOL CHEM, V264, P14342; Moonga BS, 2002, J ENDOCRINOL, V173, DOI 10.1677/joe.0.1730395; MOONGA BS, 1990, J PHYSIOL-LONDON, V429, P29, DOI 10.1113/jphysiol.1990.sp018242; PARFITT AM, 1987, J BONE MINER RES, V2, P595, DOI 10.1002/jbmr.5650020617; Partida-Sanchez S, 2001, NAT MED, V7, P1209, DOI 10.1038/nm1101-1209; Podesta M, 2000, FASEB J, V14, P680, DOI 10.1096/fasebj.14.5.680; Romanello M, 2001, BIOCHEM BIOPH RES CO, V285, P1226, DOI 10.1006/bbrc.2001.5325; Shubinsky G, 1997, IMMUNITY, V7, P315, DOI 10.1016/S1074-7613(00)80353-2; SILVER IA, 1988, EXP CELL RES, V175, P266, DOI 10.1016/0014-4827(88)90191-7; Sun L, 1999, J CELL BIOL, V146, P1161, DOI 10.1083/jcb.146.5.1161; Sun L, 2002, FASEB J, V16, DOI 10.1096/fj.01-0705com; SUN L, 2002, IN PRESS AM J PHYSL; TAKASAWA S, 1993, J BIOL CHEM, V268, P26052; TAKASAWA S, 1993, SCIENCE, V259, P370, DOI 10.1126/science.8420005; Verderio C, 2001, J NEUROCHEM, V78, P646, DOI 10.1046/j.1471-4159.2001.00455.x; Zaidi M, 1999, J BONE MINER RES, V14, P669, DOI 10.1359/jbmr.1999.14.5.669; ZAIDI M, 1995, J CLIN INVEST, V96, P1582, DOI 10.1172/JCI118197; ZAIDI M, 1989, BIOCHEM BIOPH RES CO, V163, P1461, DOI 10.1016/0006-291X(89)91143-1; ZOCCHI E, 1993, BIOCHEM BIOPH RES CO, V196, P1459, DOI 10.1006/bbrc.1993.2416	42	53	55	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAR	2003	17	3					369	375		10.1096/fj.02-0205com	http://dx.doi.org/10.1096/fj.02-0205com			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	661LT	12631576				2022-12-25	WOS:000181892600035
J	Tureci, O; Ding, JY; Hilton, H; Bian, HJ; Ohkawa, H; Braxenthaler, M; Seitz, G; Raddrizzani, L; Friess, H; Buchler, M; Sahin, U; Hammer, J				Tureci, O; Ding, JY; Hilton, H; Bian, HJ; Ohkawa, H; Braxenthaler, M; Seitz, G; Raddrizzani, L; Friess, H; Buchler, M; Sahin, U; Hammer, J			Computational dissection of tissue contamination for identification of colon cancer-specific expression profiles	FASEB JOURNAL			English	Article						expression signature; colorectal cancer; profile	GENE-EXPRESSION; MESSENGER-RNA; MATRIX METALLOPROTEINASE-1; EPITHELIAL-CELLS; MARKER; DIFFERENTIATION; ADENOMAS; PATTERNS; PROTEIN; TARGET	Microarray profiles of bulk tumor tissues reflect gene expression corresponding to malignant cells as well as to many different types of contaminating normal cells. In this report, we assess the feasibility of querying baseline multitissue transcriptome databases to dissect disease-specific genes. Using colon cancer as a model tumor, we show that the application of Boolean operators (AND, OR, BUTNOT) for database searches leads to genes with expression patterns of interest. The BUTNOT operator for example allows the assignment of "expression signatures" to normal tissue specimens. These expression signatures were then used to computationally identify contaminating cells within conventionally dissected tissue specimens. The combination of several logic operators together with an expression database based on multiple human tissue specimens can resolve the problem of tissue contamination, revealing novel cancer-specific gene expression. Several markers, previously not known to be colon cancer associated, are provided.	Johannes Gutenberg Univ Mainz, Med Klin 3, Med Klin & Poliklin 3, D-55131 Mainz, Germany; Hoffmann La Roche Inc, Roche Genom & Informat Sci, Nutley, NJ 07110 USA; Klinikum Bamberg, Inst Pathol, D-96049 Bamberg, Germany; Heidelberg Univ, Dept Surg, D-69120 Heidelberg, Germany	Johannes Gutenberg University of Mainz; Roche Holding; Ruprecht Karls University Heidelberg	Tureci, O (corresponding author), Johannes Gutenberg Univ Mainz, Med Klin 3, Med Klin & Poliklin 3, Obere Zahlbacher Str 63, D-55131 Mainz, Germany.	Tureci@mail.uni-mainz.de	Sahin, Ugur/L-4818-2017	Sahin, Ugur/0000-0003-0363-1564				Alon U, 1999, P NATL ACAD SCI USA, V96, P6745, DOI 10.1073/pnas.96.12.6745; Bekku S, 1998, RES EXP MED, V198, P175, DOI 10.1007/s004330050101; Boller K, 1997, J VIROL, V71, P4581, DOI 10.1128/JVI.71.6.4581-4588.1997; BROITMAN SA, 1993, PROG FOOD NUTR SCI, V17, P1; Cohen MB, 1998, LAB INVEST, V78, P101; DeRisi JL, 1997, SCIENCE, V278, P680, DOI 10.1126/science.278.5338.680; EmmertBuck MR, 1996, SCIENCE, V274, P998, DOI 10.1126/science.274.5289.998; Fleming RE, 1995, J CLIN INVEST, V96, P2907, DOI 10.1172/JCI118362; Golub TR, 1999, SCIENCE, V286, P531, DOI 10.1126/science.286.5439.531; Hanamura N, 1997, INT J CANCER, V73, P10, DOI 10.1002/(SICI)1097-0215(19970926)73:1<10::AID-IJC2>3.0.CO;2-4; Hanski C, 1997, LAB INVEST, V77, P685; Herrero J, 2001, BIOINFORMATICS, V17, P126, DOI 10.1093/bioinformatics/17.2.126; Khan J, 1998, CANCER RES, V58, P5009; Kinugasa T, 1998, INT J CANCER, V76, P148, DOI 10.1002/(SICI)1097-0215(19980330)76:1<148::AID-IJC23>3.3.CO;2-J; Liu XL, 1996, CANCER RES, V56, P3371; Lockhart DJ, 1996, NAT BIOTECHNOL, V14, P1675, DOI 10.1038/nbt1296-1675; Melis R, 1999, ELECTROPHORESIS, V20, P1055, DOI 10.1002/(SICI)1522-2683(19990101)20:4/5<1055::AID-ELPS1055>3.0.CO;2-O; Moch H, 1999, AM J PATHOL, V154, P981, DOI 10.1016/S0002-9440(10)65349-7; MULDER TPJ, 1990, FREE RADICAL BIO MED, V9, P501, DOI 10.1016/0891-5849(90)90128-6; Murray GI, 1996, NAT MED, V2, P461, DOI 10.1038/nm0496461; Notterman DA, 2001, CANCER RES, V61, P3124; Rechreche H, 1997, EUR J BIOCHEM, V248, P225, DOI 10.1111/j.1432-1033.1997.00225.x; RETTIG WJ, 1994, INT J CANCER, V58, P385, DOI 10.1002/ijc.2910580314; Riethmuller G, 1998, J CLIN ONCOL, V16, P1788, DOI 10.1200/JCO.1998.16.5.1788; SCHENA M, 1995, SCIENCE, V270, P467, DOI 10.1126/science.270.5235.467; SCHWEINFEST CW, 1993, P NATL ACAD SCI USA, V90, P4166, DOI 10.1073/pnas.90.9.4166; Shankavaram UT, 1997, J CELL PHYSIOL, V173, P327, DOI 10.1002/(SICI)1097-4652(199712)173:3<327::AID-JCP4>3.3.CO;2-R; Shiozawa J, 2000, MODERN PATHOL, V13, P925, DOI 10.1038/modpathol.3880169; St Croix B, 2000, SCIENCE, V289, P1197; Sturniolo T, 1999, NAT BIOTECHNOL, V17, P555, DOI 10.1038/9858; Takahashi KI, 1998, ANTICANCER RES, V18, P3381; Tschmelitsch J, 1997, CANCER RES, V57, P2181; Wellmann A, 2000, BLOOD, V96, P398; WELT S, 1994, J CLIN ONCOL, V12, P1193, DOI 10.1200/JCO.1994.12.6.1193; Werner T, 2001, PHARMACOGENOMICS, V2, P25, DOI 10.1517/14622416.2.1.25; ZOU ZQ, 1994, SCIENCE, V263, P526, DOI 10.1126/science.8290962; Zutter MM, 1998, JNCI-J NATL CANCER I, V90, P642, DOI 10.1093/jnci/90.9.642	37	35	37	0	0	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2003	17	3					376	385		10.1096/fj.02-0478com	http://dx.doi.org/10.1096/fj.02-0478com			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	661LT	12631577				2022-12-25	WOS:000181892600036
J	Abbas, S; Abu-Amer, Y				Abbas, S; Abu-Amer, Y			Dominant-negative I kappa B facilitates apoptosis of osteoclasts by tumor necrosis factor-alpha	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLONY-STIMULATING FACTOR; TAT FUSION PROTEINS; OSTEOPROTEGERIN LIGAND; ACTIVATION; INHIBITION; DIFFERENTIATION; RECEPTOR; CASPASES; CELLS; BONE	Osteoclasts are the sole bone-resorbing cells. Heightened activity of these cells under pathological conditions leads to the development of bone loss diseases, such as osteolysis, osteoporosis, and rheumatoid arthritis. We have shown previously that tumor necrosis factor alpha-(TNF) strongly induces osteoclastogenesis of preosteoclasts and do so through activation of the transcription factor, NF-kappaB. Most importantly, recent studies have shown that NF-kappaB is required for the development of osteoclasts. This transcription factor has also been proven as an essential mediator of inflammatory diseases including those related to bone. In this regard, we have shown that various mutated forms of IkappaBalpha are potent inhibitors of osteoclastogenesis. In this study, we examined the direct effect of DN-IkappaB on mature and preosteoclast development in the presence of TNF. Our findings indicate that once committed to the osteoclastogenic pathway, preosteoclasts form giant and hyperactive osteoclasts in response to TNF. However, administration of DN-IkappaB to cultures prior to TNF exposure averts the osteoclastogenic effect of TNF into apoptosis. Screening potential mediators of DN-IkappaB and TNF-induced apoptosis shows that caspase 3, caspase 9, poly(ADP-ribose) polymerase, and Bax are activated, whereas levels of Bcl-X-L, cIAP-1, and TRAF6 were reduced. Taken together, these findings suggest that under conditions of NF-kappaB inactivity levels of pro-survival factors are diminished, which in turn facilitates TNF induction of pro-apoptotic factors leading to apoptosis.	Washington Univ, Sch Med, Dept Orthopaed, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Cell Biol & Physiol, St Louis, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL)	Abu-Amer, Y (corresponding author), Washington Univ, Sch Med, Dept Orthoped Surg, 1 Barnes Hosp Plaza,11300 W Pavil,Campus Box 8233, St Louis, MO 63110 USA.	abuamery@msnotes.wustl.edu			NIAMS NIH HHS [AR-47443] Funding Source: Medline; NIDCR NIH HHS [DE-13754] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR047443] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE013754] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Abu-Amer Y, 2000, J BIOL CHEM, V275, P27307; Abu-Amer Y, 1998, J BIOL CHEM, V273, P29417, DOI 10.1074/jbc.273.45.29417; Abu-Amer Y, 2001, J CLIN INVEST, V107, P1375, DOI 10.1172/JCI10530; Abu-Amer Y, 2001, J BIOL CHEM, V276, P30499, DOI 10.1074/jbc.M104725200; AbuAmer Y, 1997, NAT MED, V3, P1189, DOI 10.1038/nm1197-1189; AbuAmer Y, 1997, J CLIN INVEST, V100, P1557, DOI 10.1172/JCI119679; Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Baldwin AS, 2001, J CLIN INVEST, V107, P3, DOI 10.1172/JCI11891; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; Boyce BF, 1999, BONE, V25, P137, DOI 10.1016/S8756-3282(99)00105-2; Darnay BG, 1998, J BIOL CHEM, V273, P20551, DOI 10.1074/jbc.273.32.20551; Deveraux QL, 1998, EMBO J, V17, P2215, DOI 10.1093/emboj/17.8.2215; Doyle BT, 2002, J LEUKOCYTE BIOL, V71, P247; Duckett CS, 2002, J CLIN INVEST, V109, P579, DOI 10.1172/JCI200215197; Franzoso G, 1997, GENE DEV, V11, P3482, DOI 10.1101/gad.11.24.3482; Herrera B, 2002, FEBS LETT, V520, P93, DOI 10.1016/S0014-5793(02)02774-6; Insogna KL, 1997, J CLIN INVEST, V100, P2476, DOI 10.1172/JCI119790; Iotsova V, 1997, NAT MED, V3, P1285, DOI 10.1038/nm1197-1285; KODAMA H, 1991, J EXP MED, V173, P269, DOI 10.1084/jem.173.1.269; Lacey DL, 2000, AM J PATHOL, V157, P435, DOI 10.1016/S0002-9440(10)64556-7; Lacey DL, 1998, CELL, V93, P165, DOI 10.1016/S0092-8674(00)81569-X; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lawrence T, 2001, NAT MED, V7, P1291, DOI 10.1038/nm1201-1291; LI J, 1996, J BONE MINER RES S, V14, P149; Madge LA, 2000, J BIOL CHEM, V275, P15458, DOI 10.1074/jbc.M001237200; Miyazaki T, 2000, J CELL BIOL, V148, P333, DOI 10.1083/jcb.148.2.333; Nagahara H, 1998, NAT MED, V4, P1449, DOI 10.1038/4042; Roy N, 1997, EMBO J, V16, P6914, DOI 10.1093/emboj/16.23.6914; Schwarz EM, 2000, J ORTHOPAED RES, V18, P472, DOI 10.1002/jor.1100180321; Shalhoub V, 1999, J CELL BIOCHEM, V72, P251; SHERR CJ, 1990, BLOOD, V75, P1; SIEBENLIST U, 2001, P NATL ACAD SCI USA, V89, P4333; Tak PP, 2001, J CLIN INVEST, V107, P7, DOI 10.1172/JCI11830; TAKAHASHI N, 1991, J BONE MINER RES, V6, P977; TANAKA S, 1993, J CLIN INVEST, V91, P257, DOI 10.1172/JCI116179; Teitelbaum SL, 2000, SCIENCE, V289, P1504, DOI 10.1126/science.289.5484.1504; THANOS D, 1995, CELL, V80, P529, DOI 10.1016/0092-8674(95)90506-5; VAN AD, 1996, SCIENCE, V274, P787; Wang CY, 1999, NAT MED, V5, P412, DOI 10.1038/7410; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; Wang CY, 1998, SCIENCE, V281, P1680, DOI 10.1126/science.281.5383.1680; Xing LP, 2002, J BONE MINER RES, V17, P1200, DOI 10.1359/jbmr.2002.17.7.1200; Yamamoto Y, 2001, J CLIN INVEST, V107, P135, DOI 10.1172/JCI11914; Zhang YH, 2001, J BIOL CHEM, V276, P563, DOI 10.1074/jbc.M008198200	46	40	42	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 30	2003	278	22					20077	20082		10.1074/jbc.M208619200	http://dx.doi.org/10.1074/jbc.M208619200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	682EH	12637573	hybrid			2022-12-25	WOS:000183078000065
J	Yu, SJ; Asa, SL; Weigel, RJ; Ezzat, S				Yu, SJ; Asa, SL; Weigel, RJ; Ezzat, S			Pituitary tumor AP-2 alpha recognizes a cryptic promoter in intron 4 of fibroblast growth factor receptor 4	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR; GENOMIC STRUCTURE; BINDING-SITE; GENE; EXPRESSION; REGION; FGFR-4; TRANSACTIVATION; IDENTIFICATION; PROLIFERATION	Fibroblast growth factor receptors (FGFRs) have been implicated in a multitude of proliferative functions, and FGFR4 is expressed differentially in normal and neoplastic pituitary. Human pituitary tumors express a truncated FGFR4 isoform (ptd-FGFR4) for which transcription is initiated from a downstream alternative site. Analysis of FGFR4 intronic sequences predicted a possible promoter within intron 4 (In4) including a classic TATA box with a possible transcriptional start site in intron 5. We show here that the human In4 sequence can direct luciferase reporter activity in transfected pituitary GH4 cells. Four overlapping fragments (A1, A2, B1, and B2) of this intron were examined by electromobility shift assay using nuclear extracts from rat pituitary tumors. Of these, fragment B2 formed complexes with nuclear rat pituitary GH4 extracts that were competed specifically by wild type but not mutant oligonucleotides for the neural crest cell lineage-derived activating transcription factor AP-2. Conversely, an AP-2 consensus sequence probe was competed by the In4 B2 oligonucleotide but not by other fragments of the same intron. The In4 B2 complex was competed partially by NFkappaB, supershifted by an AP-2 alpha-specific antibody, and co-migrated with the same probe incubated with recombinant AP-2alpha protein. We also examined the ability of primary human pituitary tumor extracts to interact with the In4 B2 fragment. Pituitary tumor-In4 B2 complexes were competed specifically by wild type AP-2 but not mutant AP-2 oligonucleotides. Western blotting revealed higher levels of AP-2alpha expression in primary human pituitary tumors than in nontumorous tissue. Mutagenesis of the putative AP-2 binding site in In4 B2 resulted in a marked loss of promoter activity in a luciferase assay. AP-2alpha transfection in the presence of the histone deacetylase inhibitor trichostatin-A resulted in enhanced expression of endogenous ptd-FGFR4. These data indicate that a cryptic promoter within intron 4 binds AP-2alpha. AP-2alpha and chromatin changes may contribute to the utilization of an alternative transcription start site leading to the genesis of the tumorigenic ptd-FGFR4 isoform.	Univ Toronto, Mt Sinai Hosp, Dept Med, Toronto, ON M5G 2M9, Canada; Univ Toronto, Freeman Ctr Endocrine Oncol, Univ Hlth Network, Dept Pathol, Toronto, ON M5G 2M9, Canada; Univ Toronto, Ontario Canc Inst, Toronto, ON M5G 2M9, Canada; Thomas Jefferson Univ, Dept Surg, Philadelphia, PA 19107 USA	University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Jefferson University	Ezzat, S (corresponding author), Univ Toronto, Mt Sinai Hosp, 600 Univ Ave,437, Toronto, ON M5G 1X5, Canada.			Asa, Sylvia/0000-0001-8418-5054; Weigel, Ronald/0000-0002-9249-0793				Asa SL, 2002, NAT REV CANCER, V2, P836, DOI 10.1038/nrc926; AVIVI A, 1992, ONCOGENE, V7, P1957; Becker M, 2000, BIOCHEM BIOPH RES CO, V276, P493, DOI 10.1006/bbrc.2000.3483; BISHOP JF, 1990, FEBS LETT, V264, P125, DOI 10.1016/0014-5793(90)80781-D; Ezzat S, 2002, J CLIN INVEST, V109, P69, DOI 10.1172/JCI200214036; EZZAT S, 1995, J CLIN ENDOCR METAB, V80, P878, DOI 10.1210/jc.80.3.878; Fiorentini C, 2002, MOL ENDOCRINOL, V16, P353, DOI 10.1210/me.16.2.353; GIVOL D, 1992, FASEB J, V6, P3362, DOI 10.1096/fasebj.6.15.1464370; Hart KC, 2000, ONCOGENE, V19, P3309, DOI 10.1038/sj.onc.1203650; HAUSER F, 1994, FEBS LETT, V345, P225, DOI 10.1016/0014-5793(94)00444-7; Hughes SE, 1997, J HISTOCHEM CYTOCHEM, V45, P1005, DOI 10.1177/002215549704500710; IVERSON RA, 1990, MOL ENDOCRINOL, V4, P1564, DOI 10.1210/mend-4-10-1564; JOHNSTON CL, 1995, BIOCHEM J, V306, P609, DOI 10.1042/bj3060609; Katsel PL, 2001, J BIOL CHEM, V276, P752, DOI 10.1074/jbc.M007553200; Koritschoner NP, 1999, ONCOGENE, V18, P5904, DOI 10.1038/sj.onc.1202979; Kostrzewa M, 1998, MAMM GENOME, V9, P131, DOI 10.1007/s003359900703; Lecomte MJ, 1999, J NEUROCHEM, V73, P1806; McEwen DG, 1998, J BIOL CHEM, V273, P5349, DOI 10.1074/jbc.273.9.5349; McPherson LA, 1999, NUCLEIC ACIDS RES, V27, P4040, DOI 10.1093/nar/27.20.4040; McPherson LA, 2002, J BIOL CHEM, V277, P45028, DOI 10.1074/jbc.M208924200; Modugno M, 2002, ONCOGENE, V21, P7478, DOI 10.1038/sj.onc.1205957; PARTANEN J, 1991, EMBO J, V10, P1347, DOI 10.1002/j.1460-2075.1991.tb07654.x; Pfisterer P, 2002, J BIOL CHEM, V277, P6637, DOI 10.1074/jbc.M108578200; Ren YS, 2001, J BIOL CHEM, V276, P17770, DOI 10.1074/jbc.M010307200; SAITO H, 1992, BIOCHEM BIOPH RES CO, V183, P688, DOI 10.1016/0006-291X(92)90537-U; TsaiMorris CH, 1996, J BIOL CHEM, V271, P14519, DOI 10.1074/jbc.271.24.14519; Yu SJ, 2002, MOL ENDOCRINOL, V16, P1069, DOI 10.1210/me.16.5.1069; Zhao F, 2001, J BIOL CHEM, V276, P40755, DOI 10.1074/jbc.M106284200	28	36	36	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 30	2003	278	22					19597	19602		10.1074/jbc.M212432200	http://dx.doi.org/10.1074/jbc.M212432200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	682EH	12642581	hybrid			2022-12-25	WOS:000183078000006
J	Hiol, A; Davey, PC; Osterhout, JL; Waheed, AA; Fischer, ER; Chen, CK; Milligan, G; Druey, KM; Jones, TLZ				Hiol, A; Davey, PC; Osterhout, JL; Waheed, AA; Fischer, ER; Chen, CK; Milligan, G; Druey, KM; Jones, TLZ			Palmitoylation regulates regulators of G-protein signaling (RGS) 16 function - I. Mutation of amino-terminal cysteine residues on RGS16 prevents its targeting to lipid rafts and palmitoylation of an internal cysteine residue	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMA-MEMBRANE LOCALIZATION; FUSION PROTEINS; ALPHA-SUBUNITS; BINDING; RECEPTOR; DOMAIN; G-ALPHA(13); ASSOCIATION; TRANSDUCIN; MODULATION	Regulators of G-protein signaling (RGS) proteins down-regulate signaling by heterotrimeric G-proteins by accelerating GTP hydrolysis on the Galpha subunits. Palmitoylation, the reversible addition of palmitate to cysteine residues, occurs on several RGS proteins and is critical for their activity. For RGS16, mutation of Cys-2 and Cys-12 blocks its incorporation of [H-3]palmitate and ability to turn-off G(i) and G(q) signaling and significantly inhibited its GTPase activating protein activity toward a Galpha subunit fused to the 5-hydroxytryptamine receptor 1A, but did not reduce its plasma membrane localization based on cell fractionation studies and immunoelectron microscopy. Palmitoylation can target proteins, including many signaling proteins, to membrane microdomains, called lipid rafts. A subpopulation of endogenous RGS16 in rat liver membranes and overexpressed RGS16 in COS cells, but not the nonpalmitoylated cysteine mutant of RGS16, localized to lipid rafts. However, disruption of lipid rafts by treatment with methyl-beta-cyclodextrin did not decrease the GTPase activating protein activity of RGS16. The lipid raft fractions were enriched in protein acyltransferase activity, and RGS16 incorporated [H-3] palmitate into a peptide fragment containing Cys-98, a highly conserved cysteine within the RGS box. These results suggest that the amino-terminal palmitoylation of an RGS protein promotes its lipid raft targeting that allows palmitoylation of a poorly accessible cysteine residue that we show in the accompanying article (Osterhout, J. L., Waheed, A. A., Hiol, A., Ward, R. J., Davey, P. C., Nini, L., Wang, J., Milligan, G., Jones, T. L. Z., and Druey, K. M. (2003) J. Biol. Chem. 278, 19309 19316) was critical for RGS16 and RGS4 GAP activity.	NIDDK, Metab Dis Branch, NIH, Bethesda, MD 20892 USA; NIAID, Mol Signal Transduct Sect, Lab Allerg Dis, NIH, Bethesda, MD 20892 USA; NIAID, Microscopy Branch, NIH, Hamilton, MT 59840 USA; Univ Utah, Dept Ophthalmol, Salt Lake City, UT 84112 USA; Univ Glasgow, Inst Biomed & Life Sci, Div Biochem & Mol Biol, Mol Pharmacol Grp, Glasgow G12 8QQ, Lanark, Scotland	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); Utah System of Higher Education; University of Utah; University of Glasgow	Jones, TLZ (corresponding author), NIDDK, Metab Dis Branch, NIH, Bldg 10,Rm 9C101, Bethesda, MD 20892 USA.	tlzj@helix.nih.gov	Milligan, Graeme/F-9426-2011	Milligan, Graeme/0000-0002-6946-3519	Biotechnology and Biological Sciences Research Council [C17789] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [Z01AI000840] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [Z01DK043010] Funding Source: NIH RePORTER	Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Bernstein LS, 2000, J BIOL CHEM, V275, P18520, DOI 10.1074/jbc.M000618200; Bhattacharyya R, 2000, J BIOL CHEM, V275, P14992, DOI 10.1074/jbc.M000415200; Brown DA, 2000, J BIOL CHEM, V275, P17221, DOI 10.1074/jbc.R000005200; BROWN WJ, 1989, METHOD CELL BIOL, V31, P553; Caron JM, 1997, MOL BIOL CELL, V8, P621, DOI 10.1091/mbc.8.4.621; Castro-Fernandez C, 2002, ENDOCRINOLOGY, V143, P1310, DOI 10.1210/en.143.4.1310; Chen CH, 1999, J BIOL CHEM, V274, P19799, DOI 10.1074/jbc.274.28.19799; Chen CH, 1997, J BIOL CHEM, V272, P8679, DOI 10.1074/jbc.272.13.8679; Chen CK, 1996, P NATL ACAD SCI USA, V93, P12885, DOI 10.1073/pnas.93.23.12885; De Vries L, 2000, ANNU REV PHARMACOL, V40, P235, DOI 10.1146/annurev.pharmtox.40.1.235; DeVries L, 1996, P NATL ACAD SCI USA, V93, P15203, DOI 10.1073/pnas.93.26.15203; Druey KM, 1999, J BIOL CHEM, V274, P18836, DOI 10.1074/jbc.274.26.18836; Dunphy JT, 1998, BBA-MOL CELL BIOL L, V1436, P245, DOI 10.1016/S0005-2760(98)00130-1; Dunphy JT, 2001, J BIOL CHEM, V276, P43300, DOI 10.1074/jbc.M104275200; Galbiati F, 1999, J BIOL CHEM, V274, P5843, DOI 10.1074/jbc.274.9.5843; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; GOLDSMITH P, 1987, J BIOL CHEM, V262, P14683; Hamm HE, 1998, J BIOL CHEM, V273, P669, DOI 10.1074/jbc.273.2.669; HANCOCK JF, 1990, CELL, V63, P133, DOI 10.1016/0092-8674(90)90294-O; JONES TLZ, 1990, P NATL ACAD SCI USA, V87, P568, DOI 10.1073/pnas.87.2.568; Kellett E, 1999, MOL PHARMACOL, V56, P684; Kourlas PJ, 2000, P NATL ACAD SCI USA, V97, P2145, DOI 10.1073/pnas.040569197; Lambright DG, 1996, NATURE, V379, P311, DOI 10.1038/379311a0; Lindwasser OW, 2001, J VIROL, V75, P7913, DOI 10.1128/JVI.75.17.7913-7924.2001; Melkonian KA, 1999, J BIOL CHEM, V274, P3910, DOI 10.1074/jbc.274.6.3910; Milligan G, 2000, TRENDS PHARMACOL SCI, V21, P24, DOI 10.1016/S0165-6147(99)01404-2; Miura Y, 2001, BIOCHEMISTRY-US, V40, P15418, DOI 10.1021/bi015574a; Moffett S, 2000, J BIOL CHEM, V275, P2191, DOI 10.1074/jbc.275.3.2191; Morales J, 1998, MOL BIOL CELL, V9, P1, DOI 10.1091/mbc.9.1.1; Nair KS, 2002, CURR BIOL, V12, P421, DOI 10.1016/S0960-9822(02)00691-7; Osterhout JL, 2003, J BIOL CHEM, V278, P19309, DOI 10.1074/jbc.M210124200; Parks IK, 2001, J BIOL CHEM, V276, P915, DOI 10.1074/jbc.M005947200; Pike LJ, 1998, J BIOL CHEM, V273, P22298, DOI 10.1074/jbc.273.35.22298; Rose JJ, 2000, J NEUROCHEM, V75, P2103, DOI 10.1046/j.1471-4159.2000.0752103.x; Ross EM, 2000, ANNU REV BIOCHEM, V69, P795, DOI 10.1146/annurev.biochem.69.1.795; Shaul PW, 1998, AM J PHYSIOL-LUNG C, V275, pL843, DOI 10.1152/ajplung.1998.275.5.L843; Siderovski DP, 1999, CRIT REV BIOCHEM MOL, V34, P215, DOI 10.1080/10409239991209273; Simons K, 2000, NAT REV MOL CELL BIO, V1, P31, DOI 10.1038/35036052; Srinivasa SP, 1998, P NATL ACAD SCI USA, V95, P5584, DOI 10.1073/pnas.95.10.5584; Tesmer JJG, 1997, CELL, V89, P251, DOI 10.1016/S0092-8674(00)80204-4; Tu YP, 1999, J BIOL CHEM, V274, P38260, DOI 10.1074/jbc.274.53.38260; Tu YP, 2001, J BIOL CHEM, V276, P20160, DOI 10.1074/jbc.M101599200; Tu YP, 1997, SCIENCE, V278, P1132, DOI 10.1126/science.278.5340.1132; Ugur O, 2000, MOL BIOL CELL, V11, P1421, DOI 10.1091/mbc.11.4.1421; Waheed AA, 2002, J BIOL CHEM, V277, P32409, DOI 10.1074/jbc.C200383200; Wedegaertner PB, 1998, BIOL SIGNAL RECEPT, V7, P125; Wolven A, 1997, MOL BIOL CELL, V8, P1159, DOI 10.1091/mbc.8.6.1159; Zheng B, 2001, SCIENCE, V294, P1939, DOI 10.1126/science.1064757; Zheng B, 2000, P NATL ACAD SCI USA, V97, P3999, DOI 10.1073/pnas.97.8.3999	49	59	60	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 23	2003	278	21					19301	19308		10.1074/jbc.M210123200	http://dx.doi.org/10.1074/jbc.M210123200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	679PY	12642593	hybrid			2022-12-25	WOS:000182932200076
J	Takahashi, Y; Hayashi, I; Tominari, Y; Rikimaru, K; Morohashi, Y; Kan, T; Natsugari, H; Fukuyama, T; Tomita, T; Iwatsubo, T				Takahashi, Y; Hayashi, I; Tominari, Y; Rikimaru, K; Morohashi, Y; Kan, T; Natsugari, H; Fukuyama, T; Tomita, T; Iwatsubo, T			Sulindac sulfide is a noncompetitive gamma-secretase inhibitor that preferentially reduces A beta 42 generation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMYLOID PRECURSOR PROTEIN; ALZHEIMERS-DISEASE; THYMOCYTE DEVELOPMENT; MUTANT PRESENILIN-2; C-TERMINUS; COMPLEX; STATE; SITE; ENDOPROTEOLYSIS; OVERPRODUCTION	Nonsteroidal anti-inflammatory drugs (NSAIDs) have been known to reduce risk for Alzheimer's disease. In addition to the anti-inflammatory effects of NSAIDs to block cylooxygenase, it has been shown recently that a subset of NSAIDs selectively inhibits the secretion of highly amyloidogenic Abeta42 from cultured cells, although the molecular target(s) of NSAIDs in reducing the activity of gamma-secretase for Abeta42 generation (gamma(42)-secretase) still remain unknown. Here we show that sulindac sulfide (SSide) directly acts on gamma-secretase and preferentially inhibits the gamma(42)-secretase activity derived from the 3-[(3-cholamidopropyl)dimethylammonio]-2-hydroxy-1-propanesulfonate-solubilized membrane fractions of HeLa cells, in an in vitro gamma-secretase assay using recombinant amyloid beta precursor protein C100 as a substrate. SSide also inhibits activities for the generation of Abeta40 as well as for Notch intracellular domain at higher concentrations. Notably, SSide displayed linear noncompetitive inhibition profiles for gamma(42)-secretase in vitro. Our data suggest that SSide is a direct inhibitor of gamma-secretase that preferentially affects the gamma(42)-secretase activity.	Univ Tokyo, Grad Sch Pharmaceut Sci, Dept Neuropathol & Neurosci, Bunkyo Ku, Tokyo 1130033, Japan; Univ Tokyo, Grad Sch Pharmaceut Sci, Dept Synthet Nat Prod Chem, Bunkyo Ku, Tokyo 1130033, Japan; Univ Tokyo, Grad Sch Pharmaceut Sci, Dept Rat Med Sci, Bunkyo Ku, Tokyo 1130033, Japan	University of Tokyo; University of Tokyo; University of Tokyo	Iwatsubo, T (corresponding author), Univ Tokyo, Grad Sch Pharmaceut Sci, Dept Neuropathol & Neurosci, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1130033, Japan.	iwatsubo@mol.f.u-tokyo.ac.jp	Tomita, Taisuke/L-5427-2015	Tomita, Taisuke/0000-0002-0075-5943; Kan, Toshiyuki/0000-0002-9709-6365; Rikimaru, Kentaro/0000-0001-5106-5523				Akiyama H, 2000, NEUROBIOL AGING, V21, P383, DOI 10.1016/S0197-4580(00)00124-X; Doerfler P, 2001, P NATL ACAD SCI USA, V98, P9312, DOI 10.1073/pnas.161102498; Dovey HF, 2001, J NEUROCHEM, V76, P173, DOI 10.1046/j.1471-4159.2001.00012.x; Durkin JT, 1999, J BIOL CHEM, V274, P20499, DOI 10.1074/jbc.274.29.20499; Esler WP, 2002, NAT CELL BIOL, V4, pE110, DOI 10.1038/ncb0502-e110b; Esler WP, 2002, P NATL ACAD SCI USA, V99, P2720, DOI 10.1073/pnas.052436599; Esler WP, 2000, NAT CELL BIOL, V2, P428, DOI 10.1038/35017062; Fortini ME, 2002, NAT REV MOL CELL BIO, V3, P673, DOI 10.1038/nrm910; Haass C, 2002, TRENDS CELL BIOL, V12, P556, DOI 10.1016/S0962-8924(02)02394-2; Hadland BK, 2001, P NATL ACAD SCI USA, V98, P7487, DOI 10.1073/pnas.131202798; Herreman A, 2000, NAT CELL BIOL, V2, P461, DOI 10.1038/35017105; in 't Veld BA, 2001, NEW ENGL J MED, V345, P1515, DOI 10.1056/NEJMoa010178; Iwata H, 2001, J BIOL CHEM, V276, P21678, DOI 10.1074/jbc.M007989200; Jantzen PT, 2002, J NEUROSCI, V22, P2246, DOI 10.1523/JNEUROSCI.22-06-02246.2002; Kimberly WT, 2003, BIOCHEMISTRY-US, V42, P137, DOI 10.1021/bi026888g; Kisselev AF, 1999, MOL CELL, V4, P395, DOI 10.1016/S1097-2765(00)80341-X; Levitan D, 2001, P NATL ACAD SCI USA, V98, P12186, DOI 10.1073/pnas.211321898; Li YM, 2000, P NATL ACAD SCI USA, V97, P6138, DOI 10.1073/pnas.110126897; Li YM, 2000, NATURE, V405, P689, DOI 10.1038/35015085; Lichtenthaler SF, 1999, P NATL ACAD SCI USA, V96, P3053, DOI 10.1073/pnas.96.6.3053; Lim GP, 2000, J NEUROSCI, V20, P5709, DOI 10.1523/JNEUROSCI.20-15-05709.2000; Lim GP, 2001, J NEUROSCI, V21, P8370, DOI 10.1523/JNEUROSCI.21-21-08370.2001; Micchelli CA, 2002, FASEB J, V16, P79, DOI 10.1096/fj.02-0394fje; Morihara T, 2002, J NEUROCHEM, V83, P1009, DOI 10.1046/j.1471-4159.2002.01195.x; Morohashi Y, 2002, J BIOL CHEM, V277, P14965, DOI 10.1074/jbc.M200897200; Myung J, 2001, MOL CELL, V7, P411, DOI 10.1016/S1097-2765(01)00188-5; Petit A, 2001, NAT CELL BIOL, V3, P507, DOI 10.1038/35074581; Schmidtke G, 2000, J BIOL CHEM, V275, P22056, DOI 10.1074/jbc.M002513200; Seiffert D, 2000, J BIOL CHEM, V275, P34086, DOI 10.1074/jbc.M005430200; Selkoe DJ, 2001, PHYSIOL REV, V81, P741, DOI 10.1152/physrev.2001.81.2.741; Shearman MS, 2000, BIOCHEMISTRY-US, V39, P8698, DOI 10.1021/bi0005456; Takasugi N, 2002, J BIOL CHEM, V277, P50198, DOI 10.1074/jbc.M205352200; Takasugi N, 2003, NATURE, V422, P438, DOI 10.1038/nature01506; Tegeder I, 2001, FASEB J, V15, P2057, DOI 10.1096/fj.01-0390rev; Tian GC, 2002, J BIOL CHEM, V277, P31499, DOI 10.1074/jbc.M112328200; Tomita T, 1999, J NEUROSCI, V19, P10627, DOI 10.1523/JNEUROSCI.19-24-10627.1999; Tomita T, 1998, J BIOL CHEM, V273, P21153, DOI 10.1074/jbc.273.33.21153; Tomita T, 2002, FEBS LETT, V520, P117, DOI 10.1016/S0014-5793(02)02802-8; Tomita T, 2001, J BIOL CHEM, V276, P33273, DOI 10.1074/jbc.M011152200; Tomita T, 1997, P NATL ACAD SCI USA, V94, P2025, DOI 10.1073/pnas.94.5.2025; Weggen S, 2001, NATURE, V414, P212, DOI 10.1038/35102591; Wiltfang J, 1997, ELECTROPHORESIS, V18, P527, DOI 10.1002/elps.1150180332; Wolfe MS, 1998, J MED CHEM, V41, P6, DOI 10.1021/jm970621b; Wolfe MS, 1999, NATURE, V398, P513, DOI 10.1038/19077; Zandi PP, 2001, NEUROBIOL AGING, V22, P811, DOI 10.1016/S0197-4580(01)00297-4; Zhang LL, 2001, BIOCHEMISTRY-US, V40, P5049, DOI 10.1021/bi0028800	46	173	197	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 16	2003	278	20					18664	18670		10.1074/jbc.M301619200	http://dx.doi.org/10.1074/jbc.M301619200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677YX	12637581	hybrid			2022-12-25	WOS:000182838300139
J	Houde, C; Roy, S; Leung, N; Nicholson, DW; Beauchemin, N				Houde, C; Roy, S; Leung, N; Nicholson, DW; Beauchemin, N			The cell adhesion molecule CEACAM1-L is a substrate of caspase-3-mediated cleavage in apoptotic mouse intestinal cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-CONVERTING-ENZYME; BILIARY GLYCOPROTEIN; POLY(ADP-RIBOSE) POLYMERASE; CYTOPLASMIC DOMAIN; CYTOCHROME-C; CASPASES; ACTIN; PROTEASE; MEMBERS; KINASE	The CEACAM1 cell adhesion molecule is a member of the carcinoembryonic antigen family. In the mouse, four distinct isoforms are generated by alternative splicing. These encode either two or four immunoglobulin domains linked through a transmembrane domain to a cytoplasmic domain that encompasses either a short 10-amino acid tail or a longer one of 73 amino acids. Inclusion of exon 7, well conserved in evolution, generates the long cytoplasmic domain. A potential caspase recognition site in mouse, rat, and human CEACAM1-L also becomes available within the peptide encoded by exon 7. We used CEACAM1-L-transfected mouse colon carcinoma CT51 cells treated with three different apoptotic agents to study its fate during cell death. We found that CEACAM1-L is cleaved resulting in rapid degradation of most of its 8-kDa cytoplasmic domain. Caspase-mediated cleavage was demonstrated using purified recombinant caspases. The long cytoplasmic domain was cleaved specifically by caspase-3 in vitro but not by caspase-7 or -8. Moreover cleavage of CEACAM1-L in apoptotic cells was blocked by addition of a selective caspase-3 inhibitor to the cultures. Using point and deletion mutants, the conserved DQRD motif in the membrane-proximal cytoplasmic domain was identified as a caspase cleavage site. We also show that once CEACAM1-L is caspase-cleaved it becomes a stronger adhesion molecule than both the shorter and the longer expressing isoforms.	McGill Univ, McGill Canc Ctr, Montreal, PQ H3G 1Y6, Canada; McGill Univ, Dept Biochem, Montreal, PQ H3G 1Y6, Canada; McGill Univ, Dept Med, Montreal, PQ H3G 1Y6, Canada; McGill Univ, Dept Oncol, Montreal, PQ H3G 1Y6, Canada; Merck Frosst Ctr Therapeut Res, Pointe Claire, PQ H9R 4P8, Canada	McGill University; McGill University; McGill University; McGill University; Merck & Company	Beauchemin, N (corresponding author), McGill Univ, McGill Canc Ctr, 3655 Promenade Sir William Osler, Montreal, PQ H3G 1Y6, Canada.	nicole.beauchemin@mcgill.ca						Beauchemin N, 1998, CELL ADHES COMMUN S, V5, P155; Beauchemin N, 1999, EXP CELL RES, V252, P243; Beauchemin N, 1997, ONCOGENE, V14, P783, DOI 10.1038/sj.onc.1200888; BRANCOLINI C, 1995, EMBO J, V14, P5179, DOI 10.1002/j.1460-2075.1995.tb00202.x; Brancolini C, 1997, J CELL BIOL, V139, P759, DOI 10.1083/jcb.139.3.759; Brummer J, 2001, AM J PATHOL, V159, P537, DOI 10.1016/S0002-9440(10)61725-7; CHEUNG PH, 1993, J BIOL CHEM, V268, P24303; Cryns VL, 1996, J BIOL CHEM, V271, P31277, DOI 10.1074/jbc.271.49.31277; Earnshaw WC, 1999, ANNU REV BIOCHEM, V68, P383, DOI 10.1146/annurev.biochem.68.1.383; Ebrahimnejad A, 2000, EXP CELL RES, V260, P365, DOI 10.1006/excr.2000.5026; Edlund M, 1996, J BIOL CHEM, V271, P1393, DOI 10.1074/jbc.271.3.1393; FRANGSMYR L, 1995, CANCER RES, V55, P2963; Gervais FG, 1998, J BIOL CHEM, V273, P17102, DOI 10.1074/jbc.273.27.17102; Han BH, 2002, J BIOL CHEM, V277, P30128, DOI 10.1074/jbc.M202931200; Herren B, 1998, MOL BIOL CELL, V9, P1589, DOI 10.1091/mbc.9.6.1589; Huber M, 1999, J BIOL CHEM, V274, P335, DOI 10.1074/jbc.274.1.335; Ilan N, 2001, FASEB J, V15, P362, DOI 10.1096/fj.00-0372com; Izzi L, 1999, ONCOGENE, V18, P5563, DOI 10.1038/sj.onc.1202935; Kayalar C, 1996, P NATL ACAD SCI USA, V93, P2234, DOI 10.1073/pnas.93.5.2234; Kirshner J, 2003, P NATL ACAD SCI USA, V100, P521, DOI 10.1073/pnas.232711199; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; Kothakota S, 1997, SCIENCE, V278, P294, DOI 10.1126/science.278.5336.294; Kunath T, 1995, ONCOGENE, V11, P2375; LAZEBNIK YA, 1994, NATURE, V371, P346, DOI 10.1038/371346a0; Mashima T, 1997, ONCOGENE, V14, P1007, DOI 10.1038/sj.onc.1200919; MCCUAIG K, 1992, CELL GROWTH DIFFER, V3, P165; Moffatt OD, 1999, J IMMUNOL, V162, P6800; NAJJAR SM, 1995, BIOCHEMISTRY-US, V34, P9341, DOI 10.1021/bi00029a009; Nath R, 1996, BIOCHEM J, V319, P683, DOI 10.1042/bj3190683; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; Obrink B, 1997, CURR OPIN CELL BIOL, V9, P616, DOI 10.1016/S0955-0674(97)80114-7; OCKLIND C, 1982, J BIOL CHEM, V257, P6788; ROSENBERG M, 1993, CANCER RES, V53, P4938; Rotonda J, 1996, NAT STRUCT BIOL, V3, P619, DOI 10.1038/nsb0796-619; Sadekova S, 2000, MOL BIOL CELL, V11, P65, DOI 10.1091/mbc.11.1.65; Schumann D, 2001, J BIOL CHEM, V276, P47421, DOI 10.1074/jbc.M109110200; SKUBITZ KM, 1995, J IMMUNOL, V155, P5382; Stupack DG, 2001, J CELL BIOL, V155, P459, DOI 10.1083/jcb.200106070; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; Thornberry NA, 1997, J BIOL CHEM, V272, P17907, DOI 10.1074/jbc.272.29.17907; VALLEJO AN, 1994, PCR METH APPL, V4, pS123; Vaux DL, 1999, CELL, V96, P245, DOI 10.1016/S0092-8674(00)80564-4; Wen LP, 1997, J BIOL CHEM, V272, P26056, DOI 10.1074/jbc.272.41.26056; Wyllie A H, 1980, Int Rev Cytol, V68, P251; WYLLIE AH, 1980, NATURE, V284, P555, DOI 10.1038/284555a0; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129	46	21	21	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 9	2003	278	19					16929	16935		10.1074/jbc.M301842200	http://dx.doi.org/10.1074/jbc.M301842200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677QG	12637508	hybrid			2022-12-25	WOS:000182818600066
J	Jia, L; Patwari, Y; Kelsey, SM; Srinivasula, SM; Agrawal, SG; Alnemri, ES; Newland, AC				Jia, L; Patwari, Y; Kelsey, SM; Srinivasula, SM; Agrawal, SG; Alnemri, ES; Newland, AC			Role of Smac in human leukaemic cell apoptosis and proliferation	ONCOGENE			English	Article						apoptosis; apaf-1; caspases; IAPs; smac	TRAIL-INDUCED APOPTOSIS; DRUG-INDUCED APOPTOSIS; CYTOCHROME-C; PROMOTES APOPTOSIS; SMAC/DIABLO; PROTEIN; MITOCHONDRIA; DEATH; OVEREXPRESSION; IDENTIFICATION	Smac (or DIABLO) is a recently identified, novel proapoptotic molecule, which is released from mitochondria into the cytosol during apoptosis. Smac functions by eliminating the caspase-inhibitory properties of the inhibitors of apoptosis proteins (IAP), particularly XIAP. In this study, we stably transfected both full-length (FL) and mature (NIT) Smac genes into the K562 and CEM leukaemic cell lines. Both FL and NIT Smac transfectants increased the sensitivity of leukaemic cells to UV light-induced apoptosis and the activation of caspase-9 and caspase-3. Purified cytosol from the mature Smac transfectants, or the addition of human recombinant Smac protein or N-7 peptide into nontransfected cytosol, showed an increased sensitivity to cytochrome c-induced activation of caspase-3. The mature Smac enhanced the susceptibility of both K562 and CEM cells to TRAIL-induced apoptosis. Overexpression of the mature Smac protein also inhibited proliferation, as detected by reduced colony formation and Ki-67 expression in leukaemic cells. Cell cycle analysis revealed that Smac transfectants displayed significant G0/G1 arrest and reduction in 5-bromo-2'-deoxyuridine (BrdU) incorporation. Smac sensitized human acute myeloid leukaemia blasts to cytochrome c-induced activation of caspase-3. However, Smac failed to overcome Apaf-l-deficiency-mediated resistance to cytochrome c in primary leukaemic blasts. In summary, this study reveals that Smac/DIABLO exhibits a potential role in increasing apoptosis and suppressing proliferation in human leukaemic cells. Importantly, it also indicates that it is crucial to evaluate the levels of Apaf-1 and XIAP proteins in patient samples before using Smac peptide therapy in the treatment of human leukaemia.	St Bartholomews & Royal London Sch Med & Dent, Dept Hematol Oncol, London E1 2AD, England; Thomas Jefferson Univ, Kimmel Canc Inst, Dept Microbiol & Immunol, Philadelphia, PA 19107 USA	University of London; Queen Mary University London; Jefferson University	Jia, L (corresponding author), St Bartholomews & Royal London Sch Med & Dent, Dept Hematol Oncol, Turner St, London E1 2AD, England.	L.jia@qmul.ac.uk	Alnemri, Emad S/B-4526-2010	Jia, Li/0000-0002-6076-8455				Altieri DC, 2001, TRENDS MOL MED, V7, P542, DOI 10.1016/S1471-4914(01)02243-2; Carson JP, 2002, CANCER RES, V62, P18; Chai JJ, 2000, NATURE, V406, P855, DOI 10.1038/35022514; Deng YB, 2002, GENE DEV, V16, P33, DOI 10.1101/gad.949602; Deveraux QL, 1998, EMBO J, V17, P2215, DOI 10.1093/emboj/17.8.2215; Du CY, 2000, CELL, V102, P33, DOI 10.1016/S0092-8674(00)00008-8; Ekert PG, 2001, J CELL BIOL, V152, P483, DOI 10.1083/jcb.152.3.483; Fulda S, 2002, NAT MED, V8, P808, DOI 10.1038/nm735; Fulda S, 2001, ONCOGENE, V20, P5865, DOI 10.1038/sj.onc.1204750; Gerlach C, 1998, LAB INVEST, V78, P129; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Guo F, 2002, BLOOD, V99, P3419, DOI 10.1182/blood.V99.9.3419; Hegde R, 2002, J BIOL CHEM, V277, P432, DOI 10.1074/jbc.M109721200; Jia L, 2001, ONCOGENE, V20, P4817, DOI 10.1038/sj.onc.1204628; Jia L, 2001, BIOCHEM BIOPH RES CO, V283, P1037, DOI 10.1006/bbrc.2001.4895; Jia L, 2001, BLOOD, V98, P414, DOI 10.1182/blood.V98.2.414; Jia L, 1999, BLOOD, V93, P2353, DOI 10.1182/blood.V93.7.2353.407k20_2353_2359; Kabra NH, 2001, P NATL ACAD SCI USA, V98, P6307, DOI 10.1073/pnas.111158698; Li LY, 2001, NATURE, V412, P95, DOI 10.1038/35083620; Liu FT, 2002, BRIT J HAEMATOL, V117, P333, DOI 10.1046/j.1365-2141.2002.03418.x; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; Liu ZH, 2000, NATURE, V408, P1004, DOI 10.1038/35050006; Partheniou F, 2001, BIOCHEM BIOPH RES CO, V287, P181, DOI 10.1006/bbrc.2001.5582; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; Srinivasula SM, 2000, J BIOL CHEM, V275, P36152, DOI 10.1074/jbc.C000533200; Srinivasula SM, 2001, NATURE, V410, P112, DOI 10.1038/35065125; Suliman A, 2001, ONCOGENE, V20, P2122, DOI 10.1038/sj.onc.1204282; Susin SA, 1999, NATURE, V397, P441, DOI 10.1038/17135; Tamm I, 2000, CLIN CANCER RES, V6, P1796; Terry NHA, 2001, METHOD CELL BIOL, V63, P355; Verhagen AM, 2000, CELL, V102, P43, DOI 10.1016/S0092-8674(00)00009-X; Zang DY, 2001, BLOOD, V98, P3058, DOI 10.1182/blood.V98.10.3058; Zhang XD, 2001, CANCER RES, V61, P7339	33	48	63	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 20	2003	22	11					1589	1599		10.1038/sj.onc.1206322	http://dx.doi.org/10.1038/sj.onc.1206322			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	655YH	12642862				2022-12-25	WOS:000181580500001
J	Rabbitt, E; Ayuk, J; Boelaert, K; Sheppard, MC; Hewison, M; Stewart, PM; Gittoes, NJL				Rabbitt, E; Ayuk, J; Boelaert, K; Sheppard, MC; Hewison, M; Stewart, PM; Gittoes, NJL			Abnormal expression of 11 beta-hydroxysteroid dehydrogenase type 2 in human pituitary adenomas: a prereceptor determinant of pituitary cell proliferation	ONCOGENE			English	Article						pituitary adenoma; 11 beta-hydroxysteroid dehydrogenase; proliferation	APPARENT MINERALOCORTICOID EXCESS; CYCLE INHIBITOR P27(KIP1); RECEPTOR EXPRESSION; MICE LACKING; TUMORS; ARREST; GROWTH; TUMORIGENESIS; HYPERPLASIA; PROGRESSION	The physiological effects of glucocorticoids (GCs) are, at least in part, mediated by inhibition of cell proliferation. Two isozymes of 11beta-hydroxysteroid dehydrogenase (11beta-HSD) interconvert cortisol (F) and inactive cortisone (E), and are thus able to modulate GC action at an autocrine level. Previously, we have demonstrated absent expression of 11beta-HSD2 in normal pituitaries; however, in a small number of pituitary tumors analysed, 11beta-HSD2 was readily demonstrable. Here we have used real-time RT-PCR to quantify expression of mRNA for 11beta-HSD1 and 2 in 105 human pituitary tumors and have performed enzyme expression and activity studies in primary pituitary cultures. Overall, pituitary tumors expressed lower levels of 11beta-HSD1 mRNA compared with normals (0.2-fold, P<0.05). In contrast, expression of 11beta-HSD2 mRNA was 9.8-fold greater in tumors than in normals (P < 0.001). Enzyme assays showed significant 11beta-HSD2 activity (71.9+/-22.3pmol/h/mg protein (mean+/-s.d.)) but no detectable 11beta-HSD1 activity. Proliferation assays showed that addition of glycyrrhetinic acid (an 11beta-HSD2 inhibitor) resulted in a 30.3+/-7.7% inhibition of cell proliferation. In summary, we describe a switch in expression from 11beta-HSD1 to 11beta-HSD2 in neoplastic pituitary tissue. We propose that abnormal expression of 11beta-HSD2 acts as a proproliferative prereceptor determinant of pituitary cell growth, and may provide a novel target for future tumor therapy.	Univ Birmingham, Queen Elizabeth Hosp, Div Med Sci, Birmingham B15 2TH, W Midlands, England	University of Birmingham	Stewart, PM (corresponding author), Univ Birmingham, Queen Elizabeth Hosp, Div Med Sci, Birmingham B15 2TH, W Midlands, England.							Bamberger CM, 1999, EUR J ENDOCRINOL, V140, P250, DOI 10.1530/eje.0.1400250; Bland R, 1999, J ENDOCRINOL, V161, P455, DOI 10.1677/joe.0.1610455; Cooper MS, 2000, BONE, V27, P375, DOI 10.1016/S8756-3282(00)00344-6; Croxtall JD, 2000, BRIT J PHARMACOL, V130, P289, DOI 10.1038/sj.bjp.0703272; Fero ML, 1996, CELL, V85, P733, DOI 10.1016/S0092-8674(00)81239-8; Franklin DS, 1998, GENE DEV, V12, P2899, DOI 10.1101/gad.12.18.2899; Gingras MC, 2000, EXP HEMATOL, V28, P350, DOI 10.1016/S0301-472X(00)00149-1; Gittoes NJL, 1997, J CLIN ENDOCR METAB, V82, P1960, DOI 10.1210/jc.82.6.1960; Hundertmark S, 1997, J ENDOCRINOL, V155, P171, DOI 10.1677/joe.0.1550171; KATO JY, 1994, CELL, V79, P487, DOI 10.1016/0092-8674(94)90257-7; Kiyokawa H, 1996, CELL, V85, P721, DOI 10.1016/S0092-8674(00)81238-6; Korbonits M, 2001, J CLIN ENDOCR METAB, V86, P2728, DOI 10.1210/jc.86.6.2728; Koyama K, 2001, J STEROID BIOCHEM, V76, P153, DOI 10.1016/S0960-0760(00)00157-6; Labrie F, 2000, TRENDS ENDOCRIN MET, V11, P421, DOI 10.1016/S1043-2760(00)00342-8; Lidhar K, 1999, J CLIN ENDOCR METAB, V84, P3823, DOI 10.1210/jc.84.10.3823; McKay LI, 1999, ENDOCR REV, V20, P435, DOI 10.1210/er.20.4.435; McTernan CL, 2001, J CLIN ENDOCR METAB, V86, P4979, DOI 10.1210/jc.86.10.4979; MOTOO Y, 1994, CANCER LETT, V86, P91, DOI 10.1016/0304-3835(94)90184-8; Nakayama K, 1996, CELL, V85, P707, DOI 10.1016/S0092-8674(00)81237-4; Nawrocki AR, 2002, J BIOL CHEM, V277, P14647, DOI 10.1074/jbc.M111549200; Rabbitt EH, 2002, FASEB J, V16, P36, DOI 10.1096/fj.01-0582com; Robson AC, 1998, MOL BRAIN RES, V61, P1, DOI 10.1016/S0169-328X(98)00161-2; Rogatsky I, 1997, MOL CELL BIOL, V17, P3181, DOI 10.1128/MCB.17.6.3181; Samuelsson MKR, 1999, MOL ENDOCRINOL, V13, P1811, DOI 10.1210/me.13.11.1811; SANCHEZ I, 1993, CELL GROWTH DIFFER, V4, P215; Shiota G, 1999, CARCINOGENESIS, V20, P59, DOI 10.1093/carcin/20.1.59; Stewart PM, 1999, VITAM HORM, V57, P249; Stewart PM, 1996, LANCET, V347, P88, DOI 10.1016/S0140-6736(96)90211-1; STEWART PM, 1987, LANCET, V2, P821; Stewart PM, 2002, TRENDS ENDOCRIN MET, V13, P94, DOI 10.1016/S1043-2760(02)00566-0; White PC, 1997, ENDOCR REV, V18, P135, DOI 10.1210/er.18.1.135; WHORWOOD CB, 1993, ENDOCRINOLOGY, V132, P2287, DOI 10.1210/en.132.6.2287	32	45	47	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 20	2003	22	11					1663	1667		10.1038/sj.onc.1206293	http://dx.doi.org/10.1038/sj.onc.1206293			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	655YH	12642869				2022-12-25	WOS:000181580500008
J	Yamashita, H; Iwase, H; Toyama, T; Fujii, Y				Yamashita, H; Iwase, H; Toyama, T; Fujii, Y			Naturally occurring dominant-negative Stat5 suppresses transcriptional activity of estrogen receptors and induces apoptosis in T47D breast cancer cells	ONCOGENE			English	Article						Stat5; estrogen receptor; signal transduction; recombinant adenovirus; breast cancer	MAMMARY-GLAND DEVELOPMENT; SIGNAL TRANSDUCER; SERINE PHOSPHORYLATION; CROSS-TALK; PHOSPHATIDYLINOSITOL 3-KINASE; GLUCOCORTICOID RECEPTOR; EPITHELIAL-CELLS; GENE-EXPRESSION; DNA-BINDING; ER-ALPHA	Signal transducer and activator of transcription (Stat) 5 regulates growth, differentiation, and survival of mammary and hematopoietic cells. The role of Stat5 in breast cancer has not been established, although Stat5 is critical for some hematopoietic malignancies. We detected for the first time that Stat5b is constitutively activated in human breast cancer cell lines, and analysed the role of Stat5 in estrogen receptor(ER)-positive breast cancer cell lines using dominant-negative variants of Stat5. Two distinct carboxyl-truncated Stat5a derivatives were generated. Stat5aDelta740 corresponded to a naturally occurring alternative splice variant, and Stat5aDelta713 was analogous to an 80 kDa Stat5a product of a nuclear protease. Stat5aDelta740 and Stat5aDelta713 displayed comparable dominant-negative properties and suppressed transcriptional activity of wildtype Stat5a and Stat5b equally well. Cotransfection experiments revealed that Stat5aDelta740 completely blocked transcriptional activity of endogenous estrogen receptor in T47D and MCF7 cells, and of both ERalpha and ERbeta in COS-7 cells. Stat5aDelta740 was selected for adenoviral delivery, and high-efficiency expression of tyrosine phosphorylated Stat5aDelta740 was achieved in infected cells. Adenoviral-mediated Stat5aDelta740 induced apoptosis in T47D cells but not in caspase-3-negative MCF7 cells. The present study indicates that overexpression of a dominant-negative variant of Stat5 suppresses ER transcriptional activity and induces apoptosis in estrogen-responsive breast cancer tissue culture cells.	Nagoya City Univ, Sch Med Sci, Dept Surg 2, Mizuho Ku, Nagoya, Aichi 4678601, Japan	Nagoya City University	Yamashita, H (corresponding author), Nagoya City Univ, Sch Med Sci, Dept Surg 2, Mizuho Ku, Kawasumi 1, Nagoya, Aichi 4678601, Japan.		Yamashita, Hiroko/D-5102-2012	Yamashita, Hiroko/0000-0003-4281-8727; Toyama, Tatsuya/0000-0003-4713-7795				Beuvink I, 2000, J BIOL CHEM, V275, P10247, DOI 10.1074/jbc.275.14.10247; Bittorf T, 2000, CELL SIGNAL, V12, P23, DOI 10.1016/S0898-6568(99)00063-7; Bjornstrom L, 2001, J MOL ENDOCRINOL, V27, P93, DOI 10.1677/jme.0.0270093; Bromberg J, 2000, ONCOGENE, V19, P2468, DOI 10.1038/sj.onc.1203476; Buettner R, 2002, CLIN CANCER RES, V8, P945; Cowley SM, 1999, J STEROID BIOCHEM, V69, P165, DOI 10.1016/S0960-0760(99)00055-2; DaSilva L, 1996, MOL CELL ENDOCRINOL, V117, P131, DOI 10.1016/0303-7207(95)03738-1; Dong F, 1998, J IMMUNOL, V161, P6503; Doppler W, 2001, MOL CELL BIOL, V21, P3266, DOI 10.1128/MCB.21.9.3266-3279.2001; Faulds MH, 2001, MOL ENDOCRINOL, V15, P1929, DOI 10.1210/me.15.11.1929; Favre-Young H, 2000, MOL ENDOCRINOL, V14, P1411, DOI 10.1210/me.14.9.1411; Frank DA, 1997, J CLIN INVEST, V100, P3140, DOI 10.1172/JCI119869; Frasor J, 2001, MOL ENDOCRINOL, V15, P2172, DOI 10.1210/me.15.12.2172; Grimley PM, 1999, CYTOKINE GROWTH F R, V10, P131, DOI 10.1016/S1359-6101(99)00011-8; Hennighausen L, 1997, J BIOL CHEM, V272, P7567, DOI 10.1074/jbc.272.12.7567; Ihle JN, 1996, CELL, V84, P331, DOI 10.1016/S0092-8674(00)81277-5; Janicke RU, 1998, J BIOL CHEM, V273, P15540, DOI 10.1074/jbc.273.25.15540; JONES N, 1979, CELL, V17, P683, DOI 10.1016/0092-8674(79)90275-7; KAZANSKY AV, 1995, MOL ENDOCRINOL, V9, P1598, DOI 10.1210/me.9.11.1598; Kirken RA, 1997, J BIOL CHEM, V272, P15459, DOI 10.1074/jbc.272.24.15459; Kirken RA, 1997, J BIOL CHEM, V272, P14098, DOI 10.1074/jbc.272.22.14098; Lacronique V, 1997, SCIENCE, V278, P1309, DOI 10.1126/science.278.5341.1309; LIU XW, 1995, P NATL ACAD SCI USA, V92, P8831, DOI 10.1073/pnas.92.19.8831; Matsumura I, 1997, MOL CELL BIOL, V17, P2933, DOI 10.1128/MCB.17.5.2933; Matsumura I, 1999, EMBO J, V18, P1367, DOI 10.1093/emboj/18.5.1367; Meyer J, 1998, BLOOD, V91, P1901, DOI 10.1182/blood.V91.6.1901.1901_1901_1908; Moriggl R, 1996, MOL CELL BIOL, V16, P5691; Mui ALF, 1996, EMBO J, V15, P2425, DOI 10.1002/j.1460-2075.1996.tb00600.x; Nieborowska-Skorska M, 1999, J EXP MED, V189, P1229, DOI 10.1084/jem.189.8.1229; Park SH, 2001, MOL ENDOCRINOL, V15, P2157, DOI 10.1210/me.15.12.2157; Petersen H, 1998, EXP CELL RES, V243, P347, DOI 10.1006/excr.1998.4160; Saji S, 2000, P NATL ACAD SCI USA, V97, P337, DOI 10.1073/pnas.97.1.337; Santos SCR, 2000, ONCOGENE, V19, P1164, DOI 10.1038/sj.onc.1203418; Schaber JD, 1998, CANCER RES, V58, P1914; Socolovsky M, 1999, CELL, V98, P181, DOI 10.1016/S0092-8674(00)81013-2; Sonoyama J, 2002, J BIOL CHEM, V277, P8076, DOI 10.1074/jbc.M111501200; Stocklin E, 1996, NATURE, V383, P726, DOI 10.1038/383726a0; Stoecklin E, 1999, J STEROID BIOCHEM, V69, P195, DOI 10.1016/S0960-0760(99)00052-7; WAKAO H, 1994, EMBO J, V13, P2182, DOI 10.1002/j.1460-2075.1994.tb06495.x; Wang DM, 1996, MOL CELL BIOL, V16, P6141; WATSON CJ, 1995, BRIT J CANCER, V71, P840, DOI 10.1038/bjc.1995.162; Watson CJ, 2001, J MAMMARY GLAND BIOL, V6, P115, DOI 10.1023/A:1009524817155; WEN ZL, 1995, CELL, V82, P241, DOI 10.1016/0092-8674(95)90311-9; Yamashita H, 1998, J BIOL CHEM, V273, P30218, DOI 10.1074/jbc.273.46.30218; Yamashita H, 2001, MOL CELL ENDOCRINOL, V183, P151, DOI 10.1016/S0303-7207(01)00546-9	45	62	67	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 20	2003	22	11					1638	1652		10.1038/sj.onc.1206277	http://dx.doi.org/10.1038/sj.onc.1206277			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	655YH	12642867				2022-12-25	WOS:000181580500006
J	Wells, J; Yan, PS; Cechvala, M; Huang, T; Farnham, PJ				Wells, J; Yan, PS; Cechvala, M; Huang, T; Farnham, PJ			Identification of novel pRb binding sites using CpG microarrays suggests that E2F recruits pRb to specific genomic sites during S phase	ONCOGENE			English	Article						pRb; E2F1; CpG island; chromatin immunoprecipitation	TARGET GENE SPECIFICITY; DNA-REPLICATION; RETINOBLASTOMA PROTEIN; CELL-CYCLE; CHROMATIN IMMUNOPRECIPITATION; EXPRESSION; COMPLEX; CLONING; FAMILY; REPAIR	The retinoblastoma (Rb) tumor suppressor protein is an important regulator of cell proliferation and differentiation. Many studies have shown that pRb can negatively regulate the activity of the E2F family of transcription factors during Go and G, phases of the cell cycle, perhaps by serving as a bridge between the E2Fs and transcriptional repressors such as histone deacetylases and methylases. However, pRb has also been shown to localize to discrete DNA foci during S phase, a time at which pRb is thought to be dissociated from E2F. Numerous other DNA binding proteins have been shown to interact with pRb, suggesting that pRb may control progression through S phase by binding to sites in the genome distinct from E2F target gene promoters. To test this hypothesis, we have identified novel pRb binding sites within the human genome using an unbiased approach which relies upon a combination of chromatin immunoprecipitation and CpG microarray analysis. To provide the greatest opportunity of finding distinct sets of pRb binding sites, we examined pRb binding in chromatin obtained from human Raji cells synchronized in either G(0)/G(1) phase or S phase. These experiments have allowed us to identify a large set of new genomic binding sites for the pRb protein. We found that some sites are occupied by pRb only during G(0)/G(1) phase, as would be predicted from previous models of pRb function. We also identified sites to which pRb bound only during S phase and other sites which were bound constitutively by pRb. Surprisingly, we found that E2F1 was present at most of the CpG islands bound by pRb, independent of the phase of the cell cycle. Thus, although pRb has the potential to interact with numerous transcription factors, our data suggest that the majority of DNA-bound pRb is recruited to E2F target promoters during both G(0)/G(1) and S phases.	Univ Wisconsin, Sch Med, McArdle Lab Canc Res, Madison, WI 53706 USA; Univ Missouri, Ellis Fischel Canc Ctr, Dept Pathol & Anat Sci, Columbia, MO 65203 USA	University of Wisconsin System; University of Wisconsin Madison; University of Missouri System; University of Missouri Columbia	Farnham, PJ (corresponding author), Univ Wisconsin, Sch Med, McArdle Lab Canc Res, 1400 Univ Ave, Madison, WI 53706 USA.	farnham@oncology.wisc.edu	Yan, Pearlly S/E-4339-2011	Yan, Pearlly S/0000-0003-1965-4920; Farnham, Peggy/0000-0003-4469-7914	NATIONAL CANCER INSTITUTE [P01CA022484, P30CA014520, R33CA084701, R29CA045240, R01CA045240] Funding Source: NIH RePORTER; NCI NIH HHS [CA14520-29, CA22484, R33CA84701, CA45240, CA1452] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Albert T, 2001, J BIOL CHEM, V276, P20482, DOI 10.1074/jbc.M100265200; Antequera F, 1999, CURR BIOL, V9, pR661, DOI 10.1016/S0960-9822(99)80418-7; Bosco G, 2001, NAT CELL BIOL, V3, P289, DOI 10.1038/35060086; Boyd KE, 1998, P NATL ACAD SCI USA, V95, P13887, DOI 10.1073/pnas.95.23.13887; Carney JP, 1998, CELL, V93, P477, DOI 10.1016/S0092-8674(00)81175-7; CROSS SH, 1995, CURR OPIN GENET DEV, V5, P309, DOI 10.1016/0959-437X(95)80044-1; FARNHAM PJ, 1993, BIOCHIM BIOPHYS ACTA, V1155, P125, DOI 10.1016/0304-419X(93)90001-S; GOODRICH DW, 1991, CELL, V67, P293, DOI 10.1016/0092-8674(91)90181-W; Harbour JW, 2000, GENE DEV, V14, P2393, DOI 10.1101/gad.813200; HELIN K, 1992, CELL, V70, P337, DOI 10.1016/0092-8674(92)90107-N; IVEYHOYLE M, 1993, MOL CELL BIOL, V13, P7802, DOI 10.1128/MCB.13.12.7802; KAELIN WG, 1992, CELL, V70, P351, DOI 10.1016/0092-8674(92)90108-O; Kennedy BK, 2000, GENE DEV, V14, P2855, DOI 10.1101/gad.842600; LEES JA, 1993, MOL CELL BIOL, V13, P7813, DOI 10.1128/MCB.13.12.7813; Lipinski MM, 1999, ONCOGENE, V18, P7873, DOI 10.1038/sj.onc.1203244; Ma YH, 2002, ARCH BIOCHEM BIOPHYS, V399, P212, DOI 10.1006/abbi.2002.2761; Maser RS, 2001, MOL CELL BIOL, V21, P6006, DOI 10.1128/MCB.21.17.6006-6016.2001; Morris EJ, 2001, ADV CANCER RES, V82, P1, DOI 10.1016/S0065-230X(01)82001-7; Muller H, 2001, GENE DEV, V15, P267, DOI 10.1101/gad.864201; Polager S, 2002, ONCOGENE, V21, P437, DOI 10.1038/sj.onc.1205102; Ponzio G, 1998, ONCOGENE, V17, P1159, DOI 10.1038/sj.onc.1202040; Ren B, 2002, GENE DEV, V16, P245, DOI 10.1101/gad.949802; Royzman I, 1999, GENE DEV, V13, P827, DOI 10.1101/gad.13.7.827; SAWAI M, 1990, EXP CELL RES, V187, P4, DOI 10.1016/0014-4827(90)90108-M; SHAN B, 1992, MOL CELL BIOL, V12, P5620, DOI 10.1128/MCB.12.12.5620; Takahashi Y, 2000, GENE DEV, V14, P804; Thomas DM, 2001, MOL CELL, V8, P303, DOI 10.1016/S1097-2765(01)00327-6; Trimarchi JM, 2002, NAT REV MOL CELL BIO, V3, P11, DOI 10.1038/nrm714; Turner WJ, 2001, J VIROL, V75, P5638, DOI 10.1128/JVI.75.12.5638-5645.2001; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; Weinmann AS, 2002, GENE DEV, V16, P235, DOI 10.1101/gad.943102; Weinmann AS, 2001, MOL CELL BIOL, V21, P6820, DOI 10.1128/MCB.21.20.6820-6832.2001; WEINTRAUB SJ, 1995, NATURE, V375, P812, DOI 10.1038/375812a0; Wells J, 2000, MOL CELL BIOL, V20, P5797, DOI 10.1128/MCB.20.16.5797-5807.2000; Wells J, 2002, P NATL ACAD SCI USA, V99, P3890, DOI 10.1073/pnas.062047499; Wells J, 2002, METHODS, V26, P48, DOI 10.1016/S1046-2023(02)00007-5; Yan PS, 2001, CANCER RES, V61, P8375; Zhang HS, 2001, ONCOGENE, V20, P3134, DOI 10.1038/sj.onc.1204338; Zwicker J, 1996, SCIENCE, V271, P1595, DOI 10.1126/science.271.5255.1595	39	108	112	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 13	2003	22	10					1445	1460		10.1038/sj.onc.1206264	http://dx.doi.org/10.1038/sj.onc.1206264			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	652ZZ	12629508				2022-12-25	WOS:000181411900002
J	Greenblatt, MS; Beaudet, JG; Gump, JR; Godin, KS; Trombley, L; Koh, J; Bond, JP				Greenblatt, MS; Beaudet, JG; Gump, JR; Godin, KS; Trombley, L; Koh, J; Bond, JP			Detailed computational study of p53 and p16: using evolutionary sequence analysis and disease-associated mutations to predict the functional consequences of allelic variants	ONCOGENE			English	Article						missense mutation; database; cell cycle; structural biology; SNP	MISSENSE MUTATIONS; HUMAN CANCERS; GENE; SUBSTITUTION; CONSERVATION; SPECTRUM	Deciding whether a missense allelic variant affects protein function is important in many contexts. We previously demonstrated that a detailed analysis of p53 intragenic conservation correlates with somatic mutation hotspots. Here we refine these evolutionary studies and expand them to the p16/Ink4a gene. We calculated that in order for 'absolute conservation' of a codon across multiple species to achieve P < 0.05, the evolutionary substitution database must contain at least 3(M) variants, where M equals the number of codons in the gene. Codons in p53 were divided into high (73% of codons), intermediate (29% of codons), and low (0 codons) likelihood of being mutation hotspots. From a database of 263 somatic missense p16 mutations, we identified only four codons that are mutational hotspots at P < 0.05 ( > 8 mutations). However, data on function, structure, and disease association support the conclusion that 11 other codons with greater than or equal to5 somatic mutations also likely indicate functionally critical residues, even though P > 0.05. We calculated p16 evolution using amino acid substitution matrices and nucleotide substitution distances. We looked for evolutionary parameters at each codon that would predict whether missense mutations were disease associated or disrupted function. The current p16 evolutionary substitution database is too small to determine whether observations of 'absolute conservation' are statistically significant. Increasing the number of sequences from three to seven significantly improved the predictive value of evolutionary computations. The sensitivity and specificity for conservation scores in predicting disease association of P16 codons is 70-80%. Despite the small p16 sequence database, our calculations of high conservation correctly predicted loss of cell cycle arrest function in 75% of tested codons, and low conservation correctly predicted wild-type function in 80-90% of codons. These data validate our hypothesis that detailed evolutionary analyses help predict the consequences of missense amino-acid variants.	Univ Vermont, Vermont Canc Ctr, Dept Med, Burlington, VT 05401 USA; Univ Vermont, Vermont Canc Ctr, Dept Pathol, Burlington, VT 05401 USA; Univ Vermont, Vermont Canc Ctr, Dept Microbiol & Med Genet, Burlington, VT 05401 USA	University of Vermont; University of Vermont; University of Vermont	Greenblatt, MS (corresponding author), IV VT, Hematol Oncol Unit, UHC Campus,St Joseph 3210, Burlington, VT 05401 USA.	marc.greenblatt@vtmednet.org			NATIONAL CANCER INSTITUTE [P30CA022435] Funding Source: NIH RePORTER; NCI NIH HHS [P30CA22435] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BOTTEMA CDK, 1991, AM J HUM GENET, V49, P820; Ciotti P, 2000, AM J HUM GENET, V67, P311, DOI 10.1086/303001; FITCH WM, 1971, SYST ZOOL, V20, P406, DOI 10.2307/2412116; GREENBLATT MS, 1994, CANCER RES, V54, P4855; Greenblatt MS, 2001, CANCER RES, V61, P4092; Greenblatt MS, 1996, CANCER RES, V56, P2130; HENIKOFF S, 1993, PROTEINS, V17, P49, DOI 10.1002/prot.340170108; INA Y, 1995, J MOL EVOL, V40, P190, DOI 10.1007/BF00167113; Lander ES, 2001, NATURE, V409, P860, DOI 10.1038/35057062; Li W. H, 1997, MOL EVOLUTION; Makalowski W, 1998, P NATL ACAD SCI USA, V95, P9407, DOI 10.1073/pnas.95.16.9407; Miller MP, 2001, HUM MOL GENET, V10, P2319, DOI 10.1093/hmg/10.21.2319; Pollock PM, 1996, GENE CHROMOSOME CANC, V15, P77, DOI 10.1002/(SICI)1098-2264(199602)15:2<77::AID-GCC1>3.0.CO;2-0; Ruas M, 1999, ONCOGENE, V18, P5423, DOI 10.1038/sj.onc.1202918; Ruas M, 1998, BBA-REV CANCER, V1378, pF115, DOI 10.1016/S0304-419X(98)00017-1; Russo AA, 1998, NATURE, V395, P237, DOI 10.1038/26155; SAITOU N, 1987, MOL BIOL EVOL, V4, P406, DOI 10.1093/oxfordjournals.molbev.a040454; Sharpless NE, 1999, CURR OPIN GENET DEV, V9, P22, DOI 10.1016/S0959-437X(99)80004-5; SmithSorensen B, 1996, HUM MUTAT, V7, P294, DOI 10.1002/(SICI)1098-1004(1996)7:4<294::AID-HUMU2>3.0.CO;2-9; WACEY AI, 1994, HUM GENET, V94, P594; Walker DR, 1999, ONCOGENE, V18, P211, DOI 10.1038/sj.onc.1202298; Walker GJ, 1999, INT J CANCER, V82, P305, DOI 10.1002/(SICI)1097-0215(19990719)82:2<305::AID-IJC24>3.0.CO;2-Z; Yang ZH, 1996, MOL BIOL EVOL, V13, P650, DOI 10.1093/oxfordjournals.molbev.a025625; Yang ZH, 1997, COMPUT APPL BIOSCI, V13, P555; Yarbrough WG, 1999, J NATL CANCER I, V91, P1569, DOI 10.1093/jnci/91.18.1569	25	65	65	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 27	2003	22	8					1150	1163		10.1038/sj.onc.1206101	http://dx.doi.org/10.1038/sj.onc.1206101			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	650EK	12606942				2022-12-25	WOS:000181249700004
J	Bunger, MK; Moran, SM; Glover, E; Thomae, TL; Lahvis, GP; Lin, BC; Bradfield, CA				Bunger, MK; Moran, SM; Glover, E; Thomae, TL; Lahvis, GP; Lin, BC; Bradfield, CA			Resistance to 2,3,7,8-tetrachlorodibenzo-p-dioxin toxicity and abnormal liver development in mice carrying a mutation in the nuclear localization sequence of the aryl hydrocarbon receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOSOLIC AH RECEPTOR; DNA-BINDING; DEFICIENT MICE; IN-VIVO; RETINOBLASTOMA PROTEIN; SIGNALING PATHWAYS; KNOCKOUT MICE; CELL-CYCLE; C-SRC; DIOXIN	The Ah receptor (AHR) mediates the metabolic adaptation to a number of planar aromatic chemicals. Essential steps in this adaptive mechanism include AHR binding of ligand in the cytosol, translocation of the receptor to the nucleus, dimerization with the Ah receptor nuclear translocator, and binding of this heterodimeric transcription factor to dioxin-responsive elements (DREs) upstream of promoters that regulate the expression of genes involved in xenobiotic metabolism. The AHR is also involved in other aspects of mammalian biology, such as the toxicity of molecules like 2,3,7,8-tetrachlorodibenzo-p-dioxin as well as regulation of normal liver development. In an effort to test whether these additional AHR-mediated processes require a nuclear event, such as DRE binding, we used homologous recombination to generate mice with a mutation in the AHR nuclear localization/DRE binding domain. These Ahr(nls) mice were found to be resistant to all 2,3,7,8-tetrachlorodibenzo-p-dioxin-induced toxic responses that we examined, including hepatomegaly, thymic involution, and cleft palate formation. Moreover, aberrations in liver development observed in these mice were identical to that observed in mice harboring a null allele at the Ahr locus. Taken in sum, these data support a model where most, if not all, of AHR-regulated biology requires nuclear localization.	Univ Wisconsin, Sch Med, McArdle Lab Canc Res, Madison, WI 53706 USA; Univ Wisconsin, Sch Med, Training Program Environm Toxicol, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison	Bradfield, CA (corresponding author), Univ Wisconsin, Sch Med, McArdle Lab Canc Res, 1400 Univ Ave, Madison, WI 53706 USA.			Lahvis, Garet/0000-0002-1986-8251	NCI NIH HHS [P01-CA22484, P01-CA14520, T32-CA09135, P01 CA022484, P30-CA07175] Funding Source: Medline; NIEHS NIH HHS [F32 ES005877-03, T32-ES07015, F32-ES05877] Funding Source: Medline; NATIONAL CANCER INSTITUTE [T32CA009135, P30CA007175, P01CA022484] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [F32ES005877, T32ES007015] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Bacsi SG, 1996, J BIOL CHEM, V271, P8843, DOI 10.1074/jbc.271.15.8843; Blankenship A, 1997, MOL PHARMACOL, V52, P667, DOI 10.1124/mol.52.4.667; BRADFIELD CA, 1988, MOL PHARMACOL, V34, P229; Carver LA, 1997, J BIOL CHEM, V272, P11452; Carver LA, 1998, J BIOL CHEM, V273, P33580, DOI 10.1074/jbc.273.50.33580; Chan WK, 1999, J BIOL CHEM, V274, P12115, DOI 10.1074/jbc.274.17.12115; DEVORE J, 1986, STAT EXPLORATION ANA; DOLWICK KM, 1993, P NATL ACAD SCI USA, V90, P8566, DOI 10.1073/pnas.90.18.8566; Dong LQ, 1996, J BIOL CHEM, V271, P7942, DOI 10.1074/jbc.271.14.7942; Dunlap DY, 2002, TOXICOLOGY, V172, P125, DOI 10.1016/S0300-483X(02)00006-9; Eguchi H, 1997, J BIOL CHEM, V272, P17640, DOI 10.1074/jbc.272.28.17640; EMA M, 1994, J BIOL CHEM, V269, P27337; Enan E, 1996, BIOCHEM PHARMACOL, V52, P1599, DOI 10.1016/S0006-2952(96)00566-7; FernandezSalguero PM, 1997, VET PATHOL, V34, P605, DOI 10.1177/030098589703400609; FernandezSalguero PM, 1996, TOXICOL APPL PHARM, V140, P173, DOI 10.1006/taap.1996.0210; Fukunaga BN, 1996, J BIOL CHEM, V271, P3743; Ge NL, 1998, J BIOL CHEM, V273, P22708, DOI 10.1074/jbc.273.35.22708; Gonzalez FJ, 1998, DRUG METAB DISPOS, V26, P1194; Gradin K, 1996, MOL CELL BIOL, V16, P5221; HANKINSON O, 1995, ANNU REV PHARMACOL, V35, P307, DOI 10.1146/annurev.pharmtox.35.1.307; Ikuta T, 1998, J BIOL CHEM, V273, P2895, DOI 10.1074/jbc.273.5.2895; JAIN S, 1994, J BIOL CHEM, V269, P31518; Klinge CM, 2000, ARCH BIOCHEM BIOPHYS, V373, P163, DOI 10.1006/abbi.1999.1552; Lahvis GP, 1998, BIOCHEM PHARMACOL, V56, P781, DOI 10.1016/S0006-2952(98)00134-8; Lahvis GP, 2000, P NATL ACAD SCI USA, V97, P10442, DOI 10.1073/pnas.190256997; LaPres JJ, 2000, J BIOL CHEM, V275, P6153, DOI 10.1074/jbc.275.9.6153; McDonnell WM, 1996, SCIENCE, V271, P223; Mimura J, 1997, GENES CELLS, V2, P645, DOI 10.1046/j.1365-2443.1997.1490345.x; NEBERT DW, 1987, ANNU REV BIOCHEM, V56, P945, DOI 10.1146/annurev.biochem.56.1.945; OKEY AB, 1989, MOL PHARMACOL, V35, P823; Peters JM, 1999, TOXICOL SCI, V47, P86, DOI 10.1093/toxsci/47.1.86; Pisano MM, 2000, METH MOL B, V137, P267; POLAND A, 1982, ANNU REV PHARMACOL, V22, P517, DOI 10.1146/annurev.pa.22.040182.002505; POLAND A, 1986, J BIOL CHEM, V261, P6352; POLAND A, 1980, MOL PHARMACOL, V17, P86; Puga A, 2000, J BIOL CHEM, V275, P2943, DOI 10.1074/jbc.275.4.2943; Reiners JJ, 1999, J BIOL CHEM, V274, P2502, DOI 10.1074/jbc.274.4.2502; Schmidt JV, 1996, ANNU REV CELL DEV BI, V12, P55, DOI 10.1146/annurev.cellbio.12.1.55; SCHMIDT JV, 1993, J BIOL CHEM, V268, P22203; Schmidt JV, 1996, P NATL ACAD SCI USA, V93, P6731, DOI 10.1073/pnas.93.13.6731; SWANSON HI, 1995, J BIOL CHEM, V270, P26292, DOI 10.1074/jbc.270.44.26292; Swanson HI, 1996, J BIOL CHEM, V271, P31657, DOI 10.1074/jbc.271.49.31657; Taya Y, 1999, DEVELOPMENT, V126, P3869; Tian Y, 1999, J BIOL CHEM, V274, P510, DOI 10.1074/jbc.274.1.510; TORADO GJ, 1963, J CELL BIOL, V17, P299; TYBULEWICZ VLJ, 1991, CELL, V65, P1153, DOI 10.1016/0092-8674(91)90011-M; Whitlock JP, 1997, DRUG METAB REV, V29, P1107, DOI 10.3109/03602539709002245; Whitlock JP, 1999, ANNU REV PHARMACOL, V39, P103, DOI 10.1146/annurev.pharmtox.39.1.103; Zaher H, 1998, MOL PHARMACOL, V54, P313, DOI 10.1124/mol.54.2.313	49	157	163	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 16	2003	278	20					17767	17774		10.1074/jbc.M209594200	http://dx.doi.org/10.1074/jbc.M209594200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677YX	12621046	hybrid			2022-12-25	WOS:000182838300024
J	Horike, N; Takemori, H; Katoh, Y; Doi, J; Min, L; Asano, T; Sun, XJ; Yamamoto, H; Kasayama, S; Muraoka, M; Nonaka, Y; Okamoto, M				Horike, N; Takemori, H; Katoh, Y; Doi, J; Min, L; Asano, T; Sun, XJ; Yamamoto, H; Kasayama, S; Muraoka, M; Nonaka, Y; Okamoto, M			Adipose-specific expression, phosphorylation of Ser(794) in insulin receptor substrate-1, and activation in diabetic animals of salt-inducible kinase-2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADRENOCORTICAL TUMOR-CELLS; EPIDERMAL GROWTH-FACTOR; PROTEIN-KINASE; ADIPOCYTE DIFFERENTIATION; PHOSPHATIDYLINOSITOL 3-KINASE; TYROSINE PHOSPHORYLATION; 3T3-L1 ADIPOCYTES; IRS PROTEINS; C/EBP-DELTA; FED RATS	Salt-inducible kinase (SIK), first cloned from the adrenal glands of rats fed a high salt diet, is a serine/threonine protein kinase belonging to an AMP-activated protein kinase family. Induced in Y1 cells at an early stage of ACTH stimulation, it regulated the initial steps of steroidogenesis. Here we report the identification of its isoform SIK2. When a green fluorescent protein-fused SIK2 was expressed in 3T3-L1 preadipocytes, it was mostly present in the cytoplasm. When coexpressed in cAMP-responsive element-reporter assay systems, SIK2 could repress the cAMP-responsive element-dependent transcription, although the degree of repression seemed weaker than that by SIK1. SIK2 was specifically expressed in adipose tissues. When 3T3-L1 cells were treated with the adipose differentiation mixture, SIK2 mRNA was induced within 1 h, the time of induction almost coinciding with that of c/EBPbeta mRNA. Coexpressed with human insulin receptor substrate-1 (IRS-1) in COS cells, SIK2 could phosphorylate Ser(794) of human IRS-1. Adenovirus-mediated overexpression of SIK2 in adipocytes elevated the level of phosphorylation at Ser(789), the mouse equivalent of human Ser(794). Moreover, the activity and content of SIK2 were elevated in white adipose tissues of db/db diabetic mice. These results suggest that highly expressed SIK2 in insulin-stimulated adipocytes phosphorylates Ser(794) of IRS-1 and, as a result, might modulate the efficiency of insulin signal transduction, eventually causing the insulin resistance in diabetic animals.	Osaka Univ, Grad Sch Med, Dept Biochem & Mol Biol H1, Suita, Osaka 5650871, Japan; Osaka Univ, Grad Sch Med, Dept Mol Med C4, Suita, Osaka 5650871, Japan; Osaka Univ, Grad Sch Frontier Biosci, Labs Biomol Networks, Suita, Osaka 5650871, Japan; Kinran Coll, Dept Life Sci, Osaka 5650873, Japan; Univ Tokyo, Grad Sch Med, Dept Internal Med, Tokyo 1130033, Japan; Univ Vermont, Coll Med, Div Endocrinol, Burlington, VT 05405 USA; Prot Express Co Ltd, Chiba 2880041, Japan; Koshien Univ, Coll Nutr, Takarazuka, Hyogo 6650006, Japan	Osaka University; Osaka University; Osaka University; University of Tokyo; University of Vermont	Okamoto, M (corresponding author), Osaka Univ, Grad Sch Med H1, Dept Biochem & Mol Biol, 2-2 Yamadaoka, Suita, Osaka 5650871, Japan.							Aguirre V, 2000, J BIOL CHEM, V275, P9047, DOI 10.1074/jbc.275.12.9047; Anai M, 1999, DIABETES, V48, P158, DOI 10.2337/diabetes.48.1.158; Belmonte N, 2001, MOL ENDOCRINOL, V15, P2037, DOI 10.1210/me.15.11.2037; DeFea K, 1997, J BIOL CHEM, V272, P31400, DOI 10.1074/jbc.272.50.31400; Doi J, 2002, J BIOL CHEM, V277, P15629, DOI 10.1074/jbc.M109365200; Doi J, 2001, J ENDOCRINOL, V168, P87, DOI 10.1677/joe.0.1680087; EldarFinkelman H, 1997, P NATL ACAD SCI USA, V94, P9660, DOI 10.1073/pnas.94.18.9660; Engelman JA, 2000, MOL ENDOCRINOL, V14, P1557, DOI 10.1210/me.14.10.1557; Greene MW, 2002, BIOCHEMISTRY-US, V41, P7082, DOI 10.1021/bi015992f; Halder SK, 1998, ENDOCRINOLOGY, V139, P3316, DOI 10.1210/en.139.7.3316; Hamilton SR, 2002, BIOCHEM BIOPH RES CO, V293, P892, DOI 10.1016/S0006-291X(02)00312-1; Haruta T, 2000, MOL ENDOCRINOL, V14, P783, DOI 10.1210/me.14.6.783; Jakobsen SN, 2001, J BIOL CHEM, V276, P46912, DOI 10.1074/jbc.C100483200; Klemm DJ, 2001, J BIOL CHEM, V276, P28430, DOI 10.1074/jbc.M103382200; Kurebayashi S, 2001, ENDOCR J, V48, P249, DOI 10.1507/endocrj.48.249; Lee GH, 1996, NATURE, V379, P632, DOI 10.1038/379632a0; Lewis GF, 2002, ENDOCR REV, V23, P201, DOI 10.1210/er.23.2.201; Li JP, 1999, J BIOL CHEM, V274, P9351, DOI 10.1074/jbc.274.14.9351; Lin XZ, 2001, MOL ENDOCRINOL, V15, P1264, DOI 10.1210/me.15.8.1264; Liu YF, 2001, J BIOL CHEM, V276, P14459, DOI 10.1074/jbc.M007281200; Ogihara T, 1997, J BIOL CHEM, V272, P25267, DOI 10.1074/jbc.272.40.25267; Ogihara T, 2001, DIABETES, V50, P573, DOI 10.2337/diabetes.50.3.573; Ozes ON, 2001, P NATL ACAD SCI USA, V98, P4640, DOI 10.1073/pnas.051042298; Paz K, 1999, J BIOL CHEM, V274, P28816, DOI 10.1074/jbc.274.40.28816; Petersen KF, 2002, AM J CARDIOL, V90, p11G; Qiao LY, 2002, J BIOL CHEM, V277, P26530, DOI 10.1074/jbc.M201494200; Ravichandran LV, 2001, J BIOL CHEM, V276, P3543, DOI 10.1074/jbc.M007231200; Reusch JEB, 2000, MOL CELL BIOL, V20, P1008, DOI 10.1128/MCB.20.3.1008-1020.2000; Reusch JEB, 2002, J BIOL CHEM, V277, P1426, DOI 10.1074/jbc.M107923200; Rosen ED, 2001, J BIOL CHEM, V276, P37731, DOI 10.1074/jbc.R100034200; Rui LY, 2001, J CLIN INVEST, V107, P181, DOI 10.1172/JCI10934; Saltiel AR, 2001, CELL, V104, P517, DOI 10.1016/S0092-8674(01)00239-2; Saltiel AR, 2001, NATURE, V414, P799, DOI 10.1038/414799a; SMAS CM, 1993, CELL, V73, P725, DOI 10.1016/0092-8674(93)90252-L; Soukas A, 2001, J BIOL CHEM, V276, P34167, DOI 10.1074/jbc.M104421200; Sul HS, 1998, PROG NUCLEIC ACID RE, V60, P317, DOI 10.1016/S0079-6603(08)60896-X; Takemori H, 1998, J BIOL CHEM, V273, P2222, DOI 10.1074/jbc.273.4.2222; Takemori H, 2002, J BIOL CHEM, V277, P42334, DOI 10.1074/jbc.M204602200; TANASIJEVIC MJ, 1993, J BIOL CHEM, V268, P18157; Wang ZN, 1999, FEBS LETT, V453, P135, DOI 10.1016/S0014-5793(99)00708-5; White MF, 1998, CURR TOP MICROBIOL, V228, P179; White MF, 2002, AM J PHYSIOL-ENDOC M, V283, pE413, DOI 10.1152/ajpendo.00514.2001; WHITE MF, 1997, DIABETOLOGIA, V40, P2; Xiang XQ, 2002, MOL ENDOCRINOL, V16, P552, DOI 10.1210/me.16.3.552; Yamamoto H, 2002, J CELL SCI, V115, P3601, DOI 10.1242/jcs.00044; YEH WC, 1995, GENE DEV, V9, P168, DOI 10.1101/gad.9.2.168; Zick Y, 2001, TRENDS CELL BIOL, V11, P437, DOI 10.1016/S0962-8924(01)02129-8	47	114	126	3	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 16	2003	278	20					18440	18447		10.1074/jbc.M211770200	http://dx.doi.org/10.1074/jbc.M211770200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677YX	12624099	hybrid			2022-12-25	WOS:000182838300111
J	Liu, L; Ben-Shlomo, H; Xu, YX; Stern, MZ; Goncharov, I; Zhang, YF; Michaeli, S				Liu, L; Ben-Shlomo, H; Xu, YX; Stern, MZ; Goncharov, I; Zhang, YF; Michaeli, S			The trypanosomatid signal recognition particle consists of two RNA molecules, a 7SL RNA homologue and a novel tRNA-like molecule	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LEPTOMONAS-COLLOSOMA; ELONGATION ARREST; BINDING-SITES; ALU DOMAIN; SPLICED LEADER; NUCLEAR EXPORT; SRP PROTEINS; IDENTIFICATION; LOCALIZATION; BRUCEI	Trypanosomatids are ancient eukaryotic parasites affecting humans and livestock. Here we report that the trypanosomatid signal recognition particle (SRP), unlike all other known SRPs in nature, contains, in addition to the 7SL RNA homologue, a short RNA molecule, termed sRNA-85. Using conventional chromatography, we discovered a small RNA molecule of 85 nucleotides co-migrating with the Leptomonas collosoma 7SL RNA. This RNA molecule was isolated, sequenced, and used to clone the corresponding gene. sRNA-85 was identified as a tRNA-like molecule that deviates from the canonical tRNA structure. The co-existence of these RNAs in a single complex was confirmed by affinity selection using an antisense oligonucleotide to sRNA-85. The two RNA molecules exist in a particle of similar to14 S that binds transiently to ribosomes. Mutations were introduced in sRNA-85 that disrupted its putative potential to interact with 7SL RNA by base pairing; such mutants were unable to bind to 7SL RNA and to ribosomes and were aberrantly distributed within the cell. We postulate that sRNA-85 may functionally replace the truncated Alu domain of 7SL RNA. The discovery of sRNA-85 raises the intriguing possibility that sRNA-85 functional homologues may exist in other lower eukaryotes and eubacteria that lack the Alu domain.	Bar Ilan Univ, Fac Life Sci, IL-52900 Ramat Gan, Israel; Weizmann Inst Sci, Dept Biol Chem, IL-76100 Rehovot, Israel	Bar Ilan University; Weizmann Institute of Science	Michaeli, S (corresponding author), Bar Ilan Univ, Fac Life Sci, IL-52900 Ramat Gan, Israel.	michaes@mail.biu.ac.il	Xu, Yu-Xin/G-4041-2010; Michaeli, Shulamit/AAC-8255-2022	Xu, Yu-Xin/0000-0002-0200-4633; Liu, Li/0000-0002-3733-6961				AGABIAN N, 1990, CELL, V61, P1157, DOI 10.1016/0092-8674(90)90674-4; ALTHOFF S, 1994, NUCLEIC ACIDS RES, V22, P1933, DOI 10.1093/nar/22.11.1933; ANDREWS DW, 1987, EMBO J, V6, P3471, DOI 10.1002/j.1460-2075.1987.tb02671.x; Arts GJ, 1998, CURR BIOL, V8, P305, DOI 10.1016/S0960-9822(98)70130-7; BEJA O, 1993, MOL BIOCHEM PARASIT, V57, P223, DOI 10.1016/0166-6851(93)90198-7; Ben-Shlomo H, 1997, NUCLEIC ACIDS RES, V25, P4977, DOI 10.1093/nar/25.24.4977; Ben-Shlomo H, 1999, J BIOL CHEM, V274, P25642, DOI 10.1074/jbc.274.36.25642; BJORK GR, 1987, ANNU REV BIOCHEM, V56, P263, DOI 10.1146/annurev.bi.56.070187.001403; Bovia F, 1996, J CELL SCI, V109, P2601; BROWN JD, 1994, EMBO J, V13, P4390, DOI 10.1002/j.1460-2075.1994.tb06759.x; BROWN S, 1987, CELL, V49, P825, DOI 10.1016/0092-8674(87)90620-9; Bui N, 1999, BIOL CHEM, V380, P135, DOI 10.1515/BC.1999.021; Burkhardt N, 1998, CRIT REV BIOCHEM MOL, V33, P95, DOI 10.1080/10409239891204189; Chaves I, 1998, P NATL ACAD SCI USA, V95, P12328, DOI 10.1073/pnas.95.21.12328; Ciufo LF, 2000, CURR BIOL, V10, P1256, DOI 10.1016/S0960-9822(00)00743-0; Clayton CE, 2002, EMBO J, V21, P1881, DOI 10.1093/emboj/21.8.1881; Cusack S, 1997, CURR OPIN STRUC BIOL, V7, P881, DOI 10.1016/S0959-440X(97)80161-3; England T E, 1980, Methods Enzymol, V65, P65; Estevez AM, 1999, GENE, V240, P247, DOI 10.1016/S0378-1119(99)00437-0; Goldring A, 1996, EXP PARASITOL, V84, P28, DOI 10.1006/expr.1996.0087; Grosshans H, 2001, J CELL BIOL, V153, P745, DOI 10.1083/jcb.153.4.745; HAUSNER TP, 1990, GENE DEV, V4, P2146, DOI 10.1101/gad.4.12a.2146; Jacobson MR, 1998, P NATL ACAD SCI USA, V95, P7981, DOI 10.1073/pnas.95.14.7981; Keenan RJ, 2001, ANNU REV BIOCHEM, V70, P755, DOI 10.1146/annurev.biochem.70.1.755; Levitan A, 1998, NUCLEIC ACIDS RES, V26, P1775, DOI 10.1093/nar/26.7.1775; Liu L, 2002, J BIOL CHEM, V277, P13745, DOI 10.1074/jbc.M110480200; Lund E, 1998, SCIENCE, V282, P2082, DOI 10.1126/science.282.5396.2082; LUTCKE H, 1995, EUR J BIOCHEM, V228, P531, DOI 10.1111/j.1432-1033.1995.0531m.x; MANS RMW, 1991, EUR J BIOCHEM, V201, P303, DOI 10.1111/j.1432-1033.1991.tb16288.x; Mason N, 2000, EMBO J, V19, P4164, DOI 10.1093/emboj/19.15.4164; MICHAELI S, 1990, J BIOL CHEM, V265, P10582; MICHAELI S, 1992, MOL BIOCHEM PARASIT, V51, P55, DOI 10.1016/0166-6851(92)90200-4; Muto A, 1998, TRENDS BIOCHEM SCI, V23, P25, DOI 10.1016/S0968-0004(97)01159-6; NAKAAR V, 1995, PARASITOL TODAY, V11, P225, DOI 10.1016/0169-4758(95)80085-9; Nakamura K, 1999, J BIOL CHEM, V274, P13569, DOI 10.1074/jbc.274.19.13569; OGG SC, 1995, CELL, V81, P1075, DOI 10.1016/S0092-8674(05)80012-1; PALFI Z, 1991, P NATL ACAD SCI USA, V88, P9097, DOI 10.1073/pnas.88.20.9097; Pederson T, 1999, FASEB J, V13, pS238, DOI 10.1096/fasebj.13.9002.S238; RHEINBERGER HJ, 1986, J BIOL CHEM, V261, P9133; Seluanov A, 1997, J BIOL CHEM, V272, P2053; Shi PY, 1998, RNA, V4, P276; SIEGEL V, 1988, CELL, V52, P39, DOI 10.1016/0092-8674(88)90529-6; SIEGEL V, 1988, TRENDS BIOCHEM SCI, V13, P314, DOI 10.1016/0968-0004(88)90127-2; SIEGEL V, 1988, P NATL ACAD SCI USA, V85, P1801, DOI 10.1073/pnas.85.6.1801; SIEGEL V, 1985, J CELL BIOL, V100, P1913, DOI 10.1083/jcb.100.6.1913; Sinha R, 1999, J BIOL CHEM, V274, P30826, DOI 10.1074/jbc.274.43.30826; SOGIN ML, 1986, P NATL ACAD SCI USA, V83, P1383, DOI 10.1073/pnas.83.5.1383; Strub K, 1999, RNA, V5, P1333, DOI 10.1017/S1355838299991045; Ulbrandt ND, 1997, CELL, V88, P187, DOI 10.1016/S0092-8674(00)81839-5; VARSHNEY U, 1991, J BIOL CHEM, V266, P24712; WALTER P, 1981, J CELL BIOL, V91, P557, DOI 10.1083/jcb.91.2.557; WATKINS KP, 1994, CELL, V76, P171, DOI 10.1016/0092-8674(94)90181-3; Weichenrieder O, 2000, NATURE, V408, P167, DOI 10.1038/35041507; Wild K, 2002, CURR OPIN STRUC BIOL, V12, P72, DOI 10.1016/S0959-440X(02)00292-0; Wilson KS, 1998, CELL, V92, P337, DOI 10.1016/S0092-8674(00)80927-7; Wolin SL, 1999, GENE DEV, V13, P1, DOI 10.1101/gad.13.1.1; Xu YX, 1997, P NATL ACAD SCI USA, V94, P8473, DOI 10.1073/pnas.94.16.8473	57	35	38	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 16	2003	278	20					18271	18280		10.1074/jbc.M209215200	http://dx.doi.org/10.1074/jbc.M209215200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677YX	12606550	hybrid			2022-12-25	WOS:000182838300090
J	Raffetseder, U; Frye, B; Rauen, T; Jurchott, K; Royer, HD; Jansen, PL; Mertens, PR				Raffetseder, U; Frye, B; Rauen, T; Jurchott, K; Royer, HD; Jansen, PL; Mertens, PR			Splicing factor SRp30c interaction with Y-box protein-1 confers nuclear YB-1 shuttling and alternative splice site selection	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RIBONUCLEOPROTEIN PARTICLES; TRANSCRIPTION FACTOR YB-1; RNA-ASSOCIATED PROTEIN; MAJOR CORE PROTEIN; BINDING-PROTEIN; FUNCTIONAL INTERACTION; EXPRESSION; OVEREXPRESSION; IDENTIFICATION; TRANSLOCATION	The multifunctional DNA- and RNA-associated Y-box protein 1 (YB-1) specifically binds to splicing recognition motifs and regulates alternative splice site selection. Here, we identify the arginine/serine-rich SRp30c protein as an interacting protein of YB-1 by performing a two-hybrid screen against a human mesangial cell cDNA library. Co-immunoprecipitation studies confirm a direct interaction of tagged proteins YB-1 and SRp30c in the absence of RNA via two independent protein domains of YB-1. A high affinity interaction is conferred through the N-terminal region. We show that the subcellular YB-1 localization is dependent on the cellular SRp30c content. In proliferating cells, YB-1 localizes to the cytoplasm, whereas FLAG-SRp30c protein is detected in the nucleus. After overexpression of YB-1 and FLAG-SRp30c, both proteins are co-localized in the nucleus, and this requires the N-terminal region of YB-1. Heat shock treatment of cells, a condition under which SRp30c accumulates in stress-induced Sam68 nuclear bodies, abrogates the co-localization and YB-1 shuttles back to the cytoplasm. Finally, the functional relevance of the YB-1/SRp30c interaction for in vivo splicing is demonstrated in the E1A minigene model system. Here, changes in splice site selection are detected, that is, overexpression of YB-1 is accompanied by preferential 5' splicing site selection and formation of the 12 S isoform.	Univ Hosp Aachen, Div Nephrol & Clin Immunol, D-52057 Aachen, Germany; Humboldt Univ, Charite, Inst Pathol, D-10099 Berlin, Germany; Univ Dusseldorf, Inst Transplant Diagnost & Cell Therapy, D-40225 Dusseldorf, Germany	RWTH Aachen University; RWTH Aachen University Hospital; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Heinrich Heine University Dusseldorf	Mertens, PR (corresponding author), Rhein Westfal TH Aachen, Med Klin 2, Pauwelsstr 30, D-52057 Aachen, Germany.	pmertens@ukaachen.de	Mertens, Peter/AAI-7310-2020; Royer, Hans-dieter/AAH-6293-2019	Raffetseder, Ute/0000-0002-7236-9793; Jurchott, Karsten/0000-0003-1589-0037				Banas B, 1999, J AM SOC NEPHROL, V10, P2314; Bargou RC, 1997, NAT MED, V3, P447, DOI 10.1038/nm0497-447; BOUVET P, 1995, J BIOL CHEM, V270, P28297; CACERES JF, 1994, SCIENCE, V265, P1706, DOI 10.1126/science.8085156; Capowski EE, 2001, J IMMUNOL, V167, P5970, DOI 10.4049/jimmunol.167.10.5970; Chansky HA, 2001, CANCER RES, V61, P3586; Chen CY, 2000, GENE DEV, V14, P1236; CHEN NN, 1995, J VIROL, V69, P5843, DOI 10.1128/JVI.69.9.5843-5848.1995; Chen TP, 1999, MOL BIOL CELL, V10, P3015, DOI 10.1091/mbc.10.9.3015; Chernukhin IV, 2000, J BIOL CHEM, V275, P29915, DOI 10.1074/jbc.M001538200; Davydova EK, 1997, NUCLEIC ACIDS RES, V25, P2911, DOI 10.1093/nar/25.14.2911; Denegri M, 2001, MOL BIOL CELL, V12, P3502, DOI 10.1091/mbc.12.11.3502; Evdokimova V, 2001, EMBO J, V20, P5491, DOI 10.1093/emboj/20.19.5491; Evdokimova VM, 1998, J BIOL CHEM, V273, P3574, DOI 10.1074/jbc.273.6.3574; Evdokimova VM, 1999, INT J BIOCHEM CELL B, V31, P139, DOI 10.1016/S1357-2725(98)00137-X; EVDOKIMOVA VM, 1995, J BIOL CHEM, V270, P3186, DOI 10.1074/jbc.270.7.3186; Gietz RD, 2002, METHOD ENZYMOL, V350, P87; Holst B, 2001, J BIOL CHEM, V276, P19793, DOI 10.1074/jbc.M100621200; Izumi H, 2001, NUCLEIC ACIDS RES, V29, P1200, DOI 10.1093/nar/29.5.1200; Kohno K, 1997, Nihon Rinsho, V55, P1054; Koike K, 1997, FEBS LETT, V417, P390, DOI 10.1016/S0014-5793(97)01296-9; MACDONALD GH, 1995, J BIOL CHEM, V270, P3527, DOI 10.1074/jbc.270.8.3527; Matsumoto K, 1998, TRENDS CELL BIOL, V8, P318, DOI 10.1016/S0962-8924(98)01300-2; Matsumoto K, 1996, J BIOL CHEM, V271, P22706, DOI 10.1074/jbc.271.37.22706; Mertens PR, 1998, J BIOL CHEM, V273, P32957, DOI 10.1074/jbc.273.49.32957; Mertens PR, 1999, J AM SOC NEPHROL, V10, P2480; Mertens PR, 2002, J BIOL CHEM, V277, P24875, DOI 10.1074/jbc.M200445200; Mertens PR, 1997, J BIOL CHEM, V272, P22905, DOI 10.1074/jbc.272.36.22905; MINICH WB, 1989, FEBS LETT, V258, P227, DOI 10.1016/0014-5793(89)81659-X; MINICH WB, 1989, FEBS LETT, V257, P257, DOI 10.1016/0014-5793(89)81547-9; Nayler O, 1998, NUCLEIC ACIDS RES, V26, P3542, DOI 10.1093/nar/26.15.3542; Norman JT, 2001, J BIOL CHEM, V276, P29880, DOI 10.1074/jbc.M103145200; Okamoto T, 2000, ONCOGENE, V19, P6194, DOI 10.1038/sj.onc.1204029; Safak M, 1999, J VIROL, V73, P10146, DOI 10.1128/JVI.73.12.10146-10157.1999; SCREATON GR, 1995, EMBO J, V14, P4336, DOI 10.1002/j.1460-2075.1995.tb00108.x; Shnyreva M, 2000, J BIOL CHEM, V275, P15498, DOI 10.1074/jbc.275.20.15498; Stein U, 2001, J BIOL CHEM, V276, P28562, DOI 10.1074/jbc.M100311200; Stickeler E, 2001, EMBO J, V20, P3821, DOI 10.1093/emboj/20.14.3821; Stoss O, 1999, J BIOL CHEM, V274, P10951, DOI 10.1074/jbc.274.16.10951; Stoss O, 2001, J BIOL CHEM, V276, P8665, DOI 10.1074/jbc.M006851200; Swamynathan SK, 1998, FASEB J, V12, P515, DOI 10.1096/fasebj.12.7.515; Thiede B, 2001, J BIOL CHEM, V276, P26044, DOI 10.1074/jbc.M101062200; Woods R. A., 2001, METH MOL B, V177, P85; Young PJ, 2002, HUM MOL GENET, V11, P577, DOI 10.1093/hmg/11.5.577	44	100	110	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 16	2003	278	20					18241	18248		10.1074/jbc.M212518200	http://dx.doi.org/10.1074/jbc.M212518200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677YX	12604611	hybrid			2022-12-25	WOS:000182838300086
J	Sabrane, K; Gambaryan, S; Brandes, RP; Holtwick, R; Voss, M; Kuhn, M				Sabrane, K; Gambaryan, S; Brandes, RP; Holtwick, R; Voss, M; Kuhn, M			Increased sensitivity to endothelial nitric oxide (NO) contributes to arterial normotension in mice with vascular smooth muscle-selective deletion of the atrial natriuretic peptide (ANP) receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GUANYLYL CYCLASE RECEPTORS; BLOOD-PRESSURE; CELLS; LACKING; EXPRESSION; SYNTHASE; HYPERTENSION; RELAXATION; CORONARY; PROTEIN	Atrial natriuretic peptide (ANP) plays a key regulatory role in arterial blood pressure homeostasis. We recently generated mice with selective deletion of the ANP receptor, guanylyl cyclase-A (GC-A), in vascular smooth muscle (SMC GC-A knockout (KO) mice) and reported that resting arterial blood pressure was completely normal in spite of clear abolition of the direct vasodilating effects of ANP (Holtwick, R., Gotthardt, M., Skryabin, B., Steinmetz, M., Potthast, R., Zetsche, B., Hammer, R. E., Herz, J., and Kuhn M. (2002) Proc. Natl. Acad. Sci. U. S. A. 99, 7142-7147). The purpose of this study was to clarify mechanisms compensating for the missing vasodilator responses to ANP. In particular, we analyzed the effect of the endothelial, cGMP-mediated vasodilators C-type natriuretic peptide and nitric oxide (NO). In isolated arteries from SMC GC-A KO mice, the vasorelaxing sensitivity to sodium nitroprusside and the endothelium-dependent vasodilator, acetylcholine, was significantly greater than in control mice. There was no difference in responses to C-type natriuretic peptide or to the activator of cGMP-dependent protein kinase I, 8-para-chlorophenylthio-cGMP. The aortic expression of soluble GC (sGC), but not of endothelial NO synthase or cGMP-dependent protein kinase I, was significantly increased in SMC GC-A KO mice. Chronic oral treatment with the NO synthase inhibitor N-w-nitro-L-arginine methyl ester increased arterial blood pressure, the effect being significantly enhanced in SMC GC-A KO mice. We conclude that SMC GC-A KO mice exhibit a higher vasodilating sensitivity to NO. This can be attributed to an enhanced expression of sGC, whereas the expression and/or activity levels of downstream cGMP-effector pathways are not involved. Increased vasodilating responsiveness to endothelial NO contributes to compensate for the missing vasodilating effect of ANP in SMC GC-A KO mice.	Univ Klinikum Munster, Inst Pharmacol & Toxicol, D-48149 Munster, Germany; Univ Wurzburg, Inst Clin Biochem & Pathobiochem, D-97080 Wurzburg, Germany; Univ Frankfurt Klinikum, Inst Cardiovasc Physiol, D-60590 Frankfurt, Germany	University of Munster; University of Wurzburg; Goethe University Frankfurt; Goethe University Frankfurt Hospital	Kuhn, M (corresponding author), Univ Klinikum Munster, Inst Pharmacol & Toxicol, Domagkstr 12, D-48149 Munster, Germany.	mkuhn@uni-muenster.de	Brandes, Ralf P/L-3058-2017; Gambaryan, Stepan/I-3940-2016	Brandes, Ralf P/0000-0002-8035-0048; Gambaryan, Stepan/0000-0002-1470-0791				Brandes RP, 2000, HYPERTENSION, V35, P231, DOI 10.1161/01.HYP.35.1.231; Brunner F, 2001, MICROVASC RES, V61, P102, DOI 10.1006/mvre.2000.2289; Chusho H, 2001, P NATL ACAD SCI USA, V98, P4016, DOI 10.1073/pnas.071389098; DREWETT JG, 1995, J BIOL CHEM, V270, P4668, DOI 10.1074/jbc.270.9.4668; DREWETT JG, 1994, ENDOCR REV, V15, P135, DOI 10.1210/er.15.2.135; EMORI T, 1993, ENDOCRINOLOGY, V133, P2474, DOI 10.1210/en.133.6.2474; GARBERS DL, 1994, J BIOL CHEM, V269, P30741; Holtwick R, 2002, P NATL ACAD SCI USA, V99, P7142, DOI 10.1073/pnas.102650499; Hussain MB, 2001, AM J PHYSIOL-HEART C, V280, pH1151, DOI 10.1152/ajpheart.2001.280.3.H1151; IGNARRO LJ, 1989, CIRC RES, V65, P1, DOI 10.1161/01.RES.65.1.1; John SWM, 1996, AM J PHYSIOL-REG I, V271, pR109, DOI 10.1152/ajpregu.1996.271.1.R109; Kojda G, 1999, CARDIOVASC RES, V42, P206, DOI 10.1016/S0008-6363(98)00315-0; LEITMAN DC, 1986, J BIOL CHEM, V261, P1650; LEITMAN DC, 1986, BIOCHIM BIOPHYS ACTA, V885, P74, DOI 10.1016/0167-4889(86)90040-6; Li DC, 1999, AM J PHYSIOL-LUNG C, V277, pL841, DOI 10.1152/ajplung.1999.277.4.L841; LINCOLN TM, 1993, FASEB J, V7, P328, DOI 10.1096/fasebj.7.2.7680013; Lopez MJ, 1997, J BIOL CHEM, V272, P23064, DOI 10.1074/jbc.272.37.23064; LOPEZ MJ, 1995, NATURE, V378, P65, DOI 10.1038/378065a0; MARKERT T, 1995, J CLIN INVEST, V96, P822, DOI 10.1172/JCI118128; Melo LG, 1998, AM J PHYSIOL-HEART C, V275, pH1826, DOI 10.1152/ajpheart.1998.275.5.H1826; MULVANY MJ, 1990, PHYSIOL REV, V70, P921, DOI 10.1152/physrev.1990.70.4.921; NAZARIO B, 1995, J CLIN INVEST, V95, P1151, DOI 10.1172/JCI117763; Oliver PM, 1997, P NATL ACAD SCI USA, V94, P14730, DOI 10.1073/pnas.94.26.14730; Pierkes M, 2002, CARDIOVASC RES, V53, P852, DOI 10.1016/S0008-6363(01)00543-0; RAVICHANDRAN LV, 1995, FEBS LETT, V374, P295, DOI 10.1016/0014-5793(95)01134-Z; Schlossmann J, 2000, NATURE, V404, P197, DOI 10.1038/35004606; Shesely EG, 1996, P NATL ACAD SCI USA, V93, P13176, DOI 10.1073/pnas.93.23.13176; STINGO AJ, 1992, AM J PHYSIOL, V263, pH1318, DOI 10.1152/ajpheart.1992.263.4.H1318; *US NAT I HLTH, 1996, NIH PUBL, V8523; WEI CM, 1994, BIOCHEM BIOPH RES CO, V205, P765, DOI 10.1006/bbrc.1994.2731; YONEMARU M, 1992, AM J PHYSIOL, V263, pL363, DOI 10.1152/ajplung.1992.263.3.L363; Zabel U, 2002, NAT CELL BIOL, V4, P307, DOI 10.1038/ncb775	32	10	12	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 16	2003	278	20					17963	17968		10.1074/jbc.M213113200	http://dx.doi.org/10.1074/jbc.M213113200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677YX	12637561	hybrid			2022-12-25	WOS:000182838300047
J	Shetty, S; Bdeir, K; Cines, DB; Idell, S				Shetty, S; Bdeir, K; Cines, DB; Idell, S			Induction of plasminogen activator inhibitor-1 by urokinase in lung epithelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA LEVEL; GROWTH-FACTOR-BETA; POSTTRANSCRIPTIONAL REGULATION; IN-VIVO; EXTRACELLULAR-MATRIX; FIBRIN DEPOSITION; BINDING-PROTEIN; RECEPTOR; TYPE-1; VITRONECTIN	The plasminogen/plasmin system, urokinase-type plasminogen activator (uPA), its receptor (uPAR), and its inhibitor (PAI-1), influence extracellular proteolysis and cell migration in lung injury or neoplasia. In this study, we sought to determine whether tcuPA (two chain uPA) alters expression of its major inhibitor PAI-1 in lung epithelial cells. The expression of PAI-1 was evaluated at the protein and mRNA level by Western blot, immunoprecipitation, and Northern blot analyses. We found that tcuPA treatment enhanced PAI-1 protein and mRNA expression in Beas2B lung epithelial cells in a time- and concentration-dependent manner. The tcuPA-mediated induction of PAI-1 involves post-transcriptional control involving stabilization of PAI-1 mRNA. Inactivation of the catalytic activity of tcuPA had little effect on PAI-1 induction and the activity of the isolated amino-terminal fragment was comparable with full-length single- or two-chain uPA. In contrast, deletion of either the uPA receptor binding growth factor domain or kringle domain (<^>kringle) from full-length single chain uPA markedly attenuated the induction of PAI-1. Induction of PAI-1 by exposure of lung epithelial cells to uPA is a newly recognized pathway by which PAI-1 could regulate local fibrinolysis and urokinase-dependent cellular responses in the setting of lung inflammation or neoplasia.	Univ Texas Hlth Ctr, Lab C6, Dept Specialty Care Serv, Tyler, TX 75708 USA; Univ Penn, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA	University of Pennsylvania	Shetty, S (corresponding author), Univ Texas Hlth Ctr, Lab C6, Dept Specialty Care Serv, 11937 US Highway 271, Tyler, TX 75708 USA.	sreerama.shetty@uthct.edu			NHLBI NIH HHS [HL60169, R01-HL-62453-01, R01-HL71147-01, HL67381, HL66442] Funding Source: Medline; PHS HHS [R01-45018-06] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL066442, R01HL062453, R01HL071147, R01HL067381, R01HL060169] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ACHBAROU A, 1994, CANCER RES, V54, P2372; ANDREASEN PA, 1987, MOL CELL BIOL, V7, P3021, DOI 10.1128/MCB.7.8.3021; AXELROD JH, 1989, MOL CELL BIOL, V9, P2133, DOI 10.1128/MCB.9.5.2133; Bajou K, 2001, J CELL BIOL, V152, P777, DOI 10.1083/jcb.152.4.777; Bdeir K, 2000, J BIOL CHEM, V275, P28532, DOI 10.1074/jbc.M001595200; BOHUSLAV J, 1995, J EXP MED, V181, P1381, DOI 10.1084/jem.181.4.1381; BOSMA PJ, 1991, J BIOL CHEM, V266, P17845; BOYD D, 1988, CANCER RES, V48, P3112; BUSSO N, 1994, J CELL BIOL, V126, P259, DOI 10.1083/jcb.126.1.259; Carmeliet P, 1998, J CELL BIOL, V140, P233, DOI 10.1083/jcb.140.1.233; Carmeliet P, 1997, CIRC RES, V81, P829; Chavakis T, 1998, BLOOD, V91, P2305, DOI 10.1182/blood.V91.7.2305.2305_2305_2312; COLUCCI M, 1985, J CLIN INVEST, V75, P818, DOI 10.1172/JCI111777; CONESE M, 1994, J BIOL CHEM, V269, P17886; DANO K, 1985, ADV CANCER RES, V44, P139, DOI 10.1016/S0065-230X(08)60028-7; DEPETRO G, 1994, EXP CELL RES, V213, P286, DOI 10.1006/excr.1994.1200; DULMER I, 1993, FEBS LETT, V322, P37; EHRLICH HJ, 1991, J CELL BIOL, V115, P1773, DOI 10.1083/jcb.115.6.1773; EMEIS JJ, 1986, J EXP MED, V163, P1260, DOI 10.1084/jem.163.5.1260; FATTAL PG, 1992, J BIOL CHEM, V267, P12412; GRONDAHLHANSEN J, 1993, CANCER RES, V53, P2513; Haj-Yehia A, 2000, FASEB J, V14, P1411, DOI 10.1096/fj.14.10.1411; Heaton JH, 1998, J BIOL CHEM, V273, P14261, DOI 10.1074/jbc.273.23.14261; Higazi AAR, 1996, BLOOD, V88, P542, DOI 10.1182/blood.V88.2.542.bloodjournal882542; IDELL S, 1992, AM J PHYSIOL, V263, pL487, DOI 10.1152/ajplung.1992.263.4.L487; IDELL S, 1995, AM J PATHOL, V147, P1318; IDELL S, 1994, AM J PHYSIOL-LUNG C, V267, pL693, DOI 10.1152/ajplung.1994.267.6.L693; Idell S, 1994, New Horiz, V2, P566; IDELL S, 1995, LUNG BIOL HEALTH DIS, V80, P743; KIRCHHEIMER JC, 1989, BLOOD, V74, P1396; KIRCHHEIMER JC, 1989, EUR J BIOCHEM, V181, P103, DOI 10.1111/j.1432-1033.1989.tb14699.x; Konakova M, 1998, EUR J BIOCHEM, V253, P421, DOI 10.1046/j.1432-1327.1998.2530421.x; KOOISTRA T, 1989, THROMB HAEMOSTASIS, V62, P723; Koshelnick Y, 1997, J BIOL CHEM, V272, P28563, DOI 10.1074/jbc.272.45.28563; LAIHO M, 1987, J BIOL CHEM, V262, P17467; LI H, 1994, J BIOL CHEM, V269, P8153; LIOTTA LA, 1991, CANCER INVEST, V9, P543, DOI 10.3109/07357909109018952; MAYER M, 1988, J BIOL CHEM, V263, P15688; Mazar A P, 1999, Angiogenesis, V3, P15, DOI 10.1023/A:1009095825561; MIGNATTI P, 1993, PHYSIOL REV, V73, P161, DOI 10.1152/physrev.1993.73.1.161; MIMURO J, 1989, J BIOL CHEM, V264, P936; Mukhina S, 2000, J BIOL CHEM, V275, P16450, DOI 10.1074/jbc.M909080199; NASKI MC, 1993, J BIOL CHEM, V268, P12367; NGUYEN G, 1994, KIDNEY INT, V46, P208, DOI 10.1038/ki.1994.261; Nykjaer A, 1997, EMBO J, V16, P2610, DOI 10.1093/emboj/16.10.2610; OSSOWSKI L, 1988, J CELL BIOL, V107, P2437, DOI 10.1083/jcb.107.6.2437; PEDERSEN H, 1994, CANCER RES, V54, P120; PEDERSEN H, 1994, CANCER RES, V54, P4671; RABBANI SA, 1992, J BIOL CHEM, V267, P14151; SAWDEY M, 1989, J BIOL CHEM, V264, P10396; SEIFFERT D, 1990, J CELL BIOL, V111, P1283, DOI 10.1083/jcb.111.3.1283; Shetty S, 2002, MOL CELL BIOCHEM, V237, P55, DOI 10.1023/A:1016558200199; Shetty S, 2000, AM J PHYSIOL-LUNG C, V278, pL148, DOI 10.1152/ajplung.2000.278.1.L148; Shetty S, 2002, AM J PHYSIOL-LUNG C, V283, pL319, DOI 10.1152/ajplung.00395.2001; Shetty S, 2001, J BIOL CHEM, V276, P24549, DOI 10.1074/jbc.M101605200; SHETTY S, 1995, ANTISENSE RES DEV, V5, P307, DOI 10.1089/ard.1995.5.307; Shetty S, 2000, J BIOL CHEM, V275, P13771, DOI 10.1074/jbc.275.18.13771; SHETTY S, 1995, AM J PHYSIOL-LUNG C, V268, pL972, DOI 10.1152/ajplung.1995.268.6.L972; Sidenius N, 2002, J BIOL CHEM, V277, P27982, DOI 10.1074/jbc.M111736200; Sitrin RG, 1999, J IMMUNOL, V163, P6193; SPRENGERS ED, 1987, BLOOD, V69, P381; Stefansson S, 1996, NATURE, V383, P441, DOI 10.1038/383441a0; Stefansson S, 1998, TRENDS CARDIOVAS MED, V8, P175, DOI 10.1016/S1050-1738(98)00003-6; Stefansson S, 2001, J BIOL CHEM, V276, P8135, DOI 10.1074/jbc.M007609200; Tang H, 1998, J BIOL CHEM, V273, P18268, DOI 10.1074/jbc.273.29.18268; Tillmann-Bogush M, 1999, J BIOL CHEM, V274, P1172, DOI 10.1074/jbc.274.2.1172; VASSALLI JD, 1991, J CLIN INVEST, V88, P1067, DOI 10.1172/JCI115405; Wei Y, 1996, SCIENCE, V273, P1551, DOI 10.1126/science.273.5281.1551	68	29	30	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 16	2003	278	20					18124	18131		10.1074/jbc.M207445200	http://dx.doi.org/10.1074/jbc.M207445200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677YX	12642587	hybrid			2022-12-25	WOS:000182838300070
J	Westhoff, T; Jankowski, J; Schmidt, S; Luo, JK; Giebing, G; Schluter, H; Tepel, M; Zidek, W; van der Giet, M				Westhoff, T; Jankowski, J; Schmidt, S; Luo, JK; Giebing, G; Schluter, H; Tepel, M; Zidek, W; van der Giet, M			Identification and characterization of adenosine 5 '-tetraphosphate in human myocardial tissue	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LASER DESORPTION IONIZATION; CARDIOVASCULAR-SYSTEM; CORONARY VASODILATATION; CHROMAFFIN GRANULES; MASS-SPECTROMETRY; P2X PURINOCEPTOR; RAT-HEART; ATP; RECEPTORS; TETRAPHOSPHATE	Endocrine functions of the human heart have been studied extensively. Only recently, nucleotidergic mechanisms have been studied in detail. Therefore, an isolation strategy was developed to isolate novel nucleotide compounds from human myocardium. The human myocardial tissue was fractionated by several chromatographic studies. A substance purified to homogeneity was identified as adenosine 5'-tetraphosphate (Ap(4)) by matrix-assisted laser desorption/ionization mass spectrometry (MALDI MS), post-source decay MALDI MS, and enzymatic cleavage analysis. Furthermore, Ap(4) was also identified in ventricular specific granules. In the isolated perfused rat heart, Ap(4) elicited dose-dependent vasodilations. Vasodilator responses were abolished in the presence of the P-2Y1 receptor antagonist MRS 2179 (1 muM) or the NO synthase inhibitor N-G-nitro-L-arginine methyl ester (50 muM). After removal of the endothelium by Triton X-100, Ap(4) induced dose-dependent vasoconstrictions. Inhibition of P-2X receptors by pyridoxal phosphate-6-azophenyl-2',4'-disulfonic acid (30 muM) or desensitization of P-2X receptors by alpha,beta-methylene ATP (alpha,beta-meATP, 1 muM) diminished these vasoconstrictor responses completely. In the present study Ap(4) has been isolated from human tissue. Ap(4) was shown to exist in human myocardial tissue and was identified in ventricular specific granules. In coronary vasculature the nucleotide exerted vasodilation via endothelial P-2Y1 receptors and vasoconstriction via P-2X receptors on vascular smooth muscle cells. Ap(4) acts as an endogenous extracellular mediator and might contribute to the regulation of coronary perfusion.	Free Univ Berlin, Klinikum Benjamin Franklin, Med Klin 4, D-12200 Berlin, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	van der Giet, M (corresponding author), Free Univ Berlin, Klinikum Benjamin Franklin, Med Klin 4, Hindenburgdamm 30, D-12200 Berlin, Germany.		Tepel, Martin/GRS-9581-2022; Schluter, Hartmut/D-1371-2015	Schluter, Hartmut/0000-0002-9358-7036; van der Giet, Markus/0000-0003-3590-5451; Tepel, Martin/0000-0002-0086-0997; Westhoff, Timm H./0000-0001-5797-834X				BARNES LD, 1985, ANAL BIOCHEM, V144, P296, DOI 10.1016/0003-2697(85)90120-4; BO XN, 1995, FEBS LETT, V375, P129, DOI 10.1016/0014-5793(95)01203-Q; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Broad RM, 2001, HANDB EXP PHARM, V151, P3; CURRIE MG, 1984, SCIENCE, V223, P67, DOI 10.1126/science.6419347; DEBOLD AJ, 1973, CARDIOVASC RES, V7, P364; EVANS RJ, 1995, MOL PHARMACOL, V48, P178; Flores NA, 1999, CARDIOVASC RES, V42, P15, DOI 10.1016/S0008-6363(99)00004-8; GarciaGuzman M, 1996, FEBS LETT, V388, P123, DOI 10.1016/0014-5793(96)00499-1; Giannella E, 1997, CIRC RES, V81, P415, DOI 10.1161/01.RES.81.3.415; Gualix J, 1996, FEBS LETT, V391, P195, DOI 10.1016/0014-5793(96)00732-6; HILLENKAMP F, 1990, METHOD ENZYMOL, V193, P280, DOI 10.1016/0076-6879(90)93420-P; HOPWOOD AM, 1987, EUR J PHARMACOL, V136, P49, DOI 10.1016/0014-2999(87)90777-1; KAUFMANN R, 1994, METHOD ENZYMOL, V193, P263; Lee CYG, 1995, J REPROD IMMUNOL, V29, P223, DOI 10.1016/0165-0378(95)00947-J; LIEBERMAN I, 1955, J AM CHEM SOC, V77, P3373, DOI 10.1021/ja01617a064; Luo J, 1999, FASEB J, V13, P695, DOI 10.1096/fasebj.13.6.695; MARRIAN DH, 1953, BIOCHIM BIOPHYS ACTA, V12, P492, DOI 10.1016/0006-3002(53)90176-0; NORDHOFF E, 1992, RAPID COMMUN MASS SP, V6, P771, DOI 10.1002/rcm.1290061212; Nori S, 1998, J VASC RES, V35, P179, DOI 10.1159/000025582; Pelleg A, 2001, HANDB EXP PHARM, V151, P73; Phillis JW, 1998, EUR J PHARMACOL, V356, P199, DOI 10.1016/S0014-2999(98)00512-3; Ralevic V, 1998, PHARMACOL REV, V50, P413; SMALL GD, 1966, BIOCHEMISTRY-US, V5, P26, DOI 10.1021/bi00865a004; Starling RC, 1998, MOL CELL BIOCHEM, V180, P171, DOI 10.1023/A:1006876031121; SULKOWSKI E, 1971, BIOCHIM BIOPHYS ACTA, V240, P443, DOI 10.1016/0005-2787(71)90538-7; Torres GE, 1999, J BIOL CHEM, V274, P6653, DOI 10.1074/jbc.274.10.6653; van der Giet M, 2002, EUR J PHARMACOL, V448, P207, DOI 10.1016/S0014-2999(02)01986-6; VANDYKE K, 1977, PHARMACOLOGY, V15, P377, DOI 10.1159/000136714; ZISMAN LS, 1995, J CLIN INVEST, V96, P1490, DOI 10.1172/JCI118186	30	10	11	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 16	2003	278	20					17735	17740		10.1074/jbc.M300288200	http://dx.doi.org/10.1074/jbc.M300288200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677YX	12609994	hybrid			2022-12-25	WOS:000182838300020
J	Buu, LM; Chen, YC; Lee, FJS				Buu, LM; Chen, YC; Lee, FJS			Functional characterization and localization of acetyl-CoA hydrolase, Ach1p, in Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COENZYME-A HYDROLASE; AMINO-ACID-SEQUENCE; RAT-LIVER; ACETATE UTILIZATION; FILAMENTOUS GROWTH; PROTEIN IMPORT; SHORT-CHAIN; YEAST; MITOCHONDRIA; GENE	Acetyl-CoA hydrolase (Ach1p), catalyzing the hydrolysis of acetyl-CoA, is presumably involved in regulating intracellular acetyl-CoA or CoASH pools; however, its intracellular functions and distribution remain to be established. Using site-directed mutagenesis analysis, we demonstrated that the enzymatic activity of Ach1p is dependent upon its putative acetyl-CoA binding sites. The ach1 mutant causes a growth defect in acetate but not in other non-fermentable carbon sources, suggesting that Ach1p is not involved in mitochondrial biogenesis. Overexpression of Ach1p, but not constructs containing acetyl-CoA binding site mutations, in ach1-1 complemented the defect of acetate utilization. By subcellular fractionation, most of the Ach1p in yeast was distributed with mitochondria and little Ach1p in the cytoplasm. By immunofluorescence microscopy, we show that Ach1p and acetyl-CoA binding site-mutated constructs, but not its N-terminal deleted construct, are localized in mitochondria. Moreover, the onset of pseudohyphal development in homozygote ach1-1 diploids was abolished. We infer that Ach1p may be involved in a novel acetyl-CoA biogenesis and/or acetate utilization in mitochondria and thereby indirectly affect pseudohyphal development in yeast.	Natl Taiwan Univ, Coll Med, Natl Taiwan Univ Hosp, Inst Mol Med, Taipei 100, Taiwan; Natl Taiwan Univ, Coll Med, Natl Taiwan Univ Hosp, Dept Internal Med, Taipei 100, Taiwan	National Taiwan University; National Taiwan University Hospital; National Taiwan University; National Taiwan University Hospital	Lee, FJS (corresponding author), Natl Taiwan Univ, Coll Med, Natl Taiwan Univ Hosp, Inst Mol Med, 7 Chung Shan S Rd, Taipei 100, Taiwan.		Chen, Yee-Chun/AGW-7535-2022	Chen, Yee-Chun/0000-0002-1816-9010; LEE, FANG-JEN/0000-0002-2167-2426				BERNSON VSM, 1976, EUR J BIOCHEM, V67, P403, DOI 10.1111/j.1432-1033.1976.tb10705.x; Boy-Marcotte E, 1998, J BACTERIOL, V180, P1044, DOI 10.1128/JB.180.5.1044-1052.1998; CONNERTON IF, 1992, J GEN MICROBIOL, V138, P1797, DOI 10.1099/00221287-138-9-1797; ELGERSMA Y, 1995, EMBO J, V14, P3472, DOI 10.1002/j.1460-2075.1995.tb07353.x; Flikweert MT, 1996, YEAST, V12, P247, DOI 10.1002/(SICI)1097-0061(19960315)12:3<247::AID-YEA911>3.0.CO;2-I; FUKAYA M, 1993, J FERMENT BIOENG, V76, P270, DOI 10.1016/0922-338X(93)90192-B; GERGELY J, 1952, J BIOL CHEM, V198, P323; GIMENO CJ, 1992, CELL, V68, P1077, DOI 10.1016/0092-8674(92)90079-R; GRIGAT KP, 1979, BIOCHEM J, V177, P71, DOI 10.1042/bj1770071; Gygi SP, 1999, MOL CELL BIOL, V19, P1720, DOI 10.1128/mcb.19.3.1720; Huang CF, 1999, J BIOL CHEM, V274, P3819, DOI 10.1074/jbc.274.6.3819; Huang CF, 2002, J CELL SCI, V115, P275; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; KNOWLES SE, 1974, BIOCHEM J, V142, P401, DOI 10.1042/bj1420401; LEE FJS, 1990, J BIOL CHEM, V265, P7413; LEE FJS, 1989, EUR J BIOCHEM, V184, P21, DOI 10.1111/j.1432-1033.1989.tb14985.x; Lee FJS, 1997, J BIOL CHEM, V272, P30998, DOI 10.1074/jbc.272.49.30998; Lee FJS, 1996, BBA-PROTEIN STRUCT M, V1297, P105, DOI 10.1016/0167-4838(96)00109-4; LEE FJS, 1988, J BIOL CHEM, V263, P14948; Lorenz MC, 2001, NATURE, V412, P83, DOI 10.1038/35083594; LOWE PN, 1988, BIOCHEM J, V250, P789, DOI 10.1042/bj2500789; MAHAN DE, 1975, BIOCHEM J, V145, P25, DOI 10.1042/bj1450025; MARATHE S, 1990, MOL CELL BIOL, V10, P2638, DOI 10.1128/MCB.10.6.2638; Neupert W, 1997, ANNU REV BIOCHEM, V66, P863, DOI 10.1146/annurev.biochem.66.1.863; NOBEL DD, 2001, YEAST, V18, P1413; Palecek SP, 2002, MICROBIOL-SGM, V148, P893, DOI 10.1099/00221287-148-4-893; PARALES RE, 1992, J BACTERIOL, V174, P4657, DOI 10.1128/JB.174.14.4657-4666.1992; PRASS RL, 1980, J BIOL CHEM, V255, P5215; Pronk JT, 1996, YEAST, V12, P1607, DOI 10.1002/(SICI)1097-0061(199612)12:16<1607::AID-YEA70>3.0.CO;2-4; ROBINSON JB, 1976, BIOCHEM BIOPH RES CO, V71, P959, DOI 10.1016/0006-291X(76)90748-8; Sambrook J., 2002, MOL CLONING LAB MANU; SANYAL A, 1995, J BIOL CHEM, V270, P11970, DOI 10.1074/jbc.270.20.11970; Schatz G, 1996, J BIOL CHEM, V271, P31763, DOI 10.1074/jbc.271.50.31763; Sherman F., 1986, METHODS YEAST GENETI; Sohling B, 1996, J BACTERIOL, V178, P871; SOLING HD, 1985, EUR J BIOCHEM, V147, P111, DOI 10.1111/j.1432-1033.1985.tb08726.x; Suematsu N, 2001, EUR J BIOCHEM, V268, P2700, DOI 10.1046/j.1432-1327.2001.02162.x; Svensson LT, 1996, EUR J BIOCHEM, V239, P526, DOI 10.1111/j.1432-1033.1996.0526u.x; van den Berg MA, 1998, YEAST, V14, P1089, DOI 10.1002/(SICI)1097-0061(19980915)14:12<1089::AID-YEA312>3.3.CO;2-B; VANROERMUND CWT, 1995, EMBO J, V14, P3480, DOI 10.1002/j.1460-2075.1995.tb07354.x; VERNET T, 1987, GENE, V52, P225, DOI 10.1016/0378-1119(87)90049-7; WIERENGA RK, 1986, J MOL BIOL, V187, P101, DOI 10.1016/0022-2836(86)90409-2; Wilusz CJ, 2001, RNA, V7, P1416; WITKOWSKI A, 1994, J BIOL CHEM, V269, P379; ZINSER E, 1995, YEAST, V11, P493, DOI 10.1002/yea.320110602	45	41	82	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 9	2003	278	19					17203	17209		10.1074/jbc.M213268200	http://dx.doi.org/10.1074/jbc.M213268200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677QG	12606555	hybrid			2022-12-25	WOS:000182818600102
J	Watson, LM; Chan, AKC; Berry, LR; Li, J; Sood, SK; Dickhout, JG; Xu, L; Werstuck, GH; Bajzar, L; Klamut, HJ; Austin, RC				Watson, LM; Chan, AKC; Berry, LR; Li, J; Sood, SK; Dickhout, JG; Xu, L; Werstuck, GH; Bajzar, L; Klamut, HJ; Austin, RC			Overexpression of the 78-kDa glucose-regulated protein/immunoglobulin-binding protein (GRP78/BiP) inhibits tissue factor procoagulant activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOPLASMIC-RETICULUM STRESS; ARTERIAL SMOOTH-MUSCLE; FACTOR EXPRESSION; FACTOR PATHWAY; ENDOTHELIAL-CELLS; MOLECULAR CHAPERONES; GENE-EXPRESSION; FACTOR ANTIGEN; GROWTH ARREST; OXIDIZED LDL	Previous studies have demonstrated that overexpression of GRP78/BiP, an endoplasmic reticulum (ER)-resident molecular chaperone, in mammalian cells inhibits the secretion of specific coagulation factors. However, the effects of GRP78/BiP on activation of the coagulation cascade leading to thrombin generation are not known. In this study, we examined whether GRP78/BiP overexpression mediates cell surface thrombin generation in a human bladder cancer cell line T24/83 having prothrombotic characteristics. We report here that cells overexpressing GRP78/BiP exhibited significant decreases in cell surface-mediated thrombin generation, prothrombin consumption and the formation of thrombin-inhibitor complexes, compared with wild-type or vector-transfected cells. This effect was attributed to the ability of GRP78/BiP to inhibit cell surface tissue factor (TF) procoagulant activity (PCA) because conversion of factor X to Xa and factor VII to VIIa were significantly lower on the surface of GRP78/ BiP-overexpressing cells. The additional findings that (i) cell surface factor Xa generation was inhibited in the absence of factor VIIa and (ii) TF PCA was inhibited by a neutralizing antibody to human TF suggests that thrombin generation is mediated exclusively by TF. GRP78/BiP overexpression did not decrease cell surface levels of TF, suggesting that the inhibition in TF PCA does not result from retention of TF in the ER by GRP78/BiP. The additional observations that both adenovirus-mediated and stable GRP78/BiP overexpression attenuated TF PCA stimulated by ionomycin or hydrogen peroxide suggest that GRP78/BiP indirectly alters TF PCA through a mechanism involving cellular Ca2+ and/or oxidative stress. Similar results were also observed in human aortic smooth muscle cells transfected with the GRP78/BiP adenovirus. Taken together, these findings demonstrate that overexpression of GRP78/BiP decreases thrombin generation by inhibiting cell surface TF PCA, thereby suppressing the prothrombotic potential of cells.	Henderson Res Ctr, Hamilton, ON L8V 1C3, Canada; McMaster Univ, Dept Pathol & Mol Med, Hamilton, ON L8V 1C3, Canada; McMaster Univ, Dept Pediat, Hamilton, ON L8V 1C3, Canada; McMaster Univ, Dept Med, Hamilton, ON L8V 1C3, Canada; Ontario Canc Inst, Div Expt Therapeut, Toronto, ON M5G 2M9, Canada	McMaster University; McMaster University; McMaster University; University of Toronto; University Toronto Affiliates; University Health Network Toronto	Austin, RC (corresponding author), Henderson Res Ctr, 711 Concess St, Hamilton, ON L8V 1C3, Canada.	raustin@thrombosis.hhscr.org	Dickhout, Jeffrey/R-2606-2019; Chan, Anthony K. C./AAR-8892-2021	Chan, Anthony K. C./0000-0003-1551-3995				[Anonymous], 1987, THROMB DIATH HAEMO; Aoki M, 2001, MOL BRAIN RES, V95, P117, DOI 10.1016/S0169-328X(01)00255-8; Ardissino D, 1997, LANCET, V349, P769, DOI 10.1016/S0140-6736(96)11189-2; BACH R, 1990, P NATL ACAD SCI USA, V87, P6995, DOI 10.1073/pnas.87.18.6995; Bach RR, 1997, BLOOD, V89, P3270, DOI 10.1182/blood.V89.9.3270; Badimon JJ, 1999, CIRCULATION, V99, P1780, DOI 10.1161/01.CIR.99.14.1780; BLONDELGUINDI S, 1993, CELL, V75, P717, DOI 10.1016/0092-8674(93)90492-9; BRAND K, 1994, ARTERIOSCLER THROMB, V14, P790, DOI 10.1161/01.ATV.14.5.790; BREIDER MA, 1994, VET PATHOL, V31, P55, DOI 10.1177/030098589403100107; Brodsky JL, 1999, J BIOL CHEM, V274, P3453, DOI 10.1074/jbc.274.6.3453; Brown J, 2000, LAB INVEST, V80, P37, DOI 10.1038/labinvest.3780006; CALLANDER NS, 1992, CANCER-AM CANCER SOC, V70, P1194, DOI 10.1002/1097-0142(19920901)70:5<1194::AID-CNCR2820700528>3.0.CO;2-E; CARSON SD, 1994, BLOOD, V84, P526; Chan AKC, 1998, AM J PHYSIOL-LUNG C, V274, pL914, DOI 10.1152/ajplung.1998.274.6.L914; CONSONNI R, 1995, THROMB HAEMOSTASIS, V74, P904; CONWAY EM, 1989, THROMB RES, V53, P231, DOI 10.1016/0049-3848(89)90098-4; DORNER AJ, 1988, MOL CELL BIOL, V8, P4063, DOI 10.1128/MCB.8.10.4063; DORNER AJ, 1990, P NATL ACAD SCI USA, V87, P7429, DOI 10.1073/pnas.87.19.7429; DORNER AJ, 1992, EMBO J, V11, P1563, DOI 10.1002/j.1460-2075.1992.tb05201.x; DRAKE TA, 1989, J CELL BIOL, V109, P389, DOI 10.1083/jcb.109.1.389; DRAKE TA, 1989, AM J PATHOL, V134, P1087; DRAKE TA, 1991, AM J PATHOL, V138, P601; FALANGA A, 1995, BLOOD, V86, P1072, DOI 10.1182/blood.V86.3.1072.bloodjournal8631072; FEI HH, 1993, ARTERIOSCLER THROMB, V13, P1711, DOI 10.1161/01.ATV.13.11.1711; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; GREGORY SA, 1989, MOL CELL BIOL, V9, P2752, DOI 10.1128/MCB.9.6.2752; Hansen CB, 1999, BLOOD, V94, P1657, DOI 10.1182/blood.V94.5.1657.417k30_1657_1664; Hatakeyama K, 1998, ATHEROSCLEROSIS, V139, P265, DOI 10.1016/S0021-9150(98)00077-X; HELENIUS A, 1994, MOL BIOL CELL, V5, P253, DOI 10.1091/mbc.5.3.253; Khechai F, 1997, ARTERIOSCL THROM VAS, V17, P2885, DOI 10.1161/01.ATV.17.11.2885; KLAUSNER RD, 1990, CELL, V62, P611, DOI 10.1016/0092-8674(90)90104-M; Knarr G, 1999, J BIOL CHEM, V274, P29850, DOI 10.1074/jbc.274.42.29850; KNARR G, 1995, J BIOL CHEM, V270, P27589, DOI 10.1074/jbc.270.46.27589; Kobayashi Y, 1998, TRANSPLANTATION, V66, P708, DOI 10.1097/00007890-199809270-00004; Kuznetsov G, 1997, J BIOL CHEM, V272, P3057, DOI 10.1074/jbc.272.5.3057; LEE A S, 1992, Current Opinion in Cell Biology, V4, P267, DOI 10.1016/0955-0674(92)90042-B; Lee AS, 2001, TRENDS BIOCHEM SCI, V26, P504, DOI 10.1016/S0968-0004(01)01908-9; Li PX, 2000, J BIOL CHEM, V275, P20127, DOI 10.1074/jbc.M909580199; Lievremont JP, 1997, J BIOL CHEM, V272, P30873, DOI 10.1074/jbc.272.49.30873; LING X, 1995, PEDIATR RES, V37, P373, DOI 10.1203/00006450-199503000-00020; Liu H, 1998, J BIOL CHEM, V273, P12858, DOI 10.1074/jbc.273.21.12858; Liu H, 1997, J BIOL CHEM, V272, P21751, DOI 10.1074/jbc.272.35.21751; LopezPedrera C, 1997, AM J HEMATOL, V56, P71, DOI 10.1002/(SICI)1096-8652(199710)56:2<71::AID-AJH1>3.0.CO;2-Y; MARMUR JD, 1993, J CLIN INVEST, V91, P2253, DOI 10.1172/JCI116452; Marmur JD, 1996, CIRCULATION, V94, P1226, DOI 10.1161/01.CIR.94.6.1226; Mechtcheriakova D, 1999, BLOOD, V93, P3811, DOI 10.1182/blood.V93.11.3811.411k40_3811_3823; Meerovitch K, 1998, J BIOL CHEM, V273, P21025, DOI 10.1074/jbc.273.33.21025; MOORE KL, 1987, J CLIN INVEST, V79, P124, DOI 10.1172/JCI112772; Morris JA, 1997, J BIOL CHEM, V272, P4327, DOI 10.1074/jbc.272.7.4327; NEMERSON Y, 1992, SEMIN HEMATOL, V29, P170; NEMERSON Y, 1988, BLOOD, V71, P1; Nishibe T, 2001, BLOOD, V97, P692, DOI 10.1182/blood.V97.3.692; Outinen PA, 1998, BIOCHEM J, V332, P213, DOI 10.1042/bj3320213; Outinen PA, 1999, BLOOD, V94, P959, DOI 10.1182/blood.V94.3.959.415k20_959_967; Pahl HL, 1999, PHYSIOL REV, V79, P683, DOI 10.1152/physrev.1999.79.3.683; Paredes N, 2003, BRIT J HAEMATOL, V120, P315, DOI 10.1046/j.1365-2141.2003.03971.x; Penn MS, 2000, BLOOD, V96, P3056; Penn MS, 1999, CIRCULATION, V99, P1753, DOI 10.1161/01.CIR.99.13.1753; RAO LVM, 1992, CANCER METAST REV, V11, P249; RAPAPORT SI, 1995, THROMB HAEMOSTASIS, V74, P7; RICKLES FR, 1995, THROMB HAEMOSTASIS, V74, P391; Ruddon RW, 1997, J BIOL CHEM, V272, P3125, DOI 10.1074/jbc.272.6.3125; Ruf W, 1996, Curr Opin Hematol, V3, P379; RUF W, 1994, FASEB J, V8, P385, DOI 10.1096/fasebj.8.6.8168689; Schecter AD, 1997, J CLIN INVEST, V100, P2276, DOI 10.1172/JCI119765; Stephens RW, 1996, THROMB RES, V84, P453, DOI 10.1016/S0049-3848(96)00213-7; TAKAHASHI K, 1990, IN VITRO CELL DEV B, V26, P265; Toschi V, 1997, CIRCULATION, V95, P594, DOI 10.1161/01.CIR.95.3.594; vandePut FHMM, 1997, J BIOL CHEM, V272, P27764, DOI 10.1074/jbc.272.44.27764; Visseren FLJ, 2000, THROMB HAEMOSTASIS, V84, P319; Wang J, 2001, BRIT J HAEMATOL, V115, P382, DOI 10.1046/j.1365-2141.2001.03095.x; Werstuck GH, 2001, J CLIN INVEST, V107, P1263, DOI 10.1172/JCI11596; WILCOX JN, 1989, P NATL ACAD SCI USA, V86, P2839, DOI 10.1073/pnas.86.8.2839; WILDGOOSE P, 1993, BIOCHEMISTRY-US, V32, P114, DOI 10.1021/bi00052a016; Wolberg AS, 2000, BIOCHEM BIOPH RES CO, V272, P332, DOI 10.1006/bbrc.2000.2783; Wolberg AS, 1999, BLOOD COAGUL FIBRIN, V10, P201, DOI 10.1097/00001721-199906000-00007; Xiao GQ, 1999, MOL BRAIN RES, V72, P121, DOI 10.1016/S0169-328X(99)00188-6; Xiao GQ, 1999, J NEUROSCI RES, V58, P652, DOI 10.1002/(SICI)1097-4547(19991201)58:5<652::AID-JNR6>3.0.CO;2-H	78	49	54	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 9	2003	278	19					17438	17447		10.1074/jbc.M301006200	http://dx.doi.org/10.1074/jbc.M301006200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677QG	12621026	hybrid			2022-12-25	WOS:000182818600131
J	Zeng, WZ; Li, XJ; Hilgemann, DW; Huang, CL				Zeng, WZ; Li, XJ; Hilgemann, DW; Huang, CL			Protein kinase C inhibits ROMK1 channel activity via a phosphatidylinositol 4,5-bisphosphate-dependent mechanism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SENSITIVE POTASSIUM CHANNELS; CORTICAL COLLECTING DUCT; K-ATP CHANNELS; PLASMA-MEMBRANE; ANIONIC PHOSPHOLIPIDS; RAT-KIDNEY; BETA-GAMMA; RECEPTOR; PIP2; ACTIVATION	The activity of apical K+ channels in cortical collecting duct (CCD) is stimulated and inhibited by protein kinase A (PKA) and C (PKC), respectively. Direct interaction between phosphatidylinositol 4,5-bisphosphate (PIP2) and the cloned CCD K+ channel, ROMK1, is critical for channel opening. We have found previously that phosphorylation of ROMK1 by PKA increases affinity of the channel for PIP2 and mutation of PKA sites reduces the affinity of ROMK1 for PIP2. In this study we investigate the molecular mechanism for PKC regulation of ROMK and report that mutants of ROMK1 with reduced PIP2 affinity exhibit an increased sensitivity to inhibition by phorbol myristate acetate (PMA). The effect of PMA can be prevented by pretreatment with calphostin-C. Activation of PKC by carbachol in Xenopus oocytes co-expressing M1 muscarinic receptors also causes inhibition of the channels. Calphostin-C prevents carbachol-induced inhibition, suggesting that activation of PKC is necessary for inhibition of the channels. PMA reduces open probability of the channel in cell-attached patch clamp recordings. After inhibition by PMA in cell-attached recordings, application of PIP2 to the cytoplasmic face of excised inside-out membranes restores channel activity. PMA reduces PIP2 content in oocyte membrane and calphostin-C prevents the reduction. These results suggest that reduction of membrane PIP2 content contributes to the inhibition of ROMK1 channels by PKC. This mechanism may underscore the inhibition of K+ secretion in CCD by hormones that activate PKC.	Univ Texas, SW Med Ctr, Dept Med, Div Nephrol, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Dept Physiol, Dallas, TX 75390 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Huang, CL (corresponding author), Univ Texas, SW Med Ctr, Dept Med, Div Nephrol, Rm J5-104A,5323 Harry Hines Blvd, Dallas, TX 75390 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL051323] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK054368] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-51323] Funding Source: Medline; NIDDK NIH HHS [DK-54368] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AnkorinaStark I, 1997, CELL CALCIUM, V22, P269, DOI 10.1016/S0143-4160(97)90065-8; Baukrowitz T, 1998, SCIENCE, V282, P1141, DOI 10.1126/science.282.5391.1141; BOON AM, 1985, BIOCHEM BIOPH RES CO, V129, P431, DOI 10.1016/0006-291X(85)90169-X; Breyer MD, 2000, AM J PHYSIOL-RENAL, V279, pF12, DOI 10.1152/ajprenal.2000.279.1.F12; CASSOLA AC, 1993, AM J PHYSIOL, V264, pF502, DOI 10.1152/ajprenal.1993.264.3.F502; Fan Z, 1997, J BIOL CHEM, V272, P5388, DOI 10.1074/jbc.272.9.5388; FIGUEROA CD, 1995, J HISTOCHEM CYTOCHEM, V43, P137, DOI 10.1177/43.2.7822771; Giebisch G, 2000, ACTA PHYSIOL SCAND, V170, P153, DOI 10.1046/j.1365-201x.2000.00770.x; Guan YF, 1998, J CLIN INVEST, V102, P194, DOI 10.1172/JCI2872; HALENDA SP, 1984, BIOCHEM BIOPH RES CO, V124, P507, DOI 10.1016/0006-291X(84)91583-3; HAYS SR, 1987, J CLIN INVEST, V80, P1561, DOI 10.1172/JCI113242; HEBERT SC, 1995, KIDNEY INT, V48, P1010, DOI 10.1038/ki.1995.383; Henry P, 1996, J PHYSIOL-LONDON, V495, P681, DOI 10.1113/jphysiol.1996.sp021625; Hilgemann DW, 1996, SCIENCE, V273, P956, DOI 10.1126/science.273.5277.956; Hill JJ, 2001, J BIOL CHEM, V276, P5505, DOI 10.1074/jbc.M008213200; HO K, 1993, NATURE, V362, P31, DOI 10.1038/362031a0; Huang CL, 1998, NATURE, V391, P803, DOI 10.1038/35882; Karle CA, 2002, CIRCULATION, V106, P1493, DOI 10.1161/01.CIR.0000029747.53262.5C; Kobrinsky E, 2000, NAT CELL BIOL, V2, P507, DOI 10.1038/35019544; Leung YM, 2000, J BIOL CHEM, V275, P10182, DOI 10.1074/jbc.275.14.10182; Light PE, 2000, P NATL ACAD SCI USA, V97, P9058, DOI 10.1073/pnas.160068997; Liou HH, 1999, P NATL ACAD SCI USA, V96, P5820, DOI 10.1073/pnas.96.10.5820; MUTO S, 1991, AM J PHYSIOL, V260, pF163, DOI 10.1152/ajprenal.1991.260.2.F163; Nasuhoglu C, 2002, ANAL BIOCHEM, V301, P243, DOI 10.1006/abio.2001.5489; Nasuhoglu C, 2002, AM J PHYSIOL-CELL PH, V283, pC223, DOI 10.1152/ajpcell.00486.2001; Ooms LM, 2000, MOL CELL BIOL, V20, P9376, DOI 10.1128/MCB.20.24.9376-9390.2000; Shyng SL, 1998, SCIENCE, V282, P1138, DOI 10.1126/science.282.5391.1138; Simon DB, 1996, NAT GENET, V14, P152, DOI 10.1038/ng1096-152; STEPHENS LR, 1993, BIOCHIM BIOPHYS ACTA, V1179, P27, DOI 10.1016/0167-4889(93)90072-W; SUGIMOTO Y, 1994, AM J PHYSIOL, V266, pF823, DOI 10.1152/ajprenal.1994.266.5.F823; Sui JL, 1998, P NATL ACAD SCI USA, V95, P1307, DOI 10.1073/pnas.95.3.1307; van Tiel CM, 2000, J BIOL CHEM, V275, P21532, DOI 10.1074/jbc.M002203200; WANG WH, 1991, P NATL ACAD SCI USA, V88, P9722, DOI 10.1073/pnas.88.21.9722; WANG WH, 1994, AM J PHYSIOL-RENAL, V267, pF599, DOI 10.1152/ajprenal.1994.267.4.F599; Wei YJ, 2002, J BIOL CHEM, V277, P46586, DOI 10.1074/jbc.M206860200; Wright FS, 1992, KIDNEY PHYSL PATHOPH, P2209; Yamamoto M, 2001, J CELL BIOL, V152, P867, DOI 10.1083/jcb.152.5.867; Zeng WZ, 2002, AM J PHYSIOL-RENAL, V282, pF826, DOI 10.1152/ajprenal.00300.2001	38	58	60	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 9	2003	278	19					16852	16856		10.1074/jbc.M300619200	http://dx.doi.org/10.1074/jbc.M300619200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677QG	12615924	hybrid			2022-12-25	WOS:000182818600055
J	Propsting, MJ; Jacob, R; Naim, HY				Propsting, MJ; Jacob, R; Naim, HY			A glutamine to proline exchange at amino acid residue 1098 in sucrase causes a temperature-sensitive arrest of sucrase-isomaltase in the endoplasmic reticulum and cis-Golgi	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LACTASE-PHLORHIZIN HYDROLASE; INTRACELLULAR-TRANSPORT; QUALITY-CONTROL; ENZYME COMPLEX; DEFICIENCY; PROTEIN; GLYCOSYLATION; BIOSYNTHESIS; EXPRESSION; MUTATIONS	A striking feature of phenotype II in congenital sucrase-isomaltase deficiency is the retention of the brush border protein sucrase-isomaltase (SI) in the cis-Golgi. This transport block is the consequence of a glutamine to proline substitution at amino acid residue 1098 of the sucrase subunit. Here we provide unequivocal biochemical and confocal data to show that the SIQ/P mutant reveals characteristics of a temperature-sensitive mutant. Thus, correct folding, competent intracellular transport, and full enzymatic activity can be partially restored by expression of the mutant SIQ/P at the permissive temperature of 20degreesC instead of 37degreesC. The acquisition of normal trafficking and function appears to utilize several cycles of anterograde and retrograde steps between the endoplasmic reticulum and the Golgi implicating the molecular chaperones calnexin and heavy chain-bindinig protein. The data presented in this communication are to our knowledge the first to implicate a temperature-sensitive mutation in an intestinal enzyme deficiency or an intestinal disorder.	Tierarztlichen Hsch Hannover, Dept Physiol Chem, D-30559 Hannover, Germany	University of Veterinary Medicine Hannover, Foundation	Naim, HY (corresponding author), Tierarztlichen Hsch Hannover, Dept Physiol Chem, Bunteweg 17, D-30559 Hannover, Germany.		Jacob, Ralf/B-8163-2011					CHENG SH, 1990, CELL, V63, P827, DOI 10.1016/0092-8674(90)90148-8; DAHLQVIST A, 1968, ANAL BIOCHEM, V22, P99, DOI 10.1016/0003-2697(68)90263-7; DOMS RW, 1987, J CELL BIOL, V105, P1957, DOI 10.1083/jcb.105.5.1957; Ellgaard L, 2001, CURR OPIN CELL BIOL, V13, P431, DOI 10.1016/S0955-0674(00)00233-7; FRANSEN JAM, 1991, J CELL BIOL, V115, P45, DOI 10.1083/jcb.115.1.45; HAMMOND C, 1994, P NATL ACAD SCI USA, V91, P913, DOI 10.1073/pnas.91.3.913; HAURI HP, 1985, P NATL ACAD SCI USA, V82, P4423, DOI 10.1073/pnas.82.13.4423; HAURI HP, 1985, J CELL BIOL, V101, P838, DOI 10.1083/jcb.101.3.838; HAURI HP, 1982, J BIOL CHEM, V257, P4522; Jacob R, 2000, J BIOL CHEM, V275, P6566, DOI 10.1074/jbc.275.9.6566; JACOB R, 1995, J BIOL CHEM, V270, P18678, DOI 10.1074/jbc.270.31.18678; Jacob R, 2000, J BIOL CHEM, V275, P10630, DOI 10.1074/jbc.275.14.10630; Jacob R, 2002, J BIOL CHEM, V277, P32141, DOI 10.1074/jbc.M204116200; Jacob R, 2002, J BIOL CHEM, V277, P8217, DOI 10.1074/jbc.M111500200; Jacob R, 2001, CURR BIOL, V11, P1444, DOI 10.1016/S0960-9822(01)00446-8; JACOB R, 1994, J BIOL CHEM, V269, P2712; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Moolenaar CEC, 1997, J CELL SCI, V110, P557; NAIM HY, 1988, J CLIN INVEST, V82, P667, DOI 10.1172/JCI113646; NAIM HY, 1988, J BIOL CHEM, V263, P7242; NAIM HY, 1991, J BIOL CHEM, V266, P12313; Ouwendijk J, 1996, J CLIN INVEST, V97, P633, DOI 10.1172/JCI118459; Stein MP, 2002, TRENDS CELL BIOL, V12, P374, DOI 10.1016/S0962-8924(02)02331-0	23	16	17	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 2	2003	278	18					16310	16314		10.1074/jbc.C300093200	http://dx.doi.org/10.1074/jbc.C300093200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	675EL	12624106	hybrid			2022-12-25	WOS:000182680000108
J	Nam, Y; Weng, AP; Aster, JC; Blacklow, SC				Nam, Y; Weng, AP; Aster, JC; Blacklow, SC			Structural requirements for assembly of the CSL center dot Intracellular Notch1 center dot Mastermind-like 1 transcriptional activation complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; PROTEIN SECONDARY STRUCTURE; RBP-J-KAPPA; MELANOGASTER NOTCH RECEPTOR; DNA-BINDING PROTEIN; T-CELL LEUKEMIA; DROSOPHILA-MELANOGASTER; CRYSTAL-STRUCTURE; ANKYRIN REPEATS; HUMAN HOMOLOG	Ligand binding by Notch receptors triggers a series of proteolytic cleavages that liberate the intracellular portion of Notch (ICN) from the cell membrane, permitting it to translocate to the nucleus. Nuclear ICN binds to a highly conserved DNA-binding transcription factor called CSL ( also known as RBP-Jkappa, CBF1, Suppressor of Hairless, and Lag-1) and recruits Mastermind-like transcriptional co-activators to form a transcriptional activation complex. Using bioinformatics tools, we identified a Rel homology region (RHR) within CSL that was used as a guide to determine the minimal protein requirements for ternary complex formation. The RHR of CSL contains both the N- and C-terminal beta-sheet domains (RHR-n and RHR-c) of typical Rel transcription factors, as judged by circular dichroism spectra. Binding of monomeric CSL to DNA requires the entire RHR of CSL and an additional 125-residue N- terminal sequence, whereas binding to ICN requires only the RHR-n domain. Although the RAM (RBP-Jkappa( recombination-signal-sequence-binding protein for Jkappa genes)-associated molecule) domain of ICN is flexible and relatively unstructured as an isolated polypeptide in solution, it associates stably with CSL on DNA. Recruitment of Mastermind-like 1 (MAML1) to CSL . ICN complexes on DNA requires inclusion of the ankyrin repeat domain of ICN, and N- and C-terminal sequences of CSL extending beyond the DNA-binding region. The requirement for cooperative assembly of the MAML1 . ICN . CSL . DNA complex suggests that a primary function of ICN is to render CSL competent for MAML loading. On the basis of our results, we present a working structural model for the organization of the MAML1 . ICN . CSL . DNA complex.	Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School	Blacklow, SC (corresponding author), Brigham & Womens Hosp, Dept Pathol, 75 Francis St, Boston, MA 02115 USA.	sblacklow@rics.bwh.harvard.edu	Weng, Andrew P/I-5015-2014	Weng, Andrew/0000-0001-7394-5425; Nam, Yunsun/0000-0002-7939-8626	NATIONAL CANCER INSTITUTE [R01CA082308, R56CA092433, R01CA092433] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL061001] Funding Source: NIH RePORTER; NCI NIH HHS [CA92433, CA82308] Funding Source: Medline; NHLBI NIH HHS [HL61001] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Artavanis-Tsakonas S, 1999, SCIENCE, V284, P770, DOI 10.1126/science.284.5415.770; ARTAVANISTSAKONAS S, 1983, P NATL ACAD SCI-BIOL, V80, P1977, DOI 10.1073/pnas.80.7.1977; ASTER J, 1994, COLD SPRING HARB SYM, V59, P125, DOI 10.1101/SQB.1994.059.01.016; Aster JC, 1997, J BIOL CHEM, V272, P11336; Aster JC, 2000, MOL CELL BIOL, V20, P7505, DOI 10.1128/MCB.20.20.7505-7515.2000; Chen FE, 1998, NATURE, V391, P410, DOI 10.1038/34956; Chen L, 1998, NATURE, V392, P42, DOI 10.1038/32100; Christensen S, 1996, DEVELOPMENT, V122, P1373; CHUNG CN, 1994, NUCLEIC ACIDS RES, V22, P2938, DOI 10.1093/nar/22.15.2938; EDELHOCH H, 1967, BIOCHEMISTRY-US, V6, P1948, DOI 10.1021/bi00859a010; Fischer D, 1999, PROTEINS, P209; FORTINI ME, 1994, CELL, V79, P273, DOI 10.1016/0092-8674(94)90196-1; Fryer CJ, 2002, GENE DEV, V16, P1397, DOI 10.1101/gad.991602; GHOSH G, 1995, NATURE, V373, P303, DOI 10.1038/373303a0; Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225; Hsieh JJD, 1999, P NATL ACAD SCI USA, V96, P23, DOI 10.1073/pnas.96.1.23; Hsieh JJD, 1996, MOL CELL BIOL, V16, P952; Huxford T, 1998, CELL, V95, P759, DOI 10.1016/S0092-8674(00)81699-2; JARRIAULT S, 1995, NATURE, V377, P355, DOI 10.1038/377355a0; Jeffries S, 2002, MOL CELL BIOL, V22, P3927, DOI 10.1128/MCB.22.11.3927-3941.2002; Kao HY, 1998, GENE DEV, V12, P2269, DOI 10.1101/gad.12.15.2269; Kato H, 1997, DEVELOPMENT, V124, P4133; Kelley LA, 2000, J MOL BIOL, V299, P499, DOI 10.1006/jmbi.2000.3741; Laue T.M., 1992, ANAL ULTRACENTRIFUGA, P90; Michel F, 2001, EMBO J, V20, P6180, DOI 10.1093/emboj/20.22.6180; Minoguchi S, 1997, MOL CELL BIOL, V17, P2679, DOI 10.1128/MCB.17.5.2679; MULLER CW, 1995, NATURE, V373, P311, DOI 10.1038/373311a0; Nam Y, 2002, CURR OPIN CHEM BIOL, V6, P501, DOI 10.1016/S1367-5931(02)00346-0; Petcherski AG, 2000, NATURE, V405, P364, DOI 10.1038/35012645; Petcherski AG, 2000, CURR BIOL, V10, pR471, DOI 10.1016/S0960-9822(00)00577-7; ROST B, 1994, PROTEINS, V19, P55, DOI 10.1002/prot.340190108; ROST B, 1993, J MOL BIOL, V232, P584, DOI 10.1006/jmbi.1993.1413; SCHWEISGUTH F, 1992, CELL, V69, P1199, DOI 10.1016/0092-8674(92)90641-O; Sreerama N, 2000, ANAL BIOCHEM, V287, P252, DOI 10.1006/abio.2000.4880; Stroud JC, 2002, NAT STRUCT BIOL, V9, P90, DOI 10.1038/nsb749; Taniguchi Y, 1998, MOL CELL BIOL, V18, P644, DOI 10.1128/MCB.18.1.644; TUN T, 1994, NUCLEIC ACIDS RES, V22, P965, DOI 10.1093/nar/22.6.965; Wallberg AE, 2002, MOL CELL BIOL, V22, P7812, DOI 10.1128/MCB.22.22.7812-7819.2002; Weng AP, 2003, MOL CELL BIOL, V23, P655, DOI 10.1128/MCB.23.2.655-664.2003; Wu LZ, 2000, NAT GENET, V26, P484, DOI 10.1038/82644; YEDVOBNICK B, 1988, GENETICS, V118, P483; Zweifel ME, 2001, BIOCHEMISTRY-US, V40, P14344, DOI 10.1021/bi011435h; Zweifel ME, 2001, BIOCHEMISTRY-US, V40, P14357, DOI 10.1021/bi011436+	43	157	183	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 6	2003	278	23					21232	21239		10.1074/jbc.M301567200	http://dx.doi.org/10.1074/jbc.M301567200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	684WY	12644465	hybrid			2022-12-25	WOS:000183230500101
J	Kumar, A; Knox, AJ; Boriek, AM				Kumar, A; Knox, AJ; Boriek, AM			CCAAT/enhancer-binding protein and activator protein-1 transcription factors regulate the expression of interleukin-8 through the mitogen-activated protein kinase pathways in response to mechanical stretch of human airway smooth muscle cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; NECROSIS-FACTOR-ALPHA; INDUCED CARDIOMYOCYTE HYPERTROPHY; SIGNAL-TRANSDUCTION PATHWAYS; INTESTINAL EPITHELIAL-CELLS; ENDOTHELIAL GROWTH-FACTOR; GENE-EXPRESSION; COOPERATIVE INTERACTION; INFLAMMATORY CYTOKINES; TYROSINE KINASES	Here we investigated the mechanisms by which mechanical stretch regulates the production of IL-8 in primary human airway smooth muscle cells (HASMC). Bronchial HASMC were subjected to cyclic mechanical stretch (12%, 1 Hz) using the computer-controlled Flex-cell Strain system. Mechanical stretch increased IL-8 mRNA expression and protein production. Cyclic stretch of HASMC also increased the kinase activities of ERK1/2, JNK1, p38, and the DNA binding activities of AP-1 and C/EBP transcription factors with little effect on NF-kappaB. The inhibition of AP-1 and C/EBP transcriptional activities blocked the production of IL-8 in culture supernatants. Furthermore, the inhibition of ERK1/2 and p38 but not JNK1 caused a significant downregulation in the expression and production of IL-8 in response to cyclic stretch. Although protein tyrosine kinases were required for the activation of both ERK1/2 and p38 kinase, stretch-activated channels, small GTPase proteins, and extracellular Ca2+ influx were required only for the activation of p38 kinase whereas phosphoinositide 3-kinase was needed for ERK1/2 activation. In addition, the phosphorylation of ERK1/2 was essential for the activation of AP-1 whereas p38 MAP kinase was needed for the activation of C/EBP. Our data demonstrate that the cyclic stretch of HASMC causes the increased production of IL-8 by activating the AP-1 and C/EBP transcription factors through the activation of ERK1/2 and p38 kinase signaling pathways.	Baylor Coll Med, Dept Med, Houston, TX 77030 USA; Univ Nottingham, City Hosp, Div Resp Med, Nottingham NG7 2RD, England	Baylor College of Medicine; Nottingham University Hospital NHS Trust; Nottingham City Hospital; University of Nottingham	Boriek, AM (corresponding author), Baylor Coll Med, Dept Med, Suite 520B,1 Baylor Plaza, Houston, TX 77030 USA.	boriek@bcm.tmc.edu		Knox, Alan/0000-0002-5906-4143; Kumar, Ashok/0000-0001-8571-2848; Kumar, Ashok/0000-0002-2444-9529	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL063134] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-63134] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Aaronson DS, 2002, SCIENCE, V296, P1653, DOI 10.1126/science.1071545; Ahn JD, 2002, CIRC RES, V90, P1325, DOI 10.1161/01.RES.0000023200.19316.D5; Alcorn MJ, 2001, J VIROL, V75, P6450, DOI 10.1128/JVI.75.14.6450-6459.2001; Ameixa C, 2002, INFECT IMMUN, V70, P4743, DOI 10.1128/IAI.70.8.4743-4746.2002; Cattaruzza M, 2001, J BIOL CHEM, V276, P36999, DOI 10.1074/jbc.M105158200; Chang LF, 2001, NATURE, V410, P37, DOI 10.1038/35065000; Chen KD, 1999, J BIOL CHEM, V274, P18393, DOI 10.1074/jbc.274.26.18393; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; Eftmova T, 2002, J BIOL CHEM, V277, P31753, DOI 10.1074/jbc.M205098200; Furuichi S, 2002, RESPIROLOGY, V7, P193, DOI 10.1046/j.1440-1843.2002.00401.x; Gao HW, 2002, J BIOL CHEM, V277, P38827, DOI 10.1074/jbc.M206224200; Gillespie PG, 2001, NATURE, V413, P194, DOI 10.1038/35093011; Hamill OP, 2001, PHYSIOL REV, V81, P685, DOI 10.1152/physrev.2001.81.2.685; Harant H, 1996, J BIOL CHEM, V271, P26954, DOI 10.1074/jbc.271.43.26954; Harris VK, 2001, ONCOGENE, V20, P1730, DOI 10.1038/sj.onc.1204249; Hedges JC, 2000, AM J RESP CELL MOL, V23, P86, DOI 10.1165/ajrcmb.23.1.4014; Hipp MS, 2002, EUR J IMMUNOL, V32, P2208, DOI 10.1002/1521-4141(200208)32:8<2208::AID-IMMU2208>3.0.CO;2-2; Holtmann H, 1999, MOL CELL BIOL, V19, P6742; Ikeda M, 1999, BIOCHEM BIOPH RES CO, V257, P668, DOI 10.1006/bbrc.1999.0532; Ingber DE, 1998, BIOL BULL-US, V194, P323, DOI 10.2307/1543102; Inoh H, 2002, FASEB J, V16, P405, DOI 10.1096/fj.01-0354fje; Jijon HB, 2002, AM J PHYSIOL-CELL PH, V283, pC31, DOI 10.1152/ajpcell.00113.2001; JUST I, 1995, J BIOL CHEM, V270, P13932, DOI 10.1074/jbc.270.23.13932; Karin M, 2001, BIOFACTORS, V15, P87, DOI 10.1002/biof.5520150207; Karin M, 1998, ANN NY ACAD SCI, V851, P139, DOI 10.1111/j.1749-6632.1998.tb08987.x; Katso R, 2001, ANNU REV CELL DEV BI, V17, P615, DOI 10.1146/annurev.cellbio.17.1.615; Kawano Yoji, 2002, Nagoya J Med Sci, V65, P1; Knox AJ, 2001, FASEB J, V15, P2480, DOI 10.1096/fj.01-0256com; Knox AJ, 2000, CLIN EXP ALLERGY, V30, P606; Ko KS, 2001, BIOCHEM BIOPH RES CO, V285, P1077, DOI 10.1006/bbrc.2001.5177; Kumar A, 2003, FASEB J, V17, P386, DOI 10.1096/fj.02-0542com; Kumar A, 2002, J BIOL CHEM, V277, P46493, DOI 10.1074/jbc.M203654200; Kumar A, 1998, J IMMUNOL, V161, P776; KUNSCH C, 1993, MOL CELL BIOL, V13, P6137, DOI 10.1128/MCB.13.10.6137; Lee LF, 1997, MOL CELL BIOL, V17, P5097, DOI 10.1128/MCB.17.9.5097; Lew AM, 1999, BIOCHEM J, V341, P647, DOI 10.1042/0264-6021:3410647; Li CH, 2000, CELL SIGNAL, V12, P435, DOI 10.1016/S0898-6568(00)00096-6; Li J, 2002, AM J PHYSIOL-LUNG C, V283, pL690, DOI 10.1152/ajplung.00060.2002; Lopez-Ilasaca M, 1998, BIOCHEM PHARMACOL, V56, P269, DOI 10.1016/S0006-2952(98)00059-8; Malek AM, 1995, J BIOMECH, V28, P1515, DOI 10.1016/0021-9290(95)00099-2; Mastronarde JG, 1998, J INFECT DIS, V177, P1275, DOI 10.1086/515279; MATSUSAKA T, 1993, P NATL ACAD SCI USA, V90, P10193, DOI 10.1073/pnas.90.21.10193; Mayr M, 2002, FASEB J, V16, P1423, DOI 10.1096/fj.02-0042fje; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; Minden A., 1997, BIOCHIM BIOPHYS ACTA, V1333, P85, DOI DOI 10.1016/S0304-419X(97)00018-8; Miyauchi A, 2000, J BIOL CHEM, V275, P3335, DOI 10.1074/jbc.275.5.3335; MUKAIDA N, 1994, J BIOL CHEM, V269, P13289; MUKAIDA N, 1990, J BIOL CHEM, V265, P21128; MUKAIDA N, 1994, J LEUKOCYTE BIOL, V56, P554, DOI 10.1002/jlb.56.5.554; Murayama T, 1997, J VIROL, V71, P5692, DOI 10.1128/JVI.71.7.5692-5695.1997; Na YJ, 2001, INT IMMUNOPHARMACOL, V1, P1877, DOI 10.1016/S1567-5769(01)00113-8; Nemeth ZH, 2002, AM J PATHOL, V161, P987, DOI 10.1016/S0002-9440(10)64259-9; Osawa Y, 2002, INFECT IMMUN, V70, P6294, DOI 10.1128/IAI.70.11.6294-6301.2002; Oudin S, 2002, AM J RESP CELL MOL, V27, P107, DOI 10.1165/ajrcmb.27.1.4766; Pang LH, 1998, J IMMUNOL, V161, P2509; Pang LH, 1997, BRIT J PHARMACOL, V121, P579, DOI 10.1038/sj.bjp.0701152; Pelham RJ, 1997, P NATL ACAD SCI USA, V94, P13661, DOI 10.1073/pnas.94.25.13661; Peyssonnaux C, 2001, BIOL CELL, V93, P53, DOI 10.1016/S0248-4900(01)01125-X; Refsnes M, 2001, TOXICOLOGY, V167, P145, DOI 10.1016/S0300-483X(01)00448-6; Ruoslahti E, 1997, SCIENCE, V276, P1345, DOI 10.1126/science.276.5317.1345; Ruwhof C, 2000, CARDIOVASC RES, V47, P23, DOI 10.1016/S0008-6363(00)00076-6; SADOSHIMA J, 1992, P NATL ACAD SCI USA, V89, P9905, DOI 10.1073/pnas.89.20.9905; Seow CY, 1998, AM J RESP CRIT CARE, V158, pS179, DOI 10.1164/ajrccm.158.supplement_2.13tac160; Smith PG, 1997, EXP CELL RES, V232, P127, DOI 10.1006/excr.1997.3492; Smith PG, 1998, EXP CELL RES, V239, P353, DOI 10.1006/excr.1997.3905; STEIN B, 1993, MOL CELL BIOL, V13, P7191, DOI 10.1128/MCB.13.11.7191; Strieter RM, 2002, AM J PHYSIOL-LUNG C, V283, pL688, DOI 10.1152/ajplung.00146.2002; Stull JT, 2001, J BIOL CHEM, V276, P2311, DOI 10.1074/jbc.R000030200; Suzuma I, 2002, J BIOL CHEM, V277, P1047, DOI 10.1074/jbc.M105336200; Toker A, 2000, MOL PHARMACOL, V57, P652, DOI 10.1124/mol.57.4.652; VANDENBURGH HH, 1982, J BIOL CHEM, V257, P13448; Wang HB, 2001, P NATL ACAD SCI USA, V98, P11295, DOI 10.1073/pnas.201201198; WANG N, 1993, SCIENCE, V260, P1124, DOI 10.1126/science.7684161; WATSON PA, 1991, FASEB J, V5, P2013, DOI 10.1096/fasebj.5.7.1707019; Wettschureck N, 2002, J MOL MED, V80, P629, DOI 10.1007/s00109-002-0370-2; Whitmarsh AJ, 1996, J MOL MED-JMM, V74, P589, DOI 10.1007/s001090050063; Wisdom R, 1999, EXP CELL RES, V253, P180, DOI 10.1006/excr.1999.4685; Yamazaki T, 1996, J BIOL CHEM, V271, P3221, DOI 10.1074/jbc.271.6.3221; Yamazaki T, 1998, CIRC RES, V82, P430, DOI 10.1161/01.RES.82.4.430; YASUMOTO K, 1992, J BIOL CHEM, V267, P22506	80	69	73	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 23	2003	278	21					18868	18876		10.1074/jbc.M212777200	http://dx.doi.org/10.1074/jbc.M212777200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	679PY	12637525	hybrid			2022-12-25	WOS:000182932200022
J	Xiao, KY; Allison, DF; Kottke, MD; Summers, S; Sorescu, GP; Faundez, V; Kowalczyk, AP				Xiao, KY; Allison, DF; Kottke, MD; Summers, S; Sorescu, GP; Faundez, V; Kowalczyk, AP			Mechanisms of VE-cadherin processing and degradation in microvascular endothelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-HORMONE RECEPTOR; DESMOPLAKIN-CONTAINING JUNCTIONS; PROTEIN-KINASE-C; BETA-CATENIN; IN-VITRO; COMPLEXUS ADHAERENTES; CYTOPLASMIC DOMAIN; BARRIER FUNCTION; P120 CATENIN; N-CADHERIN	VE-cadherin is an endothelial-specific cadherin that plays important roles in vascular morphogenesis and growth control. To investigate the mechanisms by which endothelial cells regulate cadherin cell surface levels, a VE-cadherin mutant containing the non-adhesive interleukin-2 (IL-2) receptor extracellular domain and the VE-cadherin cytoplasmic tail (IL-2R-VE-cad(cyto)) was expressed in microvascular endothelial cells. Expression of the IL-2R-VE-cad(cyto) mutant resulted in the internalization of endogenous VE-cadherin and in a dramatic decrease in endogenous VE-cadherin levels. The internalized VE-cadherin co-localized with early endosomes, and the lysosomal inhibitor chloroquine dramatically inhibited the down-regulation of VE-cadherin in cells expressing the IL-2R-VE-cad(cyto) mutant. Chloroquine treatment also resulted in the accumulation of a VE-cadherin fragment lacking the beta-catenin binding domain of the VE-cadherin cytoplasmic tail. The formation of the VE-cadherin fragment could be prevented by treating endothelial cells with proteasome inhibitors. Furthermore, inhibition of the proteasome prevented VE-cadherin internalization and inhibited the disruption of endothelial intercellular junctions by the IL-2RVEcad(cyto) mutant. These results provide new insights into the mechanisms of VE-cadherin processing and degradation in microvascular endothelial cells.	Emory Univ, Sch Med, Dept Dermatol, Atlanta, GA 30322 USA; Emory Univ, Sch Med, Dept Cell Biol, Atlanta, GA 30322 USA; Emory Univ, Sch Med, Emory Skin Dis Res Ctr, Atlanta, GA 30322 USA	Emory University; Emory University; Emory University	Kowalczyk, AP (corresponding author), Emory Univ, Sch Med, Dept Dermatol, Woodruff Mem Bldg,Rm 5007, Atlanta, GA 30322 USA.			Faundez, Victor/0000-0002-2114-5271	NIAMS NIH HHS [R01 AR048266, P30AR042687] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR048266, P30AR042687] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ABERLE H, 1994, J CELL SCI, V107, P3655; Alexander JS, 1998, INFLAMMATION, V22, P419, DOI 10.1023/A:1022325017013; AMAGAI M, 1995, J INVEST DERMATOL, V104, P27, DOI 10.1111/1523-1747.ep12613462; Anastasiadis PZ, 2000, NAT CELL BIOL, V2, P637, DOI 10.1038/35023588; Angst BD, 2001, J CELL SCI, V114, P629; Bazzoni G, 2001, MICROCIRCULATION, V8, P143, DOI 10.1038/sj.mn.7800084; Benelli R, 1999, INT J BIOL MARKER, V14, P243, DOI 10.1177/172460089901400408; Bobryshev YV, 1999, CARDIOVASC RES, V43, P1003, DOI 10.1016/S0008-6363(99)00125-X; BREVIARIO F, 1995, ARTERIOSCL THROM VAS, V15, P1229, DOI 10.1161/01.ATV.15.8.1229; Chen YT, 1999, J CELL BIOL, V144, P687, DOI 10.1083/jcb.144.4.687; Christofori G, 1999, TRENDS BIOCHEM SCI, V24, P73, DOI 10.1016/S0968-0004(98)01343-7; Corada M, 2001, BLOOD, V97, P1679, DOI 10.1182/blood.V97.6.1679; Dejana E, 2001, THROMB HAEMOSTASIS, V86, P308; Frid MG, 2002, CIRC RES, V90, P1189, DOI 10.1161/01.RES.0000021432.70309.28; FUJIMORI T, 1993, MOL BIOL CELL, V4, P37, DOI 10.1091/mbc.4.1.37; Fujita Y, 2002, NAT CELL BIOL, V4, P222, DOI 10.1038/ncb758; Gottardi CJ, 2001, CURR BIOL, V11, pR792, DOI 10.1016/S0960-9822(01)00473-0; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; Herren B, 1998, MOL BIOL CELL, V9, P1589, DOI 10.1091/mbc.9.6.1589; Hicke L, 2001, NAT REV MOL CELL BIO, V2, P195, DOI 10.1038/35056583; Huber AH, 2001, J BIOL CHEM, V276, P12301, DOI 10.1074/jbc.M010377200; JOU TS, 1995, P NATL ACAD SCI USA, V92, P5067, DOI 10.1073/pnas.92.11.5067; Kevil CG, 2001, AM J PHYSIOL-CELL PH, V281, pC1940, DOI 10.1152/ajpcell.2001.281.6.C1940; KINTNER C, 1992, CELL, V69, P225, DOI 10.1016/0092-8674(92)90404-Z; KNUDSEN KA, 1992, J CELL BIOL, V118, P671, DOI 10.1083/jcb.118.3.671; KNUDSEN KA, 1995, J CELL BIOL, V130, P67, DOI 10.1083/jcb.130.1.67; Kowalczyk AP, 1998, J CELL SCI, V111, P3045; LAFLAMME SE, 1994, J CELL BIOL, V126, P1287, DOI 10.1083/jcb.126.5.1287; Le TL, 2002, AM J PHYSIOL-CELL PH, V283, pC489, DOI 10.1152/ajpcell.00566.2001; Le TL, 1999, J CELL BIOL, V146, P219, DOI 10.1083/jcb.146.1.219; Marambaud P, 2002, EMBO J, V21, P1948, DOI 10.1093/emboj/21.8.1948; Miller JR, 1997, DEV BIOL, V192, P323, DOI 10.1006/dbio.1997.8740; Navarro P, 1995, J BIOL CHEM, V270, P30965, DOI 10.1074/jbc.270.52.30965; Nieman MT, 1999, J CELL SCI, V112, P1621; Noren NK, 2000, J CELL BIOL, V150, P567, DOI 10.1083/jcb.150.3.567; Norvell SM, 1998, J CELL SCI, V111, P1305; Pham CG, 2000, AM J PHYSIOL-HEART C, V279, pH2916, DOI 10.1152/ajpheart.2000.279.6.H2916; SCHMELZ M, 1994, DIFFERENTIATION, V57, P97, DOI 10.1046/j.1432-0436.1994.5720097.x; SCHMELZ M, 1993, EUR J CELL BIOL, V61, P274; Steinhusen U, 2001, J BIOL CHEM, V276, P4972, DOI 10.1074/jbc.M006102200; Stevens T, 2000, AM J PHYSIOL-LUNG C, V279, pL419, DOI 10.1152/ajplung.2000.279.3.L419; Strous GJ, 1996, EMBO J, V15, P3806, DOI 10.1002/j.1460-2075.1996.tb00754.x; Swaminathan S, 1999, MOL BIOL CELL, V10, P2583, DOI 10.1091/mbc.10.8.2583; Thoreson MA, 2000, J CELL BIOL, V148, P189, DOI 10.1083/jcb.148.1.189; Troxell ML, 1999, AM J PHYSIOL-CELL PH, V276, pC404, DOI 10.1152/ajpcell.1999.276.2.C404; Valiron O, 1996, J CELL SCI, V109, P2141; van Kerkhof P, 2000, J BIOL CHEM, V275, P1575, DOI 10.1074/jbc.275.3.1575; van Kerkhof P, 2001, BIOCHEM SOC T, V29, P488, DOI 10.1042/BST0290488; Venkiteswaran K, 2002, AM J PHYSIOL-CELL PH, V283, pC811, DOI 10.1152/ajpcell.00417.2001; Zhu AJ, 1996, J CELL SCI, V109, P3013	50	122	123	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 23	2003	278	21					19199	19208		10.1074/jbc.M211746200	http://dx.doi.org/10.1074/jbc.M211746200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	679PY	12626512	hybrid			2022-12-25	WOS:000182932200064
J	Angermayr, M; Oechsner, U; Bandlow, W				Angermayr, M; Oechsner, U; Bandlow, W			Reb1p-dependent DNA bending effects nucleosome positioning and constitutive transcription at the yeast profilin promoter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIN-BINDING PROTEINS; RNA-POLYMERASE-I; SACCHAROMYCES-CEREVISIAE; CHROMATIN STRUCTURE; PHOSPHATIDYLINOSITOL 4,5-BISPHOSPHATE; GENE; REB1P; SITE; SEQUENCE; ACTIVATION	The molecular basis of constitutive gene activation is largely unknown. The yeast profilin gene (PFY1), encoding a housekeeping component of the actin cytoskeleton, is constitutively transcribed at a moderate level. The PFY1 promoter dispenses with classical transactivators and a consensus TATA box; however, it contains a canonic site for the abundant multifunctional nuclear factor rDNA enhancer-binding protein (Reb1p) combined with a dA.dT element. Reb1p binds specifically in vitro. Mutation of this site reduces PFY1 expression to about 35%. A nucleosome-free gap of about 190 bp is centered at the genomic Reb1p binding site in vivo and spans the presumptive core promoter and transcriptional initiation sites. Nucleosomes at the border of the gap are positioned. Mutation of the Reb1p motif in the genomic PFY1 promoter abolishes nucleosome positioning, fills the gap with a non-positioned nucleosome, and reduces transcription by a factor of 3. From permutation studies we conclude that Reb1p induces a strong bend into the DNA. Phasing analyses indicate that it is directed toward the major groove. The data suggest that Reb1p plays an architectural role on DNA and that Reb1p-dependent DNA bending leads to a DNA conformation that is incompatible with packaging into nucleosomes and concomitantly facilitates constitutive transcription. In the absence of other transcription activators, Reb1p excludes nucleosomes and moderately stimulates transcription by distorting DNA.	Univ Munich, Bereich genet, Dept Biol 1, D-80638 Munich, Germany	University of Munich	Angermayr, M (corresponding author), Univ Munich, Bereich genet, Dept Biol 1, Maria Ward Str 1A, D-80638 Munich, Germany.							ACHSTETTER T, 1984, J BIOL CHEM, V259, P3344; ALMER A, 1986, EMBO J, V5, P2681, DOI 10.1002/j.1460-2075.1986.tb04551.x; Angermayr M, 2003, J BIOL CHEM, V278, P11026, DOI 10.1074/jbc.M210932200; Angermayr M, 1997, MOL GEN GENET, V256, P682, DOI 10.1007/s004380050616; Angermayr M, 2002, NUCLEIC ACIDS RES, V30, P4199, DOI 10.1093/nar/gkf551; Angermayr M, 1997, J BIOL CHEM, V272, P31630, DOI 10.1074/jbc.272.50.31630; ARCHER TK, 1991, MOL CELL BIOL, V11, P688, DOI 10.1128/MCB.11.2.688; BOEKE JD, 1984, MOL GEN GENET, V197, P345, DOI 10.1007/BF00330984; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CARLSSON L, 1976, J MOL BIOL, V105, P353, DOI 10.1016/0022-2836(76)90098-X; CAVALLI G, 1993, EMBO J, V12, P4603, DOI 10.1002/j.1460-2075.1993.tb06149.x; CHASMAN DI, 1990, GENE DEV, V4, P503, DOI 10.1101/gad.4.4.503; CRIVELLONE MD, 1988, J BIOL CHEM, V263, P14323; DURRIN LK, 1992, MOL CELL BIOL, V12, P1621, DOI 10.1128/MCB.12.4.1621; Erkine AM, 1996, MOL CELL BIOL, V16, P7004; FASCHER KD, 1990, EMBO J, V9, P2523, DOI 10.1002/j.1460-2075.1990.tb07432.x; FEDOR MJ, 1988, J MOL BIOL, V204, P109, DOI 10.1016/0022-2836(88)90603-1; GARTENBERG MR, 1990, P NATL ACAD SCI USA, V87, P6034, DOI 10.1073/pnas.87.16.6034; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; GILSON E, 1993, J MOL BIOL, V231, P293, DOI 10.1006/jmbi.1993.1283; GOLDSCHMIDTCLERMONT PJ, 1991, CELL, V66, P419, DOI 10.1016/0092-8674(81)90002-7; GOLDSCHMIDTCLERMONT PJ, 1990, SCIENCE, V247, P1575, DOI 10.1126/science.2157283; GRAHAM IR, 1994, MOL MICROBIOL, V12, P931, DOI 10.1111/j.1365-2958.1994.tb01081.x; GUARENTE L, 1983, METHOD ENZYMOL, V101, P181; HAARER BK, 1990, J CELL BIOL, V110, P105, DOI 10.1083/jcb.110.1.105; HAN M, 1988, CELL, V55, P1137, DOI 10.1016/0092-8674(88)90258-9; HARTWIG JH, 1989, J CELL BIOL, V109, P1571, DOI 10.1083/jcb.109.4.1571; Hartwig JH, 1991, CURR OPIN CELL BIOL, V3, P87, DOI 10.1016/0955-0674(91)90170-4; HERMANN H, 1992, GENE, V119, P137, DOI 10.1016/0378-1119(92)90079-5; HORIKOSHI M, 1992, P NATL ACAD SCI USA, V89, P1060, DOI 10.1073/pnas.89.3.1060; IYER V, 1995, EMBO J, V14, P2570, DOI 10.1002/j.1460-2075.1995.tb07255.x; KERPPOLA TK, 1993, MOL CELL BIOL, V13, P5479, DOI 10.1128/MCB.13.9.5479; KIM YC, 1993, NATURE, V365, P512, DOI 10.1038/365512a0; KOO HS, 1986, NATURE, V320, P501, DOI 10.1038/320501a0; KOO HS, 1988, P NATL ACAD SCI USA, V85, P1763, DOI 10.1073/pnas.85.6.1763; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LANG WH, 1993, MOL CELL BIOL, V13, P649, DOI 10.1128/MCB.13.1.649; LANG WH, 1995, P NATL ACAD SCI USA, V92, P9781, DOI 10.1073/pnas.92.21.9781; LASSING I, 1988, J CELL BIOCHEM, V37, P255, DOI 10.1002/jcb.240370302; LASSING I, 1985, NATURE, V314, P472, DOI 10.1038/314472a0; LOHR D, 1995, J BIOL CHEM, V270, P27671, DOI 10.1074/jbc.270.46.27671; LOHR D, 1985, NUCLEIC ACIDS RES, V13, P8409, DOI 10.1093/nar/13.23.8409; MAGDOLEN V, 1993, FEBS LETT, V316, P41, DOI 10.1016/0014-5793(93)81733-G; MAGDOLEN V, 1990, GENE, V90, P105, DOI 10.1016/0378-1119(90)90445-W; MAGDOLEN V, 1994, BBA-GENE STRUCT EXPR, V1218, P205, DOI 10.1016/0167-4781(94)90013-2; MAGDOLEN V, 1988, MOL CELL BIOL, V8, P5108, DOI 10.1128/MCB.8.12.5108; Maniatis T., 1982, MOL CLONING LAB MANU; MCBROOM LDB, 1994, J BIOL CHEM, V269, P16461; McLean M, 1995, MOL MICROBIOL, V18, P605, DOI 10.1111/j.1365-2958.1995.mmi_18040605.x; Moreira JMA, 2002, J BIOL CHEM, V277, P3202, DOI 10.1074/jbc.M108962200; MORROW BE, 1989, J BIOL CHEM, V264, P9061; MORROW BE, 1993, MOL CELL BIOL, V13, P1173, DOI 10.1128/MCB.13.2.1173; NIEDENTHAL RK, 1993, NUCLEIC ACIDS RES, V21, P4726, DOI 10.1093/nar/21.20.4726; Oechsner U, 1998, MOL GEN GENET, V260, P417, DOI 10.1007/s004380050912; Packham EA, 1996, MOL GEN GENET, V250, P348; PARVIN JD, 1995, NATURE, V373, P724, DOI 10.1038/373724a0; PINA B, 1990, J MOL BIOL, V216, P975, DOI 10.1016/S0022-2836(99)80015-1; POLLARD TD, 1986, ANNU REV BIOCHEM, V55, P987, DOI 10.1146/annurev.bi.55.070186.005011; Reagan MS, 1998, MOL GEN GENET, V259, P142, DOI 10.1007/s004380050799; REICHSTEIN E, 1979, J BIOL CHEM, V254, P6174; REMACLE JE, 1992, MOL CELL BIOL, V12, P5516, DOI 10.1128/MCB.12.12.5516; SCOTT EW, 1993, MOL CELL BIOL, V13, P543, DOI 10.1128/MCB.13.1.543; Sherman F., 1986, METHODS YEAST GENETI; STARR DB, 1995, J MOL BIOL, V250, P434; STOSSEL TP, 1985, ANNU REV CELL BIOL, V1, P353, DOI 10.1146/annurev.cb.01.110185.002033; STRAKA C, 1991, EMBO J, V10, P361, DOI 10.1002/j.1460-2075.1991.tb07957.x; STRUHL K, 1985, P NATL ACAD SCI USA, V82, P8419, DOI 10.1073/pnas.82.24.8419; STRUHL K, 1987, CELL, V49, P295, DOI 10.1016/0092-8674(87)90277-7; Svaren J, 1997, TRENDS BIOCHEM SCI, V22, P93, DOI 10.1016/S0968-0004(97)01001-3; Tanaka S, 1996, J MOL BIOL, V257, P919, DOI 10.1006/jmbi.1996.0212; TANAKA S, 1992, EMBO J, V11, P1187, DOI 10.1002/j.1460-2075.1992.tb05159.x; Thoma F, 1996, METHOD ENZYMOL, V274, P197; THOMPSON JF, 1988, NUCLEIC ACIDS RES, V16, P9687, DOI 10.1093/nar/16.20.9687; TRAVERS AA, 1990, CELL, V60, P177, DOI 10.1016/0092-8674(90)90729-X; VIGNAIS ML, 1989, J BIOL CHEM, V264, P8463; VOJTEK A, 1991, CELL, V66, P497, DOI 10.1016/0092-8674(81)90013-1; WAY M, 1990, NATURE, V344, P292, DOI 10.1038/344292a0; WEEDS A, 1982, NATURE, V296, P811, DOI 10.1038/296811a0; WU HM, 1984, NATURE, V308, P509, DOI 10.1038/308509a0; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9; ZINKEL SS, 1987, NATURE, V328, P178, DOI 10.1038/328178a0	81	27	27	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 16	2003	278	20					17918	17926		10.1074/jbc.M301806200	http://dx.doi.org/10.1074/jbc.M301806200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677YX	12637580	hybrid			2022-12-25	WOS:000182838300042
J	Buch-Pedersen, MJ; Palmgren, MG				Buch-Pedersen, MJ; Palmgren, MG			Conserved Asp(684) in transmembrane segment M6 of the plant plasma membrane P-type proton pump AHA2 is a molecular determinant of proton translocation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; H+-ATPASE; SARCOPLASMIC-RETICULUM; ALPHA-SUBUNIT; COORDINATING RESIDUES; RENAL NA,K-ATPASE; CALCIUM-PUMP; K+ IONS; BACTERIORHODOPSIN; TRANSPORT	The mechanism of proton pumping by P-type H+-ATPases is still unclear. In the plant P-type plasma membrane H+-ATPase AHA2, two charged residues, Arg(655) and Asp(684), are conserved in transmembrane segments M5 and M6, respectively, a region that has been shown be contribute to ion coordination in related P-type ATPases. Substitution of Arg(655) with either alanine or aspartate resulted in mutant enzymes exhibiting a significant shift in the P-type ATPase E1P-E2P conformational equilibrium. The mutant proteins accumulated in the E1P conformation, but were capable of conducting proton transport. This points to an important role of Arg(655) in the E1P-E2P conformational transition. The presence of a carboxylate moiety at position Asp(684) proved essential for coupling between initial proton binding and proton pumping. The finding that the carboxylate side chain of Asp(684) contributes to the proton-binding site and appears to function as an absolutely essential proton acceptor along the proton transport pathway is discussed in the context of a possible proton pumping mechanism of P-type H+-ATPases.	Royal Vet & Agr Univ, Dept Plant Biol, DK-1871 Frederiksberg C, Denmark; Univ Paris 06, CNRS, F-75252 Paris, France	University of Copenhagen; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Sorbonne Universite	Palmgren, MG (corresponding author), Royal Vet & Agr Univ, Dept Plant Biol, Thorvaldsensvej 40, DK-1871 Frederiksberg C, Denmark.	palmgren@biobase.dk	Palmgren, Michael/A-9808-2013	Palmgren, Michael/0000-0002-9982-6114				Auer M, 1998, NATURE, V392, P840, DOI 10.1038/33967; Axelsen KB, 1999, BIOCHEMISTRY-US, V38, P7227, DOI 10.1021/bi982482l; Axelsen KB, 1998, J MOL EVOL, V46, P84, DOI 10.1007/PL00006286; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRISKIN DP, 1992, J EXP BOT, V43, P269, DOI 10.1093/jxb/43.3.269; Buch-Pedersen MJ, 2000, J BIOL CHEM, V275, P39167, DOI 10.1074/jbc.M007537200; Bukrinsky JT, 2001, FEBS LETT, V494, P6, DOI 10.1016/S0014-5793(01)02301-8; CID A, 1987, CURR GENET, V12, P105, DOI 10.1007/BF00434664; CLARKE DM, 1990, J BIOL CHEM, V265, P6262; CLARKE DM, 1989, NATURE, V339, P476, DOI 10.1038/339476a0; Fillingame RH, 2000, J EXP BIOL, V203, P9; FLING SP, 1986, ANAL BIOCHEM, V155, P83, DOI 10.1016/0003-2697(86)90228-9; Gatto C, 1999, J BIOL CHEM, V274, P13737, DOI 10.1074/jbc.274.20.13737; Govindjee R, 1996, BIOPHYS J, V71, P1011, DOI 10.1016/S0006-3495(96)79302-5; Gupta SK, 1998, J BIOL CHEM, V273, P4282, DOI 10.1074/jbc.273.7.4282; HILL JE, 1986, YEAST, V2, P163, DOI 10.1002/yea.320020304; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; JEWELLMOTZ EA, 1993, BIOCHEMISTRY-US, V32, P13523, DOI 10.1021/bi00212a018; JORGENSEN PL, 1988, J MEMBRANE BIOL, V103, P95, DOI 10.1007/BF01870942; Kaplan JH, 2002, ANNU REV BIOCHEM, V71, P511, DOI 10.1146/annurev.biochem.71.102201.141218; Kuntzweiler TA, 1996, J BIOL CHEM, V271, P29682, DOI 10.1074/jbc.271.47.29682; Lanfermeijer FC, 1998, PROTEIN EXPRES PURIF, V12, P29, DOI 10.1006/prep.1997.0788; Lanyi JK, 1997, J BIOL CHEM, V272, P31209, DOI 10.1074/jbc.272.50.31209; LUTSENKO S, 1995, P NATL ACAD SCI USA, V92, P7936, DOI 10.1073/pnas.92.17.7936; MOGI T, 1988, P NATL ACAD SCI USA, V85, P4148, DOI 10.1073/pnas.85.12.4148; MOLLER M, 1986, ADV PINEAL RES, V1, P51; Morsomme P, 2000, BBA-BIOMEMBRANES, V1465, P1, DOI 10.1016/S0005-2736(00)00128-0; MRABET NT, 1992, BIOCHEMISTRY-US, V31, P2239, DOI 10.1021/bi00123a005; Neutze R, 2002, BBA-BIOMEMBRANES, V1565, P144, DOI 10.1016/S0005-2736(02)00566-7; Nielsen JM, 1998, BIOCHEMISTRY-US, V37, P1961, DOI 10.1021/bi972524q; Palmgren MG, 2001, ANNU REV PLANT PHYS, V52, P817, DOI 10.1146/annurev.arplant.52.1.817; Pedersen PA, 1997, FEBS LETT, V400, P206, DOI 10.1016/S0014-5793(96)01381-6; REGENBERG B, 1995, PLANT CELL, V7, P1655, DOI 10.1105/tpc.7.10.1655; SUBRAMANIAM S, 1990, P NATL ACAD SCI USA, V87, P1013, DOI 10.1073/pnas.87.3.1013; Sweadner KJ, 2001, BIOCHEM J, V356, P685, DOI 10.1042/0264-6021:3560685; Toyoshima C, 2000, NATURE, V405, P647, DOI 10.1038/35015017; VENEMA K, 1995, J BIOL CHEM, V270, P19659, DOI 10.1074/jbc.270.33.19659; VIK SB, 1994, J BIOL CHEM, V269, P30364; Zhang PJ, 1998, NATURE, V392, P835, DOI 10.1038/33959	39	33	36	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 16	2003	278	20					17845	17851		10.1074/jbc.M212729200	http://dx.doi.org/10.1074/jbc.M212729200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677YX	12626496	hybrid			2022-12-25	WOS:000182838300033
J	Flanagan, JJ; Chen, JC; Miao, YW; Shao, YL; Lin, JL; Bock, PE; Johnson, AE				Flanagan, JJ; Chen, JC; Miao, YW; Shao, YL; Lin, JL; Bock, PE; Johnson, AE			Signal recognition particle binds to ribosome-bound signal sequences with fluorescence-detected subnanomolar affinity that does not diminish as the nascent chain lengthens	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOPLASMIC-RETICULUM MEMBRANE; AMINOACYL-TRANSFER-RNA; ELONGATION-FACTOR-TU; PROTEIN TRANSLOCATION; MICROSOMAL-MEMBRANES; ER MEMBRANE; PRESECRETORY PROTEINS; BLOOD-COAGULATION; SECRETORY PROTEIN; ACTIVE-SITE	The binding of signal recognition particle (SRP) to ribosome-bound signal sequences has been characterized directly and quantitatively using fluorescence spectroscopy. A fluorescent probe was incorporated co-translationally into the signal sequence of a ribosome.nascent chain complex (RNC), and upon titration with SRP, a large and saturable increase in fluorescence intensity was observed. Spectral analyses of SRP and RNC association as a function of concentration allowed us to measure, at equilibrium, K-d values of 0.05-0.38 nM for SRP.RNC complexes with different signal sequences. Competitive binding experiments with nonfluorescent RNC species revealed that the nascent chain probe did not alter SRP affinity and that SRP has significant affinity for both nontranslating ribosomes (K-d = 71 nM) and RNCs that lack an exposed signal sequence (K-d = 8 nM). SRP can therefore distinguish between translating and nontranslating ribosomes. The very high signal sequence-dependent SRP.RNC affinity did not decrease as the nascent chain lengthened. Thus, the inhibition of SRP-dependent targeting of RNCs to the endoplasmic reticulum membrane observed with long nascent chains does not result from reduced SRP binding to the signal sequence, as widely thought, but rather from a subsequent step, presumably nascent chain interference of SRP.RNC association with the SRP receptor and/or translocon.	Texas A&M Univ, Hlth Sci Ctr, Dept Med Biochem & Genet, College Stn, TX 77843 USA; Texas A&M Univ, Dept Biochem & Biophys, College Stn, TX 77843 USA; Texas A&M Univ, Dept Chem, College Stn, TX 77843 USA; Univ Oklahoma, Hlth Sci Ctr, Dept Biochem & Mol Biol, Oklahoma City, OK 73104 USA; Vanderbilt Univ, Sch Med, Dept Pathol, Nashville, TN 37232 USA	Texas A&M University System; Texas A&M University College Station; Texas A&M Health Science Center; Texas A&M University System; Texas A&M University College Station; Texas A&M University System; Texas A&M University College Station; University of Oklahoma System; University of Oklahoma Health Sciences Center; Vanderbilt University	Johnson, AE (corresponding author), TAMUS HSC, Coll Med, TAMU 1114, 116 Reynolds Med Bldg, College Stn, TX 77843 USA.		Johnson, Arthur E/G-3457-2012		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R29HL038779, R01HL038779] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM026494, T32GM008523] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL38779] Funding Source: Medline; NIGMS NIH HHS [GM 26494, T32 GM08523] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABRAHAMSON JK, 1985, BIOCHEMISTRY-US, V24, P692, DOI 10.1021/bi00324a023; Bock PE, 1997, J BIOL CHEM, V272, P19837, DOI 10.1074/jbc.272.32.19837; BOCK PE, 1983, J BIOL CHEM, V258, P5079; Chapman R, 1998, ANNU REV CELL DEV BI, V14, P459, DOI 10.1146/annurev.cellbio.14.1.459; CROWLEY KS, 1993, CELL, V73, P1101, DOI 10.1016/0092-8674(93)90640-C; CROWLEY KS, 1994, CELL, V78, P461, DOI 10.1016/0092-8674(94)90424-3; DELL VA, 1990, BIOCHEMISTRY-US, V29, P1757, DOI 10.1021/bi00459a014; FALCONE D, 1991, MOL CELL BIOL, V11, P2656, DOI 10.1128/MCB.11.5.2656; GAUT JR, 1993, J BIOL CHEM, V268, P7248; HUSTEN EJ, 1987, J BIOL CHEM, V262, P12953; JANIAK F, 1990, BIOCHEMISTRY-US, V29, P4268, DOI 10.1021/bi00470a002; JANIAK F, 1992, BIOCHEMISTRY-US, V31, P5830, DOI 10.1021/bi00140a019; Johnson AE, 1999, ANNU REV CELL DEV BI, V15, P799, DOI 10.1146/annurev.cellbio.15.1.799; JOHNSON AE, 1976, BIOCHEMISTRY-US, V15, P569, DOI 10.1021/bi00648a018; JOHNSON AE, 1982, J MOL BIOL, V156, P113, DOI 10.1016/0022-2836(82)90462-4; Keenan RJ, 2001, ANNU REV BIOCHEM, V70, P755, DOI 10.1146/annurev.biochem.70.1.755; KRIEG UC, 1986, P NATL ACAD SCI USA, V83, P8604, DOI 10.1073/pnas.83.22.8604; KRIEG UC, 1989, J CELL BIOL, V109, P2033, DOI 10.1083/jcb.109.5.2033; KURZCHALIA TV, 1986, NATURE, V320, P634, DOI 10.1038/320634a0; Liao SR, 1997, CELL, V90, P31, DOI 10.1016/S0092-8674(00)80311-6; OGG SC, 1995, CELL, V81, P1075, DOI 10.1016/S0092-8674(05)80012-1; SIEGEL V, 1988, EMBO J, V7, P1769, DOI 10.1002/j.1460-2075.1988.tb03007.x; SIEGEL V, 1985, J CELL BIOL, V100, P1913, DOI 10.1083/jcb.100.6.1913; SPERRAZZA JM, 1980, BIOCHEMISTRY-US, V19, P1053, DOI 10.1021/bi00547a001; THRIFT RN, 1991, J CELL BIOL, V112, P809, DOI 10.1083/jcb.112.5.809; VONHEIJNE G, 1985, J MOL BIOL, V184, P99, DOI 10.1016/0022-2836(85)90046-4; WALTER P, 1983, METHOD ENZYMOL, V96, P84; WALTER P, 1981, J CELL BIOL, V91, P557, DOI 10.1083/jcb.91.2.557; WALTER P, 1981, J CELL BIOL, V91, P545, DOI 10.1083/jcb.91.2.545; WALTER P, 1994, ANNU REV CELL BIOL, V10, P87, DOI 10.1146/annurev.cb.10.110194.000511; Wild K, 2002, CURR OPIN STRUC BIOL, V12, P72, DOI 10.1016/S0959-440X(02)00292-0; WOLIN SL, 1993, J CELL BIOL, V121, P1211, DOI 10.1083/jcb.121.6.1211; YE J, 1991, J BIOL CHEM, V266, P23016	33	110	112	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 16	2003	278	20					18628	18637		10.1074/jbc.M300173200	http://dx.doi.org/10.1074/jbc.M300173200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677YX	12621052	hybrid			2022-12-25	WOS:000182838300135
J	Kamikubo, Y; Takaori-Kondo, A; Uchiyama, T; Hori, T				Kamikubo, Y; Takaori-Kondo, A; Uchiyama, T; Hori, T			Inhibition of cell growth by conditional expression of kpm, a human homologue of Drosophila warts/lats tumor suppressor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MYOTONIC-DYSTROPHY KINASE; PROTEIN-KINASE; DAMAGE CHECKPOINT; FISSION YEAST; GENE; PHOSPHORYLATION; CYCLE; APOPTOSIS; ACTIVATION; SEQUENCE	kpm is a human serine/threonine kinase that is homologous to Drosophila tumor suppressor warts/lats and its mammalian homologue LATS1. In order to define the biological function of kpm, we generated stable transfectants of wild-type kpm (kpm-wt), a kinase-dead mutant of kpm (kpm-kd), and luciferase in HeLa Tet-Off cells under the tetracycline-responsive promoter. Western blot analysis showed that high levels of expression of kpm-wt as well as kpm-kd with an apparent mass of 150 kDa were induced after the removal of doxycycline. Induction of kpm-wt expression resulted in a marked decline in viable cell number measured by both trypan blue dye exclusion and MTT assay, whereas that of kpm-kd or luciferase had no effect. We then analyzed the cell cycle progression and apoptosis upon induction of kpm expression. 2-3 days after removal of doxycycline, cells underwent G(2)/M arrest, demonstrated by flow cytometric analysis of propidium iodide incorporation and MPM-2 reactivity. In vitro kinase assay showed that induction of kpm-wt led to down-regulation of kinase activity of the Cdc2-cyclin B complex, which was accompanied by an increase in the hyperphosphorylated form of Cdc2 and a change of phosphorylation status of Cdc25C. Furthermore, both DAPI staining and TUNEL assay showed that the proportion of apoptotic cells increased as kpm expression was induced. Taken together, these results indicate that kpm negatively regulates cell growth by inducing G(2)/M arrest and apoptotic cell death through its kinase activity.	Kyoto Univ, Grad Sch Med, Dept Hematol & Oncol, Sakyo Ku, Kyoto 6068507, Japan	Kyoto University	Hori, T (corresponding author), Kyoto Univ, Grad Sch Med, Dept Hematol & Oncol, Sakyo Ku, 54 Shogoin Kawaracho, Kyoto 6068507, Japan.							CHOU CF, 1994, J CELL SCI, V107, P1833; DAVIS FM, 1983, P NATL ACAD SCI-BIOL, V80, P2926, DOI 10.1073/pnas.80.10.2926; DRAETTA G, 1988, CELL, V54, P17, DOI 10.1016/0092-8674(88)90175-4; GOLD R, 1994, LAB INVEST, V71, P219; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; Hori T, 2000, ONCOGENE, V19, P3101, DOI 10.1038/sj.onc.1203659; HULL HM, 1982, STAIN TECHNOL, V57, P273, DOI 10.3109/10520298209066723; JOHNSTON LH, 1990, MOL CELL BIOL, V10, P1358, DOI 10.1128/MCB.10.4.1358; JUSTICE RW, 1995, GENE DEV, V9, P534, DOI 10.1101/gad.9.5.534; KNEHR M, 1995, EXP CELL RES, V217, P546, DOI 10.1006/excr.1995.1121; KOEFFLER HP, 1980, BLOOD, V56, P265; KUANG J, 1994, MOL BIOL CELL, V5, P135, DOI 10.1091/mbc.5.2.135; KUMAGAI A, 1992, CELL, V70, P139, DOI 10.1016/0092-8674(92)90540-S; MAHADEVAN MS, 1993, HUM MOL GENET, V2, P299, DOI 10.1093/hmg/2.3.299; Matsui T, 1996, EMBO J, V15, P2208, DOI 10.1002/j.1460-2075.1996.tb00574.x; Millward TA, 1999, J BIOL CHEM, V274, P33847, DOI 10.1074/jbc.274.48.33847; Morisaki T, 2002, FEBS LETT, V529, P319, DOI 10.1016/S0014-5793(02)03360-4; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; Nishiyama Y, 1999, FEBS LETT, V459, P159, DOI 10.1016/S0014-5793(99)01224-7; OCONNOR PM, 1993, J BIOL CHEM, V268, P8298; Ohashi A, 2001, BIOL REPROD, V65, P1195, DOI 10.1095/biolreprod65.4.1195; Peng CY, 1997, SCIENCE, V277, P1501, DOI 10.1126/science.277.5331.1501; Rennel E, 2002, ANAL BIOCHEM, V309, P79, DOI 10.1016/S0003-2697(02)00250-6; Rhind N, 1997, GENE DEV, V11, P504, DOI 10.1101/gad.11.4.504; St John MAR, 1999, NAT GENET, V21, P182, DOI 10.1038/5965; Stebbins MJ, 2001, P NATL ACAD SCI USA, V98, P10775, DOI 10.1073/pnas.121186498; Sun ZX, 1996, GENE DEV, V10, P395, DOI 10.1101/gad.10.4.395; Tao WF, 1999, NAT GENET, V21, P177, DOI 10.1038/5960; Tapon N, 2002, CELL, V110, P467, DOI 10.1016/S0092-8674(02)00824-3; Valverde P, 2000, BIOCHEM BIOPH RES CO, V276, P990, DOI 10.1006/bbrc.2000.3582; Verde F, 1998, P NATL ACAD SCI USA, V95, P7526, DOI 10.1073/pnas.95.13.7526; Xia H, 2002, ONCOGENE, V21, P1233, DOI 10.1038/sj.onc.1205174; XU TA, 1995, DEVELOPMENT, V121, P1053; Yabuta N, 2000, GENOMICS, V63, P263, DOI 10.1006/geno.1999.6065; Yaffe MB, 1997, SCIENCE, V278, P1957, DOI 10.1126/science.278.5345.1957; Yang XL, 2001, ONCOGENE, V20, P6516, DOI 10.1038/sj.onc.1204817; YARDEN O, 1992, EMBO J, V11, P2159, DOI 10.1002/j.1460-2075.1992.tb05275.x	37	60	62	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 16	2003	278	20					17609	17614		10.1074/jbc.M211974200	http://dx.doi.org/10.1074/jbc.M211974200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677YX	12624101	Green Submitted, hybrid			2022-12-25	WOS:000182838300006
J	Peak, MM; Arbuckle, JL; Rodgers, KK				Peak, MM; Arbuckle, JL; Rodgers, KK			The central domain of core RAG1 preferentially recognizes single-stranded recombination signal sequence heptamer	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							V(D)J RECOMBINATION; OMENN-SYNDROME; STRUCTURE REQUIREMENTS; MUTATIONAL ANALYSIS; DNA-SEQUENCE; ACTIVE-SITE; AMINO-ACIDS; COMPLEX; CLEAVAGE; PROTEINS	RAG1 and RAG2 initiate V(D)J recombination by introducing DNA double strand breaks between each selected gene segment and its bordering recombination signal sequence (RSS) in a two-step mechanism in which the DNA is first nicked, followed by hairpin formation. The RSS consists of a conserved nonamer and heptamer sequence, in which the latter borders the site of DNA cleavage. A region within RAG1, referred to as the central domain (residues 528-760 of 1040 in the full-length protein), has been shown previously to bind specifically to the double-stranded (ds) RSS heptamer, but with both weak specificity and affinity. However, additional investigations into the RAG1-RSS heptamer interaction are required because the DNA substrate forms intermediate conformations during the V(D)J recombination reaction. These include the nicked and hairpin products, as well as likely base unpairing to produce single-stranded (ss) DNA near the cleavage site. Here, it was determined that although the central domain showed substantially higher binding affinity for ss and nicked versus ds substrate, the interaction with ss RSS was particularly robust. In addition, the central domain bound with greater sequence specificity to the ss RSS heptamer than to the ds form. This study provides important insight into the V(D)J recombination reaction, specifically that significant interaction of the RSS heptamer with RAG1 occurs only after the induction of conformational changes at the RSS heptamer.	Univ Oklahoma, Hlth Sci Ctr, Dept Biochem & Mol Biol, Oklahoma City, OK 73190 USA	University of Oklahoma System; University of Oklahoma Health Sciences Center	Rodgers, KK (corresponding author), Univ Oklahoma, Hlth Sci Ctr, Dept Biochem & Mol Biol, Oklahoma City, OK 73190 USA.			Rodgers, Karla/0000-0002-7338-0281	NIAID NIH HHS [T32 AI007633] Funding Source: Medline	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Agrawal A, 1997, CELL, V89, P43, DOI 10.1016/S0092-8674(00)80181-6; Aidinis V, 2000, J IMMUNOL, V164, P5826, DOI 10.4049/jimmunol.164.11.5826; Aidinis V, 1999, MOL CELL BIOL, V19, P6532; Arbuckle JL, 2001, J BIOL CHEM, V276, P37093, DOI 10.1074/jbc.M105988200; Corneo B, 2001, BLOOD, V97, P2772, DOI 10.1182/blood.V97.9.2772; Cuomo CA, 1996, MOL CELL BIOL, V16, P5683; Difilippantonio MJ, 1996, CELL, V87, P253, DOI 10.1016/S0092-8674(00)81343-4; Eastman QM, 1999, MOL CELL BIOL, V19, P3788; Fugmann SD, 2000, MOL CELL, V5, P97, DOI 10.1016/S1097-2765(00)80406-2; Fugmann SD, 2000, ANNU REV IMMUNOL, V18, P495, DOI 10.1146/annurev.immunol.18.1.495; Fugmann SD, 2001, MOL CELL, V8, P899, DOI 10.1016/S1097-2765(01)00352-5; Gellert M, 2002, ANNU REV BIOCHEM, V71, P101, DOI 10.1146/annurev.biochem.71.090501.150203; Godderz LJ, 2003, NUCLEIC ACIDS RES, V31, P2014, DOI 10.1093/nar/gkg281; Gomez CA, 2000, MOL CELL BIOL, V20, P5653, DOI 10.1128/MCB.20.15.5653-5664.2000; Grawunder U, 1997, NUCLEIC ACIDS RES, V25, P1375, DOI 10.1093/nar/25.7.1375; HESSE JE, 1989, GENE DEV, V3, P1053, DOI 10.1101/gad.3.7.1053; Hiom K, 1998, MOL CELL, V1, P1011, DOI 10.1016/S1097-2765(00)80101-X; Huye LE, 2002, MOL CELL BIOL, V22, P3460, DOI 10.1128/MCB.22.10.3460-3473.2002; Kim DR, 1999, GENE DEV, V13, P3070, DOI 10.1101/gad.13.23.3070; Landree MA, 1999, GENE DEV, V13, P3059, DOI 10.1101/gad.13.23.3059; Mo XM, 2000, NUCLEIC ACIDS RES, V28, P1228, DOI 10.1093/nar/28.5.1228; Qiu JX, 2001, MOL CELL, V7, P77, DOI 10.1016/S1097-2765(01)00156-3; RAMSDEN DA, 1994, NUCLEIC ACIDS RES, V22, P1785, DOI 10.1093/nar/22.10.1785; Ramsden DA, 1996, EMBO J, V15, P3197, DOI 10.1002/j.1460-2075.1996.tb00682.x; Rodgers KK, 1996, J MOL BIOL, V260, P70, DOI 10.1006/jmbi.1996.0382; Rodgers KK, 1999, NUCLEIC ACIDS RES, V27, P2938, DOI 10.1093/nar/27.14.2938; Santagata S, 2000, IMMUNOL REV, V178, P64, DOI 10.1034/j.1600-065X.2000.17818.x; Spanopoulou E, 1996, CELL, V87, P263, DOI 10.1016/S0092-8674(00)81344-6; Swanson PC, 2002, MOL CELL BIOL, V22, P1340, DOI 10.1128/MCB.22.5.1340-1351.2002; Swanson PC, 1999, MOL CELL BIOL, V19, P3674; Swanson PC, 1998, IMMUNITY, V9, P115, DOI 10.1016/S1074-7613(00)80593-2; Tsai CL, 2002, GENE DEV, V16, P1934, DOI 10.1101/gad.984502; Villa A, 1998, CELL, V93, P885, DOI 10.1016/S0092-8674(00)81448-8; Villa A, 2001, BLOOD, V97, P81, DOI 10.1182/blood.V97.1.81	34	32	33	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 16	2003	278	20					18235	18240		10.1074/jbc.M302041200	http://dx.doi.org/10.1074/jbc.M302041200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677YX	12644467	hybrid			2022-12-25	WOS:000182838300085
J	Del Valle, JM; Engel, P; Martin, M				Del Valle, JM; Engel, P; Martin, M			The cell surface expression of SAP-binding receptor CD229 is regulated via its interaction with clathrin-associated adaptor complex 2 (AP-2)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LINKED LYMPHOPROLIFERATIVE-DISEASE; GENE-PRODUCT SAP; LYMPHOCYTIC ACTIVATION MOLECULE; SORTING SIGNALS; CUTTING EDGE; BREFELDIN-A; PROTEIN SAP; MOUSE LY-9; SLAM; RECOGNITION	CD229 (Ly9) is a cell surface receptor selectively expressed on T and B lymphocytes, and it belongs to the CD150 receptor family. Like other receptors of this family, CD229 interacts with SAP/SH2D1a protein, mutation of which is responsible for the fatal X-linked lymphoproliferative disease. Receptors of the CD150 family function as costimulatory molecules, regulating cytokine production and cytotoxicity. Thus, their signaling and regulation in lymphocytes may be critical to an understanding of the pathogenesis of the X-linked lymphoproliferative disease. Here we show that CD229 interacts with the mu(2) chain of the AP-2 adaptor complex that links transmembrane proteins to clathrin-coated pits. CD229 was the only member of the CD150 family associated with AP-2. We also show that the mu(2) chain interacts with the Y470EKL motif of CD229. The integrity of this site was necessary for CD229 internalization, but it was not involved in SAP recruitment. Moreover, CD229 binds to the AP-2 complex in T and B cell lines, and it is internalized rapidly from the cell surface on T cells after antibody ligation. In contrast, cross-linking of CD229 receptors with intact antibody inhibited CD229 internalization on B cells. However, when F(ab')(2) antibodies were used, CD229 internalization was similar on T and B cells, suggesting that Fcgamma receptors control CD229 cell surface expression. Furthermore, CD229 was regulated by T cell receptor and B cell receptor signaling because coligation with antibodies against anti-CD3 and anti-IgM increased the rate of CD229 endocytosis. These data suggest that CD229 cell surface expression on lymphocytes surface is strongly and differentially regulated within the CD150 family members.	Univ Barcelona, Sch Med, Inst Invest Biomed August Pi i Sunyer, Dept Cellular Biol & Pathol,Immunol Unit, E-08036 Barcelona, Spain	University of Barcelona; Hospital Clinic de Barcelona; IDIBAPS	Martin, M (corresponding author), Fac Med, Dept Biol Celular, Unidad Inmunol, C Casanova 143, E-08036 Barcelona, Spain.		Engel, Pablo/R-5907-2019; Andorra, Margarita Martin/H-2025-2015; del Valle Mendoza, Juana/C-9805-2018	Engel, Pablo/0000-0001-8410-252X; Andorra, Margarita Martin/0000-0002-9245-4899; del Valle Mendoza, Juana/0000-0002-6011-5040				Arico M, 2001, BLOOD, V97, P1131, DOI 10.1182/blood.V97.4.1131; Aversa G, 1997, IMMUNOL CELL BIOL, V75, P202, DOI 10.1038/icb.1997.30; Bottino C, 2001, J EXP MED, V194, P235, DOI 10.1084/jem.194.3.235; Bremnes T, 1998, J BIOL CHEM, V273, P8638, DOI 10.1074/jbc.273.15.8638; Carballido JM, 1997, J IMMUNOL, V159, P4316; Castro AG, 1999, J IMMUNOL, V163, P5860; Cefai D, 1998, J IMMUNOL, V160, P2223; Chardin P, 1999, CELL, V97, P153, DOI 10.1016/S0092-8674(00)80724-2; Coffey AJ, 1998, NAT GENET, V20, P129, DOI 10.1038/2424; Collins BM, 2002, CELL, V109, P523, DOI 10.1016/S0092-8674(02)00735-3; COOKS BG, 1995, NATURE, V376, P260; Crotty S, 2003, NATURE, V421, P282, DOI 10.1038/nature01318; de la Fuente MA, 2001, BLOOD, V97, P3513, DOI 10.1182/blood.V97.11.3513; Jost M, 1998, CURR BIOL, V8, P1399, DOI 10.1016/S0960-9822(98)00022-0; Kirchhausen T, 1999, ANNU REV CELL DEV BI, V15, P705, DOI 10.1146/annurev.cellbio.15.1.705; Kirchhausen T, 2002, CELL, V109, P413, DOI 10.1016/S0092-8674(02)00751-1; Kumaresan PR, 2002, MOL IMMUNOL, V39, P1, DOI 10.1016/S0161-5890(02)00094-9; LIPPINCOTTSCHWARTZ J, 1991, CELL, V67, P601, DOI 10.1016/0092-8674(91)90534-6; Liu HY, 2000, IMMUNITY, V13, P665, DOI 10.1016/S1074-7613(00)00066-2; Marks MS, 1996, J CELL BIOL, V135, P341, DOI 10.1083/jcb.135.2.341; MARSH BJ, 1995, J CELL BIOL, V130, P1081, DOI 10.1083/jcb.130.5.1081; Martin M, 2001, J IMMUNOL, V167, P3668, DOI 10.4049/jimmunol.167.7.3668; Minskoff SA, 1998, J IMMUNOL, V161, P2079; Morra M, 2001, BLOOD, V98, P1321, DOI 10.1182/blood.V98.5.1321; Morra M, 2001, EMBO J, V20, P5840, DOI 10.1093/emboj/20.21.5840; Morra M, 2001, ANNU REV IMMUNOL, V19, P657, DOI 10.1146/annurev.immunol.19.1.657; Nakajima H, 1999, EUR J IMMUNOL, V29, P1676, DOI 10.1002/(SICI)1521-4141(199905)29:05<1676::AID-IMMU1676>3.0.CO;2-Y; Owen DJ, 1998, SCIENCE, V282, P1327, DOI 10.1126/science.282.5392.1327; Peck SR, 2000, IMMUNOGENETICS, V52, P63, DOI 10.1007/s002510000252; Poy F, 1999, MOL CELL, V4, P555, DOI 10.1016/S1097-2765(00)80206-3; Rapoport I, 1998, EMBO J, V17, P2148, DOI 10.1093/emboj/17.8.2148; Rapoport I, 1997, EMBO J, V16, P2240, DOI 10.1093/emboj/16.9.2240; SANDRIN MS, 1992, J IMMUNOL, V149, P1636; Sauter MM, 1996, J CELL BIOL, V132, P795, DOI 10.1083/jcb.132.5.795; Sayos J, 2001, BLOOD, V97, P3867, DOI 10.1182/blood.V97.12.3867; Sayos J, 2000, INT IMMUNOL, V12, P1749, DOI 10.1093/intimm/12.12.1749; Sayos J, 1998, NATURE, V395, P462, DOI 10.1038/26683; Shiratori T, 1997, IMMUNITY, V6, P583, DOI 10.1016/S1074-7613(00)80346-5; Sidorenko SP, 2003, NAT IMMUNOL, V4, P19, DOI 10.1038/ni0103-19; Tangye SG, 1999, J IMMUNOL, V162, P6981; Tovar V, 2000, IMMUNOGENETICS, V51, P788, DOI 10.1007/s002510000209; Tovar V, 2002, IMMUNOGENETICS, V54, P394, DOI 10.1007/s00251-002-0483-3; TROWBRIDGE IS, 1993, ANNU REV CELL BIOL, V9, P129, DOI 10.1146/annurev.cb.09.110193.001021; VALIANTE NM, 1993, J EXP MED, V178, P1397, DOI 10.1084/jem.178.4.1397; WOOD SA, 1991, CELL, V67, P591, DOI 10.1016/0092-8674(91)90533-5; Wu CB, 2001, NAT IMMUNOL, V2, P410, DOI 10.1038/87713	46	27	28	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 9	2003	278	19					17430	17437		10.1074/jbc.M301569200	http://dx.doi.org/10.1074/jbc.M301569200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677QG	12621057	hybrid			2022-12-25	WOS:000182818600130
J	Gaille, C; Reimmann, C; Haas, D				Gaille, C; Reimmann, C; Haas, D			Isochorismate synthase (PchA), the first and rate-limiting enzyme in salicylate biosynthesis of Pseudomonas aeruginosa	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; L-PHENYLALANINE; IN-VITRO; PYOCHELIN; ACID; PURIFICATION; CHORISMATE; GENES; SYNTHETASE; OVEREXPRESSION	In Pseudomonas aeruginosa the extracellular metabolite and siderophore pyochelin is synthesized from two major precursors, chorismate and L-cysteine via salicylate as an intermediate. The regulatory role of isochorismate synthase, the first enzyme in the pyochelin biosynthetic pathway, was studied. This enzyme is encoded by pchA, the last gene in the pchDCBA operon. The PchA protein was purified to apparent electrophoretic homogeneity from a PchA-overexpressing P. aeruginosa strain. The native enzyme was a 52-kDa monomer in solution, and its activity strictly depended on Mg2+. At pH 7.0, the optimum, a K-m = 4.5 muM and a k(cat) = 43.1 min(-1) were determined for chorismate. No feedback inhibitors or other allosteric effectors were found. The intracellular PchA concentration critically determined the rate of salicylate formation both in vitro and in vivo. In cultures grown in iron-limiting media to high cell densities, overexpression of the pchA gene resulted in overproduction of salicylate as well as in enhanced pyochelin formation. From this work and earlier studies, it is proposed that one important factor influencing the flux through the pyochelin biosynthetic pathway is the PchA concentration, which is determined at a transcriptional level, with pyochelin acting as a positive signal and iron as a negative signal.	Univ Lausanne, Inst Microbiol Fondamentale, CH-1015 Lausanne, Switzerland	University of Lausanne	Haas, D (corresponding author), Univ Lausanne, Inst Microbiol Fondamentale, CH-1015 Lausanne, Switzerland.							ANKENBAUER RG, 1988, J BACTERIOL, V170, P5344, DOI 10.1128/jb.170.11.5344-5351.1988; Audenaert K, 2002, MOL PLANT MICROBE IN, V15, P1147, DOI 10.1094/MPMI.2002.15.11.1147; BARTON HA, 1996, MOL MICROBIOL, V21, P1005; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brem D, 2001, MICROBIOL-SGM, V147, P1115, DOI 10.1099/00221287-147-5-1115; BRUNSCHWIG E, 1992, GENE, V111, P35, DOI 10.1016/0378-1119(92)90600-T; CALHOUN DH, 1973, MOL GEN GENET, V121, P117, DOI 10.1007/BF00277526; CALHOUN DH, 2001, GENOME BIOL, V2; CARMI R, 1994, J NAT PROD, V57, P1200, DOI 10.1021/np50111a002; COX CD, 1981, P NATL ACAD SCI-BIOL, V78, P4256, DOI 10.1073/pnas.78.7.4256; Dahm C, 1998, BBA-GEN SUBJECTS, V1425, P377, DOI 10.1016/S0304-4165(98)00089-0; Daruwala R, 1997, J BACTERIOL, V179, P3133, DOI 10.1128/jb.179.10.3133-3138.1997; Dosselaere F, 2001, CRIT REV MICROBIOL, V27, P75, DOI 10.1080/20014091096710; FISKE MJ, 1983, J BACTERIOL, V154, P623, DOI 10.1128/JB.154.2.623-631.1983; Gaille C, 2002, J BIOL CHEM, V277, P21768, DOI 10.1074/jbc.M202410200; Gehring AM, 1998, CHEM BIOL, V5, P573, DOI 10.1016/S1074-5521(98)90115-6; Gosset G, 2001, J BACTERIOL, V183, P4061, DOI 10.1128/JB.183.13.4061-4070.2001; Grisostomi C, 1997, BIOORG CHEM, V25, P297, DOI 10.1006/bioo.1997.1073; HAAS D, 1972, EUR J BIOCHEM, V31, P290, DOI 10.1111/j.1432-1033.1972.tb02531.x; HAAS D, 1975, EUR J BIOCHEM, V52, P377; HEINRICHS DE, 1993, J BACTERIOL, V175, P5882, DOI 10.1128/JB.175.18.5882-5889.1993; Kennedy J, 1996, MOL GEN GENET, V253, P189, DOI 10.1007/s004380050312; Khetan A, 1996, ANN NY ACAD SCI, V782, P17, DOI 10.1111/j.1749-6632.1996.tb40543.x; LAMMELI UK, 1973, J MOL BIOL, V80, P575; Lamont IL, 2002, P NATL ACAD SCI USA, V99, P7072, DOI 10.1073/pnas.092016999; LIU J, 1990, BIOCHEMISTRY-US, V29, P1417, DOI 10.1021/bi00458a012; Ludwig W, 1999, ASM NEWS, V65, P752; MADIGAN MT, 2000, BROCK BIOL MICROORGA, P212; McDonald M, 2001, J AM CHEM SOC, V123, P9459, DOI 10.1021/ja011243+; Park SM, 1997, J BACTERIOL, V179, P5309, DOI 10.1128/jb.179.17.5309-5317.1997; PATEL N, 1977, J BIOL CHEM, V252, P5839; Quadri LEN, 1999, BIOCHEMISTRY-US, V38, P14941, DOI 10.1021/bi991787c; Quadri LEN, 1998, CHEM BIOL, V5, P631, DOI 10.1016/S1074-5521(98)90291-5; Reimmann C, 1998, MICROBIOL-UK, V144, P3135, DOI 10.1099/00221287-144-11-3135; Reimmann C, 2001, J BACTERIOL, V183, P813, DOI 10.1128/JB.183.3.813-820.2001; SERINO L, 1995, MOL GEN GENET, V249, P217, DOI 10.1007/BF00290369; Serino L, 1997, J BACTERIOL, V179, P248, DOI 10.1128/jb.179.1.248-257.1997; STEELE BF, 1949, J BIOL CHEM, V177, P533; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; TIETZ D, 1987, ANAL BIOCHEM, V161, P395, DOI 10.1016/0003-2697(87)90468-4; Wang YL, 2000, NUCLEIC ACIDS RES, V28, P243, DOI 10.1093/nar/28.1.243; Wildermuth MC, 2001, NATURE, V414, P562, DOI 10.1038/35107108; Winkler ME, 1996, ESCHERICHIA COLI SAL, P485	43	74	82	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 9	2003	278	19					16893	16898		10.1074/jbc.M212324200	http://dx.doi.org/10.1074/jbc.M212324200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677QG	12624097	hybrid			2022-12-25	WOS:000182818600061
J	Hamilton, KL; Syme, CA; Devor, DC				Hamilton, KL; Syme, CA; Devor, DC			Molecular localization of the inhibitory arachidonic acid binding site to the pore of hIK1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHLORIDE SECRETORY RESPONSES; ACTIVATED POTASSIUM CHANNEL; COLONIC CELL-LINE; PROTEIN-KINASE-C; K+ CHANNEL; INTERMEDIATE-CONDUCTANCE; FATTY-ACIDS; EPITHELIAL-CELLS; PHOSPHOLIPASE A(2); ION CHANNELS	We previously demonstrated that the endogenously expressed human intermediate conductance, Ca2+-activated K+ channel (hIK1) was inhibited by arachidonic acid (AA) (Devor, D. C., and Frizzell, R. A. (1998) Am. J. Physiol. 274, C138-C148). Here we demonstrate, using the excised, inside-out patch-clamp technique, that hIK1, heterologously expressed in HEK293 cells, is inhibited 82 +/- 2% (n = 16) with 3 muM AA, being half-maximally inhibited (IC50) at 1.4 +/- 0.7 muM. In contrast, AA does not inhibit the Ca2+-dependent, small conductance K+ channel, rSK2, another member of the KCNN gene family. Therefore, we utilized chimeric hIK1/rSK2 channels to define the AA binding domain on hIK1 to the S5-Pore-S6 region of the channel. Subsequent site-directed mutagenesis revealed that mutation of Thr(250) to Ser (T250S) resulted in a channel with limited sensitivity to block by AA (8 +/- 2%, n = 8), demonstrating that Thr(250) is a key molecular determinant for the inhibition of hIK1 by AA. Likewise, when Val(275) in S6 was mutated to Ala (V275A) AA inhibited only 43 +/- 11% (n = 9) of current flow. The double mutation T250S/V275A eliminated the AA sensitivity of hIK1. Introducing the complimentary single amino acid substitutions into rSK2 (S359T and A384V) conferred partial AA sensitivity to rSK2, 21 +/- 3% and 31 +/- 3%, respectively. Further, introducing the double mutation S359T/A384V into rSK2 resulted in a 63 +/- 8% (n = 9) inhibition by AA, thereby demonstrating the ability to introduce this inhibitory AA binding site into another member of the KCNN gene family. These results demonstrate that AA interacts with the pore-lining amino acids, Thr(250) and Val(275) in hIK1, conferring inhibition of hIK1 by AA and that AA and clotrimazole share similar, if not identical, molecular sites of interaction.	Univ Pittsburgh, Sch Med, Dept Cell Biol & Physiol, Pittsburgh, PA 15261 USA; Univ Otago, Dept Physiol, Dunedin, New Zealand	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; University of Otago	Devor, DC (corresponding author), Univ Pittsburgh, Sch Med, Dept Cell Biol & Physiol, S312 BST,3500 Terrace St, Pittsburgh, PA 15261 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK054941] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK54941] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ABDELLATIF AA, 1986, PHARMACOL REV, V38, P227; ANDERSON MP, 1990, P NATL ACAD SCI USA, V87, P7334, DOI 10.1073/pnas.87.18.7334; Balestrieri ML, 1998, PROSTAG OTH LIPID M, V56, P363, DOI 10.1016/S0090-6980(98)00065-3; BARRETT KE, 1993, AM J PHYSIOL, V264, pC446, DOI 10.1152/ajpcell.1993.264.2.C446; BARRETT KE, 1995, CELL SIGNAL, V7, P225, DOI 10.1016/0898-6568(94)00087-R; Calabrese C, 2000, ALLERGY, V55, P27, DOI 10.1034/j.1398-9995.2000.00504.x; Clarke AL, 2002, AM J PHYSIOL-CELL PH, V283, pC1441, DOI 10.1152/ajpcell.00035.2002; DERUBERTIS FR, 1984, J CLIN INVEST, V74, P1614, DOI 10.1172/JCI111577; Devor DC, 1996, AM J PHYSIOL-LUNG C, V271, pL785, DOI 10.1152/ajplung.1996.271.5.L785; Devor DC, 1999, J GEN PHYSIOL, V113, P743, DOI 10.1085/jgp.113.5.743; Devor DC, 1997, AM J PHYSIOL-CELL PH, V273, pC531, DOI 10.1152/ajpcell.1997.273.2.C531; DHARMSATHAPHORN K, 1989, AM J PHYSIOL, V256, pC1224, DOI 10.1152/ajpcell.1989.256.6.C1224; DHARMSATHAPHORN K, 1986, J CLIN INVEST, V77, P348, DOI 10.1172/JCI112311; Doyle DA, 1998, SCIENCE, V280, P69, DOI 10.1126/science.280.5360.69; Gerlach AC, 2000, J BIOL CHEM, V275, P585, DOI 10.1074/jbc.275.1.585; Gerlach AC, 2001, J BIOL CHEM, V276, P10963, DOI 10.1074/jbc.M007716200; GUBITOSIKLUG RA, 1995, J BIOL CHEM, V270, P2885, DOI 10.1074/jbc.270.7.2885; Hamilton KL, 1999, PFLUG ARCH EUR J PHY, V439, P158, DOI 10.1007/s004240051140; Holmqvist MH, 2001, J NEUROSCI, V21, P4154, DOI 10.1523/JNEUROSCI.21-12-04154.2001; HONORE E, 1994, P NATL ACAD SCI USA, V91, P1937, DOI 10.1073/pnas.91.5.1937; Ishii TM, 1997, P NATL ACAD SCI USA, V94, P11651, DOI 10.1073/pnas.94.21.11651; Jensen BS, 1998, AM J PHYSIOL-CELL PH, V275, pC848, DOI 10.1152/ajpcell.1998.275.3.C848; Joiner WJ, 1997, P NATL ACAD SCI USA, V94, P11013, DOI 10.1073/pnas.94.20.11013; KACHINTORN U, 1993, BRIT J PHARMACOL, V109, P510, DOI 10.1111/j.1476-5381.1993.tb13599.x; KACHINTORN U, 1993, AM J PHYSIOL, V264, pC671, DOI 10.1152/ajpcell.1993.264.3.C671; Kim Y, 2001, PFLUG ARCH EUR J PHY, V442, P952, DOI 10.1007/s004240100626; LAWSON LD, 1987, AM J PHYSIOL, V252, pG783, DOI 10.1152/ajpgi.1987.252.6.G783; LAZAROWSKI ER, 1994, AM J PHYSIOL, V266, P406; Lin WW, 1998, BRIT J PHARMACOL, V123, P1173, DOI 10.1038/sj.bjp.0701705; LINDEMAN RP, 1992, AM J PHYSIOL, V263, pC140, DOI 10.1152/ajpcell.1992.263.1.C140; Liu Y, 2001, MOL PHARMACOL, V59, P1061, DOI 10.1124/mol.59.5.1061; Macica CM, 1998, AM J PHYSIOL-RENAL, V274, pF175, DOI 10.1152/ajprenal.1998.274.1.F175; May LG, 1999, CELL SIGNAL, V11, P179, DOI 10.1016/S0898-6568(98)00053-9; MEVES H, 1994, PROG NEUROBIOL, V43, P175, DOI 10.1016/0301-0082(94)90012-4; ORDWAY RW, 1991, TRENDS NEUROSCI, V14, P96, DOI 10.1016/0166-2236(91)90069-7; PACHECO S, 1987, CLIN SCI, V73, P361, DOI 10.1042/cs0730361; Rufo PA, 1996, J CLIN INVEST, V98, P2066, DOI 10.1172/JCI119012; Sansom SC, 1996, CLIN EXP PHARMACOL P, V23, P76; Siegel G, 2001, J BIOL CHEM, V276, P16986, DOI 10.1074/jbc.M101136200; Singh S, 2001, J PHARMACOL EXP THER, V296, P600; Stockand JD, 1998, AM J PHYSIOL-RENAL, V274, pF658, DOI 10.1152/ajprenal.1998.274.4.F658; TRAYNORKAPLAN AE, 1994, AM J PHYSIOL-CELL PH, V267, pC1224, DOI 10.1152/ajpcell.1994.267.5.C1224; VAANDRAGER AB, 1992, AM J PHYSIOL, V262, pG249, DOI 10.1152/ajpgi.1992.262.2.G249; VAJANAPHANICH M, 1994, NATURE, V371, P711, DOI 10.1038/371711a0; Villarroel A, 1996, J NEUROSCI, V16, P2522; Visentin S, 1998, GLIA, V22, P1; WANG WH, 1992, AM J PHYSIOL, V262, pF554, DOI 10.1152/ajprenal.1992.262.4.F554; WARHURST G, 1991, AM J PHYSIOL, V261, pG220, DOI 10.1152/ajpgi.1991.261.2.G220; Warth R, 1999, PFLUG ARCH EUR J PHY, V438, P437, DOI 10.1007/s004240051059; Wulff H, 2000, P NATL ACAD SCI USA, V97, P8151, DOI 10.1073/pnas.97.14.8151; Wulff H, 2001, J BIOL CHEM, V276, P32040, DOI 10.1074/jbc.M105231200; Xing MZ, 1999, J BIOL CHEM, V274, P10035, DOI 10.1074/jbc.274.15.10035	52	45	46	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 9	2003	278	19					16690	16697		10.1074/jbc.M212959200	http://dx.doi.org/10.1074/jbc.M212959200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677QG	12609997	hybrid			2022-12-25	WOS:000182818600033
J	Krenz, M; Sanbe, A; Bouyer-Dalloz, F; Gulick, J; Klevitsky, R; Hewett, TE; Osinska, HE; Lorenz, JN; Brosseau, C; Federico, A; Alpert, NR; Warshaw, DM; Perryman, MB; Helmke, SM; Robbins, J				Krenz, M; Sanbe, A; Bouyer-Dalloz, F; Gulick, J; Klevitsky, R; Hewett, TE; Osinska, HE; Lorenz, JN; Brosseau, C; Federico, A; Alpert, NR; Warshaw, DM; Perryman, MB; Helmke, SM; Robbins, J			Analysis of myosin heavy chain functionality in the heart	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENE-EXPRESSION; IN-VITRO; KINETIC DIFFERENCES; ISOFORM EXPRESSION; SKELETAL-MUSCLE; MAMMALIAN HEART; SURFACE LOOPS; LIGHT-CHAIN; ACTIN; FIBERS	Comparison of mammalian cardiac alpha- and beta-myosin heavy chain isoforms reveals 93% identity. To date, genetic methodologies have effected only minor switches in the mammalian cardiac myosin isoforms. Using cardiac-specific transgenesis, we have now obtained major myosin isoform shifts and/or replacements. Clusters of non-identical amino acids are found in functionally important regions, i.e. the surface loops 1 and 2, suggesting that these structures may regulate isoform-specific characteristics. Loop 1 alters filament sliding velocity, whereas Loop 2 modulates actin-activated ATPase rate in Dictyostelium myosin, but this remains untested in mammalian cardiac myosins. alpha-->beta isoform switches were engineered into mouse hearts via transgenesis. To assess the structural basis of isoform diversity, chimeric myosins in which the sequences of either Loop 1+Loop 2 or Loop 2 of alpha-myosin were exchanged for those of beta-myosin were expressed in vivo. 2-fold differences in filament sliding velocity and ATPase activity were found between the two isoforms. Filament sliding velocity of the Loop 1+Loop 2 chimera and the ATPase activities of both loop chimeras were not significantly different compared with alpha-myosin. In mouse cardiac isoforms, myosin functionality does not depend on Loop 1 or Loop 2 sequences and must lie partially in other non-homologous residues.	Childrens Hosp Res Fdn, Cincinnati Childrens Hosp Med Ctr, Div Mol Cardiovasc Biol, Cincinnati, OH 45229 USA; Univ Cincinnati, Dept Cellular & Mol Physiol, Cincinnati, OH 45267 USA; Univ Vermont, Coll Med, Dept Physiol & Mol Biophys, Burlington, VT 05405 USA; Univ Colorado, Hlth Sci Ctr, Dept Med, Div Cardiol, Denver, CO 80262 USA	Cincinnati Children's Hospital Medical Center; Cincinnati Children's Hospital Research Foundation; University System of Ohio; University of Cincinnati; University of Vermont; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Robbins, J (corresponding author), Div Mol Cardiovasc Biol, MLC 7020,3333 Burnet Ave, Cincinnati, OH 45229 USA.	jeff.robbins@echmc.org	Hewett, Timothy/G-1023-2011; Hewett, Timothy Edwin/GLT-1556-2022; Hewett, Timothy E/E-3241-2011	federico, antonio/0000-0002-5246-1621; Krenz, Maike/0000-0003-3784-287X	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL060546, P50HL052318, R01HL056370, R01HL066157] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL52318, HL66157, HL60546, HL56370, HL69799] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Alpert NR, 2002, AM J PHYSIOL-HEART C, V283, pH1446, DOI 10.1152/ajpheart.00274.2002; Blough ER, 1996, ANAL BIOCHEM, V233, P31, DOI 10.1006/abio.1996.0003; BOTTINELLI R, 1991, J PHYSIOL-LONDON, V437, P655, DOI 10.1113/jphysiol.1991.sp018617; CHIEN KR, 1991, FASEB J, V5, P3037, DOI 10.1096/fasebj.5.15.1835945; Fewell JG, 1998, J CLIN INVEST, V101, P2630, DOI 10.1172/JCI2825; Fitzsimons DP, 1998, J PHYSIOL-LONDON, V513, P171, DOI 10.1111/j.1469-7793.1998.171by.x; Furch M, 1998, BIOCHEMISTRY-US, V37, P6317, DOI 10.1021/bi972851y; Gulick J, 1997, CIRC RES, V80, P655, DOI 10.1161/01.RES.80.5.655; HARRIS DE, 1994, J MUSCLE RES CELL M, V15, P11, DOI 10.1007/BF00123828; Herron TJ, 2002, CIRC RES, V90, P1150, DOI 10.1161/01.RES.0000022879.57270.11; Hirayama Y, 2000, BIOCHEM BIOPH RES CO, V269, P237, DOI 10.1006/bbrc.2000.2273; IMAMURA SI, 1991, AM J PHYSIOL, V260, pH73, DOI 10.1152/ajpheart.1991.260.1.H73; James J, 1999, TRANSGENIC RES, V8, P9, DOI 10.1023/A:1008894507995; Jones WK, 1996, J CLIN INVEST, V98, P1906, DOI 10.1172/JCI118992; LITTEN RZ, 1982, CIRC RES, V50, P856, DOI 10.1161/01.RES.50.6.856; LOPES AC, 1993, J SUBMICR CYTOL PATH, V25, P263; Lorenz JN, 1997, AM J PHYSIOL-HEART C, V272, pH1137, DOI 10.1152/ajpheart.1997.272.3.H1137; MCAULIFFE JJ, 1990, CIRC RES, V66, P1204, DOI 10.1161/01.RES.66.5.1204; Metzger JM, 1999, CIRC RES, V84, P1310, DOI 10.1161/01.RES.84.11.1310; Miyata S, 2000, CIRC RES, V86, P386, DOI 10.1161/01.RES.86.4.386; MORKIN E, 1993, CIRCULATION, V87, P1451, DOI 10.1161/01.CIR.87.5.1451; Murphy CT, 2000, J MUSCLE RES CELL M, V21, P139, DOI 10.1023/A:1005610007209; Murphy CT, 1998, BIOCHEMISTRY-US, V37, P6738, DOI 10.1021/bi972903j; Nakao K, 1997, J CLIN INVEST, V100, P2362, DOI 10.1172/JCI119776; Nguyen TTT, 1996, CIRC RES, V79, P222, DOI 10.1161/01.RES.79.2.222; Palermo J, 1996, CIRC RES, V78, P504, DOI 10.1161/01.RES.78.3.504; Palmiter KA, 1999, J PHYSIOL-LONDON, V519, P669, DOI 10.1111/j.1469-7793.1999.0669n.x; PARDEE JD, 1982, METHOD CELL BIOL, V24, P271; Pereira JS, 2001, J BIOL CHEM, V276, P4409, DOI 10.1074/jbc.M006441200; POWERS FM, 1995, AM J PHYSIOL-CELL PH, V268, pC1348, DOI 10.1152/ajpcell.1995.268.6.C1348; RAYMENT I, 1993, SCIENCE, V261, P58, DOI 10.1126/science.8316858; Reiser PJ, 1998, AM J PHYSIOL-HEART C, V274, pH1048, DOI 10.1152/ajpheart.1998.274.3.H1048; REISER PJ, 1985, J BIOL CHEM, V260, P9077; Reiser PJ, 2001, AM J PHYSIOL-HEART C, V280, pH1814, DOI 10.1152/ajpheart.2001.280.4.H1814; Rosen MR, 2001, LANCET, V357, P468, DOI 10.1016/S0140-6736(00)04020-4; Rouslin W, 1996, AM J PHYSIOL-CELL PH, V270, pC1271, DOI 10.1152/ajpcell.1996.270.5.C1271; Sanbe A, 2001, J BIOL CHEM, V276, P32682, DOI 10.1074/jbc.M009975200; SANCHEZ A, 1991, J BIOL CHEM, V266, P22419; SPUDICH JA, 1994, NATURE, V372, P515, DOI 10.1038/372515a0; SUBRAMANIAM A, 1993, J BIOL CHEM, V268, P4331; Sugiura S, 1998, ADV EXP MED BIOL, V453, P125; Sweeney HL, 1998, J BIOL CHEM, V273, P6262, DOI 10.1074/jbc.273.11.6262; Tardiff JC, 2000, AM J PHYSIOL-HEART C, V278, pH412, DOI 10.1152/ajpheart.2000.278.2.H412; Tyska MJ, 2000, CIRC RES, V86, P737, DOI 10.1161/01.RES.86.7.737; UYEDA TQP, 1994, NATURE, V368, P567, DOI 10.1038/368567a0; Weiss A, 1999, J MOL BIOL, V290, P61, DOI 10.1006/jmbi.1999.2865	46	86	90	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 9	2003	278	19					17466	17474		10.1074/jbc.M210804200	http://dx.doi.org/10.1074/jbc.M210804200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677QG	12626511	hybrid			2022-12-25	WOS:000182818600134
J	Li, YX; Xie, MX; Song, XL; Gragen, S; Sachdeva, K; Wan, YS; Yan, BF				Li, YX; Xie, MX; Song, XL; Gragen, S; Sachdeva, K; Wan, YS; Yan, BF			DEC1 negatively regulates the expression of DEC2 through binding to the E-box in the proximal promoter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOOP-HELIX PROTEINS; TRANSCRIPTIONAL REPRESSION; MOLECULAR CHARACTERIZATION; INDUCED APOPTOSIS; GENE; ACTIVATION; STRA13; SPLIT; HAIRY; ENHANCER	Human DEC (differentially expressed in chondrocytes), mouse STRA (stimulated with retinoic acid), and rat SHARP (split and hairy related protein) proteins constitute a new and structurally distinct class of the basic helix-loop-helix proteins. In each species, two members are identified with a sequence identity of >90% in the basic helix-loop-helix region and similar to40% in the total proteins, respectively. Recently, we have reported that DEC1 is abundantly expressed in colon carcinomas but not in the adjacent normal tissues. The present study was undertaken to extend the expression study of DEC1 and to determine whether DEC1 and DEC2 had similar expression patterns among paired cancer-normal tissues from the colon, lung, and kidney. Without exceptions, DEC1 was markedly higher in the carcinomas, whereas the opposite was true with DEC2. In stable transfectants, tetracycline-induced expression of DEC1 caused proportional decreases in the expression of DEC2. Co-transfection with DEC1 repressed the activity of a DEC2 promoter reporter by as much as 90%. The repression was observed with wild type DEC1 but not its DNA binding-defective mutants. Studies with deletion and site-directed mutants located, in the proximal promoter, an E-box motif that supported the DEC1-mediated repression. Disruption of this E-box markedly abolished the ability of the reporter to respond to DEC1. Our findings assign for DEC1 the first target gene that is regulated through direct DNA binding. DEC/STRA/SHARP proteins are highly identical in the DNA binding domain but much more diverse in other areas. DEC1-mediated repression on the expression of DEC2 provides an important mechanism that these transcription factors regulate the cellular function not only by modulating the expression of their target genes but also the expression of members within the same class.	Univ Rhode Isl, Dept Biomed Sci, Kingston, RI 02881 USA; Providence Coll, Dept Biol, Providence, RI 02908 USA	University of Rhode Island; Providence College	Yan, BF (corresponding author), Univ Rhode Isl, Dept Biomed Sci, Kingston, RI 02881 USA.		Song, Xiulong/O-2814-2013		NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM061988] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01GM61988] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AKAZAWA C, 1992, J BIOL CHEM, V267, P21879; BISSONNETTE RP, 1994, J EXP MED, V180, P2413, DOI 10.1084/jem.180.6.2413; Boudjelal M, 1997, GENE DEV, V11, P2052, DOI 10.1101/gad.11.16.2052; Chen GQ, 1999, GENE DEV, V13, P2218, DOI 10.1101/gad.13.17.2218; CRONMILLER C, 1988, GENE DEV, V2, P1666, DOI 10.1101/gad.2.12a.1666; DAWSON SR, 1995, MOL CELL BIOL, V15, P6923; Fisher AL, 1996, MOL CELL BIOL, V16, P2670; Fujimoto K, 2001, BIOCHEM BIOPH RES CO, V280, P164, DOI 10.1006/bbrc.2000.4133; Garriga-Canut M, 2001, J BIOL CHEM, V276, P14821, DOI 10.1074/jbc.M011619200; Giebel B, 1997, P NATL ACAD SCI USA, V94, P6250, DOI 10.1073/pnas.94.12.6250; Hirose K, 1996, MOL CELL BIOL, V16, P1706; Hojo M, 2000, DEVELOPMENT, V127, P2515; Honma S, 2002, NATURE, V419, P841, DOI 10.1038/nature01123; Hu MW, 1999, ANAL BIOCHEM, V266, P233, DOI 10.1006/abio.1998.2954; Ivanova AV, 2001, J BIOL CHEM, V276, P15306, DOI 10.1074/jbc.M010516200; Katti MV, 2000, PROTEIN SCI, V9, P1203, DOI 10.1110/ps.9.6.1203; Kokubo H, 1999, BIOCHEM BIOPH RES CO, V260, P459, DOI 10.1006/bbrc.1999.0880; Li YX, 2002, BIOCHEM J, V367, P413, DOI 10.1042/BJ20020514; Littlewood T.D., 1998, HELIX LOOP HELIX TRA, P1; Massari ME, 2000, MOL CELL BIOL, V20, P429, DOI 10.1128/MCB.20.2.429-440.2000; Miyazaki K, 2002, J BIOL CHEM, V277, P47014, DOI 10.1074/jbc.M204938200; NIKOLOFF DM, 1992, NUCLEIC ACIDS RES, V20, P3253, DOI 10.1093/nar/20.12.3253; Ohtsuka T, 2001, J BIOL CHEM, V276, P30467, DOI 10.1074/jbc.M102420200; Poortinga G, 1998, EMBO J, V17, P2067, DOI 10.1093/emboj/17.7.2067; Rossner MJ, 1997, MOL CELL NEUROSCI, V9, P460, DOI 10.1006/mcne.1997.0640; Shen M, 2002, J BIOL CHEM, V277, P50112, DOI 10.1074/jbc.M206771200; SHEN M, 1997, ARCH BIOCHEM BIOPHYS, V336, P294; St-Pierre B, 2002, J BIOL CHEM, V277, P46544, DOI 10.1074/jbc.M111652200; Sun H, 2000, P NATL ACAD SCI USA, V97, P4058, DOI 10.1073/pnas.070526297; Sun H, 2001, NAT IMMUNOL, V2, P1040, DOI 10.1038/ni721; Yun Z, 2002, DEV CELL, V2, P331, DOI 10.1016/S1534-5807(02)00131-4; Zawel L, 2002, P NATL ACAD SCI USA, V99, P2848, DOI 10.1073/pnas.261714999; Zhang H, 1999, ARCH BIOCHEM BIOPHYS, V368, P14, DOI 10.1006/abbi.1999.1307; Zhu WZ, 2000, DRUG METAB DISPOS, V28, P186	34	105	108	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 9	2003	278	19					16899	16907		10.1074/jbc.M300596200	http://dx.doi.org/10.1074/jbc.M300596200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677QG	12624110	Green Published, hybrid			2022-12-25	WOS:000182818600062
J	Philippar, K; Buchsenschutz, K; Abshagen, M; Fuchs, I; Geiger, D; Lacombe, B; Hedrich, R				Philippar, K; Buchsenschutz, K; Abshagen, M; Fuchs, I; Geiger, D; Lacombe, B; Hedrich, R			The K+ channel KZM1 mediates potassium uptake into the phloem and guard cells of the C-4 grass Zea mays	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SUCROSE-EXPORT; BUNDLE-SHEATH; ARABIDOPSIS-THALIANA; PLASMA-MEMBRANE; MAIZE; EXPRESSION; LEAF; AKT1; PLASMODESMATA; SENSITIVITY	In search of K+ channel genes expressed in the leaf of the C-4 plant Zea mays, we isolated the cDNA of KZM1 (for K+ channel Zea mays 1). KZM1 showed highest similarity to the Arabidopsis K+ channels KAT1 and KAT2, which are localized in guard cells and phloem. When expressed in Xenopus oocytes, KZM1 exhibited the characteristic features of an inward-rectifying, potassium-selective channel. In contrast to KAT1- and KAT2-type K+ channels, however, KZM1 currents were insensitive to external pH changes. Northern blot analyses identified the leaf, nodes, and silks as sites of KZM1 expression. Following the separation of maize leaves into epidermal, mesophyll, and vascular fractions, quantitative real-time reverse transcriptase-PCR allowed us to localize KZM1 transcripts predominantly in vascular strands and the epidermis. Cell tissue separation and KZM1 localization were followed with marker genes such as the bundle sheath-specific ribulose-1,5-bisphosphate carboxylase, the phloem K+ channel ZMK2, and the putative sucrose transporter ZmSUT1. When expressed in Xenopus oocytes, ZmSUT1 mediated proton-coupled sucrose symport. Coexpression of ZmSUT1 with the phloem K+ channels KZM1 and ZMK2 revealed that ZMK2 is able to stabilize the membrane potential during phloem loading/unloading processes and KZM1 to mediate K+ uptake. During leaf development, sink-source transitions, and diurnal changes, KZM1 is constitutively expressed, pointing to a housekeeping function of this channel in K+ homeostasis of the maize leaf. Therefore, the voltage-dependent K+-uptake channel KZM1 seems to mediate K+ retrieval and K+ loading into the phloem as well as K+-dependent stomatal opening.	Univ Wurzburg, Lehrstuhl Mol Pflanzenphysiol & Biophys, Julius von Sachs Inst, D-97082 Wurzburg, Germany; Univ Kiel, Zentrum Biochem & Mol Biol, D-24098 Kiel, Germany	University of Wurzburg; University of Kiel	Hedrich, R (corresponding author), Univ Wurzburg, Lehrstuhl Mol Pflanzenphysiol & Biophys, Julius von Sachs Inst, Julius von Sachs Pl 2, D-97082 Wurzburg, Germany.	hedrich@botanik.uni-wuerzburg.de	Lacombe, Benoit/B-1202-2013; Hedrich, Rainer/G-8771-2011; Geiger, Dietmar/D-6914-2014; Philippar, Katrin/F-7942-2018; Geiger, Dietmar/AAH-8140-2019	Hedrich, Rainer/0000-0003-3224-1362; Geiger, Dietmar/0000-0003-0715-5710; Geiger, Dietmar/0000-0003-0715-5710; Philippar, Katrin/0000-0002-2140-4907; Lacombe, Benoit/0000-0001-9924-3093				Ache P, 2001, PLANT J, V27, P571, DOI 10.1046/j.1365-313X.2001.t01-1-01116.x; Ache P, 2000, FEBS LETT, V486, P93, DOI 10.1016/S0014-5793(00)02248-1; ANDERSON JA, 1992, P NATL ACAD SCI USA, V89, P3736, DOI 10.1073/pnas.89.9.3736; Aoki N, 1999, PLANT CELL PHYSIOL, V40, P1072, DOI 10.1093/oxfordjournals.pcp.a029489; Apweiler R, 2001, NUCLEIC ACIDS RES, V29, P37, DOI 10.1093/nar/29.1.37; Bauer CS, 2000, PLANT J, V24, P139, DOI 10.1046/j.1365-313X.2000.00844.x; Botha CEJ, 2000, PROTOPLASMA, V214, P65, DOI 10.1007/BF02524263; Daram P, 1997, EMBO J, V16, P3455, DOI 10.1093/emboj/16.12.3455; Deeken R, 2000, PLANT J, V23, P285, DOI 10.1046/j.1365-313x.2000.00791.x; Deeken R, 2002, PLANTA, V216, P334, DOI 10.1007/s00425-002-0895-1; Dennison KL, 2001, PLANT PHYSIOL, V127, P1012, DOI 10.1104/pp.010193; Ehrhardt T, 1997, FEBS LETT, V409, P166, DOI 10.1016/S0014-5793(97)00502-4; EVERT RF, 1978, PLANTA, V138, P279, DOI 10.1007/BF00386823; Evert RF, 1996, INT J PLANT SCI, V157, P247, DOI 10.1086/297344; FAIRLEYGRENOT KA, 1992, PLANTA, V186, P282, DOI 10.1007/BF00196258; FAIRLEYGRENOT KA, 1993, PLANTA, V189, P410, DOI 10.1007/BF00194439; FRITZ E, 1983, PLANTA, V159, P193, DOI 10.1007/BF00397525; FURBANK RT, 1985, PLANTA, V164, P172, DOI 10.1007/BF00396079; Gaymard F, 1996, J BIOL CHEM, V271, P22863, DOI 10.1074/jbc.271.37.22863; Gaymard F, 1998, CELL, V94, P647, DOI 10.1016/S0092-8674(00)81606-2; Geiger D, 2002, PLANT CELL, V14, P1859, DOI 10.1105/tpc.003244; HEDRICH R, 1995, EUR BIOPHYS J, V24, P107, DOI 10.1007/BF00211406; Hirsch RE, 1998, SCIENCE, V280, P918, DOI 10.1126/science.280.5365.918; Hoth S, 1997, P NATL ACAD SCI USA, V94, P4806, DOI 10.1073/pnas.94.9.4806; Hoth S, 1999, J BIOL CHEM, V274, P11599, DOI 10.1074/jbc.274.17.11599; Hoth S, 2001, PLANT CELL, V13, P943, DOI 10.1105/tpc.13.4.943; Ivashikina N, 2001, FEBS LETT, V508, P463, DOI 10.1016/S0014-5793(01)03114-3; KANAI R, 1973, PLANT PHYSIOL, V51, P1133, DOI 10.1104/pp.51.6.1133; Keunecke M, 1997, PLANT SOIL, V196, P239, DOI 10.1023/A:1004206208968; Keunecke M, 2000, PLANTA, V210, P792, DOI 10.1007/s004250050681; Kwak JM, 2001, PLANT PHYSIOL, V127, P473, DOI 10.1104/pp.010428; Lacombe B, 2000, FEBS LETT, V466, P351, DOI 10.1016/S0014-5793(00)01093-0; Lacombe B, 2000, PLANT CELL, V12, P837, DOI 10.1105/tpc.12.6.837; LIMAN ER, 1992, NEURON, V9, P861, DOI 10.1016/0896-6273(92)90239-A; Majore I, 2002, PLANT CELL PHYSIOL, V43, P844, DOI 10.1093/pcp/pcf104; Marten I, 1999, P NATL ACAD SCI USA, V96, P7581, DOI 10.1073/pnas.96.13.7581; Maser P, 2001, PLANT PHYSIOL, V126, P1646, DOI 10.1104/pp.126.4.1646; MATSUOKA M, 1994, PLANT J, V6, P311, DOI 10.1046/j.1365-313X.1994.06030311.x; Mouline K, 2002, GENE DEV, V16, P339, DOI 10.1101/gad.213902; Muller-Rober B, 1998, J EXP BOT, V49, P293, DOI 10.1093/jexbot/49.suppl_1.293; MULLERROBER B, 1995, EMBO J, V14, P2409, DOI 10.1002/j.1460-2075.1995.tb07238.x; NAKAMURA RL, 1995, PLANT PHYSIOL, V109, P371, DOI 10.1104/pp.109.2.371; NELSON T, 1992, ANNU REV PLANT PHYS, V43, P25, DOI 10.1146/annurev.pp.43.060192.000325; Neves-Piestun BG, 2001, PLANT PHYSIOL, V125, P1419, DOI 10.1104/pp.125.3.1419; Nicholas K.B., 1997, EMBNEW NEWS, V4, P14, DOI DOI 10.11118/ACTAUN201361041061; Outlaw WH, 2002, ARCH BIOCHEM BIOPHYS, V407, P63, DOI 10.1016/S0003-9861(02)00460-5; Page RDM, 1996, COMPUT APPL BIOSCI, V12, P357; Philippar K, 1999, P NATL ACAD SCI USA, V96, P12186, DOI 10.1073/pnas.96.21.12186; Pilot G, 2001, J BIOL CHEM, V276, P3215, DOI 10.1074/jbc.M007303200; Pratelli R, 2002, PLANT PHYSIOL, V128, P564, DOI [10.1104/pp.128.2.564, 10.1104/pp.010529]; PRIOUL JL, 1996, PHOTOASSIMILATE DIST, P549; Reintanz B, 2002, P NATL ACAD SCI USA, V99, P4079, DOI 10.1073/pnas.052677799; RUSSELL SH, 1985, PLANTA, V164, P448, DOI 10.1007/BF00395960; Russin WA, 1996, PLANT CELL, V8, P645, DOI 10.1105/tpc.8.4.645; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SCHACHTMAN DP, 1992, SCIENCE, V258, P1654, DOI 10.1126/science.8966547; SENTENAC H, 1992, SCIENCE, V256, P663, DOI 10.1126/science.1585180; Stitt M, 1996, PLANT CELL, V8, P565; Szyroki A, 2001, P NATL ACAD SCI USA, V98, P2917, DOI 10.1073/pnas.051616698; Tang XD, 2000, BIOPHYS J, V78, P1255, DOI 10.1016/S0006-3495(00)76682-3; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; VANBEL AJE, 1993, ANNU REV PLANT PHYS, V44, P253, DOI 10.1146/annurev.pp.44.060193.001345; Very AA, 2002, TRENDS PLANT SCI, V7, P168, DOI 10.1016/S1360-1385(02)02262-8	63	68	81	4	27	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 9	2003	278	19					16973	16981		10.1074/jbc.M212720200	http://dx.doi.org/10.1074/jbc.M212720200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677QG	12611901	hybrid			2022-12-25	WOS:000182818600072
J	Chen, DL; Li, MY; Luo, JY; Gu, W				Chen, DL; Li, MY; Luo, JY; Gu, W			Direct interactions between HIF-1 alpha and Mdm2 modulate p53 function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RING-FINGER DOMAIN; HYPOXIA; UBIQUITINATION; HIF-1; VHL; ACTIVATION; BINDING; FAMILY	The p53 tumor suppressor is maintained at low levels in normal cells by Mdm2-mediated degradation and strongly stabilized in response to various types of stress including hypoxia. Although hypoxia-inducible factor 1alpha (HIF-1alpha) has been implicated to be involved in p53 stabilization, the precise mechanism by which HIF-1alpha regulates p53-mediated function remains unknown. Here, we found that HIF-1alpha directly binds Mdm2 both in vitro and in vivo; in contrast, p53 fails to directly interact with HIF-1alpha in vitro. Interestingly, Mdm2 expression can significantly enhance the in vivo association between p53 and HIF-1alpha, indicating that Mdm2 may act as a bridge and mediate the indirect interaction between HIF-1alpha and p53 in cells. Furthermore, HIF-1alpha protects p53 degradation mediated by Mdm2, and leads to activation of p53-mediated transcription in cells. To elucidate the mechanism of HIF-1alpha-mediated effect, we also found that HIF-1alpha can significantly suppress Mdm2-mediated p53 ubiquitination in vitro and blocks Mdm2-mediated nuclear export of p53. These results have significant implications regarding the molecular mechanism by which p58 is activated by HIF-1alpha in response to hypoxia.	Columbia Univ, Inst Canc Genet, Coll Phys & Surg, New York, NY 10032 USA; Columbia Univ, Dept Pathol, Coll Phys & Surg, New York, NY 10032 USA	Columbia University; Columbia University	Gu, W (corresponding author), Columbia Univ, Inst Canc Genet, Coll Phys & Surg, Berrie Res Pavil,Rm 412C,1150 St Nicholas Ave, New York, NY 10032 USA.	wg8@columbia.edu	Luo, Jianyuan/ABI-7585-2020	Luo, Jianyuan/0000-0001-6057-2914				An WG, 1998, NATURE, V392, P405, DOI 10.1038/32925; Blagosklonny MV, 1998, J BIOL CHEM, V273, P11995, DOI 10.1074/jbc.273.20.11995; Blagosklonny MV, 2001, ONCOGENE, V20, P395, DOI 10.1038/sj.onc.1204055; Boyd SD, 2000, NAT CELL BIOL, V2, P563, DOI 10.1038/35023500; Bruick RK, 2001, SCIENCE, V294, P1337, DOI 10.1126/science.1066373; Epstein ACR, 2001, CELL, V107, P43, DOI 10.1016/S0092-8674(01)00507-4; Geyer RK, 2000, NAT CELL BIOL, V2, P569, DOI 10.1038/35023507; Giaccia AJ, 1998, GENE DEV, V12, P2973, DOI 10.1101/gad.12.19.2973; Gu W, 1997, NATURE, V387, P819, DOI 10.1038/42972; Hansson LO, 2002, P NATL ACAD SCI USA, V99, P10305, DOI 10.1073/pnas.122347199; Harris AL, 2002, NAT REV CANCER, V2, P38, DOI 10.1038/nrc704; HOFFMAN EC, 1991, SCIENCE, V252, P954, DOI 10.1126/science.1852076; Jaakkola P, 2001, SCIENCE, V292, P468, DOI 10.1126/science.1059796; Kamura T, 2000, P NATL ACAD SCI USA, V97, P10430, DOI 10.1073/pnas.190332597; Koumenis C, 2001, MOL CELL BIOL, V21, P1297, DOI 10.1128/MCB.21.4.1297-1310.2001; Li MY, 2002, J BIOL CHEM, V277, P50607, DOI 10.1074/jbc.C200578200; Maxwell PH, 1999, NATURE, V399, P271, DOI 10.1038/20459; Ohh M, 2000, NAT CELL BIOL, V2, P423, DOI 10.1038/35017054; Prives C, 1999, J PATHOL, V187, P112; Ravi R, 2000, GENE DEV, V14, P34; Ryan KM, 2001, CURR OPIN CELL BIOL, V13, P332, DOI 10.1016/S0955-0674(00)00216-7; Semenza GL, 2000, GENE DEV, V14, P1983; Semenza GL, 2001, CURR OPIN CELL BIOL, V13, P167, DOI 10.1016/S0955-0674(00)00194-0; Semenza GL, 1999, ANNU REV CELL DEV BI, V15, P551, DOI 10.1146/annurev.cellbio.15.1.551; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; WANG GL, 1995, J BIOL CHEM, V270, P1230, DOI 10.1074/jbc.270.3.1230	26	264	295	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 18	2003	278	16					13595	13598		10.1074/jbc.C200694200	http://dx.doi.org/10.1074/jbc.C200694200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	670JV	12606552	hybrid			2022-12-25	WOS:000182405000002
J	Graveel, CR; Harkins-Perry, SR; Acevedo, LG; Farnham, PJ				Graveel, CR; Harkins-Perry, SR; Acevedo, LG; Farnham, PJ			Identification and characterization of CRG-L2, a new marker for liver tumor development	ONCOGENE			English	Article						hepatocellular carcinoma; cancer testis antigen; olfactomedin domain; tumor marker; rapid amplification of cDNA ends	EXPRESSION; PROTEIN; GENE; DIETHYLNITROSAMINE; C57BL/6J; LESIONS; FAMILY; TESTIS; MEMBER; FOCI	Liver cancer is very common worldwide and the rates of hepatocellular carcinoma (HCC) have increased by over 70% in the last 2 decades in the US. Late diagnosis, because of the lack of clinical symptoms, and decreased hepatic function, because of underlying hepatic disease, lead to the extremely high mortality rates associated with HCC. Clearly, the identification of markers that are expressed early in the development of HCC and that are easily detected in high-risk patients would aid in early diagnosis and increased survival. We present the cloning and characterization of a novel gene, CRG-L2 (Cancer related gene-Liver 2), which displays high expression in murine and human hepatocellular carcinomas. Using in situ hybridization, we show that CRG-L2 mRNA levels are increased early during the development of liver tumors in C3H/HeJ mice, and that in normal tissues CRG-L2 mRNA is restricted to the murine testis and human placenta. Its restricted expression in normal tissues and unique early upregulation during tumor development make CRG-L2 an excellent candidate as a new clinical marker of HCC.	Univ Wisconsin, McArdle Lab Canc Res, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison	Farnham, PJ (corresponding author), Univ Wisconsin, McArdle Lab Canc Res, 1400 Univ Ave, Madison, WI 53706 USA.	farnham@oncology.wisc.edu		Farnham, Peggy/0000-0003-4469-7914	NCI NIH HHS [CA22484, CA14520] Funding Source: Medline; NIGMS NIH HHS [GM08349] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA022484, P30CA014520] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		*AM CANC SOC, 2002, CANC FACTS FIG 2002, P1; Borscheri N, 2001, AM J SURG PATHOL, V25, P1297, DOI 10.1097/00000478-200110000-00011; Bosch FX, 1999, SEMIN LIVER DIS, V19, P271, DOI 10.1055/s-2007-1007117; Brinkmann U, 1998, P NATL ACAD SCI USA, V95, P10757, DOI 10.1073/pnas.95.18.10757; El-Serag HB, 1999, NEW ENGL J MED, V340, P745, DOI 10.1056/NEJM199903113401001; Gilboa E, 1999, IMMUNITY, V11, P263, DOI 10.1016/S1074-7613(00)80101-6; Graveel CR, 2001, ONCOGENE, V20, P2704, DOI 10.1038/sj.onc.1204391; HANIGAN MH, 1988, CARCINOGENESIS, V9, P885, DOI 10.1093/carcin/9.6.885; KOEN H, 1983, CANCER RES, V43, P702; Kulkarni NH, 2000, GENET RES, V76, P41, DOI 10.1017/S0016672300004584; Lukas ER, 1999, MOL CARCINOGEN, V25, P295, DOI 10.1002/(SICI)1098-2744(199908)25:4<295::AID-MC8>3.0.CO;2-9; Micales BK, 2001, METHODS, V23, P313, DOI 10.1006/meth.2000.1143; MOORE MR, 1981, CANCER RES, V41, P1585; Ono T, 2001, P NATL ACAD SCI USA, V98, P3282, DOI 10.1073/pnas.041625098; Rainov NG, 1995, CLIN CANCER RES, V1, P775; Richards JE, 1998, OPHTHALMOLOGY, V105, P1698, DOI 10.1016/S0161-6420(98)99041-8; RIGBY PWJ, 1977, J MOL BIOL, V113, P237, DOI 10.1016/0022-2836(77)90052-3; Scanlan MJ, 2000, CANCER LETT, V150, P155, DOI 10.1016/S0304-3835(99)00385-7; Scanlan MJ, 2002, INT J CANCER, V98, P485, DOI 10.1002/ijc.10276; Song BC, 2002, CANCER-AM CANCER SOC, V94, P175, DOI 10.1002/cncr.10170; Struss AK, 2001, ONCOGENE, V20, P4107, DOI 10.1038/sj.onc.1204552; Tureci O, 1998, P NATL ACAD SCI USA, V95, P5211, DOI 10.1073/pnas.95.9.5211; VESSELINOVITCH SD, 1985, CANCER RES, V45, P2774; Zhang JC, 2002, GENE, V283, P83, DOI 10.1016/S0378-1119(01)00763-6	24	16	19	1	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 20	2003	22	11					1730	1736		10.1038/sj.onc.1206309	http://dx.doi.org/10.1038/sj.onc.1206309			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	655YH	12642876				2022-12-25	WOS:000181580500015
J	Takamiya, R; Takahashi, M; Myint, T; Park, YS; Miyazawa, N; Endo, T; Fujiwara, N; Sakiyama, H; Misonou, Y; Miyamoto, Y; Fujii, J; Taniguchi, N				Takamiya, R; Takahashi, M; Myint, T; Park, YS; Miyazawa, N; Endo, T; Fujiwara, N; Sakiyama, H; Misonou, Y; Miyamoto, Y; Fujii, J; Taniguchi, N			Glycation proceeds faster in mutated Cu, Zn-superoxide dismutases related to familial amyotrophic lateral sclerosis	FASEB JOURNAL			English	Article						ROS; hydrogen peroxide; copper; posttranslational modification	MUTANT CU,ZN-SUPEROXIDE DISMUTASES; END-PRODUCTS; NEURODEGENERATIVE DISEASES; IMMUNOLOGICAL DETECTION; WILD-TYPE; IN-VITRO; MUTATIONS; AGGREGATION; SOD1; GENE	Amyotrophic lateral sclerosis (ALS) involves the progressive degeneration of motor neurons in the spinal cord and motor cortex. It has been shown that 15-20% of patients with familial ALS (FALS) have defects in the Sod1 gene that encodes Cu, Zn-superoxide dismutase (SOD). To elucidate the pathological role of mutated Cu, Zn-SODs in FALS, the susceptibility of mutants to glycation was examined. Mutated Cu, Zn-SODs (G37R, G93A, and I113T) related to FALS and wild type were produced in a baculovirus/insect cell expression system. Glycated and nonglycated proteins were separated on a boronate column, and the nonglycated fraction was then incubated with glucose. The mutated Cu, Zn-SODs were found to be highly susceptible to glycation compared with the wild-type enzyme as estimated by Western blot analysis using an anti-hexitol lysine antibody. The mutated Cu, Zn-SOD incubated with glucose generated higher levels of hydrogen peroxide than the wild-type enzyme. Mutated Cu, Zn-SODs were also shown to be highly susceptible to fructation, and the fructated mutant also produced higher levels of hydrogen peroxide than the wild type. These results suggest that high susceptibility of mutated Cu, Zn-SODs to glycation could be the origin of the oxidative stress associated with neuronal dysfunction in FALS.	Osaka Univ, Sch Med, Dept Biochem, Osaka 5650871, Japan; Yamagata Univ, Sch Med, Dept Biochem, Yamagata 9909585, Japan	Osaka University; Yamagata University	Taniguchi, N (corresponding author), Osaka Univ, Sch Med, Dept Biochem, 2-2 Yamadaoka, Osaka 5650871, Japan.	proftani@biochem.med.osaka-u.ac.jp	Taniguchi, Naoyuki/A-7086-2016; Taniguchi, Naoyuki/I-4182-2014; Park, Yong Seek/ABG-6398-2021; Takahashi, Motoko/I-3154-2013	Taniguchi, Naoyuki/0000-0001-5889-5968; Park, Yong Seek/0000-0002-9260-3102; Takahashi, Motoko/0000-0002-2112-6142				ANDERSEN PM, 1999, AMYOTROPH LATERAL SC, P223; ARAI K, 1987, J BIOL CHEM, V262, P16969; BEAUCHAM.C, 1971, ANAL BIOCHEM, V44, P276, DOI 10.1016/0003-2697(71)90370-8; BORCHELT DR, 1994, P NATL ACAD SCI USA, V91, P8292, DOI 10.1073/pnas.91.17.8292; Bruijn LI, 1998, SCIENCE, V281, P1851, DOI 10.1126/science.281.5384.1851; Cleveland DW, 2000, NAT MED, V6, P1320, DOI 10.1038/82122; DENG HX, 1993, SCIENCE, V261, P1047, DOI 10.1126/science.8351519; Eum WS, 1999, MOL CELLS, V9, P110; FUJII J, 1995, J NEUROCHEM, V64, P1456; Fujii J, 1996, NEPHROL DIAL TRANSPL, V11, P34; JAING ZY, 1990, FEBS LETT, V268, P69; Kato H, 1999, GENES IMMUN, V1, P97, DOI 10.1038/sj.gene.6363638; Kato S, 2000, ACTA NEUROPATHOL, V100, P490, DOI 10.1007/s004010000226; Kawasaki Y, 1998, FEBS LETT, V441, P116, DOI 10.1016/S0014-5793(98)01529-4; Miyazawa N, 1998, BIOCHEM J, V336, P101, DOI 10.1042/bj3360101; MYINT T, 1995, BBA-MOL BASIS DIS, V1272, P73, DOI 10.1016/0925-4439(95)00067-E; NIWA J, 2002, J BIOL CHEM; Okado-Matsumoto A, 2000, FREE RADICAL RES, V33, P65, DOI 10.1080/10715760000300621; OOKAWARA T, 1992, J BIOL CHEM, V267, P18505; PAULTON KR, 1993, FUNC NEUROL, V8, P33; RABIZADEH S, 1995, P NATL ACAD SCI USA, V92, P3024, DOI 10.1073/pnas.92.7.3024; ROSEN DR, 1993, NATURE, V362, P59, DOI 10.1038/362059a0; SAKURAI T, 1998, FEBS LETT, P406; Sasaki N, 1998, AM J PATHOL, V153, P1149, DOI 10.1016/S0002-9440(10)65659-3; Shibata N, 1999, ACTA NEUROPATHOL, V97, P240, DOI 10.1007/s004010050980; Shibata N, 2001, BRAIN RES, V917, P97, DOI 10.1016/S0006-8993(01)02926-2; Shibata N, 2002, ACTA NEUROPATHOL, V104, P171, DOI 10.1007/s00401-002-0537-5; Shibata N, 2000, ACTA NEUROPATHOL, V100, P275, DOI 10.1007/s004019900173; Shinpo K, 2000, BRAIN RES, V861, P151, DOI 10.1016/S0006-8993(00)02047-3; VITEK MP, 1994, P NATL ACAD SCI USA, V91, P4766, DOI 10.1073/pnas.91.11.4766; Wong PC, 2002, NAT NEUROSCI, V5, P633, DOI 10.1038/nn0702-633	31	28	28	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2003	17	3					938	+		10.1096/fj.02-0768fje	http://dx.doi.org/10.1096/fj.02-0768fje			18	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	661LT	12626432				2022-12-25	WOS:000181892600023
J	Tarsounas, M; Davies, D; West, SC				Tarsounas, M; Davies, D; West, SC			BRCA2-dependent and independent formation of RAD51 nuclear foci	ONCOGENE			English	Article						recombination; DNA repair; genome stability; breast cancer	DNA-DAMAGE; HOMOLOGOUS RECOMBINATION; CANCER SUSCEPTIBILITY; CELL-CYCLE; BRCA2; PROTEIN; REPAIR; GENE; ASSOCIATION; DEFICIENCY	The formation of RAD51 foci in response to ionizing radiation (IR) represents an important step in the repair of DNA double-strand breaks. RAD51 foci also appear during S phase and are thought to be required for the restart of stalled or broken replication forks. The RAD51 recombinase interacts directly with the breast cancer-associated tumour suppressor BRCA2, an interaction that is required for normal recombination proficiency, radiation resistance and genome stability. In CAPAN-1 cells, which express a truncated form of BRCA2 that is cytoplasmic because of loss of the nuclear localization signal, the formation of IR-induced RAD51 foci is impaired. In this work, we show that S-phase RAD51 foci form normally in CAPAN-1 cells expressing truncated BRCA2. Moreover, we find that RAD51 specifically associates with chromatin at S phase in a reaction that is BRCA2-independent. The observed BRCA2-dependent and independent formation of RAD51 foci shows that intact BRCA2 is not required for RAD51 focus formation per se, leading us to suggest that S phase and IR-induced RAD51 foci assemble by distinct pathways with defined protein requirements.	Canc Res UK, London Res Inst, Clare Hall Labs, S Mimms EN6 3LD, Herts, England	Cancer Research UK	West, SC (corresponding author), Canc Res UK, London Res Inst, Clare Hall Labs, S Mimms EN6 3LD, Herts, England.	stephen.west@cancer.org.uk		West, Stephen/0000-0001-8848-9418; Davies, Derek/0000-0002-6977-4181				Barlow AL, 1997, EMBO J, V16, P5207, DOI 10.1093/emboj/16.17.5207; Bhattacharyya A, 2000, J BIOL CHEM, V275, P23899, DOI 10.1074/jbc.C000276200; Bishop DK, 1998, J BIOL CHEM, V273, P21482, DOI 10.1074/jbc.273.34.21482; Chen FQ, 1997, MUTAT RES-DNA REPAIR, V384, P205, DOI 10.1016/S0921-8777(97)00020-7; Chen JJ, 1998, MOL CELL, V2, P317, DOI 10.1016/S1097-2765(00)80276-2; Chen PL, 1998, P NATL ACAD SCI USA, V95, P5287, DOI 10.1073/pnas.95.9.5287; Connor F, 1997, NAT GENET, V17, P423, DOI 10.1038/ng1297-423; Darzynkiewicz Z, 1999, EXP CELL RES, V249, P1, DOI 10.1006/excr.1999.4477; Davies AA, 2001, MOL CELL, V7, P273, DOI 10.1016/S1097-2765(01)00175-7; Dimitrova DS, 1999, J CELL BIOL, V146, P709, DOI 10.1083/jcb.146.4.709; Essers J, 2002, EMBO J, V21, P2030, DOI 10.1093/emboj/21.8.2030; Flygare J, 1996, BBA-MOL CELL RES, V1312, P231, DOI 10.1016/0167-4889(96)00040-7; Godthelp BC, 2002, ONCOGENE, V21, P5002, DOI 10.1038/sj.onc.1205656; Goggins M, 1996, CANCER RES, V56, P5360; Golub EI, 1998, NUCLEIC ACIDS RES, V26, P5388, DOI 10.1093/nar/26.23.5388; HAAF T, 1995, P NATL ACAD SCI USA, V92, P2298, DOI 10.1073/pnas.92.6.2298; Howlett NG, 2002, SCIENCE, V297, P606, DOI 10.1126/science.1073834; Huber LJ, 2001, MOL CELL BIOL, V21, P4005, DOI 10.1128/MCB.21.12.4005-4015.2001; Kerr P, 2001, CURR BIOL, V11, pR668, DOI 10.1016/S0960-9822(01)00389-X; Kraakman-van der Zwet M, 2002, MOL CELL BIOL, V22, P669, DOI 10.1128/MCB.22.2.669-679.2002; Marmorstein LY, 1998, P NATL ACAD SCI USA, V95, P13869, DOI 10.1073/pnas.95.23.13869; Mizuta R, 1997, P NATL ACAD SCI USA, V94, P6927, DOI 10.1073/pnas.94.13.6927; Moens PB, 1997, CHROMOSOMA, V106, P207, DOI 10.1007/s004120050241; Moynahan ME, 2001, MOL CELL, V7, P263, DOI 10.1016/S1097-2765(01)00174-5; Moynahan ME, 1999, MOL CELL, V4, P511, DOI 10.1016/S1097-2765(00)80202-6; O'Regan P, 2001, J BIOL CHEM, V276, P22148, DOI 10.1074/jbc.M102396200; Patel KJ, 1998, MOL CELL, V1, P347, DOI 10.1016/S1097-2765(00)80035-0; Plug AW, 1996, P NATL ACAD SCI USA, V93, P5920, DOI 10.1073/pnas.93.12.5920; Raderschall E, 1999, P NATL ACAD SCI USA, V96, P1921, DOI 10.1073/pnas.96.5.1921; Scully R, 1997, CELL, V88, P265, DOI 10.1016/S0092-8674(00)81847-4; Scully R, 1997, CELL, V90, P425, DOI 10.1016/S0092-8674(00)80503-6; Sharan SK, 1997, NATURE, V386, P804, DOI 10.1038/386804a0; Spain BH, 1999, P NATL ACAD SCI USA, V96, P13920, DOI 10.1073/pnas.96.24.13920; Takei Y, 2001, EMBO REP, V2, P119, DOI 10.1093/embo-reports/kve026; Tan TLR, 1999, CURR BIOL, V9, P325, DOI 10.1016/S0960-9822(99)80142-0; Tashiro S, 2000, J CELL BIOL, V150, P283, DOI 10.1083/jcb.150.2.283; Tashiro S, 1996, ONCOGENE, V12, P2165; Tutt A, 1999, CURR BIOL, V9, P1107, DOI 10.1016/S0960-9822(99)80479-5; Venkitaraman AR, 2002, CELL, V108, P171, DOI 10.1016/S0092-8674(02)00615-3; WALKER GC, 1985, ANNU REV BIOCHEM, V54, P425, DOI 10.1146/annurev.bi.54.070185.002233; Welcsh PL, 2000, TRENDS GENET, V16, P69, DOI 10.1016/S0168-9525(99)01930-7; Xia F, 2001, P NATL ACAD SCI USA, V98, P8644, DOI 10.1073/pnas.151253498; Yu VPCC, 2000, GENE DEV, V14, P1400; Yuan SSF, 1999, CANCER RES, V59, P3547	44	152	163	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 27	2003	22	8					1115	1123		10.1038/sj.onc.1206263	http://dx.doi.org/10.1038/sj.onc.1206263			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	650EK	12606939				2022-12-25	WOS:000181249700001
J	Hullin, R; Khan, IFY; Wirtz, S; Mohacsi, P; Varadi, G; Schwartz, A; Herzig, S				Hullin, R; Khan, IFY; Wirtz, S; Mohacsi, P; Varadi, G; Schwartz, A; Herzig, S			Cardiac L-type calcium channel beta-subunits expressed in human heart have differential effects on single channel characteristics	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FUNCTIONAL EXPRESSION; ALPHA(1C) SUBUNIT; SMOOTH-MUSCLE; HUMAN VENTRICLE; MESSENGER-RNAS; CA2+ CHANNELS; MODULATION; CLONING; MYOCARDIUM; PROTEIN	L-Type calcium channels are multiprotein complexes composed of pore-forming ( Ca(V)1.2) and modulatory auxiliary alpha(2)delta- and beta-subunits. We demonstrate expression of two different isoforms for the beta(2)-subunit (beta(2a), beta(2b)) and the beta(3)-subunit (beta(3a), beta(3trunc)) in human non-failing and failing ischemic myocardium. Quantitatively, in the left ventricle expression of beta(2b) transcripts prevails in the order of > beta(3) >> beta(2a). The expressed cardiac full-length beta(3)-subunit is identical to the beta(3a)- isoform, and beta(3trunc) results from deletion of exon 6 ( 20 nn) entailing a reading frameshift and translation stop at nucleotide position 495. In failing ischemic myocardium beta(3trunc) expression increases whereas overall beta(3) expression remains unchanged. Heterologous coexpression studies demonstrated that beta(2) induced larger currents through rabbit and human cardiac Ca(V)1.2 pore subunits than beta(3) isoforms. All beta-subunits increased channel availability at single channel level, but beta(2) exerted an additional, marked stimulation of rapid gating ( open and closed times, first latency), leading to higher peak current values. We conclude that cardiac beta-subunit isoforms differentially modulate calcium inward currents because of regulatory effects within the channel protein complex. Moreover, differences in the various beta-subunit gene products present in human heart might account for altered single channel behavior found in human heart failure.	Univ Cologne, Dept Pharmacol, D-50931 Cologne, Germany; Univ Hosp, Swiss Cardiovasc Ctr Bern, CH-3010 Bern, Switzerland; Univ Cincinnati, Coll Med, Inst Mol Pharmacol & Biophys, Cincinnati, OH 45267 USA	University of Cologne; University of Bern; University Hospital of Bern; University System of Ohio; University of Cincinnati	Herzig, S (corresponding author), Univ Cologne, Dept Pharmacol, Gleueler Str 24, D-50931 Cologne, Germany.			Herzig, Stefan/0000-0001-8107-5204	NHLBI NIH HHS [P01 HL 22619] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL022619] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Beguin P, 2001, NATURE, V411, P701, DOI 10.1038/35079621; BOSSE E, 1992, EMBO J, V11, P2033, DOI 10.1002/j.1460-2075.1992.tb05260.x; BOUABOULA M, 1992, J BIOL CHEM, V267, P21830; Chen XW, 2002, CIRC RES, V91, P517, DOI 10.1161/01.RES.0000033988.13062.7C; Colecraft HM, 2002, J PHYSIOL-LONDON, V541, P435, DOI 10.1113/jphysiol.2002.018515; COLLIN T, 1993, CIRC RES, V72, P1337, DOI 10.1161/01.RES.72.6.1337; COLLIN T, 1994, EUR J BIOCHEM, V220, P257, DOI 10.1111/j.1432-1033.1994.tb18621.x; ELLIS SB, 1988, SCIENCE, V241, P1661, DOI 10.1126/science.2458626; Erhardt JA, 1998, J BIOL CHEM, V273, P35222, DOI 10.1074/jbc.273.52.35222; Freise D, 1999, BIOL CHEM, V380, P897, DOI 10.1515/BC.1999.110; Haase H, 1996, J MOL MED-JMM, V74, P99; Handrock R, 1998, CARDIOVASC RES, V37, P445, DOI 10.1016/S0008-6363(97)00257-5; Handrock R, 1999, J PHYSIOL-LONDON, V521, P31, DOI 10.1111/j.1469-7793.1999.00031.x; Hasenfuss G, 1998, CARDIOVASC RES, V37, P279, DOI 10.1016/S0008-6363(97)00277-0; Hersel Joachim, 2002, Basic Research in Cardiology, V97; Hofmann F, 1999, REV PHYSIOL BIOCH P, V139, P33, DOI 10.1007/BFb0033648; HORN R, 1991, BIOPHYS J, V60, P433, DOI 10.1016/S0006-3495(91)82069-0; HULLIN R, 1992, EMBO J, V11, P885, DOI 10.1002/j.1460-2075.1992.tb05126.x; Hullin R, 1999, CIRCULATION, V100, P155, DOI 10.1161/01.CIR.100.2.155; Iwashima Y, 2001, BIOCHEM BIOPH RES CO, V280, P923, DOI 10.1006/bbrc.2000.4122; Lauven M, 1999, N-S ARCH PHARMACOL, V360, P122, DOI 10.1007/s002109900059; MILNER RE, 1991, J BIOL CHEM, V266, P7155; Murakami M, 1996, EUR J BIOCHEM, V236, P138, DOI 10.1111/j.1432-1033.1996.t01-1-00138.x; Murphy AM, 2000, SCIENCE, V287, P488, DOI 10.1126/science.287.5452.488; Neely A, 1998, BIOPHYS J, V74, pA101; Richard S, 1998, CARDIOVASC RES, V37, P300, DOI 10.1016/S0008-6363(97)00273-3; Schroder F, 1998, CIRCULATION, V98, P969, DOI 10.1161/01.CIR.98.10.969; SCHULTZ D, 1993, P NATL ACAD SCI USA, V90, P6228, DOI 10.1073/pnas.90.13.6228; Soldatov NM, 1997, J BIOL CHEM, V272, P3560, DOI 10.1074/jbc.272.6.3560; WAGNER JA, 1986, SCIENCE, V232, P515, DOI 10.1126/science.3008330; Wei S, 2000, CIRC RES, V86, P175, DOI 10.1161/01.RES.86.2.175; WELLING A, 1991, BLOOD VESSELS, V28, P154; WELLING A, 1993, CIRC RES, V73, P974, DOI 10.1161/01.RES.73.5.974; YAMADA Y, 1995, GENOMICS, V27, P312, DOI 10.1006/geno.1995.1048; Yamaguchi H, 1998, J BIOL CHEM, V273, P19348, DOI 10.1074/jbc.273.30.19348; Yamaguchi H, 2000, BIOCHEM BIOPH RES CO, V267, P156, DOI 10.1006/bbrc.1999.1926; Yang YB, 2000, J MOL CELL CARDIOL, V32, P973, DOI 10.1006/jmcc.2000.1138	37	86	88	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 13	2003	278	24					21623	21630		10.1074/jbc.M211164200	http://dx.doi.org/10.1074/jbc.M211164200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	687AT	12606548	hybrid			2022-12-25	WOS:000183354200040
J	Lindzen, M; Aizman, R; Lifshitz, Y; Lubarski, I; Karlish, SJD; Garty, H				Lindzen, M; Aizman, R; Lifshitz, Y; Lubarski, I; Karlish, SJD; Garty, H			Structure-function relations of interactions between Na,K-ATPase, the gamma subunit, and corticosteroid hormone-induced factor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NA-K-ATPASE; IMMUNOCYTOCHEMICAL LOCALIZATION; RENAL NA,K-ATPASE; ALPHA-SUBUNIT; CHIF; EXPRESSION; REGULATOR; OCCLUSION; DISTINCT; TOPOLOGY	Corticosteroid hormone-induced factor (CHIF) and the gamma subunit of the Na,K-ATPase (gamma) are two members of the FXYD family whose function has been elucidated recently. CHIF and gamma interact with the Na+ pump and alter its kinetic properties, in different ways, which appear to serve their specific physiological roles. Although functional interactions with the Na, K-ATPase have been clearly demonstrated, it is not known which domains and which residues interact with the alpha and/or beta subunits and affect the pump kinetics. The current study provides the first systematic analysis of structure-function relations of CHIF and gamma. It is demonstrated that the stability of detergent-solubilized complexes of CHIF and gamma with alpha and/or beta subunits is determined by the trans-membrane segments, especially three residues that may be involved in hydrophobic interactions. The transmembrane segments also determine the opposite effects of CHIF and gamma on the Na+ affinity of the pump, but the amino acids involved in this functional effect are different from those responsible for stable interactions with alpha.	Weizmann Inst Sci, Dept Biol Chem, IL-76100 Rehovot, Israel	Weizmann Institute of Science	Garty, H (corresponding author), Weizmann Inst Sci, Dept Biol Chem, IL-76100 Rehovot, Israel.		Aizman, R. I./AAG-2952-2019	Aizman, R. I./0000-0002-7776-4768				Aizman R, 2002, AM J PHYSIOL-RENAL, V283, pF569, DOI 10.1152/ajprenal.00376.2001; Arystarkhova E, 1999, J BIOL CHEM, V274, P33183, DOI 10.1074/jbc.274.47.33183; ATTALI B, 1995, P NATL ACAD SCI USA, V92, P6092, DOI 10.1073/pnas.92.13.6092; Beguin P, 1997, EMBO J, V16, P4250, DOI 10.1093/emboj/16.14.4250; Beguin P, 2002, EMBO J, V21, P3264, DOI 10.1093/emboj/cdf330; Beguin P, 2001, EMBO J, V20, P3993, DOI 10.1093/emboj/20.15.3993; CAPASSO JM, 1992, J BIOL CHEM, V267, P1150; Capurro C, 1996, AM J PHYSIOL-CELL PH, V271, pC753, DOI 10.1152/ajpcell.1996.271.3.C753; Carradus M, 2000, INT CONGR SER, V1207, P301; Crambert G, 2002, P NATL ACAD SCI USA, V99, P11476, DOI 10.1073/pnas.182267299; Garty H, 2002, AM J PHYSIOL-RENAL, V283, pF607, DOI 10.1152/ajprenal.00112.2002; GARTY H, 2003, IN PRESS ANN N Y ACA; GOLDSHLEGER R, 1995, BIOCHEMISTRY-US, V34, P8668, DOI 10.1021/bi00027a016; Kuster B, 2000, J BIOL CHEM, V275, P18441, DOI 10.1074/jbc.M001411200; LINDZEN M, 2003, IN PRESS ANN N Y ACA; MERCER RW, 1993, J CELL BIOL, V121, P579, DOI 10.1083/jcb.121.3.579; MUNZER JS, 1994, J BIOL CHEM, V269, P16668; PIHAKASKIEMAUNS.K, 2003, IN PRESS ANN N Y ACA; Pu HX, 2002, J BIOL CHEM, V277, P20270, DOI 10.1074/jbc.M201009200; Pu HX, 2001, J BIOL CHEM, V276, P20370, DOI 10.1074/jbc.M010836200; Shi HK, 2001, AM J PHYSIOL-RENAL, V280, pF505, DOI 10.1152/ajprenal.2001.280.3.F505; Sweadner KJ, 2000, GENOMICS, V68, P41, DOI 10.1006/geno.2000.6274; Therien AG, 1997, J BIOL CHEM, V272, P32628, DOI 10.1074/jbc.272.51.32628; Therien AG, 1999, J BIOL CHEM, V274, P12252, DOI 10.1074/jbc.274.18.12252; Wald H, 1996, AM J PHYSIOL-RENAL, V271, pF322, DOI 10.1152/ajprenal.1996.271.2.F322; Wald H, 1997, AM J PHYSIOL-RENAL, V272, pF617, DOI 10.1152/ajprenal.1997.272.5.F617; Wetzel RK, 2001, AM J PHYSIOL-RENAL, V281, pF531, DOI 10.1152/ajprenal.2001.281.3.F531	27	36	37	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 23	2003	278	21					18738	18743		10.1074/jbc.M213253200	http://dx.doi.org/10.1074/jbc.M213253200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	679PY	12626497	hybrid			2022-12-25	WOS:000182932200006
J	Mansouri, A; Ridgway, LD; Korapati, AL; Zhang, QX; Tian, L; Wang, YB; Siddik, ZH; Mills, GB; Claret, FX				Mansouri, A; Ridgway, LD; Korapati, AL; Zhang, QX; Tian, L; Wang, YB; Siddik, ZH; Mills, GB; Claret, FX			Sustained activation of JNK/p38 MAPK pathways in response to cisplatin leads to Fas ligand induction and cell death in ovarian carcinoma cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STRESS-INDUCED APOPTOSIS; PROTEIN-KINASE PATHWAY; JUN NH2-TERMINAL KINASE; CYTOCHROME-C RELEASE; DNA-DAMAGING AGENTS; N-TERMINAL KINASE; SIGNAL-TRANSDUCTION; T-CELLS; GENOTOXIC STRESS; ANTICANCER DRUGS	The efficacy of cisplatin in cancer chemotherapy is limited by the development of resistance. Although the molecular mechanisms involved in chemoresistance are poorly understood, cellular response to cisplatin is known to involve activation of MAPK and other signal transduction pathways. An understanding of early signal transduction events in the response to cisplatin could be valuable for improving the efficacy of cancer therapy. We compared cisplatin-induced activation of three MAPKs, JNK, p38, and ERK, in a cisplatin-sensitive human ovarian carcinoma cell line (2008) and its resistant subclone (2008C13). The JNK and p38 pathways were activated differentially in response to cisplatin, with the cisplatin-sensitive cells showing prolonged activation (8-12 h) and the cisplatin-resistant cells showing only transient activation (1-3 h) of JNK and p38. In the sensitive cells, inhibition of cisplatin-induced JNK and p38 activation blocked cisplatin-induced apoptosis; persistent activation of JNK resulted in hyperphosphorylation of the c-Jun transcription factor, which in turn stimulated the transcription of an immediate downstream target, the death inducer Fas ligand (FasL). Sequestration of FasL by incubation with a neutralizing anti-FasL antibody inhibited cisplatin-induced apoptosis. In contrast, chemoresistance in 2008C13 cells was associated with failure to up-regulate FasL. Moreover, in these cells, selective stimulation of the JNK/p38 MAPK pathways by adenovirus-mediated delivery of recombinant MKK7 or MKK3 led to sensitization to apoptosis through reactivating FasL expression. Thus, the JNK > c-Jun > FasL > Fas pathway plays an important role in mediating cisplatin-induced apoptosis in ovarian cancer cells, and the duration of JNK activation is critical in determining whether cells survive or undergo apoptosis.	Univ Texas, MD Anderson Canc Ctr, Dept Mol Therapeut, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Expt Therapeut, Houston, TX 77030 USA; Univ Maryland, Sch Med, Baltimore, MD 21201 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University System of Maryland; University of Maryland Baltimore	Claret, FX (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Mol Therapeut, 1515 Holcombe Blvd,POB 317, Houston, TX 77030 USA.		Abdellah, Mansouri/B-3002-2017; Claret, Francois X/R-2104-2016	Abdellah, Mansouri/0000-0003-3856-5771; Claret, Francois X/0000-0003-4629-6495; Wang, Yibin/0000-0003-0852-0767	NCI NIH HHS [P30CA16672-24, CA16672, 5P50CA86369, R01 CA090853] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA016672, R01CA090853] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adler V, 1999, EMBO J, V18, P1321, DOI 10.1093/emboj/18.5.1321; ANDREWS PA, 1990, CANCER CELL-MON REV, V2, P35; ANDREWS PA, 1988, CANCER RES, V48, P68; Behrens A, 1999, NAT GENET, V21, P326, DOI 10.1038/6854; Benhar M, 2001, MOL CELL BIOL, V21, P6913, DOI 10.1128/MCB.21.20.6913-6926.2001; Bossy-Wetzel E, 1998, EMBO J, V17, P37, DOI 10.1093/emboj/17.1.37; Camps M, 2000, FASEB J, V14, P6, DOI 10.1096/fasebj.14.1.6; Chang LF, 2001, NATURE, V410, P37, DOI 10.1038/35065000; Cobb MH, 1999, PROG BIOPHYS MOL BIO, V71, P479, DOI 10.1016/S0079-6107(98)00056-X; Cohen SM, 2001, PROG NUCLEIC ACID RE, V67, P93, DOI 10.1016/S0079-6603(01)67026-0; Davis RJ, 2000, CELL, V103, P239, DOI 10.1016/S0092-8674(00)00116-1; Delmastro DA, 1997, CANCER CHEMOTH PHARM, V39, P245; Eichhorst ST, 2001, CANCER RES, V61, P243; Eichhorst ST, 2000, MOL CELL BIOL, V20, P7826, DOI 10.1128/MCB.20.20.7826-7837.2000; Evan G, 1998, SCIENCE, V281, P1317, DOI 10.1126/science.281.5381.1317; Faris M, 1998, J IMMUNOL, V160, P134; Faris M, 1998, MOL CELL BIOL, V18, P5414, DOI 10.1128/MCB.18.9.5414; Friesen C, 1996, NAT MED, V2, P574, DOI 10.1038/nm0596-574; Fulda S, 2000, BLOOD, V95, P301, DOI 10.1182/blood.V95.1.301.001k24_301_308; HAM J, 1995, NEURON, V14, P927, DOI 10.1016/0896-6273(95)90331-3; Herdegen T, 1998, J NEUROSCI, V18, P5124, DOI 10.1523/JNEUROSCI.18-14-05124.1998; Herr I, 2001, BLOOD, V98, P2603, DOI 10.1182/blood.V98.9.2603; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; HILBERG F, 1993, NATURE, V365, P179, DOI 10.1038/365179a0; Holmstrom TH, 2000, EMBO J, V19, P5418, DOI 10.1093/emboj/19.20.5418; Jacinto E, 1998, IMMUNITY, V8, P31, DOI 10.1016/S1074-7613(00)80456-2; Kasibhatla S, 1998, MOL CELL, V1, P543, DOI 10.1016/S1097-2765(00)80054-4; KELLAND LR, 2000, PLATIMIUM BASED DRUG; KELLEY SL, 1988, SCIENCE, V241, P1813, DOI 10.1126/science.3175622; Keyse SM, 2000, CURR OPIN CELL BIOL, V12, P186, DOI 10.1016/S0955-0674(99)00075-7; KHARBANDA S, 1995, NATURE, V376, P785, DOI 10.1038/376785a0; Kolbus A, 2000, MOL CELL BIOL, V20, P575, DOI 10.1128/MCB.20.2.575-582.2000; Le-Niculescu H, 1999, MOL CELL BIOL, V19, P751; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Lippert B., 1999, CISPLATIN CHEM BIOCH; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; Liu ZG, 1996, NATURE, V384, P273, DOI 10.1038/384273a0; MANSOURI A, 2003, IN PRESS ONCOL RES; Neel BG, 1997, CURR OPIN CELL BIOL, V9, P193, DOI 10.1016/S0955-0674(97)80063-4; Niedner H, 2001, MOL PHARMACOL, V60, P1153, DOI 10.1124/mol.60.6.1153; Osborn MT, 1996, J BIOL CHEM, V271, P30950, DOI 10.1074/jbc.271.48.30950; Palacios C, 2001, CURR BIOL, V11, P1439, DOI 10.1016/S0960-9822(01)00426-2; Pandey P, 1996, J BIOL CHEM, V271, P23775, DOI 10.1074/jbc.271.39.23775; Potapova O, 1997, J BIOL CHEM, V272, P14041, DOI 10.1074/jbc.272.22.14041; Raingeaud J, 1996, MOL CELL BIOL, V16, P1247; Reed John C., 1999, Current Opinion in Oncology, V11, P68, DOI 10.1097/00001622-199901000-00014; Sanchez-Perez I, 2000, ONCOGENE, V19, P5142, DOI 10.1038/sj.onc.1203887; Sanchez-Perez I, 1999, FEBS LETT, V453, P151, DOI 10.1016/S0014-5793(99)00690-0; Sanchez-Perez I, 1998, ONCOGENE, V16, P533, DOI 10.1038/sj.onc.1201578; Shaulian E, 2000, CELL, V103, P897, DOI 10.1016/S0092-8674(00)00193-8; SIDDIK ZH, 1987, ANAL BIOCHEM, V163, P21, DOI 10.1016/0003-2697(87)90087-X; Srinivasula SM, 1998, MOL CELL, V1, P949, DOI 10.1016/S1097-2765(00)80095-7; Stadheim TA, 2002, LEUKEMIA RES, V26, P55, DOI 10.1016/S0145-2126(01)00099-6; Tournier C, 2000, SCIENCE, V288, P870, DOI 10.1126/science.288.5467.870; Tournier C, 1997, P NATL ACAD SCI USA, V94, P7337, DOI 10.1073/pnas.94.14.7337; Treisman R, 1996, CURR OPIN CELL BIOL, V8, P205, DOI 10.1016/S0955-0674(96)80067-6; Verheij M, 1996, NATURE, V380, P75, DOI 10.1038/380075a0; Wang XF, 2000, MOL CELL BIOL, V20, P4543, DOI 10.1128/MCB.20.13.4543-4552.2000; Wang YB, 1998, J BIOL CHEM, V273, P5423, DOI 10.1074/jbc.273.10.5423; Watson A, 1998, J NEUROSCI, V18, P751; Whitfield J, 2001, NEURON, V29, P629, DOI 10.1016/S0896-6273(01)00239-2; Whitmarsh AJ, 1997, MOL CELL BIOL, V17, P2360, DOI 10.1128/MCB.17.5.2360; Wu ZG, 1997, MOL CELL BIOL, V17, P7407, DOI 10.1128/MCB.17.12.7407; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; YOSHIDA M, 1994, CANCER RES, V54, P3468; Zanke BW, 1996, CURR BIOL, V6, P606, DOI 10.1016/S0960-9822(02)00547-X; Zou H, 1997, CELL, V90, P405, DOI 10.1016/S0092-8674(00)80501-2	67	302	328	0	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 23	2003	278	21					19245	19256		10.1074/jbc.M208134200	http://dx.doi.org/10.1074/jbc.M208134200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	679PY	12637505	hybrid			2022-12-25	WOS:000182932200069
J	Cameron, SJ; Malik, S; Akaike, M; Lerner-Marmarosh, N; Yan, C; Lee, JD; Abe, J; Yang, J				Cameron, SJ; Malik, S; Akaike, M; Lerner-Marmarosh, N; Yan, C; Lee, JD; Abe, J; Yang, J			Regulation of epidermal growth factor-induced connexin 43 gap junction communication by big mitogen-activated protein kinase 1/ERK5 but not ERK1/2 kinase activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTERCELLULAR COMMUNICATION; PROTEIN-KINASE-1 BMK1; WB CELLS; C-SRC; V-SRC; PHOSPHORYLATION; ERK5; CALMODULIN; INHIBITION; DISRUPTION	The gap junction protein, Cx43, plays a pivotal role in coupling cells electrically and metabolically, and the putative phosphorylation sites that modulate its function are reflected as changes in gap junction communication. Growth factor stimulation has been correlated with a decrease in gap junction communication and a parallel activation of ERK1/2; the inhibition of epidermal growth factor (EGF)-induced Cx43 gap junction uncoupling was observed by using the MEK1/2 inhibitor, PD98059. Because 1) BMK1/ERK5, another MAPK family member also activated by growth factors, possesses a phosphorylation motif similar to ERK1/2, and 2) it has been reported that PD98059 can inhibit not only MEK1/2-ERK1/2 but also MEK5-BMK1 activation, we investigated whether BMK1 can regulate EGF-induced Cx43 gap junction uncoupling and phosphorylation, comparing this to the role of ERK1/2 on Cx43 function and phosphorylation induced by EGF. Selective activation or inactivation of ERK1/2 by using a constitutively active form or a dominant negative form of MEK1 did not regulate Cx43 gap junction coupling. In contrast, we found that BMK1, selectively activated by constitutively active MEK5alpha, induced gap junction uncoupling, and the inhibition of BMK1 activation by transfection of dominant negative BMK1 prevented EGF-induced gap junction uncoupling. Activated BMK1 selectively phosphorylates Cx43 on Ser-255 in vitro and in vivo, but not on S279/S282, which are reported as the consensus phosphorylation sites for MAPK. Furthermore, by co-immunoprecipitation, we found that BMK1 directly associates with Cx43 in vivo. These data indicate that BMK1 is more important than ERK1/2 in EGF-mediated Cx43 gap junction uncoupling by association and Cx43 Ser-255 phosphorylation.	Univ Rochester, Med Ctr, Cardiovasc Res Ctr, Rochester, NY 14642 USA; Univ Rochester, Med Ctr, Dept Pharmacol Physiol, Rochester, NY 14642 USA; Univ Rochester, Med Ctr, Dept Anesthesiol, Rochester, NY 14642 USA; Scripps Res Inst, Dept Immunol, La Jolla, CA USA	University of Rochester; University of Rochester; University of Rochester; Scripps Research Institute	Abe, J (corresponding author), Univ Rochester, Med Ctr, Cardiovasc Res Ctr, Rochester, NY 14642 USA.	Jun-ichi_Abe@urmc.rochester.edu		Yan, Chen/0000-0002-1397-6358	NHLBI NIH HHS [R01 HL66919-02] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL066919] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Abe J, 1997, J BIOL CHEM, V272, P20389, DOI 10.1074/jbc.272.33.20389; Abe J, 1996, J BIOL CHEM, V271, P16586, DOI 10.1074/jbc.271.28.16586; Cavanaugh JE, 2001, J NEUROSCI, V21, P434, DOI 10.1523/JNEUROSCI.21-02-00434.2001; Duffy HS, 2002, J PHYSIOL-PARIS, V96, P243, DOI 10.1016/S0928-4257(02)00012-8; FLORIO VA, 1994, BIOCHEMISTRY-US, V33, P8948, DOI 10.1021/bi00196a012; Gao ZH, 1999, J BIOL CHEM, V274, P5972, DOI 10.1074/jbc.274.9.5972; Giepmans BNG, 2001, CELL COMMUN ADHES, V8, P219, DOI 10.3109/15419060109080727; HII CST, 1995, J BIOL CHEM, V270, P4201, DOI 10.1074/jbc.270.9.4201; HII CST, 1995, CARCINOGENESIS, V16, P1505, DOI 10.1093/carcin/16.7.1505; Hossain MZ, 1998, J CELL PHYSIOL, V176, P332, DOI 10.1002/(SICI)1097-4652(199808)176:2<332::AID-JCP11>3.3.CO;2-O; Hossain MZ, 1999, J CELL PHYSIOL, V179, P87, DOI 10.1002/(SICI)1097-4652(199904)179:1<87::AID-JCP11>3.0.CO;2-K; Kamakura S, 1999, J BIOL CHEM, V274, P26563, DOI 10.1074/jbc.274.37.26563; Kanemitsu MY, 1997, J BIOL CHEM, V272, P22824, DOI 10.1074/jbc.272.36.22824; Karihaloo A, 2001, J BIOL CHEM, V276, P9166, DOI 10.1074/jbc.M009963200; Kasler HG, 2000, MOL CELL BIOL, V20, P8382, DOI 10.1128/MCB.20.22.8382-8389.2000; Kato Y, 1997, EMBO J, V16, P7054, DOI 10.1093/emboj/16.23.7054; Lampe PD, 2000, ARCH BIOCHEM BIOPHYS, V384, P205, DOI 10.1006/abbi.2000.2131; Lau AF, 1996, J BIOENERG BIOMEMBR, V28, P359, DOI 10.1007/BF02110112; Loo LWM, 1999, MOL CARCINOGEN, V25, P187, DOI 10.1002/(SICI)1098-2744(199907)25:3<187::AID-MC5>3.3.CO;2-F; Moorby C, 2001, EXP CELL RES, V271, P238, DOI 10.1006/excr.2001.5357; MUSIL LS, 1990, J CELL BIOL, V111, P2077, DOI 10.1083/jcb.111.5.2077; Pearson G, 2001, J BIOL CHEM, V276, P7927, DOI 10.1074/jbc.M009764200; Peracchia C, 2000, J BIOL CHEM, V275, P26220, DOI 10.1074/jbc.M004007200; Petrich BG, 2002, CIRC RES, V91, P640, DOI 10.1161/01.RES.0000035854.11082.01; Polontchouk L, 2001, FASEB J, V15, P87, DOI 10.1096/fj.01-0381fje; Rivedal E, 2001, CARCINOGENESIS, V22, P1543, DOI 10.1093/carcin/22.9.1543; Spray DC, 2001, HEART PHYSL PATHOPHY, V4, P149; Toyofuku T, 2001, J BIOL CHEM, V276, P1780, DOI 10.1074/jbc.M005826200; WADE MH, 1986, SCIENCE, V232, P525, DOI 10.1126/science.3961495; Warn-Cramer BJ, 1998, J BIOL CHEM, V273, P9188, DOI 10.1074/jbc.273.15.9188; Yan C, 2001, J BIOL CHEM, V276, P10870, DOI 10.1074/jbc.M009286200; Yoshizumi M, 2000, J BIOL CHEM, V275, P11706, DOI 10.1074/jbc.275.16.11706	32	92	93	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 16	2003	278	20					18682	18688		10.1074/jbc.M213283200	http://dx.doi.org/10.1074/jbc.M213283200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677YX	12637502	hybrid			2022-12-25	WOS:000182838300141
J	Cavet, ME; Lehoux, S; Berk, BC				Cavet, ME; Lehoux, S; Berk, BC			14-3-3 beta is a p90 ribosomal S6 kinase (RSK) isoform 1-binding protein that negatively regulates RSK kinase activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NA+/H+ EXCHANGER ISOFORM-1; RAF-1 KINASE; SUBCELLULAR-LOCALIZATION; SIGNAL-TRANSDUCTION; EXOENZYME-S; T-CELLS; IN-VIVO; IDENTIFICATION; ACTIVATION; BINDING	p90 ribosomal S6 kinase 1 (RSK1) is a serine/threonine kinase that is activated by extracellular signal-related kinases 1/2 and phosphoinositide-dependent protein kinase 1 upon mitogen stimulation. Under basal conditions, RSK1 is located in the cytosol and upon stimulation, RSK1 translocates to the plasma membrane where it is fully activated. The ability of RSK1 to bind the adapter protein 14-3-3beta was investigated because RSK1 contains several putative 14-3-3-binding motifs. We demonstrate that RSK1 specifically and directly binds 14-3-3beta. This interaction was dependent on phosphorylation of serine 154 within the motif RLSKEV of RSK1. Binding of RSK1 to 14-3-3beta was maximal under basal conditions and decreased significantly upon mitogen stimulation. After 5 min of serum stimulation, a portion of 14-3-3beta and RSK1 translocated to the membrane fraction, and immunofluorescence studies demonstrated colocalization of RSK1 and 14-3-3beta at the plasma membrane in vivo. Incubation of recombinant RSK1 with 14-3-3beta decreased RSK1 kinase activity by similar to50%. Mutation of RSK1 serine 154 increased both basal and serum-stimulated RSK activity. In addition, the epidermal growth factor response of RSK1S154A was enhanced compared with wild type RSK. The amount of RSK1S154A was significantly increased in the membrane fraction under basal conditions. Increased phosphorylation of two sites essential for RSK1 kinase activity (Ser(380) and Ser(363)) in RSK1S154A compared with RSK1 wild type, demonstrated that 14-3-3 interferes with RSK1 phosphorylation. These data suggest that 14-3-3beta binding negatively regulates RSK1 activity to maintain signal specificity and that association/dissociation of the 14-3-3-betaRSK1 complex is likely to be important for mitogen-mediated RSK1 activation.	Univ Rochester, Cardiovasc Res Ctr, Rochester, NY 14642 USA; Univ Rochester, Dept Med, Rochester, NY 14642 USA	University of Rochester; University of Rochester	Berk, BC (corresponding author), Univ Rochester, Cardiovasc Res Ctr, 601 Elmwood Ave, Rochester, NY 14642 USA.			Berk, Bradford/0000-0002-2767-4115	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL044721] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL44721, HL07949] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BONNEFOYBERARD N, 1995, P NATL ACAD SCI USA, V92, P10142, DOI 10.1073/pnas.92.22.10142; Couve A, 2001, MOL CELL NEUROSCI, V17, P317, DOI 10.1006/mcne.2000.0938; Dhillon AS, 2002, EMBO J, V21, P64, DOI 10.1093/emboj/21.1.64; Fanger GR, 1998, J BIOL CHEM, V273, P3476, DOI 10.1074/jbc.273.6.3476; Frodin M, 2000, EMBO J, V19, P2924, DOI 10.1093/emboj/19.12.2924; Frodin M, 1999, MOL CELL ENDOCRINOL, V151, P65, DOI 10.1016/S0303-7207(99)00061-1; Fu HA, 2000, ANNU REV PHARMACOL, V40, P617, DOI 10.1146/annurev.pharmtox.40.1.617; Han DC, 2001, ONCOGENE, V20, P346, DOI 10.1038/sj.onc.1204068; Hausser A, 1999, J BIOL CHEM, V274, P9258, DOI 10.1074/jbc.274.14.9258; Lehoux S, 2001, J BIOL CHEM, V276, P15794, DOI 10.1074/jbc.M100410200; Light Y, 2002, MOL CELL BIOL, V22, P4984, DOI 10.1128/MCB.22.14.4984-4996.2002; Lupas A, 1996, TRENDS BIOCHEM SCI, V21, P375, DOI 10.1016/0968-0004(96)10052-9; Masters SC, 1999, BIOCHEMISTRY-US, V38, P5216, DOI 10.1021/bi982492m; MattoYelin M, 1997, MOL BIOL CELL, V8, P1889, DOI 10.1091/mbc.8.10.1889; Meller N, 1996, MOL CELL BIOL, V16, P5782; MICHAUD NR, 1995, MOL CELL BIOL, V15, P3390; MORRISON DK, 1993, J BIOL CHEM, V268, P17309; Muslin AJ, 1996, CELL, V84, P889, DOI 10.1016/S0092-8674(00)81067-3; Muslin AJ, 2000, CELL SIGNAL, V12, P703, DOI 10.1016/S0898-6568(00)00131-5; NOMURA M, 2002, J BIOL CHEM, V7, P7; Richards SA, 1999, CURR BIOL, V9, P810, DOI 10.1016/S0960-9822(99)80364-9; Richards SA, 2001, MOL CELL BIOL, V21, P7470, DOI 10.1128/MCB.21.21.7470-7480.2001; Rommel C, 1997, MECH DEVELOP, V64, P95, DOI 10.1016/S0925-4773(97)00052-X; Roy S, 1998, MOL CELL BIOL, V18, P3947, DOI 10.1128/MCB.18.7.3947; Shaywitz AJ, 1999, ANNU REV BIOCHEM, V68, P821, DOI 10.1146/annurev.biochem.68.1.821; Takahashi E, 1999, J BIOL CHEM, V274, P20206, DOI 10.1074/jbc.274.29.20206; Toshima JY, 2001, J BIOL CHEM, V276, P43471, DOI 10.1074/jbc.M104620200; Tzivion G, 2001, ONCOGENE, V20, P6331, DOI 10.1038/sj.onc.1204777; Tzivion G, 1998, NATURE, V394, P88, DOI 10.1038/27938; van Hemert MJ, 2001, BIOESSAYS, V23, P936, DOI 10.1002/bies.1134; Vik TA, 1997, BIOCHEM BIOPH RES CO, V235, P398, DOI 10.1006/bbrc.1997.6794; Wang BC, 1999, BIOCHEMISTRY-US, V38, P12499, DOI 10.1021/bi991353h; Wang HN, 1998, J BIOL CHEM, V273, P16297, DOI 10.1074/jbc.273.26.16297; Xing HM, 2000, EMBO J, V19, P349, DOI 10.1093/emboj/19.3.349; Xing J, 1998, MOL CELL BIOL, V18, P1946, DOI 10.1128/MCB.18.4.1946; Xing J, 1996, SCIENCE, V273, P959, DOI 10.1126/science.273.5277.959; Yaffe MB, 2002, FEBS LETT, V513, P53, DOI 10.1016/S0014-5793(01)03288-4; Yaffe MB, 1997, CELL, V91, P961, DOI 10.1016/S0092-8674(00)80487-0; Zhang LX, 1997, J BIOL CHEM, V272, P13717, DOI 10.1074/jbc.272.21.13717	39	37	41	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 16	2003	278	20					18376	18383		10.1074/jbc.M208475200	http://dx.doi.org/10.1074/jbc.M208475200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677YX	12618428	hybrid			2022-12-25	WOS:000182838300103
J	Gokulan, K; Rupp, B; Pavelka, MS; Jacobs, WR; Sacchettini, JC				Gokulan, K; Rupp, B; Pavelka, MS; Jacobs, WR; Sacchettini, JC			Crystal structure of Mycobacterium tuberculosis diaminopimelate decarboxylase, an essential enzyme in bacterial lysine biosynthesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EUKARYOTIC ORNITHINE DECARBOXYLASE; TRANSFER-RNA-SYNTHETASE; LYSA GENE; DENSITY-MODIFICATION; ANGSTROM RESOLUTION; UPSTREAM REGION; SEQUENCE; BINDING; PROGRAM; REFINEMENT	The Mycobacterium tuberculosis lysA gene encodes the enzyme meso-diaminopimelate decarboxylase (DAPDC), a pyridoxal-5'-phosphate (PLP)-dependent enzyme. The enzyme catalyzes the final step in the lysine biosynthetic pathway converting meso-diaminopimelic acid (DAP) to L-lysine. The lysA gene of M. tuberculosis H37Rv has been established as essential for bacterial survival in immunocompromised mice, demonstrating that de novo biosynthesis of lysine is essential for in vivo viability. Drugs targeted against DAPDC could be efficient anti-tuberculosis drugs, and the three-dimensional structure of DAPDC from M. tuberculosis complexed with reaction product lysine and the ternary complex with PLP and lysine in the active site has been determined. The first structure of a DAPDC confirms its classification as a fold type III PLP-dependent enzyme. The structure shows a stable 2-fold dimer in head-to-tail arrangement of a triose-phosphate isomerase (TIM) barrel-like alpha/beta domain and a C-terminal beta sheet domain, similar to the ornithine decarboxylase (ODC) fold family. PLP is covalently bound via an internal aldimine, and residues from both domains and both subunits contribute to the binding pocket. Comparison of the structure with eukaryotic ODCs, in particular with a difluoromethyl ornithine (DMFO)-bound ODC from Trypanosoma bruceii, indicates that corresponding DAP-analogues might be potential inhibitors for mycobacterial DAPDCs.	Texas A&M Univ, Dept Biochem & Biophys, College Stn, TX 77843 USA; Lawrence Livermore Natl Lab, Biol & Biotechnol Res Program, Livermore, CA 94551 USA; Albert Einstein Coll Med, Dept Microbiol & Immunol, Bronx, NY 10461 USA; Albert Einstein Coll Med, Howard Hughes Med Inst, Bronx, NY 10461 USA	Texas A&M University System; Texas A&M University College Station; United States Department of Energy (DOE); Lawrence Livermore National Laboratory; Yeshiva University; Albert Einstein College of Medicine; Howard Hughes Medical Institute; Yeshiva University; Albert Einstein College of Medicine	Sacchettini, JC (corresponding author), Texas A&M Univ, Dept Biochem & Biophys, College Stn, TX 77843 USA.			Rupp, Bernhard/0000-0002-3300-6965; Jacobs, William/0000-0003-3321-3080; Gokulan, Kuppan/0000-0003-4045-5993	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P50GM062410] Funding Source: NIH RePORTER; NIGMS NIH HHS [P50 GM62410] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Almrud JJ, 2000, J MOL BIOL, V295, P7, DOI 10.1006/jmbi.1999.3331; ANDERSEN AB, 1993, GENE, V124, P105, DOI 10.1016/0378-1119(93)90768-X; ASADA Y, 1984, J BIOCHEM-TOKYO, V95, P277, DOI 10.1093/oxfordjournals.jbchem.a134594; Bourot S, 2000, J BIOL CHEM, V275, P1050, DOI 10.1074/jbc.275.2.1050; CHATTERJEE SP, 1994, PLANT MOL BIOL, V26, P285, DOI 10.1007/BF00039539; Cole ST, 1998, NATURE, V393, P537, DOI 10.1038/31159; Cowtan KD, 1996, ACTA CRYSTALLOGR D, V52, P43, DOI 10.1107/S090744499500761X; Cowtan KD, 1999, PROG BIOPHYS MOL BIO, V72, P245, DOI 10.1016/S0079-6107(99)00008-5; Cruickshank DWJ, 1999, ACTA CRYSTALLOGR D, V55, P583, DOI 10.1107/S0907444998012645; CUMMINS CS, 1996, J GEN MICROBIOL, V14, P583; ENGH RA, 1991, ACTA CRYSTALLOGR A, V47, P392, DOI 10.1107/S0108767391001071; Grishin NV, 1999, BIOCHEMISTRY-US, V38, P15174, DOI 10.1021/bi9915115; GRISHIN NV, 1995, PROTEIN SCI, V4, P1291, DOI 10.1002/pro.5560040705; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; Hendrickson WA, 1997, METHOD ENZYMOL, V276, P494, DOI 10.1016/S0076-6879(97)76074-9; HOLM L, 1995, TRENDS BIOCHEM SCI, V20, P478, DOI 10.1016/S0968-0004(00)89105-7; Ioerger T R, 1999, Proc Int Conf Intell Syst Mol Biol, P130; Jackson LK, 2000, BIOCHEMISTRY-US, V39, P11247, DOI 10.1021/bi001209s; Kantardjieff KA, 2002, ACTA CRYSTALLOGR D, V58, P735, DOI 10.1107/S0O907444901019588; Kern AD, 1999, STRUCTURE, V7, P567, DOI 10.1016/S0969-2126(99)80073-2; Kissinger CR, 1999, ACTA CRYSTALLOGR D, V55, P484, DOI 10.1107/S0907444998012517; MARCEL T, 1990, MOL MICROBIOL, V4, P1819, DOI 10.1111/j.1365-2958.1990.tb02030.x; MATTHEWS BW, 1968, J MOL BIOL, V33, P491, DOI 10.1016/0022-2836(68)90205-2; MCCANN PP, 1992, PHARMACOL THERAPEUT, V54, P195, DOI 10.1016/0163-7258(92)90032-U; McRee DE, 1999, J STRUCT BIOL, V125, P156, DOI 10.1006/jsbi.1999.4094; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; Miller J. H., 1972, EXPT MOL GENETICS, P431; MISONO H, 1986, AGR BIOL CHEM TOKYO, V50, P1455; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; OGUIZA JA, 1993, J BACTERIOL, V175, P7356, DOI 10.1128/JB.175.22.7356-7362.1993; OSTERMAN AL, 1995, J BIOL CHEM, V270, P11797, DOI 10.1074/jbc.270.20.11797; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Pavelka MS, 1996, J BACTERIOL, V178, P6496, DOI 10.1128/jb.178.22.6496-6507.1996; Pavelka MS, 1999, J BACTERIOL, V181, P4780, DOI 10.1128/JB.181.16.4780-4789.1999; POULIN R, 1992, J BIOL CHEM, V267, P150; SHARP PM, 1993, MOL MICROBIOL, V8, P200, DOI 10.1111/j.1365-2958.1993.tb01217.x; Shaw JP, 1997, BIOCHEMISTRY-US, V36, P1329, DOI 10.1021/bi961856c; SHELDRICK GM, 1995, ACTA CRYSTALLOGR B, V51, P423, DOI 10.1107/S0108768195003661; STAGIER P, 1983, J BACTERIOL, V156, P1198; STROMINGER JL, 1962, FED PROC, V21, P134; SUNDHARA.G, 1967, J BIOL CHEM, V242, P3983; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; WALLACE AC, 1995, PROTEIN ENG, V8, P127, DOI 10.1093/protein/8.2.127; WHITE PJ, 1965, BIOCHEM J, V96, P75, DOI 10.1042/bj0960075	45	63	90	3	18	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 16	2003	278	20					18588	18596		10.1074/jbc.M301549200	http://dx.doi.org/10.1074/jbc.M301549200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677YX	12637582	hybrid			2022-12-25	WOS:000182838300131
J	Yamakita, Y; Oosawa, F; Yamashiro, S; Matsumura, F				Yamakita, Y; Oosawa, F; Yamashiro, S; Matsumura, F			Caldesmon inhibits Arp2/3-mediated actin nucleation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FILAMENT NETWORK FORMATION; SMOOTH-MUSCLE CALDESMON; ARP2/3 COMPLEX; NONMUSCLE CALDESMON; F-ACTIN; WASP/SCAR PROTEINS; POLYMERIZATION; PHOSPHORYLATION; TROPOMYOSIN; BINDING	The Arp2/3 complex greatly accelerates actin polymerization, which is thought to play a major role in cell motility by inducing membrane protrusions including ruffling movements. Membrane ruffles contain a variety of actin-binding proteins, which would modulate Arp2/3-dependent actin polymerization. However, their exact roles in actin polymerization remain to be established. Because caldesmon is present in membrane ruffles, as well as in stress fibers, it may alter Arp2/3-mediated actin polymerization. We have found that caldesmon greatly retards Arp2/3-induced actin polymerization. Kinetic analyses have revealed that caldesmon inhibits the nucleation process, whereas it does not largely reduce elongation. Caldesmon is found to inhibit binding of Arp2/3 to F-actin, which apparently reduces the ability of F-actin as a secondary activator of Arp2/3-mediated nucleation. We also have found that the inhibition of the binding between actin and caldesmon either by Ca2+/calmodulin or by phosphorylation with cdc2 kinase reverses the inhibitory effect of caldesmon on Arp2/3-induced actin polymerization. Our results suggest that caldesmon may be a key protein that modulates membrane ruffling and that this may involve changes in caldesmon phosphorylation and/or intracellular calcium concentrations during signal transduction.	Rutgers State Univ, Dept Mol Biol & Biochem, Nelson Labs, Piscataway, NJ 08854 USA; Aichi Inst Technol, Toyota 47003, Japan	Rutgers State University New Brunswick	Yamakita, Y (corresponding author), Rutgers State Univ, Dept Mol Biol & Biochem, Nelson Labs, Busch Campus, Piscataway, NJ 08854 USA.		Yamakita, Yoshihiko/A-3003-2016	Yamashiro, Shigeko/0000-0001-7207-9406; Matsumura, Fumio/0000-0002-8204-153X				Blanchoin L, 2001, CURR BIOL, V11, P1300, DOI 10.1016/S0960-9822(01)00395-5; BOONSTRA J, 1995, CELL BIOL INT, V19, P413, DOI 10.1006/cbir.1995.1086; BRETSCHER A, 1984, J BIOL CHEM, V259, P2873; CASTELLINO F, 1995, J CELL BIOL, V131, P1223, DOI 10.1083/jcb.131.5.1223; CHALOVICH JM, 1995, J BIOL CHEM, V270, P9911, DOI 10.1074/jbc.270.17.9911; Condeelis J, 2001, TRENDS CELL BIOL, V11, P288, DOI 10.1016/S0962-8924(01)02008-6; Condeelis JS, 2001, SEMIN CANCER BIOL, V11, P119, DOI 10.1006/scbi.2000.0363; Egile C, 1999, J CELL BIOL, V146, P1319, DOI 10.1083/jcb.146.6.1319; Goncharova EA, 2002, BIOL CHEM, V383, P115, DOI 10.1515/BC.2002.012; HALL A, 1993, PHILOS T ROY SOC B, V340, P267, DOI 10.1098/rstb.1993.0067; HAYASHI K, 1989, BIOCHEM BIOPH RES CO, V161, P38, DOI 10.1016/0006-291X(89)91556-8; Hedges JC, 1998, AM J PHYSIOL-CELL PH, V275, pC527, DOI 10.1152/ajpcell.1998.275.2.C527; Helfman DM, 1999, MOL BIOL CELL, V10, P3097, DOI 10.1091/mbc.10.10.3097; Higgs HN, 1999, J BIOL CHEM, V274, P32531, DOI 10.1074/jbc.274.46.32531; Higgs HN, 1999, BIOCHEMISTRY-US, V38, P15212, DOI 10.1021/bi991843+; Higgs HN, 2001, ANNU REV BIOCHEM, V70, P649, DOI 10.1146/annurev.biochem.70.1.649; Humphries CL, 2002, J CELL BIOL, V159, P993, DOI 10.1083/jcb.200206113; ISHIKAWA R, 1989, J BIOL CHEM, V264, P16764; ISHIKAWA R, 1989, J BIOL CHEM, V264, P7490; KOJIOWADA M, 1984, P NATL ACAD SCI USA, V81, P3133; KOUYAMA T, 1981, EUR J BIOCHEM, V114, P33; Lamb NJC, 1996, EUR J CELL BIOL, V69, P36; LEHMAN W, 1989, J MUSCLE RES CELL M, V10, P101, DOI 10.1007/BF01739966; Lim L, 1996, EUR J BIOCHEM, V242, P171, DOI 10.1111/j.1432-1033.1996.0171r.x; LIM MS, 1986, BIOCHEM J, V238, P523, DOI 10.1042/bj2380523; Marchand JB, 2001, NAT CELL BIOL, V3, P76, DOI 10.1038/35050590; Matsumura F, 1993, CURR OPIN CELL BIOL, V5, P70, DOI 10.1016/S0955-0674(05)80010-9; Mullins RD, 1999, CURR OPIN STRUC BIOL, V9, P244; Oosawa F., 1975, THERMODYNAMICS POLYM; Pelham RJ, 2002, NATURE, V419, P82, DOI 10.1038/nature00999; Pollard TD, 2000, ANNU REV BIOPH BIOM, V29, P545, DOI 10.1146/annurev.biophys.29.1.545; Ridley AJ, 1999, BIOCHEM SOC SYMP, V65, P111; Smith CE, 1998, CRIT REV ORAL BIOL M, V9, P128, DOI 10.1177/10454411980090020101; Stevenson V, 2002, CURR BIOL, V12, P705, DOI 10.1016/S0960-9822(02)00807-2; Uruno T, 2001, NAT CELL BIOL, V3, P259, DOI 10.1038/35060051; VOROTNIKOV AV, 1994, J MUSCLE RES CELL M, V15, P37, DOI 10.1007/BF00123831; Weaver AM, 2001, CURR BIOL, V11, P370, DOI 10.1016/S0960-9822(01)00098-7; Weed SA, 2001, ONCOGENE, V20, P6418, DOI 10.1038/sj.onc.1204783; Weed SA, 2000, J CELL BIOL, V151, P29, DOI 10.1083/jcb.151.1.29; YAMAKITA Y, 1992, J BIOL CHEM, V267, P12022; YAMAKITA Y, 1990, J CELL BIOL, V111, P2487, DOI 10.1083/jcb.111.6.2487; YAMASHIRO S, 1991, NATURE, V349, P169, DOI 10.1038/349169a0; Yamashiro S, 2001, MOL BIOL CELL, V12, P239, DOI 10.1091/mbc.12.1.239; YAMASHIRO S, 1994, INT C BIOPH BIOCH CE, P113; YAMASHIRO-MATSUMURA S, 1988, Protoplasma Supplementum, V2, P9; YAMASHIROMATSUMURA S, 1988, J CELL BIOL, V106, P1973, DOI 10.1083/jcb.106.6.1973; Yamboliev IA, 2001, AM J PHYSIOL-CELL PH, V280, pC1680, DOI 10.1152/ajpcell.2001.280.6.C1680	47	42	43	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 16	2003	278	20					17937	17944		10.1074/jbc.M208739200	http://dx.doi.org/10.1074/jbc.M208739200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677YX	12637566	hybrid			2022-12-25	WOS:000182838300044
J	Abram, CL; Seals, DF; Pass, I; Salinsky, D; Maurer, L; Roth, TM; Courtneidge, SA				Abram, CL; Seals, DF; Pass, I; Salinsky, D; Maurer, L; Roth, TM; Courtneidge, SA			The adaptor protein fish associates with members of the ADAMs family and localizes to podosomes of Src-transformed cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ROUS-SARCOMA VIRUS; PX DOMAIN; PHOSPHATIDYLINOSITOL 3-PHOSPHATE; SH3 DOMAIN; METALLOPROTEASE-DISINTEGRINS; INTRAMOLECULAR INTERACTION; TYROSINE PHOSPHORYLATION; EXTRACELLULAR-MATRIX; CYTOPLASMIC DOMAIN; CELLULAR INVASION	Fish is a scaffolding protein and Src substrate. It contains an amino-terminal Phox homology (PX) domain and five Src homology 3 (SH3) domains, as well as multiple motifs for binding both SH2 and SH3 domain-containing proteins. We have determined that the PX domain of Fish binds 3-phosphorylated phosphatidylinositols (including phosphatidylinositol 3-phosphate and phosphatidylinositol 3,4-bisphosphate). Consistent with this, a fusion protein of green fluorescent protein and the Fish PX domain localized to punctate structures similar to endosomes in normal fibroblasts. However, the full-length Fish protein was largely cytoplasmic, suggesting that its PX domain may not be able to make intermolecular interactions in unstimulated cells. In Src-transformed cells, we observed a dramatic re-localization of some Fish molecules to actin-rich structures called podosomes; the PX domain was both necessary and sufficient to effect this translocation. We used a phage display screen with the fifth SH3 domain of Fish and isolated ADAM19 as a binding partner. Subsequent analyses in mammalian cells demonstrated that Fish interacts with several members of the ADAMs family, including ADAMs 12, 15, and 19. In Src-transformed cells, ADAM12 co-localized with Fish in podosomes. Because members of the ADAMs family have been implicated in growth factor processing, as well as cell adhesion and motility, Fish could be acting as an adaptor molecule that allows Src to impinge on these processes.	Van Andel Res Inst, Grand Rapids, MI 49503 USA; SUGEN Inc, San Francisco, CA 94080 USA	Van Andel Institute; Pfizer	Courtneidge, SA (corresponding author), Van Andel Res Inst, 333 Bostwick NE, Grand Rapids, MI 49503 USA.	sara.courtneidge@vai.org		Maurer, Lisa/0000-0003-0492-9805				Ago T, 1999, J BIOL CHEM, V274, P33644, DOI 10.1074/jbc.274.47.33644; Banfic H, 1998, J BIOL CHEM, V273, P13, DOI 10.1074/jbc.273.1.13; Bowden ET, 1999, ONCOGENE, V18, P4440, DOI 10.1038/sj.onc.1202827; Bravo J, 2001, MOL CELL, V8, P829, DOI 10.1016/S1097-2765(01)00372-0; Cheever ML, 2001, NAT CELL BIOL, V3, P613, DOI 10.1038/35083000; CHEN WT, 1989, J EXP ZOOL, V251, P167, DOI 10.1002/jez.1402510206; CRAMERI R, 1994, EUR J BIOCHEM, V226, P53, DOI 10.1111/j.1432-1033.1994.tb20025.x; CRAMERI R, 1993, GENE, V137, P69, DOI 10.1016/0378-1119(93)90253-Y; DAVIDPFEUTY T, 1980, P NATL ACAD SCI-BIOL, V77, P6687, DOI 10.1073/pnas.77.11.6687; Deak M, 1999, FEBS LETT, V451, P220, DOI 10.1016/S0014-5793(99)00556-6; Ellson CD, 2001, NAT CELL BIOL, V3, P679, DOI 10.1038/35083076; Ellson CD, 2002, J CELL SCI, V115, P1099; Erneux C, 1998, BBA-MOL CELL BIOL L, V1436, P185, DOI 10.1016/S0005-2760(98)00132-5; Evans JD, 2001, BIOESSAYS, V23, P62, DOI 10.1002/1521-1878(200101)23:1&lt;62::AID-BIES1008&gt;3.0.CO;2-7; Galliano MF, 2000, J BIOL CHEM, V275, P13933, DOI 10.1074/jbc.275.18.13933; Gillooly DJ, 2000, EMBO J, V19, P4577, DOI 10.1093/emboj/19.17.4577; Hiroaki H, 2001, NAT STRUCT BIOL, V8, P526, DOI 10.1038/88591; Hougaard S, 2000, BIOCHEM BIOPH RES CO, V275, P261, DOI 10.1006/bbrc.2000.3295; Howard L, 1999, J BIOL CHEM, V274, P31693, DOI 10.1074/jbc.274.44.31693; Izumi Y, 1998, EMBO J, V17, P7260, DOI 10.1093/emboj/17.24.7260; Kanai F, 2001, NAT CELL BIOL, V3, P675, DOI 10.1038/35083070; Kang Q, 2001, J BIOL CHEM, V276, P24466, DOI 10.1074/jbc.M101162200; Karathanassis D, 2002, EMBO J, V21, P5057, DOI 10.1093/emboj/cdf519; Lock P, 1998, EMBO J, V17, P4346, DOI 10.1093/emboj/17.15.4346; Mizutani K, 2002, CANCER RES, V62, P669; MONSKY WL, 1994, CANCER RES, V54, P5702; Mueller SC, 1999, J BIOL CHEM, V274, P24947, DOI 10.1074/jbc.274.35.24947; MUELLER SC, 1991, J CELL SCI, V99, P213; MUELLER SC, 1992, J CELL BIOL, V119, P1309, DOI 10.1083/jcb.119.5.1309; Nakahara H, 1998, J BIOL CHEM, V273, P9, DOI 10.1074/jbc.273.1.9; Nakahara H, 1997, P NATL ACAD SCI USA, V94, P7959, DOI 10.1073/pnas.94.15.7959; Pfaff M, 2001, J CELL SCI, V114, P2775; Poghosyan Z, 2002, J BIOL CHEM, V277, P4999, DOI 10.1074/jbc.M107430200; Ponting CP, 1996, PROTEIN SCI, V5, P2353, DOI 10.1002/pro.5560051122; Primakoff P, 2000, TRENDS GENET, V16, P83, DOI 10.1016/S0168-9525(99)01926-5; Sanjay A, 2001, J CELL BIOL, V152, P181, DOI 10.1083/jcb.152.1.181; Sato TK, 2001, SCIENCE, V294, P1881, DOI 10.1126/science.1065763; Schlondorff J, 1999, J CELL SCI, V112, P3603; Seals DF, 2003, GENE DEV, V17, P7, DOI 10.1101/gad.1039703; Suzuki A, 2000, ONCOGENE, V19, P5842, DOI 10.1038/sj.onc.1203986; TARONE G, 1985, EXP CELL RES, V159, P141, DOI 10.1016/S0014-4827(85)80044-6; TETI A, 1991, AM J PHYSIOL, V261, pC1, DOI 10.1152/ajpcell.1991.261.1.C1; Wishart MJ, 2001, CELL, V105, P817, DOI 10.1016/S0092-8674(01)00414-7; Xu JS, 2001, J CELL BIOL, V154, P1069, DOI 10.1083/jcb.200103111; Xu Y, 2001, BIOCHEM J, V360, P513, DOI 10.1042/0264-6021:3600513; Yu JW, 2001, J BIOL CHEM, V276, P44179, DOI 10.1074/jbc.M108811200; Zozulya S, 1999, NAT BIOTECHNOL, V17, P1193, DOI 10.1038/70736	47	191	202	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 9	2003	278	19					16844	16851		10.1074/jbc.M300267200	http://dx.doi.org/10.1074/jbc.M300267200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677QG	12615925	hybrid			2022-12-25	WOS:000182818600054
J	Kishimoto, H; Nakagawa, K; Watanabe, T; Kitagawa, D; Momose, H; Seo, J; Nishitai, G; Shimizu, N; Ohata, S; Tanemura, S; Asaka, S; Goto, T; Fukushi, H; Yoshida, H; Suzuki, A; Sasaki, T; Wada, T; Penninger, JM; Nishina, H; Katada, T				Kishimoto, H; Nakagawa, K; Watanabe, T; Kitagawa, D; Momose, H; Seo, J; Nishitai, G; Shimizu, N; Ohata, S; Tanemura, S; Asaka, S; Goto, T; Fukushi, H; Yoshida, H; Suzuki, A; Sasaki, T; Wada, T; Penninger, JM; Nishina, H; Katada, T			Different properties of SEK1 and MKK7 in dual phosphorylation of stress-induced activated protein kinase SAPK/JNK in embryonic stem cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SYNERGISTIC ACTIVATION; SIGNAL-TRANSDUCTION; SWITCH-LIKE; IN-VITRO; CASCADE; PROLIFERATION; APOPTOSIS; SEK1/MKK4; ISOFORMS; LACKING	Stress-activated protein kinase/c-Jun NH2-terminal kinase (SAPK/JNK), belonging to the mitogen-activated protein kinase family, plays an important role in stress signaling. SAPK/JNK activation requires the phosphorylation of both Thr and Tyr residues in its Thr-Pro-Tyr motif, and SEK1 and MKK7 have been identified as the dual specificity kinases. In this study, we generated mkk7(-/-) mouse embryonic stem (ES) cells in addition to sek1(-/-) cells and compared the two kinases in terms of the activation and phosphorylation of JNK. Although SAPK/JNK activation by various stress signals was markedly impaired in both sek1(-/-) and mkk7(-/-) ES cells, there were striking differences in the dual phosphorylation profile. The severe impairment observed in mkk7(-/-) cells was accompanied by a loss of the Thr phosphorylation of JNK without marked reduction in its Tyr-phosphorylated level. On the other hand, Thr phosphorylation of JNK in sek1(-/-) cells was also attenuated in addition to a decreased level of its Tyr phosphorylation. Analysis in human embryonic kidney 293T cells transfected with a kinase-dead SEK1 or a Thr-Pro-Phe mutant of JNK1 revealed that SEK1-induced Tyr phosphorylation of JNK1 was followed by additional Thr phosphorylation by MKK7. Furthermore, SEK1 but not MKK7 was capable of binding to JNK1 in 293T cells. These results indicate that the Tyr and Thr residues of SAPK/JNK are sequentially phosphorylated by SEK1 and MKK7, respectively, in the stress-stimulated ES cells.	Univ Tokyo, Grad Sch Pharmaceut Sci, Dept Physiol Chem, Bunkyo Ku, Tokyo 1130033, Japan; Kyushu Univ, Med Inst Bioregulat, Dept Immunol, Higashi Ku, Fukuoka 8128582, Japan; Akita Univ, Sch Med, Dept Biochem, Akita 0108543, Japan; Univ Toronto, Univ Hlth Network, Dept Med Biophys, Toronto, ON M5G 2C1, Canada; Univ Toronto, Univ Hlth Network, Dept Immunol, Toronto, ON M5G 2C1, Canada	University of Tokyo; Kyushu University; Akita University; University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto; University Toronto Affiliates; University Health Network Toronto	Nishina, H (corresponding author), Univ Tokyo, Grad Sch Pharmaceut Sci, Dept Physiol Chem, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1130033, Japan.		Ohata, Shinya/S-2320-2018; Suzuki, Akira/GYD-6697-2022; Penninger, Josef M/I-6860-2013	Ohata, Shinya/0000-0003-4333-4433; Suzuki, Akira/0000-0002-5950-8808; Penninger, Josef M/0000-0002-8194-3777; Sasaki, Takehiko/0000-0003-1837-3748				Bagowski CP, 2001, CURR BIOL, V11, P1176, DOI 10.1016/S0960-9822(01)00330-X; Brown GC, 1997, TRENDS BIOCHEM SCI, V22, P288, DOI 10.1016/S0968-0004(97)82216-5; Davis RJ, 2000, CELL, V103, P239, DOI 10.1016/S0092-8674(00)00116-1; Ferrell JE, 1997, TRENDS BIOCHEM SCI, V22, P288, DOI 10.1016/S0968-0004(97)82217-7; Ferrell JE, 1996, TRENDS BIOCHEM SCI, V21, P460, DOI 10.1016/S0968-0004(96)20026-X; Fleming Y, 2000, BIOCHEM J, V352, P145, DOI 10.1042/0264-6021:3520145; Ganiatsas S, 1998, P NATL ACAD SCI USA, V95, P6881, DOI 10.1073/pnas.95.12.6881; Huang CYF, 1996, P NATL ACAD SCI USA, V93, P10078, DOI 10.1073/pnas.93.19.10078; Lawler S, 1998, CURR BIOL, V8, P1387, DOI 10.1016/S0960-9822(98)00019-0; Lisnock J, 2000, BIOCHEMISTRY-US, V39, P3141, DOI 10.1021/bi992410+; Nishina H, 1997, NATURE, V385, P350, DOI 10.1038/385350a0; Nishina H, 1997, J EXP MED, V186, P941, DOI 10.1084/jem.186.6.941; Nishina H, 1999, DEVELOPMENT, V126, P505; Sasaki T, 2001, J EXP MED, V194, P757, DOI 10.1084/jem.194.6.757; Schaeffer HJ, 1999, MOL CELL BIOL, V19, P2435; Tournier C, 2001, GENE DEV, V15, P1419, DOI 10.1101/gad.888501; Wada T, 2001, J BIOL CHEM, V276, P30892, DOI 10.1074/jbc.M011780200; Watanabe T, 2002, DEV BIOL, V250, P332, DOI 10.1006/dbio.2002.0781; Yang D, 1997, P NATL ACAD SCI USA, V94, P3004, DOI 10.1073/pnas.94.7.3004	19	62	65	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 9	2003	278	19					16595	16601		10.1074/jbc.M213182200	http://dx.doi.org/10.1074/jbc.M213182200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677QG	12624093	hybrid			2022-12-25	WOS:000182818600021
J	Ma, YH; Yuan, J; Huang, M; Jove, R; Cress, WD				Ma, YH; Yuan, J; Huang, M; Jove, R; Cress, WD			Regulation of the cyclin D3 promoter by E2F1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR E2F1; CELL-CYCLE; RETINOBLASTOMA PROTEIN; GENE-EXPRESSION; S-PHASE; CHROMATIN IMMUNOPRECIPITATION; MICROARRAY ANALYSIS; DNA-REPLICATION; MCL-1 PROMOTER; IN-VIVO	We have previously demonstrated that ectopic expression of E2F1 is sufficient to drive quiescent cells into S phase and that E2F1 expression can contribute to oncogenic transformation. Key target genes in this process include master regulators of the cell cycle, such as cyclin E, which regulates G(1) progression, and cyclin A, which is required for the initiation of DNA synthesis. In the present work, we present novel evidence that a second G(1) cyclin, cyclin D3, is also potently activated by E2F1. First, an estrogen receptor-E2F1 fusion protein ( ER-E2F1) potently activates the endogenous cyclin D3 mRNA upon treatment with 4-hydroxytamoxifen, which induces nuclear accumulation of the otherwise cytosolic fusion protein. Furthermore, trans-activation of cyclin D3 by ER-E2F1 occurs even in the presence of the protein synthesis inhibitor cycloheximide and thus appears direct. Second, all of the growth-stimulatory members of the E2F family ( E2F1, -2, and -3A) potently activate a cyclin D3 promoter reporter, whereas growth-restraining members of the family ( E2F4, -5, and -6) have little effect. Third, recombinant E2F1 binds with high affinity to the cyclin D3 promoter in vitro. Fourth, chromatin immunoprecipitation assays demonstrate that endogenous E2F1 is associated with the cyclin D3 promoter in vivo. Finally, mapping experiments localize the essential E2F regulatory element of the cyclin D3 promoter to a noncanonical E2F site in the promoter between nucleotides -143 and -135 relative to the initiating methionine codon. We conclude that in addition to cyclins E and A, E2F family members can also activate one member of the D-type cyclins, further contributing to the ability of the stimulatory E2F family members to drive cellular proliferation.	Univ S Florida, Coll Med, Program Mol Oncol, H Lee Moffit Comprehens Canc Ctr & Res Inst, Tampa, FL 33612 USA; Univ S Florida, Coll Med, Dept Interdisciplinary Oncol, Tampa, FL 33612 USA	State University System of Florida; University of South Florida; State University System of Florida; University of South Florida	Cress, WD (corresponding author), Univ S Florida, Mol Oncol Program, H Lee Moffitt Canc Ctr, 12902 Magnolia Dr, Tampa, FL 33612 USA.	cressd@moffitt.usf.edu			NATIONAL CANCER INSTITUTE [R29CA078214] Funding Source: NIH RePORTER; NCI NIH HHS [CA78214] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adams MR, 2000, MOL CELL BIOL, V20, P3633, DOI 10.1128/MCB.20.10.3633-3639.2000; Bouchard C, 1999, EMBO J, V18, P5321, DOI 10.1093/emboj/18.19.5321; Bouchard C, 2001, GENE DEV, V15, P2042, DOI 10.1101/gad.907901; Brooks AR, 1996, J BIOL CHEM, V271, P9090, DOI 10.1074/jbc.271.15.9090; Cress WD, 1996, MOL CELL BIOL, V16, P2119; CRESS WD, 1993, MOL CELL BIOL, V13, P6314, DOI 10.1128/MCB.13.10.6314; CRESS WD, 1994, J VIROL, V68, P4212, DOI 10.1128/JVI.68.7.4213-4219.1994; Croxton R, 2002, ONCOGENE, V21, P1359, DOI 10.1038/sj.onc.1205157; Croxton R, 2002, ONCOGENE, V21, P1563, DOI 10.1038/sj.onc.1205232; DeGregori J, 1997, P NATL ACAD SCI USA, V94, P7245, DOI 10.1073/pnas.94.14.7245; EWEN ME, 1993, CELL, V73, P487, DOI 10.1016/0092-8674(93)90136-E; Ezhevsky SA, 1997, P NATL ACAD SCI USA, V94, P10699, DOI 10.1073/pnas.94.20.10699; Ezhevsky SA, 2001, MOL CELL BIOL, V21, P4773, DOI 10.1128/MCB.21.14.4773-4784.2001; Flores AM, 1998, ONCOGENE, V16, P1289, DOI 10.1038/sj.onc.1201633; He YW, 2000, ONCOGENE, V19, P3422, DOI 10.1038/sj.onc.1203682; He YW, 2002, J BIOL CHEM, V277, P23493, DOI 10.1074/jbc.M202629200; Ho A, 2002, CURR OPIN GENET DEV, V12, P47, DOI 10.1016/S0959-437X(01)00263-5; HSIAO KM, 1994, GENE DEV, V8, P1526, DOI 10.1101/gad.8.13.1526; Ishida S, 2001, MOL CELL BIOL, V21, P4684, DOI 10.1128/MCB.21.14.4684-4699.2001; JANSENDURR P, 1993, P NATL ACAD SCI USA, V90, P3685, DOI 10.1073/pnas.90.8.3685; JOHNSON DG, 1994, P NATL ACAD SCI USA, V91, P12823, DOI 10.1073/pnas.91.26.12823; JOHNSON DG, 1994, GENE DEV, V8, P1514, DOI 10.1101/gad.8.13.1514; JOHNSON DG, 1993, NATURE, V365, P349, DOI 10.1038/365349a0; Kalma Y, 2001, ONCOGENE, V20, P1379, DOI 10.1038/sj.onc.1204230; Kel AE, 2001, J MOL BIOL, V309, P99, DOI 10.1006/jmbi.2001.4650; KOWALIK TF, 1995, J VIROL, V69, P2491, DOI 10.1128/JVI.69.4.2491-2500.1995; LAU LF, 1987, P NATL ACAD SCI USA, V84, P1182, DOI 10.1073/pnas.84.5.1182; Leone G, 2000, MOL CELL BIOL, V20, P3626, DOI 10.1128/MCB.20.10.3626-3632.2000; Lundberg AS, 1998, MOL CELL BIOL, V18, P753, DOI 10.1128/MCB.18.2.753; Ma YH, 2002, ARCH BIOCHEM BIOPHYS, V399, P212, DOI 10.1006/abbi.2002.2761; Ma YH, 2003, MOL CANCER THER, V2, P73; Moberg K, 1996, MOL CELL BIOL, V16, P1436; Muller H, 2001, GENE DEV, V15, P267, DOI 10.1101/gad.864201; Nevins JR, 2001, HUM MOL GENET, V10, P699, DOI 10.1093/hmg/10.7.699; Ohtani K, 1995, P NATL ACAD SCI USA, V92, P12146, DOI 10.1073/pnas.92.26.12146; PARDEE AB, 1974, P NATL ACAD SCI USA, V71, P1286, DOI 10.1073/pnas.71.4.1286; Payton M, 2002, INT J BIOCHEM CELL B, V34, P315, DOI 10.1016/S1357-2725(01)00137-6; PHILIPP A, 1994, MOL CELL BIOL, V14, P4032, DOI 10.1128/MCB.14.6.4032; SCHULZE A, 1995, P NATL ACAD SCI USA, V92, P11264, DOI 10.1073/pnas.92.24.11264; Sears R, 1997, MOL CELL BIOL, V17, P5227, DOI 10.1128/MCB.17.9.5227; Sherr CJ, 2000, CANCER RES, V60, P3689; Takahashi Y, 2000, GENE DEV, V14, P804; Tao YX, 1997, MOL CELL BIOL, V17, P6994, DOI 10.1128/MCB.17.12.6994; Trimarchi JM, 2002, NAT REV MOL CELL BIO, V3, P11, DOI 10.1038/nrm714; Vigo E, 1999, MOL CELL BIOL, V19, P6379; Wang AJ, 1999, NUCLEIC ACIDS RES, V27, P4609, DOI 10.1093/nar/27.23.4609; Wang ZY, 1996, GENOMICS, V35, P156, DOI 10.1006/geno.1996.0334; Watanabe G, 1998, MOL CELL BIOL, V18, P3212, DOI 10.1128/MCB.18.6.3212; Weinmann AS, 2002, GENE DEV, V16, P235, DOI 10.1101/gad.943102; Weinmann AS, 2001, MOL CELL BIOL, V21, P6820, DOI 10.1128/MCB.21.20.6820-6832.2001; Wells J, 2000, MOL CELL BIOL, V20, P5797, DOI 10.1128/MCB.20.16.5797-5807.2000; Wells J, 2002, P NATL ACAD SCI USA, V99, P3890, DOI 10.1073/pnas.062047499; WU XW, 1994, P NATL ACAD SCI USA, V91, P3602, DOI 10.1073/pnas.91.9.3602; Yang M, 1996, GENE, V181, P153, DOI 10.1016/S0378-1119(96)00499-4; Zhang HS, 2000, CELL, V101, P79, DOI 10.1016/S0092-8674(00)80625-X	55	38	39	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 9	2003	278	19					16770	16776		10.1074/jbc.M212702200	http://dx.doi.org/10.1074/jbc.M212702200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677QG	12611887	hybrid			2022-12-25	WOS:000182818600044
J	Quevedo, C; Salinas, M; Alcazar, A				Quevedo, C; Salinas, M; Alcazar, A			Initiation factor 2B activity is regulated by protein phosphatase 1, which is activated by the mitogen-activated protein kinase-dependent pathway in insulin-like growth factor 1-stimulated neuronal cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCOGEN-SYNTHASE KINASE-3; GUANINE-NUCLEOTIDE-EXCHANGE; FACTOR EIF2B; TRANSLATION INITIATION; SKELETAL-MUSCLE; PC12 CELLS; PHOSPHORYLATION; STIMULATION; INHIBITION; MECHANISM	We have previously demonstrated that insulin-like growth factor 1 (IGF1) induces eukaryotic initiation factor 2B (eIF2B) activation in neuronal cells through the phosphatidylinositol 3 kinase/glycogen synthase kinase 3 pathway as well as by activation of the mitogen-activated protein kinase (MAPK)-activating kinase (MEK)/MAPK signaling pathway (Quevedo, C., Alcazar, A., and Salinas, M. (2000) J. Biol. Chem. 275, 19192-19197). This paper addresses the mechanism involved in IGF1-induced eIF2B activation via the MEK/MAPK cascade in cultured neurons treated with IGF1 and demonstrates that extracellular signal-regulated MAP kinase 1 and 2 (ERK1 and -2) immunoprecipitates of IGF1-treated neuronal cells promote this activation. This effect did not directly result from eIF2B phosphorylation by ERK immunoprecipitates. In addition, recombinant ERK1 and -2 neither activate eIF2B nor phosphorylate it. Endogenous protein phosphatase 1 and 2A catalytic subunits (PP1C and PP2AC, respectively) were co-immunoprecipitated with ERK1 and -2, and the association of ERK with PP1C was stimulated by IGF1 treatment, resulting in increased PP1 activity. ERK immunoprecipitates incubated with PP1 inhibitors did not activate eIF2B, indicating that PP1C activates eIF2B. In vitro experiments with phosphorylated eIF2B showed that recombinant PP1C (alpha isoform) dephosphorylates and activates eIF2B. Paralleling eIF2B activation, IGF1 treatment induced PP1 activation in a MEK/MAPK-dependent fashion. Moreover, the treatment of neurons with the PP1 inhibitor tautomycin inhibited PP1 activation and prevented IGF1-induced eIF2B activation. These findings strongly suggest that IGF1-induced eIF2B activation in neurons is effected by PP1, the activation of which is mediated by the MEK/MAPK signaling pathway.	Hosp Ramon y Cajal, Serv Bioquim Invest, E-28034 Madrid, Spain	Hospital Universitario Ramon y Cajal	Alcazar, A (corresponding author), Hosp Ramon y Cajal, Serv Bioquim Invest, Ctra Colmenar Km 9,1, E-28034 Madrid, Spain.							ALCAZAR A, 1995, J NEUROCHEM, V65, P754; Asano K, 1999, EMBO J, V18, P1673, DOI 10.1093/emboj/18.6.1673; BEGUM N, 1995, J BIOL CHEM, V270, P709, DOI 10.1074/jbc.270.2.709; Clemens MJ, 1999, INT J BIOCHEM CELL B, V31, P1, DOI 10.1016/S1357-2725(98)00127-7; Clemens MJ, 2001, PROG MOLEC, V27, P57; Clemens MJ, 1996, TRANSLATIONAL CONTRO, P139; COHEN P, 1988, METHOD ENZYMOL, V159, P390; Cohen PTW, 2002, J CELL SCI, V115, P241; CROSS DAE, 1994, BIOCHEM J, V303, P21, DOI 10.1042/bj3030021; DHOLAKIA JN, 1988, P NATL ACAD SCI USA, V85, P51, DOI 10.1073/pnas.85.1.51; Dudek H, 1997, SCIENCE, V275, P661, DOI 10.1126/science.275.5300.661; Foncea R, 1997, J BIOL CHEM, V272, P19115, DOI 10.1074/jbc.272.31.19115; Frame S, 2001, BIOCHEM J, V359, P1, DOI 10.1042/0264-6021:3590001; Gilligan M, 1996, J BIOL CHEM, V271, P2121, DOI 10.1074/jbc.271.4.2121; Hershey JWB, 1996, TRANSLATIONAL CONTRO; Janssens V, 2001, BIOCHEM J, V353, P417, DOI 10.1042/0264-6021:3530417; Jefferson LS, 1999, INT J BIOCHEM CELL B, V31, P191, DOI 10.1016/S1357-2725(98)00141-1; KARINCH AM, 1993, AM J PHYSIOL, V264, pE101, DOI 10.1152/ajpendo.1993.264.1.E101; Kimball SR, 1999, INT J BIOCHEM CELL B, V31, P25, DOI 10.1016/S1357-2725(98)00128-9; Kimball SR, 1998, J BIOL CHEM, V273, P30945, DOI 10.1074/jbc.273.47.30945; Kleijn M, 2000, FEBS LETT, V476, P262, DOI 10.1016/S0014-5793(00)01743-9; Kleijn M, 1998, J BIOL CHEM, V273, P5536, DOI 10.1074/jbc.273.10.5536; Liu J, 2000, J BIOL CHEM, V275, P15940, DOI 10.1074/jbc.M909303199; Manchester KL, 1997, BIOCHEM BIOPH RES CO, V239, P223, DOI 10.1006/bbrc.1997.7462; Miller TM, 1997, J BIOL CHEM, V272, P9847; OCHOA S, 1983, ARCH BIOCHEM BIOPHYS, V223, P325, DOI 10.1016/0003-9861(83)90598-2; Pain VM, 1996, EUR J BIOCHEM, V236, P747, DOI 10.1111/j.1432-1033.1996.00747.x; Paschen W, 1999, J CEREBR BLOOD F MET, V19, P1, DOI 10.1097/00004647-199901000-00001; Price NE, 1999, CURR OPIN NEUROBIOL, V9, P336, DOI 10.1016/S0959-4388(99)80049-X; Proud C G, 2001, Prog Mol Subcell Biol, V26, P95; Proud CG, 1997, BIOCHEM J, V328, P329; Quevedo C, 2000, J BIOL CHEM, V275, P19192, DOI 10.1074/jbc.M000238200; Ragolia L, 1998, MOL CELL BIOCHEM, V182, P49, DOI 10.1023/A:1006827227162; ROWLANDS AG, 1988, J BIOL CHEM, V263, P5526; Singh LP, 1996, BIOCHEMISTRY-US, V35, P3206, DOI 10.1021/bi9522099; SRINIVASAN M, 1994, J BIOL CHEM, V269, P16662; van Weeren PC, 1998, J BIOL CHEM, V273, P13150, DOI 10.1074/jbc.273.21.13150; VANLINT J, 1993, ANAL BIOCHEM, V208, P132, DOI 10.1006/abio.1993.1018; Wang XM, 2001, EMBO J, V20, P4349, DOI 10.1093/emboj/20.16.4349; WELSH GI, 1992, BIOCHEM J, V284, P19, DOI 10.1042/bj2840019; Welsh GI, 1997, ANAL BIOCHEM, V244, P16, DOI 10.1006/abio.1996.9838; WELSH GI, 1993, BIOCHEM J, V294, P625, DOI 10.1042/bj2940625; Welsh GI, 1996, J BIOL CHEM, V271, P11410, DOI 10.1074/jbc.271.19.11410; Welsh GI, 1997, FEBS LETT, V410, P418, DOI 10.1016/S0014-5793(97)00579-6; Welsh GI, 1998, FEBS LETT, V421, P125, DOI 10.1016/S0014-5793(97)01548-2; Williams DD, 2001, J BIOL CHEM, V276, P24697, DOI 10.1074/jbc.M011788200; Woods YL, 2001, BIOCHEM J, V355, P609, DOI 10.1042/bj3550609; Zhou B, 2002, J BIOL CHEM, V277, P31818, DOI 10.1074/jbc.M203969200	48	24	28	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 9	2003	278	19					16579	16586		10.1074/jbc.M212936200	http://dx.doi.org/10.1074/jbc.M212936200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677QG	12624094	hybrid			2022-12-25	WOS:000182818600019
J	Shirotani, K; Edbauer, D; Capell, A; Schmitz, J; Steiner, H; Haass, C				Shirotani, K; Edbauer, D; Capell, A; Schmitz, J; Steiner, H; Haass, C			gamma-Secretase activity is associated with a conformational change of Nicastrin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-APP; PRECURSOR PROTEIN; PRESENILIN; COMPLEX; TRAFFICKING; APH-1; EXPRESSION; CLEAVAGE; PATHWAY; PEN-2	gamma-Secretase is a high molecular weight multicomponent protein complex with an unusual intramembrane-cleaving aspartyl protease activity. gamma-Secretase is intimately associated with Alzheimer disease because it catalyzes the proteolytic cleavage, which leads to the liberation of amyloid beta-peptide. At least presenilin (PS), Nicastrin (Nct), APH-1, and PEN-2 are constituents of the gamma-secretase complex, with PS apparently providing the active site of gamma-secretase. Expression of gamma-secretase complex components is tightly regulated, however little is known about the assembly of the complex. Here we demonstrate that Nct undergoes a major conformational change during the assembly of the gamma-secretase complex. The conformational change is directly associated with gamma-secretase function and involves the entire Nct ectodomain. Loss of function mutations generated by deletions failed to undergo the conformational change. Furthermore, the conformational alteration did not occur in the absence of PS. Our data thus suggest that gamma-secretase function critically depends on the structural "activation" of Nct.	Univ Munich, Lab Alzheimers & Parkinsons Dis, Dept Biochem, Adolf Butenandt Inst, D-80336 Munich, Germany	University of Munich	Steiner, H (corresponding author), Univ Munich, Lab Alzheimers & Parkinsons Dis, Dept Biochem, Adolf Butenandt Inst, Schillerstr 44, D-80336 Munich, Germany.	hsteiner@pbm.med.uni-muenchen.de; chaass@pbm.med.uni-muenchen.de	Edbauer, Dieter/M-9906-2019	Edbauer, Dieter/0000-0002-7186-4653				Brown AJ, 2002, MOL CELL, V10, P237, DOI 10.1016/S1097-2765(02)00591-9; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; CITRON M, 1992, NATURE, V360, P672, DOI 10.1038/360672a0; Edbauer D, 2002, P NATL ACAD SCI USA, V99, P8666, DOI 10.1073/pnas.132277899; ELBEIN AD, 1990, J BIOL CHEM, V265, P15599; Esler WP, 2002, P NATL ACAD SCI USA, V99, P2720, DOI 10.1073/pnas.052436599; Francis R, 2002, DEV CELL, V3, P85, DOI 10.1016/S1534-5807(02)00189-2; Goutte C, 2002, P NATL ACAD SCI USA, V99, P775, DOI 10.1073/pnas.022523499; Gu YJ, 2003, J BIOL CHEM, V278, P7374, DOI 10.1074/jbc.M209499200; Haass C, 2002, TRENDS CELL BIOL, V12, P556, DOI 10.1016/S0962-8924(02)02394-2; Herreman A, 2003, J CELL SCI, V116, P1127, DOI 10.1242/jcs.00292; Hu Y, 2002, DEV CELL, V2, P69, DOI 10.1016/S1534-5807(01)00105-8; Kaether C, 2002, J CELL BIOL, V158, P551, DOI 10.1083/jcb.200201123; Kimberly WT, 2002, J BIOL CHEM, V277, P35113, DOI 10.1074/jbc.M204446200; Lee SF, 2002, J BIOL CHEM, V277, P45013, DOI 10.1074/jbc.M208164200; Leem JY, 2002, J BIOL CHEM, V277, P19236, DOI 10.1074/jbc.C200148200; Steiner H, 2002, J BIOL CHEM, V277, P39062, DOI 10.1074/jbc.C200469200; Yang DS, 2002, J BIOL CHEM, V277, P28135, DOI 10.1074/jbc.M110871200; Yu G, 2000, NATURE, V407, P48, DOI 10.1038/35024009	19	93	94	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 9	2003	278	19					16474	16477		10.1074/jbc.C300095200	http://dx.doi.org/10.1074/jbc.C300095200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677QG	12644462	hybrid			2022-12-25	WOS:000182818600005
J	Zou, CG; Banerjee, R				Zou, CG; Banerjee, R			Tumor necrosis factor-alpha-induced targeted proteolysis of cystathionine beta-synthase modulates redox homeostasis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; SUPEROXIDE ANION GENERATION; OXYGEN SPECIES PRODUCTION; SIGNAL-TRANSDUCTION; RAT-LIVER; HOMOCYSTEINE METABOLISM; TRANSCRIPTION FACTOR; OXIDATIVE STRESS; GENE-EXPRESSION; HEME PROTEIN	Cystathionine beta-synthase (CBS) catalyzes the first of two steps in the transsulfuration pathway that converts homocysteine to cysteine, a precursor of glutathione, a major intracellular antioxidant. Tumor necrosis factor-alpha (TNFalpha), which is known to enhance production of reactive oxygen species, increased CBS activity and glutathione levels in HepG2 cells. Western blot analysis revealed that the higher CBS activity correlated with cleavage of the enzyme to a truncated form. This cleavage was suppressed by inhibitors of superoxide production or by transfection with an expression vector for manganese superoxide dismutase. The commonly used proteasome inhibitors, MG132 and lactacystin but not N-acetyl-Leu-Leu-norleucinal, suppressed the TNFalpha-induced response. Targeted proteolysis of CBS was also observed in livers of mice injected with lipopolysaccharide, which is known to induce TNFalpha. Together, these data reveal a novel and previously unknown mechanism of regulation for homocysteine-linked glutathione homeostasis in cells challenged by oxidative stress.	Univ Nebraska, Dept Biochem, Lincoln, NE 68588 USA	University of Nebraska System; University of Nebraska Lincoln	Banerjee, R (corresponding author), Univ Nebraska, Dept Biochem, Lincoln, NE 68588 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK064959] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK64959] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BAUTISTA AP, 1990, AM J PHYSIOL, V259, pG907, DOI 10.1152/ajpgi.1990.259.6.G907; Beswick RA, 2001, HYPERTENSION, V38, P1107, DOI 10.1161/hy1101.093423; BEUTLER B, 1988, ANNU REV BIOCHEM, V57, P505, DOI 10.1146/annurev.bi.57.070188.002445; Chandel NS, 2001, J BIOL CHEM, V276, P42728, DOI 10.1074/jbc.M103074200; Clarke R, 1998, ARCH NEUROL-CHICAGO, V55, P1449, DOI 10.1001/archneur.55.11.1449; Corda S, 2001, AM J RESP CELL MOL, V24, P762, DOI 10.1165/ajrcmb.24.6.4228; CZAJA MJ, 1994, AM J PHYSIOL, V266, pG737, DOI 10.1152/ajpgi.1994.266.4.G737; Deshpande SS, 2000, FASEB J, V14, P1705, DOI 10.1096/fj.99-0910com; Diehl AM, 2000, IMMUNOL REV, V174, P160, DOI 10.1034/j.1600-0528.2002.017411.x; Dinges MM, 2001, INFECT IMMUN, V69, P7169, DOI 10.1128/IAI.69.11.7169-7172.2001; Eto K, 2002, J NEUROSCI, V22, P3386; Finkel T, 1998, CURR OPIN CELL BIOL, V10, P248, DOI 10.1016/S0955-0674(98)80147-6; Garcia-Nogales P, 1999, J NEUROCHEM, V72, P1750, DOI 10.1046/j.1471-4159.1999.721750.x; GOOSSENS V, 1995, P NATL ACAD SCI USA, V92, P8115, DOI 10.1073/pnas.92.18.8115; Goossens V, 1996, J BIOL CHEM, V271, P192, DOI 10.1074/jbc.271.1.192; Haddad JJ, 2001, FEBS LETT, V505, P269, DOI 10.1016/S0014-5793(01)02833-2; HENNET T, 1993, BIOCHEM J, V289, P587, DOI 10.1042/bj2890587; Hsu HY, 2002, J BIOL CHEM, V277, P22131, DOI 10.1074/jbc.M111883200; Ishibashi M, 1997, FREE RADICAL BIO MED, V22, P447, DOI 10.1016/S0891-5849(96)00338-3; Jacobson MD, 1996, TRENDS BIOCHEM SCI, V21, P83, DOI 10.1016/0968-0004(96)20008-8; Janosik M, 2001, AM J HUM GENET, V68, P1506, DOI 10.1086/320597; KASHIWAMATA S, 1970, BIOCHIM BIOPHYS ACTA, V212, P488, DOI 10.1016/0005-2744(70)90255-X; Kery V, 1998, ARCH BIOCHEM BIOPHYS, V355, P222, DOI 10.1006/abbi.1998.0723; Kraus JP, 1999, HUM MUTAT, V13, P362; Li CQ, 2002, CHEM RES TOXICOL, V15, P527, DOI 10.1021/tx010171x; Li YP, 1998, FASEB J, V12, P871, DOI 10.1096/fasebj.12.10.871; Lin L, 1998, CELL, V92, P819, DOI 10.1016/S0092-8674(00)81409-9; Liu Y, 1999, J BIOL CHEM, V274, P24819, DOI 10.1074/jbc.274.35.24819; Mallampalli RK, 2000, J BIOL CHEM, V275, P9699, DOI 10.1074/jbc.275.13.9699; Manna SK, 1998, J BIOL CHEM, V273, P13245, DOI 10.1074/jbc.273.21.13245; MEIER B, 1989, BIOCHEM J, V263, P539, DOI 10.1042/bj2630539; Meier M, 2001, EMBO J, V20, P3910, DOI 10.1093/emboj/20.15.3910; MILLS JL, 1995, LANCET, V345, P149, DOI 10.1016/S0140-6736(95)90165-5; Morales A, 1997, J BIOL CHEM, V272, P30371, DOI 10.1074/jbc.272.48.30371; Mosharov E, 2000, BIOCHEMISTRY-US, V39, P13005, DOI 10.1021/bi001088w; Ostrowska H, 2000, INT J BIOCHEM CELL B, V32, P747, DOI 10.1016/S1357-2725(00)00021-2; PALOMBELLA VJ, 1994, CELL, V78, P773, DOI 10.1016/S0092-8674(94)90482-0; Pantopoulos K, 1997, J BIOL CHEM, V272, P9802; PHELPS DT, 1995, AM J PHYSIOL-LUNG C, V269, pL551, DOI 10.1152/ajplung.1995.269.4.L551; Rape M, 2001, CELL, V107, P667, DOI 10.1016/S0092-8674(01)00595-5; Ratnam S, 2002, J BIOL CHEM, V277, P42912, DOI 10.1074/jbc.M206588200; REED DJ, 1980, ANAL BIOCHEM, V106, P55, DOI 10.1016/0003-2697(80)90118-9; Refsum H, 1998, ANNU REV MED, V49, P31, DOI 10.1146/annurev.med.49.1.31; Sen CK, 1996, FASEB J, V10, P709, DOI 10.1096/fasebj.10.7.8635688; Shan XY, 1998, NAT GENET, V19, P91, DOI 10.1038/ng0598-91; SKOVBY F, 1984, J BIOL CHEM, V259, P588; Sprong RC, 1998, AM J RESP CRIT CARE, V157, P1283; Suzuki YJ, 1997, FREE RADICAL BIO MED, V22, P269, DOI 10.1016/S0891-5849(96)00275-4; Taoka S, 1998, J BIOL CHEM, V273, P25179, DOI 10.1074/jbc.273.39.25179; Taoka S, 1999, BIOCHEMISTRY-US, V38, P13155, DOI 10.1021/bi990865t; Taoka S, 2002, BIOCHEMISTRY-US, V41, P10454, DOI 10.1021/bi026052d; Thannickal VJ, 2000, AM J PHYSIOL-LUNG C, V279, pL1005; Vitvitsky V, 2003, REDOX REP, V8, P57, DOI 10.1179/135100003125001260; WONG GHW, 1988, SCIENCE, V242, P941, DOI 10.1126/science.3263703; Wu HM, 2002, FEBS LETT, V526, P101, DOI 10.1016/S0014-5793(02)03151-4; ZHU H, 1994, ARCH TOXICOL, V68, P582, DOI 10.1007/s002040050118; ZUROVSKY Y, 1995, AM J KIDNEY DIS, V25, P51, DOI 10.1016/0272-6386(95)90625-8	57	71	77	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 9	2003	278	19					16802	16808		10.1074/jbc.M212376200	http://dx.doi.org/10.1074/jbc.M212376200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677QG	12615917	hybrid			2022-12-25	WOS:000182818600049
J	Finney, N; Walther, F; Mantel, PY; Stauffer, D; Rovelli, G; Dev, KK				Finney, N; Walther, F; Mantel, PY; Stauffer, D; Rovelli, G; Dev, KK			The cellular protein level of parkin is regulated by its ubiquitin-like domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIGASE ACTIVITY; JUVENILE PARKINSONISM; DISEASE; GENE; MUTATIONS; SYSTEM; STRESS; HHARI; UBCH7; BRAIN	Parkin is a ubiquitin-protein isopeptide ligase (E3) involved in ubiquitin/proteasome-mediated protein degradation. Mutations in the parkin gene cause a loss-of-function and/or alter protein levels of parkin. As a result, the toxic build-up of parkin substrates is thought to lead to autosomal recessive juvenile Parkinsonism. To identify a role for the ubiquitin-like domain (ULD) of parkin, we created a number of hemagglutinin (HA)tagged parkin constructs using mutational and structural information. Western blotting and immunocytochemistry showed a much stronger expression level for RA-parkin residues 77-465 (without ULD) than HA-par-kin full-length (with ULD). The deletion of ULD in Drosophila parkin also caused a sharp increase in expression of the truncated form, suggesting that the function of the ULD of parkin is conserved across species. By progressive deletion analysis of parkin ULD, we found that residues 1-6 of human parkin play a crucial role in controlling the expression levels of this gene. HA-parkin residues 77-465 showed ubiquitination in vivo, demonstrating that the ULD is not critical for parkin auto-ubiquitination; ubiquitination seemed to cluster on the central domain of parkin (residues 77-313). These effects were specific for the ULD of parkin and not transfection-, toxic-, epitope tag-, and/or vector-dependent. Taken together, these data suggest that the 76 most NH2-terminal residues (ULD) dramatically regulate the protein levels of parkin.	Novartis Pharma AG, Nervous Syst Res, CH-4002 Basel, Switzerland	Novartis	Dev, KK (corresponding author), Novartis Pharma AG, Nervous Syst Res, CH-4002 Basel, Switzerland.		Mantel, Pierre-Yves/N-3065-2015	Mantel, Pierre-Yves/0000-0001-9526-9309; Dev, Kumlesh/0000-0003-4274-9119				Abbas N, 1999, HUM MOL GENET, V8, P567, DOI 10.1093/hmg/8.4.567; Ardley HC, 2001, J BIOL CHEM, V276, P19640, DOI 10.1074/jbc.M011028200; Choi P, 2000, NEUROREPORT, V11, P2635, DOI 10.1097/00001756-200008210-00006; CHOI P, 2000, SOC NEUR ABSTR, V26; Chung KKK, 2001, NAT MED, V7, P1144, DOI 10.1038/nm1001-1144; Dev KK, 1999, NEUROPHARMACOLOGY, V38, P635, DOI 10.1016/S0028-3908(98)00230-5; DEV KK, 2003, IN PRESS NEUROPHARMA; Fallon L, 2002, J BIOL CHEM, V277, P486, DOI 10.1074/jbc.M109806200; Haass C, 2001, SCIENCE, V293, P224, DOI 10.1126/science.1063286; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; Hornykiewicz O, 1998, NEUROLOGY, V51, pS2, DOI 10.1212/WNL.51.2_Suppl_2.S2; Huynh DP, 2000, ANN NEUROL, V48, P737, DOI 10.1002/1531-8249(200011)48:5<737::AID-ANA7>3.3.CO;2-4; Imai Y, 2000, J BIOL CHEM, V275, P35661, DOI 10.1074/jbc.C000447200; Imai Y, 2001, CELL, V105, P891, DOI 10.1016/S0092-8674(01)00407-X; Imai Y, 2002, MOL CELL, V10, P55, DOI 10.1016/S1097-2765(02)00583-X; Joazeiro CAP, 2000, CELL, V102, P549, DOI 10.1016/S0092-8674(00)00077-5; Kahle PJ, 2000, TRENDS BIOCHEM SCI, V25, P524, DOI 10.1016/S0968-0004(00)01682-0; Kitada T, 1998, NATURE, V392, P605, DOI 10.1038/33416; Kubo S, 2001, J NEUROCHEM, V78, P42, DOI 10.1046/j.1471-4159.2001.00364.x; Leroy E, 1998, HUM GENET, V103, P424, DOI 10.1007/s004390050845; Lucking CB, 2000, NEW ENGL J MED, V342, P1560, DOI 10.1056/NEJM200005253422103; Mengesdorf T, 2002, P NATL ACAD SCI USA, V99, P15042, DOI 10.1073/pnas.232588799; Mizuno Y, 1998, J NEUROCHEM, V71, P893; Morett E, 1999, TRENDS BIOCHEM SCI, V24, P229, DOI 10.1016/S0968-0004(99)01381-X; Moynihan TP, 1999, J BIOL CHEM, V274, P30963, DOI 10.1074/jbc.274.43.30963; Shimura H, 2000, NAT GENET, V25, P302, DOI 10.1038/77060; Shimura H, 2001, SCIENCE, V293, P263, DOI 10.1126/science.1060627; Zhang Y, 2000, P NATL ACAD SCI USA, V97, P13354, DOI 10.1073/pnas.240347797; Zheng N, 2000, CELL, V102, P533, DOI 10.1016/S0092-8674(00)00057-X	29	34	38	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 2	2003	278	18					16054	16058		10.1074/jbc.C300051200	http://dx.doi.org/10.1074/jbc.C300051200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	675EL	12621021	Green Published, hybrid			2022-12-25	WOS:000182680000077
J	Geymonat, M; Spanos, A; Walker, PA; Johnston, LH; Sedgwick, SG				Geymonat, M; Spanos, A; Walker, PA; Johnston, LH; Sedgwick, SG			In vitro regulation of budding yeast Bfa1/Bub2 GAP activity by Cdc5	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE CDC5; SISTER-CHROMATID SEPARATION; SPINDLE POLE BODIES; MITOTIC EXIT; CELL-CYCLE; SCHIZOSACCHAROMYCES-POMBE; CHECKPOINT PATHWAY; EXCHANGE FACTOR; CYTOKINESIS; KINASE	The Cdc5 protein of budding yeast is a polo-like kinase that has multiple roles in mitosis including control of the mitotic exit network (MEN). MEN activity brings about loss of mitotic kinase activity so that the mitotic spindle is disassembled and cytokinesis can proceed. Activity of the MEN is regulated by a small GTPase, Tem1, which in turn is controlled by a two-component GTPase-activating protein (GAP) formed by Bfa1 and Bub2. Bfa1 has been identified as a regulatory target of Cdc5 but there are conflicting deductions from indirect in vivo assays as to whether phosphorylation inhibits or stimulates Bfa1 activity. To resolve this question, we have used direct in vitro assays to observe the effects of phosphorylation on Bfa1 activity. We show that when Bfa1 is phosphorylated by Cdc5, its GAP activity with Bub2 is inhibited although its ability to interact with Tem1 is unaffected. Thus, in vivo inactivation of Bfa1-Bub2 by Cdc5 would have a positive regulatory effect by increasing levels of Tem1-GTP so stimulating exit from mitosis.	Natl Inst Med Res, Div Yeast Genet, London NW7 1AA, England; Natl Inst Med Res, Div Prot Struct, London NW7 1AA, England	MRC National Institute for Medical Research; MRC National Institute for Medical Research	Sedgwick, SG (corresponding author), Natl Inst Med Res, Div Yeast Genet, Mill Hill, London NW7 1AA, England.							Adames NR, 2001, J CELL BIOL, V153, P159, DOI 10.1083/jcb.153.1.159; Alexandru G, 1999, EMBO J, V18, P2707, DOI 10.1093/emboj/18.10.2707; Alexandru G, 2001, CELL, V105, P459, DOI 10.1016/S0092-8674(01)00362-2; Bardin AJ, 2000, CELL, V102, P21, DOI 10.1016/S0092-8674(00)00007-6; Bardin AJ, 2001, NAT REV MOL CELL BIO, V2, P815, DOI 10.1038/35099020; Charles JF, 1998, CURR BIOL, V8, P497, DOI 10.1016/S0960-9822(98)70201-5; Chen CH, 2001, FEBS LETT, V504, P16, DOI 10.1016/S0014-5793(01)02757-0; Fesquet D, 1999, EMBO J, V18, P2424, DOI 10.1093/emboj/18.9.2424; Fournier N, 2001, ARCH MICROBIOL, V175, P62, DOI 10.1007/s002030000238; Fraschini R, 1999, J CELL BIOL, V145, P979, DOI 10.1083/jcb.145.5.979; Geymonat M, 2002, J BIOL CHEM, V277, P28439, DOI 10.1074/jbc.M202540200; Giglione C, 2001, EUR J BIOCHEM, V268, P3275, DOI 10.1046/j.1432-1327.2001.02230.x; Guertin DA, 2002, DEV CELL, V3, P779, DOI 10.1016/S1534-5807(02)00367-2; Hofken T, 2002, EMBO J, V21, P4851, DOI 10.1093/emboj/cdf481; Hu FH, 2002, CELL CYCLE, V1, P351, DOI 10.4161/cc.1.5.154; Hu FH, 2001, CELL, V107, P655, DOI 10.1016/S0092-8674(01)00580-3; Jantsch-Plunger V, 2000, J CELL BIOL, V149, P1391, DOI 10.1083/jcb.149.7.1391; Lee KS, 1997, MOL CELL BIOL, V17, P3408, DOI 10.1128/MCB.17.6.3408; Lee SE, 2001, J CELL SCI, V114, P2345; Lee SE, 2001, CURR BIOL, V11, P784, DOI 10.1016/S0960-9822(01)00228-7; Li R, 1999, P NATL ACAD SCI USA, V96, P4989, DOI 10.1073/pnas.96.9.4989; McCollum D, 2001, TRENDS CELL BIOL, V11, P89, DOI 10.1016/S0962-8924(00)01901-2; Pereira G, 2000, MOL CELL, V6, P1, DOI 10.1016/S1097-2765(05)00017-1; Pereira G, 2002, J CELL BIOL, V157, P367, DOI 10.1083/jcb.200112085; Shirayama M, 1998, EMBO J, V17, P1336, DOI 10.1093/emboj/17.5.1336; SHIRAYAMA M, 1994, MOL CELL BIOL, V14, P7476, DOI 10.1128/MCB.14.11.7476; SHIRAYAMA M, 1994, YEAST, V10, P451, DOI 10.1002/yea.320100404; SHOU WY, 2002, BMC MOL BIOL, V3; Song SG, 2001, J CELL BIOL, V152, P451, DOI 10.1083/jcb.152.3.451; Stegmeier F, 2002, CELL, V108, P207, DOI 10.1016/S0092-8674(02)00618-9; Tanaka K, 2001, EMBO J, V20, P1259, DOI 10.1093/emboj/20.6.1259; Tatsumoto T, 1999, J CELL BIOL, V147, P921, DOI 10.1083/jcb.147.5.921; Visintin R, 1998, MOL CELL, V2, P709, DOI 10.1016/S1097-2765(00)80286-5; Yoshida S, 2002, BIOCHEM BIOPH RES CO, V294, P687, DOI 10.1016/S0006-291X(02)00544-2; Yoshida S, 2002, CURR BIOL, V12, P944, DOI 10.1016/S0960-9822(02)00870-9	35	72	74	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 25	2003	278	17					14591	14594		10.1074/jbc.C300059200	http://dx.doi.org/10.1074/jbc.C300059200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	672HX	12637549	hybrid			2022-12-25	WOS:000182516100002
J	Murray, J; Zhang, B; Taylor, SW; Oglesbee, D; Fahy, E; Marusich, MF; Ghosh, SS; Capaldi, RA				Murray, J; Zhang, B; Taylor, SW; Oglesbee, D; Fahy, E; Marusich, MF; Ghosh, SS; Capaldi, RA			The subunit composition of the human NADH dehydrogenase obtained by rapid one-step immunopurification	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MITOCHONDRIAL COMPLEX-I; UBIQUINONE OXIDOREDUCTASE; RESPIRATORY-CHAIN; PROTEIN; IDENTIFICATION; LOCALIZATION; GRIM-19; MUSCLE	Defects of the NADH dehydrogenase complex are predominantly manifested in mitochondrial diseases and are significantly associated with the development of many late onset neurological disorders such as Parkinson's disease. Here we describe an immunocapture procedure for isolating this multisubunit membrane-bound complex from human tissue. Using small amounts of immunoisolated protein, one-dimensional and two-dimensional gel electrophoresis, matrix-assisted laser desorption ionization time-of-flight (MALDI-TOF) peptide mass finger printing (PMF), and nanoflow liquid chromatography mass spectrometry/mass spectrometry (LCMS/MS), we can resolve and identify the human homologues of 42 polypeptides detected so far in the more extensively studied beef heart complex 1. These polypeptides include the GRIM-19 protein, which is claimed to be involved in apoptosis, a polypeptide first identified by gene screening a's a neuronal protein, as well as a protein thought to be in differentiation linked processes. The concordance of data from human and bovine complex I isolated by different procedures adds to the certainty that these novel proteins of seemingly diverse function are a part of complex 1.	Univ Oregon, Dept Mol Biol, Eugene, OR 97403 USA; MitoKor, San Diego, CA 92121 USA	University of Oregon	Capaldi, RA (corresponding author), Univ Oregon, Dept Mol Biol, 13th St, Eugene, OR 97403 USA.	rcapaldi@oregon.uoregon.edu	Marusich, Michael/AAQ-3447-2020	Oglesbee, Devin/0000-0002-7147-5527				Aggeler R, 2002, J BIOL CHEM, V277, P33906, DOI 10.1074/jbc.M204538200; ALI ST, 1993, GENOMICS, V18, P435, DOI 10.1006/geno.1993.1493; Angell JE, 2000, J BIOL CHEM, V275, P33416, DOI 10.1074/jbc.M003929200; Arenas J, 1998, ANN NEUROL, V43, P397, DOI 10.1002/ana.410430321; Betarbet R, 2000, NAT NEUROSCI, V3, P1301, DOI 10.1038/81834; Carroll J, 2002, J BIOL CHEM, V277, P50311, DOI 10.1074/jbc.M209166200; Clauser KR, 1999, ANAL CHEM, V71, P2871, DOI 10.1021/ac9810516; Dror N, 2002, MOL PSYCHIATR, V7, P995, DOI 10.1038/sj.mp.4001116; Ducret A, 1998, PROTEIN SCI, V7, P706, DOI 10.1002/pro.5560070320; DUNCAN AMV, 1992, CYTOGENET CELL GENET, V60, P212, DOI 10.1159/000133340; Fearnley IM, 2001, J BIOL CHEM, V276, P38345, DOI 10.1074/jbc.C100444200; Hanson BJ, 2001, ELECTROPHORESIS, V22, P950, DOI 10.1002/1522-2683()22:5<950::AID-ELPS950>3.0.CO;2-D; Kim SH, 2001, LIFE SCI, V68, P2741, DOI 10.1016/S0024-3205(01)01074-8; Lenaz G, 2000, BBA-BIOENERGETICS, V1459, P397, DOI 10.1016/S0005-2728(00)00177-8; LIB M, 2003, IN PRESS ANAL BIOCH; MIZUNO Y, 1989, BIOCHEM BIOPH RES CO, V163, P1450, DOI 10.1016/0006-291X(89)91141-8; Sazanov LA, 2000, BIOCHEMISTRY-US, V39, P7229, DOI 10.1021/bi000335t; Schagger H, 2000, EMBO J, V19, P1777, DOI 10.1093/emboj/19.8.1777; SCHAPIRA AHV, 1990, J NEUROCHEM, V54, P823, DOI 10.1111/j.1471-4159.1990.tb02325.x; Shevchenko A, 1996, ANAL CHEM, V68, P850, DOI 10.1021/ac950914h; Skehel JM, 1998, FEBS LETT, V438, P301, DOI 10.1016/S0014-5793(98)01317-9; Smith, 1967, METHOD ENZYMOL, V10, P81, DOI DOI 10.1016/0076-6879(67)10016-5; Taylor SW, 2003, NAT BIOTECHNOL, V21, P281, DOI 10.1038/nbt793; Taylor SW, 2002, J PROTEOME RES, V1, P451, DOI 10.1021/pr025533g; Triepels RH, 2001, AM J MED GENET, V106, P37, DOI 10.1002/ajmg.1397; Vielhaber S, 1999, J NEUROL SCI, V169, P133, DOI 10.1016/S0022-510X(99)00236-1; Vielhaber S, 2001, J NEUROPATH EXP NEUR, V60, P1032, DOI 10.1093/jnen/60.11.1032	27	83	135	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 18	2003	278	16					13619	13622		10.1074/jbc.C300064200	http://dx.doi.org/10.1074/jbc.C300064200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	670JV	12611891	hybrid			2022-12-25	WOS:000182405000008
J	Pichierri, P; Rosselli, F; Franchitto, A				Pichierri, P; Rosselli, F; Franchitto, A			Werner's syndrome protein is phosphorylated in an ATR/ATM-dependent manner following replication arrest and DNA damage induced during the S phase of the cell cycle	ONCOGENE			English	Article						Werner's syndrome protein; RecQ helicases; ATR; replication arrest; DNA damage response	SYNDROME LYMPHOBLASTOID-CELLS; BLOOMS-SYNDROME PROTEIN; ATAXIA-TELANGIECTASIA; FUNCTIONAL INTERACTION; IONIZING-RADIATION; CHECKPOINT PATHWAY; FORK ARREST; ATM KINASE; RECOMBINATION; EXONUCLEASE	Werner's syndrome (WS) is an autosomal recessive disorder, characterized at the cellular level by genomic instability in the form of variegated translocation mosaicism and extensive deletions. Individuals with WS prematurely develop multiple age-related pathologies and exhibit increased incidence of cancer. WRN, the gene defective in WS, encodes a 160-kDa protein (WRN), which has 3'-5' exonuclease, DNA helicase and DNA-dependent ATPase activities. WRN-defective cells are hypersensitive to certain genotoxic agents that cause replication arrest and/or double-strand breaks at the replication fork, suggesting a pivotal role for WRN in the protection of the integrity of the genoma during the DNA replication process. Here, we show that WRN is phosphorylated through an ATR/ATM dependent pathway in response to replication blockage. However, we provide evidence that WRN phosphorylation is not essential for its subnuclear relocalization after replication arrest. Finally, we show that WRN and ATR colocalize after replication fork arrest, suggesting that WRN and the ATR kinase collaborate to prevent genome instability during the S phase.	Inst Gustave Roussy, CNRS, UPR2169, F-94805 Villejuif, France	Centre National de la Recherche Scientifique (CNRS); UNICANCER; Gustave Roussy	Franchitto, A (corresponding author), Inst Gustave Roussy, CNRS, UPR2169, 39 Rue Camille Desmoulins, F-94805 Villejuif, France.		Franchitto, Annapaola/K-7564-2016; Filippo, Rosselli/AAO-6393-2020; Pichierri, Pietro/AAA-5476-2021	Franchitto, Annapaola/0000-0003-4232-4727; Filippo, Rosselli/0000-0003-1080-5745; Pichierri, Pietro/0000-0002-2702-3523				Ababou M, 2002, ONCOGENE, V21, P2079, DOI 10.1038/sj.onc.1205246; Ababou M, 2000, ONCOGENE, V19, P5955, DOI 10.1038/sj.onc.1204003; Abraham RT, 2001, GENE DEV, V15, P2177, DOI 10.1101/gad.914401; BIERNE H, 1994, MOL MICROBIOL, V13, P17, DOI 10.1111/j.1365-2958.1994.tb00398.x; Bohr VA, 2001, ENVIRON MOL MUTAGEN, V38, P227, DOI 10.1002/em.1076; Brosh RM, 2002, EXP GERONTOL, V37, P491, DOI 10.1016/S0531-5565(01)00227-3; CAO G, 1991, EXP CELL RES, V193, P405, DOI 10.1016/0014-4827(91)90113-9; Cliby WA, 2002, J BIOL CHEM, V277, P1599, DOI 10.1074/jbc.M106287200; Cliby WA, 1998, EMBO J, V17, P159, DOI 10.1093/emboj/17.1.159; Constantinou A, 2000, EMBO REP, V1, P80, DOI 10.1093/embo-reports/kvd004; Cooper MP, 2000, GENE DEV, V14, P907; Falck J, 2001, NATURE, V410, P842, DOI 10.1038/35071124; FOTEDAR R, 1992, EMBO J, V11, P2177, DOI 10.1002/j.1460-2075.1992.tb05277.x; Franchitto A, 2002, J CELL BIOL, V157, P19, DOI 10.1083/jcb.200110009; Frei C, 2000, J CELL SCI, V113, P2641; FUKUCHI K, 1989, P NATL ACAD SCI USA, V86, P5893, DOI 10.1073/pnas.86.15.5893; Gatei M, 2000, CANCER RES, V60, P3299; Gatei M, 2001, J BIOL CHEM, V276, P17276, DOI 10.1074/jbc.M011681200; GEBHART E, 1988, HUM GENET, V80, P135, DOI 10.1007/BF00702855; Gray MD, 1997, NAT GENET, V17, P100, DOI 10.1038/ng0997-100; Guo ZJ, 2000, GENE DEV, V14, P2745, DOI 10.1101/gad.842500; Huang SR, 1998, NAT GENET, V20, P114, DOI 10.1038/2410; Imamura O, 2002, ONCOGENE, V21, P954, DOI 10.1038/sj.onc.1205143; Kamath-Loeb AS, 1998, J BIOL CHEM, V273, P34145, DOI 10.1074/jbc.273.51.34145; KARMAKAR P, 2002, J BIOL CHEM, V11, P11; Kim ST, 1999, J BIOL CHEM, V274, P37538, DOI 10.1074/jbc.274.53.37538; KREPINSKY AB, 1979, HUM GENET, V50, P151, DOI 10.1007/BF00390236; Li BM, 2000, J BIOL CHEM, V275, P28349, DOI 10.1074/jbc.C000289200; Marciniak RA, 1998, P NATL ACAD SCI USA, V95, P6887, DOI 10.1073/pnas.95.12.6887; Michel B, 2000, TRENDS BIOCHEM SCI, V25, P173, DOI 10.1016/S0968-0004(00)01560-7; Michel B, 1997, EMBO J, V16, P430, DOI 10.1093/emboj/16.2.430; Michel B, 2001, P NATL ACAD SCI USA, V98, P8181, DOI 10.1073/pnas.111008798; Mirzoeva OK, 2001, MOL CELL BIOL, V21, P281, DOI 10.1128/MCB.21.1.281-288.2001; Mohaghegh P, 2001, HUM MOL GENET, V10, P741, DOI 10.1093/hmg/10.7.741; Orren DK, 2001, NUCLEIC ACIDS RES, V29, P1926, DOI 10.1093/nar/29.9.1926; Pichierri P, 2000, MUTAT RES-DNA REPAIR, V459, P123, DOI 10.1016/S0921-8777(99)00065-8; Pichierri P, 2001, MOL BIOL CELL, V12, P2412, DOI 10.1091/mbc.12.8.2412; Pichierri P, 2000, MUTAT RES-FUND MOL M, V456, P45, DOI 10.1016/S0027-5107(00)00109-3; POOT M, 1992, EXP CELL RES, V202, P267, DOI 10.1016/0014-4827(92)90074-I; Poot M, 1999, HUM GENET, V104, P10, DOI 10.1007/s004390050903; Poot M, 2001, FASEB J, V15, P1224, DOI 10.1096/fj.00-0611fje; Rothstein R, 2000, GENE DEV, V14, P1; Sakamoto S, 2001, GENES CELLS, V6, P421, DOI 10.1046/j.1365-2443.2001.00433.x; SALK D, 1981, CYTOGENET CELL GENET, V30, P92, DOI 10.1159/000131596; Salk D, 1985, Basic Life Sci, V35, P419; Sanchez Y, 1997, SCIENCE, V277, P1497, DOI 10.1126/science.277.5331.1497; Sarkaria JN, 1999, CANCER RES, V59, P4375; SCAPPATICCI S, 1982, HUM GENET, V62, P16, DOI 10.1007/BF00295599; Scully R, 1997, CELL, V90, P425, DOI 10.1016/S0092-8674(00)80503-6; Scully R, 2000, ONCOGENE, V19, P6176, DOI 10.1038/sj.onc.1203971; Shao RG, 1999, EMBO J, V18, P1397, DOI 10.1093/emboj/18.5.1397; Shen JC, 1998, J BIOL CHEM, V273, P34139, DOI 10.1074/jbc.273.51.34139; Shiloh Y, 2001, CURR OPIN GENET DEV, V11, P71, DOI 10.1016/S0959-437X(00)00159-3; Tibbetts RS, 1999, GENE DEV, V13, P152, DOI 10.1101/gad.13.2.152; Tibbetts RS, 2000, GENE DEV, V14, P2989, DOI 10.1101/gad.851000; Wang HY, 2001, CANCER RES, V61, P8554; Wright JA, 1998, P NATL ACAD SCI USA, V95, P7445, DOI 10.1073/pnas.95.13.7445; Yannone SM, 2001, J BIOL CHEM, V276, P38242; ZernikKobak M, 1997, J BIOL CHEM, V272, P23896, DOI 10.1074/jbc.272.38.23896; Zhao H, 2001, MOL CELL BIOL, V21, P4129, DOI 10.1128/MCB.21.13.4129-4139.2001; Zhao S, 2000, NATURE, V405, P473, DOI 10.1038/35013083	61	101	102	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 13	2003	22	10					1491	1500		10.1038/sj.onc.1206169	http://dx.doi.org/10.1038/sj.onc.1206169			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	652ZZ	12629512				2022-12-25	WOS:000181411900006
J	Kumar, A; Boriek, AM				Kumar, A; Boriek, AM			Mechanical stress activates the nuclear factor-kappaB pathway in skeletal muscle fibers: a possible role in Duchenne muscular dystrophy	FASEB JOURNAL			English	Article						mechanical loading; TNF-alpha; IL-1 beta; free radicals	TUMOR-NECROSIS-FACTOR; B KINASE IKK; SIGNAL-TRANSDUCTION; OXIDATIVE STRESS; PROTEIN LOSS; FACTOR-ALPHA; MDX MOUSE; TNF-ALPHA; EXPRESSION; TRANSCRIPTION	The ex vivo effects of passive mechanical stretch on the activation of nuclear factor-kappaB (NF-kappaB) pathways in skeletal muscles from normal and mdx mouse, a model of Duchenne muscular dystrophy (DMD), were investigated. The NF-kappaB/DNA binding activity of the diaphragm muscle was increased by the application of axial mechanical stretch in a time-dependent manner. The increased activation of NF-kappaB was associated with a concomitant increase in I-kappaB (IkappaB) kinase activity and the degradation of IkappaBalpha protein. Pretreatment of the muscles with nifedipine (a Ca2+ channel blocker) and gadolinium(III) chloride (a stretch-activated channel blocker) did not alter the level of activation of NF-kappaB, ruling out involvement of Ca2+ influx through these channels. Furthermore, N-acetyl cysteine, a free radical inhibitor, blocked the mechanical stretch-induced NF-kappaB activation, suggesting the involvement of free radicals. Compared with normal diaphragm, the basal level of NF-kappaB activity was higher in muscles from mdx mice, and it was further enhanced in mechanically stretched muscles. Furthermore, activation of NF-kappaB and increased expression of inflammatory cytokines IL-1beta and tumor necrosis factor alpha in the mdx mouse precede the onset of muscular dystrophy. Our results show that mechanical stretch activates the classical NF-kappaB pathway and this pathway could be predominately active in DMD.	Baylor Coll Med, Dept Med, Div Pulm, Houston, TX 77030 USA	Baylor College of Medicine	Boriek, AM (corresponding author), Baylor Coll Med, Dept Med, Div Pulm, Suite 520B,1 Baylor Plaza, Houston, TX 77030 USA.	boriek@bcm.tmc.edu		Kumar, Ashok/0000-0002-2444-9529; Kumar, Ashok/0000-0001-8571-2848	PHS HHS [63134] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Anker SD, 1997, LANCET, V349, P1050, DOI 10.1016/S0140-6736(96)07015-8; Argiles JM, 1999, MED RES REV, V19, P223, DOI 10.1002/(SICI)1098-1128(199905)19:3<223::AID-MED3>3.0.CO;2-N; Baud V, 2001, TRENDS CELL BIOL, V11, P372, DOI 10.1016/S0962-8924(01)02064-5; Boriek AM, 2001, AM J PHYSIOL-CELL PH, V280, pC46, DOI 10.1152/ajpcell.2001.280.1.C46; Danialou G, 2001, FASEB J, V15, P1655, DOI 10.1096/fj.01-0030fje; Emery AEH, 2002, LANCET, V359, P687, DOI 10.1016/S0140-6736(02)07815-7; ERVASTI JM, 1990, NATURE, V345, P315, DOI 10.1038/345315a0; GarciaMartinez C, 1995, BIOCHEM BIOPH RES CO, V217, P839, DOI 10.1006/bbrc.1995.2848; GLOGAUER M, 1995, AM J PHYSIOL-CELL PH, V269, pC1093, DOI 10.1152/ajpcell.1995.269.5.C1093; Gong GZ, 2001, P NATL ACAD SCI USA, V98, P9599, DOI 10.1073/pnas.171311298; Grady RM, 1999, NAT CELL BIOL, V1, P215, DOI 10.1038/12034; GUTTRIDGE DC, 2000, SCIENCE, V289, P2363, DOI [10.1126/sci-ence.289.5488.2363, DOI 10.1126/SCI-ENCE.289.5488.2363, DOI 10.1126/science.289.5488.2363, DOI 10.1126/SCIENCE.289.5488.2363]; Hagemann C, 2001, CELL SIGNAL, V13, P863, DOI 10.1016/S0898-6568(01)00220-0; HOFFMAN EP, 1987, CELL, V51, P919, DOI 10.1016/0092-8674(87)90579-4; Hu MCT, 1999, ONCOGENE, V18, P5514, DOI 10.1038/sj.onc.1202740; Hunter RB, 2002, FASEB J, V16, P529, DOI 10.1096/fj.01-0866com; Inoh H, 2002, FASEB J, V16, P405, DOI 10.1096/fj.01-0354fje; Kamogawa Y, 2001, CARDIOVASC RES, V50, P509, DOI 10.1016/S0008-6363(01)00205-X; Karin M, 2000, SEMIN IMMUNOL, V12, P85, DOI 10.1006/smim.2000.0210; Karin M, 1999, J BIOL CHEM, V274, P27339, DOI 10.1074/jbc.274.39.27339; Karin M, 2002, NAT IMMUNOL, V3, P221, DOI 10.1038/ni0302-221; Kherif S, 1999, DEV BIOL, V205, P158, DOI 10.1006/dbio.1998.9107; Kolodziejczyk SM, 2001, CURR BIOL, V11, P1278, DOI 10.1016/S0960-9822(01)00397-9; KOTLER DP, 1989, AM J CLIN NUTR, V50, P444, DOI 10.1093/ajcn/50.3.444; Kumar A, 1998, ONCOGENE, V17, P913, DOI 10.1038/sj.onc.1201998; Langen RCJ, 2001, FASEB J, V15, P1169, DOI 10.1096/fj.00-0463; Layne MD, 1999, EXP CELL RES, V249, P177, DOI 10.1006/excr.1999.4465; Lew AM, 1999, BIOCHEM J, V341, P647, DOI 10.1042/0264-6021:3410647; Li YP, 1999, ANTIOXID REDOX SIGN, V1, P97, DOI 10.1089/ars.1999.1.1-97; Li YP, 2000, AM J PHYSIOL-REG I, V279, pR1165, DOI 10.1152/ajpregu.2000.279.4.R1165; Li YP, 1998, FASEB J, V12, P871, DOI 10.1096/fasebj.12.10.871; Llovera M, 1997, BIOCHEM BIOPH RES CO, V230, P238, DOI 10.1006/bbrc.1996.5827; Lundberg I, 1995, J NEUROIMMUNOL, V63, P9, DOI 10.1016/0165-5728(95)00122-0; MILLER SC, 1988, MOL CELL BIOL, V8, P2295, DOI 10.1128/MCB.8.6.2295; Muller JM, 1997, METHODS, V11, P301, DOI 10.1006/meth.1996.0424; Nakashima J, 1998, CLIN CANCER RES, V4, P1743; PETROF BJ, 1993, P NATL ACAD SCI USA, V90, P3710, DOI 10.1073/pnas.90.8.3710; Porreca E, 1999, THROMB HAEMOSTASIS, V81, P543; Reid MB, 2001, RESP RES, V2, P269, DOI 10.1186/rr67; Roy R R, 1991, Exerc Sport Sci Rev, V19, P269; Ruwhof C, 2000, CARDIOVASC RES, V47, P23, DOI 10.1016/S0008-6363(00)00076-6; Senftleben U, 2002, CRIT CARE MED, V30, pS18, DOI 10.1097/00003246-200201001-00003; SICINSKI P, 1989, SCIENCE, V244, P1578, DOI 10.1126/science.2662404; Silverman N, 2001, GENE DEV, V15, P2321, DOI 10.1101/gad.909001; Spencer MJ, 1997, J CLIN INVEST, V99, P2745, DOI 10.1172/JCI119464; SPENCER MJ, 1995, J BIOL CHEM, V270, P10909, DOI 10.1074/jbc.270.18.10909; STEDMAN HH, 1991, NATURE, V352, P536, DOI 10.1038/352536a0; TIDBALL JG, 1995, J CELL SCI, V108, P2197; VANDENBURGH HH, 1982, J BIOL CHEM, V257, P13448; Vandenburgh HH, 1996, AM J PHYSIOL-CELL PH, V270, pC1284, DOI 10.1152/ajpcell.1996.270.5.C1284; Watanabe N, 2001, Rinsho Byori, V49, P829; Yamazaki T, 1998, CIRC RES, V82, P430, DOI 10.1161/01.RES.82.4.430; Zhao SP, 1997, INT J CARDIOL, V58, P257, DOI 10.1016/S0167-5273(96)02873-2; Zhou LZH, 2001, FREE RADICAL BIO MED, V31, P1405, DOI 10.1016/S0891-5849(01)00719-5	54	211	218	1	12	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2003	17	3					386	396		10.1096/fj.02-0542com	http://dx.doi.org/10.1096/fj.02-0542com			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	661LT	12631578				2022-12-25	WOS:000181892600037
J	Crystal, AS; Morais, VA; Pierson, TC; Pijak, DS; Carlin, D; Lee, VMY; Doms, RW				Crystal, AS; Morais, VA; Pierson, TC; Pijak, DS; Carlin, D; Lee, VMY; Doms, RW			Membrane topology of gamma-secretase component PEN-2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMYLOID PRECURSOR PROTEIN; FAMILIAL ALZHEIMERS-DISEASE; CAENORHABDITIS-ELEGANS; BETA-SECRETASE; PRESENILIN-1; NICASTRIN; GLYCOSYLATION; COMPLEX; APH-1; NOTCH	PEN-2 is an integral membrane protein that is a necessary component of the gamma-secretase complex, which is central in the pathogenesis of Alzheimer's disease and is also required for Notch signaling. In the absence of PEN-2, Notch signaling fails to guide normal development in Caenorhabditis elegans, and amyloid beta peptide is not generated from the amyloid precursor protein. Human PEN-2 is a 101-amino acid protein containing two putative transmembrane domains. To understand its interaction with other gamma-secretase components, it is important to know the membrane topology of each member of the complex. To characterize the membrane topology of PEN-2, we introduced single amino acid changes in each of the three hydrophilic regions of PEN-2 to generate N-linked glycosylation sites. We found that the N-linked glycosylation sites present in the N- and C-terminal domains of PEN-2 were utilized, whereas a site in the hydrophilic "loop" region connecting the two transmembrane domains was not. The addition of a carbohydrate structure in the N- terminal domain of PEN-2 prevented association with presenilin 1, whereas glycosylation in the C-terminal region of PEN-2 did not, suggesting that the N- terminal domain is important for interactions with presenilin 1. Immunofluorescence microscopy with selective permeabilization of the plasma membrane of cells expressing epitope-tagged forms of PEN-2 confirmed the lumenal location of both the N and C termini. A protease protection assay also demonstrated that the loop domain of PEN-2 is cytosolic. Thus, PEN-2 spans the membrane twice, with the N and C termini facing the lumen of the endoplasmic reticulum.	Univ Penn, Dept Microbiol, Sch Med, Ctr Neurodegenerat Dis Res, Philadelphia, PA 19104 USA; Univ Penn, Dept Pathol & Lab Med, Sch Med, Ctr Neurodegenerat Dis Res, Philadelphia, PA 19104 USA; Univ Nova Lisboa, Inst Tecnol Quim & Biol, P-2780 Oeiras, Portugal; Inst Biol Expt & Tecnol, P-2780 Oeiras, Portugal	University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania; Pennsylvania Medicine; Universidade Nova de Lisboa	Doms, RW (corresponding author), Univ Penn, Dept Microbiol, Sch Med, Ctr Neurodegenerat Dis Res, 225 Johnson Pavil,3610 Hamilton Walk, Philadelphia, PA 19104 USA.			Morais, Vanessa/0000-0002-0830-0548; Crystal, Adam/0000-0002-2302-2654	NIA NIH HHS [AG-00256] Funding Source: Medline	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		BERGERON JJM, 1994, TRENDS BIOCHEM SCI, V19, P124, DOI 10.1016/0968-0004(94)90205-4; CHANG XB, 1994, J BIOL CHEM, V269, P18572; Doan A, 1996, NEURON, V17, P1023, DOI 10.1016/S0896-6273(00)80232-9; Edbauer D, 2002, P NATL ACAD SCI USA, V99, P8666, DOI 10.1073/pnas.132277899; Fortini ME, 2002, NAT REV MOL CELL BIO, V3, P673, DOI 10.1038/nrm910; Francis R, 2002, DEV CELL, V3, P85, DOI 10.1016/S1534-5807(02)00189-2; GOATE A, 1991, NATURE, V349, P704, DOI 10.1038/349704a0; Goutte C, 2002, P NATL ACAD SCI USA, V99, P775, DOI 10.1073/pnas.022523499; GU Y, 2002, J BIOL CHEM, V277, P7374; Hamilton SR, 2001, J BIOL CHEM, V276, P27981, DOI 10.1074/jbc.M100518200; Huse JT, 2000, J BIOL CHEM, V275, P33729, DOI 10.1074/jbc.M004175200; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; Kovacs DM, 1996, NAT MED, V2, P224, DOI 10.1038/nm0296-224; Lee SF, 2002, J BIOL CHEM, V277, P45013, DOI 10.1074/jbc.M208164200; Leem JY, 2002, J BIOL CHEM, V277, P19236, DOI 10.1074/jbc.C200148200; LEVYLAHAD E, 1995, SCIENCE, V269, P973, DOI 10.1126/science.7638622; Li J, 2000, BIOCHEM J, V349, P51, DOI 10.1042/0264-6021:3490051; Li XJ, 1996, NEURON, V17, P1015, DOI 10.1016/S0896-6273(00)80231-7; Li XJ, 1998, P NATL ACAD SCI USA, V95, P7109, DOI 10.1073/pnas.95.12.7109; Li YM, 2000, P NATL ACAD SCI USA, V97, P6138, DOI 10.1073/pnas.110126897; Li YM, 2000, NATURE, V405, P689, DOI 10.1038/35015085; Luo WJ, 2003, J BIOL CHEM, V278, P7850, DOI 10.1074/jbc.C200648200; MASTERS CL, 1985, P NATL ACAD SCI USA, V82, P4245, DOI 10.1073/pnas.82.12.4245; Nakai T, 1999, J BIOL CHEM, V274, P23647, DOI 10.1074/jbc.274.33.23647; Nakamura N, 1995, J CELL BIOL, V131, P1715, DOI 10.1083/jcb.131.6.1715; SHERRINGTON R, 1995, NATURE, V375, P754, DOI 10.1038/375754a0; Steiner H, 2002, J BIOL CHEM, V277, P39062, DOI 10.1074/jbc.C200469200; Vannier B, 1998, J BIOL CHEM, V273, P8675, DOI 10.1074/jbc.273.15.8675; Vassar R, 1999, SCIENCE, V286, P735, DOI 10.1126/science.286.5440.735; Wang R, 1996, J BIOL CHEM, V271, P31894, DOI 10.1074/jbc.271.50.31894; Wolfe MS, 1999, NATURE, V398, P513, DOI 10.1038/19077; Xia WM, 2000, P NATL ACAD SCI USA, V97, P9299, DOI 10.1073/pnas.97.16.9299; Yang DS, 2002, J BIOL CHEM, V277, P28135, DOI 10.1074/jbc.M110871200; Yu G, 2000, NATURE, V407, P48, DOI 10.1038/35024009; Yu G, 1998, J BIOL CHEM, V273, P16470, DOI 10.1074/jbc.273.26.16470	35	74	76	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 30	2003	278	22					20117	20123		10.1074/jbc.M213107200	http://dx.doi.org/10.1074/jbc.M213107200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	682EH	12639958	hybrid			2022-12-25	WOS:000183078000070
J	Koshkin, V; Wang, XL; Scherer, PE; Chan, CB; Wheeler, MB				Koshkin, V; Wang, XL; Scherer, PE; Chan, CB; Wheeler, MB			Mitochondrial functional state in clonal pancreatic beta-cells exposed to free fatty acids	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STIMULATED INSULIN-SECRETION; HYDROGEN-PEROXIDE GENERATION; OXYGEN SPECIES GENERATION; ELECTRON-TRANSPORT CHAIN; RAT-LIVER MITOCHONDRIA; UNCOUPLING PROTEIN-2; GLYCEROL-3-PHOSPHATE DEHYDROGENASE; DICARBOXYLATE CARRIER; PERMEABILIZED CELLS; GLUCOSE-METABOLISM	Excessive free fatty acid (FFA) exposure represents a potentially important diabetogenic condition that can impair insulin secretion from pancreatic beta-cells. Because mitochondrial oxidative phosphorylation is a main link between glucose metabolism and insulin secretion, in the present work we investigated the effects of the FFA oleate (OE) on mitochondrial function in the clonal pancreatic beta-cell line, MIN6. Both the long term ( 72 h) and short term ( immediately after application) impact of OE exposure on beta-cells was investigated. After 72 h of exposure to OE (0.4 mM, 0.5% bovine serum albumin) cells were washed and permeabilized, and mitochondrial function ( respiration, phosphorylation, membrane potential formation, production of reactive oxygen species) was measured in the absence or presence of OE. MIN6 cells exposed to OE for 72 h showed impaired glucose-stimulated insulin secretion and decreased cellular ATP. Mitochondria in OE-exposed cells retained normal functional characteristics in FFA-free medium; however, they were significantly more sensitive to the acute uncoupling effect of OE treatment. The mitochondria of OE-exposed cells displayed increased depolarization caused by acute OE treatment, which is attributable to the elevation in the FFA-transporting function of uncoupling protein 2 and the dicarboxylate carrier. These cells also had an increased production of reactive oxygen species in complex I of the mitochondrial respiratory chain that could be activated by FFA. A high level of reduction of respiratory complex I augmented acute FFA-induced uncoupling in a way compatible with activation of mitochondrial uncoupling protein by intramitochondrial superoxide. A stronger augmentation was observed in OE-exposed cells. Together, these events may underlie FFA-induced depression of the ATP/ADP ratio in beta-cells, which accounts for the defective glucose-stimulated insulin secretion associated with lipotoxicity.	Univ Toronto, Dept Physiol, Toronto, ON M5S 1A8, Canada; Univ Toronto, Dept Med, Toronto, ON M5S 1A8, Canada; Yeshiva Univ Albert Einstein Coll Med, Dept Cell Biol, Bronx, NY 10461 USA; Univ Prince Edward Isl, Dept Biomed Sci, Charlottetown, PE C1A 4P3, Canada	University of Toronto; University of Toronto; Yeshiva University; Albert Einstein College of Medicine; University of Prince Edward Island	Wheeler, MB (corresponding author), Univ Toronto, Dept Physiol, Med Sci Bldg,1 Kings Coll Circle, Toronto, ON M5S 1A8, Canada.		Chan, Catherine/C-1162-2011; Scherer, Philipp E/K-7819-2012	Chan, Catherine/0000-0003-3882-0592; Scherer, Philipp E/0000-0003-0680-3392; Wheeler, Michael B./0000-0002-7480-7267				Antinozzi PA, 2002, J BIOL CHEM, V277, P11746, DOI 10.1074/jbc.M108462200; Barbu A, 2002, MOL CELL ENDOCRINOL, V190, P75, DOI 10.1016/S0303-7207(02)00009-6; BLACK MJ, 1974, ANAL BIOCHEM, V58, P246, DOI 10.1016/0003-2697(74)90464-3; BOGUCKA K, 1990, BIOCHIM BIOPHYS ACTA, V1015, P503, DOI 10.1016/0005-2728(90)90084-H; BOVERIS A, 1973, BIOCHEM J, V134, P707, DOI 10.1042/bj1340707; Busch AK, 2002, DIABETES, V51, P977, DOI 10.2337/diabetes.51.4.977; Cadenas S, 2002, J BIOL CHEM, V277, P2773, DOI 10.1074/jbc.M109736200; Carlsson C, 1999, ENDOCRINOLOGY, V140, P3422, DOI 10.1210/en.140.8.3422; Casolo V, 2000, FEBS LETT, V474, P53, DOI 10.1016/S0014-5793(00)01576-3; Chan CB, 2001, DIABETES, V50, P1302, DOI 10.2337/diabetes.50.6.1302; Civelek VN, 1996, BIOCHEM J, V318, P615, DOI 10.1042/bj3180615; Cocco T, 1999, FREE RADICAL BIO MED, V27, P51, DOI 10.1016/S0891-5849(99)00034-9; Cuzzocrea S, 2001, PHARMACOL REV, V53, P135; Das K, 1999, BIOCHEM J, V344, P313, DOI 10.1042/0264-6021:3440313; Di Paola M, 2000, BIOCHEMISTRY-US, V39, P6660, DOI 10.1021/bi9924415; DUCHEN MR, 1993, BIOCHEM J, V294, P35, DOI 10.1042/bj2940035; Echtay KS, 2002, J BIOL CHEM, V277, P47129, DOI 10.1074/jbc.M208262200; ECHTAY KS, 2000, TNATURE, V415, P96; Estabrook R. W., 1967, METHODS ENZYMOLOGY, V10, P41, DOI DOI 10.1016/0076-6879(67)10010-4; Ferrer J, 1996, DIABETES, V45, P262, DOI 10.2337/diabetes.45.2.262; Fink BD, 2002, J BIOL CHEM, V277, P3918, DOI 10.1074/jbc.M107955200; Gorogawa S, 2002, DIABETES RES CLIN PR, V57, P1, DOI 10.1016/S0168-8227(02)00005-0; Himms-Hagen J, 2001, EXP BIOL MED, V226, P78, DOI 10.1177/153537020122600204; Ho E, 1999, FASEB J, V13, P1845, DOI 10.1096/fasebj.13.13.1845; Hofmann WE, 2001, J BIOL CHEM, V276, P12460, DOI 10.1074/jbc.M100466200; ISHIHARA H, 1993, DIABETOLOGIA, V36, P1139, DOI 10.1007/BF00401058; Joseph JW, 2002, DIABETES, V51, P3211, DOI 10.2337/diabetes.51.11.3211; Kerner J, 2000, BBA-MOL CELL BIOL L, V1486, P1, DOI 10.1016/S1388-1981(00)00044-5; KOHNKE D, 1993, FEBS LETT, V336, P90, DOI 10.1016/0014-5793(93)81616-8; Korshunov SS, 1998, FEBS LETT, V435, P215, DOI 10.1016/S0014-5793(98)01073-4; Kowaltowski AJ, 1998, FEBS LETT, V425, P213, DOI 10.1016/S0014-5793(98)00231-2; KRAUS S, 2002, P NATL ACAD SCI USA, V99, P15858; Kushnareva Y, 2002, BIOCHEM J, V368, P545, DOI 10.1042/BJ20021121; Kwong LK, 2002, METHOD ENZYMOL, V349, P341, DOI 10.1016/S0076-6879(02)49349-4; Kwong LK, 1998, ARCH BIOCHEM BIOPHYS, V350, P118, DOI 10.1006/abbi.1997.0489; Lameloise N, 2001, DIABETES, V50, P803, DOI 10.2337/diabetes.50.4.803; Langin D, 2001, NEW ENGL J MED, V345, P1772, DOI 10.1056/NEJM200112133452412; Li LX, 2001, BIOCHEM BIOPH RES CO, V282, P273, DOI 10.1006/bbrc.2001.4577; Liang Y, 1997, DIABETOLOGIA, V40, P1018, DOI 10.1007/s001250050783; Liu YB, 2002, J NEUROCHEM, V80, P780, DOI 10.1046/j.0022-3042.2002.00744.x; Lupi R, 2002, DIABETES, V51, P1437, DOI 10.2337/diabetes.51.5.1437; MACDONALD MJ, 1981, J BIOL CHEM, V256, P8287; Medvedev AV, 2002, J BIOL CHEM, V277, P42639, DOI 10.1074/jbc.M208645200; Minami K, 2000, AM J PHYSIOL-ENDOC M, V279, pE773, DOI 10.1152/ajpendo.2000.279.4.E773; MNCGARRY JD, 1925, DIABETES, V5, P7; Ouhabi R, 1998, ANAL BIOCHEM, V263, P169, DOI 10.1006/abio.1998.2776; REYNAFARJE B, 1985, ANAL BIOCHEM, V145, P406, DOI 10.1016/0003-2697(85)90381-1; Saks VA, 1998, MOL CELL BIOCHEM, V184, P81, DOI 10.1023/A:1006834912257; Sakurai K, 2001, BIOL PHARM BULL, V24, P876, DOI 10.1248/bpb.24.876; Saleh MC, 2002, DIABETOLOGIA, V45, P174, DOI 10.1007/s00125-001-0737-x; Segall L, 1999, AM J PHYSIOL-ENDOC M, V277, pE521, DOI 10.1152/ajpendo.1999.277.3.E521; Simonyan RA, 2001, BBA-BIOENERGETICS, V1505, P271, DOI 10.1016/S0005-2728(01)00168-2; Soejima A, 1996, J BIOL CHEM, V271, P26194, DOI 10.1074/jbc.271.42.26194; Stuart JA, 2001, J BIOL CHEM, V276, P18633, DOI 10.1074/jbc.M011566200; VERCESI AE, 1991, J BIOL CHEM, V266, P14431; WANG X, 2002, DIABETES S2, V1; Wieckowski MR, 1997, BIOCHEM BIOPH RES CO, V232, P414; WOELDERS H, 1988, BIOCHIM BIOPHYS ACTA, V934, P123, DOI 10.1016/0005-2728(88)90127-2; Yamagishi SI, 2001, J BIOL CHEM, V276, P25096, DOI 10.1074/jbc.M007383200; ZORATTI M, 1982, EUR J BIOCHEM, V126, P443, DOI 10.1111/j.1432-1033.1982.tb06800.x	60	96	99	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 30	2003	278	22					19709	19715		10.1074/jbc.M209709200	http://dx.doi.org/10.1074/jbc.M209709200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	682EH	12642585	hybrid			2022-12-25	WOS:000183078000020
J	Lagorce, A; Hauser, NC; Labourdette, D; Rodriguez, C; Martin-Yken, H; Arroyo, J; Hoheisel, JRD; Francois, J				Lagorce, A; Hauser, NC; Labourdette, D; Rodriguez, C; Martin-Yken, H; Arroyo, J; Hoheisel, JRD; Francois, J			Genome-wide analysis of the response to cell wall mutations in the yeast Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLOBAL GENE-EXPRESSION; PROTEIN-KINASE-C; MAP KINASE; TRANSCRIPTION FACTOR; STRESS-RESPONSE; SIGNALING PATHWAY; CYCLE REGULATOR; INTEGRITY; MUTANTS; CHITIN	Perturbations of the yeast cell wall trigger a repair mechanism that reconfigures its molecular structure to preserve cell integrity. To investigate this mechanism, we compared the global gene expression in five mutant strains, each bearing a mutation (i.e. fks1, kre6, mnn9, gas1, and knr4 mutants) that affects in a different manner the cell wall construction. Altogether, 300 responsive genes were kept based on high stringency criteria during data processing. Functional classification of these differentially expressed genes showed a substantial subset of induced genes involved in cell wall construction and an enrichment of metabolic, energy generation, and cell defense categories, whereas families of genes belonging to transcription, protein synthesis, and cellular growth were underrepresented. Clustering methods isolated a single group of similar to80 up-regulated genes that could be considered as the stereotypical transcriptional response of the cell wall compensatory mechanism. The in silico analysis of the DNA upstream region of these co-regulated genes revealed pairwise combinations of DNA-binding sites for transcriptional factors implicated in stress and heat shock responses (Msn2/4p and Hsf1p) with Rlm1p and Swi4p, two PKC1-regulated transcription factors involved in the activation genes related to cell wall biogenesis and G(1)/S transition. Moreover, this computational analysis also uncovered the 6-bp 5'-AGCCTC-3' CDRE (calcineurin-dependent response element) motif in 40% of the coregulated genes. This motif was recently shown to be the DNA binding site for Crz1p, the major effector of calcineurin-regulated gene expression in yeast. Taken altogether, the data presented here lead to the conclusion that the cell wall compensatory mechanism, as triggered by cell wall mutations, integrates three major regulatory systems: namely the PKC1-SLT2 mitogen-activated protein kinase-signaling module, the "global stress" response mediated by Msn2/4p, and the Ca2+/calcineurin-dependent pathway. The relative importance of these regulatory systems in the cell wall compensatory mechanism is discussed.	Ctr Bioingn Gilbert Durand, CNRS, UMR 5504, F-31077 Toulouse, France; INRA 792, Genopole Toulouse, F-31077 Toulouse, France; Deutsch Krebsforschungszentrum, Div Funct Genome Anal, D-69120 Heidelberg, Germany; Univ Complutense Madrid, Fac Farm, Dept Microbiol 2, E-28040 Madrid, Spain	Centre National de la Recherche Scientifique (CNRS); CNRS - Institute for Engineering & Systems Sciences (INSIS); Universite de Toulouse; Universite Federale Toulouse Midi-Pyrenees (ComUE); Institut National des Sciences Appliquees de Toulouse; INRAE; Universite de Toulouse; Universite Federale Toulouse Midi-Pyrenees (ComUE); Institut National des Sciences Appliquees de Toulouse; Centre National de la Recherche Scientifique (CNRS); Helmholtz Association; German Cancer Research Center (DKFZ); Complutense University of Madrid	Francois, J (corresponding author), Ctr Bioingn Gilbert Durand, CNRS, UMR 5504, 135 Ave Rangeuil, F-31077 Toulouse, France.	fran_jm@insa-tlse.fr	Arroyo, Javier/E-9308-2016; Martin-Yken, Helene/H-5250-2011; MARTIN-YKEN, Helene/O-7826-2019	Arroyo, Javier/0000-0002-1971-1721; Martin-Yken, Helene/0000-0002-2024-3232; MARTIN-YKEN, Helene/0000-0002-2024-3232; Francois, Jean marie/0000-0001-9884-5535; LAGORCE, ARNAUD/0000-0002-7828-0300				Alexandre H, 2001, FEBS LETT, V498, P98, DOI 10.1016/S0014-5793(01)02503-0; ANDREWS BJ, 1989, NATURE, V342, P830, DOI 10.1038/342830a0; Baetz K, 2001, MOL CELL BIOL, V21, P6515, DOI 10.1128/MCB.21.19.6515-6528.2001; BAILEY TL, 1994, P SEC INT C INTELL S, V3, P28; Beier M, 1999, NUCLEIC ACIDS RES, V27, P1970, DOI 10.1093/nar/27.9.1970; Beissbarth T, 2000, BIOINFORMATICS, V16, P1014; Bickle M, 1998, EMBO J, V17, P2235, DOI 10.1093/emboj/17.8.2235; Brazma A, 2001, NAT GENET, V29, P365, DOI 10.1038/ng1201-365; Cappellaro C, 1998, J BACTERIOL, V180, P5030, DOI 10.1128/JB.180.19.5030-5037.1998; Causton HC, 2001, MOL BIOL CELL, V12, P323, DOI 10.1091/mbc.12.2.323; Cherry JM, 1998, NUCLEIC ACIDS RES, V26, P73, DOI 10.1093/nar/26.1.73; Dallies N, 1998, YEAST, V14, P1297, DOI 10.1002/(SICI)1097-0061(1998100)14:14<1297::AID-YEA310>3.0.CO;2-L; de Nobel H, 2000, MICROBIOL-SGM, V146, P2121, DOI 10.1099/00221287-146-9-2121; DESTRUELLE M, 1994, MOL CELL BIOL, V14, P2740, DOI 10.1128/MCB.14.4.2740; Devenish RJ, 2000, BBA-BIOENERGETICS, V1458, P428, DOI 10.1016/S0005-2728(00)00092-X; Dihazi H, 2001, BIOCHEMISTRY-US, V40, P14669, DOI 10.1021/bi0155549; Dodou E, 1997, MOL CELL BIOL, V17, P1848, DOI 10.1128/MCB.17.4.1848; DRGON T, 1992, FEBS LETT, V304, P277, DOI 10.1016/0014-5793(92)80637-V; Dutton JR, 1997, EMBO J, V16, P5710, DOI 10.1093/emboj/16.18.5710; Edlind T, 2002, MOL MICROBIOL, V46, P257, DOI 10.1046/j.1365-2958.2002.03165.x; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; Estruch F, 2000, FEMS MICROBIOL REV, V24, P469, DOI 10.1016/S0168-6445(00)00035-8; Fellenberg K, 2002, BIOINFORMATICS, V18, P423, DOI 10.1093/bioinformatics/18.3.423; Fellenberg K, 2001, P NATL ACAD SCI USA, V98, P10781, DOI 10.1073/pnas.181597298; Gancedo JM, 1998, MICROBIOL MOL BIOL R, V62, P334, DOI 10.1128/MMBR.62.2.334-361.1998; Gancedo JM, 2001, FEMS MICROBIOL REV, V25, P107, DOI 10.1016/S0168-6445(00)00056-5; Garcia-Rodriguez LJ, 2000, J BACTERIOL, V182, P2428, DOI 10.1128/JB.182.9.2428-2437.2000; Gasch AP, 2000, MOL BIOL CELL, V11, P4241, DOI 10.1091/mbc.11.12.4241; GOLDMAN RC, 1995, EUR J BIOCHEM, V227, P372, DOI 10.1111/j.1432-1033.1995.tb20399.x; Hahn JS, 2002, J BIOL CHEM, V277, P21278, DOI 10.1074/jbc.M202557200; Hauser NC, 1998, YEAST, V14, P1209, DOI 10.1002/(SICI)1097-0061(19980930)14:13<1209::AID-YEA311>3.0.CO;2-N; Heinisch JJ, 1999, MOL MICROBIOL, V32, P671, DOI 10.1046/j.1365-2958.1999.01375.x; Hohmann S, 2002, MICROBIOL MOL BIOL R, V66, P300, DOI 10.1128/MMBR.66.2.300-372.2002; INNIS MA, 1990, PCR PROTOCOLS GUIDE, P177; Iyer VR, 2001, NATURE, V409, P533, DOI 10.1038/35054095; Jiang B, 2002, CURR OPIN MICROBIOL, V5, P466, DOI 10.1016/S1369-5274(02)00361-2; Jung US, 1999, MOL MICROBIOL, V34, P1049, DOI 10.1046/j.1365-2958.1999.01667.x; Kapteyn JC, 1999, MOL MICROBIOL, V31, P1835, DOI 10.1046/j.1365-2958.1999.01320.x; Ketela T, 1999, J BACTERIOL, V181, P3330, DOI 10.1128/JB.181.11.3330-3340.1999; Kitagaki H, 2002, MOL MICROBIOL, V46, P1011, DOI 10.1046/j.1365-2958.2002.03244.x; Klis FM, 2002, FEMS MICROBIOL REV, V26, P239, DOI 10.1111/j.1574-6976.2002.tb00613.x; KOLLAR R, 1995, J BIOL CHEM, V270, P1170, DOI 10.1074/jbc.270.3.1170; Kollar R, 1997, J BIOL CHEM, V272, P17762, DOI 10.1074/jbc.272.28.17762; KONOPKA JB, 1995, MOL CELL BIOL, V15, P723; Lagorce A, 2002, EUR J BIOCHEM, V269, P1697, DOI 10.1046/j.1432-1327.2002.02814.x; Lenburg ME, 1996, TRENDS BIOCHEM SCI, V21, P383, DOI 10.1016/S0968-0004(96)90127-9; Lussier M, 1996, J BIOL CHEM, V271, P11001, DOI 10.1074/jbc.271.18.11001; Lussier M, 1997, GENETICS, V147, P435; Madden K, 1997, SCIENCE, V275, P1781, DOI 10.1126/science.275.5307.1781; Martin H, 1999, MICROBIOL-SGM, V145, P249, DOI 10.1099/13500872-145-1-249; Martin H, 2000, J BIOL CHEM, V275, P1511, DOI 10.1074/jbc.275.2.1511; MARTIN H, 1993, MOL GEN GENET, V241, P177, DOI 10.1007/BF00280215; Martin-Yken H, 2002, CURR GENET, V41, P323, DOI 10.1007/s00294-002-0299-6; MartinezPastor MT, 1996, EMBO J, V15, P2227, DOI 10.1002/j.1460-2075.1996.tb00576.x; MAZUR P, 1995, MOL CELL BIOL, V15, P5671; Mewes HW, 1997, NUCLEIC ACIDS RES, V25, P28, DOI 10.1093/nar/25.1.28; Muller S, 1997, MICROBIOL-UK, V143, P3055, DOI 10.1099/00221287-143-9-3055; NEBREDA AR, 1986, GENE, V47, P245, DOI 10.1016/0378-1119(86)90068-5; NGUYEN C, 1995, GENOMICS, V29, P207, DOI 10.1006/geno.1995.1233; Okar DA, 1999, BIOFACTORS, V10, P1, DOI 10.1002/biof.5520100101; Olsen V, 1999, BIOCHEM J, V339, P407, DOI 10.1042/0264-6021:3390407; Orlean P., 1997, MOL CELLULAR BIOL YE, P229; Pan XW, 2000, MOL CELL BIOL, V20, P8364, DOI 10.1128/MCB.20.22.8364-8372.2000; Popolo L, 1999, BBA-GEN SUBJECTS, V1426, P385, DOI 10.1016/S0304-4165(98)00138-X; Popolo L, 2001, MED MYCOL, V39, P111, DOI 10.1080/744118881; POPOLO L, 1993, J BACTERIOL, V175, P1879, DOI 10.1128/JB.175.7.1879-1885.1993; Popolo L, 1997, J BACTERIOL, V179, P463, DOI 10.1128/jb.179.2.463-469.1997; Puig S, 2000, YEAST, V16, P139, DOI 10.1002/(SICI)1097-0061(20000130)16:2<139::AID-YEA512>3.3.CO;2-A; Quandt K, 1995, NUCLEIC ACIDS RES, V23, P4878, DOI 10.1093/nar/23.23.4878; Rajavel M, 1999, MOL CELL BIOL, V19, P3969; Ram AFJ, 1998, J BACTERIOL, V180, P1418, DOI 10.1128/JB.180.6.1418-1424.1998; RAM AFJ, 1994, YEAST, V10, P1019, DOI 10.1002/yea.320100804; Roberts CJ, 2000, SCIENCE, V287, P873, DOI 10.1126/science.287.5454.873; ROEMER T, 1994, J CELL BIOL, V127, P567, DOI 10.1083/jcb.127.2.567; ROSE M, 1983, METHOD ENZYMOL, V101, P167; Rose MD., 1990, METHODS YEAST GENETI; Serrano R, 2002, MOL MICROBIOL, V46, P1319, DOI 10.1046/j.1365-2958.2002.03246.x; Shahinian S, 2000, MOL MICROBIOL, V35, P477, DOI 10.1046/j.1365-2958.2000.01713.x; Sherlock G, 2000, CURR OPIN IMMUNOL, V12, P201, DOI 10.1016/S0952-7915(99)00074-6; Shimoi H, 1998, J BACTERIOL, V180, P3381, DOI 10.1128/JB.180.13.3381-3387.1998; Siderius M, 1997, MICROBIOL-SGM, V143, P3241, DOI 10.1099/00221287-143-10-3241; Smits GJ, 1999, CURR OPIN MICROBIOL, V2, P348; Smits GJ, 2001, MICROBIOL-SGM, V147, P781, DOI 10.1099/00221287-147-4-781; SORGER PK, 1991, CELL, V65, P363, DOI 10.1016/0092-8674(91)90452-5; Takabatake R, 2001, J BIOCHEM, V129, P827, DOI 10.1093/oxfordjournals.jbchem.a002926; Terashima H, 2000, MOL GEN GENET, V264, P64, DOI 10.1007/s004380000285; Uemura H, 1997, GENETICS, V147, P521; Van Helden J, 2000, YEAST, V16, P177, DOI 10.1002/(SICI)1097-0061(20000130)16:2<177::AID-YEA516>3.0.CO;2-9; Verna J, 1997, P NATL ACAD SCI USA, V94, P13804, DOI 10.1073/pnas.94.25.13804; WALSH RB, 1991, GENETICS, V128, P521; WATERLAND RA, 1991, J BIOL CHEM, V266, P4180; Wingender E, 2000, NUCLEIC ACIDS RES, V28, P316, DOI 10.1093/nar/28.1.316; Woods R. A., 2001, METH MOL B, V177, P85; YIP CL, 1994, P NATL ACAD SCI USA, V91, P2723, DOI 10.1073/pnas.91.7.2723; Yoshimoto H, 2002, J BIOL CHEM, V277, P31079, DOI 10.1074/jbc.M202718200; Zhao C, 1998, MOL CELL BIOL, V18, P1013, DOI 10.1128/MCB.18.2.1013	97	213	224	3	20	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 30	2003	278	22					20345	20357		10.1074/jbc.M211604200	http://dx.doi.org/10.1074/jbc.M211604200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	682EH	12644457	Green Published, hybrid			2022-12-25	WOS:000183078000099
J	Rao, FV; Houston, DR; Boot, RG; Aerts, JMFG; Sakuda, S; van Aalten, DMF				Rao, FV; Houston, DR; Boot, RG; Aerts, JMFG; Sakuda, S; van Aalten, DMF			Crystal structures of allosamidin derivatives in complex with human macrophage chitinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SUBSTRATE-ASSISTED CATALYSIS; HUMAN CHITOTRIOSIDASE; SACCHAROMYCES-CEREVISIAE; PARASITE INVASION; CELL-SEPARATION; MOSQUITO MIDGUT; INHIBITOR; MECHANISM; LYSOZYME; PROTEIN	The pseudotrisaccharide allosamidin is a potent family 18 chitinase inhibitor with demonstrated biological activity against insects, fungi, and the Plasmodium falciparum life cycle. The synthesis and biological properties of several derivatives have been reported. The structural interactions of allosamidin with several family 18 chitinases have been determined by x-ray crystallography previously. Here, a high resolution structure of chitotriosidase, the human macrophage chitinase, in complex with allosamidin is presented. In addition, complexes of the allosamidin derivatives demethylallosamidin, methylallosamidin, and glucoallosamidin B are described, together with their inhibitory properties. Similar to other chitinases, inhibition of the human chitinase by allosamidin derivatives lacking a methyl group is 10-fold stronger, and smaller effects are observed for the methyl and C3 epimer derivatives. The structures explain the effects on inhibition in terms of altered hydrogen bonding and hydrophobic interactions, together with displaced water molecules. The data reported here represent a first step toward structure-based design of specific allosamidin derivatives.	Univ Dundee, Sch Life Sci, Div Biol Chem & Mol Microbiol, Dundee DD1 5EH, Scotland; Univ Amsterdam, Acad Med Ctr, Dept Biochem, NL-1105 AZ Amsterdam, Netherlands; Univ Tokyo, Dept Appl Biol Chem, Bunkyo Ku, Tokyo 113, Japan	University of Dundee; University of Amsterdam; Academic Medical Center Amsterdam; University of Tokyo	van Aalten, DMF (corresponding author), Univ Dundee, Sch Life Sci, Div Biol Chem & Mol Microbiol, Dundee DD1 5EH, Scotland.		Aerts, Johannes/A-1028-2009	Aerts, Johannes/0000-0001-8168-2565; Houston, Douglas/0000-0002-3469-1546; Boot, Rolf/0000-0002-7031-3390; Sakuda, Shohei/0000-0001-7966-1167; van Aalten, Daan/0000-0002-1499-6908				Arai N, 2000, CHEM PHARM BULL, V48, P1442, DOI 10.1248/cpb.48.1442; Berecibar A, 1999, CHEM REV, V99, P779, DOI 10.1021/cr980033l; Boot RG, 2001, J BIOL CHEM, V276, P6770, DOI 10.1074/jbc.M009886200; Boot RG, 1998, J BIOL CHEM, V273, P25680, DOI 10.1074/jbc.273.40.25680; Bortone K, 2002, J MOL BIOL, V320, P293, DOI 10.1016/S0022-2836(02)00444-8; Brameld KA, 1998, J AM CHEM SOC, V120, P3571, DOI 10.1021/ja972282h; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Choi EH, 2001, GENES IMMUN, V2, P248, DOI 10.1038/sj.gene.6363767; COHEN E, 1993, ARCH INSECT BIOCHEM, V22, P245, DOI 10.1002/arch.940220118; Fusetti F, 2002, J BIOL CHEM, V277, P25537, DOI 10.1074/jbc.M201636200; HOLLAK CEM, 1994, J CLIN INVEST, V93, P1288, DOI 10.1172/JCI117084; Hooft RWW, 1996, PROTEINS, V26, P363; Houston DR, 2002, BIOCHEM J, V368, P23, DOI 10.1042/BJ20021034; Houston DR, 2002, P NATL ACAD SCI USA, V99, P9127, DOI 10.1073/pnas.132060599; Izumida H, 1996, J ANTIBIOT, V49, P829, DOI 10.7164/antibiotics.49.829; Izumida H, 1996, J ANTIBIOT, V49, P76, DOI 10.7164/antibiotics.49.76; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KATO T, 1995, TETRAHEDRON LETT, V36, P2133, DOI 10.1016/0040-4039(95)00194-H; KURANDA MJ, 1991, J BIOL CHEM, V266, P19758; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; Notredame C, 2000, J MOL BIOL, V302, P205, DOI 10.1006/jmbi.2000.4042; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; RENKEMA GH, 1995, J BIOL CHEM, V270, P2198, DOI 10.1074/jbc.270.5.2198; Renkema GH, 1997, EUR J BIOCHEM, V244, P279, DOI 10.1111/j.1432-1033.1997.00279.x; RENKEMA GH, 1997, THESIS U AMSTERDAM A; SAKUDA S, 1990, AGR BIOL CHEM TOKYO, V54, P1333, DOI 10.1080/00021369.1990.10870108; SAKUDA S, 1986, TETRAHEDRON LETT, V27, P2475, DOI 10.1016/S0040-4039(00)84560-8; SAKUDA S, 1996, CHITIN ENZYMOLOGY, V2, P203; Shiomi K, 2000, TETRAHEDRON LETT, V41, P2141, DOI 10.1016/S0040-4039(00)00099-X; Tews I, 1997, J AM CHEM SOC, V119, P7954, DOI 10.1021/ja970674i; Tsai YL, 2001, INFECT IMMUN, V69, P4048, DOI 10.1128/IAI.69.6.4048-4054.2001; van Aalten DMF, 2001, P NATL ACAD SCI USA, V98, P8979, DOI 10.1073/pnas.151103798; vanAalten DMF, 1996, J COMPUT AID MOL DES, V10, P255, DOI 10.1007/BF00355047; VANSCHELTINGA ACT, 1994, STRUCTURE, V2, P1181, DOI 10.1016/S0969-2126(94)00120-0; VANSCHELTINGA ACT, 1995, BIOCHEMISTRY-US, V34, P15619, DOI 10.1021/bi00048a003; Vinetz JM, 1999, P NATL ACAD SCI USA, V96, P14061, DOI 10.1073/pnas.96.24.14061; Vinetz JM, 2000, J BIOL CHEM, V275, P10331, DOI 10.1074/jbc.275.14.10331; Vocadlo DJ, 2001, NATURE, V412, P835, DOI 10.1038/35090602; VRIEND G, 1990, J MOL GRAPHICS, V8, P52, DOI 10.1016/0263-7855(90)80070-V; Wu Y, 2001, J BIOL CHEM, V276, P42557, DOI 10.1074/jbc.M103479200	41	67	72	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 30	2003	278	22					20110	20116		10.1074/jbc.M300362200	http://dx.doi.org/10.1074/jbc.M300362200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	682EH	12639956	Green Published, hybrid			2022-12-25	WOS:000183078000069
J	Baker, TL; Zheng, H; Walker, J; Coloff, JL; Buss, JE				Baker, TL; Zheng, H; Walker, J; Coloff, JL; Buss, JE			Distinct rates of palmitate turnover on membrane-bound cellular and oncogenic H-Ras	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; CYSTEINE-RICH DOMAIN; PLASMA-MEMBRANE; LIPID RAFTS; K-RAS; SACCHAROMYCES-CEREVISIAE; SUBCELLULAR-LOCALIZATION; SIGNAL-TRANSDUCTION; ALPHA-SUBUNITS; ZINC-FINGER	H-Ras displays dynamic cycles of GTP binding and palmitate turnover. GTP binding is clearly coupled to activation, but whether the palmitoylated COOH terminus participates in signaling, especially when constrained by membrane tethering, is unknown. As a way to compare COOH termini of membrane-bound, lipid-modified H-Ras, palmitate removal rates were measured for various forms of H-Ras in NIH 3T3 cells. Depalmitoylation occurred slowly (t(1/2) similar to2.4 h) in cellular (H-RasWT) or dominant negative (H-Ras17N) forms and more rapidly (t(1/2) similar to1 h) in oncogenic H-Ras61L or H-RasR12, T59. Combining this data with GTP binding measurements, the palmitate half-life of H-Ras in the fully GTP-bound state was estimated to be less than 10 min. Slow palmitate removal from cellular H-Ras was not explained by sequestration in caveolae, as neither cellular nor oncogenic H-Ras showed alignment with caveolin by immunofluorescence. Conversely, although it had faster palmitate removal, oncogenic H-Ras was located in the same fractions as H-RasWT on four types of density gradients, and remained fully membrane-bound. Thus the different rates of deacylation occurred even though oncogenic and cellular H-Ras appeared to be in similar locations. Instead, these results suggest that acylprotein thioesterases access oncogenic H-Ras more easily because the conformation of its COOH terminus against the membrane is altered. This previously undetected difference could help produce distinctive effector interactions and signaling of oncogenic H-Ras.	Iowa State Univ, Dept Zool Genet, Ames, IA 50011 USA; Iowa State Univ, Dept Biochem, Ames, IA 50011 USA; Iowa State Univ, Dept Biophys, Ames, IA 50011 USA	Iowa State University; Iowa State University; Iowa State University	Buss, JE (corresponding author), Iowa State Univ, Dept Biochem Biophys & Mol Biol, Ames, IA 50011 USA.	jbuss@iastate.edu		Buss, Janice/0000-0002-8086-265X	NATIONAL CANCER INSTITUTE [R01CA051890] Funding Source: NIH RePORTER; NCI NIH HHS [CA51890] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Avery J, 2000, J CELL BIOL, V148, P317, DOI 10.1083/jcb.148.2.317; Bader B, 2000, NATURE, V403, P223, DOI 10.1038/35003249; Baker TL, 2000, J BIOL CHEM, V275, P22037, DOI 10.1074/jbc.M001813200; Bhamre S, 1998, J PHARMACOL EXP THER, V286, P1482; Bijlmakers MJ, 2003, TRENDS CELL BIOL, V13, P32, DOI 10.1016/S0962-8924(02)00008-9; Booden MA, 2000, J BIOL CHEM, V275, P23559, DOI 10.1074/jbc.M001368200; BOS JL, 1997, BIOCHIM BIOPHYS ACTA, V1333, P19; BRANDTRAUF PW, 1990, J PROTEIN CHEM, V9, P137, DOI 10.1007/BF01025304; Brown DA, 1998, ANNU REV CELL DEV BI, V14, P111, DOI 10.1146/annurev.cellbio.14.1.111; Buss JE, 1995, CHEM BIOL, V2, P787, DOI 10.1016/1074-5521(95)90083-7; BUSS JE, 1986, MOL CELL BIOL, V6, P116, DOI 10.1128/MCB.6.1.116; Campbell SL, 1998, ONCOGENE, V17, P1395, DOI 10.1038/sj.onc.1202174; Carey KD, 2003, J BIOL CHEM, V278, P3185, DOI 10.1074/jbc.M207014200; CASEY PJ, 1995, SCIENCE, V268, P221, DOI 10.1126/science.7716512; Chen CA, 2000, J BIOL CHEM, V275, P23516, DOI 10.1074/jbc.M003439200; Chen X, 2001, J BIOL CHEM, V276, P34617, DOI 10.1074/jbc.M103995200; Choy E, 1999, CELL, V98, P69, DOI 10.1016/S0092-8674(00)80607-8; DEGTYAREV MY, 1993, J BIOL CHEM, V268, P23769; DEVRIESSMITS AMM, 1995, METHOD ENZYMOL, V255, P156; Drugan JK, 1996, J BIOL CHEM, V271, P233, DOI 10.1074/jbc.271.1.233; Duncan JA, 2002, J BIOL CHEM, V277, P31740, DOI 10.1074/jbc.M202505200; Duncan JA, 1998, J BIOL CHEM, V273, P15830, DOI 10.1074/jbc.273.25.15830; Dunphy JT, 1998, BBA-MOL CELL BIOL L, V1436, P245, DOI 10.1016/S0005-2760(98)00130-1; Dunphy JT, 2001, J BIOL CHEM, V276, P43300, DOI 10.1074/jbc.M104275200; Edidin M, 2001, TRENDS CELL BIOL, V11, P492, DOI 10.1016/S0962-8924(01)02139-0; Field KA, 2000, MOL BIOL CELL, V11, P3661, DOI 10.1091/mbc.11.10.3661; Gelb MH, 1998, CURR OPIN CHEM BIOL, V2, P40, DOI 10.1016/S1367-5931(98)80034-3; GIBBS JB, 1995, METHOD ENZYMOL, V255, P118; Hu CD, 1995, J BIOL CHEM, V270, P30274, DOI 10.1074/jbc.270.51.30274; Huang CF, 1999, P NATL ACAD SCI USA, V96, P412, DOI 10.1073/pnas.96.2.412; Huang CF, 1997, MOL BIOL CELL, V8, P2365, DOI 10.1091/mbc.8.12.2365; Ilangumaran S, 1998, BIOCHEM J, V335, P433, DOI 10.1042/bj3350433; Janes PW, 1999, J CELL BIOL, V147, P447, DOI 10.1083/jcb.147.2.447; Jaumot M, 2002, J BIOL CHEM, V277, P272, DOI 10.1074/jbc.M108423200; Jiang XJ, 2002, MOL BIOL CELL, V13, P1522, DOI 10.1091/mbc.01-11-0552; Kato K, 1992, Semin Cancer Biol, V3, P179; Klinghoffer RA, 1996, MOL CELL BIOL, V16, P5905; Lang T, 2001, EMBO J, V20, P2202, DOI 10.1093/emboj/20.9.2202; Li SW, 1996, J BIOL CHEM, V271, P29182, DOI 10.1074/jbc.271.46.29182; Lobo S, 2002, J BIOL CHEM, V277, P41268, DOI 10.1074/JBC.M206573200; Loisel TP, 1996, BIOCHEMISTRY-US, V35, P15923, DOI 10.1021/bi9611321; London E, 2000, BBA-BIOMEMBRANES, V1508, P182, DOI 10.1016/S0304-4157(00)00007-1; LOWY DR, 1993, ANNU REV BIOCHEM, V62, P851, DOI 10.1146/annurev.bi.62.070193.004223; LU JY, 1995, J BIOL CHEM, V270, P7251, DOI 10.1074/jbc.270.13.7251; Luo ZJ, 1997, MOL CELL BIOL, V17, P46, DOI 10.1128/MCB.17.1.46; MAGEE AI, 1987, EMBO J, V6, P3353, DOI 10.1002/j.1460-2075.1987.tb02656.x; Matallanas D, 2003, J BIOL CHEM, V278, P4572, DOI 10.1074/jbc.M209807200; McCabe JB, 1999, MOL BIOL CELL, V10, P3771, DOI 10.1091/mbc.10.11.3771; McCabe JB, 2001, MOL BIOL CELL, V12, P3601, DOI 10.1091/mbc.12.11.3601; Melkonian KA, 1999, J BIOL CHEM, V274, P3910, DOI 10.1074/jbc.274.6.3910; MILLIGAN G, 1995, TRENDS BIOCHEM SCI, V20, P181, DOI 10.1016/S0968-0004(00)89004-0; Mineo C, 1999, J BIOL CHEM, V274, P30636, DOI 10.1074/jbc.274.43.30636; Mineo C, 1996, J BIOL CHEM, V271, P11930, DOI 10.1074/jbc.271.20.11930; Moffett S, 2000, J BIOL CHEM, V275, P2191, DOI 10.1074/jbc.275.3.2191; MUMBY S M, 1990, Methods (Orlando), V1, P216, DOI 10.1016/S1046-2023(05)80320-2; Mumby SM, 2002, METHOD ENZYMOL, V344, P383; MUMBY SM, 1994, P NATL ACAD SCI USA, V91, P2800, DOI 10.1073/pnas.91.7.2800; Nassar N, 1998, NAT STRUCT BIOL, V5, P1047, DOI 10.1038/4156; Niv H, 2002, J CELL BIOL, V157, P865, DOI 10.1083/jcb.200202009; Okada T, 1999, MOL CELL BIOL, V19, P6057; OLIFF A, 1999, BIOCHIM BIOPHYS ACTA, V1423, P19; PAI EF, 1990, EMBO J, V9, P2351, DOI 10.1002/j.1460-2075.1990.tb07409.x; Parmryd I, 2003, EXP CELL RES, V285, P27, DOI 10.1016/S0014-4827(02)00048-4; Prior IA, 2003, J CELL BIOL, V160, P165, DOI 10.1083/jcb.200209091; Prior IA, 2001, NAT CELL BIOL, V3, P368, DOI 10.1038/35070050; Reuter CWM, 2000, BLOOD, V96, P1655, DOI 10.1182/blood.V96.5.1655.h8001655_1655_1669; Rizzo MA, 2001, J BIOL CHEM, V276, P34928, DOI 10.1074/jbc.M105918200; Roy S, 1997, J BIOL CHEM, V272, P20139, DOI 10.1074/jbc.272.32.20139; Roy S, 2002, MOL CELL BIOL, V22, P5128, DOI 10.1128/MCB.22.14.5128-5140.2002; Roy S, 1999, NAT CELL BIOL, V1, P98, DOI 10.1038/10067; Rubiol I, 1999, EUR J BIOCHEM, V266, P70, DOI 10.1046/j.1432-1327.1999.00815.x; Song KS, 1996, J BIOL CHEM, V271, P9690, DOI 10.1074/jbc.271.16.9690; Tu YP, 1997, SCIENCE, V278, P1132, DOI 10.1126/science.278.5340.1132; Walsh AB, 2001, J BIOL CHEM, V276, P15609, DOI 10.1074/jbc.M010573200; Watson RT, 2001, J CELL BIOL, V154, P829, DOI 10.1083/jcb.200102078; WEDEGAERTNER PB, 1995, J BIOL CHEM, V270, P503, DOI 10.1074/jbc.270.2.503; WEDEGAERTNER PB, 1994, CELL, V77, P1063, DOI 10.1016/0092-8674(94)90445-6; White MA, 2001, NAT CELL BIOL, V3, pE172, DOI 10.1038/35087098; Williams JG, 2000, J BIOL CHEM, V275, P22172, DOI 10.1074/jbc.M000397200; Willumsen BM, 1996, ONCOGENE, V13, P1901; Wittinghofer A, 1996, TRENDS BIOCHEM SCI, V21, P488, DOI 10.1016/S0968-0004(96)10064-5; Zacharias DA, 2002, SCIENCE, V296, P913, DOI 10.1126/science.1068539; Zhao LH, 2002, J BIOL CHEM, V277, P49352, DOI 10.1074/jbc.M209760200	83	76	76	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 23	2003	278	21					19292	19300		10.1074/jbc.M206956200	http://dx.doi.org/10.1074/jbc.M206956200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	679PY	12642594	hybrid			2022-12-25	WOS:000182932200075
J	Huang, Y; Kim, SO; Jiang, J; Frank, SJ				Huang, Y; Kim, SO; Jiang, J; Frank, SJ			Growth hormone-induced phosphorylation of epidermal growth factor (EGF) receptor in 3T3-F442A cells - Modulation of EGF-induced trafficking and signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article; Proceedings Paper	84th Annual Meeting of the Endocrine-Society	JUN 19-22, 2002	SAN FRANCISCO, CA	Endocrine Soc			ACTIVATED PROTEIN-KINASE; TYROSINE PHOSPHORYLATION; C-CBL; COUPLED RECEPTORS; BINDING-PROTEIN; ANGIOTENSIN-II; TRANSACTIVATION; INHIBITOR; STIMULATION; FAMILY	Growth hormone (GH) promotes signaling by causing activation of the non-receptor tyrosine kinase, JAK2, which associates with the GH receptor. GH causes phosphorylation of epidermal growth factor receptor ( EGFR; ErbB-1) and its family member, ErbB-2. For EGFR, JAK2-mediated GH-induced tyrosine phosphorylation may allow EGFR to serve as a scaffold for GH signaling. For ErbB-2, GH induces serine/threonine phosphorylation that dampens basal and EGF-induced ErbB-2 kinase activation. We now further explore GH-induced EGFR phosphorylation in 3T3-F442A, a preadipocytic fibroblast cell line that expresses endogenous GH receptor, EGFR, and ErbB-2. Using a monoclonal antibody that recognizes ERK consensus site phosphorylation (PTP101), we found that GH caused PTP101-reactive phosphorylation of EGFR. This GH-induced EGFR phosphorylation was prevented by MEK1 inhibitors but not by a protein kinase C inhibitor. Although GH did not discernibly affect EGF-induced EGFR tyrosine phosphorylation, we observed by immunoblotting a substantial decrease of EGF-induced EGFR degradation in the presence of GH. Fluorescence microscopy studies indicated that EGF-induced intracellular redistribution of an EGFR-cyan fluorescent protein chimera was markedly reduced by GH cotreatment, in support of the immunoblotting results. Notably, protection from EGF-induced degradation and inhibition of EGF-induced intracellular redistribution afforded by GH were both prevented by a MEK1 inhibitor, suggesting a role for GH-induced ERK activation in regulating the trafficking itinerary of the EGF-stimulated EGFR. Finally, we observed augmentation of early aspects of EGF signaling ( EGF-induced ERK2 activation and EGF-induced Cbl tyrosine phosphorylation) by GH cotreatment; the GH effect on EGF-induced Cbl tyrosine phosphorylation was also prevented by MEK1 inhibition. These data indicate that GH, by activating ERKs, can modulate EGF-induced EGFR trafficking and signaling and expand our understanding of mechanisms of cross-talk between the GH and EGF signaling systems.	Univ Alabama Birmingham, Dept Med, Div Endocrinol & Metab, Birmingham, AL 35294 USA; Univ Alabama Birmingham, Dept Cell Biol, Birmingham, AL 35294 USA; Vet Affairs Med Ctr, Med Serv, Endocrinol Sect, Birmingham, AL 35294 USA	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; US Department of Veterans Affairs; Veterans Health Administration (VHA)	Frank, SJ (corresponding author), Univ Alabama Birmingham, Dept Med, Div Endocrinol & Metab, 1530 3rd Ave S,BDB 861, Birmingham, AL 35294 USA.	frank@endo.dom.uab.edu			NIDDK NIH HHS [DK58259, DK46395] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK046395, R01DK046395, R56DK046395, R01DK058259, R56DK058259] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; Alroy I, 1997, FEBS LETT, V410, P83, DOI 10.1016/S0014-5793(97)00412-2; ANDERSON NG, 1992, BIOCHEM J, V284, P649, DOI 10.1042/bj2840649; ARGETSINGER LS, 1993, CELL, V74, P237, DOI 10.1016/0092-8674(93)90415-M; Bao J, 2000, J BIOL CHEM, V275, P26178, DOI 10.1074/jbc.M002367200; BAZAN JF, 1990, P NATL ACAD SCI USA, V87, P6934, DOI 10.1073/pnas.87.18.6934; Boney CM, 2001, CELL GROWTH DIFFER, V12, P379; Burke P, 2001, MOL BIOL CELL, V12, P1897, DOI 10.1091/mbc.12.6.1897; Buteau J, 2003, DIABETES, V52, P124, DOI 10.2337/diabetes.52.1.124; CAMPBELL GS, 1992, J BIOL CHEM, V267, P6074; Ceresa BP, 2000, CURR OPIN CELL BIOL, V12, P204, DOI 10.1016/S0955-0674(99)00077-0; Davey HW, 2001, ENDOCRINOLOGY, V142, P3836, DOI 10.1210/en.142.9.3836; DAVIS RJ, 1985, P NATL ACAD SCI USA, V82, P1974, DOI 10.1073/pnas.82.7.1974; DAVIS RJ, 1987, J BIOL CHEM, V262, P6832; Di Fiore PP, 2001, CELL, V106, P1, DOI 10.1016/S0092-8674(01)00428-7; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; Eguchi S, 2001, J BIOL CHEM, V276, P7957, DOI 10.1074/jbc.M008570200; EPSTEIN RJ, 1990, J BIOL CHEM, V265, P10746; Favata MF, 1998, J BIOL CHEM, V273, P18623, DOI 10.1074/jbc.273.29.18623; FRANK SJ, 1995, J BIOL CHEM, V270, P14776, DOI 10.1074/jbc.270.24.14776; Frank SJ, 2002, CYTOKINE REFERENCE O, P1; Fukazawa T, 1996, J BIOL CHEM, V271, P14554, DOI 10.1074/jbc.271.24.14554; GALISTEO ML, 1995, J BIOL CHEM, V270, P20242, DOI 10.1074/jbc.270.35.20242; GREEN H, 1976, CELL, V7, P105, DOI 10.1016/0092-8674(76)90260-9; Gschwind A, 2002, CANCER RES, V62, P6329; Guan R, 2001, ENDOCRINOLOGY, V142, P1137, DOI 10.1210/en.142.3.1137; Haglund K, 2002, P NATL ACAD SCI USA, V99, P12191, DOI 10.1073/pnas.192462299; Hall C, 2001, MOL CELL BIOL, V21, P1854, DOI 10.1128/MCB.21.5.1854-1865.2001; HEISERMANN GJ, 1988, J BIOL CHEM, V263, P13152; Hodge C, 1998, J BIOL CHEM, V273, P31327, DOI 10.1074/jbc.273.47.31327; HUNTER T, 1984, NATURE, V311, P480, DOI 10.1038/311480a0; Ihle JN, 1995, ADV IMMUNOL, V60, P1, DOI 10.1016/S0065-2776(08)60582-9; ISAKSSON OGP, 1985, ANNU REV PHYSIOL, V47, P483, DOI 10.1146/annurev.ph.47.030185.002411; Kassenbrock CK, 2002, J BIOL CHEM, V277, P24967, DOI 10.1074/jbc.M201026200; Kawanabe Y, 2002, AM J PHYSIOL-HEART C, V283, pH2671, DOI 10.1152/ajpheart.00350.2002; Kilgour E, 1996, BIOCHEM J, V315, P517, DOI 10.1042/bj3150517; Kim SO, 2002, ENDOCRINOLOGY, V143, P4856, DOI 10.1210/en.2002-220565; Kim SO, 1999, J BIOL CHEM, V274, P36015, DOI 10.1074/jbc.274.50.36015; Kim SO, 1998, J BIOL CHEM, V273, P2344, DOI 10.1074/jbc.273.4.2344; Le Roith D, 2001, ENDOCR REV, V22, P53, DOI 10.1210/er.22.1.53; LEUNG DW, 1987, NATURE, V330, P537, DOI 10.1038/330537a0; Levkowitz G, 1999, MOL CELL, V4, P1029, DOI 10.1016/S1097-2765(00)80231-2; Levkowitz G, 1996, ONCOGENE, V12, P1117; Liang L, 2000, ENDOCRINOLOGY, V141, P3328, DOI 10.1210/en.141.9.3328; Love DW, 1998, ENDOCRINOLOGY, V139, P1965, DOI 10.1210/en.139.4.1965; LUND KA, 1990, J BIOL CHEM, V265, P20517; Marinissen MT, 2001, GENE DEV, V15, P535, DOI 10.1101/gad.855801; McCole DF, 2002, J BIOL CHEM, V277, P42603, DOI 10.1074/jbc.M206487200; MOLLER C, 1992, J BIOL CHEM, V267, P23403; Morrison P, 1996, J BIOL CHEM, V271, P12891, DOI 10.1074/jbc.271.22.12891; NORTHWOOD IC, 1991, J BIOL CHEM, V266, P15266; PEARSON RB, 1991, METHOD ENZYMOL, V200, P62; Pierce KL, 2001, J BIOL CHEM, V276, P23155, DOI 10.1074/jbc.M101303200; Prenzel N, 1999, NATURE, V402, P884, DOI 10.1038/47260; Qiu Y, 1998, NATURE, V393, P83, DOI 10.1038/30012; Riese DJ, 1998, BIOESSAYS, V20, P41, DOI 10.1002/(SICI)1521-1878(199801)20:1<41::AID-BIES7>3.0.CO;2-V; Rui LY, 2000, J BIOL CHEM, V275, P2885, DOI 10.1074/jbc.275.4.2885; Saito S, 2002, BIOCHEM BIOPH RES CO, V294, P1023, DOI 10.1016/S0006-291X(02)00595-8; Soltoff SP, 1996, J BIOL CHEM, V271, P563, DOI 10.1074/jbc.271.1.563; SOTIROPOULOS A, 1994, ENDOCRINOLOGY, V135, P1292, DOI 10.1210/en.135.4.1292; Soubeyran P, 2002, NATURE, V416, P183, DOI 10.1038/416183a; TAKISHIMA K, 1988, BIOCHEM BIOPH RES CO, V157, P740, DOI 10.1016/S0006-291X(88)80312-7; TAKISHIMA K, 1991, P NATL ACAD SCI USA, V88, P2520, DOI 10.1073/pnas.88.6.2520; TOULLEC D, 1991, J BIOL CHEM, V266, P15771; Udy GB, 1997, P NATL ACAD SCI USA, V94, P7239, DOI 10.1073/pnas.94.14.7239; VANDERKUUR J, 1995, J BIOL CHEM, V270, P7587, DOI 10.1074/jbc.270.13.7587; Vanderkuur JA, 1997, ENDOCRINOLOGY, V138, P4301, DOI 10.1210/en.138.10.4301; VANDERKUUR JA, 1994, J BIOL CHEM, V269, P21709; WELLS A, 1990, SCIENCE, V247, P962, DOI 10.1126/science.2305263; Wiepz GJ, 1997, J CELL PHYSIOL, V173, P44, DOI 10.1002/(SICI)1097-4652(199710)173:1<44::AID-JCP6>3.0.CO;2-J; Wiley HS, 2003, TRENDS CELL BIOL, V13, P43; WINSTON LA, 1992, J BIOL CHEM, V267, P4747; Yamauchi T, 1997, NATURE, V390, P91, DOI 10.1038/36369; Yamazaki T, 2002, J CELL SCI, V115, P1791; Yan YB, 2002, J CELL BIOL, V158, P221, DOI 10.1083/jcb.200112026; Zhu T, 2002, J BIOL CHEM, V277, P45592, DOI 10.1074/jbc.M201385200	76	67	69	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 23	2003	278	21					18902	18913		10.1074/jbc.M300939200	http://dx.doi.org/10.1074/jbc.M300939200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	Biochemistry & Molecular Biology	679PY	12642595	hybrid			2022-12-25	WOS:000182932200026
J	Kamei, D; Murakami, M; Nakatani, Y; Ishikawa, Y; Ishii, T; Kudo, I				Kamei, D; Murakami, M; Nakatani, Y; Ishikawa, Y; Ishii, T; Kudo, I			Potential role of microsomal prostaglandin E synthase-1 in tumorigenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOSOLIC PHOSPHOLIPASE A(2); APC(DELTA-716) KNOCKOUT MICE; COLON-CANCER CELLS; MAMMARY EPITHELIAL-CELLS; E-2 SYNTHASE; INTESTINAL POLYPOSIS; ENDOTHELIAL-CELLS; ANTIINFLAMMATORY AGENT; PROTEIN PHOSPHATASE; ACTIN CYTOSKELETON	Microsomal prostaglandin E-2 synthase-1 (mPGES-1) is a stimulus-inducible enzyme that functions downstream of cyclooxygenase ( COX)-2 in the PGE(2)-biosynthetic pathway. Given the accumulating evidence that COX-2-derived PGE(2) participates in the development of various tumors, including colorectal cancer, we herein examined the potential involvement of mPGES-1 in tumorigenesis. Immunohistochemical analyses demonstrated the expression of both COX-2 and mPGES-1 in human colon cancer tissues. HCA-7, a human colorectal adenocarcinoma cell line that displays COX-2- and PGE(2)-dependent proliferation, expressed both COX-2 and mPGES-1 constitutively. Treatment of HCA-7 cells with an mPGES-1 inhibitor or antisense oligonucleotide attenuated, whereas overexpression of mPGES-1 accelerated, PGE2 production and cell proliferation. Moreover, cotransfection of COX-2 and mPGES-1 into HEK293 cells resulted in cellular transformation manifested by colony formation in soft agar culture and tumor formation when implanted subcutaneously into nude mice. cDNA array analyses revealed that this mPGES-1-directed cellular transformation was accompanied by changes in the expression of a variety of genes related to proliferation, morphology, adhesion, and the cell cycle. These results collectively suggest that aberrant expression of mPGES-1 in combination with COX-2 can contribute to tumorigenesis.	Showa Univ, Sch Pharmaceut Sci, Dept Hlth Chem, Shinagawa Ku, Tokyo 1428555, Japan; Toho Univ, Sch Med, Dept Pathol, Ohta Ku, Tokyo 1438540, Japan	Showa University	Kudo, I (corresponding author), Showa Univ, Sch Pharmaceut Sci, Dept Hlth Chem, Shinagawa Ku, 1-5-8 Hatanodai, Tokyo 1428555, Japan.							BARKER HM, 1990, GENOMICS, V7, P159, DOI 10.1016/0888-7543(90)90536-4; Bianco NR, 2002, ONCOGENE, V21, P5233, DOI 10.1038/sj.onc.1205645; Bretscher A, 2002, NAT REV MOL CELL BIO, V3, P586, DOI 10.1038/nrm882; BROWN LF, 1993, CANCER RES, V53, P4727; Buckingham JC, 1996, BRIT J PHARMACOL, V118, P1; Coffey RJ, 1997, P NATL ACAD SCI USA, V94, P657, DOI 10.1073/pnas.94.2.657; Dhavan R, 2001, NAT REV MOL CELL BIO, V2, P749, DOI 10.1038/35096019; Dohadwala M, 2002, J BIOL CHEM, V277, P50828, DOI 10.1074/jbc.M210707200; Filion F, 2001, J BIOL CHEM, V276, P34323, DOI 10.1074/jbc.M103709200; FONAGY A, 1993, J CELL PHYSIOL, V154, P16, DOI 10.1002/jcp.1041540104; FUTAKI N, 1994, PROSTAGLANDINS, V47, P55, DOI 10.1016/0090-6980(94)90074-4; Geiger B, 2002, CELL, V110, P139, DOI 10.1016/S0092-8674(02)00831-0; Girnun GD, 2002, P NATL ACAD SCI USA, V99, P13771, DOI 10.1073/pnas.162480299; Gullick WJ, 1996, CANCER SURV, V27, P339; Han R, 2002, J BIOL CHEM, V277, P16355, DOI 10.1074/jbc.M111246200; Heasley LE, 1997, J BIOL CHEM, V272, P14501, DOI 10.1074/jbc.272.23.14501; Hong KH, 2001, P NATL ACAD SCI USA, V98, P3935, DOI 10.1073/pnas.051635898; HORIKAWA I, 1995, EXP CELL RES, V220, P11, DOI 10.1006/excr.1995.1286; Howe LR, 1999, CANCER RES, V59, P1572; Ishizaki T, 2001, NAT CELL BIOL, V3, P8; Jabbour HN, 2001, BRIT J CANCER, V85, P1023; Jakobsson PJ, 1999, P NATL ACAD SCI USA, V96, P7220, DOI 10.1073/pnas.96.13.7220; KAIPAINEN A, 1993, J EXP MED, V178, P2077, DOI 10.1084/jem.178.6.2077; KARGMAN SL, 1995, CANCER RES, V55, P2556; Kim SW, 2001, J BIOL CHEM, V276, P15712, DOI 10.1074/jbc.M009905200; KONDOH N, 1992, CANCER RES, V52, P791; Lazarus M, 2002, ENDOCRINOLOGY, V143, P2410, DOI 10.1210/en.143.6.2410; Levy GN, 1997, FASEB J, V11, P234, DOI 10.1096/fasebj.11.4.9068612; Lim H, 1999, GENE DEV, V13, P1561, DOI 10.1101/gad.13.12.1561; Liu CH, 2001, J BIOL CHEM, V276, P18563, DOI 10.1074/jbc.M010787200; Maekawa M, 1999, SCIENCE, V285, P895, DOI 10.1126/science.285.5429.895; Mancini JA, 2001, J BIOL CHEM, V276, P4469, DOI 10.1074/jbc.M006865200; MARNETT LJ, 1992, CANCER RES, V52, P5575; Matsumoto H, 2002, J BIOL CHEM, V277, P29260, DOI 10.1074/jbc.M203996200; Molkentin JD, 2000, J BIOL CHEM, V275, P38949, DOI 10.1074/jbc.R000029200; Muller-Decker K, 2002, P NATL ACAD SCI USA, V99, P12483, DOI 10.1073/pnas.192323799; Murakami M, 1999, J BIOL CHEM, V274, P3103, DOI 10.1074/jbc.274.5.3103; Murakami M, 2000, J BIOL CHEM, V275, P32783, DOI 10.1074/jbc.M003505200; Mutoh M, 2002, CANCER RES, V62, P28; Naora H, 1999, IMMUNOL CELL BIOL, V77, P197, DOI 10.1046/j.1440-1711.1999.00816.x; Naraba H, 2002, J BIOL CHEM, V277, P28601, DOI 10.1074/jbc.M203618200; Narko K, 1997, J BIOL CHEM, V272, P21455, DOI 10.1074/jbc.272.34.21455; Oshima M, 1996, CELL, V87, P803, DOI 10.1016/S0092-8674(00)81988-1; Pai R, 2002, NAT MED, V8, P289, DOI 10.1038/nm0302-289; RAO CV, 1995, CANCER RES, V55, P1464; REINHART WH, 1983, GASTROENTEROLOGY, V85, P1003; ROTHE M, 1994, CELL, V78, P681, DOI 10.1016/0092-8674(94)90532-0; Ryan KM, 1996, BIOCHEM J, V314, P713, DOI 10.1042/bj3140713; SAADAT M, 1995, CANCER LETT, V94, P165, DOI 10.1016/0304-3835(95)03846-O; Satoh K, 2000, NEUROSCI LETT, V283, P221, DOI 10.1016/S0304-3940(00)00926-5; Shao JY, 2000, J BIOL CHEM, V275, P33951, DOI 10.1074/jbc.M002324200; Sheng HM, 1998, CANCER RES, V58, P362; Sheng HM, 2001, J BIOL CHEM, V276, P18075, DOI 10.1074/jbc.M009689200; Sheng HM, 1997, J CLIN INVEST, V99, P2254, DOI 10.1172/JCI119400; Sonoshita M, 2001, NAT MED, V7, P1048, DOI 10.1038/nm0901-1048; Stichtenoth DO, 2001, J IMMUNOL, V167, P469, DOI 10.4049/jimmunol.167.1.469; Subbaramaiah K, 2002, J BIOL CHEM, V277, P18649, DOI 10.1074/jbc.M111415200; Subbaramaiah K, 1996, CANCER RES, V56, P4424; Takaku K, 2000, J BIOL CHEM, V275, P34013, DOI 10.1074/jbc.C000586200; Tang DM, 1996, BIOCHEM CELL BIOL, V74, P419, DOI 10.1139/o96-046; Tanikawa N, 2002, BIOCHEM BIOPH RES CO, V291, P884, DOI 10.1006/bbrc.2002.6531; Tanioka T, 2000, J BIOL CHEM, V275, P32775, DOI 10.1074/jbc.M003504200; Tarricone C, 2001, MOL CELL, V8, P657, DOI 10.1016/S1097-2765(01)00343-4; Thompson EB, 1998, ANNU REV PHYSIOL, V60, P575, DOI 10.1146/annurev.physiol.60.1.575; Tsujii M, 1998, CELL, V93, P705, DOI 10.1016/S0092-8674(00)81433-6; TSUJII M, 1995, CELL, V83, P493, DOI 10.1016/0092-8674(95)90127-2; Ueki T, 1997, HUM PATHOL, V28, P74, DOI 10.1016/S0046-8177(97)90282-3; Uematsu S, 2002, J IMMUNOL, V168, P5811, DOI 10.4049/jimmunol.168.11.5811; van de Wetering M, 2002, CELL, V111, P241, DOI 10.1016/S0092-8674(02)01014-0; Watanabe K, 1999, CANCER RES, V59, P5093; Wehrle-Haller B, 2002, TRENDS CELL BIOL, V12, P382, DOI 10.1016/S0962-8924(02)02321-8; Williams CS, 2000, J CLIN INVEST, V105, P1589, DOI 10.1172/JCI9621; Williams CS, 1999, ONCOGENE, V18, P7908, DOI 10.1038/sj.onc.1203286; Yamagata K, 2001, J NEUROSCI, V21, P2669, DOI 10.1523/JNEUROSCI.21-08-02669.2001; Yoshimatsu K, 2001, CLIN CANCER RES, V7, P3971; Yoshimatsu K, 2001, CLIN CANCER RES, V7, P2669; You ZB, 2002, J CELL BIOL, V157, P429, DOI 10.1083/jcb.200201110	77	176	188	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 23	2003	278	21					19396	19405		10.1074/jbc.M213290200	http://dx.doi.org/10.1074/jbc.M213290200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	679PY	12626523	hybrid			2022-12-25	WOS:000182932200088
J	Lin, X; Liang, M; Liang, YY; Brunicardi, FC; Melchior, F; Feng, XH				Lin, X; Liang, M; Liang, YY; Brunicardi, FC; Melchior, F; Feng, XH			Activation of transforming growth factor-beta signaling by SUMO-1 modification of tumor suppressor Smad4/DPC4	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UBIQUITIN-LIKE PROTEIN; NUCLEAR-PORE COMPLEX; TGF-BETA; DEPENDENT DEGRADATION; SMAD2; IDENTIFICATION; TRANSCRIPTION; P15(INK4B); RANGAP1; ENZYME	Smads are important intracellular effectors in signaling pathways of the transforming growth factor-beta (TGF-beta) superfamily. Upon activation by TGF-beta, receptor-phosphorylated Smads form a complex with tumor suppressor Smad4/DPC4, and the Smad complexes then are imported into the nucleus. Although diverse pathways regulate the activity and expression of receptor-phosphorylated and inhibitory Smads, cellular factors modulating the activity of the common Smad4 remain unidentified. Here we describe the involvement of the small ubiquitin-like modifier-1 (SUMO-1) conjugation pathway in regulating the growth inhibitory and transcriptional responses of Smad4. The MH1 domain of Smad4 was shown to associate physically with Ubc9, the ubiquitin carrier protein (E2) conjugating enzyme in sumoylation. In cultured cells, Smad4 is modified by SUMO-1 at the endogenous level. The sumoylation sites were identified as two evolutionarily conserved lysine residues, Lys-113 and Lys-159, in the MH1 domain. We found that the mutations at Lys-113 and Lys-159 did not alter the ability of Smad4 to form a complex with Smad2 and FAST on the Mix. 2 promoter. Importantly, SUMO-1 overexpression enhanced TGF-beta-induced transcriptional responses. These findings identify sumoylation as a unique mechanism to modulate Smad4-dependent cellular responses.	Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA; Baylor Coll Med, Michael E DeBakey Dept Surg, Houston, TX 77030 USA; Max Planck Inst Biochem, D-82152 Martinsried, Germany	Baylor College of Medicine; Baylor College of Medicine; Max Planck Society	Feng, XH (corresponding author), Baylor Coll Med, Dept Mol & Cellular Biol, 1 Baylor Plaza,Rm 137D, Houston, TX 77030 USA.		Melchior, Frauke/E-2014-2014	Melchior, Frauke/0000-0001-9546-8797	NIGMS NIH HHS [R01 GM63773] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM063773] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Chen X, 1997, NATURE, V389, P85, DOI 10.1038/38008; Derynck R, 1998, CELL, V95, P737, DOI 10.1016/S0092-8674(00)81696-7; Derynck R, 1997, BIOCHIM BIOPHYS ACTA, V1333, P105; Desterro JMP, 1998, MOL CELL, V2, P233, DOI 10.1016/S1097-2765(00)80133-1; Desterro JMP, 1999, J BIOL CHEM, V274, P10618, DOI 10.1074/jbc.274.15.10618; Feng XH, 2000, EMBO J, V19, P5178, DOI 10.1093/emboj/19.19.5178; Feng XH, 1998, GENE DEV, V12, P2153, DOI 10.1101/gad.12.14.2153; Feng XH, 2002, MOL CELL, V9, P133, DOI 10.1016/S1097-2765(01)00430-0; Gong LM, 1997, J BIOL CHEM, V272, P28198, DOI 10.1074/jbc.272.45.28198; Gostissa M, 1999, EMBO J, V18, P6462, DOI 10.1093/emboj/18.22.6462; GYURIS J, 1993, CELL, V75, P791, DOI 10.1016/0092-8674(93)90498-F; Hay RT, 2001, TRENDS BIOCHEM SCI, V26, P332, DOI 10.1016/S0968-0004(01)01849-7; Hochstrasser M, 2001, CELL, V107, P5, DOI 10.1016/S0092-8674(01)00519-0; Kamitani T, 1998, J BIOL CHEM, V273, P26675, DOI 10.1074/jbc.273.41.26675; Lin X, 2000, J BIOL CHEM, V275, P36818, DOI 10.1074/jbc.C000580200; Lo RS, 1999, NAT CELL BIOL, V1, P472, DOI 10.1038/70258; Mahajan R, 1997, CELL, V88, P97, DOI 10.1016/S0092-8674(00)81862-0; Massague J, 2000, EMBO J, V19, P1745, DOI 10.1093/emboj/19.8.1745; Massague J, 2000, NAT REV MOL CELL BIO, V1, P169, DOI 10.1038/35043051; Matunis MJ, 1996, J CELL BIOL, V135, P1457, DOI 10.1083/jcb.135.6.1457; Melchior F, 2000, ANNU REV CELL DEV BI, V16, P591, DOI 10.1146/annurev.cellbio.16.1.591; Miyazono K, 2000, ADV IMMUNOL, V75, P115, DOI 10.1016/S0065-2776(00)75003-6; Muller S, 1999, J VIROL, V73, P5137; Okuma T, 1999, BIOCHEM BIOPH RES CO, V254, P693, DOI 10.1006/bbrc.1998.9995; Roberts AB, 1998, MINER ELECTROL METAB, V24, P111, DOI 10.1159/000057358; Robertson G, 2001, UASGCP REP, V2001, P43; Rodriguez MS, 1999, EMBO J, V18, P6455, DOI 10.1093/emboj/18.22.6455; Schwarz SE, 1998, P NATL ACAD SCI USA, V95, P560, DOI 10.1073/pnas.95.2.560; Whitman M, 2001, SCI STKE; Xu J, 2000, P NATL ACAD SCI USA, V97, P4820, DOI 10.1073/pnas.97.9.4820; Zawel L, 1998, MOL CELL, V1, P611, DOI 10.1016/S1097-2765(00)80061-1; Zhang Y, 2001, P NATL ACAD SCI USA, V98, P974, DOI 10.1073/pnas.98.3.974; Zhu HT, 1999, NATURE, V400, P687, DOI 10.1038/23293	33	105	117	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 23	2003	278	21					18714	18719		10.1074/jbc.M302243200	http://dx.doi.org/10.1074/jbc.M302243200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	679PY	12621041	hybrid			2022-12-25	WOS:000182932200003
J	Wieler, S; Gagne, JP; Vaziri, H; Poirier, GG				Wieler, S; Gagne, JP; Vaziri, H; Poirier, GG			Poly(ADP-ribose) polymerase-1 is a positive regulator of the p53-mediated G(1) arrest response following ionizing radiation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING DOMAIN; P53 IN-VITRO; CELL-DEATH; COVALENT POLY(ADP-RIBOSYL)ATION; CONSENSUS SEQUENCE; GENOMIC INTEGRITY; GAMMA-IRRADIATION; ADP-RIBOSYLATION; MAMMALIAN-CELLS; STRAND BREAKS	Poly(ADP-ribose) polymerase-1 (PARP-1) and the p53 tumor suppressor protein are both involved in the cellular response to genotoxic stress. Upon binding to the site of DNA strand breakage, PARP-1 is activated, leading to rapid and transient poly(ADP-ribosyl)ation of nuclear proteins using NAD(+) as substrate. To investigate the role of PARP-1 in the p53 response to ionizing radiation in human cells, PARP-1 function was disrupted in wild-type p53 expressing MCF-7 and BJ/TERT cells using two strategies: chemical inhibition with 1,5-dihydroxyisoquinoline, and trans-dominant inhibition by overexpression of the PARP-1 DNA-binding domain. Although a number of proteins can catalyze poly(ADP-ribosyl) ation in addition to PARP-1, we show that PARP-1 is the only detectable active species in BJ/TERT and MCF-7 cells. 1,5-Dihydroxyisoquinoline treatment prior to ionizing radiation delayed and attenuated the induction of two p53-responsive genes, p21 and mdm-2, and led to suppression of the p53-mediated G1-arrest response in MCF-7 and BJ/TERT cells. Trans-dominant inhibition of PARP-1 by overexpression of the PARP-1 DNA-binding domain in MCF-7 cells also led to a delay and attenuation in p21 induction and suppression of the p53-mediated G(1)-arrest response to ionizing radiation. Hence, inhibition of endogenous PARP-1 function suppresses the transactivation function of p53 in response to ionizing radiation. This study establishes PARP-1 as a critical regulator of the p53 response to DNA damage.	Univ Toronto, Dept Med Biophys, Toronto, ON M5G 2M9, Canada; Univ Toronto, Ontario Canc Inst, Toronto, ON M5G 2M9, Canada; CHU Laval, Res Ctr, Unit Hlth & Environm, Quebec City, PQ G1V 4G2, Canada	University of Toronto; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Laval University	Poirier, GG (corresponding author), Princess Margaret Hosp, Ontario Canc Inst, 610 Univ Ave, Toronto, ON M5G 2M9, Canada.			Benchimol, Samuel/0000-0003-3433-890X; Poirier, Guy/0000-0002-4869-1424				Agarwal ML, 1997, ONCOGENE, V15, P1035, DOI 10.1038/sj.onc.1201274; ALTHAUS FR, 1993, ENVIRON MOL MUTAGEN, V22, P278, DOI 10.1002/em.2850220417; Ame JC, 1999, J BIOL CHEM, V274, P17860, DOI 10.1074/jbc.274.25.17860; Banin S, 1998, SCIENCE, V281, P1674, DOI 10.1126/science.281.5383.1674; Beneke R, 2000, MOL CELL BIOL, V20, P6695, DOI 10.1128/MCB.20.18.6695-6703.2000; Canman CE, 1998, SCIENCE, V281, P1677, DOI 10.1126/science.281.5383.1677; CANMAN CE, 1995, GENE DEV, V9, P600, DOI 10.1101/gad.9.5.600; D'Amours D, 1999, BIOCHEM J, V342, P249, DOI 10.1042/0264-6021:3420249; deMurcia JM, 1997, P NATL ACAD SCI USA, V94, P7303, DOI 10.1073/pnas.94.14.7303; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; Giaccia AJ, 1998, GENE DEV, V12, P2973, DOI 10.1101/gad.12.19.2973; Herceg Z, 2001, MUTAT RES-FUND MOL M, V477, P97, DOI 10.1016/S0027-5107(01)00111-7; JACOBSON EL, 1985, CARCINOGENESIS, V6, P711, DOI 10.1093/carcin/6.5.711; Jayaraman L, 1999, CELL MOL LIFE SCI, V55, P76, DOI 10.1007/s000180050271; Kaminker PG, 2001, J BIOL CHEM, V276, P35891, DOI 10.1074/jbc.M105968200; Kickhoefer VA, 1999, J CELL BIOL, V146, P917, DOI 10.1083/jcb.146.5.917; Kumari SR, 1998, CANCER RES, V58, P5075; KUPPER JH, 1990, J BIOL CHEM, V265, P18721; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; LINDAHL T, 1995, TRENDS BIOCHEM SCI, V20, P405, DOI 10.1016/S0968-0004(00)89089-1; Malanga M, 1998, J BIOL CHEM, V273, P11839, DOI 10.1074/jbc.273.19.11839; MASUTANI M, 1995, BIOCHIMIE, V77, P462, DOI 10.1016/0300-9084(96)88161-2; Masutani M, 1999, MOL CELL BIOCHEM, V193, P149; Mendoza-Alvarez H, 2001, J BIOL CHEM, V276, P36425, DOI 10.1074/jbc.M105215200; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; MOLINETE M, 1993, EMBO J, V12, P2109, DOI 10.1002/j.1460-2075.1993.tb05859.x; NOZAKI T, 1994, JPN J CANCER RES, V85, P1094, DOI 10.1111/j.1349-7006.1994.tb02912.x; Pleschke JM, 2000, J BIOL CHEM, V275, P40974, DOI 10.1074/jbc.M006520200; Prives C, 1999, J PATHOL, V187, P112; Sallmann FR, 2000, J BIOL CHEM, V275, P15504, DOI 10.1074/jbc.275.20.15504; SATOH MS, 1994, BIOCHEMISTRY-US, V33, P7099, DOI 10.1021/bi00189a012; Shall S, 2000, MUTAT RES-DNA REPAIR, V460, P1, DOI 10.1016/S0921-8777(00)00016-1; SHAULIAN E, 1992, MOL CELL BIOL, V12, P5581, DOI 10.1128/MCB.12.12.5581; Shieh WM, 1998, J BIOL CHEM, V273, P30069, DOI 10.1074/jbc.273.46.30069; Simbulan-Rosenthal CM, 1999, CANCER RES, V59, P2190; Simbulan-Rosenthal CM, 2001, NEOPLASIA, V3, P179, DOI 10.1038/sj.neo.7900155; SIMONIN F, 1993, J BIOL CHEM, V268, P13454; Smith S, 1998, SCIENCE, V282, P1484, DOI 10.1126/science.282.5393.1484; Smulson ME, 2000, ADV ENZYME REGUL, V40, P183, DOI 10.1016/S0065-2571(99)00024-2; Tibbetts RS, 1999, GENE DEV, V13, P152, DOI 10.1101/gad.13.2.152; VAUGHAN M, 1981, CURR TOP CELL REGUL, V20, P205; Vaziri H, 1997, EMBO J, V16, P6018, DOI 10.1093/emboj/16.19.6018; Vaziri H, 1999, MOL CELL BIOL, V19, P2373; Vaziri H, 1998, CURR BIOL, V8, P279, DOI 10.1016/S0960-9822(98)70109-5; Wang XJ, 1998, ONCOGENE, V17, P2819, DOI 10.1038/sj.onc.1202216; Watson NC, 1997, INT J RADIAT BIOL, V72, P547, DOI 10.1080/095530097143059; Wesierska-Gadek J, 1999, CANCER RES, V59, P28; WesierskaGadek J, 1996, BIOCHEM BIOPH RES CO, V224, P96, DOI 10.1006/bbrc.1996.0990; Ziegler M, 2001, BIOESSAYS, V23, P543, DOI 10.1002/bies.1074	49	91	95	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 23	2003	278	21					18914	18921		10.1074/jbc.M211641200	http://dx.doi.org/10.1074/jbc.M211641200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	679PY	12642583	hybrid			2022-12-25	WOS:000182932200027
J	Mellwig, C; Bottcher, B				Mellwig, C; Bottcher, B			A unique resting position of the ATP-synthase from chloroplasts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELECTRON-MICROSCOPY; ALPHA-SUBUNIT; DELTA-SUBUNIT; PROTON TRANSLOCATION; DIMERIZATION DOMAIN; ANGSTROM RESOLUTION; CATALYTIC SITES; B-SUBUNITS; 2ND STALK; F-1	The chloroplast ATP-synthase catalyzes ATP synthesis coupled to transmembrane proton transport. The enzyme consists of two parts, a membrane-embedded F-0 part and an extrinsic F-1 part, which are linked by two connectors. One of these rotates during catalysis and the other remains static. Although the atomic structures of various sub-complexes and individual subunits have been reported, only limited structural information on the complex, as a whole, is available. In particular, information on the static connector is lacking. We contribute a three-dimensional map at about 20-Angstrom resolution, derived from electron cryomicroscopy of enzymes embedded in vitrified buffer followed by single particle image analysis. In the three-dimensional map both connectors, between the F-1 part and the F-0 part, are clearly visible. The static connector is tightly attached to an alpha subunit and faces the side of the neighboring beta subunit. The three-dimensional map provides a scaffold for fitting in the known atomic structures of various subunits and sub-complexes, and suggests that the oxidized, non-activated ATP-synthase from chloroplasts adopts a unique resting position.	European Mol Biol Lab, D-69117 Heidelberg, Germany	European Molecular Biology Laboratory (EMBL)	Bottcher, B (corresponding author), European Mol Biol Lab, Meyerhofstr 1, D-69117 Heidelberg, Germany.		Bottcher, Bettina/E-9397-2010	Bottcher, Bettina/0000-0002-7962-4849				ABRAHAMS JP, 1994, NATURE, V370, P621, DOI 10.1038/370621a0; AssadiPorter FM, 1995, BIOCHEMISTRY-US, V34, P16186, DOI 10.1021/bi00049a034; BELLARE JR, 1988, J ELECTRON MICR TECH, V10, P87, DOI 10.1002/jemt.1060100111; Bottcher B, 2000, J MOL BIOL, V296, P449, DOI 10.1006/jmbi.1999.3435; Bottcher B, 1998, J MOL BIOL, V281, P757, DOI 10.1006/jmbi.1998.1957; Crowther RA, 1996, J STRUCT BIOL, V116, P9, DOI 10.1006/jsbi.1996.0003; Del Rizzo PA, 2002, BIOCHEMISTRY-US, V41, P6875, DOI 10.1021/bi025736i; Dmitriev O, 1999, J BIOL CHEM, V274, P15598, DOI 10.1074/jbc.274.22.15598; Domgall I, 2002, J BIOL CHEM, V277, P13115, DOI 10.1074/jbc.M112011200; Gibbons C, 2000, NAT STRUCT BIOL, V7, P1055; GIRVIN ME, 1995, BIOCHEMISTRY-US, V34, P1635, DOI 10.1021/bi00005a020; Greie JC, 2000, EUR J BIOCHEM, V267, P3040, DOI 10.1046/j.1432-1327.2000.01327.x; Groth G, 2001, J BIOL CHEM, V276, P1345, DOI 10.1074/jbc.M008015200; HARAUZ G, 1986, OPTIK, V73, P146; Hausrath AC, 1999, P NATL ACAD SCI USA, V96, P13697, DOI 10.1073/pnas.96.24.13697; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; JUNESCH U, 1987, BIOCHIM BIOPHYS ACTA, V893, P275, DOI 10.1016/0005-2728(87)90049-1; JUNGE W, 1970, EUR J BIOCHEM, V14, P582, DOI 10.1111/j.1432-1033.1970.tb00327.x; Junge W, 1997, TRENDS BIOCHEM SCI, V22, P420, DOI 10.1016/S0968-0004(97)01129-8; Karrasch S, 1999, J MOL BIOL, V290, P379, DOI 10.1006/jmbi.1999.2897; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; McLachlin DT, 2000, J BIOL CHEM, V275, P17571, DOI 10.1074/jbc.M000375200; Meier T, 2001, FEBS LETT, V505, P353, DOI 10.1016/S0014-5793(01)02837-X; Mellwig C, 2001, J STRUCT BIOL, V133, P214, DOI 10.1006/jsbi.2001.4340; Menz RI, 2001, CELL, V106, P331, DOI 10.1016/S0092-8674(01)00452-4; Possmayer FE, 2000, BBA-BIOENERGETICS, V1459, P202, DOI 10.1016/S0005-2728(00)00148-1; Rastogi VK, 1999, NATURE, V402, P263, DOI 10.1038/46224; Revington M, 1999, J BIOL CHEM, V274, P31094, DOI 10.1074/jbc.274.43.31094; Rodgers AJW, 2000, NAT STRUCT BIOL, V7, P1051; Rodgers AJW, 1997, J BIOL CHEM, V272, P31058, DOI 10.1074/jbc.272.49.31058; Rodgers AJW, 1998, J BIOL CHEM, V273, P29406, DOI 10.1074/jbc.273.45.29406; Seelert H, 2000, NATURE, V405, P418, DOI 10.1038/35013148; Shirakihara Y, 1997, STRUCTURE, V5, P825, DOI 10.1016/S0969-2126(97)00236-0; Stock D, 1999, SCIENCE, V286, P1700, DOI 10.1126/science.286.5445.1700; vanHeel M, 1996, J STRUCT BIOL, V116, P17, DOI 10.1006/jsbi.1996.0004; VIK SB, 1994, J BIOL CHEM, V269, P30364; Wilkens S, 1997, NAT STRUCT BIOL, V4, P198, DOI 10.1038/nsb0397-198; Wilkens S, 2000, J MOL BIOL, V295, P387, DOI 10.1006/jmbi.1999.3381; Wilkens S, 1998, BBA-BIOENERGETICS, V1365, P93, DOI 10.1016/S0005-2728(98)00048-6; Yasuda R, 1998, CELL, V93, P1117, DOI 10.1016/S0092-8674(00)81456-7	40	35	38	3	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 16	2003	278	20					18544	18549		10.1074/jbc.M212852200	http://dx.doi.org/10.1074/jbc.M212852200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677YX	12624095	hybrid			2022-12-25	WOS:000182838300125
J	Mitsopoulos, C; Zihni, C; Garg, R; Ridley, AJ; Morris, JDH				Mitsopoulos, C; Zihni, C; Garg, R; Ridley, AJ; Morris, JDH			The prostate-derived sterile 20-like kinase (PSK) regulates microtubule organization and stability	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							N-TERMINAL KINASE; ACTIVATED PROTEIN-KINASE; GLYCOGEN-SYNTHASE KINASE-3-BETA; NUCLEOTIDE EXCHANGE FACTOR; P21-ACTIVATED KINASE; 3T3 CELLS; ACTIN; PATHWAYS; DYNAMICS; PHOSPHORYLATION	Sterile 20 (STE20) protein kinases, which include germinal center kinases and p21-activated protein kinases, are known to activate mitogen-activated protein kinase pathways (c-Jun NH2-terminal kinase, p38, or extracellular signal-regulated kinase), leading to changes in gene transcription. Some STE20s can also regulate the cytoskeleton, and we have shown that the germinal center kinase-like kinase prostate-derived STE20-like kinase (PSK) affects actin cytoskeletal organization. Here, we demonstrate that PSK colocalizes with microtubules; and that this localization is disrupted by the microtubule depolymerizing agent nocodazole. The association of PSK with microtubules results in the production of stabilized perinuclear microtubule cables that are nocodazole-resistant and contain increased levels of acetylated alpha-tubulin. Kinase-defective PSK (K57A) or the C terminus of PSK (amino acids 745-1235) lacking the kinase domain are sufficient for microtubule binding and stabilization, demonstrating that the catalytic activity of the protein is not required. The localization of PSK to microtubules occurs via its C terminus, and PSK binds and phosphorylates alpha- and beta-tubulin in vitro. The N terminus of PSK (1-940) is unable to bind or stabilize microtubules, demonstrating that PSK must associate with microtubules for their reorganization to occur. These results demonstrate that PSK interacts with microtubules and affects their organization and stability independently of PSK kinase activity.	GKT Sch Med & Dent, Rayne Inst, Acad Dept Surg, London SE5 9NU, England; Ludwig Inst Canc Res, Univ Coll London Branch, London W1W 7BS, England; UCL, Dept Biochem & Mol Biol, London WC1E 6BT, England	University of London; King's College London; Ludwig Institute for Cancer Research; University of London; University College London; University of London; University College London	Morris, JDH (corresponding author), GKT Sch Med & Dent, Rayne Inst, Acad Dept Surg, 123 Coldharbour Lane, London SE5 9NU, England.	jonathan.morris@kcl.ac.uk		Morris, Jonathan/0000-0002-3211-1798; Mitsopoulos, Costas/0000-0002-9116-5921; Ridley, Anne/0000-0001-8186-5708				Bagrodia S, 1999, TRENDS CELL BIOL, V9, P350, DOI 10.1016/S0962-8924(99)01618-9; Banerjee M, 2002, CURR BIOL, V12, P1233, DOI 10.1016/S0960-9822(02)00956-9; Best A, 1996, J BIOL CHEM, V271, P3756; Boutros M, 1998, CELL, V94, P109, DOI 10.1016/S0092-8674(00)81226-X; Cassimeris L, 2002, CURR OPIN CELL BIOL, V14, P18, DOI 10.1016/S0955-0674(01)00289-7; Cau J, 2001, J CELL BIOL, V155, P1029, DOI 10.1083/jcb.200104123; Chen Z, 2001, J BIOL CHEM, V276, P16070, DOI 10.1074/jbc.M100681200; Dan I, 2001, TRENDS CELL BIOL, V11, P220, DOI 10.1016/S0962-8924(01)01980-8; Daniels RH, 1999, TRENDS BIOCHEM SCI, V24, P350, DOI 10.1016/S0968-0004(99)01442-5; Danowski BA, 1998, CELL MOTIL CYTOSKEL, V40, P1; Daub H, 2001, J BIOL CHEM, V276, P1677, DOI 10.1074/jbc.C000635200; Dharmawardhane S, 1997, J CELL BIOL, V138, P1265, DOI 10.1083/jcb.138.6.1265; Drewes G, 1998, TRENDS BIOCHEM SCI, V23, P307, DOI 10.1016/S0968-0004(98)01245-6; Edwards DC, 1999, NAT CELL BIOL, V1, P253, DOI 10.1038/12963; Enomoto T, 1996, CELL STRUCT FUNCT, V21, P317, DOI 10.1247/csf.21.317; Faruki S, 2000, J CELL SCI, V113, P2557; Fu CA, 1999, J BIOL CHEM, V274, P30729, DOI 10.1074/jbc.274.43.30729; Glaven JA, 1999, J BIOL CHEM, V274, P2279, DOI 10.1074/jbc.274.4.2279; Harrison RE, 2001, NEOPLASIA, V3, P385, DOI 10.1038/sj.neo.7900180; HERSKOWITZ I, 1995, CELL, V80, P187, DOI 10.1016/0092-8674(95)90402-6; Kiosses WB, 1999, J CELL BIOL, V147, P831, DOI 10.1083/jcb.147.4.831; Krylova O, 2000, J CELL BIOL, V151, P83, DOI 10.1083/jcb.151.1.83; Li W, 1996, TOXICOL APPL PHARM, V140, P461, DOI 10.1006/taap.1996.0243; Lin PT, 2000, J NEUROSCI, V20, P9152; MacRae TH, 1997, EUR J BIOCHEM, V244, P265, DOI 10.1111/j.1432-1033.1997.00265.x; Manser E, 1997, MOL CELL BIOL, V17, P1129, DOI 10.1128/MCB.17.3.1129; Moore TM, 2000, J BIOL CHEM, V275, P4311, DOI 10.1074/jbc.275.6.4311; Nagata K, 1998, EMBO J, V17, P149, DOI 10.1093/emboj/17.1.149; Palazzo AF, 2001, NAT CELL BIOL, V3, P723, DOI 10.1038/35087035; Ren Y, 1998, J BIOL CHEM, V273, P34954, DOI 10.1074/jbc.273.52.34954; RESZKA AA, 1995, P NATL ACAD SCI USA, V92, P8881, DOI 10.1073/pnas.92.19.8881; Reynolds CH, 2000, J NEUROCHEM, V74, P1587, DOI 10.1046/j.1471-4159.2000.0741587.x; Sabourin LA, 2000, MOL CELL BIOL, V20, P684, DOI 10.1128/MCB.20.2.684-696.2000; Sanders LC, 1999, SCIENCE, V283, P2083, DOI 10.1126/science.283.5410.2083; Simon JR, 1998, J NEUROCYTOL, V27, P119, DOI 10.1023/A:1006999306413; SUN W, 2002, J BIOL CHEM, V25, P25; Tsutsumi T, 2000, J BIOL CHEM, V275, P9157, DOI 10.1074/jbc.275.13.9157; van Horck FPG, 2001, J BIOL CHEM, V276, P4948, DOI 10.1074/jbc.M003839200; Verhey KJ, 2001, J CELL BIOL, V152, P959, DOI 10.1083/jcb.152.5.959; Wagner S, 2002, J BIOL CHEM, V277, P37685, DOI 10.1074/jbc.M205899200; Wang TH, 1998, J BIOL CHEM, V273, P4928, DOI 10.1074/jbc.273.9.4928; Waterman-Storer CM, 1999, NAT CELL BIOL, V1, P45, DOI 10.1038/9018; Willard FS, 2001, CELL SIGNAL, V13, P653, DOI 10.1016/S0898-6568(01)00185-1; Yujiri T, 1999, J BIOL CHEM, V274, P12605, DOI 10.1074/jbc.274.18.12605	44	39	43	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 16	2003	278	20					18085	18091		10.1074/jbc.M213064200	http://dx.doi.org/10.1074/jbc.M213064200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677YX	12639963	hybrid			2022-12-25	WOS:000182838300065
J	Schertzer, JW; Brown, ED				Schertzer, JW; Brown, ED			Purified, recombinant TagF protein from Bacillus subtilis 168 catalyzes the polymerization of glycerol phosphate onto a membrane acceptor in vitro	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							WALL TEICHOIC-ACID; POLY(GLYCEROPHOSPHATE) GLYCEROPHOSPHOTRANSFERASE; CTP-GLYCEROL-3-PHOSPHATE CYTIDYLYLTRANSFERASE; CDP-GLYCEROL; CELL-WALLS; BACILLUS-SUBTILIS-168; GENES; ORGANIZATION; EXPRESSION; RIBITOL	We report the first characterization of a recombinant protein involved in the polymerization of wall teichoic acid. Previously, a study of the teichoic acid polymerase activity associated with membranes from Bacillus subtilis 168 strains bearing thermosensitive mutations in tagB, tagD, and tagF implicated TagF as the poly(glycerol phosphate) polymerase (Pooley, H. M., Abellan, F. X., and Karamata, D. (1992) J. Bacteriol. 174, 646-649). In the work reported here, we have demonstrated an unequivocal role for tagF in the thermosensitivity of one such mutant (tagF1) by conditional complementation at the restrictive temperature with tagF under control of the xylose promoter at the amyE locus. We have overexpressed and purified recombinant B. subtilis TagF protein, and we provide direct biochemical evidence that this enzyme is responsible for polymerization of poly( glycerol phosphate) teichoic acid in B. subtilis 168. Recombinant hexahistidine-tagged TagF protein was purified from Escherichia coli and was used to develop a novel membrane pelleting assay to monitor poly(glycerol phosphate) polymerase activity. Purified TagF was shown to incorporate radioactivity from its substrate CDP-[C-14]glycerol into a membrane fraction in vitro. This activity showed a saturable dependence on the concentration of CDP-glycerol (K-m of 340 muM) and the membrane acceptor (half-maximal activity at 650 mug of protein/ml of purified B. subtilis membranes). High pressure liquid chromatography analysis confirmed the polymeric nature of the reaction product, similar to35 glycerol phosphate units in length.	McMaster Univ, Dept Biochem, Antimicrobial Res Ctr, Hamilton, ON L8N 3Z5, Canada	McMaster University	Brown, ED (corresponding author), McMaster Univ, Dept Biochem, Antimicrobial Res Ctr, 1200 Main St W, Hamilton, ON L8N 3Z5, Canada.		Schertzer, Jonathan/P-3395-2017	Schertzer, Jonathan/0000-0002-1547-5856				ANDERSON RG, 1972, BIOCHEM J, V127, P11, DOI 10.1042/bj1270011; Badurina DS, 2003, BBA-PROTEINS PROTEOM, V1646, P196, DOI 10.1016/S1570-9639(03)00019-0; Bhavsar AP, 2001, J BACTERIOL, V183, P6688, DOI 10.1128/JB.183.22.6688-6693.2001; Bhavsar AP, 2001, APPL ENVIRON MICROB, V67, P403, DOI 10.1128/AEM.67.1.403-410.2001; BRIEHL M, 1989, J GEN MICROBIOL, V135, P1325; BURGER MM, 1964, J BIOL CHEM, V239, P3168; CUTTING SM, 1990, MOL BIOL METHODS BAC, P175; FIEDLER F, 1974, J BIOL CHEM, V249, P2684; FIEDLER F, 1974, J BIOL CHEM, V249, P2690; Fitzgerald SN, 2000, J BACTERIOL, V182, P1046, DOI 10.1128/JB.182.4.1046-1052.2000; GLASER L, 1964, J BIOL CHEM, V239, P3178; HONEYMAN AL, 1989, MOL MICROBIOL, V3, P1257, DOI 10.1111/j.1365-2958.1989.tb00276.x; ISHIMOTO N, 1966, J BIOL CHEM, V241, P639; KOJIMA N, 1983, J BIOL CHEM, V258, P9043; Lazarevic V, 2002, MICROBIOL-SGM, V148, P815, DOI 10.1099/00221287-148-3-815; LAZAREVIC V, 1995, MOL MICROBIOL, V16, P345, DOI 10.1111/j.1365-2958.1995.tb02306.x; LEAVER J, 1981, J BACTERIOL, V146, P847, DOI 10.1128/JB.146.3.847-852.1981; MAUCK J, 1972, P NATL ACAD SCI USA, V69, P2386, DOI 10.1073/pnas.69.9.2386; MAUEL C, 1991, J GEN MICROBIOL, V137, P929, DOI 10.1099/00221287-137-4-929; MAUEL C, 1989, MOL GEN GENET, V215, P388, DOI 10.1007/BF00427034; MCARTHUR HAI, 1978, FEBS LETT, V86, P193, DOI 10.1016/0014-5793(78)80561-4; Park YS, 1997, J BIOL CHEM, V272, P15161, DOI 10.1074/jbc.272.24.15161; PARK YS, 1993, J BIOL CHEM, V268, P16648; Paulsen IT, 1997, MICROBIOL-SGM, V143, P2685, DOI 10.1099/00221287-143-8-2685; POLLACK JH, 1994, J BACTERIOL, V176, P7252, DOI 10.1128/JB.176.23.7252-7259.1994; POOLEY HM, 1992, J BACTERIOL, V174, P646, DOI 10.1128/jb.174.2.646-649.1992; POOLEY HM, 1994, BACTERIAL CELL WALL, P187; Sambrook J., 1989, MOL CLONING, pA1; Sanker S, 2001, J BIOL CHEM, V276, P37922; SASAKI Y, 1983, EUR J BIOCHEM, V132, P207, DOI 10.1111/j.1432-1033.1983.tb07349.x; Soldo B, 2002, MICROBIOL-SGM, V148, P2079, DOI 10.1099/00221287-148-7-2079	31	36	37	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 16	2003	278	20					18002	18007		10.1074/jbc.M300706200	http://dx.doi.org/10.1074/jbc.M300706200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677YX	12637499	hybrid			2022-12-25	WOS:000182838300053
J	Shindo, M; Irie, K; Masuda, A; Ohigashi, H; Shirai, Y; Miyasaka, K; Saito, N				Shindo, M; Irie, K; Masuda, A; Ohigashi, H; Shirai, Y; Miyasaka, K; Saito, N			Synthesis and phorbol ester binding of the cysteine-rich domains of diacylglycerol kinase (DGK) isozymes - DGK gamma and DGK gamma are new targets of tumor-promoting phorbol esters	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLECKSTRIN HOMOLOGY DOMAIN; SITE-DIRECTED MUTAGENESIS; PROTEIN-KINASE; MOLECULAR-CLONING; C-DELTA; EXPRESSION; ZINC; SPECIFICITY; ALPHA; IDENTIFICATION	Diacylglycerol kinase (DGK) and protein kinase C (PKC) are two distinct enzyme families associated with diacylglycerol. Both enzymes have cysteine-rich C1 domains (C1A, C1B, and C1C) in the regulatory region. Although most PKC C1 domains strongly bind phorbol esters, there has been no direct evidence that DGK C1 domains bind phorbol esters. We synthesized 11 cysteine-rich sequences of DGK C1 domains with good sequence homology to those of the PKC C1 domains. Among them, only DGKgamma-C1A and DGKbeta-C1A exhibited significant binding to phorbol 12,13-dibutyrate (PDBu). Scatchard analysis of rat-DGKgamma-C1A, human-DGKgamma-C1A, and human-DGKbeta-C1A gave K-d values of 3.6, 2.8, and 14.6 nM, respectively, suggesting that DGKgamma and DGKbeta are new targets of phorbol esters. An A12T mutation of human-GK beta-C1A enhanced the affinity to bind PDBu, indicating that the beta-hydroxyl group of Thr-12 significantly contributes to the binding. The K-d value for PDBu of FLAG-tagged whole rat-DGKgamma (4.4 nM) was nearly equal to that of rat-DGKgamma-C1A (3.6 nM). Moreover, 12-O-tetradecanoylphorbol 13-acetate induced the irreversible translocation of whole rat-DGKgamma and its C1B deletion mutant, not the C1A deletion mutant, from the cytoplasm to the plasma membrane of CHO-K1 cells. These results indicate that 12-O-tetradecanoylphorbol 13-acetate binds to C1A of DGKgamma to cause its translocation.	Kyoto Univ, Grad Sch Agr, Div Food Sci & Biotechnol, Sakyo Ku, Kyoto 6068502, Japan; Appl Biosyst Japan Ltd, Chuo Ku, Tokyo 1040032, Japan; Kobe Univ, Biosignal Res Ctr, Kobe, Hyogo 6578501, Japan	Kyoto University; Thermo Fisher Scientific; Applied Biosystems; Kobe University	Irie, K (corresponding author), Kyoto Univ, Grad Sch Agr, Div Food Sci & Biotechnol, Sakyo Ku, Kitashiirakawa Oiwake Cho, Kyoto 6068502, Japan.		Shirai, Yasuhito/O-3255-2018; Irie, Kazuhiro/A-6121-2014	Irie, Kazuhiro/0000-0001-7109-8568				AHMED S, 1991, BIOCHEM J, V280, P233, DOI 10.1042/bj2800233; BLUMBERG PM, 1984, MECHANISMS TUMOR PRO, V3, P143; Bunting M, 1996, J BIOL CHEM, V271, P10230, DOI 10.1074/jbc.271.17.10230; Caricasole A, 2002, J BIOL CHEM, V277, P4790, DOI 10.1074/jbc.M110249200; CARPINO LA, 1993, J AM CHEM SOC, V115, P4397, DOI 10.1021/ja00063a082; Ding L, 1998, J BIOL CHEM, V273, P32746, DOI 10.1074/jbc.273.49.32746; ENDO Y, 1982, CHEM PHARM BULL, V30, P3457; FUJIKI H, 1985, P JPN ACAD B-PHYS, V61, P45, DOI 10.2183/pjab.61.45; GOTO K, 1994, P NATL ACAD SCI USA, V91, P13042, DOI 10.1073/pnas.91.26.13042; GOTO K, 1992, MOL BRAIN RES, V16, P75, DOI 10.1016/0169-328X(92)90196-I; GOTO K, 1993, P NATL ACAD SCI USA, V90, P7598, DOI 10.1073/pnas.90.16.7598; HOMMEL U, 1994, NAT STRUCT BIOL, V1, P383, DOI 10.1038/nsb0694-383; Houssa B, 1997, J BIOL CHEM, V272, P10422; Houssa B, 1998, BIOCHEM J, V331, P677; HUBBARD SR, 1991, SCIENCE, V254, P1776; Hurley JH, 1997, PROTEIN SCI, V6, P477; ICHIKAWA S, 1995, J BIOCHEM-TOKYO, V117, P566, DOI 10.1093/oxfordjournals.jbchem.a124745; Irie K, 1999, BIOORG MED CHEM LETT, V9, P2487, DOI 10.1016/S0960-894X(99)00413-8; Irie K, 1998, J AM CHEM SOC, V120, P9159, DOI 10.1021/ja981087f; IRIE K, 1984, AGR BIOL CHEM TOKYO, V48, P1269, DOI 10.1080/00021369.1984.10866289; JAMES HG, 1979, SAS USERS GUIDE, P357; KAZANIETZ MG, 1995, J BIOL CHEM, V270, P21852, DOI 10.1074/jbc.270.37.21852; KAZANIETZ MG, 1993, MOL PHARMACOL, V44, P298; Klauck TM, 1996, J BIOL CHEM, V271, P19781, DOI 10.1074/jbc.271.33.19781; MORI T, 1982, J BIOCHEM, V91, P427, DOI 10.1093/oxfordjournals.jbchem.a133714; PETTIT GR, 1982, J AM CHEM SOC, V104, P6846, DOI 10.1021/ja00388a092; QUEST AFG, 1992, J BIOL CHEM, V267, P10193; Sakane F, 1996, BIOCHEM J, V318, P583, DOI 10.1042/bj3180583; SAKANE F, 1990, NATURE, V344, P345, DOI 10.1038/344345a0; Sakane F, 1996, J BIOL CHEM, V271, P8394, DOI 10.1074/jbc.271.14.8394; SCHAAP D, 1990, FEBS LETT, V275, P151, DOI 10.1016/0014-5793(90)81461-V; SHARKEY NA, 1985, CANCER RES, V45, P19; Shindo M, 2001, BIOCHEM BIOPH RES CO, V289, P451, DOI 10.1006/bbrc.2001.5935; Shindo M, 2001, BIOORGAN MED CHEM, V9, P2073, DOI 10.1016/S0968-0896(01)00100-6; Shirai Y, 1998, J CELL BIOL, V143, P511, DOI 10.1083/jcb.143.2.511; Shirai Y, 2000, J BIOL CHEM, V275, P24760, DOI 10.1074/jbc.M003151200; SORG B, 1982, Z NATURFORSCH B, V37, P748; Tang W, 1996, J BIOL CHEM, V271, P10237, DOI 10.1074/jbc.271.17.10237; Topham MK, 1999, J BIOL CHEM, V274, P11447, DOI 10.1074/jbc.274.17.11447; van Blitterswijk WJ, 1999, CHEM PHYS LIPIDS, V98, P95, DOI 10.1016/S0009-3084(99)00022-5; van Blitterswijk WJ, 2000, CELL SIGNAL, V12, P595, DOI 10.1016/S0898-6568(00)00113-3; Wang QMJ, 1999, J BIOL CHEM, V274, P37233, DOI 10.1074/jbc.274.52.37233; Wang SM, 1996, J MED CHEM, V39, P2541, DOI 10.1021/jm950403n; Xu RX, 1997, BIOCHEMISTRY-US, V36, P10709, DOI 10.1021/bi970833a; ZHANG GG, 1995, CELL, V81, P917, DOI 10.1016/0092-8674(95)90011-X	45	56	61	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 16	2003	278	20					18448	18454		10.1074/jbc.M300400200	http://dx.doi.org/10.1074/jbc.M300400200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677YX	12621060	hybrid			2022-12-25	WOS:000182838300112
J	Steinbacher, S; Kaiser, J; Eisenreich, W; Huber, R; Bacher, A; Rohdich, F				Steinbacher, S; Kaiser, J; Eisenreich, W; Huber, R; Bacher, A; Rohdich, F			Structural basis of fosmidomycin action revealed by the complex with 2-C-methyl-D-erythritol 4-phosphate synthase (IspC) - Implications for the catalytic mechanism and anti-malaria drug development	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							1-DEOXY-D-XYLULOSE 5-PHOSPHATE REDUCTOISOMERASE; ISOPRENOID BIOSYNTHESIS; NONMEVALONATE PATHWAY; CRYSTAL-STRUCTURE; PHOSPHATE-PATHWAY; ESCHERICHIA-COLI; TERPENOIDS; SEQUENCE; ENZYME	2-C-Methyl-D-erythritol 4-phosphate synthase ( IspC) is the first enzyme committed to isoprenoid biosynthesis in the methylerythritol phosphate pathway, which represents an alternative route to the classical mevalonate pathway. As it is present in many pathogens and plants, but not in man, this pathway has attracted considerable interest as a target for novel antibiotics and herbicides. Fosmidomycin represents a specific high-affinity inhibitor of IspC. Very recently, its anti-malaria activity in man has been demonstrated in clinical trials. Here, we present the crystal structure of Escherichia coli IspC in complex with manganese and fosmidomycin at 2.5 Angstrom resolution. The (N-formyl-N-hydroxy) amino group provides two oxygen ligands to manganese that is present in a distorted octahedral coordination, whereas the phosphonate group is anchored in a specific pocket by numerous hydrogen bonds. Both sites are connected by a spacer of three methylene groups. The substrate molecule, 1-D-deoxyxylulose 5- phosphate, can be superimposed onto fosmidomycin, explaining the stereochemical course of the reaction.	Max Planck Inst Biochem, Abt Strukturforsch, D-82152 Martinsried, Germany; Tech Univ Munich, Lehrstuhl Organ Chem & Biochem, D-8046 Garching, Germany	Max Planck Society; Technical University of Munich	Steinbacher, S (corresponding author), CALTECH, Div Chem & Chem Engn, Mail Code 114-96, Pasadena, CA 91125 USA.	steinbac@caltech.edu	Eisenreich, Wolfgang/A-1258-2013; Kaiser, Johannes/F-7745-2013	Eisenreich, Wolfgang/0000-0002-9832-8279; Kaiser, Johannes/0000-0003-1949-4744				Arigoni D, 1997, P NATL ACAD SCI USA, V94, P10600, DOI 10.1073/pnas.94.20.10600; Arigoni D, 1999, CHEM COMMUN, P1127, DOI 10.1039/a902216c; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BROERS STJ, 1994, THESIS EIDGENOSSICHE; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Dumas R, 2001, ACCOUNTS CHEM RES, V34, P399, DOI 10.1021/ar000082w; Duvold T, 1997, TETRAHEDRON LETT, V38, P4769, DOI 10.1016/S0040-4039(97)01045-9; Eisenreich W, 2001, TRENDS PLANT SCI, V6, P78, DOI 10.1016/S1360-1385(00)01812-4; Eisenreich W, 1996, P NATL ACAD SCI USA, V93, P6431, DOI 10.1073/pnas.93.13.6431; Eisenreich W, 1998, CHEM BIOL, V5, pR221, DOI 10.1016/S1074-5521(98)90002-3; Esnouf RM, 1997, J MOL GRAPH MODEL, V15, P132, DOI 10.1016/S1093-3263(97)00021-1; Frankish H, 2002, LANCET, V360, P1075, DOI 10.1016/S0140-6736(02)11179-2; Gardner MJ, 2002, NATURE, V419, P531, DOI 10.1038/nature01094; Hecht S, 2001, J ORG CHEM, V66, P7770, DOI 10.1021/jo015890v; Hoeffler JF, 2002, EUR J BIOCHEM, V269, P4446, DOI 10.1046/j.1432-1033.2002.03150.x; Hyman RW, 2002, NATURE, V419, P534, DOI 10.1038/nature01102; Jomaa H, 1999, SCIENCE, V285, P1573, DOI 10.1126/science.285.5433.1573; Koppisch AT, 2002, BIOCHEMISTRY-US, V41, P236, DOI 10.1021/bi0118207; Kuzuyama T, 2000, J BIOL CHEM, V275, P19928, DOI 10.1074/jbc.M001820200; Kuzuyama T, 1998, TETRAHEDRON LETT, V39, P7913, DOI 10.1016/S0040-4039(98)01755-9; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Missinou MA, 2002, LANCET, V360, P1941, DOI 10.1016/S0140-6736(02)11860-5; OKUHARA M, 1980, J ANTIBIOT, V33, P13, DOI 10.7164/antibiotics.33.13; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Pellecchia M, 2002, J BIOMOL NMR, V22, P165, DOI 10.1023/A:1014256707875; Proteau PJ, 1999, ORG LETT, V1, P921, DOI 10.1021/ol990839n; Radykewicz T, 2000, FEBS LETT, V465, P157, DOI 10.1016/S0014-5793(99)01743-3; Ramachandran G N, 1968, Adv Protein Chem, V23, P283, DOI 10.1016/S0065-3233(08)60402-7; Reuter K, 2002, J BIOL CHEM, V277, P5378, DOI 10.1074/jbc.M109500200; ROHMER M, 1993, BIOCHEM J, V295, P517, DOI 10.1042/bj2950517; Rohmer M., 1999, COMPR NAT PROD CHEM, V2, P45, DOI 10.1016/B978-0-08-091283-7.00036-9; Rowsell S, 2002, J MOL BIOL, V319, P173, DOI 10.1016/S0022-2836(02)00262-0; Schwarz M, 1999, COMPREHENSIVE NATURA, V2, P367, DOI DOI 10.1016/B978-0-08-091283-7.00043-6; SCHWARZ MK, 1994, THESIS EIDGENOSSICHE; Takahashi S, 1998, P NATL ACAD SCI USA, V95, P9879, DOI 10.1073/pnas.95.17.9879; Trouiller P, 2002, LANCET, V359, P2188, DOI 10.1016/S0140-6736(02)09096-7; TURK D, 1992, THESIS TU MUNCHEN MU; Vial HJ, 2000, PARASITOL TODAY, V16, P140, DOI 10.1016/S0169-4758(00)01638-0; Wellems TE, 2002, SCIENCE, V298, P124, DOI 10.1126/science.1078167; Yajima S, 2002, J BIOCHEM, V131, P313, DOI 10.1093/oxfordjournals.jbchem.a003105; Zeidler J, 1998, Z NATURFORSCH C, V53, P980	41	147	157	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 16	2003	278	20					18401	18407		10.1074/jbc.M300993200	http://dx.doi.org/10.1074/jbc.M300993200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677YX	12621040	Green Submitted, Green Accepted, hybrid			2022-12-25	WOS:000182838300106
J	Vitavska, O; Wieczorek, H; Merzendorfer, H				Vitavska, O; Wieczorek, H; Merzendorfer, H			A novel role for subunit C in mediating binding of the H+-V-ATPase to the actin cytoskeleton	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TOBACCO HORNWORM MIDGUT; ANIMAL PLASMA-MEMBRANE; VACUOLAR-TYPE ATPASE; PROTON PUMP; TRANSPORTING EPITHELIA; ION-TRANSPORT; IN-VIVO; CLATHRIN; PURIFICATION; DISSOCIATION	Primary proton transport by V-ATPases is regulated via the reversible dissociation of the V1V0 holoenzyme into its V-1 and V-0 subcomplexes. Laser scanning microscopy of different tissues from the tobacco hornworm revealed co-localization of the holoenzyme and F-actin close to the apical membranes of the epithelial cells. In midgut goblet cells, no co-localization was observed under conditions where the V-1 complex detaches from the apical membrane. Binding studies, however, demonstrated that both the V-1 complex and the holoenzyme interact with F-actin, the latter with an apparently higher affinity. To identify F-actin binding subunits, we performed overlay blots that revealed two V-1 subunits as binding partners, namely subunit B, resembling the situation in the osteoclast V-ATPase (Holliday, L. S., Lu, M., Lee, B. S., Nelson, R. D., Solivan, S., Zhang, L., and Gluck, S. L. (2000) J. Biol. Chem. 275, 32331-32337), but, in addition, subunit C, which gets released during reversible dissociation of the holoenzyme. Overlay blots and co-pelleting assays showed that the recombinant subunit Calso binds to F-actin. When the V-1 complex was reconstituted with recombinant subunit C, enhanced binding to F-actin was observed. Thus, subunit C may function as an anchor protein regulating the linkage between V-ATPase and the actin-based cytoskeleton.	Univ Osnabruck, Dept Biol Chem, Div Anim Physiol, D-49069 Osnabruck, Germany	University Osnabruck	Merzendorfer, H (corresponding author), Univ Osnabruck, Dept Biol Chem, Div Anim Physiol, D-49069 Osnabruck, Germany.							ARNOLD H, 1970, EUR J BIOCHEM, V15, P360, DOI 10.1111/j.1432-1033.1970.tb01016.x; Baumann O, 2001, EXP CELL RES, V270, P176, DOI 10.1006/excr.2001.5343; BELL RA, 1976, ANN ENTOMOL SOC AM, V69, P365, DOI 10.1093/aesa/69.2.365; BELTRAN C, 1992, J BIOL CHEM, V267, P774; BONFANTI P, 1992, EUR J CELL BIOL, V57, P298; CIOFFI M, 1979, TISSUE CELL, V11, P467, DOI 10.1016/0040-8166(79)90057-0; Denker SP, 2002, CURR OPIN CELL BIOL, V14, P214, DOI 10.1016/S0955-0674(02)00304-6; Geyer M, 2002, J BIOL CHEM, V277, P28521, DOI 10.1074/jbc.M200522200; Geyer M, 2002, MOL BIOL CELL, V13, P2045, DOI 10.1091/mbc.02-02-0026; Graf R, 1996, J BIOL CHEM, V271, P20908, DOI 10.1074/jbc.271.34.20908; GRAF R, 1994, BBA-BIOMEMBRANES, V1190, P193, DOI 10.1016/0005-2736(94)90053-1; HO MN, 1993, J BIOL CHEM, V268, P221; Holliday LS, 2000, J BIOL CHEM, V275, P32331, DOI 10.1074/jbc.M004795200; HUSS M, 2001, STRUCTURE FUNCTION R; JUNGREIS AM, 1977, J INSECT PHYSIOL, V23, P503, DOI 10.1016/0022-1910(77)90261-X; KANE PM, 1995, J BIOL CHEM, V270, P17025; KLEIN U, 1992, J EXP BIOL, V172, P345; KLEIN U, 1991, J EXP BIOL, V161, P61; Lee BS, 1999, J BIOL CHEM, V274, P29164, DOI 10.1074/jbc.274.41.29164; LIU Q, 1994, J BIOL CHEM, V269, P31592; Lu M, 2001, J BIOL CHEM, V276, P30407, DOI 10.1074/jbc.M008768200; Lu XB, 1998, IMMUNITY, V8, P647, DOI 10.1016/S1074-7613(00)80569-5; Mandic R, 2001, MOL BIOL CELL, V12, P463, DOI 10.1091/mbc.12.2.463; MARQUETANT R, 1986, ARCH BIOCHEM BIOPHYS, V245, P404, DOI 10.1016/0003-9861(86)90231-6; Merzendorfer H, 1997, FEBS LETT, V411, P239, DOI 10.1016/S0014-5793(97)00699-6; Merzendorfer H, 2000, BBA-BIOMEMBRANES, V1467, P369, DOI 10.1016/S0005-2736(00)00233-9; MYERS M, 1993, J BIOL CHEM, V268, P9184; Nishi T, 2002, NAT REV MOL CELL BIO, V3, P94, DOI 10.1038/nrm729; PEARSE BMF, 1990, ANNU REV CELL BIOL, V6, P151, DOI 10.1146/annurev.cb.06.110190.001055; POLLARD TD, 1986, ANNU REV BIOCHEM, V55, P987, DOI 10.1146/annurev.bi.55.070186.005011; Price NC, 1996, ENZYMOLOGY LABFAX, P34; PUOPOLO K, 1992, J BIOL CHEM, V267, P5171; SCHWEIKL H, 1989, J BIOL CHEM, V264, P11136; Seol JH, 2001, NAT CELL BIOL, V3, P384, DOI 10.1038/35070067; Smardon AM, 2002, J BIOL CHEM, V277, P13831, DOI 10.1074/jbc.M200682200; SUMNER JP, 1995, J BIOL CHEM, V270, P5649, DOI 10.1074/jbc.270.10.5649; Svergun DI, 1998, BIOCHEMISTRY-US, V37, P17659, DOI 10.1021/bi982367a; Wieczorek H, 1999, BIOESSAYS, V21, P637, DOI 10.1002/(SICI)1521-1878(199908)21:8<637::AID-BIES3>3.3.CO;2-N; WIECZOREK H, 1991, J BIOL CHEM, V266, P15340; Wieczorek H, 2000, J EXP BIOL, V203, P127; WIECZOREK H, 1990, METHOD ENZYMOL, V192, P608; Xu T, 2001, J BIOL CHEM, V276, P24855, DOI 10.1074/jbc.M100637200	42	121	126	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 16	2003	278	20					18499	18505		10.1074/jbc.M212844200	http://dx.doi.org/10.1074/jbc.M212844200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677YX	12606563	hybrid			2022-12-25	WOS:000182838300119
J	Walter, SA; Cutler, RE; Martinez, R; Gishizky, M; Hill, RJ				Walter, SA; Cutler, RE; Martinez, R; Gishizky, M; Hill, RJ			Stk10, a new member of the polo-like kinase kinase family highly expressed in hematopoietic tissue	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANAPHASE-PROMOTING COMPLEX; CELL-CYCLE PROGRESSION; XENOPUS EGG EXTRACTS; PROGNOSTIC-SIGNIFICANCE; SACCHAROMYCES-CEREVISIAE; MOLECULAR-CLONING; DROSOPHILA POLO; PLK EXPRESSION; PROTEIN-KINASE; M-PHASE	The Ste20 family of serine/threonine kinases plays an important role in numerous cellular functions such as growth, apoptosis, and morphogenesis. We have identified a previously cloned but uncharacterized family member termed Stk10, which is a human homolog of murine Lok, a serine/threonine kinase highly expressed in lymphocytes. Northern analysis demonstrated that the Stk10 transcript is present in many tissues, although highest expression levels are seen in hematopoietic cells. Due to close sequence homology to human Slk and Xenopus laevis xPlkk1, two polo-like kinase kinases, we investigated whether Stk10 might also play a role as a Plk1 activator. Plk1 has been shown to be overexpressed in multiple tumor types, thus attracting high interest to its potential upstream regulators. We show here that Stk10 can associate with Plk1 in cells and furthermore can phosphorylate Plk1 in vitro. Engineered NIH-3T3 cell lines that overexpress a dominant negative version of Stk10 display an altered cell cycle phenotype characterized by increased DNA content, raising the possibility that expression of a dominant negative Stk10 may impinge upon Plk1 function in vivo; it has previously been shown that unregulated expression of Plk1 can result in a variety of nuclear defects. We suggest, therefore, that Stk10 is a novel polo-like kinase kinase that cooperates with hSlk to regulate Plk1 function in human cells.	SUGEN Inc, Dept Res, San Francisco, CA 94080 USA; SUGEN Inc, Dept Target Discovery, San Francisco, CA 94080 USA	Pfizer; Pfizer	Walter, SA (corresponding author), SUGEN Inc, Dept Res, 230 E Grand Ave, San Francisco, CA 94080 USA.	sarah-walter@sugen.com						Bin OY, 1999, ONCOGENE, V18, P6029, DOI 10.1038/sj.onc.1202983; Bin OY, 1997, J BIOL CHEM, V272, P28646, DOI 10.1074/jbc.272.45.28646; Carmena M, 1998, J CELL BIOL, V143, P659, DOI 10.1083/jcb.143.3.659; Charles JF, 1998, CURR BIOL, V8, P497, DOI 10.1016/S0960-9822(98)70201-5; Chase D, 1998, BIOCHEM J, V333, P655, DOI 10.1042/bj3330655; Cutler RE, 1997, EMBO J, V16, P1953, DOI 10.1093/emboj/16.8.1953; Descombes P, 1998, EMBO J, V17, P1328, DOI 10.1093/emboj/17.5.1328; Dietzmann K, 2001, J NEURO-ONCOL, V53, P1, DOI 10.1023/A:1011808200978; Ellinger-Ziegelbauer H, 2000, GENES CELLS, V5, P491, DOI 10.1046/j.1365-2443.2000.00337.x; Ferris DK, 1998, BIOCHEM BIOPH RES CO, V252, P340, DOI 10.1006/bbrc.1998.9648; Golan A, 2002, J BIOL CHEM, V277, P15552, DOI 10.1074/jbc.M111476200; GOLSTEYN RM, 1994, J CELL SCI, V107, P1509; HAMANAKA R, 1995, J BIOL CHEM, V270, P21086, DOI 10.1074/jbc.270.36.21086; Jang YJ, 2002, J BIOL CHEM, V277, P44115, DOI 10.1074/jbc.M202172200; Kelm O, 2002, J BIOL CHEM, V277, P25247, DOI 10.1074/jbc.M202855200; Knecht R, 1999, CANCER RES, V59, P2794; Knecht R, 2000, INT J CANCER, V89, P535; Kotani S, 1998, MOL CELL, V1, P371, DOI 10.1016/S1097-2765(00)80037-4; Kumagai A, 1996, SCIENCE, V273, P1377, DOI 10.1126/science.273.5280.1377; Kuramochi S, 1999, IMMUNOGENETICS, V49, P369, DOI 10.1007/s002510050509; Kuramochi S, 1997, J BIOL CHEM, V272, P22679, DOI 10.1074/jbc.272.36.22679; Liu XQ, 2002, P NATL ACAD SCI USA, V99, P8672, DOI 10.1073/pnas.132269599; Mundt KE, 1997, BIOCHEM BIOPH RES CO, V239, P377, DOI 10.1006/bbrc.1997.7378; Nigg EA, 1998, CURR OPIN CELL BIOL, V10, P776, DOI 10.1016/S0955-0674(98)80121-X; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; OHKURA H, 1995, GENE DEV, V9, P1059, DOI 10.1101/gad.9.9.1059; Qian YW, 1998, MOL CELL BIOL, V18, P4262, DOI 10.1128/MCB.18.7.4262; Qian YW, 1998, SCIENCE, V282, P1701, DOI 10.1126/science.282.5394.1701; Roshak AK, 2000, CELL SIGNAL, V12, P405, DOI 10.1016/S0898-6568(00)00080-2; Shirayama M, 1998, EMBO J, V17, P1336, DOI 10.1093/emboj/17.5.1336; Simizu S, 2000, NAT CELL BIOL, V2, P852, DOI 10.1038/35041102; Smith MR, 1997, BIOCHEM BIOPH RES CO, V234, P397, DOI 10.1006/bbrc.1997.6633; SUNKEL CE, 1988, J CELL SCI, V89, P25; Takai N, 2001, CANCER LETT, V164, P41, DOI 10.1016/S0304-3835(00)00703-5; Tokumitsu Y, 1999, INT J ONCOL, V15, P687; Toyoshima-Morimoto F, 2002, EMBO REP, V3, P341, DOI 10.1093/embo-reports/kvf069; Toyoshima-Morimoto F, 2001, NATURE, V410, P215, DOI 10.1038/35065617; Uchiumi T, 1997, J BIOL CHEM, V272, P9166; Wolf G, 1997, ONCOGENE, V14, P543, DOI 10.1038/sj.onc.1200862; Yuan JP, 2002, ONCOGENE, V21, P8282, DOI 10.1038/sj.onc.1206011	40	43	46	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 16	2003	278	20					18221	18228		10.1074/jbc.M212556200	http://dx.doi.org/10.1074/jbc.M212556200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677YX	12639966	hybrid			2022-12-25	WOS:000182838300083
J	Chen, Y; Wen, RR; Yang, S; Shuman, J; Zhang, EE; Yi, TL; Feng, GS; Wang, DM				Chen, Y; Wen, RR; Yang, S; Shuman, J; Zhang, EE; Yi, TL; Feng, GS; Wang, DM			Identification of Shp-2 as a Stat5A phosphatase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE-PHOSPHATASE; COLONY-STIMULATING FACTOR; SIGNAL-TRANSDUCTION; GROWTH-HORMONE; ERYTHROPOIETIN RECEPTOR; HEMATOPOIETIC-CELLS; NEGATIVE REGULATOR; PATHWAY; PROLACTIN; DEPHOSPHORYLATION	Stat5A, a member of the signal transducers and activators of transcription (Stat) family, is activated upon a single tyrosine phosphorylation. Although much is known about the activation process, the mechanism by which the tyrosine-phosphorylated Stat5A proteins are inactivated is largely unknown. In this report, we demonstrate that down-regulation of the tyrosine-phosphorylated Stat5A was via dephosphorylation. Using tyrosine-phosphorylated peptides derived from Stat5A, we were able to purify protein-tyrosine phosphatase Shp-2 from cell lysates. Shp-2, but not Shp-1, specifically interacted with Stat5A in vivo, and the interaction was tyrosine phosphorylation-dependent. Moreover, Shp-2 was able to accelerate Stat5A dephosphorylation, and dephosphorylation of Stat5A was dramatically delayed in Shp-2-deficient cells. Therefore, we conclude that Shp-2 is a Stat5A phosphatase, which down-regulates the active Stat5A in vivo.	Blood Ctr SE Wisconsin Inc, Blood Res Inst, Milwaukee, WI 53226 USA; Nanjing Univ, Inst Mol Med, Nanjing 210008, Peoples R China; Cleveland Clin Fdn, Res Inst, Dept Canc Biol, Cleveland, OH 44195 USA; Burnham Inst, La Jolla, CA 92037 USA; Med Coll Wisconsin, Dept Microbiol & Mol Genet, Milwaukee, WI 53226 USA	Versiti Blood Center of Wisconsin; Nanjing University; Cleveland Clinic Foundation; Sanford Burnham Prebys Medical Discovery Institute; Medical College of Wisconsin	Wang, DM (corresponding author), Blood Ctr SE Wisconsin Inc, Blood Res Inst, 8727 Watertown Plank Rd, Milwaukee, WI 53226 USA.		Wang, Demin/AAX-4449-2020	Wang, Demin/0000-0001-5549-3795; Zhang, Eric/0000-0002-4472-7493	NCI NIH HHS [R01 CA78606, 1R01CA79891] Funding Source: Medline; NHLBI NIH HHS [R01 HL073284] Funding Source: Medline; NIAID NIH HHS [R01 AI52327-01] Funding Source: Medline; NIGMS NIH HHS [1R01GM58893, R01GM53660] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA078606, R01CA079891] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL073284] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI052327] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM058893, R01GM053660] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ali S, 1996, EMBO J, V15, P135, DOI 10.1002/j.1460-2075.1996.tb00341.x; Aoki N, 2002, MOL ENDOCRINOL, V16, P58, DOI 10.1210/me.16.1.58; Aoki N, 2000, J BIOL CHEM, V275, P39718, DOI 10.1074/jbc.M005615200; Chen XP, 2000, IMMUNITY, V13, P287, DOI 10.1016/S1074-7613(00)00028-5; Chung CD, 1997, SCIENCE, V278, P1803, DOI 10.1126/science.278.5344.1803; Clauser KR, 1999, ANAL CHEM, V71, P2871, DOI 10.1021/ac9810516; Craggs G, 2001, J BIOL CHEM, V276, P23719, DOI 10.1074/jbc.M102846200; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; Feng GS, 1999, EXP CELL RES, V253, P47, DOI 10.1006/excr.1999.4668; FENG GS, 1994, TRENDS GENET, V10, P54, DOI 10.1016/0168-9525(94)90149-X; FUHRER DK, 1995, J BIOL CHEM, V270, P24826, DOI 10.1074/jbc.270.42.24826; Fujioka Y, 1996, MOL CELL BIOL, V16, P6887; GOUILLEUX F, 1995, EMBO J, V14, P2005, DOI 10.1002/j.1460-2075.1995.tb07192.x; Gu HH, 1997, J BIOL CHEM, V272, P16421, DOI 10.1074/jbc.272.26.16421; Haspel RL, 1996, EMBO J, V15, P6262, DOI 10.1002/j.1460-2075.1996.tb01016.x; HolgadoMadruga M, 1996, NATURE, V379, P560, DOI 10.1038/379560a0; HOU JZ, 1995, IMMUNITY, V2, P321, DOI 10.1016/1074-7613(95)90140-X; Ihle JN, 2001, CURR OPIN CELL BIOL, V13, P211, DOI 10.1016/S0955-0674(00)00199-X; IHLE JN, 1995, NATURE, V377, P591, DOI 10.1038/377591a0; Ihle JN, 1996, CELL, V84, P331, DOI 10.1016/S0092-8674(00)81277-5; Irie-Sasaki J, 2001, NATURE, V409, P349, DOI 10.1038/35053086; Jiao HY, 1996, MOL CELL BIOL, V16, P6985; Kharitonenkov A, 1997, NATURE, V386, P181, DOI 10.1038/386181a0; Kim SO, 1998, J BIOL CHEM, V273, P2344, DOI 10.1074/jbc.273.4.2344; Kim TK, 1996, SCIENCE, V273, P1717, DOI 10.1126/science.273.5282.1717; KLINGHOFFER RA, 1995, J BIOL CHEM, V270, P22208, DOI 10.1074/jbc.270.38.22208; KLINGMULLER U, 1995, CELL, V80, P729, DOI 10.1016/0092-8674(95)90351-8; LIN JX, 1995, IMMUNITY, V2, P331, DOI 10.1016/1074-7613(95)90141-8; Liu XW, 1997, GENE DEV, V11, P179, DOI 10.1101/gad.11.2.179; Moriggl R, 1999, IMMUNITY, V10, P249, DOI 10.1016/S1074-7613(00)80025-4; MUI ALF, 1995, EMBO J, V14, P1166, DOI 10.1002/j.1460-2075.1995.tb07100.x; Myers MG, 1998, J BIOL CHEM, V273, P26908, DOI 10.1074/jbc.273.41.26908; Neel BG, 1997, CURR OPIN CELL BIOL, V9, P193, DOI 10.1016/S0955-0674(97)80063-4; PALLARD C, 1995, EMBO J, V14, P2847, DOI 10.1002/j.1460-2075.1995.tb07284.x; Quelle FW, 1996, MOL CELL BIOL, V16, P1622; Rolling C, 1996, FEBS LETT, V393, P53, DOI 10.1016/0014-5793(96)00835-6; Saxton TM, 1997, EMBO J, V16, P2352, DOI 10.1093/emboj/16.9.2352; Stancato LF, 1997, MOL CELL BIOL, V17, P3833, DOI 10.1128/MCB.17.7.3833; Strous GJ, 1996, EMBO J, V15, P3806, DOI 10.1002/j.1460-2075.1996.tb00754.x; Teglund S, 1998, CELL, V93, P841, DOI 10.1016/S0092-8674(00)81444-0; ten Hoeve J, 2002, MOL CELL BIOL, V22, P5662, DOI 10.1128/MCB.22.16.5662-5668.2002; Tonks NK, 2001, CURR OPIN CELL BIOL, V13, P182, DOI 10.1016/S0955-0674(00)00196-4; Udy GB, 1997, P NATL ACAD SCI USA, V94, P7239, DOI 10.1073/pnas.94.14.7239; WAKAO H, 1994, EMBO J, V13, P2182, DOI 10.1002/j.1460-2075.1994.tb06495.x; Wang DM, 1996, MOL CELL BIOL, V16, P6141; Wang DM, 2000, EMBO J, V19, P392, DOI 10.1093/emboj/19.3.392; WITTHUHN BA, 1993, CELL, V74, P227, DOI 10.1016/0092-8674(93)90414-L; YI TL, 1995, BLOOD, V85, P87, DOI 10.1182/blood.V85.1.87.bloodjournal85187; Yin TG, 1997, J BIOL CHEM, V272, P1032, DOI 10.1074/jbc.272.2.1032; Yokoyama N, 2001, J INTERF CYTOK RES, V21, P369, DOI 10.1089/107999001750277844; You M, 1999, MOL CELL BIOL, V19, P2416, DOI 10.1128/mcb.19.3.2416; Yu CL, 2000, J BIOL CHEM, V275, P599, DOI 10.1074/jbc.275.1.599	53	89	92	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 9	2003	278	19					16520	16527		10.1074/jbc.M210572200	http://dx.doi.org/10.1074/jbc.M210572200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677QG	12615921	hybrid			2022-12-25	WOS:000182818600012
J	Chen, Y; Thai, P; Zhao, YH; Ho, YS; DeSouza, MM; Wu, R				Chen, Y; Thai, P; Zhao, YH; Ho, YS; DeSouza, MM; Wu, R			Stimulation of airway mucin gene expression by interleukin (IL)-17 through IL-6 paracrine/autocrine loop	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RESPIRATORY EPITHELIAL-CELLS; NECROSIS-FACTOR-ALPHA; NEUTROPHIL ELASTASE; MUCOCILIARY DIFFERENTIATION; MUCUS ACCUMULATION; PROTEIN EXPRESSION; TRANSGENIC MICE; MESSENGER-RNA; MUC5B MUCIN; IN-VIVO	Mucus hypersecretion and persistent airway inflammation are common features of various airway diseases, such as asthma, chronic obstructive pulmonary disease, and cystic fibrosis. One key question is: does the associated airway inflammation in these diseases affect mucus production? If so, what is the underlying mechanism? It appears that increased mucus secretion results from increased mucin gene expression and is also frequently accompanied by an increased number of mucous cells (goblet cell hyperplasia/metaplasia) in the airway epithelium. Many studies on mucin gene expression have been directed toward Th2 cytokines such as interleukin (IL)-4, IL-9, and IL-13 because of their known pathophysiological role in allergic airway diseases such as asthma. However, the effect of these cytokines has not been definitely linked to their direct interaction with airway epithelial cells. In our study, we treated highly differentiated cultures of primary human tracheobronchial epithelial (TBE) cells with a panel of cytokines (interleukin-1alpha, 1beta, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 15, 16, 17, 18, and tumor necrosis factor alpha). We found that IL-6 and IL-17 could stimulate the mucin genes, MUC5B and MUC5AC. The Th2 cytokines IL-4, IL-9, and IL-13 did not stimulate MUC5AC or MUC5B in our experiments. A similar stimulation of MUC5B/Muc5b expression by IL-6 and IL-17 was demonstrated in primary monkey and mouse TBE cells. Further investigation of MUC5B expression demonstrated that IL-17's effect is at least partly mediated through IL-6 by a JAK2-dependent autocrine/paracrine loop. Finally, evidence is presented to show that both IL-6 and IL-17 mediate MUC5B expression through the ERK signaling pathway.	Univ Calif Davis, Ctr Comparat Resp Biol & Med, Davis, CA 95616 USA; Univ Calif Davis, Div Pulm & Crit Care Med, Davis, CA 95616 USA; Wayne State Univ, Inst Environm Hlth Sci, Detroit, MI 48201 USA; GlaxoSmithKline, King Of Prussia, PA 19406 USA	University of California System; University of California Davis; University of California System; University of California Davis; Wayne State University; GlaxoSmithKline	Wu, R (corresponding author), Univ Calif Davis, Ctr Comparat Resp Biol & Med, Surge 1 Annex,Room 1121,1 Shields Ave, Davis, CA 95616 USA.	rwu@ucdavis.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL035635, R37HL035635] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P42ES004699, R01ES006230, R01ES009701] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL35635] Funding Source: Medline; NIAID NIH HHS [AI50496] Funding Source: Medline; NIEHS NIH HHS [ES05707, ES04699, ES00628, ES06230, ES09701] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Aaronson DS, 2002, SCIENCE, V296, P1653, DOI 10.1126/science.1071545; AIKAWA T, 1992, CHEST, V101, P916, DOI 10.1378/chest.101.4.916; Alimam MZ, 2000, AM J RESP CELL MOL, V22, P253, DOI 10.1165/ajrcmb.22.3.3768; Antonysamy MA, 1999, J IMMUNOL, V162, P577; Borchers MT, 1999, AM J PHYSIOL-LUNG C, V276, pL549, DOI 10.1152/ajplung.1999.276.4.L549; Burgel PR, 2001, J IMMUNOL, V167, P5948, DOI 10.4049/jimmunol.167.10.5948; Carroll N, 1996, EUR RESPIR J, V9, P709, DOI 10.1183/09031936.96.09040709; Chabaud M, 2001, ARTHRITIS RES, V3, P168, DOI 10.1186/ar294; Chen Y, 2001, AM J RESP CELL MOL, V25, P542, DOI 10.1165/ajrcmb.25.5.4298; Chen Y, 2001, AM J RESP CELL MOL, V25, P409, DOI 10.1165/ajrcmb.25.4.4413; Chen Y, 2001, AM J RESP CRIT CARE, V164, P1059, DOI 10.1164/ajrccm.164.6.2012114; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Chung KF, 2001, EUR RESPIR J, V18, p50S, DOI 10.1183/09031936.01.00229701; COHN LA, 1992, EXP LUNG RES, V18, P299, DOI 10.3109/01902149209031687; Dabbagh K, 1999, J IMMUNOL, V162, P6233; Davies JR, 1999, BIOCHEM J, V344, P321, DOI 10.1042/0264-6021:3440321; Debailleul V, 1998, J BIOL CHEM, V273, P881, DOI 10.1074/jbc.273.2.881; DICOSMO BF, 1994, J CLIN INVEST, V94, P2028, DOI 10.1172/JCI117556; Fischer BM, 2002, AM J RESP CELL MOL, V26, P447, DOI 10.1165/ajrcmb.26.4.4473; Fossiez F, 1996, J EXP MED, V183, P2593, DOI 10.1084/jem.183.6.2593; Gray TE, 1996, AM J RESP CELL MOL, V14, P104, DOI 10.1165/ajrcmb.14.1.8534481; Grunig G, 1998, SCIENCE, V282, P2261, DOI 10.1126/science.282.5397.2261; Hellings PW, 2003, AM J RESP CELL MOL, V28, P42, DOI 10.1165/rcmb.4832; Hirano T, 1998, Int Rev Immunol, V16, P249; Hovenberg HW, 1996, BIOCHEM J, V318, P319, DOI 10.1042/bj3180319; Hovenberg HW, 1996, GLYCOCONJUGATE J, V13, P839, DOI 10.1007/BF00702348; Hsieh HG, 2002, CYTOKINE, V19, P159, DOI 10.1006/cyto.2002.1952; Jayawickreme SP, 1999, AM J PHYSIOL-LUNG C, V276, pL596, DOI 10.1152/ajplung.1999.276.4.L596; Jeffery PK, 2000, CHEST, V117, p251S, DOI 10.1378/chest.117.5_suppl_1.251S; Jeffery PK, 2001, AM J RESP CRIT CARE, V164, pS28, DOI 10.1164/ajrccm.164.supplement_2.2106061; KALINER M, 1986, AM REV RESPIR DIS, V134, P612; Kim CH, 2002, ACTA OTO-LARYNGOL, V122, P638, DOI 10.1080/000164802320396321; Kim YD, 2002, MOL PHARMACOL, V62, P1112, DOI 10.1124/mol.62.5.1112; KING M, 1980, FED PROC, V39, P3080; Kips JC, 2001, EUR RESPIR J, V18, p24S, DOI 10.1183/09031936.01.00229601; Kondo M, 2002, AM J RESP CELL MOL, V27, P536, DOI 10.1165/rcmb.4682; Koo JS, 2002, EXP LUNG RES, V28, P315, DOI 10.1080/01902140252964393; Laan M, 1999, J IMMUNOL, V162, P2347; Laoukili J, 2001, J CLIN INVEST, V108, P1817, DOI 10.1172/JCI13557; Leonard WJ, 1998, ANNU REV IMMUNOL, V16, P293, DOI 10.1146/annurev.immunol.16.1.293; LEVINE SJ, 1995, AM J RESP CELL MOL, V12, P196, DOI 10.1165/ajrcmb.12.2.7865217; Longphre M, 1999, J CLIN INVEST, V104, P1375, DOI 10.1172/JCI6097; Louahed J, 2000, AM J RESP CELL MOL, V22, P649, DOI 10.1165/ajrcmb.22.6.3927; McKenzie RW, 2000, INVEST OPHTH VIS SCI, V41, P703; McMillan S, 2002, J EXP MED, V195, P51, DOI 10.1084/jem.20011732; Molet S, 2001, J ALLERGY CLIN IMMUN, V108, P430, DOI 10.1067/mai.2001.117929; MURRAY JF, 2000, TXB RESP MED, P443; Nakae S, 2002, IMMUNITY, V17, P375, DOI 10.1016/S1074-7613(02)00391-6; Ogata A, 1997, J IMMUNOL, V159, P2212; Puthier D, 1999, EUR J IMMUNOL, V29, P3945, DOI 10.1002/(SICI)1521-4141(199912)29:12<3945::AID-IMMU3945>3.0.CO;2-O; Rose MC, 2000, J AEROSOL MED, V13, P245, DOI 10.1089/jam.2000.13.245; SCHNEEBERGER EE, 1978, J CELL SCI, V32, P307; Sheehan JK, 1999, BIOCHEM J, V338, P507, DOI 10.1042/0264-6021:3380507; Shim JJ, 2001, AM J PHYSIOL-LUNG C, V280, pL134, DOI 10.1152/ajplung.2001.280.1.L134; Singer M, 2002, AM J RESP CELL MOL, V26, P74, DOI 10.1165/ajrcmb.26.1.4618; STAHL N, 1994, SCIENCE, V263, P92, DOI 10.1126/science.8272873; Subramaniam SV, 1999, BIOCHEM BIOPH RES CO, V259, P172, DOI 10.1006/bbrc.1999.0746; Subramaniam SV, 1999, BIOCHEM BIOPH RES CO, V262, P14, DOI 10.1006/bbrc.1999.1156; Temann UA, 1998, J EXP MED, V188, P1307, DOI 10.1084/jem.188.7.1307; Temann UA, 1997, AM J RESP CELL MOL, V16, P471, DOI 10.1165/ajrcmb.16.4.9115759; Thornton DJ, 1997, J BIOL CHEM, V272, P9561; Thornton DJ, 1996, BIOCHEM J, V316, P967, DOI 10.1042/bj3160967; Thornton DJ, 2000, AM J PHYSIOL-LUNG C, V278, pL1118, DOI 10.1152/ajplung.2000.278.6.L1118; Townsend MJ, 2000, IMMUNITY, V13, P573, DOI 10.1016/S1074-7613(00)00056-X; Voynow JA, 1999, AM J PHYSIOL-LUNG C, V276, pL835; Voynow Judith A, 2002, Paediatr Respir Rev, V3, P98, DOI 10.1016/S1526-0550(02)00007-0; Wills-Karp M, 1998, SCIENCE, V282, P2258, DOI 10.1126/science.282.5397.2258; Witowski J, 2000, J IMMUNOL, V165, P5814, DOI 10.4049/jimmunol.165.10.5814; Wu R, 1997, EUR RESPIR J, V10, P2398, DOI 10.1183/09031936.97.10102398; WU R, 1986, IN VITRO MODELS RESP, P1; Ye P, 2001, J EXP MED, V194, P519, DOI 10.1084/jem.194.4.519; YOO ZB, 1995, J IMMUNOL, V155, P5483; Zhou Z, 1999, J CLIN INVEST, V103, P779, DOI 10.1172/JCI5909; Ziolkowska N, 2000, J IMMUNOL, V164, P2832, DOI 10.4049/jimmunol.164.5.2832	74	429	453	2	30	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 9	2003	278	19					17036	17043		10.1074/jbc.M210429200	http://dx.doi.org/10.1074/jbc.M210429200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677QG	12624114	hybrid			2022-12-25	WOS:000182818600080
J	Gu, ZL; Zhong, P; Yan, Z				Gu, ZL; Zhong, P; Yan, Z			Activation of muscarinic receptors inhibits beta-amyloid peptide-induced signaling in cortical slices	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; LONG-TERM POTENTIATION; FOCAL ADHESION KINASE; ALZHEIMERS-DISEASE; PRECURSOR PROTEIN; TRANSGENIC MICE; TYROSINE PHOSPHORYLATION; ACETYLCHOLINE-RECEPTOR; SYNAPTIC PLASTICITY; BASAL FOREBRAIN	Deposition of fibrillar aggregates of the beta-amyloid peptide (Abeta)is a key pathologic feature during the early stage of Alzheimer's disease. The initial neuronal responses to Abeta in cortical circuits and the regulation of Abeta-induced signaling remain unclear. In this study, we found that exposure of cortical slices to Abeta(1-42) or Abeta(25-35) induced a marked increase in the activation of protein kinase C (PKC) and Ca2+/calmodulin-dependent kinase II (CaMKII), two enzymes critically involved in a variety of cellular functions. Activation of M1 muscarinic receptors, but not nicotinic receptors, significantly inhibited the Abeta activation of PKC and CaMKII. Increasing inhibitory transmission mimicked the M1 effect on Abeta, whereas blocking GABA(A) receptors eliminated the M1 action. Moreover, electrophysiological evidence shows that application of Abeta to cortical slices induced action potential firing and enhanced excitatory postsynaptic currents, whereas muscarinic agonists potently increased inhibitory postsynaptic currents. These results suggest that Abeta activates PKC and CaMKII through enhancing excitatory activity in glutamatergic synaptic networks. Activation of M1 receptors inhibits Abeta signaling by enhancing the counteracting GABA(ergic) inhibitory transmission. Thus the muscarinic reversal of the Abeta-induced biochemical and physiological changes provides a potential mechanism for the treatment of Alzheimer's disease with cholinergic enhancers.	SUNY Buffalo, Dept Physiol & Biophys, Sch Med & Biomed Sci, Buffalo, NY 14214 USA	State University of New York (SUNY) System; State University of New York (SUNY) Buffalo	Yan, Z (corresponding author), SUNY Buffalo, Dept Physiol & Biophys, Sch Med & Biomed Sci, 124 Sherman Hall, Buffalo, NY 14214 USA.				NIMH NIH HHS [MH63128] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH063128] Funding Source: NIH RePORTER	NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Adem A, 1997, LIFE SCI, V60, P1069, DOI 10.1016/S0024-3205(97)00049-0; Auld DS, 1998, TRENDS NEUROSCI, V21, P43, DOI 10.1016/S0166-2236(97)01144-2; Barria A, 1997, SCIENCE, V276, P2042, DOI 10.1126/science.276.5321.2042; Behn-Krappa A, 1999, CURR BIOL, V9, P728, DOI 10.1016/S0960-9822(99)80332-7; BONNER TI, 1987, SCIENCE, V237, P527, DOI 10.1126/science.3037705; BRORSON JR, 1995, J NEUROBIOL, V26, P325, DOI 10.1002/neu.480260305; BUCKLEY NJ, 1989, MOL PHARMACOL, V35, P469; Cai X, 2002, J PHYSIOL-LONDON, V540, P743; Chapman PF, 1999, NAT NEUROSCI, V2, P271, DOI 10.1038/6374; Chen GQ, 2000, NATURE, V408, P975, DOI 10.1038/35050103; Combs CK, 1999, J NEUROSCI, V19, P928; COYLE JT, 1983, SCIENCE, V219, P1184, DOI 10.1126/science.6338589; DAVIDSON RM, 1994, BRAIN RES, V643, P324, DOI 10.1016/0006-8993(94)90041-8; Esler WP, 2001, SCIENCE, V293, P1449, DOI 10.1126/science.1064638; Feng J, 2001, J NEUROSCI, V21, P6502, DOI 10.1523/JNEUROSCI.21-17-06502.2001; Fisher A, 2000, ANN NY ACAD SCI, V920, P315; Fraser SP, 1997, TRENDS NEUROSCI, V20, P67, DOI 10.1016/S0166-2236(96)10079-5; FURUKAWA K, 1994, NEUROREPORT, V5, P2016, DOI 10.1097/00001756-199410270-00006; GAMES D, 1995, NATURE, V373, P523, DOI 10.1038/373523a0; HAASS C, 1992, NATURE, V359, P325; HAMMER R, 1980, NATURE, V283, P90, DOI 10.1038/283090a0; Hoshi M, 1997, J BIOL CHEM, V272, P2038, DOI 10.1074/jbc.272.4.2038; Hsiao K, 1998, PROG BRAIN RES, V117, P335; Hsiao K, 1996, SCIENCE, V274, P99, DOI 10.1126/science.274.5284.99; HUNG AY, 1993, J BIOL CHEM, V268, P22959; Irizarry MC, 1997, J NEUROSCI, V17, P7053; Jhamandas JH, 2001, J NEUROPHYSIOL, V86, P1312, DOI 10.1152/jn.2001.86.3.1312; Jope RS, 1997, NEUROBIOL AGING, V18, P111, DOI 10.1016/S0197-4580(96)00205-9; Kar S, 1996, J NEUROSCI, V16, P1034; Kawaguchi Y, 1997, J NEUROPHYSIOL, V78, P1743, DOI 10.1152/jn.1997.78.3.1743; Kelly JF, 1996, P NATL ACAD SCI USA, V93, P6753, DOI 10.1073/pnas.93.13.6753; KOH JY, 1990, BRAIN RES, V533, P315, DOI 10.1016/0006-8993(90)91355-K; Kondo S, 2001, NEUROSCIENCE, V107, P551, DOI 10.1016/S0306-4522(01)00388-8; LEVEY AI, 1991, J NEUROSCI, V11, P3218; Lin L, 1999, P NATL ACAD SCI USA, V96, P12108, DOI 10.1073/pnas.96.21.12108; LUO YQ, 1995, BRAIN RES, V681, P65, DOI 10.1016/0006-8993(95)00282-U; MASTERS CL, 1985, P NATL ACAD SCI USA, V82, P4245, DOI 10.1073/pnas.82.12.4245; MATTSON MP, 1992, J NEUROSCI, V12, P376, DOI 10.1523/jneurosci.12-02-00376.1992; MATTSON MP, 1993, TRENDS NEUROSCI, V16, P409, DOI 10.1016/0166-2236(93)90009-B; McDonald DR, 1998, J NEUROSCI, V18, P4451; Messer William S. Jr., 2002, Current Topics in Medicinal Chemistry, V2, P353, DOI 10.2174/1568026024607553; MILLER SG, 1988, NEURON, V1, P593, DOI 10.1016/0896-6273(88)90109-2; MILLER SG, 1986, CELL, V44, P861, DOI 10.1016/0092-8674(86)90008-5; NATHANSON NM, 1987, ANNU REV NEUROSCI, V10, P195, DOI 10.1146/annurev.ne.10.030187.001211; Nayak AS, 1996, P NATL ACAD SCI USA, V93, P15451, DOI 10.1073/pnas.93.26.15451; NITSCH RM, 1992, SCIENCE, V258, P304, DOI 10.1126/science.1411529; PIKE CJ, 1991, BRAIN RES, V563, P311, DOI 10.1016/0006-8993(91)91553-D; Quinlan EM, 1996, J NEUROSCI, V16, P7627; Selkoe DJ, 1998, TRENDS CELL BIOL, V8, P447, DOI 10.1016/S0962-8924(98)01363-4; Selkoe DJ, 1996, J BIOL CHEM, V271, P18295, DOI 10.1074/jbc.271.31.18295; Serpell LC, 2000, BBA-MOL BASIS DIS, V1502, P16, DOI 10.1016/S0925-4439(00)00029-6; SEUBERT P, 1992, NATURE, V359, P325, DOI 10.1038/359325a0; SIMMONS MA, 1993, NEUROSCI LETT, V150, P133, DOI 10.1016/0304-3940(93)90519-Q; SITARAM N, 1978, SCIENCE, V201, P274, DOI 10.1126/science.351808; Small DH, 2001, NAT REV NEUROSCI, V2, P595, DOI 10.1038/35086072; Soderling TR, 2000, CURR OPIN NEUROBIOL, V10, P375, DOI 10.1016/S0959-4388(00)00090-8; Sommer B, 2002, CURR OPIN PHARMACOL, V2, P87, DOI 10.1016/S1471-4892(01)00126-6; Stewart AE, 1999, J NEUROPHYSIOL, V81, P72, DOI 10.1152/jn.1999.81.1.72; TANAKA C, 1994, ANNU REV NEUROSCI, V17, P551, DOI 10.1146/annurev.ne.17.030194.003003; Tanzi RE, 2001, NEURON, V32, P181, DOI 10.1016/S0896-6273(01)00476-7; TERZI E, 1994, BIOCHEMISTRY-US, V33, P1345, DOI 10.1021/bi00172a009; Vassar R, 2000, NEURON, V27, P419, DOI 10.1016/S0896-6273(00)00051-9; Weinstock M, 1995, NEURODEGENERATION, V4, P349, DOI 10.1006/neur.1995.0042; WEISS JH, 1994, J NEUROCHEM, V62, P372; WHITEHOUSE PJ, 1982, SCIENCE, V215, P1237, DOI 10.1126/science.7058341; WHITEHOUSE PJ, 1981, ANN NEUROL, V10, P122, DOI 10.1002/ana.410100203; Williamson R, 2002, J NEUROSCI, V22, P10, DOI 10.1523/JNEUROSCI.22-01-00010.2002; WINKLER J, 1995, NATURE, V375, P484, DOI 10.1038/375484a0; YANKNER BA, 1989, SCIENCE, V245, P417, DOI 10.1126/science.2474201; YANKNER BA, 1990, SCIENCE, V250, P279, DOI 10.1126/science.2218531; ZHANG C, 1994, J BIOL CHEM, V269, P25247	71	43	52	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 9	2003	278	19					17546	17556		10.1074/jbc.M209892200	http://dx.doi.org/10.1074/jbc.M209892200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677QG	12606559	hybrid			2022-12-25	WOS:000182818600144
J	Yang, L; Lin, HK; Altuwaijri, S; Xie, SZ; Wang, L; Chang, C				Yang, L; Lin, HK; Altuwaijri, S; Xie, SZ; Wang, L; Chang, C			APPL suppresses androgen receptor transactivation via potentiating Akt activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROSTATE-CANCER CELLS; PROTEIN-KINASE; PHOSPHATIDYLINOSITOL 3-KINASE; MOLECULAR-CLONING; INDUCED APOPTOSIS; C-AKT; SURVIVAL; COACTIVATOR; GROWTH; RAS	APPL may function as an adapter protein to modulate the phosphatidylinositol 3-kinase (PI3K)/Akt pathway. Although we have previously proven that the PI3K/Akt pathway can suppress androgen receptor (AR) transactivation, the potential linkage from APPL to the AR remains unclear. Here we demonstrated that APPL could suppress AR-mediated transactivation in a dose-dependent manner in LNCaP and PC-3 cells. This suppressive effect could be blocked by either dominant-negative Akt or dominant-negative PI3K or LY294002, suggesting that the APPL-mediated suppression of AR transactivation is dependent on the PI3K/Akt pathway. We also observed that APPL could further enhance the Akt-mediated suppression of AR transactivation and AR target gene using the reporter gene and Northern blot assay. APPL was able to enhance insulin-like growth factor (IGF-1)-mediated Akt activation. The abrogation of IGF-1-mediated Akt activation by the dominant-negative PI3K or LY294002 or antisense APPL suggests that APPL may function as an important adapter protein in controlling the IGF-1 --> Akt signal pathway. Co-immunoprecipitation and glutathione S-transferase pull-down assays suggest that APPL, Akt, and AR may exist in a complex and Akt may serve as an important bridge factor for the association of APPL with AR. Together, our data indicate that APPL may suppress AR transactivation via potentiating Akt activity.	Univ Rochester, Med Ctr, Dept Pathol, George Whipple Lab Canc Res, Rochester, NY 14642 USA; Univ Rochester, Med Ctr, Dept Urol, George Whipple Lab Canc Res, Rochester, NY 14642 USA; Univ Rochester, Med Ctr, Dept Radiat Oncol, George Whipple Lab Canc Res, Rochester, NY 14642 USA; Univ Rochester, Med Ctr, Ctr Canc, Rochester, NY 14642 USA	University of Rochester; University of Rochester; University of Rochester; University of Rochester	Chang, C (corresponding author), Univ Rochester, Med Ctr, Dept Pathol, George Whipple Lab Canc Res, Rochester, NY 14642 USA.	chang@urmc.rochester.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK060905, R01DK060948] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK60905, DK60948] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Andjelkovic M, 1996, P NATL ACAD SCI USA, V93, P5699, DOI 10.1073/pnas.93.12.5699; BELLACOSA A, 1993, ONCOGENE, V8, P745; BRESNICK EH, 1994, J BIOL CHEM, V269, P21110; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Campbell RA, 2001, J BIOL CHEM, V276, P9817, DOI 10.1074/jbc.M010840200; Cardone MH, 1998, SCIENCE, V282, P1318, DOI 10.1126/science.282.5392.1318; Carpenter CL, 1996, CURR OPIN CELL BIOL, V8, P153, DOI 10.1016/S0955-0674(96)80060-3; CHANG CS, 1995, CRIT REV EUKAR GENE, V5, P97, DOI 10.1615/CritRevEukarGeneExpr.v5.i2.10; CHANG CS, 1988, SCIENCE, V240, P324, DOI 10.1126/science.3353726; Coffer PJ, 1998, BIOCHEM J, V335, P1; Crowder RJ, 1998, J NEUROSCI, V18, P2933; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; Feldman BJ, 2001, NAT REV CANCER, V1, P34, DOI 10.1038/35094009; Franke TF, 1997, CELL, V88, P435, DOI 10.1016/S0092-8674(00)81883-8; Fujimoto N, 1999, J BIOL CHEM, V274, P8316, DOI 10.1074/jbc.274.12.8316; Greenlee RT, 2000, CA-CANCER J CLIN, V50, P7, DOI 10.3322/canjclin.50.1.7; Hsiao PW, 2000, MOL CELL BIOCHEM, V206, P169, DOI 10.1023/A:1007024726889; HU QJ, 1995, SCIENCE, V268, P100, DOI 10.1126/science.7701328; Inoue T, 1999, J BIOL CHEM, V274, P32309, DOI 10.1074/jbc.274.45.32309; Kang HY, 1999, J BIOL CHEM, V274, P8570, DOI 10.1074/jbc.274.13.8570; Kang HY, 2001, P NATL ACAD SCI USA, V98, P3018, DOI 10.1073/pnas.061305498; KauffmanZeh A, 1997, NATURE, V385, P544, DOI 10.1038/385544a0; KAVANAUGH WM, 1994, SCIENCE, V266, P1862, DOI 10.1126/science.7527937; Lin HK, 2001, P NATL ACAD SCI USA, V98, P7200, DOI 10.1073/pnas.121173298; Lin JQ, 1999, CANCER RES, V59, P2891; Manin M, 2002, BIOCHEM J, V366, P729, DOI 10.1042/BJ20020585; Masure S, 1999, EUR J BIOCHEM, V265, P353, DOI 10.1046/j.1432-1327.1999.00774.x; Medema RH, 2000, NATURE, V404, P782, DOI 10.1038/35008115; Mitsuuchi Y, 1999, ONCOGENE, V18, P4891, DOI 10.1038/sj.onc.1203080; MULDERS TMT, 1990, EUR J SURG ONCOL, V16, P37; Murillo H, 2001, ENDOCRINOLOGY, V142, P4795, DOI 10.1210/en.142.11.4795; Nakatani K, 1999, BIOCHEM BIOPH RES CO, V257, P906, DOI 10.1006/bbrc.1999.0559; SAKAUE H, 1995, J BIOL CHEM, V270, P11304, DOI 10.1074/jbc.270.19.11304; Sharma M, 2002, J BIOL CHEM, V277, P30935, DOI 10.1074/jbc.M201919200; THOMPSON J, 2002, END SOC 84 ANN M SAN; Wen Y, 2000, CANCER RES, V60, P6841; Yeh Shuyuan, 1999, Keio Journal of Medicine, V48, P87; Yeh SY, 1998, BIOCHEM BIOPH RES CO, V248, P361, DOI 10.1006/bbrc.1998.8974; Yeh SY, 1996, P NATL ACAD SCI USA, V93, P5517, DOI 10.1073/pnas.93.11.5517	39	53	57	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 9	2003	278	19					16820	16827		10.1074/jbc.M213163200	http://dx.doi.org/10.1074/jbc.M213163200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677QG	12621049	hybrid			2022-12-25	WOS:000182818600051
J	Kamphuis, PJGH; Gardoni, F; Kamal, A; Croiset, G; Bakker, JM; Cattabeni, F; Gispen, WH; van Bel, F; Di Luca, M; Wiegant, VM				Kamphuis, PJGH; Gardoni, F; Kamal, A; Croiset, G; Bakker, JM; Cattabeni, F; Gispen, WH; van Bel, F; Di Luca, M; Wiegant, VM			Long-lasting effects of neonatal dexamethasone treatment on spatial learning and hippocampal synaptic plasticity. Involvement of the NMDA receptor complex	FASEB JOURNAL			English	Article						glucocorticoid; rat; LTP; alpha CaMKII; NR2B	D-ASPARTATE RECEPTOR; PROTEIN-KINASE-II; MESSENGER-RNA LEVELS; TERM POTENTIATION; POSTSYNAPTIC DENSITIES; GLUTAMATE RECEPTORS; PRETERM INFANTS; NR2B SUBUNIT; ADULT RATS; GLUCOCORTICOIDS	The effects of neonatal dexamethasone (DEX) treatment on spatial learning and hippocampal synaptic plasticity were investigated in adult rats. Spatial learning in reference and working memory versions of the Morris maze was impaired in DEX-treated rats. In hippocampal slices of DEX rats, long-term depression was facilitated and potentiation was impaired. Paired-pulse facilitation was normal, suggesting a postsynaptic defect as cause of the learning and plasticity deficits. Western blot analysis of hippocampal postsynaptic densities (PSD) revealed a reduction in NR2B subunit protein, whereas the abundance of the other major N-methyl-D-aspartate (NMDA) receptor subunits (NR1, NR2A), AMPA receptor subunits (GluR2/3), scaffolding proteins, and Ca2+/calmodulin-dependent protein kinase II (alphaCaMKII) were unaltered. This selective reduction in NR2B likely resulted from altered receptor assembly rather than subunit expression, because the abundance of NR2B in the homogenate and crude synaptosomal fractions was unaltered. In addition, the activity of alphaCaMKII, an NMDA receptor complex associated protein kinase, was increased in PSD of DEX rats. The results indicate that neonatal treatment with DEX causes alterations in composition and function of the hippocampal NMDA receptor complex that persist into adulthood. These alterations likely explain the deficits in hippocampal synaptic plasticity and spatial learning induced by neonatal DEX treatment.	Univ Utrecht, Dept Pharmaccol & Anat, Rudolf Magnus Inst Neurosci, Med Ctr, NL-3508 AB Utrecht, Netherlands; Univ Utrecht, Dept Neonatol, Wilhelmina Childrens Hosp, Med Ctr, Utrecht, Netherlands; Univ Milan, Dept Pharmacol Sci, Milan, Italy	Utrecht University; Utrecht University Medical Center; Utrecht University; Wilhelmina Kinderziekenhuis; University of Milan	Wiegant, VM (corresponding author), Univ Utrecht, Dept Pharmaccol & Anat, Rudolf Magnus Inst Neurosci, Med Ctr, POB 85060, NL-3508 AB Utrecht, Netherlands.	V.M.Wiegant@med.uu.nl	Croiset, Gerda/J-5650-2014; Gardoni, Fabrizio/A-3135-2009; DiLuca, Monica/A-7632-2012	Gardoni, Fabrizio/0000-0003-4598-5563; DiLuca, Monica/0000-0003-2298-615X; Kamal, Amer/0000-0002-0545-0815				Bakker JM, 2000, J IMMUNOL, V165, P5932, DOI 10.4049/jimmunol.165.10.5932; BANNERMAN DM, 1995, NATURE, V378, P182, DOI 10.1038/378182a0; Barria A, 2002, NEURON, V35, P345, DOI 10.1016/S0896-6273(02)00776-6; Barrington K J, 2001, BMC Pediatr, V1, P1, DOI 10.1186/1471-2431-1-1; BENESOVA O, 1989, NEUROPHARMACOLOGY, V28, P89, DOI 10.1016/0028-3908(89)90073-7; Biessels GJ, 1996, DIABETES, V45, P1259, DOI 10.2337/diabetes.45.9.1259; BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; Bolt RJ, 2001, PEDIATR PULM, V32, P76, DOI 10.1002/ppul.1092; CARLIN RK, 1980, J CELL BIOL, V86, P831, DOI 10.1083/jcb.86.3.831; Clayton DA, 2002, J NEUROSCI, V22, P3628; Cull-Candy S, 2001, CURR OPIN NEUROBIOL, V11, P327, DOI 10.1016/S0959-4388(00)00215-4; CUMMINGS JJ, 1989, NEW ENGL J MED, V320, P1505, DOI 10.1056/NEJM198906083202301; Das S, 1998, NATURE, V393, P377, DOI 10.1038/30748; DEKLOET ER, 1988, PROG BRAIN RES, V73, P101; Di Luca M, 2001, NEUROREPORT, V12, P1301, DOI 10.1097/00001756-200105080-00049; DOBBING J, 1979, EARLY HUM DEV, V3, P79, DOI 10.1016/0378-3782(79)90022-7; Doyle LW, 2000, J PAEDIATR CHILD H, V36, P256; Dunah AW, 2000, MOL PHARMACOL, V57, P342; ELLIOTT EM, 1993, BRAIN RES, V602, P84, DOI 10.1016/0006-8993(93)90245-I; Ferguson SA, 2001, NEUROTOXICOL TERATOL, V23, P57, DOI 10.1016/S0892-0362(00)00115-X; Finer NN, 2000, J PEDIATR-US, V137, P9, DOI 10.1067/mpd.2000.107799; Gardoni F, 1998, J NEUROCHEM, V71, P1733; Gardoni F, 2001, J BIOL CHEM, V276, P7609, DOI 10.1074/jbc.M009922200; Grosshans DR, 2002, NAT NEUROSCI, V5, P27, DOI 10.1038/nn779; HOLLMANN M, 1994, ANNU REV NEUROSCI, V17, P31, DOI 10.1146/annurev.ne.17.030194.000335; HUMDON A, 2002, ANNU REV BIOCHEM, V71, P473; Kamphuis PJGH, 2002, NEUROENDOCRINOLOGY, V76, P158, DOI 10.1159/000064526; Kennedy MB, 2000, SCIENCE, V290, P750, DOI 10.1126/science.290.5492.750; KERR DS, 1989, SCIENCE, V245, P1505, DOI 10.1126/science.2781293; KUTSUWADA T, 1992, NATURE, V358, P36, DOI 10.1038/358036a0; LAU LF, 1995, J BIOL CHEM, V270, P20036, DOI 10.1074/jbc.270.34.20036; Lisman J, 2002, NAT REV NEUROSCI, V3, P175, DOI 10.1038/nrn753; Liu J, 1999, J NEUROSCI, V19, P8292; Malenka RC, 1999, SCIENCE, V285, P1870, DOI 10.1126/science.285.5435.1870; MALENKA RC, 1994, CELL, V78, P535, DOI 10.1016/0092-8674(94)90517-7; Matthews SG, 2000, PEDIATR RES, V47, P291, DOI 10.1203/00006450-200003000-00003; MAYFORD M, 1995, CELL, V81, P891, DOI 10.1016/0092-8674(95)90009-8; MCEWEN BS, 1995, CURR OPIN NEUROBIOL, V5, P205, DOI 10.1016/0959-4388(95)80028-X; McGowan JE, 2000, J NEUROSCI, V20, P7424; MCNAMARA RK, 1993, BRAIN RES REV, V18, P33, DOI 10.1016/0165-0173(93)90006-L; MONYER H, 1994, NEURON, V12, P529, DOI 10.1016/0896-6273(94)90210-0; MOON IS, 1994, P NATL ACAD SCI USA, V91, P3954, DOI 10.1073/pnas.91.9.3954; MORRIS RGM, 1982, NATURE, V297, P681, DOI 10.1038/297681a0; MORRIS RGM, 1986, NATURE, V319, P774, DOI 10.1038/319774a0; Nair SM, 1998, J NEUROSCI, V18, P2685; Santin LJ, 1999, BEHAV BRAIN RES, V102, P137, DOI 10.1016/S0166-4328(99)00011-X; SAPOLSKY RM, 1986, BRAIN RES REV, V11, P65, DOI 10.1016/0165-0173(86)90010-X; SCHEETZ AJ, 1994, FASEB J, V8, P745, DOI 10.1096/fasebj.8.10.8050674; Sprengel R, 1998, CELL, V92, P279, DOI 10.1016/S0092-8674(00)80921-6; Steele RJ, 1999, HIPPOCAMPUS, V9, P118, DOI 10.1002/(SICI)1098-1063(1999)9:2<118::AID-HIPO4>3.0.CO;2-8; STEINBEHRENS BA, 1994, J NEUROCHEM, V63, P596; Strack S, 2000, J BIOL CHEM, V275, P23798, DOI 10.1074/jbc.M001471200; Strack S, 1998, J BIOL CHEM, V273, P20689, DOI 10.1074/jbc.273.33.20689; Tang YP, 1999, NATURE, V401, P63, DOI 10.1038/43432; Tarnow-Mordi W, 1999, BRIT MED J, V319, P1385, DOI 10.1136/bmj.319.7222.1385; Venero C, 1999, EUR J NEUROSCI, V11, P2465, DOI 10.1046/j.1460-9568.1999.00668.x; VICEDOMINI JP, 1986, PHYSIOL BEHAV, V36, P145, DOI 10.1016/0031-9384(86)90088-0; Weiland NG, 1997, NEUROSCIENCE, V78, P653, DOI 10.1016/S0306-4522(96)00619-7; Yamakura T, 1999, PROG NEUROBIOL, V59, P279, DOI 10.1016/S0301-0082(99)00007-6; Yeh TF, 1998, PEDIATRICS, V101, part. no., DOI 10.1542/peds.101.5.e7; ZUCKER RS, 1989, ANNU REV NEUROSCI, V12, P13, DOI 10.1146/annurev.neuro.12.1.13	61	60	61	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2003	17	3					911	+		10.1096/fj.02-0333fje	http://dx.doi.org/10.1096/fj.02-0333fje			22	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	661LT	12626441				2022-12-25	WOS:000181892600018
J	Petrache, I; Birukov, K; Zaiman, AL; Crow, MT; Deng, HT; Wadgaonkar, R; Romer, LH; Garcia, JGN				Petrache, I; Birukov, K; Zaiman, AL; Crow, MT; Deng, HT; Wadgaonkar, R; Romer, LH; Garcia, JGN			Caspase-dependent cleavage of myosin light chain kinase (MLCK) is involved in TNF-alpha-mediated bovine pulmonary endothelial cell apoptosis	FASEB JOURNAL			English	Article						cytoskeleton; stress fibers; Rho kinase; blebbing; autoinhibitory domain	TUMOR-NECROSIS-FACTOR; PHOSPHORYLATION; PROTEINS; ISOFORMS; SITE; FORM	Cytoskeletal proteins are key participants in the cellular progression to apoptosis. Our previous work demonstrated the critical dependence of actomyosin rearrangement and MLC phosphorylation in TNF-alpha-induced endothelial cell apoptosis. As these events reflect the activation of the multifunctional endothelial cell (EC) MLCK isoform, we assessed the direct role of EC MLCK in the regulation of TNF-alpha-induced apoptosis. Bovine pulmonary artery endothelial cells expressing either an adenovirus encoding antisense MLCK cDNA (Ad. GFP-AS MLCK) or a dominant/ negative EC MLCK construct (EC MLCK-ATPdel) resulted in marked reductions in MLCK activity and TNF-alpha-mediated apoptosis. In contrast, a constitutively active EC MLCK lacking the carboxyl-terminal autoinhibitory domains (EC MLCK-1745) markedly enhanced the apoptotic response to TNF-alpha. Immunostaining in GFP-EC MLCK-expressing cells revealed colocalization of caspase 8 and EC MLCK along actin stress fibers after TNF-alpha. TNF-alpha induced the caspase-dependent cleavage of EC MLCK-1745 in transfected endothelial cells, which was confirmed by mass spectroscopy with in vitro cleavage by caspase 3 at LKKD (D-1703). The resulting MLCK fragments displayed significant calmodulin-independent kinase activity. These studies convincingly demonstrate that novel interactions between the apoptotic machinery and EC MLCK exist that regulate the endothelial contractile apparatus in TNF-alpha- induced apoptosis.	Johns Hopkins Univ, Sch Med, Dept Med, Div Pulm & Crit Care Med, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Anesthesiol & Crit Care Med, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Cell Biol, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Pediat, Baltimore, MD 21205 USA; Albert Einstein Coll Med, Dept Med, New York, NY USA	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Yeshiva University	Garcia, JGN (corresponding author), Johns Hopkins Asthma & Allergy Ctr, 5501 Hopkins Bayview Circle,Room 4B-77, Baltimore, MD 21224 USA.	drgarcia@jhmi.edu	Birukov, Konstantin/FJB-5755-2022; Garcia, Joe GN/E-8862-2010		NHLBI NIH HHS [K08 HL004396, HL 04396, HL 50533, HL 58064] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL058064, R01HL050533, K08HL004396] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ADELSTEIN RS, 1983, J CLIN INVEST, V72, P1863, DOI 10.1172/JCI111148; Baud V, 2001, TRENDS CELL BIOL, V11, P372, DOI 10.1016/S0962-8924(01)02064-5; Birukov KG, 2001, J BIOL CHEM, V276, P8567, DOI 10.1074/jbc.M005270200; Dudek SM, 2001, J APPL PHYSIOL, V91, P1487, DOI 10.1152/jappl.2001.91.4.1487; Earnshaw WC, 1999, ANNU REV BIOCHEM, V68, P383, DOI 10.1146/annurev.biochem.68.1.383; Garcia JGN, 1998, J APPL PHYSIOL, V84, P1817, DOI 10.1152/jappl.1998.84.5.1817; Garcia JGN, 1997, AM J RESP CELL MOL, V16, P489, DOI 10.1165/ajrcmb.16.5.9160829; HaimovitzFriedman A, 1997, J EXP MED, V186, P1831, DOI 10.1084/jem.186.11.1831; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; HERRING BP, 1990, J BIOL CHEM, V265, P16588; HOCKING DC, 1990, CIRC RES, V67, P68, DOI 10.1161/01.RES.67.1.68; ITO M, 1991, BIOCHEMISTRY-US, V30, P3498, DOI 10.1021/bi00228a021; Jin YJ, 2001, J BIOL CHEM, V276, P30342, DOI 10.1074/jbc.M102404200; Jin YJ, 2001, J BIOL CHEM, V276, P39667, DOI 10.1074/jbc.M101886200; Kawai T, 1998, MOL CELL BIOL, V18, P1642, DOI 10.1128/MCB.18.3.1642; KISCHKEL FC, 1995, EMBO J, V14, P5579, DOI 10.1002/j.1460-2075.1995.tb00245.x; Lazar V, 1999, GENOMICS, V57, P256, DOI 10.1006/geno.1999.5774; Mills JC, 1998, J CELL BIOL, V140, P627, DOI 10.1083/jcb.140.3.627; Petrache I, 2001, AM J PHYSIOL-LUNG C, V280, pL1168, DOI 10.1152/ajplung.2001.280.6.L1168; Sebbagh M, 2001, NAT CELL BIOL, V3, P346, DOI 10.1038/35070019; Siegel RM, 1998, J CELL BIOL, V141, P1243, DOI 10.1083/jcb.141.5.1243; Utz PJ, 2000, CELL DEATH DIFFER, V7, P589, DOI 10.1038/sj.cdd.4400696; Verin AD, 1998, AM J RESP CELL MOL, V19, P758, DOI 10.1165/ajrcmb.19.5.3125; Verin AD, 1998, AM J RESP CELL MOL, V19, P767, DOI 10.1165/ajrcmb.19.5.3126; WRIGHT SC, 1993, J CELL BIOCHEM, V53, P222, DOI 10.1002/jcb.240530307	25	82	86	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAR	2003	17	3					407	416		10.1096/fj.02-0672com	http://dx.doi.org/10.1096/fj.02-0672com			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	661LT	12631580				2022-12-25	WOS:000181892600039
J	Fuentes, EJ; Karnoub, AE; Booden, MA; Der, CJ; Campbell, SL				Fuentes, EJ; Karnoub, AE; Booden, MA; Der, CJ; Campbell, SL			Critical role of the pleckstrin homology domain in Dbs signaling and growth regulation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GUANINE-NUCLEOTIDE EXCHANGE; CYSTEINE-RICH DOMAINS; RHO-GTPASES; FAMILY PROTEINS; GUANOSINE TRIPHOSPHATASES; CRYSTAL-STRUCTURE; ONCOGENE PRODUCT; DISTINCT ROLES; PH DOMAINS; TRANSFORMATION	Dbl family proteins act as guanine nucleotide exchange factors and positive regulators of Rho GTPase function by stimulating formation of the active, GTP-bound state. All Dbl family Rho guanine nucleotide exchange factors possess an invariant tandem domain structure consisting of a Dbl homology (DH) catalytic domain followed by a pleckstrin homology (PH) regulatory domain. We determined previously that the PH domain of Dbs was critical for the intrinsic catalytic activity of the DH domain in vitro and for Dbs transformation in vivo. In this study, we evaluated the role of phosphoinositide binding to the PH domain in regulating the DH domain function of Dbs in vitro and in vivo. We determined that mutation of basic amino acids located within the beta(1)- beta(2) and beta(3)-beta(4) loops of the PH domain resulted in impaired phospholipid binding in vitro, yet full guanine nucleotide exchange activity in vitro was retained for RhoA and Cdc42. Surprisingly, these mutants were compromised in their ability to activate Rho GTPases in vivo and to cause transformation of NIH 3T3 cells. However, Dbs subcellular localization was impaired by these PH domain mutations, supporting a role for phospholipid interactions in facilitating membrane association. Despite the importance of phospholipid binding for Dbs function in vivo, we found that Dbs signaling and transforming activity was not stimulated by phosphatidylinositol 3-kinase activation. We suggest that the PH domain of Dbs facilitates two distinct roles in the regulation of DH domain function, one critical for GTPase association and activation in vitro and one critical for phosphoinositide binding and GTPase interaction in vivo, that together promote Dbs association with membranes.	Univ N Carolina, Lineberger Comprehens Canc Ctr, Dept Biochem & Biophys, Chapel Hill, NC 27599 USA; Univ N Carolina, Lineberger Comprehens Canc Ctr, Dept Biochem & Biophys, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill	Der, CJ (corresponding author), Univ N Carolina, Lineberger Comprehens Canc Ctr, Dept Biochem & Biophys, Chapel Hill, NC 27599 USA.		Fuentes, Ernesto/F-5129-2010	Fuentes, Ernesto/0000-0001-5812-8187; campbell, sharon/0000-0003-0311-409X; Der, Channing/0000-0002-7751-2747				Abe K, 2000, J BIOL CHEM, V275, P10141, DOI 10.1074/jbc.275.14.10141; Baumeister MA, 2003, J BIOL CHEM, V278, P11457, DOI 10.1074/jbc.M211901200; Bishop AL, 2000, BIOCHEM J, V348, P241, DOI 10.1042/0264-6021:3480241; Boettner B, 2002, GENE, V286, P155, DOI 10.1016/S0378-1119(02)00426-2; Booden MA, 2002, MOL CELL BIOL, V22, P2487, DOI 10.1128/MCB.22.8.2487-2497.2002; BUSS JE, 1989, SCIENCE, V243, P1600, DOI 10.1126/science.2648572; Chen RH, 1997, EMBO J, V16, P1351, DOI 10.1093/emboj/16.6.1351; CLARK GJ, 1995, METHOD ENZYMOL, V255, P395; Das B, 2000, J BIOL CHEM, V275, P15074, DOI 10.1074/jbc.M907269199; Fiordalisi JJ, 2001, METHOD ENZYMOL, V332, P3; Han JW, 1998, SCIENCE, V279, P558, DOI 10.1126/science.279.5350.558; HART MJ, 1994, J BIOL CHEM, V269, P62; Higgins DG, 1996, METHOD ENZYMOL, V266, P383; Hurley JH, 2000, ANNU REV BIOPH BIOM, V29, P49, DOI 10.1146/annurev.biophys.29.1.49; Huth JR, 1997, PROTEIN SCI, V6, P2359; Koshiba S, 1997, J MOL BIOL, V269, P579, DOI 10.1006/jmbi.1997.1041; Kubiseski TJ, 1997, J BIOL CHEM, V272, P1799, DOI 10.1074/jbc.272.3.1799; Lambert JM, 2002, NAT CELL BIOL, V4, P621, DOI 10.1038/ncb833; Lemmon MA, 2000, BIOCHEM J, V350, P1, DOI 10.1042/0264-6021:3500001; Lemmon MA, 2002, FEBS LETT, V513, P71, DOI 10.1016/S0014-5793(01)03243-4; Liu XH, 1998, CELL, V95, P269, DOI 10.1016/S0092-8674(00)81757-2; Nimnual AS, 1998, SCIENCE, V279, P560, DOI 10.1126/science.279.5350.560; Olson MF, 1997, ONCOGENE, V15, P2827, DOI 10.1038/sj.onc.1201594; Palmby TR, 2002, J BIOL CHEM, V277, P39350, DOI 10.1074/jbc.M202641200; Qian XL, 1998, MOL CELL BIOL, V18, P771, DOI 10.1128/MCB.18.2.771; Rossman KL, 2000, METHOD ENZYMOL, V325, P25; Rossman KL, 2002, EMBO J, V21, P1315, DOI 10.1093/emboj/21.6.1315; Russo C, 2001, J BIOL CHEM, V276, P19524, DOI 10.1074/jbc.M009742200; Sahai E, 2002, NAT CELL BIOL, V4, P408, DOI 10.1038/ncb796; Schmidt A, 2002, GENE DEV, V16, P1587, DOI 10.1101/gad.1003302; Snyder JT, 2001, J BIOL CHEM, V276, P45868, DOI 10.1074/jbc.M106731200; Snyder JT, 2002, NAT STRUCT BIOL, V9, P468, DOI 10.1038/nsb796; Soisson SM, 1998, CELL, V95, P259, DOI 10.1016/S0092-8674(00)81756-0; Wennerberg K, 2002, J BIOL CHEM, V277, P47810, DOI 10.1074/jbc.M203816200; Westwick JK, 1998, J BIOL CHEM, V273, P16739, DOI 10.1074/jbc.273.27.16739; Westwick JK, 1997, MOL CELL BIOL, V17, P1324, DOI 10.1128/MCB.17.3.1324; Wherlock M, 2002, J CELL SCI, V115, P239; WHITEHEAD I, 1995, ONCOGENE, V10, P713; WHITEHEAD I, 1995, MOL CELL BIOL, V15, P704; Whitehead IP, 1997, BIOCHIM BIOPHYS ACTA, V1332, P1; WHITEHEAD IP, 1996, J BIOL CHEM, V271, P18388; Whitehead LP, 1999, MOL CELL BIOL, V19, P7759; Worthylake DK, 2000, NATURE, V408, P682, DOI 10.1038/35047014; Zheng J, 1997, J BIOL CHEM, V272, P30340, DOI 10.1074/jbc.272.48.30340; Zheng Y, 2001, TRENDS BIOCHEM SCI, V26, P724, DOI 10.1016/S0968-0004(01)01973-9; Zheng Y, 1996, J BIOL CHEM, V271, P19017, DOI 10.1074/jbc.271.32.19017	46	21	22	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 6	2003	278	23					21188	21196		10.1074/jbc.M211792200	http://dx.doi.org/10.1074/jbc.M211792200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	684WY	12637530	hybrid			2022-12-25	WOS:000183230500096
J	Kuo, MR; Morbidoni, HR; Alland, D; Sneddon, SF; Gourlie, BB; Staveski, MM; Leonard, M; Gregory, JS; Janjigian, AD; Yee, C; Musser, JM; Kreiswirth, B; Iwamoto, H; Perozzo, R; Jacobs, WR; Sacchettini, JC; Fidock, DA				Kuo, MR; Morbidoni, HR; Alland, D; Sneddon, SF; Gourlie, BB; Staveski, MM; Leonard, M; Gregory, JS; Janjigian, AD; Yee, C; Musser, JM; Kreiswirth, B; Iwamoto, H; Perozzo, R; Jacobs, WR; Sacchettini, JC; Fidock, DA			Targeting tuberculosis and malaria through inhibition of enoyl reductase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARRIER PROTEIN REDUCTASE; FATTY-ACID SYNTHESIS; PLASMODIUM-FALCIPARUM; ACP REDUCTASE; MYCOBACTERIUM-TUBERCULOSIS; TOXOPLASMA-GONDII; CRYSTAL-STRUCTURE; ISONIAZID TARGET; MOLECULAR-BASIS; TRICLOSAN	Tuberculosis and malaria together result in an estimated 5 million deaths annually. The spread of multidrug resistance in the most pathogenic causative agents, Mycobacterium tuberculosis and Plasmodium falciparum, underscores the need to identify active compounds with novel inhibitory properties. Although genetically unrelated, both organisms use a type II fatty-acid synthase system. Enoyl acyl carrier protein reductase (ENR), a key type II enzyme, has been repeatedly validated as an effective antimicrobial target. Using high throughput inhibitor screens with a combinatorial library, we have identified two novel classes of compounds with activity against the M. tuberculosis and P. falciparum enzyme (referred to as InhA and PfENR, respectively). The crystal structure of InhA complexed with NAD(+) and one of the inhibitors was determined to elucidate the mode of binding. Structural analysis of InhA with the broad spectrum antimicrobial triclosan revealed a unique stoichiometry where the enzyme contained either a single triclosan molecule, in a configuration typical of other bacterial ENR: triclosan structures, or harbored two triclosan molecules bound to the active site. Significantly, these compounds do not require activation and are effective against wild-type and drug-resistant strains of M. tuberculosis and P. falciparum. Moreover, they provide broader chemical diversity and elucidate key elements of inhibitor binding to InhA for subsequent chemical optimization.	Texas A&M Univ, Dept Biochem & Biophys, College Stn, TX 77843 USA; Yeshiva Univ Albert Einstein Coll Med, Dept Microbiol & Immunol, Bronx, NY 10461 USA; Yeshiva Univ Albert Einstein Coll Med, Howard Hughes Med Inst, Bronx, NY 10461 USA; Univ Med & Dent New Jersey, New Jersey Med Sch, Div Infect Dis, Newark, NJ 07103 USA; Univ Med & Dent New Jersey, New Jersey Med Sch, Ctr Emerging Pathogens, Newark, NJ 07103 USA; Genzyme Corp, Genzyme Drug Discovery, Cambridge, MA 02139 USA; NIAID, Lab Human Bacterial Pathogenesis, Div Intramural Res, NIH,Rocky Mt Labs, Hamilton, MT 59840 USA; Publ Hlth Res Inst, TB Ctr, New York, NY 10016 USA	Texas A&M University System; Texas A&M University College Station; Yeshiva University; Albert Einstein College of Medicine; Howard Hughes Medical Institute; Yeshiva University; Albert Einstein College of Medicine; Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers State University New Brunswick; Rutgers State University Medical Center; Sanofi-Aventis; Genzyme Corporation; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	Sacchettini, JC (corresponding author), Texas A&M Univ, Dept Biochem & Biophys, Biochem & Biophys Bldg,Rm 221, College Stn, TX 77843 USA.	sacchett@tamu.edu		Fidock, David/0000-0001-6753-8938; Jacobs, William/0000-0003-3321-3080	NIAID NIH HHS [AI43268] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI043268, R21AI043268] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Baldock C, 1996, SCIENCE, V274, P2107, DOI 10.1126/science.274.5295.2107; BANERJEE A, 1994, SCIENCE, V263, P227, DOI 10.1126/science.8284673; Bloch K, 1977, Adv Enzymol Relat Areas Mol Biol, V45, P1; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Cooper RA, 2002, MOL PHARMACOL, V61, P35, DOI 10.1124/mol.61.1.35; DESSEN A, 1995, SCIENCE, V267, P1638, DOI 10.1126/science.7886450; Escalante P., 1998, Tubercle and Lung Disease, V79, P111, DOI 10.1054/tuld.1998.0013; Fichera ME, 1997, NATURE, V390, P407, DOI 10.1038/37132; Fidock DA, 1998, MOL PHARMACOL, V54, P1140, DOI 10.1124/mol.54.6.1140; GRASSBERGER MA, 1984, J MED CHEM, V27, P947, DOI 10.1021/jm00374a003; HAYASHI T, 1983, BIOCHEM BIOPH RES CO, V115, P1108, DOI 10.1016/S0006-291X(83)80050-3; Heath RJ, 1998, J BIOL CHEM, V273, P30316, DOI 10.1074/jbc.273.46.30316; Heath RJ, 2000, J BIOL CHEM, V275, P4654, DOI 10.1074/jbc.275.7.4654; Heath RJ, 1999, J BIOL CHEM, V274, P11110, DOI 10.1074/jbc.274.16.11110; Heerding DA, 2001, BIOORG MED CHEM LETT, V11, P2061, DOI 10.1016/S0960-894X(01)00404-8; JACKOWSKI S, 1989, J BIOL CHEM, V264, P7624; Jomaa H, 1999, SCIENCE, V285, P1573, DOI 10.1126/science.285.5433.1573; Kohler S, 1997, SCIENCE, V275, P1485, DOI 10.1126/science.275.5305.1485; Levy CW, 1999, NATURE, V398, P383, DOI 10.1038/18803; McFadden GI, 1997, BIOESSAYS, V19, P1033, DOI 10.1002/bies.950191114; McLeod R, 2001, INT J PARASITOL, V31, P109, DOI 10.1016/S0020-7519(01)00111-4; Miller WH, 2002, J MED CHEM, V45, P3246, DOI 10.1021/jm020050+; NISHIDA I, 1986, J BIOCHEM-TOKYO, V99, P1447, DOI 10.1093/oxfordjournals.jbchem.a135614; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Palmer JD, 1996, P NATL ACAD SCI USA, V93, P7432, DOI 10.1073/pnas.93.15.7432; Parikh SL, 2000, BIOCHEMISTRY-US, V39, P7645, DOI 10.1021/bi0008940; Payne DJ, 2002, ANTIMICROB AGENTS CH, V46, P3118, DOI 10.1128/AAC.46.10.3118-3124.2002; Perozzo R, 2002, J BIOL CHEM, V277, P13106, DOI 10.1074/jbc.M112000200; PETERSON DS, 1988, P NATL ACAD SCI USA, V85, P9114, DOI 10.1073/pnas.85.23.9114; Qiu XY, 1999, PROTEIN SCI, V8, P2529, DOI 10.1110/ps.8.11.2529; QUEMARD A, 1995, BIOCHEMISTRY-US, V34, P8235, DOI 10.1021/bi00026a004; Rhee JT, 1999, J CLIN MICROBIOL, V37, P1764, DOI 10.1128/JCM.37.6.1764-1770.1999; Roujeinikova A, 1999, J MOL BIOL, V294, P527, DOI 10.1006/jmbi.1999.3240; Roujeinikova A, 1999, J BIOL CHEM, V274, P30811, DOI 10.1074/jbc.274.43.30811; Rozwarski DA, 1999, J BIOL CHEM, V274, P15582, DOI 10.1074/jbc.274.22.15582; Rozwarski DA, 1998, SCIENCE, V279, P98, DOI 10.1126/science.279.5347.98; Seefeld MA, 2001, BIOORG MED CHEM LETT, V11, P2241, DOI 10.1016/S0960-894X(01)00405-X; Stewart MJ, 1999, J MOL BIOL, V290, P859, DOI 10.1006/jmbi.1999.2907; Su XZ, 1997, CELL, V91, P593, DOI 10.1016/S0092-8674(00)80447-X; Surolia N, 2001, NAT MED, V7, P167, DOI 10.1038/84612; TSAY JT, 1992, J BACTERIOL, V174, P508, DOI 10.1128/jb.174.2.508-513.1992; Vilcheze C, 2000, J BACTERIOL, V182, P4059, DOI 10.1128/JB.182.14.4059-4067.2000; Waller RF, 1998, P NATL ACAD SCI USA, V95, P12352, DOI 10.1073/pnas.95.21.12352; Wang P, 1997, MOL MICROBIOL, V23, P979, DOI 10.1046/j.1365-2958.1997.2821646.x; Ward WHJ, 1999, BIOCHEMISTRY-US, V38, P12514, DOI 10.1021/bi9907779; ZHANG Y, 1992, NATURE, V358, P591, DOI 10.1038/358591a0	46	226	241	0	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 6	2003	278	23					20851	20859		10.1074/jbc.M211968200	http://dx.doi.org/10.1074/jbc.M211968200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	684WY	12606558	hybrid			2022-12-25	WOS:000183230500054
J	Blackshear, PJ; Lai, WS; Kennington, EA; Brewer, G; Wilson, GM; Guan, XJ; Zhou, P				Blackshear, PJ; Lai, WS; Kennington, EA; Brewer, G; Wilson, GM; Guan, XJ; Zhou, P			Characteristics of the interaction of a synthetic human tristetraprolin tandem zinc finger peptide with AU-rich element-containing RNA substrates	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA; DEFICIENCY SYNDROME; PROTEINS; ALPHA; BINDING; DESTABILIZATION; DEADENYLATION; ASSOCIATION; RESONANCES; UBIQUITIN	Tristetraprolin (TTP) and its two known mammalian family members are tandem CCCH zinc finger proteins that can bind to AU-rich elements (AREs) in cellular mRNAs and destabilize those transcripts, apparently by initiating their deadenylation. Previous studies have shown that the similar to70-amino acid tandem zinc finger domain of TTP is required and sufficient for RNA binding, and that the integrity of both zinc fingers is also required. However, little is known about the kinetics or structure of the peptide-RNA interaction, in part because of difficulties in obtaining soluble recombinant protein or peptides. We characterized the binding of a synthetic 73-amino acid peptide from human TTP to the tumor necrosis factor (TNF) ARE by gel mobility shift analyses and fluorescence anisotropy experiments. Both types of studies yielded a peptide-RNA dissociation constant of similar to10 nM. Surprisingly, we found that the "footprint" from the TNF ARE required for peptide binding was only similar to9 bases and that two molecules of peptide could bind to probes containing as little as 19 bases. An identical recombinant peptide exhibited gel shift characteristics similar to those of the synthetic peptide. NMR analysis of the N-15-labeled recombinant peptide suggested that its first zinc finger was structured in solution but that the second was not. The titration of oligonucleotides representing 17, 13, and even 9 bases of the TNF ARE caused an essentially identical, dramatic shift of existing resonances, and the appearance of new resonances in the peptide spectra, so that all amino acids could be assigned. These data suggest that this TTP peptide-RNA complex is structured in solution and might be amenable to NMR structure determination.	NIEHS, Lab Signal Transduct, NIH, Dept Hlth & Human Serv, Res Triangle Pk, NC 27709 USA; NIEHS, Off Clin Res, NIH, Dept Hlth & Human Serv, Res Triangle Pk, NC 27709 USA; Duke Univ, Med Ctr, Dept Med, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Biochem, Durham, NC 27710 USA; Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Microbiol Mol Genet & Immunol, Piscataway, NJ 08854 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); Duke University; Duke University; Rutgers State University New Brunswick; Rutgers State University Medical Center	Blackshear, PJ (corresponding author), NIEHS, Lab Signal Transduct, NIH, Dept Hlth & Human Serv, A2-05,111 Alexander Dr, Res Triangle Pk, NC 27709 USA.	black009@niehs.nih.gov	Blackshear, Perry J./C-6206-2019; Wilson, Gerald/AAF-3874-2019; Zhou, Pei/O-6704-2019	Blackshear, Perry J./0000-0002-9561-8529; Zhou, Pei/0000-0002-7823-3416; Wilson, Gerald/0000-0002-1273-7507	NATIONAL CANCER INSTITUTE [R01CA052443] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [ZIAES090080, Z01ES090080] Funding Source: NIH RePORTER; NCI NIH HHS [R01-CA52443] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Amann BT, 2003, BIOCHEMISTRY-US, V42, P217, DOI 10.1021/bi026988m; Bakheet T, 2001, NUCLEIC ACIDS RES, V29, P246, DOI 10.1093/nar/29.1.246; BARTELS C, 1995, J BIOMOL NMR, V6, P1, DOI 10.1007/BF00417486; Blackshear PJ, 2002, BIOCHEM SOC T, V30, P945, DOI 10.1042/BST0300945; Carballo E, 1997, J CLIN INVEST, V100, P986, DOI 10.1172/JCI119649; Carballo E, 2000, BLOOD, V95, P1891, DOI 10.1182/blood.V95.6.1891; Carballo E, 1998, SCIENCE, V281, P1001, DOI 10.1126/science.281.5379.1001; Carballo E, 2001, BLOOD, V98, P2389, DOI 10.1182/blood.V98.8.2389; De J, 1999, GENE, V228, P133, DOI 10.1016/S0378-1119(98)00617-9; GRZESIEK S, 1992, J AM CHEM SOC, V114, P6291, DOI 10.1021/ja00042a003; JAMESON DM, 1995, METHOD ENZYMOL, V246, P283; Kronnie GT, 1999, DEV GENES EVOL, V209, P443, DOI 10.1007/s004270050276; Lai WS, 2001, J BIOL CHEM, V276, P23144, DOI 10.1074/jbc.M100680200; Lai WS, 2003, MOL CELL BIOL, V23, P3798, DOI 10.1128/MCB.23.11.3798-3812.2003; Lai WS, 2000, J BIOL CHEM, V275, P17827, DOI 10.1074/jbc.M001696200; Lai WS, 1999, MOL CELL BIOL, V19, P4311; Lakowicz JR, 1999, PRINCIPLES FLUORESCE, P291, DOI 10.1007/978-1-4757-3061-6; RAMAGE R, 1989, TETRAHEDRON LETT, V30, P2149, DOI 10.1016/S0040-4039(01)93735-9; RAMAGE R, 1994, BIOCHEM J, V299, P151, DOI 10.1042/bj2990151; Stevens CJM, 1998, INT J DEV BIOL, V42, P181; Taylor GA, 1996, IMMUNITY, V4, P445, DOI 10.1016/S1074-7613(00)80411-2; Wilson GM, 1999, J BIOL CHEM, V274, P33374, DOI 10.1074/jbc.274.47.33374; Wilson GM, 2001, J BIOL CHEM, V276, P44450, DOI 10.1074/jbc.M108521200; Wilson GM, 2001, J BIOL CHEM, V276, P8695, DOI 10.1074/jbc.M009848200; WITTEKIND M, 1993, J MAGN RESON SER B, V101, P201, DOI 10.1006/jmrb.1993.1033; Worthington MT, 1996, P NATL ACAD SCI USA, V93, P13754, DOI 10.1073/pnas.93.24.13754	26	98	99	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 30	2003	278	22					19947	19955		10.1074/jbc.M301290200	http://dx.doi.org/10.1074/jbc.M301290200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	682EH	12639954	hybrid			2022-12-25	WOS:000183078000050
J	Sun, XM; Soutar, AK				Sun, XM; Soutar, AK			The transmembrane domain and PXXP motifs of ApoE receptor 2 exclude it from carrying out clathrin-mediated endocytosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							APOLIPOPROTEIN-E RECEPTOR-2; DENSITY-LIPOPROTEIN RECEPTOR; MONOCLONAL-ANTIBODIES; SIGNALING MOLECULES; ACTIN CYTOSKELETON; CYTOPLASMIC DOMAIN; BINDING PROTEIN; KNOCKOUT MICE; MEMBRANE; EXPRESSION	The low density lipoprotein (LDL) receptor family comprises several proteins with similar structures including the LDL receptor and apoE receptor 2 (apoER2). The human brain expresses two major splice variants of apoER2 mRNA, one of which includes an additional exon that encodes 59 residues in the cytoplasmic domain. This exon is absent from the LDL receptor and contains three proline-rich (PXXP) motifs that may allow apoER2 to function as a signal transducer. To investigate the role of this insert, we took advantage of the well characterized low density lipoprotein receptor pathway. Chimeras comprising the ectodomain and transmembrane domain of the LDL receptor fused to the cytoplasmic domain of apoER2 lacking the PXXP-containing residues are able to mediate clathrin-dependent endocytosis of LDL as effectively as cells expressing the LDL receptor but not if the PXXP insert is present in the protein. Although expressed on the cell surface, the PXXP-containing chimeric receptor is excluded from clathrin vesicles as judged by its failure to co-localize with adaptor protein-2 possibly due to interaction with intracellular adaptors or scaffolding proteins. Chimeras with the transmembrane domain of apoER2, predicted to be longer than that of the LDL receptor by several residues, fail to mediate endocytosis of LDL or to co-localize with adaptor protein-2 regardless of the presence or absence of the PXXP insert. Thus features of apoER2 that distinguish it as a signaling receptor, rather than as an endocytosis receptor like the LDL receptor, reside in or near the transmembrane domain and in the proline-rich motifs.	Hammersmith Hosp, Imperial Coll Fac Med, MRC, Clin Sci Ctr,Lipoprot Grp, London W12 0NN, England	Imperial College London	Soutar, AK (corresponding author), Hammersmith Hosp, Imperial Coll Fac Med, MRC, Clin Sci Ctr,Lipoprot Grp, Ducane Rd, London W12 0NN, England.				Medical Research Council [MC_U120074271] Funding Source: Medline; MRC [MC_U120074271] Funding Source: UKRI	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		ALEXANDROPOULOS K, 1995, P NATL ACAD SCI USA, V92, P3110, DOI 10.1073/pnas.92.8.3110; Barman S, 2000, J VIROL, V74, P6538, DOI 10.1128/JVI.74.14.6538-6545.2000; BEISIEGEL U, 1981, J BIOL CHEM, V256, P1923; Bennett EM, 2001, TRAFFIC, V2, P851, DOI 10.1034/j.1600-0854.2001.21114.x; Bork P, 1997, TRENDS BIOCHEM SCI, V22, P296, DOI 10.1016/S0968-0004(97)01084-0; Buday L, 1999, BBA-REV BIOMEMBRANES, V1422, P187, DOI 10.1016/S0304-4157(99)00005-2; CHEN WJ, 1990, J BIOL CHEM, V265, P3116; Clatworthy AE, 1999, NEUROSCIENCE, V90, P903, DOI 10.1016/S0306-4522(98)00489-8; COLLAWN JF, 1991, EMBO J, V10, P3247, DOI 10.1002/j.1460-2075.1991.tb04888.x; Curran T, 1998, BRAIN RES REV, V26, P285, DOI 10.1016/S0165-0173(97)00035-0; D'Arcangelo G, 1998, BIOESSAYS, V20, P235, DOI 10.1002/(SICI)1521-1878(199803)20:3&lt;235::AID-BIES7&gt;3.0.CO;2-Q; D'Arcangelo G, 1999, NEURON, V24, P471, DOI 10.1016/S0896-6273(00)80860-0; Drakew A, 2002, EXP NEUROL, V176, P12, DOI 10.1006/exnr.2002.7918; Gebbink MFBG, 1997, J CELL BIOL, V137, P1603, DOI 10.1083/jcb.137.7.1603; Goldstein JL, 1995, METABOLIC MOL BASIS, VII, P1981; Kibbey RG, 1998, J CELL BIOL, V142, P59, DOI 10.1083/jcb.142.1.59; Kim DH, 1997, J BIOL CHEM, V272, P8498, DOI 10.1074/jbc.272.13.8498; Kim DH, 1996, J BIOL CHEM, V271, P8373, DOI 10.1074/jbc.271.14.8373; KNIGHT BL, 1986, BIOCHEM J, V238, P405, DOI 10.1042/bj2380405; LaDu MJ, 2001, NEUROCHEM INT, V39, P427, DOI 10.1016/S0197-0186(01)00050-X; Lamaze C, 1997, J BIOL CHEM, V272, P20332, DOI 10.1074/jbc.272.33.20332; Lamaze C, 1996, NATURE, V382, P177, DOI 10.1038/382177a0; Moller S, 2001, BIOINFORMATICS, V17, P646, DOI 10.1093/bioinformatics/17.7.646; Mukherjee S, 1997, PHYSIOL REV, V77, P759, DOI 10.1152/physrev.1997.77.3.759; Negri S, 2000, GENOMICS, V64, P324, DOI 10.1006/geno.2000.6129; Nichols BJ, 2001, TRENDS CELL BIOL, V11, P406, DOI 10.1016/S0962-8924(01)02107-9; PATEL DD, 1993, BIOCHEM J, V289, P569, DOI 10.1042/bj2890569; Riddell DR, 2001, J LIPID RES, V42, P998; Ridley AJ, 2001, TRAFFIC, V2, P303, DOI 10.1034/j.1600-0854.2001.002005303.x; Schaffner-Reckinger E, 2001, THROMB HAEMOSTASIS, V85, P716, DOI 10.1055/s-0037-1615658; Scheiffele P, 1997, EMBO J, V16, P5501, DOI 10.1093/emboj/16.18.5501; Schmid SL, 1997, ANNU REV BIOCHEM, V66, P511, DOI 10.1146/annurev.biochem.66.1.511; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; Stockinger W, 2000, J BIOL CHEM, V275, P25625, DOI 10.1074/jbc.M004119200; Sun XM, 1999, EUR J BIOCHEM, V262, P230, DOI 10.1046/j.1432-1327.1999.00394.x; SUN XM, 1995, ARTERIOSCL THROM VAS, V15, P219, DOI 10.1161/01.ATV.15.2.219; Trommsdorff M, 1999, CELL, V97, P689, DOI 10.1016/S0092-8674(00)80782-5; VANDRIEL IR, 1987, J BIOL CHEM, V262, P16127; Verhey KJ, 2001, J CELL BIOL, V152, P959, DOI 10.1083/jcb.152.5.959; Willnow TE, 1999, NAT CELL BIOL, V1, pE157, DOI 10.1038/14109; Yasuda J, 1999, MOL CELL BIOL, V19, P7245	41	7	7	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 30	2003	278	22					19926	19932		10.1074/jbc.M302047200	http://dx.doi.org/10.1074/jbc.M302047200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	682EH	12621059	hybrid			2022-12-25	WOS:000183078000047
J	Liu, CY; Xu, ZH; Kaufman, RJ				Liu, CY; Xu, ZH; Kaufman, RJ			Structure and intermolecular interactions of the luminal dimerization domain of human IRE1 alpha	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UNFOLDED-PROTEIN RESPONSE; ENDOPLASMIC-RETICULUM STRESS; TRANSLATIONAL CONTROL; SELECTIVE PROTEINS; BINDING; ER; SIGNALS; CELLS; BIP; DISSOCIATION	Accumulation of unfolded proteins in the lumen of the endoplasmic reticulum activates a signal transduction cascade that culminates in the transcriptional induction of genes encoding adaptive functions. One proximal sensor for this unfolded protein response is the protein kinase/endoribonuclease IRE1alpha. IRE1alpha is a type-I transmembrane glycoprotein for which the N-terminal luminal domain (NLD) senses the accumulation of unfolded proteins. Previously we demonstrated that the NLD forms a stable ligand-independent dimer linked by disulfide bridges. In this report we have identified the cysteine residues responsible for intermolecular disulfide bonding. However, this covalent interaction was not required for dimerization and/or signaling, suggesting that a cryptic dimer interface exists in the NLD that is independent of covalent disulfide interactions. Limited proteolysis of the NLD revealed characteristic fragments, all retaining the same N-terminal sequences as full-length NLD. Biochemical and functional studies using NLD truncation mutants indicated that the dimerization domain of the NLD is confined to the conserved motifs at the N-terminal regions where putative hydrophobic interactions exist. In addition, the peptide binding domain of the endoplasmic reticulum protein chaperone BiP interacted with the N-terminal region within the NLD. Our findings suggest that the NLD has at least two distinct types of interactions mediating dimerization and function in signaling, i.e. covalent interactions involving disulfide bond formation and hydrophobic interactions, with the hydrophobic interaction being the driving force for dimerization.	Univ Michigan, Med Ctr, Howard Hughes Med Inst, Dept Biol Chem, Ann Arbor, MI 48109 USA	Howard Hughes Medical Institute; University of Michigan System; University of Michigan	Kaufman, RJ (corresponding author), Univ Michigan, Med Ctr, Howard Hughes Med Inst, Dept Biol Chem, 4570 MSRB 2,1150 W Med Ctr Dr, Ann Arbor, MI 48109 USA.		Liu, Andrew C/B-3548-2009	Liu, Andrew C/0000-0003-1927-0900	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL052173] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL52173] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Bertolotti A, 2000, NAT CELL BIOL, V2, P326, DOI 10.1038/35014014; BLONDELGUINDI S, 1993, CELL, V75, P717, DOI 10.1016/0092-8674(93)90492-9; DORNER AJ, 1992, EMBO J, V11, P1563, DOI 10.1002/j.1460-2075.1992.tb05201.x; FLAHERTY KM, 1990, NATURE, V346, P623, DOI 10.1038/346623a0; GAUT JR, 1993, J BIOL CHEM, V268, P7248; Harding HP, 2001, MOL CELL, V7, P1153, DOI 10.1016/S1097-2765(01)00264-7; Kaufman RJ, 2002, NAT REV MOL CELL BIO, V3, P411, DOI 10.1038/nrm829; Lee K, 2002, GENE DEV, V16, P452, DOI 10.1101/gad.964702; LEMMON MA, 1994, TRENDS BIOCHEM SCI, V19, P459, DOI 10.1016/0968-0004(94)90130-9; Liu CY, 2000, J BIOL CHEM, V275, P24881, DOI 10.1074/jbc.M004454200; Liu CY, 2002, J BIOL CHEM, V277, P18346, DOI 10.1074/jbc.M112454200; Ma K, 2002, J BIOL CHEM, V277, P18728, DOI 10.1074/jbc.M200903200; Mori K, 2000, CELL, V101, P451, DOI 10.1016/S0092-8674(00)80855-7; Morris JA, 1997, J BIOL CHEM, V272, P4327, DOI 10.1074/jbc.272.7.4327; Okamura K, 2000, BIOCHEM BIOPH RES CO, V279, P445, DOI 10.1006/bbrc.2000.3987; Patil C, 2001, CURR OPIN CELL BIOL, V13, P349, DOI 10.1016/S0955-0674(00)00219-2; Rudiger S, 1997, EMBO J, V16, P1501, DOI 10.1093/emboj/16.7.1501; Scheuner D, 2001, MOL CELL, V7, P1165, DOI 10.1016/S1097-2765(01)00265-9; Shen JS, 2002, DEV CELL, V3, P99, DOI 10.1016/S1534-5807(02)00203-4; Tirasophon W, 1998, GENE DEV, V12, P1812, DOI 10.1101/gad.12.12.1812; Urano F, 2000, SCIENCE, V287, P664, DOI 10.1126/science.287.5453.664; Weiss A, 1998, CELL, V94, P277, DOI 10.1016/S0092-8674(00)81469-5; Zhu XT, 1996, SCIENCE, V272, P1606, DOI 10.1126/science.272.5268.1606	23	78	84	0	24	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 16	2003	278	20					17680	17687		10.1074/jbc.M300418200	http://dx.doi.org/10.1074/jbc.M300418200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677YX	12637535	hybrid			2022-12-25	WOS:000182838300014
J	Park, JM; Kunieda, T; Kubo, T				Park, JM; Kunieda, T; Kubo, T			The activity of Mblk-1, a mushroom body-selective transcription factor from the honeybee, is modulated by the Ras/MAPK pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; APLYSIA SENSORY NEURONS; LONG-TERM FACILITATION; PHOSPHORYLATION SITES; APIS-MELLIFERA; SUBSTRATE RECOGNITION; SYNAPTIC PLASTICITY; TYROSINE KINASE; BODIES; GENE	We previously identified a gene, termed Mblk-1, that encodes a putative transcription factor with two DNA-binding motifs expressed preferentially in the mushroom body of the honeybee brain, and its preferred binding sequence, termed Mblk-1-binding element (MBE) (Takeuchi, H., Kage, E., Sawata, M., Kamikouchi, A., Ohashi, K., Ohara, M., Fujiyuki, T., Kunieda, T., Sekimizu, K., Natori, S., and Kubo, T. (2001) Insect Mol Biol 10, 487-494; Park, J.-M., Kunieda. T., Takeuchi, H., and Kubo, T. (2002) Biochem. Biophys. Res. Commun. 291, 23-28). In the present study, the effect of Mblk-1 on transcription of genes containing MBE in Drosophila Schneider's Line 2 cells was examined using a luciferase assay. Mblk-1 expression transactivated promoters containing MBEs similar to2-7-fold. Deletion experiments revealed that RHF2, the second DNA-binding domain of Mblk-1, was necessary for the transcriptional activity. Furthermore, mitogen-activated protein kinase (MAPK) phosphorylated Mblk-1 at Ser-444 in vitro, and the Mblk-1-induced transactivation was stimulated by phosphorylation of Ser-444 by the Ras/MAPK pathway in the luciferase assay. These results suggest that Mblk-1 is a transcription factor that might function in the mushroom body neuronal circuits downstream of the Ras/MAPK pathway in the honeybee brain.	Univ Tokyo, Grad Sch Sci, Dept Biol Sci, Bunkyo Ku, Tokyo 1130033, Japan	University of Tokyo	Kubo, T (corresponding author), Univ Tokyo, Grad Sch Sci, Dept Biol Sci, Bunkyo Ku, Tokyo 1130033, Japan.	stkubo@mail.ecc.u-tokyo.ac.jp	Kunieda, Takekazu/G-4946-2014	Kunieda, Takekazu/0000-0002-6256-1335; Park, Jung-Min/0000-0001-9751-1592; Kubo, Takeo/0000-0002-5914-5269				Aozasa N, 2001, EUR J BIOCHEM, V268, P2506, DOI 10.1046/j.1432-1327.2001.02133.x; Atkins CM, 1998, NAT NEUROSCI, V1, P602, DOI 10.1038/2836; BAEHRECKE EH, 1995, DEV BIOL, V171, P85, DOI 10.1006/dbio.1995.1262; Bailey CH, 1997, NEURON, V18, P913, DOI 10.1016/S0896-6273(00)80331-1; Berman DE, 1998, J NEUROSCI, V18, P10037; BINETRUY B, 1991, NATURE, V351, P122, DOI 10.1038/351122a0; Blum S, 1999, J NEUROSCI, V19, P3535; BRUNNER D, 1994, CELL, V76, P875, DOI 10.1016/0092-8674(94)90362-X; CLARKLEWIS I, 1991, J BIOL CHEM, V266, P15180; Crow T, 1998, J NEUROSCI, V18, P3480; DASH PK, 1990, NATURE, V345, P718, DOI 10.1038/345718a0; DAVIS HP, 1984, PSYCHOL BULL, V96, P518, DOI 10.1037/0033-2909.96.3.518; DAVIS RL, 1993, NEURON, V11, P1, DOI 10.1016/0896-6273(93)90266-T; De Cesare D, 1998, P NATL ACAD SCI USA, V95, P12202, DOI 10.1073/pnas.95.21.12202; Deak M, 1998, EMBO J, V17, P4426, DOI 10.1093/emboj/17.15.4426; FORTINI ME, 1992, NATURE, V355, P559, DOI 10.1038/355559a0; GERBER HP, 1994, SCIENCE, V263, P808, DOI 10.1126/science.8303297; GONZALEZ FA, 1991, J BIOL CHEM, V266, P22159; GONZALEZ GA, 1991, MOL CELL BIOL, V11, P1306, DOI 10.1128/MCB.11.3.1306; GONZALEZ GA, 1989, NATURE, V337, P749, DOI 10.1038/337749a0; Heisenberg M, 1998, LEARN MEMORY, V5, P1; Ho N, 2000, J NEUROSCI, V20, P6459, DOI 10.1523/JNEUROSCI.20-17-06459.2000; HUNTER T, 1992, CELL, V70, P375, DOI 10.1016/0092-8674(92)90162-6; JANKNECHT R, 1992, EMBO J, V11, P1045, DOI 10.1002/j.1460-2075.1992.tb05143.x; Kamikouchi A, 1998, BIOCHEM BIOPH RES CO, V242, P181, DOI 10.1006/bbrc.1997.7870; Kamikouchi A, 2000, J COMP NEUROL, V417, P501, DOI 10.1002/(SICI)1096-9861(20000221)417:4&lt;501::AID-CNE8&gt;3.0.CO;2-4; Kandel ER, 2001, SCIENCE, V294, P1030, DOI 10.1126/science.1067020; KRASNOW MA, 1989, CELL, V57, P1031, DOI 10.1016/0092-8674(89)90341-3; KUBOTA K, 1993, BIOCHEM J, V296, P497, DOI 10.1042/bj2960497; Kunieda T, 2003, FEBS LETT, V535, P61, DOI 10.1016/S0014-5793(02)03858-9; Lee CY, 2000, MOL CELL, V6, P433, DOI 10.1016/S1097-2765(00)00042-3; Lisman J, 2002, NAT REV NEUROSCI, V3, P175, DOI 10.1038/nrn753; Mantrova EY, 1998, GENE DEV, V12, P1166; Martin KC, 1997, NEURON, V18, P899, DOI 10.1016/S0896-6273(00)80330-X; Mobbs P.G., 1985, P299; MOBBS PG, 1984, J INSECT PHYSIOL, V30, P43, DOI 10.1016/0022-1910(84)90107-0; MOBBS PG, 1982, PHILOS T ROY SOC B, V298, P309, DOI 10.1098/rstb.1982.0086; MOLL T, 1991, CELL, V66, P743, DOI 10.1016/0092-8674(91)90118-I; Muller U, 1997, J NEUROBIOL, V33, P33, DOI 10.1002/(SICI)1097-4695(199707)33:1<33::AID-NEU4>3.0.CO;2-E; ONEILL EM, 1994, CELL, V78, P137, DOI 10.1016/0092-8674(94)90580-0; Park JM, 2002, BIOCHEM BIOPH RES CO, V291, P23, DOI 10.1006/bbrc.2002.6397; Rosenblum K, 2002, J NEUROSCI, V22, P5432; SCHACHER S, 1988, SCIENCE, V240, P1667, DOI 10.1126/science.2454509; SCHNEIDER I, 1972, J EMBRYOL EXP MORPH, V27, P353; SCHOLZ KP, 1988, SCIENCE, V240, P1664, DOI 10.1126/science.2837826; Sweatt JD, 2001, J NEUROCHEM, V76, P1, DOI 10.1046/j.1471-4159.2001.00054.x; Takeuchi H, 2002, FEBS LETT, V513, P230, DOI 10.1016/S0014-5793(02)02319-0; Takeuchi H, 2001, INSECT MOL BIOL, V10, P487, DOI 10.1046/j.0962-1075.2001.00288.x; VONFRISCH K, 1967, SCIENCE, V158, P1072; Walz R, 2000, NEUROBIOL LEARN MEM, V73, P11, DOI 10.1006/nlme.1999.3913; Winston, 1987, BIOL HONEYBEE; Wustenberg D, 1998, EUR J NEUROSCI, V10, P2742, DOI 10.1046/j.1460-9568.1998.t01-1-00319.x; Xing J, 1996, SCIENCE, V273, P959, DOI 10.1126/science.273.5277.959; YANG MY, 1995, NEURON, V15, P45	54	33	36	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 16	2003	278	20					18689	18694		10.1074/jbc.M300486200	http://dx.doi.org/10.1074/jbc.M300486200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677YX	12637500	hybrid			2022-12-25	WOS:000182838300142
J	Frick, IM; Akesson, P; Rasmussen, M; Schmidtchen, A; Bjorck, L				Frick, IM; Akesson, P; Rasmussen, M; Schmidtchen, A; Bjorck, L			SIC, a secreted protein of Streptococcus pyogenes that inactivates antibacterial peptides	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COMPLEMENT-INHIBITING PROTEIN; DEFENSINS; BINDING; SEQUENCE; SURFACE; IDENTIFICATION; COMPONENTS; SELECTION; STRAINS	Some isolates of the significant human pathogen Streptococcus pyogenes, including virulent strains of the M1 serotype, secrete protein SIC. This molecule, secreted in large quantities, interferes with complement function. As a result of natural selection, SIC shows a high degree of variation. Here we provide a plausible explanation for this variation and the fact that strains of the M1 serotype are the most frequent cause of severe invasive S. pyogenes infections. Thus, protein SIC was found to inactivate human neutrophil alpha-defensin and LL-37, two major antibacterial peptides involved in bacterial clearance. This inactivation protected S. pyogenes against the antibacterial effect of the peptides. Moreover, SIC isolated from S. pyogenes of the M1 serotype was more powerful in this respect than SIC variants from strains of M serotypes 12 and 55, serotypes rarely connected with invasive infections.	Lund Univ, BMC, Dept Cell & Mol Biol, Sect Mol Pathogenesis, S-22184 Lund, Sweden; Univ Lund Hosp, Dept Med Microbiol Dermatol & Infect, S-22185 Lund, Sweden	Lund University; Lund University; Skane University Hospital	Frick, IM (corresponding author), Lund Univ, BMC, Dept Cell & Mol Biol, Sect Mol Pathogenesis, B14,Tornavagen 10, S-22184 Lund, Sweden.	Inga-Maria.Frick@medkem.lu.se	Schmidtchen, Artur/F-9507-2015	Rasmussen, Magnus/0000-0003-1588-5473				Akesson P, 1996, J BIOL CHEM, V271, P1081, DOI 10.1074/jbc.271.2.1081; AKESSON P, 1994, BIOCHEM J, V300, P877, DOI 10.1042/bj3000877; Ayabe T, 2002, J BIOL CHEM, V277, P5219, DOI 10.1074/jbc.M109410200; BERGE A, 1995, J BIOL CHEM, V270, P9862, DOI 10.1074/jbc.270.17.9862; Berge A, 1998, INFECT IMMUN, V66, P3449, DOI 10.1128/IAI.66.7.3449-3453.1998; Bisno AL, 1996, NEW ENGL J MED, V334, P240, DOI 10.1056/NEJM199601253340407; Boman HG, 2000, IMMUNOL REV, V173, P5, DOI 10.1034/j.1600-065X.2000.917301.x; Brandt CM, 2001, J INFECT DIS, V183, P670, DOI 10.1086/318542; Cunningham MW, 2000, CLIN MICROBIOL REV, V13, P470, DOI 10.1128/CMR.13.3.470-511.2000; Fernie-King BA, 2002, INFECT IMMUN, V70, P4908, DOI 10.1128/IAI.70.9.4908-4916.2002; Fernie-King BA, 2001, IMMUNOLOGY, V103, P390, DOI 10.1046/j.1365-2567.2001.01249.x; FISCHETTI VA, 1989, CLIN MICROBIOL REV, V2, P285, DOI 10.1128/CMR.2.3.285-314.1989; GOMI H, 1990, J IMMUNOL, V144, P4046; GREENWOOD FC, 1963, BIOCHEM J, V89, P114, DOI 10.1042/bj0890114; HANSKI E, 1995, METHOD ENZYMOL, V253, P269; Hartas J, 1999, MICROB PATHOGENESIS, V26, P25, DOI 10.1006/mpat.1998.0244; HERWALD H, 1995, J BIOL CHEM, V270, P14634; Hoe NP, 1999, NAT MED, V5, P924, DOI 10.1038/11369; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lehrer RI, 1999, CURR OPIN IMMUNOL, V11, P23, DOI 10.1016/S0952-7915(99)80005-3; Lukomski S, 2000, INFECT IMMUN, V68, P535, DOI 10.1128/IAI.68.2.535-542.2000; Musser JM, 1998, BIOMED RES REP, P185; Nagaoka I, 2000, INFLAMM RES, V49, P73, DOI 10.1007/s000110050561; NOWAK R, 1994, SCIENCE, V264, P1665, DOI 10.1126/science.8209244; Ouellette AJ, 1996, FASEB J, V10, P1280, DOI 10.1096/fasebj.10.11.8836041; Podbielski A, 1996, GENE, V177, P137, DOI 10.1016/0378-1119(96)84178-3; Rasmussen M, 1999, J BIOL CHEM, V274, P15336, DOI 10.1074/jbc.274.22.15336; Schroder JM, 1999, INT J BIOCHEM CELL B, V31, P645, DOI 10.1016/S1357-2725(99)00013-8; SELSTED ME, 1995, TRENDS CELL BIOL, V5, P114, DOI 10.1016/S0962-8924(00)88961-8; STEINER H, 1981, NATURE, V292, P246, DOI 10.1038/292246a0; Stevens DL, 2000, ANNU REV MED, V51, P271, DOI 10.1146/annurev.med.51.1.271; Stockbauer KE, 1998, P NATL ACAD SCI USA, V95, P3128, DOI 10.1073/pnas.95.6.3128	32	134	138	1	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 9	2003	278	19					16561	16566		10.1074/jbc.M301995200	http://dx.doi.org/10.1074/jbc.M301995200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677QG	12621031	hybrid			2022-12-25	WOS:000182818600017
J	Palacios, F; D'Souza-Schorey, C				Palacios, F; D'Souza-Schorey, C			Modulation of Rac1 and ARF6 activation during epithelial cell scattering	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPATOCYTE GROWTH-FACTOR; ADP-RIBOSYLATION FACTOR-6; TYROSINE PHOSPHORYLATION; ADHERENS JUNCTIONS; BETA-CATENIN; RHO FAMILY; MDCK CELLS; CADHERIN; ADHESION; GTPASE	Epithelial cell scattering encompasses the dissolution of intercellular junctions, cell-cell dissociation, cell spreading, and motility. The Rac1 and ARF6 GTPases have been shown to regulate one or more of these aforementioned processes. In fact, activated Rac1 has been shown to promote cell-cell adhesion as well as to enhance cell motility, leading to conflicting reports on the effect of Rac1 activation on epithelial cell motility. In this study, we have examined the activation profiles of endogenous Rac1 and ARF6 during the sequential stages of epithelial cell scattering. Using Madin-Darby canine kidney cells treated with hepatocyte growth factor/scatter factor or cell lines stably expressing activated v-Src, we show that Rac1 and ARF6 exhibit distinct activation profiles during cell scattering. We have found that an initial ARF6-dependent decrease in the levels of Rac1-GTP is necessary to induce cell-cell dissociation. This is followed by a steady increase in Rac1 and ARF6 activation and cell migration. In sum, this study documents the progression of ARF6 and Rac1 activities during epithelial cell scattering.	Univ Notre Dame, Dept Biol Sci, Notre Dame, IN 46556 USA; Univ Notre Dame, Walther Canc Inst, Notre Dame, IN 46556 USA	University of Notre Dame; University of Notre Dame; Walther Cancer Institute	D'Souza-Schorey, C (corresponding author), Univ Notre Dame, Dept Biol Sci, Box 369,Calvin Life Sci Bldg, Notre Dame, IN 46556 USA.							BEHRENS J, 1993, J CELL BIOL, V120, P757, DOI 10.1083/jcb.120.3.757; Benard V, 2002, METHOD ENZYMOL, V345, P349; BIRCHMEIER C, 1993, ANNU REV CELL BIOL, V9, P511, DOI 10.1146/annurev.cb.09.110193.002455; Birchmeier W, 1996, CURR TOP MICROBIOL, V213, P117; Boshans RL, 2000, MOL CELL BIOL, V20, P3685, DOI 10.1128/MCB.20.10.3685-3694.2000; Braga VMM, 1997, J CELL BIOL, V137, P1421, DOI 10.1083/jcb.137.6.1421; Fenteany G, 2000, CURR BIOL, V10, P831, DOI 10.1016/S0960-9822(00)00579-0; Gimond C, 1999, J CELL BIOL, V147, P1325, DOI 10.1083/jcb.147.6.1325; Gumbiner BM, 2000, J CELL BIOL, V148, P399, DOI 10.1083/jcb.148.3.399; Gumbiner BM, 1996, CELL, V84, P345, DOI 10.1016/S0092-8674(00)81279-9; Hordijk PL, 1997, SCIENCE, V278, P1464, DOI 10.1126/science.278.5342.1464; KINCH MS, 1995, J CELL BIOL, V130, P461, DOI 10.1083/jcb.130.2.461; Nakagawa M, 2001, J CELL SCI, V114, P1829; Noren NK, 2001, J BIOL CHEM, V276, P33305, DOI 10.1074/jbc.C100306200; Otsuki Y, 2001, P NATL ACAD SCI USA, V98, P4385, DOI 10.1073/pnas.071411598; Palacios F, 2002, NAT CELL BIOL, V4, P929, DOI 10.1038/ncb881; Palacios F, 2001, EMBO J, V20, P4973, DOI 10.1093/emboj/20.17.4973; Radhakrishna H, 1999, J CELL SCI, V112, P855; RIDLEY AJ, 1995, MOL CELL BIOL, V15, P1110; Royal I, 2000, MOL BIOL CELL, V11, P1709, DOI 10.1091/mbc.11.5.1709; Santy LC, 2001, J CELL BIOL, V154, P599, DOI 10.1083/jcb.200104019; Schmidt J W, 1993, Semin Cell Biol, V4, P161, DOI 10.1006/scel.1993.1020; Schweitzer JK, 2002, J BIOL CHEM, V277, P27210, DOI 10.1074/jbc.M201569200; SHIBAMOTO S, 1994, CELL ADHES COMMUN, V1, P295, DOI 10.3109/15419069409097261; Takaishi K, 1997, J CELL BIOL, V139, P1047, DOI 10.1083/jcb.139.4.1047; THIERY JP, 1982, DEV BIOL, V93, P324, DOI 10.1016/0012-1606(82)90121-X; Vasioukhin V, 2000, CELL, V100, P209, DOI 10.1016/S0092-8674(00)81559-7; Vasioukhin V, 2001, CURR OPIN CELL BIOL, V13, P76, DOI 10.1016/S0955-0674(00)00177-0; Yang CZ, 1998, J BIOL CHEM, V273, P4006, DOI 10.1074/jbc.273.7.4006; Yap AS, 1997, ANNU REV CELL DEV BI, V13, P119, DOI 10.1146/annurev.cellbio.13.1.119	30	76	78	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 9	2003	278	19					17395	17400		10.1074/jbc.M300998200	http://dx.doi.org/10.1074/jbc.M300998200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677QG	12609992	hybrid			2022-12-25	WOS:000182818600126
J	Sadtler, S; Laube, B; Lashub, A; Nicke, A; Betz, H; Schmalzing, G				Sadtler, S; Laube, B; Lashub, A; Nicke, A; Betz, H; Schmalzing, G			A basic cluster determines topology of the cytoplasmic M3-M4 loop of the glycine receptor alpha 1 subunit	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEMBRANE-PROTEIN TOPOLOGY; CHARGED AMINO-ACIDS; GATED ION CHANNELS; TRANSMEMBRANE PROTEIN; FUNCTIONAL EXPRESSION; ENDOPLASMIC-RETICULUM; MICROSOMAL MEMBRANE; ESCHERICHIA-COLI; SIGNAL SEQUENCE; XENOPUS OOCYTES	The inhibitory glycine receptor is a member of the ligand-gated ion channel superfamily of neurotransmitter receptors, which are composed of homologous subunits with four transmembrane segments ( M1-M4), each. Here, we demonstrate that the correct topology of the glycine receptor alpha1 subunit depends critically on six positively charged residues within a basic cluster, RFR-RKRR, located in the large cytoplasmic loop (designated M3-M4 loop) following the C-terminal end of M3. Neutralization of one or more charges of this cluster, but not of other charged residues in the M3-M4 loop, led to an aberrant translocation into the endoplasmic reticulum lumen of the M3-M4 loop. However, when two of the three basic charges located in the ectodomain linking M2 and M3 were neutralized, in addition to two charges of the basic cluster, endoplasmic reticulum disposition of the M3-M4 loop was prevented. We conclude that a high density of basic residues C-terminal to M3 is required to compensate for the presence of positively charged residues in the M2-M3 ectodomain, which otherwise impair correct membrane integration of the M3 segment.	Rhein Westfal TH Aachen, Dept Mol Pharmacol, Sch Med, D-52074 Aachen, Germany; Max Planck Inst Brain Res, Dept Neurochem, D-60528 Frankfurt, Germany	RWTH Aachen University; Max Planck Society	Schmalzing, G (corresponding author), Rhein Westfal TH Aachen, Dept Mol Pharmacol, Sch Med, Wendlingweg 2, D-52074 Aachen, Germany.			Nicke, Annette/0000-0001-6798-505X				AKAGI H, 1991, FEBS LETT, V281, P160, DOI 10.1016/0014-5793(91)80383-E; ANDERSSON H, 1994, EMBO J, V13, P2267, DOI 10.1002/j.1460-2075.1994.tb06508.x; ANDERSSON H, 1992, J BIOL CHEM, V267, P1491; ANDREWS DW, 1992, J BIOL CHEM, V267, P7761; BELTZER JP, 1991, J BIOL CHEM, V266, P973; BLOBEL G, 1980, P NATL ACAD SCI-BIOL, V77, P1496, DOI 10.1073/pnas.77.3.1496; Bogdanov M, 2002, EMBO J, V21, P2107, DOI 10.1093/emboj/21.9.2107; Buttner C, 2001, J BIOL CHEM, V276, P42978, DOI 10.1074/jbc.M102121200; GAFVELIN G, 1994, CELL, V77, P401, DOI 10.1016/0092-8674(94)90155-4; Gafvelin G, 1997, J BIOL CHEM, V272, P6119, DOI 10.1074/jbc.272.10.6119; GALLUSSER A, 1990, EMBO J, V9, P2723, DOI 10.1002/j.1460-2075.1990.tb07459.x; Goder V, 1999, J CELL BIOL, V147, P257, DOI 10.1083/jcb.147.2.257; Goder V, 2001, FEBS LETT, V504, P87, DOI 10.1016/S0014-5793(01)02712-0; Griffon N, 1999, EMBO J, V18, P4711, DOI 10.1093/emboj/18.17.4711; Harley CA, 1996, J BIOL CHEM, V271, P24625, DOI 10.1074/jbc.271.40.24625; HARTMANN E, 1989, P NATL ACAD SCI USA, V86, P5786, DOI 10.1073/pnas.86.15.5786; Harvey RJ, 2000, HANDB EXP PHARM, V147, P479; Juretic D, 2002, J CHEM INF COMP SCI, V42, P620, DOI 10.1021/ci010263s; KUHSE J, 1995, CURR OPIN NEUROBIOL, V5, P318, DOI 10.1016/0959-4388(95)80044-1; KUHSE J, 1993, NEURON, V11, P1049, DOI 10.1016/0896-6273(93)90218-G; KUHSE J, 1990, J BIOL CHEM, V265, P22317; KUROIWA T, 1991, J BIOL CHEM, V266, P9251; LANGOSCH D, 1994, EMBO J, V13, P4223, DOI 10.1002/j.1460-2075.1994.tb06742.x; LANGOSCH D, 1988, P NATL ACAD SCI USA, V85, P7394, DOI 10.1073/pnas.85.19.7394; Lewis TM, 1998, J PHYSIOL-LONDON, V507, P25, DOI 10.1111/j.1469-7793.1998.025bu.x; LIPP J, 1989, J CELL BIOL, V109, P2013, DOI 10.1083/jcb.109.5.2013; Nicke A, 1998, EMBO J, V17, P3016, DOI 10.1093/emboj/17.11.3016; Nicke A, 1999, J RECEPT SIGNAL TR R, V19, P493, DOI 10.3109/10799899909036667; NILSSON IM, 1990, CELL, V62, P1135, DOI 10.1016/0092-8674(90)90390-Z; PFEIFFER F, 1981, BRAIN RES, V226, P273, DOI 10.1016/0006-8993(81)91099-4; Rapoport TA, 1996, ANNU REV BIOCHEM, V65, P271; Sato M, 1999, J BIOL CHEM, V274, P24721, DOI 10.1074/jbc.274.35.24721; SATO T, 1990, EMBO J, V9, P2391, DOI 10.1002/j.1460-2075.1990.tb07414.x; SCHAGGER H, 1994, ANAL BIOCHEM, V217, P220, DOI 10.1006/abio.1994.1112; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHMALZING G, 1991, BIOCHEM J, V279, P329, DOI 10.1042/bj2790329; SCHMIEDEN V, 1989, EMBO J, V8, P695, DOI 10.1002/j.1460-2075.1989.tb03428.x; vanKlompenburg W, 1997, EMBO J, V16, P4261, DOI 10.1093/emboj/16.14.4261; VONHEIJNE G, 1988, EUR J BIOCHEM, V174, P671; Wahlberg JM, 1997, J CELL BIOL, V137, P555, DOI 10.1083/jcb.137.3.555; WESSELS HP, 1988, CELL, V55, P61, DOI 10.1016/0092-8674(88)90009-8; Wilkinson BM, 1996, J BIOL CHEM, V271, P25590, DOI 10.1074/jbc.271.41.25590; ZHANG JT, 1995, J BIOL CHEM, V270, P1742, DOI 10.1074/jbc.270.4.1742	43	37	37	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 9	2003	278	19					16782	16790		10.1074/jbc.M213077200	http://dx.doi.org/10.1074/jbc.M213077200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677QG	12611885	hybrid			2022-12-25	WOS:000182818600046
J	Rachidi, W; Mange, A; Senator, A; Guiraud, P; Riondel, J; Benboubetra, M; Favier, A; Lehmann, S				Rachidi, W; Mange, A; Senator, A; Guiraud, P; Riondel, J; Benboubetra, M; Favier, A; Lehmann, S			Prion infection impairs copper binding of cultured cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OXIDATIVE STRESS; WILD-TYPE; PROTEIN; MUTANT; TRANSPORT; BRAIN	The molecular mechanism of neurodegeneration in transmissible spongiform encephalopathies (TSEs) remains unclear. Using radioactive copper (Cu-64) at physiological concentration, we showed that prion infected cells display a marked reduction in copper binding. The level of full-length prion protein known to bind the metal ion was not modified in infected cells, but a fraction of this protein was not releasable from the membrane by phosphatidylinositol-specific phospholipase C. Our results suggest that prion infection modulates copper content at a cellular level and that modification of copper homeostasis plays a determinant role in the neuropathology of TSE.	CNRS, IGH, UPR 1142, F-34396 Montpellier 5, France; Fac Pharm, Lab Biol Stress Oxydant, F-38706 La Tronche, France; CNRS, UPR 1142, Inst Genet Humaine, F-34396 Montpellier, France; CNRS, CEA, Lab Les Acides Nucleiques, F-38000 Grenoble, France; Univ Setif, Fac Sci, Lab Appl Biochem, Setif 19000, Algeria	Centre National de la Recherche Scientifique (CNRS); Universite de Montpellier; Communaute Universite Grenoble Alpes; UDICE-French Research Universities; Universite Grenoble Alpes (UGA); Centre National de la Recherche Scientifique (CNRS); Universite de Montpellier; CEA; Centre National de la Recherche Scientifique (CNRS); Universite Ferhat Abbas Setif	Lehmann, S (corresponding author), CNRS, IGH, UPR 1142, 141 Rue Cardonille, F-34396 Montpellier 5, France.	Sylvain.Lehmann@igh.cnrs.fr	Mange, Alain/U-1157-2017; Rachidi, Walid/U-6423-2019; Lehmann, Sylvain/P-1301-2017; Rachidi, Walid/H-1016-2018	Mange, Alain/0000-0002-1566-9407; Lehmann, Sylvain/0000-0001-6117-562X; Rachidi, Walid/0000-0002-0829-7799; Abderrahmane, Senator/0000-0002-3472-0538				Beranger F, 2002, J BIOL CHEM, V277, P38972, DOI 10.1074/jbc.M205110200; Brown DR, 2000, EMBO J, V19, P1180, DOI 10.1093/emboj/19.6.1180; Brown DR, 2001, TRENDS NEUROSCI, V24, P85, DOI 10.1016/S0166-2236(00)01689-1; Brown DR, 1997, NATURE, V390, P684, DOI 10.1038/37733; Butterfield DA, 2001, CURR MED CHEM, V8, P815, DOI 10.2174/0929867013373048; CAUGHEY B, 1989, J VIROL, V63, P175, DOI 10.1128/JVI.63.1.175-181.1989; CHEN SG, 1995, J BIOL CHEM, V270, P19173, DOI 10.1074/jbc.270.32.19173; Chiesa R, 1998, NEURON, V21, P1339, DOI 10.1016/S0896-6273(00)80653-4; Collinge J, 2001, ANNU REV NEUROSCI, V24, P519, DOI 10.1146/annurev.neuro.24.1.519; Daude N, 1997, J BIOL CHEM, V272, P11604, DOI 10.1074/jbc.272.17.11604; Herms J, 1999, J NEUROSCI, V19, P8866, DOI 10.1523/JNEUROSCI.19-20-08866.1999; Horn N, 1999, J TRACE ELEM EXP MED, V12, P297; KRETZSCHMAR HA, 1986, AM J PATHOL, V122, P1; Lehmann S, 2002, CURR OPIN CHEM BIOL, V6, P187, DOI 10.1016/S1367-5931(02)00295-8; LEHMANN S, 1995, J BIOL CHEM, V270, P24589, DOI 10.1074/jbc.270.41.24589; Lehmann S, 1996, J BIOL CHEM, V271, P1633, DOI 10.1074/jbc.271.3.1633; Mercer JFB, 2001, TRENDS MOL MED, V7, P64, DOI 10.1016/S1471-4914(01)01920-7; Milhavet O, 2000, P NATL ACAD SCI USA, V97, P13937, DOI 10.1073/pnas.250289197; Milhavet O, 2002, BRAIN RES REV, V38, P328, DOI 10.1016/S0165-0173(01)00150-3; Milhavet O, 2000, J NEUROCHEM, V74, P222, DOI 10.1046/j.1471-4159.2000.0740222.x; Narwa R, 1999, BIOCHEMISTRY-US, V38, P8770, DOI 10.1021/bi990736c; Nishida N, 2000, J VIROL, V74, P320, DOI 10.1128/JVI.74.1.320-325.2000; Opazo C, 2003, BIOMETALS, V16, P91, DOI 10.1023/A:1020795422185; PRUSINER SB, 1982, SCIENCE, V216, P136, DOI 10.1126/science.6801762; Prusiner SB, 1998, CELL, V93, P337, DOI 10.1016/S0092-8674(00)81163-0; Rachidi W, 2003, J BIOL CHEM, V278, P9064, DOI 10.1074/jbc.M211830200; Sayre LM, 2000, CELL MOL BIOL, V46, P731; Shaked Y, 2001, J VIROL, V75, P7872, DOI 10.1128/JVI.75.17.7872-7874.2001; STAHL N, 1987, CELL, V51, P229, DOI 10.1016/0092-8674(87)90150-4; TARABOULOS A, 1992, MOL BIOL CELL, V3, P851, DOI 10.1091/mbc.3.8.851; VIRET J, 1981, BIOCHEM BIOPH RES CO, V101, P830, DOI 10.1016/0006-291X(81)91825-8; White AR, 1999, AM J PATHOL, V155, P1723, DOI 10.1016/S0002-9440(10)65487-9; Wong BS, 2000, BIOCHEM BIOPH RES CO, V273, P136, DOI 10.1006/bbrc.2000.2911; Wong BS, 2001, J NEUROCHEM, V78, P1400, DOI 10.1046/j.1471-4159.2001.00522.x	34	53	56	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 25	2003	278	17					14595	14598		10.1074/jbc.C300092200	http://dx.doi.org/10.1074/jbc.C300092200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	672HX	12637548	hybrid			2022-12-25	WOS:000182516100003
J	Vernon, EG; Malik, K; Reynolds, P; Powlesland, R; Dallosso, AR; Jackson, S; Henthorn, K; Green, ED; Brown, KW				Vernon, EG; Malik, K; Reynolds, P; Powlesland, R; Dallosso, AR; Jackson, S; Henthorn, K; Green, ED; Brown, KW			The parathyroid hormone-responsive B1 gene is interrupted by a t(1;7)(q42;p15) breakpoint associated with Wilms' tumour	ONCOGENE			English	Article						Wilms' tumour; chromosome 7; PTH-B1 gene	SHORT ARM; HETEROZYGOSITY; TRANSLOCATION; CHROMOSOME-7; CELLS; LOCUS; IDENTIFICATION; ABNORMALITIES; MUTATIONS; ALLELES	Wilms' tumour (WT) has a diverse and complex molecular aetiology, with several different loci identified by cytogenetic and molecular analyses. One such locus is on chromosome 7p, where cytogenetic abnormalities and loss of heterozygosity (LOH) indicate the presence of a Wilms' tumour suppressor gene. In order to isolate a candidate gene for this locus, we have characterized the breakpoint regions at a novel constitutional chromosome translocation (t(1;7)(q42;p15)), found in a child with WT and skeletal abnormalities. We identified two genes that were interrupted by the translocation: the parathyroid hormone-responsive B1 gene (PTH-B1) at 7p and obscurin at 1q. With no evidence for LOH at 1q42, we focused on the characterization of PTH-B1. We detected novel alternately spliced isoforms of PTH-B1, which were expressed in a wide range of adult and foetal tissues. Importantly, expression of two isoforms were disrupted in the WT of the t(1;7) patient. We also identified an additional splice isoform expressed only in 7p LOH tumours. The disruption of PTH-B1 by the t(1;7), together with aberrant splicing in sporadic WTs, suggests that PTH-B1 is a candidate for the 7p Wilms' tumour suppressor gene.	Univ Bristol, Sch Med Sci, Dept Pathol & Microbiol, CLIC Res Unit, Bristol BS8 1TD, Avon, England; MGH Canc Ctr, Boston, MA USA; NHGRI, Genome Technol Branch, NIH, Bethesda, MD 20892 USA	University of Bristol; National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI)	Brown, KW (corresponding author), Univ Bristol, Sch Med Sci, Dept Pathol & Microbiol, CLIC Res Unit, Bristol BS8 1TD, Avon, England.		dallosso, anthony/A-8335-2008; Brown, Keith/C-3355-2009	Brown, Keith/0000-0002-4258-5129; Vernon, Ellen/0000-0002-8344-1025; Dallosso, Anthony/0000-0002-1460-2550; Malik, Karim/0000-0002-8965-200X				Adams AE, 1999, BONE, V24, P305, DOI 10.1016/S8756-3282(98)00188-4; Balmain A, 2002, NATURE, V417, P235, DOI 10.1038/417235a; Baudry D, 2000, CLIN CANCER RES, V6, P3957; BENTON WD, 1977, SCIENCE, V196, P180, DOI 10.1126/science.322279; BROWN KW, 1993, GENE CHROMOSOME CANC, V8, P74, DOI 10.1002/gcc.2870080203; BROWN KW, 1989, BRIT J CANCER, V60, P25, DOI 10.1038/bjc.1989.213; BROWN KW, 2001, EXP REV MOL MED, V14; DEKRAKER J, 1979, HELV PAEDIATR ACTA, V34, P459; GESSLER M, 1990, NATURE, V343, P774, DOI 10.1038/343774a0; GRUNDY PE, 1994, CANCER RES, V54, P2331; Grundy RG, 1998, ONCOGENE, V17, P395, DOI 10.1038/sj.onc.1201927; HENRY I, 1989, P NATL ACAD SCI USA, V86, P3247, DOI 10.1073/pnas.86.9.3247; HEWITT M, 1991, J MED GENET, V28, P411, DOI 10.1136/jmg.28.6.411; KOUFOS A, 1989, AM J HUM GENET, V44, P711; Little M, 1997, HUM MUTAT, V9, P209, DOI 10.1002/(SICI)1098-1004(1997)9:3<209::AID-HUMU2>3.0.CO;2-2; Lobbert RW, 1998, GENE CHROMOSOME CANC, V21, P347, DOI 10.1002/(SICI)1098-2264(199804)21:4<347::AID-GCC9>3.0.CO;2-Z; Miozzo M, 1996, GENOMICS, V37, P310, DOI 10.1006/geno.1996.0565; Nissim-Rafinia M, 2002, TRENDS GENET, V18, P123, DOI 10.1016/S0168-9525(01)02619-1; Perotti D, 2001, GENE CHROMOSOME CANC, V31, P42, DOI 10.1002/gcc.1116; PING AJ, 1989, AM J HUM GENET, V44, P720; Powlesland RM, 2000, BRIT J CANCER, V82, P323, DOI 10.1054/bjoc.1999.0922; RADICE P, 1995, GENOMICS, V27, P497, DOI 10.1006/geno.1995.1082; REEVE AE, 1989, MOL CELL BIOL, V9, P1799, DOI 10.1128/MCB.9.4.1799; Reynolds PA, 1996, GENE CHROMOSOME CANC, V17, P151, DOI 10.1002/(SICI)1098-2264(199611)17:3<151::AID-GCC2>3.0.CO;2-3; RIVERA H, 1995, CANCER GENET CYTOGEN, V81, P97, DOI 10.1016/S0165-4608(94)00199-5; Sambrook J., 2002, MOL CLONING LAB MANU; SAWYER JR, 1993, CANCER GENET CYTOGEN, V69, P57, DOI 10.1016/0165-4608(93)90114-2; SMIT AFA, 1993, NUCLEIC ACIDS RES, V21, P1863, DOI 10.1093/nar/21.8.1863; WILMORE HP, 1994, CANCER GENET CYTOGEN, V77, P93, DOI 10.1016/0165-4608(94)90221-6; WILSON K, 1986, BIOL GUIDE PRINCIPLE; Young P, 2001, J CELL BIOL, V154, P123, DOI 10.1083/jcb.200102110	31	29	31	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 6	2003	22	9					1371	1380		10.1038/sj.onc.1206332	http://dx.doi.org/10.1038/sj.onc.1206332			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	652CA	12618763				2022-12-25	WOS:000181360900012
J	Diviani, D; Lattion, AL; Abuin, L; Staub, O; Cotecchia, S				Diviani, D; Lattion, AL; Abuin, L; Staub, O; Cotecchia, S			The adaptor complex 2 directly interacts with the alpha(1b)-adrenergic receptor and plays a role in receptor endocytosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CLATHRIN-ADAPTER; SORTING SIGNALS; BETA-ARRESTIN; BINDING-SITE; INTERNALIZATION; PHOSPHORYLATION; DESENSITIZATION; EXPRESSION; MOTIF; AP-2	Using the yeast two-hybrid system, we identified the mu(2) subunit of the clathrin adaptor complex 2 as a protein interacting with the C-tail of the alpha(1b)-adrenergic receptor (AR). Direct association between the alpha(1b)-AR and mu(2) was demonstrated using a solid phase overlay assay. The alpha(1b)-AR/mu(2) interaction occurred inside the cells, as shown by the finding that the transfected alpha(1b)-AR and the endogenous mu(2) could be coimmunoprecipitated from HEK-293 cell extracts. Mutational analysis of the alpha(1b)-AR revealed that the binding site for mu(2) does not involve canonical YXXPhi or dileucine motifs but a stretch of eight arginines on the receptor C-tail. The binding domain of mu(2) for the receptor C-tail involves both its N terminus and the subdomain B of its C-terminal portion. The alpha(1b)-AR specifically interacted with mu(2), but not with the mu(1), mu(3), or mu(4) subunits belonging to other AP complexes. The deletion of the mu(2) binding site in the C-tail markedly decreased agonist-induced receptor internalization as demonstrated by confocal microscopy as well as by the results of a surface receptor biotinylation assay. The direct association of the adaptor complex 2 with a G protein-coupled receptor has not been reported so far and might represent a common mechanism underlying clathrin-mediated receptor endocytosis.	Fac Med, Inst Pharmacol & Toxicol, CH-1005 Lausanne, Switzerland	University of Geneva	Cotecchia, S (corresponding author), Fac Med, Inst Pharmacol & Toxicol, Rue Bugnon 27, CH-1005 Lausanne, Switzerland.			Diviani, Dario/0000-0003-4375-3718				Bjorklof K, 2002, BIOCHEMISTRY-US, V41, P4281, DOI 10.1021/bi015790j; Chapman ER, 1998, J BIOL CHEM, V273, P32966, DOI 10.1074/jbc.273.49.32966; COLLAWN JF, 1990, CELL, V63, P1061, DOI 10.1016/0092-8674(90)90509-D; Collins BM, 2002, CELL, V109, P523, DOI 10.1016/S0092-8674(02)00735-3; COTECCHIA S, 1988, P NATL ACAD SCI USA, V85, P7159, DOI 10.1073/pnas.85.19.7159; Diviani D, 1997, J BIOL CHEM, V272, P28712, DOI 10.1074/jbc.272.45.28712; Diviani D, 1996, J BIOL CHEM, V271, P5049; Ferguson SSG, 2001, PHARMACOL REV, V53, P1; Ferguson SSG, 1996, SCIENCE, V271, P363, DOI 10.1126/science.271.5247.363; FONSECA MI, 1995, J BIOL CHEM, V270, P8902, DOI 10.1074/jbc.270.15.8902; Goodman OB, 1996, NATURE, V383, P447, DOI 10.1038/383447a0; Haucke V, 2000, EMBO J, V19, P6011, DOI 10.1093/emboj/19.22.6011; Kim YM, 2002, J BIOL CHEM, V277, P30760, DOI 10.1074/jbc.M204528200; Kohout TA, 2003, MOL PHARMACOL, V63, P9, DOI 10.1124/mol.63.1.9; Laporte SA, 1999, P NATL ACAD SCI USA, V96, P3712, DOI 10.1073/pnas.96.7.3712; Laporte SA, 2002, J BIOL CHEM, V277, P9247, DOI 10.1074/jbc.M108490200; LATTION AL, 1994, J BIOL CHEM, V269, P22887; LEEBLUNDBERG LMF, 1987, J BIOL CHEM, V262, P3098; Madrid R, 2001, EMBO J, V20, P7008, DOI 10.1093/emboj/20.24.7008; Mhaouty-Kodja S, 1999, MOL PHARMACOL, V55, P339, DOI 10.1124/mol.55.2.339; OHNO H, 1995, SCIENCE, V269, P1872, DOI 10.1126/science.7569928; Owen DJ, 1998, SCIENCE, V282, P1327, DOI 10.1126/science.282.5392.1327; Pearse BMF, 2000, CURR OPIN STRUC BIOL, V10, P220, DOI 10.1016/S0959-440X(00)00071-3; Perry SJ, 2002, TRENDS CELL BIOL, V12, P130, DOI 10.1016/S0962-8924(01)02239-5; Rapoport I, 1998, EMBO J, V17, P2148, DOI 10.1093/emboj/17.8.2148; Robinson MS, 2001, CURR OPIN CELL BIOL, V13, P444, DOI 10.1016/S0955-0674(00)00235-0; Rodionov DG, 1998, J BIOL CHEM, V273, P6005, DOI 10.1074/jbc.273.11.6005; Simmen T, 2002, NAT CELL BIOL, V4, P154, DOI 10.1038/ncb745; Sorkin A, 1996, J BIOL CHEM, V271, P13377, DOI 10.1074/jbc.271.23.13377; Weixel KM, 2001, J BIOL CHEM, V276, P46251, DOI 10.1074/jbc.M104545200	30	57	59	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 23	2003	278	21					19331	19340		10.1074/jbc.M302110200	http://dx.doi.org/10.1074/jbc.M302110200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	679PY	12644451	hybrid			2022-12-25	WOS:000182932200080
J	Longhi, S; Receveur-Brechot, V; Karlin, D; Johansson, K; Darbon, H; Bhella, D; Yeo, R; Finet, S; Canard, B				Longhi, S; Receveur-Brechot, V; Karlin, D; Johansson, K; Darbon, H; Bhella, D; Yeo, R; Finet, S; Canard, B			The C-terminal domain of the measles virus nucleoprotein is intrinsically disordered and folds upon binding to the C-terminal moiety of the phosphoprotein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOCAPSID-LIKE STRUCTURES; NATIVELY UNFOLDED PROTEINS; ANGLE NEUTRON-SCATTERING; X-RAY-SCATTERING; P-PROTEIN; UNSTRUCTURED PROTEINS; GENOME REPLICATION; ESCHERICHIA-COLI; RNA-SYNTHESIS; CONFORMATIONAL-CHANGES	The nucleoprotein of measles virus consists of an N-terminal moiety, N-CORE, resistant to proteolysis and a C-terminal moiety, N-TAIL, hypersensitive to proteolysis and not visible as a distinct domain by electron microscopy. We report the bacterial expression, purification, and characterization of measles virus N-TAIL. Using nuclear magnetic resonance, circular dichroism, gel filtration, dynamic light scattering, and small angle x-ray scattering, we show that N-TAIL is not structured in solution. Its sequence and spectroscopic and hydrodynamic properties indicate that N-TAIL belongs to the premolten globule subfamily within the class of intrinsically disordered proteins. The same epitopes are exposed in N-TAIL and within the nucleoprotein, which rules out dramatic conformational changes in the isolated N-TAIL domain compared with the full-length nucleoprotein. Most unstructured proteins undergo some degree of folding upon binding to their partners, a process termed "induced folding." We show that N-TAIL is able to bind its physiological partner, the phosphoprotein, and that it undergoes such an unstructured-to-structured transition upon binding to the C-terminal moiety of the phosphoprotein. The presence of flexible regions at the surface of the viral nucleocapsid would enable plastic interactions with several partners, whereas the gain of structure arising from induced folding would lead to modulation of these interactions. These results contribute to the study of the emerging field of natively unfolded proteins.	ESIL, CNRS, UMR 6098, F-13288 Marseille 09, France; Univ Aix Marseille 1, ESIL, F-13288 Marseille, France; Univ Aix Marseille 2, ESIL, F-13288 Marseille 09, France; Inst Virol, MRC, Virol Unit, Glasgow G11 5JR, Lanark, Scotland; European Synchrotron Radiat Facil, F-38043 Grenoble, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Aix-Marseille Universite; UDICE-French Research Universities; Aix-Marseille Universite; UDICE-French Research Universities; Aix-Marseille Universite; University of Glasgow; European Synchrotron Radiation Facility (ESRF)	Longhi, S (corresponding author), ESIL, CNRS, UMR 6098, Case 925,163 Ave Luminy,Campus Luminy, F-13288 Marseille 09, France.		LONGHI, Sonia/M-5305-2014; Bhella, David/J-8514-2012	LONGHI, Sonia/0000-0002-6829-6771; Bhella, David/0000-0003-2096-8310; Receveur-Brechot, Veronique/0000-0002-7464-6192; Canard, Bruno/0000-0003-4924-1991	Medical Research Council [MC_U130115834] Funding Source: Medline; MRC [MC_U130115834] Funding Source: UKRI	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Bankamp B, 1996, VIROLOGY, V216, P272, DOI 10.1006/viro.1996.0060; Bergmann A, 2000, J APPL CRYSTALLOGR, V33, P1212, DOI 10.1107/S0021889800008372; Bhella D, 2002, J GEN VIROL, V83, P1831, DOI 10.1099/0022-1317-83-8-1831; BRINKMANN U, 1989, GENE, V85, P109, DOI 10.1016/0378-1119(89)90470-8; BRIZZARD BL, 1994, BIOTECHNIQUES, V16, P730; Brown CJ, 2002, J MOL EVOL, V55, P104, DOI 10.1007/s00239-001-2309-6; BUCHHOLZ CJ, 1993, J VIROL, V67, P5803, DOI 10.1128/JVI.67.10.5803-5812.1993; BUCHHOLZ CJ, 1994, VIROLOGY, V204, P770, DOI 10.1006/viro.1994.1592; BUCKLAND R, 1989, J GEN VIROL, V70, P435, DOI 10.1099/0022-1317-70-2-435; Coronel EC, 2001, J VIROL, V75, P1117, DOI 10.1128/JVI.75.3.1117-1123.2001; Cuff JA, 1998, BIOINFORMATICS, V14, P892, DOI 10.1093/bioinformatics/14.10.892; CURRAN J, 1993, J VIROL, V67, P4358, DOI 10.1128/JVI.67.7.4358-4364.1993; Curran J, 1999, ADV VIRUS RES, V54, P403, DOI 10.1016/S0065-3527(08)60373-5; CURRAN J, 1995, J VIROL, V69, P849, DOI 10.1128/JVI.69.2.849-855.1995; Curran J, 1998, J VIROL, V72, P4274, DOI 10.1128/JVI.72.5.4274-4280.1998; Curran J, 1996, VIROLOGY, V221, P130, DOI 10.1006/viro.1996.0359; CURRAN J, 1994, VIROLOGY, V202, P875, DOI 10.1006/viro.1994.1409; CURRAN J, 1995, VIROLOGY, V214, P139, DOI 10.1006/viro.1995.9946; Daughdrill GW, 1998, BIOCHEMISTRY-US, V37, P1076, DOI 10.1021/bi971952t; De BP, 1999, MICROSC RES TECHNIQ, V47, P114, DOI 10.1002/(SICI)1097-0029(19991015)47:2<114::AID-JEMT4>3.3.CO;2-5; Dedmon MM, 2002, P NATL ACAD SCI USA, V99, P12681, DOI 10.1073/pnas.202331299; DESHPANDE KL, 1984, VIROLOGY, V139, P32, DOI 10.1016/0042-6822(84)90327-1; DIAMOND R, 1974, J MOL BIOL, V82, P371, DOI 10.1016/0022-2836(74)90598-1; Dunker AK, 2001, NAT BIOTECHNOL, V19, P805, DOI 10.1038/nbt0901-805; Dunker AK, 2001, J MOL GRAPH MODEL, V19, P26, DOI 10.1016/S1093-3263(00)00138-8; DUNKER AK, 1998, PAC S BIOCOMP, V3, P473; Dyson HJ, 2002, CURR OPIN STRUC BIOL, V12, P54, DOI 10.1016/S0959-440X(02)00289-0; EGELMAN EH, 1989, J VIROL, V63, P2233, DOI 10.1128/JVI.63.5.2233-2243.1989; FINCH JT, 1970, J GEN VIROL, V6, P141, DOI 10.1099/0022-1317-6-1-141; FOOKS AR, 1993, J GEN VIROL, V74, P1439, DOI 10.1099/0022-1317-74-7-1439; Frank J, 1996, J STRUCT BIOL, V116, P190, DOI 10.1006/jsbi.1996.0030; GAST K, 1994, EUR BIOPHYS J BIOPHY, V23, P297, DOI 10.1007/BF00213579; GIRAUDON P, 1988, VIRUS RES, V10, P137, DOI 10.1016/0168-1702(88)90011-1; Glatter O., 1982, SMALL ANGLE X RAY SC; Guinier A., 1955, SMALL ANGLE SCATTERI; HARTY RN, 1995, J GEN VIROL, V76, P2863, DOI 10.1099/0022-1317-76-11-2863; HEGGENESS MH, 1981, VIROLOGY, V114, P555, DOI 10.1016/0042-6822(81)90235-X; HEGGENESS MH, 1980, P NATL ACAD SCI-BIOL, V77, P2631, DOI 10.1073/pnas.77.5.2631; HORIKAMI SM, 1992, J VIROL, V66, P4901, DOI 10.1128/JVI.66.8.4901-4908.1992; Hua QX, 1998, BIOCHEMISTRY-US, V37, P5858, DOI 10.1021/bi9800808; HUBBARD SJ, 2001, PROTEOLYTIC ENZYMES, P233; HUBER M, 1991, VIROLOGY, V185, P299, DOI 10.1016/0042-6822(91)90777-9; Karlin D, 2002, VIROLOGY, V302, P420, DOI 10.1006/viro.2002.1634; Karlin D, 2002, VIROLOGY, V296, P251, DOI 10.1006/viro.2001.1296; Konno T, 1997, PROTEIN SCI, V6, P2242; LAMB R., 2001, FIELDS VIROLOGY, V1, P1305; Li, 1999, Genome Inform Ser Workshop Genome Inform, V10, P30; Liston P, 1997, ARCH VIROL, V142, P305, DOI 10.1007/s007050050078; LISTON P, 1995, VIRUS RES, V38, P241, DOI 10.1016/0168-1702(95)00067-Z; Liu JF, 2002, J MOL BIOL, V322, P53, DOI 10.1016/S0022-2836(02)00736-2; Marie JC, 2001, IMMUNITY, V14, P69, DOI 10.1016/S1074-7613(01)00090-5; Marion D, 2001, J BIOMOL NMR, V21, P75, DOI 10.1023/A:1011990021282; Morris MC, 1999, J PEPT SCI, V5, P263, DOI 10.1002/(SICI)1099-1387(199906)5:6<263::AID-PSC191>3.3.CO;2-1; MOYER SA, 1990, J GEN VIROL, V71, P775, DOI 10.1099/0022-1317-71-4-775; Myers TM, 1997, VIROLOGY, V229, P322, DOI 10.1006/viro.1996.8429; Myers TM, 1999, J GEN VIROL, V80, P1383, DOI 10.1099/0022-1317-80-6-1383; Narayanan T, 2001, NUCL INSTRUM METH A, V467, P1005, DOI 10.1016/S0168-9002(01)00553-8; Panick G, 1998, J MOL BIOL, V275, P389, DOI 10.1006/jmbi.1997.1454; Perez J, 2001, J MOL BIOL, V308, P721, DOI 10.1006/jmbi.2001.4611; PIOTTO M, 1992, J BIOMOL NMR, V2, P661, DOI 10.1007/BF02192855; POTHIER P, 1997, MED MALADIES INFECT, V11, P592; Ravanel K, 1997, J EXP MED, V186, P269, DOI 10.1084/jem.186.2.269; Receveur V, 1998, FEBS LETT, V426, P57, DOI 10.1016/S0014-5793(98)00309-3; Russo D, 2001, BIOCHEMISTRY-US, V40, P3958, DOI 10.1021/bi002200t; RYAN KW, 1990, VIROLOGY, V174, P515, DOI 10.1016/0042-6822(90)90105-Z; RYAN KW, 1993, VIROLOGY, V193, P376, DOI 10.1006/viro.1993.1134; Schoehn G, 2001, J VIROL, V75, P490, DOI 10.1128/JVI.75.1.490-498.2001; Spehner D, 1997, VIROLOGY, V232, P260, DOI 10.1006/viro.1997.8568; SPEHNER D, 1991, J VIROL, V65, P6296, DOI 10.1128/JVI.65.11.6296-6300.1991; SVERGUN DI, 1992, J APPL CRYSTALLOGR, V25, P495, DOI 10.1107/S0021889892001663; Tarbouriech N, 2000, VIROLOGY, V266, P99, DOI 10.1006/viro.1999.0066; Tarbouriech N, 2000, NAT STRUCT BIOL, V7, P777; tenOever BR, 2002, J VIROL, V76, P3659, DOI 10.1128/JVI.76.8.3659-3669.2002; Tompa P, 2002, TRENDS BIOCHEM SCI, V27, P527, DOI 10.1016/S0968-0004(02)02169-2; Uversky VN, 2002, EUR J BIOCHEM, V269, P2, DOI 10.1046/j.0014-2956.2001.02649.x; UVERSKY VN, 1993, BIOCHEMISTRY-US, V32, P13288, DOI 10.1021/bi00211a042; Uversky VN, 2000, PROTEINS, V41, P415, DOI 10.1002/1097-0134(20001115)41:3<415::AID-PROT130>3.3.CO;2-Z; Uversky VN, 2002, PROTEIN SCI, V11, P739, DOI 10.1110/ps.4210102; VANHOY M, 1993, CELL, V72, P587, DOI 10.1016/0092-8674(93)90077-4; WARNES A, 1995, GENE, V160, P173, DOI 10.1016/0378-1119(95)00227-W; Wilkins DK, 1999, BIOCHEMISTRY-US, V38, P16424, DOI 10.1021/bi991765q; Wright PE, 1999, J MOL BIOL, V293, P321, DOI 10.1006/jmbi.1999.3110; Zhang XS, 2002, J VIROL, V76, P8737, DOI 10.1128/JVI.76.17.8737-8746.2002	83	232	235	0	24	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 16	2003	278	20					18638	18648		10.1074/jbc.M300518200	http://dx.doi.org/10.1074/jbc.M300518200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677YX	12621042	hybrid			2022-12-25	WOS:000182838300136
J	Son, GH; Jung, H; Seong, JY; Choe, Y; Geum, D; Kim, K				Son, GH; Jung, H; Seong, JY; Choe, Y; Geum, D; Kim, K			Excision of the first intron from the gonadotropin-releasing hormone (GnRH) transcript serves as a key regulatory step for GnRH biosynthesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OPEN READING FRAME; PRE-MESSENGER-RNA; EXPRESSION IN-VIVO; GENE TRANSCRIPTS; TRANSLATIONAL CONTROL; MOUSE HYPOTHALAMUS; RAT; RECEPTOR; LOCALIZATION; SEQUENCES	The mammalian gonadotropin-releasing hormone (GnRH) gene consists of four short exons (denoted as 1, 2, 3, and 4) and three intervening introns (A, B, and C). Recently, we demonstrated that excision of the first intron (intron A) from the GnRH transcript is regulated in a tissue- and developmental stage-specific fashion and is severely attenuated in hypogonadal (hpg) mouse because of its lack of exonic splicing enhancers (ESE) 3 and 4. In the present study, we examined the influence of intron A on translational efficiency, thereby establishing a post-transcriptional control over GnRH biosynthesis. First, we verified that an intron A-retained GnRH transcript is a splicing variant but not a splicing intermediate. Intron A-retained transcripts can be transported to the cytoplasm in contrast to intron B-containing transcripts, which are restricted to the nucleus. This result implicates the intron A-retained GnRH transcript as a splicing variant; it has a long 5'-untranslated region, as the GnRH prohormone open reading frame (ORF) begins on exon 2. We investigated whether an intron A-retained GnRH transcript can properly initiate translation at the appropriate start codon and found that intron A completely blocks the translation initiation of its downstream reporter ORF both in vivo and in vitro. The inhibition of translation initiation appears to be due to the presence of a tandem repeat of ATG sequences within intron A. Constructs bearing mutations of ATGs to AAGs restored translation initiation at the downstream start codon; the extent of this restoration correlated with the number of mutated ATGs. Besides the failure in the translation initiation of GnRH-coding region in the intron A-containing variant, the present study also suggests that the interference between mature GnRH mRNA and intron A-retained splicing variant could occur to lower the efficiency of GnRH biosynthesis in the GT1-1-immortalized GnRH-producing cell line. Therefore, our results indicate that the precise and efficient excision of intron A and the joining of adjacent exons may be a critical regulatory step for the post-transcriptional regulation of GnRH biosynthesis.	Seoul Natl Univ, Sch Biol Sci, Seoul 151742, South Korea; Chonnam Natl Univ, Hormone Res Ctr, Kwangju 500757, South Korea	Seoul National University (SNU); Chonnam National University	Kim, K (corresponding author), Seoul Natl Univ, Sch Biol Sci, Seoul 151742, South Korea.		Jung, Hosung/A-4401-2012; Seong, Jae Young/A-5794-2012	Jung, Hosung/0000-0002-5059-8050; Seong, Jae Young/0000-0002-3312-6924				ADELMAN JP, 1986, P NATL ACAD SCI USA, V83, P179, DOI 10.1073/pnas.83.1.179; Child SJ, 1999, J BIOL CHEM, V274, P24335, DOI 10.1074/jbc.274.34.24335; Diba F, 2001, J CELL BIOCHEM, V81, P149, DOI 10.1002/1097-4644(20010401)81:1<149::AID-JCB1031>3.3.CO;2-N; Gore AC, 1997, FRONT NEUROENDOCRIN, V18, P209, DOI 10.1006/frne.1996.0149; GOUBAU S, 1992, ENDOCRINOLOGY, V130, P3098, DOI 10.1210/en.130.5.3098; Han J, 2001, MOL CELL ENDOCRINOL, V173, P157, DOI 10.1016/S0303-7207(00)00409-3; JAKUBOWSKI M, 1994, J BIOL CHEM, V269, P4078; Kang SS, 2000, J NEUROENDOCRINOL, V12, P421; KOZAK M, 1991, J CELL BIOL, V115, P887, DOI 10.1083/jcb.115.4.887; Lawson MA, 2002, ENDOCRINOLOGY, V143, P1404, DOI 10.1210/en.143.4.1404; Lincoln AJ, 1998, J BIOL CHEM, V273, P9552, DOI 10.1074/jbc.273.16.9552; MASON AJ, 1986, SCIENCE, V234, P1366, DOI 10.1126/science.3024317; Mize GJ, 1998, J BIOL CHEM, V273, P32500, DOI 10.1074/jbc.273.49.32500; MIZOKAMI A, 1994, J BIOL CHEM, V269, P25655; Morris DR, 2000, MOL CELL BIOL, V20, P8635, DOI 10.1128/MCB.20.23.8635-8642.2000; OLIVEIRA CC, 1995, J BIOL CHEM, V270, P8936, DOI 10.1074/jbc.270.15.8936; RADOVICK S, 1990, MOL ENDOCRINOL, V4, P476, DOI 10.1210/mend-4-3-476; Schluter G, 2000, BIOCHEM BIOPH RES CO, V268, P255, DOI 10.1006/bbrc.2000.2109; Seong JY, 1999, MOL ENDOCRINOL, V13, P1882, DOI 10.1210/me.13.11.1882; Seong JY, 2002, MOL ENDOCRINOL, V16, P2426, DOI 10.1210/me.2001-0297; Seong JY, 2001, ENDOCRINOLOGY, V142, P4454, DOI 10.1210/en.142.10.4454; SHEWARD WJ, 1985, BRAIN RES, V345, P362, DOI 10.1016/0006-8993(85)91017-0; Silverman Ann-Judith, 1994, P1683; Steinmetz EJ, 1997, CELL, V89, P491, DOI 10.1016/S0092-8674(00)80230-5; Trembleau A, 1998, BIOL CELL, V90, P39, DOI 10.1016/S0248-4900(98)80231-1; Wang Y, 1999, P NATL ACAD SCI USA, V96, P12150, DOI 10.1073/pnas.96.21.12150; XING YG, 1993, SCIENCE, V259, P1326, DOI 10.1126/science.8446901; Yeo TTS, 1996, MOL BRAIN RES, V42, P255, DOI 10.1016/S0169-328X(96)00129-5; ZHANG GH, 1994, NATURE, V372, P809; Zhen SJ, 1997, J BIOL CHEM, V272, P12620, DOI 10.1074/jbc.272.19.12620	30	24	27	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 16	2003	278	20					18037	18044		10.1074/jbc.M209850200	http://dx.doi.org/10.1074/jbc.M209850200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677YX	12639969	hybrid			2022-12-25	WOS:000182838300058
J	Stortchevoi, A; Varshney, U; RajBhandary, UL				Stortchevoi, A; Varshney, U; RajBhandary, UL			Common location of determinants in initiator transfer RNAs for initiator-elongator discrimination in bacteria and in eukaryotes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FORMYLMETHIONINE TRANSFER-RNA; AMINOACYL-TRANSFER-RNAS; TRANSFER RIBONUCLEIC-ACID; ESCHERICHIA-COLI; PROTEIN-SYNTHESIS; FACTOR TU; EF-TU; CRYSTAL-STRUCTURE; TRANSFER RNA(MET); INSERTION MODULE	Initiator tRNAs are used exclusively for initiation of protein synthesis and not for elongation. We show that both Escherichia coli and eukaryotic initiator tRNAs have negative determinants, at the same positions, that block their activity in elongation. The primary negative determinant in E. coli initiator tRNA is the C1xA72 mismatch at the end of the acceptor stem. The primary negative determinant in eukaryotic initiator tRNAs is located in the TPsiC stem, whereas a secondary negative determinant is the A1:U72 base pair at the end of the acceptor stem. Here we show that E. coli initiator tRNA also has a secondary negative determinant for elongation and that it is the U50.G64 wobble base pair, located at the same position in the TPsiC stem as the primary negative determinant in eukaryotic initiator tRNAs. Mutation of the U50.G64 wobble base pair to C50:G64 or U50:A64 base pairs increases the in vivo amber suppressor activity of initiator tRNA mutants that have changes in the acceptor stem and in the anticodon sequence necessary for amber suppressor activity. Binding assays of the mutant aminoacyl-tRNAs carrying the C50 and A64 changes to the elongation factor EF-Tu.GTP show marginally higher affinity of the C50 and A64 mutant tRNAs and increased stability of the EF-Tu.GTP-aminoacyl-tRNA ternary complexes. Other results show a large effect of the amino acid attached to a tRNA, glutamine versus methionine, on the binding affinity toward EF-Tu.GTP and on the stability of the EF-Tu.GTP.aminoacyl-tRNA ternary complex.	MIT, Dept Biol, Cambridge, MA 02139 USA	Massachusetts Institute of Technology (MIT)	RajBhandary, UL (corresponding author), MIT, Dept Biol, Rm 68-671, Cambridge, MA 02139 USA.		Varshney, Umesh/A-8062-2009; Varshney, Umesh/Q-6914-2019		NIGMS NIH HHS [R37GM17151] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM017151] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Asahara H, 2002, P NATL ACAD SCI USA, V99, P3499, DOI 10.1073/pnas.052028599; ASTROM SU, 1993, J MOL BIOL, V233, P43, DOI 10.1006/jmbi.1993.1483; ASTROM SU, 1994, CELL, V79, P535, DOI 10.1016/0092-8674(94)90262-3; BASAVAPPA R, 1991, EMBO J, V10, P3105, DOI 10.1002/j.1460-2075.1991.tb07864.x; CANONACO MA, 1986, FEBS LETT, V207, P198, DOI 10.1016/0014-5793(86)81488-0; CELIS JE, 1976, J MOL BIOL, V104, P729, DOI 10.1016/0022-2836(76)90132-7; CLARK BFC, 1966, J MOL BIOL, V17, P394, DOI 10.1016/S0022-2836(66)80150-X; DESGRES J, 1989, NUCLEIC ACIDS RES, V17, P865, DOI 10.1093/nar/17.3.865; DICKERMA.HW, 1967, J BIOL CHEM, V242, P1522; Drabkin HJ, 1998, MOL CELL BIOL, V18, P1459, DOI 10.1128/MCB.18.3.1459; Drabkin HJ, 1998, MOL CELL BIOL, V18, P5140, DOI 10.1128/MCB.18.9.5140; Dreher TW, 1999, J BIOL CHEM, V274, P666, DOI 10.1074/jbc.274.2.666; FORCHHAMMER K, 1989, NATURE, V342, P453, DOI 10.1038/342453a0; FORSTER C, 1993, NUCLEIC ACIDS RES, V21, P5679; GHOSH HP, 1982, NUCLEIC ACIDS RES, V10, P3241, DOI 10.1093/nar/10.10.3241; GIEGE R, 1973, FEBS LETT, V30, P291, DOI 10.1016/0014-5793(73)80672-6; GUILLON JM, 1993, J BACTERIOL, V175, P4507, DOI 10.1128/JB.175.14.4507-4514.1993; HERSHEY JWB, 1987, ESCHERICHIA COLI SAL, V1, P613; KIESEWETTER S, 1990, NUCLEIC ACIDS RES, V18, P4677, DOI 10.1093/nar/18.16.4677; KNOWLTON RG, 1980, J MOL BIOL, V139, P721, DOI 10.1016/0022-2836(80)90057-1; KOSSEL H, 1968, J MOL BIOL, V35, P539, DOI 10.1016/S0022-2836(68)80013-0; KOZAK M, 1983, MICROBIOL REV, V47, P1; LaRiviere FJ, 2001, SCIENCE, V294, P165, DOI 10.1126/science.1064242; LEE CP, 1991, J BIOL CHEM, V266, P18012; LEE CP, 1992, P NATL ACAD SCI USA, V89, P9262, DOI 10.1073/pnas.89.19.9262; Li SH, 1996, J BIOL CHEM, V271, P1022, DOI 10.1074/jbc.271.2.1022; LOUIE A, 1984, J BIOL CHEM, V259, P5010; MARCKER K, 1964, J MOL BIOL, V8, P835, DOI 10.1016/S0022-2836(64)80164-9; MEINNEL T, 1993, J BACTERIOL, V175, P7737, DOI 10.1128/JB.175.23.7737-7740.1993; Miller JH., 1992, SHORT COURSE BACTERI, P72; NISSEN P, 1995, SCIENCE, V270, P1464, DOI 10.1126/science.270.5241.1464; PERONA JJ, 1989, SCIENCE, V246, P1152, DOI 10.1126/science.2686030; PIPER PW, 1974, NATURE, V247, P516, DOI 10.1038/247516a0; Pleiss JA, 2001, J MOL BIOL, V308, P895, DOI 10.1006/jmbi.2001.4612; RAJBHANDARY UL, 1994, J BACTERIOL, V176, P547, DOI 10.1128/jb.176.3.547-552.1994; Rajbhandary Uttam L., 1995, P511; Ramesh V, 1997, P NATL ACAD SCI USA, V94, P13524, DOI 10.1073/pnas.94.25.13524; Ramesh V, 1998, BIOCHEMISTRY-US, V37, P15925, DOI 10.1021/bi981873x; Rudinger J, 1996, EMBO J, V15, P650, DOI 10.1002/j.1460-2075.1996.tb00397.x; Schmitt E, 1998, EMBO J, V17, P6819, DOI 10.1093/emboj/17.23.6819; SCHULMAN LH, 1985, BIOCHEMISTRY-US, V24, P7309, DOI 10.1021/bi00346a043; SEONG BL, 1989, J BIOL CHEM, V264, P6504; SEONG BL, 1987, P NATL ACAD SCI USA, V84, P8859, DOI 10.1073/pnas.84.24.8859; SEONG BL, 1987, P NATL ACAD SCI USA, V84, P334, DOI 10.1073/pnas.84.2.334; SIMSEK M, 1974, NATURE, V247, P518, DOI 10.1038/247518a0; SIMSEK M, 1972, BIOCHEM BIOPH RES CO, V49, P508, DOI 10.1016/0006-291X(72)90440-8; SOLL L, 1969, NATURE, V223, P1340, DOI 10.1038/2231340a0; Sprinzl M, 1998, NUCLEIC ACIDS RES, V26, P148, DOI 10.1093/nar/26.1.148; SUNDARI RM, 1976, J BIOL CHEM, V251, P3338; Takeuchi N, 2001, J BIOL CHEM, V276, P20064, DOI 10.1074/jbc.M101007200; Thanedar S, 2000, J BIOL CHEM, V275, P20361, DOI 10.1074/jbc.M001238200; VARSHNEY U, 1991, J BIOL CHEM, V266, P24712; VARSHNEY U, 1991, J BIOL CHEM, V266, P18018; VARSHNEY U, 1990, P NATL ACAD SCI USA, V87, P1586, DOI 10.1073/pnas.87.4.1586; VARSHNEY U, 1993, P NATL ACAD SCI USA, V90, P2305, DOI 10.1073/pnas.90.6.2305; WAGNER T, 1984, J BIOL CHEM, V259, P4706; Wu XQ, 1996, EMBO J, V15, P4734, DOI 10.1002/j.1460-2075.1996.tb00850.x; Wu XQ, 1997, J BIOL CHEM, V272, P1891, DOI 10.1074/jbc.272.3.1891; Zhang YL, 1996, FEBS LETT, V391, P330, DOI 10.1016/0014-5793(96)00789-2	59	15	16	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 16	2003	278	20					17672	17679		10.1074/jbc.M212890200	http://dx.doi.org/10.1074/jbc.M212890200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677YX	12639964	hybrid			2022-12-25	WOS:000182838300013
J	Yan, LM; Nairn, AC; Palfrey, HC; Brady, MJ				Yan, LM; Nairn, AC; Palfrey, HC; Brady, MJ			Glucose regulates EF-2 phosphorylation and protein translation by a protein phosphatase-2A-dependent mechanism in INS-1-derived 832/13 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PANCREATIC BETA-CELLS; ELONGATION FACTOR-II; PROINSULIN BIOSYNTHESIS; INSULIN EXOCYTOSIS; PHOSPHATASE 2A; RAT ISLETS; KINASE-III; LANGERHANS; DEPHOSPHORYLATION; IDENTIFICATION	The role of elongation factor (EF)-2 phosphorylation in the regulation of pancreatic beta-cell protein synthesis by glucose was investigated in the INS-1-derived cell line 832/13. Incubation of cells in media containing 1 mM glucose resulted in a progressive increase in EF-2 phosphorylation that was maximal by 1-2 h. Readdition of 10 mM glucose promoted a rapid dephosphorylation of EF-2 that was complete in 10 min and maintained over the ensuing 2 h. Similar results were obtained using primary rat islets or Min-6 insulinoma cells. The glucose effect in 832/13 cells was replicated by addition of pyruvate or alpha-ketocaproate, but not 2-deoxyglucose, suggesting that mitochondrial metabolism was required. Accordingly, glucose-mediated dephosphorylation of EF-2 was completely blocked by the mitochondrial respiratory antagonists antimycin A and oligomycin. The hyperglycemic effect was not mimicked by incubation of cells in 100 nM insulin, 30 mM potassium chloride, or 0.25 mM diazoxide, indicating that insulin secretion and/or depolarization of beta cells was not required. The locus of the high glucose effect appeared to be protein phosphatase-2A, the principal phosphatase acting on EF-2. Protein phosphatase-2A activity was stimulated by glucose addition to 832/13 cells, but neither protein phosphatase-1 nor calmodulin kinase III ( EF-2 kinase) activity was affected under these conditions. The slower rephosphorylation of EF-2 during the transition from high to low glucose may involve effects on EF-2 kinase activity. Addition of 5-aminoimidazole-4-carboxamide 1-beta-D-ribofuranoside in high glucose led to a marked stimulation of EF-2 phosphorylation, consistent with the possibility that increased AMP kinase activity in low glucose stimulates EF-2 kinase. In parallel with the effects on EF-2 dephosphorylation, addition of high glucose to 832/13 cells markedly increased the incorporation of [S-35]methionine into total protein. Taken together, these results suggest that modulation of extracellular glucose impacts protein translation rate in beta cells at least in part through regulation of the elongation step, via phosphorylation/dephosphorylation of EF-2.	Univ Chicago, Dept Med, Chicago, IL 60637 USA; Univ Chicago, Dept Neurobiol Pharmacol & Physiol, Chicago, IL 60637 USA; Yale Univ, Sch Med, Dept Psychiat, New Haven, CT 06508 USA	University of Chicago; University of Chicago; Yale University	Brady, MJ (corresponding author), Univ Chicago, Dept Med, MC 1027,5841 S Maryland Ave, Chicago, IL 60637 USA.			Nairn, Angus/0000-0002-7075-0195				Brady MJ, 1997, J BIOL CHEM, V272, P29698, DOI 10.1074/jbc.272.47.29698; Chung HY, 1999, BIOCHEMISTRY-US, V38, P10371, DOI 10.1021/bi990902g; CORTON JM, 1995, EUR J BIOCHEM, V229, P558, DOI 10.1111/j.1432-1033.1995.0558k.x; Donelan MJ, 2002, J BIOL CHEM, V277, P24232, DOI 10.1074/jbc.M203345200; Dyck JRB, 1999, EUR J BIOCHEM, V262, P184, DOI 10.1046/j.1432-1327.1999.00371.x; Gilligan M, 1996, J BIOL CHEM, V271, P2121, DOI 10.1074/jbc.271.4.2121; Goodge KA, 2000, SEMIN CELL DEV BIOL, V11, P235, DOI 10.1006/scdb.2000.0172; GRIMALDI KA, 1987, BIOCHEM J, V245, P567, DOI 10.1042/bj2450567; GUEST PC, 1991, BIOCHEM J, V274, P73, DOI 10.1042/bj2740073; Hohmeier HE, 2000, DIABETES, V49, P424, DOI 10.2337/diabetes.49.3.424; Horman S, 2002, CURR BIOL, V12, P1419, DOI 10.1016/S0960-9822(02)01077-1; Janssens V, 2001, BIOCHEM J, V353, P417, DOI 10.1042/0264-6021:3530417; Knebel A, 2002, BIOCHEM J, V367, P525, DOI 10.1042/BJ20020916; Knebel A, 2001, EMBO J, V20, P4360, DOI 10.1093/emboj/20.16.4360; Kulkarni RN, 1999, CELL, V96, P329, DOI 10.1016/S0092-8674(00)80546-2; Marin P, 1997, J NEUROSCI, V17, P3445; MCDANIEL ML, 1983, METHOD ENZYMOL, V98, P182; MITSUI K, 1993, J BIOL CHEM, V268, P13422; Murphy LI, 1996, MOL CELL ENDOCRINOL, V117, P195, DOI 10.1016/0303-7207(95)03747-0; NAIRN AC, 1987, J BIOL CHEM, V262, P17299; Nairn AC, 2001, PROG MOLEC, V27, P91; PERMUTT MA, 1974, J BIOL CHEM, V249, P2738; REDPATH NT, 1990, BIOCHEM J, V272, P175, DOI 10.1042/bj2720175; Redpath NT, 1996, EMBO J, V15, P2291, DOI 10.1002/j.1460-2075.1996.tb00582.x; Rhoads RE, 1999, J BIOL CHEM, V274, P30337, DOI 10.1074/jbc.274.43.30337; Ryazanov AG, 2002, FEBS LETT, V514, P26, DOI 10.1016/S0014-5793(02)02299-8; RYAZANOV AG, 1989, FEBS LETT, V251, P187, DOI 10.1016/0014-5793(89)81452-8; Salt IP, 1998, BIOCHEM J, V335, P533, DOI 10.1042/bj3350533; Sjoholm A, 2002, ENDOCRINOLOGY, V143, P4592, DOI 10.1210/en.2002-220672; Skelly RH, 1996, DIABETES, V45, P37, DOI 10.2337/diabetes.45.1.37; Traugh J A, 2001, Prog Mol Subcell Biol, V26, P33; Wang XM, 2001, EMBO J, V20, P4370, DOI 10.1093/emboj/20.16.4370; Webb GC, 2000, P NATL ACAD SCI USA, V97, P5773, DOI 10.1073/pnas.100126597; WELSH M, 1986, BIOCHEM J, V235, P459, DOI 10.1042/bj2350459; Xu G, 1998, J BIOL CHEM, V273, P4485, DOI 10.1074/jbc.273.8.4485; Yamaguchi H, 2001, MOL CELL, V7, P1047, DOI 10.1016/S1097-2765(01)00256-8	36	27	29	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 16	2003	278	20					18177	18183		10.1074/jbc.M301116200	http://dx.doi.org/10.1074/jbc.M301116200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677YX	12644453	hybrid			2022-12-25	WOS:000182838300077
J	Kabotyanski, EB; Rosen, JM				Kabotyanski, EB; Rosen, JM			Signal transduction pathways regulated by prolactin and Src result in different conformations of activated Stat5b	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING ACTIVITY; EPIDERMAL GROWTH-FACTOR; BETA-CASEIN GENE; COLONY-STIMULATING FACTOR; MAMMARY-GLAND DEVELOPMENT; RECEPTOR-ALPHA GENE; TRANSCRIPTION FACTOR; SERINE PHOSPHORYLATION; TYROSINE KINASES; EPITHELIAL-CELLS	Stat5 is activated by a broad spectrum of cytokines, as well as non-receptor tyrosine kinases, such as Src. In this study, the DNA binding properties of the two closely related Stat5 proteins, Stat5a and Stat5b, induced either by prolactin (Prl) or by Src were analyzed by electrophoretic mobility shift assays using several different Stat5 binding sites. Src-induced Stat5b-DNA binding complexes consistently displayed a slightly faster mobility than those induced by Prl, as well as differences in their ability to be supershifted by anti-Stat5 antibodies. IP-Westerns performed using specific antibodies directed at the N and C termini of Stat5b suggested that depending on the activating stimulus, Stat5b exhibited different conformations, which influenced antibody accessibility at its C terminus. These conformational differences may in part be due to differential effects of Prl and Src on Stat5b tyrosine phosphorylation, since Src induced several additional sites of tyrosine phosphorylation of Stat5b at residues other than Tyr-699, including Tyr-724 and Tyr-679. The latter Tyr-679 is conserved in all mammalian Stat5bs, but is not present in Stat5a. A Stat5bY679F mutant induced by Src kinase exhibited an altered pattern of nuclear localization as compared with wild-type Stat5b. Furthermore, this mutation inhibited v-Src-induced cyclin D1-luciferase reporter activity in transient transfection assays performed in Stat5a/b-deficient MEFs, suggesting that Tyr-679 phosphorylation may play a role in v-Src induced proliferation. Thus, depending on the signal transduction pathway responsible for activation, different conformations of activated Stat5 may result in selective biological responses.	Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA	Baylor College of Medicine	Rosen, JM (corresponding author), Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA.				NCI NIH HHS [CA16303] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA016303, R37CA016303] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALI S, 1992, MOL ENDOCRINOL, V6, P1242, DOI 10.1210/me.6.8.1242; Ariyoshi K, 2000, J BIOL CHEM, V275, P24407, DOI 10.1074/jbc.M909771199; AZAM M, 1995, EMBO J, V14, P1402, DOI 10.1002/j.1460-2075.1995.tb07126.x; Beadling C, 1996, EMBO J, V15, P1902, DOI 10.1002/j.1460-2075.1996.tb00541.x; Becker S, 1998, NATURE, V394, P145, DOI 10.1038/28101; Beuvink I, 2000, J BIOL CHEM, V275, P10247, DOI 10.1074/jbc.275.14.10247; Blom N, 1999, J MOL BIOL, V294, P1351, DOI 10.1006/jmbi.1999.3310; Boucheron C, 1998, J BIOL CHEM, V273, P33936, DOI 10.1074/jbc.273.51.33936; Bovolenta C, 1998, J BIOL CHEM, V273, P20779, DOI 10.1074/jbc.273.33.20779; BURDON TG, 1994, MOL ENDOCRINOL, V8, P1528, DOI 10.1210/me.8.11.1528; Caldenhoven E, 1996, J BIOL CHEM, V271, P13221, DOI 10.1074/jbc.271.22.13221; Chen XM, 1998, CELL, V93, P827, DOI 10.1016/S0092-8674(00)81443-9; COURTNEIDGE SA, 1993, DEVELOPMENT, P57; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; Ehret GB, 2001, J BIOL CHEM, V276, P6675, DOI 10.1074/jbc.M001748200; Frank DA, 1996, LEUKEMIA, V10, P1724; GOUILLEUX F, 1995, ENDOCRINOLOGY, V136, P5700, DOI 10.1210/en.136.12.5700; GOUILLEUX F, 1994, EMBO J, V13, P4361, DOI 10.1002/j.1460-2075.1994.tb06756.x; GOUILLEUX F, 1995, EMBO J, V14, P2005, DOI 10.1002/j.1460-2075.1995.tb07192.x; HORVATH CM, 1995, GENE DEV, V9, P984, DOI 10.1101/gad.9.8.984; HYNES NE, 1990, MOL CELL BIOL, V10, P4027, DOI 10.1128/MCB.10.8.4027; Ilaria RL, 1996, J BIOL CHEM, V271, P31704, DOI 10.1074/jbc.271.49.31704; John S, 1999, MOL CELL BIOL, V19, P1910; KAZANSKY AV, 1995, MOL ENDOCRINOL, V9, P1598, DOI 10.1210/me.9.11.1598; Kazansky AV, 1999, J BIOL CHEM, V274, P22484, DOI 10.1074/jbc.274.32.22484; Kirken RA, 1997, J BIOL CHEM, V272, P14098, DOI 10.1074/jbc.272.22.14098; Kloth MT, 2002, J BIOL CHEM, V277, P8693, DOI 10.1074/jbc.M111884200; Lecine P, 1996, MOL CELL BIOL, V16, P6829; Lee RJ, 1999, J BIOL CHEM, V274, P7341, DOI 10.1074/jbc.274.11.7341; LI S, 1995, MOL CELL BIOL, V15, P2063; Lin JX, 1996, J BIOL CHEM, V271, P10738, DOI 10.1074/jbc.271.18.10738; LIN JX, 1995, IMMUNITY, V2, P331, DOI 10.1016/1074-7613(95)90141-8; Liu XW, 1997, GENE DEV, V11, P179, DOI 10.1101/gad.11.2.179; Luo GY, 1997, J BIOL CHEM, V272, P26841, DOI 10.1074/jbc.272.43.26841; Matsumura I, 1997, MOL CELL BIOL, V17, P2933, DOI 10.1128/MCB.17.5.2933; Matsumura I, 1999, EMBO J, V18, P1367, DOI 10.1093/emboj/18.5.1367; Meinke A, 1996, MOL CELL BIOL, V16, P6937; Meyer WKH, 1997, J BIOL CHEM, V272, P31821, DOI 10.1074/jbc.272.50.31821; Moriggl R, 1996, MOL CELL BIOL, V16, P5691; MUI ALF, 1995, EMBO J, V14, P1166, DOI 10.1002/j.1460-2075.1995.tb07100.x; MULLER M, 1993, EMBO J, V12, P4221, DOI 10.1002/j.1460-2075.1993.tb06106.x; Olayioye MA, 1999, J BIOL CHEM, V274, P17209, DOI 10.1074/jbc.274.24.17209; PALLARD C, 1995, EMBO J, V14, P2847, DOI 10.1002/j.1460-2075.1995.tb07284.x; Paukku K, 2000, BIOCHEM J, V345, P759, DOI 10.1042/0264-6021:3450759; Pfeffer LM, 1997, SCIENCE, V276, P1418, DOI 10.1126/science.276.5317.1418; Pfitzner E, 1998, MOL ENDOCRINOL, V12, P1582, DOI 10.1210/mend.12.10.0180; PIERRE S, 1994, MOL ENDOCRINOL, V8, P1720, DOI 10.1210/me.8.12.1720; RAUGHT B, 1994, MOL CELL BIOL, V14, P1752, DOI 10.1128/MCB.14.3.1752; RIPPERGER JA, 1995, J BIOL CHEM, V270, P29998, DOI 10.1074/jbc.270.50.29998; RUFFJAMISON S, 1995, P NATL ACAD SCI USA, V92, P4215, DOI 10.1073/pnas.92.10.4215; Schaefer TS, 1997, MOL CELL BIOL, V17, P5307, DOI 10.1128/MCB.17.9.5307; Schroeder MD, 2002, MOL ENDOCRINOL, V16, P45, DOI 10.1210/me.16.1.45; SEIDEL HM, 1995, P NATL ACAD SCI USA, V92, P3041, DOI 10.1073/pnas.92.7.3041; Seyfert HM, 2000, J MOL EVOL, V50, P550, DOI 10.1007/s002390010058; Soldaini E, 2000, MOL CELL BIOL, V20, P389, DOI 10.1128/MCB.20.1.389-401.2000; Stocklin E, 1996, NATURE, V383, P726, DOI 10.1038/383726a0; Teglund S, 1998, CELL, V93, P841, DOI 10.1016/S0092-8674(00)81444-0; Udy GB, 1997, P NATL ACAD SCI USA, V94, P7239, DOI 10.1073/pnas.94.14.7239; Verdier F, 1998, MOL CELL BIOL, V18, P5852, DOI 10.1128/MCB.18.10.5852; Vinkemeier U, 1998, SCIENCE, V279, P1048, DOI 10.1126/science.279.5353.1048; WAKAO H, 1994, EMBO J, V13, P2182, DOI 10.1002/j.1460-2075.1994.tb06495.x; Wang DM, 1996, MOL CELL BIOL, V16, P6141; Wang DM, 2000, EMBO J, V19, P392, DOI 10.1093/emboj/19.3.392; Wen X, 1999, J BIOL CHEM, V274, P38204, DOI 10.1074/jbc.274.53.38204; WEN ZL, 1995, CELL, V82, P241, DOI 10.1016/0092-8674(95)90311-9; Wen ZL, 1997, NUCLEIC ACIDS RES, V25, P2062, DOI 10.1093/nar/25.11.2062; Wyszomierski SL, 2001, MOL ENDOCRINOL, V15, P228, DOI 10.1210/me.15.2.228; Xu XA, 1996, SCIENCE, V273, P794, DOI 10.1126/science.273.5276.794; Yamashita H, 1998, J BIOL CHEM, V273, P30218, DOI 10.1074/jbc.273.46.30218	69	30	32	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 9	2003	278	19					17218	17227		10.1074/jbc.M301578200	http://dx.doi.org/10.1074/jbc.M301578200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677QG	12621061	hybrid			2022-12-25	WOS:000182818600104
J	Morlon-Guyot, J; Helmy, M; Lombard-Frasca, S; Pignol, D; Pieroni, G; Beaumelle, B				Morlon-Guyot, J; Helmy, M; Lombard-Frasca, S; Pignol, D; Pieroni, G; Beaumelle, B			Identification of the ricin lipase site and implication in cytotoxicity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANS-GOLGI NETWORK; A-CHAIN; ENDOPLASMIC-RETICULUM; INTERNALIZED RICIN; CRYSTAL-STRUCTURE; B-CHAIN; PROTEIN; TRANSLOCATION; CELLS; TOXIN	Ricin is a heterodimeric plant toxin and the prototype of type II ribosome-inactivating proteins. Its B-chain is a lectin that enables cell binding. After endocytosis, the A-chain translocates through the membrane of intracellular compartments to reach the cytosol where its N-glycosidase activity inactivates ribosomes, thereby arresting protein synthesis. We here show that ricin possesses a functional lipase active site at the interface between the two subunits. It involves residues from both chains. Mutation to alanine of catalytic serine 221 on the A-chain abolished ricin lipase activity. Moreover, this mutation slowed down the A-chain translocation rate and inhibited toxicity by 35%. Lipase activity is therefore required for efficient ricin A-chain translocation and cytotoxicity. This conclusion was further supported by structural examination of type II ribosome-inactivating proteins that showed that this lipase site is present in toxic (ricin and abrin) but is altered in nontoxic (ebulin 1 and mistletoe lectin I) members of this family.	Univ Montpellier 2, Dept Biol Sante, CNRS, UMR 5539, F-34095 Montpellier 05, France; Fac Med Marseille, INSERM, U476, F-13385 Marseille, France; CEA Cadarache, Dept Ecophysiol Vegetale & Microbiol, Lab Bioenerget Cellulaire, F-13107 St Paul Les Durance, France	Centre National de la Recherche Scientifique (CNRS); Universite de Montpellier; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Aix-Marseille Universite; CEA	Beaumelle, B (corresponding author), Univ Montpellier 2, Dept Biol Sante, CNRS, UMR 5539, Case 107, F-34095 Montpellier 05, France.			Beaumelle, Bruno/0000-0002-4912-9134; PIGNOL, David/0000-0002-8070-0319				Alami M, 1998, MOL BIOL CELL, V9, P387, DOI 10.1091/mbc.9.2.387; Beaumelle B, 1997, J BIOL CHEM, V272, P22097, DOI 10.1074/jbc.272.35.22097; BEAUMELLE B, 1993, J BIOL CHEM, V268, P23661; BILGE A, 1995, J BIOL CHEM, V270, P23720, DOI 10.1074/jbc.270.40.23720; CHADDOCK JA, 1993, PROTEIN ENG, V6, P425, DOI 10.1093/protein/6.4.425; Day PJ, 2002, BIOCHEMISTRY-US, V41, P2836, DOI 10.1021/bi012012i; Eschenburg S, 1998, BIOCHEM BIOPH RES CO, V247, P367, DOI 10.1006/bbrc.1998.8760; Falnes PO, 2000, CURR OPIN CELL BIOL, V12, P407, DOI 10.1016/S0955-0674(00)00109-5; Frankel AE, 1997, LEUKEMIA, V11, P22, DOI 10.1038/sj.leu.2400517; GREGG EO, 1987, J IMMUNOL, V138, P4502; GRUENBERG J, 1995, CURR OPIN CELL BIOL, V7, P552, DOI 10.1016/0955-0674(95)80013-1; Helmy M, 1999, BIOCHEM BIOPH RES CO, V258, P252, DOI 10.1006/bbrc.1999.0618; HUDSON TH, 1987, J BIOL CHEM, V262, P16484; Hussain MM, 2000, ATHEROSCLEROSIS, V148, P1; JAEGER KE, 1994, FEMS MICROBIOL REV, V15, P29, DOI 10.1016/0168-6445(94)90025-6; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kitaoka Y, 1998, EUR J BIOCHEM, V257, P255, DOI 10.1046/j.1432-1327.1998.2570255.x; Kobayashi T, 1998, NATURE, V392, P193, DOI 10.1038/32440; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Kreitman RJ, 1999, CURR OPIN IMMUNOL, V11, P570, DOI 10.1016/S0952-7915(99)00005-9; LANDT O, 1990, GENE, V96, P125, DOI 10.1016/0378-1119(90)90351-Q; LEWIS MS, 1986, J BIOL CHEM, V261, P1571; Lombard S, 2001, BIOCHEM J, V358, P773, DOI 10.1042/0264-6021:3580773; LORD JM, 1994, FASEB J, V8, P201, DOI 10.1096/fasebj.8.2.8119491; MLSNA D, 1993, PROTEIN SCI, V2, P429; MONTFORT W, 1987, J BIOL CHEM, V262, P5398; MOULIN A, 1994, P NATL ACAD SCI USA, V91, P11328, DOI 10.1073/pnas.91.24.11328; OLLIS DL, 1992, PROTEIN ENG, V5, P197, DOI 10.1093/protein/5.3.197; OLSNES S, 1976, J BIOL CHEM, V251, P3985; Pascal JM, 2001, PROTEINS, V43, P319, DOI 10.1002/prot.1043; Rohrer J, 2001, MOL BIOL CELL, V12, P1623, DOI 10.1091/mbc.12.6.1623; RUTENBER E, 1991, PROTEINS, V10, P260, DOI 10.1002/prot.340100310; Sandvig K, 2000, EMBO J, V19, P5943, DOI 10.1093/emboj/19.22.5943; Schrag JD, 1997, STRUCTURE, V5, P187, DOI 10.1016/S0969-2126(97)00178-0; TAHIROV TH, 1995, J MOL BIOL, V250, P354, DOI 10.1006/jmbi.1995.0382; UTSUMI T, 1989, FEBS LETT, V242, P255, DOI 10.1016/0014-5793(89)80480-6; VANDEURS B, 1988, J CELL BIOL, V106, P253, DOI 10.1083/jcb.106.2.253; VANDEURS B, 1990, EUR J CELL BIOL, V51, P96; VANDEURS B, 1986, J CELL BIOL, V102, P37, DOI 10.1083/jcb.102.1.37; Wesche J, 1999, J BIOL CHEM, V274, P34443, DOI 10.1074/jbc.274.48.34443	40	32	35	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 9	2003	278	19					17006	17011		10.1074/jbc.M209516200	http://dx.doi.org/10.1074/jbc.M209516200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677QG	12611897	Green Published, hybrid			2022-12-25	WOS:000182818600076
J	Takida, S; Wedegaertner, PB				Takida, S; Wedegaertner, PB			Heterotrimer formation, together with isoprenylation, is required for plasma membrane targeting of G beta gamma	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DUAL LIPID MODIFICATION; G-PROTEIN; ENDOPLASMIC-RETICULUM; SACCHAROMYCES-CEREVISIAE; CAAX MOTIF; G-ALPHA; LOCALIZATION; PRENYLATION; SUBUNIT; PALMITOYLATION	Nascent beta and gamma subunits of heterotrimeric G proteins need to be targeted to the cytoplasmic face of the plasma membrane (PM) in order to transmit signals. We show that beta(1)gamma(2) is poorly targeted to the PM and predominantly localized to endoplasmic reticulum (ER) membranes when expressed in HEK293 cells, but co-expression of a G protein alpha subunit allows strong PM localization of the beta(1)gamma(2). Furthermore, C-terminal isoprenylation of the gamma subunit is necessary but not sufficient for PM localization of beta(1)gamma(2). Isoprenylation of gamma(2) and localization of beta(1)gamma(2) to the ER occurs independently of alpha expression. Efficient PM localization of beta(1)gamma(2) in the absence of co-expressed alpha is observed when a site for palmitoylation, a putative second membrane targeting signal, is introduced into gamma(2). When a mutant of alpha(s) is targeted to mitochondria, beta(1)gamma(2) follows, consistent with an important role for alpha in promoting subcellular localization of betagamma. Furthermore, we directly demonstrate the requirement for alpha by showing that disruption of heterotrimer formation by the introduction of alpha binding mutations into beta(1) impedes PM targeting of beta(1)gamma(2). The results indicate that two membrane targeting signals, lipid modification and alpha binding, make concerted contributions to PM localization of betagamma.	Thomas Jefferson Univ, Dept Microbiol & Immunol, Kimmel Canc Ctr, Philadelphia, PA 19107 USA	Jefferson University	Wedegaertner, PB (corresponding author), Thomas Jefferson Univ, Dept Microbiol & Immunol, Kimmel Canc Ctr, 233 S 10th St,839 BLSB, Philadelphia, PA 19107 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R55GM056444, R01GM056444, R56GM056444] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM56444] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Apolloni A, 2000, MOL CELL BIOL, V20, P2475, DOI 10.1128/MCB.20.7.2475-2487.2000; Chen CA, 2001, ONCOGENE, V20, P1643, DOI 10.1038/sj.onc.1204185; Choy E, 1999, CELL, V98, P69, DOI 10.1016/S0092-8674(00)80607-8; Dai Q, 1998, J BIOL CHEM, V273, P15030, DOI 10.1074/jbc.273.24.15030; DEGTYAREV MY, 1994, J BIOL CHEM, V269, P30898; Denker SP, 1996, J CELL BIOL, V133, P1027, DOI 10.1083/jcb.133.5.1027; Dunphy JT, 1998, BBA-MOL CELL BIOL L, V1436, P245, DOI 10.1016/S0005-2760(98)00130-1; Evanko DS, 2000, J BIOL CHEM, V275, P1327, DOI 10.1074/jbc.275.2.1327; Evanko DS, 2001, J BIOL CHEM, V276, P23945, DOI 10.1074/jbc.M101154200; Fishburn CS, 2000, P NATL ACAD SCI USA, V97, P1085, DOI 10.1073/pnas.97.3.1085; Fishburn CS, 1999, J BIOL CHEM, V274, P18793, DOI 10.1074/jbc.274.26.18793; Ford CE, 1998, SCIENCE, V280, P1271, DOI 10.1126/science.280.5367.1271; Fu HW, 1999, RECENT PROG HORM RES, V54, P315; Gelb MH, 1998, CURR OPIN CHEM BIOL, V2, P40, DOI 10.1016/S1367-5931(98)80034-3; Gotta M, 2001, NAT CELL BIOL, V3, P297, DOI 10.1038/35060092; HANCOCK JF, 1990, CELL, V63, P133, DOI 10.1016/0092-8674(90)90294-O; HANCOCK JF, 1991, EMBO J, V10, P4033, DOI 10.1002/j.1460-2075.1991.tb04979.x; Higgins JB, 1996, CELL SIGNAL, V8, P433, DOI 10.1016/S0898-6568(96)00071-X; Hirschman JE, 1999, MOL CELL BIOL, V19, P7705; INIGUEZLLUHI JA, 1992, J BIOL CHEM, V267, P23409; Lambright DG, 1996, NATURE, V379, P311, DOI 10.1038/379311a0; Li Y, 1998, J BIOL CHEM, V273, P16265, DOI 10.1074/jbc.273.26.16265; Lobo S, 2002, J BIOL CHEM, V277, P41268, DOI 10.1074/JBC.M206573200; Manahan CL, 2000, MOL BIOL CELL, V11, P957, DOI 10.1091/mbc.11.3.957; Michaelson D, 2002, MOL BIOL CELL, V13, P3294, DOI 10.1091/mbc.E02-02-0095; Morales J, 1998, MOL BIOL CELL, V9, P1, DOI 10.1091/mbc.9.1.1; MUNTZ KH, 1992, MOL BIOL CELL, V3, P49, DOI 10.1091/mbc.3.1.49; Schmidt WK, 1998, P NATL ACAD SCI USA, V95, P11175, DOI 10.1073/pnas.95.19.11175; SHORE GC, 1995, EUR J BIOCHEM, V227, P9, DOI 10.1111/j.1432-1033.1995.tb20354.x; Song JP, 1996, J BIOL CHEM, V271, P20273, DOI 10.1074/jbc.271.34.20273; WALL MA, 1995, CELL, V83, P1047, DOI 10.1016/0092-8674(95)90220-1; Wedegaertner PB, 1998, BIOL SIGNAL RECEPT, V7, P125; Zhao LH, 2002, J BIOL CHEM, V277, P49352, DOI 10.1074/jbc.M209760200	33	77	77	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 9	2003	278	19					17284	17290		10.1074/jbc.M213239200	http://dx.doi.org/10.1074/jbc.M213239200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677QG	12609996	hybrid			2022-12-25	WOS:000182818600112
J	Weihofen, A; Lemberg, MK; Friedmann, E; Rueeger, H; Schmitz, A; Paganetti, P; Rovelli, G; Martoglio, B				Weihofen, A; Lemberg, MK; Friedmann, E; Rueeger, H; Schmitz, A; Paganetti, P; Rovelli, G; Martoglio, B			Targeting presenilin-type aspartic protease signal peptide peptidase with gamma-secretase inhibitors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMYLOID PRECURSOR PROTEIN; FAMILIAL ALZHEIMERS-DISEASE; VIRUS CORE PROTEIN; INTRAMEMBRANE PROTEOLYSIS; INTRACELLULAR DOMAIN; THYMOCYTE DEVELOPMENT; BETA-SECRETASE; CLEAVAGE; APP; IDENTIFICATION	Presenilin is implicated in the pathogenesis of Alzheimer's disease. It is thought to constitute the catalytic subunit of the gamma-secretase complex that catalyzes intramembrane cleavage of beta-amyloid precursor protein, the last step in the generation of amyloidogenic Abeta peptides. The latter are major constituents of amyloid plaques in the brain of Alzheimer's disease patients. Inhibitors of gamma-secretase are considered potential therapeutics for the treatment of this disease because they prevent production of Abeta peptides. Recently, we discovered a family of presenilin-type aspartic proteases. The founding member, signal peptide peptidase, catalyzes intramembrane cleavage of distinct signal peptides in the endoplasmic reticulum membrane of animals. In humans, the protease plays a crucial role in the immune system. Moreover, it is exploited by the hepatitis C virus for the processing of the structural components of the virion and hence is an attractive target for anti-infective intervention. Signal peptide peptidase and presenilin share identical active site motifs and both catalyze intramembrane proteolysis. These common features let us speculate that gamma-secretase inhibitors directed against presenilin may also inhibit signal peptide peptidase. Here we demonstrate that some of the most potent known gamma-secretase inhibitors efficiently inhibit signal peptide peptidase. However, we found compounds that showed higher specificity for one or the other protease. Our findings highlight the possibility of developing selective inhibitors aimed at reducing Abeta generation without affecting other intramembrane-cleaving aspartic proteases.	ETH Honggerberg, Swiss Fed Inst Technol, Inst Biochem, CH-8093 Zurich, Switzerland; Novartis Pharma AG, Nervous Syst Res, CH-4002 Basel, Switzerland	Swiss Federal Institutes of Technology Domain; ETH Zurich; Novartis	Martoglio, B (corresponding author), ETH Honggerberg, Swiss Fed Inst Technol, Inst Biochem, CH-8093 Zurich, Switzerland.	bruno.martoglio@bc.biol.ethz.ch	Paganetti, Paolo/AAF-8039-2020; Lemberg, Marius K/B-8881-2016; Weihofen, Andreas/A-1566-2011	Lemberg, Marius K/0000-0002-0996-1268; Weihofen, Andreas/0000-0001-6265-9087; Paganetti, Paolo/0000-0003-1896-6324				Beher D, 2001, J BIOL CHEM, V276, P45394, DOI 10.1074/jbc.M103075200; Braud VM, 1998, NATURE, V391, P795, DOI 10.1038/35869; Cao XW, 2001, SCIENCE, V293, P115, DOI 10.1126/science.1058783; De Strooper B, 1999, NATURE, V398, P518, DOI 10.1038/19083; Doerfler P, 2001, P NATL ACAD SCI USA, V98, P9312, DOI 10.1073/pnas.161102498; Esler WP, 2000, NAT CELL BIOL, V2, P428, DOI 10.1038/35017062; GLENNER GG, 1984, BIOCHEM BIOPH RES CO, V120, P885, DOI 10.1016/S0006-291X(84)80190-4; Grigorenko AP, 2002, BIOCHEMISTRY-MOSCOW+, V67, P826, DOI 10.1023/A:1016365227942; Haass C, 2002, TRENDS CELL BIOL, V12, P556, DOI 10.1016/S0962-8924(02)02394-2; Hadland BK, 2001, P NATL ACAD SCI USA, V98, P7487, DOI 10.1073/pnas.131202798; Hegde RS, 2002, MOL CELL, V10, P697, DOI 10.1016/S1097-2765(02)00692-5; Hope RG, 2000, J GEN VIROL, V81, P1913, DOI 10.1099/0022-1317-81-8-1913; JARRETT JT, 1993, BIOCHEMISTRY-US, V32, P4693, DOI 10.1021/bi00069a001; Josien H, 2002, CURR OPIN DRUG DI DE, V5, P513; Kaether C, 2002, J CELL BIOL, V158, P551, DOI 10.1083/jcb.200201123; KANG J, 1987, NATURE, V325, P733, DOI 10.1038/325733a0; Kimberly WT, 2001, J BIOL CHEM, V276, P40288, DOI 10.1074/jbc.C100447200; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lammich S, 2002, J BIOL CHEM, V277, P44754, DOI 10.1074/jbc.M206872200; Lee HJ, 2002, J BIOL CHEM, V277, P6318, DOI 10.1074/jbc.M110371200; Leissring MA, 2002, P NATL ACAD SCI USA, V99, P4697, DOI 10.1073/pnas.072033799; Lemberg MK, 2002, MOL CELL, V10, P735, DOI 10.1016/S1097-2765(02)00655-X; Lemberg MK, 2001, J IMMUNOL, V167, P6441, DOI 10.4049/jimmunol.167.11.6441; LEVYLAHAD E, 1995, SCIENCE, V269, P973, DOI 10.1126/science.7638622; Li YM, 2000, P NATL ACAD SCI USA, V97, P6138, DOI 10.1073/pnas.110126897; Li YM, 2000, NATURE, V405, P689, DOI 10.1038/35015085; McLauchlan J, 2002, EMBO J, V21, P3980, DOI 10.1093/emboj/cdf414; MULLAN M, 1992, NAT GENET, V1, P345, DOI 10.1038/ng0892-345; Mumm JS, 2000, DEV BIOL, V228, P151, DOI 10.1006/dbio.2000.9960; Nadin A, 2001, TETRAHEDRON, V57, P1861, DOI 10.1016/S0040-4020(00)01167-4; Ni CY, 2001, SCIENCE, V294, P2179, DOI 10.1126/science.1065412; Petit A, 2001, NAT CELL BIOL, V3, P507, DOI 10.1038/35074581; Ponting CP, 2002, HUM MOL GENET, V11, P1037, DOI 10.1093/hmg/11.9.1037; Radtke F, 2002, IMMUNOL REV, V187, P65, DOI 10.1034/j.1600-065X.2002.18706.x; SchraderFischer G, 1996, BRAIN RES, V716, P91, DOI 10.1016/0006-8993(96)00002-9; Selkoe DJ, 2001, PHYSIOL REV, V81, P741, DOI 10.1152/physrev.2001.81.2.741; Selkoe DJ, 1999, NATURE, V399, pA23, DOI 10.1038/399a023; Shearman MS, 2000, BIOCHEMISTRY-US, V39, P8698, DOI 10.1021/bi0005456; SHERRINGTON R, 1995, NATURE, V375, P754, DOI 10.1038/375754a0; Sinha S, 1999, NATURE, V402, P537, DOI 10.1038/990114; Steiner H, 2000, NAT CELL BIOL, V2, P848, DOI 10.1038/35041097; Steiner H, 1999, BIOCHEMISTRY-US, V38, P14600, DOI 10.1021/bi9914210; Vassar R, 1999, SCIENCE, V286, P735, DOI 10.1126/science.286.5440.735; Weihofen A, 2000, J BIOL CHEM, V275, P30951, DOI 10.1074/jbc.M005980200; Weihofen A, 2003, TRENDS CELL BIOL, V13, P71, DOI 10.1016/S0962-8924(02)00041-7; Weihofen A, 2002, SCIENCE, V296, P2215, DOI 10.1126/science.1070925; Wiltfang J, 1997, ELECTROPHORESIS, V18, P527, DOI 10.1002/elps.1150180332; Wolfe MS, 2002, NAT REV DRUG DISCOV, V1, P859, DOI 10.1038/nrd938; Wolfe MS, 1998, J MED CHEM, V41, P6, DOI 10.1021/jm970621b; Wolfe MS, 2002, SCIENCE, V296, P2156, DOI 10.1126/science.1073844; Wolfe MS, 2001, J MED CHEM, V44, P2039, DOI 10.1021/jm0004897; Wolfe MS, 1999, BIOCHEMISTRY-US, V38, P4720, DOI 10.1021/bi982562p; Wolfe MS, 1999, NATURE, V398, P513, DOI 10.1038/19077	53	110	113	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 9	2003	278	19					16528	16533		10.1074/jbc.M301372200	http://dx.doi.org/10.1074/jbc.M301372200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677QG	12621027	hybrid			2022-12-25	WOS:000182818600013
J	Noren, NK; Arthur, WT; Burridge, K				Noren, NK; Arthur, WT; Burridge, K			Cadherin engagement inhibits RhoA via p190RhoGAP	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-CELL-ADHESION; GTPASE-ACTIVATING PROTEIN; TYROSINE PHOSPHORYLATION; FAMILY GTPASES; C-SRC; V-SRC; ACTIN CYTOSKELETON; EPITHELIAL-CELLS; EXCHANGE FACTOR; P190 RHOGAP	Cadherins are transmembrane receptors that mediate cell-cell adhesion in epithelial cells. A number of changes occur during cadherin-mediated junction formation, one of which is a rearrangement of the actin cytoskeleton. Key regulators of actin cytoskeletal dynamics in cells are the Rho family of GTPases. We have demonstrated in previous studies that cadherin signaling suppresses RhoA activity and activates Rac1. The signaling events downstream of cadherins that modulate the activity of Rho family proteins remain unknown.. Here we have identified a pathway by which RhoA becomes inactivated by cadherins. To determine whether cadherins regulate RhoA through activation of a GTPase-activating protein (GAP) for RhoA, we used constitutively active RhoA to isolate activated GAPs. Using this assay, we have identified the RhoA-specific GAP, p190RhoGAP, downstream from engaged cadherins. We found that cadherin engagement induced tyrosine phosphorylation of p190RhoGAP and increased its binding to p120RasGAP. The increased precipitation of p190RhoGAP with 63LRhoA was blocked by addition of PP2 suggesting that Src family kinases are required downstream from cadherin signaling. The inhibition of RhoA activity by cadherins was antagonized by expression of a dominant negative p190RhoGAP. Taken, together, these data demonstrate that p190RhoGAP activity is critical for RhoA inactivation by cadherins.	Univ N Carolina, Dept Dev & Cell Biol, Chapel Hill, NC 27599 USA; Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill	Noren, NK (corresponding author), Burnham Inst, 10901 N Torrey Pines Rd, La Jolla, CA 92037 USA.		Noren Hooten, Nicole/J-5498-2019	Noren Hooten, Nicole/0000-0002-1683-3838	NIDCR NIH HHS [DE13079] Funding Source: Medline; NIGMS NIH HHS [GM29860] Funding Source: Medline; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [P60DE013079] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM029860] Funding Source: NIH RePORTER	NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Arthur WT, 2002, J BIOL CHEM, V277, P42964, DOI 10.1074/jbc.M207401200; Arthur WT, 2002, BIOL RES, V35, P239, DOI 10.4067/S0716-97602002000200016; Arthur WT, 2001, MOL BIOL CELL, V12, P2711, DOI 10.1091/mbc.12.9.2711; Arthur WT, 2000, CURR BIOL, V10, P719, DOI 10.1016/S0960-9822(00)00537-6; BEHRENS J, 1993, J CELL BIOL, V120, P757, DOI 10.1083/jcb.120.3.757; Betson M, 2002, J BIOL CHEM, V277, P36962, DOI 10.1074/jbc.M207358200; Braga VMM, 1997, J CELL BIOL, V137, P1421, DOI 10.1083/jcb.137.6.1421; Brouns MR, 2000, DEVELOPMENT, V127, P4891; Brouns MR, 2001, NAT CELL BIOL, V3, P361, DOI 10.1038/35070042; CHANG JH, 1995, J CELL BIOL, V130, P355, DOI 10.1083/jcb.130.2.355; CHEN SY, 1994, ONCOGENE, V9, P2691; Fincham VJ, 1999, J CELL SCI, V112, P947; Frame MC, 2002, NAT REV MOL CELL BIO, V3, P233, DOI 10.1038/nrm779; Hordijk PL, 1997, SCIENCE, V278, P1464, DOI 10.1126/science.278.5342.1464; Hu KQ, 1997, EMBO J, V16, P473, DOI 10.1093/emboj/16.3.473; Jou TS, 1998, J CELL BIOL, V142, P85, DOI 10.1083/jcb.142.1.85; Kim SH, 2000, J BIOL CHEM, V275, P36999, DOI 10.1074/jbc.M003430200; Kinch M S, 1997, Cell Adhes Commun, V4, P425, DOI 10.3109/15419069709004459; Kovacs EM, 2002, J BIOL CHEM, V277, P6708, DOI 10.1074/jbc.M109640200; Kulkarni SV, 2000, J CELL BIOL, V149, P457, DOI 10.1083/jcb.149.2.457; Kuroda S, 1997, BIOCHEM BIOPH RES CO, V240, P430, DOI 10.1006/bbrc.1997.7675; Lampugnani MG, 2002, MOL BIOL CELL, V13, P1175, DOI 10.1091/mbc.01-07-0368; MATSUYOSHI N, 1992, J CELL BIOL, V118, P703, DOI 10.1083/jcb.118.3.703; MICHALIDES R, 1994, CELL ADHES COMMUN, V2, P481, DOI 10.3109/15419069409014212; MORAN MF, 1991, MOL CELL BIOL, V11, P1804, DOI 10.1128/MCB.11.4.1804; Nakagawa M, 2001, J CELL SCI, V114, P1829; Nakahara H, 1998, J BIOL CHEM, V273, P9, DOI 10.1074/jbc.273.1.9; Noren NK, 2001, J BIOL CHEM, V276, P33305, DOI 10.1074/jbc.C100306200; Noren NK, 2000, J CELL BIOL, V150, P567, DOI 10.1083/jcb.150.3.567; Ren XD, 1999, EMBO J, V18, P578, DOI 10.1093/emboj/18.3.578; Ren XR, 2001, J CELL BIOL, V152, P971, DOI 10.1083/jcb.152.5.971; Roof RW, 1998, MOL CELL BIOL, V18, P7052, DOI 10.1128/MCB.18.12.7052; SETTLEMAN J, 1992, NATURE, V359, P153, DOI 10.1038/359153a0; Takaishi K, 1997, J CELL BIOL, V139, P1047, DOI 10.1083/jcb.139.4.1047; TAPON N, 1997, CURR OPIN CELL BIOL, V9, P87; Tatsis N, 1998, J BIOL CHEM, V273, P34631, DOI 10.1074/jbc.273.51.34631; TSUKITA S, 1991, J CELL BIOL, V113, P867, DOI 10.1083/jcb.113.4.867; VAN AL, 1997, GENE DEV, V11, P2295; Yap AS, 2003, J CELL BIOL, V160, P11, DOI 10.1083/jcb.200208156; Zhong CL, 1997, MOL BIOL CELL, V8, P2329, DOI 10.1091/mbc.8.11.2329	40	136	138	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 18	2003	278	16					13615	13618		10.1074/jbc.C200657200	http://dx.doi.org/10.1074/jbc.C200657200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	670JV	12606561	hybrid			2022-12-25	WOS:000182405000007
J	Murray, SA; Zheng, HW; Gu, L; Xiao, ZXJ				Murray, SA; Zheng, HW; Gu, L; Xiao, ZXJ			IGF-1 activates p21 to inhibit UV-induced cell death	ONCOGENE			English	Article						IGF-1; Akt; p53; p21; UV and apoptosis	SERINE-THREONINE KINASE; MYC-INDUCED APOPTOSIS; NF-KAPPA-B; P53-INDUCED APOPTOSIS; TUMOR-SUPPRESSOR; CANCER-CELLS; TRANSCRIPTION FACTOR; GROWTH-FACTORS; DNA-DAMAGE; P53	The insulin-like growth factor-1 (IGF-1) and its downstream effector Akt have been documented as survival factors in response to a variety of stress signals. In this study, we show that IGF-1 activates p21 protein expression in a p53-dependent manner. Inhibition of PI-3 kinase or ectopic expression of a dominant-negative Akt blocks the effect of IGF-1 on the upregulation of p21 expression. In addition, IGF-1 prevents the UV irradiation-mediated suppression of p21 and MDM2 expression. Furthermore, p21 is important for IGF-1-mediated cell survival upon UV irradiation. Taken together, these data indicate that IGF-1 may activate p21 in executing its survival function upon genotoxic insults.	Boston Univ, Sch Med, Dept Biochem, Boston, MA 02118 USA; Boston Univ, Sch Med, Dept Med, Boston, MA 02118 USA	Boston University; Boston University	Xiao, ZXJ (corresponding author), Boston Univ, Sch Med, Dept Biochem, Boston, MA 02118 USA.	jxiao@bu.edu		Zheng, Hongwu/0000-0002-5823-4913	NATIONAL CANCER INSTITUTE [R01CA079804] Funding Source: NIH RePORTER; NCI NIH HHS [R01CA79804] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Asada M, 1999, EMBO J, V18, P1223, DOI 10.1093/emboj/18.5.1223; Ashcroft M, 2002, ONCOGENE, V21, P1955, DOI 10.1038/sj.onc.1205276; Biggs WH, 1999, P NATL ACAD SCI USA, V96, P7421, DOI 10.1073/pnas.96.13.7421; BRUGAROLAS J, 1995, NATURE, V377, P552, DOI 10.1038/377552a0; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; BUCKBINDER L, 1995, NATURE, V377, P646, DOI 10.1038/377646a0; Bunz F, 1999, J CLIN INVEST, V104, P263, DOI 10.1172/JCI6863; Cardone MH, 1998, SCIENCE, V282, P1318, DOI 10.1126/science.282.5392.1318; Carter CS, 2002, TRENDS GENET, V18, P295, DOI 10.1016/S0168-9525(02)02696-3; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; DEL PL, 1997, SCIENCE, V278, P687; Dudek H, 1997, SCIENCE, V275, P661, DOI 10.1126/science.275.5300.661; GEIER A, 1995, CANCER INVEST, V13, P480, DOI 10.3109/07357909509024911; Gooch JL, 1999, BREAST CANCER RES TR, V56, P1, DOI 10.1023/A:1006208721167; Gorospe M, 1997, ONCOGENE, V14, P929, DOI 10.1038/sj.onc.1200897; Gottlieb TM, 2002, ONCOGENE, V21, P1299, DOI 10.1038/sj.onc.1205181; Grimberg A, 2000, J CELL PHYSIOL, V183, P1, DOI 10.1002/(SICI)1097-4652(200004)183:1<1::AID-JCP1>3.0.CO;2-J; HARRINGTON EA, 1994, EMBO J, V13, P3286, DOI 10.1002/j.1460-2075.1994.tb06630.x; Hermeking H, 1997, MOL CELL, V1, P3, DOI 10.1016/S1097-2765(00)80002-7; Kamijo T, 1998, P NATL ACAD SCI USA, V95, P8292, DOI 10.1073/pnas.95.14.8292; KauffmanZeh A, 1997, NATURE, V385, P544, DOI 10.1038/385544a0; Kennedy SG, 1997, GENE DEV, V11, P701, DOI 10.1101/gad.11.6.701; Kitamura T, 1998, MOL CELL BIOL, V18, P3708, DOI 10.1128/MCB.18.7.3708; Kops GJPL, 1999, NATURE, V398, P630, DOI 10.1038/19328; Kulik G, 1997, MOL CELL BIOL, V17, P1595, DOI 10.1128/MCB.17.3.1595; Lakin ND, 1999, ONCOGENE, V18, P7644, DOI 10.1038/sj.onc.1203015; Lawlor MA, 2000, MOL CELL BIOL, V20, P8983, DOI 10.1128/MCB.20.23.8983-8995.2000; Lawlor MA, 2000, J CELL BIOL, V151, P1131, DOI 10.1083/jcb.151.6.1131; Lawrence JW, 2001, J BIOL CHEM, V276, P31521, DOI 10.1074/jbc.M103306200; Lu X, 1996, ONCOGENE, V13, P413; Matsui T, 1999, CIRCULATION, V100, P2373, DOI 10.1161/01.CIR.100.23.2373; Mayo LD, 2001, P NATL ACAD SCI USA, V98, P11598, DOI 10.1073/pnas.181181198; McKay BC, 1998, ONCOGENE, V17, P545, DOI 10.1038/sj.onc.1201963; Meek DW, 1999, ONCOGENE, V18, P7666, DOI 10.1038/sj.onc.1202951; Mitsuuchi Y, 2000, CANCER RES, V60, P5390; MIYASHITA T, 1995, CELL, V80, P293; Nakano K, 2001, MOL CELL, V7, P683, DOI 10.1016/S1097-2765(01)00214-3; Nghiem P, 2001, P NATL ACAD SCI USA, V98, P9092, DOI 10.1073/pnas.161281798; Oda E, 2000, SCIENCE, V288, P1053, DOI 10.1126/science.288.5468.1053; Oda K, 2000, CELL, V102, P849, DOI 10.1016/S0092-8674(00)00073-8; Okubo Y, 1998, J BIOL CHEM, V273, P25961, DOI 10.1074/jbc.273.40.25961; Ozes ON, 1999, NATURE, V401, P82; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; Polyak K, 1996, GENE DEV, V10, P1945, DOI 10.1101/gad.10.15.1945; Pomerantz J, 1998, CELL, V92, P713, DOI 10.1016/S0092-8674(00)81400-2; Rossig L, 2001, MOL CELL BIOL, V21, P5644, DOI 10.1128/MCB.21.16.5644-5657.2001; ROSSIG L, 2002, J BIOL CHEM, V4, P4; Sandhu MS, 2002, J NATL CANCER I, V94, P972; Shaulian E, 2000, CELL, V103, P897, DOI 10.1016/S0092-8674(00)00193-8; Sherr CJ, 2000, CURR OPIN GENET DEV, V10, P94, DOI 10.1016/S0959-437X(99)00038-6; Shimoke K, 1999, DEV BRAIN RES, V112, P245, DOI 10.1016/S0165-3806(98)00172-2; Stewart CEH, 1996, PHYSIOL REV, V76, P1005, DOI 10.1152/physrev.1996.76.4.1005; Stott FJ, 1998, EMBO J, V17, P5001, DOI 10.1093/emboj/17.17.5001; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Vousden KH, 2002, NAT REV CANCER, V2, P594, DOI 10.1038/nrc864; Vousden KH, 2002, BBA-REV CANCER, V1602, P47, DOI 10.1016/S0304-419X(02)00035-5; Waldman T, 1996, NATURE, V381, P713, DOI 10.1038/381713a0; Wang JA, 1999, INT J RADIAT BIOL, V75, P301, DOI 10.1080/095530099140483; Woods DB, 2001, EXP CELL RES, V264, P56, DOI 10.1006/excr.2000.5141; Wu L, 1997, MOL MED, V3, P441, DOI 10.1007/BF03401691; Xu SQ, 2000, BIOCHEM BIOPH RES CO, V269, P179, DOI 10.1006/bbrc.2000.2247; Zeng XY, 2000, CANCER RES, V60, P6184; Zhang YP, 1998, CELL, V92, P725, DOI 10.1016/S0092-8674(00)81401-4; Zhou BHP, 2001, NAT CELL BIOL, V3, P973, DOI 10.1038/ncb1101-973; Zhou BHP, 2001, NAT CELL BIOL, V3, P245, DOI 10.1038/35060032	67	24	25	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 20	2003	22	11					1703	1711		10.1038/sj.onc.1206327	http://dx.doi.org/10.1038/sj.onc.1206327			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	655YH	12642873				2022-12-25	WOS:000181580500012
J	Ferrara, P; Andermarcher, E; Bossis, G; Acquaviva, C; Brockly, F; Jariel-Encontre, I; Piechaczyk, M				Ferrara, P; Andermarcher, E; Bossis, G; Acquaviva, C; Brockly, F; Jariel-Encontre, I; Piechaczyk, M			The structural determinants responsible for c-Fos protein proteasomal degradation differ according to the conditions of expression	ONCOGENE			English	Article						c-Fos; protein degradation; proteasome	IN-VITRO; PROTOONCOGENE PRODUCT; G0-TO-G1 TRANSITION; MOUSE FIBROBLASTS; V-FOS; JUN; AP-1; PHOSPHORYLATION; TRANSCRIPTION; KINASE	c-fos gene is expressed constitutively in a number of tissues as well as in certain tumor cells and is inducible, in general rapidly and transiently, in virtually all other cell types by a variety of stimuli. Its protein product, c-Fos, is a short-lived transcription factor that heterodimerizes with various protein partners within the AP-1 transcription complex via leucine zipper/leucine zipper interactions for binding to specific DNA sequences. It is mostly, if not exclusively, degraded by the proteasome. To localize the determinant(s) responsible for its instability, we have conducted a genetic analysis in which the half-lives of c-Fos mutants and chimeras made with the stable EGFP reporter protein were compared under two experimental conditions taken as example of continous and inducible expression. Those were constitutive expression in asynchronously growing Balb/C 3T3 mouse embryo fibroblasts and transient induction in the same cells undergoing the G0/G1 phase transition upon stimulation by serum. Our work shows that c-Fos is degraded faster in synchronous-than in asynchronous cells. This difference in turnover is primarily accounted for by several mechanisms. First, in asynchronous cells, a unique C-terminal destabilizer is active whereas, in serum-stimulated cells two destabilizers located at both extremities of the protein are functional. Second, heterodimerization and/or binding to DNA accelerates protein degradation only during the G0/G1 phase transition. Adding another level of complexity to turnover control, phosphorylation at serines 362 and 374, which are c-Fos phosphorylation sites largely modified during the G0/G1 phase transition, stabilizes c-Fos much more efficiently in asynchronous than in serum-stimulated cells. In both cases, the reduced degradation rate is due to inhibition of the activity of the C-terminal destabilizer. However, in serum-stimulated cells, this effect is partially masked by the activation of the N-terminal destabilizer and basic domain/leucine zipper-dependent mechanisms. Taken together, our data show that multiple degradation mechanisms, differing according to the conditions of expression, may operate on c-Fos to ensure a proper level and/or timing of expression. Moreover, they also indicate that the half-life of c-Fos during the G0/G1 phase transition is determined by a delicate balance between opposing stabilizing and destabilizing mechanisms operating at the same time.	CNRS, UMR 5535, Inst Mol Genet, IFR24, F-34293 Montpellier 05, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Universite de Montpellier	Piechaczyk, M (corresponding author), CNRS, UMR 5535, Inst Mol Genet, IFR24, 1919 Route Mende, F-34293 Montpellier 05, France.	piechaczyk@igm.cnrs-mop.fr	PIECHACZYK, Marc/E-7896-2013; Bossis, Guillaume/C-7172-2012; Acquaviva, Claire/N-4306-2017	PIECHACZYK, Marc/0000-0003-1367-2597; Acquaviva, Claire/0000-0002-0227-9813; bossis, guillaume/0000-0002-3349-8250				ABATE C, 1990, CELL GROWTH DIFFER, V1, P455; Acquaviva C, 2001, ONCOGENE, V20, P7563, DOI 10.1038/sj.onc.1204880; Angel P, 2001, ONCOGENE, V20, P2413, DOI 10.1038/sj.onc.1204380; Bakiri L, 2002, MOL CELL BIOL, V22, P4952, DOI 10.1128/MCB.22.13.4952-4964.2002; Chaussepied M, 1998, MOL BIOCHEM PARASIT, V94, P215, DOI 10.1016/S0166-6851(98)00070-X; Chen JS, 1997, J NEUROSCI, V17, P4933; CHEN RH, 1993, P NATL ACAD SCI USA, V90, P10952, DOI 10.1073/pnas.90.23.10952; Chen RH, 1996, ONCOGENE, V12, P1493; Chinenov Y, 2001, ONCOGENE, V20, P2438, DOI 10.1038/sj.onc.1204385; Coux Olivier, 2002, Prog Mol Subcell Biol, V29, P85; Curran T, 1988, ONCOGENE HDB, P307; DeMartino GN, 1999, J BIOL CHEM, V274, P22123, DOI 10.1074/jbc.274.32.22123; DOBRZANSKI P, 1991, MOL CELL BIOL, V11, P5470, DOI 10.1128/MCB.11.11.5470; EIBL B, 1995, CYTOKINES MOL THER, V1, P29; Ferdous A, 2001, MOL CELL, V7, P981, DOI 10.1016/S1097-2765(01)00250-7; FUJII M, 1991, ONCOGENE, V6, P1023; Gamberi G, 1998, ONCOLOGY-BASEL, V55, P556, DOI 10.1159/000011912; Gianni M, 2002, EMBO J, V21, P3760, DOI 10.1093/emboj/cdf374; Glickman MH, 2002, PHYSIOL REV, V82, P373, DOI 10.1152/physrev.00027.2001; Gonzalez F, 2002, SCIENCE, V296, P548, DOI 10.1126/science.1069490; GRUDA MC, 1994, ONCOGENE, V9, P2537; Hafezi F, 1997, NAT MED, V3, P346, DOI 10.1038/nm0397-346; He HL, 1998, J BIOL CHEM, V273, P25015, DOI 10.1074/jbc.273.39.25015; Herdegen T, 2001, ONCOGENE, V20, P2424, DOI 10.1038/sj.onc.1204387; HermidaMatsumoto ML, 1996, J BIOL CHEM, V271, P4930; HUANG TS, 1995, CANCER LETT, V96, P1, DOI 10.1016/0304-3835(95)03918-M; IWAHASHI M, 1994, BRIT J HAEMATOL, V86, P193, DOI 10.1111/j.1365-2141.1994.tb03275.x; Jochum W, 2001, ONCOGENE, V20, P2401, DOI 10.1038/sj.onc.1204389; JOHNSON RS, 1992, CELL, V71, P577, DOI 10.1016/0092-8674(92)90592-Z; KANAITSUKA T, 1988, ACTA PATHOL JAPON, V38, P1523; Kanaitsuka T, 1987, Nihon Naika Gakkai Zasshi, V76, P1595; Kim YH, 2000, BRAIN RES, V872, P227, DOI 10.1016/S0006-8993(00)02477-X; Kisselev AF, 2001, CHEM BIOL, V8, P739, DOI 10.1016/S1074-5521(01)00056-4; KOVARY K, 1992, MOL CELL BIOL, V12, P5015, DOI 10.1128/MCB.12.11.5015; KOVARY K, 1991, MOL CELL BIOL, V11, P2451, DOI 10.1128/MCB.11.5.2451; Krappmann D, 1996, EMBO J, V15, P6716, DOI 10.1002/j.1460-2075.1996.tb01061.x; Lallemand D, 1997, ONCOGENE, V14, P819, DOI 10.1038/sj.onc.1200901; Li XQ, 1998, J BIOL CHEM, V273, P34970, DOI 10.1074/jbc.273.52.34970; Macian F, 2001, ONCOGENE, V20, P2476, DOI 10.1038/sj.onc.1204386; Malek NP, 2001, NATURE, V413, P323, DOI 10.1038/35095083; Masson N, 2001, EMBO J, V20, P5197, DOI 10.1093/emboj/20.18.5197; Masuyama H, 1998, J CELL BIOCHEM, V71, P429, DOI 10.1002/(SICI)1097-4644(19981201)71:3<429::AID-JCB11>3.0.CO;2-P; MIAO GG, 1994, MOL CELL BIOL, V14, P4295, DOI 10.1128/MCB.14.6.4295; Navon A, 2001, MOL CELL, V8, P1339, DOI 10.1016/S1097-2765(01)00407-5; OKAZAKI K, 1995, EMBO J, V14, P5048, DOI 10.1002/j.1460-2075.1995.tb00187.x; PAPAVASSILIOU AG, 1992, SCIENCE, V258, P1941, DOI 10.1126/science.1470918; Perkins G, 2001, EMBO J, V20, P4836, DOI 10.1093/emboj/20.17.4836; Pickart CM, 2001, ANNU REV BIOCHEM, V70, P503, DOI 10.1146/annurev.biochem.70.1.503; PIECHACZYK M, 1994, CRIT REV ONCOL HEMAT, V17, P93, DOI 10.1016/1040-8428(94)90021-3; RANSONE LJ, 1990, P NATL ACAD SCI USA, V87, P3806, DOI 10.1073/pnas.87.10.3806; RECH J, 1989, NUCLEIC ACIDS RES, V17, P2874, DOI 10.1093/nar/17.7.2874; Rechsteiner M, 1996, TRENDS BIOCHEM SCI, V21, P267, DOI 10.1016/S0968-0004(96)10031-1; ROGERS S, 1986, SCIENCE, V234, P364, DOI 10.1126/science.2876518; ROUX P, 1990, CELL, V63, P341, DOI 10.1016/0092-8674(90)90167-D; Rubio N, 1996, J NEUROVIROL, V2, P167, DOI 10.3109/13550289609146879; Salvat C, 1998, ONCOGENE, V17, P327, DOI 10.1038/sj.onc.1201922; Sambrook J, 1989, MOL CLONING; SCHREIBER M, 1995, EMBO J, V14, P5338, DOI 10.1002/j.1460-2075.1995.tb00218.x; SCHUERMANN M, 1989, CELL, V56, P507, DOI 10.1016/0092-8674(89)90253-5; Shaulian E, 2001, ONCOGENE, V20, P2390, DOI 10.1038/sj.onc.1204383; STANCOVSKI I, 1995, MOL CELL BIOL, V15, P7106; Su KH, 2000, BIOCHEM J, V348, P281, DOI 10.1042/0264-6021:3480281; Tajima S, 2002, J VIROL, V76, P2557, DOI 10.1128/JVI.76.5.2557-2562.2002; Tansey WP, 2001, GENE DEV, V15, P1045, DOI 10.1101/gad.896501; Thomas D, 2000, CURR BIOL, V10, pR341, DOI 10.1016/S0960-9822(00)00462-0; TSURUMI C, 1995, MOL CELL BIOL, V15, P5682; van Dam H, 2001, ONCOGENE, V20, P2453, DOI 10.1038/sj.onc.1204239; Wang WL, 1996, P NATL ACAD SCI USA, V93, P8236, DOI 10.1073/pnas.93.16.8236; WANG ZQ, 1992, NATURE, V360, P741, DOI 10.1038/360741a0; Zhang JH, 2002, NAT GENET, V30, P416, DOI 10.1038/ng859	70	53	53	1	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 13	2003	22	10					1461	1474		10.1038/sj.onc.1206266	http://dx.doi.org/10.1038/sj.onc.1206266			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	652ZZ	12629509				2022-12-25	WOS:000181411900003
J	Weston, CR; Balmanno, K; Chalmers, C; Hadfield, K; Molton, SA; Ley, R; Wagner, EF; Cook, SJ				Weston, CR; Balmanno, K; Chalmers, C; Hadfield, K; Molton, SA; Ley, R; Wagner, EF; Cook, SJ			Activation of ERK1/2 by Delta Raf-1 : ER* represses bim expression independently of the JNK or PI3K pathways	ONCOGENE			English	Article						apoptosis; bim; ERK; Raf; JNK; PI3K	PROGRAMMED CELL-DEATH; BCL-2 FAMILY-MEMBER; C-JUN; BH3 DOMAIN; MOLECULAR-CLONING; CYCLE ARREST; PROTEIN BIM; APOPTOSIS; SURVIVAL; GENE	CC139 fibroblasts are one of several model systems in which the Raf --> MEK --> ERK1/2 pathway can inhibit apoptosis independently of the PI3K pathway; however, the precise mechanism for this protective effect is not known. Serum withdrawal from CC139 fibroblasts resulted in the rapid onset of apoptosis, which was prevented by actinomycin D or cycloheximide. Serum withdrawal promoted the rapid, de novo accumulation of BiMEL, a proapoptotic 'BH3-only' member of the Bcl-2 protein family. BiMEL expression was an early event, occurring several hours prior to caspase activation. In contrast to studies in neurons, activation of the JNK - cJun pathway was neither necessary nor sufficient to induce BiMEL expression. Selective inhibition of either the ERK pathway (with U0126) or the PI3K pathway (with LY294002) caused an increase in the expression of BiMEL. Furthermore, selective activation of the ERK1/2 pathway by DeltaRaf-1:ER*:ER* substantially reduced BiMEL expression, abolished conformational changes in Bax and blocked the appearance of apoptotic cells. The ability of DeltaRaf-1:ER* to repress Bim(EL) expression required the ERK pathway but was independent of the PI3K --> PDK --> PKB pathway. Thus, serum withdrawal-induced expression of BiMEL occurs independently of the JNK --> c-Jun pathway and can be repressed by the ERK pathway independently of the PI3K pathway. This may contribute to Raf- and Ras-induced cell survival at low serum concentrations.	Babraham Inst, Signalling Programme, Cambridge CB2 4AT, England; Res IMP, A-1030 Vienna, Austria; Univ Massachusetts, Sch Med, Howard Hughes Med Inst, Worcester, MA 01605 USA	UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Babraham Institute; Vienna Biocenter (VBC); Research Institute of Molecular Pathology (IMP); Howard Hughes Medical Institute; University of Massachusetts System; University of Massachusetts Worcester	Cook, SJ (corresponding author), Babraham Inst, Signalling Programme, Cambridge CB2 4AT, England.	simon.cook@bbsrc.ac.uk		Wagner, Erwin F/0000-0001-7872-0196; Balmanno, Kathryn/0000-0002-6417-3889	Biotechnology and Biological Sciences Research Council [BBS/E/B/0000H457, BBS/E/B/0000C199] Funding Source: Medline	Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC))		Adams JM, 2001, TRENDS BIOCHEM SCI, V26, P61, DOI 10.1016/S0968-0004(00)01740-0; Ballif BA, 2001, CELL GROWTH DIFFER, V12, P397; Balmanno K, 1999, ONCOGENE, V18, P3085, DOI 10.1038/sj.onc.1202647; Bouillet P, 1999, SCIENCE, V286, P1735, DOI 10.1126/science.286.5445.1735; Bouillet P, 2001, MAMM GENOME, V12, P163, DOI 10.1007/s003350010242; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Cook SJ, 1999, MOL CELL BIOL, V19, P330; Datta SR, 2000, MOL CELL, V6, P41, DOI 10.1016/S1097-2765(00)00006-X; Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766; Dijkers PF, 2000, CURR BIOL, V10, P1201, DOI 10.1016/S0960-9822(00)00728-4; Downward J, 1998, CURR OPIN GENET DEV, V8, P49, DOI 10.1016/S0959-437X(98)80061-0; Erhardt P, 1999, MOL CELL BIOL, V19, P5308; ESTUS S, 1994, J CELL BIOL, V127, P1717, DOI 10.1083/jcb.127.6.1717; Favata MF, 1998, J BIOL CHEM, V273, P18623, DOI 10.1074/jbc.273.29.18623; Garner AP, 2002, ONCOGENE, V21, P8089, DOI 10.1038/sj.onc.1206000; HAM J, 1995, NEURON, V14, P927, DOI 10.1016/0896-6273(95)90331-3; Harris CA, 2001, J BIOL CHEM, V276, P37754; Hengartner MO, 2000, NATURE, V407, P770, DOI 10.1038/35037710; HILBERG F, 1992, ONCOGENE, V7, P2371; Hsu SY, 1998, MOL ENDOCRINOL, V12, P1432, DOI 10.1210/me.12.9.1432; Huser M, 2001, EMBO J, V20, P1940, DOI 10.1093/emboj/20.8.1940; Imaizumi K, 1999, J BIOL CHEM, V274, P7975, DOI 10.1074/jbc.274.12.7975; Imaizumi K, 1997, J BIOL CHEM, V272, P18842, DOI 10.1074/jbc.272.30.18842; Kelekar A, 1998, TRENDS CELL BIOL, V8, P324, DOI 10.1016/S0962-8924(98)01321-X; Kinoshita T, 1997, ONCOGENE, V15, P619, DOI 10.1038/sj.onc.1201234; Le Gall M, 2000, MOL BIOL CELL, V11, P1103, DOI 10.1091/mbc.11.3.1103; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Makin GWJ, 2001, EMBO J, V20, P6306, DOI 10.1093/emboj/20.22.6306; Marani M, 2002, MOL CELL BIOL, V22, P3577, DOI 10.1128/MCB.22.11.3577-3589.2002; MARTIN DP, 1988, J CELL BIOL, V106, P829, DOI 10.1083/jcb.106.3.829; Martinou JC, 2001, NAT REV MOL CELL BIO, V2, P63, DOI 10.1038/35048069; Mikula M, 2001, EMBO J, V20, P1952, DOI 10.1093/emboj/20.8.1952; Miyashita MUT, 2001, FEBS LETT, V509, P135, DOI 10.1016/S0014-5793(01)03145-3; Nakano K, 2001, MOL CELL, V7, P683, DOI 10.1016/S1097-2765(01)00214-3; O'Connor L, 1998, EMBO J, V17, P384, DOI 10.1093/emboj/17.2.384; O'Reilly LA, 2000, AM J PATHOL, V157, P449, DOI 10.1016/S0002-9440(10)64557-9; Oda E, 2000, SCIENCE, V288, P1053, DOI 10.1126/science.288.5468.1053; Putcha GV, 2001, NEURON, V29, P615, DOI 10.1016/S0896-6273(01)00238-0; Puthalakath H, 2002, CELL DEATH DIFFER, V9, P505, DOI 10.1038/sj.cdd.4400998; Schreiber M, 1999, GENE DEV, V13, P607, DOI 10.1101/gad.13.5.607; Schulze A, 2001, GENE DEV, V15, P981, DOI 10.1101/gad.191101; Shinjyo T, 2001, MOL CELL BIOL, V21, P854, DOI 10.1128/MCB.21.3.854-864.2001; Talapatra S, 2001, J PHARMACOL EXP THER, V298, P873; VASQUEZ F, 2000, BIOCHIM BIOPHYS ACTA, V1470, pM21; Wei MC, 2001, SCIENCE, V292, P727, DOI 10.1126/science.1059108; Whitfield J, 2001, NEURON, V29, P629, DOI 10.1016/S0896-6273(01)00239-2; Wojnowski L, 1997, NAT GENET, V16, P293, DOI 10.1038/ng0797-293; Woods D, 1997, MOL CELL BIOL, V17, P5598, DOI 10.1128/MCB.17.9.5598; Yu J, 2001, MOL CELL, V7, P673, DOI 10.1016/S1097-2765(01)00213-1; Zamzami N, 1998, ONCOGENE, V16, P2265, DOI 10.1038/sj.onc.1201989; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3	52	154	159	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 6	2003	22	9					1281	1293		10.1038/sj.onc.1206261	http://dx.doi.org/10.1038/sj.onc.1206261			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	652CA	12618753				2022-12-25	WOS:000181360900002
J	Glatz, R; Schmidt, O; Asgari, S				Glatz, R; Schmidt, O; Asgari, S			Characterization of a novel protein with homology to C-type lectins expressed by the Cotesia rubecula bracovirus in larvae of the lepidopteran host, Pieris rapae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PARASITOID WASP; POLYDNAVIRUS REPLICATION; HELIOTHIS-VIRESCENS; VIRUS; PURIFICATION; GENOME; SUPPRESSION; CONGREGATA; HEMOLYMPH; IMMUNITY	Polydnaviruses are essential for the survival of many Ichneumonoid endoparasitoids, providing active immune suppression of the host in which parasitoid larvae develop. The Cotesia rubecula bracovirus is unique among polydnaviruses in that only four major genes are detected in parasitized host ( Pieris rapae) tissues, and gene expression is transient. Here we describe a novel C. rubecula bracovirus gene (CrV3) encoding a lectin monomer composed of 159 amino acids, which has conserved residues consistent with invertebrate and mammalian C-type lectins. Bacterially expressed CrV3 agglutinated sheep red blood cells in a divalent ion-dependent but Ca2+-independent manner. Agglutination was inhibited by EDTA but not by biological concentrations of any saccharides tested. Two monomers of similar to14 and similar to17 kDa in size were identified on SDS-PAGE in parasitized P. rapae larvae. The 17-kDa monomer was found to be an N-glyscosylated form of the 14-kDa monomer. CrV3 is produced in infected hemocytes and fat body cells and subsequently secreted into hemolymph. We propose that CrV3 is a novel lectin, the first characterized from an invertebrate virus. CrV3 shows over 60% homology with hypothetical proteins isolated from polydnaviruses in two other Cotesia wasps, indicating that these proteins may also be C-type lectins and that a novel polydnavirus lectin family exists in Cotesia-associated bracoviruses. CrV3 is probably interacting with components in host hemolymph, resulting in suppression of the Pieris immune response. The high similarity of CrV3 with invertebrate lectins, as opposed to those from viruses, may indicate that some bracovirus functions were acquired from their hosts.	Univ Adelaide, Dept Appl & Mol Ecol, Glen Osmond, SA 5064, Australia	University of Adelaide	Asgari, S (corresponding author), Univ Adelaide, Dept Appl & Mol Ecol, Waite Campus, Glen Osmond, SA 5064, Australia.	sassan.asgari@adelaide.edu.au	Glatz, Richard/AAF-9483-2019; Asgari, Sassan/G-2678-2011	Glatz, Richard/0000-0001-8889-3701; Asgari, Sassan/0000-0001-7885-6544				ALBRECHT U, 1994, J GEN VIROL, V75, P3353, DOI 10.1099/0022-1317-75-12-3353; ASGARI S, 1994, J INSECT PHYSIOL, V40, P789, DOI 10.1016/0022-1910(94)90008-6; Asgari S, 1996, J GEN VIROL, V77, P2653, DOI 10.1099/0022-1317-77-10-2653; Asgari S, 1997, J GEN VIROL, V78, P3061, DOI 10.1099/0022-1317-78-11-3061; Asgari S, 1998, P NATL ACAD SCI USA, V95, P3690, DOI 10.1073/pnas.95.7.3690; Balgopal MM, 1996, J INSECT PHYSIOL, V42, P337, DOI 10.1016/0022-1910(95)00111-5; BECKAGE NE, 1994, ARCH INSECT BIOCHEM, V26, P165, DOI 10.1002/arch.940260209; CAVENER DR, 1991, NUCLEIC ACIDS RES, V19, P3185, DOI 10.1093/nar/19.12.3185; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Cui LW, 1997, ARCH INSECT BIOCHEM, V36, P251, DOI 10.1002/(SICI)1520-6327(1997)36:4<251::AID-ARCH2>3.0.CO;2-V; Cui LW, 1997, J VIROL, V71, P8504, DOI 10.1128/JVI.71.11.8504-8513.1997; DRICKAMER K, 1993, ANNU REV CELL BIOL, V9, P237, DOI 10.1146/annurev.cb.09.110193.001321; EDSON KM, 1981, SCIENCE, V211, P582, DOI 10.1126/science.7455695; FLEMING JAGW, 1986, J VIROL, V57, P552, DOI 10.1128/JVI.57.2.552-562.1986; GIGA Y, 1968, BIOCHEMISTRY-US, V8, P2629; GUZO D, 1987, J INSECT PHYSIOL, V33, P19, DOI 10.1016/0022-1910(87)90100-4; HAMMARST.S, 1971, BIOCHEMISTRY-US, V10, P1681; Haq S, 1996, J BIOL CHEM, V271, P20213, DOI 10.1074/jbc.271.33.20213; HARWOOD SH, 1994, INSECT BIOCHEM MOLEC, V24, P685, DOI 10.1016/0965-1748(94)90056-6; Kilpatrick DC, 2002, BBA-GEN SUBJECTS, V1572, P187, DOI 10.1016/S0304-4165(02)00308-2; KRELL PJ, 1982, J VIROL, V43, P859, DOI 10.1128/JVI.43.3.859-870.1982; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lavine MD, 1996, J INSECT PHYSIOL, V42, P41, DOI 10.1016/0022-1910(95)00081-X; Lawrence Pauline O., 1993, P59; LI XS, 1994, J VIROL, V68, P7482, DOI 10.1128/JVI.68.11.7482-7489.1994; Loukas A, 2000, PARASITOL TODAY, V16, P333, DOI 10.1016/S0169-4758(00)01704-X; Luckhart S, 1996, DEV COMP IMMUNOL, V20, P1, DOI 10.1016/0145-305X(95)00040-Z; MARCHALONIS JJ, 1968, J MOL BIOL, V32, P453, DOI 10.1016/0022-2836(68)90022-3; MURAMOTO K, 1990, BIOCHIM BIOPHYS ACTA, V1039, P42, DOI 10.1016/0167-4838(90)90224-4; NORTON WN, 1983, CELL TISSUE RES, V231, P387; Pasquier-Barre F, 2002, J GEN VIROL, V83, P2035, DOI 10.1099/0022-1317-83-8-2035; Saito T, 1997, J BIOL CHEM, V272, P30703, DOI 10.1074/jbc.272.49.30703; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SHARON N, 1989, LECTINS; Stoltz D., 1992, Journal of Hymenoptera Research, V1, P125; Stoltz D B, 1979, Adv Virus Res, V24, P125, DOI 10.1016/S0065-3527(08)60393-0; STOLTZ DB, 1986, J INSECT PHYSIOL, V32, P377, DOI 10.1016/0022-1910(86)90051-X; STOLTZ DB, 1986, VIROLOGY, V155, P120, DOI 10.1016/0042-6822(86)90173-X; STOLTZ DB, 1990, J GEN VIROL, V71, P1051, DOI 10.1099/0022-1317-71-5-1051; STRAND MR, 1992, J GEN VIROL, V73, P1627, DOI 10.1099/0022-1317-73-7-1627; STRAND MR, 1991, J INSECT PHYSIOL, V37, P839, DOI 10.1016/0022-1910(91)90080-J; Tanaka K, 2002, APPL ENTOMOL ZOOL, V37, P323, DOI 10.1303/aez.2002.323; Turnbull M, 2002, ADV VIRUS RES, V58, P203, DOI 10.1016/S0065-3527(02)58006-4; VINSON SB, 1980, Q REV BIOL, V55, P143, DOI 10.1086/411731; WEBB BA, 1986, J INSECT PHYSIOL, V32, P339, DOI 10.1016/0022-1910(86)90046-6; Webb BA, 1998, VIRUSES, P105; Webb BA, 1998, J INSECT PHYSIOL, V44, P785, DOI 10.1016/S0022-1910(98)00011-0	49	41	46	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 30	2003	278	22					19743	19750		10.1074/jbc.M301396200	http://dx.doi.org/10.1074/jbc.M301396200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	682EH	12644452	hybrid			2022-12-25	WOS:000183078000024
J	Glick, E; Chau, JS; Vigna, KL; McCulloch, SD; Adman, ET; Kunkel, TA; Loeb, LA				Glick, E; Chau, JS; Vigna, KL; McCulloch, SD; Adman, ET; Kunkel, TA; Loeb, LA			Amino acid substitutions at conserved tyrosine 52 alter fidelity and bypass efficiency of human DNA polymerase eta	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI DINB; THYMINE DIMER BYPASS; CRYSTAL-STRUCTURE; ERROR-PRONE; REPLICATION; MUTATIONS; PROTEIN; LOCALIZATION; MECHANISM; REPAIR	DNA polymerase eta (Poleta) is a member of a new class of DNA polymerases that is able to copy DNA containing damaged nucleotides. These polymerases are highly error-prone during copying of unaltered DNA templates. We analyzed the relationship between bypass efficiency and fidelity of DNA synthesis by introducing substitutions for Tyr-52, a highly conserved amino acid, within the human DNA polymerase eta (hPoleta) finger domain. Most substitutions for Tyr-52 caused reduction in bypass of UV-associated damage, measured by the ability to rescue the viability of UV-sensitive yeast cells at a high UV dose. For most mutants, the reduction in bypass ability paralleled the reduction in polymerization activity. Interestingly, the hPoleta Y52E mutant exhibited a greater reduction in bypass efficiency than polymerization activity. The reduction in bypass efficiency was accompanied by an up to 11-fold increase in the incorporation of complementary nucleotides relative to non-complementary nucleotides. The fidelity of DNA synthesis, measured by copying a gapped M13 DNA template in vitro, was also enhanced as much as 15-fold; the enhancement resulted from a decrease in transitions, which were relatively frequent, and a large decrease in transversions. Our demonstration that an amino acid substitution within the active site enhances the fidelity of DNA synthesis by hPoleta, one of the most inaccurate of DNA polymerases, supports the hypothesis that even error-prone DNA polymerases function in base selection.	Univ Washington, Dept Pathol, Joseph Gottstein Mem Canc Res Lab, Seattle, WA 98195 USA; Univ Washington, Dept Biol Struct, Seattle, WA 98195 USA; NIEHS, Mol Genet Lab, NIH, Res Triangle Pk, NC 27709 USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)	Loeb, LA (corresponding author), Univ Washington, Dept Pathol, Joseph Gottstein Mem Canc Res Lab, Seattle, WA 98195 USA.	laloeb@u.washington.edu	Kunkel, Thomas A./D-5088-2019	Kunkel, Thomas A./0000-0002-9900-1788	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [ZIAES065070, U01ES011045, P30ES007033, Z01ES065070] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P01AG001751] Funding Source: NIH RePORTER; NIA NIH HHS [AG01751] Funding Source: Medline; NIEHS NIH HHS [P30ES07033, ES11045] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		AMES BN, 1991, MUTAT RES, V250, P3, DOI 10.1016/0027-5107(91)90157-J; Arndt JW, 2001, BIOCHEMISTRY-US, V40, P5368, DOI 10.1021/bi002176j; Bebenek K, 1995, METHOD ENZYMOL, V262, P217; Berman HM, 2002, ACTA CRYSTALLOGR D, V58, P899, DOI 10.1107/S0907444902003451; Boudsocq F, 2002, DNA REPAIR, V1, P343, DOI 10.1016/S1568-7864(02)00019-8; Cleaver JC, 1999, SCIENCE, V285, P212, DOI 10.1126/science.285.5425.212; Cleaver JE, 1999, CANCER RES, V59, P1102; Doublie S, 1998, NATURE, V391, P251, DOI 10.1038/34593; FERSHT AR, 1974, PROC R SOC SER B-BIO, V187, P397, DOI 10.1098/rspb.1974.0084; Friedberg EC, 2002, SCIENCE, V296, P1627, DOI 10.1126/science.1070236; Friedberg EC, 2001, CELL, V107, P9, DOI 10.1016/S0092-8674(01)00509-8; Gerlach VL, 1999, P NATL ACAD SCI USA, V96, P11922, DOI 10.1073/pnas.96.21.11922; Glick E, 2001, EMBO J, V20, P7303, DOI 10.1093/emboj/20.24.7303; Haracska L, 2001, MOL CELL BIOL, V21, P7199, DOI 10.1128/MCB.21.21.7199-7206.2001; Holmquist GP, 2002, MUTAT RES-FUND MOL M, V510, P1, DOI 10.1016/S0027-5107(02)00247-6; Johnson RE, 1999, SCIENCE, V285, P263, DOI 10.1126/science.285.5425.263; Johnson RE, 2000, J BIOL CHEM, V275, P7447, DOI 10.1074/jbc.275.11.7447; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kannouche P, 2001, GENE DEV, V15, P158, DOI 10.1101/gad.187501; Kannouche P, 2002, EMBO J, V21, P6246, DOI 10.1093/emboj/cdf618; Kondratick CM, 2001, MOL CELL BIOL, V21, P2018, DOI 10.1128/MCB.21.6.2018-2025.2001; Kunkel TA, 2003, DNA REPAIR, V2, P135, DOI 10.1016/S1568-7864(02)00224-0; Lindahl T, 1999, SCIENCE, V286, P1897, DOI 10.1126/science.286.5446.1897; LINDAHL T, 1972, BIOCHEMISTRY-US, V11, P3610, DOI 10.1021/bi00769a018; Ling H, 2001, CELL, V107, P91, DOI 10.1016/S0092-8674(01)00515-3; LIVNEH Z, 2001, J BIOL CHEM, V22, P22; LOEB LA, 1991, CANCER RES, V51, P3075; Masutani C, 1999, NATURE, V399, P700, DOI 10.1038/21447; Masutani C, 1999, EMBO J, V18, P3491, DOI 10.1093/emboj/18.12.3491; Matsuda T, 2001, J MOL BIOL, V312, P335, DOI 10.1006/jmbi.2001.4937; Matsuda T, 2000, NATURE, V404, P1011, DOI 10.1038/35010014; McDonald JP, 1997, GENETICS, V147, P1557; McDonald JP, 2001, PHILOS T R SOC B, V356, P53, DOI 10.1098/rstb.2000.0748; Mildvan A S, 1974, Annu Rev Biochem, V43, P357, DOI 10.1146/annurev.bi.43.070174.002041; Nelson JR, 1996, NATURE, V382, P729, DOI 10.1038/382729a0; Osheroff WP, 1999, J BIOL CHEM, V274, P3642, DOI 10.1074/jbc.274.6.3642; Silvian LF, 2001, NAT STRUCT BIOL, V8, P984, DOI 10.1038/nsb1101-984; Sutton MD, 2001, P NATL ACAD SCI USA, V98, P8342, DOI 10.1073/pnas.111036998; Suzuki M, 1997, J BIOL CHEM, V272, P11228; Trincao J, 2001, MOL CELL, V8, P417, DOI 10.1016/S1097-2765(01)00306-9; Washington MT, 2000, P NATL ACAD SCI USA, V97, P3094, DOI 10.1073/pnas.050491997; WEINER SJ, 1986, J COMPUT CHEM, V7, P230, DOI 10.1002/jcc.540070216; Zhou BL, 2001, MOL CELL, V8, P427, DOI 10.1016/S1097-2765(01)00310-0	43	14	15	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 23	2003	278	21					19341	19346		10.1074/jbc.M300686200	http://dx.doi.org/10.1074/jbc.M300686200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	679PY	12644469	hybrid			2022-12-25	WOS:000182932200081
J	Weng, L; Van Bockstaele, DR; Wauters, J; Van Marck, E; Plum, J; Berneman, ZN; Merregaert, J				Weng, L; Van Bockstaele, DR; Wauters, J; Van Marck, E; Plum, J; Berneman, ZN; Merregaert, J			A novel alternative spliced chondrolectin isoform lacking the transmembrane domain is expressed during T cell maturation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-TYPE LECTINS; ANIMAL LECTINS; PROTEIN; RECEPTOR; PHENOTYPE; BINDING; SEQUENCES; HOMOLOGY; ANTIGEN; LAYILIN	Chondrolectin (CHODL) is a novel type I transmembrane protein containing one carbohydrate recognition domain (CRD) of C-type lectins. Recently, data base searching revealed a variant of CHODL (AK022689) with a different 5' leader sequence derived from a new putative upstream alternative promoter (P-2). The P-2 promoter gives rise to at least three additional alternatively spliced isoforms, designated as CHODLf, CHODLfDeltaE, and CHODLDeltaE. Of all variants, the alternative exon E-splicing isoforms (CHODLfDeltaE/CHODLDeltaE) are expressed exclusively in the T lymphocyte lineage and are regulated during T lymphopoiesis. Peripheral T lymphocytes demonstrated a unique exon E-splicing pattern in comparison with end maturation stage thymocytes, suggesting its association with the post-thymic maturation of T cells. Since exon E encodes the transmembrane domain of CHODL, the exon E-skipping variant results in a non-transmembrane domain-containing isoform (CHODLfDeltaE/CHODLDeltaE) terminating in the QDEL sequence, thus suggesting different functional attributes of CHODL isoforms during the development of T cells. Double label immunofluoresence experiments demonstrated that the transmembrane-containing isoform (CHODLf) colocalizes with rBet1 to the endoplasmic reticulum-Golgi apparatus. In summary, this study describes the molecular characterization of novel members of the chondrolectin family associated with T cell maturation and a subcellular localization of CHODLf in the endoplasmic reticulum-Golgi apparatus.	Univ Antwerp, Univ Antwerp Hosp, Fac Med, Lab Expt Hematol, B-2650 Edegem, Belgium; Univ Antwerp, Univ Antwerp Hosp, Dept Biomed Sci, Lab Mol Biotechnol, B-2650 Edegem, Belgium; Univ Antwerp, Fac Med, Pathol Lab, B-2610 Wilrijk, Belgium; Univ Antwerp, Fac Med, Med Genet Lab, B-2610 Wilrijk, Belgium; State Univ Ghent, Dept Clin Chem Microbiol & Immunol, B-9000 Ghent, Belgium	University of Antwerp; University of Antwerp; University of Antwerp; University of Antwerp; Ghent University	Merregaert, J (corresponding author), Univ Antwerp, Dept Biomed Sci, Lab Mol Biotechnol, Univ Pl 1, B-2610 Wilrijk, Belgium.		Plum, Jean/A-4357-2008					ANDRES DA, 1991, J BIOL CHEM, V266, P14277; ARTHUR RP, 1986, J EXP MED, V163, P774, DOI 10.1084/jem.163.4.774; Bono P, 2001, MOL BIOL CELL, V12, P891, DOI 10.1091/mbc.12.4.891; Borowsky ML, 1998, J CELL BIOL, V143, P429, DOI 10.1083/jcb.143.2.429; BUHRING HJ, 1991, LEUKEMIA, V5, P854; DRICKAMER K, 1986, J BIOL CHEM, V261, P6878; DRICKAMER K, 1984, J BIOL CHEM, V259, P770; Hattori M, 2000, NATURE, V405, P311, DOI 10.1038/35012518; Helenius A, 1997, TRENDS CELL BIOL, V7, P193; HOSSEINZADEH H, 1993, J IMMUNOL, V150, P1670; IKUTA K, 1987, P NATL ACAD SCI USA, V84, P819, DOI 10.1073/pnas.84.3.819; Kilpatrick DC, 2002, BBA-GEN SUBJECTS, V1572, P187, DOI 10.1016/S0304-4165(02)00308-2; KRUSIUS T, 1987, J BIOL CHEM, V262, P13120; LASKY LA, 1989, CELL, V56, P1045, DOI 10.1016/0092-8674(89)90637-5; LUDWIG T, 1995, TRENDS CELL BIOL, V5, P202, DOI 10.1016/S0962-8924(00)89000-5; McFarland RD, 2000, P NATL ACAD SCI USA, V97, P4215, DOI 10.1073/pnas.070061597; Protin U, 1999, J IMMUNOL, V163, P4917; SAMBROOK J, 1989, MOL CLONING, V2, P9; SPARSHOTT SM, 1991, EUR J IMMUNOL, V21, P993, DOI 10.1002/eji.1830210420; TOUGH DF, 1994, J EXP MED, V179, P1127, DOI 10.1084/jem.179.4.1127; Weng L, 2002, GENOMICS, V80, P62, DOI 10.1006/geno.2002.6806; WENG L, 2003, IN PRESS GENE AMST	22	10	12	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 23	2003	278	21					19164	19170		10.1074/jbc.M300653200	http://dx.doi.org/10.1074/jbc.M300653200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	679PY	12621022	hybrid			2022-12-25	WOS:000182932200059
J	Bjornson, KP; Modrich, P				Bjornson, KP; Modrich, P			Differential and simultaneous adenosine di- and triphosphate binding by MutS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA MISMATCH REPAIR; RESISTANCE PROTEIN MRP1; ESCHERICHIA-COLI; HMUTS-ALPHA; TRANSLOCATION MECHANISM; MOLECULAR SWITCH; ATP HYDROLYSIS; SLIDING CLAMP; STRAND BREAK; ABC-ATPASE	The roles of ATP binding and hydrolysis in the function of MutS in mismatch repair are poorly understood. As one means of addressing this question, we have determined the affinities and number of adenosine di- and triphosphate binding sites within MutS. Nitrocellulose filter binding assay and equilibrium fluorescence anisotropy measurements have demonstrated that MutS has one high affinity binding site for ADP and one high affinity site for nonhydrolyzable ATP analogues per dimer equivalent. Low concentrations of 5'-adenylylimidodiphosphate (AMPPNP) promote ADP binding and a large excess of AMPPNP is required to displace ADP from the protein. Fluorescence energy transfer and filter binding assays indicate that ADP and nonhydrolyzable ATP analogues can bind simultaneously to adjacent subunits within the MutS oligomer with affinities in the low micromolar range. These findings suggest that the protein exists primarily as the ATP.MutS.ADP ternary complex in solution and that this may be the form of the protein that is involved in DNA encounters in vivo.	Duke Univ, Med Ctr, Howard Hughes Med Inst, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Biochem, Durham, NC 27710 USA	Duke University; Howard Hughes Medical Institute; Duke University	Modrich, P (corresponding author), Duke Univ, Med Ctr, Howard Hughes Med Inst, Box 3711, Durham, NC 27710 USA.	modrich@biochem.duke.edu		Modrich, Paul/0000-0001-8708-9885	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM023719, R01GM023719] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM23719] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aleksandrov L, 2002, J BIOL CHEM, V277, P15419, DOI 10.1074/jbc.M111713200; Allen DJ, 1997, EMBO J, V16, P4467, DOI 10.1093/emboj/16.14.4467; Bjornson KP, 2000, BIOCHEMISTRY-US, V39, P3176, DOI 10.1021/bi992286u; Blackwell LJ, 1998, J BIOL CHEM, V273, P32049, DOI 10.1074/jbc.273.48.32049; Blackwell LJ, 2001, J BIOL CHEM, V276, P34339, DOI 10.1074/jbc.M104256200; Blackwell LJ, 1998, J BIOL CHEM, V273, P32055, DOI 10.1074/jbc.273.48.32055; BRUNI R, 1988, NUCLEIC ACIDS RES, V16, P4875, DOI 10.1093/nar/16.11.4875; Buermeyer AB, 1999, ANNU REV GENET, V33, P533, DOI 10.1146/annurev.genet.33.1.533; CHI NW, 1994, J BIOL CHEM, V269, P29984; CLEGG RM, 1992, METHOD ENZYMOL, V211, P353; COOPER DL, 1993, J BIOL CHEM, V268, P11823; Dao V, 1998, J BIOL CHEM, V273, P9202, DOI 10.1074/jbc.273.15.9202; DRUMMOND JT, 1995, SCIENCE, V268, P1909, DOI 10.1126/science.7604264; Galio L, 1999, NUCLEIC ACIDS RES, V27, P2325, DOI 10.1093/nar/27.11.2325; Gradia S, 2000, J BIOL CHEM, V275, P3922, DOI 10.1074/jbc.275.6.3922; Gradia S, 1997, CELL, V91, P995, DOI 10.1016/S0092-8674(00)80490-0; Gradia S, 1999, MOL CELL, V3, P255, DOI 10.1016/S1097-2765(00)80316-0; GRILLEY M, 1989, J BIOL CHEM, V264, P1000; HABER LT, 1991, EMBO J, V10, P2707, DOI 10.1002/j.1460-2075.1991.tb07815.x; Harfe BD, 2000, ANNU REV GENET, V34, P359, DOI 10.1146/annurev.genet.34.1.359; Hess MT, 2002, J BIOL CHEM, V277, P25545, DOI 10.1074/jbc.M202282200; Holland IB, 1999, J MOL BIOL, V293, P381, DOI 10.1006/jmbi.1999.2993; Hopfner KP, 2000, CELL, V101, P789, DOI 10.1016/S0092-8674(00)80890-9; Hou YX, 2000, J BIOL CHEM, V275, P20280, DOI 10.1074/jbc.M001109200; Hou YX, 2002, J BIOL CHEM, V277, P5110, DOI 10.1074/jbc.M107133200; Iaccarino I, 2000, J BIOL CHEM, V275, P2080, DOI 10.1074/jbc.275.3.2080; Jiricny J, 1998, EMBO J, V17, P6427, DOI 10.1093/emboj/17.22.6427; Jones PM, 1999, FEMS MICROBIOL LETT, V179, P187, DOI 10.1111/j.1574-6968.1999.tb08727.x; Junop MS, 2001, MOL CELL, V7, P1, DOI 10.1016/S1097-2765(01)00149-6; Kolodner RD, 1999, CURR OPIN GENET DEV, V9, P89, DOI 10.1016/S0959-437X(99)80013-6; LAHUE RS, 1989, SCIENCE, V245, P160, DOI 10.1126/science.2665076; Lakowicz JR, 1999, PRINCIPLES FLUORESCE, P291, DOI 10.1007/978-1-4757-3061-6; Lamers MH, 2000, NATURE, V407, P711, DOI 10.1038/35037523; MARQUARDT DW, 1963, J SOC IND APPL MATH, V11, P431, DOI 10.1137/0111030; Modrich P, 1996, ANNU REV BIOCHEM, V65, P101, DOI 10.1146/annurev.bi.65.070196.000533; Obmolova G, 2000, NATURE, V407, P703, DOI 10.1038/35037509; PARKER BO, 1992, P NATL ACAD SCI USA, V89, P1730, DOI 10.1073/pnas.89.5.1730; Schofield MJ, 2001, J BIOL CHEM, V276, P28291, DOI 10.1074/jbc.M103148200; Senior AE, 1998, ACTA PHYSIOL SCAND, V163, P213; Sixma TK, 2001, CURR OPIN STRUC BIOL, V11, P47, DOI 10.1016/S0959-440X(00)00169-X; SU SS, 1988, J BIOL CHEM, V263, P6829; Viswanathan M, 2001, J BIOL CHEM, V276, P31053, DOI 10.1074/jbc.M105481200; WONG I, 1993, P NATL ACAD SCI USA, V90, P5428, DOI 10.1073/pnas.90.12.5428; Worth L, 1998, J BIOL CHEM, V273, P23176, DOI 10.1074/jbc.273.36.23176; WU TH, 1994, J BACTERIOL, V176, P5393, DOI 10.1128/JB.176.17.5393-5400.1994	45	52	79	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 16	2003	278	20					18557	18562		10.1074/jbc.M301101200	http://dx.doi.org/10.1074/jbc.M301101200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677YX	12624105	hybrid			2022-12-25	WOS:000182838300127
J	Maki, N; Hafkemeyer, P; Dey, S				Maki, N; Hafkemeyer, P; Dey, S			Allosteric modulation of human P-glycoprotein - Inhibition of transport by preventing substrate translocation and dissociation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MULTIDRUG-RESISTANCE; CYCLOSPORINE-A; BINDING-SITES; TUMOR-CELLS; VERAPAMIL; REVERSAL; RESIDUES; DOMAIN; MDR1; GENE	The human multidrug transporter P-glycoprotein (Pgp, ABCB1) contributes to the poor bioavailability of many anticancer and antimicrobial agents as well as to drug resistance at the cellular level. For rational design of effective Pgp inhibitors, a clear understanding of its mechanism of action and functional regulation is essential. In this study, we demonstrate that inhibition of Pgp-mediated drug transport by cis-(Z)-flupentixol, a thioxanthene derivative, occurs through an allosteric mechanism. Unlike competitive inhibitors, such as cyclosporin A and verapamil, cis-(Z)-flupentixol does not interfere with substrate ([I-125]iodoarylazidoprazosin) recognition by Pgp, instead it prevents substrate translocation and dissociation, resulting in a stable but reversible Pgp-substrate complex. cis-(Z)-Flupentixol-induced complex formation requires involvement of the Pgp substrate site, because agents that either physically compete (cyclosporin A) for or indirectly occlude (vanadate) the substrate-binding site prevent formation of the complex. Allosteric modulation by cis-(Z)-flupentixol involves a conformational change in Pgp detectable by monoclonal antibody UIC2 binding to a conformation-sensitive external epitope of Pgp. The conformational change observed is distinct from that induced by Pgp substrates or competitive inhibitors. A single amino acid substitution (F983A) in TM12 of Pgp that impairs inhibition by cis-(Z)-flupentixol of Pgp-mediated drug transport also affects stabilization of the Pgp-substrate complex as well as the characteristic conformational change. Taken together, our results describe the molecular mechanism by which the Pgp modulator cis-(Z)flupentixol allosterically inhibits drug transport.	Uniformed Serv Univ Hlth Sci, Dept Biochem & Mol Biol, F Edward Hebert Sch Med, Bethesda, MD 20814 USA; Univ Freiburg, Dept Med 2, D-79106 Freiburg, Germany	Uniformed Services University of the Health Sciences - USA; University of Freiburg	Dey, S (corresponding author), Uniformed Serv Univ Hlth Sci, Dept Biochem & Mol Biol, F Edward Hebert Sch Med, 4301 Jones Bridge Rd, Bethesda, MD 20814 USA.							Ambudkar SV, 1999, ANNU REV PHARMACOL, V39, P361, DOI 10.1146/annurev.pharmtox.39.1.361; AMBUDKAR SV, 1992, P NATL ACAD SCI USA, V89, P8472, DOI 10.1073/pnas.89.18.8472; AMBUDKAR SV, 1997, J BIOL CHEM, V272, P21260; Ayesh S, 1996, BBA-MOL BASIS DIS, V1316, P8, DOI 10.1016/0925-4439(96)00008-7; AZZARIA M, 1989, MOL CELL BIOL, V9, P5289, DOI 10.1128/MCB.9.12.5289; Boer R, 1996, BIOCHEMISTRY-US, V35, P1387, DOI 10.1021/bi951912u; CHEN CJ, 1986, CELL, V47, P381, DOI 10.1016/0092-8674(86)90595-7; Christopoulos A, 2002, NAT REV DRUG DISCOV, V1, P198, DOI 10.1038/nrd746; Dey S, 1999, BIOCHEMISTRY-US, V38, P6630, DOI 10.1021/bi983038l; Dey S, 1997, P NATL ACAD SCI USA, V94, P10594, DOI 10.1073/pnas.94.20.10594; DIDIER A, 1995, ANTI-CANCER DRUG, V6, P669, DOI 10.1097/00001813-199510000-00006; FERRY DR, 1995, BIOCHEM PHARMACOL, V49, P1851, DOI 10.1016/0006-2952(94)00517-P; FORD JM, 1993, CYTOTECHNOLOGY, V12, P171, DOI 10.1007/BF00744664; FORD JM, 1990, CANCER RES, V50, P1748; FORD JM, 1989, MOL PHARMACOL, V35, P105; GOTTESMAN MM, 1993, ANNU REV BIOCHEM, V62, P385, DOI 10.1146/annurev.bi.62.070193.002125; GREENBERGER LM, 1990, J BIOL CHEM, V265, P4394; GREENBERGER LM, 1993, J BIOL CHEM, V268, P11417; Hafkemeyer P, 1998, BIOCHEMISTRY-US, V37, P16400, DOI 10.1021/bi980871+; HIGGINS CF, 1992, ANNU REV CELL BIOL, V8, P67, DOI 10.1146/annurev.cb.08.110192.000435; Liu RH, 1996, BIOCHEMISTRY-US, V35, P11865, DOI 10.1021/bi960823u; Loo TW, 1997, J BIOL CHEM, V272, P20986, DOI 10.1074/jbc.272.34.20986; Loo TW, 2001, J BIOL CHEM, V276, P14972, DOI 10.1074/jbc.M100407200; Loo TW, 2000, J BIOL CHEM, V275, P39272, DOI 10.1074/jbc.M007741200; Martin C, 2000, MOL PHARMACOL, V58, P624, DOI 10.1124/mol.58.3.624; Martin C, 1997, BRIT J PHARMACOL, V122, P765, DOI 10.1038/sj.bjp.0701429; Martin C, 1999, BRIT J PHARMACOL, V128, P403, DOI 10.1038/sj.bjp.0702807; Mechetner EB, 1997, P NATL ACAD SCI USA, V94, P12908, DOI 10.1073/pnas.94.24.12908; METZ MZ, 1995, VIROLOGY, V208, P634, DOI 10.1006/viro.1995.1194; Murren JR, 2002, CLIN CANCER RES, V8, P633; Ramachandra M, 1998, BIOCHEMISTRY-US, V37, P5010, DOI 10.1021/bi973045u; RAVIV Y, 1990, J BIOL CHEM, V265, P3975; SAEKI T, 1993, J BIOL CHEM, V268, P6077; SAFA AR, 1994, BIOCHEMISTRY-US, V33, P256, DOI 10.1021/bi00167a034; Sikic BI, 1999, ONCOLOGY-NY, V13, P183; Sonveaux N, 1996, J BIOL CHEM, V271, P24617, DOI 10.1074/jbc.271.40.24617; SPOELSTRA EC, 1994, EUR J BIOCHEM, V221, P363, DOI 10.1111/j.1432-1033.1994.tb18748.x; STEIN WD, 1994, MOL PHARMACOL, V45, P763; Tan B, 2000, CURR OPIN ONCOL, V12, P450, DOI 10.1097/00001622-200009000-00011; TSUJI A, 1993, BIOCHEM PHARMACOL, V46, P1096, DOI 10.1016/0006-2952(93)90677-O; TSURUO T, 1981, CANCER RES, V41, P1967; TWENTYMAN PR, 1990, BRIT J CANCER, V62, P89, DOI 10.1038/bjc.1990.235	42	85	88	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 16	2003	278	20					18132	18139		10.1074/jbc.M210413200	http://dx.doi.org/10.1074/jbc.M210413200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677YX	12642584	hybrid			2022-12-25	WOS:000182838300071
J	Niu, WY; Huang, C; Nawaz, Z; Levy, M; Somwar, R; Li, DL; Bilan, PJ; Klip, A				Niu, WY; Huang, C; Nawaz, Z; Levy, M; Somwar, R; Li, DL; Bilan, PJ; Klip, A			Maturation of the regulation of GLUT4 activity by p38 MAPK during l6 cell myogenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT ADIPOSE-CELLS; ACTIVATED PROTEIN-KINASE; GLUCOSE-TRANSPORT ACTIVITY; INSULIN-INDUCED TRANSLOCATION; SKELETAL-MUSCLE; 3T3-L1 ADIPOCYTES; POTENTIAL ROLE; GLUCOSE-TRANSPORTER-4 TRANSLOCATION; PHOSPHATIDYLINOSITOL 3-KINASE; SUBCELLULAR TRAFFICKING	Insulin stimulates glucose uptake in skeletal muscle cells and fat cells by promoting the rapid translocation of GLUT4 glucose transporters to the plasma membrane. Recent work from our laboratory supports the concept that insulin also stimulates the intrinsic activity of GLUT4 through a signaling pathway that includes p38 MAPK. Here we show that regulation of GLUT4 activity by insulin develops during maturation of skeletal muscle cells into myotubes in concert with the ability of insulin to stimulate p38 MAPK. In L6 myotubes expressing GLUT4 that carries an exofacial myc-epitope (L6-GLUT4myc), insulin-stimulated GLUT4myc translocation equals in magnitude the glucose uptake response. Inhibition of p38 MAPK with SB203580 reduces insulin-stimulated glucose uptake without affecting GLUT4myc translocation. In contrast, in myoblasts, the magnitude of insulin-stimulated glucose uptake is significantly lower than that of GLUT4myc translocation and is insensitive to SB203580. Activation of p38 MAPK by insulin is considerably higher in myotubes than in myoblasts, as is the activation of upstream kinases MKK3/MKK6. In contrast, the activation of all three Akt isoforms and GLUT4 translocation are similar in myoblasts and myotubes. Furthermore, GLUT4myc translocation and phosphorylation of regulatory sites on Akt in L6-GLUT4myc myotubes are equally sensitive to insulin, whereas glucose uptake and phosphorylation of regulatory sites on p38 MAPK show lower sensitivity to the hormone. These observations draw additional parallels between Akt and GLUT4 translocation and between p38 MAPK and GLUT4 activation. Regulation of GLUT4 activity by insulin develops upon muscle cell differentiation and correlates with p38 MAPK activation by insulin.	Hosp Sick Children, Cell Biol Programme, Toronto, ON M5G 1X8, Canada	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids)	Klip, A (corresponding author), Hosp Sick Children, Cell Biol Programme, 555 Univ Ave, Toronto, ON M5G 1X8, Canada.		Huang, Carol/H-2248-2014					Abel ED, 2001, NATURE, V409, P729, DOI 10.1038/35055575; Barnes K, 2002, J CELL SCI, V115, P2433; BARON AD, 1988, AM J PHYSIOL, V255, pE769, DOI 10.1152/ajpendo.1988.255.6.E769; BEGUINOT F, 1986, ENDOCRINOLOGY, V118, P446, DOI 10.1210/endo-118-1-446; Cho H, 2001, SCIENCE, V292, P1728, DOI 10.1126/science.292.5522.1728; Ciaraldi TP, 2001, J CLIN ENDOCR METAB, V86, P5838, DOI 10.1210/jc.86.12.5838; CLARK AE, 1991, BIOCHEM J, V278, P235, DOI 10.1042/bj2780235; CLARK AE, 1990, BIOCHEM J, V269, P615, DOI 10.1042/bj2690615; Ferrara CM, 1999, BIOCHEM J, V343, P571, DOI 10.1042/0264-6021:3430571; Foster LJ, 2001, J BIOL CHEM, V276, P44212, DOI 10.1074/jbc.M102964200; GOODYEAR LJ, 1991, AM J PHYSIOL, V261, pE556, DOI 10.1152/ajpendo.1991.261.5.E556; GUMA A, 1995, AM J PHYSIOL-ENDOC M, V268, pE613, DOI 10.1152/ajpendo.1995.268.4.E613; HANSEN P, 1995, AM J PHYSIOL-CELL PH, V268, pC30, DOI 10.1152/ajpcell.1995.268.1.C30; Hansen PA, 1998, J BIOL CHEM, V273, P26157, DOI 10.1074/jbc.273.40.26157; HARRISON SA, 1992, J BIOL CHEM, V267, P3783; HIRSHMAN MF, 1990, J BIOL CHEM, V265, P987; Hruz PW, 2002, DIABETES, V51, P937, DOI 10.2337/diabetes.51.4.937; Huang C, 2002, DIABETES, V51, P2090, DOI 10.2337/diabetes.51.7.2090; JOOST HG, 1988, BIOCHEM J, V249, P155, DOI 10.1042/bj2490155; KAHN BB, 1988, J CLIN INVEST, V82, P691, DOI 10.1172/JCI113649; KING PA, 1992, J CLIN INVEST, V90, P1568, DOI 10.1172/JCI116025; Kishi K, 1998, DIABETES, V47, P550, DOI 10.2337/diabetes.47.4.550; KLIP A, 1982, BIOCHIM BIOPHYS ACTA, V687, P265, DOI 10.1016/0005-2736(82)90555-7; KLIP A, 1983, CAN J BIOCHEM CELL B, V61, P644, DOI 10.1139/o83-081; KLIP A, 1987, FEBS LETT, V224, P224, DOI 10.1016/0014-5793(87)80452-0; KLIP A, 1984, AM J PHYSIOL, V247, pE494; Kohn AD, 1996, J BIOL CHEM, V271, P31372, DOI 10.1074/jbc.271.49.31372; KONO T, 1982, J BIOL CHEM, V257, P942; Konrad D, 2002, DIABETES, V51, P2719, DOI 10.2337/diabetes.51.9.2719; Kyriakis JM, 1996, J BIOL CHEM, V271, P24313, DOI 10.1074/jbc.271.40.24313; Li DL, 2001, J BIOL CHEM, V276, P22883, DOI 10.1074/jbc.M010143200; MARETTE A, 1992, AM J PHYSIOL, V263, pC443, DOI 10.1152/ajpcell.1992.263.2.C443; Murata H, 2002, AIDS, V16, P859, DOI 10.1097/00002030-200204120-00005; OmatsuKanbe M, 1996, BIOCHEM J, V315, P25, DOI 10.1042/bj3150025; Ono K, 2000, CELL SIGNAL, V12, P1, DOI 10.1016/S0898-6568(99)00071-6; Ploug T, 1998, J CELL BIOL, V142, P1429, DOI 10.1083/jcb.142.6.1429; RODNICK KJ, 1992, J BIOL CHEM, V267, P6278; ROSHOLT MN, 1994, AM J PHYSIOL, V266, pR95, DOI 10.1152/ajpregu.1994.266.1.R95; RUDICH A, 2003, IN PRESS DIABETOLOGI; Ryder JW, 1999, BIOCHEM J, V342, P321, DOI 10.1042/0264-6021:3420321; SATOH S, 1993, J BIOL CHEM, V268, P17820; SATOH S, 1991, DIABETES S1, V40, pA85; SHETTY M, 1993, J BIOL CHEM, V268, P17225; Shimizu Y, 1998, BIOCHEM J, V330, P397, DOI 10.1042/bj3300397; Shulman GI, 2000, J CLIN INVEST, V106, P171, DOI 10.1172/JCI10583; SIMPSON IA, 1983, BIOCHIM BIOPHYS ACTA, V763, P393, DOI 10.1016/0167-4889(83)90101-5; Somwar R, 2000, DIABETES, V49, P1794, DOI 10.2337/diabetes.49.11.1794; Somwar R, 2002, J BIOL CHEM, V277, P50386, DOI 10.1074/jbc.M205277200; Somwar R, 2001, BIOCHEM J, V359, P639, DOI 10.1042/0264-6021:3590639; Somwar R, 2001, J BIOL CHEM, V276, P46079, DOI 10.1074/jbc.M109093200; Sweeney G, 1999, J BIOL CHEM, V274, P10071, DOI 10.1074/jbc.274.15.10071; Tanti JF, 1997, ENDOCRINOLOGY, V138, P2005, DOI 10.1210/en.138.5.2005; TSAKIRIDIS T, 1994, J BIOL CHEM, V269, P29934; Ueki K, 1998, J BIOL CHEM, V273, P5315, DOI 10.1074/jbc.273.9.5315; Ueyama A, 1999, AM J PHYSIOL-ENDOC M, V277, pE572, DOI 10.1152/ajpendo.1999.277.3.E572; Wang QH, 1998, FEBS LETT, V427, P193, DOI 10.1016/S0014-5793(98)00423-2; Wang QH, 1999, MOL CELL BIOL, V19, P4008; WILSON CM, 1994, BIOCHEM J, V299, P755, DOI 10.1042/bj2990755; YAFFE D, 1968, P NATL ACAD SCI USA, V61, P477, DOI 10.1073/pnas.61.2.477; YANG J, 1993, J BIOL CHEM, V268, P4600; Zierath JB, 1997, DIABETES, V46, P215, DOI 10.2337/diabetes.46.2.215; Zisman A, 2000, NAT MED, V6, P924, DOI 10.1038/78693	62	76	78	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 16	2003	278	20					17953	17962		10.1074/jbc.M211136200	http://dx.doi.org/10.1074/jbc.M211136200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677YX	12637564	hybrid			2022-12-25	WOS:000182838300046
J	Vu-Dac, N; Gervois, P; Jakel, H; Nowak, M; Bauge, E; Dehondt, N; Staels, B; Pennacchio, LA; Rubin, EM; Fruchart-Najib, J; Fruchart, JC				Vu-Dac, N; Gervois, P; Jakel, H; Nowak, M; Bauge, E; Dehondt, N; Staels, B; Pennacchio, LA; Rubin, EM; Fruchart-Najib, J; Fruchart, JC			Apolipoprotein A5, a crucial determinant of plasma triglyceride levels, is highly responsive to peroxisome proliferator-activated receptor alpha activators	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FAMILIAL COMBINED HYPERLIPIDEMIA; CORONARY HEART-DISEASE; C-III EXPRESSION; GENE-CLUSTER; PPAR-ALPHA; HYPERTRIGLYCERIDEMIA; MICE; OVEREXPRESSION; POLYMORPHISMS; SUPERFAMILY	The recently discovered APOA5 gene has been shown in humans and mice to be important in determining plasma triglyceride levels, a major cardiovascular disease risk factor. apoAV represents the first described apolipoprotein where overexpression lowers triglyceride levels. Since fibrates represent a commonly used therapy for lowering plasma triglycerides in humans, we investigated their ability to modulate APOA5 gene expression and consequently influence plasma triglyceride levels. Human primary hepatocytes treated with Wy 14,643 or fenofibrate displayed a strong induction of APOA5 mRNA. Deletion and mutagenesis analyses of the proximal APOA5 promoter firmly demonstrate the presence of a functional peroxisome proliferator-activated receptor response element. These findings demonstrate that APOA5 is a highly responsive peroxisome proliferator-activated receptor alpha target gene and support its role as a major mediator for how fibrates reduce plasma triglycerides in humans.	Inst Pasteur, INSERM, U545, Dept Atherosclerose, F-59019 Lille, France; Fac Pharm Lille 1, F-59019 Lille, France; Univ Calif Berkeley, Lawrence Berkeley Lab, Genome Sci Dept, Berkeley, CA 94720 USA; Univ Calif Berkeley, Lawrence Berkeley Lab, Joint Genome Inst, Berkeley, CA 94720 USA	Institut National de la Sante et de la Recherche Medicale (Inserm); Le Reseau International des Instituts Pasteur (RIIP); Universite de Lille - ISITE; Institut Pasteur Lille; Universite de Lille; Universite de Lille - ISITE; Universite de Lille; United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley; United States Department of Energy (DOE); Joint Genome Institute - JGI; Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley	Vu-Dac, N (corresponding author), Inst Pasteur, INSERM, U545, Dept Atherosclerose, BP 245, F-59019 Lille, France.		Staels, Bart/N-9497-2016; Bauge, Eric/R-6522-2018	Staels, Bart/0000-0002-3784-1503; Pennacchio, Len/0000-0002-8748-3732; Dehondt, Helene/0000-0003-2900-4673; Bauge, Eric/0000-0001-9994-8667				Allayee H, 1998, AM J HUM GENET, V63, P577, DOI 10.1086/301983; Boisfer E, 1999, J BIOL CHEM, V274, P11564, DOI 10.1074/jbc.274.17.11564; Coste H, 2002, J BIOL CHEM, V277, P27120, DOI 10.1074/jbc.M203421200; Cullen P, 2000, AM J CARDIOL, V86, P943, DOI 10.1016/S0002-9149(00)01127-9; DAMMERMAN M, 1993, P NATL ACAD SCI USA, V90, P4562, DOI 10.1073/pnas.90.10.4562; DREYER C, 1992, CELL, V68, P879, DOI 10.1016/0092-8674(92)90031-7; Fraser JD, 1997, J BIOL CHEM, V272, P13892, DOI 10.1074/jbc.272.21.13892; Grundy SM, 1998, AM J CARDIOL, V81, p18B, DOI 10.1016/S0002-9149(98)00033-2; Haim M, 1999, CIRCULATION, V100, P475, DOI 10.1161/01.CIR.100.5.475; HAYDEN MR, 1987, AM J HUM GENET, V40, P421; HERTZ R, 1995, J BIOL CHEM, V270, P13470, DOI 10.1074/jbc.270.22.13470; Huang YD, 1998, J BIOL CHEM, V273, P26388, DOI 10.1074/jbc.273.41.26388; ISSEMANN I, 1990, NATURE, V347, P645, DOI 10.1038/347645a0; JugeAubry C, 1997, J BIOL CHEM, V272, P25252, DOI 10.1074/jbc.272.40.25252; LADIAS JAA, 1992, J BIOL CHEM, V267, P15849; Lawrence JW, 2001, J BIOL CHEM, V276, P31521, DOI 10.1074/jbc.M103306200; Lemieux I, 2002, CAN J CARDIOL, V18, P725; MAEDA N, 1994, J BIOL CHEM, V269, P23610; Pennacchio LA, 2002, HUM MOL GENET, V11, P3031, DOI 10.1093/hmg/11.24.3031; Pennacchio LA, 2001, SCIENCE, V294, P169, DOI 10.1126/science.1064852; Ribalta J, 2002, CLIN CHEM, V48, P1597; Schoonjans K, 1996, EMBO J, V15, P5336, DOI 10.1002/j.1460-2075.1996.tb00918.x; SHACHTER NS, 1994, J CLIN INVEST, V93, P1683, DOI 10.1172/JCI117151; STAELS B, 1995, J CLIN INVEST, V95, P705, DOI 10.1172/JCI117717; Talmud PJ, 2002, HUM MOL GENET, V11, P3039, DOI 10.1093/hmg/11.24.3039; van der Vliet HN, 2002, BIOCHEM BIOPH RES CO, V295, P1156, DOI 10.1016/S0006-291X(02)00808-2; van der Vliet HN, 2001, J BIOL CHEM, V276, P44512, DOI 10.1074/jbc.M106888200; Vu-Dac N, 1998, J CLIN INVEST, V102, P625, DOI 10.1172/JCI1581; Vu-Dac N, 1998, J BIOL CHEM, V273, P25713, DOI 10.1074/jbc.273.40.25713; VUDAC N, 1995, J CLIN INVEST, V96, P741, DOI 10.1172/JCI118118; WOJCIECHOWSKI AP, 1991, NATURE, V349, P161, DOI 10.1038/349161a0	31	177	193	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 16	2003	278	20					17982	17985		10.1074/jbc.M212191200	http://dx.doi.org/10.1074/jbc.M212191200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677YX	12637506	hybrid			2022-12-25	WOS:000182838300050
J	Lotz, GP; Lin, HY; Harst, A; Obermann, WMJ				Lotz, GP; Lin, HY; Harst, A; Obermann, WMJ			Aha1 binds to the middle domain of Hsp90, contributes to client protein activation, and stimulates the ATPase activity of the molecular chaperone	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK-PROTEIN; NITRIC-OXIDE SYNTHASE; STEROID-RECEPTOR; TYROSINE KINASE; IN-VIVO; CYCLE; HEAT-SHOCK-PROTEIN-90; IDENTIFICATION; DIMERIZATION; HYDROLYSIS	The ATP-dependent molecular chaperone Hsp90 is an essential and abundant stress protein in the eukaryotic cytosol that cooperates with a cohort of cofactors/cochaperones to fulfill its cellular tasks. We have identified Aha1 (activator of Hsp90 ATPase) and its relative Hch1 (high copy Hsp90 suppressor) as binding partners of Hsp90 in Saccharomyces cerevisiae. By using genetic and biochemical approaches, the middle domain of Hsp90 (amino acids 272-617) was found to mediate the interaction with Aha1 and Hch1. Data base searches revealed that homologues of Aha1 are conserved from yeast to man, whereas Hch1 was found to be restricted to lower eukaryotes like S. cerevisiae and Candida albicans. In experiments with purified proteins, Aha1 but not Hch1 stimulated the intrinsic ATPase activity of Hsp90 5-fold. To establish their cellular role further, we deleted the genes encoding Aha1 and Hch1 in S. cerevisiae. In vivo experiments demonstrated that Aha1 and Hch1 contributed to efficient activation of the heterologous Hsp90 client protein v-Src. Moreover, Aha1 and Hch1 became crucial for cell viability under non-optimal growth conditions when Hsp90 levels are limiting. Thus, our results identify a novel type of cofactor involved in the regulation of the molecular chaperone Hsp90.	Univ Bonn, Inst Genet, Prot Folding Grp, D-53117 Bonn, Germany	University of Bonn	Obermann, WMJ (corresponding author), Univ Bonn, Inst Genet, Prot Folding Grp, Romerstr 164, D-53117 Bonn, Germany.		Obermann, Wolfgang/AAN-3896-2020	Lotz, Gregor/0000-0002-0231-5503				ALIGUE R, 1994, EMBO J, V13, P6099, DOI 10.1002/j.1460-2075.1994.tb06956.x; Bohen SP, 1998, MOL CELL BIOL, V18, P3330, DOI 10.1128/MCB.18.6.3330; Buchner J, 1999, TRENDS BIOCHEM SCI, V24, P136, DOI 10.1016/S0968-0004(99)01373-0; Caplan AJ, 1999, TRENDS CELL BIOL, V9, P262, DOI 10.1016/S0962-8924(99)01580-9; Chadli A, 2000, P NATL ACAD SCI USA, V97, P12524, DOI 10.1073/pnas.220430297; Chang HCJ, 1997, MOL CELL BIOL, V17, P318, DOI 10.1128/MCB.17.1.318; Chen SY, 1996, MOL ENDOCRINOL, V10, P682, DOI 10.1210/me.10.6.682; Connell P, 2001, NAT CELL BIOL, V3, P93, DOI 10.1038/35050618; Dey B, 1996, MOL BIOL CELL, V7, P91, DOI 10.1091/mbc.7.1.91; Dittmar KD, 1997, J BIOL CHEM, V272, P13047, DOI 10.1074/jbc.272.20.13047; Dittmar KD, 1996, J BIOL CHEM, V271, P12833, DOI 10.1074/jbc.271.22.12833; Duina AA, 1996, SCIENCE, V274, P1713, DOI 10.1126/science.274.5293.1713; Fang YF, 1998, MOL CELL BIOL, V18, P3727, DOI 10.1128/MCB.18.7.3727; Fontana J, 2002, CIRC RES, V90, P866, DOI 10.1161/01.RES.0000016837.26733.BE; Freeman BC, 1996, EMBO J, V15, P2969, DOI 10.1002/j.1460-2075.1996.tb00660.x; Garcia-Cardena G, 1998, NATURE, V392, P821, DOI 10.1038/33934; Giaever G, 2002, NATURE, V418, P387, DOI 10.1038/nature00935; Johnson BD, 1998, J BIOL CHEM, V273, P3679, DOI 10.1074/jbc.273.6.3679; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Minami Y, 1996, J BIOL CHEM, V271, P19617, DOI 10.1074/jbc.271.32.19617; Nair SC, 1996, CELL STRESS CHAPERON, V1, P237, DOI 10.1379/1466-1268(1996)001<0237:APOMCI>2.3.CO;2; Nathan DF, 1999, P NATL ACAD SCI USA, V96, P1409, DOI 10.1073/pnas.96.4.1409; Nathan DF, 1997, P NATL ACAD SCI USA, V94, P12949, DOI 10.1073/pnas.94.24.12949; NATHAN DF, 1995, MOL CELL BIOL, V15, P3917; Obermann WMJ, 1998, J CELL BIOL, V143, P901, DOI 10.1083/jcb.143.4.901; Owen BAL, 2002, J BIOL CHEM, V277, P7086, DOI 10.1074/jbc.M111450200; OwensGrillo JK, 1996, J BIOL CHEM, V271, P13468, DOI 10.1074/jbc.271.23.13468; Panaretou B, 1998, EMBO J, V17, P4829, DOI 10.1093/emboj/17.16.4829; Panaretou B, 2002, MOL CELL, V10, P1307, DOI 10.1016/S1097-2765(02)00785-2; Pratt WB, 1997, ENDOCR REV, V18, P306, DOI 10.1210/er.18.3.306; Prodromou C, 2000, EMBO J, V19, P4383, DOI 10.1093/emboj/19.16.4383; Prodromou C, 1999, EMBO J, V18, P754, DOI 10.1093/emboj/18.3.754; Prodromou C, 1997, CELL, V90, P65, DOI 10.1016/S0092-8674(00)80314-1; Scheibel T, 1998, P NATL ACAD SCI USA, V95, P1495, DOI 10.1073/pnas.95.4.1495; Scheufler C, 2000, CELL, V101, P199, DOI 10.1016/S0092-8674(00)80830-2; Silverstein AM, 1998, J BIOL CHEM, V273, P20090, DOI 10.1074/jbc.273.32.20090; SMITH DF, 1993, MOL ENDOCRINOL, V7, P1418, DOI 10.1210/me.7.11.1418; Stebbins CE, 1997, CELL, V89, P239, DOI 10.1016/S0092-8674(00)80203-2; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Xu Y, 1999, P NATL ACAD SCI USA, V96, P109, DOI 10.1073/pnas.96.1.109; XU Y, 1993, P NATL ACAD SCI USA, V90, P7074, DOI 10.1073/pnas.90.15.7074; Young JC, 1997, FEBS LETT, V418, P139, DOI 10.1016/S0014-5793(97)01363-X; Young JC, 1998, J BIOL CHEM, V273, P18007, DOI 10.1074/jbc.273.29.18007; Young JC, 2001, J CELL BIOL, V154, P267, DOI 10.1083/jcb.200104079	44	166	177	1	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 9	2003	278	19					17228	17235		10.1074/jbc.M212761200	http://dx.doi.org/10.1074/jbc.M212761200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677QG	12604615	hybrid			2022-12-25	WOS:000182818600105
J	Dziennis, S; Habecker, BA				Dziennis, S; Habecker, BA			Cytokine suppression of dopamine-beta-hydroxylase by extracellular signal-regulated kinase-dependent and -independent pathways	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CILIARY NEUROTROPHIC FACTOR; LEUKEMIA INHIBITORY FACTOR; NEUROTRANSMITTER BIOSYNTHETIC GENES; NEUROBLASTOMA CELL-LINE; TRANSCRIPTION FACTOR; HOMEODOMAIN PROTEIN; SYMPATHETIC NEURONS; ONCOSTATIN-M; GROWTH-FACTOR; RECEPTOR COMPONENTS	Cholinergic differentiation factors (CDFs) suppress no-radrenergic properties and induce cholinergic properties in sympathetic neurons. The CDFs leukemia inhibitory factor (LIF) and ciliary neurotrophic factor (CNTF) bind to a LIFR.gp130 receptor complex to activate Jak/signal transducers and activators of transcription and Ras/mitogen-activated protein kinases signaling pathways. Little is known about how these differentiation factors suppress noradrenergic properties. We used sympathetic neurons and SK-N-BE(2)M17 neuroblastoma cells to investigate CDF down-regulation of the norepinephrine synthetic enzyme dopamine-beta-hydroxylase (DBH). LIF and CNTF activated extracellular signal-regulated kinases (ERKs) I and 2 but not p38 or Jun N-terminal kinases in both cell types. Preventing ERK activation with PD98059 blocked CNTF suppression of DBH protein in sympathetic neurons but did not prevent the loss of DBH mRNA. CNTF decreased transcription of a DBH promoter-luciferase reporter construct in SK-N-BE(2)M17 cells, and this was also ERK-independent. Cytokine inhibition of DBH promoter activity did not require a silencer element but was prevented by overexpression of the transcriptional activator Phox2a. Inhibiting ERK activation increased basal DBH transcription in SK-N-BE(2)M17 cells, and DBH mRNA in sympathetic neurons. Transfection of Phox2a into PD98059-treated M17 cells resulted in a synergistic increase in DBH promoter activity compared with Phox2a or PD98059 alone. These data suggest that CDFs down-regulate DBH protein via an ERK-dependent pathway but inhibit DBH gene expression through an ERK-independent pathway. They further suggest that ERK activity inhibits basal DBH gene expression.	Oregon Hlth Sci Univ, Dept Physiol Pharmacol, Portland, OR 97239 USA	Oregon Health & Science University	Habecker, BA (corresponding author), Oregon Hlth Sci Univ, Dept Physiol Pharmacol, L334,3181 SW Sam Jackson Pk Rd, Portland, OR 97239 USA.			Habecker, Beth/0000-0002-4658-8730	NHLBI NIH HHS [HL 68231, R01 HL068231] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL068231] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Adachi M, 2002, J BIOL CHEM, V277, P22915, DOI 10.1074/jbc.M201695200; Afar R, 1996, MOL BRAIN RES, V36, P79, DOI 10.1016/0169-328X(95)00247-P; AKIRA S, 1994, CELL, V77, P63, DOI 10.1016/0092-8674(94)90235-6; BAUMANN H, 1993, J BIOL CHEM, V268, P8414; BOULTON TG, 1995, P NATL ACAD SCI USA, V92, P6915, DOI 10.1073/pnas.92.15.6915; Brodski C, 2000, P NATL ACAD SCI USA, V97, P9683, DOI 10.1073/pnas.160080697; CERVINI R, 1994, NEUROREPORT, V5, P1346; Comer AM, 1999, BRAIN RES PROTOC, V4, P367, DOI 10.1016/S1385-299X(99)00042-2; CORCORAN JJ, 1990, AM J PHYSIOL, V259, pC161, DOI 10.1152/ajpcell.1990.259.1.C161; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; DAVIS S, 1993, SCIENCE, V260, P1805, DOI 10.1126/science.8390097; Eilers A, 1998, J NEUROSCI, V18, P1713; English JM, 2002, TRENDS PHARMACOL SCI, V23, P40, DOI 10.1016/S0165-6147(00)01865-4; Faris M, 1996, AIDS, V10, P369, DOI 10.1097/00002030-199604000-00004; GAGNON C, 1976, J NEUROCHEM, V27, P1083, DOI 10.1111/j.1471-4159.1976.tb00312.x; GEARING DP, 1992, SCIENCE, V255, P1434, DOI 10.1126/science.1542794; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; Harrington AW, 2002, J NEUROSCI, V22, P156, DOI 10.1523/JNEUROSCI.22-01-00156.2002; Hawrot E, 1979, Methods Enzymol, V58, P574; IP NY, 1992, CELL, V69, P1121, DOI 10.1016/0092-8674(92)90634-O; Ishiguro H, 1995, MOL BRAIN RES, V34, P251, DOI 10.1016/0169-328X(95)00170-W; JOHNSON JA, 1994, J BIOL CHEM, V269, P18856; Kim CH, 1999, J BIOL CHEM, V274, P6507, DOI 10.1074/jbc.274.10.6507; Kim HS, 1998, J NEUROSCI, V18, P8247; LANDIS SC, 1988, DEV BIOL, V126, P129, DOI 10.1016/0012-1606(88)90246-1; LANDIS SC, 1994, PROG BRAIN RES, V100, P19; Li WQ, 2001, J IMMUNOL, V166, P3491, DOI 10.4049/jimmunol.166.5.3491; LUTTICKEN C, 1994, SCIENCE, V263, P89, DOI 10.1126/science.8272872; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; Morin X, 1997, NEURON, V18, P411, DOI 10.1016/S0896-6273(00)81242-8; Niu HF, 1998, GENE DEV, V12, P1953, DOI 10.1101/gad.12.13.1953; Pattyn A, 1999, NATURE, V399, P366, DOI 10.1038/20700; Pearson G, 2001, ENDOCR REV, V22, P153, DOI 10.1210/er.22.2.153; Pene F, 2002, ONCOGENE, V21, P6587, DOI 10.1038/sj.onc.1205923; PENNICA D, 1995, J BIOL CHEM, V270, P10915, DOI 10.1074/jbc.270.18.10915; Proud CG, 1996, TRENDS BIOCHEM SCI, V21, P181, DOI 10.1016/0968-0004(96)10016-5; RAO MS, 1990, DEV BIOL, V139, P65, DOI 10.1016/0012-1606(90)90279-R; Rosoff ML, 1999, CELL MOL NEUROBIOL, V19, P289, DOI 10.1023/A:1006937413310; SCHIEMANN WP, 1994, J BIOL CHEM, V269, P6376; SCHWARZSCHILD MA, 1994, J NEUROCHEM, V63, P1246; SHASKUS J, 1992, J BIOL CHEM, V267, P18821; STAHL N, 1993, J BIOL CHEM, V268, P7628; STAHL N, 1994, SCIENCE, V263, P92, DOI 10.1126/science.8272873; STAHL N, 1995, SCIENCE, V267, P1349, DOI 10.1126/science.7871433; Swanson DJ, 1997, J BIOL CHEM, V272, P27382, DOI 10.1074/jbc.272.43.27382; Swanson DJ, 2000, J BIOL CHEM, V275, P2911, DOI 10.1074/jbc.275.4.2911; SYMES A, 1994, MOL ENDOCRINOL, V8, P1750, DOI 10.1210/me.8.12.1750; Symes A, 1997, J BIOL CHEM, V272, P9648; SYMES AJ, 1993, P NATL ACAD SCI USA, V90, P572, DOI 10.1073/pnas.90.2.572; TAGA T, 1995, CURR OPIN IMMUNOL, V7, P17, DOI 10.1016/0952-7915(95)80024-7; Tiveron MC, 1996, J NEUROSCI, V16, P7649; VIRDEE K, 1995, EUR J NEUROSCI, V7, P2159, DOI 10.1111/j.1460-9568.1995.tb00637.x; Yang CY, 1998, J NEUROCHEM, V71, P1813; Yokogami K, 2000, CURR BIOL, V10, P47, DOI 10.1016/S0960-9822(99)00268-7; Zellmer E, 1995, J NEUROSCI, V15, P8109; ZHONG Z, 1994, SCIENCE, V264, P95, DOI 10.1126/science.8140422; Zigmond RE, 1996, PERSPECT DEV NEUROBI, V4, P75	57	28	29	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 2	2003	278	18					15897	15904		10.1074/jbc.M212480200	http://dx.doi.org/10.1074/jbc.M212480200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	675EL	12609984	hybrid			2022-12-25	WOS:000182680000056
J	Zeisig, BB; Garcia-Cuellar, MP; Winkler, TH; Slany, RK				Zeisig, BB; Garcia-Cuellar, MP; Winkler, TH; Slany, RK			The oncoprotein MLL-ENL disturbs hematopoietic lineage determination and transforms a biphenotypic lymphoid/myeloid cell	ONCOGENE			English	Article						leukemia; MLL; fusion protein; mixed-lineage leukemia	ACUTE LYMPHOBLASTIC-LEUKEMIA; INTERNAL TANDEM DUPLICATION; ACUTE MYELOID LEUKEMIAS; BONE-MARROW; HEMATOLOGICAL MALIGNANCIES; 11Q23 TRANSLOCATIONS; DROSOPHILA-TRITHORAX; MAMMALIAN TRITHORAX; FETAL LIVER; MUTANT MICE	Mixed-lineage leukemia (MLL) fusion proteins are associated with a unique class of leukemia that is characterized by the simultaneous expression of lymphoid-specific as well as myeloid-specific genes. Here we report the first experimental model of MLL. Murine bone marrow cells were retrovirally transduced to express the MLL-eleven nineteen leukemia (MLL-ENL) fusion protein. When cultivated in flt-3 ligand, stem cell factor and interleukin-7 (IL-7) in a stroma-free culture system MLL-ENL-transduced as well as control cells showed a wave of B-lymphopoiesis. Whereas the controls exhausted their proliferative capacity in a CD19+/B220+ state, a continuously proliferating CD19-/B220+ cell population emerged in the MLL-ENL-transduced cultures. Despite the lymphoid surface marker, these cells were of monocytoid morphology. The immortalized cells contained unrearranged retrovirus, expressed MLL-ENL mRNA and were able to grow in syngenic recipients. From the diseased animals an MLL-ENL positive, B220+/CD19-cell type could be reisolated and cultivated in vitro. In analogy to human MLL, MLL-ENL-transformed cells not only coexpressed lymphocyte-specific (rag1, rag2, pax5, Tdt) and monocyte-specific genes (lysozyme, c-fms), but also showed rearrangements of the genomic immunoglobulin locus. This model shows that MLL-ENL influences events of early lineage determination and it will enable the investigation of the underlying molecular processes.	Univ Erlangen Nurnberg, Dept Genet, D-91058 Erlangen, Germany	University of Erlangen Nuremberg	Slany, RK (corresponding author), Univ Erlangen Nurnberg, Dept Genet, Staudtstr 5, D-91058 Erlangen, Germany.							Armstrong SA, 2002, NAT GENET, V30, P41, DOI 10.1038/ng765; Ayton PM, 2001, ONCOGENE, V20, P5695, DOI 10.1038/sj.onc.1204639; Behm FG, 1996, BLOOD, V87, P2870, DOI 10.1182/blood.V87.7.2870.bloodjournal8772870; Butler LH, 1997, BLOOD, V89, P3361, DOI 10.1182/blood.V89.9.3361; Corral J, 1996, CELL, V85, P853, DOI 10.1016/S0092-8674(00)81269-6; CUMANO A, 1992, NATURE, V356, P612, DOI 10.1038/356612a0; Dannaeus K, 1999, EXP HEMATOL, V27, P1646, DOI 10.1016/S0301-472X(99)00106-X; DiMartino JF, 1999, BRIT J HAEMATOL, V106, P614, DOI 10.1046/j.1365-2141.1999.01439.x; DiMartino JF, 2000, BLOOD, V96, P3887, DOI 10.1182/blood.V96.12.3887.h8003887_3887_3893; DJABALI M, 1992, NAT GENET, V2, P113, DOI 10.1038/ng1092-113; Dobson CL, 2000, EMBO J, V19, P843, DOI 10.1093/emboj/19.5.843; Dobson CL, 1999, EMBO J, V18, P3564, DOI 10.1093/emboj/18.13.3564; Eberhard D, 2000, EMBO J, V19, P2292, DOI 10.1093/emboj/19.10.2292; GU Y, 1992, CELL, V71, P701, DOI 10.1016/0092-8674(92)90603-A; Hanson RD, 1999, P NATL ACAD SCI USA, V96, P14372, DOI 10.1073/pnas.96.25.14372; Hess JL, 1997, BLOOD, V90, P1799, DOI 10.1182/blood.V90.5.1799; Huret JL, 2001, LEUKEMIA, V15, P987, DOI 10.1038/sj.leu.2402135; Kelly LM, 2002, BLOOD, V99, P310, DOI 10.1182/blood.V99.1.310; Kottaridis PD, 2001, BLOOD, V98, P1752, DOI 10.1182/blood.V98.6.1752; Lavau C, 2000, P NATL ACAD SCI USA, V97, P10984, DOI 10.1073/pnas.190167297; Lavau C, 2000, EMBO J, V19, P4655, DOI 10.1093/emboj/19.17.4655; Lavau C, 1997, EMBO J, V16, P4226, DOI 10.1093/emboj/16.14.4226; Mahmoudi T, 2001, ONCOGENE, V20, P3055, DOI 10.1038/sj.onc.1204330; Martensson IL, 1997, J EXP MED, V185, P653, DOI 10.1084/jem.185.4.653; Montecino-Rodriguez E, 2001, NAT IMMUNOL, V2, P83, DOI 10.1038/83210; Nutt S L, 2001, Int Rev Immunol, V20, P65, DOI 10.3109/08830180109056723; Nutt SL, 1998, EMBO J, V17, P2319, DOI 10.1093/emboj/17.8.2319; Nutt SL, 1999, NATURE, V401, P556, DOI 10.1038/44076; PUI CH, 1991, BLOOD, V77, P440; Schreiner S, 2001, CANCER RES, V61, P6480; Schreiner SA, 1999, LEUKEMIA, V13, P1525, DOI 10.1038/sj.leu.2401534; Slany RK, 1998, MOL CELL BIOL, V18, P122, DOI 10.1128/MCB.18.1.122; TKACHUK DC, 1992, CELL, V71, P691, DOI 10.1016/0092-8674(92)90602-9; Yagi H, 1998, BLOOD, V92, P108, DOI 10.1182/blood.V92.1.108.413k11_108_117; Yeoh EJ, 2002, CANCER CELL, V1, P133, DOI 10.1016/S1535-6108(02)00032-6; Yu BD, 1998, P NATL ACAD SCI USA, V95, P10632, DOI 10.1073/pnas.95.18.10632; YU BD, 1995, NATURE, V378, P505, DOI 10.1038/378505a0; ZIEMINVANDERPOEL S, 1991, P NATL ACAD SCI USA, V88, P10735, DOI 10.1073/pnas.88.23.10735	38	44	45	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 20	2003	22	11					1629	1637		10.1038/sj.onc.1206104	http://dx.doi.org/10.1038/sj.onc.1206104			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	655YH	12642866				2022-12-25	WOS:000181580500005
J	Delgado, M; Ganea, D				Delgado, M; Ganea, D			Neuroprotective effect of vasoactive intestinal peptide (VIP) in a mouse model of Parkinson's disease by blocking microglial activation	FASEB JOURNAL			English	Article						neurodegeneration; microglia; inflammation; MPTP neurotoxicity	NITRIC-OXIDE SYNTHASE; TUMOR-NECROSIS-FACTOR; 1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE MPTP; DOPAMINERGIC NEURODEGENERATION; INDUCED NEUROTOXICITY; ALPHA-SYNUCLEIN; TRANSGENIC MICE; MESSENGER-RNA; GLIAL-CELLS; RAT-BRAIN	Parkinson's disease (PD) is a common neurodegenerative disorder with no effective protective treatment, characterized by a massive degeneration of dopaminergic neurons in the substantia nigra (SNpc) and the subsequent loss of their projecting nerve fibers in the striatum. To elucidate PD pathogenic factors, and thus to develop therapeutic strategies, a murine PD model based on the administration of the neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) has been used extensively. It has been demonstrated that activated microglia cells actively participate in the pathogenesis of MPTP-induced PD through the release of cytotoxic factors. Because current treatments for PD are not effective, considerable research focused lately on a number of regulatory molecules termed microglia-deactivating factors. Vasoactive intestinal peptide (VIP), a neuropeptide with a potent anti-inflammatory effect, has been found to be protective in several inflammatory disorders. This study investigates the putative protective effect of VIP in the MPTP model for PD. VIP treatment significantly decreases MPTP-induced dopaminergic neuronal loss in SNpc and nigrostriatal nerve-fiber loss. VIP prevents MPTP-induced activation of microglia in SNpc and striatum and the expression of the cytotoxic mediators, iNOS, interleukin 1beta, and numor necrosis factor alpha. VIP emerges as a potential valuable neuroprotective agent for the treatment of pathologic conditions in the central nervous system, such as PD, where inflammation-induced neurodegeneration occurs.	Univ Complutense, Dept Cell Biol, Sch Biol, Fac Biol, E-28040 Madrid, Spain; Rutgers State Univ, Dept Biol Sci, Newark, NJ 07102 USA; CSIC, Inst Parasitol & Biomed Lopez Neyra, Granada 18001, Spain	Complutense University of Madrid; Rutgers State University Newark; Rutgers State University New Brunswick; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Parasitologia y Biomedicina Lopez-Neyra (IPBLN)	Delgado, M (corresponding author), Univ Complutense, Dept Cell Biol, Sch Biol, Fac Biol, E-28040 Madrid, Spain.	mariodm@bio.ucm.es	Delgado, Mario/P-1524-2016	Delgado, Mario/0000-0003-1893-5982				Ara J, 1998, P NATL ACAD SCI USA, V95, P7659, DOI 10.1073/pnas.95.13.7659; BEAL MF, 1990, NEUROSCI LETT, V108, P36; BLOEM BR, 1990, J NEUROL SCI, V97, P273, DOI 10.1016/0022-510X(90)90225-C; de Yebenes EG, 1999, J NEUROCHEM, V73, P812, DOI 10.1046/j.1471-4159.1999.0730812.x; Dehmer T, 2000, J NEUROCHEM, V74, P2213, DOI 10.1046/j.1471-4159.2000.0742213.x; Delgado M, 2003, J LEUKOCYTE BIOL, V73, P155, DOI 10.1189/jlb.0702372; Delgado M, 1999, J IMMUNOL, V162, P1200; Delgado M, 2002, J MOL MED, V80, P16, DOI 10.1007/s00109-001-0291-5; Delgado M, 2002, GLIA, V39, P148, DOI 10.1002/glia.10098; Delgado M, 2001, NAT MED, V7, P563, DOI 10.1038/87887; Goedert M, 2001, NAT REV NEUROSCI, V2, P492, DOI 10.1038/35081564; Gomariz RP, 2001, CURR PHARM DESIGN, V7, P89, DOI 10.2174/1381612013398374; Gonzalez-Scarano F, 1999, ANNU REV NEUROSCI, V22, P219, DOI 10.1146/annurev.neuro.22.1.219; Gourlet P, 1997, PEPTIDES, V18, P1539, DOI 10.1016/S0196-9781(97)00228-3; Grunblatt E, 2001, J NEUROCHEM, V78, P1, DOI 10.1046/j.1471-4159.2001.00397.x; Grunblatt E, 2000, J NEUROL, V247, P95; Harmar AJ, 1998, PHARMACOL REV, V50, P265; Hulley P, 1995, EUR J NEUROSCI, V7, P2431, DOI 10.1111/j.1460-9568.1995.tb01041.x; Hunot S, 1999, J NEUROSCI, V19, P3440; JAVITCH JA, 1983, EUR J PHARMACOL, V90, P461, DOI 10.1016/0014-2999(83)90574-5; Jenner P, 1996, NEUROLOGY, V47, pS161, DOI 10.1212/WNL.47.6_Suppl_3.161S; Jenner P, 1998, ANN NEUROL, V44, pS72, DOI 10.1002/ana.410440712; Kim WG, 2000, J NEUROSCI, V20, P6309, DOI 10.1523/JNEUROSCI.20-16-06309.2000; KINDT MV, 1987, J PHARMACOL EXP THER, V242, P858; Klevenyi P, 1999, NEUROREPORT, V10, P635, DOI 10.1097/00001756-199902250-00035; Kohutnicka M, 1998, IMMUNOPHARMACOLOGY, V39, P167, DOI 10.1016/S0162-3109(98)00022-8; Kreutzberg GW, 1996, TRENDS NEUROSCI, V19, P312, DOI 10.1016/0166-2236(96)10049-7; KRIEGLSTEIN K, 1995, EMBO J, V14, P736, DOI 10.1002/j.1460-2075.1995.tb07052.x; Li MW, 2000, SCIENCE, V288, P335, DOI 10.1126/science.288.5464.335; Liberatore GT, 1999, NAT MED, V5, P1403; LIPTON JM, 1993, NEUROBIOLOGY CYTOK B, P61; McGeer PL, 2001, ADV NEUROL, V86, P83; MIZUNO Y, 1995, BBA-MOL BASIS DIS, V1271, P265, DOI 10.1016/0925-4439(95)00038-6; Nadeau S, 2000, J NEUROSCI, V20, P3456, DOI 10.1523/JNEUROSCI.20-09-03456.2000; Pennathur S, 1999, J BIOL CHEM, V274, P34621, DOI 10.1074/jbc.274.49.34621; Pozo D, 2000, IMMUNOL TODAY, V21, P7, DOI 10.1016/S0167-5699(99)01525-X; Przedborski S, 1996, P NATL ACAD SCI USA, V93, P4565, DOI 10.1073/pnas.93.10.4565; Przedborski S, 2001, J NEUROCHEM, V76, P637, DOI 10.1046/j.1471-4159.2001.00174.x; PRZEDBORSKI S, 1992, J NEUROSCI, V12, P1658; PRZEDBORSKI S, 1998, MOV DISORD S, V13, P135; PRZEDBORSKI S, 2000, OXIDAT STRESS DIS, V5, P273; Quan N, 1998, NEUROSCIENCE, V83, P281, DOI 10.1016/S0306-4522(97)00350-3; Rajora N, 1997, J NEUROSCI, V17, P2181; RODNITZKY RL, 1995, NEUROSCIENCE MED, P417; SCHAPIRA AHV, 1990, J NEUROCHEM, V54, P823, DOI 10.1111/j.1471-4159.1990.tb02325.x; SCHULZ JB, 1995, J NEUROCHEM, V64, P936, DOI 10.1046/j.1471-4159.1995.64020936.x; SRIRAM K, 2002, FASEB J; Vila M, 2001, CURR OPIN NEUROL, V14, P483, DOI 10.1097/00019052-200108000-00009; Vila M, 2001, P NATL ACAD SCI USA, V98, P2837, DOI 10.1073/pnas.051633998; WHITFIELD HJ, 1990, CELL MOL NEUROBIOL, V10, P145, DOI 10.1007/BF00733641; Wu DC, 2002, J NEUROSCI, V22, P1763, DOI 10.1523/JNEUROSCI.22-05-01763.2002; Xia MG, 1997, J PHARMACOL EXP THER, V281, P629	52	139	154	0	4	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2003	17	3					944	+		10.1096/fj.02-0799fje	http://dx.doi.org/10.1096/fj.02-0799fje			18	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	661LT	12626429				2022-12-25	WOS:000181892600029
J	Zhang, JH; Li, W; Sanders, MA; Sumpio, BE; Panja, A; Basson, MD				Zhang, JH; Li, W; Sanders, MA; Sumpio, BE; Panja, A; Basson, MD			Regulation of the intestinal epithelial response to cyclic strain by extracellular matrix proteins	FASEB JOURNAL			English	Article						deformation; enterocyte; fibronectin; FAK; integrin; MAPK	EPIDERMAL-GROWTH-FACTOR; FOCAL ADHESION KINASE; SMOOTH-MUSCLE-CELLS; MECHANICAL STRAIN; SMALL-BOWEL; ENDOTHELIAL-CELLS; BRUSH-BORDER; DNA-SYNTHESIS; FIBRONECTIN; INTEGRIN	Repetitive mechanical deformation may stimulate intestinal epithelial proliferation. Because the extracellular matrix modulates static intestinal epithelial biology, we examined whether matrix proteins influence intestinal epithelial responses to deformation. Human Caco-2(BBE) cells and nontransformed human enterocytes (HIPEC) were subjected to 10% average cyclic strain at 10 cycles/min on flexible membranes precoated with matrix proteins without or with plasma fibronectin or functional anti-integrin antibodies in the medium. Strain stimulated proliferation, focal adhesion kinase, extracellular signal-regulated protein kinase (ERK), p38, and Jun N-terminal kinase similarly on collagen I or IV, and more weakly on laminin, but had no effect on fibronectin. MEK blockade (PD98059) prevented strain-stimulated proliferation on collagen but did not affect proliferation on fibronectin. Adding tissue fibronectin to a collagen substrate or plasma fibronectin to the media suppressed strain's mitogenic and signal effects, but not those of epidermal growth factor. Functional antibodies to the alpha5 or alphav integrin subunit blocked strain's effects on Caco-2 proliferation and ERK activation, although ligation of the alpha2 or alpha6 subunit did not. Repetitive strain also stimulated, and fibronectin inhibited, human intestinal primary epithelial cell proliferation. Repetitive deformation stimulates transformed and nontransformed human intestinal epithelial proliferation in a matrix-dependent manner. Tissue or plasma fibronectin may regulate the intestinal epithelial response to strain via integrins containing alpha5 or alphav.	John D Dingell VA Med Ctr, Dept Surg, Detroit, MI 48201 USA; Wayne State Univ, Dept Surg, Detroit, MI 48202 USA; Yale Univ, New Haven, CT 06520 USA; Tianjin Med Univ, Canc Hosp, Tianjin, Peoples R China; W Haven VA Hosp, West Haven, CT USA; SUNY Albany, Dept Med, Albany, NY 12246 USA	Wayne State University; Yale University; Tianjin Medical University; State University of New York (SUNY) System; State University of New York (SUNY) Albany	Basson, MD (corresponding author), John D Dingell VA Med Ctr, Dept Surg, 4646 John R St, Detroit, MI 48201 USA.	Marc.Basson@med.va.gov						Basson MD, 1996, J CELL PHYSIOL, V168, P476, DOI 10.1002/(SICI)1097-4652(199608)168:2<476::AID-JCP26>3.0.CO;2-#; Basson MD, 1996, EXP CELL RES, V225, P301, DOI 10.1006/excr.1996.0180; Basson MD, 2002, METABOLISM, V51, P1525, DOI 10.1053/meta.2002.36303; BASSON MD, 1992, J CLIN INVEST, V90, P15, DOI 10.1172/JCI115828; Basson MD, 2000, CELL PHYSIOL BIOCHEM, V10, P27, DOI 10.1159/000016332; BASSON MD, 2000, J GI SURG, V4, P435; Beaulieu JF, 1997, PROG HISTOCHEM CYTOC, V31, P1; DEVRIES JE, 1986, INT J CANCER, V38, P465, DOI 10.1002/ijc.2910380403; DiazGonzalez F, 1996, MOL BIOL CELL, V7, P1939, DOI 10.1091/mbc.7.12.1939; EMENAKER NJ, 1998, SURG FORUM, V49, P612; FALLINGBORG J, 1985, SCAND J GASTROENTERO, V20, P1062, DOI 10.3109/00365528509088872; FELDMAN EJ, 1976, GASTROENTEROLOGY, V70, P712; FRIEDMAN HI, 1977, ANAT RECORD, V188, P77, DOI 10.1002/ar.1091880109; Gahtan V, 1999, J VASC SURG, V29, P1031, DOI 10.1016/S0741-5214(99)70244-2; Gong JG, 1998, J BIOL CHEM, V273, P1662, DOI 10.1074/jbc.273.3.1662; HALLDEN G, 1994, AM J PHYSIOL-GASTR L, V267, pG730, DOI 10.1152/ajpgi.1994.267.4.G730; Han OH, 1998, AM J PHYSIOL-GASTR L, V275, pG534, DOI 10.1152/ajpgi.1998.275.3.G534; Hipper A, 2000, PFLUG ARCH EUR J PHY, V440, P19, DOI 10.1007/s004240000246; Ikeda M, 1999, AM J PHYSIOL-HEART C, V276, pH614; INOUE Y, 1993, JPEN-PARENTER ENTER, V17, P165, DOI 10.1177/0148607193017002165; Kornblihtt AR, 1996, FASEB J, V10, P248, DOI 10.1096/fasebj.10.2.8641558; Kosmehl H, 1996, VIRCHOWS ARCH, V429, P311; KOUKOULIS GK, 1993, VIRCHOWS ARCH B, V63, P373, DOI 10.1007/BF02899286; Kozlova NI, 2001, ONCOGENE, V20, P4710, DOI 10.1038/sj.onc.1204619; Kuwada SK, 2000, MOL BIOL CELL, V11, P2485, DOI 10.1091/mbc.11.7.2485; Lee JW, 2000, MOL BIOL CELL, V11, P1973, DOI 10.1091/mbc.11.6.1973; Li W, 2001, AM J PHYSIOL-GASTR L, V280, pG75, DOI 10.1152/ajpgi.2001.280.1.G75; Liang FQ, 2000, J BIOL CHEM, V275, P20355, DOI 10.1074/jbc.M001660200; Liang H, 2000, MED BIOL ENG COMPUT, V38, P35, DOI 10.1007/BF02344686; LICHTENBERGER LM, 1979, AM J PHYSIOL, V237, pE98, DOI 10.1152/ajpendo.1979.237.1.E98; LOUVARD D, 1992, ANNU REV CELL BIOL, V8, P157, DOI 10.1146/annurev.cb.08.110192.001105; Lussier C, 2000, MICROSC RES TECHNIQ, V51, P169; Malik A K, 1992, Indian J Pathol Microbiol, V35, P88; Matsuda N, 1998, BIOCHEM BIOPH RES CO, V249, P350, DOI 10.1006/bbrc.1998.9151; MATSUDA T, 1983, JPN J CLIN ONCOL, V13, P327; MAYHEW TM, 1990, J ELECTRON MICR TECH, V16, P45, DOI 10.1002/jemt.1060160107; MCNEIL PL, 1989, GASTROENTEROLOGY, V96, P1238, DOI 10.1016/S0016-5085(89)80010-1; MIFTAKHOV RN, 1994, MED ENG PHYS, V16, P406, DOI 10.1016/1350-4533(90)90007-U; OTTERSON MF, 1993, SURG CLIN N AM, V73, P1173; Panja A, 2000, LAB INVEST, V80, P1473, DOI 10.1038/labinvest.3780154; PETERSON MD, 1992, J CELL SCI, V102, P581; Pillai RB, 1999, DIGEST DIS SCI, V44, P1565, DOI 10.1023/A:1026654725101; POLIN RA, 1990, REV INFECT DIS, V12, pS428; Rebres RA, 1996, AM J PHYSIOL-LUNG C, V271, pL409, DOI 10.1152/ajplung.1996.271.3.L409; Reusch HP, 1997, BIOCHEM BIOPH RES CO, V237, P239, DOI 10.1006/bbrc.1997.7121; Reusch P, 1996, CIRC RES, V79, P1046, DOI 10.1161/01.RES.79.5.1046; Sanders MA, 2000, J BIOL CHEM, V275, P38040, DOI 10.1074/jbc.M003871200; SCHWARZBAUER JE, 1991, BIOESSAYS, V13, P527, DOI 10.1002/bies.950131006; Seko Y, 1999, BIOCHEM BIOPH RES CO, V259, P8, DOI 10.1006/bbrc.1999.0720; SHIRAKAMI A, 1986, HORM METAB RES, V18, P345, DOI 10.1055/s-2007-1012311; SONNENBERG A, 1988, NATURE, V336, P487, DOI 10.1038/336487a0; TASMANJONES C, 1982, DIGEST DIS SCI, V27, P519, DOI 10.1007/BF01296731; TUCKER RP, 1994, PERSPECT DEV NEUROBI, V2, P1; TUTTON PJM, 1976, VIRCHOWS ARCH B, V20, P139; Wang DS, 2001, ENDOTHELIUM-NEW YORK, V8, P283, DOI 10.3109/10623320109090806; WAYNER EA, 1988, J CELL BIOL, V107, P1881, DOI 10.1083/jcb.107.5.1881; WILLIAMSON RCN, 1978, NEW ENGL J MED, V298, P1393, DOI 10.1056/NEJM197806222982505; WILSON E, 1995, J CLIN INVEST, V96, P2364, DOI 10.1172/JCI118293; WOMACK WA, 1987, AM J PHYSIOL, V252, pG250, DOI 10.1152/ajpgi.1987.252.2.G250; Wozniak M, 2000, J BONE MINER RES, V15, P1731, DOI 10.1359/jbmr.2000.15.9.1731; Xu RJ, 1996, REPROD FERT DEVELOP, V8, P35, DOI 10.1071/RD9960035; Yano Y, 1996, AM J PHYSIOL-CELL PH, V271, pC635, DOI 10.1152/ajpcell.1996.271.2.C635; Yokosaki Y, 1996, J BIOL CHEM, V271, P24144, DOI 10.1074/jbc.271.39.24144; Yu CF, 2000, AM J PHYSIOL-GASTR L, V278, pG952, DOI 10.1152/ajpgi.2000.278.6.G952; Yun JK, 1999, TISSUE ENG, V5, P67, DOI 10.1089/ten.1999.5.67	65	58	60	0	4	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2003	17	3					926	+		10.1096/fj.02-0663fje	http://dx.doi.org/10.1096/fj.02-0663fje			22	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	661LT	12626437				2022-12-25	WOS:000181892600026
J	Koropatkin, NM; Liu, HW; Holden, HM				Koropatkin, NM; Liu, HW; Holden, HM			High resolution X-ray structure of tyvelose epimerase from Salmonella typhi	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UDP-GALACTOSE 4-EPIMERASE; ESCHERICHIA-COLI; CATALYTIC MECHANISM; CRYSTAL-STRUCTURE; GLUCOSE; ENTERICA; INSIGHTS; PATHWAY; ENZYMES; SUGARS	Tyvelose epimerase catalyzes the last step in the biosynthesis of tyvelose by converting CDP-D-paratose to CDP-D-tyvelose. This unusual 3,6-dideoxyhexose occurs in the O-antigens of some types of Gram-negative bacteria. Here we describe the cloning, protein purification, and high-resolution x-ray crystallographic analysis of tyvelose epimerase from Salmonella typhi complexed with CDP. The enzyme from S. typhi is a homotetramer with each subunit containing 339 amino acid residues and a tightly bound NAD(+) cofactor. The quaternary structure of the enzyme displays 222 symmetry and can be aptly described as a dimer of dimers. Each subunit folds into two distinct lobes: the N-terminal motif responsible for NAD(+) binding and the C-terminal region that harbors the binding site for CDP. The analysis described here demonstrates that tyvelose epimerase belongs to the short-chain dehydrogenase/reductase superfamily of enzymes. Indeed, its active site is reminiscent to that observed for UDP-galactose 4-epimerase, an enzyme that plays a key role in galactose metabolism. Unlike UDP-galactose 4-epimerase where the conversion of configuration occurs about C-4 of the UDP-glucose or UDP-galactose substrates, in the reaction catalyzed by tyvelose epimerase, the inversion of stereochemistry occurs at C-2. On the basis of the observed binding mode for CDP, it is possible to predict the manner in which the substrate, CDP-paratose, and the product, CDP-tyvelose, might be accommodated within the active site of tyvelose epimerase.	Univ Wisconsin, Dept Biochem, Madison, WI 53706 USA; Univ Texas, Coll Pharm, Div Med Chem, Austin, TX 78712 USA; Univ Texas, Dept Chem & Biochem, Austin, TX 78712 USA	University of Wisconsin System; University of Wisconsin Madison; University of Texas System; University of Texas Austin; University of Texas System; University of Texas Austin	Holden, HM (corresponding author), Univ Wisconsin, Dept Biochem, Madison, WI 53706 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK047814, R56DK047814] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM035906, R01GM035906] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK47814] Funding Source: Medline; NIGMS NIH HHS [GM35906] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Allard STM, 2001, CELL MOL LIFE SCI, V58, P1650, DOI 10.1007/PL00000803; Allard STM, 2001, J MOL BIOL, V307, P283, DOI 10.1006/jmbi.2000.4470; Cowtan K, 1998, ACTA CRYSTALLOGR D, V54, P487, DOI 10.1107/S0907444997011980; Deacon AM, 2000, STRUCT FOLD DES, V8, P453, DOI 10.1016/S0969-2126(00)00128-3; Frey PA, 1996, FASEB J, V10, P461, DOI 10.1096/fasebj.10.4.8647345; Hallis TM, 2000, J AM CHEM SOC, V122, P10493, DOI 10.1021/ja0022021; Hallis TM, 1999, ACCOUNTS CHEM RES, V32, P579, DOI 10.1021/ar9602056; He XMM, 2002, ANNU REV BIOCHEM, V71, P701, DOI 10.1146/annurev.biochem.71.110601.135339; Hirose K, 2002, J CLIN MICROBIOL, V40, P633, DOI 10.1128/JCM.40.02.633-636.2002; LEE B, 1971, J MOL BIOL, V55, P379, DOI 10.1016/0022-2836(71)90324-X; Madigan M. T., 1996, BIOL MICROORGANISMS; Mulichak AM, 2002, BIOCHEMISTRY-US, V41, P15578, DOI 10.1021/bi0266683; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Roussel A, 1990, ACTA CRYSTALLOGR A, V46, pC66; Somoza JR, 2000, STRUCTURE, V8, P123, DOI 10.1016/S0969-2126(00)00088-5; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; Thoden JB, 2000, BIOCHEMISTRY-US, V39, P5691, DOI 10.1021/bi000215l; Thoden JB, 1996, PROTEIN SCI, V5, P2149, DOI 10.1002/pro.5560051102; Thoden JB, 1996, BIOCHEMISTRY-US, V35, P2557, DOI 10.1021/bi952715y; Thoden JB, 1996, BIOCHEMISTRY-US, V35, P5137, DOI 10.1021/bi9601114; Thoden JB, 1998, BIOCHEMISTRY-US, V37, P11469, DOI 10.1021/bi9808969; TRONRUD DE, 1987, ACTA CRYSTALLOGR A, V43, P489, DOI 10.1107/S0108767387099124; VANDUYNE GD, 1993, J MOL BIOL, V229, P105, DOI 10.1006/jmbi.1993.1012	24	19	21	0	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 6	2003	278	23					20874	20881		10.1074/jbc.M301948200	http://dx.doi.org/10.1074/jbc.M301948200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	684WY	12642575	hybrid			2022-12-25	WOS:000183230500057
J	Kerschensteiner, D; Monje, F; Stocker, M				Kerschensteiner, D; Monje, F; Stocker, M			Structural determinants of the regulation of the voltage-gated potassium channel Kv2.1 by the modulatory alpha-subunit Kv9.3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							2 INACTIVATION MECHANISMS; C-TYPE INACTIVATION; K+ CHANNEL; RAT-BRAIN; TETRAETHYLAMMONIUM BLOCKADE; XENOPUS-OOCYTES; TERMINAL DOMAIN; BETA-SUBUNIT; N-TERMINUS; EXPRESSION	Voltage-gated potassium (Kv) channels containing alpha-subunits of the Kv2 subfamily mediate delayed rectifier currents in excitable cells. Channels formed by Kv2.1 alpha-subunits inactivate from open- and closed states with both forms of inactivation serving different physiological functions. Here we show that open- and closed-state inactivation of Kv2.1 can be distinguished by the sensitivity to intracellular tetraethylammonium and extracellular potassium and lead to the same inactivated conformation. The functional properties of Kv2.1 are regulated by its association with modulatory alpha-subunits (Kv5, Kv6, Kv8, and Kv9). For instance, Kv9.3 changes the state preference of Kv2.1 inactivation by accelerating closed-state inactivation and inhibiting open- state inactivation. An N-terminal regulatory domain (NRD) has been suggested to determine the function of the modulatory alpha-subunit Kv8.1. However, when we tested the NRD of Kv9.3, we found that the functional properties of chimeric Kv2.1 channels containing the NRD of Kv9.3 (Kv2.1(NRD)) did not resemble those of Kv2.1/Kv9.3 heteromers, thus questioning the role of the NRD in Kv9 subunits. A further region of interest is a PXP motif in the sixth transmembrane segment. This motif is conserved among all alpha-subunits of the Kv1, Kv2, Kv3, and Kv4 subfamilies, whereas the second proline is not conserved in any modulatory alpha-subunit. Exchanging this proline in Kv2.1 for the corresponding residue of Kv9.3 resulted in channels (Kv2.1-P410T) that show all hallmarks of the regulation of Kv2.1 by Kv9.3. The effect prevailed in heteromeric channels following co-expression of Kv2.1-P410T with Kv2.1. These data suggest that the alteration of the PXP motif is an important determinant of the regulatory function of modulatory alpha-subunits.	Max Planck Inst Expt Med, Abt Mol Biol Neuronaler Signale, D-37075 Gottingen, Germany; Univ Gottingen, Neurol Klin, D-37075 Gottingen, Germany; Ctr Int Fis, Edificio Manuel Ancizar, Bogota AA4948, Colombia; UCL, Wellcome Lab Mol Pharmacol, London WC1E 6BT, England	Max Planck Society; University of Gottingen; University of London; University College London	Kerschensteiner, D (corresponding author), Max Planck Inst Expt Med, Abt Mol Biol Neuronaler Signale, Herman Rein Str 3, D-37075 Gottingen, Germany.	dkersch@gwdg.de	Stocker, Martin/C-1844-2008					An WF, 2000, NATURE, V403, P553, DOI 10.1038/35000592; Bahring R, 2001, J BIOL CHEM, V276, P23888, DOI 10.1074/jbc.M101320200; Bahring R, 2001, J BIOL CHEM, V276, P22923, DOI 10.1074/jbc.M100483200; BAUKROWITZ T, 1995, NEURON, V15, P951, DOI 10.1016/0896-6273(95)90185-X; Beck EJ, 2002, J PHYSIOL-LONDON, V538, P691, DOI 10.1113/jphysiol.2001.013127; Bixby KA, 1999, NAT STRUCT BIOL, V6, P38; Blaine JT, 2001, J NEUROSCI, V21, P1473, DOI 10.1523/JNEUROSCI.21-05-01473.2001; Campomanes CR, 2002, J BIOL CHEM, V277, P8298, DOI 10.1074/jbc.M110276200; Castellano A, 1997, J NEUROSCI, V17, P4652; Chiara MD, 1999, J NEUROSCI, V19, P6865, DOI 10.1523/JNEUROSCI.19-16-06865.1999; CHOI KL, 1991, P NATL ACAD SCI USA, V88, P5092, DOI 10.1073/pnas.88.12.5092; CHRISTIE MJ, 1990, NEURON, V4, P405, DOI 10.1016/0896-6273(90)90052-H; DECOURSEY TE, 1990, J GEN PHYSIOL, V95, P617, DOI 10.1085/jgp.95.4.617; del Camino D, 2001, NEURON, V32, P649, DOI 10.1016/S0896-6273(01)00487-1; del Camino D, 2000, NATURE, V403, P321, DOI 10.1038/35002099; Doyle DA, 1998, SCIENCE, V280, P69, DOI 10.1126/science.280.5360.69; Du J, 2000, J PHYSIOL-LONDON, V522, P19, DOI 10.1111/j.1469-7793.2000.t01-2-00019.xm; DURELL SR, 1992, BIOPHYS J, V62, P238, DOI 10.1016/S0006-3495(92)81809-X; Frazier CJ, 2000, BIOPHYS J, V78, P1872, DOI 10.1016/S0006-3495(00)76736-1; FRECH GC, 1989, NATURE, V340, P642, DOI 10.1038/340642a0; GRISSMER S, 1989, BIOPHYS J, V55, P203, DOI 10.1016/S0006-3495(89)82793-6; Hille B., 2001, IONIC CHANNELS EXCIT, P814; Holmqvist MH, 2002, P NATL ACAD SCI USA, V99, P1035, DOI 10.1073/pnas.022509299; Hugnot JP, 1996, EMBO J, V15, P3322, DOI 10.1002/j.1460-2075.1996.tb00697.x; IKEDA SR, 1995, J PHYSIOL-LONDON, V486, P267, DOI 10.1113/jphysiol.1995.sp020809; Immke D, 1999, J GEN PHYSIOL, V113, P819, DOI 10.1085/jgp.113.6.819; ISACOFF EY, 1990, NATURE, V345, P530, DOI 10.1038/345530a0; Javadpour MM, 1999, BIOPHYS J, V77, P1609, DOI 10.1016/S0006-3495(99)77009-8; Jerng HH, 1999, J GEN PHYSIOL, V113, P641, DOI 10.1085/jgp.113.5.641; Johnston D, 2000, J PHYSIOL-LONDON, V525, P75, DOI 10.1111/j.1469-7793.2000.00075.x; Kerschensteiner D, 1999, BIOPHYS J, V77, P248, DOI 10.1016/S0006-3495(99)76886-4; Kiss L, 1999, BIOPHYS J, V76, P253, DOI 10.1016/S0006-3495(99)77194-8; Klemic KG, 1998, BIOPHYS J, V74, P1779, DOI 10.1016/S0006-3495(98)77888-9; Kramer JW, 1998, AM J PHYSIOL-CELL PH, V274, pC1501, DOI 10.1152/ajpcell.1998.274.6.C1501; Kreusch A, 1998, NATURE, V392, P945, DOI 10.1038/31978; KURATA HT, 2002, J BIOL CHEM, V20, P20; Levy DI, 1996, BIOPHYS J, V70, P798, DOI 10.1016/S0006-3495(96)79619-4; LI M, 1992, SCIENCE, V257, P1225, DOI 10.1126/science.1519059; MacDonald PE, 2002, J BIOL CHEM, V277, P44938, DOI 10.1074/jbc.M205532200; MACKINNON R, 1991, NATURE, V350, P232, DOI 10.1038/350232a0; Malin SA, 2002, J NEUROSCI, V22, P10094; Molina A, 1997, J PHYSIOL-LONDON, V499, P361, DOI 10.1113/jphysiol.1997.sp021933; MONOD J, 1965, J MOL BIOL, V12, P88, DOI 10.1016/S0022-2836(65)80285-6; Ottschytsch N, 2002, P NATL ACAD SCI USA, V99, P7986, DOI 10.1073/pnas.122617999; Pascual JM, 1997, AM J PHYSIOL-CELL PH, V273, pC1849, DOI 10.1152/ajpcell.1997.273.6.C1849; Patel AJ, 1997, EMBO J, V16, P6615, DOI 10.1093/emboj/16.22.6615; Post MA, 1996, FEBS LETT, V399, P177, DOI 10.1016/S0014-5793(96)01316-6; QUATTROCKI EA, 1994, NEURON, V12, P73, DOI 10.1016/0896-6273(94)90153-8; RETTIG J, 1994, NATURE, V369, P289, DOI 10.1038/369289a0; Roe MW, 1996, J BIOL CHEM, V271, P32241, DOI 10.1074/jbc.271.50.32241; RUPPERSBERG JP, 1990, NATURE, V345, P535, DOI 10.1038/345535a0; Salinas M, 1997, J BIOL CHEM, V272, P24371, DOI 10.1074/jbc.272.39.24371; Salinas M, 1997, J BIOL CHEM, V272, P8774, DOI 10.1074/jbc.272.13.8774; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Sano A, 2002, EPILEPSIA, V43, P26, DOI 10.1046/j.1528-1157.43.s.9.7.x; Schultz JH, 2001, CIRC RES, V88, P483, DOI 10.1161/01.RES.88.5.483; SHEN NV, 1993, NEURON, V11, P67; Smirnov SV, 2002, J PHYSIOL-LONDON, V538, P867, DOI 10.1113/jphysiol.2001.013003; Starkus JG, 1997, J GEN PHYSIOL, V110, P539, DOI 10.1085/jgp.110.5.539; Stocker M, 1998, BIOCHEM BIOPH RES CO, V248, P927, DOI 10.1006/bbrc.1998.9072; Stocker M, 1999, J NEUROCHEM, V72, P1725, DOI 10.1046/j.1471-4159.1999.721725.x; STUHMER W, 1992, METHOD ENZYMOL, V207, P319; Takimoto K, 2002, J BIOL CHEM, V277, P26904, DOI 10.1074/jbc.M203651200; VANDONGEN AMJ, 1990, NEURON, V5, P433, DOI 10.1016/0896-6273(90)90082-Q; Xu HD, 1999, CIRC RES, V85, P623, DOI 10.1161/01.RES.85.7.623; Zhou M, 2001, NATURE, V411, P657, DOI 10.1038/35079500	66	37	39	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 16	2003	278	20					18154	18161		10.1074/jbc.M213117200	http://dx.doi.org/10.1074/jbc.M213117200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677YX	12642579	hybrid			2022-12-25	WOS:000182838300074
J	Kietzmann, T; Samoylenko, A; Immenschuh, S				Kietzmann, T; Samoylenko, A; Immenschuh, S			Transcriptional regulation of heme oxygenase-1 gene expression by MAP kinases of the JNK and p38 pathways in primary cultures of rat Hepatocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; EPIDERMAL GROWTH-FACTOR; INDUCIBLE FACTOR-I; RESPONSE ELEMENT; MAMMALIAN-CELLS; SODIUM ARSENITE; MESSENGER-RNA; NITRIC-OXIDE; SIGNALING PATHWAY; HEPATOMA-CELLS	Heme oxygenase-1 (HO-1) gene expression is induced by various oxidative stress stimuli including sodium arsenite. Since mitogen-activated protein kinases (MAPKs) are involved in stress signaling we investigated the role of arsenite and MAPKs for HO-1 gene regulation in primary rat hepatocytes. The Jun N-terminal kinase (JNK) inhibitor SP600125 decreased sodium arsenite-mediated induction of HO-1 mRNA expression. HO-1 protein and luciferase activity of reporter gene constructs with -754 bp of the HO-1 promoter were induced by overexpression of kinases of the JNK pathway and MKK3. By contrast, overexpression of Raf-1 and ERK2 did not affect expression whereas overexpression of p38alpha, beta, and delta decreased and p38gamma increased HO-1 expression. Electrophoretic mobility shift assays (EMSA) revealed that a CRE/AP-1 element (-668/-654) bound c-Jun, a target of the JNK pathway. Deletion or mutation of the CRE/AP-1 obliterated the JNK- and c-Jun-dependent up-regulation of luciferase activity. EMSA also showed that an E-box (-47/-42) was bound by a putative p38 target c-Max. Mutation of the E-box strongly reduced MKK3, p38 isoform-, and c-Max-dependent effects on luciferase activity. Thus, the HO-1 CRE/AP-1 element mediates HO-1 gene induction via activation of JNK/c-Jun whereas p38 isoforms act through a different mechanism via the E-box.	Univ Gottingen, Inst Biochem & Mol Zellbiol, D-37073 Gottingen, Germany; Univ Giessen, Inst Klin Chem & Pathobiochem, D-35393 Giessen, Germany	University of Gottingen; Justus Liebig University Giessen	Kietzmann, T (corresponding author), Univ Gottingen, Inst Biochem & Mol Zellbiol, Humboldtallee 23, D-37073 Gottingen, Germany.	tkietzm@gwdg.de	Samoylenko, Anatoliy/AAZ-9623-2021; Samoylenko, Anatoliy/HDM-7330-2022; Immenschuh, Stephan/AAM-9181-2020; Samoylenko, Anatoliy/AAN-1992-2021	Samoylenko, Anatoliy/0000-0002-0240-897X; Immenschuh, Stephan/0000-0003-3722-5791; Samoylenko, Anatoliy/0000-0002-0240-897X; Kietzmann, Thomas/0000-0003-0242-8636				Alam J, 2000, J BIOL CHEM, V275, P27694; Alam J, 1999, J BIOL CHEM, V274, P26071, DOI 10.1074/jbc.274.37.26071; ALAM J, 1994, J BIOL CHEM, V269, P1001; ALAM J, 1995, J BIOL CHEM, V270, P11977, DOI 10.1074/jbc.270.20.11977; APPLEGATE LA, 1991, CANCER RES, V51, P974; Chen G, 2000, J BIOL CHEM, V275, P38973, DOI 10.1074/jbc.M002856200; Chen K, 2000, CELL MOL BIOL, V46, P609; Chen W, 1998, MOL CELL BIOL, V18, P5178, DOI 10.1128/MCB.18.9.5178; Choi AMK, 1996, AM J RESP CELL MOL, V15, P9, DOI 10.1165/ajrcmb.15.1.8679227; Davis RJ, 1999, BIOCHEM SOC SYMP, P1; DENT P, 1995, MOL CELL BIOL, V15, P4125; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; Elbirt KK, 1998, J BIOL CHEM, V273, P8922, DOI 10.1074/jbc.273.15.8922; FEIG LA, 1988, MOL CELL BIOL, V8, P3235, DOI 10.1128/MCB.8.8.3235; GOMEZ N, 1991, NATURE, V353, P170, DOI 10.1038/353170a0; Gudi T, 1996, J BIOL CHEM, V271, P4597; HAI T, 1991, P NATL ACAD SCI USA, V88, P3720, DOI 10.1073/pnas.88.9.3720; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; Han JH, 1996, J BIOL CHEM, V271, P2886, DOI 10.1074/jbc.271.6.2886; HOEFFLER JP, 1988, SCIENCE, V242, P1430, DOI 10.1126/science.2974179; HURLIN PJ, 1995, EMBO J, V14, P5646, DOI 10.1002/j.1460-2075.1995.tb00252.x; Immenschuh S, 1998, MOL PHARMACOL, V53, P483, DOI 10.1124/mol.53.3.483; Immenschuh S, 1998, BIOCHEM J, V334, P141, DOI 10.1042/bj3340141; IMMENSCHUH S, 1995, BIOCHEMISTRY-US, V34, P13407, DOI 10.1021/bi00041a018; Ishii T, 2000, J BIOL CHEM, V275, P16023, DOI 10.1074/jbc.275.21.16023; IVASHKIV LB, 1990, MOL CELL BIOL, V10, P1609, DOI 10.1128/MCB.10.4.1609; Jacobs JM, 1999, TOXICOL APPL PHARM, V157, P51, DOI 10.1006/taap.1999.8659; Jiang Y, 1996, J BIOL CHEM, V271, P17920, DOI 10.1074/jbc.271.30.17920; Jiang Y, 1997, J BIOL CHEM, V272, P30122, DOI 10.1074/jbc.272.48.30122; Karin M, 1997, CURR OPIN CELL BIOL, V9, P240, DOI 10.1016/S0955-0674(97)80068-3; KEYSE SM, 1989, P NATL ACAD SCI USA, V86, P99, DOI 10.1073/pnas.86.1.99; Kietzmann T, 1999, BLOOD, V94, P4177, DOI 10.1182/blood.V94.12.4177.424k14_4177_4185; Kietzmann T, 1997, BIOCHEM J, V321, P17, DOI 10.1042/bj3210017; Kietzmann T, 1999, MOL PHARMACOL, V56, P46, DOI 10.1124/mol.56.1.46; KOIZUMI T, 1995, J BIOL CHEM, V270, P21779, DOI 10.1074/jbc.270.37.21779; KRETZNER L, 1992, NATURE, V359, P426, DOI 10.1038/359426a0; Kyriakis JM, 2001, PHYSIOL REV, V81, P807, DOI 10.1152/physrev.2001.81.2.807; Lander HM, 1997, J BIOL CHEM, V272, P17810, DOI 10.1074/jbc.272.28.17810; Lavoie JN, 1996, J BIOL CHEM, V271, P20608, DOI 10.1074/jbc.271.34.20608; Lee PJ, 1997, J BIOL CHEM, V272, P5375, DOI 10.1074/jbc.272.9.5375; Lee PJ, 2000, AM J PHYSIOL-LUNG C, V279, pL175, DOI 10.1152/ajplung.2000.279.1.L175; Liu YS, 1996, FREE RADICAL BIO MED, V21, P771, DOI 10.1016/0891-5849(96)00176-1; Lu TH, 1998, GENE, V207, P177, DOI 10.1016/S0378-1119(97)00623-9; Ludwig S, 1998, J BIOL CHEM, V273, P1917, DOI 10.1074/jbc.273.4.1917; Maeshima H, 1996, NUCLEIC ACIDS RES, V24, P2959, DOI 10.1093/nar/24.15.2959; Maines MD, 1997, ANNU REV PHARMACOL, V37, P517, DOI 10.1146/annurev.pharmtox.37.1.517; MAINES MD, 1988, FASEB J, V2, P2557, DOI 10.1096/fasebj.2.10.3290025; Masuya Y, 1998, J BIOCHEM-TOKYO, V124, P628; McCoubrey WK, 1997, EUR J BIOCHEM, V247, P725, DOI 10.1111/j.1432-1033.1997.00725.x; Meroni G, 1997, EMBO J, V16, P2892, DOI 10.1093/emboj/16.10.2892; MULLER RM, 1987, J BIOL CHEM, V262, P6795; MURRE C, 1994, BBA-GENE STRUCT EXPR, V1218, P129, DOI 10.1016/0167-4781(94)90001-9; Nebreda AR, 2000, TRENDS BIOCHEM SCI, V25, P257, DOI 10.1016/S0968-0004(00)01595-4; Oguro T, 1998, J PHARMACOL EXP THER, V287, P773; OKINAGA S, 1993, EUR J BIOCHEM, V212, P167, DOI 10.1111/j.1432-1033.1993.tb17647.x; Otterbein LE, 2000, NAT MED, V6, P422, DOI 10.1038/74680; PILZ RB, 1995, FASEB J, V9, P552, DOI 10.1096/fasebj.9.7.7737465; Poss KD, 1997, P NATL ACAD SCI USA, V94, P10919, DOI 10.1073/pnas.94.20.10919; Pramanik R, 2003, J BIOL CHEM, V278, P4831, DOI 10.1074/jbc.M207732200; Raingeaud J, 1996, MOL CELL BIOL, V16, P1247; RIZZARDINI M, 1993, BIOCHEM J, V290, P343, DOI 10.1042/bj2900343; Sandau KB, 1999, MOL PHARMACOL, V56, P744; SAWADOGO M, 1985, CELL, V43, P165, DOI 10.1016/0092-8674(85)90021-2; SCHONTHAL A, 1989, ONCOGENE, V4, P629; Shaulian E, 2001, ONCOGENE, V20, P2390, DOI 10.1038/sj.onc.1204383; Silberbach M, 2001, CELL SIGNAL, V13, P221, DOI 10.1016/S0898-6568(01)00139-5; Soh JW, 2001, J BIOL CHEM, V276, P16406, DOI 10.1074/jbc.C100079200; Takai Y, 2001, PHYSIOL REV, V81, P153, DOI 10.1152/physrev.2001.81.1.153; Takeda A, 2000, J BIOL CHEM, V275, P5395, DOI 10.1074/jbc.275.8.5395; Tchan MC, 2000, J BIOL CHEM, V275, P37454, DOI 10.1074/jbc.M004264200; TENHUNEN R, 1968, P NATL ACAD SCI USA, V61, P748, DOI 10.1073/pnas.61.2.748; Tibbles LA, 1999, CELL MOL LIFE SCI, V55, P1230, DOI 10.1007/s000180050369; Vuong H, 2000, J BIOL CHEM, V275, P32250, DOI 10.1074/jbc.M005227200; Whitmarsh AJ, 1997, MOL CELL BIOL, V17, P2360, DOI 10.1128/MCB.17.5.2360; Xu SC, 1996, P NATL ACAD SCI USA, V93, P5291, DOI 10.1073/pnas.93.11.5291; Yu R, 2000, J BIOL CHEM, V275, P39907, DOI 10.1074/jbc.M004037200; ZERVOS AS, 1995, P NATL ACAD SCI USA, V92, P10531, DOI 10.1073/pnas.92.23.10531; Zhang H, 1997, J BIOL CHEM, V272, P17416, DOI 10.1074/jbc.272.28.17416	78	164	168	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 16	2003	278	20					17927	17936		10.1074/jbc.M203929200	http://dx.doi.org/10.1074/jbc.M203929200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677YX	12637567	hybrid			2022-12-25	WOS:000182838300043
J	Tan, LJ; Peng, HB; Osaki, M; Choy, BK; Auron, PE; Sandell, LJ; Goldring, MB				Tan, LJ; Peng, HB; Osaki, M; Choy, BK; Auron, PE; Sandell, LJ; Goldring, MB			Egr-1 mediates transcriptional repression of COL2A1 promoter activity by interleukin-1 beta	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; IMMEDIATE-EARLY GENE; II PROCOLLAGEN GENE; NF-KAPPA-B; HUMAN CHONDROCYTES; FACTOR-ALPHA; CELL-LINE; C-FOS; DIFFERENTIAL EXPRESSION; NEGATIVE MODULATOR	Following induction and activation of the early growth response (Egr)-1 transcription factor in human chondrocytes, interleukin-1beta (IL-1beta) suppresses the expression of the type II collagen gene (COL2A1), associated with induction of Egr-1 binding activity in nuclear extracts. The COL2A1 proximal promoter contains overlapping binding sites for Egr-1 and Sp1 family members at -119/-112 bp and -81/-74 bp. Mutations that block binding of Sp1 and Sp3 to either site markedly reduce constitutive expression of the core promoter. IL-1beta-induced Egr-1 binds strongly to the -119/-112 bp site, and mutations that block Egr-1 binding prevent inhibition by IL-1beta. Cotransfection with pCMV-Egr1 potentiates the inhibition of COL2A1 promoter activity by IL-1beta, whereas overexpression of dominant-negative Egr-1 mutant, Wilm's tumor-1 (WT1)/Egr1, Sp1, or Sp3 reverses the inhibition by IL-1beta. Cotransfection of pGL2-COL2/Gal4,in which we substituted the critical residue for Egr-1 binding with a Gal4 binding domain and a pCMV-Gal4-Egr1 chimera permits an inhibitory response to IL-1beta that is reversed by overexpression of Gal4-CBP. Our results indicate that IL-1beta-induced activation of Egr-1 binding is required for inhibition of COL2A1 proximal promoter activity and suggest that Egr-1 acts as a repressor of a constitutively expressed collagen gene by preventing interactions between Sp1 and the general transcriptional machinery.	Harvard Inst Med, New England Baptist Bone & Joint Inst, Boston, MA 02115 USA; Beth Israel Deaconess Med Ctr, Div Rheumatol, Boston, MA 02115 USA; Washington Univ, Sch Med, Dept Orthopaed Surg, St Louis, MO 63110 USA	Harvard University; Harvard Medical School; New England Baptist Hospital; Harvard University; Beth Israel Deaconess Medical Center; Washington University (WUSTL)	Goldring, MB (corresponding author), Harvard Inst Med, New England Baptist Bone & Joint Inst, Room 246,4 Blackfan Circle, Boston, MA 02115 USA.	mgoldrin@bidmc.harvard.edu			NCI NIH HHS [CA68544] Funding Source: Medline; NIAMS NIH HHS [AR45378] Funding Source: Medline; NIA NIH HHS [AG22021] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA068544] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR045378] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG022021, R56AG022021] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		AICHER WK, 1994, J IMMUNOL, V152, P5940; ALAKOKKO L, 1995, BIOCHEM J, V308, P923, DOI 10.1042/bj3080923; Auron PE, 1998, CYTOKINE GROWTH F R, V9, P221, DOI 10.1016/S1359-6101(98)00018-5; BENTON HP, 1988, BIOCHEM BIOPH RES CO, V154, P421, DOI 10.1016/0006-291X(88)90703-6; CAO XM, 1992, J BIOL CHEM, V267, P1345; CHASMAN DI, 1989, MOL CELL BIOL, V9, P4746, DOI 10.1128/MCB.9.11.4746; Chaudhary LR, 1996, MOL CELL BIOCHEM, V156, P69; CSERJESI P, 1995, DEVELOPMENT, V121, P1099; Dharmavaram RM, 1997, J BIOL CHEM, V272, P26918, DOI 10.1074/jbc.272.43.26918; Di Battista JA, 1999, OSTEOARTHR CARTILAGE, V7, P395, DOI 10.1053/joca.1998.0222; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Ding GJF, 1998, J BIOL CHEM, V273, P28897, DOI 10.1074/jbc.273.44.28897; Du BH, 2000, J BIOL CHEM, V275, P39039, DOI 10.1074/jbc.M005159200; EDWARDS DR, 1992, EMBO J, V11, P2415, DOI 10.1002/j.1460-2075.1992.tb05306.x; Fitzgerald KA, 1999, J IMMUNOL, V162, P4920; GASHLER AL, 1993, MOL CELL BIOL, V13, P4556, DOI 10.1128/MCB.13.8.4556; Ghayor C, 2000, J BIOL CHEM, V275, P27421; Ghayor C, 2001, J BIOL CHEM, V276, P36881, DOI 10.1074/jbc.M105083200; Goldring MB, 2000, ARTHRITIS RHEUM-US, V43, P1916, DOI 10.1002/1529-0131(200009)43:9<1916::AID-ANR2>3.0.CO;2-I; GOLDRING MB, 1994, J CLIN INVEST, V94, P2307, DOI 10.1172/JCI117595; GOLDRING MB, 1994, J CELL BIOCHEM, V54, P85, DOI 10.1002/jcb.240540110; GOLDRING MB, 1988, J CLIN INVEST, V82, P2026, DOI 10.1172/JCI113823; Greenwel P, 2000, MOL CELL BIOL, V20, P912, DOI 10.1128/MCB.20.3.912-918.2000; Haas TL, 1999, J BIOL CHEM, V274, P22679, DOI 10.1074/jbc.274.32.22679; HAGEN G, 1994, EMBO J, V13, P3843, DOI 10.1002/j.1460-2075.1994.tb06695.x; Hallahan DE, 1995, J BIOL CHEM, V270, P30303, DOI 10.1074/jbc.270.51.30303; HORTON WE, 1992, DNA CELL BIOL, V11, P193, DOI 10.1089/dna.1992.11.193; Huang RP, 1999, J CELL BIOCHEM, V73, P227, DOI 10.1002/(SICI)1097-4644(19990501)73:2<227::AID-JCB9>3.0.CO;2-B; Inagaki Y, 2001, J BIOL CHEM, V276, P16573, DOI 10.1074/jbc.M010485200; Ito K, 2000, MOL CELL BIOL, V20, P6891, DOI 10.1128/MCB.20.18.6891-6903.2000; Jain N, 1996, J BIOL CHEM, V271, P13530, DOI 10.1074/jbc.271.23.13530; Ji CH, 1997, J BIOL CHEM, V272, P21260, DOI 10.1074/jbc.272.34.21260; Khachigian LM, 1996, SCIENCE, V271, P1427, DOI 10.1126/science.271.5254.1427; LEE SL, 1995, J BIOL CHEM, V270, P9971, DOI 10.1074/jbc.270.17.9971; Lefebvre V, 1998, MATRIX BIOL, V16, P529; Lefebvre V, 1998, EMBO J, V17, P5718, DOI 10.1093/emboj/17.19.5718; Leung KKH, 1998, J CELL BIOL, V141, P1291, DOI 10.1083/jcb.141.6.1291; Lim CP, 1998, ONCOGENE, V16, P2915, DOI 10.1038/sj.onc.1201834; Liu CT, 2000, J BIOL CHEM, V275, P20315, DOI 10.1074/jbc.M909046199; Liu CT, 1999, J BIOL CHEM, V274, P4400, DOI 10.1074/jbc.274.7.4400; LIU JW, 1993, CELL GROWTH DIFFER, V4, P611; Loeser RF, 2000, OSTEOARTHR CARTILAGE, V8, P96, DOI 10.1053/joca.1999.0277; MADDEN SL, 1991, SCIENCE, V253, P1550, DOI 10.1126/science.1654597; Marshall OJ, 2000, MOL GENET METAB, V71, P455, DOI 10.1006/mgme.2000.3081; MCMAHON AP, 1990, DEVELOPMENT, V108, P281; MINOWA T, 1994, J BIOL CHEM, V269, P11656; MUKHOPADHYAY K, 1995, J BIOL CHEM, V270, P27711, DOI 10.1074/jbc.270.46.27711; Murakami S, 2000, P NATL ACAD SCI USA, V97, P1113, DOI 10.1073/pnas.97.3.1113; Murakami S, 2000, J BIOL CHEM, V275, P3687, DOI 10.1074/jbc.275.5.3687; Murray D, 2000, J BIOL CHEM, V275, P3610, DOI 10.1074/jbc.275.5.3610; MUTHUKKUMAR S, 1995, MOL CELL BIOL, V15, P6262; NGUYEN HQ, 1993, CELL, V72, P197, DOI 10.1016/0092-8674(93)90660-I; Nowling TK, 2000, J BIOL CHEM, V275, P3810, DOI 10.1074/jbc.275.6.3810; Okazaki K, 2002, J BIOL CHEM, V277, P31526, DOI 10.1074/jbc.M202815200; Osaki M, 2003, BIOCHEM J, V369, P103, DOI 10.1042/BJ20020928; Philipsen S, 1999, NUCLEIC ACIDS RES, V27, P2991, DOI 10.1093/nar/27.15.2991; Poole A.R., 1997, ARTHRITIS ALLIED CON, P255; Riquet FB, 2001, J BIOL CHEM, V276, P38665, DOI 10.1074/jbc.M009881200; Robbins JR, 2000, ARTHRITIS RHEUM, V43, P2189, DOI 10.1002/1529-0131(200010)43:10<2189::AID-ANR6>3.0.CO;2-S; Rudders S, 2001, J BIOL CHEM, V276, P3302, DOI 10.1074/jbc.M006507200; RYAN MC, 1990, GENOMICS, V8, P41, DOI 10.1016/0888-7543(90)90224-I; SANDELL LJ, 1991, J CELL BIOL, V114, P1307, DOI 10.1083/jcb.114.6.1307; Sandell LJ, 1996, CONNECT TISSUE RES, V35, P1, DOI 10.3109/03008209609029168; Santiago FS, 1999, AM J PATHOL, V155, P897, DOI 10.1016/S0002-9440(10)65189-9; SAVAGNER P, 1995, DNA CELL BIOL, V14, P501, DOI 10.1089/dna.1995.14.501; Silverman ES, 1999, AM J PATHOL, V154, P665, DOI 10.1016/S0002-9440(10)65312-6; Silverman ES, 1998, BIOCHEM J, V336, P183, DOI 10.1042/bj3360183; Sperling P, 2000, EUR J BIOCHEM, V267, P3801, DOI 10.1046/j.1432-1327.2000.01418.x; Srivastava S, 1998, J CLIN INVEST, V102, P1850, DOI 10.1172/JCI4561; SUKHATME VP, 1988, CELL, V53, P37, DOI 10.1016/0092-8674(88)90485-0; SUVA LJ, 1991, MOL CELL BIOL, V11, P2503, DOI 10.1128/MCB.11.5.2503; TYLER JA, 1988, COLLAGEN REL RES, V8, P393; VIKKULA M, 1992, BIOCHEM J, V285, P287, DOI 10.1042/bj2850287; Wang D, 1997, ONCOGENE, V14, P2291, DOI 10.1038/sj.onc.1201069; Wang FL, 2000, OSTEOARTHR CARTILAGE, V8, P161, DOI 10.1053/joca.1999.0295; WANG LQ, 1991, J BIOL CHEM, V266, P19878; Xu SC, 2001, DNA CELL BIOL, V20, P359, DOI 10.1089/10445490152122479	77	106	109	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 16	2003	278	20					17688	17700		10.1074/jbc.M301676200	http://dx.doi.org/10.1074/jbc.M301676200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677YX	12637574	hybrid			2022-12-25	WOS:000182838300015
J	Wildey, GM; Patil, S; Howe, PH				Wildey, GM; Patil, S; Howe, PH			Smad3 potentiates transforming growth factor beta (TGF beta)-induced apoptosis and expression of the BH3-only protein bim in WEHI 231 B lymphocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BCL-2 FAMILY-MEMBER; SIGNAL-REGULATED KINASE; FYVE DOMAIN PROTEIN; TGF-BETA; INDUCE APOPTOSIS; BINDING PROTEIN; DOWN-REGULATION; BH3 DOMAIN; SURVIVAL; ACTIVATION	Transforming growth factor-beta (TGFbeta) is a potent growth inhibitor and inducer of apoptosis in B lymphocytes and is essential for immune regulation and maintenance of self-tolerance. Here we show that exogenous overexpression of Smad3 potentiates TGFbeta-induced apoptosis and expression of the pro-apoptotic protein Bim in WEHI 231 B lymphocytes. Overexpression of dominant-negative forms of Smad3 abrogate these TGFbeta-induced responses. We also demonstrate that TGFbeta induces Bim protein expression concomitant with its induction of apoptosis in the mouse progenitor B lymphocyte cell line, Ba/F3. Enhanced expression of Bim protein induced by TGFbeta is associated with an increased association of Bim with Bcl-2 and a concomitant loss of mitochondrial membrane potential. Furthermore, we find that the anti-apoptotic effect of the pro-survival cytokine CD40 results in the abrogation of TGFbeta-mediated Bim induction. Our data provide the first evidence of Bim expression levels that are increased by the addition of a pro-apoptotic cytokine, TGFbeta, and also suggest that the TGFbeta-specific transcription factor Smad3 plays a role in mediating Bim expression levels and apoptosis.	Cleveland Clin Fdn, Lerner Res Inst, Dept Cell Biol, Cleveland, OH 44195 USA	Cleveland Clinic Foundation	Howe, PH (corresponding author), Cleveland Clin Fdn, Lerner Res Inst, Dept Cell Biol, NC-1, Cleveland, OH 44195 USA.	howep@ccf.org		Wildey, Gary/0000-0001-7105-1313	NATIONAL CANCER INSTITUTE [R01CA055536, R29CA055536, R01CA080095] Funding Source: NIH RePORTER; NCI NIH HHS [CA80095, CA55536] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Arsura M, 1996, IMMUNITY, V5, P31, DOI 10.1016/S1074-7613(00)80307-6; Atfi A, 1997, J BIOL CHEM, V272, P1429, DOI 10.1074/jbc.272.3.1429; Bakin AV, 2000, J BIOL CHEM, V275, P36803, DOI 10.1074/jbc.M005912200; Bhowmick NA, 2001, MOL BIOL CELL, V12, P27, DOI 10.1091/mbc.12.1.27; Bouillet P, 1999, SCIENCE, V286, P1735, DOI 10.1126/science.286.5445.1735; Bouillet P, 2001, MAMM GENOME, V12, P163, DOI 10.1007/s003350010242; Bouillet P, 2002, NATURE, V415, P922, DOI 10.1038/415922a; Brodin G, 1999, CANCER RES, V59, P2731; Brown TL, 1999, J BIOL CHEM, V274, P23256, DOI 10.1074/jbc.274.33.23256; Chen RH, 1997, CELL GROWTH DIFFER, V8, P821; Chen X, 1997, NATURE, V389, P85, DOI 10.1038/38008; Curnock AP, 1998, CELL IMMUNOL, V187, P77, DOI 10.1006/cimm.1998.1335; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; DEL PL, 1997, SCIENCE, V278, P687; Dijkers PF, 2002, J CELL BIOL, V156, P531, DOI 10.1083/jcb.200108084; Dijkers PF, 2000, CURR BIOL, V10, P1201, DOI 10.1016/S0960-9822(00)00728-4; Engel ME, 1998, J BIOL CHEM, V273, P9921, DOI 10.1074/jbc.273.16.9921; Engel ME, 1999, J BIOL CHEM, V274, P37413, DOI 10.1074/jbc.274.52.37413; Francis JM, 2000, J BIOL CHEM, V275, P39137, DOI 10.1074/jbc.M007212200; Frey RS, 1997, CANCER RES, V57, P628; Fruman DA, 1999, SCIENCE, V283, P393, DOI 10.1126/science.283.5400.393; Hanafusa H, 1999, J BIOL CHEM, V274, P27161, DOI 10.1074/jbc.274.38.27161; Harris CA, 2001, J BIOL CHEM, V276, P37754; HARTSOUGH MT, 1995, J BIOL CHEM, V270, P7117, DOI 10.1074/jbc.270.13.7117; Hocevar BA, 1999, EMBO J, V18, P1345, DOI 10.1093/emboj/18.5.1345; Hocevar BA, 2001, EMBO J, V20, P2789, DOI 10.1093/emboj/20.11.2789; Hsing AY, 1996, CANCER RES, V56, P5146; Ishisaki A, 1999, J BIOL CHEM, V274, P13637, DOI 10.1074/jbc.274.19.13637; Ishisaki A, 1998, J BIOL CHEM, V273, P24293, DOI 10.1074/jbc.273.38.24293; Jang CW, 2002, NAT CELL BIOL, V4, P51, DOI 10.1038/ncb731; Kelekar A, 1998, TRENDS CELL BIOL, V8, P324, DOI 10.1016/S0962-8924(98)01321-X; Kim BC, 2002, MOL CELL BIOL, V22, P1369, DOI 10.1128/MCB.22.5.1369-1378.2002; KYPRIANOU N, 1989, MOL ENDOCRINOL, V3, P1515, DOI 10.1210/mend-3-10-1515; Labbe E, 1998, MOL CELL, V2, P109, DOI 10.1016/S1097-2765(00)80119-7; Larisch S, 2000, NAT CELL BIOL, V2, P915, DOI 10.1038/35046566; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; LIN JK, 1992, CANCER RES, V52, P385; MAMI Y, 2001, FEBS LETT, V509, P135; Marani M, 2002, MOL CELL BIOL, V22, P3577, DOI 10.1128/MCB.22.11.3577-3589.2002; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; Massague J, 2000, GENE DEV, V14, P627; Miura S, 2000, MOL CELL BIOL, V20, P9346, DOI 10.1128/MCB.20.24.9346-9355.2000; Morris SM, 2001, TRAFFIC, V2, P111, DOI 10.1034/j.1600-0854.2001.020206.x; Mucsi I, 1996, J BIOL CHEM, V271, P16567, DOI 10.1074/jbc.271.28.16567; O'Connor L, 1998, EMBO J, V17, P384, DOI 10.1093/emboj/17.2.384; O'Reilly LA, 2000, AM J PATHOL, V157, P449, DOI 10.1016/S0002-9440(10)64557-9; OBERHAMMER FA, 1992, P NATL ACAD SCI USA, V89, P5408, DOI 10.1073/pnas.89.12.5408; Patil S, 2000, J BIOL CHEM, V275, P38363, DOI 10.1074/jbc.M004861200; Perlman R, 2001, NAT CELL BIOL, V3, P708, DOI 10.1038/35087019; Piek E, 1999, FASEB J, V13, P2105, DOI 10.1096/fasebj.13.15.2105; Putcha GV, 2001, NEURON, V29, P615, DOI 10.1016/S0896-6273(01)00238-0; Puthalakath H, 2002, CELL DEATH DIFFER, V9, P505, DOI 10.1038/sj.cdd.4400998; Puthalakath H, 1999, MOL CELL, V3, P287, DOI 10.1016/S1097-2765(00)80456-6; Sano Y, 1999, J BIOL CHEM, V274, P8949, DOI 10.1074/jbc.274.13.8949; Shinjyo T, 2001, MOL CELL BIOL, V21, P854, DOI 10.1128/MCB.21.3.854-864.2001; Stahl M, 2002, J IMMUNOL, V168, P5024, DOI 10.4049/jimmunol.168.10.5024; Sugiyama T, 2002, ONCOGENE, V21, P4944, DOI 10.1038/sj.onc.1205621; Tsukazaki T, 1998, CELL, V95, P779, DOI 10.1016/S0092-8674(00)81701-8; Vander Heiden MG, 1999, NAT CELL BIOL, V1, pE209, DOI 10.1038/70237; Whitfield J, 2001, NEURON, V29, P629, DOI 10.1016/S0896-6273(01)00239-2; Wrana JL, 2000, CELL, V100, P189, DOI 10.1016/S0092-8674(00)81556-1; Yamamura Y, 2000, J BIOL CHEM, V275, P36295, DOI 10.1074/jbc.M006023200; YAN ZF, 1994, J BIOL CHEM, V269, P13231; Yanagisawa K, 1998, ONCOGENE, V17, P1743, DOI 10.1038/sj.onc.1202052; Yeo CY, 1999, J BIOL CHEM, V274, P26584, DOI 10.1074/jbc.274.37.26584; Zamzami N, 2000, METHOD ENZYMOL, V322, P208; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3; Zong WX, 2001, GENE DEV, V15, P1481, DOI 10.1101/gad.897601	68	84	89	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 16	2003	278	20					18069	18077		10.1074/jbc.M211958200	http://dx.doi.org/10.1074/jbc.M211958200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677YX	12637528	hybrid			2022-12-25	WOS:000182838300063
J	Wu, J; Woodard, RW				Wu, J; Woodard, RW			Escherichia coli YrbI is 3-deoxy-D-manno-octulosonate 8-phosphate phosphatase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CONTINUOUS SPECTROPHOTOMETRIC ASSAY; P-TYPE ATPASE; SALMONELLA-TYPHIMURIUM; INORGANIC-PHOSPHATE; MOLECULAR-CLONING; DATABASE SEARCH; GENE-EXPRESSION; LETHAL MUTANT; SYNTHETASE; SYNTHASE	3-Deoxy-D-manno-octulosonate 8-phosphate (KDO 8-P) phosphatase, which catalyzes the hydrolysis of KDO 8-P to KDO and inorganic phosphate, is the last enzyme in the KDO biosynthetic pathway for which the gene has not been identified. Wild-type KDO 8-P phosphatase was purified from Escherichia coli B, and the N-terminal amino acid sequence matched a hypothetical protein encoded by the E. coli open reading frame, yrbI. The yrbI gene, which encodes for a protein of 188 amino acids, was cloned, and the gene product was overexpressed in E. coli. The recombinant enzyme is a tetramer and requires a divalent metal cofactor for activity. Optimal enzymatic activity is observed at pH 5.5. The enzyme is highly specific for KDO 8-P with an apparent K-m of 75 muM and a k(cat) of 175 s(-1) in the presence of 1 mM Mg2+. Amino acid sequence analysis indicates that KDO 8-P phosphatase is a member of the haloacid dehalogenase hydrolase superfamily.	Univ Michigan, Dept Med Chem, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Chem, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Woodard, RW (corresponding author), Univ Michigan, Coll Pharm, 428 Church St, Ann Arbor, MI 48109 USA.			Woodard, Ronald/0000-0002-7472-3653	NIGMS NIH HHS [GM 53069] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM053069] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Aravind L, 1998, TRENDS BIOCHEM SCI, V23, P127, DOI 10.1016/S0968-0004(98)01189-X; Baranov PV, 2001, NUCLEIC ACIDS RES, V29, P264, DOI 10.1093/nar/29.1.264; BELUNIS CJ, 1995, J BIOL CHEM, V270, P27646, DOI 10.1074/jbc.270.46.27646; BERGER H, 1975, BIOCHEM SOC T, V3, P1096, DOI 10.1042/bst0031096; CLEMENTZ T, 1991, J BIOL CHEM, V266, P9687; DOTSON GD, 1995, J BIOL CHEM, V270, P13698, DOI 10.1074/jbc.270.23.13698; ENGELBERGKULKA H, 1994, MOL MICROBIOL, V11, P3, DOI 10.1111/j.1365-2958.1994.tb00283.x; GHALAMBOR MA, 1966, J BIOL CHEM, V241, P3222; GOLDMAN RC, 1986, J BIOL CHEM, V261, P5831; GOLDMAN RC, 1985, J BACTERIOL, V163, P256, DOI 10.1128/JB.163.1.256-261.1985; Jelakovic S, 1996, FEBS LETT, V391, P157, DOI 10.1016/0014-5793(96)00724-7; KOONIN EV, 1994, J MOL BIOL, V244, P125, DOI 10.1006/jmbi.1994.1711; LANZETTA PA, 1979, ANAL BIOCHEM, V100, P95, DOI 10.1016/0003-2697(79)90115-5; Lunn JE, 2000, P NATL ACAD SCI USA, V97, P12914, DOI 10.1073/pnas.230430197; Parsons JF, 2002, PROTEINS, V46, P393, DOI 10.1002/prot.10057; Radaev S, 2000, ACTA CRYSTALLOGR D, V56, P516, DOI 10.1107/S0907444900002389; Radaev S, 2000, J BIOL CHEM, V275, P9476, DOI 10.1074/jbc.275.13.9476; RAETZ CRH, 1990, ANNU REV BIOCHEM, V59, P129, DOI 10.1146/annurev.bi.59.070190.001021; Raetz CRH, 2002, ANNU REV BIOCHEM, V71, P635, DOI 10.1146/annurev.biochem.71.110601.135414; RAY PH, 1980, J BACTERIOL, V142, P60, DOI 10.1128/JB.142.1.60-68.1980; RICK PD, 1982, J BACTERIOL, V150, P447, DOI 10.1128/JB.150.2.447-455.1982; RICK PD, 1977, J BIOL CHEM, V252, P4895; RICK PD, 1972, P NATL ACAD SCI USA, V69, P3756, DOI 10.1073/pnas.69.12.3756; Ridder IS, 1999, BIOCHEM J, V339, P223, DOI 10.1042/0264-6021:3390223; Rieger CE, 1997, ANAL BIOCHEM, V246, P86, DOI 10.1006/abio.1996.9962; SEKINE Y, 1994, J MOL BIOL, V235, P1406, DOI 10.1006/jmbi.1994.1097; Selengut JD, 2001, BIOCHEMISTRY-US, V40, P12704, DOI 10.1021/bi011405e; Sheflyan GY, 1998, J AM CHEM SOC, V120, P11027, DOI 10.1021/ja9816281; Stukey J, 1997, PROTEIN SCI, V6, P469; Tate WP, 1999, BIOCHEMISTRY-MOSCOW+, V64, P1342; Thaller MC, 1998, PROTEIN SCI, V7, P1647, DOI 10.1002/pro.5560070722; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Tzeng YL, 2002, J BIOL CHEM, V277, P24103, DOI 10.1074/jbc.M200931200; Wang WR, 2001, STRUCTURE, V9, P65, DOI 10.1016/S0969-2126(00)00558-X; WEBB MR, 1992, P NATL ACAD SCI USA, V89, P4884, DOI 10.1073/pnas.89.11.4884; WOISETSCHLAGER M, 1988, J BACTERIOL, V170, P5382, DOI 10.1128/jb.170.11.5382-5384.1988; WOISETSCHLAGER M, 1987, MOL GEN GENET, V207, P369, DOI 10.1007/BF00331603	38	57	59	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 16	2003	278	20					18117	18123		10.1074/jbc.M301983200	http://dx.doi.org/10.1074/jbc.M301983200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677YX	12639950	hybrid			2022-12-25	WOS:000182838300069
J	Gu, Y; Xu, YC; Wu, RF; Nwariaku, FE; Souza, RF; Flores, SC; Terada, LS				Gu, Y; Xu, YC; Wu, RF; Nwariaku, FE; Souza, RF; Flores, SC; Terada, LS			p47(phox) participates in activation of RelA in endothelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; PHAGOCYTE NADPH OXIDASE; TUMOR-NECROSIS-FACTOR; AMINO-TERMINAL KINASE; TRANSCRIPTION FACTOR; SH3 DOMAIN; IL-1 RECEPTOR; P65 SUBUNIT; PHOSPHATIDYLINOSITOL 3-KINASE; DEPENDENT MECHANISM	Activation of endothelial cell NF-kappaB by interleukin (IL)-1 constitutes an event critical to the progression of the innate immune response. In this context, oxidants have been associated with NF-kappaB activation, although the molecular source and mechanism of targeting have remained obscure. We found that RelA, essential for NF-kappaB activation by IL-1, was associated with the NADPH oxidase adapter protein p47(phox) in yeast two-hybrid, coprecipitation, and in vitro binding studies. RelA and p47-GFP also colocalized in endothelial cells in focal submembranous dorsoventral protrusions. Overexpression of p47(phox) synergized with IL-1beta in the activation of an artificial kappaB-luciferase reporter and specifically augmented IL-1beta-induced RelA transactivation activity. p47(phox) overexpression also greatly increased IL-1beta-stimulated RelA phosphorylation, whereas it had no effect on I-kappaB degradation or on RelA nuclear translocation or kappaB binding. The tandem SH3 domains of p47(phox) were found to associate with a proline-rich mid-region of RelA (RelA-PR) located between the Rel homology and transactivation domains. The RelA-PR peptide blocked interaction of p47(phox) and RelA, and ectopic expression of RelA-PR abrogated IL-1beta-induced transactivation of the NF-kappaB-dependent E-selectin promoter. Further, suppression of NADPH oxidase function through the inhibitor diphenylene iodonium, the superoxide dismutase mimetic Mn(III) tetrakis(4-benzoic acid) porphyrin ( MnTBAP), or expression of a dominant interfering mutant of a separate NADPH oxidase subunit (p67(V204A)) decreased IL-1beta-induced E-selectin promoter activation, suggesting that p47(phox) facilitates NF-kappaB activation through linkage with the NADPH oxidase. IL-1beta rapidly increased tyrosine phosphorylation of IL-1 type I receptor-associated proteins, suggesting that oxidants may operate through inactivation of local protein-tyrosine phosphatases in the proximal IL-1beta signaling pathway leading to RelA activation.	Dallas Vet Affairs Med Ctr, Dallas, TX 75216 USA; Webb Waring Lung Inst, Denver, CO 80262 USA; Univ Texas SW, Dept Internal Med, Dallas, TX 75216 USA; Univ Texas SW, Dept Surg, Dallas, TX 75216 USA	University of Texas System; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Southwestern Medical Center Dallas	Terada, LS (corresponding author), Dallas Vet Affairs Med Ctr, MC 151,4500 S Lancaster Rd, Dallas, TX 75216 USA.			Terada, Lance/0000-0001-7441-9734	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL061897, R01HL067256] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL067256, R01-HL67256, R01 HL061897, R01-HL61897] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Abid MR, 2000, FEBS LETT, V486, P252, DOI 10.1016/S0014-5793(00)02305-X; Abu-Amer Y, 1998, J BIOL CHEM, V273, P29417, DOI 10.1074/jbc.273.45.29417; Adachi O, 1998, IMMUNITY, V9, P143, DOI 10.1016/S1074-7613(00)80596-8; Ago T, 1999, J BIOL CHEM, V274, P33644, DOI 10.1074/jbc.274.47.33644; Arbibe L, 2000, NAT IMMUNOL, V1, P533, DOI 10.1038/82797; Are AF, 2000, EXP CELL RES, V256, P533, DOI 10.1006/excr.2000.4830; Barrett WC, 1999, J BIOL CHEM, V274, P34543, DOI 10.1074/jbc.274.49.34543; Bird TA, 1997, J BIOL CHEM, V272, P32606, DOI 10.1074/jbc.272.51.32606; Bonizzi G, 1999, MOL CELL BIOL, V19, P1950; Bonnard M, 2000, EMBO J, V19, P4976, DOI 10.1093/emboj/19.18.4976; Bowie AG, 1997, J BIOL CHEM, V272, P25941, DOI 10.1074/jbc.272.41.25941; Burns K, 2000, NAT CELL BIOL, V2, P346, DOI 10.1038/35014038; Cao ZD, 1996, NATURE, V383, P443, DOI 10.1038/383443a0; Cao ZD, 1996, SCIENCE, V271, P1128, DOI 10.1126/science.271.5252.1128; Chintala SK, 1998, J BIOL CHEM, V273, P13545, DOI 10.1074/jbc.273.22.13545; Cota-Gomez A, 2002, J BIOL CHEM, V277, P14390, DOI 10.1074/jbc.M108591200; Dahan I, 2002, J BIOL CHEM, V277, P8421, DOI 10.1074/jbc.M109778200; deMendez I, 1997, MOL CELL BIOL, V17, P2177, DOI 10.1128/MCB.17.4.2177; DiDonato JA, 1997, NATURE, V388, P548, DOI 10.1038/41493; Gorlach A, 2000, CIRC RES, V87, P26, DOI 10.1161/01.RES.87.1.26; Gu Y, 2002, EXP CELL RES, V272, P62, DOI 10.1006/excr.2001.5404; Gu Y, 2001, VIROLOGY, V286, P62, DOI 10.1006/viro.2001.0998; Han CH, 1998, J BIOL CHEM, V273, P16663, DOI 10.1074/jbc.273.27.16663; HENKEL T, 1993, NATURE, V365, P182, DOI 10.1038/365182a0; Hiroaki H, 2001, NAT STRUCT BIOL, V8, P526, DOI 10.1038/88591; Hoeflich KP, 2000, NATURE, V406, P86, DOI 10.1038/35017574; Huang J, 1999, J BIOL CHEM, V274, P19731, DOI 10.1074/jbc.274.28.19731; Jefferies C, 2001, MOL CELL BIOL, V21, P4544, DOI 10.1128/MCB.21.14.4544-4552.2001; Jefferies CA, 2000, J BIOL CHEM, V275, P3114, DOI 10.1074/jbc.275.5.3114; Johnson JL, 1998, J BIOL CHEM, V273, P35147, DOI 10.1074/jbc.273.52.35147; LEWIS H, 1994, MOL CELL BIOL, V14, P5701, DOI 10.1128/MCB.14.9.5701; Li JM, 2002, J BIOL CHEM, V277, P19952, DOI 10.1074/jbc.M110073200; Madge LA, 2000, J BIOL CHEM, V275, P15458, DOI 10.1074/jbc.M001237200; Madrid LV, 2000, MOL CELL BIOL, V20, P1626, DOI 10.1128/MCB.20.5.1626-1638.2000; Marmiroli S, 1998, FEBS LETT, V438, P49, DOI 10.1016/S0014-5793(98)01270-8; NAUMANN M, 1994, EMBO J, V13, P4597, DOI 10.1002/j.1460-2075.1994.tb06781.x; Ninomiya-Tsuji J, 1999, NATURE, V398, P252, DOI 10.1038/18465; Price MO, 2002, BLOOD, V99, P2653, DOI 10.1182/blood.V99.8.2653; Regnier CH, 1997, CELL, V90, P373, DOI 10.1016/S0092-8674(00)80344-X; Rothwarf DM, 1998, NATURE, V395, P297, DOI 10.1038/26261; SCHMITZ ML, 1995, J BIOL CHEM, V270, P15576, DOI 10.1074/jbc.270.26.15576; SCHRECK R, 1991, EMBO J, V10, P2247, DOI 10.1002/j.1460-2075.1991.tb07761.x; Shiose A, 2000, J BIOL CHEM, V275, P13793, DOI 10.1074/jbc.275.18.13793; Sizemore N, 1999, MOL CELL BIOL, V19, P4798; Sulciner DJ, 1996, MOL CELL BIOL, V16, P7115; Sumimoto H, 1996, J BIOL CHEM, V271, P22152, DOI 10.1074/jbc.271.36.22152; Takaesu G, 2000, MOL CELL, V5, P649, DOI 10.1016/S1097-2765(00)80244-0; Takehana K, 2002, BIOCHEM BIOPH RES CO, V293, P945, DOI 10.1016/S0006-291X(02)00322-4; Wang D, 1998, J BIOL CHEM, V273, P29411, DOI 10.1074/jbc.273.45.29411; Wei ZH, 1999, CIRC RES, V85, P682, DOI 10.1161/01.RES.85.8.682; Woronicz JD, 1997, SCIENCE, V278, P866, DOI 10.1126/science.278.5339.866; Xu YX, 2002, J BIOL CHEM, V277, P28051, DOI 10.1074/jbc.M202665200; Yoza BK, 1996, J BIOL CHEM, V271, P18306, DOI 10.1074/jbc.271.31.18306; Zandi E, 1997, CELL, V91, P243, DOI 10.1016/S0092-8674(00)80406-7	54	23	24	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 9	2003	278	19					17210	17217		10.1074/jbc.M210314200	http://dx.doi.org/10.1074/jbc.M210314200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677QG	12618429	hybrid			2022-12-25	WOS:000182818600103
J	Jiang, ZF; Zamanian-Daryoush, M; Nie, HQ; Silva, AM; Williams, BRG; Li, XX				Jiang, ZF; Zamanian-Daryoush, M; Nie, HQ; Silva, AM; Williams, BRG; Li, XX			Poly(dI center dot dC)-induced toll-like receptor 3 (TLR3)-mediated activation of NF kappa B and MAP kinase is through an interleukin-1 receptor-associated kinase (IRAK)-independent pathway employing the signaling components TLR3-TRAF6-TAK1-TAB2-PKR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOUBLE-STRANDED-RNA; INNATE IMMUNE-RESPONSE; IL-1 RECEPTOR; ADAPTER MOLECULE; GENE-EXPRESSION; DROSOPHILA TOLL; PROTEIN; TAK1; ALPHA; IRAK	Recent studies show that a member of the interleukin-1 (IL-1)/Toll receptor superfamily, Toll-like receptor 3 (TLR3), recognizes double-stranded RNA (dsRNA). Because of the similarity in their cytoplasmic domains, IL-1/Toll receptors share signaling components that associate with the IL-1 receptor, including IL-1 receptor-associated kinase (IRAK), MyD88, and TRAF6. However, we find that, in response to dsRNA, TLR3 can mediate the activation of both NFkappaB and mitogen-activated protein (MAP) kinases in IL-1-unresponsive mutant cell lines, including IRAK-deficient I1A and I3A cells, which are defective in a component that is downstream of IL-1R but upstream of IRAK. These results clearly indicate that TLR3 does not simply share the signaling components employed by the IL-1 receptor. Through biochemical analyses we have identified an IRAK-independent TLR3-mediated pathway. Upon binding of dsRNA to TLR3, TRAF6, TAK1, and TAB2 are recruited to the receptor to form a complex, which then translocates to the cytosol where TAK1 is phosphorylated and activated. The dsRNA-dependent protein kinase (PKR) is also detected in this signal-induced TAK1 complex. Kinase inactive mutants of TAK1 (TAK1DN) and PKR (PKRDN) inhibit poly(dI.dC)-induced TLR3-mediated NFkappaB activation, suggesting that both of these kinases play important roles in this pathway.	Cleveland Clin Fdn, Dept Immunol, Lerner Res Inst, Cleveland, OH 44195 USA; Cleveland Clin Fdn, Dept Canc Biol, Lerner Res Inst, Cleveland, OH 44195 USA	Cleveland Clinic Foundation; Cleveland Clinic Foundation	Li, XX (corresponding author), Cleveland Clin Fdn, Dept Immunol, Lerner Res Inst, 9500 Euclid Ave, Cleveland, OH 44195 USA.		Williams, Bryan R. G./A-5021-2009	Williams, Bryan R. G./0000-0002-4969-1151; Silva, Aristobolo/0000-0001-7473-7433	NIGMS NIH HHS [GM 600020] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Adachi O, 1998, IMMUNITY, V9, P143, DOI 10.1016/S1074-7613(00)80596-8; Akira S, 2001, NAT IMMUNOL, V2, P675, DOI 10.1038/90609; Alexopoulou L, 2001, NATURE, V413, P732, DOI 10.1038/35099560; Bowie A, 2000, J LEUKOCYTE BIOL, V67, P508, DOI 10.1002/jlb.67.4.508; Burns K, 2000, NAT CELL BIOL, V2, P346, DOI 10.1038/35014038; Cao ZD, 1996, NATURE, V383, P443, DOI 10.1038/383443a0; Chuang TH, 2000, EUR CYTOKINE NETW, V11, P372; Fitzgerald KA, 2001, NATURE, V413, P78, DOI 10.1038/35092578; Goh KC, 2000, EMBO J, V19, P4292, DOI 10.1093/emboj/19.16.4292; Hacker H, 2000, J EXP MED, V192, P595, DOI 10.1084/jem.192.4.595; Hayashi F, 2001, NATURE, V410, P1099, DOI 10.1038/35074106; Hemmi H, 2000, NATURE, V408, P740, DOI 10.1038/35047123; Horng T, 2002, NATURE, V420, P329, DOI 10.1038/nature01180; Horng T, 2001, NAT IMMUNOL, V2, P835, DOI 10.1038/ni0901-835; Iordanov MS, 2001, MOL CELL BIOL, V21, P61, DOI 10.1128/MCB.21.1.61-72.2001; Jacinto R, 2002, J IMMUNOL, V168, P6136, DOI 10.4049/jimmunol.168.12.6136; Jiang ZF, 2002, MOL CELL BIOL, V22, P7158, DOI 10.1128/MCB.22.20.7158-7167.2002; Kawai T, 1999, IMMUNITY, V11, P115, DOI 10.1016/S1074-7613(00)80086-2; KESSLER DS, 1990, GENE DEV, V4, P1753, DOI 10.1101/gad.4.10.1753; KUMAR A, 1994, P NATL ACAD SCI USA, V91, P6288, DOI 10.1073/pnas.91.14.6288; Li SY, 2002, P NATL ACAD SCI USA, V99, P5567, DOI 10.1073/pnas.082100399; Li XX, 1999, MOL CELL BIOL, V19, P4643; Li XX, 2001, P NATL ACAD SCI USA, V98, P4461, DOI 10.1073/pnas.071054198; LORD KA, 1990, ONCOGENE, V5, P1095; Lovenberg TW, 1996, J NEUROIMMUNOL, V70, P113, DOI 10.1016/S0165-5728(96)00047-1; Majumder S, 1998, J NEUROSCI RES, V54, P169, DOI 10.1002/(SICI)1097-4547(19981015)54:2<169::AID-JNR5>3.0.CO;2-C; Medzhitov R, 1997, NATURE, V388, P394, DOI 10.1038/41131; Mercurio F, 1997, SCIENCE, V278, P860, DOI 10.1126/science.278.5339.860; Mitcham JL, 1996, J BIOL CHEM, V271, P5777, DOI 10.1074/jbc.271.10.5777; Ninomiya-Tsuji J, 1999, NATURE, V398, P252, DOI 10.1038/18465; Oshiumi H, 2003, NAT IMMUNOL, V4, P161, DOI 10.1038/ni886; Parnet P, 1996, J BIOL CHEM, V271, P3967; Poltorak A, 1998, SCIENCE, V282, P2085, DOI 10.1126/science.282.5396.2085; Qian YC, 2001, J BIOL CHEM, V276, P41661, DOI 10.1074/jbc.M102262200; Regnier CH, 1997, CELL, V90, P373, DOI 10.1016/S0092-8674(00)80344-X; Rock FL, 1998, P NATL ACAD SCI USA, V95, P588, DOI 10.1073/pnas.95.2.588; SCHINDLER U, 1994, MOL CELL BIOL, V14, P5820, DOI 10.1128/MCB.14.9.5820; Suzuki N, 2002, NATURE, V416, P750, DOI 10.1038/nature736; Takaesu G, 2000, MOL CELL, V5, P649, DOI 10.1016/S1097-2765(00)80244-0; Takaesu G, 2001, MOL CELL BIOL, V21, P2475, DOI 10.1128/MCB.21.7.2475-2484.2001; Takeuchi O, 1999, GENE, V231, P59, DOI 10.1016/S0378-1119(99)00098-0; Takeuchi O, 2000, J IMMUNOL, V164, P554, DOI 10.4049/jimmunol.164.2.554; Takeuchi O, 1999, IMMUNITY, V11, P443, DOI 10.1016/S1074-7613(00)80119-3; Thomassen E, 1999, CYTOKINE, V11, P389, DOI 10.1006/cyto.1998.0452; Toshchakov V, 2002, NAT IMMUNOL, V3, P392, DOI 10.1038/ni774; Underhill DM, 1999, NATURE, V401, P811, DOI 10.1038/44605; Underhill DM, 1999, P NATL ACAD SCI USA, V96, P14459, DOI 10.1073/pnas.96.25.14459; Wang C, 2001, NATURE, V412, P346, DOI 10.1038/35085597; Wesche H, 1997, IMMUNITY, V7, P837, DOI 10.1016/S1074-7613(00)80402-1; Woronicz JD, 1997, SCIENCE, V278, P866, DOI 10.1126/science.278.5339.866; Yamamoto M, 2002, NATURE, V420, P324, DOI 10.1038/nature01182; Yamamoto M, 2002, J IMMUNOL, V169, P6668, DOI 10.4049/jimmunol.169.12.6668; Ye H, 2002, NATURE, V418, P443, DOI 10.1038/nature00888; Zamanian-Daryoush M, 2000, MOL CELL BIOL, V20, P1278, DOI 10.1128/MCB.20.4.1278-1290.2000; Zandi E, 1997, CELL, V91, P243, DOI 10.1016/S0092-8674(00)80406-7	55	249	259	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 9	2003	278	19					16713	16719		10.1074/jbc.M300562200	http://dx.doi.org/10.1074/jbc.M300562200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677QG	12609980	hybrid			2022-12-25	WOS:000182818600036
J	Gorlatova, NV; Elokdah, H; Fan, K; Crandall, DL; Lawrence, DA				Gorlatova, NV; Elokdah, H; Fan, K; Crandall, DL; Lawrence, DA			Mapping of a conformational epitope on plasminogen activator inhibitor-1 by random mutagenesis - Implications for serpin function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REACTIVE CENTER LOOP; ATHEROSCLEROTIC HUMAN ARTERIES; INDUCED PULMONARY FIBROSIS; BETA-SHEET-A; PROTEASE COMPLEXES; ANTITHROMBIN-III; STRUCTURAL BASIS; HEPARIN-BINDING; BOND LOOP; MECHANISM	The mechanism for the conversion of plasminogen activator inhibitor-1 (PAI-1) from the active to the latent conformation is not well understood. Recently, a monoclonal antibody, 33138, was described that rapidly converts PAI-1 to the latent conformation (Verhamme, I., Kvassman, J. O., Day, D., Debrock, S., Vleugels, N., Declerck, P. J., and Shore, J. D. (1999) J. Biol. Chem. 274, 17511-17517). In an attempt to understand this interaction, and more broadly to understand the mechanism of the natural transition of PAI-1 to the latent conformation, we have used random mutagenesis to identify the 33B8 epitope in PAI-1. This site involves at least 8 amino acids scattered over more than two-thirds of the linear sequence that form a compact epitope on the PAI-1 three-dimensional structure. Surface plasmon resonance studies indicate a high affinity interaction between latent PAI-1 and 33B8 that is similar to100-fold higher than comparable binding to active PALL Structural modeling results together with surface plasmon resonance analysis of parental and site-directed PAI-1 mutants with disrupted 33B8 binding suggest the existence of a specific PAI-1 intermediate structure that is stabilized by 33B8 binding. These analyses strongly suggest that this intermediate form of PAI-1 has a partial insertion of the reactive center loop into beta-sheet A, and together, these data have significant implications for the general serpin mechanism of proteinase inhibition..	Amer Red Cross, Holland Lab, Dept Vasc Biol, Rockville, MD 20855 USA; Wyeth Res, Collegeville, PA 19426 USA; Wyeth Res, Princeton, NJ 08543 USA	American Red Cross; Pfizer; Pfizer	Lawrence, DA (corresponding author), Amer Red Cross, Holland Lab, Dept Vasc Biol, 15601 Crabbs Branch Way, Rockville, MD 20855 USA.			Lawrence, Daniel/0000-0003-3126-1935	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL055374, R01HL055747] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 55747, HL 55374] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Belzar KJ, 2002, J BIOL CHEM, V277, P8551, DOI 10.1074/jbc.M110807200; BERKENPAS MB, 1995, EMBO J, V14, P2969, DOI 10.1002/j.1460-2075.1995.tb07299.x; BJORK I, 1992, J BIOL CHEM, V267, P1976; BJORK I, 1992, J BIOL CHEM, V267, P19047; CARMELIET P, 1993, J CLIN INVEST, V92, P2756, DOI 10.1172/JCI116893; Carrell RW, 1992, CURR OPIN STRUC BIOL, V2, P438; Debrock S, 1997, BBA-PROTEIN STRUCT M, V1337, P257, DOI 10.1016/S0167-4838(96)00173-2; Eitzman DT, 2000, BLOOD, V96, P4212; Eitzman DT, 1996, J CLIN INVEST, V97, P232, DOI 10.1172/JCI118396; FA M, 1995, BIOCHEMISTRY-US, V34, P13833, DOI 10.1021/bi00042a015; Farrehi PM, 1998, CIRCULATION, V97, P1002; Gooptu B, 2000, P NATL ACAD SCI USA, V97, P67, DOI 10.1073/pnas.97.1.67; HAMSTEN A, 1987, LANCET, V2, P3; Hattori N, 2000, J CLIN INVEST, V106, P1341, DOI 10.1172/JCI10531; HEKMAN CM, 1985, J BIOL CHEM, V260, P11581; Huntington JA, 2000, NATURE, V407, P923, DOI 10.1038/35038119; Huntington JA, 1996, BIOCHEMISTRY-US, V35, P8495, DOI 10.1021/bi9604643; JUHANVAGUE I, 1987, THROMB HAEMOSTASIS, V57, P67; JuhanVague I, 1997, THROMB HAEMOSTASIS, V78, P656; Koh KK, 1997, NEW ENGL J MED, V336, P683, DOI 10.1056/NEJM199703063361002; Kvassman JO, 1998, BIOCHEMISTRY-US, V37, P15491, DOI 10.1021/bi9814787; KVASSMAN JO, 1995, J BIOL CHEM, V270, P27942, DOI 10.1074/jbc.270.46.27942; LAWRENCE D, 1989, EUR J BIOCHEM, V186, P523, DOI 10.1111/j.1432-1033.1989.tb15238.x; Lawrence DA, 2000, J BIOL CHEM, V275, P5839, DOI 10.1074/jbc.275.8.5839; LAWRENCE DA, 1990, J BIOL CHEM, V265, P20293; LAWRENCE DA, 1995, J BIOL CHEM, V270, P25309, DOI 10.1074/jbc.270.43.25309; LAWRENCE DA, 1994, J BIOL CHEM, V269, P27657; MOTTONEN J, 1992, NATURE, V355, P270, DOI 10.1038/355270a0; Olson ST, 2001, BIOCHEMISTRY-US, V40, P11742, DOI 10.1021/bi0107290; Plotnick MI, 1996, BIOCHEMISTRY-US, V35, P7586, DOI 10.1021/bi960233w; SCHNEIDERMAN J, 1992, P NATL ACAD SCI USA, V89, P6998, DOI 10.1073/pnas.89.15.6998; SCHREUDER HA, 1994, NAT STRUCT BIOL, V1, P48, DOI 10.1038/nsb0194-48; SCHULZE AJ, 1990, EUR J BIOCHEM, V194, P51, DOI 10.1111/j.1432-1033.1990.tb19425.x; Sharp AM, 1999, STRUCTURE, V7, P111, DOI 10.1016/S0969-2126(99)80018-5; Siemens HJG, 1999, J CLIN ANESTH, V11, P622, DOI 10.1016/S0952-8180(99)00119-1; Skinner R, 1997, J MOL BIOL, V266, P601, DOI 10.1006/jmbi.1996.0798; Stefansson S, 1996, NATURE, V383, P441, DOI 10.1038/383441a0; Stratikos E, 1997, P NATL ACAD SCI USA, V94, P453, DOI 10.1073/pnas.94.2.453; Taatjes DJ, 1997, ULTRASTRUCT PATHOL, V21, P527, DOI 10.3109/01913129709016369; VANBOECKEL CAA, 1994, NAT STRUCT BIOL, V1, P423, DOI 10.1038/nsb0794-423; Vaughan DE, 1998, J INVEST MED, V46, P370; Verhamme I, 1999, J BIOL CHEM, V274, P17511, DOI 10.1074/jbc.274.25.17511; WILCZYNSKA M, 1995, J BIOL CHEM, V270, P29652; Wilczynska M, 1997, NAT STRUCT BIOL, V4, P354, DOI 10.1038/nsb0597-354; WRIGHT HT, 1995, PROTEINS, V22, P210, DOI 10.1002/prot.340220303	45	37	41	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 2	2003	278	18					16329	16335		10.1074/jbc.M208420200	http://dx.doi.org/10.1074/jbc.M208420200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	675EL	12606560	hybrid			2022-12-25	WOS:000182680000111
J	Trebak, M; Bird, GSJ; McKay, RRM; Birnbaumer, L; Putney, JW				Trebak, M; Bird, GSJ; McKay, RRM; Birnbaumer, L; Putney, JW			Signaling mechanism for receptor-activated canonical transient receptor potential 3 (TRPC3) channels	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CAPACITATIVE CALCIUM-ENTRY; INOSITOL TRISPHOSPHATE RECEPTOR; CA2+-PERMEABLE CATION CHANNEL; OPERATED HTRP3 CHANNELS; CA2+ CHANNELS; PHOSPHOLIPASE-C; FEEDBACK INHIBITION; CELLS; RELEASE; RAT	Canonical transient receptor potential 3 (TRPC3) is a receptor-activated, calcium permeant, non-selective cation channel. TRPC3 has been shown to interact physically with the N-terminal domain of the inositol 1,4,5-trisphosphate receptor, consistent with a "conformational coupling" mechanism for its activation. Here we show that low concentrations of agonists that fail to produce levels of inositol 1,4,5-trisphosphate sufficient to induce Ca2+ release from intracellular stores substantially activate TRPC3. By several experimental approaches, we demonstrate that neither inositol 1,4,5-trisphosphate nor G proteins are required for TRPC3 activation. However, diacylglycerols were sufficient to activate TRPC3 in a protein kinase C-independent manner. Surface receptor agonists and exogenously applied diacylglycerols were not additive in activating TRPC3. In addition, inhibition of metabolism of diacylglycerol slowed the reversal of receptor-dependent TRPC3 activation. We conclude that receptor-mediated activation of phospholipase C in intact cells activates TRPC3 via diacylglycerol production, independently of G proteins, protein kinase C, or inositol 1,4,5-trisphosphate.	NIEHS, NIH, Lab Signal Transduct, Res Triangle Pk, NC 27709 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)	Trebak, M (corresponding author), NIEHS, NIH, Lab Signal Transduct, POB 12233, Res Triangle Pk, NC 27709 USA.		Bird, Gary/AAI-8186-2021; Putney, James W/F-7247-2019; Trebak, Mohamed/E-7405-2014	Bird, Gary/0000-0003-1389-8748; Putney, James W/0000-0002-3379-4789; 	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [ZIAES090087, ZIGES101684, Z01ES101684, Z01ES090087] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Bakowski D, 2001, J PHYSIOL-LONDON, V532, P55, DOI 10.1111/j.1469-7793.2001.0055g.x; BERRIDGE MJ, 1995, BIOCHEM J, V312, P1, DOI 10.1042/bj3120001; BIRD GS, 1991, NATURE, V352, P162, DOI 10.1038/352162a0; BIRD GS, 1992, J BIOL CHEM, V267, P17722; Birnbaumer L, 1996, P NATL ACAD SCI USA, V93, P15195, DOI 10.1073/pnas.93.26.15195; Boulay G, 1999, P NATL ACAD SCI USA, V96, P14955, DOI 10.1073/pnas.96.26.14955; Braun FJ, 2001, J BIOL CHEM, V276, P1063, DOI 10.1074/jbc.M008348200; Broad LM, 1999, J PHYSIOL-LONDON, V517, P121, DOI 10.1111/j.1469-7793.1999.0121z.x; Broad LM, 2001, J BIOL CHEM, V276, P15945, DOI 10.1074/jbc.M011571200; BROWN KD, 1987, BIOCHEM J, V245, P631, DOI 10.1042/bj2450631; DECOURCELLES DD, 1985, J BIOL CHEM, V260, P5762; Elliott AC, 2001, CELL CALCIUM, V30, P73, DOI 10.1054/ceca.2001.0215; Gregory RB, 2001, BIOCHEM J, V354, P285, DOI 10.1042/0264-6021:3540285; Hofmann T, 1999, NATURE, V397, P259, DOI 10.1038/16711; Inoue R, 2001, CIRC RES, V88, P325, DOI 10.1161/01.RES.88.3.325; IRVINE RF, 1990, FEBS LETT, V263, P5, DOI 10.1016/0014-5793(90)80692-C; Iwasaki H, 2001, RECEPTOR CHANNEL, V7, P429; Kiselyov K, 1998, NATURE, V396, P478, DOI 10.1038/24890; Kiselyov K, 1999, MOL CELL, V4, P423, DOI 10.1016/S1097-2765(00)80344-5; Luo D, 2001, J BIOL CHEM, V276, P5613, DOI 10.1074/jbc.M007524200; Ma HT, 2000, SCIENCE, V287, P1647, DOI 10.1126/science.287.5458.1647; Ma HT, 2001, J BIOL CHEM, V276, P18888, DOI 10.1074/jbc.M100944200; MARGOLIS B, 1989, CELL, V57, P1101, DOI 10.1016/0092-8674(89)90047-0; McKay RR, 2000, BIOCHEM J, V351, P735, DOI 10.1042/0264-6021:3510735; Okada T, 1999, J BIOL CHEM, V274, P27359, DOI 10.1074/jbc.274.39.27359; OZAWA K, 1993, J BIOL CHEM, V268, P2280; Prakriya M, 2001, J PHYSIOL-LONDON, V536, P3, DOI 10.1111/j.1469-7793.2001.t01-1-00003.x; Putney Jr JW, 1997, CAPACITATIVE CALCIUM; PUTNEY JW, 1986, CELL CALCIUM, V7, P1, DOI 10.1016/0143-4160(86)90026-6; Putney JW, 1999, BIOESSAYS, V21, P38; PUTNEY JW, 1990, CELL CALCIUM, V11, P611, DOI 10.1016/0143-4160(90)90016-N; RANDRIAMAMPITA C, 1993, NATURE, V364, P809, DOI 10.1038/364809a0; SUTHERLAND CA, 1982, J BIOL CHEM, V257, P4006; Trebak M, 2002, J BIOL CHEM, V277, P21617, DOI 10.1074/jbc.M202549200; Vazquez G, 2001, P NATL ACAD SCI USA, V98, P11777, DOI 10.1073/pnas.201238198; Venkatachalam K, 2001, J BIOL CHEM, V276, P33980, DOI 10.1074/jbc.C100321200; Zhu X, 1998, J BIOL CHEM, V273, P133, DOI 10.1074/jbc.273.1.133	37	130	132	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 2	2003	278	18					16244	16252		10.1074/jbc.M300544200	http://dx.doi.org/10.1074/jbc.M300544200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	675EL	12606542	hybrid			2022-12-25	WOS:000182680000100
J	Do, TN; Rosal, RV; Drew, L; Raffo, AJ; Michl, J; Pincus, MR; Friedman, FK; Petrylak, DP; Cassai, N; Szmulewicz, J; Sidhu, G; Fine, RL; Brandt-Rauf, PW				Do, TN; Rosal, RV; Drew, L; Raffo, AJ; Michl, J; Pincus, MR; Friedman, FK; Petrylak, DP; Cassai, N; Szmulewicz, J; Sidhu, G; Fine, RL; Brandt-Rauf, PW			Preferential induction of necrosis in human breast cancer cells by a p53 peptide derived from the MDM2 binding site	ONCOGENE			English	Article						breast cancer; p53; MDM2; necrosis	TUMOR-SUPPRESSOR GENE; C-TERMINAL PEPTIDE; IN-VIVO; INTRACELLULAR DELIVERY; MUTANT P53; ANTENNAPEDIA HOMEODOMAIN; PROTEIN TRANSDUCTION; CIRCULAR-DICHROISM; 3RD HELIX; DOMAIN	p53 is the most frequently altered gene in human cancer and therefore represents an ideal target for cancer therapy. Several amino terminal p53-derived synthetic peptides were tested for their antiproliferative effects on breast cancer cell lines MDA-MB-468 (mutant p53), MCF-7 (overexpressed wild-type p53), and MDA-MB-157 (null p53). p53(15)Ant peptide representing the majority of the mouse double minute clone 2 binding site on p53 (amino acids 12-26) fused to the Drosophila carrier protein Antennapedia was the most effective. p53(15)Ant peptide induced rapid, nonapoptotic cell death resembling necrosis in all breast cancer cells; however, minimal cytotoxicity was observed in the nonmalignant breast epithelial cells MCF-10-2A and MCF-10F. Bioinformatic/biophysical analysis utilizing hydrophobic moment and secondary structure predictions as well as circular dichroism spectroscopy revealed an alpha-helical hydrophobic peptide structure with membrane disruptive potential. Based on these findings, p53(15)Ant peptide may be a novel peptide cancer therapeutic because it induces necrotic cell death and not apoptosis, which is uncommon in traditional cancer therapy.	Columbia Univ, Dept Environm Hlth Sci, Mailman Sch Publ Hlth, New York, NY 10032 USA; Columbia Univ Coll Phys & Surg, Div Med Oncol, Expt Therapeut Program, New York, NY 10032 USA; Harbor VA Med Ctr, Dept Pathol & Lab Med, Manhasset, NY 10010 USA; Harbor VA Med Ctr, Dept Pathol & Lab Med, Brooklyn, NY 11209 USA; Suny Downstate Med Ctr, Dept Pathol, Brooklyn, NY 11203 USA; NIH, Lab Metab, Bethesda, MD 20892 USA	Columbia University; Columbia University; State University of New York (SUNY) System; State University of New York (SUNY) Downstate Medical Center; National Institutes of Health (NIH) - USA	Brandt-Rauf, PW (corresponding author), Columbia Univ, Dept Environm Hlth Sci, Mailman Sch Publ Hlth, New York, NY 10032 USA.		Friedman, Fred/O-6173-2019; Friedman, Fred K/D-4208-2016	Friedman, Fred/0000-0002-0284-7067; 	NATIONAL CANCER INSTITUTE [R01CA042500, R01CA082528] Funding Source: NIH RePORTER; NATIONAL INSTITUTE FOR OCCUPATIONAL SAFETY AND HEALTH [R01OH004192] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA 42500, CA 82528] Funding Source: Medline; NIOSH CDC HHS [OH 04192] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE FOR OCCUPATIONAL SAFETY AND HEALTH(United States Department of Health & Human ServicesCenters for Disease Control & Prevention - USANational Institute for Occupational Safety & Health (NIOSH)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIOSH CDC HHS		Berlose JP, 1996, EUR J BIOCHEM, V242, P372, DOI 10.1111/j.1432-1033.1996.0372r.x; Bottger A, 1997, CURR BIOL, V7, P860, DOI 10.1016/S0960-9822(06)00374-5; BRUGIDOU J, 1995, BIOCHEM BIOPH RES CO, V214, P685, DOI 10.1006/bbrc.1995.2340; Couet J, 1997, J BIOL CHEM, V272, P6525, DOI 10.1074/jbc.272.10.6525; DEKROON AIP, 1993, LIPID PEPTIDE INTERA; DELACONSTANTINO.G, 1987, ANTICANCER RES, V7, P1011; Derossi D, 1996, J BIOL CHEM, V271, P18188, DOI 10.1074/jbc.271.30.18188; Derossi D, 1998, TRENDS CELL BIOL, V8, P84, DOI 10.1016/S0962-8924(97)01214-2; EISENBERG D, 1984, P NATL ACAD SCI-BIOL, V81, P140, DOI 10.1073/pnas.81.1.140; Fahraeus R, 1999, J PATHOL, V187, P138; FINE RL, 1996, ONCOLOGIST, V1, P261; Foster BA, 1999, SCIENCE, V286, P2507, DOI 10.1126/science.286.5449.2507; GARNIER JG, 1996, METHOD ENZYMOL, P540; Harris CC, 1996, JNCI-J NATL CANCER I, V88, P1442, DOI 10.1093/jnci/88.20.1442; Kanovsky M, 2001, P NATL ACAD SCI USA, V98, P12438, DOI 10.1073/pnas.211280698; Kim AL, 1999, J BIOL CHEM, V274, P34924, DOI 10.1074/jbc.274.49.34924; Kussie PH, 1996, SCIENCE, V274, P948, DOI 10.1126/science.274.5289.948; LEVINE AJ, 1994, BRIT J CANCER, V69, P409, DOI 10.1038/bjc.1994.76; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; LOFTS FJ, 1993, ONCOGENE, V8, P2813; Midgley CA, 2000, ONCOGENE, V19, P2312, DOI 10.1038/sj.onc.1203593; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; OZBUN MA, 1995, ADV CANCER RES, V66, P71, DOI 10.1016/S0065-230X(08)60252-3; PERCZEL A, 1991, PROTEIN ENG, V4, P669, DOI 10.1093/protein/4.6.669; Prives C, 1999, J PATHOL, V187, P112; Prochiantz A, 1999, ANN NY ACAD SCI, V886, P172, DOI 10.1111/j.1749-6632.1999.tb09410.x; Rousselle C, 2000, MOL PHARMACOL, V57, P679, DOI 10.1124/mol.57.4.679; Schwarze SR, 2000, TRENDS CELL BIOL, V10, P290, DOI 10.1016/S0962-8924(00)01771-2; Schwarze SR, 2000, TRENDS PHARMACOL SCI, V21, P45, DOI 10.1016/S0165-6147(99)01429-7; SEGREST JP, 1990, PROTEINS, V8, P103, DOI 10.1002/prot.340080202; Selivanova G, 1999, MOL CELL BIOL, V19, P3395; Selivanova G, 1997, NAT MED, V3, P632, DOI 10.1038/nm0697-632; SHERBET GV, 1989, EXP CELL BIOL, V57, P198; Soussi T, 2000, Bull Cancer, V87, P689; SOUSSI T, 1990, ONCOGENE, V5, P945; Soussi T, 2000, ANN NY ACAD SCI, V910, P121; SPECTOR AA, 1987, CANCER RES, V47, P4529; SREERAMA N, 1993, ANAL BIOCHEM, V209, P32, DOI 10.1006/abio.1993.1079; Velculescu VE, 1996, CLIN CHEM, V42, P858; Wang JL, 2000, CANCER RES, V60, P1498; Wasylyk C, 1999, ONCOGENE, V18, P1921, DOI 10.1038/sj.onc.1202528; Yeung TK, 1999, BIOCHEM BIOPH RES CO, V263, P398, DOI 10.1006/bbrc.1999.1375; Zhang RW, 2000, CURR PHARM DESIGN, V6, P393, DOI 10.2174/1381612003400911	43	72	86	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 13	2003	22	10					1431	1444		10.1038/sj.onc.1206258	http://dx.doi.org/10.1038/sj.onc.1206258			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	652ZZ	12629507				2022-12-25	WOS:000181411900001
J	Murakami, D; Okamoto, I; Nagano, O; Kawano, Y; Tomita, T; Iwatsubo, T; De Strooper, B; Yumoto, E; Saya, H				Murakami, D; Okamoto, I; Nagano, O; Kawano, Y; Tomita, T; Iwatsubo, T; De Strooper, B; Yumoto, E; Saya, H			Presenilin-dependent gamma-secretase activity mediates the intramembranous cleavage of CD44	ONCOGENE			English	Article						CD44; gamma-secretase; presenilin; intramembranous cleavage	FAMILIAL ALZHEIMERS-DISEASE; AMYLOID PRECURSOR PROTEIN; INTRACELLULAR DOMAIN; E-CADHERIN; MISSENSE MUTATIONS; CALCIUM INFLUX; BETA-CATENIN; RHO-FAMILY; GENE; RECEPTOR	CD44 is the major adhesion molecule for the extracellular matrix components and is implicated in a wide variety of physiological and pathological processes including the regulation of tumor cell growth and metastasis. Our previous studies have shown that CD44 undergoes sequential proteolytic cleavages in the extracellular and transmembrane domains and the cleavage product derived from CD44 intramembranous cleavage acts as a signal transduction molecule. However, the underlying mechanism of the intramembranous cleavage of CD44 remains to be elucidated. In the present study, we report for the first time that CD44 is a substrate of the presenilin (PS)-dependent gamma-secretase. We demonstrate that the intramembranous cleavage of CD44 induced by 12-O-tetradecanoylphorbol 13-acetate (TPA) treatment or mechanical scraping is blocked by gamma-secretase inhibitors in U251MG cells and that this cleavage is also inhibited in PS-deficient mouse embryonic fibroblasts. Furthermore, we showed that PSI is redistributed to ruffling areas of the plasma membrane similarly to CD44 after TPA treatment, supporting our biochemical observation that PSI is involved in the intramembranous cleavage of CD44. Our present findings suggest important implications for understanding CD44-dependent signal transduction and a potential role of PS/gamma-secretase activity in the functional regulation of adhesion molecules.	Kumamoto Univ, Sch Med, Dept Tumor Genet & Biol, Kumamoto 8600811, Japan; Kumamoto Univ, Sch Med, Dept Otolaryngol Head & Neck Surg, Kumamoto 8608556, Japan; Kumamoto Univ, Sch Med, Dept Internal Med 1, Kumamoto 8608556, Japan; Univ Tokyo, Grad Sch Pharmaceut Sci, Dept Neuropathol & Neurosci, Bunkyo Ku, Tokyo 1130033, Japan; Katholieke Univ Leuven, Ctr Human Genet, B-3000 Louvain, Belgium; Flanders Interuniv Inst Biotechnol VIB, B-3000 Louvain, Belgium	Kumamoto University; Kumamoto University; Kumamoto University; University of Tokyo; KU Leuven; Flanders Institute for Biotechnology (VIB)	Saya, H (corresponding author), Kumamoto Univ, Sch Med, Dept Tumor Genet & Biol, 2-2-1 Honjo, Kumamoto 8600811, Japan.	hsaya@gpo.kumamoto-u.ac.jp	de+Strooper, Bart/Z-1638-2019; Tomita, Taisuke/L-5427-2015; Saya, Hideyuki/J-4325-2013; Nagano, Osamu/J-5874-2013; De Strooper, Bart/F-6507-2012	Tomita, Taisuke/0000-0002-0075-5943; Nagano, Osamu/0000-0002-7630-142X; De Strooper, Bart/0000-0001-5455-5819; Murakami, Daizo/0000-0001-8668-800X				ARUFFO A, 1990, CELL, V61, P1303, DOI 10.1016/0092-8674(90)90694-A; Baek SH, 2002, CELL, V110, P55, DOI 10.1016/S0092-8674(02)00809-7; Cao XW, 2001, SCIENCE, V293, P115, DOI 10.1126/science.1058783; CULTY M, 1990, J CELL BIOL, V111, P2765, DOI 10.1083/jcb.111.6.2765; De Strooper B, 2001, NAT CELL BIOL, V3, pE221, DOI 10.1038/ncb1001-e221; De Strooper B, 1999, NATURE, V398, P518, DOI 10.1038/19083; DeStrooper B, 1997, J BIOL CHEM, V272, P3590, DOI 10.1074/jbc.272.6.3590; Egeblad M, 2002, NAT REV CANCER, V2, P161, DOI 10.1038/nrc745; Esler WP, 2001, SCIENCE, V293, P1449, DOI 10.1126/science.1064638; EVIN G, 1995, BIOCHEMISTRY-US, V34, P14185, DOI 10.1021/bi00043a024; GUNTHERT U, 1991, CELL, V65, P13, DOI 10.1016/0092-8674(91)90403-L; Herreman A, 2000, NAT CELL BIOL, V2, P461, DOI 10.1038/35017105; Herreman A, 1999, P NATL ACAD SCI USA, V96, P11872, DOI 10.1073/pnas.96.21.11872; Hooper NM, 1997, BIOCHEM J, V321, P265, DOI 10.1042/bj3210265; Ito K, 1999, ONCOGENE, V18, P7080, DOI 10.1038/sj.onc.1203191; Kaether C, 2002, J CELL BIOL, V158, P551, DOI 10.1083/jcb.200201123; Kawano Y, 2000, J BIOL CHEM, V275, P29628, DOI 10.1074/jbc.M002440200; Lee HJ, 2002, J BIOL CHEM, V277, P6318, DOI 10.1074/jbc.M110371200; LESLEY J, 1998, FRONT BIOSCI, V3, P616; LEVYLAHAD E, 1995, SCIENCE, V269, P973, DOI 10.1126/science.7638622; Marambaud P, 2002, EMBO J, V21, P1948, DOI 10.1093/emboj/21.8.1948; May P, 2002, J BIOL CHEM, V277, P18736, DOI 10.1074/jbc.M201979200; Ni CY, 2001, SCIENCE, V294, P2179, DOI 10.1126/science.1065412; Noe V, 2001, J CELL SCI, V114, P111; Okamoto I, 1999, J BIOL CHEM, V274, P25525, DOI 10.1074/jbc.274.36.25525; Okamoto I, 2001, J CELL BIOL, V155, P755, DOI 10.1083/jcb.200108159; Okamoto I, 1999, ONCOGENE, V18, P1435, DOI 10.1038/sj.onc.1202447; ROGAEV EI, 1995, NATURE, V376, P775, DOI 10.1038/376775a0; Sadot E, 1998, P NATL ACAD SCI USA, V95, P15339, DOI 10.1073/pnas.95.26.15339; Seiffert D, 2000, J BIOL CHEM, V275, P34086, DOI 10.1074/jbc.M005430200; Shearman MS, 2000, BIOCHEMISTRY-US, V39, P8698, DOI 10.1021/bi0005456; SHERRINGTON R, 1995, NATURE, V375, P754, DOI 10.1038/375754a0; Struhl G, 2000, MOL CELL, V6, P625, DOI 10.1016/S1097-2765(00)00061-7; Weber GF, 2002, CANCER RES, V62, P2281	34	119	124	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 13	2003	22	10					1511	1516		10.1038/sj.onc.1206298	http://dx.doi.org/10.1038/sj.onc.1206298			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	652ZZ	12629514				2022-12-25	WOS:000181411900008
J	Fujioka, S; Sclabas, GM; Schmidt, C; Niu, JG; Frederick, WA; Dong, QG; Abbruzzese, JL; Evans, DB; Baker, C; Chiao, PJ				Fujioka, S; Sclabas, GM; Schmidt, C; Niu, JG; Frederick, WA; Dong, QG; Abbruzzese, JL; Evans, DB; Baker, C; Chiao, PJ			Inhibition of constitutive NF-kappa B activity by I kappa B alpha M suppresses tumorigenesis	ONCOGENE			English	Article						I kappa B alpha; NF-kappa B; tumorigenesis; angiogenesis; pancreatic cancer	ENDOTHELIAL GROWTH-FACTOR; PANCREATIC-CANCER CELLS; ANGIOGENESIS; EXPRESSION; INTERLEUKIN-8; APOPTOSIS; ADENOCARCINOMA; METASTASIS; INDUCTION; PROTEINS	We have demonstrated that nuclear factor-kappaB (NF-kappaB) is constitutively activated in human pancreatic adenocarcinoma and human pancreatic cancer cell lines but not in normal pancreatic tissues or in immortalized, nontumorigenic pancreatic epithelial cells, suggesting that NF-kappaB plays a critical role in the development of pancreatic adenocarcinoma. To elucidate the role of constitutive NF- kappaB activity in human pancreatic cancer cells, we generated pancreatic tumor cell lines that express a phosphorylation defective IkappaBalpha (S32, 36A) (IkappaBalphaM) that blocks NF-kappaB, activity. In this study, we showed that inhibiting constitutive NF-kappaB activity by expressing IkappaBalphaM suppressed the tumorigenicity of a nonmetastatic human pancreatic cancer cell line, PANC-1, in an orthotopic nude mouse model. Immunohistochemical analysis showed that PANC-1-derived tumors expressed vascular endothelial growth factor (VEGF) and induced angiogenesis. Inhibiting NF-kappaB signaling by expressing licBaM significantly reduced expression of Bcl-x(L) and Bcl-2. The cytokine-induced expression of VEGF and Interleukin-8 in PANC-1 cells is also decreased. Taken together, these results suggest that the inhibition of NF-kappaB signaling can suppress tumorigenesis of pancreatic cancer cells and that the NF-kappaB signaling pathway is a potential target for anticancer agents.	Univ Texas, MD Anderson Canc Ctr, Dept Mol & Cellular Oncol, Unit 107, Houston, TX 77030 USA; Univ Texas, Dept Surg Oncol, Houston, TX 77030 USA; Univ Texas, Grad Sch Biomed Sci, Houston, TX 77030 USA; Univ Texas, Dept Gastrointestinal Med Oncol, Houston, TX 77030 USA; Univ Texas, Dept Canc Biol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; University of Texas System; University of Texas System; University of Texas System	Chiao, PJ (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Mol & Cellular Oncol, Unit 107, 1515 Holcombe Blvd, Houston, TX 77030 USA.			Schmidt, Christian/0000-0002-1260-9732	NATIONAL CANCER INSTITUTE [R01CA075517, R29CA073675, P01CA078778] Funding Source: NIH RePORTER; NCI NIH HHS [CA78778, CA73675, CA 75517] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; BRAMHALL SR, 1995, BRIT J SURG, V82, P111, DOI 10.1002/bjs.1800820137; Breslin TM, 2001, ANN SURG ONCOL, V8, P123, DOI 10.1007/s10434-001-0123-4; Chang TC, 1997, FEBS LETT, V415, P11, DOI 10.1016/S0014-5793(97)01083-1; CHIAO PJ, 1994, P NATL ACAD SCI USA, V91, P28, DOI 10.1073/pnas.91.1.28; DEJARDIN E, 1995, ONCOGENE, V11, P1835; Dong QG, 2002, ONCOGENE, V21, P6510, DOI 10.1038/sj.onc.1205848; FERRARA N, 1995, BREAST CANCER RES TR, V36, P127, DOI 10.1007/BF00666035; FOLKMAN J, 1989, NATURE, V339, P58, DOI 10.1038/339058a0; Folkman J, 1992, Semin Cancer Biol, V3, P65; FOLKMAN J, 1990, JNCI-J NATL CANCER I, V82, P4, DOI 10.1093/jnci/82.1.4; Fujioka S, 2003, CLIN CANCER RES, V9, P346; Fukumura D, 1998, CELL, V94, P715, DOI 10.1016/S0092-8674(00)81731-6; Gilmore TD, 1996, ONCOGENE, V13, P1367; Grau AM, 1997, CANCER RES, V57, P3929; Grisham MB, 1999, METHOD ENZYMOL, V300, P345; HU DE, 1993, INFLAMMATION, V17, P135, DOI 10.1007/BF00916100; Huang S, 2000, CANCER RES, V60, P5334; Huang SY, 2001, ONCOGENE, V20, P4188, DOI 10.1038/sj.onc.1204535; Jemal A, 2002, CA-CANCER J CLIN, V52, P23, DOI 10.3322/canjclin.52.1.23; KITAJIMA I, 1992, SCIENCE, V258, P1792, DOI 10.1126/science.1299224; Klingler K, 1997, INFECT IMMUN, V65, P5272, DOI 10.1128/IAI.65.12.5272-5278.1997; KOCH AE, 1992, SCIENCE, V258, P1798, DOI 10.1126/science.1281554; Lee TH, 2002, J BIOL CHEM, V277, P10445, DOI 10.1074/jbc.M107348200; Leek RD, 1996, CANCER RES, V56, P4625; LEIBOVICH SJ, 1987, NATURE, V329, P630, DOI 10.1038/329630a0; LIOTTA LA, 1991, CELL, V64, P327, DOI 10.1016/0092-8674(91)90642-C; LU D, 1991, ONCOGENE, V6, P1235; MILLAUER B, 1993, CELL, V72, P835, DOI 10.1016/0092-8674(93)90573-9; Mohammad RM, 2001, ANTI-CANCER DRUG, V12, P735, DOI 10.1097/00001813-200110000-00005; MOORE BE, 1988, VIROLOGY, V162, P377, DOI 10.1016/0042-6822(88)90478-3; MUKAIDA N, 1990, J BIOL CHEM, V265, P21128; Naviaux RK, 1996, J VIROL, V70, P5701, DOI 10.1128/JVI.70.8.5701-5705.1996; NERI A, 1991, CELL, V67, P1075, DOI 10.1016/0092-8674(91)90285-7; OHNO H, 1990, CELL, V60, P991, DOI 10.1016/0092-8674(90)90347-H; Parborell F, 2002, BIOL REPROD, V67, P481, DOI 10.1095/biolreprod67.2.481; PASSANITI A, 1992, LAB INVEST, V67, P519; Sawai H, 2001, PANCREAS, V23, P399, DOI 10.1097/00006676-200111000-00011; Schwarte-Waldhoff I, 2000, P NATL ACAD SCI USA, V97, P9624, DOI 10.1073/pnas.97.17.9624; Shono T, 1996, MOL CELL BIOL, V16, P4231; STRIETER RM, 1992, AM J PATHOL, V141, P1279; SYLLA BS, 1986, MOL CELL BIOL, V6, P4709, DOI 10.1128/MCB.6.12.4709; Teraoka H, 2001, BRIT J CANCER, V85, P612, DOI 10.1054/bjoc.2001.1941; Tsai LC, 2000, ANTICANCER RES, V20, P2441; Tsuzuki Y, 2001, LAB INVEST, V81, P1439, DOI 10.1038/labinvest.3780357; VERMA IM, 1995, GENE DEV, V9, P2723, DOI 10.1101/gad.9.22.2723; Wang WX, 1999, ONCOGENE, V18, P4554, DOI 10.1038/sj.onc.1202833; Wang WX, 1999, CLIN CANCER RES, V5, P119; Xu ZW, 2001, INT J CANCER, V94, P268, DOI 10.1002/ijc.1447; Yancopoulos GD, 2000, NATURE, V407, P242, DOI 10.1038/35025215; Yoshida A, 1999, INVEST OPHTH VIS SCI, V40, P1624; YOSHIMURA T, 1987, J IMMUNOL, V139, P788	52	138	152	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 6	2003	22	9					1365	1370		10.1038/sj.onc.1206323	http://dx.doi.org/10.1038/sj.onc.1206323			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	652CA	12618762				2022-12-25	WOS:000181360900011
J	Gill, SK; Bhattacharya, M; Ferguson, SSG; Rylett, RJ				Gill, SK; Bhattacharya, M; Ferguson, SSG; Rylett, RJ			Identification of a novel nuclear localization signal common to 69-and 82-kDa human choline acetyltransferase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-BINDING-PROTEINS; EXPORT SIGNAL; IMPORT; TRANSPORT; PHOSPHORYLATION; EXPRESSION; PATHWAY; DOMAIN; GENE; ACTIVATION	We demonstrated previously that 69- and 82-kDa human choline acetyltransferase are localized predominantly to the cytoplasm and the nucleus, respectively. We have now identified a nuclear localization signal common to both forms of enzyme using confocal microscopy to study the subcellular compartmentalization of choline acetyltransferase tagged with green fluorescent protein in living HEK 293 cells. To identify functional nuclear localization and export signals, portions of full-length 69-kDa choline acetyltransferase were cloned into the vector peGFP-N1 and the cellular distribution patterns of the fusion proteins observed. Of the nine constructs studied, one yielded a protein with nuclear localization and another produced a protein with cytoplasmic localization. Mutation of the critical amino acids in this novel putative nuclear localization signal in the 69- and 82-kDa enzymes demonstrated that it is functional in both proteins. Moreover, 69-kDa choline acetyltransferase but not the 82-kDa enzyme is transported out of the nucleus by the leptomycin B-sensitive Crm-1 export pathway. By using bikaryon cells expressing both 82-kDa choline acetyltransferase and the nuclear protein heterogeneous nuclear ribonucleoprotein with green and red fluorescent tags, respectively, we found that the 82-kDa enzyme does not shuttle out of the nucleus in measurable amounts. These data suggest that 69- kDa choline acetyltransferase is a nucleocytoplasmic shuttling protein with a predominantly cytoplasmic localization determined by a functional nuclear localization signal and unidentified putative nuclear export signal. For 82-kDa choline acetyltransferase, the presence of the unique amino-terminal nuclear localization signal plus the newly identified nuclear localization signal may be involved in a process leading to predominantly nuclear accumulation of this enzyme, or alternatively, the two nuclear localization signals may be sufficient to overcome the force(s) driving nuclear export.	Univ Western Ontario, Dept Physiol & Pharmacol, London, ON N6A 5C1, Canada; Univ Western Ontario, Robarts Res Inst, London, ON N6A 5C1, Canada	Western University (University of Western Ontario); Western University (University of Western Ontario)	Rylett, RJ (corresponding author), Univ Western Ontario, Dept Physiol & Pharmacol, Med Sci Bldg, London, ON N6A 5C1, Canada.	jane.rylett@fmd.uwo.ca	Rylett, Rebecca Jane/K-3597-2013	Rylett, Rebecca Jane/0000-0002-9158-9599				BEJANIN S, 1994, J BIOL CHEM, V269, P21944; Bhattacharya M, 2002, NAT CELL BIOL, V4, P547, DOI 10.1038/ncb821; Bogerd HP, 1999, J BIOL CHEM, V274, P9771, DOI 10.1074/jbc.274.14.9771; Chalfie M, 1998, GREEN FLUORESCENT PROTEIN: PROPERTIES, APPLICATIONS, AND PROTOCOLS, pVII; DINGWALL C, 1991, TRENDS BIOCHEM SCI, V16, P478, DOI 10.1016/0968-0004(91)90184-W; Dobransky T, 2003, J BIOL CHEM, V278, P5883, DOI 10.1074/jbc.M212080200; Dobransky T, 2001, J BIOL CHEM, V276, P22244, DOI 10.1074/jbc.M011702200; Dobransky T, 2000, BIOCHEM J, V349, P141, DOI 10.1042/0264-6021:3490141; Dostie J, 2000, EMBO J, V19, P3142, DOI 10.1093/emboj/19.12.3142; Dunn HG, 2001, CAN J NEUROL SCI, V28, P16; Engel K, 1998, EMBO J, V17, P3363, DOI 10.1093/emboj/17.12.3363; ERICKSON JD, 1994, J BIOL CHEM, V269, P21929; Farjot G, 2000, J VIROL, V74, P6068, DOI 10.1128/JVI.74.13.6068-6076.2000; FISCHER U, 1995, CELL, V82, P475, DOI 10.1016/0092-8674(95)90436-0; FONNUM F, 1969, BIOCHEM J, V115, P465, DOI 10.1042/bj1150465; Gorlich D, 1998, EMBO J, V17, P2721, DOI 10.1093/emboj/17.10.2721; Gorlich D, 1999, ANNU REV CELL DEV BI, V15, P607, DOI 10.1146/annurev.cellbio.15.1.607; Henderson BR, 2000, EXP CELL RES, V256, P213, DOI 10.1006/excr.2000.4825; Howell JL, 2002, BIOTECHNIQUES, V32, P80, DOI 10.2144/02321st04; Huang TT, 2000, P NATL ACAD SCI USA, V97, P1014, DOI 10.1073/pnas.97.3.1014; Kaffman A, 1998, NATURE, V396, P482, DOI 10.1038/24898; KAIN SR, 1995, BIOTECHNIQUES, V19, P650; Kao HY, 2001, J BIOL CHEM, V276, P47496, DOI 10.1074/jbc.M107631200; Kasa P, 1997, PROG NEUROBIOL, V52, P511, DOI 10.1016/S0301-0082(97)00028-2; Kim JE, 2000, P NATL ACAD SCI USA, V97, P14340, DOI 10.1073/pnas.011511898; Kudo N, 1999, P NATL ACAD SCI USA, V96, P9112, DOI 10.1073/pnas.96.16.9112; Kudo N, 1998, EXP CELL RES, V242, P540, DOI 10.1006/excr.1998.4136; Lee DCY, 1999, J BIOL CHEM, V274, P29031, DOI 10.1074/jbc.274.41.29031; LIND GJ, 1993, INVEST OPHTH VIS SCI, V34, P2943; LIND GJ, 1995, INVEST OPHTH VIS SCI, V36, P1492; Lipowsky G, 2000, EMBO J, V19, P4362, DOI 10.1093/emboj/19.16.4362; Meyer BE, 1996, J VIROL, V70, P2350, DOI 10.1128/JVI.70.4.2350-2359.1996; Michael WM, 1997, EMBO J, V16, P3587, DOI 10.1093/emboj/16.12.3587; MICHAEL WM, 1995, CELL, V83, P415; Misawa H, 1997, MOL BRAIN RES, V44, P323, DOI 10.1016/S0169-328X(96)00231-8; Oda Y, 1999, PATHOL INT, V49, P921, DOI 10.1046/j.1440-1827.1999.00977.x; OssarehNazari B, 1997, SCIENCE, V278, P141, DOI 10.1126/science.278.5335.141; PINOLROMA S, 1992, NATURE, V355, P730, DOI 10.1038/355730a0; Pollard VW, 1996, CELL, V86, P985, DOI 10.1016/S0092-8674(00)80173-7; Resendes MC, 1999, J BIOL CHEM, V274, P19417, DOI 10.1074/jbc.274.27.19417; Rizzuto R, 1996, CURR BIOL, V6, P183, DOI 10.1016/S0960-9822(02)00451-7; Robert I, 2001, J NEUROCHEM, V79, P9, DOI 10.1046/j.1471-4159.2001.00508.x; Rosario M, 2001, MOL CELL BIOL, V21, P3750, DOI 10.1128/MCB.21.11.3750-3762.2001; Tachibana T, 1999, FEBS LETT, V442, P235, DOI 10.1016/S0014-5793(98)01664-0; Tang H, 1999, MOL CELL BIOL, V19, P3540; Wang AH, 2001, MOL CELL BIOL, V21, P5992, DOI 10.1128/MCB.21.17.5992-6005.2001; WEN W, 1995, CELL, V82, P463, DOI 10.1016/0092-8674(95)90435-2; Whitehouse PJ, 1998, J CLIN PSYCHIAT, V59, P19; Wu J, 1999, J BIOL CHEM, V274, P29202, DOI 10.1074/jbc.274.41.29202; Xiao Z, 2001, J BIOL CHEM, V276, P39404, DOI 10.1074/jbc.M103117200	50	22	23	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 30	2003	278	22					20217	20224		10.1074/jbc.M213153200	http://dx.doi.org/10.1074/jbc.M213153200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	682EH	12637523	hybrid			2022-12-25	WOS:000183078000083
J	Mutsuda, M; Michel, KP; Zhang, XF; Montgomery, BL; Golden, SS				Mutsuda, M; Michel, KP; Zhang, XF; Montgomery, BL; Golden, SS			Biochemical properties of CikA, an unusual phytochrome-like histidine protein kinase that resets the circadian clock in Synechococcus elongatus PCC 7942	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PSEUDO-RESPONSE REGULATORS; GAF DOMAIN; TRANSCRIPTION; INSIGHT; SENSORS; BLUE; BACTERIOPHYTOCHROMES; AUTOPHOSPHORYLATION; PHOTORECEPTORS; CRYPTOCHROMES	We recently described the cikA (circadian input kinase A) gene, whose product supplies environmental information to the circadian oscillator in the cyanobacterium Synechococcus elongatus PCC 7942. CikA possesses three distinct domains: a GAF, a histidine protein kinase (HPK), and a receiver domain similar to those of the response regulator family. To determine how CikA functions in providing circadian input, we constructed modified alleles to tag and truncate the protein, allowing analysis of each domain individually. CikA covalently bound bilin chromophores in vitro, even though it lacks the expected ligand residues, and the GAF domain influenced but did not entirely account for this function. Full-length CikA and truncated variants that carry the HPK domain showed autophosphorylation activity. Deletion of the GAF domain or the N-terminal region adjacent to GAF dramatically reduced autophosphorylation, whereas elimination of the receiver domain increased activity 10-fold. Assays to test phosphorelay from the HPK to the cryptic receiver domain, which lacks the conserved aspartyl residue that serves as a phosphoryl acceptor in response regulators, were negative. We propose that the cryptic receiver is a regulatory domain that interacts with an unknown protein partner to modulate the autokinase activity of CikA but does not work as bona fide receiver domain in a phosphorelay.	Texas A&M Univ, Dept Biol, College Stn, TX 77843 USA; Univ Calif Davis, Sect Mol & Cellular Biol, Davis, CA 95616 USA	Texas A&M University System; Texas A&M University College Station; University of California System; University of California Davis	Golden, SS (corresponding author), Texas A&M Univ, Dept Biol, 3258 TAMU, College Stn, TX 77843 USA.	sgolden@tamu.edu			NIGMS NIH HHS [GM62419-02] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM062419] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ahmad M, 1999, CURR OPIN PLANT BIOL, V2, P230, DOI 10.1016/S1369-5266(99)80040-5; Ahmad M, 1998, NATURE, V392, P720, DOI 10.1038/33701; Andersson CR, 2000, METHOD ENZYMOL, V305, P527; Aravind L, 1997, TRENDS BIOCHEM SCI, V22, P458, DOI 10.1016/S0968-0004(97)01148-1; Bhoo SH, 2001, NATURE, V414, P776, DOI 10.1038/414776a; BUSTOS SA, 1991, J BACTERIOL, V173, P7525, DOI 10.1128/jb.173.23.7525-7533.1991; Cashmore AR, 1999, SCIENCE, V284, P760, DOI 10.1126/science.284.5415.760; Ceriani MF, 1999, SCIENCE, V285, P553, DOI 10.1126/science.285.5427.553; Chang C, 1998, PLANT PHYSIOL, V117, P723, DOI 10.1104/pp.117.3.723; Davis SJ, 1999, SCIENCE, V286, P2517, DOI 10.1126/science.286.5449.2517; Dunlap JC, 1999, CELL, V96, P271, DOI 10.1016/S0092-8674(00)80566-8; Dunlap JC, 1999, GENES CELLS, V4, P1, DOI 10.1046/j.1365-2443.1999.00239.x; Emery P, 1998, CELL, V95, P669, DOI 10.1016/S0092-8674(00)81637-2; Fankhauser C, 2001, J BIOL CHEM, V276, P11453, DOI 10.1074/jbc.R100006200; Gambetta GA, 2001, P NATL ACAD SCI USA, V98, P10566, DOI 10.1073/pnas.191375198; Giraud E, 2002, NATURE, V417, P202, DOI 10.1038/417202a; Golden S. S., 1994, MOL BIOL CYANOBACTER, P693; HERDMAN M, 2001, BERGEYS MANUAL SYSTE, V1, P776; Ho YSJ, 2000, EMBO J, V19, P5288, DOI 10.1093/emboj/19.20.5288; Hughes J, 1997, NATURE, V386, P663, DOI 10.1038/386663a0; Jiang ZY, 1999, SCIENCE, V285, P406, DOI 10.1126/science.285.5426.406; Jorissen HJMM, 2002, PHOTOCHEM PHOTOBIOL, V75, P554, DOI 10.1562/0031-8655(2002)075<0554:PWNBCT>2.0.CO;2; Jorissen HJMM, 2002, EUR J BIOCHEM, V269, P2662, DOI 10.1046/j.1432-1033.2002.02928.x; Kamei A, 2001, J BACTERIOL, V183, P1505, DOI 10.1128/JB.183.5.1505-1510.2001; KARNIOL B, 2003, P NATL ACAD SCI US; Kehoe DM, 1996, SCIENCE, V273, P1409, DOI 10.1126/science.273.5280.1409; LI LM, 1992, J BIOL CHEM, V267, P19204; Lindner I, 2000, ANGEW CHEM INT EDIT, V39, P3269, DOI 10.1002/1521-3773(20000915)39:18<3269::AID-ANIE3269>3.0.CO;2-I; Liu Y, 1999, CELL MOL LIFE SCI, V55, P1195, DOI 10.1007/s000180050366; Makino S, 2000, PLANT CELL PHYSIOL, V41, P791, DOI 10.1093/pcp/41.6.791; Makino S, 2001, PLANT CELL PHYSIOL, V42, P334, DOI 10.1093/pcp/pce036; Matsushika A, 2000, PLANT CELL PHYSIOL, V41, P1002, DOI 10.1093/pcp/pcd043; MCCLEARY WR, 1990, J BACTERIOL, V172, P6661, DOI 10.1128/jb.172.12.6661-6668.1990; McDowell MT, 2001, PLANT PHYSIOL, V126, P1546, DOI 10.1104/pp.126.4.1546; McWatters H, 1999, CURR BIOL, V9, pR633, DOI 10.1016/S0960-9822(99)80410-2; Montgomery BL, 2002, TRENDS PLANT SCI, V7, P357, DOI 10.1016/S1360-1385(02)02304-X; Nishiwaki T, 2000, P NATL ACAD SCI USA, V97, P495, DOI 10.1073/pnas.97.1.495; O'Hara BP, 1999, EMBO J, V18, P5175, DOI 10.1093/emboj/18.19.5175; Plautz JD, 1997, J BIOL RHYTHM, V12, P204, DOI 10.1177/074873049701200302; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Schmitz O, 2000, SCIENCE, V289, P765, DOI 10.1126/science.289.5480.765; Somers DE, 1998, SCIENCE, V282, P1488, DOI 10.1126/science.282.5393.1488; Stock AM, 2000, ANNU REV BIOCHEM, V69, P183, DOI 10.1146/annurev.biochem.69.1.183; Stock J.B., 1995, 2 COMPONENT SIGNAL T, P25; Strayer C, 2000, SCIENCE, V289, P768, DOI 10.1126/science.289.5480.768; Taylor BL, 1999, MICROBIOL MOL BIOL R, V63, P479, DOI 10.1128/MMBR.63.2.479-506.1999; West AH, 2001, TRENDS BIOCHEM SCI, V26, P369, DOI 10.1016/S0968-0004(01)01852-7; Williams SB, 2002, P NATL ACAD SCI USA, V99, P15357, DOI 10.1073/pnas.232517099; Wu SH, 2000, BIOCHEMISTRY-US, V39, P13487, DOI 10.1021/bi001123z; Yeh KC, 1998, P NATL ACAD SCI USA, V95, P13976, DOI 10.1073/pnas.95.23.13976; Yeh KC, 1997, SCIENCE, V277, P1505, DOI 10.1126/science.277.5331.1505; Zhulin IB, 1997, TRENDS BIOCHEM SCI, V22, P331, DOI 10.1016/S0968-0004(97)01110-9	52	74	82	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 23	2003	278	21					19102	19110		10.1074/jbc.M213255200	http://dx.doi.org/10.1074/jbc.M213255200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	679PY	12626498	hybrid			2022-12-25	WOS:000182932200051
J	Berger, I; Bieniossek, C; Schaffitzel, C; Hassler, M; Santelli, E; Richmond, TJ				Berger, I; Bieniossek, C; Schaffitzel, C; Hassler, M; Santelli, E; Richmond, TJ			Direct interaction of Ca2+/calmodulin inhibits histone deacetylase 5 repressor core binding to myocyte enhancer factor 2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR MEF2; ANGSTROM RESOLUTION; CARDIAC-HYPERTROPHY; CRYSTAL-STRUCTURE; DNA-BINDING; IN-VIVO; CALMODULIN; CHROMATIN; FAMILY; DIFFERENTIATION	Myocyte enhancer factor 2 (MEF2) proteins play a pivotal role in the differentiation of cardiac and skeletal muscle cells. MEF2 factors are regulated by histone deacetylase enzymes such as histone deacetylase 5 (HDAC5). HDAC5 in turn is responsive to Ca2+ signaling mediated by the intracellular calcium sensor calmodulin. Here a combination of proteolytic fragmentation, matrix-assisted laser desorption ionization mass spectrometry, Edman degradation, circular dichroism, gel filtration, and surface plasmon resonance studies is utilized to define and characterize a stable core domain of HDAC5 and to examine its interactions with MEF2a and calmodulin. Results from real time binding experiments provide evidence for direct interaction of Ca2+/calmodulin with HDAC5 inhibiting MEF2a association with this enzyme.	ETH Honggerberg, Inst Mol Biol & Biophys, ETH Zurich, CH-8093 Zurich, Switzerland	Swiss Federal Institutes of Technology Domain; ETH Zurich	Richmond, TJ (corresponding author), ETH Honggerberg, Inst Mol Biol & Biophys, ETH Zurich, CH-8093 Zurich, Switzerland.			Berger, Imre/0000-0001-7518-9045; Berger-Schaffitzel, Christiane Helene/0000-0002-1516-9760; Hassler, Markus/0000-0001-9827-3477				Bertos NR, 2001, BIOCHEM CELL BIOL, V79, P243, DOI 10.1139/bcb-79-3-243; BILLINGSLEY ML, 1985, P NATL ACAD SCI USA, V82, P7585, DOI 10.1073/pnas.82.22.7585; Bouche N, 2002, J BIOL CHEM, V277, P21851, DOI 10.1074/jbc.M200268200; Chang KT, 2002, AGEING RES REV, V1, P313, DOI 10.1016/S1568-1637(02)00003-X; CHIEN YH, 1984, MOL CELL BIOL, V4, P507, DOI 10.1128/MCB.4.3.507; CORNELIUSSEN B, 1994, NATURE, V368, P760, DOI 10.1038/368760a0; Davey CA, 2002, J MOL BIOL, V319, P1097, DOI 10.1016/S0022-2836(02)00386-8; Deisseroth K, 1998, NATURE, V392, P198, DOI 10.1038/32448; Eberharter A, 2002, EMBO REP, V3, P224, DOI 10.1093/embo-reports/kvf053; Fischer DD, 2002, J BIOL CHEM, V277, P6656, DOI 10.1074/jbc.M108055200; Fischle W, 2001, BIOCHEM CELL BIOL, V79, P337, DOI 10.1139/bcb-79-3-337; FONANA A, 1999, PROTEOLYTIC ENZYMES, P257; Gaiser F, 2000, J MOL BIOL, V302, P1119, DOI 10.1006/jmbi.2000.4110; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; GOSSETT LA, 1989, MOL CELL BIOL, V9, P5022, DOI 10.1128/MCB.9.11.5022; Gray SG, 2001, EXP CELL RES, V262, P75, DOI 10.1006/excr.2000.5080; Grozinger CM, 2000, P NATL ACAD SCI USA, V97, P7835, DOI 10.1073/pnas.140199597; Grozinger CM, 1999, P NATL ACAD SCI USA, V96, P4868, DOI 10.1073/pnas.96.9.4868; Grunstein M, 1997, NATURE, V389, P349, DOI 10.1038/38664; Guarente L, 2000, GENE DEV, V14, P1021; Hicks GR, 1995, ANNU REV CELL DEV BI, V11, P155, DOI 10.1146/annurev.cb.11.110195.001103; HLODAN R, 1995, NAT STRUCT BIOL, V2, P587, DOI 10.1038/nsb0795-587; Huang K, 2000, EMBO J, V19, P2615, DOI 10.1093/emboj/19.11.2615; Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127; Johnstone RW, 2002, NAT REV DRUG DISCOV, V1, P287, DOI 10.1038/nrd772; Kao HY, 2002, J BIOL CHEM, V277, P187, DOI 10.1074/jbc.M108931200; Lemercier C, 2000, J BIOL CHEM, V275, P15594, DOI 10.1074/jbc.M908437199; Lu JR, 2000, P NATL ACAD SCI USA, V97, P4070, DOI 10.1073/pnas.080064097; LUBYPHELPS K, 1995, J BIOL CHEM, V270, P21532, DOI 10.1074/jbc.270.37.21532; Luger K, 1997, NATURE, V389, P251, DOI 10.1038/38444; Mao ZX, 1999, SCIENCE, V286, P785, DOI 10.1126/science.286.5440.785; McKinsey TA, 2001, MOL CELL BIOL, V21, P6312, DOI 10.1128/MCB.21.18.6312-6321.2001; McKinsey TA, 2002, TRENDS BIOCHEM SCI, V27, P40, DOI 10.1016/S0968-0004(01)02031-X; Miska EA, 1999, EMBO J, V18, P5099, DOI 10.1093/emboj/18.18.5099; Molkentin JD, 1996, MOL CELL BIOL, V16, P2627; Onions J, 2000, BIOCHEMISTRY-US, V39, P4366, DOI 10.1021/bi992533u; Osawa M, 1999, NAT STRUCT BIOL, V6, P819; Passier R, 2000, J CLIN INVEST, V105, P1395, DOI 10.1172/JCI8551; Penheiter AR, 2002, J BIOL CHEM, V277, P17728, DOI 10.1074/jbc.M111608200; POLLOCK R, 1991, GENE DEV, V5, P2327, DOI 10.1101/gad.5.12a.2327; Rhoads AR, 1997, FASEB J, V11, P331, DOI 10.1096/fasebj.11.5.9141499; Santelli E, 2000, J MOL BIOL, V297, P437, DOI 10.1006/jmbi.2000.3568; Schumacher MA, 2001, NATURE, V410, P1120, DOI 10.1038/35074145; SHATZMAN AR, 1987, ANN NY ACAD SCI, V478, P233; SHORE P, 1995, EUR J BIOCHEM, V229, P1, DOI 10.1111/j.1432-1033.1995.tb20430.x; Sparrow DB, 1999, EMBO J, V18, P5085, DOI 10.1093/emboj/18.18.5085; Strahl BD, 2000, NATURE, V403, P41, DOI 10.1038/47412; Taunton J, 1996, SCIENCE, V272, P408, DOI 10.1126/science.272.5260.408; THULIN E, 1984, BIOCHEMISTRY-US, V23, P1862, DOI 10.1021/bi00303a043; Tsukiyama T, 2002, NAT REV MOL CELL BIO, V3, P422, DOI 10.1038/nrm828; Verdel A, 1999, J BIOL CHEM, V274, P2440, DOI 10.1074/jbc.274.4.2440; Wade PA, 2001, HUM MOL GENET, V10, P693, DOI 10.1093/hmg/10.7.693; Wang AH, 1999, MOL CELL BIOL, V19, P7816; Wang AH, 2000, MOL CELL BIOL, V20, P6904, DOI 10.1128/MCB.20.18.6904-6912.2000; Widom J, 1998, ANNU REV BIOPH BIOM, V27, P285, DOI 10.1146/annurev.biophys.27.1.285; Yang WM, 1996, P NATL ACAD SCI USA, V93, P12845, DOI 10.1073/pnas.93.23.12845; Yang WM, 1997, J BIOL CHEM, V272, P28001, DOI 10.1074/jbc.272.44.28001; Youn HD, 2000, J BIOL CHEM, V275, P22563, DOI 10.1074/jbc.C000304200; Youn HD, 1999, SCIENCE, V286, P790, DOI 10.1126/science.286.5440.790; Zhang CL, 2002, CELL, V110, P479, DOI 10.1016/S0092-8674(02)00861-9; Zhang CL, 2002, MOL CELL BIOL, V22, P7302, DOI 10.1128/MCB.22.20.7302-7312.2002; Zhang F, 1998, NAT STRUCT BIOL, V5, P180, DOI 10.1038/nsb0398-180; Zhou XB, 2001, P NATL ACAD SCI USA, V98, P10572, DOI 10.1073/pnas.191375098	63	34	36	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 16	2003	278	20					17625	17635		10.1074/jbc.M301646200	http://dx.doi.org/10.1074/jbc.M301646200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677YX	12626519	hybrid			2022-12-25	WOS:000182838300008
J	Ferry, G; Tellier, E; Try, A; Gres, S; Naime, I; Simon, MF; Rodriguez, M; Boucher, J; Tack, I; Gesta, S; Chomarat, P; Dieu, M; Raes, M; Galizzi, JP; Valet, P; Boutin, JA; Saulnier-Blache, JS				Ferry, G; Tellier, E; Try, A; Gres, S; Naime, I; Simon, MF; Rodriguez, M; Boucher, J; Tack, I; Gesta, S; Chomarat, P; Dieu, M; Raes, M; Galizzi, JP; Valet, P; Boutin, JA; Saulnier-Blache, JS			Autotaxin is released from adipocytes, catalyzes lysophosphatidic acid synthesis, and activates preadipocyte proliferation - Up-regulated expression with adipocyte differentiation and obesity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LYSOPHOSPHOLIPASE-D ACTIVITY; INSULIN-RESISTANCE; ADIPOSE-TISSUE; MOTILITY; RECEPTOR; PYROPHOSPHATASE; PROTEIN; CLONING; GROWTH; IDENTIFICATION	Our group has recently demonstrated (Gesta, S., Simon, M., Rey, A., Sibrac, D., Girard, A., Lafontan, M., Valet, P., and Saulnier-Blache, J. S. (2002) J. Lipid Res. 43, 904-910) the presence, in adipocyte conditioned-medium, of a soluble lysophospholipase D-activity (LPLDact) involved in synthesis of the bioactive phospholipid lysophosphatidic acid (LPA). In the present report, LPLDact was purified from 3T3F442A adipocyte-conditioned medium and identified as the type II ecto-nucleotide pyrophosphatase phosphodiesterase, autotaxin (ATX). A unique ATX cDNA was cloned from 3T3F442A adipocytes, and its recombinant expression in COS-7 cells led to extracellular release of LPLDact. ATX mRNA expression was highly up-regulated during adipocyte differentiation of 3T3F442A-preadipocytes. This up-regulation was paralleled by the ability of newly differentiated adipocytes to release LPLDact and LPA. Differentiation-dependent up-regulation of ATX expression was also observed in a primary culture of mouse preadipocytes. Treatment of 3T3F442A-preadipocytes with concentrated conditioned medium from ATX-expressing COS-7 cells led to an increase in cell number as compared with concentrated conditioned medium from ATX non-expressing COS-7 cells. The specific effect of ATX on preadipocyte proliferation was completely suppressed by co-treatment with a LPA-hydrolyzing phospholipase, phospholipase B. Finally, ATX expression was found in mature adipocytes isolated from mouse adipose tissue and was substantially increased in genetically obese-diabetic db/db mice when compared with their lean siblings. In conclusion, the present work shows that ATX is responsible for the LPLDact released by adipocytes and exerts a paracrine control on preadipocyte growth via an LPA-dependent mechanism. Up-regulations of ATX expression with adipocyte differentiation and genetic obesity suggest a possible involvement of this released protein in the development of adipose tissue and obesity-associated pathologies.	CHU Rangueil, INSERM, U586, Inst Louis Bugnard, F-31403 Toulouse 4, France; CHU Rangueil, INSERM, U388, F-31403 Toulouse 4, France; Ctr Rech Croissy, Inst Rech Servier, F-78290 Croissy Sur Seine, France; Univ Namur, B-5000 Namur, Belgium	CHU de Toulouse; Institut National de la Sante et de la Recherche Medicale (Inserm); CHU de Toulouse; Institut National de la Sante et de la Recherche Medicale (Inserm); Servier; Institut de Recherches Internationales Servier; University of Namur	Saulnier-Blache, JS (corresponding author), CHU Rangueil, INSERM, U586, Inst Louis Bugnard, F-31403 Toulouse 4, France.	saulnier@toulouse.inserm.fr	Valet, Philippe/N-7472-2017; Saulnier-Blache, Jean Sebastien/X-7729-2018; Boutin, Jean Albert/W-9103-2019; Boucher, Jeremie/G-6602-2015	Valet, Philippe/0000-0001-6520-7393; Boutin, Jean Albert/0000-0003-0068-7204; Dieu, Marc/0000-0002-3902-542X; Saulnier-Blache, Jean Sebastien/0000-0002-8971-7723				Aoki J, 2002, J BIOL CHEM, V277, P48737, DOI 10.1074/jbc.M206812200; Betuing S, 1997, BIOCHEM BIOPH RES CO, V235, P765, DOI 10.1006/bbrc.1997.6887; Bollen M, 2000, CRIT REV BIOCHEM MOL, V35, P393, DOI 10.1080/10409230091169249; Chun J, 2002, PHARMACOL REV, V54, P265, DOI 10.1124/pr.54.2.265; Clair T, 1997, J BIOL CHEM, V272, P996, DOI 10.1074/jbc.272.2.996; CRANDALL DL, 1990, FASEB J, V4, P141, DOI 10.1096/fasebj.4.2.2404816; DESLEX S, 1987, EXP CELL RES, V168, P15, DOI 10.1016/0014-4827(87)90412-5; Gaits F, 1997, FEBS LETT, V410, P54, DOI 10.1016/S0014-5793(97)00411-0; Gesta S, 2002, J LIPID RES, V43, P904; GREEN H, 1976, CELL, V7, P105, DOI 10.1016/0092-8674(76)90260-9; Hausman D B, 2001, Obes Rev, V2, P239, DOI 10.1046/j.1467-789X.2001.00042.x; KAWAGOE H, 1995, GENOMICS, V30, P380, DOI 10.1006/geno.1995.0036; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lee HY, 1996, J BIOL CHEM, V271, P24408, DOI 10.1074/jbc.271.40.24408; Lee HY, 1996, BIOCHEM BIOPH RES CO, V218, P714, DOI 10.1006/bbrc.1996.0127; Lee HY, 2002, FEBS LETT, V515, P137, DOI 10.1016/S0014-5793(02)02457-2; Liliom K, 1998, AM J PHYSIOL-CELL PH, V274, pC1065, DOI 10.1152/ajpcell.1998.274.4.C1065; MacDougald OA, 2002, TRENDS ENDOCRIN MET, V13, P5, DOI 10.1016/S1043-2760(01)00517-3; MADDUX BA, 1995, NATURE, V373, P448, DOI 10.1038/373448a0; McIntyre TM, 2003, P NATL ACAD SCI USA, V100, P131, DOI 10.1073/pnas.0135855100; Mohamed-Ali V, 1998, INT J OBESITY, V22, P1145, DOI 10.1038/sj.ijo.0800770; MURATA J, 1994, J BIOL CHEM, V269, P30479; Nam SW, 2001, CANCER RES, V61, P6938; Pages C, 2001, J BIOL CHEM, V276, P11599, DOI 10.1074/jbc.M010111200; Pender C, 2002, METABOLISM, V51, P465, DOI 10.1053/meta.2002.31327; Piao JH, 1999, CYTOGENET CELL GENET, V87, P172, DOI 10.1159/000015459; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; Sakoda H, 1999, DIABETES, V48, P1365, DOI 10.2337/diabetes.48.7.1365; Saulnier-Blache JS, 2000, J LIPID RES, V41, P1947; Shevchenko A, 1996, ANAL CHEM, V68, P850, DOI 10.1021/ac950914h; Spiegelman BM, 1996, CELL, V87, P377, DOI 10.1016/S0092-8674(00)81359-8; STRACKE ML, 1992, J BIOL CHEM, V267, P2524; TIGYI G, 1992, J BIOL CHEM, V267, P21360; Tigyi G, 2001, PROSTAG OTH LIPID M, V64, P47, DOI 10.1016/S0090-6980(01)00107-1; Tokumura A, 1999, BIOL REPROD, V61, P195, DOI 10.1095/biolreprod61.1.195; Tokumura A, 1998, LIPIDS, V33, P1009, DOI 10.1007/s11745-998-0299-2; Tokumura A, 2002, J BIOL CHEM, V277, P39436, DOI 10.1074/jbc.M205623200; Umezu-Goto M, 2002, J CELL BIOL, V158, P227, DOI 10.1083/jcb.200204026; VAGNER S, 1995, MOL CELL BIOL, V15, P35, DOI 10.1128/MCB.15.1.35; Valet P, 1998, J CLIN INVEST, V101, P1431, DOI 10.1172/JCI806; Westermann AM, 1998, ANN ONCOL, V9, P437, DOI 10.1023/A:1008217129273; Xu Y, 1995, CLIN CANCER RES, V1, P1223	42	185	196	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 16	2003	278	20					18162	18169		10.1074/jbc.M301158200	http://dx.doi.org/10.1074/jbc.M301158200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677YX	12642576	Green Accepted, Green Submitted, hybrid			2022-12-25	WOS:000182838300075
J	Gascoyne, DM; Kypta, RM; Vivanco, MDM				Gascoyne, DM; Kypta, RM; Vivanco, MDM			Glucocorticoids inhibit apoptosis during fibrosarcoma development by transcriptionally activating Bcl-x(L)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BCL-2 FAMILY MEMBERS; TRANSGENIC MICE; CELL-DEATH; EPITHELIAL-CELLS; X GENE; RECEPTOR; CANCER; DEXAMETHASONE; EXPRESSION; LINE	Glucocorticoids influence many physiological processes, and in particular apoptosis, often with opposite effects depending on the cell type examined. We found that during fibrosarcoma development there is a strong increase in apoptosis at the tumor stage, which is repressed by dexamethasone to levels observed in normal fibroblasts. The anti-apoptotic Bcl-2 family protein Bcl-x(L) is induced by dexamethasone at the transcriptional level at all stages of fibrosarcoma development. The ligand-activated glucocorticoid receptor (GR) activates the Bcl-x promoter in transient transfection experiments, and GR binds to specific Bcl-x promoter sequences in vitro and in vivo. Furthermore, a GR antagonist abolishes this effect, indicating that Bcl-x(L) induction is mediated by GR. Importantly, exogenous Bcl-x(L) inhibits apoptosis and caspase-3 activity in fibrosarcoma cells to levels found in dexamethasone-treated fibrosarcoma cells. We conclude that Bcl-x(L) is a key target mediating the anti-apoptotic effects of glucocorticoids during fibrosarcoma development. These observations provide further understanding of the molecular basis of glucocorticoid regulation of cell death during tumorigenesis.	Inst Canc Res, Breakthrough Toby Robins Breast Canc Res Ctr, London SW3 6JB, England; Univ London Imperial Coll Sci Technol & Med, Div Med, Dept Canc Med, Prostate Canc Res Grp, London W12 0NN, England	Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK; Imperial College London	Vivanco, MDM (corresponding author), Inst Canc Res, Breakthrough Toby Robins Breast Canc Res Ctr, 237 Fulham Rd, London SW3 6JB, England.		Kypta, Robert/F-7699-2011; Vivanco, Maria/G-2393-2011	Kypta, Robert/0000-0002-2389-310X; Vivanco, Maria/0000-0002-9540-247X				Adams JM, 2001, TRENDS BIOCHEM SCI, V26, P61, DOI 10.1016/S0968-0004(00)01740-0; ALNEMRI ES, 1995, J BIOL CHEM, V270, P4312, DOI 10.1074/jbc.270.9.4312; Amundson SA, 2000, CANCER RES, V60, P6101; Anzick SL, 1997, SCIENCE, V277, P965, DOI 10.1126/science.277.5328.965; ARENDS MJ, 1994, AM J PATHOL, V144, P1045; ASKEW DS, 1991, ONCOGENE, V6, P1915; BEATO M, 1995, CELL, V83, P851, DOI 10.1016/0092-8674(95)90201-5; Boruk M, 1998, MOL ENDOCRINOL, V12, P1749, DOI 10.1210/me.12.11.1749; BOSSYWETZEL E, 1992, GENE DEV, V6, P2340, DOI 10.1101/gad.6.12a.2340; Bryckaert M, 1999, ONCOGENE, V18, P7584, DOI 10.1038/sj.onc.1203200; Chandran UR, 1996, J BIOL CHEM, V271, P20412, DOI 10.1074/jbc.271.34.20412; Chang TC, 1997, FEBS LETT, V415, P11, DOI 10.1016/S0014-5793(97)01083-1; COLE TJ, 1995, STEROIDS, V60, P93, DOI 10.1016/0039-128X(94)00009-2; Earnshaw WC, 1999, ANNU REV BIOCHEM, V68, P383, DOI 10.1146/annurev.biochem.68.1.383; Evan G, 1998, SCIENCE, V281, P1317, DOI 10.1126/science.281.5381.1317; Evans-Storms RB, 2000, ENDOCRINOLOGY, V141, P1854, DOI 10.1210/en.141.5.1854; FENG ZW, 1995, J CELL BIOL, V131, P1095, DOI 10.1083/jcb.131.4.1095; GONZALEZGARCIA M, 1994, DEVELOPMENT, V120, P3033; Gorman AM, 2000, NEUROSCIENCE, V96, P417, DOI 10.1016/S0306-4522(99)00565-5; Grillot DAM, 1997, J IMMUNOL, V158, P4750; Gross A, 1999, GENE DEV, V13, P1899, DOI 10.1101/gad.13.15.1899; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; HANAHAN D, 1988, ANNU REV GENET, V22, P479, DOI 10.1146/annurev.ge.22.120188.002403; Jacobs-Helber SM, 1998, MOL CELL BIOL, V18, P3699, DOI 10.1128/MCB.18.7.3699; KANDEL J, 1991, CELL, V66, P1095, DOI 10.1016/0092-8674(91)90033-U; KauffmanZeh A, 1997, NATURE, V385, P544, DOI 10.1038/385544a0; Kaufmann SH, 2000, BIOESSAYS, V22, P1007, DOI 10.1002/1521-1878(200011)22:11<1007::AID-BIES7>3.3.CO;2-W; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; LACEY M, 1986, NATURE, V322, P609, DOI 10.1038/322609a0; Leonardos L, 1999, CANCER LETT, V143, P29, DOI 10.1016/S0304-3835(99)00176-7; Liu ZG, 2002, VIROLOGY, V295, P230, DOI 10.1006/viro.2001.1351; LOTEM J, 1995, CELL GROWTH DIFFER, V6, P647; Messmer UK, 2000, BRIT J PHARMACOL, V129, P1673, DOI 10.1038/sj.bjp.0703255; MIESFELD R, 1987, SCIENCE, V236, P423, DOI 10.1126/science.3563519; NORDEEN SK, 1990, MOL ENDOCRINOL, V4, P1866, DOI 10.1210/mend-4-12-1866; PAGLIACCI MC, 1993, J ENDOCRINOL INVEST, V16, P591, DOI 10.1007/BF03347677; Pascussi JM, 2003, MOL ENDOCRINOL, V17, P42, DOI 10.1210/me.2002-0244; Pecci A, 1997, J BIOL CHEM, V272, P11791, DOI 10.1074/jbc.272.18.11791; Planey SL, 2000, BIOCHEM BIOPH RES CO, V279, P307, DOI 10.1006/bbrc.2000.3922; RAFF MC, 1992, NATURE, V356, P397, DOI 10.1038/356397a0; Reed JC, 1999, J CLIN ONCOL, V17, P2941, DOI 10.1200/JCO.1999.17.9.2941; Roca R, 2003, P NATL ACAD SCI USA, V100, P3113, DOI 10.1073/pnas.0634912100; Schorr K, 2000, CANCER RES, V60, P5950; Shi YG, 2002, MOL CELL, V9, P459, DOI 10.1016/S1097-2765(02)00482-3; SIPPOLATHIELE M, 1989, MOL CELL BIOL, V9, P925, DOI 10.1128/MCB.9.3.925; Sivaraman L, 2000, BREAST CANCER RES TR, V62, P185, DOI 10.1023/A:1006410111706; Smets LA, 1999, ADV EXP MED BIOL, V457, P607; Tolosa E, 1999, NEUROIMMUNOMODULAT, V6, P90, DOI 10.1159/000026368; VIVANCO MD, 1995, EMBO J, V14, P2217, DOI 10.1002/j.1460-2075.1995.tb07216.x; Weller M, 1997, NEUROLOGY, V48, P1704, DOI 10.1212/WNL.48.6.1704; William R, 1998, J IMMUNOL, V161, P957; Woo M, 1998, GENE DEV, V12, P806, DOI 10.1101/gad.12.6.806; Zong WX, 2001, GENE DEV, V15, P1481, DOI 10.1101/gad.897601	53	70	73	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 16	2003	278	20					18022	18029		10.1074/jbc.M301812200	http://dx.doi.org/10.1074/jbc.M301812200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677YX	12637494	hybrid			2022-12-25	WOS:000182838300056
J	Gidda, SK; Miersch, O; Levitin, A; Schmidt, J; Wasternack, C; Varin, L				Gidda, SK; Miersch, O; Levitin, A; Schmidt, J; Wasternack, C; Varin, L			Biochemical and molecular characterization of a hydroxyjasmonate sulfotransferase from Arabidopsis thaliana	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALLENE OXIDE CYCLASE; JASMONIC ACID; GENE-EXPRESSION; OXYLIPIN SIGNATURE; CIS-JASMONE; OCTADECANOIDS; BIOSYNTHESIS; SULFATION; POTATO; INACTIVATION	12-Hydroxyjasmonate, also known as tuberonic acid, was first isolated from Solanum tuberosum and was shown to have tuber-inducing properties. It is derived from the ubiquitously occurring jasmonic acid, an important signaling molecule mediating diverse developmental processes and plant defense responses. We report here that the gene AtST2a from Arabidopsis thaliana encodes a hydroxyjasmonate sulfotransferase. The recombinant AtST2a protein was found to exhibit strict specificity for 11- and 12-hydroxyjasmonate with Km values of 50 and 10 muM, respectively. Furthermore, 12-hydroxyjasmonate and its sulfonated derivative are shown to be naturally occurring in A. thaliana. The exogenous application of methyljasmonate to A. thaliana plants led to increased levels of both metabolites, whereas treatment with 12-hydroxyjasmonate led to increased level of 12-hydroxyjasmonate sulfate without affecting the endogenous level of jasmonic acid. AtST2a expression was found to be induced following treatment with methyljasmonate and 12-hydroxyjasmonate. In contrast, the expression of the methyljasmonate-responsive gene Thi2.1, a marker gene in plant defense responses, is not induced upon treatment with 12-hydroxyjasmonate indicating the existence of independent signaling pathways responding to jasmonic acid and 12-hydroxyjasmonic acid. Taken together, the results suggest that the hydroxylation and sulfonation reactions might be components of a pathway that inactivates excess jasmonic acid in plants. Alternatively, the function of AtST2a might be to control the biological activity of 12-hydroxyjasmonic acid.	Concordia Univ, Dept Biol, Ctr Struct & Funct Genom, Montreal, PQ H3G 1M8, Canada; Leibniz Inst Plant Biochem, D-06120 Halle An Der Saale, Germany	Concordia University - Canada; Leibniz Institut fur Pflanzenbiochemie	Varin, L (corresponding author), Concordia Univ, Dept Biol, Ctr Struct & Funct Genom, 1455 De Maisonneuve Blvd W, Montreal, PQ H3G 1M8, Canada.	varinl@clone.concordia.ca						ACHENBACH H, 1994, PHYTOCHEMISTRY, V35, P1527, DOI 10.1016/S0031-9422(00)86890-9; Banoglu E, 1997, DRUG METAB DISPOS, V25, P1304; Birkett MA, 2000, P NATL ACAD SCI USA, V97, P9329, DOI 10.1073/pnas.160241697; Blechert S, 1999, PLANTA, V207, P470, DOI 10.1007/s004250050506; Bohlmann H, 1998, FEBS LETT, V437, P281, DOI 10.1016/S0014-5793(98)01251-4; Boss B, 1999, PHYTOCHEMISTRY, V50, P219, DOI 10.1016/S0031-9422(98)00526-3; CASHMORE AR, 1982, METHODS CHLOROPLAST, P387; CUI BL, 1993, CHEM PHARM BULL, V41, P178, DOI 10.1248/cpb.41.178; EPPLE P, 1995, PLANT PHYSIOL, V109, P813, DOI 10.1104/pp.109.3.813; Hause B, 2000, PLANT J, V24, P113, DOI 10.1046/j.1365-313x.2000.00861.x; HELDER H, 1993, PHYSIOL PLANTARUM, V88, P647, DOI 10.1111/j.1399-3054.1993.tb01384.x; HOBKIRK R, 1993, TRENDS ENDOCRIN MET, V4, P69, DOI 10.1016/S1043-2760(05)80018-9; Koch T, 1999, PLANT PHYSIOL, V121, P153, DOI 10.1104/pp.121.1.153; Koch T, 1997, HELV CHIM ACTA, V80, P838, DOI 10.1002/hlca.19970800318; KODA Y, 1992, INT REV CYTOL, V135, P155, DOI 10.1016/S0074-7696(08)62040-9; Kramell R, 2000, PLANT PHYSIOL, V123, P177, DOI 10.1104/pp.123.1.177; Kramell R, 1997, FEBS LETT, V414, P197, DOI 10.1016/S0014-5793(97)01005-3; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Liu MC, 1999, BIOCHEM BIOPH RES CO, V254, P65, DOI 10.1006/bbrc.1998.9872; Marsolais F, 1995, J BIOL CHEM, V270, P30458, DOI 10.1074/jbc.270.51.30458; Marsolais F, 2000, RECENT ADV PHYTOCHEM, V34, P433, DOI 10.1016/S0079-9920(00)80015-5; Marsolais F, 1999, BIOCHEMISTRY-US, V38, P4066, DOI 10.1021/bi982239m; MATSUURA H, 1993, BIOSCI BIOTECH BIOCH, V57, P1253, DOI 10.1271/bbb.57.1253; MCMASTER GK, 1977, P NATL ACAD SCI USA, V74, P4835, DOI 10.1073/pnas.74.11.4835; Miersch O, 1998, PHYTOCHEMISTRY, V47, P327, DOI 10.1016/S0031-9422(97)00617-1; MIERSCH O, 1991, PHYTOCHEMISTRY, V30, P4049, DOI 10.1016/0031-9422(91)83464-V; Miersch O, 1999, PHYTOCHEMISTRY, V50, P353, DOI 10.1016/S0031-9422(98)00597-4; ROTH JA, 1986, TRENDS PHARMACOL SCI, V7, P404, DOI 10.1016/0165-6147(86)90402-5; Rouleau M, 1999, J BIOL CHEM, V274, P20925, DOI 10.1074/jbc.274.30.20925; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Schaller F, 2000, PLANTA, V210, P979, DOI 10.1007/s004250050706; SEMBDNER G, 1994, PLANT MOL BIOL, V26, P1459, DOI 10.1007/BF00016485; Seo HS, 2001, P NATL ACAD SCI USA, V98, P4788, DOI 10.1073/pnas.081557298; Staswick PE, 2002, PLANT CELL, V14, P1405, DOI 10.1105/tpc.000885; Stenzel I, 2003, PLANT J, V33, P577, DOI 10.1046/j.1365-313X.2003.01647.x; Stintzi A, 2001, P NATL ACAD SCI USA, V98, P12837, DOI 10.1073/pnas.211311098; Strott CA, 1996, ENDOCR REV, V17, P670, DOI 10.1210/er.17.6.670; Thomas SG, 1999, P NATL ACAD SCI USA, V96, P4698, DOI 10.1073/pnas.96.8.4698; Varin L, 1997, FASEB J, V11, P517, DOI 10.1096/fasebj.11.7.9212075; Varin L, 1997, PLANT J, V12, P831, DOI 10.1046/j.1365-313X.1997.12040831.x; VICK BA, 1984, PLANT PHYSIOL, V75, P458, DOI 10.1104/pp.75.2.458; VISSER TJ, 1994, CHEM-BIOL INTERACT, V92, P293, DOI 10.1016/0009-2797(94)90071-X; Wasternack C, 1997, TRENDS PLANT SCI, V2, P302, DOI 10.1016/S1360-1385(97)89952-9; Wasternack C, 2002, PROG NUCLEIC ACID RE, V72, P165, DOI 10.1016/S0079-6603(02)72070-9; Weber H, 1997, P NATL ACAD SCI USA, V94, P10473, DOI 10.1073/pnas.94.19.10473; Windsor ML, 1997, PHYTOCHEMISTRY, V45, P931, DOI 10.1016/S0031-9422(97)00022-8; Yoshihara T, 1996, PLANT CELL PHYSIOL, V37, P586, DOI 10.1093/oxfordjournals.pcp.a028985; YOSHIHARA T, 1989, AGR BIOL CHEM TOKYO, V53, P2835, DOI 10.1080/00021369.1989.10869712; Ziegler J, 2000, J BIOL CHEM, V275, P19132, DOI 10.1074/jbc.M002133200	49	134	144	1	25	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 16	2003	278	20					17895	17900		10.1074/jbc.M211943200	http://dx.doi.org/10.1074/jbc.M211943200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677YX	12637544	hybrid			2022-12-25	WOS:000182838300039
J	Hartigan, N; Garrigue-Antar, L; Kadler, KE				Hartigan, N; Garrigue-Antar, L; Kadler, KE			Bone morphogenetic protein-1 (BMP-1) - Identification of the minimal domain structure for procollagen C-proteinase activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FAMILY; METALLOPROTEINASES; HOMOLOG; OXIDASE; GENE	Bone morphogenetic protein-1 (BMP-1) is a shorter spliced variant of mammalian tolloid (mTld), both of which cleave the C-propeptides of type I procollagen during the synthesis of extracellular matrix collagen fibrils. The fact that BMP-1 and mTld both exhibit procollagen C-proteinase (PCP) activity and that BMP-1 is the smaller variant might indicate that BMP-1 comprises the minimal required sequences for PCP activity. BMP-1 comprises a metalloproteinase domain, three CUB domains, and an epidermal growth factor (EGF)-like domain, which is located between the second and third CUB (complement components C1r/C1s,the sea urchin protein Uegf, and BMP-1) domains. In this study we showed the following. 1) The CUB1 domain is required for secretion of the molecule. Domain swapping experiments, in which CUB1 and other CUB domains were interchanged, resulted in retention of the proteins by cells. Therefore, CUB1 and its location immediately adjacent to the metalloproteinase domain are essential for secretion of the protein. 2) Mutants lacking the EGF-like and CUB3 domains exhibited full C-proteinase activity. In contrast, mutants lacking the CUB2 domain were poor C-proteinases. 3) Further studies showed that Glu-483 on the beta4-beta5 loop of CUB2 is essential for C-proteinase activity of BMP-1. In conclusion, the study showed that the minimal domain structure for PCP activity is considerably shorter than expected and comprises the metalloproteinase domain and the CUB1 and CUB2 domains of BMP-1.	Univ Manchester, Sch Biol Sci, Wellcome Trust Ctr Cell Matrix Res, Manchester M13 9PT, Lancs, England	University of Manchester	Kadler, KE (corresponding author), Univ Manchester, Sch Biol Sci, Wellcome Trust Ctr Cell Matrix Res, Stopford Bldg 2-205,Oxford Rd, Manchester M13 9PT, Lancs, England.		KADLER, KARL/ABI-2403-2020	KADLER, KARL/0000-0003-4977-4683; Garrigue-Antar, Laure/0000-0001-6331-8882				Amano S, 2000, J BIOL CHEM, V275, P22728, DOI 10.1074/jbc.M002345200; BOND JS, 1995, PROTEIN SCI, V4, P1247, DOI 10.1002/pro.5560040701; BORK P, 1993, J MOL BIOL, V17, P565; CHILDS SR, 1994, DEV BIOL, V162, P209, DOI 10.1006/dbio.1994.1079; FINELLI AL, 1994, DEVELOPMENT, V120, P861; Garrigue-Antar L, 2002, J BIOL CHEM, V277, P43327, DOI 10.1074/jbc.M207342200; Garrigue-Antar L, 2001, J BIOL CHEM, V276, P26237, DOI 10.1074/jbc.M010814200; Kessler E, 1996, SCIENCE, V271, P360, DOI 10.1126/science.271.5247.360; Li SW, 1996, P NATL ACAD SCI USA, V93, P5127, DOI 10.1073/pnas.93.10.5127; Panchenko MV, 1996, J BIOL CHEM, V271, P7113, DOI 10.1074/jbc.271.12.7113; Rattenholl A, 2002, J BIOL CHEM, V277, P26372, DOI 10.1074/jbc.M203247200; Romao MJ, 1997, J MOL BIOL, V274, P650, DOI 10.1006/jmbi.1997.1423; Scott IC, 1999, DEV BIOL, V213, P283, DOI 10.1006/dbio.1999.9383; Scott IC, 2000, J BIOL CHEM, V275, P30504, DOI 10.1074/jbc.M004846200; Sieron AL, 2000, BIOCHEMISTRY-US, V39, P3231, DOI 10.1021/bi992312o; Suzuki N, 1996, DEVELOPMENT, V122, P3587; TAKAHARA K, 1994, J BIOL CHEM, V269, P32572; URIST MR, 1965, SCIENCE, V150, P893, DOI 10.1126/science.150.3698.893; Uzel MI, 2001, J BIOL CHEM, V276, P22537, DOI 10.1074/jbc.M102352200; Veitch DP, 2003, J BIOL CHEM, V278, P15661, DOI 10.1074/jbc.M210588200; WOZNEY JM, 1988, SCIENCE, V242, P1528, DOI 10.1126/science.3201241	21	61	63	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 16	2003	278	20					18045	18049		10.1074/jbc.M211448200	http://dx.doi.org/10.1074/jbc.M211448200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677YX	12637537	hybrid			2022-12-25	WOS:000182838300059
J	Nedialkov, YA; Gong, XQ; Hovde, SL; Yamaguchi, Y; Handa, H; Geiger, JH; Yan, HG; Burton, ZF				Nedialkov, YA; Gong, XQ; Hovde, SL; Yamaguchi, Y; Handa, H; Geiger, JH; Yan, HG; Burton, ZF			NTP-driven translocation by human RNA polymerase II	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR-IIF; HEPATITIS-DELTA VIRUS; 3.3 ANGSTROM RESOLUTION; NUCLEOTIDE INCORPORATION; ELONGATION COMPLEX; CRYSTAL-STRUCTURE; KINETIC-ANALYSIS; SINGLE-MOLECULE; PROMOTER ESCAPE; DNA	We report a "running start, two-bond" protocol to analyze elongation by human RNA polymerase II (RNAP II). In this procedure, the running start allowed us to measure rapid rates of elongation and provided detailed insight into the RNAP II mechanism. Formation of two bonds was tracked to ensure that at least one translocation event was analyzed. By using this method, RNAP II is stalled briefly at a defined template position before restoring the next NTP. Significantly, slow reaction steps are identified both before and after phosphodiester bond synthesis, and both of these steps can be highly dependent on the next templated NTP. The initial and final NTP-driven events, however, are not identical, because the slow step after chemistry, which includes translocation and pyrophosphate release, is regulated differently by elongation factors hepatitis delta antigen and transcription factor IIF. Because recovery from a stall and the processive transition from one bond to the next can be highly NTP-dependent, we conclude that translocation can be driven by the incoming substrate NTP, a model fully consistent with the RNAP II elongation complex structure.	Michigan State Univ, Dept Biochem & Mol Biol, E Lansing, MI 48824 USA; Michigan State Univ, Dept Chem, E Lansing, MI 48824 USA; Tokyo Inst Technol, Grad Sch Biosci & Biotechnol, Yokohama, Kanagawa 2268503, Japan; Tokyo Inst Technol, Frontier Collaborat Res Ctr, Yokohama, Kanagawa 2268503, Japan	Michigan State University; Michigan State University; Tokyo Institute of Technology; Tokyo Institute of Technology	Burton, ZF (corresponding author), Michigan State Univ, Dept Biochem & Mol Biol, E Lansing, MI 48824 USA.	Burton@msu.edu	Yamaguchi, Yuki/B-9390-2015; gong, xue/GYQ-8649-2022	Yamaguchi, Yuki/0000-0002-0197-614X; Geiger, James/0000-0002-9443-4488				Adelman K, 2002, P NATL ACAD SCI USA, V99, P13538, DOI 10.1073/pnas.212358999; Arndt JW, 2001, BIOCHEMISTRY-US, V40, P5368, DOI 10.1021/bi002176j; BENGAL E, 1991, MOL CELL BIOL, V11, P1195, DOI 10.1128/MCB.11.3.1195; Chang JH, 2002, EMBO J, V21, P157, DOI 10.1093/emboj/21.1.157; Conaway JW, 2000, TRENDS BIOCHEM SCI, V25, P375, DOI 10.1016/S0968-0004(00)01615-7; Cramer Patrick, 2001, Science (Washington D C), V292, P1863, DOI 10.1126/science.1059493; Doublie S, 1998, NATURE, V391, P251, DOI 10.1038/34593; Dunlap CA, 2002, BIOCHEMISTRY-US, V41, P11226, DOI 10.1021/bi025837g; Dvir A, 2002, BBA-GENE STRUCT EXPR, V1577, P208, DOI 10.1016/S0167-4781(02)00453-0; Epshtein V, 2002, MOL CELL, V10, P623, DOI 10.1016/S1097-2765(02)00640-8; Forde NR, 2002, P NATL ACAD SCI USA, V99, P11682, DOI 10.1073/pnas.142417799; Foster JE, 2001, CELL, V106, P243, DOI 10.1016/S0092-8674(01)00420-2; FU TB, 1993, J VIROL, V67, P6965, DOI 10.1128/JVI.67.12.6965-6972.1993; Funk JD, 2002, J BIOL CHEM, V277, P46998, DOI 10.1074/jbc.M206249200; Gnatt AL, 2001, SCIENCE, V292, P1876, DOI 10.1126/science.1059495; Guajardo R, 1998, J MOL BIOL, V281, P777, DOI 10.1006/jmbi.1998.1988; Guajardo R, 1997, J MOL BIOL, V265, P8, DOI 10.1006/jmbi.1996.0707; Guthold M, 2001, CHEMBIOCHEM, V2, P167; Huang JB, 2000, J MOL BIOL, V303, P347, DOI 10.1006/jmbi.2000.4150; IZBAN MG, 1992, J BIOL CHEM, V267, P13647; JOHNSON KA, 1993, ANNU REV BIOCHEM, V62, P685, DOI 10.1146/annurev.bi.62.070193.003345; JOHNSON KA, 1995, METHOD ENZYMOL, V249, P38; JOHNSON MD, 1992, PHYSICIAN SPORTSMED, V20, P60, DOI 10.1080/00913847.1992.11947449; Julicher F, 1998, BIOPHYS J, V74, P1169, DOI 10.1016/S0006-3495(98)77833-6; Kim D, 2001, MOL CELLS, V11, P267; Korzheva N, 1998, COLD SPRING HARB SYM, V63, P337, DOI 10.1101/sqb.1998.63.337; Krogan NJ, 2002, MOL CELL BIOL, V22, P6979, DOI 10.1128/MCB.22.20.6979-6992.2002; Kuzmic P, 1996, ANAL BIOCHEM, V237, P260, DOI 10.1006/abio.1996.0238; Lei L, 1999, MOL CELL BIOL, V19, P8372; Li Y, 1998, EMBO J, V17, P7514, DOI 10.1093/emboj/17.24.7514; Li Y, 2001, PROTEIN SCI, V10, P1225, DOI 10.1110/ps.250101; Macnaughton TB, 2002, J VIROL, V76, P3920, DOI 10.1128/JVI.76.8.3920-3927.2002; Modahl LE, 2000, MOL CELL BIOL, V20, P6030, DOI 10.1128/MCB.20.16.6030-6039.2000; NEDIALKOV YA, 2003, IN PRESS METHODS ENZ; PATEL SS, 1991, BIOCHEMISTRY-US, V30, P511, DOI 10.1021/bi00216a029; PRICE DH, 1989, MOL CELL BIOL, V9, P1465, DOI 10.1128/MCB.9.4.1465; Renner DB, 2001, J BIOL CHEM, V276, P42601, DOI 10.1074/jbc.M104967200; SHAPIRO DJ, 1988, DNA-J MOLEC CELL BIO, V7, P47, DOI 10.1089/dna.1988.7.47; Shilatifard A, 1998, FASEB J, V12, P1437, DOI 10.1096/fasebj.12.14.1437; Showalter AK, 2002, BIOCHEMISTRY-US, V41, P10571, DOI 10.1021/bi026021i; TAN SY, 1994, J BIOL CHEM, V269, P25684; Vassylyev DG, 2002, NATURE, V417, P712, DOI 10.1038/nature752; von Hippel PH, 1998, SCIENCE, V281, P660, DOI 10.1126/science.281.5377.660; WANG BQ, 1994, PROTEIN EXPRES PURIF, V5, P476, DOI 10.1006/prep.1994.1067; WANG BQ, 1993, PROTEIN EXPRES PURIF, V4, P207, DOI 10.1006/prep.1993.1027; Wang HY, 1998, BIOPHYS J, V74, P1186, DOI 10.1016/S0006-3495(98)77834-8; Wang MD, 1998, SCIENCE, V282, P902, DOI 10.1126/science.282.5390.902; WONG I, 1991, BIOCHEMISTRY-US, V30, P526, DOI 10.1021/bi00216a030; Yamaguchi Y, 2001, SCIENCE, V293, P124, DOI 10.1126/science.1057925; Yamaguchi Y, 2002, MICROBES INFECT, V4, P1169, DOI 10.1016/S1286-4579(02)01641-6; Yan Q, 1999, J BIOL CHEM, V274, P35668, DOI 10.1074/jbc.274.50.35668; YIN H, 1995, SCIENCE, V270, P1653, DOI 10.1126/science.270.5242.1653; Zhang GY, 1999, CELL, V98, P811, DOI 10.1016/S0092-8674(00)81515-9	53	70	73	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 16	2003	278	20					18303	18312		10.1074/jbc.M301103200	http://dx.doi.org/10.1074/jbc.M301103200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677YX	12637520	hybrid			2022-12-25	WOS:000182838300094
J	Williams, RC; Rees, ML; Jacobs, MF; Pragai, Z; Thwaite, JE; Baillie, LWJ; Emmerson, PT; Harwood, CR				Williams, RC; Rees, ML; Jacobs, MF; Pragai, Z; Thwaite, JE; Baillie, LWJ; Emmerson, PT; Harwood, CR			Production of Bacillus anthracis protective antigen is dependent on the extracellular chaperone, PrsA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN SECRETION; SIGNAL PEPTIDASES; ALPHA-AMYLASE; SUBTILIS; EXPRESSION; GENE; BINDING; CLONING; PATHWAY; GROWTH	Protective antigen (PA) is a component of the Bacillus anthracis lethal and edema toxins and the basis of the current anthrax vaccine. In its heptameric form, PA targets host cells and internalizes the enzymatically active components of the toxins, namely lethal and edema factors. PA and other toxin components are secreted from B. anthracis using the Sec-dependent secretion pathway. This requires them to be translocated across the cytoplasmic membrane in an unfolded state and then to be folded into their native configurations on the trans side of the membrane, prior to their release from the environment of the cell wall. In this study we show that recombinant PA (rPA) requires the extracellular chaperone PrsA for efficient folding when produced in the heterologous host, B. subtilis; increasing the concentration of PrsA leads to an increase in rPA production. To determine the likelihood of PrsA being required for PA production in its native host, we have analyzed the B. anthracis genome sequence for the presence of genes encoding homologues of B. subtilis PrsA. We identified three putative B. anthracis PrsA proteins (PrsAA, PrsAB, and PrsAC) that are able to complement the activity of B. subtilis PrsA with respect to cell viability and rPA secretion, as well as that of AmyQ, a protein previously shown to be PrsA-dependent.	Univ Newcastle Upon Tyne, Sch Med, Sch Cell & Mol Biosci, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England; NIDCR, Oral Infect & Immunol Branch, NIH, Bethesda, MD 20892 USA; Def Sci & Technol Lab, Salisbury SP4 OJQ, Wilts, England	Newcastle University - UK; National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR); Defence Science & Technology Laboratory	Harwood, CR (corresponding author), Univ Newcastle Upon Tyne, Sch Med, Sch Cell & Mol Biosci, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.		Baillie, Les/AAG-7090-2020; Harwood, Colin/AGF-0120-2022	Baillie, Les/0000-0002-8186-223X; Harwood, Colin/0000-0002-3624-0001				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; ANAGNOSTOPOULOS C, 1961, J BACTERIOL, V81, P741, DOI 10.1128/JB.81.5.741-746.1961; AVAKYAN AA, 1965, J BACTERIOL, V90, P1082, DOI 10.1128/JB.90.4.1082-1095.1965; BAILLIE LWJ, 1994, LETT APPL MICROBIOL, V19, P225, DOI 10.1111/j.1472-765X.1994.tb00949.x; Barnard JP, 1999, INFECT IMMUN, V67, P562, DOI 10.1128/IAI.67.2.562-567.1999; BELTON FC, 1954, BRIT J EXP PATHOL, V35, P144; Bensing BA, 2002, MOL MICROBIOL, V44, P1081, DOI 10.1046/j.1365-2958.2002.02949.x; Bron S, 1998, J BIOTECHNOL, V64, P3, DOI 10.1016/S0168-1656(98)00099-6; BRON S, 1990, MOL BIOL METHODS BAC, P75; Hyyrylainen HL, 2000, J BIOL CHEM, V275, P26696; IVINS BE, 1986, INFECT IMMUN, V54, P537, DOI 10.1128/IAI.54.2.537-542.1986; Jongbloed JDH, 2000, J BIOL CHEM, V275, P41350, DOI 10.1074/jbc.M004887200; KONTINEN VP, 1993, MOL MICROBIOL, V8, P727, DOI 10.1111/j.1365-2958.1993.tb01616.x; LACEY RW, 1976, J MED MICROBIOL, V7, P285; Lenz LL, 2002, MOL MICROBIOL, V45, P1043, DOI 10.1046/j.1365-2958.2002.03072.x; LEPPLA SH, 1991, ANTHRAX TOXIN COMPLE, P277; MAKINO S, 1989, J BACTERIOL, V171, P722, DOI 10.1128/jb.171.2.722-730.1989; Miller J, 1998, LETT APPL MICROBIOL, V26, P56, DOI 10.1046/j.1472-765X.1998.00274.x; Mock M, 2001, ANNU REV MICROBIOL, V55, P647, DOI 10.1146/annurev.micro.55.1.647; PALVA I, 1982, GENE, V19, P81, DOI 10.1016/0378-1119(82)90191-3; PEZARD C, 1991, INFECT IMMUN, V59, P3472, DOI 10.1128/IAI.59.10.3472-3477.1991; Pragai Z, 2000, J BACTERIOL, V182, P6819, DOI 10.1128/JB.182.23.6819-6823.2000; SINGH Y, 1989, J BIOL CHEM, V264, P19103; Stover AG, 1999, J BACTERIOL, V181, P1664; Stover AG, 1999, J BACTERIOL, V181, P5476; Tjalsma H, 1997, J BIOL CHEM, V272, P25983, DOI 10.1074/jbc.272.41.25983; Tjalsma H, 2000, MICROBIOL MOL BIOL R, V64, P515, DOI 10.1128/MMBR.64.3.515-547.2000; Turnbull PCB, 2000, CURR OPIN INFECT DIS, V13, P113, DOI 10.1097/00001432-200004000-00004; Vagner V, 1998, MICROBIOL-SGM, V144, P3097, DOI 10.1099/00221287-144-11-3097; van Dijl JM, 2002, J BIOTECHNOL, V98, P243, DOI 10.1016/S0168-1656(02)00135-9; Vitikainen M, 2001, J BACTERIOL, V183, P1881, DOI 10.1128/JB.183.6.1881-1890.2001; WU XC, 1991, J BACTERIOL, V173, P4952, DOI 10.1128/jb.173.16.4952-4958.1991	32	49	58	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 16	2003	278	20					18056	18062		10.1074/jbc.M301244200	http://dx.doi.org/10.1074/jbc.M301244200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677YX	12606539	hybrid			2022-12-25	WOS:000182838300061
J	Zou, W; Amcheslavsky, A; Bar-Shavit, Z				Zou, W; Amcheslavsky, A; Bar-Shavit, Z			CpG oligodeoxynucleotides modulate the osteoclastogenic activity of osteoblasts via toll-like receptor 9	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; NECROSIS-FACTOR-ALPHA; COLONY-STIMULATING FACTOR; BONE-RESORPTION; BACTERIAL-DNA; IN-VITRO; DIFFERENTIATION FACTOR; STROMAL CELLS; OSTEOPROTEGERIN LIGAND; RHEUMATOID-ARTHRITIS	Regulation of osteoclastogenesis by lipopolysaccharide (LPS) is mediated via its interactions with toll-like receptor 4 (TLR4) on both osteoclast-and osteoblast-lineage cells. We have recently demonstrated that CpG oligodeoxynucleotides (CpG ODNs), known to mimic bacterial DNA, modulate osteoclastogenesis via interactions with osteoclast precursors. In the present study we characterize the interactions of CpG ODNs with osteoblasts, in comparison with LPS. We find that, similar to LPS, CpG ODNs modulate osteoclastogenesis in bone marrow cell/osteoblast co-cultures, although in a somewhat different pattern. Osteoblasts express receptors for both LPS and CpG ODN (TLR4 and TLR9, respectively). The osteoblastic TLR9 transmits signals into the cell as demonstrated by NFkappaB activation as well as by extracellular-regulated kinase (ERK) and p38 phosphorylation. Similar to LPS, CpG ODN increases in osteoblasts the expression of tumor necrosis factor (TNF)-alpha and macrophage-colony stimulating factor (M-CSF). The two TLR ligands do not affect osteoprotegerin expression in osteoblasts. CpG ODN does not significantly affect receptor activator of NFkappaB ligand (RANKL) expression, in contrast to LPS, which induces the expression of this molecule. In the co-cultures CpG ODN induces RANKL expression in osteoblasts as a result of the more efficient TNF-alpha induction. CpG ODN activity (modulation of osteoclastogenesis, gene expression, ERK and p38 phosphorylation, and nuclear translocation of NFkappaB) is specific, because the control oligodeoxynucleotide, not containing CpG, is inactive. Furthermore, these effects (unlike the LPS effects) are inhibited by chloroquine, suggesting a requirement for endosomal maturation/acidification, the classic CpG ODN mode of action. We conclude that CpG ODN, upon TLR9 ligation, induces osteoblasts osteoclastogenic activity.	Hebrew Univ Jerusalem, Hubert H Humphrey Ctr Expt Med & Canc Res, Fac Med, IL-91120 Jerusalem, Israel	Hebrew University of Jerusalem	Bar-Shavit, Z (corresponding author), Hebrew Univ Jerusalem, Hubert H Humphrey Ctr Expt Med & Canc Res, Fac Med, POB 12272, IL-91120 Jerusalem, Israel.			Zou, Wei/0000-0001-8081-268X				Akira S, 2001, NAT IMMUNOL, V2, P675, DOI 10.1038/90609; Alexopoulou L, 2001, NATURE, V413, P732, DOI 10.1038/35099560; Aliprantis AO, 1999, SCIENCE, V285, P736, DOI 10.1126/science.285.5428.736; Baer M, 1998, MOL CELL BIOL, V18, P5678, DOI 10.1128/MCB.18.10.5678; Bauer S, 2001, P NATL ACAD SCI USA, V98, P9237, DOI 10.1073/pnas.161293498; Chiang CY, 1999, INFECT IMMUN, V67, P4231, DOI 10.1128/IAI.67.8.4231-4236.1999; Choi BK, 2001, J PERIODONTOL, V72, P1172, DOI 10.1902/jop.2000.72.9.1172; Collin-Osdoby P, 2002, J BONE MINER RES, V17, P1859, DOI 10.1359/jbmr.2002.17.10.1859; DALY CG, 1980, J ORAL PATHOL MED, V9, P1, DOI 10.1111/j.1600-0714.1980.tb01383.x; Doyle A., 1996, CELL TISSUE CULTURE, P11; Franzoso G, 1997, GENE DEV, V11, P3482, DOI 10.1101/gad.11.24.3482; GOLDMAN R, 1979, J NATL CANCER I, V63, P1009; Gravallese EM, 1998, AM J PATHOL, V152, P943; Hacker H, 1998, EMBO J, V17, P6230, DOI 10.1093/emboj/17.21.6230; Hartmann G, 1999, P NATL ACAD SCI USA, V96, P9305, DOI 10.1073/pnas.96.16.9305; Hartmann G, 2000, J IMMUNOL, V164, P944, DOI 10.4049/jimmunol.164.2.944; Hartmann G, 2000, J IMMUNOL, V164, P1617, DOI 10.4049/jimmunol.164.3.1617; Hayashi F, 2001, NATURE, V410, P1099, DOI 10.1038/35074106; Hemmi H, 2000, NATURE, V408, P740, DOI 10.1038/35047123; Hofbauer LC, 1999, BONE, V25, P255, DOI 10.1016/S8756-3282(99)00162-3; Horwood NJ, 1998, ENDOCRINOLOGY, V139, P4743, DOI 10.1210/en.139.11.4743; Iotsova V, 1997, NAT MED, V3, P1285, DOI 10.1038/nm1197-1285; ISHIHARA Y, 1991, J PERIODONTAL RES, V26, P155, DOI 10.1111/j.1600-0765.1991.tb01639.x; Ito HO, 1996, ARCH ORAL BIOL, V41, P439, DOI 10.1016/0003-9969(96)00002-7; Jiang YL, 2002, INFECT IMMUN, V70, P3143, DOI 10.1128/IAI.70.6.3143-3148.2002; Jimi E, 1996, ENDOCRINOLOGY, V137, P2187; Kikuchi T, 2001, J IMMUNOL, V166, P3574, DOI 10.4049/jimmunol.166.5.3574; Kimble RB, 1996, J BIOL CHEM, V271, P28890, DOI 10.1074/jbc.271.46.28890; Klinman DM, 1996, P NATL ACAD SCI USA, V93, P2879, DOI 10.1073/pnas.93.7.2879; Krieg AM, 2000, CURR OPIN IMMUNOL, V12, P35, DOI 10.1016/S0952-7915(99)00048-5; Krug A, 2001, EUR J IMMUNOL, V31, P2154, DOI 10.1002/1521-4141(200107)31:7<2154::AID-IMMU2154>3.0.CO;2-U; Lacey DL, 1998, CELL, V93, P165, DOI 10.1016/S0092-8674(00)81569-X; Lipford GB, 1998, TRENDS MICROBIOL, V6, P496, DOI 10.1016/S0966-842X(98)01408-5; MARTIN TJ, 1994, J CELL BIOCHEM, V56, P357, DOI 10.1002/jcb.240560312; Merkel KD, 1999, AM J PATHOL, V154, P203, DOI 10.1016/S0002-9440(10)65266-2; MILLAR SJ, 1986, INFECT IMMUN, V51, P302, DOI 10.1128/IAI.51.1.302-306.1986; Nair SP, 1996, INFECT IMMUN, V64, P2371, DOI 10.1128/IAI.64.7.2371-2380.1996; Nakashima T, 2000, BIOCHEM BIOPH RES CO, V275, P768, DOI 10.1006/bbrc.2000.3379; NOVAK JF, 1995, MICROBIOS, V81, P241; ORCEL P, 1993, AM J PHYSIOL, V264, pE391, DOI 10.1152/ajpendo.1993.264.3.E391; OURSLER MJ, 1988, DEV BIOL, V127, P170, DOI 10.1016/0012-1606(88)90198-4; Pahl HL, 1996, J EXP MED, V183, P1829, DOI 10.1084/jem.183.4.1829; Poltorak A, 1998, SCIENCE, V282, P2085, DOI 10.1126/science.282.5396.2085; Quinn JMW, 1998, ENDOCRINOLOGY, V139, P4424, DOI 10.1210/endo.139.10.6331; Romas E, 2002, BONE, V30, P340, DOI 10.1016/S8756-3282(01)00682-2; Sambrook J., 2002, MOL CLONING LAB MANU; Schwandner R, 1999, J BIOL CHEM, V274, P17406, DOI 10.1074/jbc.274.25.17406; Simonet WS, 1997, CELL, V89, P309, DOI 10.1016/S0092-8674(00)80209-3; Suda T, 1999, ENDOCR REV, V20, P345, DOI 10.1210/er.20.3.345; TAKAHASHI N, 1991, ENDOCRINOLOGY, V128, P1792, DOI 10.1210/endo-128-4-1792; Takami M, 2002, J IMMUNOL, V169, P1516, DOI 10.4049/jimmunol.169.3.1516; Takeda S, 1999, ENDOCRINOLOGY, V140, P1005, DOI 10.1210/en.140.2.1005; Teitelbaum SL, 2000, SCIENCE, V289, P1504, DOI 10.1126/science.289.5484.1504; Udagawa N, 2000, ENDOCRINOLOGY, V141, P3478, DOI 10.1210/en.141.9.3478; UDAGAWA N, 1990, P NATL ACAD SCI USA, V87, P7260, DOI 10.1073/pnas.87.18.7260; Udagawa N, 1996, BONE, V18, P511, DOI 10.1016/8756-3282(96)00076-2; Weiner GJ, 2000, J LEUKOCYTE BIOL, V68, P455; Yi AK, 1999, INT IMMUNOL, V11, P2015, DOI 10.1093/intimm/11.12.2015; Yi AK, 1998, J IMMUNOL, V160, P1240; Yi AK, 1998, J IMMUNOL, V161, P4493; Yi AK, 2001, INT IMMUNOL, V13, P1391, DOI 10.1093/intimm/13.11.1391; Zou W, 2002, FASEB J, V16, P274, DOI 10.1096/fj.01-0586com; Zou W, 2002, J BONE MINER RES, V17, P1211, DOI 10.1359/jbmr.2002.17.7.1211; Zou W, 2001, J CELL BIOCHEM, V83, P70, DOI 10.1002/jcb.1202	64	74	77	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 9	2003	278	19					16732	16740		10.1074/jbc.M212473200	http://dx.doi.org/10.1074/jbc.M212473200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677QG	12611893	hybrid			2022-12-25	WOS:000182818600039
J	Dobson, DE; Scholtes, LD; Valdez, KE; Sullivan, DR; Mengeling, BJ; Cilmi, S; Turco, SJ; Beverley, SM				Dobson, DE; Scholtes, LD; Valdez, KE; Sullivan, DR; Mengeling, BJ; Cilmi, S; Turco, SJ; Beverley, SM			Functional identification of galactosyltransferases (SCGs) required for species-specific modifications of the lipophosphoglycan adhesin controlling Leishmania major-sand fly interactions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTOZOAN PARASITE LEISHMANIA; ANTIGENIC VARIATION; CELL-SURFACE; DEVELOPMENTAL MODIFICATION; TRYPANOSOMA-BRUCEI; VIRULENCE GENES; STAGE; PROMASTIGOTES; VECTOR; EXPRESSION	Lipophosphoglycan (LPG) is an abundant surface molecule that plays key roles in the infectious cycle of Leishmania major. The dominant feature of LPG is a polymer of phosphoglycan (PG) (6Galbeta1,4Manalpha1-PO4) repeating units. In L. major these are extensively substituted with Gal(beta1,3) side chains, which are required for binding to midgut lectins and survival. We utilized evolutionary polymorphisms in LPG structure and cross-species transfections to recover genes encoding the LPG side chain beta1,3-galactosyltransferases (betaGalTs). A dispersed family of six SCG genes was recovered, whose predicted proteins exhibited characteristics of eukaryotic GalTs. At least four of these proteins showed significant LPG side chain betaGaIT activity; SCG3 exhibited initiating GaIT activity whereas SCG2 showed both initiating and elongating GaIT activity. However, the activity of SCG2 was context-dependent, being largely silent in its normal genomic milieu, and different strains show considerable variation in the extent of LPG galactosylation. Thus the L. major genome encodes a family of SCGs with varying specificity and activity, and we propose that strain-specific LPG galactosylation patterns reflect differences in their expression.	Washington Univ, Sch Med, Dept Mol Microbiol, St Louis, MO 63110 USA; Univ Kentucky, Med Ctr, Dept Biochem, Lexington, KY 40536 USA; Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA	Washington University (WUSTL); University of Kentucky; Harvard University; Harvard Medical School	Dobson, DE (corresponding author), Washington Univ, Sch Med, Dept Mol Microbiol, St Louis, MO 63110 USA.			Beverley, Stephen/0000-0001-5319-0811	NIAID NIH HHS [AI 31078, AI 20941] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI031078, R37AI020941, R01AI020941] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Al-Qahtani A, 1998, BIOCHEM J, V331, P521, DOI 10.1042/bj3310521; ASHFORD RW, 1992, PARASITOL TODAY, V8, P104, DOI 10.1016/0169-4758(92)90249-2; Barbour AG, 2000, EMERG INFECT DIS, V6, P449, DOI 10.3201/eid0605.000502; Barry JD, 2001, ADV PARASIT, V49, P1, DOI 10.1016/S0065-308X(01)49037-3; BEVERLEY SM, 1988, NUCLEIC ACIDS RES, V16, P925, DOI 10.1093/nar/16.3.925; Beverley SM, 2003, NAT REV GENET, V4, P11, DOI 10.1038/nrg980; Beverley SM, 1998, TRENDS MICROBIOL, V6, P35, DOI 10.1016/S0966-842X(97)01180-3; Butcher BA, 1996, J BIOL CHEM, V271, P20573, DOI 10.1074/jbc.271.34.20573; CALLAHAN HL, 1991, J BIOL CHEM, V266, P18427; CLAYTON C, 1992, PROG NUCLEIC ACID RE, V43, P37, DOI 10.1016/S0079-6603(08)61043-0; Cunningham ML, 2001, MOL BIOCHEM PARASIT, V113, P199, DOI 10.1016/S0166-6851(01)00213-4; Descoteaux A, 2002, EMBO J, V21, P4458, DOI 10.1093/emboj/cdf447; DESCOTEAUX A, 1995, SCIENCE, V269, P1869, DOI 10.1126/science.7569927; Dillon RJ, 1999, PARASITOLOGY, V118, P27, DOI 10.1017/S0031182098003588; Ha DS, 1996, MOL BIOCHEM PARASIT, V77, P57, DOI 10.1016/0166-6851(96)02580-7; Ilg T, 2001, MED MICROBIOL IMMUN, V190, P13, DOI 10.1007/s004300100071; Ilg T, 1996, J BIOL CHEM, V271, P21583, DOI 10.1074/jbc.271.35.21583; Joshi PB, 1998, MOL MICROBIOL, V27, P519, DOI 10.1046/j.1365-2958.1998.00689.x; KAPLER GM, 1990, MOL CELL BIOL, V10, P1084, DOI 10.1128/MCB.10.3.1084; KELLEHER M, 1994, MOL BIOCHEM PARASIT, V66, P187, DOI 10.1016/0166-6851(94)90146-5; Kyes S, 2001, ANNU REV MICROBIOL, V55, P673, DOI 10.1146/annurev.micro.55.1.673; LEBOWITZ JH, 1990, P NATL ACAD SCI USA, V87, P9736, DOI 10.1073/pnas.87.24.9736; Mahoney AB, 1999, BIOCHEMISTRY-US, V38, P9813, DOI 10.1021/bi990741g; MCCONVILLE MJ, 1995, BIOCHEM J, V310, P807, DOI 10.1042/bj3100807; MCCONVILLE MJ, 1992, EMBO J, V11, P3593, DOI 10.1002/j.1460-2075.1992.tb05443.x; MOODY SF, 1993, J BIOL CHEM, V268, P18457; MULVEY MA, 2000, ADHESION BACTERIAL E, V1; Ng K, 1996, BIOCHEM J, V317, P247, DOI 10.1042/bj3170247; ORLANDI PA, 1987, J BIOL CHEM, V262, P10384; Pedrosa AL, 2002, MOL BIOCHEM PARASIT, V122, P141, DOI 10.1016/S0166-6851(02)00093-2; Pelletier I, 2002, J BIOL CHEM, V277, P17663, DOI 10.1074/jbc.M201562200; PIMENTA PFP, 1992, SCIENCE, V256, P1812, DOI 10.1126/science.1615326; PIMENTA PFP, 1994, P NATL ACAD SCI USA, V91, P9155, DOI 10.1073/pnas.91.19.9155; Roditi I, 2002, TRENDS MICROBIOL, V10, P128, DOI 10.1016/S0966-842X(02)02309-0; RYAN KA, 1993, GENE, V131, P145, DOI 10.1016/0378-1119(93)90684-U; RYAN KA, 1993, P NATL ACAD SCI USA, V90, P8609, DOI 10.1073/pnas.90.18.8609; Sacks D, 2001, ANNU REV MICROBIOL, V55, P453, DOI 10.1146/annurev.micro.55.1.453; SACKS DL, 1990, MOL BIOCHEM PARASIT, V42, P225, DOI 10.1016/0166-6851(90)90165-I; SACKS DL, 1985, J IMMUNOL, V135, P564; Sacks DL, 2001, CELL MICROBIOL, V3, P189, DOI 10.1046/j.1462-5822.2001.00115.x; SACKS DL, 1995, J EXP MED, V181, P685, DOI 10.1084/jem.181.2.685; SACKS DL, 1987, J IMMUNOL, V139, P3099; SACKS DL, 1989, EXP PARASITOL, V69, P100, DOI 10.1016/0014-4894(89)90176-8; SINGER SJ, 1990, ANNU REV CELL BIOL, V6, P247, DOI 10.1146/annurev.cb.06.110190.001335; Spath GF, 2000, P NATL ACAD SCI USA, V97, P9258, DOI 10.1073/pnas.160257897; Sundstrom P, 1999, CURR OPIN MICROBIOL, V2, P353, DOI 10.1016/S1369-5274(99)80062-9; THOMAS JR, 1992, J BIOL CHEM, V267, P6829; TITUS RG, 1995, P NATL ACAD SCI USA, V92, P10267, DOI 10.1073/pnas.92.22.10267; Tosi LRO, 2000, NUCLEIC ACIDS RES, V28, P784, DOI 10.1093/nar/28.3.784; TURCO SJ, 1991, MOL BIOCHEM PARASIT, V45, P91, DOI 10.1016/0166-6851(91)90030-A; Wiese M, 1999, MOL BIOCHEM PARASIT, V102, P325, DOI 10.1016/S0166-6851(99)00095-X; Wiggins CAR, 1998, P NATL ACAD SCI USA, V95, P7945, DOI 10.1073/pnas.95.14.7945	52	35	42	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 2	2003	278	18					15523	15531		10.1074/jbc.M301568200	http://dx.doi.org/10.1074/jbc.M301568200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	675EL	12604613	hybrid			2022-12-25	WOS:000182680000010
J	Wessendorf, S; Schwaenen, C; Kohlhammer, H; Kienle, D; Wrobel, G; Barth, TFE; Nessling, M; Moller, P; Dohner, H; Lichter, P; Bentz, M				Wessendorf, S; Schwaenen, C; Kohlhammer, H; Kienle, D; Wrobel, G; Barth, TFE; Nessling, M; Moller, P; Dohner, H; Lichter, P; Bentz, M			Hidden gene amplifications in aggressive B-cell non-Hodgkin lymphomas detected by microarray-based comparative genomic hybridization	ONCOGENE			English	Article						CGH; microarray; gene amplification; lymphoma	DNA COPY-NUMBER; ABERRATIONS; IMBALANCES; DELETIONS; NEOPLASMS; SURVIVAL; STAGE; GAINS	DNA amplifications are important mechanisms for protooncogene activation. Comparative genomic hybridization (CGH) to metaphase chromosome preparations has revealed amplifications in 10-20% of B-cell lymphomas (B-NHL). We analysed a series of 16 aggressive non-Hodgkin lymphomas by the new approach termed Matrix-CGH (M-CGH) using genomic DNA microarrays as hybridization target. For M-CGH, a dedicated B-cell lymphoma chip was constructed containing 496 genomic targets covering oncogenes, tumor suppressor genes as well as chromosome regions frequently altered in B-NHL. In 10 of 16 samples a total of 15 DNA amplifications were identified. The amplicons included BCL2, REL, CCND1, CCND2, JAK2, FGF4 and MDM2. Four of the 15 amplifications remained undetected by chromosomal CGH. The respective amplicons mapped to bands 2p13, 9p13-p21 and 12q24 and, were confirmed by fluorescence in situ hybridization. Furthermore, for four genomically amplified genes real-time quantitative reverse transcription polymerase chain reaction revealed elevated mRNA expression levels. These data show the superior diagnostic sensitivity of the newly developed diagnostic tool. As only a small portion of the genome (approximately 1.5%) has been analysed by the present DNA array, it is likely that gene amplifications are much more common in aggressive lymphomas than previously assumed.	Univ Ulm, Med Klin, Abt Innere Med 3, D-89081 Ulm, Germany; Deutsch Krebsforschungszentrum, Abt Mol Genet, D-69120 Heidelberg, Germany; Univ Ulm, Abt Pathol, D-89081 Ulm, Germany	Ulm University; Helmholtz Association; German Cancer Research Center (DKFZ); Ulm University	Bentz, M (corresponding author), Univ Ulm, Med Klin, Abt Innere Med 3, Robert Koch Str 8, D-89081 Ulm, Germany.		Döhner, Hartmut/C-8933-2016	Döhner, Hartmut/0000-0003-2116-5536				Alizadeh AA, 2000, NATURE, V403, P503, DOI 10.1038/35000501; Barth TFE, 2001, GENE CHROMOSOME CANC, V31, P316, DOI 10.1002/gcc.1150; Bentz M, 1998, GENE CHROMOSOME CANC, V21, P172, DOI 10.1002/(SICI)1098-2264(199802)21:2<172::AID-GCC14>3.0.CO;2-T; BRODEUR GM, 1984, SCIENCE, V224, P1121, DOI 10.1126/science.6719137; DUMANOIR S, 1993, HUM GENET, V90, P590, DOI 10.1007/BF00202476; GRIBBEN JG, 1991, BLOOD, V78, P3275; Houldsworth J, 1996, BLOOD, V87, P25; Jaffe ES, 2001, WORLD HLTH ORG CLASS; Joos S, 1996, BLOOD, V87, P1571, DOI 10.1182/blood.V87.4.1571.bloodjournal8741571; KALLIONIEMI A, 1992, SCIENCE, V258, P818, DOI 10.1126/science.1359641; Kirchhoff M, 1999, GENE CHROMOSOME CANC, V25, P410, DOI 10.1002/(SICI)1098-2264(199908)25:4<410::AID-GCC17>3.0.CO;2-J; Klein CA, 1999, P NATL ACAD SCI USA, V96, P4494, DOI 10.1073/pnas.96.8.4494; Knuutila S, 1998, AM J PATHOL, V152, P1107; Korz C, 2002, BLOOD, V99, P4554, DOI 10.1182/blood.V99.12.4554; LICHTER P, 1995, METHOD ENZYMOL, V254, P334; Pinkel D, 1998, NAT GENET, V20, P207, DOI 10.1038/2524; Pollack JR, 1999, NAT GENET, V23, P41, DOI 10.1038/12640; Rao PH, 1998, BLOOD, V92, P234, DOI 10.1182/blood.V92.1.234.413k22_234_240; Rosenwald A, 2002, NEW ENGL J MED, V346, P1937, DOI 10.1056/NEJMoa012914; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; Snijders AM, 2001, NAT GENET, V29, P263, DOI 10.1038/ng754; SolinasToldo S, 1997, GENE CHROMOSOME CANC, V20, P399, DOI 10.1002/(SICI)1098-2264(199712)20:4<399::AID-GCC12>3.0.CO;2-I; Werner CA, 1997, AM J PATHOL, V151, P335; Wessendorf S, 2002, LAB INVEST, V82, P47, DOI 10.1038/labinvest.3780394	24	74	76	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 6	2003	22	9					1425	1429		10.1038/sj.onc.1206297	http://dx.doi.org/10.1038/sj.onc.1206297			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	652CA	12618769				2022-12-25	WOS:000181360900018
J	Tuck, AB; Hota, C; Wilson, SM; Chambers, AF				Tuck, AB; Hota, C; Wilson, SM; Chambers, AF			Osteopontin-induced migration of human mammary epithelial cells involves activation of EGF receptor and multiple signal transduction pathways	ONCOGENE			English	Article						osteopontin (OPN); migration; mammary epithelial cells; breast cancer; EGFR; signal transduction	EPIDERMAL GROWTH-FACTOR; BREAST-CANCER; ALPHA(V)BETA(3) INTEGRIN; CARCINOMA-CELLS; EXPRESSION; PHOSPHORYLATION; KINASE; SURVIVAL; BETA-1-INTEGRIN; TUMORIGENICITY	Osteopontin (OPN) is a secreted, integrin-binding glycophosphoprotein that has been implicated in breast cancer. We previously showed that OPN-induced cell migration of mammary epithelial cells (MEC) depends on binding to cell surface integrins and involves activation of the hepatocyte growth factor (HGF) receptor, Met. Here, we show that OPN-induced migration of MEC also requires activation of the epidermal growth factor (EGF) pathway. Synergism was seen between EGF and OPN in inducing cell migration. Furthermore, incubation of cells with exogenous OPN increased ligand (TGFalpha > EGF) and EGF receptor (EGFR) mRNA expression, as well as EGFR kinase activity. Treatment of cells with anti-TGFalpha or anti-EGFR antibody, or with tyrphostin-25 (EGFR inhibitor), significantly impaired the cell migration response to OPN. Other more broad-spectrum tyrosine kinase inhibitors and the growth factor/receptor interaction inhibitor, suramin, also inhibited OPN-induced migration. Using specific signal transduction pathway inhibitors, we have screened for involvement of MEK (MAP kinase kinase), phosphatidylinositol 3-kinase, phospholipase C (PLC), and protein kinase C (PKC). Results implicated all of these pathways in OPN-induced cell migration, the most pronounced effect being seen with PLC and PKC inhibitors. These results suggest that induction of MEC migration by OPN involves a cascade of events including at least two growth factor/receptor pathways and multiple downstream signal transduction pathways. A number of potential targets are thus provided for strategies aimed at blocking the malignancy-promoting effects of OPN.	Univ Western Ontario, London Hlth Sci Ctr, Dept Pathol, London, ON N6A 5A5, Canada; Univ Western Ontario, London Hlth Sci Ctr, Dept Oncol, London, ON N6A 5A5, Canada; London Reg Canc Ctr, London, ON N6A 4L6, Canada	London Health Sciences Centre; Western University (University of Western Ontario); London Health Sciences Centre; Western University (University of Western Ontario); Western University (University of Western Ontario)	Tuck, AB (corresponding author), Univ Western Ontario, London Hlth Sci Ctr, Dept Pathol, Univ Campus,POB 5339,Stn B, London, ON N6A 5A5, Canada.		Chambers, Ann F/L-6285-2015	Chambers, Ann F/0000-0002-9509-5123				Adelsman MA, 1999, MOL BIOL CELL, V10, P2861, DOI 10.1091/mbc.10.9.2861; BAND V, 1990, CANCER RES, V50, P7351; BELLAHCENE A, 1995, AM J PATHOL, V146, P95; BROWN LF, 1994, AM J PATHOL, V145, P610; Comoglio P M, 1993, EXS, V65, P131; DERYNCK R, 1984, CELL, V38, P287, DOI 10.1016/0092-8674(84)90550-6; DONATO NJ, 1989, J BIOL CHEM, V264, P20474; Furger Kara A., 2001, Current Molecular Medicine (Hilversum), V1, P621, DOI 10.2174/1566524013363339; Giancotti FG, 1999, SCIENCE, V285, P1028, DOI 10.1126/science.285.5430.1028; HIROTA S, 1995, LAB INVEST, V72, P64; Jones PL, 1997, J CELL BIOL, V139, P279, DOI 10.1083/jcb.139.1.279; Kassis J, 1999, CLIN CANCER RES, V5, P2251; Kermorgant S, 2001, CARCINOGENESIS, V22, P1035, DOI 10.1093/carcin/22.7.1035; Lee JW, 2002, BBA-MOL CELL RES, V1542, P23, DOI 10.1016/S0167-4889(01)00161-6; Miyamoto S, 1996, J CELL BIOL, V135, P1633, DOI 10.1083/jcb.135.6.1633; Moro L, 2002, J BIOL CHEM, V277, P9405, DOI 10.1074/jbc.M109101200; MURRAY JC, 1986, NUCLEIC ACIDS RES, V14, P5117, DOI 10.1093/nar/14.12.5117; PRICE JE, 1990, CANCER RES, V50, P717; Price JT, 1999, CANCER RES, V59, P5475; Qiao H, 2000, CELL GROWTH DIFFER, V11, P123; Schneller M, 1997, EMBO J, V16, P5600, DOI 10.1093/emboj/16.18.5600; Schwartz MA, 1997, J CELL BIOL, V139, P575, DOI 10.1083/jcb.139.3.575; Schwartz MA, 2002, NAT CELL BIOL, V4, pE65, DOI 10.1038/ncb0402-e65; SENGER DR, 1988, CANCER RES, V48, P5770; Singhal H, 1997, CLIN CANCER RES, V3, P605; Sodek J, 2000, CRIT REV ORAL BIOL M, V11, P279, DOI 10.1177/10454411000110030101; Soldi R, 1999, EMBO J, V18, P882, DOI 10.1093/emboj/18.4.882; Tuck AB, 2000, J CELL BIOCHEM, V78, P465, DOI 10.1002/1097-4644(20000901)78:3<465::AID-JCB11>3.0.CO;2-C; Tuck AB, 1999, ONCOGENE, V18, P4237, DOI 10.1038/sj.onc.1202799; Tuck AB, 1998, INT J CANCER, V79, P502, DOI 10.1002/(SICI)1097-0215(19981023)79:5<502::AID-IJC10>3.0.CO;2-3; Tuck AB, 2001, J MAMMARY GLAND BIOL, V6, P419, DOI 10.1023/A:1014734930781; TUCK AB, 1991, J NATL CANCER I, V83, P485; TUCK AB, 1990, CLIN EXP METASTAS, V8, P417, DOI 10.1007/BF00058153; Wang F, 1998, P NATL ACAD SCI USA, V95, P14821, DOI 10.1073/pnas.95.25.14821; Wang R, 1996, P NATL ACAD SCI USA, V93, P8425, DOI 10.1073/pnas.93.16.8425; Wells A, 1999, INT J BIOCHEM CELL B, V31, P637, DOI 10.1016/S1357-2725(99)00015-1; Wells A, 2000, ADV CANCER RES, V78, P31; XU YH, 1984, NATURE, V309, P806, DOI 10.1038/309806a0; XUAN JW, 1995, J CELL BIOCHEM, V57, P680, DOI 10.1002/jcb.240570413; XUAN JW, 1994, J CELL BIOCHEM, V54, P247, DOI 10.1002/jcb.240540213	40	109	127	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 27	2003	22	8					1198	1205		10.1038/sj.onc.1206209	http://dx.doi.org/10.1038/sj.onc.1206209			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	650EK	12606946				2022-12-25	WOS:000181249700008
J	Fan, DP; Zheng, Y; Yang, DW; Wang, JJ				Fan, DP; Zheng, Y; Yang, DW; Wang, JJ			NMR solution structure and dynamics of an exchangeable apolipoprotein, Locusta migratoria apolipophorin III	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIPID-BINDING; SPECTROSCOPY; CONFORMATION; HELIX; RELAXATION; PARTICLES; DOMAIN; ALPHA; N-15	We report here the NMR structure and backbone dynamics of an exchangeable apolipoprotein, apoLp-III, from the insect Locusta migratoria. The NMR structure adopts an up-and-down elongated five-helix bundle, which is similar to the x-ray crystal structure of this protein. A short helix, helix 4', is observed that is perpendicular to the bundle and fully solvent-exposed. NMR experimental parameters confirm the existence of this short helix, which is proposed to serve as a recognition helix for apoLp-III binding to lipoprotein surfaces. The L. migratoria apoLp-III helix bundle displays several characteristic structural features that regulate the reversible lipoprotein binding activity of apoLp-III. The buried hydrophilic residues and exposed hydrophobic residues readily adjust the marginal stability of apoLp-III, facilitating the helix bundle opening. Specifically, upon lipoprotein binding the locations and orientations of the buried hydrophilic residues modulate the apoLp-III helix bundle to adopt a possible opening at the hinge that is opposite the recognition short helix, helix 4'. The backbone dynamics provide additional support to the recognition role of helix 4' and this preferred conformational adaptation of apoLp-III upon lipid binding. In this case, the lipid-bound open conformation contains two lobes linked by hinge loops. One lobe contains helices 2 and 3, and the other lobe contains helices 1, 4, and 5. This preferred bundle opening is different from the original proposal on the basis of the x-ray crystal structure of this protein (Breiter, D. R., Kanost, M. R., Benning, M. M., Wesenberg, G., Law, J. H., Wells, M. A., Rayment, I., and Holden, H. M. ( 1991) Biochemistry 30, 603 - 608), but it efficiently uses helix 4' as the recognition short helix. The buried interhelical H-bonds are found to be mainly located between the two lobes, potentially providing a specific driving force for the helix bundle recovery of apoLp-III from the lipid-bound open conformation. Finally, we compare the NMR structures of Manduca sexta apoLp-III and L. migratoria apoLp-III and present a united scheme for the structural basis of the reversible lipoprotein binding activity of apoLp-III.	So Illinois Univ, Sch Med, Dept Biochem & Mol Biol, Carbondale, IL 62901 USA; Natl Univ Singapore, Dept Biol Sci, Singapore 117543, Singapore; Natl Univ Singapore, Dept Chem, Singapore 117543, Singapore	Southern Illinois University System; Southern Illinois University; National University of Singapore; National University of Singapore	Wang, JJ (corresponding author), So Illinois Univ, Sch Med, Dept Biochem & Mol Biol, Carbondale, IL 62901 USA.		yang, daiwen/H-8408-2012	yang, daiwen/0000-0002-6804-0071				Akke M, 1996, J AM CHEM SOC, V118, P911, DOI 10.1021/ja953503r; Borhani DW, 1997, P NATL ACAD SCI USA, V94, P12291, DOI 10.1073/pnas.94.23.12291; BREITER DR, 1991, BIOCHEMISTRY-US, V30, P603, DOI 10.1021/bi00217a002; BRUNGER AT, 1992, XPLOR VERSION 3 1; Cornilescu G, 1999, J BIOMOL NMR, V13, P289, DOI 10.1023/A:1008392405740; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; Fan DP, 2001, J BIOMOL NMR, V19, P83, DOI 10.1023/A:1008398720439; FARROW NA, 1994, BIOCHEMISTRY-US, V33, P5984, DOI 10.1021/bi00185a040; GARRETT DS, 1991, J MAGN RESON, V95, P214, DOI 10.1016/0022-2364(91)90341-P; Gursky O, 1996, P NATL ACAD SCI USA, V93, P2991, DOI 10.1073/pnas.93.7.2991; KAWOOYA JK, 1986, J BIOL CHEM, V261, P3588; LASKOWSKI RA, 1991, ACTA CRYSTALLOGR A, V47, P110; McInnes C, 1998, J BIOL CHEM, V273, P27357, DOI 10.1074/jbc.273.42.27357; Narayanaswami V, 1996, J BIOL CHEM, V271, P26855, DOI 10.1074/jbc.271.43.26855; Narayanaswami V, 1999, P NATL ACAD SCI USA, V96, P4366, DOI 10.1073/pnas.96.8.4366; Narayanaswami V, 2000, BBA-MOL CELL BIOL L, V1483, P15, DOI 10.1016/S1388-1981(99)00176-6; NIGLES M, 1988, FEBS LETT, V229, P129; Okon M, 2001, FEBS LETT, V487, P390, DOI 10.1016/S0014-5793(00)02375-9; Rogers DP, 1997, BIOCHEMISTRY-US, V36, P288, DOI 10.1021/bi961876e; Rozek A, 1999, BIOCHEMISTRY-US, V38, P14475, DOI 10.1021/bi982966h; RYAN RO, 1993, J BIOL CHEM, V268, P1525; SEGREST JP, 1994, ADV PROTEIN CHEM, V45, P303; SOULAGES JL, 1995, P NATL ACAD SCI USA, V92, P5650, DOI 10.1073/pnas.92.12.5650; Soulages JL, 2001, J BIOL CHEM, V276, P34162, DOI 10.1074/jbc.M105836200; Wang JJ, 1997, J BIOL CHEM, V272, P17912, DOI 10.1074/jbc.272.29.17912; WANG JJ, 1995, BIOCHEMISTRY-US, V34, P6755, DOI 10.1021/bi00020a021; Wang JJ, 2002, P NATL ACAD SCI USA, V99, P1188, DOI 10.1073/pnas.032565999; Wang JJ, 1998, BIOCHEM CELL BIOL, V76, P276, DOI 10.1139/bcb-76-2-3-276; Weers PMM, 2000, BIOCHEMISTRY-US, V39, P6874, DOI 10.1021/bi992891x; Weers PMM, 1999, J BIOL CHEM, V274, P21804, DOI 10.1074/jbc.274.31.21804; Weers PMM, 1998, BBA-LIPID LIPID MET, V1393, P99, DOI 10.1016/S0005-2760(98)00063-0; WEISGRABER KH, 1994, ADV PROTEIN CHEM, V45, P249; WILSON C, 1991, SCIENCE, V252, P1817, DOI 10.1126/science.2063194; WISHART DS, 1994, VADAR VERSION 1 2	34	43	44	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 6	2003	278	23					21212	21220		10.1074/jbc.M208486200	http://dx.doi.org/10.1074/jbc.M208486200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	684WY	12621043	hybrid			2022-12-25	WOS:000183230500099
J	Balasubramanyam, K; Swaminathan, V; Ranganathan, A; Kundu, TK				Balasubramanyam, K; Swaminathan, V; Ranganathan, A; Kundu, TK			Small molecule modulators of histone acetyltransferase p300	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACETYLATION; TRANSCRIPTION; CBP	Histone acetyltransferases (HATs) are a group of enzymes that play a significant role in the regulation of gene expression. These enzymes covalently modify the N-terminal lysine residues of histones by the addition of acetyl groups from acetyl-CoA. Dysfunction of these enzymes is often associated with the manifestation of several diseases, predominantly cancer. Here we report that anacardic acid from cashew nut shell liquid is a potent inhibitor of p300 and p300/CBP-associated factor histone acetyltranferase activities. Although it does not affect DNA transcription, HAT-dependent transcription from a chromatin template was strongly inhibited by anacardic acid. Furthermore, we describe the design and synthesis of an amide derivative N-(4-chloro-3-trifluoromethyl-phenyl)-2-ethoxy-6-pentadecyl-benzamide (CTPB) using anacardic acid as a synthon, which remarkably activates p300 HAT activity but not that of p300/CBP- associated factor. Although CTPB does not affect DNA transcription, it enhances the p300 HAT-dependent transcriptional activation from in vitro assembled chromatin template. However, it has no effect on histone deacetylase activity. These compounds would be useful as biological switching molecules for probing into the role of p300 in transcriptional studies and may also be useful as new chemical entities for the development of anticancer drugs.	Jawaharlal Nehru Ctr Adv Sci Res, Mol Biol & Genet Unit, Transript & Dis Lab, Bangalore 560064, Karnataka, India; Jawaharlal Nehru Ctr Adv Sci Res, Chem & Phys Mat Unit, Bangalore 560064, Karnataka, India	Department of Science & Technology (India); Jawaharlal Nehru Center for Advanced Scientific Research (JNCASR); Department of Science & Technology (India); Jawaharlal Nehru Center for Advanced Scientific Research (JNCASR)	Kundu, TK (corresponding author), Jawaharlal Nehru Ctr Adv Sci Res, Mol Biol & Genet Unit, Transript & Dis Lab, Bangalore 560064, Karnataka, India.			Venkatesh, Swaminathan/0000-0001-9837-1501; Kundu, Tapas/0000-0001-7790-214X				Ait-Si-Ali S, 1998, NATURE, V396, P184, DOI 10.1038/24190; ALLFREY VG, 1964, P NATL ACAD SCI USA, V51, P786, DOI 10.1073/pnas.51.5.786; CHANG FC, 1964, TETRAHEDRON LETT, P2969; Costanzo A, 2002, MOL CELL, V9, P175, DOI 10.1016/S1097-2765(02)00431-8; CULLIS PM, 1982, J BIOL CHEM, V257, P2165; Giles RH, 1998, TRENDS GENET, V14, P178, DOI 10.1016/S0168-9525(98)01438-3; KIONG LS, 1981, J CHEM SOC PERK T 1, P1942, DOI 10.1039/p19810001942; KUBO I, 1993, J AGR FOOD CHEM, V41, P1012, DOI 10.1021/jf00030a035; Kumar BRP, 2001, J BIOL CHEM, V276, P16804, DOI 10.1074/jbc.M100934200; Kundu TK, 1999, MOL CELL BIOL, V19, P1605; Kundu TK, 2000, MOL CELL, V6, P551, DOI 10.1016/S1097-2765(00)00054-X; Lau OD, 2000, MOL CELL, V5, P589, DOI 10.1016/S1097-2765(00)80452-9; Marks PA, 2001, NAT REV CANCER, V1, P194, DOI 10.1038/35106079; Murata T, 2001, HUM MOL GENET, V10, P1071, DOI 10.1093/hmg/10.10.1071; Redner RL, 1999, BLOOD, V94, P417, DOI 10.1182/blood.V94.2.417.414k49_417_428; Roth SY, 2001, ANNU REV BIOCHEM, V70, P81, DOI 10.1146/annurev.biochem.70.1.81; SHOBHA SV, 1991, J AGR FOOD CHEM, V39, P2214, DOI 10.1021/jf00012a022; Sterner DE, 2000, MICROBIOL MOL BIOL R, V64, P435, DOI 10.1128/MMBR.64.2.435-459.2000; Wang ZX, 1997, GENE DEV, V11, P1315, DOI 10.1101/gad.11.10.1315	19	378	399	0	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 23	2003	278	21					19134	19140		10.1074/jbc.M301580200	http://dx.doi.org/10.1074/jbc.M301580200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	679PY	12624111	hybrid			2022-12-25	WOS:000182932200055
J	Bischofberger, P; Han, WJ; Feifel, B; Schonfeld, HJ; Christen, P				Bischofberger, P; Han, WJ; Feifel, B; Schonfeld, HJ; Christen, P			D-Peptides as inhibitors of the DnaK/DnaJ/GrpE chaperone system	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SUBSTRATE-BINDING; ESCHERICHIA-COLI; DNAK; GRPE; CYCLE	DnaK, a Hsp70 homolog of Escherichia coli, together with its co-chaperones DnaJ and GrpE protects denatured proteins from aggregation and promotes their refolding by an ATP-consuming mechanism. DnaJ not only stimulates the gamma-phosphate cleavage of DnaK-bound ATP but also binds polypeptide substrates on its own. Unfolded polypeptides, such as denatured luciferase, thus form ternary complexes with DnaJ and DnaK. A previous study has shown that D-peptides compete with L-peptides for the same binding site in DnaJ but do not bind to DnaK (Feifel, B., Schonfeld, H.-J., and Christen, P. (1998) J. Biol. Chem. 273, 11999-12002). Here we report that D-peptides efficiently inhibit the refolding of denatured luciferase by the DnaK/DnaJ/GrpE chaperone system (EC50 = 1-2 muM). The inhibition of the chaperone action is due to the binding of D-peptide to DnaJ (K-d = 1-2 muM), which seems to preclude DnaJ from forming ternary (ATP.DnaK)(m).substrate.DnaJ(n) complexes. Apparently, simultaneous binding of DnaJ and DnaK to one and the same target polypeptide is essential for effective chaperone action.	Univ Zurich, Inst Biochem, CH-8057 Zurich, Switzerland; F Hoffmann La Roche & Co Ltd, Pharmaceut Res, CH-4070 Basel, Switzerland	University of Zurich; Roche Holding	Christen, P (corresponding author), Univ Zurich, Inst Biochem, Winterhurerstr 190, CH-8057 Zurich, Switzerland.	christen@bioc.unizh.ch						BUCHBERGER A, 1994, EMBO J, V13, P1687, DOI 10.1002/j.1460-2075.1994.tb06433.x; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; Feifel B, 1998, J BIOL CHEM, V273, P11999, DOI 10.1074/jbc.273.20.11999; Feifel B, 1996, EUR J BIOCHEM, V237, P318, DOI 10.1111/j.1432-1033.1996.0318n.x; Fink A.L., 1998, MOL CHAPERONES LIFE, P123; Greene MK, 1998, P NATL ACAD SCI USA, V95, P6108, DOI 10.1073/pnas.95.11.6108; Grimshaw JPA, 2001, J BIOL CHEM, V276, P6098, DOI 10.1074/jbc.M009290200; Han WJ, 2003, J BIOL CHEM, V278, P19038, DOI 10.1074/jbc.M300756200; Kim SY, 2002, J BIOL CHEM, V277, P44778, DOI 10.1074/jbc.M206176200; Kudlicki W, 1996, J BIOL CHEM, V271, P31160, DOI 10.1074/jbc.271.49.31160; Laufen T, 1999, P NATL ACAD SCI USA, V96, P5452, DOI 10.1073/pnas.96.10.5452; Pierpaoli EV, 1998, J BIOL CHEM, V273, P6643, DOI 10.1074/jbc.273.12.6643; Rudiger S, 2001, EMBO J, V20, P1042, DOI 10.1093/emboj/20.5.1042; SCHMID D, 1994, SCIENCE, V263, P971, DOI 10.1126/science.8310296; SCHONFELD HJ, 1995, J BIOL CHEM, V270, P2183, DOI 10.1074/jbc.270.5.2183; SCHRODER H, 1993, EMBO J, V12, P4137, DOI 10.1002/j.1460-2075.1993.tb06097.x; SZABO A, 1994, P NATL ACAD SCI USA, V91, P10345, DOI 10.1073/pnas.91.22.10345; Zhu XT, 1996, SCIENCE, V272, P1606, DOI 10.1126/science.272.5268.1606	18	30	31	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 23	2003	278	21					19044	19047		10.1074/jbc.M300922200	http://dx.doi.org/10.1074/jbc.M300922200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	679PY	12637539	hybrid			2022-12-25	WOS:000182932200043
J	Das, S; El-Deiry, WS; Somasundaram, K				Das, S; El-Deiry, WS; Somasundaram, K			Regulation of the p53 homolog p73 by adenoviral oncogene E1A	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							WILD-TYPE P73; P53-RELATED PROTEIN P73; TUMOR-SUPPRESSOR; CELL-CYCLE; HUMAN NEUROBLASTOMAS; HUMAN CANCERS; GENE; EXPRESSION; APOPTOSIS; ACTIVATION	p73 is a p53 homolog, as they are similar structurally and functionally. Unlike p53, p73 is not inactivated by the products of viral oncogenes such as SV40 T antigen and human papilloma virus E6. Here we show that the product of adenoviral oncogene E1A inhibits the transcriptional activation by both p73alpha and p73beta. Electrophoretic mobility shift assays revealed that E1A does not inhibit the sequence-specific DNA binding by p73. Transcriptional activation by a fusion protein containing the Gal4 DNA-binding domain and either of the activation domains of p73 was inhibited by wild-type (WT) E1A, but not by the N-terminal deletion mutant E1A(Delta2-36). E1A(Delta2-36), which does not bind to the p300/CBP family of coactivators, failed to inhibit p73-mediated transcription, whereas E1A(DeltaCR2), a deletion mutant that does not bind to the pRb family of proteins, inhibited p73-mediated transcription as efficiently as WT E1A. Consistent with these observations, growth arrest induced by p73 expressed from a recombinant adenovirus was abrogated by WT E1A, which correlated with inhibition of p73-mediated induction of p21(WAF1/CIP1) by E1A. However, p73 was able to induce p21(WAF1/CIP1) and to mediate growth arrest in the presence of E1A(Delta2-36). Furthermore, the expression of either wild-type E1A or E1A(Delta2-36) resulted in the stabilization of endogenous p73. However, p73 stabilized in response to the expression of E1A(Delta2-36), but not WT E1A, was able to activate the expression of p21(WAF1/CIP1). These results suggest that the transcriptional activation function of p73 is specifically targeted by E1A through a mechanism involving p300/CBP proteins during the process of transformation and that p73 may have a role to play as a tumor suppressor.	Indian Inst Sci, Dept Microbiol & Cell Biol, Bangalore 560012, Karnataka, India; Univ Penn, Howard Hughes Med Inst, Philadelphia, PA 19104 USA	Indian Institute of Science (IISC) - Bangalore; Howard Hughes Medical Institute; University of Pennsylvania	Somasundaram, K (corresponding author), Indian Inst Sci, Dept Microbiol & Cell Biol, Bangalore 560012, Karnataka, India.		El-Deiry, Wafik/AAJ-6080-2020	El-Deiry, Wafik/0000-0002-9577-8266; Das, Sanjeev/0000-0002-3594-1033				AVANTAGGIATI MI, 1997, CELL, V8, P1175; BALABAN GB, 1986, CANCER GENET CYTOGEN, V19, P113, DOI 10.1016/0165-4608(86)90378-X; Balint E, 1999, ONCOGENE, V18, P3923, DOI 10.1038/sj.onc.1202781; BAND V, 1993, EMBO J, V12, P1847, DOI 10.1002/j.1460-2075.1993.tb05833.x; BARBONETTI J, 1993, GENE DEV, V7, P2565; BRODEUR GM, 1977, CANCER-AM CANCER SOC, V40, P2256, DOI 10.1002/1097-0142(197711)40:5<2256::AID-CNCR2820400536>3.0.CO;2-1; Dobner T, 1996, SCIENCE, V272, P1470, DOI 10.1126/science.272.5267.1470; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; DRACOPOLI NC, 1989, P NATL ACAD SCI USA, V86, P4614, DOI 10.1073/pnas.86.12.4614; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; ELDEIRY WS, 1995, CANCER RES, V55, P2910; Flores ER, 2002, NATURE, V416, P560, DOI 10.1038/416560a; Fuchs M, 2001, CELL, V106, P297, DOI 10.1016/S0092-8674(01)00450-0; Gu W, 1997, NATURE, V387, P819, DOI 10.1038/42972; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; Ikawa S, 1999, CELL DEATH DIFFER, V6, P1154, DOI 10.1038/sj.cdd.4400631; Imyanitov EN, 1999, ONCOGENE, V18, P4640, DOI 10.1038/sj.onc.1202863; Irwin M, 2000, NATURE, V407, P645, DOI 10.1038/35036614; Jost CA, 1997, NATURE, V389, P191, DOI 10.1038/38298; Kaghad M, 1997, CELL, V90, P809, DOI 10.1016/S0092-8674(00)80540-1; Kang MJ, 2000, CLIN CANCER RES, V6, P1767; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; Kovalev S, 1998, CELL GROWTH DIFFER, V9, P897; LAVIGUEUR A, 1989, MOL CELL BIOL, V9, P3982, DOI 10.1128/MCB.9.9.3982; Lee CW, 1999, ONCOGENE, V18, P4171, DOI 10.1038/sj.onc.1202793; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; Lill NL, 1997, NATURE, V387, P823, DOI 10.1038/42981; Lissy NA, 2000, NATURE, V407, P642, DOI 10.1038/35036608; LOWE SW, 1993, GENE DEV, V7, P535, DOI 10.1101/gad.7.4.535; Mai M, 1998, CANCER RES, V58, P2347; Marin MC, 1998, MOL CELL BIOL, V18, P6316, DOI 10.1128/MCB.18.11.6316; Marin MC, 2000, BBA-REV CANCER, V1470, pM93, DOI 10.1016/S0304-419X(00)00010-X; MORAN E, 1993, CURR OPIN GENET DEV, V3, P63, DOI 10.1016/S0959-437X(05)80342-9; MYMRYK JS, 1994, ONCOGENE, V9, P1187; Nomoto S, 1998, CANCER RES, V58, P1380; Ongkeko WM, 1999, CURR BIOL, V9, P829, DOI 10.1016/S0960-9822(99)80367-4; Osada M, 1998, NAT MED, V4, P839, DOI 10.1038/nm0798-839; Peters UR, 1999, CANCER RES, V59, P4233; Prabhu NS, 1998, INT J ONCOL, V13, P5; SHEPHERD SE, 1993, J VIROL, V67, P2944, DOI 10.1128/JVI.67.5.2944-2949.1993; Sherr CJ, 1998, GENE DEV, V12, P2984, DOI 10.1101/gad.12.19.2984; Somasundaram K, 1996, P NATL ACAD SCI USA, V93, P3088, DOI 10.1073/pnas.93.7.3088; Somasundaram K, 1997, ONCOGENE, V14, P1047, DOI 10.1038/sj.onc.1201002; Steegenga WT, 1996, MOL CELL BIOL, V16, P2101; Steegenga WT, 1999, MOL CELL BIOL, V19, P3885; Takada N, 1999, CANCER RES, V59, P2810; TAYLOR DA, 1993, MOL CELL BIOL, V13, P4714, DOI 10.1128/MCB.13.8.4714; Trink B, 1998, NAT MED, V4, P747, DOI 10.1038/nm0798-747; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; Yang AN, 1998, MOL CELL, V2, P305, DOI 10.1016/S1097-2765(00)80275-0; YEW PR, 1992, NATURE, V357, P82, DOI 10.1038/357082a0; Yokomizo A, 1999, ONCOGENE, V18, P1629, DOI 10.1038/sj.onc.1202474; Zaika A, 2001, J BIOL CHEM, V276, P11310, DOI 10.1074/jbc.M005737200; Zaika AI, 1999, CANCER RES, V59, P3257; Zeng XY, 2000, MOL CELL BIOL, V20, P1299, DOI 10.1128/MCB.20.4.1299-1310.2000; Zeng XY, 1999, MOL CELL BIOL, V19, P3257; Zeng YX, 1997, NAT GENET, V15, P78, DOI 10.1038/ng0197-78	58	25	26	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 16	2003	278	20					18313	18320		10.1074/jbc.M211704200	http://dx.doi.org/10.1074/jbc.M211704200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677YX	12639967	hybrid			2022-12-25	WOS:000182838300095
J	Wielinga, PR; van der Heijden, I; Reid, G; Beijnen, JH; Wijnholds, J; Borst, P				Wielinga, PR; van der Heijden, I; Reid, G; Beijnen, JH; Wijnholds, J; Borst, P			Characterization of the MRP4- and MRP5-mediated transport of cyclic nucleotides from intact cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GUANOSINE 3',5'-CYCLIC-MONOPHOSPHATE CGMP; MULTIDRUG-RESISTANCE PROTEIN-4; ORGANIC ANION TRANSPORTER; SMOOTH-MUSCLE; CEREBELLAR NEURONS; HUMAN ERYTHROCYTES; GUANYLATE-CYCLASE; GMP EFFLUX; CAMP; PHOSPHODIESTERASE	Cyclic nucleotides are known to be effluxed from cultured cells or isolated tissues. Two recently described members of the multidrug resistance protein family, MRP4 and MRP5, might be involved in this process, because they transport the 3',5'-cyclic nucleotides, cAMP and cGMP, into inside-out membrane vesicles. We have investigated cGMP and cAMP efflux from intact HEK293 cells overexpressing MRP4 or MRP5. The intracellular production of cGMP and cAMP was stimulated with the nitric oxide releasing compound sodium nitroprusside and the adenylate cyclase stimulator forskolin, respectively. MRP4- and MRP5-overexpressing cells effluxed more cGMP and cAMP than parental cells in an ATP-dependent manner. In contrast to a previous report we found no glutathione requirement for cyclic nucleotide transport. Transport increased proportionally with intracellular cyclic nucleotide concentrations over a calculated range of 20-600 muM, indicating low affinity transport. In addition to several classic inhibitors of organic anion transport, prostaglandins A(1) and E-1, the steroid progesterone and the anti-cancer drug estramustine all inhibited cyclic nucleotide efflux. The efflux mediated by MRP4 and MRP5 did not lead to a proportional decrease in the intracellular cGMP or cAMP levels but reduced cGMP by maximally 2-fold over the first hour. This was also the case when phosphodiesterase-mediated cyclic nucleotide hydrolysis was inhibited by 3-isobutyl-1-methylxanthine, conditions in which efflux was maximal. These data indicate that MRP4 and MRP5 are low affinity cyclic nucleotide transporters that may at best function as overflow pumps, decreasing steep increases in cGMP levels under conditions where cGMP synthesis is strongly induced and phosphodiesterase activity is limiting.	Netherlands Canc Inst, Div Mol Biol, NL-1066 CX Amsterdam, Netherlands; Netherlands Canc Inst, Ctr Biomed Genet, NL-1066 CX Amsterdam, Netherlands; Slotervaart Hosp, Dept Pharm & Pharmacol, NL-1066 EC Amsterdam, Netherlands; Royal Dutch Acad Sci, Netherlands Ophthalm Res Inst, NL-1105 BA Amsterdam, Netherlands	Netherlands Cancer Institute; Netherlands Cancer Institute; Slotervaart Hospital; Royal Netherlands Academy of Arts & Sciences; Netherlands Institute for Neuroscience (NIN-KNAW)	Borst, P (corresponding author), Netherlands Canc Inst, Div Mol Biol, Plesmanlaan 121, NL-1066 CX Amsterdam, Netherlands.		Wijnholds, Jan/V-3896-2018	Wijnholds, Jan/0000-0003-0099-460X; Reid, Glen/0000-0001-6465-5223; Wielinga, Peter/0000-0002-8830-0010				Ahlstrom M, 1999, BIOCHEM PHARMACOL, V58, P1335, DOI 10.1016/S0006-2952(99)00199-9; ARDAILLOU N, 1993, EXP NEPHROL, V1, P253; Bakre MM, 2000, EUR J BIOCHEM, V267, P179, DOI 10.1046/j.1432-1327.2000.00986.x; Bankir L, 2002, AM J PHYSIOL-RENAL, V282, pF376, DOI 10.1152/ajprenal.00202.2001; Beavo JA, 2002, NAT REV MOL CELL BIO, V3, P710, DOI 10.1038/nrm911; Bera TK, 2001, MOL MED, V7, P509, DOI 10.1007/BF03401856; Borst P, 1999, BBA-BIOMEMBRANES, V1461, P347, DOI 10.1016/S0005-2736(99)00167-4; BOWES C, 1990, NATURE, V347, P677, DOI 10.1038/347677a0; BROADUS AE, 1970, J CLIN INVEST, V49, P2222, DOI 10.1172/JCI106441; BRUNTON LL, 1988, METHOD ENZYMOL, V159, P83; Chen ZS, 2002, CANCER RES, V62, P3144; Chen ZS, 2001, J BIOL CHEM, V276, P33747, DOI 10.1074/jbc.M104833200; Conrad KP, 1999, AM J PHYSIOL-RENAL, V277, pF48, DOI 10.1152/ajprenal.1999.277.1.F48; Corbin JD, 2000, EUR J BIOCHEM, V267, P2760, DOI 10.1046/j.1432-1327.2000.01297.x; Crane JK, 2000, ARCH BIOCHEM BIOPHYS, V376, P163, DOI 10.1006/abbi.2000.1703; Evers R, 1997, FEBS LETT, V419, P112, DOI 10.1016/S0014-5793(97)01442-7; HAMET P, 1989, J BIOL CHEM, V264, P12364; HEASLEY LE, 1985, J BIOL CHEM, V260, P1514; HEASLEY LE, 1985, MOL PHARMACOL, V27, P60; Jackson EK, 2001, AM J PHYSIOL-RENAL, V281, pF597, DOI 10.1152/ajprenal.2001.281.4.F597; Jedlitschky G, 2000, J BIOL CHEM, V275, P30069, DOI 10.1074/jbc.M005463200; KANAI N, 1995, SCIENCE, V268, P866, DOI 10.1126/science.7754369; Keppler D, 1997, BIOL CHEM, V378, P787; Lai LQ, 2002, BIOCHEM J, V361, P497, DOI 10.1042/0264-6021:3610497; Li YH, 1997, J CELL BIOL, V139, P1317, DOI 10.1083/jcb.139.5.1317; LOLLEY RN, 1977, SCIENCE, V196, P664, DOI 10.1126/science.193183; Mercapide J, 1999, BIOCHEM PHARMACOL, V58, P1675, DOI 10.1016/S0006-2952(99)00252-X; Montoliu C, 1999, NEUROPHARMACOLOGY, V38, P1883, DOI 10.1016/S0028-3908(99)00071-4; Murthy KS, 2001, BIOCHEM J, V360, P199, DOI 10.1042/0264-6021:3600199; Okada D, 2002, BIOCHEMISTRY-US, V41, P9672, DOI 10.1021/bi025727+; Orbo A, 1998, EUR J CANCER, V34, P1460, DOI 10.1016/S0959-8049(98)00079-3; PATEL MJ, 1995, J PHARMACOL EXP THER, V273, P16; Pedraza CE, 2001, FEBS LETT, V507, P303, DOI 10.1016/S0014-5793(01)03003-4; Poulopoulou C, 1998, J PHARMACOL EXP THER, V286, P99; Reid G, 2003, MOL PHARMACOL, V63, P1094, DOI 10.1124/mol.63.5.1094; RINDLER MJ, 1978, J BIOL CHEM, V253, P5431; Schuetz JD, 1999, NAT MED, V5, P1048, DOI 10.1038/12487; Schuster VL, 1998, ANNU REV PHYSIOL, V60, P221, DOI 10.1146/annurev.physiol.60.1.221; Soderling SH, 2000, CURR OPIN CELL BIOL, V12, P174, DOI 10.1016/S0955-0674(99)00073-3; Stoos BA, 1997, BIOCHEM PHARMACOL, V53, P631, DOI 10.1016/S0006-2952(96)00858-1; Sundkvist E, 2002, BIOCHEM PHARMACOL, V63, P945, DOI 10.1016/S0006-2952(01)00940-6; Sundkvist E, 2000, BBA-BIOMEMBRANES, V1463, P121, DOI 10.1016/S0005-2736(99)00184-4; Tammur J, 2001, GENE, V273, P89, DOI 10.1016/S0378-1119(01)00572-8; TIETZE F, 1969, ANAL BIOCHEM, V27, P502, DOI 10.1016/0003-2697(69)90064-5; TJORNHAMMAR ML, 1983, J BIOL CHEM, V258, P6882; Touyz RM, 1997, J NEUROCHEM, V68, P1451; Van Aubel RAMH, 2002, J AM SOC NEPHROL, V13, DOI 10.1681/ASN.V133595; VANHAASTERT PJ, 1997, FEBS LETT, V410, P285; Wielinga PR, 2002, MOL PHARMACOL, V62, P1321, DOI 10.1124/mol.62.6.1321; Wijnholds J, 2000, P NATL ACAD SCI USA, V97, P7476, DOI 10.1073/pnas.120159197; WU XB, 1993, MOL PHARMACOL, V43, P564; Yabuuchi H, 2001, BIOCHEM BIOPH RES CO, V288, P933, DOI 10.1006/bbrc.2001.5865	52	226	233	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 16	2003	278	20					17664	17671		10.1074/jbc.M212723200	http://dx.doi.org/10.1074/jbc.M212723200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677YX	12637526	hybrid			2022-12-25	WOS:000182838300012
J	Xiong, SG; She, HY; Takeuchi, H; Han, B; Engelhardt, JF; Barton, CH; Zandi, E; Giulivi, C; Tsukamoto, H				Xiong, SG; She, HY; Takeuchi, H; Han, B; Engelhardt, JF; Barton, CH; Zandi, E; Giulivi, C; Tsukamoto, H			Signaling role of intracellular iron in NF-kappa B activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; DNA-BINDING ACTIVITY; RAT KUPFFER CELLS; NITRIC-OXIDE; LIPID-PEROXIDATION; FACTOR-ALPHA; TYROSINE PHOSPHORYLATION; HYDROGEN-PEROXIDE; MACROPHAGES; PEROXYNITRITE	Iron chelators inhibit endotoxin-induced NF-kappaB activation in hepatic macrophages (HMs), suggesting a role for the intracellular chelatable pool of iron in NF-kappaB activation. The present study tested this hypothesis. Analysis of Fe-59-loaded HMs stimulated with lipopolysaccharide (LPS), revealed a previously unreported, transient rise in intracellular low molecular weight (LMW).Fe-59 complex ([LMW.Fe](i)) at less than or equal to2 min returning to the basal level within 15 min. The [LMW.Fe](i) response preceded IkappaB kinase (IKK) (greater than or equal to15 min) and NF-kappaB (greater than or equal to30 min) activation. Iron chelators (1,2-dimethyl-3-hydroxypyridin-4-one and N,N'-bis-2-hydroxybenzylethylenediamine-N, N'-diacetic acid) abrogated the [LMW.Fe](i) response and IKK and NF-kappaB activation. The [LMW.Fe](i) response was also observed in tumor necrosis factor alpha (TNFalpha)-stimulated HMs and RAW264.7 cells treated with LPS and interferon-gamma but not in primary rat hepatocytes or myofibroblastic cells exposed to LPS or TNFalpha. Both [LMW.Fe](i) response and IKK activation in LPS-stimulated HMs were inhibited by diphenylene iodonium (nonspecific inhibitor for flavin-containing oxidases), L-N-6-(1-iminoethyl)lysine (selective iNOS inhibitor), and adenoviral-mediated expression of a dominant negative mutant of Rac1 or Cu, Zn-superoxide dismutase, suggesting the role of (NO)-N-. and O-2(-). in mediating the iron signaling. In fact, this inhibition was recapitulated by a cell-permeable scavenger of ONOO-, 5,10,15,20-tetrakis (4-sulfonatophenyl) porphyrinato iron (III) chloride. Conversely, ONOO- alone induced both [LMW.Fe](i) response and IKK activation. Finally, direct addition of ferrous iron to cultured HMs activated IKK and NF-kappaB. These results support a novel signaling role for [LMW.Fe](i) in IKK activation, which appears to be induced by ONOO- and selectively operative in macrophages.	Univ So Calif, Keck Sch Med, Dept Pathol, Los Angeles, CA 90033 USA; Univ So Calif, Keck Sch Med, Dept Mol Microbiol & Immunol, Los Angeles, CA 90033 USA; Univ Iowa, Coll Med, Dept Internal Med, Iowa City, IA 52242 USA; Univ Iowa, Coll Med, Ctr Gene Therapy, Iowa City, IA 52242 USA; Univ Southampton, Div Biochem & Mol Biol, Southampton S016 6YD, Hants, England; Univ Minnesota, Dept Chem, Duluth, MN 55812 USA; Greater Los Angeles Healthcare Syst, Dept Vet Affairs, Los Angeles, CA 90073 USA	University of Southern California; University of Southern California; University of Iowa; University of Iowa; University of Southampton; University of Minnesota System; University of Minnesota Duluth	Tsukamoto, H (corresponding author), Univ So Calif, Keck Sch Med, Dept Pathol, 1333 San Pablo St,NMMR-402, Los Angeles, CA 90033 USA.		Giulivi, Cecilia/AAV-6774-2021; Giulivi, Cecilia/ABB-7809-2020	Giulivi, Cecilia/0000-0003-1033-7435; Engelhardt, John/0000-0003-2389-9277	NIAAA NIH HHS [R37AA06603, P50AA11999, R24AA12885, T32-AA07578] Funding Source: Medline; NIDDK NIH HHS [P30DK48522] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK048522] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [T32AA007578, R37AA006603, R24AA012885, P50AA011999] Funding Source: NIH RePORTER	NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		ANDERSON MT, 1994, P NATL ACAD SCI USA, V91, P11527, DOI 10.1073/pnas.91.24.11527; Atkinson PGP, 1999, IMMUNOLOGY, V96, P656; Az-ma T, 1999, BRIT J PHARMACOL, V126, P1462, DOI 10.1038/sj.bjp.0702438; BAEUERLE PA, 1989, GENE DEV, V3, P1689, DOI 10.1101/gad.3.11.1689; Blackwell JM, 1996, MOL MED TODAY, V2, P205, DOI 10.1016/1357-4310(96)88773-9; Boldt DH, 1999, AM J MED SCI, V318, P207, DOI 10.1097/00000441-199910000-00001; Bonizzi G, 1997, J IMMUNOL, V159, P5264; Bonizzi G, 1996, EUR J BIOCHEM, V242, P544, DOI 10.1111/j.1432-1033.1996.0544r.x; Bonizzi G, 1999, MOL CELL BIOL, V19, P1950; Bootman MD, 2001, J CELL SCI, V114, P2213; Cairo G, 2002, BIOCHEMISTRY-US, V41, P7435, DOI 10.1021/bi025756k; CAIRO G, 1995, J BIOL CHEM, V270, P700, DOI 10.1074/jbc.270.2.700; CHAUDHRI G, 1989, J IMMUNOL, V143, P1290; COLLART MA, 1990, MOL CELL BIOL, V10, P1498, DOI 10.1128/MCB.10.4.1498; DRAPIER JC, 1993, EMBO J, V12, P3643, DOI 10.1002/j.1460-2075.1993.tb06038.x; Filep JG, 1998, J IMMUNOL, V161, P5656; Fox ES, 1998, J LEUKOCYTE BIOL, V63, P509, DOI 10.1002/jlb.63.4.509; FUHRMAN B, 1994, ATHEROSCLEROSIS, V111, P65, DOI 10.1016/0021-9150(94)90192-9; Ghosh S, 2002, CELL, V109, pS81, DOI 10.1016/S0092-8674(02)00703-1; Gogvadze V, 2002, ARCH BIOCHEM BIOPHYS, V398, P198, DOI 10.1006/abbi.2001.2721; Gow AJ, 1996, FEBS LETT, V385, P63, DOI 10.1016/0014-5793(96)00347-X; Hirota K, 1999, J BIOL CHEM, V274, P27891, DOI 10.1074/jbc.274.39.27891; IKEBUCHI Y, 1991, J BIOL CHEM, V266, P13233; JIANG XS, 1993, CELL IMMUNOL, V148, P397, DOI 10.1006/cimm.1993.1121; JOSEPHSON RA, 1991, J BIOL CHEM, V266, P2354; Kang JL, 2000, MOL CELL BIOCHEM, V215, P1, DOI 10.1023/A:1026581301366; KONDO H, 1988, HEPATOLOGY, V8, P32, DOI 10.1002/hep.1840080108; Kurose I, 1997, J CLIN INVEST, V99, P867, DOI 10.1172/JCI119251; LIH M, 1997, AM J PHYSIOL, V272, pG1355; Loegering DJ, 1996, J LEUKOCYTE BIOL, V59, P357, DOI 10.1002/jlb.59.3.357; LU SC, 1993, J CLIN INVEST, V92, P1188, DOI 10.1172/JCI116689; MASINI A, 1989, BIOCHIM BIOPHYS ACTA, V1014, P133, DOI 10.1016/0167-4889(89)90025-6; Matata BM, 2002, J BIOL CHEM, V277, P2330, DOI 10.1074/jbc.M106393200; MITOMO K, 1994, GENE, V145, P197; Olynyk JK, 2001, J GASTROEN HEPATOL, V16, P438, DOI 10.1046/j.1440-1746.2001.02456.x; REIF DW, 1990, ARCH BIOCHEM BIOPHYS, V283, P537, DOI 10.1016/0003-9861(90)90680-W; Rothwarf DM, 1998, NATURE, V395, P297, DOI 10.1038/26261; ROVERI A, 1992, ARCH BIOCHEM BIOPHYS, V297, P265, DOI 10.1016/0003-9861(92)90671-I; Sanlioglu S, 2001, J BIOL CHEM, V276, P30188, DOI 10.1074/jbc.M102061200; SCHRECK R, 1994, METHOD ENZYMOL, V234, P151; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SCHULZEOSTHOFF K, 1993, EMBO J, V12, P3095, DOI 10.1002/j.1460-2075.1993.tb05978.x; SHIBANUMA M, 1994, FEBS LETT, V353, P62, DOI 10.1016/0014-5793(94)01014-5; Singh S, 1996, J BIOL CHEM, V271, P31049, DOI 10.1074/jbc.271.49.31049; STAAL FJT, 1990, P NATL ACAD SCI USA, V87, P9943, DOI 10.1073/pnas.87.24.9943; THOMAS CE, 1985, J BIOL CHEM, V260, P3275; TOLEDANO MB, 1991, P NATL ACAD SCI USA, V88, P4328, DOI 10.1073/pnas.88.10.4328; Tsukamoto H, 1999, AM J PHYSIOL-GASTR L, V277, pG1240, DOI 10.1152/ajpgi.1999.277.6.G1240; VANASBECK BS, 1984, J INFECTION, V8, P232, DOI 10.1016/S0163-4453(84)93955-0; Virag L, 1999, MOL PHARMACOL, V56, P824; WARREN S, 1993, LYMPHOKINE CYTOK RES, V12, P75; Watts RN, 2002, EUR J BIOCHEM, V269, P3383, DOI 10.1046/j.1432-1033.2002.02987.x; Weiss G, 2002, EUR J CLIN INVEST, V32, P70, DOI 10.1046/j.1365-2362.2002.0320s1070.x; Wyllie S, 2002, MICROBES INFECT, V4, P351, DOI 10.1016/S1286-4579(02)01548-4; YEGOROV DY, 1993, FREE RADICAL BIO MED, V15, P565, DOI 10.1016/0891-5849(93)90158-Q	55	134	143	0	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 16	2003	278	20					17646	17654		10.1074/jbc.M210905200	http://dx.doi.org/10.1074/jbc.M210905200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677YX	12637578	hybrid			2022-12-25	WOS:000182838300010
J	Abrahamsen, H; Vang, T; Tasken, K				Abrahamsen, H; Vang, T; Tasken, K			Protein kinase A intersects Src signaling in membrane microdomains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							T-CELL ACTIVATION; FAMILY TYROSINE KINASES; GROWTH-FACTOR RECEPTOR; LIPID RAFTS; DOWN-REGULATION; EGF RECEPTORS; PHOSPHORYLATION; PP60C-SRC; CSK; BINDING	Regulation of Src kinase activity is tightly coupled to the phosphorylation status of the C-terminal regulatory tyrosine Tyr(527), which, when phosphorylated by Csk, represses Src. Here, we demonstrate that activation of Csk through a prostaglandin E-2-cAMP-protein kinase A (PKA) pathway inhibits Src. This inhibitory pathway is operative in detergent-resistant membrane fractions where cAMP-elevating agents activate Csk, resulting in a concomitant decrease in Src activity. The inhibitory effect on Src depends on a detergent-resistant membrane-anchored Csk and co-localization of all components of the inhibitory pathway in membrane microdomains. Furthermore, epidermal growth factor-induced activation of Src and phosphorylation of the Src substrates Cbl and focal adhesion kinase are inhibited by activation of the cAMP-PKA-Csk pathway. We propose a novel mechanism whereby G protein-coupled receptors inhibit Src signaling by activation of Csk in a cAMP-PKA-dependent manner.	Univ Oslo, Inst Basic Med Sci, Dept Med Biochem, N-0317 Oslo, Norway	University of Oslo	Tasken, K (corresponding author), Univ Oslo, Inst Basic Med Sci, Dept Med Biochem, Box 1112,Blindern, N-0317 Oslo, Norway.		Abrahamsen, Hilde/E-5323-2010	Tasken, Kjetil/0000-0003-2841-4697				Barbier AJ, 1999, J BIOL CHEM, V274, P14067, DOI 10.1074/jbc.274.20.14067; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brdicka T, 2000, J EXP MED, V191, P1591, DOI 10.1084/jem.191.9.1591; Brown MT, 1996, BBA-REV CANCER, V1287, P121, DOI 10.1016/0304-419X(96)00003-0; BURGERING BMT, 1993, EMBO J, V12, P4211, DOI 10.1002/j.1460-2075.1993.tb06105.x; Cao HM, 2002, J BIOL CHEM, V277, P8771, DOI 10.1074/jbc.C100661200; CARTWRIGHT CA, 1987, CELL, V49, P83, DOI 10.1016/0092-8674(87)90758-6; Cary LA, 2000, NATURE, V404, P945, DOI 10.1038/35010257; CHACKALAPARAMPIL I, 1988, CELL, V52, P801, DOI 10.1016/0092-8674(88)90422-9; COOPER JA, 1986, SCIENCE, V231, P1431, DOI 10.1126/science.2420005; COOPER JA, 1986, MOL CELL BIOL, V6, P4467, DOI 10.1128/MCB.6.12.4467; COURTNEIDGE SA, 1985, EMBO J, V4, P1471, DOI 10.1002/j.1460-2075.1985.tb03805.x; Dhillon AS, 2002, MOL CELL BIOL, V22, P3237, DOI 10.1128/MCB.22.10.3237-3246.2002; Dumaz N, 2002, MOL CELL BIOL, V22, P3717, DOI 10.1128/MCB.22.11.3717-3728.2002; Hunter T, 2000, CELL, V100, P113, DOI 10.1016/S0092-8674(00)81688-8; IMAMOTO A, 1993, CELL, V73, P1117, DOI 10.1016/0092-8674(93)90641-3; KAECH S, 1991, NATURE, V350, P431, DOI 10.1038/350431a0; Kassenbrock CK, 2002, J BIOL CHEM, V277, P24967, DOI 10.1074/jbc.M201026200; Kawabuchi M, 2000, NATURE, V404, P999, DOI 10.1038/35010121; KMIECIK TE, 1987, CELL, V49, P65, DOI 10.1016/0092-8674(87)90756-2; Lowry WE, 2002, DEV CELL, V2, P733, DOI 10.1016/S1534-5807(02)00175-2; Ma YC, 2000, CELL, V102, P635, DOI 10.1016/S0092-8674(00)00086-6; MATSUDA M, 1990, SCIENCE, V248, P1537, DOI 10.1126/science.1694307; Mineo C, 1999, J BIOL CHEM, V274, P30636, DOI 10.1074/jbc.274.43.30636; MORGAN DO, 1989, CELL, V57, P775, DOI 10.1016/0092-8674(89)90792-7; NADA S, 1993, CELL, V73, P1125, DOI 10.1016/0092-8674(93)90642-4; NADA S, 1991, NATURE, V351, P69, DOI 10.1038/351069a0; Neet K, 1996, GENES CELLS, V1, P147, DOI 10.1046/j.1365-2443.1996.d01-234.x; OKADA M, 1989, J BIOL CHEM, V264, P20886; Petrelli A, 2002, NATURE, V416, P187, DOI 10.1038/416187a; Ringerike T, 2002, J CELL SCI, V115, P1331; Schmitt JM, 2002, MOL CELL, V9, P85, DOI 10.1016/S1097-2765(01)00432-4; SHENOY S, 1989, CELL, V57, P763, DOI 10.1016/0092-8674(89)90791-5; Simons K, 2000, NAT REV MOL CELL BIO, V1, P31, DOI 10.1038/35036052; Soubeyran P, 2002, NATURE, V416, P183, DOI 10.1038/416183a; Takeuchi S, 2000, J BIOL CHEM, V275, P29183, DOI 10.1074/jbc.C000326200; Thomas SM, 1997, ANNU REV CELL DEV BI, V13, P513, DOI 10.1146/annurev.cellbio.13.1.513; Torgersen KM, 2001, J BIOL CHEM, V276, P29313, DOI 10.1074/jbc.C100014200; Vang T, 1998, BBA-PROTEIN STRUCT M, V1384, P285, DOI 10.1016/S0167-4838(97)00202-1; Vang T, 2001, J EXP MED, V193, P497, DOI 10.1084/jem.193.4.497; Xavier R, 1998, IMMUNITY, V8, P723, DOI 10.1016/S1074-7613(00)80577-4; YACIUK P, 1989, MOL CELL BIOL, V9, P2453, DOI 10.1128/MCB.9.6.2453; Zhang WG, 1998, IMMUNITY, V9, P239, DOI 10.1016/S1074-7613(00)80606-8; Zheng XM, 2000, EMBO J, V19, P964, DOI 10.1093/emboj/19.5.964	44	44	45	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 9	2003	278	19					17170	17177		10.1074/jbc.M211426200	http://dx.doi.org/10.1074/jbc.M211426200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677QG	12606547	hybrid			2022-12-25	WOS:000182818600097
J	Chung, JW; Hong, SJ; Kim, KJ; Goti, D; Stins, MF; Shin, S; Dawson, VL; Dawson, TM; Kim, KS				Chung, JW; Hong, SJ; Kim, KJ; Goti, D; Stins, MF; Shin, S; Dawson, VL; Dawson, TM; Kim, KS			37-kDa laminin receptor precursor modulates cytotoxic necrotizing factor 1-mediated RhoA activation and bacterial uptake	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MICROVASCULAR ENDOTHELIAL-CELLS; ESCHERICHIA-COLI INVASION; BINDING-PROTEIN; PRION PROTEIN; FACTOR TYPE-1; K1 INVASION; GENE LOCUS; FACTOR-I; IDENTIFICATION; CONTRIBUTES	Cytotoxic necrotizing factor 1 (CNF1) is a bacterial toxin known to activate Rho GTPases and induce host cell cytoskeleton rearrangements. The constitutive activation of Rho GTPases by CNF1 is shown to enhance bacterial uptake in epithelial cells and human brain microvascular endothelial cells. However, it is unknown how exogenous CNF1 exhibits such phenotypes in eukaryotic cells. Here, we identified 37-kDa laminin receptor precursor (LRP) as the receptor for CNF1 from screening the cDNA library of human brain microvascular endothelial cells by the yeast two-hybrid system using the N-terminal domain of CNF1 as bait. CNF1-mediated RhoA activation and bacterial uptake were inhibited by exogenous LRP or LRP antisense oligodeoxynucleotides, whereas they were increased in LRP-overexpressing cells. These findings indicate that the CNF1 interaction with LRP is the initial step required for CNF1-mediated RhoA activation and bacterial uptake in eukaryotic cells.	Johns Hopkins Univ, Sch Med, Dept Pediat, Div Pediat Infect Dis, Baltimore, MD 21287 USA; Johns Hopkins Univ, Sch Med, Dept Neurol, Baltimore, MD 21287 USA; Johns Hopkins Univ, Sch Med, Dept Neurosci, Baltimore, MD 21287 USA; Johns Hopkins Univ, Sch Med, Dept Physiol, Baltimore, MD 21287 USA; Johns Hopkins Univ, Sch Med, Inst Cell Engn, Baltimore, MD 21287 USA	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University	Kim, KS (corresponding author), Johns Hopkins Univ, Sch Med, Dept Pediat, Div Pediat Infect Dis, 600 N Wolfe St,Pk 256, Baltimore, MD 21287 USA.		Stins, Monique/W-2621-2018; Dawson, Valina/Y-9757-2019	Dawson, Valina/0000-0002-2915-3970				Backstrom M, 1997, MOL MICROBIOL, V24, P489, DOI 10.1046/j.1365-2958.1997.3541721.x; Badger JL, 2000, MOL MICROBIOL, V36, P174, DOI 10.1046/j.1365-2958.2000.01840.x; BLANCO J, 1992, FEMS MICROBIOL LETT, V96, P155, DOI 10.1016/0378-1097(92)90396-6; Broek IV, 2001, BRIT J CANCER, V85, P1387, DOI 10.1054/bjoc.2001.2078; CAPRIOLI A, 1983, INFECT IMMUN, V39, P1300, DOI 10.1128/IAI.39.3.1300-1306.1983; Clausse N, 1996, DNA CELL BIOL, V15, P1009, DOI 10.1089/dna.1996.15.1009; Contamin S, 2000, MOL BIOL CELL, V11, P1775, DOI 10.1091/mbc.11.5.1775; Donaldson Elaine A., 2000, Molecular Cell Biology Research Communications, V3, P53, DOI 10.1006/mcbr.2000.0191; Falnes PO, 2000, CURR OPIN CELL BIOL, V12, P407, DOI 10.1016/S0955-0674(00)00109-5; FALZANO L, 1993, MOL MICROBIOL, V9, P1247, DOI 10.1111/j.1365-2958.1993.tb01254.x; FIORENTINI C, 1988, TOXICON, V26, P1047, DOI 10.1016/0041-0101(88)90203-6; Flatau G, 1997, NATURE, V387, P729, DOI 10.1038/42743; Gauczynski S, 2001, EMBO J, V20, P5863, DOI 10.1093/emboj/20.21.5863; Hoffman JA, 2000, INFECT IMMUN, V68, P5062, DOI 10.1128/IAI.68.9.5062-5067.2000; Huang SH, 1999, INFECT IMMUN, V67, P2103, DOI 10.1128/IAI.67.5.2103-2109.1999; Huang SH, 2001, J INFECT DIS, V183, P1071, DOI 10.1086/319290; Hundt C, 2001, EMBO J, V20, P5876, DOI 10.1093/emboj/20.21.5876; Khan NA, 2002, J BIOL CHEM, V277, P15607, DOI 10.1074/jbc.M112224200; Lemichez E, 1997, MOL MICROBIOL, V24, P1061, DOI 10.1046/j.1365-2958.1997.4151781.x; Lerm M, 1999, INFECT IMMUN, V67, P496, DOI 10.1128/IAI.67.2.496-503.1999; Ludwig GV, 1996, J VIROL, V70, P5592, DOI 10.1128/JVI.70.8.5592-5599.1996; McKenna DJ, 2001, EXP EYE RES, V73, P81, DOI 10.1006/exer.2001.1013; Menard S, 1998, BREAST CANCER RES TR, V52, P137, DOI 10.1023/A:1006171403765; Meysick KC, 2001, INFECT IMMUN, V69, P2066, DOI 10.1128/IAI.69.4.2066-2074.2001; Modugno M, 2002, ONCOGENE, V21, P7478, DOI 10.1038/sj.onc.1205957; NAGLICH JG, 1992, CELL, V69, P1051, DOI 10.1016/0092-8674(92)90623-K; Narumi K, 1999, JPN J CANCER RES, V90, P425, DOI 10.1111/j.1349-7006.1999.tb00765.x; PELLEGRINI R, 1994, INT J CANCER S, V8, P116; Prasadarao NV, 1999, INFECT IMMUN, V67, P5775, DOI 10.1128/IAI.67.11.5775-5783.1999; Prasadarao NV, 1999, INFECT IMMUN, V67, P1131, DOI 10.1128/IAI.67.3.1131-1138.1999; Rieger R, 1997, NAT MED, V3, P1383, DOI 10.1038/nm1297-1383; Rittinger K, 1997, NATURE, V389, P758, DOI 10.1038/39651; Schmidt G, 1997, NATURE, V387, P725, DOI 10.1038/42735; Sorokin AV, 2000, BIOCHEMISTRY-MOSCOW+, V65, P546; Stins MF, 1997, J NEUROIMMUNOL, V76, P81, DOI 10.1016/S0165-5728(97)00036-2; WANG KS, 1992, J VIROL, V66, P4992, DOI 10.1128/JVI.66.8.4992-5001.1992; Wang Y, 1999, INFECT IMMUN, V67, P4751, DOI 10.1128/IAI.67.9.4751-4756.1999	37	86	87	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 9	2003	278	19					16857	16862		10.1074/jbc.M301028200	http://dx.doi.org/10.1074/jbc.M301028200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677QG	12615923	hybrid			2022-12-25	WOS:000182818600056
J	Mould, AP; Barton, SJ; Askari, JA; McEwan, PA; Buckley, PA; Craig, SE; Humphries, MJ				Mould, AP; Barton, SJ; Askari, JA; McEwan, PA; Buckley, PA; Craig, SE; Humphries, MJ			Conformational changes in the integrin beta A domain provide a mechanism for signal transduction via hybrid domain movement	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							I-DOMAIN; MONOCLONAL-ANTIBODY; BINDING-SITE; EXTRACELLULAR SEGMENT; REGULATORY REGION; CRYSTAL-STRUCTURE; CELL-ADHESION; ALPHA 5; LIGAND; ACTIVATION	The ligand-binding head region of integrin beta subunits contains a von Willebrand factor type A domain (betaA). Ligand binding activity is regulated through conformational changes in betaA, and ligand recognition also causes conformational changes that are transduced from this domain. The molecular basis of signal transduction to and from betaA is uncertain. The epitopes of mAbs 15/7 and HUTS-4 lie in the beta(1) subunit hybrid domain, which is connected to the lower face of betaA. Changes in the expression of these epitopes are induced by conformational changes in betaA caused by divalent cations, function perturbing mAbs, or ligand recognition. Recombinant truncated alpha(5)beta1 with a mutation L358A in the alpha7 helix of betaA has constitutively high expression of the 15/7 and HUTS-4 epitopes, mimics the conformation of the ligand-occupied receptor, and has high constitutive ligand binding activity. The epitopes of 15/7 and HUTS-4 map to a region of the hybrid domain that lies close to an interface with the alpha subunit. Taken together, these data suggest that the transduction of conformational changes through betaA involves shape shifting in the alpha7 helix region, which is linked to a swing of the hybrid domain away from the alpha subunit.	Univ Manchester, Sch Biol Sci, Wellcome Trust Ctr Cell Matrix Res, Manchester M13 9PT, Lancs, England	University of Manchester	Mould, AP (corresponding author), Univ Manchester, Sch Biol Sci, Wellcome Trust Ctr Cell Matrix Res, 2-205 Stopford Bldg,Oxford Rd, Manchester M13 9PT, Lancs, England.	paul.mould@man.ac.uk		Mould, Paul/0000-0003-0076-6228; Humphries, Martin/0000-0002-4331-6967; mcewan, paul/0000-0001-6097-1528				Arnaout MA, 2002, IMMUNOL REV, V186, P125, DOI 10.1034/j.1600-065X.2002.18612.x; Arnaout MA, 2002, CURR OPIN CELL BIOL, V14, P641, DOI 10.1016/S0955-0674(02)00371-X; BAZZONI G, 1995, J BIOL CHEM, V270, P25570, DOI 10.1074/jbc.270.43.25570; BELGOVA N, 2002, NAT STRUCT BIOL, V9, P282; Burrows L, 1999, BIOCHEM J, V344, P527, DOI 10.1042/0264-6021:3440527; Calderwood DA, 1997, J BIOL CHEM, V272, P12311, DOI 10.1074/jbc.272.19.12311; Coe APF, 2001, J BIOL CHEM, V276, P35854, DOI 10.1074/jbc.M103639200; Crommie D, 1998, J CELL BIOCHEM, V71, P63, DOI 10.1002/(SICI)1097-4644(19981001)71:1<63::AID-JCB7>3.0.CO;2-#; Curley GP, 1999, CELL MOL LIFE SCI, V56, P427, DOI 10.1007/s000180050443; DANEN EHJ, 1995, J BIOL CHEM, V270, P21612, DOI 10.1074/jbc.270.37.21612; DRANSFIELD I, 1992, J CELL BIOL, V116, P219, DOI 10.1083/jcb.116.1.219; DU XP, 1991, CELL, V79, P659; Giancotti FG, 1999, SCIENCE, V285, P1028, DOI 10.1126/science.285.5430.1028; Hantgan RR, 1999, BIOCHEMISTRY-US, V38, P14461, DOI 10.1021/bi9907680; Hato T, 1998, J CELL BIOL, V141, P1685, DOI 10.1083/jcb.141.7.1685; Huang CC, 2000, J BIOL CHEM, V275, P21514, DOI 10.1074/jbc.M002286200; Hughes PE, 1998, TRENDS CELL BIOL, V8, P359, DOI 10.1016/S0962-8924(98)01339-7; Humphries JD, 2000, J BIOL CHEM, V275, P20337, DOI 10.1074/jbc.M000568200; Humphries MJ, 2000, BIOCHEM SOC T, V28, P311, DOI 10.1042/0300-5127:0280311; Huth JR, 2000, P NATL ACAD SCI USA, V97, P5231, DOI 10.1073/pnas.97.10.5231; Hynes RO, 2002, CELL, V110, P673, DOI 10.1016/S0092-8674(02)00971-6; Lee JO, 1995, STRUCTURE, V3, P1333, DOI 10.1016/S0969-2126(01)00271-4; Liddington RC, 2002, J CELL BIOL, V158, P833, DOI 10.1083/jcb.200206011; Liddington RC, 2002, STRUCTURE, V10, P605, DOI 10.1016/S0969-2126(02)00766-9; Lu CF, 2001, P NATL ACAD SCI USA, V98, P2393, DOI 10.1073/pnas.041618598; Luque A, 1996, J BIOL CHEM, V271, P11067, DOI 10.1074/jbc.271.19.11067; MIYAMOTO S, 1995, SCIENCE, V267, P883, DOI 10.1126/science.7846531; Mizoue LS, 2002, CURR OPIN STRUC BIOL, V12, P459, DOI 10.1016/S0959-440X(02)00348-2; MOULD AP, 1995, J BIOL CHEM, V270, P26270, DOI 10.1074/jbc.270.44.26270; Mould AP, 2002, J BIOL CHEM, V277, P19800, DOI 10.1074/jbc.M201571200; Mould AP, 1997, J BIOL CHEM, V272, P17283, DOI 10.1074/jbc.272.28.17283; Mould AP, 1996, J BIOL CHEM, V271, P20365, DOI 10.1074/jbc.271.34.20365; Mould AP, 1996, J CELL SCI, V109, P2613; MOULD AP, 1995, FEBS LETT, V363, P118, DOI 10.1016/0014-5793(95)00301-O; MULLER B, 1993, J BIOL CHEM, V268, P6800; Ni HY, 1998, J BIOL CHEM, V273, P7981, DOI 10.1074/jbc.273.14.7981; Ni HY, 1998, CELL ADHES COMMUN, V5, P257, DOI 10.3109/15419069809040296; PuzonMcLaughlin W, 1996, J BIOL CHEM, V271, P16580, DOI 10.1074/jbc.271.28.16580; Ridgway JBB, 1996, PROTEIN ENG, V9, P617, DOI 10.1093/protein/9.7.617; Sheppard D, 2000, MATRIX BIOL, V19, P203, DOI 10.1016/S0945-053X(00)00065-2; Shih DT, 1997, J CELL SCI, V110, P2619; Shimaoka M, 2002, ANNU REV BIOPH BIOM, V31, P485, DOI 10.1146/annurev.biophys.31.101101.140922; TAKADA Y, 1993, J BIOL CHEM, V268, P17597; Takagi J, 2002, CELL, V110, P599, DOI 10.1016/S0092-8674(02)00935-2; Takagi J, 2002, IMMUNOL REV, V186, P141, DOI 10.1034/j.1600-065X.2002.18613.x; TUCKWELL D, 1995, J CELL SCI, V108, P1629; Vinogradova O, 2002, CELL, V110, P587, DOI 10.1016/S0092-8674(02)00906-6; Xiong JP, 2001, SCIENCE, V294, P339, DOI 10.1126/science.1064535; Xiong JP, 2000, J BIOL CHEM, V275, P38762, DOI 10.1074/jbc.C000563200; Xiong JP, 2002, SCIENCE, V296, P151, DOI 10.1126/science.1069040; Xiong YM, 2001, J BIOL CHEM, V276, P19340, DOI 10.1074/jbc.M008903200; Yan B, 2000, J BIOL CHEM, V275, P7249, DOI 10.1074/jbc.275.10.7249; YEDNOCK TA, 1995, J BIOL CHEM, V270, P28740, DOI 10.1074/jbc.270.48.28740	53	101	107	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 9	2003	278	19					17028	17035		10.1074/jbc.M213139200	http://dx.doi.org/10.1074/jbc.M213139200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677QG	12615914	hybrid			2022-12-25	WOS:000182818600079
J	Simonet, VC; Basle, A; Klose, KE; Delcour, AH				Simonet, VC; Basle, A; Klose, KE; Delcour, AH			The Vibrio cholerae Porins OmpU and OmpT have distinct channel properties	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OUTER-MEMBRANE PROTEIN; ESCHERICHIA-COLI; BACTERIAL PORINS; BILE RESISTANCE; PATCH-CLAMP; VIRULENCE; TOXR; RECONSTITUTION; ANGUILLARUM; EXPRESSION	Numerous environmental signals regulate the production of virulence factors and the composition of the outer membrane of Vibrio cholerae. In particular, bile promotes the ToxR-dependent expression of the porin OmpU. Strains expressing solely OmpU are more resistant to bile, are better able to colonize the intestine, and produce more cholera toxin than strains expressing solely the OmpT porin. To gain some understanding in the physiological relevance and the molecular mechanism underlying these porin-dependent phenotypes, we have undertaken a thorough electrophysiological characterization of the channel properties of the two porins. Purified OmpU or OmpT was reconstituted in liposomes suitable for patch clamp and in planar lipid bilayers. The high resolution of the patch clamp technique allowed us to analyze in detail the behavior of single OmpU and OmpT channels. Both channels exhibit closing transitions to various conductance states. OmpT is a much more dynamic channel than OmpU, displaying frequent and prolonged closures, even at low transmembrane potentials. With a critical voltage for closure V-c of approximately +/-90 mV, OmpT is much more voltage-sensitive than OmpU (with a V-c of approximately +/-160 mV), a feature that is also readily apparent in the voltage dependence of closing probability observed in patch clamp in the +/-100 mV range. OmpT has low ionic selectivity (P-K/P-Cl=similar to4), whereas OmpU is more cation-selective (P-K/P-Cl=similar to14). The distinct functional properties of the two porins are likely to play an integrated role with environmental regulation of their expression. For example, the higher selectivity of OmpU for cations provides a possible explanation for the protective role played by this porin in a bile-containing environment, because this type of selectivity would restrict the flux of anionic bile salts through the outer membrane and thus would reduce the exposure of the cytoplasmic membrane to this natural detergent.	Univ Houston, Dept Biol & Biochem, Houston, TX 77204 USA; Univ Texas, Hlth Sci Ctr, Dept Microbiol & Immunol, San Antonio, TX 78229 USA	University of Houston System; University of Houston; University of Texas System; University of Texas Health San Antonio	Delcour, AH (corresponding author), Univ Houston, Dept Biol & Biochem, 369 Sci & Res Bldg 2, Houston, TX 77204 USA.			Basle, Arnaud/0000-0002-4899-3086	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R56AI051333, R29AI034905, R01AI051333, R01AI034905] Funding Source: NIH RePORTER; NIAID NIH HHS [AI34905, AI51333] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALM RA, 1986, FEMS MICROBIOL LETT, V37, P99, DOI 10.1111/j.1574-6968.1986.tb01774.x; Benz Roland, 1997, Microbiologia (Madrid), V13, P321; BOLLA JM, 1995, J BACTERIOL, V177, P4266, DOI 10.1128/jb.177.15.4266-4271.1995; Chakrabarti Sr, 1996, J BACTERIOL, V178, P524, DOI 10.1128/jb.178.2.524-530.1996; COWAN SW, 1992, NATURE, V358, P727, DOI 10.1038/358727a0; Crawford JA, 1998, MOL MICROBIOL, V29, P235, DOI 10.1046/j.1365-2958.1998.00925.x; Davey ML, 1998, APPL ENVIRON MICROB, V64, P138; De E, 2001, MOL MICROBIOL, V41, P189, DOI 10.1046/j.1365-2958.2001.02501.x; DELCOUR AH, 1989, BIOPHYS J, V56, P631, DOI 10.1016/S0006-3495(89)82710-9; Delcour AH, 1997, FEMS MICROBIOL LETT, V151, P115, DOI 10.1016/S0378-1097(97)00166-3; FOUREL D, 1994, EUR J BIOCHEM, V222, P625, DOI 10.1111/j.1432-1033.1994.tb18905.x; Gupta S, 1997, INFECT IMMUN, V65, P1131, DOI 10.1128/IAI.65.3.1131-1134.1997; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; Hille B, 1992, IONIC CHANNELS EXCIT, P341; Iyer R, 1997, J BIOL CHEM, V272, P18595, DOI 10.1074/jbc.272.30.18595; Jacob-Dubuisson F, 1999, J BIOL CHEM, V274, P37731, DOI 10.1074/jbc.274.53.37731; KOGA T, 1994, MICROBIOL IMMUNOL, V38, P931, DOI 10.1111/j.1348-0421.1994.tb02149.x; LANG HN, 1993, MOL MICROBIOL, V10, P891, DOI 10.1111/j.1365-2958.1993.tb00960.x; Li CYC, 2000, MOL MICROBIOL, V35, P189, DOI 10.1046/j.1365-2958.2000.01699.x; Liu NZ, 1997, BBA-BIOMEMBRANES, V1326, P201, DOI 10.1016/S0005-2736(97)00024-2; MILLER VL, 1988, J BACTERIOL, V170, P2575, DOI 10.1128/JB.170.6.2575-2583.1988; Nakasone N, 1998, INFECT IMMUN, V66, P4726, DOI 10.1128/IAI.66.10.4726-4728.1998; NIKAIDO H, 1996, ESCHERICHIA COLI SAL, P29; Nitzan Y, 1999, CURR MICROBIOL, V38, P1, DOI 10.1007/PL00006764; Provenzano D, 2000, P NATL ACAD SCI USA, V97, P10220, DOI 10.1073/pnas.170219997; Provenzano D, 2000, INFECT IMMUN, V68, P1491, DOI 10.1128/IAI.68.3.1491-1497.2000; Provenzano D, 2001, J BACTERIOL, V183, P3652, DOI 10.1128/JB.183.12.3652-3662.2001; SAHU GK, 1994, INFECT IMMUN, V62, P5624, DOI 10.1128/IAI.62.12.5624-5631.1994; Samartzidou H, 1998, EMBO J, V17, P93, DOI 10.1093/emboj/17.1.93; SEN K, 1988, J BIOL CHEM, V263, P1182; Simon M, 1996, J BACTERIOL, V178, P4182, DOI 10.1128/jb.178.14.4182-4188.1996; Skorupski K, 1997, MOL MICROBIOL, V25, P1003, DOI 10.1046/j.1365-2958.1997.5481909.x; SPERANDIO V, 1995, INFECT IMMUN, V63, P4433, DOI 10.1128/IAI.63.11.4433-4438.1995; Van Gelder P, 2000, BIOPHYS CHEM, V85, P153, DOI 10.1016/S0301-4622(99)00153-2; Wibbenmeyer JA, 2002, INFECT IMMUN, V70, P121, DOI 10.1128/IAI.70.1.121-126.2002	35	50	52	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 9	2003	278	19					17539	17545		10.1074/jbc.M301202200	http://dx.doi.org/10.1074/jbc.M301202200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677QG	12606562	hybrid			2022-12-25	WOS:000182818600143
J	Huang, LL; Sexton, DJ; Skogerson, K; Devlin, M; Smith, R; Sanyal, I; Parry, T; Kent, R; Enright, J; Wu, QL; Conley, G; DeOliveira, D; Morganelli, L; Ducar, M; Wescott, CR; Ladner, RC				Huang, LL; Sexton, DJ; Skogerson, K; Devlin, M; Smith, R; Sanyal, I; Parry, T; Kent, R; Enright, J; Wu, QL; Conley, G; DeOliveira, D; Morganelli, L; Ducar, M; Wescott, CR; Ladner, RC			Novel peptide inhibitors of angiotensin-converting enzyme 2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HYDROLYSIS; CAPTOPRIL; MECHANISM	Angiotensin-converting enzyme 2 (ACE2), a recently identified human homolog of ACE, is a novel metallocarboxypeptidase with specificity, tissue distribution, and function distinct from those of ACE. ACE2 may play a unique role in the renin-angiotensin system and mediate cardiovascular and renal function. Here we report the discovery of ACE2 peptide inhibitors through selection of constrained peptide libraries displayed on phage. Six constrained peptide libraries were constructed and selected against FLAG-tagged ACE2 target. ACE2 peptide binders were identified and classified into five groups, based on their effects on ACE2 activity. Peptides from the first three classes exhibited none, weak, or mode-rate inhibition on ACE2. Peptides from the fourth class exhibited strong inhibition, with equilibrium inhibition constants (K-i values) from 0.38 to 1.7 gm. Peptides from the fifth class exhibited very strong inhibition, with K-i values <0.14 muM. The most potent inhibitor, DX600, had a Ki of 2.8 nM. Steady-state enzyme kinetic analysis showed that these potent ACE2 inhibitors exhibited a mixed competitive and non-competitive type of inhibition. They were not hydrolyzed by ACE2. Furthermore, they did not inhibit ACE activity, and thus were specific to ACE2. Finally, they also inhibited ACE2 activity toward its natural substrate angiotensin 1, suggesting that they would be functional in vivo. As novel ACE2-specific peptide inhibitors, they should be useful in elucidation of ACE2 in vivo function, thus contributing to our better understanding of the biology of cardiovascular regulation. Our results also demonstrate that library selection by phage display technology can be a rapid and efficient way to discover potent and specific protease inhibitors.	Dyax Corp, Div Res, Cambridge, MA 02139 USA; Human Genome Sci Inc, Rockville, MD 20850 USA	GlaxoSmithKline; Human Genome Sciences Inc	Huang, LL (corresponding author), Dyax Corp, Div Res, 300 Technol Square, Cambridge, MA 02139 USA.	lhuang@dyax.com		Sexton, Daniel J/0000-0001-9604-5948				CORVOL P, 1995, METHOD ENZYMOL, V248, P283; Crackower MA, 2002, NATURE, V417, P822, DOI 10.1038/nature00786; Dales NA, 2002, J AM CHEM SOC, V124, P11852, DOI 10.1021/ja0277226; Donoghue M, 2000, CIRC RES, V87, pE1, DOI 10.1161/01.res.87.5.e1; DORER FE, 1974, CIRC RES, V34, P824, DOI 10.1161/01.RES.34.6.824; DRUMMER OH, 1990, BIOCHEM PHARMACOL, V39, P513, DOI 10.1016/0006-2952(90)90058-S; Eriksson U, 2002, CURR BIOL, V12, pR745, DOI 10.1016/S0960-9822(02)01255-1; Fairbrother WJ, 1998, BIOCHEMISTRY-US, V37, P17754, DOI 10.1021/bi981931e; JOHNSON H, 1989, PEPTIDES, V10, P489, DOI 10.1016/0196-9781(89)90133-2; Lemos VS, 2002, BRIT J PHARMACOL, V135, P1743, DOI 10.1038/sj.bjp.0704630; Marceau F, 1998, CLIN REV ALLERG IMMU, V16, P385, DOI 10.1007/BF02737658; MENDELSOHN FAO, 1981, CLIN SCI, V61, pS277, DOI 10.1042/cs061277s; OKUDA M, 1985, J BIOCHEM-TOKYO, V98, P621, DOI 10.1093/oxfordjournals.jbchem.a135318; OPARIL S, 1971, CIRC RES, V29, P682, DOI 10.1161/01.RES.29.6.682; Ren YL, 2002, HYPERTENSION, V39, P799, DOI 10.1161/hy0302.104673; Segel I. H., 1993, ENZYME KINETICS BEHA, P100; SKEGGS LT, 1956, J EXP MED, V103, P295, DOI 10.1084/jem.103.3.295; SNYDER RA, 1986, BIOCHIM BIOPHYS ACTA, V871, P1, DOI 10.1016/0167-4838(86)90125-1; Tipnis SR, 2000, J BIOL CHEM, V275, P33238, DOI 10.1074/jbc.M002615200; Turner AJ, 2002, TRENDS PHARMACOL SCI, V23, P177, DOI 10.1016/S0165-6147(00)01994-5; Vickers C, 2002, J BIOL CHEM, V277, P14838, DOI 10.1074/jbc.M200581200	21	161	193	8	25	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 2	2003	278	18					15532	15540		10.1074/jbc.M212934200	http://dx.doi.org/10.1074/jbc.M212934200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	675EL	12606557	hybrid			2022-12-25	WOS:000182680000011
J	Yang, TTC; Chow, CW				Yang, TTC; Chow, CW			Transcription cooperation by NFAT center dot C/EBP composite enhancer complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED T-CELLS; CCAAT/ENHANCER-BINDING PROTEIN; MUSCLE FIBER-TYPE; FACTOR-ALPHA GENE; NUCLEAR FACTOR; ADIPOCYTE DIFFERENTIATION; DNA-BINDING; PPAR-GAMMA; PHOSPHATASE CALCINEURIN; SIGNAL-TRANSDUCTION	The nuclear factor of activated T cells (NFAT) group of transcription factors regulates gene expression in immune and non-immune cells. NFAT-mediated gene transcription is orchestrated, in part, by formation of a composite regulatory element. Here we demonstrate that NFAT interacts with transcription factor CCAAT/enhancer-binding protein (C/EBP) to form a composite enhancer complex, to potentiate expression of the peroxisome proliferator-activated receptor-gamma2 gene. Formation of a ternary NFAT.C/EBP.DNA complex is required for the transcriptional cooperation. A similar NFAT.C/EBP composite element is found in the regulatory region of the insulin-like growth factor 2, angiotensin-converting enzyme homolog, and transcription factor POU4F3 genes. Thus, the NFAT.C/EBP composite element represents a novel regulatory enhancer to direct NFAT-mediated gene transcription.	Yeshiva Univ Albert Einstein Coll Med, Dept Mol Pharmacol, Bronx, NY 10461 USA	Yeshiva University; Albert Einstein College of Medicine	Chow, CW (corresponding author), Yeshiva Univ Albert Einstein Coll Med, Dept Mol Pharmacol, 1300 Morris Pk Ave, Bronx, NY 10461 USA.				NIDDK NIH HHS [R01 DK063167-05, R01 DK063167-03, R01 DK063167-01A2, R01 DK063167-04, R01 DK063167, R01 DK063167-02] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK063167] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Agarwal S, 2000, IMMUNITY, V12, P643, DOI 10.1016/S1074-7613(00)80215-0; Aramburu J, 1998, MOL CELL, V1, P627, DOI 10.1016/S1097-2765(00)80063-5; Beals CR, 1997, GENE DEV, V11, P824, DOI 10.1101/gad.11.7.824; Bert AG, 2000, J IMMUNOL, V165, P5646, DOI 10.4049/jimmunol.165.10.5646; Blaeser F, 2000, J BIOL CHEM, V275, P197, DOI 10.1074/jbc.275.1.197; BOISE LH, 1993, MOL CELL BIOL, V13, P1911, DOI 10.1128/MCB.13.3.1911; Bower KE, 2002, J BIOL CHEM, V277, P34967, DOI 10.1074/jbc.M205048200; Buck M, 1999, MOL CELL, V4, P1087, DOI 10.1016/S1097-2765(00)80237-3; Buck M, 2001, MOL CELL, V8, P807, DOI 10.1016/S1097-2765(01)00374-4; Chen L, 1998, NATURE, V392, P42, DOI 10.1038/32100; Chin ER, 1998, GENE DEV, V12, P2499, DOI 10.1101/gad.12.16.2499; Chow CW, 2000, MOL CELL BIOL, V20, P5227, DOI 10.1128/MCB.20.14.5227-5234.2000; Chow CW, 1999, MOL CELL BIOL, V19, P2300; Chow CW, 1997, SCIENCE, V278, P1638, DOI 10.1126/science.278.5343.1638; Chow CW, 2000, MOL CELL BIOL, V20, P702, DOI 10.1128/MCB.20.2.702-712.2000; Clark MP, 1998, NUCLEIC ACIDS RES, V26, P1801, DOI 10.1093/nar/26.7.1801; Cowherd RM, 1999, SEMIN CELL DEV BIOL, V10, P3, DOI 10.1006/scdb.1998.0276; Crabtree GR, 2001, J BIOL CHEM, V276, P2313, DOI 10.1074/jbc.R000024200; Crabtree GR, 1999, CELL, V96, P611, DOI 10.1016/S0092-8674(00)80571-1; Darlington GJ, 1998, J BIOL CHEM, V273, P30057, DOI 10.1074/jbc.273.46.30057; Davis RJ, 2000, CELL, V103, P239, DOI 10.1016/S0092-8674(00)00116-1; DESCOMBES P, 1991, CELL, V67, P569, DOI 10.1016/0092-8674(91)90531-3; Duncliffe KN, 1997, IMMUNITY, V6, P175, DOI 10.1016/S1074-7613(00)80424-0; DURAND DB, 1988, MOL CELL BIOL, V8, P1715, DOI 10.1128/MCB.8.4.1715; Elberg G, 2000, J BIOL CHEM, V275, P27815; ELGIN SCR, 1981, CELL, V27, P413, DOI 10.1016/0092-8674(81)90381-0; Fajas L, 1997, J BIOL CHEM, V272, P18779, DOI 10.1074/jbc.272.30.18779; FEIL R, 1995, DEV GENET, V17, P240, DOI 10.1002/dvg.1020170309; Felsenfeld G, 1996, P NATL ACAD SCI USA, V93, P9384, DOI 10.1073/pnas.93.18.9384; Feske S, 2001, NAT IMMUNOL, V2, P316, DOI 10.1038/86318; Graef IA, 2001, CELL, V105, P863, DOI 10.1016/S0092-8674(01)00396-8; Graef IA, 1999, NATURE, V401, P703, DOI 10.1038/44378; Greally JM, 1997, MAMM GENOME, V8, P805, DOI 10.1007/s003359900583; Hanlon M, 2001, J BIOL CHEM, V276, P38449, DOI 10.1074/jbc.M102165200; Ho IC, 1998, P NATL ACAD SCI USA, V95, P15537, DOI 10.1073/pnas.95.26.15537; HOEY T, 1995, IMMUNITY, V2, P461, DOI 10.1016/1074-7613(95)90027-6; JAIN J, 1992, NATURE, V356, P801, DOI 10.1038/356801a0; JAIN JN, 1993, NATURE, V365, P352, DOI 10.1038/365352a0; JAIN JN, 1993, J IMMUNOL, V151, P837; Krebs JE, 2000, CRIT REV EUKAR GENE, V10, P1; Lekstrom-Himes J, 1998, J BIOL CHEM, V273, P28545, DOI 10.1074/jbc.273.44.28545; LIN FT, 1993, P NATL ACAD SCI USA, V90, P9606, DOI 10.1073/pnas.90.20.9606; Loh C, 1996, J BIOL CHEM, V271, P10884, DOI 10.1074/jbc.271.18.10884; Luo C, 1996, J EXP MED, V184, P141, DOI 10.1084/jem.184.1.141; MACDOUGALD OA, 1995, ANNU REV BIOCHEM, V64, P345, DOI 10.1146/annurev.bi.64.070195.002021; Macian F, 2000, EMBO J, V19, P4783, DOI 10.1093/emboj/19.17.4783; Macian F, 2001, ONCOGENE, V20, P2476, DOI 10.1038/sj.onc.1204386; Macian F, 2002, CELL, V109, P719, DOI 10.1016/S0092-8674(02)00767-5; MCKNIGHT SL, 1989, GENE DEV, V3, P2021, DOI 10.1101/gad.3.12b.2021; Minden A., 1997, BIOCHIM BIOPHYS ACTA, V1333, P85, DOI DOI 10.1016/S0304-419X(97)00018-8; Miskin JE, 2000, J VIROL, V74, P9412, DOI 10.1128/JVI.74.20.9412-9420.2000; Molkentin JD, 1998, CELL, V93, P215, DOI 10.1016/S0092-8674(00)81573-1; NORTHROP JP, 1994, NATURE, V369, P497, DOI 10.1038/369497a0; NORTHROP JP, 1993, J BIOL CHEM, V268, P2917; Okamura H, 2000, MOL CELL, V6, P539, DOI 10.1016/S1097-2765(00)00053-8; Parkin SE, 2002, J BIOL CHEM, V277, P23563, DOI 10.1074/jbc.M202184200; Poli V, 1998, J BIOL CHEM, V273, P29279, DOI 10.1074/jbc.273.45.29279; Rao A, 2000, BRIT MED BULL, V56, P969, DOI 10.1258/0007142001903634; Rao A, 1997, ANNU REV IMMUNOL, V15, P707, DOI 10.1146/annurev.immunol.15.1.707; Ren DL, 2002, GENE DEV, V16, P27, DOI 10.1101/gad.953802; Roesler WJ, 2001, ANNU REV NUTR, V21, P141, DOI 10.1146/annurev.nutr.21.1.141; Rosen ED, 2001, J BIOL CHEM, V276, P37731, DOI 10.1074/jbc.R100034200; Saneyoshi T, 2002, NATURE, V417, P295, DOI 10.1038/417295a; Santini MP, 2001, P NATL ACAD SCI USA, V98, P9575, DOI 10.1073/pnas.161299698; SEARS RC, 1994, MOL CELL BIOL, V14, P4855, DOI 10.1128/MCB.14.7.4855; Shi XM, 2000, J CELL BIOCHEM, V76, P518, DOI 10.1002/(SICI)1097-4644(20000301)76:3<518::AID-JCB18>3.0.CO;2-M; Sun LJ, 1997, P NATL ACAD SCI USA, V94, P4919, DOI 10.1073/pnas.94.10.4919; Tenen DG, 1997, BLOOD, V90, P489, DOI 10.1182/blood.V90.2.489.489_489_519; TONTONOZ P, 1995, CURR OPIN GENET DEV, V5, P571, DOI 10.1016/0959-437X(95)80025-5; TRAUTWEIN C, 1994, J CLIN INVEST, V93, P2554, DOI 10.1172/JCI117266; TRAUTWEIN C, 1993, NATURE, V364, P544, DOI 10.1038/364544a0; Tsai EY, 1996, MOL CELL BIOL, V16, P5232; Tsai EY, 1996, MOL CELL BIOL, V16, P459; Veenstra GJC, 2001, TRENDS BIOCHEM SCI, V26, P665, DOI 10.1016/S0968-0004(01)01970-3; Wang XZ, 1996, SCIENCE, V272, P1347, DOI 10.1126/science.272.5266.1347; Weston CR, 2002, CURR OPIN GENET DEV, V12, P14, DOI 10.1016/S0959-437X(01)00258-1; WILLIAMS SC, 1995, EMBO J, V14, P3170, DOI 10.1002/j.1460-2075.1995.tb07319.x; Wu H, 2000, EMBO J, V19, P1963, DOI 10.1093/emboj/19.9.1963; WU ZD, 1995, GENE DEV, V9, P2350, DOI 10.1101/gad.9.19.2350; Wu ZD, 1996, MOL CELL BIOL, V16, P4128; Yang TTC, 2002, MOL CELL BIOL, V22, P3892, DOI 10.1128/MCB.22.11.3892-3904.2002; Yun Z, 2002, DEV CELL, V2, P331, DOI 10.1016/S1534-5807(02)00131-4; Zhou P, 1998, CELL, V92, P687, DOI 10.1016/S0092-8674(00)81136-8; ZHU YJ, 1995, P NATL ACAD SCI USA, V92, P7921, DOI 10.1073/pnas.92.17.7921	84	49	55	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 2	2003	278	18					15874	15885		10.1074/jbc.M211560200	http://dx.doi.org/10.1074/jbc.M211560200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	675EL	12606546	hybrid			2022-12-25	WOS:000182680000054
J	Liu, JW; Shen, JJ; Tanzillo-Swarts, A; Bhatia, B; Maldonado, CM; Person, MD; Lau, SS; Tang, DG				Liu, JW; Shen, JJ; Tanzillo-Swarts, A; Bhatia, B; Maldonado, CM; Person, MD; Lau, SS; Tang, DG			Annexin II expression is reduced or lost in prostate cancer cells and its re-expression inhibits prostate cancer cell migration	ONCOGENE			English	Article						annexins; prostate cancer; cell migration; proteomics; progression	ENHANCED EXPRESSION; CARCINOMA CELLS; DOWN-REGULATION; GENE FAMILY; CALPACTIN-I; IDENTIFICATION; RECEPTOR; PROTEIN; LOCALIZATION; APOPTOSIS	While studying Bim, a BH3-only proapoptotic protein, we identified an similar to36kDa protein, which was abundantly expressed in all five strains of primary normal human prostate (NHP) epithelial cells but significantly reduced or lost in seven prostate cancer cell lines. The similar to36kDa protein was subsequently identified as annexin II by proteomic approach and confirmed by Western blotting using an annexin II-specific antibody. Conventional and 2D SDS-PAGE, together with Western blotting, also revealed reduced or lost expression of annexin I in prostate cancer cells. Subcellular localization studies revealed that in NHP cells, annexin II was distributed both in the cytosol and underneath the plasma membrane, but not on the cell surface. Prostate cancer cells showed reduced levels as well as altered expression patterns of annexin II. Since annexins play important roles in maintaining Ca2+ homeostasis and regulating the cytoskeleton and cell motility, we hypothesized that the reduced or lost expression of annexin I/II might promote certain aggressive phenotypes of prostate cancer cells. In subsequent experiments, we indeed observed that restoration of annexin II expression inhibited the migration of the transfected prostate cancer cells without affecting cell proliferation or apoptosis. Hence, our results suggest that annexin II, and, likely, annexin I, may be endogenous suppressors of prostate cancer cell migration and their reduced or lost expression may contribute to prostate cancer development and progression.	Univ Texas, MD Anderson Canc Ctr, Dept Carcinogenesis, Div Sci Pk Res, Smithville, TX 78957 USA; Univ Texas, Coll Pharm, Ctr Mol & Cellular Toxicol, Div Pharmacol & Toxicol, Austin, TX 78712 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; University of Texas Austin	Tang, DG (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Carcinogenesis, Div Sci Pk Res, Pk Rd,1C, Smithville, TX 78957 USA.	dtang@sprd1.mdacc.tmc.edu	Tang, Dean/AAI-3457-2020	Tang, Dean/0000-0001-5029-1174; Tanzillo-Swarts, Angela/0000-0001-9277-3761	NCI NIH HHS [CA-90297] Funding Source: Medline; NIEHS NIH HHS [ES07784] Funding Source: Medline; NIGMS NIH HHS [GM39338] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA090297] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES007784] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM039338, R01GM039338] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aarli A, 1997, AM J REPROD IMMUNOL, V38, P313; Ahn SH, 1997, CLIN EXP METASTAS, V15, P151, DOI 10.1023/A:1018452810915; Balch C, 1997, EXP CELL RES, V237, P259, DOI 10.1006/excr.1997.3817; BIANCHI R, 1995, BIOCHEM BIOPH RES CO, V208, P910, DOI 10.1006/bbrc.1995.1421; Chetcuti A, 2001, CANCER RES, V61, P6331; Chiang YP, 1999, MOL CELL BIOCHEM, V199, P139, DOI 10.1023/A:1006942128672; Chiang YP, 1996, BBA-MOL CELL RES, V1313, P295, DOI 10.1016/0167-4889(96)00103-6; CHUNG CY, 1994, J CELL BIOL, V126, P539, DOI 10.1083/jcb.126.2.539; COLE SPC, 1992, BRIT J CANCER, V65, P498, DOI 10.1038/bjc.1992.103; ELKSO E, 1980, CELL, V21, P829; FROHLICH M, 1990, MOL CELL BIOL, V10, P3216, DOI 10.1128/MCB.10.6.3216; GUPTA S, 2002, P AACR, V43, pA5; HAJJAR KA, 1994, J BIOL CHEM, V269, P21191; Hajjar KA, 2000, ANN NY ACAD SCI, V902, P265; HUANG KS, 1986, CELL, V46, P191, DOI 10.1016/0092-8674(86)90736-1; IKEBUCHI NW, 1990, J BIOL CHEM, V265, P3392; LEE SW, 1992, P NATL ACAD SCI USA, V89, P2504, DOI 10.1073/pnas.89.6.2504; Liu JW, 2002, CANCER RES, V62, P2976; Ma ASP, 1996, ARCH DERMATOL RES, V288, P596, DOI 10.1007/s004030050109; MA ASP, 1994, J CELL SCI, V107, P1973; Mai JX, 2000, BBA-PROTEIN STRUCT M, V1477, P215, DOI 10.1016/S0167-4838(99)00274-5; Menaa C, 1999, J CLIN INVEST, V103, P1605, DOI 10.1172/JCI6374; Morgan RO, 1997, CELL MOL LIFE SCI, V53, P508, DOI 10.1007/s000180050064; Navone NM, 1997, CLIN CANCER RES, V3, P2493; Paweletz CP, 2000, CANCER RES, V60, P6293; Pencil SD, 1998, CLIN EXP METASTAS, V16, P113, DOI 10.1023/A:1021917017109; Pol A, 1997, BIOCHEM J, V327, P741, DOI 10.1042/bj3270741; RAYNAL P, 1994, BBA-REV BIOMEMBRANES, V1197, P63, DOI 10.1016/0304-4157(94)90019-1; REEVES SA, 1992, CANCER RES, V52, P6871; ROSENFELD J, 1992, ANAL BIOCHEM, V203, P173, DOI 10.1016/0003-2697(92)90061-B; Solito E, 2001, BRIT J PHARMACOL, V133, P217, DOI 10.1038/sj.bjp.0704054; Srivastava M, 2001, P NATL ACAD SCI USA, V98, P4575, DOI 10.1073/pnas.071055798; TAKAHASHI S, 1994, J BIOL CHEM, V269, P28696; Tang DG, 1998, CANCER RES, V58, P3466; Tang SH, 2002, J BIOL CHEM, V277, P16189, DOI 10.1074/jbc.M111936200; THIEL C, 1992, J CELL SCI, V103, P733; VISHWANATHA JK, 1993, CARCINOGENESIS, V14, P2575, DOI 10.1093/carcin/14.12.2575; Zobiack N, 2001, FEBS LETT, V500, P137, DOI 10.1016/S0014-5793(01)02604-7; ZOKAS L, 1987, J CELL BIOL, V105, P2111, DOI 10.1083/jcb.105.5.2111	39	118	129	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 13	2003	22	10					1475	1485		10.1038/sj.onc.1206196	http://dx.doi.org/10.1038/sj.onc.1206196			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	652ZZ	12629510				2022-12-25	WOS:000181411900004
J	Heiniger, CD; Kostadinova, RM; Rochat, MK; Serra, A; Ferrari, P; Dick, B; Frey, BM; Frey, FJ				Heiniger, CD; Kostadinova, RM; Rochat, MK; Serra, A; Ferrari, P; Dick, B; Frey, BM; Frey, FJ			Hypoxia causes down-regulation of 11 beta-hydroxysteroid dehydrogenase type 2 by induction of Egr-1	FASEB JOURNAL			English	Article						oxygen deprivation; kidney; cortisol; antimycin A; LLC-PK1	OBSTRUCTIVE PULMONARY-DISEASE; SALT-SENSITIVITY; GENE-EXPRESSION; HIGH-ALTITUDE; MINERALOCORTICOID RECEPTORS; LLC-PK1 CELLS; NA+ CHANNEL; HYPERTENSION; ALDOSTERONE; INHIBITION	Hypoxia causes several renal tubular dysfunctions, including abnormal handling of potassium and sodium and increased blood pressure. Therefore, we investigated the impact of hypoxia on 11beta-hydroxysteroid dehydrogenase (11beta-HSD2) enzyme, a crucial prereceptor gatekeeper for renal glucocorticosteroid-mediated mineralocorticoid action. The effect of hypoxia was assessed in vitro by incubating LLC-PK1 cells with antimycin A, an inhibitor of mitochondrial oxidative phosphorylation. Antimycin A induced a dose- and time-dependent reduction of 11beta-HSD2 activity. The early growth response gene, Egr-1, a gene known to be stimulated by hypoxia was investigated because of a potential Egr-1 binding site in the promoter region of 11beta-HSD2. Antimycin A induced Egr-1 protein and Egr-1-regulated luciferase gene expression. This induction was prevented with the MAPKK inhibitor PD 98059. Overexpression of Egr-1 reduced endogenous 11beta-HSD2 activity in LLC-PK1 cells, indicating that MAPK ERK is involved in the regulation of 11beta-HSD2 in vitro. In vivo experiments in rats revealed that Egr-1 protein increases, whereas 11beta-HSD2 mRNA decreases, in kidney tissue after unilateral renal ischemia and in humans the renal activity of 11beta-HSD2 as assessed by the urinary ratio of (tetrahydrocortisol+5alpha-tetrahydrocortisol)/tetrahydrocortisone declined when volunteers were exposed to hypoxemia at high altitude up to 7000 m. Thus, hypoxia decreases 11beta-HSD2 transcription and activity by inducing Egr-1 in vivo and in vitro. This mechanism might account for enhanced renal sodium retention and hypertension associated with hypoxic conditions.	Univ Bern, Div Nephrol & Hypertens, CH-3010 Bern, Switzerland	University of Bern	Frey, FJ (corresponding author), Univ Bern, Inselspital, Div Nephrol Hypertens, Freiburgstr 15, CH-3010 Bern, Switzerland.	felix.frey@insel.ch		Ferrari, Paolo/0000-0002-9619-3104				Agarwal AK, 2000, HYPERTENSION, V36, P187, DOI 10.1161/01.HYP.36.2.187; Agarwal AK, 1996, MOL CELL ENDOCRINOL, V121, P93, DOI 10.1016/0303-7207(96)03855-5; ALBISTON AL, 1994, MOL CELL ENDOCRINOL, V105, P11; ARRIZA JL, 1987, SCIENCE, V237, P268, DOI 10.1126/science.3037703; BARTSCH P, 1991, J APPL PHYSIOL, V71, P136; Biller KJ, 2001, AM J PHYSIOL-RENAL, V280, pF172, DOI 10.1152/ajprenal.2001.280.1.F172; BONVENTRE JV, 1991, CELL REGUL, V2, P251, DOI 10.1091/mbc.2.3.251; CHRISTENSEN BM, 1975, AVIAT SPACE ENVIR MD, V46, P16; Dagher PC, 2000, AM J PHYSIOL-CELL PH, V279, pC1270, DOI 10.1152/ajpcell.2000.279.4.C1270; Escher G, 1997, J EXP MED, V186, P189, DOI 10.1084/jem.186.2.189; Ferrari P, 2001, HYPERTENSION, V38, P1330, DOI 10.1161/hy1101.096112; FREY FJ, 1987, ENDOCR REV, V8, P453, DOI 10.1210/edrv-8-4-453; FUNDER JW, 1988, SCIENCE, V242, P583, DOI 10.1126/science.2845584; Fuster D, 1998, ENDOCRINOLOGY, V139, P3849, DOI 10.1210/en.139.9.3849; GONZALEZ NC, 1994, J APPL PHYSIOL, V77, P1341, DOI 10.1152/jappl.1994.77.3.1341; Hagar H, 1996, KIDNEY INT, V49, P355, DOI 10.1038/ki.1996.52; Heiniger CD, 2001, FEBS LETT, V507, P351, DOI 10.1016/S0014-5793(01)03004-6; Johnson RJ, 2002, NEW ENGL J MED, V346, P913, DOI 10.1056/NEJMra011078; KEYNES RJ, 1982, J ENDOCRINOL, V92, P131, DOI 10.1677/joe.0.0920131; Kinane TB, 1995, J BIOL CHEM, V270, P30760, DOI 10.1074/jbc.270.51.30760; Laghmani K, 2001, J CLIN INVEST, V107, P1563, DOI 10.1172/JCI11234; LECKIE C, 1995, ENDOCRINOLOGY, V136, P5561, DOI 10.1210/en.136.12.5561; Lovati E, 1999, J CLIN ENDOCR METAB, V84, P3745, DOI 10.1210/jc.84.10.3745; MALHOTRA MS, 1975, AVIAT SPACE ENVIR MD, V46, P409; Mazzeo RS, 1998, J APPL PHYSIOL, V84, P1151, DOI 10.1152/jappl.1998.84.4.1151; MOUE Y, 1995, J APPL PHYSIOL, V79, P1657, DOI 10.1152/jappl.1995.79.5.1657; MUNCK A, 1984, ENDOCR REV, V5, P25, DOI 10.1210/edrv-5-1-25; Murotsuki J, 1997, AM J PHYSIOL-REG I, V272, pR201, DOI 10.1152/ajpregu.1997.272.1.R201; MUROTSUKI J, 1995, AM J OBSTET GYNECOL, V173, P30, DOI 10.1016/0002-9378(95)90165-5; Murotsuki J, 1998, BIOL REPROD, V58, P234, DOI 10.1095/biolreprod58.1.234; NARAYFEJESTOTH A, 1994, AM J PHYSIOL, V266, pF76, DOI 10.1152/ajprenal.1994.266.1.F76; Narikiyo T, 2002, J CLIN INVEST, V109, P401, DOI 10.1172/JCI13229; Odermatt A, 2001, J BIOL CHEM, V276, P28484, DOI 10.1074/jbc.M100374200; OLSEN NV, 1993, J APPL PHYSIOL, V74, P2166; Peppard PE, 2000, NEW ENGL J MED, V342, P1378, DOI 10.1056/NEJM200005113421901; PINES A, 1977, BRIT J DIS CHEST, V71, P203, DOI 10.1016/0007-0971(77)90111-5; Quattropani C, 2001, J CLIN INVEST, V108, P1299, DOI 10.1172/JCI200112745; Raff H, 1996, J APPL PHYSIOL, V81, P604, DOI 10.1152/jappl.1996.81.2.604; RAFF H, 1993, AM JPHYSL, V265, pR8520; RAMIREZ G, 1988, J CLIN ENDOCR METAB, V67, P1162, DOI 10.1210/jcem-67-6-1162; SAHAI A, 1997, AM J PHYSIOL, V272, P809; SAPOLSKY R, 1987, SCIENCE, V238, P522, DOI 10.1126/science.2821621; Schoof E, 2001, J CLIN ENDOCR METAB, V86, P1313, DOI 10.1210/jc.86.3.1313; Schumacher M, 2002, TRANSPLANTATION, V74, P66, DOI 10.1097/00007890-200207150-00012; Schwachtgen JL, 1998, J CLIN INVEST, V101, P2540, DOI 10.1172/JCI1404; SHACKLETON CHL, 1993, J STEROID BIOCHEM, V45, P127, DOI 10.1016/0960-0760(93)90132-G; Snyder PM, 2002, ENDOCR REV, V23, P258, DOI 10.1210/er.23.2.258; SOMERS VK, 1991, J CLIN INVEST, V87, P1953, DOI 10.1172/JCI115221; STEWART AG, 1995, THORAX, V50, P838, DOI 10.1136/thx.50.8.838; STEWART AG, 1994, THORAX, V49, P995, DOI 10.1136/thx.49.10.995; Stewart PM, 1999, VITAM HORM, V57, P249; STEWART PM, 1988, J CLIN INVEST, V82, P340, DOI 10.1172/JCI113592; STEWART PM, 1987, LANCET, V2, P821; Sun K, 1997, ENDOCRINOLOGY, V138, P4912, DOI 10.1210/en.138.11.4912; Thottassery JV, 1999, J BIOL CHEM, V274, P3199, DOI 10.1074/jbc.274.5.3199; VENKATACHALAM MA, 1988, J CLIN INVEST, V81, P745, DOI 10.1172/JCI113380; Wang XY, 2001, J CLIN INVEST, V108, P215, DOI 10.1172/JCI200110366; Warnock DG, 2001, AM J MED SCI, V322, P302, DOI 10.1097/00000441-200112000-00002; Wilson RC, 1998, P NATL ACAD SCI USA, V95, P10200, DOI 10.1073/pnas.95.17.10200; Yan SF, 1999, J BIOL CHEM, V274, P15030, DOI 10.1074/jbc.274.21.15030	60	54	55	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAR	2003	17	3					917	+		10.1096/fj.02-0582fje	http://dx.doi.org/10.1096/fj.02-0582fje			22	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	661LT	12626438				2022-12-25	WOS:000181892600019
J	Vincourt, JB; Jullien, D; Amalric, F; Girard, JP				Vincourt, JB; Jullien, D; Amalric, F; Girard, JP			Molecular and functional characterization of SLC26A11, a sodium-independent sulfate transporter from high endothelial venules	FASEB JOURNAL			English	Article						endothelial cells; sulfation; L-selectin; lymphocyte migration; sulfate/anion exchanger	PERIPHERAL LYMPH-NODES; L-SELECTIN; GENE ENCODES; SACCHAROMYCES-CEREVISIAE; EXPRESSION CLONING; PENDRED SYNDROME; MOTOR PROTEIN; CELLS; LIGAND; MUTATIONS	Lymphocyte emigration from the blood into most secondary lymphoid organs and chronically inflamed tissues occurs at the level of high endothelial venules (HEV). A unique characteristic of HEV endothelial cells (HEVEC) is their capacity to incorporate large amounts of sulfate into sialomucin-type counter-receptors for the lymphocyte homing receptor L-selectin. We have previously shown that sulfate uptake into HEVEC is mediated by two distinct functional classes of sulfate transporters: Na+-coupled transporters and sulfate/anion exchangers. Here, we report the molecular characterization from human HEVEC of SLC26A11, a novel member of the SLC26 sulfate/anion exchanger family. Functional expression studies in COS-7 and Sf9 insect cells revealed that SLC26A11 is targeted to the cell membrane and exhibits Na+-independent sulfate transport activity, sensitive to the anion exchanger inhibitor 4,4-diisothiocyanostilbene-2,2-disulfonic acid (DIDS). Northern blot analysis showed the highest SLC26A11 transcript levels in placenta, kidney, and brain. The SLC26A11 gene mapped to human chromosome 17q25, very close to the hereditary hearing loss diseases loci DFNA20, DFNA26, and USH1G. RT-PCR analysis of SLC26 sulfate transporters in human HEVEC revealed coexpression of SLC26A11 with SLC26A2/DTDST and lack of SLC26A1/SAT1, SLC26A3/DRA, and SLC26A8/TAT1. Together, our results indicate that SLC26A11 is a novel Na+-independent sulfate transporter that may cooperate with SLC26A2 to mediate DIDS-sensitive sulfate uptake into HEVEC.	Inst Pharmacol & Biol Struct, Lab Biol Vasc, Inst Pharmacol & Biol Struct, CNRS,UMR 5089, F-31077 Toulouse, France; ENDOCUBE, F-31312 Labege, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Universite de Toulouse; Universite Toulouse III - Paul Sabatier	Girard, JP (corresponding author), Inst Pharmacol & Biol Struct, Lab Biol Vasc, Inst Pharmacol & Biol Struct, CNRS,UMR 5089, 205 Route Narbonne, F-31077 Toulouse, France.	Jean-Philippe.Girard@ipbs.fr	GIRARD, Jean-Philippe/F-5229-2010	GIRARD, Jean-Philippe/0000-0002-9154-1691				ANDREWS P, 1982, J CELL SCI, V57, P277; Baekkevold ES, 1999, LAB INVEST, V79, P327; BAUMHUETER S, 1993, SCIENCE, V262, P436, DOI 10.1126/science.7692600; BISSIG M, 1994, J BIOL CHEM, V269, P3017; Bistrup A, 1999, J CELL BIOL, V145, P899, DOI 10.1083/jcb.145.4.899; Butcher EC, 1996, SCIENCE, V272, P60, DOI 10.1126/science.272.5258.60; Byeon MK, 1998, PROTEIN EXPRES PURIF, V12, P67, DOI 10.1006/prep.1997.0809; Cherest H, 1997, GENETICS, V145, P627; Everett LA, 1997, NAT GENET, V17, P411, DOI 10.1038/ng1297-411; FREEMONT AJ, 1988, J PATHOL, V155, P225, DOI 10.1002/path.1711550308; Girard JP, 1999, P NATL ACAD SCI USA, V96, P12772, DOI 10.1073/pnas.96.22.12772; GIRARD JP, 1995, IMMUNOL TODAY, V16, P449, DOI 10.1016/0167-5699(95)80023-9; Girard JP, 1998, FASEB J, V12, P603, DOI 10.1096/fasebj.12.7.603; HASTBACKA J, 1994, CELL, V78, P1073, DOI 10.1016/0092-8674(94)90281-X; HEMMERICH S, 1994, J EXP MED, V180, P2219, DOI 10.1084/jem.180.6.2219; Hemmerich S, 2001, IMMUNITY, V15, P237, DOI 10.1016/S1074-7613(01)00188-1; Hiraoka N, 1999, IMMUNITY, V11, P79, DOI 10.1016/S1074-7613(00)80083-7; Hoglund P, 1996, NAT GENET, V14, P316, DOI 10.1038/ng1196-316; IMAI Y, 1993, NATURE, V361, P555; Knauf F, 2001, P NATL ACAD SCI USA, V98, P9425, DOI 10.1073/pnas.141241098; LASKY LA, 1992, CELL, V69, P927, DOI 10.1016/0092-8674(92)90612-G; Li XC, 1998, NAT GENET, V18, P215, DOI 10.1038/ng0398-215; Lohi H, 2002, J BIOL CHEM, V277, P14246, DOI 10.1074/jbc.M111802200; Lohi H, 2000, GENOMICS, V70, P102, DOI 10.1006/geno.2000.6355; MARKOVICH D, 1993, P NATL ACAD SCI USA, V90, P8073, DOI 10.1073/pnas.90.17.8073; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; Morell RJ, 2000, GENOMICS, V63, P1, DOI 10.1006/geno.1999.6058; Mustapha M, 2002, HUM GENET, V110, P348, DOI 10.1007/s00439-002-0690-x; Oliver D, 2001, SCIENCE, V292, P2340, DOI 10.1126/science.1060939; Rossi A, 2001, HUM MUTAT, V17, P159, DOI 10.1002/humu.1; Satoh H, 1998, J BIOL CHEM, V273, P12307, DOI 10.1074/jbc.273.20.12307; Scott DA, 1999, NAT GENET, V21, P440, DOI 10.1038/7783; Shailubhai K, 1997, GLYCOBIOLOGY, V7, P305; SILBERG DG, 1995, J BIOL CHEM, V270, P11897, DOI 10.1074/jbc.270.20.11897; SMITH FW, 1995, MOL GEN GENET, V247, P709, DOI 10.1007/BF00290402; SMITH FW, 1995, P NATL ACAD SCI USA, V92, P9373, DOI 10.1073/pnas.92.20.9373; Soulet F, 2001, BIOCHEM BIOPH RES CO, V289, P591, DOI 10.1006/bbrc.2001.5960; STREETER PR, 1988, J CELL BIOL, V107, P1853, DOI 10.1083/jcb.107.5.1853; SupertiFurga A, 1996, NAT GENET, V12, P100, DOI 10.1038/ng0196-100; Tangemann K, 1999, J EXP MED, V190, P935, DOI 10.1084/jem.190.7.935; Toure A, 2001, J BIOL CHEM, V276, P20309, DOI 10.1074/jbc.M011740200; Vincourt JB, 2002, GENOMICS, V79, P249, DOI 10.1006/geno.2002.6689; Waldegger S, 2001, GENOMICS, V72, P43, DOI 10.1006/geno.2000.6445; Yang T, 2000, AM J HUM GENET, V67, P300; Yeh JC, 2001, CELL, V105, P957, DOI 10.1016/S0092-8674(01)00394-4; Zheng J, 2000, NATURE, V405, P149, DOI 10.1038/35012009	46	64	65	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAR	2003	17	3					890	+		10.1096/fj.02-0787fje	http://dx.doi.org/10.1096/fj.02-0787fje			21	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	661LT	12626430				2022-12-25	WOS:000181892600025
J	Marx, UC; Korsinczky, MLJ; Schirra, HJ; Jones, A; Condie, B; Otvos, L; Craik, DJ				Marx, UC; Korsinczky, MLJ; Schirra, HJ; Jones, A; Condie, B; Otvos, L; Craik, DJ			Enzymatic cyclization of a potent Bowman-Birk protease inhibitor, sunflower trypsin inhibitor-1, and solution structure of an acyclic precursor peptide	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SERINE-PROTEASE; SUBSTRATE-SPECIFICITY; PLANT CYCLOTIDES; KNOTTED PROTEINS; REACTIVE-SITE; SEEDS; PURIFICATION; BINDING; DOMAIN; FAMILY	The most potent known naturally occurring Bowman-Birk inhibitor, sunflower trypsin inhibitor-1 (SFTI-1), is a bicyclic 14-amino acid peptide from sunflower seeds comprising one disulfide bond and a cyclic backbone. At present, little is known about the cyclization mechanism of SFTI-1. We show here that an acyclic permutant of SFTI-1 open at its scissile bond, SFTI-1[ 6,5], also functions as an inhibitor of trypsin and that it can be enzymatically backbone-cyclized by incubation with bovine beta-trypsin. The resulting ratio of cyclic SFTI-1 to SFTI1[6,5] is similar to9:1 regardless of whether trypsin is incubated with SFTI-1[ 6,5] or SFTI-1. Enzymatic resynthesis of the scissile bond to form cyclic SFTI-1 is a novel mechanism of cyclization of SFTI-1[ 6,5]. Such a reaction could potentially occur on a trypsin affinity column as used in the original isolation procedure of SFTI-1. We therefore extracted SFTI-1 from sunflower seeds without a trypsin purification step and confirmed that the backbone of SFTI-1 is indeed naturally cyclic. Structural studies on SFTI-1[ 6,5] revealed high heterogeneity, and multiple species of SFTI-1[ 6,5] were identified. The main species closely resembles the structure of cyclic SFTI-1 with the broken binding loop able to rotate between a cis/trans geometry of the I7-P8 bond with the cis conformer being similar to the canonical binding loop conformation. The non-reactive loop adopts a beta-hairpin structure as in cyclic wild-type SFTI-1. Another species exhibits an isoaspartate residue at position 14 and provides implications for possible in vivo cyclization mechanisms.	Univ Queensland, Inst Mol Biosci, Brisbane, Qld 4072, Australia; Univ Bayreuth, Lehrstuhl Biopolymere, D-95447 Bayreuth, Germany; Wistar Inst Anat & Biol, Philadelphia, PA 19104 USA	University of Queensland; University of Bayreuth; The Wistar Institute	Craik, DJ (corresponding author), Univ Queensland, Inst Mol Biosci, Brisbane, Qld 4072, Australia.	d.craik@imb.uq.edu	Craik, David/B-1695-2010; Schirra, Horst Joachim/B-4210-2009	Craik, David/0000-0003-0007-6796; Schirra, Horst Joachim/0000-0002-7541-246X; Marx, Ute C./0000-0002-7077-9940				ARDELT W, 1985, BIOCHEMISTRY-US, V24, P5313, DOI 10.1021/bi00341a007; BAX A, 1985, J MAGN RESON, V65, P355, DOI 10.1016/0022-2364(85)90018-6; Brauer ABE, 2001, J MOL BIOL, V306, P799, DOI 10.1006/jmbi.2000.4410; BRUNGER AT, 1996, X PLOR MANUAL VERSIO; Craik DJ, 1999, J MOL BIOL, V294, P1327, DOI 10.1006/jmbi.1999.3383; Craik DJ, 2002, CURR OPIN DRUG DI DE, V5, P251; Descours A, 2002, CHEMBIOCHEM, V3, P318, DOI 10.1002/1439-7633(20020402)3:4<318::AID-CBIC318>3.0.CO;2-W; DRYJANSKI M, 1990, BIOL CHEM H-S, V371, P889, DOI 10.1515/bchm3.1990.371.2.889; FINKENSTADT WR, 1967, J BIOL CHEM, V242, P771; Gewolb J, 2002, SCIENCE, V295, P2205, DOI 10.1126/science.295.5563.2205; Hernandez JF, 2000, BIOCHEMISTRY-US, V39, P5722, DOI 10.1021/bi9929756; Iwai H, 1999, FEBS LETT, V459, P166, DOI 10.1016/S0014-5793(99)01220-X; Jennings C, 2001, P NATL ACAD SCI USA, V98, P10614, DOI 10.1073/pnas.191366898; KHARRAT A, 1995, EMBO J, V14, P3572, DOI 10.1002/j.1460-2075.1995.tb07363.x; Konarev AV, 2000, THEOR APPL GENET, V100, P82, DOI 10.1007/s001220050012; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; Korsinczky MLJ, 2001, J MOL BIOL, V311, P579, DOI 10.1006/jmbi.2001.4887; Laskowski M, 2000, BBA-PROTEIN STRUCT M, V1477, P324, DOI 10.1016/S0167-4838(99)00284-8; Laskowski RA, 1996, J BIOMOL NMR, V8, P477, DOI 10.1007/BF00228148; Li Peng, 2002, Current Topics in Medicinal Chemistry, V2, P325, DOI 10.2174/1568026023394209; Long YQ, 2001, BIOORG MED CHEM LETT, V11, P2515, DOI 10.1016/S0960-894X(01)00493-0; Luckett S, 1999, J MOL BIOL, V290, P525, DOI 10.1006/jmbi.1999.2891; McBride JD, 2001, CURR MED CHEM, V8, P909, DOI 10.2174/0929867013372832; Morita S, 1996, J BIOCHEM-TOKYO, V119, P1094, DOI 10.1093/oxfordjournals.jbchem.a021353; Morita S, 1996, J BIOCHEM-TOKYO, V119, P711, DOI 10.1093/oxfordjournals.jbchem.a021300; MORITA S, 1994, PLANT CELL PHYSIOL, V35, P1049; Neudecker P, 2001, J BIOL CHEM, V276, P22756, DOI 10.1074/jbc.M101657200; Nilges M, 1998, PROG NUCL MAG RES SP, V32, P107, DOI 10.1016/S0079-6565(97)00025-3; NISHINO N, 1977, J BIOCHEM, V82, P901, DOI 10.1093/oxfordjournals.jbchem.a131767; OTLEWSKI J, 1994, BIOCHEMISTRY-US, V33, P208, DOI 10.1021/bi00167a027; PAVONE V, 1994, J CHEM SOC PERK T 2, P1047, DOI 10.1039/p29940001047; Ranson NA, 1997, J MOL BIOL, V266, P656, DOI 10.1006/jmbi.1996.0815; SCHECHTER I, 1967, BIOCHEM BIOPH RES CO, V27, P157, DOI 10.1016/S0006-291X(67)80055-X; SKLENAR V, 1993, J MAGN RESON SER A, V102, P241, DOI 10.1006/jmra.1993.1098; Tang YQ, 1999, SCIENCE, V286, P498, DOI 10.1126/science.286.5439.498; Trabi M, 2002, TRENDS BIOCHEM SCI, V27, P132, DOI 10.1016/S0968-0004(02)02057-1; WALTHAM MC, 1988, BIOCHEM PHARMACOL, V37, P535, DOI 10.1016/0006-2952(88)90225-0; Wei W, 1999, INT J PHARMACEUT, V185, P129, DOI 10.1016/S0378-5173(99)00152-0; WERNER MH, 1992, BIOCHEMISTRY-US, V31, P999, DOI 10.1021/bi00119a008; WISHART DS, 1995, J BIOMOL NMR, V5, P67, DOI 10.1007/BF00227471; WOLF MJ, 1990, PHYTOCHEMISTRY, V29, P2419, DOI 10.1016/0031-9422(90)85159-D; Wuthrich K, 1986, NMR PROTEINS NUCL AC; Zablotna E, 2002, BIOCHEM BIOPH RES CO, V292, P855, DOI 10.1006/bbrc.2002.6746	43	66	82	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 13	2003	278	24					21782	21789		10.1074/jbc.M212996200	http://dx.doi.org/10.1074/jbc.M212996200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	687AT	12621047	hybrid			2022-12-25	WOS:000183354200060
J	Blevins, MB; Smith, AM; Phillips, EM; Powers, MA				Blevins, MB; Smith, AM; Phillips, EM; Powers, MA			Complex formation among the RNA export proteins Nup98, Rae1/Gle2, and TAP	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR-PORE COMPLEX; MESSENGER-RNA; NUCLEOPORIN NUP98; RAE1 GENE; POLY(A)(+) RNA; BINDING-SITES; TRANSPORT; DOMAIN; INTERACTS; CYTOPLASM	Most nucleocytoplasmic traffic through the nuclear pore complex is mediated by soluble receptors of the importin/exportin or karyopherin family. mRNA export is unique in that no receptor of this family has been implicated in trafficking of the bulk of mRNAs. Instead, many diverse proteins have been linked to mRNA export, but an all-encompassing model remains elusive. Understanding how these proteins interact with each other is central to the development of such a model. Here, we have focused on the interactions between three proteins implicated in mRNA export, Nup98, Rae1/Gle2, and TAP. We have defined the binary complexes that form among these proteins. We find that Gle2 requires two sites within TAP for stable interaction. Strikingly, rather than a general affinity for all nucleoporin FG repeats, TAP has highest affinity for a specific region within the GLFG domain of Nup98, indicating that not all repeats are identical in function. We have established that the ternary complex can form through simultaneous binding of both Gle2 and TAP to adjacent sites on Nup98. In contrast, Nup98 competes with TAP for Gle2 binding; when bound to Nup98, Gle2 no longer interacts directly with TAP. From these interactions, we propose that Gle2 may act to deliver TAP to Nup98 and that this may represent the first in a series of interactions between an export complex and a nucleoporin.	Emory Univ, Sch Med, Dept Cell Biol, Atlanta, GA 30322 USA	Emory University	Powers, MA (corresponding author), Emory Univ, Sch Med, Dept Cell Biol, Atlanta, GA 30322 USA.			Blevins, Melanie/0000-0002-5135-7099	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM059975] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-59975] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; Babu JR, 2003, J CELL BIOL, V160, P341, DOI 10.1083/jcb.200211048; Bachi A, 2000, RNA, V6, P136, DOI 10.1017/S1355838200991994; Bharathi A, 1997, GENE, V198, P251, DOI 10.1016/S0378-1119(97)00322-3; Braun IC, 2002, MOL CELL BIOL, V22, P5405, DOI 10.1128/MCB.22.15.5405-5418.2002; Braun IC, 2001, J BIOL CHEM, V276, P20536, DOI 10.1074/jbc.M100400200; Braun IC, 1999, EMBO J, V18, P1953, DOI 10.1093/emboj/18.7.1953; BROWN JA, 1995, J BIOL CHEM, V270, P7411, DOI 10.1074/jbc.270.13.7411; Campbell L, 2003, J CELL SCI, V116, P617, DOI 10.1242/jcs.00255; Cronshaw JA, 2002, J CELL BIOL, V158, P915, DOI 10.1083/jcb.200206106; Cullen BR, 2003, J CELL SCI, V116, P587, DOI 10.1242/jcs.00268; Dasso M, 2001, CELL, V104, P321, DOI 10.1016/S0092-8674(01)00218-5; Denning DP, 2002, J BIOL CHEM, V277, P33447, DOI 10.1074/jbc.M203499200; Dreyfuss G, 2002, NAT REV MOL CELL BIO, V3, P195, DOI 10.1038/nrm760; Fahrenkrog B, 2001, CURR TOP MICROBIOL, V259, P95; Fischer T, 2002, EMBO J, V21, P5843, DOI 10.1093/emboj/cdf590; Fontoura BMA, 2000, J BIOL CHEM, V275, P31289, DOI 10.1074/jbc.M004651200; Fontoura BMA, 2001, P NATL ACAD SCI USA, V98, P3208, DOI 10.1073/pnas.061014698; Fribourg S, 2001, MOL CELL, V8, P645, DOI 10.1016/S1097-2765(01)00348-3; Gallouzi IE, 2001, SCIENCE, V294, P1895, DOI 10.1126/science.1064693; Gorlich D, 1999, ANNU REV CELL DEV BI, V15, P607, DOI 10.1146/annurev.cellbio.15.1.607; Grant RP, 2002, NAT STRUCT BIOL, V9, P247, DOI 10.1038/nsb773; Griffis ER, 2003, MOL BIOL CELL, V14, P600, DOI 10.1091/mbc.E02-09-0582; Griffis ER, 2002, MOL BIOL CELL, V13, P1282, DOI 10.1091/mbc.01-11-0538; Guzik BW, 2001, MOL CELL BIOL, V21, P2545, DOI 10.1128/MCB.21.7.2545-2554.2001; Hodel AE, 2002, MOL CELL, V10, P347, DOI 10.1016/S1097-2765(02)00589-0; Jones AL, 2000, P NATL ACAD SCI USA, V97, P3224, DOI 10.1073/pnas.050432997; Kraemer D, 1997, P NATL ACAD SCI USA, V94, P9119, DOI 10.1073/pnas.94.17.9119; Le Hir H, 2000, EMBO J, V19, P6860, DOI 10.1093/emboj/19.24.6860; Liker E, 2000, EMBO J, V19, P5587, DOI 10.1093/emboj/19.21.5587; Luo MJ, 2001, NATURE, V413, P644, DOI 10.1038/35098106; MACAULAY C, 1995, J BIOL CHEM, V270, P254, DOI 10.1074/jbc.270.1.254; Maquat LE, 2001, CELL, V104, P173, DOI 10.1016/S0092-8674(01)00202-1; Murphy R, 1996, MOL BIOL CELL, V7, P1921, DOI 10.1091/mbc.7.12.1921; Nakielny S, 1999, CELL, V99, P677, DOI 10.1016/S0092-8674(00)81666-9; NEER EJ, 1994, NATURE, V371, P297, DOI 10.1038/371297a0; POWERS MA, 1995, J CELL BIOL, V128, P721, DOI 10.1083/jcb.128.5.721; Powers MA, 1997, J CELL BIOL, V136, P241, DOI 10.1083/jcb.136.2.241; Pritchard CEJ, 1999, J CELL BIOL, V145, P237, DOI 10.1083/jcb.145.2.237; RADU A, 1995, CELL, V81, P215, DOI 10.1016/0092-8674(95)90331-3; Reed R, 2002, CELL, V108, P523, DOI 10.1016/S0092-8674(02)00627-X; Rost B, 2000, METH MOL B, V143, P71; Rout MP, 2000, J CELL BIOL, V148, P635, DOI 10.1083/jcb.148.4.635; Ryan KJ, 2000, CURR OPIN CELL BIOL, V12, P361, DOI 10.1016/S0955-0674(00)00101-0; Sabri N, 2000, RNA, V6, P1597, DOI 10.1017/S1355838200001138; Schmitt I, 2001, J BIOL CHEM, V276, P42355, DOI 10.1074/jbc.M103916200; Shamsher MK, 2002, P NATL ACAD SCI USA, V99, P14195, DOI 10.1073/pnas.212518199; Snay-Hodge CA, 1998, EMBO J, V17, P2663, DOI 10.1093/emboj/17.9.2663; Strasser K, 2002, NATURE, V417, P304, DOI 10.1038/nature746; Strawn LA, 2001, J BIOL CHEM, V276, P6445, DOI 10.1074/jbc.M008311200; Vasu S, 2001, J CELL BIOL, V155, P339, DOI 10.1083/jcb.200108007; Vasu SK, 2001, CURR OPIN CELL BIOL, V13, P363, DOI 10.1016/S0955-0674(00)00221-0; Wang XS, 2001, J BIOL CHEM, V276, P26559, DOI 10.1074/jbc.M101083200; Watkins JL, 1998, P NATL ACAD SCI USA, V95, P6779, DOI 10.1073/pnas.95.12.6779; Weis K, 2002, CURR OPIN CELL BIOL, V14, P328, DOI 10.1016/S0955-0674(02)00337-X; Whalen WA, 1997, YEAST, V13, P1167, DOI 10.1002/(SICI)1097-0061(19970930)13:12<1167::AID-YEA154>3.3.CO;2-F; Wiegand HL, 2002, MOL CELL BIOL, V22, P245, DOI 10.1128/MCB.22.1.245-256.2002; Yoon JH, 2000, MOL CELL BIOL, V20, P8767, DOI 10.1128/MCB.20.23.8767-8782.2000; Zolotukhin AS, 2002, J BIOL CHEM, V277, P3935, DOI 10.1074/jbc.M107598200	59	102	105	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 6	2003	278	23					20979	20988		10.1074/jbc.M302061200	http://dx.doi.org/10.1074/jbc.M302061200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	684WY	12637516	hybrid			2022-12-25	WOS:000183230500070
J	Savina, A; Furlan, M; Vidal, M; Colombo, MI				Savina, A; Furlan, M; Vidal, M; Colombo, MI			Exosome release is regulated by a calcium-dependent mechanism in K562 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSFERRIN RECEPTOR; SIGNAL-TRANSDUCTION; SECRETORY GRANULES; MONENSIN; EXOCYTOSIS; PATHWAY; INSULIN; RETICULOCYTES; CA2+-ATPASE; ENDOCYTOSIS	Multivesicular bodies (MVBs) are endocytic structures that contain small vesicles formed by the budding of an endosomal membrane into the lumen of the compartment. Fusion of MVBs with the plasma membrane results in secretion of the small internal vesicles termed exosomes. K562 cells are a hematopoietic cell line that releases exosomes. The application of monensin (MON) generated large MVBs that were labeled with a fluorescent lipid. Exosome release was markedly enhanced by MON treatment, a Na+/H+ exchanger that induces changes in intracellular calcium (Ca2+). To explore the possibility that the effect of MON on exosome release was caused via an increase in Ca2+, we have used a calcium ionophore and a chelator of intracellular Ca2+. Our results indicate that increasing intracellular Ca2+ stimulates exosome secretion. Furthermore, MON-stimulated exosome release was completely eliminated by 1,2-bis(2-aminophenoxy) ethane-N,N,N',N'-tetraacetic acid acetoxymethyl ester (BAPTA-AM), implying a requirement for Ca2+ in this process. We have observed that the large MVBs generated in the presence of MON accumulated Ca2+ as determined by labeling with Fluo3-AM, suggesting that intralumenal Ca2+ might play a critical role in the secretory process. Interestingly, our results indicate that transferrin (Tf) stimulated exosome release in a Ca2+-dependent manner, suggesting that Tf might be a physiological stimulus for exosome release in K562 cells.	Univ Nacl Cuyo, Fac Ciencias Med, IHEM,CONICET, Lab Biol Celular & Mol, RA-5500 Mendoza, Argentina; Univ Montpellier 2, Unite Mixte Rech 5539, F-34095 Montpellier, France	Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET); University Nacional Cuyo Mendoza; Universite de Montpellier	Colombo, MI (corresponding author), Univ Nacl Cuyo, Fac Ciencias Med, IHEM,CONICET, Lab Biol Celular & Mol, Casilla de Correo 56, RA-5500 Mendoza, Argentina.	mcolombo@fmed2.uncu.edu.ar						Balla T, 2001, CURR PHARM DESIGN, V7, P475, DOI 10.2174/1381612013397906; Beraldo FH, 2001, CELL CALCIUM, V29, P439, DOI 10.1054/ceca.2001.0207; BLONDEL O, 1994, P NATL ACAD SCI USA, V91, P7777, DOI 10.1073/pnas.91.16.7777; Carafoli E, 2002, P NATL ACAD SCI USA, V99, P1115, DOI 10.1073/pnas.032427999; Christensen KA, 2002, J CELL SCI, V115, P599; CLAPHAM DE, 1995, CELL, V80, P259, DOI 10.1016/0092-8674(95)90408-5; Clayton A, 2001, J IMMUNOL METHODS, V247, P163, DOI 10.1016/S0022-1759(00)00321-5; Cullen PJ, 2002, NAT REV MOL CELL BIO, V3, P339, DOI 10.1038/nrm808; Denzer K, 2000, J CELL SCI, V113, P3365; Domotor E, 1999, J PHYSIOL-LONDON, V515, P147, DOI 10.1111/j.1469-7793.1999.147ad.x; FITTSCHEN C, 1991, J LEUKOCYTE BIOL, V50, P517, DOI 10.1002/jlb.50.5.517; Gerber SH, 2002, DIABETES, V51, pS3, DOI 10.2337/diabetes.51.2007.S3; HARDING C, 1983, J CELL BIOL, V97, P329, DOI 10.1083/jcb.97.2.329; HARDING C, 1984, EUR J CELL BIOL, V35, P256; Heijnen HFG, 1999, BLOOD, V94, P3791, DOI 10.1182/blood.V94.11.3791.423a22_3791_3799; HO IK, 1969, J NEUROCHEM, V16, P1505, DOI 10.1111/j.1471-4159.1969.tb09905.x; IZUMI F, 1986, BIOCHEM PHARMACOL, V35, P2937, DOI 10.1016/0006-2952(86)90489-2; JOHNSTONE RM, 1989, BLOOD, V74, P1844; Johnstone RM, 1996, J CELL PHYSIOL, V168, P333, DOI 10.1002/(SICI)1097-4652(199608)168:2<333::AID-JCP12>3.0.CO;2-4; JOHNSTONE RM, 1991, J CELL PHYSIOL, V147, P27, DOI 10.1002/jcp.1041470105; Knight DE, 2002, TRAFFIC, V3, P298, DOI 10.1034/j.1600-0854.2002.030407.x; Kohgo Y, 2002, INT J HEMATOL, V76, P213, DOI 10.1007/BF02982790; KOK JW, 1990, EUR J CELL BIOL, V53, P173; Marta CB, 2002, J NEUROSCI RES, V69, P488, DOI 10.1002/jnr.10317; Martinez JR, 1996, BIOCHEM J, V320, P627, DOI 10.1042/bj3200627; Mayer A, 1999, CURR OPIN CELL BIOL, V11, P447, DOI 10.1016/S0955-0674(99)80064-7; Mills IG, 2001, J CELL SCI, V114, P1959; Mousavi SA, 2001, BBA-BIOMEMBRANES, V1510, P243, DOI 10.1016/S0005-2736(00)00354-0; NASSARGENTINA V, 1994, CELL CALCIUM, V16, P475, DOI 10.1016/0143-4160(94)90077-9; Passos APD, 1998, BIOCHEM BIOPH RES CO, V245, P155, DOI 10.1006/bbrc.1998.8338; PETERS PJ, 1989, EUR J IMMUNOL, V19, P1469, DOI 10.1002/eji.1830190819; PRESSMAN BC, 1976, ANNU REV BIOCHEM, V45, P501, DOI 10.1146/annurev.bi.45.070176.002441; Raposo G, 1996, J EXP MED, V183, P1161, DOI 10.1084/jem.183.3.1161; Reinhardt TA, 2000, AM J PHYSIOL-CELL PH, V279, pC1595, DOI 10.1152/ajpcell.2000.279.5.C1595; Rizzuto R, 2001, CURR OPIN NEUROBIOL, V11, P306, DOI 10.1016/S0959-4388(00)00212-9; Sainte-Marie J, 1997, EUR J BIOCHEM, V250, P689, DOI 10.1111/j.1432-1033.1997.00689.x; Savina A, 2002, J CELL SCI, V115, P2505; Scheenen WJJM, 1998, J BIOL CHEM, V273, P19002, DOI 10.1074/jbc.273.30.19002; Sorin A, 1997, J BIOL CHEM, V272, P9895; STEIN BS, 1984, J BIOL CHEM, V259, P4762; Stoorvogel W, 2002, TRAFFIC, V3, P321, DOI 10.1034/j.1600-0854.2002.30502.x; Takahashi A, 1999, PHYSIOL REV, V79, P1089, DOI 10.1152/physrev.1999.79.4.1089; TARTAKOFF AM, 1983, CELL, V32, P1026, DOI 10.1016/0092-8674(83)90286-6; TAYLOR CW, 1991, PHARMACOL THERAPEUT, V51, P97, DOI 10.1016/0163-7258(91)90043-L; THASTRUP O, 1990, P NATL ACAD SCI USA, V87, P2466, DOI 10.1073/pnas.87.7.2466; Thery C, 2002, NAT REV IMMUNOL, V2, P569, DOI 10.1038/nri855; THORSTENSEN K, 1993, SCAND J CLIN LAB INV, V53, P113, DOI 10.3109/00365519309090703; Tucker WC, 2002, BIOCHEM J, V366, P1, DOI 10.1042/BJ20020776; Verkhratsky A, 1996, CELL CALCIUM, V19, P1, DOI 10.1016/S0143-4160(96)90009-3; Vidal M, 1997, J CELL SCI, V110, P1867; VIDAL M, 1995, BIOCHEM MOL BIOL INT, V35, P889; Wang XD, 1999, J INVEST MED, V47, P388; Wasle B, 2002, CELL SIGNAL, V14, P191, DOI 10.1016/S0898-6568(01)00257-1; Zitvogel L, 1998, NAT MED, V4, P594, DOI 10.1038/nm0598-594	54	539	555	6	65	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 30	2003	278	22					20083	20090		10.1074/jbc.M301642200	http://dx.doi.org/10.1074/jbc.M301642200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	682EH	12639953	hybrid			2022-12-25	WOS:000183078000066
J	Volz, A; Ehlers, A; Younger, R; Forbes, S; Trowsdale, J; Schnorr, D; Beck, S; Ziegler, A				Volz, A; Ehlers, A; Younger, R; Forbes, S; Trowsdale, J; Schnorr, D; Beck, S; Ziegler, A			Complex transcription and splicing of odorant receptor genes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAJOR HISTOCOMPATIBILITY COMPLEX; PUTATIVE OLFACTORY RECEPTOR; GERM-CELLS; FUNCTIONAL IDENTIFICATION; MOLECULAR-MECHANISMS; MATING PREFERENCES; GENOMIC STRUCTURE; EXPRESSION; MOUSE; SEQUENCE	Human major histocompatibility ( human leucocyte antigen (HLA)) complex-linked odorant receptor ( OR) genes are among the best characterized OR genes in the human genome. In addition to their functions as odorant receptors in olfactory epithelium, they have been suggested to play a role in the fertilization process. Here, we report the first in-depth analysis of their expression and regulation within testicular tissue. Sixteen HLA-linked OR and three non-HLA-linked OR were analyzed. One OR gene ( hs6M1-16, in positive transcriptional orientation) exhibited six different transcriptional start sites combined with extensive alternative splicing within the 5'-untranslated region, the coding exon, and the 3'-untranslated region. Long distance splicing, exon sharing, and premature polyadenylation were features of another three OR loci ( hs6M1-18, -21, and -27, all upstream of hs6M1-16, but in negative transcriptional orientation). Determination of the transcriptional start sites of these OR genes identified a region of 81 bp with potential bi-directional transcriptional activity. The results demonstrate that HLA-linked OR genes are subject to unusually complex transcriptional regulatory mechanisms.	Humboldt Univ, Univ Klinikum Charite, Inst Immungenet, D-14050 Berlin, Germany; Wellcome Trust Sanger Inst, Cambridge CB10 1SA, England; Univ Cambridge, Dept Pathol, Div Immunol, Cambridge CB2 1QP, England; Humboldt Univ, Univ Klinikum Charite, Urol Klin, D-10117 Berlin, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Wellcome Trust Sanger Institute; University of Cambridge; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Ziegler, A (corresponding author), Humboldt Univ, Univ Klinikum Charite, Inst Immungenet, Spandauer Damm 130, D-14050 Berlin, Germany.	andreas.ziegler@charite.de						ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; Asai H, 1996, BIOCHEM BIOPH RES CO, V221, P240, DOI 10.1006/bbrc.1996.0580; Barth AL, 1997, NEURON, V19, P359, DOI 10.1016/S0896-6273(00)80945-9; Beaudoing E, 2000, GENOME RES, V10, P1001, DOI 10.1101/gr.10.7.1001; BENARIE N, 1994, HUM MOL GENET, V3, P229, DOI 10.1093/hmg/3.2.229; Borst P, 2002, CELL, V109, P5, DOI 10.1016/S0092-8674(02)00711-0; Boulanger LM, 2001, CURR OPIN NEUROBIOL, V11, P568, DOI 10.1016/S0959-4388(00)00251-8; Branscomb A, 2000, GENETICS, V156, P785; BUCK L, 1991, CELL, V65, P175, DOI 10.1016/0092-8674(91)90418-X; Bulger M, 2000, P NATL ACAD SCI USA, V97, P14560, DOI 10.1073/pnas.97.26.14560; CHESS A, 1994, CELL, V78, P823, DOI 10.1016/S0092-8674(94)90562-2; Chiu IM, 2001, PROG NUCLEIC ACID RE, V70, P155, DOI 10.1016/S0079-6603(01)70016-5; Dixon AK, 1998, NUCLEIC ACIDS RES, V26, P4426, DOI 10.1093/nar/26.19.4426; Down TA, 2002, GENOME RES, V12, P458, DOI 10.1101/gr.216102; Dreyer WJ, 1998, P NATL ACAD SCI USA, V95, P9072, DOI 10.1073/pnas.95.16.9072; Dreyer WJ, 1999, GENETICA, V107, P249, DOI 10.1023/A:1003909311678; DRUTEL G, 1995, RECEPTOR CHANNEL, V3, P33; Dryer L, 1999, TRENDS PHARMACOL SCI, V20, P413, DOI 10.1016/S0165-6147(99)01381-4; Dryer L, 2000, BIOESSAYS, V22, P803, DOI 10.1002/1521-1878(200009)22:9&lt;803::AID-BIES5&gt;3.0.CO;2-K; Ehlers A, 2000, GENOME RES, V10, P1968, DOI 10.1101/gr.10.12.1968; Fuchs T, 2001, HUM GENET, V108, P1, DOI 10.1007/s004390000436; Glusman G, 2001, GENOME RES, V11, P685, DOI 10.1101/gr.171001; Glusman G, 1996, GENOMICS, V37, P147, DOI 10.1006/geno.1996.0536; GRAHAM FL, 1977, J GEN VIROL, V36, P59, DOI 10.1099/0022-1317-36-1-59; Hecht NB, 1998, BIOESSAYS, V20, P555, DOI 10.1002/(SICI)1521-1878(199807)20:7<555::AID-BIES6>3.3.CO;2-J; Kim J, 2000, GENOMICS, V64, P114, DOI 10.1006/geno.1999.6112; Klingenhoff A, 1999, BIOINFORMATICS, V15, P180, DOI 10.1093/bioinformatics/15.3.180; Kratz E, 2002, TRENDS GENET, V18, P29, DOI 10.1016/S0168-9525(01)02579-3; Krautwurst D, 1998, CELL, V95, P917, DOI 10.1016/S0092-8674(00)81716-X; Kyewski B, 2002, TRENDS IMMUNOL, V23, P364, DOI 10.1016/S1471-4906(02)02248-2; Lander ES, 2001, NATURE, V409, P860, DOI 10.1038/35057062; Lane RP, 2002, GENOME RES, V12, P81, DOI 10.1101/gr.197901; Lane RP, 2001, P NATL ACAD SCI USA, V98, P7390, DOI 10.1073/pnas.131215398; Lee SG, 2000, MOL CELLS, V10, P47, DOI 10.1007/s10059-000-0047-z; LIN HH, 1995, NATURE, V376, P263, DOI 10.1038/376263a0; Ling K, 1999, P NATL ACAD SCI USA, V96, P7922, DOI 10.1073/pnas.96.14.7922; Mironov AA, 1999, GENOME RES, V9, P1288, DOI 10.1101/gr.9.12.1288; Mombaerts P, 1996, CURR OPIN NEUROBIOL, V6, P481, DOI 10.1016/S0959-4388(96)80053-5; Mombaerts P, 1996, CELL, V87, P675, DOI 10.1016/S0092-8674(00)81387-2; Mombaerts P, 2001, ANNU REV GENOM HUM G, V2, P493, DOI 10.1146/annurev.genom.2.1.493; Murrell JR, 1999, J NEUROSCI, V19, P8260; PARMENTIER M, 1992, NATURE, V355, P453, DOI 10.1038/355453a0; Penn D, 1998, ADV IMMUNOL, V69, P411, DOI 10.1016/S0065-2776(08)60612-4; Proudfoot N, 1996, CELL, V87, P779, DOI 10.1016/S0092-8674(00)81982-0; Quandt K, 1995, NUCLEIC ACIDS RES, V23, P4878, DOI 10.1093/nar/23.23.4878; Rawson NE, 2000, J NEUROCHEM, V75, P185, DOI 10.1046/j.1471-4159.2000.0750185.x; RESSLER KJ, 1993, CELL, V73, P597, DOI 10.1016/0092-8674(93)90145-G; Rouquier S, 1998, HUM MOL GENET, V7, P1337, DOI 10.1093/hmg/7.9.1337; Scherf M, 2000, J MOL BIOL, V297, P599, DOI 10.1006/jmbi.2000.3589; Serizawa S, 2000, NAT NEUROSCI, V3, P687, DOI 10.1038/76641; SINGER MS, 1995, NATURE, V377, P19, DOI 10.1038/377019b0; Sosinsky A, 2000, GENOMICS, V70, P49, DOI 10.1006/geno.2000.6363; Speca DJ, 1999, NEURON, V23, P487, DOI 10.1016/S0896-6273(00)80802-8; Tatsura H, 2001, FEBS LETT, V488, P139, DOI 10.1016/S0014-5793(00)02411-X; Touhara K, 1999, P NATL ACAD SCI USA, V96, P4040, DOI 10.1073/pnas.96.7.4040; VANDERHAEGHEN P, 1993, J CELL BIOL, V123, P1441, DOI 10.1083/jcb.123.6.1441; Vanderhaeghen P, 1997, BIOCHEM BIOPH RES CO, V237, P283, DOI 10.1006/bbrc.1997.7043; Vanderhaeghen P, 1997, GENOMICS, V39, P239, DOI 10.1006/geno.1996.4490; Venter JC, 2001, SCIENCE, V291, P1304, DOI 10.1126/science.1058040; WALENSKY LD, 1995, MOL MED, V1, P130, DOI 10.1007/BF03401561; Walensky LD, 1998, J BIOL CHEM, V273, P9378, DOI 10.1074/jbc.273.16.9378; Wang F, 1998, CELL, V93, P47, DOI 10.1016/S0092-8674(00)81145-9; WANG MM, 1993, NATURE, V364, P121, DOI 10.1038/364121a0; Wang SS, 1997, J NEUROSCI, V17, P4149; Wetzel CH, 1999, J NEUROSCI, V19, P7426, DOI 10.1523/JNEUROSCI.19-17-07426.1999; YAMAZAKI K, 1976, J EXP MED, V144, P1324, DOI 10.1084/jem.144.5.1324; Young JM, 2002, HUM MOL GENET, V11, P535, DOI 10.1093/hmg/11.5.535; Younger RM, 2001, GENOME RES, V11, P519, DOI 10.1101/gr.GR-1603R; Zhao HQ, 1998, SCIENCE, V279, P237, DOI 10.1126/science.279.5348.237; Ziegler A, 2000, MAJOR HISTOCOMPATIBILITY COMPLEX, P110; Ziegler A, 2002, AM J REPROD IMMUNOL, V48, P34, DOI 10.1034/j.1600-0897.2002.01097.x; Ziegler A, 2000, HUM IMMUNOL, V61, P1281, DOI 10.1016/S0198-8859(00)00219-6; ZIEGLER A, 2003, IN PRESS HLA 2002 IM; Zozulya S, 2001, GENOME BIOL, V2	74	28	33	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 30	2003	278	22					19691	19701		10.1074/jbc.M212424200	http://dx.doi.org/10.1074/jbc.M212424200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	682EH	12637542	hybrid			2022-12-25	WOS:000183078000018
J	Dorr, C; Zaparty, M; Tjaden, B; Brinkmann, H; Siebers, B				Dorr, C; Zaparty, M; Tjaden, B; Brinkmann, H; Siebers, B			The hexokinase of the hyperthermophile Thermoproteus tenax - ATP-dependent hexokinases and ADP-dependent glucokinases, two alternatives for glucose phosphorylation in Archaea	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENTNER-DOUDOROFF-PATHWAY; N-ACETYLNEURAMINIC ACID; EMBDEN-MEYERHOF PATHWAY; PYROCOCCUS-FURIOSUS; BACILLUS-SUBTILIS; SUGAR KINASES; GLYCERALDEHYDE-3-PHOSPHATE DEHYDROGENASE; BIOCHEMICAL-CHARACTERIZATION; EVOLUTIONARY RELATIONSHIPS; CATABOLITE REPRESSION	The phosphorylation of glucose by different sugar kinases plays an essential role in Archaea because of the absence of a phosphoenolpyruvate-dependent transferase system characteristic for Bacteria. In the genome of the hyperthermophilic Archaeon Thermoproteus tenax a gene was identified with sequence similarity to glucokinases of the so-called ROK family (repressor protein, open reading frame, sugar kinase). The T. tenax enzyme, like the recently described ATP-dependent "glucokinase" from Aeropyrum pernix, shows the typical broad substrate specificity of hexokinases catalyzing not only phosphorylation of glucose but also of other hexoses such as fructose, mannose, or 2-deoxyglucose, and thus both enzymes represent true hexokinases. The T. tenax hexokinase shows strikingly low if at all any regulatory properties and thus fulfills no important control function at the beginning of the variant of the Embden-Meyerhof-Parnas pathway in T. tenax. Transcript analyses reveal that the hxk gene of T. tenax is cotranscribed with an upstream located orfX, which codes for an 11-kDa protein of unknown function. Growth-dependent studies and promoter analyses suggest that post-transcriptional RNA processing might be involved in the generation of the monocistronic hxk message, which is observed only under heterotrophic growth conditions. Data base searches revealed T. tenax hexokinase homologs in some archaeal, few eukaryal, and many bacterial genomes. Phylogenetic analyses confirm that the archaeal hexokinase is a member of the so-called ROK family, which, however, should be referred to as ROK group because it represents a group within the bacterial glucokinase fructokinase subfamily II of the hexokinase family. Thus, archaeal hexokinases represent a second major group of glucose-phosphorylating enzymes in Archaea beside the recently described archaeal ADP-dependent glucokinases, which were recognized as members of the ribokinase family. The distribution of the two types of sugar kinases, differing in their cosubstrate as well as substrate specificity, within Archaea is discussed on the basis of physiological constraints of the respective organisms.	Univ Duisburg Essen, Dept Microbiol, FB 9, D-45117 Essen, Germany; Univ Montreal, Dept Biochem, Montreal, PQ H3C 3J7, Canada	University of Duisburg Essen; Universite de Montreal	Siebers, B (corresponding author), Univ Duisburg Essen, Dept Microbiol, FB 9, Univ Str 5, D-45117 Essen, Germany.	bettina.siebers@uni-essen.de		Siebers, Bettina/0000-0002-9905-541X				ANGELL S, 1992, MOL MICROBIOL, V6, P2833, DOI 10.1111/j.1365-2958.1992.tb01463.x; Bell SD, 2001, CURR OPIN MICROBIOL, V4, P208, DOI 10.1016/S1369-5274(00)00190-9; BORK P, 1993, PROTEIN SCI, V2, P31; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brunner NA, 1998, J BIOL CHEM, V273, P6149, DOI 10.1074/jbc.273.11.6149; Brunner NA, 2001, EXTREMOPHILES, V5, P101, DOI 10.1007/s007920100181; BUDGEN N, 1986, FEBS LETT, V196, P207, DOI 10.1016/0014-5793(86)80247-2; Cardenas ML, 1998, BBA-MOL CELL RES, V1401, P242, DOI 10.1016/S0167-4889(97)00150-X; CHANGHOON K, J BACTERIOL, V179, P7631; Concha MI, 2000, FEMS MICROBIOL LETT, V186, P97, DOI 10.1111/j.1574-6968.2000.tb09088.x; DOELLE HW, 1982, EUR J APPL MICROBIOL, V14, P241, DOI 10.1007/BF00498471; FISCHER F, 1983, NATURE, V301, P511, DOI 10.1038/301511a0; FOTHERGILLGILMORE LA, 1993, PROG BIOPHYS MOL BIO, V59, P105, DOI 10.1016/0079-6107(93)90001-Z; GOWARD CR, 1986, BIOCHEM J, V237, P415, DOI 10.1042/bj2370415; Hansen T, 2002, J BACTERIOL, V184, P5955, DOI 10.1128/JB.184.21.5955-5965.2002; Hansen T, 2000, ARCH MICROBIOL, V173, P103, DOI 10.1007/s002039900114; HENGARTNER H, 1973, FEBS LETT, V37, P212, DOI 10.1016/0014-5793(73)80461-2; Hinderlich S, 1997, J BIOL CHEM, V272, P24313, DOI 10.1074/jbc.272.39.24313; Huelsenbeck JP, 2001, BIOINFORMATICS, V17, P754, DOI 10.1093/bioinformatics/17.8.754; Ito S, 2001, STRUCTURE, V9, P205, DOI 10.1016/S0969-2126(01)00577-9; KENGEN SWM, 1994, J BIOL CHEM, V269, P17537; Kengen SWM, 1995, J BIOL CHEM, V270, P30453, DOI 10.1074/jbc.270.51.30453; Koga S, 2000, J BIOCHEM-TOKYO, V128, P1079, DOI 10.1093/oxfordjournals.jbchem.a022836; KREUZER P, 1989, J BACTERIOL, V171, P3840, DOI 10.1128/jb.171.7.3840-3845.1989; Kumar S, 2001, BIOINFORMATICS, V17, P1244, DOI 10.1093/bioinformatics/17.12.1244; KWAKMAN JH, 1997, J BACTERIOL, V176, P2694; Labes A, 2001, ARCH MICROBIOL, V176, P329, DOI 10.1007/s002030100330; Park SY, 2000, FEMS MICROBIOL LETT, V188, P209, DOI 10.1016/S0378-1097(00)00238-X; PHILIPPE H, 1993, NUCLEIC ACIDS RES, V21, P5264, DOI 10.1093/nar/21.22.5264; PLUMBRIDGE J, 1995, EMBO J, V14, P3958, DOI 10.1002/j.1460-2075.1995.tb00067.x; Plumbridge J, 1999, J BACTERIOL, V181, P47, DOI 10.1128/JB.181.1.47-54.1999; PLUMBRIDGE JA, 1989, MOL MICROBIOL, V3, P505, DOI 10.1111/j.1365-2958.1989.tb00197.x; Pohl E, 2002, J BIOL CHEM, V277, P19938, DOI 10.1074/jbc.M112244200; PORTER EV, 1982, BIOCHIM BIOPHYS ACTA, V709, P178; RANGASWAMY V, 1994, J BACTERIOL, V176, P5505, DOI 10.1128/JB.176.17.5505-5512.1994; RANGASWAMY V, 1994, BIOCHIM BIOPHYS ACTA, V28, P106; Ronimus RS, 1999, EXTREMOPHILES, V3, P121, DOI 10.1007/s007920050107; Ronimus RS, 2001, BBA-GENE STRUCT EXPR, V1517, P384, DOI 10.1016/S0167-4781(00)00301-8; Ronimus RS, 2001, FEMS MICROBIOL LETT, V202, P85, DOI 10.1111/j.1574-6968.2001.tb10784.x; Rosana-Ani L, 1999, FEMS MICROBIOL LETT, V171, P89, DOI 10.1016/S0378-1097(98)00585-0; Sakuraba H, 2002, J BIOL CHEM, V277, P12495, DOI 10.1074/jbc.C200059200; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SCHONHEIT P, 1995, WORLD J MICROB BIOT, V11, P26, DOI 10.1007/BF00339135; Schramm A, 2001, METHOD ENZYMOL, V331, P62; Schramm A, 2000, J BACTERIOL, V182, P2001, DOI 10.1128/JB.182.7.2001-2009.2000; Selig M, 1997, ARCH MICROBIOL, V167, P217, DOI 10.1007/BF03356097; Siebers B, 1997, ARCH MICROBIOL, V168, P120, DOI 10.1007/s002030050477; SIEBERS B, 1993, FEMS MICROBIOL LETT, V111, P1; Siebers B, 1998, J BACTERIOL, V180, P2137, DOI 10.1128/JB.180.8.2137-2143.1998; Siebers B, 2001, J BIOL CHEM, V276, P28710, DOI 10.1074/jbc.M103447200; Skarlatos P, 1998, J BACTERIOL, V180, P3222, DOI 10.1128/JB.180.12.3222-3226.1998; SOLS A, 1958, BIOCHIM BIOPHYS ACTA, V30, P92; Soppa J, 1999, MOL MICROBIOL, V31, P1589, DOI 10.1046/j.1365-2958.1999.01274.x; Soppa J, 1999, MOL MICROBIOL, V31, P1295, DOI 10.1046/j.1365-2958.1999.01273.x; Spath C, 1997, J BACTERIOL, V179, P7603; Strimmer K, 1996, MOL BIOL EVOL, V13, P964, DOI 10.1093/oxfordjournals.molbev.a025664; Swofford D.L., 1999, PAUP PHYLOGENETIC AN; Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876; TITGEMEYER F, 1994, MICROBIOL-UK, V140, P2349, DOI 10.1099/13500872-140-9-2349; Tuininga JE, 1999, J BIOL CHEM, V274, P21023, DOI 10.1074/jbc.274.30.21023; Verhees CH, 2002, BIOCHEM J, V366, P121, DOI 10.1042/BJ20011597; Verhees CH, 2001, J BACTERIOL, V183, P7145, DOI 10.1128/JB.183.24.7145-7153.2001; WAGNER E, 1995, J BACTERIOL, V177, P6144, DOI 10.1128/jb.177.21.6144-6152.1995; Wu G, 2001, GENE, V264, P265, DOI 10.1016/S0378-1119(01)00329-8; YU JP, 1994, J BACTERIOL, V176, P325, DOI 10.1128/JB.176.2.325-332.1994; ZEMBRZUSKI B, 1992, J BACTERIOL, V174, P3455, DOI 10.1128/JB.174.11.3455-3460.1992; ZILLIG W, 1981, ZBL BAKT MIK HYG I C, V2, P205, DOI 10.1016/S0721-9571(81)80001-4	67	46	49	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 23	2003	278	21					18744	18753		10.1074/jbc.M301914200	http://dx.doi.org/10.1074/jbc.M301914200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	679PY	12626506	hybrid			2022-12-25	WOS:000182932200007
J	Ninomiya-Tsuji, J; Kajino, T; Ono, K; Ohtomo, T; Matsumoto, M; Shiina, M; Mihara, M; Tsuchiya, M; Matsumoto, K				Ninomiya-Tsuji, J; Kajino, T; Ono, K; Ohtomo, T; Matsumoto, M; Shiina, M; Mihara, M; Tsuchiya, M; Matsumoto, K			A resorcylic acid lactone, 5Z-7-oxozeaenol, prevents inflammation by inhibiting the catalytic activity of TAK1 MAPK kinase kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; I-KAPPA-B; BETA SIGNAL-TRANSDUCTION; PATHWAY; IL-1; INTERLEUKIN-1; MACROPHAGES; INDUCTION; RECEPTOR; CASCADE	TAK1, a member of the mitogen-activated kinase kinase kinase (MAPKKK) family, participates in proinflammatory cellular signaling pathways by activating JNK/p38 MAPKs and NF-kappaB. To identify drugs that prevent inflammation, we screened inhibitors of TAK1 catalytic activity. We identified a natural resorcylic lactone of fungal origin, 5Z-7-oxozeaenol, as a highly potent inhibitor of TAK1. This compound did not effectively inhibit the catalytic activities of the MEKK1 or ASK1 MAPKKKs, suggesting that 5Z-7-oxozeaenol is a selective inhibitor of TAK1. In cell culture, 5Z-7-oxozeaenol blocked interleukin-1- induced activation of TAK1, JNK/p38 MAPK, IkappaB kinases, and NF-kappaB, resulting in inhibition of cyclooxgenase-2 production. Furthermore, in vivo 5Z-7-oxozeaenol was able to inhibit picryl chloride-induced ear swelling. Thus, 5Z-7-oxozeaenol blocks proinflammatory signaling by selectively inhibiting TAK1 MAPKKK.	Nagoya Univ, Grad Sch Sci, Dept Mol Biol, Chikusa Ku, Nagoya, Aichi 4648602, Japan; Japan Sci & Technol Corp, CREST, Chikusa Ku, Nagoya, Aichi 4648602, Japan; Chugai Pharmaceut Co Ltd, Fuji Gotemba Res Labs, Gotemba, Shizuoka 4128513, Japan; N Carolina State Univ, Dept Environm & Mol Toxicol, Raleigh, NC 27695 USA	Nagoya University; Japan Science & Technology Agency (JST); Chugai Pharmaceutical Co., Ltd.; Roche Holding; University of North Carolina; North Carolina State University	Matsumoto, K (corresponding author), Nagoya Univ, Grad Sch Sci, Dept Mol Biol, Chikusa Ku, Nagoya, Aichi 4648602, Japan.			Ninomiya-Tsuji, Jun/0000-0002-5584-0176				Cao ZD, 1996, SCIENCE, V271, P1128, DOI 10.1126/science.271.5252.1128; Dinarello CA, 1996, BLOOD, V87, P2095, DOI 10.1182/blood.V87.6.2095.bloodjournal8762095; Goto YS, 2000, INT ARCH ALLERGY IMM, V123, P341, DOI 10.1159/000053647; Hirai S, 1996, ONCOGENE, V12, P641; Ichijo H, 1997, SCIENCE, V275, P90, DOI 10.1126/science.275.5296.90; Irie T, 2000, FEBS LETT, V467, P160, DOI 10.1016/S0014-5793(00)01146-7; Ishitani T, 2003, MOL CELL BIOL, V23, P1379, DOI 10.1128/MCB.23.4.1379-1389.2003; Ishitani T, 1999, NATURE, V399, P798, DOI 10.1038/21674; Ishitani T, 2003, MOL CELL BIOL, V23, P131, DOI 10.1128/MCB.23.1.131-139.2003; Kishimoto K, 2000, J BIOL CHEM, V275, P7359, DOI 10.1074/jbc.275.10.7359; KRUEGER GG, 1989, J INVEST DERMATOL, V92, P32; LAVAUD P, 1991, J INVEST DERMATOL, V97, P101, DOI 10.1111/1523-1747.ep12478438; Malinin NL, 1997, NATURE, V385, P540, DOI 10.1038/385540a0; Mochida Y, 2000, J BIOL CHEM, V275, P32747, DOI 10.1074/jbc.M003042200; Moriguchi T, 1996, J BIOL CHEM, V271, P13675, DOI 10.1074/jbc.271.23.13675; Ninomiya-Tsuji J, 1999, NATURE, V398, P252, DOI 10.1038/18465; Rawlins P, 1999, INT J IMMUNOPHARMACO, V21, P799, DOI 10.1016/S0192-0561(99)00047-8; Sakurai H, 1999, J BIOL CHEM, V274, P10641, DOI 10.1074/jbc.274.15.10641; Shibuya H, 1998, EMBO J, V17, P1019, DOI 10.1093/emboj/17.4.1019; Shibuya H, 1996, SCIENCE, V272, P1179, DOI 10.1126/science.272.5265.1179; Shirakabe K, 1997, J BIOL CHEM, V272, P8141, DOI 10.1074/jbc.272.13.8141; Smith WL, 2000, ANNU REV BIOCHEM, V69, P145, DOI 10.1146/annurev.biochem.69.1.145; Takaesu G, 2003, J MOL BIOL, V326, P105, DOI 10.1016/S0022-2836(02)01404-3; Takaesu G, 2000, MOL CELL, V5, P649, DOI 10.1016/S1097-2765(00)80244-0; Takaesu G, 2001, MOL CELL BIOL, V21, P2475, DOI 10.1128/MCB.21.7.2475-2484.2001; Takehana K, 1999, BIOCHEM BIOPH RES CO, V257, P19, DOI 10.1006/bbrc.1999.0401; Vidal S, 2001, GENE DEV, V15, P1900, DOI 10.1101/gad.203301; WESTON WL, 1976, ANN ALLERGY, V37, P346; Williams DH, 1998, BIOCHEMISTRY-US, V37, P9579, DOI 10.1021/bi972914c; Woronicz JD, 1997, SCIENCE, V278, P866, DOI 10.1126/science.278.5339.866; YAMAGUCHI K, 1995, SCIENCE, V270, P2008, DOI 10.1126/science.270.5244.2008; YAN MH, 1994, NATURE, V372, P798; Yin MJ, 1998, CELL, V93, P875, DOI 10.1016/S0092-8674(00)81447-6; Zhao A, 1999, J ANTIBIOT, V52, P1086, DOI 10.7164/antibiotics.52.1086	34	338	349	4	32	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 16	2003	278	20					18485	18490		10.1074/jbc.M207453200	http://dx.doi.org/10.1074/jbc.M207453200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677YX	12624112	hybrid			2022-12-25	WOS:000182838300117
J	Rodeheffer, MS; Shadel, GS				Rodeheffer, MS; Shadel, GS			Multiple interactions involving the amino-terminal domain of yeast mtRNA polymerase determine the efficiency of mitochondrial protein synthesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; RNA-POLYMERASE; GENE-EXPRESSION; MEMBRANE; TRANSCRIPTION; RIBOSOMES; TRANSLATION; STABILITY; PRODUCT; INTRONS	The amino-terminal domain (ATD) of Saccharomyces cerevisiae mitochondrial RNA polymerase has been shown to provide a functional link between transcription and post-transcriptional events during mitochondrial gene expression. This connection is mediated in large part by its interactions with the matrix protein Nam1p and, based on genetic phenotypes, the mitochondrial membrane protein Sls1p. These observations led us to propose previously that mtRNA polymerase, Nam1p, and Sls1p work together to coordinate transcription and translation of mtDNA-encoded gene products. Here we demonstrate by specific labeling of mitochondrial gene products in vivo that Nam1p and Sls1p indeed work together in a pathway that is required globally for efficient mitochondrial translation. Likewise, mutations in the ATD result in similar global reductions in mitochondrial translation efficiency and sensitivity to the mitochondrial translation inhibitor erythromycin. These data, coupled with the observation that the ATD is required to co-purify Sls1p in association with mtDNA nucleoids, suggest that efficient expression of mtDNA-encoded genes in yeast involves a complex series of interactions that localize active transcription complexes to the inner membrane in order to coordinate translation with transcription.	Emory Univ, Sch Med, Rollins Res Ctr, Dept Biochem, Atlanta, GA 30322 USA; Emory Univ, Sch Med, Rollins Res Ctr, Grad Program Biochem Cell & Dev Biol, Atlanta, GA 30322 USA	Emory University; Emory University	Shadel, GS (corresponding author), Emory Univ, Sch Med, Rollins Res Ctr, Dept Biochem, Atlanta, GA 30322 USA.	gshadel@emory.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL059655] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL059655, HL59655, R01 HL059655-05A1] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ASHER E B, 1989, Molecular and General Genetics, V215, P517, DOI 10.1007/BF00427051; Bryan AC, 2002, GENETICS, V160, P75; DIECKMANN CL, 1994, INT REV CYTOL, V152, P145, DOI 10.1016/S0074-7696(08)62556-5; Fox TD, 1996, EXPERIENTIA, V52, P1130, DOI 10.1007/BF01952112; FOX TD, 1991, METHOD ENZYMOL, V194, P149; GREENLEAF AL, 1986, P NATL ACAD SCI USA, V83, P3391, DOI 10.1073/pnas.83.10.3391; GROUDINSKY O, 1993, MOL GEN GENET, V240, P419, DOI 10.1007/BF00280396; GRUBBS FE, 1969, TECHNOMETRICS, V11, P1, DOI 10.2307/1266761; Kaufman BA, 2000, P NATL ACAD SCI USA, V97, P7772, DOI 10.1073/pnas.140063197; KURIYAMA Y, 1973, J CELL BIOL, V59, P776, DOI 10.1083/jcb.59.3.776; LAZOWSKA J, 1980, CELL, V22, P333, DOI 10.1016/0092-8674(80)90344-X; LISOWSKY T, 1990, MOL GEN GENET, V220, P186; Liu MQ, 2000, J BIOL CHEM, V275, P29400, DOI 10.1074/jbc.M002173200; MARZUKI S, 1986, BIOCHIM BIOPHYS ACTA, V866, P120, DOI 10.1016/0167-4781(86)90108-9; MASTERS BS, 1987, CELL, V51, P89, DOI 10.1016/0092-8674(87)90013-4; Naithani S, 2003, MOL BIOL CELL, V14, P324, DOI 10.1091/mbc.E02-08-0490; O'Rourke TW, 2002, MOL CELL BIOL, V22, P4086, DOI 10.1128/MCB.22.12.4086-4093.2002; PEL HJ, 1993, MOL BIOL REP, V18, P1, DOI 10.1007/BF01006890; Poyton R O, 1996, Methods Enzymol, V264, P36, DOI 10.1016/S0076-6879(96)64006-3; Proudfoot NJ, 2002, CELL, V108, P501, DOI 10.1016/S0092-8674(02)00617-7; Rodeheffer MS, 2001, J BIOL CHEM, V276, P8616, DOI 10.1074/jbc.M009901200; Rouillard JM, 1996, MOL GEN GENET, V252, P700, DOI 10.1007/s004380050279; Sambrook J, 2001, MOL CLONING LAB MANU; Sanchirico ME, 1998, EMBO J, V17, P5796, DOI 10.1093/emboj/17.19.5796; Shadel GS, 1999, AM J HUM GENET, V65, P1230, DOI 10.1086/302630; SHERMAN F, 1991, METHOD ENZYMOL, V194, P3; SPITHILL TW, 1978, MOL GEN GENET, V164, P155, DOI 10.1007/BF00267380; WALLIS MG, 1994, EUR J BIOCHEM, V222, P27, DOI 10.1111/j.1432-1033.1994.tb18837.x; Wang YH, 1999, P NATL ACAD SCI USA, V96, P8046, DOI 10.1073/pnas.96.14.8046; Zhang Y, 2000, RNA, V6, P937, DOI 10.1017/S1355838200991726	30	57	58	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 16	2003	278	20					18695	18701		10.1074/jbc.M301399200	http://dx.doi.org/10.1074/jbc.M301399200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677YX	12637560	Green Accepted, hybrid			2022-12-25	WOS:000182838300143
J	Singh, S; Zlotnick, A				Singh, S; Zlotnick, A			Observed hysteresis of virus capsid disassembly is implicit in kinetic models of assembly	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SUBUNIT ASSOCIATION; PROTEIN; DISSOCIATION; PERSPECTIVE; PARTICLES; SURFACE	For many protein multimers, association and dissociation reactions fail to reach the same end point; there is hysteresis preventing one and/or the other reaction from equilibrating. We have studied in vitro assembly of dimeric hepatitis B virus (HBV) capsid protein and dissociation of the resulting T = 4 icosahedral capsids. Empty HBV capsids composed of 120 capsid protein dimers were more resistant to dissociation by dilution or denaturants than anticipated from assembly experiments. Using intrinsic fluorescence, circular dichroism, and size exclusion chromatography, we showed that denaturants dissociate the HBV capsids without unfolding the capsid protein; unfolding of dimer only occurred at higher denaturant concentrations. The apparent energy of interaction between dimers measured in dissociation experiments was much stronger than when measured in assembly studies. Unlike assembly, capsid dissociation did not have the concentration dependence expected for a 120-subunit complex; consequently the apparent association energy systematically varied with reactant concentration. These data are evidence of hysteresis for HBV capsid dissociation. Simulations of capsid assembly and dissociation reactions recapitulate and provide an explanation for the observed behavior; these results are also applicable to oligomeric and multidomain proteins. In our calculations, we find that dissociation is impeded by temporally elevated concentrations of intermediates; this has the paradoxical effect of favoring re-assembly of those intermediates despite the global trend toward dissociation. Hysteresis masks all but the most dramatic decreases in contact energy. In contrast, assembly reactions rapidly approach equilibrium. These results provide the first rigorous explanation of how virus capsids can remain intact under extreme conditions but are still capable of "breathing." A biological implication of enhanced stability is that a triggering event may be required to initiate virus uncoating.	Univ Oklahoma, Hlth Sci Ctr, Dept Biochem & Mol Biol, Oklahoma City, OK 73190 USA	University of Oklahoma System; University of Oklahoma Health Sciences Center	Zlotnick, A (corresponding author), Univ Oklahoma, Hlth Sci Ctr, Dept Biochem & Mol Biol, Oklahoma City, OK 73190 USA.	adam-zlotnick@ouhsc.edu		Zlotnick, Adam/0000-0001-9945-6267				Bothner B, 1998, J BIOL CHEM, V273, P673, DOI 10.1074/jbc.273.2.673; Brooks CL, 1998, P NATL ACAD SCI USA, V95, P11037, DOI 10.1073/pnas.95.19.11037; Ceres P, 2002, BIOCHEMISTRY-US, V41, P11525, DOI 10.1021/bi0261645; Chan HS, 1998, PROTEINS, V30, P2, DOI 10.1002/(SICI)1097-0134(19980101)30:1<2::AID-PROT2>3.0.CO;2-R; Clementi C, 1999, P NATL ACAD SCI USA, V96, P9616, DOI 10.1073/pnas.96.17.9616; CROWTHER RA, 1994, CELL, V77, P943, DOI 10.1016/0092-8674(94)90142-2; DAPOIAN AT, 1993, J MOL BIOL, V231, P999, DOI 10.1006/jmbi.1993.1347; DAVIS JM, 1993, J BIOL CHEM, V268, P25965; DILL KA, 1995, PROTEIN SCI, V4, P561; Dinner AR, 2000, TRENDS BIOCHEM SCI, V25, P331, DOI 10.1016/S0968-0004(00)01610-8; Endres D, 2002, BIOPHYS J, V83, P1217, DOI 10.1016/S0006-3495(02)75245-4; Fasshauer D, 2002, NAT STRUCT BIOL, V9, P144, DOI 10.1038/nsb750; FERSHT AR, 1999, STRUCTURE MECH PROTE, P93; *HOUGHT MIFFL CO, 1996, AM HERITAGE DICT, P652; KENNEY JM, 1995, STRUCTURE, V3, P1009, DOI 10.1016/S0969-2126(01)00237-4; Lewis JK, 1998, P NATL ACAD SCI USA, V95, P6774, DOI 10.1073/pnas.95.12.6774; LI QH, 1994, J VIROL, V68, P3965, DOI 10.1128/JVI.68.6.3965-3970.1994; ONUCHIC JN, 1995, P NATL ACAD SCI USA, V92, P3626, DOI 10.1073/pnas.92.8.3626; Oosawa F., 1975, THERMODYNAMICS POLYM; Pace C N, 1986, Methods Enzymol, V131, P266; Pace CN, 2000, PROTEINS, P1; SERRANO L, 1990, BIOCHEMISTRY-US, V29, P9343, DOI 10.1021/bi00492a006; SHORTLE D, 1995, ADV PROTEIN CHEM, V46, P217, DOI 10.1016/S0065-3233(08)60336-8; SILVA JL, 1988, J MOL BIOL, V199, P149, DOI 10.1016/0022-2836(88)90385-3; STANNARD LM, 1979, J GEN VIROL, V45, P509, DOI 10.1099/0022-1317-45-2-509; THOMSEN JS, 1953, PHYS REV, V91, P1263, DOI 10.1103/PhysRev.91.1263; Tsang SK, 2001, J VIROL, V75, P4984, DOI 10.1128/JVI.75.11.4984-4989.2001; Watts NR, 2002, EMBO J, V21, P876, DOI 10.1093/emboj/21.5.876; Weber G, 1996, BIOPHYS J, V70, P167, DOI 10.1016/S0006-3495(96)79557-7; WINGFIELD PT, 1995, BIOCHEMISTRY-US, V34, P4919, DOI 10.1021/bi00015a003; Wynne SA, 1999, MOL CELL, V3, P771, DOI 10.1016/S1097-2765(01)80009-5; Zlotnick A, 1999, BIOCHEMISTRY-US, V38, P14644, DOI 10.1021/bi991611a; ZLOTNICK A, 1994, J MOL BIOL, V241, P59, DOI 10.1006/jmbi.1994.1473; Zlotnick A, 2002, J VIROL, V76, P4848, DOI 10.1128/JVI.76.10.4848-4854.2002; Zlotnick A, 1996, BIOCHEMISTRY-US, V35, P7412, DOI 10.1021/bi9604800	35	122	122	0	20	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 16	2003	278	20					18249	18255		10.1074/jbc.M211408200	http://dx.doi.org/10.1074/jbc.M211408200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677YX	12639968	hybrid			2022-12-25	WOS:000182838300087
J	Min, KW; Hwang, JW; Lee, JS; Park, Y; Tamura, T; Yoon, JB				Min, KW; Hwang, JW; Lee, JS; Park, Y; Tamura, T; Yoon, JB			TIP120A associates with cullins and modulates ubiquitin ligase activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TBP-INTERACTING PROTEIN; F-BOX PROTEINS; TUMOR-SUPPRESSOR PROTEIN; RNA POLYMERASE-II; ELONGIN-B; COMPLEX; SCF; BINDING; TRANSCRIPTION; DEGRADATION	The cullin-containing ubiquitin-protein isopeptide ligases (E3s) play an important role in regulating the abundance of key proteins involved in cellular processes such as cell cycle and cytokine signaling. They have multisubunit modular structures in which substrate recognition and the catalysis of ubiquitination are carried out by distinct polypeptides. In a search for proteins involved in regulation of cullin-containing E3 ubiquitin ligases we immunopurified CUL4B-containing complex from HeLa cells and identified TIP120A as an associated protein by mass spectrometry. Immunoprecipitation of cullins revealed that all cullins tested specifically interacted with TIP120A. Reciprocal immuno-affinity purification of TIP120A confirmed the stable interaction of TIP120A with cullin family proteins. TIP120A formed a complex with CUL1 and Rbx1; but interfered with the binding of Skp1 and F-box proteins to CULL TIP120A greatly reduced the ubiquitination of phosphorylated IkappaBalpha by SCFbeta-TrCP ubiquitin ligase. These results suggest that TIP120A functions as a negative regulator of SCF E3 ubiquitin ligases and may modulate other cullin ligases in a similar fashion.	Yonsei Univ, Dept Biochem, Seoul 120749, South Korea; Yonsei Univ, Prot Network Res Ctr, Seoul 120749, South Korea; Chiba Univ, Fac Sci, Dept Biol, Chiba 2638522, Japan	Yonsei University; Yonsei University; Chiba University	Yoon, JB (corresponding author), Yonsei Univ, Dept Biochem, Seoul 120749, South Korea.			Yoon, Jong-Bok/0000-0002-3563-0702				Bai C, 1996, CELL, V86, P263, DOI 10.1016/S0092-8674(00)80098-7; Carrano AC, 1999, NAT CELL BIOL, V1, P193, DOI 10.1038/12013; Cenciarelli C, 1999, CURR BIOL, V9, P1177, DOI 10.1016/S0960-9822(00)80020-2; CHIANG CM, 1993, EMBO J, V12, P2749, DOI 10.1002/j.1460-2075.1993.tb05936.x; De Sepulveda P, 2000, J BIOL CHEM, V275, P14005, DOI 10.1074/jbc.C000106200; Deshaies RJ, 1999, ANNU REV CELL DEV BI, V15, P435, DOI 10.1146/annurev.cellbio.15.1.435; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DUAN DR, 1995, SCIENCE, V269, P1402, DOI 10.1126/science.7660122; Farras R, 2001, EMBO J, V20, P2742, DOI 10.1093/emboj/20.11.2742; Furukawa M, 2000, MOL CELL BIOL, V20, P8185, DOI 10.1128/MCB.20.21.8185-8197.2000; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; Hilton DJ, 1998, P NATL ACAD SCI USA, V95, P114, DOI 10.1073/pnas.95.1.114; Hochstrasser M, 1996, ANNU REV GENET, V30, P405, DOI 10.1146/annurev.genet.30.1.405; Ivan M, 2001, SCIENCE, V292, P464, DOI 10.1126/science.1059817; Kamura T, 2000, P NATL ACAD SCI USA, V97, P10430, DOI 10.1073/pnas.190332597; Kamura T, 1999, SCIENCE, V284, P657, DOI 10.1126/science.284.5414.657; Kamura T, 1998, GENE DEV, V12, P3872, DOI 10.1101/gad.12.24.3872; Kayukawa K, 2001, GENES CELLS, V6, P165, DOI 10.1046/j.1365-2443.2001.00407.x; KIBEL A, 1995, SCIENCE, V269, P1444, DOI 10.1126/science.7660130; Kipreos ET, 2002, GENOME BIOL; KISHIDA T, 1995, CANCER RES, V55, P4544; Lyapina SA, 1998, P NATL ACAD SCI USA, V95, P7451, DOI 10.1073/pnas.95.13.7451; Makino Y, 1999, MOL CELL BIOL, V19, P7951; Michel JJ, 1998, CELL GROWTH DIFFER, V9, P435; Monni R, 2001, ONCOGENE, V20, P849, DOI 10.1038/sj.onc.1204201; Ohh M, 2000, NAT CELL BIOL, V2, P423, DOI 10.1038/35017054; Ohta T, 1999, MOL CELL, V3, P535, DOI 10.1016/S1097-2765(00)80482-7; Pickart CM, 2001, ANNU REV BIOCHEM, V70, P503, DOI 10.1146/annurev.biochem.70.1.503; Seol JH, 1999, GENE DEV, V13, P1614, DOI 10.1101/gad.13.12.1614; Skowyra D, 1997, CELL, V91, P209, DOI 10.1016/S0092-8674(00)80403-1; Skowyra D, 1999, SCIENCE, V284, P662, DOI 10.1126/science.284.5414.662; Tan PL, 1999, MOL CELL, V3, P527, DOI 10.1016/S1097-2765(00)80481-5; Verma R, 2000, MOL BIOL CELL, V11, P3425, DOI 10.1091/mbc.11.10.3425; Wilm M, 1996, NATURE, V379, P466, DOI 10.1038/379466a0; Winston JT, 1999, CURR BIOL, V9, P1180, DOI 10.1016/S0960-9822(00)80021-4; Yogosawa S, 1999, BIOCHEM BIOPH RES CO, V266, P123, DOI 10.1006/bbrc.1999.1773; Yogosawa S, 1996, BIOCHEM BIOPH RES CO, V229, P612, DOI 10.1006/bbrc.1996.1852; ZHANG H, 1995, CELL, V82, P915, DOI 10.1016/0092-8674(95)90271-6; Zhang JG, 1999, P NATL ACAD SCI USA, V96, P2071, DOI 10.1073/pnas.96.5.2071; Zheng N, 2002, NATURE, V416, P703, DOI 10.1038/416703a	40	64	76	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 2	2003	278	18					15905	15910		10.1074/jbc.M213070200	http://dx.doi.org/10.1074/jbc.M213070200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	675EL	12609982	hybrid			2022-12-25	WOS:000182680000057
J	Nufer, O; Mitrovic, S; Hauri, HP				Nufer, O; Mitrovic, S; Hauri, HP			Profile-based data base scanning for animal L-type lectins and characterization of VIPL, a novel VIP36-like endoplasmic reticulum protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GOLGI INTERMEDIATE COMPARTMENT; MANNOSIDASE-LIKE PROTEIN; FACTOR-VIII DEFICIENCY; COMBINED FACTOR-V; EARLY SECRETORY PATHWAY; MEMBRANE-PROTEIN; LEGUMINOUS LECTINS; RECYCLING PATHWAY; ERGIC-53 GENE; SACCHAROMYCES-CEREVISIAE	Consensus profiles were established to screen data bases for novel animal L-type lectins. The profiles were generated from linear sequence motifs of the human L-type lectin-like membrane proteins ERGIC-53, ERGL, and VIP36 and by optimal alignment of the entire carbohydrate recognition domain of these proteins. The search revealed numerous orthologous and homologous L-type lectin-like proteins in animals, protozoans, and yeast, as well as the sequence of a novel family member related to VIP36, named VIPL for VIP36-like. Sequence analysis suggests that VIPL is a ubiquitously expressed protein and appeared earlier in evolution than VIP36. The cDNA of VIPL was cloned and expressed in cell culture. VIPL is a high-mannose type I membrane glycoprotein with similar domain organization as VIP36. Unlike VIP36 and ERGIC-53 that are predominantly associated with postendoplasmic reticulum (ER) membranes and cycle in the early secretory pathway, VIPL is a non-cycling resident protein of the ER. Mutagenesis experiments indicate that ER retention of VIPL involves a RKR di-arginine signal. Overexpression of VIPL redistributed ERGIC-53 to the ER without affecting the cycling of the KDEL-receptor and the overall morphology of the early secretory pathway. The results suggest that VIPL may function as a regulator of ERGIC-53.	Univ Basel, Bioctr, CH-4056 Basel, Switzerland	University of Basel	Hauri, HP (corresponding author), Univ Basel, Bioctr, Klingelbergstr 70, CH-4056 Basel, Switzerland.							Andersson H, 1999, J BIOL CHEM, V274, P15080, DOI 10.1074/jbc.274.21.15080; Antonny B, 2001, CURR OPIN CELL BIOL, V13, P438, DOI 10.1016/S0955-0674(00)00234-9; APPEL RD, 1994, TRENDS BIOCHEM SCI, V19, P258, DOI 10.1016/0968-0004(94)90153-8; Appenzeller C, 1999, NAT CELL BIOL, V1, P330, DOI 10.1038/14020; ARAR C, 1995, J BIOL CHEM, V270, P3551, DOI 10.1074/jbc.270.8.3551; ARIDOR M, 1995, J CELL BIOL, V131, P875, DOI 10.1083/jcb.131.4.875; Ausubel F.A., 1997, CURRENT PROTOCOLS MO, DOI DOI 10.1.4; Bailey TL, 1998, J COMPUT BIOL, V5, P211, DOI 10.1089/cmb.1998.5.211; Bateman A, 2002, NUCLEIC ACIDS RES, V30, P276, DOI 10.1093/nar/30.1.276; Chevet E, 2001, CURR OPIN STRUC BIOL, V11, P120, DOI 10.1016/S0959-440X(00)00168-8; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Dansako H, 2001, ANN HEMATOL, V80, P292; Dodd RB, 2001, GLYCOBIOLOGY, V11, p71R, DOI 10.1093/glycob/11.5.71R; Ellgaard L, 2001, CURR OPIN CELL BIOL, V13, P431, DOI 10.1016/S0955-0674(00)00233-7; FIEDLER K, 1994, CELL, V77, P625, DOI 10.1016/0092-8674(94)90047-7; Fiedler K, 1996, J CELL SCI, V109, P271; FUJIKI Y, 1982, J CELL BIOL, V93, P97, DOI 10.1083/jcb.93.1.97; Fullekrug J, 1999, J CELL SCI, V112, P2813; Golling G, 2002, NAT GENET, V31, P135, DOI 10.1038/ng896; GRIBSKOV M, 1987, P NATL ACAD SCI USA, V84, P4355, DOI 10.1073/pnas.84.13.4355; Hara-Kuge S, 1999, GLYCOBIOLOGY, V9, P833, DOI 10.1093/glycob/9.8.833; Hara-Kuge S, 2002, J BIOL CHEM, V277, P16332, DOI 10.1074/jbc.M112188200; Hauri HP, 2000, J CELL SCI, V113, P587; Hauri HP, 2000, FEBS LETT, V476, P32, DOI 10.1016/S0014-5793(00)01665-3; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Hofmann K, 1999, NUCLEIC ACIDS RES, V27, P215, DOI 10.1093/nar/27.1.215; HORTON RM, 1989, GENE, V77, P61, DOI 10.1016/0378-1119(89)90359-4; Hosokawa N, 2001, EMBO REP, V2, P415, DOI 10.1093/embo-reports/kve084; Itin C, 1996, MOL BIOL CELL, V7, P483, DOI 10.1091/mbc.7.3.483; ITIN C, 1995, J CELL BIOL, V131, P57, DOI 10.1083/jcb.131.1.57; ITIN C, 1995, EMBO J, V14, P2250, DOI 10.1002/j.1460-2075.1995.tb07219.x; Jakob CA, 2001, EMBO REP, V2, P423; Kappeler F, 1997, J BIOL CHEM, V272, P31801, DOI 10.1074/jbc.272.50.31801; Klumperman J, 1998, J CELL SCI, V111, P3411; KOZAK M, 1987, J MOL BIOL, V196, P947, DOI 10.1016/0022-2836(87)90418-9; Lahtinen U, 1996, J BIOL CHEM, V271, P4031; Linstedt AD, 1997, MOL BIOL CELL, V8, P1073, DOI 10.1091/mbc.8.6.1073; LINSTEDT AD, 1993, MOL BIOL CELL, V4, P679, DOI 10.1091/mbc.4.7.679; LIPPINCOTTSCHWARTZ J, 1990, CELL, V60, P821, DOI 10.1016/0092-8674(90)90096-W; Loris R, 2002, BBA-GEN SUBJECTS, V1572, P198, DOI 10.1016/S0304-4165(02)00309-4; Lupas A, 1996, METHOD ENZYMOL, V266, P513; Ma D, 2002, CURR OPIN NEUROBIOL, V12, P287, DOI 10.1016/S0959-4388(02)00319-7; Nakatsukasa K, 2001, J BIOL CHEM, V276, P8635, DOI 10.1074/jbc.C100023200; Neerman-Arbez M, 1999, BLOOD, V93, P2253; Nichols WC, 1998, CELL, V93, P61, DOI 10.1016/S0092-8674(00)81146-0; Nichols WC, 1999, BLOOD, V93, P2261; Nielsen H, 1997, Int J Neural Syst, V8, P581, DOI 10.1142/S0129065797000537; Nufer O, 2002, J CELL SCI, V115, P619; Parodi AJ, 2000, ANNU REV BIOCHEM, V69, P69, DOI 10.1146/annurev.biochem.69.1.69; Rost B, 1996, METHOD ENZYMOL, V266, P525; Sambrook J., 2002, MOL CLONING LAB MANU; Sato K, 2002, MOL BIOL CELL, V13, P2518, DOI 10.1091/mbc.E02-01-0027; SCHRODER S, 1995, J CELL BIOL, V131, P895, DOI 10.1083/jcb.131.4.895; SCHUTZE MP, 1994, EMBO J, V13, P1696, DOI 10.1002/j.1460-2075.1994.tb06434.x; SCHWEIZER A, 1993, J CELL SCI, V104, P671; SCHWEIZER A, 1988, J CELL BIOL, V107, P1643, DOI 10.1083/jcb.107.5.1643; Sharma V, 1997, J MOL BIOL, V267, P433, DOI 10.1006/jmbi.1996.0863; Takahashi Y, 2000, J BIOCHEM-TOKYO, V128, P723, DOI 10.1093/oxfordjournals.jbchem.a022807; Tang BL, 1995, EUR J CELL BIOL, V68, P398; Teasdale RD, 1996, ANNU REV CELL DEV BI, V12, P27, DOI 10.1146/annurev.cellbio.12.1.27; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Tusnady GE, 1998, J MOL BIOL, V283, P489, DOI 10.1006/jmbi.1998.2107; Velloso LM, 2002, J BIOL CHEM, V277, P15979, DOI 10.1074/jbc.M112098200; Vollenweider F, 1998, J CELL BIOL, V142, P377, DOI 10.1083/jcb.142.2.377; Yamashita K, 1999, BBA-GEN SUBJECTS, V1473, P147, DOI 10.1016/S0304-4165(99)00175-0; Yerushalmi N, 2001, GENE, V265, P55, DOI 10.1016/S0378-1119(01)00347-X; Zerangue N, 1999, NEURON, V22, P537, DOI 10.1016/S0896-6273(00)80708-4; Zerangue N, 2001, P NATL ACAD SCI USA, V98, P2431, DOI 10.1073/pnas.051630198; [No title captured]	69	48	51	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 2	2003	278	18					15886	15896		10.1074/jbc.M211199200	http://dx.doi.org/10.1074/jbc.M211199200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	675EL	12609988	hybrid			2022-12-25	WOS:000182680000055
J	Song, JX				Song, JX			Tyrosine phosphorylation of the well packed EphrinB cytoplasmic beta-hairpin for reverse signaling - Structural consequences and binding properties	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-PROTEIN INTERACTIONS; NUCLEAR-MAGNETIC-RESONANCE; EPH RECEPTORS; NMR-SPECTROSCOPY; IN-VIVO; MORPHOGENESIS; LIGANDS; DOMAIN	Tyrosine phosphorylation of the 22-residue cytoplasmic region of ephrinB induces its binding to the SH2 domain of Grb4, thus initiating reverse signaling pathways controlling cytoskeleton assembly and remodeling. Recently, the region corresponding to this 22-residue motif was demonstrated to adopt a well packed beta-hairpin structure with a high conformational stability in the unphosphorylated cytoplasmic subdomain. However, because the binding to Grb4 is phosphorylation-dependent and the hairpin contains three conserved tyrosine residues that may be phosphorylated, the key events remain unknown as to how tyrosine phosphorylation affects the structure of this well packed beta-hairpin and which phosphorylation site is relevant to SH2 domain binding. By characterizing the structural and binding properties of six 22-residue SH2 domain-binding motifs with different phosphorylated sites, the present study reveals that, as shown by circular dichroism and NMR, the unphosphorylated 22-residue motif adopts a well formed beta-hairpin structure in isolation from the ephrinB cytoplasmic subdomain. However, this beta-hairpin is radically abolished by tyrosine phosphorylation, regardless of the relative location and number of Tyr residues. Unexpectedly, the peptides with either Tyr(304) or Tyr(316) phosphorylated show high affinity binding to SH2 domain, whereas the peptide with Tyr(311) phosphorylated has no detectable binding. This implies that ephrinB with Tyr(311) phosphorylated might have a currently unidentified binding partner distinct from the Grb4 protein, because Tyr(311) is known to be phosphorylated in vivo. Based on the results above, it is thus proposed that the disruption of the tight side-chain packing by tyrosine phosphorylation in the well structured region of a signaling protein may represent a general activation mechanism by which a cryptic binding site is disclosed for new protein-protein interactions.	Natl Univ Singapore, Dept Biochem, Singapore, Singapore; Natl Univ Singapore, Dept Biol Sci, Singapore, Singapore; Natl Res Council Canada, Biotechnol Res Inst, Montreal, PQ H4P 2R2, Canada	National University of Singapore; National University of Singapore; National Research Council Canada	Song, JX (corresponding author), Natl Univ Singapore, Dept Biochem, 10 Kent Rideg Crescent, Singapore, Singapore.		Song, Jianxing/J-3617-2013; Song, Jianxing/H-8026-2012	Song, Jianxing/0000-0003-0224-6322				Adams RH, 2000, TRENDS CARDIOVAS MED, V10, P183, DOI 10.1016/S1050-1738(00)00046-3; Adams RH, 2001, CELL, V104, P57, DOI 10.1016/S0092-8674(01)00191-X; [Anonymous], 1996, CIRCULAR DICHROISM C; Barbar E, 2001, BIOCHEMISTRY-US, V40, P9734, DOI 10.1021/bi010483z; BAX A, 1985, J MAGN RESON, V65, P355, DOI 10.1016/0022-2364(85)90018-6; Cowan CA, 2002, TRENDS CELL BIOL, V12, P339, DOI 10.1016/S0962-8924(02)02317-6; Cowan CA, 2001, NATURE, V413, P174, DOI 10.1038/35093123; Dodelet VC, 2000, ONCOGENE, V19, P5614, DOI 10.1038/sj.onc.1203856; Dyson HJ, 1996, ANNU REV PHYS CHEM, V47, P369, DOI 10.1146/annurev.physchem.47.1.369; Flanagan JG, 1998, ANNU REV NEUROSCI, V21, P309, DOI 10.1146/annurev.neuro.21.1.309; Himanen JP, 2003, TRENDS NEUROSCI, V26, P46, DOI 10.1016/S0166-2236(02)00005-X; Holder N, 1999, DEVELOPMENT, V126, P2033; JEENER J, 1979, J CHEM PHYS, V71, P4546, DOI 10.1063/1.438208; JOHNSON LN, 1993, ANNU REV BIOPH BIOM, V22, P199, DOI 10.1146/annurev.bb.22.060193.001215; Kalo MS, 2001, J BIOL CHEM, V276, P38940, DOI 10.1074/jbc.M105815200; Kullander K, 2001, NEURON, V29, P73, DOI 10.1016/S0896-6273(01)00181-7; Kullander K, 2002, NAT REV MOL CELL BIO, V3, P475, DOI 10.1038/nrm856; Lu Q, 2001, CELL, V105, P69, DOI 10.1016/S0092-8674(01)00297-5; Marks F., 1996, PROTEIN PHOSPHORYLAT; Mellitzer G, 2000, CURR OPIN NEUROBIOL, V10, P400, DOI 10.1016/S0959-4388(00)00095-7; MORTISHIRESMITH RJ, 1995, BIOCHEMISTRY-US, V34, P7603, DOI 10.1021/bi00023a006; Murai KK, 2002, NEURON, V33, P159, DOI 10.1016/S0896-6273(02)00565-2; Palmer A, 2002, MOL CELL, V9, P725, DOI 10.1016/S1097-2765(02)00488-4; Patel BN, 2002, CURR OPIN CELL BIOL, V14, P221, DOI 10.1016/S0955-0674(02)00308-3; Pawson T, 2001, TRENDS CELL BIOL, V11, P504, DOI 10.1016/S0962-8924(01)02154-7; Sattler M, 1999, PROG NUCL MAG RES SP, V34, P93, DOI 10.1016/S0079-6565(98)00025-9; Song JX, 1999, NAT STRUCT BIOL, V6, P129, DOI 10.1038/5815; Song JX, 2002, BIOCHEMISTRY-US, V41, P10942, DOI 10.1021/bi025815u; Song JX, 1998, BIOCHEM CELL BIOL, V76, P177; Steinmetz MO, 2001, EMBO REP, V2, P505, DOI 10.1093/embo-reports/kve105; Szilak L, 1997, NAT STRUCT BIOL, V4, P112, DOI 10.1038/nsb0297-112; Tanaka M, 2003, EMBO J, V22, P847, DOI 10.1093/emboj/cdg088; Tholey A, 1999, BIOPHYS J, V76, P76, DOI 10.1016/S0006-3495(99)77179-1; WAGNER G, 1982, J MOL BIOL, V155, P347, DOI 10.1016/0022-2836(82)90009-2; Wuthrich K, 1986, NMR PROTEINS NUCL AC; Zhang OW, 1997, J MOL BIOL, V272, P9, DOI 10.1006/jmbi.1997.1219; Zuiderweg ERP, 2002, BIOCHEMISTRY-US, V41, P1, DOI 10.1021/bi011870b	37	18	18	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 4	2003	278	27					24714	24720		10.1074/jbc.M210625200	http://dx.doi.org/10.1074/jbc.M210625200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	695HJ	12606549	hybrid, Green Submitted			2022-12-25	WOS:000183824800058
J	Bianconi, ML				Bianconi, ML			Calorimetric determination of thermodynamic parameters of reaction reveals different enthalpic compensations of the yeast hexokinase isozymes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARBON CATABOLITE REPRESSION; SACCHAROMYCES-CEREVISIAE; REGULATORY ELEMENTS; CATALYTIC-ACTIVITY; HXK2 GENES; GLUCOSE; BINDING; PII; PHOSPHORYLATION; DISSOCIATION	The change in enthalpy and rate constants for the reactions of yeast hexokinase isozymes, PI (Hxk1) and PII (Hxk2), was determined at pH 7.6 and 25 degreesC by isothermal titration calorimetry. The reactions were done in five buffer systems with enthalpy of protonation varying from -1.22 kcal/mol ( phosphate) to -11.51 kcal/mol ( Tris), allowing the determination of the number of protons released during glucose phosphorylation. The reaction is exothermic for both isozymes with a small, but significant ( p < 0.0001), difference in the enthalpy of reaction (Delta H-R), with an Delta H-R of -5.1 +/- 0.2 ( mean +/- S. D.) kcal/mol for Hxk1, and an Delta H-R of -3.3 +/- 0.3 (mean +/- S. D.) kcal/mol for Hxk2. The K-m for ATP determined by ITC was very similar to those reported in the literature for both isozymes. The effect of NaCl and KCl, from 0 to 200 mM, showed that although the rate of reaction decreases with increasing ionic strength, no change in the Delta H-R was observed suggesting an entropic nature for the ionic strength. The differences in Delta H-R obtained here for both isozymes strongly suggest that, besides glucose phosphorylation, another side reaction such as ATP hydrolysis and/or enzyme phosphorylation is taking place.	Univ Fed Rio de Janeiro, Inst Ciencias Biomed, Dept Bioquim Med, Predio CCS, BR-21941590 Rio De Janeiro, Brazil	Universidade Federal do Rio de Janeiro	Bianconi, ML (corresponding author), Univ Fed Rio de Janeiro, Inst Ciencias Biomed, Dept Bioquim Med, Predio CCS, Bloco E,Sala 38, BR-21941590 Rio De Janeiro, Brazil.	bianconi@bioqmed.ufrj.br						ANDERSON CM, 1978, J MOL BIOL, V123, P207, DOI 10.1016/0022-2836(78)90321-2; ANDERSON CM, 1978, J MOL BIOL, V123, P1, DOI 10.1016/0022-2836(78)90373-X; BARCLAY K, 1975, ANAL LETT, V8, P33; BENNETT WS, 1978, P NATL ACAD SCI USA, V75, P4848, DOI 10.1073/pnas.75.10.4848; Chaves RS, 1999, BIOCHEM BIOPH RES CO, V254, P345, DOI 10.1006/bbrc.1998.9954; de la Cera T, 2002, J MOL BIOL, V319, P703, DOI 10.1016/S0022-2836(02)00377-7; DELAFUEN.G, 1970, EUR J BIOCHEM, V16, P226; deMeis L, 1997, FEBS LETT, V406, P201, DOI 10.1016/S0014-5793(97)00244-5; DERECHIN M, 1972, BIOCHEMISTRY-US, V11, P1793, DOI 10.1021/bi00760a009; DeWinde JH, 1996, EUR J BIOCHEM, V241, P633; Dynesen J, 1998, APPL MICROBIOL BIOT, V50, P579, DOI 10.1007/s002530051338; EASTERBY JS, 1972, EUR J BIOCHEM, V28, P241, DOI 10.1111/j.1432-1033.1972.tb01907.x; ENTIAN KD, 1982, J BIOL CHEM, V257, P870; ENTIAN KD, 1980, MOL GEN GENET, V178, P633, DOI 10.1007/BF00337871; FROHLICH KU, 1985, GENE, V36, P105, DOI 10.1016/0378-1119(85)90074-5; Fukada H, 1998, PROTEINS, V33, P159, DOI 10.1002/(SICI)1097-0134(19981101)33:2<159::AID-PROT2>3.3.CO;2-F; GANCEDO JM, 1992, EUR J BIOCHEM, V206, P297, DOI 10.1111/j.1432-1033.1992.tb16928.x; Herrero P, 1998, FEBS LETT, V434, P71, DOI 10.1016/S0014-5793(98)00872-2; Herrero P, 1996, NUCLEIC ACIDS RES, V24, P1822, DOI 10.1093/nar/24.10.1822; HOGGETT JG, 1976, EUR J BIOCHEM, V66, P65, DOI 10.1111/j.1432-1033.1976.tb10426.x; HOGGETT JG, 1976, EUR J BIOCHEM, V68, P347, DOI 10.1111/j.1432-1033.1976.tb10821.x; Hohmann S, 1999, MICROBIOL-UK, V145, P703, DOI 10.1099/13500872-145-3-703; KAJI A, 1965, J BIOL CHEM, V240, P4454; KODAMA T, 1982, J BIOL CHEM, V257, P4238; KOPETZKI E, 1985, GENE, V39, P95, DOI 10.1016/0378-1119(85)90113-1; Kraakman LS, 1999, BIOCHEM J, V343, P159, DOI 10.1042/0264-6021:3430159; KRIEGEL TM, 1994, BIOCHEMISTRY-US, V33, P148, DOI 10.1021/bi00167a019; Lonhienne T, 2001, BBA-PROTEIN STRUCT M, V1545, P349, DOI 10.1016/S0167-4838(00)00296-X; MA H, 1986, MOL CELL BIOL, V6, P4046, DOI 10.1128/MCB.6.11.4046; MartinezCampa C, 1996, FEMS MICROBIOL LETT, V137, P69, DOI 10.1016/0378-1097(96)00034-1; MAYES EL, 1983, EUR J BIOCHEM, V133, P127, DOI 10.1111/j.1432-1033.1983.tb07437.x; Mayordomo I, 2001, YEAST, V18, P923, DOI 10.1002/yea.737; MILLAR NC, 1987, BIOCHEM J, V248, P683, DOI 10.1042/bj2480683; MONTEROLOMELI M, 1992, BIOCHIM BIOPHYS ACTA, V1120, P305, DOI 10.1016/0167-4838(92)90252-9; Moreno F, 2002, FEMS MICROBIOL REV, V26, P83, DOI 10.1111/j.1574-6976.2002.tb00600.x; Moreno-Herrero F, 1999, FEBS LETT, V459, P427, DOI 10.1016/S0014-5793(99)01289-2; MORIN PE, 1991, BIOCHEMISTRY-US, V30, P8494, DOI 10.1021/bi00098a030; Randez-Gil F, 1998, FEBS LETT, V425, P475, DOI 10.1016/S0014-5793(98)00289-0; Rodriguez A, 2001, BIOCHEM J, V355, P625, DOI 10.1042/bj3550625; ROSE M, 1991, EUR J BIOCHEM, V199, P511, DOI 10.1111/j.1432-1033.1991.tb16149.x; Saboury AA, 2002, J BIOCHEM MOL BIOL, V35, P302, DOI 10.5483/BMBRep.2002.35.3.302; SCHMIDT JJ, 1973, ARCH BIOCHEM BIOPHYS, V158, P458, DOI 10.1016/0003-9861(73)90537-7; SHILL JP, 1974, BIOCHEMISTRY-US, V13, P3864, DOI 10.1021/bi00716a007; SMITH TF, 1981, J MOL BIOL, V147, P195, DOI 10.1016/0022-2836(81)90087-5; STEITZ TA, 1977, J BIOL CHEM, V252, P4494; TAKAHASHI K, 1981, BIOCHEMISTRY-US, V20, P4693, DOI 10.1021/bi00519a026; Todd MJ, 2001, ANAL BIOCHEM, V296, P179, DOI 10.1006/abio.2001.5218; VOJTEK AB, 1990, EUR J BIOCHEM, V190, P371, DOI 10.1111/j.1432-1033.1990.tb15585.x; WILLIAMS BA, 1993, J ORG CHEM, V58, P3507, DOI 10.1021/jo00065a010; WISEMAN T, 1989, ANAL BIOCHEM, V179, P131, DOI 10.1016/0003-2697(89)90213-3; WOMACK F, 1978, ARCH BIOCHEM BIOPHYS, V191, P742, DOI 10.1016/0003-9861(78)90415-0; YOURTEE DM, 1975, ANAL LETT, V8, P41, DOI 10.1080/00032717508060359	52	66	68	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 23	2003	278	21					18709	18713		10.1074/jbc.M211103200	http://dx.doi.org/10.1074/jbc.M211103200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	679PY	12611889	hybrid			2022-12-25	WOS:000182932200002
J	Hotchkiss, KA; Ashton, AW; Schwartz, EL				Hotchkiss, KA; Ashton, AW; Schwartz, EL			Thymidine phosphorylase and 2-deoxyribose stimulate human endothelial cell migration by specific activation of the integrins alpha(5)beta(1) and alpha(V)beta(3)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FOCAL ADHESION KINASE; RIBOSE-BINDING-PROTEIN; GROWTH-FACTOR; TUMOR-GROWTH; TYROSINE PHOSPHORYLATION; FIBRONECTIN RECEPTOR; ANGIOGENIC ACTIVITY; MESODERMAL DEFECTS; BLOOD-VESSELS; MICE LACKING	Thymidine phosphorylase is an angiogenic factor that is frequently overexpressed in solid tumors, in rheumatoid arthritis, and in response to inflammatory cytokines. Our previous studies showed that cells expressing thymidine phosphorylase stimulated endothelial cell migration in vitro. This was a consequence of the intracellular metabolism of thymidine by thymidine phosphorylase and subsequent extracellular release of 2-deoxyribose. The mechanisms by which 2-deoxyribose might mediate thymidine phosphorylase-induced cell migration in vitro, however, are obscure. Here we show that both thymidine phosphorylase and 2-deoxyribose stimulated the formation of focal adhesions and the tyrosine 397 phosphorylation of focal adhesion kinase in human umbilical vein endothelial cells. Although similar actions occurred upon treatment with the angiogenic factor vascular endothelial growth factor (VEGF), thymidine phosphorylase differed from VEGF in that its effect on endothelial cell migration was blocked by antibodies to either integrin alpha(5)beta(1) or alpha(v)beta(3), whereas VEGF-induced endothelial cell migration was only blocked by the alpha(v)beta(3) antibody. Further, thymidine phosphorylase and 2-deoxyribose, but not VEGF, increased the association of both focal adhesion kinase and the focal adhesion-associated protein vinculin with integrin alpha(5)beta(1) and, in intact cells, increased the co-localization of focal adhesion kinase with alpha(5)beta(1). Thymidine phosphorylase and 2-deoxyribose-induced focal adhesion kinase phosphorylation was blocked by the antibodies to alpha(5)beta(1) and alpha(v)beta(3), directly linking the migration and signaling components of thymidine phosphorylase and 2-deoxyribose action. Cell surface expression of alpha(5)beta(1) was also increased by thymidine phosphorylase and 2-deoxyribose. These experiments are the first to demonstrate a direct effect of thymidine phosphorylase and 2-deoxyribose on signaling pathways associated with endothelial cell migration.	Albert Einstein Coll Med, Dept Oncol, Bronx, NY 10467 USA; Albert Einstein Coll Med, Dept Med Cardiol, Bronx, NY 10467 USA	Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine	Schwartz, EL (corresponding author), Montefiore Med Ctr, Albert Einstein Canc Ctr, Dept Oncol, 111 E 210th St, Bronx, NY 10467 USA.				NATIONAL CANCER INSTITUTE [R01CA054422, R01CA089352] Funding Source: NIH RePORTER; NCI NIH HHS [R01-CA89352, R01-CA54422, P01-CA13330] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AKSAMIT RR, 1974, BIOCHEMISTRY-US, V13, P4473, DOI 10.1021/bi00719a001; ASAI K, 1992, J BIOL CHEM, V267, P20311; Ashton AW, 1999, J BIOL CHEM, V274, P35562, DOI 10.1074/jbc.274.50.35562; Bader BL, 1998, CELL, V95, P507, DOI 10.1016/S0092-8674(00)81618-9; BLYSTONE SD, 1995, J CELL BIOL, V130, P745, DOI 10.1083/jcb.130.3.745; BLYSTONE SD, 1994, J CELL BIOL, V127, P1129, DOI 10.1083/jcb.127.4.1129; BODARY SC, 1990, J BIOL CHEM, V265, P5938; Bretscher MS, 1996, CELL, V85, P465, DOI 10.1016/S0092-8674(00)81246-5; BROOKS PC, 1994, SCIENCE, V264, P569, DOI 10.1126/science.7512751; BROOKS PC, 1994, CELL, V79, P1157, DOI 10.1016/0092-8674(94)90007-8; Burridge K, 1996, ANNU REV CELL DEV BI, V12, P463, DOI 10.1146/annurev.cellbio.12.1.463; CALALB MB, 1995, MOL CELL BIOL, V15, P954; Carmeliet P, 2000, NATURE, V407, P249, DOI 10.1038/35025220; DRAKE CJ, 1995, J CELL SCI, V108, P2655; Eliceiri BP, 2001, CURR OPIN CELL BIOL, V13, P563, DOI 10.1016/S0955-0674(00)00252-0; Ferrara N, 1997, ENDOCR REV, V18, P4, DOI 10.1210/er.18.1.4; FINNIS C, 1993, EUR J BIOCHEM, V212, P201, DOI 10.1111/j.1432-1033.1993.tb17651.x; FOLKMAN J, 1992, J BIOL CHEM, V267, P10931; FOLKMAN J, 1995, NAT MED, V1, P27, DOI 10.1038/nm0195-27; FRIEDLANDER M, 1995, SCIENCE, V270, P1500, DOI 10.1126/science.270.5241.1500; FURUKAWA T, 1992, NATURE, V356, P668, DOI 10.1038/356668a0; GEORGE EL, 1993, DEVELOPMENT, V119, P1079; Giancotti FG, 1999, SCIENCE, V285, P1028, DOI 10.1126/science.285.5430.1028; Goh KL, 1997, DEVELOPMENT, V124, P4309; GROARKE JM, 1983, J BIOL CHEM, V258, P2952; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Hanks SK, 1997, BIOESSAYS, V19, P137, DOI 10.1002/bies.950190208; HARAGUCHI M, 1994, NATURE, V368, P198, DOI 10.1038/368198a0; Hotchkiss KA, 2003, CANCER RES, V63, P527; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; Ikeda R, 2002, BIOCHEM BIOPH RES CO, V291, P806, DOI 10.1006/bbrc.2002.6432; ISHIKAWA F, 1989, NATURE, V338, P557, DOI 10.1038/338557a0; Kerbel R, 2002, NAT REV CANCER, V2, P727, DOI 10.1038/nrc905; Kim E, 2002, BBA-MOL CELL RES, V1593, P9, DOI 10.1016/S0167-4889(02)00275-6; Kim S, 2000, J BIOL CHEM, V275, P33920, DOI 10.1074/jbc.M003668200; Kim S, 2000, AM J PATHOL, V156, P1345, DOI 10.1016/S0002-9440(10)65005-5; Kletsas D, 1998, BIOCHEM BIOPH RES CO, V243, P416, DOI 10.1006/bbrc.1997.7975; Lahav J, 2002, BLOOD, V100, P2472, DOI 10.1182/blood-2001-12-0339; LANGUINO LR, 1989, J CELL BIOL, V109, P2455, DOI 10.1083/jcb.109.5.2455; Lauffenburger DA, 1996, CELL, V84, P359, DOI 10.1016/S0092-8674(00)81280-5; LUCCIONI C, 1994, INT J CANCER, V58, P517, DOI 10.1002/ijc.2910580411; Maeda K, 1996, BRIT J CANCER, V73, P884, DOI 10.1038/bjc.1996.177; McLean GW, 2000, J BIOL CHEM, V275, P23333, DOI 10.1074/jbc.M909322199; MILLAUER B, 1993, CELL, V72, P835, DOI 10.1016/0092-8674(93)90573-9; MOGHADDAM A, 1992, BIOCHEMISTRY-US, V31, P12141, DOI 10.1021/bi00163a024; MOGHADDAM A, 1995, P NATL ACAD SCI USA, V92, P998, DOI 10.1073/pnas.92.4.998; O'Byrne KJ, 2000, BRIT J CANCER, V82, P1427, DOI 10.1054/bjoc.1999.1129; Paik JH, 2001, J BIOL CHEM, V276, P11830, DOI 10.1074/jbc.M009422200; Parsons JT, 2000, ONCOGENE, V19, P5606, DOI 10.1038/sj.onc.1203877; PYTELA R, 1985, CELL, V40, P191, DOI 10.1016/0092-8674(85)90322-8; Relf M, 1997, CANCER RES, V57, P963; Reynolds LE, 2002, NAT MED, V8, P27, DOI 10.1038/nm0102-27; Rodriguez-Fernandez JL, 1998, J BIOL CHEM, V273, P19321, DOI 10.1074/jbc.273.30.19321; Ruest PJ, 2000, CELL GROWTH DIFFER, V11, P41; SCHALLER MD, 1992, P NATL ACAD SCI USA, V89, P5192, DOI 10.1073/pnas.89.11.5192; Schlaepfer DD, 1999, PROG BIOPHYS MOL BIO, V71, P435, DOI 10.1016/S0079-6107(98)00052-2; Schwartz MA, 2001, TRENDS CELL BIOL, V11, P466, DOI 10.1016/S0962-8924(01)02152-3; Senger DR, 1996, AM J PATHOL, V149, P293; Simon KO, 1997, J BIOL CHEM, V272, P29380, DOI 10.1074/jbc.272.46.29380; Soldi R, 1999, EMBO J, V18, P882, DOI 10.1093/emboj/18.4.882; SUMIZAWA T, 1993, J BIOCHEM-TOKYO, V114, P9, DOI 10.1093/oxfordjournals.jbchem.a124146; Suzuma K, 1998, INVEST OPHTH VIS SCI, V39, P1028; TAKABAYASHI Y, 1996, J NATL CANCER I, V88, P1110; Takahashi Y, 1996, J NATL CANCER I, V88, P1146, DOI 10.1093/jnci/88.16.1146; Taverna D, 2001, CANCER RES, V61, P5255; van Triest B, 2000, CLIN CANCER RES, V6, P1063; XU YL, 1994, J INVEST DERMATOL, V102, P833, DOI 10.1111/1523-1747.ep12382086; Yan BX, 2001, BIOCHEMISTRY-US, V40, P8861, DOI 10.1021/bi002902i; YANG JT, 1993, DEVELOPMENT, V119, P1093; Zhu GH, 2002, ONCOGENE, V21, P8477, DOI 10.1038/sj.onc.1206030	70	63	64	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 23	2003	278	21					19272	19279		10.1074/jbc.M212670200	http://dx.doi.org/10.1074/jbc.M212670200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	679PY	12639965	hybrid			2022-12-25	WOS:000182932200072
J	Tordjman, J; Chauvet, G; Quette, J; Beale, EG; Forest, C; Antoine, B				Tordjman, J; Chauvet, G; Quette, J; Beale, EG; Forest, C; Antoine, B			Thiazolidinediones block fatty acid release by inducing glyceroneogenesis in fat cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADIPOSE-TISSUE; INSULIN-RESISTANCE; PPAR-GAMMA; GENE; PATHOGENESIS; ADIPOCYTES; EXPRESSION; OBESITY; PROTEIN	Thiazolidinediones are used to treat type 2 diabetes mellitus because they decrease plasma glucose, insulin, triglyceride, and fatty acid levels. Thiazolidinediones are agonists for peroxisome proliferator-activated receptor gamma, a nuclear receptor that is highly expressed in fat tissue. We identify glyceroneogenesis as a target of thiazolidinediones in cultured adipocytes and fat tissues of Wistar rats. The activation of glyceroneogenesis by thiazolidinediones occurs mainly in visceral fat, the same fat depot that is specifically implicated in the progression of obesity to type 2 diabetes. The increase in glyceroneogenesis is a result of the induction of its key enzyme, phosphoenolpyruvate carboxykinase, whose gene expression is peroxisome proliferator-activated receptor gamma-dependent in adipocytes. The main role of this metabolic pathway is to allow the re-esterification of fatty acids via a futile cycle in adipocytes, thus lowering fatty acid release into the plasma. The importance of such a fatty acid re-esterification process in the control of lipid homeostasis is highlighted by the existence of a second thiazolidinedione-induced pathway involving glycerol kinase. We show that glyceroneogenesis accounts for at least 75% of the whole thiazolidinedione effect. Because elevated plasma fatty acids promote insulin resistance, these results suggest that the glyceroneogenesis-dependent fatty acid-lowering effect of thiazolidinediones could be an essential aspect of the antidiabetic action of these drugs.	Univ Paris 05, Ctr Univ, INSERM, UMRS 530, F-75006 Paris, France; Texas Tech Univ, Hlth Sci Ctr, Dept Biochem & Cell Biol, Lubbock, TX 79430 USA	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Texas Tech University System; Texas Tech University; Texas Tech University Health Science Center	Antoine, B (corresponding author), Univ Paris 05, Ctr Univ, INSERM, UMRS 530, 45 Rue St Peres, F-75006 Paris, France.	benedicte.antoine@biomedicale.univ-paris5.fr	Beale, Elmus/GNM-8181-2022	Beale, Elmus/0000-0002-7758-0600; Forest, Claude/0000-0003-3401-8148	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM039895] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01-GM39895] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Beale EG, 2002, FASEB J, V16, P1695, DOI 10.1096/fj.02-0407rev; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Boden G, 1997, DIABETES, V46, P3, DOI 10.2337/diabetes.46.1.3; Boyko EJ, 2000, DIABETES CARE, V23, P465, DOI 10.2337/diacare.23.4.465; CHANG HC, 1966, J BIOL CHEM, V241, P2413; Chao L, 2000, J CLIN INVEST, V106, P1221, DOI 10.1172/JCI11245; Franckhauser S, 2002, DIABETES, V51, P624, DOI 10.2337/diabetes.51.3.624; Glorian M, 2001, BIOCHIMIE, V83, P933, DOI 10.1016/S0300-9084(01)01343-8; Guan HP, 2002, NAT MED, V8, P1122, DOI 10.1038/nm780; HUBBARD RW, 1969, LIPIDS, V5, P114; Lebovitz HE, 2001, J CLIN ENDOCR METAB, V86, P280, DOI 10.1210/jc.86.1.280; LEE Y, 1994, P NATL ACAD SCI USA, V91, P10878, DOI 10.1073/pnas.91.23.10878; LEHMANN JM, 1995, J BIOL CHEM, V270, P12953, DOI 10.1074/jbc.270.22.12953; MACDONALD MJ, 1981, BIOCHIM BIOPHYS ACTA, V663, P302, DOI 10.1016/0005-2760(81)90216-2; Martin G, 1997, J BIOL CHEM, V272, P28210, DOI 10.1074/jbc.272.45.28210; MCGARRY JD, 1992, SCIENCE, V258, P766, DOI 10.1126/science.1439783; Oakes ND, 2001, DIABETES, V50, P1158, DOI 10.2337/diabetes.50.5.1158; Olswang Y, 2002, P NATL ACAD SCI USA, V99, P625, DOI 10.1073/pnas.022616299; RANDLE PJ, 1963, LANCET, V1, P785; RESHEF L, 1969, J BIOL CHEM, V244, P1994; RESHEFF L, 1970, J BIOL CHEM, V245, P5979; Rosen ED, 2001, J BIOL CHEM, V276, P37731, DOI 10.1074/jbc.R100034200; Saltiel AR, 1996, DIABETES, V45, P1661, DOI 10.2337/diabetes.45.12.1661; TCHKONIA T, 2001, CURR OPIN ENDOCRINOL, V8, P227; Unger RH, 2001, FASEB J, V15, P312, DOI 10.1096/fj.00-0590; Van Hermelen V, 1999, J BIOL CHEM, V274, P18243, DOI 10.1074/jbc.274.26.18243; Way JM, 2001, ENDOCRINOLOGY, V142, P1269, DOI 10.1210/en.142.3.1269	27	149	155	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 23	2003	278	21					18785	18790		10.1074/jbc.M206999200	http://dx.doi.org/10.1074/jbc.M206999200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	679PY	12644461	hybrid			2022-12-25	WOS:000182932200012
J	Muller, C; Richter, S; Rinas, U				Muller, C; Richter, S; Rinas, U			Kinetics control preferential heterodimer formation of platelet-derived growth factor from unfolded A- and B-chains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECOMBINANT ESCHERICHIA-COLI; INTERCHAIN DISULFIDE BONDS; CRYSTAL-STRUCTURE; A-CHAIN; PDGF; RENATURATION; PURIFICATION; STABILITY; SEQUENCE; RECEPTOR	The folding and assembly of platelet-derived growth factor (PDGF), a potent mitogen involved in wound-healing processes and member of the cystine knot growth factor family, was studied. The kinetics of the formation of disulfide-bonded dimers were investigated under redox reshuffling conditions starting either from unfolded and reduced PDGF-A- or B-chains or an equimolar mixture of both chains. It is shown that in all cases the formation of disulfide-bonded dimers is a very slow process occurring in the time scale of hours with a first-order rate-determining step. The formation of disulfide-bonded PDGF-AA or PDGF-BB homodimers displayed identical kinetics, indicating that both monomeric forms as well as the dimerized homodimer have similar folding and assembly pathways. In contrast, the formation of the heterodimer occurred three times more rapidly compared with the formation of the homodimers. As both monomeric forms revealed similar renaturation kinetics, it can be concluded that the first-order rate-determining folding step does not occur during monomer folding but must be attributed to conformational rearrangements of the dimerized, not yet disulfide-bonded protein. These structural rearrangements allow a more rapid formation of intermolecular disulfide bonds between the two different monomers of a heterodimer compared with the formation of the disulfide bonds between two identical monomers. The preferential formation of disulfide-bonded heterodimers from an equimolar mixture of unfolded A- and B-chains is thus a kinetically controlled process. Moreover, similar activation enthalpies for the formation of all different isoforms suggest that faster heterodimerization is controlled by entropic factors.	GBF Natl Res Ctr Biotechnol, Div Biochem Engn, D-38124 Braunschweig, Germany	Helmholtz Association; Helmholtz-Center for Infection Research	Rinas, U (corresponding author), GBF Natl Res Ctr Biotechnol, Div Biochem Engn, Mascheroder Weg 1, D-38124 Braunschweig, Germany.			Rinas, Ursula/0000-0003-4940-5749				BETSHOLTZ C, 1986, NATURE, V320, P695, DOI 10.1038/320695a0; BUCHNER J, 1991, BIO-TECHNOL, V9, P157, DOI 10.1038/nbt0291-157; Gilbertson DG, 2001, J BIOL CHEM, V276, P27406, DOI 10.1074/jbc.M101056200; HAMMACHER A, 1988, J BIOL CHEM, V263, P16493; HANNINK M, 1989, BIOCHIM BIOPHYS ACTA, V989, P1, DOI 10.1016/0304-419X(89)90031-0; HELDIN CH, 1992, EMBO J, V11, P4251, DOI 10.1002/j.1460-2075.1992.tb05523.x; HELDIN CH, 1989, TRENDS GENET, V5, P108, DOI 10.1016/0168-9525(89)90040-1; Hinck AP, 1996, BIOCHEMISTRY-US, V35, P8517, DOI 10.1021/bi9604946; HOPPE J, 1990, EUR J BIOCHEM, V187, P207, DOI 10.1111/j.1432-1033.1990.tb15296.x; ISAACS NW, 1995, CURR OPIN STRUC BIOL, V5, P391, DOI 10.1016/0959-440X(95)80102-2; JAENICKE R, 1991, BIOCHEMISTRY-US, V30, P3147, DOI 10.1021/bi00227a001; JAENICKE R, 1979, BIOCHEMISTRY-US, V18, P1217, DOI 10.1021/bi00574a016; Jaenicke R, 1986, Methods Enzymol, V131, P218; KENNEY WC, 1994, J BIOL CHEM, V269, P12351; LaRochelle WJ, 2001, NAT CELL BIOL, V3, P517, DOI 10.1038/35074593; MEYERINGOLD W, 1993, TRENDS BIOTECHNOL, V11, P387, DOI 10.1016/0167-7799(93)90098-T; MEYERINGOLD W, 1995, CELL BIOL INT, V19, P389, DOI 10.1006/cbir.1995.1084; MILLA ME, 1994, BIOCHEMISTRY-US, V33, P1125, DOI 10.1021/bi00171a011; Muller C, 1999, J CHROMATOGR A, V855, P203, DOI 10.1016/S0021-9673(99)00660-3; Muller YA, 2002, J BIOL CHEM, V277, P43410, DOI 10.1074/jbc.M206438200; OEFNER C, 1992, EMBO J, V11, P3921, DOI 10.1002/j.1460-2075.1992.tb05485.x; OSTMAN A, 1988, J BIOL CHEM, V263, P16202; PHILO JS, 1993, BIOCHEMISTRY-US, V32, P10812, DOI 10.1021/bi00091a036; PRESTRELSKI SJ, 1994, INT J PEPT PROT RES, V44, P357; RAINES EW, 1985, METHOD ENZYMOL, V109, P749; Rattenholl A, 2001, J MOL BIOL, V305, P523, DOI 10.1006/jmbi.2000.4295; ROSS R, 1986, CELL, V46, P155, DOI 10.1016/0092-8674(86)90733-6; RUDOLPH R, 1986, BIOCHEMISTRY-US, V25, P1662, DOI 10.1021/bi00355a033; Scheufler C, 1999, J MOL BIOL, V287, P103, DOI 10.1006/jmbi.1999.2590; SCHNEPPE B, 1994, GENE, V143, P201, DOI 10.1016/0378-1119(94)90097-3; SEEGER A, 1995, ENZYME MICROB TECH, V17, P947, DOI 10.1016/0141-0229(94)00123-9	31	4	4	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 16	2003	278	20					18330	18335		10.1074/jbc.M212317200	http://dx.doi.org/10.1074/jbc.M212317200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677YX	12615918	hybrid			2022-12-25	WOS:000182838300097
J	Wolk, K; Kunz, S; Crompton, NEA; Volk, HD; Sabat, R				Wolk, K; Kunz, S; Crompton, NEA; Volk, HD; Sabat, R			Multiple mechanisms of reduced major histocompatibility complex class II expression in endotoxin tolerance	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							T-CELL SELECTION; INVARIANT CHAIN; ANTIGEN PRESENTATION; MICE LACKING; IFN-GAMMA; MONOCYTES; TRANSPORT; ALPHA; INTERLEUKIN-10; DEGRADATION	Patients after polytrauma, burns, or septic shock frequently develop a life-threatening immunodeficiency. This state is associated with specific functional alterations of monocytic cells. We previously proposed endotoxin tolerance, the monocyte state after acute response to lipopolysaccharide, as a respective model system. One major feature in both the clinical situation and the in vitro model is the dramatic down-regulation of monocyte major histocompatibility complex (MHC) class II surface expression, which is associated with impaired antigen presentation capacity. This study focused on the mechanisms behind reduced MHC class II expression in endotoxin tolerance. Endotoxin priming provoked a decrease of monocyte intracellular MHC class II. It also led to a reduced expression of the chaperonic invariant chain and to an inhibited synthesis of the major lysosomal enzyme for final cleavage of the invariant chain going along with a relative accumulation of p10. The expression of HLA-DM necessary for loading MHC class II with antigenic peptide was also decreased. Additionally, reduced export of MHC class II alphabeta complexes to the cell surface was observed. The down-regulation of HLA-DR, invariant chain, and HLA-DM was regulated at the mRNA level and may be the consequence of reduced class II transactivator expression observed in this study. The simultaneous interference at different regulatory levels may explain the uniquely strong and long lasting MHC class II down-modulating effect of endotoxin priming compared with transforming growth factor-beta and interleukin-10. These results not only contribute to a better understanding of experimental endotoxin tolerance but may also give rise to new therapeutics for temporary immunodeficiency and, conversely, for MHC class II-dependent diseases such as autoimmunity and transplant rejection.	Humboldt Univ, Med Sch Charite, Inst Med Immunol, D-10117 Berlin, Germany; Paul Scherrer Inst, CH-5232 Villigen, Switzerland	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Swiss Federal Institutes of Technology Domain; Paul Scherrer Institute	Sabat, R (corresponding author), Humboldt Univ, Med Sch Charite, Interdisciplinary Grp Mol Immunopathol, Schumannstr 20-21, D-10098 Berlin, Germany.	robert.sabat@charite.de	Wolk, Kerstin/O-1205-2013; volk, hans-dieter/AAV-8053-2021	volk, hans-dieter/0000-0002-7743-6668; Wolk, Kerstin/0000-0002-7689-4130				Alfonso C, 2000, ANNU REV IMMUNOL, V18, P113, DOI 10.1146/annurev.immunol.18.1.113; Angus D C, 2001, Crit Care Med, V29, P1303, DOI 10.1097/00003246-200107000-00002; BIKOFF EK, 1993, J EXP MED, V177, P1699, DOI 10.1084/jem.177.6.1699; Brachet V, 1997, J CELL BIOL, V137, P51, DOI 10.1083/jcb.137.1.51; Chang CH, 1996, IMMUNITY, V4, P167, DOI 10.1016/S1074-7613(00)80681-0; CRESSWELL P, 1994, ANNU REV IMMUNOL, V12, P259, DOI 10.1146/annurev.immunol.12.1.259; CZARNIECKI CW, 1988, J IMMUNOL, V140, P4217; Docke WD, 1997, NAT MED, V3, P678, DOI 10.1038/nm0697-678; Fiebiger E, 2001, J EXP MED, V193, P881, DOI 10.1084/jem.193.8.881; FungLeung WP, 1996, SCIENCE, V271, P1278, DOI 10.1126/science.271.5253.1278; Galati G, 1997, CYTOMETRY, V27, P77, DOI 10.1002/(SICI)1097-0320(19970101)27:1<77::AID-CYTO10>3.0.CO;2-P; HAAS JG, 1990, P NATL ACAD SCI USA, V87, P9563, DOI 10.1073/pnas.87.24.9563; HENRICSON BE, 1993, INFECT IMMUN, V61, P2325, DOI 10.1128/IAI.61.6.2325-2333.1993; Karp CL, 1998, EUR J IMMUNOL, V28, P3128, DOI 10.1002/(SICI)1521-4141(199810)28:10<3128::AID-IMMU3128>3.0.CO;2-T; Kern F, 1998, NAT MED, V4, P975, DOI 10.1038/nm0898-975; Koppelman B, 1997, IMMUNITY, V7, P861, DOI 10.1016/S1074-7613(00)80404-5; Nakagawa T, 1998, SCIENCE, V280, P450, DOI 10.1126/science.280.5362.450; Nakagawa TY, 1999, IMMUNITY, V10, P207, DOI 10.1016/S1074-7613(00)80021-7; NEEFJES JJ, 1992, EMBO J, V11, P411, DOI 10.1002/j.1460-2075.1992.tb05069.x; Pierre P, 1998, CELL, V93, P1135, DOI 10.1016/S0092-8674(00)81458-0; Piskurich JF, 1998, J IMMUNOL, V160, P233; RANDOW F, 1995, J EXP MED, V181, P1887, DOI 10.1084/jem.181.5.1887; Riese RJ, 2000, CURR OPIN IMMUNOL, V12, P107, DOI 10.1016/S0952-7915(99)00058-8; Shi GP, 2000, J EXP MED, V191, P1177, DOI 10.1084/jem.191.7.1177; Shi GP, 1999, IMMUNITY, V10, P197, DOI 10.1016/S1074-7613(00)80020-5; VIVILLE S, 1993, CELL, V72, P635, DOI 10.1016/0092-8674(93)90081-Z; Wolk K, 2002, J IMMUNOL, V168, P5397, DOI 10.4049/jimmunol.168.11.5397; Wolk K, 2000, BLOOD, V96, P218, DOI 10.1182/blood.V96.1.218.013k04_218_223; WRAIGHT CJ, 1990, J BIOL CHEM, V265, P5787; Wysocka M, 2001, J IMMUNOL, V166, P7504, DOI 10.4049/jimmunol.166.12.7504; ZHANG XK, 1993, J EXP MED, V177, P511, DOI 10.1084/jem.177.2.511; ZIEGLERHEITBROCK HWL, 1992, IMMUNOLOGY, V75, P264	32	61	64	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 16	2003	278	20					18030	18036		10.1074/jbc.M207714200	http://dx.doi.org/10.1074/jbc.M207714200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677YX	12637533	hybrid			2022-12-25	WOS:000182838300057
J	Suzuki, YJ; Day, RM; Tan, CC; Sandven, TH; Liang, QR; Molkentin, JD; Fanburg, BL				Suzuki, YJ; Day, RM; Tan, CC; Sandven, TH; Liang, QR; Molkentin, JD; Fanburg, BL			Activation of GATA-4 by serotonin in pulmonary artery smooth muscle cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR; EXON/INTRON ORGANIZATION; PROMOTER ACTIVITY; SUPEROXIDE ANION; CYCLIN D2; AP-1 SITE; IN-VIVO; GENE; HYPERTENSION; EXPRESSION	Serotonin (5-hydroxytryptamine (5-HT)) is a mitogen of pulmonary artery smooth muscle cells (PASMC) and plays an important role in the development of pulmonary hypertension. Signal transduction initiated by 5-HT involves serotonin transporter-dependent generation of reactive oxygen species and activation of the MEK-ERK pathway. However, the downstream transcriptional regulatory components have not been identified. In systemic smooth muscle cells, GATA-6 has been shown to regulate mitogenesis by driving cells into a quiescent state, and the down-regulation of GATA-6 induces mitogenesis. Thus, the present study tested the hypothesis that 5-HT induces mitogenesis of PASMC by down-regulating GATA-6. Quiescent bovine PASMC were treated with 5-HT, and the binding activity of nuclear extracts toward GATA DNA sequence was monitored. Surprisingly, PASMC express GATA-4, and 5-HT up-regulates the GATA DNA binding activity. Pretreatment of cells with inhibitors of serotonin transporter, reactive oxygen species, and MEK blocks GATA-4 activation by 5-HT. GATA-4 is not activated when the ERK phosphorylation site is mutated, indicating that 5-HT phosphorylates GATA-4 via the MEK/ERK pathway. GATA up-regulation is also induced by other mitogens of PASMC such as endothelin-1 and platelet-derived growth factor. Dominant negative mutants of GATA-4 suppress cyclin D2 expression and cell growth, indicating that GATA-4 activation regulates PASMC proliferation. Thus, GATA-4 mediates 5-HT-induced growth of PASMC and may be an important therapeutic target for the prevention of pulmonary hypertension.	Tufts Univ, USDA, Human Nutr Res Ctr Aging, Boston, MA 02111 USA; Tufts Univ, New England Med Ctr, Tupper Res Inst, Pulm Crit Care & Sleep Div,Dept Med, Boston, MA 02111 USA; Univ Cincinnati, Childrens Hosp, Med Ctr, Dept Pediat, Cincinnati, OH 45229 USA	Tufts University; United States Department of Agriculture (USDA); Tufts Medical Center; Tufts University; Cincinnati Children's Hospital Medical Center; University System of Ohio; University of Cincinnati	Suzuki, YJ (corresponding author), Tufts Univ, USDA, Human Nutr Res Ctr Aging, 711 Washington St, Boston, MA 02111 USA.	yuichiro.suzuki@tufts.edu		Molkentin, Jeffery/0000-0002-3558-6529	NHLBI NIH HHS [R01-HL32723, R01 HL072844, R01-HL67340] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL032723, R01HL072844, R01HL067340] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Abenhaim L, 1996, NEW ENGL J MED, V335, P609, DOI 10.1056/NEJM199608293350901; BECKER BN, 1992, MOL PHARMACOL, V42, P817; Brooks AR, 1996, J BIOL CHEM, V271, P9090, DOI 10.1074/jbc.271.15.9090; Eddahibi S, 1997, AM J PHYSIOL-HEART C, V272, pH1173, DOI 10.1152/ajpheart.1997.272.3.H1173; Eddahibi S, 2000, J CLIN INVEST, V105, P1555, DOI 10.1172/JCI8678; Eddahibi S, 2001, RESP RES, V3, DOI 10.1186/rr181; Eddahibi S, 2001, J CLIN INVEST, V108, P1141, DOI 10.1172/JCI12805; GuilletDeniau I, 1997, J BIOL CHEM, V272, P14825, DOI 10.1074/jbc.272.23.14825; HERVE P, 1990, AM J MED, V89, P117, DOI 10.1016/0002-9343(90)90111-P; HERVE P, 1995, AM J MED, V99, P249, DOI 10.1016/S0002-9343(99)80156-9; Huang TT, 1999, MOL CELL ENDOCRINOL, V152, P21, DOI 10.1016/S0303-7207(99)00067-2; Jun DY, 1997, MOL CELLS, V7, P537; Kim Y, 2003, MOL PHARMACOL, V63, P368, DOI 10.1124/mol.63.2.368; Kitta K, 2003, J BIOL CHEM, V278, P4705, DOI 10.1074/jbc.M211616200; Kitta K, 2001, BIOCHEM J, V359, P375, DOI 10.1042/0264-6021:3590375; LEE SL, 1991, CIRC RES, V68, P1362, DOI 10.1161/01.RES.68.5.1362; LEE SL, 1992, J CELL PHYSIOL, V150, P396, DOI 10.1002/jcp.1041500224; Lee SL, 2001, AM J PHYSIOL-LUNG C, V281, pL646, DOI 10.1152/ajplung.2001.281.3.L646; Lee SL, 2001, FASEB J, V15, P1324, DOI 10.1096/fj.00-0431fje; Lee SL, 1999, AM J PHYSIOL-LUNG C, V277, pL282, DOI 10.1152/ajplung.1999.277.2.L282; LEE SL, 1994, AM J PHYSIOL, V266, pL46, DOI 10.1152/ajplung.1994.266.1.L46; Lee SL, 1998, FREE RADICAL BIO MED, V24, P855, DOI 10.1016/S0891-5849(97)00359-6; Lee SL, 1997, AM J PHYSIOL-CELL PH, V272, pC223, DOI 10.1152/ajpcell.1997.272.1.C223; Liang QR, 2001, J BIOL CHEM, V276, P30245, DOI 10.1074/jbc.M102174200; Liang QR, 2001, MOL CELL BIOL, V21, P7460, DOI 10.1128/MCB.21.21.7460-7469.2001; Mano T, 1999, CIRC RES, V84, P647, DOI 10.1161/01.RES.84.6.647; Molkentin JD, 2000, J BIOL CHEM, V275, P38949, DOI 10.1074/jbc.R000029200; MOLKENTIN JD, 1994, MOL CELL BIOL, V14, P4947, DOI 10.1128/MCB.14.7.4947; Molkentin JD, 1998, CELL, V93, P215, DOI 10.1016/S0092-8674(00)81573-1; Morimoto T, 2000, J BIOL CHEM, V275, P13721, DOI 10.1074/jbc.275.18.13721; Perlman H, 1998, J BIOL CHEM, V273, P13713, DOI 10.1074/jbc.273.22.13713; Rothman RB, 1999, CIRCULATION, V100, P869, DOI 10.1161/01.CIR.100.8.869; SATO K, 1992, AM REV RESPIR DIS, V145, P793, DOI 10.1164/ajrccm/145.4_Pt_1.793; SIMON MC, 1995, NAT GENET, V11, P9, DOI 10.1038/ng0995-9; Suzuki E, 1996, GENOMICS, V38, P283, DOI 10.1006/geno.1996.0630; SUZUKI YJ, 2003, IN PRESS AM J RESP C, V167; Takahashi S, 1998, BLOOD, V92, P434, DOI 10.1182/blood.V92.2.434.414k24_434_442; Tanaka H, 2000, BLOOD, V95, P1264, DOI 10.1182/blood.V95.4.1264.004k09_1264_1273; Tsai FY, 1997, BLOOD, V89, P3636, DOI 10.1182/blood.V89.10.3636.3636_3636_3643; Wang ZY, 1996, GENOMICS, V35, P156, DOI 10.1006/geno.1996.0334; Wilcox CB, 2000, MOL CELL ENDOCRINOL, V170, P41, DOI 10.1016/S0303-7207(00)00327-0	41	59	73	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 9	2003	278	19					17525	17531		10.1074/jbc.M210465200	http://dx.doi.org/10.1074/jbc.M210465200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677QG	12615926	hybrid			2022-12-25	WOS:000182818600141
J	Perrin, MH; DiGruccio, MR; Koerber, SC; Rivier, JE; Kunitake, KS; Bain, DL; Fischer, WH; Vale, WW				Perrin, MH; DiGruccio, MR; Koerber, SC; Rivier, JE; Kunitake, KS; Bain, DL; Fischer, WH; Vale, WW			A soluble form of the first extracellular domain of mouse type 2 beta corticotropin-releasing factor receptor reveals differential ligand specificity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							METABOTROPIC GLUTAMATE-RECEPTOR; HORMONE-BINDING DOMAIN; N-TERMINAL DOMAIN; HIGH-AFFINITY; XENOPUS-LAEVIS; AMINO-ACIDS; UROTENSIN-I; UROCORTIN; IDENTIFICATION; EXPRESSION	The heptahelical receptors for corticotropin-releasing factor (CRF), CRFR1 and CRFR2, display different specificities for CRF family ligands: CRF and urocortin I bind to CRFR1 with high affinity, whereas urocortin II and III bind to this receptor with very low affinities. In contrast, all the urocortins bind with high affinities, and CRF binds with lower affinity to CRFR2. The first extracellular domain (ECD1) of CRFR1 is important for ligand recognition. Here, we characterize a bacterially expressed soluble protein, ECD1-CRFR2,6, corresponding to the ECD1 of mouse CRFR2beta. The K-i values for binding to ECD1-CRFR2beta are: astressin = 10.7 (5.4-21.1) nM, urocortin I = 6.4 (4.7-8.7) nm, urocortin II = 6.9 (5.8-8.3) nM, CRF = 97 (22-430) nM, urocortin III sauvagine >200 nm. These affinities are similar to those for binding to a chimeric receptor in which the ECD1 of CRFR2,6 replaces the ECD of the type 1B activin receptor (ALK4). The ECD1-CRFR2beta possesses a disulfide arrangement identical to that of the ECD1 of CRFR1, namely Cys(45-)Cys(70), Cys(60)-Cys(103), and Cys(84)-Cys(118). As determined by circular dichroism, ECD1-CRFR2beta undergoes conformational changes upon binding astressin. These data reinforce the importance of the ECD1 of CRF receptors for ligand recognition and raise the interesting possibility that different ligands having similar affinity for the full-length receptor may, nevertheless, have different affinities for microdomains of the receptor.	Clayton Fdn, Labs Peptide Biol, Salk Inst, La Jolla, CA 92037 USA	Salk Institute	Perrin, MH (corresponding author), Clayton Fdn, Labs Peptide Biol, Salk Inst, 10010 N Torrey Pines Rd, La Jolla, CA 92037 USA.			DiGruccio, Michael/0000-0002-9375-2425	NIDDK NIH HHS [DK 26741] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK026741] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Arai M, 2001, ENDOCRINOLOGY, V142, P446, DOI 10.1210/en.142.1.446; Assil IQ, 2001, BIOCHEMISTRY-US, V40, P1187, DOI 10.1021/bi001758y; Assil-Kishawi I, 2002, J BIOL CHEM, V277, P32558, DOI 10.1074/jbc.M204964200; BOHM G, 1992, PROTEIN ENG, V5, P191, DOI 10.1093/protein/5.3.191; Brar BK, 2000, J BIOL CHEM, V275, P8508, DOI 10.1074/jbc.275.12.8508; BRAR BK, 2002, ENCY HORMONES RELATE, P313; CHANG CP, 1993, NEURON, V11, P1187, DOI 10.1016/0896-6273(93)90230-O; CHEN RP, 1993, P NATL ACAD SCI USA, V90, P8967, DOI 10.1073/pnas.90.19.8967; Dautzenberg FM, 1997, J NEUROCHEM, V69, P1640; Dautzenberg FM, 1998, P NATL ACAD SCI USA, V95, P4941, DOI 10.1073/pnas.95.9.4941; Dautzenberg FM, 1999, J NEUROCHEM, V73, P821, DOI 10.1046/j.1471-4159.1999.0730821.x; Dautzenberg FM, 2002, MOL PHARMACOL, V61, P1132, DOI 10.1124/mol.61.5.1132; Dautzenberg FM, 2001, J PHARMACOL EXP THER, V296, P113; Donaldson CJ, 1996, ENDOCRINOLOGY, V137, P3896, DOI 10.1210/endo.137.9.8756563; Goldsmith PK, 1999, J BIOL CHEM, V274, P11303, DOI 10.1074/jbc.274.16.11303; Grammatopoulos DK, 2000, MOL ENDOCRINOL, V14, P2076, DOI 10.1210/me.14.12.2076; Grauschopf U, 2000, BIOCHEMISTRY-US, V39, P8878, DOI 10.1021/bi0001426; Greenwald J, 1999, NAT STRUCT BIOL, V6, P18; GULYAS J, 1995, P NATL ACAD SCI USA, V92, P10575, DOI 10.1073/pnas.92.23.10575; Hofmann BA, 2001, PROTEIN SCI, V10, P2050, DOI 10.1110/ps.12101; Hsu SY, 2001, NAT MED, V7, P605, DOI 10.1038/87936; KISHIMOTO T, 1995, P NATL ACAD SCI USA, V92, P1108, DOI 10.1073/pnas.92.4.1108; Kunishima N, 2000, NATURE, V407, P971, DOI 10.1038/35039564; Lewis K, 2001, P NATL ACAD SCI USA, V98, P7570, DOI 10.1073/pnas.121165198; Liaw CW, 1997, MOL ENDOCRINOL, V11, P980, DOI 10.1210/me.11.7.980; Liaw CW, 1997, MOL ENDOCRINOL, V11, P2048, DOI 10.1210/me.11.13.2048; LOVENBERG TW, 1995, P NATL ACAD SCI USA, V92, P836, DOI 10.1073/pnas.92.3.836; Ludvigsen S, 2001, BIOCHEMISTRY-US, V40, P9082, DOI 10.1021/bi010433u; Okamoto T, 1998, J BIOL CHEM, V273, P13089, DOI 10.1074/jbc.273.21.13089; PERRIN M, 1995, P NATL ACAD SCI USA, V92, P2969, DOI 10.1073/pnas.92.7.2969; Perrin MH, 1999, ANN NY ACAD SCI, V885, P312, DOI 10.1111/j.1749-6632.1999.tb08687.x; Perrin MH, 2001, J BIOL CHEM, V276, P31528, DOI 10.1074/jbc.M101838200; Perrin MH, 1998, ENDOCRINOLOGY, V139, P566, DOI 10.1210/en.139.2.566; Perrin MH, 1999, J PHARMACOL EXP THER, V288, P729; Remy JJ, 2001, J BIOL CHEM, V276, P1681, DOI 10.1074/jbc.M005206200; Reyes TM, 2001, P NATL ACAD SCI USA, V98, P2843, DOI 10.1073/pnas.051626398; Ruhmann A, 1999, PEPTIDES, V20, P1311, DOI 10.1016/S0196-9781(99)00136-9; Schmidt A, 2001, J BIOL CHEM, V276, P23373, DOI 10.1074/jbc.M100057200; STENZEL P, 1995, MOL ENDOCRINOL, V9, P637, DOI 10.1210/me.9.5.637; TENDIJKE P, 1993, ONCOGENE, V8, P2879; VALE W, 1981, SCIENCE, V213, P1394, DOI 10.1126/science.6267699; VAUGHAN J, 1995, NATURE, V378, P287, DOI 10.1038/378287a0; VITA N, 1993, FEBS LETT, V335, P1, DOI 10.1016/0014-5793(93)80427-V; Wille S, 1999, J NEUROCHEM, V72, P388, DOI 10.1046/j.1471-4159.1999.0720388.x; Wilmen A, 1996, FEBS LETT, V398, P43, DOI 10.1016/S0014-5793(96)01214-8; Yu JX, 1996, ENDOCRINOLOGY, V137, P192, DOI 10.1210/en.137.1.192	46	53	56	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 2	2003	278	18					15595	15600		10.1074/jbc.M210476200	http://dx.doi.org/10.1074/jbc.M210476200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	675EL	12611895	hybrid			2022-12-25	WOS:000182680000019
J	Nasr, AF; Nutini, M; Palombo, B; Guerra, E; Alberti, S				Nasr, AF; Nutini, M; Palombo, B; Guerra, E; Alberti, S			Mutations of TP53 induce loss of DNA methylation and amplification of the TROP1 gene	ONCOGENE			English	Article						DNA methylation; gene amplification; genome instability; p53; Trop-1	WILD-TYPE P53; CHROMOSOME INSTABILITY; COLON-CANCER; MUTANT P53; HOMOLOGOUS RECOMBINATION; METHYLTRANSFERASE GENE; RETINOBLASTOMA GENE; COLORECTAL-CANCER; CELLS; EXPRESSION	p53 and DNA methylation play key roles in the maintenance of genome stability. In this work, we demonstrate that the two mechanisms are linked and that p53 plays a role in the maintenance of the DNA methylation levels. The loss of p53 was shown to induce loss of DNA methylation in the TROP1 gene, a human cancer-expressed locus that undergoes amplification when hypomethylated. This demethylation was reverted by the reintroduction of a wild-type TP53 (wt TP53) in the TP53-null cells. Using a gene-amplification assay in vivo, we demonstrate that the loss of p53 leads to a demethylation-dependent TROP1 gene amplification. The induction of gene amplification was reverted by the expression of a wtTP53 gene or by in vitro methylation of the transfected DNA with the Sss I DNA methylase. Taken together, these findings demonstrate that the inactivation of TP53 induces loss of DNA methylation and DNA methylation-dependent gene amplification.	Ist Ric Farmacol Mario Negri, Consorzio Mario Negri Sud, Dept Cell Biol & Oncol, Expt Oncol Lab, I-66030 Santa Maria Imbaro, Chieti, Italy	Consorzio Mario Negri Sud; Istituto di Ricerche Farmacologiche Mario Negri IRCCS	Alberti, S (corresponding author), Univ G DAnnunzio, Sch Med, Inst Med & Aging, Chieti, Italy.		Alberti, Saverio/M-4511-2014	Alberti, Saverio/0000-0002-4647-6042; Guerra, Emanuela/0000-0002-7091-8621				Ahuja N, 1997, CANCER RES, V57, P3370; ALBERTI S, 1994, P NATL ACAD SCI USA, V91, P5833, DOI 10.1073/pnas.91.13.5833; Baylin SB, 2001, HUM MOL GENET, V10, P687, DOI 10.1093/hmg/10.7.687; Bertrand P, 1997, ONCOGENE, V14, P1117, DOI 10.1038/sj.onc.1200931; BISCHOFF FZ, 1990, CANCER RES, V50, P7979; BLANDINO G, 1995, ONCOGENE, V10, P731; Blobel GA, 2000, BLOOD, V95, P745, DOI 10.1182/blood.V95.3.745.003k05_745_755; Calabrese G, 2001, CYTOGENET CELL GENET, V92, P164, DOI 10.1159/000056891; Carroll PE, 1999, ONCOGENE, V18, P1935, DOI 10.1038/sj.onc.1202515; Coquelle A, 1997, CELL, V89, P215, DOI 10.1016/S0092-8674(00)80201-9; ELDEIRY WS, 1991, P NATL ACAD SCI USA, V88, P3470, DOI 10.1073/pnas.88.8.3470; Esteller M, 2001, CANCER RES, V61, P3225; FEINBERG AP, 1988, CANCER RES, V48, P1159; Fuks F, 2001, EMBO J, V20, P2536, DOI 10.1093/emboj/20.10.2536; GIULOTTO E, 1987, CELL, V48, P837, DOI 10.1016/0092-8674(87)90080-8; GOETZ SE, 1985, SCIENCE, V228, P187; HARE JT, 1985, P NATL ACAD SCI USA, V82, P7350, DOI 10.1073/pnas.82.21.7350; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; HORI T, 1983, MUTAT RES, V121, P47, DOI 10.1016/0165-7992(83)90085-4; HSIEH CL, 1992, EMBO J, V11, P315, DOI 10.1002/j.1460-2075.1992.tb05054.x; ISSA JPJ, 1993, J NATL CANCER I, V85, P1235, DOI 10.1093/jnci/85.15.1235; Jackson-Grusby L, 2001, NAT GENET, V27, P31, DOI 10.1038/83730; Jones PA, 1997, P NATL ACAD SCI USA, V94, P2103, DOI 10.1073/pnas.94.6.2103; LAIRD PW, 1994, HUM MOL GENET, V3, P1487, DOI 10.1093/hmg/3.suppl_1.1487; LAIRD PW, 1995, CELL, V81, P197, DOI 10.1016/0092-8674(95)90329-1; Lengauer C, 1998, NATURE, V396, P643, DOI 10.1038/25292; Lengauer C, 1997, P NATL ACAD SCI USA, V94, P2545, DOI 10.1073/pnas.94.6.2545; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; MAKOS M, 1992, P NATL ACAD SCI USA, V89, P1929, DOI 10.1073/pnas.89.5.1929; MALKIN D, 1990, SCIENCE, V250, P1233, DOI 10.1126/science.1978757; Mitelman F, 2000, MUTAT RES-REV MUTAT, V462, P247, DOI 10.1016/S1383-5742(00)00006-5; Murphy M, 1999, GENE DEV, V13, P2490, DOI 10.1101/gad.13.19.2490; Patra SK, 2001, BIOCHEM BIOPH RES CO, V287, P705, DOI 10.1006/bbrc.2001.5639; PERRY ME, 1992, MUTAT RES, V276, P189, DOI 10.1016/0165-1110(92)90008-W; Pradhan S, 2002, EMBO J, V21, P779, DOI 10.1093/emboj/21.4.779; RABBITTS TH, 1994, NATURE, V372, P143, DOI 10.1038/372143a0; Robertson KD, 2000, NAT REV GENET, V1, P11, DOI 10.1038/35049533; Saintigny Y, 2002, ONCOGENE, V21, P488, DOI 10.1038/sj.onc.1205040; Sambrook J., 2002, MOL CLONING LAB MANU; Soares J, 1999, CANCER, V85, P112, DOI 10.1002/(SICI)1097-0142(19990101)85:1<112::AID-CNCR16>3.3.CO;2-K; STEIN R, 1982, P NATL ACAD SCI-BIOL, V79, P61, DOI 10.1073/pnas.79.1.61; STRNAD J, 1989, CANCER RES, V49, P314; Tuck-Muller CM, 2000, CYTOGENET CELL GENET, V89, P121, DOI 10.1159/000015590; WAHL GM, 1984, NATURE, V307, P516, DOI 10.1038/307516a0; WRIGHT JA, 1990, P NATL ACAD SCI USA, V87, P1791, DOI 10.1073/pnas.87.5.1791; Xu GL, 1999, NATURE, V402, P187, DOI 10.1038/46052; YIN YX, 1992, CELL, V70, P937, DOI 10.1016/0092-8674(92)90244-7; Zheng L, 2002, CANCER RES, V62, P2498	49	28	28	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 20	2003	22	11					1668	1677		10.1038/sj.onc.1206248	http://dx.doi.org/10.1038/sj.onc.1206248			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	655YH	12642870				2022-12-25	WOS:000181580500009
J	Presneau, N; Mes-Masson, AM; Ge, B; Provencher, D; Hudson, TJ; Tonin, PN				Presneau, N; Mes-Masson, AM; Ge, B; Provencher, D; Hudson, TJ; Tonin, PN			Patterns of expression of chromosome 17 genes in primary cultures of normal ovarian surface epithelia and epithelial ovarian cancer cell lines	ONCOGENE			English	Article						ovarian cancer; cell lines; DNA microarray; chromosome 17; gene expression	ALLELIC LOSS; MICROARRAY ANALYSIS; DELETION UNIT; TUMORS DISTAL; FREQUENT LOSS; P53 GENE; BREAST; REGION; CANDIDATE; HETEROZYGOSITY	Oligonucleotide microarray analysis was applied to assess the expression profile of 332 probe sets representing 308 genes or expressed sequence tags (ESTs) that map to chromosome 17 in order to address epigenetic events that result in alterations in gene expression in epithelial ovarian cancer (EOC). Expression profiles were generated from 12 primary cultures derived from normal ovarian surface epithelium (NOSE) and four long-term cultures (TOV-81D, TOV-112D, TOV-21G and OV-90) derived from EOCs that have been previously characterized and shown to mimic features of the tumoral cells from which they were derived. The expression values of all 332 probe sets is highly correlated across the 12 NOSEs (89% correlation coefficients > 0.90). In two-way comparisons, differential patterns of gene expression were observed for 157 probe sets for which the expression value of at least one EOC cell tine fell outside the limits of the range of expression of the 12 NOSEs. When compared to NOSEs, four genes displayed similar differential patterns of gene expression across all four EOC cell lines, and 26 genes displayed similar differential patterns of gene expression across the three EOC cell lines (TOV-112D, TOV-21G and OV-90) representing tumoral cells derived from the most aggressive disease. A total of 17 genes displayed differential patterns of gene expression greater than threefold in at least one EOC cell line in comparison to NOSE, and three genes were differentially expressed greater than threefold across all aggressive cell lines. The analysis of a selected number of genes by RT-PCR revealed patterns of gene expression comparable to those observed by microarray analysis in the majority of samples tested. Comparison of expression profiles of differentially expressed genes identified by microarray analysis in two-way comparisons of the EOC cell lines and the NOSEs with published reports revealed 10 genes previously implicated in ovarian tumorigenesis and 18 in tumorigenesis of other types of cancer. The differential pattern of gene expression of genes that map to both the p and q arm of chromosome 17 is consistent with the hypothesis that a number of genes that map to this chromosome are implicated in the etiology of ovarian cancer.	McGill Univ, Ctr Hlth, Res Inst, Montreal, PQ H3G 1A4, Canada; McGill Univ, Ctr Hlth, Montreal Genome Ctr, Montreal, PQ H3G 1A4, Canada; McGill Univ, Dept Human Genet, Montreal, PQ H3A 1B1, Canada; CHU Montreal, Notre Dame Hosp, Ctr Rech, Inst Canc Montreal, Montreal, PQ H2L 4M1, Canada; Univ Montreal, Dept Med, Montreal, PQ H3C 3J7, Canada; Univ Montreal, Dept Obstet Gynecol, Montreal, PQ H3C 3J7, Canada; McGill Univ, Dept Med, Montreal, PQ H3G 1Y6, Canada	McGill University; McGill University; McGill University; Universite de Montreal; Universite de Montreal; Universite de Montreal; McGill University	Tonin, PN (corresponding author), Montreal Gen Hosp, Room L10-120,1650 Cedar Ave, Montreal, PQ H3G 1A4, Canada.	patricia.tonin@mcgill.ca	Pillay, Nischalan/F-9536-2012	Mes-Masson, Anne-Marie/0000-0002-6498-266X				Auersperg N, 2001, ENDOCR REV, V22, P255, DOI 10.1210/er.22.2.255; CLIBY W, 1993, CANCER RES, V53, P2393; Davidson B, 1999, CLIN EXP METASTAS, V17, P799, DOI 10.1023/A:1006723011835; Davidson B, 2001, EUR J CANCER, V37, P2040, DOI 10.1016/S0959-8049(01)00235-0; Dion F, 2000, ONCOGENE, V19, P1466, DOI 10.1038/sj.onc.1203463; ECCLES DM, 1990, ONCOGENE, V5, P1599; ECCLES DM, 1992, BRIT J CANCER, V65, P40, DOI 10.1038/bjc.1992.8; FOULKES WD, 1993, INT J CANCER, V54, P220, DOI 10.1002/ijc.2910540210; GODWIN AK, 1994, AM J HUM GENET, V55, P666; Golub TR, 1999, SCIENCE, V286, P531, DOI 10.1126/science.286.5439.531; Hoff C, 2000, GENOMICS, V70, P26, DOI 10.1006/geno.2000.6353; JACOBS IJ, 1993, CANCER RES, V53, P1218; Kalikin LM, 1997, ONCOGENE, V14, P1991, DOI 10.1038/sj.onc.1201013; Kauraniemi P, 2001, CANCER RES, V61, P8235; Kikkawa F, 1997, CANCER LETT, V120, P109, DOI 10.1016/S0304-3835(97)00295-4; Konishi H, 1998, ONCOGENE, V17, P2095, DOI 10.1038/sj.onc.1202128; KRUK PA, 1990, LAB INVEST, V63, P132; LEARY JA, 1995, INT J CANCER, V64, P189, DOI 10.1002/ijc.2910640308; LEE JH, 1990, CANCER RES, V50, P2724; LOUNIS H, 1994, EXP CELL RES, V215, P303, DOI 10.1006/excr.1994.1346; Lucito R, 2000, GENOME RES, V10, P1726, DOI 10.1101/gr.138300; MANDAI M, 1994, CANCER RES, V54, P1825; Manderson EN, 2002, GENOME RES, V12, P112, DOI 10.1101/gr.174202; Merajver SD, 1995, CLIN CANCER RES, V1, P539; Mertens F, 1997, CANCER RES, V57, P2765; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; OKAMOTO A, 1991, CANCER RES, V51, P5171; Papp J, 1996, BRIT J CANCER, V74, P1592, DOI 10.1038/bjc.1996.594; Phelan CM, 1998, CANCER RES, V58, P1004; PHILLIPS N, 1993, INT J CANCER, V54, P85, DOI 10.1002/ijc.2910540115; Pieretti M, 1995, INT J CANCER, V64, P434, DOI 10.1002/ijc.2910640614; Pollack JR, 1999, NAT GENET, V23, P41, DOI 10.1038/12640; Provencher DM, 2000, IN VITRO CELL DEV-AN, V36, P357; Ross DT, 2000, NAT GENET, V24, P227, DOI 10.1038/73432; RUSSELL SEH, 1990, ONCOGENE, V5, P1581; SATO T, 1991, CANCER RES, V51, P5118; Schneider J, 1996, ANTICANCER RES, V16, P1197; Schneider J, 2000, BRIT J CANCER, V82, P1662; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; Tangir J, 1996, ONCOGENE, V12, P735; TAVASSOLI M, 1993, GENE CHROMOSOME CANC, V8, P195, DOI 10.1002/gcc.2870080310; Teng DHF, 2001, GENOMICS, V74, P352, DOI 10.1006/geno.2001.6551; Tonin PN, 2001, ONCOGENE, V20, P6617, DOI 10.1038/sj.onc.1204804; TSAO SW, 1991, ANTICANCER RES, V11, P1975; Welsh JB, 2001, P NATL ACAD SCI USA, V98, P1176, DOI 10.1073/pnas.98.3.1176; YANGFENG TL, 1993, INT J CANCER, V54, P546, DOI 10.1002/ijc.2910540405	46	28	28	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 13	2003	22	10					1568	1579		10.1038/sj.onc.1206219	http://dx.doi.org/10.1038/sj.onc.1206219			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	652ZZ	12629520	Bronze			2022-12-25	WOS:000181411900014
J	Marvanova, M; Menager, J; Bezard, E; Bontrop, RE; Pradier, L; Wong, G				Marvanova, M; Menager, J; Bezard, E; Bontrop, RE; Pradier, L; Wong, G			Microarray analysis of nonhuman primates: validation of experimental models in neurological disorders	FASEB JOURNAL			English	Article						high-density oligonucleotide array; gene expression; prefrontal cortex (PFC); nonhuman primates (NHPs)	DENSITY OLIGONUCLEOTIDE ARRAYS; DNA HYBRIDIZATION EVIDENCE; PARKINSONS-DISEASE; ALZHEIMERS-DISEASE; HOMINOID PHYLOGENY; SQUIRREL-MONKEY; AIDS VACCINE; HUMANS; MPTP; CHIMPANZEES	Nonhuman primates (NHPs) have provided robust experimental animal models for many human-related diseases due to their similar physiologies. Nonetheless, profound differences remain in the acquisition, progression, and outcome of important diseases such as AIDS and Alzheimer's, for which the underlying basis remains obscure. We explored the utility of human high-density oligonucleotide arrays to survey the transcription profile of NHP genomes. Total RNA from prefrontal cortices of human (Homo sapiens), common chimpanzee (Pan troglodytes), cynomolgous macaque (Macaca fascicularis), and common marmoset (Callithrix jacchus) was labeled and hybridized to Affymetrix U95A GeneChip probe arrays. Corresponding data obtained previously from common chimpanzee and orangutan (Pongo pygmaeus) were added for comparison. Qualitative (present or not detected) and quantitative (expression level) analysis indicated that many genes known to be involved in human neurological disorders were present and regulated in NHPs. A gene involved in dopamine metabolism (catechol-O-methyltransferase) was absent in macaque and marmoset. Glutamate receptor 2 was upregulated, and transcription-associated genes were down-regulated in NHPs compared with humans. We demonstrate that transcript profiling of NHPs could provide comparative genomic data to validate and better focus experimental animal models of human neurological disorders.	Univ Kuopio, AI Virtanen Inst, Funct Genom & Bioinformat Lab, Dept Neurobiol, FIN-70211 Kuopio, Finland; Aventis Pharma, Dept Neudegenerat Dis, F-94400 Vitry Sur Seine, France; CNRS, UMR 5543, Dept Neurophysiol, F-33076 Bordeaux, France; Biomed Primate Res Ctr, NL-2280 Rijswijk, Netherlands	University of Eastern Finland; Sanofi-Aventis; Sanofi France; Centre National de la Recherche Scientifique (CNRS)	Wong, G (corresponding author), Univ Kuopio, AI Virtanen Inst, Funct Genom & Bioinformat Lab, Dept Neurobiol, POB 1627, FIN-70211 Kuopio, Finland.	garry.wong@uku.fi	Bontrop, Ronald E./D-4844-2011; Bezard, Erwan/A-8173-2008; Bezard, Erwan/ABD-5153-2021; Bontrop, Ronald E/J-3628-2012	Bontrop, Ronald E/0000-0003-0874-6467; Bezard, Erwan/0000-0002-0410-4638				Barros M, 2002, NEUROSCI BIOBEHAV R, V26, P187, DOI 10.1016/S0149-7634(01)00064-1; Bezard E, 2001, J NEUROSCI, V21, P6853, DOI 10.1523/JNEUROSCI.21-17-06853.2001; Brown PO, 1999, NAT GENET, V21, P33, DOI 10.1038/4462; BURNS RS, 1983, P NATL ACAD SCI-BIOL, V80, P4546, DOI 10.1073/pnas.80.14.4546; Chen FC, 2001, AM J HUM GENET, V68, P444, DOI 10.1086/318206; Chu L., 2001, GENOME INFO, V12, P227; DOUDET D, 1985, BRAIN RES, V335, P194, DOI 10.1016/0006-8993(85)90294-X; Duyckaerts C, 1997, NEUROBIOL AGING, V18, P267, DOI 10.1016/S0197-4580(97)80306-5; Emerich DF, 1997, NATURE, V386, P395, DOI 10.1038/386395a0; Enard W, 2002, SCIENCE, V296, P340, DOI 10.1126/science.1068996; ERWIN J, 1995, NONHUMAN PRIMATES BI, P117; FERRARI G, 1994, J ACQ IMMUN DEF SYND, V7, P325; Ghosh KK, 2001, J NEUROSCI, V21, P8636, DOI 10.1523/JNEUROSCI.21-21-08636.2001; Goodman M, 1998, MOL PHYLOGENET EVOL, V9, P585, DOI 10.1006/mpev.1998.0495; GOODMAN M, 1990, J MOL EVOL, V30, P260, DOI 10.1007/BF02099995; Hacia JG, 1998, NAT GENET, V18, P155, DOI 10.1038/ng0298-155; Hendrickx AG, 2000, HUM EXP TOXICOL, V19, P219, DOI 10.1191/096032700678815756; HERKENHAM M, 1991, NEUROSCIENCE, V40, P133, DOI 10.1016/0306-4522(91)90180-V; Hof PR, 2002, BRAIN RES, V928, P175, DOI 10.1016/S0006-8993(01)03345-5; IMAI H, 1988, BRAIN RES, V474, P327, DOI 10.1016/0006-8993(88)90446-5; KATZ JL, 1991, PSYCHOPHARMACOLOGY, V103, P33, DOI 10.1007/BF02244070; Kendall AL, 2000, BRAIN, V123, P1442, DOI 10.1093/brain/123.7.1442; Khan J, 1999, BIOCHIM BIOPHYS ACTA, V1423, P17; KING FA, 1988, SCIENCE, V240, P1475, DOI 10.1126/science.3287624; KING MC, 1975, SCIENCE, V188, P107, DOI 10.1126/science.1090005; Lane MA, 2000, EXP GERONTOL, V35, P533, DOI 10.1016/S0531-5565(00)00102-9; LANGSTON JW, 1984, BRAIN RES, V292, P390; Lipshutz RJ, 1999, NAT GENET, V21, P20, DOI 10.1038/4447; Lockhart DJ, 1996, NAT BIOTECHNOL, V14, P1675, DOI 10.1038/nbt1296-1675; McMurray DN, 2000, CLIN INFECT DIS, V30, pS210, DOI 10.1086/313885; Nathanson N, 1999, J MED PRIMATOL, V28, P146, DOI 10.1111/j.1600-0684.1999.tb00263.x; Nathanson N, 1999, AIDS, V13, pS113; Ollomo B, 1997, AM J TROP MED HYG, V56, P440, DOI 10.4269/ajtmh.1997.56.440; Osada N, 2001, GENE, V275, P31, DOI 10.1016/S0378-1119(01)00665-5; OSADA N, 2002, GENOME BIOL, V3; PODLISNY MB, 1991, AM J PATHOL, V138, P1423; Price DL, 1991, BRAIN PATHOL, V1, P287, DOI 10.1111/j.1750-3639.1991.tb00672.x; Schena M, 1996, P NATL ACAD SCI USA, V93, P10614, DOI 10.1073/pnas.93.20.10614; Sibal L R, 2001, ILAR J, V42, P74; SIBLEY CG, 1990, J MOL EVOL, V30, P202, DOI 10.1007/BF02099992; SIBLEY CG, 1984, J MOL EVOL, V20, P2, DOI 10.1007/BF02101980; SIBLEY CG, 1987, J MOL EVOL, V26, P99, DOI 10.1007/BF02111285; Varki A, 2000, GENOME RES, V10, P1065, DOI 10.1101/gr.10.8.1065; WENK GL, 1993, BEHAV BRAIN RES, V57, P117, DOI 10.1016/0166-4328(93)90127-C; ZOU J, 2002, GENOME BIOL, V3	45	60	62	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAR	2003	17	3					929	+		10.1096/fj.02-0681fje	http://dx.doi.org/10.1096/fj.02-0681fje			19	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	661LT	12626435				2022-12-25	WOS:000181892600017
J	Ciaccio, C; Rosati, A; De Sanctis, G; Sinibaldi, F; Marini, S; Santucci, R; Ascenzi, P; Welinder, KG; Coletta, M				Ciaccio, C; Rosati, A; De Sanctis, G; Sinibaldi, F; Marini, S; Santucci, R; Ascenzi, P; Welinder, KG; Coletta, M			Relationships of ligand binding, redox properties, and protonation in Coprinus cinereus peroxidase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME-C PEROXIDASE; SITE-DIRECTED MUTAGENESIS; CRYSTAL-STRUCTURE; ANGSTROM RESOLUTION; HORSERADISH-PEROXIDASE; MANGANESE PEROXIDASE; ARTHROMYCES-RAMOSUS; ASP245->ASN MUTANT; FUNGAL PEROXIDASE; HUMAN-HEMOGLOBIN	The pH dependence of the redox potentials and kinetics for CO association and dissociation was determined between pH 3.0 and 13.0 at 25 degreesC for the wild-type Coprinus cinereus fungal peroxidase and for a site-directed mutant in which Asp(245), which is H-bonded to N-delta of the imidazole of the proximal His(183), was substituted with Asn. The determination of these functional properties allowed this information to be merged in a self-consistent fashion and to formulate for the first time a complete scheme employing the minimum number of groups required to describe the whole proton-linked behavior of both redox and ligand binding properties. The overall pH dependence can be accounted for by four redox- and ligand-linked groups. The proximal H-bond, which is strictly conserved in all peroxidases, will still be present in the site-specific mutant, but will no longer have an ionic character, and this event will bring about an alteration of redox equilibria and CO binding kinetics, envisaging a relevant role played by this H-bond also in modulating redox properties and ligand binding equilibria.	Univ Roma Tor Vergata, Dept Expt Med & Biochem Sci, I-00133 Rome, Italy; Univ Roma Tre, Dept Biol, I-00146 Rome, Italy; Univ Camerino, Dept Mol Cellular & Anim Biol, I-62032 Camerino, Italy; Univ Aalborg, Dept Biotechnol, DK-9000 Aalborg, Denmark	University of Rome Tor Vergata; Roma Tre University; University of Camerino; Aalborg University	Coletta, M (corresponding author), Univ Roma Tor Vergata, Dept Expt Med & Biochem Sci, Via Montpellier 1, I-00133 Rome, Italy.		Marini, Stefano/B-1161-2012; Coletta, Massimo/N-9049-2015; Coletta, Massimiliano/GSN-5927-2022	Marini, Stefano/0000-0003-1299-6696; COLETTA, Massimiliano/0000-0002-5489-9467; Welinder, Karen Gjesing/0000-0002-5409-0131				Abelskov AK, 1997, BIOCHEMISTRY-US, V36, P9453, DOI 10.1021/bi970387r; Brunori M, 2000, BIOPHYS CHEM, V86, P221, DOI 10.1016/S0301-4622(00)00142-3; COLETTA M, 1985, J BIOL CHEM, V260, P4151; COLETTA M, 1988, J BIOL CHEM, V263, P18286; Decatur SM, 1999, BIOCHEMISTRY-US, V38, P11086, DOI 10.1021/bi9908888; Dunford HB, 2001, J BIOL INORG CHEM, V6, P819; Ferri T, 1998, BIOELECTROCH BIOENER, V44, P177, DOI 10.1016/S0302-4598(97)00088-3; FINZEL BC, 1984, J BIOL CHEM, V259, P3027; Fukuyama K, 1997, J BIOL CHEM, V272, P5752, DOI 10.1074/jbc.272.9.5752; Gajhede M, 1997, NAT STRUCT BIOL, V4, P1032, DOI 10.1038/nsb1297-1032; Gibson QH, 1999, BIOCHEMISTRY-US, V38, P5191, DOI 10.1021/bi982970t; HARBURY HA, 1957, J BIOL CHEM, V225, P1009; KUNISHIMA N, 1994, J MOL BIOL, V235, P331, DOI 10.1016/S0022-2836(05)80037-3; LAMBRIGHT DG, 1994, BIOCHEMISTRY-US, V33, P5518, DOI 10.1021/bi00184a021; MILLER MA, 1990, BIOCHEMISTRY-US, V29, P9978, DOI 10.1021/bi00494a031; MILLER MA, 1990, BIOCHEMISTRY-US, V29, P1777, DOI 10.1021/bi00459a017; Mukai M, 2001, J BIOL CHEM, V276, P7272, DOI 10.1074/jbc.M009280200; MURRAY LP, 1988, P NATL ACAD SCI USA, V85, P2151, DOI 10.1073/pnas.85.7.2151; Neri F, 1998, EUR J BIOCHEM, V251, P830, DOI 10.1046/j.1432-1327.1998.2510830.x; PERUTZ MF, 1989, Q REV BIOPHYS, V22, P139, DOI 10.1017/S0033583500003826; PETERSEN JFW, 1994, FEBS LETT, V339, P291, DOI 10.1016/0014-5793(94)80433-8; POULOS TL, 1993, J BIOL CHEM, V268, P4429; Santucci R, 2000, BIOCHEM J, V349, P85, DOI 10.1042/0264-6021:3490085; Scott EE, 2001, J BIOL CHEM, V276, P5177, DOI 10.1074/jbc.M008282200; Smulevich G, 1996, BIOCHEMISTRY-US, V35, P10576, DOI 10.1021/bi9605898; SUNDARAMOORTHY M, 1994, J BIOL CHEM, V269, P32759; Unzai S, 1998, J BIOL CHEM, V273, P23150, DOI 10.1074/jbc.273.36.23150; Veitch NC, 1996, BIOCHEMISTRY-US, V35, P14370, DOI 10.1021/bi961582t; WELINDER KG, 1995, BIOCHEM SOC T, V23, P257, DOI 10.1042/bst0230257; WELINDER KG, 1992, CURR OPIN STRUC BIOL, V2, P383; WELINDER KG, 1993, Patent No. 9324618	31	6	6	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 23	2003	278	21					18730	18737		10.1074/jbc.M212034200	http://dx.doi.org/10.1074/jbc.M212034200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	679PY	12621034	hybrid			2022-12-25	WOS:000182932200005
J	Moeckel, GW; Zhang, L; Fogo, AB; Hao, CM; Pozzi, A; Breyer, MD				Moeckel, GW; Zhang, L; Fogo, AB; Hao, CM; Pozzi, A; Breyer, MD			COX2 activity promotes organic osmolyte accumulation and adaptation of renal medullary interstitial cells to hypertonic stress	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLOOXYGENASE-2; EXPRESSION; INHIBITORS; SURVIVAL; CLONING; CULTURE; BETAINE; KIDNEY	The mechanism by which COX2 inhibition decreases renal cell survival is poorly understood. In the present study we examined the effect of COX2 activity on organic osmolyte accumulation in renal medulla and in cultured mouse renal medullary interstitial cells (MMICs) and its role in facilitating cell survival. Hypertonicity increased accumulation of the organic osmolytes inositol, sorbitol, and betaine in cultured mouse medullary interstitial cells. Pretreatment of MMICs with a COX2-specific inhibitor (SC58236, 10 mumol/liter) dramatically reduced osmolyte accumulation ( by 79 +/- 9, 57 +/- 12, and 96 +/- 10% for inositol, sorbitol, and betaine respectively, p < 0.05). Similarly, 24 h of dehydration increased inner medullary inositol, sorbitol, and betaine concentrations in vivo by 85 +/- 10, 197 +/- 28, and 190 +/- 24 pmol/&mu;g of protein, respectively, but this increase was also blunted ( by 100 +/- 5, 66 +/- 15, and 81 +/- 9% for inositol, sorbitol, and betaine, respectively, p < 0.05) by pretreatment with an oral COX2 inhibitor. Dehydrated COX2-/- mice also exhibited an impressive defect in sorbitol accumulation ( 88 +/- 9% less than wild type, p < 0.05) after dehydration. COX2 inhibition ( COX2 inhibitor-treated or COX2-/- MMICs) dramatically reduced the expression of organic osmolyte uptake mechanisms including betaine (BGT1) and sodium-myo-inositol transporter and aldose reductase mRNA expression under hypertonic conditions. Importantly, preincubation of COX2 inhibitor-treated MMICs with organic osmolytes restored their ability to survive hypertonic stress. In conclusion, osmolyte accumulation in the kidney inner medulla is dependent on COX2 activity, and providing exogenous osmolytes reverses COX2-induced cell death. These findings may have implications for the pathogenesis of analgesic nephropathy.	Vanderbilt Univ, Med Ctr, Sch Med, Dept Pathol,Renal Pathol Div, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Dept Med, Div Nephrol, Nashville, TN 37232 USA	Vanderbilt University; Vanderbilt University	Moeckel, GW (corresponding author), Vanderbilt Univ, Med Ctr, Sch Med, Dept Pathol,Renal Pathol Div, MCN C-2317,1161 21st Ave So, Nashville, TN 37232 USA.			Breyer, Matthew/0000-0003-1880-371X; Moeckel, Gilbert/0000-0002-6059-0837	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P50DK039261, K08DK059975] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK39261, K08 DK59975] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BECK FX, 1990, CELL VOLUME REGULATI, P132; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Burger-Kentischer A, 1999, KIDNEY INT, V55, P1417, DOI 10.1046/j.1523-1755.1999.00382.x; Chandrasekharan NV, 2002, P NATL ACAD SCI USA, V99, P13926, DOI 10.1073/pnas.162468699; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Crofford LJ, 1997, J RHEUMATOL, V24, P15; DEWITT DL, 1988, P NATL ACAD SCI USA, V85, P1412, DOI 10.1073/pnas.85.5.1412; DUNN MJ, 1976, PROSTAG OTH LIPID M, V12, P37, DOI 10.1016/S0090-6980(76)80005-6; GARCIAPEREZ A, 1991, PHYSIOL REV, V71, P1081, DOI 10.1152/physrev.1991.71.4.1081; Grupp C, 1999, EXP NEPHROL, V7, P377; Guan YF, 1997, AM J PHYSIOL-RENAL, V273, pF18, DOI 10.1152/ajprenal.1997.273.1.F18; HANSEN MB, 1989, J IMMUNOL METHODS, V119, P203, DOI 10.1016/0022-1759(89)90397-9; Hao CM, 1999, AM J PHYSIOL-RENAL, V277, pF352, DOI 10.1152/ajprenal.1999.277.3.F352; Hao CM, 2000, J CLIN INVEST, V106, P973, DOI 10.1172/JCI9956; HARRIS RC, 1994, J CLIN INVEST, V94, P2504, DOI 10.1172/JCI117620; Herschman HR, 1996, BBA-LIPID LIPID MET, V1299, P125, DOI 10.1016/0005-2760(95)00194-8; HLA T, 1991, J BIOL CHEM, V266, P24059; Horio M, 2001, NEPHROL DIAL TRANSPL, V16, P483, DOI 10.1093/ndt/16.3.483; Kaufmann WE, 1996, P NATL ACAD SCI USA, V93, P2317, DOI 10.1073/pnas.93.6.2317; Komhoff M, 2000, KIDNEY INT, V57, P414; Komhoff M., 1997, AM J PHYSIOL, V272, P460; Lim H, 1997, CELL, V91, P197, DOI 10.1016/S0092-8674(00)80402-X; MACKNIGHT ADC, 1988, RENAL PHYSIOL BIOCH, V11, P114; MOECKEL GW, 1994, AM J PHYSIOL, V266, pF512, DOI 10.1152/ajprenal.1994.266.3.F512; Moeckel GW, 1997, AM J PHYSIOL-RENAL, V272, pF100, DOI 10.1152/ajprenal.1997.272.1.F100; Moeckel GW, 1997, AM J PHYSIOL-RENAL, V272, pF94, DOI 10.1152/ajprenal.1997.272.1.F94; MOLLAND EA, 1978, KIDNEY INT, V13, P5, DOI 10.1038/ki.1978.2; Simmons D.L., 1991, PROSTAGLANDINS LEUKO, P67; WEINHOLD PA, 1963, P SOC EXP BIOL MED, V112, P165; YANCEY PH, 1990, AM J PHYSIOL, V258, pC156, DOI 10.1152/ajpcell.1990.258.1.C156; Yang TX, 1999, AM J PHYSIOL-RENAL, V277, pF1, DOI 10.1152/ajprenal.1999.277.1.F1	31	58	64	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 23	2003	278	21					19352	19357		10.1074/jbc.M302209200	http://dx.doi.org/10.1074/jbc.M302209200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	679PY	12637551	hybrid			2022-12-25	WOS:000182932200083
J	Du, LN; Zhang, XP; Han, YY; Burke, NA; Kochanek, PM; Watkins, SC; Graham, SH; Carcillo, JA; Szabo, C; Clark, RSB				Du, LN; Zhang, XP; Han, YY; Burke, NA; Kochanek, PM; Watkins, SC; Graham, SH; Carcillo, JA; Szabo, C; Clark, RSB			Intra-mitochondrial poly(ADP-ribosylation) contributes to NAD(+) depletion and cell death induced by oxidative stress	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LONG-TERM POTENTIATION; NITRIC-OXIDE SYNTHASE; POLYMERASE INHIBITORS; DNA DAMAGE; RAT-BRAIN; APOPTOSIS; PEROXYNITRITE; SYNTHETASE; REPAIR; ACTIVATION	Poly(ADP-ribosylation), primarily via poly(ADP-ribose) polymerase-1 (PARP-1), is a pluripotent cellular process important for maintenance of genomic integrity and RNA transcription in cells. However, during conditions of oxidative stress and energy depletion, poly(ADP-ribosylation) paradoxically contributes to mitochondrial failure and cell death. Although it has been presumed that poly(ADP-ribosylation) within the nucleus mediates this pathologic process, PARP-1 and other poly(ADP-ribosyltransferases) are also localized within mitochondria. To this end, the presence of PARP-1 and poly(ADP-ribosylation) were verified within mitochondrial fractions from primary cortical neurons and fibroblasts. Inhibition of poly(ADP-ribosylation) within the mitochondrial compartment preserved transmembrane potential (DeltaPsi(m)), NAD(+) content, and cellular respiration, prevented release of apoptosis-inducing factor, and reduced neuronal cell death triggered by oxidative stress. Treatment with liposomal NAD(+) also preserved DeltaPsi(m) and cellular respiration during oxidative stress. Furthermore, inhibition of poly(ADP-ribosylation) prevented intranuclear localization of apoptosis-inducing factor and protected neurons from excitotoxic injury; and PARP-1 null fibroblasts were protected from oxidative stress-induced cell death. Collectively these data suggest that poly(ADP-ribosylation) compartmentalized to the mitochondria can be converted from a homeostatic process to a mechanism of cell death when oxidative stress is accompanied by energy depletion. These data implicate intra-mitochondrial poly(ADP-ribosylation) as an important therapeutic target for central nervous system and other diseases associated with oxidative stress and energy failure.	Univ Pittsburgh, Safar Ctr Resuscitat Res, Dept Crit Care Med, Pittsburgh, PA 15260 USA; Univ Pittsburgh, Safar Ctr Resuscitat Res, Dept Cell Biol & Physiol, Pittsburgh, PA 15260 USA; Univ Pittsburgh, Safar Ctr Resuscitat Res, Dept Pediat, Pittsburgh, PA 15260 USA; Univ Pittsburgh, Safar Ctr Resuscitat Res, Dept Neurol, Pittsburgh, PA 15260 USA; Vet Affairs Pittsburgh Hlth Syst, Ctr Geriatr Res Educ & Clin, Pittsburgh, PA 15261 USA; Inotek Pharmaceut Corp, Beverly, MA 01915 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Geriatric Research Education & Clinical Center; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Pittsburgh Healthcare System; Inotek Pharmaceuticals	Clark, RSB (corresponding author), Univ Pittsburgh, Safar Ctr Resuscitat Res, Dept Crit Care Med, 3434 5th Ave, Pittsburgh, PA 15260 USA.		Szabo, Csaba/D-1882-2013; Szabo, Csaba/ABG-2644-2021; Watkins, Simon/ABG-2590-2021; Kochanek, Patrick M/D-2371-2015	Watkins, Simon/0000-0003-4092-1552; Kochanek, Patrick M/0000-0002-2627-913X	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [T32HD040686] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS038620, P50NS030318] Funding Source: NIH RePORTER; NICHD NIH HHS [T32 HD 40686] Funding Source: Medline; NINDS NIH HHS [P50 NS30318, R01 NS38620] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BAUER PI, 1995, BIOCHIMIE, V77, P374, DOI 10.1016/0300-9084(96)88149-1; Brorson JR, 1999, J NEUROSCI, V19, P147, DOI 10.1523/JNEUROSCI.19-01-00147.1999; Buckman JF, 2001, J NEUROSCI, V21, P5054, DOI 10.1523/JNEUROSCI.21-14-05054.2001; BURZIO LO, 1981, BIOCHEM BIOPH RES CO, V103, P369, DOI 10.1016/0006-291X(81)91702-2; DAWSON TM, 1995, NEW HORIZONS, V3, P86; Dawson VL, 1996, NEUROCHEM INT, V29, P97, DOI 10.1016/0197-0186(95)00149-2; DRIGGERS WJ, 1993, J BIOL CHEM, V268, P22042; Druzhyna N, 2000, DIABETES, V49, P1849, DOI 10.2337/diabetes.49.11.1849; Eliasson MJL, 1997, NAT MED, V3, P1089, DOI 10.1038/nm1097-1089; Endres M, 1998, EUR J PHARMACOL, V351, P377, DOI 10.1016/S0014-2999(98)00381-1; Ghafourifar P, 1999, J BIOL CHEM, V274, P31185, DOI 10.1074/jbc.274.44.31185; Grishko VI, 1999, NUCLEIC ACIDS RES, V27, P4510, DOI 10.1093/nar/27.22.4510; Ha HC, 2002, P NATL ACAD SCI USA, V99, P3270, DOI 10.1073/pnas.052712399; Halmosi R, 2001, MOL PHARMACOL, V59, P1497, DOI 10.1124/mol.59.6.1497; Han YY, 2001, RES COMMUN MOL PATH, V110, P107; Joza N, 2001, NATURE, V410, P549, DOI 10.1038/35069004; Kleppisch T, 1999, J NEUROSCI, V19, P48, DOI 10.1523/JNEUROSCI.19-01-00048.1999; Lee HM, 2002, J NEUROCHEM, V80, P928, DOI 10.1046/j.0022-3042.2002.00774.x; Leist M, 1997, J EXP MED, V185, P1481, DOI 10.1084/jem.185.8.1481; Lemaire C, 1998, FEBS LETT, V425, P266, DOI 10.1016/S0014-5793(98)00252-X; Los M, 2002, MOL BIOL CELL, V13, P978, DOI 10.1091/mbc.01-05-0272; MASMOUDI A, 1993, BIOCHEM MOL BIOL INT, V29, P77; MASMOUDI A, 1988, J NEUROCHEM, V51, P188, DOI 10.1111/j.1471-4159.1988.tb04854.x; Mosgoeller W, 1996, J CELL SCI, V109, P409; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; NISSELBA.JS, 1969, ANAL BIOCHEM, V27, P212, DOI 10.1016/0003-2697(69)90025-6; Pieper AA, 2000, P NATL ACAD SCI USA, V97, P1845, DOI 10.1073/pnas.97.4.1845; SATCHELL MA, 2003, IN PRESS J NEUROCHEM; SCHUMAN EM, 1994, P NATL ACAD SCI USA, V91, P11958, DOI 10.1073/pnas.91.25.11958; Smith S, 1998, SCIENCE, V282, P1484, DOI 10.1126/science.282.5393.1484; Susin SA, 2000, J EXP MED, V192, P571, DOI 10.1084/jem.192.4.571; Susin SA, 1999, NATURE, V397, P441, DOI 10.1038/17135; Susin SA, 1996, J EXP MED, V184, P1331, DOI 10.1084/jem.184.4.1331; Szabo C, 1996, BRAIN RES BULL, V41, P131, DOI 10.1016/S0361-9230(96)00159-1; Szabo C, 1998, P NATL ACAD SCI USA, V95, P3867, DOI 10.1073/pnas.95.7.3867; Szabo C, 1996, P NATL ACAD SCI USA, V93, P1753, DOI 10.1073/pnas.93.5.1753; Trucco C, 1998, NUCLEIC ACIDS RES, V26, P2644, DOI 10.1093/nar/26.11.2644; Tulin A, 2003, SCIENCE, V299, P560, DOI 10.1126/science.1078764; Virag L, 1998, J IMMUNOL, V161, P3753; Virag L, 2002, PHARMACOL REV, V54, P375, DOI 10.1124/pr.54.3.375; Votyakova TV, 2001, J NEUROCHEM, V79, P266, DOI 10.1046/j.1471-4159.2001.00548.x; Wang ZQ, 1997, GENE DEV, V11, P2347, DOI 10.1101/gad.11.18.2347; Whalen MJ, 1999, J CEREBR BLOOD F MET, V19, P835, DOI 10.1097/00004647-199908000-00002; Yakes FM, 1997, P NATL ACAD SCI USA, V94, P514, DOI 10.1073/pnas.94.2.514; Yu SW, 2002, SCIENCE, V297, P259, DOI 10.1126/science.1072221; ZHANG J, 1994, SCIENCE, V263, P687, DOI 10.1126/science.8080500; Zhang XP, 2002, J NEUROCHEM, V82, P181, DOI 10.1046/j.1471-4159.2002.00975.x	47	266	273	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 16	2003	278	20					18426	18433		10.1074/jbc.M301295200	http://dx.doi.org/10.1074/jbc.M301295200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677YX	12626504	hybrid			2022-12-25	WOS:000182838300109
J	Hatae, N; Kita, A; Tanaka, S; Sugimoto, Y; Ichikawa, A				Hatae, N; Kita, A; Tanaka, S; Sugimoto, Y; Ichikawa, A			Induction of adherent activity in mastocytoma P-815 cells by the cooperation of two prostaglandin E-2 receptor subtypes, EP3 and EP4	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAST-CELLS; PROSTANOID RECEPTORS; TERMINAL DOMAINS; EP(3) SUBTYPE; 2 ISOFORMS; LAMININ; ADHESION; EXPRESSION; CLONING; KINASE	In this study, we investigated the role of PGE(2) in mouse mastocytoma P-815 cell adhesion to extracellular matrix proteins (ECMs) in vitro. We report that PGE(2) accelerated ProNectin F-TM ( a proteolytic fragment of fibronectin)-mediated adhesion, which was abolished by addition of the GRGDS peptide, an inhibitor of the RDG binding site of ProNectin F-TM. We show that the cAMP level and cAMP-regulated protein kinase (PKA) activity are critical mediators of this PGE(2) effect, because the cell-permeable cAMP analogue 8-Br-cAMP accelerated P-815 cell adhesion to ProNectin FTM and the pharmacological inhibitor of PKA, H-89, blocked PGE(2)-mediated adhesion. Consistent with mRNA expression of the G(s)-coupled EP4- and G(i)-coupled EP3-PGE receptor subtypes, P-815 cell adhesion was accelerated by treatment with a selective EP4 agonist, ONO-AE1-329, but not a selective EP1/EP3 agonist, sulprostone. However, simultaneous treatment with ONO-AE1-329 and sulprostone resulted in augmentation of both the cAMP level and cell adhesion. The augmentation of EP3-mediated cAMP synthesis was dose-dependent, without affecting the half-maximal concentration for EP4- mediated G(s)-activity, which was inhibited by a G(i) inhibitor, pertussis toxin. In conclusion, these findings suggest that PGE2 accelerates RGD-dependent adhesion via cooperative activation between EP3 and EP4 and contributes to the recruitment of mast cells to the ECM during inflammation.	Kyoto Univ, Fac Sci,Grad Sch Pharmaceut Sci, Dept Physiol Chem, Sakyo Ku, Kyoto 606, Japan	Kyoto University	Ichikawa, A (corresponding author), Kyoto Univ, Fac Sci,Grad Sch Pharmaceut Sci, Dept Physiol Chem, Sakyo Ku, Kyoto 606, Japan.		TANAKA, Satoshi/B-1624-2011; Sugimoto, Yukihiko/AAV-6470-2021; Tanaka, Satoshi/H-6800-2019	TANAKA, Satoshi/0000-0002-3468-7694; Sugimoto, Yukihiko/0000-0001-6973-932X; Tanaka, Satoshi/0000-0002-3468-7694				AKIYAMA SK, 1985, J BIOL CHEM, V260, P402; ANDERSON JP, 1994, BIOPOLYMERS, V34, P1049, DOI 10.1002/bip.360340808; BIANCHINE PJ, 1992, J IMMUNOL, V149, P3665; COLEMAN RA, 1994, PHARMACOL REV, V46, P205; DASTYCH J, 1991, IMMUNOLOGY, V73, P478; Dormond O, 2002, J BIOL CHEM, V277, P45838, DOI 10.1074/jbc.M209213200; Dormond O, 2001, NAT MED, V7, P1041, DOI 10.1038/nm0901-1041; FEREMAN AD, 1992, NATURE, V356, P159; Hanke S, 2001, MOL CELL BIOL, V21, P8452, DOI 10.1128/MCB.21.24.8452-8460.2001; Hatae N, 2002, BIOCHEM BIOPH RES CO, V290, P162, DOI 10.1006/bbrc.2001.6169; HONDA A, 1993, J BIOL CHEM, V268, P7759; HU ZQ, 1995, J IMMUNOL, V155, P2134; IRIE A, 1993, EUR J BIOCHEM, V217, P313, DOI 10.1111/j.1432-1033.1993.tb18248.x; IRIE A, 1994, BIOCHEM BIOPH RES CO, V204, P303, DOI 10.1006/bbrc.1994.2460; Kameyoshi Y, 2000, ARCH DERMATOL RES, V292, P240, DOI 10.1007/s004030050481; KATSUYAMA M, 1995, FEBS LETT, V372, P151, DOI 10.1016/0014-5793(95)00966-D; KINASHI T, 1995, BLOOD, V86, P2086, DOI 10.1182/blood.V86.6.2086.bloodjournal8662086; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Narumiya S, 1999, PHYSIOL REV, V79, P1193, DOI 10.1152/physrev.1999.79.4.1193; NEGISHI M, 1995, J BIOL CHEM, V270, P16122, DOI 10.1074/jbc.270.27.16122; NEGISHI M, 1993, J BIOL CHEM, V268, P9517; OHUCHI K, 1982, INT ARCH ALLER A IMM, V68, P326, DOI 10.1159/000233121; Saito H, 1996, J IMMUNOL, V157, P343; Southall MD, 2001, J BIOL CHEM, V276, P16083, DOI 10.1074/jbc.M011408200; SUGIMOTO Y, 1992, J BIOL CHEM, V267, P6463; SUGIMOTO Y, 1993, J BIOL CHEM, V268, P2712; THOMPSON HL, 1989, J IMMUNOL, V143, P4188; THOMPSON HL, 1991, IMMUNOLOGY, V72, P144; THOMPSON HL, 1990, J IMMUNOL, V145, P3425; THOMPSON HL, 1989, J IMMUNOL, V143, P2323; WALSH LJ, 1991, LAB INVEST, V65, P433; Wu CY, 1999, J CELL SCI, V112, P4485	32	20	21	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 16	2003	278	20					17977	17981		10.1074/jbc.M301312200	http://dx.doi.org/10.1074/jbc.M301312200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677YX	12637575	hybrid			2022-12-25	WOS:000182838300049
J	Vreede, J; van der Horst, MA; Hellingwerf, KJ; Crielaard, W; van Aalten, DMF				Vreede, J; van der Horst, MA; Hellingwerf, KJ; Crielaard, W; van Aalten, DMF			PAS domains - Common structure and common flexibility	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOTOACTIVE YELLOW PROTEIN; INDUCED CONFORMATIONAL-CHANGES; PURPLE PHOTOTROPHIC BACTERIUM; ECTOTHIORHODOSPIRA-HALOPHILA; ESSENTIAL DYNAMICS; CRYSTAL-STRUCTURE; PHOTOCYCLE INTERMEDIATE; SIGNAL-TRANSDUCTION; ANGSTROM RESOLUTION; MOLECULAR-DYNAMICS	PAS ((P) under bar ER-(A) under bar RNT-(S) under bar IM) domains are a family of sensor protein domains involved in signal transduction in a wide range of organisms. Recent structural studies have revealed that these domains contain a structurally conserved alpha/beta-fold, whereas almost no conservation is observed at the amino acid sequence level. The photoactive yellow protein, a bacterial light sensor, has been proposed as the PAS structural prototype yet contains an N-terminal helix-turn-helix motif not found in other PAS domains. Here we describe the atomic resolution structure of a photoactive yellow protein deletion mutant lacking this motif, revealing that the PAS domain is indeed able to fold independently and is not affected by the removal of these residues. Computer simulations of currently known PAS domain structures reveal that these domains are not only structurally conserved but are also similar in their conformational flexibilities. The observed motions point to a possible common mechanism for communicating ligand binding/activation to downstream transducer proteins.	Univ Dundee, Sch Life Sci, Wellcome Trust Bioctr, Dundee DD1 5EH, Scotland; Univ Amsterdam, Swammerdam Inst Life Sci, Dept Microbiol, NL-1018 WV Amsterdam, Netherlands	University of Dundee; University of Amsterdam	van der Horst, MA (corresponding author), Univ Dundee, Sch Life Sci, Wellcome Trust Bioctr, Dundee DD1 5EH, Scotland.		Vreede, Jocelyne/G-4525-2010	van Aalten, Daan/0000-0002-1499-6908				AMADEI A, 1993, PROTEINS, V17, P412, DOI 10.1002/prot.340170408; Anantharaman V, 2001, J MOL BIOL, V307, P1271, DOI 10.1006/jmbi.2001.4508; Baltuska A, 1997, CHEM PHYS LETT, V270, P263, DOI 10.1016/S0009-2614(97)00376-X; Biondi RM, 2002, EMBO J, V21, P4219, DOI 10.1093/emboj/cdf437; BORGSTAHL GEO, 1995, BIOCHEMISTRY-US, V34, P6278, DOI 10.1021/bi00019a004; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Cabral JHM, 1998, CELL, V95, P649, DOI 10.1016/S0092-8674(00)81635-9; Changenet P, 1998, CHEM PHYS LETT, V282, P276, DOI 10.1016/S0009-2614(97)01334-1; Chosrowjan H, 1997, CHEM PHYS LETT, V270, P267, DOI 10.1016/S0009-2614(97)00365-5; Crosson S, 2001, P NATL ACAD SCI USA, V98, P2995, DOI 10.1073/pnas.051520298; Crosson S, 2003, BIOCHEMISTRY-US, V42, P2, DOI 10.1021/bi026978l; de Groot BL, 1998, PROTEINS, V31, P116, DOI 10.1002/(SICI)1097-0134(19980501)31:2<116::AID-PROT2>3.0.CO;2-K; deGroot BL, 1997, PROTEINS, V29, P240, DOI 10.1002/(SICI)1097-0134(199710)29:2<240::AID-PROT11>3.0.CO;2-O; deGroot BL, 1996, BIOPHYS J, V71, P1707, DOI 10.1016/S0006-3495(96)79372-4; Dux P, 1998, BIOCHEMISTRY-US, V37, P12689, DOI 10.1021/bi9806652; Genick UK, 1998, NATURE, V392, P206, DOI 10.1038/32462; Genick UK, 1997, SCIENCE, V275, P1471, DOI 10.1126/science.275.5305.1471; Gong WM, 1998, P NATL ACAD SCI USA, V95, P15177, DOI 10.1073/pnas.95.26.15177; Hendriks J, 1999, J BIOL CHEM, V274, P17655, DOI 10.1074/jbc.274.25.17655; HOFF WD, 1994, BIOPHYS J, V67, P1691, DOI 10.1016/S0006-3495(94)80643-5; Hoff WD, 1999, BIOCHEMISTRY-US, V38, P1009, DOI 10.1021/bi980504y; HOLM L, 1993, J MOL BIOL, V233, P123, DOI 10.1006/jmbi.1993.1489; Imamoto Y, 2002, BIOCHEMISTRY-US, V41, P13595, DOI 10.1021/bi0264768; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kort R, 1996, FEBS LETT, V382, P73, DOI 10.1016/0014-5793(96)00149-4; Mello LV, 2002, J BIOL CHEM, V277, P36678, DOI 10.1074/jbc.M205140200; MEYER TE, 1991, BIOPHYS J, V59, P988, DOI 10.1016/S0006-3495(91)82313-X; MEYER TE, 1989, BIOPHYS J, V56, P559, DOI 10.1016/S0006-3495(89)82703-1; MEYER TE, 1987, BIOCHEMISTRY-US, V26, P418, DOI 10.1021/bi00376a012; MILLER A, 1998, BIOCHIM BIOPHYS ACTA, V1141, P190; NAMBU JR, 1991, CELL, V67, P1157, DOI 10.1016/0092-8674(91)90292-7; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Pellequer JL, 1998, P NATL ACAD SCI USA, V95, P5884, DOI 10.1073/pnas.95.11.5884; Perman B, 1998, SCIENCE, V279, P1946, DOI 10.1126/science.279.5358.1946; Rubinstenn G, 1998, NAT STRUCT BIOL, V5, P568, DOI 10.1038/823; Sasaki J, 2002, BIOCHEMISTRY-US, V41, P1915, DOI 10.1021/bi011721t; Sheldrick GM, 1997, METHOD ENZYMOL, V277, P319, DOI 10.1016/S0076-6879(97)77018-6; SPRENGER WW, 1993, J BACTERIOL, V175, P3096, DOI 10.1128/JB.175.10.3096-3104.1993; Taylor BL, 1999, MICROBIOL MOL BIOL R, V63, P479, DOI 10.1128/MMBR.63.2.479-506.1999; Ujj L, 1998, BIOPHYS J, V75, P406, DOI 10.1016/S0006-3495(98)77525-3; van Aalten DMF, 2000, BIOCHEMISTRY-US, V39, P10082, DOI 10.1021/bi000952h; van Aalten DMF, 1998, PROTEIN ENG, V11, P873, DOI 10.1093/protein/11.10.873; van Aalten DMF, 2002, J BIOL CHEM, V277, P6463, DOI 10.1074/jbc.M109313200; van Aalten DMF, 2002, ACTA CRYSTALLOGR D, V58, P585, DOI 10.1107/S0907444902001257; Van Aalten DMF, 2000, PROTEIN SCI, V9, P64; van der Horst MA, 2001, FEBS LETT, V497, P26, DOI 10.1016/S0014-5793(01)02427-9; VanAalten DMF, 1997, J COMPUT CHEM, V18, P169, DOI 10.1002/(SICI)1096-987X(19970130)18:2<169::AID-JCC3>3.0.CO;2-T; VANAALTEN DMF, 1995, PROTEINS, V22, P45, DOI 10.1002/prot.340220107; vanAalten DMF, 1996, BIOPHYS J, V70, P684, DOI 10.1016/S0006-3495(96)79608-X; vanAalten DMF, 1995, PROTEIN ENG, V8, P1129; vanAalten DMF, 1997, BIOPHYS J, V73, P2891, DOI 10.1016/S0006-3495(97)78317-6; VanBrederode ME, 1996, BIOPHYS J, V71, P365, DOI 10.1016/S0006-3495(96)79234-2; VRIEND G, 1990, J MOL GRAPHICS, V8, P52, DOI 10.1016/0263-7855(90)80070-V; Xie AH, 1996, BIOCHEMISTRY-US, V35, P14671, DOI 10.1021/bi9623035; Xie AH, 2001, BIOCHEMISTRY-US, V40, P1510, DOI 10.1021/bi002449a; Zhulin IB, 1997, TRENDS BIOCHEM SCI, V22, P331, DOI 10.1016/S0968-0004(97)01110-9	57	71	72	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 16	2003	278	20					18434	18439		10.1074/jbc.M301701200	http://dx.doi.org/10.1074/jbc.M301701200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677YX	12639952	hybrid, Green Submitted			2022-12-25	WOS:000182838300110
J	He, LH; Lemasters, JJ				He, LH; Lemasters, JJ			Heat shock suppresses the permeability transition in rat liver mitochondria	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMALL STRESS PROTEINS; ALPHA-B-CRYSTALLIN; INDUCED CELL-DEATH; OXIDATIVE STRESS; CYCLOSPORINE-A; INDUCED APOPTOSIS; PORE; INJURY; INCREASE; HSP70	Heat shock proteins inhibit apoptotic and necrotic cell death in various cell types. However, the specific mechanism underlying protection by heat shock proteins remains unclear. To test the hypothesis that heat shock proteins inhibit cell death by blocking opening of mitochondrial permeability transition (MPT) pores, mitochondria from heat-preconditioned rat livers were isolated by differential centrifugation. Heat shock inhibited MPT pore opening induced by 50 muM CaCl2 plus 5 muM HgCl2 or 1 muM mastoparan and by 200 muM CaCl2 alone. Half-maximal swelling was delayed 15 min or more after heat shock compared with control. Heat shock also increased the threshold of unregulated (Ca2+-independent and cyclosporin A-insensitive) MPT pore opening induced by higher doses of HgCl2 and mastoparan. Heat shock treatment decreased mitochondrial reactive oxygen species formation by 27% but did not change mitochondrial respiration, membrane potential, Ca2+ uptake, or total glutathione in mitochondrial and cytosolic extracts of liver. Western blot analysis showed that mitochondrial Hsp25 increased, whereas Hsp10, Hsp60, Hsp70, Hsp75, cyclophilin D, and voltage-dependent anion channel did not change after heat shock. These results indicate that heat shock causes resistance to opening of MPT pores, which may contribute to heat shock protection against cellular injury.	Univ N Carolina, Dept Cell & Dev Biol, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill	Lemasters, JJ (corresponding author), Univ N Carolina, Dept Cell & Dev Biol, CB 7090,236 Taylor Hall, Chapel Hill, NC 27599 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK059340, R37DK037034, R01DK037034] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R37AG007218, R01AG007218] Funding Source: NIH RePORTER; NIA NIH HHS [AG07218] Funding Source: Medline; NIDDK NIH HHS [DK59340, DK37034] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ahn JH, 1999, MOL CELLS, V9, P200; Arrigo AP, 1998, BIOL CHEM, V379, P19; Bernardi P, 1999, PHYSIOL REV, V79, P1127, DOI 10.1152/physrev.1999.79.4.1127; Blattner JR, 2001, ANAL BIOCHEM, V295, P220, DOI 10.1006/abio.2001.5219; Bornman L, 1998, BIOCHEM BIOPH RES CO, V246, P836, DOI 10.1006/bbrc.1998.8717; BROEKEMEIER KM, 1989, BIOCHEM BIOPH RES CO, V163, P561, DOI 10.1016/0006-291X(89)92174-8; Bruey JM, 2000, NAT CELL BIOL, V2, P645, DOI 10.1038/35023595; CASPERS GJ, 1995, J MOL EVOL, V40, P238, DOI 10.1007/BF00163229; CROMPTON M, 1987, BIOCHEM J, V245, P915, DOI 10.1042/bj2450915; Diez-Fernandez C, 2002, FREE RADICAL BIO MED, V33, P835, DOI 10.1016/S0891-5849(02)00975-9; Dokladny K, 2001, AM J PHYSIOL-REG I, V280, pR338, DOI 10.1152/ajpregu.2001.280.2.R338; Downs CA, 1999, ARCH BIOCHEM BIOPHYS, V365, P344, DOI 10.1006/abbi.1999.1177; Fontaine E, 1999, J BIOENERG BIOMEMBR, V31, P335, DOI 10.1023/A:1005475802350; GORNALL AG, 1949, J BIOL CHEM, V177, P751; He LH, 2002, FEBS LETT, V512, P1, DOI 10.1016/S0014-5793(01)03314-2; Huser J, 1998, BIOPHYS J, V74, P2129, DOI 10.1016/S0006-3495(98)77920-2; Kirchhoff SR, 2002, CIRCULATION, V105, P2899, DOI 10.1161/01.CIR.0000019403.35847.23; Kowaltowski AJ, 2001, FEBS LETT, V495, P12, DOI 10.1016/S0014-5793(01)02316-X; Kregel KC, 2002, J APPL PHYSIOL, V92, P2177, DOI 10.1152/japplphysiol.01267.2001; Kristal BS, 1999, J BIOL CHEM, V274, P23169, DOI 10.1074/jbc.274.33.23169; Lemasters JJ, 1998, BBA-BIOENERGETICS, V1366, P177, DOI 10.1016/S0005-2728(98)00112-1; LEMASTERS JJ, 1984, J BIOL CHEM, V259, P3058; LENARTOWICZ E, 1991, J BIOENERG BIOMEMBR, V23, P679, DOI 10.1007/BF00785817; Li F, 2002, AM J PHYSIOL-CELL PH, V283, pC917, DOI 10.1152/ajpcell.00517.2001; Lin DT, 2002, J BIOL CHEM, V277, P31134, DOI 10.1074/jbc.M112035200; Mehlen P, 1996, J BIOL CHEM, V271, P16510, DOI 10.1074/jbc.271.28.16510; Mehlen P, 1996, EMBO J, V15, P2695, DOI 10.1002/j.1460-2075.1996.tb00630.x; Mosser DD, 2000, MOL CELL BIOL, V20, P7146, DOI 10.1128/MCB.20.19.7146-7159.2000; PETRONILLI V, 1993, J BIOL CHEM, V268, P1011; PETRONILLI V, 1994, BBA-BIOENERGETICS, V1187, P255, DOI 10.1016/0005-2728(94)90122-8; Petronilli V, 1999, BIOPHYS J, V76, P725, DOI 10.1016/S0006-3495(99)77239-5; PETRONILLI V, 1994, J BIOL CHEM, V269, P16638; PFEIFFER DR, 1995, J BIOL CHEM, V270, P4923, DOI 10.1074/jbc.270.9.4923; Plumier JCL, 1996, CELL STRESS CHAPERON, V1, P13, DOI 10.1379/1466-1268(1996)001<0013:HSIMPA>2.3.CO;2; Polla BS, 1996, P NATL ACAD SCI USA, V93, P6458, DOI 10.1073/pnas.93.13.6458; Preville X, 1999, EXP CELL RES, V247, P61, DOI 10.1006/excr.1998.4347; Samali A, 2001, CELL STRESS CHAPERON, V6, P49, DOI 10.1379/1466-1268(2001)006<0049:HPMOTC>2.0.CO;2; Takuma K, 2002, BRAIN RES, V946, P232, DOI 10.1016/S0006-8993(02)02888-3; Uchinami H, 2002, AM J PHYSIOL-GASTR L, V282, pG962, DOI 10.1152/ajpgi.00466.2001; van de Klundert FAJM, 1998, EUR J CELL BIOL, V75, P38, DOI 10.1016/S0171-9335(98)80044-7; Wyttenbach A, 2002, HUM MOL GENET, V11, P1137, DOI 10.1093/hmg/11.9.1137; Yan LJ, 2002, EMBO J, V21, P5164, DOI 10.1093/emboj/cdf528	42	64	73	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 9	2003	278	19					16755	16760		10.1074/jbc.M300153200	http://dx.doi.org/10.1074/jbc.M300153200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677QG	12611884	hybrid, Green Published			2022-12-25	WOS:000182818600042
J	Swank, DM; Knowles, AF; Kronert, WA; Suggs, JA; Morrill, GE; Nikkhoy, M; Manipon, GG; Bernstein, SI				Swank, DM; Knowles, AF; Kronert, WA; Suggs, JA; Morrill, GE; Nikkhoy, M; Manipon, GG; Bernstein, SI			Variable N-terminal regions of muscle myosin heavy chain modulate ATPase rate and actin sliding velocity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DROSOPHILA-MELANOGASTER; INTERDOMAIN INTERACTIONS; FUNCTIONAL DOMAINS; ALTERNATIVE EXONS; SKELETAL-MUSCLE; MOTOR DOMAIN; ISOFORMS; GENE; BINDING; CONTRACTION	We integratively assessed the function of alternative versions of a region near the N terminus of Drosophila muscle myosin heavy chain (encoded by exon 3a or 3b). We exchanged the alternative exon 3 regions between an embryonic isoform and the indirect flight muscle isoform. Each chimeric myosin was expressed in Drosophila indirect flight muscle, in the absence of other myosin isoforms, allowing for purified protein analysis and whole organism locomotory studies. The flight muscle isoform generates higher in vitro actin sliding velocity and solution ATPase rates than the embryonic isoform. Exchanging the embryonic exon 3 region into the flight muscle isoform decreased ATPase rates to embryonic levels but did not affect actin sliding velocity or flight muscle ultrastructure. Interestingly, this swap only slightly impaired flight ability. Exchanging the flight muscle-specific exon 3 region into the embryonic isoform increased actin sliding velocity 3-fold and improved indirect flight muscle ultrastructure integrity but failed to rescue the flightless phenotype of flies expressing embryonic myosin. These results suggest that the two structural versions of the exon 3 domain independently influence the kinetics of at least two steps of the actomyosin cross-bridge cycle.	San Diego State Univ, Dept Biol, San Diego, CA 92182 USA; San Diego State Univ, Inst Mol Biol, San Diego, CA 92182 USA; San Diego State Univ, Dept Chem, San Diego, CA 92182 USA	California State University System; San Diego State University; California State University System; San Diego State University; California State University System; San Diego State University	Swank, DM (corresponding author), San Diego State Univ, Dept Biol, San Diego, CA 92182 USA.	dswank@sunstroke.sdsu.edu		Bernstein, Sanford/0000-0001-7094-5390	NIGMS NIH HHS [GM32443, GM 58906] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R25GM058906, R01GM032443] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Alpert NR, 2002, AM J PHYSIOL-HEART C, V283, pH1446, DOI 10.1152/ajpheart.00274.2002; BARANY M, 1967, J GEN PHYSIOL, V50, P197, DOI 10.1085/jgp.50.6.197; BARANY M, 1967, EUR J BIOCHEM, V2, P156, DOI 10.1111/j.1432-1033.1967.tb00120.x; BERNSTEIN SI, 1983, NATURE, V302, P393, DOI 10.1038/302393a0; Bernstein SI, 1997, J MOL BIOL, V271, P1, DOI 10.1006/jmbi.1997.1160; Burghardt TP, 2001, BIOCHEMISTRY-US, V40, P4834, DOI 10.1021/bi002388g; Burghardt TP, 2001, BIOCHEMISTRY-US, V40, P4821, DOI 10.1021/bi002387o; CANDE WZ, 1986, METHOD ENZYMOL, V134, P473; CRIPPS RM, 1994, J CELL BIOL, V126, P689, DOI 10.1083/jcb.126.3.689; CRIPPS RM, 2000, INTRO DNA LIVING CEL; Dickinson MH, 1997, BIOPHYS J, V73, P3122, DOI 10.1016/S0006-3495(97)78338-3; DRUMMOND DR, 1991, MOL GEN GENET, V226, P70, DOI 10.1007/BF00273589; Geeves MA, 1999, ANNU REV BIOCHEM, V68, P687, DOI 10.1146/annurev.biochem.68.1.687; GEORGE EL, 1989, MOL CELL BIOL, V9, P2957, DOI 10.1128/MCB.9.7.2957; GRIGLIATTI TA, 1998, DROSOPHILA PRACTICAL, P85; HASTINGS GA, 1991, J CELL BIOL, V114, P263, DOI 10.1083/jcb.114.2.263; HESS N, 1989, CELLULAR MOL BIOL MU, P621; Hirayama Y, 1997, EUR J BIOCHEM, V246, P380, DOI 10.1111/j.1432-1033.1997.t01-2-00380.x; KRON SJ, 1991, METHOD ENZYMOL, V196, P399; Kronert WA, 1999, J CELL BIOL, V144, P989, DOI 10.1083/jcb.144.5.989; Kurzawa-Goertz SE, 1998, BIOCHEMISTRY-US, V37, P7517, DOI 10.1021/bi972844+; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lauzon AM, 1998, J MUSCLE RES CELL M, V19, P825, DOI 10.1023/A:1005489501357; Littlefield KP, 2003, AM J PHYSIOL-CELL PH, V284, pC1031, DOI 10.1152/ajpcell.00474.2002; LOWEY S, 1993, J BIOL CHEM, V268, P20414; Murphy CT, 2000, J MUSCLE RES CELL M, V21, P139, DOI 10.1023/A:1005610007209; Murphy CT, 1998, BIOCHEMISTRY-US, V37, P6738, DOI 10.1021/bi972903j; ODONNELL PT, 1988, J CELL BIOL, V107, P2601, DOI 10.1083/jcb.107.6.2601; PARDEE JD, 1982, METHOD ENZYMOL, V85, P164; Pereira JS, 2001, J BIOL CHEM, V276, P4409, DOI 10.1074/jbc.M006441200; Razzaq A, 1999, J BIOL CHEM, V274, P28321, DOI 10.1074/jbc.274.40.28321; ROUX KH, 1995, PCR PRIMER LAB MANUA; Rovner AS, 1997, J MUSCLE RES CELL M, V18, P103, DOI 10.1023/A:1018689102122; ROZEK CE, 1983, CELL, V32, P23, DOI 10.1016/0092-8674(83)90493-2; RUPPEL KM, 1994, J BIOL CHEM, V269, P18773; SPUDICH JA, 1994, NATURE, V372, P515, DOI 10.1038/372515a0; Swank DM, 2000, MICROSC RES TECHNIQ, V50, P430, DOI 10.1002/1097-0029(20000915)50:6<430::AID-JEMT2>3.0.CO;2-E; Swank DM, 2002, NAT CELL BIOL, V4, P312, DOI 10.1038/ncb776; Swank DM, 2001, J BIOL CHEM, V276, P15117, DOI 10.1074/jbc.M008379200; Sweeney HL, 1998, J BIOL CHEM, V273, P6262, DOI 10.1074/jbc.273.11.6262; Tyska MJ, 2002, CELL MOTIL CYTOSKEL, V51, P1, DOI 10.1002/cm.10014; Wells L, 1996, EMBO J, V15, P4454, DOI 10.1002/j.1460-2075.1996.tb00822.x; Yengo CM, 2002, J BIOL CHEM, V277, P24114, DOI 10.1074/jbc.M111253200; Zhang SX, 2001, MECH DEVELOP, V101, P35, DOI 10.1016/S0925-4773(00)00549-9	44	24	24	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 9	2003	278	19					17475	17482		10.1074/jbc.M212727200	http://dx.doi.org/10.1074/jbc.M212727200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677QG	12606545	hybrid			2022-12-25	WOS:000182818600135
J	Takenobu, H; Yamazaki, A; Hirata, M; Umata, T; Mekada, E				Takenobu, H; Yamazaki, A; Hirata, M; Umata, T; Mekada, E			The stress- and inflammatory cytokine-induced ectodomain shedding of heparin-binding epidermal growth factor-like growth factor is mediated by p38 MAPK, distinct from the 12-O-tetradecanoylphorbol-13-acetate- and lysophosphatidic acid-induced signaling cascades	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIPHTHERIA-TOXIN RECEPTOR; MESSENGER-RNA LEVELS; SMOOTH-MUSCLE-CELLS; PROTEIN-KINASE-C; EGF-RECEPTOR; HB-EGF; FACTOR GENE; ACTIVATION; EXPRESSION; JUXTACRINE	Heparin-binding epidermal growth factor-like growth factor (HB-EGF) is a critical growth factor for a number of physiological and pathological processes. HB-EGF is synthesized as a membrane-anchored form (pro-HBEGF), and pro-HB-EGF is cleaved at the cell surface to yield soluble HB-EGF by a mechanism called "ectodomain shedding." We show here that the ectodomain shedding of pro-HB-EGF in Vero cells is induced by various stress-inducing stimuli, including UV light, osmotic pressure, hyperoxidation, and translation inhibitors. The pro-inflammatory cytokine interleukin-1beta also stimulated the ectodomain shedding of pro-HB-EGF. An inhibitor of p38 MAPK (SB203580) or the expression of a dominant-negative (dn) form of p38 MAPK inhibited the stress-induced ectodomain shedding of pro-HB-EGF, whereas an inhibitor of JNK (SP600125) or the expression of dnJNK1 did not. 12-O-Tetradecanoylphorbol-13-acetate (TPA) and lysophosphatidic acid (LPA) are also potent inducers of pro-HB-EGF shedding in Vero cells. Stress-induced pro-HB-EGF shedding was not inhibited by the inhibitors of TPA- or LPA-induced pro-HB-EGF shedding or by dn forms of molecules involved in the TPA- or LPA-induced pro-HB-EGF shedding pathway. Reciprocally, SB203580 or dnp38 MAPK did not inhibit TPA- or LPA-induced pro-HB-EGF shedding. These results indicate that stress-induced pro-HB-EGF shedding is mediated by p38 MAPK and that the signaling pathway induced by stress is distinct from the TPA- or LPA-induced pro-HB-EGF shedding pathway.	Osaka Univ, Microbial Dis Res Inst, Dept Cell Biol, Suita, Osaka 5650871, Japan; Kurume Univ, Inst Life Sci, Fukuoka 8390861, Japan	Osaka University; Kurume University	Mekada, E (corresponding author), Osaka Univ, Microbial Dis Res Inst, Dept Cell Biol, 2-2 Yamadaoka, Suita, Osaka 5650871, Japan.	emekada@biken.osaka-u.ac.jp		Mekada, Eisuke/0000-0001-8858-4781; Takenobu, Hisanori/0000-0001-7355-1565				Arribas J, 1996, J BIOL CHEM, V271, P11376, DOI 10.1074/jbc.271.19.11376; Asakura M, 2002, NAT MED, V8, P35, DOI 10.1038/nm0102-35; Bennett BL, 2001, P NATL ACAD SCI USA, V98, P13681, DOI 10.1073/pnas.251194298; Black RA, 1998, CURR OPIN CELL BIOL, V10, P654, DOI 10.1016/S0955-0674(98)80042-2; Blobel CP, 2000, CURR OPIN CELL BIOL, V12, P606, DOI 10.1016/S0955-0674(00)00139-3; BLOTNICK S, 1994, P NATL ACAD SCI USA, V91, P2890, DOI 10.1073/pnas.91.8.2890; BRADSHAW D, 1993, AGENTS ACTIONS, V38, P135, DOI 10.1007/BF02027225; CANO E, 1994, MOL CELL BIOL, V14, P7352, DOI 10.1128/MCB.14.11.7352; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; DAS SK, 1994, DEVELOPMENT, V120, P1071; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; Eguchi S, 2001, J BIOL CHEM, V276, P7957, DOI 10.1074/jbc.M008570200; Elenius K, 1997, EMBO J, V16, P1268, DOI 10.1093/emboj/16.6.1268; Fan HZ, 1999, EMBO J, V18, P6962, DOI 10.1093/emboj/18.24.6962; Fang L, 2001, EMBO J, V20, P1931, DOI 10.1093/emboj/20.8.1931; Franzke CW, 2002, EMBO J, V21, P5026, DOI 10.1093/emboj/cdf532; Fu SL, 1999, P NATL ACAD SCI USA, V96, P5716, DOI 10.1073/pnas.96.10.5716; Fujino T, 1998, CARDIOVASC RES, V38, P365, DOI 10.1016/S0008-6363(98)00010-8; Fujishiro M, 2001, J BIOL CHEM, V276, P19800, DOI 10.1074/jbc.M101087200; Fujiyama S, 2001, CIRC RES, V88, P22, DOI 10.1161/01.RES.88.1.22; Gechtman Z, 1999, J BIOL CHEM, V274, P28828, DOI 10.1074/jbc.274.40.28828; GOISHI K, 1995, MOL BIOL CELL, V6, P967, DOI 10.1091/mbc.6.8.967; Han JH, 1996, J BIOL CHEM, V271, P2886, DOI 10.1074/jbc.271.6.2886; HIGASHIYAMA S, 1991, SCIENCE, V251, P936, DOI 10.1126/science.1840698; HIGASHIYAMA S, 1992, J BIOL CHEM, V267, P6205; HIGASHIYAMA S, 1995, J CELL BIOL, V128, P929, DOI 10.1083/jcb.128.5.929; HIRAI S, 1994, EMBO J, V13, P2331, DOI 10.1002/j.1460-2075.1994.tb06517.x; Hirata M, 2001, BIOCHEM BIOPH RES CO, V283, P915, DOI 10.1006/bbrc.2001.4879; Hooper NM, 1997, BIOCHEM J, V321, P265, DOI 10.1042/bj3210265; Igura T, 1996, ARTERIOSCL THROM VAS, V16, P1524, DOI 10.1161/01.ATV.16.12.1524; Iwamoto R, 2000, CYTOKINE GROWTH F R, V11, P335, DOI 10.1016/S1359-6101(00)00013-7; IWAMOTO R, 1994, EMBO J, V13, P2322, DOI 10.1002/j.1460-2075.1994.tb06516.x; Iwamoto R, 1999, J BIOL CHEM, V274, P25906, DOI 10.1074/jbc.274.36.25906; Izumi Y, 1998, EMBO J, V17, P7260, DOI 10.1093/emboj/17.24.7260; Koh YH, 2001, J BIOCHEM-TOKYO, V130, P351, DOI 10.1093/oxfordjournals.jbchem.a002993; Kyriakis JM, 2001, PHYSIOL REV, V81, P807, DOI 10.1152/physrev.2001.81.2.807; LEE JC, 1994, NATURE, V372, P739, DOI 10.1038/372739a0; Lemjabbar H, 2002, NAT MED, V8, P41, DOI 10.1038/nm0102-41; Levine SJ, 1996, AM J RESP CELL MOL, V14, P254, DOI 10.1165/ajrcmb.14.3.8845176; MARIKOVSKY M, 1993, P NATL ACAD SCI USA, V90, P3889, DOI 10.1073/pnas.90.9.3889; Michalsky MP, 2001, J PEDIATR SURG, V36, P1130, DOI 10.1053/jpsu.2001.25730; MITAMURA T, 1992, J CELL BIOL, V118, P1389, DOI 10.1083/jcb.118.6.1389; MIYAGAWA J, 1995, J CLIN INVEST, V95, P404, DOI 10.1172/JCI117669; Miyazaki Y, 2001, GASTROENTEROLOGY, V120, P108, DOI 10.1053/gast.2001.20950; Montero JC, 2002, BIOCHEM J, V363, P211, DOI 10.1042/0264-6021:3630211; MORITA T, 1993, BIOCHEM BIOPH RES CO, V197, P256, DOI 10.1006/bbrc.1993.2469; NAKAMURA K, 1995, J CELL BIOL, V129, P1691, DOI 10.1083/jcb.129.6.1691; Nguyen HT, 2000, AM J PHYSIOL-CELL PH, V279, pC1155, DOI 10.1152/ajpcell.2000.279.4.C1155; OHNO S, 1994, J BIOL CHEM, V269, P17495; PERRELLA MA, 1994, J BIOL CHEM, V269, P27045; Prenzel N, 1999, NATURE, V402, P884, DOI 10.1038/47260; RAAB G, 1997, BIOCHIM BIOPHYS ACTA, V1333, P179; Rizoli SB, 1999, J BIOL CHEM, V274, P22072, DOI 10.1074/jbc.274.31.22072; Sakai M, 2001, EXP NEPHROL, V9, P28; Sunnarborg SW, 2002, J BIOL CHEM, V277, P12838, DOI 10.1074/jbc.M112050200; Takemura T, 2001, J AM SOC NEPHROL, V12, P964, DOI 10.1681/ASN.V125964; Tokumaru S, 2000, J CELL BIOL, V151, P209, DOI 10.1083/jcb.151.2.209; Umata T, 2001, J BIOL CHEM, V276, P30475, DOI 10.1074/jbc.M103673200; Weskamp G, 1996, J CELL BIOL, V132, P717, DOI 10.1083/jcb.132.4.717; Yabkowitz R, 1999, BLOOD, V93, P1969, DOI 10.1182/blood.V93.6.1969.406k14_1969_1979; Yan YB, 2002, J CELL BIOL, V158, P221, DOI 10.1083/jcb.200112026; YOSHIZUMI M, 1992, J BIOL CHEM, V267, P9467	63	57	59	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 9	2003	278	19					17255	17262		10.1074/jbc.M211835200	http://dx.doi.org/10.1074/jbc.M211835200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677QG	12611888	hybrid			2022-12-25	WOS:000182818600108
J	Taouil, K; Hinnrasky, J; Hologne, C; Corlieu, P; Klossek, JM; Puchelle, E				Taouil, K; Hinnrasky, J; Hologne, C; Corlieu, P; Klossek, JM; Puchelle, E			Stimulation of beta 2-adrenergic receptor increases cystic fibrosis transmembrane conductance regulator expression in human airway epithelial cells through a cAMP/protein kinase A-independent pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOMAIN INTERACTION CONTROLS; BETA(2)-ADRENERGIC RECEPTOR; CFTR; PROTEIN; ASSOCIATION; SYSTEM	PSD-95/Dlg-A/ZO-1 (PDZ) domains play an essential role in determining cell polarity. The Na+/H+ exchanger regulatory factor (NHERF), also known as EBP50, contains two PDZ domains that mediate the assembly of transmembrane and cytosolic proteins into functional signal transduction complexes. Moreover, it has been shown that cystic fibrosis transmembrane conductance regulator (CFTR) and beta(2)-adrenergic receptor (beta(2)AR) bind equally well to the PDZ1 domain of EBP50. We hypothesized that beta(2)AR activation may regulate CFTR protein expression. To verify this, we evaluated the effects of a pharmacologically relevant concentration of salmeterol (2.10(-7) M), a long acting beta(2)AR agonist, on CFTR expression in primary human airway epithelial cells (HAEC). beta(2)AR stimulation induced a time-dependent increase in apical CFTR protein expression, with a maximal response reached after treatment for 24 h. This effect was post-transcriptional, dependent upon the beta(2)AR agonist binding to beta(2)AR and independent of the known beta(2)AR agonist-mediated cAMP/PKA pathway. We demonstrated by immunohistochemistry that CFTR, beta(2)AR, and EBP50 localize to the apical membrane of HAEC. Analyses of anti-EBP50 protein immunoprecipitate showed that salmeterol induced an increase in the amount of CFTR that binds to EBP50. These data suggest that beta(2)AR activation regulates the association of CFTR with EBP50 in polarized HAEC.	Ctr Hosp Univ Maison Blanche, INSERM 514, IFR 53, F-51092 Reims, France; Hop Tenon, F-75020 Paris, France; Hop Jean Bernard, F-86021 Poitiers, France	CHU de Reims; Institut National de la Sante et de la Recherche Medicale (Inserm); Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Tenon - APHP; UDICE-French Research Universities; Sorbonne Universite; CHU Poitiers; Universite de Poitiers	Puchelle, E (corresponding author), Ctr Hosp Univ Maison Blanche, INSERM 514, IFR 53, 45 Rue Cognacq Jay, F-51092 Reims, France.	epuche@worldnet.fr						BREZILLON S, 1995, LAB INVEST, V72, P191; Brown D, 2000, AM J PHYSIOL-RENAL, V278, pF192, DOI 10.1152/ajprenal.2000.278.2.F192; Cao TT, 1999, NATURE, V401, P286, DOI 10.1038/45816; Castillon N, 2002, LAB INVEST, V82, P989, DOI 10.1097/01.LAB.0000022221.88025.43; CHENG SH, 1990, CELL, V63, P827, DOI 10.1016/0092-8674(90)90148-8; DAVIS PB, 1990, AM J PHYSIOL, V258, pC71, DOI 10.1152/ajpcell.1990.258.1.C71; DUPUIT F, 1995, J CLIN INVEST, V96, P1601, DOI 10.1172/JCI118199; Fanning AS, 1999, J CLIN INVEST, V103, P767, DOI 10.1172/JCI6509; Hall RA, 1998, NATURE, V392, P626, DOI 10.1038/33458; Hall RA, 1998, P NATL ACAD SCI USA, V95, P8496, DOI 10.1073/pnas.95.15.8496; Howard M, 2000, AM J PHYSIOL-CELL PH, V279, pC375, DOI 10.1152/ajpcell.2000.279.2.C375; Howard M, 1996, KIDNEY INT, V49, P1642, DOI 10.1038/ki.1996.239; Jiang TR, 1997, AM J PHYSIOL-HEART C, V273, pH1044, DOI 10.1152/ajpheart.1997.273.2.H1044; JORISSEN M, 1991, EUR RESPIR J, V4, P210; Kalin N, 1999, J CLIN INVEST, V103, P1379, DOI 10.1172/JCI5731; KELSEN SG, 1995, AM J RESP CRIT CARE, V152, P1774, DOI 10.1164/ajrccm.152.6.8520736; Kelsen SG, 1997, AM J PHYSIOL-LUNG C, V272, pL916, DOI 10.1152/ajplung.1997.272.5.L916; Loffing J, 1998, AM J PHYSIOL-CELL PH, V275, pC913, DOI 10.1152/ajpcell.1998.275.4.C913; Maudsley S, 2000, MOL CELL BIOL, V20, P8352, DOI 10.1128/MCB.20.22.8352-8363.2000; Milewski MI, 2001, J CELL SCI, V114, P719; Mostov KE, 2000, CURR OPIN CELL BIOL, V12, P483, DOI 10.1016/S0955-0674(00)00120-4; Moyer BD, 1999, J CLIN INVEST, V104, P1353, DOI 10.1172/JCI7453; NIJKAMP FP, 1992, PHYSIOL REV, V72, P323, DOI 10.1152/physrev.1992.72.2.323; Pilewski JM, 1999, PHYSIOL REV, V79, P215; Short DB, 1998, J BIOL CHEM, V273, P19797, DOI 10.1074/jbc.273.31.19797; Spicuzza L, 2001, BRIT J PHARMACOL, V133, P1201, DOI 10.1038/sj.bjp.0704213; Sun F, 2000, J BIOL CHEM, V275, P29539, DOI 10.1074/jbc.M004961200; Swiatecka-Urban A, 2002, J BIOL CHEM, V277, P40099, DOI 10.1074/jbc.M206964200; TURKI J, 1995, AM J PHYSIOL-LUNG C, V269, pL709, DOI 10.1152/ajplung.1995.269.5.L709	29	44	44	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 9	2003	278	19					17320	17327		10.1074/jbc.M212227200	http://dx.doi.org/10.1074/jbc.M212227200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677QG	12621035	hybrid			2022-12-25	WOS:000182818600117
J	Agathanggelou, A; Dallol, A; Zochbauer-Muller, S; Morrissey, C; Honorio, S; Hesson, L; Martinsson, T; Fong, KM; Kuo, MJ; Yuen, PW; Maher, ER; Minna, JD; Latif, F				Agathanggelou, A; Dallol, A; Zochbauer-Muller, S; Morrissey, C; Honorio, S; Hesson, L; Martinsson, T; Fong, KM; Kuo, MJ; Yuen, PW; Maher, ER; Minna, JD; Latif, F			Epigenetic inactivation of the candidate 3p21.3 suppressor gene BLU in human cancers	ONCOGENE			English	Article						epigenetic inactivation; 3p21.3 region; human cancers	SINGLE NUCLEOTIDE POLYMORPHISM; HUMAN-CHROMOSOME 3P21.3; HIPPEL-LINDAU-DISEASE; CHANNEL SUBUNIT GENE; HUMAN LUNG-CANCER; 3P ALLELE LOSS; NEUROBLASTOMA TUMORS; RENAL-CARCINOMA; BREAST-CANCER; IDENTIFICATION	Many distinct regions of 3p show frequent allelic losses in a wide range of tumour types. Previously, the BLU candidate tumour suppressor gene (TSG) encoded by a gene-rich critical deleted region in 3p21.3 was found to be inactivated rarely in lung cancer, although expression was downregulated in a subset of lung tumour cell lines. To elucidate the role of BLU in tumorigenesis, we analysed BLU promoter methylation status in tumour cell lines and detected promoter region hypermethylation in 39% lung, 42% breast, 50% kidney, 86% neuroblastoma and 80% nasopharyngeal (NPC) tumour cell lines. Methylation of the BLU promoter region correlated with the down-regulation of BLU transcript expression in tumour cell lines. Expression was recovered in tumour cell lines treated with 5-aza 2-deoxycytidine. Exogenous expression of BLU in neuroblastoma (SK-N-SH) and NSCLC (NCI-H1299) resulted in reduced colony formation efficiency, in vitro. Furthermore, methylation of the BLU promoter region was detected in primary sporadic SCLC (14%), NSCLC (19%) and neuroblastoma (41%). As frequent methylation of the RASSF1A 3p21.3 TSG has also been reported in these tumour types, we investigated whether BLU and RASSF1A methylation were independent or related events. No correlation was found between hypermethylation of RASSF1A and BLU promoter region CpG islands in SCLC or neuroblastoma. However, there was association between RASSF1A and BLU methylation in NSCLC (P = 0.0031). Our data suggest that in SCLC and neuroblastoma, RASSF1A and BLU methylations are unrelated events and not a manifestation of a regional alteration in epigenetic status, while in NSCLC there may be a regional methylation effect. Together, these data suggest a significant role for epigenetic inactivation of BLU in the pathogenesis of common human cancers and that methylation inactivation of BLU occurs independent of RASSF1A in SCLC and neuroblastoma tumours.	Univ Birmingham, Sch Med, Dept Paediat & Child Hlth, Sect Med & Mol Genet, Birmingham B15 2TT, W Midlands, England; Univ Texas, SW Med Ctr, Hamon Ctr Therapeut Oncol Res, Dallas, TX USA; Univ Gothenburg, Sahlgrenska Hosp Ostra, Dept Clin Genet, S-41685 Gothenburg, Sweden; Prince Charles Hosp, Brisbane, Qld 4032, Australia; Birmingham Childrens Hosp, Birmingham B4 6NH, W Midlands, England; Univ Hong Kong, Dept Surg, Hong Kong, Hong Kong, Peoples R China; Univ Birmingham, Sch Med, Canc Res UK, Renal Mol Oncol Res Grp, Birmingham B15 2TT, W Midlands, England	University of Birmingham; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Gothenburg; Prince Charles Hospital; University of Birmingham; University of Hong Kong; Cancer Research UK; University of Birmingham	Latif, F (corresponding author), Univ Birmingham, Sch Med, Dept Paediat & Child Hlth, Sect Med & Mol Genet, Birmingham B15 2TT, W Midlands, England.	flatif@hgmp.mrc.ac.uk	Martinsson, Tommy/J-4140-2013; Fong, Kwun M/G-6369-2010; Dallol, Ashraf/H-8661-2012; Zöchbauer-Müller, Sabine/B-8399-2012; MAHER, EAMONN R/A-9507-2008; Hesson, Luke/HDM-0311-2022	Martinsson, Tommy/0000-0002-9403-3123; Dallol, Ashraf/0000-0002-8803-228X; Zöchbauer-Müller, Sabine/0000-0002-6777-1729; MAHER, EAMONN R/0000-0002-6226-6918; Fong, Kwun/0000-0002-6507-1403	NATIONAL CANCER INSTITUTE [P50CA070907, R01CA071618] Funding Source: NIH RePORTER; NCI NIH HHS [CA71618, P50 CA70907] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Agathanggelou A, 2001, ONCOGENE, V20, P1509, DOI 10.1038/sj.onc.1204175; Amann JM, 2001, MOL CELL BIOL, V21, P6470, DOI 10.1128/MCB.21.19.6470-6483.2001; Angeloni D, 2000, MOL CELL PROBE, V14, P53, DOI 10.1006/mcpr.1999.0277; Angeloni D, 2001, MOL CELL PROBE, V15, P125, DOI 10.1006/mcpr.2000.0341; Ansieau S, 2002, J BIOL CHEM, V277, P4906, DOI 10.1074/jbc.M110078200; Astuti D, 2001, ONCOGENE, V20, P7573, DOI 10.1038/sj.onc.1204968; Burbee DG, 2001, JNCI-J NATL CANCER I, V93, P691, DOI 10.1093/jnci/93.9.691; Clifford SC, 2001, ADV CANCER RES, V82, P85, DOI 10.1016/S0065-230X(01)82003-0; Dammann R, 2000, NAT GENET, V25, P315, DOI 10.1038/77083; Ejeskar K, 1998, BRIT J CANCER, V77, P1787, DOI 10.1038/bjc.1998.297; FEINSTEIN PG, 1995, GENETICS, V140, P573; Foster K, 1995, EUR J CANCER, V31A, P2392, DOI 10.1016/0959-8049(95)00437-8; Fullwood P, 1999, CANCER RES, V59, P4662; GNARRA JR, 1994, NAT GENET, V7, P85, DOI 10.1038/ng0594-85; HERMAN JG, 1994, P NATL ACAD SCI USA, V91, P9700, DOI 10.1073/pnas.91.21.9700; Honorio S, 2001, MOL CELL PROBE, V15, P391, DOI 10.1006/mcpr.2001.0382; LATIF F, 1993, SCIENCE, V260, P1317, DOI 10.1126/science.8493574; LeBoeuf RD, 1998, J BIOL CHEM, V273, P361, DOI 10.1074/jbc.273.1.361; Lerman MI, 2000, CANCER RES, V60, P6116; Lutterbach B, 1998, MOL CELL BIOL, V18, P3604, DOI 10.1128/MCB.18.6.3604; Maitra A, 2001, AM J PATHOL, V159, P119, DOI 10.1016/S0002-9440(10)61679-3; Martinez A, 2000, J CLIN PATHOL-MOL PA, V53, P137, DOI 10.1136/mp.53.3.137; Martinez A, 2001, J CLIN PATHOL-MOL PA, V54, P300, DOI 10.1136/mp.54.5.300; Masselink H, 2000, ONCOGENE, V19, P1538, DOI 10.1038/sj.onc.1203421; Michelson RJ, 1999, J BIOL CHEM, V274, P30510, DOI 10.1074/jbc.274.43.30510; SEKIDO Y, 1994, ONCOGENE, V9, P1599; Sekido Y, 1998, ONCOGENE, V16, P3151, DOI 10.1038/sj.onc.1201858; Sundaresan V, 1998, ONCOGENE, V17, P1723, DOI 10.1038/sj.onc.1202103; Wei MH, 1996, CANCER RES, V56, P1487; Wistuba II, 2000, CANCER RES, V60, P1949; Wolford JK, 1998, GENE, V212, P103, DOI 10.1016/S0378-1119(98)00141-3; Yan H, 2002, NAT GENET, V30, P25, DOI 10.1038/ng799; Zochbauer-Muller S, 2001, CANCER RES, V61, P249	33	80	90	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 13	2003	22	10					1580	1588		10.1038/sj.onc.1206243	http://dx.doi.org/10.1038/sj.onc.1206243			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	652ZZ	12629521				2022-12-25	WOS:000181411900015
J	Harks, EGA; Camina, JP; Peters, PHJ; Ypey, DL; Scheenen, WJJM; van Zoelen, EJJ; Theuvenet, APR				Harks, EGA; Camina, JP; Peters, PHJ; Ypey, DL; Scheenen, WJJM; van Zoelen, EJJ; Theuvenet, APR			Besides affecting intracellular calcium signaling, 2-APB reversibly blocks gap junctional coupling in confluent monolayers, thereby allowing the measurement of single-cell membrane currents in undissociated cells	FASEB JOURNAL			English	Article						patch-clamp; ion channels; IP3 receptor; store-operated calcium entry	INOSITOL TRISPHOSPHATE RECEPTOR; OPERATED CA2+ CHANNELS; SMOOTH-MUSCLE CELLS; RAT-KIDNEY CELLS; 2-AMINOETHOXYDIPHENYL BORATE; GUINEA-PIG; PHENOTYPIC TRANSFORMATION; LYSOPHOSPHATIDIC ACID; NRK FIBROBLASTS; MOLECULAR-BASIS	2-Aminoethoxydiphenyl borate (2-APB) has been widely used as a blocker of the IP3 receptor and TRP channels, including store-operated calcium channels. We now show in monolayers of normal rat kidney cells (NRK/49F) that 2-APB completely and reversibly blocks gap junctional intercellular communication at concentrations similar to that required for inhibition of PGF2alpha-induced increases in intracellular calcium. Gap junctional conductances between NRK cells were estimated with single-electrode patch-clamp measurements and were fully blocked by 2-APB (50 muM), when applied extracellularly but not via the patch pipette. Half maximal inhibition (IC50) of electrical coupling in NRK cells was achieved at 5.7 muM. Similar results were obtained for human embryonic kidney epithelial cells (HEK293/tsA201) with an IC50 of 10.3 muM. Using 2-APB as an electrical uncoupler of monolayer cells, we could thus measure inward rectifier potassium, L-type calcium, and calcium-dependent chloride membrane currents in confluent NRK monolayers, with properties similar to those in dissociated NRK cells in the absence of 2-APB. The electrical uncoupling action described here is a new 2-APB property that promises to provide a powerful pharmacological tool to study single-cell properties in cultured confluent monolayers and intact tissues by electrical and chemical uncoupling of the cells without the need of prior dissociation.	Univ Nijmegen, Dept Cell Biol, Inst Cellular Signaling, Nijmegen, Netherlands; Leiden Univ, Dept Physiol, Med Ctr, NL-2300 RA Leiden, Netherlands; Complejo Hosp Univ Santiago, Dept Med, Mol Endocrinol Lab, Santiago De Compostela, Spain; Univ Nijmegen, Dept Cellular Anim Physiol, Inst Cellular Signaling, Nijmegen, Netherlands	Radboud University Nijmegen; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Complexo Hospitalario Universitario de Santiago de Compostela; Radboud University Nijmegen	Theuvenet, APR (corresponding author), Toernooiveld 1, NL-6525 ED Nijmegen, Netherlands.	ATheuv@sci.kun.nl	Scheenen, Wim/E-3674-2012; van Zoelen, Everardus J./D-9192-2012					AFINK GB, 1994, J CELL BIOCHEM, V56, P480, DOI 10.1002/jcb.240560408; Bohmer C, 2001, PFLUG ARCH EUR J PHY, V442, P688; Bootman MD, 2002, FASEB J, V16, DOI 10.1096/fj.02-0037rev; Braun FJ, 2001, J BIOL CHEM, V276, P1063, DOI 10.1074/jbc.M008348200; Bruzzone R, 1996, EUR J BIOCHEM, V238, P1, DOI 10.1111/j.1432-1033.1996.0001q.x; BULJUBASIC N, 1992, ANESTHESIOLOGY, V76, P990, DOI 10.1097/00000542-199206000-00020; Cornelisse LN, 2002, J NEUROENDOCRINOL, V14, P778, DOI 10.1046/j.1365-2826.2002.00838.x; DEROOS AD, 1997, THESIS U NIJMEGEN; deRoos ADG, 1997, CELL CALCIUM, V22, P195, DOI 10.1016/S0143-4160(97)90013-0; DeRoos ADG, 1997, J CELL PHYSIOL, V170, P166, DOI 10.1002/(SICI)1097-4652(199702)170:2<166::AID-JCP8>3.0.CO;2-M; deRoos ADG, 1996, PFLUG ARCH EUR J PHY, V431, P556, DOI 10.1007/s004240050035; Dobryndeva Y, 2001, MOL PHARMACOL, V60, P541; Fu X, 2000, AM J OBSTET GYNECOL, V182, P582, DOI 10.1067/mob.2000.102707; Giepmans BNG, 2001, J BIOL CHEM, V276, P8544, DOI 10.1074/jbc.M005847200; Goldberg GS, 1999, NAT CELL BIOL, V1, P457, DOI 10.1038/15693; Gregory RB, 2001, BIOCHEM J, V354, P285, DOI 10.1042/0264-6021:3540285; Gros DB, 1996, BIOESSAYS, V18, P719, DOI 10.1002/bies.950180907; Harks EGA, 2001, J PHARMACOL EXP THER, V298, P1033; HOSSAIN MZ, 2000, SCI STKE, pE1; Imai T, 2002, N-S ARCH PHARMACOL, V366, P282, DOI 10.1007/s00210-002-0596-0; Kukkonen JP, 2001, CELL CALCIUM, V30, P117, DOI 10.1054/ceca.2001.0219; Kumar NM, 1996, CELL, V84, P381, DOI 10.1016/S0092-8674(00)81282-9; Lahaye DHTP, 1999, BBA-MOL CELL RES, V1449, P107, DOI 10.1016/S0167-4889(99)00002-6; Lahaye DHTP, 1999, FEBS LETT, V446, P256, DOI 10.1016/S0014-5793(99)00216-1; Lampe PD, 2000, ARCH BIOCHEM BIOPHYS, V384, P205, DOI 10.1006/abbi.2000.2131; Lee YT, 1999, EUR J PHARMACOL, V378, P349, DOI 10.1016/S0014-2999(99)00485-9; Li HY, 1996, J CELL BIOL, V134, P1019, DOI 10.1083/jcb.134.4.1019; Li L, 1998, LIFE SCI, V62, pPL289; Ma HT, 2000, SCIENCE, V287, P1647, DOI 10.1126/science.287.5458.1647; Ma HT, 2002, J BIOL CHEM, V277, P6915, DOI 10.1074/jbc.M107755200; Ma HT, 2001, J BIOL CHEM, V276, P18888, DOI 10.1074/jbc.M100944200; Maruyama T, 1997, J BIOCHEM-TOKYO, V122, P498; Narumiya S, 1999, PHYSIOL REV, V79, P1193, DOI 10.1152/physrev.1999.79.4.1193; Neuhaus J, 2002, WORLD J UROL, V20, P250, DOI 10.1007/s00345-002-0289-9; Neuhaus J, 2002, CELL TISSUE RES, V309, P301, DOI 10.1007/s00441-002-0559-2; NIGGLI E, 1989, AM J PHYSIOL, V256, pC273, DOI 10.1152/ajpcell.1989.256.2.C273; TAKENSKWAK BR, 1992, AM J PHYSIOL, V262, pC1531, DOI 10.1152/ajpcell.1992.262.6.C1531; van Rossum DB, 2000, J BIOL CHEM, V275, P28562, DOI 10.1074/jbc.M003147200; van Zoelen E J, 1991, Crit Rev Oncog, V2, P311; WHITE MM, 1990, MOL PHARMACOL, V37, P720; Wilson HL, 2002, J BIOL CHEM, V277, P34017, DOI 10.1074/jbc.M205120200; Wu J, 2000, MOL PHARMACOL, V58, P1368, DOI 10.1124/mol.58.6.1368; Wu XY, 2002, J BIOL CHEM, V277, P13597, DOI 10.1074/jbc.M110881200; Zhou L, 1999, J CELL BIOL, V144, P1033, DOI 10.1083/jcb.144.5.1033	44	62	67	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2003	17	3					941	+		10.1096/fj.02-0786fje	http://dx.doi.org/10.1096/fj.02-0786fje			21	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	661LT	12626431				2022-12-25	WOS:000181892600022
J	Ni, CW; Hsieh, HJ; Chao, YJ; Wang, DL				Ni, CW; Hsieh, HJ; Chao, YJ; Wang, DL			Shear flow attenuates serum-induced STAT3 activation in endothelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NITRIC-OXIDE SYNTHASE; SIGNAL-REGULATED KINASE; EARLY GROWTH RESPONSE-1; GENE-EXPRESSION; SUPEROXIDE-DISMUTASE; STRESS; IL-6; PHOSPHORYLATION; MECHANISMS; APOPTOSIS	Vascular endothelial cells (ECs) are constantly exposed to flow-induced shear stress. Shear stress is known to induce signaling cascades, including the extracellular signal-regulated protein kinase (ERK) pathway. STAT3 transcription factor plays a key role in cytokine stimulation. Recent studies indicate that STAT3 is involved in growth factor-induced cell cycle. In the present study, we have examined STAT3 activation of ECs under conditions of shear flow. Bovine aortic ECs cultured with serum at static state show a serum concentration-dependent phosphorylation at Tyr-705 of STAT3, whereas there is a constant basal phosphorylation at Ser-727. In ECs subjected to shear flow, a shear dose-dependent phosphorylation of Ser-727 and ERK1/2 was observed. In contrast, a concomitantly shear dose-dependent inhibition of phosphorylation at Tyr-705 was exhibited. Shear stress on ECs increased the association of ERK1/2 to STAT3. ECs treated with MEK inhibitor (U0126 or PD98059) consistently and significantly reduced the shear-induced ERK1/2 and Ser727 phosphorylation, indicating that ERK1/2 is upstream of Ser-727 phosphorylation. Interestingly, shear-induced inhibition in Tyr-705 phosphorylation was abolished in these same inhibitor-treated ECs. Similarly, ECs transfected with a dominant positive mutant of MEK1 enhanced the phosphorylation of Ser-727 with the attenuation of the Tyr-705 phosphorylation. In contrast, when ECs were transfected with dominant positive mutant of MEKK1, JNK upstream, no change in the phosphorylation of Ser-727 and Tyr-705 was observed. These results indicate that shear flow induces the phosphorylation of Ser727 via ERK1/2 pathway, and this Ser-727 phosphorylation inhibits Tyr-705 phosphorylation in STAT3. As a result, shear flow reduced the translocation of STAT3 into nucleus. This study shows for the first time that shear flow may play a significant role by attenuating STAT3 activation and thus may reduce inflammatory responses and/or serum-induced endothelial proliferation.	Acad Sinica, Inst Biomed Sci, Div Cardiovasc, Taipei 11529, Taiwan	Academia Sinica - Taiwan	Wang, DL (corresponding author), Acad Sinica, Inst Biomed Sci, Div Cardiovasc, Taipei 11529, Taiwan.	lingwang@ibms.sinica.edu.tw		Ni, Chih-Wen/0000-0002-7343-282X				Abid MR, 2001, FASEB J, V15, P2548, DOI 10.1096/fj.01-0338fje; Ali MH, 1999, AM J PHYSIOL-LUNG C, V277, pL1057, DOI 10.1152/ajplung.1999.277.5.L1057; Bartoli M, 2000, J BIOL CHEM, V275, P33189, DOI 10.1074/jbc.C000318200; Benekli M, 2003, BLOOD, V101, P2940, DOI 10.1182/blood-2002-04-1204; Boo YC, 2002, J BIOL CHEM, V277, P3388, DOI 10.1074/jbc.M108789200; Chen CC, 1996, CYTOKINE, V8, P58, DOI 10.1006/cyto.1995.0008; Chen XL, 2003, J BIOL CHEM, V278, P703, DOI 10.1074/jbc.M203161200; Chiu JJ, 1999, CIRC RES, V85, P238, DOI 10.1161/01.RES.85.3.238; Chiu JJ, 1997, ARTERIOSCL THROM VAS, V17, P3570, DOI 10.1161/01.ATV.17.12.3570; Chung JK, 1997, MOL CELL BIOL, V17, P6508, DOI 10.1128/MCB.17.11.6508; Corson MA, 1996, CIRC RES, V79, P984, DOI 10.1161/01.RES.79.5.984; DAVIES PF, 1995, PHYSIOL REV, V75, P519, DOI 10.1152/physrev.1995.75.3.519; De Keulenaer GW, 1998, CIRC RES, V82, P1094, DOI 10.1161/01.RES.82.10.1094; DEODD, 2002, J BIOL CHEM, V277, P21237; Deshpande SS, 2000, FASEB J, V14, P1705, DOI 10.1096/fj.99-0910com; Dimmeler S, 1999, ARTERIOSCL THROM VAS, V19, P656, DOI 10.1161/01.ATV.19.3.656; Fleming I, 1998, CIRC RES, V82, P686, DOI 10.1161/01.RES.82.6.686; GOMIKIEWICZ A, 2000, FASEB J, V14, P1093; Hermann C, 1997, ARTERIOSCL THROM VAS, V17, P3588, DOI 10.1161/01.ATV.17.12.3588; Hirano T, 2000, ONCOGENE, V19, P2548, DOI 10.1038/sj.onc.1203551; Hsieh HJ, 1998, J CELL PHYSIOL, V175, P156, DOI 10.1002/(SICI)1097-4652(199805)175:2<156::AID-JCP5>3.0.CO;2-N; Jain N, 1998, ONCOGENE, V17, P3157, DOI 10.1038/sj.onc.1202238; Jalali S, 1998, ARTERIOSCL THROM VAS, V18, P227, DOI 10.1161/01.ATV.18.2.227; Jo H, 1997, J BIOL CHEM, V272, P1395, DOI 10.1074/jbc.272.2.1395; Kijima T, 2002, CELL GROWTH DIFFER, V13, P355; Levy DE, 2002, J CLIN INVEST, V109, P1143, DOI 10.1172/JCI200215650; Lin K, 2000, P NATL ACAD SCI USA, V97, P9385, DOI 10.1073/pnas.170282597; Masuda M, 2002, CANCER RES, V62, P3351; Matsumoto Y, 1998, BLOOD, V91, P4164, DOI 10.1182/blood.V91.11.4164.411k29_4164_4172; Nakagami H, 2001, HYPERTENSION, V37, P581, DOI 10.1161/01.HYP.37.2.581; Ni CW, 2003, J CELL PHYSIOL, V195, P428, DOI 10.1002/jcp.10259; Niu GL, 2002, ONCOGENE, V21, P2000, DOI 10.1038/sj.onc.1205260; Simon AR, 2000, SCIENCE, V290, P144, DOI 10.1126/science.290.5489.144; Stankova J, 1996, AM J PHYSIOL-CELL PH, V271, pC1073, DOI 10.1152/ajpcell.1996.271.4.C1073; Sundaresan M, 1996, BIOCHEM J, V318, P379, DOI 10.1042/bj3180379; Surapisitchat J, 2001, P NATL ACAD SCI USA, V98, P6476, DOI 10.1073/pnas.101134098; Takahashi M, 1996, J CLIN INVEST, V98, P2623, DOI 10.1172/JCI119083; Traub O, 1998, ARTERIOSCL THROM VAS, V18, P677, DOI 10.1161/01.ATV.18.5.677; Valdembri D, 2001, FASEB J, V15, P225, DOI 10.1096/fj.01-0633fje; Vignais ML, 1999, MOL CELL BIOL, V19, P3727; Volk T, 2000, MOL CELL BIOCHEM, V206, P105, DOI 10.1023/A:1007059616914; Wang YZ, 2000, ONCOGENE, V19, P2075, DOI 10.1038/sj.onc.1203548; Wung BS, 2001, ARTERIOSCL THROM VAS, V21, P1941, DOI 10.1161/hq1201.099428; Wung BS, 1997, CIRC RES, V81, P1, DOI 10.1161/01.RES.81.1.1; Wung BS, 1999, CIRC RES, V84, P804; Zeng ZZ, 2002, J BIOL CHEM, V277, P41213, DOI 10.1074/jbc.M204508200; Zhang Y, 2000, J BIOL CHEM, V275, P24935, DOI 10.1074/jbc.M002383200; Zong CS, 2000, J BIOL CHEM, V275, P15099, DOI 10.1074/jbc.M000089200; Zou YP, 1998, INT J MOL MED, V1, P827	49	25	25	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 30	2003	278	22					19702	19708		10.1074/jbc.M300893200	http://dx.doi.org/10.1074/jbc.M300893200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	682EH	12637510	Green Published, hybrid			2022-12-25	WOS:000183078000019
J	Royle, L; Roos, A; Harvey, DJ; Wormald, MR; van Gijlswijk-Janssen, D; Redwan, EM; Wilson, IA; Daha, MR; Dwek, RA; Rudd, PM				Royle, L; Roos, A; Harvey, DJ; Wormald, MR; van Gijlswijk-Janssen, D; Redwan, EM; Wilson, IA; Daha, MR; Dwek, RA; Rudd, PM			Secretory IgA N- and O-glycans provide a link between the innate and adaptive immune systems	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PERFORMANCE LIQUID-CHROMATOGRAPHY; MEDIATED EPITHELIAL TRANSPORT; HUMAN GASTRIC EPITHELIUM; BINDING LECTIN PATHWAY; NORMAL HUMAN SERUM; FC-ALPHA-R; IMMUNOGLOBULIN-A; HUMAN-MILK; J-CHAIN; MASS-SPECTROMETRY	Secretory IgA (SIgA) is a multi-polypeptide complex consisting of a secretory component (SC) covalently attached to dimeric IgA containing one joining (J) chain. We present the analysis of both the N- and O-glycans on the individual peptides from this complex. Based on these data, we have constructed a molecular model of SIgA1 with all its glycans, in which the Fab arms form a T shape and the SC is wrapped around the heavy chains. The O-glycan regions on the heavy (H) chains and the SC N- glycans have adhesin-binding glycan epitopes including galactose-linked beta1-4 and beta1-3 to GlcNAc, fucose-linked alpha1-3 and alpha1-4 to GlcNAc and alpha1-2 to galactose, and alpha2-3 and alpha2-6-linked sialic acids. These glycan epitopes provide SIgA with further bacteria-binding sites in addition to the four Fab-binding sites, thus enabling SIgA to participate in both innate and adaptive immunity. We also show that the N- glycans on the H chains of both SIgA1 and SIgA2 present terminal GlcNAc and mannose residues that are normally masked by SC, but that can be unmasked and recognized by mannose-binding lectin, by disrupting the SC-H chain noncovalent interactions.	Univ Oxford, Dept Biochem, Glycobiol Inst, Oxford OX1 3QU, England; Leiden Univ, Med Ctr, Dept Nephrol, Leiden, Netherlands; Scripps Res Inst, Dept Mol Biol, La Jolla, CA 92037 USA	University of Oxford; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Scripps Research Institute	Rudd, PM (corresponding author), Univ Oxford, Dept Biochem, Glycobiol Inst, Oxford OX1 3QU, England.		Harvey, David/A-5579-2013; Redwan, Elrashdy Moustafa/I-1769-2012; Redwan, Elrashdy M/M-9586-2019; Wormald, Mark R/G-2785-2011	Redwan, Elrashdy Moustafa/0000-0001-8246-0075; Redwan, Elrashdy M/0000-0001-8246-0075; Wormald, Mark R/0000-0002-4853-2773; Redwan, Elarshdy/0000-0001-5246-8164; Harvey, David/0000-0003-0544-771X				Atkin JD, 1996, J IMMUNOL, V157, P156; BAENZIGER J, 1974, J BIOL CHEM, V249, P7270; BAENZIGER JU, 1979, J BIOL CHEM, V254, P4063; Berman HM, 2000, NUCLEIC ACIDS RES, V28, P235, DOI 10.1093/nar/28.1.235; BIGGE JC, 1995, ANAL BIOCHEM, V230, P229, DOI 10.1006/abio.1995.1468; Boehm MK, 1999, J MOL BIOL, V286, P1421, DOI 10.1006/jmbi.1998.2556; BOREN T, 1993, SCIENCE, V262, P1892, DOI 10.1126/science.8018146; Bos NA, 1996, INFECT IMMUN, V64, P616, DOI 10.1128/IAI.64.2.616-623.1996; Burns JW, 1996, SCIENCE, V272, P104, DOI 10.1126/science.272.5258.104; Chuang PD, 1997, J IMMUNOL, V158, P724; Corthesy B, 2002, TRENDS BIOTECHNOL, V20, P65, DOI 10.1016/S0167-7799(01)01874-1; Corthesy B, 1999, BIOL CHEM, V380, P1251, DOI 10.1515/BC.1999.160; Crottet P, 1998, J IMMUNOL, V161, P5445; Dallas SD, 1998, J MED MICROBIOL, V47, P879, DOI 10.1099/00222615-47-10-879; de Oliveira IR, 2001, FEMS MICROBIOL LETT, V203, P29, DOI 10.1016/S0378-1097(01)00332-9; DEFIJTER JW, 1995, J IMMUNOL METHODS, V187, P221, DOI 10.1016/0022-1759(95)00188-8; FALK P, 1993, P NATL ACAD SCI USA, V90, P2035, DOI 10.1073/pnas.90.5.2035; FALLGRENGEBAUER E, 1995, ADV EXP MED BIOL, V371, P625; FEINSTEIN A, 1971, ANN NY ACAD SCI, V190, P104, DOI 10.1111/j.1749-6632.1971.tb13526.x; FIELD MC, 1994, BIOCHEM J, V299, P261, DOI 10.1042/bj2990261; GENESTE C, 1986, IMMUNOL LETT, V13, P221, DOI 10.1016/0165-2478(86)90105-7; Guile GR, 1996, ANAL BIOCHEM, V240, P210, DOI 10.1006/abio.1996.0351; GUILE GR, 1994, ANAL BIOCHEM, V222, P231, DOI 10.1006/abio.1994.1478; Hammerschmidt S, 1997, MOL MICROBIOL, V25, P1113, DOI 10.1046/j.1365-2958.1997.5391899.x; Hanisch FA, 2001, BIOL CHEM, V382, P143, DOI 10.1515/BC.2001.022; HARVEY DJ, 1993, RAPID COMMUN MASS SP, V7, P614, DOI 10.1002/rcm.1290070712; Hexham JM, 1999, J EXP MED, V189, P747, DOI 10.1084/jem.189.4.747; Heystek HC, 2002, J IMMUNOL, V168, P102, DOI 10.4049/jimmunol.168.1.102; Hough MA, 1999, J MOL BIOL, V287, P579, DOI 10.1006/jmbi.1999.2610; Hughes GJ, 1999, BBA-PROTEIN STRUCT M, V1434, P86, DOI 10.1016/S0167-4838(99)00168-5; IMBERTY A, 1995, PROTEIN ENG, V8, P699, DOI 10.1093/protein/8.7.699; Iwase H, 1996, J BIOCHEM-TOKYO, V120, P393; Johansen FE, 2001, J IMMUNOL, V167, P5185, DOI 10.4049/jimmunol.167.9.5185; KERR MA, 1990, BIOCHEM J, V271, P285, DOI 10.1042/bj2710285; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Krugmann S, 1997, BIOCHEM SOC T, V25, pS323, DOI 10.1042/bst025323s; Kuster B, 1997, ANAL BIOCHEM, V250, P82, DOI 10.1006/abio.1997.2199; Lamm ME, 1997, ANNU REV MICROBIOL, V51, P311, DOI 10.1146/annurev.micro.51.1.311; Mattu TS, 1998, J BIOL CHEM, V273, P2260, DOI 10.1074/jbc.273.4.2260; MIZOGUCHI A, 1982, J BIOL CHEM, V257, P9612; Morton HC, 1996, CRIT REV IMMUNOL, V16, P423; MOSTOV KE, 1984, NATURE, V308, P37, DOI 10.1038/308037a0; Norderhaug IN, 1999, CRIT REV IMMUNOL, V19, P481; Novak J, 2000, MOL IMMUNOL, V37, P1047, DOI 10.1016/S0161-5890(01)00019-0; PATEL T, 1993, BIOCHEMISTRY-US, V32, P679, DOI 10.1021/bi00053a037; Petersen SV, 2001, MOL IMMUNOL, V38, P133; Petrescu AJ, 1999, GLYCOBIOLOGY, V9, P343, DOI 10.1093/glycob/9.4.343; Phalipon A, 2002, IMMUNITY, V17, P107, DOI 10.1016/S1074-7613(02)00341-2; PIERCECRETEL A, 1984, EUR J BIOCHEM, V139, P337, DOI 10.1111/j.1432-1033.1984.tb08012.x; PIERCECRETEL A, 1982, EUR J BIOCHEM, V125, P383, DOI 10.1111/j.1432-1033.1982.tb06694.x; PIERCECRETEL A, 1981, EUR J BIOCHEM, V114, P169, DOI 10.1111/j.1432-1033.1981.tb06188.x; PIERCECRETEL A, 1989, EUR J BIOCHEM, V182, P457, DOI 10.1111/j.1432-1033.1989.tb14853.x; PURKAYASTHA S, 1979, J BIOL CHEM, V254, P6583; Roos A, 2001, J IMMUNOL, V167, P2861, DOI 10.4049/jimmunol.167.5.2861; Royle L, 2002, ANAL BIOCHEM, V304, P70, DOI 10.1006/abio.2002.5619; Rudd PM, 1997, J BIOL CHEM, V272, P7229, DOI 10.1074/jbc.272.11.7229; Schroten H, 1998, INFECT IMMUN, V66, P3971, DOI 10.1128/IAI.66.8.3971-3973.1998; Sharon N, 2000, GLYCOCONJUGATE J, V17, P659, DOI 10.1023/A:1011091029973; Shevchenko A, 1996, ANAL CHEM, V68, P850, DOI 10.1021/ac950914h; Tanaka A, 1998, GLYCOCONJUGATE J, V15, P995, DOI 10.1023/A:1006989910120; TAYLOR AK, 1988, MOL CELL BIOL, V8, P4197, DOI 10.1128/MCB.8.10.4197; Thornton BP, 1996, J IMMUNOL, V156, P1235; Uemura K, 2002, J IMMUNOL, V169, P6945, DOI 10.4049/jimmunol.169.12.6945; Vaerman JP, 1998, IMMUNOLOGY, V95, P90; van Egmond M, 2001, TRENDS IMMUNOL, V22, P205, DOI 10.1016/S1471-4906(01)01873-7; van Spriel AB, 2002, J IMMUNOL, V169, P3831, DOI 10.4049/jimmunol.169.7.3831; WEIS WI, 1992, NATURE, V360, P127, DOI 10.1038/360127a0; Wilm M, 1996, NATURE, V379, P466, DOI 10.1038/379466a0; WOLD AE, 1990, INFECT IMMUN, V58, P3073, DOI 10.1128/IAI.58.9.3073-3077.1990; Wright A, 1997, TRENDS BIOTECHNOL, V15, P26, DOI 10.1016/S0167-7799(96)10062-7; Zamze S, 1998, EUR J BIOCHEM, V258, P243, DOI 10.1046/j.1432-1327.1998.2580243.x; Zhang JR, 2000, CELL, V102, P827, DOI 10.1016/S0092-8674(00)00071-4; ZIKAN J, 1985, P NATL ACAD SCI USA, V82, P5905, DOI 10.1073/pnas.82.17.5905	73	243	262	0	29	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 30	2003	278	22					20140	20153		10.1074/jbc.M301436200	http://dx.doi.org/10.1074/jbc.M301436200			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	682EH	12637583	hybrid			2022-12-25	WOS:000183078000073
J	Jensen, A; Calvayrac, G; Karahalil, B; Bohr, VA; Stevnsner, T				Jensen, A; Calvayrac, G; Karahalil, B; Bohr, VA; Stevnsner, T			Mammalian 8-oxoguanine DNA glycosylase 1 incises 8-oxoadenine opposite cytosine in nuclei and mitochondria, while a different glycosylase incises 8-oxoadenine opposite guanine in nuclei	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BASE EXCISION-REPAIR; OXIDATIVE DAMAGE; LIVER-MITOCHONDRIA; REACTION-MECHANISM; HUMAN HOMOLOG; HUMAN-CELLS; RAT-LIVER; ENDONUCLEASE; PROTEIN; LESIONS	Cells are continuously exposed to oxidative species, which cause several types of oxidative DNA lesions. Repair of some of these lesions has been well characterized but little is known about the repair of many DNA lesions. The oxidized adenine base, 7,8-dihydro-8-oxoadenine (8-oxoA), is a relatively common DNA lesion, which is believed to be mutagenic in mammalian cells. This study investigates repair of 8-oxoA in nuclear and mitochondrial mammalian extracts. In nuclei, 8-oxoA: C and 8-oxoA: G base pairs are recognized and cleaved; in contrast, only 8-oxoA: C base pairs are cleaved in mitochondria. High stability of the DNA helix increased the efficiency of incision of 8-oxoA, and the efficiency decreased at DNA bends and condensed regions of the helix. Using liver extracts from mice knocked out for 8-oxoguanine DNA glycosylase 1 (OGG1), we demonstrated that OGG1 is the only glycosylase that incises 8-oxoA, when base-paired with cytosine in mitochondria and nuclei, but a different enzyme incises 8-oxoA when base-paired with guanine in the nucleus. Consistent with this result, a covalent DNA-protein complex was trapped using purified human OGG1 or human nuclear or mitochondrial extracts with a DNA substrate containing an 8-oxoA: C base pair.	NIA, Lab Mol Gerontol, NIH, Baltimore, MD 21224 USA; Aarhus Univ, Dept Mol Biol, Danish Ctr Mol Gerontol, DK-8000 Aarhus C, Denmark; Gazi Univ, Fac Pharm, Dept Toxicol, TR-06330 Ankara, Turkey	National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); Aarhus University; Gazi University	Bohr, VA (corresponding author), NIA, Lab Mol Gerontol, NIH, Box 1,5600 Nathan Shock Dr, Baltimore, MD 21224 USA.	vbohr@nih.gov	Karahalil, Bensu/AFU-8097-2022; Bohr, Vilhelm/AAP-5931-2020	Stevnsner, Tinna/0000-0003-1007-0427	NATIONAL INSTITUTE ON AGING [Z01AG000733, ZIAAG000733, Z01AG000727, ZIAAG000727] Funding Source: NIH RePORTER	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ABOUKHALIL S, 1985, BIOCHEM BIOPH RES CO, V127, P1039, DOI 10.1016/S0006-291X(85)80049-8; Allinson SL, 2001, EMBO J, V20, P6919, DOI 10.1093/emboj/20.23.6919; ARNOTT S, 1974, J MOL BIOL, V88, P509, DOI 10.1016/0022-2836(74)90498-7; Aspinwall R, 1997, P NATL ACAD SCI USA, V94, P109, DOI 10.1073/pnas.94.1.109; Bernards AS, 2002, J BIOL CHEM, V277, P20960, DOI 10.1074/jbc.C200181200; Bjoras M, 2002, J MOL BIOL, V317, P171, DOI 10.1006/jmbi.2002.5400; Croteau DL, 1997, J BIOL CHEM, V272, P27338, DOI 10.1074/jbc.272.43.27338; de Souza-Pinto NC, 2001, FREE RADICAL BIO MED, V30, P916, DOI 10.1016/S0891-5849(01)00483-X; de Souza-Pinto NC, 2001, CANCER RES, V61, P5378; Dianov GL, 2001, PROG NUCLEIC ACID RE, V68, P285; FEIG DI, 1994, CANCER RES, V54, pS1890; Girard PM, 1998, CARCINOGENESIS, V19, P1299, DOI 10.1093/carcin/19.7.1299; GROLLMAN AP, 1993, TRENDS GENET, V9, P246, DOI 10.1016/0168-9525(93)90089-Z; Hazra IK, 1998, NUCLEIC ACIDS RES, V26, P5116, DOI 10.1093/nar/26.22.5116; Hazra TK, 2002, J BIOL CHEM, V277, P30417, DOI 10.1074/jbc.C200355200; Hill JW, 2001, NUCLEIC ACIDS RES, V29, P430, DOI 10.1093/nar/29.2.430; Hudson EK, 1998, FREE RADICAL RES, V29, P573, DOI 10.1080/10715769800300611; Ide H, 1997, CELL BIOL TOXICOL, V13, P405, DOI 10.1023/A:1007467726635; IYER V, 1995, EMBO J, V14, P2570, DOI 10.1002/j.1460-2075.1995.tb07255.x; Jaruga P, 1996, NUCLEIC ACIDS RES, V24, P1389, DOI 10.1093/nar/24.8.1389; KAMIYA H, 1995, NUCLEIC ACIDS RES, V23, P2893, DOI 10.1093/nar/23.15.2893; KAMIYA H, 1995, CARCINOGENESIS, V16, P883, DOI 10.1093/carcin/16.4.883; KAWAKAMI K, 1993, FEBS LETT, V335, P251, DOI 10.1016/0014-5793(93)80740-L; Klungland A, 1999, P NATL ACAD SCI USA, V96, P13300, DOI 10.1073/pnas.96.23.13300; KOO HS, 1986, NATURE, V320, P501, DOI 10.1038/320501a0; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Mambo E, 2002, CANCER RES, V62, P1349; Masuda Y, 1998, J BIOL CHEM, V273, P30360, DOI 10.1074/jbc.273.46.30360; Matsumoto Y, 2001, NUCLEIC ACIDS RES, V29, P1975, DOI 10.1093/nar/29.9.1975; MEINKOTH J, 1984, ANAL BIOCHEM, V138, P267, DOI 10.1016/0003-2697(84)90808-X; Morland I, 2002, NUCLEIC ACIDS RES, V30, P4926, DOI 10.1093/nar/gkf618; Nash HM, 1996, CURR BIOL, V6, P968, DOI 10.1016/S0960-9822(02)00641-3; OLINSKI R, 1992, FEBS LETT, V309, P193, DOI 10.1016/0014-5793(92)81093-2; Ozawa T, 1997, BIOSCIENCE REP, V17, P237, DOI 10.1023/A:1027324410022; Parker A, 2000, NUCLEIC ACIDS RES, V28, P3206, DOI 10.1093/nar/28.17.3206; PAYNE CM, 1995, LEUKEMIA LYMPHOMA, V19, P43, DOI 10.3109/10428199509059662; Rosenquist TA, 1997, P NATL ACAD SCI USA, V94, P7429, DOI 10.1073/pnas.94.14.7429; SHIGENAGA MK, 1994, P NATL ACAD SCI USA, V91, P10771, DOI 10.1073/pnas.91.23.10771; Shinmura A, 2000, NUCLEIC ACIDS RES, V28, P4912, DOI 10.1093/nar/28.24.4912; Slupphaug G, 1996, NATURE, V384, P87, DOI 10.1038/384087a0; Slupska MM, 1999, J BACTERIOL, V181, P6210, DOI 10.1128/JB.181.19.6210-6213.1999; Souza-Pinto NC, 1999, NUCLEIC ACIDS RES, V27, P1935, DOI 10.1093/nar/27.8.1935; Suter B, 2000, NUCLEIC ACIDS RES, V28, P4083, DOI 10.1093/nar/28.21.4083; Takao M, 1999, NUCLEIC ACIDS RES, V27, P3638, DOI 10.1093/nar/27.18.3638; Takao M, 2002, J BIOL CHEM, V277, P42205, DOI 10.1074/jbc.M206884200; TCHOU J, 1995, J BIOL CHEM, V270, P11671, DOI 10.1074/jbc.270.19.11671; Tuo JS, 2002, J BIOL CHEM, V277, P30832, DOI 10.1074/jbc.M204814200; WANG YJ, 1995, CHEM-BIOL INTERACT, V94, P135, DOI 10.1016/0009-2797(94)03327-5; Wiseman H, 1996, BIOCHEM J, V313, P17, DOI 10.1042/bj3130017; Zharkov DO, 2000, J BIOL CHEM, V275, P28607, DOI 10.1074/jbc.M002441200	50	43	45	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 23	2003	278	21					19541	19548		10.1074/jbc.M301504200	http://dx.doi.org/10.1074/jbc.M301504200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	679PY	12644468	hybrid			2022-12-25	WOS:000182932200105
J	Osterhout, JL; Waheed, AA; Hiol, A; Ward, RJ; Davey, PC; Nini, L; Wang, J; Milligan, G; Jones, TLZ; Druey, KM				Osterhout, JL; Waheed, AA; Hiol, A; Ward, RJ; Davey, PC; Nini, L; Wang, J; Milligan, G; Jones, TLZ; Druey, KM			Palmitoylation regulates regulator of G-protein signaling (RGS) 16 function - II. Palmitoylation of a cysteine residue in the RGS box is critical for RGS16 GTPase accelerating activity and regulation of G(i)-coupled signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR-CONSTITUTIVE ACTIVITY; PLASMA-MEMBRANE LOCALIZATION; ACTIVATING PROTEINS; PHOSPHORYLATION; GAIP; INHIBITION; INTERACTS; BINDING; KINASE; DOMAIN	Palmitoylation is a reversible post-translational modification used by cells to regulate protein activity. The regulator of G-protein signaling (RGS) proteins RGS4 and RGS16 share conserved cysteine (Cys) residues that undergo palmitoylation. In the accompanying article (Hiol, A., Davey, P. C., Osterhout, J. L., Waheed, A. A., Fischer, E. R., Chen, C. K., Milligan, G., Druey, K. M., and Jones, T. L. Z. (2003) J. Biol. Chem. 278, 19301-19308), we determined that mutation of NH2-terminal cysteine residues in RGS16 (Cys-2 and Cys-12) reduced GTPase accelerating (GAP) activity toward a 5-hydroxytryptamine (5-HT1A)/Galpha(o1) receptor fusion protein in cell membranes. NH2-terminal acylation also permitted palmitoylation of a cysteine residue in the RGS box of RGS16 (Cys-98). Here we investigated the role of internal palmitoylation in RGS16 localization and GAP activity. Mutation of RGS16 Cys-98 or RGS4 Cys-95 to alanine reduced GAP activity on the 5-HT1A/Galpha(o1) fusion protein and regulation of adenylyl cyclase inhibition. The C98A mutation had no effect on RGS16 localization or GAP activity toward purified G-protein alpha subunits. Enzymatic palmitoylation of RGS16 resulted in internal palmitoylation on residue Cys-98. Palmitoylated RGS16 or RGS4 WT but not C98A or C95A preincubated with membranes expressing 5-HT1a/Galpha(o1) displayed increased GAP activity over time. These results suggest that palmitoylation of a Cys residue in the RGS box is critical for RGS16 and RGS4 GAP activity and their ability to regulate G(i)-coupled signaling in mammalian cells.	NIDDK, Metab Dis Branch, NIH, Bethesda, MD 20892 USA; NIAID, Mol Signal Transduct Sect, Lab Allerg Dis, NIH, Bethesda, MD 20892 USA; Univ Glasgow, Inst Biomed & Life Sci, Div Biochem & Mol Biol, Mol Pharmacol Grp, Glasgow G12 8QQ, Lanark, Scotland	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); University of Glasgow	Jones, TLZ (corresponding author), NIDDK, Metab Dis Branch, NIH, Bldg 10,Rm 9C101, Bethesda, MD 20892 USA.	tlzj@helix.nih.gov	Milligan, Graeme/F-9426-2011	Milligan, Graeme/0000-0002-6946-3519	Biotechnology and Biological Sciences Research Council [C17789] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [Z01AI000840] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [Z01DK043010] Funding Source: NIH RePORTER	Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Benzing T, 2002, J BIOL CHEM, V277, P32954, DOI 10.1074/jbc.M200859200; Berman DM, 1996, CELL, V86, P445, DOI 10.1016/S0092-8674(00)80117-8; Bernstein LS, 2000, J BIOL CHEM, V275, P18520, DOI 10.1074/jbc.M000618200; Bhattacharyya R, 2000, J BIOL CHEM, V275, P14992, DOI 10.1074/jbc.M000415200; Burgon PG, 2001, J BIOL CHEM, V276, P32828, DOI 10.1074/jbc.M100960200; Castro-Fernandez C, 2002, ENDOCRINOLOGY, V143, P1310, DOI 10.1210/en.143.4.1310; Chen CA, 2001, ONCOGENE, V20, P1643, DOI 10.1038/sj.onc.1204185; Chen CH, 1999, J BIOL CHEM, V274, P19799, DOI 10.1074/jbc.274.28.19799; Chen CH, 1998, FEBS LETT, V422, P359, DOI 10.1016/S0014-5793(98)00042-8; Chen CH, 2001, FEBS LETT, V504, P16, DOI 10.1016/S0014-5793(01)02757-0; Chen CK, 1996, P NATL ACAD SCI USA, V93, P12885, DOI 10.1073/pnas.93.23.12885; Chikumi H, 2002, J BIOL CHEM, V277, P12463, DOI 10.1074/jbc.M108504200; Cunningham ML, 2001, J BIOL CHEM, V276, P5438, DOI 10.1074/jbc.M007699200; De Vries L, 2000, ANNU REV PHARMACOL, V40, P235, DOI 10.1146/annurev.pharmtox.40.1.235; Derrien A, 2001, J BIOL CHEM, V276, P48532, DOI 10.1074/jbc.M108862200; DeVries L, 1996, P NATL ACAD SCI USA, V93, P15203, DOI 10.1073/pnas.93.26.15203; Druey KM, 1997, P NATL ACAD SCI USA, V94, P12851, DOI 10.1073/pnas.94.24.12851; Druey KM, 1999, J BIOL CHEM, V274, P18836, DOI 10.1074/jbc.274.26.18836; Fischer T, 2000, P NATL ACAD SCI USA, V97, P4040, DOI 10.1073/pnas.97.8.4040; Garrison TR, 1999, J BIOL CHEM, V274, P36387, DOI 10.1074/jbc.274.51.36387; Hiol A, 2003, J BIOL CHEM, V278, P19301, DOI 10.1074/jbc.M210123200; Hollinger S, 2002, PHARMACOL REV, V54, P527, DOI 10.1124/pr.54.3.527; Hu G, 2001, J BIOL CHEM, V276, P22287, DOI 10.1074/jbc.M011539200; Huang CF, 1997, P NATL ACAD SCI USA, V94, P6159, DOI 10.1073/pnas.94.12.6159; Hughes TE, 2001, J BIOL CHEM, V276, P4227, DOI 10.1074/jbc.M007608200; Iiri T, 1996, P NATL ACAD SCI USA, V93, P14592, DOI 10.1073/pnas.93.25.14592; Kellett E, 1999, MOL PHARMACOL, V56, P684; Moy FJ, 2000, BIOCHEMISTRY-US, V39, P7063, DOI 10.1021/bi992760w; Nair KS, 2002, CURR BIOL, V12, P421, DOI 10.1016/S0960-9822(02)00691-7; Niu JX, 2002, BIOCHEM J, V365, P677, DOI 10.1042/BJ20020390; Ogier-Denis E, 2000, J BIOL CHEM, V275, P39090, DOI 10.1074/jbc.M006198200; Ouyang YS, 2003, J BIOL CHEM, V278, P11115, DOI 10.1074/jbc.M212606200; Popov SG, 2000, J BIOL CHEM, V275, P18962, DOI 10.1074/jbc.M001128200; Rose JJ, 2000, J NEUROCHEM, V75, P2103, DOI 10.1046/j.1471-4159.2000.0752103.x; Ross EM, 2000, ANNU REV BIOCHEM, V69, P795, DOI 10.1146/annurev.biochem.69.1.795; Srinivasa SP, 1998, P NATL ACAD SCI USA, V95, P5584, DOI 10.1073/pnas.95.10.5584; Tesmer JJG, 1997, CELL, V89, P251, DOI 10.1016/S0092-8674(00)80204-4; Tu YP, 1999, J BIOL CHEM, V274, P38260, DOI 10.1074/jbc.274.53.38260; Tu YP, 2001, J BIOL CHEM, V276, P20160, DOI 10.1074/jbc.M101599200; Welsby PJ, 2002, MOL PHARMACOL, V61, P1211, DOI 10.1124/mol.61.5.1211; Wieland T, 2000, J BIOL CHEM, V275, P28500, DOI 10.1074/jbc.M004187200; Zeng WZ, 1998, J BIOL CHEM, V273, P34687, DOI 10.1074/jbc.273.52.34687; Zheng B, 2000, P NATL ACAD SCI USA, V97, P3999, DOI 10.1073/pnas.97.8.3999	43	34	35	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 23	2003	278	21					19309	19316		10.1074/jbc.M210124200	http://dx.doi.org/10.1074/jbc.M210124200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	679PY	12642592	hybrid			2022-12-25	WOS:000182932200077
J	Rolli-Derkinderen, M; Machavoine, F; Baraban, JM; Grolleau, A; Beretta, L; Dy, M				Rolli-Derkinderen, M; Machavoine, F; Baraban, JM; Grolleau, A; Beretta, L; Dy, M			ERK and p38 inhibit the expression of 4E-BP1 repressor of translation through induction of Egr-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED-PROTEIN-KINASE; CAP-DEPENDENT TRANSLATION; INITIATION-FACTOR 4E; NERVE GROWTH-FACTOR; MAP-KINASE; GENE-EXPRESSION; TRANSCRIPTION FACTOR; C-JUN; HISTIDINE-DECARBOXYLASE; DIFFERENTIAL REGULATION	4E-BP1 plays a major role in translation by inhibiting cap-dependent translation initiation. Several reports have investigated the regulation of 4E-BP1 phosphorylation, which varies along with cell differentiation and upon various stimulations, but very little is known about the regulation of its expression. In a first part, we show that the expression of 4E-BP1 protein and transcript decreases in hematopoietic cell lines cultivated in the presence of phorbol 12-myristate 13-acetate (PMA). This decrease depends on the activation of the ERK/ mitogen-activated protein kinases. 4E-BP1 expression also decreases when the p38/mitogen-activated protein kinase pathway is activated by granulocyte/macrophage colony-stimulating factor but to a lesser extent than with PMA. In a second part, we examine how 4e-bp1 promoter activity is regulated. PMA and granulocyte/ macrophage colony-stimulating factor induce Egr-1 expression through ERK and p38 activation, respectively. Using a dominant negative mutant of Egr, ZnEgr, we show that this transcription factor is responsible for the inhibition of 4e-bp1 promoter activity. In a third part we show that histidine decarboxylase, whose activity and expression are inversely correlated with 4E-BP1 expression, is a potential target for the translational machinery. These data (i) are the first evidence of a new role of ERK and p38 on the translational machinery and (ii) demonstrate that 4E-BP1 is a new target for Egr-1.	Univ Paris 05, Hop Necker, Inst Federat Rech Necker Enfants Malad, CNRS,FRE 2444, F-75015 Paris, France; Johns Hopkins Univ, Sch Med, Dept Neurosci Psychiat & Behav Sci, Baltimore, MD 21205 USA; Univ Michigan, Dept Microbiol & Immunol, Ann Arbor, MI 48109 USA	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Cite; Johns Hopkins University; University of Michigan System; University of Michigan	Dy, M (corresponding author), 161 Rue Sevres, F-75743 Paris 15, France.	dy@necker.fr	Julius, Annabelle/A-7276-2010; Rolli-Derkinderen, Malvyne/K-2406-2015	Baraban, Jay/0000-0002-8165-2638; Laura, Beretta/0000-0002-2054-684X				AHLERS A, 1994, MOL PHARMACOL, V46, P1077; AHN NG, 1992, J NEUROCHEM, V59, P147, DOI 10.1111/j.1471-4159.1992.tb08885.x; ALESSI DR, 1995, CURR BIOL, V5, P283, DOI 10.1016/S0960-9822(95)00059-5; Beretta L, 1998, J IMMUNOL, V160, P3269; Beretta L, 1996, EMBO J, V15, P658, DOI 10.1002/j.1460-2075.1996.tb00398.x; Beretta L, 1996, J VIROL, V70, P8993, DOI 10.1128/JVI.70.12.8993-8996.1996; Beyaert R, 1996, EMBO J, V15, P1914, DOI 10.1002/j.1460-2075.1996.tb00542.x; Brunet A, 1996, SCIENCE, V272, P1652, DOI 10.1126/science.272.5268.1652; CAO XM, 1993, J BIOL CHEM, V268, P16949; Carter S, 1998, ONCOGENE, V16, P2787, DOI 10.1038/sj.onc.1201802; CHENG T, 1994, J BIOL CHEM, V269, P30848; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Crawley JB, 1997, J BIOL CHEM, V272, P15023, DOI 10.1074/jbc.272.23.15023; Craxton A, 1998, J IMMUNOL, V161, P3225; DaSilva J, 1997, J BIOL CHEM, V272, P28373, DOI 10.1074/jbc.272.45.28373; DONZE O, 1995, EMBO J, V14, P3828, DOI 10.1002/j.1460-2075.1995.tb00052.x; Dy M, 1999, EXP HEMATOL, V27, P1295, DOI 10.1016/S0301-472X(99)00070-3; Fukunaga R, 1997, EMBO J, V16, P1921, DOI 10.1093/emboj/16.8.1921; Gingras AC, 1999, ANNU REV BIOCHEM, V68, P913, DOI 10.1146/annurev.biochem.68.1.913; Gingras AC, 2001, GENE DEV, V15, P2852; Gingras AC, 1998, GENE DEV, V12, P502, DOI 10.1101/gad.12.4.502; Grolleau A, 2000, LEUKEMIA, V14, P1909, DOI 10.1038/sj.leu.2401904; Grolleau A, 1999, J IMMUNOL, V162, P3491; Grolleau A, 2002, J BIOL CHEM, V277, P22175, DOI 10.1074/jbc.M202014200; Guillonneau X, 1998, J BIOL CHEM, V273, P22367, DOI 10.1074/jbc.273.35.22367; HAGHIGHAT A, 1995, EMBO J, V14, P5701, DOI 10.1002/j.1460-2075.1995.tb00257.x; Hall-Jackson CA, 1998, BRIT J CANCER, V78, P641, DOI 10.1038/bjc.1998.554; Han J, 1997, NATURE, V386, P296, DOI 10.1038/386296a0; Hashimoto S, 2000, J PHARMACOL EXP THER, V293, P370; Hazzalin CA, 1998, MOL CELL BIOL, V18, P1844, DOI 10.1128/MCB.18.4.1844; Hazzalin CA, 1997, ONCOGENE, V15, P2321, DOI 10.1038/sj.onc.1201403; Herbert TP, 2002, J BIOL CHEM, V277, P11591, DOI 10.1074/jbc.M110367200; Hu YH, 1997, ARTERIOSCL THROM VAS, V17, P2808, DOI 10.1161/01.ATV.17.11.2808; Janknecht R, 1997, EMBO J, V16, P1620, DOI 10.1093/emboj/16.7.1620; Karin M, 1998, ANN NY ACAD SCI, V851, P139, DOI 10.1111/j.1749-6632.1998.tb08987.x; Knauf U, 2001, MOL CELL BIOL, V21, P5500, DOI 10.1128/MCB.21.16.5500-5511.2001; Knebel A, 2001, EMBO J, V20, P4360, DOI 10.1093/emboj/20.16.4360; KOSAKO H, 1994, EMBO J, V13, P2131, DOI 10.1002/j.1460-2075.1994.tb06489.x; Larsen CM, 1998, J BIOL CHEM, V273, P15294, DOI 10.1074/jbc.273.24.15294; Levkovitz Y, 2002, J NEUROSCI, V22, P3845, DOI 10.1523/JNEUROSCI.22-10-03845.2002; Liu GM, 2002, J BIOL CHEM, V277, P8810, DOI 10.1074/jbc.M110477200; LIU JW, 1992, CELL GROWTH DIFFER, V3, P307; Maeda K, 1998, EXP HEMATOL, V26, P325; Meier R, 1996, EUR J BIOCHEM, V236, P796, DOI 10.1111/j.1432-1033.1996.00796.x; MINICH WB, 1994, P NATL ACAD SCI USA, V91, P7668, DOI 10.1073/pnas.91.16.7668; Pietersma A, 1997, BIOCHEM BIOPH RES CO, V230, P44, DOI 10.1006/bbrc.1996.5886; Pyronnet S, 1999, EMBO J, V18, P270, DOI 10.1093/emboj/18.1.270; Raingeaud J, 1996, MOL CELL BIOL, V16, P1247; Raught B, 1999, INT J BIOCHEM CELL B, V31, P43, DOI 10.1016/S1357-2725(98)00131-9; Raught B, 2000, EMBO J, V19, P434, DOI 10.1093/emboj/19.3.434; Read MA, 1997, J BIOL CHEM, V272, P2753, DOI 10.1074/jbc.272.5.2753; Reiser COA, 1998, BIOCHEM J, V330, P1107; Rincon M, 1998, EMBO J, V17, P2817, DOI 10.1093/emboj/17.10.2817; Rolli M, 1999, J BIOL CHEM, V274, P19559, DOI 10.1074/jbc.274.28.19559; Rolli-Derkinderen M, 2000, BIOL CHEM, V381, P193, DOI 10.1515/BC.2000.026; ROSSOMANDO AJ, 1991, J BIOL CHEM, V266, P20270; Scheper GC, 2001, MOL CELL BIOL, V21, P743, DOI 10.1128/MCB.21.3.743-754.2001; Schneider R, 2001, MOL CELL BIOL, V21, P8238, DOI 10.1128/MCB.21.23.8238-8246.2001; Schultz H, 1997, J CELL PHYSIOL, V173, P310, DOI 10.1002/(SICI)1097-4652(199712)173:3<310::AID-JCP2>3.0.CO;2-Q; Tee AR, 2002, MOL CELL BIOL, V22, P1674, DOI 10.1128/MCB.22.6.1674-1683.2002; Tilly BC, 1996, FEBS LETT, V395, P133, DOI 10.1016/0014-5793(96)01028-9; vonManteuffel SR, 1996, P NATL ACAD SCI USA, V93, P4076, DOI 10.1073/pnas.93.9.4076; WANG X, 2001, EMBO J, V16, P4320; Wang XZ, 1996, SCIENCE, V272, P1347, DOI 10.1126/science.272.5266.1347; Waskiewicz AJ, 1999, MOL CELL BIOL, V19, P1871; Waskiewicz AJ, 1997, EMBO J, V16, P1909, DOI 10.1093/emboj/16.8.1909; Wasylyk B, 1998, TRENDS BIOCHEM SCI, V23, P213, DOI 10.1016/S0968-0004(98)01211-0; Whitmarsh AJ, 1997, MOL CELL BIOL, V17, P2360, DOI 10.1128/MCB.17.5.2360; Wong WK, 2002, J BIOL CHEM, V277, P22222, DOI 10.1074/jbc.M202844200; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326	70	50	51	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 23	2003	278	21					18859	18867		10.1074/jbc.M211696200	http://dx.doi.org/10.1074/jbc.M211696200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	679PY	12618431	hybrid			2022-12-25	WOS:000182932200021
J	Dolder, M; Walzel, B; Speer, O; Schlattner, U; Wallimann, T				Dolder, M; Walzel, B; Speer, O; Schlattner, U; Wallimann, T			Inhibition of the mitochondrial permeability transition by creatine kinase substrates - Requirement for microcompartmentation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADENINE-NUCLEOTIDE TRANSLOCASE; ADP/ATP CARRIER; SKELETAL-MUSCLE; PHOSPHORYLCREATINE SHUTTLE; LYMPHOCYTE APOPTOSIS; CRYSTAL-STRUCTURE; CYCLOSPORINE-A; CYCLOPHILIN-D; BRAIN-TYPE; IN-SITU	Mitochondria from transgenic mice, expressing enzymatically active mitochondrial creatine kinase in liver, were analyzed for opening of the permeability transition pore in the absence and presence of creatine kinase substrates but with no external adenine nucleotides added. In mitochondria from these transgenic mice, cyclosporin A-inhibited pore opening was delayed by creatine or cyclocreatine but not by beta-guanidinopropionic acid. This observation correlated with the ability of these substrates to stimulate state 3 respiration in the presence of extramitochondrial ATP. The dependence of transition pore opening on calcium and magnesium concentration was studied in the presence and absence of creatine. If mitochondrial creatine kinase activity decreased (i.e. by omitting magnesium from the medium), protection of permeability transition pore opening by creatine or cyclocreatine was no longer seen. Likewise, when creatine kinase was added externally to liver mitochondria from wild-type mice that do not express mitochondrial creatine kinase in liver, no protective effect on pore opening by creatine and its analog was observed. All these findings indicate that mitochondrial creatine kinase activity located within the intermembrane and intercristae space, in conjunction with its tight functional coupling to oxidative phosphorylation, via the adenine nucleotide translocase, can modulate mitochondrial permeability transition in the presence of creatine. These results are of relevance for the design of creatine analogs for cell protection as potential adjuvant therapeutic tools against neurodegenerative diseases.	ETH Honggerberg, Inst Cell Biol, CH-8093 Zurich, Switzerland	Swiss Federal Institutes of Technology Domain; ETH Zurich	Dolder, M (corresponding author), ETH Honggerberg, Inst Biotechnol, CH-8093 Zurich, Switzerland.		Schlattner, Uwe/D-1267-2009; Wallimann, Theo/C-6047-2008	Schlattner, Uwe/0000-0003-1159-5911; Wallimann, Theo/0000-0003-4957-5836				ANKARCRONA M, 1995, NEURON, V15, P961, DOI 10.1016/0896-6273(95)90186-8; Bauer MKA, 1999, J CELL BIOL, V147, P1493, DOI 10.1083/jcb.147.7.1493; Belzacq AS, 2002, BIOCHIMIE, V84, P167, DOI 10.1016/S0300-9084(02)01366-4; Bernardi P, 1999, PHYSIOL REV, V79, P1127, DOI 10.1152/physrev.1999.79.4.1127; BERNARDI P, 1993, J BIOL CHEM, V268, P1005; Bernardi P, 1998, BIOFACTORS, V8, P273, DOI 10.1002/biof.5520080315; BESSMAN SP, 1981, SCIENCE, V211, P448, DOI 10.1126/science.6450446; Beutner G, 1998, BBA-BIOMEMBRANES, V1368, P7, DOI 10.1016/S0005-2736(97)00175-2; Boehm EA, 1996, BBA-BIOENERGETICS, V1274, P119, DOI 10.1016/0005-2728(96)00018-7; Brdiczka D, 1998, BIOFACTORS, V8, P235, DOI 10.1002/biof.5520080311; Brenner C, 2000, ONCOGENE, V19, P329, DOI 10.1038/sj.onc.1203298; Brewer GJ, 2000, J NEUROCHEM, V74, P1968, DOI 10.1046/j.1471-4159.2000.0741968.x; Brustovetsky N, 2001, J NEUROCHEM, V76, P425, DOI 10.1046/j.1471-4159.2001.00052.x; Brustovetsky N, 2002, BIOCHEMISTRY-US, V41, P11804, DOI 10.1021/bi0200110; Brustovetsky N, 1996, BIOCHEMISTRY-US, V35, P8483, DOI 10.1021/bi960833v; Castedo M, 1996, J IMMUNOL, V157, P512; CLARK JF, 1994, BIOCHEM J, V300, P211, DOI 10.1042/bj3000211; Crompton M, 1999, BIOCHEM J, V341, P233, DOI 10.1042/0264-6021:3410233; Crompton M, 1998, EUR J BIOCHEM, V258, P729, DOI 10.1046/j.1432-1327.1998.2580729.x; DIERKS T, 1990, BIOCHIM BIOPHYS ACTA, V1028, P268, DOI 10.1016/0005-2736(90)90176-O; Eder M, 1999, PROTEIN SCI, V8, P2258; Eder M, 2000, PROTEINS, V39, P216, DOI 10.1002/(SICI)1097-0134(20000515)39:3<216::AID-PROT40>3.0.CO;2-#; Fiore C, 1998, BIOCHIMIE, V80, P137, DOI 10.1016/S0300-9084(98)80020-5; Fontaine E, 1998, J BIOL CHEM, V273, P25734, DOI 10.1074/jbc.273.40.25734; Fontaine E, 1998, J BIOL CHEM, V273, P12662, DOI 10.1074/jbc.273.20.12662; GROSS M, 1993, BIOCHEMISTRY-US, V32, P13933, DOI 10.1021/bi00213a024; Halestrap AP, 1997, J BIOL CHEM, V272, P3346, DOI 10.1074/jbc.272.6.3346; Halestrap AP, 2002, BIOCHIMIE, V84, P153, DOI 10.1016/S0300-9084(02)01375-5; Huang SG, 2001, ARCH BIOCHEM BIOPHYS, V394, P67, DOI 10.1006/abbi.2001.2520; INDIVERI C, 1992, BIOCHIM BIOPHYS ACTA, V1140, P53, DOI 10.1016/0005-2728(92)90019-X; Jacotot E, 2000, J EXP MED, V191, P33, DOI 10.1084/jem.191.1.33; Kaldis Philipp, 1997, Advances in Developmental Biology, V5, P275, DOI 10.1016/S1566-3116(08)60040-7; Kay L, 2000, J BIOL CHEM, V275, P6937, DOI 10.1074/jbc.275.10.6937; KLINGENBERG M, 1985, ENZYMES BIOL MEMBR, V4, P511; Klivenyi P, 1999, NAT MED, V5, P347, DOI 10.1038/6568; Kraft T, 2000, J MUSCLE RES CELL M, V21, P691, DOI 10.1023/A:1005623002979; Linder MD, 2002, J BIOL CHEM, V277, P937, DOI 10.1074/jbc.M107610200; Lohret TA, 1996, J BIOL CHEM, V271, P4846; Marchetti P, 1996, J IMMUNOL, V157, P4830; Matthews RT, 1998, J NEUROSCI, V18, P156; Matthews RT, 1999, EXP NEUROL, V157, P142, DOI 10.1006/exnr.1999.7049; Miller K, 1997, AM J PHYSIOL-CELL PH, V272, pC1193, DOI 10.1152/ajpcell.1997.272.4.C1193; NOVGORODOV SA, 1994, ARCH BIOCHEM BIOPHYS, V311, P219, DOI 10.1006/abbi.1994.1230; OGorman E, 1997, FEBS LETT, V414, P253, DOI 10.1016/S0014-5793(97)01045-4; Passaquin AC, 2002, NEUROMUSCULAR DISORD, V12, P174, DOI 10.1016/S0960-8966(01)00273-5; PASTORINO JG, 1994, J BIOL CHEM, V269, P31041; Pulido SM, 1998, FEBS LETT, V439, P357, DOI 10.1016/S0014-5793(98)01399-4; Ruck A, 1998, FEBS LETT, V426, P97, DOI 10.1016/S0014-5793(98)00317-2; Saks VA, 1996, BBA-BIOENERGETICS, V1274, P81, DOI 10.1016/0005-2728(96)00011-4; SAKS VA, 1995, J MOL CELL CARDIOL, V27, P625, DOI 10.1016/S0022-2828(08)80056-9; Saks VA, 1998, MOL CELL BIOCHEM, V184, P81, DOI 10.1023/A:1006834912257; Schlattner U, 1998, MOL CELL BIOCHEM, V184, P125, DOI 10.1023/A:1006851330913; Scorrano L, 1999, J BIOL CHEM, V274, P22581, DOI 10.1074/jbc.274.32.22581; Tafani M, 2000, AM J PATHOL, V156, P2111, DOI 10.1016/S0002-9440(10)65082-1; Tarnopolsky MA, 2001, ANN NEUROL, V49, P561, DOI 10.1002/ana.1028; Ventura-Clapier R, 1998, MOL CELL BIOCHEM, V184, P231, DOI 10.1023/A:1006840508139; WALLIMANN T, 1994, CURR BIOL, V4, P42, DOI 10.1016/S0960-9822(00)00008-7; WALLIMANN T, 1992, BIOCHEM J, V281, P21, DOI 10.1042/bj2810021; WALLIMANN T, 1977, J CELL BIOL, V75, P297, DOI 10.1083/jcb.75.2.297; WALLIMANN T, 1984, J BIOL CHEM, V259, P5238; WEGMANN G, 1991, DIFFERENTIATION, V46, P77, DOI 10.1111/j.1432-0436.1991.tb00868.x; Woodfield K, 1998, BIOCHEM J, V336, P287, DOI 10.1042/bj3360287; Zamzami N, 2001, NAT REV MOL CELL BIO, V2, P67, DOI 10.1038/35048073	63	160	168	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 16	2003	278	20					17760	17766		10.1074/jbc.M208705200	http://dx.doi.org/10.1074/jbc.M208705200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677YX	12621025	hybrid			2022-12-25	WOS:000182838300023
J	Gilch, S; Wopfner, F; Renner-Muller, I; Kremmer, E; Bauer, C; Wolf, E; Brem, G; Groschup, MH; Schatzl, HM				Gilch, S; Wopfner, F; Renner-Muller, I; Kremmer, E; Bauer, C; Wolf, E; Brem, G; Groschup, MH; Schatzl, HM			Polyclonal anti-PrP auto-antibodies induced with dimeric PrP interfere efficiently with PrPSc propagation in prion-infected cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALZHEIMERS-DISEASE; PROTEIN ISOFORMS; DELAYS ONSET; SCRAPIE; MICE; INFECTIVITY; REPLICATION; MODEL; PATHOGENESIS; CONVERSION	Prion diseases are neurodegenerative infectious disorders for which no prophylactic regimens are known. In order to induce antibodies/auto-antibodies directed against surface-located PrPc, we used a covalently linked dimer of mouse prion protein expressed recombinantly in Escherichia coli. Employing dimeric PrP as an immunogen we were able to effectively overcome autotolerance against murine PrP in PrP wild-type mice without inducing obvious side effects. Treatment of prion-infected mouse cells with polyclonal anti-PrP antibodies generated in rabbit or auto-antibodies produced in mice significantly inhibited endogenous PrPSc synthesis. We show that polyclonal antibodies are binding to surface-located PrPc, thereby interfering with prion biogenesis. This effect is much more pronounced in the presence of full IgG molecules, which, unlike Fab fragments, seem to induce a significant cross-linking of surface PrP. In addition, we found immune responses against different epitopes when comparing antibodies induced in rabbits and PrP wild-type mice. Only in the auto-antibody situation in mice an immune reaction against a region of PrP is found that was reported to be involved in the PrPSc conversion process. Our data point to the possibility of developing means for an active immunoprophylaxis against prion diseases.	Univ Munich, Max Von Pettenkofer Inst Virol, Gene Ctr Munich, D-81377 Munich, Germany; Gene Ctr Munich, Inst Mol Anim Breeding, Munich, Germany; GSF, Natl Res Ctr Environm & Hlth, Inst Mol Immunol, Munich, Germany; Ludwig Boltzmann Inst Cyto Immuno & Mol Genet Res, A-1210 Vienna, Austria; Fed Res Ctr Virus Dis Anim, D-17498 Isle Riems, Germany; Tech Univ Munich, Inst Virol, D-80802 Munich, Germany	University of Munich; University of Munich; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; University of Munich; Ludwig Boltzmann Institute; Technical University of Munich	Schatzl, HM (corresponding author), Univ Munich, Max Von Pettenkofer Inst Virol, Gene Ctr Munich, Feodor Lynen Str 25, D-81377 Munich, Germany.		Schatzl, Hermann/G-4958-2011	Schatzl, Hermann/0000-0003-4972-8740; Wolf, Eckhard/0000-0002-0430-9510				Ahmad-Nejad P, 2002, EUR J IMMUNOL, V32, P1958, DOI 10.1002/1521-4141(200207)32:7<1958::AID-IMMU1958>3.0.CO;2-U; Betemps D, 2001, BIOCHEM BIOPH RES CO, V281, P101, DOI 10.1006/bbrc.2001.4326; Blattler T, 1997, NATURE, V389, P69, DOI 10.1038/37981; BORCHELT DR, 1992, J BIOL CHEM, V267, P16188; Brown KL, 1999, NAT MED, V5, P1308, DOI 10.1038/15264; BUELER HR, 1992, NATURE, V256, P577; CAUGHEY B, 1991, J BIOL CHEM, V266, P18217; Caughey B, 2001, TRENDS BIOCHEM SCI, V26, P235, DOI 10.1016/S0968-0004(01)01792-3; COHEN FE, 1994, SCIENCE, V264, P530, DOI 10.1126/science.7909169; Enari M, 2001, P NATL ACAD SCI USA, V98, P9295, DOI 10.1073/pnas.151242598; Gilch S, 2001, EMBO J, V20, P3957, DOI 10.1093/emboj/20.15.3957; Heppner FL, 2001, SCIENCE, V294, P178, DOI 10.1126/science.1063093; Horiuchi M, 1999, EMBO J, V18, P3193, DOI 10.1093/emboj/18.12.3193; Horiuchi M, 2001, J BIOL CHEM, V276, P15489, DOI 10.1074/jbc.M100288200; Ingram DK, 2001, TRENDS NEUROSCI, V24, P305, DOI 10.1016/S0166-2236(00)01796-3; Janus C, 2000, NATURE, V408, P979, DOI 10.1038/35050110; Kaneko K, 1997, P NATL ACAD SCI USA, V94, P10069, DOI 10.1073/pnas.94.19.10069; Klein MA, 2001, NAT MED, V7, P488, DOI 10.1038/86567; Klein MA, 1997, NATURE, V390, P687, DOI 10.1038/37789; KOCISKO DA, 1995, P NATL ACAD SCI USA, V92, P3923, DOI 10.1073/pnas.92.9.3923; KRAUSSLICH HG, 1991, P NATL ACAD SCI USA, V88, P3213, DOI 10.1073/pnas.88.8.3213; Mabbott NA, 2001, NAT MED, V7, P485, DOI 10.1038/86562; Mallucci GR, 2002, EMBO J, V21, P202, DOI 10.1093/emboj/21.3.202; Morgan D, 2000, NATURE, V408, P982, DOI 10.1038/35050116; Peretz D, 2001, NATURE, V412, P739, DOI 10.1038/35089090; Perrier V, 2000, P NATL ACAD SCI USA, V97, P6073, DOI 10.1073/pnas.97.11.6073; Proske D, 2002, CHEMBIOCHEM, V3, P717, DOI 10.1002/1439-7633(20020802)3:8<717::AID-CBIC717>3.0.CO;2-C; PRUSINER SB, 1993, P NATL ACAD SCI USA, V90, P10608, DOI 10.1073/pnas.90.22.10608; Prusiner SB, 1998, P NATL ACAD SCI USA, V95, P13363, DOI 10.1073/pnas.95.23.13363; SCOTT M, 1993, CELL, V73, P979, DOI 10.1016/0092-8674(93)90275-U; Sethi S, 2002, LANCET, V360, P229, DOI 10.1016/S0140-6736(02)09513-2; Sigurdsson EM, 2002, AM J PATHOL, V161, P13, DOI 10.1016/S0002-9440(10)64151-X; TARABOULOS A, 1995, J CELL BIOL, V129, P121, DOI 10.1083/jcb.129.1.121; TELLING GC, 1995, CELL, V83, P79, DOI 10.1016/0092-8674(95)90236-8; Weissmann C, 2001, PHILOS T R SOC B, V356, P177, DOI 10.1098/rstb.2000.0763; Williamson RA, 1996, P NATL ACAD SCI USA, V93, P7279, DOI 10.1073/pnas.93.14.7279; Wopfner F, 1999, J MOL BIOL, V289, P1163, DOI 10.1006/jmbi.1999.2831	37	91	103	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 16	2003	278	20					18524	18531		10.1074/jbc.M210723200	http://dx.doi.org/10.1074/jbc.M210723200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677YX	12637572	hybrid			2022-12-25	WOS:000182838300122
J	Macdonald, A; Crowder, K; Street, A; McCormick, C; Saksela, K; Harris, M				Macdonald, A; Crowder, K; Street, A; McCormick, C; Saksela, K; Harris, M			The hepatitis C virus non-structural NS5A protein inhibits activating protein-1 function by perturbing Ras-ERK pathway signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-CYCLE ARREST; FULL-LENGTH; MAP KINASE; X-PROTEIN; TRANSCRIPTION FACTORS; HBX PROTEIN; TYPE-1 NEF; HIV-1 NEF; GROWTH; EXPRESSION	The hepatitis C virus nonstructural 5A (NS5A) protein is a pleiotropic phosphoprotein that has been shown to associate with a wide variety of cellular signaling proteins. Of particular interest is the observation that a highly conserved C-terminal Class II polyproline motif within NS5A mediated association with the Src homology 3 domains of members of the Src family of tyrosine kinases and the mitogenic adaptor protein Grb2 (A. Macdonald, K. Crowder, A. Street, C. McCormick, and M. Harris, submitted for publication). In this study, we analyzed the consequences of NS5A expression on mitogenic signaling pathways within a variety of cell lines. Utilizing a transient luciferase reporter system, we observed that NS5A inhibited the activity of the mitogenic and stress-activated transcription factor activating protein-1 (AP1). This inhibition was dependent upon a Class II polyproline motif within NS5A. Using a combination of dominant active and negative mutants of components of the MAPK signaling pathways, selective inhibitors, together with immunoblotting with phospho-specific and phosphorylation-independent antibodies, we determined the signaling pathways targeted by NS5A to inhibit AP1. These studies demonstrated that in both stable NS5A-expressing cells and Huh-7-derived cells harboring subgenomic hepatitis C virus (HCV) replicons, this inhibition was mediated through the ERK signaling pathway. Importantly, a comparable inhibition of AP1 reporter activity was observed in hepatocyte-derived cell lines transduced with a baculovirus vector driving expression of full-length HCV polyprotein. In conclusion, these data strongly suggest a role for the NS5A protein in the perturbation of mitogenic signaling pathways in HCV-infected hepatocytes.	Univ Leeds, Dept Biochem & Mol Biol, Div Microbiol, Leeds LS2 9JT, W Yorkshire, England; Tampere Univ Hosp, Inst Med Technol, FIN-33014 Tampere, Finland	University of Leeds; Tampere University; Tampere University Hospital	Harris, M (corresponding author), Univ Leeds, Dept Biochem & Mol Biol, Div Microbiol, Leeds LS2 9JT, W Yorkshire, England.	mharris@bmb.leeds.ac.uk		Harris, Mark/0000-0002-9821-1003; McCormick, Christopher/0000-0002-6155-9161; Macdonald, Andrew/0000-0002-5978-4693				ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; Aoubala M, 2001, J GEN VIROL, V82, P1637, DOI 10.1099/0022-1317-82-7-1637; Arbuthnot P, 2000, J GASTROEN HEPATOL, V15, P357, DOI 10.1046/j.1440-1746.2000.02069.x; Arima N, 2001, J BIOL CHEM, V276, P12675, DOI 10.1074/jbc.M008329200; Bartenschlager R, 2000, J GEN VIROL, V81, P1631, DOI 10.1099/0022-1317-81-7-1631; BARTENSCHLAGER R, 1994, J VIROL, V68, P5045, DOI 10.1128/JVI.68.8.5045-5055.1994; BENN J, 1995, P NATL ACAD SCI USA, V92, P11215, DOI 10.1073/pnas.92.24.11215; Biggs TE, 1999, J MOL BIOL, V290, P21, DOI 10.1006/jmbi.1999.2849; CARPENTER G, 1979, ANNU REV BIOCHEM, V48, P193, DOI 10.1146/annurev.bi.48.070179.001205; CHOO QL, 1991, P NATL ACAD SCI USA, V88, P2451, DOI 10.1073/pnas.88.6.2451; Chung JK, 1997, MOL CELL BIOL, V17, P6508, DOI 10.1128/MCB.17.11.6508; CROSS JC, 1993, P NATL ACAD SCI USA, V90, P8078, DOI 10.1073/pnas.90.17.8078; DENT P, 1992, SCIENCE, V257, P1404, DOI 10.1126/science.1326789; DORIA M, 1995, EMBO J, V14, P4747, DOI 10.1002/j.1460-2075.1995.tb00156.x; Eickelberg O, 1999, J BIOL CHEM, V274, P12933, DOI 10.1074/jbc.274.18.12933; Erhardt A, 2002, VIROLOGY, V292, P272, DOI 10.1006/viro.2001.1227; Fanger GR, 1997, CURR OPIN GENET DEV, V7, P67, DOI 10.1016/S0959-437X(97)80111-6; FURUKAWA T, 1979, J GEN VIROL, V45, P81, DOI 10.1099/0022-1317-45-1-81; Gale MJ, 1998, CLIN DIAGN VIROL, V10, P157; Ghosh AK, 1999, J GEN VIROL, V80, P1179, DOI 10.1099/0022-1317-80-5-1179; Ghosh AK, 2000, J BIOL CHEM, V275, P7184, DOI 10.1074/jbc.275.10.7184; Goh KC, 2000, EMBO J, V19, P4292, DOI 10.1093/emboj/19.16.4292; Gong GZ, 2001, P NATL ACAD SCI USA, V98, P9599, DOI 10.1073/pnas.171311298; GREEN S, 1988, NUCLEIC ACIDS RES, V16, P369, DOI 10.1093/nar/16.1.369; HAYSTEAD TAJ, 1992, FEBS LETT, V306, P17, DOI 10.1016/0014-5793(92)80828-5; He YP, 2002, J VIROL, V76, P9207, DOI 10.1128/JVI.76.18.9207-9217.2002; He YP, 2001, J VIROL, V75, P5090, DOI 10.1128/JVI.75.11.5090-5098.2001; Heim MH, 1999, J VIROL, V73, P8469, DOI 10.1128/JVI.73.10.8469-8475.1999; Herdegen T, 1998, BRAIN RES REV, V28, P370, DOI 10.1016/S0165-0173(98)00018-6; Higuchi R., 1992, PCR TECHNOLOGY, P61; HSU JC, 1993, CANCER RES, V53, P3789; Ichaso N, 2001, ONCOGENE, V20, P7908, DOI 10.1038/sj.onc.1204859; Ichijo H, 1999, ONCOGENE, V18, P6087, DOI 10.1038/sj.onc.1203129; Jain N, 1998, ONCOGENE, V17, P3157, DOI 10.1038/sj.onc.1202238; KANEKO T, 1994, BIOCHEM BIOPH RES CO, V205, P320, DOI 10.1006/bbrc.1994.2667; Kim WR, 2002, HEPATOLOGY, V36, pS30, DOI 10.1053/jhep.2002.36791; Korkaya H, 2001, J BIOL CHEM, V276, P42389, DOI 10.1074/jbc.M101546200; Krieger N, 2001, J VIROL, V75, P4614, DOI 10.1128/JVI.75.10.4614-4624.2001; LANGECARTER CA, 1994, RECENT PROG HORM RES, V49, P341; LANGECARTER CA, 1994, SCIENCE, V265, P1458, DOI 10.1126/science.8073291; LEEVERS SJ, 1994, NATURE, V369, P411, DOI 10.1038/369411a0; Lohmann V, 2001, J VIROL, V75, P1437, DOI 10.1128/JVI.75.3.1437-1449.2001; Lohmann V, 1999, SCIENCE, V285, P110, DOI 10.1126/science.285.5424.110; Manninen A, 2000, J BIOL CHEM, V275, P16513, DOI 10.1074/jbc.M910032199; Manninen A, 1998, VIROLOGY, V250, P273, DOI 10.1006/viro.1998.9381; McCormick CJ, 2002, J GEN VIROL, V83, P383, DOI 10.1099/0022-1317-83-2-383; Moscatello DK, 1998, J BIOL CHEM, V273, P200, DOI 10.1074/jbc.273.1.200; Murphy LO, 2002, NAT CELL BIOL, V4, P556, DOI 10.1038/ncb822; Nijhara R, 2001, J VIROL, V75, P10348, DOI 10.1128/JVI.75.21.10348-10358.2001; Poggioli GJ, 2001, J VIROL, V75, P7429, DOI 10.1128/JVI.75.16.7429-7434.2001; RAO VN, 1993, CANCER RES, V53, P215; Renkema GH, 1999, CURR BIOL, V9, P1407, DOI 10.1016/S0960-9822(00)80086-X; Renkema GH, 2001, J VIROL, V75, P2154, DOI 10.1128/JVI.75.5.2154-2160.2001; Richards SA, 1999, CURR BIOL, V9, P810, DOI 10.1016/S0960-9822(99)80364-9; Roberts ML, 1998, VIROLOGY, V240, P93, DOI 10.1006/viro.1997.8901; Saragovi HU, 1999, DNA CELL BIOL, V18, P763, DOI 10.1089/104454999314908; Tan SL, 1999, P NATL ACAD SCI USA, V96, P5533, DOI 10.1073/pnas.96.10.5533; Tu H, 1999, VIROLOGY, V263, P30, DOI 10.1006/viro.1999.9893; Tyler KL, 2001, TRENDS MICROBIOL, V9, P560, DOI 10.1016/S0966-842X(01)02103-5; Widmann C, 1999, PHYSIOL REV, V79, P143, DOI 10.1152/physrev.1999.79.1.143; WILLIAMSON MP, 1994, BIOCHEM J, V297, P249, DOI 10.1042/bj2970249; YAN SF, 1995, J BIOL CHEM, V270, P11463, DOI 10.1074/jbc.270.19.11463; Yanagi M, 1997, P NATL ACAD SCI USA, V94, P8738, DOI 10.1073/pnas.94.16.8738; Yoon K, 1999, J GEN VIROL, V80, P2951, DOI 10.1099/0022-1317-80-11-2951; Yoshida T, 2002, J EXP MED, V196, P641, DOI 10.1084/jem.20012127; Yu CF, 2002, J BIOL CHEM, V277, P19382, DOI 10.1074/jbc.M200732200	66	131	133	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 16	2003	278	20					17775	17784		10.1074/jbc.M210900200	http://dx.doi.org/10.1074/jbc.M210900200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677YX	12621033	hybrid			2022-12-25	WOS:000182838300025
J	Nagata, K; Kawajiri, A; Matsui, S; Takagishi, M; Shiromizu, T; Saitoh, N; Izawa, I; Kiyono, T; Itoh, TJ; Hotani, H; Inagaki, M				Nagata, K; Kawajiri, A; Matsui, S; Takagishi, M; Shiromizu, T; Saitoh, N; Izawa, I; Kiyono, T; Itoh, TJ; Hotani, H; Inagaki, M			Filament formation of MSF-A, a mammalian septin, in human mammary epithelial cells depends on interactions with microtubules	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACUTE MYELOID-LEUKEMIA; OVARIAN-TUMORS; DIVISION CYCLE; CHROMOSOME 17Q; ALLELIC LOSS; MDCK CELLS; BUD NECK; PROTEIN; GENE; REGION	Septins are a family of conserved proteins implicated in a variety of cellular functions such as cytokinesis and vesicle trafficking, but their properties and modes of action are largely unknown. Here we now report findings of immunocytochemical and biochemical characterization of a mammalian septin, MSF-A. Using an antibody specific for MSF subfamily proteins, MSF-A was found to be expressed predominantly in mammary human mammary epithelial cells (HMEC). MSF-A was associated with microtubules in interphase HMEC cells as it localized with the mitotic spindle and the bundle of microtubule at midzone during mitosis. Biochemical analysis revealed direct binding of MSF-A with polymerized tubulin through its central region containing guanine nucleotide-interactive motifs. GTPase activity, however, was not required for the association. Conditions that disrupt the microtubule network also disrupted the MSF-A-containing filament structure, resulting in a punctate cytoplasmic pattern. Depletion of MSF-A using small interfering RNAs caused incomplete cell division and resulted in the accumulation of binucleated cells. Unlike Nedd5, an MSF mutant deficient in GTPase activity forms filament indistinguishable from that of the wild type in COS cells. These results strongly suggest that septin filaments may interact not only with actin filaments but also with microtubule networks and that GTPase activity of MSF-A is not indispensable to incorporation of MSF-A into septin filaments.	Aichi Canc Ctr, Res Inst, Div Biochem, Chikusa Ku, Nagoya, Aichi 4648681, Japan; Aichi Canc Ctr, Res Inst, Div Virol, Chikusa Ku, Nagoya, Aichi 4648681, Japan; Nagoya Univ, Sch Med, Dept Pathol, Nagoya, Aichi 4668550, Japan; Nagoya Univ, Grad Sch Sci, Div Biol Sci, Nagoya, Aichi 4648602, Japan	Aichi Cancer Center; Aichi Cancer Center; Nagoya University; Nagoya University	Inagaki, M (corresponding author), Aichi Canc Ctr, Res Inst, Div Biochem, Chikusa Ku, 1-1 Kanokoden, Nagoya, Aichi 4648681, Japan.		Inagaki, Masaki/B-9920-2016; Kiyono, Tohru/H-5834-2011					Beites CL, 1999, NAT NEUROSCI, V2, P434, DOI 10.1038/8100; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BREITFELD PP, 1990, J CELL BIOL, V111, P2365, DOI 10.1083/jcb.111.6.2365; Carroll CW, 1998, J CELL BIOL, V143, P709, DOI 10.1083/jcb.143.3.709; Chant J, 1996, CELL, V84, P187, DOI 10.1016/S0092-8674(00)80972-1; COLE NB, 1995, CURR OPIN CELL BIOL, V7, P55, DOI 10.1016/0955-0674(95)80045-X; Field CM, 1999, TRENDS CELL BIOL, V9, P387, DOI 10.1016/S0962-8924(99)01632-3; Gladfelter AS, 2001, CURR OPIN MICROBIOL, V4, P681, DOI 10.1016/S1369-5274(01)00269-7; HARTWELL LH, 1971, EXP CELL RES, V69, P265, DOI 10.1016/0014-4827(71)90223-0; Hsu SC, 1998, NEURON, V20, P1111, DOI 10.1016/S0896-6273(00)80493-6; HUNZIKER W, 1990, EMBO J, V9, P3515, DOI 10.1002/j.1460-2075.1990.tb07560.x; Itoh TJ, 1997, BIOCHEMISTRY-US, V36, P12574, DOI 10.1021/bi962606z; Kalikin LM, 1997, ONCOGENE, V14, P1991, DOI 10.1038/sj.onc.1201013; Kalikin LM, 2000, GENOMICS, V63, P165, DOI 10.1006/geno.1999.6077; Kartmann B, 2001, J CELL SCI, V114, P839; Kinoshita M, 1997, GENE DEV, V11, P1535, DOI 10.1101/gad.11.12.1535; LAFONT F, 1994, NATURE, V372, P801; Larisch S, 2000, NAT CELL BIOL, V2, P915, DOI 10.1038/35046566; Longtine MS, 1996, CURR OPIN CELL BIOL, V8, P106, DOI 10.1016/S0955-0674(96)80054-8; Longtine MS, 1998, J CELL BIOL, V143, P719, DOI 10.1083/jcb.143.3.719; McIlhatton MA, 2001, ONCOGENE, V20, P5930, DOI 10.1038/sj.onc.1204752; Megonigal MD, 1998, P NATL ACAD SCI USA, V95, P6413, DOI 10.1073/pnas.95.11.6413; MURATA M, 1992, BIOL CELL, V75, P127, DOI 10.1016/0248-4900(92)90132-K; Nagata K, 1998, EMBO J, V17, P149, DOI 10.1093/emboj/17.1.149; NAGATA KI, 1992, J BIOL CHEM, V267, P19600; NEUFELD TP, 1994, CELL, V77, P371, DOI 10.1016/0092-8674(94)90152-X; Osaka M, 1999, P NATL ACAD SCI USA, V96, P6428, DOI 10.1073/pnas.96.11.6428; Phelan CM, 1998, CANCER RES, V58, P1004; Russell SEH, 2000, CANCER RES, V60, P4729; SAITO H, 1993, CANCER RES, V53, P3382; Surka MC, 2002, MOL BIOL CELL, V13, P3532, DOI 10.1091/mbc.E02-01-0042; Taki T, 1999, CANCER RES, V59, P4261; THEILE M, 1995, ONCOGENE, V10, P439; Trimble WS, 1999, J MEMBRANE BIOL, V169, P75, DOI 10.1007/s002329900519; Xie H, 1999, CELL MOTIL CYTOSKEL, V43, P52, DOI 10.1002/(SICI)1097-0169(1999)43:1<52::AID-CM6>3.0.CO;2-5; Zhang Y, 2000, P NATL ACAD SCI USA, V97, P13354, DOI 10.1073/pnas.240347797	36	155	159	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 16	2003	278	20					18538	18543		10.1074/jbc.M205246200	http://dx.doi.org/10.1074/jbc.M205246200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677YX	12626509	hybrid			2022-12-25	WOS:000182838300124
J	Otto, GP; Wu, MY; Kazgan, N; Anderson, OR; Kessin, RH				Otto, GP; Wu, MY; Kazgan, N; Anderson, OR; Kessin, RH			Macroautophagy is required for multicellular development of the social amoeba Dictyostelium discoideum	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							YEAST SACCHAROMYCES-CEREVISIAE; PROTEIN CONJUGATION SYSTEM; AUTOPHAGOSOME FORMATION; VACUOLE; GENE; CYTOPLASM; MEMBRANE; PATHWAYS; COMPLEX; AUTOPHAGOCYTOSIS	Macroautophagy is a mechanism employed by eukaryotic cells to recycle non-essential cellular components during starvation, differentiation, and development. Two conjugation reactions related to ubiquitination are essential for autophagy: Apg12p conjugation to Apg5p, and Apg8p conjugation to the lipid phosphatidylethanolamine. These reactions require the action of the E1-like enzyme, Apg7p, and the E2-like enzymes, Apg3p and Apg10p. In Dictyostelium, development is induced by starvation, conditions under which autophagy is required for survival in yeast and plants. We have identified Dictyostelium homologues of 10 budding yeast autophagy genes. We have generated mutations in apg5 and apg7 that produce defects typically associated with an abrogation of autophagy. Mutants are not grossly affected in growth, but survival during nitrogen starvation is severely reduced. Starved mutant cells show little turnover of cellular constituents by electron microscopy, whereas wild-type cells show significant cytoplasmic degradation and reduced organelle number. Bulk protein degradation during starvation-induced development is reduced in the autophagy mutants. Development is aberrant; the autophagy mutants do not aggregate in plaques on bacterial lawns, but they do proceed further in development on nitrocellulose filters, forming defective fruiting bodies. The autophagy mutations are cell autonomous, because wild-type cells in a chimaera do not rescue development of the autophagy mutants. We have complemented the mutant phenotypes by expression of the cognate gene fused to green fluorescent protein. A green fluorescent protein fusion of the autophagosome marker Apg8 mislocalizes in the two autophagy mutants. We show that the Apg5-Apg12 conjugation system is conserved in Dictyostelium.	Columbia Univ, Dept Anat & Cell Biol, New York, NY 10032 USA; Columbia Univ, Lamont Doherty Earth Observ, Dept Biol, Palisades, NY 10964 USA	Columbia University; Columbia University	Kessin, RH (corresponding author), Columbia Univ, Dept Anat & Cell Biol, Rm 12-517,630 W 168th St, New York, NY 10032 USA.			Otto, Grant/0000-0001-8709-3366; Wu, Mary Y./0000-0002-2074-6171	NIGMS NIH HHS [GM33136] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM033136] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDERSON OR, 1994, J EUKARYOT MICROBIOL, V41, P124, DOI 10.1111/j.1550-7408.1994.tb01484.x; Cuervo AM, 2000, TRAFFIC, V1, P570, DOI 10.1034/j.1600-0854.2000.010707.x; Cuervo AM, 2000, J CELL SCI, V113, P4441; Dice J F, 1990, Semin Cell Biol, V1, P449; Doelling JH, 2002, J BIOL CHEM, V277, P33105, DOI 10.1074/jbc.M204630200; DUNN WA, 1990, J CELL BIOL, V110, P1935, DOI 10.1083/jcb.110.6.1935; FRANKE J, 1977, P NATL ACAD SCI USA, V74, P2157, DOI 10.1073/pnas.74.5.2157; George MD, 2000, MOL BIOL CELL, V11, P969, DOI 10.1091/mbc.11.3.969; Hanaoka H, 2002, PLANT PHYSIOL, V129, P1181, DOI 10.1104/pp.011024; Ichimura Y, 2000, NATURE, V408, P488, DOI 10.1038/35044114; Kamada Y, 2000, J CELL BIOL, V150, P1507, DOI 10.1083/jcb.150.6.1507; Kametaka S, 1998, J BIOL CHEM, V273, P22284, DOI 10.1074/jbc.273.35.22284; Kessin R.H., 2001, DICTYOSTELIUM EVOLUT; Kihara A, 2001, J CELL BIOL, V152, P519, DOI 10.1083/jcb.152.3.519; Kirisako T, 2000, J CELL BIOL, V151, P263, DOI 10.1083/jcb.151.2.263; Kirisako T, 1999, J CELL BIOL, V147, P435, DOI 10.1083/jcb.147.2.435; Kuma A, 2002, J BIOL CHEM, V277, P18619, DOI 10.1074/jbc.M111889200; KUSPA A, 1992, P NATL ACAD SCI USA, V89, P8803, DOI 10.1073/pnas.89.18.8803; Lang T, 2000, J BACTERIOL, V182, P2125, DOI 10.1128/JB.182.8.2125-2133.2000; Levi S, 2000, PLASMID, V44, P231, DOI 10.1006/plas.2000.1487; Mizushima N, 1998, NATURE, V395, P395, DOI 10.1038/26506; Mizushima N, 1998, J BIOL CHEM, V273, P33889, DOI 10.1074/jbc.273.51.33889; Mizushima N, 1999, EMBO J, V18, P3888, DOI 10.1093/emboj/18.14.3888; MORTIMORE GE, 1988, J BIOL CHEM, V263, P2506; Niemann A, 2000, J HISTOCHEM CYTOCHEM, V48, P251, DOI 10.1177/002215540004800210; NODA T, 1995, BIOCHEM BIOPH RES CO, V210, P126, DOI 10.1006/bbrc.1995.1636; Noda T, 2000, J CELL BIOL, V148, P465, DOI 10.1083/jcb.148.3.465; Noda T, 1998, J BIOL CHEM, V273, P3963, DOI 10.1074/jbc.273.7.3963; PAPADOPOULOS T, 1987, EXP CELL RES, V171, P110, DOI 10.1016/0014-4827(87)90255-2; PODGORSKI GJ, 1989, MOL CELL BIOL, V9, P3938, DOI 10.1128/MCB.9.9.3938; Reggiori F, 2002, EUKARYOT CELL, V1, P11, DOI 10.1128/EC.01.1.11-21.2002; Schlumpberger M, 1997, J BACTERIOL, V179, P1068, DOI 10.1128/jb.179.4.1068-1076.1997; Shintani T, 2001, J BIOL CHEM, V276, P30452, DOI 10.1074/jbc.M102346200; Shintani T, 1999, EMBO J, V18, P5234, DOI 10.1093/emboj/18.19.5234; Souza GM, 1998, DEVELOPMENT, V125, P2291; SUSSMAN M, 1987, METHOD CELL BIOL, V28, P9; Suzuki K, 2001, EMBO J, V20, P5971, DOI 10.1093/emboj/20.21.5971; Tanida I, 1999, MOL BIOL CELL, V10, P1367, DOI 10.1091/mbc.10.5.1367; THUMM M, 1994, FEBS LETT, V349, P275, DOI 10.1016/0014-5793(94)00672-5; TSUKADA M, 1993, FEBS LETT, V333, P169, DOI 10.1016/0014-5793(93)80398-E; TUTTLE DL, 1995, J CELL SCI, V108, P25; Wang CW, 2001, J BIOL CHEM, V276, P30442, DOI 10.1074/jbc.M102342200; WHITE GJ, 1961, BIOCHIM BIOPHYS ACTA, V53, P285, DOI 10.1016/0006-3002(61)90441-3; WU L, 1990, GENE, V91, P51, DOI 10.1016/0378-1119(90)90161-J; Yuan WP, 1999, MOL BIOL CELL, V10, P1353, DOI 10.1091/mbc.10.5.1353	45	179	193	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 16	2003	278	20					17636	17645		10.1074/jbc.M212467200	http://dx.doi.org/10.1074/jbc.M212467200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677YX	12626495	hybrid			2022-12-25	WOS:000182838300009
J	Wei, LH; Kuo, ML; Chen, CA; Chou, CH; Lai, KB; Lee, CN; Hsieh, CY				Wei, LH; Kuo, ML; Chen, CA; Chou, CH; Lai, KB; Lee, CN; Hsieh, CY			Interleukin-6 promotes cervical tumor growth by VEGF-dependent angiogenesis via a STAT3 pathway	ONCOGENE			English	Article						angiogenesis; cervical cancer; cytokine; interleukin-6; STAT3; vascular endothelial growth factor	MESSENGER-RNA; KAPOSIS-SARCOMA; IN-VITRO; CERVICOVAGINAL SECRETIONS; FACTOR EXPRESSION; GENE-EXPRESSION; CELL-GROWTH; CANCER; IL-6; CYTOKINE	Interleukin-6 (IL-6) has received particular attention in the pathogenesis of cervical cancer, although the underlying mechanism remains elusive. This study revealed that IL-6 promotes in vivo tumor growth of human cervical cancer C33A cells, but does not substantially alter their in vitro growth kinetics. The in vivo angiogenic assays showed that IL-6 increases angiogenic activity in human cervical cancer cells, an effect that is specifically associated with upregulation of vascular endothelial growth factor (VEGF). Also, using anti-VEGF antibody to block VEGF function significantly inhibited IL-6-mediated angiogenesis and tumor growth in nude mice, strongly supporting the critical role of VEGF in the IL-6-mediated cervical tumorigenesis. Accordingly, the signaling pathway downstream of IL-6/ IL-6R responsible for the regulation of VEGF was investigated. Notably, pharmacological inhibition of PI3-K or MAPK failed to inhibit IL-6-mediated transcriptional upregulation of VEGF. Meanwhile, blocking STAT3 pathway with dominant-negative mutant STAT3D effectively abolished IL-6-induced VEGF mRNA. In transient transfections, a luciferase reporter construct containing the full-length 1.5-kb VEGF promoter or a 1.2-kb fragment lacking the known hypoxic-response element also exhibited the same degree of response to IL-6. Additionally, transient transfection of STAT3D downregulated the 1.2-kb VEGF promoter luciferase reporter stimulated by IL-6. Based on the above phenomenon combined with the concomitant increased tumor expression of IL-6 and VEGF in cervical cancer tissues, we conclude that IL-6 may promote cervical tumorigenesis by activating VEGF-mediated angiogenesis via a STAT3 pathway.	Natl Taiwan Univ Hosp, Coll Med, Dept Obstet & Gynecol, Taipei 100, Taiwan; Natl Taiwan Univ Hosp, Dept Oncol, Taipei 100, Taiwan; Natl Taiwan Univ, Coll Med, Inst Toxicol, Lab Mol & Cellular Toxicol, Taipei 100, Taiwan	National Taiwan University; National Taiwan University Hospital; National Taiwan University; National Taiwan University Hospital; National Taiwan University	Hsieh, CY (corresponding author), Natl Taiwan Univ Hosp, Coll Med, Dept Obstet & Gynecol, 7 Chung Shan S Rd, Taipei 100, Taiwan.	cyhsieh@ha.mc.ntu.edu.tw	Wei, Lin-Hung/B-1188-2008; Kuo, Min-Liang/C-4872-2009	Lee, Chien-Nan/0000-0002-1725-0407; CHEN, CHI-AN/0000-0001-6670-7939; Wei, Lin-Hung/0000-0001-8789-0859; KUO, MIN-LIANG/0000-0002-7139-0144				Aoki Y, 1999, BLOOD, V93, P4034, DOI 10.1182/blood.V93.12.4034.412k38_4034_4043; BELEC L, 1995, CYTOKINE, V7, P568, DOI 10.1006/cyto.1995.0077; Carmeliet P, 2000, NAT MED, V6, P389, DOI 10.1038/74651; Castrilli G, 1997, BRIT J CANCER, V75, P855, DOI 10.1038/bjc.1997.152; Chen Z, 1999, CLIN CANCER RES, V5, P1369; Cheng WF, 1999, OBSTET GYNECOL, V93, P761, DOI 10.1016/S0029-7844(98)00505-5; Cheng WF, 2000, OBSTET GYNECOL, V96, P721, DOI 10.1016/S0029-7844(00)01025-5; DANFORTH DN, 1993, CANCER RES, V53, P1538; Dankbar B, 2000, BLOOD, V95, P2630, DOI 10.1182/blood.V95.8.2630; Dobbs SP, 1997, BRIT J CANCER, V76, P1410, DOI 10.1038/bjc.1997.571; EUSTACE D, 1993, GYNECOL ONCOL, V50, P15, DOI 10.1006/gyno.1993.1156; Ferrara N, 1997, ENDOCR REV, V18, P4, DOI 10.1210/er.18.1.4; Fujimoto J, 1999, BRIT J CANCER, V79, P1249, DOI 10.1038/sj.bjc.6690200; Fujimoto J, 1999, BRIT J CANCER, V80, P827, DOI 10.1038/sj.bjc.6690428; Fujimoto J, 1997, CANCER LETT, V111, P21, DOI 10.1016/S0304-3835(96)04485-0; Fujimoto J, 2000, CANCER RES, V60, P2632; GUIDI AJ, 1995, J NATL CANCER I, V87, P1237, DOI 10.1093/jnci/87.16.1237; Hanahan D, 1996, CELL, V86, P353, DOI 10.1016/S0092-8674(00)80108-7; Hirano T, 2000, ONCOGENE, V19, P2548, DOI 10.1038/sj.onc.1203551; Hirano Toshio, 1997, Cytokine and Growth Factor Reviews, V8, P241, DOI 10.1016/S1359-6101(98)80005-1; HORVATH CM, 1995, GENE DEV, V9, P984, DOI 10.1101/gad.9.8.984; IGLESIAS M, 1995, AM J PATHOL, V146, P944; Jee SH, 2001, ONCOGENE, V20, P198, DOI 10.1038/sj.onc.1204076; Jiang BH, 2001, CELL GROWTH DIFFER, V12, P363; KISHIMOTO T, 1995, BLOOD, V86, P1243, DOI 10.1182/blood.V86.4.1243.bloodjournal8641243; KLEIN B, 1995, BLOOD, V85, P863, DOI 10.1182/blood.V85.4.863.bloodjournal854863; Kodama J, 1999, EUR J CANCER, V35, P485, DOI 10.1016/S0959-8049(98)00410-9; Kodama J, 2001, CLIN CANCER RES, V7, P2826; Lee JS, 2002, GYNECOL ONCOL, V85, P469, DOI 10.1006/gyno.2002.6648; Lopez-Ocejo O, 2000, ONCOGENE, V19, P4611, DOI 10.1038/sj.onc.1203817; Mahnke JL, 2000, FERTIL STERIL, V73, P166, DOI 10.1016/S0015-0282(99)00466-5; Masood R, 1999, BLOOD, V93, P1038, DOI 10.1182/blood.V93.3.1038.403a14_1038_1044; MATEO RB, 1994, AM J PHYSIOL, V266, pR1840, DOI 10.1152/ajpregu.1994.266.6.R1840; MOTRO B, 1990, P NATL ACAD SCI USA, V87, P3092, DOI 10.1073/pnas.87.8.3092; MURAKAMI M, 1993, SCIENCE, V260, P1808, DOI 10.1126/science.8511589; Nicholas J, 1997, NAT MED, V3, P287, DOI 10.1038/nm0397-287; Niu GL, 2002, ONCOGENE, V21, P2000, DOI 10.1038/sj.onc.1205260; Okamoto M, 1997, CANCER RES, V57, P141; Page C, 2000, INT J ONCOL, V17, P23; PASSANITI A, 1992, LAB INVEST, V67, P519; Richter HE, 1999, AM J OBSTET GYNECOL, V181, P940, DOI 10.1016/S0002-9378(99)70329-7; SCHIFFMAN MH, 1995, CANCER-AM CANCER SOC, V76, P1888, DOI 10.1002/1097-0142(19951115)76:10+<1888::AID-CNCR2820761305>3.0.CO;2-H; SILLMAN F, 1981, AM J OBSTET GYNECOL, V139, P154, DOI 10.1016/0002-9378(81)90438-5; SmithMcCune K, 1997, CANCER RES, V57, P1294; SMITHMCCUNE KK, 1994, CANCER RES, V54, P800; Taga T, 1997, ANNU REV IMMUNOL, V15, P797, DOI 10.1146/annurev.immunol.15.1.797; TAKIZAWA H, 1993, CANCER RES, V53, P4175; TARTOUR E, 1994, CANCER RES, V54, P6243; Tilg H, 1997, IMMUNOL TODAY, V18, P428, DOI 10.1016/S0167-5699(97)01103-1; Tjiong MY, 1999, GYNECOL ONCOL, V73, P285, DOI 10.1006/gyno.1999.5358; Valdembri D, 2001, FASEB J, V15, P225, DOI 10.1096/fj.01-0633fje; Wei LH, 2001, ONCOGENE, V20, P5799, DOI 10.1038/sj.onc.1204733; Wei LH, 2001, GYNECOL ONCOL, V82, P49, DOI 10.1006/gyno.2001.6235; Xu L, 2002, J BIOL CHEM, V277, P11368, DOI 10.1074/jbc.M108347200; YAMAUCHITAKIHARA K, 1995, CIRCULATION, V91, P1520, DOI 10.1161/01.CIR.91.5.1520; YAN SF, 1995, J BIOL CHEM, V270, P11463, DOI 10.1074/jbc.270.19.11463; zur Hausen H, 2002, NAT REV CANCER, V2, P342, DOI 10.1038/nrc798	57	405	433	0	21	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 13	2003	22	10					1517	1527		10.1038/sj.onc.1206226	http://dx.doi.org/10.1038/sj.onc.1206226			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	652ZZ	12629515				2022-12-25	WOS:000181411900009
J	Greenwood, J; Walters, CE; Pryce, G; Kanuga, N; Beraud, E; Baker, D; Adamson, P				Greenwood, J; Walters, CE; Pryce, G; Kanuga, N; Beraud, E; Baker, D; Adamson, P			Lovastatin inhibits brain endothelial cell Rho-mediated lymphocyte migration and attenuates experimental autoimmune encephalomyelitis	FASEB JOURNAL			English	Article						statins; blood-brain barrier; leukocyte recruitment; multiple sclerosis	EXPERIMENTAL ALLERGIC ENCEPHALOMYELITIS; CENTRAL-NERVOUS-SYSTEM; COA REDUCTASE INHIBITOR; MYELIN BASIC-PROTEIN; IN-VITRO; BLOOD-BRAIN; TRANSENDOTHELIAL MIGRATION; MULTIPLE-SCLEROSIS; LEWIS RATS; ICAM-1	Neuroinflammatory diseases, such as multiple sclerosis (MS), result from aberrant leukocyte traffic into the central nervous system (CNS). To breach the specialized blood-brain barrier, activated leukocytes interact with CNS endothelial cells (EC) and activate a CD54-mediated signaling pathway controlling the Rho GTPase. To function correctly Rho requires posttranslational prenylation, and this can be inhibited by depleting the supply of isoprenoids through inhibition of the cholesterol synthesis pathway with 3-hydroxy-3-methylglutaryl CoA reductase (HMG-CoA reductase) inhibitors (statins). Here we show that treatment of brain EC in vitro with lovastatin inhibits Rho-mediated transendothelial T cell migration. This effect can be reversed by supplementation with mevalonolactone, the downstream product of HMG-CoA reductase, or by ectopic expression of myristoylated Rho, which remains active in the absence of prenylation. In a relapsing-remitting mouse model of MS, lovastatin treatment inhibited leukocyte migration into the CNS and significantly attenuated the development of both acute and relapsing clinical disease. These studies demonstrate that the indirect pharmacological inhibition of Rho proteins in brain EC by statins can inhibit a key stage in the pathogenesis of neuroinflammation, namely leukocyte migration across the blood-brain barrier. These studies demonstrate a novel effect of statins in modulating the immune response in neuroinflammtory diseases and may provide additional rationale for their use in the treatment of MS.	UCL, Div Cell Biol, Inst Ophthalmol, London EC1V 9EL, England; UCL, Dept Neuroinflammat, Inst Neurol, London WC1N 1PJ, England; Univ Aix Marseille 2, Fac Med, Immunol Lab, Marseille, France	University of London; University College London; University of London; University College London; UDICE-French Research Universities; Aix-Marseille Universite	Greenwood, J (corresponding author), UCL, Div Cell Biol, Inst Ophthalmol, Bath St, London EC1V 9EL, England.	j.greenwood@ucl.ac.uk		Greenwood, John/0000-0003-4496-2984	Multiple Sclerosis Society [541, 675] Funding Source: Medline; Wellcome Trust [062403] Funding Source: Medline	Multiple Sclerosis Society(National Multiple Sclerosis Society); Wellcome Trust(Wellcome TrustEuropean Commission)		ADAMSON P, 1992, J CELL BIOL, V119, P617, DOI 10.1083/jcb.119.3.617; Adamson P, 2002, FASEB J, V16, DOI 10.1096/fj.02-0035com; ADAMSON P, 1992, J BIOL CHEM, V267, P20033; Adamson P, 1999, J IMMUNOL, V162, P2964; ALLEN SJ, 1993, CELL IMMUNOL, V146, P335, DOI 10.1006/cimm.1993.1031; Amor S, 1996, J IMMUNOL, V156, P3000; Backlund PS, 1997, J BIOL CHEM, V272, P33175, DOI 10.1074/jbc.272.52.33175; BAKER D, 1990, J NEUROIMMUNOL, V28, P261, DOI 10.1016/0165-5728(90)90019-J; BERAUD E, 1986, J IMMUNOL, V136, P511; BERAUD E, 1993, J NEUROIMMUNOL, V47, P41, DOI 10.1016/0165-5728(93)90283-5; CHAKRABARTI R, 1991, J BIOL CHEM, V266, P12216; Etienne S, 1998, J IMMUNOL, V161, P5755; Etienne-Manneville S, 2000, J IMMUNOL, V165, P3375, DOI 10.4049/jimmunol.165.6.3375; Greenwood J, 1996, J NEUROIMMUNOL, V71, P51, DOI 10.1016/S0165-5728(96)00130-0; GREENWOOD J, 1995, IMMUNOLOGY, V86, P408; HICKEY WF, 1991, J NEUROSCI RES, V28, P254, DOI 10.1002/jnr.490280213; JAHNER D, 1991, MOL CELL BIOL, V11, P3682; Kwak B, 2000, NAT MED, V6, P1399, DOI 10.1038/82219; LEBOWITZ PF, 1995, MOL CELL BIOL, V15, P6613; Lefer AM, 1999, CIRCULATION, V100, P178, DOI 10.1161/01.CIR.100.2.178; MALE D, 1994, IMMUNOLOGY, V81, P366; MCPHERSON R, 1993, J CLIN IMMUNOL, V13, P439, DOI 10.1007/BF00920019; Neuhaus O, 2002, NEUROLOGY, V59, P990, DOI 10.1212/WNL.59.7.990; ONEILL JK, 1992, J NEUROIMMUNOL, V38, P53, DOI 10.1016/0165-5728(92)90090-8; Pryce G, 1997, J NEUROIMMUNOL, V75, P84, DOI 10.1016/S0165-5728(97)00006-4; Reiss Y, 1998, EUR J IMMUNOL, V28, P3086, DOI 10.1002/(SICI)1521-4141(199810)28:10<3086::AID-IMMU3086>3.3.CO;2-Q; Stanislaus R, 1999, NEUROSCI LETT, V269, P71, DOI 10.1016/S0304-3940(99)00414-0; Stanislaus R, 2001, J NEUROSCI RES, V66, P155, DOI 10.1002/jnr.1207; Steinman L, 2001, NAT IMMUNOL, V2, P762, DOI 10.1038/ni0901-762; Walters CE, 2002, J IMMUNOL, V168, P4087, DOI 10.4049/jimmunol.168.8.4087; Weber C, 1997, J AM COLL CARDIOL, V30, P1212, DOI 10.1016/S0735-1097(97)00324-0; Weitz-Schmidt G, 2001, NAT MED, V7, P687, DOI 10.1038/89058; Wong BM, 2001, J LEUKOCYTE BIOL, V69, P959; Yoshida M, 2001, ARTERIOSCL THROM VAS, V21, P1165, DOI 10.1161/hq0701.092143; Youssef S, 2002, NATURE, V420, P78, DOI 10.1038/nature01158	35	185	196	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAR	2003	17	3					905	+		10.1096/fj.02-1014fje	http://dx.doi.org/10.1096/fj.02-1014fje			16	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	661LT	12626426	Green Accepted			2022-12-25	WOS:000181892600027
J	Ramana, KV; Chandra, D; Srivastava, S; Bhatnagar, A; Srivastava, SK				Ramana, KV; Chandra, D; Srivastava, S; Bhatnagar, A; Srivastava, SK			Nitric oxide regulates the polyol pathway of glucose metabolism in vascular smooth muscle cells	FASEB JOURNAL			English	Article						aldose reductase; glutathiolation; diabetes; nitric oxide and nitrosothiols	ALDOSE REDUCTASE; SIGNALING MECHANISMS; COMPLICATIONS; IDENTIFICATION; PREVENTION; TRANSPORT; STRESS	Increased reduction of glucose via the polyol pathway enzyme aldose reductase (AR) has been linked to the development of secondary diabetic complications. Because AR is a redox-sensitive protein, which in vitro is readily modified by NO donors, we tested the hypothesis that NO may be a physiological regulator of AR. We found that administration of the NO synthase (NOS) inhibitor N-G-nitro-L-arginine methyl ester (L-NAME) increased sorbitol accumulation in the aorta of nondiabetic and diabetic rats, whereas treatment with L-arginine (a precursor of NO) or nitroglycerine patches prevented sorbitol accumulation. When incubated ex vivo with high glucose, sorbitol accumulation was increased by L-NAME and prevented by L-arginine in strips of aorta from rats or wild-type, but not eNOS-deficient, mice. Exposure to NO donors also inhibited AR and prevented sorbitol accumulation in rat aortic vascular smooth muscle cells (VSMC) in culture. The NO donors also increased the incorporation of radioactivity in the AR protein immunoprecipitated from VSMC in which the glutathione pool was prelabeled with [S-35]-cysteine. Based on these observations, we suggest that NO regulates the vascular synthesis of polyols by S-thiolating AR; therefore, increasing NO synthesis or bioavailability may be useful in preventing diabetes-induced changes in the polyol pathway.	Univ Texas, Dept Human Biol Chem & Genet, Med Branch, Galveston, TX 77555 USA; Univ Louisville, Dept Med, Div Cardiol, Louisville, KY 40292 USA	University of Texas System; University of Texas Medical Branch Galveston; University of Louisville	Srivastava, SK (corresponding author), Univ Texas, Dept Human Biol Chem & Genet, Med Branch, Room 6-644,Basic Sci Bldg, Galveston, TX 77555 USA.	ssrivast@utmb.edu	Srivastava, Sanjay/D-3921-2012; Ramana, Kota/C-5460-2012; Bhatnagar, Aruni/H-7791-2013	Ramana, Kota/0000-0001-6502-7800	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL065618, R01HL059378] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK036118, R01DK036118] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL59378, HL65618] Funding Source: Medline; NIDDK NIH HHS [DK 36118] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Akaike T, 2000, FREE RADICAL RES, V33, P461, DOI 10.1080/10715760000301001; BHATNAGAR A, 1992, BIOCHEM MED METAB B, V48, P91, DOI 10.1016/0885-4505(92)90055-4; BURG MB, 1995, AM J PHYSIOL, V268, P983; Chandra A, 1997, BIOCHEMISTRY-US, V36, P15801, DOI 10.1021/bi9714722; Czech MP, 1999, J BIOL CHEM, V274, P1865, DOI 10.1074/jbc.274.4.1865; Denninger JW, 1999, BBA-BIOENERGETICS, V1411, P334, DOI 10.1016/S0005-2728(99)00024-9; Dixit BL, 2000, J BIOL CHEM, V275, P21587, DOI 10.1074/jbc.M909235199; Grant CM, 1999, MOL CELL BIOL, V19, P2650; Henry Y, 1999, CELL MOL LIFE SCI, V55, P1003, DOI 10.1007/s000180050351; Hotta N, 1997, Nagoya J Med Sci, V60, P89; Jez JM, 1997, BIOCHEM J, V326, P625, DOI 10.1042/bj3260625; KADOR PF, 1985, ANNU REV PHARMACOL, V25, P691, DOI 10.1146/annurev.pa.25.040185.003355; Kassab E, 2001, VASC MED, V6, P249, DOI 10.1177/1358836X0100600409; King GL, 1996, DIABETES, V45, pS105, DOI 10.2337/diab.45.3.S105; Klatt P, 2000, EUR J BIOCHEM, V267, P4928, DOI 10.1046/j.1432-1327.2000.01601.x; LEE AYW, 1995, P NATL ACAD SCI USA, V92, P2780, DOI 10.1073/pnas.92.7.2780; Litherland GJ, 2001, MOL MEMBR BIOL, V18, P195; LIU SQ, 1993, BIOCHIM BIOPHYS ACTA, V1164, P268, DOI 10.1016/0167-4838(93)90258-S; Ramana KV, 2000, BIOCHEMISTRY-US, V39, P12172, DOI 10.1021/bi000796e; Recchia Fabio A, 2002, Heart Fail Rev, V7, P141, DOI 10.1023/A:1015324508556; RUDERMAN NB, 1992, FASEB J, V6, P2905, DOI 10.1096/fasebj.6.11.1644256; Seo HG, 2000, MOL PHARMACOL, V57, P709, DOI 10.1124/mol.57.4.709; Srivastava S, 2001, BIOCHEM J, V358, P111, DOI 10.1042/0264-6021:3580111; SRIVASTAVA SK, 1985, P NATL ACAD SCI USA, V82, P7222, DOI 10.1073/pnas.82.21.7222; Torreilles J, 2001, FRONT BIOSCI-LANDMRK, V6, pD1161, DOI 10.2741/Torreill; Traverse JH, 2002, AM J PHYSIOL-HEART C, V282, pH2278, DOI 10.1152/ajpheart.00504.2001; van Goor H, 2001, NITRIC OXIDE-BIOL CH, V5, P525, DOI 10.1006/niox.2001.0382; West AR, 2002, SYNAPSE, V44, P227, DOI 10.1002/syn.10076; WU JT, 1993, J CLIN LAB ANAL, V7, P293, DOI 10.1002/jcla.1860070510; Yabe-Nishimura C, 1998, PHARMACOL REV, V50, P21	30	72	74	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2003	17	3					417	425		10.1096/fj.02-0722com	http://dx.doi.org/10.1096/fj.02-0722com			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	661LT	12631581				2022-12-25	WOS:000181892600040
J	Ishikawa, T; Chen, J; Wang, JX; Okada, F; Sugiyama, T; Kobayashi, T; Shindo, M; Higashino, F; Katoh, H; Asaka, M; Kondo, T; Hosokawa, M; Kobayashi, M				Ishikawa, T; Chen, J; Wang, JX; Okada, F; Sugiyama, T; Kobayashi, T; Shindo, M; Higashino, F; Katoh, H; Asaka, M; Kondo, T; Hosokawa, M; Kobayashi, M			Adrenomedullin antagonist suppresses in vivo growth of human pancreatic cancer cells in SCID mice by suppressing angiogenesis	ONCOGENE			English	Article						pancreatic cancer; hypoxia; adrenomedullin; angiogenesis; adrenomedullin antagonist	POSSIBLE PROMOTION MECHANISM; AUTOCRINE GROWTH; EXPRESSION; HYPOXIA; APOPTOSIS; PEPTIDE; LINES; RECEPTORS	Since it is reported that adrenomedullin (AM) upregulated by hypoxia inhibits hypoxic cell death, we examined the effects of AM antagonist (AM C-terminal fragment; AM(22-52)) on the growth of pancreatic cancer cells. We, for the first time, demonstrated that AM antagonist significantly reduced the in vivo growth of the pancreatic cancer cell line. Immunohistochemical. analysis demonstrated that the mean diameter of blood vessels was significantly smaller in the tumor tissues treated with AM antagonist than in those treated with AM N-terminal fragment (AM(1-25)), and that the PCNA-labeling index was lower in the former than in the latter. Then we demonstrated that AM antagonist showed no effect on the in vitro growth of the pancreatic cancer cell line. These results showed that AM played an important role in the growth of pancreatic cancer cells in vivo, suggesting that AM antagonist might be a useful tool for treating pancreatic cancers.	Hokkaido Univ, Inst Med Genet, Div Canc Pathobiol, Kita Ku, Sapporo, Hokkaido 0600815, Japan; Hokkaido Univ, Grad Sch Med, Dept Gastroenterol & Hematol, Sapporo, Hokkaido, Japan; Hokkaido Univ, Grad Sch Med, Dept Surg Oncol, Sapporo, Hokkaido, Japan; Hokkaido Univ, Grad Dent Sch, Dept Oral Pathobiol Sci, Sapporo, Hokkaido, Japan	Hokkaido University; Hokkaido University; Hokkaido University; Hokkaido University	Kobayashi, M (corresponding author), Hokkaido Univ, Inst Med Genet, Div Canc Pathobiol, Kita Ku, Kita 15,Nishi 7, Sapporo, Hokkaido 0600815, Japan.	mkobaya@med.hokudai.ac.jp	Shindoh, Masanobu/A-4799-2012; Asaka, Masahiro/A-5948-2012; Higashino, Fumihiro/F-8510-2012; Kondo, Takeshi/G-2103-2012	Shindoh, Masanobu/0000-0002-7782-5823; Kondo, Takeshi/0000-0001-7455-5824; Okada, Futoshi/0000-0003-4733-1037; Kobayashi, Masanobu/0000-0002-7445-9741				Akakura N, 2001, CANCER RES, V61, P6548; Browder T, 2000, J BIOL CHEM, V275, P1521, DOI 10.1074/jbc.275.3.1521; Carmeliet P, 1998, NATURE, V394, P485, DOI 10.1038/28867; Carmeliet P, 2000, NAT MED, V6, P389, DOI 10.1038/74651; Choi S, 2000, CLIN EXP METASTAS, V18, P45, DOI 10.1023/A:1026507713080; Cormier-Regard S, 1998, J BIOL CHEM, V273, P17787, DOI 10.1074/jbc.273.28.17787; DRAKE CJ, 1995, P NATL ACAD SCI USA, V92, P7657, DOI 10.1073/pnas.92.17.7657; EGUCHI S, 1994, ENDOCRINOLOGY, V135, P2454, DOI 10.1210/en.135.6.2454; FOLKMAN J, 1995, NAT MED, V1, P27, DOI 10.1038/nm0195-27; Garayoa M, 2000, MOL ENDOCRINOL, V14, P848, DOI 10.1210/me.14.6.848; Hayakawa H, 1999, HYPERTENSION, V33, P689, DOI 10.1161/01.HYP.33.2.689; Kato H, 1997, ENDOCRINOLOGY, V138, P2615, DOI 10.1210/en.138.6.2615; Kerbel RS, 2000, CARCINOGENESIS, V21, P505, DOI 10.1093/carcin/21.3.505; Miller MJ, 1996, J BIOL CHEM, V271, P23345; Muff R, 2001, PEPTIDES, V22, P1765, DOI 10.1016/S0196-9781(01)00515-0; Nakayama M, 1998, BIOCHEM BIOPH RES CO, V243, P514, DOI 10.1006/bbrc.1998.8131; Niizeki H, 2002, BRIT J CANCER, V86, P1914, DOI 10.1038/sj.bjc.6600331; NUKI C, 1993, BIOCHEM BIOPH RES CO, V196, P245, DOI 10.1006/bbrc.1993.2241; Oehler MK, 2002, ONCOGENE, V21, P2815, DOI 10.1038/sj.onc.1205374; Oehler MK, 2001, ONCOGENE, V20, P2937, DOI 10.1038/sj.onc.1204422; Ouafik L, 2002, AM J PATHOL, V160, P1279, DOI 10.1016/S0002-9440(10)62555-2; Rocchi P, 2001, CANCER RES, V61, P1196; Suri C, 1998, SCIENCE, V282, P468, DOI 10.1126/science.282.5388.468; Watanabe TX, 1996, BIOCHEM BIOPH RES CO, V219, P59, DOI 10.1006/bbrc.1996.0181; Yancopoulos GD, 2000, NATURE, V407, P242, DOI 10.1038/35025215; ZHAO L, 1996, AM J PHYSIOL, V271, P622	26	75	83	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 27	2003	22	8					1238	1242		10.1038/sj.onc.1206207	http://dx.doi.org/10.1038/sj.onc.1206207			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	650EK	12606950	Green Submitted			2022-12-25	WOS:000181249700012
J	Sugimoto, H; Sugimoto, S; Tatei, K; Obinata, H; Bakovic, M; Izumi, T; Vance, DE				Sugimoto, H; Sugimoto, S; Tatei, K; Obinata, H; Bakovic, M; Izumi, T; Vance, DE			Identification of Ets-1 as an important transcriptional activator of CTP : phosphocholine cytidylyltransferase alpha in COS-7 cells and co-activation with transcriptional enhancer factor-4	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHATIDYLETHANOLAMINE N-METHYLTRANSFERASE; RAT-LIVER CTP; KAPPA-B; CTPPHOSPHOCHOLINE CYTIDYLYLTRANSFERASE; PHOSPHATIDYLCHOLINE SYNTHESIS; PHOSPHORYLCHOLINE CYTIDYLYLTRANSFERASE; PHOSPHORYLATION SITES; PHYSICAL INTERACTIONS; SIGNAL-TRANSDUCTION; REGULATORY ELEMENT	Phosphatidylcholine biosynthesis via the CDP-choline pathway is primarily regulated by CTP: phosphocholine cytidylyltransferase (CT). Transcriptional enhancer factor-4 (TEF-4) enhances the transcription of CTalpha in COS-7 cells by interactions with the basal transcription machinery (Sugimoto, H., Bakovic, M., Yamashita, S., and Vance, D. E. ( 2001) J. Biol. Chem. 276, 12338 - 12344). To identify the most important transcription factor involved in basal CTalpha transcription, we made CTalpha promoter-deletion and - mutated constructs linked to a luciferase reporter and transfected them into COS-7 cells. The results indicate that an important site regulating basal CTalpha transcription is -53/-47 (GACTTCC), which is a putative consensus-binding site of Ets transcription factors (GGAA) in the opposite orientation. Gel shift analyses indicated the existence of a binding protein for -53/-47 ( GACTTCC) in nuclear extracts of COS-7 cells. When anti-Ets-1 antibody was incubated with the probe in gel shift analyses, the intensity of the binding protein was decreased. The binding of endogenous Ets-1 to the promoter probe was increased when TEF-4 was expressed; however, the amount of Ets-1 detected by immunoblotting was unchanged. When cells were transfected with Ets-1 cDNA, the luciferase activity of CTalpha promoter constructs was greatly enhanced. Co-transfection experiments with Ets-1 and TEF-4 showed enhanced expression of reporter constructs as well as CTalpha mRNA. These results suggest that Ets-1 is an important transcriptional activator of the CTalpha gene and that Ets-1 activity is enhanced by TEF-4.	Gunma Univ, Sch Med, Dept Biochem, Maebashi, Gumma 3718511, Japan; Japan Sci & Technol Corp, CREST, Tokyo 1130033, Japan; Univ Guelph, Dept Human Biol & Nutr Sci, Guelph, ON N1G 2W1, Canada; Univ Alberta, Dept Biochem, Edmonton, AB T6G 2S2, Canada; Univ Alberta, Canadian Inst Hlth Res Grp Mol & Cell Biol Lipids, Edmonton, AB T6G 2S2, Canada	Gunma University; Japan Science & Technology Agency (JST); University of Guelph; University of Alberta; University of Alberta	Izumi, T (corresponding author), Gunma Univ, Sch Med, Dept Biochem, Maebashi, Gumma 3718511, Japan.	takizumi@med.gunma-u.ac.jp; dennis.vance@ualberta.ca						ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; Arnold RS, 1997, BIOCHEMISTRY-US, V36, P6149, DOI 10.1021/bi970023z; Bakovic M, 1999, BBA-MOL CELL BIOL L, V1438, P147, DOI 10.1016/S1388-1981(99)00042-6; Bakovic M, 2000, J LIPID RES, V41, P583; Bakovic M, 2003, J BIOL CHEM, V278, P14753, DOI 10.1074/jbc.M300162200; Bassuk AG, 1997, J VIROL, V71, P3563, DOI 10.1128/JVI.71.5.3563-3573.1997; BHAT NK, 1990, P NATL ACAD SCI USA, V87, P3723, DOI 10.1073/pnas.87.10.3723; BOGGS KP, 1995, J BIOL CHEM, V270, P7757, DOI 10.1074/jbc.270.13.7757; BORIES JC, 1995, NATURE, V377, P635, DOI 10.1038/377635a0; Cui Z, 1997, BBA-LIPID LIPID MET, V1346, P10, DOI 10.1016/S0005-2760(97)00012-X; Dittmer J, 1997, J BIOL CHEM, V272, P4953, DOI 10.1074/jbc.272.8.4953; DITTMER J, 1998, BIOCHIM BIOPHYS ACTA, V1377, P1; FELDMAN DA, 1987, J BIOL CHEM, V262, P9075; GHYSDAEL J, 1986, P NATL ACAD SCI USA, V83, P1714, DOI 10.1073/pnas.83.6.1714; Gilmore TD, 1999, ONCOGENE, V18, P6842, DOI 10.1038/sj.onc.1203237; Golfman LS, 2001, J BIOL CHEM, V276, P43688, DOI 10.1074/jbc.M108170200; GOTTSCHALK LR, 1993, J EXP MED, V178, P1681, DOI 10.1084/jem.178.5.1681; Gri G, 1998, J BIOL CHEM, V273, P6431, DOI 10.1074/jbc.273.11.6431; Hadri L, 2002, J BIOL CHEM, V277, P36471, DOI 10.1074/jbc.M204731200; Hogan M, 1996, BIOCHEM J, V314, P799, DOI 10.1042/bj3140799; HOUWELING M, 1994, J BIOL CHEM, V269, P7544; Houweling M, 1997, BBA-LIPID LIPID MET, V1346, P1, DOI 10.1016/S0005-2760(97)00011-8; HOUWELING M, 1993, EUR J BIOCHEM, V214, P927, DOI 10.1111/j.1432-1033.1993.tb17996.x; Jacquemin P, 1996, J BIOL CHEM, V271, P21775, DOI 10.1074/jbc.271.36.21775; JOHN S, 1995, MOL CELL BIOL, V15, P1786; Johnson JE, 1999, MOL MEMBR BIOL, V16, P217, DOI 10.1080/096876899294544; KALMAR GB, 1990, P NATL ACAD SCI USA, V87, P6029, DOI 10.1073/pnas.87.16.6029; Kast HR, 2001, J LIPID RES, V42, P1266; Kavurma MM, 2002, J BIOL CHEM, V277, P36244, DOI 10.1074/jbc.M200463200; Kent C, 1997, BBA-LIPID LIPID MET, V1348, P79, DOI 10.1016/S0005-2760(97)00112-4; KOLA I, 1993, P NATL ACAD SCI USA, V90, P7588, DOI 10.1073/pnas.90.16.7588; Krehan A, 2000, J BIOL CHEM, V275, P18327, DOI 10.1074/jbc.M909736199; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lagace TK, 2000, J BIOL CHEM, V275, P14367, DOI 10.1074/jbc.275.19.14367; LEPRINCE D, 1983, NATURE, V306, P395, DOI 10.1038/306395a0; Li RZ, 2000, ONCOGENE, V19, P6514, DOI 10.1038/sj.onc.1204035; Lykidis A, 2001, PROG NUCLEIC ACID RE, V65, P361; Lykidis A, 1999, J BIOL CHEM, V274, P26992, DOI 10.1074/jbc.274.38.26992; LYMKIDIS A, 1998, J BIOL CHEM, V237, P14022; MACDONALD JIS, 1994, J BIOL CHEM, V269, P10529; Mallampalli RK, 2002, BIOCHEM J, V362, P81, DOI 10.1042/0264-6021:3620081; NUNN MF, 1983, NATURE, V306, P391, DOI 10.1038/306391a0; PELECH SL, 1982, J BIOL CHEM, V257, P4198; SACCHI N, 1986, SCIENCE, V231, P379, DOI 10.1126/science.3941901; Sapi E, 1998, CANCER RES, V58, P1027; Seidel JJ, 2002, GENE DEV, V16, P127, DOI 10.1101/gad.950902; Sementchenko VI, 2000, ONCOGENE, V19, P6533, DOI 10.1038/sj.onc.1204034; Sementchenko VI, 1998, ONCOGENE, V17, P2883, DOI 10.1038/sj.onc.1202220; Sesca E, 1996, BIOCHEM BIOPH RES CO, V229, P158, DOI 10.1006/bbrc.1996.1773; Slupsky CM, 1998, P NATL ACAD SCI USA, V95, P12129, DOI 10.1073/pnas.95.21.12129; SOHAL PS, 1990, J BIOL CHEM, V265, P11746; Sugimoto H, 2001, J BIOL CHEM, V276, P12338, DOI 10.1074/jbc.M100090200; Tang W, 1997, J BIOL CHEM, V272, P13146, DOI 10.1074/jbc.272.20.13146; Tessitore L, 1999, CARCINOGENESIS, V20, P561, DOI 10.1093/carcin/20.4.561; Tessitore L, 1999, BIOCHEM J, V337, P23, DOI 10.1042/0264-6021:3370023; Tessitore L, 2000, INT J CANCER, V86, P362, DOI 10.1002/(SICI)1097-0215(20000501)86:3&lt;362::AID-IJC10&gt;3.0.CO;2-A; TESSNER TG, 1991, J BIOL CHEM, V266, P16261; Thomas RS, 1997, ONCOGENE, V14, P2845, DOI 10.1038/sj.onc.1201125; Valter MM, 1999, CANCER RES, V59, P5608; Vance D.E., 2002, BIOCH LIPIDS LIPOPRO, P205; WANG YL, 1995, J BIOL CHEM, V270, P17843, DOI 10.1074/jbc.270.30.17843; WATSON DK, 1988, P NATL ACAD SCI USA, V85, P7862, DOI 10.1073/pnas.85.21.7862; WATSON DK, 1985, P NATL ACAD SCI USA, V82, P7294, DOI 10.1073/pnas.82.21.7294; WEINHOLD PA, 1986, J BIOL CHEM, V261, P5104; Werner MH, 1997, J BIOMOL NMR, V10, P317, DOI 10.1023/A:1018399711996; WOTTON D, 1994, MOL CELL BIOL, V14, P840, DOI 10.1128/MCB.14.1.840; XIAO JH, 1991, CELL, V65, P551, DOI 10.1016/0092-8674(91)90088-G; Yang BS, 1996, MOL CELL BIOL, V16, P538; YANG W, 1995, J BIOL CHEM, V270, P16503, DOI 10.1074/jbc.270.28.16503; YASUNAMI M, 1995, J BIOL CHEM, V270, P18649, DOI 10.1074/jbc.270.31.18649; Yordy JS, 2000, ONCOGENE, V19, P6503, DOI 10.1038/sj.onc.1204036; Zhang DJ, 2000, J BIOL CHEM, V275, P35368, DOI 10.1074/jbc.M007099200	72	13	14	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 30	2003	278	22					19716	19722		10.1074/jbc.M301590200	http://dx.doi.org/10.1074/jbc.M301590200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	682EH	12642588	hybrid			2022-12-25	WOS:000183078000021
J	Wang, PB; Valentijn, AJ; Gilmore, AP; Streuli, CH				Wang, PB; Valentijn, AJ; Gilmore, AP; Streuli, CH			Early events in the anoikis program occur in the absence of caspase activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FOCAL ADHESION KINASE; CYTOCHROME-C RELEASE; JUN NH2-TERMINAL KINASE; EXTRACELLULAR-MATRIX; MAMMARY-GLAND; SIGNAL-TRANSDUCTION; BAX TRANSLOCATION; INDUCED APOPTOSIS; TUMOR-REGRESSION; EPITHELIAL-CELLS	Adhesion of many cell types to the extracellular matrix is essential to maintain their survival. In the absence of integrin-mediated signals, normal epithelial cells undergo a form of apoptosis termed anoikis. It has been proposed that the activation of initiator caspases is an early event in anoikis, resulting in Bid cleavage and cytochrome c release from mitochondria. We have previously demonstrated that the loss of integrin signaling in mammary epithelial cells results in apoptosis and that this is dependent upon translocation of Bax from the cytosol to the mitochondria. In this paper, we ask whether caspases are required for Bax activation and the associated changes within mitochondria. We show that Bax activation occurs extremely rapidly, within 15 min after loss of integrin-mediated adhesion to extracellular matrix. The conformational changes associated with Bax activation are independent of caspases including the initiator caspase-8. We also examined downstream events in the apoptosis program and found that cytochrome c release occurs after a delay of at least 1 h, with subsequent activation of the effector caspase-3. This delay is not due to a requirement for new protein synthesis, since cycloheximide has no effect on the kinetics of Bax activation, cytochrome c release, caspase-3 cleavage, or apoptosis. Together, our data indicate that the cellular decision for anoikis in mammary epithelial cells occurs in the absence of caspase activation. Moreover, although the conformational changes in Bax are rapid and synchronous, the subsequent events occur stochastically and with considerable delays.	Univ Manchester, Sch Biol Sci, Manchester M13 9PT, Lancs, England	University of Manchester	Streuli, CH (corresponding author), Univ Manchester, Sch Biol Sci, Stopford Bldg,Oxford Rd, Manchester M13 9PT, Lancs, England.							Almeida EAC, 2000, J CELL BIOL, V149, P741, DOI 10.1083/jcb.149.3.741; Aoudjit F, 2001, J CELL BIOL, V152, P633, DOI 10.1083/jcb.152.3.633; BROOKS PC, 1994, CELL, V79, P1157, DOI 10.1016/0092-8674(94)90007-8; Coniglio SJ, 2001, J BIOL CHEM, V276, P28113, DOI 10.1074/jbc.M102299200; Desagher S, 1999, J CELL BIOL, V144, P891, DOI 10.1083/jcb.144.5.891; DiPersio CM, 2000, J CELL SCI, V113, P3051; Eskes R, 2000, MOL CELL BIOL, V20, P929, DOI 10.1128/MCB.20.3.929-935.2000; Farrelly N, 1999, J CELL BIOL, V144, P1337, DOI 10.1083/jcb.144.6.1337; Frisch SM, 1996, J CELL BIOL, V134, P793, DOI 10.1083/jcb.134.3.793; FRISCH SM, 1994, J CELL BIOL, V124, P619, DOI 10.1083/jcb.124.4.619; Frisch SM, 1999, CURR BIOL, V9, P1047, DOI 10.1016/S0960-9822(99)80455-2; Gilmore AP, 2000, J CELL BIOL, V149, P431, DOI 10.1083/jcb.149.2.431; Goldstein JC, 2000, NAT CELL BIOL, V2, P156, DOI 10.1038/35004029; Hood JD, 2002, SCIENCE, V296, P2404, DOI 10.1126/science.1070200; Ilic D, 1998, J CELL BIOL, V143, P547; Kaufmann SH, 2001, TRENDS CELL BIOL, V11, P526, DOI 10.1016/S0962-8924(01)02173-0; Khwaja A, 1997, EMBO J, V16, P2783, DOI 10.1093/emboj/16.10.2783; KITTRELL FS, 1992, CANCER RES, V52, P1924; Lei K, 2002, MOL CELL BIOL, V22, P4929, DOI 10.1128/MCB.22.13.4929-4942.2002; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; LIPFERT L, 1992, J CELL BIOL, V119, P905, DOI 10.1083/jcb.119.4.905; Madesh M, 2002, J BIOL CHEM, V277, P5651, DOI 10.1074/jbc.M108171200; Marani M, 2002, MOL CELL BIOL, V22, P3577, DOI 10.1128/MCB.22.11.3577-3589.2002; Marti A, 2001, MECH DEVELOP, V104, P89, DOI 10.1016/S0925-4773(01)00381-1; MARTIN DP, 1988, J CELL BIOL, V106, P829, DOI 10.1083/jcb.106.3.829; MEREDITH JE, 1993, MOL BIOL CELL, V4, P953, DOI 10.1091/mbc.4.9.953; Metcalfe AD, 1999, J CELL SCI, V112, P1771; Miranti CK, 2002, NAT CELL BIOL, V4, pE83, DOI 10.1038/ncb0402-e83; MIYASHITA T, 1995, CELL, V80, P293; Pullan S, 1996, J CELL SCI, V109, P631; Putcha GV, 1999, J NEUROSCI, V19, P7476, DOI 10.1523/JNEUROSCI.19-17-07476.1999; Reed JC, 2002, MOL CELL, V9, P1, DOI 10.1016/S1097-2765(02)00437-9; Rehm M, 2002, J BIOL CHEM, V277, P24506, DOI 10.1074/jbc.M110789200; Roucou X, 2002, BIOCHEM J, V368, P915, DOI 10.1042/BJ20020972; Rytomaa M, 1999, CURR BIOL, V9, P1043, DOI 10.1016/S0960-9822(99)80454-0; Rytomaa M, 2000, ONCOGENE, V19, P4461, DOI 10.1038/sj.onc.1203805; Samali A, 1999, EMBO J, V18, P2040, DOI 10.1093/emboj/18.8.2040; Scorrano L, 2002, DEV CELL, V2, P55, DOI 10.1016/S1534-5807(01)00116-2; Sohn BH, 2001, BIOCHEM J, V360, P31, DOI 10.1042/0264-6021:3600031; Song J, 2000, J CLIN INVEST, V106, P1209, DOI 10.1172/JCI10411; Stupack DG, 2001, J CELL BIOL, V155, P459, DOI 10.1083/jcb.200106070; Tsuruta F, 2002, J BIOL CHEM, V277, P14040, DOI 10.1074/jbc.M108975200; Wajant H, 2002, SCIENCE, V296, P1635, DOI 10.1126/science.1071553; Wei MC, 2001, SCIENCE, V292, P727, DOI 10.1126/science.1059108; Yin XM, 1999, NATURE, V400, P886, DOI 10.1038/23730	46	48	53	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 30	2003	278	22					19917	19925		10.1074/jbc.M210337200	http://dx.doi.org/10.1074/jbc.M210337200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	682EH	12621032	hybrid			2022-12-25	WOS:000183078000046
J	Benach, J; Lee, I; Edstrom, W; Kuzin, AP; Chiang, YW; Acton, TB; Montelione, GT; Hunt, JF				Benach, J; Lee, I; Edstrom, W; Kuzin, AP; Chiang, YW; Acton, TB; Montelione, GT; Hunt, JF			The 2.3-angstrom crystal structure of the shikimate 5-dehydrogenase orthologue YdiB from Escherichia coli suggests a novel catalytic environment for an NAD-dependent dehydrogenase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COMPLETE GENOME SEQUENCE; X-RAY ANALYSIS; ALCOHOL-DEHYDROGENASE; PROTEIN; ACID; CRYSTALLIZATION; RECOGNITION; CLONING; ENZYME; DEHYDROQUINASE	We present here the 2.3-Angstrom crystal structure of the Escherichia coli YdiB protein, an orthologue of shikimate 5-dehydrogenase. This enzyme catalyzes the reduction of 3-dehydroshikimate to shikimate as part of the shikimate pathway, which is absent in mammals but required for the de novo synthesis of aromatic amino acids, quinones, and folate in many other organisms. In this context, the shikimate pathway has been promoted as a target for the development of antimicrobial agents. The crystal structure of YdiB shows that the protomer contains two alpha/beta domains connected by two alpha-helices, with the N-terminal domain being novel and the C-terminal domain being a Rossmann fold. The NAD(+) cofactor, which co-purified with the enzyme, is bound to the Rossmann domain in an elongated fashion with the nicotinamide ring in the pro-R conformation. Its binding site contains several unusual features, including a cysteine residue in close apposition to the nicotinamide ring and a clamp over the ribose of the adenosine moiety formed by phenylalanine and lysine residues. The structure explains the specificity for NAD versus NADP in different members of the shikimate dehydrogenase family on the basis of variations in the amino acid identity of several other residues in the vicinity of this ribose group. A cavity lined by residues that are 100% conserved among all shikimate dehydrogenases is found between the two domains of YdiB, in close proximity to the hydride acceptor site on the nicotinamide ring. Shikimate was modeled into this site in a geometry such that all of its heteroatoms form high quality hydrogen bonds with these invariant residues. Their strong conservation in all orthologues supports the possibility of developing broad spectrum inhibitors of this enzyme. The nature and disposition of the active site residues suggest a novel reaction mechanism in which an aspartate acts as the general acid/base catalyst during the hydride transfer reaction.	Columbia Univ, Dept Biol Sci, New York, NY 10027 USA; Columbia Univ, NE Struct Genom Consortium, New York, NY 10027 USA; Rutgers State Univ, Dept Mol Biol & Biochem, Piscataway, NJ 08854 USA; Rutgers State Univ, NE Struct Genom Consortium, Piscataway, NJ 08854 USA	Columbia University; Columbia University; Rutgers State University New Brunswick; Rutgers State University New Brunswick	Hunt, JF (corresponding author), Columbia Univ, Dept Biol Sci, New York, NY 10027 USA.	hunt@sid.bio.columbia.edu		Montelione, Gaetano/0000-0002-9440-3059	NIGMS NIH HHS [P50-GM62413] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P50GM062413] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; ANTON IA, 1988, BIOCHEM J, V249, P319, DOI 10.1042/bj2490319; Blattner FR, 1997, SCIENCE, V277, P1453, DOI 10.1126/science.277.5331.1453; BONNER CA, 1994, BIOCHEM J, V302, P11, DOI 10.1042/bj3020011; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; CAIN RB, 1972, BIOCHEM J, V127, pP15; CARSON M, 1987, J MOL GRAPHICS, V5, P103, DOI 10.1016/0263-7855(87)80010-3; CHAUDHURI S, 1987, METHOD ENZYMOL, V142, P315; CHAUDHURI S, 1985, BIOCHEM J, V226, P217, DOI 10.1042/bj2260217; DAVIES GM, 1994, ANTIMICROB AGENTS CH, V38, P403, DOI 10.1128/AAC.38.2.403; Doublie S, 1996, FEBS LETT, V384, P219, DOI 10.1016/0014-5793(96)00316-X; DOWSETT JR, 1972, BIOCHIM BIOPHYS ACTA, V276, P344, DOI 10.1016/0005-2744(72)90994-1; Ermler U, 2002, STRUCTURE, V10, P1127, DOI 10.1016/S0969-2126(02)00802-X; Eschenburg S, 2002, PLANTA, V216, P129, DOI 10.1007/s00425-002-0908-0; EWART CDC, 1995, ANTIMICROB AGENTS CH, V39, P87, DOI 10.1128/AAC.39.1.87; Filling C, 2002, J BIOL CHEM, V277, P25677, DOI 10.1074/jbc.M202160200; Hayashi T, 2001, DNA RES, V8, P11, DOI 10.1093/dnares/8.1.11; Hoffman SL, 2002, NATURE, V415, P702, DOI 10.1038/415702a; HOLM L, 1993, J MOL BIOL, V233, P123, DOI 10.1006/jmbi.1993.1489; INOUE T, 1989, J BACTERIOL, V171, P3115, DOI 10.1128/jb.171.6.3115-3122.1989; Jansson M, 1996, J BIOMOL NMR, V7, P131; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; JORNVALL H, 1981, P NATL ACAD SCI-BIOL, V78, P4226, DOI 10.1073/pnas.78.7.4226; Jude DA, 1996, BBA-BIOMEMBRANES, V1279, P125, DOI 10.1016/0005-2736(95)00295-2; KARLE IL, 1961, ACTA CRYSTALLOGR, V14, P497, DOI 10.1107/S0365110X61001583; Knop DR, 2001, J AM CHEM SOC, V123, P10173, DOI 10.1021/ja0109444; KROOK M, 1990, BIOCHEMISTRY-US, V29, P738, DOI 10.1021/bi00455a021; Kunst F, 1997, NATURE, V390, P249, DOI 10.1038/36786; Li K, 1999, BIOTECHNOL BIOENG, V64, P61; Maclean J, 2000, ACTA CRYSTALLOGR D, V56, P512, DOI 10.1107/S0907444900002377; Madsen D, 2002, J APPL CRYSTALLOGR, V35, P137, DOI 10.1107/S0021889802000602; Magalhaes MLB, 2002, PROTEIN EXPRES PURIF, V26, P59, DOI 10.1016/S1046-5928(02)00509-0; McDevitt D, 2002, J APPL MICROBIOL, V92, p28S, DOI 10.1046/j.1365-2672.92.5s1.16.x; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; PERSSON B, 1991, EUR J BIOCHEM, V200, P537, DOI 10.1111/j.1432-1033.1991.tb16215.x; RAMASWAMY S, 1994, BIOCHEMISTRY-US, V33, P5230, DOI 10.1021/bi00183a028; Roberts CW, 2002, J INFECT DIS, V185, pS25, DOI 10.1086/338004; Roberts F, 1998, NATURE, V393, P801, DOI 10.1038/31723; Rossman M.G., 1975, ENZYMES, V11, P61, DOI 10.1016/S1874-6047(08)60210-3; Roszak AW, 2002, STRUCTURE, V10, P493, DOI 10.1016/S0969-2126(02)00747-5; Schonbrunn E, 2001, P NATL ACAD SCI USA, V98, P1376, DOI 10.1073/pnas.98.4.1376; SCOPES RK, 1983, FEBS LETT, V156, P303, DOI 10.1016/0014-5793(83)80517-1; TANAKA N, 1995, J BIOCHEM-TOKYO, V118, P871, DOI 10.1093/jb/118.5.871; Tatusov RL, 1997, SCIENCE, V278, P631, DOI 10.1126/science.278.5338.631; Terwilliger TC, 2001, ACTA CRYSTALLOGR D, V57, P1755, DOI 10.1107/S0907444901013737; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; vanMontfort RLM, 1997, STRUCTURE, V5, P217, DOI 10.1016/S0969-2126(97)00180-9; WIERENGA RK, 1986, J MOL BIOL, V187, P101, DOI 10.1016/0022-2836(86)90409-2; WILSON DK, 1992, SCIENCE, V257, P81, DOI 10.1126/science.1621098; Zhou JJ, 1997, MOL MICROBIOL, V23, P799, DOI 10.1046/j.1365-2958.1997.2681633.x	50	42	48	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 23	2003	278	21					19176	19182		10.1074/jbc.M301348200	http://dx.doi.org/10.1074/jbc.M301348200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	679PY	12624088	hybrid			2022-12-25	WOS:000182932200061
J	Salt, IP; Morrow, VA; Brandie, FM; Connell, JMC; Petrie, JR				Salt, IP; Morrow, VA; Brandie, FM; Connell, JMC; Petrie, JR			High glucose inhibits insulin-stimulated nitric oxide production without reducing endothelial nitric-oxide synthase Ser(1177) phosphorylation in human aortic endothelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT DIABETES-MELLITUS; PROTEIN-KINASE-C; CARDIOVASCULAR-DISEASE; 3T3-L1 ADIPOCYTES; IN-VIVO; ACTIVATION; AKT; EXPRESSION; VASODILATION; RELEASE	Recent studies have indicated that insulin activates endothelial nitric-oxide synthase ( eNOS) by protein kinase B (PKB)-mediated phosphorylation at Ser(1177) in endothelial cells. Because hyperglycemia contributes to endothelial dysfunction and decreased NO availability in types 1 and 2 diabetes mellitus, we have studied the effects of high glucose ( 25 mM, 48 h) on insulin signaling pathways that regulate NO production in human aortic endothelial cells. High glucose inhibited insulin-stimulated NO synthesis but was without effect on NO synthesis stimulated by increasing intracellular Ca2+ concentration. This was accompanied by reduced expression of IRS-2 and attenuated insulin-stimulated recruitment of PI3K to IRS-1 and IRS-2, yet insulin-stimulated PKB activity and phosphorylation of eNOS at Ser(1177) were unaffected. Inhibition of insulin-stimulated NO synthesis by high glucose was unaffected by an inhibitor of PKC. Furthermore, high glucose down-regulated the expression of CAP and Cbl, and insulin-stimulated Cbl phosphorylation, components of an insulin signaling cascade previously characterized in adipocytes. These data suggest that high glucose specifically inhibits insulin-stimulated NO synthesis and down-regulates some aspects of insulin signaling, including the CAP-Cbl signaling pathway, yet this is not a result of reduced PKB-mediated eNOS phosphorylation at Ser(1177). Therefore, we propose that phosphorylation of eNOS at Ser(1177) is not sufficient to stimulate NO production in cells cultured at 25 mM glucose.	Univ Glasgow, Inst Biomed & Life Sci, Div Biochem & Mol Biol, Henry Wellcome Lab Cell Biol, Glasgow G12 8QQ, Lanark, Scotland; Univ Glasgow, Western Infirm, Gardiner Inst, Div Cardiovasc & Med Sci, Glasgow G11 6NT, Lanark, Scotland	University of Glasgow; University of Glasgow	Salt, IP (corresponding author), Univ Glasgow, Inst Biomed & Life Sci, Div Biochem & Mol Biol, Henry Wellcome Lab Cell Biol, Davidson Bldg, Glasgow G12 8QQ, Lanark, Scotland.			Salt, Ian/0000-0003-0055-3724; s, hema/0000-0002-3440-9475				Baumann CA, 2000, NATURE, V407, P202, DOI 10.1038/35025089; CALVER AL, 1992, J CLIN INVEST, V90, P2546; CHESTER AH, 1990, LANCET, V336, P897, DOI 10.1016/0140-6736(90)92269-N; Chiang SH, 2001, NATURE, V410, P944, DOI 10.1038/35073608; Cleland SJ, 1998, CLIN EXP PHARMACOL P, V25, P175, DOI 10.1111/j.1440-1681.1998.t01-15-.x; Cleland SJ, 2000, HYPERTENSION, V35, P507, DOI 10.1161/01.HYP.35.1.507; Cosentino F, 1997, CIRCULATION, V96, P25; Dimmeler S, 1999, NATURE, V399, P601, DOI 10.1038/21224; Ding YX, 2000, AM J PHYSIOL-ENDOC M, V279, pE11, DOI 10.1152/ajpendo.2000.279.1.E11; Du XL, 2001, J CLIN INVEST, V108, P1341, DOI 10.1172/JCI11235; Fulton D, 1999, NATURE, V399, P597, DOI 10.1038/21218; Gallis B, 1999, J BIOL CHEM, V274, P30101, DOI 10.1074/jbc.274.42.30101; Hsueh WA, 1997, DIABETES REV, V5, P343; JOHNSTONE MT, 1993, CIRCULATION, V88, P2510, DOI 10.1161/01.CIR.88.6.2510; Kim F, 2001, AM J PHYSIOL-CELL PH, V280, pC1057, DOI 10.1152/ajpcell.2001.280.5.C1057; Kuboki K, 2000, CIRCULATION, V101, P676, DOI 10.1161/01.CIR.101.6.676; Michell BJ, 2001, J BIOL CHEM, V276, P17625, DOI 10.1074/jbc.C100122200; Michell BJ, 1999, CURR BIOL, V9, P845, DOI 10.1016/S0960-9822(99)80371-6; MONCADA S, 1991, PHARMACOL REV, V43, P109; Montagnani M, 2001, J BIOL CHEM, V276, P30392, DOI 10.1074/jbc.M103702200; Nadler ST, 2001, AM J PHYSIOL-ENDOC M, V281, pE1249, DOI 10.1152/ajpendo.2001.281.6.E1249; Petrie JR, 1996, CIRCULATION, V93, P1331, DOI 10.1161/01.CIR.93.7.1331; Previs SF, 2000, J BIOL CHEM, V275, P38990, DOI 10.1074/jbc.M006490200; Ribon V, 1998, P NATL ACAD SCI USA, V95, P14751, DOI 10.1073/pnas.95.25.14751; Salt IP, 2000, DIABETES, V49, P1649, DOI 10.2337/diabetes.49.10.1649; SCHERRER U, 1994, J CLIN INVEST, V94, P2511, DOI 10.1172/JCI117621; SCHNYDER B, 2002, AM J PHYSIOL, V282, pE89; STEINBERG HO, 1994, J CLIN INVEST, V94, P1172, DOI 10.1172/JCI117433; Ting HH, 1996, J CLIN INVEST, V97, P22, DOI 10.1172/JCI118394; Vallance P, 1999, CLIN SCI, V97, P343, DOI 10.1042/CS19990175; Way KJ, 2001, DIABETIC MED, V18, P945, DOI 10.1046/j.0742-3071.2001.00638.x; WIESE RJ, 1995, J BIOL CHEM, V270, P3442, DOI 10.1074/jbc.270.7.3442; WILLIAMS SB, 1996, J AM COLL CARDIOL, V27, P564; Zeng GY, 1996, J CLIN INVEST, V98, P894, DOI 10.1172/JCI118871	34	68	70	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 23	2003	278	21					18791	18797		10.1074/jbc.M210618200	http://dx.doi.org/10.1074/jbc.M210618200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	679PY	12644458	hybrid			2022-12-25	WOS:000182932200013
J	Shah, BH; Farshori, MP; Jambusaria, A; Catt, KJ				Shah, BH; Farshori, MP; Jambusaria, A; Catt, KJ			Roles of Src and epidermal growth factor receptor transactivation in transient and sustained ERK1/2 responses to gonadotropin-releasing hormone receptor activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTORS; SIGNAL-REGULATED KINASE-1/2; PROLONGED NUCLEAR RETENTION; ANGIOTENSIN-II; EGF RECEPTOR; BETA-ARRESTIN; MAPK CASCADE; C-FOS; RAS; MECHANISMS	The duration as well as the magnitude of mitogen-activated protein kinase activation has been proposed to regulate gene expression and other specific intracellular responses in individual cell types. Activation of ERK1/2 by the hypothalamic neuropeptide gonadotropin-releasing hormone (GnRH) is relatively sustained in alphaT3-1 pituitary gonadotropes and HEK293 cells but is transient in immortalized GT1-7 neurons. Each of these cell types expresses the epidermal growth factor receptor (EGFR) and responds to EGF stimulation with significant but transient ERK1/2 phosphorylation. However, GnRH-induced ERK1/2 phosphorylation caused by EGFR transactivation was confined to GT1-7 cells and was attenuated by EGFR kinase inhibition. Neither EGF nor GnRH receptor activation caused translocation of phospho-ERK1/2 into the nucleus in GT1-7 cells. In contrast, agonist stimulation of GnRH receptors expressed in HEK293 cells caused sustained phosphorylation and nuclear translocation of ERK1/2 by a protein kinase C-dependent but EGFR-independent pathway. GnRH-induced activation of ERK1/2 was attenuated by the selective Src kinase inhibitor PP2 and the negative regulatory C-terminal Src kinase in GT1-7 cells but not in HEK293 cells. In GT1-7 cells, GnRH stimulated phosphorylation and nuclear translocation of the ERK1/2-dependent protein, p90(RSK-1) (RSK-1). These results indicate that the duration of ERK1/2 activation depends on the signaling pathways utilized by GnRH in specific target cells. Whereas activation of the G(q)/protein kinase C pathway in HEK293 cells causes sustained phosphorylation and translocation of ERK1/2 to the nucleus, transactivation of the EGFR by GnRH in GT1-7 cells elicits transient ERK1/2 signals without nuclear accumulation. These findings suggest that transactivation of the tightly regulated EGFR can account for the transient ERK1/2 responses that are elicited by stimulation of certain G protein-coupled receptors.	NICHD, ERRB, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)	Catt, KJ (corresponding author), NICHD, ERRB, NIH, Bldg 49,Rm 6A36, Bethesda, MD 20892 USA.	catt@helix.nih.gov			EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [ZIAHD000184] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [Z01HD000184] Funding Source: NIH RePORTER	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Abe K, 2000, NEUROSCI LETT, V282, P89, DOI 10.1016/S0304-3940(00)00867-3; Adachi T, 2002, J CELL PHYSIOL, V192, P151, DOI 10.1002/jcp.10124; Benard O, 2001, J BIOL CHEM, V276, P4554, DOI 10.1074/jbc.M006995200; Boglari G, 1998, EUR J CELL BIOL, V75, P54, DOI 10.1016/S0171-9335(98)80046-0; Bonni A, 1999, SCIENCE, V286, P1358, DOI 10.1126/science.286.5443.1358; Brightman FA, 2000, FEBS LETT, V482, P169, DOI 10.1016/S0014-5793(00)02037-8; Cantley LC, 2002, SCIENCE, V296, P1655, DOI 10.1126/science.296.5573.1655; CESNJAJ M, 1993, ENDOCRINOLOGY, V133, P3042, DOI 10.1210/en.133.6.3042; Daub H, 1997, EMBO J, V16, P7032, DOI 10.1093/emboj/16.23.7032; DeGraff JL, 1999, J BIOL CHEM, V274, P11253, DOI 10.1074/jbc.274.16.11253; Della Rocca GJ, 1999, J BIOL CHEM, V274, P13978, DOI 10.1074/jbc.274.20.13978; DellaRocca GJ, 1997, J BIOL CHEM, V272, P19125, DOI 10.1074/jbc.272.31.19125; Dikic I, 1996, NATURE, V383, P547, DOI 10.1038/383547a0; Eguchi S, 1998, J BIOL CHEM, V273, P8890, DOI 10.1074/jbc.273.15.8890; Eguchi S, 2001, J BIOL CHEM, V276, P7957, DOI 10.1074/jbc.M008570200; Frodin M, 1999, MOL CELL ENDOCRINOL, V151, P65, DOI 10.1016/S0303-7207(99)00061-1; Grosse R, 2000, J BIOL CHEM, V275, P12251, DOI 10.1074/jbc.275.16.12251; Gschwind A, 2001, ONCOGENE, V20, P1594, DOI 10.1038/sj.onc.1204192; Heding A, 1998, J BIOL CHEM, V273, P11472, DOI 10.1074/jbc.273.19.11472; Hislop JN, 2001, J BIOL CHEM, V276, P39685, DOI 10.1074/jbc.M104542200; Kao SC, 2001, J BIOL CHEM, V276, P18169, DOI 10.1074/jbc.M008870200; Krsmanovic LZ, 2001, MOL ENDOCRINOL, V15, P429, DOI 10.1210/me.15.3.429; Liang CC, 2001, J BIOL CHEM, V276, P21146, DOI 10.1074/jbc.M010669200; Liu FJ, 2002, MOL ENDOCRINOL, V16, P419, DOI 10.1210/me.16.3.419; Marinissen MJ, 2001, TRENDS PHARMACOL SCI, V22, P368, DOI 10.1016/S0165-6147(00)01678-3; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; McArdle CA, 2002, J ENDOCRINOL, V173, P1, DOI 10.1677/joe.0.1730001; Ochoa A, 1997, J NEUROSCI RES, V49, P739, DOI 10.1002/(SICI)1097-4547(19970915)49:6<739::AID-JNR8>3.3.CO;2-3; Pierce KL, 2001, ONCOGENE, V20, P1532, DOI 10.1038/sj.onc.1204184; Pouyssegur J, 2002, BIOCHEM PHARMACOL, V64, P755, DOI 10.1016/S0006-2952(02)01135-8; Prenzel N, 1999, NATURE, V402, P884, DOI 10.1038/47260; QIU MS, 1992, NEURON, V9, P705, DOI 10.1016/0896-6273(92)90033-A; Schlessinger J, 2000, CELL, V103, P211, DOI 10.1016/j.cell.2010.06.011; Seta K, 2002, J BIOL CHEM, V277, P9268, DOI 10.1074/jbc.M109221200; Shah BH, 2003, J BIOL CHEM, V278, P2866, DOI 10.1074/jbc.m208783200; Shah BH, 2002, MOL PHARMACOL, V61, P343, DOI 10.1124/mol.61.2.343; Stanciu M, 2002, J BIOL CHEM, V277, P4010, DOI 10.1074/jbc.M104479200; Tanimura S, 2002, J BIOL CHEM, V277, P28256, DOI 10.1074/jbc.M202866200; Tari AM, 2001, SEMIN ONCOL, V28, P142, DOI 10.1053/sonc.2001.28555; Tohgo AK, 2002, J BIOL CHEM, V277, P9429, DOI 10.1074/jbc.M106457200; Turner NA, 2001, CELL SIGNAL, V13, P269, DOI 10.1016/S0898-6568(01)00135-8; Vrecl M, 1998, MOL ENDOCRINOL, V12, P1818, DOI 10.1210/me.12.12.1818; Willars GB, 1999, J BIOL CHEM, V274, P30146, DOI 10.1074/jbc.274.42.30146; Wright JD, 1996, BBA-MOL CELL RES, V1312, P85, DOI 10.1016/0167-4889(96)00027-4; Yamada M, 1997, PROG NEUROBIOL, V51, P19, DOI 10.1016/S0301-0082(96)00046-9; Yao Z, 2001, ONCOGENE, V20, P7588, DOI 10.1038/sj.onc.1204963; Zhang J, 1996, J BIOL CHEM, V271, P18302, DOI 10.1074/jbc.271.31.18302; Zwick E, 2002, TRENDS MOL MED, V8, P17, DOI 10.1016/S1471-4914(01)02217-1; Zwick E, 1999, TRENDS PHARMACOL SCI, V20, P408, DOI 10.1016/S0165-6147(99)01373-5	49	77	78	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 23	2003	278	21					19118	19126		10.1074/jbc.M212932200	http://dx.doi.org/10.1074/jbc.M212932200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	679PY	12642580	hybrid			2022-12-25	WOS:000182932200053
J	Clarke, P; Meintzer, SM; Moffitt, LA; Tyler, KL				Clarke, P; Meintzer, SM; Moffitt, LA; Tyler, KL			Two distinct phases of virus-induced nuclear factor kappa B regulation enhance tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis in virus-infected cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REOVIRUS-INDUCED APOPTOSIS; TRAIL-INDUCED APOPTOSIS; TRANSCRIPTION FACTOR; CANCER-CELLS; FACTOR-ALPHA; TRANSFORMING PROTEIN; REQUIRES ACTIVATION; SENSITIZES CELLS; DEATH RECEPTORS; PATHWAY	Cellular transcription factors are often utilized by infecting viruses to promote viral growth and influence cell fate. We have previously shown that nuclear factor kappaB (NF-kappaB) is activated after reovirus infection and that this activation is required for virus-induced apoptosis. In this report we identify a second phase of reovirus-induced NF-kappaB regulation. We show that at later times post-infection NF-kappaB activation is blocked in reovirus-infected cells. This results in the termination of virus-induced NF-kappaB activity and the inhibition of tumor necrosis factor alpha and etoposide-induced NF-kappaB activation in infected cells. Reovirus-induced inhibition of NF-kappaB activation occurs by a mechanism that prevents IkappaBalpha degradation and that is blocked in the presence of the viral RNA synthesis inhibitor, ribavirin. Reovirus-induced apoptosis is mediated by tumor necrosis factor-related apoptosis inducing ligand (TRAIL) in a variety of epithelial cell lines. Herein we show that ribavirin inhibits reovirus-induced apoptosis in TRAIL-resistant HEK293 cells and prevents the ability of reovirus infection to sensitize TRAIL-resistant cells to TRAIL-induced apoptosis. Furthermore, TRAIL-induced apoptosis is enhanced in HEK293 cells expressing IkappaBDeltaN2, which blocks NF-kappaB activation. These results indicate that the ability of reovirus to inhibit NF-kappaB activation sensitizes HEK293 cells to TRAIL and facilitates virus-induced apoptosis in TRAIL-resistant cells. Our findings demonstrate that two distinct phases of virus-induced NF-kappaB regulation are required to efficiently activate host cell apoptotic responses to reovirus infection.	Univ Colorado, Hlth Sci Ctr, Dept Neurol, Denver, CO 80262 USA; Univ Colorado, Hlth Sci Ctr, Dept Med Microbiol & Immunol, Denver, CO 80262 USA; Denver Vet Affairs Med Ctr, Denver, CO 80220 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; US Department of Veterans Affairs; Veterans Health Administration (VHA); Veterans Affairs Medical Center - Denver	Tyler, KL (corresponding author), Univ Colorado, Hlth Sci Ctr, Dept Neurol B 182, 4200 E 9th Ave, Denver, CO 80262 USA.		Tyler, Kenneth L./J-2420-2019	Tyler, Kenneth L./0000-0003-3294-5888	NIA NIH HHS [1R01AG14071] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [R01AG014071] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; BAEUERLE PA, 1989, GENE DEV, V3, P1689, DOI 10.1101/gad.3.11.1689; BAEUERLE PA, 1988, SCIENCE, V242, P540, DOI 10.1126/science.3140380; Barton ES, 2001, CELL, V104, P441, DOI 10.1016/S0092-8674(01)00231-8; BEG AA, 1992, GENE DEV, V6, P1899, DOI 10.1101/gad.6.10.1899; BROCKMAN JA, 1995, MOL CELL BIOL, V15, P2809; BROWN K, 1995, SCIENCE, V267, P1485, DOI 10.1126/science.7878466; Casola A, 2002, VIROLOGY, V298, P8, DOI 10.1006/viro.2002.1475; CHEN Z, 1995, GENE DEV, V9, P1585; Clarke P, 2000, J VIROL, V74, P8135, DOI 10.1128/JVI.74.17.8135-8139.2000; Clarke P, 2001, ONCOGENE, V20, P6910, DOI 10.1038/sj.onc.1204842; Clarke P, 2003, APOPTOSIS, V8, P141, DOI 10.1023/A:1022966508671; Conaldi PG, 1998, J CLIN INVEST, V102, P2041, DOI 10.1172/JCI3480; Connolly JL, 2000, J VIROL, V74, P2981, DOI 10.1128/JVI.74.7.2981-2989.2000; Connolly JL, 2002, J VIROL, V76, P1632, DOI 10.1128/JVI.76.4.1632-1641.2002; Connolly JL, 2001, J VIROL, V75, P4029, DOI 10.1128/JVI.75.9.4029-4039.2001; DeBiasi RL, 2001, J VIROL, V75, P351, DOI 10.1128/JVI.75.1.351-361.2001; Debiasi RL, 1999, J VIROL, V73, P695, DOI 10.1128/JVI.73.1.695-701.1999; DUKE RC, 1992, CURRENT PROTOCOLS IM; GHOSH S, 1990, CELL, V62, P1019, DOI 10.1016/0092-8674(90)90276-K; Gibson SB, 2000, MOL CELL BIOL, V20, P205, DOI 10.1128/MCB.20.1.205-212.2000; Herbein G, 1998, NATURE, V395, P189, DOI 10.1038/26026; Hiscott J, 2001, J CLIN INVEST, V107, P143, DOI 10.1172/JCI11918; Jan JT, 2000, J VIROL, V74, P8680, DOI 10.1128/JVI.74.18.8680-8691.2000; Jeremias I, 1998, EUR J IMMUNOL, V28, P143, DOI 10.1002/(SICI)1521-4141(199801)28:01<143::AID-IMMU143>3.0.CO;2-3; Kaplan D, 1998, J VIROL, V72, P6279, DOI 10.1128/JVI.72.8.6279-6282.1998; Karin M, 2002, NAT IMMUNOL, V3, P221, DOI 10.1038/ni0302-221; Keane MM, 2000, BREAST CANCER RES TR, V64, P211, DOI 10.1023/A:1006458407515; Kominsky DJ, 2002, CELL DEATH DIFFER, V9, P926, DOI 10.1038/sj.cdd.4401045; LIN KI, 1995, J CELL BIOL, V131, P1149, DOI 10.1083/jcb.131.5.1149; Lin KI, 1998, J CELL BIOL, V141, P1479, DOI 10.1083/jcb.141.7.1479; May MJ, 1997, SEMIN CANCER BIOL, V8, P63, DOI 10.1006/scbi.1997.0057; Oberhaus SM, 1997, J VIROL, V71, P2100, DOI 10.1128/JVI.71.3.2100-2106.1997; Oya M, 2001, ONCOGENE, V20, P3888, DOI 10.1038/sj.onc.1204525; Pahl HL, 1997, TRENDS BIOCHEM SCI, V22, P63, DOI 10.1016/S0968-0004(96)10073-6; Powell PP, 1996, J VIROL, V70, P8527, DOI 10.1128/JVI.70.12.8527-8533.1996; Ravi R, 2001, NAT CELL BIOL, V3, P409, DOI 10.1038/35070096; Rayet B, 1998, J VIROL, V72, P8893, DOI 10.1128/JVI.72.11.8893-8903.1998; Richardson-Burns SM, 2002, J NEUROVIROL, V8, P365, DOI 10.1080/13550280260422677; ROULSTON A, 1995, MICROBIOL REV, V59, P481, DOI 10.1128/MMBR.59.3.481-505.1995; Shao RP, 1999, J BIOL CHEM, V274, P21495, DOI 10.1074/jbc.274.31.21495; Shetty S, 2002, APOPTOSIS, V7, P413, DOI 10.1023/A:1020031023947; Shrivastava A, 1998, J VIROL, V72, P9722, DOI 10.1128/JVI.72.12.9722-9728.1998; Sieg S, 1996, J VIROL, V70, P8747, DOI 10.1128/JVI.70.12.8747-8751.1996; Spalding AC, 2002, ONCOGENE, V21, P260, DOI 10.1038/sj.onc.1205048; Su F, 1997, P NATL ACAD SCI USA, V94, P8744, DOI 10.1073/pnas.94.16.8744; Sun SC, 1999, ONCOGENE, V18, P6948, DOI 10.1038/sj.onc.1203220; Sylla BS, 1998, P NATL ACAD SCI USA, V95, P10106, DOI 10.1073/pnas.95.17.10106; Tai DI, 2000, HEPATOLOGY, V31, P656, DOI 10.1002/hep.510310316; TAKIZAWA T, 1995, VIROLOGY, V209, P288, DOI 10.1006/viro.1995.1260; TAKIZAWA T, 1993, J GEN VIROL, V74, P2347, DOI 10.1099/0022-1317-74-11-2347; Teodoro JG, 1997, J VIROL, V71, P1739, DOI 10.1128/JVI.71.3.1739-1746.1997; Thomas RP, 2002, SURGERY, V132, P127, DOI 10.1067/msy.2002.124930; Tollefson AE, 1998, NATURE, V392, P726, DOI 10.1038/33712; TRAENCKNER EBM, 1995, EMBO J, V14, P2876, DOI 10.1002/j.1460-2075.1995.tb07287.x; Tyler KL, 1996, J VIROL, V70, P7984, DOI 10.1128/JVI.70.11.7984-7991.1996; TYLER KL, 1995, J VIROL, V69, P6972, DOI 10.1128/JVI.69.11.6972-6979.1995; Tyler KL, 2001, TRENDS MICROBIOL, V9, P560, DOI 10.1016/S0966-842X(01)02103-5; VERMA IM, 1995, GENE DEV, V9, P2723, DOI 10.1101/gad.9.22.2723; Wang GH, 1997, J VIROL, V71, P8928, DOI 10.1128/JVI.71.11.8928-8932.1997; Weil R, 1999, MOL CELL BIOL, V19, P6345; You LR, 1999, J VIROL, V73, P1672, DOI 10.1128/JVI.73.2.1672-1681.1999	62	43	45	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 16	2003	278	20					18092	18100		10.1074/jbc.M300265200	http://dx.doi.org/10.1074/jbc.M300265200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677YX	12637521	hybrid			2022-12-25	WOS:000182838300066
J	Rochdi, MD; Parent, JL				Rochdi, MD; Parent, JL			G alpha(q)-coupled receptor internalization specifically induced by G alpha(q) signaling - Regulation by EBP50	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; CONSTITUTIVE INTERNALIZATION; THROMBOXANE A(2); OPIOID RECEPTOR; DOWN-REGULATION; ACTIVATION; BETA; ENDOCYTOSIS; ALPHA; RHOA	In the present report, we investigated the effect of ezrin-radixin-moesin-binding phosphoprotein 50 (EBP50) expression on the agonist-induced internalization of the thromboxane A(2) beta receptor (TPbeta receptor). Interestingly, we found that EBP50 almost completely blocked TPbeta receptor internalization, which could not be reversed by overexpression of G protein-coupled receptor (GPCR) kinases and arrestins. Because we recently demonstrated that EBP50 can bind to and inhibit Galpha(q), we next studied whether Galpha(q) signaling could induce TPbeta receptor internalization, addressing the long standing question about the relationship between GPCR signaling and their internalization. Expression of a constitutively active Galpha(q) mutant (Galpha(q)-R183C) resulted in a robust internalization of the TPbeta receptor, which was unaffected by expression of dominant negative mutants of arrestin-2 and -3, but inhibited by expression of EBP50 or dynamin-K44A, a dominant negative mutant of dynamin. Phospholipase Cbeta and protein kinase C did not appear to significantly contribute to internalization of the TPbeta receptor, suggesting that Galpha(q) induces receptor internalization through a phospholipase Cbeta- and protein kinase C-independent pathway. Surprisingly, there appears to be specificity in Galpha protein-mediated GPCR internalization. Galpha(q)-R183C also induced the internalization of CXCR4 (Galpha(q)-coupled), whereas it failed to do so for the beta(2)-adrenergic receptor (Galpha(s)-coupled). Moreover, Galpha(s)-R201C, a constitutively active form of Galpha(s), had no effect on internalization of the TPbeta, CXCR4, and beta(2)-adrenergic receptors. Thus, we showed that Galpha protein signaling can lead to internalization of GPCRs, with specificity in both the Galpha proteins and GPCRs that are involved. Furthermore, a new function has been described for EBP50 in its capacity to inhibit receptor endocytosis.	Univ Sherbrooke, Fac Med, Serv Rhumatol, Sherbrooke, PQ J1H 5N4, Canada; Univ Sherbrooke, Ctr Rech Clin, Sherbrooke, PQ J1H 5N4, Canada	University of Sherbrooke; University of Sherbrooke	Parent, JL (corresponding author), Univ Sherbrooke, Fac Med, Serv Rhumatol, 3001,12 Ave Nord, Sherbrooke, PQ J1H 5N4, Canada.							BASU SK, 1981, CELL, V24, P493, DOI 10.1016/0092-8674(81)90340-8; Booden MA, 2002, MOL CELL BIOL, V22, P4053, DOI 10.1128/MCB.22.12.4053-4061.2002; Cao TT, 1999, NATURE, V401, P286, DOI 10.1038/45816; Cavalli V, 2001, FEBS LETT, V498, P190, DOI 10.1016/S0014-5793(01)02484-X; Chikumi H, 2002, J BIOL CHEM, V277, P27130, DOI 10.1074/jbc.M204715200; Conchon S, 1998, AM J PHYSIOL-ENDOC M, V274, pE336, DOI 10.1152/ajpendo.1998.274.2.E336; da Rocha AB, 2002, ONCOLOGIST, V7, P17, DOI 10.1634/theoncologist.7-1-17; Ferguson SSG, 2001, PHARMACOL REV, V53, P1; Hinshaw JE, 2000, ANNU REV CELL DEV BI, V16, P483, DOI 10.1146/annurev.cellbio.16.1.483; HIRATA M, 1991, NATURE, V349, P617, DOI 10.1038/349617a0; Hollinger S, 2002, PHARMACOL REV, V54, P527, DOI 10.1124/pr.54.3.527; Krupnick JG, 1997, J BIOL CHEM, V272, P32507, DOI 10.1074/jbc.272.51.32507; Li J, 2001, MOL PHARMACOL, V60, P1064, DOI 10.1124/mol.60.5.1064; Miserey-Lenkei S, 2002, J BIOL CHEM, V277, P5891, DOI 10.1074/jbc.M108398200; Murthy A, 1998, J BIOL CHEM, V273, P1273, DOI 10.1074/jbc.273.3.1273; Orsini MJ, 1999, J BIOL CHEM, V274, P31076, DOI 10.1074/jbc.274.43.31076; Orsini MJ, 1998, J BIOL CHEM, V273, P34616, DOI 10.1074/jbc.273.51.34616; Parent JL, 2001, J BIOL CHEM, V276, P7079, DOI 10.1074/jbc.M009375200; Parent JL, 1999, J BIOL CHEM, V274, P8941, DOI 10.1074/jbc.274.13.8941; RAYCHOWDHURY MK, 1994, J BIOL CHEM, V269, P19256; Reczek D, 1997, J CELL BIOL, V139, P169, DOI 10.1083/jcb.139.1.169; Rochdi MD, 2002, J BIOL CHEM, V277, P40751, DOI 10.1074/jbc.M207910200; Sakurada S, 2001, AM J PHYSIOL-CELL PH, V281, pC571, DOI 10.1152/ajpcell.2001.281.2.C571; Shenolikar S, 2001, AM J PHYSIOL-RENAL, V280, pF389, DOI 10.1152/ajprenal.2001.280.3.F389; SMRCKA AV, 1993, J BIOL CHEM, V268, P9667; Tsao P, 2001, TRENDS PHARMACOL SCI, V22, P91, DOI 10.1016/S0165-6147(00)01620-5; WEINMAN EJ, 1995, J CLIN INVEST, V95, P2143, DOI 10.1172/JCI117903; Xiang B, 2001, J BIOL CHEM, V276, P4709, DOI 10.1074/jbc.M006187200; Zeng HY, 2002, J BIOL CHEM, V277, P46791, DOI 10.1074/jbc.M206133200	29	45	45	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 16	2003	278	20					17827	17837		10.1074/jbc.M210319200	http://dx.doi.org/10.1074/jbc.M210319200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677YX	12626493	hybrid			2022-12-25	WOS:000182838300031
J	Storz, P; Doppler, H; Johannes, FJ; Toker, A				Storz, P; Doppler, H; Johannes, FJ; Toker, A			Tyrosine phosphorylation of protein kinase D in the pleckstrin homology domain leads to activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANS-GOLGI NETWORK; MU PKC-MU; C-MU; PROTEOLYTIC CLEAVAGE; MOLECULAR-CLONING; IDENTIFICATION; PATHWAY; MEMBER; FAMILY; CELLS	Protein kinase D (PKD) is a member of the AGC family of Ser/Thr kinases and is distantly related to protein kinase C (PKC). Formerly known as PKCmu, PKD contains protein domains not found in conventional PKC isoforms. A functional pleckstrin homology (PH) domain is critical for the regulation of PKD activity. Here we report that PKD is tyrosine-phosphorylated within the PH domain, leading to activation. This phosphorylation is mediated by a pathway that consists of the Src and Abl tyrosine kinases and occurs in response to stimulation with pervanadate and oxidative stress. Mutational analysis revealed three tyrosine phosphorylation sites (Tyr(432), Tyr(463), and Tyr(502)), which are regulated by the Src-Abl pathway, and phosphorylation of only one of these (Tyr(463)) leads to PKD activation. By using a phospho-specific antibody, we show that Abl directly phosphorylates PKD at Tyr(463) in vitro, and in cells phosphorylation of this site is sufficient to mediate full activation of PKD. Mutation of the other two sites, Tyr(432) and Tyr(502), had no significant influence on PKD activity. These data reveal a tyrosine phosphorylation-dependent activation mechanism for PKD and suggest that this event contributes to the release of the autoinhibitory PKD PH domain leading to kinase activation and downstream responses.	Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Dept Pathol, Boston, MA 02215 USA; Fraunhofer Inst Interfacial Engn & Biotechnol, D-70569 Stuttgart, Germany	Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Fraunhofer Gesellschaft	Toker, A (corresponding author), Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Dept Pathol, 330 Brookline Ave, Boston, MA 02215 USA.				NATIONAL CANCER INSTITUTE [R01CA075134] Funding Source: NIH RePORTER; NCI NIH HHS [CA 75134] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Baron CL, 2002, SCIENCE, V295, P325, DOI 10.1126/science.1066759; Brandlin I, 2002, J BIOL CHEM, V277, P45451, DOI 10.1074/jbc.M205299200; Brandlin I, 2002, J BIOL CHEM, V277, P6490, DOI 10.1074/jbc.M106083200; Cenni V, 2002, BIOCHEM J, V363, P537, DOI 10.1042/0264-6021:3630537; Endo K, 2000, J BIOL CHEM, V275, P18476, DOI 10.1074/jbc.M002266200; Gschwendt M, 1997, J BIOL CHEM, V272, P20742, DOI 10.1074/jbc.272.33.20742; Hausser A, 2002, J CELL BIOL, V156, P65, DOI 10.1083/jcb.200110047; Hausser A, 2001, FEBS LETT, V492, P39, DOI 10.1016/S0014-5793(01)02219-0; Haussermann S, 1999, FEBS LETT, V462, P442, DOI 10.1016/S0014-5793(99)01577-X; Hayashi A, 1999, BBA-MOL CELL RES, V1450, P99, DOI 10.1016/S0167-4889(99)00040-3; Iglesias T, 1998, J BIOL CHEM, V273, P410, DOI 10.1074/jbc.273.1.410; Iglesias T, 1998, J BIOL CHEM, V273, P27662, DOI 10.1074/jbc.273.42.27662; Jamora C, 1999, CELL, V98, P59, DOI 10.1016/S0092-8674(00)80606-6; JOHANNES FJ, 1995, EUR J BIOCHEM, V227, P303, DOI 10.1111/j.1432-1033.1995.tb20389.x; JOHANNES FJ, 1994, J BIOL CHEM, V269, P6140; Liljedahl M, 2001, CELL, V104, P409, DOI 10.1016/S0092-8674(01)00228-8; Maeda Y, 2001, EMBO J, V20, P5982, DOI 10.1093/emboj/20.21.5982; Matthews SA, 2000, J EXP MED, V191, P2075, DOI 10.1084/jem.191.12.2075; Matthews SA, 1999, J BIOL CHEM, V274, P26543, DOI 10.1074/jbc.274.37.26543; Nishikawa K, 1997, J BIOL CHEM, V272, P952, DOI 10.1074/jbc.272.2.952; Rey O, 2001, J BIOL CHEM, V276, P32616, DOI 10.1074/jbc.M101649200; Sidorenko SP, 1996, IMMUNITY, V5, P353, DOI 10.1016/S1074-7613(00)80261-7; Storz P, 2003, EMBO J, V22, P109, DOI 10.1093/emboj/cdg009; Sturany S, 2001, J BIOL CHEM, V276, P3310, DOI 10.1074/jbc.M008719200; Toker Alex, 1998, Frontiers in Bioscience, V3, pD1134; VALVERDE AM, 1994, P NATL ACAD SCI USA, V91, P8572, DOI 10.1073/pnas.91.18.8572; Van Lint J, 2002, INT J BIOCHEM CELL B, V34, P577, DOI 10.1016/S1357-2725(01)00163-7; Van Lint J, 2002, TRENDS CELL BIOL, V12, P193, DOI 10.1016/S0962-8924(02)02262-6; Van Lint J, 1998, J BIOL CHEM, V273, P7038, DOI 10.1074/jbc.273.12.7038; Vertommen D, 2000, J BIOL CHEM, V275, P19567, DOI 10.1074/jbc.M001357200; Waldron RT, 2000, J BIOL CHEM, V275, P17114, DOI 10.1074/jbc.M908959199; Waldron RT, 1999, J BIOL CHEM, V274, P9224, DOI 10.1074/jbc.274.14.9224; Waldron RT, 2003, J BIOL CHEM, V278, P154, DOI 10.1074/jbc.M208075200; Zugaza JL, 1997, J BIOL CHEM, V272, P23952, DOI 10.1074/jbc.272.38.23952	34	102	104	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 16	2003	278	20					17969	17976		10.1074/jbc.M213224200	http://dx.doi.org/10.1074/jbc.M213224200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677YX	12637538	hybrid			2022-12-25	WOS:000182838300048
J	Chen, CY; Luo, SC; Kuo, CF; Lin, YS; Wu, JJ; Lin, MT; Liu, CC; Jeng, WY; Chuang, WJ				Chen, CY; Luo, SC; Kuo, CF; Lin, YS; Wu, JJ; Lin, MT; Liu, CC; Jeng, WY; Chuang, WJ			Maturation processing and characterization of streptopain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXTRACELLULAR CYSTEINE PROTEASE; GROUP-A STREPTOCOCCUS; PYROGENIC EXOTOXIN-B; PAPAIN PRECURSOR; VIRULENCE FACTOR; PROTEOLYTIC ACTIVITY; ENDOTHELIAL-CELLS; IN-VITRO; EXPRESSION; ZYMOGEN	Streptopain is a cysteine protease expressed by Streptococcus pyogenes. To study the maturation mechanism of streptopain, wild-type and Q186N, C192S, H340R, N356D and W357A mutant proteins were expressed in Escherichia coli and purified to homogeneity. Proteolytic analyses showed that the maturation of prostreptococcal pyrogenic exotoxin B zymogen (pro-SPE B) involves eight intermediates with a combination of cis- and trans-processing. Based on the sequences of these intermediates, the substrate specificity of streptopain favors a hydrophobic residue at the P2 site. The relative autocatalytic rates of these mutants exhibited the order Q186N > W357A > N356D, C192S, H340R. Interestingly, the N356D mutant containing protease activity could not be converted into the 28-kDa form by autoprocessing. This observation suggested that Asn(356) might involve the cis- processing of the propeptide. In addition, the maturation rates of pro-SPE B with trypsin and plasmin were 10- and 60-fold slower than that with active mature streptopain. These findings indicate that active mature streptopain likely plays the most important role in the maturation of pro-SPE B under physiological conditions.	Natl Cheng Kung Univ, Coll Med, Dept Biochem, Tainan 701, Taiwan; Natl Cheng Kung Univ, Coll Med, Dept Microbiol & Immunol, Tainan 701, Taiwan; Natl Cheng Kung Univ, Coll Med, Dept Med Technol, Tainan 701, Taiwan; Natl Cheng Kung Univ, Coll Med, Dept Pediat, Tainan 701, Taiwan	National Cheng Kung University; National Cheng Kung University; National Cheng Kung University; National Cheng Kung University	Chuang, WJ (corresponding author), Natl Cheng Kung Univ, Coll Med, Dept Biochem, 1 Univ Rd, Tainan 701, Taiwan.	wjcnmr@mail.ncku.edu.tw	Wu, Jiunn-Jong/E-6075-2011; Luo, Shih-Chi/C-1042-2011	Luo, Shih-Chi/0000-0001-7723-3230				Aiyar A, 1996, Methods Mol Biol, V57, P177; Berquin IM, 1996, ADV EXP MED BIOL, V389, P281; BISNO AL, 1991, NEW ENGL J MED, V325, P783, DOI 10.1056/NEJM199109123251106; Burns EH, 1998, MICROB PATHOGENESIS, V24, P333, DOI 10.1006/mpat.1998.0204; Doran JD, 1999, EUR J BIOCHEM, V263, P145, DOI 10.1046/j.1432-1327.1999.00473.x; GORDON VM, 1994, INFECT IMMUN, V62, P333, DOI 10.1128/IAI.62.2.333-340.1994; Groves MR, 1998, PROTEINS, V32, P504, DOI 10.1002/(SICI)1097-0134(19980901)32:4<504::AID-PROT8>3.0.CO;2-F; Gubba S, 2000, INFECT IMMUN, V68, P3716, DOI 10.1128/IAI.68.6.3716-3719.2000; Gubba S, 1998, INFECT IMMUN, V66, P765, DOI 10.1128/IAI.66.2.765-770.1998; HAUSER AR, 1990, J BACTERIOL, V172, P4536, DOI 10.1128/jb.172.8.4536-4542.1990; HOGE CW, 1993, JAMA-J AM MED ASSOC, V269, P384, DOI 10.1001/jama.269.3.384; Kagawa TF, 2000, P NATL ACAD SCI USA, V97, P2235, DOI 10.1073/pnas.040549997; KAPUR V, 1993, MICROB PATHOGENESIS, V15, P327, DOI 10.1006/mpat.1993.1083; KARRER KM, 1993, P NATL ACAD SCI USA, V90, P3063, DOI 10.1073/pnas.90.7.3063; Kazmi SU, 2001, INFECT IMMUN, V69, P4988, DOI 10.1128/IAI.69.8.4988-4995.2001; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; Kuo CF, 1999, INFECT IMMUN, V67, P126, DOI 10.1128/IAI.67.1.126-130.1999; Kuo CF, 1998, INFECT IMMUN, V66, P3931, DOI 10.1128/IAI.66.8.3931-3935.1998; LIU TY, 1965, J BIOL CHEM, V240, P1138; Lukomski S, 1999, INFECT IMMUN, V67, P1779; Matsuka YV, 1999, INFECT IMMUN, V67, P4326, DOI 10.1128/IAI.67.9.4326-4333.1999; McQueney MS, 1997, J BIOL CHEM, V272, P13955, DOI 10.1074/jbc.272.21.13955; Menard R, 1998, J BIOL CHEM, V273, P4478, DOI 10.1074/jbc.273.8.4478; Molinari G, 1999, CURR OPIN MICROBIOL, V2, P56, DOI 10.1016/S1369-5274(99)80010-1; Musser JM, 1996, INFECT IMMUN, V64, P1913, DOI 10.1128/IAI.64.6.1913-1917.1996; Nomizu M, 2001, J BIOL CHEM, V276, P44551, DOI 10.1074/jbc.M106306200; OHARANEMOTO Y, 1994, CAN J MICROBIOL, V40, P930, DOI 10.1139/m94-149; PERCZEL A, 1992, ANAL BIOCHEM, V203, P83, DOI 10.1016/0003-2697(92)90046-A; PERCZEL A, 1991, PROTEIN ENG, V4, P669, DOI 10.1093/protein/4.6.669; POONKING R, 1993, J EXP MED, V178, P759, DOI 10.1084/jem.178.2.759; *QIAGEN INC, 1992, QIAGEN MAN; Rozman J, 1999, FEBS LETT, V459, P358, DOI 10.1016/S0014-5793(99)01302-2; Stockbauer KE, 1999, P NATL ACAD SCI USA, V96, P242, DOI 10.1073/pnas.96.1.242; TAI JY, 1976, J BIOL CHEM, V251, P1955; Tarui T, 2002, J BIOL CHEM, V277, P33564, DOI 10.1074/jbc.M205514200; TRAVIS J, 1995, TRENDS MICROBIOL, V3, P405, DOI 10.1016/S0966-842X(00)88988-X; Tsai PJ, 1998, INFECT IMMUN, V66, P1460, DOI 10.1128/IAI.66.4.1460-1466.1998; Turk B, 1997, BIOL CHEM, V378, P141; VERNET T, 1991, J BIOL CHEM, V266, P21451; VERNET T, 1995, J BIOL CHEM, V270, P10838, DOI 10.1074/jbc.270.18.10838; VERNET T, 1993, PROTEIN ENG, V6, P213, DOI 10.1093/protein/6.2.213	41	56	56	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 9	2003	278	19					17336	17343		10.1074/jbc.M209038200	http://dx.doi.org/10.1074/jbc.M209038200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677QG	12621045	hybrid			2022-12-25	WOS:000182818600119
J	Kumar, S; Scott, EE; Liu, H; Halpert, JR				Kumar, S; Scott, EE; Liu, H; Halpert, JR			A rational approach to re-engineer cytochrome P4502B1 regioselectivity based on the crystal structure of cytochrome P4502C5	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; SUBSTRATE RECOGNITION SITES; AMINO-ACID; HYDROXYLASE-ACTIVITY; CATALYTIC PROPERTIES; MEMBRANE-BINDING; MOLECULAR-BASIS; SPECIFICITY; RESIDUES; ENZYME	The regioselectivity for progesterone hydroxylation by cytochrome P450 2B1 was re-engineered based on the x-ray crystal structure of cytochrome P450 2C5. 2B1 is a high K-m progesterone 16alpha-hydroxylase, whereas 2C5 is a low K-m progesterone 21-hydroxylase. Initially, nine individual 2B1 active-site residues were changed to the corresponding 2C5 residues, and the mutants were purified from an Escherichia coli expression system and assayed for progesterone hydroxylation. At 150 muM progesterone, I114A, F297G, and V363L showed 5-15% of the 21-hydroxylase activity of 2C5, whereas F206V showed high activity for an unknown product and a 13-fold decrease in K-m. Therefore, a quadruple mutant, I114A/F206V/F297G/V363L (Q), was constructed that showed 60% of 2C5 progesterone 21-hydroxylase activity and 57% regioselectivity. Based on their 2C5-like testosterone hydroxylation profiles, S294D and I477F alone and in combination were added to the quadruple mutant. All three mutants showed enhanced regioselectivity (70%) for progesterone 21-hydroxylation, whereas only Q/I477F had a higher k(cat). Finally, the remaining three single mutants, V103I, V367L, and G478V, were added to Q/I477F and Q/S294D/I477F, yielding seven additional multiple mutants. Among these, Q/V103I/S294D/I477F showed the highest k(cat) (3-fold higher than that of 2C5) and 80% regioselectivity for progesterone 21-hydroxylation. Docking of progesterone into a three-dimensional model of this mutant indicated that 21-hydroxylation is favored. In conclusion, a systematic approach to convert P450 regioselectivity across subfamilies suggests that active-site residues are mainly responsible for regioselectivity differences between 2B1 and 2C5 and validates the reliability of 2B1 models based on the crystal structure of 2C5.	Univ Texas, Med Branch, Dept Pharmacol & Toxicol, Galveston, TX 77555 USA	University of Texas System; University of Texas Medical Branch Galveston	Kumar, S (corresponding author), Univ Texas, Med Branch, Dept Pharmacol & Toxicol, 301 Univ Blvd, Galveston, TX 77555 USA.	sakumar@utmb.edu			NIEHS NIH HHS [ES03619, ES06676] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES006676, R01ES003619] Funding Source: NIH RePORTER	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Afzelius L, 2001, MOL PHARMACOL, V59, P909, DOI 10.1124/mol.59.4.909; CIACCIO PJ, 1989, ARCH BIOCHEM BIOPHYS, V271, P284, DOI 10.1016/0003-9861(89)90279-8; Cirino PC, 2002, CURR OPIN CHEM BIOL, V6, P130, DOI 10.1016/S1367-5931(02)00305-8; Cosme J, 2000, J BIOL CHEM, V275, P2545, DOI 10.1074/jbc.275.4.2545; Domanski TL, 1999, J PHARMACOL EXP THER, V290, P1141; Domanski TL, 2001, CURR DRUG METAB, V2, P117, DOI 10.2174/1389200013338612; Domanski TL, 2001, ARCH BIOCHEM BIOPHYS, V394, P21, DOI 10.1006/abbi.2001.2504; Farinas ET, 2001, CURR OPIN BIOTECH, V12, P545, DOI 10.1016/S0958-1669(01)00261-0; GOLDSTEIN JA, 1994, PHARMACOGENETICS, V4, P285, DOI 10.1097/00008571-199412000-00001; GOTOH O, 1992, J BIOL CHEM, V267, P83; GrahamLorence S, 1996, FASEB J, V10, P206, DOI 10.1096/fasebj.10.2.8641554; HALPERT JR, 1993, J BIOL CHEM, V268, P4453; Harlow GR, 1997, BBA-PROTEIN STRUCT M, V1338, P259, DOI 10.1016/S0167-4838(96)00209-9; HASEMANN CA, 1995, STRUCTURE, V3, P41, DOI 10.1016/S0969-2126(01)00134-4; HE YA, 1994, BIOCHEMISTRY-US, V33, P4419, DOI 10.1021/bi00180a040; He YQ, 1996, ARCH BIOCHEM BIOPHYS, V335, P152, DOI 10.1006/abbi.1996.0493; He YQ, 1998, ARCH BIOCHEM BIOPHYS, V350, P333, DOI 10.1006/abbi.1997.0516; Hoch U, 2000, J BIOL CHEM, V275, P26952; Ibeanu GC, 1996, J BIOL CHEM, V271, P12496, DOI 10.1074/jbc.271.21.12496; JUVONEN RO, 1991, J BIOL CHEM, V266, P16431; KEDZIE KM, 1991, J BIOL CHEM, V266, P22515; Kobayashi Y, 1998, DRUG METAB DISPOS, V26, P1026; Lewis DFV, 2002, J INORG BIOCHEM, V91, P502, DOI 10.1016/S0162-0134(02)00429-4; LINDBERG RLP, 1989, NATURE, V339, P632, DOI 10.1038/339632a0; Luo Zongshu, 1994, Archives of Biochemistry and Biophysics, V309, P52; Miles CS, 2000, BBA-PROTEIN STRUCT M, V1543, P383, DOI 10.1016/S0167-4838(00)00236-3; Nakayama K, 2001, J BIOL CHEM, V276, P31459, DOI 10.1074/jbc.M103943200; Negishi M, 1996, FASEB J, V10, P683, DOI 10.1096/fasebj.10.7.8635685; Negishi M, 1996, BIOCHIMIE, V78, P685, DOI 10.1016/S0300-9084(97)82525-4; OMURA T, 1964, J BIOL CHEM, V239, P2379; Parikh A, 1999, BIOCHEMISTRY-US, V38, P5283, DOI 10.1021/bi990142+; PAULSEN MD, 1992, J COMPUT AID MOL DES, V6, P449, DOI 10.1007/BF00130396; PAULSEN MD, 1991, PROTEINS, V11, P184, DOI 10.1002/prot.340110304; Pikuleva IA, 2001, BIOCHEMISTRY-US, V40, P7621, DOI 10.1021/bi010193i; Podust LM, 2001, P NATL ACAD SCI USA, V98, P3068, DOI 10.1073/pnas.061562898; Poulos Thomas L., 1995, P125; POULOS TL, 1985, J BIOL CHEM, V260, P6122; Scott EE, 2001, ARCH BIOCHEM BIOPHYS, V395, P57, DOI 10.1006/abbi.2001.2574; Scott EE, 2002, CHEM RES TOXICOL, V15, P1407, DOI 10.1021/tx020057u; Spatzenegger M, 2003, J PHARMACOL EXP THER, V304, P477, DOI 10.1124/jpet.102.043323; Spatzenegger M, 2001, MOL PHARMACOL, V59, P475, DOI 10.1124/mol.59.3.475; Strobel SM, 1997, BIOCHEMISTRY-US, V36, P11697, DOI 10.1021/bi9710176; SZKLARZ GD, 1995, BIOCHEMISTRY-US, V34, P14312, DOI 10.1021/bi00044a008; Tsao CC, 2001, BIOCHEMISTRY-US, V40, P1937, DOI 10.1021/bi001678u; Uno T, 1997, BIOCHEMISTRY-US, V36, P3193, DOI 10.1021/bi962654j; Waller CL, 1996, DRUG METAB DISPOS, V24, P203; Williams D, 2000, PERFORM RES, V5, P131	47	47	47	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 9	2003	278	19					17178	17184		10.1074/jbc.M212515200	http://dx.doi.org/10.1074/jbc.M212515200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677QG	12609983	hybrid			2022-12-25	WOS:000182818600098
J	Leung, YM; Kang, YH; Gao, XD; Xia, FZ; Xie, HL; Sheu, L; Tsuk, S; Lotan, I; Tsushima, RG; Gaisano, HY				Leung, YM; Kang, YH; Gao, XD; Xia, FZ; Xie, HL; Sheu, L; Tsuk, S; Lotan, I; Tsushima, RG; Gaisano, HY			Syntaxin 1A binds to the cytoplasmic C terminus of Kv2.1 to regulate channel gating and trafficking	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT K+ CHANNELS; PANCREATIC BETA-CELLS; INSULIN-SECRETION; CALCIUM CHANNELS; CA2+ CHANNELS; SMOOTH-MUSCLE; PROTEINS; EXOCYTOSIS; EXPRESSION; SNAP-25	Voltage-gated K+ (Kv) 2.1 is the dominant Kv channel that controls membrane repolarization in rat islet beta-cells and downstream insulin exocytosis. We recently showed that exocytotic SNARE protein SNAP-25 directly binds and modulates rat islet beta-cell Kv 2.1 channel protein at the cytoplasmic N terminus. We now show that SNARE protein syntaxin 1A (Syn-1A) binds and modulates rat islet beta-cell Kv2.1 at its cytoplasmic C terminus (Kv2.1C). In HEK293 cells overexpressing Kv2.1, we observed identical effects of channel inhibition by dialyzed GST-Syn-1A, which could be blocked by Kv2.1C domain proteins (C1: amino acids 412-633, C2: amino acids 634-853), but not the Kv2.1 cytoplasmic N terminus (amino acids 1-182). This was confirmed by direct binding of GST-Syn-1A to the Kv2.1C1 and C2 domains proteins. These findings are in contrast to our recent report showing that Syn-1A binds and modulates the cytoplasmic N terminus of neuronal Kv1.1 and not by its C terminus. Co-expression of Syn-1A in Kv2.1-expressing HEK293 cells inhibited Kv2.1 surfacing, which caused a reduction of Kv2.1 current density. In addition, Syn-1A caused a slowing of Kv2.1 current activation and reduction in the slope factor of steady-state inactivation, but had no affect on inactivation kinetics or voltage dependence of activation. Taken together, SNAP-25 and Syn-1A mediate secretion not only through its participation in the exocytotic SNARE complex, but also by regulating membrane potential and calcium entry through their interaction with Kv and Ca2(+) channels. In contrast to Ca2+ channels, where these SNARE proteins act on a common synprint site, the SNARE proteins act not only on distinct sites within a Kv channel, but also on distinct sites between different Kv channel families.	Univ Toronto, Dept Med, Toronto, ON M5S 1A8, Canada; Univ Toronto, Dept Physiol, Toronto, ON M5S 1A8, Canada; Tel Aviv Univ, Sackler Sch Med, Dept Physiol, IL-69978 Tel Aviv, Israel; Tel Aviv Univ, Sackler Sch Med, Dept Pharmacol, IL-69978 Tel Aviv, Israel	University of Toronto; University of Toronto; Tel Aviv University; Sackler Faculty of Medicine; Tel Aviv University; Sackler Faculty of Medicine	Tsushima, RG (corresponding author), Univ Toronto, Dept Med, Med Sci Bldg,Rm 7226,1 Kings Coll Circle, Toronto, ON M5S 1A8, Canada.	r.tsushima@utoronto.ca			NIDDK NIH HHS [DK55160] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R21DK055160] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Atlas D, 2001, J NEUROCHEM, V77, P972, DOI 10.1046/j.1471-4159.2001.00347.x; Catterall WA, 1999, ANN NY ACAD SCI, V868, P144, DOI 10.1111/j.1749-6632.1999.tb11284.x; Fili O, 2001, J NEUROSCI, V21, P1964, DOI 10.1523/JNEUROSCI.21-06-01964.2001; Gerber SH, 2002, DIABETES, V51, pS3, DOI 10.2337/diabetes.51.2007.S3; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HENQUIN JC, 1979, BIOCHIM BIOPHYS ACTA, V587, P579, DOI 10.1016/0304-4165(79)90010-2; Hille B., 1992, IONIC CHANNELS EXCIT, V2 ed, P115; Jarvis SE, 2001, J NEUROSCI, V21, P2939, DOI 10.1523/JNEUROSCI.21-09-02939.2001; Ji JZ, 2002, DIABETES, V51, P1425, DOI 10.2337/diabetes.51.5.1425; Ji JZ, 2002, J BIOL CHEM, V277, P20195, DOI 10.1074/jbc.M201034200; Ji JZ, 2002, GASTROENTEROLOGY, V122, P994, DOI 10.1053/gast.2002.32412; Kang Y, 2002, DIABETOLOGIA, V45, P231, DOI 10.1007/s00125-001-0718-0; MacDonald PE, 2002, J BIOL CHEM, V277, P44938, DOI 10.1074/jbc.M205532200; MacDonald PE, 2002, MOL ENDOCRINOL, V16, P2452, DOI 10.1210/me.2002-0058; MacDonald PE, 2001, MOL ENDOCRINOL, V15, P1423, DOI 10.1210/me.15.8.1423; Michaelevski L, 2002, J BIOL CHEM, V277, P34909, DOI 10.1074/jbc.M203943200; Nichols CG, 2002, AM J PHYSIOL-ENDOC M, V283, pE403, DOI 10.1152/ajpendo.00168.2002; Rettig J, 2002, SCIENCE, V298, P781, DOI 10.1126/science.1075375; Rhodes KJ, 1997, J NEUROSCI, V17, P8246; Rizo J, 2002, NAT REV NEUROSCI, V3, P641, DOI 10.1038/nrn898; Roe MW, 1996, J BIOL CHEM, V271, P32241, DOI 10.1074/jbc.271.50.32241; Schultz JH, 2001, CIRC RES, V88, P483, DOI 10.1161/01.RES.88.5.483; Seagar M, 1998, J BIOENERG BIOMEMBR, V30, P347, DOI 10.1023/A:1021937605818; SMITH PA, 1990, J GEN PHYSIOL, V95, P1041, DOI 10.1085/jgp.95.6.1041; Wiser O, 1996, EMBO J, V15, P4100, DOI 10.1002/j.1460-2075.1996.tb00785.x; Xu CL, 1999, AM J PHYSIOL-GASTR L, V277, pG1055, DOI 10.1152/ajpgi.1999.277.5.G1055; Yellen G, 2002, NATURE, V419, P35, DOI 10.1038/nature00978	27	107	109	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 9	2003	278	19					17532	17538		10.1074/jbc.M213088200	http://dx.doi.org/10.1074/jbc.M213088200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677QG	12621036	hybrid			2022-12-25	WOS:000182818600142
J	Li, XL; Gould, SJ				Li, XL; Gould, SJ			The dynamin-like GTPase DLP1 is essential for peroxisome division and is recruited to peroxisomes in part by PEX11	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CLATHRIN-MEDIATED ENDOCYTOSIS; PLECKSTRIN HOMOLOGY DOMAIN; SACCHAROMYCES-CEREVISIAE; MAMMALIAN-CELLS; ENDOPLASMIC-RETICULUM; BIOGENESIS DISORDERS; PROLIFERATION; IDENTIFICATION; DEFICIENCY; ABUNDANCE	Peroxisome division involves the conserved PEX11 peroxisomal membrane proteins and in yeast has been shown to require Vps1p, a dynamin-like protein. We show here that DLP1, the human homolog of the yeast DNM1 and VPS1 genes, plays an important role in peroxisome division in human cells. Disruption of DLP1 function by either RNA interference or overexpressing dominant negative DLP1 mutants causes a dramatic reduction in peroxisome abundance, although overexpression of functional DLP1 has no effect on peroxisome abundance. Overexpression of PEX11 induces peroxisome division in a multistep process involving elongation of preexisting peroxisomes followed by their division. We find that DLP1 is dispensable for the first phase of this process but essential for the second. Furthermore, we show that DLP1 associates with peroxisomes and that PEX11 overexpression recruits DLP1 to peroxisome membranes. However, we were unable to detect physical interaction between PEX11 and DLP1, and the stoichiometry of PEX11 and peroxisome-associated DLP1 was far less than 1:1. Based on these and other aspects, we propose that DLP1 performs an essential but transient role in peroxisome division and that PEX11 promotes peroxisome division by recruiting DLP1 to peroxisome membranes through an indirect mechanism.	Johns Hopkins Univ, Sch Med, Dept Biol Chem, Baltimore, MD 21205 USA	Johns Hopkins University	Gould, SJ (corresponding author), Johns Hopkins Univ, Sch Med, Dept Biol Chem, 725 N Wolfe St, Baltimore, MD 21205 USA.		Li, Xiaoling/A-2994-2015	Li, Xiaoling/0000-0001-5920-7784				Achiriloaie M, 1999, MOL CELL BIOL, V19, P1410; Brachmann CB, 1998, YEAST, V14, P115; Chang CC, 1999, J CELL SCI, V112, P1579; Chang CC, 1997, NAT GENET, V15, P385, DOI 10.1038/ng0497-385; Danino D, 2001, CURR OPIN CELL BIOL, V13, P454, DOI 10.1016/S0955-0674(00)00236-2; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; ERDMANN R, 1995, J CELL BIOL, V128, P509, DOI 10.1083/jcb.128.4.509; ERDMANN R, 1989, P NATL ACAD SCI USA, V86, P5419, DOI 10.1073/pnas.86.14.5419; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; Gurvitz A, 2001, J BIOL CHEM, V276, P31825, DOI 10.1074/jbc.M105989200; Guthrie C, 1991, GUIDE YEAST GENETICS; HINSHAW JE, 1995, NATURE, V374, P190, DOI 10.1038/374190a0; Hoepfner D, 2001, J CELL BIOL, V155, P979, DOI 10.1083/jcb.200107028; Jones JM, 2000, BIOCHEM BIOPH RES CO, V275, P233, DOI 10.1006/bbrc.2000.3285; Kamimoto T, 1998, J BIOL CHEM, V273, P1044, DOI 10.1074/jbc.273.2.1044; Kim J, 2000, ANNU REV BIOCHEM, V69, P303, DOI 10.1146/annurev.biochem.69.1.303; LAZAROW PB, 1985, ANNU REV CELL BIOL, V1, P489, DOI 10.1146/annurev.cb.01.110185.002421; Li XL, 2002, MOL CELL BIOL, V22, P4358, DOI 10.1128/MCB.22.12.4358-4365.2002; Li XL, 2002, MOL CELL BIOL, V22, P8226, DOI 10.1128/MCB.22.23.8226-8240.2002; Li XL, 2002, J CELL BIOL, V156, P643, DOI 10.1083/jcb.200112028; Lorenz P, 1998, EMBO J, V17, P3542, DOI 10.1093/emboj/17.13.3542; Marks B, 2001, NATURE, V410, P231, DOI 10.1038/35065645; MARSHALL PA, 1995, J CELL BIOL, V129, P345, DOI 10.1083/jcb.129.2.345; McNiven MA, 1998, CELL, V94, P151, DOI 10.1016/S0092-8674(00)81414-2; Merrifield CJ, 2002, NAT CELL BIOL, V4, P691, DOI 10.1038/ncb837; MIHALIK SJ, 1992, PROG CLIN BIOL RES, V357, P239; Passreiter M, 1998, J CELL BIOL, V141, P373, DOI 10.1083/jcb.141.2.373; Pitts KR, 1999, MOL BIOL CELL, V10, P4403, DOI 10.1091/mbc.10.12.4403; POLLTHE BT, 1988, AM J HUM GENET, V42, P422; Purdue PE, 2001, ANNU REV CELL DEV BI, V17, P701, DOI 10.1146/annurev.cellbio.17.1.701; Ringstad N, 1999, NEURON, V24, P143, DOI 10.1016/S0896-6273(00)80828-4; Sacksteder KA, 2000, J CELL BIOL, V148, P931, DOI 10.1083/jcb.148.5.931; Sacksteder KA, 2000, ANNU REV GENET, V34, P623, DOI 10.1146/annurev.genet.34.1.623; SAKAI Y, 1995, J BACTERIOL, V177, P6773, DOI 10.1128/jb.177.23.6773-6781.1995; Salim K, 1996, EMBO J, V15, P6241, DOI 10.1002/j.1460-2075.1996.tb01014.x; Schrader M, 1998, J BIOL CHEM, V273, P29607, DOI 10.1074/jbc.273.45.29607; Sesaki H, 1999, J CELL BIOL, V147, P699, DOI 10.1083/jcb.147.4.699; SLAWECKI ML, 1995, J CELL SCI, V108, P1817; South ST, 2000, J CELL BIOL, V149, P1345, DOI 10.1083/jcb.149.7.1345; South ST, 2001, P NATL ACAD SCI USA, V98, P12027, DOI 10.1073/pnas.221289498; Takei K, 1999, NAT CELL BIOL, V1, P33, DOI 10.1038/9004; Vallis Y, 1999, CURR BIOL, V9, P257, DOI 10.1016/S0960-9822(99)80114-6; Warnock Dale E., 1996, Bioessays, V18, P885, DOI 10.1002/bies.950181107; Yoon Y, 1998, J CELL BIOL, V140, P779, DOI 10.1083/jcb.140.4.779	44	167	174	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 9	2003	278	19					17012	17020		10.1074/jbc.M212031200	http://dx.doi.org/10.1074/jbc.M212031200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677QG	12618434	hybrid			2022-12-25	WOS:000182818600077
J	Lievens, PMJ; Liboi, E				Lievens, PMJ; Liboi, E			The thanatophoric dysplasia type II mutation hampers complete maturation of fibroblast growth factor receptor 3 (FGFR3), which activates signal transducer and activator of transcription 1 (STAT1) from the endoplasmic reticulum	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MULTIPLE-MYELOMA; PROLIFERATION; SPECIFICITY; DWARFISM; SULFATE	The K650E substitution in the fibroblast growth factor receptor 3 (FGFR3) causes constitutive tyrosine kinase activity of the receptor and is associated to the lethal skeletal disorder, thanatophoric dysplasia type II (TDII). The underlying mechanisms of how the activated FGFR3 causes TDII remains to be elucidated. FGFR3 is a transmembrane glycoprotein, which is synthesized through three isoforms, with various degrees of N-glycosylation. We have studied whether immature FGFR3 isoforms mediate the abnormal signaling in TDII. We show that synthesis of TDII-FGFR3 presents two phosphorylated forms: the immature non-glycosylated 98-kDa peptides and the intermediate 120-kDa glycomers. The mature, fully glycosylated 130-kDa forms, detected in wild type FGFR3, are not present in TDII. Endoglycosidase H cleaves the sugars on TDII intermediates thus indicating their intracellular localization in the endoplasmic reticulum. Accordingly, TDII-FGFR3-GFP co-localizes with calreticulin in the endoplasmic reticulum. Furthermore, following TDII transfection, signal transducer and activator of transcription 1 (STAT1) is phosphorylated in the absence of FGFR3 ligand and brefeldin A does not inhibit its activation. On the contrary, the cell membrane-anchored FRS2alpha protein is not activated in TDII cells. The opposite situation is observed in stable TDII cell clones where, despite the presence of phosphorylated mature receptor, STAT1 is not activated whereas FRS2alpha is phosphorylated. We speculate that the selection process favors cells defective in STAT1 activation through the 120-kDa TDII-FGFR3, thus allowing growth of the TDII cell clones. Accordingly, apoptosis is observed following TDII- FGFR3 transfection. These observations highlight the importance of the immature TDII- FGFR3 proteins as mediators of an abnormal signaling in TDII.	Univ Verona, Sch Med, Dept Neurol Sci, Div Biochem, I-37134 Verona, Italy	University of Verona	Liboi, E (corresponding author), Univ Verona, Sch Med, Dept Neurol Sci, Div Biochem, I-37134 Verona, Italy.	elio.liboi@univr.it			Telethon [GP0164Y01] Funding Source: Medline	Telethon(Fondazione Telethon)		BASILICO C, 1992, ADV CANCER RES, V59, P115, DOI 10.1016/S0065-230X(08)60305-X; Chesi M, 2001, BLOOD, V97, P729, DOI 10.1182/blood.V97.3.729; GIVOL D, 1992, FASEB J, V6, P3362, DOI 10.1096/fasebj.6.15.1464370; Iwata T, 2000, HUM MOL GENET, V9, P1603, DOI 10.1093/hmg/9.11.1603; KEEGAN K, 1991, ONCOGENE, V6, P2229; KLAUSNER RD, 1992, J CELL BIOL, V116, P1071, DOI 10.1083/jcb.116.5.1071; Krause KH, 1997, CELL, V88, P439, DOI 10.1016/S0092-8674(00)81884-X; Legeai-Mallet L, 1998, J BIOL CHEM, V273, P13007, DOI 10.1074/jbc.273.21.13007; Li CL, 1999, HUM MOL GENET, V8, P35, DOI 10.1093/hmg/8.1.35; MALIKA S, 1999, GENE DEV, V13, P1361; Mohammadi M, 1996, MOL CELL BIOL, V16, P977; Naski MC, 1996, NAT GENET, V13, P233, DOI 10.1038/ng0696-233; Neilson KM, 1996, J BIOL CHEM, V271, P25049, DOI 10.1074/jbc.271.40.25049; O'Brien MA, 2001, BIOTECHNIQUES, V30, P886, DOI 10.2144/01304pf01; Ornitz DM, 2000, BIOESSAYS, V22, P108, DOI 10.1002/(SICI)1521-1878(200002)22:2<108::AID-BIES2>3.0.CO;2-M; ORNITZ DM, 1992, J BIOL CHEM, V267, P16305; Ronchetti D, 2001, ONCOGENE, V20, P3553, DOI 10.1038/sj.onc.1204465; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SILLENCE DO, 1979, AM J PATHOL, V96, P813; SPIVAKKROIZMAN T, 1994, CELL, V79, P1015, DOI 10.1016/0092-8674(94)90032-9; Su WCS, 1997, NATURE, V386, P288, DOI 10.1038/386288a0; Szebenyi G, 1999, INT REV CYTOL, V185, P45; TARENTINO AL, 1974, J BIOL CHEM, V249, P811; TAVORMINA PL, 1995, NAT GENET, V9, P321, DOI 10.1038/ng0395-321; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; Webster MK, 1997, TRENDS GENET, V13, P178, DOI 10.1016/S0168-9525(97)01131-1; Webster MK, 1996, MOL CELL BIOL, V16, P4081; Wong A, 2002, P NATL ACAD SCI USA, V99, P6684, DOI 10.1073/pnas.052138899	28	52	53	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 9	2003	278	19					17344	17349		10.1074/jbc.M212710200	http://dx.doi.org/10.1074/jbc.M212710200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677QG	12624096	hybrid			2022-12-25	WOS:000182818600120
J	Tseng, CN; Zhang, LL; Cascio, M; Wang, ZZ				Tseng, CN; Zhang, LL; Cascio, M; Wang, ZZ			Calcium plays a critical role in determining the acetylcholine receptor-clustering activities of alternatively spliced isoforms of agrin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CIRCULAR-DICHROISM SPECTRA; VERTEBRATE NEUROMUSCULAR-JUNCTION; ALPHA-DYSTROGLYCAN; SYNAPTIC DIFFERENTIATION; POSTSYNAPTIC APPARATUS; MUSCLE-FIBERS; MESSENGER-RNA; CELL-SURFACE; BINDING; PROTEIN	Neural agrin, an extracellular matrix protein secreted by motor neurons, plays a key role in clustering of nicotinic acetylcholine receptors (AChR) on postsynaptic membranes of the neuromuscular junction. The action of agrin is critically dependent on an eight-amino acid insert (z8 insert) in the third of three consecutive laminin-like globular (G3) domains near the C terminus of neural agrin. Alternatively spliced agrin isoforms in non-neural tissue including muscle lack the z8 insert and are biologically inactive. Extracellular calcium has been shown to be imperative for the AChR-clustering activity of neural agrin. It is unclear, however, whether calcium preferentially interacts with the neural isoform or whether it acts solely as an intracellular messenger that mediates agrin signaling. Here, we report the G3 domain of rat neural agrin (AgG3z8) expressed in Pichia pastoris promoted AChR clustering on surface of C2C12 myotubes in a calcium-dependent manner. Direct binding of calcium to AgG3z8 was demonstrated by trypsin digestion and thermal denaturation experiments. Moreover, calcium induced a significant change in the conformation of AgG3z8, and the effect was correlated with an enhanced binding affinity of the protein to muscle receptor. Mutation of calcium-binding residues in the G3 domain diminished the conformational change of neural agrin, reduced its binding affinity to muscle membrane, and inhibited AChR-clustering activity. Conversely, the G3 domain of muscle agrin (AgG3z0) displayed little structural change in the presence of calcium, bound poorly to muscle surface, and was inactive in AChR-clustering assays. We conclude that distinct interactions of the G3 domain with calcium determine the biological activities of alternatively spliced agrin isoforms during synapse formation.	Univ Pittsburgh, Sch Med, Dept Neurobiol, Pittsburgh, PA 15261 USA; Univ Pittsburgh, Sch Med, Dept Mol Genet & Biochem, Pittsburgh, PA 15261 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Wang, ZZ (corresponding author), Univ Pittsburgh, Sch Med, Dept Neurobiol, 3500 Terrace St,E1440 BST, Pittsburgh, PA 15261 USA.		Tseng, Chao-Neng/A-3798-2014	Tseng, Chao-Neng/0000-0001-9972-7987	NCRR NIH HHS [1S10RR11998] Funding Source: Medline; NINDS NIH HHS [NS38301] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [S10RR011998] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS038301] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Alexandrescu AT, 2001, J BIOMOL NMR, V20, P295, DOI 10.1023/A:1011256008944; BLOCH RJ, 1983, J NEUROSCI, V3, P2670; Borges LS, 2002, J NEUROBIOL, V50, P69, DOI 10.1002/neu.10020; BOWE MA, 1995, ANNU REV NEUROSCI, V18, P443; Bowen DC, 1996, J NEUROCHEM, V66, P2580; CAMPANELLI JT, 1991, CELL, V67, P909, DOI 10.1016/0092-8674(91)90364-5; Campanelli JT, 1996, DEVELOPMENT, V122, P1663; Cornish T, 1999, J CELL SCI, V112, P1213; Denzer AJ, 1997, CELL TISSUE RES, V290, P357, DOI 10.1007/s004410050941; Deyst KA, 1998, DEV BRAIN RES, V110, P185, DOI 10.1016/S0165-3806(98)00105-9; Escher G, 1996, J CELL SCI, V109, P2959; FALLON JR, 1994, TRENDS NEUROSCI, V17, P469, DOI 10.1016/0166-2236(94)90135-X; FERNS M, 1992, NEURON, V8, P1079, DOI 10.1016/0896-6273(92)90129-2; FERNS MJ, 1993, NEURON, V11, P491, DOI 10.1016/0896-6273(93)90153-I; Gesemann M, 1998, J BIOL CHEM, V273, P600, DOI 10.1074/jbc.273.1.600; Gesemann M, 1996, NEURON, V16, P755, DOI 10.1016/S0896-6273(00)80096-3; GESEMANN M, 1995, J CELL BIOL, V128, P625, DOI 10.1083/jcb.128.4.625; Glass DJ, 1996, CELL, V85, P513, DOI 10.1016/S0092-8674(00)81252-0; Glass DJ, 1996, COLD SPRING HARB SYM, V61, P435; Glass DJ, 1997, CURR OPIN NEUROBIOL, V7, P379, DOI 10.1016/S0959-4388(97)80066-9; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; Hoch W, 1999, EUR J BIOCHEM, V265, P1, DOI 10.1046/j.1432-1327.1999.00765.x; HOCH W, 1994, EMBO J, V13, P2814, DOI 10.1002/j.1460-2075.1994.tb06575.x; Hohenester E, 1999, MOL CELL, V4, P783, DOI 10.1016/S1097-2765(00)80388-3; HUNTER WM, 1964, BIOCHEM J, V91, P43, DOI 10.1042/bj0910043; Johnson WC, 1999, PROTEINS, V35, P307, DOI 10.1002/(SICI)1097-0134(19990515)35:3<307::AID-PROT4>3.0.CO;2-3; Jones G, 1999, J NEUROSCI, V19, P3376; MCMAHAN UJ, 1990, COLD SPRING HARB SYM, V55, P407; Megeath LJ, 1998, J NEUROSCI, V18, P672; Meier T, 1997, J NEUROSCI, V17, P6534; NITKIN RM, 1987, J CELL BIOL, V105, P2471, DOI 10.1083/jcb.105.6.2471; OToole JJ, 1996, P NATL ACAD SCI USA, V93, P7369, DOI 10.1073/pnas.93.14.7369; Ruegg MA, 1998, TRENDS NEUROSCI, V21, P22, DOI 10.1016/S0166-2236(97)01154-5; Sanes JR, 2001, NAT REV NEUROSCI, V2, P791, DOI 10.1038/35097557; Sanes JR, 1999, ANNU REV NEUROSCI, V22, P389, DOI 10.1146/annurev.neuro.22.1.389; SHADIACK AM, 1991, J NEUROBIOL, V22, P617, DOI 10.1002/neu.480220607; SMITH MA, 1994, NEURON, V12, P795, DOI 10.1016/0896-6273(94)90332-8; Sreerama N, 2000, ANAL BIOCHEM, V287, P243, DOI 10.1006/abio.2000.4879; Sreerama N, 2001, ANAL BIOCHEM, V299, P271, DOI 10.1006/abio.2001.5420; STONE DM, 1995, J NEUROSCI, V15, P6767; SUGIYAMA J, 1994, NEURON, V13, P103, DOI 10.1016/0896-6273(94)90462-6; Timpl R, 2000, MATRIX BIOL, V19, P309, DOI 10.1016/S0945-053X(00)00072-X; Tisi D, 2000, EMBO J, V19, P1432, DOI 10.1093/emboj/19.7.1432; TSEN G, 1995, J BIOL CHEM, V270, P3392, DOI 10.1074/jbc.270.7.3392; TSEN GS, 1995, J BIOL CHEM, V270, P15934, DOI 10.1074/jbc.270.27.15934; WALLACE BG, 1989, J NEUROSCI, V9, P1294; WALLACE BG, 1988, J CELL BIOL, V107, P267, DOI 10.1083/jcb.107.1.267	47	19	20	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 9	2003	278	19					17236	17245		10.1074/jbc.M300282200	http://dx.doi.org/10.1074/jbc.M300282200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677QG	12621054	hybrid			2022-12-25	WOS:000182818600106
J	Zhu, M; Fink, AL				Zhu, M; Fink, AL			Lipid binding inhibits alpha-synuclein fibril formation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PARKINSONS-DISEASE; SECONDARY STRUCTURE; AMPHIPATHIC HELIX; PROTEIN; MEMBRANE; ASSOCIATION; FAMILY	Parkinson's disease is the second most common neurodegenerative disorder, and the cause is unknown; however, substantial evidence implicates the aggregation of alpha-synuclein as a critical factor in the etiology of the disease. alpha-Synuclein is a relatively abundant brain protein of unknown function, and the purified protein is intrinsically unfolded. The amino acid sequence has seven repeats with an apolipoprotein lipid-binding motif, which are predicted to form amphiphilic helices. We have investigated the interaction of alpha-synuclein with lipid vesicles of different sizes and properties by monitoring the effects on the conformation of the protein and the kinetics of fibrillation. The nature of the interaction of alpha-synuclein with vesicles was highly dependent on the phospholipid composition, the ratio of alpha-synuclein to phospholipid, and the size of the vesicles. The strongest interactions were between alpha-synuclein and vesicles composed of 1,2-dipalmitoyl-sn-glycero-3-phosphate/1,2-dipalmitoyl-sn-glycero-3-phosphocholine and 1,2-dipalmitoyl-sn-glycero-3-phospho-RAC-(1-glycerol)/1,2-dipalmitoyl-sn- glycero-3-phosphocholine and involved formation of helical structure in alpha-synuclein. A strong correlation was observed between the induction of alpha-helix in alpha-synuclein and the inhibition of fibril formation. Thus, helical, membrane-bound alpha-synuclein is unlikely to contribute to aggregation and fibrillation. Given that a significant fraction of alpha-synuclein is membrane-bound in dopaminergic neurons, this observation has significant physiological significance.	Univ Calif Santa Cruz, Dept Chem & Biochem, Santa Cruz, CA 95064 USA	University of California System; University of California Santa Cruz	Fink, AL (corresponding author), Univ Calif Santa Cruz, Dept Chem & Biochem, Santa Cruz, CA 95064 USA.				NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS039985] Funding Source: NIH RePORTER; NINDS NIH HHS [NS39985] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		CHEN YH, 1972, BIOCHEMISTRY-US, V11, P4120, DOI 10.1021/bi00772a015; Clayton DF, 1998, TRENDS NEUROSCI, V21, P249, DOI 10.1016/S0166-2236(97)01213-7; Cole NB, 2002, J BIOL CHEM, V277, P6344, DOI 10.1074/jbc.M108414200; Davidson WS, 1998, J BIOL CHEM, V273, P9443, DOI 10.1074/jbc.273.16.9443; Eliezer D, 2001, J MOL BIOL, V307, P1061, DOI 10.1006/jmbi.2001.4538; GEORGE JM, 1995, NEURON, V15, P361, DOI 10.1016/0896-6273(95)90040-3; Irizarry MC, 1996, J NEUROPATH EXP NEUR, V55, P889, DOI 10.1097/00005072-199608000-00004; Jo EJ, 2000, J BIOL CHEM, V275, P34328, DOI 10.1074/jbc.M004345200; Lee HJ, 2002, J BIOL CHEM, V277, P671, DOI 10.1074/jbc.M107045200; MAROTEAUX L, 1988, J NEUROSCI, V8, P2804; MAROTEAUX L, 1991, MOL BRAIN RES, V11, P335, DOI 10.1016/0169-328X(91)90043-W; McLean PJ, 2000, J BIOL CHEM, V275, P8812, DOI 10.1074/jbc.275.12.8812; Narayanan V, 2001, BIOCHEMISTRY-US, V40, P9927, DOI 10.1021/bi002952n; Nielsen L, 2001, BIOCHEMISTRY-US, V40, P8397, DOI 10.1021/bi0105983; Perrin RJ, 2000, J BIOL CHEM, V275, P34393, DOI 10.1074/jbc.M004851200; SEGREST JP, 1990, PROTEINS, V8, P103, DOI 10.1002/prot.340080202; SEGREST JP, 1992, J LIPID RES, V33, P141; Spillantini MG, 1998, P NATL ACAD SCI USA, V95, P6469, DOI 10.1073/pnas.95.11.6469; Uversky VN, 2002, FEBS LETT, V515, P99, DOI 10.1016/S0014-5793(02)02446-8; Uversky VN, 2001, J BIOL CHEM, V276, P10737, DOI 10.1074/jbc.M010907200; Uversky VN, 2001, J BIOL CHEM, V276, P44284, DOI 10.1074/jbc.M105343200; Uversky VN, 2001, FEBS LETT, V500, P105, DOI 10.1016/S0014-5793(01)02597-2; Uversky VN, 2001, FEBS LETT, V509, P31, DOI 10.1016/S0014-5793(01)03121-0; Walde P, 2001, BIOMOL ENG, V18, P143, DOI 10.1016/S1389-0344(01)00088-0	24	249	253	1	32	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 9	2003	278	19					16873	16877		10.1074/jbc.M210136200	http://dx.doi.org/10.1074/jbc.M210136200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677QG	12621030	hybrid			2022-12-25	WOS:000182818600058
J	Cheng, D; Nelson, TC; Chen, J; Walker, SG; Wardwell-Swanson, J; Meegalla, R; Taub, R; Billheimer, JT; Ramaker, M; Feder, JN				Cheng, D; Nelson, TC; Chen, J; Walker, SG; Wardwell-Swanson, J; Meegalla, R; Taub, R; Billheimer, JT; Ramaker, M; Feder, JN			Identification of acyl coenzyme A : Monoacylglycerol acyltransferase 3, an intestinal specific enzyme implicated in dietary fat absorption	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIACYLGLYCEROL ACYLTRANSFERASE; TRIACYLGLYCEROL; ORLISTAT; CLONING; FAMILY; DGAT2	Acyl coenzyme A:monoacylglycerol acyltransferase (MGAT) catalyzes the synthesis of diacylglycerol using 2-monoacylglycerol and fatty acyl coenzyme A. This enzymatic reaction is believed to be an essential and rate-limiting step for the absorption of fat in the small intestine. Although the first MGAT-encoding cDNA, designated MGAT1, has been recently isolated, it is not expressed in the small intestine and hence cannot account for the high intestinal MGAT enzyme activity that is important for the physiology of fat absorption. In the current study, we report the identification of a novel MGAT, designated MGAT3, and present evidence that it fulfills the criteria to be the elusive intestinal MGAT. MGAT3 encodes a -36kDa transmembrane protein that is highly homologous to MGAT1 and -2. In humans, expression of MGAT3 is restricted to gastrointestinal tract with the highest level found in the ileum. At the cellular level, recombinant MGAT3 is localized to the endoplasmic reticulum. Recombinant MGAT3 enzyme activity produced in insect Sf`9 cells selectively acylates 2-monoacylglycerol with higher efficiency than other stereoisomers. The molecular identification of MGAT3 will facilitate the evaluation of using intestinal MGAT as a potential point of intervention for antiobesity therapies.	Bristol Myers Squibb Co, Pharmaceut Res Inst, Princeton, NJ 08543 USA	Bristol-Myers Squibb	Cheng, D (corresponding author), Bristol Myers Squibb Co, Pharmaceut Res Inst, POB 5400, Princeton, NJ 08543 USA.							BELL RM, 1980, ANNU REV BIOCHEM, V49, P459, DOI 10.1146/annurev.bi.49.070180.002331; BRINDLEY DN, 1966, BIOCHIM BIOPHYS ACTA, V125, P92, DOI 10.1016/0005-2760(66)90147-0; BRINDLEY DN, 1965, BIOCHIM BIOPHYS ACTA, V106, P495, DOI 10.1016/0005-2760(65)90066-4; Buhman KK, 2002, J BIOL CHEM, V277, P25474, DOI 10.1074/jbc.M202013200; CAO J, 2003, J BIOL CHEM; Cases S, 2001, J BIOL CHEM, V276, P38870, DOI 10.1074/jbc.M106219200; COLEMAN RA, 1992, METHOD ENZYMOL, V209, P98; Kolanowski J, 1999, DRUG SAFETY, V20, P119, DOI 10.2165/00002018-199920020-00003; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; Lardizabal KD, 2001, J BIOL CHEM, V276, P38862, DOI 10.1074/jbc.M106168200; Lehner R, 1996, PROG LIPID RES, V35, P169, DOI 10.1016/0163-7827(96)00005-7; LEHNER R, 1995, J BIOL CHEM, V270, P13630, DOI 10.1074/jbc.270.23.13630; LEVY E, 1992, CAN J PHYSIOL PHARM, V70, P413, DOI 10.1139/y92-052; Lucas KH, 2001, ANN PHARMACOTHER, V35, P314; LYKIDIS A, 1995, EUR J BIOCHEM, V230, P892, DOI 10.1111/j.1432-1033.1995.tb20633.x; Smith SJ, 2000, NAT GENET, V25, P87, DOI 10.1038/75651; Yen CLE, 2002, P NATL ACAD SCI USA, V99, P8512, DOI 10.1073/pnas.132274899; ZHI JG, 1995, J CLIN PHARMACOL, V35, P1103, DOI 10.1002/j.1552-4604.1995.tb04034.x	18	110	133	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 18	2003	278	16					13611	13614		10.1074/jbc.C300042200	http://dx.doi.org/10.1074/jbc.C300042200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	670JV	12618427	hybrid			2022-12-25	WOS:000182405000006
J	Loo, TW; Bartlett, MC; Clarke, DM				Loo, TW; Bartlett, MC; Clarke, DM			Substrate-induced conformational, changes in the transmembrane segments of human P-glycoprotein - Direct evidence for the substrate-induced fit mechanism for drug binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STIMULATED ATPASE ACTIVITY; DISULFIDE CROSS-LINKING; CYSTEINE-SCANNING MUTAGENESIS; MULTIDRUG-RESISTANCE; FUNCTIONAL CONSEQUENCES; MEMBRANE TOPOLOGY; DOMAIN; TRANSPORT; IDENTIFICATION; RESIDUES	The human multidrug resistance P-glycoprotein (Pgp, ABCB1) is quite promiscuous in that it can transport a broad range of structurally diverse compounds out of the cell. We hypothesized that the transmembrane (TM) segments that constitute the drug-binding site are quite mobile such that drug binding occurs through a "substrate-induced fit" mechanism. Here, we used cysteine-scanning mutagenesis and oxidative cross-linking to test for substrate-induced changes in the TM segments. Pairs of cysteines were introduced into a Cys-less P-gp and the mutants treated with oxidant (copper phenanthroline) in the presence or absence of various drug,substrates. We show that cyclosporin A promoted cross-linking between residues P350C(TM6)/G939C(TM11), while colchicine and demecolcine promoted cross-linking between residues P350C(TM6)/V991C(TM12). Progesterone promoted. cross-linking between residues P350C(TM6)/A935C(TM11), P350C(TM6)/G939C(TM11), as well as between residues P350C(TM6)/V991C(TM12). Other substrates such as vinblastine, verapamil, cis-(Z)-flupenthixol or trans-(E)-flupenthixol did not induce cross-linking at these sites. These results provide direct evidence that the packing of the TM segments in the drug-binding site is changed when P-gp binds to a particular substrate. The induced-fit mechanism explains how P-gp can accommodate a broad range of compounds.	Univ Toronto, Dept Med, Canadian Inst Hlth, Res Grp Membrane Biol, Toronto, ON M5S 1A8, Canada; Univ Toronto, Dept Biochem, Toronto, ON M5S 1A8, Canada	University of Toronto; University of Toronto	Clarke, DM (corresponding author), Univ Toronto, Dept Med, Canadian Inst Hlth, Res Grp Membrane Biol, Rm 7342,Med Sci Bldg,1 Kings Coll Circle, Toronto, ON M5S 1A8, Canada.		Clarke, David M./A-1112-2008	Clarke, David M./0000-0003-4335-7184; Loo, Tip W/0000-0003-2108-0188	NCI NIH HHS [CA80900] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA080900] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ambudkar SV, 1997, J BIOL CHEM, V272, P21160, DOI 10.1074/jbc.272.34.21160; Ambudkar SV, 1999, ANNU REV PHARMACOL, V39, P361, DOI 10.1146/annurev.pharmtox.39.1.361; Borst P, 2002, ANNU REV BIOCHEM, V71, P537, DOI 10.1146/annurev.biochem.71.102301.093055; CHEN CJ, 1986, CELL, V47, P381, DOI 10.1016/0092-8674(86)90595-7; CHIFFLET S, 1988, ANAL BIOCHEM, V168, P1, DOI 10.1016/0003-2697(88)90002-4; CHOI K, 1991, P NATL ACAD SCI USA, V88, P7386, DOI 10.1073/pnas.88.16.7386; Dayan G, 1996, J BIOL CHEM, V271, P11652, DOI 10.1074/jbc.271.20.11652; Dey S, 1999, BIOCHEMISTRY-US, V38, P6630, DOI 10.1021/bi983038l; Dey S, 1997, P NATL ACAD SCI USA, V94, P10594, DOI 10.1073/pnas.94.20.10594; DOIGE CA, 1992, BIOCHIM BIOPHYS ACTA, V1109, P149, DOI 10.1016/0005-2736(92)90078-Z; HORIO M, 1989, J BIOL CHEM, V264, P14880; KAST C, 1995, BIOCHEMISTRY-US, V34, P4402, DOI 10.1021/bi00013a032; Loo TW, 1997, J BIOL CHEM, V272, P709, DOI 10.1074/jbc.272.2.709; Loo TW, 2003, J BIOL CHEM, V278, P1575, DOI 10.1074/jbc.M211307200; Loo TW, 2000, J BIOL CHEM, V275, P19435, DOI 10.1074/jbc.C000222200; Loo TW, 1996, J BIOL CHEM, V271, P27488, DOI 10.1074/jbc.271.44.27488; Loo TW, 1999, J BIOL CHEM, V274, P35388, DOI 10.1074/jbc.274.50.35388; Loo TW, 1999, J BIOL CHEM, V274, P24759, DOI 10.1074/jbc.274.35.24759; Loo TW, 1997, J BIOL CHEM, V272, P20986, DOI 10.1074/jbc.272.34.20986; LOO TW, 1993, J BIOL CHEM, V268, P3143; Loo TW, 1996, J BIOL CHEM, V271, P27482, DOI 10.1074/jbc.271.44.27482; Loo TW, 1997, J BIOL CHEM, V272, P31945, DOI 10.1074/jbc.272.51.31945; Loo TW, 2000, J BIOL CHEM, V275, P5253, DOI 10.1074/jbc.275.8.5253; LOO TW, 1995, J BIOL CHEM, V270, P843, DOI 10.1074/jbc.270.2.843; Loo TW, 2002, J BIOL CHEM, V277, P44332, DOI 10.1074/jbc.M208433200; Loo TW, 1998, J BIOL CHEM, V273, P14671, DOI 10.1074/jbc.273.24.14671; Loo TW, 2001, J BIOL CHEM, V276, P36877, DOI 10.1074/jbc.C100467200; LOO TW, 1995, J BIOL CHEM, V270, P21449, DOI 10.1074/jbc.270.37.21449; LOO TW, 1994, J BIOL CHEM, V269, P7750; Loo TW, 2001, J BIOL CHEM, V276, P14972, DOI 10.1074/jbc.M100407200; Loo TW, 2000, J BIOL CHEM, V275, P39272, DOI 10.1074/jbc.M007741200; LOO TW, 1995, J BIOL CHEM, V270, P22957, DOI 10.1074/jbc.270.39.22957; LOO TW, 1993, J BIOL CHEM, V268, P19965; LOO TW, 1994, J BIOL CHEM, V269, P28683; Sarkadi B, 1997, SEMIN CANCER BIOL, V8, P171, DOI 10.1006/scbi.1997.0069; TAMAI I, 1991, J BIOL CHEM, V266, P16796; Urbatsch IL, 2001, J BIOL CHEM, V276, P26980, DOI 10.1074/jbc.M010829200; Vo QD, 1999, J BIOL CHEM, V274, P20318, DOI 10.1074/jbc.274.29.20318; YANG CPH, 1990, J BIOL CHEM, V265, P10282	39	153	161	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 18	2003	278	16					13603	13606		10.1074/jbc.C300073200	http://dx.doi.org/10.1074/jbc.C300073200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	670JV	12609990	hybrid			2022-12-25	WOS:000182405000004
J	Ogasahara, K; Ishida, M; Yutani, K				Ogasahara, K; Ishida, M; Yutani, K			Stimulated interaction between alpha and beta subunits of tryptophan synthase from hyperthermophile enhances its thermal stability	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACTERIUM THERMOTOGA-MARITIMA; TRIOSEPHOSPHATE ISOMERASE TIM; ANTIGEN-ANTIBODY INTERACTION; SALT BRIDGE FORMATION; CRYSTAL-STRUCTURE; PYROCOCCUS-FURIOSUS; ESCHERICHIA-COLI; ALPHA(2)BETA(2) COMPLEX; THERMODYNAMIC ANALYSIS; ENTROPIC CONTRIBUTION	Tryptophan synthase from hyperthermophile, Pyrococcus furiosus, was found to be a tetrameric form (alpha(2)beta(2)) composed of a and 132 subunits. To elucidate the relationship between the features of the subunit association and the thermal stability of the tryptophan synthase, the subunit association and thermal stability were examined by isothermal titration calorimetry and differential scanning calorimetry, respectively, in comparison with those of the counterpart from Escherichia coli. The association constants between the a and P subunits in the hyperthermophile protein were of the order of 108 M-1, which were higher by two orders of magnitude than those in the mesophile one. The negative values of the heat capacity change and enthalpy change upon the subunit association were much lower in the hyperthermophile protein than in the mesophile one, indicating that the conformational change of the hyperthermophile protein coupled to the subunit association is slight. The denaturation temperature of the a subunit from the hyperthermophile was enhanced by 17 degreesC due to the formation of the alpha(2)beta(2) complex. This increment in denaturation temperature due to complex formation could be quantitatively estimated by the increase in the association constant compared with that of the counterpart from E. coli.	Kwansei Gakuin Univ, Grad Sch Sci, Sanda City, Hyogo 6671337, Japan; Osaka Univ, Inst Prot Res, Suita, Osaka 5650871, Japan; Tokyo Univ Fisheries, Minato Ku, Tokyo 1088477, Japan	Kwansei Gakuin University; Osaka University; Tokyo University of Marine Science & Technology	Yutani, K (corresponding author), Kwansei Gakuin Univ, Grad Sch Sci, Gakuen 2-1, Sanda City, Hyogo 6671337, Japan.	yutani@ksc.kwansei.ac.jp	ISHIDA, Masami/O-1909-2014					Arnott MA, 2000, J MOL BIOL, V304, P657, DOI 10.1006/jmbi.2000.4240; Auerbach G, 1998, STRUCTURE, V6, P769, DOI 10.1016/S0969-2126(98)00078-1; Backmann J, 2001, METHOD ENZYMOL, V334, P328; Beaucamp N, 1997, PROTEIN SCI, V6, P2159; Bell GS, 1998, ACTA CRYSTALLOGR D, V54, P1419, DOI 10.1107/S0907444998004910; Dams T, 1996, EUR J BIOCHEM, V240, P274, DOI 10.1111/j.1432-1033.1996.0274h.x; DURCHSCHLAG H, 1986, THERMODYNAMIC DATA B, P45; HARTLEY RW, 1993, BIOCHEMISTRY-US, V32, P5978, DOI 10.1021/bi00074a008; HATHAWAY GM, 1970, BIOCHEMISTRY-US, V9, P1801, DOI 10.1021/bi00810a020; Hettwer S, 2002, J BIOL CHEM, V277, P8194, DOI 10.1074/jbc.M111541200; Hiraga K, 1996, EUR J BIOCHEM, V240, P63, DOI 10.1111/j.1432-1033.1996.0063h.x; Hiraga K, 1997, J BIOL CHEM, V272, P4935, DOI 10.1074/jbc.272.8.4935; HYDE CC, 1988, J BIOL CHEM, V263, P17857; Ishida M, 2002, FEMS MICROBIOL LETT, V216, P179, DOI 10.1111/j.1574-6968.2002.tb11433.x; Ishikawa K, 2002, STRUCTURE, V10, P877, DOI 10.1016/S0969-2126(02)00779-7; Jaenicke R, 1996, ADV PROTEIN CHEM, V48, P181; Jaenicke R, 1998, CURR OPIN STRUC BIOL, V8, P738, DOI 10.1016/S0959-440X(98)80094-8; Jaenicke R, 2001, METHOD ENZYMOL, V334, P438; KIRINO H, 1994, EUR J BIOCHEM, V220, P275, DOI 10.1111/j.1432-1033.1994.tb18623.x; Kohlhoff M, 1996, FEBS LETT, V383, P245, DOI 10.1016/0014-5793(96)00249-9; Lim JH, 1997, J MOL BIOL, V270, P259, DOI 10.1006/jmbi.1997.1105; Maes D, 1999, PROTEINS, V37, P441, DOI 10.1002/(SICI)1097-0134(19991115)37:3<441::AID-PROT11>3.3.CO;2-Z; Makhatadze GI, 1995, ADV PROTEIN CHEM, V47, P307, DOI 10.1016/S0065-3233(08)60548-3; Miles E W, 1979, Adv Enzymol Relat Areas Mol Biol, V49, P127; MILES EW, 1991, ADV ENZYMOL RAMB, V64, P93; MILES EW, 1987, METHOD ENZYMOL, V142, P398; OGASAHARA K, 1980, J BIOCHEM-TOKYO, V88, P1733, DOI 10.1093/oxfordjournals.jbchem.a133148; Ogasahara K, 2001, EUR J BIOCHEM, V268, P3233, DOI 10.1046/j.1432-1327.2001.02220.x; OGASAHARA K, 1992, J BIOL CHEM, V267, P5222; Pan P, 1997, TRENDS BIOCHEM SCI, V22, P22, DOI 10.1016/S0968-0004(96)10066-9; Petsko GA, 2001, METHOD ENZYMOL, V334, P469; Rees DC, 2001, METHOD ENZYMOL, V334, P423; REMETA DP, 1995, PURE APPL CHEM, V67, P1859, DOI 10.1351/pac199567111859; Rhee S, 1997, BIOCHEMISTRY-US, V36, P7664, DOI 10.1021/bi9700429; Russell RJM, 1997, BIOCHEMISTRY-US, V36, P9983, DOI 10.1021/bi9705321; SCHELLMAN JA, 1976, BIOPOLYMERS, V15, P999, DOI 10.1002/bip.1976.360150513; SCHELLMAN JA, 1975, BIOPOLYMERS, V14, P999, DOI 10.1002/bip.1975.360140509; Schneider TR, 1998, BIOCHEMISTRY-US, V37, P5394, DOI 10.1021/bi9728957; Shiroishi M, 2001, J BIOL CHEM, V276, P23042, DOI 10.1074/jbc.M100480200; SPOLAR RS, 1994, SCIENCE, V263, P777, DOI 10.1126/science.8303294; Tanaka H, 2001, J BIOCHEM-TOKYO, V130, P107, DOI 10.1093/oxfordjournals.jbchem.a002948; Tang XF, 2000, EUR J BIOCHEM, V267, P6369, DOI 10.1046/j.1432-1327.2000.01721.x; Thoma R, 2000, STRUCTURE, V8, P265, DOI 10.1016/S0969-2126(00)00106-4; TSUMOTO K, 1995, J BIOL CHEM, V270, P18551, DOI 10.1074/jbc.270.31.18551; TSUMOTO K, 1994, J BIOL CHEM, V269, P28777; Tsumoto K, 1996, J BIOL CHEM, V271, P32612, DOI 10.1074/jbc.271.51.32612; Villeret V, 1998, P NATL ACAD SCI USA, V95, P2801, DOI 10.1073/pnas.95.6.2801; Walden H, 2001, J MOL BIOL, V306, P745, DOI 10.1006/jmbi.2000.4433; Weyand M, 1999, BIOCHEMISTRY-US, V38, P16469, DOI 10.1021/bi9920533; White JT, 2001, P NATL ACAD SCI USA, V98, P13019, DOI 10.1073/pnas.241406698; WISEMAN T, 1989, ANAL BIOCHEM, V179, P131, DOI 10.1016/0003-2697(89)90213-3; Yamagata Y, 2001, J BIOL CHEM, V276, P11062, DOI 10.1074/jbc.M009987200; YANOFSKY C, 1972, ENZYMES, V3, P1; YIP KSP, 1995, STRUCTURE, V3, P1147, DOI 10.1016/S0969-2126(01)00251-9; YUTANI K, 1987, J BIOL CHEM, V262, P13429; Zhang XF, 2001, J MOL BIOL, V306, P1099, DOI 10.1006/jmbi.2000.4435; ZHAO GP, 1992, J BIOL CHEM, V267, P526	57	29	29	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 14	2003	278	11					8922	8928		10.1074/jbc.M210893200	http://dx.doi.org/10.1074/jbc.M210893200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	654YF	12643278	hybrid			2022-12-25	WOS:000181524000009
J	Descamps, FJ; Van den Steen, PE; Martens, E; Ballaux, F; Geboes, K; Opdenakker, G				Descamps, FJ; Van den Steen, PE; Martens, E; Ballaux, F; Geboes, K; Opdenakker, G			Gelatinase B is diabetogenic in acute and chronic pancreatitis by cleaving insulin	FASEB JOURNAL			English	Article						diabetes; inflammation; neutrophil; islets of Langerhans	HUMAN T-LYMPHOCYTES; MATRIX METALLOPROTEINASES; TISSUE INHIBITORS; CELLS; IDENTIFICATION; SPECIFICITIES; GENERATION; ACTIVATION; ANTIBODY; FIBROSIS	Genetic, endocrine, and environmental factors contribute to the development of diabetes. Much information has been gathered on the homeostasis mechanisms of glucose regulation by insulin-producing pancreatic cells. Here we demonstrate high expression levels of gelatinase B (matrix metalloproteinase-9, MMP-9) by neutrophils in acute pancreatitis and by ductular epithelial cells in chronic pancreatitis. Because gelatinase B processes cytokines and chemokines, we investigated whether and how gelatinase B cleaves insulin. Pure human neutrophil gelatinase B was found to destroy insulin by cleavage at 10 sites. Pancreatic islet and ductular cells are relatively spared in comparison with the complete destruction of acinar cells of the exocrine pancreas in chronic pancreatitis. High expression levels of gelatinase B are maintained in the immediate proximity of insulin-secreting cells. Consequently, diabetes may be worsened by enzymatic degradation of insulin by gelatinase B and by the consequent enhancement of the autoimmune process. Gelatinase B is diabetogenic in acute and chronic pancreatitis by cleaving insulin.	Univ Leuven, Rega Inst Med Res, Lab Mol Immunol, B-3000 Louvain, Belgium; Univ Leuven, Dept Morphol & Mol Pathol, B-3000 Louvain, Belgium	KU Leuven; KU Leuven	Opdenakker, G (corresponding author), Univ Leuven, Rega Inst Med Res, Lab Mol Immunol, Minderbroedersstr 10, B-3000 Louvain, Belgium.	ghislain.opdenakker@rega.kuleuven.ac.be	Opdenakker, Ghislain/V-8562-2019; Opdenakker, Ghislain/Q-3130-2017; Martens, Erik/F-9214-2015; Van den Steen, Philippe E/K-5132-2012	Opdenakker, Ghislain/0000-0003-1714-2294; Opdenakker, Ghislain/0000-0003-1714-2294; Martens, Erik/0000-0002-7947-6567; Van den Steen, Philippe E/0000-0002-7334-9145				ADAMS MJ, 1969, NATURE, V224, P491, DOI 10.1038/224491a0; BAEKKESKOV S, 1990, NATURE, V347, P151, DOI 10.1038/347151a0; BANKS RE, 1991, CYTOKINE, V3, P12, DOI 10.1016/1043-4666(91)90004-W; CHRISTIE MR, 1990, J EXP MED, V172, P789, DOI 10.1084/jem.172.3.789; Ebihara I, 1998, AM J KIDNEY DIS, V32, P544, DOI 10.1016/S0272-6386(98)70015-0; Fernandez-Patron C, 2001, FASEB J, V15, P2230, DOI 10.1096/fj.01-0178com; Grillet B, 1997, BRIT J RHEUMATOL, V36, P744; Ishihara T, 1998, PANCREAS, V17, P412, DOI 10.1097/00006676-199811000-00013; Kobayashi Y, 1999, J IMMUNOL, V163, P5989; MONTGOMERY AMP, 1993, BIOCHIM BIOPHYS ACTA, V1176, P265, DOI 10.1016/0167-4889(93)90054-S; Muhs BE, 2001, J SURG RES, V101, P21, DOI 10.1006/jsre.2001.6244; MURPHY G, 1995, METHOD ENZYMOL, V248, P496; NETZELARNETT S, 1993, BIOCHEMISTRY-US, V32, P6427, DOI 10.1021/bi00076a016; Ng EK, 2001, J SURG RES, V96, P6, DOI 10.1006/jsre.2000.6048; OPDENAKKER G, 1994, IMMUNOL TODAY, V15, P103, DOI 10.1016/0167-5699(94)90151-1; Opdenakker G, 2001, TRENDS IMMUNOL, V22, P571, DOI 10.1016/S1471-4906(01)02023-3; Paemen L, 1995, EUR J BIOCHEM, V234, P759, DOI 10.1111/j.1432-1033.1995.759_a.x; PROOST P, 1993, J IMMUNOL, V150, P1000; PROOST P, 1993, BIOCHEM BIOPH RES CO, V192, P53; Pu Z, 2002, P NATL ACAD SCI USA, V99, P8844, DOI 10.1073/pnas.092260499; SANJEEVI CB, 2002, ANN NEW YORK ACAD SC, V958; Schonbeck U, 1998, J IMMUNOL, V161, P3340; Smith GD, 2001, ACTA CRYSTALLOGR D, V57, P1091, DOI 10.1107/S0907444901007685; Van Den Steen PE, 2002, FASEB J, V16, DOI 10.1096/fj.01-0688com; Van den Steen PE, 2000, BLOOD, V96, P2673, DOI 10.1182/blood.V96.8.2673.h8002673_2673_2681; WEEKS BS, 1993, J CELL PHYSIOL, V157, P644, DOI 10.1002/jcp.1041570326; Wegmann DR, 2000, J AUTOIMMUN, V15, P286, DOI 10.1006/jaut.2000.0444; WEGMANN DR, 1994, EUR J IMMUNOL, V24, P1853, DOI 10.1002/eji.1830240820; Yokota T, 2002, J SURG RES, V104, P106, DOI 10.1006/jsre.2002.6403; ZHOU H, 1993, BIOCHIM BIOPHYS ACTA, V1177, P174, DOI 10.1016/0167-4889(93)90037-P	30	41	43	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAR	2003	17	3					887	+		10.1096/fj.02-0725fje	http://dx.doi.org/10.1096/fj.02-0725fje			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	661LT	12626433				2022-12-25	WOS:000181892600024
J	Mochizuki, M; Kadoya, Y; Wakabayashi, Y; Kato, K; Okazaki, I; Yamada, M; Sato, T; Sakairi, N; Nishi, N; Nomizu, M				Mochizuki, M; Kadoya, Y; Wakabayashi, Y; Kato, K; Okazaki, I; Yamada, M; Sato, T; Sakairi, N; Nishi, N; Nomizu, M			Laminin-1 peptide-conjugated chitosan membranes as a novel approach for cell engineering	FASEB JOURNAL			English	Article						basement membrane; cell attachment; integrin; proteoglycan; neurite outgrowth	MOUSE LAMININ; G-DOMAIN; BRANCHING MORPHOGENESIS; BINDING SEQUENCES; GLOBULAR DOMAIN; ALPHA-1; IDENTIFICATION; TISSUE; CHAIN; ADHESION	Laminin, a major component of the basement membrane, has diverse biological activities. Recently, we identified various biologically active sequences on laminin-1 by using a large set of synthetic peptides. Chitosan, a polysaccharide, is biodegradable and has been used as a biomaterial. Here, we conjugated several biologically active laminin peptides onto chitosan membranes and measured the cell attachment activity of peptide-conjugated chitosan membranes with various cell types. The active laminin peptide-conjugated chitosan membranes promoted cell attachment with cell type specificity. A99 (AGTFALRGDNPQG)-chitosan membrane promoted cell attachment with well-organized actin stress fibers. This adhesion was inhibited by EDTA but not by heparin. AG73 (RKRLQVQLSIRT)-chitosan membrane promoted cell attachment with filopodia formation, and this adhesion was inhibited by heparin but not by EDTA. These data suggest that the A99-chitosan membrane interacted with an integrin cellular receptor and that the AG73-chitosan membrane promoted proteoglycan-mediated cell attachment, as previously reported. Furthermore, both AG73-chitosan and A99-chitosan membranes effectively promoted neurite outgrowth with PC12 rat pheochromocytoma cells. We conclude that conjugation on a chitosan membrane is applicable for testing quantitatively the biological activity of synthetic peptides and that these constructs have a potential ability to serve as bioadhesive materials for tissue regeneration and engineering.	Hokkaido Univ, Lab Biomat Chem, Div Biosci, Grad Sch Environm Earth Sci,Kita Ku, Sapporo, Hokkaido 0600810, Japan; Kitasato Univ, Sch Med, Dept Anat, Sagamihara, Kanagawa 2288555, Japan	Hokkaido University; Kitasato University	Nomizu, M (corresponding author), Hokkaido Univ, Lab Biomat Chem, Div Biosci, Grad Sch Environm Earth Sci,Kita Ku, Kita 10 Nishi 5, Sapporo, Hokkaido 0600810, Japan.	nomizu@ees.hokudai.ac.jp	Yamada, Masanori/AAC-7412-2019	Yamada, Masanori/0000-0002-9793-8825				BURGESON RE, 1994, MATRIX BIOL, V14, P209, DOI 10.1016/0945-053X(94)90184-8; CHANDY T, 1990, BIOMATER ARTIF CELL, V18, P1, DOI 10.3109/10731199009117286; Colognato H, 2000, DEV DYNAM, V218, P213, DOI 10.1002/(SICI)1097-0177(200006)218:2<213::AID-DVDY1>3.0.CO;2-R; Engbring JA, 2002, CANCER RES, V62, P3549; Fleischmajer R, 1998, J CELL SCI, V111, P1929; Gallaher CM, 2000, J NUTR, V130, P2753, DOI 10.1093/jn/130.11.2753; Gumbiner BM, 1996, CELL, V84, P345, DOI 10.1016/S0092-8674(00)81279-9; Henriksen I, 1996, INT J PHARM, V145, P231, DOI 10.1016/S0378-5173(96)04776-X; Hern DL, 1998, J BIOMED MATER RES, V39, P266, DOI 10.1002/(SICI)1097-4636(199802)39:2<266::AID-JBM14>3.0.CO;2-B; Hoffman MP, 1998, J BIOL CHEM, V273, P28633, DOI 10.1074/jbc.273.44.28633; Hoffman MP, 2001, J BIOL CHEM, V276, P22077, DOI 10.1074/jbc.M100774200; Hosokawa Y, 1999, DEV GROWTH DIFFER, V41, P207; Hubbell JA, 1999, CURR OPIN BIOTECH, V10, P123, DOI 10.1016/S0958-1669(99)80021-4; Iivanainen A, 1999, J BIOL CHEM, V274, P14107, DOI 10.1074/jbc.274.20.14107; Kadoya Y, 1998, DEV DYNAM, V212, P394; Kim WH, 1998, INT J CANCER, V77, P632, DOI 10.1002/(SICI)1097-0215(19980812)77:4<632::AID-IJC25>3.0.CO;2-6; Kumar MNVR, 2000, REACT FUNCT POLYM, V46, P1; Kuratomi Y, 1999, EXP CELL RES, V249, P386, DOI 10.1006/excr.1999.4497; KURITA K, 1977, MAKROMOL CHEM, V178, P3197; Malinda KM, 1999, FASEB J, V13, P53, DOI 10.1096/fasebj.13.1.53; Miner JH, 1997, J CELL BIOL, V137, P685, DOI 10.1083/jcb.137.3.685; Nomizu M, 1997, J BIOL CHEM, V272, P32198, DOI 10.1074/jbc.272.51.32198; Nomizu M, 1998, J BIOL CHEM, V273, P32491, DOI 10.1074/jbc.273.49.32491; NOMIZU M, 1995, J BIOL CHEM, V270, P20583, DOI 10.1074/jbc.270.35.20583; Nomizu M, 2000, ARCH BIOCHEM BIOPHYS, V378, P311, DOI 10.1006/abbi.2000.1828; Ponce ML, 1999, CIRC RES, V84, P688, DOI 10.1161/01.RES.84.6.688; Ponce ML, 2001, FASEB J, V15, P1389, DOI 10.1096/fj.00-0736com; RASHEED S, 1974, CANCER, V33, P1027, DOI 10.1002/1097-0142(197404)33:4<1027::AID-CNCR2820330419>3.0.CO;2-Z; Richard BL, 1996, EXP CELL RES, V228, P98, DOI 10.1006/excr.1996.0304; RUOSLAHTI E, 1987, SCIENCE, V238, P491, DOI 10.1126/science.2821619; Song SY, 1997, INT J CANCER, V71, P436, DOI 10.1002/(SICI)1097-0215(19970502)71:3<436::AID-IJC22>3.0.CO;2-C; SONNENBERG A, 1990, J CELL BIOL, V110, P2145, DOI 10.1083/jcb.110.6.2145; Suh JKF, 2000, BIOMATERIALS, V21, P2589; TASHIRO K, 1991, J CELL PHYSIOL, V146, P451, DOI 10.1002/jcp.1041460316; Weeks BS, 1998, EXP CELL RES, V243, P375, DOI 10.1006/excr.1998.4157; YANNAS IV, 1982, SCIENCE, V215, P174, DOI 10.1126/science.7031899	36	88	90	1	15	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2003	17	3					875	+		10.1096/fj.02-0564fje	http://dx.doi.org/10.1096/fj.02-0564fje			20	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	661LT	12626440				2022-12-25	WOS:000181892600030
J	Zhao, M; Song, B; Pu, J; Forrester, JV; McCaig, CD				Zhao, M; Song, B; Pu, J; Forrester, JV; McCaig, CD			Direct visualization of a stratified epithelium reveals that wounds heal by unified sliding of cell sheets	FASEB JOURNAL			English	Article						wound healing; stratified epithelium; corneal epithelium; corneal organ culture; cell migration	3-DIMENSIONAL CONFOCAL MICROSCOPY; HINDBRAIN NEURAL CREST; TIME-LAPSE ANALYSIS; CORNEA IN-VIVO; ELECTRIC-FIELD; KERATINOCYTE MIGRATION; RABBIT CORNEA; CLOSURE; REEPITHELIALIZATION; FIBRONECTIN	Observing cells in their original niche is a key link between the information gleaned from planar culture and in vivo physiology and pathology. A new approach combining the transparency of the cornea, Hoffman modulation optics, and digital imaging allowed movements of individual corneal cells to be viewed directly in situ. 3-Dimensional time-lapse movies imaging unstained cells within the stratified corneal epithelium during wound healing were made. Tracking cell movements dynamically provided a definitive answer to the long-standing question: does a stratified epithelium heal by "sliding" of cell sheets as a coherent unit or do individual cells "leap frog" each other at the wound margin? A wound in the corneal epithelium healed primarily by sliding of the whole epithelium, with similar to95% of cells moving with similar speed and trajectories and with little change in their relative position. Only 5% of cells changed layers, with equal proportions moving up or down. Epithelial healing in situ occurred in three phases: a latency, migration, and reconstruction phase. This model provides a unique system to study the behaviors of individual cells in their original niche. It shows that cells slide into a wound as a unified unit to heal a stratified epithelium.	Univ Aberdeen, Dept Biomed Sci, Inst Med Sci, Aberdeen AB25 2ZD, Scotland; Univ Aberdeen, Dept Ophthalmol, Inst Med Sci, Aberdeen AB25 2ZD, Scotland	University of Aberdeen; University of Aberdeen	Zhao, M (corresponding author), Univ Aberdeen, Dept Biomed Sci, Inst Med Sci, Aberdeen AB25 2ZD, Scotland.	m.zhao@abdn.ac.uk; c.mccaig@abdn.ac.uk	McCaig, Colin/B-1774-2010; Song, Bing/AAB-4755-2021	Song, Bing/0000-0001-9356-2333	Wellcome Trust [068012] Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BARLATI S, 1990, EXP EYE RES, V51, P1, DOI 10.1016/0014-4835(90)90162-N; Bohnke M, 1999, PROG RETIN EYE RES, V18, P553, DOI 10.1016/S1350-9462(98)00028-7; BUCK RC, 1979, INVEST OPHTH VIS SCI, V18, P767; CHAN KY, 1986, EXP EYE RES, V42, P417, DOI 10.1016/0014-4835(86)90002-3; CHAN KY, 1989, INVEST OPHTH VIS SCI, V30, P2488; CHIANG MC, 1992, EXP EYE RES, V54, P999, DOI 10.1016/0014-4835(92)90164-N; CROSSON CE, 1986, INVEST OPHTH VIS SCI, V27, P464; Danjo Y, 2002, EXP EYE RES, V74, P199, DOI 10.1006/exer.2001.1115; DONALDSON DJ, 1988, J INVEST DERMATOL, V90, P623, DOI 10.1111/1523-1747.ep12560762; GARLICK JA, 1994, LAB INVEST, V70, P916; GIBBINS JR, 1978, PATHOLOGY, V10, P207, DOI 10.3109/00313027809063503; Gipson I K, 1995, Curr Opin Ophthalmol, V6, P3; HAIK BG, 1977, INVEST OPHTH VIS SCI, V16, P787; HANNA C, 1966, AM J OPHTHALMOL, V61, P55, DOI 10.1016/0002-9394(66)90747-1; HOFFMAN R, 1977, J MICROSC-OXFORD, V110, P205, DOI 10.1111/j.1365-2818.1977.tb00033.x; HOFFMAN R, 1975, NATURE, V254, P586, DOI 10.1038/254586a0; JUMBLATT MM, 1986, INVEST OPHTH VIS SCI, V27, P8; Knight B, 2000, CURR BIOL, V10, P576, DOI 10.1016/S0960-9822(00)00486-3; Koster RW, 2001, CURR BIOL, V11, P1858, DOI 10.1016/S0960-9822(01)00585-1; KRAWCZYK WS, 1971, J CELL BIOL, V49, P247, DOI 10.1083/jcb.49.2.247; Kulesa P, 2000, DEVELOPMENT, V127, P2843; Kulesa PM, 2000, DEVELOPMENT, V127, P1161; KUWABARA T, 1976, INVEST OPHTH VISUAL, V15, P4; Laplante AF, 2001, FASEB J, V15, P2377, DOI 10.1096/fj.01-0250com; Martin P, 1997, SCIENCE, V276, P75, DOI 10.1126/science.276.5309.75; Masters BR, 2001, OPHTHALMIC RES, V33, P125, DOI 10.1159/000055658; Masters BR, 1999, METHOD ENZYMOL, V307, P536; McCaig CD, 2002, TRENDS NEUROSCI, V25, P354, DOI 10.1016/S0166-2236(02)02174-4; Nishida T, 1996, Curr Opin Ophthalmol, V7, P2, DOI 10.1097/00055735-199608000-00002; ORTONNE JP, 1981, VIRCHOWS ARCH A, V392, P217, DOI 10.1007/BF00430822; PFISTER RR, 1975, INVEST OPHTH VISUAL, V14, P648; RADICE GP, 1980, DEV BIOL, V76, P26, DOI 10.1016/0012-1606(80)90360-7; Rorth P, 2002, TRENDS CELL BIOL, V12, P325, DOI 10.1016/S0962-8924(02)02311-5; Rovee D.T., 1972, EPIDERMAL WOUND HEAL, P71; Song B, 2002, P NATL ACAD SCI USA, V99, P13577, DOI 10.1073/pnas.202235299; SRINIVASAN BD, 1977, EXP EYE RES, V25, P343, DOI 10.1016/0014-4835(77)90101-4; Sta Iglesia Drina D., 1998, Wound Repair and Regeneration, V6, P531; Stenn KS., 1992, WOUND HEALING BIOCH, P115; VAUGHAN RB, 1966, J CELL SCI, V1, P407; WEISS PAUL, 1961, P13; Wilson SE, 1999, PROG RETIN EYE RES, V18, P293, DOI 10.1016/S1350-9462(98)00017-2; Wilson SE, 2001, PROG RETIN EYE RES, V20, P625, DOI 10.1016/S1350-9462(01)00008-8; Zhao M, 1999, MOL BIOL CELL, V10, P1259, DOI 10.1091/mbc.10.4.1259; Zhao M, 1996, J CELL SCI, V109, P1405; Zhao M, 1997, CURR EYE RES, V16, P973, DOI 10.1076/ceyr.16.10.973.9014; Zhao M, 1996, INVEST OPHTH VIS SCI, V37, P2548; Zhao M, 1999, P NATL ACAD SCI USA, V96, P4942, DOI 10.1073/pnas.96.9.4942; ZHAO M, 2002, FASEB J, V16; Zieske JD, 2001, CURR OPIN OPHTHALMOL, V12, P237, DOI 10.1097/00055735-200108000-00001	49	61	61	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAR	2003	17	3					397	406		10.1096/fj.02-0610com	http://dx.doi.org/10.1096/fj.02-0610com			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	661LT	12631579	Green Accepted			2022-12-25	WOS:000181892600038
J	Rau, T; Nose, M; Remmers, U; Weil, J; Weissmuller, A; Davia, K; Harding, S; Peppel, K; Koch, WJ; Eschenhagen, T				Rau, T; Nose, M; Remmers, U; Weil, J; Weissmuller, A; Davia, K; Harding, S; Peppel, K; Koch, WJ; Eschenhagen, T			Overexpression of wild-type G alpha i-2 suppresses beta-adrenergic signaling in cardiac myocytes	FASEB JOURNAL			English	Article						G protein; heart failure; beta-adrenergic receptors; adenovirus; gene transfer	ENGINEERED HEART-TISSUE; G-PROTEIN; ADENYLATE-CYCLASE; PERTUSSIS-TOXIN; G(I-ALPHA) PROTEINS; RECEPTOR KINASE; ADULT-RAT; GI-ALPHA; EXPRESSION; INCREASE	The role of Galphai-2 overexpression in desensitization of beta-adrenergic signaling in heart failure is controversial. An adenovirus-based approach was used to investigate whether overexpression of Galphai-2 impairs beta-adrenergic stimulation of adenylyl cyclase (AC) activity and cAMP levels in neonatal rat cardiac myocytes (NRCM) and cell shortening of adult rat ventricular myocytes (ARVM). Infection of NRCM with Ad5Galphai-2 increased Galphai-2 by 50-600% in a virus dose-dependent manner. Overexpression was paralleled by suppression of GTP- and isoprenaline-stimulated AC by 10-72% (P<0.001) in a PTX-sensitive manner. Isoprenaline-stimulated shortening of Ad5G alpha i-2-infected ARVM was attenuated by 34% (P<0.01). Ad5Galphai-2/GFP (Galphai-2, green fluorescent protein; bicistronic) was constructed to monitor transfection homogeneity and target Galphai-2 overexpression to levels found in heart failure. At Galphai-2 levels of 93% above control, isoprenaline-stimulated AC activity and cAMP levels were reduced by 17% and 40% (P<0.02), respectively. 1- and 2-adrenergic stimulation was reduced similarly. Our results suggest that (a) the G alpha i-2 system exhibits tonic inhibition of stimulated AC in cardiac myocytes, (b) G alpha i-2-mediated inhibition is concentration-dependent and occurs at G alpha i-2 levels seen in heart failure, and (c) G alpha i-2-mediated inhibition affects both 1- and 2-adrenergic stimulation of AC. The data argue for an important, independent role of the G alpha i-2 increase in heart failure.	Univ Erlangen Nurnberg, Inst Pharmacol & Toxicol, D-91054 Erlangen, Germany; Univ Hamburg Hosp, Inst Pharmacol & Toxicol, D-2000 Hamburg, Germany; Imperial Coll Sch Med, NHLI, London, England; Duke Univ, Sch Med, Durham, NC USA	University of Erlangen Nuremberg; University of Hamburg; University Medical Center Hamburg-Eppendorf; Imperial College London; Duke University	Eschenhagen, T (corresponding author), Univ Erlangen Nurnberg, Inst Pharmacol & Toxicol, Fahrstr 17, D-91054 Erlangen, Germany.	eschenhagen@pharmakologie.uni-erlangen.de		Harding, Sian/0000-0002-3651-6354				AbiGerges N, 1997, MOL PHARMACOL, V52, P482, DOI 10.1124/mol.52.3.482; Akaishi Y, 1997, J MOL CELL CARDIOL, V29, P765, DOI 10.1006/jmcc.1996.0315; Akhter SA, 1997, P NATL ACAD SCI USA, V94, P12100, DOI 10.1073/pnas.94.22.12100; AnandSrivastava MB, 1996, MOL CELL BIOCHEM, V157, P163; BOHM M, 1990, CIRCULATION, V82, P1249, DOI 10.1161/01.CIR.82.4.1249; BOHM M, 1988, EUR HEART J, V9, P844; BOHM M, 1992, HYPERTENSION, V20, P103, DOI 10.1161/01.HYP.20.1.103; BRISTOW MR, 1984, J CLIN INVEST, V74, P212, DOI 10.1172/JCI111404; BRISTOW MR, 1991, CIRCULATION, V84, P1024, DOI 10.1161/01.CIR.84.3.1024; BRISTOW MR, 1982, MOL PHARMACOL, V21, P671; BRISTOW MR, 1982, NEW ENGL J MED, V307, P205, DOI 10.1056/NEJM198207223070401; BRODDE OE, 1991, EUR HEART J, V12, P54, DOI 10.1093/eurheartj/12.suppl_F.54; Brodde OE, 1998, J CARDIOVASC PHARM, V31, P585, DOI 10.1097/00005344-199804000-00018; BROWN LA, 1992, BRIT J PHARMACOL, V106, P115, DOI 10.1111/j.1476-5381.1992.tb14302.x; COLUCCI WS, 1990, CIRCULATION, V82, P44; Davia K, 1999, PHYSIOL GENOMICS, V1, P41, DOI 10.1152/physiolgenomics.1999.1.2.41; Donahue JK, 2000, NAT MED, V6, P1395; Engelhardt S, 1996, J AM COLL CARDIOL, V27, P146, DOI 10.1016/0735-1097(95)00425-4; Eschenhagen T, 1997, FASEB J, V11, P683, DOI 10.1096/fasebj.11.8.9240969; Eschenhagen T, 1996, CIRCULATION, V93, P763, DOI 10.1161/01.CIR.93.4.763; FELDMAN AM, 1988, J CLIN INVEST, V82, P189, DOI 10.1172/JCI113569; Fink C, 2000, FASEB J, V14, P669, DOI 10.1096/fasebj.14.5.669; Gong HB, 2000, BRIT J PHARMACOL, V131, P594, DOI 10.1038/sj.bjp.0703591; Gong HB, 2002, CIRCULATION, V105, P2497, DOI 10.1161/01.CIR.0000017187.61348.95; Grimm M, 1998, J MOL CELL CARDIOL, V30, P1917, DOI 10.1006/jmcc.1998.0769; Hajjar RJ, 1997, CIRCULATION, V95, P423; HANF R, 1993, J PHYSIOL-LONDON, V461, P743, DOI 10.1113/jphysiol.1993.sp019539; HARDING SE, 1988, J MOL CELL CARDIOL, V20, P635, DOI 10.1016/S0022-2828(88)80121-4; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; Heubach UF, 2002, BRIT J PHARMACOL, V136, P217, DOI 10.1038/sj.bjp.0704700; HILF G, 1989, EUR J BIOCHEM, V186, P725, DOI 10.1111/j.1432-1033.1989.tb15266.x; Huang WY, 2000, NAT MED, V6, P482, DOI 10.1038/74914; Jakubik J, 1995, FEBS LETT, V377, P275, DOI 10.1016/0014-5793(95)01360-1; Janssen PML, 2002, CARDIOVASC RES, V55, P300, DOI 10.1016/S0008-6363(02)00406-6; KATADA T, 1984, J BIOL CHEM, V259, P3568; KOCH WJ, 1995, SCIENCE, V268, P1350, DOI 10.1126/science.7761854; LAUGWITZ KL, 1993, NEURON, V10, P233, DOI 10.1016/0896-6273(93)90314-H; Lutz S, 2002, N-S ARCH PHARMACOL, V365, P50, DOI 10.1007/s00210-001-0500-3; NEUMANN J, 1988, LANCET, V2, P936; NOVOTNY J, 1994, BIOCHEM MOL BIOL INT, V34, P993; O'Donnell JM, 2001, CIRC RES, V88, P415; Redfern CH, 2000, P NATL ACAD SCI USA, V97, P4826, DOI 10.1073/pnas.97.9.4826; RUDOLPH U, 1995, J CLIN IMMUNOL, V15, pS101, DOI 10.1007/BF01540899; SCHMITZ W, 1989, J CARDIOVASC PHARM, V14, pS11, DOI 10.1097/00005344-198914003-00003; SCHUTZ W, 1992, TRENDS PHARMACOL SCI, V13, P376, DOI 10.1016/0165-6147(92)90116-N; SCHWINGER RHG, 1990, AM HEART J, V119, P899, DOI 10.1016/S0002-8703(05)80329-1; Sigmund M, 1996, EUR J CLIN PHARMACOL, V51, P127, DOI 10.1007/s002280050172; UNGERER M, 1993, CIRCULATION, V87, P454, DOI 10.1161/01.CIR.87.2.454; WONG YH, 1991, NATURE, V351, P63, DOI 10.1038/351063a0; Xiao RP, 1999, CIRC RES, V84, P43; XIAO RP, 1995, MOL PHARMACOL, V47, P322; Yamada M, 1998, PHARMACOL REV, V50, P723; Zimmermann WH, 2000, BIOTECHNOL BIOENG, V68, P106	53	35	36	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2003	17	1					523	+		10.1096/fj.02-0660fje	http://dx.doi.org/10.1096/fj.02-0660fje			23	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	653TT	12631586				2022-12-25	WOS:000181453700016
J	Zargarian, L; Benleumi, MS; Renisio, JG; Merad, H; Maroun, RG; Wieber, F; Mauffret, O; Porumb, H; Troalen, F; Fermandjian, S				Zargarian, L; Benleumi, MS; Renisio, JG; Merad, H; Maroun, RG; Wieber, F; Mauffret, O; Porumb, H; Troalen, F; Fermandjian, S			Strategy to discriminate between high and low affinity bindings of human immunodeficiency virus, type 1 integrase to viral DNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOTO-CROSS-LINKING; CARBOXYL-TERMINAL DOMAINS; HIV-1 INTEGRASE; CATALYTIC DOMAIN; CRYSTAL-STRUCTURE; ACTIVE-SITE; SECONDARY STRUCTURE; STRAND TRANSFER; PROTEIN; SEQUENCE	The last decade has contributed to our understanding of the three-dimensional structure of the human immunodeficiency virus, type 1 (HIV-1) integrase (IN) and to the description of how the enzyme catalyzes the viral DNA integration into the host DNA. Recognition of the viral DNA termini by IN is sequence-specific, and that of the host DNA does not require particular sequence, although in physicochemical studies IN fails to discriminate between the two interactions. Here, such discrimination was allowed thanks to a model system using designed oligonucleotides and peptides as binding structures. Spectroscopic (circular dichroism, NMR, and fluorescence anisotropy) techniques and biochemical (enzymatic and filter binding) assays clearly indicated that the amphipathic helix alpha4, located at the catalytic domain surface, is responsible for the specific high affinity binding of the enzyme to viral DNA. Analogues of the alpha4 peptide having increased helicity and still bearing the biologically relevant lysines 156 and 159 on the DNA binding face, and oligonucleotides conserving an intact attachment site, are required to achieve high affinity complexes (K-d of 1.5 nM). Data corroborate previous in vivo results obtained with mutated viruses.	Inst Gustave Roussy, Dept Biol & Pharmacol Struct, CNRS, UMR 8113, F-94805 Villejuif, France; Ecole Normale Super, F-94235 Cachan, France; Univ St Joseph, CST Mar Roukos, Fac Sci, Dept Sci Vie & Terre, Beirut 11072050, Lebanon; Inst Gustave Roussy, Dept Biol Clin, Lab Microchim & Immunol Mol, F-94805 Villejuif, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UNICANCER; Gustave Roussy; UDICE-French Research Universities; Universite Paris Saclay; Saint Joseph University Beirut; UNICANCER; Gustave Roussy	Fermandjian, S (corresponding author), Inst Gustave Roussy, Dept Biol & Pharmacol Struct, CNRS, UMR 8113, PR2,39 Rue Camille Desmoulins, F-94805 Villejuif, France.			Wieber, Frederic/0000-0001-7167-9813				Asante-Appiah E, 1999, ADV VIRUS RES, V52, P351, DOI 10.1016/S0065-3527(08)60306-1; Asante-Appiah E, 1997, ANTIVIR RES, V36, P139, DOI 10.1016/S0166-3542(97)00046-6; Austin RJ, 2002, J AM CHEM SOC, V124, P10966, DOI 10.1021/ja026610b; BARRESINOUSSI F, 1983, SCIENCE, V220, P868, DOI 10.1126/science.6189183; Brown P. O., 1997, P161; BUJACZ G, 1995, J MOL BIOL, V253, P333, DOI 10.1006/jmbi.1995.0556; BUJALOWSKI W, 1987, BIOCHEMISTRY-US, V26, P3099, DOI 10.1021/bi00385a023; BUSHMAN FD, 1991, P NATL ACAD SCI USA, V88, P1339, DOI 10.1073/pnas.88.4.1339; Cai ML, 1997, NAT STRUCT BIOL, V4, P567, DOI 10.1038/nsb0797-567; Chen JCH, 2000, P NATL ACAD SCI USA, V97, P8233, DOI 10.1073/pnas.150220297; Chen ZG, 2000, J MOL BIOL, V296, P521, DOI 10.1006/jmbi.1999.3451; Craigie R, 2001, J BIOL CHEM, V276, P23213, DOI 10.1074/jbc.R100027200; CRAIGIE R, 1990, CELL, V62, P829, DOI 10.1016/0092-8674(90)90126-Y; CRAM DJ, 1988, SCIENCE, V240, P760, DOI 10.1126/science.3283937; Debyser Zeger, 2002, Antiviral Chemistry & Chemotherapy, V13, P1; DYDA F, 1994, SCIENCE, V266, P1981, DOI 10.1126/science.7801124; Eijkelenboom APAM, 1997, CURR BIOL, V7, P739, DOI 10.1016/S0960-9822(06)00332-0; EJKELENBOOM APA, 1995, NAT STRUCT BIOL, V2, P807; Engelman A, 1999, ADV VIRUS RES, V52, P411, DOI 10.1016/S0065-3527(08)60309-7; ENGELMAN A, 1993, EMBO J, V12, P3269, DOI 10.1002/j.1460-2075.1993.tb05996.x; ENGELMAN A, 1994, J VIROL, V68, P5911, DOI 10.1128/JVI.68.9.5911-5917.1994; ENGELMAN A, 1992, J VIROL, V66, P6361, DOI 10.1128/JVI.66.11.6361-6369.1992; ENGELMAN A, 1991, CELL, V67, P1211, DOI 10.1016/0092-8674(91)90297-C; Esposito D, 1998, EMBO J, V17, P5832, DOI 10.1093/emboj/17.19.5832; Fasman G.D., 1996, CIRCULAR DICHROISM C; Garnier J, 1996, METHOD ENZYMOL, V266, P540; Goldgur Y, 1999, P NATL ACAD SCI USA, V96, P13040, DOI 10.1073/pnas.96.23.13040; Goldgur Y, 1998, P NATL ACAD SCI USA, V95, P9150, DOI 10.1073/pnas.95.16.9150; Greenwald J, 1999, BIOCHEMISTRY-US, V38, P8892, DOI 10.1021/bi9907173; GRIESINGER C, 1988, J AM CHEM SOC, V110, P7870, DOI 10.1021/ja00231a044; Hansen MST, 1998, GENET ENG P, V20, P41; Hazuda DJ, 2000, SCIENCE, V287, P646, DOI 10.1126/science.287.5453.646; Heuer TS, 1998, BIOCHEMISTRY-US, V37, P6667, DOI 10.1021/bi972949c; Heuer TS, 1997, BIOCHEMISTRY-US, V36, P10655, DOI 10.1021/bi970782h; HEYDUK T, 1990, P NATL ACAD SCI USA, V87, P1744, DOI 10.1073/pnas.87.5.1744; Hill JJ, 1997, METHOD ENZYMOL, V278, P390; Hindmarsh P, 1999, MICROBIOL MOL BIOL R, V63, P836, DOI 10.1128/MMBR.63.4.836-843.1999; Jamin N, 1996, INT J QUANTUM CHEM, V59, P333, DOI 10.1002/(SICI)1097-461X(1996)59:4<333::AID-QUA7>3.0.CO;2-Z; Jenkins TM, 1996, J BIOL CHEM, V271, P7712, DOI 10.1074/jbc.271.13.7712; Jenkins TM, 1997, EMBO J, V16, P6849, DOI 10.1093/emboj/16.22.6849; KATZ RA, 1990, CELL, V63, P87, DOI 10.1016/0092-8674(90)90290-U; Katzman M, 1996, J VIROL, V70, P9069, DOI 10.1128/JVI.70.12.9069-9073.1996; KATZMAN M, 1989, J VIROL, V63, P5319, DOI 10.1128/JVI.63.12.5319-5327.1989; Katzman M, 1999, ADV VIRUS RES, V52, P371, DOI 10.1016/S0065-3527(08)60307-3; Krebs D, 1998, EUR J BIOCHEM, V253, P236, DOI 10.1046/j.1432-1327.1998.2530236.x; KUMAR A, 1981, BIOCHEM BIOPH RES CO, V95, P1; LAFEMINA RL, 1991, J VIROL, V65, P5624, DOI 10.1128/JVI.65.10.5624-5630.1991; LETILLY V, 1993, BIOCHEMISTRY-US, V32, P7753, DOI 10.1021/bi00081a021; LODI PJ, 1995, BIOCHEMISTRY-US, V34, P9826, DOI 10.1021/bi00031a002; Maignan S, 1998, J MOL BIOL, V282, P359, DOI 10.1006/jmbi.1998.2002; Maroun RG, 1999, EUR J BIOCHEM, V260, P145, DOI 10.1046/j.1432-1327.1999.00130.x; Maroun RG, 1999, J BIOL CHEM, V274, P34174, DOI 10.1074/jbc.274.48.34174; Munoz V, 1997, BIOPOLYMERS, V41, P495, DOI 10.1002/(SICI)1097-0282(19970415)41:5<495::AID-BIP2>3.3.CO;2-6; Nabel GJ, 2001, NATURE, V410, P1002, DOI 10.1038/35073500; Piot P, 2001, NATURE, V410, P968, DOI 10.1038/35073639; PIOTTO M, 1992, J BIOMOL NMR, V2, P661, DOI 10.1007/BF02192855; Pommier Y, 2000, ANTIVIR RES, V47, P139, DOI 10.1016/S0166-3542(00)00112-1; Pommier Y, 1997, ANTIVIR CHEM CHEMOTH, V8, P463, DOI 10.1177/095632029700800601; Pommier Y, 1999, ADV VIRUS RES, V52, P427, DOI 10.1016/S0065-3527(08)60310-3; Richman DD, 2001, NATURE, V410, P995, DOI 10.1038/35073673; SHERMAN PA, 1990, P NATL ACAD SCI USA, V87, P5119, DOI 10.1073/pnas.87.13.5119; SHERMAN PA, 1992, J VIROL, V66, P3593, DOI 10.1128/JVI.66.6.3593-3601.1992; Sourgen F, 1996, EUR J BIOCHEM, V240, P765, DOI 10.1111/j.1432-1033.1996.0765h.x; VANGENT DC, 1993, EMBO J, V12, P3261, DOI 10.1002/j.1460-2075.1993.tb05995.x; VINK C, 1991, J VIROL, V65, P4636, DOI 10.1128/JVI.65.9.4636-4644.1991; Wang JY, 2001, EMBO J, V20, P7333, DOI 10.1093/emboj/20.24.7333; Weiss RA, 2001, NATURE, V410, P963, DOI 10.1038/35073632; WISHART DS, 1995, J BIOMOL NMR, V6, P135, DOI 10.1007/BF00211777; Wuthrich K, 1986, NMR PROTEIN NUCL ACI; Yang ZN, 2000, J MOL BIOL, V296, P535, DOI 10.1006/jmbi.1999.3463; ZHONG LX, 1992, P NATL ACAD SCI USA, V89, P4462, DOI 10.1073/pnas.89.10.4462	71	17	17	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 30	2003	278	22					19966	19973		10.1074/jbc.M211711200	http://dx.doi.org/10.1074/jbc.M211711200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	682EH	12626494	hybrid			2022-12-25	WOS:000183078000052
J	Habermeier, A; Wolf, S; Martine, U; Graf, P; Closs, EI				Habermeier, A; Wolf, S; Martine, U; Graf, P; Closs, EI			Two amino acid residues determine the low substrate affinity of human cationic amino acid transporter-2A	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ECOTROPIC MURINE RETROVIRUSES; CELL-SURFACE RECEPTOR; MEMBRANE; FAMILY; IDENTIFICATION; EXPRESSION; MEMBER	Mammalian cationic amino acid transporters ( CAT) differ in their substrate affinity and sensitivity to trans-stimulation. The apparent K-m values for cationic amino acids and the sensitivity to trans-stimulation of CAT-1, -2B, and -3 are characteristic of system y(+). In contrast, CAT-2A exhibits a 10-fold lower substrate affinity and is largely independent of substrate at the trans-side of the membrane. CAT-2A and -2B demonstrate such divergent transport properties, even though their amino acid sequences differ only in a stretch of 42 amino acids. Here, we identify two amino acid residues within this 42-amino acid domain of the human CAT-2A protein that are responsible for the apparent low affinity of both the extracellular and intracellular substrate-binding sites. These residues are located in the fourth intracellular loop, suggesting that they are not part of the translocation pathway. Rather, they may be responsible for the low affinity conformation of the substrate-binding sites. The sensitivity to trans-stimulation is not determined by the same amino acid residues as the substrate affinity and must involve a more complex interaction between individual amino acid residues. In addition to the 42-amino acid domain, the adjacent transmembrane domain X seems to be involved in this function.	Johannes Gutenberg Univ Mainz, Dept Pharmacol, D-55101 Mainz, Germany	Johannes Gutenberg University of Mainz	Closs, EI (corresponding author), Johannes Gutenberg Univ Mainz, Dept Pharmacol, Obere Zahlbacher Str 67, D-55101 Mainz, Germany.	Closs@mail.uni-mainz.de	Closs, Ellen/ABD-5217-2020	Closs, Ellen/0000-0002-9505-2289				Closs E, 2000, NITRIC OXIDE BIOL PA, P225; CLOSS EI, 1993, J BIOL CHEM, V268, P20796; CLOSS EI, 1993, J BIOL CHEM, V268, P7538; Closs EI, 1997, BIOCHEMISTRY-US, V36, P6462, DOI 10.1021/bi962829p; CLOSS EI, 1999, MEMBRANE TRANSPORTER, P229; Deves R, 1998, PHYSIOL REV, V78, P487, DOI 10.1152/physrev.1998.78.2.487; Ito K, 1997, J BIOL CHEM, V272, P26780, DOI 10.1074/jbc.272.42.26780; Kakuda DK, 1993, TRANSGENE, V1, P91; KAVANAUGH MP, 1994, J BIOL CHEM, V269, P15445; KIM JW, 1991, NATURE, V352, P725, DOI 10.1038/352725a0; KOERNER TJ, 1991, METHOD ENZYMOL, V194, P477; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; Simons P C, 1981, Methods Enzymol, V77, P235; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; VONHEIJNE G, 1992, J MOL BIOL, V225, P487, DOI 10.1016/0022-2836(92)90934-C; WANG H, 1991, NATURE, V352, P729, DOI 10.1038/352729a0; WANG H, 1994, VIROLOGY, V202, P1058, DOI 10.1006/viro.1994.1439; Wolf S, 2002, BIOCHEM J, V364, P767, DOI 10.1042/BJ20020084	18	20	20	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 23	2003	278	21					19492	19499		10.1074/jbc.M210254200	http://dx.doi.org/10.1074/jbc.M210254200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	679PY	12637504	hybrid			2022-12-25	WOS:000182932200099
J	Coeytaux, E; Coulaud, D; Le Cam, E; Danos, O; Kichler, A				Coeytaux, E; Coulaud, D; Le Cam, E; Danos, O; Kichler, A			The cationic amphipathic alpha-helix of HIV-1 viral protein R (Vpr) binds to nucleic acids, permeabilizes membranes, and efficiently transfects cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; C-TERMINAL DOMAIN; GENE-TRANSFER; NMR STRUCTURE; DNA; CYCLE; CHOLESTEROL; INFECTION; MECHANISM; PEPTIDES	Viral protein R (Vpr) is a small protein of 96 amino acids that is conserved among the lentiviruses human immunodeficiency virus type 1 (HIV-1), HIV-2, and simian immunodeficiency virus. We recently sought to determine whether the karyophilic properties of Vpr, as well as its ability to bind nucleic acids, could be used to deliver DNA into cells. We have found that the C-terminal domain of Vpr-(52-96) is able to efficiently transfect various cell lines. Here, we show that the shortest active sequence for gene transfer corresponds to the domain that adopts a alpha-helix conformation. DNA binding studies and permeabilization assays performed on cells demonstrated that the peptides that are efficient in transfection condense plasmid DNA and are membranolytic. Electron microscopy studies and transfection experiments performed in the presence of inhibitors of the endocytic processes indicated that the major entry pathway of Vpr- DNA complexes is through endocytosis. Taken together, the results show that the cationic C-terminal alpha-helix of Vpr has DNA-condensing as well as membrane-destabilizing capabilities, both properties that are indispensable for efficient DNA transfection.	Genethon, CNRS, Unite Mixte Rech 8115, F-91002 Evry, France; Inst Gustave Roussy, CNRS, UMR 8126, F-94805 Villejuif, France	Centre National de la Recherche Scientifique (CNRS); Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Universite Paris Saclay; UNICANCER; Gustave Roussy	Kichler, A (corresponding author), Genethon, CNRS, Unite Mixte Rech 8115, 1 Bis Rue Int,BP 60, F-91002 Evry, France.	akich@genethon.fr		Kichler, Antoine/0000-0003-0593-2424; Le cam, Eric/0000-0002-6832-6117				Bartz SR, 1996, J VIROL, V70, P2324, DOI 10.1128/JVI.70.4.2324-2331.1996; BLONDELLE SE, 1991, BIOCHEMISTRY-US, V30, P4671, DOI 10.1021/bi00233a006; BOUSSIF O, 1995, P NATL ACAD SCI USA, V92, P7297, DOI 10.1073/pnas.92.16.7297; Bouyac-Bertoia M, 2001, MOL CELL, V7, P1025, DOI 10.1016/S1097-2765(01)00240-4; Brunner S, 2000, GENE THER, V7, P401, DOI 10.1038/sj.gt.3301102; BUKRINSKY MI, 1993, NATURE, V365, P666, DOI 10.1038/365666a0; COHEN EA, 1990, J ACQ IMMUN DEF SYND, V3, P11; Colin M, 2000, GENE THER, V7, P139, DOI 10.1038/sj.gt.3301056; CONNOR RI, 1995, VIROLOGY, V206, P935, DOI 10.1006/viro.1995.1016; de Noronha CMC, 2001, SCIENCE, V294, P1105, DOI 10.1126/science.1063957; de Rocquigny H, 2000, EUR J BIOCHEM, V267, P3654, DOI 10.1046/j.1432-1327.2000.01397.x; Eckstein DA, 2001, J EXP MED, V194, P1407, DOI 10.1084/jem.194.10.1407; Fouchier RAM, 1998, J VIROL, V72, P6004, DOI 10.1128/JVI.72.7.6004-6013.1998; Fujimoto T, 2000, J CELL SCI, V113, P3509; Goh WC, 1998, NAT MED, V4, P65, DOI 10.1038/nm0198-065; Henklein P, 2000, J BIOL CHEM, V275, P32016, DOI 10.1074/jbc.M004044200; Jacotot E, 2000, J EXP MED, V191, P33, DOI 10.1084/jem.191.1.33; Jenkins Y, 2001, J VIROL, V75, P10537, DOI 10.1128/JVI.75.21.10537-10542.2001; Jenkins Y, 1998, J CELL BIOL, V143, P875, DOI 10.1083/jcb.143.4.875; Kichler A, 2000, J VIROL, V74, P5424, DOI 10.1128/JVI.74.12.5424-5431.2000; Kino T, 1999, J EXP MED, V189, P51, DOI 10.1084/jem.189.1.51; Macreadie IG, 1996, MOL MICROBIOL, V19, P1185, DOI 10.1111/j.1365-2958.1996.tb02464.x; Matsui H, 1997, J BIOL CHEM, V272, P1117, DOI 10.1074/jbc.272.2.1117; Nemerow GR, 2000, VIROLOGY, V274, P1, DOI 10.1006/viro.2000.0468; Nicol F, 1996, BIOPHYS J, V71, P3288, DOI 10.1016/S0006-3495(96)79521-8; Nie ZL, 1998, J VIROL, V72, P4104, DOI 10.1128/JVI.72.5.4104-4115.1998; Niidome T, 1997, J BIOL CHEM, V272, P15307, DOI 10.1074/jbc.272.24.15307; OHTANI Y, 1989, EUR J BIOCHEM, V186, P17, DOI 10.1111/j.1432-1033.1989.tb15171.x; PAXTON W, 1993, J VIROL, V67, P7229, DOI 10.1128/JVI.67.12.7229-7237.1993; Piller SC, 1999, J VIROL, V73, P4230, DOI 10.1128/JVI.73.5.4230-4238.1999; PLANK C, 1994, J BIOL CHEM, V269, P12918; Popov S, 1998, EMBO J, V17, P909, DOI 10.1093/emboj/17.4.909; Rittner K, 2002, MOL THER, V5, P104, DOI 10.1006/mthe.2002.0523; Rodal SK, 1999, MOL BIOL CELL, V10, P961, DOI 10.1091/mbc.10.4.961; Schuler W, 1999, J MOL BIOL, V285, P2105, DOI 10.1006/jmbi.1998.2381; Stewart SA, 1997, J VIROL, V71, P5579, DOI 10.1128/JVI.71.7.5579-5592.1997; SWANSON JA, 1995, TRENDS CELL BIOL, V5, P424, DOI 10.1016/S0962-8924(00)89101-1; Vodicka MA, 1998, GENE DEV, V12, P175, DOI 10.1101/gad.12.2.175; Wecker K, 1999, EUR J BIOCHEM, V266, P359, DOI 10.1046/j.1432-1327.1999.00858.x; Wecker K, 2002, EUR J BIOCHEM, V269, P3779, DOI 10.1046/j.1432-1033.2002.03067.x; Wyman TB, 1997, BIOCHEMISTRY-US, V36, P3008, DOI 10.1021/bi9618474; ZABNER J, 1995, J BIOL CHEM, V270, P18997, DOI 10.1074/jbc.270.32.18997; Zauner W, 1998, ADV DRUG DELIVER REV, V30, P97, DOI 10.1016/S0169-409X(97)00110-5; Zennou V, 2000, CELL, V101, P173, DOI 10.1016/S0092-8674(00)80828-4; Zhang SG, 1998, GENE, V212, P157, DOI 10.1016/S0378-1119(98)00178-4; ZHOU XH, 1994, BBA-BIOMEMBRANES, V1189, P195, DOI 10.1016/0005-2736(94)90066-3; Zuhorn IS, 2002, J BIOL CHEM, V277, P18021, DOI 10.1074/jbc.M111257200	47	51	61	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 16	2003	278	20					18110	18116		10.1074/jbc.M300248200	http://dx.doi.org/10.1074/jbc.M300248200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677YX	12639957	hybrid			2022-12-25	WOS:000182838300068
J	Le Page, F; Schreiber, V; Dherin, C; de Murcia, G; Boiteux, S				Le Page, F; Schreiber, V; Dherin, C; de Murcia, G; Boiteux, S			Poly(ADP-ribose) polymerase-1 (PARP-1) is required in murine cell lines for base excision repair of oxidative DNA damage in the absence of DNA polymerase beta	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION-COUPLED REPAIR; PURIFIED HUMAN PROTEINS; OGG1 GENE; SACCHAROMYCES-CEREVISIAE; LIGASE III; AP LYASE; ESCHERICHIA-COLI; HUMAN HOMOLOG; ABASIC SITE; GLYCOSYLASE	Oxidative DNA base damage is mainly corrected by the base excision repair (BER) pathway, which can be divided into two subpathways depending on the length of the resynthetized patch, either one nucleotide for short patch BER or several nucleotides for long patch BER. The role of proteins in the course of BER processes has been investigated in vitro using purified enzymes and cell-free extracts. In this study, we have investigated the repair of 8-oxo-7,8-dihydroguanine (8-oxoG) in vivo using wild-type, polymerase beta(-/-) (Polbeta(-/-)), poly(ADP-ribose) polymerase-1(-/-) (PARP-1(-/-)), and Polbeta(-/-)PARP-1(-/-) 3T3 cell lines. We used non replicating plasmids containing a 8-oxoG:C base pair to study the repair of the lesion located in a transcribed sequence (TS) or in a non-transcribed sequence (NTS). The results show that 8-oxoG repair in TS is not significantly impaired in cells deficient in Polbeta or PARP-1 or both. Whereas 8-oxoG repair in NTS is normal in Polbeta-null cells, it is delayed in PARP-1-null cells and greatly impaired in cells deficient in both Polbeta and PARP-1. The removal of 8-oxoG and presumably the cleavage at the resulting apurinic/apyrimidinic site are not affected in the PARP-1(-/-)Polbeta(-/-) cell lines. However, 8-oxoG repair is incomplete, yielding plasmid molecules with a nick at the site of the lesion. Therefore, PARP-1(-/-)Polbeta(-/-) cell lines cannot perform 5'-dRP removal and/or DNA repair synthesis. Furthermore, the poly(ADP-ribosyl) ation activity of PARP-1 is essential for 8-oxoG repair in a Polbeta(-/-) context, because expression of the catalytically inactive PARP-1 (E988K) mutant does not restore 8-oxoG repair, whereas an wild type PARP-1 does.	CEA Radiobiol Mol & Cellulaire, CNRS,UMR 217, Dept Radiobiol & Radiopathol, Direct Sci Vivant, F-92265 Fontenay Aux Roses, France; Univ Strasbourg 1, Ecole Super Biotechnol Strasbourg, CNRS, Unite Propre Rech 9003, F-67400 Illkirch Graffenstaden, France	CEA; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Le Page, F (corresponding author), CEA Radiobiol Mol & Cellulaire, CNRS,UMR 217, Dept Radiobiol & Radiopathol, Direct Sci Vivant, F-92265 Fontenay Aux Roses, France.	lepage@dsvidf.cea.fr	Schreiber, Valérie/M-5007-2016	Schreiber, Valérie/0000-0003-0507-639X				Aburatani H, 1997, CANCER RES, V57, P2151; Allinson SL, 2001, EMBO J, V20, P6919, DOI 10.1093/emboj/20.23.6919; Arai K, 1997, ONCOGENE, V14, P2857, DOI 10.1038/sj.onc.1201139; Beckman KB, 1997, J BIOL CHEM, V272, P19633, DOI 10.1074/jbc.272.32.19633; Beneke R, 2000, MOL CELL BIOL, V20, P6695, DOI 10.1128/MCB.20.18.6695-6703.2000; Bjoras M, 1997, EMBO J, V16, P6314, DOI 10.1093/emboj/16.20.6314; Boiteux S, 2000, ARCH BIOCHEM BIOPHYS, V377, P1, DOI 10.1006/abbi.2000.1773; BOITEUX S, 1990, J BIOL CHEM, V265, P3916; Burkle A, 2001, BIOESSAYS, V23, P795, DOI 10.1002/bies.1115; Caldecott KW, 1996, NUCLEIC ACIDS RES, V24, P4387, DOI 10.1093/nar/24.22.4387; Caldecott KW, 1995, NUCLEIC ACIDS RES, V23, P4836, DOI 10.1093/nar/23.23.4836; Cappelli E, 1997, J BIOL CHEM, V272, P23970, DOI 10.1074/jbc.272.38.23970; Dantzer F, 2000, BIOCHEMISTRY-US, V39, P7559, DOI 10.1021/bi0003442; deMurcia JM, 1997, P NATL ACAD SCI USA, V94, P7303, DOI 10.1073/pnas.94.14.7303; Dianov G, 1998, J BIOL CHEM, V273, P33811, DOI 10.1074/jbc.273.50.33811; Dianov GL, 1999, J BIOL CHEM, V274, P13741, DOI 10.1074/jbc.274.20.13741; Dogliotti E, 2001, PROG NUCLEIC ACID RE, V68, P3; DUWAT P, 1995, MICROBIOL-UK, V141, P411, DOI 10.1099/13500872-141-2-411; FEIG DI, 1994, CANCER RES, V54, pS1890; Fernet M, 2000, INT J RADIAT BIOL, V76, P1621, DOI 10.1080/09553000050201118; Fortini P, 2000, NUCLEIC ACIDS RES, V28, P3040, DOI 10.1093/nar/28.16.3040; Fortini P, 1998, BIOCHEMISTRY-US, V37, P3575, DOI 10.1021/bi972999h; FREIDBERG EC, 1995, DNA REPAIR MUTAGENES; Gary R, 1999, J BIOL CHEM, V274, P4354, DOI 10.1074/jbc.274.7.4354; Gentil A, 1997, BIOL CHEM, V378, P1287; Girard PM, 1997, NUCLEIC ACIDS RES, V25, P3204, DOI 10.1093/nar/25.16.3204; GU H, 1994, SCIENCE, V265, P103, DOI 10.1126/science.8016642; Herceg Z, 2001, MUTAT RES-FUND MOL M, V477, P97, DOI 10.1016/S0027-5107(01)00111-7; Horton JK, 2000, J BIOL CHEM, V275, P2211, DOI 10.1074/jbc.275.3.2211; Kim K, 1998, J BIOL CHEM, V273, P8842, DOI 10.1074/jbc.273.15.8842; Klungland A, 1997, EMBO J, V16, P3341, DOI 10.1093/emboj/16.11.3341; Kubota Y, 1996, EMBO J, V15, P6662, DOI 10.1002/j.1460-2075.1996.tb01056.x; KUPPER JH, 1995, MOL CELL BIOL, V15, P3154; Lavrik OI, 2001, J BIOL CHEM, V276, P25541, DOI 10.1074/jbc.M102125200; Le Page F, 2000, P NATL ACAD SCI USA, V97, P8397, DOI 10.1073/pnas.140137297; Le Page F, 2000, CANCER RES, V60, P5548; Le Page F, 2000, CELL, V101, P159, DOI 10.1016/S0092-8674(00)80827-2; Le Page F, 2002, METHOD ENZYMOL, V353, P536; Le Page F, 1998, NUCLEIC ACIDS RES, V26, P1276, DOI 10.1093/nar/26.5.1276; Lindahl T, 1999, SCIENCE, V286, P1897, DOI 10.1126/science.286.5446.1897; LINDAHL T, 1982, ANNU REV BIOCHEM, V51, P61, DOI 10.1146/annurev.bi.51.070182.000425; Lu RZ, 1997, CURR BIOL, V7, P397, DOI 10.1016/S0960-9822(06)00187-4; Masson M, 1998, MOL CELL BIOL, V18, P3563, DOI 10.1128/MCB.18.6.3563; Masutani M, 2000, MUTAT RES-REV MUTAT, V462, P159, DOI 10.1016/S1383-5742(00)00033-8; MATSUMOTO Y, 1995, SCIENCE, V269, P699, DOI 10.1126/science.7624801; MATSUMOTO Y, 1991, MOL CELL BIOL, V11, P4441, DOI 10.1128/MCB.11.9.4441; MATSUMOTO Y, 1994, MOL CELL BIOL, V14, P6187, DOI 10.1128/MCB.14.9.6187; MENCK CFM, 1989, MUTAT RES, V220, P101, DOI 10.1016/0165-1110(89)90015-8; MICHAELS ML, 1992, J BACTERIOL, V174, P6321, DOI 10.1128/JB.174.20.6321-6325.1992; Mitra S, 2001, ENVIRON MOL MUTAGEN, V38, P180, DOI 10.1002/em.1070; Nash HM, 1996, CURR BIOL, V6, P968, DOI 10.1016/S0960-9822(02)00641-3; Nicholl ID, 1997, BIOCHEMISTRY-US, V36, P7557, DOI 10.1021/bi962950w; Nishimura S, 2002, FREE RADICAL BIO MED, V32, P813, DOI 10.1016/S0891-5849(02)00778-5; Osterod M, 2002, ONCOGENE, V21, P8232, DOI 10.1038/sj.onc.1206027; Pascucci B, 1999, J BIOL CHEM, V274, P33696, DOI 10.1074/jbc.274.47.33696; Podlutsky AJ, 2001, EMBO J, V20, P1477, DOI 10.1093/emboj/20.6.1477; Prasad R, 2001, J BIOL CHEM, V276, P32411, DOI 10.1074/jbc.C100292200; Prasad R, 2000, J BIOL CHEM, V275, P4460, DOI 10.1074/jbc.275.6.4460; Radicella JP, 1997, P NATL ACAD SCI USA, V94, P8010, DOI 10.1073/pnas.94.15.8010; RoldanArjona T, 1997, P NATL ACAD SCI USA, V94, P8016, DOI 10.1073/pnas.94.15.8016; Rolli V, 1997, BIOCHEMISTRY-US, V36, P12147, DOI 10.1021/bi971055p; Rosenquist TA, 1997, P NATL ACAD SCI USA, V94, P7429, DOI 10.1073/pnas.94.14.7429; Sanderson RJ, 2002, DNA REPAIR, V1, P547, DOI 10.1016/S1568-7864(02)00054-X; SCHREIBER V, 1992, EMBO J, V11, P3263, DOI 10.1002/j.1460-2075.1992.tb05404.x; Schreiber V, 2002, J BIOL CHEM, V277, P23028, DOI 10.1074/jbc.M202390200; Shall S, 2000, MUTAT RES-DNA REPAIR, V460, P1, DOI 10.1016/S0921-8777(00)00016-1; Shinmura K, 1997, MUTAT RES-DNA REPAIR, V385, P75, DOI 10.1016/S0921-8777(97)00041-4; Sobol RW, 2000, NATURE, V405, P807, DOI 10.1038/35015598; Sobol RW, 1996, NATURE, V379, P183, DOI 10.1038/379183a0; STARY A, 1992, J GEN VIROL, V73, P1679, DOI 10.1099/0022-1317-73-7-1679; Stucki M, 1998, ONCOGENE, V17, P835, DOI 10.1038/sj.onc.1202001; Sugo N, 2000, EMBO J, V19, P1397, DOI 10.1093/emboj/19.6.1397; TAJIRI T, 1995, MUTAT RES-DNA REPAIR, V336, P257, DOI 10.1016/0921-8777(94)00062-B; Thomas D, 1997, MOL GEN GENET, V254, P171, DOI 10.1007/s004380050405; Trucco C, 1998, NUCLEIC ACIDS RES, V26, P2644, DOI 10.1093/nar/26.11.2644; Tulin A, 2002, GENE DEV, V16, P2108, DOI 10.1101/gad.1003902; vanderKemp PA, 1996, P NATL ACAD SCI USA, V93, P5197, DOI 10.1073/pnas.93.11.5197; Vidal AE, 2001, NUCLEIC ACIDS RES, V29, P1285, DOI 10.1093/nar/29.6.1285; Vodenicharov MD, 2000, NUCLEIC ACIDS RES, V28, P3887, DOI 10.1093/nar/28.20.3887; Wang ZQ, 1997, GENE DEV, V11, P2347, DOI 10.1101/gad.11.18.2347; WIEBAUER K, 1990, P NATL ACAD SCI USA, V87, P5842, DOI 10.1073/pnas.87.15.5842; WISEMAN H, 1995, CANCER LETT, V93, P113, DOI 10.1016/0304-3835(95)03792-U; Yung TMC, 2001, J BIOL CHEM, V276, P11279, DOI 10.1074/jbc.M008044200; Ziegler M, 2001, BIOESSAYS, V23, P543, DOI 10.1002/bies.1074	84	60	60	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 16	2003	278	20					18471	18477		10.1074/jbc.M212905200	http://dx.doi.org/10.1074/jbc.M212905200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677YX	12637553	hybrid			2022-12-25	WOS:000182838300115
J	McDonald, C; Vacratsis, PO; Bliska, JB; Dixon, JE				McDonald, C; Vacratsis, PO; Bliska, JB; Dixon, JE			The Yersinia virulence factor YopM forms a novel protein complex with two cellular kinases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-RELATED KINASE-2; LEUCINE-RICH REPEAT; SIGNAL-TRANSDUCTION; POTENTIAL EFFECTOR; DOWN-REGULATION; MAP KINASES; PESTIS YOPM; HELA-CELLS; S6 KINASE; IDENTIFICATION	Pathogenic Yersinia contain a virulence plasmid that encodes genes for intracellular effectors, which neutralize the host immune response. One effector, YopM, is necessary for Yersinia virulence, but its function in host cells is unknown. To identify potential cellular pathways affected by YopM, proteins that co-immunoprecipitate with YopM in mammalian cells were isolated and identified by mass spectrometry. Results demonstrate that two kinases, protein kinase C-like 2 (PRK2) and ribosomal S6 protein kinase 1 (RSK1), interact directly with YopM. These two kinases associate only when YopM is present, and expression of YopM in cells stimulates the activity of both kinases. RSK1 is activated directly by interaction with YopM, and RSK1 kinase activity is required for YopM-stimulated PRK2 activity. YopM activation of RSK1 occurs independently of the actions of YopJ on the MAPK pathway. YopM is also required for Yersinia-induced changes in RSK1 mobility in infected macrophage cells. These results identify the first intracellular targets of YopM and suggest YopM acts to stimulate the activity of PRK2 and RSK1.	Univ Michigan, Sch Med, Dept Biol Chem, Inst Life Sci, Ann Arbor, MI 48109 USA; SUNY Stony Brook, Ctr Infect Dis, Dept Mol Genet & Microbiol, Stony Brook, NY 11794 USA	University of Michigan System; University of Michigan; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	Dixon, JE (corresponding author), Univ Michigan, Sch Med, Dept Biol Chem, Inst Life Sci, Ann Arbor, MI 48109 USA.			McDonald, Christine/0000-0002-6745-9487	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI043389, F32AI054053] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK018024, R01DK018849] Funding Source: NIH RePORTER; NIAID NIH HHS [R01 AI43389, F32 AI054053-02, F32 AI054053] Funding Source: Medline; NIDDK NIH HHS [R37 DK18024, R01 DK18849] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Bauman AL, 2002, NAT CELL BIOL, V4, pE203, DOI 10.1038/ncb0802-e203; BLENIS J, 1993, P NATL ACAD SCI USA, V90, P5889, DOI 10.1073/pnas.90.13.5889; Boland A, 1996, EMBO J, V15, P5191, DOI 10.1002/j.1460-2075.1996.tb00904.x; Boland A, 1998, MICROB PATHOGENESIS, V25, P343, DOI 10.1006/mpat.1998.0247; Bottone EJ, 1997, CLIN MICROBIOL REV, V10, P257, DOI 10.1128/CMR.10.2.257; Braverman LE, 1999, J BIOL CHEM, V274, P5542, DOI 10.1074/jbc.274.9.5542; Cornelis GR, 1998, MICROBIOL MOL BIOL R, V62, P1315, DOI 10.1128/MMBR.62.4.1315-1352.1998; Cryns VL, 1997, J BIOL CHEM, V272, P29449, DOI 10.1074/jbc.272.47.29449; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Evdokimov AG, 2001, J MOL BIOL, V312, P807, DOI 10.1006/jmbi.2001.4973; Frodin M, 1999, MOL CELL ENDOCRINOL, V151, P65, DOI 10.1016/S0303-7207(99)00061-1; FURSTE JP, 1986, GENE, V48, P119, DOI 10.1016/0378-1119(86)90358-6; GROVE JR, 1993, BIOCHEMISTRY-US, V32, P7727, DOI 10.1021/bi00081a018; Juris SJ, 2002, CELL MICROBIOL, V4, P201, DOI 10.1046/j.1462-5822.2002.00182.x; Kobe B, 2001, CURR OPIN STRUC BIOL, V11, P725, DOI 10.1016/S0959-440X(01)00266-4; Koh H, 2000, J BIOL CHEM, V275, P34451, DOI 10.1074/jbc.M001753200; Lee SJ, 2000, DEV BIOL, V228, P166, DOI 10.1006/dbio.2000.9943; Lee VT, 1998, MOL MICROBIOL, V28, P593, DOI 10.1046/j.1365-2958.1998.00822.x; LEUNG KY, 1990, INFECT IMMUN, V58, P3262, DOI 10.1128/IAI.58.10.3262-3271.1990; Levchenko A, 2000, P NATL ACAD SCI USA, V97, P5818, DOI 10.1073/pnas.97.11.5818; MULDER B, 1989, INFECT IMMUN, V57, P2534, DOI 10.1128/IAI.57.8.2534-2541.1989; Orth K, 1999, SCIENCE, V285, P1920, DOI 10.1126/science.285.5435.1920; Palmer LE, 1998, MOL MICROBIOL, V27, P953, DOI 10.1046/j.1365-2958.1998.00740.x; Palmer LE, 1999, INFECT IMMUN, V67, P708, DOI 10.1128/IAI.67.2.708-716.1999; PALMER RH, 1995, EUR J BIOCHEM, V227, P344, DOI 10.1111/j.1432-1033.1995.tb20395.x; PALMER RH, 1994, FEBS LETT, V356, P5, DOI 10.1016/0014-5793(94)01202-4; Perry RD, 1997, CLIN MICROBIOL REV, V10, P35, DOI 10.1128/CMR.10.1.35; Quilliam LA, 1996, J BIOL CHEM, V271, P28772, DOI 10.1074/jbc.271.46.28772; REISNER BS, 1992, INFECT IMMUN, V60, P5242, DOI 10.1128/IAI.60.12.5242-5252.1992; Richards SA, 1999, CURR BIOL, V9, P810, DOI 10.1016/S0960-9822(99)80364-9; Sauvonnet N, 2002, J BIOL CHEM, V277, P25133, DOI 10.1074/jbc.M203239200; Schaeffer HJ, 1999, MOL CELL BIOL, V19, P2435; Shimamura A, 2000, CURR BIOL, V10, P127, DOI 10.1016/S0960-9822(00)00310-9; Skrzypek E, 2003, INFECT IMMUN, V71, P937, DOI 10.1128/IAI.71.2.937-947.2003; Skrzypek E, 1998, MOL MICROBIOL, V30, P1051, DOI 10.1046/j.1365-2958.1998.01135.x; Sun WY, 2000, J BIOL CHEM, V275, P24421, DOI 10.1074/jbc.M003148200; Vacratsis PO, 2002, BIOCHEMISTRY-US, V41, P5613, DOI 10.1021/bi016075c; Vincent S, 1997, MOL CELL BIOL, V17, P2247, DOI 10.1128/MCB.17.4.2247; Yu WP, 1997, J BIOL CHEM, V272, P10030; Zhang WZ, 2000, ANAL CHEM, V72, P2482, DOI 10.1021/ac991363o; Zong H, 1999, J BIOL CHEM, V274, P4551, DOI 10.1074/jbc.274.8.4551	41	122	129	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 16	2003	278	20					18514	18523		10.1074/jbc.M301226200	http://dx.doi.org/10.1074/jbc.M301226200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677YX	12626518	hybrid			2022-12-25	WOS:000182838300121
J	Kang, KW; Choi, SY; Cho, MK; Lee, CH; Kim, SG				Kang, KW; Choi, SY; Cho, MK; Lee, CH; Kim, SG			Thrombin induces nitric-oxide synthase via G alpha(12/13)-coupled protein kinase C-dependent I-kappa B alpha phosphorylation and JNK-mediated I-kappa B alpha degradation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOTOXIN-INDUCED HYPOTENSION; SEVERE SEPSIS; SEPTIC SHOCK; COAGULATION INHIBITORS; MURINE MACROPHAGES; SIGNALING PATHWAYS; ACTIVATION; RECEPTOR; CELLS; INFLAMMATION	An imbalance between thrombin and antithrombin III contributed to vascular hyporeactivity in sepsis, which can be attributed to excess NO production by inducible nitric-oxide synthase (iNOS). In view of the importance of the thrombin-activated coagulation pathway and excess NO as the culminating factors in vascular hyporeactivity, this study investigated the effects of thrombin on the induction of iNOS and NO production in macrophages. Thrombin induced iNOS protein in the Raw264.7 cells, which was inhibited by a thrombin inhibitor, LB30057. Thrombin increased NF-kappaB DNA binding, whose band was supershifted with anti-p65 and anti-p50 antibodies. Thrombin elicited the phosphorylation and degradation of I-kappaBalpha prior to the nuclear translocation of p65. The NF-kappaB-mediated iNOS induction was stimulated by the overexpression of activated mutants of Galpha(12/13) (Galpha(12/13)QL). Protein kinase C depletion inhibited I-kappaBalpha degradation, NF-kappaB activation, and iNOS induction by thrombin or the iNOS induction by Galpha(12/13)QL. JNK, p38 kinase, and ERK were all activated by thrombin. JNK inhibition by the stable transfection with a dominant negative mutant of JNK1 (JNK1(-)) completely suppressed the NF-kappaB-mediated iNOS induction by thrombin. Conversely, the inhibition of p38 kinase enhanced the expression of iNOS. In addition, JNK and p38 kinase oppositely controlled the NF-kappaB-mediated iNOS induction by Galpha(12/13)QL. Hence, iNOS induction by thrombin was regulated by the opposed functions of JNK and p38 kinase downstream of Galpha(12/13). In the JNK1(-) cells, thrombin did not increase either the NF-kappaB binding activity or I-kappaBalpha degradation despite I-kappaBalpha phosphorylation. These results demonstrated that thrombin induces iNOS in macrophages via Galpha(12) and Galpha(13), which leads to NF-kappaB activation involving the protein kinase C-dependent phosphorylation of I-kappaBalpha and the JNK-dependent degradation of phosphorylated I-kappaBalpha.	Seoul Natl Univ, Coll Pharm, Natl Res Lab, Seoul 151742, South Korea; Seoul Natl Univ, Pharmaceut Sci Res Inst, Seoul 151742, South Korea; Hanyang Univ, Coll Med, Inst Biomed Sci, Seoul 133791, South Korea	Seoul National University (SNU); Seoul National University (SNU); Hanyang University	Kim, SG (corresponding author), Seoul Natl Univ, Coll Pharm, Natl Res Lab, Sillim Dong, Seoul 151742, South Korea.	sgk@snu.ac.kr						Bogatkevich GS, 2001, J BIOL CHEM, V276, P45184, DOI 10.1074/jbc.M106441200; Bokarewa MI, 2001, MICROB PATHOGENESIS, V30, P247, DOI 10.1006/mpat.2000.0425; Chen BC, 2001, BRIT J PHARMACOL, V134, P1055, DOI 10.1038/sj.bjp.0704334; CHEN ZJ, 1995, GENE DEV, V9, P1586, DOI 10.1101/gad.9.13.1586; CHESROWN SE, 1994, BIOCHEM BIOPH RES CO, V200, P126, DOI 10.1006/bbrc.1994.1424; Chi LG, 2001, J THROMB THROMBOLYS, V11, P19, DOI 10.1023/A:1008900109285; Cho MK, 2002, NITRIC OXIDE-BIOL CH, V6, P319, DOI 10.1006/niox.2001.0415; Esmon CT, 2000, HAEMOSTASIS, V30, P34; Esmon CT, 2001, THROMB HAEMOSTASIS, V86, P51; Esmon CT, 2000, BBA-PROTEIN STRUCT M, V1477, P349, DOI 10.1016/S0167-4838(99)00266-6; Evans TJ, 1996, IMMUNOBIOLOGY, V195, P655, DOI 10.1016/S0171-2985(96)80029-5; Gardner A, 2002, CELL SIGNAL, V14, P499, DOI 10.1016/S0898-6568(01)00279-0; Gohla A, 1999, J BIOL CHEM, V274, P17901, DOI 10.1074/jbc.274.25.17901; HESSELVIK JF, 1989, CRIT CARE MED, V17, P724, DOI 10.1097/00003246-198908000-00002; Isobe H, 2002, BLOOD, V99, P1638, DOI 10.1182/blood.V99.5.1638; Isobe H, 2001, CIRCULATION, V104, P1171, DOI 10.1161/hc3501.093799; Jho EH, 1997, J BIOL CHEM, V272, P24468, DOI 10.1074/jbc.272.39.24468; Jiang Y, 1998, NATURE, V395, P808, DOI 10.1038/27454; Kaur J, 2003, AM J PHYSIOL-HEART C, V284, pH1095, DOI 10.1152/ajpheart.00016.2002; Kim SG, 1997, MOL PHARMACOL, V51, P225, DOI 10.1124/mol.51.2.225; Komatsuzaki K, 2001, BIOCHEM BIOPH RES CO, V289, P1211, DOI 10.1006/bbrc.2001.6085; Kozasa T, 1998, SCIENCE, V280, P2109, DOI 10.1126/science.280.5372.2109; Kristof AS, 2001, J BIOL CHEM, V276, P8445, DOI 10.1074/jbc.M009563200; LI CCH, 1995, BIOCHEM BIOPH RES CO, V215, P292, DOI 10.1006/bbrc.1995.2465; Luchi M, 2000, INFECT IMMUN, V68, P1899, DOI 10.1128/IAI.68.4.1899-1904.2000; MACMICKING JD, 1995, CELL, V81, P641, DOI 10.1016/0092-8674(95)90085-3; Mann HJ, 2002, AM J HEALTH-SYST PH, V59, pS19, DOI 10.1093/ajhp/59.suppl_1.S19; Martin CB, 2001, ONCOGENE, V20, P1953, DOI 10.1038/sj.onc.1204281; Maruyama I, 1997, ANN NY ACAD SCI, V811, P429, DOI 10.1111/j.1749-6632.1997.tb52024.x; Mavrommatis AC, 2001, INTENS CARE MED, V27, P1853, DOI 10.1007/s00134-001-1139-8; Mavrommatis AC, 2000, CRIT CARE MED, V28, P451, DOI 10.1097/00003246-200002000-00027; Meli R, 2001, J NEUROCHEM, V79, P556, DOI 10.1046/j.1471-4159.2001.00617.x; MONCADA S, 1991, PHARMACOL REV, V43, P109; Nadal-Wollbold F, 2002, FEBS LETT, V531, P475, DOI 10.1016/S0014-5793(02)03587-1; Nancy V, 1999, J BIOL CHEM, V274, P8737, DOI 10.1074/jbc.274.13.8737; Naor Z, 1998, FRONT NEUROENDOCRIN, V19, P1, DOI 10.1006/frne.1997.0162; Nguyen QD, 2002, FASEB J, V16, P565, DOI 10.1096/fj.01-0525com; Nielsen JD, 1998, BLOOD COAGUL FIBRIN, V9, pS11; Nieuwland R, 2000, BLOOD, V95, P930, DOI 10.1182/blood.V95.3.930.003k46_930_935; Oelschlager C, 2002, BLOOD, V99, P4015, DOI 10.1182/blood.V99.11.4015; Offermanns S, 1996, J BIOL CHEM, V271, P26044, DOI 10.1074/jbc.271.42.26044; PHILIPPE J, 1991, THROMB HAEMOSTASIS, V65, P291; Prins JM, 1996, FEMS IMMUNOL MED MIC, V16, P283; Salvucci O, 1998, BLOOD, V92, P2093, DOI 10.1182/blood.V92.6.2093.418k31_2093_2102; Silkoff PE, 2000, J ALLERGY CLIN IMMUN, V105, P438, DOI 10.1067/mai.2000.104938; Speigelman VS, 2001, J BIOL CHEM, V276, P27152, DOI 10.1074/jbc.M100031200; Strukova SM, 2001, BIOCHEMISTRY-MOSCOW+, V66, P8, DOI 10.1023/A:1002869310180; STUEHR DJ, 1989, J EXP MED, V169, P1011, DOI 10.1084/jem.169.3.1011; Symeonides S, 1999, INFECT DIS CLIN N AM, V13, P449, DOI 10.1016/S0891-5520(05)70085-4; SZABO C, 1994, P NATL ACAD SCI USA, V91, P271, DOI 10.1073/pnas.91.1.271; SZABO C, 1994, SHOCK, V2, P145, DOI 10.1097/00024382-199408000-00011; Thijs LG, 2000, CRIT CARE MED, V28, pS68, DOI 10.1097/00003246-200009001-00015; van der Poll T, 2001, J ENDOTOXIN RES, V7, P301, DOI 10.1177/09680519010070040301; Venet C, 2000, INTENS CARE MED, V26, P538, DOI 10.1007/s001340051201; VoynoYasenetskaya TA, 1996, J BIOL CHEM, V271, P21081, DOI 10.1074/jbc.271.35.21081; Wang TL, 2002, INT IMMUNOPHARMACOL, V2, P1509, DOI 10.1016/S1567-5769(02)00058-9; Williams BY, 1998, MOL PHARMACOL, V54, P889, DOI 10.1124/mol.54.5.889; Wong J M, 1995, Adv Pharmacol, V34, P155; XIE QW, 1993, J EXP MED, V177, P1779, DOI 10.1084/jem.177.6.1779	59	49	52	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 9	2003	278	19					17368	17378		10.1074/jbc.M300471200	http://dx.doi.org/10.1074/jbc.M300471200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677QG	12606553	hybrid			2022-12-25	WOS:000182818600123
J	Kuhn, U; Nemeth, A; Meyer, S; Wahle, E				Kuhn, U; Nemeth, A; Meyer, S; Wahle, E			The RNA binding domains of the nuclear poly(A)-binding protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ARGININE METHYLATION; CRYSTAL-STRUCTURE; ESCHERICHIA-COLI; IN-VITRO; SACCHAROMYCES-CEREVISIAE; RICH DOMAIN; POLY(A); RECOGNITION; GENE; NUCLEOLIN	The nuclear poly(A)-binding protein (PABPN1) is involved in the synthesis of the mRNA poly(A) tails in most eukaryotes. We report that the protein contains two RNA binding domains, a ribonucleoprotein-type RNA binding domain (RNP domain) located approximately in the middle of the protein sequence and an arginine-rich C-terminal domain. The C-terminal domain also promotes self-association of PABPN1 and moderately cooperative binding to RNA. Whereas the isolated RNP domain binds specifically to poly(A), the isolated C-terminal domain binds non-specifically to RNA and other polyanions. Despite this nonspecific RNA binding by the C-terminal domain, selection experiments show that adenosine residues throughout the entire minimal binding site of similar to11 nucleotides are recognized specifically. UV-induced cross-links with oligo(A) carrying photoactivatable nucleotides at different positions all map to the RNP domain, suggesting that most or all of the base-specific contacts are made by the RNP domain, whereas the C-terminal domain may contribute nonspecific contacts, conceivably to the same nucleotides. Asymmetric dimethylation of 13 arginine residues in the C-terminal domain has no detectable influence on the interaction of the protein with RNA. The N-terminal domain of PABPN1 is not required for RNA binding but is essential for the stimulation of poly(A) polymerase.	Univ Halle Wittenberg, Inst Biochem, D-06099 Halle An Der Saale, Germany; Univ Giessen, Inst Biochem, D-35392 Giessen, Germany	Martin Luther University Halle Wittenberg; Justus Liebig University Giessen	Wahle, E (corresponding author), Univ Halle Wittenberg, Inst Biochem, D-06099 Halle An Der Saale, Germany.	ewahle@biochemtech.uni-halle.de		Wahle, Elmar/0000-0003-2504-0677				AbdulMana N, 1996, BIOCHEMISTRY-US, V35, P3545, DOI 10.1021/bi952298p; ADAM SA, 1986, MOL CELL BIOL, V6, P2932, DOI 10.1128/MCB.6.8.2932; Adinolfi S, 1999, RNA, V5, P1248, DOI 10.1017/S1355838299990647; Allain FHT, 2000, EMBO J, V19, P6870, DOI 10.1093/emboj/19.24.6870; Avis JM, 1996, J MOL BIOL, V257, P398, DOI 10.1006/jmbi.1996.0171; Bagni C, 1998, J BIOL CHEM, V273, P10868, DOI 10.1074/jbc.273.18.10868; Bedford MT, 2000, J BIOL CHEM, V275, P16030, DOI 10.1074/jbc.M909368199; Benoit B, 1999, NUCLEIC ACIDS RES, V27, P3771, DOI 10.1093/nar/27.19.3771; BIENROTH S, 1993, EMBO J, V12, P585, DOI 10.1002/j.1460-2075.1993.tb05690.x; Bouvet P, 1998, J BIOL CHEM, V273, P19025, DOI 10.1074/jbc.273.30.19025; Brais B, 1998, NAT GENET, V18, P164, DOI 10.1038/ng0298-164; BRINKMANN U, 1989, GENE, V85, P109, DOI 10.1016/0378-1119(89)90470-8; BURD CG, 1994, SCIENCE, V265, P615, DOI 10.1126/science.8036511; BURD CG, 1991, MOL CELL BIOL, V11, P3419, DOI 10.1128/MCB.11.7.3419; Calado A, 2000, HUM MOL GENET, V9, P2321, DOI 10.1093/oxfordjournals.hmg.a018924; Calado A, 2000, RNA, V6, P245, DOI 10.1017/S1355838200991908; Calado A, 2000, J CELL SCI, V113, P2309; Cartegni L, 1996, J MOL BIOL, V259, P337, DOI 10.1006/jmbi.1996.0324; CASASFINET JR, 1993, J MOL BIOL, V229, P873, DOI 10.1006/jmbi.1993.1093; Chen ZY, 1999, EMBO J, V18, P2273, DOI 10.1093/emboj/18.8.2273; COBIANCHI F, 1988, J BIOL CHEM, V263, P1063; Cote J, 2003, MOL BIOL CELL, V14, P274, DOI 10.1091/mbc.E02-08-0484; Darnell JC, 2001, CELL, V107, P489, DOI 10.1016/S0092-8674(01)00566-9; Deardorff JA, 1997, J MOL BIOL, V269, P67, DOI 10.1006/jmbi.1997.1013; Deo RC, 1999, CELL, V98, P835, DOI 10.1016/S0092-8674(00)81517-2; Ding JZ, 1999, GENE DEV, V13, P1102, DOI 10.1101/gad.13.9.1102; Fan XP, 2001, HUM MOL GENET, V10, P2341, DOI 10.1093/hmg/10.21.2341; Friesen WJ, 2001, MOL CELL, V7, P1111, DOI 10.1016/S1097-2765(01)00244-1; Gary JD, 1998, PROG NUCLEIC ACID RE, V61, P65, DOI 10.1016/S0079-6603(08)60825-9; GHISOLFI L, 1992, EUR J BIOCHEM, V209, P541, DOI 10.1111/j.1432-1033.1992.tb17318.x; GHISOLFI L, 1992, J BIOL CHEM, V267, P2955; GORLACH M, 1994, J BIOL CHEM, V269, P23074; Green DM, 2002, J BIOL CHEM, V277, P7752, DOI 10.1074/jbc.M110053200; Handa N, 1999, NATURE, V398, P579, DOI 10.1038/19242; Kambach C, 1999, CELL, V96, P375, DOI 10.1016/S0092-8674(00)80550-4; Keller RW, 2000, J MOL BIOL, V297, P569, DOI 10.1006/jmbi.2000.3572; KILEDJIAN M, 1992, EMBO J, V11, P2655, DOI 10.1002/j.1460-2075.1992.tb05331.x; KRAUSE S, 1994, EXP CELL RES, V214, P75, DOI 10.1006/excr.1994.1235; Kuhn U, 1996, J MOL BIOL, V256, P20, DOI 10.1006/jmbi.1996.0065; Martin G, 1996, EMBO J, V15, P2593, DOI 10.1002/j.1460-2075.1996.tb00617.x; Meyer S, 2002, BIOCHEMISTRY-US, V41, P6082, DOI 10.1021/bi0160866; Mowen KA, 2001, CELL, V104, P731, DOI 10.1016/S0092-8674(02)08085-6; NAGAI K, 1995, TRENDS BIOCHEM SCI, V20, P235, DOI 10.1016/S0968-0004(00)89024-6; Nagai K, 1996, CURR OPIN STRUC BIOL, V6, P53, DOI 10.1016/S0959-440X(96)80095-9; NEMETH A, 1995, NUCLEIC ACIDS RES, V23, P4034, DOI 10.1093/nar/23.20.4034; Nichols RC, 2000, EXP CELL RES, V256, P522, DOI 10.1006/excr.2000.4827; OUBRIDGE C, 1994, NATURE, V372, P432, DOI 10.1038/372432a0; PICARD V, 1994, NUCLEIC ACIDS RES, V22, P2587, DOI 10.1093/nar/22.13.2587; Pintucci G, 1996, MOL BIOL CELL, V7, P1249, DOI 10.1091/mbc.7.8.1249; Price SR, 1998, NATURE, V394, P645, DOI 10.1038/29234; Puig O, 2001, METHODS, V24, P218, DOI 10.1006/meth.2001.1183; Raman B, 2001, NUCLEIC ACIDS RES, V29, P3377, DOI 10.1093/nar/29.16.3377; Ruegsegger U, 1996, J BIOL CHEM, V271, P6107; Sachs A, 2000, COLD SPRING HARBOR M, V39, P447; SACHS AB, 1986, CELL, V45, P827, DOI 10.1016/0092-8674(86)90557-X; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; Schwartz DC, 2000, COLD SPRING HARBOR M, V39, P807; Shen EC, 1998, GENE DEV, V12, P679, DOI 10.1101/gad.12.5.679; Smith JJ, 1999, J BIOL CHEM, V274, P13229, DOI 10.1074/jbc.274.19.13229; STAYTON MM, 1983, J BIOL CHEM, V258, P3205; Valentini SR, 1999, RNA, V5, P272, DOI 10.1017/S1355838299981633; Vanhamme L, 1998, J BIOL CHEM, V273, P21825, DOI 10.1074/jbc.273.34.21825; Varani G, 1998, ANNU REV BIOPH BIOM, V27, P407, DOI 10.1146/annurev.biophys.27.1.407; WAHLE E, 1993, J BIOL CHEM, V268, P2937; WAHLE E, 1991, CELL, V66, P759, DOI 10.1016/0092-8674(91)90119-J; WAHLE E, 1995, J BIOL CHEM, V270, P2800, DOI 10.1074/jbc.270.6.2800; Winstall E, 2000, J BIOL CHEM, V275, P21817, DOI 10.1074/jbc.M002412200; Xu W, 2001, SCIENCE, V294, P2507, DOI 10.1126/science.1065961; Yun CY, 2000, J CELL BIOL, V150, P707, DOI 10.1083/jcb.150.4.707	70	65	67	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 9	2003	278	19					16916	16925		10.1074/jbc.M209886200	http://dx.doi.org/10.1074/jbc.M209886200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677QG	12637556	hybrid			2022-12-25	WOS:000182818600064
J	Sutton, A; Shia, WJ; Band, D; Kaufman, PD; Osada, S; Workman, JL; Sternglanz, R				Sutton, A; Shia, WJ; Band, D; Kaufman, PD; Osada, S; Workman, JL; Sternglanz, R			Sas4 and Sas5 are required for the histone acetyltransferase activity of Sas2 in the SAS complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ASSEMBLY FACTOR-I; RNA-POLYMERASE-II; SACCHAROMYCES-CEREVISIAE; SILENCING PROTEIN; DNA-REPLICATION; CHROMATIN; ACETYLATION; ASF1; HETEROCHROMATIN; TRANSCRIPTION	The SAS2 gene is involved in transcriptional silencing in Saccharomyces cerevisiae. Based on its primary sequence, the Sas2 protein is predicted to be a member of the MYST family of histone acetyltransferases (HATs). Sas2 forms a complex with Sas4 and Sas5, which are required for its silencing function. Here we show that recombinant Sas2 has HAT activity that absolutely requires Sas4 and is stimulated by Sas5. The recombinant SAS complex acetylates H4 lysine 16 and H3 lysine 14. Furthermore, a purified SAS complex from yeast shows similar activity and specificity. In contrast to other MYST HATs, neither the recombinant nor the native SAS complex acetylated nucleosomal histones under conditions that were optimum for acetylating free histones. Finally, although the SAS subunits interact genetically and physically with Asf1, a histone deposition factor, association of H3 and H4 with Asf1 blocks their acetylation by the SAS complex, raising the possibility that the SAS HAT complex may acetylate free histones prior to their deposition onto DNA by Asf1 or CAF-I.	SUNY Stony Brook, Dept Biochem & Cell Biol, Stony Brook, NY 11794 USA; Penn State Univ, Dept Biochem & Mol Biol, Howard Hughes Med Inst, University Pk, PA 16802 USA; Univ Calif Berkeley, Lawrence Berkeley Lab, Berkeley, CA 94720 USA; Univ Calif Berkeley, Dept Mol & Cellular Biol, Berkeley, CA 94720 USA; Osaka Univ, Grad Sch Pharmaceut Sci, Lab Environm Biochem, Suita, Osaka 5650871, Japan	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; Howard Hughes Medical Institute; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley; University of California System; University of California Berkeley; Osaka University	Sternglanz, R (corresponding author), SUNY Stony Brook, Dept Biochem & Cell Biol, Stony Brook, NY 11794 USA.			Kaufman, Paul/0000-0003-3089-313X				Allard S, 1999, EMBO J, V18, P5108, DOI 10.1093/emboj/18.18.5108; Cairns BR, 1996, MOL CELL BIOL, V16, P3308; Carruthers LM, 1999, METHOD ENZYMOL, V304, P19; Donze D, 2001, EMBO J, V20, P520, DOI 10.1093/emboj/20.3.520; Eberharter A, 1998, METHODS, V15, P315, DOI 10.1006/meth.1998.0635; EhrenhoferMurray AE, 1997, GENETICS, V145, P923; Enomoto S, 1997, GENE DEV, V11, P358, DOI 10.1101/gad.11.3.358; Grant PA, 1997, GENE DEV, V11, P1640, DOI 10.1101/gad.11.13.1640; GRAZIANO V, 1988, J MOL BIOL, V203, P997, DOI 10.1016/0022-2836(88)90124-6; Guthrie C, 1991, METHODS ENZYMOLOGY, V194; HENRICKSEN LA, 1994, J BIOL CHEM, V269, P11121; HENRY NL, 1994, GENE DEV, V8, P2868, DOI 10.1101/gad.8.23.2868; John S, 2000, GENE DEV, V14, P1196; Kaufman PD, 1997, GENE DEV, V11, P345, DOI 10.1101/gad.11.3.345; KAUFMAN PD, 1995, CELL, V81, P1105, DOI 10.1016/S0092-8674(05)80015-7; KIM YJ, 1994, CELL, V77, P599, DOI 10.1016/0092-8674(94)90221-6; Kimura A, 2002, NAT GENET, V32, P370, DOI 10.1038/ng993; Krawitz DC, 2002, MOL CELL BIOL, V22, P614, DOI 10.1128/MCB.22.2.614-625.2002; Levenstein ME, 2002, J BIOL CHEM, V277, P8749, DOI 10.1074/jbc.M111212200; Meijsing SH, 2001, GENE DEV, V15, P3169, DOI 10.1101/gad.929001; Osada S, 2001, GENE DEV, V15, P3155, DOI 10.1101/gad.907201; Puig O, 2001, METHODS, V24, P218, DOI 10.1006/meth.2001.1183; Reifsnyder C, 1996, NAT GENET, V14, P42, DOI 10.1038/ng0996-42; Richards EJ, 2002, CELL, V108, P489, DOI 10.1016/S0092-8674(02)00644-X; Sharp JA, 2001, CURR BIOL, V11, P463, DOI 10.1016/S0960-9822(01)00140-3; Sherman JM, 1997, TRENDS GENET, V13, P308, DOI 10.1016/S0168-9525(97)01198-0; SIMON RH, 1979, NUCLEIC ACIDS RES, V6, P689, DOI 10.1093/nar/6.2.689; Singer MS, 1998, GENETICS, V150, P613; Sterner DE, 2000, MICROBIOL MOL BIOL R, V64, P435, DOI 10.1128/MMBR.64.2.435-459.2000; Suka N, 2002, NAT GENET, V32, P378, DOI 10.1038/ng1017; Sutton A, 2001, GENETICS, V158, P587; Tan S, 2001, PROTEIN EXPRES PURIF, V21, P224, DOI 10.1006/prep.2000.1363; Tyler JK, 1999, NATURE, V402, P555, DOI 10.1038/990147; Tyler JK, 2001, MOL CELL BIOL, V21, P6574, DOI 10.1128/MCB.21.19.6574-6584.2001; Verreault A, 1996, CELL, V87, P95, DOI 10.1016/S0092-8674(00)81326-4; Xu EY, 1999, GENETICS, V153, P25	36	68	76	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 9	2003	278	19					16887	16892		10.1074/jbc.M210709200	http://dx.doi.org/10.1074/jbc.M210709200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677QG	12626510	hybrid			2022-12-25	WOS:000182818600060
J	Wang, Q; Moyret-Lalle, C; Couzon, F; Surbiguet-Clippe, C; Saurin, JC; Lorca, T; Navarro, C; Puisieux, A				Wang, Q; Moyret-Lalle, C; Couzon, F; Surbiguet-Clippe, C; Saurin, JC; Lorca, T; Navarro, C; Puisieux, A			Alterations of anaphase-promoting complex genes in human colon cancer cells	ONCOGENE			English	Article						APC/C; cyclosome; ubiquitination; colon cancer; cyclin B1	APC-DEPENDENT PROTEOLYSIS; HUMAN COLORECTAL CANCERS; B-TYPE CYCLINS; MITOTIC EXIT; OVEREXPRESSION; CHECKPOINT; MUTATIONS; PROTEINS; MITOSIS; KINASE	Ubiquitin-mediated proteolysis of cell cycle regulators is a major element of the cell cycle control. The anaphase-promoting complex (APC/C) is a large multisubunit ubiquitin-protein ligase required for the ubiquitination and degradation of G1 and mitotic checkpoint regulators. APC/C-dependent proteolysis regulates cyclin levels in G1, and triggers the separation of sister chromatids at the metaphase-anaphase transition and the destruction of mitotic cyclins at the end of mitosis. Furthermore, it was recently shown that APC/C regulates the degradation of crucial regulators of signal transduction pathways. We report here gene alterations in several components of this complex in human colon cancer cells, including APC6/CDC16 and APC8/CDC23 which are known to be key function elements. The experimental expression of a truncation mutant of APC8/CDC23 subunit (CDC23DeltaTPR) leads to abnormal levels of APC/C targets such as cyclin B1 and disturbs the cell cycle progression of colon epithelial cells through mitosis. Overall, these data support the hypothesis of a deleterious role of these mutations during colorectal carcinogenesis.	INSERM, Ctr Leon Berard, Ctr Oncol Genet, U453, F-69008 Lyon 08, France; Fac Pharm Lyon, F-69373 Lyon, France; Hop Edouard Herriot, Federat Special Digest, F-69437 Lyon 03, France; CNRS, UPR 1086, Ctr Rech Biochim Macromol, F-34293 Montpellier 5, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Centre Leon Berard; UDICE-French Research Universities; Universite Claude Bernard Lyon 1; CHU Lyon; Centre National de la Recherche Scientifique (CNRS); Universite de Montpellier	Puisieux, A (corresponding author), INSERM, Ctr Leon Berard, Ctr Oncol Genet, U453, 28 Rue Laennec, F-69008 Lyon 08, France.		Moyret-Lalle, Caroline/G-2742-2013	Moyret-Lalle, Caroline/0000-0002-8359-2018; Lorca, Thierry/0000-0003-2007-8924; PUISIEUX, Alain/0000-0002-9938-3798				Bischoff JR, 1998, EMBO J, V17, P3052, DOI 10.1093/emboj/17.11.3052; Cahill DP, 1998, NATURE, V392, P300, DOI 10.1038/32688; COMBARET V, 1995, INT J CANCER, V61, P185, DOI 10.1002/ijc.2910610208; Elledge SJ, 1996, SCIENCE, V274, P1664, DOI 10.1126/science.274.5293.1664; Gieffers C, 2001, MOL CELL, V7, P907, DOI 10.1016/S1097-2765(01)00234-9; Heaney AP, 2000, LANCET, V355, P716, DOI 10.1016/S0140-6736(99)10238-1; Irniger S, 1997, J CELL SCI, V110, P1523; Kawasaki A, 2001, J CELL BIOL, V152, P275, DOI 10.1083/jcb.152.2.275; Noton E, 2000, MOL CELL, V5, P85, DOI 10.1016/S1097-2765(00)80405-0; Peters JM, 2002, MOL CELL, V9, P931, DOI 10.1016/S1097-2765(02)00540-3; Sarafan-Vasseur N, 2002, ONCOGENE, V21, P2051, DOI 10.1038/sj.onc.1205257; Shah JV, 2000, CELL, V103, P997, DOI 10.1016/S0092-8674(00)00202-6; Soria JC, 2000, CANCER RES, V60, P4000; Strohmaier H, 2001, NATURE, V413, P316, DOI 10.1038/35095076; Visintin R, 1997, SCIENCE, V278, P460, DOI 10.1126/science.278.5337.460; Wang AJ, 1997, J CANCER RES CLIN, V123, P124, DOI 10.1007/BF01269891; Wang Q, 1999, HUM GENET, V105, P79, DOI 10.1007/s004390051067; Wasch R, 2002, NATURE, V418, P556, DOI 10.1038/nature00856; Yin XY, 2001, CANCER RES, V61, P6487; Zachariae W, 1996, MOL BIOL CELL, V7, P791, DOI 10.1091/mbc.7.5.791; Zhang YK, 2001, MOL CELL BIOL, V21, P5190, DOI 10.1128/MCB.21.15.5190-5199.2001; Zhao ND, 1998, GENOMICS, V53, P184, DOI 10.1006/geno.1998.5473	22	85	91	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 13	2003	22	10					1486	1490		10.1038/sj.onc.1206224	http://dx.doi.org/10.1038/sj.onc.1206224			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	652ZZ	12629511	Bronze			2022-12-25	WOS:000181411900005
J	Yamasaki, S; Nishida, K; Yoshida, Y; Itoh, M; Hibi, M; Hirano, T				Yamasaki, S; Nishida, K; Yoshida, Y; Itoh, M; Hibi, M; Hirano, T			Gab1 is required for EGF receptor signaling and the transformation by activated ErbB2	ONCOGENE			English	Article						EGF; Gab1; ERK; transformation; signal transduction	GROWTH-FACTOR RECEPTORS; CELL ANTIGEN RECEPTORS; DOCKING PROTEIN GAB1; TYROSINE KINASE; C-MET; EPITHELIAL MORPHOGENESIS; PLECKSTRIN HOMOLOGY; SEVENLESS PROTEIN; REGULATED KINASE; IN-VIVO	Grb2-associated binder-1 (Gab1) is a pleckstrin homology (PH) domain-containing adapter molecule that is believed to function downstream of receptors for growth factors and cytokines. We previously found that deficiency in the mouse Gab1 gene led to embryonic lethality and defects in ERK activation in response to growth factors and cytokines. Here, we established immortalized Gab1-/- cell lines and analysed roles of Gab1 in growth factor-mediated signaling and oncogenesis. EGF-dependent activation of c-Raf and Mek1/2, which function upstream of ERKs, was perturbed in Gab1-/- cells. EGF-mediated upregulation of GTP-bound form of Ras was also reduced in these cells. EGF-dependent GTP/GDP exchange activity for Ras was suppressed in the Gab1-/- cells and expression of a constitutively active Sos restored ERK activation in these cells, indicating that Gab1 functions upstream of Ras. Furthermore, activated form of ErbB2 (active ErbB2)-mediated transformation, such as colony formation in soft agar and tumor formation in nude mice, was strongly suppressed when the Gab1-/- cells were transfected with active ErbB2, whereas the active Sos efficiently induced transformation of Gab1-/- cells. The data show that Gab1 plays an essential role in EGF-receptor/ErbB-mediated cell proliferation and oncogenesis.	Osaka Univ, Grad Sch Med, Dept Mol Oncol C7, Suita, Osaka 5650871, Japan; Osaka Univ, Grad Sch Frontier Biosci, Lab Dev Immunol, Suita, Osaka 5650871, Japan; RIKEN, RCAI, Lab Cytokine Signaling, Yokohama, Kanagawa, Japan	Osaka University; Osaka University; RIKEN	Hirano, T (corresponding author), Osaka Univ, Grad Sch Med, Dept Mol Oncol C7, 2-2 Yamadaoka, Suita, Osaka 5650871, Japan.		Hibi, Masahiko/I-6215-2014; Hirano, Toshio/C-8194-2009	Hibi, Masahiko/0000-0002-9142-4444; 				AKIYAMA T, 1991, MOL CELL BIOL, V11, P833, DOI 10.1128/MCB.11.2.833; Anborgh PH, 1999, MOL CELL BIOL, V19, P4611; ARONHEIM A, 1994, CELL, V78, P949, DOI 10.1016/0092-8674(94)90271-2; Bausenwein BS, 2000, MECH DEVELOP, V90, P205, DOI 10.1016/S0925-4773(99)00252-X; BUDAY L, 1993, MOL CELL BIOL, V13, P1903, DOI 10.1128/MCB.13.3.1903; Chen BB, 2000, NAT GENET, V24, P296, DOI 10.1038/73528; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; Das B, 2000, J BIOL CHEM, V275, P15074, DOI 10.1074/jbc.M907269199; deRooij J, 1997, ONCOGENE, V14, P623, DOI 10.1038/sj.onc.1201005; GrausPorta D, 1997, EMBO J, V16, P1647, DOI 10.1093/emboj/16.7.1647; Gu HH, 2000, MOL CELL BIOL, V20, P7109, DOI 10.1128/MCB.20.19.7109-7120.2000; Gu HH, 1998, MOL CELL, V2, P729, DOI 10.1016/S1097-2765(00)80288-9; Herbst R, 1999, EMBO J, V18, P6950, DOI 10.1093/emboj/18.24.6950; Herbst R, 1996, CELL, V85, P899, DOI 10.1016/S0092-8674(00)81273-8; Hibi M, 2000, LEUKEMIA LYMPHOMA, V37, P299, DOI 10.3109/10428190009089430; HolgadoMadruga M, 1996, NATURE, V379, P560, DOI 10.1038/379560a0; Hunter T, 2000, CELL, V100, P113, DOI 10.1016/S0092-8674(00)81688-8; HYNES NE, 1994, BBA-REV CANCER, V1198, P165, DOI 10.1016/0304-419X(94)90012-4; Itoh M, 2000, MOL CELL BIOL, V20, P3695, DOI 10.1128/MCB.20.10.3695-3704.2000; Liu Y, 2002, FEBS LETT, V515, P1, DOI 10.1016/S0014-5793(02)02425-0; Lock LS, 2000, J BIOL CHEM, V275, P31536, DOI 10.1074/jbc.M003597200; Maroun CR, 2000, MOL CELL BIOL, V20, P8513, DOI 10.1128/MCB.20.22.8513-8525.2000; Nishida K, 1999, BLOOD, V93, P1809, DOI 10.1182/blood.V93.6.1809.406k35_1809_1816; Olayioye MA, 2000, EMBO J, V19, P3159, DOI 10.1093/emboj/19.13.3159; PAWSON T, 1992, CELL, V71, P359, DOI 10.1016/0092-8674(92)90504-6; Qu CK, 1999, P NATL ACAD SCI USA, V96, P8528, DOI 10.1073/pnas.96.15.8528; Raabe T, 1996, CELL, V85, P911, DOI 10.1016/S0092-8674(00)81274-X; Rodrigues GA, 2000, MOL CELL BIOL, V20, P1448, DOI 10.1128/MCB.20.4.1448-1459.2000; Sachs M, 2000, J CELL BIOL, V150, P1375, DOI 10.1083/jcb.150.6.1375; Sakkab D, 2000, J BIOL CHEM, V275, P10772, DOI 10.1074/jbc.275.15.10772; Schaeper U, 2000, J CELL BIOL, V149, P1419, DOI 10.1083/jcb.149.7.1419; Schlessinger J, 2000, CELL, V103, P211, DOI 10.1016/j.cell.2010.06.011; SIMON MA, 1991, CELL, V67, P701, DOI 10.1016/0092-8674(91)90065-7; Takahashi-Tezuka M, 1998, MOL CELL BIOL, V18, P4109, DOI 10.1128/MCB.18.7.4109; Weidner KM, 1996, NATURE, V384, P173, DOI 10.1038/384173a0; Wolf I, 2002, MOL CELL BIOL, V22, P231, DOI 10.1128/MCB.22.1.231-244.2002; Zhao CM, 1999, J BIOL CHEM, V274, P19649, DOI 10.1074/jbc.274.28.19649	37	54	54	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 13	2003	22	10					1546	1556		10.1038/sj.onc.1206284	http://dx.doi.org/10.1038/sj.onc.1206284			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	652ZZ	12629518				2022-12-25	WOS:000181411900012
J	Klingelhofer, J; Troyanovsky, RB; Laur, OY; Troyanovsky, S				Klingelhofer, J; Troyanovsky, RB; Laur, OY; Troyanovsky, S			Exchange of catenins in cadherin-catenin complex	ONCOGENE			English	Article						cadherin; catenins; APC; adhesion	APC TUMOR-SUPPRESSOR; BETA-CATENIN; CELL-ADHESION; TYROSINE PHOSPHORYLATION; FUNCTIONAL-ANALYSIS; ALPHA-CATENIN; DROSOPHILA; BINDING; LOCALIZATION; JUNCTIONS	beta-Catenin is an intracellular multifunctional protein. In complex with the transmembrane adhesive receptor E-cadherin, it becomes plasma membrane-associated and mediates intercellular adhesion. A cytosolic pool of beta-catenin interacts with DNA-binding proteins and participates in signal transduction. To reveal the possible cross-talk between these two pools, we studied whether beta-catenin is exchanged between its free and cadherin-bound states. We found that pulse-labeled beta-catenin replaces the beta-catenin bound to the cell surface prebiotinylated E-cadherin immediately after synthesis. Approximately 25% of all pulse-labeled beta-catenin destined for E-cadherin associates with this protein via this mechanism. The rest of the newly synthesized beta-catenin arrives at the plasma membrane in a complex with the E-cadherin precursor. Immediately after arrival, this beta-catenin pool is transferred to the prebiotinylated E-cadherin. beta-Catenin released from E-cadherin may participate in new exchange cycles. This beta-catenin exchange is strongly affected in cells that contain mutations in the tumor suppressor gene APC. This process may contribute significantly to both cell-cell adhesion and beta-catenin-dependent signaling.	Washington Univ, Sch Med, Div Dermatol, St Louis, MO 63110 USA	Washington University (WUSTL)	Troyanovsky, S (corresponding author), Washington Univ, Sch Med, Div Dermatol, Campus Box 8123,660 S Euclid Ave, St Louis, MO 63110 USA.		Klingelhöfer, Jörg/C-1676-2013		NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P01AR045254] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR44106-04, AR45254-01] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Aono S, 1999, J CELL BIOL, V145, P551, DOI 10.1083/jcb.145.3.551; Balsamo J, 1996, J CELL BIOL, V134, P801, DOI 10.1083/jcb.134.3.801; Bienz M, 1999, CURR OPIN GENET DEV, V9, P595, DOI 10.1016/S0959-437X(99)00016-7; Chitaev NA, 1998, J CELL BIOL, V142, P837, DOI 10.1083/jcb.142.3.837; Gottardi CJ, 2001, J CELL BIOL, V153, P1049, DOI 10.1083/jcb.153.5.1049; Hamada F, 2002, NAT CELL BIOL, V4, P208, DOI 10.1038/ncb755; HEASMAN J, 1994, CELL, V79, P791, DOI 10.1016/0092-8674(94)90069-8; HINCK L, 1994, J CELL BIOL, V125, P1327, DOI 10.1083/jcb.125.6.1327; Ilyas M, 1997, P NATL ACAD SCI USA, V94, P10330, DOI 10.1073/pnas.94.19.10330; Kaibuchi K, 1999, CURR OPIN CELL BIOL, V11, P591, DOI 10.1016/S0955-0674(99)00014-9; KINCH MS, 1995, J CELL BIOL, V130, P461, DOI 10.1083/jcb.130.2.461; Klingelhofer J, 2002, MOL CELL BIOL, V22, P7449, DOI 10.1128/MCB.22.21.7449-7458.2002; KLYMKOWSKY MW, 1995, CELL, V83, P5, DOI 10.1016/0092-8674(95)90226-0; Laur OY, 2002, ARCH BIOCHEM BIOPHYS, V400, P141, DOI 10.1006/abbi.2002.2774; McCartney BM, 2001, NAT CELL BIOL, V3, P933, DOI 10.1038/ncb1001-933; NAGAFUCHI A, 1994, J CELL BIOL, V127, P235, DOI 10.1083/jcb.127.1.235; Orsulic S, 1999, J CELL SCI, V112, P1237; OZAWA M, 1992, J CELL BIOL, V116, P989, DOI 10.1083/jcb.116.4.989; Ozawa M, 1998, J BIOL CHEM, V273, P6166, DOI 10.1074/jbc.273.11.6166; Peifer M, 2000, SCIENCE, V287, P1606, DOI 10.1126/science.287.5458.1606; Piedra J, 2001, J BIOL CHEM, V276, P20436, DOI 10.1074/jbc.M100194200; Provost E, 1999, CURR OPIN CELL BIOL, V11, P567, DOI 10.1016/S0955-0674(99)00015-0; Rosin-Arbesfeld R, 2001, EMBO J, V20, P5929, DOI 10.1093/emboj/20.21.5929; Sanson B, 1996, NATURE, V383, P627, DOI 10.1038/383627a0; Schmelz M, 1998, CELL TISSUE RES, V294, P11, DOI 10.1007/s004410051152; Troyanovsky RB, 1996, J CELL SCI, V109, P3069; Yap AS, 1997, ANNU REV CELL DEV BI, V13, P119, DOI 10.1146/annurev.cellbio.13.1.119	27	32	32	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 27	2003	22	8					1181	1188		10.1038/sj.onc.1206245	http://dx.doi.org/10.1038/sj.onc.1206245			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	650EK	12606944				2022-12-25	WOS:000181249700006
J	Li, J; Zhang, ZQ; Dai, ZY; Plass, C; Morrison, C; Wang, Y; Wiest, JS; Anderson, MW; You, M				Li, J; Zhang, ZQ; Dai, ZY; Plass, C; Morrison, C; Wang, Y; Wiest, JS; Anderson, MW; You, M			LOH of chromosome 12p correlates with Kras2 mutation in non-small cell lung cancer	ONCOGENE			English	Article						wild-type Kras2; mutations; lung cancer; loss of heterozygosity; tumor suppressor	ACUTE LYMPHOBLASTIC-LEUKEMIA; RAS ONCOGENE ACTIVATION; SUSCEPTIBILITY LOCUS; CLINICAL-SIGNIFICANCE; FREQUENT DELETION; POINT MUTATION; SHORT ARM; GENE; ADENOCARCINOMA; CARCINOGENESIS	Previous observation has shown that the wild-type Kras2 allele is a suppressor of lung cancer in mice. Here we report that loss of heterozygosity (LOH) of chromosome 12p was detected in similar to50% of human lung adenocarcinomas and large cell carcinomas, and Kras2 mutations were detected at codon 12 in similar to40% of adenocarcinomas and large cell carcinomas. Interestingly, all of the lung adenocarcinomas and large cell carcinomas containing a Kras2 mutation exhibited allelic loss of the wild-type Kras2 allele when a correlation between LOH of the region on chromosome 12p and Kras2 mutation was made. These results from human lung cancer tissues provide a strong evidence in support of our previous observation in mouse models that the wild-type Kras2 is a tumor suppressor of lung cancer.	Ohio State Univ, Ctr Comprehens Canc, Div Human Canc Genet, Columbus, OH 43210 USA; OncoImmune LTD, Columbus, OH 43210 USA; Ohio State Univ, Ctr Comprehens Canc, Dept Pathol, Columbus, OH 43210 USA; Ohio State Univ, Ctr Comprehens Canc, Sch Publ Hlth, Columbus, OH 43210 USA; Univ Cincinnati, Dept Environm Hlth, Cincinnati, OH 45267 USA	James Cancer Hospital & Solove Research Institute; University System of Ohio; Ohio State University; James Cancer Hospital & Solove Research Institute; University System of Ohio; Ohio State University; James Cancer Hospital & Solove Research Institute; University System of Ohio; Ohio State University; University System of Ohio; University of Cincinnati	You, M (corresponding author), Ohio State Univ, Ctr Comprehens Canc, Div Human Canc Genet, 420 W 12th Ave, Columbus, OH 43210 USA.	you-l@medctr.osu.edu	Plass, Christoph/H-7192-2014		Intramural NIH HHS [ZIA BC010448-09] Funding Source: Medline; NCI NIH HHS [R01 CA 78797, P30 CA016058, R41 CA 093204, P30 CA 16058, R01 CA 58554, R01 CA058554] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA078797, R41CA093204, P30CA016058, R01CA058554] Funding Source: NIH RePORTER	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDERSON MW, 1992, ENVIRON HEALTH PERSP, V98, P13, DOI 10.2307/3431243; Baccichet A, 1997, BRIT J HAEMATOL, V99, P107, DOI 10.1046/j.1365-2141.1997.3663180.x; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; Beaupre DM, 1999, J CLIN ONCOL, V17, P1071, DOI 10.1200/JCO.1999.17.3.1071; Beaupre DM, 1999, CANCER RES, V59, P2971; BLIN N, 1976, NUCLEIC ACIDS RES, V3, P2303, DOI 10.1093/nar/3.9.2303; BOS JL, 1989, CANCER RES, V49, P4682; BREMNER R, 1990, CELL, V61, P407, DOI 10.1016/0092-8674(90)90523-H; BUCHMANN A, 1991, CANCER RES, V51, P4097; BURMER GC, 1991, ENVIRON HEALTH PERSP, V93, P27, DOI 10.2307/3431164; De Gregorio L, 1998, INT J CANCER, V79, P269, DOI 10.1002/(SICI)1097-0215(19980619)79:3<269::AID-IJC10>3.3.CO;2-J; Dragani TA, 2000, CANCER RES, V60, P5017; GARIBOLDI M, 1993, NAT GENET, V3, P132, DOI 10.1038/ng0293-132; HEGI ME, 1994, CANCER RES, V54, P6257; KIARIS H, 1995, INT J ONCOL, V7, P413; Kibel AS, 1998, CANCER RES, V58, P5652; LI SR, 1994, LUNG CANCER-J IASLC, V11, P19, DOI 10.1016/0169-5002(94)90279-8; Manenti G, 1997, MAMM GENOME, V8, P801, DOI 10.1007/s003359900582; MARIYAMA M, 1989, JPN J CANCER RES, V80, P622, DOI 10.1111/j.1349-7006.1989.tb01687.x; MARSHALL CJ, 1991, TRENDS GENET, V7, P91, DOI 10.1016/0168-9525(91)90063-V; MILLS NE, 1995, CANCER RES, V55, P1444; PERUCHO M, 1981, CELL, V27, P467, DOI 10.1016/0092-8674(81)90388-3; Pinto MM, 1997, ACTA CYTOL, V41, P427, DOI 10.1159/000332535; REYNOLDS SH, 1991, P NATL ACAD SCI USA, V88, P1085, DOI 10.1073/pnas.88.4.1085; RODENHUIS S, 1992, CANCER RES, V52, pS2665; RODENHUIS S, 1988, CANCER RES, V48, P5738; SHIBATA D, 1990, CANCER RES, V50, P1279; SUZUKI Y, 1990, ONCOGENE, V5, P1037; Takeuchi S, 1996, CANCER RES, V56, P738; Takeuchi S, 1996, BLOOD, V87, P3368, DOI 10.1182/blood.V87.8.3368.bloodjournal8783368; Thompson TA, 2002, ONCOGENE, V21, P2797, DOI 10.1038/sj.onc.1205391; VOGELSTEIN B, 1988, NEW ENGL J MED, V319, P525, DOI 10.1056/NEJM198809013190901; WANG Y, 1993, CANCER RES, V53, P1620; Yanagitani N, 2002, CARCINOGENESIS, V23, P1177, DOI 10.1093/carcin/23.7.1177; YOU M, 1992, P NATL ACAD SCI USA, V89, P5804, DOI 10.1073/pnas.89.13.5804; Zhang ZQ, 2001, NAT GENET, V29, P25, DOI 10.1038/ng721	36	43	45	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 27	2003	22	8					1243	1246		10.1038/sj.onc.1206192	http://dx.doi.org/10.1038/sj.onc.1206192			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	650EK	12606951	Green Accepted			2022-12-25	WOS:000181249700013
J	Ghorbel, MT; Sharman, G; Leroux, M; Barrett, T; Donovan, DM; Becker, KG; Murphy, D				Ghorbel, MT; Sharman, G; Leroux, M; Barrett, T; Donovan, DM; Becker, KG; Murphy, D			Microarray analysis reveals interleukin-6 as a novel secretory product of the hypothalamo-neurohypophyseal system	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PITUITARY-ADRENAL AXIS; GENE-EXPRESSION; MESSENGER-RNA; HYPOTHALAMONEUROHYPOPHYSEAL SYSTEM; RAT-BRAIN; CDNA MICROARRAYS; DNA ARRAYS; IN-VITRO; VASOPRESSIN; NEURONS	Physiological activation of the hypothalamo-neurohypophyseal system (HNS) by dehydration results is a massive release of vasopressin (VP) from the posterior pituitary. This is accompanied by a functional remodeling of the HNS. In this study we used cDNA arrays in an attempt to identify genes that exhibit differential expression in the hypothalamus following dehydration. Our study revealed nine candidate genes, including interleukin-6 (IL-6) as a putative novel secretory product of HNS worthy of further analysis. In situ hybridization and immunocytochemistry confirmed that IL-6 is robustly expressed in the supraoptic (SON) and the paraventricular (PVN) nuclei of the hypothalamus. By double-staining immunofluorescence we showed that IL-6 is largely co-localized with VP in the SON and PVN. In situ hybridization, immunocytochemistry, and Western blotting all revealed IL-6 up-regulation in the SON and PVN following dehydration, thus validating the array data. The same dehydration stimulus resulted in an increase in IL-6 immunoreactivity in the axons of the internal zone of the median eminence and a marked reduction in IL-6-like material in the posterior pituitary gland. We thus suggest that IL-6 takes the same secretory pathway as VP and is secreted from the posterior pituitary following a physiological stimulus.	Univ Bristol, Bristol Royal Infirm, Univ Res Ctr Neuroendocrinol, Bristol BS2 8HW, Avon, England; NIA, DNA Array Unit, NIH, Baltimore, MD 21224 USA; USDA, Biotechnol & Germplasm Lab, Beltsville, MD 20705 USA	Bristol Royal Infirmary; University of Bristol; National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); United States Department of Agriculture (USDA)	Ghorbel, MT (corresponding author), Univ Bristol, Sch Med Sci, Dept Anat, MRC Ctr Synapt Plast, Univ Walk, Bristol BS8 1TD, Avon, England.	m.ghorbel@bris.ac.uk	Murphy, David/C-3967-2012	Murphy, David/0000-0003-2946-0353; Becker, Kevin/0000-0002-6794-6656				BARGMANN W., 1966, INT REV CYTOL, V19, P183; BOURQUE CW, 1994, FRONT NEUROENDOCRIN, V15, P231, DOI 10.1006/frne.1994.1010; Burbach JPH, 2001, PHYSIOL REV, V81, P1197, DOI 10.1152/physrev.2001.81.3.1197; Cartmell T, 2000, J PHYSIOL-LONDON, V526, P653, DOI 10.1111/j.1469-7793.2000.00653.x; De Laurentiis A, 2000, NEUROIMMUNOMODULAT, V7, P77, DOI 10.1159/000026423; Duggan DJ, 1999, NAT GENET, V21, P10, DOI 10.1038/4434; Eisen MB, 1999, METHOD ENZYMOL, V303, P179; GADIENT RA, 1994, NEUROSCI LETT, V182, P243, DOI 10.1016/0304-3940(94)90807-9; Gionis D, 2003, J PEDIATR ENDOCR MET, V16, P49; Hatton GI, 1997, ANNU REV NEUROSCI, V20, P375, DOI 10.1146/annurev.neuro.20.1.375; HONDA K, 1990, J PHYSIOL-LONDON, V431, P225, DOI 10.1113/jphysiol.1990.sp018328; JHAMANDAS JH, 1989, BRAIN RES, V487, P52, DOI 10.1016/0006-8993(89)90939-6; King HC, 2001, JAMA-J AM MED ASSOC, V286, P2280, DOI 10.1001/jama.286.18.2280; KRUKOFF TL, 1994, NEUROENDOCRINOLOGY, V59, P590, DOI 10.1159/000126709; LENG G, 1982, J PHYSIOL-LONDON, V326, P35, DOI 10.1113/jphysiol.1982.sp014175; LI ZH, 1993, AM J PHYSIOL, V265, pR302, DOI 10.1152/ajpregu.1993.265.2.R302; LIGHTMAN SL, 1987, J PHYSIOL-LONDON, V394, P23, DOI 10.1113/jphysiol.1987.sp016858; Lipsitt DR, 1999, GEN HOSP PSYCHIAT, V21, P1; Mastorakos G, 1995, ANN NY ACAD SCI, V771, P438, DOI 10.1111/j.1749-6632.1995.tb44700.x; MASTORAKOS G, 1994, J CLIN ENDOCR METAB, V79, P934, DOI 10.1210/jc.79.4.934; MCALLEN RM, 1990, AM J PHYSIOL, V259, pR593, DOI 10.1152/ajpregu.1990.259.3.R593; MEISTER B, 1990, CELL TISSUE RES, V260, P279, DOI 10.1007/BF00318631; Murphy D, 2002, ADV PHYSIOL EDUC, V26, P256, DOI 10.1152/advan.00043.2002; Murphy D, 1998, BIOESSAYS, V20, P741, DOI 10.1002/(SICI)1521-1878(199809)20:9<741::AID-BIES7>3.0.CO;2-J; NISSEN R, 1994, NEUROSCIENCE, V59, P115, DOI 10.1016/0306-4522(94)90103-1; Raber J, 1997, J NEUROSCI, V17, P9473; REEVES WB, 1992, POSTERIOR PITUITARY; RUSSELL JA, 1995, EXP PHYSIOL, V80, P307, DOI 10.1113/expphysiol.1995.sp003850; SCHAFER MKH, 1994, BIOL CHEM H-S, V375, P737; SCHENA M, 1995, SCIENCE, V270, P467, DOI 10.1126/science.270.5235.467; SCHOBITZ B, 1993, EUR J NEUROSCI, V5, P1426, DOI 10.1111/j.1460-9568.1993.tb00210.x; SHERMAN TG, 1986, NEUROENDOCRINOLOGY, V44, P222, DOI 10.1159/000124649; SHERMAN TG, 1986, FASEB J, V45, P2323; Tanaka M, 1999, P NATL ACAD SCI USA, V96, P1088, DOI 10.1073/pnas.96.3.1088; Theodosis DT, 1998, CELL MOL NEUROBIOL, V18, P285, DOI 10.1023/A:1022577105819; Vawter MP, 2001, BRAIN RES BULL, V55, P641, DOI 10.1016/S0361-9230(01)00522-6; YANG CR, 1994, J PHYSIOL-LONDON, V477, P59, DOI 10.1113/jphysiol.1994.sp020171; YASIN SA, 1994, J NEUROENDOCRINOL, V6, P179, DOI 10.1111/j.1365-2826.1994.tb00570.x; Young RA, 2000, CELL, V102, P9, DOI 10.1016/S0092-8674(00)00005-2; ZENG Q, 1994, J NEUROENDOCRINOL, V6, P469, DOI 10.1111/j.1365-2826.1994.tb00610.x	40	55	55	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 23	2003	278	21					19280	19285		10.1074/jbc.M209902200	http://dx.doi.org/10.1074/jbc.M209902200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	679PY	12639960	hybrid			2022-12-25	WOS:000182932200073
J	Ibarra, CA; Chowdhury, P; Petrich, JW; Atkins, WM				Ibarra, CA; Chowdhury, P; Petrich, JW; Atkins, WM			The anomalous pK(a) of Tyr-9 in glutathione S-transferase A1-1 catalyzes product release	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-TERMINAL HELIX; ACTIVE-SITE; DRUG-RESISTANCE; HEXYL GLUTATHIONE; CRYSTAL-STRUCTURE; KINETIC-ANALYSIS; PROTON RELEASE; ALPHA-CLASS; BINDING; MECHANISM	The pK(a) of the catalytic Tyr-9 in glutathione S-transferase (GST) A1-1 is lowered from 10.3 to similar to8.1 in the apoenzyme and similar to9.0 with a GSH conjugate bound at the active site. However, a clear functional role for the unusual Tyr-9 pK(a) has not been elucidated. GSTA1-1 also includes a dynamic C terminus that undergoes a ligand-dependent disorder-to-order transition. Previous studies suggest a functional link between Tyr-9 ionization and C-terminal dynamics. Here we directly probe the role of Tyr-9 ionization in ligand binding and C-terminal conformation. An engineered mutant of rGSTA1-1, W21F/F222W, which contains a single Trp at the C terminus, was used as a fluorescent reporter of pH-dependent C-terminal dynamics. This mutant exhibited a pH-dependent change in Trp-222 emission properties consistent with changes in C-terminal solvation or conformation. The apparent pK(a) values for the conformational transition were 7.9 +/- 0.1 and 9.3 +/- 0.1 for the apoenzyme and ligand-bound enzyme, respectively, in excellent agreement with the pK(a) for Tyr-9 in these states. The Y9F/W21F/F222W mutant, however, exhibited no such pH-dependent changes. Time-resolved fluorescence anisotropy studies revealed a ligand-dependent, Tyr-9-dependent, change in the order parameter of Trp-222. However, no pH dependence was observed. In equilibrium and pre-steady-state ligand binding studies, product conjugate had a decreased equilibrium binding affinity (K-D), concomitant with increased binding and dissociation rates, at higher pH values. Furthermore, the recovered pK(a) values for the pH-dependent microscopic rate constants ranged from 7.7 to 8.4, also in agreement with the pK(a) of Tyr-9. In contrast, the Y9F/W21F/F222W mutant had no pH-dependent transition in K-D or rate constants for ligand binding or dissociation. The combined results indicate that the macroscopic populations of "open" and "closed" states of the C terminus are not determined solely by the ionization state of Tyr-9. However, the rates of transition between these states are faster for the ionized Tyr-9. The ionized Tyr-9 states provide a parallel pathway for product dissociation, which is kinetically and thermodynamically favored. In silico kinetic models further support the functional role for the parallel dissociation pathway provided by ionized Tyr-9.	Univ Washington, Dept Med Chem, Seattle, WA 98195 USA; Iowa State Univ, Dept Chem, Ames, IA 50011 USA	University of Washington; University of Washington Seattle; Iowa State University	Atkins, WM (corresponding author), Univ Washington, Dept Med Chem, Box 357610, Seattle, WA 98195 USA.		Petrich, Jacob/L-1005-2015; Chowdhury, Pramit/AAP-8164-2021	Chowdhury, Pramit/0000-0002-9593-2577	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F31GM020088, R01GM062284] Funding Source: NIH RePORTER; NIGMS NIH HHS [F31 GM020088, R01 GM062284, GM62284] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Adman ET, 2001, PROTEINS, V42, P192, DOI 10.1002/1097-0134(20010201)42:2<192::AID-PROT60>3.0.CO;2-#; Allardyce CS, 1999, BIOCHEM J, V343, P525, DOI 10.1042/0264-6021:3430525; Armstrong RN, 1997, CHEM RES TOXICOL, V10, P2, DOI 10.1021/tx960072x; Atkins WM, 1997, PROTEIN SCI, V6, P873; ATKINS WM, 1993, J BIOL CHEM, V268, P19188; BJORNESTEDT R, 1995, J MOL BIOL, V247, P765; Board PG, 1997, BIOCHEM J, V328, P929; Board PG, 2000, J BIOL CHEM, V275, P24798, DOI 10.1074/jbc.M001706200; Caccuri AM, 1998, BIOCHEMISTRY-US, V37, P3028, DOI 10.1021/bi971903g; Caccuri AM, 1999, BIOCHEM J, V344, P419, DOI 10.1042/0264-6021:3440419; Codreanu SG, 2002, BIOCHEMISTRY-US, V41, P15161, DOI 10.1021/bi026776p; COLES B, 1990, CRIT REV BIOCHEM MOL, V25, P47, DOI 10.3109/10409239009090605; Dirr HW, 1999, BIOCHEMISTRY-US, V38, P15631, DOI 10.1021/bi991179x; Gustafsson A, 1999, BIOCHEMISTRY-US, V38, P16268, DOI 10.1021/bi991482y; HABIG WH, 1974, J BIOL CHEM, V249, P7130; Hayes JD, 1995, CRIT REV BIOCHEM MOL, V30, P445, DOI 10.3109/10409239509083491; Ibarra C, 2001, BIOCHEMISTRY-US, V40, P10614, DOI 10.1021/bi010672h; LAKOWICZ JR, 1999, PRINCIPLES FLUORESCE, P156; Le Trong I, 2002, PROTEINS, V48, P618, DOI 10.1002/prot.10162; MANNERVIK B, 1988, CRC CR REV BIOCH MOL, V23, P283, DOI 10.3109/10409238809088226; Nieslanik BS, 1999, BIOCHEMISTRY-US, V38, P6971, DOI 10.1021/bi9829130; Nieslanik BS, 2001, BIOCHEMISTRY-US, V40, P3536, DOI 10.1021/bi001869x; Nieslanik BS, 2000, J BIOL CHEM, V275, P17447, DOI 10.1074/jbc.M002083200; Nilsson LO, 2000, P NATL ACAD SCI USA, V97, P9408, DOI 10.1073/pnas.150084897; O'Brien M, 2000, J PHARMACOL EXP THER, V294, P480; Parsons JF, 1996, J AM CHEM SOC, V118, P2295, DOI 10.1021/ja960022e; TEW KD, 1994, CANCER RES, V54, P4313; Thorson JS, 1998, J AM CHEM SOC, V120, P451, DOI 10.1021/ja9731682; WANG RW, 1989, ARCH BIOCHEM BIOPHYS, V269, P536, DOI 10.1016/0003-9861(89)90137-9; WANG RW, 1993, PROTEIN SCI, V2, P2085, DOI 10.1002/pro.5560021209; Widersten M, 1996, BIOCHEMISTRY-US, V35, P7731, DOI 10.1021/bi9601619	31	18	18	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 23	2003	278	21					19257	19265		10.1074/jbc.M301566200	http://dx.doi.org/10.1074/jbc.M301566200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	679PY	12637518	hybrid, Green Accepted			2022-12-25	WOS:000182932200070
J	Wang, SW; Zhu, JY				Wang, SW; Zhu, JY			Evidence for a relief of repression mechanism for activation of the human telomerase reverse transcriptase promoter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HISTONE DEACETYLASE INHIBITOR; HUMAN-CELLS; HTERT GENE; C-MYC; CELLULAR SENESCENCE; DNA METHYLATION; TUMOR-CELLS; IN-VIVO; SUBUNIT; CHROMATIN	The transcriptional activation of human telomerase reverse transcriptase ( hTERT) is an important step during cellular immortalization and tumorigenesis. To study how this activation occurs during immortalization, we have established a set of genetically related pre-crisis cells and their immortal progeny. As expected, hTERT mRNA was detected in our telomerase-positive immortal cells but not in pre-crisis cells or telomerase-negative immortal cells. However, transiently transfected luciferase reporters controlled by hTERT promoter sequences exhibited similar levels of luciferase activity in both telomerase-positive and -negative cells, suggesting that the endogenous chromatin context is likely required for hTERT regulation. Analysis of chromatin susceptibility to DNase I digestion consistently identified a DNase I hypersensitivity site (DHS) near the hTERT transcription initiation site in telomerase-positive cells. In addition, the histone deacetylase inhibitor trichostatin A (TSA) induced hTERT transcription and also a general increase in chromatin sensitivity to DNase treatment in telomerase-negative cells. The TSA-induced hTERT transcription in pre-crisis cells was accompanied by the formation of a DHS at the hTERT promoter. Furthermore, the TSA-induced hTERT transcription and chromatin alterations were not blocked by cycloheximide, suggesting that this induction does not require de novo protein synthesis and that TSA induces hTERT expression through the inhibition of histone deacetylation at the hTERT promoter. Taken together, our results suggest that the endogenous chromatin environment plays a critical role in the regulation of hTERT expression during cellular immortalization.	Penn State Univ, Coll Med, Dept Cellular & Mol Physiol, Hershey, PA 17033 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health	Zhu, JY (corresponding author), Penn State Univ, Coll Med, Dept Cellular & Mol Physiol, Hershey, PA 17033 USA.		zhu, ji/HDM-1538-2022					Aisner DL, 2002, CURR OPIN GENET DEV, V12, P80, DOI 10.1016/S0959-437X(01)00268-4; Azizkhan Jane C., 1993, Critical Reviews in Eukaryotic Gene Expression, V3, P229; Baur JA, 2001, SCIENCE, V292, P2075, DOI 10.1126/science.1062329; BRYAN TM, 1995, EMBO J, V14, P4240, DOI 10.1002/j.1460-2075.1995.tb00098.x; Bryce LA, 2000, NEOPLASIA, V2, P197, DOI 10.1038/sj.neo.7900092; Cong YS, 2000, J BIOL CHEM, V275, P35665, DOI 10.1074/jbc.C000637200; Crowe DL, 2001, NUCLEIC ACIDS RES, V29, P2789, DOI 10.1093/nar/29.13.2789; Dessain SK, 2000, CANCER RES, V60, P537; Devereux TR, 1999, CANCER RES, V59, P6087; Ducrest AL, 2002, ONCOGENE, V21, P541, DOI 10.1038/sj.onc.1205081; Ducrest AL, 2001, CANCER RES, V61, P7594; Greenberg RA, 1999, ONCOGENE, V18, P1219, DOI 10.1038/sj.onc.1202669; Hodny Z, 2000, BIOCHEM J, V346, P93, DOI 10.1042/0264-6021:3460093; Horikawa I, 2002, MOL BIOL CELL, V13, P2585, DOI 10.1091/mbc.E01-11-0107; Horikawa I, 1999, CANCER RES, V59, P826; Hou M, 2002, EXP CELL RES, V274, P25, DOI 10.1006/excr.2001.5462; Jacobson A, 1996, ANNU REV BIOCHEM, V65, P693, DOI 10.1146/annurev.bi.65.070196.003401; JEONG SW, 1994, NUCLEIC ACIDS RES, V22, P370, DOI 10.1093/nar/22.3.370; Kang SS, 1999, J BIOL CHEM, V274, P13085, DOI 10.1074/jbc.274.19.13085; Klingelhutz AJ, 1996, NATURE, V380, P79, DOI 10.1038/380079a0; Krupp G, 1997, NUCLEIC ACIDS RES, V25, P919, DOI 10.1093/nar/25.4.919; Kyo S, 2000, NUCLEIC ACIDS RES, V28, P669, DOI 10.1093/nar/28.3.669; Kyo S, 1999, CANCER RES, V59, P5917; LI BY, 1994, J BIOL CHEM, V269, P7756; Lomvardas S, 2001, CELL, V106, P685, DOI 10.1016/S0092-8674(01)00490-1; LUNDBLAD V, 1993, CELL, V73, P347, DOI 10.1016/0092-8674(93)90234-H; Meyerson M, 1997, CELL, V90, P785, DOI 10.1016/S0092-8674(00)80538-3; Misiti S, 2000, MOL CELL BIOL, V20, P3764, DOI 10.1128/MCB.20.11.3764-3771.2000; MORIN GB, 1989, CELL, V59, P521, DOI 10.1016/0092-8674(89)90035-4; Nakamura TM, 1997, SCIENCE, V277, P955, DOI 10.1126/science.277.5328.955; Oh S, 1999, BIOCHEM BIOPH RES CO, V263, P361, DOI 10.1006/bbrc.1999.1366; Oshimura M, 1997, EUR J CANCER, V33, P710, DOI 10.1016/S0959-8049(97)00090-7; PENG J, 1995, SCIENCE, V269, P1236; PEREIRASMITH OM, 1983, SCIENCE, V221, P964, DOI 10.1126/science.6879195; Robertson KD, 2002, ONCOGENE, V21, P5361, DOI 10.1038/sj.onc.1205609; Shay JW, 2000, NEOPLASIA, V2, P195, DOI 10.1038/sj.neo.7900093; Sjottem E, 1997, J MOL BIOL, V267, P490, DOI 10.1006/jmbi.1997.0893; Struhl K, 1998, GENE DEV, V12, P599, DOI 10.1101/gad.12.5.599; Szutorisz H, 2001, ONCOGENE, V20, P2600, DOI 10.1038/sj.onc.1204346; Takakura M, 1999, CANCER RES, V59, P551; Takakura M, 2001, NUCLEIC ACIDS RES, V29, P3006, DOI 10.1093/nar/29.14.3006; Turner BM, 2002, CELL, V111, P285, DOI 10.1016/S0092-8674(02)01080-2; Utley RT, 1997, J BIOL CHEM, V272, P12642, DOI 10.1074/jbc.272.19.12642; Wang J, 1998, GENE DEV, V12, P1769, DOI 10.1101/gad.12.12.1769; Wick M, 1999, GENE, V232, P97, DOI 10.1016/S0378-1119(99)00108-0; WRIGHT WE, 1992, EXP GERONTOL, V27, P383, DOI 10.1016/0531-5565(92)90069-C; Wu KJ, 1999, NAT GENET, V21, P220, DOI 10.1038/6010; Xu DW, 2001, P NATL ACAD SCI USA, V98, P3826, DOI 10.1073/pnas.071043198; Zhu JY, 1999, P NATL ACAD SCI USA, V96, P3723, DOI 10.1073/pnas.96.7.3723	49	56	62	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 23	2003	278	21					18842	18850		10.1074/jbc.M209544200	http://dx.doi.org/10.1074/jbc.M209544200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	679PY	12611896	hybrid			2022-12-25	WOS:000182932200019
J	Diaz-Lopez, T; Lages-Gonzalo, M; Serrano-Lopez, A; Alfonso, C; Rivas, G; Diaz-Orejas, R; Giraldo, R				Diaz-Lopez, T; Lages-Gonzalo, M; Serrano-Lopez, A; Alfonso, C; Rivas, G; Diaz-Orejas, R; Giraldo, R			Structural changes in RepA, a plasmid replication initiator, upon binding to origin DNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK PROTEINS; DOUBLE-STRANDED-DNA; MINI-F PLASMID; HOST-RANGE; ESCHERICHIA-COLI; RECOGNITION COMPLEX; NEGATIVE CONTROL; ATPASE ACTIVITY; CLPA CHAPERONE; COPY NUMBER	RepA protein is the DNA replication initiator of the Pseudomonas plasmid pPS10. RepA dimers bind to an inversely repeated operator sequence in repA promoter, thus repressing its own synthesis, whereas monomers bind to four directly repeated sequences (iterons) to initiate DNA replication. We had proposed previously that RepA is composed of two winged-helix (WH) domains, a structural unit also present in eukaryotic and archaeal initiators. To bind to the whole iteron sequence through both domains, RepA should couple monomerization to a conformational change in the N-terminal WH, which includes a leucine zipper-like sequence motif. We show for the first time that, by itself, binding to iteron DNA in vitro dissociates RepA dimers into monomers and alters RepA conformation, suggesting an allosteric effect. Furthermore, we also show that similar changes in RepA are promoted by mutations that substitute two Leu residues of the putative leucine zipper by Ala, destabilizing the hydrophobic core of the first WH. We propose that this mutant (RepA-2L2A) resembles a transient folding intermediate in the pathway leading to active monomers. These findings, together with the known activation of other Rep-type proteins by chaperones, are relevant to understand the molecular basis of plasmid DNA replication initiation.	CSIC, Dept Mol Microbiol, E-28006 Madrid, Spain; CSIC, Dept Prot Struct & Funct, E-28006 Madrid, Spain; CSIC, Analyt Ultracentrifugat Facil, Ctr Invest Biol, E-28006 Madrid, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); Consejo Superior de Investigaciones Cientificas (CSIC); Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Investigaciones Biologicas (CIB)	Giraldo, R (corresponding author), CSIC, Dept Mol Microbiol, C Velazquez 144, E-28006 Madrid, Spain.		Rivas, German/AAG-7458-2022; Alfonso, Carlos/K-1316-2014; Rivas, German/AFL-7528-2022; Giraldo, Rafael/P-3289-2014	Rivas, German/0000-0003-3450-7478; Alfonso, Carlos/0000-0001-7165-4800; Rivas, German/0000-0003-3450-7478; Giraldo, Rafael/0000-0002-5358-7488				Abril AM, 1997, BIOCHEMISTRY-US, V36, P11901, DOI 10.1021/bi970994e; Baker TA, 1998, CELL, V92, P295, DOI 10.1016/S0092-8674(00)80923-X; Blasina A, 1996, P NATL ACAD SCI USA, V93, P3559, DOI 10.1073/pnas.93.8.3559; BOHM G, 1992, PROTEIN ENG, V5, P191, DOI 10.1093/protein/5.3.191; BRENNER M, 1991, P NATL ACAD SCI USA, V88, P405, DOI 10.1073/pnas.88.2.405; Bukau B, 1998, CELL, V92, P351, DOI 10.1016/S0092-8674(00)80928-9; Chattoraj DK, 2000, MOL MICROBIOL, V37, P467, DOI 10.1046/j.1365-2958.2000.01986.x; Chattoraj DK, 1996, GENES CELLS, V1, P189, DOI 10.1046/j.1365-2443.1996.d01-235.x; COHEN S, 2000, HORIZONTAL GENE POOL, P1; Cruickshank J, 2000, J BIOL CHEM, V275, P22273, DOI 10.1074/jbc.M001414200; Dao-Thi MH, 2000, J MOL BIOL, V299, P1373, DOI 10.1006/jmbi.2000.3815; DASGUPTA S, 1993, J MOL BIOL, V232, P23, DOI 10.1006/jmbi.1993.1367; del Solar G, 1998, MICROBIOL MOL BIOL R, V62, P434, DOI 10.1128/MMBR.62.2.434-464.1998; DEVIEDMA DG, 1995, J MOL BIOL, V247, P211, DOI 10.1006/jmbi.1994.0134; deViedma DG, 1996, EMBO J, V15, P925, DOI 10.1002/j.1460-2075.1996.tb00427.x; deViedma DG, 1995, NUCLEIC ACIDS RES, V23, P5048, DOI 10.1093/nar/23.24.5048; Dibbens JA, 1997, MOL MICROBIOL, V26, P185, DOI 10.1046/j.1365-2958.1997.5691920.x; DURLAND RH, 1990, J BACTERIOL, V172, P3849, DOI 10.1128/jb.172.7.3849-3858.1990; FERNANDEZTRESGUERRES ME, 1995, J BACTERIOL, V177, P4377, DOI 10.1128/jb.177.15.4377-4384.1995; FILUTOWICZ M, 1986, P NATL ACAD SCI USA, V83, P9645, DOI 10.1073/pnas.83.24.9645; Gajiwala KS, 2000, CURR OPIN STRUC BIOL, V10, P110, DOI 10.1016/S0959-440X(99)00057-3; Giraldo R, 1998, EMBO J, V17, P4511, DOI 10.1093/emboj/17.15.4511; GIRALDO R, 1989, NATURE, V342, P866, DOI 10.1038/342866a0; Giraldo R, 2001, P NATL ACAD SCI USA, V98, P4938, DOI 10.1073/pnas.081079298; Giraldo R., 1992, DNA REPLICATION REGU, P225; Goloubinoff P, 1999, P NATL ACAD SCI USA, V96, P13732, DOI 10.1073/pnas.96.24.13732; Hoskins JR, 2000, P NATL ACAD SCI USA, V97, P8892, DOI 10.1073/pnas.97.16.8892; Hoskins JR, 2000, J BIOL CHEM, V275, P35361, DOI 10.1074/jbc.M006288200; INGMER H, 1995, J MOL BIOL, V250, P309, DOI 10.1006/jmbi.1995.0378; ISHIAI M, 1994, P NATL ACAD SCI USA, V91, P3839, DOI 10.1073/pnas.91.9.3839; Ishikawa T, 2001, P NATL ACAD SCI USA, V98, P4328, DOI 10.1073/pnas.081543698; Jen-Jacobson L, 2000, STRUCTURE, V8, P1015, DOI 10.1016/S0969-2126(00)00501-3; Kawasaki Y, 1996, MOL GEN GENET, V253, P42, DOI 10.1007/s004380050294; KAWASAKI Y, 1990, MOL GEN GENET, V220, P277; Kim SY, 2002, J BIOL CHEM, V277, P44778, DOI 10.1074/jbc.M206176200; Klemm RD, 1997, CELL, V88, P493, DOI 10.1016/S0092-8674(00)81889-9; Komori H, 1999, EMBO J, V18, P4597, DOI 10.1093/emboj/18.17.4597; Konieczny I, 1997, J BIOL CHEM, V272, P20173, DOI 10.1074/jbc.272.32.20173; Konieczny I, 1997, P NATL ACAD SCI USA, V94, P14378, DOI 10.1073/pnas.94.26.14378; Kornberg A., 1992, DNA REPLICATION; Kruger R, 2001, J MOL BIOL, V306, P945, DOI 10.1006/jmbi.2000.4426; Lee DG, 2000, EMBO J, V19, P4774, DOI 10.1093/emboj/19.17.4774; Lee DG, 2000, CURR OPIN CELL BIOL, V12, P280, DOI 10.1016/S0955-0674(00)00089-2; Liu JY, 2000, MOL CELL, V6, P637, DOI 10.1016/S1097-2765(00)00062-9; Mauricio L, 1997, J BIOL CHEM, V272, P19295, DOI 10.1074/jbc.272.31.19295; Messer W, 2002, FEMS MICROBIOL REV, V26, P355, DOI 10.1016/S0168-6445(02)00127-4; MUKHOPADHYAY G, 1994, EMBO J, V13, P2089, DOI 10.1002/j.1460-2075.1994.tb06484.x; NIETO C, 1992, J MOL BIOL, V223, P415, DOI 10.1016/0022-2836(92)90661-3; Pacek M, 2001, J BIOL CHEM, V276, P23639, DOI 10.1074/jbc.M100255200; Pak M, 1997, P NATL ACAD SCI USA, V94, P4901, DOI 10.1073/pnas.94.10.4901; PAPP PP, 1994, J BIOL CHEM, V269, P23563; Park K, 1998, J BIOL CHEM, V273, P24906, DOI 10.1074/jbc.273.38.24906; Park K, 2001, EMBO J, V20, P7323, DOI 10.1093/emboj/20.24.7323; Ptitsyn OB, 1995, ADV PROTEIN CHEM, V47, P83, DOI 10.1016/S0065-3233(08)60546-X; Schuck P, 2000, BIOPOLYMERS, V54, P328, DOI 10.1002/1097-0282(20001015)54:5<328::AID-BIP40>3.0.CO;2-P; Sharma R, 2001, EMBO J, V20, P4577, DOI 10.1093/emboj/20.16.4577; SOZHAMANNAN S, 1993, J BACTERIOL, V175, P3546, DOI 10.1128/jb.175.11.3546-3555.1993; Speck C, 2001, EMBO J, V20, P1469, DOI 10.1093/emboj/20.6.1469; SPOLAR RS, 1994, SCIENCE, V263, P777, DOI 10.1126/science.8303294; SWACK JA, 1987, J BACTERIOL, V169, P3737, DOI 10.1128/jb.169.8.3737-3742.1987; Toukdarian AE, 1996, J BIOL CHEM, V271, P7072, DOI 10.1074/jbc.271.12.7072; Urh M, 1998, J MOL BIOL, V283, P619, DOI 10.1006/jmbi.1998.2120; Viadiu H, 2000, MOL CELL, V5, P889, DOI 10.1016/S1097-2765(00)80329-9; Wang H, 2002, J BIOL CHEM, V277, P2225, DOI 10.1074/jbc.M109430200; WICKNER S, 1992, P NATL ACAD SCI USA, V89, P10345, DOI 10.1073/pnas.89.21.10345; WICKNER S, 1991, P NATL ACAD SCI USA, V88, P7903, DOI 10.1073/pnas.88.18.7903; WICKNER S, 1994, P NATL ACAD SCI USA, V91, P12218, DOI 10.1073/pnas.91.25.12218; Wu JZ, 1997, P NATL ACAD SCI USA, V94, P13967, DOI 10.1073/pnas.94.25.13967; Zheng N, 1999, GENE DEV, V13, P666, DOI 10.1101/gad.13.6.666	69	48	48	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 16	2003	278	20					18606	18616		10.1074/jbc.M212024200	http://dx.doi.org/10.1074/jbc.M212024200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677YX	12637554	hybrid, Green Submitted			2022-12-25	WOS:000182838300133
J	Fan, HZ; Turck, CW; Derynck, R				Fan, HZ; Turck, CW; Derynck, R			Characterization of growth factor-induced serine phosphorylation of tumor necrosis factor-alpha converting enzyme and of an alternatively translated polypeptide	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR TYROSINE KINASE; ACTIVATED PROTEIN-KINASE; SELECTIN ADHESION MOLECULE; MAP KINASE; TGF-ALPHA; METALLOPROTEASE-DISINTEGRIN; CELL-SURFACE; TRANSMEMBRANE PROTEINS; DEPENDENT MECHANISM; SIGNAL-TRANSDUCTION	Tumor necrosis factor-alpha converting enzyme (TACE) is a prototype member of the adamalysin family of transmembrane metalloproteases that effects ectodomain cleavage and release of many transmembrane proteins, including transforming growth factor-alpha. Growth factors that act through tyrosine kinase receptors, as well as other stimuli, induce shedding through activation of the Erk mitogen-activated protein (MAP) kinase pathway without the need of new protein synthesis. How MAP kinase regulates shedding by TACE is not known. We now report that the cytoplasmic domain of TACE is phosphorylated in response to growth factor stimulation. We also identified a naturally expressed smaller polypeptide corresponding to most of the cytoplasmic domain of TACE. This protein, which we named SPRACT, is derived through alternative translation of the TACE-coding sequence and is, similarly to TACE, phosphorylated in response to growth factor and phorbol 12-myristate 13-acetate stimulation. Phosphoamino acid analysis revealed that growth factor-induced phosphorylation of TACE occurs only on serine and not on threonine or tyrosine. Tryptic mapping experiments coupled with site-directed mutagenesis identified Ser(819) as the major target of growth factor-induced phosphorylation, whereas Ser(791) undergoes dephosphorylation in response to growth factor stimulation. The phosphorylation of Ser(819), but not the dephosphorylation of Ser(791), depends on activation of the Erk MAP kinase pathway. Increased SPRACT expression or mutation of the TACE cytoplasmic domain to inactivate growth factor-induced phosphorylation did not detectably affect growth factor-induced shedding of transmembrane transforming growth factor-alpha by TACE. The roles of SPRACT and the cytoplasmic phosphorylation of TACE remain to be defined.	Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Physiol & Biophys, Piscataway, NJ 08854 USA; Univ Calif San Francisco, Dept Growth & Dev, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Anat, Cell Biol Program, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Anat, Program Dev Biol, San Francisco, CA 94143 USA; Canc Inst New Jersey, Piscataway, NJ 08854 USA; Univ Calif San Francisco, Howard Hughes Med Inst, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA	Rutgers State University New Brunswick; Rutgers State University Medical Center; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers Cancer Institute of New Jersey; Howard Hughes Medical Institute; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Fan, HZ (corresponding author), Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Physiol & Biophys, 675 Hoes Lane R514, Piscataway, NJ 08854 USA.		Fan, Huizhou/E-5835-2012	FAN, HUIZHOU/0000-0002-4903-926X	NATIONAL CANCER INSTITUTE [R01CA054826] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [P01DE013904] Funding Source: NIH RePORTER; NCI NIH HHS [CA54826] Funding Source: Medline; NIDCR NIH HHS [DE13904] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Aguilar Z, 2001, J BIOL CHEM, V276, P44099, DOI 10.1074/jbc.M103442200; Arribas J, 1996, J BIOL CHEM, V271, P11376, DOI 10.1074/jbc.271.19.11376; BEUTLER B, 1986, NATURE, V320, P584, DOI 10.1038/320584a0; Black RA, 1997, NATURE, V385, P729, DOI 10.1038/385729a0; Black RA, 2002, INT J BIOCHEM CELL B, V34, P1, DOI 10.1016/S1357-2725(01)00097-8; Blobel CP, 2000, CURR OPIN CELL BIOL, V12, P606, DOI 10.1016/S0955-0674(00)00139-3; Boissel JP, 1998, NITRIC OXIDE-BIOL CH, V2, P337, DOI 10.1006/niox.1998.0189; BRACHMANN R, 1989, CELL, V56, P691, DOI 10.1016/0092-8674(89)90591-6; Brou C, 2000, MOL CELL, V5, P207, DOI 10.1016/S1097-2765(00)80417-7; BUTCHER EC, 1992, ADV EXP MED BIOL, V323, P181; Cerretti DP, 1999, BIOCHEM BIOPH RES CO, V263, P810, DOI 10.1006/bbrc.1999.1322; Conway JG, 2001, J PHARMACOL EXP THER, V298, P900; CROWE PD, 1995, J EXP MED, V181, P1205, DOI 10.1084/jem.181.3.1205; de Mora JF, 2000, MOL CELL BIOL, V20, P5041, DOI 10.1128/MCB.20.14.5041-5047.2000; DERYNCK R, 1992, ADV CANCER RES, V58, P27, DOI 10.1016/S0065-230X(08)60289-4; Diaz-Rodriguez E, 2002, MOL BIOL CELL, V13, P2031, DOI 10.1091/mbc.01-11-0561; EHLERS MRW, 1991, BIOCHEMISTRY-US, V30, P10065, DOI 10.1021/bi00106a001; Fan HZ, 1999, EMBO J, V18, P6962, DOI 10.1093/emboj/18.24.6962; Feehan C, 1996, J BIOL CHEM, V271, P7019, DOI 10.1074/jbc.271.12.7019; Gechtman Z, 1999, J BIOL CHEM, V274, P28828, DOI 10.1074/jbc.274.40.28828; Gerli R, 2001, J IMMUNOL, V166, P832, DOI 10.4049/jimmunol.166.2.832; Gutwein P, 2000, J BIOL CHEM, V275, P15490, DOI 10.1074/jbc.275.20.15490; Hooper NM, 1997, BIOCHEM J, V321, P265, DOI 10.1042/bj3210265; Imperiale M J, 1995, Curr Top Microbiol Immunol, V199 ( Pt 2), P139; Iwamoto R, 2000, CYTOKINE GROWTH F R, V11, P335, DOI 10.1016/S1359-6101(00)00013-7; Izumi Y, 1998, EMBO J, V17, P7260, DOI 10.1093/emboj/17.24.7260; Kahn J, 1998, CELL, V92, P809, DOI 10.1016/S0092-8674(00)81408-7; KISHIMOTO TK, 1989, SCIENCE, V245, P1238, DOI 10.1126/science.2551036; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; Lewis TS, 1998, ADV CANCER RES, V74, P49, DOI 10.1016/S0065-230X(08)60765-4; Luetteke N C, 1990, Semin Cancer Biol, V1, P265; Lum L, 1999, J BIOL CHEM, V274, P13613, DOI 10.1074/jbc.274.19.13613; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; MASSAGUE J, 1993, ANNU REV BIOCHEM, V62, P515, DOI 10.1146/annurev.bi.62.070193.002503; McDermott MF, 1999, CELL, V97, P133, DOI 10.1016/S0092-8674(00)80721-7; Merlos-Suarez A, 1999, BIOCHEM SOC T, V27, P243, DOI 10.1042/bst0270243; Montero JC, 2000, MOL CELL NEUROSCI, V16, P631, DOI 10.1006/mcne.2000.0896; Montero JC, 2002, BIOCHEM J, V363, P211, DOI 10.1042/0264-6021:3630211; Moss ML, 1997, NATURE, V385, P733, DOI 10.1038/385733a0; Namchuk M, 1997, J BIOL CHEM, V272, P1548, DOI 10.1074/jbc.272.3.1548; Nelson KK, 1999, BIOCHEM J, V343, P673, DOI 10.1042/0264-6021:3430673; Okada-Ban M, 2000, INT J BIOCHEM CELL B, V32, P263, DOI 10.1016/S1357-2725(99)00133-8; PANDIELLA A, 1991, BIOCHEM SOC T, V19, P259, DOI 10.1042/bst0190259; PANDIELLA A, 1991, J BIOL CHEM, V266, P5769; PANDIELLA A, 1991, P NATL ACAD SCI USA, V88, P1726, DOI 10.1073/pnas.88.5.1726; Pearson G, 2001, ENDOCR REV, V22, P153, DOI 10.1210/er.22.2.153; Peschon JJ, 1998, SCIENCE, V282, P1281, DOI 10.1126/science.282.5392.1281; Reddy P, 2000, J BIOL CHEM, V275, P14608, DOI 10.1074/jbc.275.19.14608; Rio C, 2000, J BIOL CHEM, V275, P10379, DOI 10.1074/jbc.275.14.10379; Rizoli SB, 1999, J BIOL CHEM, V274, P22072, DOI 10.1074/jbc.274.31.22072; Robinson MJ, 1998, CURR BIOL, V8, P1141, DOI 10.1016/S0960-9822(07)00485-X; Schlondorff J, 2000, BIOCHEM J, V347, P131, DOI 10.1042/0264-6021:3470131; Schlondorff J, 2001, J BIOL CHEM, V276, P14665, DOI 10.1074/jbc.M010741200; Shi W, 2000, J CELL BIOL, V148, P591, DOI 10.1083/jcb.148.3.591; Solomon KA, 1997, J IMMUNOL, V159, P4524; Strausbaugh HJ, 1999, NAT MED, V5, P1057, DOI 10.1038/12497; Sunnarborg SW, 2002, J BIOL CHEM, V277, P12838, DOI 10.1074/jbc.M112050200; Umata T, 2001, J BIOL CHEM, V276, P30475, DOI 10.1074/jbc.M103673200; Vagner S, 2001, EMBO REP, V2, P893, DOI 10.1093/embo-reports/kve208; Vecchi M, 1998, J BIOL CHEM, V273, P20589, DOI 10.1074/jbc.273.32.20589; Vecchi M, 1997, J CELL BIOL, V139, P995, DOI 10.1083/jcb.139.4.995; Werb Z, 1998, SCIENCE, V282, P1279, DOI 10.1126/science.282.5392.1279; WONG ST, 1989, CELL, V56, P495, DOI 10.1016/0092-8674(89)90252-3; Xu KP, 2001, AM J PHYSIOL-CELL PH, V281, pC603, DOI 10.1152/ajpcell.2001.281.2.C603; YAGAMIHIROMASA T, 1995, NATURE, V377, P652, DOI 10.1038/377652a0; Zheng YF, 2002, J BIOL CHEM, V277, P42463, DOI 10.1074/jbc.M207459200; Zhou W, 2002, INFLAMM RES, V51, P91, DOI 10.1007/BF02684009; Zhou WL, 2000, J BIOL CHEM, V275, P34737, DOI 10.1074/jbc.M003756200; Zhu GZ, 1999, GENE, V234, P227, DOI 10.1016/S0378-1119(99)00208-5	69	97	101	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 16	2003	278	20					18617	18627		10.1074/jbc.M300331200	http://dx.doi.org/10.1074/jbc.M300331200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677YX	12621058	hybrid			2022-12-25	WOS:000182838300134
J	Hirayama, S; Sugiura, R; Lu, YB; Maeda, T; Kawagishi, K; Yokoyama, M; Tohda, H; Giga-Hama, Y; Shuntoh, H; Kuno, T				Hirayama, S; Sugiura, R; Lu, YB; Maeda, T; Kawagishi, K; Yokoyama, M; Tohda, H; Giga-Hama, Y; Shuntoh, H; Kuno, T			Zinc finger protein Prz1 regulates Ca2+ but not Cl- homeostasis in fission yeast - Identification of distinct branches of calcineurin signaling pathway in fission yeast	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR-GENETIC-ANALYSIS; SACCHAROMYCES-CEREVISIAE; SCHIZOSACCHAROMYCES-POMBE; TRANSCRIPTION FACTOR; BINDING PROTEIN; CYCLOSPORINE-A; PHOSPHATASE; EXPRESSION; HOMOLOG; CYTOKINESIS	Calcineurin is an important mediator that connects the Ca2+-dependent signaling to various cellular responses in a wide variety of cell types and organisms. In budding yeast, activated calcineurin exerts its function mainly by regulating the Crz1p/Tcn1 transcription factor. Here, we cloned the fission yeast prz1(+) gene, which encodes a zinc finger transcription factor highly homologous to Crz1/Tcn1. Similar to the results in budding yeast, calcineurin dephosphorylated Prz1 and resulted in the trans-location of Prz1 from the cytoplasm to the nucleus. Prz1 expression was stimulated by high extracellular Ca2+ in a calcineurin-dependent fashion. However, unlike in budding yeast, the prz1-null cells did not show any phenotype similar to those previously reported in calcineurin deletion such as aberrant cell morphology, mating defect, or hypersensitivity to Cl-. Instead, the prz1-null cells showed hypersensitivity to Ca2+, consistent with a dramatic decrease in transcription of Pmc1 Ca2+ pump. Interestingly, overexpression of Prz1 did not suppress the Cl- hypersensitivity of calcineurin deletion, and overexpression of Pmp1 MAPK phosphatase suppressed the Cl- hypersensitivity of calcineurin deletion but not the Ca2+ hypersensitivity of prz1 deletion. In addition, mutations in the its2(+)/cps1(+), its8(+), and its10(+)/cdc7(+) genes that showed synthetic lethal genetic interaction with calcineurin deletion did not exhibit synthetic lethality with the prz1 deletion. Our results suggest that calcineurin activates at least two distinct signaling branches, i.e. the Prz1-dependent transcriptional regulation and an unknown mechanism, which functions antagonistically with the Pmk1 MAPK pathway.	Kobe Univ, Grad Sch Med, Dept Genome Sci, Div Mol Pharmacol & Pharmacogenom,Chuo Ku, Kobe, Hyogo 6500017, Japan; Kobe Univ, Grad Sch Med, Div Cardiovasc & Resp Med, Chuo Ku, Kobe, Hyogo 6500017, Japan; Asahi Glass Co Ltd, Res Ctr, ASPEX Div, Kanagawa Ku, Yokohama, Kanagawa 2218755, Japan; Kobe Univ, Sch Med, Fac Hlth Sci, Suma Ku, Kobe, Hyogo 6500142, Japan	Kobe University; Kobe University; AGC Inc; Kobe University	Kuno, T (corresponding author), Kobe Univ, Grad Sch Med, Dept Genome Sci, Div Mol Pharmacol & Pharmacogenom,Chuo Ku, 7-5-1 Kusunoki Cho, Kobe, Hyogo 6500017, Japan.	tkuno@med.kobe-u.ac.jp	Tohda, Hideki/H-3162-2013; Tohda, Hideki/O-5132-2019					Cheng H, 2002, MOL BIOL CELL, V13, P2963, DOI 10.1091/mbc.01-09-0463; CLIPSTONE NA, 1992, NATURE, V357, P695, DOI 10.1038/357695a0; Crabtree GR, 2001, J BIOL CHEM, V276, P2313, DOI 10.1074/jbc.R000024200; Cunningham KW, 1996, MOL CELL BIOL, V16, P2226; CUNNINGHAM KW, 1994, J CELL BIOL, V124, P351, DOI 10.1083/jcb.124.3.351; CYERT MS, 1992, MOL CELL BIOL, V12, P3460, DOI 10.1128/MCB.12.8.3460; CYERT MS, 1991, P NATL ACAD SCI USA, V88, P7376, DOI 10.1073/pnas.88.16.7376; FARCASANU IC, 1995, EUR J BIOCHEM, V232, P712, DOI 10.1111/j.1432-1033.1995.tb20865.x; Fujita M, 2002, GENETICS, V161, P971; Graef IA, 2001, CELL, V105, P863, DOI 10.1016/S0092-8674(01)00396-8; HEIM R, 1995, NATURE, V373, P663, DOI 10.1038/373663b0; HENDEY B, 1992, SCIENCE, V258, P296, DOI 10.1126/science.1384129; Ishiguro J, 1997, J BACTERIOL, V179, P7653, DOI 10.1128/jb.179.24.7653-7662.1997; KLEE CB, 1979, P NATL ACAD SCI USA, V76, P6270, DOI 10.1073/pnas.76.12.6270; KOHRER K, 1991, METHOD ENZYMOL, V194, P398; KUNO T, 1991, BIOCHEM BIOPH RES CO, V180, P1159, DOI 10.1016/S0006-291X(05)81188-X; Lafuente MJ, 1997, FEBS LETT, V420, P39, DOI 10.1016/S0014-5793(97)01486-5; LIU J, 1991, CELL, V66, P807, DOI 10.1016/0092-8674(91)90124-H; LIU Y, 1991, MOL GEN GENET, V227, P52, DOI 10.1007/BF00260706; Lu YB, 2002, GENES CELLS, V7, P1009, DOI 10.1046/j.1365-2443.2002.00582.x; Mansuy IM, 1998, CELL, V92, P39, DOI 10.1016/S0092-8674(00)80897-1; Matheos DP, 1997, GENE DEV, V11, P3445, DOI 10.1101/gad.11.24.3445; MAUNDRELL K, 1993, GENE, V123, P127, DOI 10.1016/0378-1119(93)90551-D; MENDOZA I, 1994, J BIOL CHEM, V269, P8792; Molkentin JD, 1998, CELL, V93, P215, DOI 10.1016/S0092-8674(00)81573-1; MORENO S, 1991, METHOD ENZYMOL, V194, P795; MUKAI H, 1991, J BIOCHEM, V110, P402, DOI 10.1093/oxfordjournals.jbchem.a123593; NAKAMURA T, 1993, EMBO J, V12, P4063, DOI 10.1002/j.1460-2075.1993.tb06090.x; OKEEFE SJ, 1992, NATURE, V357, P692, DOI 10.1038/357692a0; PERUTZ MF, 1994, P NATL ACAD SCI USA, V91, P5355, DOI 10.1073/pnas.91.12.5355; Pozos TC, 1996, MOL CELL BIOL, V16, P3730; ROTHSTEIN RJ, 1983, METHOD ENZYMOL, V101, P202; Stathopoulos AM, 1997, GENE DEV, V11, P3432, DOI 10.1101/gad.11.24.3432; Stathopoulos-Gerontides A, 1999, GENE DEV, V13, P798, DOI 10.1101/gad.13.7.798; Sugiura R, 1999, NATURE, V399, P479, DOI 10.1038/20951; Sugiura R, 1998, EMBO J, V17, P140, DOI 10.1093/emboj/17.1.140; Sugiura R, 2002, GENES CELLS, V7, P619, DOI 10.1046/j.1365-2443.2002.00557.x; Sugiura R, 2001, CELL MOL LIFE SCI, V58, P278, DOI 10.1007/PL00000855; Toda T, 1996, MOL CELL BIOL, V16, P6752; Wang HG, 1999, SCIENCE, V284, P339, DOI 10.1126/science.284.5412.339; Yada T, 2001, J BIOL CHEM, V276, P13579, DOI 10.1074/jbc.M009260200; YOSHIDA T, 1994, J CELL SCI, V107, P1725; Yoshimoto H, 2002, J BIOL CHEM, V277, P31079, DOI 10.1074/jbc.M202718200; Zhang YJ, 2000, J BIOL CHEM, V275, P35600, DOI 10.1074/jbc.M005575200	44	71	75	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 16	2003	278	20					18078	18084		10.1074/jbc.M212900200	http://dx.doi.org/10.1074/jbc.M212900200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677YX	12637524	hybrid			2022-12-25	WOS:000182838300064
J	Kassavetis, GA; Han, SL; Naji, S; Geiduschek, EP				Kassavetis, GA; Han, SL; Naji, S; Geiduschek, EP			The role of transcription initiation factor IIIB subunits in promoter opening probed by photochemical cross-linking	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-POLYMERASE-III; START-SITE SELECTION; OPEN COMPLEX-FORMATION; RESTRICTION-ENDONUCLEASE; PREINITIATION COMPLEX; PHOTOAFFINITY PROBES; PROTEIN INTERACTIONS; ESCHERICHIA-COLI; BINDING PROTEIN; FACTOR TFIIIB	The core transcription initiation factor (TF) IIIB recruits its conjugate RNA polymerase (pol) III to the promoter and also plays an essential role in promoter opening. TFIIIB assembled with certain deletion mutants of its Brf1 and Bdp1 subunits is competent in pol III recruitment, but the resulting preinitiation complex does not open the promoter. Whether Brf1 and Bdp1 participate in opening the promoter by direct DNA interaction (as sigma subunits of bacterial RNA polymerases do) or indirectly by their action on pol III has been approached by site-specific photochemical protein-DNA cross-linking of TFIIIB-pol III-U6 RNA gene promoter complexes. Brf1, Bdp1, and several pol III subunits can be crosslinked to the nontranscribed strand of the U6 promoter at base pair -9/-8 and +2/+3 (relative to the transcriptional start as +1), respectively the upstream and downstream ends of the DNA segment that opens up into the transcription bubble. Cross-linking of Bdp1 and Brf1 is detected at 0 AdegreesC in closed preinitiation complexes and at 30 degreesC in complexes that are partly open, but also it is detected in mutant TFIIIB-pol III-DNA complexes that are unable to open the promoter. In contrast, promoter opening-defective TFIIIB mutants generate significant changes of cross-linking of polymerase subunits. The weight of this evidence argues in favor of an indirect mode of action of TFIIIB in promoter opening.	Univ Calif San Diego, Div Biol Sci, La Jolla, CA 92093 USA; Univ Calif San Diego, Ctr Mol Genet, La Jolla, CA 92093 USA	University of California System; University of California San Diego; University of California System; University of California San Diego	Kassavetis, GA (corresponding author), Univ Calif San Diego, Div Biol Sci, 9500 Gilman Dr, La Jolla, CA 92093 USA.							Andrau JC, 1999, J MOL BIOL, V288, P511, DOI 10.1006/jmbi.1999.2724; Andrau JC, 2001, EUR J BIOCHEM, V268, P5167, DOI 10.1046/j.0014-2956.2001.02445.x; BARTHOLOMEW B, 1993, MOL CELL BIOL, V13, P942, DOI 10.1128/MCB.13.2.942; Bartholomew B, 1995, METHOD ENZYMOL, V262, P476; BARTHOLOMEW B, 1990, EMBO J, V9, P2197, DOI 10.1002/j.1460-2075.1990.tb07389.x; BARTHOLOMEW B, 1994, J BIOL CHEM, V269, P18090; Brun I, 1997, EMBO J, V16, P5730, DOI 10.1093/emboj/16.18.5730; Bushnell DA, 1996, J BIOL CHEM, V271, P20170, DOI 10.1074/jbc.271.33.20170; Cannon WV, 2000, NAT STRUCT BIOL, V7, P594; Chedin S, 1998, COLD SPRING HARB SYM, V63, P381, DOI 10.1101/sqb.1998.63.381; Cho EJ, 1999, J BIOL CHEM, V274, P25807, DOI 10.1074/jbc.274.36.25807; Douziech M, 2000, MOL CELL BIOL, V20, P8168, DOI 10.1128/MCB.20.21.8168-8177.2000; Favre A, 1998, J PHOTOCH PHOTOBIO B, V42, P109, DOI 10.1016/S1011-1344(97)00116-4; Flores A, 1999, P NATL ACAD SCI USA, V96, P7815, DOI 10.1073/pnas.96.14.7815; Geiduschek EP, 2001, J MOL BIOL, V310, P1, DOI 10.1006/jmbi.2001.4732; Grove A, 2002, EMBO J, V21, P704, DOI 10.1093/emboj/21.4.704; Guo YL, 2000, GENE DEV, V14, P2242, DOI 10.1101/gad.794800; Hahn S, 2000, GENE DEV, V14, P719; Hawkes NA, 1999, J BIOL CHEM, V274, P14337, DOI 10.1074/jbc.274.20.14337; Helmann JD, 1999, BIOCHEMISTRY-US, V38, P5959, DOI 10.1021/bi990206g; Holstege FCP, 1997, METHODS, V12, P203, DOI 10.1006/meth.1997.0472; Jeltsch A, 1998, J MOL BIOL, V275, P747, DOI 10.1006/jmbi.1997.1492; Joazeiro CAP, 1996, GENE DEV, V10, P725, DOI 10.1101/gad.10.6.725; KASSAVETIS GA, 1989, MOL CELL BIOL, V9, P2551, DOI 10.1128/MCB.9.6.2551; Kassavetis GA, 1999, EMBO J, V18, P5042, DOI 10.1093/emboj/18.18.5042; Kassavetis GA, 1998, P NATL ACAD SCI USA, V95, P9196, DOI 10.1073/pnas.95.16.9196; Kassavetis GA, 1997, MOL CELL BIOL, V17, P5299, DOI 10.1128/MCB.17.9.5299; Kassavetis GA, 2002, EMBO J, V21, P5508, DOI 10.1093/emboj/cdf533; Kassavetis GA, 2001, EMBO J, V20, P2823, DOI 10.1093/emboj/20.11.2823; Kim TK, 2000, SCIENCE, V288, P1418, DOI 10.1126/science.288.5470.1418; Kovach MJ, 2002, J BIOL CHEM, V277, P14530, DOI 10.1074/jbc.M108197200; Kumar A, 1998, COLD SPRING HARB SYM, V63, P121, DOI 10.1101/sqb.1998.63.121; Lannutti BJ, 1996, BIOCHEMISTRY-US, V35, P9821, DOI 10.1021/bi960525x; Marr MT, 1997, SCIENCE, V276, P1258, DOI 10.1126/science.276.5316.1258; Matlock DL, 2000, BIOCHEMISTRY-US, V39, P12274, DOI 10.1021/bi001433h; Nickels BE, 2002, MOL CELL, V10, P611, DOI 10.1016/S1097-2765(02)00648-2; NIKIFOROV TT, 1992, NUCLEIC ACIDS RES, V20, P1209, DOI 10.1093/nar/20.6.1209; Nudler E, 2002, GENES CELLS, V7, P755, DOI 10.1046/j.1365-2443.2002.00563.x; Pardee TS, 1998, J BIOL CHEM, V273, P17859, DOI 10.1074/jbc.273.28.17859; PINTO I, 1994, J BIOL CHEM, V269, P30569; Ranish JA, 1999, GENE DEV, V13, P49, DOI 10.1101/gad.13.1.49; RECORD J, 1996, ESCHERICHIA COLI SAL, P792; Roberts JW, 1998, COLD SPRING HARB SYM, V63, P319, DOI 10.1101/sqb.1998.63.319; Rombel I, 1998, COLD SPRING HARB SYM, V63, P157, DOI 10.1101/sqb.1998.63.157; Schramm L, 2002, GENE DEV, V16, P2593, DOI 10.1101/gad.1018902; Shah SMA, 1999, J BIOL CHEM, V274, P28736, DOI 10.1074/jbc.274.40.28736; Thorogood H, 1996, BIOCHEMISTRY-US, V35, P8723, DOI 10.1021/bi960230j; THUILLIER V, 1995, EMBO J, V14, P351, DOI 10.1002/j.1460-2075.1995.tb07009.x; Wang ZX, 1997, GENE DEV, V11, P1315, DOI 10.1101/gad.11.10.1315; WHITE RJ, 2002, GENE TRANSCRIPTION M, P113; WHITEHALL SK, 1995, GENE DEV, V9, P2974, DOI 10.1101/gad.9.23.2974; Willis IM, 2002, GENE DEV, V16, P1337, DOI 10.1101/gad.998102	52	21	21	2	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 16	2003	278	20					17912	17917		10.1074/jbc.M300743200	http://dx.doi.org/10.1074/jbc.M300743200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677YX	12637540	hybrid			2022-12-25	WOS:000182838300041
J	Mead, JR; Hughes, TR; Irvine, SA; Singh, NN; Ramji, DP				Mead, JR; Hughes, TR; Irvine, SA; Singh, NN; Ramji, DP			Interferon-gamma stimulates the expression of the inducible cAMP early repressor in macrophages through the activation of casein kinase 2 - A potentially novel pathway for interferon-gamma-mediated inhibition of gene transcription	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING-PROTEIN ISOFORMS; CYCLE-REGULATED PHOSPHORYLATION; DENSITY-LIPOPROTEIN RECEPTOR; LONG-TERM DESENSITIZATION; NECROSIS-FACTOR-ALPHA; FOAM CELL-FORMATION; IFN-GAMMA; DIFFERENTIAL REGULATION; HUMAN MONOCYTES; SELECTIVE-INHIBITION	Interferon-gamma (IFN-gamma) is a pleiotropic cytokine that modulates the immune function, cell proliferation, apoptosis, macrophage activation, and numerous other cellular responses. These biological actions of IFN-gamma are characterized by both the activation and the inhibition of gene transcription. Unfortunately, in contrast to gene activation, the mechanisms through which the cytokine suppresses gene transcription remain largely unclear. We show here for the first time that exposure of macrophages to IFN-gamma leads to a dramatic induction in the expression of the inducible cAMP early repressor (ICER), a potent inhibitor of gene transcription. In addition, a synergistic action of IFN-gamma and calcium in the activation of ICER expression was identified. The IFN-gamma-mediated activation of ICER expression was not blocked by H89, bisindoylmaleimide, SB202190, PD98059, W7, and AG490, which inhibit protein kinase A, protein kinase C, p38 mitogen-activated protein kinase, extracellular signal-regulated kinase, calcium-calmodulin-dependent protein kinase, and Janus kinase-2, respectively. In contrast, apigenin, a selective casein kinase 2 (CK2) inhibitor, was found to inhibit response. Consistent with this finding, IFN-gamma stimulated CK2 activity and the level of phosphorylated cAMP response element-binding protein, which is known to induce ICER gene transcription, and this response was inhibited in the presence of apigenin. These studies, therefore, identify a previously uncharacterized pathway, involving the IFN-gamma-mediated stimulation of CK2 activity, activation of cAMP response element-binding protein, and increased production of ICER, which may then play an important role in the inhibition of macrophage gene transcription by this cytokine.	Cardiff Univ, Cardiff Sch Biosci, Cardiff CF10 3US, S Glam, Wales	Cardiff University	Ramji, DP (corresponding author), Cardiff Univ, Cardiff Sch Biosci, Museum Ave,POB 911, Cardiff CF10 3US, S Glam, Wales.	ramji@cardiff.ac.uk	irvine, scott/B-1090-2019; irvine, scott/A-2392-2019; Ramji, Dipak/A-7092-2010	irvine, scott/0000-0002-8926-1543; Ramji, Dipak/0000-0002-6419-5578				Ala-aho R, 2000, ONCOGENE, V19, P248, DOI 10.1038/sj.onc.1203306; Antoine M, 1996, MOL CELL ENDOCRINOL, V120, P1, DOI 10.1016/0303-7207(96)03806-3; AUWERX JH, 1989, BIOCHEMISTRY-US, V28, P4563, DOI 10.1021/bi00437a009; Bodor J, 2002, EUR J IMMUNOL, V32, P203, DOI 10.1002/1521-4141(200201)32:1<203::AID-IMMU203>3.0.CO;2-C; Bodor J, 1998, J BIOL CHEM, V273, P9544, DOI 10.1074/jbc.273.16.9544; Bodor J, 2001, J LEUKOCYTE BIOL, V69, P1053; Boehm U, 1997, ANNU REV IMMUNOL, V15, P749, DOI 10.1146/annurev.immunol.15.1.749; Buechler C, 2000, J LEUKOCYTE BIOL, V67, P97, DOI 10.1002/jlb.67.1.97; BYRON KA, 1991, CLIN EXP IMMUNOL, V85, P307; Channavajhala P, 2002, ONCOGENE, V21, P5280, DOI 10.1038/sj.onc.1205640; Chujor CSN, 1996, EUR J IMMUNOL, V26, P1253, DOI 10.1002/eji.1830260611; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; Davies GE, 2000, BIOCHEM BIOPH RES CO, V271, P346, DOI 10.1006/bbrc.2000.2630; De Cesare D, 2000, PROG NUCLEIC ACID RE, V64, P343, DOI 10.1016/S0079-6603(00)64009-6; Der SD, 1998, P NATL ACAD SCI USA, V95, P15623, DOI 10.1073/pnas.95.26.15623; DESANCTIS JB, 1994, IMMUNOLOGY, V81, P605; Diaz A, 1997, INT J BIOCHEM CELL B, V29, P251, DOI 10.1016/S1357-2725(96)00112-4; Dowd DR, 1997, MOL CELL ENDOCRINOL, V128, P29, DOI 10.1016/S0303-7207(96)04012-9; Egwuagu CE, 2002, J IMMUNOL, V168, P3181, DOI 10.4049/jimmunol.168.7.3181; Fitzgerald LR, 1996, J NEUROCHEM, V67, P490; Foka P, 2001, BIOCHEM BIOPH RES CO, V285, P430, DOI 10.1006/bbrc.2001.5203; Ford HL, 2000, J BIOL CHEM, V275, P22245, DOI 10.1074/jbc.M002446200; GENG YJ, 1992, J CLIN INVEST, V89, P1322, DOI 10.1172/JCI115718; Gil MP, 2001, P NATL ACAD SCI USA, V98, P6680, DOI 10.1073/pnas.111163898; Granger RL, 2000, BBA-MOL BASIS DIS, V1501, P171, DOI 10.1016/S0925-4439(00)00016-8; Heninger E, 2000, INFLAMM RES, V49, P393, DOI 10.1007/s000110050606; HIPSKIND RA, 1994, MOL CELL BIOL, V14, P6219, DOI 10.1128/MCB.14.9.6219; Horvai AE, 1997, P NATL ACAD SCI USA, V94, P1074, DOI 10.1073/pnas.94.4.1074; Hughes TR, 2002, J BIOL CHEM, V277, P11097, DOI 10.1074/jbc.M106774200; Hussain MA, 2000, DIABETES, V49, P1681, DOI 10.2337/diabetes.49.10.1681; Ikeda Y, 1999, BIOCHEM BIOPH RES CO, V262, P494, DOI 10.1006/bbrc.1999.1226; Iwata M, 2001, JPN J OPHTHALMOL, V45, P13, DOI 10.1016/S0021-5155(00)00296-3; Jikihara H, 1996, BIOL REPROD, V54, P1311, DOI 10.1095/biolreprod54.6.1311; Kameda T, 1999, BBA-GENE STRUCT EXPR, V1445, P31, DOI 10.1016/S0167-4781(99)00018-4; Kamolmatyakul S, 2001, J DENT RES, V80, P351, DOI 10.1177/00220345010800011001; Katsanakis KD, 2002, ANTICANCER RES, V22, P755; Kockar FT, 2001, NUCLEIC ACIDS RES, V29, P362, DOI 10.1093/nar/29.2.362; Kominsky SL, 2000, CANCER RES, V60, P3904; Kong SE, 1999, ANAL BIOCHEM, V271, P111, DOI 10.1006/abio.1999.4123; Kosaka S, 2001, CIRCULATION, V103, P1142, DOI 10.1161/01.CIR.103.8.1142; Kousteni S, 1998, MECH DEVELOP, V77, P143, DOI 10.1016/S0925-4773(98)00128-2; KOVACS EJ, 1988, J IMMUNOL, V141, P3101; Krueger DA, 1999, MOL ENDOCRINOL, V13, P1207, DOI 10.1210/me.13.7.1207; LALLI E, 1995, P NATL ACAD SCI USA, V92, P9633, DOI 10.1073/pnas.92.21.9633; LAMARRE J, 1993, J CLIN INVEST, V91, P1219, DOI 10.1172/JCI116283; Lee JC, 2000, IMMUNOPHARMACOLOGY, V47, P185, DOI 10.1016/S0162-3109(00)00206-X; Lewis M, 1999, J CELL BIOCHEM, V72, P373, DOI 10.1002/(SICI)1097-4644(19990301)72:3<373::AID-JCB7>3.0.CO;2-N; Lodie TA, 1997, J IMMUNOL, V158, P1848; Ma ZD, 2001, J IMMUNOL, V167, P5150, DOI 10.4049/jimmunol.167.9.5150; Mao DL, 1998, MOL ENDOCRINOL, V12, P492, DOI 10.1210/me.12.4.492; MOLINA CA, 1993, CELL, V75, P875, DOI 10.1016/0092-8674(93)90532-U; Monaco L, 1997, ONCOGENE, V15, P2493, DOI 10.1038/sj.onc.1201636; MONACO L, 1995, P NATL ACAD SCI USA, V92, P10673, DOI 10.1073/pnas.92.23.10673; NISHIKAWA T, 1993, J CLIN ENDOCR METAB, V77, P1084, DOI 10.1210/jc.77.4.1084; OSANTO S, 1992, EUR J CANCER, V28A, P1622, DOI 10.1016/0959-8049(92)90055-7; Penton-Rol G, 1998, J IMMUNOL, V160, P3869; Peri A, 2002, EUR J ENDOCRINOL, V146, P759, DOI 10.1530/eje.0.1460759; Peri A, 2001, J CLIN ENDOCR METAB, V86, P2111, DOI 10.1210/jc.86.5.2111; Polentarutti N, 1998, EUR J IMMUNOL, V28, P496, DOI 10.1002/(SICI)1521-4141(199802)28:02<496::AID-IMMU496>3.0.CO;2-V; Qin HW, 1998, J IMMUNOL, V161, P6664; QIU ZH, 1994, J BIOL CHEM, V269, P19480; Ramana CV, 2002, TRENDS IMMUNOL, V23, P96, DOI 10.1016/S1471-4906(01)02118-4; Ramana CV, 2001, P NATL ACAD SCI USA, V98, P6674, DOI 10.1073/pnas.111164198; RAMJI DP, 1993, NUCLEIC ACIDS RES, V21, P289, DOI 10.1093/nar/21.2.289; Regenhard P, 2001, J LEUKOCYTE BIOL, V69, P651; Ringheim GE, 1996, BIOCHEM BIOPH RES CO, V224, P246, DOI 10.1006/bbrc.1996.1015; Ruetten H, 1997, BRIT J PHARMACOL, V122, P59, DOI 10.1038/sj.bjp.0701345; Saavedra AP, 2000, ENDOCRINOLOGY, V141, P606, DOI 10.1210/en.141.2.606; Sabatakos G, 1998, BIOCHEM J, V334, P205, DOI 10.1042/bj3340205; Saeki K, 1999, BIOCHEM J, V338, P49, DOI 10.1042/0264-6021:3380049; SCHNYDERCANDRIAN S, 1995, J LEUKOCYTE BIOL, V57, P929, DOI 10.1002/jlb.57.6.929; Shaywitz AJ, 1999, ANNU REV BIOCHEM, V68, P821, DOI 10.1146/annurev.biochem.68.1.821; Shen J, 2001, J IMMUNOL, V167, P4919, DOI 10.4049/jimmunol.167.9.4919; Shirazi Y, 1998, J Hum Virol, V1, P69; Sibinga NES, 1999, J BIOL CHEM, V274, P12139, DOI 10.1074/jbc.274.17.12139; Song DH, 2000, J BIOL CHEM, V275, P23790, DOI 10.1074/jbc.M909107199; Stark GR, 1998, ANNU REV BIOCHEM, V67, P227, DOI 10.1146/annurev.biochem.67.1.227; Storvik M, 2000, J PHARMACOL EXP THER, V294, P52; Sung JY, 2001, J BIOL CHEM, V276, P13858, DOI 10.1074/jbc.M010610200; Tengku-Muhammad TS, 1998, CYTOKINE, V10, P38, DOI 10.1006/cyto.1997.0254; Tengku-Muhammad TS, 2000, CYTOKINE, V12, P1430, DOI 10.1006/cyto.2000.0711; Tengku-Muhammad TS, 2000, CYTOKINE, V12, P720, DOI 10.1006/cyto.1999.0620; TengkuMuhammad TS, 1996, CYTOKINE, V8, P525, DOI 10.1006/cyto.1996.0071; Thommesen L, 2000, J BIOL CHEM, V275, P4244, DOI 10.1074/jbc.275.6.4244; Thommesen L, 2001, AM J PHYSIOL-ENDOC M, V281, pE1316, DOI 10.1152/ajpendo.2001.281.6.E1316; THORNBERG H, 2001, BIOCHEM J, V354, P169; Tinti C, 1996, J BIOL CHEM, V271, P25375, DOI 10.1074/jbc.271.41.25375; Tsai SC, 2002, J BIOL CHEM, V277, P31826, DOI 10.1074/jbc.M204149200; TURAKOCKAR F, 2001, NUCLEIC ACIDS RES, V29, P3632; Uyttersprot N, 1999, EUR J BIOCHEM, V259, P370, DOI 10.1046/j.1432-1327.1999.00049.x; VARGA J, 1995, J CLIN INVEST, V96, P475, DOI 10.1172/JCI118058; Yehia G, 2001, J BIOL CHEM, V276, P35272, DOI 10.1074/jbc.M105404200; Yoshikawa H, 2001, NAT GENET, V28, P29, DOI 10.1038/88225; Yuan WH, 1999, J CELL PHYSIOL, V179, P97, DOI 10.1002/(SICI)1097-4652(199904)179:1<97::AID-JCP12>3.3.CO;2-5; Zhang XF, 2001, BLOOD, V97, P3342, DOI 10.1182/blood.V97.11.3342	95	49	51	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 16	2003	278	20					17741	17751		10.1074/jbc.M301602200	http://dx.doi.org/10.1074/jbc.M301602200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677YX	12609974	hybrid			2022-12-25	WOS:000182838300021
J	Schramm, G; Falcone, FH; Gronow, A; Haisch, K; Mamat, U; Doenhoff, MJ; Oliveira, G; Galle, J; Dahinden, CA; Haas, H				Schramm, G; Falcone, FH; Gronow, A; Haisch, K; Mamat, U; Doenhoff, MJ; Oliveira, G; Galle, J; Dahinden, CA; Haas, H			Molecular characterization of an interleukin-4-inducing factor from Schistosoma mansoni eggs	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN BLOOD BASOPHILS; EPSILON-RI+ CELLS; TH2 RESPONSES; PERIPHERAL-BLOOD; IMMUNOGLOBULIN-E; V(H)3 REGION; T-CELLS; IGE; INDUCTION; IL-4	The eggs of the parasitic trematode Schistosoma mansoni are powerful inducers of a T helper type 2 (Th2) immune response and immunoglobulin E (IgE) production. S. mansoni egg extract (SmEA) stimulates human basophils to rapidly release large amounts of interleukin (IL)-4, the key promoter of a Th2 response. Here we show purification and sequence of the IL-4-inducing principle of S. mansoni eggs (IPSE). Stimulation studies with human basophils using SmEA fractions and natural and recombinant IPSE as well as neutralization and immunodepletion studies using antibodies to recombinant IPSE demonstrate that IPSE is the bioactive principle in SmEA leading to activation of basophils and to expression of IL-4 and IL-13. Regarding the mechanism of action, blot analysis showed that IPSE is an IgE-binding factor, suggesting that it becomes effective via cross-linking receptor-bound IgE on basophils. Immunohistology revealed that IPSE is enriched in and secreted from the subshell area of the schistosome egg. We conclude from these data that IPSE may be an important parasite-derived component for skewing the immune response toward Th2.	Forschungszentrum Borstel, Div Cellular Allergol, D-23845 Borstel, Germany; Univ Wales, Sch Biol Sci, Bangor LL57 2UW, Gwynedd, Wales; Fiocruz MS, Ctr Pesquisas Rene Rachou, BR-30190002 Belo Horizonte, MG, Brazil; Univ Hosp Bern, Inselspital, Inst Immunol & Allergol, CH-3010 Bern, Switzerland	Forschungszentrum Borstel; Bangor University; Fundacao Oswaldo Cruz; University of Bern; University Hospital of Bern	Haas, H (corresponding author), Forschungszentrum Borstel, Div Cellular Allergol, Parkallee 22, D-23845 Borstel, Germany.	hhaas@fz-borstel.de	Falcone, Franco H/F-9210-2013; Falcone, Franco/AAE-8026-2021; Oliveira, Guilherme/E-2624-2014	Falcone, Franco H/0000-0002-1732-9932; Falcone, Franco/0000-0002-1732-9932; Oliveira, Guilherme/0000-0003-0054-3438; Doenhoff, Michael/0000-0002-0163-6903				Ashton PD, 2001, PARASITOLOGY, V122, P329, DOI 10.1017/S0031182001007351; BOROS DL, 1970, J EXP MED, V132, P488, DOI 10.1084/jem.132.3.488; BRUNNER T, 1993, J EXP MED, V177, P605, DOI 10.1084/jem.177.3.605; CARTER CE, 1978, J PARASITOL, V64, P385, DOI 10.2307/3279763; DEBRAY H, 1989, CARBOHYD RES, V185, P15, DOI 10.1016/0008-6215(89)84017-0; Devouassoux G, 1999, J ALLERGY CLIN IMMUN, V104, P811, DOI 10.1016/S0091-6749(99)70292-7; DOENHOFF MJ, 1981, T ROY SOC TROP MED H, V75, P41, DOI 10.1016/0035-9203(81)90012-2; DUNNE DW, 1991, PARASITOLOGY, V103, P225, DOI 10.1017/S0031182000059503; Dunzendorfer S, 2001, J ALLERGY CLIN IMMUN, V108, P581, DOI 10.1067/mai.2001.118518; Eglite S, 2000, J IMMUNOL, V165, P2183, DOI 10.4049/jimmunol.165.4.2183; Falcone FH, 1996, EUR J IMMUNOL, V26, P1147, DOI 10.1002/eji.1830260528; Haas H, 1999, INT ARCH ALLERGY IMM, V119, P86, DOI 10.1159/000024182; Haas H, 1999, EUR J IMMUNOL, V29, P918, DOI 10.1002/(SICI)1521-4141(199903)29:03&lt;918::AID-IMMU918&gt;3.0.CO;2-T; Haisch K, 1999, J IMMUNOL METHODS, V226, P129, DOI 10.1016/S0022-1759(99)00059-9; Haisch K, 2001, PARASITE IMMUNOL, V23, P427, DOI 10.1046/j.1365-3024.2001.00392.x; Haselhorst T, 2001, J AM CHEM SOC, V123, P10705, DOI 10.1021/ja011156h; HEUKESHOVEN J, 1988, ELECTROPHORESIS, V9, P28, DOI 10.1002/elps.1150090106; HSIEH CS, 1992, P NATL ACAD SCI USA, V89, P6065, DOI 10.1073/pnas.89.13.6065; Kaplan AP, 2001, INT ARCH ALLERGY IMM, V124, P423, DOI 10.1159/000053777; KYHSEANDERSEN J, 1984, J BIOCHEM BIOPH METH, V10, P203, DOI 10.1016/0165-022X(84)90040-X; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEARY JJ, 1983, P NATL ACAD SCI-BIOL, V80, P4045, DOI 10.1073/pnas.80.13.4045; Marone G, 2000, CRIT REV IMMUNOL, V20, P477; Marone G., 2000, MAST CELLS BASOPHILS; OCHENSBERGER B, 1995, BLOOD, V86, P4039, DOI 10.1182/blood.V86.11.4039.bloodjournal86114039; Okano M, 2001, J IMMUNOL, V167, P442, DOI 10.4049/jimmunol.167.1.442; Okano M, 1999, ALLERGY, V54, P593, DOI 10.1034/j.1398-9995.1999.00063.x; Okano M, 1999, J IMMUNOL, V163, P6712; Oliveira G, 2001, TRENDS PARASITOL, V17, P108, DOI 10.1016/S1471-4922(00)01802-X; Oliveira GC, 1995, MOL BIOCHEM PARASIT, V75, P119, DOI 10.1016/0166-6851(95)02508-1; Patella V, 2000, J IMMUNOL, V164, P589, DOI 10.4049/jimmunol.164.2.589; Patella V, 1998, J IMMUNOL, V161, P5647; PAUL WE, 1994, CELL, V76, P241, DOI 10.1016/0092-8674(94)90332-8; PEARCE EJ, 1991, J EXP MED, V173, P159, DOI 10.1084/jem.173.1.159; ROMAGNANI S, 1992, IMMUNOL TODAY, V13, P379, DOI 10.1016/0167-5699(92)90083-J; Sambrook J., 2001, MOL CLONING; SEDER RA, 1992, J EXP MED, V176, P1091, DOI 10.1084/jem.176.4.1091; Shimoda K, 1996, NATURE, V380, P630, DOI 10.1038/380630a0; Uguccioni M, 1997, J CLIN INVEST, V100, P1137, DOI 10.1172/JCI119624; VANDAM GJ, 1995, CIRCULATING GUT ASS, P21; VELLA AT, 1992, J IMMUNOL, V148, P2283; VELUPILLAI P, 1994, P NATL ACAD SCI USA, V91, P18, DOI 10.1073/pnas.91.1.18	42	139	146	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 16	2003	278	20					18384	18392		10.1074/jbc.M300497200	http://dx.doi.org/10.1074/jbc.M300497200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677YX	12624091	hybrid			2022-12-25	WOS:000182838300104
J	Chandra, D; Tang, DG				Chandra, D; Tang, DG			Mitochondrially localized active caspase-9 and caspase-3 result mostly from translocation from the cytosol and partly from caspase-mediated activation in the organelle - Lack of evidence for Apaf-1-mediated procaspase-9 activation in the mitochondria	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROGRAMMED CELL-DEATH; ENDOPLASMIC-RETICULUM STRESS; ETOPOSIDE-INDUCED APOPTOSIS; CYTOCHROME-C RELEASE; NUCLEAR-LOCALIZATION; MOUSE-LIVER; MEMBRANE; APAF-1; PATHWAY; EXPRESSION	Active caspase-9 and caspase-3 have been observed in the mitochondria, but their origins are unclear. Theoretically, procaspase-9 might be activated in the mitochondria in a cytochrome c/Apaf-1-dependent manner, or activated caspase-9 and -3 may translocate to the mitochondria, or the mitochondrially localized procaspases may be activated by the translocated active caspases. Here we present evidence that the mitochondrially localized active caspase-9 and -3 result mostly from translocation from the cytosol ( into the intermembrane space) and partly from caspase-mediated activation in the organelle rather than from the Apaf-1-mediated activation. Apaf-1 localizes exclusively in the cytosol and, upon apoptotic stimulation, translocates to the perinuclear area but not to the mitochondria. In most cases, the mitochondrially localized procaspase-9 and -3 are released early during apoptosis and translocate to the cytosol and/or perinuclear area. Cytochrome c and the mitochondrial matrix protein Hsp60 are also rapidly released to the cytosol early during apoptosis. Both the early release of proteins like cytochrome c and Hsp60 from the mitochondria as well as the later translocation of the active caspase-9/-3 are partially inhibited by cyclosporin A, an inhibitor of mitochondrial membrane permeabilization. The mitochondrial active caspases may function as a positive feedback mechanism to further activate other or residual mitochondrial procaspases, degrade mitochondrial constituents, and disintegrate mitochondrial functions.	Univ Texas, MD Anderson Canc Ctr, Dept Carcinogenesis, Div Sci Pk Res, Smithville, TX 78957 USA	University of Texas System; UTMD Anderson Cancer Center	Tang, DG (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Carcinogenesis, Div Sci Pk Res, Pk Rd 1C, Smithville, TX 78957 USA.	dtang@sprd1.mdacc.tmc.edu	Tang, Dean/AAI-3457-2020	Tang, Dean/0000-0001-5029-1174; Chandra, Dhyan/0000-0001-7272-9384	NCI NIH HHS [CA 90297] Funding Source: Medline; NIEHS NIH HHS [ES07784] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA090297] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES007784] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Angelastro JM, 2001, J BIOL CHEM, V276, P12190, DOI 10.1074/jbc.M009523200; Antonsson B, 2001, J BIOL CHEM, V276, P11615, DOI 10.1074/jbc.M010810200; Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; Bratton SB, 2001, CELL DEATH DIFFER, V8, P425, DOI 10.1038/sj.cdd.4400834; Bratton SB, 2001, EMBO J, V20, P998, DOI 10.1093/emboj/20.5.998; Budihardjo I, 1999, ANNU REV CELL DEV BI, V15, P269, DOI 10.1146/annurev.cellbio.15.1.269; Chalfant CE, 2002, J BIOL CHEM, V277, P12587, DOI 10.1074/jbc.M112010200; Chandler JM, 1998, J BIOL CHEM, V273, P10815, DOI 10.1074/jbc.273.18.10815; Chandra D, 2002, J BIOL CHEM, V277, P50842, DOI 10.1074/jbc.M207622200; Chen FL, 2000, SCIENCE, V287, P1485, DOI 10.1126/science.287.5457.1485; Colussi PA, 1998, J BIOL CHEM, V273, P24535, DOI 10.1074/jbc.273.38.24535; Costantini P, 2002, CELL DEATH DIFFER, V9, P82, DOI 10.1038/sj.cdd.4400932; Debatin KM, 2002, ONCOGENE, V21, P8786, DOI 10.1038/sj.onc.1206039; Deng YB, 2002, GENE DEV, V16, P33, DOI 10.1101/gad.949602; Faleiro L, 2000, J CELL BIOL, V151, P951, DOI 10.1083/jcb.151.5.951; Fujita E, 2002, CELL DEATH DIFFER, V9, P1108, DOI 10.1038/sj.cdd.4401080; Guo Y, 2002, J BIOL CHEM, V277, P13430, DOI 10.1074/jbc.M108029200; Hausmann G, 2000, J CELL BIOL, V149, P623, DOI 10.1083/jcb.149.3.623; Horvitz HR, 1999, CANCER RES, V59, p1701S; Jemmerson R, 2002, CELL DEATH DIFFER, V9, P538, DOI 10.1038/sj.cdd.4400981; Joshi B, 1999, CANCER RES, V59, P4343; Krajewska M, 1997, CANCER RES, V57, P1605; Krajewski S, 1999, P NATL ACAD SCI USA, V96, P5752, DOI 10.1073/pnas.96.10.5752; Krebs JF, 1999, J CELL BIOL, V144, P915, DOI 10.1083/jcb.144.5.915; Kuwana T, 2002, CELL, V111, P331, DOI 10.1016/S0092-8674(02)01036-X; Lassus P, 2002, SCIENCE, V297, P1352, DOI 10.1126/science.1074721; Li SC, 2002, J BIOL CHEM, V277, P26912, DOI 10.1074/jbc.M200726200; Mancini M, 1998, J CELL BIOL, V140, P1485, DOI 10.1083/jcb.140.6.1485; Mancini M, 2000, J CELL BIOL, V149, P603, DOI 10.1083/jcb.149.3.603; Mao PL, 1998, J BIOL CHEM, V273, P23621, DOI 10.1074/jbc.273.37.23621; Marsden VS, 2002, NATURE, V419, P634, DOI 10.1038/nature01101; Martins LM, 1997, J BIOL CHEM, V272, P7421, DOI 10.1074/jbc.272.11.7421; Morishima N, 2002, J BIOL CHEM, V277, P34287, DOI 10.1074/jbc.M204973200; Nakagawa T, 2000, NATURE, V403, P98, DOI 10.1038/47513; Nakagawara A, 1997, CANCER RES, V57, P4578; Nakanishi K, 2001, J BIOL CHEM, V276, P41237, DOI 10.1074/jbc.M105648200; Paroni G, 2002, J BIOL CHEM, V277, P15147, DOI 10.1074/jbc.M112338200; PETIT PX, 1990, EUR J BIOCHEM, V194, P389, DOI 10.1111/j.1432-1033.1990.tb15632.x; Qin ZH, 2001, J BIOL CHEM, V276, P8079, DOI 10.1074/jbc.M007028200; Rao RV, 2002, J BIOL CHEM, V277, P21836, DOI 10.1074/jbc.M202726200; Read SH, 2002, J CELL BIOL, V159, P739, DOI 10.1083/jcb.200209004; Ricci JE, 2003, J CELL BIOL, V160, P65, DOI 10.1083/jcb.200208089; Robertson JD, 2002, J BIOL CHEM, V277, P29803, DOI 10.1074/jbc.M204185200; Ruiz-Vela A, 2002, FEBS LETT, V517, P133, DOI 10.1016/S0014-5793(02)02607-8; Salvesen GS, 1997, CELL, V91, P443, DOI 10.1016/S0092-8674(00)80430-4; Samali A, 1998, FEBS LETT, V431, P167, DOI 10.1016/S0014-5793(98)00740-6; Scorrano L, 2002, DEV CELL, V2, P55, DOI 10.1016/S1534-5807(01)00116-2; Slee EA, 1999, J CELL BIOL, V144, P281, DOI 10.1083/jcb.144.2.281; Srinivasula SM, 2001, NATURE, V410, P112, DOI 10.1038/35065125; Srinivasula SM, 1998, MOL CELL, V1, P949, DOI 10.1016/S1097-2765(00)80095-7; Susin SA, 1999, J EXP MED, V189, P381, DOI 10.1084/jem.189.2.381; Tang DG, 1998, CANCER RES, V58, P3466; Tang DG, 1998, BIOCHEM BIOPH RES CO, V242, P380, DOI 10.1006/bbrc.1997.7969; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; van Loo G, 2002, CELL DEATH DIFFER, V9, P1031, DOI 10.1038/sj.cdd.4401088; van Loo G, 2002, CELL DEATH DIFFER, V9, P1207, DOI 10.1038/sj.cdd.4401101; Wang XD, 2001, GENE DEV, V15, P2922; Zhivotovsky B, 1999, CELL DEATH DIFFER, V6, P644, DOI 10.1038/sj.cdd.4400536	58	60	61	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 9	2003	278	19					17408	17420		10.1074/jbc.M300750200	http://dx.doi.org/10.1074/jbc.M300750200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677QG	12611882	hybrid			2022-12-25	WOS:000182818600128
J	Grobler, JA; Markel, EJ; Fay, JF; Graham, DJ; Simcoe, AL; Ludmerer, SW; Murray, EM; Migliaccio, G; Flores, OA				Grobler, JA; Markel, EJ; Fay, JF; Graham, DJ; Simcoe, AL; Ludmerer, SW; Murray, EM; Migliaccio, G; Flores, OA			Identification of a key determinant of hepatitis C virus cell culture adaptation in domain II of NS3 helicase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INFECTIOUS MOLECULAR CLONE; CDNA-CLONE; CRYSTAL-STRUCTURE; RNA REPLICATION; GENOTYPE 1B; MUTATIONS; SEQUENCE; INTERFERON-ALPHA-2B; TRANSCRIPTS; RIBAVIRIN	Efficient replication of hepatitis C virus (HCV) replicons in cell culture is associated with specific sequences not generally observed in vivo. These cell culture adaptive mutations dramatically increase the frequency with which replication is established in vitro. However, replicons derived from HCV isolates that have been shown to replicate in chimpanzees do not replicate in cell culture even when these adaptive mutations are introduced. To better understand this apparent paradox, we performed a gain-of-function screen to identify sequences that could confer cell culture replication competence to replicons derived from chimpanzee infectious HCV isolates. We found that residue 470 in domain II of the NS3 helicase is a critical determinant in cell culture adaptation. Substitutions in residue 470 when combined with the NS5A-S232I adaptive mutation are both necessary and sufficient to confer cell culture replication to otherwise inactive replicons, including those derived from genotype 1b HCV-BK and genotype 1a HCV-H77 isolates. The specific substitution at residue 470 required for replication is context-dependent, with R470M and P470L being optimal for the activity of HCV-BK and HCV-H77 replicons, respectively. Together these data indicate that mutations in the NS3 helicase domain II act in concert with previously identified adaptive mutations and predict that introduction of compatible residues at these positions can confer cell culture replication activity to diverse HCV isolates.	Merck Res Labs, Dept Biol Chem, West Point, PA 19486 USA; Ist Ric Biol Mol P Angeletti, I-00040 Pomezia, Italy	Merck & Company; Merck & Company	Flores, OA (corresponding author), Merck Res Labs, Dept Biol Chem, POB 4,WP26A-4000, West Point, PA 19486 USA.	osvaldo_flores@merck.com						Bartenschlager R, 2000, J GEN VIROL, V81, P1631, DOI 10.1099/0022-1317-81-7-1631; Beard MR, 1999, HEPATOLOGY, V30, P316, DOI 10.1002/hep.510300137; Blight KJ, 2000, SCIENCE, V290, P1972, DOI 10.1126/science.290.5498.1972; Bukh J, 2002, P NATL ACAD SCI USA, V99, P14416, DOI 10.1073/pnas.212532699; CHOO QL, 1989, SCIENCE, V244, P359, DOI 10.1126/science.2523562; Conley AJ, 1998, HEPATOLOGY, V28, p560A; Farci P, 2000, SEMIN LIVER DIS, V20, P103; Guo JT, 2001, J VIROL, V75, P8516, DOI 10.1128/JVI.75.18.8516-8523.2001; Hong Z, 1999, VIROLOGY, V256, P36, DOI 10.1006/viro.1999.9603; Ikeda M, 2002, J VIROL, V76, P2997, DOI 10.1128/JVI.76.6.2997-3006.2002; Kim JL, 1998, STRUCTURE, V6, P89, DOI 10.1016/S0969-2126(98)00010-0; Kolykhalov AA, 1997, SCIENCE, V277, P570, DOI 10.1126/science.277.5325.570; Kolykhalov AA, 1996, J VIROL, V70, P3363, DOI 10.1128/JVI.70.6.3363-3371.1996; Krieger N, 2001, J VIROL, V75, P4614, DOI 10.1128/JVI.75.10.4614-4624.2001; Lanford RE, 2001, J GEN VIROL, V82, P1291, DOI 10.1099/0022-1317-82-6-1291; Levin MK, 1999, J BIOL CHEM, V274, P31839, DOI 10.1074/jbc.274.45.31839; Lohmann V, 2001, J VIROL, V75, P1437, DOI 10.1128/JVI.75.3.1437-1449.2001; Lohmann V, 1999, SCIENCE, V285, P110, DOI 10.1126/science.285.5424.110; McHutchison JG, 1998, NEW ENGL J MED, V339, P1485, DOI 10.1056/NEJM199811193392101; Murray EM, 2003, J VIROL, V77, P2928, DOI 10.1128/JVI.77.5.2928-2935.2003; Poynard T, 1998, LANCET, V352, P1426, DOI 10.1016/S0140-6736(98)07124-4; Reed KE, 2000, CURR TOP MICROBIOL, V242, P55; TAKAMIZAWA A, 1991, J VIROL, V65, P1105, DOI 10.1128/JVI.65.3.1105-1113.1991; TANAKA T, 1995, BIOCHEM BIOPH RES CO, V215, P744, DOI 10.1006/bbrc.1995.2526; Thomson M, 2001, GASTROENTEROLOGY, V121, P1226, DOI 10.1053/gast.2001.28669; TSUKIYAMAKOHARA K, 1992, J VIROL, V66, P1476, DOI 10.1128/JVI.66.3.1476-1483.1992; WANG KS, 1986, NATURE, V323, P508, DOI 10.1038/323508a0; WANT C, 1993, J VIROL, V67, P3338; Wasley A, 2000, SEMIN LIVER DIS, V20, P1, DOI 10.1055/s-2000-9506; Yanagi M, 1998, VIROLOGY, V244, P161, DOI 10.1006/viro.1998.9092; Yanagi M, 1999, VIROLOGY, V262, P250, DOI 10.1006/viro.1999.9889; Yanagi M, 1997, P NATL ACAD SCI USA, V94, P8738, DOI 10.1073/pnas.94.16.8738; Yao NH, 1999, STRUCTURE, V7, P1353, DOI 10.1016/S0969-2126(00)80025-8; Yao NH, 1997, NAT STRUCT BIOL, V4, P463, DOI 10.1038/nsb0697-463	34	38	48	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 9	2003	278	19					16741	16746		10.1074/jbc.M212602200	http://dx.doi.org/10.1074/jbc.M212602200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677QG	12615931	hybrid			2022-12-25	WOS:000182818600040
J	Jores, L; Wagner, R				Jores, L; Wagner, R			Essential steps in the ppGpp-dependent regulation of bacterial ribosomal RNA promoters can be explained by substrate competition	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-RATE CONTROL; ESCHERICHIA-COLI; GUANOSINE TETRAPHOSPHATE; TRANSCRIPTION INITIATION; STRINGENT CONTROL; COMPLEX-FORMATION; IN-VIVO; POLYMERASE; MECHANISM; MUTANTS	Transcription of stable RNA genes is known to be dramatically reduced in the presence of guanosine tetraphosphate (ppGpp), the mediator of the stringent response. Using in vitro transcription systems with ribosomal RNA P1 promoters, we have analyzed which step of the initiation cycle is inhibited by the effector ppGpp. We show that formation of the ternary transcription initiation complex consisting of RNA polymerase holoenzyme, the promoter DNA, and the first initiating nucleotide triphosphate is the major step at which ppGpp exerts its regulation. Neither primary binding of RNA polymerase to the promoter nor isomerization to the open binary complexes or the subsequent promoter clearance steps contributes notably to the observed inhibition. The effect of ppGpp-dependent inhibition in the formation of the ternary transcription initiation complex could be mimicked by nucleotide derivatives known to bind to the RNA polymerase active center. Using these model compounds, almost identical inhibition characteristics were observed as seen with ppGpp. The results support the previously published model, which suggests that ppGpp-dependent inhibition is based on competition between the inhibitor molecules and NTP substrates for access to the active center of RNA polymerase.	Univ Dusseldorf, Inst Phys Biol, D-40225 Dusseldorf, Germany	Heinrich Heine University Dusseldorf	Wagner, R (corresponding author), Univ Dusseldorf, Inst Phys Biol, Univ Str 1, D-40225 Dusseldorf, Germany.	r.wagner@rz.uni-duesseldorf.de						BARACCHINI E, 1988, J BIOL CHEM, V263, P2597; Barker MM, 2001, J BACTERIOL, V183, P6315, DOI 10.1128/JB.183.21.6315-6323.2001; Barker MM, 2001, J MOL BIOL, V305, P673, DOI 10.1006/jmbi.2000.4327; Barker MM, 2001, J MOL BIOL, V305, P689, DOI 10.1006/jmbi.2000.4328; BECK C, 1973, J MOL BIOL, V78, P117, DOI 10.1016/0022-2836(73)90431-2; BURGESS RR, 1975, BIOCHEMISTRY-US, V14, P4634, DOI 10.1021/bi00692a011; Carmona M, 2000, J BACTERIOL, V182, P4711, DOI 10.1128/JB.182.17.4711-4718.2000; Cashel M., 1996, ESCHERICHIA COLI SAL, P1458; CHAMBERLIN MJ, 1979, J BIOL CHEM, V254, P61; Choy HE, 2000, J BIOL CHEM, V275, P6783, DOI 10.1074/jbc.275.10.6783; Colland F, 2002, GENES CELLS, V7, P233, DOI 10.1046/j.1365-2443.2002.00517.x; Epshtein V, 2002, MOL CELL, V10, P623, DOI 10.1016/S1097-2765(02)00640-8; Gaal T, 1997, SCIENCE, V278, P2092, DOI 10.1126/science.278.5346.2092; GESTELAND RF, 1966, J MOL BIOL, V16, P67, DOI 10.1016/S0022-2836(66)80263-2; GONZALEZ N, 1977, ARCH BIOCHEM BIOPHYS, V182, P404, DOI 10.1016/0003-9861(77)90521-5; GOURSE RL, 1988, NUCLEIC ACIDS RES, V16, P9789, DOI 10.1093/nar/16.20.9789; Heinemann M, 1997, EUR J BIOCHEM, V247, P990, DOI 10.1111/j.1432-1033.1997.00990.x; HERNANDEZ VJ, 1995, J MOL BIOL, V252, P536; Hsu LM, 1996, METHOD ENZYMOL, V273, P59; JENSEN KF, 1990, MICROBIOL REV, V54, P89, DOI 10.1128/MMBR.54.2.89-100.1990; Jishage M, 2002, GENE DEV, V16, P1260, DOI 10.1101/gad.227902; KINGSTON RE, 1981, J BIOL CHEM, V256, P2787; Korzheva N, 2000, SCIENCE, V289, P619, DOI 10.1126/science.289.5479.619; Krohn M, 1996, J BIOL CHEM, V271, P23884, DOI 10.1074/jbc.271.39.23884; Kubori T, 1996, J MOL BIOL, V256, P449, DOI 10.1006/jmbi.1996.0100; Kvint K, 2000, J BIOL CHEM, V275, P14795, DOI 10.1074/jbc.C000128200; Lacour S, 2002, BIOCHEM BIOPH RES CO, V292, P922, DOI 10.1006/bbrc.2002.6744; LANGERT W, 1991, J BIOL CHEM, V266, P21608; Laurie AD, 2003, J BIOL CHEM, V278, P1494, DOI 10.1074/jbc.M209268200; MIZUSHIMASUGANO J, 1985, EMBO J, V4, P1053, DOI 10.1002/j.1460-2075.1985.tb03738.x; OHLSEN KL, 1992, J BIOL CHEM, V267, P19813; Potrykus K, 2002, J BIOL CHEM, V277, P43785, DOI 10.1074/jbc.M208768200; Raghavan A, 1998, BIOPHYS CHEM, V75, P7, DOI 10.1016/S0301-4622(98)00185-9; REDDY PS, 1995, MOL MICROBIOL, V15, P255, DOI 10.1111/j.1365-2958.1995.tb02240.x; RIGGS DL, 1986, P NATL ACAD SCI USA, V83, P9333, DOI 10.1073/pnas.83.24.9333; SASSEDWIGHT S, 1989, J BIOL CHEM, V264, P8074; SASSEDWIGHT S, 1991, METHOD ENZYMOL, V208, P146; Schroder O, 2000, J MOL BIOL, V298, P737, DOI 10.1006/jmbi.2000.3708; SHAND RF, 1989, J BACTERIOL, V171, P737, DOI 10.1128/jb.171.2.737-743.1989; STEFANO JE, 1979, BIOCHEMISTRY-US, V18, P1063, DOI 10.1021/bi00573a020; SZALEWSKAPALASZ A, 1994, EMBO J, V13, P5779, DOI 10.1002/j.1460-2075.1994.tb06916.x; Toulokhonov II, 2001, J BIOL CHEM, V276, P1220, DOI 10.1074/jbc.M007184200; TRAVERS AA, 1980, J BACTERIOL, V141, P973, DOI 10.1128/JB.141.2.973-976.1980; TRAVERS AA, 1984, NUCLEIC ACIDS RES, V12, P2605, DOI 10.1093/nar/12.6.2605; VOGEL U, 1994, J BACTERIOL, V176, P2807, DOI 10.1128/JB.176.10.2807-2813.1994; VOGEL U, 1994, J BIOL CHEM, V269, P16236; Wagner R, 2002, J MOL MICROB BIOTECH, V4, P331; Wagner R, 2000, TRANSCRIPTION REGULA; ZACHARIAS M, 1990, NUCLEIC ACIDS RES, V18, P6271, DOI 10.1093/nar/18.21.6271; ZACHARIAS M, 1989, EMBO J, V8, P3357, DOI 10.1002/j.1460-2075.1989.tb08498.x; Zhou YN, 1998, P NATL ACAD SCI USA, V95, P2908, DOI 10.1073/pnas.95.6.2908	51	31	31	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 9	2003	278	19					16834	16843		10.1074/jbc.M300196200	http://dx.doi.org/10.1074/jbc.M300196200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677QG	12621053	hybrid			2022-12-25	WOS:000182818600053
J	Yuan, Y; Hilliard, G; Ferguson, T; Millhorn, DE				Yuan, Y; Hilliard, G; Ferguson, T; Millhorn, DE			Cobalt inhibits the interaction between hypoxia-inducible factor-alpha and von Hippel-Lindau protein by direct binding to hypoxia-inducible factor-alpha	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-SUPPRESSOR PROTEIN; PAS DOMAIN PROTEIN-1; PROLYL HYDROXYLATION; HIF-ALPHA; TRANSACTIVATION; UBIQUITYLATION; ERYTHROPOIETIN; FACTOR-1-ALPHA; DESTRUCTION; EXPRESSION	The hypoxia-inducible factor (HIF) activates the expression of genes that contain a hypoxia response element. The alpha-subunits of the HIF transcription factors are degraded by proteasomal pathways during normoxia but are stabilized under hypoxic conditions. The von Hippel-Lindau protein (pVHL) mediates the ubiquitination and rapid degradation of HIF-alpha (including HIF-1alpha and HIF-2alpha). Post-translational hydroxylation of a proline residue in the oxygen-dependent degradation (ODD) domain of HIF-alpha is required for the interaction between HIF and VHL. It has previously been established that cobalt mimics hypoxia and causes accumulation of HIF-1alpha and HIF-2alpha. However, little is known about the mechanism by which this occurs. In an earlier study, we demonstrated that cobalt binds directly to the ODD domain of HIF-2alpha. Here we provide the first evidence that cobalt inhibits pVHL binding to HIF-alpha even when HIF-alpha is hydroxylated. Deletion of 17 amino acids within the ODD domain of HIF-2alpha that are required for pVHL binding prevented the binding of cobalt and stabilized HIF-2alpha during normoxia. These findings show that cobalt mimics hypoxia, at least in part, by occupying the VHL-binding domain of HIF-alpha and thereby preventing the degradation of HIF-alpha.	Univ Cincinnati, Dept Genome Sci, Genome Res Inst, Cincinnati, OH 45267 USA	University System of Ohio; University of Cincinnati	Millhorn, DE (corresponding author), Univ Cincinnati, Dept Genome Sci, Genome Res Inst, 231 Albert Sabin Way,POB 670505, Cincinnati, OH 45267 USA.				NHLBI NIH HHS [HL 59945, HL 33831] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL033831, R37HL033831, R01HL059945] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Brown JM, 2000, MOL MED TODAY, V6, P157, DOI 10.1016/S1357-4310(00)01677-4; Cockman ME, 2000, J BIOL CHEM, V275, P25733, DOI 10.1074/jbc.M002740200; Conrad PW, 1999, J BIOL CHEM, V274, P33709, DOI 10.1074/jbc.274.47.33709; CZYZYKKRZESKA MF, 1992, J NEUROCHEM, V58, P1538, DOI 10.1111/j.1471-4159.1992.tb11376.x; Epstein ACR, 2001, CELL, V107, P43, DOI 10.1016/S0092-8674(01)00507-4; GOLDBERG MA, 1994, J BIOL CHEM, V269, P4355; Huang LE, 1996, J BIOL CHEM, V271, P32253, DOI 10.1074/jbc.271.50.32253; Huang LE, 1998, P NATL ACAD SCI USA, V95, P7987, DOI 10.1073/pnas.95.14.7987; Ivan M, 2001, SCIENCE, V292, P464, DOI 10.1126/science.1059817; Jaakkola P, 2001, SCIENCE, V292, P468, DOI 10.1126/science.1059796; JELKMANN W, 1992, PHYSIOL REV, V72, P449, DOI 10.1152/physrev.1992.72.2.449; Kamura T, 2000, P NATL ACAD SCI USA, V97, P10430, DOI 10.1073/pnas.190332597; Lando D, 2002, SCIENCE, V295, P858, DOI 10.1126/science.1068592; Lehmann E, 1999, J AM SOC MASS SPECTR, V10, P27, DOI 10.1016/S1044-0305(98)00116-0; Masson N, 2001, EMBO J, V20, P5197, DOI 10.1093/emboj/20.18.5197; Maxwell PH, 1999, NATURE, V399, P271, DOI 10.1038/20459; O'Rourke JF, 1999, J BIOL CHEM, V274, P2060, DOI 10.1074/jbc.274.4.2060; Semenza GL, 1999, ANNU REV CELL DEV BI, V15, P551, DOI 10.1146/annurev.cellbio.15.1.551; SEMENZA GL, 1994, J BIOL CHEM, V269, P23757; Tian H, 1997, GENE DEV, V11, P72, DOI 10.1101/gad.11.1.72; WANG GL, 1995, P NATL ACAD SCI USA, V92, P5510, DOI 10.1073/pnas.92.12.5510; Wiesener MS, 1998, BLOOD, V92, P2260, DOI 10.1182/blood.V92.7.2260.2260_2260_2268; Yuan Y, 2001, BIOCHEM BIOPH RES CO, V288, P849, DOI 10.1006/bbrc.2001.5835	23	472	501	0	41	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 2	2003	278	18					15911	15916		10.1074/jbc.M300463200	http://dx.doi.org/10.1074/jbc.M300463200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	675EL	12606543	hybrid			2022-12-25	WOS:000182680000058
J	Baumann, S; Hess, J; Eichhorst, ST; Krueger, A; Angel, P; Krammer, PH; Kirchhoff, S				Baumann, S; Hess, J; Eichhorst, ST; Krueger, A; Angel, P; Krammer, PH; Kirchhoff, S			An unexpected role for FosB in activation-induced cell death of T cells	ONCOGENE			English	Article						activation-induced cell death; CD95 ligand; AP-1; T cells	FAS-LIGAND EXPRESSION; NF-KAPPA-B; INDUCED APOPTOSIS; TRANSCRIPTION FACTORS; GENE-EXPRESSION; CARCINOMA CELLS; CYCLOSPORINE-A; UP-REGULATION; C-FOS; PROMOTER	The CD95 (APO-1/Fas) system plays a major role in induction of apoptosis in lymphoid and nonlymphoid tissues. The CD95 (APO-1/Fas) ligand (CD95L) is induced in response to a variety of signals including TCR/CD3 stimulation or application of chemotherapeutic drugs. Here we report that an AP-1 site located in the 5' untranslated region of the CD95L gene is required for TCR/CD3-mediated induction of the human CD95L promoter. Electrophoretic mobility shift assays using nuclear extracts of Jurkat T cells as well as TCR/CD3-restimulated primary human T cells demonstrated specific binding of AP-1, predominantly composed of c-Jun and FosB, to this sequence. Ectopic expression of transdominant negative Jun mutants strongly reduced CD95L promoter activity and activation-induced cell death (AICD), confirming the functional significance of FosB/c-Jun binding. Thus, our results demonstrate an important novel function for FosB dimerized with c-Jun in TCR/CD3-mediated AICD in human T cells.	German Canc Res Ctr, Div Immunogenet, D-69120 Heidelberg, Germany; Tumor Immunol Program, D-69120 Heidelberg, Germany	Helmholtz Association; German Cancer Research Center (DKFZ)	Krammer, PH (corresponding author), German Canc Res Ctr, Div Immunogenet, G0300,Neuenheimer Feld 280, D-69120 Heidelberg, Germany.		Hess, Jochen/ABE-1144-2021; Krueger, Andreas/B-9427-2009; Krueger, Andreas/M-9769-2019; Piris, Miguel A/AAP-1445-2020	Hess, Jochen/0000-0003-3493-1711; Krueger, Andreas/0000-0001-7873-7334; Krueger, Andreas/0000-0001-7873-7334; Piris, Miguel A/0000-0001-5839-3634				ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; Chang LF, 2001, NATURE, V410, P37, DOI 10.1038/35065000; Chow WA, 2000, J IMMUNOL, V164, P3512, DOI 10.4049/jimmunol.164.7.3512; COCKERILL GW, 1995, BLOOD, V86, P2689; Crabtree GR, 1999, CELL, V96, P611, DOI 10.1016/S0092-8674(00)80571-1; DHEIN J, 1995, NATURE, V373, P438, DOI 10.1038/373438a0; Eichhorst ST, 2000, MOL CELL BIOL, V20, P7826, DOI 10.1128/MCB.20.20.7826-7837.2000; Faris M, 1998, J IMMUNOL, V160, P134; Friesen C, 1996, NAT MED, V2, P574, DOI 10.1038/nm0596-574; Hafezi F, 1997, NAT MED, V3, P346, DOI 10.1038/nm0397-346; Harwood FG, 2000, J BIOL CHEM, V275, P10023, DOI 10.1074/jbc.275.14.10023; Holtz-Heppelmann CJ, 1998, J BIOL CHEM, V273, P4416, DOI 10.1074/jbc.273.8.4416; Ivanov VN, 1997, J BIOL CHEM, V272, P8558; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; Kasibhatla S, 1998, MOL CELL, V1, P543, DOI 10.1016/S1097-2765(00)80054-4; Kasibhatla S, 1999, J BIOL CHEM, V274, P987, DOI 10.1074/jbc.274.2.987; Kirchhoff S, 2000, J IMMUNOL, V165, P6293, DOI 10.4049/jimmunol.165.11.6293; Kolbus A, 2000, MOL CELL BIOL, V20, P575, DOI 10.1128/MCB.20.2.575-582.2000; Li-Weber M, 2000, EUR J IMMUNOL, V30, P661, DOI 10.1002/1521-4141(200002)30:2<661::AID-IMMU661>3.3.CO;2-C; Li-Weber M, 1998, EUR J IMMUNOL, V28, P2373, DOI 10.1002/(SICI)1521-4141(199808)28:08<2373::AID-IMMU2373>3.0.CO;2-T; Li-Weber M, 1999, EUR J IMMUNOL, V29, P3017, DOI 10.1002/(SICI)1521-4141(199909)29:09<3017::AID-IMMU3017>3.0.CO;2-R; Lidwell K, 2000, J NEUROSCI RES, V62, P427, DOI 10.1002/1097-4547(20001101)62:3<427::AID-JNR13>3.0.CO;2-O; Macian F, 2000, EMBO J, V19, P4783, DOI 10.1093/emboj/19.17.4783; Matsui K, 2000, J IMMUNOL, V164, P3002, DOI 10.4049/jimmunol.164.6.3002; Mittelstadt PR, 1998, MOL CELL BIOL, V18, P3744, DOI 10.1128/MCB.18.7.3744; Mittelstadt PR, 1999, J BIOL CHEM, V274, P3222, DOI 10.1074/jbc.274.5.3222; Norian LA, 1998, J IMMUNOL, V161, P1078; Passegue E, 2000, EMBO J, V19, P2969, DOI 10.1093/emboj/19.12.2969; Rao A, 1997, ANNU REV IMMUNOL, V15, P707, DOI 10.1146/annurev.immunol.15.1.707; Rivera I, 1998, J BIOL CHEM, V273, P22382, DOI 10.1074/jbc.273.35.22382; ROONEY JW, 1995, IMMUNITY, V2, P473, DOI 10.1016/1074-7613(95)90028-4; Schmitz I, 2000, INT J BIOCHEM CELL B, V32, P1123, DOI 10.1016/S1357-2725(00)00048-0; STEIN B, 1993, EMBO J, V12, P3879, DOI 10.1002/j.1460-2075.1993.tb06066.x; SU B, 1994, CELL, V77, P727, DOI 10.1016/0092-8674(94)90056-6; Weitzman JB, 2000, MOL CELL, V6, P1109, DOI 10.1016/S1097-2765(00)00109-X; Yamamura Y, 2000, J BIOL CHEM, V275, P36295, DOI 10.1074/jbc.M006023200; Zhang J, 2000, J EXP MED, V191, P1017, DOI 10.1084/jem.191.6.1017	37	32	33	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 6	2003	22	9					1333	1339		10.1038/sj.onc.1206126	http://dx.doi.org/10.1038/sj.onc.1206126			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	652CA	12618758				2022-12-25	WOS:000181360900007
J	Schafer, M; Ewald, N; Schafer, C; Stapler, A; Piper, HM; Noll, T				Schafer, M; Ewald, N; Schafer, C; Stapler, A; Piper, HM; Noll, T			Signaling of hypoxia-induced autonomous proliferation of endothelial cells	FASEB JOURNAL			English	Article						angiogenesis; extracellular signal-regulated kinase; inositol-3-phosphate-sensitive Ca2+ release	GROWTH-FACTOR; KINASE; MECHANISMS; CALCIUM; PROTEIN; CARDIOMYOCYTES; ANGIOGENESIS; INVOLVEMENT; ACTIVATION; DEPLETION	Endothelial cells exhibit an autonomous proliferative response to hypoxia, independent of paracrine effectors. In cultured endothelial cells of porcine aorta, we analyzed the signaling and compared hypoxia with mitochondrial inhibition by rotenone. Particularly, roles of the mitogen-activated protein kinase (MAPK) kinase (MEK)/MAPK pathway and cytosolic Ca2+ were studied. Hypoxia resulted in increased proliferation by 65+/-2%. Hypoxia induced transient activation of p42 MAPK (phosphorylation rose from 11+/-5 to 51+/-7%), followed by translocation of p42 MAPK into the nucleus. The proliferative response was diminished after inhibition of the MEK/MAPK pathway by PD 98059 (20 muM) or UO 126 (10 muM) but not sensitive to 8-phenyltheophillin (10 muM), an adenosine receptor blocker, nor to a neutralizing antibody for vascular endothelial growth factor (VEGF). Inhibition of intracellular Ca2+ release, capacitive Ca2+ influx, or removal of extracellular Ca2+ prevented hypoxic Ca2+ overload and the proliferative response. Suppression of cytosolic Ca2+ rise did not interfere with activation of p42 MAPK but abolished its nuclear translocation. Effects of hypoxia were mimicked by rotenone (10 muM). Transient hypoxic inhibition of mitochondria induces a proliferative endothelial response mediated through Ca2+-independent activation and Ca2+-dependent nuclear translocation of p42 MAPK. This proliferative response is independent of adenosine or VEGF.	Univ Giessen, Inst Physiol, D-35392 Giessen, Germany	Justus Liebig University Giessen	Piper, HM (corresponding author), Univ Giessen, Inst Physiol, Aulweg 129, D-35392 Giessen, Germany.	Michael.Piper@physiologie.med.uni-giessen.de						Bustamante JO, 2000, PFLUG ARCH EUR J PHY, V439, P433, DOI 10.1007/s004240050960; Carmeliet P, 2000, NAT MED, V6, P389, DOI 10.1038/74651; Ferrara N, 1997, ENDOCR REV, V18, P4, DOI 10.1210/er.18.1.4; Gafni J, 1997, NEURON, V19, P723, DOI 10.1016/S0896-6273(00)80384-0; GODFREY K, 1985, NEW ENGL J MED, V313, P1450, DOI 10.1056/NEJM198512053132305; GREBER UF, 1995, J CELL BIOL, V128, P5, DOI 10.1083/jcb.128.1.5; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; LI QA, 1987, BIOCHEM BIOPH RES CO, V147, P120; Massfelder T, 1997, P NATL ACAD SCI USA, V94, P13630, DOI 10.1073/pnas.94.25.13630; MEININGER CJ, 1990, AM J PHYSIOL, V258, pH198, DOI 10.1152/ajpheart.1990.258.1.H198; MEININGER CJ, 1988, AM J PHYSIOL, V255, P554; Minet E, 2000, FEBS LETT, V468, P53, DOI 10.1016/S0014-5793(00)01181-9; Muller JN, 1997, J BIOL CHEM, V272, P23435, DOI 10.1074/jbc.272.37.23435; NOLL T, 1995, AM J PHYSIOL-HEART C, V268, pH1462, DOI 10.1152/ajpheart.1995.268.4.H1462; Oosthuyse B, 2001, NAT GENET, V28, P131, DOI 10.1038/88842; Pedram A, 1998, J BIOL CHEM, V273, P26722, DOI 10.1074/jbc.273.41.26722; Risau W, 1997, NATURE, V386, P671, DOI 10.1038/386671a0; Schafer M, 2001, AM J PHYSIOL-HEART C, V280, pH1002, DOI 10.1152/ajpheart.2001.280.3.H1002; Schluter KD, 1999, AM J PHYSIOL-HEART C, V276, pH1655, DOI 10.1152/ajpheart.1999.276.5.H1655; Spahr R., 1990, CELL CULTURE TECHNIQ, P220; STEHNOBITTEL L, 1995, SCIENCE, V270, P1835, DOI 10.1126/science.270.5243.1835; Suzuki E, 2000, J BIOL CHEM, V275, P3637, DOI 10.1074/jbc.275.5.3637	22	23	23	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JAN	2003	17	1					449	+		10.1096/fj.02-0398fje	http://dx.doi.org/10.1096/fj.02-0398fje			23	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	653TT	12631583				2022-12-25	WOS:000181453700014
J	Van Eck, M; Twisk, J; Hoekstra, M; Van Rij, BT; Van der Lans, CAC; Bos, IST; Kruijt, JK; Kuipers, F; Van Berkel, TJC				Van Eck, M; Twisk, J; Hoekstra, M; Van Rij, BT; Van der Lans, CAC; Bos, IST; Kruijt, JK; Kuipers, F; Van Berkel, TJC			Differential effects of scavenger receptor BI deficiency on lipid metabolism in cells of the arterial wall and in the liver	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIGH-DENSITY-LIPOPROTEIN; BILIARY CHOLESTEROL SECRETION; SR-BI; OVEREXPRESSION; EXPRESSION; DISEASE; BINDING; GENE; ATHEROSCLEROSIS; IDENTIFICATION	Scavenger receptor class B, type I (SRBI) is a key regulator of high density lipoprotein (HDL) metabolism. It facilitates the efflux of cholesterol from cells in peripheral tissues to HDL and mediates the selective uptake of cholesteryl esters from HDL in the liver. We investigated the effects of SRBI deficiency in the arterial wall and in the liver using SRBI-deficient mice and wild-type littermates fed a Western-type diet. The SRBI-deficient mice showed massive accumulation of cholesterol-rich HDL in the circulation, reflecting impaired delivery to the liver. Strikingly, SRBI deficiency did not alter hepatic cholesterol ( ester) content nor did it affect the expression of key regulators of hepatic cholesterol homeostasis, including HMG-CoA reductase, the low density lipoprotein receptor, and cholesterol 7alpha-hydroxylase. However, a similar to40% reduction in biliary cholesterol content was observed, and the expression of ABCG8 and ABCG5, ATP half-transporters implicated in the transport of sterols from the liver to the bile, was attenuated by 70 and 35%, respectively. In contrast to the situation in the liver, SRBI deficiency did result in lipid deposition in the aorta and atherosclerosis. Vascular mRNA analysis showed increased expression of inflammatory markers as well as of genes involved in cellular cholesterol homeostasis. Our data show that, although hepatic cholesterol homeostasis is maintained upon feeding a Western-type diet, SRBI deficiency is associated with de-regulation of cholesterol homeostasis in the arterial wall that results in an increased susceptibility to atherosclerosis.	Leiden Univ, Gorlaeus Labs, Leiden Amsterdam Ctr Drug Res, Div Biopharmaceut, NL-2300 RA Leiden, Netherlands; Univ Groningen Hosp, Dept Pediat, Ctr Liver Digest Metab Dis, NL-9700 RB Groningen, Netherlands	Leiden University; Leiden University - Excl LUMC; University of Groningen	Van Eck, M (corresponding author), Leiden Univ, Gorlaeus Labs, Leiden Amsterdam Ctr Drug Res, Div Biopharmaceut, Einsteinweg 55,POB 9502, NL-2300 RA Leiden, Netherlands.	m.eck@LACDR.LeidenUniv.nl	Van Berkel, Theo/ABD-7677-2021	van Eck, Miranda/0000-0003-3936-3194; Kuipers, Folkert/0000-0003-2518-737X; Hoekstra, Menno/0000-0001-7463-2893				Acton S, 1996, SCIENCE, V271, P518, DOI 10.1126/science.271.5248.518; Berge KE, 2000, SCIENCE, V290, P1771, DOI 10.1126/science.290.5497.1771; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Braun A, 2002, CIRC RES, V90, P270, DOI 10.1161/hh0302.104462; Chawla A, 2001, SCIENCE, V294, P1866, DOI 10.1126/science.294.5548.1866; Chen WG, 2000, J BIOL CHEM, V275, P30794, DOI 10.1074/jbc.M004552200; Chinetti G, 2000, CIRCULATION, V101, P2411, DOI 10.1161/01.CIR.101.20.2411; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; de la Llera-Moya M, 2001, J LIPID RES, V42, P1969; GAMBLE W, 1978, J LIPID RES, V19, P1068; Glomset J A, 1980, Adv Intern Med, V25, P91; GORDON DJ, 1989, NEW ENGL J MED, V321, P1311; Greene DJ, 2001, J BIOL CHEM, V276, P4804, DOI 10.1074/jbc.M008725200; Groen AK, 2001, J CLIN INVEST, V108, P843, DOI 10.1172/JCI12473; Hirano K, 1999, CIRC RES, V85, P108; Ito T, 2000, CIRCULATION, V102, P311; Ji Y, 1997, J BIOL CHEM, V272, P20982, DOI 10.1074/jbc.272.34.20982; Ji Y, 1999, J BIOL CHEM, V274, P33398, DOI 10.1074/jbc.274.47.33398; Jian B, 1998, J BIOL CHEM, V273, P5599, DOI 10.1074/jbc.273.10.5599; Jonas A, 2000, BBA-MOL CELL BIOL L, V1529, P245, DOI 10.1016/S1388-1981(00)00153-0; Klucken J, 2000, P NATL ACAD SCI USA, V97, P817, DOI 10.1073/pnas.97.2.817; Kosek AB, 1999, BIOCHEM BIOPH RES CO, V258, P548, DOI 10.1006/bbrc.1999.0690; Kozarsky KF, 2000, ARTERIOSCL THROM VAS, V20, P721, DOI 10.1161/01.ATV.20.3.721; Landschulz KT, 1996, J CLIN INVEST, V98, P984, DOI 10.1172/JCI118883; Lee MH, 2001, CURR OPIN LIPIDOL, V12, P141, DOI 10.1097/00041433-200104000-00007; Li XM, 2002, J BIOL CHEM, V277, P27256, DOI 10.1074/jbc.M203267200; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Mardones P, 2002, J NUTR, V132, P443, DOI 10.1093/jn/132.3.443; Mardones P, 2001, J LIPID RES, V42, P170; PIETERS MN, 1991, BIOCHEM J, V280, P359, DOI 10.1042/bj2800359; Plosch T, 2002, J BIOL CHEM, V277, P33870, DOI 10.1074/jbc.M206522200; Reardon CA, 2001, CURR OPIN LIPIDOL, V12, P167, DOI 10.1097/00041433-200104000-00010; REDGRAVE TG, 1975, ANAL BIOCHEM, V65, P42, DOI 10.1016/0003-2697(75)90488-1; RHOADS GG, 1976, NEW ENGL J MED, V294, P293, DOI 10.1056/NEJM197602052940601; Rigotti A, 1997, P NATL ACAD SCI USA, V94, P12610, DOI 10.1073/pnas.94.23.12610; Ross R, 1999, NEW ENGL J MED, V340, P115, DOI 10.1056/NEJM199901143400207; RUSSELL DW, 1992, CARDIOVASC DRUG THER, V6, P103, DOI 10.1007/BF00054556; Schmitz G, 2001, J LIPID RES, V42, P1513; SCHWARTZ CC, 1978, SCIENCE, V200, P62, DOI 10.1126/science.204996; SETCHELL KDR, 1983, J LIPID RES, V24, P1085; Silver DL, 2001, J BIOL CHEM, V276, P25287, DOI 10.1074/jbc.M101726200; Stangl H, 1999, J BIOL CHEM, V274, P32692, DOI 10.1074/jbc.274.46.32692; Trigatti B, 1999, P NATL ACAD SCI USA, V96, P9322, DOI 10.1073/pnas.96.16.9322; Ueda Y, 2000, J BIOL CHEM, V275, P20368, DOI 10.1074/jbc.M000730200; Van Lenten BJ, 2001, TRENDS CARDIOVAS MED, V11, P155, DOI 10.1016/S1050-1738(01)00095-0; Wang N, 1998, J BIOL CHEM, V273, P32920, DOI 10.1074/jbc.273.49.32920; Webb NR, 1998, J BIOL CHEM, V273, P15241, DOI 10.1074/jbc.273.24.15241; Wellington CL, 2002, LAB INVEST, V82, P273, DOI 10.1038/labinvest.3780421; Yeh YC, 2002, ATHEROSCLEROSIS, V161, P95, DOI 10.1016/S0021-9150(01)00642-6; Yu LQ, 2002, J CLIN INVEST, V110, P671, DOI [10.1172/JCI200216001, 10.1172/JCI0216001]	50	184	185	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 27	2003	278	26					23699	23705		10.1074/jbc.M211233200	http://dx.doi.org/10.1074/jbc.M211233200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	692AR	12639961	hybrid, Green Published			2022-12-25	WOS:000183638600063
J	Bianchi, E; Denti, S; Catena, R; Rossetti, G; Polo, S; Gasparian, S; Putignano, S; Rogge, L; Pardi, R				Bianchi, E; Denti, S; Catena, R; Rossetti, G; Polo, S; Gasparian, S; Putignano, S; Rogge, L; Pardi, R			Characterization of human constitutive photomorphogenesis protein 1, a RING finger ubiquitin ligase that interacts with Jun transcription factors and modulates their transcriptional activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIGHT CONTROL; C-JUN; AP-1; COP1; GENE; BINDING; IDENTIFICATION; DEGRADATION; REPRESSION; COMPLEX	RING finger proteins have been implicated in many fundamental cellular processes, including the control of gene expression. A key regulator of light-dependent development in Arabidopsis thaliana is the constitutive photomorphogenesis protein 1 (atCOP1), a RING finger protein that plays an essential role in translating light/ dark signals into specific changes in gene transcription. atCOP1 binds the basic leucine zipper factor HY5 and suppresses its transcriptional activity through a yet undefined mechanism that results in HY5 degradation in response to darkness. Furthermore, the pleiotropic phenotype of atCOP1 mutants indicates that atCOP1 may be a central regulator of several transcriptional pathways. Here we report the cloning and characterization of the human orthologue of atCOP1. Human COP1 (huCOP1) distributes both to the cytoplasm and the nucleus of cells and shows a striking degree of sequence conservation with atCOP1, suggesting the possibility of a functional conservation as well. In co-immunoprecipitation assays huCOP1 specifically binds basic leucine zipper factors of the Jun family. As a functional consequence of this interaction, expression of huCOP1 in mammalian cells downregulates c-Jun-dependent transcription and the expression of the AP-1 target genes, urokinase and matrix metalloproteinase 1. The RING domain of huCOP1 displays ubiquitin ligase activity in an autoubiquitination assay in vitro; however, suppression of AP-1-dependent transcription by huCOP1 occurs in the absence of changes in c-Jun protein levels, suggesting that this inhibitory effect is independent of c-Jun degradation. Our findings indicate that huCOP1 is a novel regulator of AP-1-dependent transcription sharing the important properties of Arabidopsis COP1 in the control of gene expression.	DIBIT, Lab Leukocyte Biol, I-20132 Milan, Italy; Univ Vita Salute San Raffaele, I-20132 Milan, Italy; Inst Pasteur, Dept Immunol, Immunoregulat Lab, F-75724 Paris, France; European Inst Oncol, Dept Expt Oncol, I-20141 Milan, Italy	Vita-Salute San Raffaele University; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; IRCCS European Institute of Oncology (IEO)	Bianchi, E (corresponding author), DIBIT, Lab Leukocyte Biol, Via Olgettina 58, I-20132 Milan, Italy.	ebianchi@pasteur.fr	Polo, Simona/P-3509-2014; rossetti, grazisa/C-3722-2015; Rogge, Lars/GYJ-6142-2022	rossetti, grazisa/0000-0001-6361-311X; Polo, Simona/0000-0001-5536-9399; Rogge, Lars/0000-0003-1262-9204	Telethon [E.1300] Funding Source: Medline	Telethon(Fondazione Telethon)		Akasaka T, 2001, DEVELOPMENT, V128, P1587; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; Ang LH, 1998, MOL CELL, V1, P213, DOI 10.1016/S1097-2765(00)80022-2; Ausubel FM., 1992, CURRENT PROTOCOLS MO, V3; Bach I, 1999, NAT GENET, V22, P394, DOI 10.1038/11970; Bianchi E, 2000, NATURE, V404, P617, DOI 10.1038/35007098; Borden KLB, 2000, J MOL BIOL, V295, P1103, DOI 10.1006/jmbi.1999.3429; Busso D, 2000, J BIOL CHEM, V275, P22815, DOI 10.1074/jbc.M002578200; Casey Graham, 1997, Current Opinion in Oncology, V9, P88; Chamovitz DA, 1996, CELL, V86, P115, DOI 10.1016/S0092-8674(00)80082-3; Chinenov Y, 2001, ONCOGENE, V20, P2438, DOI 10.1038/sj.onc.1204385; Claret FX, 1996, NATURE, V383, P453, DOI 10.1038/383453a0; Combet C, 2000, TRENDS BIOCHEM SCI, V25, P147, DOI 10.1016/S0968-0004(99)01540-6; DECESARE D, 1995, ONCOGENE, V11, P365; Freemont PS, 2000, CURR BIOL, V10, pR84, DOI 10.1016/S0960-9822(00)00287-6; GUTMAN A, 1990, EMBO J, V9, P2241, DOI 10.1002/j.1460-2075.1990.tb07394.x; Hardtke CS, 2002, PLANT J, V30, P385, DOI 10.1046/j.1365-313X.2002.01298.x; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Holm M, 2001, EMBO J, V20, P118, DOI 10.1093/emboj/20.1.118; Houvras Y, 2000, J BIOL CHEM, V275, P36230, DOI 10.1074/jbc.M002539200; Ibanez-Tallon I, 2002, BLOOD, V100, P3325, DOI 10.1182/blood.V100.9.3325; Joazeiro CAP, 2000, CELL, V102, P549, DOI 10.1016/S0092-8674(00)00077-5; Jochum W, 2001, ONCOGENE, V20, P2401, DOI 10.1038/sj.onc.1204389; Karin M, 1997, CURR OPIN CELL BIOL, V9, P240, DOI 10.1016/S0955-0674(97)80068-3; Karin M, 2000, ANNU REV IMMUNOL, V18, P621, DOI 10.1146/annurev.immunol.18.1.621; Kleemann R, 2000, NATURE, V408, P211, DOI 10.1038/35041591; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Kuras L, 2002, MOL CELL, V10, P69, DOI 10.1016/S1097-2765(02)00561-0; Kwok SF, 1996, PLANT PHYSIOL, V110, P731, DOI 10.1104/pp.110.3.731; Leveillard T, 1997, J BIOL CHEM, V272, P30651, DOI 10.1074/jbc.272.49.30651; Lorick KL, 1999, P NATL ACAD SCI USA, V96, P11364, DOI 10.1073/pnas.96.20.11364; Mizuno Y, 2001, CURR OPIN NEUROL, V14, P477, DOI 10.1097/00019052-200108000-00008; Moilanen AM, 1998, MOL CELL BIOL, V18, P5128, DOI 10.1128/MCB.18.9.5128; Naumann M, 1999, J BIOL CHEM, V274, P35297, DOI 10.1074/jbc.274.50.35297; Ostendorff HP, 2002, NATURE, V416, P99, DOI 10.1038/416099a; Osterlund MT, 2000, NATURE, V405, P462, DOI 10.1038/35013076; Osterlund MT, 1999, TRENDS CELL BIOL, V9, P113, DOI 10.1016/S0962-8924(99)01499-3; Peterson CL, 2002, EMBO REP, V3, P319, DOI 10.1093/embo-reports/kvf075; Pickart CM, 2001, ANNU REV BIOCHEM, V70, P503, DOI 10.1146/annurev.biochem.70.1.503; Reyes JC, 2001, TRENDS BIOCHEM SCI, V26, P18, DOI 10.1016/S0968-0004(00)01732-1; RINCON M, 1994, EMBO J, V13, P4370, DOI 10.1002/j.1460-2075.1994.tb06757.x; Sasaki A, 2002, J BIOL CHEM, V277, P22541, DOI 10.1074/jbc.M109728200; Saurin AJ, 1996, TRENDS BIOCHEM SCI, V21, P208, DOI 10.1016/S0968-0004(96)80017-X; Schmidt D, 2002, P NATL ACAD SCI USA, V99, P2872, DOI 10.1073/pnas.052559499; Seeger M, 1998, FASEB J, V12, P469, DOI 10.1096/fasebj.12.6.469; Shaulian E, 2001, ONCOGENE, V20, P2390, DOI 10.1038/sj.onc.1204383; Tanimoto K, 2000, EMBO J, V19, P4298, DOI 10.1093/emboj/19.16.4298; Tiedt R, 2001, EMBO J, V20, P4143, DOI 10.1093/emboj/20.15.4143; Torii KU, 1998, EMBO J, V17, P5577, DOI 10.1093/emboj/17.19.5577; vonArnim AG, 1997, PLANT PHYSIOL, V114, P779, DOI 10.1104/pp.114.3.779; VONARNIM AG, 1994, CELL, V79, P1035, DOI 10.1016/0092-8674(94)90034-5; Wang HY, 1999, CURR BIOL, V9, P711, DOI 10.1016/S0960-9822(99)80314-5; Yaffe MB, 2001, CURR OPIN CELL BIOL, V13, P131, DOI 10.1016/S0955-0674(00)00189-7; Yin XY, 2001, ONCOGENE, V20, P2908, DOI 10.1038/sj.onc.1204417; Zhang YG, 2001, J VIROL, V75, P9571, DOI 10.1128/JVI.75.20.9571-9578.2001	55	80	83	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 30	2003	278	22					19682	19690		10.1074/jbc.M212681200	http://dx.doi.org/10.1074/jbc.M212681200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	682EH	12615916	Green Published, hybrid			2022-12-25	WOS:000183078000017
J	Kawatani, M; Imoto, M				Kawatani, M; Imoto, M			Deletion of the BH1 domain of Bcl-2 accelerates apoptosis by acting in a dominant negative fashion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME-C; X-L; FAMILY-MEMBERS; MITOCHONDRIAL DYSFUNCTION; YEAST MITOCHONDRIA; CONSERVED DOMAINS; CELL-DEATH; BAX; PROTEIN; HETERODIMERIZATION	To investigate the exact biochemical functions by which Bcl-2 regulates apoptosis, we established a stable human small cell lung carcinoma cell line, Ms-1, overexpressing wild-type human Bcl-2 or various deletion and point mutants thereof, and examined the effect of these Bcl-2 mutants on apoptosis induced by antitumor drugs such as camptothecin. Cytochrome c release, caspase-3(-like) protease activation, and apoptosis induced by antitumor drugs were accelerated by overexpression of Bcl-2 lacking a Bcl-2 homology (BH) 1 domain (Bcl-2/ DeltaBH1), but not by that of BH2, BH3, or BH4 domain-deleted Bcl-2. A similar result was obtained upon the substitution of glycine 145 with alanine in the BH1 domain (Bcl-2/G145A),which failed to interact with either Bax or Bak. Pro-apoptotic Bax and Bak have been known to be activated in response to antitumor drugs, and Bcl-2/ G145A as well as Bcl-2/DeltaBH1 also accelerated Bax- or Bak-induced apoptosis in HEK293T cells. These two mutants still retained the ability to interact with wild-type Bcl-2 and Bcl-x(L), and abrogated the inhibitory effect of wild-type Bcl-2 or Bcl-x(L) on Bax- or Bak-induced apoptosis. In addition, immunoprecipitation studies revealed that Bcl-2/DeltaBH1 and Bcl-2/ G145A interrupted the association between wild-type Bcl-2 and Bax/Bak. Taken together, our results demonstrate that Bcl2/DeltaBH1 or Bcl-2/ G145A acts as a dominant negative of endogenous anti-apoptotic proteins such as Bcl-2 and Bcl-x(L), thereby enhancing antitumor drug-induced apoptosis, and that this dominant negative activity requires both a failure of interaction with Bax and Bak through the BH1 domain of Bcl-2 and retention of the ability to interact with Bcl-2 and Bcl-x(L).	Keio Univ, Fac Sci & Technol, Dept Biosci & Informat, Kohoku Ku, Yokohama, Kanagawa 2238522, Japan	Keio University	Imoto, M (corresponding author), Keio Univ, Fac Sci & Technol, Dept Biosci & Informat, Kohoku Ku, 3-14-1 Hiyohi, Yokohama, Kanagawa 2238522, Japan.	imoto@bio.keio.ac.jp		Kawatani, Makoto/0000-0002-9571-4916				Antonsson B, 2001, J BIOL CHEM, V276, P11615, DOI 10.1074/jbc.M010810200; BORNER C, 1994, J CELL BIOL, V126, P1059, DOI 10.1083/jcb.126.4.1059; Cheng EHY, 1996, NATURE, V379, P554, DOI 10.1038/379554a0; Cheng EHYA, 2001, MOL CELL, V8, P705, DOI 10.1016/S1097-2765(01)00320-3; Choi WS, 2000, J NEUROCHEM, V74, P1621, DOI 10.1046/j.1471-4159.2000.0741621.x; Clem RJ, 1998, P NATL ACAD SCI USA, V95, P554, DOI 10.1073/pnas.95.2.554; Desagher S, 2000, TRENDS CELL BIOL, V10, P369, DOI 10.1016/S0962-8924(00)01803-1; Godlewski MM, 2001, ANTI-CANCER DRUG, V12, P607, DOI 10.1097/00001813-200108000-00008; Gross A, 1999, GENE DEV, V13, P1899, DOI 10.1101/gad.13.15.1899; Gross A, 1998, EMBO J, V17, P3878, DOI 10.1093/emboj/17.14.3878; HANADA M, 1995, J BIOL CHEM, V270, P11962, DOI 10.1074/jbc.270.20.11962; Hsu YT, 1997, P NATL ACAD SCI USA, V94, P3668, DOI 10.1073/pnas.94.8.3668; Hu YM, 1998, P NATL ACAD SCI USA, V95, P4386, DOI 10.1073/pnas.95.8.4386; Huang DCS, 1998, EMBO J, V17, P1029, DOI 10.1093/emboj/17.4.1029; Hunter JJ, 1996, MOL CELL BIOL, V16, P877; Jansen B, 2000, LANCET, V356, P1728, DOI 10.1016/S0140-6736(00)03207-4; KAWATANI M, 2003, IN PRESS EXP CELL RE; Kelekar A, 1997, MOL CELL BIOL, V17, P7040, DOI 10.1128/MCB.17.12.7040; Knudson CM, 1997, NAT GENET, V16, P358, DOI 10.1038/ng0897-358; Lee LC, 1996, J BIOL CHEM, V271, P23284, DOI 10.1074/jbc.271.38.23284; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; MARTIN SJ, 1995, CRIT REV ONCOL HEMAT, V18, P137, DOI 10.1016/1040-8428(94)00124-C; Mikhailov V, 2001, J BIOL CHEM, V276, P18361, DOI 10.1074/jbc.M100655200; Minn AJ, 1999, EMBO J, V18, P632, DOI 10.1093/emboj/18.3.632; Muchmore SW, 1996, NATURE, V381, P335, DOI 10.1038/381335a0; Nechushtan A, 1999, EMBO J, V18, P2330, DOI 10.1093/emboj/18.9.2330; Oh YJ, 1997, MOL BRAIN RES, V51, P133, DOI 10.1016/S0169-328X(97)00229-5; Pan GH, 1998, J BIOL CHEM, V273, P5841, DOI 10.1074/jbc.273.10.5841; Priault M, 1999, EUR J BIOCHEM, V260, P684, DOI 10.1046/j.1432-1327.1999.00198.x; Reed JC, 1997, NATURE, V387, P773, DOI 10.1038/42867; Roucou X, 2000, FEBS LETT, V471, P235, DOI 10.1016/S0014-5793(00)01404-6; Sattler M, 1997, SCIENCE, V275, P983, DOI 10.1126/science.275.5302.983; SEDLAK TW, 1995, P NATL ACAD SCI USA, V92, P7834, DOI 10.1073/pnas.92.17.7834; Shibasaki F, 1997, NATURE, V386, P728, DOI 10.1038/386728a0; Shimizu S, 1999, NATURE, V399, P483, DOI 10.1038/20959; Shimizu S, 2000, ONCOGENE, V19, P4309, DOI 10.1038/sj.onc.1203788; StClair EG, 1997, J BIOL CHEM, V272, P29347; Theodorakis P, 2002, CANCER RES, V62, P3373; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; van Loo G, 2002, CELL DEATH DIFFER, V9, P1031, DOI 10.1038/sj.cdd.4401088; von Haefen C, 2002, ONCOGENE, V21, P4009, DOI 10.1038/sj.onc.1205497; Wang GQ, 2001, J BIOL CHEM, V276, P34307, DOI 10.1074/jbc.M103526200; Wang HG, 1998, HISTOL HISTOPATHOL, V13, P521, DOI 10.14670/HH-13.521; Wang HG, 1996, CELL, V87, P629, DOI 10.1016/S0092-8674(00)81383-5; Wang XD, 2001, GENE DEV, V15, P2922; Wei MC, 2001, SCIENCE, V292, P727, DOI 10.1126/science.1059108; White E, 1996, GENE DEV, V10, P1, DOI 10.1101/gad.10.1.1; Wolter KG, 1997, J CELL BIOL, V139, P1281, DOI 10.1083/jcb.139.5.1281; YIN XM, 1994, NATURE, V369, P321, DOI 10.1038/369321a0; Zong WX, 2001, GENE DEV, V15, P1481, DOI 10.1101/gad.897601; Zou H, 1997, CELL, V90, P405, DOI 10.1016/S0092-8674(00)80501-2	52	27	38	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 30	2003	278	22					19732	19742		10.1074/jbc.M213038200	http://dx.doi.org/10.1074/jbc.M213038200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	682EH	12644466	hybrid			2022-12-25	WOS:000183078000023
J	Mukai, Y; Davie, JK; Dent, SYR				Mukai, Y; Davie, JK; Dent, SYR			Physical and functional interaction of the yeast corepressor Tup1 with mRNA 5 '-triphosphatase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-POLYMERASE-II; CARBOXY-TERMINAL DOMAIN; GROUCHO/TRANSDUCIN-LIKE ENHANCER; DEPENDENT PROTEIN-KINASE; SACCHAROMYCES-CEREVISIAE; MESSENGER-RNA; CAPPING ENZYME; GLUCOSE REPRESSION; TRANSCRIPTIONAL REPRESSOR; CYC8-TUP1 COREPRESSOR	The Tup1-Ssn6 complex is an important corepressor in Saccharomyces cerevisiae that inhibits transcription through interactions with the basal transcription machinery and by remodeling chromatin. In a two-hybrid screen for factors that interact with the Schizosaccharomyces pombe Tup1 ortholog, Tup11, we isolated the pct1(+) cDNA. The pct1(+) gene encodes an mRNA 5'-triphosphatase, which catalyzes the first step of mRNA capping reactions. Pct1 did not interact with the S. pombe Ssn6 ortholog. In vitro glutathione S-transferase pull-down experiments revealed that Pct1 binds to the WD repeat regions of Tup11 and the functionally redundant Tup12 protein. Similarly, the S. cerevisiae Tup1 protein associates with the mRNA 5'-triphosphatase encoded by the CET1 gene. The highly conserved C-terminal domain of Cet1 interacts with Tup1 in vitro, and Tup1-Ssn6 complexes co-purify with the Cet1 protein, indicating that in vivo interactions also occur between these proteins. Over-expression of CET1 compromised repression of an MFA2-lacZ reporter gene that is subject to Tup1-Ssn6 repression. These genetic and biochemical interactions between Tup1-Ssn6 and Cet1 indicate that the capping enzyme associated with RNA polymerase II is a target of the corepressor complex.	Osaka Univ, Grad Sch Engn, Dept Biotechnol, Suita, Osaka 5650871, Japan; Univ Texas, MD Anderson Canc Ctr, Dept Biochem & Mol Biol, Houston, TX 77030 USA	Osaka University; University of Texas System; UTMD Anderson Cancer Center	Mukai, Y (corresponding author), Osaka Univ, Grad Sch Engn, Dept Biotechnol, 2-1 Yamadaoka, Suita, Osaka 5650871, Japan.		Dent, Sharon YR/F-1746-2011	Dent, Sharon YR/0000-0002-4824-3269	NIGMS NIH HHS [GM51189] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BALASUBRAMANIAN B, 1993, MOL CELL BIOL, V13, P6071, DOI 10.1128/MCB.13.10.6071; BALCIUNAS D, 1995, NUCLEIC ACIDS RES, V23, P4421, DOI 10.1093/nar/23.21.4421; Bone JR, 2001, J BIOL CHEM, V276, P1808, DOI 10.1074/jbc.M008668200; BURKE D, 2000, METHODS YEAST GENETI, P123; Chen GQ, 1999, GENE DEV, V13, P2218, DOI 10.1101/gad.13.17.2218; CHEN SM, 1993, MOL CELL BIOL, V13, P831, DOI 10.1128/MCB.13.2.831; Chiu YL, 2001, J BIOL CHEM, V276, P12959, DOI 10.1074/jbc.M007901200; Cho EJ, 1997, GENE DEV, V11, P3319, DOI 10.1101/gad.11.24.3319; Conlan RS, 2001, J MOL BIOL, V309, P1007, DOI 10.1006/jmbi.2001.4742; Davie JK, 2002, MOL CELL BIOL, V22, P693, DOI 10.1128/MCB.22.3.693-703.2002; Deckert J, 2001, MOL CELL BIOL, V21, P2726, DOI 10.1128/MCB.21.8.2726-2735.2001; Edmondson DG, 1998, COLD SPRING HARB SYM, V63, P459, DOI 10.1101/sqb.1998.63.459; Edmondson DG, 1996, GENE DEV, V10, P1247, DOI 10.1101/gad.10.10.1247; Fisher AL, 1998, GENE DEV, V12, P1931, DOI 10.1101/gad.12.13.1931; Grbavec D, 1999, BIOCHEM J, V337, P13, DOI 10.1042/0264-6021:3370013; Gromoller A, 2000, EMBO J, V19, P6845, DOI 10.1093/emboj/19.24.6845; Huang MX, 1998, CELL, V94, P595, DOI 10.1016/S0092-8674(00)81601-3; JIANG YW, 1992, MOL CELL BIOL, V12, P4503, DOI 10.1128/MCB.12.10.4503; JOVE R, 1984, J BIOL CHEM, V259, P8513; KELEHER CA, 1992, CELL, V68, P709, DOI 10.1016/0092-8674(92)90146-4; KOMACHI K, 1994, GENE DEV, V8, P2857, DOI 10.1101/gad.8.23.2857; KUCHIN S, 1995, P NATL ACAD SCI USA, V92, P4006, DOI 10.1073/pnas.92.9.4006; Labib K, 2000, SCIENCE, V288, P1643, DOI 10.1126/science.288.5471.1643; Lima CD, 1999, CELL, V99, P533, DOI 10.1016/S0092-8674(00)81541-X; McCracken S, 1997, GENE DEV, V11, P3306, DOI 10.1101/gad.11.24.3306; Mukai Y, 1999, MOL CELL BIOL, V19, P8461; Myers LC, 2002, MOL CELL, V10, P883, DOI 10.1016/S1097-2765(02)00644-5; Myers LC, 1998, GENE DEV, V12, P45, DOI 10.1101/gad.12.1.45; NEIMAN AM, 1994, P NATL ACAD SCI USA, V91, P3398, DOI 10.1073/pnas.91.8.3398; Palaparti A, 1997, J BIOL CHEM, V272, P26604, DOI 10.1074/jbc.272.42.26604; Papamichos-Chronakis M, 2000, J BIOL CHEM, V275, P8397, DOI 10.1074/jbc.275.12.8397; Papamichos-Chronakis M, 2002, MOL CELL, V9, P1297, DOI 10.1016/S1097-2765(02)00545-2; Park SH, 1999, MOL CELL BIOL, V19, P2044; Pei Y, 2001, BMC Microbiol, V1, P29, DOI 10.1186/1471-2180-1-29; Piruat JI, 1997, GENETICS, V147, P1585; Proft M, 2002, MOL CELL, V9, P1307, DOI 10.1016/S1097-2765(02)00557-9; Proft M, 2001, EMBO J, V20, P1123, DOI 10.1093/emboj/20.5.1123; RASMUSSEN EB, 1993, P NATL ACAD SCI USA, V90, P7923, DOI 10.1073/pnas.90.17.7923; Redd MJ, 1997, J BIOL CHEM, V272, P11193; Robyr D, 2002, CELL, V109, P437, DOI 10.1016/S0092-8674(02)00746-8; ROTH SY, 1995, CURR OPIN GENET DEV, V5, P168, DOI 10.1016/0959-437X(95)80004-2; SAKAI A, 1990, MOL CELL BIOL, V10, P4130, DOI 10.1128/MCB.10.8.4130; Schwer B, 1998, NUCLEIC ACIDS RES, V26, P2050, DOI 10.1093/nar/26.9.2050; SIKORSKI RS, 1989, GENETICS, V122, P19; SMITH RL, 1995, GENE DEV, V9, P2903, DOI 10.1101/gad.9.23.2903; Song WJ, 1996, MOL CELL BIOL, V16, P115; Sprague ER, 2000, EMBO J, V19, P3016, DOI 10.1093/emboj/19.12.3016; STIFANI S, 1992, NAT GENET, V2, P119, DOI 10.1038/ng1092-119; TREITEL MA, 1995, P NATL ACAD SCI USA, V92, P3132, DOI 10.1073/pnas.92.8.3132; Tsukamoto T, 1997, BIOCHEM BIOPH RES CO, V239, P116, DOI 10.1006/bbrc.1997.7439; TZAMARIAS D, 1995, GENE DEV, V9, P821, DOI 10.1101/gad.9.7.821; TZAMARIAS D, 1994, NATURE, V369, P758, DOI 10.1038/369758a0; Varanasi US, 1996, MOL CELL BIOL, V16, P6707; Wahi M, 1998, COLD SPRING HARB SYM, V63, P447, DOI 10.1101/sqb.1998.63.447; WAHI M, 1995, GENETICS, V140, P79; Watson AD, 2000, GENE DEV, V14, P2737, DOI 10.1101/gad.829100; Wen YX, 1999, GENE DEV, V13, P1774, DOI 10.1101/gad.13.14.1774; WILLIAMS FE, 1991, MOL CELL BIOL, V11, P3307, DOI 10.1128/MCB.11.6.3307; Wu JS, 2001, MOL CELL, V7, P117, DOI 10.1016/S1097-2765(01)00160-5; ZITOMER RS, 1992, MICROBIOL REV, V56, P1	60	8	8	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 23	2003	278	21					18895	18901		10.1074/jbc.M302155200	http://dx.doi.org/10.1074/jbc.M302155200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	679PY	12637515	hybrid			2022-12-25	WOS:000182932200025
J	Sazanov, LA; Carroll, J; Holt, P; Toime, L; Fearnley, IM				Sazanov, LA; Carroll, J; Holt, P; Toime, L; Fearnley, IM			A role for native lipids in the stabilization and two-dimensional crystallization of the Escherichia coli NADH-ubiquinone oxidoreductase (complex I)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME-C-OXIDASE; 3-DIMENSIONAL STRUCTURE; ELECTRON-MICROSCOPY; MEMBRANE; PROTEIN; DEHYDROGENASE; RESOLUTION; IDENTIFICATION; MITOCHONDRIA; CONFORMATION	NADH-ubiquinone oxidoreductase ( complex I or NDH-1) was purified from the BL21 strain of Escherichia coli using an improved procedure. The complex was effectively stabilized by addition of divalent cations and lipids, making the preparation suitable for structural studies. The ubiquinone reductase activity of the enzyme was fully restored by addition of native E. coli lipids. Two different two-dimensional crystal forms, with p2 and p3 symmetry, were obtained using lipids containing native E. coli extracts. Analysis of the crystals showed that they are formed by fully intact complex I in an L-shaped conformation. Activity assays and single particle analysis indicated that complex I maintains this structure in detergent solution and does not adopt a different conformation in the active state. Thus, we provide the first experimental evidence that complex I from E. coli has an L-shape in a lipid bilayer and confirm that this is also the case for the active enzyme in solution. This suggests strongly that bacterial complex I exists in an L-shaped conformation in vivo. Our results also indicate that native lipids play an important role in the activation, stabilization and, as a consequence, crystallization of purified complex I from E. coli.	MRC, Dunn Human Nutr Unit, Cambridge CB2 2XY, England	UK Research & Innovation (UKRI); Medical Research Council UK (MRC); MRC Human Nutrition Research	Sazanov, LA (corresponding author), MRC, Dunn Human Nutr Unit, Wellcome Trust Med Res Council Bldg,Hills Rd, Cambridge CB2 2XY, England.	sazanov@mrc-dunn.cam.ac.uk	Sazanov, Leonid A/ABF-2125-2021	Sazanov, Leonid A/0000-0002-0977-7989				Abramson J, 2001, BBA-PROTEIN STRUCT M, V1544, P1, DOI 10.1016/S0167-4838(00)00241-7; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Bottcher B, 2002, J BIOL CHEM, V277, P17970, DOI 10.1074/jbc.M112357200; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Braun M, 1998, BIOCHEMISTRY-US, V37, P1861, DOI 10.1021/bi971176p; Carroll J, 2002, J BIOL CHEM, V277, P50311, DOI 10.1074/jbc.M209166200; Crowther RA, 1996, J STRUCT BIOL, V116, P9, DOI 10.1006/jsbi.1996.0003; David P, 2002, BBA-BIOENERGETICS, V1553, P268, DOI 10.1016/S0005-2728(01)00248-1; Essen LO, 1998, P NATL ACAD SCI USA, V95, P11673, DOI 10.1073/pnas.95.20.11673; FEARNLEY IM, 1992, BIOCHIM BIOPHYS ACTA, V1140, P105, DOI 10.1016/0005-2728(92)90001-I; FINEL M, 1992, BIOCHEMISTRY-US, V31, P11425, DOI 10.1021/bi00161a022; Friedrich T, 1998, BBA-BIOENERGETICS, V1364, P134, DOI 10.1016/S0005-2728(98)00024-3; Friedrich T, 2001, J BIOENERG BIOMEMBR, V33, P169, DOI 10.1023/A:1010722717257; Gomez B, 1999, BIOCHEMISTRY-US, V38, P9031, DOI 10.1021/bi990603r; Grigorieff N, 1998, J MOL BIOL, V277, P1033, DOI 10.1006/jmbi.1998.1668; Guenebaut V, 1997, J MOL BIOL, V265, P409, DOI 10.1006/jmbi.1996.0753; Guenebaut V, 1998, J MOL BIOL, V276, P105, DOI 10.1006/jmbi.1997.1518; Hatefi Y, 1978, Methods Enzymol, V53, P11; HOFHAUS G, 1991, J MOL BIOL, V221, P1027, DOI 10.1016/0022-2836(91)80190-6; KIKUNO R, 1985, FEBS LETT, V189, P85, DOI 10.1016/0014-5793(85)80847-4; LEIF H, 1995, EUR J BIOCHEM, V230, P538, DOI 10.1111/j.1432-1033.1995.tb20594.x; LEONARD K, 1987, J MOL BIOL, V194, P277, DOI 10.1016/0022-2836(87)90375-5; MANN M, 1994, ANAL CHEM, V66, P4390, DOI 10.1021/ac00096a002; Rigaud JL, 1997, J STRUCT BIOL, V118, P226, DOI 10.1006/jsbi.1997.3848; ROBINSON NC, 1982, BIOCHEMISTRY-US, V21, P184, DOI 10.1021/bi00530a031; Sazanov LA, 2000, BIOCHEMISTRY-US, V39, P7229, DOI 10.1021/bi000335t; Sazanov LA, 2000, J MOL BIOL, V302, P455, DOI 10.1006/jmbi.2000.4079; Schapira AHV, 1998, BBA-BIOENERGETICS, V1364, P261, DOI 10.1016/S0005-2728(98)00032-2; Spehr V, 1999, BIOCHEMISTRY-US, V38, P16261, DOI 10.1021/bi9919605; Tsukihara T, 1996, SCIENCE, V272, P1136, DOI 10.1126/science.272.5265.1136; Unden G, 1997, BBA-BIOENERGETICS, V1320, P217, DOI 10.1016/S0005-2728(97)00034-0; Ushakova AV, 1999, BBA-BIOENERGETICS, V1409, P143, DOI 10.1016/S0005-2728(98)00156-X; van Montfort BA, 2002, J MASS SPECTROM, V37, P322, DOI 10.1002/jms.288; vanHeel M, 1996, J STRUCT BIOL, V116, P17, DOI 10.1006/jsbi.1996.0004; Videira A, 1998, BBA-BIOENERGETICS, V1364, P89, DOI 10.1016/S0005-2728(98)00020-6; Wackwitz B, 1999, MOL GEN GENET, V262, P876, DOI 10.1007/s004380051153; WALKER JE, 1992, Q REV BIOPHYS, V25, P253, DOI 10.1017/S003358350000425X; Wilm M, 1996, NATURE, V379, P466, DOI 10.1038/379466a0; Yagi T, 1998, BBA-BIOENERGETICS, V1364, P125, DOI 10.1016/S0005-2728(98)00023-1	40	68	72	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 23	2003	278	21					19483	19491		10.1074/jbc.M208959200	http://dx.doi.org/10.1074/jbc.M208959200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	679PY	12637579	hybrid			2022-12-25	WOS:000182932200098
J	Beuers, U; Denk, GU; Soroka, CJ; Wimmer, R; Rust, C; Paumgartner, G; Boyer, JL				Beuers, U; Denk, GU; Soroka, CJ; Wimmer, R; Rust, C; Paumgartner, G; Boyer, JL			Taurolithocholic acid exerts cholestatic effects via phosphatidylinositol 3-kinase-dependent mechanisms in perfused rat livers and rat hepatocyte couplets	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; 3-KINASE LIPID PRODUCTS; PHOSPHOINOSITIDE 3-KINASE; TAUROURSODEOXYCHOLIC ACID; BILE-ACIDS; URSODEOXYCHOLIC ACID; TRANSPORT; PATHOGENESIS; SECRETION; PATHWAYS	Taurolithocholic acid (TLCA) is a potent cholestatic agent. Our recent work suggested that TLCA impairs hepatobiliary exocytosis, insertion of transport proteins into apical hepatocyte membranes, and bile flow by protein kinase Cepsilon (PKCepsilon)-dependent mechanisms. Products of phosphatidylinositol 3-kinases (PI3K) stimulate PKCepsilon. We studied the role of PI3K for TLCA-induced cholestasis in isolated perfused rat liver (IPRL) and isolated rat hepatocyte couplets (IRHC). In IPRL, TLCA (10 mumol/liter) impaired bile flow by 51%, biliary secretion of horseradish peroxidase, a marker of vesicular exocytosis, by 46%, and the Mrp2 substrate, 2,4-dinitrophenyl-S-glutathione, by 95% and stimulated PI3K-dependent protein kinase B, a marker of PI3K activity, by 154% and PKCepsilon membrane binding by 23%. In IRHC, TLCA (2.5 mumol/liter) impaired canalicular secretion of the fluorescent bile acid, cholylglycylamido fluorescein, by 50%. The selective PI3K inhibitor, wortmannin (100 nmol/liter), and the anticholestatic bile acid tauroursodeoxycholic acid (TUDCA, 25 mumol/liter) independently and additively reversed the effects of TLCA on bile flow, exocytosis, organic anion secretion, PI3K-dependent protein kinase B activity, and PKCepsilon membrane binding in IPRL. Wortmannin also reversed impaired bile acid secretion in IRHC. These data strongly suggest that TLCA exerts cholestatic effects by PI3K- and PKCepsilon-dependent mechanisms that are reversed by tauroursodeoxycholic acid in a PI3K-independent way.	Univ Munich, Klinikum Grosshadern, Dept Med 2, D-81377 Munich, Germany; Yale Univ, Sch Med, Ctr Liver, New Haven, CT 06510 USA	University of Munich; Yale University	Beuers, U (corresponding author), Univ Munich, Klinikum Grosshadern, Dept Med 2, Marchioninistr 15, D-81377 Munich, Germany.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK025636, R37DK025636, P30DK034989] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 25636, DK P30-34989] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANWER MS, 1988, HEPATOLOGY, V8, P887, DOI 10.1002/hep.1840080430; BERGMEYER HU, 1983, METHOD ENZYMAT AN, V3, P574; Beuers U, 1996, GASTROENTEROLOGY, V110, P1553, DOI 10.1053/gast.1996.v110.pm8613063; Beuers U, 2001, HEPATOLOGY, V33, P1206, DOI 10.1053/jhep.2001.24034; BEUERS U, 1993, GASTROENTEROLOGY, V104, P604, DOI 10.1016/0016-5085(93)90433-D; Beuers U, 1999, HEPATOLOGY, V29, P477, DOI 10.1002/hep.510290227; Beuers U, 1998, HEPATOLOGY, V28, P1449, DOI 10.1002/hep.510280601; BEUERS U, 1993, J CLIN INVEST, V92, P2984, DOI 10.1172/JCI116921; BEUERS U, 1999, BILE ACIDS CHOLESTAS, P180; BOYER JL, 1995, GASTROENTEROLOGY, V109, P1600, DOI 10.1016/0016-5085(95)90649-5; BURGOYNE RD, 1993, BIOCHEM J, V293, P305, DOI 10.1042/bj2930305; Cenni V, 2002, BIOCHEM J, V363, P537, DOI 10.1042/0264-6021:3630537; COMBETTES L, 1990, EUR J BIOCHEM, V190, P619, DOI 10.1111/j.1432-1033.1990.tb15617.x; COMBETTES L, 1988, J BIOL CHEM, V263, P2299; Crawford JM, 1996, SEMIN LIVER DIS, V16, P169, DOI 10.1055/s-2007-1007230; Folli F, 1997, GASTROENTEROLOGY, V113, P954, DOI 10.1016/S0016-5085(97)70192-6; Foukas LC, 2002, J BIOL CHEM, V277, P37124, DOI 10.1074/jbc.M202101200; JAVITT NB, 1968, J CLIN INVEST, V47, P1002, DOI 10.1172/JCI105790; JAVITT NB, 1966, NATURE, V210, P1262, DOI 10.1038/2101262a0; KAKIS G, 1978, GASTROENTEROLOGY, V75, P595; KAKIS G, 1980, LAB INVEST, V43, P73; Kullak-Ublick GA, 2000, J HEPATOL, V32, P3, DOI 10.1016/S0168-8278(00)80411-0; Kurz AK, 2000, BIOCHEM J, V350, P207, DOI 10.1042/0264-6021:3500207; Lazaridis KN, 2001, J HEPATOL, V35, P134, DOI 10.1016/S0168-8278(01)00092-7; MARINELLI RA, 1992, BIOCHIM BIOPHYS ACTA, V1125, P44, DOI 10.1016/0005-2760(92)90153-M; Milkiewicz P, 1999, HEPATOLOGY, V29, P471, DOI 10.1002/hep.510290215; Misra S, 1999, P NATL ACAD SCI USA, V96, P5814, DOI 10.1073/pnas.96.10.5814; Misra S, 1998, J BIOL CHEM, V273, P26638, DOI 10.1074/jbc.273.41.26638; Moriya S, 1996, P NATL ACAD SCI USA, V93, P151, DOI 10.1073/pnas.93.1.151; POWIS G, 1994, CANCER RES, V54, P2419; Rameh LE, 1999, J BIOL CHEM, V274, P8347, DOI 10.1074/jbc.274.13.8347; ROMA MG, 1994, J HEPATOL, V20, P603, DOI 10.1016/S0168-8278(05)80347-2; Rust C, 2000, J BIOL CHEM, V275, P20210, DOI 10.1074/jbc.M909992199; Sapin C, 1997, EXP CELL RES, V231, P308, DOI 10.1006/excr.1997.3488; SCHOLMERICH J, 1990, J HEPATOL, V10, P280, DOI 10.1016/0168-8278(90)90133-C; SCHTEINGART DC, 1994, BILE ACIDS HEPATOBIL, P177; STRAVITZ RT, 1996, AM J PHYSIOL, V271, P293; Toker A, 2000, CELL, V103, P185, DOI 10.1016/S0092-8674(00)00110-0; Toker A, 2000, MOL PHARMACOL, V57, P652, DOI 10.1124/mol.57.4.652; TOKER A, 1994, J BIOL CHEM, V269, P32358; Trauner M, 1998, NEW ENGL J MED, V339, P1217, DOI 10.1056/NEJM199810223391707; Vanhaesebroeck B, 1999, EXP CELL RES, V253, P239, DOI 10.1006/excr.1999.4701; WAHLLANDER A, 1979, EUR J BIOCHEM, V96, P441, DOI 10.1111/j.1432-1033.1979.tb13056.x; Webster CRL, 2000, J BIOL CHEM, V275, P29754, DOI 10.1074/jbc.M002831200	44	66	68	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 16	2003	278	20					17810	17818		10.1074/jbc.M209898200	http://dx.doi.org/10.1074/jbc.M209898200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677YX	12626520	hybrid			2022-12-25	WOS:000182838300029
J	Erlendsson, LS; Acheson, RM; Hederstedt, L; Le Brun, NE				Erlendsson, LS; Acheson, RM; Hederstedt, L; Le Brun, NE			Bacillus subtilis ResA is a thiol-disulfide oxidoreductase involved in cytochrome c synthesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THIOREDOXIN-LIKE PROTEIN; OXIDATION-REDUCTION PROPERTIES; ESCHERICHIA-COLI THIOREDOXIN; BOND FORMATION INVIVO; IN-VIVO; REDOX PROPERTIES; PARACOCCUS-DENITRIFICANS; PERIPLASMIC THIOREDOXIN; ACTIVE-SITE; BIOGENESIS	Covalent attachment of heme to apocytochromes c in bacteria occurs on the outside of the cytoplasmic membrane and requires two reduced cysteinyls at the heme binding site. A constructed ResA-deficient Bacillus subtilis strain was found to lack c-type cytochromes. Cytochrome c synthesis was restored in the mutant by: (i) in trans expression of resA; (ii) deficiency in BdbD, a thioldisulfide oxidoreductase that catalyzes formation of an intramolecular disulfide bond in apocytochrome c after transfer of the polypeptide across the cytoplasmic membrane; or (iii) by addition of the reductant dithiothreitol to the growth medium. In vivo studies of ResA showed that it is membrane-associated with its thioredoxin-like domain on the outside of the cytoplasmic membrane. Analysis of a soluble form of the protein revealed two redox reactive cysteine residues with a midpoint potential of about -340 mV at pH 7. We conclude that ResA, probably together with another thiol-disulfide oxidoreductase, CcdA, is required for the reduction of the cysteinyls in the heme binding site of apocytochrome c.	Univ E Anglia, Sch Chem Sci & Pharm, Ctr Met Prot Spect & Biol, Norwich NR4 7TJ, Norfolk, England; Lund Univ, Dept Cell & Organism Biol, SE-22362 Lund, Sweden	University of East Anglia; Lund University	Le Brun, NE (corresponding author), Univ E Anglia, Sch Chem Sci & Pharm, Ctr Met Prot Spect & Biol, Norwich NR4 7TJ, Norfolk, England.	n.le-brun@uea.ac.uk		Le Brun, Nick/0000-0001-9780-4061; Hederstedt, Lars/0000-0002-6650-6296; Erlendsson, Lydur Skuli/0000-0002-6783-3686				ARONSON AI, 1976, BACTERIOL REV, V40, P360, DOI 10.1128/MMBR.40.2.360-402.1976; BARDWELL JCA, 1993, P NATL ACAD SCI USA, V90, P1038, DOI 10.1073/pnas.90.3.1038; Beckett CS, 2000, MOL MICROBIOL, V38, P465, DOI 10.1046/j.1365-2958.2000.02174.x; BENGTSSON J, 1998, J BACTERIOL, V181, P6825; BERGLUND O, 1970, J BIOL CHEM, V245, P6030; CREIGHTON TE, 1980, NATURE, V284, P487, DOI 10.1038/284487a0; Daltrop O, 2002, P NATL ACAD SCI USA, V99, P7872, DOI 10.1073/pnas.132259099; Erlendsson LS, 2002, J BACTERIOL, V184, P1423, DOI 10.1128/JB.184.5.1423-1429.2002; Fabianek RA, 1998, J BACTERIOL, V180, P1947, DOI 10.1128/JB.180.7.1947-1950.1998; Fabianek RA, 1997, J BIOL CHEM, V272, P4467, DOI 10.1074/jbc.272.7.4467; FORTNAGEL P, 1968, J BACTERIOL, V95, P1431, DOI 10.1128/JB.95.4.1431-1438.1968; GLEASON FK, 1992, PROTEIN SCI, V1, P609, DOI 10.1002/pro.5560010507; HAIMA P, 1987, MOL GEN GENET, V209, P335, DOI 10.1007/BF00329663; HAWKINS HC, 1991, BIOCHEM J, V275, P341, DOI 10.1042/bj2750341; HEDERSTEDT L, 1986, METHOD ENZYMOL, V126, P399; Hirasawa M, 1999, BIOCHEMISTRY-US, V38, P5200, DOI 10.1021/bi982783v; HOCH JA, 1991, METHOD ENZYMOL, V204, P305; HOFFMANN K, 1993, BIOL CHEM HOPPESEYLE, V374, P166; HOLMGREN A, 1972, J BIOL CHEM, V247, P1992; HUTCHISON RS, 1995, METHOD ENZYMOL, V252, P220; Johansson P, 1999, MICROBIOL-SGM, V145, P529, DOI 10.1099/13500872-145-3-529; Katzen F, 2000, CELL, V103, P769, DOI 10.1016/S0092-8674(00)00180-X; Kranz R, 1998, MOL MICROBIOL, V29, P383, DOI 10.1046/j.1365-2958.1998.00869.x; KRAUSE G, 1991, J BIOL CHEM, V266, P9494; Krimm I, 1998, EUR J BIOCHEM, V255, P185, DOI 10.1046/j.1432-1327.1998.2550185.x; Krogh A, 2001, J MOL BIOL, V305, P567, DOI 10.1006/jmbi.2000.4315; Kunst F, 1997, NATURE, V390, P249, DOI 10.1038/36786; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Le Brun NE, 2000, MOL MICROBIOL, V36, P638, DOI 10.1046/j.1365-2958.2000.01883.x; LOFERER H, 1993, EMBO J, V12, P3373, DOI 10.1002/j.1460-2075.1993.tb06011.x; LOFERER H, 1995, J BIOL CHEM, V270, P26178, DOI 10.1074/jbc.270.44.26178; LUNDSTROM J, 1993, BIOCHEMISTRY-US, V32, P6649, DOI 10.1021/bi00077a018; LUNDSTROM J, 1990, J BIOL CHEM, V265, P9114; MANOIL C, 1990, J BACTERIOL, V172, P515, DOI 10.1128/jb.172.2.515-518.1990; MARMUR J, 1961, J MOL BIOL, V3, P208, DOI 10.1016/S0022-2836(61)80047-8; Meima R, 2002, J BIOL CHEM, V277, P6994, DOI 10.1074/jbc.M111380200; Monika EM, 1997, J MOL BIOL, V271, P679, DOI 10.1006/jmbi.1997.1227; Nakano MM, 2001, J BACTERIOL, V183, P1938, DOI 10.1128/JB.183.6.1938-1944.2001; Nielsen H, 1997, PROTEIN ENG, V10, P1, DOI 10.1093/protein/10.1.1; PACE CN, 1995, PROTEIN SCI, V4, P2411, DOI 10.1002/pro.5560041120; Page MD, 1997, MOL MICROBIOL, V24, P977, DOI 10.1046/j.1365-2958.1997.4061775.x; Page MD, 1998, TRENDS BIOCHEM SCI, V23, P103, DOI 10.1016/S0968-0004(98)01173-6; PAGE MD, 1990, MOL MICROBIOL, V4, P1181, DOI 10.1111/j.1365-2958.1990.tb00693.x; Pettigrew G.W., 1987, CYTOCHROMES C BIOL A; Reid E, 2001, BIOCHEM J, V355, P51, DOI 10.1042/0264-6021:3550051; RIDDLES PW, 1983, METHOD ENZYMOL, V91, P49; Roth R, 2001, BBA-BIOENERGETICS, V1504, P352, DOI 10.1016/S0005-2728(00)00265-6; SALAMON Z, 1992, ARCH BIOCHEM BIOPHYS, V299, P193, DOI 10.1016/0003-9861(92)90262-U; Sambrook J, 2001, MOL CLONING LAB MANU; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; Schiott T, 2000, J BACTERIOL, V182, P2845, DOI 10.1128/JB.182.10.2845-2854.2000; Schiott T, 1997, J BACTERIOL, V179, P4523, DOI 10.1128/jb.179.14.4523-4529.1997; Schiott T, 1997, J BACTERIOL, V179, P1962, DOI 10.1128/jb.179.6.1962-1973.1997; Setterdahl AT, 2000, BIOCHEMISTRY-US, V39, P10172, DOI 10.1021/bi000663t; Sone M, 1997, J BIOL CHEM, V272, P10349; Sun GF, 1996, J BACTERIOL, V178, P1374, DOI 10.1128/jb.178.5.1374-1385.1996; ThonyMeyer L, 1997, MICROBIOL MOL BIOL R, V61, P337; ThonyMeyer L, 1997, EUR J BIOCHEM, V246, P794, DOI 10.1111/j.1432-1033.1997.t01-1-00794.x; Tjalsma H, 2000, MICROBIOL MOL BIOL R, V64, P515, DOI 10.1128/MMBR.64.3.515-547.2000; Vagner V, 1998, MICROBIOL-SGM, V144, P3097, DOI 10.1099/00221287-144-11-3097; VANDEROOST J, 1991, MOL MICROBIOL, V5, P2063; WUNDERLICH M, 1993, PROTEIN SCI, V2, P717, DOI 10.1002/pro.5560020503; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9; Yu J, 1998, J BIOL CHEM, V273, P8860, DOI 10.1074/jbc.273.15.8860; ZAPUN A, 1993, BIOCHEMISTRY-US, V32, P5083, DOI 10.1021/bi00070a016	65	72	78	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 16	2003	278	20					17852	17858		10.1074/jbc.M300103200	http://dx.doi.org/10.1074/jbc.M300103200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677YX	12637552	hybrid			2022-12-25	WOS:000182838300034
J	Lesne, S; Docagne, F; Gabriel, C; Liot, R; Lahiri, DK; Buee, L; Plawinski, L; Delacourte, A; MacKenzie, ET; Buisson, A; Vivien, D				Lesne, S; Docagne, F; Gabriel, C; Liot, R; Lahiri, DK; Buee, L; Plawinski, L; Delacourte, A; MacKenzie, ET; Buisson, A; Vivien, D			Transforming growth factor-beta 1 potentiates amyloid-beta generation in astrocytes and in transgenic mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALZHEIMERS-DISEASE; PRECURSOR PROTEIN; CEREBRAL-ISCHEMIA; NEURONAL ORIGIN; MESSENGER-RNAS; EXPRESSION; GROWTH-FACTOR-BETA-1; GENE; CULTURES; CELLS	Accumulation of the amyloid-beta peptide (Abeta) in the brain is crucial for development of Alzheimer's disease. Expression of transforming growth factor-beta1 (TGF-beta1), an immunosuppressive cytokine, has been correlated in vivo with Abeta accumulation in transgenic mice and recently with Abeta clearance by activated microglia. Here, we demonstrate that TGF-beta1 drives the production of Abeta40/42 by astrocytes leading to Abeta production in TGF-beta1 transgenic mice. First, TGF-beta1 induces the overexpression of the amyloid precursor protein (APP) in astrocytes but not in neurons, involving a highly conserved TGF-B1-responsive element in the 5'-untranslated region (+54/ +74) of the APP promotor. Second, we demonstrated an increased release of soluble APP-beta which led to TGF-beta1-induced Abeta generation in both murine and human astrocytes. These results demonstrate that TGF-beta1 potentiates Abeta production in human astrocytes and may enhance the formation of plaques burden in the brain of Alzheimer's disease patients.	Univ Caen, Ctr Cyceron, CNRS, UMR 6551, F-14074 Caen, France; Indiana Univ, Sch Med, Inst Psychiat Res, Dept Psychiat, Indianapolis, IN 46202 USA; INSERM, U422, F-59045 Lille, France	Centre National de la Recherche Scientifique (CNRS); Universite de Caen Normandie; Indiana University System; Indiana University-Purdue University Indianapolis; Institut National de la Sante et de la Recherche Medicale (Inserm)	Vivien, D (corresponding author), Univ Caen, Ctr Cyceron, CNRS, UMR 6551, IFR47,Blvd Henri Becquerel,BP 5229, F-14074 Caen, France.	d.vivien@neuro.unicaen.fr	buisson, alain/AAI-8218-2020; Docagne, Fabian/S-8308-2018; Mackenzie, Eric Thomson/L-1938-2015; BUEE, Luc/B-3126-2010; Lahiri, Debomoy/AAZ-3322-2020	buisson, alain/0000-0002-4281-7911; BUEE, Luc/0000-0002-6261-4230; Docagne, Fabian/0000-0003-1745-0625; Liot, Geraldine/0000-0002-4784-7693; Plawinski, Laurent/0000-0002-5288-4413; VIVIEN, DENIS/0000-0002-7636-2185; MacKenzie, Eric T/0000-0003-1057-7033; Lesne, Sylvain/0000-0001-9411-1868				Amara FM, 1999, MOL BRAIN RES, V71, P42, DOI 10.1016/S0169-328X(99)00158-8; Apelt J, 2001, BRAIN RES, V894, P21, DOI 10.1016/S0006-8993(00)03176-0; Barelli HL, 1997, MOL MED, V3, P695, DOI 10.1007/BF03401708; BERKENBOSCH F, 1990, J NEUROSCI RES, V25, P431, DOI 10.1002/jnr.490250321; Buisson A, 1998, FASEB J, V12, P1683, DOI 10.1096/fasebj.12.15.1683; BUSCIGLIO J, 1993, P NATL ACAD SCI USA, V90, P2092, DOI 10.1073/pnas.90.5.2092; CRAS P, 1990, AM J PATHOL, V137, P241; deCaestecker MP, 1997, J BIOL CHEM, V272, P13690, DOI 10.1074/jbc.272.21.13690; DELACOURTE A, 1989, CR ACAD SCI III-VIE, V308, P359; Dennler S, 1998, EMBO J, V17, P3091, DOI 10.1093/emboj/17.11.3091; deWinter JP, 1997, ONCOGENE, V14, P1891, DOI 10.1038/sj.onc.1201017; Docagne F, 1999, FASEB J, V13, P1315, DOI 10.1096/fasebj.13.11.1315; FILLIT H, 1991, NEUROSCI LETT, V129, P318, DOI 10.1016/0304-3940(91)90490-K; FLANDERS KC, 1995, NEUROLOGY, V45, P1561, DOI 10.1212/WNL.45.8.1561; GLENNER GG, 1984, BIOCHEM BIOPH RES CO, V122, P1131, DOI 10.1016/0006-291X(84)91209-9; GRAY CW, 1993, MOL BRAIN RES, V19, P251, DOI 10.1016/0169-328X(93)90037-P; GRIFFIN WST, 1989, P NATL ACAD SCI USA, V86, P7611; HAASS C, 1992, NATURE, V359, P322, DOI 10.1038/359322a0; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; HUELL M, 1995, ACTA NEUROPATHOL, V89, P544; KANG J, 1989, NUCLEIC ACIDS RES, V17, P2130, DOI 10.1093/nar/17.5.2130; KOH JY, 1987, J NEUROSCI METH, V20, P83, DOI 10.1016/0165-0270(87)90041-0; Komesli S, 1998, EUR J BIOCHEM, V254, P505, DOI 10.1046/j.1432-1327.1998.2540505.x; Lahiri DK, 2000, MOL BRAIN RES, V77, P185, DOI 10.1016/S0169-328X(00)00051-6; LeBlanc AC, 1996, J NEUROCHEM, V66, P2300; LeBlanc AC, 1997, J NEUROCHEM, V68, P1183; LEBLANC AC, 1991, FEBS LETT, V292, P171, DOI 10.1016/0014-5793(91)80861-V; Luedecking EK, 2000, HUM GENET, V106, P565, DOI 10.1007/s004390050026; MANN DMA, 1992, ACTA NEUROPATHOL, V83, P415, DOI 10.1007/BF00713534; Massague J, 2000, NAT REV MOL CELL BIO, V1, P169, DOI 10.1038/35043051; MASTERS CL, 1985, EMBO J, V4, P2757, DOI 10.1002/j.1460-2075.1985.tb04000.x; Rose K, 1993, IN VITRO BIOL METHOD, P46; Ruocco A, 1999, J CEREBR BLOOD F MET, V19, P1345, DOI 10.1097/00004647-199912000-00008; Selkoe DJ, 2001, PHYSIOL REV, V81, P741, DOI 10.1152/physrev.2001.81.2.741; SEUBERT P, 1993, NATURE, V361, P260, DOI 10.1038/361260a0; SHIVERS BD, 1988, EMBO J, V7, P1365, DOI 10.1002/j.1460-2075.1988.tb02952.x; SIMAN R, 1989, NEURON, V3, P275, DOI 10.1016/0896-6273(89)90252-3; SOLA C, 1993, MOL BRAIN RES, V17, P41, DOI 10.1016/0169-328X(93)90071-V; Song WH, 1998, GENE, V217, P151, DOI 10.1016/S0378-1119(98)00337-0; Tomoda T, 1996, DEV BIOL, V179, P79, DOI 10.1006/dbio.1996.0242; VANDERWAL EA, 1993, NEUROREPORT, V4, P69, DOI 10.1097/00001756-199301000-00018; Vivien D, 1998, J NEUROCHEM, V70, P2296; VIVIEN D, 1995, J BIOL CHEM, V270, P7134, DOI 10.1074/jbc.270.13.7134; WRANA JL, 1994, NATURE, V370, P341, DOI 10.1038/370341a0; Wyss-Coray T, 2001, NAT MED, V7, P612, DOI 10.1038/87945; WyssCoray T, 1997, NATURE, V389, P603, DOI 10.1038/39321; WYSSCORAY T, 1995, AM J PATHOL, V147, P53; Zhao J, 1996, J BIOL CHEM, V271, P31407, DOI 10.1074/jbc.271.49.31407	48	100	104	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 16	2003	278	20					18408	18418		10.1074/jbc.M300819200	http://dx.doi.org/10.1074/jbc.M300819200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677YX	12626500	hybrid			2022-12-25	WOS:000182838300107
J	Rome, S; Clement, K; Rabasa-Lhoret, R; Loizon, E; Poitou, C; Barsh, GS; Riou, JP; Laville, M; Vidal, H				Rome, S; Clement, K; Rabasa-Lhoret, R; Loizon, E; Poitou, C; Barsh, GS; Riou, JP; Laville, M; Vidal, H			Microarray profiling of human skeletal muscle reveals that insulin regulates not similar to 800 genes during a hyperinsulinemic clamp	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEASOME INHIBITORS; SIGNALING PATHWAY; RECEPTOR-ALPHA; EXPRESSION; PROTEIN; GLUT4; UBIQUITIN; SYSTEM; PHOSPHORYLATION; TRANSCRIPTION	Insulin action in target tissues involved precise regulation of gene expression. To define the set of insulin-regulated genes in human skeletal muscle, we analyzed the global changes in mRNA levels during a 3-h hyperinsulinemic euglycemic clamp in vastus lateralis muscle of six healthy subjects. Using 29,308 cDNA element microarrays, we found that the mRNA expression of 762 genes, including 353 expressed sequence tags, was significantly modified during insulin infusion. 478 were up-regulated and 284 down-regulated. Most of the genes with known function are novel targets of insulin. They are involved in the transcriptional and translational regulation (29%), intermediary and energy metabolisms (14%), intracellular signaling (12%), and cytoskeleton and vesicle traffic (9%). Other categories consisted of genes coding for receptors, carriers, and transporters (8%), components of the ubiquitin/proteasome pathways (7%) and elements of the immune response (5.5%). These results thus define a transcriptional signature of insulin action in human skeletal muscle. They will help to better define the mechanisms involved in the reduction of insulin effectiveness in pathologies such as type 2 diabetes mellitus, a disease characterized by defective regulation of gene expression in response to insulin.	Fac Med R Laennec, INSERM, U449, F-69372 Lyon 08, France; Fac Med R Laennec, Human Nutr Res Ctr, F-69372 Lyon 08, France; Univ Paris 06, Dept Nutr, Hotel Dieu, EA3502, F-75004 Paris, France; Stanford Univ, Sch Med, Beckman Ctr, Howard Hughes Med Inst,Dept Pediat & Genet, Stanford, CA 94305 USA	Institut National de la Sante et de la Recherche Medicale (Inserm); Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Hotel-Dieu - APHP; UDICE-French Research Universities; Sorbonne Universite; Howard Hughes Medical Institute; Stanford University	Rome, S (corresponding author), Fac Med R Laennec, INSERM, U449, Rue G Paradin, F-69372 Lyon 08, France.	srome@univ-lyon1.fr	Clément, karine/R-1120-2017; Vidal, Hubert/M-6674-2017	Vidal, Hubert/0000-0002-9467-0317; LOIZON, Emmanuelle/0000-0002-0723-0736; ROME, SOPHIE/0000-0003-3986-5936				ANDERSEN PH, 1993, J CLIN ENDOCR METAB, V77, P27, DOI 10.1210/jc.77.1.27; Auwerx J, 1999, DIABETOLOGIA, V42, P1033, DOI 10.1007/s001250051268; BAUGH LR, 2001, NUCLEIC ACIDS RES, V29, P2; Baumann CA, 2000, NATURE, V407, P202, DOI 10.1038/35025089; Bevan P, 2001, J CELL SCI, V114, P1429; Blanquart C, 2002, J BIOL CHEM, V277, P37254, DOI 10.1074/jbc.M110598200; Bortoluzzi S, 2000, GENOME RES, V10, P344, DOI 10.1101/gr.10.3.344; Brasaemle DL, 1997, J LIPID RES, V38, P2249; Carayannopoulos MO, 2000, P NATL ACAD SCI USA, V97, P7313, DOI 10.1073/pnas.97.13.7313; CHEATHAM B, 1995, ENDOCR REV, V16, P117, DOI 10.1210/er.16.2.117; CHRIVIA JC, 1993, NATURE, V365, P855, DOI 10.1038/365855a0; Clement K, 2002, GENOME RES, V12, P281, DOI 10.1101/gr.207702; Conaway RC, 2002, SCIENCE, V296, P1254, DOI 10.1126/science.1067466; Ducluzeau PH, 2001, DIABETES, V50, P1134, DOI 10.2337/diabetes.50.5.1134; Dyck DJ, 2001, AM J PHYSIOL-ENDOC M, V281, pE600, DOI 10.1152/ajpendo.2001.281.3.E600; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; Foretz M, 1999, P NATL ACAD SCI USA, V96, P12737, DOI 10.1073/pnas.96.22.12737; GELFAND RA, 1987, J CLIN INVEST, V80, P1, DOI 10.1172/JCI113033; Giorgino F, 2000, P NATL ACAD SCI USA, V97, P1125, DOI 10.1073/pnas.97.3.1125; GOLDSTEIN BJ, 1992, J CELL BIOCHEM, V48, P33, DOI 10.1002/jcb.240480107; Grimble RF, 2002, CURR OPIN CLIN NUTR, V5, P551, DOI 10.1097/00075197-200209000-00015; Hauser S, 2000, J BIOL CHEM, V275, P18527, DOI 10.1074/jbc.M001297200; Hirano Y, 2001, J BIOL CHEM, V276, P36431, DOI 10.1074/jbc.M105200200; Huang J, 2001, P NATL ACAD SCI USA, V98, P13084, DOI 10.1073/pnas.241368698; Ibberson M, 2000, J BIOL CHEM, V275, P4607, DOI 10.1074/jbc.275.7.4607; Jiang ZY, 2002, J BIOL CHEM, V277, P509, DOI 10.1074/jbc.M108280200; KELLEY DE, 1990, AM J PHYSIOL, V258, pE923, DOI 10.1152/ajpendo.1990.258.6.E923; Laville M, 1996, J CLIN INVEST, V98, P43, DOI 10.1172/JCI118775; Lawrence JC, 1997, DIABETES, V46, P541, DOI 10.2337/diabetes.46.4.541; Luiken JJFP, 2002, DIABETES, V51, P3113, DOI 10.2337/diabetes.51.10.3113; Matsushima-Nishiwaki R, 2001, CANCER RES, V61, P7675; Mimnaugh EG, 1997, BIOCHEMISTRY-US, V36, P14418, DOI 10.1021/bi970998j; OBrien RM, 1996, PHYSIOL REV, V76, P1109, DOI 10.1152/physrev.1996.76.4.1109; Pendergrass M, 1998, DIABETES, V47, P387, DOI 10.2337/diabetes.47.3.387; Pietu G, 1999, GENOME RES, V9, P195; Rankinen T, 2002, MED SCI SPORT EXER, V34, P1219, DOI 10.1097/00005768-200208000-00001; Rondinone CM, 2002, BIOCHEM BIOPH RES CO, V296, P1257, DOI 10.1016/S0006-291X(02)02083-1; SMYTHE C, 1991, EUR J BIOCHEM, V200, P625, DOI 10.1111/j.1432-1033.1991.tb16225.x; Sreekumar R, 2002, DIABETES, V51, P1913, DOI 10.2337/diabetes.51.6.1913; Thurmond DC, 2001, MOL MEMBR BIOL, V18, P237; Tsakiridis T, 1999, MICROSC RES TECHNIQ, V47, P79, DOI 10.1002/(SICI)1097-0029(19991015)47:2<79::AID-JEMT1>3.0.CO;2-S; Tusher VG, 2001, P NATL ACAD SCI USA, V98, P5116, DOI 10.1073/pnas.091062498; Wang J, 2000, ANAL SCI, V16, P457, DOI 10.2116/analsci.16.457; Welle S, 1999, GENOME RES, V9, P506; White MF, 1998, RECENT PROG HORM RES, V53, P119; Yechoor VK, 2002, P NATL ACAD SCI USA, V99, P10587, DOI 10.1073/pnas.142301999	46	153	160	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 16	2003	278	20					18063	18068		10.1074/jbc.M300293200	http://dx.doi.org/10.1074/jbc.M300293200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677YX	12621037	hybrid			2022-12-25	WOS:000182838300062
J	Yen, CLE; Farese, RV				Yen, CLE; Farese, RV			MGAT2, a monoacylglycerol acyltransferase expressed in the small intestine	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIACYLGLYCEROL ACYLTRANSFERASE; PURIFICATION; ACTIVATION; CLONING; FAMILY; DGAT2; CELLS	Acyl CoA:monoacylglycerol acyltransferase (MGAT) catalyzes the synthesis of diacylglycerol, a precursor of triacylglycerol. In the intestine, MGAT plays a major role in the absorption of dietary fat by catalyzing the resynthesis of triacylglycerol in enterocytes. This resynthesis is required for the assembly of lipoproteins that transport absorbed fat to other tissues. Despite intense efforts, a gene encoding an intestinal MGAT has not been found. Previously, we identified a gene encoding MGAT1, which in mice is expressed in the stomach, kidney, adipose tissue, and liver but not in the intestine. We now report the identification of homologous genes in humans and mice encoding MGAT2. Expression of the MGAT2 cDNA in either insect or mammalian cells markedly increased MGAT activity in cell membranes. MGAT activity was proportional to the level of MGAT2 protein expressed, and the amount of diacylglycerol produced depended on the concentration of MGAT substrates (fatty acyl CoA or monoacylglycerol). In humans, the MGAT2 gene is highly expressed in the small intestine, liver, stomach, kidney, colon, and white adipose tissue; in mice, it is expressed predominantly in the small intestine. The discovery of the MGAT2 gene will facilitate studies to determine the functional role of MGAT2 in fat absorption in the intestine and to determine whether blocking MGAT activity in enterocytes is a feasible approach to inhibit fat absorption and treat obesity.	Univ Calif San Francisco, Gladstone Inst Cardiovasc Dis, San Francisco, CA 94141 USA; Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA; Univ Calif San Francisco, Cardiovasc Res Inst, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; The J David Gladstone Institutes; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Farese, RV (corresponding author), Univ Calif San Francisco, Gladstone Inst Cardiovasc Dis, POB 419100, San Francisco, CA 94141 USA.		Adiels, Martin/C-9278-2011		NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R56DK056084, R01DK056084] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK56084, R01 DK056084] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BELL RM, 1980, ANNU REV BIOCHEM, V49, P459, DOI 10.1146/annurev.bi.49.070180.002331; BHAT BG, 1993, ARCH BIOCHEM BIOPHYS, V300, P663, DOI 10.1006/abbi.1993.1092; Brockerhoff H., 1974, LIPOLYTIC ENZYMES, P25; CAO J, 2003, J BIOL CHEM; Cases S, 2001, J BIOL CHEM, V276, P38870, DOI 10.1074/jbc.M106219200; Chen HC, 2002, J CLIN INVEST, V109, P1049, DOI [10.1172/JCI200214672, 10.1172/JCI0214672]; COLEMAN RA, 1984, J BIOL CHEM, V259, P8934; GREENSPAN MD, 1968, J BIOL CHEM, V243, P6273; GRIGOR MR, 1982, BIOCHIM BIOPHYS ACTA, V712, P464, DOI 10.1016/0005-2760(82)90273-9; HOFFMAN AGD, 1982, BIOCHIM BIOPHYS ACTA, V710, P53, DOI 10.1016/0005-2760(82)90189-8; JAMDAR SC, 1992, ARCH BIOCHEM BIOPHYS, V296, P419, DOI 10.1016/0003-9861(92)90592-K; JOHNSTON JM, 1977, LIPID METABOLISM MAM, P151; Johnston JM, 1976, LIPID ABSORPTION BIO, P85; Kayden H. J., 1967, J CLIN INVEST, V46, P1965; Kuksis A, 2001, INTESTINAL LIPID MET, P185; Lardizabal KD, 2001, J BIOL CHEM, V276, P38862, DOI 10.1074/jbc.M106168200; LEHNER R, 1993, LIPIDS, V28, P29, DOI 10.1007/BF02536356; MANGANARO F, 1985, CAN J BIOCHEM CELL B, V63, P341, DOI 10.1139/o85-050; MOSTAFA N, 1994, LIPIDS, V29, P785, DOI 10.1007/BF02536701; Phan CT, 2001, FRONT BIOSCI-LANDMRK, V6, pD299, DOI 10.2741/Phan; SANSBURY K, 1989, J LIPID RES, V30, P1251; TENU JP, 1972, EUR J BIOCHEM, V26, P112, DOI 10.1111/j.1432-1033.1972.tb01746.x; WHITMAN WB, 1979, J BIOL CHEM, V254, P184; XIA T, 1993, AM J PHYSIOL, V265, pR414, DOI 10.1152/ajpregu.1993.265.2.R414; Yen CLE, 2002, P NATL ACAD SCI USA, V99, P8512, DOI 10.1073/pnas.132274899	25	134	155	1	27	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 16	2003	278	20					18532	18537		10.1074/jbc.M301633200	http://dx.doi.org/10.1074/jbc.M301633200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677YX	12621063	hybrid			2022-12-25	WOS:000182838300123
J	Carrino, DA; Onnerfjord, P; Sandy, JD; Cs-Szabo, G; Scott, PG; Sorrell, JM; Heinegard, D; Caplan, AI				Carrino, DA; Onnerfjord, P; Sandy, JD; Cs-Szabo, G; Scott, PG; Sorrell, JM; Heinegard, D; Caplan, AI			Age-related changes in the proteoglycans of human skin - Specific cleavage of decorin to yield a major catabolic fragment in adult skin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DERMATAN SULFATE PROTEOGLYCANS; LEUCINE-RICH REPEAT; ARTICULAR-CARTILAGE; MATRIX METALLOPROTEINASES; CORE PROTEINS; I COLLAGEN; DEGRADATION; AGGRECAN; BINDING; GROWTH	Dramatic changes occur in skin as a function of age, including changes in morphology, physiology, and mechanical properties. Changes in extracellular matrix molecules also occur, and these changes likely contribute to the overall age-related changes in the physical properties of skin. The major proteoglycans detected in extracts of human skin are decorin and versican. In addition, adult human skin contains a truncated form of decorin, whereas fetal skin contains virtually undetectable levels of this truncated decorin. Analysis of this molecule, herein referred to as decorunt, indicates that it is a catabolic fragment of decorin rather than a splice variant. With antibody probes to the core protein, decorunt is found to lack the carboxyl-terminal portion of decorin. Further analysis by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry shows that the carboxyl terminus of decorunt is at Phe(170) of decorin. This result indicates that decorunt represents the amino-terminal 43% of the mature decorin molecule. Such a structure is inconsistent with alternative splicing of decorin and suggests that decorunt is a catabolic fragment of decorin. A neoepitope antiserum, anti-VRKVTF, was generated against the carboxyl terminus of decorunt. This antiserum does not recognize intact decorin in any skin proteoglycan sample tested on immunoblots but recognizes every sample of decorunt tested. The results with anti-VRKVTF confirm the identification of the carboxyl terminus of decorunt. Analysis of collagen binding by surface plasmon resonance indicates that the affinity of decorunt for type I collagen is 100-fold less than that of decorin. This observation correlates with the structural analysis of decorunt, in that it lacks regions of decorin previously shown to be important for interaction with type I collagen. The detection of a catabolic fragment of decorin suggests the existence of a specific catabolic pathway for this proteoglycan. Because of the capacity of decorin to influence collagen fibrillogenesis, catabolism of decorin may have important functional implications with respect to the dermal collagen network.	Case Western Reserve Univ, Dept Biol, Skeletal Res Ctr, Cleveland, OH 44106 USA; Lund Univ, Ctr Biomed, Dept Cell & Mol Biol, Sect Connect Tissue Biol, SE-22184 Lund, Sweden; Shriners Hosp Children, Ctr Skeletal Dev & Pediat Orthoped Res, Tampa, FL 33612 USA; Univ S Florida, Dept Pharmacol & Therapeut, Tampa, FL 33612 USA; Rush Presbyterian St Lukes Med Ctr, Dept Biochem, Chicago, IL 60612 USA; Univ Alberta, Dept Biochem, Edmonton, AB T6G 2H7, Canada	Case Western Reserve University; Lund University; State University System of Florida; University of South Florida; Rush University; University of Alberta	Carrino, DA (corresponding author), Case Western Reserve Univ, Dept Biol, Skeletal Res Ctr, Cleveland, OH 44106 USA.		Onnerfjord, Patrik/R-3131-2019	Onnerfjord, Patrik/0000-0002-2345-2937; Caplan, Arnold/0000-0002-8677-6621				Agren UM, 1997, J INVEST DERMATOL, V109, P219, DOI 10.1111/1523-1747.ep12319412; BENTLEY JP, 1979, J INVEST DERMATOL, V73, P80, DOI 10.1111/1523-1747.ep12532769; Breen M., 1972, CONNECT TISSUE RES, V1, P291, DOI [10.3109/03008207209152087, DOI 10.3109/03008207209152087]; BROWN DC, 1990, MATRIX, V9, P468, DOI 10.1016/S0934-8832(11)80016-8; CARRINO DA, 1991, BIOCHEM INT, V24, P485; Carrino DA, 2000, ARCH BIOCHEM BIOPHYS, V373, P91, DOI 10.1006/abbi.1999.1545; Caterson B, 2000, MATRIX BIOL, V19, P333, DOI 10.1016/S0945-053X(00)00078-0; CHOI HU, 1989, J BIOL CHEM, V264, P2876; Colige A, 2002, J BIOL CHEM, V277, P5756, DOI 10.1074/jbc.M105601200; DALY CH, 1979, J INVEST DERMATOL, V73, P84, DOI 10.1111/1523-1747.ep12532770; DANIELSON KG, 1993, GENOMICS, V15, P146, DOI 10.1006/geno.1993.1022; Danielson KG, 1997, J CELL BIOL, V136, P729, DOI 10.1083/jcb.136.3.729; FLEISCHMAJER R, 1991, J STRUCT BIOL, V106, P82, DOI 10.1016/1047-8477(91)90065-5; FLEISCHMAJER R, 1972, BIOCHIM BIOPHYS ACTA, V279, P265, DOI 10.1016/0304-4165(72)90142-0; FUSHIMI H, 1989, J INTERN MED, V226, P409, DOI 10.1111/j.1365-2796.1989.tb01416.x; GARG HG, 1990, CARBOHYD RES, V207, P295, DOI 10.1016/0008-6215(90)84056-Z; Gearing AJH, 2002, IMMUNOL LETT, V81, P41, DOI 10.1016/S0165-2478(01)00333-9; Gronski TJ, 1997, J BIOL CHEM, V272, P12189, DOI 10.1074/jbc.272.18.12189; HABUCHI H, 1986, J BIOL CHEM, V261, P1031; HONDA T, 1986, Journal of Dermatology (Tokyo), V13, P326; Imai K, 1997, BIOCHEM J, V322, P809, DOI 10.1042/bj3220809; Iozzo RV, 1999, J BIOL CHEM, V274, P4489, DOI 10.1074/jbc.274.8.4489; Jeanmaire C, 2001, BRIT J DERMATOL, V145, P10, DOI 10.1046/j.1365-2133.2001.04275.x; Kamada A, 1996, ARCH ORAL BIOL, V41, P951, DOI 10.1016/S0003-9969(96)00031-3; Kresse H, 1997, J BIOL CHEM, V272, P18404, DOI 10.1074/jbc.272.29.18404; LAVKER RM, 1987, J INVEST DERMATOL, V88, pS44, DOI 10.1111/1523-1747.ep12468934; LONGAS MO, 1987, CARBOHYD RES, V159, P127, DOI 10.1016/S0008-6215(00)90010-7; MATSUNAGA E, 1986, J INVEST DERMATOL, V87, P221, DOI 10.1111/1523-1747.ep12696553; MAYS PK, 1988, MECH AGEING DEV, V45, P203, DOI 10.1016/0047-6374(88)90002-4; MEYER LJM, 1994, J INVEST DERMATOL, V102, P385, DOI 10.1111/1523-1747.ep12371800; Mohan MJ, 2002, BIOCHEMISTRY-US, V41, P9462, DOI 10.1021/bi0260132; Moragas A, 1998, ANAL QUANT CYTOL, V20, P493; Mort JS, 2001, ARTHRITIS RES, V3, P337, DOI 10.1186/ar325; Moscatello DK, 1998, J CLIN INVEST, V101, P406, DOI 10.1172/JCI846; NAKANO T, 1988, BIOMED RES-TOKYO, V9, P269, DOI 10.2220/biomedres.9.269; Parks WC, 1998, BIOL EXTRAC, P263; PEARCE RH, 1972, J INVEST DERMATOL, V58, P347, DOI 10.1111/1523-1747.ep12540531; Pinnell SR, 1983, BIOCH PHYSL SKIN, P385; Pratta MA, 2000, J BIOL CHEM, V275, P39096, DOI 10.1074/jbc.M006201200; RADA JA, 1993, EXP EYE RES, V56, P635, DOI 10.1006/exer.1993.1081; RICHARD S, 1993, J INVEST DERMATOL, V100, P705, DOI 10.1111/1523-1747.ep12472356; Rodriguez-Manzaneque JC, 2002, BIOCHEM BIOPH RES CO, V293, P501; ROUGHLEY PJ, 1993, BIOCHEM J, V295, P421, DOI 10.1042/bj2950421; Sandy JD, 2001, J BIOL CHEM, V276, P13372, DOI 10.1074/jbc.M009737200; Santra M, 2002, J BIOL CHEM, V277, P35671, DOI 10.1074/jbc.M205317200; Santra M, 2000, J BIOL CHEM, V275, P35153, DOI 10.1074/jbc.M006821200; Schonherr E, 1998, ARCH BIOCHEM BIOPHYS, V355, P241, DOI 10.1006/abbi.1998.0720; SCOTT PG, 1993, J BIOL CHEM, V268, P11558; Soejima K, 2001, J BIOCHEM-TOKYO, V130, P475, DOI 10.1093/oxfordjournals.jbchem.a003009; STEUER S, 1993, DERMATAN SULFATE PRO, P115; Stracke JO, 2000, FEBS LETT, V478, P52, DOI 10.1016/S0014-5793(00)01819-6; SVENSSON L, 1995, J BIOL CHEM, V270, P20712, DOI 10.1074/jbc.270.35.20712; Sztrolovics R, 1999, BIOCHEM J, V339, P571, DOI 10.1042/0264-6021:3390571; TAKEMA Y, 1994, BRIT J DERMATOL, V131, P641, DOI 10.1111/j.1365-2133.1994.tb04975.x; Tortorella MD, 2001, OSTEOARTHR CARTILAGE, V9, P539, DOI 10.1053/joca.2001.0427; VETTER U, 1993, GENOMICS, V15, P161, DOI 10.1006/geno.1993.1023; Westling J, 2002, J BIOL CHEM, V277, P16059, DOI 10.1074/jbc.M108607200; WILLEN MD, 1991, J INVEST DERMATOL, V96, P968, DOI 10.1111/1523-1747.ep12476335; YAMAUCHI M, 1988, BIOCHEM BIOPH RES CO, V152, P898, DOI 10.1016/S0006-291X(88)80124-4	59	68	73	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 9	2003	278	19					17566	17572		10.1074/jbc.M300124200	http://dx.doi.org/10.1074/jbc.M300124200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677QG	12621051	hybrid			2022-12-25	WOS:000182818600146
J	Carvalho, J; Zheng, XFS				Carvalho, J; Zheng, XFS			Domains of Gln3p interacting with karyopherins, Ure2p, and the target of rapamycin protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; NUCLEAR-LOCALIZATION; SIGNALING PATHWAYS; GATA FACTORS; TOR; NITROGEN; EXPRESSION; GENE; ACTIVATION; COMPLEXES	Gln3p is a GATA-type transcription factor responsive to the quality of nitrogen and carbon. In preferred nitrogen such as glutamine, Gln3p is phosphorylated and sequestered in the cytoplasm in a manner that is dependent on the target of rapamycin (TOR) protein and Ure2p. In nonpreferred nitrogen or nitrogen starvation, Gln3p is dephosphorylated and imported into the nucleus via karyopherin alpha/Srp1p. Upon reintroduction of preferred nitrogen, Gln3p is exported from the nucleus by Crm1p/Xpo1p. Although recent work has provided insights into Gln3p, a more detailed understanding is needed to elucidate the mechanism of its localization and function. In this study, we show that Gln3p contains canonical nuclear localization signal and nuclear export signal sequences necessary for its localization and interaction with its relevant karyopherins. In addition, we identify an N-terminal domain of Gln3p interacting with Ure2p and a C-terminal region for binding to TOR. Finally, we find a lysine/arginine-rich domain essential for the rapamycin-sensitive function, but dispensable for its localization. Our results reveal key domains of Gln3p important for its function and regulation.	Washington Univ, Sch Med, Dept Pathol & Immunol, St Louis, MO 63110 USA	Washington University (WUSTL)	Zheng, XFS (corresponding author), Washington Univ, Sch Med, Dept Pathol & Immunol, Campus Box 8069,660 S Euclid Ave, St Louis, MO 63110 USA.	zheng@pathology.wustl.edu			NATIONAL CANCER INSTITUTE [R01CA077668] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM062817] Funding Source: NIH RePORTER; NCI NIH HHS [R01CA77668] Funding Source: Medline; NIGMS NIH HHS [R01GM62817] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abraham RT, 2002, CELL, V111, P9, DOI 10.1016/S0092-8674(02)01009-7; Beck T, 1999, NATURE, V402, P689, DOI 10.1038/45287; Bertram PG, 2002, MOL CELL BIOL, V22, P1246, DOI 10.1128/MCB.22.4.1246-1252.2002; Bertram PG, 2000, J BIOL CHEM, V275, P35727, DOI 10.1074/jbc.M004235200; Blinder D, 1996, J BACTERIOL, V178, P4734, DOI 10.1128/jb.178.15.4734-4736.1996; BLINDER D, 1995, J BACTERIOL, V177, P4190, DOI 10.1128/jb.177.14.4190-4193.1995; Cardenas ME, 1999, GENE DEV, V13, P3271, DOI 10.1101/gad.13.24.3271; Carvalho J, 2001, J BIOL CHEM, V276, P25359, DOI 10.1074/jbc.M103050200; Chan TF, 2000, P NATL ACAD SCI USA, V97, P13227, DOI 10.1073/pnas.240444197; Chan TF, 2001, J BIOL CHEM, V276, P6463, DOI 10.1074/jbc.M008162200; Coffman JA, 1996, MOL CELL BIOL, V16, P847; Cooper TG, 2002, FEMS MICROBIOL REV, V26, P223, DOI 10.1111/j.1574-6976.2002.tb00612.x; COSCHIGANO PW, 1991, MOL CELL BIOL, V11, P822, DOI 10.1128/MCB.11.2.822; COURCHESNE WE, 1988, J BACTERIOL, V170, P708, DOI 10.1128/jb.170.2.708-713.1988; Crespo JL, 2001, J BIOL CHEM, V276, P34441, DOI 10.1074/jbc.M103601200; Dennis PB, 1999, CURR OPIN GENET DEV, V9, P49, DOI 10.1016/S0959-437X(99)80007-0; Fornerod M, 1997, CELL, V90, P1051, DOI 10.1016/S0092-8674(00)80371-2; Guthrie C., 1991, GUIDE YEAST GENETICS, V194; Hardwick JS, 1999, P NATL ACAD SCI USA, V96, P14866, DOI 10.1073/pnas.96.26.14866; Helliwell SB, 1998, CURR BIOL, V8, P1211, DOI 10.1016/S0960-9822(07)00511-8; Hicks GR, 1995, ANNU REV CELL DEV BI, V11, P155, DOI 10.1146/annurev.cb.11.110195.001103; Hidalgo M, 2000, ONCOGENE, V19, P6680, DOI 10.1038/sj.onc.1204091; Komeili A, 2000, J CELL BIOL, V151, P863, DOI 10.1083/jcb.151.4.863; Kulkarni AA, 2001, J BIOL CHEM, V276, P32136, DOI 10.1074/jbc.M104580200; KUNZ J, 1993, CELL, V73, P585, DOI 10.1016/0092-8674(93)90144-F; Kuruvilla FG, 1999, CHEM BIOL, V6, pR129, DOI 10.1016/S1074-5521(99)80070-2; Loewith R, 2002, MOL CELL, V10, P457, DOI 10.1016/S1097-2765(02)00636-6; Magasanik B, 2002, GENE, V290, P1, DOI 10.1016/S0378-1119(02)00558-9; MINEHART PL, 1991, MOL CELL BIOL, V11, P6216, DOI 10.1128/MCB.11.12.6216; Neville M, 1997, CURR BIOL, V7, P767, DOI 10.1016/S0960-9822(06)00335-6; OMICHINSKI JG, 1993, SCIENCE, V261, P438, DOI 10.1126/science.8332909; Rohde J, 2001, J BIOL CHEM, V276, P9583, DOI 10.1074/jbc.R000034200; Schmelzle T, 2000, CELL, V103, P253, DOI 10.1016/S0092-8674(00)00117-3; Shamji AF, 2000, CURR BIOL, V10, P1574, DOI 10.1016/S0960-9822(00)00866-6; STANBROUGH M, 1995, P NATL ACAD SCI USA, V92, P9450, DOI 10.1073/pnas.92.21.9450; Svetlov V, 1997, J BACTERIOL, V179, P7644, DOI 10.1128/jb.179.24.7644-7652.1997; ZHENG XF, 1995, CELL, V82, P121, DOI 10.1016/0092-8674(95)90058-6	37	43	44	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 9	2003	278	19					16878	16886		10.1074/jbc.M300429200	http://dx.doi.org/10.1074/jbc.M300429200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677QG	12624103	hybrid			2022-12-25	WOS:000182818600059
J	Harding, A; Giles, N; Burgess, A; Hancock, JF; Gabrielli, BG				Harding, A; Giles, N; Burgess, A; Hancock, JF; Gabrielli, BG			Mechanism of mitosis-specific activation of MEK1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							XENOPUS EGG EXTRACTS; SOMATIC-CELL MITOSIS; PROTEIN-KINASE; MAP-KINASE; PHOSPHOINOSITIDE 3-KINASE; G(2)/M TRANSITION; N-RAS; CYCLE; PATHWAY; BINDING	Activation of cyclin B-Cdc2 is an absolute requirement for entry into mitosis, but other protein kinase pathways that also have mitotic functions are activated during G(2)/M progression. The MAPK cascade has well established roles in entry and exit from mitosis in Xenopus, but relatively little is known about the regulation and function of this pathway in mammalian mitosis. Here we report a detailed analysis of the activity of all components of the Ras/Raf/MEK/ERK pathway in HeLa cells during normal G(2)/M. The focus of this pathway is the dramatic activation of an endomembrane-associated MEK1 without the corresponding activation of the MEK substrate ERK. This is because of the uncoupling of MEK1 activation from ERK activation. The mechanism of this uncoupling involves the cyclin B-Cdc2-dependent proteolytic cleavage of the N-terminal ERK-binding domain of MEK1 and the phosphorylation of Thr(286). These results demonstrate that cyclin B-Cdc2 activity regulates signaling through the MAPK pathway in mitosis.	Univ Queensland, Canc Biol Program, Ctr Immunol & Canc Res, Brisbane, Qld 4102, Australia; Univ Queensland, Inst Mol Biosci, Brisbane, Qld 4102, Australia	University of Queensland; University of Queensland	Gabrielli, BG (corresponding author), Univ Queensland, Ctr Immunol & Canc Res, Princess Alexandra Hosp, Brisbane, Qld 4102, Australia.		Harding, Angus/B-4120-2012; Gabrielli, Brian G/B-3655-2011; Burgess, Andrew/H-3339-2019; Burgess, Andrew/C-7952-2009	Gabrielli, Brian G/0000-0003-3933-1651; Burgess, Andrew/0000-0003-4536-9226; Burgess, Andrew/0000-0003-4536-9226; Hancock, John/0000-0003-0542-4710				Bardwell AJ, 2001, J BIOL CHEM, V276, P10374, DOI 10.1074/jbc.M010271200; Bitangcol JC, 1998, MOL BIOL CELL, V9, P451, DOI 10.1091/mbc.9.2.451; BLAGOSKLONNY MV, 1995, CANCER RES, V55, P4623; CATLING AD, 1995, MOL CELL BIOL, V15, P5214; Clyde-Smith J, 2000, J BIOL CHEM, V275, P32260, DOI 10.1074/jbc.M006087200; Colanzi A, 2000, J CELL BIOL, V149, P331, DOI 10.1083/jcb.149.2.331; Duesbery NS, 1998, SCIENCE, V280, P734, DOI 10.1126/science.280.5364.734; Edelmann HML, 1996, J BIOL CHEM, V271, P963, DOI 10.1074/jbc.271.2.963; Gabrielli BG, 1996, J CELL SCI, V109, P1081; Hayne C, 2000, J BIOL CHEM, V275, P31876, DOI 10.1074/jbc.M002766200; Johnson L, 1997, GENE DEV, V11, P2468, DOI 10.1101/gad.11.19.2468; Laird AD, 1999, J BIOL CHEM, V274, P4430, DOI 10.1074/jbc.274.7.4430; Lavoie JN, 1996, J BIOL CHEM, V271, P20608, DOI 10.1074/jbc.271.34.20608; McGuire TF, 2001, J BIOL CHEM, V276, P26365, DOI 10.1074/jbc.M010101200; Meijer L, 1997, EUR J BIOCHEM, V243, P527, DOI 10.1111/j.1432-1033.1997.t01-2-00527.x; MINSHULL J, 1994, CELL, V79, P475, DOI 10.1016/0092-8674(94)90256-9; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; NORBURY C, 1991, EMBO J, V10, P3321, DOI 10.1002/j.1460-2075.1991.tb04896.x; Roberts EC, 2002, MOL CELL BIOL, V22, P7226, DOI 10.1128/MCB.22.20.7226-7241.2002; ROSSOMANDO AJ, 1994, MOL CELL BIOL, V14, P1594, DOI 10.1128/MCB.14.3.1594; Roy S, 1997, J BIOL CHEM, V272, P20139, DOI 10.1074/jbc.272.32.20139; Schaeffer HJ, 1998, SCIENCE, V281, P1668, DOI 10.1126/science.281.5383.1668; Shapiro PS, 1998, J CELL BIOL, V142, P1533, DOI 10.1083/jcb.142.6.1533; TAMEMOTO H, 1992, J BIOL CHEM, V267, P20293; Tamura K, 2000, CANCER RES, V60, P1317; Walter SA, 2000, MOL BIOL CELL, V11, P887, DOI 10.1091/mbc.11.3.887; Wang XQ, 1996, CANCER RES, V56, P2510; Wolfman JC, 2000, J BIOL CHEM, V275, P19315, DOI 10.1074/jbc.M000250200; Wright JH, 1999, P NATL ACAD SCI USA, V96, P11335, DOI 10.1073/pnas.96.20.11335; Yan J, 1998, J BIOL CHEM, V273, P24052, DOI 10.1074/jbc.273.37.24052; Zecevic M, 1998, J CELL BIOL, V142, P1547, DOI 10.1083/jcb.142.6.1547	31	47	48	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 9	2003	278	19					16747	16754		10.1074/jbc.M301015200	http://dx.doi.org/10.1074/jbc.M301015200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677QG	12609978	hybrid			2022-12-25	WOS:000182818600041
J	Laliberte, RE; Perregaux, DG; Hoth, LR; Rosner, PJ; Jordan, CK; Peese, KM; Eggler, JF; Dombroski, MA; Geoghegan, KF; Gabel, CA				Laliberte, RE; Perregaux, DG; Hoth, LR; Rosner, PJ; Jordan, CK; Peese, KM; Eggler, JF; Dombroski, MA; Geoghegan, KF; Gabel, CA			Glutathione S-transferase omega 1-1 is a target of cytokine release inhibitory drugs and may be responsible for their effect on interleukin-1 beta posttranslational processing	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLLAGEN-INDUCED ARTHRITIS; CHLORIDE-ION CHANNEL; MOLECULAR-CLONING; TNF-ALPHA; CRYSTAL-STRUCTURE; HUMAN MONOCYTES; P2Z RECEPTOR; ATP; IDENTIFICATION; ACTIVATION	Stimulus-induced posttranslational processing of human monocyte interleukin-1beta(IL-1beta) is accompanied by major changes to the intracellular ionic environment, activation of caspase-1, and cell death. Certain diarylsulfonylureas inhibit this response, and are designated cytokine release inhibitory drugs (CRIDs). CRIDs arrest activated monocytes so that caspase-1 remains inactive and plasma membrane latency is preserved. Affinity labeling with [C-14] CRIDs and affinity chromatography on immobilized CRID were used in seeking potential protein targets of their action. Following treatment of intact human monocytes with an epoxide-bearing [C-14] CRID, glutathione S-transferase (GST) Omega 1-1 was identified as a preferred target. Moreover, labeling of this polypeptide correlated with irreversible inhibition of ATP-induced IL-1beta posttranslational processing. When extracts of human monocytic cells were chromatographed on a CRID affinity column, GST Omega 1-1 bound selectively to the affinity matrix and was eluted by soluble CRID. Recombinant GST Omega 1-1 readily incorporated [C-14] CRID epoxides, but labeling was negated by co-incubation with S-substituted glutathiones or by mutagenesis of the catalytic center Cys(32) to alanine. Peptide mapping by high performance liquid chromatography-mass spectrometry also demonstrated that Cys(32) was the site of modification. Although S-alkylglutathiones did not arrest ATP-induced IL-1beta posttranslational processing or inhibit [C-14] CRID incorporation into cell-associated GST Omega 1-1, a glutathione-CRID adduct effectively demonstrated these attributes. Therefore, the ability of CRIDs to arrest stimulus-induced IL-1beta posttranslational processing may be attributable to their interaction with GST Omega 1-1.	Pfizer Inc, Pfizer Global Res & Dev, Dept Antibacterials Immunol & Inflammat, Groton, CT 06340 USA; Pfizer Inc, Pfizer Global Res & Dev, Dept Exploratory Med Sci, Groton, CT 06340 USA	Pfizer; Pfizer	Gabel, CA (corresponding author), Pfizer Inc, Pfizer Global Res & Dev, Dept Antibacterials Immunol & Inflammat, Mailstop 8220-2123, Groton, CT 06340 USA.	christopher_a_gabel@groton.pfizer.com						AHOKAS JT, 1985, BIOCHEM PHARMACOL, V34, P2157, DOI 10.1016/0006-2952(85)90411-3; Alzola E, 1998, J BIOL CHEM, V273, P30208, DOI 10.1074/jbc.273.46.30208; AURON PE, 1984, P NATL ACAD SCI-BIOL, V81, P7907, DOI 10.1073/pnas.81.24.7907; BHAKDI S, 1990, J CLIN INVEST, V85, P1746, DOI 10.1172/JCI114631; Board PG, 2000, J BIOL CHEM, V275, P24798, DOI 10.1074/jbc.M001706200; Borges CR, 2002, J BIOL CHEM, V277, P48295, DOI 10.1074/jbc.M209042200; Bresnihan B, 1998, ARTHRITIS RHEUM, V41, P2196, DOI 10.1002/1529-0131(199812)41:12<2196::AID-ART15>3.3.CO;2-U; BUISMAN HP, 1988, P NATL ACAD SCI USA, V85, P7988, DOI 10.1073/pnas.85.21.7988; CERRETTI DP, 1992, SCIENCE, V256, P97, DOI 10.1126/science.1373520; Cheneval D, 1998, J BIOL CHEM, V273, P17846, DOI 10.1074/jbc.273.28.17846; CLELLAND JD, 1992, BIOCHEM PHARMACOL, V44, P1953, DOI 10.1016/0006-2952(92)90097-3; Dinarello C A, 1998, Int Rev Immunol, V16, P457, DOI 10.3109/08830189809043005; DIRR H, 1994, EUR J BIOCHEM, V220, P645, DOI 10.1111/j.1432-1033.1994.tb18666.x; Dixon DP, 2002, J BIOL CHEM, V277, P30859, DOI 10.1074/jbc.M202919200; Dulhunty A, 2001, J BIOL CHEM, V276, P3319, DOI 10.1074/jbc.M007874200; Eaton P, 2002, J BIOL CHEM, V277, P21189, DOI 10.1074/jbc.M200591200; Eggler JF, 2002, J LABELLED COMPD RAD, V45, P785, DOI 10.1002/jlcr.602; ELMOATASSIM C, 1992, J BIOL CHEM, V267, P23664; ENG JK, 1994, J AM SOC MASS SPECTR, V5, P976, DOI 10.1016/1044-0305(94)80016-2; Ferrari D, 1997, NEUROPHARMACOLOGY, V36, P1295, DOI 10.1016/S0028-3908(97)00137-8; Ferrari D, 1997, J IMMUNOL, V159, P1451; Ferrari D, 1997, J CELL BIOL, V139, P1635, DOI 10.1083/jcb.139.7.1635; Fratelli M, 2002, P NATL ACAD SCI USA, V99, P3505, DOI 10.1073/pnas.052592699; Geoghegan K. F., 1996, CURRENT PROTOCOLS PR; Harrop SJ, 2001, J BIOL CHEM, V276, P44993, DOI 10.1074/jbc.M107804200; Hayes JD, 1999, FREE RADICAL RES, V31, P273, DOI 10.1080/10715769900300851; Hentze H, 2002, J BIOL CHEM, V277, P5588, DOI 10.1074/jbc.M110766200; Hide I, 2000, J NEUROCHEM, V75, P965, DOI 10.1046/j.1471-4159.2000.0750965.x; HOGQUIST KA, 1991, P NATL ACAD SCI USA, V88, P8485, DOI 10.1073/pnas.88.19.8485; Hughes FM, 1997, J BIOL CHEM, V272, P30567, DOI 10.1074/jbc.272.48.30567; Humphreys BD, 2000, J BIOL CHEM, V275, P26792; Ishikawa T, 1998, J BIOL CHEM, V273, P28708, DOI 10.1074/jbc.273.44.28708; JahngenHodge J, 1997, J BIOL CHEM, V272, P28218, DOI 10.1074/jbc.272.45.28218; JASYS VJ, 2003, INPRESS SYN COMM, V33; Jonscher KR, 1997, ANAL BIOCHEM, V244, P1, DOI 10.1006/abio.1996.9877; Joosten LAB, 1999, J IMMUNOL, V163, P5049; Kim M, 2001, EMBO J, V20, P6347, DOI 10.1093/emboj/20.22.6347; Kodym R, 1999, J BIOL CHEM, V274, P5131, DOI 10.1074/jbc.274.8.5131; LALIBERTE R, 1994, J IMMUNOL, V153, P2168; Laliberte RE, 1999, J BIOL CHEM, V274, P36944, DOI 10.1074/jbc.274.52.36944; Liebau E, 2000, MOL BIOCHEM PARASIT, V109, P101, DOI 10.1016/S0166-6851(00)00232-2; Maeno E, 2000, P NATL ACAD SCI USA, V97, P9487, DOI 10.1073/pnas.140216197; MARCH CJ, 1985, NATURE, V315, P641, DOI 10.1038/315641a0; Marrs KA, 1996, ANNU REV PLANT PHYS, V47, P127, DOI 10.1146/annurev.arplant.47.1.127; Martinon F, 2002, MOL CELL, V10, P417, DOI 10.1016/S1097-2765(02)00599-3; MEURY J, 1990, ARCH MICROBIOL, V154, P475, DOI 10.1007/BF00245231; Michel AD, 1998, BRIT J PHARMACOL, V125, P1194, DOI 10.1038/sj.bjp.0702205; MILLER BE, 1995, J IMMUNOL, V154, P1331; MOSLEY B, 1987, J BIOL CHEM, V262, P2941; MUNGER JS, 1991, J BIOL CHEM, V266, P18832; Ness LS, 1999, J BIOL CHEM, V274, P9524, DOI 10.1074/jbc.274.14.9524; Nobel CSI, 1997, CHEM RES TOXICOL, V10, P1319, DOI 10.1021/tx970131m; Park JB, 1996, BIOCHEM J, V315, P931, DOI 10.1042/bj3150931; Parvathenani LK, 2003, J BIOL CHEM, V278, P13309, DOI 10.1074/jbc.M209478200; PERREGAUX D, 1992, J IMMUNOL, V149, P1294; PERREGAUX D, 1994, J BIOL CHEM, V269, P15195; Perregaux DG, 1998, AM J PHYSIOL-CELL PH, V275, pC1538, DOI 10.1152/ajpcell.1998.275.6.C1538; Perregaux DG, 1996, J BIOL CHEM, V271, P29830, DOI 10.1074/jbc.271.47.29830; Perregaux DG, 2002, J IMMUNOL, V168, P3024, DOI 10.4049/jimmunol.168.6.3024; Perregaux DG, 2001, J PHARMACOL EXP THER, V299, P187; Perregaux DG, 1996, J IMMUNOL, V157, P57; Rassendren F, 1997, J BIOL CHEM, V272, P5482, DOI 10.1074/jbc.272.9.5482; Ridderstrom M, 1997, BIOCHEM J, V328, P231, DOI 10.1042/bj3280231; Rossjohn J, 1996, PROTEIN ENG, V9, P327, DOI 10.1093/protein/9.4.327; Rouimi P, 2001, BIOCHEM J, V358, P257, DOI 10.1042/0264-6021:3580257; RUBARTELLI A, 1990, EMBO J, V9, P1503, DOI 10.1002/j.1460-2075.1990.tb08268.x; Schilling WP, 1999, AM J PHYSIOL-CELL PH, V277, pC766, DOI 10.1152/ajpcell.1999.277.4.C766; Seres T, 1996, J IMMUNOL, V156, P1973; Shenton D, 2002, J BIOL CHEM, V277, P16853, DOI 10.1074/jbc.M200559200; SINGER II, 1988, J EXP MED, V167, P389, DOI 10.1084/jem.167.2.389; SINNING I, 1993, J MOL BIOL, V232, P192, DOI 10.1006/jmbi.1993.1376; STEINBERG TH, 1987, J BIOL CHEM, V262, P8884; STEVENSON FT, 1992, J CELL PHYSIOL, V152, P223, DOI 10.1002/jcp.1041520202; Stone K. L., 1993, PRACTICAL GUIDE PROT, P43; Sullivan DM, 2000, BIOCHEMISTRY-US, V39, P11121, DOI 10.1021/bi0007674; Surprenant A, 1996, SCIENCE, V272, P735, DOI 10.1126/science.272.5262.735; Thompson GJ, 2001, BIOCHEM J, V357, P137, DOI 10.1042/0264-6021:3570137; THORNBERRY NA, 1992, NATURE, V356, P768, DOI 10.1038/356768a0; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Traub LM, 1997, CURR OPIN CELL BIOL, V9, P527, DOI 10.1016/S0955-0674(97)80029-4; Tulk BM, 1998, AM J PHYSIOL-RENAL, V274, pF1140, DOI 10.1152/ajprenal.1998.274.6.F1140; Valenzuela SM, 1997, J BIOL CHEM, V272, P12575, DOI 10.1074/jbc.272.19.12575; VEJDELEK ZJ, 1977, COLLECT CZECH CHEM C, V42, P1992, DOI 10.1135/cccc19771992; Virginio C, 1999, J PHYSIOL-LONDON, V519, P335, DOI 10.1111/j.1469-7793.1999.0335m.x; WALEV I, 1995, EMBO J, V14, P1607, DOI 10.1002/j.1460-2075.1995.tb07149.x; WALTER P, 1994, ANNU REV CELL BIOL, V10, P87, DOI 10.1146/annurev.cb.10.110194.000511; WANG RW, 1992, J BIOL CHEM, V267, P19866; WELLS WW, 1995, METHOD ENZYMOL, V252, P30; Williams RO, 2000, J IMMUNOL, V165, P7240, DOI 10.4049/jimmunol.165.12.7240; Xia B, 2001, J MOL BIOL, V310, P907, DOI 10.1006/jmbi.2001.4721	90	150	162	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 9	2003	278	19					16567	16578		10.1074/jbc.M211596200	http://dx.doi.org/10.1074/jbc.M211596200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677QG	12624100	hybrid			2022-12-25	WOS:000182818600018
J	Martinez, J; Moeller, I; Erdjument-Bromage, H; Tempst, P; Lauring, B				Martinez, J; Moeller, I; Erdjument-Bromage, H; Tempst, P; Lauring, B			Parkinson's disease-associated alpha-synuclein is a calmodulin substrate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MULTIPLE SYSTEM ATROPHY; LEWY-BODY-DISEASE; CENTRAL-NERVOUS-SYSTEM; A-BETA COMPONENT; NACP/ALPHA-SYNUCLEIN; IN-VITRO; NEURODEGENERATIVE DISORDERS; ALZHEIMERS-DISEASE; PRECURSOR PROTEIN; CROSS-LINKING	alpha-Synuclein is a neuronal protein thought to be central in the pathogenesis of Parkinson's disease (PD) because it comprises the fibrillar core of Lewy bodies, one of the histologically defining lesions of PD, and because mutations in alpha-synuclein cause autosomal dominant PD. Although its physiologic role is uncertain, alpha-synuclein is a synaptic protein that may contribute to plasticity. We produced synuclein with incorporated photoprobes to identify and purify novel synuclein-interacting proteins both to begin to clarify the physiology of synuclein and to identify factors that may regulate synuclein conformation. We detected several cross-links and purified and identified one as calmodulin (CaM). CaM binds to both wild type and PD-associated mutant alpha-synucleins in a calcium-dependent manner. We further demonstrate that CaM and alpha-synuclein interact in intact cells in a calcium-dependent manner and that activated CaM accelerates the formation of synuclein fibrils in vitro. We hypothesize that the known calcium control of synuclein function is mediated through CaM interaction and that CaM potentially alters synuclein conformation.	Columbia Univ Coll Phys & Surg, Dept Pathol, New York, NY 10032 USA; Columbia Univ Coll Phys & Surg, Taub Inst Res Alzheimers Dis & Aging Brain, New York, NY 10032 USA; Mem Sloan Kettering Canc Ctr, Sloan Kettering Inst, Program Mol Biol, New York, NY 10021 USA	Columbia University; Columbia University; Memorial Sloan Kettering Cancer Center	Lauring, B (corresponding author), Columbia Univ Coll Phys & Surg, Dept Pathol, BB-1427 650 W 168th St, New York, NY 10032 USA.	bl320@columbia.edu		Erdjument-Bromage, Hediye/0000-0003-0224-3594; Tempst, Paul/0000-0002-6680-3987				Abeliovich A, 2000, NEURON, V25, P239, DOI 10.1016/S0896-6273(00)80886-7; Arai T, 1999, NEUROSCI LETT, V259, P83, DOI 10.1016/S0304-3940(98)00890-8; Arima K, 1998, BRAIN RES, V808, P93, DOI 10.1016/S0006-8993(98)00734-3; Bofill-Cardona E, 2000, J BIOL CHEM, V275, P32672, DOI 10.1074/jbc.M002780200; Conway KA, 2000, BIOCHEMISTRY-US, V39, P2552, DOI 10.1021/bi991447r; Conway KA, 2000, P NATL ACAD SCI USA, V97, P571, DOI 10.1073/pnas.97.2.571; Conway KA, 1998, NAT MED, V4, P1318, DOI 10.1038/3311; Conway KA, 2000, ANN NY ACAD SCI, V920, P42; Davidson WS, 1998, J BIOL CHEM, V273, P9443, DOI 10.1074/jbc.273.16.9443; de Silva HA, 2000, CURR OPIN GENET DEV, V10, P292; Dickson DW, 1999, AM J PATHOL, V155, P1241, DOI 10.1016/S0002-9440(10)65226-1; Duda JE, 2000, J NEUROSCI RES, V61, P121, DOI 10.1002/1097-4547(20000715)61:2<121::AID-JNR1>3.0.CO;2-4; El-Agnaf OMA, 1998, FEBS LETT, V440, P67, DOI 10.1016/S0014-5793(98)01419-7; Eliezer D, 2001, J MOL BIOL, V307, P1061, DOI 10.1006/jmbi.2001.4538; Engelender S, 1999, NAT GENET, V22, P110, DOI 10.1038/8820; Erdjument-Bromage H, 1998, J CHROMATOGR A, V826, P167, DOI 10.1016/S0021-9673(98)00705-5; ERICKSON AH, 1983, METHOD ENZYMOL, V96, P38; Feany MB, 2000, NATURE, V404, P394, DOI 10.1038/35006074; Fenyo D, 1998, ELECTROPHORESIS, V19, P998, DOI 10.1002/elps.1150190615; GEORGE JM, 1995, NEURON, V15, P361, DOI 10.1016/0896-6273(95)90040-3; Geromanos S, 2000, ANAL CHEM, V72, P777, DOI 10.1021/ac991071n; GNEGY ME, 1993, ANNU REV PHARMACOL, V33, P45, DOI 10.1146/annurev.pa.33.040193.000401; GORLICH D, 1991, METHOD CELL BIOL, V34, P241; Hashimoto M, 1998, BRAIN RES, V799, P301, DOI 10.1016/S0006-8993(98)00514-9; Hashimoto M, 2001, NEURON, V32, P213, DOI 10.1016/S0896-6273(01)00462-7; HENDRICK JP, 1993, P NATL ACAD SCI USA, V90, P10216, DOI 10.1073/pnas.90.21.10216; Irizarry MC, 1998, J NEUROPATH EXP NEUR, V57, P334, DOI 10.1097/00005072-199804000-00005; Irizarry MC, 1996, J NEUROPATH EXP NEUR, V55, P889, DOI 10.1097/00005072-199608000-00004; IWAI A, 1995, NEURON, V14, P467, DOI 10.1016/0896-6273(95)90302-X; Jenco JM, 1998, BIOCHEMISTRY-US, V37, P4901, DOI 10.1021/bi972776r; Jo EJ, 2000, J BIOL CHEM, V275, P34328, DOI 10.1074/jbc.M004345200; Kruger R, 1998, NAT GENET, V18, P106, DOI 10.1038/ng0298-106; Lee FJS, 2001, FASEB J, V15, P916, DOI 10.1096/fj.00-0334com; MANN M, 1993, BIOL MASS SPECTROM, V22, P338, DOI 10.1002/bms.1200220605; MAROTEAUX L, 1988, J NEUROSCI, V8, P2804; MAROTEAUX L, 1991, MOL BRAIN RES, V11, P335, DOI 10.1016/0169-328X(91)90043-W; Martin JB, 1999, NEW ENGL J MED, V340, P1970, DOI 10.1056/NEJM199906243402507; Masliah E, 2000, SCIENCE, V287, P1265, DOI 10.1126/science.287.5456.1265; Moller I, 1998, P NATL ACAD SCI USA, V95, P13425, DOI 10.1073/pnas.95.23.13425; Narhi L, 1999, J BIOL CHEM, V274, P9843, DOI 10.1074/jbc.274.14.9843; Nielsen MS, 2001, J BIOL CHEM, V276, P22680, DOI 10.1074/jbc.M101181200; Okochi M, 2000, J BIOL CHEM, V275, P390, DOI 10.1074/jbc.275.1.390; Ostrerova N, 1999, J NEUROSCI, V19, P5782, DOI 10.1523/JNEUROSCI.19-14-05782.1999; Perrin RJ, 2000, J BIOL CHEM, V275, P34393, DOI 10.1074/jbc.M004851200; Pfund C, 1998, EMBO J, V17, P3981, DOI 10.1093/emboj/17.14.3981; Polymeropoulos MH, 1997, SCIENCE, V276, P2045, DOI 10.1126/science.276.5321.2045; Polymeropoulos MH, 2000, ANN NY ACAD SCI, V920, P28; Polymeropoulos MH, 1998, J NEUROL, V245, pP1, DOI 10.1007/PL00007740; Pronin AN, 2000, J BIOL CHEM, V275, P26515, DOI 10.1074/jbc.M003542200; Schumacher MA, 2001, NATURE, V410, P1120, DOI 10.1038/35074145; SOLLNER T, 1992, NATURE, V355, P84, DOI 10.1038/355084a0; Spillantini MG, 1998, P NATL ACAD SCI USA, V95, P6469, DOI 10.1073/pnas.95.11.6469; Spillantini MG, 1997, NATURE, V388, P839, DOI 10.1038/42166; Spillantini MG, 1998, NEUROSCI LETT, V251, P205, DOI 10.1016/s0304-3940(98)00504-7; Sveinbjornsdottir S, 2000, NEW ENGL J MED, V343, P1765, DOI 10.1056/NEJM200012143432404; Tu PH, 1998, ANN NEUROL, V44, P415, DOI 10.1002/ana.410440324; van der Putten H, 2000, J NEUROSCI, V20, P6021, DOI 10.1523/JNEUROSCI.20-16-06021.2000; Wakabayashi K, 1999, NEUROPATH APPL NEURO, V25, P363; Weinreb PH, 1996, BIOCHEMISTRY-US, V35, P13709, DOI 10.1021/bi961799n; WIEDMANN B, 1994, NATURE, V370, P434, DOI 10.1038/370434a0	60	65	68	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 9	2003	278	19					17379	17387		10.1074/jbc.M209020200	http://dx.doi.org/10.1074/jbc.M209020200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677QG	12610000	hybrid			2022-12-25	WOS:000182818600124
J	Tiran, Z; Peretz, A; Attali, B; Elson, A				Tiran, Z; Peretz, A; Attali, B; Elson, A			Phosphorylation-dependent regulation of Kv2.1 channel activity at tyrosine 124 by Src and by protein-tyrosine phosphatase epsilon	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GATED POTASSIUM CHANNEL; K+ CHANNEL; CYTOPLASMIC FORMS; SCHWANN-CELLS; ION CHANNELS; T1 DOMAIN; MODULATION; KINASES; INHIBITION; CURRENTS	Voltage-gated potassium (Kv) channels are a complex and heterogeneous family of proteins that play major roles in brain and cardiac excitability. Although Kv channels are activated by changes in cell membrane potential, tyrosine phosphorylation of channel subunits can modulate the extent of channel activation by depolarization. We have previously shown that dephosphorylation of Kv2.1 by the nonreceptor-type tyrosine phosphatase PTPepsilon (cyt-PTPepsilon) down-regulates channel activity and counters its phosphorylation and upregulation by Src or Fyn. In the present study, we identify tyrosine 124 within the T1 cytosolic domain of Kv2.1 as a target site for the activities of Src and cyt-PTPepsilon. Tyr124 is phosphorylated by Src in vitro; in whole cells, Y124F Kv2.1 is significantly less phosphorylated by Src and loses most of its ability to bind the D245A substrate-trapping mutant of cyt-PTPepsilon. Phosphorylation of Tyr124 is critical for Src-mediated up-regulation of Kv2.1 channel activity, since Y124F Kv2.1-mediated K+ currents are only marginally up-regulated by Src, in contrast with a 3-fold up-regulation of wild-type Kv2.1 channels by the kinase. Other properties of Kv2.1, such as expression levels, subcellular localization, and voltage dependence of channel activation, are unchanged in Y124F Kv2.1, indicating that the effects of the Y124F mutation are specific. Together, these results indicate that Tyr124 is a significant site at which the mutually antagonistic activities of Src and cyt-PTPepsilon affect Kv2.1 phosphorylation and activity.	Weizmann Inst Sci, Dept Mol Genet, IL-76100 Rehovot, Israel; Tel Aviv Univ, Sackler Sch Med, Dept Physiol, IL-69978 Tel Aviv, Israel	Weizmann Institute of Science; Tel Aviv University; Sackler Faculty of Medicine	Elson, A (corresponding author), Weizmann Inst Sci, Dept Mol Genet, IL-76100 Rehovot, Israel.			Elson, Ari/0000-0001-9808-9135				Abitbol I, 1999, EMBO J, V18, P4137, DOI 10.1093/emboj/18.15.4137; Andersen JN, 2001, MOL CELL BIOL, V21, P7117, DOI 10.1128/MCB.21.21.7117-7136.2001; Baranauskas G, 1999, J NEUROSCI, V19, P6394; BROWNE DL, 1994, NAT GENET, V8, P136, DOI 10.1038/ng1094-136; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; Cushman SJ, 2000, NAT STRUCT BIOL, V7, P403; Davis MJ, 2001, AM J PHYSIOL-HEART C, V281, pH1835, DOI 10.1152/ajpheart.2001.281.5.H1835; Du J, 1998, NEUROSCIENCE, V84, P37, DOI 10.1016/S0306-4522(97)00519-8; Du J, 2000, J PHYSIOL-LONDON, V522, P19, DOI 10.1111/j.1469-7793.2000.t01-2-00019.xm; ELSON A, 1995, J BIOL CHEM, V270, P26116, DOI 10.1074/jbc.270.44.26116; Elson A, 1995, P NATL ACAD SCI USA, V92, P12235, DOI 10.1073/pnas.92.26.12235; Fadool DA, 1998, J NEUROSCI, V18, P6126; Fadool DA, 1997, J NEUROPHYSIOL, V78, P1563, DOI 10.1152/jn.1997.78.3.1563; Flint AJ, 1997, P NATL ACAD SCI USA, V94, P1680, DOI 10.1073/pnas.94.5.1680; Gil-Henn H, 2000, ONCOGENE, V19, P4375, DOI 10.1038/sj.onc.1203790; GILHENN H, 2003, J BIOL CHEM     0221; Gulbins E, 1997, P NATL ACAD SCI USA, V94, P7661, DOI 10.1073/pnas.94.14.7661; Holmes TC, 1996, J NEUROSCI, V16, P1581; Holmes TC, 1996, SCIENCE, V274, P2089, DOI 10.1126/science.274.5295.2089; Holmes TC, 1997, J NEUROSCI, V17, P8964; HUNTER T, 1995, CELL, V80, P225, DOI 10.1016/0092-8674(95)90405-0; Huyer G, 1997, J BIOL CHEM, V272, P843, DOI 10.1074/jbc.272.2.843; Imbrici P, 2000, PFLUG ARCH EUR J PHY, V441, P257, DOI 10.1007/s004240000406; Jonas EA, 1996, CURR OPIN NEUROBIOL, V6, P318, DOI 10.1016/S0959-4388(96)80114-0; Keating MT, 2001, CELL, V104, P569, DOI 10.1016/S0092-8674(01)00243-4; Kraut J, 2002, EXP CELL RES, V281, P182, DOI 10.1006/excr.2002.5661; KRUEGER NX, 1990, EMBO J, V9, P3241, DOI 10.1002/j.1460-2075.1990.tb07523.x; Levitan IB, 1999, ADV SEC MESS PHOSPH, V33, P3; MacFarlane SN, 2000, J NEUROSCI, V20, P5245, DOI 10.1523/JNEUROSCI.20-14-05245.2000; Malin SA, 2002, J NEUROSCI, V22, P10094; Martens JR, 1999, TRENDS CARDIOVAS MED, V9, P253, DOI 10.1016/S1050-1738(00)00037-2; Minor DL, 2000, CELL, V102, P657, DOI 10.1016/S0092-8674(00)00088-X; Nitabach MN, 2001, P NATL ACAD SCI USA, V98, P705, DOI 10.1073/pnas.031446198; Peretz A, 2000, EMBO J, V19, P4036, DOI 10.1093/emboj/19.15.4036; Peretz A, 1999, J PHYSIOL-LONDON, V519, P373, DOI 10.1111/j.1469-7793.1999.0373m.x; PONGS O, 1995, SEMIN NEUROSCI, V7, P137, DOI 10.1006/smns.1995.0015; SAP J, 1990, P NATL ACAD SCI USA, V87, P6112, DOI 10.1073/pnas.87.16.6112; SHEN NV, 1995, NEURON, V14, P625, DOI 10.1016/0896-6273(95)90319-4; SIEGELBAUM SA, 1994, CURR BIOL, V4, P242, DOI 10.1016/S0960-9822(00)00054-3; Sobko A, 1998, EMBO J, V17, P4723, DOI 10.1093/emboj/17.16.4723; Songyang Zhou, 1995, Trends in Biochemical Sciences, V20, P470, DOI 10.1016/S0968-0004(00)89103-3; Strang C, 2001, J BIOL CHEM, V276, P28493, DOI 10.1074/jbc.M010540200; Strauss O, 2002, INVEST OPHTH VIS SCI, V43, P1645; Szabo I, 1996, J BIOL CHEM, V271, P20465, DOI 10.1074/jbc.271.34.20465; Toledano-Katchalski H, 1999, ONCOGENE, V18, P5024, DOI 10.1038/sj.onc.1202883; Tonks NK, 2001, CURR OPIN CELL BIOL, V13, P182, DOI 10.1016/S0955-0674(00)00196-4; Tsai W, 1999, EMBO J, V18, P109, DOI 10.1093/emboj/18.1.109; Weinreich F, 2000, CURR OPIN NEUROBIOL, V10, P409, DOI 10.1016/S0959-4388(00)00089-1; Yellen G, 2002, NATURE, V419, P35, DOI 10.1038/nature00978; Yi BA, 2001, P NATL ACAD SCI USA, V98, P11016, DOI 10.1073/pnas.191351798; Yu XM, 1997, SCIENCE, V275, P674, DOI 10.1126/science.275.5300.674	51	48	52	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 9	2003	278	19					17509	17514		10.1074/jbc.M212766200	http://dx.doi.org/10.1074/jbc.M212766200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677QG	12615930	hybrid			2022-12-25	WOS:000182818600139
J	Sano, H; Kane, S; Sano, E; Miinea, CP; Asara, JM; Lane, WS; Garner, CW; Lienhard, GE				Sano, H; Kane, S; Sano, E; Miinea, CP; Asara, JM; Lane, WS; Garner, CW; Lienhard, GE			Insulin-stimulated phosphorylation of a Rab GTPase-activating protein regulates GLUT4 translocation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SYNIP	Insulin stimulates the rapid translocation of intracellular glucose transporters of the GLUT4 isotype to the plasma membrane in fat and muscle cells. The connections between known insulin signaling pathways and the protein machinery of this membrane-trafficking process have not been fully defined. Recently, we identified a 160-kDa protein in adipocytes, designated AS160, that is phosphorylated by the insulin-activated kinase Akt. This protein contains a GTPase-activating domain (GAP) for Rabs, which are small G proteins required for membrane trafficking. In the present study we have identified six sites of in vivo phosphorylation on AS160. These sites lie in the motif characteristic of Akt phosphorylation, and insulin treatment increased phosphorylation at five of the sites. Expression of AS160 with two or more of these sites mutated to alanine markedly inhibited insulin-stimulated GLUT4 translocation in 3T3-L1 adipocytes. Moreover, this inhibition did not occur when the GAP function in the phosphorylation site mutant was inactivated by a point mutation. These findings strongly indicate that insulin-stimulated phosphorylation of AS160 is required for GLUT4 translocation and that this phosphorylation signals translocation through inactivation of the Rab GAP function.	Dartmouth Coll Sch Med, Dept Biochem, Hanover, NH 03755 USA; Abilene Christian Univ, Dept Chem, Abilene, TX 79699 USA; Harvard Univ, Microchem & Proteom Anal Facil, Dept Mol & Cellular Biol, Cambridge, MA 02138 USA	Dartmouth College; Abilene Christian University; Harvard University	Lienhard, GE (corresponding author), Dartmouth Coll Sch Med, Dept Biochem, Vail Bldg, Hanover, NH 03755 USA.	gustav.e.lienhard@dartmouth.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R55DK025336, R56DK042816, R56DK025336, R01DK025336, R01DK042816] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01 DK042816, R01 DK025336, DK25336, DK42816] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Cormont M, 2001, MOL MEMBR BIOL, V18, P213; Czech MP, 1999, J BIOL CHEM, V274, P1865, DOI 10.1074/jbc.274.4.1865; Dawson K, 2001, BIOCHEM BIOPH RES CO, V287, P445, DOI 10.1006/bbrc.2001.5620; Kane S, 2002, J BIOL CHEM, V277, P22115, DOI 10.1074/jbc.C200198200; Khan AH, 2002, DIABETOLOGIA, V45, P1475, DOI 10.1007/s00125-002-0974-7; Min J, 1999, MOL CELL, V3, P751, DOI 10.1016/S1097-2765(01)80007-1; Rak A, 2000, EMBO J, V19, P5105, DOI 10.1093/emboj/19.19.5105; Wang L, 2003, J CELL BIOL, V160, P365, DOI 10.1083/jcb.200209095; Will E, 2001, J BIOL CHEM, V276, P12135, DOI 10.1074/jbc.M011451200; Wu XH, 2000, NATURE, V405, P477, DOI 10.1038/35013089; Yaffe MB, 2001, NAT BIOTECHNOL, V19, P348, DOI 10.1038/86737; Yamada E, 2002, DIABETES, V51, pA44; Zeigerer A, 2002, MOL BIOL CELL, V13, P2421, DOI 10.1091/mbc.E02-02-0071; Zerial M, 2001, NAT REV MOL CELL BIO, V2, P107, DOI 10.1038/35052055	14	694	724	2	56	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 25	2003	278	17					14599	14602		10.1074/jbc.C300063200	http://dx.doi.org/10.1074/jbc.C300063200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	672HX	12637568	hybrid			2022-12-25	WOS:000182516100004
J	Lou, ZK; Chini, CCS; Minter-Dykhouse, K; Chen, JJ				Lou, ZK; Chini, CCS; Minter-Dykhouse, K; Chen, JJ			Mediator of DNA damage checkpoint protein 1 regulates BRCA1 localization and phosphorylation in DNA damage checkpoint control	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOUBLE-STRAND BREAKS; HISTONE H2AX; GENOMIC INSTABILITY; NUCLEAR FOCI; FHA DOMAIN; IN-VIVO; 53BP1; REPAIR; ATM; PATHWAYS	BRCA1 is a tumor suppressor involved in DNA repair and damage-induced checkpoint controls. In response to DNA damage, BRCA1 relocalizes to nuclear foci at the sites of DNA lesions. However, little is known about the regulation of BRCA1 relocalization following DNA damage. Here we show that mediator of DNA damage checkpoint protein 1 (MDC1) previously named NFBD1 or Kiaa0170,is a proximate mediator of DNA damage responses that regulates BRCA1 function. MDC1 regulates ataxia-telangiectasia-mutated (ATM)-dependent phosphorylation events at the site of DNA damage. Importantly down-regulation of MDC1 abolishes the relocalization and hyperphosphorylation of BRCA1 following DNA damage, which coincides with defective G(2)/M checkpoint control in response to DNA damage. Taken together these data suggest that MDC1 regulates BRCA1 function in DNA damage checkpoint control.	Mayo Clin & Mayo Fdn, Dept Oncol, Rochester, MN 55905 USA	Mayo Clinic	Chen, JJ (corresponding author), Mayo Clin & Mayo Fdn, Dept Oncol, Guggenheim Bldg,Rm 1342,200 1st St SW, Rochester, MN 55905 USA.		Minter Dykhouse, Katherine/L-4573-2013	Minter Dykhouse, Katherine/0000-0003-4363-5826	NATIONAL CANCER INSTITUTE [R01CA089239, R01CA092312] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA89239, CA92312] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Anderson L, 2001, MOL CELL BIOL, V21, P1719, DOI 10.1128/MCB.21.5.1719-1729.2001; Bassing CH, 2002, P NATL ACAD SCI USA, V99, P8173, DOI 10.1073/pnas.122228699; Bell DW, 1999, SCIENCE, V286, P2528, DOI 10.1126/science.286.5449.2528; Callebaut I, 1997, FEBS LETT, V400, P25, DOI 10.1016/S0014-5793(96)01312-9; Carney JP, 1998, CELL, V93, P477, DOI 10.1016/S0092-8674(00)81175-7; Celeste A, 2002, SCIENCE, V296, P922, DOI 10.1126/science.1069398; Cortez D, 1999, SCIENCE, V286, P1162, DOI 10.1126/science.286.5442.1162; DiTullio RA, 2002, NAT CELL BIOL, V4, P998, DOI 10.1038/ncb892; Durocher D, 2002, FEBS LETT, V513, P58, DOI 10.1016/S0014-5793(01)03294-X; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Gatei M, 2000, CANCER RES, V60, P3299; Gowen LC, 1998, SCIENCE, V281, P1009, DOI 10.1126/science.281.5379.1009; HOFMANN K, 1995, TRENDS BIOCHEM SCI, V20, P347, DOI 10.1016/S0968-0004(00)89072-6; Lou ZK, 2003, NATURE, V421, P957, DOI 10.1038/nature01447; Paull TT, 2000, CURR BIOL, V10, P886, DOI 10.1016/S0960-9822(00)00610-2; Peng AM, 2003, J BIOL CHEM, V278, P8873, DOI 10.1074/jbc.C300001200; Rappold I, 2001, J CELL BIOL, V153, P613, DOI 10.1083/jcb.153.3.613; Rogakou EP, 1999, J CELL BIOL, V146, P905, DOI 10.1083/jcb.146.5.905; Schultz LB, 2000, J CELL BIOL, V151, P1381, DOI 10.1083/jcb.151.7.1381; Scully R, 1997, CELL, V90, P425, DOI 10.1016/S0092-8674(00)80503-6; Shang YL, 2003, J BIOL CHEM, V278, P6323, DOI 10.1074/jbc.M210749200; Wang B, 2002, SCIENCE, V298, P1435, DOI 10.1126/science.1076182; Ward IM, 2001, J BIOL CHEM, V276, P47755, DOI 10.1074/jbc.C100587200; Wu LJC, 1996, NAT GENET, V14, P430, DOI 10.1038/ng1296-430; Xu B, 2001, MOL CELL BIOL, V21, P3445, DOI 10.1128/MCB.21.10.3445-3450.2001; Xu XL, 1999, MOL CELL, V3, P389, DOI 10.1016/S1097-2765(00)80466-9; Xu XZ, 2003, J BIOL CHEM, V278, P8795, DOI 10.1074/jbc.M211392200; Yarden RI, 2002, NAT GENET, V30, P285, DOI 10.1038/ng837; Zhao H, 2001, MOL CELL BIOL, V21, P4129, DOI 10.1128/MCB.21.13.4129-4139.2001	29	106	120	4	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 18	2003	278	16					13599	13602		10.1074/jbc.C300060200	http://dx.doi.org/10.1074/jbc.C300060200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	670JV	12611903	hybrid			2022-12-25	WOS:000182405000003
J	Shigeno, M; Nako, K; Ichikawa, T; Suzuki, K; Kawakami, A; Abiru, S; Miyazoe, S; Nakagawa, Y; Ishikawa, H; Hamasaki, K; Nakata, K; Ishii, N; Eguchi, K				Shigeno, M; Nako, K; Ichikawa, T; Suzuki, K; Kawakami, A; Abiru, S; Miyazoe, S; Nakagawa, Y; Ishikawa, H; Hamasaki, K; Nakata, K; Ishii, N; Eguchi, K			Interferon-alpha sensitizes human hepatoma cells to TRAIL-induced apoptosis through DR5 upregulation and NF-kappa B inactivation	ONCOGENE			English	Article						TRAIL; interferon-alpha; hepatoma; DR5 survivin; NF-kappa B	HUMAN HEPATOCELLULAR-CARCINOMA; CYTOTOXIC LIGAND TRAIL; LUNG-CANCER CELLS; IN-VIVO; CHEMOTHERAPEUTIC-AGENTS; TRANSCRIPTION FACTORS; CASPASE-8 ACTIVATION; IONIZING-RADIATION; MEDIATED APOPTOSIS; DEATH RECEPTOR-4	Tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL), a member of the TNF superfamily, induces apoptosis in a variety of cancer cells with little or no effect on normal cells. Human hepatoma cells, however, are resistant to TRAIL-induced apoptosis. Since interferon-alpha (IFN-alpha) is capable of enhancing TNF-alpha-induced apoptosis in certain cancer cells, we evaluated the effect of IFN-alpha on TRAIL-induced apoptosis of human hepatoma cells. IFN-alpha pretreatment enhanced TRAIL-induced apoptosis of HuH-7 and Hep3B cells, in which IFN-alpha upregulated the expression of DR5, a death receptor of TRAIL, and downregulated the expression of survivin, which has an antiapoptotic function. In contrast, IFN-alpha did not enhance TRAIL-induced apoptosis of HepG2 cells, in which expression of DR5 and survivin was not affected by IFN-alpha. On the other hand, TRAIL activated NF-kappaB composed of RelA-p50 heterodimer, a key transcription factor regulating cell survival, in HuH-7 and HepG2 cells. However, IFN-alpha pretreatment repressed the TRAIL-mediated activation of NF-kappaB and decreased its transcriptional activity in HuH-7 but not in HepG2 cells. Moreover, IFN-alpha pretreatment clearly augmented TRAIL-mediated caspase-8 activation in HuH-7 cells. Our results suggest that IFN-alpha could sensitize certain human hepatoma cells to TRAIL-induced apoptosis by stimulating its death signaling and by repressing the survival function in these cells.	Nagasaki Univ, Sch Med, Dept Internal Med 1, Nagasaki 8528501, Japan; Nagasaki Univ, Hlth Res Ctr, Nagasaki 8528501, Japan; Nagasaki Univ, Dept Clin Pharmacol, Nagasaki 8528501, Japan	Nagasaki University; Nagasaki University; Nagasaki University	Eguchi, K (corresponding author), Nagasaki Univ, Sch Med, Dept Internal Med 1, 1-7-1 Sakamoto, Nagasaki 8528501, Japan.							Ashkenazi A, 1999, J CLIN INVEST, V104, P155, DOI 10.1172/JCI6926; Barkett M, 1999, ONCOGENE, V18, P6910, DOI 10.1038/sj.onc.1203238; Belka C, 2001, ONCOGENE, V20, P2190, DOI 10.1038/sj.onc.1204318; Chawla-Sarkar M, 2001, CLIN CANCER RES, V7, P1821; Chen CL, 2000, MOL CELL BIOL, V20, P2687, DOI 10.1128/MCB.20.8.2687-2695.2000; Chen Q, 2001, BLOOD, V98, P2183, DOI 10.1182/blood.V98.7.2183; Chinnaiyan AM, 2000, P NATL ACAD SCI USA, V97, P1754, DOI 10.1073/pnas.030545097; Degli-Esposti MA, 1997, IMMUNITY, V7, P813, DOI 10.1016/S1074-7613(00)80399-4; DegliEsposti MA, 1997, J EXP MED, V186, P1165, DOI 10.1084/jem.186.7.1165; Di Pietro R, 2001, BLOOD, V97, P2596, DOI 10.1182/blood.V97.9.2596; Emery JG, 1998, J BIOL CHEM, V273, P14363, DOI 10.1074/jbc.273.23.14363; Fanger NA, 1999, J EXP MED, V190, P1155, DOI 10.1084/jem.190.8.1155; Gibson SB, 2000, MOL CELL BIOL, V20, P205, DOI 10.1128/MCB.20.1.205-212.2000; Griffith TS, 2002, CANCER RES, V62, P3093; Grossman D, 2001, P NATL ACAD SCI USA, V98, P635, DOI 10.1073/pnas.230450097; GUTTERMAN JU, 1994, P NATL ACAD SCI USA, V91, P1198, DOI 10.1073/pnas.91.4.1198; Ichikawa T, 2001, BIOCHEM BIOPH RES CO, V280, P933, DOI 10.1006/bbrc.2000.4228; Inan MS, 2000, GASTROENTEROLOGY, V118, P724, DOI 10.1016/S0016-5085(00)70142-9; Ito T, 2000, HEPATOLOGY, V31, P1080, DOI 10.1053/he.2000.6496; Jo M, 2000, NAT MED, V6, P564, DOI 10.1038/75045; Kayagaki N, 1999, J EXP MED, V189, P1451, DOI 10.1084/jem.189.9.1451; Kischkel FC, 2000, IMMUNITY, V12, P611, DOI 10.1016/S1074-7613(00)80212-5; Kobayashi K, 1999, P NATL ACAD SCI USA, V96, P1457, DOI 10.1073/pnas.96.4.1457; Lacour S, 2001, CANCER RES, V61, P1645; Lawrence D, 2001, NAT MED, V7, P383, DOI 10.1038/86397; Li FZ, 1998, NATURE, V396, P580, DOI 10.1038/25141; Manna SK, 2000, J IMMUNOL, V165, P4927, DOI 10.4049/jimmunol.165.9.4927; Nagane M, 2000, CANCER RES, V60, P847; NAKABAYASHI H, 1984, JPN J CANCER RES, V75, P151; Nakao K, 1999, J BIOL CHEM, V274, P28075, DOI 10.1074/jbc.274.40.28075; Nimmanapalli R, 2001, CANCER RES, V61, P759; Olie RA, 2000, CANCER RES, V60, P2805; Pan GH, 1997, SCIENCE, V276, P111, DOI 10.1126/science.276.5309.111; Ravi R, 2001, NAT CELL BIOL, V3, P409, DOI 10.1038/35070096; Schneider P, 1997, IMMUNITY, V7, P831, DOI 10.1016/S1074-7613(00)80401-X; Sheridan JP, 1997, SCIENCE, V277, P818, DOI 10.1126/science.277.5327.818; Suk K, 2001, FEBS LETT, V495, P66, DOI 10.1016/S0014-5793(01)02335-3; Sun SY, 2000, CANCER RES, V60, P7149; Tamm I, 1998, CANCER RES, V58, P5315; Toomey NL, 2001, ONCOGENE, V20, P7029, DOI 10.1038/sj.onc.1204895; Walczak H, 1999, NAT MED, V5, P157, DOI 10.1038/5517; Wang CY, 1998, SCIENCE, V281, P1680, DOI 10.1126/science.281.5383.1680; Wen Y, 2000, CANCER RES, V60, P42; Yamanaka T, 2000, HEPATOLOGY, V32, P482, DOI 10.1053/jhep.2000.16266; Zhou Q, 2000, CANCER RES, V60, P2611	45	103	118	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 20	2003	22	11					1653	1662		10.1038/sj.onc.1206139	http://dx.doi.org/10.1038/sj.onc.1206139			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	655YH	12642868				2022-12-25	WOS:000181580500007
J	Apati, A; Janossy, J; Brozik, A; Bauer, PI; Magocsi, M				Apati, A; Janossy, J; Brozik, A; Bauer, PI; Magocsi, M			Calcium induces cell survival and proliferation through the activation of the MAPK pathway in a human hormone-dependent leukemia cell line, TF-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MURINE ERYTHROLEUKEMIA-CELLS; COLONY-STIMULATING FACTOR; REGULATED KINASE PATHWAY; SIGNALING PATHWAY; PROTEIN-KINASE; GENE-EXPRESSION; SARCOPLASMIC-RETICULUM; TYROSINE KINASE; PC12 CELLS; GM-CSF	Survival and proliferation of cells of a human myeloerythroid CD34+ leukemia cell line (TF-1) depend on the presence of granulocyte-macrophage colony-stimulating factor or interleukin-3. Upon hormone withdrawal these cells stop proliferating and undergo apoptotic process. In this report we demonstrate that a controlled increase in [Ca2+](i) induces hormone-independent survival and proliferation of TF-1 cells. We found that moderate elevation of [Ca2+](i) by the addition of cyclopiasonic-acid protected TF1 cells from apoptosis. Furthermore, a higher, but transient elevation of [Ca2+](i) by ionomycin treatment induced cell proliferation. In both cases caspase-3 activity was reduced, and Bcl-2 was upregulated. Higher elevation of [Ca2+](i) by ionomycin induced MEK-dependent biphasic ERK1/2 activation, sufficient to move the cells from G(0)/G(1) to S/M phases. Meanwhile, activation of ERK1/2, phosphorylation of the Elk-1 transcription factor, and, consequently, a substantial elevation of Egr-1 and c-Fos levels and AP-1 DNA binding were observed. Moderate elevation of [Ca2+](i), on the other hand, caused a delayed monophasic activation of ERK1/2 and Elk-1 that was accompanied with only a small increase of Egr-1 and c-Fos levels and AP-1 DNA binding. The specific MEK-1 kinase inhibitor, PD98059, inhibited all the effects of increasing [Ca2+](i), indicating that the MAPK/ERK pathway activation is essential for TF-1 cell survival and proliferation. Based on these results we suggest that the elevation of the [Ca2+](i) may influence the cytokine dependence of hemopoietic progenitors and may contribute to pathological hematopoiesis.	Natl Med Ctr, Dept Cell Metab, Inst Haematol & Immunol, H-1113 Budapest, Hungary; Hungarian Acad Sci, Inst Enzymol, H-1113 Budapest, Hungary; Semmelweis Univ, Dept Med Biochem, H-1088 Budapest, Hungary	Eotvos Lorand Research Network; Hungarian Academy of Sciences; Hungarian Research Centre for Natural Sciences; Semmelweis University	Magocsi, M (corresponding author), Natl Med Ctr, Dept Cell Metab, Inst Haematol & Immunol, Dioszegi Ut 64, H-1113 Budapest, Hungary.	magocsi@biomembrane.hu	Apáti, Ágota/N-1697-2019	Apáti, Ágota/0000-0003-0380-8139				Adachi T, 2000, J IMMUNOL, V165, P2198, DOI 10.4049/jimmunol.165.4.2198; Alvarado-Moreno JA, 2000, REV INVEST CLIN, V52, P645; ARAI K, 1990, ANNU REV BIOCHEM, V59, P783, DOI 10.1146/annurev.biochem.59.1.783; ASKEW DS, 1991, ONCOGENE, V6, P1915; Barsacchi R, 1999, FEBS LETT, V461, P273, DOI 10.1016/S0014-5793(99)01468-4; BASHEY A, 1994, BLOOD, V83, P949, DOI 10.1182/blood.V83.4.949.bloodjournal834949; Berridge MJ, 2000, NAT REV MOL CELL BIO, V1, P11, DOI 10.1038/35036035; Boucher MJ, 2000, J CELL BIOCHEM, V79, P355, DOI 10.1002/1097-4644(20001201)79:3<355::AID-JCB20>3.3.CO;2-S; Carrion AM, 1999, NATURE, V398, P80, DOI 10.1038/18044; Chung KC, 2000, EUR J BIOCHEM, V267, P4676, DOI 10.1046/j.1432-1327.2000.01517.x; Cook JG, 1997, NATURE, V390, P85, DOI 10.1038/36355; Coulon V, 1999, J BIOL CHEM, V274, P30439, DOI 10.1074/jbc.274.43.30439; Cron RQ, 1999, J IMMUNOL, V162, P860; Darzynkiewicz Z, 1997, CYTOMETRY, V27, P1; Egea J, 2000, MOL CELL BIOL, V20, P1931, DOI 10.1128/MCB.20.6.1931-1946.2000; Egea J, 1999, J BIOL CHEM, V274, P75, DOI 10.1074/jbc.274.1.75; Fam NP, 1997, MOL CELL BIOL, V17, P1396, DOI 10.1128/MCB.17.3.1396; FRANKLIN JL, 1994, PHILOS T ROY SOC B, V345, P251, DOI 10.1098/rstb.1994.0102; Grewal SS, 2000, J BIOL CHEM, V275, P34433, DOI 10.1074/jbc.M004728200; Hardingham GE, 1997, NATURE, V385, P260, DOI 10.1038/385260a0; Haverstick DM, 2000, CANCER RES, V60, P1002; Johnson CM, 1997, J NEUROSCI, V17, P6189; Jones SM, 2001, NAT CELL BIOL, V3, P165, DOI 10.1038/35055073; Katoch SS, 1999, J CELL PHYSIOL, V179, P208, DOI 10.1002/(SICI)1097-4652(199905)179:2<208::AID-JCP11>3.0.CO;2-#; KITAMURA T, 1989, J CELL PHYSIOL, V140, P323, DOI 10.1002/jcp.1041400219; Kohn EC, 1996, CANCER RES, V56, P569; Kolonics A, 2001, CELL SIGNAL, V13, P743, DOI 10.1016/S0898-6568(01)00201-7; KOSHIKAWA N, 1992, CANCER RES, V52, P5046; Koshikawa N, 1998, AM J PATHOL, V153, P937, DOI 10.1016/S0002-9440(10)65635-0; Liu CT, 1996, P NATL ACAD SCI USA, V93, P11831, DOI 10.1073/pnas.93.21.11831; Lotem J, 1998, P NATL ACAD SCI USA, V95, P4601, DOI 10.1073/pnas.95.8.4601; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; McCubrey JA, 2000, LEUKEMIA, V14, P9, DOI 10.1038/sj.leu.2401657; McNeil SE, 1998, J BIOL CHEM, V273, P1114, DOI 10.1074/jbc.273.2.1114; Mintz E, 1997, BBA-BIOENERGETICS, V1318, P52, DOI 10.1016/S0005-2728(96)00132-6; Miyata S, 1999, J BIOCHEM, V125, P1067, DOI 10.1093/oxfordjournals.jbchem.a022388; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; Nguyen HN, 2002, BRAIN RES, V924, P159, DOI 10.1016/S0006-8993(01)03229-2; OKUDA K, 1992, BLOOD, V79, P2880; Palaga T, 1996, EXP CELL RES, V228, P92, DOI 10.1006/excr.1996.0303; Pan Z, 2000, J BIOL CHEM, V275, P19978, DOI 10.1074/jbc.M908329199; Petak I, 1998, CANCER RES, V58, P614; RODRIGUEZTARDUCHY G, 1990, EMBO J, V9, P2997, DOI 10.1002/j.1460-2075.1990.tb07492.x; RODRIGUEZTARDUCHY G, 1992, J IMMUNOL, V148, P1416; Schaefer A, 1998, BIOCHEM J, V335, P505, DOI 10.1042/bj3350505; Schaefer A, 1996, J BIOL CHEM, V271, P13484, DOI 10.1074/jbc.271.23.13484; SEIDLER NW, 1989, J BIOL CHEM, V264, P17816; SHENG M, 1988, MOL CELL BIOL, V8, P2787, DOI 10.1128/MCB.8.7.2787; SU B, 1994, CELL, V77, P727, DOI 10.1016/0092-8674(94)90056-6; Tang H, 2000, J BIOL CHEM, V275, P8389, DOI 10.1074/jbc.275.12.8389; TREISMAN R, 1995, EMBO J, V14, P4905, DOI 10.1002/j.1460-2075.1995.tb00173.x; TSIEN RY, 1982, J CELL BIOL, V94, P325, DOI 10.1083/jcb.94.2.325; WEISINGER G, 1995, BIOCHEM BIOPH RES CO, V214, P530, DOI 10.1006/bbrc.1995.2319; Yuan PX, 2001, J BIOL CHEM, V276, P31674, DOI 10.1074/jbc.M104309200	54	55	57	0	20	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 14	2003	278	11					9235	9243		10.1074/jbc.M205528200	http://dx.doi.org/10.1074/jbc.M205528200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	654YF	12643264	hybrid			2022-12-25	WOS:000181524000047
J	Qiu, CP; Yu, MS; Shan, L; Snyderwine, EG				Qiu, CP; Yu, MS; Shan, L; Snyderwine, EG			Allelic imbalance and altered expression of genes in chromosome 2q11-2q16 from rat mammary gland carcinomas induced by 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine	ONCOGENE			English	Article						heterocyclic amines; allelic imbalance; quantitative real-time polymerase chain reaction; microsatellite instability; loss of heterozygosity; gene expression; rat chromosome 2q	RASGTPASE ACTIVATING PROTEIN; SPRAGUE-DAWLEY RATS; BREAST-CANCER; EPITHELIAL-CELLS; PHOSPHATIDYLINOSITOL 3-KINASE; MICROSATELLITE INSTABILITY; PROSTATE-CANCER; ONCOSTATIN-M; DIETARY-FAT; TUMORS	2-Amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP), a compound found in cooked meat, is a mammary gland carcinogen in rats. Comparative genomic hybridization of PhIP-induced rat mammary gland carcinomas revealed loss in the centromeric region of 2q, a region known to carry the mammary carcinoma susceptibility 1 (Mcs1) gene and several other genes relevant to carcinogenesis. Allelic imbalance, specifically microsatellite instability and loss of heterozygosity, was examined in mammary gland carcinomas induced by PhIP in Sprague-Dawley (SD) x Wistar Furth F1 hybrid rats. In a polymerase chain reaction (PCR)-based assay with 34 microsatellite markers coinciding to 2q11-2q16, nine markers revealed allelic imbalance. The frequency of imbalance in the tumors varied from 10 to 100% depending on the specific marker. However, none of the markers coinciding with the Mcs1 gene locus showed allelic imbalance, suggesting that alterations at this locus were not associated with PhIP-induced rat mammary gland cancer. The expression of several genes physically mapped to 2q11-2q16 and potentially involved in carcinogenesis including Ccnb (cyclin B1), Ccnh (cyclin H), Rasa (Ras GAP), RasgrJ2, Pi3kr1 (p85alpha), and Il6st (gp130) was also examined by quantitative real-time PCR and immunohistochemistry (IHC) across a large bank of PhIP-induced SD rat mammary gland carcinomas. By quantitative real-time PCR, the mRNA expression of Rasa, Pi3kr1, Ccnh, and 1l6st in carcinomas was, respectively, 22-, 20-, three- and threefold higher in carcinomas than in control mammary gland tissues (P<0.05, Student's t-test). A statistically sixfold lower expression of Rasgrf 2 was detected in carcinomas whereas no significant change in Ccnb1 expression was observed. The findings from quantitative real-time PCR were confirmed by IHC for each gene. In addition, the proliferation index in mammary gland carcinomas as assessed by PCNA was found to correlate with the overexpression of Cyclin H by IHC analysis (P<0.05, Spearman Rank Order Correlation). The findings from the current study implicate molecular alterations in the proximal region of 2q in PhIP-induced rat mammary gland carcinomas.	NCI, Ctr Canc Res,Lab Expt Carcinogenesis, Chem Carcinogenesis Sect, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Snyderwine, EG (corresponding author), NCI, Ctr Canc Res,Lab Expt Carcinogenesis, Chem Carcinogenesis Sect, NIH, Bldg 37,Room 4134,37 Convent Dr MSC 4262, Bethesda, MD 20892 USA.				DIVISION OF BASIC SCIENCES - NCI [Z01BC010037] Funding Source: NIH RePORTER	DIVISION OF BASIC SCIENCES - NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Barshack I, 1998, MODERN PATHOL, V11, P271; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; Christian AT, 2002, MUTAT RES-FUND MOL M, V506, P113, DOI 10.1016/S0027-5107(02)00157-4; Crichton MB, 1996, MOL CELL ENDOCRINOL, V118, P215, DOI 10.1016/0303-7207(96)03761-6; Davidson B, 1998, PATHOL RES PRACT, V194, P399, DOI 10.1016/S0344-0338(98)80030-7; Fernandez-Medarde A, 2002, MOL CELL BIOL, V22, P2498, DOI 10.1128/MCB.22.8.2498-2504.2002; Gershtein ES, 1999, CLIN CHIM ACTA, V287, P59, DOI 10.1016/S0009-8981(99)00118-7; GHOSHAL A, 1994, CARCINOGENESIS, V15, P2429, DOI 10.1093/carcin/15.11.2429; Gire V, 2000, ONCOGENE, V19, P2269, DOI 10.1038/sj.onc.1203544; Grant SL, 2001, GROWTH FACTORS, V19, P153, DOI 10.3109/08977190109001083; Haag JD, 1996, MOL CARCINOGEN, V17, P134, DOI 10.1002/(SICI)1098-2744(199611)17:3<134::AID-MC5>3.3.CO;2-N; Hokaiwado N, 2001, CANCER LETT, V163, P187, DOI 10.1016/S0304-3835(00)00693-5; HSU LC, 1994, CANCER RES, V54, P2765; Karan D, 2002, CARCINOGENESIS, V23, P967, DOI 10.1093/carcin/23.6.967; Kerangueven F, 1997, CANCER RES, V57, P5469; Ko LJ, 1997, MOL CELL BIOL, V17, P7220, DOI 10.1128/MCB.17.12.7220; Laes JF, 2001, MAMM GENOME, V12, P199, DOI 10.1007/s003350010268; LAYTON DW, 1995, CARCINOGENESIS, V16, P39, DOI 10.1093/carcin/16.1.39; Leblanc V, 1999, ONCOGENE, V18, P4884, DOI 10.1038/sj.onc.1202855; Liu JW, 1998, CYTOKINE, V10, P295, DOI 10.1006/cyto.1997.0283; LOWY DR, 1993, ANNU REV BIOCHEM, V62, P851, DOI 10.1146/annurev.bi.62.070193.004223; Mills GB, 2001, SEMIN ONCOL, V28, P125, DOI 10.1053/sonc.2001.28554; Quan X, 2000, CYTOGENET CELL GENET, V88, P119, DOI 10.1159/000015503; Roberts-Thomson SJ, 1997, MOL CARCINOGEN, V20, P348, DOI 10.1002/(SICI)1098-2744(199712)20:4<348::AID-MC4>3.0.CO;2-F; Rodriguez-Viciana P, 2001, METHOD ENZYMOL, V333, P37; RodriguezViciana P, 1997, CELL, V89, P457, DOI 10.1016/S0092-8674(00)80226-3; RodriguezViciana P, 1996, EMBO J, V15, P2442, DOI 10.1002/j.1460-2075.1996.tb00602.x; RUSSO J, 1990, LAB INVEST, V62, P244; Schultz P, 2000, CELL, V102, P599, DOI 10.1016/S0092-8674(00)00082-9; Shan L, 2002, CARCINOGENESIS, V23, P1561, DOI 10.1093/carcin/23.10.1561; Shepel LA, 1998, GENETICS, V149, P289; Sinha R, 2000, J NATL CANCER I, V92, P1352, DOI 10.1093/jnci/92.16.1352; Snyderwine EG, 1998, NUTR CANCER, V31, P160, DOI 10.1080/01635589809514698; SNYDERWINE EG, 2000, FOOD BORNE CARCINOGE, P241; Szpirer C, 1999, MAMM GENOME, V10, P30, DOI 10.1007/s003359900937; Tomlinson IPM, 2002, GENE CHROMOSOME CANC, V34, P349, DOI 10.1002/gcc.10085; Toyota M, 1996, MOL CARCINOGEN, V15, P176, DOI 10.1002/(SICI)1098-2744(199603)15:3<176::AID-MC3>3.0.CO;2-G; Watanabe N, 2001, CANCER RES, V61, P2632; Yang JY, 2002, J BIOL CHEM, V277, P14641, DOI 10.1074/jbc.M111540200; Yu MS, 2002, CARCINOGENESIS, V23, P2123, DOI 10.1093/carcin/23.12.2123; Yu MS, 2000, MOL CARCINOGEN, V27, P76, DOI 10.1002/(SICI)1098-2744(200002)27:2<76::AID-MC3>3.0.CO;2-7	41	15	18	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 27	2003	22	8					1253	1260		10.1038/sj.onc.1206233	http://dx.doi.org/10.1038/sj.onc.1206233			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	650EK	12606953				2022-12-25	WOS:000181249700015
J	Wang, JL; de Montellano, PRO				Wang, JL; de Montellano, PRO			The binding sites on human heme oxygenase-1 for cytochrome P450 reductase and biliverdin reductase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRYSTAL-STRUCTURE; P450 REDUCTASE; ELECTROSTATIC INTERACTIONS; DIRECTED MUTAGENESIS; RESIDUES; PROTEIN; 2B4; ASSOCIATION; BILIRUBIN; COMPLEX	Human heme oxygenase-1 (hHO-1) catalyzes the NADPH-cytochrome P450 reductase-dependent oxidation of heme to biliverdin, CO, and free iron. The biliverdin is subsequently reduced to bilirubin by biliverdin reductase. Earlier kinetic studies suggested that biliverdin reductase facilitates the release of biliverdin from hHO-1 (Liu, Y., and Ortiz de Montellano, P. R. (2000) J. Biol. Chem. 275, 5297-5307). We have investigated the binding of P450 reductase and biliverdin reductase to truncated, soluble hHO-1 by fluorescence resonance energy transfer and site-specific mutagenesis. P450 reductase and biliverdin reductase bind to truncated hHO-1 with K-d=0.4+/-0.1 and 0.2+/-0.1 muM, respectively. FRET experiments indicate that biliverdin reductase and P450 reductase compete for binding to truncated hHO-1. Mutation of surface ionic residues shows that hHO-1 residues Lys(18), Lys(22), Lys(179), Arg(183), Arg(198), Glu(19), Glu(127), and Glu(190) contribute to the binding of cytochrome P450 reductase. The mutagenesis results and a computational analysis of the protein surfaces partially define the binding site for P450 reductase. An overlapping binding site including Lys(18), Lys(22), Lys(179), Arg(183), and Arg(185) is similarly defined for biliverdin reductase. These results confirm the binding of biliverdin reductase to hHO-1 and define binding sites of the two reductases.	Univ Calif San Francisco, Dept Pharmaceut Chem, San Francisco, CA 94143 USA	University of California System; University of California San Francisco	de Montellano, PRO (corresponding author), Univ Calif San Francisco, Dept Pharmaceut Chem, 600 16th St,N572D, San Francisco, CA 94143 USA.	ortiz@cgl.ucsf.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK030297] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK30297] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Auclair K., 2003, PORPHYRIN HDB, V12, P183; Baranano DE, 2001, TRENDS NEUROSCI, V24, P99, DOI 10.1016/S0166-2236(00)01716-1; Bridges A, 1998, J BIOL CHEM, V273, P17036, DOI 10.1074/jbc.273.27.17036; Davydov DR, 2000, BIOCHEMISTRY-US, V39, P6489, DOI 10.1021/bi992936u; Davydov DR, 1996, BIOCHIMIE, V78, P734, DOI 10.1016/S0300-9084(97)82531-X; DAVYDOV DR, 1995, ARCH BIOCHEM BIOPHYS, V320, P330, DOI 10.1016/0003-9861(95)90017-9; De Montellano PRO, 2001, ADV INORG CHEM, V51, P359; Dolphin, 1979, PORPHYRINS, VVI, P257; Dore S, 1999, P NATL ACAD SCI USA, V96, P2445, DOI 10.1073/pnas.96.5.2445; Duckers HJ, 2001, NAT MED, V7, P693, DOI 10.1038/89068; IYANAGI T, 1981, BIOCHEMISTRY-US, V20, P1722, DOI 10.1021/bi00510a004; IYANAGI T, 1974, BIOCHEMISTRY-US, V13, P1701, DOI 10.1021/bi00705a023; Juan SH, 2001, CIRCULATION, V104, P1519, DOI 10.1161/hc3801.095663; KATCHALSKIKATZIR E, 1992, P NATL ACAD SCI USA, V89, P2195, DOI 10.1073/pnas.89.6.2195; Kikuchi A, 2001, NAT STRUCT BIOL, V8, P221, DOI 10.1038/84955; KUTTY RK, 1981, J BIOL CHEM, V256, P3956; Lightning LK, 2001, J BIOL CHEM, V276, P10612, DOI 10.1074/jbc.M010349200; Liu Y, 2000, J BIOL CHEM, V275, P5297, DOI 10.1074/jbc.275.8.5297; MCCOUBREY WK, 1994, EUR J BIOCHEM, V222, P597, DOI 10.1111/j.1432-1033.1994.tb18902.x; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Pereira PJB, 2001, NAT STRUCT BIOL, V8, P215, DOI 10.1038/84948; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SCHACTER BA, 1972, J BIOL CHEM, V247, P3601; Schuller DJ, 1999, NAT STRUCT BIOL, V6, P860; Schuller DJ, 2001, BIOCHEMISTRY-US, V40, P11552, DOI 10.1021/bi0110239; Sevrioukova IF, 1999, P NATL ACAD SCI USA, V96, P1863, DOI 10.1073/pnas.96.5.1863; Shen A.L., 1993, HDB EXPT PHARM, P35; SHEN AL, 1991, J BIOL CHEM, V266, P19976; SHEN AL, 1995, J BIOL CHEM, V270, P27475, DOI 10.1074/jbc.270.46.27475; SHEN SJ, 1993, ARCH BIOCHEM BIOPHYS, V304, P257, DOI 10.1006/abbi.1993.1347; SHIMIZU T, 1991, J BIOL CHEM, V266, P3372; STOCKER R, 1987, SCIENCE, V235, P1043, DOI 10.1126/science.3029864; Sugishima M, 2000, FEBS LETT, V471, P61, DOI 10.1016/S0014-5793(00)01353-3; TENHUNEN R, 1969, J BIOL CHEM, V244, P6388; Uzel C, 1998, SEMIN HEMATOL, V35, P27; Vakser IA, 1999, P NATL ACAD SCI USA, V96, P8477, DOI 10.1073/pnas.96.15.8477; VERMILION JL, 1978, J BIOL CHEM, V253, P8812; VOZNESENSKY AI, 1994, J BIOL CHEM, V269, P15724; VOZNESENSKY AI, 1992, J BIOL CHEM, V267, P14669; Wang M, 1997, P NATL ACAD SCI USA, V94, P8411, DOI 10.1073/pnas.94.16.8411; Whitby FG, 2002, J MOL BIOL, V319, P1199, DOI 10.1016/S0022-2836(02)00383-2; Wilks A, 1998, BIOCHEMISTRY-US, V37, P2889, DOI 10.1021/bi972720x; WILKS A, 1995, BIOCHEMISTRY-US, V34, P4421, DOI 10.1021/bi00013a034; WILKS A, 1993, J BIOL CHEM, V268, P22357; YOSHIDA T, 1980, J BIOL CHEM, V255, P4418; Zakhary R, 1997, P NATL ACAD SCI USA, V94, P14848, DOI 10.1073/pnas.94.26.14848	46	70	72	1	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 30	2003	278	22					20069	20076		10.1074/jbc.M300989200	http://dx.doi.org/10.1074/jbc.M300989200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	682EH	12626517	hybrid			2022-12-25	WOS:000183078000064
J	Lee, TS; Tsai, HL; Chau, LY				Lee, TS; Tsai, HL; Chau, LY			Induction of heme oxygenase-1 expression in murine macrophages is essential for the anti-inflammatory effect of low dose 15-deoxy-Delta(12,14)-prostaglandin J(2)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED RECEPTOR-GAMMA; NITRIC-OXIDE SYNTHASE; NF-KAPPA-B; PROTEIN-KINASE PATHWAY; PPAR-GAMMA; CYCLOPENTENONE PROSTAGLANDINS; CARBON-MONOXIDE; GENE-EXPRESSION; FATTY-ACIDS; INHIBITION	15-Deoxy-Delta(12,14)-prostaglandin J(2) (15d-PGJ(2)), a cyclopentenone prostaglandin, displays a potent anti-inflammatory effect at micromolar concentrations (> 2 muM) through direct inhibition of nuclear factor (NF)-kappaB activation. Here we show that at submicromolar concentrations (0.1-0.5 muM) 15d-PGJ(2) retains the ability to suppress the production of tumor necrosis factor-alpha (TNF-alpha) and nitric oxide ( NO) in lipopolysaccharide (LPS)-activated murine J774 macrophages under the conditions of a prolonged incubation (> 12 h). Western blot analysis revealed that the expression of the cytoprotective enzyme, heme oxygenase-1 (HO-1), was induced and coincident with the anti-inflammatory action of 15d-PGJ(2). Inhibition of HO-1 activity or scavenging carbon monoxide (CO), a byproduct derived from heme degradation, significantly attenuated the suppressive activity of 15d-PGJ(2). Furthermore, LPS-induced NF-kappaB activation assessed by the inhibitory protein of NF-kappaB (IkappaB) degradation and p50 nuclear translocation was diminished in cells subjected to prolonged treatment with the low concentration of 15d-PGJ(2). Treatment of cells with the protein synthesis inhibitor, cycloheximide, or the specific p38 MAP kinase inhibitor, SB203580, blocked the induction of HO-1 and suppression of LPS-induced IkappaB degradation mediated by 15d-PGJ(2). Likewise, HO inhibitor and CO scavenger were effective in abolishing the inhibitory effects of 15d-PGJ(2) on NF-kappaB activation induced by LPS. The functional role of CO was further demonstrated by the use of a CO releasing molecule, tricarbonyldichlororuthenium(II) dimer, which significantly suppressed LPS-induced nuclear translocation of p50 as assessed by confocal immunofluorescence. Collectively, these data suggest that even at submicromolar concentrations 15d-PGJ(2) can exert an anti-inflammatory effect in macrophages through a mechanism that involves the action of HO/CO.	Acad Sinica, Inst Biomed Sci, Div Cardiovasc Res, Taipei 11529, Taiwan	Academia Sinica - Taiwan	Chau, LY (corresponding author), Acad Sinica, Inst Biomed Sci, Div Cardiovasc Res, Taipei 11529, Taiwan.		Lee, Tzong-Shyuan/AAE-5803-2020; Chau, Lee-Young/N-7659-2018	Lee, Tzong-Shyuan/0000-0002-9593-4062; Chau, Lee-Young/0000-0002-6316-2328				Abraham NG, 1996, CELL PHYSIOL BIOCHEM, V6, P129, DOI 10.1159/000154819; Brouard S, 2002, J BIOL CHEM, V277, P17950, DOI 10.1074/jbc.M108317200; Bureau F, 2002, J IMMUNOL, V168, P5318, DOI 10.4049/jimmunol.168.10.5318; Castrillo A, 2000, MOL CELL BIOL, V20, P1692, DOI 10.1128/MCB.20.5.1692-1698.2000; Cernuda-Morollon E, 2001, J BIOL CHEM, V276, P35530, DOI 10.1074/jbc.M104518200; Chawla A, 2001, NAT MED, V7, P48, DOI 10.1038/83336; Colville-Nash PR, 1998, J IMMUNOL, V161, P978; Diab A, 2002, J IMMUNOL, V168, P2508, DOI 10.4049/jimmunol.168.5.2508; FORMAN BM, 1995, CELL, V83, P803, DOI 10.1016/0092-8674(95)90193-0; Gilmore TD, 1999, ONCOGENE, V18, P6842, DOI 10.1038/sj.onc.1203237; Gilroy DW, 1999, NAT MED, V5, P698, DOI 10.1038/9550; Harris SG, 2002, J IMMUNOL, V168, P1372, DOI 10.4049/jimmunol.168.3.1372; Jiang CY, 1998, NATURE, V391, P82, DOI 10.1038/34184; Kawahito Y, 2000, J CLIN INVEST, V106, P189, DOI 10.1172/JCI9652; Kitamura Y, 1999, NEUROSCI LETT, V262, P129, DOI 10.1016/S0304-3940(99)00055-5; Kliewer SA, 1997, P NATL ACAD SCI USA, V94, P4318, DOI 10.1073/pnas.94.9.4318; KLIEWER SA, 1995, CELL, V83, P813, DOI 10.1016/0092-8674(95)90194-9; Krey G, 1997, MOL ENDOCRINOL, V11, P779, DOI 10.1210/me.11.6.779; Kyriakis JM, 2001, PHYSIOL REV, V81, P807, DOI 10.1152/physrev.2001.81.2.807; Lee TS, 2002, NAT MED, V8, P240, DOI 10.1038/nm0302-240; Li M, 2000, MOL CELL BIOL, V20, P4699, DOI 10.1128/MCB.20.13.4699-4707.2000; MacMicking J, 1997, ANNU REV IMMUNOL, V15, P323, DOI 10.1146/annurev.immunol.15.1.323; MAINES MD, 1988, FASEB J, V2, P2557, DOI 10.1096/fasebj.2.10.3290025; Motterlini R, 2002, CIRC RES, V90, pE17, DOI 10.1161/hh0202.104530; Otterbein LE, 2000, AM J PHYSIOL-LUNG C, V279, pL1029, DOI 10.1152/ajplung.2000.279.6.L1029; Otterbein LE, 2000, NAT MED, V6, P422, DOI 10.1038/74680; Ricote M, 1998, NATURE, V391, P79, DOI 10.1038/34178; Rossi A, 2000, NATURE, V403, P103, DOI 10.1038/47520; Sarady JK, 2002, AM J RESP CELL MOL, V27, P739, DOI 10.1165/rcmb.4816; Scapagnini G, 2002, MOL PHARMACOL, V61, P554, DOI 10.1124/mol.61.3.554; Straus DS, 2000, P NATL ACAD SCI USA, V97, P4844, DOI 10.1073/pnas.97.9.4844; Straus DS, 2001, MED RES REV, V21, P185, DOI 10.1002/med.1006.abs; Wang LJ, 1998, AM J PATHOL, V152, P711; Wayman NS, 2002, FASEB J, V16, P1027, DOI 10.1096/fj.01-0793com; XIE QW, 1994, J BIOL CHEM, V269, P4705; Zhang X, 2001, J IMMUNOL, V166, P7104, DOI 10.4049/jimmunol.166.12.7104	36	193	195	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 23	2003	278	21					19325	19330		10.1074/jbc.M300498200	http://dx.doi.org/10.1074/jbc.M300498200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	679PY	12642589	hybrid			2022-12-25	WOS:000182932200079
J	Limsirichaikul, S; Ogawa, M; Niimi, A; Iwai, S; Murate, T; Yoshida, S; Suzuki, M				Limsirichaikul, S; Ogawa, M; Niimi, A; Iwai, S; Murate, T; Yoshida, S; Suzuki, M			The Gly-952 residue of Saccharomyces cerevisiae DNA polymerase alpha is important in discriminating correct deoxyribonucleotides from incorrect ones	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							I KLENOW FRAGMENT; MISPAIR EXTENSION KINETICS; AMINO-ACID SUBSTITUTIONS; ACTIVE-SITE; NUCLEOTIDE INCORPORATION; O-HELIX; REPLICATION FIDELITY; DEOXYNUCLEOSIDE TRIPHOSPHATE; REVERSE-TRANSCRIPTASE; CRYSTAL-STRUCTURE	Gly-952 is a conserved residue in Saccharomyces cerevisiae DNA polymerase alpha (pol alpha) that is strictly required for catalytic activity and for genetic complementation of a pol alpha-deficient yeast strain. This study analyzes the role of Gly-952 by characterizing the biochemical properties of Gly-952 mutants. Analysis of the nucleotide incorporation specificity of pol alpha G952A showed that this mutant incorporates nucleotides with extraordinarily low fidelity. In a steady-state kinetic assay to measure nucleotide misincorporation, pol alpha G952A incorporated incorrect nucleotides more efficiently than correct nucleotides opposite template C, G, and T. The fidelity of the G952A mutant polymerase was highest at template A, where the ratio of incorporation of dCMP to dTMP was as high as 0.37. Correct nucleotide insertion was 500- to 3500-fold lower for G952A than for wild type pol alpha, with up to 22-fold increase in pyrimidine misincorporation. The Km for G952A pol alpha bound to mismatched termini T:T, T C, C A, and A C was 71- to 460-fold lower than to a matched terminus. Furthermore, pol alpha G952A preferentially incorporated pyrimidine instead of dAMP opposite an abasic site, cis-syn cyclobutane di-thymine, or (6-4) di-thymine photoproduct. These data demonstrate that Gly-952 is a critical residue for catalytic efficiency and error prevention in S. cerevisiae pol alpha.	Nagoya Univ, Canc Cell Biol Lab, Dis Mechanism & Control Res Inst, Grad Sch Med, Nagoya, Aichi 4668550, Japan; Univ Tokyo, Dept Chem & Biotechnol, Sch Engn, Bunkyo Ku, Tokyo 1138656, Japan; Nagoya Univ, Sch Hlth Sci, Nagoya, Aichi 4618673, Japan	Nagoya University; University of Tokyo; Nagoya University	Suzuki, M (corresponding author), Nagoya Univ, Canc Cell Biol Lab, Dis Mechanism & Control Res Inst, Grad Sch Med, Nagoya, Aichi 4668550, Japan.		Suzuki, Motoshi/I-7246-2014	Suzuki, Motoshi/0000-0003-0682-5006				ASTATKE M, 1995, J BIOL CHEM, V270, P1945, DOI 10.1074/jbc.270.4.1945; Astatke M, 1998, J MOL BIOL, V278, P147, DOI 10.1006/jmbi.1998.1672; Beard WA, 1996, J BIOL CHEM, V271, P12141, DOI 10.1074/jbc.271.21.12141; Beard WA, 2002, J BIOL CHEM, V277, P47393, DOI 10.1074/jbc.M210036200; Bell JB, 1997, J BIOL CHEM, V272, P7345, DOI 10.1074/jbc.272.11.7345; BLASCO MA, 1993, J BIOL CHEM, V268, P16763; Burgers PMJ, 2001, J BIOL CHEM, V276, P43487, DOI 10.1074/jbc.R100056200; CARROLL SS, 1991, BIOCHEMISTRY-US, V30, P804, DOI 10.1021/bi00217a034; COPELAND WC, 1993, J BIOL CHEM, V268, P11041; CREIGHTON S, 1992, J BIOL CHEM, V267, P2633; DONG Q, 1995, J BIOL CHEM, V270, P21563, DOI 10.1074/jbc.270.37.21563; Doublie S, 1998, NATURE, V391, P251, DOI 10.1038/34593; Franklin MC, 2001, CELL, V105, P657, DOI 10.1016/S0092-8674(01)00367-1; FREY MW, 1995, BIOCHEMISTRY-US, V34, P9185, DOI 10.1021/bi00028a031; Friedberg EC, 2000, P NATL ACAD SCI USA, V97, P5681, DOI 10.1073/pnas.120152397; GOODMAN MF, 1993, CRIT REV BIOCHEM MOL, V28, P83, DOI 10.3109/10409239309086792; Iwai S, 1996, J AM CHEM SOC, V118, P7642, DOI 10.1021/ja9603158; Johnson RE, 2000, NATURE, V406, P1015, DOI 10.1038/35023030; Kiefer JR, 1998, NATURE, V391, P304, DOI 10.1038/34693; KUCHTA RD, 1987, BIOCHEMISTRY-US, V26, P8410, DOI 10.1021/bi00399a057; Kunkel TA, 2000, ANNU REV BIOCHEM, V69, P497, DOI 10.1146/annurev.biochem.69.1.497; Li Y, 1998, EMBO J, V17, P7514, DOI 10.1093/emboj/17.24.7514; LOEB LA, 1982, ANNU REV BIOCHEM, V51, P429, DOI 10.1146/annurev.bi.51.070182.002241; MENDELMAN LV, 1990, J BIOL CHEM, V265, P2338; MENDELMAN LV, 1989, J BIOL CHEM, V264, P14415; Minnick DT, 1999, J BIOL CHEM, V274, P3067, DOI 10.1074/jbc.274.5.3067; MURATA T, 1990, NUCLEIC ACIDS RES, V18, P7279, DOI 10.1093/nar/18.24.7279; Ogawa M, 2003, J BIOL CHEM, V278, P19071, DOI 10.1074/jbc.M208605200; PANDEY VN, 1994, J BIOL CHEM, V269, P13259; Patel PH, 2000, P NATL ACAD SCI USA, V97, P5095, DOI 10.1073/pnas.97.10.5095; Patel PH, 2001, J MOL BIOL, V308, P823, DOI 10.1006/jmbi.2001.4619; Patel PH, 2000, J BIOL CHEM, V275, P40266, DOI 10.1074/jbc.M005757200; PERRINO FW, 1989, J BIOL CHEM, V264, P2898; Ponamarev MV, 2002, J BIOL CHEM, V277, P15225, DOI 10.1074/jbc.C200100200; Saturno J, 1997, J MOL BIOL, V269, P313, DOI 10.1006/jmbi.1997.1053; Shah AM, 2001, J BIOL CHEM, V276, P10824, DOI 10.1074/jbc.M008680200; Shah AM, 2001, BIOCHEMISTRY-US, V40, P11372, DOI 10.1021/bi010755y; Shinkai A, 2001, J BIOL CHEM, V276, P18836, DOI 10.1074/jbc.M011472200; Steitz TA, 1999, J BIOL CHEM, V274, P17395, DOI 10.1074/jbc.274.25.17395; Suzuki M, 1996, P NATL ACAD SCI USA, V93, P9670, DOI 10.1073/pnas.93.18.9670; Suzuki M, 2000, J BIOL CHEM, V275, P32728, DOI 10.1074/jbc.M000097200; Suzuki M, 1997, J BIOL CHEM, V272, P11228; TABOR S, 1995, P NATL ACAD SCI USA, V92, P6339, DOI 10.1073/pnas.92.14.6339; TOPAL MD, 1976, NATURE, V263, P285, DOI 10.1038/263285a0; Tosaka A, 2001, J BIOL CHEM, V276, P27562, DOI 10.1074/jbc.M010635200; Trincao J, 2001, MOL CELL, V8, P417, DOI 10.1016/S1097-2765(01)00306-9; WONG I, 1991, BIOCHEMISTRY-US, V30, P526, DOI 10.1021/bi00216a030; Yang GW, 2002, BIOCHEMISTRY-US, V41, P2526, DOI 10.1021/bi0119924; Yang GW, 1999, BIOCHEMISTRY-US, V38, P8094, DOI 10.1021/bi990653w; Yoshida K, 2001, NUCLEIC ACIDS RES, V29, P4206, DOI 10.1093/nar/29.20.4206	50	8	9	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 23	2003	278	21					19079	19086		10.1074/jbc.M208604200	http://dx.doi.org/10.1074/jbc.M208604200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	679PY	12637558	hybrid			2022-12-25	WOS:000182932200048
J	Burkart, A; Samii, B; Corvera, S; Shpetner, HS				Burkart, A; Samii, B; Corvera, S; Shpetner, HS			Regulation of the SHP-2 tyrosine phosphatase by a novel cholesterol- and cell confluence-dependent mechanism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL GROWTH-FACTOR; ANNEXIN-II TETRAMER; ENDOTHELIAL-CELLS; FACTOR RECEPTOR; F-ACTIN; SIGNAL-TRANSDUCTION; PROTEIN COMPLEX; LIPID RAFTS; MDCK CELLS; PHOSPHORYLATION	Endothelial cells approaching confluence exhibit marked decreases in tyrosine phosphorylation of receptor tyrosine kinases and adherens junctions proteins, required for cell cycle arrest and adherens junctions stability. Recently, we demonstrated a close correlation in endothelial cells between membrane cholesterol and tyrosine phosphorylation of adherens junctions proteins. Here, we probe the mechanistic basis for this correlation. We find that as endothelial cells reach confluence, the tyrosine phosphatase SHP-2 is recruited to a low-density membrane fraction in a cholesterol-dependent manner. Binding of SHP-2 to this fraction was not abolished by phenyl phosphate, strongly suggesting that this binding was mediated by other regions of SHP-2 beside its SH2 domains. Annexin II, previously implicated in cholesterol trafficking, was associated in a complex with SHP-2, and both proteins localized to adhesion bands in confluent endothelial monolayers. These studies reveal a novel, cholesterol-dependent mechanism for the recruitment of signaling proteins to specific plasma membrane domains via their interactions with annexin II.	Univ Massachusetts, Med Ctr, Dept Mol Med, Sch Med, Worcester, MA 01605 USA; Worcester Polytech Inst, Dept Biotechnol, Worcester, MA 01609 USA	University of Massachusetts System; University of Massachusetts Worcester; Worcester Polytechnic Institute	Shpetner, HS (corresponding author), Univ Massachusetts, Med Ctr, Dept Mol Med, Sch Med, 373 Plantat St,Suite 107, Worcester, MA 01605 USA.							Ayala-Sanmartin J, 2001, BBA-BIOMEMBRANES, V1510, P18, DOI 10.1016/S0005-2736(00)00262-5; Babiychuk EB, 2000, J CELL BIOL, V150, P1113, DOI 10.1083/jcb.150.5.1113; Barabe F, 2002, J BIOL CHEM, V277, P13473, DOI 10.1074/jbc.M112149200; BENNETT AM, 1994, P NATL ACAD SCI USA, V91, P7335, DOI 10.1073/pnas.91.15.7335; CASE RD, 1994, J BIOL CHEM, V269, P10467; Corvera S, 2000, J BIOL CHEM, V275, P31414, DOI 10.1074/jbc.M001708200; DRUST DS, 1988, NATURE, V331, P88, DOI 10.1038/331088a0; ELIAS PM, 1978, J CELL BIOL, V78, P577, DOI 10.1083/jcb.78.2.577; ESPARISOGANDO A, 1994, AM J PHYSIOL, V267, pC166, DOI 10.1152/ajpcell.1994.267.1.C166; Filipenko NR, 2001, J BIOL CHEM, V276, P5310, DOI 10.1074/jbc.M009710200; Furuchi T, 1998, J BIOL CHEM, V273, P21099, DOI 10.1074/jbc.273.33.21099; HARDER T, 1994, BBA-MOL CELL RES, V1223, P375, DOI 10.1016/0167-4889(94)90098-1; Harder T, 1997, MOL BIOL CELL, V8, P533, DOI 10.1091/mbc.8.3.533; HARDER T, 1993, J CELL BIOL, V123, P1119, DOI 10.1083/jcb.123.5.1119; HAUSDORFF SF, 1995, J BIOL CHEM, V270, P12965, DOI 10.1074/jbc.270.22.12965; Hu YY, 2001, J BIOL CHEM, V276, P48549, DOI 10.1074/jbc.M105513200; JOHNSTONE SA, 1992, J BIOL CHEM, V267, P25976; JONES PG, 1992, J BIOL CHEM, V267, P13993; Kabouridis PS, 2000, EUR J IMMUNOL, V30, P954, DOI 10.1002/1521-4141(200003)30:3<954::AID-IMMU954>3.3.CO;2-P; Lacalle RA, 2002, J CELL BIOL, V157, P277, DOI 10.1083/jcb.200109031; Lampugnani MG, 1997, J CELL SCI, V110, P2065; Masuda M, 1997, FEBS LETT, V408, P331, DOI 10.1016/S0014-5793(97)00457-2; MATSUYOSHI N, 1992, J CELL BIOL, V118, P703, DOI 10.1083/jcb.118.3.703; Noguchi T, 1996, J BIOL CHEM, V271, P27652, DOI 10.1074/jbc.271.44.27652; Oliferenko S, 1999, J CELL BIOL, V146, P843, DOI 10.1083/jcb.146.4.843; Rahimi N, 1999, MOL BIOL CELL, V10, P3401, DOI 10.1091/mbc.10.10.3401; Sagot I, 1997, FEBS LETT, V410, P229, DOI 10.1016/S0014-5793(97)00594-2; SHIBAMOTO S, 1994, CELL ADHES COMMUN, V1, P295, DOI 10.3109/15419069409097261; Siminovitch KA, 1998, SEMIN IMMUNOL, V10, P329, DOI 10.1006/smim.1998.0125; Sorby M, 1996, J BIOL CHEM, V271, P10963; Stan RV, 1997, MOL BIOL CELL, V8, P595, DOI 10.1091/mbc.8.4.595; Uittenbogaard A, 2002, J BIOL CHEM, V277, P4925, DOI 10.1074/jbc.M109278200; Ukropec JA, 2000, J BIOL CHEM, V275, P5983, DOI 10.1074/jbc.275.8.5983; Visconti PE, 1999, J BIOL CHEM, V274, P3235, DOI 10.1074/jbc.274.5.3235; Xu FP, 2001, J BIOL CHEM, V276, P29479, DOI 10.1074/jbc.M104428200; Zeuschner D, 2001, EUR J CELL BIOL, V80, P499, DOI 10.1078/0171-9335-00184	36	20	20	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 16	2003	278	20					18360	18367		10.1074/jbc.M210701200	http://dx.doi.org/10.1074/jbc.M210701200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677YX	12611902	hybrid			2022-12-25	WOS:000182838300101
J	Cabral, A; Fischer, DF; Vermeij, WP; Backendorf, C				Cabral, A; Fischer, DF; Vermeij, WP; Backendorf, C			Distinct functional interactions of human Skn-1 isoforms with Ese-1 during keratinocyte terminal differentiation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ETS TRANSCRIPTION FACTORS; PROLINE-RICH PROTEINS; POU DOMAIN FACTORS; EPIDERMAL DIFFERENTIATION; ENVELOPE PRECURSOR; DNA-BINDING; EXPRESSION; FAMILY; GENE; CONTAINS	Among the three major POU proteins expressed in human skin, Oct-1, Tst-1/Oct-6, and Skn-1/Oct-11, only the latter induced SPRR2A, a marker of keratinocyte terminal differentiation. In this study, we have identified three Skn-1 isoforms, which encode proteins with various N termini, generated by alternative promoter usage. These isotypes showed distinct expression patterns in various skin samples, internal squamous epithelia, and cultured human keratinocytes. Skn-1a and Skn-1d1 bound the SPRR2A octamer site with comparable affinity and functioned as transcriptional activators. Skn-1d2 did not affect SPRR2A expression. Skn-1a, the largest protein, functionally cooperated with Ese-1/Elf-3, an epithelial-specific transcription factor, previously implicated in SPRR2A induction. This cooperativity, which depended on an N-terminal pointed-like domain in Skn-1a, was not found for Skn-1d1. Actually, Skn-1d1 counteracted the cooperativity between Skn-1a and Ese-1. Apparently, the human Skn-1 locus encodes multifunctional protein isotypes, subjected to biochemical cross-talk, which are likely to play a major role in the fine-tuning of keratinocyte terminal differentiation.	Leiden Univ, Leiden Inst Chem, Gorlaeus Labs, Mol Genet Lab, NL-2300 RA Leiden, Netherlands	Leiden University; Leiden University - Excl LUMC	Backendorf, C (corresponding author), Leiden Univ, Leiden Inst Chem, Gorlaeus Labs, Mol Genet Lab, POB 9502, NL-2300 RA Leiden, Netherlands.		Cabral, Adriana/AAX-3284-2021	Fischer, David/0000-0002-6690-0197; Vermeij, Wilbert/0000-0002-9690-1385				ANDERSEN B, 1993, SCIENCE, V260, P78, DOI 10.1126/science.7682011; Andersen B, 1997, J BIOL CHEM, V272, P15905, DOI 10.1074/jbc.272.25.15905; Andersen B, 1997, GENE DEV, V11, P1873, DOI 10.1101/gad.11.14.1873; Andersen B, 2001, ENDOCR REV, V22, P2, DOI 10.1210/er.22.1.2; Arrowsmith CH, 1999, CELL DEATH DIFFER, V6, P1169, DOI 10.1038/sj.cdd.4400619; Cabral A, 2001, J CELL SCI, V114, P3837; Cabral A, 2001, J BIOL CHEM, V276, P19231, DOI 10.1074/jbc.M100336200; CLERC RG, 1988, GENE DEV, V2, P1570, DOI 10.1101/gad.2.12a.1570; Eckert RL, 1997, J INVEST DERMATOL, V109, P501, DOI 10.1111/1523-1747.ep12336477; EDWARDS JBDM, 1991, NUCLEIC ACIDS RES, V19, P5227, DOI 10.1093/nar/19.19.5227; Fischer DF, 1996, MOL CELL BIOL, V16, P5365, DOI 10.1128/mcb.16.10.5365; FUCHS E, 1990, J CELL BIOL, V111, P2807, DOI 10.1083/jcb.111.6.2807; GIBBS S, 1993, GENOMICS, V16, P630, DOI 10.1006/geno.1993.1240; GOLDSBOROUGH AS, 1993, NUCLEIC ACIDS RES, V21, P127, DOI 10.1093/nar/21.1.127; Hildesheim J, 2001, J CELL SCI, V114, P1913; Hildesheim J, 1999, J BIOL CHEM, V274, P26399, DOI 10.1074/jbc.274.37.26399; HOHL D, 1995, J INVEST DERMATOL, V104, P902, DOI 10.1111/1523-1747.ep12606176; Holbrook K., 1994, KERATINOCYTE HDB, P3; Jang SI, 2000, J BIOL CHEM, V275, P15295, DOI 10.1074/jbc.275.20.15295; Kelley LA, 2000, J MOL BIOL, V299, P499, DOI 10.1006/jmbi.2000.3741; KLEMM JD, 1994, CELL, V77, P21, DOI 10.1016/0092-8674(94)90231-3; Lee JH, 1996, J BIOL CHEM, V271, P4561; Li RZ, 2000, ONCOGENE, V19, P6514, DOI 10.1038/sj.onc.1204035; Lohman FP, 1997, ONCOGENE, V14, P1623, DOI 10.1038/sj.onc.1200974; Marenholz I, 2001, GENOME RES, V11, P341, DOI 10.1101/gr.114801; Oettgen P, 1997, MOL CELL BIOL, V17, P4419, DOI 10.1128/MCB.17.8.4419; PRESLAND RB, 2000, BRIT J DERMATOL, V11, P383; Ryan AK, 1997, GENE DEV, V11, P1207, DOI 10.1101/gad.11.10.1207; Sark MWJ, 1999, EXP CELL RES, V250, P475, DOI 10.1006/excr.1999.4532; Sark MWJ, 1998, J BIOL CHEM, V273, P24683, DOI 10.1074/jbc.273.38.24683; Slupsky CM, 1998, P NATL ACAD SCI USA, V95, P12129, DOI 10.1073/pnas.95.21.12129; STURM RA, 1988, GENE DEV, V2, P1582, DOI 10.1101/gad.2.12a.1582; Sugihara TM, 2001, J BIOL CHEM, V276, P33036, DOI 10.1074/jbc.M103000200; Wang WK, 2001, ACTA CRYSTALLOGR D, V57, P545, DOI 10.1107/S0907444901002529; WEGNER M, 1993, P NATL ACAD SCI USA, V90, P4743, DOI 10.1073/pnas.90.10.4743; Wegner M, 1993, CURR OPIN CELL BIOL, V5, P488, DOI 10.1016/0955-0674(93)90015-I; Yukawa K, 1996, J VIROL, V70, P10, DOI 10.1128/JVI.70.1.10-16.1996	37	29	32	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 16	2003	278	20					17792	17799		10.1074/jbc.M300508200	http://dx.doi.org/10.1074/jbc.M300508200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677YX	12624109	hybrid, Green Published			2022-12-25	WOS:000182838300027
J	Dai, E; Guan, HY; Liu, LY; Little, S; McFadden, G; Vaziri, S; Cao, HN; Ivanova, IA; Bocksch, L; Lucas, A				Dai, E; Guan, HY; Liu, LY; Little, S; McFadden, G; Vaziri, S; Cao, HN; Ivanova, IA; Bocksch, L; Lucas, A			Serp-1, a viral anti-inflammatory serpin, regulates cellular serine proteinase and serpin responses to vascular injury	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMINOGEN-ACTIVATOR INHIBITOR-1; NEOINTIMA FORMATION; GENE-TRANSFER; TRANSPLANT VASCULOPATHY; INCREASED EXPRESSION; KINETIC-ANALYSIS; ARTERIAL INJURY; RECEPTOR; VITRONECTIN; UROKINASE	Complex DNA viruses have tapped into cellular serpin responses that act as key regulatory steps in coagulation and inflammatory cascades. Serp-1 is one such viral serpin that effectively protects virus-infected tissues from host inflammatory responses. When given as purified protein, Serp-1 markedly inhibits vascular monocyte invasion and plaque growth in animal models. We have investigated mechanisms of viral serpin inhibition of vascular inflammatory responses. In vascular injury models, Serp-1 altered early cellular plasminogen activator (tissue plasminogen activator), inhibitor (PAI-1), and receptor (urokinase-type plasminogen activator) expression (p < 0.01). Serp-1, but not a reactive center loop mutant, up-regulated PAI-1 serpin expression in human endothelial cells. Treatment of endothelial cells with antibody to urokinase-type plasminogen activator and vitronectin blocked Serp-1-induced changes. Significantly, Serp-1 blocked intimal hyperplasia (p < 0.0001) after aortic allograft transplant (p < 0.0001) in PAI-1-deficient mice. Serp-1 also blocked plaque growth after aortic isograft transplant and after wire-induced injury (p < 0.05) in PAI-1-deficient mice indicating that increase in PAI-1 expression is not required for Serp-1 to block vasculopathy development. Serp-1 did not inhibit plaque growth in uPAR-deficient mice after aortic allograft transplant. We conclude that the poxviral serpin, Serp-1, attenuates vascular inflammatory responses to injury through a pathway mediated by native uPA receptors and vitronectin.	Univ Western Ontario, John P Robarts Res Inst, Vasc Biol Res Grp, London, ON N6A 5K8, Canada; Univ Western Ontario, Univ Hosp, London Hlth Sci Ctr, Div Cardiol, London, ON N6A 5K8, Canada; Univ Western Ontario, Dept Microbiol & Immunol, London, ON N6A 5K8, Canada	Western University (University of Western Ontario); London Health Sciences Centre; Western University (University of Western Ontario); Western University (University of Western Ontario)	Lucas, A (corresponding author), Univ Western Ontario, John P Robarts Res Inst, Vasc Biol Res Grp, 100 Perth Dr,POB 5015, London, ON N6A 5K8, Canada.	arl@robarts.ca		McFadden, Grant/0000-0002-2556-3526				BARKA T, 1993, J HISTOCHEM CYTOCHEM, V41, P1863, DOI 10.1177/41.12.8245434; Blasi F, 1997, IMMUNOL TODAY, V18, P415, DOI 10.1016/S0167-5699(97)01121-3; BOT I, 2002, PRECLINICAL EVALUATI, P11; Bustin SA, 2000, J MOL ENDOCRINOL, V25, P169, DOI 10.1677/jme.0.0250169; CARMELIET P, 1994, NATURE, V368, P419, DOI 10.1038/368419a0; Carmeliet P, 1997, CIRCULATION, V96, P3180, DOI 10.1161/01.CIR.96.9.3180; CARMELIET P, 1995, FASEB J, V9, P934, DOI 10.1096/fasebj.9.10.7615162; Chang AW, 1998, ARTERIOSCL THROM VAS, V18, P1855, DOI 10.1161/01.ATV.18.12.1855; Chavakis T, 1998, BLOOD, V91, P2305, DOI 10.1182/blood.V91.7.2305.2305_2305_2312; Deng G, 1996, J CELL BIOL, V134, P1563, DOI 10.1083/jcb.134.6.1563; ESTREICHER A, 1990, J CELL BIOL, V111, P783, DOI 10.1083/jcb.111.2.783; FALCONE DJ, 1993, J BIOL CHEM, V268, P11951; Falkenberg M, 2002, P NATL ACAD SCI USA, V99, P10665, DOI 10.1073/pnas.162236599; FORSYTH KD, 1994, CLIN EXP IMMUNOL, V95, P277; Germer M, 1998, EUR J BIOCHEM, V253, P669, DOI 10.1046/j.1432-1327.1998.2530669.x; GETTINS P, 1992, HEMATOL ONCOL CLIN N, V6, P1393, DOI 10.1016/S0889-8588(18)30282-X; Gladson CL, 2000, NEUROSCI LETT, V283, P157, DOI 10.1016/S0304-3940(00)00876-4; Hasenstab D, 1997, CIRC RES, V80, P490, DOI 10.1161/01.RES.80.4.490; Hausen B, 2001, TRANSPLANTATION, V72, P364, DOI 10.1097/00007890-200108150-00003; Hayry P, 1996, TRANSPL P, V28, P2337; JACKSON CL, 1992, ANN NY ACAD SCI, V667, P141, DOI 10.1111/j.1749-6632.1992.tb51606.x; KOULACK J, 1995, MICROSURG, V16, P110, DOI 10.1002/micr.1920160213; Levi M, 2001, CIRCULATION, V103, P2014; Libby P, 2002, CIRCULATION, V105, P1135, DOI 10.1161/hc0902.104353; Lijnen HR, 1998, ARTERIOSCL THROM VAS, V18, P1035, DOI 10.1161/01.ATV.18.7.1035; Liu LY, 2000, J CLIN INVEST, V105, P1613, DOI 10.1172/JCI8934; Lucas A, 2000, J HEART LUNG TRANSPL, V19, P1029, DOI 10.1016/S1053-2498(00)00190-X; Lucas A, 1996, CIRCULATION, V94, P2890, DOI 10.1161/01.CIR.94.11.2890; MANEJWALA FM, 1991, DEV BIOL, V144, P301, DOI 10.1016/0012-1606(91)90423-Z; McMahon GA, 2001, J BIOL CHEM, V276, P33964, DOI 10.1074/jbc.M105980200; Miller L, 1995, J HEART LUNG TRANSPL, V14, pS227; Miller LW, 2000, CIRCULATION, V101, P1598, DOI 10.1161/01.CIR.101.13.1598; Moons L, 1998, J CLIN INVEST, V102, P1788, DOI 10.1172/JCI3316; Nagai N, 1999, CIRCULATION, V99, P2440, DOI 10.1161/01.CIR.99.18.2440; Nash P, 1998, J BIOL CHEM, V273, P20982, DOI 10.1074/jbc.273.33.20982; Ploplis VA, 2001, ANN NY ACAD SCI, V936, P466; Reidy MA, 1996, CIRC RES, V78, P405, DOI 10.1161/01.RES.78.3.405; Rocnik EF, 1998, J CLIN INVEST, V101, P1889, DOI 10.1172/JCI1025; Ross R, 1999, NEW ENGL J MED, V340, P115, DOI 10.1056/NEJM199901143400207; SAWA H, 1993, CIRC RES, V73, P671, DOI 10.1161/01.RES.73.4.671; SAXNE T, 1993, J RHEUMATOL, V20, P91; SEIFFERT D, 1991, BIOCHIM BIOPHYS ACTA, V1078, P23, DOI 10.1016/0167-4838(91)90087-G; SESTINI R, 1995, CLIN CHEM, V41, P826; Silverman GA, 2001, J BIOL CHEM, V276, P33293, DOI 10.1074/jbc.R100016200; Sjoland H, 2000, ARTERIOSCL THROM VAS, V20, P846, DOI 10.1161/01.ATV.20.3.846; Stefansson S, 1996, NATURE, V383, P441, DOI 10.1038/383441a0; Stefansson S, 1998, TRENDS CARDIOVAS MED, V8, P175, DOI 10.1016/S1050-1738(98)00003-6; Stefansson S, 1998, J BIOL CHEM, V273, P6358, DOI 10.1074/jbc.273.11.6358; Stoop AA, 2000, ARTERIOSCL THROM VAS, V20, P1143, DOI 10.1161/01.ATV.20.4.1143; Strauss BH, 1999, CIRCULATION, V100, P1616, DOI 10.1161/01.CIR.100.15.1616; Turner PC, 2001, ASM NEWS, V67, P201; UPTON C, 1990, VIROLOGY, V179, P618, DOI 10.1016/0042-6822(90)90129-F; Yamamoto M, 1997, CANCER RES, V57, P2799; Zalai CV, 2002, FUND CL CAR, V45, P447	54	45	54	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 16	2003	278	20					18563	18572		10.1074/jbc.M209683200	http://dx.doi.org/10.1074/jbc.M209683200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677YX	12637546	hybrid			2022-12-25	WOS:000182838300128
J	Leighton, M; Kadler, KE				Leighton, M; Kadler, KE			Paired basic/furin-like proprotein convertase cleavage of pro-BMP-1 in the trans-Golgi network	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BONE MORPHOGENETIC PROTEIN-1; PROCOLLAGEN C-PROTEINASE; PRECURSOR PROTEINS; ASTACIN FAMILY; BREFELDIN-A; FURIN; ACTIVATION; MATRIX; METALLOPROTEINASES; COLLAGEN	Bone morphogenetic protein (BMP)-1 is a zinc-dependent metalloproteinase that cleaves a variety of extracellular matrix substrates, including type I procollagen. Little is known about the site of action of BMP-1, although the extracellular matrix seems likely to be it. BMP-1 is synthesized with an N-terminal prodomain. The removal of the prodomain presumably activates the proteinase. In this study we show that the prodomain is cleaved in the trans-Golgi network (TGN) and by furin-like/paired basic proprotein convertases. Inhibitors of furin resulted in the secretion of pro-BMP-1, which could not cleave procollagen. Recombinant furin cleaved the prodomain from pro-BMP-1. Site-directed mutagenesis of the prodomain cleavage site (RSRR) to RSAA resulted in efficient secretion of pro-BMP-1. Therefore, prodomain cleavage was not required for secretion. Using peptide N-glycosidase and neuraminidase digestion to determine the post-translational status of pro-BMP-1 during its conversion to BMP-1, we showed that BMP-1 first appears in the TGN during sialylation of the molecule. Furthermore, immunofluorescence studies using an antibody to the nascent N terminus of BMP-1 showed localization to the TGN and plasma membrane. The observation that BMP-1 occurs inside the cell raises the possibility that BMP-1 might begin to cleave its substrates prior to secretion to the extracellular matrix.	Univ Manchester, Sch Biol Sci, Wellcome Trust Ctr Cell Matrix Res, Manchester M13 9PT, Lancs, England	University of Manchester	Kadler, KE (corresponding author), Univ Manchester, Sch Biol Sci, Wellcome Trust Ctr Cell Matrix Res, Stopford Bldg 2-205,Oxford Rd, Manchester M13 9PT, Lancs, England.		KADLER, KARL/ABI-2403-2020	KADLER, KARL/0000-0003-4977-4683				Amano S, 2000, J BIOL CHEM, V275, P22728, DOI 10.1074/jbc.M002345200; BIRK DE, 1990, J CELL SCI, V95, P649; BODE W, 1993, FEBS LETT, V331, P134, DOI 10.1016/0014-5793(93)80312-I; BOND JS, 1995, PROTEIN SCI, V4, P1247, DOI 10.1002/pro.5560040701; Chan M, 2001, EUR J BIOCHEM, V268, P3423, DOI 10.1046/j.1432-1327.2001.02241.x; DENAULT JB, 1995, FEBS LETT, V362, P276, DOI 10.1016/0014-5793(95)00249-9; Denault JB, 1996, FEBS LETT, V379, P113, DOI 10.1016/0014-5793(95)01487-X; FUJIWARA T, 1988, J BIOL CHEM, V263, P18545; Garrigue-Antar L, 2002, J BIOL CHEM, V277, P43327, DOI 10.1074/jbc.M207342200; Garrigue-Antar L, 2001, J BIOL CHEM, V276, P26237, DOI 10.1074/jbc.M010814200; HOJIMA Y, 1985, J BIOL CHEM, V260, P5996; Kang TB, 2002, CANCER RES, V62, P675; Kessler E, 1996, SCIENCE, V271, P360, DOI 10.1126/science.271.5247.360; Kridel SJ, 2001, J BIOL CHEM, V276, P20572, DOI 10.1074/jbc.M100900200; Lee SB, 1997, J BIOL CHEM, V272, P19059, DOI 10.1074/jbc.272.30.19059; Li SW, 1996, P NATL ACAD SCI USA, V93, P5127, DOI 10.1073/pnas.93.10.5127; LIPPINCOTTSCHWARTZ J, 1989, CELL, V56, P801, DOI 10.1016/0092-8674(89)90685-5; Logeat F, 1998, P NATL ACAD SCI USA, V95, P8108, DOI 10.1073/pnas.95.14.8108; Molloy SS, 1999, TRENDS CELL BIOL, V9, P28, DOI 10.1016/S0962-8924(98)01382-8; Nakayama K, 1997, BIOCHEM J, V327, P625, DOI 10.1042/bj3270625; Prescott AR, 1997, EUR J CELL BIOL, V72, P238; Raghunath M, 1999, J CELL SCI, V112, P1093; Rattenholl A, 2002, J BIOL CHEM, V277, P26372, DOI 10.1074/jbc.M203247200; Reynolds SD, 2000, GENE, V248, P233, DOI 10.1016/S0378-1119(00)00114-1; Sarras MP, 1996, BIOESSAYS, V18, P439, DOI 10.1002/bies.950180604; Scott IC, 2001, NATURE, V410, P475, DOI 10.1038/35068572; Scott IC, 1999, DEV BIOL, V213, P283, DOI 10.1006/dbio.1999.9383; Scott IC, 2000, J BIOL CHEM, V275, P30504, DOI 10.1074/jbc.M004846200; Seidah NG, 1999, BRAIN RES, V848, P45, DOI 10.1016/S0006-8993(99)01909-5; Shapiro J, 1997, J HISTOCHEM CYTOCHEM, V45, P3, DOI 10.1177/002215549704500102; Sieron AL, 2000, BIOCHEMISTRY-US, V39, P3231, DOI 10.1021/bi992312o; TAKAHASHI S, 1995, J BIOL CHEM, V270, P26565, DOI 10.1074/jbc.270.44.26565; TARTAKOFF AM, 1983, CELL, V32, P1026, DOI 10.1016/0092-8674(83)90286-6; Unsold C, 2002, J BIOL CHEM, V277, P5596, DOI 10.1074/jbc.M110003200; Uzel MI, 2001, J BIOL CHEM, V276, P22537, DOI 10.1074/jbc.M102352200; Veitch DP, 2003, J BIOL CHEM, V278, P15661, DOI 10.1074/jbc.M210588200; Yana I, 2000, MOL BIOL CELL, V11, P2387, DOI 10.1091/mbc.11.7.2387; Zhou A, 1999, J BIOL CHEM, V274, P20745, DOI 10.1074/jbc.274.30.20745	38	75	83	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 16	2003	278	20					18478	18484		10.1074/jbc.M213021200	http://dx.doi.org/10.1074/jbc.M213021200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677YX	12637569	hybrid			2022-12-25	WOS:000182838300116
J	Migliorini, MM; Behre, EH; Brew, S; Ingham, KC; Strickland, DK				Migliorini, MM; Behre, EH; Brew, S; Ingham, KC; Strickland, DK			Allosteric modulation of ligand binding to low density lipoprotein receptor-related protein by the receptor-associated protein requires critical lysine residues within its carboxyl-terminal domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COMPLEMENT-TYPE REPEATS; ALPHA-2-MACROGLOBULIN RECEPTOR; 39-KDA PROTEIN; MOLECULAR CHAPERONE; RAP; DISSECTION; SITES; ER; IDENTIFICATION; CLUSTER	The low density lipoprotein receptor-related protein (LRP) is a large endocytic receptor that recognizes more than 30 different ligands and plays important roles in protease and lipoprotein catabolism. Ligand binding to newly synthesized LRP is modulated by the receptor-associated protein (RAP), an endoplasmic reticulum-resident protein that functions as a molecular chaperone and prevents ligands from associating with LRP via an allosteric-type mechanism. RAP is a multidomain protein that contains two independent LRP binding sites, one located at the amino-terminal portion of the molecule and the other at the carboxyl-terminal portion of the molecule. The objective of the present investigation was to gain insight into how these two regions of RAP interact with LRP and function to modulate its ligand binding properties. These objectives were accomplished by random mutagenesis of RAP, which identified two critical lysine residues, Lys-256 and Lys-270, within the carboxyl-terminal domain that are necessary for binding of this region of RAP to LRP and to heparin. RAP molecules in which either of these two lysine residues was mutated still bound LRP but with reduced affinity. Furthermore, the mutant RAPs were significantly impaired in their ability to inhibit alpha(2)M* binding to LRP via allosteric mechanisms. In contrast, the mutant RAP molecules were still effective at inhibiting uPA.PAI-1 binding to LRP. These results confirm that both LRP binding sites within RAP cooperate to inhibit ligand binding via an allosteric mechanism.	Amer Red Cross, Jerome H Holland Lab Biomed Sci, Dept Vasc Biol, Rockville, MD 20855 USA; Amer Red Cross, Jerome H Holland Lab Biomed Sci, Dept Biochem, Rockville, MD 20855 USA	American Red Cross; American Red Cross	Strickland, DK (corresponding author), Amer Red Cross, Jerome H Holland Lab Biomed Sci, Dept Vasc Biol, 15601 Crabbs Branch Way, Rockville, MD 20855 USA.				NHLBI NIH HHS [HL54710, HL50784] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL054710, R01HL050784] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Andersen OM, 2001, BIOCHEMISTRY-US, V40, P15408, DOI 10.1021/bi0110692; ASHCOM JD, 1990, J CELL BIOL, V110, P1041, DOI 10.1083/jcb.110.4.1041; BIEMESDERFER D, 1993, AM J PHYSIOL, V264, pF1011, DOI 10.1152/ajprenal.1993.264.6.F1011; BU GJ, 1995, EMBO J, V14, P2269, DOI 10.1002/j.1460-2075.1995.tb07221.x; Ellgaard L, 1997, EUR J BIOCHEM, V244, P544, DOI 10.1111/j.1432-1033.1997.00544.x; Filimonov V V, 1982, Mol Biol (Mosk), V16, P551; HERZ J, 1992, CELL, V71, P411, DOI 10.1016/0092-8674(92)90511-A; HERZ J, 1991, J BIOL CHEM, V266, P21232; Herz J, 2001, J CLIN INVEST, V108, P779, DOI 10.1172/JCI200113992; Horn IR, 1997, J BIOL CHEM, V272, P13608, DOI 10.1074/jbc.272.21.13608; Hsieh JC, 2003, CELL, V112, P355, DOI 10.1016/S0092-8674(03)00045-X; JENSEN PH, 1989, FEBS LETT, V255, P275, DOI 10.1016/0014-5793(89)81105-6; LAWRENCE DA, 1994, J BIOL CHEM, V269, P15223; Medved LV, 1999, J BIOL CHEM, V274, P717, DOI 10.1074/jbc.274.2.717; Melman L, 2001, J BIOL CHEM, V276, P29338, DOI 10.1074/jbc.M103717200; Mikhailenko I, 2001, J BIOL CHEM, V276, P39484, DOI 10.1074/jbc.M104382200; Neels JG, 1999, J BIOL CHEM, V274, P31305, DOI 10.1074/jbc.274.44.31305; Nielsen PR, 1997, P NATL ACAD SCI USA, V94, P7521, DOI 10.1073/pnas.94.14.7521; Obermoeller LM, 1997, J BIOL CHEM, V272, P10761; Obermoeller-McCormick LM, 2001, J CELL SCI, V114, P899; ORLANDO RA, 1994, P NATL ACAD SCI USA, V91, P3161, DOI 10.1073/pnas.91.8.3161; Privalov P L, 1986, Methods Enzymol, V131, P4; Strickland DK, 2002, TRENDS ENDOCRIN MET, V13, P66, DOI 10.1016/S1043-2760(01)00526-4; STRICKLAND DK, 1991, J BIOL CHEM, V266, P13364; STRICKLAND DK, 1990, J BIOL CHEM, V265, P17401; Vash B, 1998, BLOOD, V92, P3277, DOI 10.1182/blood.V92.9.3277.421k50_3277_3285; WARSHAWSKY I, 1993, J BIOL CHEM, V268, P22046; WARSHAWSKY I, 1994, J BIOL CHEM, V269, P3325; WARSHAWSKY I, 1995, BIOCHEMISTRY-US, V34, P3404, DOI 10.1021/bi00010a032; WEINER MP, 1994, GENE, V151, P119, DOI 10.1016/0378-1119(94)90641-6; WILLIAMS SE, 1992, J BIOL CHEM, V267, P9035; Willnow TE, 1996, EMBO J, V15, P2632, DOI 10.1002/j.1460-2075.1996.tb00623.x; WILLNOW TE, 1994, J BIOL CHEM, V269, P15827; WILLNOW TE, 1995, P NATL ACAD SCI USA, V92, P4537, DOI 10.1073/pnas.92.10.4537	34	45	53	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 16	2003	278	20					17986	17992		10.1074/jbc.M212592200	http://dx.doi.org/10.1074/jbc.M212592200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677YX	12637503	hybrid			2022-12-25	WOS:000182838300051
J	Mogk, A; Schlieker, C; Strub, C; Rist, W; Weibezahn, J; Bukau, B				Mogk, A; Schlieker, C; Strub, C; Rist, W; Weibezahn, J; Bukau, B			Roles of individual domains and conserved motifs of the AAA plus chaperone ClpB in oligomerization, ATP hydrolysis, and chaperone activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-ACTIVATED ATPASE; ESCHERICHIA-COLI; BINDING-SITES; CYANOBACTERIUM SYNECHOCOCCUS; SACCHAROMYCES-CEREVISIAE; THERMUS-THERMOPHILUS; POLYACRYLAMIDE GELS; CRYSTAL-STRUCTURE; MECHANISM; COMPLEX	ClpB of Escherichia coli is an ATP-dependent ring-forming chaperone that mediates the resolubilization of aggregated proteins in cooperation with the DnaK chaperone system. ClpB belongs to the Hsp100/Clp subfamily of AAA+ proteins and is composed of an N-terminal domain and two AAA-domains that are separated by a "linker" region. Here we present a detailed structure-function analysis of ClpB, dissecting the individual roles of ClpB domains and conserved motifs in oligomerization, ATP hydrolysis, and chaperone activity. Our results show that ClpB oligomerization is strictly dependent on the presence of the C-terminal domain of the second AAA-domain, while ATP binding to the first AAA-domains stabilized the ClpB oligomer. Analysis of mutants of conserved residues in Walker A and B and sensor 2 motifs revealed that both AAA-domains contribute to the basal ATPase activity of ClpB and communicate in a complex manner. Chaperone activity strictly depends on ClpB oligomerization and the presence of a residual ATPase activity. The N-domain is dispensable for oligomerization and for the disaggregating activity in vitro and in vivo. In contrast the presence of the linker region, although not involved in oligomerization, is essential for ClpB chaperone activity.	Zentrum Mol Biol, D-69120 Heidelberg, Germany; Univ Freiburg, Inst Biochem & Mol Biol, D-79104 Freiburg, Germany	Ruprecht Karls University Heidelberg; University of Freiburg	Mogk, A (corresponding author), Zentrum Mol Biol, Neuenheimer Feld 282, D-69120 Heidelberg, Germany.	a.mogk@zmbh-uni-heidelberg.de; bukau@zmbh.uni-heidelberg.de		Rist, Wolfgang/0000-0002-0626-3544; Bukau, Bernd/0000-0003-0521-7199				Banecki B, 2001, J BIOL CHEM, V276, P18843, DOI 10.1074/jbc.M007507200; Barnett ME, 2000, J BIOL CHEM, V275, P37565, DOI 10.1074/jbc.M005211200; Beinker P, 2002, J BIOL CHEM, V277, P47160, DOI 10.1074/jbc.M207853200; Bochtler M, 2000, NATURE, V403, P800, DOI 10.1038/35001629; Cashikar AG, 2002, MOL CELL, V9, P751, DOI 10.1016/S1097-2765(02)00499-9; Celerin M, 1998, J BACTERIOL, V180, P5173, DOI 10.1128/JB.180.19.5173-5182.1998; Clarke AK, 2000, J BACTERIOL, V182, P7092, DOI 10.1128/JB.182.24.7092-7096.2000; Dougan DA, 2002, MOL CELL, V9, P673, DOI 10.1016/S1097-2765(02)00485-9; Eriksson MJ, 2001, J BACTERIOL, V183, P7392, DOI 10.1128/JB.183.24.7392-7396.2001; FRASER CM, 1995, SCIENCE, V270, P397, DOI 10.1126/science.270.5235.397; Goloubinoff P, 1999, P NATL ACAD SCI USA, V96, P13732, DOI 10.1073/pnas.96.24.13732; Guo FS, 2002, J BIOL CHEM, V277, P46743, DOI 10.1074/jbc.M207796200; Hattendorf DA, 2002, EMBO J, V21, P12, DOI 10.1093/emboj/21.1.12; Himmelreich R, 1996, NUCLEIC ACIDS RES, V24, P4420, DOI 10.1093/nar/24.22.4420; Karata K, 1999, J BIOL CHEM, V274, P26225, DOI 10.1074/jbc.274.37.26225; Kim KI, 2000, J MOL BIOL, V303, P655, DOI 10.1006/jmbi.2000.4165; Kim YI, 2001, NAT STRUCT BIOL, V8, P230, DOI 10.1038/84967; Krzewska J, 2001, FEBS LETT, V489, P92, DOI 10.1016/S0014-5793(00)02423-6; Laufen T, 1999, P NATL ACAD SCI USA, V96, P5452, DOI 10.1073/pnas.96.10.5452; Li JZ, 2002, J MOL BIOL, V318, P1127, DOI 10.1016/S0022-2836(02)00188-2; Lo JH, 2001, PROTEIN SCI, V10, P551, DOI 10.1110/ps.41401; Meyer HH, 2000, EMBO J, V19, P2181, DOI 10.1093/emboj/19.10.2181; Mogk A, 1999, EMBO J, V18, P6934, DOI 10.1093/emboj/18.24.6934; Motohashi K, 1999, P NATL ACAD SCI USA, V96, P7184, DOI 10.1073/pnas.96.13.7184; Neuwald AF, 1999, GENOME RES, V9, P27; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Ogura T, 2001, GENES CELLS, V6, P575, DOI 10.1046/j.1365-2443.2001.00447.x; PARK JH, 1988, J BACTERIOL, V170, P921, DOI 10.1128/jb.170.2.921-926.1988; PARSELL DA, 1994, J BIOL CHEM, V269, P4480; Rouiller I, 2000, MOL CELL, V6, P1485, DOI 10.1016/S1097-2765(00)00144-1; Schirmer EC, 1996, TRENDS BIOCHEM SCI, V21, P289, DOI 10.1016/0968-0004(96)10038-4; Schirmer EC, 1998, J BIOL CHEM, V273, P15546, DOI 10.1074/jbc.273.25.15546; Schlee S, 2001, J MOL BIOL, V306, P889, DOI 10.1006/jmbi.2001.4455; Schmid FX, 1991, CURR OPIN STRUC BIOL, V1, P36, DOI 10.1016/0959-440X(91)90008-H; SEOL JH, 1995, J BIOL CHEM, V270, P8087, DOI 10.1074/jbc.270.14.8087; Shevchenko A, 1996, ANAL CHEM, V68, P850, DOI 10.1021/ac950914h; SINGH SK, 1994, J BIOL CHEM, V269, P29537; Singh SK, 2001, J BIOL CHEM, V276, P29420, DOI 10.1074/jbc.M103489200; Smith CK, 1999, P NATL ACAD SCI USA, V96, P6678, DOI 10.1073/pnas.96.12.6678; Sousa MC, 2000, CELL, V103, P633, DOI 10.1016/S0092-8674(00)00166-5; Tek V, 2002, PROTEIN SCI, V11, P1192, DOI 10.1110/ps.4860102; Tomoyasu T, 2001, MOL MICROBIOL, V40, P397, DOI 10.1046/j.1365-2958.2001.02383.x; Watanabe YH, 2002, J BIOL CHEM, V277, P5804, DOI 10.1074/jbc.M109349200; Wilm M, 1996, NATURE, V379, P466, DOI 10.1038/379466a0; WOO KM, 1992, J BIOL CHEM, V267, P20429; Zolkiewski M, 1999, J BIOL CHEM, V274, P28083, DOI 10.1074/jbc.274.40.28083; Zolkiewski M, 1999, PROTEIN SCI, V8, P1899, DOI 10.1110/ps.8.9.1899	47	205	207	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 16	2003	278	20					17615	17624		10.1074/jbc.M209686200	http://dx.doi.org/10.1074/jbc.M209686200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677YX	12624113	hybrid			2022-12-25	WOS:000182838300007
J	Garnovskaya, MN; Mukhin, YV; Vlasova, TM; Raymond, JR				Garnovskaya, MN; Mukhin, YV; Vlasova, TM; Raymond, JR			Hypertonicity activates Na+/H+ exchange through Janus kinase 2 and calmodulin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INSULIN-STIMULATED PHOSPHORYLATION; CELL-VOLUME REGULATION; ASCITES TUMOR-CELLS; PROTEIN-KINASE; TYROSINE PHOSPHORYLATION; 5-HT1A RECEPTOR; GROWTH-FACTOR; ISOFORM-1 NHE1; OSMOTIC SHOCK; H+ EXCHANGER	The type 1 sodium-hydrogen exchanger (NHE-1) is a ubiquitous electroneutral membrane transporter that is activated by hypertonicity in many cells. NHE-1 may be an important pathway for Na+ entry during volume restoration, yet the molecular mechanisms underlying the osmotic regulation of NHE-1 are poorly understood. In the present study we conducted a screen for important signaling molecules that could be involved in hypertonicity-induced activation of NHE-1 in CHO-K1 cells. Hypertonicity rapidly activated NHE-1 in a concentration-dependent manner as assessed by proton microphysiometry and by measurements of intracellular pH on a FLIPR(TM) (fluorometric imaging plate reader). Inhibitors of Ca2+/calmodulin (CaM) and Janus kinase 2 (Jak2) attenuated this activation, whereas neither calcium chelation nor inhibitors of protein kinase C, the Ras-ERK1/2 pathway, Src kinase, and Ca2+/calmodulin-dependent enzymes had significant effects. Hypertonicity also resulted in the rapid tyrosine phosphorylation of Jak2 and STAT3 (the major substrate of Jak2) and CaM. Phosphorylation of Jak2 and CaM were blocked by AG490, an inhibitor of Jak2. Immunoprecipitation studies showed that hypertonicity stimulates the assembly of a signaling complex that includes CaM, Jak2, and NHE-1. Formation of the complex could be blocked by AG490. Thus, we propose that hypertonicity induces activation of NHE-1 in CHO-K1 cells in large part through the following pathway: hypertonicity 3 Jak2 phosphorylation and activation 3 tyrosine phosphorylation of CaM 3 association of CaM with NHE-1 --> NHE-1 activation.	Med Univ S Carolina, Dept Med, Div Nephrol, Charleston, SC 29425 USA; Ralph H Johnson Vet Affairs Med Ctr, Med Serv, Charleston, SC 29425 USA; Ralph H Johnson Vet Affairs Med Ctr, Res Serv, Charleston, SC 29425 USA	Medical University of South Carolina; US Department of Veterans Affairs; Veterans Health Administration (VHA); Ralph H Johnson VA Medical Center; US Department of Veterans Affairs; Veterans Health Administration (VHA); Ralph H Johnson VA Medical Center	Garnovskaya, MN (corresponding author), Med Univ S Carolina, Dept Med, Div Nephrol, 96 Jonathan Lucas St,Rm 829 CSB,POB 250623, Charleston, SC 29425 USA.			Garnovskaya, Maria/0000-0002-6216-038X	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK052448, K01DK002694, R56DK052448] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK52448, KO1-DK02694] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Abe J, 1999, J BIOL CHEM, V274, P21003, DOI 10.1074/jbc.274.30.21003; Aharonovitz O, 1996, J BIOL CHEM, V271, P16494, DOI 10.1074/jbc.271.28.16494; Benaim G, 1998, COMP BIOCHEM PHYS C, V120, P57, DOI 10.1016/S0742-8413(98)00006-1; BERTRAND B, 1994, J BIOL CHEM, V269, P13703; BIANCHINI L, 1995, AM J PHYSIOL-CELL PH, V269, pC998, DOI 10.1152/ajpcell.1995.269.4.C998; Bianchini L, 1997, J BIOL CHEM, V272, P271; BORON WF, 1977, AM J PHYSIOL, V233, pC61, DOI 10.1152/ajpcell.1977.233.3.C61; Bouaboula M, 1999, FEBS LETT, V449, P61, DOI 10.1016/S0014-5793(99)00395-6; BUSCH S, 1995, J BIOL CHEM, V270, P17898, DOI 10.1074/jbc.270.30.17898; Corti C, 1999, EUR J BIOCHEM, V262, P790, DOI 10.1046/j.1432-1327.1999.00441.x; DeFrutos T, 1997, BIOL CHEM, V378, P31, DOI 10.1515/bchm.1997.378.1.31; FUKAMI Y, 1986, P NATL ACAD SCI USA, V83, P4190, DOI 10.1073/pnas.83.12.4190; Garnovskaya MN, 1996, BIOCHEMISTRY-US, V35, P13716, DOI 10.1021/bi961764n; Garnovskaya MN, 1998, BIOCHEM J, V330, P489; Garnovskaya MN, 1997, J BIOL CHEM, V272, P7770, DOI 10.1074/jbc.272.12.7770; Gatsios P, 1998, J BIOL CHEM, V273, P22962, DOI 10.1074/jbc.273.36.22962; GRINSTEIN S, 1985, J GEN PHYSIOL, V85, P765, DOI 10.1085/jgp.85.5.765; GRINSTEIN S, 1992, J BIOL CHEM, V267, P23823; Joyal JL, 1996, BIOCHEMISTRY-US, V35, P6267, DOI 10.1021/bi9600198; Kapus A, 1999, J BIOL CHEM, V274, P8093, DOI 10.1074/jbc.274.12.8093; Krump E, 1997, J BIOL CHEM, V272, P17303, DOI 10.1074/jbc.272.28.17303; MATSUDA S, 1995, J BIOL CHEM, V270, P12781, DOI 10.1074/jbc.270.21.12781; MCCONNELL HM, 1992, SCIENCE, V257, P1906, DOI 10.1126/science.1329199; Mukhin YV, 2001, J BIOL CHEM, V276, P17339, DOI 10.1074/jbc.M010834200; Pedersen SF, 1996, J MEMBRANE BIOL, V149, P141, DOI 10.1007/s002329900015; Prpic V, 1998, AM J PHYSIOL-GASTR L, V275, pG689, DOI 10.1152/ajpgi.1998.275.4.G689; Putney LK, 2002, ANNU REV PHARMACOL, V42, P527, DOI 10.1146/annurev.pharmtox.42.092001.143801; SACKS DB, 1989, BIOCHEM J, V263, P803, DOI 10.1042/bj2630803; SACKS DB, 1992, BIOCHEM BIOPH RES CO, V188, P754, DOI 10.1016/0006-291X(92)91120-F; SACKS DB, 1992, BIOCHEM J, V286, P211, DOI 10.1042/bj2860211; Sacks DB, 1996, EUR J BIOCHEM, V239, P98, DOI 10.1111/j.1432-1033.1996.0098u.x; Sauvage M, 2000, EUR J BIOCHEM, V267, P955, DOI 10.1046/j.1432-1327.2000.01084.x; SAVILLE MK, 1994, BIOCHEM J, V299, P863, DOI 10.1042/bj2990863; Schroeder K.S., 1996, J BIOMOL SCREEN, V1, P75, DOI DOI 10.1177/108705719600100205; Shrode LD, 1997, AM J PHYSIOL-CELL PH, V272, pC1968, DOI 10.1152/ajpcell.1997.272.6.C1968; SHRODE LD, 1995, AM J PHYSIOL-CELL PH, V269, pC257, DOI 10.1152/ajpcell.1995.269.1.C257; Snabaitis AK, 2000, CIRC RES, V86, P214, DOI 10.1161/01.RES.86.2.214; Szaszi K, 1997, J BIOL CHEM, V272, P16670, DOI 10.1074/jbc.272.26.16670; Takahashi E, 1999, J BIOL CHEM, V274, P20206, DOI 10.1074/jbc.274.29.20206; THOMAS JA, 1979, BIOCHEMISTRY-US, V18, P2210, DOI 10.1021/bi00578a012; Voyno-Yasenetskaya TA, 1998, BIOL SIGNAL RECEPT, V7, P118; Wakabayashi S, 1997, PHYSIOL REV, V77, P51, DOI 10.1152/physrev.1997.77.1.51; WAKABAYASHI S, 1994, J BIOL CHEM, V269, P13710; WAKABAYASHI S, 1994, J BIOL CHEM, V269, P5583; Yan WH, 2001, J BIOL CHEM, V276, P31349, DOI 10.1074/jbc.M102679200	45	57	59	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 9	2003	278	19					16908	16915		10.1074/jbc.M209883200	http://dx.doi.org/10.1074/jbc.M209883200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677QG	12626508	hybrid			2022-12-25	WOS:000182818600063
J	Hirano, Y; Murata, S; Tanaka, K; Shimizu, M; Sato, R				Hirano, Y; Murata, S; Tanaka, K; Shimizu, M; Sato, R			Sterol regulatory element-binding proteins are negatively regulated through SUMO-1 modification independent of the ubiquitin/26 S proteasome pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COVALENT MODIFICATION; TRANSCRIPTION FACTOR; CONJUGATING ENZYME; P53 ACTIVITY; GENE; CLEAVAGE; PML; ACTIVATION; ATTACHMENT; MEMBRANES	Sterol regulatory element-binding proteins (SREBPs) are major transcription factors that activate the genes involved in cholesterol and fatty acid biosynthesis. We here report that the nuclear forms of SREBPs are modified by the small ubiquitin-related modifier (SUMO)-1. Mutational analyses identified two major sumoylation sites (Lys(123) and Lys(418)) in SREBP-1a and a single site (Lys(464)) in SREBP-2. Mutant SREBPs lacking one or two sumoylation sites exhibited increased transactivation capacity on an SREBP-responsive promoter. Overexpression of SUMO-1 reduced whereas its dominant negative form increased mRNA levels of SREBP-responsive genes. Nuclear SREBPs interacted with the SUMO-1-conjugating enzyme Ubc9, and overexpression of a dominant negative form of Ubc9 increased the mRNA levels of SREBP-responsive genes. Pulse-chase experiments revealed that sumoylation did not affect the degradation of SREBPs through the ubiquitin-proteasome pathway. In vitro ubiquitylation assay showed no competition between ubiquitin and SUMO-1 for the same lysine. Considered together, our results indicate that SUMO-1 modification suppresses the transactivation capacity of nuclear SREBPs in a manner different from the negative regulatory mechanism mediated by proteolysis.	Univ Tokyo, Dept Appl Biol Chem, Grad Sch Agr & Life Sci, Tokyo 1138657, Japan; Tokyo Metropolitan Inst Med Sci, Dept Mol Oncol, Tokyo 1138613, Japan	University of Tokyo; Tokyo Metropolitan Institute of Medical Science	Sato, R (corresponding author), Univ Tokyo, Dept Appl Biol Chem, Grad Sch Agr & Life Sci, Tokyo 1138657, Japan.	aroysato@mail.ecc.u-tokyo.ac.jp	Murata, Shigeo/A-1426-2010	Murata, Shigeo/0000-0002-3177-3503				Bernier-Villamor V, 2002, CELL, V108, P345, DOI 10.1016/S0092-8674(02)00630-X; Bies J, 2002, J BIOL CHEM, V277, P8999, DOI 10.1074/jbc.M110453200; Brown MS, 1999, P NATL ACAD SCI USA, V96, P11041, DOI 10.1073/pnas.96.20.11041; Desterro JMP, 1998, MOL CELL, V2, P233, DOI 10.1016/S1097-2765(00)80133-1; Desterro JMP, 1997, FEBS LETT, V417, P297, DOI 10.1016/S0014-5793(97)01305-7; Espenshade PJ, 1999, J BIOL CHEM, V274, P22795, DOI 10.1074/jbc.274.32.22795; Fogal V, 2000, EMBO J, V19, P6185, DOI 10.1093/emboj/19.22.6185; Gong LM, 1997, J BIOL CHEM, V272, P28198, DOI 10.1074/jbc.272.45.28198; Goodson ML, 2001, J BIOL CHEM, V276, P18513, DOI 10.1074/jbc.M008066200; Hirano Y, 2001, J BIOL CHEM, V276, P36431, DOI 10.1074/jbc.M105200200; Hochstrasser M, 2001, CELL, V107, P5, DOI 10.1016/S0092-8674(01)00519-0; Hoege C, 2002, NATURE, V419, P135, DOI 10.1038/nature00991; Hong YL, 2001, J BIOL CHEM, V276, P40263, DOI 10.1074/jbc.M104714200; Hua XX, 1996, CELL, V87, P415, DOI 10.1016/S0092-8674(00)81362-8; Iniguez-Lluhi JA, 2000, MOL CELL BIOL, V20, P6040, DOI 10.1128/MCB.20.16.6040-6050.2000; Inoue J, 1998, J BIOCHEM-TOKYO, V123, P1191; Inoue J, 2001, BIOCHEM BIOPH RES CO, V283, P1157, DOI 10.1006/bbrc.2001.4915; Jin CW, 2001, INT J BIOL MACROMOL, V28, P227, DOI 10.1016/S0141-8130(00)00169-0; Johnson ES, 1997, J BIOL CHEM, V272, P26799, DOI 10.1074/jbc.272.43.26799; Johnson ES, 1997, EMBO J, V16, P5509, DOI 10.1093/emboj/16.18.5509; Kamitani T, 1997, J BIOL CHEM, V272, P14001, DOI 10.1074/jbc.272.22.14001; Kim J, 2002, J BIOL CHEM, V277, P38037, DOI 10.1074/jbc.M207235200; Kim KI, 2002, J CELL PHYSIOL, V191, P257, DOI 10.1002/jcp.10100; Kirsh O, 2002, EMBO J, V21, P2682, DOI 10.1093/emboj/21.11.2682; Le Drean Y, 2002, ENDOCRINOLOGY, V143, P3482, DOI 10.1210/en.2002-220135; Mahajan R, 1997, CELL, V88, P97, DOI 10.1016/S0092-8674(00)81862-0; Mattsson K, 2001, P NATL ACAD SCI USA, V98, P1012, DOI 10.1073/pnas.031566998; Minty A, 2000, J BIOL CHEM, V275, P36316, DOI 10.1074/jbc.M004293200; Muller S, 2000, J BIOL CHEM, V275, P13321, DOI 10.1074/jbc.275.18.13321; Muller S, 2001, NAT REV MOL CELL BIO, V2, P202, DOI 10.1038/35056591; Murata S, 2001, EMBO REP, V2, P1133, DOI 10.1093/embo-reports/kve246; Nagoshi E, 1999, MOL BIOL CELL, V10, P2221, DOI 10.1091/mbc.10.7.2221; Nakahara M, 2002, J BIOL CHEM, V277, P37229, DOI 10.1074/jbc.M206749200; Osborne TF, 2000, J BIOL CHEM, V275, P32379, DOI 10.1074/jbc.R000017200; Poukka H, 2000, P NATL ACAD SCI USA, V97, P14145, DOI 10.1073/pnas.97.26.14145; Rawson RB, 1997, MOL CELL, V1, P47, DOI 10.1016/S1097-2765(00)80006-4; Saitoh H, 1997, TRENDS BIOCHEM SCI, V22, P374, DOI 10.1016/S0968-0004(97)01102-X; Sakai J, 1996, CELL, V85, P1037, DOI 10.1016/S0092-8674(00)81304-5; Sampson DA, 2001, J BIOL CHEM, V276, P21664, DOI 10.1074/jbc.M100006200; Sato R, 1999, J BIOL CHEM, V274, P24714, DOI 10.1074/jbc.274.35.24714; Sato R, 2000, J BIOL CHEM, V275, P12497, DOI 10.1074/jbc.275.17.12497; Sato R, 1996, J BIOL CHEM, V271, P26461, DOI 10.1074/jbc.271.43.26461; SATO R, 1994, J BIOL CHEM, V269, P17267; Schwienhorst I, 2000, MOL GEN GENET, V263, P771, DOI 10.1007/s004380000254; Seeler JS, 2001, MOL CELL BIOL, V21, P3314, DOI 10.1128/MCB.21.10.3314-3324.2001; Sternsdorf T, 1997, J CELL BIOL, V139, P1621, DOI 10.1083/jcb.139.7.1621; Tatham MH, 2001, J BIOL CHEM, V276, P35368, DOI 10.1074/jbc.M104214200; Varshavsky A, 1997, TRENDS BIOCHEM SCI, V22, P383, DOI 10.1016/S0968-0004(97)01122-5; WANG XD, 1994, CELL, V77, P53, DOI 10.1016/0092-8674(94)90234-8; Yeh ETH, 2000, GENE, V248, P1, DOI 10.1016/S0378-1119(00)00139-6; Zhong S, 2000, BLOOD, V95, P2748, DOI 10.1182/blood.V95.9.2748.009k31a_2748_2752	51	89	93	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 9	2003	278	19					16809	16819		10.1074/jbc.M212448200	http://dx.doi.org/10.1074/jbc.M212448200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677QG	12615929	hybrid			2022-12-25	WOS:000182818600050
J	Hou, YL; Lascola, J; Dulin, NO; Ye, RD; Browning, DD				Hou, YL; Lascola, J; Dulin, NO; Ye, RD; Browning, DD			Activation of cGMP-dependent protein kinase by protein kinase C	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLIC-GMP; NITRIC-OXIDE; SMOOTH-MUSCLE; AUTOPHOSPHORYLATION SITE; FUNCTIONAL-ANALYSIS; PHOSPHORYLATION; RECEPTOR; SIGNAL; AUTOINHIBITION; PROLIFERATION	The cGMP-dependent protein kinases (PKG) are emerging as important components of mainstream signal transduction pathways. Nitric oxide-induced cGMP formation by stimulation of soluble guanylate cyclase is generally accepted as being the most widespread mechanism underlying PKG activation. In the present study, PKG was found to be a target for phorbol 12-myristate 13-acetate (PMA)-responsive protein kinase C (PKC). PKG1alpha became phosphorylated in HEK-293 cells stimulated with PMA and also in vitro using purified components. PKC-dependent phosphorylation was found to activate PKG as measured by phosphorylation of vasodilator-stimulated phosphoprotein, and by in vitro kinase assays. Although there are 11 potential PKC substrate recognition sites in PKG1alpha, threonine 58 was examined due to its proximity to the pseudosubstrate domain. Antibodies generated against the phosphorylated form of this region were used to demonstrate phosphorylation in response to PMA treatment of the cells with kinetics similar to vasodilator-stimulated phosphoprotein phosphorylation. A phospho-mimetic mutation at this site (T58E) generated a partially activated PKG that was more sensitive to cGMP levels. A phospho-null mutation (T58A) revealed that this residue is important but not sufficient for PKG activation by PKC. Taken together, these findings outline a novel signal transduction pathway that links PKC stimulation with cyclic nucleotide-independent activation of PKG.	Med Coll Georgia, Dept Biochem, Augusta, GA 30912 USA; Univ Chicago, Pulm & Crit Care Med Sect, Chicago, IL 60637 USA; Univ Illinois, Dept Pharmacol, Chicago, IL 60612 USA	University System of Georgia; Augusta University; University of Chicago; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Browning, DD (corresponding author), Med Coll Georgia, Dept Biochem, CB2510,1120 15th St, Augusta, GA 30912 USA.	dbrowning@mail.mcg.edu	Ye, Richard/ABF-2413-2020; Ye, Richard/O-5223-2016	Ye, Richard/0000-0002-2164-5620; Ye, Richard/0000-0002-2164-5620; Browning, Darren/0000-0003-0497-7620				AITKEN A, 1984, BIOCHIM BIOPHYS ACTA, V790, P219, DOI 10.1016/0167-4838(84)90025-6; Browning DD, 1999, J BIOL CHEM, V274, P537, DOI 10.1074/jbc.274.1.537; Browning DD, 2001, J BIOL CHEM, V276, P13039, DOI 10.1074/jbc.M009187200; Browning DD, 2000, J BIOL CHEM, V275, P2811, DOI 10.1074/jbc.275.4.2811; Chu DM, 1998, J BIOL CHEM, V273, P14649, DOI 10.1074/jbc.273.23.14649; Davis A, 2003, CELL SIGNAL, V15, P597, DOI 10.1016/S0898-6568(02)00148-1; Dempsey EC, 2000, AM J PHYSIOL-LUNG C, V279, pL429, DOI 10.1152/ajplung.2000.279.3.L429; FELBEL J, 1988, J BIOL CHEM, V263, P16764; Fischer TA, 2001, J BIOL CHEM, V276, P5967, DOI 10.1074/jbc.M009781200; FOSTER JL, 1981, J BIOL CHEM, V256, P5029; Francis S H, 1988, Second Messengers Phosphoproteins, V12, P301; Francis SH, 1999, CRIT REV CL LAB SCI, V36, P275, DOI 10.1080/10408369991239213; Francis SH, 2002, FRONT BIOSCI-LANDMRK, V7, pD580, DOI 10.2741/francis; Francis SH, 1996, J BIOL CHEM, V271, P20748, DOI 10.1074/jbc.271.34.20748; Francis SH, 1998, METHODS, V14, P81, DOI 10.1006/meth.1997.0567; GAMM DM, 1995, J BIOL CHEM, V270, P27380, DOI 10.1074/jbc.270.45.27380; GLASS DB, 1983, J BIOL CHEM, V258, P4797; Hofmann F, 2000, J CELL SCI, V113, P1671; HOFMANN F, 1985, EUR J BIOCHEM, V147, P361, DOI 10.1111/j.1432-1033.1985.tb08758.x; Hood J, 1998, J BIOL CHEM, V273, P23504, DOI 10.1074/jbc.273.36.23504; Komalavilas P, 1999, J BIOL CHEM, V274, P34301, DOI 10.1074/jbc.274.48.34301; KOMALAVILAS P, 1994, J BIOL CHEM, V269, P8701; LANDGRAF W, 1986, EUR J BIOCHEM, V154, P113, DOI 10.1111/j.1432-1033.1986.tb09365.x; Lincoln TM, 2001, J APPL PHYSIOL, V91, P1421, DOI 10.1152/jappl.2001.91.3.1421; Lincoln TM, 1996, METHOD ENZYMOL, V269, P149; MACKENZIE CW, 1982, J BIOL CHEM, V257, P5589; Mochly-Rosen D, 1998, FASEB J, V12, P35; Orstavik S, 1997, GENOMICS, V42, P311, DOI 10.1006/geno.1997.4743; Parenti A, 1998, J BIOL CHEM, V273, P4220, DOI 10.1074/jbc.273.7.4220; PRYZWANSKY KB, 1995, BLOOD, V85, P222, DOI 10.1182/blood.V85.1.222.bloodjournal851222; Ruth P, 1999, PHARMACOL THERAPEUT, V82, P355, DOI 10.1016/S0163-7258(98)00067-9; Schlossmann J, 2000, NATURE, V404, P197, DOI 10.1038/35004606; Silberbach M, 1999, J BIOL CHEM, V274, P24858, DOI 10.1074/jbc.274.35.24858; Silberbach M, 2001, CELL SIGNAL, V13, P221, DOI 10.1016/S0898-6568(01)00139-5; Smith JA, 1996, J BIOL CHEM, V271, P20756, DOI 10.1074/jbc.271.34.20756; Smolenski A, 1998, N-S ARCH PHARMACOL, V358, P134, DOI 10.1007/PL00005234; Smolenski A, 1998, J BIOL CHEM, V273, P20029, DOI 10.1074/jbc.273.32.20029; TAKIO K, 1983, J BIOL CHEM, V258, P5531; Taylor MK, 2002, J BIOL CHEM, V277, P37242, DOI 10.1074/jbc.M202060200; Vandecasteele G, 2001, J PHYSIOL-LONDON, V533, P329, DOI 10.1111/j.1469-7793.2001.0329a.x; WYATT TA, 1991, J BIOL CHEM, V266, P21274; Yao X, 2000, FASEB J, V14, P932, DOI 10.1096/fasebj.14.7.932	42	27	27	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 9	2003	278	19					16706	16712		10.1074/jbc.M300045200	http://dx.doi.org/10.1074/jbc.M300045200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677QG	12609995	hybrid			2022-12-25	WOS:000182818600035
J	Liu, G; Xia, T; Chen, XB				Liu, G; Xia, T; Chen, XB			The activation domains, the proline-rich domain, and the C-terminal basic domain in p53 are necessary for acetylation of histones on the proximal p21 promoter and interaction with p300/CREB-binding protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CREB-BINDING PROTEIN; CELL-CYCLE ARREST; TUMOR-SUPPRESSOR; TRANSCRIPTIONAL REGULATION; COLORECTAL-CANCER; DNA-BINDING; GENE; APOPTOSIS; RECRUITMENT; COACTIVATORS	The p53 transcription factor contains two separate tandem activation domains (AD1 and AD2), a proline-rich domain (PRD), and a C-terminal basic domain (BD). Previously, we have shown that these domains are necessary for transcriptional activity. To further characterize the role of these domains in transactivation, we analyzed the regulation of p21, a well characterized p53 target gene, by various p53 mutants deficient in one or more of these domains. We found that the induction of endogenous p21 is compromised by AD1-deficient p53 (p53(AD1(-))), AD2-deficient p53 (p53(AD2(-))), both AD1- and AD2-deficient p53 (p53(AD1(-) AD2(-))), p53(DeltaPRD), which lacks PRD, and p53(DeltaBD), which lacks BD. However, p53(AD2(-)), p53(DeltaPRD), and p53(DeltaBD) are still capable of activating exogenous p21 promoter to an extent comparable with that by wild-type p53. Thus, we performed chromatin immunoprecipitation assay to measure the DNA binding ability of various p53 mutants in vivo. We found that like wild-type p53, these p53 mutants are capable of binding to the p53 response elements in the p21 promoter. In contrast, we found that the extent of acetylated histones on the p21 promoter, especially the proximal promoter, and the amount of interaction with p300/CREB-binding protein, which contain histone acetyltransferase activity, directly correlate with the activity of p53 to induce endogenous p21. Furthermore, we showed that down-regulation of p300/CBP by short interference RNA markedly decreases the ability of p53 to induce endogenous p21. These data lead us to hypothesize that when p53 binds to the responsive element(s) of a target gene, its ability to interact with histone acetyltransferase-containing proteins and subsequently the acetylation of histones bound to the proximal promoter dictate the induction level of a target gene.	Univ Alabama, Dept Cell Biol, Birmingham, AL 35294 USA	University of Alabama System; University of Alabama Birmingham	Chen, XB (corresponding author), MCLM 660,1530 3rd Ave S, Birmingham, AL 35294 USA.			Liu, Gang/0000-0003-2615-131X; , Gang/0000-0002-6999-7633	NATIONAL CANCER INSTITUTE [R01CA081237, R01CA076069, R29CA076069] Funding Source: NIH RePORTER; NCI NIH HHS [CA81237, CA76069] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ahn J, 2001, NAT STRUCT BIOL, V8, P730, DOI 10.1038/nsb0901-730; Avantaggiati ML, 1997, CELL, V89, P1175, DOI 10.1016/S0092-8674(00)80304-9; Ayed A, 2001, NAT STRUCT BIOL, V8, P756, DOI 10.1038/nsb0901-756; Barlev NA, 2001, MOL CELL, V8, P1243, DOI 10.1016/S1097-2765(01)00414-2; Chen XB, 1999, MOL MED TODAY, V5, P387, DOI 10.1016/S1357-4310(99)01545-2; Cheung P, 2000, CELL, V103, P263, DOI 10.1016/S0092-8674(00)00118-5; Chinery R, 1997, NAT MED, V3, P1233, DOI 10.1038/nm1197-1233; Cosma MP, 2002, MOL CELL, V10, P227, DOI 10.1016/S1097-2765(02)00604-4; Dickman S, 1997, SCIENCE, V277, P1605, DOI 10.1126/science.277.5332.1605; Dohn M, 2001, ONCOGENE, V20, P6503, DOI 10.1038/sj.onc.1204816; Dohn M, 2001, ONCOGENE, V20, P3193, DOI 10.1038/sj.onc.1204427; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Emerson BM, 2002, CELL, V109, P267, DOI 10.1016/S0092-8674(02)00740-7; Espinosa JM, 2001, MOL CELL, V8, P57, DOI 10.1016/S1097-2765(01)00283-0; Featherstone M, 2002, CURR OPIN GENET DEV, V12, P149, DOI 10.1016/S0959-437X(02)00280-0; Gu W, 1997, NATURE, V387, P819, DOI 10.1038/42972; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; HOLLSTEIN M, 1994, NUCLEIC ACIDS RES, V22, P3551; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; Ito A, 2001, EMBO J, V20, P1331, DOI 10.1093/emboj/20.6.1331; Kadam S, 2002, CURR OPIN CELL BIOL, V14, P262, DOI 10.1016/S0955-0674(02)00330-7; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Lill NL, 1997, NATURE, V387, P823, DOI 10.1038/42981; Liu G, 2002, ONCOGENE, V21, P7195, DOI 10.1038/sj.onc.1205862; Liu L, 1999, MOL CELL BIOL, V19, P1202; LOBO SM, 1989, CELL, V58, P55, DOI 10.1016/0092-8674(89)90402-9; MIYASHITA T, 1995, CELL, V80, P293; Nakano K, 2001, MOL CELL, V7, P683, DOI 10.1016/S1097-2765(01)00214-3; Nozell S, 2002, ONCOGENE, V21, P1285, DOI 10.1038/sj.onc.1205191; Sakaguchi K, 1998, GENE DEV, V12, P2831, DOI 10.1101/gad.12.18.2831; Scolnick DM, 1997, CANCER RES, V57, P3693; Vo N, 2001, J BIOL CHEM, V276, P13505, DOI 10.1074/jbc.R000025200; VOGELSTEIN B, 1992, CELL, V70, P523, DOI 10.1016/0092-8674(92)90421-8; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Woychik NA, 2002, CELL, V108, P453, DOI 10.1016/S0092-8674(02)00646-3; Yu J, 2001, MOL CELL, V7, P673, DOI 10.1016/S1097-2765(01)00213-1; Zhu JH, 2000, MOL CELL BIOL, V20, P5602, DOI 10.1128/MCB.20.15.5602-5618.2000; Zhu JH, 1998, J BIOL CHEM, V273, P13030, DOI 10.1074/jbc.273.21.13030; Zhu JH, 2000, J BIOL CHEM, V275, P39927, DOI 10.1074/jbc.M005676200; Zhu JH, 1999, ONCOGENE, V18, P2149, DOI 10.1038/sj.onc.1202533; Zhu KC, 1999, ONCOGENE, V18, P7740, DOI 10.1038/sj.onc.1203235	43	93	93	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 9	2003	278	19					17557	17565		10.1074/jbc.M210696200	http://dx.doi.org/10.1074/jbc.M210696200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677QG	12609999	hybrid			2022-12-25	WOS:000182818600145
J	Pattingre, S; Bauvy, C; Codogno, P				Pattingre, S; Bauvy, C; Codogno, P			Amino acids interfere with the ERK1/2-dependent control of macroautophagy by controlling the activation of Raf-1 in human colon cancer HT-29 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CONTROLS AUTOPHAGIC SEQUESTRATION; ALPHA-INTERACTING PROTEIN; ISOLATED RAT HEPATOCYTES; EPIDERMAL GROWTH-FACTOR; OKADAIC ACID; KINASE ACTIVATION; PHOSPHATASE 2A; IN-VIVO; PHOSPHORYLATION; INHIBITION	Activation of ERK1/2 stimulates macroautophagy in the human colon cancer cell line HT-29 by favoring the phosphorylation of the Galpha-interacting protein (GAIP) in an amino acid-dependent manner (Ogier-Denis, E., Pattingre, S., El Benna, J., and Codogno, P. (2000) J. Biol. Chem. 275, 39090-39095). Here we show that ERK1/2 activation by aurintricarboxylic acid (ATA) treatment induces the phosphorylation of GAIP in an amino acid-dependent manner. Accordingly, ATA challenge increased the rate of macroautophagy, whereas epidermal growth factor did not significantly affect macroautophagy and GAIP phosphorylation status. In fact, ATA activated the ERK1/2 signaling pathway, whereas epidermal growth factor stimulated both the ERK1/2 pathway and the class I phosphoinositide 3-kinase pathway, known to decrease the rate of macroautophagy. Amino acids interfered with the ATA-induced macroautophagy by inhibiting the activation of the kinase Raf-1. The role of the Ras/Raf-1/ERK1/2 signaling pathway in the GAIP- and amino acid-dependent control of macroautophagy was confirmed in HT-29 cells expressing the Ras(G12V, T35S) mutant. Similar to the protein phosphatase 2A inhibitor okadaic acid, amino acids sustained the phosphorylation of Ser(259), which is involved in the negative regulation of Raf-1. In conclusion, these results add a novel target to the amino acid signaling-dependent control of macroautophagy in intestinal cells.	INSERM, U504, F-94807 Villejuif, France	Institut National de la Sante et de la Recherche Medicale (Inserm)	Codogno, P (corresponding author), INSERM, U504, 16 Ave Paul Vaillant Couturier, F-94807 Villejuif, France.		Codogno, Patrice/G-1384-2013	Codogno, Patrice/0000-0002-5492-3180; Ogier-Denis, Eric/0000-0002-0057-7593; Pattingre, Sophie/0000-0001-6284-6050				Abraham D, 2000, J BIOL CHEM, V275, P22300, DOI 10.1074/jbc.M003259200; Arico S, 2001, J BIOL CHEM, V276, P35243, DOI 10.1074/jbc.C100319200; Avruch J, 2001, RECENT PROG HORM RES, V56, P127, DOI 10.1210/rp.56.1.127; Balendran A, 1999, J BIOL CHEM, V274, P37400, DOI 10.1074/jbc.274.52.37400; BALLARD FJ, 1985, EXP CELL RES, V157, P172, DOI 10.1016/0014-4827(85)90160-0; BLANKSON H, 1995, EXP CELL RES, V218, P522, DOI 10.1006/excr.1995.1187; BLOMMAART EFC, 1995, J BIOL CHEM, V270, P2320, DOI 10.1074/jbc.270.5.2320; Bursch W, 2001, CELL DEATH DIFFER, V8, P569, DOI 10.1038/sj.cdd.4400852; De Vries L, 2000, ANNU REV PHARMACOL, V40, P235, DOI 10.1146/annurev.pharmtox.40.1.235; Deng XM, 2000, P NATL ACAD SCI USA, V97, P1578, DOI 10.1073/pnas.97.4.1578; Dhillon AS, 2002, EMBO J, V21, P64, DOI 10.1093/emboj/21.1.64; Dunn William A. Jr., 1994, Trends in Cell Biology, V4, P139, DOI 10.1016/0962-8924(94)90069-8; Favre B, 1997, J BIOL CHEM, V272, P13856, DOI 10.1074/jbc.272.21.13856; Franch HA, 2002, J AM SOC NEPHROL, V13, DOI 10.1681/ASN.V134903; Franch HA, 2001, J BIOL CHEM, V276, P19126, DOI 10.1074/jbc.M101777200; Hariri M, 2000, MOL BIOL CELL, V11, P255, DOI 10.1091/mbc.11.1.255; Haussinger D, 1999, GASTROENTEROLOGY, V116, P921, DOI 10.1016/S0016-5085(99)70076-4; HOLEN I, 1992, BIOCHEM J, V284, P633, DOI 10.1042/bj2840633; HOLEN I, 1993, EUR J BIOCHEM, V215, P113, DOI 10.1111/j.1432-1033.1993.tb18013.x; Holm TM, 2002, BLOOD, V99, P1817, DOI 10.1182/blood.V99.5.1817; HOURI JJ, 1993, BIOCHEM BIOPH RES CO, V197, P805, DOI 10.1006/bbrc.1993.2550; HOURI JJ, 1995, BIOCHEM J, V309, P521, DOI 10.1042/bj3090521; Janssen KP, 2002, GASTROENTEROLOGY, V123, P492, DOI 10.1053/gast.2002.34786; KauffmanZeh A, 1997, NATURE, V385, P544, DOI 10.1038/385544a0; Kihara A, 2001, J CELL BIOL, V152, P519, DOI 10.1083/jcb.152.3.519; Klionsky DJ, 2000, SCIENCE, V290, P1717, DOI 10.1126/science.290.5497.1717; Klionsky DT, 1999, ANNU REV CELL DEV BI, V15, P1, DOI 10.1146/annurev.cellbio.15.1.1; Liang XH, 1999, NATURE, V402, P672, DOI 10.1038/45257; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; Mortimore G. E., 1994, CELLULAR PROTEOLYTIC, P65; Munafo DB, 2002, TRAFFIC, V3, P472, DOI 10.1034/j.1600-0854.2002.30704.x; Ogier-Denis E, 2003, BBA-REV CANCER, V1603, P113, DOI 10.1016/S0304-419X(03)00004-0; Ogier-Denis E, 2000, J BIOL CHEM, V275, P39090, DOI 10.1074/jbc.M006198200; OgierDenis E, 1997, J BIOL CHEM, V272, P24599, DOI 10.1074/jbc.272.39.24599; OgierDenis E, 1996, J BIOL CHEM, V271, P28593, DOI 10.1074/jbc.271.45.28593; OGIERDENIS E, 1995, J BIOL CHEM, V270, P13, DOI 10.1074/jbc.270.1.13; Ohsumi Y, 2001, NAT REV MOL CELL BIO, V2, P211, DOI 10.1038/35056522; OKADA N, 1995, J BIOL CHEM, V270, P16464, DOI 10.1074/jbc.270.27.16464; Peterson RT, 1999, P NATL ACAD SCI USA, V96, P4438, DOI 10.1073/pnas.96.8.4438; Petiot A, 1999, BIOCHEM J, V337, P289, DOI 10.1042/0264-6021:3370289; Petiot A, 2000, J BIOL CHEM, V275, P992, DOI 10.1074/jbc.275.2.992; RodriguezViciana P, 1997, CELL, V89, P457, DOI 10.1016/S0092-8674(00)80226-3; Rui H, 1998, J BIOL CHEM, V273, P28, DOI 10.1074/jbc.273.1.28; Sebolt-Leopold JS, 1999, NAT MED, V5, P810, DOI 10.1038/10533; SEGLEN PO, 1982, P NATL ACAD SCI-BIOL, V79, P1889, DOI 10.1073/pnas.79.6.1889; SEGLEN PO, 1992, EXPERIENTIA, V48, P158, DOI 10.1007/BF01923509; Tanaka Y, 2000, NATURE, V406, P902, DOI 10.1038/35022595; Taupin D, 1999, GASTROENTEROLOGY, V116, P1072, DOI 10.1016/S0016-5085(99)70010-7; Thumm M, 2000, MICROSC RES TECHNIQ, V51, P563, DOI 10.1002/1097-0029(20001215)51:6<563::AID-JEMT6>3.0.CO;2-8; van Sluijters DA, 2000, BIOCHEM J, V351, P545, DOI 10.1042/0264-6021:3510545; Vanhaesebroeck B, 2000, BIOCHEM J, V346, P561, DOI 10.1042/0264-6021:3460561; Waguri S, 1999, ARCH HISTOL CYTOL, V62, P423, DOI 10.1679/aohc.62.423; White MA, 1996, J BIOL CHEM, V271, P16439, DOI 10.1074/jbc.271.28.16439; Wurmser AE, 2002, J CELL BIOL, V158, P761, DOI 10.1083/jcb.200112050; Zimmermann S, 1999, SCIENCE, V286, P1741, DOI 10.1126/science.286.5445.1741	56	232	251	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 9	2003	278	19					16667	16674		10.1074/jbc.M210998200	http://dx.doi.org/10.1074/jbc.M210998200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677QG	12609989	hybrid			2022-12-25	WOS:000182818600030
J	Kovalenko, D; Yang, XH; Nadeau, RJ; Harkins, LK; Friesel, R				Kovalenko, D; Yang, XH; Nadeau, RJ; Harkins, LK; Friesel, R			Sef inhibits fibroblast growth factor signaling by inhibiting FGFR1 tyrosine phosphorylation and subsequent ERK activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR RECEPTORS; INDUCED ANTAGONIST; KINASE PATHWAY; IN-VIVO; PROTEINS; BINDING; GENE; EMBRYOGENESIS; ADENOVIRUS; EXPRESSION	Signaling through fibroblast growth factor receptors (FGFRs) is essential for many cellular processes including proliferation and migration as well as differentiation events such as angiogenesis, osteogenesis, and chondrogenesis. Recently, genetic screens in Drosophila and gene expression screens in zebrafish have resulted in the identification of several feedback inhibitors of FGF signaling. One of these, Sef (similar expression to fgf genes), encodes a transmembrane protein that belongs to the FGF synexpression group. Here we show that like zebrafish Sef (zSef), mouse Sef (mSef) interacts with FGFR1 and that the cytoplasmic domain of mSef mediates this interaction. Overexpression of mSef in NIH3T3 cells results in a decrease in FGF-induced cell proliferation associated with a decrease in Tyr phosphorylation of FGFR1 and FRS2. As a consequence, there is a reduction in the phosphorylation of Raf-1 at Ser(338), MEK1/2 at Ser(217) and Ser(221), and ERK1/2 at Thr(202) and Tyr(204). Furthermore, mSef inhibits ERK activation mediated by a constitutively activated FGFR1 but not by a constitutively active Ras and decreases FGF but not PDGF-mediated activation of Akt. These results indicate that Sef exerts its inhibitory effects at the level of FGFR and upstream of Ras providing an additional level of negative regulation of FGF signaling.	Maine Med Ctr, Inst Res, Ctr Mol Med, Scarborough, ME 04074 USA; Univ Maine, Cooperat Grad Program Mol Genet & Cell Biol, Orono, ME 04469 USA	Maine Medical Center; University of Maine System; University of Maine Orono	Friesel, R (corresponding author), Maine Med Ctr, Inst Res, Ctr Mol Med, 81 Res Dr, Scarborough, ME 04074 USA.				NCRR NIH HHS [RR15555] Funding Source: Medline; NHLBI NIH HHS [HL65301] Funding Source: Medline; NIDCR NIH HHS [DE13248] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR015555] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL065301] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE013248] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		BURGESS WH, 1990, MOL CELL BIOL, V10, P4770, DOI 10.1128/MCB.10.9.4770; Chong LD, 2000, MOL CELL BIOL, V20, P724, DOI 10.1128/MCB.20.2.724-734.2000; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; Fasbender A, 1997, J BIOL CHEM, V272, P6479, DOI 10.1074/jbc.272.10.6479; Friesel R, 1999, THROMB HAEMOSTASIS, V82, P748; FRIESEL R, 1989, MOL CELL BIOL, V9, P1857, DOI 10.1128/MCB.9.5.1857; Furthauer M, 2002, NAT CELL BIOL, V4, P170, DOI 10.1038/ncb750; Furthauer M, 2001, DEVELOPMENT, V128, P2175; Gross I, 2001, J BIOL CHEM, V276, P46460, DOI 10.1074/jbc.M108234200; Hacohen N, 1998, CELL, V92, P253, DOI 10.1016/S0092-8674(00)80919-8; Hardy S, 1997, J VIROL, V71, P1842, DOI 10.1128/JVI.71.3.1842-1849.1997; Impagnatiello MA, 2001, J CELL BIOL, V152, P1087, DOI 10.1083/jcb.152.5.1087; Kouhara H, 1997, CELL, V89, P693, DOI 10.1016/S0092-8674(00)80252-4; Kudoh T, 2001, GENOME RES, V11, P1979, DOI 10.1101/gr.209601; LaVallee TM, 1998, J CELL BIOL, V141, P1647, DOI 10.1083/jcb.141.7.1647; Lin W, 2002, MECH DEVELOP, V113, P163, DOI 10.1016/S0925-4773(02)00018-7; Minowada G, 1999, DEVELOPMENT, V126, P4465; Mood K, 2002, J BIOL CHEM, V277, P33196, DOI 10.1074/jbc.M203894200; Naski M.C., 1998, FRONT BIOSCI-LANDMRK, V3, pd781, DOI [10.2741/a321, DOI 10.2741/A321]; Neilson KM, 1996, J BIOL CHEM, V271, P25049, DOI 10.1074/jbc.271.40.25049; Ong SH, 2001, P NATL ACAD SCI USA, V98, P6074, DOI 10.1073/pnas.111114298; Ong SH, 2000, MOL CELL BIOL, V20, P979, DOI 10.1128/MCB.20.3.979-989.2000; Ornitz DM, 2002, GENE DEV, V16, P1446, DOI 10.1101/gad.990702; ORNITZ DM, 2001, GENOME BIOL; PRUDOVSKY I, 1994, J BIOL CHEM, V269, P31720; Prudovsky IA, 1996, J BIOL CHEM, V271, P14198, DOI 10.1074/jbc.271.24.14198; Tsang M, 2002, NAT CELL BIOL, V4, P165, DOI 10.1038/ncb749; Yusoff P, 2002, J BIOL CHEM, V277, P3195, DOI 10.1074/jbc.M108368200	28	125	133	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 18	2003	278	16					14087	14091		10.1074/jbc.C200606200	http://dx.doi.org/10.1074/jbc.C200606200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	670JV	12604616	hybrid			2022-12-25	WOS:000182405000069
J	Schuster, B; Kovaleva, M; Sun, Y; Regenhard, P; Matthews, V; Grotzinger, J; Rose-John, S; Kallen, KJ				Schuster, B; Kovaleva, M; Sun, Y; Regenhard, P; Matthews, V; Grotzinger, J; Rose-John, S; Kallen, KJ			Signaling of human ciliary neurotrophic factor (CNTF) revisited - The interleukin-6 receptor can serve as an alpha-receptor for CNTF	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LEUKEMIA INHIBITORY FACTOR; AMYOTROPHIC-LATERAL-SCLEROSIS; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; MYELIN OLIGODENDROCYTE GLYCOPROTEIN; IL-6-DEFICIENT MICE; FACTOR PREVENTS; ONCOSTATIN-M; REGIONAL DISTRIBUTION; HUNTINGTONS-DISEASE; NULL MUTATION	Human ciliary neurotrophic factor (CNTF) is a neurotrophic cytokine that exerts a neuroprotective effect in multiple sclerosis and amyotrophic lateral sclerosis. Clinical application of human CNTF, however, was prevented by high toxicity at higher dosages. Human CNTF elicits cellular responses by induction of a receptor complex consisting of the CNTF alpha-receptor (CNTFR), which is not involved in signal transduction, and the beta-receptors gp130 and leukemia inhibitory factor receptor (LIFR). Previous studies with rat CNTF demonstrated that rat CNTF is unable to interact with the human interleukin-6 alpha-receptor, whereas at high concentrations, it can directly induce a signaling heterodinter of human gp130 and human LIFR in the absence of the CNTF receptor. Here, we demonstrate that human CNTF cannot directly induce a heterodimer of human gp130 and LIFR. However, human CNTF can use both the membrane-bound and the soluble human IL-6R as a substitute for its cognate alpha-receptor and thus widen the target spectrum of human CNTF. Engineering a CNTFR-specific human CNTF variant may therefore be a prerequisite to improving the safety profile of CNTF.	Univ Kiel, Biochem Inst, D-24098 Kiel, Germany; Zhejiang Univ, Coll Life Sci, Hangzhou 310027, Peoples R China	University of Kiel; Zhejiang University	Kallen, KJ (corresponding author), Univ Kiel, Biochem Inst, Olshaussenstr 40, D-24098 Kiel, Germany.		Schuster, Bjorn/G-6339-2014; Kovaleva, Marina/A-3402-2014; Rose-John, Stefan/A-7998-2010	Kovaleva, Marina/0000-0002-3907-1776; Rose-John, Stefan/0000-0002-7519-3279				Aasland D, 2002, J MOL BIOL, V315, P637, DOI 10.1006/jmbi.2001.5282; Alexander WS, 1999, CURR BIOL, V9, P605, DOI 10.1016/S0960-9822(99)80266-8; ANAND P, 1995, NAT MED, V1, P168, DOI 10.1038/nm0295-168; Anderson KD, 1996, P NATL ACAD SCI USA, V93, P7346, DOI 10.1073/pnas.93.14.7346; Atreya R, 2000, NAT MED, V6, P583, DOI 10.1038/75068; BAUMANN H, 1993, J BIOL CHEM, V268, P8414; CARSON M, 1991, J APPL CRYSTALLOGR, V24, P946; CHEN GC, 1977, ANAL LETT, V10, P1195, DOI 10.1080/00032717708067855; Chong NHV, 1999, INVEST OPHTH VIS SCI, V40, P1298; CLATTERBUCK RE, 1993, P NATL ACAD SCI USA, V90, P2222, DOI 10.1073/pnas.90.6.2222; DAVIS S, 1993, SCIENCE, V260, P1805, DOI 10.1126/science.8390097; DAVIS S, 1993, SCIENCE, V259, P1736, DOI 10.1126/science.7681218; de Almeida LP, 2001, NEUROBIOL DIS, V8, P433, DOI 10.1006/nbdi.2001.0388; DECHIARA TM, 1995, CELL, V83, P313, DOI 10.1016/0092-8674(95)90172-8; Elson GCA, 1998, J IMMUNOL, V161, P1371; Elson GCA, 2000, NAT NEUROSCI, V3, P867, DOI 10.1038/78765; Emerich DF, 1997, NATURE, V386, P395, DOI 10.1038/386395a0; Eugster HP, 1998, EUR J IMMUNOL, V28, P2178, DOI 10.1002/(SICI)1521-4141(199807)28:07<2178::AID-IMMU2178>3.0.CO;2-D; GEARING DP, 1994, P NATL ACAD SCI USA, V91, P1119, DOI 10.1073/pnas.91.3.1119; Giess R, 2002, AM J HUM GENET, V70, P1277, DOI 10.1086/340427; Giess R, 2002, ARCH NEUROL-CHICAGO, V59, P407, DOI 10.1001/archneur.59.3.407; Gloaguen I, 1997, P NATL ACAD SCI USA, V94, P6456, DOI 10.1073/pnas.94.12.6456; Grotzinger J, 1999, BIOL CHEM, V380, P803, DOI 10.1515/BC.1999.100; GRUTZINGER J, 1997, PROTEINS, V27, P96; Guillet C, 1999, J NEUROSCI, V19, P1257; Heinrich PC, 1998, BIOCHEM J, V334, P297, DOI 10.1042/bj3340297; HELGREN ME, 1994, CELL, V76, P493, DOI 10.1016/0092-8674(94)90113-9; HUGHES SM, 1988, NATURE, V335, P70, DOI 10.1038/335070a0; Hurst SM, 2001, IMMUNITY, V14, P705, DOI 10.1016/S1074-7613(01)00151-0; IP NY, 1991, J NEUROSCI, V11, P3124; JOSTOCK T, 1998, J IMMUNOL METHODS, V273, P173; Kallen KJ, 2002, BBA-MOL CELL RES, V1592, P323, DOI 10.1016/S0167-4889(02)00325-7; Kallen KJ, 1999, J BIOL CHEM, V274, P11859, DOI 10.1074/jbc.274.17.11859; Kalra SP, 2001, P NATL ACAD SCI USA, V98, P4279, DOI 10.1073/pnas.091101498; Lambert PD, 2001, P NATL ACAD SCI USA, V98, P4652, DOI 10.1073/pnas.061034298; LARKFORS L, 1994, EUR J NEUROSCI, V6, P1015, DOI 10.1111/j.1460-9568.1994.tb00596.x; LaVail MM, 1998, INVEST OPHTH VIS SCI, V39, P592; Lelievre E, 2001, J BIOL CHEM, V276, P22476, DOI 10.1074/jbc.M101681200; LIN LFH, 1989, SCIENCE, V246, P1023, DOI 10.1126/science.2587985; Linker RA, 2002, NAT MED, V8, P620, DOI 10.1038/nm0602-620; MASU Y, 1993, NATURE, V365, P27, DOI 10.1038/365027a0; MCDONALD NQ, 1995, EMBO J, V14, P2689, DOI 10.1002/j.1460-2075.1995.tb07269.x; Meazza C, 1997, NEUROIMMUNOMODULAT, V4, P271, DOI 10.1159/000097347; Mendel I, 1998, EUR J IMMUNOL, V28, P1727, DOI 10.1002/(SICI)1521-4141(199805)28:05<1727::AID-IMMU1727>3.0.CO;2-#; Miller RG, 1996, NEUROLOGY, V47, P1329, DOI 10.1212/WNL.47.5.1329; Miller RG, 1996, ANN NEUROL, V39, P256, DOI 10.1002/ana.410390215; Mosley B, 1996, J BIOL CHEM, V271, P32635, DOI 10.1074/jbc.271.51.32635; NESBITT JE, 1993, BIOCHEM BIOPH RES CO, V190, P544, DOI 10.1006/bbrc.1993.1082; Okuda Y, 1998, INT IMMUNOL, V10, P703, DOI 10.1093/intimm/10.5.703; OPPENHEIM RW, 1991, SCIENCE, V251, P1616, DOI 10.1126/science.2011743; Ozbek S, 1998, J BIOL CHEM, V273, P21374, DOI 10.1074/jbc.273.33.21374; PANAYOTATOS N, 1993, J BIOL CHEM, V268, P19000; Peterson WM, 2000, J NEUROSCI, V20, P4081; Plun-Favreau H, 2001, EMBO J, V20, P1692, DOI 10.1093/emboj/20.7.1692; Robak T, 1998, MEDIAT INFLAMM, V7, P347, DOI 10.1080/09629359890875; Robledo O, 1997, J BIOL CHEM, V272, P4855, DOI 10.1074/jbc.272.8.4855; ROSEJOHN S, 1994, BIOCHEM J, V300, P281, DOI 10.1042/bj3000281; Samoilova EB, 1998, J IMMUNOL, V161, P6480; SATO K, 1993, CANCER RES, V53, P851; SCHOOLTINK H, 1992, FEBS LETT, V314, P280, DOI 10.1016/0014-5793(92)81489-9; Senaldi G, 1999, P NATL ACAD SCI USA, V96, P11458, DOI 10.1073/pnas.96.20.11458; SENDTNER M, 1992, NATURE, V358, P502, DOI 10.1038/358502a0; Sendtner M, 1996, CURR BIOL, V6, P686, DOI 10.1016/S0960-9822(09)00450-3; SENDTNER M, 1990, NATURE, V345, P440, DOI 10.1038/345440a0; Shi Y, 1999, BIOCHEM BIOPH RES CO, V262, P132, DOI 10.1006/bbrc.1999.1181; Simon R, 1995, NEUROREPORT, V7, P153, DOI 10.1097/00001756-199512000-00037; STOCKLI KA, 1989, NATURE, V342, P920, DOI 10.1038/342920a0; STOCKLI KA, 1991, J CELL BIOL, V115, P447, DOI 10.1083/jcb.115.2.447; Taga T, 1997, ANNU REV IMMUNOL, V15, P797, DOI 10.1146/annurev.immunol.15.1.797; TAKAHASHI R, 1994, NAT GENET, V7, P79, DOI 10.1038/ng0594-79; van Gunsteren W, 1996, BIOMOLECULAR SIMULAT; VRIEND G, 1990, J MOL GRAPHICS, V8, P52, DOI 10.1016/0263-7855(90)80070-V; WEIERGRABER O, 1995, EUR J BIOCHEM, V234, P661, DOI 10.1111/j.1432-1033.1995.661_b.x	73	116	132	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 14	2003	278	11					9528	9535		10.1074/jbc.M210044200	http://dx.doi.org/10.1074/jbc.M210044200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	654YF	12643274	hybrid			2022-12-25	WOS:000181524000087
J	Qiang, YW; Endo, Y; Rubin, JS; Rudikoff, S				Qiang, YW; Endo, Y; Rubin, JS; Rudikoff, S			Wnt signaling in B-cell neoplasia	ONCOGENE			English	Article						Wnt; beta-catenin; myeloma; morphology; Rho	BETA-CATENIN; PROTEIN; RECEPTOR; RHO; PROLIFERATION; INTERLEUKIN-6; WINGLESS; MYELOMA; TRANSDUCTION; ACTIVATION	Wnts comprise a family of secreted proteins that interact with receptors consisting of a Frizzled (Fz) family member alone or complexed with LDL receptor-related proteins (LRP5/6). Wnt signaling plays a crucial role in both development and differentiation, and activation of a 'canonical' Writ pathway resulting in P-catenin stabilization is associated with several types of human cancers. To date, little is known about potential Wnt signaling in mature lymphocytes or lymphoid neoplasia. Herein, we have analysed Wnt signaling in mature B cells (lymphomas) and plasma cells (multiple myeloma). Both Fz and LRP5/6 mRNAs were expressed in myeloma lines, but LRP5/6 were not observed in lymphomas. In myelomas, a canonical Wnt signaling pathway was activated following treatment with Wnt-3a as assessed by accumulation of beta-catenin, but beta-catenin levels actually decreased in lymphoma cells. Wnt-3a treatment further led to striking morphological changes in myeloma cells accompanied by rearrangement of the actin cytoskeleton. Morphological changes were associated with a second Wnt pathway dependent on Rho activation. These results suggest that Writ responsiveness is a stage-specific phenomenon in B-cell development and that the morphological changes associated with Wnt signaling may play a role in the motility and metastatic potential of myeloma cells.	NCI, Cellular & Mol Biol Lab, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Rudikoff, S (corresponding author), NCI, Cellular & Mol Biol Lab, NIH, Bldg 37, Bethesda, MD 20892 USA.	Rudikoff@helix.nih.gov	Qiang, Ya-Wei/Q-2206-2019	Qiang, Ya-Wei/0000-0002-2479-1412	DIVISION OF BASIC SCIENCES - NCI [Z01BC005553] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [Z01BC010251, ZIABC010251] Funding Source: NIH RePORTER	DIVISION OF BASIC SCIENCES - NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BATAILLE R, 1992, HEMATOL ONCOL CLIN N, V6, P285, DOI 10.1016/S0889-8588(18)30345-9; BERGUI L, 1989, J EXP MED, V170, P613, DOI 10.1084/jem.170.2.613; Brandon C, 2000, BLOOD, V96, P4132, DOI 10.1182/blood.V96.13.4132.h8004132_4132_4141; Ferlin M, 2000, BRIT J HAEMATOL, V111, P626, DOI 10.1046/j.1365-2141.2000.02364.x; Ge NL, 2000, BLOOD, V96, P2856; Gong YQ, 2001, CELL, V107, P513, DOI 10.1016/S0092-8674(01)00571-2; Habas R, 2001, CELL, V107, P843, DOI 10.1016/S0092-8674(01)00614-6; HILBERT DM, 1995, J EXP MED, V182, P243, DOI 10.1084/jem.182.1.243; Ioannidis V, 2001, NAT IMMUNOL, V2, P691, DOI 10.1038/90623; Ishizaki T, 2000, MOL PHARMACOL, V57, P976; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; Lattanzio G, 1997, AM J PATHOL, V151, P689; Lee JS, 1999, J BIOL CHEM, V274, P21464, DOI 10.1074/jbc.274.30.21464; Little RD, 2002, AM J HUM GENET, V70, P11, DOI 10.1086/338450; LU ZY, 1995, BLOOD, V86, P3123; Mao BY, 2001, NATURE, V411, P321, DOI 10.1038/35077108; McWhirter JR, 1999, P NATL ACAD SCI USA, V96, P11464, DOI 10.1073/pnas.96.20.11464; Miller JR, 1999, ONCOGENE, V18, P7860, DOI 10.1038/sj.onc.1203245; Niesvizky R, 1997, CANCER INVEST, V15, P85, DOI 10.3109/07357909709018921; OOSTERWEGEL M, 1993, DEVELOPMENT, V118, P439; Peifer M, 2000, SCIENCE, V287, P1606, DOI 10.1126/science.287.5458.1606; Pinson KI, 2000, NATURE, V407, P535, DOI 10.1038/35035124; Polakis P, 2000, GENE DEV, V14, P1837; Qiang YW, 2002, BLOOD, V99, P4138, DOI 10.1182/blood.V99.11.4138; Ren XD, 1999, EMBO J, V18, P578, DOI 10.1093/emboj/18.3.578; Reya T, 2000, IMMUNITY, V13, P15, DOI 10.1016/S1074-7613(00)00004-2; Semenov MV, 2001, CURR BIOL, V11, P951, DOI 10.1016/S0960-9822(01)00290-1; Semenov MV, 1997, GENOMICS, V42, P302, DOI 10.1006/geno.1997.4713; Shibamoto S, 1998, GENES CELLS, V3, P659; Tamai K, 2000, NATURE, V407, P530, DOI 10.1038/35035117; Uren A, 2000, J BIOL CHEM, V275, P4374, DOI 10.1074/jbc.275.6.4374; vandeWetering M, 1996, MOL CELL BIOL, V16, P745; Wehrli M, 2000, NATURE, V407, P527, DOI 10.1038/35035110; Winter CG, 2001, CELL, V105, P81, DOI 10.1016/S0092-8674(01)00298-7; Wodarz A, 1998, ANNU REV CELL DEV BI, V14, P59, DOI 10.1146/annurev.cellbio.14.1.59; Yamane T, 2001, J IMMUNOL, V167, P765, DOI 10.4049/jimmunol.167.2.765; YANAGAWA SI, 1995, GENE DEV, V9, P1087, DOI 10.1101/gad.9.9.1087; ZHANG XG, 1994, BLOOD, V83, P3654; Zhurinsky J, 2000, J CELL SCI, V113, P3127	39	132	138	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 13	2003	22	10					1536	1545		10.1038/sj.onc.1206239	http://dx.doi.org/10.1038/sj.onc.1206239			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	652ZZ	12629517				2022-12-25	WOS:000181411900011
J	Gohda, J; Nomura, Y; Suzuki, H; Arai, H; Akiyama, T; Inoue, J				Gohda, J; Nomura, Y; Suzuki, H; Arai, H; Akiyama, T; Inoue, J			Elimination of the vertebrate Escherichia coli Ras-like protein homologue leads to cell cycle arrest at G1 phase and apoptosis	ONCOGENE			English	Article						apoptosis; KH domain; GTP-binding protein; RNA-binding protein	GTP-BINDING PROTEIN; 16S RIBOSOMAL-RNA; FRAGILE-X SYNDROME; STREPTOCOCCUS-PNEUMONIAE; CYTOCHROME-C; ERA GTPASE; KH DOMAIN; GENE; DISRUPTION; FAMILY	Homologues of the Escherichia coli (E. colt) Ras-like protein (ERA), a GTP-binding protein with RNA binding activity, have recently been found in various species, including human, mouse, and Antirrhinum majus. Depletion of prokaryotic ERA blocks cell division without affecting chromosome segregation. However, the physiological function of eukaryotic ERA is largely unknown. We have performed a genetic analysis of chicken ERA (GdERA) in DT40 cells. Depletion of GdERA diminished the growth rate of the cells, accompanied by an accumulation of apoptotic cells. The analysis of cell cycle indicates that the elimination of GdERA caused arrest at G1 phase, but not at M phase, which highlights the distinct role of vertebrate ERA in the cell cycle progression compared to prokaryotic ERA. Furthermore, human ERA (HsERA) rescued the phenotype of GdERA-deficient cells, whereas a mutant of HsERA deprived of RNA-binding activity did not. These data suggest that vertebrate ERA regulates the G1 phase progression via an as yet unknown molecular mechanism, which involves RNA recognition by ERA.	Univ Tokyo, Inst Med Sci, Dept Canc Biol, Div Cellular & Mol Biol,Minato Ku, Tokyo 1088639, Japan; Univ Tokyo, Grad Sch Pharmaceut Sci, Dept Hlth Chem, Bunkyo Ku, Tokyo 1130033, Japan	University of Tokyo; University of Tokyo	Inoue, J (corresponding author), Univ Tokyo, Inst Med Sci, Dept Canc Biol, Div Cellular & Mol Biol,Minato Ku, 4-6-1 Shirokanedai, Tokyo 1088639, Japan.			Akiyama, Taishin/0000-0002-0341-6154				Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; AHNN J, 1986, P NATL ACAD SCI USA, V83, P8849, DOI 10.1073/pnas.83.23.8849; Akiyama T, 2001, GENES CELLS, V6, P987, DOI 10.1046/j.1365-2443.2001.00480.x; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; Britton RA, 2000, GENOMICS, V67, P78, DOI 10.1006/geno.2000.6243; BUERSTEDDE JM, 1991, CELL, V67, P179, DOI 10.1016/0092-8674(91)90581-I; GOLLOP N, 1991, J BACTERIOL, V173, P2265, DOI 10.1128/JB.173.7.2265-2270.1991; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; HALL A, 1990, SCIENCE, V249, P635, DOI 10.1126/science.2116664; Hang JQ, 2001, EUR J BIOCHEM, V268, P5570, DOI 10.1046/j.1432-1033.2001.02493.x; INADA T, 1989, J BACTERIOL, V171, P5017, DOI 10.1128/jb.171.9.5017-5024.1989; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; Lahti JM, 1999, METHODS, V17, P305, DOI 10.1006/meth.1999.0744; LERNER CG, 1991, MOL MICROBIOL, V5, P951, DOI 10.1111/j.1365-2958.1991.tb00770.x; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Meier TI, 2000, MICROBIOL-UK, V146, P1071, DOI 10.1099/00221287-146-5-1071; Meier TI, 1999, J BACTERIOL, V181, P5242, DOI 10.1128/JB.181.17.5242-5249.1999; Musco G, 1996, CELL, V85, P237, DOI 10.1016/S0092-8674(00)81100-9; Sayed A, 1999, BIOCHEM BIOPH RES CO, V264, P51, DOI 10.1006/bbrc.1999.1471; SIMON MI, 1991, SCIENCE, V252, P802, DOI 10.1126/science.1902986; SIOMI H, 1994, CELL, V77, P33, DOI 10.1016/0092-8674(94)90232-1; Tsujimoto Y, 2000, FEBS LETT, V466, P6, DOI 10.1016/S0014-5793(99)01761-5; Wang J, 1996, GENE DEV, V10, P2588, DOI 10.1101/gad.10.20.2588; Winding P, 2001, J IMMUNOL METHODS, V249, P1, DOI 10.1016/S0022-1759(00)00333-1	25	13	15	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 6	2003	22	9					1340	1348		10.1038/sj.onc.1206287	http://dx.doi.org/10.1038/sj.onc.1206287			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	652CA	12618759				2022-12-25	WOS:000181360900008
J	Ostrovsky, O; Bengal, E				Ostrovsky, O; Bengal, E			The mitogen-activated protein kinase cascade promotes myoblast cell survival by stabilizing the cyclin-dependent kinase inhibitor, p21(WAF1) protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SKELETAL-MUSCLE DIFFERENTIATION; DISTINCT SIGNALING PATHWAYS; MEK-ERK PATHWAY; MYOGENIC DIFFERENTIATION; MAP KINASE; MYOCYTE DIFFERENTIATION; CANCER CELLS; RAS; PROLIFERATION; P21(CIP1)	During myogenesis, proliferating myoblasts withdraw from the cell cycle and are either eliminated by programmed cell death or differentiate into mature myotubes. Previous studies indicate that mitogen-activated protein kinase ( MAPK) activity is significantly induced with the onset of terminal differentiation of C2 myoblasts. We have investigated the part played by the MAPK pathway in the differentiation of C2 myoblasts. Specific activation of MAPK by expression of an active Raf1-estrogen receptor chimera protein reduced significantly the number of myoblasts undergoing programmed cell death in the differentiation medium. Activation of Raf1 prevented the proteolytic activation of the proapoptotic caspase 9-protein during differentiation. The antiapoptotic function of Raf1 correlated with accumulation of the p21(WAF1) protein resulting from its increased stability. Antisense expression of p21 was used to determine whether the p21(WAF1) protein mediated the antiapoptotic activity of Raf1. Reduction of p21(WAF1) protein in muscle cells abolished the antiapoptotic activity of the MAPK pathway. We conclude that MAPK contributes to muscle differentiation by preventing apoptotic cell death of differentiating myoblasts and that this activity is mediated by stabilization of the p21(WAF1) protein.	Technion Israel Inst Technol, Fac Med, Dept Biochem, Rappaport Inst Res Med Sci, IL-31096 Haifa, Israel	Technion Israel Institute of Technology; Rappaport Faculty of Medicine	Bengal, E (corresponding author), Technion Israel Inst Technol, Fac Med, Dept Biochem, Rappaport Inst Res Med Sci, POB 9649, IL-31096 Haifa, Israel.							Ballif BA, 2001, CELL GROWTH DIFFER, V12, P397; Bao WJ, 2002, MOL CELL BIOL, V22, P4587, DOI 10.1128/MCB.22.13.4587-4597.2002; Bergmann A, 1998, CELL, V95, P331, DOI 10.1016/S0092-8674(00)81765-1; Bonni A, 1999, SCIENCE, V286, P1358, DOI 10.1126/science.286.5443.1358; Coolican SA, 1997, J BIOL CHEM, V272, P6653, DOI 10.1074/jbc.272.10.6653; Crespo P, 2000, CELL MOL LIFE SCI, V57, P1613, DOI 10.1007/PL00000645; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; DAVIS RL, 1990, CELL, V60, P733, DOI 10.1016/0092-8674(90)90088-V; DEL PL, 1997, SCIENCE, V278, P687; Erhardt P, 1999, MOL CELL BIOL, V19, P5308; Fujio Y, 1999, MOL CELL BIOL, V19, P5073; Gauld SB, 2002, J IMMUNOL, V168, P3855, DOI 10.4049/jimmunol.168.8.3855; Gredinger E, 1998, J BIOL CHEM, V273, P10436, DOI 10.1074/jbc.273.17.10436; Haining WN, 1999, P NATL ACAD SCI USA, V96, P4936, DOI 10.1073/pnas.96.9.4936; HALEVY O, 1995, SCIENCE, V267, P1018, DOI 10.1126/science.7863327; HOLLENBERG SM, 1993, P NATL ACAD SCI USA, V90, P8028, DOI 10.1073/pnas.90.17.8028; Jones NC, 2001, J CELL PHYSIOL, V186, P104, DOI 10.1002/1097-4652(200101)186:1<104::AID-JCP1015>3.0.CO;2-0; Kim GY, 2002, J BIOL CHEM, V277, P29792, DOI 10.1074/jbc.M201299200; Kurada P, 1998, CELL, V95, P319, DOI 10.1016/S0092-8674(00)81764-X; Lawlor MA, 2000, MOL CELL BIOL, V20, P8983, DOI 10.1128/MCB.20.23.8983-8995.2000; Lawlor MA, 2000, J CELL BIOL, V151, P1131, DOI 10.1083/jcb.151.6.1131; Lawlor MA, 2000, MOL CELL BIOL, V20, P3256, DOI 10.1128/MCB.20.9.3256-3265.2000; Li Y, 2002, J BIOL CHEM, V277, P11352, DOI 10.1074/jbc.M109062200; Liu Y, 1996, CANCER RES, V56, P31; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; McMahon M, 2001, METHOD ENZYMOL, V332, P401; Naviaux RK, 1996, J VIROL, V70, P5701, DOI 10.1128/JVI.70.8.5701-5705.1996; Nunez G, 1998, ONCOGENE, V17, P3237, DOI 10.1038/sj.onc.1202581; Park JS, 2000, MOL BIOL CELL, V11, P2915, DOI 10.1091/mbc.11.9.2915; Ramocki MB, 1997, MOL CELL BIOL, V17, P3547, DOI 10.1128/MCB.17.7.3547; Ravi RK, 1998, J CLIN INVEST, V101, P153, DOI 10.1172/JCI831; Ravi RK, 1999, J CELL BIOCHEM, V72, P458, DOI 10.1002/(SICI)1097-4644(19990315)72:4<458::AID-JCB2>3.0.CO;2-C; Rommel C, 1999, SCIENCE, V286, P1738, DOI 10.1126/science.286.5445.1738; Samuel DS, 1999, HORM METAB RES, V31, P55, DOI 10.1055/s-2007-978699; Sarbassov DD, 1997, MOL ENDOCRINOL, V11, P2038, DOI 10.1210/me.11.13.2038; Sarbassov DD, 1998, MOL ENDOCRINOL, V12, P1870, DOI 10.1210/me.12.12.1870; Sheaff RJ, 2000, MOL CELL, V5, P403, DOI 10.1016/S1097-2765(00)80435-9; Sheng HM, 2001, J BIOL CHEM, V276, P14498, DOI 10.1074/jbc.M010093200; SKAPEK SX, 1995, SCIENCE, V267, P1022, DOI 10.1126/science.7863328; Stefanovsky VY, 2001, MOL CELL, V8, P1063, DOI 10.1016/S1097-2765(01)00384-7; Stewart CEH, 1996, J BIOL CHEM, V271, P11330, DOI 10.1074/jbc.271.19.11330; Tashker JS, 2002, MOL BIOL CELL, V13, P393, DOI 10.1091/mbc.01-06-0291; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Tombes RM, 1998, BIOCHEM J, V330, P1451; Tortorella LL, 2001, J BIOL CHEM, V276, P13709, DOI 10.1074/jbc.M100091200; Tureckova J, 2001, J BIOL CHEM, V276, P39264, DOI 10.1074/jbc.M104991200; Verhagen AM, 2002, APOPTOSIS, V7, P163, DOI 10.1023/A:1014318615955; Walsh K, 1997, CURR OPIN GENET DEV, V7, P597, DOI 10.1016/S0959-437X(97)80005-6; Walsh K, 1997, Prog Cell Cycle Res, V3, P53; Wang J, 1996, SCIENCE, V273, P359, DOI 10.1126/science.273.5273.359; Wang J, 1997, CANCER RES, V57, P351; Wang PH, 1998, BIOCHEM BIOPH RES CO, V245, P912, DOI 10.1006/bbrc.1998.8540; Weyman CM, 1998, ENDOCRINOLOGY, V139, P1794, DOI 10.1210/en.139.4.1794; Weyman CM, 1997, ONCOGENE, V14, P697, DOI 10.1038/sj.onc.1200874; Woods D, 1997, MOL CELL BIOL, V17, P5598, DOI 10.1128/MCB.17.9.5598; Wu ZG, 2000, MOL CELL BIOL, V20, P3951, DOI 10.1128/MCB.20.11.3951-3964.2000; Xu Q, 2000, J BIOL CHEM, V275, P36750, DOI 10.1074/jbc.M005030200; YAFFE D, 1977, NATURE, V270, P725, DOI 10.1038/270725a0; Zacksenhaus E, 1996, GENE DEV, V10, P3051, DOI 10.1101/gad.10.23.3051; Zetser A, 2001, DEV BIOL, V240, P168, DOI 10.1006/dbio.2001.0465; Zhang PM, 1999, GENE DEV, V13, P213, DOI 10.1101/gad.13.2.213	61	39	40	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 6	2003	278	23					21221	21231		10.1074/jbc.M211357200	http://dx.doi.org/10.1074/jbc.M211357200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	684WY	12637563	hybrid			2022-12-25	WOS:000183230500100
J	Pattingre, S; De Vries, L; Bauvy, C; Chantret, I; Cluzeaud, F; Ogier-Denis, E; Vandewalle, A; Codogno, P				Pattingre, S; De Vries, L; Bauvy, C; Chantret, I; Cluzeaud, F; Ogier-Denis, E; Vandewalle, A; Codogno, P			The g-protein regulator AGS3 controls an early event during macroautophagy in human intestinal HT-29 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CONTROLS AUTOPHAGIC SEQUESTRATION; ALPHA-INTERACTING PROTEIN; HETEROTRIMERIC G-PROTEIN; TETRATRICOPEPTIDE REPEAT; SUBCELLULAR-DISTRIBUTION; DISSOCIATION INHIBITOR; RAT HEPATOCYTES; GOLGI MEMBRANES; LINE HT-29; VACUOLES	AGS3 contains GoLoco or G-protein regulatory motifs in its COOH-terminal half that stabilize the GDP-bound conformation of the alpha-subunit of the trimeric G(i3) protein. The latter is part of a signaling pathway that controls the lysosomal-autophagic catabolism in human colon cancer HT-29 cells. In the present work we show that the mRNA encoding for AGS3 is expressed in human intestinal cell lines (Caco-2 and HT-29) whatever their state of differentiation. Together with the full-length form, minute amounts of the mRNA encoding a NH2-terminal truncated form of AGS3, previously characterized in cardiac tissues, were also detected. Both the endogenous form of AGS3 and a tagged expressed form have a localization compatible with a role in the Galpha(i3)-dependent control of autophagy. Accordingly, expressing its non-Galpha(i3)-interacting NH2-terminal domain or its Galpha(i3)-interacting COOH-terminal domain reversed the stimulatory role of AGS3 on autophagy. On the basis of biochemical and morphometric analysis, we conclude that AGS3 is involved in an early event during the autophagic pathway probably prior to the formation of the autophagosome. These data demonstrate that AGS3 is a novel partner of the Galpha(i3) protein in the control of a major catabolic pathway.	INSERM, U504, F-94807 Villejuif, France; Univ Calif San Diego, Dept Mol & Cellular Biol, La Jolla, CA 92093 USA; Univ Paris 07, INSERM, U478, F-75018 Paris, France	Institut National de la Sante et de la Recherche Medicale (Inserm); University of California System; University of California San Diego; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	Codogno, P (corresponding author), INSERM, U504, 16 Ave Paul Vaillant Couturier, F-94807 Villejuif, France.		Ogier-Denis, Eric/E-5030-2016; Codogno, Patrice/G-1384-2013; CHANTRET, Isabelle/AAF-7134-2021	Codogno, Patrice/0000-0002-5492-3180; CHANTRET, Isabelle/0000-0002-0896-1274; Pattingre, Sophie/0000-0001-6284-6050; Ogier-Denis, Eric/0000-0002-0057-7593				Anglade P, 1997, HISTOL HISTOPATHOL, V12, P25; Baba M, 1995, CELL STRUCT FUNCT, V20, P465, DOI 10.1247/csf.20.465; Ballif BA, 1996, P NATL ACAD SCI USA, V93, P5544, DOI 10.1073/pnas.93.11.5544; Berg TO, 1998, J BIOL CHEM, V273, P21883, DOI 10.1074/jbc.273.34.21883; Bernard ML, 2001, J BIOL CHEM, V276, P1585, DOI 10.1074/jbc.M005291200; BIEDERBICK A, 1995, EUR J CELL BIOL, V66, P3; Blatch GL, 1999, BIOESSAYS, V21, P932, DOI 10.1002/(SICI)1521-1878(199911)21:11<932::AID-BIES5>3.0.CO;2-N; Blumer JB, 2002, J BIOL CHEM, V277, P15897, DOI 10.1074/jbc.M112185200; Bursch W, 2000, ANN NY ACAD SCI, V926, P1, DOI 10.1111/j.1749-6632.2000.tb05594.x; De Vries L, 2000, ANNU REV PHARMACOL, V40, P235, DOI 10.1146/annurev.pharmtox.40.1.235; De Vries L, 2000, P NATL ACAD SCI USA, V97, P14364, DOI 10.1073/pnas.97.26.14364; Dorn BR, 2002, CELL MICROBIOL, V4, P1, DOI 10.1046/j.1462-5822.2002.00164.x; DUNN WA, 1990, J CELL BIOL, V110, P1923, DOI 10.1083/jcb.110.6.1923; Dunn William A. Jr., 1994, Trends in Cell Biology, V4, P139, DOI 10.1016/0962-8924(94)90069-8; FENGSRUD M, 1995, EXP CELL RES, V221, P504, DOI 10.1006/excr.1995.1402; Fengsrud M, 2000, EUR J CELL BIOL, V79, P871, DOI 10.1078/0171-9335-00125; GORDON PB, 1993, J BIOL CHEM, V268, P26107; Harano T, 2001, BIOCHEM J, V357, P157, DOI 10.1042/0264-6021:3570157; Hariri M, 2000, MOL BIOL CELL, V11, P255, DOI 10.1091/mbc.11.1.255; Holm TM, 2002, BLOOD, V99, P1817, DOI 10.1182/blood.V99.5.1817; HOURI JJ, 1995, BIOCHEM J, V309, P521, DOI 10.1042/bj3090521; Ishihara N, 2001, MOL BIOL CELL, V12, P3690, DOI 10.1091/mbc.12.11.3690; Kihara A, 2001, J CELL BIOL, V152, P519, DOI 10.1083/jcb.152.3.519; Kim J, 2000, ANNU REV BIOCHEM, V69, P303, DOI 10.1146/annurev.biochem.69.1.303; Kimple RJ, 2001, J BIOL CHEM, V276, P29275, DOI 10.1074/jbc.M103208200; Klionsky DJ, 2000, SCIENCE, V290, P1717, DOI 10.1126/science.290.5497.1717; Klionsky DT, 1999, ANNU REV CELL DEV BI, V15, P1, DOI 10.1146/annurev.cellbio.15.1.1; LAWRENCE BP, 1992, J CELL SCI, V102, P515; LESUFFLEUR T, 1991, INT J CANCER, V49, P721, DOI 10.1002/ijc.2910490516; LESUFFLEUR T, 1990, CANCER RES, V50, P6334; Liang XH, 1999, NATURE, V402, P672, DOI 10.1038/45257; Lin P, 1999, J CELL BIOL, V145, P279, DOI 10.1083/jcb.145.2.279; Liou W, 1997, J CELL BIOL, V136, P61, DOI 10.1083/jcb.136.1.61; Mortimore G. E., 1994, CELLULAR PROTEOLYTIC, P65; Munafo DB, 2002, TRAFFIC, V3, P472, DOI 10.1034/j.1600-0854.2002.30704.x; MURAYAMA T, 1983, J BIOL CHEM, V258, P3319; Natochin M, 2000, J BIOL CHEM, V275, P40981, DOI 10.1074/jbc.M006478200; Natochin M, 2001, BIOCHEMISTRY-US, V40, P5322, DOI 10.1021/bi015505w; Nishino I, 2000, NATURE, V406, P906, DOI 10.1038/35022604; NUOFFER C, 1994, ANNU REV BIOCHEM, V63, P949, DOI 10.1146/annurev.bi.63.070194.004505; Ogier-Denis E, 2000, J BIOL CHEM, V275, P39090, DOI 10.1074/jbc.M006198200; OgierDenis E, 1997, J BIOL CHEM, V272, P24599, DOI 10.1074/jbc.272.39.24599; OgierDenis E, 1996, J BIOL CHEM, V271, P28593, DOI 10.1074/jbc.271.45.28593; OGIERDENIS E, 1995, J BIOL CHEM, V270, P13, DOI 10.1074/jbc.270.1.13; Petersen A, 2001, HUM MOL GENET, V10, P1243, DOI 10.1093/hmg/10.12.1243; Peterson YK, 2000, J BIOL CHEM, V275, P33193, DOI 10.1074/jbc.C000509200; Petiot A, 1999, BIOCHEM J, V337, P289, DOI 10.1042/0264-6021:3370289; PINTO M, 1983, BIOL CELL, V47, P323; Pizzinat N, 2001, J BIOL CHEM, V276, P16601, DOI 10.1074/jbc.M007573200; SEGLEN PO, 1982, P NATL ACAD SCI-BIOL, V79, P1889, DOI 10.1073/pnas.79.6.1889; SEGLEN PO, 1992, EXPERIENTIA, V48, P158, DOI 10.1007/BF01923509; STOW JL, 1991, J CELL BIOL, V114, P1113, DOI 10.1083/jcb.114.6.1113; STROMHAUG PE, 1993, BIOCHEM J, V291, P115, DOI 10.1042/bj2910115; Suhy DA, 2000, J VIROL, V74, P8953, DOI 10.1128/JVI.74.19.8953-8965.2000; Sulzer D, 2000, P NATL ACAD SCI USA, V97, P11869, DOI 10.1073/pnas.97.22.11869; Takesono A, 1999, J BIOL CHEM, V274, P33202, DOI 10.1074/jbc.274.47.33202; Talloczy Z, 2002, P NATL ACAD SCI USA, V99, P190, DOI 10.1073/pnas.012485299; Tanaka Y, 2000, NATURE, V406, P902, DOI 10.1038/35022595; van Sluijters DA, 2000, BIOCHEM J, V351, P545, DOI 10.1042/0264-6021:3510545; Villard L, 2000, EUR J HUM GENET, V8, P125, DOI 10.1038/sj.ejhg.5200432; WEIBEL ER, 1969, J CELL BIOL, V42, P68, DOI 10.1083/jcb.42.1.68; Weiss TS, 2001, P NATL ACAD SCI USA, V98, P14961, DOI 10.1073/pnas.261572098; Wylie F, 1999, AM J PHYSIOL-CELL PH, V276, pC497, DOI 10.1152/ajpcell.1999.276.2.C497; YAMAMOTO A, 1990, J HISTOCHEM CYTOCHEM, V38, P573, DOI 10.1177/38.4.2319125	64	58	60	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 6	2003	278	23					20995	21002		10.1074/jbc.M300917200	http://dx.doi.org/10.1074/jbc.M300917200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	684WY	12642577	hybrid			2022-12-25	WOS:000183230500072
J	Qin, L; Qiu, P; Wang, LQ; Li, X; Swarthout, JT; Soteropoulos, P; Tolias, P; Partridge, NC				Qin, L; Qiu, P; Wang, LQ; Li, X; Swarthout, JT; Soteropoulos, P; Tolias, P; Partridge, NC			Gene expression profiles and transcription factors involved in parathyroid hormone signaling in osteoblasts revealed by microarray and bioinformatics	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; ENDOTHELIAL GROWTH-FACTOR; BINDING-PROTEIN; 1,25-DIHYDROXYVITAMIN D-3; BONE-RESORPTION; CELLS; DIFFERENTIATION; RECEPTOR; PROLIFERATION; STIMULATION	Parathyroid hormone (PTH) binds to its receptor PTH1R ( parathyroid hormone 1 receptor) in osteoblastic cells to regulate bone remodeling and calcium homeostasis. While prolonged exposure to PTH causes increased bone resorption, intermittent injections of PTH have an anabolic effect on bone. The molecular mechanisms regulating these processes are still largely unknown. Here, we present our results on gene expression profile changes in the PTH-treated osteoblastic cell line, UMR 106-01, using DNA microarray analysis. A total of 125 known genes and 30 unknown expressed sequence tags ( ESTs) were found to have at least 2-fold expression changes after PTH treatment at 4, 12, and 24 h. 14 genes were previously known to be PTH-regulated but many were unknown to be regulated by PTH prior to our experiments. Real-time reverse transcriptase-PCR confirmed that 90 and 50% of the genes are regulated more than 2-fold by PTH in UMR 106-01 and rat primary osteoblastic cells, respectively. Most genes belong to the following protein families: hormones, growth factors, and receptors; signal transduction pathway proteins; transcription factors; proteases; metabolic enzymes; structural and matrix proteins; transporters; etc. These results provide a comprehensive and deeper knowledge about PTH regulation of osteoblastic gene expression. Next, we designed a computational method to extract information about transcription factors likely involved in regulating these genes. These factors include those previously known to be involved in PTH signaling (AP-1 and the cAMP response element-binding protein), those that were identified by microarray data (C/EBP), and some novel transcription factors ( AP-2, AP-4, SP1, FoxD3, etc.). Our results suggest that a reliable bioinformatics approach can be easily applied for other systems.	Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Physiol & Biophys, Piscataway, NJ 08854 USA; Schering Plough Corp, Res Inst, Bioinformat Grp, Kenilworth, NJ 07033 USA; Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Microbiol & Mol Genet, Newark, NJ 07107 USA; Univ Med & Dent New Jersey, New Jersey Med Sch, Publ Hlth Res Inst, Ctr Appl Genom, Newark, NJ 07107 USA	Rutgers State University New Brunswick; Rutgers State University Medical Center; Merck & Company; Schering Plough Corporation; Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers State University New Brunswick; Rutgers State University Medical Center	Partridge, NC (corresponding author), Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Physiol & Biophys, 675 Hoes Lane, Piscataway, NJ 08854 USA.	partrinc@umdnj.edu	Qin, Ling/B-3147-2012	Swarthout, John/0000-0002-3043-9386; Partridge, Nicola/0000-0002-5406-4814	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK048109] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK48109] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ABASSI ZA, 1992, HYPERTENSION, V20, P89, DOI 10.1161/01.HYP.20.1.89; Ahmed N, 2000, CYTOKINE, V12, P289, DOI 10.1006/cyto.1999.0588; Bassi DE, 2000, MOL CARCINOGEN, V28, P63, DOI 10.1002/1098-2744(200006)28:2<63::AID-MC1>3.3.CO;2-3; Bhangu PS, 2001, BONE, V29, P16, DOI 10.1016/S8756-3282(01)00482-3; Black BL, 1998, ANNU REV CELL DEV BI, V14, P167, DOI 10.1146/annurev.cellbio.14.1.167; BRONDELLO JM, 1995, ONCOGENE, V10, P1895; BRUDER JM, 2001, ENDOCRINOL METAB, P1090; CHASE LR, 1970, J BIOL CHEM, V245, P1520; Chenu C, 1998, BONE, V22, P295, DOI 10.1016/S8756-3282(97)00295-0; CIVITELLI R, 1988, AM J PHYSIOL, V255, pE660, DOI 10.1152/ajpendo.1988.255.5.E660; Cole JA, 1999, ENDOCRINOLOGY, V140, P5771, DOI 10.1210/en.140.12.5771; Datta HK, 1996, J ENDOCRINOL, V149, P269, DOI 10.1677/joe.0.1490269; Deckers MML, 2000, ENDOCRINOLOGY, V141, P1667, DOI 10.1210/en.141.5.1667; DOBNIG H, 1995, ENDOCRINOLOGY, V136, P3632, DOI 10.1210/en.136.8.3632; Dottori M, 2001, DEVELOPMENT, V128, P4127; Farach-Carson MC, 2002, STEROIDS, V67, P467, DOI 10.1016/S0039-128X(01)00168-4; Feldman D, 1999, AM J MED, V107, P637, DOI 10.1016/S0002-9343(99)00283-1; FORREST SM, 1985, CALCIFIED TISSUE INT, V37, P51, DOI 10.1007/BF02557679; GARRETT IR, 1990, J CLIN INVEST, V85, P632, DOI 10.1172/JCI114485; Gutierrez S, 2002, J BIOL CHEM, V277, P1316, DOI 10.1074/jbc.M106611200; Horwood NJ, 1998, J CLIN INVEST, V101, P595, DOI 10.1172/JCI1333; HU YF, 1990, GENE DEV, V4, P1741, DOI 10.1101/gad.4.10.1741; Huang XQ, 1997, GENOMICS, V46, P37, DOI 10.1006/geno.1997.4984; Hurley MM, 1999, J BONE MINER RES, V14, P776, DOI 10.1359/jbmr.1999.14.5.776; JUPPNER H, 1991, SCIENCE, V254, P1024, DOI 10.1126/science.1658941; Kasperk CH, 1997, CALCIFIED TISSUE INT, V60, P368, DOI 10.1007/s002239900245; Kitten AM, 2001, J CELL PHYSIOL, V187, P218, DOI 10.1002/jcp.1072; Linkhart TA, 1996, BONE, V19, pS1, DOI 10.1016/S8756-3282(96)00138-X; NG KW, 1983, CALCIFIED TISSUE INT, V35, P624, DOI 10.1007/BF02405105; Oklu R, 2000, BIOCHEM J, V352, P601, DOI 10.1042/0264-6021:3520601; Onishi T, 1997, ENDOCRINOLOGY, V138, P1995, DOI 10.1210/en.138.5.1995; ONYIA JE, 1995, BONE, V17, P479, DOI 10.1016/8756-3282(95)00332-2; PARTRIDGE NC, 1980, FEBS LETT, V115, P139, DOI 10.1016/0014-5793(80)80744-7; PARTRIDGE NC, 1982, ENDOCRINOLOGY, V111, P178, DOI 10.1210/endo-111-1-178; PARTRIDGE NC, 1981, ENDOCRINOLOGY, V108, P213, DOI 10.1210/endo-108-1-213; Patton AJ, 1998, BONE, V22, P645, DOI 10.1016/S8756-3282(98)00061-1; Qiu P, 2002, MAMM GENOME, V13, P327, DOI 10.1007/s00335-001-2141-8; Raouf A, 2002, BONE, V30, P463, DOI 10.1016/S8756-3282(01)00699-8; Schiller PC, 1999, J BONE MINER RES, V14, P1504, DOI 10.1359/jbmr.1999.14.9.1504; Schlaeppi JM, 1997, ENDOCR RES, V23, P213, DOI 10.3109/07435809709031855; Schorle H, 1996, NATURE, V381, P235, DOI 10.1038/381235a0; Semler DE, 2000, CELL CALCIUM, V28, P55, DOI 10.1054/ceca.2000.0129; SHALHOUB V, 1989, BIOCHEMISTRY-US, V28, P5318, DOI 10.1021/bi00439a002; Swarthout JT, 2002, GENE, V282, P1, DOI 10.1016/S0378-1119(01)00798-3; Swarthout JT, 2002, J BONE MINER RES, V17, P1401, DOI 10.1359/jbmr.2002.17.8.1401; Swarthout JT, 2001, J BIOL CHEM, V276, P7586, DOI 10.1074/jbc.M007400200; Teitelbaum SL, 2000, SCIENCE, V289, P1504, DOI 10.1126/science.289.5484.1504; Tyson DR, 1999, ENDOCRINOLOGY, V140, P1255, DOI 10.1210/en.140.3.1255; Umayahara Y, 1999, J BIOL CHEM, V274, P10609, DOI 10.1074/jbc.274.15.10609; Vaes BLT, 2002, J BONE MINER RES, V17, P2106, DOI 10.1359/jbmr.2002.17.12.2106; VERHEIJEN MHG, 1995, ENDOCRINOLOGY, V136, P3331, DOI 10.1210/en.136.8.3331; Verheijen MHG, 1997, J BIOL CHEM, V272, P3423, DOI 10.1074/jbc.272.6.3423; Wang DS, 1997, ENDOCRINOLOGY, V138, P2953, DOI 10.1210/en.138.7.2953; Wang LQ, 2001, J BIOL CHEM, V276, P43604, DOI 10.1074/jbc.M106570200; Wingender E, 2000, NUCLEIC ACIDS RES, V28, P316, DOI 10.1093/nar/28.1.316	55	140	151	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 30	2003	278	22					19723	19731		10.1074/jbc.M212226200	http://dx.doi.org/10.1074/jbc.M212226200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	682EH	12644456	hybrid			2022-12-25	WOS:000183078000022
J	Hardie, RC; Martin, F; Chyb, S; Raghu, P				Hardie, RC; Martin, F; Chyb, S; Raghu, P			Rescue of light responses in the Drosophila "null" phospholipase C mutant, norpAP(24), by the diacylglycerol kinase mutant, rdgA, and by metabolic inhibition	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SENSITIVE CHANNELS TRP; IN-VIVO; SIGNAL-TRANSDUCTION; VISUAL TRANSDUCTION; G-PROTEIN; PHOTORECEPTORS; PHOTOTRANSDUCTION; PHOSPHORYLATION; GENE; ACTIVATION	Light responses in Drosophila are reportedly abolished in severe mutants of the phospholipase C ( PLC) gene, norpA. However, on establishing the whole-cell recording configuration in photoreceptors of the supposedly null allele, norpA(P24), we detected a small (similar to15 pA) inward current that represented spontaneous light channel activity. The current decayed during similar to20 min, after which tiny residual responses (< 2 pA) were elicited by intense flashes. Both spontaneous currents and light responses appeared to be mediated by residual PLC activity, because they were enhanced by impairing diacylglycerol (DAG) kinase function by mutation (rdgA) or by restricting ATP but were reduced or abolished by a mutation of the PLC-specific G(q) alpha subunit. It was reported recently that metabolic inhibition activated the light-sensitive transient receptor potential and transient receptor potential-like channels, even in norpAP24, leading to the conclusion that this action was independent of PLC (Agam, K., von Campenhausen, M., Levy, S., Ben-Ami, H. C., Cook, B., Kirschfeld, K., and Minke, B. ( 2000) J. Neurosci. 20, 5748-5755). However, we found that channel activation by metabolic inhibitors in norpAP24 was strictly dependent on the residual PLC activity underlying the spontaneous current, because the inhibitors failed to activate any channels after the spontaneous current had decayed. By contrast, polyunsaturated fatty acids invariably activated the channels independently of PLC. The results strongly support the obligatory requirement for PLC and DAG in Drosophila phototransduction, suggest that activation by metabolic inhibition is primarily because of the failure of diacylglycerol kinase, and are consistent with the proposal that polyunsaturated fatty acids, which are potential DAG metabolites, act directly on the channels.	Univ Cambridge, Dept Anat, Cambridge CB2 3DY, England	University of Cambridge	Hardie, RC (corresponding author), Univ Cambridge, Dept Anat, Downing St, Cambridge CB2 3DY, England.		Chyb, Sylwester/B-5783-2009; Martin, Fernando/AAZ-1300-2020; Padinjat, Raghu/Z-5578-2019	Hardie, Roger/0000-0001-5531-3264; Martin, Fernando/0000-0003-4380-567X				Agam K, 2000, J NEUROSCI, V20, P5748, DOI 10.1523/JNEUROSCI.20-15-05748.2000; Alloway PG, 1999, P NATL ACAD SCI USA, V96, P6072, DOI 10.1073/pnas.96.11.6072; Benham CD, 2002, NEUROPHARMACOLOGY, V42, P873, DOI 10.1016/S0028-3908(02)00047-3; BLOOMQUIST BT, 1988, CELL, V54, P723, DOI 10.1016/S0092-8674(88)80017-5; Chorna-Ornan I, 2001, J NEUROSCI, V21, P2622, DOI 10.1523/JNEUROSCI.21-08-02622.2001; Chyb S, 1999, NATURE, V397, P255, DOI 10.1038/16703; Clapham DE, 2001, NAT REV NEUROSCI, V2, P387, DOI 10.1038/35077544; Cook B, 2000, NAT CELL BIOL, V2, P296, DOI 10.1038/35010571; DOZA YN, 1992, EUR J BIOCHEM, V209, P1035, DOI 10.1111/j.1432-1033.1992.tb17379.x; Estacion M, 2001, J PHYSIOL-LONDON, V530, P1, DOI 10.1111/j.1469-7793.2001.0001m.x; Hardie RC, 2002, NEURON, V36, P689, DOI 10.1016/S0896-6273(02)01048-6; Hardie RC, 2003, ANNU REV PHYSIOL, V65, P735, DOI 10.1146/annurev.physiol.65.092101.142505; Hardie RC, 1996, J NEUROSCI, V16, P2924; HARDIE RC, 1991, P ROY SOC B-BIOL SCI, V245, P203, DOI 10.1098/rspb.1991.0110; HARDIE RC, 1994, J GEN PHYSIOL, V103, P389, DOI 10.1085/jgp.103.3.389; HARDIE RC, 1992, NEURON, V8, P643, DOI 10.1016/0896-6273(92)90086-S; Hardie RC, 2001, NATURE, V413, P186, DOI 10.1038/35093002; Hardie RC, 2001, NEURON, V30, P149, DOI 10.1016/S0896-6273(01)00269-0; Huber A, 1996, J BIOL CHEM, V271, P11710, DOI 10.1074/jbc.271.20.11710; Hwang SC, 1996, J BIOL CHEM, V271, P18342, DOI 10.1074/jbc.271.31.18342; Liu MY, 2000, J BIOL CHEM, V275, P12194, DOI 10.1074/jbc.275.16.12194; MASAI I, 1993, P NATL ACAD SCI USA, V90, P11157, DOI 10.1073/pnas.90.23.11157; MATSUMOTO H, 1994, NEURON, V12, P997, DOI 10.1016/0896-6273(94)90309-3; Minke B, 2002, PHYSIOL REV, V82, P429, DOI 10.1152/physrev.00001.2002; MINKE B, 1992, SOC GEN PHY, V47, P201; Montell C, 1999, ANNU REV CELL DEV BI, V15, P231, DOI 10.1146/annurev.cellbio.15.1.231; Montell C., 2001, SCI STKE; Niemeyer BA, 1996, CELL, V85, P651, DOI 10.1016/S0092-8674(00)81232-5; PAK WL, 1976, SCIENCE, V194, P956, DOI 10.1126/science.824732; Pearn MT, 1996, J BIOL CHEM, V271, P4937; Raghu P, 2000, NEURON, V26, P169, DOI 10.1016/S0896-6273(00)81147-2; Reuss H, 1997, NEURON, V19, P1249, DOI 10.1016/S0896-6273(00)80416-X; Scott K, 1998, NATURE, V395, P805, DOI 10.1038/27448; SCOTT K, 1995, NEURON, V15, P919, DOI 10.1016/0896-6273(95)90182-5; Sekiya F, 1999, CHEM PHYS LIPIDS, V98, P3, DOI 10.1016/S0009-3084(99)00013-4; SHORTRIDGE RD, 1991, J BIOL CHEM, V266, P12474; Thackeray JR, 1998, DEVELOPMENT, V125, P5033; Topham MK, 1999, J BIOL CHEM, V274, P11447, DOI 10.1074/jbc.274.17.11447	39	33	34	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 23	2003	278	21					18851	18858		10.1074/jbc.M300310200	http://dx.doi.org/10.1074/jbc.M300310200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	679PY	12621055	hybrid			2022-12-25	WOS:000182932200020
J	Imamura, H; Fushinobu, S; Yamamoto, M; Kumasaka, T; Jeon, BS; Wakagi, T; Matsuzawa, H				Imamura, H; Fushinobu, S; Yamamoto, M; Kumasaka, T; Jeon, BS; Wakagi, T; Matsuzawa, H			Crystal structures of 4-alpha-glucanotransferase from Thermococcus litoralis and its complex with an inhibitor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LARGE CYCLIC GLUCANS; CYCLODEXTRIN GLYCOSYLTRANSFERASE; GLYCOSYL HYDROLASES; THERMUS-AQUATICUS; 3-DIMENSIONAL STRUCTURE; ESCHERICHIA-COLI; ELECTRON-DENSITY; AQUEOUS-SOLUTION; ALPHA-AMYLASE; GENE CLONING	Thermococcus litoralis 4-alpha-glucanotransferase (TLGT) belongs to glucoside hydrolase family 57 and catalyzes the disproportionation of amylose and the formation of large cyclic alpha-1,4-glucan ( cycloamylose) from linear amylose. We determined the crystal structure of TLGT with and without an inhibitor, acarbose. TLGT is composed of two domains: an N-terminal domain ( domain I), which contains a (beta/alpha)(7) barrel fold, and a C-terminal domain ( domain II), which has a twisted beta-sandwich fold. In the structure of TLGT complexed with acarbose, the inhibitor was bound at the cleft within domain I, indicating that domain I is a catalytic domain of TLGT. The acarbose-bound structure also clarified that Glu(123) and Asp(214) were the catalytic nucleophile and acid/base catalyst, respectively, and revealed the residues involved in substrate binding. It seemed that TLGT produces large cyclic glucans by preventing the production of small cyclic glucans by steric hindrance, which is achieved by three lids protruding into the active site cleft, as well as an extended active site cleft. Interestingly, domain I of TLGT shares some structural features with the catalytic domain of Golgi alpha-mannosidase from Drosophila melanogaster, which belongs to glucoside hydrolase family 38. Furthermore, the catalytic residue of the two enzymes is located in the same position. These observations suggest that families 57 and 38 evolved from a common ancestor.	Aomori Univ, Dept Biosci & Biotechnol, Kohbata, Aomori 0300943, Japan; Univ Tokyo, Dept Biotechnol, Bunkyo Ku, Tokyo 1138657, Japan; RIKEN, Inst Phys & Chem Res, Harima Inst, Mikazuki, Hyogo 6785148, Japan	University of Tokyo; RIKEN	Matsuzawa, H (corresponding author), JST, ERATO, ATP Syst Project, Midori Ku, 5800-3 Nagatsuta, Yokohama, Kanagawa 2260026, Japan.		Imamura, Hiromi/AAD-5109-2019; Yamamoto, Masaki/B-7844-2015; Fushinobu, Shinya/E-4987-2011; Kumasaka, Takashi/D-7428-2018; Wakagi, Takayoshi/AAJ-4145-2021	Imamura, Hiromi/0000-0002-1896-0443; Yamamoto, Masaki/0000-0002-1311-1768; Fushinobu, Shinya/0000-0003-1346-6435; Kumasaka, Takashi/0000-0001-9289-1557; 				Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Christopher JA, 1998, J MOL GRAPH MODEL, V16, P285; COUTINHO PM, 1999, CARBOHYDRATE ACTIVE; Cowtan K., 1994, JOINT CCP4 ESF EACBM, V31, P34; DAVIES G, 1995, STRUCTURE, V3, P853, DOI 10.1016/S0969-2126(01)00220-9; Davies GJ, 1997, BIOCHEM J, V321, P557, DOI 10.1042/bj3210557; Gouet P, 1999, BIOINFORMATICS, V15, P305, DOI 10.1093/bioinformatics/15.4.305; Henrissat B, 1996, BIOCHEM J, V316, P695, DOI 10.1042/bj3160695; HOLM L, 1993, J MOL BIOL, V233, P123, DOI 10.1006/jmbi.1993.1489; Imamura H, 1999, FEBS LETT, V457, P393, DOI 10.1016/S0014-5793(99)01081-9; Imamura H., 2001, Journal of Applied Glycoscience, V48, P171; Imamura H, 2001, BIOCHEMISTRY-US, V40, P12400, DOI 10.1021/bi011017c; Jeon BS, 1997, EUR J BIOCHEM, V248, P171, DOI 10.1111/j.1432-1033.1997.00171.x; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Juers DH, 1999, PROTEIN SCI, V8, P122; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; Katsuya Y, 1998, J MOL BIOL, V281, P885, DOI 10.1006/jmbi.1998.1992; Kim MJ, 1999, ARCH BIOCHEM BIOPHYS, V371, P277, DOI 10.1006/abbi.1999.1423; Kitamura S, 1999, MACROMOL RAPID COMM, V20, P612, DOI 10.1002/(SICI)1521-3927(19991201)20:12<612::AID-MARC612>3.0.CO;2-E; Kitamura S, 1997, CARBOHYD RES, V304, P303, DOI 10.1016/S0008-6215(97)00278-4; KLEIN C, 1991, J MOL BIOL, V217, P737, DOI 10.1016/0022-2836(91)90530-J; Kleywegt GJ, 1999, ACTA CRYSTALLOGR D, V55, P1878, DOI 10.1107/S0907444999010495; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Leslie AGW, 1992, JOINT CCP4 ESF EAMCB, V26; Machida S, 2000, FEBS LETT, V486, P131, DOI 10.1016/S0014-5793(00)02258-4; MATSUURA Y, 1984, J BIOCHEM-TOKYO, V95, P697, DOI 10.1093/oxfordjournals.jbchem.a134659; MCCARTER JD, 1994, CURR OPIN STRUC BIOL, V4, P885, DOI 10.1016/0959-440X(94)90271-2; McRee DE, 1999, J STRUCT BIOL, V125, P156, DOI 10.1006/jsbi.1999.4094; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; Nagano N, 1999, PROTEIN SCI, V8, P2072, DOI 10.1110/ps.8.10.2072; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Przylas I, 2000, J MOL BIOL, V296, P873, DOI 10.1006/jmbi.1999.3503; Przylas I, 2000, EUR J BIOCHEM, V267, P6903, DOI 10.1046/j.1432-1033.2000.01790.x; ROUVINEN J, 1990, SCIENCE, V249, P380, DOI 10.1126/science.2377893; SPEZIO M, 1993, BIOCHEMISTRY-US, V32, P9906, DOI 10.1021/bi00089a006; SVENSSON B, 1994, PLANT MOL BIOL, V25, P141, DOI 10.1007/BF00023233; Tachibana Y, 2000, J BIOSCI BIOENG, V90, P406, DOI [10.1016/S1389-1723(01)80009-8, 10.1263/jbb.90.406]; Takaha T, 1996, J BIOL CHEM, V271, P2902, DOI 10.1074/jbc.271.6.2902; Takaha T, 1999, BIOTECHNOL GENET ENG, V16, P257, DOI 10.1080/02648725.1999.10647978; Terada Y, 1999, APPL ENVIRON MICROB, V65, P910; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Uitdehaag JCM, 1999, J BIOL CHEM, V274, P34868, DOI 10.1074/jbc.274.49.34868; Uitdehaag JCM, 2001, PROTEINS, V43, P327, DOI 10.1002/prot.1044; van den Elsen JMH, 2001, EMBO J, V20, P3008, DOI 10.1093/emboj/20.12.3008; Vieille C, 2001, MICROBIOL MOL BIOL R, V65, P1, DOI 10.1128/MMBR.65.1.1-43.2001; WAKARCHUK WW, 1994, PROTEIN SCI, V3, P467; Xavier KB, 1999, J BACTERIOL, V181, P3358, DOI 10.1128/JB.181.11.3358-3367.1999	49	66	71	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 23	2003	278	21					19378	19386		10.1074/jbc.M213134200	http://dx.doi.org/10.1074/jbc.M213134200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	679PY	12618437	hybrid			2022-12-25	WOS:000182932200086
J	Akiyama, Y; Ito, K				Akiyama, Y; Ito, K			Reconstitution of membrane proteolysis by FtsH	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ATP-DEPENDENT PROTEASE; ESCHERICHIA-COLI; MEDIATED PROTEOLYSIS; PLASMA-MEMBRANE; HFLB; PROTEINS; DEGRADATION; COMPLEX; FORMS; ROLES	Escherichia coli FtsH is a membrane-bound and ATP-dependent protease responsible for degradation of several membrane proteins. The FtsH action is processive and presumably involves dislocation of the substrate from the membrane to the cytosol. Although elucidation of its molecular mechanism requires an in vitro reaction system, in vitro activities of this enzyme against membrane protein substrates have only been assayed using detergent-solubilized components. Here we report on the construction of in vitro reaction systems for FtsH-catalyzed membrane protein degradation. A combination of two inverted membrane vesicles or of two proteoliposomes, one bearing the enzyme and the other bearing a substrate, was fused by polyethylene glycol 3350 treatment. Addition of ATP then resulted in degradation of the substrate. It was shown that FtsH can function in the process of membrane proteins degradation without aid from any other cellular factors.	Kyoto Univ, Inst Virus Res, Kyoto 6068507, Japan	Kyoto University	Akiyama, Y (corresponding author), Kyoto Univ, Inst Virus Res, Kyoto 6068507, Japan.							AKIYAMA Y, 1992, J BIOL CHEM, V267, P22440; Akiyama Y, 1998, J BIOL CHEM, V273, P22326, DOI 10.1074/jbc.273.35.22326; Akiyama Y, 1999, BIOCHEMISTRY-US, V38, P11693, DOI 10.1021/bi991177c; AKIYAMA Y, 1994, J BIOL CHEM, V269, P5218; AKIYAMA Y, 1995, J BIOL CHEM, V270, P23485, DOI 10.1074/jbc.270.40.23485; AKIYAMA Y, 1993, J BIOL CHEM, V268, P8146; Akiyama Y, 1996, FEBS LETT, V399, P26, DOI 10.1016/S0014-5793(96)01283-5; Akiyama Y, 2002, P NATL ACAD SCI USA, V99, P8066, DOI 10.1073/pnas.122616899; Akiyama Y, 1996, J BIOL CHEM, V271, P31196, DOI 10.1074/jbc.271.49.31196; Akiyama Y, 2001, BIOCHEMISTRY-US, V40, P7687, DOI 10.1021/bi010039w; Akiyama Y, 2000, EMBO J, V19, P3888, DOI 10.1093/emboj/19.15.3888; AKIYAMA Y, 1998, HDB PROTEOLYTIC ENZY, P1502; Chiba S, 2002, J BACTERIOL, V184, P4775, DOI 10.1128/JB.184.17.4775-4782.2002; Chiba S, 2000, EMBO REP, V1, P47, DOI 10.1093/embo-reports/kvd005; Davis R., 1980, ADV BACTERIAL GENETI; DERMAN AI, 1991, J BACTERIOL, V173, P7719, DOI 10.1128/jb.173.23.7719-7722.1991; Glick BS, 1996, PROTEIN SCI, V5, P2651, DOI 10.1002/pro.5560051229; Gottesman S, 1999, CURR OPIN MICROBIOL, V2, P142, DOI 10.1016/S1369-5274(99)80025-3; Inaba K, 2002, EMBO J, V21, P2646, DOI 10.1093/emboj/21.11.2646; Kihara A, 1996, EMBO J, V15, P6122, DOI 10.1002/j.1460-2075.1996.tb01000.x; KIHARA A, 1995, P NATL ACAD SCI USA, V92, P4532, DOI 10.1073/pnas.92.10.4532; Kihara A, 1998, J MOL BIOL, V279, P175, DOI 10.1006/jmbi.1998.1781; Kihara A, 1999, EMBO J, V18, P2970, DOI 10.1093/emboj/18.11.2970; Langosch D, 2001, J MOL BIOL, V311, P709, DOI 10.1006/jmbi.2001.4889; Leonhard K, 2000, MOL CELL, V5, P629, DOI 10.1016/S1097-2765(00)80242-7; MESSING J, 1981, NUCLEIC ACIDS RES, V9, P309, DOI 10.1093/nar/9.2.309; MORI H, 2003, IN PRESS J BIOL CHEM, V278; MORIYAMA Y, 1991, J BIOL CHEM, V266, P22141; Murphy KC, 1998, J BACTERIOL, V180, P2063, DOI 10.1128/JB.180.8.2063-2071.1998; Ogura T, 1999, MOL MICROBIOL, V31, P833, DOI 10.1046/j.1365-2958.1999.01221.x; Sambrook J., 2002, MOL CLONING LAB MANU; Shimohata N, 2002, GENES CELLS, V7, P653, DOI 10.1046/j.1365-2443.2002.00554.x; TOMOYASU T, 1993, J BACTERIOL, V175, P1352, DOI 10.1128/JB.175.5.1352-1357.1993; Weihofen A, 2003, TRENDS CELL BIOL, V13, P71, DOI 10.1016/S0962-8924(02)00041-7	34	34	34	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 16	2003	278	20					18146	18153		10.1074/jbc.M302152200	http://dx.doi.org/10.1074/jbc.M302152200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677YX	12642574	hybrid			2022-12-25	WOS:000182838300073
J	Oehrl, W; Rubio, I; Wetzker, R				Oehrl, W; Rubio, I; Wetzker, R			Serine 338 phosphorylation is dispensable for activation of c-Raf1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KINASE SIGNALING PATHWAY; EPIDERMAL GROWTH-FACTOR; PROTEIN-KINASE; PHOSPHATIDYLINOSITOL 3-KINASE; PLASMA-MEMBRANE; PHOSPHOINOSITIDE 3-KINASE; RAF ACTIVATION; AMINO-TERMINUS; GTPASE RAC2; B-RAF	Numerous extracellular agonists induce consecutive stimulation of Ras guanine nucleotide exchange factors, Ras and c-Raf1, as the starting point of the intracellular mitogen-activated protein kinase cascade. Recent data point to a more complex reaction pattern of this simple sequence. This study was aimed at elucidating the activation process of endogenous c-Raf1 in U937 cells. Treatment of permeabilized U937 cells with the nonhydrolyzable nucleotide guanosine 5'-3-O-(thio) triphosphate (GTPgammaS) induced prolonged stimulation of Ras and c-Raf1 activity. Intriguingly, both signaling proteins expressed differential responses toward specific inhibitors of phosphoinositide 3-kinases and tyrosine kinases, which indicates diverse signaling reactions feeding into Ras and cRaf-1. Phosphorylation of c-Raf1 serine 338 by p21-activated kinase has been recently reported to contribute to phosphoinositide 3-kinase-dependent activation of c-Raf1. However, in U937 cells stimulation of c-Raf1 activity by GTPgammaS did not correlate with p21-activated kinase activity and Ser-338 phosphorylation. Thus Ser-338 phosphorylation appears dispensable for c-Raf1 activation under the conditions used. Together these data deny an essential role for serine 338 phosphorylation in c-Raf1 activation and disclose divergent signaling connections of Ras and c-Raf1 in U937 cells.	Univ Jena, Inst Mol Cell Biol, D-07747 Jena, Germany	Friedrich Schiller University of Jena	Wetzker, R (corresponding author), Univ Jena, Inst Mol Cell Biol, D-07747 Jena, Germany.		Wetzker, Reinhard/AAD-8713-2019					Akasaki T, 1999, J BIOL CHEM, V274, P18055, DOI 10.1074/jbc.274.25.18055; Arai H, 1996, MOL PHARMACOL, V50, P522; Barnard D, 1998, ONCOGENE, V17, P1539, DOI 10.1038/sj.onc.1202061; Brummer T, 2002, EMBO J, V21, P5611, DOI 10.1093/emboj/cdf588; BUDAY L, 1995, ONCOGENE, V11, P1327; Chaudhary A, 2000, CURR BIOL, V10, P551, DOI 10.1016/S0960-9822(00)00475-9; Chiloeches A, 2001, MOL CELL BIOL, V21, P2423, DOI 10.1128/MCB.21.7.2423-2434.2001; Clerk A, 2001, MOL CELL BIOL, V21, P1173, DOI 10.1128/MCB.21.4.1173-1184.2001; Diaz B, 1997, MOL CELL BIOL, V17, P4509, DOI 10.1128/MCB.17.8.4509; Douville E, 1997, ONCOGENE, V15, P373, DOI 10.1038/sj.onc.1201214; Downward J, 1997, ADV SEC MESS PHOSPH, V31, P1; Duckworth BC, 1997, J BIOL CHEM, V272, P27665, DOI 10.1074/jbc.272.44.27665; FABIAN JR, 1993, MOL CELL BIOL, V13, P7170, DOI 10.1128/MCB.13.11.7170; Frost JA, 1997, EMBO J, V16, P6426, DOI 10.1093/emboj/16.21.6426; Hagemann C, 1999, EXP CELL RES, V253, P34, DOI 10.1006/excr.1999.4689; Hall-Jackson CA, 1999, CHEM BIOL, V6, P559, DOI 10.1016/S1074-5521(99)80088-X; Hawes BE, 1996, J BIOL CHEM, V271, P12133, DOI 10.1074/jbc.271.21.12133; HU QJ, 1995, SCIENCE, V268, P100, DOI 10.1126/science.7701328; JELINEK T, 1994, MOL CELL BIOL, V14, P8212, DOI 10.1128/MCB.14.12.8212; King AJ, 1998, NATURE, V396, P180, DOI 10.1038/24184; KOIDE H, 1993, P NATL ACAD SCI USA, V90, P8683, DOI 10.1073/pnas.90.18.8683; KOLCH W, 1993, NATURE, V364, P249, DOI 10.1038/364249a0; LANGLOIS WJ, 1995, J BIOL CHEM, V270, P25320, DOI 10.1074/jbc.270.43.25320; LEEVERS SJ, 1994, NATURE, V369, P411, DOI 10.1038/369411a0; MARAIS R, 1995, EMBO J, V14, P3136, DOI 10.1002/j.1460-2075.1995.tb07316.x; Mason CS, 1999, EMBO J, V18, P2137, DOI 10.1093/emboj/18.8.2137; MOODIE SA, 1993, SCIENCE, V260, P1658, DOI 10.1126/science.8503013; MORRISON DK, 1993, J BIOL CHEM, V268, P17309; Morrison DK, 1997, CURR OPIN CELL BIOL, V9, P174, DOI 10.1016/S0955-0674(97)80060-9; Roberts AW, 1999, IMMUNITY, V10, P183, DOI 10.1016/S1074-7613(00)80019-9; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; Rommel C, 1997, MECH DEVELOP, V64, P95, DOI 10.1016/S0925-4773(97)00052-X; Rommel C, 1996, ONCOGENE, V12, P609; Rommel C, 1999, SCIENCE, V286, P1738, DOI 10.1126/science.286.5445.1738; Rubio I, 2000, CURR BIOL, V10, P1225, DOI 10.1016/S0960-9822(00)00731-4; Schmidt M, 2000, J BIOL CHEM, V275, P41011, DOI 10.1074/jbc.M003716200; Schulte TW, 1996, MOL CELL BIOL, V16, P5839; Scita G, 2000, EMBO J, V19, P2393, DOI 10.1093/emboj/19.11.2393; STEPHENS L, 1993, J BIOL CHEM, V268, P17162; STOKOE D, 1994, SCIENCE, V264, P1463, DOI 10.1126/science.7811320; Sun HY, 2000, CURR BIOL, V10, P281, DOI 10.1016/S0960-9822(00)00359-6; Takahashi T, 1999, ONCOGENE, V18, P2221, DOI 10.1038/sj.onc.1202527; Tzivion G, 1998, NATURE, V394, P88, DOI 10.1038/27938; WARTMANN M, 1994, J BIOL CHEM, V269, P6695; Wennstrom S, 1999, MOL CELL BIOL, V19, P4279; Zimmermann S, 1999, SCIENCE, V286, P1741, DOI 10.1126/science.286.5445.1741; Ziogas A, 1998, J BIOL CHEM, V273, P24108, DOI 10.1074/jbc.273.37.24108	48	9	9	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 16	2003	278	20					17819	17826		10.1074/jbc.M209951200	http://dx.doi.org/10.1074/jbc.M209951200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677YX	12626521	hybrid			2022-12-25	WOS:000182838300030
J	Rossenu, S; Leyman, S; Dewitte, D; Peelaers, D; Jonckheere, V; Van Troys, M; Vandekerckhove, J; Ampe, C				Rossenu, S; Leyman, S; Dewitte, D; Peelaers, D; Jonckheere, V; Van Troys, M; Vandekerckhove, J; Ampe, C			A phage display-based method for determination of relative affinities of mutants - Application to the actin-binding motifs in thymosin beta 4 and the villin headpiece	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-PROTEIN INTERACTIONS; F-ACTIN; NMR-SPECTROSCOPY; SITE; CONFORMATION; TECHNOLOGY; BETA(4); MUTAGENESIS; INTERFACES; SELECTION	We propose phage display combined with enzyme-linked immunosorbent assay as a tool for the systematic analysis of protein-protein interactions by investigating the binding behavior of variants to a partner protein. Via enzyme-linked immunosorbent assay we determine both the amount of fusion protein presented at the phage surface and the amount of complex formed, the ratio of which is proportional to the affinity. Hence this method enables us to calculate the relative affinities of a large number of mutants. As model systems, we investigated actin-binding motifs conserved in a number of proteins binding monomeric or filamentous actin. The hexapeptide motifs LKKTET, present in thymosin beta4, and LKKEKG, present in the villin headpiece, were mutated, and the variants were analyzed. Study of the positional tolerance allows postulating that the motifs, although similar in primary structures adopt different conformations when bound to actin. In addition, our data show that the second and the fourth amino acid of the thymosin beta4 motif and the first three residues of the villin headpiece motif are most important for actin binding. The latter result challenges the charged crown hypothesis for the villin headpiece filamentous actin interaction.	Univ Ghent, Dept Biochem, Fac Med & Hlth Sci, B-9000 Ghent, Belgium; State Univ Ghent VIB, Dept Med Prot Res, Fac Med & Hlth Sci, B-9000 Ghent, Belgium	Ghent University; Flanders Institute for Biotechnology (VIB); Ghent University	Ampe, C (corresponding author), Univ Ghent, Dept Biochem, Fac Med & Hlth Sci, Baertsoenkaai 3, B-9000 Ghent, Belgium.	christophe.ampe@rug.ac.be	Ampe, Christophe/B-5534-2012	Van Troys, Marleen/0000-0003-4283-8103				Ballweber E, 2002, J MOL BIOL, V315, P613, DOI 10.1006/jmbi.2001.5281; BASS S, 1990, PROTEINS, V8, P309, DOI 10.1002/prot.340080405; Bennett KL, 2000, PROTEIN SCI, V9, P1503, DOI 10.1110/ps.9.8.1503; Bourdet-Sicard R, 1999, EMBO J, V18, P5853, DOI 10.1093/emboj/18.21.5853; CHOO Y, 1994, P NATL ACAD SCI USA, V91, P11168, DOI 10.1073/pnas.91.23.11168; CZISCH M, 1993, EUR J BIOCHEM, V218, P335, DOI 10.1111/j.1432-1033.1993.tb18382.x; DeLano WL, 2002, CURR OPIN STRUC BIOL, V12, P14, DOI 10.1016/S0959-440X(02)00283-X; Doering DS, 1996, BIOCHEMISTRY-US, V35, P12677, DOI 10.1021/bi9615699; Ehrlich GK, 2000, METHODS MOL BIOL, V147, P195; Englander SW, 1996, CURR OPIN STRUC BIOL, V6, P18, DOI 10.1016/S0959-440X(96)80090-X; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; FRANK R, 1992, TETRAHEDRON, V48, P9217, DOI 10.1016/S0040-4020(01)85612-X; FRIEDERICH E, 1992, CELL, V70, P81, DOI 10.1016/0092-8674(92)90535-K; GRIBSKOV M, 1984, NUCLEIC ACIDS RES, V12, P539, DOI 10.1093/nar/12.1Part2.539; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Hoogenboom HR, 1998, IMMUNOTECHNOLOGY, V4, P1, DOI 10.1016/S1380-2933(98)00007-4; Huff T, 2001, INT J BIOCHEM CELL B, V33, P205, DOI 10.1016/S1357-2725(00)00087-X; JIN L, 1994, J PROTEIN SCI, V12, P2351; KISHCHENKO G, 1994, J MOL BIOL, V241, P208, DOI 10.1006/jmbi.1994.1489; Lo Conte L, 1999, J MOL BIOL, V285, P2177; LOWMAN HB, 1991, BIOCHEMISTRY-US, V30, P10832, DOI 10.1021/bi00109a004; McKnight CJ, 1997, NAT STRUCT BIOL, V4, P180, DOI 10.1038/nsb0397-180; Meloen RH, 2000, J MOL RECOGNIT, V13, P352, DOI 10.1002/1099-1352(200011/12)13:6<352::AID-JMR509>3.0.CO;2-C; MERTENS N, 1995, BIO-TECHNOL, V13, P175, DOI 10.1038/nbt0295-175; Reineke U, 2001, CURR OPIN BIOTECH, V12, P59, DOI 10.1016/S0958-1669(00)00178-6; Rhyner Claudio, 2002, Current Pharmaceutical Biotechnology, V3, P13, DOI 10.2174/1389201023378535; Rossenu S, 1997, J PROTEIN CHEM, V16, P499, DOI 10.1023/A:1026317612554; Safer D, 1997, BIOCHEMISTRY-US, V36, P5806, DOI 10.1021/bi970185v; Safer D, 1997, CELL MOTIL CYTOSKEL, V38, P163, DOI 10.1002/(SICI)1097-0169(1997)38:2<163::AID-CM5>3.0.CO;2-8; SAGGIO I, 1995, GENE, V152, P35, DOI 10.1016/0378-1119(94)00733-9; Serebriiskii IG, 2001, BIOTECHNIQUES, V30, P634, DOI 10.2144/01303dd02; Simenel C, 2000, EUR J BIOCHEM, V267, P3530, DOI 10.1046/j.1432-1327.2000.01380.x; SPUDICH JA, 1971, J BIOL CHEM, V246, P4866; SWINDELLS MB, 1995, NAT STRUCT BIOL, V2, P596, DOI 10.1038/nsb0795-596; TAKASHI R, 1988, BIOCHEMISTRY-US, V27, P938, DOI 10.1021/bi00403a015; VANCOMPERNOLLE K, 1992, EMBO J, V11, P4739, DOI 10.1002/j.1460-2075.1992.tb05579.x; VANDEKERCKHOVE JS, 1989, J CELL BIOL, V109, P619, DOI 10.1083/jcb.109.2.619; VanTroys M, 1996, EMBO J, V15, P201, DOI 10.1002/j.1460-2075.1996.tb00350.x; VANTROYS M, 1999, BIOCHIM BIOPHYS ACTA, V1447, P323; Vardar D, 1999, J MOL BIOL, V294, P1299, DOI 10.1006/jmbi.1999.3321; Vardar D, 2002, CELL MOTIL CYTOSKEL, V52, P9, DOI 10.1002/cm.10027; von Mering C, 2002, NATURE, V417, P399, DOI 10.1038/nature750; WELLS JA, 1991, METHOD ENZYMOL, V202, P390; ZARBOCK J, 1990, BIOCHEMISTRY-US, V29, P7814, DOI 10.1021/bi00486a006; Zuiderweg ERP, 2002, BIOCHEMISTRY-US, V41, P1, DOI 10.1021/bi011870b	45	21	23	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 9	2003	278	19					16642	16650		10.1074/jbc.M208311200	http://dx.doi.org/10.1074/jbc.M208311200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677QG	12606551	hybrid			2022-12-25	WOS:000182818600027
J	Cruet-Hennequart, S; Maubant, S; Luis, J; Gauduchon, P; Staedel, C; Dedhar, S				Cruet-Hennequart, S; Maubant, S; Luis, J; Gauduchon, P; Staedel, C; Dedhar, S			alpha(v) integrins regulate cell proliferation through integrin-linked kinase (ILK) in ovarian cancer cells	ONCOGENE			English	Article						integrins; ILK; signal transduction; cell cycle; ovarian cancer	FORKHEAD TRANSCRIPTION FACTORS; EXTRACELLULAR-MATRIX; CYCLE PROGRESSION; PROTEIN-KINASE; ALPHA-V-BETA-3 INTEGRINS; GROWTH-FACTOR; BETA-CATENIN; LINE IGROV1; PTEN GENE; ADHESION	Integrins regulate both adhesion and signaling processes involved in proliferation and survival. alpha(v)beta(3) and alpha(v)beta(5) integrins have been shown to mediate cell adhesion and migration. Here we used human ovarian cancer cell lines (IGROV1, SKOV-3) that express alpha(v)beta(3) and alpha(v)beta(5) to study their role in cell proliferation and the signaling pathways involved. We found that alpha(v) integrins regulate cell proliferation through activation of integrin-linked kinase (ILK). An anti-alpha(v)-blocking antibody specifically inhibits the growth of IGROV1 and SKOV-3. The inhibition of cell proliferation involves 043 in IGROV1 cells, and both alpha(v)beta(3) and alpha(v)beta(5) in SKOV-3 cells. The reduced growth rate induced by alpha(v) integrin blockade is linked in both cell lines to G1/S cell cycle arrest. alpha(v) integrin blockade by neutralizing antibody as well as cyclic-RGD peptide caused an inhibition of ILK activity and phosphorylation of PKB/Akt on serine-473 but not on threonine-308, and was accompanied by an increase in p27(Kip1) expression. Overexpression of wild-type ILK rescued the phosphorylation of PKB/Akt on serine-473 in cells treated with anti-alpha(v) antibody. Inhibition of ILK by a pharmacological inhibitor results in inhibition of cell proliferation, PKB/Akt phosphorylation and increase of p27(Kip1). These results demonstrate that alpha(v) integrins regulate ovarian cancer cell proliferation through ILK.	British Columbia Canc Agcy, Jack Bell Res Ctr, Vancouver, BC V6H 3Z6, Canada; Vancouver Hosp & Hlth Sci Ctr, Jack Bell Res Ctr, Vancouver, BC V6H 3Z6, Canada; Univ British Columbia, Dept Biochem & Mol Biol, Vancouver, BC V5Z 1M9, Canada; Ctr Francois Baclesse, UPRES EA 1772, Grp Reg Etud Canc, F-14076 Caen 05, France; Fac Pharm Marseille, UMR CNRS 6032, Lab Biochim & Biol Cellulaire, F-13085 Marseille, France; Univ Bordeaux 2, INSERM, U386, F-33076 Bordeaux, France	British Columbia Cancer Agency; University of British Columbia; University of British Columbia; University of British Columbia; UNICANCER; Centre Francois Baclesse; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite de Bordeaux	Dedhar, S (corresponding author), British Columbia Canc Agcy, Jack Bell Res Ctr, 2660 Oak St, Vancouver, BC V6H 3Z6, Canada.		LUIS, José/M-3071-2013; GAUDUCHON, Pascal/K-6492-2015	Staedel, Cathy/0000-0003-0488-0239; Dedhar, Shoukat/0000-0003-4355-1657				Assoian RK, 1997, CURR OPIN CELL BIOL, V9, P93, DOI 10.1016/S0955-0674(97)80157-3; Attwell S, 2000, ONCOGENE, V19, P3811, DOI 10.1038/sj.onc.1203711; Auersperg N, 1998, SEMIN ONCOL, V25, P281; Burridge K, 1996, ANNU REV CELL DEV BI, V12, P463, DOI 10.1146/annurev.cellbio.12.1.463; CANNISTRA SA, 1995, GYNECOL ONCOL, V58, P216, DOI 10.1006/gyno.1995.1214; CARREIRAS F, 1995, INT J CANCER, V63, P530, DOI 10.1002/ijc.2910630413; Carreiras F, 1999, INT J CANCER, V80, P285; Carreiras F, 1999, GYNECOL ONCOL, V72, P312, DOI 10.1006/gyno.1998.5262; Caruso DA, 2001, CELL DEATH DIFFER, V8, P665, DOI 10.1038/sj.cdd.4400865; Casalini P, 2001, J BIOL CHEM, V276, P12449, DOI 10.1074/jbc.M009732200; Cruet S, 1999, GYNECOL ONCOL, V75, P254, DOI 10.1006/gyno.1999.5572; Dahia PLM, 2000, ENDOCR-RELAT CANCER, V7, P115, DOI 10.1677/erc.0.0070115; Dedhar S, 2000, CURR OPIN CELL BIOL, V12, P250, DOI 10.1016/S0955-0674(99)00083-6; Delcommenne M, 1998, P NATL ACAD SCI USA, V95, P11211, DOI 10.1073/pnas.95.19.11211; DESHANE J, 1994, GENE THER, V1, P332; Downward J, 1998, CURR OPIN GENET DEV, V8, P49, DOI 10.1016/S0959-437X(98)80061-0; Eliceiri BP, 2001, CURR OPIN CELL BIOL, V13, P563, DOI 10.1016/S0955-0674(00)00252-0; Friedlander DR, 1996, CANCER RES, V56, P1939; Friedrich EB, 2002, J BIOL CHEM, V277, P16371, DOI 10.1074/jbc.M201240200; Frisch SM, 1997, CURR OPIN CELL BIOL, V9, P701, DOI 10.1016/S0955-0674(97)80124-X; GARDNER MJ, 1995, CANCER LETT, V91, P229, DOI 10.1016/0304-3835(95)03743-G; Gottschalk AR, 2001, CANCER RES, V61, P2105; Hannigan GE, 1996, NATURE, V379, P91, DOI 10.1038/379091a0; Hapke S, 2001, J BIOL CHEM, V276, P26340, DOI 10.1074/jbc.M100181200; Hellstrom I, 2001, CANCER RES, V61, P2420; Howe A, 1998, CURR OPIN CELL BIOL, V10, P220, DOI 10.1016/S0955-0674(98)80144-0; Hulleman E, 2001, CELL MOL LIFE SCI, V58, P80, DOI 10.1007/PL00000780; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; Kurose K, 2001, AM J PATHOL, V158, P2097, DOI 10.1016/S0002-9440(10)64681-0; LEHMANN M, 1994, CANCER RES, V54, P2102; Leung-Hagesteijn C, 2001, EMBO J, V20, P2160, DOI 10.1093/emboj/20.9.2160; Li DM, 1998, P NATL ACAD SCI USA, V95, P15406, DOI 10.1073/pnas.95.26.15406; Li FG, 1999, J CELL SCI, V112, P4589; Liu SC, 2000, J CELL SCI, V113, P3563; Medema RH, 2000, NATURE, V404, P782, DOI 10.1038/35008115; Minaguchi T, 1999, CANCER RES, V59, P6063; Nakamura N, 2000, MOL CELL BIOL, V20, P8969, DOI 10.1128/MCB.20.23.8969-8982.2000; Obata K, 1998, CANCER RES, V58, P2095; Persad S, 2000, P NATL ACAD SCI USA, V97, P3207, DOI 10.1073/pnas.060579697; Persad S, 2001, J CELL BIOL, V153, P1161, DOI 10.1083/jcb.153.6.1161; Persad S, 2001, J BIOL CHEM, V276, P27462, DOI 10.1074/jbc.M102940200; Petitclerc E, 1999, CANCER RES, V59, P2724; PFAFF M, 1994, J BIOL CHEM, V269, P20233; Poulain L, 1998, INT J CANCER, V78, P454, DOI 10.1002/(SICI)1097-0215(19981109)78:4<454::AID-IJC11>3.0.CO;2-6; Radeva G, 1997, J BIOL CHEM, V272, P13937, DOI 10.1074/jbc.272.21.13937; Saito M, 2000, INT J CANCER, V85, P160, DOI 10.1002/(SICI)1097-0215(20000115)85:2<160::AID-IJC2>3.0.CO;2-5; Seger D, 2001, J BIOL CHEM, V276, P16998, DOI 10.1074/jbc.M003766200; Sieg DJ, 2000, NAT CELL BIOL, V2, P249, DOI 10.1038/35010517; Tan C, 2002, J BIOL CHEM, V277, P3109, DOI 10.1074/jbc.M108673200; Tan C, 2001, ONCOGENE, V20, P133, DOI 10.1038/sj.onc.1204052; Troussard AA, 2000, ONCOGENE, V19, P5444, DOI 10.1038/sj.onc.1203928; Troussard AA, 1999, MOL CELL BIOL, V19, P7420; van Leeuwen R L, 1996, Exp Dermatol, V5, P308; Wong NC, 1998, CLIN EXP METASTAS, V16, P50; Wu CY, 1998, J BIOL CHEM, V273, P528, DOI 10.1074/jbc.273.1.528; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Zheng DQ, 2000, J BIOL CHEM, V275, P24565, DOI 10.1074/jbc.M002646200	57	125	126	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 20	2003	22	11					1688	1702		10.1038/sj.onc.1206347	http://dx.doi.org/10.1038/sj.onc.1206347			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	655YH	12642872				2022-12-25	WOS:000181580500011
J	Haviernik, P; Schmidt, M; Hu, XR; Wolff, L				Haviernik, P; Schmidt, M; Hu, XR; Wolff, L			Consistent inactivation of p19(Arf) but not p15(Ink4b) in murine myeloid cells transformed in vivo by deregulated c-Myc	ONCOGENE			English	Article						INK4; tumor suppressor; p15(Ink4b); p19(Arf); c-myc; myeloid leukemia	ACUTE LYMPHOBLASTIC-LEUKEMIA; KINASE INHIBITOR P15(INK4B); CYCLIN-DEPENDENT KINASES; TUMOR-SUPPRESSOR GENE; RETINOBLASTOMA-PROTEIN; CDK INHIBITORS; GROWTH SUPPRESSION; BREAST-CANCER; INK4 FAMILY; TGF-BETA	Cyclin-dependent kinase inhibitors p16(INK4a) and p-15(INK4b), encoded by the CDKN2A and B loci, play an important role in negative regulation of the cell cycle. Furthermore, p19(ARF) also encoded by the CDKN2A locus, has been shown to regulate positively the p53 pathway leading to growth arrest and apoptosis. All three genes have been inactivated in human tumors. In myeloid cells, p15(INK4b) mRNA is upregulated during cytokine-induced differentiation and/or growth arrest, and hypermethylation of the p15(INK4b) gene promoter region is a common event in acute myeloid leukemia. In the present study, we examined murine monocyte/macrophage tumors with deregulated c-myc for evidence of Ink4 gene inactivation. p15(Ink4b) mRNA and protein were detected in the majority of leukemias, and p16(Ink4a) mRNA and protein were highly expressed in two of them. pRb was in a hypophosphorylated state in most of the neoplasms indicating that the Cdk inhibitors that were expressed in the cells were functional. The observed expression of p15(Ink4b) is inconsistent with their proliferation state, although it might be expected to be expressed owing to the maturity of the cells. These data suggest, therefore, that deregulated c-Myc bypasses the pRb restriction point and cell cycle arrest in these tumors. An examination of p19(Arf) exons revealed deletions of the gene in up to 94% of the tumors. Since this gene shares exon 2 with p16(Ink4),, it is often difficult to determine which gene is the relevant tumor suppressor. However, the loss of only the p19(Arf)-specific exon 1beta was observed in a tumor that had normal p16(Ink4a), protein expression. In addition, the p19(Arf)-specific exon was deleted in another tumor that expressed a functional chimeric protein, p15Ex1-p16Ex2-3; it was demonstrated here that this fusion protein is capable of inducing G1 arrest. These data overall supports the hypothesis that the critical inactivation event in these hematopoietic neoplasms is elimination of p19(Arf), and not Ink4 function.	NCI, Cellular Oncol Lab, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Wolff, L (corresponding author), NCI, Cellular Oncol Lab, NIH, Bethesda, MD 20892 USA.							Adams PD, 2001, BBA-REV CANCER, V1471, pM123, DOI 10.1016/S0304-419X(01)00019-1; Alevizopoulos K, 1997, EMBO J, V16, P5322, DOI 10.1093/emboj/16.17.5322; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Amanullah A, 2000, ONCOGENE, V19, P2967, DOI 10.1038/sj.onc.1203638; Batova A, 1997, CANCER RES, V57, P832; Claassen GF, 2000, P NATL ACAD SCI USA, V97, P9498, DOI 10.1073/pnas.150006697; Coller HA, 2000, P NATL ACAD SCI USA, V97, P3260, DOI 10.1073/pnas.97.7.3260; Cooper CL, 1997, BLOOD, V89, P3155, DOI 10.1182/blood.V89.9.3155; Drexler HG, 1998, LEUKEMIA, V12, P845, DOI 10.1038/sj.leu.2401043; Eischen CM, 1999, GENE DEV, V13, P2658, DOI 10.1101/gad.13.20.2658; Esteller M, 2001, CANCER RES, V61, P3225; GUAN KL, 1994, GENE DEV, V8, P2939, DOI 10.1101/gad.8.24.2939; GUNNING P, 1983, MOL CELL BIOL, V3, P787, DOI 10.1128/MCB.3.5.787; GUTIERREZ MI, 1992, CANCER RES, V52, P1032; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; Harbour JW, 1999, CELL, V98, P859, DOI 10.1016/S0092-8674(00)81519-6; Harper JW, 1996, CURR OPIN GENET DEV, V6, P56; Herman JG, 1997, CANCER RES, V57, P837; Herzog CR, 1997, MAMM GENOME, V8, P65, DOI 10.1007/s003359900352; Iravani M, 1997, ONCOGENE, V15, P2609, DOI 10.1038/sj.onc.1201428; Ishiguro A, 1996, BLOOD, V87, P5225, DOI 10.1182/blood.V87.12.5225.bloodjournal87125225; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; Kamijo T, 1997, CELL, V91, P649, DOI 10.1016/S0092-8674(00)80452-3; KEYOMARSI K, 1994, CANCER RES, V54, P380; Krimpenfort P, 2001, NATURE, V413, P83, DOI 10.1038/35092584; Kulkarni MS, 2002, LEUKEMIA, V16, P127, DOI 10.1038/sj.leu.2402328; Lasorella A, 2000, NATURE, V407, P592, DOI 10.1038/35036504; Lasorella A, 1996, MOL CELL BIOL, V16, P2570; LIEBERMANN DA, 1989, ONCOGENE, V4, P583; LUKAS J, 1995, NATURE, V375, P503, DOI 10.1038/375503a0; Lukas J, 1997, GENE DEV, V11, P1479, DOI 10.1101/gad.11.11.1479; Lundberg AS, 1998, MOL CELL BIOL, V18, P753, DOI 10.1128/MCB.18.2.753; Malumbres M, 2000, BIOL CHEM, V381, P827, DOI 10.1515/BC.2000.105; Malumbres M, 1999, ONCOGENE, V18, P385, DOI 10.1038/sj.onc.1202299; Malumbres M, 2000, MOL CELL BIOL, V20, P2915, DOI 10.1128/MCB.20.8.2915-2925.2000; Malumbres M, 1997, ONCOGENE, V14, P1361, DOI 10.1038/sj.onc.1200969; MARTIN SL, 1995, GENE, V153, P261, DOI 10.1016/0378-1119(94)00785-Q; MEDEMA RH, 1995, P NATL ACAD SCI USA, V92, P6289, DOI 10.1073/pnas.92.14.6289; Morris EJ, 2001, ADV CANCER RES, V82, P1, DOI 10.1016/S0065-230X(01)82001-7; NOBORI T, 1994, NATURE, V368, P753, DOI 10.1038/368753a0; O'Hagan RC, 2000, GENE DEV, V14, P2185, DOI 10.1101/gad.827200; Porter PL, 1997, NAT MED, V3, P222, DOI 10.1038/nm0297-222; QUELLE DE, 1995, CELL, V83, P993; QUELLE DE, 1995, ONCOGENE, V11, P635; Reinach PS, 2000, CELL PROLIFERAT, V33, P189, DOI 10.1046/j.1365-2184.2000.00162.x; REYNISDOTTIR I, 1995, GENE DEV, V9, P1831, DOI 10.1101/gad.9.15.1831; Roussel MF, 1999, ONCOGENE, V18, P5311, DOI 10.1038/sj.onc.1202998; Ruas M, 1998, BBA-REV CANCER, V1378, pF115, DOI 10.1016/S0304-419X(98)00017-1; Schmidt M, 2001, ONCOGENE, V20, P6205, DOI 10.1038/sj.onc.1204821; Schmidt M, 2000, MOL CELL BIOL, V20, P1970, DOI 10.1128/MCB.20.6.1970-1981.2000; SERRANO M, 1995, SCIENCE, V267, P249, DOI 10.1126/science.7809631; Sharpless NE, 2001, NATURE, V413, P86, DOI 10.1038/35092592; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; Sherr CJ, 2000, CURR OPIN GENET DEV, V10, P94, DOI 10.1016/S0959-437X(99)00038-6; Sherr CJ, 1998, GENE DEV, V12, P2984, DOI 10.1101/gad.12.19.2984; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; SUN XH, 1991, MOL CELL BIOL, V11, P5603, DOI 10.1128/MCB.11.11.5603; Teofili L, 1998, EXP HEMATOL, V26, P1133; Teofili L, 2000, EXP HEMATOL, V28, P519, DOI 10.1016/S0301-472X(00)00139-9; Uchida T, 1997, BLOOD, V90, P1403, DOI 10.1182/blood.V90.4.1403.1403_1403_1409; Weinberg RA, 1997, CELL, V88, P573, DOI 10.1016/S0092-8674(00)81897-8; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; WOLFF L, 1986, CURR TOP MICROBIOL, V132, P33; WOLFF L, 1988, J IMMUNOL, V141, P681; Yang W, 2001, ONCOGENE, V20, P1688, DOI 10.1038/sj.onc.1204245; Zhang SL, 2001, MOL CELL BIOL, V21, P310, DOI 10.1128/MCB.21.1.310-318.2001; Zhang YP, 1998, CELL, V92, P725, DOI 10.1016/S0092-8674(00)81401-4; Zindy F, 1998, GENE DEV, V12, P2424, DOI 10.1101/gad.12.15.2424	69	11	11	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 20	2003	22	11					1600	1610		10.1038/sj.onc.1206268	http://dx.doi.org/10.1038/sj.onc.1206268			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	655YH	12642863				2022-12-25	WOS:000181580500002
J	Walker, JB; Hughes, B; James, I; Haddock, P; Kluft, C; Bajzar, L				Walker, JB; Hughes, B; James, I; Haddock, P; Kluft, C; Bajzar, L			Stabilization versus inhibition of TAFIa by competitive inhibitors in vitro	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVABLE FIBRINOLYSIS INHIBITOR; JUGULAR-VEIN THROMBOLYSIS; D DOMAIN-II; CRYSTAL-STRUCTURE; PROCARBOXYPEPTIDASE-B; PLASMINOGEN ACTIVATOR; PROTEOLYTIC CLEAVAGE; MEDIATED ACTIVATION; CARBOXYPEPTIDASE-A; THERMAL-STABILITY	Two competitive inhibitors of TAFIa (activated thrombin-activable fibrinolysis inhibitor), 2-guanidinoethyl-mercaptosuccinic acid and potato tuber carboxypeptidase inhibitor, variably affect fibrinolysis of clotted human plasma. Depending on their concentration, the inhibitors shortened, prolonged, or had no effect on lysis in vitro. The inhibitor-induced effects were both tissue-type plasminogenactivator(tPA) andTAFIa concentration- dependent. Inhibitor-dependent prolongation was favored at lower tPA concentrations. The magnitude of the prolongation increased with TAFIa concentration, and the maximal prolongation observed at each TAFIa concentration increased saturably with respect to TAFIa. A theoretical maximal prolongation of 20-fold was derived from a plot of the maximum prolongation versus TAFIa. This represents, for the first time, a measurement of the maximal antifibrinolytic potential of TAFIa in vitro. Because TAFIa spontaneously decays, the stabilization of TAFIa was investigated as a mechanism explaining the inhibitor-dependent prolongation of lysis. Both inhibitors stabilized TAFIa in a concentration-dependent, non-saturable manner. Although their K-1 values differed by three orders of magnitude, TAFIa was identically stabilized when the fraction of inhibitor-bound TAFIa was the same. The data fit a model whereby only free TAFIa decays. Therefore, the variable effects of competitive inhibitors of TAFla on fibrinolysis can be rationalized in terms of free TAFla and lysis time relative to the half-life of TAFIa.	Henerson Res Ctr, Hamilton, ON L8V 1C3, Canada; McMaster Univ, Hamilton, ON L8V 1C3, Canada; Pfizer Ltd, Global Res & Dev, Sandwich Labs, Sandwich CT13 9NJ, Kent, England; TNO PG, Gaubius Inst, NL-2333 CK Leiden, Netherlands	McMaster University; Pfizer; Netherlands Organization Applied Science Research	Bajzar, L (corresponding author), Henerson Res Ctr, 711 Concess St, Hamilton, ON L8V 1C3, Canada.							Aloy P, 2001, J BIOL CHEM, V276, P16177, DOI 10.1074/jbc.M011457200; Bajzar L, 1996, J BIOL CHEM, V271, P16603, DOI 10.1074/jbc.271.28.16603; BAJZAR L, 1995, J BIOL CHEM, V270, P14477, DOI 10.1074/jbc.270.24.14477; Bajzar L, 1998, J BIOL CHEM, V273, P2792, DOI 10.1074/jbc.273.5.2792; Bajzar L, 1996, BLOOD, V88, P2093, DOI 10.1182/blood.V88.6.2093.bloodjournal8862093; BARENHOLZ Y, 1977, BIOCHEMISTRY-US, V16, P2806, DOI 10.1021/bi00631a035; Boffa MB, 1998, J BIOL CHEM, V273, P2127, DOI 10.1074/jbc.273.4.2127; Boffa MB, 2000, J BIOL CHEM, V275, P12868, DOI 10.1074/jbc.275.17.12868; CAMPBELL W, 1989, BIOCHEM BIOPH RES CO, V162, P933, DOI 10.1016/0006-291X(89)90762-6; EATON DL, 1991, J BIOL CHEM, V266, P21833; FRICKER LD, 1983, BIOCHEM BIOPH RES CO, V111, P994, DOI 10.1016/0006-291X(83)91398-0; Gomis-Ruth FX, 1999, EMBO J, V18, P5817, DOI 10.1093/emboj/18.21.5817; HENDRIKS D, 1990, BIOCHIM BIOPHYS ACTA, V1034, P86, DOI 10.1016/0304-4165(90)90157-R; Klement P, 1999, BLOOD, V94, P2735, DOI 10.1182/blood.V94.8.2735.420k30_2735_2743; Marx PF, 2000, J BIOL CHEM, V275, P12410, DOI 10.1074/jbc.275.17.12410; Marx PF, 2002, BIOCHEMISTRY-US, V41, P1211, DOI 10.1021/bi0115683; Marx PF, 2002, BIOCHEMISTRY-US, V41, P6688, DOI 10.1021/bi015982e; Minnema MC, 1998, J CLIN INVEST, V101, P10, DOI 10.1172/JCI781; MOLINA MA, 1994, J BIOL CHEM, V269, P21467; Nagashima M, 2000, THROMB RES, V98, P333, DOI 10.1016/S0049-3848(00)00184-5; Nesheim M, 1997, THROMB HAEMOSTASIS, V78, P386; REES DC, 1982, J MOL BIOL, V160, P475, DOI 10.1016/0022-2836(82)90309-6; Refino C. J., 1998, Fibrinolysis and Proteolysis, V12, P29; RYAN CA, 1974, J BIOL CHEM, V249, P5495; Schatteman KA, 1999, THROMB HAEMOSTASIS, V82, P1718, DOI 10.1055/s-0037-1614904; Schneider M, 2002, J BIOL CHEM, V277, P1021, DOI 10.1074/jbc.M104444200; Schneider MM, 2001, BLOOD, V98, p254A; TAN AK, 1995, BIOCHEMISTRY-US, V34, P5811, DOI 10.1021/bi00017a012; VondemBorne PAK, 1997, J CLIN INVEST, V99, P2323, DOI 10.1172/JCI119412; Walker JB, 2001, J BIOL CHEM, V276, P3138, DOI 10.1074/jbc.M005876200; Wang W, 1998, J BIOL CHEM, V273, P27176, DOI 10.1074/jbc.273.42.27176	31	52	54	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 14	2003	278	11					8913	8921		10.1074/jbc.M205006200	http://dx.doi.org/10.1074/jbc.M205006200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	654YF	12643276	Green Published, hybrid			2022-12-25	WOS:000181524000008
J	Tyagi, A; Agarwal, R; Agarwal, C				Tyagi, A; Agarwal, R; Agarwal, C			Grape seed extract inhibits EGF-induced and constitutively active mitogenic signaling but activates JNK in human prostate carcinoma DU145 cells: possible role in antiproliferation and apoptosis	ONCOGENE			English	Article						prostate cancer; MAPK; AP1; apoptosis; grape seed extract	EPIDERMAL GROWTH-FACTOR; NF-KAPPA-B; PROTEIN-KINASE PATHWAY; CANCER CELLS; C-JUN; MAP KINASES; STRESS; TRANSDUCTION; RECEPTORS; DEATH	A loss of functional androgen receptor and an enhanced expression of growth factor receptors and associated ligands are causal genetic events in prostate cancer (PCA) progression. These genetic alterations lead to an epigenetic mechanism where a feedback autocrine loop between membrane receptor and ligand (e.g. EGFR-TGFalpha) results in a constitutive activation of MAPK-Elk1-AP1-mediated mitogenic signaling in human PCA at an advanced and androgen-independent stage. We rationalized that inhibiting these epigenetic events could be useful in controlling advanced PCA growth. Recently, we found that grape seed extract (GSE), a dietary supplement rich in flavonoid procyanidins, inhibits advanced and androgen-independent human PCA DU145 cell growth in culture and nude mice. Here, we performed detailed mechanistic studies to define the effect of GSE on EGFR-Shc-MAPK-Elk1-AP1-mediated mitogenic signaling in DU145 cells. Pretreatment of serum-starved cells with GSE resulted in 70% to almost complete inhibition of EGF-induced EGFR activation and 50% to complete inhibition of She activation, which corroborated with a comparable decrease in EGF-induced Shc binding to EGFR. Conversely, EGF-induced ERK1/2 phosphorylation was inhibited only by lower doses of GSE; in fact, higher doses showed an increase. Additional studies showed that GSE alone causes a dose- and time-dependent increase in ERK1/2 phosphorylation in starved DU145 cells that is inhibited by an MEK1 inhibitor PD98059. Independent of this increase in ERK1/2 phosphorylation, GSE showed a strong inhibition of ERK1/2 kinase activity to Elk1 in both cellular and cell-free systems. GSE treatment of cells also inhibited both EGF-induced and constitutively active Elk1 phosphorylation and AP1 activation. GSE treatment also showed DNA synthesis inhibition in starved and EGF-stimulated cells as well as loss of cell viability and apoptotic death that was further increased by adding MEK1 inhibitor. Since GSE strongly induced apoptosis independent of its affect on an increase in phospho-ERK1/2, we hypothesized that apoptotic effect of GSE could be by other mechanism(s) including its effect on stress-associated MAPK, the JNK. Indeed, GSE-treated cells showed a strong and sustained increase in phospho-JNK1/JNK2 levels, JNK activity and phospho-cJun levels. An inhibition of GSE-induced JNK activation by a novel JNK inhibitor SP600125 resulted in a significant reversal of GSE-induced apoptotic death suggesting the involvement of JNK activation by GSE in its apoptosis response. Together, these results suggest that anticancer effects of GSE in PCA be mediated via impairment of EGFR-ERK1/2-Elk1-AP1-mediated mitogenic signaling and activation of JNK causing growth inhibition and apoptosis, respectively.	Univ Colorado, Hlth Sci Ctr, Sch Pharm, Dept Pharmaceut Sci, Denver, CO 80262 USA; Univ Colorado, Hlth Sci Ctr, Ctr Canc, Denver, CO 80262 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Agarwal, C (corresponding author), Univ Colorado, Hlth Sci Ctr, Sch Pharm, Dept Pharmaceut Sci, 4200 E 9th Ave,Box C238, Denver, CO 80262 USA.	Chapia.Agarwal@UCHSC.edu			NATIONAL CANCER INSTITUTE [R01CA083741, R29CA064514, R01CA064514] Funding Source: NIH RePORTER; NCI NIH HHS [CA83741, CA64514] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Agarwal C, 2000, MOL CARCINOGEN, V28, P129, DOI 10.1002/1098-2744(200007)28:3&lt;129::AID-MC1&gt;3.0.CO;2-0; Agarwal R, 2000, BIOCHEM PHARMACOL, V60, P1051, DOI 10.1016/S0006-2952(00)00385-3; Bartolome B, 1996, J CHROMATOGR A, V723, P19, DOI 10.1016/0021-9673(95)00839-X; Bennett BL, 2001, P NATL ACAD SCI USA, V98, P13681, DOI 10.1073/pnas.251194298; Bhatia N, 2001, PROSTATE, V46, P98; CLARKE PR, 1994, CURR BIOL, V4, P647, DOI 10.1016/S0960-9822(00)00144-5; Cohen P, 1997, TRENDS CELL BIOL, V7, P353, DOI 10.1016/S0962-8924(97)01105-7; CONNOLLY JM, 1989, PROSTATE, V15, P177, DOI 10.1002/pros.2990150211; DAI TN, 1995, ONCOGENE, V10, P849; Deak JC, 1998, P NATL ACAD SCI USA, V95, P5595, DOI 10.1073/pnas.95.10.5595; Dhanalakshmi S, 2002, ONCOGENE, V21, P1759, DOI 10.1038/sj.onc.1205240; Dragsted L O, 1998, Arch Toxicol Suppl, V20, P209; ESCRIBANOBAILON T, 1992, J AGR FOOD CHEM, V40, P1794, DOI 10.1021/jf00022a013; Gioeli D, 1999, CANCER RES, V59, P279; Goillot E, 1997, P NATL ACAD SCI USA, V94, P3302, DOI 10.1073/pnas.94.7.3302; GOLDMAN R, 1990, BIOCHEMISTRY-US, V29, P11024, DOI 10.1021/bi00502a002; Grasso AW, 1997, ONCOGENE, V15, P2705, DOI 10.1038/sj.onc.1201447; Greenlee RT, 2001, CA-CANCER J CLIN, V51, P15, DOI 10.3322/canjclin.51.1.15; Harris KA, 2001, DRUGS, V61, P2177, DOI 10.2165/00003495-200161150-00003; Hirota K, 2001, J BIOL CHEM, V276, P25953, DOI 10.1074/jbc.M011021200; Ichijo H, 1999, ONCOGENE, V18, P6087, DOI 10.1038/sj.onc.1203129; Jiang Y, 1996, J BIOL CHEM, V271, P17920, DOI 10.1074/jbc.271.30.17920; Karin M, 1997, CURR OPIN CELL BIOL, V9, P240, DOI 10.1016/S0955-0674(97)80068-3; Kyriakis JM, 1996, J BIOL CHEM, V271, P24313, DOI 10.1074/jbc.271.40.24313; Lenczowski JM, 1997, MOL CELL BIOL, V17, P170, DOI 10.1128/MCB.17.1.170; Leppa S, 1999, ONCOGENE, V18, P6158, DOI 10.1038/sj.onc.1203173; LEVITZKI A, 1995, SCIENCE, V267, P1782, DOI 10.1126/science.7892601; Lin JQ, 1999, CANCER RES, V59, P2891; Liu B, 2001, BRIT J CANCER, V85, P303, DOI 10.1054/bjoc.2001.1910; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; Mukhopadhyay A, 2001, ONCOGENE, V20, P7597, DOI 10.1038/sj.onc.1204997; Nishina H, 1997, NATURE, V385, P350, DOI 10.1038/385350a0; Palayoor ST, 1999, ONCOGENE, V18, P7389, DOI 10.1038/sj.onc.1203160; PULVERER BJ, 1991, NATURE, V353, P670, DOI 10.1038/353670a0; Putz T, 1999, CANCER RES, V59, P227; Robinson D, 1996, P NATL ACAD SCI USA, V93, P5958, DOI 10.1073/pnas.93.12.5958; Rodrigues GA, 1997, EMBO J, V16, P2634, DOI 10.1093/emboj/16.10.2634; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; Sato M, 2001, FREE RADICAL BIO MED, V31, P729, DOI 10.1016/S0891-5849(01)00626-8; Segawa N, 2001, CANCER RES, V61, P6060; SEGER R, 1995, FASEB J, V9, P726, DOI 10.1096/fasebj.9.9.7601337; Smith A, 1997, CURR BIOL, V7, P893, DOI 10.1016/S0960-9822(06)00380-0; Sporn MB, 2000, CARCINOGENESIS, V21, P525, DOI 10.1093/carcin/21.3.525; TILLOTSON JK, 1991, CANCER LETT, V60, P109, DOI 10.1016/0304-3835(91)90216-5; Tournier C, 2000, SCIENCE, V288, P870, DOI 10.1126/science.288.5467.870; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; Wattenberg LW, 1997, P SOC EXP BIOL MED, V216, P133; WHITMARSH AJ, 1995, SCIENCE, V269, P403, DOI 10.1126/science.7618106; Yang GY, 1998, CARCINOGENESIS, V19, P611, DOI 10.1093/carcin/19.4.611; Yang XL, 1997, CELL, V89, P1067, DOI 10.1016/S0092-8674(00)80294-9; Yu R, 2000, CANCER RES, V60, P2384; Zanke BW, 1996, CURR BIOL, V6, P606, DOI 10.1016/S0960-9822(02)00547-X; Zhao J, 1999, CARCINOGENESIS, V20, P1737, DOI 10.1093/carcin/20.9.1737; Zi XL, 2000, CANCER RES, V60, P5617; Zi XL, 1998, CANCER RES, V58, P1920; Zi ZL, 1999, P NATL ACAD SCI USA, V96, P7490, DOI 10.1073/pnas.96.13.7490	58	114	120	1	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 6	2003	22	9					1302	1316		10.1038/sj.onc.1206265	http://dx.doi.org/10.1038/sj.onc.1206265			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	652CA	12618755				2022-12-25	WOS:000181360900004
J	Zeng, PY; Rane, N; Du, W; Chintapalli, J; Prendergast, GC				Zeng, PY; Rane, N; Du, W; Chintapalli, J; Prendergast, GC			Role for RhoB and PRK in the suppression of epithelial cell transformation by farnesyltransferase inhibitors	ONCOGENE			English	Article						Ras; Rac; Rho; actin	INFLAMMATORY BREAST-CANCER; PROTEIN-KINASE; RAS TRANSFORMATION; SMALL GTPASE; N-RAS; ACTIVATION; MECHANISM; PRENYLATION; APOPTOSIS; REVERSION	Recent genetic investigations have established that RhoB gain-of-function is sufficient to mediate the antitransforming effects of farnesyltransferase inhibitors (FTIs) in H-Ras-transformed fibroblast systems. In this study, we addressed the breadth and mechanism of RhoB action in epithelial cells transformed by oncoproteins which are themselves insensitive to FTI inactivation. Rat intestinal epithelial (RIE) cells transformed by activated K-Ras or Rac1 were highly sensitive to FTI-induced actin reorganization and growth inhibition, despite the inability of FTI to block prenylation of either K-Ras or Rac1. Ectopic expression of the geranylgeranylated RhoB isoform elicited in cells by FTI treatment phenocopied these effects. Analysis of RhoB effector domain mutants pointed to a role for PRK, a Rho effector kinase implicated in the physiological function of RhoB in intracellular receptor trafficking, and these findings were supported further by experiments in a fibroblast system. We propose that FTIs recruit the antioncogenic RhoB protein in the guise of RhoB-GG to interfere with signaling by pro-oncogenic Rho proteins, possibly by sequestering common exchange factors or effectors such as PRK that are important for cell transformation.	Lankenau Inst Med Res, Wynnewood, PA 19096 USA; DuPont Pharmaceut Co, Glenolden Lab, Canc Res Grp, Glenolden, PA USA; Wistar Inst Anat & Biol, Philadelphia, PA 19104 USA; Thomas Jefferson Univ, Jefferson Med Sch, Dept Pathol Anat & Cell Biol, Philadelphia, PA 19107 USA	Lankenau Medical Center; Lankenau Institute for Medical Research; DuPont; The Wistar Institute; Jefferson University	Prendergast, GC (corresponding author), Lankenau Inst Med Res, 100 Lancaster Ave, Wynnewood, PA 19096 USA.	prendergastg@mlhs.org			NATIONAL CANCER INSTITUTE [R01CA082222] Funding Source: NIH RePORTER; NCI NIH HHS [CA82222, R01 CA082222] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADAMSON P, 1992, J CELL BIOL, V119, P617, DOI 10.1083/jcb.119.3.617; Adjei AA, 2001, JNCI-J NATL CANCER I, V93, P1062, DOI 10.1093/jnci/93.14.1062; Balendran A, 1999, CURR BIOL, V9, P393, DOI 10.1016/S0960-9822(99)80186-9; Cox AD, 2001, DRUGS, V61, P723, DOI 10.2165/00003495-200161060-00002; Cryns VL, 1997, J BIOL CHEM, V272, P29449, DOI 10.1074/jbc.272.47.29449; Du W, 1999, CANCER RES, V59, P2059; Du W, 1999, MOL CELL BIOL, V19, P1831; Du W, 1999, CANCER RES, V59, P4208; Flynn P, 2000, J BIOL CHEM, V275, P11064, DOI 10.1074/jbc.275.15.11064; Gampel A, 1999, CURR BIOL, V9, P955, DOI 10.1016/S0960-9822(99)80422-9; HAWLEY RG, 1994, GENE THER, V1, P136; KHOSRAVIFAR R, 1995, MOL CELL BIOL, V15, P6443; Koh H, 2000, J BIOL CHEM, V275, P34451, DOI 10.1074/jbc.M001753200; KOHL NE, 1993, SCIENCE, V260, P1934, DOI 10.1126/science.8316833; KOHL NE, 1995, NAT MED, V1, P792, DOI 10.1038/nm0895-792; LEBOWITZ PF, 1995, MOL CELL BIOL, V15, P6613; Lebowitz PF, 1997, CANCER RES, V57, P708; Lebowitz PF, 1997, J BIOL CHEM, V272, P15591, DOI 10.1074/jbc.272.25.15591; Lebowitz PF, 1997, J BIOL CHEM, V272, P16093, DOI 10.1074/jbc.272.26.16093; Lerner EC, 1997, ONCOGENE, V15, P1283, DOI 10.1038/sj.onc.1201296; Liao JF, 1997, J BIOL CHEM, V272, P25951, DOI 10.1074/jbc.272.41.25951; Liu AX, 2001, P NATL ACAD SCI USA, V98, P6192, DOI 10.1073/pnas.111137198; Liu AX, 2001, MOL CELL BIOL, V21, P6906, DOI 10.1128/MCB.21.20.6906-6912.2001; Liu AX, 2000, FEBS LETT, V481, P205, DOI 10.1016/S0014-5793(00)02003-2; Liu AX, 2000, MOL CELL BIOL, V20, P6105, DOI 10.1128/MCB.20.16.6105-6113.2000; Mellor H, 1998, J BIOL CHEM, V273, P4811, DOI 10.1074/jbc.273.9.4811; Olson MF, 1998, NATURE, V394, P295, DOI 10.1038/28425; Prendergast G C, 2000, Lancet Oncol, V1, P73, DOI 10.1016/S1470-2045(00)00073-5; Prendergast GC, 2001, NAT REV CANCER, V1, P162, DOI 10.1038/35101096; Prendergast GC, 2000, CURR OPIN CELL BIOL, V12, P166, DOI 10.1016/S0955-0674(99)00072-1; PRENDERGAST GC, 1994, MOL CELL BIOL, V14, P4193, DOI 10.1128/MCB.14.6.4193; Prendergast GC, 2001, EXPERT OPIN INV DRUG, V10, P2105, DOI 10.1517/13543784.10.12.2105; Prendergast GC, 2000, SEMIN CANCER BIOL, V10, P443, DOI 10.1006/scbi.2000.0335; Prendergast GC, 1999, CANCER RES, V59, P5924; QIU RG, 1995, P NATL ACAD SCI USA, V92, P11781, DOI 10.1073/pnas.92.25.11781; Rowell CA, 1997, J BIOL CHEM, V272, P14093, DOI 10.1074/jbc.272.22.14093; Rowinsky EK, 1999, J CLIN ONCOL, V17, P3631, DOI 10.1200/JCO.1999.17.11.3631; Sahai E, 1998, EMBO J, V17, P1350, DOI 10.1093/emboj/17.5.1350; Sebti SM, 2000, ONCOGENE, V19, P6584, DOI 10.1038/sj.onc.1204146; Suzuki N, 1998, P NATL ACAD SCI USA, V95, P15356, DOI 10.1073/pnas.95.26.15356; Takahashi M, 1998, P NATL ACAD SCI USA, V95, P11566, DOI 10.1073/pnas.95.20.11566; van Golen KL, 1999, CLIN CANCER RES, V5, P2511; van Golen KL, 2000, CANCER RES, V60, P5832; van Golen KL, 2002, MOL CANCER THER, V1, P575; van Golen KL, 2000, NEOPLASIA, V2, P418, DOI 10.1038/sj.neo.7900115; Whyte DB, 1997, J BIOL CHEM, V272, P14459, DOI 10.1074/jbc.272.22.14459; Zohar M, 1998, ONCOGENE, V17, P991, DOI 10.1038/sj.onc.1202022	47	36	38	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 27	2003	22	8					1124	1134		10.1038/sj.onc.1206181	http://dx.doi.org/10.1038/sj.onc.1206181			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	650EK	12606940				2022-12-25	WOS:000181249700002
